Comparison 0
with 0
alkaline B-gene
phosphatases I-gene
and 0
5 B-gene
- I-gene
nucleotidase I-gene

Pharmacologic 0
aspects 0
of 0
neonatal 0
hyperbilirubinemia 0
. 0

When 0
CSF 0
[ 0
HCO3 0
- 0
] 0
is 0
shown 0
as 0
a 0
function 0
of 0
CSF 0
PCO2 0
the 0
data 0
of 0
K 0
- 0
depleted 0
rats 0
are 0
no 0
longer 0
displaced 0
when 0
compared 0
to 0
controls 0
but 0
still 0
have 0
a 0
significantly 0
greater 0
slope 0
( 0
1.21 0
+/ 0
- 0
0.23 0
vs 0
. 0

Flurazepam 0
thus 0
appears 0
to 0
be 0
an 0
effective 0
hypnotic 0
drug 0
with 0
the 0
optimum 0
dose 0
for 0
use 0
in 0
general 0
practice 0
being 0
15 0
mg 0
at 0
night 0
. 0

Beta 0
blocking 0
agents 0
. 0

When 0
extracorporeal 0
CO2 0
removal 0
approximated 0
CO2 0
production 0
( 0
VCO2 0
) 0
, 0
alveolar 0
ventilation 0
almost 0
ceased 0
. 0

Intravenous 0
administration 0
( 0
25 0
mg/kg 0
) 0
of 0
carbonic B-gene
anhydrase I-gene
inhibitors 0
( 0
acetazolamide 0
, 0
methazolamide 0
, 0
dichlorphenamide 0
, 0
sulthiame 0
) 0
induced 0
an 0
early 0
important 0
rise 0
of 0
cortical 0
p 0
O2 0
, 0
which 0
is 0
not 0
dependent 0
on 0
increase 0
of 0
p 0
O2 0
and 0
p 0
CO2 0
and 0
decrease 0
of 0
pH 0
in 0
arterial 0
blood 0
. 0

Teratological 0
study 0
of 0
etoperidone 0
in 0
the 0
rat 0
and 0
rabbit 0
. 0

Colorectal 0
polyps 0
should 0
be 0
removed 0
endoscopically 0
whenever 0
possible 0
. 0

The 0
variable 0
HMG B-gene
dosage 0
regimen 0
was 0
found 0
to 0
offer 0
no 0
advantages 0
when 0
compared 0
with 0
our 0
standard 0
daily 0
dosage 0
regimen 0
. 0

When 0
the 0
CO2 0
content 0
reached 0
9 0
Vol 0
% 0
the 0
animals 0
became 0
apathic 0
and 0
lost 0
body 0
weight 0
. 0

Serum B-gene
gamma I-gene
glutamyltransferase I-gene
in 0
the 0
diagnosis 0
of 0
liver 0
disease 0
in 0
cattle 0
. 0

By 0
contrast 0
, 0
secretory B-gene
HI I-gene
antibodies I-gene
were 0
not 0
demonstrated 0
at 0
the 0
onset 0
of 0
illness 0
in 0
any 0
of 0
the 0
patients 0
, 0
but 0
their 0
formation 0
started 0
early 0
and 0
the 0
antibodies 0
reached 0
maximal 0
levels 0
about 0
10 0
days 0
after 0
onset 0
of 0
illness 0
. 0

With 0
the 0
exception 0
of 0
virus 0
assay 0
and 0
quantitation 0
, 0
these 0
methods 0
are 0
simple 0
and 0
inexpensive 0
enough 0
to 0
be 0
done 0
in 0
typical 0
shellfish 0
microbiology 0
laboratories 0
. 0

Characteristics 0
of 0
lipase B-gene
activity 0
. 0

Takayasu 0
's 0
disease 0
: 0
association 0
with 0
HLA B-gene
- I-gene
B5 I-gene
. 0

SGPT B-gene
, 0
SGOT B-gene
, 0
and 0
alkaline B-gene
phosphatase I-gene
concentrations 0
were 0
essentially 0
normal 0
in 0
all 0
subjects 0
. 0

Gamma B-gene
glutamyl I-gene
transpeptidase I-gene
( 0
GGTP B-gene
) 0
activity 0
in 0
the 0
seminal 0
fluid 0

Patients 0
with 0
Parkinson 0
's 0
disease 0
showed 0
a 0
relatively 0
high 0
incidence 0
to 0
psychoses 0
during 0
drug 0
treatment 0
( 0
51.47 0
% 0
) 0
. 0

Selective 0
stimulation 0
of 0
central 0
alpha B-gene
- I-gene
autoreceptors I-gene
following 0
treatment 0
with 0
alpha 0
- 0
methyldopa 0
and 0
FLA 0
136 0
. 0

Anti 0
- 0
anxiety 0
action 0
of 0
diazepam 0
after 0
intra 0
- 0
amygdaloid 0
application 0
in 0
the 0
rat 0
. 0

Abstracts 0
. 0

Removal 0
of 0
thick 0
, 0
permanently 0
altered 0
mucoas 0
is 0
recommended 0
even 0
in 0
the 0
absence 0
of 0
squamous 0
epithelium 0
. 0

An 0
IgG B-gene
monoclonal 0
gammopathy 0
was 0
present 0
in 0
the 0
serum 0
of 0
4 0
patients 0
and 0
Bence 0
- 0
Joanes 0
proteinuria 0
was 0
found 0
in 0
1 0
patient 0
. 0

Studies 0
on 0
immunoglobulin B-gene
E I-gene
: 0
the 0
impact 0
of 0
a 0
sojourn 0
with 0
Professor 0
Dan 0
H 0
. 0

Peroxydase B-gene
reaction 0
stains 0
were 0
negative 0
, 0
chloroacetate B-gene
esterase I-gene
were 0
strongly 0
positive 0
. 0

Ten 0
out 0
- 0
patients 0
with 0
pustulosis 0
palmaris 0
et 0
plantaris 0
were 0
examined 0
with 0
direct 0
immunofluorescence 0
( 0
IF 0
) 0
technique 0
for 0
deposition 0
of 0
fibrinogen B-gene
, 0
fibrin B-gene
or 0
its 0
degradation 0
products 0
( 0
FR B-gene
- I-gene
antigen I-gene
) 0
in 0
affected 0
and 0
unaffected 0
skin 0
, 0
together 0
with 0
heparin 0
- 0
precipitable 0
fraction 0
( 0
HPF 0
) 0
, 0
cryoglobulin B-gene
and 0
total 0
plasma 0
fibrinogen B-gene
in 0
the 0
blood 0
. 0

Of 0
600 0
mediastinoscopies 0
carried 0
out 0
from 0
1966 0
to 0
1973 0
, 0
479 0
were 0
performed 0
to 0
assess 0
the 0
operability 0
of 0
a 0
pulmonary 0
carcinoma 0
. 0

A 0
mixture 0
of 0
human B-gene
albumin I-gene
5 0
% 0
and 0
hydroxy 0
- 0
ethyl 0
- 0
starch 0
was 0
used 0
as 0
a 0
solution 0
for 0
dilution 0
. 0

In 0
the 0
matched 0
control 0
group 0
the 0
acquisition 0
- 0
rate 0
of 0
both 0
symptomatic 0
and 0
asymptomatic 0
0acteriuria 0
was 0
over 0
12 0
% 0
, 0
a 0
figure 0
similar 0
to 0
the 0
percentage 0
of 0
women 0
present 0
in 0
the 0
practice 0
population 0
during 0
one 0
year 0
with 0
transient 0
, 0
symptomatic 0
, 0
and 0
persistent 0
A.B 0
. 0

Late 0
complications 0
of 0
catheterisation 0
for 0
intravenous 0
nutrition 0
. 0

Prenatal 0
diagnosis 0
of 0
galactosaemia 0
. 0

Sings 0
which 0
are 0
indicative 0
of 0
metaplastic 0
erythropoiesis 0
are 0
absent 0
. 0

False 0
positive 0
amniotic B-gene
fluid I-gene
alpha I-gene
fetoprotein I-gene
levels 0
resulting 0
from 0
contamination 0
with 0
fetal 0
blood 0
: 0
results 0
of 0
an 0
experiment 0
. 0

Serum 0
- 0
ferritin B-gene
in 0
diagnosis 0
of 0
haemochromatosis 0
. 0

In 0
2 0
subjects 0
the 0
phytomitogen 0
reactivity 0
of 0
the 0
lymphocytes 0
was 0
improved 0
after 0
treatment 0
. 0

Patients 0
at 0
risk 0
of 0
hypothyroidism 0
. 0

Albumin B-gene
and 0
cyclic 0
AMP 0
levels 0
in 0
peritoneal 0
fluids 0
in 0
the 0
child 0

Preface 0
. 0

Thirty 0
- 0
five 0
strains 0
of 0
Legionnaires 0
' 0
disease 0
bacteria 0
were 0
shown 0
to 0
belong 0
in 0
four 0
distinct 0
serologic 0
groups 0
on 0
the 0
basis 0
of 0
findings 0
obtained 0
with 0
direct 0
fluorescent 0
antibody 0
testing 0
. 0

On 0
the 0
other 0
hand 0
factor B-gene
IX I-gene
activity 0
is 0
decreased 0
in 0
coumarin 0
treatment 0
with 0
factor B-gene
IX I-gene
antigen 0
remaining 0
normal 0
. 0

The 0
concentration 0
of 0
alpha B-gene
2 I-gene
- I-gene
macroglobulin I-gene
, 0
alpha B-gene
1 I-gene
- I-gene
antitrypsin I-gene
, 0
plasminogen B-gene
, 0
C3 B-gene
- I-gene
complement I-gene
, 0
fibrinogen B-gene
degradation I-gene
products I-gene
( 0
FDP B-gene
) 0
and 0
fibrinolytic 0
activity 0
, 0
were 0
studied 0
in 0
the 0
aqueous 0
humour 0
and 0
serum 0
from 0
nine 0
patients 0
with 0
Fuchs 0
' 0
endothelial 0
dystrophy 0
, 0
17 0
patients 0
with 0
uncomplicated 0
senile 0
cataract 0
and 0
in 0
the 0
secondary 0
aqueous 0
from 0
six 0
cataract 0
patients 0
. 0

Only 0
17 0
% 0
of 0
all 0
patients 0
admitted 0
it 0
at 0
all 0
times 0
. 0

Prazosin 0
alone 0
was 0
effective 0
in 0
volume 0
responsive 0
patients 0
at 0
a 0
dose 0
of 0
5 0
+/ 0
- 0
1.0 0
mg 0
daily 0
. 0

T4 0
and 0
FT4I 0
followed 0
parallel 0
courses 0
in 0
both 0
groups 0
; 0
during 0
the 0
first 0
45 0
days 0
, 0
however 0
, 0
the 0
values 0
were 0
significantly 0
lower 0
in 0
premature 0
infants 0
under 0
34 0
weeks 0
' 0
EGA 0
than 0
in 0
term 0
infants 0
( 0
P 0
less 0
than 0
0.001 0
) 0
. 0

A 0
three 0
- 0
phased 0
analysis 0
of 0
treatment 0
plans 0
for 0
45 0
patients 0
was 0
undertaken 0
. 0

Aspirin 0
intolerance 0
: 0
unaltered 0
susceptibility 0
of 0
platelet B-gene
cyclo I-gene
- I-gene
oxygenase I-gene
to 0
inhibition 0
by 0
aspirin 0
in 0
vitro 0
. 0

These 0
results 0
indicate 0
that 0
cynomolgus 0
monkeys 0
are 0
either 0
less 0
sensitive 0
or 0
respond 0
differently 0
than 0
rhesus 0
monkeys 0
to 0
some 0
of 0
the 0
pharmacological 0
effects 0
of 0
norcocaine 0
. 0

59 0
cases 0
of 0
surgically 0
resectable 0
cancers 0
( 0
T1 0
, 0
T2 0
, 0
T3 0
, 0
N0 0
, 0
N1 0
) 0
had 0
a 0
minimum 0
followup 0
of 0
two 0
years 0
( 0
average 0
4 0
years 0
+/ 0
- 0
3 0
months 0
) 0
. 0

The 0
effect 0
of 0
CBZ 0
and 0
DPH 0
can 0
be 0
explained 0
by 0
interference 0
with 0
thyroid 0
hormone 0
binding 0
to 0
TBG B-gene
combined 0
with 0
enzyme 0
- 0
induced 0
increased 0
metabolic 0
clearance 0
rate 0
of 0
thyroid 0
hormones 0
without 0
homeostatic 0
maintenance 0
of 0
premedication 0
levels 0
of 0
FT4 0
and 0
FT3 0
. 0

The 0
present 0
research 0
evaluated 0
the 0
possibility 0
that 0
polyethylene 0
glycol 0
400 0
( 0
PEG 0
400 0
) 0
might 0
be 0
efficacious 0
, 0
toxic 0
, 0
or 0
both 0
. 0

According 0
to 0
their 0
functional 0
properties 0
the 0
latter 0
neurons 0
were 0
subdivided 0
into 0
: 0
( 0
a 0
) 0
neurons 0
responding 0
to 0
stimuli 0
near 0
the 0
eyes 0
; 0
( 0
b 0
) 0
neurons 0
triggered 0
by 0
complex 0
visual 0
stimuli 0
; 0
( 0
c 0
) 0
neurons 0
inhibited 0
by 0
visual 0
stimuli 0
. 0

Pentobarbital 0
( 0
1 0
, 0
3 0
, 0
10 0
, 0
and 0
17.5 0
mg/kg 0
) 0
was 0
also 0
tested 0
in 0
combination 0
with 0
rate 0
- 0
decreasing 0
doses 0
of 0
normeperidine 0
( 0
17.5 0
mg/kg 0
) 0
, 0
anileridine 0
( 0
10 0
mg/kg 0
) 0
, 0
alphaprodine 0
( 0
10 0
mg/kg 0
) 0
, 0
and 0
fentanyl 0
( 0
0.3 0
mg/kg 0
) 0
. 0

Pb 0
foil 0
( 0
0.55 0
gcm 0
- 0
2 0
) 0
provided 0
the 0
best 0
overall 0
improvement 0
. 0

An 0
anatomical 0
and 0
histochemical 0
study 0
has 0
been 0
undertaken 0
and 0
as 0
a 0
result 0
emphasis 0
is 0
given 0
to 0
recent 0
hypotheses 0
that 0
suggest 0
there 0
are 0
similarities 0
with 0
Type 0
IV 0
glycogen 0
storage 0
disease 0
( 0
Andersen 0
's 0
disease 0
) 0
which 0
, 0
although 0
clinically 0
distinct 0
, 0
has 0
the 0
same 0
enzyme 0
defect 0
. 0

All 0
groups 0
were 0
tested 0
in 0
a 0
Hebb 0
- 0
Williams 0
maze 0
at 0
100 0
approximately 0
10 0
days 0
of 0
age 0
. 0

Erythromycin 0
and 0
clindamycin 0
resistance 0
in 0
Corynebacterium 0
diphtheriae 0
from 0
skin 0
lesions 0
. 0

Imposed 0
angular 0
displacements 0
of 0
monkey 0
's 0
wrist 0
produce 0
three 0
major 0
peaks 0
of 0
activity 0
( 0
terms 0
M1 0
, 0
M2 0
, 0
and 0
M3 0
peaks 0
) 0
in 0
the 0
averaged 0
gross 0
EMG 0
activity 0
ot 0
the 0
stretched 0
muscles 0
. 0

Hemolytic 0
disease 0
of 0
African 0
newborn 0
. 0

In 0
this 0
animal 0
, 0
infected 0
with 0
what 0
was 0
judged 0
previously 0
to 0
be 0
the 0
less 0
virulent 0
of 0
the 0
two 0
T. 0
cruzi 0
stocks 0
used 0
( 0
'strain 0
7 0
' 0
) 0
, 0
there 0
was 0
severe 0
myocarditis 0
, 0
with 0
myofibre 0
degeneration 0
, 0
and 0
lesions 0
of 0
the 0
oesophagus 0
. 0

The 0
majority 0
of 0
MRF 0
units 0
were 0
behaviorally 0
incongruent 0
; 0
in 0
the 0
most 0
frequently 0
observed 0
case 0
, 0
their 0
activity 0
failed 0
to 0
change 0
reliably 0
when 0
behavior 0
habituated 0
. 0

Variability 0
within 0
Down 0
's 0
syndrome 0
( 0
trisomy 0
- 0
21 0
) 0
: 0
empirically 0
observed 0
sex 0
differences 0
in 0
IQs 0
. 0

VII 0
. 0

Several 0
demographic 0
indices 0
of 0
isolated 0
populations 0
in 0
Uzbekistan 0

2. 0
- 0
- 0
concepts 0
of 0
higher 0
nervous 0
function 0
in 0
the 0
USSR 0
. 0

The 0
maintenance 0
of 0
increased 0
myocardial 0
capillary 0
density 0
required 0
a 0
similar 0
amount 0
of 0
exercise 0
, 0
and 0
at 0
least 0
1 0
h 0
of 0
exercise 0
once 0
a 0
week 0
was 0
necessary 0
to 0
maintain 0
the 0
enlargement 0
of 0
ECA.20 0

These 0
observations 0
have 0
led 0
us 0
to 0
conclude 0
that 0
an 0
elevated 0
VIII 0
- 0
ratio 0
is 0
a 0
very 0
sensitive 0
indicator 0
of 0
intravascular 0
coagulation 0
. 0

Eight 0
hours 0
after 0
the 0
administration 0
of 0
colchicine 0
, 0
the 0
serum B-gene
ceruloplasmin I-gene
level 0
began 0
to 0
rise 0
again 0
in 0
female 0
rats 0
, 0
but 0
not 0
in 0
male 0
rats 0
. 0

Radioimmunoassays 0
of 0
pregnenolone 0
, 0
progesterone 0
, 0
dehydroepiandrosterone 0
( 0
DHA 0
) 0
16 0
alpha 0
- 0
hydroxy 0
- 0
DHA 0
, 0
estriol 0
, 0
and 0
cortisol 0
were 0
performed 0
on 0
a 0
total 0
of 0
0 0
; 0
1 0
ml 0
; 0
of 0
fetal 0
plasma 0
, 0
collected 0
during 0
the 0
course 0
of 0
normal 0
vaginal 0
delivery 0
. 0

In 0
only 0
two 0
patients 0
were 0
we 0
able 0
to 0
demonstrate 0
changes 0
suggestive 0
of 0
pulmonary 0
metastases 0
any 0
earlier 0
with 0
a 0
99mTc 0
- 0
EHDP 0
scan 0
than 0
with 0
chest 0
radiographs 0
and 0
one 0
of 0
these 0
resolved 0
spontaneously 0
. 0

The 0
majority 0
of 0
tumors 0
occurred 0
in 0
the 0
nasal 0
cavities 0
, 0
although 0
significant 0
incidences 0
were 0
also 0
found 0
in 0
the 0
larynx 0
, 0
trachea 0
and 0
stem 0
bronchi 0
. 0

Prediction 0
of 0
the 0
times 0
of 0
sandfly 0
development 0

Native 0
human B-gene
fibrinogen I-gene
was 0
brought 0
to 0
coagulation 0
by 0
adding 0
thrombin B-gene
. 0

No 0
post 0
- 0
operative 0
haemorrhages 0
from 0
the 0
prostheses 0
were 0
observed 0
. 0

The 0
Southern 0
technique 0
allowed 0
a 0
further 0
localization 0
of 0
the 0
region 0
of 0
most 0
extensive 0
transcription 0
to 0
a 0
1.8 0
kb 0
HindIII B-gene
- 0
EcoRI B-gene
fragment 0
. 0

Accepting 0
arbitrarily 0
chosen 0
limits 0
of 0
maximized 0
errors 0
of 0
+/ 0
- 0
10 0
% 0
, 0
it 0
could 0
be 0
shown 0
that 0
the 0
system 0
did 0
not 0
work 0
acceptably 0
when 0
the 0
mean 0
carbon 0
dioxide 0
concentration 0
was 0
below 0
1.5 0
vol. 0
% 0
within 0
the 0
fresh 0
gas 0
flow 0
rates 0
( 0
2.2 0
- 0
- 0
7.7 0
1 0
min 0
- 0
1 0
) 0
and 0
the 0
range 0
of 0
minute 0
ventilation 0
( 0
4 0
- 0
- 0
10 0
1 0
min 0
- 0
1 0
) 0
employed 0
. 0

SV 0
increased 0
less 0
in 0
SHR 0
, 0
mainly 0
reflecting 0
the 0
reduced 0
diastolic 0
compliance 0
of 0
the 0
hypertrophied 0
SHR 0
left 0
ventricle 0
and 0
the 0
consequent 0
rightward 0
shift 0
of 0
its 0
Frank 0
- 0
Starling 0
curve 0
. 0

The 0
carcass 0
of 0
a 0
great 0
horned 0
owl 0
( 0
Bubo 0
virginianus 0
) 0
, 0
which 0
had 0
been 0
found 0
moribund 0
in 0
southern 0
Ontario 0
, 0
was 0
presented 0
for 0
necropsy 0
. 0

The 0
inner 0
ears 0
were 0
exposed 0
by 0
microdissection 0
, 0
and 0
the 0
vestibular 0
sensory 0
regions 0
were 0
either 0
sectioned 0
and 0
studied 0
with 0
light 0
or 0
electron 0
microscopy 0
, 0
or 0
prepared 0
and 0
studied 0
with 0
the 0
surface 0
specimen 0
technique 0
. 0

Patulin 0
is 0
extracted 0
from 0
apple 0
butter 0
samples 0
with 0
ethyl 0
acetate 0
and 0
the 0
extract 0
is 0
cleaned 0
up 0
on 0
a 0
silica 0
gel 0
column 0
, 0
using 0
benzene 0
- 0
ethyl 0
acetate 0
( 0
75+25 0
) 0
as 0
the 0
eluant 0
. 0

Steroid 0
glucuronides 0
in 0
amniotic 0
fluid 0
at 0
term 0
. 0

The 0
matrix 0
surrounding 0
the 0
clusters 0
either 0
showed 0
a 0
normal 0
morphology 0
or 0
a 0
homogeneous 0
appearance 0
, 0
within 0
which 0
faint 0
cross 0
striations 0
but 0
no 0
distinctly 0
fibrillar 0
outlines 0
could 0
be 0
identified 0
. 0

Riboflavin 0
did 0
not 0
affect 0
the 0
percentage 0
of 0
aflatoxin 0
- 0
treated 0
animals 0
with 0
abnormal 0
urinary 0
excretion 0
patterns 0
, 0
but 0
did 0
increase 0
the 0
magnitude 0
of 0
the 0
disturbances 0
in 0
elimination 0
of 0
kynurenic 0
and 0
xanthurenic 0
acids 0
. 0

Polyglactin 0
910 0
suture 0
absorption 0
and 0
the 0
role 0
of 0
cellular 0
enzymes 0
. 0

The 0
incidence 0
of 0
DNCB 0
reactions 0
was 0
78 0
per 0
cent 0
for 0
Stage 0
I 0
and 0
II 0
cancers 0
( 0
37 0
patinets 0
) 0
, 0
73 0
per 0
cent 0
for 0
resectable 0
Stage 0
III 0
cancer 0
( 0
22 0
patients 0
) 0
, 0
and 0
66 0
per 0
cent 0
in 0
patients 0
with 0
unresectable 0
or 0
inoperable 0
Stage 0
III 0
cancer 0
. 0

Studies 0
of 0
lipoproteins 0
should 0
, 0
however 0
, 0
be 0
made 0
in 0
children 0
from 0
families 0
known 0
to 0
have 0
FH 0
or 0
early 0
coronary 0
heart 0
disease 0
. 0

Sixteen 0
other 0
normal 0
subjects 0
with 0
2 0
g 0
of 0
Metyrapone 0
are 0
best 0
responses 0
. 0

EEG 0
theta 0
waves 0
and 0
psychological 0
phenomena 0
: 0
a 0
review 0
and 0
analysis 0
. 0

REM 0
dream 0
content 0
was 0
scored 0
for 0
categories 0
suggesting 0
the 0
predominant 0
influence 0
of 0
the 0
left 0
hemisphere 0
, 0
e.g. 0
, 0
good 0
ego 0
functioning 0
, 0
verbalization 0
, 0
or 0
the 0
right 0
hemisphere 0
, 0
e.g. 0
, 0
music 0
, 0
spatial 0
salience 0
, 0
bizarreness 0
. 0

Innervation 0
of 0
the 0
ventral 0
diaphragm 0
of 0
the 0
locust 0
( 0
Locusta 0
migratoria 0
) 0
. 0

Ectopic 0
ACTH B-gene
syndrome 0
and 0
medullary 0
thyroid 0
carcinoma 0
. 0

A 0
striking 0
finding 0
in 0
all 0
of 0
the 0
studies 0
was 0
a 0
positive 0
correlation 0
between 0
PI 0
ACTH B-gene
and 0
MSH B-gene
contents 0
. 0

Chronic 0
hypophosphatemia 0
is 0
the 0
most 0
common 0
type 0
of 0
`` 0
resistant 0
'' 0
rickets 0
. 0

There 0
was 0
no 0
correlation 0
between 0
serum B-gene
LH I-gene
and 0
chronological 0
or 0
bone 0
age 0
in 0
this 0
age 0
group 0
, 0
which 0
suggests 0
that 0
the 0
correlation 0
found 0
is 0
not 0
due 0
to 0
age 0
- 0
related 0
parallel 0
phenomena 0
. 0

Molecular 0
neurochemistry 0
of 0
addictive 0
drugs 0
. 0

Efforts 0
were 0
made 0
to 0
determine 0
the 0
amount 0
of 0
time 0
required 0
for 0
kidney 0
lesions 0
to 0
develop 0
and 0
, 0
if 0
possible 0
, 0
to 0
delineate 0
the 0
potential 0
site 0
of 0
action 0
of 0
PBB 0
. 0

Effect 0
of 0
succimer 0
on 0
the 0
intensity 0
of 0
tricarboxylic B-gene
acid I-gene
dehydrogenase I-gene
reactions 0
in 0
the 0
brain 0
of 0
rats 0
poisoned 0
with 0
mercuric 0
chloride 0

Distribution 0
and 0
correlations 0
of 0
serum 0
uric 0
- 0
acid 0
in 0
two 0
French 0
adult 0
populations 0
: 0
13,885 0
men 0
and 0
6,861 0
women 0

The 0
incidence 0
of 0
hepatitis B-gene
B I-gene
antigen I-gene
following 0
transfusion 0
was 0
about 0
2.8 0
per 0
cent 0
. 0

Technetium 0
- 0
99m 0
stannous 0
pyrophosphate 0
myocardial 0
scintigrams 0
were 0
obtained 0
in 0
138 0
clinically 0
stable 0
patients 0
32.7 0
+/ 0
- 0
47.3 0
weeks 0
( 0
range 0
6 0
to 0
260 0
) 0
after 0
acute 0
myocardial 0
infarction 0
. 0

A 0
similar 0
phenomenon 0
has 0
been 0
reported 0
in 0
a 0
few 0
humans 0
. 0

The 0
decline 0
in 0
the 0
activity 0
of 0
cytochrome B-gene
oxidase I-gene
, 0
peroxidase B-gene
and 0
in 0
the 0
lipid 0
content 0
of 0
peripheral 0
neutrophils 0
was 0
followed 0
by 0
a 0
decrease 0
in 0
the 0
phagocytic 0
activity 0
. 0

Treatment 0
of 0
2 0
patients 0
with 0
pseudohypoparathyroidism 0
type 0
I 0
with 0
vitamin 0
- 0
D 0
- 0
3 0
and 0
1 0
alpha 0
- 0
Hydroxycholecalciferol 0
consecutively 0
resulted 0
in 0
a 0
nonuniform 0
response 0
with 0
regard 0
to 0
the 0
normalisation 0
of 0
serum 0
- 0
calcium 0
. 0

Workers 0
with 0
`` 0
sensitivity 0
'' 0
to 0
toluene 0
diisocyanate 0
( 0
TDI 0
) 0
studied 0
in 0
depth 0
in 0
an 0
attempt 0
to 0
determine 0
mechanisms 0
of 0
bronchial 0
hyperreactivity 0
. 0

Total 0
VO2 0
was 0
decreased 0
in 0
both 0
groups 0
during 0
severe 0
hypoxia 0
but 0
limb 0
VO2 0
was 0
maintained 0
in 0
the 0
beta 0
- 0
block 0
group 0
. 0
beta 0
- 0
Block 0
prevented 0
the 0
fall 0
in 0
total 0
and 0
limb 0
peripheral 0
resistance 0
seen 0
in 0
severe 0
hypoxia 0
but 0
did 0
not 0
alter 0
the 0
consistently 0
more 0
efficient 0
utilization 0
of 0
total 0
O2 0
delivery 0
shown 0
by 0
the 0
limb 0
in 0
comparison 0
to 0
the 0
whole 0
body 0
by 0
higher 0
O2 0
extraction 0
ratios 0
and 0
lower 0
venous 0
O2 0
pressure 0
. 0
beta B-gene
- I-gene
Vasodilator I-gene
receptors I-gene
evidently 0
played 0
an 0
active 0
part 0
in 0
the 0
vasodilatation 0
seen 0
during 0
severe 0
hypoxia 0
. 0

Phenobarbital 0
- 0
induced 0
alterations 0
in 0
the 0
metabolism 0
of 0
[ 0
3H 0
] 0
vitamin 0
D3 0
by 0
the 0
perfused 0
rachitic 0
rat 0
liver 0
in 0
vitro 0
. 0

Modulation 0
of 0
25 B-gene
- I-gene
hydroxyvitamin I-gene
D3 I-gene
- I-gene
24 I-gene
- I-gene
hydroxylase I-gene
by 0
aminophylline 0
: 0
a 0
cytochrome B-gene
P I-gene
- I-gene
450 I-gene
monooxygenase I-gene
system 0
. 0

In 0
both 0
these 0
respects 0
, 0
however 0
, 0
the 0
DBP B-gene
mRNA I-gene
resembles 0
the 0
late 0
messengers 0
of 0
SV40 0
and 0
polyoma 0
viruses 0
. 0

Effect 0
of 0
corticosteroid 0
- 0
containing 0
antirheumatic 0
combination 0
drugs 0
on 0
endogenous 0
ACTH B-gene
and 0
cortisol 0
production 0
. 0

Serum B-gene
ACTH I-gene
did 0
not 0
respond 0
to 0
insulin B-gene
and 0
metyrapone 0
. 0

Anatomy 0
of 0
the 0
RNA 0
and 0
gene 0
products 0
of 0
MC29 0
and 0
MH2 0
, 0
two 0
defective 0
avian 0
tumor 0
viruses 0
causing 0
acute 0
leukemia 0
and 0
carcinoma 0
: 0
evidence 0
for 0
a 0
new 0
class 0
of 0
transforming 0
genes 0
. 0

Bertioga 0
( 0
Guama 0
group 0
) 0
and 0
Anhembi 0
( 0
Bunyamwera 0
group 0
) 0
, 0
two 0
new 0
arboviruses 0
isolated 0
in 0
Sao 0
Paulo 0
, 0
Brazil 0
. 0

Gamma B-gene
glutamyl I-gene
transpeptidase I-gene
activity 0
was 0
increased 0
up 0
to 0
15 0
times 0
above 0
the 0
upper 0
normal 0
limit 0
in 0
children 0
, 0
who 0
received 0
aminopyrine 0
for 0
two 0
weeks 0
or 0
longer 0
. 0

XXI 0
. 0

A 0
gas 0
- 0
liquid 0
chromatographic 0
method 0
for 0
the 0
determination 0
of 0
p 0
- 0
chlorophenoxyisobutyric 0
( 0
CPIB 0
) 0
acid 0
in 0
blood 0
plasma 0
is 0
described 0
. 0

Dopamine B-gene
receptor I-gene
blockade 0
and 0
the 0
neuroleptics 0
, 0
a 0
crystallographic 0
study 0
. 0

V 0
. 0

A 0
rapid 0
fluorimetric 0
procedure 0
for 0
the 0
determination 0
of 0
the 0
fungicide 0
5 0
- 0
fluorocytosine 0
in 0
serum 0
is 0
described 0
. 0

The 0
'field 0
of 0
stress 0
' 0
of 0
the 0
supervisory 0
nurse 0

How 0
do 0
graduates 0
of 0
different 0
types 0
of 0
programs 0
perform 0
on 0
state 0
boards 0
? 0

Similarly 0
, 0
maternal B-gene
serum I-gene
somatomedin I-gene
A I-gene
was 0
significantly 0
reduced 0
in 0
rats 0
nursing 0
large 0
litters 0
. 0

The 0
sequences 0
following 0
the 0
X. 0
borealis 0
oocyte 0
and 0
somatic 0
5S B-gene
genes I-gene
are 0
identical 0
in 0
12 0
of 0
the 0
first 0
14 0
residues 0
and 0
contain 0
two 0
or 0
more 0
T 0
clusters 0
, 0
as 0
does 0
the 0
corresponding 0
region 0
of 0
X. B-gene
laevis I-gene
oocyte I-gene
5S I-gene
DNA I-gene
. 0

This 0
mechanism 0
is 0
not 0
due 0
to 0
the 0
observed 0
grain 0
boundary 0
precipitates 0
. 0

This 0
report 0
has 0
reviewed 0
some 0
of 0
the 0
reasons 0
for 0
treatment 0
failures 0
and 0
has 0
presented 0
a 0
philosophy 0
for 0
their 0
management 0
. 0

Diagnosis 0
and 0
treatment 0
planning 0
in 0
Class 0
II 0
, 0
division 0
2 0

Because 0
of 0
serious 0
infections 0
( 0
fever 0
larger 0
than 0
or 0
equal 0
to 0
101 0
degrees 0
F. 0
granulocytes 0
less 0
than 0
1,000/mm 0
, 0
3 0
and 0
hospitalization 0
) 0
and 0
1 0
drug 0
death 0
in 0
the 0
first 0
4 0
patients 0
, 0
oral 0
calcium 0
leucovorin 0
, 0
20 0
to 0
30 0
mg/m2 0
orally 0
, 0
was 0
given 0
2 0
days 0
after 0
methotrexate 0
in 0
subsequent 0
treatment 0
cycles 0
. 0

It 0
seems 0
that 0
the 0
way 0
in 0
which 0
drugs 0
modify 0
a 0
patient 0
's 0
serum 0
chemistry 0
may 0
be 0
used 0
to 0
assess 0
the 0
efficacy 0
with 0
which 0
they 0
control 0
the 0
inflammatory 0
process 0
. 0

Here 0
the 0
conventional 0
tests 0
clearly 0
pointed 0
to 0
the 0
presence 0
of 0
retrocochlear 0
disease 0
. 0

The 0
end 0
- 0
stage 0
or 0
involutional 0
phase 0
of 0
proliferative 0
diabetic 0
retinopathy 0
may 0
result 0
in 0
stabilization 0
of 0
vision 0
for 0
long 0
periods 0
of 0
time 0
. 0

On 0
the 0
basis 0
of 0
serum B-gene
alpha1AT I-gene
quantitation 0
, 0
newborn 0
infants 0
may 0
be 0
separated 0
into 0
two 0
groups 0
, 0
characterized 0
respectively 0
by 0
concentrations 0
above 0
or 0
below 0
150 0
mg 0
% 0
. 0

In 0
patients 0
who 0
were 0
not 0
vented 0
, 0
there 0
was 0
overall 0
significant 0
depression 0
of 0
function 0
( 0
67 0
+/ 0
- 0
5 0
% 0
of 0
control 0
; 0
range 0
, 0
91 0
- 0
- 0
45 0
% 0
, 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Changes 0
in 0
body 0
weight 0
and 0
agonistic 0
behavior 0
were 0
also 0
recorded 0
. 0

The 0
uterine 0
response 0
to 0
prostaglandin 0
E2 0
( 0
PGE2 0
) 0
and 0
prostaglandin 0
F2alpha 0
( 0
administered 0
by 0
intravenous 0
and 0
intrauterine 0
routes 0
) 0
was 0
evaluated 0
during 0
different 0
phases 0
of 0
the 0
menstrual 0
cycle 0
in 0
five 0
functionally 0
infertile 0
women 0
. 0

A 0
total 0
of 0
26 0
BCG 0
strains 0
, 0
out 0
of 0
them 0
10 0
Czechoslovak 0
strains 0
( 0
2 0
lyophilized 0
cultures 0
of 0
BCG 0
of 0
different 0
batch 0
, 0
6 0
strains 0
isolated 0
from 0
abscesses 0
of 0
children 0
after 0
BCG 0
- 0
vaccination 0
and 0
2 0
strains 0
from 0
fatal 0
cases 0
after 0
BCG 0
- 0
vaccination 0
) 0
and 0
16 0
strains 0
obtained 0
from 0
foreign 0
laboratories 0
, 0
were 0
used 0
. 0

High 0
levels 0
of 0
serum 0
calcitonin B-gene
were 0
found 0
in 0
patients 0
with 0
chronic 0
renal 0
failure 0
. 0

Detection 0
of 0
anti 0
- 0
lymphocyte 0
antibodies 0
using 0
the 0
immunoperoxidase B-gene
antiglobulin B-gene
technic 0
. 0

The 0
response 0
of 0
serum B-gene
GH I-gene
to 0
arginine 0
infusion 0
was 0
normal 0
, 0
while 0
that 0
to 0
insulin B-gene
- 0
induced 0
hypoglycemia 0
was 0
poor 0
. 0

The 0
mortality 0
rate 0
and 0
histopathological 0
features 0
of 0
Nocardia 0
asteroides 0
and 0
Nocardia 0
brasiliensis 0
infections 0
in 0
congenitally 0
athymic 0
( 0
nude 0
) 0
mice 0
of 0
ICR 0
and 0
C3H/eB 0
origins 0
were 0
quite 0
different 0
from 0
what 0
we 0
found 0
for 0
Swiss 0
white 0
mice 0
and 0
other 0
inbred 0
mouse 0
strains 0
( 0
namely 0
, 0
C57/BL/6J 0
, 0
New 0
Zealand 0
Black 0
, 0
BALB/c 0
, 0
CBA/LAC 0
, 0
and 0
C3H/eB 0
) 0
. 0

Williams 0
, 0
2 0
August 0
1977 0
. 0

Use 0
of 0
radioactive 0
isotopes 0
in 0
the 0
chemistry 0
of 0
proteins 0

( 0
Emeritus 0
) 0
John 0
Henri 0
Roosegaarde 0
Bisschop 0

Disrupted 0
vaccines 0
and 0
whole 0
- 0
virus 0
vaccines 0
containing 0
type B-gene
B I-gene
antigen I-gene
only 0
did 0
not 0
cause 0
significant 0
reactivity 0
. 0

255 0
- 0
61 0
. 0

Antenatal 0
diagnosis 0
of 0
haematological 0
disorders 0
- 0
- 0
'1978 0
' 0
. 0

Hepatic 0
oxygen 0
supply 0
and 0
selected 0
blood 0
parameters 0
were 0
recorded 0
in 0
fasted 0
male 0
rates 0
given 0
20 0
- 0
- 0
30 0
mg/kg 0
Escherichia B-gene
coli I-gene
endotoxin I-gene
intraperitoneally 0
. 0

Gonadal 0
dysfunction 0
in 0
patients 0
with 0
ataxia 0
telangiectasia 0
. 0

The 0
maximum 0
period 0
of 0
treatment 0
was 0
73 0
( 0
oral 0
) 0
, 0
73 0
( 0
intraperitoneal 0
) 0
or 0
75 0
( 0
dermal 0
) 0
weeks 0
. 0

A 0
study 0
of 0
the 0
comparative 0
efficacy 0
of 0
diflucortolone 0
valerate 0
0.3 0
% 0
ointment 0
and 0
clobetasol 0
propionate 0
0.05 0
% 0
ointment 0
. 0

Most 0
of 0
the 0
phenomena 0
of 0
azotaemic 0
osteodystrophy 0
are 0
encountered 0
in 0
simple 0
vitamin 0
D 0
deficiency 0
; 0
as 0
in 0
that 0
condition 0
, 0
deficiency 0
of 0
1,25 0
- 0
dihydroxycholecalciferol 0
may 0
be 0
of 0
primary 0
significance 0
in 0
causing 0
secondary 0
hyperparathyroidism 0
in 0
renal 0
failure 0
. 0

Basal 0
FSH B-gene
and 0
LH B-gene
levels 0
were 0
significantly 0
lower 0
in 0
addicts 0
; 0
after 0
GnRH B-gene
stimulation 0
the 0
addicts 0
' 0
FSH B-gene
and 0
LH B-gene
values 0
increased 0
but 0
not 0
significantly 0
compared 0
to 0
controls 0
. 0

Adriamycin 0
: 0
comparison 0
of 0
a 0
5 0
- 0
week 0
schedule 0
with 0
a 0
3 0
- 0
week 0
schedule 0
in 0
the 0
treatment 0
of 0
breast 0
cancer 0
. 0

Follow 0
- 0
up 0
controls 0
of 0
luteinizing B-gene
hormone I-gene
( 0
LH B-gene
) 0
, 0
follicle B-gene
stimulating I-gene
hormone I-gene
( 0
FSH B-gene
) 0
, 0
prolactin B-gene
( 0
HPRL B-gene
) 0
, 0
oestradiol 0
( 0
E2 0
) 0
, 0
progesterone 0
( 0
P 0
) 0
and 0
testosterone 0
( 0
T 0
) 0
in 0
the 0
catabolic 0
and 0
healing 0
phase 0
of 0
burn 0
disease 0
. 0

Renin B-gene
studies 0
performed 0
in 0
34 0
hypertensive 0
patients 0
and 0
in 0
a 0
control 0
group 0
of 0
11 0
recipients 0
showed 0
that 0
elevation 0
of 0
plasma B-gene
renin I-gene
activity 0
and 0
of 0
plasma 0
aldosterone 0
level 0
is 0
frequent 0
but 0
difficult 0
to 0
interpret 0
, 0
particularly 0
when 0
a 0
renal 0
artery 0
stenosis 0
is 0
observed 0
. 0

A 0
randomized 0
clinical 0
trial 0
in 0
sixty 0
- 0
two 0
adult 0
patients 0
suffering 0
from 0
typhoid 0
fever 0
, 0
proved 0
by 0
blood 0
and 0
marrow 0
culture 0
, 0
showed 0
that 0
amoxycillin 0
in 0
a 0
dosage 0
schedule 0
of 0
1 0
g 0
8 0
- 0
hourly 0
orally 0
for 0
fourteen 0
days 0
was 0
better 0
than 0
chloramphenicol 0
with 0
regard 0
to 0
clinical 0
and 0
temperature 0
response 0
and 0
in 0
respect 0
of 0
carriers 0
and 0
relapse 0
rates 0
. 0

202 0
- 0
8 0
. 0

Bone 0
marrow 0
transplantation 0
- 0
1979 0
. 0

In 0
this 0
article 0
, 0
the 0
clinical 0
actions 0
of 0
the 0
principal 0
dopamine B-gene
receptor I-gene
stimulating 0
agents 0
( 0
apomorphine 0
and 0
its 0
derivatives 0
; 0
piribedil 0
, 0
rye 0
- 0
ergot 0
derivatives 0
) 0
are 0
discussed 0
on 0
the 0
basis 0
of 0
their 0
biochemical 0
and 0
pharmacological 0
properties 0
. 0

The 0
unilateral 0
vestibular 0
hypofunction 0
. 0

Thus 0
, 0
the 0
inhibition 0
of 0
pepsin B-gene
in 0
human 0
gastric 0
juice 0
does 0
not 0
appear 0
to 0
have 0
a 0
major 0
influence 0
on 0
the 0
healing 0
of 0
duodenal 0
ulcer 0
. 0

The 0
IDF 0
standard 0
method 0
for 0
the 0
detection 0
of 0
penicillin 0
in 0
milk 0
is 0
not 0
suitable 0
for 0
the 0
detection 0
of 0
sulphonamide 0
residues 0
in 0
milk 0
. 0

Capsular 0
antigens 0
of 0
Staphylococcus 0
aureus 0

The 0
course 0
of 0
endotoxin 0
fever 0
remained 0
uninfluenced 0
by 0
ALS 0
. 0

2 0
new 0
Algerian 0
cases 0

Seventy 0
- 0
one 0
percent 0
of 0
patients 0
treated 0
with 0
ticarcillin 0
alone 0
responded 0
favorably 0
. 0

Accurate 0
pathologic 0
staging 0
identifies 0
patients 0
who 0
are 0
potentially 0
curable 0
with 0
radiotherapy 0
. 0

Inherent 0
hematology 0
of 0
old 0
age 0

Neomycin 0
is 0
fairly 0
effective 0
against 0
staphylococci 0
, 0
less 0
effective 0
against 0
streptococci 0
, 0
and 0
fairly 0
effective 0
against 0
gram 0
- 0
negative 0
intestinal 0
organisms 0
. 0

It 0
was 0
concluded 0
, 0
that 0
on 0
a 0
given 0
section 0
, 0
75,7 0
per 0
cent 0
of 0
the 0
trabeculae 0
were 0
in 0
contact 0
with 0
vascular 0
cavities 0
. 0

2 0
. 0

Changes 0
in 0
tissue 0
PCO2 0
were 0
less 0
dramatic 0
and 0
did 0
not 0
vary 0
significantly 0
from 0
those 0
recorded 0
in 0
venous 0
blood 0
. 0

Ultrasonic 0
evaluation 0
of 0
renal 0
calculi 0
. 0

Recognition 0
of 0
emphysema 0
was 0
poor 0
when 0
radiographs 0
of 0
inadequate 0
quality 0
were 0
included 0
( 0
anteroposterior 0
films 0
or 0
films 0
from 0
patients 0
with 0
acute 0
or 0
chronic 0
lung 0
disease 0
) 0
. 0

Isolation 0
of 0
T. 0
gambiense 0
strains 0
in 0
Zaire 0
and 0
their 0
adaptation 0
to 0
laboratory 0
animals 0

Pharmacokinetic 0
profile 0
of 0
clonazepam 0
in 0
rhesus 0
monkeys 0
. 0

Immunologic 0
mechanisms 0
in 0
chronic 0
brucellosis 0
in 0
humans 0
. 0

Intestinal 0
adaptation 0
( 0
first 0
of 0
two 0
parts 0
) 0
. 0

In 0
patients 0
who 0
had 0
received 0
no 0
previous 0
drug 0
treatment 0
, 0
log 0
baseline 0
plasma B-gene
renin I-gene
activity 0
and 0
change 0
in 0
mean 0
blood 0
pressure 0
after 0
SQ 0
20881 0
correlated 0
significantly 0
( 0
r 0
= 0
0.651 0
, 0
P 0
less 0
than 0
0.05 0
) 0
. 0

These 0
techniques 0
have 0
been 0
used 0
by 0
many 0
people 0
for 0
many 0
years 0
and 0
no 0
claim 0
is 0
being 0
made 0
for 0
any 0
innovation 0
in 0
this 0
regard 0
. 0

40 0
patients 0
with 0
chronic 0
osteomyelitis 0
were 0
treated 0
per 0
os 0
with 0
the 0
bactericidal 0
beta 0
- 0
lactam 0
- 0
antibiotic 0
cephalexin 0
during 0
3 0
to 0
60 0
weeks 0
. 0

A 0
total 0
of 0
57 0
patients 0
with 0
Hodgkin 0
's 0
disease 0
limited 0
to 0
above 0
the 0
diaphragm 0
( 0
Stages 0
I 0
and 0
II 0
, 0
A 0
and 0
B 0
) 0
were 0
treated 0
with 0
radiation 0
therapy 0
alone 0
at 0
the 0
University 0
of 0
Florida 0
between 0
1964 0
and 0
1974 0
. 0

Year 0
one 0
of 0
the 0
first 0
general 0
practitioner 0
medical 0
unit 0
in 0
the 0
greater 0
Glasgow 0
area 0
. 0

This 0
multiple 0
- 0
electrode 0
array 0
for 0
round 0
window 0
cochlear 0
implantation 0
is 0
a 0
robust 0
, 0
reliable 0
system 0
for 0
inserting 0
20 0
mm 0
along 0
the 0
scala 0
tympani 0
with 0
a 0
minimum 0
of 0
trauma 0
and 0
can 0
provide 0
for 0
bipolar 0
stimulation 0
. 0

As 0
authorized 0
by 0
the 0
World 0
Health 0
Organization 0
29th 0
Expert 0
Committee 0
on 0
Biological 0
Standardization 0
, 0
the 0
preparation 0
of 0
human B-gene
prolactin I-gene
in 0
ampoules 0
coded 0
75/504 0
has 0
been 0
established 0
as 0
the 0
International 0
Reference 0
Preparation 0
( 0
IRP 0
) 0
of 0
human B-gene
prolactin I-gene
for 0
immunoassay 0
. 0

i 0
. 0

Biliary 0
- 0
enteric 0
fistulas 0

Plasma 0
ion 0
changes 0
in 0
venous 0
blood 0
incubated 0
with 0
beta B-gene
receptor I-gene
blockers 0
and 0
subjected 0
to 0
tonometry 0
in 0
vitro 0
. 0

Such 0
marked 0
differences 0
are 0
found 0
occasionally 0
in 0
the 0
literature 0
: 0
heterophile 0
antibodies 0
against 0
bovine B-gene
gammaglobulin I-gene
are 0
regarded 0
as 0
responsible 0
for 0
the 0
interference 0
in 0
the 0
Sephadex 0
system 0
of 0
RIST 0
. 0

`` 0
Let 0
the 0
hundred 0
flowers 0
bloom 0
'' 0
. 0

Various 0
treatment 0
modalities 0
are 0
reviewed 0
in 0
the 0
context 0
of 0
the 0
psychology 0
as 0
well 0
as 0
the 0
physiology 0
of 0
severe 0
intractable 0
pain 0
. 0

Lethal 0
Tachmalcor 0
( 0
4 0
- 0
( 0
3' 0
- 0
diethylamino 0
- 0
2' 0
- 0
hydroxypropyl 0
) 0
- 0
ajmaline 0
) 0
poisoning 0
in 0
childhood 0

Ophthalmosonographic 0
evaluation 0
of 0
blood 0
flow 0
velocity 0
in 0
arteriocavernous 0
fistula 0

Serum 0
ferritin B-gene
concentration 0
and 0
bone 0
marrow 0
iron 0
stores 0
. 0

The 0
systolic 0
pressure 0
gradient 0
( 0
SPG 0
) 0
between 0
the 0
left 0
ventricle 0
( 0
LV 0
) 0
and 0
left 0
atrium 0
( 0
LA 0
) 0
was 0
obtained 0
from 0
high 0
- 0
fidelity 0
pressure 0
transducers 0
. 0

A 0
prospective 0
trail 0
comparing 0
hysterectomy 0
, 0
hysterectomy 0
plus 0
vaginal 0
radium 0
, 0
and 0
uterine 0
radium 0
plus 0
hysterectomy 0
in 0
stage 0
I 0
endometrial 0
carcinoma 0
. 0

On 0
the 0
basis 0
of 0
a 0
patient 0
's 0
report 0
of 0
one 0
inaccurate 0
Clinitemp 0
, 0
we 0
undertook 0
to 0
investigate 0
the 0
accuracy 0
of 0
this 0
thermometer 0
. 0

Cryoglobulinemia 0
in 0
Raynaud 0
's 0
syndrome 0

Data 0
were 0
processed 0
with 0
a 0
semi 0
- 0
automatic 0
computer 0
program 0
which 0
develops 0
an 0
averaged 0
- 0
volume 0
curve 0
from 0
an 0
assigned 0
LV 0
region 0
- 0
of 0
- 0
interest 0
. 0

The 0
preferential 0
serum B-gene
IgA I-gene
response 0
observed 0
in 0
the 0
patient 0
population 0
suggests 0
that 0
bronchial 0
associated 0
lymphoid 0
tissue 0
in 0
the 0
diseased 0
lung 0
is 0
an 0
important 0
source 0
of 0
circulating 0
IgA B-gene
. 0

Ultimate 0
strengthes 0
seem 0
to 0
be 0
reached 0
for 0
cast 0
cobalt 0
alloys 0
, 0
whereas 0
titanium 0
alloys 0
, 0
such 0
as 0
Ta 0
6 0
V 0
, 0
present 0
very 0
high 0
fatigue 0
limit 0
under 0
corrosion 0
. 0

The 0
effects 0
of 0
intracisternal 0
injection 0
( 0
i.c.i 0
. 0
) 0
of 0
clonidine 0
( 0
1 0
microgram 0
kg 0
- 0
1 0
) 0
on 0
blood 0
pressure 0
and 0
heart 0
rate 0
were 0
studied 0
in 0
conscious 0
rabbits 0
with 0
an 0
implanted 0
catheter 0
in 0
the 0
cisterna 0
magna 0
. 0

Platelet 0
number 0
and 0
life 0
span 0
were 0
determined 0
in 0
the 0
last 0
trimester 0
of 0
pregnancy 0
in 0
22 0
women 0
who 0
were 0
delivered 0
of 0
small 0
- 0
for 0
- 0
gestational 0
age 0
( 0
SGA 0
) 0
infants 0
and 0
in 0
21 0
women 0
with 0
infants 0
having 0
normal 0
birth 0
weights 0
. 0

Serial 0
measurements 0
of 0
total 0
serum 0
IgE B-gene
appears 0
to 0
be 0
a 0
useful 0
index 0
of 0
disease 0
activity 0
in 0
ABPA 0
. 0

In 0
the 0
8 0
patients 0
the 0
difference 0
betweent 0
he 0
mean 0
diastolic 0
values 0
of 0
delta 0
PU 0
and 0
delta 0
PM 0
was 0
- 0
0.54 0
+/ 0
- 0
1.0 0
( 0
SD 0
) 0
mmHg 0
. 0

A 0
rise 0
of 0
hemoglobin B-gene
concentration 0
accompanied 0
by 0
an 0
increase 0
of 0
the 0
total 0
iron 0
in 0
the 0
blood 0
serum 0
of 0
white 0
mice 0
was 0
found 0
under 0
oxygen 0
pressure 0
of 0
4 0
atm 0
for 0
an 0
hour 0
( 0
preconvulsive 0
state 0
) 0
and 0
6 0
atm 0
( 0
convulsive 0
state 0
) 0
. 0

Nernst 0
- 0
- 0
Planck 0
analog 0
equations 0
and 0
stationary 0
state 0
membrane 0
electric 0
potentials 0
. 0

Effects 0
of 0
methylene 0
chloride 0
, 0
trichloroethane 0
, 0
trichloroethylene 0
, 0
tetrachloroethylene 0
and 0
toluene 0
on 0
the 0
development 0
of 0
chick 0
embryos 0
. 0

Effect 0
of 0
intraventricular 0
administration 0
of 0
streptolysin B-gene
O I-gene
on 0
the 0
electroencephalogram 0
of 0
rabbits 0
. 0

In 0
this 0
situation 0
the 0
convlusion 0
threshold 0
for 0
the 0
8 0
substances 0
is 0
as 0
follows 0
: 0
pethidine 0
20 0
mg.kg 0
- 0
1 0
I.V. 0
, 0
piritramide 0
30 0
, 0
morphine 0
180 0
, 0
phenoperidine 0
4 0
, 0
R 0
39 0
209 0
5 0
, 0
fentanyl 0
4 0
, 0
sufentanil 0
4 0
and 0
R 0
34 0
995 0
10 0
mg.kg 0
- 0
1 0
I.V 0
. 0

The 0
biochemistry 0
of 0
amniotic 0
fluid 0
with 0
poor 0
fetal 0
growth 0
. 0

Roentgenographically 0
, 0
the 0
lesion 0
was 0
usually 0
a 0
well 0
- 0
defined 0
and 0
benign 0
appearing 0
one 0
, 0
either 0
purely 0
lytic 0
( 0
3 0
cases 0
) 0
or 0
with 0
central 0
radiodensity 0
( 0
2 0
cases 0
) 0
. 0

Effects 0
of 0
chronic 0
descending 0
tractotomy 0
on 0
the 0
response 0
patterns 0
of 0
neurons 0
in 0
the 0
trigeminal 0
nuclei 0
principalis 0
and 0
oralis 0
. 0

Efficacy 0
of 0
a 0
three 0
- 0
versus 0
a 0
five 0
- 0
week 0
alcohol 0
treatment 0
program 0
. 0

Resistance 0
to 0
the 0
simulated 0
physiologic 0
environment 0
was 0
tested 0
by 0
measured 0
retention 0
of 0
mechanical 0
properties 0
after 0
immersion 0
times 0
in 0
pseudo 0
- 0
extracellular 0
fluid 0
( 0
PECF 0
) 0
at 0
37 0
degrees 0
C 0
for 0
as 0
long 0
as 0
three 0
years 0
. 0

Isolated 0
calcaneal 0
tuberculous 0
osteomyelitis 0
. 0

It 0
is 0
concluded 0
that 0
opiate B-gene
receptors I-gene
bordering 0
the 0
fourth 0
cerebral 0
ventricle 0
mediate 0
the 0
cardiovascular 0
and 0
hypnotic 0
action 0
of 0
fentanyl 0
. 0

In 0
case 0
of 0
a 0
pathologically 0
convoluted 0
internal 0
carotid 0
the 0
common 0
carotid 0
artery 0
was 0
resected 0
with 0
an 0
end 0
- 0
to 0
- 0
end 0
anastomosis 0
. 0

This 0
expression 0
assumes 0
: 0
( 0
1 0
) 0
a 0
laminar 0
flow 0
regimen 0
during 0
expiration 0
, 0
and 0
( 0
2 0
) 0
a 0
constant 0
CT 0
value 0
over 0
the 0
range 0
of 0
VT 0
. 0

These 0
data 0
confirm 0
the 0
existence 0
of 0
hyperlipemic 0
abdominal 0
crisis 0
as 0
a 0
distinct 0
entity 0
and 0
testify 0
to 0
the 0
importance 0
of 0
recognizing 0
this 0
syndrome 0
in 0
order 0
to 0
avoid 0
the 0
occurrence 0
of 0
acute 0
pancreatitis 0
and 0
the 0
performance 0
of 0
unnecessary 0
and 0
potentially 0
harmful 0
surgery 0
. 0

In 0
addition 0
a 0
significant 0
Treatment 0
X 0
Strain 0
interaction 0
was 0
due 0
to 0
the 0
larger 0
defecation 0
numbers 0
displayed 0
by 0
the 0
taurine 0
- 0
injected 0
MR 0
rats 0
relative 0
to 0
the 0
saline 0
- 0
injected 0
MR 0
rats 0
. 0

Their 0
conduction 0
velocity 0
ranged 0
from 0
0.23 0
to 0
0.98 0
m/sec 0
( 0
group 0
C 0
) 0
. 0

The 0
failures 0
frequently 0
were 0
related 0
to 0
patient 0
intolerance 0
or 0
poor 0
mechanical 0
fit 0
and 0
occurred 0
in 0
the 0
first 0
few 0
days 0
or 0
first 0
few 0
months 0
after 0
insertion 0
. 0

The 0
major 0
urinary 0
metabolites 0
were 0
3 0
- 0
( 0
3 0
- 0
carboxyphenyl 0
) 0
- 0
5 0
- 0
hydroxymethyl 0
- 0
2 0
- 0
oxazolidinone 0
and 0
a 0
glucuronide 0
of 0
toloxatone 0
. 0

These 0
characteristics 0
indicated 0
the 0
pronounced 0
activity 0
of 0
collagenous 0
fiber 0
synthesis 0
and 0
the 0
matrix 0
of 0
the 0
osteoid 0
tissue 0
. 0

The 0
ventilation 0
did 0
not 0
increase 0
when 0
PACO2 0
was 0
increased 0
. 0

Carbohydrate 0
metabolism 0
and 0
the 0
semen 0
profile 0
: 0
glucose 0
, 0
insulin B-gene
, 0
and 0
sperm 0
studies 0
. 0

It 0
has 0
come 0
out 0
that 0
CAEC 0
is 0
between 0
CC 0
and 0
CIEC 0
and 0
that 0
attacks 0
of 0
biliary 0
fever 0
and 0
high 0
levels 0
of 0
alkaline B-gene
phosphatase I-gene
and 0
transaminases 0
in 0
the 0
serum 0
are 0
the 0
helpful 0
findings 0
for 0
preoperative 0
diagnosis 0
. 0

The 0
sub 0
- 0
acute 0
inhalation 0
toxicity 0
of 0
furfural 0
was 0
studied 0
in 0
Syrian 0
golden 0
hamsters 0
. 0

Changes 0
of 0
thirtynine 0
serum 0
protein 0
components 0
following 0
surgical 0
stress 0
. 0

These 0
differences 0
are 0
smaller 0
than 0
those 0
described 0
in 0
standard 0
textbooks 0
. 0

A 0
study 0
of 0
the 0
E.O.R.T.C 0
. 0

The 0
present 0
study 0
examined 0
the 0
dependence 0
of 0
difference 0
tone 0
level 0
[ 0
L 0
( 0
f2 0
- 0
f1 0
) 0
] 0
on 0
the 0
following 0
parameters 0
of 0
the 0
two 0
- 0
tone 0
input 0
: 0
f1 0
, 0
f2/f1 0
( 0
f2 0
greater 0
than 0
f1 0
) 0
, 0
L1 0
, 0
L2 0
, 0
and 0
L1 0
= 0
L2 0
. 0

An 0
intravenous 0
preparation 0
of 0
doxycycline 0
( 0
DOTC 0
, 0
Vibramycin 0
'Pfizer 0
' 0
) 0
, 0
a 0
long 0
- 0
lasting 0
tetracycline 0
, 0
was 0
administered 0
mainly 0
by 0
drip 0
infusion 0
for 0
a 0
series 0
of 0
study 0
in 0
the 0
pediatrics 0
field 0
, 0
and 0
the 0
results 0
were 0
as 0
follows 0
: 0
1 0
) 0
DOTC 0
( 0
100 0
mg 0
) 0
was 0
dissolved 0
in 0
a 0
100 0
ml 0
of 0
glucose 0
solution 0
and 0
2 0
- 0
- 0
3 0
mg/kg 0
was 0
administered 0
intravenously 0
. 0

5 0
) 0
Before 0
and 0
ten 0
days 0
after 0
DOTC 0
infusion 0
, 0
laboratory 0
tests 0
for 0
liver 0
and 0
renal 0
functions 0
and 0
blood 0
were 0
performed 0
. 0

Structural 0
characteristics 0
of 0
the 0
erythrocyte 0
membrane 0
, 0
peroxidation 0
processes 0
and 0
antioxidant 0
function 0
in 0
children 0
with 0
diffuse 0
glomerulonephritis 0

The 0
enteric 0
route 0
is 0
the 0
principal 0
mode 0
of 0
transmission 0
for 0
hepatitis 0
A 0
, 0
but 0
maximal 0
levels 0
of 0
hepatitis 0
A 0
virus 0
excretion 0
occur 0
before 0
the 0
onset 0
of 0
jaundice 0
. 0

All 0
13 0
patients 0
showed 0
endoscopic 0
evidence 0
of 0
oesophagitis 0
, 0
moderate 0
in 0
4 0
and 0
severe 0
in 0
9 0
. 0

Urinary 0
excretion 0
of 0
oestrone 0
, 0
oestradiol 0
- 0
17 0
beta 0
and 0
oestriol 0
in 0
pregnancies 0
complicated 0
by 0
steroid B-gene
sulphatase I-gene
deficiency 0
. 0

Both 0
reduced 0
spontaneous 0
locomotor 0
activity 0
in 0
mice 0
, 0
protected 0
them 0
from 0
death 0
from 0
amphetamine 0
induced 0
toxicity 0
, 0
prolonged 0
hexobarbitone 0
sleeping 0
time 0
and 0
caused 0
a 0
depletion 0
of 0
catecholamines 0
from 0
various 0
organs 0
of 0
the 0
rat 0
. 0

On 0
the 0
role 0
of 0
transferrin B-gene
in 0
the 0
uptake 0
of 0
gallium 0
by 0
tumor 0
cells 0
. 0

Irradiation 0
of 0
human 0
blood 0
platelets 0
with 0
UV 0
- 0
A 0
in 0
vitro 0
impairs 0
their 0
ability 0
to 0
aggregate 0
after 0
challenge 0
with 0
collagen B-gene
. 0

With 0
certain 0
exceptions 0
the 0
method 0
was 0
considered 0
suitable 0
in 0
the 0
routine 0
intravenous 0
cholangiography 0
. 0

Following 0
the 0
satisfactory 0
results 0
and 0
taking 0
into 0
account 0
that 0
the 0
complications 0
had 0
reduced 0
to 0
a 0
very 0
low 0
rate 0
( 0
in 0
2 0
cases 0
lead 0
tip 0
displacement 0
and 0
pouch 0
haematoma 0
occurred 0
respectively 0
) 0
, 0
the 0
Authors 0
consider 0
the 0
adopted 0
method 0
an 0
useful 0
approach 0
for 0
PMK 0
implantation 0
particularly 0
when 0
the 0
use 0
of 0
the 0
vena 0
cephalica 0
is 0
deemed 0
impossible 0
. 0

When 0
two 0
determinations 0
were 0
performed 0
on 0
12 0
samples 0
of 0
plasma 0
taken 0
from 0
normal 0
adults 0
in 0
October 0
, 0
the 0
values 0
were 0
22.6 0
+/ 0
- 0
4.8 0
and 0
21.0 0
+/ 0
- 0
3.6 0
( 0
mean 0
+/ 0
- 0
SD 0
) 0
ng/ml 0
, 0
respectively 0
. 0

The 0
six 0
commonest 0
causes 0
of 0
death 0
varied 0
in 0
the 0
three 0
ethnic 0
groups 0
. 0

Although 0
Grice 0
's 0
operation 0
has 0
been 0
used 0
all 0
over 0
the 0
world 0
, 0
no 0
systematic 0
account 0
of 0
it 0
has 0
been 0
found 0
in 0
the 0
literature 0
( 0
including 0
publications 0
dealing 0
with 0
technique 0
) 0
, 0
which 0
presents 0
it 0
in 0
terms 0
related 0
to 0
the 0
basic 0
`` 0
classical 0
'' 0
principles 0
on 0
which 0
the 0
operation 0
was 0
conceived 0
. 0

( 0
5 0
) 0
No 0
changes 0
were 0
observed 0
in 0
the 0
gastric 0
venous 0
blood 0
flow 0
by 0
continuous 0
intravenous 0
injection 0
of 0
cimetidine 0
, 0
but 0
by 0
rapid 0
injection 0
both 0
the 0
flow 0
was 0
augmented 0
and 0
the 0
systemic 0
blood 0
pressure 0
decreased 0
transiently 0
. 0

Study 0
on 0
re 0
- 0
establishment 0
of 0
ovulation 0
after 0
termination 0
of 0
sex 0
- 0
steroidal 0
treatment 0
- 0
- 0
compared 0
with 0
re 0
- 0
appearance 0
of 0
ovulation 0
after 0
abortion 0
and 0
premature 0
delivery 0
. 0

Pharmacokinetics 0
of 0
Carbamazepine 0
in 0
man 0
: 0
a 0
review 0
. 0

Of 0
the 0
compounds 0
tested 0
, 0
alpha 0
- 0
( 0
3 0
- 0
methyl 0
- 0
2 0
- 0
quinoxalinyl 0
) 0
- 0
N 0
- 0
methylnitrone 0
1,4 0
- 0
dioxide 0
( 0
2 0
) 0
was 0
the 0
most 0
active 0
agent 0
in 0
vivo 0
against 0
the 0
gram 0
- 0
negative 0
and 0
the 0
gram 0
- 0
positive 0
organisms 0
. 0

Changes 0
in 0
ionic 0
content 0
of 0
the 0
mucous 0
suggest 0
that 0
cholinergic 0
mechanisms 0
affect 0
pressure 0
in 0
the 0
excretory 0
duct 0
of 0
the 0
gland 0
. 0

Calves 0
fed 0
MCT 0
- 0
milk 0
had 0
significantly 0
lower 0
blood 0
cholesterol 0
than 0
calves 0
fed 0
T 0
- 0
or 0
SBO 0
- 0
milk 0
. 0

Delayed 0
mortality 0
of 0
mice 0
following 0
inhalation 0
of 0
acute 0
doses 0
of 0
CH2O 0
, 0
SO2Cl2 0
, 0
and 0
Br2 0
. 0

Guinea 0
pigs 0
weighing 0
300 0
approximately 0
350 0
g 0
were 0
used 0
. 0

Under 0
halothane 0
anesthesia 0
, 0
the 0
flow 0
pneumocardiogram 0
( 0
PnCG 0
) 0
and 0
its 0
time 0
derivative 0
( 0
acceleration 0
pneumocardiogram 0
or 0
dPn/dt 0
) 0
were 0
transduced 0
during 0
apnea 0
by 0
a 0
small 0
high 0
- 0
gain 0
pneumotachograph 0
. 0

Sensory 0
kindling 0
: 0
implications 0
for 0
development 0
of 0
sensory 0
prostheses 0
. 0

It 0
is 0
concluded 0
that 0
stereotypy 0
can 0
be 0
evoked 0
also 0
in 0
the 0
case 0
when 0
the 0
striatal 0
dopaminergic 0
tone 0
is 0
normal 0
or 0
even 0
below 0
normal 0
: 0
it 0
is 0
the 0
equilibrium 0
of 0
the 0
striatal 0
cholinergic 0
- 0
dopaminergic 0
systems 0
which 0
must 0
be 0
shifted 0
towards 0
dopamine 0
, 0
which 0
is 0
necessary 0
for 0
the 0
development 0
of 0
this 0
behavioral 0
manifestation 0
. 0

None 0
of 0
the 0
cystometrograms 0
showed 0
uninhibited 0
detrusor 0
contractions 0
. 0

In 0
the 0
duodenum 0
a 0
small 0
part 0
of 0
the 0
administered 0
dose 0
was 0
transformed 0
to 0
3H 0
- 0
alpha 0
- 0
acetyldigoxin 0
. 0

Functional 0
effects 0
following 0
subacute 0
administration 0
. 0

Treatment 0
of 0
Graves 0
' 0
disease 0
. 0

Although 0
it 0
has 0
been 0
shown 0
that 0
it 0
is 0
possible 0
to 0
use 0
orally 0
administered 0
testosterone 0
to 0
maintain 0
se 0
- 0
T 0
levels 0
in 0
the 0
normal 0
male 0
range 0
, 0
the 0
convenience 0
to 0
the 0
patient 0
must 0
be 0
balanced 0
against 0
the 0
cost 0
and 0
possible 0
side 0
effects 0
of 0
the 0
large 0
doses 0
required 0
. 0

Contrary 0
to 0
1,8 0
- 0
dihydroxy 0
- 0
9 0
- 0
anthrone 0
, 0
1,8,9 0
- 0
triacetoxyanthracene 0
and 0
1,8 0
- 0
diacetoxy 0
- 0
9 0
- 0
anthrone 0
are 0
effective 0
against 0
psoriatic 0
lesions 0
without 0
accompanying 0
inflammations 0
of 0
the 0
skin 0
. 0

Etiopathogenetic 0
and 0
therapeutic 0
problems 0
in 0
acute 0
orbital 0
inflammation 0

Nursing 0
of 0
patients 0
with 0
gynecological 0
diseases 0

We 0
measured 0
basal 0
plasma 0
prolactin B-gene
concentrations 0
( 0
in 0
samples 0
obtained 0
during 0
the 0
early 0
follicular 0
phase 0
) 0
in 0
25 0
normal 0
( 0
control 0
) 0
women 0
and 0
in 0
a 0
similar 0
group 0
of 0
40 0
patients 0
with 0
a 0
long 0
- 0
standing 0
history 0
of 0
infertility 0
. 0

Ovarian 0
allotransplantation 0
in 0
human 0
. 0

Allergic 0
reaction 0
to 0
Patent 0
Blue 0
Violet 0
during 0
lymphography 0
. 0

Screening 0
of 0
asthma 0
patients 0
by 0
determination 0
of 0
IgE B-gene
and 0
by 0
comprehension 0
of 0
spectrum 0
of 0
allergospecific B-gene
IgE I-gene
antibodies I-gene

The 0
induction 0
of 0
seizures 0
in 0
`` 0
Papio 0
papio 0
'' 0
following 0
allylglycine 0
alone 0
or 0
in 0
combination 0
with 0
intermittent 0
photic 0
stimulation 0

A 0
highly 0
significant 0
correlation 0
was 0
found 0
between 0
the 0
presence 0
of 0
fibrinolytic 0
degradation 0
products 0
( 0
FDP 0
) 0
and 0
the 0
incidence 0
of 0
nephropathy 0
and 0
renal 0
insufficiency 0
, 0
as 0
well 0
as 0
between 0
the 0
presence 0
of 0
fibrin B-gene
monomers I-gene
( 0
Godal 0
's 0
ethanol 0
- 0
gelification 0
test 0
) 0
and 0
the 0
evolutive 0
signs 0
of 0
the 0
primary 0
disease 0
( 0
fever 0
, 0
accelerated 0
ESR 0
) 0
. 0

One 0
- 0
third 0
of 0
the 0
men 0
with 0
azoospermia 0
and 0
with 0
sperm 0
density 0
of 0
less 0
than 0
10 0
million 0
had 0
marked 0
FSH B-gene
elevation 0
and 0
our 0
experience 0
confirms 0
the 0
work 0
of 0
others 0
that 0
this 0
indicates 0
a 0
poor 0
prognosis 0
. 0

In 0
girls 0
prolactin B-gene
levels 0
rise 0
at 0
stage 0
2 0
, 0
and 0
are 0
higher 0
after 0
menarche 0
; 0
in 0
boys 0
there 0
is 0
no 0
change 0
in 0
prolactin B-gene
levels 0
. 0

It 0
was 0
concluded 0
that 0
both 0
of 0
these 0
surgical 0
procedures 0
were 0
as 0
effective 0
as 0
pinealectomy 0
in 0
reversing 0
the 0
pineal 0
- 0
induced 0
alterations 0
in 0
the 0
reproductive 0
physiology 0
of 0
the 0
blind 0
- 0
anosmic 0
female 0
rat 0
. 0

2 0
cases 0
of 0
toxic 0
lymphomononucleosis 0

Such 0
an 0
hemoglobin B-gene
solution 0
was 0
shown 0
to 0
exhibit 0
a 0
high 0
affinity 0
for 0
oxygen 0
and 0
a 0
low 0
Bohr 0
effect 0
( 0
assessed 0
from 0
the 0
delta 0
log 0
Po2/delta 0
pH 0
ratio 0
) 0
. 0

A 0
one 0
- 0
week 0
ulcer 0
therapy 0
with 0
atropine 0
and 0
Vikalin 0
( 0
Roter 0
) 0
led 0
to 0
a 0
significant 0
( 0
p 0
less 0
than 0
0.01 0
) 0
reduction 0
of 0
the 0
nocturnal 0
proteolytic 0
activity 0
. 0

In 0
one 0
patient 0
with 0
severe 0
diarrhea 0
the 0
estriol 0
concentration 0
in 0
serum 0
was 0
low 0
until 0
the 0
intestinal 0
function 0
normalised 0
and 0
the 0
estriol 0
concentration 0
went 0
up 0
exactly 0
when 0
the 0
diarrhea 0
stopped 0
. 0

Serum 0
levels 0
of 0
IgG B-gene
and 0
IgM B-gene
were 0
also 0
raised 0
, 0
but 0
contrary 0
to 0
the 0
findings 0
of 0
other 0
observers 0
IgA B-gene
levels 0
were 0
normal 0
. 0

Experimental 0
ischemic 0
heart 0
disease 0
induced 0
by 0
thromboxane 0
A2 0
in 0
rabbits 0
. 0

Vitrectomy 0
in 0
ocular 0
traumatology 0

To 0
study 0
the 0
sensitivity 0
of 0
some 0
central 0
brain 0
structures 0
to 0
the 0
action 0
of 0
an 0
electromagnetic 0
field 0
of 0
decimeter 0
waves 0
( 0
EMF 0
of 0
DW 0
) 0
a 0
dynamic 0
investigation 0
of 0
single 0
unit 0
activity 0
was 0
undertaken 0
. 0

No 0
systematic 0
L 0
- 0
R 0
differences 0
were 0
observed 0
. 0

A 0
decrease 0
of 0
the 0
lysozyme B-gene
activity 0
coincided 0
with 0
the 0
clinical 0
improvement 0
of 0
the 0
bacterial 0
meningitis 0
. 0

This 0
implies 0
that 0
the 0
groups 0
do 0
not 0
just 0
differ 0
along 0
one 0
dimension 0
, 0
but 0
along 0
three 0
dimensions 0
. 0

Deep 0
tans 0
were 0
induced 0
over 0
the 0
backs 0
of 0
volunteers 0
with 0
repeated 0
exposure 0
to 0
longwave 0
ultraviolet 0
radiation 0
( 0
UV 0
- 0
A 0
) 0
. 0

1 0
The 0
effects 0
in 0
normal 0
subjects 0
of 0
a 0
single 0
oral 0
dose 0
of 0
Motival 0
( 0
one 0
tablet 0
, 0
containing 0
fluphenazine 0
0.5 0
mg 0
and 0
nortriptyline 0
10 0
mg 0
) 0
on 0
the 0
contingent 0
negative 0
variation 0
( 0
CNV 0
) 0
, 0
reaction 0
time 0
, 0
heart 0
rate 0
, 0
blood 0
pressure 0
and 0
self 0
- 0
rating 0
scales 0
for 0
alertness 0
, 0
anxiety 0
, 0
tension 0
, 0
detachment 0
and 0
depression 0
were 0
compared 0
with 0
those 0
of 0
diazepam 0
( 0
5 0
mg 0
and 0
7.5 0
mg 0
) 0
and 0
placebo 0
or 0
propranolol 0
( 0
60 0
mg 0
) 0
. 0

Stress 0
effects 0
on 0
affiliation 0
preferences 0
among 0
subjects 0
possessing 0
the 0
type 0
A 0
coronary 0
- 0
prone 0
behavior 0
pattern 0
. 0

These 0
show 0
that 0
the 0
collagen B-gene
in 0
this 0
tissue 0
is 0
modified 0
compared 0
with 0
that 0
in 0
tendon 0
. 0

Smoking 0
was 0
regarded 0
as 0
the 0
major 0
contribution 0
to 0
pulmonary 0
dysfunction 0
. 0

The 0
malignity 0
of 0
nevoid 0
lentigo 0
. 0

Elimination 0
of 0
bagassosis 0
in 0
Louisiana 0
paper 0
manufacturing 0
plant 0
workers 0
. 0

These 0
responses 0
were 0
compared 0
with 0
others 0
in 0
the 0
same 0
subjects 0
under 0
the 0
same 0
conditions 0
and 0
it 0
was 0
concluded 0
that 0
the 0
antihypertensive 0
effect 0
of 0
labetalol 0
is 0
explained 0
by 0
concurrent 0
blockade 0
of 0
alpha B-gene
- I-gene
and I-gene
beta I-gene
- I-gene
adrenoceptors I-gene
. 0

Diuretics 0
: 0
basic 0
clinical 0
pharmacology 0
and 0
therapeutic 0
use 0
. 0

Three 0
patients 0
with 0
four 0
renoureteral 0
units 0
have 0
undergone 0
single 0
- 0
stage 0
reconstruction 0
involving 0
ureteroureterostomy 0
and 0
ipsilateral 0
ureteroneocystostomy 0
following 0
temporary 0
loop 0
cutaneous 0
ureterostomy 0
. 0

Evaluation 0
of 0
the 0
Du 0
Pont 0
aca 0
ammonia 0
procedure 0
. 0

Internally 0
oriented 0
patients 0
' 0
scores 0
on 0
Rotter 0
's 0
Internal 0
- 0
External 0
Locus 0
of 0
Control 0
Scale 0
remained 0
the 0
same 0
over 0
treatment 0
but 0
those 0
of 0
externally 0
oriented 0
patients 0
shifted 0
toward 0
greater 0
internal 0
control 0
. 0

Action 0
of 0
strontium 0
- 0
90 0
and 0
metaphos 0
on 0
Cyprinus 0
carpio 0

Kodak 0
XV 0
- 0
2 0
film 0
is 0
wrapped 0
around 0
a 0
cylindrical 0
water 0
- 0
filled 0
phantom 0
and 0
the 0
dose 0
distribution 0
is 0
recorded 0
. 0

Diagnosis 0
and 0
differential 0
diagnosis 0

The 0
multiple 0
factors 0
affecting 0
plasma 0
renin B-gene
activity 0
in 0
essential 0
hypertension 0
. 0

Cortisone 0
induced 0
bone 0
changes 0
and 0
its 0
response 0
to 0
lipid 0
clearing 0
agents 0
. 0

2 0
) 0
The 0
time 0
- 0
sharing 0
principle 0
was 0
applied 0
to 0
gain 0
high 0
stability 0
. 0

When 0
blood 0
samples 0
of 0
patients 0
with 0
hyperbilirubinemia 0
were 0
analyzed 0
, 0
direct 0
measurement 0
of 0
ZPP 0
by 0
this 0
fluorimeter 0
yielded 0
significantly 0
higher 0
levels 0
than 0
did 0
an 0
alternate 0
extraction 0
method 0
. 0

Delayed 0
hypersensitivity 0
in 0
man 0
: 0
effects 0
of 0
systemic 0
anticoagulation 0
. 0

In 0
three 0
of 0
the 0
seven 0
, 0
inhalation 0
of 0
2 0
ml 0
normal 0
saline 0
produced 0
FEV1 0
falls 0
of 0
25 0
% 0
to 0
30 0
% 0
, 0
but 0
these 0
falls 0
were 0
not 0
as 0
great 0
as 0
each 0
subject 0
's 0
reactions 0
to 0
the 0
test 0
solutions 0
. 0

Experimental 0
studies 0
on 0
virus 0
excretion 0
and 0
non 0
- 0
arthropod 0
transmission 0
. 0

Potency 0
of 0
enflurane 0
in 0
dogs 0
: 0
comparison 0
with 0
halothane 0
and 0
isoflurane 0
. 0

Prevention 0
of 0
acute 0
paraquat 0
toxicity 0
in 0
rats 0
by 0
superoxide B-gene
dismutase I-gene
. 0

Measurement 0
of 0
magnesium 0
absorption 0
in 0
man 0
using 0
stable 0
26Mg 0
as 0
a 0
tracer 0
. 0

Increased 0
urinary 0
riboflavin 0
excretion 0
resulting 0
from 0
boric 0
acid 0
ingestion 0
. 0

Radionuclide 0
angiography 0
and 0
static 0
whole 0
body 0
imaging 0
performed 0
with 0
technetium 0
- 0
99m 0
- 0
labeled 0
particulates 0
can 0
clearly 0
demonstrate 0
differential 0
shunting 0
in 0
patients 0
with 0
patent 0
ductus 0
arteriosus 0
( 0
PDA 0
) 0
with 0
Eisenmenger 0
physiology 0
. 0

Looming 0
detectors 0
in 0
the 0
human 0
visual 0
pathway 0
. 0

Escherichia 0
of 0
a 0
single 0
sero 0
- 0
anzymatic 0
type 0
( 0
06a6b 0
: 0
K13 0
: 0
H1 0
) 0
were 0
isolated 0
in 0
a 0
group 0
affection 0
. 0

The 0
method 0
described 0
may 0
prove 0
useful 0
in 0
studying 0
the 0
physiology 0
of 0
the 0
nasal 0
cycle 0
. 0

At 0
the 0
same 0
time 0
we 0
obtained 0
easily 0
understandable 0
EEG 0
- 0
information 0
which 0
has 0
never 0
previously 0
been 0
available 0
to 0
us 0
. 0

Analysis 0
of 0
liver 0
biopsy 0
specimens 0
from 0
patients 0
with 0
hepatitis 0
showed 0
a 0
large 0
variation 0
in 0
the 0
mean 0
iron 0
content 0
of 0
the 0
liver 0
ferritin B-gene
molecules 0
. 0

Female 0
mice 0
were 0
significantly 0
more 0
resistant 0
to 0
infection 0
than 0
males 0
. 0

During 0
the 0
following 0
9 0
1/2 0
years 0
three 0
sequential 0
liver 0
biopsies 0
were 0
performed 0
. 0

Angiotensin B-gene
effect 0
in 0
the 0
human 0
kidney 0
. 0

Procion 0
yellow 0
dye 0
was 0
injected 0
intracellularly 0
into 0
large 0
auditory 0
fibers 0
of 0
goldfish 0
to 0
investigate 0
the 0
relationship 0
between 0
the 0
response 0
type 0
of 0
these 0
fibers 0
and 0
their 0
site 0
of 0
termination 0
in 0
the 0
saccular 0
macula 0
. 0

Incidental 0
findings 0
in 0
the 0
epidermis 0
and 0
in 0
the 0
intraepidermal 0
eccrine 0
sweat 0
duct 0
units 0
. 0

Silicosis 0
mortality 0

These 0
consisted 0
of 0
beading 0
and 0
strictures 0
mainly 0
of 0
the 0
intrahepatic 0
biliary 0
tree 0
( 0
IHB 0
) 0
. 0

Pentane 0
and 0
ethane 0
, 0
which 0
arise 0
during 0
lipid 0
peroxidation 0
in 0
vivo 0
, 0
were 0
measured 0
by 0
gas 0
chromatography 0
in 0
breath 0
samples 0
of 0
rats 0
fed 0
for 0
8 0
weeks 0
a 0
vitamin 0
E 0
- 0
deficient 0
diet 0
to 0
which 0
had 0
been 0
added 0
0 0
, 0
11 0
, 0
or 0
40 0
IU 0
vitamin 0
E 0
acetate 0
per 0
kg 0
. 0

Thromboplastic 0
and 0
fibrynolytic 0
activity 0
of 0
the 0
blood 0
after 0
administration 0
of 0
intralipid 0
in 0
men 0
with 0
history 0
of 0
myocardial 0
infarction 0
up 0
to 0
45 0
year 0
of 0
life 0

The 0
authors 0
report 0
the 0
clinicopathologic 0
findings 0
in 0
four 0
cases 0
of 0
adult 0
women 0
with 0
rhabdomyosarcomas 0
that 0
originated 0
in 0
the 0
endometrium 0
or 0
cervix 0
, 0
or 0
both 0
. 0

The 0
effect 0
of 0
pure 0
natural 0
porcine B-gene
secretin I-gene
on 0
endocrine 0
and 0
exocrine 0
pancreatic 0
secretion 0
was 0
studied 0
in 0
the 0
totally 0
isolated 0
perfused 0
porcine 0
pancreas 0
. 0

Biometric 0
analysis 0
of 0
intraocular 0
lens 0
power 0
required 0
to 0
produce 0
emmetropia 0
: 0
results 0
of 0
450 0
implants 0
. 0

Urine 0
antibodies 0
could 0
not 0
be 0
demonstrated 0
in 0
any 0
other 0
cases 0
. 0

Althoug 0
RBF 0
tended 0
to 0
increase 0
after 0
the 0
therapy 0
, 0
there 0
was 0
no 0
statistically 0
significant 0
change 0
in 0
RBF 0
, 0
GFR 0
and 0
cardiac 0
output 0
. 0

99mTc 0
phytate 0
, 0
198Au 0
colloid 0
, 0
and 0
99mTc 0
antimony 0
sulfide 0
have 0
been 0
used 0
; 0
the 0
last 0
appears 0
to 0
have 0
been 0
the 0
most 0
satisfactory 0
. 0

Six 0
patients 0
with 0
glomerulonephritis 0
in 0
association 0
with 0
a 0
ventriculovascular 0
shunt 0
were 0
treated 0
with 0
three 0
basic 0
modes 0
of 0
therapy 0
. 0

The 0
mass 0
of 0
UO2 0
in 0
the 0
extrapulmonary 0
bronchi 0
and 0
first 0
bifurcation 0
decreased 0
more 0
slowly 0
over 0
0 0
- 0
- 0
8 0
d 0
after 0
inhalation 0
than 0
the 0
corresponding 0
mass 0
on 0
the 0
trachea 0
. 0

Synovial 0
cysts 0
of 0
the 0
hip 0
joint 0

A 0
suspected 0
hypothalamic 0
dysfunction 0
and 0
a 0
slightly 0
impaired 0
pituitary 0
function 0
manifested 0
as 0
GH B-gene
deficiency 0
were 0
their 0
common 0
endocrinological 0
features 0
. 0

A 0
sharp 0
outbreak 0
of 0
influenza 0
A 0
occurred 0
on 0
the 0
base 0
during 0
February 0
that 0
was 0
due 0
to 0
an 0
A/Texas/1/77 0
- 0
like 0
virus 0
, 0
a 0
variant 0
of 0
the 0
A/Victoria/3/75 0
prototpye 0
. 0

Because 0
decreases 0
in 0
the 0
disfluency 0
rates 0
of 0
stutterers 0
were 0
observed 0
during 0
the 0
presentation 0
of 0
all 0
three 0
stimulus 0
words 0
, 0
the 0
data 0
failed 0
to 0
support 0
the 0
operant 0
model 0
. 0

Effect 0
of 0
time 0
and 0
dose 0
on 0
alterations 0
following 0
inhalation 0
of 0
plutonium 0
- 0
239 0
dioxide 0
aerosol 0
in 0
rat 0
. 0

In 0
biopsies 0
CK B-gene
- I-gene
MB I-gene
fraction 0
of 0
total 0
myocardial 0
CPK B-gene
was 0
37 0
% 0
, 0
the 0
total B-gene
- I-gene
CPK I-gene
activity 0
of 0
human 0
skeletal 0
muscles 0
still 0
shows 0
a 0
5 0
% 0
fraction 0
of 0
CK B-gene
- I-gene
MB I-gene
. 0

Value 0
of 0
determination 0
of 0
alkaline B-gene
phosphatase I-gene
isoenzymes I-gene
for 0
differential 0
diagnosis 0
of 0
obstructive 0
jaundice 0
and 0
biliary 0
liver 0
cirrhosis 0

A 0
one 0
- 0
way 0
analysis 0
of 0
variance 0
, 0
performed 0
separately 0
for 0
men 0
and 0
women 0
for 0
differences 0
among 0
the 0
three 0
phobic 0
groups 0
on 0
field 0
dependence 0
, 0
showed 0
significance 0
( 0
rho 0
less 0
than 0
.05 0
) 0
for 0
the 0
females 0
, 0
with 0
the 0
famale 0
agoraphobic 0
being 0
more 0
field 0
dependent 0
than 0
the 0
female 0
simple 0
phobic 0
groups 0
, 0
but 0
not 0
for 0
the 0
males 0
. 0

Several 0
free 0
2nd 0
- 0
generation 0
schizonts 0
, 0
which 0
varied 0
in 0
diameter 0
from 0
11 0
to 0
21.6 0
micrometer 0
, 0
were 0
found 0
on 0
the 0
epithelial 0
surface 0
of 0
the 0
cecum 0
. 0

The 0
calculated 0
pD2 0
values 0
were 0
8.8 0
for 0
E 0
, 0
8.6 0
for 0
DHE 0
and 0
6.6 0
for 0
M 0
. 0

Newcastle 0
disease 0
virus 0
surveillance 0
in 0
Hong 0
Kong 0
on 0
local 0
and 0
imported 0
poultry 0
. 0

It 0
was 0
postulated 0
that 0
persistent 0
challenge 0
by 0
M. 0
leprae 0
or 0
its 0
antigens 0
to 0
the 0
IgA B-gene
immunocytes 0
of 0
the 0
intestinal 0
epithelium 0
might 0
have 0
induced 0
tolerance 0
leading 0
to 0
IgA B-gene
deficiency 0
and 0
subsequent 0
subtotal 0
atrophy 0
of 0
the 0
intestinal 0
villi 0
in 0
the 0
patients 0
with 0
lepromatous 0
leprosy 0
. 0

Treatment 0
of 0
hypertension 0
with 0
a 0
combination 0
of 0
the 0
adrenergic B-gene
beta I-gene
receptor I-gene
blockader 0
, 0
obsidan 0
, 0
and 0
the 0
vasodilator 0
, 0
apressin 0

Orthop 0
. 0

Thyroid 0
disease 0
and 0
pregnancy 0
. 0

Residues 0
removed 0
from 0
transcripts 0
by 0
splicing 0
were 0
identified 0
. 0

To 0
minimize 0
reflux 0
into 0
the 0
blind 0
loop 0
, 0
a 0
number 0
of 0
technical 0
steps 0
are 0
considered 0
indispensable 0
: 0
1 0
) 0
fluted 0
section 0
of 0
the 0
jejunal 0
stump 0
; 0
2 0
) 0
isoperistaltic 0
construction 0
of 0
the 0
anastomosis 0
and 0
, 0
particularly 0
, 0
3 0
) 0
the 0
creation 0
of 0
a 0
single 0
or 0
double 0
valve 0
system 0
upstream 0
from 0
the 0
anastomosis 0
by 0
spiral 0
introflexion 0
of 0
the 0
mucosa 0
using 0
seroserous 0
stitches 0
parallel 0
and 0
perpendicular 0
to 0
the 0
ileal 0
lumen 0
. 0

At 0
this 0
stage 0
, 0
the 0
eventual 0
high 0
mortality 0
of 0
acute 0
ischemia 0
is 0
established 0
whatever 0
the 0
urgency 0
of 0
the 0
operation 0
or 0
the 0
skill 0
with 0
which 0
it 0
is 0
performed 0
. 0

Pathogens 0
( 0
Staphylococcus 0
aureus 0
or 0
Gram 0
- 0
negative 0
bacilli 0
) 0
were 0
isolated 0
from 0
only 0
one 0
member 0
of 0
staff 0
in 0
small 0
numbers 0
and 0
irregularly 0
and 0
rarely 0
in 0
large 0
numbers 0
from 0
patients 0
. 0

The 0
histochemistry 0
and 0
ultrastructure 0
of 0
calcified 0
cerebellar 0
deposits 0
described 0
by 0
Tonge 0
et 0
al 0
. 0

A 0
36 0
year 0
- 0
old 0
woman 0
was 0
given 0
Ergotamine 0
Tartrate 0
4.5 0
mg 0
p.d 0
. 0
during 0
seven 0
days 0
, 0
after 0
an 0
abortion 0
( 0
a 0
still 0
birth 0
) 0
. 0

Reaction 0
times 0
to 0
tachistoscopically 0
presented 0
stimuli 0
in 0
diabetics 0

Two 0
out 0
of 0
five 0
patients 0
undergoing 0
selective 0
spinal 0
arteriography 0
developed 0
transient 0
neurological 0
complications 0
during 0
the 0
injection 0
of 0
Urografin 0
310 0
M 0
. 0

The 0
data 0
indicate 0
a 0
three 0
- 0
phase 0
reaction 0
after 0
B1 0
injection 0
: 0
Phase 0
1 0
- 0
- 0
shortly 0
after 0
injection 0
there 0
is 0
a 0
drop 0
of 0
all 0
parameters 0
lasting 0
for 0
30 0
sec 0
. 0

Serum B-gene
relaxin I-gene
levels 0
in 0
prostaglandin 0
E2 0
induced 0
abortions 0
. 0

A 0
- 0
- 0
A 0
natural 0
hydrostatic 0
phenomenon 0
, 0
at 0
the 0
level 0
of 0
the 0
ends 0
of 0
the 0
plantar 0
arcs 0
, 0
diffuses 0
body 0
weight 0
, 0
as 0
PAIN 0
plays 0
the 0
role 0
of 0
outsentry 0
( 0
fig. 0
- 0
- 0
1 0
) 0
( 0
5 0
) 0
; 0
B 0
- 0
- 0
Plantar 0
perforating 0
ulceration 0
( 0
PPU 0
) 0
is 0
caused 0
by 0
a 0
combination 0
of 0
INSENSITIVITY 0
and 0
TRAUMATIS 0
( 0
1 0
) 0
; 0
C 0
- 0
- 0
The 0
patient 0
reposing 0
, 0
as 0
body 0
weight 0
( 0
traumatism 0
) 0
effects 0
disappear 0
, 0
cicatrization 0
process 0
can 0
be 0
easily 0
observed 0
; 0
D 0
- 0
- 0
PNEUMATIC 0
INSOLE 0
, 0
being 0
elastic 0
, 0
diffuses 0
localized 0
compression 0
at 0
the 0
ends 0
of 0
the 0
plantar 0
arcs 0
, 0
reduces 0
attrition 0
, 0
makes 0
easier 0
blood 0
circulation 0
, 0
as 0
well 0
as 0
cure 0
and 0
prophylaxis 0
of 0
PPU 0
( 0
fig. 0
- 0
- 0
6 0
) 0
( 0
3 0
) 0
. 0

Effect 0
of 0
indoramin 0
in 0
small 0
doses 0
on 0
the 0
central 0
vasomotor 0
loci 0
has 0
been 0
studied 0
in 0
chloralose 0
anesthetized 0
cats 0
by 0
localizing 0
it 0
to 0
the 0
central 0
sites 0
. 0

As 0
expected 0
, 0
the 0
heparin 0
did 0
produce 0
increased 0
recalcification 0
times 0
and 0
the 0
development 0
of 0
occasional 0
subcutaneous 0
hematomas 0
. 0

Contingency 0
contracting 0
between 0
clients 0
and 0
their 0
parents/caregivers 0
was 0
used 0
to 0
specify 0
consequences 0
for 0
daily 0
self 0
- 0
monitoring 0
, 0
reduced 0
caloric 0
intake 0
, 0
weight 0
loss 0
, 0
and 0
exercise 0
. 0

Dietetics 0
of 0
childhood 0
- 0
and 0
juvenile 0
diabetes 0

The 0
results 0
of 0
a 0
quantitative 0
study 0
of 0
vasculosyncytial 0
membranes 0
in 0
123 0
placentas 0
are 0
presented 0
. 0

The 0
micromethod 0
uses 0
microcuvettes 0
and 0
substitutes 0
ferrozine 0
for 0
the 0
bathophenanthroline 0
chromogen 0
of 0
the 0
ICSH 0
. 0

Platelet 0
serotonin 0
( 0
5 0
- 0
HT 0
) 0
and 0
5 B-gene
- I-gene
HT I-gene
releasing I-gene
factor I-gene
in 0
plasma 0
of 0
migrainous 0
patients 0
. 0

The 0
overall 0
incidence 0
of 0
SIDS 0
was 0
1.43 0
per 0
1,000 0
live 0
births 0
. 0

The 0
vigilance 0
task 0
and 0
the 0
measurement 0
of 0
attentional 0
deficits 0
. 0

The 0
December 0
armed 0
revolt 0
in 0
Moscow 0
and 0
the 0
paramedical 0
personnel 0

Significant 0
increases 0
in 0
mean 0
serum 0
E2 0
concentration 0
( 0
100 0
to 0
150 0
pg/ml 0
) 0
were 0
noted 0
at 0
6 0
and 0
8 0
hours 0
after 0
administration 0
on 0
day 0
1 0
and 0
at 0
8 0
hours 0
on 0
day 0
4 0
. 0

The 0
motor 0
unit 0
viewed 0
from 0
above 0
. 0

Avian 0
reproductive 0
system 0
: 0
daily 0
variations 0
in 0
responses 0
to 0
hormones 0
. 0

Biological 0
properties 0
of 0
sumithion 0
. 0

Serological 0
studies 0
of 0
antibodies 0
to 0
Epstein 0
- 0
Barr 0
virus 0
in 0
infectious 0
mononucleosis 0

Carcinoembryonic B-gene
antigen I-gene
( 0
CEA B-gene
) 0
procedures 0
and 0
clinical 0
evaluation 0
. 0

We 0
remain 0
convinced 0
that 0
antilymphocyte B-gene
globulin I-gene
( 0
ALG B-gene
) 0
is 0
a 0
potent 0
immunosuppressive 0
agent 0
in 0
humans 0
. 0

On 0
the 0
basis 0
of 0
a 0
global 0
assessment 0
patients 0
showed 0
a 0
highly 0
significant 0
preference 0
for 0
imipramine 0
compared 0
with 0
placebo 0
as 0
adjunctive 0
therapy 0
. 0

39 0
- 0
47 0
. 0

Patients 0
were 0
subclassified 0
into 0
age 0
- 0
matched 0
groups 0
of 0
primary 0
untreated 0
cancer 0
( 0
21 0
) 0
, 0
recurrent 0
cancer 0
( 0
18 0
) 0
, 0
and 0
`` 0
cured 0
'' 0
patients 0
who 0
had 0
been 0
free 0
of 0
disease 0
for 0
at 0
least 0
9 0
months 0
( 0
16 0
) 0
. 0

Absorption 0
varied 0
between 0
65 0
and 0
95 0
per 0
cent 0
, 0
with 0
a 0
mean 0
absorption 0
of 0
80 0
per 0
cent 0
, 0
in 0
both 0
pregnant 0
and 0
non 0
- 0
pregnant 0
subjects 0
. 0

Bacteriostatic 0
and 0
bacteriacidal 0
activity 0
of 0
hydroxy 0
- 0
9 0
ellipticine 0
in 0
vitro 0

Advances 0
in 0
the 0
management 0
of 0
gynecologic 0
cancer 0
- 0
- 0
radiation 0
therapy 0
. 0

The 0
clinico 0
- 0
pathological 0
data 0
from 0
a 0
patient 0
with 0
irreversible 0
post 0
- 0
partum 0
renal 0
failure 0
( 0
IPRF 0
) 0
are 0
presented 0
. 0

Personal 0
satisfaction 0
in 0
nursing 0
: 0
an 0
encounter 0
with 0
extremely 0
hostile 0
patients 0

Dialyzable 0
transfer B-gene
factor I-gene
. 0

19 0
- 0
32 0
. 0

Rheumatoid B-gene
factor I-gene
and 0
antinuclear 0
antibody 0
tests 0
were 0
frequently 0
positive 0
, 0
and 0
reactions 0
to 0
gold 0
therapy 0
were 0
more 0
frequent 0
than 0
in 0
other 0
rheumatoid 0
populations 0
. 0

The 0
effect 0
of 0
hydrostatic 0
pressure 0
on 0
the 0
swimming 0
activity 0
of 0
three 0
hyponeustonic 0
crustacea 0
, 0
Anomalocera 0
patersoni 0
, 0
Pontella 0
mediterranea 0
, 0
Labidocera 0
wollastoni 0

This 0
report 0
presents 0
an 0
analysis 0
of 0
the 0
vocal 0
repertoire 0
of 0
howler 0
monkeys 0
( 0
Alouatta 0
palliata 0
) 0
observed 0
during 0
a 0
field 0
study 0
in 0
southwestern 0
Panama 0
. 0

Up 0
to 0
now 0
the 0
number 0
of 0
patients 0
examined 0
is 0
about 0
300 0
, 0
additionally 0
6 0
persons 0
who 0
underwent 0
binephrectomy 0
. 0

Deflunia 0
was 0
well 0
tolerated 0
by 0
25 0
patients 0
, 0
very 0
well 0
tolerated 0
by 0
2 0
. 0

III 0
. 0

A 0
new 0
instrument 0
has 0
been 0
designed 0
for 0
freeze 0
- 0
fracturing 0
of 0
biological 0
material 0
in 0
ultra 0
high 0
vacuum 0
. 0

Pancreatic 0
and 0
biliary 0
secretion 0
and 0
gastric 0
emptying 0
rates 0
of 0
a 0
liquid 0
test 0
meal 0
( 0
LTM 0
) 0
were 0
determined 0
in 0
normal 0
persons 0
, 0
in 0
patients 0
with 0
subtotal 0
gastrectomy 0
with 0
gastroduodenostomy 0
( 0
STG 0
- 0
BI 0
) 0
or 0
with 0
gastrojejunostomy 0
( 0
STG 0
- 0
BII 0
) 0
, 0
and 0
in 0
patients 0
with 0
truncal 0
vagotomy 0
and 0
pyloroplasty 0
( 0
V 0
& 0
P 0
) 0
. 0

Abnormal 0
calcium 0
metabolism 0
in 0
normocalcaemic 0
sarcoidosis 0
. 0

Also 0
, 0
except 0
in 0
one 0
patient 0
who 0
developed 0
gallstones 0
following 0
institution 0
of 0
colestipol 0
, 0
saturation 0
of 0
gallbladder 0
bile 0
with 0
cholesterol 0
was 0
not 0
markedly 0
increased 0
by 0
this 0
drug 0
alone 0
. 0

A 0
five 0
- 0
phase 0
experiment 0
was 0
designed 0
to 0
investigate 0
( 0
a 0
) 0
whether 0
contingent 0
music 0
- 0
listening 0
would 0
act 0
as 0
a 0
reinforcer 0
to 0
increase 0
arithmetic 0
performance 0
of 0
EMR 0
children 0
and 0
( 0
b 0
) 0
whether 0
this 0
contingent 0
reinforcement 0
would 0
affect 0
preference 0
for 0
that 0
reinforcer 0
. 0

The 0
responsiveness 0
of 0
visual 0
cortex 0
( 0
VC 0
) 0
and 0
superior 0
colliculus 0
( 0
SC 0
) 0
was 0
simultaneously 0
compared 0
following 0
conditioning 0
`` 0
ON 0
'' 0
or 0
`` 0
OFF 0
'' 0
stimulation 0
, 0
in 0
the 0
rabbit 0
. 0

A 0
diagnosis 0
of 0
MS 0
was 0
made 0
based 0
on 0
subtle 0
neurologic 0
signs 0
, 0
spinal 0
fluid 0
gamma B-gene
globulin I-gene
elevations 0
, 0
and 0
abnormalities 0
in 0
neuropsychological 0
testing 0
. 0

If 0
, 0
however 0
, 0
the 0
mean 0
temperature 0
rise 0
was 0
higher 0
( 0
0.57 0
degrees 0
C 0
or 0
0.69 0
degrees 0
C 0
) 0
, 0
such 0
a 0
selection 0
practically 0
resulted 0
in 0
the 0
disappearance 0
of 0
'passable 0
' 0
qualifications 0
in 0
the 0
triplet 0
groups 0
and 0
a 0
great 0
predominance 0
of 0
'to 0
be 0
rejected 0
' 0
qualifications 0
in 0
the 0
large 0
groups 0
. 0

The 0
elevated 0
Viso 0
V 0
in 0
the 0
RDS 0
group 0
suggests 0
an 0
increase 0
in 0
small 0
airway 0
resistance 0
secondary 0
to 0
the 0
disease 0
or 0
to 0
its 0
therapy 0
. 0

The 0
psychological 0
tests 0
consisted 0
of 0
a 0
free 0
- 0
recall 0
task 0
, 0
a 0
test 0
for 0
visuomotor 0
coordination 0
and 0
a 0
recognition 0
task 0
. 0

Selective 0
bronchial 0
intubation 0
in 0
the 0
management 0
of 0
unilateral 0
pulmonary 0
interstitial 0
emphysema 0
. 0

The 0
background 0
processes 0
depending 0
on 0
the 0
etiological 0
factor 0
and 0
the 0
character 0
of 0
lesion 0
of 0
the 0
epithelium 0
are 0
divided 0
into 0
dyshormonal 0
, 0
inflammatory 0
, 0
and 0
posttraumatic 0
. 0

The 0
sense 0
of 0
self 0
. 0

Eleven 0
strains 0
of 0
Fusarium 0
poae 0
and 0
F. 0
sporotrichioides 0
from 0
the 0
U.S.S.R. 0
and 0
7 0
strains 0
of 0
these 0
species 0
and 0
one 0
of 0
F. 0
sporotrichioides 0
var 0
. 0
tricinctum 0
from 0
U.S.A. 0
and 0
France 0
have 0
been 0
compared 0
as 0
to 0
their 0
capacity 0
to 0
yield 0
T B-gene
- I-gene
2 I-gene
toxin I-gene
. 0

Current 0
diagnostic 0
uses 0
of 0
computerized 0
tomography 0
in 0
clinical 0
medicine 0
. 0

A 0
follow 0
- 0
up 0
study 0
of 0
22 0
patients 0
with 0
Ebstein 0
's 0
anomaly 0
has 0
been 0
performed 0
. 0

Deaths 0
stopped 0
11 0
hours 0
after 0
copper 0
concentrations 0
decreased 0
below 0
0.2 0
ppm 0
and 0
signs 0
of 0
distress 0
stopped 0
in 0
surviving 0
pinfish 0
by 0
approximately 0
6 0
hours 0
after 0
the 0
last 0
death 0
. 0

Recurrence 0
of 0
bladder 0
tumors 0
among 0
the 0
original 0
9 0
cases 0
has 0
occurred 0
only 0
among 0
the 0
5 0
whose 0
properdin B-gene
levels 0
remained 0
below 0
the 0
median 0
. 0

Adaptation 0
of 0
taurocholate 0
transport 0
maximum 0
to 0
increased 0
secretory 0
load 0
in 0
the 0
rat 0
. 0

Dangers 0
in 0
use 0
of 0
live 0
- 0
virus 0
vaccines 0
. 0

Treatment 0
with 0
heparin 0
, 0
plasminogen B-gene
activators 0
and 0
fibrinogenolytic 0
agents 0
was 0
disappointing 0
although 0
renal 0
function 0
has 0
stabilized 0
in 0
one 0
patient 0
on 0
long 0
term 0
oral 0
anticoagulant 0
therapy 0
. 0

In 0
diethyl 0
ether 0
solution 0
the 0
main 0
peak 0
is 0
that 0
of 0
2 0
- 0
benzylidenamio 0
- 0
1 0
- 0
phenylpropane 0
, 0
which 0
has 0
a 0
retention 0
time 0
of 0
23,2 0
minutes 0
under 0
the 0
condition 0
delineated 0
. 0

Amikacin 0
was 0
used 0
in 0
the 0
treatment 0
of 0
56 0
serious 0
gram 0
- 0
negative 0
infections 0
in 0
54 0
patients 0
of 0
whom 0
47 0
survived 0
. 0

The 0
data 0
normally 0
available 0
are 0
insufficient 0
and 0
take 0
no 0
account 0
of 0
the 0
direction 0
of 0
recirculation 0
, 0
which 0
may 0
be 0
a 0
determining 0
factor 0
. 0

During 0
activity 0
III 0
, 0
one 0
patient 0
developed 0
angina 0
. 0

Estimation 0
of 0
L 0
- 0
alanine 0
in 0
serum 0
or 0
plasma 0
using 0
the 0
LKB 0
reaction 0
rate 0
analyser 0
. 0

The 0
acids 0
were 0
obtained 0
by 0
hydrolysis 0
of 0
the 0
corresponding 0
esters 0
, 0
and 0
their 0
anti 0
- 0
inflammatory 0
activity 0
was 0
tested 0
. 0

Unrecognized 0
amnionitis 0
and 0
prematurity 0
: 0
a 0
preliminary 0
report 0
. 0

Evaluation 0
of 0
the 0
new 0
Gravigard 0
IUCD 0
inserter 0
. 0

Bacterial 0
meningitis 0
secondary 0
to 0
abscess 0
of 0
the 0
nasal 0
septum 0
. 0

Serum B-gene
amylase I-gene
became 0
markedly 0
elevated 0
( 0
2,624 0
CU/100 0
ml 0
) 0
, 0
as 0
did 0
the 0
serum 0
FFA 0
( 0
29.19 0
mEq/liter 0
) 0
. 0

In 0
the 0
control 0
preparation 0
before 0
weight 0
was 0
allowed 0
to 0
increase 0
, 0
isogravimetric 0
capillary 0
pressure 0
( 0
Pci 0
) 0
averaged 0
8 0
mmHg 0
lower 0
than 0
colloid 0
osmotic 0
pressure 0
of 0
the 0
plasma 0
( 0
IIp 0
) 0
. 0

Infants 0
who 0
died 0
in 0
the 0
first 0
12 0
hours 0
from 0
'IVH 0
only 0
' 0
had 0
suffered 0
severe 0
birth 0
asphyxia 0
but 0
in 0
those 0
who 0
died 0
later 0
the 0
main 0
symptom 0
was 0
recurrent 0
apnoea 0
. 0

The 0
morphological 0
effects 0
of 0
two 0
snake 0
venoms 0
, 0
N. 0
naja 0
and 0
A. 0
piscivorus 0
, 0
and 0
of 0
the 0
Direct B-gene
Lytic I-gene
Factor I-gene
and 0
Phospholipase B-gene
- I-gene
A I-gene
, 0
compounds 0
purified 0
from 0
N. 0
naja 0
crude 0
venom 0
, 0
were 0
investigated 0
on 0
lung 0
and 0
cremaster 0
vessels 0
of 0
rats 0
. 0

Since 0
GAGs 0
are 0
the 0
components 0
of 0
cartilage 0
matrix 0
, 0
the 0
depletion 0
of 0
which 0
is 0
associated 0
with 0
osteoarthrosis 0
, 0
a 0
method 0
for 0
measuring 0
sulphated 0
GAG 0
synthesis 0
in 0
culture 0
has 0
been 0
investigated 0
. 0

The 0
length 0
scales 0
of 0
the 0
turbulence 0
were 0
also 0
estimated 0
: 0
at 0
a 0
Reynolds 0
number 0
near 0
4,000 0
the 0
macroscale 0
is 0
about 0
1.25 0
mm 0
, 0
the 0
Taylor 0
microscale 0
is 0
about 0
0.85 0
mm 0
, 0
and 0
the 0
Kolmogoroff 0
scale 0
is 0
near 0
0.075 0
mm 0
. 0

Well 0
- 0
visualised 0
arteriograms 0
of 0
the 0
limbs 0
can 0
be 0
obtained 0
by 0
xeroradiography 0
after 0
rapid 0
manual 0
injection 0
of 0
contrast 0
- 0
medium 0
into 0
an 0
arm 0
vein 0
, 0
as 0
demonstrated 0
in 0
28 0
patients 0
. 0

No 0
hypotension 0
was 0
noted 0
in 0
patients 0
with 0
toxemia 0
and 0
only 0
2 0
ran 0
a 0
fever 0
above 0
37.5 0
degrees 0
C 0
. 0

The 0
sera 0
and 0
nasal 0
secretions 0
of 0
142 0
patients 0
, 0
who 0
were 0
positive 0
in 0
HD 0
or 0
mites 0
skin 0
test 0
, 0
were 0
subjected 0
to 0
a 0
radioallergosorbent 0
test 0
( 0
RAST 0
) 0
for 0
estimating 0
the 0
specific 0
IgE B-gene
antibody I-gene
activity 0
to 0
mites 0
. 0

Wherever 0
the 0
site 0
of 0
the 0
conditioning 0
stimulation 0
, 0
these 0
modifications 0
disappeared 0
after 0
ischaemia 0
of 0
the 0
leg 0
. 0

Diallylnitrosamine 0
( 0
DAN 0
) 0
, 0
one 0
of 0
the 0
few 0
nitrosamines 0
tested 0
thus 0
far 0
that 0
has 0
not 0
induced 0
neoplasms 0
in 0
rats 0
, 0
caused 0
a 0
high 0
incidence 0
of 0
respiratory 0
tract 0
tumors 0
in 0
Syrian 0
golden 0
hamsters 0
treated 0
sc 0
with 0
single 0
or 0
weekly 0
doses 0
of 0
the 0
compound 0
. 0

Near 0
term 0
, 0
under 0
experimental 0
conditions 0
, 0
maternal 0
and 0
fetal 0
blood 0
gases 0
, 0
pH 0
, 0
uterine 0
and 0
umbilical 0
blood 0
flows 0
were 0
measured 0
or 0
calculated 0
. 0

Haemodynamic 0
responses 0
to 0
antagonism 0
of 0
bocurarine 0
block 0
with 0
atropine 0
- 0
neostigmine 0
mixture 0
in 0
children 0
. 0

The 0
mechanism 0
by 0
which 0
large 0
molecules 0
, 0
such 0
as 0
the 0
diphosphonate 0
99mTc 0
- 0
labeled 0
EHDP 0
or 0
99mTc 0
- 0
labeled 0
pyrophosphate 0
, 0
pass 0
through 0
capillaries 0
in 0
bone 0
is 0
by 0
passive 0
diffusion 0
. 0

Twenty 0
- 0
nine 0
days 0
after 0
injection 0
of 0
5.8 0
mCi 0
of 0
Tc 0
- 0
99m 0
, 0
which 0
gives 0
28 0
rads 0
to 0
the 0
testis 0
, 0
the 0
number 0
of 0
sperm 0
hads 0
decreased 0
to 0
70 0
% 0
of 0
control 0
. 0

Self 0
- 0
emasculation 0
is 0
the 0
end 0
result 0
of 0
an 0
unusual 0
psychiatric 0
disorder 0
, 0
which 0
initially 0
requires 0
surgical 0
treatment 0
. 0

Possibility 0
of 0
a 0
TSH B-gene
- 0
Screening 0
method 0
for 0
detection 0
of 0
hypothyroidism 0
in 0
the 0
newborn 0

Thus 0
analysis 0
indicated 0
no 0
reliable 0
evidence 0
that 0
conscious 0
presleep 0
suggestions 0
become 0
incorporated 0
into 0
dream 0
content 0
. 0

The 0
prevalence 0
of 0
hepatitis B-gene
B I-gene
surface I-gene
antigen I-gene
( 0
HBsAg B-gene
) 0
and 0
anti B-gene
- I-gene
HBs I-gene
was 0
determined 0
by 0
a 0
sensitive 0
double 0
- 0
antibody 0
radio 0
- 0
immunoassay 0
technique 0
in 0
a 0
series 0
of 0
patients 0
with 0
chronic 0
liver 0
diseases 0
. 0

It 0
was 0
concluded 0
that 0
patients 0
with 0
acute 0
respiratory 0
failure 0
requiring 0
artificial 0
ventilation 0
have 0
two 0
componenents 0
of 0
the 0
pulmonary 0
shunt 0
, 0
one 0
parallel 0
with 0
and 0
the 0
other 0
inversely 0
related 0
with 0
the 0
PAO2 0
. 0

Decreased 0
cardiac 0
glycogen 0
following 0
phenformin 0
injection 0
in 0
hyperglycemic 0
, 0
hyperinsulinemic 0
anaesthetized 0
rats 0
. 0

Biological 0
evaluation 0
of 0
mibolerone 0
in 0
the 0
female 0
Beagle 0
. 0

Levels 0
of 0
both 0
PGF 0
and 0
PGFM 0
were 0
significantly 0
higher 0
during 0
early 0
spontaneous 0
labour 0
, 0
at 0
a 0
cervical 0
dilatation 0
of 0
less 0
than 0
4 0
cm 0
, 0
than 0
before 0
the 0
onset 0
of 0
labour 0
. 0

The 0
most 0
common 0
cause 0
of 0
renal 0
deterioration 0
in 0
the 0
spinal 0
cord 0
injured 0
patient 0
is 0
irreversible 0
vesicoureteral 0
reflux 0
. 0

Propranolol 0
( 0
Inderal 0
) 0
administered 0
in 0
a 0
dose 0
which 0
blocks 0
the 0
beta 0
- 0
adrenergic 0
apparatus 0
of 0
the 0
heart 0
prevents 0
the 0
development 0
of 0
the 0
positive 0
inotropic 0
effect 0
of 0
therapeutic 0
doses 0
of 0
strophanthin 0
K 0
on 0
a 0
hypodynamic 0
left 0
ventricular 0
myocardium 0
. 0

Recent 0
studies 0
have 0
shown 0
the 0
rat 0
larynx 0
to 0
be 0
an 0
important 0
organ 0
in 0
the 0
evaluation 0
of 0
irritancy 0
of 0
inhaled 0
materials 0
. 0

Scanning 0
electron 0
microscopic 0
investigations 0
on 0
the 0
formation 0
of 0
Reissner 0
's 0
fiber 0
in 0
Rattus 0
rattus 0

Feeding 0
behavior 0
, 0
circannual 0
body 0
weight 0
and 0
hibernation 0
rhythms 0
in 0
European 0
hamsters 0
lesioned 0
in 0
the 0
noradrenergic 0
ascending 0
bundles 0

Role 0
of 0
the 0
infectious 0
- 0
disease 0
specialist 0
of 0
a 0
polyclinic 0
in 0
reducing 0
the 0
incidence 0
of 0
communicable 0
diseases 0

These 0
observed 0
drug 0
interactions 0
, 0
plus 0
the 0
known 0
effect 0
of 0
probenecid 0
to 0
block 0
secretion 0
of 0
PZA 0
, 0
have 0
to 0
be 0
considered 0
in 0
evaluating 0
the 0
effect 0
of 0
the 0
two 0
drugs 0
given 0
together 0
, 0
compared 0
to 0
the 0
effect 0
of 0
each 0
drug 0
given 0
separately 0
. 0

Circulatory 0
arrest 0
in 0
the 0
operating 0
room 0
. 0

At 0
a 0
systolic 0
blood 0
pressure 0
( 0
BP 0
) 0
of 0
60 0
mmHg 0
, 0
C02 0
responsiveness 0
was 0
abolished 0
, 0
but 0
was 0
maintained 0
at 0
higher 0
levels 0
of 0
BP 0
. 0

Iodine 0
- 0
123 0
was 0
satisfactorily 0
imaged 0
only 0
with 0
the 0
MEC 0
and 0
pinhole 0
collimators 0
, 0
which 0
in 0
turn 0
yielded 0
MTF 0
values 0
comparable 0
to 0
those 0
measured 0
for 0
99mTc 0
. 0

Petrous 0
meningioma 0
en 0
plaque 0
presenting 0
as 0
a 0
right 0
middle 0
ear 0
tumor 0
. 0

The 0
difficulties 0
to 0
analyse 0
prostaglandins 0
( 0
PG 0
) 0
by 0
gas 0
- 0
liquid 0
chromatography 0
are 0
mainly 0
due 0
to 0
the 0
lack 0
of 0
sensitivity 0
of 0
the 0
gas 0
- 0
chromatograph 0
itself 0
( 0
higher 0
than 0
200 0
ng 0
) 0
and 0
to 0
the 0
poor 0
resolution 0
of 0
the 0
packed 0
columns 0
. 0

On 0
cessation 0
of 0
steroid 0
therapy 0
the 0
patient 0
was 0
noted 0
to 0
have 0
radiologic 0
manifestations 0
of 0
hypertrophic 0
osteoarthropathy 0
( 0
HOA 0
) 0
as 0
well 0
as 0
clinical 0
and 0
laboratory 0
features 0
of 0
rheumatoid 0
arthritis 0
( 0
RA 0
) 0
. 0

The 0
effect 0
of 0
food 0
on 0
procainamide 0
absorption 0
. 0

After 0
giving 0
a 0
survey 0
on 0
the 0
situation 0
of 0
antibiotic 0
resistance 0
in 0
the 0
region 0
of 0
Northern 0
Bavaria 0
during 0
1973/74 0
and 0
comparing 0
the 0
activity 0
of 0
a 0
sulfamethoxazole 0
( 0
SMZ 0
) 0
trimethoprim 0
( 0
TMP 0
) 0
combination 0
to 0
other 0
commonly 0
used 0
antibiotics 0
and 0
chemotherapeutic 0
agents 0
, 0
the 0
results 0
of 0
tests 0
with 0
the 0
new 0
combination 0
of 0
N1 0
- 0
( 0
4,5 0
- 0
dimethyl 0
- 0
2 0
- 0
oxazolyl 0
) 0
- 0
sulfanilamide 0
) 0
( 0
sulfamoxole 0
) 0
and 0
2,4 0
- 0
diamino 0
- 0
5 0
- 0
( 0
3,4,5 0
- 0
trimethoxy 0
- 0
benzyl 0
) 0
- 0
pyrimidine 0
( 0
trimethoprim 0
) 0
at 0
a 0
ratio 0
of 0
5:1 0
( 0
CN 0
3123 0
; 0
Nevin 0
, 0
Supristol 0
) 0
are 0
compared 0
to 0
those 0
of 0
tests 0
with 0
TMP/SMZ 0
. 0

RESULTS 0
: 0
Total 0
IgE B-gene
levels 0
showed 0
a 0
tendency 0
to 0
diminish 0
. 0

Does 0
afferent 0
loop 0
syndrome 0
exist 0
? 0
] 0
It 0
is 0
the 0
author 0
's 0
opinion 0
that 0
diagnosis 0
of 0
the 0
`` 0
adducent 0
loop 0
syndrome 0
'' 0
is 0
unlikely 0
to 0
be 0
correct 0
in 0
patients 0
subjected 0
to 0
Billroth 0
- 0
II 0
gastrectomy 0
. 0

Letter 0
: 0
Is 0
actinic 0
( 0
solar 0
) 0
damage 0
the 0
provoking 0
cause 0
of 0
'post 0
- 0
inflammatory 0
elastolysis 0
and 0
cutis 0
laxa 0
( 0
PECL 0
) 0
' 0
? 0

These 0
data 0
suggest 0
that 0
spontaneous 0
recovery 0
of 0
central 0
respiratory 0
function 0
after 0
intoxication 0
with 0
Soman 0
or 0
Sarin 0
may 0
not 0
be 0
related 0
to 0
the 0
return 0
of 0
AChE B-gene
activity 0
. 0

Batch 0
cultures 0
of 0
S. 0
mutans 0
serotype 0
a 0
demonstrated 0
no 0
growth 0
on 0
MSB 0
agar 0
. 0

Also 0
, 0
samples 0
of 0
serum 0
were 0
absorbed 0
with 0
the 0
various 0
solid 0
- 0
phase 0
allergens 0
and 0
the 0
reactivity 0
of 0
the 0
remaining 0
IgE B-gene
antibodies I-gene
was 0
determined 0
. 0

Crisis 0
of 0
the 0
therapeutic 0
community 0
in 0
Great 0
Britain 0

Pregnant 0
women 0
at 0
term 0
had 0
the 0
lowest 0
levels 0
of 0
antithrombin B-gene
III I-gene
. 0

Hematology 0
problem 0
of 0
the 0
month 0
: 0
band 0
or 0
seg 0
? 0

It 0
is 0
possible 0
that 0
cyclic 0
variations 0
in 0
heme 0
turnover 0
are 0
related 0
to 0
changes 0
in 0
erythrocyte 0
characteristics 0
during 0
the 0
progesterone 0
phase 0
. 0

Haemodilution 0
in 0
cardiopulmonary 0
bypass 0
using 0
a 0
gelatine 0
derivative 0
for 0
priming 0
. 0

Extramedullary 0
plasmacytoma 0
of 0
the 0
parotid 0
gland 0

I 0
. 0

The 0
recovered 0
calves 0
were 0
tested 0
for 0
immunity 0
to 0
homologous 0
severe 0
challenge 0
, 0
50 0
or 0
73 0
days 0
after 0
the 0
first 0
infection 0
. 0

The 0
performance 0
of 0
three 0
commonly 0
used 0
chemical 0
cartridge 0
respirators 0
for 0
SO2 0
was 0
measured 0
under 0
working 0
conditions 0
in 0
a 0
copper 0
smelter 0
. 0

The 0
neuroleptic 0
- 0
induced 0
increase 0
in 0
central 0
DA 0
turnover 0
( 0
an 0
indicator 0
for 0
the 0
degree 0
of 0
DA B-gene
receptor I-gene
blocking 0
) 0
was 0
found 0
to 0
be 0
positively 0
correlated 0
with 0
the 0
therapeutic 0
effect 0
of 0
neuroleptics 0
and 0
the 0
development 0
of 0
hypokinetic 0
- 0
rigid 0
symptoms 0
. 0

Rainbow 0
trout 0
were 0
obtained 0
from 0
a 0
commercial 0
trout 0
farm 0
, 0
kept 0
in 0
running 0
water 0
and 0
feeding 0
in 0
experimental 0
pellets 0
for 0
4 0
to 0
8 0
weeks 0
. 0

Stimulation 0
of 0
macrophage 0
function 0
by 0
killed 0
Bordetella 0
pertussis 0
cells 0
did 0
not 0
show 0
any 0
beneficial 0
effect 0
as 0
an 0
increased 0
susceptibility 0
became 0
apparent 0
. 0

Primary 0
amenorrhoea 0
in 0
a 0
phenotypically 0
female 0
individual 0
with 0
a 0
karyotype 0
46 0
, 0
xy 0
and 0
bilateral 0
gonadoblastoma 0

Toward 0
absolute 0
methods 0
in 0
clinical 0
chemistry 0
: 0
application 0
of 0
mass 0
fragmentography 0
to 0
high 0
- 0
accuracy 0
analyses 0
. 0

Application 0
of 0
the 0
2 0
- 0
deoxy 0
- 0
D 0
- 0
glucose 0
method 0
to 0
the 0
coupling 0
of 0
cerebral 0
metabolism 0
and 0
blood 0
flow 0
. 0

Serum 0
gastrin B-gene
levels 0
did 0
not 0
change 0
in 0
either 0
group 0
; 0
however 0
, 0
background 0
serum 0
gastrin B-gene
concentrations 0
were 0
significantly 0
greater 0
for 0
V 0
& 0
P 0
patients 0
than 0
V 0
& 0
A 0
patients 0
throughout 0
the 0
study 0
. 0

Efferent 0
projections 0
of 0
the 0
ventral 0
portion 0
of 0
the 0
putamen 0
to 0
the 0
frontal 0
, 0
parietal 0
and 0
temporal 0
regions 0
of 0
the 0
cat 0
cerebral 0
cortex 0

Preflight 0
, 0
inflight 0
, 0
and 0
postflight 0
exercise 0
response 0
tests 0
were 0
conducted 0
on 0
the 0
astronauts 0
of 0
the 0
second 0
Skylab 0
mission 0
( 0
Skylab 0
3 0
) 0
as 0
part 0
of 0
an 0
evaluation 0
of 0
physiological 0
adaptation 0
to 0
long 0
- 0
term 0
weightlessness 0
. 0

Mean 0
corpuscular B-gene
hemoglobin I-gene
concentrations 0
remained 0
normal 0
for 0
48 0
h 0
and 0
then 0
decreased 0
in 0
both 0
groups 0
, 0
the 0
CO2 0
group 0
showing 0
the 0
larger 0
decrease 0
. 0

All 0
Cu 0
values 0
obtained 0
from 0
the 0
organs 0
investigated 0
had 0
reached 0
a 0
saturation 0
level 0
at 0
8 0
mug 0
Cu/g 0
diet 0
with 0
the 0
exception 0
of 0
the 0
values 0
for 0
body 0
Cu 0
found 0
in 0
the 0
dams 0
that 0
were 0
killed 0
on 0
the 0
day 0
of 0
delivery 0
. 0

The 0
effect 0
of 0
calcitonin B-gene
, 0
a 0
large 0
amount 0
of 0
calcium 0
given 0
orally 0
, 0
pentagastrin 0
and 0
glucagon B-gene
on 0
plasma 0
47Ca 0
radioactivity 0
curves 0
in 0
subjects 0
pretreated 0
with 0
47Ca 0
was 0
examined 0
. 0

State 0
of 0
the 0
body 0
in 0
disorders 0
of 0
diurnal 0
physiological 0
rhythms 0
and 0
long 0
- 0
term 0
hypokinesia 0

Oxygen 0
tension 0
of 0
the 0
small 0
lymph 0
vessels 0
( 0
PLO2 0
) 0
of 0
the 0
rabbit 0
hind 0
limb 0
was 0
measured 0
with 0
both 0
a 0
flow 0
- 0
through 0
micro 0
chamber 0
and 0
a 0
polarographic 0
catheter 0
- 0
tip 0
oxygen 0
electrode 0
to 0
obtain 0
experimental 0
data 0
on 0
the 0
source 0
of 0
oxygen 0
in 0
the 0
lymph 0
. 0

The 0
response 0
of 0
the 0
plasma B-gene
fibrinogen I-gene
level 0
to 0
the 0
subucutaneous 0
injection 0
of 0
turpentine 0
and 0
to 0
the 0
intravenous 0
injection 0
of 0
endotoxin 0
was 0
measured 0
in 0
normal 0
rabbits 0
and 0
in 0
rabbits 0
made 0
granulocytopenic 0
and 0
thrombocytopenic 0
with 0
busulfan 0
. 0

Constantly 0
rectilinear 0
pressure 0
curves 0
without 0
uterine 0
activities 0
are 0
interpreted 0
as 0
characteristic 0
tocographic 0
criteria 0
of 0
an 0
advanced 0
ectopic 0
gravidity 0
. 0

Since 0
myoglobin B-gene
is 0
co 0
- 0
extracted 0
with 0
the 0
hemoglobin B-gene
, 0
the 0
2 0
heme 0
pigments 0
are 0
separated 0
in 0
one 0
portion 0
of 0
the 0
extract 0
by 0
precipitating 0
the 0
hemoglobin B-gene
in 0
an 0
85 0
% 0
( 0
NH4 0
) 0
2SO4 0
solution 0
. 0

Considering 0
these 0
sources 0
of 0
error 0
some 0
of 0
the 0
variability 0
in 0
the 0
present 0
investigation 0
might 0
be 0
avoided 0
by 0
systematic 0
instructions 0
. 0

E 0
50 0
, 0
843 0
( 0
1994 0
) 0
] 0
. 0

Six 0
patients 0
with 0
the 0
diagnosis 0
of 0
acute 0
mania 0
were 0
treated 0
with 0
high 0
doses 0
of 0
the 0
beta 0
- 0
adrenergic 0
blocking 0
agent 0
propranolol 0
. 0

Effect 0
of 0
trauma 0
on 0
plasma B-gene
glucagon I-gene
and 0
insulin B-gene
concentrations 0
in 0
sheep 0
. 0

With 0
the 0
help 0
of 0
a 0
nomogram 0
one 0
can 0
read 0
off 0
the 0
refraction 0
, 0
when 0
axis 0
length 0
and 0
corneal 0
curvature 0
are 0
known 0
. 0

This 0
up 0
- 0
grading 0
of 0
the 0
final 0
score 0
by 0
the 0
CA 0
component 0
is 0
greater 0
( 0
3 0
- 0
8 0
% 0
) 0
in 0
the 0
less 0
able 0
students 0
with 0
scores 0
below 0
the 0
mean 0
level 0
. 0

Compared 0
to 0
controls 0
, 0
both 0
UB 0
and 0
OCS 0
rats 0
showed 0
a 0
small 0
but 0
significant 0
post 0
- 0
operative 0
reduction 0
in 0
the 0
nocturnality 0
of 0
drinking 0
. 0

Effect 0
of 0
indomethacin 0
on 0
coronary 0
circulation 0
: 0
effect 0
on 0
ECG 0
tracing 0

Dual 0
innervation 0
of 0
fast 0
fibers 0
in 0
trunk 0
muscles 0
of 0
lamprey 0
larvae 0

The 0
feed 0
consumed 0
which 0
was 0
lowered 0
by 0
25 0
% 0
initially 0
, 0
did 0
not 0
alter 0
later 0
. 0

Certain 0
characteristics 0
of 0
eye 0
changes 0
in 0
patients 0
with 0
pheochromocytoma 0
including 0
Sipple 0
's 0
syndrome 0

The 0
color 0
- 0
word 0
interference 0
effect 0
previously 0
reported 0
with 0
normal 0
populations 0
when 0
given 0
the 0
Stroop 0
test 0
was 0
demonstrated 0
for 0
this 0
retarded 0
sample 0
using 0
a 0
special 0
format 0
. 0

It 0
was 0
found 0
that 0
under 0
the 0
selected 0
conditions 0
a 0
linear 0
dependence 0
exists 0
between 0
the 0
betaI 0
% 0
value 0
and 0
lgC 0
within 0
the 0
range 0
of 0
0.5 0
- 0
- 0
10 0
mug 0
ruscogenin 0
. 0

The 0
influence 0
of 0
adrenergic 0
nerves 0
of 0
the 0
response 0
of 0
blood 0
vessels 0
in 0
the 0
rabbit 0
ear 0
to 0
2 B-gene
- I-gene
- I-gene
phenylalanine I-gene
- I-gene
8 I-gene
- I-gene
lysine I-gene
vasopressin I-gene
( 0
Octapressin B-gene
) 0
. 0

Potscoital 0
test 0

I 0
. 0

When 0
a 0
tumour 0
is 0
present 0
nipple 0
discharge 0
is 0
of 0
little 0
importance 0
for 0
the 0
diagnosis 0
and 0
treatment 0
. 0

Studies 0
of 0
biochemical 0
and 0
morphological 0
changes 0
( 0
between 0
normal 0
and 0
treated 0
animals 0
) 0
show 0
that 0
chrysotile 0
induces 0
an 0
increase 0
in 0
the 0
lung 0
free 0
cell 0
population 0
and 0
pulmonary 0
surfactant 0
levels 0
. 0

Infrared 0
measurements 0
of 0
temperature 0
changes 0
and 0
estimates 0
of 0
the 0
heating 0
produced 0
at 0
the 0
mical 0
. 0

Who 0
says 0
'National 0
Health 0
Dis 0
- 0
service 0
' 0
. 0

Is 0
criticism 0
of 0
patient 0
care 0
justified 0
and 0
does 0
it 0
have 0
educational 0
value 0
? 0
Patients 0
' 0
criticism 0
contributes 0
to 0
improved 0
patient 0
care 0

Critique 0
of 0
`` 0
Interactive 0
Effects 0
of 0
Test 0
Anxiety 0
and 0
Credit/No 0
Credit 0
or 0
A 0
- 0
F 0
Grade 0
Condition 0
upon 0
Short 0
- 0
term 0
and 0
Long 0
- 0
term 0
Recall 0
of 0
Course 0
Information 0
. 0

These 0
studies 0
have 0
shown 0
that 0
the 0
majority 0
of 0
tested 0
staphylococci 0
were 0
resistant 0
to 0
penicillin 0
G 0
, 0
erythromycin 0
, 0
and 0
produced 0
beta B-gene
- I-gene
lactamase I-gene
. 0

Since 0
1968 0
, 0
a 0
steep 0
decrease 0
in 0
the 0
number 0
of 0
strains 0
resistant 0
to 0
three 0
or 0
more 0
antibiotics 0
( 0
multiple 0
- 0
resistant 0
) 0
and 0
in 0
strains 0
of 0
the 0
83A 0
complex 0
was 0
noticed 0
. 0

Improvement 0
of 0
nursing 0
instruction 0
to 0
be 0
given 0
at 0
the 0
time 0
of 0
discharge 0
from 0
the 0
ward 0
for 0
premature 0
infants 0

No 0
difference 0
in 0
the 0
clinical 0
acceptability 0
could 0
be 0
ascertained 0
between 0
the 0
two 0
groups 0
. 0

After 0
90 0
d 0
a 0
subsurface 0
, 0
radiolucent 0
caries 0
- 0
like 0
lesion 0
was 0
observed 0
in 0
two 0
specimens 0
only 0
. 0

The 0
contraceptive 0
pattern 0
of 0
157 0
women 0
was 0
analysed 0
and 0
13.8 0
percent 0
were 0
using 0
inefficient 0
methods 0
. 0

Plethysmographic 0
technique 0
and 0
indirect 0
blood 0
pressure 0
recordings 0
were 0
used 0
. 0

I 0
. 0

The 0
second 0
and 0
third 0
responded 0
similarly 0
to 0
either 0
a 0
combined 0
cyclophosphamide 0
+ 0
antilymphocyte B-gene
globulin I-gene
( 0
ALG B-gene
) 0
treatment 0
or 0
to 0
ALG B-gene
administration 0
preceded 0
by 0
a 0
small 0
dosage 0
of 0
cyclophosphamide 0
, 0
which 0
had 0
proved 0
ineffective 0
when 0
administered 0
alone 0
. 0

Evidence 0
is 0
presented 0
that 0
Leber 0
's 0
military 0
aneurysm 0
retinitis 0
is 0
not 0
a 0
separate 0
entity 0
but 0
a 0
special 0
form 0
of 0
Coats 0
' 0
disease 0
. 0

Fibrin B-gene
cloaking 0
along 0
the 0
catheter 0
was 0
found 0
in 0
20 0
patients 0
studied 0
by 0
pull 0
- 0
out 0
arteriography 0
and 0
was 0
unassociated 0
with 0
clinical 0
symptoms 0
. 0

The 0
influence 0
of 0
a 0
mobile 0
pupil 0
on 0
the 0
response 0
in 0
the 0
DC 0
- 0
ERG 0
is 0
demonstrated 0
. 0

A 0
newly 0
synthesized 0
anti 0
- 0
inflammatory 0
agent 0
, 0
Y 0
- 0
8004 0
demonstrated 0
a 0
greater 0
inhibition 0
than 0
did 0
indomethacin 0
( 0
IM 0
) 0
. 0
on 0
inflammatory 0
response 0
such 0
as 0
ultraviolet 0
erythema 0
in 0
guinea 0
pigs 0
, 0
carrageenin 0
edema 0
, 0
evans 0
blue 0
and 0
carrageenin 0
- 0
induced 0
pleuritis 0
and 0
acetic 0
acid 0
- 0
induced 0
peritonitis 0
in 0
rats 0
. 0

As 0
stands 0
shifted 0
in 0
dominance 0
from 0
pine 0
to 0
fir 0
with 0
age 0
, 0
subalpine 0
fir 0
appeared 0
to 0
maintain 0
gradually 0
increasing 0
rates 0
of 0
whole 0
- 0
forest 0
productivity 0
until 0
stands 0
were 0
approximately 0
400 0
years 0
old 0
. 0

Alpha B-gene
- I-gene
1 I-gene
antitrypsin I-gene
and 0
Indian 0
childhood 0
cirrhosis 0
. 0

Lymphocyte 0
subpopulations 0
, 0
serum B-gene
IgE I-gene
and 0
total 0
eosinophil 0
counts 0
in 0
patients 0
with 0
bronchial 0
asthma 0
. 0

A 0
range 0
of 0
normal 0
ventricular 0
measurements 0
for 0
the 0
EMI 0
scan 0
is 0
suggested 0
. 0

A 0
comparison 0
of 0
physical 0
and 0
cytogenetic 0
estimates 0
of 0
radiation 0
dose 0
in 0
patients 0
treated 0
with 0
iodine 0
- 0
131 0
for 0
thyroid 0
carcinoma 0
. 0

Technique 0
for 0
obtaining 0
refined 0
ceramics 0
with 0
dense 0
mass 0

Mean 0
total 0
lung 0
capacity 0
, 0
functional 0
residual 0
capacity 0
, 0
and 0
residual 0
volume 0
increased 0
significantly 0
, 0
and 0
the 0
mean 0
closing 0
volume 0
, 0
the 0
lung 0
volume 0
above 0
residual 0
volume 0
at 0
which 0
phase 0
IV 0
begins 0
, 0
decreased 0
significantly 0
with 0
11 0
cm 0
H20 0
continuous 0
positive 0
airway 0
pressure 0
; 0
differences 0
at 0
5 0
cm 0
H20 0
were 0
not 0
significant 0
. 0

Current 0
status 0
of 0
zinc 0
deficiency 0
in 0
the 0
pathogenesis 0
of 0
neurological 0
, 0
dermatological 0
and 0
musculoskeletal 0
disorders 0
. 0

Calcium 0
and 0
phosphorus 0
metabolism 0
in 0
chronic 0
uremia 0
. 0

Modern 0
studies 0
, 0
conducted 0
with 0
Delta 0
- 0
9 0
- 0
THC 0
, 0
in 0
healthy 0
voluntaries 0
, 0
again 0
suggest 0
the 0
comparison 0
or 0
even 0
the 0
identity 0
of 0
the 0
modifications 0
caused 0
by 0
cannabis 0
with 0
sleep 0
and 0
dream 0
. 0

The 0
correcting 0
action 0
of 0
tropatepine 0
hydrochloride 0
upon 0
the 0
extrapyramidal 0
effects 0
induced 0
by 0
neuroleptics 0
has 0
been 0
studied 0
in 0
32 0
acute 0
psychotic 0
states 0
. 0

Epididymal 0
growth 0
was 0
retarded 0
in 0
animals 0
maintained 0
solely 0
on 0
chickpea 0
haulm 0
and 0
improved 0
with 0
supplementation 0
. 0

Two 0
patients 0
were 0
treated 0
with 0
both 0
regimens 0
. 0

Results 0
obtained 0
for 0
chloramphenicol 0
- 0
containing 0
preparations 0
are 0
presented 0
, 0
and 0
both 0
dissolution 0
curves 0
and 0
cup 0
- 0
plate 0
assays 0
demonstrate 0
that 0
chloramphenicol 0
has 0
far 0
superior 0
release 0
( 0
and 0
hence 0
activity 0
) 0
from 0
creams 0
than 0
from 0
ophthalmic 0
ointments 0
. 0

IgG B-gene
levels 0
of 0
1/100 0
were 0
present 0
in 0
only 0
four 0
out 0
of 0
ten 0
samples 0
obtained 0
150 0
days 0
after 0
the 0
clinical 0
onset 0
. 0

Letter 0
: 0
Perspectives 0
in 0
bone 0
marrow 0
transplantation 0
. 0

Assessment 0
of 0
the 0
carcinogenicity 0
of 0
non 0
- 0
nutritive 0
sweetners 0
II 0
: 0
Cyclamates 0
and 0
cyclohexylamine 0
. 0

The 0
discordant 0
behaviour 0
in 0
weakly 0
infected 0
mice 0
was 0
due 0
to 0
the 0
occurrence 0
in 0
some 0
animals 0
of 0
a 0
second 0
phase 0
of 0
more 0
rapid 0
increase 0
of 0
the 0
parasitemia 0
. 0

Residual 0
amphotericin 0
B 0
was 0
detected 0
in 0
the 0
feces 0
of 0
the 0
mice 0
only 0
while 0
they 0
were 0
receiving 0
the 0
0.3 0
mg/ml 0
dose 0
level 0
. 0

There 0
was 0
a 0
slight 0
increase 0
in 0
total 0
transferrin B-gene
2 0
hr 0
after 0
1 0
tablet 0
and 0
values 0
remained 0
high 0
throughout 0
the 0
experiment 0
. 0

Following 0
intravenous 0
administration 0
, 0
the 0
myocardial 0
concentration 0
of 0
tracer 0
thallium 0
- 0
201 0
, 0
potassium 0
- 0
43 0
, 0
and 0
rubidium 0
- 0
81 0
were 0
determined 0
in 0
mice 0
; 0
thallium 0
was 0
present 0
in 0
the 0
greatest 0
concentration 0
in 0
the 0
myocardium 0
( 0
2.08 0
% 0
compared 0
1.25 0
% 0
for 0
potassium 0
and 0
1.15 0
% 0
for 0
rubidium 0
at 0
10 0
minutes 0
) 0
. 0

Thromboplastin B-gene
time 0
, 0
partial 0
thromboplastin B-gene
time 0
, 0
thrombin B-gene
time 0
, 0
heat 0
- 0
dependent 0
fibrin B-gene
, 0
clot 0
retraction 0
, 0
and 0
clotting B-gene
factors I-gene
II I-gene
, I-gene
V I-gene
, I-gene
VIII I-gene
, I-gene
IX I-gene
, I-gene
X I-gene
, 0
and 0
the 0
platelet 0
count 0
were 0
determined 0
. 0

The 0
data 0
support 0
the 0
notion 0
that 0
suppression 0
of 0
images 0
during 0
binocular 0
rivalry 0
is 0
independent 0
in 0
both 0
eyes 0
. 0

Glycogen 0
utilization 0
was 0
increased 0
, 0
but 0
tissue 0
levels 0
of 0
creatine 0
phosphate 0
, 0
ATP 0
, 0
and 0
lactate 0
were 0
similar 0
to 0
those 0
in 0
hearts 0
receiving 0
normal 0
flow 0
. 0

The 0
records 0
from 0
1948 0
through 0
1967 0
of 0
344 0
previously 0
untreated 0
patients 0
with 0
squamous 0
cell 0
carcinoma 0
of 0
the 0
oral 0
cavity 0
, 0
oropharynx 0
, 0
supraglottic 0
larynx 0
and 0
hypopharynx 0
who 0
had 0
clinically 0
positive 0
cervical 0
lymph 0
node 0
metastases 0
staged 0
N1 0
, 0
N2A 0
, 0
or 0
N2B 0
, 0
and 0
whose 0
initial 0
neck 0
treatment 0
consisted 0
of 0
external 0
radiation 0
therapy 0
alone 0
were 0
reviewed 0
. 0

With 0
0.5 0
vol. 0
- 0
% 0
, 0
the 0
corresponding 0
values 0
were 0
345 0
mumol/1 0
( 0
5.72 0
mg/100 0
ml 0
) 0
and 0
137 0
mumol/1 0
( 0
2.25 0
mg/100 0
ml 0
) 0
respectively 0
. 0

The 0
authors 0
describe 0
the 0
technique 0
of 0
transverse 0
axial 0
tomography 0
of 0
the 0
spine 0
and 0
give 0
a 0
detailed 0
description 0
of 0
the 0
axial 0
anatomy 0
of 0
the 0
normal 0
lumbar 0
spine 0
from 0
L 0
- 0
4 0
to 0
the 0
sacrum 0
. 0

Owing 0
to 0
parental 0
attitude 0
, 0
a 0
low 0
protein 0
diet 0
( 0
1 0
- 0
5 0
g/kg 0
) 0
was 0
introduced 0
only 0
late 0
. 0

In 0
none 0
of 0
the 0
44 0
type 0
I 0
attacks 0
and 0
29 0
type 0
II 0
attacks 0
which 0
were 0
recorded 0
did 0
circulatory 0
changes 0
; 0
the 0
latter 0
were 0
different 0
in 0
the 0
two 0
groups 0
. 0

A 0
clinically 0
useful 0
diagnostic 0
method 0
has 0
been 0
developed 0
for 0
detecting 0
and 0
quantitating 0
periods 0
of 0
apnea 0
in 0
pediatric 0
patients 0
. 0

The 0
other 0
hypoglycaemic 0
patient 0
showed 0
an 0
exaggerated 0
insulin B-gene
release 0
in 0
response 0
to 0
tolbutamide 0
. 0

Nerve 0
stimulation 0
( 0
1.5 0
- 0
12 0
cycles/s 0
) 0
produced 0
frequency 0
- 0
dependent 0
reductions 0
in 0
CBF 0
, 0
a 0
decrease 0
of 0
50 0
percent 0
occurring 0
with 0
the 0
highest 0
frequency 0
. 0

Effect 0
of 0
ingestion 0
of 0
Norbiogest 0
during 0
the 0
quiescent 0
period 0
of 0
the 0
genital 0
organs 0

Risk 0
of 0
infection 0
in 0
the 0
treatment 0
of 0
fractures 0

Bulbar 0
pouches 0
were 0
perfused 0
with 0
solutions 0
of 0
0.9 0
% 0
Na 0
C1 0
, 0
0.1 0
N 0
HC1 0
, 0
40 0
% 0
glucose 0
, 0
40 0
% 0
NaC1 0
, 0
and 0
40 0
% 0
peptone 0
or 0
with 0
0.1 0
% 0
solutions 0
of 0
acetylcholine 0
chloride 0
. 0

Liver 0
microsomes 0
of 0
the 0
shag 0
showed 0
smaller 0
than 0
8 0
% 0
of 0
the 0
epoxide B-gene
hydrase I-gene
activity 0
and 0
smaller 0
than 0
14 0
% 0
of 0
the 0
hydroxylating 0
capacity 0
of 0
liver 0
microsomes 0
from 0
the 0
rat 0
. 0

Prolonged 0
heavy 0
work 0
effected 0
an 0
increase 0
of 0
10.3 0
plus 0
or 0
minus 0
0.9 0
mmHg 0
in 0
in 0
vivo 0
P50 0
( 0
7.30 0
PH 0
- 0
v 0
, 0
41 0
degrees 0
C 0
- 0
v 0
, 0
and 0
45 0
Pv 0
- 0
CO2 0
) 0
; 0
due 0
entirely 0
to 0
the 0
additive 0
effects 0
of 0
increased 0
venous 0
temperature 0
and 0
[ 0
H+ 0
] 0
. 0

A 0
clinical 0
, 0
serological 0
and 0
prognostic 0
study 0

The 0
American 0
Burkitt 0
Lymphoma 0
Registry 0
: 0
a 0
progress 0
report 0
. 0

Vitrectomy 0
with 0
an 0
alternative 0
instrument 0
system 0
. 0

The 0
metabolic 0
clearance 0
rate 0
of 0
progesterone 0
was 0
295 0
+/ 0
- 0
49 0
( 0
S.E 0
. 0
) 0
1/day 0
. 0

This 0
sequence 0
is 0
almost 0
identical 0
with 0
that 0
of 0
human B-gene
luteinizing I-gene
hormone I-gene
( 0
Sairam 0
, 0
M 0
. 0

The 0
mean 0
plasma 0
sodium 0
concentration 0
which 0
was 0
135.95 0
( 0
+/ 0
- 0
SD 0
4.14 0
) 0
mEq/kg 0
before 0
diuretic 0
treatment 0
was 0
significantly 0
decreased 0
during 0
treatment 0
to 0
129.19 0
( 0
+/ 0
- 0
SD 0
2.77 0
) 0
mEq/kg 0
, 0
P 0
less 0
than 0
0.001 0
. 0

Editorial 0
: 0
Low 0
- 0
dose 0
heparin 0
and 0
the 0
prevention 0
of 0
venous 0
thromboembolic 0
disease 0
. 0

At 0
the 0
very 0
high 0
dose 0
levels 0
used 0
, 0
sodium 0
saccharin 0
and 0
sodium 0
cyclamate 0
were 0
weak 0
solitary 0
carcinogens 0
producing 0
4/253 0
and 0
3/228 0
bladder 0
tumours 0
respectively 0
, 0
and 0
the 0
first 0
of 0
these 0
tumours 0
did 0
not 0
appear 0
for 0
more 0
than 0
80 0
weeks 0
. 0

Effects 0
of 0
perceptual 0
salience 0
on 0
the 0
matrix 0
task 0
performance 0
of 0
four 0
- 0
and 0
six 0
- 0
year 0
- 0
old 0
children 0
. 0

Glucose B-gene
- I-gene
6 I-gene
- I-gene
phosphate I-gene
dehydrogenase I-gene
( 0
G B-gene
- I-gene
6 I-gene
- I-gene
PD I-gene
) 0
deficiency 0
in 0
the 0
newborn 0
. 0

The 0
eluting 0
solvent 0
was 0
methanol 0
- 0
chloroform 0
( 0
10+90 0
) 0
at 0
a 0
flow 0
rate 0
of 0
2.0 0
ml/min 0
. 0

The 0
bronchial 0
epithelia 0
of 0
all 0
smoke 0
- 0
exposed 0
animals 0
were 0
hyperplastic 0
, 0
and 0
their 0
ultrastructure 0
showed 0
invaginations 0
, 0
tilt 0
of 0
nuclear 0
axes 0
, 0
an 0
increase 0
in 0
the 0
number 0
and 0
size 0
of 0
lysosomes 0
and 0
multivesiculated 0
bodies 0
, 0
and 0
increased 0
numbers 0
of 0
enlarged 0
intramitochondrial 0
granules 0
. 0

The 0
routine 0
administration 0
of 0
fat 0
- 0
soluble 0
vitamins 0
appears 0
unnecessary 0
but 0
it 0
is 0
prudent 0
to 0
measure 0
prothrombin B-gene
time 0
and 0
serum 0
vitamins 0
A 0
and 0
E 0
at 0
intervals 0
. 0

Prostaglandins 0
F 0
( 0
PGF 0
) 0
were 0
measured 0
in 0
uterine 0
vein 0
, 0
ovarian 0
artery 0
, 0
and 0
jugular 0
vein 0
plasma 0
and 0
in 0
the 0
endometrial 0
tissues 0
at 0
various 0
times 0
during 0
the 0
bovine 0
estrous 0
cycle 0
, 0
and 0
were 0
compared 0
to 0
peripheral 0
plasma 0
progesterone 0
levels 0
. 0

Before 0
this 0
date 0
, 0
the 0
drug 0
directly 0
inhibits 0
fetal 0
weight 0
gain 0
, 0
whereas 0
the 0
sensitivity 0
of 0
the 0
placenta 0
is 0
only 0
transient 0
at 0
day 0
16 0
resulting 0
in 0
maximum 0
weight 0
decrease 0
of 0
this 0
organ 0
24 0
h 0
later 0
. 0

Groups 0
of 0
ten 0
dependent 0
and 0
ten 0
saline 0
mice 0
were 0
singly 0
tested 0
in 0
both 0
light 0
and 0
dark 0
conditions 0
in 0
each 0
of 0
five 0
covered 0
cylinders 0
( 0
2 0
- 0
23 0
in 0
high 0
) 0
. 0

The 0
effects 0
initiated 0
from 0
the 0
nucleus 0
accumbens 0
septi 0
were 0
most 0
marked 0
. 0

The 0
appearance 0
of 0
dyskinetic 0
movement 0
disorders 0
in 0
humans 0
following 0
the 0
chronic 0
use 0
of 0
levodopa 0
or 0
amphetamine 0
may 0
be 0
a 0
manifestation 0
of 0
similarly 0
increased 0
dopamine B-gene
receptor I-gene
site I-gene
sensitivity 0
within 0
the 0
striatum 0
. 0

Association 0
with 0
HL B-gene
- I-gene
A I-gene
W I-gene
- I-gene
27 I-gene
. 0

Letter 0
: 0
Lactose 0
tolerance 0
tests 0
as 0
a 0
predictor 0
of 0
milk 0
tolerance 0
. 0

Retinoblastoma 0
: 0
a 0
study 0
of 0
natural 0
history 0
and 0
prognosis 0
of 0
268 0
cases 0
. 0

Like 0
pineal 0
melatonin 0
, 0
serum 0
melatonin 0
was 0
high 0
at 0
mid 0
- 0
dark 0
and 0
low 0
at 0
mid 0
- 0
light 0
. 0

D 0
. 0

Atherosclerosis 0

The 0
authors 0
concluded 0
that 0
ultrasonic 0
Doppler 0
- 0
cardiography 0
can 0
be 0
used 0
for 0
measuring 0
the 0
relative 0
changes 0
in 0
the 0
stroke 0
volume 0
. 0

The 0
attainment 0
of 0
sexual 0
maturity 0
in 0
terms 0
of 0
secondary 0
sexual 0
characteristics 0
, 0
the 0
production 0
of 0
spermatozoa 0
in 0
the 0
male 0
, 0
and 0
the 0
cyclical 0
female 0
pattern 0
with 0
release 0
of 0
ova 0
are 0
end 0
- 0
points 0
of 0
the 0
developmental 0
process 0
. 0

However 0
, 0
a 0
10 0
- 0
- 0
15 0
% 0
lengthening 0
of 0
the 0
partial 0
thromboplastin B-gene
time 0
is 0
evident 0
after 0
24 0
hours 0
of 0
storage 0
. 0

Caution 0
should 0
be 0
exercised 0
in 0
the 0
use 0
of 0
these 0
dyes 0
for 0
lymphograms 0
. 0

This 0
reveals 0
a 0
new 0
test 0
for 0
short 0
saphenous 0
incompetence 0
and 0
shows 0
that 0
14 0
per 0
cent 0
of 0
varices 0
stem 0
from 0
a 0
saphenopopliteal 0
reflux 0
. 0

Three 0
groups 0
of 0
patients 0
who 0
had 0
undergone 0
subtotal 0
thyroidectomy 0
for 0
Graves 0
's 0
disease 0
, 0
toxic 0
multinodular 0
goitre 0
, 0
or 0
euthyroid 0
multinodular 0
goitre 0
12 0
to 0
15 0
years 0
before 0
and 0
in 0
whom 0
a 0
normal 0
serum 0
thyroxine 0
( 0
T 0
- 0
4 0
) 0
level 0
was 0
found 0
were 0
each 0
divided 0
into 0
two 0
subgroups 0
on 0
the 0
basis 0
of 0
a 0
normal 0
or 0
a 0
raised 0
serum 0
thyrotrophin B-gene
concentration 0
. 0

Routine 0
isotope 0
cystography 0
using 0
99M 0
Tc 0
sulfur 0
colloid 0
for 0
detection 0
and 0
follow 0
- 0
up 0
of 0
vesico 0
- 0
ureteral 0
reflux 0

Air 0
ion 0
action 0
on 0
bacteria 0
. 0

No 0
evidence 0
of 0
either 0
positive 0
or 0
negative 0
chemography 0
was 0
found 0
. 0

The 0
interpretation 0
of 0
antibiotic 0
disc 0
sensitivities 0
. 0

Following 0
retransfusion 0
, 0
the 0
affected 0
epithelial 0
lining 0
appeared 0
greatly 0
distended 0
over 0
the 0
oedematous 0
lamina 0
propria 0
, 0
with 0
almost 0
complete 0
loss 0
of 0
structural 0
detail 0
. 0

A 0
study 0
of 0
chromosomes 0
of 0
lymphocytes 0
from 0
patients 0
treated 0
with 0
hycanthone 0
. 0

Characteristics 0
of 0
anesthesia 0
and 0
resuscitation 0
in 0
emergency 0
lung 0
surgery 0

Study 0
of 0
the 0
physico 0
- 0
chemical 0
state 0
of 0
plutonium 0
- 0
239 0
in 0
a 0
citrate 0
solution 0
- 0
blood 0
system 0

Tobramycin 0
60 0
mg 0
did 0
not 0
show 0
any 0
remarkable 0
effect 0
, 0
but 0
dibecacin 0
100 0
mg 0
produced 0
a 0
slight 0
potentiating 0
effect 0
on 0
the 0
action 0
of 0
d 0
- 0
tubocurarine 0
. 0

In 0
about 0
one 0
third 0
of 0
the 0
cases 0
this 0
operation 0
results 0
in 0
tonal 0
and 0
vocal 0
improvement 0
for 0
patients 0
suffering 0
from 0
progressive 0
perceptive 0
deafness 0
. 0

The 0
specific 0
electrical 0
resistance 0
of 0
the 0
cerebrospinal 0
fluid 0
was 0
measured 0
by 0
means 0
of 0
conductometry 0
in 0
14 0
cases 0
of 0
meningitis 0
purulenta 0
, 0
17 0
cases 0
of 0
meningitis 0
serosa 0
, 0
10 0
cases 0
of 0
encephalitis 0
and 0
in 0
32 0
control 0
subjects 0
. 0

2 0
- 0
Chemical 0
occlusion 0
of 0
vas 0
is 0
quite 0
effective 0
in 0
producing 0
a 0
block 0
in 0
the 0
vas 0
deferens 0
of 0
dogs 0
. 0

Besides 0
, 0
we 0
found 0
in 0
3 0
patients 0
increased 0
serum B-gene
immunoglobulins I-gene
, 0
chiefly 0
IgG B-gene
, 0
as 0
first 0
Russe 0
, 0
Busey 0
and 0
Barbeau 0
demonstrated 0
in 0
a 0
large 0
French 0
- 0
Canadian 0
family 0
. 0

We 0
suggest 0
that 0
such 0
occlusions 0
occurred 0
at 0
the 0
time 0
of 0
the 0
infarction 0
. 0

Streptococcal 0
preparation 0
( 0
OK 0
- 0
432 0
) 0
, 0
a 0
new 0
type 0
of 0
anti 0
- 0
cancer 0
agent 0
, 0
was 0
given 0
to 0
the 0
patients 0
with 0
advanced 0
cancer 0
in 0
combination 0
with 0
Mitomycin 0
- 0
C 0
, 0
5 0
- 0
FU 0
and 0
Cytosine 0
arabinoside 0
. 0

Generally 0
, 0
a 0
correlation 0
was 0
observed 0
between 0
highest 0
concentrations 0
of 0
CSF B-gene
immunoglobulins I-gene
and 0
degree 0
of 0
meningeal 0
inflammatory 0
response 0
, 0
even 0
if 0
this 0
was 0
a 0
component 0
of 0
other 0
neurological 0
diseases 0
. 0

Maternal 0
lactation 0

Experimental 0
cardiotoxicity 0
of 0
adriamycin 0

Muscular 0
pathology 0

Demonstration 0
of 0
the 0
agent 0
was 0
performed 0
from 0
the 0
6th 0
to 0
the 0
11th 0
day 0
p.i 0
. 0
by 0
direct 0
microscopic 0
methods 0
( 0
Stamp 0
and 0
auramine 0
staining 0
, 0
fluorescent 0
antibody 0
technique 0
) 0
; 0
the 0
Coxiella 0
content 0
was 0
determined 0
by 0
titration 0
in 0
embryonated 0
hen 0
's 0
eggs 0
. 0

The 0
patients 0
were 0
divided 0
into 0
4 0
groups 0
receiving 0
NLA 0
II 0
with 0
or 0
without 0
nalorphine 0
, 0
morphine 0
or 0
Micoren 0
. 0

The 0
alterations 0
of 0
5 0
- 0
HT 0
and 0
5 0
- 0
HIAA 0
levels 0
in 0
several 0
regions 0
of 0
the 0
brain 0
under 0
the 0
conditions 0
examined 0
may 0
indicate 0
that 0
IDPN 0
's 0
neurotoxicity 0
primarily 0
affects 0
5 0
- 0
HT 0
- 0
containing 0
neurones 0
. 0

( 0
5 0
) 0
An 0
increase 0
in 0
leukocyte 0
- 0
counts 0
occurred 0
on 0
the 0
administration 0
of 0
serum 0
obtained 0
from 0
rabbit 0
during 0
phase 0
- 0
2 0
. 0

The 0
results 0
obtained 0
tend 0
to 0
prove 0
that 0
the 0
reticuloendothelial 0
system 0
mainly 0
participated 0
in 0
beryllium 0
retention 0
. 0

In 0
both 0
cases 0
, 0
at 0
the 0
end 0
of 0
exposure 0
the 0
same 0
level 0
of 0
blood B-gene
carboxyhemoglobin I-gene
( 0
COHb B-gene
) 0
( 0
about 0
50 0
% 0
) 0
was 0
reached 0
. 0

The 0
results 0
indicate 0
that 0
increased 0
pulmonary 0
blood 0
flow 0
and 0
decreased 0
pulmonary 0
vascular 0
resistance 0
with 0
advancing 0
gestation 0
are 0
due 0
to 0
an 0
increase 0
in 0
the 0
total 0
number 0
of 0
vessels 0
and 0
increased 0
vasomotor 0
reactivity 0
is 0
related 0
to 0
an 0
increase 0
in 0
the 0
total 0
amount 0
of 0
smooth 0
muscle 0
while 0
the 0
thickness 0
of 0
muscle 0
in 0
individual 0
vessels 0
remains 0
constant 0
. 0

Reduction 0
in 0
dosage 0
restored 0
normal 0
taste 0
sense 0
in 0
all 0
three 0
, 0
but 0
in 0
two 0
the 0
drug 0
had 0
to 0
be 0
discontinued 0
because 0
of 0
persisting 0
high 0
transaminase 0
levels 0
. 0

The 0
calcium 0
ratio 0
( 0
mean 0
ratio 0
of 0
the 0
predicted 0
to 0
measured 0
TBCa 0
) 0
in 0
men 0
was 0
1.000 0
+/ 0
- 0
7.8 0
% 0
and 0
in 0
women 0
0.996 0
+/ 0
- 0
7.1 0
% 0
. 0

A 0
late 0
diagnosis 0
of 0
retinoblastoma 0
is 0
an 0
unquestionable 0
fact 0
that 0
allows 0
its 0
growth 0
and 0
leads 0
to 0
a 0
deterioration 0
in 0
the 0
outlook 0
. 0

Total 0
cholesterol 0
was 0
measured 0
in 0
amniotic 0
fluids 0
collected 0
at 0
different 0
stages 0
of 0
gestation 0
. 0

Her 0
serum 0
FT3 0
concentration 0
was 0
, 0
however 0
, 0
much 0
higher 0
than 0
the 0
ranges 0
in 0
normal 0
pregnancy 0
or 0
in 0
GTD 0
patients 0
without 0
clinical 0
hyperthyroidism 0
. 0

The 0
authors 0
found 0
that 0
except 0
for 0
fear 0
and 0
pugnacity 0
all 0
husband 0
- 0
wife 0
trait 0
correlations 0
were 0
positive 0
, 0
in 0
contrast 0
to 0
Winch 0
's 0
principle 0
of 0
type 0
I 0
complementarity 0
. 0

A 0
note 0
on 0
the 0
phase 0
- 0
plane 0
technique 0
representation 0
of 0
cardiac 0
action 0
potentials 0
. 0

3 0
activities 0
of 0
the 0
factor B-gene
II I-gene
molecule 0
in 0
the 0
newborn 0
infant 0
at 0
term 0

The 0
concept 0
of 0
`` 0
structural 0
identifiability 0
'' 0
is 0
employed 0
in 0
this 0
analysis 0
to 0
determine 0
which 0
model 0
parameters 0
can 0
be 0
and 0
which 0
can 0
not 0
be 0
determined 0
`` 0
uniquely 0
'' 0
from 0
given 0
input 0
- 0
output 0
data 0
; 0
a 0
step 0
- 0
by 0
- 0
step 0
procedure 0
based 0
on 0
an 0
extension 0
of 0
this 0
concept 0
is 0
presented 0
for 0
adapting 0
the 0
overall 0
approach 0
to 0
the 0
experimental 0
design 0
problem 0
. 0

However 0
, 0
we 0
did 0
detect 0
lot 0
- 0
to 0
- 0
lot 0
variation 0
and 0
differences 0
in 0
performance 0
between 0
narrow 0
bandpass 0
and 0
wide 0
bandpass 0
spectrophotometers 0
. 0

The 0
cochlear 0
compromise 0
. 0

A 0
case 0
observed 0
in 0
Saigon 0

Hypertonic 0
glucose 0
administered 0
intrajejunally 0
in 0
Heidenhain 0
pouch 0
dogs 0
resulted 0
in 0
an 0
equal 0
inhibition 0
of 0
pentagastrin 0
- 0
induced 0
acid 0
secretion 0
from 0
the 0
pouch 0
and 0
the 0
main 0
stomach 0
, 0
whereas 0
hypertonic 0
saline 0
had 0
no 0
effect 0
. 0

Acquired 0
factor B-gene
VIII I-gene
inhibitor 0
in 0
non 0
- 0
hemophilic 0
patients 0

Biohydrogenation 0
of 0
linoleic 0
acid 0
into 0
octadecenoic 0
acid 0
was 0
observed 0
. 0

The 0
study 0
of 0
calcium 0
metabolism 0
in 0
ten 0
thalassaemic 0
children 0
comperatively 0
with 0
controls 0
after 0
oral 0
administration 0
of 0
47Ca 0
has 0
shown 0
diminished 0
intestinal 0
absorption 0
. 0

Chlamydial 0
agents 0
were 0
isolated 0
from 0
the 0
semen 0
near 0
the 0
end 0
of 0
the 0
chlamydemic 0
phase 0
. 0

Because 0
of 0
the 0
increased 0
CPK B-gene
activity 0
found 0
in 0
normal 0
newborns 0
, 0
screening 0
for 0
Duchenne 0
- 0
type 0
muscular 0
dystrophy 0
should 0
be 0
postponed 0
for 0
a 0
few 0
weeks 0
after 0
delivery 0
. 0

In 0
contrast 0
, 0
the 0
insulin B-gene
response 0
had 0
returned 0
to 0
the 0
non 0
- 0
pregnant 0
value 0
by 0
the 0
second 0
day 0
of 0
the 0
puerperium 0
. 0

The 0
authors 0
report 0
the 0
results 0
of 0
a 0
series 0
of 0
toxicological 0
tests 0
conducted 0
on 0
plastic 0
materials 0
( 0
polyethylene 0
) 0
activated 0
with 0
tetraphenylbutadiene 0
( 0
TPB 0
) 0
an 0
additive 0
recently 0
proposed 0
as 0
a 0
sensitizer 0
capable 0
of 0
photodegrading 0
plastic 0
materials 0
. 0

Mutational 0
analysis 0
of 0
the 0
major 0
homology 0
region 0
of 0
Mason 0
- 0
Pfizer 0
monkey 0
virus 0
by 0
use 0
of 0
saturation 0
mutagenesis 0
. 0

One 0
site 0
, 0
PAL B-gene
, 0
occurs 0
within 0
the 0
10 0
bp 0
sequence 0
GGGGAGGAGG 0
. 0

Nuclear 0
extracts 0
prepared 0
from 0
both 0
neural 0
and 0
non 0
- 0
neural 0
cell 0
lines 0
, 0
mouse 0
brain 0
, 0
and 0
mouse 0
liver 0
contain 0
proteins 0
that 0
recognize 0
and 0
bind 0
to 0
the 0
PROX 0
and 0
PAL 0
sequences 0
indicating 0
that 0
proteins 0
which 0
bind 0
to 0
these 0
target 0
sequences 0
are 0
widespread 0
. 0

To 0
determine 0
if 0
the 0
NF B-gene
( I-gene
H I-gene
) I-gene
promoter I-gene
can 0
be 0
activated 0
in 0
a 0
tissue 0
specific 0
manner 0
during 0
development 0
transgenic 0
mice 0
containing 0
the 0
promoter 0
region 0
linked 0
to 0
a 0
beta B-gene
- I-gene
galactosidase I-gene
reporter I-gene
gene I-gene
were 0
generated 0
. 0

Here 0
we 0
describe 0
and 0
map 0
two 0
more 0
new 0
genes 0
identified 0
as 0
allele 0
- 0
specific 0
suppressors 0
that 0
compensate 0
for 0
carboxy 0
- 0
terminal 0
truncation 0
of 0
PET122 B-gene
. 0

Previous 0
studies 0
have 0
shown 0
[ 0
Hisanaga 0
, 0
S. 0
, 0
Kusubata 0
, 0
M. 0
, 0
Okumura 0
, 0
E. 0
& 0
Kishimoto 0
, 0
T 0
. 0

Treatment 0
and 0
staining 0
of 0
smears 0
and 0
sections 0
for 0
detection 0
of 0
microorganisms 0

The 0
apparent 0
Kd 0
of 0
the 0
MetRS/CAU B-gene
operator I-gene
complex I-gene
is 0
one 0
order 0
magnitude 0
higher 0
than 0
that 0
of 0
the 0
ThrRS/CGU B-gene
operator I-gene
complex I-gene
. 0

A 0
significant 0
direct 0
relationship 0
was 0
observed 0
between 0
the 0
percent 0
area 0
density 0
of 0
smooth 0
muscle 0
and 0
the 0
percent 0
change 0
in 0
peak 0
urinary 0
flow 0
rate 0
. 0

Rabbit B-gene
skeletal I-gene
muscle I-gene
glycogenin I-gene
. 0

Characterization 0
of 0
the 0
human B-gene
gene I-gene
encoding I-gene
cytokeratin I-gene
17 I-gene
and 0
its 0
expression 0
pattern 0
. 0

Animals 0
that 0
received 0
DSP 0
- 0
4 0
were 0
significantly 0
retarded 0
in 0
motor 0
recovery 0
compared 0
with 0
the 0
saline 0
group 0
. 0

The 0
prophylactic 0
use 0
of 0
new 0
medication 0
for 0
patients 0
between 0
the 0
first 0
and 0
second 0
cycle 0
of 0
chemotherapy 0
, 0
in 0
agreement 0
with 0
the 0
estimates 0
calculated 0
, 0
does 0
not 0
save 0
health 0
care 0
costs 0
but 0
may 0
improve 0
the 0
quality 0
of 0
life 0
in 0
these 0
patients 0
and 0
permit 0
the 0
continuation 0
of 0
a 0
therapeutic 0
schedule 0
without 0
interruption 0
which 0
may 0
improve 0
the 0
life 0
expectancy 0
of 0
the 0
patient 0
. 0

AP 0
was 0
induced 0
by 0
intraductal 0
infusion 0
of 0
two 0
different 0
concentrations 0
of 0
glycodeoxycholic 0
acid 0
( 0
GDOC 0
17 0
mmol 0
and 0
34 0
mmol 0
) 0
. 0

The 0
isolation 0
of 0
this 0
gene 0
was 0
based 0
on 0
the 0
identification 0
of 0
the 0
Y 0
- 0
231 0
cosmid 0
that 0
contains 0
CpG 0
rich 0
sequences 0
( 0
HTF 0
islands 0
) 0
in 0
its 0
human 0
insert 0
. 0

Tissue B-gene
plasminogen I-gene
activator I-gene
, 0
its 0
inhibitor 0
and 0
other 0
parameters 0
of 0
fibrinolysis 0
in 0
blood 0
of 0
patients 0
operated 0
for 0
mild 0
hypertrophy 0
of 0
the 0
prostate 0

Gene 0
constructs 0
consisting 0
of 0
human B-gene
growth I-gene
hormone I-gene
( 0
hGH B-gene
) 0
gene 0
driven 0
by 0
promoter/regulatory 0
sequence 0
of 0
mouse B-gene
metallothionein I-gene
( 0
mMT B-gene
) 0
, 0
viral B-gene
thymidine I-gene
kinase I-gene
( 0
vTK B-gene
) 0
, 0
rat B-gene
cholecystokinin I-gene
( 0
rCCK B-gene
) 0
, 0
or 0
chicken B-gene
beta I-gene
- I-gene
actin I-gene
( 0
cBA B-gene
) 0
gene 0
were 0
injected 0
into 0
the 0
cytoplasm 0
of 0
fertilized 0
medaka 0
eggs 0
via 0
the 0
micropyle 0
. 0

Serum 0
gastrin B-gene
and 0
AFP B-gene
levels 0
had 0
the 0
same 0
evolution 0
and 0
appear 0
to 0
have 0
the 0
same 0
interest 0
to 0
follow 0
the 0
course 0
of 0
the 0
disease 0
. 0

Prospects 0
for 0
controlled 0
- 0
delivery 0
systems 0
. 0

The 0
mean 0
( 0
+/ 0
- 0
SD 0
) 0
PaO2 0
increased 0
from 0
80.8 0
+/ 0
- 0
26.9 0
mmHg 0
before 0
to 0
89.8 0
+/ 0
- 0
27.3 0
mmHg 0
after 0
the 0
infusion 0
( 0
P 0
< 0
0.05 0
) 0
and 0
the 0
PaCO2 0
decreased 0
from 0
42.4 0
+/ 0
- 0
8.3 0
to 0
39.6 0
+/ 0
- 0
7.9 0
mmHg 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Though 0
hepatomegaly 0
and 0
mild 0
elevation 0
of 0
enzymes 0
can 0
be 0
observed 0
in 0
a 0
significant 0
proportion 0
of 0
patients 0
, 0
involvement 0
of 0
liver 0
leading 0
to 0
acute 0
hepatitis 0
or 0
liver 0
cell 0
necrosis 0
is 0
a 0
relatively 0
uncommon 0
complication 0
in 0
P. 0
falciparum 0
malaria 0
. 0

For 0
the 0
first 0
group 0
, 0
the 0
maximal 0
decrease 0
in 0
plasma 0
potassium 0
elicited 0
by 0
salbutamol 0
was 0
0.80 0
+/ 0
- 0
0.19 0
, 0
0.48 0
+/ 0
- 0
0.22 0
, 0
and 0
0.78 0
+/ 0
- 0
0.46 0
mmol/l 0
, 0
and 0
for 0
the 0
second 0
group 0
, 0
maximal 0
decrement 0
was 0
1.31 0
+/ 0
- 0
0.37 0
, 0
0.70 0
+/ 0
- 0
0.24 0
, 0
and 0
0.84 0
+/ 0
- 0
0.17 0
mmol/l 0
for 0
the 0
iv 0
, 0
po 0
, 0
and 0
it 0
routes 0
, 0
respectively 0
. 0

The 0
two 0
drugs 0
increase 0
the 0
rate 0
of 0
early 0
diastolic 0
filling 0
. 0

A 0
statistically 0
significant 0
improvement 0
due 0
to 0
the 0
administration 0
of 0
Bromergon 0
was 0
observed 0
in 0
symptoms 0
associated 0
with 0
overreactiveness 0
to 0
normal 0
prolactin B-gene
levels 0
, 0
i.e 0
. 0
abdominal 0
tension 0
, 0
edema 0
, 0
weight 0
gain 0
and 0
breast 0
tenderness 0
. 0

The 0
magnitude 0
of 0
the 0
early 0
response 0
was 0
241 0
+/ 0
- 0
51 0
% 0
in 0
A 0
( 0
% 0
baseline 0
RL 0
; 0
mean 0
+/ 0
- 0
SE 0
) 0
, 0
and 0
significantly 0
less 0
in 0
B 0
( 0
119 0
+/ 0
- 0
7 0
% 0
) 0
and 0
C 0
( 0
131 0
+/ 0
- 0
16 0
% 0
) 0
( 0
p 0
< 0
0.01 0
) 0
. 0

Most 0
of 0
the 0
patients 0
presented 0
with 0
Transient 0
Ischemic 0
Attacks 0
( 0
64 0
% 0
) 0
or 0
Reversible 0
Ischemic 0
Neurologic 0
Deficits 0
( 0
19 0
% 0
) 0
. 0

We 0
cloned 0
the 0
third 0
human 0
gene 0
for 0
the 0
LD78 B-gene
, 0
termed 0
LD78 B-gene
gamma I-gene
and 0
the 0
sequence 0
analysis 0
showed 0
that 0
it 0
is 0
a 0
5' 0
- 0
truncated 0
pseudogene 0
. 0

This 0
analysis 0
, 0
together 0
with 0
a 0
consideration 0
of 0
the 0
SCBs 0
found 0
upstream 0
of 0
known 0
SWI4,6 B-gene
- 0
dependent 0
genes 0
, 0
leads 0
to 0
the 0
proposal 0
of 0
a 0
revised 0
consensus 0
sequence 0
for 0
this 0
important 0
regulatory 0
element 0
. 0

Mutational 0
analysis 0
of 0
a 0
DNA 0
sequence 0
involved 0
in 0
linking 0
gene 0
expression 0
to 0
the 0
cell 0
cycle 0
. 0

The 0
natural 0
history 0
of 0
these 0
lesions 0
, 0
locoregional 0
efficiency 0
of 0
the 0
different 0
treatments 0
used 0
, 0
the 0
part 0
played 0
by 0
chemotherapy 0
, 0
survival 0
, 0
causes 0
of 0
death 0
and 0
therapeutic 0
modalities 0
used 0
as 0
a 0
last 0
measure 0
, 0
have 0
been 0
analysed 0
. 0

The 0
method 0
was 0
adapted 0
for 0
the 0
determination 0
of 0
nadolol 0
racemate 0
A 0
by 0
a 0
change 0
in 0
mobile 0
phase 0
composition 0
. 0

In 0
general 0
, 0
however 0
, 0
this 0
study 0
provided 0
little 0
evidence 0
of 0
any 0
effect 0
of 0
supplementation 0
to 0
athletic 0
performance 0
for 0
athletes 0
consuming 0
the 0
dietary 0
RDIs 0
. 0

In 0
the 0
absence 0
of 0
histological 0
criteria 0
, 0
which 0
it 0
is 0
difficult 0
to 0
demand 0
in 0
view 0
of 0
the 0
variability 0
of 0
results 0
and 0
potential 0
dangers 0
of 0
endomyocardial 0
biopsy 0
involving 0
such 0
thin 0
and 0
fragile 0
ventricular 0
walls 0
, 0
the 0
diagnosis 0
of 0
ACRV 0
is 0
based 0
upon 0
the 0
concomitant 0
existence 0
of 0
: 0
( 0
1 0
) 0
electrophysiological 0
criteria 0
: 0
ventricular 0
arrhythmias 0
, 0
in 0
particular 0
sustained 0
monomorphous 0
VT 0
, 0
with 0
the 0
particular 0
feature 0
of 0
a 0
very 0
high 0
degree 0
of 0
sensitivity 0
to 0
adrenergic 0
stimulation 0
( 0
exercise 0
) 0
, 0
the 0
existence 0
of 0
late 0
potentials 0
on 0
the 0
high 0
amplification 0
ECG 0
, 0
a 0
highly 0
specific 0
sign 0
, 0
though 0
unfortunately 0
of 0
poor 0
sensitivity 0
in 0
localized 0
froms 0
, 0
those 0
which 0
are 0
most 0
difficult 0
to 0
identify 0
( 0
2 0
) 0
; 0
segmentary 0
morphological 0
and 0
kinetic 0
RV 0
abnormalities 0
, 0
most 0
often 0
resulting 0
in 0
localized 0
akinetic 0
or 0
dyskinetic 0
parietal 0
vaulting 0
, 0
with 0
stasis 0
`` 0
in 0
situ 0
'' 0
. 0

In 0
7 0
of 0
9 0
cases 0
, 0
the 0
enhancer 0
is 0
fused 0
to 0
the 0
c B-gene
- I-gene
myc I-gene
bearing I-gene
sequences I-gene
of 0
chromosome 0
8 0
. 0

These 0
components 0
both 0
had 0
a 0
median 0
R2 0
of 0
0.84 0
, 0
compared 0
to 0
median 0
R2s 0
ranging 0
from 0
0.37 0
to 0
0.83 0
for 0
five 0
commonly 0
used 0
ad 0
hoc 0
EEG 0
components 0
. 0

The 0
obtained 0
results 0
were 0
compared 0
with 0
control 0
group 0
( 0
10 0
female 0
volunteers 0
) 0
. 0

100 0
years 0
of 0
dentistry 0
at 0
the 0
Friedrich 0
Schiller 0
University 0
in 0
Jena 0

The 0
target 0
contained 0
between 0
positions 0
- 0
403 0
and 0
- 0
125 0
acts 0
independently 0
of 0
orientation 0
, 0
in 0
different 0
cell 0
types 0
and 0
species 0
, 0
and 0
in 0
the 0
context 0
of 0
a 0
heterologous 0
promoter 0
. 0

66:469 0
- 0
479 0
, 0
1992 0
) 0
. 0

Synergistic 0
transactivation 0
of 0
the 0
BMRF1 B-gene
promoter I-gene
by 0
the 0
Z/c B-gene
Z/c I-gene
- I-gene
myb I-gene
combination 0
appears 0
to 0
involve 0
direct 0
binding 0
by 0
the 0
Z B-gene
protein I-gene
but 0
not 0
the 0
c B-gene
- I-gene
myb I-gene
protein I-gene
. 0

The 0
UCR 0
core 0
sequence 0
, 0
CGCCATTTT 0
, 0
binds 0
a 0
ubiquitous 0
nuclear 0
factor 0
and 0
mediates 0
negative 0
regulation 0
of 0
MuLV 0
promoter 0
activity 0
. 0

These 0
studies 0
show 0
that 0
UCRBP B-gene
binds 0
to 0
various 0
target 0
motifs 0
that 0
are 0
distinct 0
from 0
the 0
UCR 0
motif 0
: 0
the 0
adeno B-gene
- I-gene
associated I-gene
virus I-gene
P5 I-gene
promoter I-gene
and 0
elements 0
in 0
the 0
immunoglobulin B-gene
light I-gene
- I-gene
and I-gene
heavy I-gene
- I-gene
chain I-gene
genes 0
, 0
as 0
well 0
as 0
elements 0
in 0
ribosomal B-gene
protein I-gene
genes I-gene
. 0

Possibly 0
, 0
the 0
scr1 B-gene
- I-gene
1 I-gene
mutation I-gene
does 0
not 0
affect 0
signal 0
recognition 0
or 0
translational 0
arrest 0
but 0
instead 0
results 0
in 0
maintenance 0
of 0
translational 0
arrest 0
of 0
AEP B-gene
synthesis 0
. 0

The 0
cellular 0
sequences 0
5 0
' 0
to 0
the 0
viral 0
integration 0
site 0
exhibited 0
85 0
to 0
97 0
% 0
identity 0
to 0
several 0
sequences 0
belonging 0
to 0
the 0
mouse B-gene
L1 I-gene
family I-gene
of 0
long 0
interspersed 0
repetitive 0
sequences 0
. 0

Both 0
Rep78 B-gene
and 0
Rep68 B-gene
cut 0
the 0
terminal 0
AAV 0
sequence 0
at 0
the 0
same 0
site 0
( 0
nucleotide 0
124 0
) 0
. 0

Nucleotide 0
sequence 0
analysis 0
revealed 0
that 0
TAR B-gene
- I-gene
binding I-gene
protein I-gene
is 0
very 0
similar 0
to 0
the 0
CREB2 B-gene
protein I-gene
. 0

These 0
results 0
indicate 0
that 0
both 0
N 0
- 0
and 0
C 0
- 0
terminal 0
mutations 0
are 0
required 0
to 0
inhibit 0
transrepression 0
by 0
FBR B-gene
protein I-gene
and 0
that 0
multiple 0
structural 0
mutations 0
accompanied 0
by 0
posttranslational 0
protein 0
modification 0
alter 0
gene 0
regulation 0
by 0
FBR B-gene
protein I-gene
. 0

The 0
JS78 0
mutation 0
changes 0
Gln243 0
in 0
gp0.7 0
to 0
an 0
amber 0
codon 0
, 0
which 0
explains 0
the 0
production 0
of 0
the 0
truncated 0
, 0
30 B-gene
- I-gene
kDa I-gene
gp0.7 I-gene
- I-gene
related I-gene
polypeptide I-gene
, 0
and 0
implicates 0
the 0
11 0
- 0
kDa 0
C 0
- 0
terminal 0
domain 0
in 0
host 0
transcription 0
shut 0
- 0
off 0
. 0

A 0
patient 0
suffering 0
from 0
heparin 0
- 0
associated 0
thrombocytopenia 0
( 0
HAT 0
) 0
, 0
recurrent 0
arteriothromboses 0
, 0
and 0
acute 0
renal 0
failure 0
after 0
treatment 0
with 0
standard 0
heparin 0
is 0
described 0
. 0

The 0
predicted 0
receptor 0
structure 0
includes 0
a 0
cysteine 0
- 0
rich 0
extracellular 0
domain 0
, 0
a 0
single 0
hydrophobic 0
transmembrane 0
domain 0
, 0
and 0
a 0
predicted 0
cytoplasmic B-gene
serine/threonine I-gene
kinase I-gene
domain I-gene
. 0

Drosophila B-gene
UbcD1 I-gene
encodes 0
a 0
highly 0
conserved 0
ubiquitin B-gene
- 0
conjugating 0
enzyme 0
involved 0
in 0
selective 0
protein 0
degradation 0
. 0

Analysis 0
of 0
the 0
entire 0
16.7 0
- 0
kb 0
mt 0
genome 0
determined 0
that 0
a 0
MDP1 B-gene
mediates 0
cleavage 0
of 0
chick 0
mtDNA 0
in 0
vitro 0
at 0
three 0
H 0
- 0
and 0
two 0
L 0
- 0
strand 0
sequence 0
- 0
specific 0
target 0
sites 0
located 0
within 0
a 0
90 0
- 0
bp 0
A 0
+ 0
T 0
- 0
rich 0
genomic 0
tract 0
, 0
theoretically 0
capable 0
of 0
forming 0
stable 0
secondary 0
structures 0
, 0
approximately 0
200 0
bases 0
upstream 0
from 0
the 0
H 0
- 0
strand 0
origin 0
( 0
OH 0
) 0
of 0
replication 0
. 0

The 0
goal 0
of 0
the 0
present 0
study 0
was 0
to 0
determine 0
the 0
feasibility 0
of 0
retrovirus 0
mediated 0
expression 0
of 0
rp47phox B-gene
in 0
the 0
HL60 0
and 0
U937 0
human 0
hematopoietic 0
cell 0
lines 0
, 0
and 0
in 0
an 0
Epstein 0
- 0
Barr 0
virus 0
transformed 0
B 0
- 0
lymphocyte 0
cell 0
line 0
( 0
EBV 0
- 0
BCL 0
) 0
derived 0
from 0
a 0
p47phox B-gene
- 0
deficient 0
CGD 0
patient 0
. 0

Comparison 0
with 0
the 0
sequence 0
databanks 0
show 0
that 0
Tactile B-gene
is 0
a 0
member 0
of 0
the 0
immunoglobulin B-gene
gene I-gene
superfamily I-gene
, 0
with 0
similarity 0
to 0
Drosophila B-gene
amalgam I-gene
, 0
the 0
melanoma B-gene
Ag I-gene
MUC I-gene
- I-gene
18 I-gene
, 0
members 0
of 0
the 0
carcinoembryonic B-gene
Ag I-gene
family I-gene
, 0
the 0
poliovirus B-gene
receptor I-gene
, 0
and 0
the 0
neural B-gene
cell I-gene
adhesion I-gene
molecule I-gene
. 0

A 0
rather 0
similar 0
pattern 0
of 0
results 0
was 0
obtained 0
with 0
respect 0
to 0
LMP2B B-gene
mRNA I-gene
expression 0
, 0
such 0
transcripts 0
being 0
detectable 0
only 0
in 0
a 0
subset 0
of 0
tumors 0
, 0
and 0
then 0
at 0
apparently 0
low 0
levels 0
. 0

The 0
phenotypes 0
of 0
the 0
ICP0 B-gene
nonsense 0
mutants 0
were 0
intermediate 0
between 0
those 0
of 0
the 0
wild 0
- 0
type 0
virus 0
and 0
7134 0
in 0
that 0
the 0
more 0
ICP0 B-gene
- I-gene
coding I-gene
sequence I-gene
expressed 0
by 0
a 0
given 0
nonsense 0
mutant 0
, 0
the 0
more 0
wild 0
type 0
- 0
like 0
was 0
its 0
phenotype 0
. 0

Analysis 0
of 0
nucleotide 0
sequence 0
of 0
the 0
rightmost 0
43 0
kbp 0
of 0
herpesvirus 0
saimiri 0
( 0
HVS 0
) 0
L 0
- 0
DNA 0
: 0
general 0
conservation 0
of 0
genetic 0
organization 0
between 0
HVS 0
and 0
Epstein 0
- 0
Barr 0
virus 0
. 0

Treatment 0
with 0
MK 0
- 0
801 0
induced 0
a 0
burst 0
suppression 0
in 0
the 0
EEG 0
and 0
a 0
transient 0
drop 0
( 0
11.4 0
+/ 0
- 0
6.5 0
mm 0
Hg 0
) 0
in 0
the 0
mean 0
arterial 0
pressure 0
. 0

In 0
contrast 0
, 0
gel 0
mobility 0
shift 0
experiments 0
have 0
failed 0
to 0
reveal 0
that 0
HAP2 B-gene
or 0
HAP3 B-gene
binds 0
to 0
domain 0
1 0
or 0
that 0
hap3 B-gene
mutations 0
affect 0
the 0
complexes 0
bound 0
to 0
it 0
. 0

Myogenic 0
differentiation 0
can 0
be 0
inhibited 0
by 0
the 0
adenovirus 0
E1a B-gene
protein I-gene
in 0
the 0
rat 0
L6 0
muscle 0
cell 0
line 0
. 0

The 0
experiment 0
results 0
showed 0
: 0
( 0
i 0
) 0
not 0
only 0
1O2 0
, 0
but 0
also 0
free 0
radicals 0
( 0
O2 0
- 0
. 0
.OH 0
and 0
YHPD 0
- 0
. 0
) 0
can 0
be 0
formed 0
by 0
the 0
aid 0
of 0
YHPD 0
; 0
and 0
( 0
ii 0
) 0
as 0
to 0
the 0
ability 0
of 0
producing 0
1O2 0
, 0
YHPD 0
less 0
than 0
BHPD 0
, 0
while 0
for 0
generating 0
O2 0
- 0
. 0
and 0
.OH 0
, 0
YHPD 0
greater 0
than 0
BHPD 0
. 0

Two 0
points 0
are 0
indicated 0
: 0
first 0
, 0
the 0
photosensitized 0
damage 0
of 0
YHPD 0
is 0
interrelated 0
to 0
not 0
only 0
1O2 0
, 0
but 0
also 0
free 0
radicals 0
( 0
O2 0
- 0
. 0
.OH 0
and 0
YHPD 0
- 0
. 0
) 0
; 0
second 0
, 0
although 0
the 0
photosensitized 0
damage 0
of 0
YHPD 0
is 0
stronger 0
than 0
that 0
of 0
BHPD 0
, 0
yet 0
the 0
photosensitized 0
damage 0
is 0
negatively 0
correlated 0
to 0
the 0
yield 0
of 0
1O2 0
but 0
positively 0
correlated 0
to 0
those 0
of 0
O2 0
- 0
. 0
and 0
OH 0
. 0

Acad 0
. 0

Both 0
in 0
vitro 0
- 0
synthesized 0
S2 B-gene
protein I-gene
and 0
synthetic 0
peptides 0
corresponding 0
to 0
S2 B-gene
are 0
shown 0
to 0
react 0
positively 0
with 0
sera 0
obtained 0
from 0
EIAV 0
- 0
infected 0
horses 0
, 0
providing 0
the 0
first 0
direct 0
evidence 0
of 0
expression 0
of 0
this 0
protein 0
in 0
infected 0
animals 0
. 0

Many 0
canonical 0
TATA 0
sequences 0
are 0
present 0
upstream 0
from 0
these 0
VZV 0
transcriptional 0
start 0
sites 0
but 0
, 0
apparently 0
, 0
are 0
not 0
used 0
. 0

The 0
ORF 0
4 0
gene 0
was 0
minimally 0
active 0
, 0
whereas 0
the 0
ORF 0
62 0
gene 0
gave 0
twofold 0
induction 0
; 0
both 0
genes 0
, 0
acting 0
together 0
, 0
gave 0
fivefold 0
induction 0
. 0

Interestingly 0
, 0
the 0
IR5 B-gene
ORF I-gene
of 0
EHV 0
- 0
1 0
possesses 0
a 0
sequence 0
of 0
13 0
amino 0
acids 0
( 0
CAYWCCLGHAFAC 0
) 0
that 0
is 0
a 0
perfect 0
match 0
to 0
the 0
consensus 0
zinc 0
finger 0
motif 0
( 0
C 0
- 0
X2 0
- 0
4 0
- 0
C 0
- 0
X2 0
- 0
15 0
- 0
C/H 0
- 0
X2 0
- 0
4 0
- 0
C/H 0
) 0
. 0

The 0
DNA 0
sequence 0
of 0
the 0
sulfate B-gene
activation I-gene
locus I-gene
from 0
Escherichia 0
coli 0
K 0
- 0
12 0
has 0
been 0
determined 0
. 0

The 0
unphosphorylated 0
form 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
is 0
designated 0
IIA 0
, 0
whereas 0
the 0
phosphorylated 0
form 0
is 0
designated 0
IIO 0
. 0

RNA B-gene
polymerase I-gene
IIA I-gene
was 0
recovered 0
in 0
transcriptionally 0
active 0
complexes 0
in 0
reactions 0
in 0
which 0
the 0
input 0
enzyme 0
was 0
RNA B-gene
polymerase I-gene
IIA I-gene
. 0

Fructokinase B-gene
activity 0
is 0
elevated 0
up 0
to 0
twofold 0
when 0
Z. 0
mobilis 0
was 0
grown 0
on 0
fructose 0
instead 0
of 0
glucose 0
, 0
and 0
there 0
was 0
a 0
parallel 0
increase 0
in 0
frk B-gene
mRNA I-gene
levels 0
. 0

Plasma 0
membranes 0
of 0
cultured 0
cells 0
contain 0
high 0
affinity 0
receptors 0
for 0
high B-gene
density I-gene
lipoprotein I-gene
( 0
HDL B-gene
) 0
that 0
appear 0
to 0
mediate 0
removal 0
of 0
excess 0
intracellular 0
cholesterol 0
. 0

After 0
the 0
first 0
28 0
patients 0
vincristine 0
was 0
replaced 0
by 0
teniposide 0
( 0
VM 0
- 0
26 0
) 0
due 0
to 0
neurotoxicity 0
. 0

These 0
results 0
indicate 0
that 0
an 0
internal 0
short 0
element 0
located 0
at 0
the 0
very 0
5 0
' 0
terminal 0
of 0
L1 B-gene
sequence I-gene
and 0
the 0
nuclear 0
factor 0
binding 0
to 0
the 0
element 0
play 0
a 0
crucial 0
role 0
in 0
the 0
transcription 0
of 0
human B-gene
L1 I-gene
. 0

Tumor 0
cells 0
were 0
focally 0
immunoreactive 0
for 0
neuron B-gene
- I-gene
specific I-gene
enolase I-gene
, 0
insulin B-gene
, 0
glucagon B-gene
and 0
VIP B-gene
. 0

A 0
recombinant 0
with 0
a 0
5 0
' 0
end 0
from 0
src B-gene
and 0
a 0
3 0
' 0
end 0
from 0
ros B-gene
, 0
called 0
SRC B-gene
x 0
ROS B-gene
, 0
transformed 0
chicken 0
embryo 0
fibroblasts 0
( 0
CEF 0
) 0
to 0
a 0
spindle 0
shape 0
morphology 0
, 0
mimicking 0
that 0
of 0
UR2 B-gene
. 0

ROS B-gene
x 0
SRC B-gene
( 0
R B-gene
) 0
contains 0
a 0
16 0
- 0
amino 0
- 0
acid 0
deletion 0
that 0
includes 0
the 0
3 0
' 0
half 0
of 0
the 0
transmembrane 0
domain 0
of 0
ros B-gene
. 0

To 0
define 0
the 0
number 0
and 0
nature 0
of 0
the 0
E6 B-gene
and 0
E7 B-gene
gene I-gene
products 0
expressed 0
in 0
BPV 0
- 0
1 0
- 0
transformed 0
cells 0
, 0
we 0
performed 0
immunoprecipitation 0
experiments 0
with 0
antisera 0
raised 0
to 0
bacterially 0
expressed 0
BPV B-gene
- I-gene
1 I-gene
E6 I-gene
and 0
E7 B-gene
fusion I-gene
proteins I-gene
. 0

Transient 0
transfection 0
assays 0
showed 0
that 0
site 0
A 0
is 0
necessary 0
and 0
sufficient 0
for 0
RXR B-gene
alpha I-gene
- 0
mediated 0
transactivation 0
of 0
the 0
apoAI B-gene
gene I-gene
basal I-gene
promoter I-gene
in 0
human 0
hepatoma 0
HepG2 0
cells 0
in 0
the 0
presence 0
of 0
RA 0
and 0
that 0
this 0
transactivation 0
is 0
abolished 0
by 0
increasing 0
amounts 0
of 0
cotransfected 0
ARP B-gene
- I-gene
1 I-gene
. 0

The 0
enhancer 0
region 0
of 0
Akv 0
murine 0
leukemia 0
virus 0
contains 0
the 0
sequence 0
motif 0
ACAGATGG 0
. 0

Two 0
splice 0
variants 0
of 0
ALF1 B-gene
cDNA I-gene
have 0
been 0
found 0
, 0
differing 0
by 0
a 0
72 0
- 0
bp 0
insertion 0
, 0
coding 0
for 0
putative 0
proteins 0
of 0
682 0
and 0
706 0
amino 0
acids 0
. 0

A 0
third 0
prominent 0
component 0
of 0
apparent 0
molecular 0
mass 0
16 0
kDa 0
displayed 0
several 0
properties 0
, 0
including 0
ability 0
to 0
bind 0
45Ca2+ 0
, 0
that 0
are 0
characteristic 0
of 0
the 0
regulatory 0
( 0
B 0
) 0
subunit 0
of 0
mammalian B-gene
calcineurin I-gene
and 0
was 0
recognized 0
by 0
an 0
antiserum 0
raised 0
against 0
bovine B-gene
calcineurin I-gene
. 0

As 0
was 0
observed 0
previously 0
for 0
MATa B-gene
cna1 B-gene
cna2 B-gene
double 0
mutants 0
, 0
MATa B-gene
cnb1 B-gene
mutants I-gene
were 0
defective 0
in 0
their 0
ability 0
to 0
recover 0
from 0
alpha B-gene
- I-gene
factor I-gene
- 0
induced 0
growth 0
arrest 0
. 0

Antibodies 0
against 0
this 0
purified 0
protein 0
localize 0
RIM1 B-gene
to 0
mitochondria 0
. 0

METHODS 0
: 0
IgG B-gene
antibodies I-gene
vs 0
HHV 0
- 0
6 0
( 0
anti B-gene
- I-gene
HHV I-gene
- I-gene
6 I-gene
- I-gene
IgG I-gene
) 0
were 0
determined 0
by 0
indirect 0
immunofluorescence 0
in 0
100 0
IVDA 0
( 0
29 0
seronegative 0
and 0
71 0
seropositive 0
for 0
HIV 0
- 0
1 0
of 0
which 0
45 0
were 0
in 0
stage 0
II 0
and 0
26 0
in 0
IV 0
- 0
C1 0
of 0
CDC 0
) 0
as 0
well 0
as 0
in 0
100 0
healthy 0
subjects 0
of 0
a 0
similar 0
age 0
( 0
control 0
group 0
) 0
. 0

A 0
position 0
- 0
independent 0
activation 0
domain 0
which 0
contained 0
conserved 0
regions 0
II 0
and 0
III 0
was 0
identified 0
at 0
the 0
carboxyl 0
terminus 0
of 0
the 0
HNF B-gene
- I-gene
3 I-gene
beta I-gene
protein I-gene
( 0
amino 0
acids 0
361 0
to 0
458 0
) 0
. 0

HNF B-gene
- I-gene
3 I-gene
beta I-gene
amino I-gene
- I-gene
terminal I-gene
sequences I-gene
defined 0
by 0
conserved 0
region 0
IV 0
also 0
contributed 0
to 0
transactivation 0
, 0
but 0
region 0
IV 0
activity 0
required 0
the 0
participation 0
of 0
the 0
region 0
II 0
- 0
III 0
domain 0
. 0

Possible 0
roles 0
of 0
RAD5 B-gene
putative 0
ATPase/DNA B-gene
ATPase/DNA I-gene
helicase I-gene
activity 0
in 0
DNA 0
repair 0
and 0
in 0
the 0
maintenance 0
of 0
wild 0
- 0
type 0
rates 0
of 0
instability 0
of 0
simple 0
repetitive 0
sequences 0
are 0
discussed 0
. 0

Susceptibilities 0
of 0
540 0
anaerobic 0
gram 0
- 0
negative 0
bacilli 0
to 0
amoxicillin 0
, 0
amoxicillin 0
- 0
BRL 0
42715 0
, 0
amoxicillin 0
- 0
clavulanate 0
, 0
temafloxacin 0
, 0
and 0
clindamycin 0
. 0

Nocodazole 0
arrest 0
of 0
DU249 0
cells 0
was 0
exploited 0
for 0
the 0
detection 0
of 0
an 0
M 0
- 0
phase 0
- 0
activated 0
MBP B-gene
kinase I-gene
that 0
was 0
resolved 0
from 0
p41 B-gene
MAP I-gene
kinase I-gene
by 0
phenyl 0
- 0
Superose 0
chromatography 0
. 0

The 0
hit1 B-gene
- I-gene
1 I-gene
mutation 0
caused 0
a 0
defect 0
in 0
synthesis 0
of 0
a 0
74 B-gene
- I-gene
kD I-gene
heat I-gene
shock I-gene
protein I-gene
. 0

The 0
319 0
base 0
pair 0
region 0
immediately 0
upstream 0
of 0
the 0
CAP 0
site 0
is 0
characterized 0
by 0
the 0
lack 0
of 0
a 0
proximal 0
TATA 0
box 0
and 0
the 0
presence 0
of 0
sequences 0
similar 0
to 0
GC 0
boxes 0
, 0
CACCC 0
boxes 0
, 0
CCAAT 0
boxes 0
, 0
activator B-gene
protein I-gene
2 I-gene
( 0
Ap B-gene
- I-gene
2 I-gene
) 0
sites 0
, 0
partial 0
glucocorticoid 0
response 0
elements 0
( 0
GREs 0
) 0
, 0
and 0
partial 0
cyclic 0
AMP 0
response 0
elements 0
( 0
CREs 0
) 0
. 0

Cloning 0
and 0
primary 0
structure 0
of 0
neurocan 0
, 0
a 0
developmentally 0
regulated 0
, 0
aggregating 0
chondroitin 0
sulfate 0
proteoglycan 0
of 0
brain 0
. 0

In 0
rats 0
anaesthetized 0
with 0
+ 0
- 0
chloralose 0
the 0
changes 0
in 0
extracellular 0
pH 0
and 0
K+ 0
in 0
spinal 0
cord 0
dorsal 0
horn 0
were 0
studied 0
using 0
pH 0
and 0
K+ 0
ion 0
- 0
selective 0
electrodes 0
. 0

Replication 0
of 0
bovine 0
papillomavirus 0
- 0
1 0
( 0
BPV 0
- 0
1 0
) 0
DNA 0
requires 0
two 0
viral 0
gene 0
products 0
, 0
the 0
E1 B-gene
protein I-gene
and 0
the 0
full B-gene
- I-gene
length I-gene
E2 I-gene
protein I-gene
. 0

Insertional 0
inactivation 0
of 0
sms B-gene
led 0
to 0
increased 0
sensitivity 0
to 0
the 0
alkylating 0
agent 0
methylmethane 0
sulfonate 0
, 0
but 0
not 0
to 0
a 0
requirement 0
for 0
serine 0
or 0
other 0
metabolites 0
. 0

These 0
findings 0
suggest 0
that 0
the 0
MAP B-gene
kinase I-gene
activator/MAP I-gene
activator/MAP I-gene
kinase I-gene
system 0
may 0
be 0
the 0
downstream 0
components 0
of 0
ras B-gene
signal 0
transduction 0
pathways 0
. 0

NSCL B-gene
- I-gene
1 I-gene
is 0
expressed 0
in 0
a 0
larger 0
number 0
of 0
these 0
cell 0
lines 0
. 0

Labile 0
LTR B-gene
- I-gene
binding I-gene
proteins I-gene
appear 0
to 0
be 0
essential 0
for 0
c B-gene
- I-gene
myc I-gene
hyperexpression 0
, 0
since 0
both 0
LTR 0
- 0
enhanced 0
transcription 0
and 0
the 0
activities 0
of 0
LTR B-gene
- I-gene
binding I-gene
proteins I-gene
are 0
specifically 0
decreased 0
after 0
inhibition 0
of 0
protein 0
synthesis 0
( 0
A 0
. 0

Ruddell 0
, 0
M 0
. 0

A 0
single 0
MEF B-gene
- I-gene
2 I-gene
site I-gene
is 0
a 0
major 0
positive 0
regulatory 0
element 0
required 0
for 0
transcription 0
of 0
the 0
muscle 0
- 0
specific 0
subunit 0
of 0
the 0
human B-gene
phosphoglycerate I-gene
mutase I-gene
gene I-gene
in 0
skeletal 0
and 0
cardiac 0
muscle 0
cells 0
. 0

Truncation 0
variants 0
of 0
peptides 0
isolated 0
from 0
MHC B-gene
class I-gene
II I-gene
molecules I-gene
suggest 0
sequence 0
motifs 0
. 0

Although 0
the 0
E 0
- 0
box 0
consensus 0
is 0
minimally 0
defined 0
as 0
CANNTG 0
, 0
the 0
adjacent 0
nucleotides 0
of 0
functional 0
E 0
- 0
boxes 0
are 0
variable 0
for 0
genes 0
regulated 0
by 0
the 0
bHLH B-gene
proteins I-gene
. 0

Intermediate 0
levels 0
of 0
gene 0
activity 0
were 0
observed 0
for 0
TnI B-gene
enhancers I-gene
containing 0
E 0
- 0
boxes 0
derived 0
from 0
the 0
MCK B-gene
left I-gene
E I-gene
- I-gene
box I-gene
site I-gene
or 0
from 0
the 0
Ig B-gene
kappa I-gene
E2 I-gene
E I-gene
- I-gene
box I-gene
. 0

T B-gene
- I-gene
cell I-gene
receptor I-gene
beta I-gene
( 0
TCR B-gene
beta I-gene
) 0
gene 0
rearrangements 0
occur 0
in 0
a 0
third 0
of 0
early 0
B 0
- 0
cell 0
acute 0
lymphoblastic 0
leukemias 0
( 0
ALLs 0
) 0
. 0

The 0
CANNTG 0
motifs 0
were 0
found 0
to 0
bind 0
MyoD B-gene
and 0
myogenin B-gene
fusion I-gene
proteins I-gene
and 0
to 0
interact 0
with 0
proteins 0
in 0
nuclear 0
extracts 0
from 0
cultured 0
myotubes 0
. 0

Peripheral 0
polyneuropathy 0
associated 0
with 0
multiple 0
myeloma 0
. 0

We 0
have 0
cloned 0
and 0
sequenced 0
COX12 B-gene
, 0
the 0
nuclear 0
gene 0
for 0
subunit B-gene
VIb I-gene
of 0
Saccharomyces B-gene
cerevisiae I-gene
cytochrome I-gene
c I-gene
oxidase I-gene
. 0

The 0
structure 0
of 0
the 0
calcineurin B-gene
A I-gene
gene I-gene
was 0
determined 0
by 0
comparison 0
of 0
the 0
genomic 0
and 0
cDNA 0
sequences 0
. 0

The 0
basal 0
promoter 0
elements 0
of 0
murine B-gene
cytochrome I-gene
c I-gene
oxidase I-gene
subunit I-gene
IV I-gene
gene I-gene
consist 0
of 0
tandemly 0
duplicated 0
ets B-gene
motifs 0
that 0
bind 0
to 0
GABP B-gene
- I-gene
related I-gene
transcription I-gene
factors I-gene
. 0

Lastly 0
, 0
there 0
are 0
multiple 0
instances 0
in 0
which 0
short 0
oligonucleotide 0
direct 0
repeats 0
flank 0
a 0
region 0
absent 0
from 0
either 0
variola 0
or 0
vaccinia 0
virus 0
. 0

Here 0
we 0
show 0
that 0
short 0
synthetic 0
peptides 0
containing 0
the 0
pRB B-gene
- I-gene
binding I-gene
sequences I-gene
of 0
E1A B-gene
are 0
sufficient 0
for 0
interaction 0
with 0
p107 B-gene
, 0
cyclin B-gene
A I-gene
, 0
and 0
p130 B-gene
. 0

These 0
mutants 0
grow 0
normally 0
in 0
3T6 0
mouse 0
fibroblast 0
cells 0
, 0
and 0
they 0
do 0
not 0
complement 0
the 0
wild 0
- 0
type 0
virus 0
in 0
coinfection 0
experiments 0
of 0
C2 0
myoblasts 0
. 0

The 0
MICs 0
of 0
this 0
compound 0
against 0
90 0
% 0
of 0
these 0
organisms 0
, 0
except 0
for 0
methicillin 0
- 0
resistant 0
S. 0
aureus 0
, 0
ranged 0
from 0
less 0
than 0
or 0
equal 0
to 0
0.006 0
to 0
3.13 0
micrograms/ml 0
. 0

The 0
minimal 0
promoter 0
of 0
the 0
RII B-gene
beta I-gene
gene I-gene
was 0
composed 0
of 0
two 0
adjacent 0
functional 0
elements 0
. 0

Mapping 0
the 0
cAMP B-gene
receptor I-gene
protein I-gene
contact I-gene
site I-gene
on 0
the 0
alpha 0
subunit 0
of 0
Escherichia B-gene
coli I-gene
RNA I-gene
polymerase I-gene
. 0

Here 0
we 0
show 0
that 0
epidermal B-gene
growth I-gene
factor I-gene
or 0
platelet B-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
stimulation 0
of 0
intact 0
human 0
or 0
murine 0
cells 0
leads 0
to 0
phosphorylation 0
of 0
Nck B-gene
protein I-gene
on 0
tyrosine 0
, 0
serine 0
, 0
and 0
threonine 0
residues 0
. 0

A 0
major 0
mechanism 0
whereby 0
steroid B-gene
hydroxylase I-gene
gene I-gene
transcription 0
is 0
regulated 0
in 0
the 0
adrenal 0
cortex 0
requires 0
the 0
pituitary 0
peptide 0
hormone 0
, 0
ACTH B-gene
, 0
which 0
acts 0
via 0
cAMP 0
. 0

A 0
combination 0
of 0
comparative 0
sequence 0
analysis 0
and 0
thermodynamic 0
methods 0
reveals 0
the 0
conservation 0
of 0
tertiary 0
structure 0
elements 0
in 0
the 0
5 0
' 0
untranslated 0
region 0
( 0
UTR 0
) 0
of 0
human 0
enteroviruses 0
and 0
rhinoviruses 0
. 0

The 0
- 0
64/ 0
- 0
37 0
region 0
interacted 0
with 0
purified 0
Sp1 B-gene
and 0
an 0
unidentified 0
protein 0
( 0
s 0
) 0
, 0
proximal B-gene
regulatory I-gene
factor I-gene
( I-gene
s I-gene
) I-gene
I I-gene
( 0
PRF B-gene
- I-gene
I I-gene
) 0
. 0

Km 0
and 0
Vmax 0
for 0
two 0
substrates 0
, 0
src B-gene
- I-gene
related I-gene
peptide I-gene
and 0
poly 0
( 0
Glu 0
, 0
Tyr 0
) 0
( 0
4:1 0
) 0
, 0
were 0
2.4 0
mM 0
and 0
2.5 0
mumol 0
min 0
- 0
1 0
mg 0
- 0
1 0
and 0
0.26 0
mM 0
and 0
1.2 0
mumol 0
min 0
- 0
1 0
mg 0
- 0
1 0
, 0
respectively 0
. 0

This 0
soluble 0
form 0
of 0
the 0
HGFr B-gene
( 0
sHGFr B-gene
) 0
bound 0
HGF B-gene
with 0
an 0
affinity 0
similar 0
to 0
that 0
of 0
the 0
authentic 0
, 0
membrane 0
- 0
associated 0
receptor 0
. 0

Strategies 0
for 0
blood 0
screening 0
for 0
the 0
hepatitis 0
C 0
virus 0
and 0
for 0
the 0
human 0
immunodeficiency 0
virus 0
in 0
high 0
risk 0
groups 0
. 0

Also 0
, 0
the 0
human B-gene
glycoprotein I-gene
alpha I-gene
- I-gene
subunit I-gene
promoter I-gene
was 0
induced 0
10 0
- 0
fold 0
by 0
FSK B-gene
in 0
GH4 0
rat 0
pituitary 0
cells 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

Comparison 0
of 0
data 0
obtained 0
with 0
the 0
results 0
of 0
chronic 0
treatment 0
with 0
the 0
opioid 0
antagonist 0
permits 0
to 0
conclude 0
that 0
the 0
chronic 0
blockade 0
increases 0
the 0
fatiguability 0
to 0
a 0
great 0
extent 0
than 0
chronic 0
activation 0
of 0
opioid 0
system 0
. 0

Laboratory 0
studies 0
using 0
Ca45 0
labeled 0
teeth 0
and 0
biologically 0
stained 0
teeth 0
confirmed 0
that 0
the 0
dentifrice 0
did 0
not 0
decalcify 0
enamel 0
or 0
bleach 0
teeth 0
. 0

Structure 0
and 0
expression 0
of 0
a 0
gene 0
from 0
Arabidopsis 0
thaliana 0
encoding 0
a 0
protein 0
related 0
to 0
SNF1 B-gene
protein 0
kinase 0
. 0

We 0
have 0
cloned 0
and 0
characterized 0
a 0
55 0
- 0
kb 0
region 0
of 0
DNA 0
surrounding 0
HRAS1 B-gene
. 0

The 0
ORF1 0
protein 0
was 0
found 0
to 0
be 0
highly 0
homologous 0
to 0
the 0
putative 0
potexvirus B-gene
RNA I-gene
replicases I-gene
; 0
ORF2 0
, 0
- 0
3 0
, 0
- 0
5 0
and 0
- 0
6 0
proteins 0
also 0
have 0
analogues 0
among 0
the 0
potex 0
- 0
and/or 0
carlavirus 0
- 0
encoded 0
proteins 0
. 0

A 0
total 0
of 0
281 0
patients 0
were 0
divided 0
into 0
groups 0
according 0
to 0
their 0
clinical 0
diagnosis 0
and 0
were 0
examined 0
using 0
capnography 0
, 0
spirometry 0
and 0
blood 0
- 0
gas 0
analysis 0
. 0

The 0
relationships 0
between 0
the 0
partial 0
pressures 0
of 0
O2 0
and 0
CO2 0
as 0
well 0
as 0
between 0
their 0
gradients 0
, 0
become 0
stronger 0
with 0
the 0
increase 0
of 0
the 0
ventilation 0
- 0
perfusion 0
ratio 0
. 0

No 0
significant 0
correlations 0
of 0
peak 0
VO2 0
were 0
observed 0
between 0
the 0
3 0
tests 0
. 0

An 0
RNA B-gene
- I-gene
binding I-gene
protein I-gene
gene I-gene
( 0
rbp1 B-gene
) 0
from 0
Drosophila 0
melanogaster 0
, 0
encoding 0
an 0
RNA 0
recognition 0
motif 0
and 0
an 0
Arg 0
- 0
Ser 0
rich 0
( 0
RS 0
) 0
domain 0
, 0
has 0
been 0
characterized 0
. 0

Some 0
research 0
studies 0
have 0
related 0
this 0
kind 0
of 0
tumors 0
with 0
prolonged 0
ingestion 0
of 0
H2 0
inhibitors 0
and 0
others 0
antacid 0
. 0

A 0
comparative 0
study 0
of 0
the 0
total 0
protein 0
profiles 0
of 0
wild 0
- 0
type 0
S. 0
entomophila 0
UC9 0
and 0
mutant 0
UC21 0
revealed 0
that 0
the 0
mutant 0
lacked 0
an 0
approximately 0
44 0
- 0
kDa 0
protein 0
and 0
overexpressed 0
an 0
approximately 0
20 0
- 0
kDa 0
protein 0
. 0

Characterization 0
of 0
the 0
regulon 0
controlled 0
by 0
the 0
leucine B-gene
- I-gene
responsive I-gene
regulatory I-gene
protein I-gene
in 0
Escherichia 0
coli 0
. 0

Mapping 0
of 0
the 0
mouse B-gene
ornithine I-gene
decarboxylase I-gene
- I-gene
related I-gene
sequence I-gene
family I-gene
. 0

This 0
mutation 0
also 0
results 0
in 0
markedly 0
decreased 0
levels 0
of 0
CAD B-gene
mRNA I-gene
and 0
protein 0
in 0
the 0
mutant 0
. 0

The 0
rationale 0
for 0
continuous 0
dopaminergic 0
stimulation 0
in 0
patients 0
with 0
Parkinson 0
's 0
disease 0
. 0

Mutational 0
studies 0
revealed 0
that 0
it 0
was 0
the 0
homeodomain B-gene
binding I-gene
site I-gene
II I-gene
sequence I-gene
that 0
was 0
required 0
for 0
this 0
regulation 0
. 0

Thus 0
, 0
the 0
pol B-gene
alpha I-gene
- 0
primase B-gene
complex 0
appears 0
to 0
act 0
processively 0
for 0
only 0
a 0
short 0
distance 0
. 0

Interestingly 0
, 0
the 0
positions 0
of 0
these 0
introns 0
have 0
been 0
conserved 0
in 0
comparison 0
with 0
the 0
genes 0
of 0
two 0
other 0
transglutaminase 0
- 0
like 0
activities 0
described 0
in 0
the 0
literature 0
, 0
but 0
the 0
TGM1 B-gene
gene I-gene
is 0
by 0
far 0
the 0
smallest 0
characterized 0
to 0
date 0
because 0
its 0
introns 0
are 0
relatively 0
smaller 0
. 0

In 0
a 0
retrospective 0
analysis 0
of 0
data 0
from 0
35 0
cases 0
with 0
malignant 0
lymphoma 0
from 0
a 0
cohort 0
of 0
2017 0
HIV 0
- 0
infected 0
patients 0
, 0
the 0
stage 0
of 0
HIV 0
- 0
disease 0
, 0
the 0
CD4 B-gene
counts 0
at 0
the 0
time 0
of 0
diagnosis 0
, 0
and 0
the 0
use 0
of 0
antineoplastic 0
agents 0
or 0
radiotherapy 0
were 0
correlated 0
with 0
outcome 0
. 0

1 0
. 0

Effects 0
of 0
dioxins 0
on 0
thyroid 0
function 0
in 0
newborn 0
babies 0
. 0

cDNA 0
clones 0
encoding 0
Arabidopsis 0
thaliana 0
and 0
Zea B-gene
mays I-gene
mitochondrial I-gene
chaperonin I-gene
HSP60 B-gene
and 0
gene 0
expression 0
during 0
seed 0
germination 0
and 0
heat 0
shock 0
. 0

Amino 0
acid 0
sequence 0
comparison 0
revealed 0
significant 0
homology 0
between 0
the 0
yeast B-gene
and I-gene
Escherichia I-gene
coli I-gene
gamma I-gene
- I-gene
glutamyl I-gene
kinases I-gene
throughout 0
their 0
lengths 0
. 0

The 0
single 0
site 0
of 0
glycosylation 0
is 0
located 0
near 0
the 0
C 0
- 0
terminus 0
in 0
the 0
N 0
- 0
glycosylation 0
sequon 0
- 0
Asn 0
- 0
Cys 0
- 0
Ser 0
- 0
in 0
which 0
Cys 0
forms 0
part 0
of 0
a 0
disulphide 0
bridge 0
. 0

The 0
pulmonary 0
toxic 0
events 0
induced 0
by 0
acute 0
nitrogen 0
dioxide 0
( 0
NO 0
) 0
2 0
exposure 0
were 0
studied 0
in 0
the 0
rat 0
to 0
develop 0
an 0
inhalation 0
model 0
to 0
investigate 0
therapeutic 0
measures 0
. 0

The 0
pulmonary 0
effects 0
observed 0
, 0
became 0
more 0
pronounced 0
with 0
increasing 0
NO2 0
concentrations 0
( 0
0 0
, 0
25 0
, 0
75 0
, 0
125 0
, 0
175 0
or 0
200 0
ppm 0
, 0
1 0
ppm 0
NO2 0
= 0
1.88 0
mg 0
m 0
- 0
3 0
NO2 0
) 0
and 0
exposure 0
times 0
( 0
5 0
, 0
10 0
, 0
20 0
or 0
30 0
min 0
) 0
. 0

Interaction 0
of 0
H B-gene
- I-gene
2Eb I-gene
with 0
an 0
IAP B-gene
retrotransposon I-gene
in 0
the 0
A20/2J 0
B 0
cell 0
lymphoma 0
. 0

Gestational 0
trophoblastic 0
diseases 0
: 0
recent 0
advances 0
in 0
the 0
understanding 0
of 0
cytogenetics 0
, 0
histopathology 0
, 0
and 0
natural 0
history 0
. 0

With 0
the 0
exception 0
of 0
mutants 0
that 0
remove 0
the 0
membrane 0
anchor 0
domain 0
, 0
all 0
of 0
the 0
mutant 0
glycoproteins 0
retained 0
the 0
ability 0
to 0
cause 0
fusion 0
of 0
CD4 B-gene
- 0
bearing 0
cells 0
. 0

The 0
subunit 0
protein 0
of 0
curli B-gene
was 0
highly 0
homologous 0
at 0
its 0
amino 0
terminus 0
to 0
SEF B-gene
- I-gene
17 I-gene
, 0
the 0
subunit 0
protein 0
of 0
thin 0
, 0
aggregative 0
fimbriae 0
of 0
Salmonella 0
enteritidis 0
27655 0
strain 0
3b 0
, 0
suggesting 0
that 0
these 0
fibres 0
form 0
a 0
novel 0
class 0
of 0
surface 0
organelles 0
on 0
enterobacteria 0
. 0

Substitution 0
of 0
the 0
DR1 B-gene
beta I-gene
chain I-gene
with 0
H B-gene
- I-gene
2E I-gene
beta I-gene
k I-gene
led 0
to 0
a 0
dramatic 0
loss 0
of 0
recognition 0
; 0
alpha 0
chain 0
substitution 0
had 0
a 0
less 0
marked 0
effect 0
. 0

This 0
negative 0
regulatory 0
pathway 0
may 0
be 0
important 0
for 0
determining 0
cell 0
fate 0
or 0
maintaining 0
an 0
inducible 0
state 0
in 0
the 0
ventroposterior 0
region 0
of 0
the 0
embryo 0
. 0

The 0
distal 0
portion 0
of 0
the 0
rat B-gene
insulin I-gene
I I-gene
gene I-gene
5' I-gene
- I-gene
flanking I-gene
DNA I-gene
contains 0
two 0
sequence 0
elements 0
, 0
the 0
Far 0
and 0
FLAT 0
elements 0
, 0
that 0
can 0
function 0
in 0
combination 0
, 0
but 0
not 0
separately 0
, 0
as 0
a 0
beta 0
- 0
cell 0
- 0
specific 0
transcriptional 0
enhancer 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
exhibited 0
98 0
% 0
identity 0
to 0
the 0
human 0
cellular 0
transglutaminase 0
sequence 0
. 0

This 0
computation 0
is 0
performed 0
by 0
a 0
parallel 0
network 0
of 0
locally 0
connected 0
neuron 0
- 0
like 0
elements 0
. 0

Repeated 0
efforts 0
to 0
isolate 0
recombinant 0
baculoviruses 0
containing 0
a 0
wild 0
- 0
type 0
kinase 0
failed 0
, 0
whereas 0
recombinants 0
expressing 0
a 0
nonfunctional 0
kinase 0
with 0
a 0
catalytic 0
domain 0
II 0
mutation 0
were 0
readily 0
isolated 0
. 0

Finally 0
, 0
we 0
determined 0
that 0
the 0
P68 B-gene
amino 0
terminus 0
was 0
both 0
necessary 0
and 0
sufficient 0
for 0
binding 0
dsRNA 0
as 0
we 0
were 0
able 0
to 0
transfer 0
dsRNA 0
- 0
binding 0
properties 0
to 0
a 0
reporter 0
gene 0
product 0
previously 0
unable 0
to 0
bind 0
RNA 0
. 0

From 0
August 0
1989 0
to 0
October 0
1990 0
, 0
83 0
pregnant 0
Chinese 0
women 0
were 0
the 0
subjects 0
for 0
measuring 0
the 0
levels 0
of 0
plasma 0
functional 0
antithrombin B-gene
III I-gene
( 0
AT B-gene
III I-gene
) 0
activity 0
. 0

Visual 0
acuity 0
may 0
be 0
decreased 0
by 0
transient 0
changes 0
in 0
refractive 0
error 0
caused 0
by 0
sulfonamides 0
, 0
the 0
antifungal 0
agent 0
metronidazole 0
, 0
thiazide 0
diuretics 0
, 0
and 0
carbonic B-gene
anhydrase I-gene
inhibitors 0
. 0

Currents 0
aspects 0
of 0
H2 B-gene
receptor I-gene
antagonists 0
in 0
the 0
treatment 0
of 0
ulcers 0

In 0
addition 0
, 0
a 0
21 0
- 0
mer 0
subrepeat 0
structure 0
is 0
also 0
present 0
in 0
each 0
unit 0
. 0

Sequencing 0
revealed 0
one 0
large 0
open 0
reading 0
frame 0
encoding 0
a 0
39 0
- 0
kDa 0
protein 0
. 0

These 0
sites 0
are 0
also 0
potential 0
keratan 0
sulfate 0
attachment 0
sites 0
. 0

We 0
propose 0
that 0
plasmids 0
of 0
the 0
pLS1 0
family 0
( 0
pE194 0
, 0
pADB201 0
, 0
and 0
pLB4 0
) 0
share 0
functional 0
and 0
structural 0
characteristics 0
for 0
the 0
regulation 0
of 0
their 0
copy 0
numbers 0
. 0

Perturbation 0
of 0
dNTP 0
pools 0
also 0
affected 0
the 0
frameshift 0
fidelity 0
of 0
the 0
replicative 0
yeast B-gene
DNA I-gene
polymerase I-gene
alpha I-gene
. 0

Differential 0
expression 0
of 0
the 0
`` 0
B 0
'' 0
subunit 0
of 0
the B-gene
vacuolar I-gene
H I-gene
( I-gene
+ I-gene
) I-gene
- I-gene
ATPase I-gene
in 0
bovine 0
tissues 0
. 0

In 0
addition 0
, 0
the 0
hGCSFR B-gene
gene I-gene
was 0
chromosomally 0
localized 0
by 0
Southern 0
blot 0
analysis 0
of 0
its 0
segregation 0
pattern 0
in 0
a 0
panel 0
of 0
rodent 0
- 0
human 0
hybrid 0
DNAs 0
using 0
the 0
radiolabeled 0
cDNA 0
probe 0
. 0

We 0
have 0
isolated 0
and 0
characterised 0
a 0
differentially 0
- 0
regulated 0
gene 0
family 0
in 0
the 0
protozoan 0
parasite 0
Leishmania 0
major 0
. 0

At 0
some 0
sites 0
, 0
% 0
T 0
is 0
greatly 0
increased 0
by 0
Cl 0
- 0
concentrations 0
up 0
to 0
1 0
M 0
, 0
while 0
at 0
other 0
sites 0
% 0
T 0
is 0
reduced 0
or 0
unaffected 0
by 0
these 0
conditions 0
. 0

Necrosis 0
appears 0
6 0
h 0
after 0
TA 0
infusion 0
, 0
being 0
5.77 0
% 0
in 0
extent 0
after 0
12 0
h 0
, 0
14.9 0
% 0
after 0
24 0
h 0
and 0
animals 0
die 0
with 0
an 0
area 0
of 0
29.5 0
% 0
necrosis 0
. 0

In 0
summary 0
, 0
the 0
segments 0
of 0
C3 B-gene
represented 0
by 0
amino 0
acid 0
residues 0
1082 0
- 0
1118 0
, 0
1117 0
- 0
1155 0
, 0
1234 0
- 0
1294 0
and 0
1312 0
- 0
1404 0
accommodate 0
C3 B-gene
( I-gene
D I-gene
) I-gene
epitopes I-gene
that 0
are 0
expressed 0
by 0
erythrocyte 0
- 0
bound 0
C3 B-gene
fragments I-gene
, 0
but 0
not 0
by 0
the 0
corresponding 0
fluid 0
- 0
phase 0
fragment 0
, 0
whereas 0
the 0
segments 0
spanning 0
residues 0
973 0
- 0
1026 0
and 0
1477 0
- 0
1510 0
contain 0
C3 B-gene
( I-gene
D I-gene
) I-gene
epitopes I-gene
that 0
are 0
exposed 0
exclusively 0
in 0
denatured 0
C3 B-gene
and 0
therefore 0
hidden 0
in 0
physiological 0
fragments 0
of 0
the 0
protein 0
. 0

These 0
exons 0
, 0
further 0
identified 0
as 0
exons 0
9 0
, 0
10 0
, 0
and 0
11 0
, 0
together 0
encode 0
the 0
37 0
amino 0
acid 0
residues 0
present 0
in 0
alpha B-gene
s1 I-gene
- I-gene
casein I-gene
variant I-gene
A I-gene
but 0
missing 0
in 0
variant 0
F 0
. 0

We 0
also 0
report 0
here 0
the 0
complete 0
structural 0
organization 0
of 0
the 0
goat B-gene
alpha I-gene
s1 I-gene
- I-gene
casein I-gene
transcription I-gene
unit I-gene
, 0
deduced 0
from 0
polymerase 0
chain 0
reaction 0
experiments 0
. 0

Homodimers 0
of 0
the 0
three 0
proteins 0
specifically 0
recognize 0
the 0
G 0
- 0
box 0
motif 0
, 0
with 0
GBF1 B-gene
and 0
GBF3 B-gene
binding 0
symmetrically 0
to 0
this 0
palindromic 0
sequence 0
. 0

Neither 0
gene 0
possesses 0
a 0
distinct 0
transcriptional 0
start 0
site 0
as 0
shown 0
by 0
nuclease B-gene
S1 I-gene
analysis 0
. 0

The 0
hydrophobicity 0
plot 0
of 0
NHE B-gene
- I-gene
3 I-gene
is 0
very 0
similar 0
to 0
that 0
of 0
NHE B-gene
- I-gene
1 I-gene
and 0
NHE B-gene
- I-gene
2 I-gene
. 0

The 0
initial 0
translation 0
protein 0
encoded 0
by 0
the 0
cDNA 0
is 0
53,932 0
kDa 0
and 0
possesses 0
a 0
hydrophilic 0
amino 0
acid 0
composition 0
with 0
glutamic 0
acid 0
comprising 0
22 0
% 0
of 0
the 0
total 0
amino 0
acid 0
residues 0
. 0

Each 0
group 0
received 0
15 0
ml/kg 0
of 0
either 0
6 0
% 0
pentafraction 0
, 0
6 0
% 0
pentastarch 0
, 0
or 0
plasma 0
followed 0
two 0
hours 0
later 0
by 0
1.5 0
micrograms/kg/0.5 0
hr 0
E 0
. 0

Genetic 0
and 0
biochemical 0
evidence 0
suggests 0
that 0
v B-gene
- I-gene
Crk I-gene
can 0
induce 0
transformation 0
of 0
chicken 0
embryo 0
fibroblasts 0
by 0
influencing 0
the 0
activity 0
of 0
cellular 0
proteins 0
involved 0
in 0
growth 0
regulation 0
. 0

We 0
have 0
constructed 0
, 0
using 0
synthetic 0
DNA 0
oligonucleotides 0
, 0
a 0
U14 B-gene
snRNA I-gene
gene I-gene
which 0
has 0
been 0
positioned 0
behind 0
a 0
T7 B-gene
RNA I-gene
polymerase I-gene
promoter I-gene
site I-gene
and 0
then 0
inserted 0
into 0
a 0
plasmid 0
. 0

Gene 0
and 0
pseudogene 0
of 0
the 0
mouse 0
cation 0
- 0
dependent 0
mannose B-gene
6 I-gene
- I-gene
phosphate I-gene
receptor I-gene
. 0

The 0
chick 0
axon 0
- 0
associated 0
surface 0
glycoprotein 0
neurofascin B-gene
is 0
implicated 0
in 0
axonal 0
growth 0
and 0
fasciculation 0
as 0
revealed 0
by 0
antibody 0
perturbation 0
experiments 0
. 0

The 0
carcinoma 0
was 0
restricted 0
within 0
the 0
epithelium 0
in 0
one 0
, 0
the 0
mucosal 0
layer 0
in 0
five 0
, 0
and 0
the 0
submucosal 0
layer 0
in 0
two 0
. 0

In 0
addition 0
, 0
C/EBP B-gene
beta I-gene
and 0
C/EBP B-gene
gamma I-gene
readily 0
heterodimerize 0
with 0
each 0
other 0
as 0
well 0
as 0
with 0
C/EBP B-gene
alpha I-gene
. 0

In 0
contrast 0
, 0
tobacco B-gene
GS I-gene
- I-gene
2 I-gene
is 0
composed 0
of 0
subunits 0
of 0
identical 0
size 0
in 0
all 0
organs 0
examined 0
. 0

Between 0
acoR B-gene
and 0
acoXABC B-gene
, 0
two 0
different 0
types 0
of 0
sequences 0
with 0
dual 0
rotational 0
symmetry 0
[ 0
CAC 0
- 0
( 0
N11 0
to 0
N18 0
) 0
- 0
GTG 0
and 0
TGT 0
- 0
( 0
N10 0
to 0
N14 0
) 0
- 0
ACA 0
] 0
were 0
found 0
; 0
these 0
sequences 0
are 0
similar 0
to 0
NtrC B-gene
and 0
NifA B-gene
upstream I-gene
activator I-gene
sequences I-gene
, 0
respectively 0
. 0

Although 0
the 0
effects 0
of 0
the 0
calcium 0
supplement 0
or 0
calcium 0
antagonist 0
alone 0
were 0
significant 0
, 0
such 0
hypotensive 0
responses 0
were 0
not 0
optimal 0
or 0
predictable 0
or 0
clearly 0
dose 0
- 0
dependent 0
. 0

C. 0
, 0
Sun 0
, 0
J. 0
, 0
Hsu 0
, 0
M. 0
- 0
Y. 0
, 0
Vallejo 0
- 0
Ramirez 0
, 0
J. 0
, 0
Inouye 0
, 0
S. 0
, 0
and 0
Inouye 0
, 0
M 0
. 0

Surprisingly 0
, 0
the 0
full 0
- 0
deletion 0
mutant 0
showed 0
a 0
strong 0
block 0
in 0
virus 0
release 0
, 0
suggesting 0
that 0
NC B-gene
is 0
involved 0
in 0
virus 0
assembly 0
. 0

Furthermore 0
it 0
was 0
suggested 0
that 0
FK506 0
plasma 0
levels 0
were 0
concerned 0
with 0
the 0
appearance 0
of 0
side 0
effect 0
. 0

Thirty 0
percent 0
of 0
patients 0
were 0
tapered 0
off 0
all 0
steroids 0
, 0
and 0
the 0
average 0
steroid 0
dose 0
in 0
the 0
group 0
who 0
received 0
steroids 0
was 0
8.6 0
mg 0
of 0
prednisone 0
per 0
day 0
. 0

Thus 0
, 0
cibenzoline 0
is 0
an 0
effective 0
antiarrhythmic 0
agent 0
with 0
a 0
favourable 0
pharmacokinetic 0
profile 0
that 0
may 0
be 0
considered 0
with 0
other 0
class 0
I 0
drugs 0
in 0
patients 0
requiring 0
therapy 0
for 0
high 0
risk 0
arrhythmias 0
. 0

T B-gene
antigen I-gene
contains 0
four 0
H 0
- 0
2Db 0
- 0
restricted 0
cytotoxic 0
T 0
lymphocyte 0
( 0
CTL 0
) 0
recognition 0
epitopes 0
that 0
are 0
targets 0
for 0
CTL 0
clones 0
Y 0
- 0
1 0
, 0
Y 0
- 0
2 0
, 0
Y 0
- 0
3 0
, 0
and 0
Y 0
- 0
5 0
. 0

The 0
method 0
requires 0
a 0
reversed 0
- 0
phase 0
column 0
and 0
a 0
paired 0
- 0
ion 0
technique 0
to 0
separate 0
docusate 0
sodium 0
from 0
other 0
components 0
. 0

Here 0
we 0
demonstrate 0
that 0
the 0
protein 0
product 0
of 0
the 0
ref B-gene
- I-gene
1 I-gene
gene I-gene
stimulates 0
the 0
DNA 0
binding 0
activity 0
of 0
Fos B-gene
- 0
Jun B-gene
heterodimers 0
, 0
Jun B-gene
- 0
Jun B-gene
homodimers 0
and 0
Hela 0
cell 0
AP B-gene
- I-gene
1 I-gene
proteins I-gene
as 0
well 0
as 0
that 0
of 0
several 0
other 0
transcription 0
factors 0
including 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
, 0
Myb B-gene
and 0
members 0
of 0
the 0
ATF/CREB B-gene
family 0
. 0

The 0
pulpal 0
tissues 0
of 0
the 0
permanent 0
mandibular 0
molars 0
were 0
amputated 0
and 0
then 0
dressed 0
with 0
calcium 0
hydrate 0
. 0

Northern 0
blot 0
analyses 0
demonstrate 0
that 0
3.9 0
- 0
and 0
5 0
- 0
kilobase 0
mRNAs 0
corresponding 0
to 0
the 0
cDNA 0
were 0
present 0
in 0
all 0
tissues 0
examined 0
, 0
suggesting 0
that 0
the 0
protein 0
it 0
encodes 0
performs 0
a 0
housekeeping 0
function 0
. 0

The 0
ARG B-gene
SH2 B-gene
domain I-gene
exhibited 0
relatively 0
weak 0
affinity 0
for 0
BCR B-gene
and 0
was 0
determined 0
to 0
bind 0
about 0
10 0
- 0
fold 0
less 0
strongly 0
than 0
the 0
ABL B-gene
SH2 B-gene
domain I-gene
. 0

We 0
analyzed 0
an 0
EBV 0
B 0
- 0
cell 0
clone 0
, 0
E29.1 0
, 0
derived 0
from 0
an 0
11 0
week 0
- 0
old 0
embryo 0
, 0
and 0
secreting 0
both 0
IgM B-gene
kappa I-gene
and 0
IgM B-gene
lambda I-gene
. 0

Interestingly 0
, 0
this 0
activation 0
occurred 0
only 0
when 0
the 0
regions 0
were 0
cloned 0
in 0
the 0
same 0
relative 0
orientation 0
in 0
which 0
they 0
exist 0
on 0
wild 0
- 0
type 0
pCF10 0
. 0

In 0
rats 0
, 0
we 0
examined 0
the 0
effect 0
of 0
an 0
omentum 0
wrapping 0
on 0
the 0
vascularization 0
of 0
the 0
trachea 0
and 0
on 0
regeneration 0
of 0
the 0
mucosal 0
epithelium 0
in 0
the 0
very 0
early 0
stage 0
after 0
free 0
tracheal 0
grafting 0
. 0

To 0
study 0
a 0
possible 0
functional 0
role 0
of 0
this 0
putative 0
chicken 0
ICS B-gene
, 0
an 0
oligonucleotide 0
spanning 0
the 0
upstream 0
sequences 0
of 0
the 0
BF B-gene
- I-gene
IV I-gene
gene I-gene
( 0
- 0
174/ 0
- 0
194 0
) 0
was 0
cloned 0
singly 0
or 0
in 0
multiple 0
copies 0
before 0
the 0
herpes 0
TK B-gene
promoter I-gene
controlling 0
the 0
chloramphenicol B-gene
acetyl I-gene
transferase I-gene
( 0
CAT B-gene
) 0
gene 0
( 0
pBLCAT2 B-gene
) 0
. 0

In 0
general 0
, 0
two 0
separate 0
high 0
- 0
performance 0
liquid 0
chromatographic 0
runs 0
were 0
performed 0
, 0
one 0
for 0
the 0
gamma 0
- 0
aminobutyric 0
acid 0
determination 0
and 0
one 0
for 0
the 0
determination 0
of 0
the 0
monoamines 0
. 0

We 0
report 0
the 0
successful 0
use 0
of 0
electroconvulsive 0
therapy 0
for 0
treatment 0
of 0
severe 0
depression 0
in 0
a 0
young 0
man 0
with 0
adult 0
GM2 0
gangliosidosis 0
. 0

Entry 0
of 0
yeast 0
cells 0
into 0
the 0
mitotic 0
cell 0
cycle 0
( 0
Start 0
) 0
involves 0
a 0
form 0
of 0
the 0
CDC28 B-gene
kinase I-gene
that 0
associates 0
with 0
G1 0
- 0
specific 0
cyclins B-gene
encoded 0
by 0
CLN1 B-gene
and 0
CLN2 B-gene
( 0
ref 0
. 0

Through 0
Southern 0
blot 0
analyses 0
of 0
DNA 0
from 0
backcross 0
and 0
cogenic 0
mice 0
, 0
recombinant 0
inbred 0
strains 0
, 0
and 0
somatic 0
cell 0
hybrids 0
, 0
the 0
genetic 0
loci 0
that 0
produce 0
the 0
cyclin B-gene
B1 I-gene
- I-gene
related I-gene
sequences I-gene
( 0
designated 0
loci B-gene
Cycb1 I-gene
- I-gene
rs1 I-gene
to 0
Cycb1 B-gene
- I-gene
rs9 I-gene
) 0
were 0
mapped 0
on 0
mouse 0
chromosomes 0
5 0
, 0
1 0
, 0
17 0
, 0
4 0
, 0
14 0
, 0
13 0
, 0
7 0
, 0
X 0
, 0
and 0
8 0
, 0
respectively 0
. 0

Again 0
residue 0
Glu 0
- 0
381 0
of 0
beta 0
was 0
notably 0
reduced 0
and 0
no 0
missing 0
residue 0
from 0
the 0
epsilon 0
peptide 0
could 0
be 0
identified 0
, 0
but 0
the 0
peptide 0
sequence 0
limited 0
the 0
possible 0
choices 0
to 0
Ser 0
- 0
106 0
, 0
Ser 0
- 0
107 0
, 0
or 0
Ser 0
- 0
108 0
. 0

Porcelain 0
to 0
dentin 0
bond 0
strength 0
with 0
a 0
dentin 0
adhesive 0
. 0

TBPf 0
is 0
defined 0
as 0
a 0
quotient 0
of 0
the 0
difference 0
of 0
the 0
first 0
and 0
the 0
second 0
measurement 0
: 0
TBPf 0
= 0
( 0
P1 0
- 0
P2 0
) 0
/ 0
( 0
A1 0
- 0
A2 0
) 0
. 0

It 0
was 0
concluded 0
that 0
Scotchbond 0
2 0
and 0
Prisma 0
Universal 0
Bond 0
2 0
are 0
effective 0
and 0
are 0
the 0
dentine 0
bonding 0
agents 0
of 0
choice 0
. 0

From 0
all 0
clinically 0
important 0
yeasts 0
species 0
, 0
a 0
total 0
of 0
96 0
% 0
were 0
identified 0
by 0
ATB 0
method 0
according 0
to 0
conventional 0
methods 0
. 0

The 0
neurohypophysial 0
vasopressin B-gene
and 0
oxytocin B-gene
content 0
was 0
bioassayed 0
by 0
pressor 0
effect 0
following 0
Dekanski 0
or 0
milk 0
- 0
ejection 0
activity 0
in 0
vitro 0
following 0
van 0
Dongen 0
and 0
Hays 0
, 0
respectively 0
. 0

Comments 0
are 0
given 0
on 0
the 0
present 0
status 0
of 0
regulations 0
concerning 0
water 0
in 0
swimming 0
pools 0
and 0
baths 0
- 0
- 0
1991 0
- 0
- 0
( 0
in 0
connection 0
with 0
the 0
KOK 0
regulations 0
- 0
- 0
1972 0
- 0
- 0
and 0
the 0
Federal 0
German 0
standard 0
[ 0
DIN 0
] 0
No 0
. 0

If 0
no 0
reply 0
was 0
received 0
, 0
telephone 0
contact 0
or 0
home 0
visits 0
were 0
made 0
. 0

The 0
treatment 0
group 0
also 0
showed 0
in 0
vivo 0
T 0
- 0
cell 0
activation 0
with 0
an 0
initial 0
lymphopenia 0
followed 0
by 0
a 0
rebound 0
lymphocytosis 0
and 0
upregulation 0
of 0
the 0
subset 0
markers 0
CD25 B-gene
( 0
interleukin B-gene
2 I-gene
receptor I-gene
) 0
and 0
CD45RO B-gene
( 0
T 0
- 0
memory 0
cells 0
) 0
. 0

Urease B-gene
activity 0
, 0
judged 0
as 0
the 0
amount 0
of 0
ammonia 0
production 0
from 0
urea 0
, 0
could 0
be 0
measured 0
at 0
25 0
ng 0
per 0
tube 0
( 0
S/N 0
= 0
1.5 0
) 0
with 0
Jack B-gene
bean I-gene
meal I-gene
urease I-gene
. 0

Consequently 0
, 0
significant 0
differences 0
between 0
the 0
measured 0
and 0
calculated 0
methods 0
were 0
noted 0
in 0
oxygen 0
uptake 0
( 0
213 0
+/ 0
- 0
41 0
ml/min 0
vs 0
193 0
+/ 0
- 0
25 0
ml/min 0
, 0
p 0
< 0
0.001 0
) 0
, 0
oxygen 0
delivery 0
( 0
780 0
+/ 0
- 0
297 0
ml/min 0
vs 0
716 0
+/ 0
- 0
296 0
ml/min 0
, 0
p 0
< 0
0.001 0
) 0
, 0
and 0
cardiac 0
output 0
( 0
5.8 0
+/ 0
- 0
2.2 0
L/min 0
vs 0
5.3 0
+/ 0
- 0
1.8 0
L/min 0
, 0
p 0
< 0
0.001 0
) 0
. 0

Although 0
a 0
wide 0
range 0
of 0
cognitive 0
functions 0
had 0
been 0
tested 0
, 0
all 0
but 0
one 0
seizure 0
occurred 0
during 0
assessment 0
of 0
memory 0
performance 0
. 0

The 0
experiments 0
show 0
that 0
it 0
is 0
the 0
micromilieu 0
of 0
the 0
alveoli 0
and 0
the 0
condition 0
of 0
the 0
AM 0
( 0
certain 0
physiological 0
activation 0
states 0
, 0
such 0
as 0
phagocytic 0
activity 0
) 0
that 0
essentially 0
determine 0
the 0
degree 0
of 0
recovery 0
. 0

Negatively 0
supercoiled 0
plasmid 0
pUC19 0
did 0
not 0
compete 0
, 0
whereas 0
an 0
otherwise 0
identical 0
plasmid 0
pUC19 0
( 0
CG 0
) 0
, 0
which 0
contained 0
a 0
( 0
dG 0
- 0
dC 0
) 0
7 0
segment 0
in 0
the 0
Z 0
- 0
form 0
was 0
an 0
excellent 0
competitor 0
. 0

A 0
cDNA 0
library 0
of 0
tumour 0
cells 0
was 0
screened 0
with 0
an 0
interleukin B-gene
2 I-gene
gene 0
- 0
specific 0
probe 0
. 0

Our 0
experiments 0
suggest 0
that 0
the 0
SCL B-gene
gene I-gene
can 0
be 0
a 0
target 0
for 0
the 0
erythroid B-gene
transcription I-gene
factor I-gene
GATA I-gene
- I-gene
1 I-gene
and 0
that 0
the 0
SCL B-gene
gene I-gene
product I-gene
serves 0
as 0
a 0
positive 0
regulator 0
of 0
erythroid 0
differentiation 0
. 0

In 0
contrast 0
, 0
the 0
lumenal 0
domains 0
of 0
Sec12p B-gene
, 0
Stl1p B-gene
and 0
Stl2p B-gene
are 0
very 0
different 0
in 0
size 0
and 0
do 0
not 0
show 0
any 0
appreciable 0
homology 0
. 0

Complexes 0
containing 0
wild 0
- 0
type 0
and 0
either 0
his175 B-gene
or I-gene
his273 I-gene
mutant I-gene
p53 I-gene
proteins I-gene
are 0
completely 0
unable 0
to 0
bind 0
to 0
the 0
RGC B-gene
DNA I-gene
sequence I-gene
. 0

These 0
temperature 0
- 0
and 0
cold 0
- 0
sensitive 0
strains 0
were 0
used 0
to 0
prepare 0
extracts 0
deficient 0
in 0
BRF1 B-gene
activity 0
and 0
were 0
tested 0
for 0
transcriptional 0
activity 0
by 0
RNA B-gene
polymerases I-gene
I I-gene
, I-gene
II I-gene
, I-gene
and I-gene
III I-gene
in 0
vitro 0
. 0

These 0
results 0
lead 0
us 0
to 0
hypothesize 0
that 0
a 0
single 0
multisubunit B-gene
TFIID I-gene
protein I-gene
supports 0
transcriptional 0
stimulation 0
by 0
diverse 0
activation 0
domains 0
and 0
from 0
a 0
TATA 0
- 0
less 0
promoter 0
. 0

The 0
gene 0
sequence 0
also 0
identified 0
a 0
340 0
- 0
nucleotide 0
RNA 0
in 0
total 0
yeast 0
RNA 0
and 0
in 0
purified 0
RNase B-gene
MRP I-gene
enzyme I-gene
preparations 0
. 0

The 0
RNase B-gene
MRP I-gene
RNA I-gene
gene I-gene
was 0
deleted 0
by 0
insertional 0
replacement 0
and 0
found 0
to 0
be 0
essential 0
for 0
cellular 0
viability 0
, 0
indicating 0
a 0
critical 0
nuclear 0
role 0
for 0
RNase B-gene
MRP I-gene
. 0

Clone 0
pSRc200 0
hybrid 0
selected 0
an 0
mRNA 0
that 0
on 0
cell 0
- 0
free 0
translation 0
produced 0
a 0
38 0
- 0
kDa 0
polypeptide 0
. 0

From 0
these 0
results 0
, 0
CBF B-gene
- I-gene
A I-gene
is 0
a 0
novel 0
CArG 0
box 0
- 0
, 0
ssDNA B-gene
- I-gene
and I-gene
RNA I-gene
- I-gene
binding I-gene
protein I-gene
, 0
as 0
well 0
as 0
a 0
repressive 0
transcriptional 0
factor 0
. 0

Cleavage 0
by 0
the 0
intron 0
- 0
encoded 0
enzyme 0
( 0
I B-gene
- I-gene
CreI I-gene
) 0
occurs 0
5 0
bp 0
and 0
1 0
bp 0
3 0
' 0
to 0
the 0
intron 0
insertion 0
site 0
( 0
in 0
the 0
3' 0
- 0
exon 0
) 0
in 0
the 0
top 0
( 0
/ 0
) 0
and 0
bottom 0
( 0
, 0
) 0
strands 0
, 0
respectively 0
, 0
resulting 0
in 0
4 0
- 0
nt 0
single 0
- 0
stranded 0
overhangs 0
with 0
3' 0
- 0
OH 0
termini 0
. 0

Surprisingly 0
, 0
the 0
Xenopus B-gene
U7 I-gene
gene I-gene
contains 0
two 0
adjacent 0
octamer 0
- 0
binding 0
motifs 0
located 0
only 0
12 0
and 0
24 0
bp 0
upstream 0
from 0
the 0
PSE B-gene
, 0
instead 0
of 0
the 0
usual 0
location 0
around 0
150 0
- 0
200 0
bp 0
upstream 0
. 0

The 0
results 0
support 0
earlier 0
reports 0
that 0
collagenase B-gene
inhibitors 0
are 0
useful 0
in 0
controlling 0
blister 0
formation 0
in 0
recessive 0
dystrophic 0
epidermolysis 0
bullosa 0
. 0

Mutational 0
analysis 0
of 0
essential 0
IncP 0
alpha 0
plasmid 0
transfer 0
genes 0
traF B-gene
and 0
traG B-gene
and 0
involvement 0
of 0
traF B-gene
in 0
phage 0
sensitivity 0
. 0

The 0
promoter 0
was 0
stimulated 0
8 0
- 0
20 0
- 0
fold 0
by 0
phorbol 0
esters 0
accounting 0
for 0
the 0
previously 0
observed 0
transcriptional 0
activation 0
of 0
protein B-gene
kinase I-gene
C I-gene
beta I-gene
. 0

In 0
humans 0
, 0
four 0
AMP B-gene
deaminase I-gene
variants I-gene
, 0
termed 0
M B-gene
( 0
muscle 0
) 0
, 0
L B-gene
( 0
liver 0
) 0
, 0
E1 B-gene
, 0
and 0
E2 B-gene
( 0
erythrocyte 0
) 0
can 0
be 0
distinguished 0
by 0
a 0
variety 0
of 0
biochemical 0
and 0
immunological 0
criteria 0
. 0

Western 0
blot 0
analyses 0
detect 0
anti B-gene
- I-gene
E I-gene
- 0
specific 0
immunoreactivity 0
in 0
affinity 0
- 0
purified 0
extracts 0
derived 0
from 0
the 0
bacterial 0
expression 0
of 0
a 0
truncated B-gene
AMPD3 I-gene
cDNA I-gene
. 0

These 0
results 0
demonstrate 0
that 0
endogenous 0
N 0
- 0
methylation 0
of 0
salsolinol 0
into 0
N 0
- 0
methylsalsolinol 0
occurs 0
in 0
the 0
brain 0
in 0
vivo 0
. 0

DR1 B-gene
molecules I-gene
purified 0
from 0
human 0
lymphoblastoid 0
cell 0
lines 0
could 0
specifically 0
bind 0
to 0
these 0
peptide 0
sequences 0
expressed 0
on 0
the 0
phage 0
surface 0
. 0

This 0
article 0
describes 0
the 0
collaborative 0
care 0
of 0
the 0
woman 0
participating 0
in 0
maternal 0
blood 0
donation 0
for 0
intrauterine 0
transfusion 0
. 0

Chronic 0
hepatitis 0
B 0
in 0
adopted 0
Romanian 0
children 0
. 0

Behind 0
the 0
ATPase B-gene
cluster I-gene
, 0
two 0
open 0
reading 0
frames 0
were 0
detected 0
that 0
are 0
not 0
homologous 0
to 0
any 0
known 0
chloroplast 0
gene 0
. 0

Therefore 0
, 0
recombinant 0
human 0
Ads 0
that 0
express 0
noninfectious 0
HIV 0
or 0
other 0
microbial 0
proteins 0
are 0
attractive 0
vaccine 0
candidates 0
. 0

Alignment 0
of 0
the 0
selected 0
sequences 0
allowed 0
us 0
to 0
predict 0
a 0
consensus 0
sequence 0
for 0
binding 0
of 0
the 0
individual 0
homodimeric 0
Rel B-gene
- I-gene
related I-gene
proteins I-gene
, 0
and 0
DNA 0
- 0
protein 0
binding 0
analysis 0
of 0
the 0
selected 0
DNA 0
sequences 0
revealed 0
sequence 0
specificity 0
of 0
the 0
proteins 0
. 0

Using 0
either 0
a 0
p50 B-gene
- 0
or 0
p65 B-gene
p65 I-gene
- I-gene
selected I-gene
kappa I-gene
B I-gene
motif I-gene
, 0
which 0
displayed 0
differential 0
binding 0
with 0
respect 0
to 0
the 0
other 0
protein 0
, 0
little 0
to 0
no 0
binding 0
was 0
observed 0
with 0
the 0
heterodimeric B-gene
NF I-gene
- I-gene
kappa I-gene
B I-gene
complex I-gene
. 0

However 0
, 0
a 0
cosmid 0
clone 0
containing 0
the 0
entire 0
mouse B-gene
alpha I-gene
1 I-gene
( I-gene
I I-gene
) I-gene
gene I-gene
, 0
including 0
3.7 0
kb 0
of 0
5' 0
- 0
and 0
4 0
kb 0
of 0
3' 0
- 0
flanking 0
DNA 0
, 0
was 0
expressed 0
at 0
reduced 0
levels 0
in 0
fibroblasts 0
overexpressing 0
oncogenic B-gene
ras I-gene
. 0

To 0
define 0
transcriptional 0
control 0
elements 0
responsible 0
for 0
muscle 0
- 0
specific 0
expression 0
of 0
the 0
human B-gene
myoglobin I-gene
gene I-gene
, 0
we 0
performed 0
mutational 0
analysis 0
of 0
upstream 0
sequences 0
( 0
nucleotide 0
positions 0
- 0
373 0
to 0
+7 0
relative 0
to 0
the 0
transcriptional 0
start 0
site 0
) 0
linked 0
to 0
a 0
firefly B-gene
luciferase I-gene
gene I-gene
. 0

Sequencing 0
analysis 0
has 0
shown 0
that 0
each 0
rap1t B-gene
allele I-gene
contains 0
a 0
nonsense 0
mutation 0
within 0
a 0
discrete 0
region 0
between 0
amino 0
acids 0
663 0
and 0
684 0
. 0

By 0
screening 0
a 0
Y1 0
cell 0
cDNA 0
library 0
with 0
the 0
DNA 0
- 0
binding 0
region 0
of 0
the 0
H B-gene
- I-gene
2RIIBP I-gene
nuclear I-gene
hormone I-gene
receptor I-gene
cDNA I-gene
, 0
we 0
isolated 0
a 0
cDNA 0
that 0
is 0
selectively 0
expressed 0
in 0
steroidogenic 0
cells 0
. 0

Autopsy 0
demonstrated 0
good 0
survival 0
of 0
the 0
transplanted 0
cells 0
with 0
good 0
integration 0
with 0
the 0
brain 0
of 0
the 0
recipient 0
and 0
traces 0
of 0
positive 0
immunocytochemical 0
reaction 0
for 0
tyrosine B-gene
hydroxylase I-gene
. 0

The 0
technique 0
of 0
the 0
TEE 0
visualization 0
of 0
the 0
proximal 0
coronary 0
arteries 0
is 0
described 0
. 0

The 0
sequence 0
of 0
this 0
region 0
shows 0
high 0
G+C 0
content 0
( 0
62 0
% 0
) 0
, 0
which 0
is 0
particularly 0
emphasized 0
in 0
the 0
200 0
bp 0
upstream 0
from 0
the 0
mRNA 0
start 0
( 0
80 0
% 0
G+C 0
) 0
. 0

In 0
the 0
eight 0
patients 0
with 0
persistent 0
generalized 0
lymph 0
- 0
adenopathy 0
( 0
PGL 0
) 0
and 0
nontender 0
, 0
nonenlarging 0
nodes 0
, 0
pathologic 0
analysis 0
revealed 0
lymphoid 0
hyperplasia 0
. 0

PaO2 0
threshold 0
was 0
determined 0
through 0
an 0
indwelling 0
O2 0
sensor 0
catheter 0
. 0

We 0
found 0
that 0
both 0
the 0
E26 0
virus 0
- 0
encoded 0
v B-gene
- I-gene
ets I-gene
and 0
the 0
myeloid/B B-gene
- I-gene
cell I-gene
- I-gene
specific I-gene
factor I-gene
PU.1 I-gene
bind 0
efficiently 0
to 0
this 0
site 0
in 0
vitro 0
. 0

By 0
using 0
lambda 0
gt11 0
expression 0
cloning 0
with 0
oligonucleotides 0
corresponding 0
to 0
the 0
human 0
immunodeficiency 0
virus 0
1 0
TATA 0
element 0
, 0
we 0
report 0
the 0
identification 0
of 0
a 0
cellular 0
protein 0
with 0
a 0
calculated 0
molecular 0
mass 0
of 0
123 0
kDa 0
that 0
we 0
designate 0
TATA B-gene
element I-gene
modulatory I-gene
factor I-gene
( 0
TMF B-gene
) 0
. 0

Blood 0
levels 0
of 0
melatonin 0
, 0
serotonin 0
, 0
cortisol 0
, 0
and 0
prolactin B-gene
in 0
relation 0
to 0
the 0
circadian 0
rhythm 0
of 0
platelet 0
serotonin 0
uptake 0
. 0

We 0
could 0
n't 0
detect 0
any 0
effect 0
of 0
n 0
- 0
3 0
FA 0
supplementation 0
on 0
total 0
cholesterol 0
, 0
HDL B-gene
cholesterol I-gene
, 0
LDL B-gene
cholesterol I-gene
, 0
apo B-gene
A1 I-gene
, 0
Lp B-gene
( I-gene
a I-gene
) I-gene
, 0
HbA1C B-gene
, 0
glucose 0
, 0
fibrinogen B-gene
, 0
factor B-gene
VIII I-gene
, 0
antithrombin B-gene
III I-gene
, 0
plasminogen B-gene
activator I-gene
inhibitor I-gene
, 0
tissue B-gene
plasminogen I-gene
activator I-gene
and 0
von B-gene
Willebrand I-gene
factor I-gene
concentration 0
, 0
on 0
bleeding 0
time 0
or 0
on 0
systolic 0
or 0
diastolic 0
blood 0
pressure 0
. 0

In 0
8 0
healthy 0
volunteers 0
there 0
were 0
no 0
significant 0
differences 0
in 0
AUC 0
, 0
peak 0
plasma 0
concentrations 0
or 0
time 0
to 0
peak 0
concentration 0
when 0
OXC 0
was 0
administered 0
either 0
with 0
or 0
without 0
ERY 0
. 0

Using 0
5 0
ng/mL 0
as 0
the 0
cutoff 0
, 0
the 0
sensitivity 0
of 0
CEA B-gene
was 0
68 0
% 0
. 0

Rolandic 0
spikes 0
and 0
cognitive 0
function 0
. 0

The 0
effect 0
of 0
sodium 0
18 0
beta 0
- 0
glycyrrhetate 0
( 0
SGA 0
) 0
on 0
experimental 0
arrhythmia 0
was 0
investigated 0
. 0

Thus 0
, 0
chronic 0
hematocrit 0
decrease 0
induced 0
by 0
H 0
or 0
P 0
resulted 0
in 0
a 0
significant 0
fall 0
in 0
blood 0
pressure 0
compared 0
to 0
control 0
( 0
201 0
+/ 0
- 0
3 0
v 0
175 0
+/ 0
- 0
4 0
, 0
167 0
+/ 0
- 0
4 0
mm 0
Hg 0
, 0
respectively 0
; 0
P 0
< 0
.05 0
) 0
. 0

The 0
effects 0
of 0
diltiazem 0
were 0
stereoselective 0
, 0
thus 0
the 0
potentiation 0
induced 0
by 0
d 0
- 0
cis 0
diltiazem 0
was 0
significantly 0
greater 0
in 0
all 0
cases 0
than 0
that 0
induced 0
by 0
l 0
- 0
cis 0
diltiazem 0
, 0
which 0
suggests 0
that 0
calcium 0
channel 0
blockade 0
plays 0
a 0
role 0
in 0
these 0
interactions 0
. 0

Localization 0
of 0
the 0
brachial 0
plexus 0
with 0
the 0
nerve 0
stimulator 0
is 0
equally 0
effective 0
at 0
the 0
interscalene 0
, 0
supraclavicular 0
, 0
and 0
axillary 0
sites 0
. 0

Substitution 0
of 0
either 0
Val33 0
( 0
by 0
Gly 0
) 0
or 0
Gly28 0
( 0
by 0
Ser 0
) 0
, 0
two 0
of 0
the 0
most 0
conserved 0
residues 0
in 0
all 0
protein 0
kinases 0
, 0
resulted 0
in 0
enzyme 0
with 0
marginally 0
detectable 0
activity 0
. 0

Significance 0
of 0
the 0
biopsy 0
site 0
of 0
the 0
latissimus 0
dorsi 0
muscle 0
for 0
fiber 0
typing 0
. 0

The 0
TIMP B-gene
( 0
- 0
59/ 0
- 0
53 0
) 0
AP1 B-gene
site 0
is 0
a 0
promiscuous 0
motif 0
that 0
binds 0
c B-gene
- I-gene
Fos/c I-gene
Fos/c I-gene
- I-gene
Jun I-gene
AP1 B-gene
translated 0
in 0
vitro 0
and 0
is 0
an 0
effective 0
competitor 0
for 0
binding 0
of 0
nuclear B-gene
AP1 I-gene
factors I-gene
to 0
the 0
consensus 0
TRE 0
, 0
but 0
in 0
addition 0
it 0
binds 0
factors 0
that 0
do 0
not 0
associate 0
with 0
the 0
consensus 0
TRE 0
. 0

Involvement 0
of 0
AP1 B-gene
and 0
PEA3 B-gene
binding I-gene
sites I-gene
in 0
the 0
regulation 0
of 0
murine B-gene
tissue I-gene
inhibitor I-gene
of I-gene
metalloproteinases I-gene
- I-gene
1 I-gene
( 0
TIMP B-gene
- I-gene
1 I-gene
) 0
transcription 0
. 0

Of 0
the 0
serum B-gene
neutralizing I-gene
( I-gene
SN I-gene
) I-gene
antibody I-gene
negative 0
calves 0
89.7 0
% 0
( 0
26/29 0
) 0
and 0
92.8 0
% 0
( 0
90/97 0
) 0
developed 0
SN B-gene
antibody I-gene
1 0
month 0
after 0
intranasal 0
and 0
intramuscular 0
vaccination 0
, 0
respectively 0
. 0

Fractionation 0
of 0
crude 0
nuclear 0
extracts 0
by 0
heparin 0
- 0
agarose 0
chromatography 0
indicates 0
that 0
PCAT B-gene
- I-gene
1 I-gene
is 0
more 0
prevalent 0
in 0
extracts 0
prepared 0
from 0
salt 0
- 0
stressed 0
leaf 0
tissue 0
. 0

A 0
controlled 0
trial 0
of 0
recombinant B-gene
human I-gene
granulocyte I-gene
- I-gene
macrophage I-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
after 0
total 0
body 0
irradiation 0
, 0
high 0
- 0
dose 0
chemotherapy 0
, 0
and 0
autologous 0
bone 0
marrow 0
transplantation 0
for 0
acute 0
lymphoblastic 0
leukemia 0
or 0
malignant 0
lymphoma 0
. 0

These 0
data 0
demonstrate 0
that 0
DMVA 0
does 0
not 0
cause 0
more 0
myocardial 0
trauma 0
than 0
CPB 0
when 0
used 0
to 0
provide 0
resuscitative 0
circulatory 0
support 0
. 0

The 0
IgG B-gene
subclass 0
profile 0
of 0
untreated 0
coeliac 0
disease 0
was 0
found 0
to 0
be 0
the 0
same 0
as 0
in 0
healthy 0
controls 0
( 0
IgG1 B-gene
approximately 0
IgG2 B-gene
> 0
IgG3 B-gene
> 0
IgG4 B-gene
) 0
, 0
with 0
only 0
the 0
magnitude 0
of 0
the 0
individual 0
subclass 0
responses 0
being 0
increased 0
in 0
coeliac 0
patients 0
. 0

Examination 0
of 0
ANCA B-gene
is 0
not 0
only 0
a 0
significant 0
contribution 0
towards 0
a 0
more 0
accurate 0
diagnosis 0
of 0
renal 0
vasculitis 0
, 0
but 0
also 0
an 0
indicator 0
of 0
the 0
activity 0
of 0
the 0
disease 0
and 0
thus 0
of 0
the 0
effectiveness 0
of 0
immunosuppressive 0
treatment 0
. 0

On 0
the 0
other 0
hand 0
, 0
total 0
pinealectomy 0
in 0
these 0
already 0
sympathectomized 0
blinded 0
rabbits 0
always 0
resulted 0
in 0
a 0
substantial 0
deceleration 0
of 0
the 0
rhythms 0
( 0
mean 0
delta 0
tau 0
= 0
+0.23 0
h 0
) 0
. 0

Cicatricial 0
pemphigoid 0
is 0
an 0
autoimmune 0
systemic 0
disease 0
characterized 0
by 0
chronic 0
conjunctival 0
cicatrization 0
. 0

The 0
effects 0
of 0
two 0
levels 0
of 0
caffeine 0
ingestion 0
on 0
excess 0
postexercise 0
oxygen 0
consumption 0
in 0
untrained 0
women 0
. 0

The 0
distinguishing 0
features 0
involved 0
eight 0
amino 0
acid 0
changes 0
, 0
including 0
a 0
single 0
lysine 0
deletion 0
relative 0
to 0
a 0
primate 0
consensus 0
sequence 0
in 0
the 0
first 0
complementary 0
- 0
determing 0
region 0
of 0
V1J1 B-gene
. 0

4 0
. 0

The 0
in 0
vivo 0
profile 0
of 0
ZFH B-gene
- I-gene
2 I-gene
in 0
the 0
larval 0
CNS 0
shows 0
intriguing 0
overlap 0
with 0
DDC B-gene
in 0
specific 0
serotonin 0
and 0
dopamine 0
neurons 0
. 0

Unlike 0
the 0
introns 0
of 0
other 0
duplicated 0
ribosomal B-gene
protein I-gene
genes I-gene
which 0
are 0
highly 0
diverged 0
, 0
the 0
duplicated 0
S13 B-gene
genes I-gene
have 0
two 0
nearly 0
identical 0
DNA 0
sequences 0
of 0
25 0
and 0
31 0
bp 0
in 0
length 0
within 0
their 0
introns 0
. 0

In 0
a 0
prospective 0
, 0
randomized 0
clinical 0
trial 0
we 0
compared 0
the 0
efficacy 0
of 0
subcutaneously 0
( 0
SC 0
) 0
administered 0
( 0
every 0
8 0
h 0
) 0
calcium 0
heparin 0
to 0
intravenous 0
( 0
IV 0
) 0
sodium 0
heparin 0
in 0
the 0
treatment 0
of 0
proximal 0
deep 0
- 0
vein 0
thrombosis 0
( 0
DVT 0
) 0
. 0

The 0
highest 0
prevalence 0
of 0
reported 0
pet 0
allergy 0
, 0
chronic 0
cough 0
, 0
wheeze 0
, 0
attacks 0
of 0
shortness 0
of 0
breath 0
with 0
wheezing 0
, 0
and 0
doctor 0
- 0
diagnosed 0
asthma 0
was 0
found 0
in 0
children 0
who 0
had 0
pets 0
in 0
the 0
past 0
but 0
not 0
anymore 0
. 0

Therefore 0
, 0
it 0
would 0
be 0
advantageous 0
to 0
identify 0
such 0
persons 0
and 0
treat 0
them 0
preferentially 0
. 0

On 0
the 0
basis 0
of 0
these 0
unique 0
properties 0
, 0
the 0
newly 0
characterized 0
hemagglutinin B-gene
has 0
been 0
termed 0
Limulus B-gene
18K I-gene
agglutination I-gene
- I-gene
aggregation I-gene
factor I-gene
( 0
18K B-gene
- I-gene
LAF I-gene
) 0
. 0

The 0
shift 0
to 0
the 0
nonpermissive 0
temperature 0
is 0
accompanied 0
by 0
the 0
loss 0
of 0
guanyl 0
nucleotide 0
- 0
dependent 0
activity 0
of 0
adenylylcyclase B-gene
in 0
vitro 0
. 0

Clin 0
. 0

The 0
data 0
indicate 0
that 0
the 0
minimal 0
catalytic 0
domain 0
of 0
Nmt1p B-gene
is 0
located 0
between 0
Ile59 0
- 0
- 0
> 0
Phe96 0
and 0
Gly451 0
- 0
- 0
> 0
Leu455 0
. 0

It 0
corresponds 0
to 0
the 0
complete 0
mitochondrial 0
presequence 0
and 0
the 0
lipoyl 0
- 0
bearing 0
domain 0
that 0
are 0
encoded 0
by 0
exons 0
I 0
through 0
IV 0
of 0
the 0
functional 0
E2 B-gene
gene I-gene
. 0

Human 0
neutrophil 0
response 0
to 0
short 0
- 0
term 0
exposure 0
to 0
F 0
- 0
75 0
cobalt 0
- 0
based 0
alloy 0
. 0

Disruption 0
of 0
microtubules 0
did 0
not 0
affect 0
the 0
fidelity 0
or 0
kinetics 0
of 0
vacuolar 0
protein 0
sorting 0
, 0
indicating 0
that 0
Vps1p B-gene
function 0
is 0
not 0
dependent 0
on 0
microtubules 0
. 0

A 0
mutant 0
form 0
of 0
Vps1p B-gene
lacking 0
the 0
entire 0
GTP 0
- 0
binding 0
domain 0
interfered 0
with 0
vacuolar 0
protein 0
sorting 0
in 0
wild 0
- 0
type 0
cells 0
. 0

According 0
to 0
out 0
field 0
research 0
, 0
the 0
tick 0
fauna 0
was 0
very 0
rich 0
throughout 0
that 0
area 0
, 0
and 0
it 0
was 0
permissible 0
enough 0
to 0
determine 0
ticks 0
as 0
the 0
vectors 0
, 0
based 0
on 0
arising 0
of 0
anti B-gene
- I-gene
SF I-gene
group I-gene
rickettsiae I-gene
( 0
SFGR B-gene
) 0
antibody 0
in 0
mice 0
inoculated 0
with 0
some 0
tick 0
emulsions 0
, 0
findings 0
of 0
rickettsiae 0
reactive 0
to 0
patient 0
sera 0
or 0
a 0
species 0
- 0
specific 0
monoclonal 0
antibody 0
to 0
JSFR B-gene
in 0
the 0
hemolymph 0
cells 0
of 0
some 0
ticks 0
, 0
and 0
electron 0
microscopical 0
observations 0
of 0
SFGR B-gene
in 0
various 0
internal 0
organs 0
including 0
the 0
salivary 0
gland 0
of 0
ticks 0
. 0

The 0
second 0
method 0
, 0
the 0
`` 0
macro 0
'' 0
assay 0
, 0
has 0
a 0
sensitivity 0
range 0
of 0
0.03 0
- 0
5.0 0
micrograms 0
phosphorus 0
with 0
100 0
- 0
500 0
microliters 0
HClO4 0
. 0

Nucleotide 0
sequence 0
and 0
transcriptional 0
analysis 0
of 0
the 0
polyhedrin B-gene
gene I-gene
of 0
Spodoptera 0
exigua 0
nuclear 0
polyhedrosis 0
virus 0
. 0

Validation 0
of 0
automated 0
systems 0
- 0
- 0
system 0
definition 0
. 0

As 0
a 0
consequence 0
of 0
dark 0
rearing 0
, 0
the 0
numerical 0
density 0
of 0
cortical 0
neurons 0
in 0
area 0
17 0
amounted 0
to 0
about 0
double 0
of 0
the 0
value 0
observed 0
in 0
normally 0
reared 0
kittens 0
and 0
was 0
also 0
significantly 0
higher 0
in 0
area 0
18 0
. 0

These 0
results 0
suggest 0
that 0
decreased 0
class 0
I 0
enhancer 0
activity 0
in 0
Ad12 0
- 0
transformed 0
cells 0
may 0
, 0
at 0
least 0
in 0
part 0
, 0
be 0
due 0
to 0
the 0
higher 0
levels 0
of 0
an 0
enhancer 0
- 0
specific 0
factor 0
, 0
possibly 0
acting 0
as 0
a 0
repressor 0
. 0

A 0
second 0
domain 0
, 0
located 0
in 0
the 0
C 0
- 0
terminal 0
437 0
amino 0
acids 0
of 0
IE1 B-gene
, 0
is 0
required 0
for 0
inhibitory 0
and 0
DNA 0
- 0
binding 0
activities 0
. 0

In 0
order 0
to 0
investigate 0
the 0
blood 0
compatibility 0
of 0
autogenous 0
vein 0
graft 0
( 0
AVG 0
) 0
, 0
changes 0
in 0
prostacyclin 0
( 0
PGI2 0
) 0
production 0
following 0
harvesting 0
and 0
arterial 0
implantation 0
were 0
studied 0
experimentally 0
. 0

Subcutaneous 0
administration 0
of 0
the 0
somatostatin B-gene
analogue 0
, 0
octreotide 0
, 0
100 0
micrograms 0
thrice 0
daily 0
, 0
resulted 0
in 0
a 0
sustained 0
improvement 0
in 0
diarrhoea 0
and 0
disappearance 0
of 0
faecal 0
incontinence 0
without 0
reducing 0
calcitonin B-gene
levels 0
. 0

Anti B-gene
- I-gene
CRK I-gene
antibodies I-gene
detect 0
a 0
53kDa 0
protein 0
in 0
extracts 0
of 0
C.fasciculata 0
in 0
agreement 0
with 0
the 0
size 0
predicted 0
from 0
the 0
nucleotide 0
sequence 0
of 0
the 0
cloned 0
gene 0
. 0

205 0
, 0
285 0
- 0
290 0
] 0
and 0
was 0
subsequently 0
cloned 0
and 0
sequenced 0
[ 0
J 0
. 0

Nonreplicating 0
vaccinia 0
vector 0
efficiently 0
expresses 0
recombinant 0
genes 0
. 0

Use 0
of 0
free 0
- 0
access 0
minerals 0
. 0

Interferon B-gene
type I-gene
I I-gene
in 0
protective 0
body 0
reactions 0
in 0
an 0
experimental 0
Klebsiella 0
infection 0

No 0
other 0
changes 0
in 0
hematopoietic 0
differentiation 0
status 0
were 0
observed 0
in 0
association 0
with 0
Id B-gene
- I-gene
SCL I-gene
expression 0
. 0

Respiratory 0
interaction 0
after 0
spinal 0
anesthesia 0
and 0
sedation 0
with 0
midazolam 0
. 0

For 0
pressure 0
greater 0
than 0
121 0
atm 0
abs 0
, 0
an 0
increased 0
excitability 0
of 0
the 0
tadpoles 0
made 0
it 0
difficult 0
to 0
distinguish 0
the 0
righting 0
reflex 0
from 0
involuntary 0
movements 0
. 0

One 0
air 0
embolism 0
occurred 0
; 0
this 0
was 0
the 0
only 0
filter 0
- 0
or 0
retrieval 0
- 0
related 0
complication 0
. 0

The 0
5 0
' 0
region 0
of 0
ADH5 B-gene
contains 0
consensus 0
binding 0
sites 0
for 0
the 0
transcriptional 0
regulatory 0
proteins 0
, 0
Sp1 B-gene
, 0
AP2 B-gene
, 0
LF B-gene
- I-gene
A1 I-gene
, 0
NF B-gene
- I-gene
1 I-gene
, 0
NF B-gene
- I-gene
A2 I-gene
, 0
and 0
NF B-gene
- I-gene
E1 I-gene
. 0

V 0
. 0

These 0
data 0
indicate 0
that 0
RNK B-gene
- I-gene
Met I-gene
- I-gene
1 I-gene
is 0
a 0
serine B-gene
protease I-gene
with 0
unique 0
activity 0
that 0
is 0
expressed 0
in 0
the 0
granules 0
of 0
large 0
granular 0
lymphocytes 0
. 0

Purification 0
and 0
cloning 0
of 0
a 0
novel 0
serine B-gene
protease I-gene
, 0
RNK B-gene
- I-gene
Met I-gene
- I-gene
1 I-gene
, 0
from 0
the 0
granules 0
of 0
a 0
rat 0
natural 0
killer 0
cell 0
leukemia 0
. 0

We 0
describe 0
here 0
17 0
dominant B-gene
GCN2 I-gene
mutations I-gene
that 0
lead 0
to 0
derepression 0
of 0
GCN4 B-gene
expression 0
in 0
the 0
absence 0
of 0
amino 0
acid 0
starvation 0
. 0

Administration 0
of 0
growth B-gene
hormone I-gene
leads 0
to 0
faster 0
growth 0
, 0
but 0
also 0
faster 0
bone 0
maturation 0
. 0

Comparisons 0
with 0
the 0
available 0
amino 0
acid 0
residue 0
( 0
aa 0
) 0
sequence 0
information 0
from 0
the 0
complete 0
CPMV B-gene
RNA I-gene
1 I-gene
sequence I-gene
and 0
the 0
partial 0
sequence 0
of 0
red B-gene
clover I-gene
mottle I-gene
virus I-gene
RNA I-gene
1 I-gene
suggest 0
that 0
CPSMV B-gene
RNA I-gene
1 I-gene
specifies 0
the 0
expected 0
set 0
of 0
five 0
mature 0
proteins 0
: 0
32K B-gene
proteinase I-gene
cofactor I-gene
, 0
58K B-gene
presumed I-gene
helicase I-gene
, 0
VPg B-gene
5' I-gene
- I-gene
linked I-gene
protein I-gene
of 0
the 0
genomic 0
RNAs 0
, 0
24K B-gene
proteinase I-gene
, 0
and 0
87K B-gene
presumed I-gene
polymerase I-gene
, 0
separated 0
by 0
four 0
cleavage 0
sites 0
. 0

Rice B-gene
dwarf I-gene
phytoreovirus I-gene
segment I-gene
S12 I-gene
transcript I-gene
is 0
tricistronic 0
in 0
vitro 0
. 0

In 0
addition 0
, 0
the 0
utility 0
of 0
beta B-gene
2 I-gene
transferrin I-gene
assay 0
in 0
the 0
diagnosis 0
of 0
cerebrospinal 0
fluid 0
otorrhea 0
is 0
presented 0
. 0

Cold 0
cardioplegia 0
was 0
administered 0
at 0
45 0
mm 0
Hg 0
every 0
20 0
minutes 0
for 0
2 0
hours 0
. 0

The 0
addition 0
of 0
diatrizoate 0
to 0
the 0
IPRK 0
led 0
to 0
a 0
dose 0
- 0
dependent 0
biphasic 0
change 0
in 0
RPF 0
and 0
GFR 0
characterized 0
by 0
an 0
initial 0
transient 0
increase 0
followed 0
by 0
a 0
marked 0
and 0
sustained 0
decrease 0
. 0

To 0
prepare 0
for 0
analyses 0
with 0
the 0
family 0
variables 0
, 0
we 0
next 0
present 0
descriptive 0
data 0
based 0
on 0
separate 0
principal 0
components 0
analysis 0
( 0
PCA 0
) 0
and 0
multidimensional 0
scaling 0
analysis 0
( 0
MDS 0
) 0
of 0
14 0
self 0
- 0
reported 0
health 0
scores 0
for 0
husbands 0
and 0
for 0
wives 0
. 0

The 0
structural 0
genes 0
encoding 0
glyceraldehyde B-gene
- I-gene
3 I-gene
- I-gene
phosphate I-gene
dehydrogenase I-gene
( 0
GAPDH B-gene
) 0
, 0
3 B-gene
- I-gene
phosphoglycerate I-gene
kinase I-gene
( 0
PGK B-gene
) 0
and 0
the 0
N 0
- 0
terminal 0
part 0
of 0
triosephosphate B-gene
isomerase I-gene
( 0
TIM B-gene
) 0
from 0
mesophilic 0
Bacillus 0
megaterium 0
DSM319 0
have 0
been 0
cloned 0
as 0
a 0
gene 0
cluster 0
( 0
gap B-gene
operon I-gene
) 0
by 0
complementation 0
of 0
an 0
Escherichia 0
coli 0
gap B-gene
amber I-gene
mutant I-gene
. 0

Pseudomonas B-gene
aeruginosa I-gene
exotoxin I-gene
A I-gene
: 0
its 0
role 0
in 0
retardation 0
of 0
wound 0
healing 0
: 0
the 0
1992 0
Lindberg 0
Award 0
. 0

Laboratory 0
studies 0
showed 0
that 0
the 0
direct 0
fluorescent 0
- 0
antibody 0
kits 0
were 0
the 0
least 0
sensitive 0
in 0
this 0
case 0
and 0
did 0
not 0
detect 0
fewer 0
than 0
10 0
( 0
4 0
) 0
elementary 0
bodies 0
per 0
ml 0
, 0
while 0
most 0
ELISA 0
kits 0
detected 0
between 0
130 0
and 0
600 0
elementary 0
bodies 0
per 0
ml 0
. 0

To 0
study 0
the 0
significance 0
of 0
these 0
domains 0
and 0
the 0
overall 0
evolutionary 0
conservation 0
of 0
the 0
gene 0
, 0
the 0
homolog 0
from 0
Drosophila 0
melanogaster 0
was 0
isolated 0
by 0
low 0
stringency 0
hybridizations 0
using 0
two 0
flanking 0
probes 0
of 0
the 0
human B-gene
ERCC3 I-gene
cDNA I-gene
. 0

Mono 0
- 0
ADP 0
- 0
ribosylation 0
is 0
a 0
reversible 0
modification 0
of 0
proteins 0
, 0
with 0
NAD 0
: 0
arginine B-gene
ADP I-gene
- I-gene
ribosyltransferases I-gene
( 0
EC B-gene
2.4.2.31 I-gene
) 0
and 0
ADP B-gene
- I-gene
ribosylarginine I-gene
hydrolases I-gene
( 0
EC B-gene
3.2.2.19 I-gene
) 0
catalyzing 0
the 0
opposing 0
reactions 0
in 0
an 0
ADP 0
- 0
ribosylation 0
cycle 0
. 0

For 0
this 0
reason 0
, 0
the 0
particle 0
forming 0
capacity 0
of 0
derivatives 0
of 0
the 0
HIV B-gene
- I-gene
1 I-gene
group I-gene
specific I-gene
core I-gene
antigen I-gene
p55 I-gene
gag I-gene
was 0
assayed 0
and 0
compared 0
dependent 0
on 0
various 0
expression 0
systems 0
: 0
recombinant 0
bacteria 0
, 0
vaccinia 0
- 0
and 0
baculoviruses 0
were 0
established 0
encoding 0
the 0
entire 0
core B-gene
protein I-gene
p55 I-gene
either 0
in 0
its 0
authentic 0
sequence 0
or 0
lacking 0
the 0
myristylation 0
consensus 0
signal 0
. 0

The 0
tramtrack B-gene
( 0
ttk B-gene
) 0
gene 0
of 0
Drosophila 0
encodes 0
69 0
- 0
kDa 0
and 0
88 0
- 0
kDa 0
proteins 0
through 0
alternative 0
splicing 0
of 0
the 0
primary 0
ttk B-gene
transcript I-gene
. 0

Removal 0
of 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
by 0
hemodialysis 0
and 0
hemofiltration 0
: 0
a 0
four 0
year 0
follow 0
up 0
. 0

Removal 0
of 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
by 0
hemodialysis 0
and 0
hemofiltration 0
: 0
a 0
four 0
year 0
follow 0
up 0
. 0

Adapromine 0
was 0
established 0
to 0
evoke 0
a 0
decrease 0
of 0
the 0
amplitude 0
of 0
the 0
dominant 0
peak 0
and 0
dominant 0
theta 0
- 0
activity 0
in 0
power 0
spectra 0
of 0
the 0
EEG 0
in 0
the 0
cortex 0
and 0
hippocamp 0
, 0
with 0
an 0
increase 0
of 0
rapid 0
wave 0
activity 0
in 0
the 0
beta 0
2 0
range 0
in 0
the 0
right 0
cortex 0
and 0
hippocamp 0
. 0

These 0
sequences 0
were 0
then 0
used 0
to 0
clone 0
the 0
full 0
- 0
length 0
genes 0
from 0
a 0
yeast 0
genomic 0
library 0
. 0

GAL4 B-gene
- 0
VP16 B-gene
- 0
mediated 0
antirepression 0
required 0
an 0
auxiliary 0
factor 0
, 0
denoted 0
as 0
a 0
co 0
- 0
antirepressor 0
, 0
which 0
was 0
partially 0
purified 0
from 0
Drosophila 0
embryos 0
. 0

After 0
28 0
days 0
of 0
haloperidol 0
treatment 0
, 0
similar 0
changes 0
were 0
observed 0
for 0
delta 0
, 0
together 0
with 0
an 0
increase 0
of 0
alpha 0
1 0
, 0
and 0
a 0
decrease 0
of 0
fast 0
beta 0
. 0

Four 0
ruminally 0
and 0
duodenally 0
cannulated 0
Hampshire 0
wethers 0
were 0
used 0
in 0
a 0
4 0
x 0
4 0
Latin 0
square 0
experiment 0
to 0
determine 0
whether 0
linoleoyl 0
methionine 0
and 0
calcium 0
linoleate 0
would 0
increase 0
duodenal 0
flow 0
of 0
unsaturated 0
fatty 0
acids 0
( 0
C18:2 0
+ 0
cis 0
C18:1 0
) 0
. 0

Truncated B-gene
ICSBP I-gene
lacking 0
the 0
first 0
33 0
amino 0
- 0
terminal 0
amino 0
acids 0
fails 0
to 0
bind 0
to 0
the 0
ICS B-gene
, 0
indicating 0
that 0
at 0
least 0
part 0
of 0
the 0
DNA 0
binding 0
domain 0
is 0
located 0
within 0
the 0
well 0
conserved 0
amino 0
terminus 0
. 0

Therefore 0
, 0
ICSBP B-gene
may 0
be 0
involved 0
in 0
maintaining 0
submaximal 0
transcriptional 0
activity 0
of 0
IFN B-gene
- 0
inducible 0
genes 0
in 0
hematopoietic 0
cells 0
. 0

A 0
case 0
of 0
chronic 0
hepatitis 0
C 0
with 0
primary 0
hypothyroidism 0
manifested 0
during 0
interferon B-gene
treatment 0

Dynamic 0
decision 0
making 0
: 0
human 0
control 0
of 0
complex 0
systems 0
. 0

A 0
coiled B-gene
- I-gene
coil I-gene
related I-gene
protein I-gene
specific 0
for 0
synapsed 0
regions 0
of 0
meiotic 0
prophase 0
chromosomes 0
. 0

Comparable 0
amounts 0
of 0
alpha B-gene
5 I-gene
beta I-gene
1 I-gene
integrin I-gene
were 0
isolated 0
from 0
these 0
cells 0
by 0
chromatography 0
of 0
detergent 0
extracts 0
on 0
a 0
fibronectin B-gene
cell 0
- 0
binding 0
fragment 0
affinity 0
column 0
and 0
elution 0
with 0
EDTA 0
. 0

Abstracts 0
. 0

These 0
results 0
indicate 0
a 0
possible 0
involvement 0
of 0
endogenous 0
opioid 0
peptides 0
in 0
the 0
cardiac 0
effects 0
due 0
to 0
myocardial 0
ischaemia 0
and 0
reperfusion 0
, 0
mediated 0
by 0
opiate B-gene
receptors I-gene
through 0
opiate 0
antagonism 0
. 0

From 0
this 0
library 0
, 0
LEU2 B-gene
and 0
HIS3 B-gene
cDNAs 0
were 0
recovered 0
at 0
a 0
frequency 0
of 0
about 0
1 0
in 0
10 0
( 0
4 0
) 0
and 0
in 0
12 0
out 0
of 0
13 0
cases 0
these 0
were 0
expressed 0
in 0
a 0
galactose 0
- 0
dependent 0
manner 0
. 0

Among 0
these 0
, 0
ACT1 B-gene
was 0
isolated 0
four 0
times 0
, 0
and 0
NSR1 B-gene
three 0
times 0
. 0

Since 0
CENP B-gene
- I-gene
B I-gene
gene I-gene
is 0
conserved 0
in 0
mammalian 0
species 0
and 0
CENP B-gene
- I-gene
B I-gene
boxes I-gene
are 0
found 0
also 0
in 0
mouse 0
centromere 0
satellite 0
DNA 0
( 0
minor 0
satellite 0
) 0
, 0
this 0
sequence 0
- 0
specific 0
DNA 0
- 0
protein 0
interaction 0
may 0
be 0
important 0
for 0
some 0
kind 0
of 0
common 0
centromere 0
function 0
. 0

Interestingly 0
, 0
a 0
portion 0
of 0
the 0
tail 0
domain 0
( 0
aa 0
, 0
1,094 0
- 0
1,830 0
) 0
shares 0
58 0
% 0
amino 0
acid 0
sequence 0
identity 0
with 0
a 0
723 0
- 0
aa 0
protein 0
from 0
mouse 0
brain 0
reported 0
to 0
be 0
a 0
glutamic B-gene
acid I-gene
decarboxylase I-gene
. 0

However 0
, 0
in 0
the 0
subgroup 0
with 0
normal 0
Ht 0
( 0
< 0
0.45 0
l/l 0
; 0
n 0
= 0
201 0
) 0
there 0
was 0
a 0
significant 0
reduction 0
( 0
p 0
< 0
0.05 0
) 0
of 0
the 0
mortality 0
after 0
3 0
months 0
( 0
27 0
% 0
and 0
16 0
% 0
, 0
respectively 0
) 0
and 0
an 0
increase 0
of 0
independence 0
at 0
home 0
( 0
35 0
% 0
and 0
48 0
% 0
, 0
respectively 0
) 0
due 0
to 0
a 0
reduction 0
of 0
the 0
viscosity 0
by 0
means 0
of 0
haemodilution 0
with 0
albumin B-gene
( 0
a 0
specific 0
viscosity 0
effect 0
in 0
the 0
normovolaemic 0
group 0
) 0
. 0

Distribution 0
and 0
changing 0
morphological 0
course 0

The 0
appropriate 0
use 0
and 0
benefits 0
of 0
bile 0
acid 0
sequestrants 0
, 0
nicotinic 0
acid 0
, 0
fibric 0
acids 0
, 0
3 B-gene
- I-gene
hydroxy I-gene
- I-gene
3 I-gene
- I-gene
methylglutaryl I-gene
coenzyme I-gene
A I-gene
( I-gene
HMG I-gene
- I-gene
CoA I-gene
) I-gene
reductase I-gene
inhibitors 0
, 0
and 0
probucol 0
are 0
individually 0
discussed 0
, 0
whereas 0
nonpharmacologic 0
approaches 0
used 0
in 0
conjunction 0
with 0
the 0
drugs 0
are 0
recommended 0
emphatically 0
. 0

This 0
may 0
result 0
in 0
more 0
reabsorption 0
and 0
hence 0
reduced 0
renal 0
clearance 0
. 0

The 0
major 0
pathological 0
findings 0
of 0
the 0
placenta 0
were 0
prematuration 0
and 0
hypoplasia 0
. 0

Green 0
pepper 0
significantly 0
inhibited 0
N 0
- 0
nitrosothiazolidine 0
- 0
carboxylic 0
acid 0
formation 0
relative 0
to 0
ascorbic 0
acid 0
alone 0
. 0

A 0
genomic 0
clone 0
, 0
pTt21 0
, 0
containing 0
DNA 0
apparently 0
transcribed 0
specifically 0
in 0
Trypanosoma 0
cruzi 0
trypomastigotes 0
, 0
was 0
obtained 0
by 0
differentially 0
screening 0
a 0
genomic 0
library 0
with 0
trypomastigote 0
and 0
epimastigote 0
cDNA 0
. 0

Brucellosis 0
- 0
- 0
1990 0

Assay 0
of 0
urea 0
by 0
immobilized 0
urease B-gene
coupled 0
to 0
a 0
differential 0
pH 0
- 0
meter 0
. 0

RESULTS 0
: 0
In 0
the 0
AGA 0
group 0
, 0
both 0
fetal 0
and 0
maternal 0
serum 0
prolactin B-gene
concentration 0
increased 0
significantly 0
with 0
gestation 0
( 0
P 0
< 0
0.001 0
and 0
P 0
< 0
0.01 0
, 0
respectively 0
) 0
. 0

One 0
phage 0
clone 0
contains 0
a 0
junction 0
between 0
alpha 0
satellite 0
DNA 0
and 0
a 0
novel 0
low 0
- 0
copy 0
repeated 0
sequence 0
. 0

The 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
lactoferrin I-gene
gene I-gene
was 0
isolated 0
from 0
a 0
human 0
placental 0
genomic 0
library 0
. 0

Therefore 0
, 0
the 0
molecular 0
mechanisms 0
of 0
the 0
estrogen 0
action 0
that 0
govern 0
the 0
lactoferrin B-gene
gene I-gene
expression 0
differ 0
between 0
mouse 0
and 0
human 0
. 0

BiP670 B-gene
retains 0
basal 0
and 0
Ca2+ 0
ionophore 0
A23187 0
- 0
inducible 0
activities 0
. 0

The 0
CEM 0
receives 0
registration 0
updates 0
via 0
an 0
HL7 0
message 0
and 0
evaluates 0
data 0
dependencies 0
in 0
rules 0
via 0
an 0
interface 0
to 0
the 0
relational 0
database 0
. 0

Magnetic 0
resonance 0
spectroscopy 0
( 0
MRS 0
) 0
and 0
imaging 0
( 0
MRI 0
) 0
are 0
now 0
well 0
established 0
techniques 0
for 0
the 0
study 0
of 0
cellular 0
metabolism 0
and 0
gross 0
structure 0
of 0
muscle 0
. 0

Simultaneously 0
a 0
greater 0
NA 0
was 0
found 0
with 0
no 0
change 0
in 0
plasma 0
epinephrine 0
response 0
. 0

We 0
investigated 0
the 0
diagnostic 0
value 0
of 0
a 0
new 0
in 0
vitro 0
test 0
, 0
Pharmacia 0
CAP 0
System 0
( 0
Pharmacia 0
Diagnostics 0
AB 0
, 0
Uppsala 0
, 0
Sweden 0
) 0
, 0
for 0
the 0
quantitative 0
measurement 0
of 0
allergen B-gene
- I-gene
specific I-gene
IgE I-gene
antibodies I-gene
by 0
comparison 0
with 0
RAST 0
in 0
2 0
groups 0
of 0
patients 0
, 0
71 0
atopic 0
and 0
48 0
non 0
- 0
atopic 0
. 0

Patients 0
receiving 0
VPA 0
showed 0
differences 0
in 0
attention 0
, 0
visuomotor 0
performance 0
, 0
verbal 0
span 0
and 0
sensory 0
discrimination 0
tasks 0
at 0
T1 0
, 0
in 0
visuomotor 0
performance 0
at 0
T2 0
and 0
in 0
spatial 0
span 0
at 0
T3 0
, 0
whereas 0
no 0
differences 0
were 0
detected 0
at 0
T4 0
. 0

We 0
found 0
that 0
the 0
gene 0
segment 0
containing 0
the 0
mu 0
m 0
poly 0
( 0
A 0
) 0
signals 0
, 0
along 0
with 0
536 0
bp 0
of 0
downstream 0
flanking 0
sequence 0
, 0
acted 0
as 0
a 0
transcription 0
terminator 0
in 0
both 0
myeloma 0
cells 0
and 0
L 0
cell 0
fibroblasts 0
. 0

As 0
a 0
part 0
of 0
a 0
large 0
examination 0
, 0
total 0
and 0
free 0
serum 0
cholesterol 0
, 0
total 0
lipid 0
and 0
triglyceride 0
levels 0
were 0
determined 0
. 0

Alena 0
is 0
a 0
nurse 0
in 0
Prague 0
- 0
- 0
she 0
dreams 0
of 0
higher 0
wages 0
and 0
a 0
trip 0
across 0
the 0
ocean 0

Dopamine 0
neurons 0
in 0
subjects 0
that 0
received 0
6 0
- 0
OHDA 0
were 0
protected 0
by 0
pre 0
- 0
treatment 0
with 0
GBR 0
- 0
12909 0
. 0

DIBA 0
was 0
more 0
sensitive 0
and 0
had 0
a 0
better 0
negative 0
predictive 0
value 0
and 0
a 0
lower 0
false 0
negative 0
percentage 0
than 0
DFAT 0
. 0

Caries 0
and 0
parodontitis 0
have 0
been 0
one 0
of 0
the 0
most 0
spread 0
diseases 0
of 0
mankind 0
. 0

The 0
results 0
of 0
this 0
study 0
demonstrate 0
that 0
strongyloidiasis 0
was 0
the 0
cause 0
of 0
sudden 0
death 0
. 0

A 0
second 0
large 0
group 0
of 0
disorders 0
in 0
pregnancy 0
is 0
caused 0
by 0
effects 0
of 0
infections 0
of 0
the 0
mother 0
without 0
pathogens 0
being 0
transmitted 0
to 0
the 0
embryo 0
or 0
the 0
placenta 0
. 0

Four 0
short 0
nucleotide 0
sequences 0
( 0
boxes 0
I 0
to 0
IV 0
) 0
contribute 0
to 0
the 0
light 0
responsiveness 0
of 0
the 0
parsley B-gene
chalcone I-gene
synthase I-gene
promoter I-gene
. 0

The 0
case 0
described 0
is 0
that 0
of 0
a 0
72 0
- 0
year 0
- 0
old 0
man 0
with 0
ochronosis 0
who 0
suffered 0
a 0
hyperextension 0
injury 0
to 0
his 0
spine 0
in 0
a 0
fall 0
, 0
resulting 0
in 0
a 0
fracture 0
through 0
an 0
ankylosed 0
L2 0
- 0
L3 0
disk 0
space 0
. 0

The 0
mean 0
blood 0
flow 0
in 0
the 0
penile 0
foreskin 0
was 0
estimated 0
to 0
be 0
15 0
ml/min/100 0
g 0
and 0
it 0
increased 0
to 0
150 0
- 0
200 0
% 0
after 0
the 0
induction 0
of 0
anesthesia 0
, 0
and 0
then 0
decreased 0
to 0
72 0
% 0
at 0
the 0
tip 0
of 0
the 0
created 0
parameatal 0
foreskin 0
flap 0
. 0

ME1a1 B-gene
, 0
a 0
16 0
- 0
base 0
- 0
pair 0
nuclear 0
factor 0
binding 0
site 0
residing 0
between 0
the 0
c B-gene
- I-gene
MYC I-gene
P1 I-gene
and I-gene
P2 I-gene
transcription I-gene
initiation I-gene
sites I-gene
, 0
is 0
required 0
for 0
P2 0
activity 0
. 0

The 0
next 0
twenty 0
years 0
of 0
prevention 0
in 0
Indian 0
country 0
: 0
visionary 0
, 0
complex 0
, 0
and 0
practical 0
. 0

Exogenous 0
LHRH B-gene
is 0
also 0
known 0
to 0
facilitate 0
mating 0
behavior 0
in 0
several 0
species 0
. 0

The 0
first 0
146 0
consecutive 0
patients 0
treated 0
with 0
EVL 0
during 0
the 0
period 0
from 0
August 0
, 0
1986 0
to 0
July 0
, 0
1989 0
are 0
reported 0
. 0

Replacing 0
the 0
aspartic 0
acid 0
with 0
a 0
lysine 0
but 0
not 0
with 0
an 0
alanine 0
or 0
valine 0
residue 0
allowed 0
formation 0
of 0
disulfide 0
- 0
linked 0
dimers 0
. 0

During 0
V 0
- 0
A 0
bypass 0
, 0
hemodynamics 0
were 0
stable 0
. 0

Greater 0
rupture 0
force 0
was 0
required 0
in 0
the 0
adult 0
pigs 0
than 0
in 0
the 0
young 0
pigs 0
. 0

At 0
rest 0
AFF 0
was 0
significantly 0
higher 0
in 0
UT 0
( 0
29 0
% 0
) 0
as 0
compared 0
to 0
AT 0
( 0
25 0
% 0
) 0
and 0
UEA 0
( 0
25 0
% 0
) 0
. 0

We 0
investigated 0
the 0
smoking 0
habits 0
of 0
relapsers 0
1 0
year 0
after 0
quitting 0
in 0
a 0
smoking 0
cessation 0
trial 0
using 0
nicotine 0
or 0
placebo 0
patches 0
. 0

Exposure 0
to 0
hepatitis 0
B 0
virus 0
in 0
the 0
general 0
population 0
of 0
Hisayama 0
, 0
Japan 0
: 0
significance 0
of 0
isolated 0
antibody 0
to 0
hepatitis B-gene
B I-gene
surface I-gene
antigen I-gene
in 0
general 0
population 0
. 0

Because 0
of 0
this 0
latter 0
phenomenon 0
, 0
we 0
were 0
able 0
to 0
identify 0
a 0
particular 0
cysteine 0
motif 0
that 0
was 0
repeated 0
multiple 0
times 0
in 0
Dfurin2 B-gene
but 0
present 0
only 0
twice 0
in 0
mammalian B-gene
furin I-gene
. 0

On 0
the 0
other 0
hand 0
, 0
neither 0
phosphate 0
buffered 0
saline 0
injection 0
into 0
the 0
ES 0
nor 0
primary 0
KLH B-gene
challenges 0
of 0
the 0
ES 0
were 0
capable 0
of 0
elevating 0
the 0
threshold 0
level 0
and 0
changing 0
the 0
latency 0
. 0

A 0
newly 0
developed 0
broad 0
- 0
spectrum 0
fluoroquinolone 0
, 0
levofloxacin 0
( 0
LVFX 0
, 0
DR 0
- 0
3355 0
) 0
, 0
was 0
evaluated 0
in 0
vitro 0
and 0
in 0
vivo 0
in 0
comparison 0
with 0
ciprofloxacin 0
( 0
CPFX 0
) 0
, 0
ofloxacin 0
( 0
OFLX 0
) 0
and 0
norfloxacin 0
( 0
NFLX 0
) 0
. 0

The 0
mean 0
serum 0
creatinine 0
levels 0
were 0
similar 0
at 0
one 0
year 0
( 0
SPK 0
1.8 0
, 0
KTA 0
1.9 0
mg/d 0
) 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Model 0
predictions 0
were 0
in 0
accord 0
with 0
the 0
nine 0
- 0
year 0
survival 0
experience 0
of 0
women 0
in 0
the 0
HIP 0
trial 0
, 0
and 0
, 0
with 0
the 0
exception 0
of 0
women 0
40 0
- 0
44 0
years 0
old 0
, 0
with 0
HIP 0
data 0
on 0
18 0
- 0
year 0
survival 0
. 0

High 0
- 0
resolution 0
computed 0
tomography 0
in 0
the 0
diagnosis 0
of 0
miliary 0
tuberculosis 0
. 0

Previously 0
, 0
we 0
showed 0
that 0
SNF2 B-gene
, 0
SNF5 B-gene
, 0
and 0
SNF6 B-gene
function 0
interdependently 0
in 0
transcriptional 0
activation 0
, 0
possibly 0
forming 0
a 0
heteromeric 0
complex 0
. 0

We 0
show 0
that 0
LexA B-gene
- 0
GAL4 B-gene
and 0
LexA B-gene
- 0
Bicoid B-gene
fusion 0
proteins 0
are 0
both 0
dependent 0
on 0
SNF2 B-gene
, 0
SNF5 B-gene
, 0
and 0
SNF6 B-gene
for 0
activation 0
of 0
target 0
genes 0
containing 0
one 0
or 0
multiple 0
lexA B-gene
operators I-gene
. 0

George 0
T 0
. 0

A 0
lambda 0
gt10 0
cDNA 0
library 0
was 0
constructed 0
from 0
poly 0
( 0
A 0
) 0
+ 0
RNA 0
of 0
young 0
green 0
leaves 0
of 0
spinach 0
. 0

NE B-gene
and 0
PR3 B-gene
assist 0
in 0
the 0
destruction 0
of 0
phagocytosed 0
microorganisms 0
, 0
cleave 0
the 0
important 0
connective B-gene
- I-gene
tissue I-gene
protein I-gene
elastin I-gene
, 0
and 0
generate 0
chemotactic 0
activities 0
by 0
forming 0
alpha B-gene
1 I-gene
- I-gene
proteinase I-gene
inhibitor I-gene
complexes I-gene
and 0
elastin B-gene
peptides I-gene
. 0

Selected 0
topics 0
in 0
pediatric 0
ultrasonography 0
- 0
- 0
1992 0
. 0

Methods 0
included 0
24 0
- 0
hour 0
dietary 0
recall 0
, 0
menu 0
weights 0
, 0
and 0
recipe 0
analysis 0
. 0

Factors 0
associated 0
with 0
afterdrop 0
included 0
age 0
, 0
end 0
- 0
of 0
- 0
surgery 0
temperature 0
( 0
both 0
positively 0
) 0
and 0
body 0
mass 0
( 0
negatively 0
) 0
. 0

Both 0
GH B-gene
deficiency 0
and 0
impaired 0
spinal 0
growth 0
may 0
result 0
in 0
short 0
stature 0
, 0
whereas 0
the 0
occurrence 0
of 0
early 0
puberty 0
in 0
association 0
with 0
GH B-gene
deficiency 0
reduces 0
the 0
time 0
available 0
for 0
GH B-gene
therapy 0
. 0

By 0
contrast 0
, 0
d B-gene
( I-gene
T2AG3T I-gene
) I-gene
and 0
d B-gene
( I-gene
T2G4T I-gene
) I-gene
form 0
only 0
the 0
G 0
- 0
quadruplex 0
monomer 0
structures 0
independent 0
of 0
K 0
cation 0
concentration 0
as 0
reported 0
previously 0
[ 0
Sen 0
, 0
D. 0
, 0
& 0
Gilbert 0
, 0
W 0
. 0

Differentiating 0
among 0
renal 0
stones 0
. 0

IFI B-gene
16 I-gene
mRNA I-gene
was 0
found 0
to 0
be 0
constitutively 0
expressed 0
in 0
lymphoid 0
cells 0
and 0
in 0
cell 0
lines 0
of 0
both 0
the 0
T 0
and 0
B 0
lineages 0
. 0

Mitochondria 0
- 0
lytic 0
action 0
of 0
warfarin 0
in 0
lymphocytes 0
. 0

Exon 0
- 0
intron 0
junctions 0
in 0
the 0
human 0
and 0
rat B-gene
AdoMet I-gene
decarboxylase I-gene
genes I-gene
were 0
in 0
identical 0
positions 0
except 0
that 0
exons 0
6 0
and 0
7 0
of 0
the 0
human 0
gene 0
formed 0
a 0
single 0
exon 0
in 0
the 0
rat 0
gene 0
. 0

Interferon B-gene
- I-gene
alpha I-gene
- 0
induced 0
gene 0
expression 0
: 0
evidence 0
for 0
a 0
selective 0
effect 0
of 0
ouabain 0
on 0
activation 0
of 0
the 0
ISGF3 B-gene
transcription I-gene
complex I-gene
. 0

The 0
cDNA 0
has 0
an 0
open 0
reading 0
frame 0
of 0
900 0
amino 0
acids 0
capable 0
of 0
encoding 0
a 0
97 0
- 0
kDa 0
protein 0
. 0

Moreover 0
, 0
LD50 0
in 0
mice 0
of 0
RP 0
- 0
170 0
( 0
4.3 0
g/kg 0
on 0
i.v 0
. 0
) 0
was 0
increased 0
to 0
5.2 0
g/kg 0
by 0
oral 0
administration 0
. 0

Among 0
the 0
few 0
proteins 0
of 0
the 0
eukaryotic 0
nucleolus 0
that 0
have 0
been 0
characterized 0
, 0
four 0
proteins 0
, 0
nucleolin B-gene
, 0
fibrillarin B-gene
, 0
SSB1 B-gene
and 0
NSR1 B-gene
, 0
possess 0
a 0
common 0
structural 0
motif 0
, 0
the 0
GAR 0
domain 0
, 0
which 0
is 0
rich 0
in 0
glycine 0
and 0
arginine 0
residues 0
. 0

Thus 0
, 0
this 0
study 0
provides 0
evidence 0
that 0
a 0
novel 0
, 0
ubiquitous 0
factor 0
( 0
HF B-gene
- I-gene
1a I-gene
) 0
and 0
a 0
muscle 0
factor 0
( 0
HF B-gene
- I-gene
1b/MEF I-gene
1b/MEF I-gene
- I-gene
2 I-gene
) 0
can 0
form 0
a 0
novel 0
, 0
E 0
- 0
box 0
- 0
independent 0
pathway 0
for 0
muscle 0
- 0
specific 0
expression 0
in 0
ventricular 0
cardiac 0
muscle 0
cells 0
. 0

Mutations 0
in 0
either 0
gene 0
block 0
some 0
crucial 0
late 0
step 0
in 0
assembly 0
of 0
F1 B-gene
, 0
causing 0
the 0
alpha 0
and 0
beta 0
subunits 0
to 0
accumulate 0
in 0
mitochondria 0
as 0
inactive 0
aggregates 0
( 0
Ackerman 0
, 0
S 0
. 0

Expense 0
limits 0
the 0
use 0
of 0
hepatitis 0
B 0
vaccines 0
, 0
but 0
low 0
- 0
dose 0
intradermal 0
immunization 0
has 0
been 0
evaluated 0
as 0
a 0
cost 0
- 0
saving 0
strategy 0
in 0
numerous 0
studies 0
. 0

Estrogen 0
replacement 0
therapy 0
and 0
risk 0
of 0
breast 0
cancer 0
: 0
results 0
of 0
two 0
meta 0
- 0
analyses 0
. 0

Switching 0
FDC 0
- 0
P1/MAC 0
cells 0
from 0
growth 0
in 0
M B-gene
- I-gene
CSF I-gene
to 0
GM B-gene
- I-gene
CSF I-gene
caused 0
the 0
selective 0
degradation 0
of 0
c B-gene
- I-gene
fms I-gene
mRNA I-gene
within 0
6 0
h 0
after 0
factor 0
switching 0
. 0

There 0
was 0
however 0
, 0
no 0
significant 0
difference 0
in 0
the 0
prevalence 0
of 0
chronic 0
respiratory 0
symptoms 0
between 0
animal 0
food 0
workers 0
with 0
positive 0
and 0
negative 0
skin 0
tests 0
to 0
house 0
dust 0
or 0
to 0
fish 0
flour 0
or 0
among 0
those 0
with 0
increased 0
or 0
normal 0
IgE B-gene
( 0
except 0
for 0
dyspnea 0
) 0
. 0

An 0
unexpected 0
finding 0
was 0
the 0
presence 0
at 0
position 0
- 0
403 0
to 0
- 0
385 0
of 0
a 0
putative 0
dioxin 0
responsive 0
element 0
, 0
a 0
sequence 0
found 0
to 0
be 0
responsible 0
for 0
the 0
induction 0
of 0
transcription 0
of 0
the 0
cytochrome B-gene
P450IA1 I-gene
gene I-gene
( 0
CYPIA1 B-gene
) 0
and 0
other 0
genes 0
involved 0
in 0
detoxification/activation 0
of 0
polycyclic 0
aromatic 0
hydrocarbons 0
. 0

The 0
gene 0
encoding 0
TRP B-gene
- I-gene
2 I-gene
maps 0
to 0
mouse 0
chromosome 0
14 0
, 0
in 0
the 0
region 0
of 0
the 0
coat B-gene
colour I-gene
mutation I-gene
slaty I-gene
. 0

Using 0
bovine B-gene
and I-gene
murine I-gene
c I-gene
- I-gene
myb I-gene
clones 0
, 0
no 0
change 0
in 0
the 0
rate 0
of 0
c B-gene
- I-gene
myb I-gene
gene I-gene
transcription 0
or 0
mRNA 0
stability 0
was 0
detected 0
during 0
the 0
cell 0
cycle 0
. 0

A 0
13 0
base 0
- 0
pair 0
oligonucleotide 0
spanning 0
nucleotides 0
+80 0
to 0
+92 0
of 0
the 0
5 B-gene
S I-gene
RNA I-gene
gene I-gene
retained 0
specific 0
and 0
high 0
- 0
affinity 0
binding 0
, 0
although 0
the 0
latter 0
was 0
reduced 0
sixfold 0
relative 0
to 0
longer 0
DNA 0
fragments 0
. 0

Moreover 0
, 0
the 0
reconstitution 0
of 0
eUSF B-gene
and 0
TFIID B-gene
- 0
depleted 0
transcription 0
complexes 0
with 0
purified 0
protein 0
fractions 0
demonstrate 0
that 0
not 0
only 0
TFIID B-gene
but 0
also 0
eUSF B-gene
essentially 0
participates 0
in 0
complex 0
formation 0
even 0
on 0
H5 B-gene
promoter I-gene
mutations 0
lacking 0
the 0
TATA 0
- 0
box 0
. 0

A 0
comparison 0
of 0
the 0
amino 0
acid 0
sequence 0
of 0
the 0
T. 0
thermophilus 0
enzyme 0
with 0
that 0
of 0
the 0
Escherichia 0
coli 0
enzyme 0
showed 0
( 0
i 0
) 0
a 0
37 0
% 0
overall 0
similarity 0
; 0
( 0
ii 0
) 0
the 0
conservation 0
of 0
the 0
Ser 0
residue 0
, 0
which 0
is 0
known 0
to 0
be 0
phosphorylated 0
in 0
the 0
E. 0
coli 0
enzyme 0
, 0
and 0
of 0
the 0
surrounding 0
sequence 0
; 0
and 0
( 0
iii 0
) 0
the 0
presence 0
of 0
141 0
extra 0
residues 0
at 0
the 0
C 0
terminus 0
of 0
the 0
T. 0
thermophilus 0
enzyme 0
. 0

Radiolabelled 0
palmitate 0
was 0
not 0
incorporated 0
into 0
the 0
mutated 0
protein 0
, 0
showing 0
that 0
lipid 0
modification 0
occurs 0
at 0
the 0
Cys 0
- 0
22 0
residue 0
. 0

17 0
volunteer 0
deaf 0
Ss 0
were 0
compared 0
with 0
18 0
volunteer 0
hearing 0
Ss 0
on 0
the 0
Stanford 0
Hypnotic 0
Clinical 0
Scale 0
( 0
SHCS 0
) 0
of 0
Morgan 0
and 0
J 0
. 0

Mature B-gene
tobacco I-gene
L12 I-gene
protein I-gene
has 0
44 0
% 0
amino 0
acid 0
identity 0
with 0
ribosomal 0
protein 0
L7/L12 B-gene
of 0
Escherichia 0
coli 0
. 0

Nuclear B-gene
- I-gene
encoded I-gene
chloroplast I-gene
ribosomal I-gene
protein I-gene
L12 I-gene
of I-gene
Nicotiana I-gene
tabacum I-gene
: 0
characterization 0
of 0
mature 0
protein 0
and 0
isolation 0
and 0
sequence 0
analysis 0
of 0
cDNA 0
clones 0
encoding 0
its 0
cytoplasmic 0
precursor 0
. 0

The 0
gene 0
encoding 0
IFN B-gene
- I-gene
gamma I-gene
was 0
previously 0
found 0
to 0
contain 0
an 0
intronic 0
enhancer 0
element 0
that 0
was 0
not 0
tissue 0
- 0
specific 0
in 0
its 0
activity 0
, 0
despite 0
the 0
restricted 0
expression 0
of 0
the 0
intact 0
IFN B-gene
- I-gene
gamma I-gene
- I-gene
encoding I-gene
gene I-gene
. 0

Molecular 0
cloning 0
of 0
the 0
polypeptide 0
component 0
of 0
the 0
Rel B-gene
- I-gene
related I-gene
human I-gene
p75 I-gene
nucleoprotein I-gene
complex I-gene
has 0
revealed 0
its 0
identity 0
with 0
the 0
65 0
- 0
kDa 0
( 0
p65 B-gene
) 0
subunit 0
of 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
. 0

Because 0
single 0
- 0
chamber 0
rate 0
- 0
adaptive 0
atrial 0
pacing 0
leaves 0
the 0
patient 0
exposed 0
to 0
the 0
risk 0
of 0
future 0
development 0
of 0
AV 0
block 0
and 0
DDD 0
pacing 0
does 0
not 0
provide 0
chronotropic 0
support 0
, 0
it 0
is 0
likely 0
that 0
the 0
new 0
rate 0
- 0
adaptive 0
dual 0
- 0
chamber 0
( 0
DDDR 0
) 0
devices 0
will 0
be 0
used 0
in 0
a 0
significant 0
number 0
of 0
these 0
patients 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

When 0
transiently 0
transfected 0
into 0
K562 0
cells 0
, 0
this 0
Lg B-gene
genomic 0
clone 0
is 0
actively 0
transcribed 0
, 0
suggesting 0
that 0
, 0
although 0
it 0
possesses 0
the 0
characteristics 0
of 0
a 0
processed 0
pseudogene 0
, 0
it 0
is 0
likely 0
to 0
correspond 0
to 0
the 0
gene 0
encoding 0
this 0
new 0
ferritin B-gene
subunit I-gene
. 0

Of 0
the 0
drugs 0
orally 0
administered 0
, 0
WR 0
- 0
168643 0
was 0
the 0
best 0
protector 0
with 0
a 0
DMF 0
of 0
1.51 0
. 0

Characterization 0
of 0
these 0
R 0
subunits 0
by 0
their 0
8 0
- 0
azido 0
- 0
cAMP 0
photoaffinity 0
labeling 0
and 0
immunoreactivity 0
, 0
as 0
well 0
as 0
by 0
a 0
phosphorylation 0
- 0
dependent 0
mobility 0
shift 0
on 0
sodium 0
dodecyl 0
sulfate 0
- 0
polyacrylamide 0
gel 0
electrophoresis 0
( 0
SDS 0
- 0
PAGE 0
) 0
, 0
indicated 0
subunit 0
sizes 0
of 0
RII B-gene
beta I-gene
( 0
53 0
kDa 0
) 0
greater 0
than 0
RII B-gene
alpha I-gene
dephosphoform 0
( 0
51 0
kDa 0
) 0
greater 0
than 0
RI B-gene
alpha I-gene
( 0
49 0
kDa 0
) 0
. 0

Comparison 0
of 0
the 0
genomic 0
DNA 0
sequence 0
with 0
that 0
of 0
the 0
four 0
different 0
mRNAs 0
indicates 0
that 0
these 0
transcripts 0
are 0
produced 0
by 0
alternative 0
splicing 0
of 0
the 0
murine 0
pre 0
- 0
mRNA 0
according 0
to 0
a 0
cassette 0
model 0
. 0

During 0
the 0
1980 0
's 0
, 0
quantifications 0
of 0
immunoserological 0
testings 0
, 0
especially 0
C B-gene
reactive I-gene
protein I-gene
, 0
rheumatoid B-gene
factor I-gene
and 0
antistreptolysin B-gene
O I-gene
, 0
progressed 0
rapidly 0
. 0

Within 0
the 0
human 0
enhancer 0
, 0
these 0
two 0
sites 0
are 0
located 0
within 0
the 0
previously 0
defined 0
DNase B-gene
I I-gene
footprints I-gene
, 0
NFAT B-gene
- I-gene
1 I-gene
and 0
NFIL B-gene
- I-gene
2B I-gene
, 0
respectively 0
. 0

The 0
cardiac B-gene
myosin I-gene
light I-gene
chain I-gene
- I-gene
2 I-gene
( 0
MLC B-gene
- I-gene
2 I-gene
) 0
gene 0
promoter 0
contains 0
several 0
positive 0
and 0
negative 0
cis 0
- 0
acting 0
sequences 0
that 0
are 0
involved 0
in 0
the 0
regulation 0
of 0
its 0
expression 0
. 0

Deletion 0
mutagenesis 0
demonstrated 0
that 0
these 0
two 0
elements 0
are 0
involved 0
in 0
the 0
positive 0
regulation 0
of 0
MLC B-gene
- I-gene
2 I-gene
gene I-gene
transcription 0
. 0

Disruption 0
mutations 0
have 0
been 0
constructed 0
in 0
the 0
SLK1 B-gene
gene I-gene
. 0
slk1 B-gene
null I-gene
mutants I-gene
can 0
not 0
grow 0
at 0
37 0
degrees 0
C 0
, 0
but 0
many 0
cells 0
can 0
grow 0
at 0
30 0
, 0
24 0
, 0
and 0
17 0
degrees 0
C 0
. 0

Molecular 0
and 0
genetic 0
analysis 0
of 0
the 0
yeast B-gene
early I-gene
meiotic I-gene
recombination I-gene
genes I-gene
REC102 I-gene
and 0
REC107/MER2 B-gene
. 0

The 0
p130 B-gene
and 0
p62 B-gene
tyrosine 0
- 0
phosphorylated 0
proteins 0
that 0
complexed 0
v B-gene
- I-gene
Src I-gene
SH2 B-gene
in 0
vitro 0
also 0
associated 0
with 0
v B-gene
- I-gene
Src I-gene
in 0
v B-gene
- I-gene
src I-gene
- 0
transformed 0
Rat 0
- 0
2 0
cells 0
; 0
this 0
in 0
vivo 0
binding 0
was 0
dependent 0
on 0
the 0
v B-gene
- I-gene
Src I-gene
SH2 B-gene
domain 0
. 0

Probable 0
progressive 0
multifocal 0
leukoencephalopathy 0
( 0
PML 0
) 0
was 0
diagnosed 0
on 0
the 0
basis 0
of 0
clinical 0
picture 0
and 0
magnetic 0
resonance 0
imaging 0
in 0
a 0
63 0
- 0
year 0
- 0
old 0
man 0
with 0
a 0
complete 0
remission 0
of 0
a 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
. 0

These 0
data 0
support 0
a 0
possible 0
biological 0
significance 0
of 0
the 0
frameshift 0
to 0
occur 0
at 0
this 0
position 0
of 0
the 0
large 0
overlap 0
by 0
including 0
the 0
putative 0
RNA 0
template 0
- 0
binding 0
site 0
of 0
the 0
PLRV B-gene
replicase I-gene
in 0
the 0
ORF2a/ORF2b B-gene
transframe I-gene
protein I-gene
. 0

Proprotein 0
processing 0
occurs 0
intracellularly 0
. 0

A 0
32P 0
- 0
labeled 0
LAP B-gene
DNA 0
- 0
binding 0
and 0
dimerization 0
domain 0
`` 0
zipper 0
probe 0
'' 0
was 0
used 0
to 0
isolate 0
a 0
clone 0
that 0
encodes 0
a 0
new B-gene
C/EBP I-gene
- I-gene
homologous I-gene
protein I-gene
protein I-gene
: I-gene
CHOP I-gene
- I-gene
10 0
. 0

Using 0
a 0
degenerate 0
oligodeoxyribonucleotide 0
( 0
oligo 0
) 0
based 0
on 0
the 0
N 0
- 0
terminal 0
aa 0
sequence 0
, 0
plus 0
an 0
internal 0
oligo 0
homologous 0
to 0
a 0
conserved 0
region 0
within 0
the 0
portion 0
of 0
CYP1 B-gene
and 0
CYP2 B-gene
that 0
had 0
been 0
deleted 0
in 0
the 0
genome 0
, 0
a 0
CYP3 B-gene
- I-gene
specific I-gene
DNA I-gene
fragment I-gene
was 0
generated 0
by 0
the 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
using 0
GL81 0
genomic 0
DNA 0
as 0
a 0
substrate 0
. 0

Stringent 0
hybridization 0
of 0
EHS B-gene
- I-gene
1 I-gene
back 0
to 0
primate 0
genomic 0
DNA 0
indicates 0
two 0
distinct 0
EHS B-gene
- I-gene
1 I-gene
loci I-gene
in 0
normal 0
human 0
DNA 0
, 0
an 0
identical 0
band 0
pattern 0
in 0
chimpanzee 0
DNA 0
, 0
and 0
a 0
single 0
locus 0
in 0
rhesus 0
monkey 0
DNA 0
. 0

The 0
level 0
of 0
carboxyl B-gene
- I-gene
terminal I-gene
parathyroid I-gene
hormone I-gene
in 0
the 0
patients 0
with 0
thyroid 0
carcinoma 0
was 0
higher 0
than 0
that 0
in 0
the 0
patients 0
without 0
thyroid 0
carcinoma 0
( 0
P 0
less 0
than 0
0.05 0
) 0
. 0

The 0
Caenorhabditis B-gene
elegans I-gene
vitellogenin I-gene
genes I-gene
are 0
subject 0
to 0
sex 0
- 0
, 0
stage 0
- 0
, 0
and 0
tissue 0
- 0
specific 0
regulation 0
: 0
they 0
are 0
expressed 0
solely 0
in 0
the 0
adult 0
hermaphrodite 0
intestine 0
. 0

The 0
MET4 B-gene
gene 0
was 0
cloned 0
, 0
and 0
its 0
sequence 0
reveals 0
that 0
it 0
encodes 0
a 0
protein 0
related 0
to 0
the 0
family 0
of 0
the 0
bZIP B-gene
transcriptional I-gene
activators I-gene
. 0

The 0
functions 0
of 0
isolated 0
portions 0
of 0
the 0
insulin B-gene
, 0
IAPP B-gene
, 0
and 0
beta B-gene
GK I-gene
promoters I-gene
were 0
studied 0
by 0
using 0
transient 0
expression 0
and 0
DNA 0
binding 0
assays 0
. 0

It 0
is 0
believed 0
that 0
these 0
domains 0
are 0
important 0
for 0
directing 0
specific 0
protein 0
- 0
protein 0
interactions 0
necessary 0
for 0
the 0
proper 0
functioning 0
of 0
Src B-gene
. 0

The 0
c B-gene
- I-gene
Ets I-gene
- I-gene
1 I-gene
oncoprotein I-gene
is 0
a 0
transcription 0
activator 0
that 0
specifically 0
binds 0
to 0
DNA 0
. 0

Previous 0
transactivation 0
experiments 0
indicated 0
that 0
three 0
amino 0
acids 0
residing 0
in 0
this 0
region 0
, 0
Gly 0
, 0
Ser 0
and 0
Val 0
, 0
appear 0
to 0
be 0
critical 0
for 0
target 0
- 0
site 0
discrimination 0
. 0

GR63178A 0
is 0
a 0
water 0
- 0
soluble 0
analogue 0
of 0
mitoquidone 0
, 0
a 0
pentacyclic 0
pyrroloquinone 0
. 0

Marker 0
rescue 0
analysis 0
has 0
localized 0
ts8 B-gene
to 0
a 0
910 0
- 0
bp 0
internal 0
segment 0
of 0
rpoB B-gene
that 0
encodes 0
the 0
Rif B-gene
domain I-gene
. 0

This 0
vector 0
transfected 0
into 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
directs 0
expression 0
of 0
a 0
secreted 0
mature 0
protein 0
at 0
levels 0
up 0
to 0
200 0
mg 0
of 0
LAPP/liter 0
of 0
culture 0
medium 0
. 0

Competition 0
analysis 0
by 0
gel 0
mobility 0
shift 0
electrophoresis 0
indicates 0
that 0
this 0
DNA 0
- 0
protein 0
interaction 0
is 0
novel 0
and 0
not 0
related 0
to 0
many 0
transcription 0
factors 0
previously 0
reported 0
. 0

This 0
DNA 0
motif 0
represents 0
a 0
novel 0
protein 0
- 0
binding 0
sequence 0
. 0

OBJECTIVE 0
: 0
The 0
study 0
was 0
designed 0
to 0
investigate 0
the 0
frequency 0
of 0
alterations 0
in 0
serum 0
creatinine 0
in 0
patients 0
with 0
psoriasis 0
receiving 0
5 0
mg/kg/day 0
of 0
cyclosporine 0
. 0

Intrapocket 0
chemotherapy 0
in 0
adult 0
periodontitis 0
using 0
a 0
new 0
controlled 0
- 0
release 0
insert 0
containing 0
ofloxacin 0
( 0
PT 0
- 0
01 0
) 0
. 0

Electromagnetic 0
blood 0
flow 0
( 0
BF 0
) 0
probe 0
was 0
applied 0
on 0
the 0
left 0
anterior 0
descending 0
artery 0
( 0
LAD 0
) 0
. 0

Hence 0
temperature 0
and 0
virF B-gene
are 0
both 0
required 0
for 0
the 0
induction 0
of 0
the 0
yop B-gene
regulon I-gene
. 0

Problems 0
remain 0
to 0
be 0
resolved 0
in 0
the 0
area 0
of 0
quantitative 0
risk 0
assessment 0
. 0

The 0
recently 0
developed 0
gamma B-gene
- I-gene
interferon I-gene
( 0
IFN B-gene
- I-gene
gamma I-gene
) 0
assay 0
system 0
for 0
the 0
diagnosis 0
of 0
bovine 0
tuberculosis 0
in 0
cattle 0
has 0
been 0
accredited 0
by 0
the 0
Standing 0
Committee 0
on 0
Agriculture 0
for 0
use 0
in 0
Australia 0
. 0

Control 0
Tmuscle 0
was 0
35.8 0
+/ 0
- 0
0.7 0
degrees 0
C 0
, 0
with 0
control 0
Wi 0
, 0
max 0
being 0
51.6 0
( 0
SD 0
8.7 0
) 0
W.kg 0
- 0
1 0
. 0

The 0
Klebsiella B-gene
aerogenes I-gene
gene I-gene
maoA I-gene
, 0
which 0
is 0
involved 0
in 0
the 0
synthesis 0
of 0
monoamine B-gene
oxidase I-gene
, 0
was 0
induced 0
by 0
tyramine 0
and 0
the 0
related 0
compounds 0
, 0
subjected 0
to 0
catabolite 0
and 0
ammonium 0
ion 0
repression 0
, 0
and 0
cloned 0
. 0

However 0
, 0
other 0
regions 0
of 0
the 0
plasmid 0
are 0
also 0
efficiently 0
repaired 0
. 0

Eight 0
of 0
14 0
infectious 0
or 0
inflammatory 0
lesions 0
could 0
be 0
detected 0
in 0
the 0
early 0
scan 0
( 0
4 0
- 0
6 0
h 0
p.i 0
. 0
) 0
. 0

Thus 0
, 0
the 0
human B-gene
D1A I-gene
gene I-gene
belongs 0
to 0
the 0
category 0
of 0
tissue 0
- 0
specific 0
, 0
regulated 0
genes 0
that 0
have 0
housekeeping 0
- 0
type 0
promoters 0
. 0

Similar 0
observations 0
have 0
been 0
made 0
previously 0
for 0
other 0
genes 0
. 0

Preceptorship 0
of 0
CNS 0
students 0
: 0
an 0
exploratory 0
study 0
. 0

To 0
determine 0
the 0
genetic 0
basis 0
for 0
the 0
differences 0
between 0
the 0
cardiac 0
and 0
brain B-gene
AE3 I-gene
variants I-gene
, 0
we 0
isolated 0
and 0
characterized 0
the 0
rat 0
gene 0
. 0

The 0
1.7 0
kb 0
cloned 0
fragment 0
was 0
sequenced 0
and 0
shown 0
to 0
contain 0
the 0
entire 0
fliA B-gene
gene I-gene
. 0

Institution 0
of 0
both 0
intravenous 0
and 0
intracisternal 0
administration 0
of 0
amphotericin 0
B 0
and 0
possibly 0
concomitant 0
intravenous 0
administration 0
of 0
dexamethasone 0
may 0
be 0
warranted 0
in 0
situations 0
in 0
which 0
the 0
association 0
of 0
C. 0
immitis 0
with 0
CNS 0
vasculitis 0
or 0
encephalitis 0
appears 0
likely 0
before 0
serologic 0
or 0
cultural 0
confirmation 0
of 0
C. 0
immitis 0
infection 0
involving 0
the 0
CNS 0
is 0
available 0
. 0

Lac B-gene
operators 0
were 0
introduced 0
into 0
several 0
positions 0
within 0
the 0
CAB B-gene
promoter I-gene
and 0
operator 0
- 0
free 0
plasmid 0
was 0
used 0
as 0
control 0
. 0

Overproduction 0
, 0
purification 0
and 0
characterization 0
of 0
M.HinfI B-gene
methyltransferase I-gene
and 0
its 0
deletion 0
mutant 0
. 0

Various 0
companies 0
produce 0
this 0
type 0
of 0
lens 0
. 0

From 0
March 0
5 0
through 0
October 0
26 0
, 0
1991 0
, 0
eight 0
persons 0
were 0
diagnosed 0
with 0
elevated 0
blood 0
lead 0
levels 0
( 0
BLLs 0
) 0
at 0
a 0
local 0
hospital 0
and 0
were 0
reported 0
to 0
the 0
notifiable 0
disease 0
surveillance 0
system 0
maintained 0
by 0
the 0
Alabama 0
Department 0
of 0
Public 0
Health 0
( 0
ADPH 0
) 0
. 0

According 0
to 0
the 0
changes 0
of 0
perfusion 0
defects 0
between 0
Ex 0
, 0
RD 0
and 0
ReI 0
images 0
, 0
they 0
were 0
classified 0
into 0
3 0
types 0
: 0
Type 0
I 0
; 0
perfusion 0
defect 0
on 0
the 0
RD 0
image 0
was 0
identical 0
to 0
ReI 0
image 0
( 0
75 0
% 0
) 0
Type 0
I 0
was 0
divided 0
into 0
2 0
subgroups 0
whether 0
perfusion 0
defect 0
at 0
Ex 0
was 0
unchanged 0
( 0
Ia 0
, 0
42 0
% 0
) 0
or 0
improved 0
( 0
Ib 0
, 0
33 0
% 0
) 0
on 0
the 0
RD 0
image 0
. 0

Keck 0
, 0
C.J 0
. 0

Twenty 0
- 0
eight 0
( 0
7.0 0
% 0
) 0
infants 0
without 0
periventricular 0
hemorrhage 0
were 0
revealed 0
as 0
having 0
spastic 0
cerebral 0
palsy 0
by 0
neurodevelopmental 0
evaluation 0
in 0
later 0
infancy 0
. 0

A 0
possible 0
mechanism 0
is 0
that 0
elevated 0
alveolar 0
pressure 0
and 0
decreased 0
cardiac 0
output 0
eliminate 0
blood 0
flow 0
from 0
corner 0
vessels 0
in 0
nondependent 0
high 0
VA/Q 0
regions 0
. 0

Computer 0
- 0
aided 0
`` 0
FRAME 0
'' 0
analysis 0
revealed 0
four 0
possible 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
, 0
three 0
in 0
one 0
direction 0
and 0
one 0
in 0
the 0
opposite 0
direction 0
. 0

Domain 0
II 0
is 0
highly 0
homologous 0
to 0
the 0
LDL B-gene
receptor I-gene
and 0
contains 0
four 0
repeats 0
with 0
perfect 0
conservation 0
of 0
all 0
6 0
consecutive 0
cysteines 0
. 0

In 0
both 0
cities 0
, 0
HTLV 0
- 0
I/II 0
prevalence 0
increased 0
significantly 0
with 0
age 0
, 0
and 0
the 0
New 0
Orleans 0
age 0
- 0
and 0
sex 0
- 0
adjusted 0
HTLV 0
- 0
I/II 0
prevalence 0
was 0
significantly 0
higher 0
than 0
that 0
of 0
Baltimore 0
( 0
P 0
less 0
than 0
.001 0
) 0
. 0

Here 0
, 0
we 0
present 0
evidence 0
for 0
a 0
model 0
in 0
which 0
mRNA 0
sequences 0
up 0
to 0
around 0
100 0
nucleotides 0
downstream 0
from 0
the 0
start 0
codon 0
of 0
21K 0
fold 0
back 0
and 0
base 0
- 0
pair 0
to 0
the 0
21K 0
translation 0
initiation 0
region 0
, 0
thereby 0
decreasing 0
the 0
translation 0
initiation 0
frequency 0
. 0

Hybridization 0
data 0
indicate 0
that 0
6F6.2 B-gene
corresponds 0
to 0
the 0
previously 0
characterized 0
m6F6 B-gene
cDNA I-gene
clone I-gene
and 0
that 0
6F6.1 B-gene
and 0
6F6.3 B-gene
, 0
but 0
not 0
6F6.2 B-gene
, 0
are 0
adjacent 0
to 0
alpha B-gene
- I-gene
type I-gene
genes I-gene
. 0

The 0
SEN1 B-gene
gene I-gene
corresponds 0
to 0
a 0
6,336 0
- 0
bp 0
open 0
reading 0
frame 0
coding 0
for 0
a 0
2,112 0
- 0
amino 0
- 0
acid 0
protein 0
( 0
molecular 0
mass 0
, 0
239 0
kDa 0
) 0
. 0

Protein B-gene
tyrosine I-gene
kinases I-gene
( 0
PTKs B-gene
) 0
are 0
implicated 0
in 0
the 0
control 0
of 0
cell 0
growth 0
by 0
virtue 0
of 0
their 0
frequent 0
appearance 0
as 0
products 0
of 0
retroviral 0
oncogenes 0
, 0
as 0
intracellular 0
signal 0
transducers 0
, 0
and 0
as 0
growth B-gene
factor I-gene
receptors I-gene
or 0
components 0
thereof 0
. 0

The 0
IA4 B-gene
mAb I-gene
was 0
identified 0
among 0
a 0
series 0
of 0
antibodies 0
raised 0
in 0
BALB/c 0
mice 0
after 0
immunization 0
against 0
a 0
HLA B-gene
class 0
I 0
- 0
deficient 0
, 0
lymphokine 0
- 0
activated 0
killer 0
( 0
LAK 0
) 0
- 0
susceptible 0
EBV 0
- 0
B 0
lymphocyte 0
line 0
. 0

In 0
a 0
randomized 0
double 0
- 0
blind 0
cross 0
- 0
over 0
study 0
, 0
the 0
subjects 0
received 0
theophylline 0
5 0
mg.kg 0
- 0
1 0
per 0
day 0
with 0
omeprazole 0
20 0
mg 0
per 0
day 0
or 0
identical 0
placebo 0
during 0
two 0
periods 0
, 0
each 0
of 0
7 0
days 0
, 0
separated 0
by 0
a 0
washout 0
period 0
of 0
7 0
days 0
. 0

Primer 0
extension 0
and 0
mung B-gene
bean I-gene
and I-gene
S1 I-gene
nuclease I-gene
mapping 0
indicated 0
multiple 0
transcription 0
initiation 0
sites 0
and 0
were 0
consistent 0
with 0
Northern 0
analyses 0
. 0

Two 0
variant 0
PRP B-gene
- I-gene
precursor I-gene
alleles I-gene
occur 0
which 0
slightly 0
differ 0
in 0
the 0
number 0
of 0
repeats 0
in 0
domain 0
C 0
. 0

Unlike 0
the 0
typical 0
enhancer 0
element 0
, 0
this 0
region 0
functions 0
in 0
an 0
orientation 0
- 0
dependent 0
manner 0
. 0

In 0
the 0
last 0
20 0
years 0
, 0
the 0
therapeutic 0
uses 0
of 0
botulinum B-gene
toxin I-gene
, 0
a 0
potent 0
neurotoxin 0
, 0
have 0
been 0
investigated 0
. 0

Allagille 0
's 0
syndrome 0
associated 0
with 0
antenatal 0
ascites 0

Sensitivity 0
and 0
specificity 0
was 0
established 0
for 0
the 0
Pharmacia 0
CAP 0
System 0
and 0
the 0
DPC 0
AlaSTAT 0
System 0
by 0
comparison 0
with 0
results 0
of 0
the 0
skin 0
prick 0
test 0
. 0

PSI B-gene
- I-gene
G I-gene
and 0
PSI B-gene
- I-gene
K I-gene
probably 0
have 0
evolved 0
from 0
a 0
gene 0
duplication 0
of 0
an 0
ancestral 0
gene 0
. 0

At 0
the 0
C 0
- 0
terminus 0
of 0
the 0
protein 0
is 0
a 0
domain 0
that 0
contains 0
sequences 0
very 0
similar 0
to 0
those 0
found 0
in 0
the 0
breakpoint 0
cluster 0
region 0
gene 0
product 0
, 0
n B-gene
- I-gene
chimerin I-gene
, 0
and 0
rho B-gene
GAP I-gene
, 0
all 0
of 0
which 0
have 0
been 0
shown 0
to 0
possess 0
intrinsic 0
GAP B-gene
activity 0
on 0
small B-gene
GTPases I-gene
. 0

Site 0
- 0
directed 0
mutagenesis 0
revealed 0
that 0
two 0
clusters 0
of 0
basic 0
amino 0
acids 0
within 0
a 0
conserved 0
basic 0
region 0
and 0
two 0
amphipathic 0
helices 0
within 0
the 0
adjacent 0
HLH 0
domain 0
are 0
essential 0
for 0
sequence 0
- 0
specific 0
DNA 0
binding 0
and 0
hetero 0
- 0
oligomerization 0
, 0
respectively 0
. 0

Dimerization 0
of 0
Myf B-gene
- I-gene
5 I-gene
with 0
the 0
ubiquitously 0
expressed 0
bHLH 0
protein 0
E12 B-gene
not 0
only 0
increases 0
the 0
affinity 0
for 0
DNA 0
but 0
also 0
stimulates 0
transactivation 0
independently 0
of 0
DNA 0
binding 0
. 0

The 0
circadian 0
rhythmicity 0
of 0
sleep 0
was 0
pronounced 0
. 0

SEA 0
was 0
recorded 0
with 0
bidirectional 0
filters 0
at 0
25 0
- 0
250 0
HZ 0
and 0
40 0
- 0
250 0
Hz 0
using 0
Simson 0
method 0
. 0

Neural 0
- 0
specific 0
expression 0
, 0
genomic 0
structure 0
, 0
and 0
chromosomal 0
localization 0
of 0
the 0
gene 0
encoding 0
the 0
zinc B-gene
- I-gene
finger I-gene
transcription I-gene
factor I-gene
NGFI I-gene
- I-gene
C I-gene
. 0

An 0
experiment 0
examined 0
the 0
effects 0
of 0
treatment 0
with 0
gonadotrophin B-gene
releasing I-gene
hormone I-gene
( 0
100 0
micrograms 0
GnRH B-gene
injected 0
24 0
h 0
after 0
progestagen 0
sponge 0
removal 0
) 0
, 0
season 0
of 0
treatment 0
( 0
autumn 0
v. 0
spring 0
) 0
, 0
the 0
effect 0
of 0
supplementary 0
feeding 0
with 0
lupin 0
grain 0
( 0
in 0
autumn 0
only 0
, 0
from 0
12 0
days 0
before 0
until 0
8 0
days 0
after 0
sponge 0
removal 0
) 0
on 0
the 0
time 0
of 0
ovulation 0
in 0
182 0
mature 0
Merino 0
ewes 0
superovulated 0
with 0
a 0
combination 0
of 0
400 0
I.U 0
. 0
pregnant B-gene
mare I-gene
serum I-gene
gonadotrophin I-gene
( 0
PMSG B-gene
) 0
and 0
12 0
mg 0
follicle B-gene
stimulating I-gene
hormone I-gene
( 0
FSH B-gene
- I-gene
P I-gene
) 0
. 0

Drug 0
- 0
drug 0
interactions 0
are 0
most 0
likely 0
to 0
occur 0
in 0
patients 0
receiving 0
multiple 0
medications 0
and 0
with 0
drugs 0
that 0
have 0
a 0
narrow 0
therapeutic 0
window 0
. 0

The 0
sequence 0
data 0
now 0
permit 0
a 0
detailed 0
interpretation 0
of 0
the 0
X 0
- 0
ray 0
crystallographic 0
structure 0
of 0
the 0
enzyme 0
and 0
the 0
cloning 0
and 0
expression 0
of 0
the 0
clostridial 0
gene 0
will 0
facilitate 0
site 0
- 0
directed 0
mutagenesis 0
. 0

Total 0
body 0
irradiation 0
was 0
delivered 0
according 0
to 0
a 0
hyperfractionated 0
scheme 0
of 0
12 0
fractions 0
given 0
three 0
per 0
day 0
5 0
hr 0
apart 0
for 0
4 0
days 0
. 0

A 0
reduction 0
in 0
blood 0
pressure 0
was 0
only 0
observed 0
at 0
the 0
end 0
of 0
the 0
study 0
, 0
from 0
142 0
+/ 0
- 0
17/86.6 0
+/ 0
- 0
9.1 0
to 0
139 0
+/ 0
- 0
13/82.9 0
+/ 0
- 0
8.9 0
mmHg 0
( 0
P 0
less 0
than 0
0.05 0
for 0
DBP 0
) 0
. 0

AgMNPV 0
and 0
Orgyia 0
pseudotsugata 0
MNPV 0
( 0
OpMNPV 0
) 0
are 0
similar 0
in 0
terms 0
of 0
promoter 0
structure 0
and 0
polyhedrin B-gene
primary I-gene
sequence I-gene
, 0
and 0
the 0
polyhedrin B-gene
gene I-gene
of 0
both 0
viruses 0
is 0
transcribed 0
in 0
the 0
anti 0
- 0
clockwise 0
direction 0
in 0
relation 0
to 0
their 0
physical 0
maps 0
. 0

A 0
gene 0
homologous 0
to 0
the 0
Escherichia B-gene
coli I-gene
dnaA I-gene
gene I-gene
was 0
isolated 0
from 0
Pseudomonas 0
putida 0
and 0
its 0
transcription 0
was 0
investigated 0
in 0
E. 0
coli 0
as 0
well 0
as 0
in 0
P. 0
putida 0
. 0

STP1 B-gene
is 0
an 0
unessential 0
yeast 0
gene 0
involved 0
in 0
the 0
removal 0
of 0
intervening 0
sequences 0
from 0
some 0
, 0
but 0
not 0
all 0
, 0
families 0
of 0
intervening 0
sequence 0
- 0
containing 0
pre 0
- 0
tRNAs 0
. 0

Using 0
these 0
antibodies 0
, 0
we 0
were 0
able 0
to 0
define 0
the 0
conditions 0
to 0
completely 0
solubilize 0
the 0
Cdc25 B-gene
protein I-gene
. 0

GCR1 B-gene
gene I-gene
function 0
is 0
required 0
for 0
high 0
- 0
level 0
glycolytic 0
gene 0
expression 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

The 0
decay 0
curves 0
of 0
chlorophyll 0
fluorescence 0
showed 0
a 0
superposition 0
of 0
three 0
exponentially 0
decaying 0
components 0
with 0
time 0
constants 0
of 0
T1 0
= 0
100 0
- 0
200 0
ps 0
, 0
T2 0
= 0
300 0
- 0
500 0
ps 0
and 0
T3 0
= 0
2.0 0
- 0
3.5 0
ns 0
. 0

After 0
tilting 0
, 0
systolic 0
blood 0
pressure 0
fell 0
an 0
average 0
of 0
17 0
% 0
in 0
patients 0
who 0
cramped 0
infrequently 0
( 0
p 0
= 0
0.0031 0
) 0
but 0
only 0
10 0
% 0
in 0
frequently 0
cramping 0
patients 0
. 0

These 0
results 0
are 0
consistent 0
with 0
the 0
roles 0
that 0
CCK B-gene
and 0
trypsin B-gene
inhibitors 0
are 0
believed 0
to 0
play 0
in 0
the 0
negative 0
feedback 0
control 0
of 0
pancreatic 0
exocrine 0
function 0
. 0

Most 0
apneic 0
events 0
occurred 0
during 0
Stages 0
I 0
and 0
II 0
, 0
and 0
REM 0
, 0
but 0
this 0
proportion 0
was 0
less 0
during 0
the 0
gamma 0
OH 0
study 0
( 0
77.9 0
+/ 0
- 0
8.9 0
% 0
) 0
than 0
during 0
the 0
control 0
studies 0
( 0
92.3 0
+/ 0
- 0
1.9 0
and 0
95.9 0
+/ 0
- 0
2.2 0
% 0
) 0
, 0
apneas 0
occurring 0
even 0
during 0
SWS 0
with 0
gamma 0
OH 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Eight 0
rabbits 0
were 0
exposed 0
to 0
0.7 0
+/ 0
- 0
0.4 0
mg/m3 0
Co2+ 0
as 0
CoCl2 0
and 0
1.2 0
+/ 0
- 0
0.7 0
mg/m3 0
Cr3+ 0
as 0
Cr 0
( 0
NO3 0
) 0
3 0
( 0
group 0
Co 0
+ 0
Cr 0
) 0
, 0
eight 0
to 0
0.6 0
+/ 0
- 0
0.5 0
mg/m3 0
Co2+ 0
( 0
group 0
Co 0
) 0
, 0
and 0
eight 0
to 0
filtered 0
air 0
( 0
control 0
group 0
) 0
, 0
for 0
4 0
months 0
, 0
5 0
days/week 0
, 0
and 0
6 0
hr/day 0
. 0

16 0
women 0
were 0
treated 0
with 0
methadone 0
to 0
prevent 0
withdrawal 0
symptoms 0
. 0

Disruption 0
demonstrates 0
that 0
CDC14 B-gene
is 0
an 0
essential 0
gene 0
. 0

Coronary 0
flow 0
was 0
reduced 0
by 0
10 0
% 0
in 0
the 0
phosphocreatine 0
and 0
by 0
18 0
% 0
in 0
the 0
control 0
group 0
. 0

The 0
60A B-gene
transcripts I-gene
and 0
protein 0
are 0
first 0
detected 0
at 0
the 0
onset 0
of 0
gastrulation 0
, 0
primarily 0
in 0
the 0
mesoderm 0
of 0
the 0
extending 0
germ 0
band 0
. 0

A 0
724 0
- 0
bp 0
segment 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
consisting 0
of 0
the 0
proximal 0
E 0
- 0
box 0
flanked 0
upstream 0
by 0
a 0
mammalian 0
- 0
specific 0
352 0
- 0
bp 0
region 0
was 0
sufficient 0
for 0
maximal 0
transcriptional 0
activation 0
in 0
postconfluent 0
BC3H1 0
myoblasts 0
. 0

These 0
results 0
indicate 0
that 0
baculovirus 0
- 0
expressed 0
TR B-gene
mediates 0
transcriptional 0
activation 0
and 0
repression 0
in 0
a 0
promoter 0
- 0
specific 0
manner 0
in 0
vitro 0
. 0

Influence 0
of 0
neural 0
regulation 0
on 0
anti 0
- 0
arrhythmic 0
effects 0
of 0
GABA 0
in 0
rats 0

Recent 0
investigations 0
have 0
detailed 0
a 0
selective 0
dye 0
release 0
technique 0
in 0
which 0
a 0
pulse 0
of 0
laser 0
light 0
induces 0
the 0
release 0
of 0
a 0
fluorescent 0
dye 0
from 0
temperature 0
- 0
sensitive 0
liposomes 0
circulating 0
in 0
the 0
retinal 0
vasculature 0
. 0

And 0
the 0
natural 0
barriers 0
? 0

Three 0
pyridoxine 0
derivatives 0
have 0
been 0
isolated 0
from 0
the 0
fresh 0
stem 0
bark 0
of 0
Albizzia 0
julibrissin 0
DURAZZ.. 0

The 0
serum 0
erythropoietin B-gene
( 0
EPO B-gene
) 0
concentrations 0
of 0
15 0
male 0
triathletes 0
( 0
26.3 0
U.ml 0
- 0
1 0
) 0
were 0
significantly 0
lower 0
than 0
those 0
of 0
45 0
male 0
distance 0
runners 0
( 0
31.6 0
U.ml 0
- 0
1 0
; 0
P 0
less 0
than 0
0.05 0
) 0
. 0

The 0
coating 0
materials 0
were 0
poloxamine 0
904 0
, 0
poloxamine 0
908 0
, 0
poloxamine 0
1508 0
, 0
poloxamer 0
338 0
, 0
and 0
Brij 0
35 0
. 0

The 0
eating 0
and 0
drinking 0
patterns 0
of 0
pygmy 0
goats 0
fed 0
ad 0
lib 0
and 0
kept 0
on 0
a 0
12 0
h 0
light/12 0
h 0
dark 0
cycle 0
were 0
recorded 0
and 0
analyzed 0
. 0

The 0
present 0
study 0
highlights 0
the 0
improvement 0
in 0
sputum 0
amoxycillin 0
( 0
amoxy 0
) 0
levels 0
when 0
a 0
combination 0
tablet 0
, 0
amoxy 0
500 0
mg 0
plus 0
bromhexeine 0
8 0
mg 0
, 0
is 0
administered 0
as 0
compared 0
to 0
plain 0
amoxy 0
500 0
mg 0
. 0

His 0
HC B-gene
II I-gene
activity 0
and 0
antigen 0
levels 0
were 0
49 0
% 0
and 0
50 0
% 0
, 0
respectively 0
, 0
and 0
his 0
daughter 0
also 0
showed 0
similar 0
low 0
levels 0
. 0

Argatroban 0
may 0
be 0
more 0
effective 0
under 0
low 0
HC B-gene
II I-gene
conditions 0
because 0
of 0
its 0
potent 0
inhibition 0
of 0
thrombin B-gene
activity 0
at 0
sites 0
of 0
vascular 0
wall 0
damage 0
. 0

These 0
results 0
support 0
the 0
diagnostic 0
validity 0
of 0
NFPD 0
in 0
CP/NCA 0
patients 0
, 0
because 0
such 0
patients 0
had 0
a 0
family 0
history 0
of 0
panic 0
disorder 0
similar 0
to 0
patients 0
with 0
a 0
more 0
classical 0
panic 0
disorder 0
presentation 0
. 0

FDA 0
regulations 0
for 0
growth 0
factors 0
and 0
related 0
products 0
. 0

Because 0
the 0
adrenergic 0
nervous 0
system 0
influences 0
cardiac 0
arrhythmias 0
and 0
myocardial 0
infarction 0
can 0
directly 0
affect 0
sympathetic 0
innervation 0
in 0
the 0
heart 0
, 0
we 0
investigated 0
the 0
role 0
of 0
the 0
sympathetic 0
nervous 0
system 0
on 0
reentry 0
in 0
the 0
canine 0
heart 0
4 0
days 0
after 0
infarction 0
. 0

DESIGN 0
: 0
Serum 0
aldosterone 0
and 0
plasma B-gene
renin I-gene
activity 0
were 0
measured 0
supine 0
prior 0
to 0
and 0
60 0
, 0
90 0
, 0
120 0
minutes 0
after 0
oral 0
captopril 0
, 0
25 0
mg 0
. 0

Furthermore 0
, 0
no 0
transcripts 0
of 0
the 0
same 0
size 0
and 0
having 0
the 0
same 0
developmental 0
profile 0
as 0
those 0
generated 0
by 0
the 0
wild B-gene
- I-gene
type I-gene
E10 I-gene
fragment I-gene
were 0
identified 0
by 0
probes 0
covering 0
the 0
remainder 0
of 0
the 0
cloned 0
region 0
. 0

Intravenous 0
amine 0
pressor 0
tests 0
in 0
healthy 0
volunteers 0
. 0

The 0
mean 0
minimum 0
steady 0
- 0
state 0
concentration 0
after 0
the 0
oral 0
regimen 0
( 0
23 0
micrograms.l 0
- 0
1 0
) 0
was 0
78 0
% 0
of 0
that 0
after 0
the 0
intramuscular 0
regime 0
( 0
29 0
micrograms.l 0
- 0
1 0
) 0
. 0

In 0
an 0
ongoing 0
study 0
the 0
performance 0
of 0
the 0
SMSP 0
is 0
being 0
compared 0
with 0
that 0
of 0
the 0
Mini 0
Speech 0
Processor 0
( 0
MSP 0
) 0
. 0

Both 0
parents 0
are 0
clinically 0
normal 0
and 0
unrelated 0
. 0

These 0
mutant 0
proteins 0
retained 0
the 0
ability 0
to 0
competitively 0
inhibit 0
kappa B-gene
B I-gene
- 0
mediated 0
transcriptional 0
activation 0
of 0
the 0
human B-gene
immunodeficiency I-gene
virus I-gene
long I-gene
terminal I-gene
repeat I-gene
but 0
failed 0
to 0
efficiently 0
transform 0
chicken 0
lymphoid 0
cells 0
both 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

The 0
sequence 0
- 0
specific 0
interaction 0
of 0
nuclear B-gene
factor I-gene
HiNF I-gene
- I-gene
D I-gene
with 0
this 0
key 0
proximal 0
promoter 0
element 0
of 0
the 0
H4 B-gene
- I-gene
FO108 I-gene
gene I-gene
is 0
cell 0
cycle 0
regulated 0
in 0
normal 0
diploid 0
cells 0
( 0
J 0
. 0

In 0
conclusion 0
, 0
to 0
study 0
and 0
overcome 0
TI 0
region 0
- 0
based 0
expression 0
problems 0
it 0
is 0
worthwhile 0
to 0
start 0
out 0
with 0
a 0
versatile 0
vector 0
containing 0
exhaustive 0
mutations 0
in 0
the 0
periShine 0
- 0
Dalgarno 0
sequences 0
; 0
as 0
a 0
rule 0
the 0
coding 0
MTI 0
subregion 0
can 0
be 0
kept 0
unchanged 0
. 0

Four 0
of 0
these 0
five 0
subjects 0
also 0
performed 0
mixed 0
sequences 0
under 0
conditional 0
control 0
of 0
the 0
words 0
( 0
e.g. 0
, 0
A1 0
- 0
- 0
- 0
- 0
B2 0
- 0
- 0
- 0
- 0
A3 0
- 0
- 0
- 0
- 0
B4 0
- 0
- 0
- 0
- 0
A5 0
and 0
its 0
reversal 0
) 0
, 0
verifying 0
that 0
the 0
stimuli 0
which 0
occupied 0
the 0
same 0
position 0
in 0
each 0
sequence 0
were 0
members 0
of 0
the 0
same 0
class 0
. 0

UF 0
- 0
021 0
ophthalmic 0
solution 0
( 0
0.03 0
to 0
0.24 0
% 0
) 0
, 0
when 0
topically 0
applied 0
to 0
the 0
eyes 0
of 0
rabbits 0
, 0
caused 0
dose 0
- 0
dependent 0
IOP 0
reduction 0
( 0
2.8 0
to 0
5.2 0
mmHg 0
) 0
, 0
without 0
transient 0
IOP 0
rise 0
. 0

While 0
blood 0
pressure 0
and 0
noradrenergic 0
activity 0
, 0
assessed 0
as 0
changes 0
in 0
the 0
plasma 0
levels 0
and 0
urinary 0
excretion 0
of 0
norepinephrine 0
, 0
remained 0
unaffected 0
in 0
the 0
Pl 0
group 0
, 0
a 0
significant 0
drop 0
in 0
the 0
supine 0
systolic 0
and 0
diastolic 0
blood 0
pressures 0
, 0
as 0
well 0
as 0
in 0
the 0
resting 0
venous 0
norepinephrine 0
level 0
and 0
in 0
urinary 0
norepinephrine 0
excretion 0
was 0
found 0
after 0
the 0
first 0
month 0
of 0
dF 0
administration 0
. 0

Wild 0
- 0
type 0
protein 0
bound 0
azido 0
- 0
ATP 0
well 0
, 0
but 0
mutants 0
with 0
substitutions 0
in 0
the 0
consensus 0
amino 0
acids 0
were 0
unable 0
to 0
bind 0
azido 0
- 0
ATP 0
. 0

Therefore 0
, 0
with 0
a 0
biopsy 0
from 0
the 0
stoma 0
site 0
there 0
is 0
a 0
risk 0
of 0
missing 0
early 0
rejection 0
. 0

Whole 0
blood 0
serotonin 0
levels 0
were 0
investigated 0
in 0
a 0
control 0
group 0
( 0
n 0
= 0
35 0
) 0
and 0
in 0
a 0
group 0
of 0
chronic 0
renal 0
failure 0
patients 0
( 0
n 0
= 0
127 0
) 0
on 0
various 0
treatment 0
regimen 0
i.e 0
. 0
conservative 0
treatment 0
( 0
n 0
= 0
39 0
) 0
, 0
maintenance 0
haemodialysis 0
( 0
n 0
= 0
35 0
) 0
and 0
after 0
renal 0
transplantation 0
( 0
n 0
= 0
53 0
) 0
. 0

Tissues 0
and 0
exudates 0
contain 0
sufficient 0
thymidine 0
for 0
growth 0
of 0
anaerobic 0
bacteria 0
in 0
the 0
presence 0
of 0
inhibitory 0
levels 0
of 0
trimethoprim 0
- 0
sulfamethoxazole 0
. 0

The 0
homologies 0
between 0
RAD16 B-gene
, 0
RAD54 B-gene
and 0
SNF2 B-gene
are 0
also 0
shared 0
by 0
several 0
additional 0
, 0
recently 0
isolated 0
yeast 0
and 0
Drosophila 0
genes 0
. 0

But 0
the 0
application 0
solutions 0
of 0
instrument 0
disinfectants 0
should 0
not 0
be 0
used 0
longer 0
than 0
one 0
day 0
. 0

In 0
the 0
Rett 0
syndrome 0
we 0
, 0
therefore 0
, 0
suspect 0
there 0
are 0
disturbances 0
in 0
the 0
brain 0
stem 0
functions 0
especially 0
in 0
the 0
ascending 0
reticular 0
activating 0
system 0
which 0
is 0
related 0
to 0
elevation 0
of 0
the 0
conscious 0
level 0
. 0

In 0
a 0
similar 0
experiment 0
, 0
simultaneous 0
nitrofurazone 0
administration 0
and 0
S. 0
enteritidis 0
challenge 0
resulted 0
in 0
no 0
significant 0
differences 0
in 0
S. 0
enteritidis 0
isolation 0
frequency 0
. 0

In 0
agreement 0
with 0
this 0
southern 0
blotting 0
of 0
mouse 0
DNA 0
with 0
SmN B-gene
probes 0
reveals 0
bands 0
, 0
additional 0
to 0
those 0
derived 0
from 0
the 0
pseudogene 0
, 0
which 0
are 0
characteristic 0
of 0
an 0
intron 0
- 0
containing 0
SmN B-gene
gene I-gene
. 0

Two 0
cDNAs 0
encoding 0
casein B-gene
kinase I-gene
- I-gene
1 I-gene
have 0
been 0
isolated 0
from 0
a 0
yeast 0
cDNA 0
library 0
and 0
termed 0
CKI1 B-gene
and 0
CKI2 B-gene
. 0

Incidence 0
rate 0
ranging 0
between 0
122/100,000/year 0
and 0
190/100,000/year 0
were 0
found 0
( 0
minimum 0
, 0
estimated 0
and 0
raw 0
datasets 0
) 0
. 0

The 0
observed 0
sequence 0
variation 0
disrupts 0
the 0
first 0
ORF 0
in 0
many 0
Y B-gene
's 0
while 0
most 0
of 0
the 0
second 0
ORF 0
including 0
the 0
putative 0
helicase B-gene
region I-gene
is 0
unaffected 0
. 0

The 0
final 0
screening 0
yielded 0
a 0
clone 0
containing 0
a 0
2 0
kilobase 0
( 0
kb 0
) 0
insert 0
. 0

Lesions 0
were 0
made 0
by 0
pressure 0
injection 0
of 0
kainic 0
acid 0
into 0
the 0
SOC 0
through 0
a 0
stereotaxically 0
positioned 0
glass 0
micropipette 0
. 0

A 0
38 0
- 0
bp 0
poly 0
( 0
dA 0
- 0
dT 0
) 0
region 0
was 0
found 0
to 0
be 0
a 0
positive 0
regulator 0
of 0
Act1 B-gene
promoter I-gene
activity 0
. 0

We 0
identified 0
a 0
protein 0
, 0
termed 0
NFIL B-gene
- I-gene
1 I-gene
beta I-gene
A I-gene
( 0
NF B-gene
beta I-gene
A I-gene
) 0
, 0
that 0
binds 0
to 0
a 0
highly 0
conserved 0
12 0
- 0
bp 0
DNA 0
sequence 0
( 0
- 0
49 0
to 0
- 0
38 0
) 0
located 0
upstream 0
of 0
the 0
TATA 0
box 0
motif 0
in 0
both 0
the 0
human B-gene
and I-gene
murine I-gene
IL I-gene
- I-gene
1 I-gene
beta I-gene
genes I-gene
. 0

We 0
tried 0
amphotericin 0
B 0
( 0
AmB 0
) 0
, 0
and 0
remission 0
of 0
the 0
tumor 0
was 0
obtained 0
. 0

Cutis 0
aplasia 0
. 0

The 0
DRF B-gene
- I-gene
2 I-gene
nuclear I-gene
protein I-gene
has 0
characteristics 0
similar 0
to 0
those 0
of 0
the 0
muscle 0
- 0
specific 0
regulatory 0
factor 0
, 0
MEF B-gene
- I-gene
2 I-gene
( 0
Buskin 0
and 0
Hauschka 0
1989 0
; 0
Gossett 0
et 0
al. 0
, 0
1989 0
) 0
. 0

From 0
the 0
15 0
- 0
kb 0
clone 0
a 0
4 B-gene
- I-gene
kb I-gene
EcoRI I-gene
fragment I-gene
containing 0
the 0
first 0
two 0
exons 0
and 0
2.6 0
kb 0
of 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
opn B-gene
gene I-gene
was 0
sequenced 0
, 0
and 0
the 0
transcriptional 0
start 0
site 0
determined 0
by 0
primer 0
extension 0
analysis 0
and 0
S1 B-gene
nuclease I-gene
mapping 0
. 0

Cardiovascular 0
risk 0
factors 0
were 0
measured 0
by 0
standardized 0
techniques 0
. 0

Production 0
costs 0
included 0
feed 0
, 0
non 0
- 0
feed 0
operating 0
, 0
fixed 0
, 0
and 0
replacement 0
stock 0
costs 0
. 0

We 0
report 0
a 0
patient 0
developing 0
factor B-gene
VII I-gene
inhibitor I-gene
possibly 0
as 0
a 0
reaction 0
to 0
penicillin 0
administration 0
; 0
it 0
gave 0
rise 0
to 0
fatal 0
haemorrhage 0
. 0

This 0
is 0
in 0
contrast 0
with 0
the 0
classical 0
'oxygen 0
debt 0
hypothesis 0
' 0
, 0
which 0
states 0
that 0
the 0
oxygen 0
debt 0
and 0
lactate 0
clearance 0
are 0
linked 0
. 0

Account 0
was 0
taken 0
of 0
noncellular 0
and 0
nonhuman 0
elements 0
in 0
the 0
smears 0
; 0
they 0
included 0
mucus 0
, 0
Charcot 0
- 0
Layden 0
crystals 0
, 0
pollen 0
grains 0
, 0
vegetal 0
fragments 0
and 0
fungi 0
. 0

The 0
results 0
indicate 0
that 0
the 0
carbon 0
- 0
perfused 0
areas 0
and 0
MBF 0
in 0
the 0
liver 0
, 0
renal 0
cortex 0
, 0
spleen 0
, 0
and 0
small 0
intestinal 0
serosa 0
( 0
only 0
MBF 0
) 0
increased 0
significantly 0
5 0
h 0
after 0
CLP 0
. 0

In 0
addition 0
a 0
greater 0
proportion 0
of 0
women 0
in 0
the 0
sweeping 0
group 0
had 0
a 0
cervical 0
dilatation 0
of 0
4 0
cm 0
or 0
more 0
at 0
the 0
first 0
vaginal 0
examination 0
in 0
the 0
labour 0
ward 0
( 0
16/33 0
( 0
49 0
% 0
) 0
vs 0
5/32 0
( 0
16 0
% 0
) 0
; 0
OR 0
4.39 0
; 0
95 0
% 0
CI 0
1.56 0
to 0
12.32 0
; 0
P 0
= 0
0.005 0
) 0
. 0

Lewis 0
, 0
N 0
. 0

A 0
control 0
group 0
of 0
nine 0
women 0
( 0
age 0
23 0
- 0
40 0
years 0
) 0
on 0
oral 0
contraceptives 0
( 0
Nordette 0
- 0
28 0
) 0
was 0
also 0
studied 0
four 0
times 0
during 0
a 0
pill 0
cycle 0
. 0

This 0
accurate 0
and 0
rapid 0
method 0
makes 0
the 0
MLPA 0
test 0
logistically 0
feasible 0
for 0
large 0
- 0
scale 0
screening 0
. 0

The 0
modalities 0
for 0
using 0
reference 0
values 0
for 0
individual 0
subjects 0
as 0
well 0
as 0
for 0
groups 0
are 0
then 0
discussed 0
and 0
the 0
main 0
points 0
of 0
research 0
which 0
must 0
be 0
faced 0
in 0
the 0
near 0
future 0
regarding 0
reference 0
values 0
are 0
highlighted 0
. 0

The 0
clinical 0
application 0
of 0
the 0
antibody 0
- 0
targeted 0
Phthalocyanine 0
was 0
performed 0
in 0
3 0
patients 0
suffering 0
from 0
an 0
advanced 0
ovarian 0
carcinoma 0
( 0
FIGO 0
III 0
) 0
. 0

We 0
found 0
that 0
lung 0
cancer 0
tissues 0
of 0
positive 0
67Ga 0
scan 0
expressed 0
TFR B-gene
, 0
but 0
those 0
of 0
a 0
negative 0
scan 0
did 0
not 0
. 0

This 0
open 0
reading 0
frame 0
was 0
confirmed 0
the 0
correct 0
one 0
by 0
direct 0
amino 0
- 0
terminal 0
sequence 0
analysis 0
of 0
the 0
overproduced 0
msgB B-gene
gene I-gene
product I-gene
. 0

In 0
this 0
study 0
, 0
we 0
purified 0
and 0
characterized 0
the 0
recombinant B-gene
furin I-gene
from 0
the 0
conditioned 0
medium 0
of 0
these 0
cells 0
. 0

The 0
virus 0
encodes 0
a 0
40 0
- 0
kDa 0
protein 0
, 0
tax B-gene
, 0
that 0
is 0
important 0
for 0
the 0
immortalization 0
of 0
T 0
cells 0
. 0

However 0
, 0
butyrate 0
was 0
at 0
least 0
2 0
- 0
fold 0
more 0
effective 0
in 0
stimulating 0
CAT B-gene
activity 0
of 0
fusion 0
genes 0
containing 0
upstream 0
sequences 0
( 0
- 0
834 0
to 0
- 0
576 0
) 0
than 0
those 0
containing 0
proximal 0
sequences 0
( 0
- 0
456 0
to 0
- 0
172 0
) 0
, 0
suggesting 0
two 0
regions 0
in 0
the 0
PSG1 B-gene
- I-gene
I I-gene
gene I-gene
that 0
mediate 0
the 0
butyrate 0
response 0
. 0

An 0
examination 0
of 0
the 0
role 0
of 0
the 0
carboxyl 0
terminus 0
in 0
regulating 0
NGFI B-gene
- I-gene
B I-gene
transcriptional 0
activity 0
revealed 0
that 0
, 0
in 0
accordance 0
with 0
other 0
nuclear 0
receptors 0
, 0
mutants 0
lacking 0
portions 0
of 0
the 0
carboxyl 0
terminus 0
had 0
greatly 0
decreased 0
activity 0
. 0

Altogether 0
these 0
results 0
indicate 0
that 0
the 0
Syn B-gene
5 I-gene
locus I-gene
segregates 0
from 0
the 0
gene 0
specifying 0
gH B-gene
, 0
to 0
a 0
region 0
encompassing 0
portions 0
of 0
the 0
TK B-gene
and 0
UL B-gene
24 I-gene
genes I-gene
, 0
and 0
that 0
the 0
syn B-gene
mutation I-gene
does 0
not 0
affect 0
the 0
expression 0
or 0
activity 0
of 0
TK B-gene
. 0

Nucleoprotein 0
( 0
N 0
) 0
expressed 0
by 0
both 0
recombinant 0
vaccinia 0
virus 0
and 0
TGEV 0
had 0
a 0
relative 0
molecular 0
mass 0
( 0
Mr 0
) 0
of 0
47,000 0
and 0
was 0
susceptible 0
to 0
degradation 0
at 0
the 0
C 0
- 0
terminus 0
yielding 0
discrete 0
breakdown 0
products 0
. 0

Recently 0
, 0
the 0
3.6 B-gene
- I-gene
kb I-gene
full I-gene
- I-gene
length I-gene
alpha I-gene
- I-gene
GalNAc I-gene
cDNA I-gene
sequence I-gene
was 0
isolated 0
and 0
found 0
to 0
have 0
remarkable 0
nucleotide 0
and 0
predicted 0
amino 0
acid 0
homology 0
( 0
55.8 0
and 0
46.9 0
% 0
, 0
respectively 0
) 0
with 0
the 0
human B-gene
alpha I-gene
- I-gene
galactosidase I-gene
A I-gene
( 0
alpha B-gene
- I-gene
Gal I-gene
A I-gene
) 0
cDNA 0
. 0

Patients 0
with 0
an 0
enzymatic 0
activity 0
below 0
X 0
- 0
- 0
1 0
manifested 0
a 0
decrease 0
of 0
the 0
content 0
of 0
IgA B-gene
, 0
IgG B-gene
, 0
IgM B-gene
, 0
T 0
and 0
B 0
lymphocytes 0
, 0
and 0
of 0
phagocytic 0
activity 0
of 0
neutrophils 0
as 0
compared 0
to 0
patients 0
exhibiting 0
a 0
high 0
enzymatic 0
activity 0
. 0

The 0
reason 0
that 0
nitrous 0
oxide 0
does 0
not 0
produce 0
hydroxyl 0
radicals 0
readily 0
might 0
be 0
that 0
the 0
one 0
- 0
electron 0
reduction 0
proceeds 0
through 0
an 0
N2O 0
- 0
intermediate 0
which 0
is 0
energetically 0
very 0
unfavourable 0
: 0
EO 0
( 0
N2O/N2O 0
- 0
) 0
= 0
- 0
1.1 0
V 0
. 0

All 0
mutant B-gene
JCV I-gene
T I-gene
antigens I-gene
bound 0
to 0
JCV 0
and 0
SV40 0
origins 0
of 0
DNA 0
replication 0
. 0

The 0
relation 0
between 0
myocardial B-gene
beta I-gene
- I-gene
adrenergic I-gene
receptor I-gene
and 0
left 0
ventricular 0
( 0
LV 0
) 0
function 0
was 0
studied 0
in 0
10 0
patients 0
, 0
aged 0
41 0
to 0
61 0
years 0
( 0
average 0
51 0
) 0
, 0
with 0
LV 0
volume 0
overload 0
mainly 0
due 0
to 0
chronic 0
mitral 0
regurgitation 0
. 0

Since 0
each 0
transcript 0
appears 0
to 0
encode 0
the 0
same 0
protein 0
, 0
this 0
complexity 0
may 0
reflect 0
the 0
need 0
for 0
lineage 0
- 0
specific 0
or 0
differentiation 0
- 0
dependent 0
control 0
of 0
expression 0
. 0

In 0
patients 0
with 0
limited 0
disease 0
, 0
the 0
survival 0
in 0
the 0
alternating 0
arm 0
was 0
significantly 0
superior 0
to 0
the 0
survival 0
in 0
the 0
CAV 0
arm 0
( 0
P 0
= 0
.014 0
) 0
or 0
the 0
survival 0
in 0
the 0
PE 0
arm 0
( 0
P 0
= 0
.023 0
) 0
. 0

We 0
identify 0
the 0
`` 0
M 0
region 0
'' 0
of 0
the B-gene
muscle I-gene
- I-gene
specific I-gene
Xenopus I-gene
cardiac I-gene
actin I-gene
gene I-gene
promoter I-gene
from 0
- 0
282 0
to 0
- 0
348 0
as 0
necessary 0
for 0
the 0
embryonic 0
expression 0
of 0
a 0
cardiac B-gene
actin I-gene
actin I-gene
- I-gene
beta I-gene
- I-gene
globin I-gene
reporter 0
gene 0
injected 0
into 0
fertilized 0
eggs 0
. 0

In 0
addition 0
to 0
the 0
previously 0
identified 0
and 0
characterized 0
attenuator B-gene
1 I-gene
situated 0
93 0
nucleotides 0
downstream 0
from 0
the 0
major 0
late 0
transcription 0
start 0
site 0
, 0
a 0
second 0
attenuator 0
, 0
attenuator B-gene
2 I-gene
, 0
situated 0
55 0
nucleotides 0
downstream 0
from 0
it 0
, 0
has 0
been 0
identified 0
. 0

EBNA B-gene
- I-gene
2 I-gene
and 0
the 0
cis 0
- 0
acting 0
CD23 B-gene
element I-gene
increased 0
TK B-gene
- 0
promoted 0
mRNA 0
and 0
did 0
not 0
alter 0
the 0
herpes B-gene
simplex I-gene
virus I-gene
TK I-gene
promoter I-gene
transcription I-gene
start I-gene
site I-gene
. 0

These 0
experiments 0
delineate 0
a 0
186 0
- 0
bp 0
, 0
EBNA B-gene
- I-gene
2 I-gene
- 0
responsive 0
cell 0
DNA 0
fragment 0
and 0
provide 0
firm 0
evidence 0
that 0
EBNA B-gene
- I-gene
2 I-gene
transactivates 0
transcription 0
of 0
cell 0
genes 0
. 0

Plasma 0
vitamin 0
E 0
, 0
total 0
lipids 0
and 0
myeloperoxidase B-gene
levels 0
during 0
spinal 0
surgery 0
. 0

Transfecting 0
the 0
cloned 0
bovine 0
PBR/IBP B-gene
cDNA 0
into 0
COS 0
- 0
7 0
cells 0
resulted 0
in 0
an 0
11 0
- 0
fold 0
increase 0
in 0
the 0
density 0
of 0
high 0
affinity 0
[ 0
3H 0
] 0
PK 0
11195 0
binding 0
sites 0
which 0
had 0
only 0
low 0
affinity 0
for 0
Ro5 0
- 0
4864 0
. 0

The 0
initial 0
phase 0
of 0
increased 0
vascular 0
permeability 0
in 0
the 0
peritoneal 0
cavity 0
and 0
LTB4 0
production 0
was 0
dose 0
dependently 0
inhibited 0
by 0
the 0
5 0
- 0
LO 0
inhibitors 0
phenidone 0
, 0
BW 0
A4C 0
, 0
A63162 0
, 0
and 0
ICI 0
207 0
968 0
but 0
not 0
by 0
dexamethasone 0
or 0
colchicine 0
. 0

Discrepant 0
results 0
with 0
a 0
latex 0
agglutination 0
test 0
in 0
the 0
assessment 0
of 0
cytomegalovirus 0
antibody 0
status 0
of 0
cardiac 0
transplant 0
donors 0
. 0

Each 0
mRNA 0
contained 0
five 0
or 0
six 0
internal 0
uridine 0
residues 0
, 0
which 0
were 0
transcribed 0
using 0
a 0
mixture 0
of 0
UTP 0
and 0
thio 0
- 0
UTP 0
. 0

We 0
have 0
isolated 0
and 0
sequenced 0
two 0
overlapping 0
cDNA 0
fragments 0
which 0
could 0
encode 0
the 0
complete 0
amino 0
acid 0
sequence 0
of 0
rat B-gene
testis I-gene
fructose I-gene
- I-gene
6 I-gene
- I-gene
phosphate,2 I-gene
- I-gene
kinase I-gene
: 0
fructose B-gene
- I-gene
2,6 I-gene
- I-gene
bisphosphatase I-gene
. 0

We 0
have 0
identified 0
SWI5 B-gene
's 0
nuclear 0
localization 0
signal 0
( 0
NLS 0
) 0
and 0
show 0
that 0
it 0
can 0
confer 0
cell 0
cycle 0
- 0
dependent 0
nuclear 0
entry 0
to 0
a 0
heterologous 0
protein 0
. 0

In 0
contrast 0
to 0
behavioral 0
deviation 0
( 0
the 0
avoidance 0
conditioning 0
lost 0
) 0
, 0
the 0
haloperidol 0
intrastriatal 0
microinjections 0
did 0
not 0
affect 0
the 0
DA 0
synaptic 0
level 0
in 0
rostral 0
neostriatum 0
. 0

In 0
similar 0
transient 0
transfection 0
experiments 0
in 0
HeLa 0
cells 0
, 0
overexpression 0
of 0
the 0
wt B-gene
human I-gene
retinoblastoma I-gene
susceptibility I-gene
gene I-gene
product I-gene
, 0
RB B-gene
, 0
was 0
found 0
to 0
repress 0
the 0
serum 0
- 0
induced 0
IL B-gene
- I-gene
6 I-gene
( 0
- 0
225 0
to 0
+13 0
) 0
, 0
c B-gene
- I-gene
fos I-gene
( 0
- 0
711 0
to 0
+42 0
) 0
, 0
and 0
beta B-gene
- I-gene
actin I-gene
( 0
- 0
3400 0
to 0
+912 0
) 0
promoters 0
but 0
not 0
the 0
PRV 0
- 0
induced 0
IL B-gene
- I-gene
6 I-gene
( 0
- 0
110 0
to 0
+13 0
) 0
or 0
the 0
serum 0
- 0
induced 0
MHC B-gene
( 0
- 0
528 0
to 0
- 0
38 0
) 0
promoters 0
. 0

This 0
repression 0
was 0
mediated 0
through 0
binding 0
to 0
the 0
E2 B-gene
DNA I-gene
- I-gene
binding I-gene
site I-gene
immediately 0
upstream 0
of 0
the 0
P105 B-gene
promoter 0
TATA 0
box 0
and 0
could 0
be 0
abrogated 0
by 0
preincubation 0
of 0
the 0
HPV B-gene
- I-gene
18 I-gene
P105 I-gene
promoter I-gene
template 0
with 0
the 0
nuclear 0
extract 0
allowing 0
the 0
formation 0
of 0
the 0
preinitiation 0
complex 0
. 0

We 0
did 0
not 0
detect 0
p50 B-gene
in 0
association 0
with 0
native B-gene
glucocorticoid I-gene
receptor I-gene
in 0
L 0
cells 0
or 0
with 0
the 0
overexpressed 0
glucocorticoid B-gene
receptor I-gene
in 0
Chinese 0
hamster 0
ovary 0
cells 0
. 0

Two 0
putative 0
12 0
- 0
O 0
- 0
tetradecanoyl 0
- 0
phorbol 0
- 0
13 0
- 0
acetate 0
( 0
TPA 0
) 0
response 0
elements 0
, 0
that 0
might 0
serve 0
as 0
binding 0
sites 0
for 0
the 0
transcription B-gene
factor I-gene
AP I-gene
- I-gene
1 I-gene
and 0
a 0
consensus 0
sequence 0
of 0
a 0
transforming B-gene
growth I-gene
factor I-gene
beta I-gene
1 I-gene
( 0
TGF B-gene
- I-gene
beta I-gene
1 I-gene
) 0
inhibitory 0
element 0
were 0
found 0
in 0
the 0
promoter 0
region 0
. 0

TPA 0
and 0
TGF B-gene
- I-gene
beta I-gene
1 I-gene
did 0
not 0
markedly 0
affect 0
the 0
activities 0
of 0
the 0
72 0
- 0
kDa 0
enzyme 0
. 0

They 0
were 0
almost 0
regularly 0
excited 0
by 0
pressure 0
to 0
the 0
ipsilateral 0
cornea 0
or 0
to 0
both 0
corneas 0
at 0
a 0
strength 0
well 0
above 0
the 0
human 0
corneal 0
pain 0
threshold 0
. 0

Feed 0
intake 0
was 0
not 0
affected 0
by 0
dietary 0
KCl 0
or 0
NaHCO3 0
supplementation 0
, 0
but 0
average 0
daily 0
gain 0
increased 0
with 0
increased 0
K 0
and 0
tended 0
to 0
be 0
reduced 0
by 0
dietary 0
NaHCO3 0
. 0

Extraction 0
procedure 0
for 0
the 0
measurement 0
of 0
butyltin 0
compounds 0
in 0
biological 0
tissues 0
using 0
toluene 0
, 0
HBr 0
, 0
and 0
tropolone 0
. 0

In 0
this 0
study 0
, 0
we 0
have 0
cloned 0
a 0
region 0
that 0
complements 0
the 0
exoenzyme B-gene
S I-gene
- 0
deficient 0
phenotype 0
of 0
strain 0
388 0
exs1 B-gene
: 0
:Tn1 B-gene
, 0
a 0
chromosomal B-gene
Tn1 I-gene
insertional I-gene
mutation I-gene
. 0

axl 0
, 0
a 0
transforming 0
gene 0
isolated 0
from 0
primary 0
human 0
myeloid 0
leukemia 0
cells 0
, 0
encodes 0
a 0
novel 0
receptor B-gene
tyrosine I-gene
kinase I-gene
. 0

Alignment 0
of 0
the 0
amino 0
acid 0
sequences 0
surrounding 0
Tyr 0
- 0
766 0
with 0
corresponding 0
regions 0
of 0
other 0
FGFRs B-gene
revealed 0
conserved 0
tyrosine 0
residues 0
in 0
all 0
known 0
members 0
of 0
the 0
FGFR B-gene
family I-gene
. 0

The 0
single 0
most 0
important 0
element 0
, 0
by 0
linker 0
- 0
scanning 0
analysis 0
, 0
is 0
a 0
10 0
- 0
bp 0
region 0
that 0
contains 0
a 0
CCAAT 0
motif 0
. 0

Capnography 0
curves 0
of 0
40 0
HVS 0
patients 0
, 0
40 0
non 0
- 0
HVS 0
patients 0
with 0
psycho 0
- 0
somatic 0
complaints 0
and 0
26 0
healthy 0
controls 0
were 0
analyzed 0
. 0

The 0
transcription 0
initiation 0
site 0
was 0
determined 0
to 0
occur 0
66 0
bp 0
upstream 0
of 0
the 0
initiating 0
Met 0
. 0

All 0
anti B-gene
- I-gene
I I-gene
and 0
anti B-gene
- I-gene
i I-gene
CA I-gene
were 0
shown 0
to 0
express 0
VH4 B-gene
heavy I-gene
chains I-gene
, 0
and 0
14 0
of 0
17 0
CA B-gene
expressed 0
a 0
previously 0
described 0
VH4 B-gene
second 0
hypervariable 0
region 0
determinant 0
, 0
termed 0
VH4 B-gene
- I-gene
HV2a I-gene
. 0

Intron 0
K1 B-gene
cox1.2 I-gene
is 0
not 0
found 0
in 0
S. 0
cerevisiae 0
and 0
appears 0
at 0
an 0
unique 0
location 0
in 0
K. 0
lactis 0
. 0

We 0
have 0
determined 0
that 0
the 0
mutants 0
define 0
two 0
complementation 0
groups 0
, 0
designated 0
cgs1+ B-gene
and 0
cgs2+ B-gene
( 0
continues 0
to 0
grow 0
in 0
stationary 0
) 0
. 0

However 0
, 0
alterations 0
in 0
electrostatic 0
and 0
hydrophobic 0
interactions 0
created 0
by 0
the 0
three 0
amino 0
acid 0
substitutions 0
prevent 0
the 0
conformational 0
change 0
in 0
the 0
enzyme 0
usually 0
produced 0
by 0
calmodulin B-gene
binding 0
. 0

The 0
results 0
of 0
induced 0
coexpression 0
were 0
also 0
supported 0
by 0
rapid 0
generation 0
of 0
FeLV 0
recombinants 0
when 0
FeLV 0
- 0
C 0
was 0
used 0
to 0
infect 0
the 0
feline 0
3201B 0
cell 0
line 0
that 0
constitutively 0
expresses 0
high 0
levels 0
of 0
endogenous 0
FeLV 0
- 0
specific 0
mRNAs 0
. 0

Recombination 0
between 0
feline 0
leukemia 0
virus 0
subgroup 0
B 0
or 0
C 0
and 0
endogenous 0
env B-gene
elements 0
alters 0
the 0
in 0
vitro 0
biological 0
activities 0
of 0
the 0
viruses 0
. 0

The 0
nucleotide 0
sequences 0
at 0
the 0
5 0
' 0
and 0
3 0
' 0
ends 0
of 0
these 0
introns 0
are 0
characteristic 0
of 0
spliced 0
transcripts 0
from 0
eukaryotic 0
protein 0
- 0
encoding 0
genes 0
, 0
with 0
one 0
significant 0
difference 0
; 0
i.e. 0
, 0
the 0
5 0
' 0
end 0
of 0
the 0
LAT B-gene
intron I-gene
is 0
GC 0
instead 0
of 0
the 0
consensus 0
sequence 0
GT 0
. 0

At 0
1 0
, 0
5 0
, 0
and 0
9 0
months 0
after 0
initial 0
isolation 0
of 0
C. 0
kutscheri 0
from 0
the 0
oral 0
cavity 0
, 0
hamsters 0
were 0
euthanatized 0
, 0
and 0
attempts 0
were 0
made 0
to 0
culture 0
C. 0
kutscheri 0
from 0
13 0
additional 0
sites 0
. 0

The 0
strategy 0
has 0
been 0
used 0
to 0
determine 0
2.6 0
kilobases 0
of 0
nucleotide 0
sequence 0
in 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
ADE I-gene
1 I-gene
locus I-gene
. 0

Two 0
independent 0
promoters 0
as 0
well 0
as 0
5 0
' 0
untranslated 0
regions 0
regulate 0
Dd B-gene
ras I-gene
expression 0
in 0
Dictyostelium 0
. 0

The 0
results 0
suggested 0
that 0
, 0
depending 0
upon 0
the 0
cell 0
type 0
, 0
gene 0
cotransfer 0
using 0
aminoglycoside 0
resistance 0
as 0
a 0
selectable 0
marker 0
may 0
seriously 0
perturb 0
important 0
cellular 0
control 0
mechanisms 0
such 0
as 0
the 0
PKC B-gene
pathway 0
leading 0
to 0
activation 0
of 0
gene 0
expression 0
. 0

Transfer 0
RNA 0
genes 0
from 0
Dictyostelium 0
discoideum 0
are 0
frequently 0
associated 0
with 0
repetitive 0
elements 0
and 0
contain 0
consensus 0
boxes 0
in 0
their 0
5 0
' 0
and 0
3' 0
- 0
flanking 0
regions 0
. 0

Therefore 0
, 0
the 0
strD B-gene
and 0
strE B-gene
genes I-gene
could 0
serve 0
as 0
universal 0
probes 0
indicative 0
of 0
the 0
presence 0
of 0
biosynthetic 0
capacity 0
for 0
6 0
- 0
deoxyhexose 0
moieties 0
. 0

The 0
two 0
genes 0
code 0
for 0
polypeptides B-gene
of I-gene
420 I-gene
amino I-gene
acids I-gene
( I-gene
M.HgiCI I-gene
) I-gene
and 0
345 B-gene
amino I-gene
acids I-gene
( I-gene
R.HgiCI I-gene
) I-gene
. 0

Expression 0
of 0
the 0
wt1 B-gene
gene I-gene
via 0
transient 0
transfection 0
in 0
COS 0
- 0
1 0
cells 0
revealed 0
a 0
52 0
kDa 0
protein 0
which 0
was 0
immunoprecipitated 0
by 0
both 0
the 0
N 0
- 0
terminal 0
- 0
and 0
C 0
- 0
terminal 0
- 0
specific 0
antisera 0
. 0

The 0
factor 0
which 0
binds 0
to 0
the 0
TR B-gene
promoter I-gene
co 0
- 0
sedimented 0
with 0
SV40 0
chromosomes 0
extracted 0
late 0
in 0
infection 0
. 0

Temafloxacin 0
400 0
mg 0
b.i.d 0
. 0
administered 0
orally 0
for 0
28 0
days 0
represents 0
a 0
safe 0
and 0
effective 0
treatment 0
for 0
chronic 0
bacterial 0
prostatitis 0
. 0

Its 0
neuromuscular 0
effects 0
are 0
similar 0
to 0
a 0
single 0
ED90 0
dose 0
of 0
vecuronium 0
. 0

The 0
patient 0
with 0
a 0
prolonged 0
fever 0
caused 0
by 0
dissecting 0
aneurysm 0
of 0
the 0
aorta 0
in 0
whom 0
pleuropneumonia 0
masked 0
the 0
real 0
diseases 0
has 0
been 0
presented 0
. 0

The 0
resulting 0
clone 0
pKB11 B-gene
, 0
which 0
has 0
a 0
1369 0
- 0
base 0
pair 0
( 0
bp 0
) 0
cDNA 0
insert 0
, 0
overlapping 0
pCAD142 B-gene
by 0
781 0
bp 0
, 0
was 0
identified 0
by 0
hybridization 0
methods 0
and 0
sequence 0
analysis 0
and 0
found 0
to 0
contain 0
the 0
entire 0
cDNA 0
sequence 0
for 0
the 0
amino 0
end 0
of 0
the 0
CAD B-gene
polypeptide I-gene
. 0

This 0
conclusion 0
was 0
confirmed 0
by 0
Northern 0
blotting 0
analysis 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
CAD B-gene
gene I-gene
. 0

We 0
report 0
the 0
isolation 0
of 0
genomic 0
and 0
cDNA 0
clones 0
of 0
the 0
light 0
- 0
independent 0
Sn B-gene
: I-gene
bol3 I-gene
allele I-gene
. 0

Histamine 0
- 0
2 0
blockade 0
in 0
psoriasis 0

Its 0
clearance 0
has 0
been 0
found 0
to 0
be 0
decreased 0
( 0
typically 0
by 0
around 0
25 0
% 0
, 0
but 0
often 0
by 0
far 0
more 0
) 0
by 0
erythromycin 0
, 0
troleandomycin 0
( 0
triacetyloleandomycin 0
) 0
, 0
roxithromycin 0
, 0
enoxacin 0
, 0
ciprofloxacin 0
, 0
pefloxacin 0
, 0
norfloxacin 0
, 0
ofloxacin 0
, 0
fluoroquinolone 0
T 0
- 0
3262 0
, 0
pipemidic 0
acid 0
, 0
cimetidine 0
, 0
etintidine 0
, 0
propranolol 0
, 0
verapamil 0
, 0
diltiazem 0
, 0
nifedipine 0
, 0
furosemide 0
( 0
frusemide 0
) 0
, 0
at 0
least 0
some 0
anovulent 0
agents 0
, 0
viloxazine 0
, 0
allopurinol 0
, 0
ticlopidine 0
, 0
idrocilamide 0
, 0
thiabendazole 0
, 0
disulfiram 0
, 0
influenza 0
- 0
and 0
BCG 0
- 0
vaccination 0
, 0
interferon B-gene
, 0
and 0
caffeine 0
( 0
half 0
- 0
life 0
increase 0
) 0
. 0

A 0
third 0
is 0
a 0
partial 0
element 0
terminating 0
at 0
a 0
probable 0
internal 0
restriction 0
site 0
used 0
for 0
cloning 0
. 0

We 0
enrolled 0
253 0
HIV B-gene
- I-gene
antibody I-gene
positive 0
heroin 0
addicts 0
without 0
HIV 0
- 0
related 0
disease 0
( 0
n 0
= 0
81 0
) 0
or 0
with 0
persistent 0
generalized 0
lymphadenopathy 0
( 0
n 0
= 0
172 0
) 0
in 0
a 0
prospective 0
study 0
to 0
evaluate 0
clinical 0
progression 0
to 0
AIDS 0
related 0
complex 0
( 0
ARC 0
) 0
or 0
AIDS 0
and 0
to 0
identify 0
factors 0
of 0
possible 0
prognostic 0
relevance 0
. 0

No 0
homology 0
was 0
found 0
between 0
RNA14 B-gene
and 0
RNA15 B-gene
or 0
between 0
RNA14 B-gene
and 0
other 0
proteins 0
contained 0
in 0
data 0
banks 0
. 0

Mutations 0
in 0
the 0
yeast B-gene
RNA14 I-gene
and 0
RNA15 B-gene
genes I-gene
result 0
in 0
an 0
abnormal 0
mRNA 0
decay 0
rate 0
; 0
sequence 0
analysis 0
reveals 0
an 0
RNA 0
- 0
binding 0
domain 0
in 0
the 0
RNA15 B-gene
protein I-gene
. 0

Myocardial 0
infarction 0
in 0
patients 0
with 0
previous 0
bypass 0
surgery 0
. 0

The 0
most 0
striking 0
difference 0
in 0
the 0
birch B-gene
NAD I-gene
( I-gene
P I-gene
) I-gene
H I-gene
- I-gene
NR I-gene
sequence I-gene
in 0
comparison 0
to 0
NADH B-gene
- I-gene
NR I-gene
sequences I-gene
was 0
found 0
at 0
the 0
putative 0
pyridine 0
nucleotide 0
binding 0
site 0
. 0

A 0
single 0
amino 0
acid 0
difference 0
in 0
the 0
C 0
- 0
terminal 0
region 0
influences 0
dominant 0
negative 0
activity 0
and 0
receptor 0
dimer 0
formation 0
. 0

No 0
such 0
benefits 0
were 0
seen 0
for 0
children 0
with 0
CD4+ B-gene
counts 0
below 0
0.2 0
x 0
10 0
( 0
9 0
) 0
per 0
liter 0
at 0
entry 0
. 0

Because 0
the 0
human B-gene
Antp I-gene
TATAA I-gene
binding I-gene
protein I-gene
is 0
expressed 0
in 0
both 0
lymphoid 0
and 0
non 0
- 0
lymphoid 0
cells 0
, 0
we 0
suggest 0
that 0
this 0
homeobox B-gene
gene I-gene
has 0
evolved 0
a 0
more 0
general 0
transcriptional 0
regulatory 0
function 0
in 0
higher 0
eukaryotic 0
cells 0
. 0

The 0
95 0
% 0
confidence 0
values 0
( 0
2SD 0
) 0
for 0
the 0
change 0
in 0
Ros 0
required 0
to 0
exclude 0
natural 0
variability 0
were 0
0.39 0
, 0
0.50 0
and 0
0.53 0
cmH2O 0
l 0
- 0
1 0
s 0
, 0
respectively 0
. 0

Among 0
953 0
infants 0
in 0
22 0
neonatal 0
care 0
units 0
studied 0
, 0
23 0
% 0
( 0
median 0
value 0
, 0
range 0
0 0
- 0
78 0
) 0
were 0
found 0
to 0
be 0
faecally 0
colonized 0
with 0
one 0
of 0
21 0
distinct 0
nosocomial 0
strains 0
of 0
Escherichia 0
coli 0
, 0
Klebsiella 0
or 0
Enterobacter 0
spp 0
. 0

Biochemical 0
studies 0
revealed 0
the 0
expected 0
loss 0
of 0
ChAT B-gene
activity 0
in 0
the 0
dorsal 0
and 0
ventral 0
hippocampi 0
of 0
lesioned 0
animals 0
along 0
with 0
elevated 0
levels 0
of 0
norepinephrine 0
( 0
NE 0
) 0
in 0
the 0
dorsal 0
hippocampus 0
of 0
MS/HSI 0
animals 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

The 0
localization 0
of 0
this 0
proteoglycan 0
locus 0
in 0
the 0
human 0
genome 0
and 0
the 0
availability 0
of 0
new 0
RFLPs 0
provide 0
the 0
tools 0
for 0
future 0
studies 0
of 0
human 0
diseases 0
where 0
the 0
HSPG2 B-gene
proteoglycan I-gene
gene I-gene
is 0
suspected 0
to 0
be 0
involved 0
. 0

After 0
2 0
min 0
of 0
dobutamine 0
injection 0
, 0
or 0
after 0
20 0
min 0
of 0
pimobendan 0
injection 0
, 0
the 0
myocardium 0
was 0
removed 0
, 0
and 0
used 0
for 0
determination 0
of 0
the 0
tissue 0
levels 0
of 0
metabolites 0
of 0
energy 0
and 0
carbohydrate 0
metabolism 0
. 0

During 0
coronary 0
stenosis 0
, 0
on 0
the 0
contrary 0
, 0
intracoronary 0
procaterol 0
at 0
the 0
same 0
dose 0
significantly 0
deteriorated 0
regional 0
myocardial 0
dysfunction 0
without 0
changing 0
LCX 0
flow 0
, 0
global 0
hemodynamics 0
and 0
cardiac 0
lactate 0
metabolism 0
. 0

Here 0
we 0
present 0
evidence 0
that 0
major B-gene
IE I-gene
proteins I-gene
IE86 B-gene
, 0
IE72 B-gene
, 0
and 0
IE55 B-gene
are 0
capable 0
of 0
trans 0
- 0
activating 0
the 0
HIV B-gene
LTR I-gene
in 0
a 0
T 0
- 0
cell 0
line 0
, 0
HUT 0
- 0
78 0
. 0

In 0
a 0
country 0
where 0
general 0
HIV 0
prevalence 0
is 0
low 0
, 0
the 0
strategy 0
is 0
cost 0
- 0
effective 0
for 0
location 0
and 0
counselling 0
of 0
unknowingly 0
seropositive 0
individuals 0
. 0

The 0
cis 0
- 0
acting 0
element 0
mediating 0
glucocorticoid 0
inducibility 0
of 0
the 0
chicken B-gene
glutamine I-gene
synthetase I-gene
gene I-gene
has 0
been 0
identified 0
. 0

However 0
, 0
the 0
increase 0
in 0
biliary 0
excretion 0
did 0
not 0
compensate 0
for 0
the 0
reduced 0
elimination 0
of 0
bretylium 0
and 0
hexylsalicylic 0
acid 0
via 0
the 0
kidney 0
. 0

Diagnostic 0
value 0
of 0
cerebrospinal B-gene
fluid I-gene
immunoglobulin I-gene
G I-gene
( 0
IgG B-gene
) 0
in 0
pediatric 0
neurological 0
diseases 0
. 0

Expression 0
of 0
six 0
genes 0
, 0
ipaB B-gene
, 0
ipaC B-gene
, 0
invE B-gene
, 0
invG B-gene
, 0
invJ B-gene
, 0
and 0
invK B-gene
, 0
was 0
apparently 0
regulated 0
by 0
the 0
positive 0
regulator 0
virF B-gene
. 0

Inducible 0
VT 0
was 0
suppressed 0
entirely 0
in 0
one 0
patient 0
. 0

Venkatesan 0
, 0
and 0
D 0
. 0

The 0
presence 0
of 0
the 0
corresponding 0
mature 0
mRNA 0
transcripts 0
( 0
3.2 0
- 0
3.5 0
kilobase 0
pairs 0
( 0
kb 0
] 0
in 0
human 0
fibroblasts 0
was 0
shown 0
by 0
Northern 0
blot 0
hybridization 0
, 0
S1 B-gene
nuclease I-gene
protection 0
assay 0
, 0
and 0
the 0
polymerase 0
chain 0
reaction 0
. 0

Approximately 0
50 0
% 0
of 0
the 0
ribosomal 0
DNA 0
( 0
rDNA 0
) 0
units 0
of 0
Drosophila 0
melanogaster 0
are 0
inactivated 0
by 0
two 0
different 0
28 B-gene
S I-gene
RNA I-gene
ribosomal I-gene
gene I-gene
insertions 0
( 0
type 0
I 0
and 0
type 0
II 0
) 0
. 0

Gap B-gene
b3 I-gene
consists 0
of 0
two 0
polypeptide 0
chains 0
( 0
Mr 0
= 0
110,000 0
and 0
30,000 0
) 0
, 0
which 0
seem 0
to 0
be 0
proteolytic 0
cleavage 0
products 0
connected 0
by 0
disulfide 0
bonds 0
from 0
a 0
precursor 0
protein 0
. 0

However 0
, 0
the 0
rtFc B-gene
gamma I-gene
R I-gene
alpha I-gene
cDNA I-gene
clone 0
is 0
complementary 0
to 0
at 0
least 0
two 0
different 0
- 0
sized 0
mRNAs 0
expressed 0
by 0
CRNK 0
- 0
16 0
cells 0
, 0
contrasting 0
the 0
single 0
Fc B-gene
gamma I-gene
R I-gene
- I-gene
related I-gene
mRNA I-gene
species 0
expressed 0
by 0
human 0
and 0
mouse 0
natural 0
killer 0
cells 0
. 0

Both 0
genes 0
comprise 0
three 0
exons 0
, 0
two 0
introns 0
and 0
an 0
unusually 0
long 0
3' 0
- 0
untranslated 0
region 0
( 0
3.2 0
kilobase 0
pairs 0
) 0
, 0
specificying 0
a 0
mRNA 0
of 0
approximately 0
4.1 0
kilobases 0
. 0

Stable 0
expression 0
of 0
the 0
chimeric 0
alpha B-gene
i I-gene
( I-gene
54 I-gene
) I-gene
/s I-gene
polypeptide 0
in 0
Chinese 0
hamster 0
ovary 0
( 0
CHO 0
) 0
cells 0
constitutively 0
increased 0
both 0
cAMP 0
synthesis 0
and 0
cAMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
activity 0
. 0

This 0
exon 0
, 0
here 0
named 0
exon 0
0 0
, 0
contained 0
the 0
entire 0
5 0
' 0
untranslated 0
region 0
and 0
the 0
N 0
- 0
terminal 0
signal 0
sequence 0
of 0
the 0
polypeptide 0
. 0

Treatment 0
of 0
human 0
myeloid 0
cell 0
lines 0
HL 0
- 0
60 0
and 0
U937 0
with 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
( 0
PMA 0
) 0
increased 0
within 0
2 0
h 0
cellular 0
levels 0
of 0
the 0
RNA 0
hybridizable 0
to 0
LD78 B-gene
cDNA I-gene
. 0

A 0
new 0
, 0
flexible 0
fiberoptic 0
ventriculoscope 0
for 0
observation 0
of 0
the 0
ventricles 0
and 0
major 0
cisterns 0
is 0
reported 0
. 0

Isopenicillin B-gene
N I-gene
isomerase I-gene
( 0
epimerase B-gene
) 0
has 0
been 0
purified 0
from 0
Streptomyces 0
clavuligerus 0
, 0
and 0
the 0
amino 0
acid 0
sequence 0
of 0
the 0
N 0
- 0
terminus 0
has 0
been 0
determined 0
. 0

Serum 0
IgG B-gene
was 0
initially 0
elevated 0
in 0
6 0
patients 0
. 0

The 0
patient 0
initially 0
attained 0
complete 0
remission 0
( 0
CR1 0
) 0
with 0
conventional 0
chemotherapy 0
and 0
then 0
relapsed 0
14 0
months 0
later 0
. 0

157 0
+/ 0
- 0
16 0
mg/dl 0
; 0
NS 0
) 0
, 0
glucose 0
levels 0
, 0
and 0
basal 0
( 0
17 0
+/ 0
- 0
4 0
vs 0
. 0

Platelet 0
aggregation 0
and 0
metabolic 0
control 0
are 0
not 0
affected 0
by 0
calcium 0
antagonist 0
treatment 0
in 0
type 0
II 0
diabetes 0
mellitus 0
. 0

Wnt B-gene
- I-gene
1 I-gene
( 0
int B-gene
- I-gene
1 I-gene
) 0
is 0
a 0
cellular 0
oncogene 0
often 0
activated 0
by 0
insertion 0
of 0
proviral 0
DNA 0
of 0
the 0
mouse 0
mammary 0
tumor 0
virus 0
. 0

Induction 0
of 0
Jurkat 0
leukemic 0
T 0
cells 0
with 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
and 0
ionomycin 0
did 0
not 0
affect 0
the 0
level 0
of 0
FKBP B-gene
mRNA I-gene
. 0

GLUT5 B-gene
mRNA I-gene
is 0
expressed 0
at 0
highest 0
levels 0
in 0
small 0
intestine 0
and 0
at 0
much 0
lower 0
levels 0
in 0
kidney 0
, 0
skeletal 0
muscle 0
, 0
and 0
adipose 0
tissue 0
. 0

e 0
. 0

We 0
speculate 0
that 0
these 0
tumors 0
may 0
represent 0
congenital 0
hamartomatous 0
growths 0
. 0

Identification 0
and 0
characterization 0
of 0
the 0
promoter 0
for 0
the 0
cytotactin B-gene
gene I-gene
. 0

Surprisingly 0
, 0
there 0
is 0
no 0
sequence 0
homology 0
between 0
this 0
region 0
of 0
Ly B-gene
- I-gene
6E I-gene
and 0
the 0
established 0
consensus 0
for 0
the 0
interferon B-gene
- I-gene
stimulated I-gene
response I-gene
element I-gene
, 0
which 0
has 0
been 0
shown 0
functionally 0
important 0
to 0
all 0
previously 0
characterized 0
alpha/beta B-gene
interferon I-gene
- 0
inducible 0
promoters 0
. 0

Relatively 0
large 0
DNA 0
rearrangements 0
spanning 0
the 0
region 0
with 0
tandem 0
direct 0
repeats 0
encoding 0
the 0
carboxy 0
- 0
terminal 0
histone B-gene
H1 I-gene
- I-gene
like I-gene
structure 0
of 0
AlgP B-gene
were 0
detected 0
in 0
several 0
strains 0
upon 0
conversion 0
from 0
the 0
mucoid 0
to 0
the 0
nonmucoid 0
phenotype 0
. 0

( 0
1988 0
) 0
J 0
. 0

These 0
results 0
strongly 0
suggested 0
that 0
similar 0
, 0
if 0
not 0
identical 0
, 0
the 0
CArG B-gene
box I-gene
binding I-gene
proteins I-gene
interact 0
with 0
the 0
functionally 0
different 0
promoter 0
element 0
in 0
the 0
VLC1 B-gene
, 0
cardiac B-gene
alpha I-gene
- I-gene
actin I-gene
, 0
and 0
c B-gene
- I-gene
fos I-gene
genes I-gene
. 0

Polyadenylation 0
of 0
B4 B-gene
RNA I-gene
, 0
which 0
occurs 0
very 0
early 0
during 0
maturation 0
, 0
is 0
limited 0
to 0
150 0
residues 0
, 0
and 0
it 0
is 0
this 0
number 0
that 0
is 0
required 0
for 0
polysomal 0
recruitment 0
. 0

Co 0
- 0
existence 0
of 0
these 0
regulatory 0
elements 0
with 0
other 0
elements 0
, 0
such 0
as 0
the 0
AP B-gene
- I-gene
2 I-gene
element I-gene
or 0
CCAAT 0
box 0
, 0
was 0
also 0
found 0
. 0

Recently 0
, 0
studies 0
of 0
agents 0
that 0
disrupt 0
collagen B-gene
synthesis 0
and 0
deposition 0
have 0
yielded 0
several 0
new 0
angiogenesis 0
inhibitors 0
. 0

Since 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
this 0
gene 0
is 0
likely 0
involved 0
in 0
hormonal 0
regulation 0
of 0
its 0
expression 0
, 0
we 0
have 0
isolated 0
and 0
partially 0
characterized 0
an 0
avian 0
fatty B-gene
acid I-gene
synthase I-gene
gene 0
. 0

A 0
new 0
set 0
of 0
cDNA 0
clones 0
spanning 0
approximately 0
3.2 0
kb 0
was 0
isolated 0
from 0
a 0
lambda 0
- 0
ZAP 0
goose 0
liver 0
cDNA 0
library 0
using 0
the 0
5' 0
- 0
most 0
exon 0
- 0
containing 0
fragment 0
of 0
the 0
5' 0
- 0
most 0
genomic 0
DNA 0
clone 0
. 0

Northern 0
blotting 0
analysis 0
indicates 0
that 0
expression 0
of 0
the 0
genes 0
corresponding 0
to 0
these 0
clones 0
is 0
confined 0
to 0
pollen 0
tissue 0
. 0

Whereas 0
cDNA 0
hybridization 0
to 0
genomic 0
DNA 0
blots 0
indicated 0
a 0
small 0
subfamily 0
of 0
G0S19 B-gene
genes I-gene
, 0
simple 0
patterns 0
of 0
bands 0
indicated 0
that 0
most 0
cDNAs 0
, 0
including 0
G0S30 B-gene
cDNA I-gene
, 0
corresponded 0
to 0
single 0
- 0
copy 0
genes 0
. 0

Lymphoproliferative 0
disorders 0
arising 0
under 0
immunosuppression 0
with 0
FK 0
506 0
: 0
initial 0
observations 0
in 0
a 0
large 0
transplant 0
population 0
. 0

The 0
Drosophila B-gene
suppressor I-gene
of I-gene
sable I-gene
gene I-gene
encodes 0
a 0
polypeptide 0
with 0
regions 0
similar 0
to 0
those 0
of 0
RNA 0
- 0
binding 0
proteins 0
. 0

2:121 0
- 0
133 0
, 0
1988 0
) 0
. 0

It 0
is 0
, 0
however 0
, 0
extremely 0
homologous 0
to 0
a 0
third 0
'non 0
- 0
classical 0
' 0
gene 0
, 0
HLA B-gene
- I-gene
5.4 I-gene
, 0
and 0
to 0
the 0
chimpanzee 0
gene 0
, 0
Ch28 B-gene
. 0

Although 0
the 0
N13 0
- 0
N20 0
interpeak 0
interval 0
remained 0
stable 0
because 0
of 0
the 0
parallel 0
shift 0
of 0
the 0
2 0
peaks 0
, 0
the 0
central 0
conduction 0
time 0
measured 0
from 0
onset 0
latencies 0
of 0
N11 0
and 0
N20 0
significantly 0
increased 0
. 0

Using 0
avidin B-gene
- I-gene
biotin I-gene
complex 0
DNA 0
binding 0
assays 0
, 0
a 0
series 0
of 0
overlapping 0
alpha B-gene
promoter I-gene
DNA I-gene
sequences I-gene
between 0
- 0
170 0
to 0
29 0
basepairs 0
were 0
tested 0
, 0
but 0
each 0
failed 0
to 0
bind 0
GR B-gene
, 0
whereas 0
a 0
control 0
GRE 0
avidly 0
bound 0
receptor 0
. 0

Sequence 0
determination 0
of 0
isolated 0
peptides 0
suggested 0
that 0
Asn120 0
is 0
glycosylated 0
, 0
Asn65 0
and 0
Asn109 0
glycosylated 0
in 0
some 0
molecules 0
but 0
not 0
in 0
others 0
, 0
and 0
Asn72 0
not 0
glycosylated 0
. 0

The 0
DNA 0
sequence 0
conferring 0
AP B-gene
- I-gene
1 I-gene
activity 0
was 0
located 0
in 0
the 0
proximal 0
promoter 0
region 0
. 0

The 0
murine B-gene
mutation I-gene
dominant I-gene
white I-gene
spotting I-gene
( 0
W B-gene
) 0
is 0
in 0
the 0
proto 0
- 0
oncogene 0
, 0
c B-gene
- I-gene
kit I-gene
. 0

Isolation 0
and 0
characterization 0
of 0
the 0
rat 0
chromosomal 0
gene 0
for 0
a 0
polypeptide 0
( 0
pS1 B-gene
) 0
antigenically 0
related 0
to 0
statin B-gene
. 0

The 0
proteins 0
differ 0
in 0
the 0
presence 0
or 0
absence 0
of 0
a 0
21 0
- 0
amino 0
- 0
acid 0
sequence 0
located 0
24 0
amino 0
acids 0
C 0
terminal 0
of 0
the 0
translational 0
initiation 0
codon 0
. 0

Our 0
results 0
also 0
indicate 0
the 0
existence 0
of 0
sequences 0
downstream 0
of 0
- 0
0.11 0
kb 0
which 0
can 0
influence 0
the 0
pattern 0
of 0
tissue 0
- 0
specific 0
expression 0
of 0
the 0
HLA B-gene
- I-gene
B7 I-gene
gene I-gene
and 0
the 0
ability 0
of 0
this 0
gene 0
to 0
respond 0
to 0
gamma B-gene
interferon I-gene
. 0

The 0
SH2 B-gene
and 0
SH3 B-gene
domains I-gene
of 0
pp60src B-gene
direct 0
stable 0
association 0
with 0
tyrosine 0
phosphorylated 0
proteins 0
p130 B-gene
and 0
p110 B-gene
. 0

Chem 0
. 0

These 0
clones 0
overlapped 0
and 0
contained 0
the 0
structural 0
gene 0
encoding 0
the 0
complete 0
C5 B-gene
alpha I-gene
- I-gene
chain I-gene
and 0
90 0
% 0
of 0
the 0
beta 0
- 0
chain 0
. 0

The 0
C5 B-gene
alpha I-gene
- I-gene
chain I-gene
was 0
encoded 0
by 0
49 0
kilobases 0
containing 0
26 0
exons 0
; 0
the 0
beta 0
- 0
chain 0
was 0
encoded 0
by 0
29 0
kilobases 0
containing 0
16 0
exons 0
. 0

Heterozygous 0
mutation 0
in 0
the 0
G+5 0
position 0
of 0
intron 0
33 0
of 0
the 0
pro B-gene
- I-gene
alpha I-gene
2 I-gene
( I-gene
I I-gene
) I-gene
gene I-gene
( 0
COL1A2 B-gene
) 0
that 0
causes 0
aberrant 0
RNA 0
splicing 0
and 0
lethal 0
osteogenesis 0
imperfecta 0
. 0

The 0
nucleotide 0
sequences 0
of 0
these 0
genes 0
differ 0
at 0
only 0
nine 0
positions 0
, 0
resulting 0
in 0
three 0
amino 0
acid 0
differences 0
. 0

The 0
protein 0
predicted 0
by 0
the 0
sequence 0
of 0
the 0
human B-gene
pim I-gene
- I-gene
1 I-gene
proto I-gene
- I-gene
oncogene I-gene
shares 0
extensive 0
homology 0
with 0
known 0
serine/threonine B-gene
protein I-gene
kinases I-gene
, 0
and 0
yet 0
the 0
human B-gene
Pim I-gene
- I-gene
1 I-gene
enzyme I-gene
has 0
previously 0
been 0
reported 0
to 0
exhibit 0
protein B-gene
tyrosine I-gene
kinase I-gene
activity 0
both 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

A 0
full B-gene
- I-gene
length I-gene
human I-gene
pim I-gene
- I-gene
1 I-gene
cDNA I-gene
was 0
subcloned 0
into 0
the 0
bacterial 0
vector 0
pGEX 0
- 0
2T 0
and 0
the 0
Pim B-gene
- I-gene
1 I-gene
protein I-gene
expressed 0
as 0
a 0
fusion 0
product 0
with 0
bacterial B-gene
glutathione I-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
. 0

This 0
report 0
substantiates 0
that 0
at 0
least 0
two 0
of 0
the 0
18 0
kDa 0
hsps B-gene
in 0
maize 0
are 0
products 0
of 0
different 0
but 0
related 0
genes 0
. 0

The 0
10 0
kDa 0
polypeptide 0
was 0
phosphorylated 0
in 0
vitro 0
by 0
incubating 0
wheat 0
etioplast 0
membranes 0
with 0
[ 0
gamma 0
32P 0
] 0
ATP 0
. 0

Homology 0
with 0
the 0
human 0
protein 0
is 0
only 0
34 0
% 0
in 0
the 0
tandem 0
repeat 0
domain 0
, 0
mainly 0
showing 0
conservation 0
of 0
serines 0
and 0
threonines 0
, 0
presumed 0
sites 0
of 0
O 0
- 0
linked 0
carbohydrate 0
attachment 0
. 0

In 0
addition 0
to 0
targeting 0
partially 0
assembled 0
Ti B-gene
alpha I-gene
- I-gene
beta I-gene
CD3 B-gene
gamma I-gene
delta I-gene
epsilon I-gene
TCR B-gene
complexes I-gene
to 0
the 0
cell 0
surface 0
, 0
CD3 B-gene
zeta I-gene
appears 0
to 0
be 0
essential 0
for 0
interleukin B-gene
- I-gene
2 I-gene
production 0
after 0
TCR B-gene
stimulation 0
with 0
antigen/major B-gene
histocompatibility I-gene
complex I-gene
. 0

When 0
desipramine 0
was 0
injected 0
16 0
hrs 0
after 0
fluoxetine 0
injection 0
, 0
brain 0
levels 0
of 0
desipramine 0
were 0
no 0
longer 0
elevated 0
. 0

Opposite 0
effects 0
of 0
CYP1 B-gene
are 0
observed 0
in 0
aerobic 0
, 0
heme 0
- 0
sufficient 0
cells 0
. 0

A 0
segmental 0
analysis 0
of 0
the 0
key 0
regions 0
of 0
HLA B-gene
- I-gene
DR1 I-gene
that 0
control 0
T 0
cell 0
allorecognition 0
was 0
performed 0
by 0
using 0
a 0
series 0
of 0
transfected 0
cell 0
lines 0
expressing 0
the 0
products 0
of 0
recombinant 0
DRB/H B-gene
DRB/H I-gene
- I-gene
2Eb I-gene
genes 0
, 0
paired 0
with 0
either 0
DR B-gene
alpha I-gene
or 0
H B-gene
- I-gene
2E I-gene
alpha I-gene
. 0

We 0
characterized 0
cDNA 0
clones 0
specific 0
for 0
the 0
extracellular 0
matrix 0
glycoprotein 0
undulin B-gene
. 0

Finally 0
, 0
some 0
point 0
mutations 0
in 0
the 0
Gag B-gene
- 0
Pol B-gene
PR 0
domain 0
inhibited 0
activation 0
of 0
RT B-gene
in 0
trans 0
by 0
a 0
wild 0
- 0
type 0
PR B-gene
, 0
suggesting 0
that 0
the 0
correct 0
conformation 0
of 0
the 0
PR B-gene
domain 0
in 0
Gag B-gene
- 0
Pol B-gene
is 0
prerequisite 0
for 0
activation 0
of 0
RT B-gene
. 0

The 0
alpha B-gene
inhibin I-gene
promoter I-gene
containing 0
a 0
mutated 0
CRE 0
was 0
not 0
regulated 0
by 0
forskolin 0
in 0
granulosa 0
cells 0
and 0
did 0
not 0
bind 0
the 0
CREB B-gene
protein I-gene
. 0

Regulation 0
of 0
the 0
alpha B-gene
inhibin I-gene
gene I-gene
by 0
cyclic 0
adenosine 0
3',5' 0
- 0
monophosphate 0
after 0
transfection 0
into 0
rat 0
granulosa 0
cells 0
. 0

Comparison 0
of 0
the 0
nucleotide 0
sequences 0
between 0
the 0
human 0
and 0
bovine 0
DNA 0
showed 0
that 0
the 0
sequence 0
similarity 0
extended 0
2400 0
bp 0
downstream 0
from 0
the 0
coding 0
region 0
. 0

Cloning 0
of 0
a 0
human 0
cDNA 0
encoding 0
a 0
CDC2 B-gene
- I-gene
related I-gene
kinase I-gene
by 0
complementation 0
of 0
a 0
budding B-gene
yeast I-gene
cdc28 I-gene
mutation 0
. 0

In 0
patients 0
with 0
osteomyelitis 0
and 0
joint 0
empyema 0
( 0
n 0
= 0
48 0
) 0
PMN B-gene
elastase I-gene
had 0
a 0
sensitivity 0
of 0
77 0
% 0
, 0
which 0
was 0
only 0
exceeded 0
by 0
that 0
of 0
the 0
unspecific 0
erythrocyte 0
sedimentation 0
rate 0
( 0
sensitivity 0
89 0
% 0
) 0
. 0

E. 0
, 0
Hession 0
, 0
C. 0
, 0
Goff 0
, 0
D. 0
, 0
Griffiths 0
, 0
B. 0
, 0
Tizard 0
, 0
R. 0
, 0
Newman 0
, 0
B. 0
, 0
Chi 0
- 0
Rosso 0
, 0
G. 0
, 0
and 0
Lobb 0
, 0
R. 0
, 0
( 0
1990 0
) 0
Cell 0
63 0
, 0
1349 0
- 0
1356 0
) 0
. 0

The 0
above 0
results 0
mean 0
that 0
the 0
increase 0
in 0
alpha B-gene
- I-gene
adrenergic I-gene
receptors I-gene
makes 0
the 0
prostate 0
, 0
which 0
has 0
been 0
already 0
hypertrophied 0
, 0
less 0
elastic 0
, 0
inhibiting 0
external 0
urinary 0
sphincter 0
function 0
. 0

An 0
approximately 0
2 B-gene
- I-gene
kilobase I-gene
B2 I-gene
transcript I-gene
was 0
expressed 0
in 0
all 0
alfalfa 0
organs 0
tested 0
. 0

These 0
results 0
indicate 0
that 0
the 0
sulfhydryl 0
group 0
of 0
certain 0
angiotensin B-gene
converting I-gene
enzyme I-gene
inhibitors 0
can 0
potentiate 0
their 0
effect 0
on 0
the 0
endogenous 0
nitrovasodilator 0
EDRF B-gene
. 0

Pharmacokinetics 0
of 0
FK 0
506 0
in 0
transplant 0
patients 0
. 0

A 0
second 0
even 0
more 0
significant 0
match 0
to 0
this 0
E. 0
coli 0
region 0
was 0
found 0
in 0
the 0
retroviral B-gene
ribonuclease I-gene
H I-gene
( 0
RNase B-gene
H I-gene
) 0
domain 0
, 0
and 0
corresponds 0
precisely 0
to 0
a 0
region 0
that 0
has 0
been 0
aligned 0
by 0
previous 0
investigators 0
with 0
the 0
E. B-gene
coli I-gene
RNase I-gene
H I-gene
, 0
suggesting 0
that 0
Pol B-gene
I I-gene
helices 0
O 0
and 0
P 0
are 0
homologous 0
to 0
helices 0
A 0
and 0
D 0
of 0
the 0
RNase B-gene
H I-gene
crystal 0
structure 0
, 0
respectively 0
. 0

Analysis 0
of 0
the 0
deduced 0
amino 0
acid 0
sequence 0
suggests 0
that 0
CHIP28 B-gene
protein I-gene
contains 0
six 0
bilayer 0
- 0
spanning 0
domains 0
, 0
two 0
exofacial 0
potential 0
N 0
- 0
glycosylation 0
sites 0
, 0
and 0
intracellular 0
N 0
and 0
C 0
termini 0
. 0

The 0
qualitative 0
concentrations 0
of 0
HCG B-gene
had 0
a 0
sensitivity 0
of 0
37.5 0
% 0
and 0
a 0
specificity 0
of 0
100 0
% 0
. 0

The 0
reduced 0
rate 0
of 0
F 0
absorption 0
and 0
slower 0
rise 0
in 0
plasma 0
F 0
concentration 0
accompanying 0
delayed 0
gastric 0
emptying 0
indicate 0
that 0
passage 0
of 0
F 0
into 0
the 0
small 0
intestine 0
is 0
the 0
major 0
factor 0
in 0
rapid 0
F 0
absorption 0
. 0

The 0
activity 0
of 0
serum B-gene
lipase I-gene
and 0
amylase B-gene
distinctly 0
increased 0
at 0
3 0
h 0
and 0
went 0
up 0
to 0
the 0
maximum 0
at 0
12 0
h 0
after 0
injection 0
of 0
Na 0
- 0
Tc 0
. 0

They 0
were 0
checked 0
for 0
anti B-gene
- I-gene
HCV I-gene
( 0
anti B-gene
- I-gene
C100 I-gene
- I-gene
3 I-gene
) 0
with 0
HCV 0
EIA 0
kit 0
( 0
Abbott 0
Lab. 0
, 0
North 0
Chicago 0
, 0
IL 0
) 0
. 0

Diltiazem 0
resulted 0
in 0
a 0
significant 0
increase 0
in 0
epicardial 0
diameter 0
( 0
+10 0
% 0
; 0
p 0
= 0
0.001 0
) 0
and 0
in 0
coronary 0
blood 0
flow 0
( 0
CBF 0
) 0
( 0
+30 0
% 0
; 0
p 0
= 0
0.0001 0
) 0
. 0

The 0
first 0
transfusion 0
resulted 0
in 0
a 0
platelet 0
increment 0
to 0
32 0
Gpt/l 0
( 0
CCI 0
11 0
) 0
. 0

These 0
risk 0
factors 0
can 0
be 0
divided 0
into 0
2 0
groups 0
: 0
local 0
vessel 0
wall 0
- 0
related 0
factors 0
, 0
and 0
local 0
( 0
focal 0
action 0
) 0
systemic 0
factors 0
. 0

Epidemiology 0
and 0
prevention 0
of 0
hospital 0
infections 0
in 0
the 0
Local 0
Health 0
Unit 0
of 0
Sassari 0
: 0
profile 0
of 0
bacterial 0
resistance 0
and 0
antimicrobial 0
agents 0
of 0
large 0
usage 0
. 0

PRDII B-gene
- I-gene
BF1 I-gene
- I-gene
derived I-gene
cDNAs I-gene
did 0
not 0
result 0
in 0
stimulation 0
of 0
either 0
basal 0
or 0
tat B-gene
- 0
induced 0
activated 0
gene 0
expression 0
. 0

Vaccinia 0
virus 0
( 0
VV 0
) 0
is 0
a 0
potent 0
immunogen 0
, 0
but 0
the 0
nature 0
of 0
VV 0
proteins 0
involved 0
in 0
the 0
activation 0
of 0
the 0
immune 0
response 0
of 0
the 0
host 0
is 0
not 0
yet 0
known 0
. 0

Max B-gene
: 0
functional 0
domains 0
and 0
interaction 0
with 0
c B-gene
- I-gene
Myc I-gene
. 0

86 0
: 0
3199 0
- 0
3203 0
) 0
or 0
G1 0
to 0
S 0
phase 0
( 0
Reilly 0
, 0
C 0
. 0

Substitutions 0
introduced 0
at 0
bases 0
surrounding 0
the 0
ICR2 B-gene
motif I-gene
yielded 0
levels 0
of 0
pRNA 0
replication 0
that 0
differed 0
, 0
depending 0
on 0
the 0
maintenance 0
of 0
a 0
putative 0
5 0
' 0
stem 0
- 0
loop 0
structure 0
in 0
the 0
positive 0
strand 0
of 0
the 0
viral 0
genome 0
. 0

Zn 0
( 0
II 0
) 0
coordination 0
domain 0
mutants 0
of 0
T4 0
gene B-gene
32 I-gene
protein 0
. 0

Zn 0
( 0
II 0
) 0
coordination 0
domain 0
mutants 0
of 0
T4 B-gene
gene I-gene
32 I-gene
protein I-gene
. 0

The 0
tissue 0
specificity 0
of 0
gene 0
expression 0
was 0
identical 0
to 0
that 0
described 0
previously 0
for 0
the 0
CaMV B-gene
35S I-gene
domain I-gene
B I-gene
enhancer I-gene
element I-gene
. 0

The 0
pathophysiology 0
and 0
clinical 0
management 0
of 0
acute 0
brain 0
injury 0
in 0
infancy 0
and 0
childhood 0
are 0
presented 0
using 0
acute 0
traumatic 0
brain 0
injury 0
as 0
a 0
model 0
. 0

Transcripts 0
from 0
a 0
second 0
POU B-gene
- I-gene
domain I-gene
gene I-gene
, 0
Oct B-gene
- I-gene
25 I-gene
, 0
were 0
present 0
at 0
low 0
levels 0
in 0
oocytes 0
and 0
early 0
embryos 0
and 0
were 0
dramatically 0
upregulated 0
during 0
early 0
gastrulation 0
. 0

In 0
some 0
early 0
B 0
cells 0
and 0
Abelson 0
murine 0
leukemia 0
virus 0
- 0
transformed 0
pre 0
- 0
B 0
- 0
cell 0
lines 0
, 0
LT B-gene
mRNA I-gene
is 0
constitutively 0
expressed 0
. 0

The 0
genome 0
of 0
Thogoto 0
virus 0
comprises 0
six 0
segments 0
of 0
single 0
- 0
stranded 0
, 0
negative 0
sense 0
RNA 0
. 0

These 0
tumors 0
were 0
classified 0
into 0
three 0
broad 0
groups 0
: 0
I 0
, 0
cystadenoma 0
; 0
II 0
, 0
cystadenocarcinoma 0
; 0
and 0
III 0
, 0
adenocarcinoma 0
with 0
mucin B-gene
production 0
or 0
an 0
associated 0
cyst 0
. 0

Immunostaining 0
of 0
cells 0
transfected 0
with 0
these 0
constructs 0
revealed 0
that 0
both 0
the 0
myristoylated 0
and 0
nonmyristoylated 0
mutants 0
were 0
localized 0
in 0
nuclei 0
, 0
whereas 0
wild B-gene
- I-gene
type I-gene
PKC I-gene
alpha I-gene
was 0
primarily 0
cytoplasmic 0
and 0
perinuclear 0
. 0

We 0
have 0
partially 0
sequenced 0
the 0
RAP74 B-gene
protein I-gene
from 0
purified 0
HeLa 0
cells 0
, 0
cloned 0
its 0
complementary 0
DNA 0
and 0
shown 0
that 0
its 0
translation 0
product 0
can 0
interact 0
with 0
RAP30 B-gene
in 0
vitro 0
as 0
well 0
as 0
in 0
vivo 0
. 0

Effects 0
of 0
thromboxane B-gene
synthetase I-gene
inhibition 0
on 0
postburn 0
mesenteric 0
vascular 0
resistance 0
and 0
the 0
rate 0
of 0
bacterial 0
translocation 0
in 0
a 0
chronic 0
porcine 0
model 0
. 0

The 0
primary 0
pancreatic 0
insult 0
seemed 0
to 0
be 0
unaffected 0
by 0
the 0
treatment 0
, 0
because 0
neither 0
the 0
rise 0
in 0
plasma B-gene
lipase I-gene
nor 0
the 0
development 0
of 0
ascites 0
or 0
the 0
extension 0
of 0
the 0
pancreatic 0
necrosis 0
were 0
diminished 0
. 0

The 0
size 0
of 0
the 0
mutant 0
molecule 0
corresponds 0
to 0
the 0
unprocessed 0
cytoplasmic 0
precursor 0
( 0
pre B-gene
- I-gene
super I-gene
- I-gene
pro I-gene
- I-gene
PrB I-gene
) 0
, 0
as 0
detected 0
in 0
sec61 B-gene
mutants I-gene
, 0
when 0
translocation 0
into 0
the 0
endoplasmic 0
reticulum 0
is 0
blocked 0
. 0

Thus 0
, 0
the 0
active 0
- 0
site 0
mutation 0
prevents 0
the 0
wild 0
- 0
type 0
processing 0
of 0
the 0
N 0
- 0
glycosylated 0
73 0
- 0
kDa 0
precursor 0
of 0
PrB B-gene
to 0
the 0
41.5 B-gene
kDa I-gene
pro I-gene
- I-gene
PrB I-gene
in 0
the 0
endoplasmic 0
reticulum 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
exhibited 0
70 0
% 0
identity 0
to 0
that 0
of 0
Bacillus B-gene
stearothermophilus I-gene
TyrTS I-gene
and 0
55 0
% 0
identity 0
to 0
that 0
of 0
E. B-gene
coli I-gene
TyrTS I-gene
, 0
while 0
identity 0
to 0
a 0
second 0
cryptic 0
B. B-gene
subtilis I-gene
TyrTS I-gene
gene I-gene
, 0
designated 0
tyrZ B-gene
, 0
was 0
only 0
27 0
% 0
. 0

Heat 0
- 0
inducible 0
CAT B-gene
activity 0
was 0
detectable 0
when 0
additional 0
sequences 0
from 0
the 0
native 0
promoter 0
containing 0
three 0
CCAAT 0
boxes 0
and 0
a 0
single 0
HSE 0
were 0
present 0
in 0
the 0
constructions 0
. 0

SETTING 0
- 0
- 0
Women 0
, 0
Infants 0
, 0
and 0
Children 0
clinics 0
in 0
Minneapolis 0
, 0
Minn 0
. 0

Testosterone 0
, 0
free 0
testosterone 0
, 0
non B-gene
- I-gene
sex I-gene
hormone I-gene
- I-gene
binding I-gene
globulin I-gene
- 0
bound 0
testosterone 0
, 0
and 0
free 0
androgen 0
index 0
: 0
which 0
testosterone 0
measurement 0
is 0
most 0
relevant 0
to 0
reproductive 0
and 0
sexual 0
function 0
in 0
men 0
with 0
epilepsy 0
? 0

BACKGROUND 0
: 0
The 0
effectiveness 0
of 0
monoamine B-gene
oxidase I-gene
inhibitors 0
( 0
MAOIs 0
) 0
in 0
tricyclic 0
resistant 0
depression 0
has 0
received 0
surprisingly 0
little 0
systematic 0
study 0
. 0

The 0
upstream 0
delta 0
- 0
alpha 0
breakpoint 0
is 0
flanked 0
by 0
the 0
direct 0
repeats 0
of 0
the 0
acceptor 0
splice 0
site 0
, 0
whereas 0
the 0
down 0
- 0
stream 0
alpha 0
- 0
delta 0
breakpoint 0
is 0
located 0
in 0
the 0
adjacent 0
intron 0
. 0

Patients 0
with 0
moderate 0
PDDAT 0
were 0
impaired 0
on 0
all 0
serial 0
positions 0
for 0
both 0
spatial 0
order 0
and 0
spatial 0
recognition 0
memory 0
. 0

Bone 0
and 0
bones 0
. 0

One 0
patients 0
had 0
plasma B-gene
C I-gene
- I-gene
peptide I-gene
greater 0
than 0
3 0
pM 0
and 0
was 0
therefore 0
excluded 0
from 0
analysis 0
. 0

Complex 0
repetitive 0
discharges 0
were 0
observed 0
in 0
muscles 0
of 0
mdx 0
mice 0
but 0
no 0
complex 0
repetitive 0
discharges 0
or 0
other 0
abnormalities 0
were 0
observed 0
in 0
muscles 0
of 0
normal 0
control 0
mice 0
. 0

Management 0
often 0
involves 0
beta 0
- 0
and 0
calcium 0
channel 0
blocking 0
drugs 0
or 0
type 0
IC 0
antiarrhythmic 0
drugs 0
. 0

To 0
overcome 0
this 0
problem 0
, 0
we 0
have 0
overexpressed 0
Kex2p B-gene
using 0
the 0
baculovirus/insect 0
cell 0
expression 0
system 0
. 0

J 0
. 0

The 0
major B-gene
49 I-gene
- I-gene
kDa I-gene
core I-gene
protein I-gene
in 0
the 0
liver 0
HSPG B-gene
preparation 0
was 0
found 0
to 0
be 0
reactive 0
to 0
an 0
antibody 0
that 0
specifically 0
recognizes 0
the 0
cytoplasmic 0
domain 0
of 0
fibroglycan B-gene
. 0

While 0
no 0
obvious 0
transmembrane 0
regions 0
were 0
identified 0
, 0
several 0
short 0
hydrophobic 0
amino 0
acid 0
stretches 0
were 0
found 0
to 0
be 0
localized 0
in 0
and 0
around 0
the 0
Pro 0
II 0
region 0
, 0
and 0
these 0
may 0
be 0
responsible 0
for 0
attachment 0
of 0
precursors 0
to 0
membranes 0
. 0

Toxicity 0
was 0
mild 0
, 0
mainly 0
consisting 0
of 0
emesis 0
( 0
81 0
% 0
of 0
the 0
patients 0
; 0
66 0
% 0
of 0
the 0
courses 0
) 0
, 0
leukopenia 0
of 0
World 0
Health 0
Organization 0
( 0
WHO 0
) 0
grade 0
1 0
to 0
2 0
( 0
47 0
% 0
of 0
the 0
patients 0
; 0
18 0
% 0
of 0
the 0
courses 0
) 0
, 0
and 0
thrombocytopenia 0
( 0
12 0
% 0
of 0
the 0
patients 0
; 0
3 0
% 0
of 0
the 0
courses 0
) 0
. 0

W.G 0
. 0

This 0
study 0
confirms 0
, 0
although 0
individual 0
reaction 0
is 0
remarkably 0
different 0
, 0
transportation 0
as 0
a 0
potent 0
stressor 0
for 0
Beagle 0
dogs 0
. 0

A 0
mouse B-gene
brain I-gene
beta I-gene
- I-gene
spectrin I-gene
of 0
cDNA 0
was 0
identified 0
within 0
a 0
lambda 0
Gt11 0
expression 0
library 0
using 0
an 0
antibody 0
which 0
specifically 0
binds 0
with 0
the 0
235 B-gene
kDa I-gene
spectrin I-gene
beta I-gene
- I-gene
subunit I-gene
. 0

RESULTS 0
: 0
Plasma B-gene
AVP I-gene
responses 0
to 0
osmotic 0
stimulation 0
, 0
and 0
non 0
- 0
osmotic 0
inhibition 0
by 0
drinking 0
, 0
were 0
normal 0
in 0
patients 0
with 0
compulsive 0
water 0
drinking 0
. 0

The 0
fragments 0
of 0
each 0
region 0
were 0
amplified 0
by 0
polymerase 0
chain 0
reaction 0
and 0
analyzed 0
by 0
gel 0
electrophoresis 0
to 0
detect 0
single 0
- 0
strand 0
conformation 0
polymorphism 0
. 0

The 0
csbA B-gene
fusion I-gene
was 0
maximally 0
expressed 0
during 0
early 0
stationary 0
phase 0
in 0
cells 0
grown 0
in 0
Luria 0
broth 0
containing 0
5 0
% 0
glucose 0
and 0
0.2 0
% 0
glutamine 0
. 0

The 0
constraints 0
of 0
primase B-gene
recognition I-gene
sequences I-gene
, 0
nucleotide 0
substrate 0
requirements 0
, 0
and 0
the 0
effects 0
of 0
additional 0
proteins 0
on 0
oligoribonucleotide 0
synthesis 0
by 0
the 0
63 B-gene
- I-gene
kDa I-gene
gene I-gene
4 I-gene
protein I-gene
have 0
been 0
examined 0
using 0
templates 0
of 0
defined 0
sequence 0
. 0

Thrombolytic 0
therapy 0
in 0
spontaneous 0
coronary 0
artery 0
dissection 0
. 0

A 0
prospective 0
trial 0
was 0
carried 0
out 0
in 0
156 0
unselected 0
patients 0
( 0
41 0
men 0
, 0
mean 0
age 0
67.5 0
years 0
, 0
115 0
women 0
, 0
mean 0
age 0
71.4 0
years 0
) 0
who 0
had 0
undergone 0
total 0
hip 0
joint 0
replacement 0
because 0
of 0
degenerative 0
or 0
inflammatory 0
arthritis 0
or 0
fracture 0
of 0
the 0
neck 0
of 0
the 0
femur 0
. 0

When 0
both 0
lesions 0
were 0
complete 0
lateral 0
hemisections 0
in 0
weanling 0
operates 0
, 0
little 0
behavioral 0
recovery 0
was 0
observed 0
, 0
similar 0
to 0
complete 0
spinal 0
cord 0
transection 0
( 0
N 0
= 0
3 0
) 0
. 0

Human 0
SRF B-gene
- I-gene
related I-gene
proteins I-gene
: 0
DNA 0
- 0
binding 0
properties 0
and 0
potential 0
regulatory 0
targets 0
. 0

We 0
have 0
isolated 0
cDNAs 0
for 0
a 0
gene 0
coding 0
for 0
a 0
G B-gene
protein I-gene
alpha I-gene
subunit I-gene
from I-gene
tomato I-gene
( 0
Lycopersicon 0
esculentum 0
, 0
cv 0
. 0

Growth 0
factor 0
stimulation 0
of 0
cells 0
causes 0
the 0
phosphorylation 0
of 0
the 0
c B-gene
- I-gene
Myc I-gene
transcriptional I-gene
activation I-gene
domain I-gene
at 0
Ser62 0
within 0
a 0
proline 0
- 0
rich 0
region 0
that 0
is 0
highly 0
conserved 0
among 0
members 0
of 0
the 0
Myc B-gene
family I-gene
( 0
Alvarez 0
, 0
E. 0
, 0
Northwood 0
, 0
I.C. 0
, 0
Gonzalez 0
, 0
F 0
. 0

The 0
authors 0
evaluated 0
the 0
potential 0
for 0
thrombotic 0
complications 0
arising 0
from 0
implantation 0
of 0
a 0
ventricular 0
assist 0
device 0
( 0
Sarns/3M 0
- 0
VAD 0
) 0
in 0
four 0
calves 0
. 0

Cardiac 0
output 0
( 0
CO 0
) 0
was 0
significantly 0
higher 0
( 0
p 0
less 0
than 0
0.0005 0
) 0
in 0
the 0
MBBF 0
group 0
. 0

Amino 0
acid 0
residues 0
147 0
- 0
167 0
of 0
the 0
previously 0
reported 0
sequence 0
are 0
replaced 0
by 0
new 0
residues 0
147 0
to 0
150 0
. 0

Transcriptional 0
activation 0
by 0
the 0
HIV B-gene
- I-gene
1 I-gene
Tat I-gene
protein I-gene
requires 0
specific 0
residues 0
in 0
the 0
hexanucleotide 0
loop 0
and 0
trinucleotide 0
bulge 0
of 0
the 0
TAR B-gene
RNA 0
stem 0
- 0
loop 0
structure 0
found 0
in 0
the 0
5' 0
- 0
untranslated 0
leader 0
of 0
all 0
viral 0
transcripts 0
. 0

We 0
obtained 0
quantitative 0
evidence 0
on 0
the 0
coding 0
of 0
interaural 0
time 0
differences 0
( 0
ITDs 0
) 0
of 0
click 0
stimuli 0
by 0
40 0
single 0
neurons 0
in 0
the 0
auditory 0
cortex 0
of 0
anesthetized 0
albino 0
rats 0
. 0

These 0
results 0
strongly 0
suggest 0
that 0
locally 0
- 0
applied 0
TTC 0
in 0
combination 0
with 0
FDBA 0
enhances 0
new 0
bone 0
formation 0
in 0
experimental 0
alveolar 0
bone 0
defects 0
. 0

As 0
an 0
initial 0
step 0
towards 0
the 0
characterization 0
of 0
replicative 0
DNA B-gene
polymerases I-gene
of I-gene
trypanosomes I-gene
, 0
we 0
have 0
cloned 0
, 0
sequenced 0
and 0
examined 0
the 0
expression 0
of 0
the 0
Trypanosoma 0
( 0
Trypanozoon 0
) 0
brucei 0
brucei 0
gene 0
that 0
encodes 0
the 0
DNA B-gene
polymerase I-gene
alpha I-gene
catalytic I-gene
core I-gene
( 0
pol B-gene
alpha I-gene
) 0
. 0

In 0
addition 0
, 0
there 0
was 0
a 0
significant 0
increase 0
in 0
postdexamethasone 0
cortical 0
concentrations 0
with 0
age 0
( 0
p 0
less 0
than 0
0.01 0
; 0
r 0
= 0
0.31 0
) 0
. 0

Pulmonary 0
hypertension 0
, 0
with 0
or 0
without 0
coronary 0
arterial 0
narrowing 0
, 0
is 0
the 0
major 0
condition 0
leading 0
to 0
isolated 0
atrial 0
infarction 0
. 0

The 0
volume 0
fraction 0
( 0
Vv 0
) 0
and 0
number/mm2 0
( 0
Na 0
) 0
of 0
all 0
capillaries 0
( 0
perfused 0
and 0
nonperfused 0
) 0
in 0
a 0
given 0
area 0
of 0
brain 0
were 0
determined 0
after 0
staining 0
for 0
alkaline B-gene
phosphatase I-gene
. 0

Airway 0
pressure 0
and 0
air 0
flow 0
were 0
measured 0
at 0
the 0
endotracheal 0
tube 0
in 0
13 0
children 0
on 0
a 0
variety 0
of 0
ventilators 0
. 0

Appl 0
. 0

Issues 0
of 0
distribution 0
of 0
kinetic 0
energy 0
of 0
traumatizing 0
object 0
in 0
direct 0
contact 0
interaction 0
with 0
head 0
during 0
impact 0
are 0
discussed 0
from 0
position 0
of 0
biomechanics 0
. 0

CONCLUSION 0
: 0
Monitoring 0
SpO2 0
at 0
the 0
nasal 0
septum 0
site 0
is 0
more 0
reliable 0
than 0
monitoring 0
it 0
at 0
the 0
finger 0
site 0
in 0
hypothermic 0
patients 0
. 0

Diltiazem 0
decreased 0
the 0
total 0
body 0
clearance 0
from 0
34.0 0
+/ 0
- 0
8.0 0
to 0
28.6 0
+/ 0
- 0
6.1 0
mL/min 0
( 0
P 0
less 0
than 0
.01 0
) 0
, 0
and 0
prolonged 0
the 0
elimination 0
half 0
- 0
life 0
from 0
12.6 0
+/ 0
- 0
3.0 0
to 0
14.3 0
+/ 0
- 0
2.5 0
hours 0
( 0
P 0
less 0
than 0
.01 0
) 0
of 0
antipyrine 0
without 0
any 0
changes 0
in 0
volume 0
of 0
distribution 0
. 0

The 0
granules 0
grew 0
as 0
the 0
melted 0
material 0
immersed 0
into 0
the 0
void 0
space 0
among 0
the 0
adhered 0
particles 0
. 0

Hence 0
, 0
the 0
uPA B-gene
promoter I-gene
contains 0
multiple 0
weak 0
cis 0
- 0
acting 0
elements 0
distributed 0
over 0
7.0 0
kb 0
5 0
' 0
to 0
the 0
translation 0
start 0
site 0
. 0

Substituting 0
a 0
Ser 0
for 0
Gly69 0
or 0
a 0
Glu 0
for 0
Lys 0
71 0
in 0
the 0
conserved 0
TGEK B-gene
tetrapeptide I-gene
in 0
finger 0
II 0
of 0
TFIIIA B-gene
resulted 0
in 0
the 0
loss 0
of 0
DNA 0
binding 0
. 0

P 0
. 0

In 0
one 0
, 0
exploratory 0
behavior 0
( 0
assessed 0
by 0
hole 0
pokes 0
) 0
and 0
locomotion 0
were 0
assessed 0
during 0
a 0
10 0
- 0
min 0
test 0
session 0
. 0

The 0
model 0
is 0
able 0
to 0
anticipate 0
why 0
the 0
effect 0
of 0
water 0
fluoridation 0
on 0
caries 0
prevalence 0
is 0
most 0
pronounced 0
when 0
caries 0
is 0
diagnosed 0
at 0
cavity 0
level 0
. 0

12 0
- 0
O 0
- 0
Tetradecanoylphorbol 0
13 0
- 0
acetate 0
was 0
found 0
to 0
inhibit 0
rapidly 0
and 0
potently 0
the 0
expression 0
of 0
mRNAs 0
coding 0
for 0
the 0
myogenic 0
regulators 0
CMD1 B-gene
and 0
myogenin B-gene
. 0

In 0
Xenopus 0
laevis 0
, 0
the 0
gene 0
encoding 0
the 0
elongation B-gene
factor I-gene
1 I-gene
- I-gene
alpha I-gene
variant I-gene
EF B-gene
- I-gene
1 I-gene
alpha I-gene
O I-gene
, 0
where 0
O 0
stands 0
for 0
oocyte 0
, 0
is 0
expressed 0
in 0
oocytes 0
and 0
early 0
embryos 0
. 0

These 0
introns 0
belong 0
to 0
the 0
class 0
of 0
nuclear 0
pre 0
- 0
mRNA 0
introns 0
and 0
contain 0
typical 0
5' 0
- 0
and 0
3' 0
- 0
consensus 0
sequences 0
, 0
as 0
well 0
as 0
unique 0
features 0
. 0

The 0
mRNA 0
identified 0
in 0
both 0
human 0
and 0
rat 0
cells 0
with 0
the 0
human B-gene
clathrin I-gene
clone 0
revealed 0
transcripts 0
of 0
approximately 0
6.5 0
kb 0
, 0
which 0
is 0
consistent 0
with 0
the 0
predicted 0
180 0
kDa 0
molecular 0
weight 0
of 0
the 0
clathrin B-gene
heavy I-gene
chain I-gene
. 0

In 0
this 0
report 0
, 0
almost 0
6 0
kb 0
of 0
DNA 0
sequence 0
is 0
presented 0
, 0
including 0
1251 0
bp 0
5 0
' 0
to 0
the 0
gene 0
, 0
over 0
4 0
kb 0
of 0
exon 0
and 0
exon 0
- 0
intron 0
junctions 0
, 0
and 0
583 0
bp 0
3 0
' 0
to 0
the 0
gene 0
. 0

An 0
8 0
- 0
h 0
exposure 0
to 0
10 0
mg 0
DMEA/m3 0
corresponds 0
to 0
a 0
postexposure 0
plasma 0
concentration 0
and 0
2 0
- 0
h 0
postexposure 0
urinary 0
excretion 0
of 0
4.9 0
mumol/l 0
and 0
75 0
mmol/mol 0
creatinine 0
, 0
respectively 0
. 0

Antibodies 0
specific 0
to 0
rE12 B-gene
and 0
rNFIL B-gene
- I-gene
6 I-gene
disrupt 0
nucleoprotein 0
complexes 0
with 0
these 0
DNA 0
- 0
binding 0
sites 0
, 0
confirming 0
the 0
interaction 0
of 0
native 0
in 0
vivo 0
factors 0
. 0

A 0
method 0
is 0
described 0
for 0
detecting 0
targeted 0
events 0
at 0
the 0
mu B-gene
heavy I-gene
chain I-gene
gene I-gene
which 0
relies 0
on 0
co 0
- 0
conversion 0
( 0
or 0
co 0
- 0
exchange 0
) 0
of 0
a 0
point 0
mutation 0
with 0
a 0
selectable 0
marker 0
contained 0
on 0
a 0
replacement 0
vector 0
. 0

Allergenic 0
activity 0
of 0
allergen 0
extract 0
Ambrosia 0
elatior 0
( 0
AE 0
) 0
was 0
tested 0
in 0
fifteen 0
volunteers 0
extremely 0
sensitive 0
to 0
the 0
allergen 0
. 0

This 0
study 0
was 0
aimed 0
at 0
assessing 0
whether 0
c 0
- 0
DDP 0
administration 0
immediately 0
before 0
radiotherapy 0
could 0
increase 0
frequency 0
and 0
duration 0
of 0
objective 0
responses 0
, 0
as 0
well 0
as 0
survival 0
, 0
in 0
patients 0
affected 0
with 0
locally 0
advanced 0
stages 0
of 0
squamous 0
carcinomas 0
of 0
the 0
head 0
and 0
neck 0
. 0

Two 0
potential 0
regulatory 0
sequences 0
for 0
DNA 0
binding 0
proteins 0
were 0
found 0
in 0
the 0
non 0
- 0
coding 0
5 0
' 0
region 0
: 0
a 0
HAP2/HAP3 B-gene
consensus 0
recognition 0
sequence 0
at 0
nucleotide 0
- 0
154 0
and 0
a 0
HAP2/HAP3 I-gene

Marked 0
thrombocytopenia 0
, 0
depletion 0
of 0
serum B-gene
fibrinogen I-gene
and 0
prolonged 0
prothrombin B-gene
and 0
activated 0
partial 0
thromboplastin B-gene
time 0
, 0
were 0
recorded 0
at 0
5 0
to 0
10 0
and 0
30 0
to 0
40 0
minutes 0
after 0
intravenous 0
envenomation 0
. 0

We 0
exploit 0
the 0
properties 0
of 0
LexA B-gene
fusion I-gene
proteins I-gene
to 0
study 0
the 0
dimerization 0
and 0
DNA 0
- 0
contacting 0
domains 0
of 0
cRel B-gene
. 0

Plasma 0
lipid 0
and 0
lipoprotein 0
profiles 0
were 0
compared 0
in 0
elderly 0
female 0
runners 0
( 0
RU 0
: 0
n 0
= 0
15 0
, 0
aged 0
66 0
+/ 0
- 0
5 0
years 0
, 0
body 0
fat 0
20 0
+/ 0
- 0
4 0
% 0
, 0
training 0
distance 0
35 0
+/ 0
- 0
15 0
km 0
week 0
- 0
1 0
, 0
VO2max 0
36 0
+/ 0
- 0
4 0
ml 0
kg 0
- 0
1 0
min 0
- 0
1 0
, 0
mean 0
+/ 0
- 0
SD 0
) 0
and 0
age 0
- 0
matched 0
untrained 0
women 0
( 0
UT 0
: 0
n 0
= 0
28 0
, 0
66 0
+/ 0
- 0
4 0
years 0
, 0
body 0
fat 0
26 0
+/ 0
- 0
6 0
% 0
, 0
VO2max 0
26 0
+/ 0
- 0
3 0
ml 0
kg 0
- 0
1 0
min 0
- 0
1 0
) 0
. 0

Auditory 0
threshold 0
shifts 0
, 0
as 0
measured 0
by 0
the 0
auditory 0
evoked 0
brainstem 0
response 0
, 0
were 0
measured 0
at 0
2,4,8,12,16 0
, 0
20 0
and 0
24 0
kHz 0
. 0

Fundamental 0
and 0
clinical 0
evaluation 0
of 0
equilibrium 0
dialysis 0
- 0
- 0
radioimmunoassay 0
system 0
for 0
measurement 0
of 0
serum 0
free 0
thyroxine 0

We 0
conclude 0
that 0
TA 0
caused 0
a 0
specific 0
decrease 0
in 0
AGD 0
on 0
GD 0
20 0
that 0
was 0
largely 0
reversed 0
by 0
PCD 0
23 0
. 0

When 0
examined 0
as 0
adults 0
( 0
8 0
weeks 0
old 0
) 0
, 0
the 0
external 0
genitalia 0
of 0
TA 0
- 0
exposed 0
offspring 0
were 0
normal 0
. 0

After 0
PTCA 0
, 0
ejection 0
fraction 0
increased 0
from 0
54 0
+/ 0
- 0
8 0
% 0
to 0
59 0
+/ 0
- 0
8 0
% 0
( 0
p 0
less 0
than 0
0.05 0
) 0
and 0
regional 0
function 0
improved 0
significantly 0
( 0
maximal 0
standard 0
deviation 0
before 0
PTCA 0
: 0
2.8 0
+/ 0
- 0
0.8 0
; 0
after 0
PTCA 0
: 0
1.9 0
+/ 0
- 0
0.9 0
- 0
segments 0
below 0
the 0
first 0
standard 0
deviation 0
before 0
PTCA 0
: 0
31 0
+/ 0
- 0
16 0
; 0
after 0
PTCA 0
: 0
19 0
+/ 0
- 0
17 0
) 0
. 0

The 0
alcoholic 0
patient 0
, 0
his 0
work 0
and 0
the 0
subjectivity 0
of 0
the 0
period 0

These 0
data 0
suggest 0
that 0
the 0
combined 0
treatment 0
with 0
a 0
thromboxane B-gene
synthetase I-gene
inhibitor 0
and 0
a 0
thromboxane B-gene
receptor I-gene
antagonist 0
provides 0
a 0
better 0
protection 0
against 0
digoxin 0
intoxication 0
than 0
with 0
either 0
agent 0
alone 0
. 0

A 0
330 0
- 0
kb 0
YAC 0
, 0
A148A7 0
, 0
spanned 0
from 0
the 0
HLA B-gene
- 0
DQA1 B-gene
locus 0
through 0
the 0
Y3/Ring B-gene
Y3/Ring I-gene
4 I-gene
locus 0
and 0
extended 0
at 0
least 0
130 0
kb 0
centromeric 0
of 0
YAC 0
B1D12 0
. 0

Interspecific 0
backcross 0
analysis 0
using 0
progeny 0
derived 0
from 0
matings 0
of 0
( 0
C57BL/6J 0
x 0
Mus 0
spretus 0
) 0
F1 0
x 0
C57BL/6J 0
mice 0
indicates 0
that 0
the 0
thrombospondin B-gene
gene I-gene
is 0
tightly 0
linked 0
to 0
the 0
Fshb B-gene
, 0
Actcl B-gene
, 0
Ltk B-gene
, 0
and 0
B2M B-gene
loci I-gene
on 0
murine 0
chromosome 0
2 0
. 0

Adverse 0
foetal 0
outcome 0
in 0
specific 0
IgM B-gene
positive 0
Chlamydia 0
trachomatis 0
infection 0
in 0
pregnancy 0
. 0

Using 0
an 0
image 0
- 0
processing 0
computer 0
, 0
regional 0
LV 0
time 0
- 0
density 0
curves 0
were 0
constructed 0
for 0
one 0
cardiac 0
cycle 0
. 0

In 0
a 0
second 0
patient 0
the 0
VT 0
became 0
nonsustained 0
. 0

If 0
delay 0
has 0
occurred 0
between 0
centrifugation 0
and 0
the 0
measurement 0
, 0
causing 0
substantial 0
loss 0
of 0
CO2 0
, 0
equilibration 0
of 0
the 0
sample 0
with 0
a 0
gas 0
mixture 0
corresponding 0
to 0
PCO2 0
= 0
5.3 0
kPa 0
prior 0
to 0
the 0
measurement 0
is 0
recommended 0
. 0

The 0
possible 0
mechanisms 0
underlying 0
differences 0
in 0
post 0
- 0
tetanic 0
effects 0
from 0
muscle 0
and 0
cutaneous 0
afferents 0
in 0
adults 0
and 0
neonates 0
are 0
discussed 0
. 0

We 0
examined 0
behavioral 0
alterations 0
in 0
the 0
brown 0
cockroach 0
, 0
Periplaneta 0
brunnea 0
, 0
infected 0
with 0
the 0
acanthocephalan 0
, 0
Moniliformis 0
moniliformis 0
. 0

First 0
, 0
the 0
finding 0
of 0
a 0
monomeric 0
Alu B-gene
family 0
repeat 0
at 0
the 0
junction 0
between 0
nonhomology 0
block 0
I 0
and 0
homology 0
block 0
Y 0
of 0
the 0
alpha B-gene
2 I-gene
gene I-gene
- I-gene
containing I-gene
unit I-gene
in I-gene
rhesus I-gene
macaque I-gene
suggests 0
that 0
the 0
dimeric 0
Alu B-gene
family 0
repeat 0
, 0
Alu B-gene
3 I-gene
, 0
at 0
the 0
orthologous 0
position 0
in 0
human 0
was 0
generated 0
by 0
insertion 0
of 0
a 0
monomeric 0
Alu B-gene
family 0
repeat 0
into 0
the 0
3 0
' 0
end 0
of 0
another 0
preexisting 0
Alu B-gene
family 0
repeat 0
. 0

The 0
sequence 0
of 0
the 0
repressor 0
locus 0
, 0
c 0
, 0
of 0
the 0
Streptomyces 0
temperate 0
phage 0
, 0
phi 0
C31 0
, 0
was 0
shown 0
previously 0
to 0
contain 0
an 0
open 0
reading 0
frame 0
encoding 0
a 0
74 0
kDa 0
protein 0
. 0

The 0
EPO B-gene
levels 0
were 0
distinctly 0
increased 0
before 0
transfusion 0
; 0
they 0
did 0
not 0
significantly 0
change 0
just 0
after 0
transfusion 0
, 0
but 0
subsequently 0
decreased 0
. 0

This 0
differential 0
sensitivity 0
to 0
DB 0
, 0
as 0
measured 0
by 0
a 0
lower 0
concentration 0
of 0
DB 0
which 0
caused 0
loss 0
of 0
righting 0
in 0
LS 0
, 0
was 0
accompanied 0
by 0
an 0
equal 0
rate 0
of 0
water 0
- 0
soluble 0
barbiturate 0
brain 0
distribution 0
and 0
elimination 0
in 0
the 0
two 0
lines 0
. 0

The 0
existence 0
of 0
threshold 0
concentrations 0
, 0
above 0
which 0
certain 0
phenomena 0
may 0
occur 0
, 0
strengthens 0
the 0
role 0
of 0
sentinels 0
. 0

However 0
, 0
it 0
was 0
synthesized 0
at 0
both 0
temperatures 0
after 0
addition 0
of 0
A23187 0
. 0

Felodipine 0
did 0
not 0
alter 0
the 0
baseline 0
FEV1 0
, 0
but 0
showed 0
a 0
small 0
significant 0
inhibitory 0
effect 0
upon 0
histamine 0
and 0
AMP 0
induced 0
bronchoconstriction 0
. 0

Ten 0
out 0
of 0
10 0
patients 0
with 0
progressive 0
disease 0
had 0
mast 0
cells 0
greater 0
than 0
or 0
equal 0
to 0
0.5 0
% 0
, 0
hyaluronan 0
greater 0
than 0
or 0
equal 0
to 0
50 0
micrograms.l 0
- 0
1 0
and 0
fibronectin B-gene
greater 0
than 0
or 0
equal 0
to 0
350 0
micrograms.l 0
- 0
1 0
compared 0
to 0
eight 0
out 0
of 0
41 0
patients 0
with 0
stable 0
or 0
regressive 0
disease 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Our 0
mapping 0
results 0
did 0
not 0
suggest 0
involvement 0
of 0
this 0
gene 0
in 0
previously 0
mapped 0
genetic 0
disorders 0
or 0
in 0
known 0
neoplasia 0
- 0
associated 0
translocation 0
breakpoints 0
. 0

Relatively 0
little 0
is 0
known 0
regarding 0
the 0
role 0
of 0
5 B-gene
- I-gene
HT2 I-gene
receptor I-gene
activity 0
in 0
male 0
rat 0
sexual 0
behavior 0
. 0

These 0
changes 0
were 0
n't 0
so 0
significant 0
in 0
the 0
group 0
of 0
obese 0
children 0
who 0
did 0
n't 0
lose 0
weight 0
. 0

Arsenic 0
contents 0
in 0
native 0
copper 0

In 0
ten 0
other 0
experiments 0
( 0
5 0
experimental 0
and 0
5 0
control 0
rats 0
) 0
99mTc 0
- 0
sulfur 0
colloid 0
was 0
injected 0
intravenously 0
. 0

Magnetotherapy 0
of 0
hepatitis 0
A 0
and 0
B 0
in 0
children 0

These 0
results 0
were 0
superior 0
to 0
those 0
in 0
24 0
patients 0
with 0
conventional 0
end 0
- 0
to 0
- 0
end 0
sutures 0
on 0
clinical 0
testing 0
. 0

Mutational 0
analysis 0
supports 0
a 0
role 0
for 0
multiple 0
structural 0
features 0
in 0
the 0
C 0
- 0
terminal 0
secretion 0
signal 0
of 0
Escherichia B-gene
coli I-gene
haemolysin I-gene
. 0

Among 0
blood 0
donors 0
in 0
the 0
Republic 0
of 0
Serbia 0
, 0
regardless 0
the 0
number 0
of 0
blood 0
donations 0
, 0
the 0
percentage 0
of 0
female 0
donors 0
is 0
significantly 0
lower 0
compared 0
to 0
the 0
percentage 0
of 0
male 0
blood 0
donors 0
. 0

Extramedullary 0
relapse 0
in 0
childhood 0
leukemia 0
. 0

Mycoplasma 0
pneumoniae 0
was 0
isolated 0
from 0
the 0
pleural 0
fluid 0
of 0
this 0
patient 0
. 0

RU486 0
and 0
ONO 0
802 0
in 0
combination 0
have 0
been 0
shown 0
to 0
be 0
effective 0
in 0
early 0
termination 0
of 0
pregnancy 0
. 0

The 0
presence 0
of 0
local 0
abnormalities 0
in 0
both 0
patients 0
can 0
support 0
the 0
hypothesis 0
that 0
the 0
cortex 0
, 0
especially 0
of 0
the 0
temporal 0
anterior 0
lobe 0
, 0
is 0
involved 0
in 0
the 0
origin 0
of 0
the 0
laughing 0
seizures 0
. 0

In 0
line 0
with 0
the 0
small 0
values 0
for 0
QS/QC 0
, 0
our 0
results 0
further 0
indicate 0
that 0
even 0
large 0
, 0
well 0
- 0
perfused 0
, 0
occluded 0
air 0
spaces 0
in 0
the 0
lung 0
will 0
hardly 0
affect 0
the 0
recovered 0
ventilation/perfusion 0
distribution 0
obtained 0
from 0
inert 0
gas 0
data 0
when 0
CDCSF6 0
exceeds 0
0.1 0
ml.min 0
- 0
1.mmHg 0
- 0
1 0
. 0

Many 0
cells 0
were 0
negative 0
for 0
endothelial 0
- 0
cell 0
markers 0
, 0
and 0
they 0
reacted 0
with 0
a 0
monoclonal 0
antibody 0
against 0
muscle 0
actin B-gene
. 0

CT 0
abnormalities 0
noted 0
in 0
term 0
babies 0
included 0
hemorrhage 0
( 0
subarachnoid 0
5.8 0
% 0
, 0
intracerebral 0
11.6 0
% 0
) 0
, 0
hypodensity 0
( 0
mild 0
23.2 0
% 0
, 0
moderate 0
11.6 0
% 0
severe 0
5.8 0
% 0
) 0
; 0
hypodensity 0
with 0
hemorrhage 0
5.8 0
% 0
and 0
cerebral 0
atrophy 0
5.8 0
% 0
. 0

The 0
effects 0
of 0
contrast 0
media 0
on 0
coagulation B-gene
factor I-gene
XII I-gene
. 0

Pigs 0
were 0
switched 0
from 0
the 0
growing 0
to 0
the 0
finishing 0
diet 0
at 0
57 0
and 0
61 0
kg 0
in 0
Exp 0
. 0

In 0
sixteen 0
patients 0
with 0
moderate 0
essential 0
hypertension 0
the 0
effects 0
of 0
10 0
- 0
day 0
nifedipine 0
treatment 0
on 0
serum 0
uric 0
acid 0
and 0
renal 0
excretion 0
of 0
uric 0
acid 0
were 0
evaluated 0
. 0

TPTA 0
produced 0
brain 0
congestion 0
, 0
and 0
hepatic 0
and 0
pulmonary 0
petechial 0
and 0
generalized 0
hemorrhages 0
. 0

Examples 0
are 0
using 0
more 0
subjects 0
or 0
an 0
improved 0
research 0
design 0
, 0
developing 0
consensus 0
statements 0
or 0
using 0
meta 0
- 0
analysis 0
. 0

A 0
two 0
phase 0
slug 0
flow 0
tubular 0
heat 0
exchanger 0
was 0
used 0
for 0
the 0
thermal 0
inactivation 0
of 0
Listeria 0
monocytogenes 0
in 0
natural 0
infected 0
milk 0
from 0
seven 0
cows 0
. 0

So 0
far 0
15 0
children 0
have 0
been 0
studied 0
. 0

Regional 0
cerebral 0
blood 0
flow 0
( 0
rCBF 0
) 0
measurements 0
and 0
psychiatric 0
ratings 0
were 0
performed 0
on 0
seven 0
schizophrenic 0
patients 0
( 0
mean 0
age 0
= 0
41.4 0
years 0
) 0
who 0
had 0
been 0
examined 0
18 0
years 0
previously 0
in 0
a 0
study 0
that 0
used 0
similar 0
psychiatric 0
ratings 0
and 0
a 0
comparable 0
rCBF 0
technique 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
identified 0
a 0
strong 0
positive 0
cis 0
- 0
regulatory 0
element 0
at 0
- 0
70 0
bp 0
to 0
- 0
75 0
bp 0
in 0
the 0
LpS1 B-gene
beta I-gene
promoter I-gene
with 0
the 0
sequence 0
( 0
G 0
) 0
6 0
and 0
a 0
similar 0
, 0
more 0
distal 0
cis 0
- 0
element 0
at 0
- 0
721 0
bp 0
to 0
- 0
726 0
bp 0
. 0

The 0
present 0
study 0
reports 0
visual 0
evoked 0
potential 0
responses 0
to 0
pattern 0
reversal 0
( 0
VEP 0
- 0
P 0
) 0
in 0
ten 0
third 0
trimester 0
pregnant 0
women 0
and 0
changes 0
in 0
latency 0
of 0
NPN 0
complex 0
when 0
compared 0
with 0
these 0
responses 0
in 0
the 0
non 0
pregnant 0
state 0
. 0

No 0
case 0
of 0
SMF 0
demonstrated 0
expansive 0
tumorous 0
growth 0
. 0

Different 0
doses 0
of 0
15 0
- 0
methyl 0
- 0
PGF2 0
alpha 0
( 0
0.125 0
- 0
10 0
mg 0
) 0
were 0
used 0
to 0
induce 0
luteolysis 0
and 0
oestrus 0
in 0
7 0
heifers 0
with 0
28 0
treatments 0
on 0
day 0
8 0
- 0
12 0
of 0
the 0
oestrous 0
cycle 0
. 0

Review 0
of 0
the 0
literature 0
and 0
report 0
of 0
a 0
case 0
of 0
a 0
dermoid 0
cyst 0
. 0

Resolution 0
of 0
thermographic 0
asymmetry 0
and/or 0
decrease 0
in 0
Delta 0
T 0
was 0
demonstrated 0
in 0
approximately 0
81 0
% 0
of 0
the 0
post 0
- 0
treatment 0
population 0
. 0

In 0
all 0
instances 0
the 0
apparent 0
alcohol 0
responses 0
were 0
very 0
small 0
and 0
never 0
exceeded 0
a 0
reading 0
of 0
1 0
microgram/100ml 0
for 0
breath 0
samples 0
more 0
than 0
10min 0
post 0
- 0
exposure 0
. 0

Maize B-gene
rbcS I-gene
promoter I-gene
activity 0
depends 0
on 0
sequence 0
elements 0
not 0
found 0
in 0
dicot B-gene
rbcS I-gene
promoters I-gene
. 0

Measurements 0
were 0
done 0
with 0
a 0
commercial 0
haematofluorometer 0
Buchler 0
ZF 0
which 0
was 0
calibrated 0
to 0
the 0
average 0
haematocrit 0
value 0
of 0
0.42 0
. 0

The 0
relatively 0
scanty 0
number 0
of 0
examples 0
, 0
which 0
could 0
be 0
justified 0
by 0
the 0
variety 0
and 0
complexity 0
of 0
combined 0
exposure 0
, 0
allows 0
to 0
conclude 0
that 0
life 0
- 0
style 0
factors 0
have 0
considerable 0
influence 0
on 0
interindividual 0
differences 0
in 0
susceptibility 0
to 0
xenobiotics 0
toxicity 0
. 0

The 0
12S B-gene
E1A I-gene
product I-gene
does 0
not 0
activate 0
a 0
TRE 0
sequence 0
, 0
but 0
cotransfection 0
with 0
c B-gene
- I-gene
jun I-gene
circumvents 0
this 0
lack 0
of 0
stimulation 0
. 0

After 0
treatment 0
with 0
tunicamycin 0
, 0
the 0
transfectants 0
secreted 0
unglycosylated 0
18 0
- 0
kDa 0
polypeptides 0
which 0
could 0
also 0
bind 0
IgE B-gene
. 0

PAS1 B-gene
, 0
a 0
yeast 0
gene 0
required 0
for 0
peroxisome 0
biogenesis 0
, 0
encodes 0
a 0
member 0
of 0
a 0
novel 0
family 0
of 0
putative 0
ATPases B-gene
. 0

The 0
gene 0
is 0
1,139 0
base 0
pairs 0
( 0
bp 0
) 0
long 0
, 0
and 0
, 0
like 0
other 0
members 0
of 0
the 0
SIG B-gene
family I-gene
, 0
the 0
beta B-gene
TG I-gene
gene I-gene
is 0
divided 0
into 0
3 0
exons 0
. 0

The 0
pp90rsk B-gene
- I-gene
protein I-gene
kinase I-gene
activity 0
( 0
referred 0
to 0
as 0
rsk B-gene
- I-gene
kinase I-gene
) 0
is 0
also 0
not 0
related 0
to 0
cofactor 0
- 0
dependent 0
signal 0
transducing 0
protein 0
kinases 0
such 0
as 0
the 0
cyclic B-gene
AMP I-gene
- I-gene
dependent I-gene
protein I-gene
kinases I-gene
, 0
members 0
of 0
the 0
protein B-gene
kinase I-gene
C I-gene
family I-gene
, 0
or 0
other 0
Ca2 B-gene
( I-gene
+ I-gene
) I-gene
- I-gene
dependent I-gene
protein I-gene
kinases I-gene
. 0

Human B-gene
GATA I-gene
- I-gene
3 I-gene
: 0
a 0
lineage 0
- 0
restricted 0
transcription 0
factor 0
that 0
regulates 0
the 0
expression 0
of 0
the 0
T B-gene
cell I-gene
receptor I-gene
alpha I-gene
gene I-gene
. 0

Like 0
many 0
eukaryotic 0
transcription 0
factors 0
, 0
these 0
proteins 0
bind 0
to 0
DNA 0
as 0
dimers 0
. 0

Furthermore 0
, 0
the 0
UvrA B-gene
protein I-gene
interacts 0
with 0
the 0
UvrB B-gene
protein I-gene
to 0
modulate 0
its 0
activities 0
, 0
both 0
in 0
solution 0
and 0
in 0
association 0
with 0
DNA 0
, 0
where 0
the 0
UvrAB B-gene
complex I-gene
possesses 0
a 0
helicase B-gene
activity 0
. 0

The 0
ED30 0
values 0
were 0
2.4 0
and 0
2.2 0
mg/kg 0
and 0
similar 0
to 0
the 0
respective 0
values 0
of 0
nifedipine 0
( 0
ED 0
30:2.4,2.1 0
mg/kg 0
) 0
. 0

Southwestern 0
blot 0
analysis 0
demonstrated 0
that 0
this 0
phosphoprotein 0
can 0
bind 0
the 0
kappa B-gene
B I-gene
element I-gene
directly 0
and 0
specifically 0
. 0

Thus 0
, 0
the 0
positive 0
effect 0
of 0
NS1 B-gene
on 0
the 0
steady 0
- 0
state 0
levels 0
of 0
P4 B-gene
transcripts I-gene
depends 0
on 0
the 0
amplification 0
of 0
gene 0
copy 0
number 0
and 0
the 0
integrity 0
of 0
the 0
terminal 0
repeats 0
. 0

The 0
minus 0
- 0
end 0
- 0
directed 0
microtubule 0
motors 0
, 0
the 0
dyneins B-gene
, 0
may 0
also 0
constitute 0
a 0
superfamily 0
of 0
force 0
- 0
generating 0
proteins 0
with 0
distinct 0
attachment 0
domains 0
. 0

It 0
is 0
transparent 0
, 0
cheap 0
to 0
be 0
made 0
, 0
and 0
easy 0
to 0
empty 0
and 0
was 0
tested 0
in 0
118 0
animals 0
for 0
two 0
and 0
four 0
weeks 0
. 0

The 0
incompatibility 0
group 0
W 0
plasmid 0
pSa 0
suppresses 0
Agrobacterium 0
tumefaciens 0
oncogenicity 0
( 0
J 0
. 0

Potential 0
translational 0
start 0
signals 0
are 0
upstream 0
of 0
ORF1 0
and 0
ORF2 0
. 0

Imaging 0
of 0
D2 B-gene
dopamine I-gene
receptor I-gene

The 0
Thr161Val 0
mutation 0
causes 0
a 0
lethal 0
phenotype 0
in 0
the 0
fission 0
yeast 0
Schizosaccharomyces 0
pombe 0
, 0
while 0
replacement 0
of 0
Thr161 0
with 0
glutamic 0
acid 0
, 0
potentially 0
mimicking 0
phosphorylation 0
, 0
causes 0
uncoordination 0
of 0
mitosis 0
and 0
multiple 0
cytokinesis 0
. 0

The 0
abundance 0
of 0
transcripts 0
from 0
several 0
unrelated 0
genes 0
is 0
decreased 0
in 0
cdc68 B-gene
- I-gene
1 I-gene
mutant I-gene
cells 0
after 0
transfer 0
to 0
the 0
restrictive 0
temperature 0
, 0
while 0
at 0
least 0
one 0
transcript 0
, 0
from 0
the 0
HSP82 B-gene
gene I-gene
, 0
persists 0
in 0
an 0
aberrant 0
fashion 0
. 0

Deregulation 0
of 0
their 0
expression 0
may 0
contribute 0
to 0
malignant 0
transformation 0
associated 0
with 0
HTLV 0
- 0
1 0
infection 0
. 0

The 0
murine B-gene
Mov I-gene
- I-gene
34 I-gene
gene I-gene
: 0
full 0
- 0
length 0
cDNA 0
and 0
genomic 0
organization 0
. 0

CREB B-gene
was 0
identified 0
as 0
one 0
of 0
the 0
protein 0
components 0
in 0
several 0
of 0
the 0
gel 0
shift 0
complexes 0
formed 0
with 0
the 0
variant 0
CRE 0
. 0

The 0
spectrum 0
of 0
histologically 0
diagnosed 0
malignant 0
neoplasms 0
in 0
Sabah 0
, 0
1983 0
- 0
1988 0
. 0

When 0
transfected 0
into 0
Drosophila 0
SL 0
- 0
2 0
cells 0
, 0
pCAT 0
plasmid 0
containing 0
2,090 0
bp 0
of 0
5' 0
- 0
flanking 0
region 0
shows 0
a 0
3.0 0
- 0
to 0
3.5 0
- 0
fold 0
increase 0
in 0
chloramphenicol B-gene
acetyltransferase I-gene
activity 0
after 0
induction 0
with 0
retinoic 0
acid 0
and/or 0
8 0
- 0
bromo 0
- 0
cAMP 0
. 0

Two 0
alternatively 0
spliced 0
5 0
' 0
UTRs 0
, 0
designated 0
type 0
I 0
and 0
type 0
II 0
, 0
of 0
222 0
and 0
115 0
bp 0
, 0
respectively 0
, 0
were 0
found 0
associated 0
with 0
PFP B-gene
. 0

The 0
N 0
- 0
terminus 0
of 0
another 0
open 0
reading 0
frame 0
was 0
found 0
3 0
' 0
from 0
nifA B-gene
and 0
tentatively 0
identified 0
as 0
nifB B-gene
by 0
amino 0
acid 0
sequence 0
comparison 0
. 0

The 0
RNA 0
genome 0
of 0
rabbit 0
hemorrhagic 0
disease 0
virus 0
( 0
RHDV 0
) 0
was 0
molecularly 0
cloned 0
. 0

Therefore 0
, 0
we 0
have 0
developed 0
a 0
system 0
to 0
study 0
nuclear 0
targeting 0
in 0
plants 0
and 0
have 0
established 0
that 0
the 0
nuclear 0
transport 0
machinery 0
is 0
similar 0
in 0
monocots 0
and 0
dicots 0
. 0

A 0
novel 0
cDNA 0
clone 0
termed 0
R2 0
was 0
isolated 0
by 0
subtractive 0
hybridization 0
of 0
a 0
cDNA 0
library 0
of 0
phytohemagglutinin B-gene
( 0
PHA B-gene
) 0
/phorbol 0
myristate 0
acetate 0
- 0
stimulated 0
Jurkat 0
cells 0
and 0
by 0
rescreening 0
a 0
cDNA 0
library 0
of 0
PHA 0
- 0
stimulated 0
peripheral 0
blood 0
lymphocytes 0
. 0

In 0
conclusion 0
, 0
we 0
observed 0
a 0
great 0
regeneration 0
ability 0
following 0
mechanical 0
injury 0
in 0
the 0
nasal 0
mucosa 0
. 0

There 0
occurred 0
a 0
linear 0
relationship 0
between 0
the 0
drop 0
in 0
glucose B-gene
- I-gene
6 I-gene
- I-gene
phosphatase I-gene
dehydrogenase I-gene
activity 0
and 0
in 0
vitamin 0
E 0
level 0
, 0
on 0
one 0
hand 0
, 0
and 0
the 0
duration 0
of 0
poisoning 0
with 0
sodium 0
nitrite 0
. 0

A 0
vector 0
containing 0
a 0
transcriptionally 0
inactive 0
neomycin B-gene
phosphotransferase I-gene
II I-gene
gene I-gene
was 0
used 0
to 0
select 0
promoter 0
sequences 0
from 0
a 0
pool 0
of 0
random 0
genomic 0
DNA 0
fragments 0
. 0

Chagas 0
' 0
disease 0
, 0
visceral 0
leishmaniasis 0
, 0
anti B-gene
- I-gene
nuclear I-gene
factor I-gene
, 0
schistosomiasis 0
, 0
rheumatoid B-gene
factor I-gene
and 0
normal 0
controls 0
. 0

Previous 0
analysis 0
of 0
the 0
98 0
- 0
bp 0
sequence 0
has 0
delineated 0
several 0
protein 0
- 0
binding 0
domains 0
that 0
are 0
recognized 0
by 0
nuclear 0
factors 0
present 0
in 0
human 0
brain 0
cells 0
. 0

The 0
second 0
transcriptional 0
unit 0
, 0
designated 0
UL26.5 B-gene
, 0
predicted 0
to 0
specify 0
a 0
protein 0
of 0
329 0
amino 0
acids 0
, 0
encodes 0
the 0
family B-gene
35 I-gene
proteins I-gene
; 0
it 0
is 0
transcribed 0
by 0
an 0
mRNA 0
which 0
initiates 0
at 0
approximately 0
nucleotide 0
+1000 0
of 0
the 0
UL26 B-gene
transcription 0
initiation 0
site 0
and 0
is 0
translated 0
from 0
the 0
methionine 0
initiation 0
codon 0
located 0
at 0
position 0
+1099 0
of 0
the 0
UL26 B-gene
transcriptional I-gene
unit I-gene
. 0

The 0
adeno B-gene
- I-gene
associated I-gene
virus I-gene
( I-gene
AAV I-gene
) I-gene
rep I-gene
gene I-gene
encodes 0
four 0
proteins 0
( 0
Rep78 B-gene
, 0
Rep68 B-gene
, 0
Rep52 B-gene
, 0
and 0
Rep40 B-gene
) 0
required 0
for 0
AAV 0
DNA 0
replication 0
and 0
AAV 0
gene 0
regulation 0
. 0

A 0
larger 0
region 0
upstream 0
of 0
human B-gene
CMV I-gene
dbp I-gene
also 0
mediated 0
replication 0
in 0
transient 0
assays 0
. 0

It 0
also 0
contains 0
a 0
picornaviral B-gene
3C I-gene
- I-gene
like I-gene
protease I-gene
domain I-gene
and 0
two 0
papain B-gene
- I-gene
like I-gene
protease I-gene
domains I-gene
. 0

However 0
, 0
the 0
relative 0
positions 0
of 0
the 0
VV 0
genes 0
( 0
genus 0
Orthopoxvirus 0
) 0
are 0
different 0
than 0
those 0
of 0
the 0
corresponding 0
ORFs 0
in 0
SFV 0
( 0
genus 0
Leporipoxvirus 0
) 0
, 0
indicating 0
complex 0
rearrangements 0
of 0
DNA 0
in 0
the 0
genome 0
of 0
one 0
or 0
both 0
of 0
these 0
viruses 0
subsequent 0
to 0
their 0
divergence 0
from 0
a 0
common 0
ancestor 0
. 0

This 0
result 0
suggests 0
that 0
phosphorylation 0
of 0
Thr 0
14 0
and/or 0
Tyr 0
15 0
inhibits 0
p34cdc2 B-gene
kinase I-gene
activity 0
, 0
in 0
line 0
with 0
the 0
location 0
of 0
these 0
residues 0
within 0
the 0
putative 0
ATP 0
binding 0
site 0
of 0
the 0
kinase 0
. 0

In 0
short 0
- 0
term 0
cotransfections 0
, 0
a 0
pFRTK B-gene
- 0
CAT B-gene
target 0
containing 0
EBNA B-gene
- I-gene
1 I-gene
- I-gene
binding I-gene
sites I-gene
from 0
the 0
EBV 0
origin 0
of 0
plasmid 0
replication 0
, 0
ori B-gene
- I-gene
P I-gene
, 0
was 0
transactivated 0
by 0
a 0
carboxy B-gene
- I-gene
terminal I-gene
EBNA I-gene
- I-gene
1 I-gene
construction I-gene
( 0
amino 0
acids 0
450 0
to 0
641 0
) 0
that 0
also 0
carried 0
a 0
c B-gene
- I-gene
myc I-gene
nuclear I-gene
localization I-gene
signal I-gene
. 0

The 0
findings 0
are 0
compatible 0
with 0
the 0
idea 0
that 0
the 0
genes 0
encoding 0
PDGF B-gene
receptors I-gene
in 0
glioma 0
cells 0
are 0
regulated 0
in 0
concert 0
with 0
other 0
genes 0
, 0
the 0
expression 0
of 0
which 0
may 0
reflect 0
the 0
developmental 0
program 0
of 0
normal 0
glia 0
cell 0
lineages 0
. 0

Suggestive 0
evidence 0
was 0
obtained 0
that 0
cstA B-gene
is 0
involved 0
in 0
peptide 0
utilization 0
. 0

This 0
study 0
tested 0
the 0
hypothesis 0
that 0
sodium 0
channel 0
blocking 0
drugs 0
selectively 0
prolong 0
the 0
late 0
potential 0
, 0
or 0
terminal 0
low 0
amplitude 0
signal 0
, 0
portion 0
of 0
the 0
signal 0
- 0
averaged 0
QRS 0
complex 0
and 0
that 0
prolongation 0
of 0
the 0
late 0
potential 0
would 0
correlate 0
with 0
slowing 0
of 0
ventricular 0
tachycardia 0
. 0

Identification 0
and 0
nucleotide 0
sequence 0
of 0
Rhizobium B-gene
meliloti I-gene
insertion I-gene
sequence I-gene
ISRm3 I-gene
: 0
similarity 0
between 0
the 0
putative 0
transposase B-gene
encoded 0
by 0
ISRm3 B-gene
and 0
those 0
encoded 0
by 0
Staphylococcus B-gene
aureus I-gene
IS256 I-gene
and 0
Thiobacillus B-gene
ferrooxidans I-gene
IST2 I-gene
. 0

To 0
determine 0
the 0
relationship 0
of 0
these 0
viruses 0
, 0
the 0
complete 0
DNA 0
sequence 0
of 0
KV 0
consisting 0
of 0
4754 0
bp 0
was 0
determined 0
. 0

Whereas 0
a 0
PR55 B-gene
beta I-gene
transcript I-gene
of 0
about 0
2.3 0
kb 0
was 0
detected 0
at 0
high 0
levels 0
in 0
the 0
neuroblastoma 0
derived 0
cell 0
line 0
LA 0
- 0
N 0
- 0
1 0
, 0
the 0
level 0
of 0
the 0
mRNA 0
was 0
very 0
low 0
in 0
the 0
other 0
human 0
cell 0
lines 0
analyzed 0
. 0

Heterodimers 0
of 0
myogenin B-gene
and 0
E12 B-gene
( 0
or 0
MyoD B-gene
and 0
E12 B-gene
) 0
specifically 0
bound 0
a 0
restriction 0
fragment 0
extending 0
from 0
- 0
200 0
to 0
- 0
103 0
relative 0
to 0
the 0
start 0
of 0
cardiac B-gene
alpha I-gene
- I-gene
actin I-gene
transcription 0
. 0

The 0
effects 0
of 0
c B-gene
- I-gene
myc I-gene
were 0
further 0
dissected 0
by 0
showing 0
that 0
c B-gene
- I-gene
myc I-gene
can 0
inhibit 0
differentiation 0
independently 0
of 0
Id B-gene
, 0
a 0
negative 0
regulator 0
of 0
muscle 0
differentiation 0
. 0

Stable 0
association 0
of 0
U2 B-gene
snRNP I-gene
with 0
the 0
branchpoint 0
sequence 0
of 0
mammalian 0
pre 0
- 0
mRNAs 0
requires 0
binding 0
of 0
a 0
non 0
- 0
snRNP 0
protein 0
to 0
the 0
polypyrimidine 0
tract 0
. 0

Naturally 0
acquired 0
antibodies 0
were 0
demonstrated 0
in 0
some 0
rabbits 0
kept 0
on 0
commercial 0
farms 0
. 0

The 0
Italian 0
Lung 0
Cancer 0
Task 0
Force 0
( 0
FONICAP 0
) 0
. 0

The 0
promoter 0
activity 0
of 0
the 0
gene B-gene
encoding I-gene
Alzheimer I-gene
beta I-gene
- I-gene
amyloid I-gene
precursor I-gene
protein I-gene
( 0
APP B-gene
) 0
is 0
regulated 0
by 0
two 0
blocks 0
of 0
upstream 0
sequences 0
. 0

Biol 0
. 0

Nucleotide 0
sequences 0
between 0
the 0
env B-gene
gene I-gene
and 0
the 0
LTR B-gene
of I-gene
SFV I-gene
- I-gene
1 I-gene
were 0
determined 0
. 0

This 0
element 0
was 0
used 0
to 0
screen 0
an 0
EMBL3 0
mouse 0
genomic 0
library 0
. 0

The 0
MVV 0
- 0
value 0
is 0
under 0
the 0
predicted 0
level 0
in 0
the 0
case 0
of 0
67 0
- 0
76 0
percent 0
. 0

The 0
rad9.192 B-gene
DNA I-gene
repair I-gene
mutant I-gene
from I-gene
the I-gene
fission I-gene
yeast I-gene
, I-gene
Schizosaccharomyces I-gene
pombe I-gene
, 0
is 0
sensitive 0
to 0
both 0
UV 0
and 0
ionising 0
radiation 0
. 0

Review 0
: 0
deterioration 0
of 0
glucose 0
tolerance 0
with 0
age 0
: 0
the 0
role 0
of 0
insulin B-gene
resistance 0
. 0

The 0
5 0
' 0
region 0
shows 0
strong 0
sequence 0
similarity 0
to 0
Escherichia 0
coli 0
consensus 0
promoters 0
and 0
ribosome 0
- 0
binding 0
sequences 0
and 0
allows 0
high 0
levels 0
of 0
expression 0
in 0
E. 0
coli 0
. 0

Premature 0
initiation 0
of 0
mitosis 0
in 0
yeast 0
lacking 0
RCC1 B-gene
or 0
an 0
interacting 0
GTPase B-gene
. 0

The 0
method 0
has 0
been 0
routinely 0
used 0
in 0
our 0
laboratory 0
for 0
1 0
year 0
and 0
has 0
proven 0
to 0
be 0
a 0
reliable 0
procedure 0
for 0
the 0
biological 0
control 0
of 0
occupational 0
exposure 0
to 0
toluene 0
and/or 0
xylene 0
. 0

The 0
patient 0
was 0
a 0
78 0
- 0
year 0
- 0
old 0
male 0
in 0
whom 0
skin 0
lesions 0
preceded 0
the 0
diagnosis 0
of 0
myelofibrosis 0
. 0

Oculus 0
- 0
500 0
is 0
a 0
group 0
of 0
high 0
resolution 0
imaging 0
boards 0
for 0
use 0
with 0
IBM 0
- 0
AT 0
and 0
compatible 0
computers 0
. 0

The 0
human 0
cDNA 0
was 0
used 0
to 0
demonstrate 0
that 0
tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
could 0
rapidly 0
stimulate 0
MARCKS B-gene
gene I-gene
transcription 0
in 0
the 0
human 0
promyelocytic 0
leukemia 0
cell 0
line 0
HL60 0
. 0

After 0
resection 0
of 0
the 0
proximal 0
fragment 0
, 0
all 0
scaphoid 0
contact 0
area 0
and 0
pressure 0
was 0
born 0
by 0
the 0
distal 0
scaphoid 0
fragment 0
. 0

Plate 0
luting 0
, 0
a 0
technique 0
that 0
uses 0
polymethylmethacrylate 0
( 0
PMMA 0
) 0
interposed 0
between 0
the 0
plate 0
and 0
the 0
bone 0
, 0
as 0
well 0
as 0
between 0
the 0
screw 0
heads 0
and 0
the 0
plate 0
, 0
to 0
improve 0
the 0
stability 0
of 0
internal 0
fixation 0
was 0
tested 0
in 0
vitro 0
using 0
20 0
paired 0
equine 0
third 0
metacarpal 0
bones 0
with 0
mid 0
- 0
diaphyseal 0
osteotomies 0
plated 0
with 0
six 0
- 0
hole 0
broad 0
ASIF 0
compression 0
plates 0
. 0

These 0
features 0
were 0
considered 0
consistent 0
with 0
a 0
diagnosis 0
of 0
Rothmund 0
- 0
Thomson 0
syndrome 0
. 0

Thyroid 0
lymphoma 0
and 0
its 0
management 0
. 0

The 0
protein 0
encoded 0
by 0
ORF113 B-gene
contains 0
a 0
transmembrane 0
domain 0
. 0

Space 0
limitations 0
prevent 0
an 0
exhaustive 0
review 0
of 0
all 0
biologic 0
pharmaceuticals 0
, 0
such 0
as 0
tissue B-gene
plasminogen I-gene
activating I-gene
substance I-gene
, 0
hormones 0
( 0
e.g. 0
, 0
thyroid 0
, 0
insulin B-gene
, 0
growth B-gene
hormone I-gene
, 0
erythropoietin B-gene
) 0
, 0
clotting 0
factors 0
, 0
and 0
blood 0
products 0
. 0

Dd B-gene
PK1 I-gene
RNA I-gene
decreases 0
after 0
6 0
h 0
of 0
starvation 0
to 0
re 0
- 0
accumulate 0
once 0
the 0
cells 0
have 0
aggregated 0
. 0

The 0
various 0
forms 0
of 0
sickle 0
cell 0
disease 0
share 0
the 0
common 0
feature 0
of 0
an 0
abnormal 0
globin B-gene
chain I-gene
that 0
, 0
under 0
certain 0
conditions 0
such 0
as 0
hypoxia 0
, 0
results 0
in 0
the 0
sickling 0
of 0
red 0
blood 0
cells 0
and 0
obstruction 0
of 0
blood 0
vessels 0
. 0

The 0
primary 0
structure 0
of 0
each 0
of 0
the 0
three 0
proteins 0
has 0
about 0
70 0
% 0
homology 0
with 0
that 0
of 0
mouse B-gene
contrapsin I-gene
, 0
in 0
contrast 0
to 0
43 0
- 0
46 0
% 0
homology 0
with 0
that 0
of 0
rat B-gene
alpha I-gene
1 I-gene
- I-gene
protease I-gene
inhibitor 0
. 0

Patterns 0
of 0
connections 0
underlying 0
cross 0
- 0
modality 0
integration 0
were 0
studied 0
by 0
injecting 0
distinguishable 0
, 0
retrograde 0
tracers 0
( 0
Fluoro 0
- 0
Gold 0
and 0
diamidino 0
yellow 0
) 0
in 0
pairwise 0
manner 0
into 0
different 0
sensory 0
representations 0
( 0
visual 0
, 0
somatosensory 0
, 0
and 0
auditory 0
) 0
in 0
the 0
cerebral 0
cortex 0
of 0
the 0
rat 0
. 0

Young 0
CD 0
- 0
1 0
mice 0
, 0
4 0
days 0
old 0
, 0
exposed 0
to 0
0.1 0
% 0
nicotine 0
sulfate 0
on 0
gestational 0
days 0
6 0
- 0
20 0
were 0
compared 0
with 0
untreated 0
pups 0
of 0
the 0
same 0
age 0
to 0
determine 0
its 0
effect 0
on 0
the 0
development 0
of 0
mandibular 0
first 0
molars 0
. 0

USF B-gene
synthesized 0
in 0
an 0
in 0
vitro 0
transcription 0
and 0
translation 0
system 0
also 0
binds 0
to 0
the 0
ADH B-gene
promoter I-gene
as 0
well 0
as 0
to 0
the 0
MLP 0
. 0

The 0
across 0
- 0
fiber 0
pattern 0
of 0
the 0
responses 0
to 0
hypotonic 0
NaCl 0
solutions 0
correlated 0
strongly 0
to 0
that 0
elicited 0
by 0
distilled 0
H2O 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

Arterial 0
radioactivity 0
content 0
after 0
the 0
intravenous 0
administration 0
of 0
HMPAO 0
in 0
seven 0
human 0
subjects 0
was 0
analyzed 0
. 0

Linear 0
regression 0
analysis 0
was 0
performed 0
and 0
the 0
following 0
result 0
was 0
obtained 0
: 0
clearance 0
( 0
HMPAO 0
) 0
= 0
0.07 0
+ 0
0.43 0
. 0
rCBF 0
with 0
a 0
high 0
significance 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
IN I-gene
, 0
expressed 0
in 0
Escherichia 0
coli 0
, 0
was 0
purified 0
to 0
near 0
homogeneity 0
. 0

Thigh 0
girth 0
correlated 0
positively 0
with 0
HDL B-gene
and 0
HDL2 B-gene
- I-gene
C I-gene
and 0
mass 0
, 0
and 0
with 0
LDL B-gene
particle 0
size 0
among 0
women 0
. 0

Contributions 0
from 0
pairs 0
of 0
source 0
and 0
target 0
volume 0
elements 0
are 0
summed 0
for 0
the 0
S 0
values 0
between 0
the 0
tumor 0
and 0
itself 0
, 0
between 0
the 0
remaining 0
healthy 0
host 0
organ 0
and 0
itself 0
, 0
and 0
between 0
the 0
tumor 0
and 0
the 0
remaining 0
healthy 0
host 0
organ 0
, 0
with 0
the 0
reciprocity 0
theorem 0
assumed 0
for 0
the 0
last 0
. 0

Tests 0
showed 0
that 0
an 0
overall 0
impression 0
of 0
the 0
force 0
applied 0
could 0
be 0
obtained 0
from 0
a 0
laboratory 0
simulation 0
, 0
but 0
that 0
clearing 0
cement 0
and 0
testing 0
cement 0
were 0
not 0
modelled 0
by 0
this 0
method 0
. 0

The 0
cDNA 0
contained 0
an 0
open 0
reading 0
frame 0
of 0
1392 0
bp 0
that 0
predicted 0
a 0
protein 0
of 0
464 0
amino 0
acids 0
and 0
a 0
molecular 0
mass 0
of 0
52 0
kDa 0
; 0
this 0
protein 0
has 0
97 0
% 0
identity 0
to 0
rat B-gene
liver I-gene
glucokinase I-gene
. 0

Analysis 0
of 0
viral 0
mutants 0
in 0
vivo 0
demonstrated 0
that 0
the 0
NFIII/OCT B-gene
NFIII/OCT I-gene
- I-gene
1 I-gene
binding 0
site 0
and 0
a 0
conserved 0
ATF B-gene
motif I-gene
were 0
important 0
for 0
efficient 0
viral 0
growth 0
. 0

Recovery 0
of 0
radiolabelled 0
BA 0
through 0
urine 0
( 0
28 0
% 0
) 0
and 0
faeces 0
( 0
22 0
% 0
) 0
up 0
to 0
96 0
hrs 0
averaged 0
50 0
% 0
, 0
whereas 0
residual 0
radioactivity 0
in 0
liver 0
and 0
testis 0
experienced 0
a 0
recovery 0
of 0
29 0
% 0
in 0
scorbutic 0
animals 0
. 0

Saccharomyces 0
cerevisiae 0
has 0
been 0
used 0
widely 0
both 0
as 0
a 0
model 0
system 0
for 0
unraveling 0
the 0
biochemical 0
, 0
genetic 0
, 0
and 0
molecular 0
details 0
of 0
gene 0
expression 0
and 0
the 0
secretion 0
process 0
, 0
and 0
as 0
a 0
host 0
for 0
the 0
production 0
of 0
heterologous 0
proteins 0
of 0
biotechnological 0
interest 0
. 0

Paradoxically 0
, 0
however 0
, 0
the 0
GH B-gene
receptor I-gene
cloned 0
from 0
liver 0
exhibits 0
no 0
sequence 0
similarity 0
to 0
receptors 0
with 0
known 0
signal 0
transduction 0
mechanisms 0
, 0
including 0
those 0
exhibiting 0
ligand 0
- 0
activated 0
tyrosine B-gene
kinase I-gene
activity 0
. 0

This 0
indicates 0
that 0
under 0
certain 0
experimental 0
conditions 0
cdc2/p58 B-gene
and 0
cdc2/p58 I-gene

Mutation 0
analysis 0
implicated 0
multiple 0
segments 0
of 0
the 0
5 0
' 0
untranslated 0
region 0
as 0
contributing 0
to 0
the 0
inhibitory 0
effect 0
. 0

Identification 0
of 0
Ets B-gene
- 0
and 0
notch B-gene
- 0
related 0
subunits 0
in 0
GA B-gene
binding I-gene
protein I-gene
. 0

The 0
enzymatic 0
response 0
of 0
neutrophils 0
and 0
monocytes 0
was 0
similar 0
although 0
the 0
magnitude 0
of 0
the 0
NADPH B-gene
oxidase I-gene
activity 0
was 0
significantly 0
higher 0
in 0
neutrophils 0
than 0
in 0
monocytes 0
. 0

In 0
the 0
ileum 0
, 0
enterotoxin 0
increased 0
the 0
luminal 0
disappearance 0
( 0
P 0
less 0
than 0
0.05 0
) 0
and 0
peripheral 0
blood 0
appearance 0
( 0
P 0
less 0
than 0
0.001 0
) 0
of 0
chloroquine 0
. 0

Formalin 0
activated 0
both 0
SNO 0
NS 0
and 0
NnS 0
neurones 0
, 0
but 0
, 0
when 0
they 0
responded 0
, 0
NS 0
neurones 0
( 0
n 0
= 0
5 0
) 0
showed 0
only 0
the 0
first 0
phase 0
of 0
activity 0
while 0
NnS 0
neurones 0
showed 0
either 0
one 0
( 0
n 0
= 0
13 0
) 0
or 0
two 0
phases 0
( 0
n 0
= 0
6 0
) 0
. 0

Uptake 0
of 0
ofloxacin 0
by 0
Escherichia 0
coli 0

It 0
is 0
concluded 0
that 0
attention 0
to 0
these 0
issues 0
can 0
substantially 0
improve 0
the 0
quality 0
of 0
research 0
on 0
AIDS 0
related 0
behaviors 0
on 0
Black 0
communities 0
. 0

The 0
effectiveness 0
of 0
alpha 0
- 0
mercapto 0
- 0
beta 0
- 0
( 0
2 0
- 0
furyl 0
) 0
acrylic 0
acid 0
( 0
MFA 0
) 0
and 0
N 0
- 0
benzyl 0
- 0
N 0
- 0
dithiocarboxy 0
- 0
D 0
- 0
glucamine 0
( 0
NaB 0
) 0
, 0
used 0
in 0
combination 0
, 0
in 0
the 0
mobilization 0
and 0
excretion 0
of 0
lead 0
was 0
investigated 0
in 0
rats 0
. 0

These 0
results 0
suggest 0
that 0
beta B-gene
- I-gene
1 I-gene
may 0
act 0
as 0
a 0
tissue 0
- 0
specific 0
, 0
trans 0
- 0
acting 0
regulator 0
of 0
the 0
expression 0
of 0
the 0
beta B-gene
- I-gene
zein I-gene
gene I-gene
in 0
developing 0
maize 0
endosperm 0
. 0

This 0
study 0
examines 0
the 0
effects 0
of 0
hypovolemia 0
on 0
the 0
extracellular 0
ptO2 0
and 0
ptH 0
distributions 0
at 0
multiple 0
tissue 0
sites 0
using 0
a 0
recently 0
developed 0
multipoint 0
microelectrode 0
, 0
that 0
provides 0
simultaneous 0
measurements 0
of 0
ptO2 0
and 0
ptH 0
. 0

All 0
members 0
are 0
also 0
capable 0
of 0
activating 0
in 0
vivo 0
transcription 0
from 0
promoters 0
that 0
contain 0
a 0
C/EBP B-gene
- I-gene
binding I-gene
site I-gene
. 0

The 0
domains 0
involved 0
in 0
superactivation 0
appear 0
to 0
be 0
a 0
subset 0
of 0
those 0
necessary 0
to 0
achieve 0
synergistic 0
activation 0
. 0

Information 0
on 0
conserved 0
noncoding 0
sequences 0
will 0
help 0
in 0
studies 0
on 0
the 0
regulation 0
of 0
the 0
pro B-gene
alpha I-gene
1 I-gene
( I-gene
II I-gene
) I-gene
collagen I-gene
gene I-gene
. 0

Chlamydia 0
trachomatis 0
and 0
Chlamydia 0
psittaci 0
were 0
not 0
affected 0
by 0
methanol 0
fixation 0
. 0

Although 0
human 0
infections 0
with 0
bacteraemia 0
due 0
to 0
Pasteurella 0
multocida 0
are 0
not 0
uncommon 0
, 0
endocarditis 0
associated 0
with 0
P. 0
haemolytica 0
is 0
rare 0
. 0

For 0
SMX 0
at 0
pH 0
7.0 0
, 0
a 0
1:1 0
complex 0
is 0
formed 0
, 0
but 0
at 0
pH 0
7.5 0
HPCD 0
has 0
little 0
effect 0
on 0
the 0
solubility 0
of 0
the 0
highly 0
ionized 0
SMX 0
, 0
presumably 0
since 0
only 0
un 0
- 0
ionized 0
molecules 0
can 0
form 0
inclusion 0
complexes 0
with 0
the 0
HPCD 0
. 0

PO2 0
measurements 0
using 0
a 0
double 0
barrelled 0
recess 0
type 0
microelectrodes 0
were 0
measured 0
in 0
the 0
optic 0
nerve 0
head 0
of 0
miniature 0
pigs 0
in 0
normoxia 0
and 0
hyperoxia 0
. 0

POU B-gene
- 0
specific 0
and 0
POU B-gene
- 0
homeo 0
domains 0
of 0
Oct3 B-gene
were 0
produced 0
in 0
Echerichia 0
coli 0
for 0
characterization 0
of 0
DNA 0
binding 0
to 0
the 0
octamer 0
sequence 0
. 0

A 0
deletion 0
series 0
of 0
the 0
5 0
' 0
flanking 0
region 0
was 0
created 0
from 0
position 0
- 0
1329 0
to 0
- 0
74 0
relative 0
to 0
the 0
transcriptional 0
initiation 0
site 0
and 0
similarly 0
examined 0
in 0
transgenic 0
tobacco 0
. 0

The 0
nucleotide 0
( 0
nt 0
) 0
sequences 0
of 0
the 0
exons 0
, 0
exon/intron 0
boundaries 0
and 0
5' 0
- 0
and 0
3' 0
- 0
untranslated 0
regions 0
were 0
determined 0
. 0

Out 0
of 0
40 0
patients 0
, 0
who 0
initially 0
did 0
not 0
show 0
eye 0
complications 0
due 0
to 0
leprosy 0
, 0
37 0
patients 0
were 0
essentially 0
the 0
same 0
10 0
years 0
later 0
. 0

Thus 0
, 0
two 0
very 0
different 0
regulatory 0
elements 0
are 0
used 0
to 0
mediate 0
estrogen 0
induction 0
of 0
related 0
genes 0
in 0
chickens 0
and 0
amphibians 0
. 0

Toxicity 0
was 0
very 0
mild 0
with 0
both 0
regimens 0
, 0
although 0
sedation 0
was 0
significantly 0
higher 0
in 0
arm 0
B 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Experimentally 0
in 0
green 0
monkeys 0
, 0
Syrian 0
hamsters 0
and 0
white 0
mice 0
the 0
authors 0
studied 0
the 0
pathogenic 0
properties 0
of 0
a 0
new 0
virus 0
Issyk 0
- 0
Kul 0
. 0

Increasing 0
mean 0
arterial 0
pressure 0
by 0
phenylephrine 0
infusion 0
to 0
levels 0
much 0
greater 0
than 0
produced 0
by 0
NMA 0
and 0
NNA 0
caused 0
only 0
small 0
reductions 0
in 0
cardiac 0
output 0
. 0

J 0
. 0

Limits 0
of 0
energy 0
turnover 0
in 0
relation 0
to 0
physical 0
performance 0
were 0
addressed 0
in 0
terms 0
of 0
upper 0
and 0
lower 0
limit 0
, 0
changes 0
during 0
a 0
training 0
programme 0
and 0
how 0
to 0
regulate 0
energy 0
balance 0
at 0
a 0
changing 0
energy 0
turnover 0
. 0

With 0
stepwise 0
reductions 0
in 0
flow 0
, 0
the 0
peak 0
( 0
S 0
) 0
and 0
trough 0
( 0
D 0
) 0
points 0
of 0
the 0
maximum 0
shifted 0
- 0
frequency 0
envelope 0
fell 0
in 0
parallel 0
in 0
a 0
linear 0
fashion 0
until 0
D 0
reached 0
zero 0
. 0

The 0
IE0 B-gene
gene I-gene
product 0
also 0
transactivated 0
the 0
IE1 B-gene
promoter I-gene
but 0
did 0
not 0
affect 0
expression 0
from 0
its 0
own 0
promoter 0
. 0

Moreover 0
, 0
promoters 0
containing 0
a 0
TATA 0
box 0
in 0
the 0
absence 0
of 0
Sp1 B-gene
sites I-gene
or 0
Sp1 B-gene
sites I-gene
in 0
the 0
absence 0
of 0
a 0
TATA 0
box 0
were 0
equally 0
inducible 0
in 0
vitro 0
, 0
as 0
was 0
an 0
RNA B-gene
polymerase I-gene
III I-gene
promoter I-gene
. 0

Evaluation 0
of 0
left 0
ventricular 0
function 0
using 0
gated 0
planar 0
myocardial 0
imaging 0
with 0
Tc 0
- 0
99m 0
- 0
MIBI 0

Ivermectin 0
uptake 0
and 0
distribution 0
in 0
the 0
plasma 0
and 0
tissue 0
of 0
Sudanese 0
and 0
Mexican 0
patients 0
infected 0
with 0
Onchocerca 0
volvulus 0
. 0

Bone 0
marrow 0
abnormalities 0
in 0
Hodgkin 0
's 0
disease 0
are 0
reviewed 0
and 0
the 0
current 0
understanding 0
of 0
the 0
pathological 0
mechanisms 0
leading 0
to 0
aplastic 0
anemia 0
is 0
discussed 0
. 0

The 0
smaller 0
uptake 0
rate 0
and 0
faster 0
clearance 0
rate 0
resulted 0
in 0
the 0
lower 0
BCF 0
for 0
SWA 0
killifish 0
. 0

The 0
currently 0
proposed 0
extended 0
arch 0
repair 0
should 0
be 0
reserved 0
for 0
the 0
small 0
group 0
of 0
infants 0
with 0
transverse 0
aortic 0
arch 0
to 0
ascending 0
aorta 0
diameter 0
ratios 0
( 0
arch 0
indices 0
) 0
of 0
less 0
than 0
0.25 0
. 0

DNA 0
hybridization 0
analysis 0
revealed 0
that 0
both 0
pigmented 0
and 0
nonpigmented 0
cells 0
of 0
Y. 0
pestis 0
possess 0
a 0
DNA 0
locus 0
homologous 0
to 0
the 0
Escherichia B-gene
coli I-gene
fur I-gene
gene I-gene
. 0

Increases 0
in 0
the 0
perfusate 0
PCO2 0
but 0
not 0
in 0
the 0
perfusate 0
H+ 0
were 0
highly 0
correlated 0
with 0
decreases 0
in 0
both 0
myocardial 0
contractility 0
and 0
oxygen 0
consumption 0
( 0
r2 0
= 0
.88 0
) 0
. 0

Expression 0
was 0
cell 0
cycle 0
controlled 0
, 0
with 0
steady 0
- 0
state 0
RNA 0
levels 0
significantly 0
higher 0
in 0
growth 0
- 0
arrested 0
than 0
in 0
growth 0
- 0
stimulated 0
cells 0
. 0

Determinants 0
of 0
recurrent 0
ischaemia 0
and 0
revascularisation 0
procedures 0
after 0
thrombolysis 0
with 0
recombinant 0
tissue B-gene
plasminogen I-gene
activator I-gene
in 0
primary 0
coronary 0
occlusion 0
. 0

Therefore 0
, 0
the 0
rbcL B-gene
- 0
rbcS B-gene
locus 0
seems 0
to 0
be 0
barely 0
expressed 0
under 0
a 0
standard 0
condition 0
for 0
photoautotrophic 0
growth 0
. 0

Relationship 0
between 0
mitochondrial B-gene
NADH I-gene
- I-gene
ubiquinone I-gene
reductase I-gene
and 0
a 0
bacterial B-gene
NAD I-gene
- I-gene
reducing I-gene
hydrogenase I-gene
. 0

Analysis 0
of 0
mRNA 0
expression 0
shows 0
that 0
AT B-gene
- I-gene
BP1 I-gene
and 0
AT B-gene
- I-gene
BP2 I-gene
are 0
expressed 0
in 0
all 0
the 0
tissues 0
examined 0
. 0

We 0
report 0
two 0
patients 0
receiving 0
maintenance 0
valproate 0
, 0
one 0
with 0
resolving 0
acute 0
hepatitis 0
C 0
and 0
the 0
other 0
with 0
chronic 0
persistent 0
hepatitis 0
C 0
, 0
with 0
incidental 0
microvesicular 0
steatosis 0
demonstrated 0
on 0
oil 0
- 0
red 0
O 0
stains 0
. 0

3 0
cases 0

UDP B-gene
- I-gene
Gal I-gene
: I-gene
Gal I-gene
beta I-gene
1 I-gene
- I-gene
- I-gene
- I-gene
- I-gene
4GlcNAc I-gene
alpha I-gene
1 I-gene
- I-gene
- I-gene
- I-gene
- I-gene
3 I-gene
- I-gene
galactosyltransferase I-gene
is 0
a 0
terminal B-gene
glycosyltransferase I-gene
that 0
is 0
widely 0
expressed 0
in 0
a 0
variety 0
of 0
mammalian 0
species 0
, 0
with 0
the 0
notable 0
exception 0
of 0
man 0
, 0
apes 0
, 0
and 0
Old 0
World 0
monkeys 0
. 0

A 0
synthetic 0
oligonucleotide 0
containing 0
the 0
SRE 0
sequence 0
from 0
the 0
mouse B-gene
c I-gene
- I-gene
fos I-gene
gene I-gene
promoter I-gene
( 0
- 0
299 0
to 0
- 0
322 0
) 0
was 0
radioactively 0
labeled 0
, 0
used 0
as 0
a 0
probe 0
for 0
the 0
mobility 0
shift 0
assay 0
and 0
Southwestern 0
( 0
DNA 0
- 0
protein 0
) 0
blotting 0
, 0
and 0
also 0
used 0
for 0
sequence 0
- 0
specific 0
affinity 0
chromatography 0
. 0

Sequence 0
requirements 0
for 0
premature 0
transcription 0
arrest 0
within 0
the 0
first 0
intron 0
of 0
the 0
mouse B-gene
c I-gene
- I-gene
fos I-gene
gene I-gene
. 0

Infarct 0
regional 0
ejection 0
fraction 0
improved 0
by 0
10.1 0
+/ 0
- 0
2.1 0
% 0
between 0
early 0
and 0
late 0
studies 0
when 0
the 0
infarct 0
- 0
related 0
artery 0
was 0
patent 0
and 0
by 0
4.8 0
+/ 0
- 0
1.4 0
% 0
if 0
it 0
was 0
occluded 0
( 0
p 0
= 0
0.048 0
) 0
; 0
changes 0
in 0
global 0
and 0
noninfarct 0
regional 0
ejection 0
fraction 0
were 0
similar 0
irrespective 0
of 0
perfusion 0
status 0
. 0

One 0
of 0
its 0
lysine 0
residues 0
is 0
modified 0
by 0
spermidine 0
to 0
form 0
hypusine 0
, 0
a 0
posttranslational 0
modification 0
unique 0
to 0
eIF B-gene
- I-gene
5A I-gene
. 0

The 0
plasmid 0
shuffle 0
technique 0
was 0
used 0
to 0
replace 0
the 0
wild 0
- 0
type 0
gene 0
with 0
the 0
mutant 0
form 0
, 0
resulting 0
in 0
failure 0
of 0
the 0
yeast 0
cells 0
to 0
grow 0
. 0

If 0
this 0
is 0
the 0
case 0
, 0
identification 0
and 0
characterization 0
of 0
transcripts 0
from 0
the 0
Ig B-gene
loci I-gene
should 0
permit 0
a 0
better 0
understanding 0
of 0
the 0
gene 0
rearrangement 0
process 0
. 0

Transcription 0
of 0
the 0
metH B-gene
gene I-gene
in I-gene
Salmonella I-gene
typhimurium I-gene
and I-gene
Escherichia I-gene
coli I-gene
is 0
positively 0
regulated 0
by 0
the 0
metR B-gene
gene I-gene
product I-gene
, 0
a 0
DNA 0
binding 0
protein 0
. 0

Disruption 0
of 0
the 0
chromosomal B-gene
AAR1 I-gene
gene I-gene
in 0
alpha 0
and 0
a/alpha 0
cells 0
conferred 0
the 0
nonmating 0
phenotype 0
, 0
and 0
the 0
a/alpha 0
diploids 0
could 0
not 0
sporulate 0
. 0

The 0
effect 0
of 0
ICRF 0
- 0
187 0
on 0
the 0
antitumor 0
response 0
induced 0
by 0
the 0
combination 0
of 0
ADR 0
and 0
WBH 0
was 0
also 0
investigated 0
in 0
order 0
to 0
assess 0
alterations 0
in 0
the 0
therapeutic 0
index 0
of 0
this 0
combined 0
therapeutic 0
modality 0
treatment 0
. 0

The 0
ORF 0
was 0
analyzed 0
for 0
secondary 0
structural 0
features 0
, 0
and 0
the 0
sequence 0
data 0
bases 0
were 0
searched 0
for 0
homologies 0
. 0

This 0
study 0
indicates 0
that 0
this 0
dose 0
- 0
intense 0
regimen 0
can 0
be 0
safely 0
administered 0
, 0
even 0
with 0
the 0
use 0
of 0
purged 0
marrow 0
, 0
with 0
an 0
acceptable 0
toxicity 0
profile 0
. 0

Mitomycin 0
- 0
C 0
can 0
cause 0
severe 0
necrosis 0
and 0
ulceration 0
when 0
extravasated 0
inadvertently 0
into 0
skin 0
and 0
soft 0
tissues 0
following 0
IV 0
drug 0
administration 0
. 0

In 0
this 0
study 0
, 0
we 0
have 0
cloned 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
nidogen I-gene
gene I-gene
. 0

INTERVENTIONS 0
: 0
Patients 0
received 0
rt B-gene
- I-gene
PA I-gene
, 0
heparin 0
, 0
and 0
aspirin 0
. 0

Consistent 0
with 0
the 0
in 0
vivo 0
result 0
, 0
the 0
pseudorevertant 0
endonucleases 0
in 0
the 0
crude 0
cell 0
extract 0
display 0
site 0
- 0
specific 0
partial 0
DNA 0
cleavage 0
activity 0
. 0

Additionally 0
, 0
I B-gene
kappa I-gene
B I-gene
beta I-gene
, 0
but 0
not 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
, 0
also 0
prevented 0
the 0
binding 0
of 0
Rel B-gene
to 0
the 0
kappa B-gene
B I-gene
site I-gene
. 0

Sequence 0
analysis 0
reveals 0
that 0
the 0
DNA 0
binding 0
domain 0
of 0
ILF B-gene
has 0
strong 0
homology 0
to 0
the 0
recently 0
described 0
fork B-gene
head I-gene
DNA I-gene
binding I-gene
domain I-gene
found 0
in 0
the 0
Drosophila B-gene
homeotic I-gene
protein I-gene
fork I-gene
head I-gene
and 0
a 0
family 0
of 0
hepatocyte B-gene
nuclear I-gene
factors I-gene
, 0
HNF B-gene
- I-gene
3 I-gene
. 0

Lengthy 0
and 0
repeated 0
hemodialyses 0
were 0
required 0
to 0
lower 0
lithemia 0
to 0
nontoxic 0
ranges 0
. 0

A 0
single 0
i.p 0
. 0
injection 0
of 0
d 0
, 0
l 0
- 0
baclofen 0
10 0
mg/kg 0
both 0
reduced 0
noradrenaline 0
( 0
NA 0
) 0
biosynthesis 0
in 0
vivo 0
( 0
31 0
% 0
) 0
and 0
the 0
endogenous 0
concentration 0
of 0
normetanephrine 0
( 0
NMN 0
) 0
( 0
32 0
% 0
) 0
and 0
increased 0
NA 0
levels 0
( 0
28 0
% 0
) 0
. 0

Fufang 0
wuzi 0
yanzong 0
pills 0
have 0
strong 0
leukogenic 0
effect 0
on 0
cyclophosphamide 0
induced 0
leukopenia 0
in 0
mice 0
. 0

Mutations 0
in 0
the 0
small 0
subunit 0
of 0
ribulosebisphosphate B-gene
carboxylase I-gene
affect 0
subunit 0
binding 0
and 0
catalysis 0
. 0

The 0
structural 0
changes 0
in 0
intra 0
- 0
acinar 0
artery 0
manifested 0
mainly 0
by 0
an 0
increase 0
in 0
number 0
of 0
muscular 0
artery 0
resulting 0
from 0
muscularization 0
of 0
precursor 0
cells 0
( 0
pericytes 0
and 0
intermediate 0
cells 0
) 0
located 0
within 0
partially 0
muscular 0
and 0
nonmuscular 0
arterial 0
wall 0
to 0
smooth 0
muscle 0
cell 0
, 0
and 0
by 0
the 0
medial 0
wall 0
thickened 0
due 0
to 0
hypertrophy 0
and 0
hyperplasia 0
of 0
smooth 0
muscle 0
cells 0
as 0
well 0
as 0
accumulation 0
of 0
a 0
large 0
amount 0
of 0
collagen B-gene
, 0
especially 0
the 0
type B-gene
1 I-gene
collagen I-gene
. 0

These 0
results 0
suggest 0
that 0
NZ 0
- 0
107 0
may 0
be 0
a 0
useful 0
drug 0
for 0
the 0
treatment 0
of 0
bronchial 0
asthma 0
by 0
reducing 0
late 0
- 0
phase 0
airway 0
responses 0
and 0
airway 0
hyperreactivity 0
. 0

In 0
study 0
2 0
, 0
the 0
correlation 0
coefficients 0
between 0
the 0
ISO2 0
measurements 0
obtained 0
at 0
the 0
ulcer 0
margin 0
and 0
at 0
the 0
adjacent 0
normal 0
mucosa 0
, 0
and 0
delta 0
ISO2 0
obtained 0
by 0
the 0
experienced 0
observer 0
and 0
one 0
of 0
the 0
three 0
learners 0
were 0
0.94 0
, 0
0.97 0
, 0
and 0
0.94 0
, 0
respectively 0
. 0

Bronchial 0
mucosa 0
tattooing 0
in 0
persons 0
exposed 0
to 0
different 0
industrial 0
aerosols 0
did 0
not 0
depend 0
on 0
the 0
forms 0
of 0
PC 0
, 0
DB 0
and 0
the 0
diseases 0
' 0
stages 0
. 0

Anti B-gene
- I-gene
HBc I-gene
production 0
of 0
PBMC 0
was 0
enhanced 0
remarkably 0
in 0
this 0
case 0
. 0

Sequence 0
analysis 0
of 0
the 0
sMtCK B-gene
genomic I-gene
upstream I-gene
sequences I-gene
reveals 0
a 0
typical 0
TATAA 0
box 0
within 0
the 0
80 0
base 0
pairs 0
( 0
bp 0
) 0
that 0
, 0
by 0
transfection 0
experiments 0
, 0
are 0
sufficient 0
to 0
promote 0
expression 0
of 0
chimeric 0
plasmids 0
with 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
. 0

Sequence 0
analysis 0
of 0
the 0
sMtCK B-gene
genomic I-gene
upstream I-gene
sequences I-gene
reveals 0
a 0
typical 0
TATAA 0
box 0
within 0
the 0
80 0
base 0
pairs 0
( 0
bp 0
) 0
that 0
, 0
by 0
transfection 0
experiments 0
, 0
are 0
sufficient 0
to 0
promote 0
expression 0
of 0
chimeric 0
plasmids 0
with 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
. 0

The 0
cDNA 0
segment 0
is 0
flanked 0
by 0
the 0
immunoglobulin B-gene
gene I-gene
recombination I-gene
signal I-gene
sequences I-gene
so 0
that 0
the 0
cDNA 0
segment 0
can 0
invert 0
and 0
the 0
human B-gene
IL I-gene
- I-gene
2R I-gene
L I-gene
chain I-gene
is 0
subsequently 0
expressed 0
under 0
the 0
control 0
of 0
the 0
SV40 B-gene
promoter I-gene
. 0

Lipoprotein B-gene
lipase I-gene
( 0
LPL B-gene
) 0
, 0
a 0
key 0
enzyme 0
in 0
normal 0
lipoprotein 0
metabolism 0
, 0
has 0
a 0
complex 0
pattern 0
of 0
regulation 0
and 0
tissue 0
- 0
specific 0
expression 0
. 0

Deletion 0
of 0
the 0
proximal 0
octanucleotide 0
motif 0
from 0
the 0
plasmid 0
containing 0
the 0
- 0
461 0
fragment 0
of 0
the 0
LPL B-gene
promoter I-gene
, 0
resulted 0
in 0
a 0
79 0
and 0
76 0
% 0
decrease 0
in 0
the 0
level 0
of 0
expression 0
in 0
transfected 0
3T3 0
- 0
L1 0
adipocytes 0
and 0
HepG2 0
hepatocytes 0
, 0
respectively 0
. 0

We 0
examined 0
the 0
binding 0
of 0
purified 0
T3 B-gene
receptor I-gene
alpha I-gene
( 0
T3R B-gene
alpha I-gene
) 0
, 0
overexpressed 0
in 0
Escherichia 0
coli 0
, 0
to 0
wild 0
- 0
type 0
and 0
up 0
and 0
down 0
mutations 0
of 0
the 0
rGH B-gene
T3RE B-gene
to 0
evaluate 0
whether 0
transcriptional 0
potency 0
correlates 0
with 0
changes 0
in 0
T3R B-gene
binding 0
. 0

Comparison 0
of 0
the 0
cDNA 0
- 0
predicted 0
avian B-gene
TnIcardiac I-gene
amino I-gene
acid I-gene
sequences I-gene
with 0
known 0
TnI B-gene
sequences I-gene
indicated 0
1 0
) 0
that 0
the 0
presence 0
of 0
an 0
N 0
- 0
terminal 0
extension 0
sequence 0
carrying 0
a 0
dual 0
protein B-gene
kinase I-gene
A I-gene
phosphorylation 0
target 0
site 0
and 0
an 0
adjacent 0
proline 0
- 0
rich 0
segment 0
is 0
an 0
ancient 0
cardiac 0
- 0
specific 0
feature 0
of 0
TnI B-gene
which 0
has 0
been 0
conserved 0
since 0
the 0
bird/mammal 0
divergence 0
, 0
2 0
) 0
that 0
features 0
of 0
the 0
near 0
- 0
N 0
- 0
terminal 0
troponin B-gene
C I-gene
( 0
TnC B-gene
) 0
- 0
binding 0
site 0
sequence 0
suggest 0
isoform 0
- 0
specific 0
adaptation 0
of 0
TnI B-gene
and 0
TnC B-gene
, 0
and 0
3 0
) 0
that 0
the 0
avian 0
TnIcardiac B-gene
internal 0
actin/TnC B-gene
- I-gene
binding I-gene
, I-gene
actomyosin I-gene
- I-gene
inhibitory I-gene
, I-gene
domain I-gene
shows 0
significant 0
sequence 0
divergence 0
from 0
mammalian B-gene
TnIcardiac I-gene
sequences I-gene
, 0
including 0
the 0
absence 0
of 0
a 0
protein B-gene
kinase I-gene
C I-gene
target 0
site 0
which 0
is 0
a 0
cardiac 0
- 0
specific 0
feature 0
of 0
TnI B-gene
in 0
mammals 0
. 0

Ventilatory 0
management 0
casebook 0
. 0

An 0
ASSEMBLER 0
routine 0
for 0
on 0
- 0
line 0
graphic 0
display 0
and 0
averaging 0
of 0
data 0
acquired 0
on 0
a 0
personal 0
microcomputer 0
. 0

Expression 0
of 0
the 0
mouse B-gene
TSH I-gene
beta I-gene
gene I-gene
, 0
therefore 0
, 0
gives 0
rise 0
to 0
multiple 0
mRNAs 0
, 0
each 0
with 0
a 0
unique 0
5' 0
- 0
untranslated 0
region 0
. 0

Habituation 0
of 0
completely 0
isolated 0
neurons 0
of 0
the 0
edible 0
snail 0
to 0
electrical 0
stimulation 0
. 0

It 0
was 0
found 0
that 0
the 0
ROSP 0
undergoes 0
a 0
number 0
of 0
fluctuations 0
in 0
the 0
negative 0
and 0
positive 0
directions 0
with 0
a 0
gradually 0
decreasing 0
amplitude 0
in 0
the 0
course 0
of 0
5 0
- 0
25 0
days 0
following 0
the 0
operation 0
, 0
after 0
which 0
relatively 0
stable 0
negative 0
values 0
of 0
the 0
ROSP 0
are 0
established 0
on 0
the 0
average 0
in 0
electrodes 0
implanted 0
to 0
the 0
level 0
of 0
the 0
dura 0
mater 0
, 0
and 0
positive 0
values 0
in 0
electrodes 0
implanted 0
to 0
the 0
level 0
of 0
the 0
pia 0
mater 0
. 0

Blood 0
flow 0
velocity 0
waveforms 0
were 0
recorded 0
by 0
pulsed 0
Doppler 0
examination 0
of 0
the 0
fetal 0
internal 0
carotid 0
and 0
middle 0
cerebral 0
arteries 0
using 0
the 0
established 0
transabdominal 0
route 0
as 0
well 0
as 0
a 0
new 0
transvaginal 0
approach 0
. 0

Quantitative 0
analysis 0
of 0
DNA 0
using 0
flow 0
cytometry 0
and 0
immunocytochemical 0
findings 0
in 0
16 0
cases 0
of 0
cardiac 0
myxomas 0

Sequence 0
analysis 0
revealed 0
that 0
in 0
addition 0
to 0
the 0
non 0
- 0
spliced 0
variant 0
, 0
multiple 0
mRNA 0
species 0
were 0
generated 0
by 0
alternative 0
splicing 0
resulting 0
in 0
the 0
exclusion 0
of 0
92 0
, 0
166 0
, 0
170 0
, 0
174 0
and 0
263 0
nucleotides 0
( 0
nt 0
) 0
, 0
respectively 0
, 0
from 0
exon 0
1 0
. 0

Position 0
22 0
is 0
an 0
isoleucine 0
in 0
the 0
complete B-gene
SsoL12 I-gene
protein I-gene
sequence I-gene
, 0
coded 0
by 0
an 0
AUA 0
codon 0
. 0

Symptoms 0
due 0
to 0
the 0
action 0
of 0
mastocyte 0
mediators 0
were 0
observed 0
. 0

In 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
, 0
copper 0
levels 0
exert 0
some 0
control 0
over 0
the 0
level 0
of 0
SOD1 B-gene
expression 0
. 0

Of 0
these 0
179 0
samples 0
, 0
Mobiluncus 0
SP 0
was 0
observed 0
in 0
35 0
( 0
19.6 0
% 0
) 0
using 0
Gram 0
staining 0
and 0
in 0
18 0
( 0
10.1 0
% 0
) 0
this 0
microorganism 0
was 0
isolated 0
in 0
agar 0
RLK 0
and 0
anaerobic 0
atmosphere 0
. 0

Previous 0
investigators 0
have 0
suggested 0
that 0
subretinal 0
blood 0
damages 0
the 0
retina 0
in 0
part 0
because 0
of 0
its 0
solid 0
fibrin B-gene
meshwork 0
. 0

Twenty 0
- 0
four 0
hours 0
later 0
, 0
the 0
animals 0
were 0
randomized 0
to 0
subretinal 0
treatment 0
with 0
2.5 0
micrograms 0
of 0
tissue B-gene
plasminogen I-gene
activator I-gene
or 0
a 0
similar 0
volume 0
of 0
physiologic 0
saline 0
. 0

Neuro 0
- 0
otological 0
examinations 0
revealed 0
spontaneous 0
downbeat 0
nystagmus 0
, 0
bilateral 0
gaze 0
nystagmus 0
and 0
rebound 0
nystagmus 0
. 0

Since 0
the 0
morphology 0
of 0
the 0
lesions 0
can 0
mimic 0
that 0
of 0
other 0
cutaneous 0
disorders 0
, 0
Bowen 0
's 0
disease 0
is 0
often 0
not 0
recognized 0
initially 0
. 0

Equine 0
amnion 0
and 0
live 0
yeast 0
cell 0
derivative 0
were 0
evaluated 0
as 0
a 0
biological 0
dressing 0
and 0
as 0
a 0
topical 0
wound 0
medicament 0
respectively 0
, 0
in 0
the 0
treatment 0
of 0
granulating 0
wounds 0
of 0
the 0
distal 0
portion 0
of 0
the 0
limbs 0
of 0
horses 0
. 0

To 0
lower 0
the 0
current 0
high 0
incidence 0
of 0
NANB 0
- 0
induced 0
PTH 0
, 0
in 0
1986 0
, 0
the 0
American 0
Association 0
of 0
Blood 0
Banks 0
( 0
AABB 0
) 0
recommended 0
testing 0
for 0
these 0
PTH 0
- 0
associated 0
`` 0
surrogate 0
'' 0
markers 0
on 0
all 0
donated 0
units 0
of 0
blood 0
. 0

Insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
1 I-gene
( 0
IGF B-gene
- I-gene
1 I-gene
) 0
in 0
burn 0
patients 0
. 0

Fusion 0
of 0
ubiquitin B-gene
to 0
pADPRP B-gene
increased 0
the 0
yield 0
of 0
pADPRP B-gene
approximately 0
10 0
- 0
fold 0
compared 0
to 0
that 0
of 0
the 0
unfused 0
enzyme 0
. 0

In 0
group 0
III 0
, 0
patients 0
also 0
received 0
their 0
own 0
mediastinal 0
drainage 0
blood 0
, 0
shed 0
for 0
6 0
hours 0
after 0
operation 0
, 0
after 0
concentration 0
and 0
washing 0
in 0
a 0
MBRS 0
. 0

The 0
suppression 0
was 0
also 0
demonstrated 0
in 0
a 0
transient 0
expression 0
assay 0
in 0
vivo 0
using 0
isolated 0
barley 0
endosperms 0
. 0

The 0
effect 0
of 0
salmon B-gene
calcitonin I-gene
nasal 0
spray 0
in 0
women 0
with 0
established 0
osteoporosis 0
has 0
also 0
been 0
studied 0
. 0

Skeletal 0
muscle 0
metaboreceptor 0
responses 0
are 0
impaired 0
in 0
heart 0
failure 0
. 0

Skeletal 0
muscle 0
metaboreceptor 0
exercise 0
responses 0
are 0
attenuated 0
in 0
heart 0
failure 0
. 0

Evaluation 0
of 0
antiepileptic 0
drug 0
effect 0
on 0
membrane 0
fluidity 0
. 0

The 0
examinations 0
were 0
performed 0
on 0
two 0
groups 0
of 0
20 0
( 0
using 0
AmF/SnF2 0
) 0
- 0
, 0
resp 0
. 0

RNA 0
gel 0
retardation 0
and 0
competition 0
analyses 0
indicate 0
that 0
TRP B-gene
- I-gene
185 I-gene
binding 0
is 0
strongly 0
dependent 0
on 0
the 0
TAR 0
RNA 0
loop 0
sequences 0
. 0

The 0
vaccine 0
used 0
was 0
known 0
to 0
be 0
immunogenic 0
for 0
older 0
children 0
and 0
adults 0
. 0

Both 0
groups 0
then 0
underwent 0
hypnotic 0
induction 0
, 0
and 0
completed 0
the 0
test 0
again 0
( 0
R2 0
) 0
. 0

Applications 0
of 0
three 0
- 0
dimensional 0
analysis 0
to 0
the 0
auditory 0
P300 0
. 0

The 0
construct 0
was 0
introduced 0
into 0
BW2001 0
( 0
xth 0
- 0
11 0
, 0
nfo 0
- 0
2 0
) 0
strain 0
cells 0
of 0
Escherichia 0
coli 0
. 0

Recombinant B-gene
human I-gene
TFIID I-gene
supported 0
weak 0
basal 0
transcription 0
in 0
heat 0
- 0
treated 0
nuclear 0
extracts 0
whereas 0
a 0
partially 0
purified 0
TFIID B-gene
fraction 0
from 0
HeLa 0
cells 0
reconstituted 0
a 0
maximal 0
level 0
of 0
transcription 0
. 0

Only 0
after 0
a 0
pretreatment 0
aimed 0
at 0
increasing 0
its 0
oxide 0
surface 0
layer 0
was 0
titanium 0
powder 0
found 0
to 0
accelerate 0
the 0
precipitation 0
from 0
solutions 0
containing 0
2 0
mmol/L 0
CaCl2 0
, 0
2 0
mmol/L 0
KH2PO4 0
, 0
50 0
mmol/L 0
Hepes 0
, 0
pH 0
7.2 0
, 0
and 0
to 0
induce 0
precipitation 0
from 0
metastable 0
solutions 0
containing 0
1.2 0
mmol/L 0
CaCl2 0
, 0
1.2 0
mmol/L 0
KH2PO4 0
, 0
50 0
mmol/L 0
Hepes 0
, 0
pH 0
7.2 0
, 0
at 0
37 0
degrees 0
C 0
. 0

We 0
conclude 0
that 0
solidification 0
could 0
occur 0
in 0
all 0
feeds 0
containing 0
casein B-gene
and 0
that 0
alternative 0
feeds 0
should 0
be 0
considered 0
in 0
patients 0
with 0
increased 0
gastric 0
acidity 0
. 0

Neither 0
model 0
, 0
as 0
applied 0
, 0
provided 0
a 0
satisfactory 0
account 0
of 0
the 0
effects 0
of 0
the 0
main 0
variables 0
of 0
number 0
of 0
tones 0
and 0
amount 0
of 0
perturbation 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

This 0
generalization 0
of 0
MFP 0
involves 0
defining 0
an 0
appropriate 0
high 0
- 0
resolution 0
cost 0
function 0
, 0
parametrizing 0
the 0
search 0
space 0
of 0
the 0
environment 0
and 0
source 0
, 0
constructing 0
solutions 0
of 0
the 0
wave 0
equation 0
, 0
and 0
utilizing 0
a 0
nonlinear 0
optimization 0
method 0
to 0
search 0
the 0
parameter 0
landscape 0
for 0
the 0
global 0
minimum 0
of 0
the 0
cost 0
function 0
. 0

Determination 0
of 0
an 0
RNA 0
structure 0
involved 0
in 0
splicing 0
inhibition 0
of 0
a 0
muscle 0
- 0
specific 0
exon 0
. 0

Endothelial 0
cells 0
stored 0
with 0
University 0
of 0
Wisconsin 0
solution 0
excluded 0
trypan 0
blue 0
better 0
( 0
1.0 0
% 0
+/ 0
- 0
0.5 0
% 0
cells 0
stained 0
, 0
p 0
less 0
than 0
0.001 0
. 0

The 0
original 0
technique 0
was 0
developed 0
in 0
the 0
1960 0
's 0
to 0
analyze 0
the 0
inner 0
ear 0
fluid 0
as 0
a 0
diagnostic 0
procedure 0
( 0
i.e. 0
, 0
diagnostic 0
labyrinthotomy 0
) 0
in 0
acoustic 0
neuroma 0
suspects 0
. 0

The 0
effect 0
of 0
diffusion 0
limitation 0
was 0
quantified 0
in 0
terms 0
of 0
the 0
ratio 0
O2 0
uptake/O2 0
requirement 0
( 0
= 0
fraction 0
of 0
cross 0
- 0
sectional 0
area 0
supplied 0
with 0
O2 0
) 0
, 0
assuming 0
local 0
O2 0
requirement 0
per 0
unit 0
volume 0
to 0
be 0
constant 0
and 0
independent 0
of 0
PO2 0
at 0
PO2 0
greater 0
than 0
0 0
. 0

( 0
2 0
) 0
Diffusion 0
limitation 0
in 0
the 0
heterogeneous 0
model 0
sets 0
in 0
at 0
a 0
lower 0
O2 0
requirement 0
value 0
, 0
and 0
increases 0
more 0
gradually 0
with 0
increasing 0
O2 0
requirement 0
, 0
than 0
in 0
the 0
corresponding 0
homogeneous 0
models 0
with 0
the 0
same 0
average 0
cylinder 0
diameter 0
. 0

The 0
antihypertensive 0
effect 0
of 0
Estulic 0
has 0
been 0
examined 0
over 0
a 0
12 0
- 0
month 0
period 0
in 0
101 0
hypertensive 0
patients 0
. 0

At 0
the 0
time 0
of 0
the 0
seizure 0
, 0
the 0
patient 0
was 0
asked 0
to 0
read 0
a 0
test 0
phrase 0
aloud 0
until 0
it 0
was 0
read 0
correctly 0
and 0
clearly 0
. 0

Monitoring 0
patients 0
with 0
acute 0
leukemia 0
for 0
IL B-gene
- I-gene
1 I-gene
and 0
TNF B-gene
levels 0
throughout 0
the 0
clinical 0
course 0
of 0
disease 0
may 0
help 0
clarify 0
the 0
causes 0
of 0
febrile 0
episodes 0
. 0

Echinococcus 0
granulosus 0
was 0
diagnosed 0
by 0
fine 0
- 0
needle 0
aspiration 0
cytology 0
of 0
a 0
lung 0
cyst 0
in 0
a 0
6 0
- 0
yr 0
- 0
old 0
white 0
female 0
in 0
central 0
Missouri 0
. 0

The 0
sequence 0
was 0
determined 0
of 0
6493 0
nucleotides 0
encompassing 0
the 0
bet B-gene
genes I-gene
of I-gene
Escherichia I-gene
coli I-gene
which 0
encode 0
the 0
osmoregulatory 0
choline 0
- 0
glycine 0
betaine 0
pathway 0
. 0

A 0
7 0
- 0
day 0
treatment 0
of 0
amphotericin 0
B 0
( 0
5 0
mg/kg/day 0
i.p 0
. 0
) 0
significantly 0
reduced 0
the 0
glomerular 0
filtration 0
rate 0
( 0
GFR 0
) 0
measured 0
as 0
inuline 0
clearance 0
and 0
creatinine 0
clearance 0
( 0
0.74 0
+/ 0
- 0
0.29 0
and 0
0.16 0
+/ 0
- 0
0.04 0
ml/min 0
, 0
respectively 0
) 0
in 0
comparison 0
to 0
vehicle 0
- 0
treated 0
rats 0
( 0
2.04 0
+/ 0
- 0
0.23 0
and 0
1.29 0
+/ 0
- 0
0.19 0
ml/min 0
, 0
respectively 0
) 0
. 0

Evolution 0
of 0
lesions 0
did 0
not 0
necessarily 0
follow 0
a 0
regular 0
progression 0
through 0
the 0
later 0
stages 0
of 0
the 0
vitelliform 0
classification 0
. 0

Confocal 0
fluorescence 0
microscopy 0
in 0
modern 0
cell 0
biology 0
. 0

Toluene 0
is 0
the 0
chemical 0
most 0
frequently 0
present 0
in 0
cases 0
involving 0
volatile 0
solvents 0
. 0

Fortunately 0
DDT 0
- 0
, 0
HCH 0
- 0
and 0
HCB 0
- 0
levels 0
decreased 0
in 0
breast 0
milk 0
during 0
the 0
last 0
years 0
. 0

A 0
herpesvirus 0
proteinase 0
activity 0
has 0
been 0
identified 0
and 0
partially 0
characterized 0
by 0
using 0
the 0
cloned 0
enzyme 0
and 0
substrate 0
genes 0
in 0
transient 0
transfection 0
assays 0
. 0

Adult 0
H 0
, 0
but 0
not 0
R 0
, 0
manifested 0
the 0
burrowing 0
preference 0
whenever 0
offered 0
the 0
opportunity 0
. 0

The 0
rear 0
silver 0
liquid 0
chamber 0
was 0
threefold 0
thick 0
to 0
17 0
MeV 0
protons 0
in 0
water 0
and 0
it 0
efficiently 0
produced 0
either 0
13N 0
by 0
the 0
16O 0
( 0
p 0
, 0
alpha 0
) 0
13N 0
reaction 0
or 0
[ 0
18F 0
] 0
fluoride 0
ion 0
by 0
the 0
18O 0
( 0
p 0
, 0
n 0
) 0
18F 0
reaction 0
. 0

Heterogeneous 0
electron 0
transfer 0
of 0
cytochrome B-gene
c I-gene
facilitated 0
by 0
polypyrrole 0
and 0
methylene 0
blue 0
polypyrrole 0
film 0
modified 0
electrodes 0
. 0

Selective 0
activation 0
of 0
adrenaline 0
secretion 0
by 0
the 0
rat 0
adrenal 0
in 0
neuroglycopenia 0
detected 0
via 0
microdialysis 0

Urine 0
specimens 0
containing 0
either 0
phencyclidine 0
( 0
PCP 0
) 0
or 0
11 0
- 0
nor 0
- 0
delta 0
9 0
- 0
tetrahydrocannabinol 0
- 0
9 0
- 0
carboxylic 0
acid 0
( 0
9 0
- 0
THC 0
- 0
COOH 0
) 0
were 0
adulterated 0
with 0
sodium 0
chloride 0
, 0
bleach 0
, 0
vinegar 0
, 0
potassium 0
hydroxide 0
, 0
liquid 0
soap 0
, 0
2 0
- 0
propanol 0
, 0
and 0
ammonia 0
. 0

The 0
1489 0
- 0
base 0
pair 0
EFIA B-gene
cDNA 0
encodes 0
a 0
322 0
- 0
amino 0
acid 0
protein 0
which 0
is 0
nearly 0
identical 0
to 0
two 0
previously 0
described 0
human 0
DNA 0
binding 0
proteins 0
. 0

Four 0
putative 0
positive 0
cDNA 0
clones 0
were 0
isolated 0
, 0
and 0
the 0
largest 0
insert 0
( 0
pASB B-gene
- I-gene
1 I-gene
) 0
was 0
sequenced 0
in 0
both 0
orientations 0
. 0

Sci 0
. 0

Dose 0
standardisation 0
of 0
botulinum B-gene
toxin I-gene
. 0

The 0
coding 0
sequence 0
for 0
a 0
260 0
- 0
amino 0
- 0
acid 0
residue 0
polypeptide 0
was 0
interrupted 0
by 0
a 0
single 0
short 0
intron 0
of 0
60 0
base 0
pairs 0
( 0
bp 0
) 0
, 0
and 0
about 0
70 0
% 0
of 0
the 0
deduced 0
amino 0
acid 0
sequence 0
of 0
the 0
Drosophila B-gene
PCNA I-gene
was 0
identical 0
to 0
the 0
rat 0
and 0
human B-gene
PCNA I-gene
polypeptides I-gene
, 0
with 0
conserved 0
unique 0
repeats 0
of 0
leucine 0
in 0
the 0
C 0
- 0
terminal 0
region 0
. 0

Translational 0
fusions 0
of 0
the 0
aroF B-gene
regulatory I-gene
regions I-gene
to 0
lacZ B-gene
were 0
constructed 0
and 0
then 0
introduced 0
in 0
single 0
copy 0
into 0
the 0
E. 0
coli 0
chromosome 0
. 0
beta B-gene
- I-gene
Galactosidase I-gene
assays 0
for 0
tyrR 0
- 0
mediated 0
regulation 0
of 0
aroF B-gene
- 0
lacZ B-gene
expression 0
revealed 0
that 0
the 0
E. B-gene
coli I-gene
TyrR I-gene
repressor I-gene
apparently 0
recognizes 0
the 0
operators 0
of 0
both 0
organisms 0
with 0
about 0
equal 0
efficiency 0
. 0

Along 0
with 0
previously 0
mapped 0
genes 0
including 0
Ly B-gene
- I-gene
1 I-gene
and 0
CD20 B-gene
, 0
OSBP B-gene
defines 0
a 0
new 0
conserved 0
syntenic 0
group 0
on 0
the 0
long 0
arm 0
of 0
chromosome 0
11 0
in 0
the 0
human 0
and 0
the 0
proximal 0
end 0
of 0
chromosome 0
19 0
in 0
the 0
mouse 0
. 0

During 0
exercise 0
K+ 0
is 0
released 0
from 0
contracting 0
muscle 0
and 0
plasma 0
K+ 0
concentration 0
rises 0
. 0

Following 0
treatment 0
, 0
serum 0
estradiol 0
levels 0
were 0
higher 0
in 0
groups 0
E 0
+ 0
T 0
and 0
E 0
than 0
in 0
group 0
C 0
. 0

We 0
conclude 0
that 0
the 0
beta 0
- 0
adrenergic 0
agonist 0
, 0
isoproterenol 0
, 0
has 0
little 0
influence 0
on 0
vascular 0
capacitance 0
or 0
liver 0
volume 0
of 0
dogs 0
, 0
unless 0
the 0
hepatic 0
outflow 0
resistance 0
is 0
elevated 0
by 0
agents 0
such 0
as 0
histamine 0
. 0

DNA 0
sequence 0
and 0
evolution 0
of 0
the 0
CPS B-gene
domain I-gene
of 0
the 0
Syrian B-gene
hamster I-gene
multifunctional I-gene
protein I-gene
CAD I-gene
. 0

Here 0
we 0
show 0
that 0
these 0
synthetic 0
binding 0
sites 0
have 0
a 0
more 0
restricted 0
and 0
specific 0
ability 0
to 0
enhance 0
transcription 0
when 0
assayed 0
in 0
transformed 0
embryos 0
. 0

After 0
base 0
- 0
line 0
CBF 0
was 0
established 0
, 0
hexamethonium 0
bromide 0
( 0
2 0
mg/kg 0
iv 0
) 0
, 0
ipratropium 0
bromide 0
( 0
0.5 0
microgram/kg 0
iv 0
) 0
, 0
indomethacin 0
( 0
2 0
mg/kg 0
iv 0
) 0
, 0
or 0
intravenous 0
0.9 0
% 0
saline 0
was 0
administered 0
. 0

A 0
high 0
- 0
frequency 0
restriction 0
fragment 0
length 0
polymorphism 0
was 0
evident 0
in 0
the 0
DNA 0
from 0
29 0
unrelated 0
individuals 0
using 0
the 0
enzyme 0
BglII B-gene
. 0

The 0
antilog 0
transformation 0
of 0
pH 0
did 0
not 0
improve 0
the 0
results 0
. 0

Telomeres 0
prevent 0
end 0
- 0
to 0
- 0
end 0
fusions 0
and 0
exonucleolytic 0
degradation 0
, 0
enable 0
the 0
end 0
of 0
the 0
linear 0
DNA 0
molecule 0
to 0
replicate 0
, 0
and 0
function 0
in 0
cell 0
division 0
. 0

One 0
of 0
these 0
is 0
located 0
in 0
the 0
5' 0
- 0
untranslated 0
region 0
, 0
and 0
may 0
encode 0
regulatory 0
sequences 0
. 0

The 0
native 0
enzyme 0
purified 0
from 0
protease B-gene
- I-gene
B I-gene
- 0
deficient 0
URA2 B-gene
- 0
transformed 0
cells 0
, 0
was 0
phosphorylated 0
in 0
vitro 0
using 0
catalytic 0
subunits 0
of 0
pure 0
cAMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
. 0

This 0
study 0
suggests 0
that 0
BSPMs 0
are 0
useful 0
in 0
the 0
assessment 0
of 0
AMI 0
in 0
terms 0
of 0
diagnosis 0
, 0
location 0
and 0
extent 0
of 0
myocardial 0
infarct 0
. 0

A 0
bovine 0
abomasum 0
lambda 0
gt11 0
cDNA 0
library 0
was 0
screened 0
with 0
a 0
monoclonal 0
antibody 0
raised 0
against 0
the 0
rabbit B-gene
H I-gene
, I-gene
K I-gene
- I-gene
ATPase I-gene
beta I-gene
subunit I-gene
. 0

Judicious 0
use 0
of 0
laboratory 0
testing 0
, 0
including 0
monitoring 0
of 0
CD4 B-gene
cell 0
counts 0
, 0
is 0
recommended 0
. 0

There 0
is 0
no 0
TATA 0
box 0
appropriately 0
spaced 0
upstream 0
from 0
the 0
transcription 0
initiation 0
site 0
. 0

Characterization 0
of 0
the 0
5 0
' 0
end 0
of 0
the 0
growth 0
- 0
regulated 0
Syrian B-gene
hamster I-gene
CAD I-gene
gene I-gene
. 0

Early 0
cirrhosis 0
, 0
an 0
early 0
modality 0
of 0
the 0
evolution 0
of 0
acute 0
hepatitis 0
. 0

Examination 0
of 0
immediate B-gene
- I-gene
early I-gene
transcription I-gene
factor I-gene
expression 0
during 0
the 0
MDI 0
regimen 0
revealed 0
that 0
RA 0
mediated 0
an 0
elevated 0
, 0
prolonged 0
expression 0
of 0
c B-gene
- I-gene
Jun I-gene
mRNA I-gene
accompanied 0
by 0
diminished 0
expression 0
of 0
c B-gene
- I-gene
Fos I-gene
and 0
Jun B-gene
- I-gene
B I-gene
mRNAs I-gene
. 0

Although 0
heart 0
rate 0
and 0
diastolic 0
pressure 0
rose 0
in 0
some 0
degree 0
1 0
min 0
after 0
intubation 0
, 0
free 0
and 0
total 0
CA 0
concentrations 0
did 0
not 0
increase 0
during 0
study 0
period 0
. 0

Processing 0
, 0
secretion 0
, 0
and 0
immunoreactivity 0
of 0
carboxy B-gene
terminally I-gene
truncated I-gene
dengue I-gene
- I-gene
2 I-gene
virus I-gene
envelope I-gene
proteins I-gene
expressed 0
in 0
insect 0
cells 0
by 0
recombinant 0
baculoviruses 0
. 0

Combined 0
therapy 0
with 0
MK 0
- 0
801 0
and 0
nimodipine 0
for 0
protection 0
of 0
ischemic 0
brain 0
damage 0
. 0

Initial 0
screening 0
of 0
a 0
rat 0
liver 0
cDNA 0
library 0
with 0
an 0
oligonucleotide 0
probe 0
derived 0
from 0
the 0
rat 0
SCP2 B-gene
protein 0
sequence 0
revealed 0
an 0
825 0
- 0
base 0
pair 0
cDNA 0
clone 0
coding 0
for 0
the 0
complete 0
SCP2 B-gene
protein 0
sequence 0
. 0

Cloning 0
, 0
expression 0
, 0
and 0
nucleotide 0
sequence 0
of 0
rat B-gene
liver I-gene
sterol I-gene
carrier I-gene
protein I-gene
2 I-gene
cDNAs I-gene
. 0

The 0
addition 0
of 0
an 0
equimolar 0
complex 0
of 0
the 0
fourth 0
and 0
seventh 0
largest 0
subunits 0
, 0
purified 0
from 0
pol B-gene
II I-gene
holoenzyme I-gene
by 0
ion 0
- 0
exchange 0
chromatography 0
in 0
the 0
presence 0
of 0
urea 0
, 0
restored 0
promoter 0
- 0
directed 0
initiation 0
activity 0
to 0
pol B-gene
II I-gene
delta I-gene
4/7 I-gene
. 0

We 0
report 0
here 0
the 0
identification 0
of 0
HSF B-gene
in 0
the 0
fission 0
yeast 0
Schizosaccharomyces 0
pombe 0
. 0

Induction 0
requires 0
the 0
ACE1 B-gene
gene I-gene
product I-gene
, 0
which 0
binds 0
to 0
specific 0
sites 0
in 0
the 0
promoter 0
region 0
of 0
the 0
CUP1 B-gene
gene I-gene
. 0

Gel 0
mobility 0
shift 0
assays 0
using 0
a 0
synthetic 0
E6 B-gene
motif I-gene
detected 0
a 0
B 0
- 0
cell 0
- 0
specific 0
complex 0
in 0
addition 0
to 0
a 0
ubiquitous 0
band 0
found 0
also 0
in 0
T 0
cells 0
and 0
HeLa 0
cells 0
. 0

Seven 0
clones 0
encoding 0
interferon B-gene
response I-gene
element I-gene
binding I-gene
factors I-gene
have 0
been 0
isolated 0
from 0
a 0
mouse 0
fibroblast 0
lambda 0
gt11 0
cDNA 0
library 0
by 0
using 0
a 0
32P 0
end 0
- 0
labeled 0
tandem 0
trimer 0
of 0
the 0
mouse B-gene
( I-gene
2' I-gene
- I-gene
5 I-gene
' I-gene
) I-gene
oligoadenylate I-gene
synthetase I-gene
gene I-gene
interferon 0
response 0
element 0
as 0
a 0
probe 0
. 0

The 0
sequence 0
of 0
four 0
clones 0
was 0
sufficient 0
to 0
construct 0
a 0
3018 B-gene
- I-gene
bp I-gene
BAL I-gene
cDNA I-gene
structure 0
. 0

The 0
application 0
of 0
these 0
instruments 0
allows 0
occlusion 0
of 0
the 0
ascending 0
aorta 0
traversed 0
by 0
the 0
perfusion 0
cannula 0
inserted 0
directly 0
or 0
through 0
the 0
apex 0
of 0
the 0
heart 0
as 0
well 0
as 0
simultaneous 0
left 0
ventricular 0
venting 0
. 0

Adenylosuccinate B-gene
synthetase I-gene
( 0
IMP 0
: 0
L B-gene
- I-gene
aspartate I-gene
ligase I-gene
( 0
GDP 0
) 0
, 0
EC B-gene
6.3.4.4 I-gene
) 0
plays 0
an 0
important 0
role 0
in 0
purine 0
biosynthesis 0
catalyzing 0
the 0
GTP 0
- 0
dependent 0
conversion 0
of 0
IMP 0
to 0
AMP 0
. 0

Immunophenotyping 0
in 0
four 0
cases 0
, 0
demonstrated 0
non 0
- 0
B 0
, 0
non 0
- 0
T 0
cell 0
origin 0
in 0
three 0
and 0
pre 0
- 0
B 0
cell 0
origin 0
in 0
one 0
. 0

DNA 0
- 0
protein 0
UV 0
cross 0
- 0
linking 0
studies 0
indicated 0
that 0
UHF B-gene
- I-gene
1 I-gene
has 0
an 0
electrophoretic 0
mobility 0
on 0
sodium 0
dodecyl 0
sulfate 0
- 0
acrylamide 0
gels 0
of 0
approximately 0
85 0
kDa 0
and 0
suggested 0
that 0
additional 0
proteins 0
, 0
specific 0
to 0
each 0
promoter 0
, 0
bind 0
to 0
each 0
site 0
. 0

The 0
results 0
strengthen 0
the 0
conclusion 0
that 0
predominantly 0
dynamic 0
activity 0
increases 0
the 0
G4 B-gene
content 0
of 0
mature 0
innervated 0
fast 0
muscles 0
. 0

The 0
specific 0
interaction 0
between 0
a 0
defined 0
structural 0
element 0
of 0
the 0
human 0
immunodeficiency 0
virus 0
mRNA 0
( 0
RRE B-gene
, 0
the 0
Rev B-gene
response I-gene
element I-gene
) 0
and 0
the 0
virus B-gene
- I-gene
encoded I-gene
protein I-gene
Rev I-gene
has 0
been 0
implicated 0
in 0
the 0
regulation 0
of 0
the 0
export 0
of 0
unspliced 0
or 0
singly 0
spliced 0
mRNA 0
from 0
the 0
nucleus 0
to 0
the 0
cytoplasm 0
. 0

We 0
reviewed 0
the 0
records 0
of 0
151 0
patients 0
with 0
optic 0
neuritis 0
examined 0
over 0
an 0
eight 0
- 0
year 0
period 0
. 0

Cut 0
- 0
off 0
levels 0
that 0
define 0
abnormality 0
are 0
rather 0
arbitrary 0
and 0
this 0
decreases 0
the 0
specificity 0
of 0
the 0
test 0
in 0
apparently 0
healthy 0
patients 0
. 0

Alanine B-gene
aminotransferase I-gene
in 0
clinical 0
practice 0
. 0

Nucleotide 0
sequence 0
analysis 0
of 0
the 0
Pseudomonas B-gene
putida I-gene
PpG7 I-gene
salicylate I-gene
hydroxylase I-gene
gene I-gene
( 0
nahG B-gene
) 0
and 0
its 0
3' 0
- 0
flanking 0
region 0
. 0

All 0
six 0
ARF B-gene
cDNAs I-gene
are 0
more 0
similar 0
to 0
each 0
other 0
than 0
to 0
other 0
approximately 0
20 B-gene
- I-gene
kDa I-gene
guanine I-gene
nucleotide I-gene
- I-gene
binding I-gene
proteins I-gene
. 0

The 0
long 0
terminal 0
repeat 0
( 0
LTR 0
) 0
of 0
the 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
contains 0
three 0
binding 0
sites 0
for 0
the 0
transcriptional 0
factor 0
Sp1 B-gene
. 0

DNA 0
from 0
PCR 0
was 0
labeled 0
and 0
used 0
to 0
isolate 0
several 0
lambda 0
gt11 0
cDNA 0
clones 0
, 0
including 0
one 0
full 0
- 0
length 0
one 0
( 0
Dd B-gene
kinase I-gene
- I-gene
2 I-gene
) 0
. 0

Radiation 0
- 0
induced 0
changes 0
in 0
the 0
area 0
of 0
alveoli 0
and 0
septa 0
as 0
well 0
as 0
collagen B-gene
content 0
were 0
seen 0
11 0
weeks 0
after 0
irradiation 0
. 0

The 0
first 0
follow 0
- 0
up 0
was 0
at 0
a 0
nearly 0
constant 0
interval 0
of 0
5.1 0
years 0
in 0
Caerphilly 0
and 0
3.2 0
years 0
in 0
Speedwell 0
; 0
251 0
major 0
IHD 0
events 0
had 0
occurred 0
. 0

A 0
. 0

Perilunar 0
luxation 0
- 0
- 0
an 0
unusual 0
injury 0
demanding 0
immediate 0
and 0
correct 0
treatment 0

Landsberg 0
( 0
La 0
- 0
O 0
) 0
and 0
cv 0
. 0

In 0
summary 0
, 0
at 0
equianesthetic 0
concentrations 0
, 0
desflurane 0
and 0
isoflurane 0
produced 0
similar 0
hemodynamic 0
effects 0
; 0
however 0
, 0
in 0
the 0
absence 0
of 0
drugs 0
that 0
inhibit 0
autonomic 0
reflexes 0
, 0
desflurane 0
had 0
less 0
negative 0
inotropic 0
activity 0
and 0
produced 0
less 0
decrease 0
in 0
arterial 0
pressure 0
. 0

We 0
report 0
here 0
the 0
isolation 0
of 0
a 0
full 0
- 0
length 0
cDNA 0
clone 0
coding 0
for 0
a 0
hitherto 0
undiscovered 0
isoform 0
of 0
the 0
bovine B-gene
C I-gene
- I-gene
subunit I-gene
. 0

Isoform B-gene
C I-gene
beta I-gene
2 I-gene
, 0
an 0
unusual 0
form 0
of 0
the 0
bovine 0
catalytic 0
subunit 0
of 0
cAMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
. 0

Salient 0
applications 0
of 0
PB 0
- 0
PK 0
modeling 0
to 0
toxicological 0
problems 0
are 0
illustrated 0
with 0
examples 0
. 0

Patients 0
with 0
apparently 0
minor 0
CT 0
abnormalities 0
may 0
have 0
significant 0
epidural 0
disease 0
. 0

The 0
cdr1 B-gene
sequence I-gene
includes 0
an 0
additional 0
237 0
amino 0
acids 0
of 0
the 0
contiguous 0
fragment 0
and 0
encodes 0
a 0
product 0
of 0
predicted 0
Mr 0
67,000 0
. 0

Armed 0
with 0
a 0
clear 0
understanding 0
of 0
the 0
pathophysiologic 0
pathways 0
that 0
may 0
cause 0
and/or 0
contribute 0
to 0
the 0
development 0
of 0
unconjugated 0
hyperbilirubinemia 0
and 0
the 0
associated 0
jaundice 0
, 0
the 0
practitioner 0
will 0
be 0
successful 0
in 0
helping 0
the 0
family 0
understand 0
their 0
child 0
's 0
illness 0
. 0

Displacement 0
thresholds 0
of 0
peripheral 0
sites 0
in 0
monocular 0
human 0
vision 0
were 0
obtained 0
. 0

The 0
authors 0
report 0
a 0
case 0
in 0
which 0
stereotactic 0
irrigation 0
of 0
a 0
brain 0
cyst 0
was 0
temporally 0
associated 0
with 0
respiratory 0
distress 0
. 0

ELISA 0
was 0
found 0
to 0
make 0
a 0
contribution 0
to 0
the 0
diagnosis 0
of 0
tuberculosis 0
similar 0
to 0
that 0
of 0
sputum 0
smear 0
. 0

In 0
this 0
paper 0
, 0
we 0
report 0
a 0
detailed 0
study 0
of 0
the 0
structure 0
and 0
the 0
functional 0
role 0
of 0
the 0
MalT B-gene
binding I-gene
sites I-gene
located 0
in 0
the 0
adjacent 0
and 0
divergent 0
pulAp B-gene
and 0
pulCp B-gene
promoters I-gene
. 0

Despite 0
the 0
small 0
number 0
of 0
patients 0
, 0
on 0
the 0
basis 0
of 0
this 0
report 0
, 0
we 0
can 0
confirm 0
that 0
1.5 0
MU/day 0
of 0
alpha B-gene
- I-gene
IFN I-gene
is 0
an 0
adequate 0
treatment 0
for 0
patients 0
with 0
hairy 0
cell 0
leukemia 0
. 0

Paroxysmal 0
fluctuations 0
in 0
observed 0
parasitemia 0
in 0
Plasmodium 0
falciparum 0
malaria 0
. 0

No 0
positive 0
family 0
history 0
was 0
obtained 0
. 0

Occupational 0
asthma 0
and 0
rhinoconjunctivitis 0
from 0
inhalation 0
of 0
crystalline 0
bovine B-gene
serum I-gene
albumin I-gene
powder 0
. 0

A 0
further 0
subdivision 0
of 0
Category 0
pN1 0
into 0
pN1a 0
( 0
metastasis 0
in 0
single 0
node 0
) 0
and 0
pN1b 0
( 0
two 0
or 0
more 0
nodes 0
) 0
is 0
recommended 0
. 0

Amino 0
acid 0
sequence 0
comparisons 0
of 0
the 0
E74A B-gene
protein I-gene
reveal 0
a 0
highly 0
conserved 0
C 0
- 0
terminal 0
region 0
that 0
is 0
rich 0
in 0
basic 0
amino 0
acid 0
residues 0
and 0
which 0
has 0
been 0
proposed 0
to 0
possess 0
sequence 0
- 0
specific 0
DNA 0
binding 0
activity 0
. 0

We 0
found 0
that 0
the 0
relative 0
strengths 0
of 0
the 0
promoters 0
were 0
similar 0
in 0
different 0
contexts 0
. 0

Grasso 0
, 0
and 0
A 0
. 0

After 0
6 0
months 0
, 0
definite 0
improvement 0
in 0
strength 0
occurred 0
in 0
4 0
of 0
7 0
carnitine 0
- 0
treated 0
patients 0
and 0
in 0
none 0
of 0
7 0
controls 0
. 0

Age 0
at 0
POI 0
and 0
asymptote 0
were 0
achieved 0
later 0
for 0
Line 0
RBC2 0
than 0
for 0
Line 0
F 0
. 0

To 0
identify 0
the 0
DNA 0
sequences 0
that 0
cis 0
- 0
regulate 0
the 0
expression 0
of 0
the 0
rat B-gene
liver I-gene
pyruvate I-gene
kinase I-gene
( 0
L B-gene
- I-gene
PK I-gene
) 0
genes 0
, 0
a 0
series 0
of 0
constructs 0
in 0
which 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
genes I-gene
is 0
driven 0
by 0
various 0
deleted 0
fragments 0
of 0
the 0
3200 0
base 0
pairs 0
( 0
bp 0
) 0
upstream 0
of 0
the 0
L B-gene
- I-gene
PK I-gene
gene I-gene
cap I-gene
site I-gene
have 0
been 0
assayed 0
for 0
transient 0
expression 0
after 0
introduction 0
into 0
hepatoma 0
HepG2 0
cells 0
, 0
rat 0
hepatocytes 0
in 0
primary 0
culture 0
, 0
fibroblast 0
LTK 0
- 0
cells 0
, 0
myogenic 0
C2C12 0
cells 0
, 0
and 0
CHO 0
cells 0
. 0

The 0
disturbance 0
of 0
pulmonary 0
gas 0
exchange 0
, 0
as 0
revealed 0
by 0
the 0
high 0
value 0
of 0
AaDO2 0
, 0
existed 0
without 0
left 0
ventricular 0
dysfunction 0
, 0
and 0
AaDO2 0
had 0
no 0
significant 0
relationship 0
with 0
any 0
of 0
the 0
hemodynamic 0
parameters 0
including 0
the 0
difference 0
between 0
plasma 0
colloid 0
osmotic 0
pressure 0
and 0
PCW 0
. 0

A 0
dose 0
of 0
3 0
and 0
6 0
micrograms/kg/day 0
GM B-gene
- I-gene
CSF I-gene
reduces 0
the 0
severity 0
of 0
neutropenia 0
and 0
thrombocytopenia 0
after 0
carboplatin 0
- 0
cyclophosphamide 0
chemotherapy 0
, 0
which 0
may 0
lead 0
to 0
more 0
effective 0
chemotherapy 0
for 0
ovarian 0
cancer 0
in 0
the 0
future 0
. 0

These 0
differences 0
involve 0
specific 0
hydrogen 0
- 0
bonding 0
interactions 0
between 0
the 0
protein 0
and 0
DNA 0
, 0
including 0
guanine 0
N7 0
sites 0
in 0
the 0
major 0
groove 0
of 0
DNA 0
, 0
and 0
alterations 0
in 0
DNA 0
phosphodiester 0
conformation 0
induced 0
by 0
protein 0
binding 0
. 0

Biochemical 0
analysis 0
demonstrates 0
that 0
the 0
BJ1 B-gene
protein I-gene
is 0
associated 0
with 0
nucleosomes 0
and 0
is 0
released 0
from 0
chromatin 0
by 0
agents 0
which 0
intercalate 0
into 0
DNA 0
, 0
as 0
previously 0
shown 0
for 0
the 0
high B-gene
mobility I-gene
group I-gene
proteins I-gene
( 0
HMGs B-gene
) 0
. 0

I 0
propose 0
that 0
their 0
gene 0
products 0
bind 0
to 0
the 0
chromatin 0
to 0
establish 0
or 0
maintain 0
a 0
proper 0
higher 0
order 0
structure 0
as 0
a 0
prerequisite 0
for 0
a 0
regulated 0
gene 0
expression 0
. 0

The 0
C4BP B-gene
alpha I-gene
gene I-gene
is 0
organized 0
as 0
follows 0
: 0
the 0
first 0
exon 0
codes 0
for 0
the 0
first 0
198 0
nucleotides 0
of 0
the 0
5 0
' 0
UTR 0
. 0

The 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
Rev I-gene
protein I-gene
is 0
a 0
positive 0
posttranscriptional 0
regulator 0
of 0
viral 0
structural 0
gene 0
expression 0
and 0
essential 0
for 0
virus 0
replication 0
. 0

Once 0
the 0
proliferation 0
of 0
fibroblasts 0
and 0
collagen B-gene
synthesis 0
had 0
led 0
to 0
an 0
increase 0
of 0
mechanical 0
strength 0
, 0
no 0
negative 0
effect 0
on 0
wound 0
healing 0
could 0
be 0
detected 0
applying 0
the 0
same 0
chemotherapeutic 0
agents 0
. 0

The 0
CDC7 B-gene
gene I-gene
has 0
two 0
in 0
- 0
frame 0
AUG 0
codons 0
as 0
possible 0
translation 0
start 0
sites 0
, 0
which 0
would 0
produce 0
58 0
- 0
and 0
56 0
- 0
kDa 0
proteins 0
, 0
respectively 0
. 0

During 0
the 0
years 0
1980 0
- 0
87 0
a 0
total 0
of 0
287 0
persons 0
received 0
disability 0
pensions 0
in 0
the 0
municipality 0
of 0
Nordreisa 0
in 0
northern 0
Norway 0
. 0

HeLa 0
and 0
Jurkat 0
cell 0
lines 0
carrying 0
the 0
nef B-gene
gene I-gene
linked 0
to 0
the 0
CMV 0
promoter 0
or 0
the 0
HIV B-gene
- I-gene
1 I-gene
LTR I-gene
were 0
isolated 0
by 0
coselection 0
for 0
neomycin 0
resistance 0
. 0

Differences 0
in 0
the 0
clinical 0
presentation 0
and 0
the 0
gross 0
appearance 0
of 0
the 0
two 0
cases 0
are 0
described 0
, 0
and 0
similarities 0
in 0
the 0
microscopic 0
features 0
are 0
discussed 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
: 0
The 0
two 0
groups 0
were 0
similar 0
on 0
entry 0
into 0
the 0
study 0
, 0
including 0
mean 0
FEV1 0
measurements 0
( 0
0.70 0
L 0
atropine/0.60 0
L 0
metaproterenol 0
, 0
P 0
greater 0
than 0
.05 0
) 0
. 0

Using 0
an 0
ELISA 0
, 0
we 0
found 0
that 0
surfactant B-gene
protein I-gene
A I-gene
( 0
SP B-gene
- I-gene
A I-gene
) 0
was 0
markedly 0
elevated 0
in 0
the 0
pneumonia 0
patients 0
. 0

In 0
view 0
of 0
the 0
short 0
t1/2 0
, 0
we 0
used 0
three 0
doses/day 0
. 0

Temporal 0
control 0
of 0
GUS B-gene
expression 0
was 0
found 0
to 0
involve 0
two 0
negative 0
regulatory 0
sequences 0
, 0
NRS1 0
( 0
- 0
391 0
to 0
- 0
295 0
) 0
and 0
NRS2 0
( 0
- 0
518 0
to 0
- 0
418 0
) 0
, 0
as 0
well 0
as 0
the 0
positive 0
domain 0
UAS1 0
. 0

We 0
purified 0
a 0
Ca2+/calmodulin B-gene
( I-gene
CaM I-gene
) I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
CaM B-gene
kinase I-gene
) 0
from 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
with 0
properties 0
similar 0
to 0
mammalian B-gene
type I-gene
II I-gene
CaM I-gene
kinases I-gene
. 0

In 0
most 0
cases 0
, 0
DR4 B-gene
- 0
homozygous 0
, 0
DRB1 B-gene
- 0
heterozygous 0
individuals 0
could 0
be 0
genotyped 0
with 0
the 0
panel 0
of 0
probes 0
. 0

Two 0
patients 0
had 0
immediate 0
adverse 0
effects 0
from 0
NMF 0
; 0
one 0
had 0
a 0
grand 0
mal 0
seizure 0
and 0
the 0
other 0
developed 0
severe 0
abdominal 0
pain 0
. 0

The 0
muscles 0
from 0
the 0
ischemic 0
group 0
had 0
significantly 0
lower 0
( 0
P 0
less 0
than 0
.05 0
) 0
values 0
for 0
capillary 0
density 0
and 0
capillary 0
to 0
fiber 0
ratio 0
and 0
significantly 0
higher 0
intercapillary 0
distance 0
than 0
those 0
from 0
the 0
normal 0
group 0
. 0

The 0
prevalence 0
of 0
opportunistic 0
infection 0
among 0
surviving 0
AIDS 0
patients 0
and 0
the 0
probability 0
of 0
being 0
in 0
tumour 0
response 0
following 0
cancer 0
therapy 0
conditional 0
on 0
being 0
alive 0
are 0
two 0
examples 0
of 0
such 0
functions 0
. 0

Serum B-gene
TNF I-gene
concentrations 0
were 0
elevated 0
at 0
diagnosis 0
and 0
gradually 0
decreased 0
toward 0
the 0
reference 0
limits 0
by 0
week 0
16 0
. 0

Genomic 0
clones 0
encompassing 0
the 0
human B-gene
ETS1 I-gene
gene I-gene
were 0
isolated 0
and 0
utilized 0
to 0
define 0
its 0
molecular 0
organization 0
. 0

Polymerase 0
chain 0
reaction 0
analysis 0
of 0
ETS1 B-gene
cDNA I-gene
identified 0
several 0
amplified 0
products 0
, 0
indicating 0
alternative 0
splicing 0
. 0

Most 0
of 0
the 0
expressed 0
human B-gene
E3 I-gene
polypeptides I-gene
( 0
five 0
bands 0
) 0
were 0
found 0
in 0
the 0
insoluble 0
pellet 0
while 0
primarily 0
full B-gene
- I-gene
length I-gene
mature I-gene
E3 I-gene
was 0
found 0
in 0
the 0
soluble 0
fraction 0
. 0

To 0
test 0
promotor 0
function 0
, 0
chimeric 0
genes 0
were 0
constructed 0
linking 0
fragments 0
of 0
chicken 0
IGF B-gene
- I-gene
I I-gene
5' 0
- 0
flanking 0
DNA 0
to 0
a 0
promoterless 0
reporter 0
plasmid 0
. 0

The 0
alpha B-gene
4 I-gene
gene I-gene
5 0
' 0
flanking 0
region 0
acted 0
as 0
a 0
promoter 0
in 0
transfection 0
assays 0
. 0

Characterization 0
of 0
the 0
alpha B-gene
4 I-gene
integrin I-gene
gene I-gene
promoter I-gene
. 0

Only 0
the 0
3.0 0
- 0
kb 0
transcript 0
was 0
detected 0
in 0
adult 0
tissues 0
, 0
where 0
its 0
expression 0
was 0
restricted 0
almost 0
exclusively 0
to 0
the 0
central 0
nervous 0
system 0
. 0

Two 0
homologues 0
of 0
the 0
rhombotin B-gene
gene I-gene
have 0
now 0
been 0
isolated 0
. 0

Angina 0
haemorrhagica 0
bullosa 0
causing 0
respiratory 0
obstruction 0
postoperatively 0
. 0

We 0
examined 0
the 0
effects 0
of 0
long 0
- 0
term 0
perfusion 0
with 0
pyridoxalated 0
hemoglobin B-gene
polyoxyethylene 0
conjugate 0
( 0
PHP 0
) 0
solution 0
on 0
cardiac 0
function 0
of 0
isolated 0
rat 0
hearts 0
. 0

Conclusion 0
: 0
inlet 0
type 0
VSD 0
and 0
perimembranous 0
type 0
TOF 0
have 0
anatomic 0
features 0
in 0
which 0
the 0
proximal 0
His 0
bundle 0
tends 0
to 0
be 0
jeopardized 0
by 0
suturing 0
for 0
VSD 0
closure 0
. 0

The 0
gcd2 B-gene
- I-gene
503 I-gene
mutation 0
also 0
results 0
in 0
polysome 0
runoff 0
, 0
accumulation 0
of 0
inactive 0
80S B-gene
ribosomal I-gene
couples I-gene
, 0
and 0
accumulation 0
of 0
at 0
least 0
one 0
of 0
the 0
subunits 0
of 0
the 0
general B-gene
translation I-gene
initiation I-gene
factor I-gene
2 I-gene
( 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
) 0
in 0
43S B-gene
- 0
48S B-gene
particles 0
following 0
a 0
shift 0
to 0
the 0
restrictive 0
temperature 0
. 0

Eight 0
patients 0
with 0
ARC 0
and 0
renal 0
failure 0
were 0
recently 0
evaluated 0
. 0

To 0
measure 0
the 0
enhancer 0
activity 0
of 0
DR60 B-gene
, 0
a 0
reporter 0
plasmid 0
was 0
constructed 0
that 0
contained 0
DR60 B-gene
cloned 0
upstream 0
of 0
the 0
reporter 0
chloramphenicol B-gene
acetyltransferase I-gene
gene I-gene
under 0
the 0
control 0
of 0
the 0
delayed 0
- 0
early 0
39K 0
promoter 0
. 0

A 0
single 0
case 0
of 0
an 0
adenocarcinoma 0
, 0
arising 0
in 0
a 0
retroperitoneal 0
enterogenous 0
cyst 0
and 0
which 0
presented 0
as 0
a 0
left 0
renal 0
cyst 0
, 0
is 0
reported 0
. 0

Using 0
the 0
polymerase 0
chain 0
reaction 0
, 0
we 0
analyzed 0
the 0
U6 B-gene
RNA I-gene
genes I-gene
of 0
52 0
organisms 0
. 0

Both 0
tear 0
volume 0
and 0
tear 0
flow 0
were 0
found 0
to 0
be 0
significantly 0
( 0
P 0
less 0
than 0
0.001 0
) 0
decreased 0
up 0
to 0
6 0
h 0
after 0
instillation 0
, 0
reaching 0
a 0
minimum 0
90 0
min 0
after 0
application 0
( 0
tear 0
volume 0
: 0
- 0
63 0
% 0
; 0
tear 0
flow 0
: 0
- 0
71 0
% 0
) 0
. 0

Hydrophobicity 0
analysis 0
indicated 0
that 0
the 0
KlaA B-gene
and 0
KlaB B-gene
polypeptides I-gene
are 0
likely 0
to 0
be 0
soluble 0
, 0
whereas 0
the 0
KlaC B-gene
polypeptide I-gene
was 0
predicted 0
to 0
have 0
four 0
potential 0
membrane 0
- 0
spanning 0
domains 0
. 0

To 0
facilitate 0
the 0
availability 0
of 0
important 0
new 0
therapeutic 0
agents 0
, 0
the 0
Food 0
and 0
Drug 0
Administration 0
( 0
FDA 0
) 0
in 0
the 0
mid 0
- 0
1970s 0
began 0
assigning 0
therapeutic 0
ratings 0
to 0
investigational 0
new 0
drugs 0
and 0
holding 0
end 0
- 0
of 0
- 0
phase 0
II 0
conferences 0
with 0
drug 0
sponsors 0
. 0

In 0
contrast 0
, 0
similar 0
rates 0
of 0
B. 0
sphaericus 0
products 0
, 0
ABG 0
- 0
6184 0
technical 0
powder 0
and 0
BSP 0
- 0
2 0
flowable 0
concentrate 0
, 0
produced 0
no 0
significant 0
reduction 0
. 0

The 0
remainder 0
( 0
18.4 0
% 0
) 0
was 0
with 0
IgA B-gene
nephropathy 0
, 0
which 0
was 0
histologically 0
mild 0
. 0

Grossly 0
, 0
the 0
experimental 0
vulvitis 0
was 0
identical 0
to 0
the 0
field 0
condition 0
, 0
and 0
bacteria 0
indistinguishable 0
from 0
the 0
inoculated 0
strains 0
were 0
reisolated 0
. 0

3 0
. 0

Furthermore 0
, 0
the 0
DNA B-gene
polymerase I-gene
II I-gene
complex I-gene
was 0
difficult 0
to 0
obtain 0
from 0
dpb2 B-gene
- I-gene
1 I-gene
mutant 0
cells 0
, 0
suggesting 0
that 0
a 0
stable 0
DNA B-gene
polymerase I-gene
II I-gene
complex I-gene
requires 0
DPB2 B-gene
and 0
is 0
essential 0
for 0
chromosomal 0
replication 0
. 0

To 0
determine 0
whether 0
mononuclear 0
cell 0
secretory 0
products 0
contribute 0
to 0
the 0
changes 0
in 0
bone 0
turnover 0
that 0
characterize 0
the 0
development 0
of 0
postmenopausal 0
osteoporosis 0
, 0
we 0
evaluated 0
the 0
effects 0
of 0
oophorectomy 0
and 0
subsequent 0
estrogen 0
replacement 0
on 0
the 0
spontaneous 0
secretion 0
of 0
interleukin B-gene
1 I-gene
( 0
IL B-gene
- I-gene
1 I-gene
) 0
and 0
tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
( 0
TNF B-gene
- I-gene
alpha I-gene
) 0
and 0
on 0
the 0
phytohemagglutinin B-gene
A I-gene
- 0
induced 0
secretion 0
of 0
granulocyte B-gene
- I-gene
macrophage I-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
( 0
GM B-gene
- I-gene
CSF I-gene
) 0
from 0
peripheral 0
blood 0
mononuclear 0
cells 0
. 0

There 0
were 0
45 0
to 0
56 0
nt 0
differences 0
between 0
the 0
virulent 0
and 0
avirulent 0
groups 0
while 0
there 0
were 0
6 0
to 0
14 0
nt 0
differences 0
among 0
four 0
avirulent 0
strains 0
. 0

The 0
standard 0
principles 0
of 0
surgical 0
management 0
must 0
be 0
adhered 0
to 0
when 0
using 0
Sandostatin 0
to 0
treat 0
patients 0
with 0
these 0
disorders 0
. 0

Some 0
of 0
the 0
PCR 0
products 0
contained 0
mutations 0
in 0
ATG1 B-gene
and/or 0
ATG2 B-gene
. 0

Hemorrhagic 0
shock 0
and 0
bacterial 0
translocation 0
in 0
a 0
swine 0
model 0
. 0

These 0
data 0
suggest 0
that 0
the 0
levels 0
of 0
oxygen 0
free 0
radicals 0
were 0
increased 0
in 0
hepatocytes 0
and 0
mitochondria 0
. 0

The 0
sequence 0
of 0
the 0
pMxL1 0
plasmid 0
containing 0
the 0
invertible 0
region 0
contains 0
a 0
perfect 0
tandem 0
repeat 0
of 0
19 0
bp 0
in 0
the 0
orientation 0
1 0
nonexpressed 0
pilin B-gene
gene I-gene
at 0
the 0
middle 0
of 0
the 0
recombination 0
junction 0
site 0
. 0

No 0
evidence 0
for 0
the 0
presence 0
of 0
introns 0
within 0
the 0
acvA B-gene
gene I-gene
has 0
been 0
found 0
. 0

These 0
observations 0
, 0
together 0
with 0
the 0
occurrence 0
of 0
putative 0
4' 0
- 0
phosphopantetheine 0
- 0
attachment 0
sites 0
and 0
a 0
putative 0
thioesterase B-gene
site I-gene
, 0
are 0
discussed 0
with 0
reference 0
to 0
the 0
reaction 0
sequence 0
leading 0
to 0
production 0
of 0
the 0
ACV B-gene
tripeptide I-gene
. 0

Pargyline 0
, 0
a 0
monoamine B-gene
oxidase I-gene
inhibitor 0
, 0
reduces 0
peak 0
3 0
transiently 0
( 0
max 0
. 0

When 0
given 0
the 0
choice 0
between 0
an 0
estrous 0
female 0
and 0
a 0
sexually 0
active 0
male 0
in 0
the 0
AOF 0
, 0
flutamide 0
females 0
, 0
as 0
well 0
as 0
controls 0
, 0
preferred 0
the 0
male 0
partner 0
. 0

Hypoxic 0
ventilatory 0
responses 0
were 0
- 0
1.99 0
+/ 0
- 0
0.37 0
L/min/ 0
% 0
SaO2 0
in 0
the 0
relatives 0
and 0
- 0
1.54 0
+/ 0
- 0
0.25 0
L/min/ 0
% 0
SaO2 0
in 0
the 0
control 0
subjects 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Very 0
small 0
deletions 0
within 0
the 0
conserved 0
region 0
completely 0
abolished 0
transforming 0
activity 0
of 0
dbl B-gene
, 0
while 0
extensive 0
deletion 0
outside 0
of 0
this 0
region 0
had 0
no 0
effect 0
. 0

This 0
computerized 0
list 0
was 0
linked 0
to 0
the 0
central 0
files 0
of 0
the 0
Massachusetts 0
Cancer 0
Registry 0
and 0
cases 0
diagnosed 0
between 0
1982 0
and 0
1988 0
were 0
identified 0
. 0

We 0
also 0
present 0
evidence 0
for 0
a 0
negative 0
regulatory 0
element 0
in 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
Mlu B-gene
I I-gene
upstream I-gene
activation I-gene
sequence I-gene
. 0

A 0
method 0
for 0
establishing 0
stimulus 0
control 0
of 0
ethanol 0
responding 0
was 0
developed 0
. 0

Mechanism 0
of 0
activation 0
of 0
the 0
vav B-gene
protooncogene I-gene
. 0
vav B-gene
is 0
a 0
human 0
locus 0
that 0
appears 0
to 0
be 0
specifically 0
expressed 0
in 0
cells 0
of 0
hematopoietic 0
origin 0
regardless 0
of 0
their 0
differentiation 0
lineage 0
. 0

Endothelial 0
cell 0
seeding 0
. 0

Menetrier 0
disease 0
in 0
a 0
child 0
. 0

After 0
hemodynamic 0
stabilization 0
, 0
the 0
goal 0
of 0
therapy 0
is 0
to 0
diminish 0
the 0
chance 0
that 0
an 0
ulcer 0
will 0
continue 0
to 0
bleed 0
or 0
will 0
rebleed 0
. 0

Thirty 0
seven 0
patients 0
( 0
amitriptyline 0
n 0
= 0
16 0
, 0
moclobemide 0
n 0
= 0
21 0
) 0
completed 0
the 0
six 0
week 0
protocol 0
, 0
which 0
was 0
conducted 0
under 0
double 0
blind 0
conditions 0
. 0

The 0
stimulus 0
threshold 0
for 0
EER 0
showed 0
a 0
less 0
individual 0
variation 0
than 0
amplitude 0
. 0

Analysis 0
of 0
electrically 0
evoked 0
response 0
( 0
EER 0
) 0
in 0
relation 0
to 0
the 0
central 0
visual 0
pathway 0
of 0
the 0
cat 0
( 0
1 0
) 0
. 0

Furthermore 0
, 0
plasma 0
fibrinogen B-gene
levels 0
increased 0
by 0
a 0
mean 0
of 0
17.6 0
% 0
, 0
a 0
potentially 0
adverse 0
effect 0
of 0
gemfibrozil 0
that 0
has 0
not 0
been 0
previously 0
reported 0
. 0

Gemfibrozil 0
in 0
hyperlipidaemic 0
patients 0
with 0
peripheral 0
arterial 0
disease 0
: 0
some 0
undiscovered 0
actions 0
. 0

An 0
RME1 B-gene
- 0
independent 0
pathway 0
for 0
sporulation 0
control 0
in 0
Saccharomyces 0
cerevisiae 0
acts 0
through 0
IME1 B-gene
transcript I-gene
accumulation 0
. 0

The 0
role 0
of 0
pharmacological 0
profiling 0
in 0
safety 0
assessment 0
. 0

Its 0
application 0
in 0
Madagascar 0
: 0
advantages 0
and 0
disadvantages 0

In 0
all 0
cases 0
, 0
high 0
- 0
level 0
expression 0
of 0
the 0
truncated B-gene
avian I-gene
integrins I-gene
was 0
obtained 0
. 0

The 0
authors 0
evaluate 0
the 0
clinical 0
efficacy 0
of 0
EMB 0
AZS 0
in 0
recurrent 0
ulcer 0
after 0
operation 0
on 0
the 0
stomach 0
caused 0
by 0
a 0
high 0
level 0
of 0
acid 0
production 0
and 0
ulcerative 0
gastroduodenal 0
bleeding 0
. 0

In 0
adulthood 0
these 0
rats 0
were 0
hyperactive 0
and 0
learned 0
the 0
active 0
avoidance 0
response 0
later 0
than 0
the 0
controls 0
. 0

To 0
investigate 0
the 0
regulation 0
of 0
Spec B-gene
gene I-gene
activity 0
, 0
the 0
region 0
around 0
the 0
Spec1 B-gene
transcriptional I-gene
initiation I-gene
site I-gene
was 0
analyzed 0
for 0
sites 0
of 0
protein 0
- 0
DNA 0
interaction 0
. 0

Phosphopeptide 0
mapping 0
revealed 0
the 0
same 0
autophosphorylation 0
sites 0
utilized 0
by 0
EGFR B-gene
- I-gene
IC I-gene
as 0
those 0
identified 0
in 0
wild B-gene
- I-gene
type I-gene
EGFR I-gene
. 0

The 0
encoded 0
sequence 0
revealed 0
a 0
typical 0
signal 0
peptide 0
, 0
a 0
predominantly 0
hydrophilic 0
707 0
amino 0
acid 0
residue 0
domain 0
with 0
8 0
N 0
- 0
glycosylation 0
sites 0
, 0
a 0
transmembrane 0
domain 0
, 0
and 0
a 0
C 0
- 0
terminal 0
domain 0
of 0
52 0
amino 0
acids 0
. 0

The 0
TCF B-gene
- I-gene
1 I-gene
alpha I-gene
binding I-gene
site I-gene
was 0
also 0
required 0
for 0
TCR B-gene
alpha I-gene
enhancer I-gene
activity 0
in 0
transcriptionally 0
active 0
extracts 0
from 0
Jurkat 0
but 0
not 0
HeLa 0
cells 0
, 0
confirming 0
that 0
TCF B-gene
- I-gene
1 I-gene
alpha I-gene
is 0
a 0
T B-gene
- I-gene
cell I-gene
- I-gene
specific I-gene
transcription I-gene
factor I-gene
. 0

A 0
new 0
semi 0
- 0
automatic 0
method 0
for 0
quantifying 0
regional 0
cerebral 0
uptake 0
of 0
99m 0
technetium 0
- 0
hexamethylpropylene 0
amine 0
oxime 0
( 0
99mTc 0
- 0
HMPAO 0
) 0
was 0
used 0
to 0
assess 0
single 0
photon 0
emission 0
tomograms 0
from 0
5 0
normal 0
subjects 0
, 0
14 0
patients 0
with 0
Alzheimer 0
's 0
disease 0
, 0
14 0
patients 0
with 0
dementia 0
of 0
frontal 0
lobe 0
type 0
and 0
4 0
patients 0
with 0
dementia 0
with 0
motor 0
neurone 0
disease 0
. 0

The 0
results 0
showed 0
that 0
fog 0
, 0
up 0
to 0
a 0
level 0
of 0
base 0
plus 0
fog 0
of 0
0.6 0
optical 0
density 0
units 0
, 0
had 0
no 0
influence 0
on 0
the 0
diagnostic 0
accuracy 0
in 0
the 0
absence 0
of 0
any 0
compensation 0
. 0

IdB 0
1031 0
was 0
first 0
extracted 0
by 0
liquid 0
- 0
solid 0
partition 0
and 0
the 0
extracts 0
were 0
evaporated 0
and 0
analysed 0
on 0
a 0
reversed 0
- 0
phase 0
column 0
under 0
isocratic 0
conditions 0
, 0
using 0
either 0
an 0
electrochemical 0
or 0
a 0
UV 0
detector 0
. 0

In 0
this 0
model 0
, 0
eltoprazine 0
has 0
a 0
very 0
specific 0
anti 0
- 0
aggressive 0
( 0
serenic 0
) 0
profile 0
, 0
inhibiting 0
aggression 0
while 0
social 0
interaction 0
and 0
exploration 0
are 0
not 0
decreased 0
but 0
even 0
enhanced 0
; 0
inactivity 0
, 0
a 0
measure 0
for 0
sedation 0
, 0
is 0
not 0
affected 0
. 0

A 0
new 0
method 0
for 0
the 0
in 0
vitro 0
transfer 0
of 0
delayed 0
hypersensitivity 0
by 0
dialysed 0
transfer B-gene
factor I-gene
. 0

Effect 0
of 0
separate 0
and 0
combined 0
effects 0
of 0
plutonium 0
- 0
239 0
, 0
hexachlorobutadiene 0
and 0
tributyl 0
phosphate 0
on 0
the 0
thymus 0
gland 0
of 0
rats 0

Data 0
collection 0
was 0
made 0
with 0
a 0
query 0
language 0
, 0
and 0
data 0
analysis 0
performed 0
with 0
an 0
interactive 0
knowledge 0
- 0
based 0
statistical 0
tool 0
, 0
MAXITAB 0
, 0
employing 0
a 0
multivariate 0
tabular 0
analysis 0
technique 0
. 0

ARPIA 0
has 0
been 0
implemented 0
by 0
using 0
a 0
relational 0
DBMS 0
, 0
very 0
cheap 0
and 0
highly 0
diffused 0
on 0
personal 0
computers 0
. 0

Diuresis 0
was 0
induced 0
by 0
scheduled 0
drinking 0
of 0
tea 0
( 0
150 0
ml/h 0
) 0
. 0

Diagnostic 0
value 0
of 0
adenosine B-gene
deaminase I-gene
activity 0
in 0
tuberculous 0
effusions 0
. 0

Femoral 0
strain 0
adaptation 0
after 0
total 0
hip 0
replacement 0
: 0
a 0
comparison 0
of 0
cemented 0
and 0
porous 0
ingrowth 0
components 0
in 0
canines 0
. 0

Immuno 0
- 0
cytochemistry 0
, 0
using 0
antisera 0
against 0
Campylobacter 0
jejuni 0
, 0
showed 0
that 0
the 0
positive 0
staining 0
in 0
altered 0
epithelial 0
cells 0
were 0
restricted 0
to 0
intracellular 0
organisms 0
having 0
a 0
structure 0
resembling 0
Campylobacter 0
spp 0
. 0

Promoter 0
activities 0
were 0
estimated 0
using 0
beta B-gene
- I-gene
glucuronidase I-gene
and 0
neomycin B-gene
phosphotransferase I-gene
II I-gene
reporter I-gene
gene I-gene
systems I-gene
. 0

The 0
5 0
' 0
regions 0
of 0
these 0
two 0
soybean B-gene
actin I-gene
genes I-gene
contain 0
many 0
unusual 0
features 0
including 0
( 0
CT 0
) 0
repeats 0
and 0
long 0
stretches 0
of 0
pyrimidine 0
- 0
rich 0
DNA 0
. 0

All 0
8 0
( 0
100 0
% 0
) 0
patients 0
with 0
fulminant 0
hepatic 0
failure 0
who 0
received 0
grafts 0
survived 0
, 0
including 0
3 0
who 0
received 0
ABO 0
- 0
incompatible 0
grafts 0
, 0
though 0
2 0
of 0
these 0
subsequently 0
required 0
retransplantation 0
. 0

No 0
patient 0
had 0
a 0
history 0
of 0
excess 0
alcohol 0
intake 0
, 0
or 0
prolonged 0
intake 0
of 0
hepatotoxic 0
drugs 0
and 0
steroids 0
, 0
and 0
were 0
not 0
obese 0
or 0
malnourished 0
. 0

An 0
evolutionary 0
comparison 0
of 0
amino 0
acid 0
sequences 0
of 0
34 0
HSP70 B-gene
proteins I-gene
from 0
17 0
species 0
suggests 0
that 0
BiP B-gene
genes I-gene
share 0
a 0
common 0
ancestor 0
, 0
which 0
diverged 0
from 0
other 0
HSP70 B-gene
genes I-gene
near 0
the 0
time 0
when 0
eukaryotes 0
first 0
appeared 0
. 0

Spore 0
inocula 0
( 0
approximately 0
10 0
( 0
6 0
) 0
/coupon 0
) 0
were 0
dried 0
onto 0
0.5 0
- 0
in 0
. 0

However 0
, 0
overexpression 0
of 0
both 0
the 0
STE4 B-gene
and 0
STE18 B-gene
proteins I-gene
did 0
not 0
generate 0
a 0
stronger 0
pheromone 0
response 0
than 0
overexpression 0
of 0
STE4 B-gene
in 0
the 0
presence 0
of 0
wild 0
- 0
type 0
levels 0
of 0
STE18 B-gene
. 0

Reverse 0
transcription 0
- 0
PCR 0
was 0
then 0
used 0
to 0
clone 0
from 0
human 0
poly 0
( 0
A 0
) 0
+ 0
RNA 0
the 0
cDNA 0
corresponding 0
to 0
the 0
expressed 0
homolog 0
of 0
psi B-gene
ARF I-gene
4 I-gene
, 0
referred 0
to 0
as 0
human B-gene
ARF I-gene
4 I-gene
. 0

To 0
evaluate 0
the 0
cost 0
and 0
benefits 0
of 0
screening 0
tests 0
for 0
Chlamydia 0
trachomatis 0
in 0
adolescent 0
males 0
, 0
we 0
developed 0
a 0
decision 0
analysis 0
model 0
and 0
compared 0
the 0
leukocyte B-gene
esterase I-gene
urine 0
dipstick 0
test 0
with 0
culture 0
, 0
with 0
direct 0
- 0
smear 0
fluorescent 0
antibody 0
( 0
DFA 0
) 0
, 0
and 0
with 0
the 0
option 0
of 0
no 0
screening 0
( 0
no 0
treatment 0
) 0
. 0

Sequencing 0
the 0
gene 0
for 0
an 0
imipenem 0
- 0
cefoxitin 0
- 0
hydrolyzing 0
enzyme 0
( 0
CfiA B-gene
) 0
from 0
Bacteroides 0
fragilis 0
TAL2480 0
reveals 0
strong 0
similarity 0
between 0
CfiA B-gene
and 0
Bacillus B-gene
cereus I-gene
beta I-gene
- I-gene
lactamase I-gene
II I-gene
. 0

The 0
cloned 0
HindIII B-gene
fragment I-gene
, 0
which 0
was 0
shown 0
by 0
DNA 0
sequence 0
analysis 0
to 0
encode 0
the 0
N 0
- 0
terminal 0
half 0
of 0
the 0
B. B-gene
subtilis I-gene
IF2 I-gene
protein I-gene
and 0
0.2 0
kb 0
of 0
upstream 0
flanking 0
sequence 0
, 0
was 0
utilized 0
as 0
a 0
homologous 0
probe 0
to 0
clone 0
an 0
overlapping 0
2.76 B-gene
- I-gene
kb I-gene
ClaI I-gene
chromosomal I-gene
fragment I-gene
containing 0
the 0
entire B-gene
IF2 I-gene
structural I-gene
gene I-gene
. 0

The 0
N 0
- 0
terminal 0
115 0
amino 0
acids 0
correspond 0
to 0
a 0
putative 0
DNA 0
- 0
binding 0
domain 0
and 0
show 0
significant 0
sequence 0
similarity 0
with 0
other 0
cloned 0
IFN B-gene
response I-gene
factors I-gene
( 0
IRF B-gene
- I-gene
1 I-gene
and 0
IRF B-gene
- I-gene
2 I-gene
) 0
. 0

Maternal 0
seizures 0
had 0
occurred 0
during 0
pregnancy 0
in 0
52 0
per 0
cent 0
. 0

It 0
encodes 0
a 0
protein 0
with 0
three 0
zinc 0
fingers 0
similar 0
to 0
those 0
of 0
the 0
transcription B-gene
factor I-gene
Sp1 I-gene
. 0

Krox B-gene
- I-gene
24 I-gene
is 0
therefore 0
a 0
sequence 0
- 0
specific 0
transcriptional 0
activator 0
. 0

The 0
interindividual 0
variability 0
of 0
the 0
parameters 0
is 0
taken 0
into 0
consideration 0
by 0
interactively 0
determining 0
the 0
threshold 0
levels 0
. 0

The 0
patients 0
were 0
divided 0
into 0
3 0
subgroups 0
: 0
1 0
) 0
13 0
N+ 0
patients 0
with 0
multiple 0
hot 0
spots 0
( 0
greater 0
than 0
2 0
) 0
( 0
N+ 0
IM 0
) 0
; 0
2 0
) 0
24 0
N+ 0
patients 0
with 0
single 0
hot 0
spots 0
( 0
less 0
than 0
or 0
equal 0
to 0
2 0
) 0
( 0
N+ 0
IS 0
) 0
; 0
3 0
) 0
12 0
N 0
- 0
patients 0
with 0
single 0
hot 0
spots 0
( 0
less 0
than 0
or 0
equal 0
to 0
2 0
) 0
( 0
N 0
- 0
IS 0
) 0
. 0

Inspired 0
CO2 0
causing 0
changes 0
from 0
hypo 0
- 0
to 0
normocapnia 0
has 0
previously 0
been 0
shown 0
to 0
improve 0
arterial 0
O2 0
tension 0
( 0
PaO2 0
) 0
and 0
to 0
reduce 0
alveolar 0
- 0
arterial 0
O2 0
difference 0
. 0

Expression 0
, 0
nucleotide 0
sequence 0
and 0
mutational 0
analysis 0
of 0
two 0
open 0
reading 0
frames 0
in 0
the 0
nif B-gene
gene I-gene
region I-gene
of I-gene
Anabaena I-gene
sp I-gene
. I-gene
strain I-gene
PCC7120 I-gene
. 0

Further 0
, 0
they 0
are 0
consistent 0
with 0
the 0
suggestion 0
that 0
sites 0
homologous 0
to 0
the 0
CAR1 B-gene
URS I-gene
may 0
be 0
situated 0
in 0
the 0
5' 0
- 0
flanking 0
regions 0
of 0
multiple 0
unrelated 0
yeast 0
genes 0
. 0

Our 0
results 0
suggest 0
that 0
a 0
sequence 0
match 0
between 0
enhancers 0
and 0
certain 0
promoter 0
elements 0
is 0
critical 0
. 0

This 0
Mr 0
is 0
similar 0
to 0
those 0
of 0
the 0
purified B-gene
smg I-gene
p25A I-gene
GDI I-gene
estimated 0
by 0
sodium 0
dodecyl 0
sulfate 0
- 0
polyacrylamide 0
gel 0
electrophoresis 0
and 0
sucrose 0
density 0
gradient 0
ultracentrifugation 0
, 0
which 0
are 0
about 0
54,000 0
and 0
65,000 0
, 0
respectively 0
. 0

Yeast 0
mutants 0
assigned 0
to 0
the 0
pet B-gene
complementation 0
group 0
G104 0
were 0
found 0
to 0
lack 0
alpha B-gene
- I-gene
ketoglutarate I-gene
dehydrogenase I-gene
activity 0
as 0
a 0
result 0
of 0
mutations 0
in 0
the 0
dihydrolipoyl B-gene
transsuccinylase I-gene
( 0
KE2 B-gene
) 0
component 0
of 0
the 0
complex 0
. 0

Critical 0
residues 0
required 0
for 0
repression 0
are 0
located 0
within 0
the 0
C 0
- 0
terminal 0
27 0
amino 0
acids 0
of 0
c B-gene
- I-gene
Fos I-gene
, 0
since 0
v B-gene
- I-gene
Fos I-gene
and 0
C 0
- 0
terminal 0
truncations 0
of 0
c B-gene
- I-gene
Fos I-gene
did 0
not 0
down 0
regulate 0
. 0

We 0
also 0
discovered 0
a 0
V B-gene
lambda I-gene
pseudogene I-gene
, 0
called 0
psi B-gene
V I-gene
lambda I-gene
1 I-gene
, 0
3 0
kb 0
upstream 0
of 0
the 0
U266 B-gene
lambda I-gene
gene I-gene
. 0

In 0
this 0
paper 0
, 0
we 0
have 0
analyzed 0
the 0
structure 0
of 0
human 0
gene 0
for 0
Gx B-gene
alpha I-gene
, 0
which 0
spans 0
more 0
than 0
60 0
kilobases 0
. 0

A 0
long 0
follow 0
- 0
up 0
study 0
revealed 0
that 0
convalescent 0
stage 0
children 0
still 0
have 0
the 0
potency 0
to 0
have 0
an 0
immediate 0
type 0
hypersensitivity 0
reaction 0
on 0
exposure 0
to 0
mite 0
antigen 0
, 0
with 0
a 0
high 0
titer 0
of 0
mite B-gene
specific I-gene
IgE I-gene
in 0
their 0
sera 0
, 0
but 0
they 0
are 0
free 0
from 0
asthmatic 0
attacks 0
because 0
of 0
the 0
reduction 0
in 0
the 0
amount 0
of 0
mite 0
antigen 0
in 0
the 0
body 0
, 0
as 0
shown 0
by 0
the 0
reduction 0
in 0
the 0
amount 0
of 0
mite B-gene
specific I-gene
IgG I-gene
. 0

But 0
no 0
influence 0
was 0
observed 0
at 0
lower 0
concentrations 0
than 0
1/4 0
MIC 0
of 0
AMK 0
. 0

Uses 0
of 0
orthoclone 0
OKT3 B-gene
for 0
prophylaxis 0
of 0
rejection 0
and 0
induction 0
in 0
initial 0
nonfunction 0
in 0
kidney 0
transplantation 0
. 0

Uses 0
of 0
orthoclone 0
OKT3 0
for 0
prophylaxis 0
of 0
rejection 0
and 0
induction 0
in 0
initial 0
nonfunction 0
in 0
kidney 0
transplantation 0
. 0

Furthermore 0
, 0
we 0
notice 0
two 0
potential 0
consensus 0
motifs 0
which 0
are 0
also 0
found 0
in 0
corresponding 0
positions 0
in 0
the 0
genes 0
for 0
the 0
nerve B-gene
growth I-gene
factor I-gene
receptor I-gene
and 0
the 0
68 B-gene
- I-gene
kDa I-gene
neurofilament I-gene
protein I-gene
. 0

In 0
addition 0
, 0
the 0
- 0
119 0
to 0
- 0
81 0
fragment 0
of 0
the 0
CCK B-gene
promoter I-gene
contains 0
a 0
transcriptional 0
enhancer 0
that 0
potentiates 0
the 0
transcription 0
from 0
the 0
herpes 0
simplex 0
virus 0
thymidine B-gene
kinase I-gene
promoter I-gene
in 0
a 0
position 0
- 0
and 0
orientation 0
- 0
independent 0
manner 0
. 0

Thirty 0
minutes 0
of 0
supine 0
restraint 0
decreased 0
DOPAC 0
concentrations 0
in 0
the 0
median 0
eminence 0
of 0
female 0
rats 0
that 0
were 0
not 0
exposed 0
to 0
ether 0
, 0
and 0
brief 0
exposure 0
to 0
ether 0
enhanced 0
this 0
effect 0
. 0

Influence 0
of 0
metoprolol 0
treatment 0
on 0
sympatho 0
- 0
adrenal 0
activation 0
of 0
fibrinolysis 0
. 0

Five 0
of 0
10 0
scars 0
studied 0
decreased 0
at 0
least 0
50 0
% 0
in 0
linear 0
dimensions 0
. 0

Managing 0
dysphagia 0
in 0
a 0
chronic 0
care 0
setting 0
: 0
an 0
introduction 0
. 0

Gel 0
- 0
mobility 0
- 0
shift 0
assays 0
confirmed 0
that 0
the 0
Raji 0
nuclear 0
proteins 0
that 0
bound 0
to 0
W 0
and 0
V 0
elements 0
were 0
competed 0
with 0
by 0
an 0
HLA B-gene
- I-gene
DRA I-gene
X I-gene
- I-gene
box I-gene
oligonucleotide I-gene
. 0

In 0
Denmark 0
only 0
1 0
- 0
3 0
cases 0
of 0
transfusion 0
- 0
associated 0
hepatitis 0
NANB 0
( 0
TAH 0
- 0
NANB 0
) 0
are 0
registered 0
annually 0
or 0
about 0
1 0
case 0
per 0
100,000 0
units 0
transfused 0
. 0

The 0
NF1 B-gene
locus I-gene
encodes 0
a 0
protein 0
functionally 0
related 0
to 0
mammalian B-gene
GAP I-gene
and 0
yeast B-gene
IRA I-gene
proteins I-gene
. 0

Hence 0
, 0
the 0
replacement 0
of 0
Phe 0
- 0
62 0
with 0
Ser 0
specifically 0
affects 0
a 0
determinant 0
on 0
the 0
lambda B-gene
I I-gene
light I-gene
chain I-gene
that 0
is 0
necessary 0
for 0
the 0
intracellular 0
transport 0
of 0
this 0
molecule 0
. 0

A 0
second 0
isotype 0
of 0
Raja B-gene
immunoglobulin I-gene
heavy I-gene
chain I-gene
genes I-gene
has 0
been 0
detected 0
by 0
screening 0
a 0
spleen 0
cDNA 0
library 0
with 0
homologous 0
Raja B-gene
VH I-gene
- 0
and 0
CH1 B-gene
- 0
specific 0
probes 0
complementing 0
the 0
respective 0
regions 0
of 0
the 0
mu B-gene
- I-gene
like I-gene
isotype I-gene
. 0

Petko 0
, 0
and 0
S 0
. 0

Disruption 0
of 0
ARF2 B-gene
causes 0
no 0
detectable 0
phenotype 0
. 0

Human 0
recombinant 0
DNA 0
- 0
derived 0
antihemophilic B-gene
factor I-gene
( 0
factor B-gene
VIII I-gene
) 0
in 0
the 0
treatment 0
of 0
hemophilia 0
A. 0
recombinant 0
Factor B-gene
VIII I-gene
Study 0
Group 0
. 0

Like 0
other 0
members 0
of 0
this 0
family 0
, 0
the 0
AP B-gene
- I-gene
4 I-gene
HLH 0
motif 0
and 0
the 0
adjacent 0
basic 0
domain 0
are 0
necessary 0
and 0
sufficient 0
to 0
confer 0
site 0
- 0
specific 0
DNA 0
binding 0
. 0

Furthermore 0
, 0
expression 0
of 0
the 0
promoter 0
in 0
embryonic 0
Drosophila 0
melanogaster 0
cells 0
that 0
lack 0
MyoD1 B-gene
and 0
Sp1 B-gene
is 0
strictly 0
dependent 0
on 0
all 0
three 0
sites 0
remaining 0
intact 0
and 0
on 0
the 0
presence 0
of 0
exogenously 0
supplied 0
Sp1 B-gene
and 0
MyoD1 B-gene
. 0

Effects 0
of 0
a 0
selective 0
monoamine B-gene
oxidase I-gene
( I-gene
MAO I-gene
) I-gene
- I-gene
- I-gene
A I-gene
inhibitor 0
, 0
clorgyline 0
, 0
a 0
selective 0
MAO B-gene
- I-gene
B I-gene
inhibitor 0
, 0
deprenyl 0
, 0
and 0
a 0
non 0
- 0
selective 0
MAO B-gene
inhibitor 0
, 0
nialamide 0
, 0
were 0
investigated 0
on 0
footshock 0
- 0
induced 0
aggression 0
( 0
FIA 0
) 0
in 0
paired 0
rats 0
. 0

To 0
identify 0
structural 0
features 0
of 0
residues 0
flanking 0
the 0
c 0
- 0
region 0
that 0
influence 0
the 0
fidelity 0
and 0
efficiency 0
of 0
signal 0
peptidase 0
cleavage 0
as 0
well 0
as 0
co 0
- 0
translational 0
translocation 0
, 0
we 0
introduced 0
six 0
amino 0
acid 0
substitutions 0
into 0
the 0
COOH 0
terminus 0
of 0
the 0
hydrophobic 0
core 0
and 0
seven 0
substitutions 0
at 0
the 0
NH2 0
terminus 0
of 0
the 0
mature 0
region 0
( 0
the 0
+1 0
position 0
) 0
of 0
a 0
model 0
eukaryotic B-gene
preprotein I-gene
- I-gene
human I-gene
pre I-gene
( I-gene
delta I-gene
pro I-gene
) I-gene
apoA I-gene
- I-gene
II I-gene
. 0

Additionally 0
, 0
although 0
c B-gene
- I-gene
fos I-gene
and 0
egr B-gene
- I-gene
1 I-gene
mRNAs I-gene
are 0
expressed 0
at 0
elevated 0
levels 0
in 0
stimulated 0
liver 0
cells 0
, 0
fos B-gene
- I-gene
B I-gene
, 0
fra B-gene
- I-gene
1 I-gene
, 0
and 0
egr B-gene
- I-gene
2 I-gene
are 0
not 0
, 0
which 0
suggests 0
that 0
factors 0
in 0
addition 0
to 0
the 0
serum B-gene
response I-gene
factor I-gene
participate 0
in 0
the 0
regulation 0
of 0
immediate B-gene
- I-gene
early I-gene
gene I-gene
induction 0
. 0

Of 0
848 0
patients 0
, 0
819 0
cases 0
with 0
complete 0
description 0
of 0
patient 0
's 0
background 0
were 0
evaluable 0
: 0
Group 0
A 0
( 0
surgery 0
+ 0
MMC 0
+ 0
5 0
- 0
FU 0
: 0
chemotherapy 0
) 0
253 0
cases 0
, 0
group 0
B 0
( 0
surgery 0
+ 0
MMC 0
+ 0
5 0
- 0
FU 0
+ 0
OK 0
- 0
432 0
or 0
PSK 0
: 0
immunochemotherapy 0
) 0
282 0
and 0
group 0
C 0
( 0
surgery 0
alone 0
) 0
284 0
. 0

The 0
nuclear 0
proteins 0
encoded 0
by 0
the 0
c B-gene
- I-gene
fos I-gene
and 0
c B-gene
- I-gene
jun I-gene
protooncogenes I-gene
are 0
expressed 0
during 0
the 0
proliferation 0
period 0
of 0
osteoblast 0
phenotype 0
development 0
. 0

This 0
model 0
is 0
further 0
supported 0
by 0
binding 0
of 0
the 0
Fos B-gene
- 0
Jun B-gene
complex 0
at 0
an 0
AP B-gene
- I-gene
1 I-gene
site I-gene
in 0
the 0
type B-gene
alpha I-gene
I I-gene
collagen I-gene
promoter I-gene
that 0
is 0
contiguous 0
with 0
, 0
but 0
not 0
overlapping 0
, 0
the 0
VDRE 0
. 0

PBSX B-gene
is 0
induced 0
by 0
agents 0
which 0
elicit 0
the 0
SOS 0
response 0
. 0

A 0
bacteriological 0
relapse 0
requiring 0
treatment 0
occurred 0
by 0
5 0
years 0
in 0
16.8 0
% 0
of 0
113 0
R3 0
, 0
5.2 0
% 0
of 0
97 0
R5 0
, 0
and 0
20.0 0
% 0
of 0
115 0
Z5 0
patients 0
with 0
organisms 0
sensitive 0
to 0
streptomycin 0
and 0
isoniazid 0
initially 0
. 0

In 0
the 0
controls 0
, 0
it 0
was 0
found 0
that 0
all 0
right 0
- 0
handed 0
and 0
10 0
out 0
of 0
14 0
left 0
- 0
handed 0
control 0
subjects 0
showed 0
a 0
right 0
VHF 0
( 0
i.e. 0
, 0
left 0
hemisphere 0
) 0
advantage 0
. 0

Although 0
no 0
Rh B-gene
- I-gene
antibodies I-gene
were 0
demonstrable 0
, 0
a 0
similar 0
mechanism 0
can 0
be 0
postulated 0
for 0
the 0
Rh 0
- 0
system 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
has 0
the 0
greatest 0
homology 0
( 0
61 0
% 0
) 0
to 0
the 0
green B-gene
alga I-gene
Scenedemus I-gene
obliquus I-gene
plastocyanin I-gene
. 0

Higher 0
fasting 0
serum 0
gastrin B-gene
concentration 0
( 0
102.0 0
+/ 0
- 0
21.1 0
vs 0
63.3 0
+/ 0
- 0
8.3 0
ng.l 0
- 0
1 0
) 0
, 0
and 0
greater 0
postprandial 0
gastrin B-gene
release 0
( 0
AUC0 0
- 0
120 0
: 0
16690 0
+/ 0
- 0
2648 0
vs 0
10654 0
+/ 0
- 0
1283 0
ng.l 0
- 0
1 0
min 0
) 0
were 0
observed 0
after 0
VTP 0
- 0
HM 0
than 0
after 0
VTP 0
- 0
Cas 0
. 0

The 0
experimental 0
group 0
consisted 0
of 0
61 0
examinees 0
class 0
II/2 0
orthodontic 0
anomalies 0
. 0

This 0
study 0
was 0
performed 0
to 0
clarify 0
the 0
location 0
of 0
a 0
transesophageal 0
echocardiographic 0
( 0
TEE 0
) 0
transducer 0
when 0
obtaining 0
the 0
short 0
- 0
axis 0
view 0
of 0
the 0
left 0
ventricle 0
( 0
S 0
- 0
LV 0
) 0
. 0

Subjects 0
were 0
16 0
male 0
chronic 0
schizophrenics 0
consisting 0
of 0
8 0
DST 0
suppressors 0
and 0
8 0
nonsuppressors 0
. 0

From 0
S3 0
( 0
CBF 0
: 0
79 0
- 0
60 0
% 0
) 0
to 0
S5 0
( 0
CBF 0
: 0
39 0
- 0
0 0
% 0
) 0
, 0
% 0
WTh 0
, 0
1/TPC 0
and 0
1/T 0
were 0
significantly 0
decreased 0
from 0
those 0
of 0
the 0
control 0
levels 0
( 0
all 0
p 0
less 0
than 0
0.01 0
) 0
. 0

In 0
this 0
article 0
we 0
propose 0
to 0
find 0
out 0
the 0
percentage 0
of 0
normal 0
occlusion 0
and 0
the 0
distribution 0
of 0
maloclusions 0
, 0
according 0
to 0
the 0
anteroposterior 0
relationship 0
between 0
the 0
dental 0
archs 0
( 0
following 0
the 0
ANGLE3 0
classification 0
) 0
. 0

In 0
that 0
case 0
, 0
the 0
ratio 0
of 0
brush 0
abrasion 0
was 0
0.268 0
, 0
compressive 0
and 0
transverse 0
strength 0
, 0
124.3 0
and 0
86.3 0
MPa 0
respectively 0
, 0
hardness 0
, 0
43.2 0
Hk 0
, 0
water 0
absorption 0
14.2 0
micrograms/mm3 0
and 0
thermal 0
expansion 0
coefficient 0
, 0
47.4 0
x 0
10 0
( 0
- 0
6 0
) 0
/degrees 0
C 0
. 0

9 0
, 0
1498 0
- 0
1506 0
) 0
. 0

In 0
a 0
highly 0
select 0
group 0
of 0
stable 0
hypertensive 0
patients 0
, 0
we 0
have 0
assessed 0
the 0
strength 0
of 0
association 0
between 0
various 0
blood 0
pressure 0
measurements 0
( 0
24 0
h 0
average 0
automated 0
ambulatory 0
blood 0
pressure 0
, 0
4 0
h 0
automated 0
ambulatory 0
morning 0
average 0
blood 0
pressure 0
, 0
multiple 0
office 0
visit 0
average 0
blood 0
pressure 0
, 0
and 0
a 0
single 0
office 0
visit 0
average 0
blood 0
pressure 0
) 0
and 0
various 0
echocardiographic 0
indices 0
of 0
hypertensive 0
cardiac 0
target 0
organ 0
damage 0
( 0
left 0
atrial 0
diameter 0
, 0
left 0
ventricular 0
end 0
diastolic 0
diameter 0
, 0
posterior 0
wall 0
thickness 0
, 0
combined 0
wall 0
thickness 0
, 0
relative 0
wall 0
thickness 0
, 0
left 0
ventricular 0
mass 0
and 0
mass 0
index 0
, 0
and 0
combined 0
wall 0
thickness/left 0
ventricular 0
diastolic 0
diameter 0
ratio 0
) 0
. 0

We 0
have 0
previously 0
identified 0
, 0
by 0
screening 0
a 0
lambda 0
gt11 0
expression 0
library 0
, 0
murine B-gene
protein I-gene
mXBP I-gene
, 0
which 0
binds 0
to 0
a 0
sequence 0
which 0
overlaps 0
the 0
3 0
' 0
end 0
of 0
the 0
murine B-gene
class I-gene
II I-gene
major I-gene
histocompatibility I-gene
complex I-gene
A I-gene
alpha I-gene
gene I-gene
X I-gene
box I-gene
, 0
a 0
conserved 0
transcription 0
element 0
found 0
upstream 0
of 0
all 0
class 0
II 0
genes 0
. 0

The 0
p36 B-gene
gene I-gene
is 0
at 0
least 0
22 0
kb 0
in 0
length 0
and 0
has 0
a 0
coding 0
sequence 0
of 0
approximately 0
1 0
kb 0
, 0
representing 0
only 0
4.5 0
% 0
of 0
the 0
gene 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

This 0
multimodality 0
treatment 0
for 0
locally 0
advanced 0
gynecologic 0
tumors 0
appears 0
feasible 0
with 0
modification 0
, 0
and 0
continued 0
work 0
exploring 0
this 0
approach 0
is 0
encouraged 0
. 0

A 0
contiguous 0
and 0
sequentially 0
occupied 0
secondary 0
Fur B-gene
- I-gene
binding I-gene
site I-gene
in 0
entC B-gene
was 0
protected 0
at 0
higher 0
Fur B-gene
concentrations 0
, 0
extending 0
the 0
protected 0
region 0
to 0
+49 0
, 0
and 0
sequestering 0
the 0
putative 0
Shine 0
- 0
Dalgarno 0
sequence 0
. 0

The 0
major 0
promoter 0
responds 0
strongly 0
to 0
virus 0
- 0
encoded 0
trans 0
activators 0
EIA B-gene
and 0
EIV B-gene
and 0
contains 0
four 0
elements 0
: 0
a 0
TAGA 0
motif 0
analogous 0
to 0
the 0
TATA 0
box 0
, 0
two 0
EIIF B-gene
sites I-gene
present 0
in 0
an 0
inverted 0
orientation 0
, 0
and 0
an 0
ATF/CREB B-gene
site 0
. 0

With 0
the 0
modified 0
fingertip 0
- 0
to 0
- 0
floor 0
( 0
MFTF 0
) 0
method 0
, 0
patients 0
stand 0
on 0
a 0
stool 0
and 0
forward 0
bend 0
so 0
that 0
measurements 0
can 0
be 0
taken 0
on 0
patients 0
who 0
are 0
able 0
to 0
touch 0
the 0
floor 0
or 0
reach 0
beyond 0
the 0
level 0
of 0
the 0
floor 0
. 0

No 0
significant 0
differences 0
could 0
be 0
seen 0
in 0
response 0
rates 0
according 0
to 0
the 0
concentration 0
of 0
estrogen B-gene
receptors I-gene
or 0
presence 0
of 0
progesteron B-gene
receptors I-gene
in 0
this 0
group 0
of 0
patients 0
. 0

Teicoplanin 0
was 0
given 0
most 0
often 0
because 0
of 0
persistent 0
fever 0
or 0
initial 0
Gram 0
- 0
positive 0
bacteraemia 0
and 0
only 0
one 0
- 0
third 0
of 0
these 0
cases 0
responded 0
. 0

Luteinizing B-gene
hormone I-gene
- I-gene
releasing I-gene
hormone I-gene
analog 0
therapy 0
of 0
uterine 0
fibroid 0
: 0
analysis 0
of 0
results 0
obtained 0
with 0
buserelin 0
administered 0
intranasally 0
and 0
goserelin 0
administered 0
subcutaneously 0
as 0
a 0
monthly 0
depot 0
. 0

In 0
Experiments 0
1 0
and 0
2 0
, 0
infants 0
, 0
like 0
adults 0
, 0
initially 0
categorized 0
novel 0
objects 0
on 0
the 0
basis 0
of 0
physical 0
appearance 0
, 0
but 0
only 0
if 0
trained 0
with 0
multiple 0
exemplars 0
, 0
after 0
delays 0
of 0
1 0
and 0
7 0
days 0
. 0

The 0
clinical 0
picture 0
of 0
the 0
disease 0
was 0
significantly 0
different 0
from 0
anthropogenic 0
cutaneous 0
leishmaniasis 0
caused 0
by 0
L. 0
tropica 0
but 0
similar 0
to 0
cutaneous 0
patterns 0
caused 0
by 0
L. 0
infantum 0
which 0
was 0
a 0
prevalent 0
pattern 0
in 0
the 0
southern 0
France 0
. 0

Although 0
there 0
are 0
no 0
octamer 0
elements 0
in 0
the 0
adenovirus 0
genome 0
that 0
are 0
known 0
to 0
be 0
important 0
for 0
transcription 0
, 0
there 0
are 0
octamer 0
elements 0
in 0
the 0
viral 0
terminal 0
repeat 0
sequences 0
. 0

In 0
comparison 0
with 0
the 0
16 0
introns 0
reported 0
in 0
AHA3 B-gene
, 0
AHA2 B-gene
is 0
missing 0
one 0
intron 0
in 0
the 0
5' 0
- 0
untranslated 0
region 0
and 0
a 0
second 0
intron 0
in 0
the 0
C 0
- 0
terminal 0
coding 0
region 0
. 0

Northern 0
blot 0
analysis 0
indicates 0
that 0
AHA2 B-gene
mRNA I-gene
relative 0
to 0
total 0
cellular 0
RNA 0
is 0
expressed 0
at 0
significantly 0
higher 0
levels 0
in 0
root 0
tissue 0
as 0
compared 0
with 0
shoot 0
tissue 0
. 0

Impaction 0
of 0
gastrostomy 0
tube 0
in 0
the 0
abdominal 0
wall 0
. 0

Both 0
antidepressants 0
elevated 0
the 0
pain 0
threshold 0
acutely 0
, 0
while 0
pretreatment 0
with 0
pCPA 0
largely 0
blocked 0
the 0
analgesia 0
. 0

Sci 0
. 0

A 0
needs 0
assessment 0
of 0
these 0
families 0
was 0
also 0
done 0
. 0

TCR B-gene
alpha I-gene
and I-gene
beta I-gene
gene I-gene
expression 0
may 0
be 0
regulated 0
by 0
a 0
common 0
set 0
of 0
T B-gene
- I-gene
cell I-gene
nuclear I-gene
proteins I-gene
in 0
that 0
the 0
T B-gene
beta I-gene
2 I-gene
element I-gene
binding 0
a 0
set 0
of 0
cyclic B-gene
AMP I-gene
response I-gene
element I-gene
- I-gene
binding I-gene
proteins I-gene
that 0
are 0
also 0
bound 0
by 0
the 0
T B-gene
alpha I-gene
1 I-gene
element I-gene
of 0
the 0
human 0
TCR B-gene
alpha I-gene
enhancer 0
and 0
the 0
decamer 0
element 0
present 0
in 0
a 0
large 0
number 0
of 0
human 0
and 0
murine 0
TCR B-gene
beta I-gene
promoters 0
. 0

The 0
3 0
' 0
stem 0
- 0
loop 0
is 0
highly 0
divergent 0
in 0
structure 0
among 0
species 0
and 0
lies 0
immediately 0
upstream 0
of 0
the 0
binding 0
site 0
for 0
Sm B-gene
proteins I-gene
. 0

The 0
deleted 0
nucleotide 0
sequence 0
corresponded 0
to 0
sequences 0
that 0
, 0
by 0
analogy 0
to 0
the 0
organization 0
of 0
the 0
type B-gene
I I-gene
collagen I-gene
genes I-gene
, 0
should 0
be 0
precisely 0
encoded 0
by 0
exon 0
41 0
of 0
the 0
COL3A1 B-gene
gene I-gene
. 0

These 0
losses 0
account 0
for 0
the 0
resistance 0
of 0
EDS 0
- 0
IV 0
collagen B-gene
to 0
cyanogen 0
bromide 0
and 0
mammalian B-gene
collagenase I-gene
digestion 0
. 0

A 0
4.8 0
- 0
kilobase 0
BamHI B-gene
- 0
HindIII B-gene
fragment 0
encoding 0
the 0
entire B-gene
Neurospora I-gene
crassa I-gene
CuZn I-gene
superoxide I-gene
dismutase I-gene
gene I-gene
( 0
herein 0
designated 0
sod B-gene
- I-gene
1 I-gene
) 0
was 0
isolated 0
from 0
a 0
genomic 0
library 0
using 0
two 0
60 0
- 0
base 0
deoxyoligonucleotide 0
probes 0
corresponding 0
to 0
the 0
published 0
N. 0
crassa 0
amino 0
acid 0
sequence 0
. 0

Two 0
other 0
peptides 0
, 0
either 0
partially 0
or 0
totally 0
lacking 0
the 0
basic 0
region 0
, 0
but 0
containing 0
the 0
intact 0
leucine 0
zipper 0
domain 0
, 0
readily 0
form 0
dimers 0
but 0
do 0
not 0
bind 0
to 0
the 0
CRE 0
. 0

In 0
contrast 0
, 0
the 0
CRE 0
of 0
the 0
human B-gene
c I-gene
- I-gene
fos I-gene
promoter I-gene
located 0
at 0
- 0
60 0
was 0
weakly 0
induced 0
by 0
cAMP 0
and 0
E1a B-gene
in 0
both 0
HeLa 0
and 0
PC12 0
cells 0
. 0

We 0
have 0
isolated 0
and 0
sequenced 0
the 0
gene 0
encoding 0
the 0
human B-gene
U1 I-gene
- I-gene
70K I-gene
snRNP I-gene
protein I-gene
. 0

Although 0
popular 0
this 0
hypothesis 0
is 0
far 0
from 0
explaining 0
all 0
the 0
clinical 0
facts 0
, 0
namely 0
that 0
rigidity 0
is 0
equal 0
in 0
extensor 0
and 0
flexor 0
, 0
proximal 0
and 0
distal 0
muscles 0
. 0

Using 0
appropriate 0
synthetic 0
HSE 0
oligonucleotides 0
, 0
three 0
types 0
of 0
clones 0
with 0
potential 0
HSE 0
binding 0
domains 0
were 0
isolated 0
from 0
a 0
tomato 0
lambda 0
gt11 0
expression 0
library 0
by 0
DNA 0
- 0
ligand 0
screening 0
. 0

Fluid 0
( 0
AVLF 0
) 0
31 0
. 0

The 0
results 0
supported 0
the 0
therapeutic 0
principle 0
of 0
TCM 0
: 0
Treating 0
patients 0
according 0
to 0
their 0
pathophysiological 0
patterns 0
. 0

The 0
nmr B-gene
gene I-gene
is 0
the 0
major 0
negative 0
regulatory 0
gene 0
in 0
the 0
nitrogen 0
control 0
circuit 0
of 0
Neurospora 0
crassa 0
, 0
which 0
, 0
together 0
with 0
positive 0
regulatory 0
genes 0
, 0
governs 0
the 0
expression 0
of 0
multiple 0
unlinked 0
structural 0
genes 0
of 0
the 0
circuit 0
. 0

The 0
4 0
days 0
dexamethasone 0
suppression 0
test 0
showed 0
more 0
than 0
80 0
% 0
suppression 0
of 0
dehydroepiandrosterone 0
- 0
sulphate 0
and 0
a 0
variable 0
( 0
40 0
- 0
60 0
% 0
) 0
reduction 0
of 0
testosterone 0
and 0
androstenedione 0
levels 0
. 0

The 0
ratio 0
of 0
P 0
- 0
31 0
NMR 0
- 0
S 0
derived 0
inorganic 0
phosphates 0
[ 0
Pi 0
] 0
to 0
phosphocreatine 0
[ 0
PCr 0
] 0
was 0
significantly 0
greater 0
at 0
rest 0
in 0
LVH 0
baboons 0
[ 0
0.53 0
+/ 0
- 0
0.06 0
versus 0
controls 0
= 0
0.41 0
+/ 0
- 0
0.17 0
; 0
P 0
less 0
than 0
0.05 0
] 0
. 0

Cutaneous 0
necrosis 0
associated 0
with 0
protein B-gene
S I-gene
deficiency 0
. 0

Critical 0
study 0

Regional 0
cerebral 0
blood 0
flow 0
was 0
measured 0
using 0
N 0
- 0
isopropyl 0
- 0
123I 0
- 0
iodoamphetamine 0
with 0
single 0
- 0
photon 0
emission 0
computed 0
tomography 0
( 0
CT 0
) 0
in 0
16 0
aged 0
patients 0
with 0
noninsulin 0
- 0
dependent 0
diabetes 0
mellitus 0
( 0
NIDDM 0
, 0
average 0
age 0
72.8 0
years 0
, 0
average 0
fasting 0
plasma 0
glucose 0
7.7 0
mmol/L 0
) 0
, 0
and 0
12 0
nondiabetic 0
subjects 0
( 0
71.6 0
years 0
, 0
5.3 0
mmol/L 0
) 0
. 0

Mean 0
ROI 0
- 0
A/B 0
ratio 0
was 0
49.6 0
+/ 0
- 0
1.7 0
% 0
in 0
the 0
diabetic 0
group 0
, 0
significantly 0
lower 0
than 0
the 0
57.9 0
+/ 0
- 0
1.6 0
% 0
at 0
the 0
nondiabetic 0
group 0
( 0
p 0
less 0
than 0
0.005 0
) 0
. 0

These 0
data 0
strongly 0
implicate 0
the 0
normal 0
product 0
of 0
the 0
int B-gene
- I-gene
2 I-gene
gene I-gene
, 0
which 0
is 0
related 0
to 0
the 0
fibroblast B-gene
growth I-gene
factor I-gene
family I-gene
, 0
as 0
a 0
contributory 0
factor 0
in 0
virally 0
induced 0
mammary 0
tumors 0
. 0

This 0
result 0
indicates 0
that 0
separate 0
complexes 0
exist 0
containing 0
ankyrin B-gene
and 0
fodrin B-gene
with 0
either 0
uvomorulin B-gene
or 0
Na+ B-gene
, I-gene
K+ I-gene
- I-gene
ATPase I-gene
. 0

These 0
genes 0
are 0
expressed 0
within 0
a 0
few 0
hours 0
of 0
the 0
initiation 0
of 0
development 0
; 0
their 0
mRNAs 0
accumulate 0
to 0
a 0
peak 0
at 0
12 0
hr 0
and 0
persist 0
until 0
culmination 0
. 0

The 0
PC2 B-gene
protein I-gene
also 0
shows 0
great 0
similarity 0
to 0
the 0
incomplete 0
NH2 0
- 0
terminal 0
sequence 0
of 0
the 0
human B-gene
furin I-gene
gene I-gene
product I-gene
, 0
a 0
putative 0
membrane 0
- 0
inserted 0
receptor 0
- 0
like 0
molecule 0
. 0

Whether 0
or 0
not 0
there 0
are 0
sequences 0
conferring 0
cAMP 0
responsiveness 0
which 0
are 0
common 0
both 0
to 0
P B-gene
- I-gene
450scc I-gene
and 0
the 0
other 0
steroidogenic 0
P B-gene
- I-gene
450 I-gene
genes I-gene
remains 0
to 0
be 0
established 0
. 0

In 0
this 0
study 0
, 0
we 0
used 0
footprinting 0
and 0
gel 0
mobility 0
retardation 0
assays 0
to 0
reveal 0
that 0
bacterially 0
synthesized 0
Zta B-gene
fusion I-gene
proteins I-gene
bound 0
directly 0
to 0
six 0
TGTGCAA 0
- 0
like 0
motifs 0
within 0
DSL B-gene
. 0

The 0
zta B-gene
transactivator I-gene
involved 0
in 0
induction 0
of 0
lytic 0
cycle 0
gene 0
expression 0
in 0
Epstein 0
- 0
Barr 0
virus 0
- 0
infected 0
lymphocytes 0
binds 0
to 0
both 0
AP B-gene
- I-gene
1 I-gene
and 0
ZRE B-gene
sites I-gene
in 0
target 0
promoter 0
and 0
enhancer 0
regions 0
. 0

It 0
is 0
the 0
human 0
homolog 0
of 0
the 0
mouse B-gene
Mx I-gene
protein I-gene
involved 0
in 0
resistance 0
to 0
influenza 0
virus 0
. 0

Fragments 0
containing 0
the 0
21 0
- 0
base 0
- 0
pair 0
repeat 0
region 0
, 0
the 0
enhancer B-gene
of I-gene
simian I-gene
virus I-gene
40 I-gene
or 0
both 0
strongly 0
stimulated 0
beta B-gene
- I-gene
galactosidase I-gene
synthesis 0
, 0
and 0
three 0
fragments 0
from 0
the 0
polyomavirus B-gene
enhancer I-gene
region I-gene
stimulated 0
moderate 0
levels 0
. 0

The 0
sites 0
targeted 0
for 0
mutagenesis 0
, 0
residues 0
60 0
, 0
61 0
, 0
and 0
66 0
, 0
are 0
located 0
within 0
a 0
putative 0
helical 0
loop 0
structure 0
which 0
may 0
be 0
involved 0
in 0
substrate 0
recognition 0
by 0
the 0
enzyme 0
. 0

The 0
possible 0
benefits 0
of 0
LMW 0
heparin 0
( 0
reduced 0
frequency 0
of 0
bleeding 0
, 0
alleviation 0
of 0
hypertriglyceridemia 0
) 0
were 0
not 0
, 0
however 0
, 0
apparent 0
, 0
possibly 0
because 0
of 0
the 0
short 0
observation 0
period 0
and 0
the 0
low 0
incidence 0
of 0
hemorrhagic 0
complications 0
in 0
routine 0
dialyses 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
of 0
destrin B-gene
is 0
165 0
residues 0
long 0
and 0
is 0
very 0
similar 0
( 0
71 0
% 0
identical 0
) 0
to 0
that 0
of 0
cofilin B-gene
, 0
a 0
widely 0
distributed 0
, 0
pH 0
- 0
sensitive 0
actin B-gene
- 0
modulating 0
protein 0
. 0

Summers 0
, 0
Virology 0
89:517 0
- 0
527 0
, 0
1978 0
) 0
. 0

With 0
only 0
purified 0
T B-gene
antigen I-gene
in 0
the 0
presence 0
of 0
topoisomerase B-gene
I I-gene
to 0
unwind 0
purified 0
DNA 0
, 0
ori 0
- 0
auxiliary 0
sequences 0
strongly 0
facilitated 0
T B-gene
- I-gene
antigen I-gene
- 0
dependent 0
DNA 0
conformational 0
changes 0
consistent 0
with 0
melting 0
the 0
first 0
50 0
base 0
pairs 0
. 0

A 0
rabbit 0
antiserum 0
was 0
raised 0
against 0
a 0
synthetic 0
peptide 0
corresponding 0
to 0
a 0
hydrophilic 0
portion 0
of 0
the 0
translated 0
murine 0
cDNA 0
sequence 0
. 0

Conservation 0
of 0
function 0
of 0
Drosophila B-gene
melanogaster I-gene
abl I-gene
and 0
murine B-gene
v I-gene
- I-gene
abl I-gene
proteins I-gene
in 0
transformation 0
of 0
mammalian 0
cells 0
. 0

In 0
transient 0
cotransfection 0
assays 0
using 0
Chang 0
liver 0
cells 0
( 0
CCL 0
13 0
) 0
, 0
pM1 0
DNA 0
exerts 0
a 0
6 0
- 0
to 0
10 0
- 0
fold 0
trans 0
- 0
activating 0
effect 0
on 0
the 0
expression 0
of 0
the 0
pSV2CAT 0
reporter 0
plasmid 0
. 0

We 0
have 0
determined 0
the 0
nucleotide 0
( 0
nt 0
) 0
sequence 0
of 0
the 0
7.5 B-gene
- I-gene
kb I-gene
COR I-gene
segment I-gene
that 0
encompasses 0
a 0
cluster 0
of 0
six 0
genes 0
( 0
CYC1 B-gene
, 0
UTR1 B-gene
, 0
UTR3 B-gene
, 0
OSM1 B-gene
, 0
tRNA B-gene
( I-gene
Gly I-gene
) I-gene
and 0
RAD7 B-gene
) 0
located 0
on 0
chromosome 0
X 0
of 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

Specific 0
binding 0
of 0
the 0
protein 0
factors 0
to 0
the 0
sites 0
, 0
possibly 0
to 0
the 0
three 0
Mt 0
sequences 0
, 0
may 0
play 0
an 0
important 0
role 0
in 0
the 0
coordinate 0
regulation 0
of 0
the 0
transcription 0
of 0
nuclear 0
genes 0
encoding 0
subunits 0
responsible 0
for 0
mitochondrial 0
oxidative 0
phosphorylation 0
. 0

This 0
points 0
to 0
a 0
specific 0
interference 0
with 0
HSV 0
- 0
induced 0
DNA 0
amplification 0
. 0

No 0
recombination 0
signal 0
sequences 0
have 0
been 0
found 0
contiguous 0
to 0
the 0
recombination 0
point 0
. 0

The 0
antinociceptive 0
properties 0
, 0
as 0
measured 0
by 0
the 0
tail 0
- 0
flick 0
and 0
hot 0
- 0
plate 0
tests 0
, 0
and 0
the 0
motor 0
effects 0
of 0
an 0
intrathecally 0
- 0
administered 0
benzodiazepine 0
agonist 0
midazolam 0
, 0
alone 0
, 0
and 0
in 0
combination 0
with 0
morphine 0
, 0
was 0
examined 0
in 0
rats 0
. 0

Constructs 0
were 0
made 0
in 0
which 0
an 0
AATAAA 0
and 0
the 0
GT 0
- 0
rich 0
region 0
were 0
separated 0
by 0
various 0
distances 0
ranging 0
from 0
7 0
to 0
43 0
bp 0
. 0

To 0
address 0
this 0
issue 0
, 0
the 0
gene 0
for 0
factor B-gene
Y I-gene
has 0
been 0
cloned 0
molecularly 0
and 0
its 0
DNA 0
sequence 0
has 0
been 0
determined 0
. 0

We 0
cloned 0
and 0
sequenced 0
the 0
cDNAs 0
against 0
genomic 0
RNA 0
and 0
mRNA 0
for 0
phosphoprotein B-gene
( I-gene
P I-gene
) I-gene
of 0
human 0
parainfluenza 0
type 0
2 0
virus 0
( 0
PIV 0
- 0
2 0
) 0
. 0
cDNA 0
clone 0
from 0
genomic 0
RNA 0
was 0
1439 0
nucleotides 0
in 0
length 0
excluding 0
poly 0
( 0
A 0
) 0
and 0
was 0
found 0
to 0
have 0
two 0
small 0
open 0
reading 0
frames 0
encoding 0
proteins 0
of 0
233 0
and 0
249 0
amino 0
acids 0
. 0

We 0
show 0
that 0
cytR B-gene
expression 0
is 0
negatively 0
controlled 0
by 0
the 0
CytR B-gene
protein I-gene
and 0
positively 0
affected 0
by 0
the 0
cAMP/CAP B-gene
complex I-gene
. 0

To 0
identify 0
these 0
sites 0
, 0
the 0
deduced 0
amino 0
acid 0
sequence 0
of 0
the 0
3T3 0
- 0
L1 0
adipocyte B-gene
insulin I-gene
receptor I-gene
of 0
the 0
mouse 0
was 0
determined 0
. 0

PAO 0
blocks 0
turnover 0
of 0
the 0
phosphoryl 0
group 0
of 0
pp15 B-gene
, 0
causing 0
its 0
accumulation 0
, 0
and 0
thereby 0
appears 0
to 0
interrupt 0
signal 0
transmission 0
from 0
the 0
receptor 0
to 0
the 0
glucose 0
- 0
transport 0
system 0
. 0

It 0
is 0
likely 0
that 0
the 0
sequence 0
similarities 0
reflect 0
a 0
common 0
molecular 0
architecture 0
of 0
the 0
two 0
heme 0
binding 0
sites 0
and 0
of 0
a 0
copper 0
binding 0
site 0
in 0
these 0
enzymes 0
. 0

The 0
cDNA 0
sequence 0
has 0
an 0
813 0
- 0
bp 0
open 0
reading 0
frame 0
( 0
ORF 0
) 0
whose 0
predicted 0
amino 0
acid 0
sequence 0
is 0
97.6 0
% 0
identical 0
to 0
the 0
272 0
carboxy 0
- 0
terminal 0
amino 0
acids 0
of 0
the 0
human B-gene
ets I-gene
- I-gene
1 I-gene
protein I-gene
. 0

To 0
characterize 0
the 0
O7 B-gene
- I-gene
LPS I-gene
region I-gene
, 0
the 0
recombinant 0
cosmids 0
pJHCV31 0
and 0
pJHCV32 0
were 0
mutagenized 0
by 0
transposon 0
mutagenesis 0
with 0
Tn3HoHo1 B-gene
, 0
which 0
carries 0
a 0
promoterless 0
lac B-gene
operon I-gene
and 0
can 0
therefore 0
generate 0
lacZ B-gene
transcriptional 0
fusions 0
with 0
target 0
DNA 0
sequences 0
. 0

The 0
sacT B-gene
gene I-gene
regulating 0
the 0
sacPA B-gene
operon I-gene
in I-gene
Bacillus I-gene
subtilis I-gene
shares 0
strong 0
homology 0
with 0
transcriptional 0
antiterminators 0
. 0

The 0
TraD B-gene
protein I-gene
( I-gene
83,899 I-gene
Da I-gene
) I-gene
contains 0
three 0
hydrophobic 0
regions 0
, 0
of 0
which 0
two 0
are 0
located 0
near 0
the 0
amino 0
- 0
terminal 0
region 0
. 0

The 0
protein 0
product 0
of 0
orfD B-gene
, 0
which 0
is 0
probably 0
a 0
new 0
tra B-gene
gene I-gene
( 0
named 0
traX B-gene
) 0
, 0
contains 0
65 0
% 0
hydrophobic 0
amino 0
acids 0
, 0
especially 0
rich 0
in 0
alanine 0
and 0
leucine 0
. 0

Various 0
mutant B-gene
HN I-gene
genes I-gene
were 0
constructed 0
to 0
examine 0
the 0
role 0
of 0
residues 0
flanking 0
the 0
signal 0
- 0
anchor 0
domain 0
, 0
including 0
the 0
cytoplasmic 0
tail 0
, 0
on 0
assembly 0
and 0
intracellular 0
transport 0
of 0
the 0
HN B-gene
glycoprotein I-gene
. 0

Our 0
studies 0
extend 0
these 0
findings 0
and 0
show 0
that 0
the 0
E2 B-gene
transactivation I-gene
gene I-gene
is 0
expressed 0
from 0
multiple 0
promoters 0
. 0

Furthermore 0
, 0
analysis 0
of 0
the 0
E2 B-gene
proteins I-gene
present 0
in 0
various 0
cell 0
lines 0
harboring 0
specific 0
BPV 0
- 0
1 0
mutants 0
, 0
including 0
the 0
2558 0
acceptor 0
mutant 0
, 0
proves 0
that 0
alternate 0
modes 0
of 0
E2 B-gene
expression 0
exist 0
. 0

Disruption 0
of 0
the 0
IRA2 B-gene
gene I-gene
resulted 0
in 0
( 0
i 0
) 0
increased 0
sensitivity 0
to 0
heat 0
shock 0
and 0
nitrogen 0
starvation 0
, 0
( 0
ii 0
) 0
sporulation 0
defects 0
, 0
and 0
( 0
iii 0
) 0
suppression 0
of 0
the 0
lethality 0
of 0
the 0
cdc25 B-gene
mutant I-gene
. 0

This 0
cohort 0
of 0
patients 0
was 0
selected 0
on 0
the 0
basis 0
of 0
clinical 0
stage 0
. 0

A 0
gene 0
in 0
Drosophila 0
melanogaster 0
that 0
maps 0
cytologically 0
to 0
2C1 0
- 0
3 0
on 0
the 0
distal 0
portion 0
of 0
the 0
X 0
- 0
chromosome 0
encodes 0
a 0
member 0
of 0
the 0
steroid/thyroid B-gene
hormone I-gene
receptor I-gene
superfamily I-gene
. 0

A 0
portion 0
of 0
Region 0
II 0
also 0
resembles 0
part 0
of 0
the 0
human 0
c B-gene
- I-gene
jun I-gene
oncoprotein 0
's 0
leucine 0
zipper 0
, 0
which 0
in 0
turn 0
, 0
has 0
been 0
demonstrated 0
to 0
be 0
the 0
heterodimerization 0
site 0
between 0
the 0
jun B-gene
and 0
fos B-gene
oncoproteins I-gene
. 0

To 0
determine 0
whether 0
vanadate 0
could 0
inhibit 0
PEPCK B-gene
gene I-gene
transcription 0
, 0
a 0
series 0
of 0
chimeric 0
genes 0
containing 0
several 0
deletions 0
in 0
the 0
P B-gene
- I-gene
enolypyruvate I-gene
carboxykinase I-gene
promoter I-gene
between 0
- 0
550 0
and 0
- 0
68 0
was 0
linked 0
to 0
the 0
structural 0
genes 0
for 0
either 0
amino B-gene
- I-gene
3 I-gene
- I-gene
glycosyl I-gene
phosphotransferase I-gene
( 0
neo B-gene
) 0
or 0
chloramphenicol B-gene
acetyltransferase I-gene
and 0
introduced 0
into 0
hepatoma 0
cells 0
using 0
three 0
methods 0
: 0
( 0
a 0
) 0
infection 0
with 0
a 0
Moloney 0
murine 0
leukemia 0
virus 0
- 0
based 0
retrovirus 0
, 0
( 0
b 0
) 0
transfection 0
and 0
stable 0
selection 0
for 0
neo B-gene
expression 0
, 0
or 0
( 0
c 0
) 0
transient 0
expression 0
of 0
chloroamphenicol B-gene
acetyltransferase I-gene
. 0

The 0
diagnosis 0
of 0
miliary 0
tuberculosis 0
should 0
be 0
systematically 0
considered 0
in 0
ARDS 0
of 0
unknown 0
origin 0
. 0

In 0
order 0
to 0
characterize 0
the 0
functional 0
elements 0
of 0
the 0
promoter 0
that 0
in 0
some 0
way 0
must 0
respond 0
to 0
these 0
regulatory 0
signals 0
, 0
a 0
number 0
of 0
promoter 0
mutations 0
were 0
constructed 0
, 0
including 0
a 0
set 0
of 0
linker 0
- 0
scanning 0
mutations 0
across 0
the 0
entire 0
promoter 0
region 0
. 0

A 0
DNA 0
motif 0
related 0
to 0
the 0
cAMP 0
- 0
responsive 0
element 0
and 0
an 0
exon B-gene
- I-gene
located I-gene
activator I-gene
protein I-gene
- I-gene
2 I-gene
binding I-gene
site I-gene
in 0
the 0
human B-gene
tissue I-gene
- I-gene
type I-gene
plasminogen I-gene
activator I-gene
gene I-gene
promoter I-gene
cooperate 0
in 0
basal 0
expression 0
and 0
convey 0
activation 0
by 0
phorbol 0
ester 0
and 0
cAMP 0
. 0

The 0
26S B-gene
rRNA I-gene
binding I-gene
ribosomal I-gene
protein I-gene
equivalent 0
to 0
bacterial B-gene
protein I-gene
L11 I-gene
is 0
encoded 0
by 0
unspliced 0
duplicated 0
genes 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Five 0
healthy 0
male 0
subjects 0
inspired 0
air 0
for 0
20 0
min 0
and 0
then 0
5 0
% 0
CO2/95 0
% 0
O2 0
for 0
30 0
min 0
, 0
of 0
which 0
the 0
first 0
10 0
min 0
was 0
used 0
to 0
achieve 0
a 0
steady 0
- 0
state 0
end 0
- 0
tidal 0
CO2 0
measurement 0
. 0

Significant 0
correlations 0
were 0
obtained 0
between 0
changes 0
in 0
SSEP 0
in 0
response 0
to 0
AS 0
and 0
the 0
presence 0
of 0
not 0
deep 0
residual 0
- 0
organic 0
disturbances 0
, 0
so 0
- 0
called 0
`` 0
ground 0
'' 0
in 0
psychogenic 0
disorders 0
. 0

The 0
transcripts 0
were 0
equally 0
active 0
with 0
or 0
without 0
a 0
5 0
' 0
methylated 0
capstructure 0
as 0
expected 0
, 0
since 0
EMCV 0
- 0
RNA 0
is 0
one 0
of 0
the 0
mRNAs 0
capable 0
of 0
internal 0
initiation 0
. 0

The 0
E6/E7 B-gene
promoter 0
of 0
all 0
genital 0
human 0
papillomaviruses 0
is 0
responsible 0
for 0
expression 0
of 0
the 0
viral 0
transforming 0
genes 0
. 0

A 0
case 0
of 0
Goodpasture 0
's 0
syndrome 0
. 0

Seventy 0
- 0
two 0
of 0
73 0
negative 0
controls 0
and 0
all 0
positive 0
blocks 0
as 0
seen 0
on 0
soft 0
tissue 0
radiographs 0
( 0
STRs 0
) 0
were 0
correctly 0
coded 0
( 0
specificity 0
98.6 0
% 0
, 0
sensitivity 0
100 0
% 0
) 0
. 0

No 0
symptomatic 0
abnormality 0
has 0
been 0
noted 0
in 0
the 0
neonatal 0
period 0
except 0
periventricular 0
calcifications 0
. 0

Immunohistochemical 0
analysis 0
of 0
several 0
rat 0
organs 0
also 0
showed 0
staining 0
in 0
epithelial 0
cells 0
. 0

Both 0
strains 0
grew 0
very 0
poorly 0
, 0
or 0
not 0
at 0
all 0
, 0
on 0
nonfermentable 0
carbon 0
sources 0
and 0
exhibited 0
, 0
at 0
most 0
, 0
only 0
5 0
% 0
of 0
wild B-gene
- I-gene
type I-gene
ubiquinol I-gene
- I-gene
cytochrome I-gene
c I-gene
oxidoreductase I-gene
activity 0
. 0

Regulation 0
of 0
irgA B-gene
by 0
iron 0
in 0
V. 0
cholerae 0
occurs 0
at 0
the 0
transcriptional 0
level 0
, 0
and 0
there 0
is 0
an 0
interrupted 0
dyad 0
symmetric 0
sequence 0
in 0
the 0
vicinity 0
of 0
the 0
promoter 0
that 0
is 0
homologous 0
to 0
Fur B-gene
binding I-gene
sites I-gene
of 0
E. 0
coli 0
. 0

Transcription 0
of 0
the 0
first 0
operon 0
coding 0
for 0
m 0
- 0
xylene 0
- 0
degrading 0
enzymes 0
on 0
the 0
TOL 0
plasmid 0
of 0
Pseudomonas 0
putida 0
is 0
activated 0
by 0
the 0
xylR B-gene
gene I-gene
product I-gene
in 0
the 0
presence 0
of 0
m 0
- 0
xylene 0
. 0

The 0
recombinant 0
contains 0
the 0
normal 0
beta B-gene
A I-gene
- I-gene
globin I-gene
gene I-gene
, 0
the 0
mutant 0
gene 0
and 0
Ylp 0
vector 0
sequences 0
between 0
the 0
two 0
copies 0
. 0

Some 0
of 0
the 0
mutations 0
obtained 0
do 0
not 0
contain 0
a 0
copy 0
of 0
the 0
Ulysses B-gene
element I-gene
at 0
the 0
mutant 0
locus 0
, 0
suggesting 0
that 0
a 0
different 0
transposable 0
element 0
may 0
be 0
responsible 0
for 0
the 0
mutation 0
. 0

Determination 0
of 0
diquat 0
in 0
biological 0
materials 0
by 0
electron 0
spin 0
resonance 0
spectroscopy 0
. 0

We 0
show 0
also 0
that 0
RA 0
represses 0
the 0
transcriptional 0
activity 0
of 0
a 0
reporter 0
gene 0
containing 0
a 0
TPA 0
responding 0
AP1 B-gene
binding I-gene
site I-gene
driving 0
the 0
HSV B-gene
tk I-gene
promoter I-gene
. 0

Moreover 0
, 0
radiolabeled 0
EFI B-gene
, 0
NF B-gene
- I-gene
Y I-gene
, 0
or 0
CBF B-gene
DNAs I-gene
give 0
rise 0
to 0
identical 0
gel 0
retardation 0
patterns 0
in 0
extracts 0
from 0
a 0
variety 0
of 0
different 0
cell 0
types 0
. 0

Risk 0
factors 0
influencing 0
lymph 0
nodes 0
metastasis 0
in 0
lung 0
cancer 0
with 0
stage 0
I 0
, 0
II 0
or 0
IIIA 0

Multifunctional B-gene
protein I-gene
kinase I-gene
( 0
MFPK B-gene
) 0
phosphorylates 0
ATP B-gene
- I-gene
citrate I-gene
lyase I-gene
on 0
peptide B-gene
B I-gene
on 0
two 0
sites 0
, 0
BT 0
and 0
BS 0
, 0
on 0
threonine 0
and 0
serine 0
, 0
respectively 0
, 0
inhibitor B-gene
2 I-gene
on 0
a 0
threonyl 0
residue 0
, 0
and 0
glycogen B-gene
synthase I-gene
at 0
sites 0
2 0
and 0
3 0
. 0

The 0
characterized 0
Y B-gene
' I-gene
repeated I-gene
sequence I-gene
families I-gene
provide 0
an 0
experimental 0
system 0
in 0
which 0
repeated 0
sequence 0
interactions 0
and 0
subsequent 0
evolution 0
can 0
be 0
studied 0
. 0

The 0
electrically 0
induced 0
motile 0
responses 0
were 0
not 0
suppressed 0
in 0
the 0
presence 0
of 0
dinitrophenol 0
or 0
cytochalasin 0
B 0
. 0

Unlike 0
p59v B-gene
- 0
rel B-gene
, 0
which 0
is 0
a 0
nuclear 0
protein 0
in 0
CEF 0
, 0
indirect 0
immunofluorescence 0
showed 0
that 0
p68c B-gene
- 0
rel B-gene
in 0
JD214c 0
- 0
rel 0
infected 0
CEF 0
is 0
located 0
exclusively 0
in 0
the 0
cytoplasm 0
of 0
these 0
cells 0
, 0
even 0
though 0
the 0
sequence 0
of 0
p68c B-gene
- 0
rel B-gene
showed 0
that 0
it 0
contains 0
a 0
nuclear 0
localizing 0
sequence 0
identical 0
to 0
the 0
one 0
previously 0
identified 0
in 0
p59v B-gene
- 0
rel B-gene
. 0

Kinetic 0
experiments 0
revealed 0
that 0
within 0
10 0
min 0
this 0
radiolabeled 0
precursor 0
protein 0
was 0
converted 0
in 0
HL 0
- 0
60 0
cells 0
into 0
an 0
Mr 0
approximately 0
150,000 0
chondroitin 0
sulfate 0
proteoglycan 0
intermediate 0
. 0

Blood 0
flow 0
and 0
velocity 0
( 0
measured 0
using 0
Doppler 0
ultrasound 0
) 0
gradually 0
decreased 0
during 0
diastole 0
and 0
ultimately 0
reversed 0
in 0
direction 0
as 0
cotyledon 0
resistance 0
was 0
increased 0
up 0
to 0
14 0
fold 0
. 0

A 0
total 0
of 0
112 0
patients 0
received 0
anistreplase 0
and 0
119 0
received 0
heparin 0
within 0
a 0
mean 0
period 0
of 0
188 0
+/ 0
- 0
62 0
min 0
following 0
the 0
onset 0
of 0
symptoms 0
. 0

However 0
, 0
primary 0
transcripts 0
of 0
a 0
variant B-gene
tRNA I-gene
( I-gene
Val I-gene
) I-gene
( I-gene
UAC I-gene
) I-gene
gene I-gene
are 0
processing 0
deficient 0
under 0
standard 0
growth 0
conditions 0
( 0
30 0
degrees 0
C 0
) 0
, 0
due 0
to 0
a 0
slightly 0
altered 0
5 0
' 0
flanking 0
region 0
. 0

The 0
promoter 0
activity 0
was 0
measured 0
by 0
a 0
transient 0
expression 0
of 0
a 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
gene 0
connected 0
with 0
various 0
5' 0
- 0
deletion 0
mutants 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
. 0

Three 0
of 0
the 0
short 0
ORFs 0
in 0
the 0
central 0
region 0
of 0
BIV 0
have 0
been 0
identified 0
by 0
location 0
and 0
structural 0
similarity 0
to 0
the 0
nonstructural/regulatory 0
genes 0
( 0
vif B-gene
, 0
tat B-gene
, 0
and 0
rev B-gene
) 0
of 0
other 0
lentiviruses 0
; 0
we 0
also 0
discovered 0
two 0
unique 0
ORFs 0
, 0
termed 0
W 0
and 0
Y 0
, 0
which 0
may 0
serve 0
as 0
exons 0
for 0
novel 0
genes 0
. 0

The 0
Saccharomyces B-gene
cerevisiae I-gene
14DM I-gene
gene I-gene
, 0
encoding 0
cytochrome B-gene
P450 I-gene
lanosterol I-gene
14 I-gene
alpha I-gene
- I-gene
demethylase I-gene
( 0
14DM B-gene
) 0
, 0
was 0
overexpressed 0
in 0
various 0
S. 0
cerevisiae 0
strains 0
under 0
the 0
control 0
of 0
three 0
strong 0
heterologous 0
yeast 0
transcription 0
promoters 0
( 0
pADC1 B-gene
, 0
pGPD B-gene
, 0
pPHO5 B-gene
) 0
and 0
under 0
the 0
control 0
of 0
its 0
own 0
promoter 0
. 0

Truncations 0
composed 0
of 0
78 0
and 0
64 0
amino 0
acids 0
were 0
translocated 0
across 0
the 0
endoplasmic 0
reticulum 0
membrane 0
, 0
and 0
translocation 0
was 0
found 0
to 0
be 0
strictly 0
co 0
- 0
translational 0
and 0
SRP B-gene
- 0
dependent 0
. 0

Pulmonary 0
vascular 0
resistance 0
was 0
not 0
altered 0
, 0
ejection 0
fraction 0
remained 0
unchanged 0
and 0
isovolumic 0
relaxation 0
period 0
was 0
lengthened 0
( 0
119 0
+/ 0
- 0
20.1 0
to 0
147.39 0
+/ 0
- 0
21.15 0
, 0
P 0
less 0
than 0
0.05 0
) 0
. 0

The 0
ANB1 B-gene
locus I-gene
of 0
Saccharomyces 0
cerevisiae 0
encodes 0
the 0
protein B-gene
synthesis I-gene
initiation I-gene
factor I-gene
eIF I-gene
- I-gene
4D I-gene
. 0

The 0
contribution 0
that 0
alternative 0
splicing 0
events 0
in 0
c B-gene
- I-gene
myb I-gene
expression 0
may 0
make 0
on 0
c B-gene
- I-gene
myb I-gene
function 0
remains 0
to 0
be 0
elucidated 0
. 0

Serum B-gene
beta I-gene
2 I-gene
- I-gene
microglobulin I-gene
levels 0
( 0
beta B-gene
- I-gene
2 I-gene
- I-gene
M I-gene
) 0
were 0
studied 0
in 0
150 0
drug 0
addicts 0
, 0
50 0
of 0
them 0
asymptomatic 0
carriers 0
of 0
anti B-gene
HIV I-gene
- I-gene
1 I-gene
antibodies I-gene
, 0
50 0
symptomatic 0
carriers 0
with 0
persistent 0
generalized 0
lymphadenopathy 0
( 0
P.G.L 0
. 0
) 0
and 0
50 0
serum 0
negative 0
patients 0
who 0
had 0
been 0
living 0
in 0
a 0
closed 0
community 0
for 0
at 0
least 0
2 0
years 0
. 0

This 0
emancipation 0
of 0
the 0
ability 0
to 0
copulate 0
from 0
hormonal 0
influence 0
makes 0
female 0
sexual 0
motivation 0
the 0
primary 0
regulator 0
of 0
mating 0
in 0
primates 0
. 0

No 0
therapy 0
exists 0
for 0
halting 0
the 0
progression 0
of 0
the 0
disease 0
with 0
the 0
possible 0
exception 0
of 0
laser 0
photocoagulation 0
treatment 0
used 0
to 0
ablate 0
subretinal 0
neovascular 0
membranes 0
in 0
an 0
attempt 0
to 0
avoid 0
complications 0
of 0
subretinal 0
hemorrhages 0
. 0

R 0
. 0

Specific 0
hyperimmune B-gene
globulins I-gene
to 0
pathogens 0
such 0
as 0
Haemophilus 0
influenzae 0
and 0
Streptococcus 0
pneumoniae 0
have 0
also 0
been 0
studied 0
. 0

Therapeutic 0
effects 0
of 0
cefpirome 0
( 0
HR 0
810 0
) 0
on 0
experimental 0
mixed 0
infections 0
with 0
Enterococcus 0
faecalis 0
and 0
Escherichia 0
coli 0
in 0
mice 0
. 0

Regulation 0
of 0
yeast B-gene
LEU2 I-gene
. 0

Homozygous 0
individuals 0
usually 0
develop 0
purpura 0
fulminans 0
as 0
newborns 0
; 0
heterozygous 0
protein B-gene
C I-gene
- 0
deficient 0
individuals 0
are 0
at 0
increased 0
risk 0
for 0
venous 0
thrombosis 0
and 0
pulmonary 0
embolism 0
. 0

Ischemic 0
stroke 0
due 0
to 0
protein B-gene
C I-gene
deficiency 0
. 0

TREB7 B-gene
and 0
TREB36 B-gene
protected 0
all 0
three 0
repeats 0
of 0
the 0
21 0
bp 0
, 0
but 0
TREB5 B-gene
protected 0
only 0
the 0
second 0
repeat 0
. 0

These 0
results 0
suggest 0
that 0
5 0
KE 0
X 0
3/W 0
may 0
be 0
the 0
optimal 0
regimen 0
to 0
augment 0
the 0
antitumor 0
immunity 0
of 0
RNL 0
. 0

Analysis 0
of 0
various 0
deletion 0
mutants 0
indicates 0
that 0
the 0
sequence 0
requirements 0
for 0
binding 0
by 0
QBP B-gene
in 0
vitro 0
are 0
indistinguishable 0
from 0
those 0
necessary 0
for 0
Q 0
activity 0
in 0
vivo 0
, 0
strongly 0
suggesting 0
that 0
QBP B-gene
is 0
required 0
for 0
the 0
function 0
of 0
this 0
TATA 0
- 0
independent 0
promoter 0
. 0

Since 0
general B-gene
regulatory I-gene
factor I-gene
I I-gene
( 0
GRFI B-gene
) 0
/repressor/activator B-gene
site I-gene
binding I-gene
protein I-gene
1 I-gene
( 0
RAP1 B-gene
) 0
/translation B-gene
upstream I-gene
factor I-gene
( 0
TUF B-gene
) 0
is 0
believed 0
to 0
be 0
an 0
activator 0
of 0
MAT B-gene
alpha I-gene
expression 0
, 0
we 0
examined 0
whether 0
PYK1 B-gene
, 0
which 0
is 0
known 0
to 0
be 0
regulated 0
by 0
GRFI/RAP1/TUF B-gene
, 0
is 0
also 0
affected 0
by 0
the 0
GRFI/RAP1/TUF I-gene

Yeast B-gene
Gal11 I-gene
protein I-gene
mediates 0
the 0
transcriptional 0
activation 0
signal 0
of 0
two 0
different 0
transacting 0
factors 0
, 0
Gal4 B-gene
and 0
general B-gene
regulatory I-gene
factor I-gene
I/repressor/activator I-gene
I/repressor/activator I-gene
site I-gene
binding I-gene
protein I-gene
1/translation I-gene
1/translation I-gene
upstream I-gene
factor I-gene
. 0

Deletion 0
from 0
either 0
the 0
N 0
- 0
or 0
C 0
- 0
terminal 0
ends 0
of 0
repA B-gene
( 0
28 0
and 0
69 0
codons 0
, 0
respectively 0
, 0
out 0
of 0
the 0
286 0
- 0
codon 0
open 0
reading 0
frame 0
) 0
affected 0
the 0
initiator 0
but 0
not 0
the 0
inhibitory 0
activity 0
. 0

The 0
two 0
larger 0
peptides 0
, 0
one 0
containing 0
amino 0
acids 0
1 0
- 0
228 0
and 0
the 0
other 0
containing 0
amino 0
acids 0
85 0
- 0
228 0
, 0
formed 0
dimers 0
in 0
solution 0
and 0
bound 0
DNA 0
specifically 0
as 0
a 0
dimer 0
. 0

In 0
vitro 0
transcription 0
extracts 0
from 0
ret1 B-gene
- I-gene
1 I-gene
cells 0
terminate 0
less 0
efficiently 0
at 0
weak 0
transcription 0
termination 0
signals 0
than 0
those 0
from 0
RET1 B-gene
cells 0
, 0
using 0
a 0
variety 0
of 0
tRNA 0
templates 0
. 0

Guiding 0
patients 0
in 0
the 0
decision 0
should 0
involve 0
a 0
multidisciplinary 0
team 0
composed 0
of 0
a 0
surgical 0
oncologist 0
, 0
geneticist 0
, 0
pathologist 0
, 0
psychotherapist 0
and 0
plastic 0
surgeon 0
. 0

IgG B-gene
and 0
IgM B-gene
antibody 0
activity 0
was 0
determined 0
by 0
adding 0
a 0
1:100 0
dilution 0
of 0
serum 0
to 0
plates 0
coated 0
with 0
A60 B-gene
antigen I-gene
. 0

These 0
factors 0
belong 0
to 0
a 0
set 0
of 0
genetically 0
distinct 0
molecules 0
, 0
including 0
AP B-gene
- I-gene
4 I-gene
and 0
MLTF B-gene
, 0
that 0
bind 0
to 0
the 0
CACCTGTC 0
motif 0
or 0
related 0
sequences 0
. 0

Among 0
known 0
flea 0
larvae 0
, 0
the 0
genus 0
Anomiopsyllus 0
( 0
Anomiopsyllinae 0
, 0
Anomiopsyllini 0
) 0
is 0
as 0
distinctive 0
in 0
larval 0
form 0
as 0
are 0
the 0
adults 0
. 0

Here 0
, 0
we 0
have 0
used 0
specific 0
antibody 0
to 0
identify 0
and 0
characterize 0
the 0
SSN6 B-gene
protein I-gene
. 0

These 0
latter 0
results 0
showed 0
that 0
the 0
ABFI B-gene
protein I-gene
, 0
like 0
the 0
RAP1 B-gene
protein I-gene
, 0
bound 0
sequences 0
required 0
for 0
positive 0
as 0
well 0
as 0
negative 0
regulation 0
of 0
gene 0
expression 0
. 0

Clinical 0
nutrition 0
of 0
adult 0
horses 0
. 0

The 0
computer 0
- 0
programmed 0
cytocentrifuge 0
is 0
currently 0
most 0
popular 0
. 0

RNase B-gene
protection 0
assays 0
reveal 0
that 0
this 0
gene 0
, 0
unr B-gene
, 0
is 0
transcribed 0
in 0
the 0
same 0
direction 0
as 0
N B-gene
- I-gene
ras I-gene
and 0
that 0
its 0
3 0
' 0
end 0
is 0
located 0
just 0
130 0
base 0
pairs 0
away 0
from 0
the 0
point 0
at 0
which 0
N B-gene
- I-gene
ras I-gene
transcription 0
begins 0
. 0

Isolation 0
of 0
a 0
temperature 0
- 0
sensitive 0
mutant 0
with 0
an 0
altered 0
tRNA B-gene
nucleotidyltransferase I-gene
and 0
cloning 0
of 0
the 0
gene B-gene
encoding I-gene
tRNA I-gene
nucleotidyltransferase I-gene
in I-gene
the I-gene
yeast I-gene
Saccharomyces I-gene
cerevisiae I-gene
. 0

The 0
juxtamembrane 0
region 0
of 0
the 0
insulin B-gene
receptor I-gene
( I-gene
IR I-gene
) I-gene
beta I-gene
- I-gene
subunit I-gene
contains 0
an 0
unphosphorylated 0
tyrosyl 0
residue 0
( 0
Tyr960 0
) 0
that 0
is 0
essential 0
for 0
insulin B-gene
- 0
stimulated 0
tyrosyl 0
phosphorylation 0
of 0
some 0
endogenous 0
substrates 0
and 0
certain 0
biological 0
responses 0
( 0
White 0
, 0
M.F. 0
, 0
Livingston 0
, 0
J.N. 0
, 0
Backer 0
, 0
J.M. 0
, 0
Lauris 0
, 0
V. 0
, 0
Dull 0
, 0
T.J. 0
, 0
Ullrich 0
, 0
A. 0
, 0
and 0
Kahn 0
, 0
C.R 0
. 0

This 0
gene 0
joins 0
the 0
group 0
of 0
genes 0
whose 0
members 0
are 0
rapidly 0
transcribed 0
in 0
response 0
to 0
insulin B-gene
and 0
other 0
mitogens 0
. 0

The 0
3 0
' 0
region 0
, 0
GA2 B-gene
, 0
is 0
necessary 0
for 0
maximal 0
expression 0
. 0

1 0
, 0
among 0
which 0
nine 0
have 0
been 0
cloned 0
and 0
two 0
( 0
potentially 0
functional 0
) 0
sequenced 0
. 0

Pups 0
placed 0
into 0
the 0
novel 0
environment 0
with 0
their 0
mothers 0
exhibited 0
an 0
intermediate 0
level 0
of 0
DA 0
turnover 0
. 0

The 0
efficacy 0
and 0
safety 0
of 0
a 0
novel 0
percutaneous 0
anaesthetic 0
preparation 0
based 0
on 0
amethocaine 0
has 0
been 0
investigated 0
in 0
the 0
paediatric 0
clinical 0
environment 0
. 0

Homozygous 0
protein B-gene
C I-gene
( 0
PC B-gene
) 0
deficiency 0
is 0
reported 0
in 0
two 0
siblings 0
( 0
girl 0
and 0
boy 0
) 0
who 0
received 0
their 0
proper 0
diagnoses 0
at 0
the 0
ages 0
of 0
7 0
4/12 0
and 0
1 0
3/12 0
years 0
respectively 0
. 0

The 0
grandfather 0
and 0
the 0
granddaughter 0
both 0
had 0
microtia 0
and 0
meatal 0
atresia 0
, 0
whereas 0
the 0
daughter 0
had 0
a 0
normal 0
outer 0
ear 0
except 0
for 0
a 0
narrow 0
meatus 0
and 0
auricular 0
appendages 0
. 0

Abnormal 0
intrapulmonary 0
shunting 0
( 0
IPS 0
) 0
, 0
which 0
was 0
proved 0
in 0
4 0
cases 0
by 0
whole 0
- 0
body 0
radionuclide 0
scanning 0
with 0
99mTc 0
- 0
MAA 0
, 0
is 0
suggested 0
as 0
the 0
major 0
cause 0
of 0
cyanosis 0
in 0
liver 0
cirrhosis 0
. 0

The 0
urinary 0
protein 0
, 0
serum 0
albumin B-gene
, 0
BUN 0
and 0
SCr 0
all 0
had 0
very 0
significant 0
improvement 0
. 0

More 0
generally 0
, 0
Ets1 B-gene
and 0
Ets2 B-gene
could 0
regulate 0
transcription 0
of 0
cellular 0
genes 0
. 0

Within 0
this 0
sequence 0
the 0
MSAS B-gene
gene I-gene
was 0
identified 0
as 0
a 0
5322 0
- 0
bp 0
- 0
long 0
open 0
reading 0
frame 0
coding 0
for 0
a 0
protein 0
of 0
1774 0
amino 0
acids 0
and 0
190,731 0
Da 0
molecular 0
mass 0
. 0

Horseradish B-gene
peroxidase I-gene
as 0
a 0
permeability 0
marker 0
in 0
injured 0
rat 0
caudal 0
and 0
iliac 0
arteries 0
. 0

Standardized 0
gastric 0
wall 0
specimens 0
from 0
the 0
area 0
of 0
grossly 0
healed 0
ulcers 0
were 0
obtained 0
, 0
processed 0
, 0
and 0
evaluated 0
by 0
light 0
microscopy 0
and 0
by 0
transmission 0
electron 0
microscopy 0
. 0

2 0
. 0

The 0
effects 0
of 0
coenzyme 0
Q10 0
( 0
CoQ 0
) 0
and 0
captopril 0
on 0
functional 0
capacity 0
, 0
hemodynamics 0
and 0
survival 0
were 0
studied 0
in 0
154 0
rats 0
that 0
recovered 0
after 0
experimental 0
myocardial 0
infarction 0
. 0

Evidence 0
that 0
therapeutic 0
alterations 0
of 0
a 0
circadian 0
rhythm 0
for 0
gastric 0
emptying 0
response 0
may 0
be 0
possible 0
. 0

The 0
interrelation 0
of 0
the 0
levels 0
of 0
glucocorticoids 0
and 0
insulin B-gene
in 0
the 0
blood 0
of 0
irradiated 0
animals 0

This 0
last 0
includes 0
tissue 0
O2 0
transfer 0
( 0
Ft 0
' 0
) 0
and 0
mitochondrial 0
O2 0
utilization 0
( 0
Fm 0
' 0
) 0
. 0

Foveating 0
saccades 0
, 0
therefore 0
, 0
can 0
be 0
distinguished 0
from 0
other 0
FEMs 0
on 0
the 0
basis 0
of 0
speed 0
. 0

Incidence 0
correlated 0
with 0
the 0
grade 0
of 0
oral 0
hygiene 0
und 0
periodontal 0
disease 0
. 0

Our 0
study 0
shows 0
that 0
the 0
area 0
of 0
Alcoy 0
is 0
a 0
medium 0
MS 0
risk 0
region 0
according 0
to 0
the 0
thesis 0
of 0
Kurzke 0
, 0
although 0
high 0
MS 0
areas 0
may 0
be 0
found 0
, 0
thus 0
confirming 0
that 0
MS 0
distribution 0
in 0
southern 0
Europe 0
is 0
not 0
uniform 0
. 0

On 0
an 0
antithrombin B-gene
unit 0
basis 0
, 0
CY 0
216 0
and 0
CY 0
222 0
were 0
equivalent 0
and 0
more 0
potent 0
than 0
UH 0
. 0

Chick B-gene
brain I-gene
actin I-gene
depolymerizing I-gene
factor I-gene
( 0
ADF B-gene
) 0
is 0
a 0
19 0
- 0
kDa 0
protein 0
that 0
severs 0
actin B-gene
filaments I-gene
and 0
binds 0
actin B-gene
monomers I-gene
. 0

Initial 0
experience 0
with 0
a 0
serotonin 0
agonist 0
. 0

Comprehensive 0
care 0
of 0
the 0
patient 0
exposed 0
to 0
a 0
human 0
teratogen 0
may 0
also 0
include 0
discussion 0
of 0
prenatal 0
diagnostic 0
procedures 0
and 0
other 0
pregnancy 0
management 0
options 0
. 0

Primer 0
extension 0
analysis 0
and 0
RNA 0
sequencing 0
demonstrates 0
that 0
the 0
transcription 0
start 0
point 0
of 0
rat B-gene
ODC I-gene
mRNA I-gene
is 0
located 0
303 0
nt 0
upstream 0
from 0
the 0
A 0
residue 0
in 0
the 0
start 0
codon 0
. 0

For 0
85Sr 0
, 0
larger 0
- 0
than 0
- 0
expected 0
distribution 0
coefficients 0
were 0
obtained 0
in 0
the 0
desorption 0
experiments 0
, 0
an 0
indication 0
of 0
the 0
irreversible 0
formation 0
of 0
metal 0
- 0
oxyhydroxides 0
during 0
a 0
slow 0
reaction 0
. 0

Gene 0
constructs 0
possessing 0
the 0
complete B-gene
tat I-gene
, 0
rev B-gene
( 0
tat+ B-gene
rev+ B-gene
) 0
and 0
env B-gene
genes I-gene
were 0
transiently 0
expressed 0
in 0
COS 0
- 0
1 0
cells 0
as 0
precursor B-gene
SU I-gene
- I-gene
TM I-gene
( 0
gp160 B-gene
) 0
, 0
SU.TM B-gene
( 0
gp120 B-gene
x I-gene
41 I-gene
) 0
, 0
and 0
nucleolar B-gene
rev I-gene
protein I-gene
. 0

This 0
growth 0
arrest 0
is 0
partly 0
suppressed 0
on 0
minimal 0
medium 0
or 0
under 0
conditions 0
in 0
which 0
the 0
cells 0
are 0
less 0
dependent 0
on 0
mitochondrial 0
metabolism 0
. 0

Patients 0
with 0
detectable 0
serum 0
TNF B-gene
levels 0
had 0
significantly 0
lower 0
serum 0
T3 0
concentrations 0
compared 0
to 0
those 0
with 0
undetectable 0
levels 0
[ 0
1.072 0
+/ 0
- 0
0.588 0
vs 0
. 0

Giant 0
pilomatrix 0
carcinoma 0
: 0
report 0
and 0
review 0
of 0
the 0
literature 0
. 0

Further 0
studies 0
of 0
mandibular 0
movement 0
at 0
initial 0
tooth 0
contact 0
. 0

Each 0
parent 0
interacted 0
with 0
their 0
4 0
- 0
or 0
5 0
- 0
year 0
- 0
old 0
son 0
or 0
daughter 0
in 0
each 0
of 0
two 0
conversations 0
- 0
- 0
unstructured 0
( 0
social 0
conversation 0
) 0
and 0
structured 0
( 0
task 0
activity 0
) 0
. 0

Droperidol 0
- 0
induced 0
extrapyramidal 0
symptoms 0
in 0
an 0
adolescent 0
following 0
strabismus 0
surgery 0
. 0

These 0
results 0
indicate 0
that 0
the 0
cis 0
- 0
regulatory 0
elements 0
required 0
for 0
developmental 0
control 0
of 0
the 0
HaG3 B-gene
- I-gene
A I-gene
helianthinin I-gene
gene I-gene
are 0
located 0
in 0
a 0
2.4 0
kb 0
upstream 0
region 0
of 0
this 0
gene 0
. 0

The 0
induction 0
by 0
pseudorabies 0
virus 0
of 0
an 0
IL B-gene
- I-gene
6 I-gene
construct I-gene
containing 0
the 0
IL B-gene
- I-gene
6 I-gene
TATA I-gene
box I-gene
and 0
the 0
RNA 0
start 0
site 0
( 0
`` 0
initiator 0
'' 0
or 0
Inr 0
element 0
) 0
but 0
not 0
the 0
MRE 0
region 0
was 0
also 0
repressed 0
by 0
Dex 0
in 0
the 0
presence 0
of B-gene
wild I-gene
- I-gene
type I-gene
GR 0
. 0

Some 0
mutations 0
affected 0
Dhfr B-gene
in 0
a 0
qualitative 0
manner 0
, 0
such 0
as 0
by 0
changing 0
the 0
startpoint 0
of 0
one 0
of 0
the 0
major 0
Dhfr B-gene
transcripts I-gene
or 0
changing 0
the 0
relative 0
abundance 0
of 0
the 0
two 0
major 0
Dhfr B-gene
transcripts I-gene
. 0

The 0
glial 0
cyst 0
wall 0
was 0
lined 0
in 0
part 0
by 0
flattened 0
or 0
cuboidal 0
epithelium 0
. 0

We 0
conclude 0
that 0
class 0
I 0
cytologic 0
smears 0
with 0
moderate 0
to 0
severe 0
inflammation 0
may 0
be 0
associated 0
with 0
findings 0
of 0
condylomata 0
and 0
cervical 0
dysplasia 0
. 0

As 0
in 0
mammals 0
, 0
considerable 0
nucleotide 0
diversity 0
was 0
observed 0
at 0
the 0
junctions 0
of 0
the 0
variable 0
, 0
diversity 0
, 0
and 0
joining 0
elements 0
in 0
chicken B-gene
TCR I-gene
beta I-gene
cDNAs I-gene
. 0

The 0
protooncogene 0
c B-gene
- I-gene
myb I-gene
encodes 0
a 0
nuclear 0
transcription 0
factor 0
that 0
binds 0
to 0
DNA 0
in 0
a 0
sequence 0
- 0
specific 0
manner 0
and 0
transactivates 0
transcription 0
of 0
several 0
viral 0
and 0
cellular 0
genes 0
. 0

Modification 0
by 0
this 0
latter 0
compound 0
was 0
so 0
extensive 0
that 0
the 0
amount 0
of 0
membrane 0
- 0
associated 0
N 0
- 0
myristoylated 0
protein 0
was 0
decreased 0
. 0

S6 B-gene
kinase I-gene
activation 0
requires 0
displacement 0
of 0
this 0
inhibitory 0
segment 0
, 0
which 0
is 0
proposed 0
to 0
occur 0
consequent 0
to 0
its 0
multiple 0
phosphorylation 0
. 0

Rats 0
with 0
one 0
olfactory 0
bulb 0
removed 0
and 0
the 0
contralateral 0
naris 0
closed 0
can 0
detect 0
odors 0
. 0

Expression 0
of 0
the 0
human 0
T B-gene
cell I-gene
receptor I-gene
( I-gene
TCR I-gene
) I-gene
alpha I-gene
gene I-gene
is 0
regulated 0
by 0
a 0
T 0
cell 0
- 0
specific 0
transcriptional 0
enhancer 0
that 0
is 0
located 0
4.5 0
kilobases 0
( 0
kb 0
) 0
3 0
' 0
to 0
the 0
C B-gene
alpha I-gene
gene I-gene
segment I-gene
. 0

The 0
Ets B-gene
- I-gene
1 I-gene
binding I-gene
site I-gene
was 0
localized 0
to 0
a 0
17 0
- 0
base 0
pair 0
( 0
bp 0
) 0
region 0
from 0
the 0
3 0
' 0
end 0
of 0
T B-gene
alpha I-gene
2 I-gene
. 0

Cerebral 0
flow 0
and 0
resistance 0
showed 0
minor 0
reductions 0
with 0
HD 0
. 0

Utilization 0
of 0
alternative 0
polyadenylation 0
signals 0
was 0
previously 0
shown 0
to 0
generate 0
two 0
sialophorin B-gene
mRNAs I-gene
of I-gene
1.9 I-gene
and I-gene
4.3 I-gene
kb I-gene
, 0
which 0
differ 0
in 0
the 0
length 0
of 0
their 0
3 0
' 0
untranslated 0
regions 0
. 0

Presidential 0
address 0
1990 0
- 0
- 0
coming 0
in 0
from 0
the 0
cold 0
. 0

Human 0
T 0
- 0
cell 0
leukemia 0
virus 0
type 0
I 0
( 0
HTLV 0
- 0
I 0
) 0
encodes 0
a 0
40 0
- 0
kDa 0
nuclear 0
protein 0
, 0
Tax B-gene
, 0
which 0
stimulates 0
transcription 0
from 0
three 0
21 0
- 0
base 0
pair 0
( 0
bp 0
) 0
repeats 0
in 0
its 0
U3 0
region 0
. 0

We 0
have 0
now 0
identified 0
, 0
after 0
21 0
serial 0
undiluted 0
passages 0
of 0
MHV 0
, 0
a 0
small B-gene
DI I-gene
RNA I-gene
, 0
DIssF B-gene
, 0
which 0
is 0
efficiently 0
packaged 0
into 0
virions 0
. 0

The 0
Jenkins 0
Activity 0
Survey 0
and 0
the 0
CPI 0
- 0
revised 0
: 0
further 0
evidence 0
of 0
adaptive 0
and 0
maladaptive 0
type 0
A 0
traits 0
. 0

There 0
was 0
evidence 0
of 0
attenuated 0
regression 0
slopes 0
relating 0
recalled 0
to 0
observed 0
portion 0
sizes 0
for 0
4 0
of 0
the 0
10 0
food 0
groups 0
; 0
adjusted 0
r2 0
values 0
for 0
the 0
recalled 0
portion 0
sizes 0
ranged 0
from 0
0.02 0
to 0
0.94 0
. 0

The 0
result 0
suggests 0
that 0
this 0
non 0
- 0
invasive 0
TTD 0
method 0
is 0
easily 0
available 0
and 0
useful 0
in 0
monitoring 0
the 0
intraoperative 0
cardiac 0
output 0
. 0

The 0
TUP1 B-gene
gene I-gene
was 0
isolated 0
in 0
a 0
screen 0
for 0
genes 0
that 0
regulate 0
mating 0
type 0
( 0
V.L 0
. 0

The 0
SUP44 B-gene
suppressor I-gene
mutation I-gene
occurs 0
near 0
a 0
region 0
of 0
the 0
protein 0
that 0
corresponds 0
to 0
the 0
known 0
positions 0
of 0
alterations 0
in 0
E. B-gene
coli I-gene
S5 I-gene
ram I-gene
mutations I-gene
. 0

Interestingly 0
, 0
disruption 0
of 0
the 0
VPS34 B-gene
locus I-gene
resulted 0
in 0
a 0
temperature 0
- 0
sensitive 0
growth 0
defect 0
, 0
indicating 0
that 0
the 0
VPS34 B-gene
gene I-gene
is 0
essential 0
for 0
vegetative 0
growth 0
only 0
at 0
elevated 0
growth 0
temperatures 0
. 0

We 0
describe 0
a 0
case 0
of 0
a 0
perinephric 0
abscess 0
treated 0
with 0
amphotericin 0
B 0
and 0
nephrectomy 0
. 0

This 0
, 0
together 0
with 0
the 0
data 0
obtained 0
with 0
haloperidol 0
, 0
suggests 0
that 0
a 0
minimal 0
increase 0
in 0
the 0
firing 0
rate 0
of 0
LC 0
cells 0
( 0
+140 0
% 0
) 0
is 0
required 0
before 0
it 0
could 0
influence 0
the 0
turnover 0
of 0
NA 0
, 0
as 0
measured 0
by 0
DOPAC 0
changes 0
. 0

This 0
interaction 0
occurs 0
over 0
a 0
wide 0
range 0
of 0
both 0
parameters 0
; 0
for 0
charge 0
density 0
from 0
at 0
least 0
10 0
to 0
800 0
microC/cm2 0
and 0
, 0
for 0
charge 0
per 0
phase 0
, 0
from 0
at 0
least 0
0.05 0
to 0
5.0 0
microC 0
per 0
phase 0
. 0

Perceptions 0
of 0
illness 0
intrusiveness 0
were 0
significantly 0
higher 0
when 0
both 0
muscle 0
cramp 0
and 0
headache 0
symptoms 0
occurred 0
during 0
one 0
or 0
more 0
assessment 0
intervals 0
as 0
compared 0
to 0
when 0
muscle 0
cramps 0
or 0
headaches 0
, 0
only 0
, 0
occurred 0
. 0

Results 0
have 0
surprisingly 0
revealed 0
the 0
presence 0
of 0
three 0
U14 B-gene
snRNA I-gene
- I-gene
homologous I-gene
regions I-gene
positioned 0
within 0
introns 0
5 0
, 0
6 0
, 0
and 0
8 0
of 0
the 0
mouse 0
cognate 0
hsc70 B-gene
heat 0
shock 0
gene 0
. 0

65 0
- 0
kilodalton 0
protein 0
phosphorylated 0
by 0
interleukin B-gene
2 I-gene
stimulation 0
bears 0
two 0
putative 0
actin B-gene
- I-gene
binding I-gene
sites I-gene
and 0
two 0
calcium 0
- 0
binding 0
sites 0
. 0

The 0
highly 0
restrained 0
girls 0
had 0
a 0
significantly 0
higher 0
EAT 0
score 0
than 0
the 0
low 0
- 0
restrained 0
girls 0
, 0
and 0
shared 0
with 0
their 0
mothers 0
a 0
susceptibility 0
to 0
the 0
disinhibitory 0
effects 0
of 0
negative 0
mood 0
states 0
on 0
their 0
eating 0
behaviour 0
. 0

The 0
Mauriceville 0
and 0
Varkud 0
mitochondrial 0
plasmids 0
are 0
closely 0
related 0
, 0
closed 0
- 0
circular 0
DNAs 0
( 0
3.6 0
and 0
3.7 0
kb 0
, 0
respectively 0
) 0
that 0
have 0
characteristics 0
of 0
mtDNA 0
introns 0
and 0
retroid 0
elements 0
. 0

The 0
circadian 0
rhythm 0
, 0
however 0
, 0
was 0
not 0
affected 0
and 0
the 0
difference 0
between 0
minimum 0
( 0
12.00 0
h 0
) 0
and 0
maximum 0
( 0
18.50 0
h 0
) 0
serum 0
concentrations 0
was 0
31.3 0
% 0
. 0

Sequence 0
and 0
genetic 0
organization 0
of 0
a 0
Zymomonas 0
mobilis 0
gene 0
cluster 0
that 0
encodes 0
several 0
enzymes 0
of 0
glucose 0
metabolism 0
. 0

Most 0
strains 0
( 0
95 0
% 0
) 0
of 0
S. 0
lugdunensis 0
produced 0
a 0
delta B-gene
hemolysin I-gene
like 0
that 0
seen 0
with 0
nine 0
other 0
species 0
of 0
CNS 0
. 0

For 0
this 0
, 0
cDNAs 0
containing 0
the 0
60K 0
, 0
87K 0
, 0
110K 0
and 0
170K 0
protein 0
coding 0
sequences 0
were 0
each 0
provided 0
with 0
an 0
ATG 0
start 0
codon 0
and 0
the 0
cDNA 0
containing 0
the 0
60K 0
coding 0
sequence 0
with 0
a 0
TAA 0
stop 0
codon 0
immediately 0
downstream 0
of 0
the 0
coding 0
sequence 0
. 0

Finally 0
, 0
a 0
complementary 0
footprinting 0
analysis 0
of 0
the 0
upstream 0
region 0
of 0
the 0
constitutively 0
expressed 0
HSC82 B-gene
gene I-gene
reveals 0
the 0
presence 0
of 0
three 0
discrete 0
protein 0
complexes 0
. 0

Pathophysiology 0
of 0
bone 0
loss 0
in 0
castrated 0
animals 0
. 0

Auditory 0
- 0
visual 0
interaction 0
in 0
the 0
generation 0
of 0
saccades 0
in 0
man 0
. 0

First 0
, 0
each 0
lung 0
was 0
cut 0
into 0
slices 0
, 0
from 0
which 0
primary 0
disectors 0
were 0
sampled 0
systematically 0
with 0
a 0
known 0
sampling 0
fraction 0
. 0

The 0
upstream 0
promoter 0
is 0
located 0
within 0
the 0
coding 0
sequence 0
of 0
a 0
divergent 0
gene 0
expressing 0
a 0
protein 0
of 0
Mr 0
39 0
kDa 0
of 0
unknown 0
function 0
. 0

Assuming 0
O2 0
consumption 0
of 0
the 0
isolated 0
skin 0
to 0
be 0
same 0
as 0
in 0
situ 0
, 0
calculations 0
showed 0
that 0
when 0
water 0
PO2 0
was 0
high 0
( 0
150 0
mm 0
Hg 0
) 0
, 0
about 0
40 0
% 0
of 0
total 0
cutaneous 0
O2 0
uptake 0
was 0
consumed 0
by 0
the 0
skin 0
. 0

Experiments 0
showed 0
that 0
temporary 0
arrest 0
of 0
pulmonary 0
circulation 0
under 0
conditions 0
of 0
extracorporeal 0
circulation 0
is 0
attended 0
by 0
the 0
development 0
of 0
ischemia 0
of 0
the 0
respiratory 0
pulmonary 0
tissue 0
. 0

MCh 0
infusion 0
caused 0
a 0
concentration 0
- 0
dependent 0
increase 0
in 0
airway 0
resistance 0
at 0
constant 0
QBA 0
. 0

Taste 0
reactivity 0
tests 0
were 0
used 0
to 0
examine 0
the 0
orofacial 0
responses 0
of 0
alcohol 0
preferring 0
( 0
P 0
) 0
rats 0
and 0
alcohol 0
nonpreferring 0
( 0
NP 0
) 0
rats 0
to 0
the 0
taste 0
of 0
alcohol 0
. 0

Plasma 0
concentrations 0
of 0
atracurium 0
and 0
laudanosine 0
were 0
0.73 0
- 0
3.11 0
micrograms 0
ml 0
- 0
1 0
and 0
0.48 0
- 0
8.65 0
micrograms 0
ml 0
- 0
1 0
, 0
respectively 0
; 0
CSF 0
concentration 0
of 0
laudanosine 0
was 0
70 0
- 0
440 0
ng 0
ml 0
- 0
1 0
. 0

Plasma 0
Al 0
was 0
obtained 0
during 0
each 0
baseline 0
and 0
drug 0
course 0
. 0

The 0
survival 0
in 0
the 0
case 0
of 0
these 0
patients 0
was 0
studied 0
five 0
years 0
later 0
. 0

The 0
occurrence 0
, 0
maintenance 0
and 0
possible 0
involvement 0
of 0
these 0
repeated 0
sequences 0
, 0
capable 0
of 0
forming 0
stable 0
secondary 0
structures 0
, 0
are 0
discussed 0
in 0
relation 0
to 0
their 0
location 0
in 0
the 0
region 0
of 0
control 0
signals 0
. 0

IST B-gene
is 0
not 0
the 0
RNA 0
target 0
( 0
TAR 0
) 0
for 0
Tat B-gene
trans 0
- 0
activation 0
; 0
however 0
, 0
because 0
it 0
relies 0
entirely 0
on 0
cellular 0
factors 0
for 0
activity 0
, 0
IST B-gene
may 0
serve 0
to 0
provide 0
abundant 0
RNA 0
targets 0
for 0
Tat B-gene
trans 0
- 0
activation 0
without 0
a 0
requirement 0
for 0
full 0
- 0
length 0
viral 0
mRNA 0
expression 0
. 0

Genotoxic 0
activity 0
of 0
a 0
tobacco 0
- 0
specific 0
nitrosamine 0
. 0

The 0
endodontal 0
treatment 0
need 0
has 0
been 0
forming 0
a 0
clinical 0
order 0
of 0
magnitude 0
. 0

1 0
( 0
`` 0
long 0
method 0
'' 0
) 0
and 0
the 0
HML 0
method 0
. 0

These 0
results 0
may 0
suggest 0
involvement 0
of 0
peripheral 0
enkephalins 0
in 0
pain 0
modulation 0
in 0
patients 0
with 0
episodic 0
cluster 0
headache 0
. 0

Effects 0
of 0
cisapride 0
on 0
upper 0
- 0
gastrointestinal 0
motility 0
and 0
digestive 0
hormones 0

Common 0
foot 0
pathologies 0
are 0
heel 0
pain 0
, 0
metatarsalgia 0
, 0
hammertoes 0
and 0
clawtoes 0
, 0
bunions 0
, 0
hallux 0
rigidus 0
, 0
corns 0
and 0
calluses 0
, 0
nail 0
pathologies 0
, 0
arthritis 0
, 0
and 0
neuropathies 0
. 0

Liver 0
dysfunction 0
in 0
the 0
presence 0
of 0
different 0
adverse 0
reactions 0
presented 0
with 0
a 0
higher 0
activity 0
in 0
the 0
blood 0
serum 0
of 0
indicator 0
liver 0
enzymes 0
and 0
its 0
impaired 0
protein 0
- 0
forming 0
function 0
. 0

Coenzyme 0
Q10 0
: 0
blood 0
levels 0
and 0
metabolic 0
demand 0
. 0

The 0
CT 0
characteristics 0
are 0
discussed 0
and 0
the 0
recent 0
literature 0
is 0
reviewed 0
. 0

Unfortunately 0
, 0
these 0
preservatives 0
may 0
also 0
interfere 0
with 0
microbiological 0
assays 0
used 0
to 0
determine 0
product 0
sterility 0
or 0
bioburden 0
levels 0
. 0

In 0
26 0
patients 0
with 0
angina 0
pectoris 0
, 0
the 0
changes 0
of 0
LVEF 0
, 0
LVESV 0
and 0
PSP/LVESV 0
were 0
more 0
sensitive 0
for 0
the 0
detection 0
of 0
exercise 0
- 0
induced 0
ischemia 0
than 0
the 0
appearance 0
of 0
chest 0
pain 0
and 0
the 0
changes 0
of 0
ECG 0
. 0

In 0
both 0
groups 0
there 0
were 0
5 0
management 0
failure 0
of 0
therapy 0
, 0
so 0
that 0
alternative 0
medication 0
or 0
a 0
cesarean 0
section 0
lead 0
to 0
delivery 0
. 0

Serum 0
Fibrin B-gene
Degradation I-gene
Products I-gene
( 0
FDP B-gene
) 0
were 0
determined 0
in 0
50 0
oral 0
cancer 0
patients 0
and 0
50 0
normal 0
individuals 0
prior 0
to 0
any 0
kind 0
of 0
treatment 0
. 0

The 0
uteroglobin B-gene
promoter I-gene
contains 0
a 0
noncanonical 0
estrogen 0
responsive 0
element 0
. 0

Prostaglandin 0
synthesis 0
inhibitors 0
have 0
been 0
shown 0
to 0
delay 0
healing 0
of 0
bone 0
and 0
this 0
has 0
led 0
to 0
limitations 0
on 0
their 0
use 0
clinically 0
in 0
some 0
situations 0
. 0

The 0
inspiratory 0
oxygen 0
concentration 0
needed 0
( 0
FiO2 0
) 0
and 0
the 0
Horowitz 0
quotient 0
differed 0
in 0
a 0
highly 0
significant 0
manner 0
beginning 0
on 0
the 0
1st 0
day 0
after 0
trauma 0
. 0

The 0
corn 0
and 0
mineral 0
oil 0
emulsions 0
were 0
almost 0
as 0
effective 0
as 0
milk 0
but 0
less 0
effective 0
than 0
sucrose 0
( 0
0.3M 0
) 0
in 0
stimulating 0
ingestion 0
. 0

Significance 0
of 0
thin 0
glomerular 0
basement 0
membranes 0
in 0
hematuric 0
children 0
. 0

Significance 0
of 0
cytokine 0
production 0
and 0
adhesion 0
molecules 0
in 0
malarial 0
immunopathology 0
. 0

The 0
former 0
procedure 0
is 0
economical 0
but 0
complicated 0
, 0
whereas 0
the 0
latter 0
is 0
simple 0
and 0
labour 0
- 0
saving 0
, 0
but 0
a 0
special 0
ultrafiltration 0
tube 0
is 0
required 0
. 0

Simple 0
method 0
for 0
determination 0
of 0
the 0
cephalosporin 0
DQ 0
- 0
2556 0
in 0
biological 0
fluids 0
by 0
high 0
- 0
performance 0
liquid 0
chromatography 0
. 0

Since 0
one 0
group 0
of 0
adolescents 0
more 0
difficult 0
to 0
influence 0
are 0
those 0
whose 0
parents 0
smoke 0
, 0
parental 0
involvement 0
in 0
smoking 0
prevention 0
may 0
be 0
a 0
powerful 0
enhancer 0
. 0

Further 0
research 0
is 0
recommended 0
to 0
identify 0
the 0
coping 0
styles 0
associated 0
with 0
the 0
high 0
EE/low 0
EE 0
research 0
classification 0
. 0

Staining 0
with 0
IF 0
MoAB 0
alone 0
of 0
BAL 0
fluid 0
only 0
seemed 0
to 0
be 0
even 0
more 0
sensitive 0
than 0
silver 0
methenamine 0
staining 0
of 0
BAL 0
, 0
TBB 0
and 0
brushing 0
material 0
. 0

Ultrastructural 0
and 0
morphometric 0
study 0
of 0
the 0
myeloid 0
parenchyma 0
cells 0
of 0
mice 0
prior 0
and 0
after 0
X 0
- 0
ray 0
exposure 0

Using 0
an 0
audiotape 0
cassette 0
and 0
headphones 0
the 0
duration 0
of 0
the 0
hallucinations 0
decreased 0
significantly 0
. 0

The 0
mean 0
change 0
in 0
HbA1 B-gene
, 0
adjusted 0
for 0
the 0
initial 0
value 0
, 0
was 0
- 0
0.4 0
% 0
in 0
the 0
experimental 0
and 0
+0.5 0
% 0
in 0
the 0
control 0
group 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Effect 0
of 0
biliary 0
obstruction 0
and 0
cholangitis 0
on 0
serum B-gene
SPan I-gene
- I-gene
1 I-gene
level 0

Very 0
good 0
accuracy 0
( 0
r 0
greater 0
than 0
0.9 0
) 0
was 0
found 0
when 0
except 0
comparing 0
H*2 0
with 0
the 0
other 0
machine 0
and 0
the 0
reference 0
methods 0
, 0
except 0
for 0
MCHCH 0
and 0
basophil 0
count 0
. 0

The 0
second 0
part 0
of 0
this 0
paper 0
shows 0
some 0
medical 0
applications 0
of 0
these 0
two 0
aspects 0
of 0
NMR 0
, 0
with 0
help 0
of 0
some 0
examples 0
, 0
taken 0
from 0
the 0
literature 0
, 0
according 0
to 0
what 0
is 0
concerned 0
with 0
endocrinology 0
. 0

Interlimb 0
coordination 0
during 0
fictive 0
locomotion 0
in 0
the 0
thalamic 0
cat 0
. 0

Antileukoproteinase B-gene
( 0
ALP B-gene
) 0
is 0
a 0
low 0
mol 0
wt 0
mucosal 0
secretory 0
protein 0
which 0
, 0
in 0
human 0
tissues 0
, 0
inhibits 0
the 0
activities 0
of 0
the 0
neutral 0
serine B-gene
lysosomal I-gene
proteinases I-gene
elastase B-gene
and 0
cathepsin B-gene
- I-gene
G I-gene
. 0

By 0
introducing 0
a 0
series 0
of 0
deletions 0
in 0
the 0
vimentin B-gene
promoter 0
, 0
we 0
further 0
restrict 0
these 0
sequences 0
to 0
30 0
base 0
pairs 0
, 0
located 0
between 0
241 0
and 0
210 0
base 0
pairs 0
upstream 0
of 0
the 0
mRNA 0
cap 0
site 0
. 0

In 0
particular 0
, 0
71 0
and 0
69 0
% 0
amino 0
acid 0
sequence 0
similarities 0
were 0
identified 0
with 0
hsp70 B-gene
of I-gene
Escherichia I-gene
coli I-gene
and I-gene
Bacillus I-gene
megaterium I-gene
, 0
respectively 0
. 0

No 0
causal 0
relations 0
may 0
be 0
inferred 0
from 0
the 0
correlation 0
between 0
the 0
level 0
of 0
trapezius 0
activity 0
and 0
complaints 0
, 0
though 0
it 0
indicates 0
that 0
individual 0
, 0
inexpedient 0
muscle 0
activity 0
patterns 0
may 0
constitute 0
an 0
important 0
risk 0
factor 0
for 0
development 0
of 0
musculo 0
- 0
skeletal 0
complaints 0
. 0

All 0
89 0
participating 0
household 0
members 0
were 0
anti B-gene
- I-gene
HIV I-gene
seronegative 0
, 0
and 0
78 0
who 0
were 0
tested 0
were 0
serum B-gene
p24 I-gene
antigen I-gene
negative 0
. 0

Analysis 0
with 0
additional 0
anti 0
- 0
peptide 0
antibodies 0
specific 0
for 0
alpha B-gene
, I-gene
beta I-gene
, I-gene
or I-gene
gamma I-gene
PKC I-gene
indicated 0
that 0
all 0
three 0
types 0
of 0
PKC B-gene
are 0
expressed 0
in 0
JK 0
cells 0
; 0
however 0
, 0
JKPE 0
cells 0
lost 0
a 0
major 0
approximately 0
82 0
kDa 0
immunoreactive 0
cytosolic 0
protein 0
detectable 0
with 0
anti B-gene
- I-gene
PKC I-gene
alpha I-gene
antibody I-gene
. 0

To 0
those 0
of 0
us 0
who 0
are 0
not 0
satisfied 0
with 0
the 0
present 0
outlook 0
there 0
is 0
much 0
to 0
be 0
investigated 0
and 0
much 0
to 0
be 0
contributed 0
. 0

To 0
determine 0
the 0
effects 0
on 0
the 0
pulmonary 0
barrier 0
of 0
several 0
surface 0
active 0
agents 0
, 0
a 0
series 0
of 0
metered 0
dose 0
inhalers 0
( 0
MDIs 0
) 0
was 0
prepared 0
and 0
used 0
to 0
dose 0
aerosolized 0
surfactant 0
to 0
the 0
airways 0
of 0
isolated 0
perfused 0
rat 0
lungs 0
. 0

The 0
beta 0
chain 0
contains 0
five 0
potential 0
N 0
- 0
linked 0
glycosylation 0
sites 0
, 0
and 0
endoglycosidase B-gene
digestion 0
suggested 0
that 0
the 0
beta 0
chain 0
contained 0
multiple 0
complex 0
carbohydrate 0
side 0
chains 0
. 0

The 0
therapeutic 0
protocole 0
used 0
at 0
the 0
Gustave 0
Roussy 0
Institute 0
for 0
invasive 0
epithelioma 0
of 0
the 0
uterine 0
cervix 0
rests 0
, 0
for 0
limited 0
forms 0
( 0
T1B 0
- 0
T2 0
proximal 0
) 0
, 0
on 0
combined 0
radiology 0
and 0
surgery 0
. 0

Thyrotropin B-gene
- 0
induced 0
expression 0
of 0
a 0
gene 0
for 0
a 0
ribosomal B-gene
protein I-gene
related 0
to 0
the 0
trk B-gene
oncogene I-gene
. 0

The 0
introns 0
are 0
1.6 0
- 0
1.9 0
kbp 0
long 0
. 0

After 0
an 0
initial 0
titration 0
period 0
and 0
adjustment 0
of 0
the 0
therapeutic 0
dose 0
, 0
the 0
individual 0
doses 0
were 0
from 0
21 0
to 0
500 0
micrograms/24 0
hrs 0
( 0
mean 0
160 0
micrograms/24 0
hrs 0
) 0
. 0

In 0
the 0
first 0
series 0
of 0
experiments 0
, 0
Sprague 0
- 0
Dawley 0
male 0
rats 0
were 0
implanted 0
unilaterally 0
with 0
guide 0
cannulas 0
aimed 0
at 0
the 0
lateral 0
ventricle 0
. 0

Use 0
of 0
Selenastrum 0
capricornutum 0
and 0
Microfeast 0
as 0
food 0
for 0
Daphnia 0
pulex 0
. 0

The 0
persistence 0
of 0
members 0
of 0
the 0
prostigmatid 0
families 0
Tydeidae 0
, 0
Nanorchestidae 0
and 0
Tarsonemidae 0
in 0
the 0
moisture 0
- 0
deficient 0
90 0
% 0
- 0
concentration 0
treatments 0
supports 0
previous 0
evidence 0
of 0
adaptations 0
to 0
low 0
- 0
water 0
- 0
content 0
habitats 0
. 0

To 0
define 0
the 0
mechanism 0
responsible 0
for 0
the 0
loss 0
of 0
transcription 0
elongation 0
blockage 0
and 0
resulting 0
c B-gene
- I-gene
myc I-gene
deregulation 0
in 0
Burkitt 0
's 0
lymphoma 0
, 0
we 0
analyzed 0
transcription 0
patterns 0
after 0
transfer 0
of 0
normal 0
and 0
Burkitt 0
's 0
lymphoma 0
c B-gene
- I-gene
myc I-gene
alleles 0
into 0
murine 0
cells 0
and 0
Xenopus 0
oocyte 0
germinal 0
vesicles 0
. 0

Erythrocyte 0
protoporphyrin 0
concentration 0
increased 0
significantly 0
( 0
P 0
less 0
than 0
0.05 0
) 0
by 0
14 0
days 0
in 0
dogs 0
fed 0
the 0
basal 0
diet 0
, 0
and 0
remained 0
significantly 0
high 0
relative 0
to 0
that 0
in 0
dogs 0
of 0
the 0
other 0
dietary 0
groups 0
for 0
the 0
remainder 0
of 0
the 0
study 0
. 0

The 0
coding 0
sequences 0
of 0
the 0
Crry B-gene
gene I-gene
encompass 0
over 0
25 0
kb 0
of 0
DNA 0
, 0
whereas 0
the 0
Crry B-gene
- 0
ps B-gene
sequences 0
are 0
included 0
within 0
a 0
single 0
5.6 B-gene
- I-gene
kb I-gene
Eco I-gene
- I-gene
R1 I-gene
fragment I-gene
. 0

The 0
genomic 0
and 0
transcriptional 0
complexity 0
of 0
the 0
Crry B-gene
and 0
Crry B-gene
- 0
ps B-gene
genes 0
. 0

From 0
an 0
RNK 0
- 0
16 0
lambda 0
- 0
gt11 0
library 0
, 0
we 0
have 0
isolated 0
and 0
sequenced 0
a 0
novel 0
cDNA 0
rat B-gene
NK I-gene
cell I-gene
protease I-gene
1 I-gene
( 0
RNKP B-gene
- I-gene
1 I-gene
) 0
that 0
has 0
characteristics 0
unique 0
to 0
serine B-gene
proteases I-gene
. 0

The 0
induction 0
of 0
RNKP B-gene
- I-gene
1 I-gene
expression 0
in 0
the 0
Con B-gene
A I-gene
- 0
cultured 0
spleen 0
cells 0
is 0
accompanied 0
by 0
increases 0
in 0
both 0
NK 0
and 0
lymphokine 0
- 0
activated 0
killer 0
lymphocyte 0
activities 0
. 0

The 0
paper 0
is 0
concerned 0
with 0
the 0
data 0
on 0
change 0
in 0
the 0
blood 0
level 0
of 0
ACTH B-gene
, 0
STH B-gene
, 0
TSH B-gene
, 0
cortisol 0
, 0
T3 0
, 0
insulin B-gene
, 0
C B-gene
- I-gene
peptide I-gene
during 0
a 0
25 0
- 0
minute 0
session 0
of 0
respiration 0
using 0
a 0
gaseous 0
hypoxic 0
mixture 0
with 0
10 0
% 0
oxygen 0
( 0
GHM 0
- 0
10 0
) 0
. 0

The 0
abscess 0
was 0
debrided 0
and 0
the 0
septum 0
was 0
patched 0
with 0
a 0
single 0
layer 0
of 0
autologous 0
pericardium 0
. 0

In 0
18 0
% 0
lymphography 0
was 0
clearly 0
positive 0
and 0
CT 0
negative 0
. 0

The 0
present 0
study 0
examined 0
the 0
effect 0
of 0
intensity 0
, 0
rate 0
, 0
and 0
polarity 0
on 0
the 0
spectral 0
content 0
of 0
ABRs 0
of 0
15 0
normal 0
- 0
hearing 0
subjects 0
. 0

Similar 0
memory 0
impairments 0
found 0
in 0
medial 0
septal 0
- 0
vertical 0
diagonal 0
band 0
of 0
Broca 0
and 0
nucleus 0
basalis 0
lesioned 0
rats 0
: 0
are 0
memory 0
defects 0
induced 0
by 0
nucleus 0
basalis 0
lesions 0
related 0
to 0
the 0
degree 0
of 0
non 0
- 0
specific 0
subcortical 0
cell 0
loss 0
? 0
The 0
function 0
of 0
nucleus 0
basalis 0
( 0
NB 0
) 0
and 0
medial 0
septal 0
- 0
vertical 0
diagonal 0
band 0
of 0
Broca 0
( 0
MS 0
- 0
VDBB 0
) 0
in 0
a 0
place 0
navigation 0
task 0
requiring 0
reference 0
memory 0
was 0
investigated 0
. 0

Studies 0
also 0
have 0
alluded 0
to 0
a 0
relationship 0
between 0
the 0
MSMR 0
cyst 0
and 0
certain 0
signs 0
or 0
symptoms 0
of 0
disease 0
. 0

The 0
BAL 0
- 0
to 0
- 0
plasma 0
specific 0
activity 0
of 0
urea 0
was 0
about 0
twice 0
that 0
of 0
Na+ 0
, 0
indicating 0
that 0
urea 0
diffused 0
into 0
the 0
ELF 0
more 0
rapidly 0
than 0
Na+ 0
during 0
the 0
70 0
s 0
that 0
elapsed 0
between 0
the 0
time 0
the 0
radioactive 0
urea 0
and 0
Na+ 0
were 0
injected 0
into 0
the 0
circulation 0
and 0
the 0
time 0
when 0
lavage 0
was 0
complete 0
. 0

The 0
kappa 0
coefficient 0
of 0
agreement 0
between 0
the 0
Patho 0
Dx 0
Kit 0
and 0
the 0
standard 0
method 0
was 0
0.958 0
. 0

Senior 0
systems 0
- 0
- 0
45 0
; 0
Mental 0
health 0
and 0
illness 0
in 0
old 0
age 0
- 0
- 0
3 0
. 0

When 0
normalized 0
for 0
imaging 0
time 0
, 0
all 0
parameters 0
are 0
significantly 0
higher 0
with 0
RASE 0
, 0
with 0
a 0
C/A 0
per 0
unit 0
time 0
that 0
was 0
338 0
% 0
higher 0
. 0

Patients 0
with 0
acute 0
myocardial 0
infarction 0
had 0
higher 0
plasma 0
concentrations 0
of 0
neutrophil B-gene
elastase I-gene
and 0
the 0
non 0
- 0
peroxide 0
diene 0
conjugated 0
isomer 0
of 0
linoleic 0
acid 0
than 0
normal 0
volunteers 0
or 0
patients 0
with 0
stable 0
ischaemic 0
heart 0
disease 0
. 0

Determination 0
of 0
three 0
- 0
dimensional 0
imaging 0
properties 0
of 0
a 0
light 0
microscope 0
system 0
. 0

The 0
cis 0
- 0
acting 0
element 0
, 0
identified 0
as 0
CACGTGACCCG 0
, 0
is 0
located 0
34 0
bp 0
upstream 0
from 0
the 0
transcription 0
initiation 0
site 0
, 0
and 0
contains 0
the 0
core 0
sequence 0
of 0
the 0
upstream 0
promoter 0
sequence 0
of 0
Ad2MLP B-gene
. 0

The 0
clinical 0
relevance 0
of 0
these 0
findings 0
is 0
strengthened 0
by 0
the 0
observation 0
that 0
similar 0
results 0
were 0
obtained 0
when 0
P.HCl 0
was 0
given 0
by 0
the 0
intravenous 0
route 0
. 0

TMBr B-gene
- I-gene
1 I-gene
is 0
identical 0
to 0
striated B-gene
muscle I-gene
alpha I-gene
- I-gene
tropomyosin I-gene
from 0
amino 0
acids 0
1 0
through 0
258 0
but 0
contains 0
a 0
novel 0
COOH 0
- 0
terminal 0
region 0
from 0
amino 0
acids 0
259 0
through 0
281 0
. 0

The 0
procedure 0
has 0
been 0
applied 0
to 0
three 0
materials 0
: 0
particle 0
board 0
with 0
carpet 0
; 0
gypsum 0
board 0
with 0
wallpaper 0
; 0
and 0
plywood 0
with 0
polyurethane 0
lacquer 0
, 0
for 0
which 0
the 0
steady 0
- 0
state 0
emission 0
factors 0
( 0
mg 0
m 0
- 0
2 0
h 0
- 0
1 0
) 0
of 0
several 0
compounds 0
are 0
given 0
. 0

Intron 0
1 0
is 0
6.5 0
kb 0
long 0
, 0
and 0
the 0
minimal 0
sizes 0
of 0
introns 0
2 0
and 0
3 0
are 0
estimated 0
to 0
be 0
32 0
kb 0
each 0
. 0

After 0
4 0
h 0
, 0
lesions 0
in 0
the 0
secretory 0
part 0
of 0
the 0
stomach 0
were 0
scored 0
and 0
mucosal 0
prostaglandin 0
E2 0
synthesis 0
was 0
determined 0
by 0
the 0
ex 0
vivo 0
prostaglandin 0
generation 0
technique 0
. 0

Comparison 0
of 0
transmembrane 0
and 0
cytoplasmic 0
domains 0
to 0
a 0
third 0
cell 0
- 0
surface 0
proteoglycan 0
, 0
48K5 B-gene
from 0
human 0
lung 0
fibroblasts 0
( 0
Marynen 0
, 0
P. 0
, 0
Zhang 0
, 0
J. 0
, 0
Cassiman 0
, 0
J. 0
, 0
Vanden 0
Berghe 0
, 0
H. 0
, 0
and 0
David 0
, 0
C 0
. 0

Approximately 0
65 0
% 0
of 0
the 0
total 0
cAMP B-gene
- I-gene
dependent I-gene
phosphotransferase I-gene
activity 0
is 0
recovered 0
in 0
particulate 0
fractions 0
of 0
homogenates 0
prepared 0
from 0
asynchronous 0
populations 0
of 0
C. 0
elegans 0
. 0

High 0
levels 0
of 0
C B-gene
subunits I-gene
are 0
observed 0
in 0
several 0
subsequent 0
larval 0
and 0
adult 0
stages 0
of 0
development 0
. 0

A 0
second 0
, 0
novel 0
C 0
subunit 0
( 0
CeCAT B-gene
alpha I-gene
' I-gene
, 0
374 0
residues 0
) 0
has 0
a 0
unique 0
56 0
- 0
residue 0
carboxyl 0
- 0
terminal 0
region 0
that 0
is 0
generated 0
by 0
the 0
alternative 0
splicing 0
of 0
the 0
C B-gene
pre I-gene
- I-gene
mRNA I-gene
. 0

The 0
alternative 0
exon 0
introduces 0
the 0
novel 0
carboxyl 0
terminus 0
and 0
a 0
new 0
translation 0
stop 0
signal 0
, 0
while 0
simultaneously 0
converting 0
the 0
coding 0
sequence 0
for 0
40 0
carboxyl 0
- 0
terminal 0
residues 0
in 0
CeCAT B-gene
alpha I-gene
into 0
3' 0
- 0
untranslated 0
nucleotides 0
. 0

French 0
, 0
M 0
. 0

Slowly 0
adapting 0
type 0
I 0
mechanoreceptor 0
discharge 0
as 0
a 0
function 0
of 0
dynamic 0
force 0
versus 0
dynamic 0
displacement 0
of 0
glabrous 0
skin 0
of 0
raccoon 0
and 0
squirrel 0
monkey 0
hand 0
. 0

Methods 0
used 0
include 0
Cobb 0
angle 0
and 0
a 0
segmental 0
evaluation 0
( 0
T7 0
- 0
T12 0
) 0
of 0
each 0
of 0
convex 0
and 0
concave 0
rib 0
- 0
vertebra 0
angles 0
( 0
RVAs 0
) 0
, 0
rib 0
- 0
vertebra 0
angle 0
differences 0
( 0
RVADs 0
) 0
, 0
vertebral 0
rotation 0
, 0
tilt 0
and 0
displacement 0
. 0

Plasma 0
lecithin/cholesterol B-gene
acyltransferase I-gene
( 0
LCAT B-gene
) 0
activity 0
in 0
multiple 0
- 0
organ 0
donors 0
: 0
a 0
predictor 0
of 0
allograft 0
viability 0
in 0
clinical 0
liver 0
transplantation 0
. 0

Lars 0
has 0
AIDS 0
- 0
- 0
a 0
more 0
dignified 0
life 0
with 0
care 0
at 0
home 0
. 0

Axillary 0
nodal 0
status 0
, 0
tumour 0
progesterone B-gene
receptor I-gene
status 0
, 0
and 0
season 0
of 0
tumour 0
detection 0
significantly 0
influenced 0
survival 0
in 0
both 0
older 0
( 0
greater 0
than 0
50 0
yrs 0
) 0
and 0
younger 0
( 0
less 0
than 0
50 0
yrs 0
) 0
patients 0
. 0

The 0
application 0
of 0
these 0
microelectrodes 0
to 0
the 0
measurement 0
of 0
rapid 0
, 0
transient 0
changes 0
in 0
retinal 0
[ 0
K+ 0
] 0
o 0
is 0
presented 0
. 0

Expression 0
, 0
cellular 0
localization 0
and 0
in 0
vitro 0
transcription 0
studies 0
establish 0
that 0
cloned B-gene
hUBF I-gene
encodes 0
a 0
nucleolar 0
factor 0
that 0
binds 0
specifically 0
to 0
the 0
upstream 0
control 0
element 0
and 0
core 0
of 0
the 0
rRNA 0
gene 0
promoter 0
to 0
activate 0
transcription 0
in 0
a 0
binding 0
site 0
- 0
dependent 0
manner 0
. 0

Combining 0
multiple 0
laboratory 0
studies 0
may 0
be 0
of 0
value 0
in 0
predetermining 0
the 0
eventual 0
outcome 0
in 0
near 0
- 0
drowning 0
. 0

Accumulations 0
of 0
Tl+1 0
( 0
202Tl 0
label 0
) 0
were 0
6 0
times 0
those 0
for 0
Ga 0
or 0
In 0
in 0
the 0
brain 0
and 0
muscles 0
, 0
and 0
.1 0
times 0
in 0
plasma 0
. 0

There 0
was 0
a 0
gradual 0
increase 0
in 0
the 0
myocyte 0
diameter 0
according 0
to 0
age 0
in 0
the 0
biopsy 0
and 0
autopsy 0
specimens 0
. 0

Despite 0
the 0
absence 0
of 0
exercise 0
- 0
induced 0
asthma 0
( 0
EIA 0
) 0
while 0
breathing 0
WH 0
air 0
, 0
asthmatic 0
patients 0
still 0
had 0
significantly 0
higher 0
mean 0
GH 0
increments 0
than 0
normal 0
subjects 0
( 0
9.2 0
vs 0
2.3 0
ng/ml 0
, 0
P 0
less 0
than 0
0.05 0
) 0
. 0

The 0
afferents 0
' 0
phase 0
of 0
response 0
was 0
unmodified 0
by 0
electrical 0
EVS 0
stimulation 0
. 0

Solving 0
an 0
age 0
old 0
problem 0
. 0

The 0
distribution 0
of 0
their 0
fibrinogen B-gene
levels 0
was 0
Gaussian 0
, 0
but 0
more 0
wide 0
- 0
based 0
than 0
the 0
distribution 0
of 0
our 0
normal 0
controls 0
. 0

In 0
a 0
stepwise 0
logistic 0
regression 0
analysis 0
of 0
SPT 0
and 0
RAST 0
data 0
, 0
the 0
occurrence 0
of 0
serum B-gene
IgE I-gene
antibodies I-gene
to I-gene
P. I-gene
orbiculare I-gene
had 0
the 0
highest 0
explanatory 0
value 0
for 0
current 0
eczema 0
. 0

The 0
examination 0
was 0
focused 0
on 0
assessment 0
of 0
different 0
types 0
of 0
drusen 0
, 0
on 0
evaluation 0
of 0
the 0
development 0
and 0
incidence 0
of 0
risk 0
factors 0
leading 0
to 0
complications 0
and 0
loss 0
of 0
central 0
vision 0
. 0

They 0
were 0
then 0
subjected 0
to 0
whole 0
- 0
body 0
heat 0
stress 0
( 0
water 0
- 0
perfused 0
suits 0
) 0
, 0
and 0
the 0
3 0
minutes 0
of 0
LBNP 0
was 0
repeated 0
. 0

An 0
NF1 B-gene
- I-gene
related I-gene
vitellogenin I-gene
activator I-gene
element I-gene
mediates 0
transcription 0
from 0
the 0
estrogen 0
- 0
regulated 0
Xenopus B-gene
laevis I-gene
vitellogenin I-gene
promoter I-gene
. 0

A 0
poor 0
correlation 0
was 0
also 0
observed 0
between 0
PbB 0
and 0
ALAD B-gene
activity 0
of 0
the 0
stearate 0
workers 0
. 0

At 0
the 0
carboxyl 0
terminus 0
, 0
deletion 0
as 0
far 0
as 0
residue 0
388 0
did 0
not 0
affect 0
in 0
vitro 0
TRF.C B-gene
assembly 0
, 0
although 0
trans 0
- 0
activating 0
activity 0
was 0
abolished 0
. 0

The 0
effects 0
of 0
mean 0
luminance 0
were 0
also 0
measured 0
and 0
a 0
general 0
expression 0
that 0
would 0
take 0
them 0
into 0
account 0
was 0
derived 0
. 0

Effect 0
of 0
hyperglycemia 0
on 0
pain 0
threshold 0
in 0
alloxan 0
- 0
diabetic 0
rats 0
. 0

We 0
have 0
synthesized 0
[ 0
7,7 0
- 0
2H2 0
] 0
- 0
19 0
- 0
OHA 0
with 0
high 0
deuterium 0
content 0
and 0
, 0
together 0
with 0
[ 0
7,7 0
- 0
2H2 0
] 0
A 0
and 0
[ 0
9,11 0
- 0
2H2 0
] 0
estrone 0
( 0
E1 0
) 0
, 0
have 0
developed 0
a 0
quantitative 0
assay 0
of 0
serum 0
level 0
19 0
- 0
OHA 0
, 0
A 0
, 0
and 0
E1 0
using 0
the 0
gas 0
chromatography/mass 0
spectrometry 0
- 0
mass 0
fragmentography 0
method 0
to 0
monitor 0
individual 0
subjects 0
throughout 0
pregnancy 0
. 0

Sequence 0
analysis 0
of 0
these 0
genes 0
and 0
their 0
surrounding 0
sequences 0
are 0
presented 0
and 0
compared 0
with 0
other 0
known 0
tRNA 0
genes 0
from 0
plant 0
mitochondria 0
. 0

Experiments 0
were 0
performed 0
in 0
which 0
brain 0
- 0
stem 0
auditory 0
- 0
evoked 0
responses 0
( 0
BAERs 0
) 0
were 0
elicited 0
by 0
two 0
types 0
of 0
pseudorandom 0
pulse 0
trains 0
: 0
maximum 0
length 0
sequences 0
( 0
MLS 0
) 0
and 0
Legendre 0
sequences 0
( 0
LGS 0
) 0
. 0

Since 0
the 0
UfAP B-gene
and 0
UTMP B-gene
share 0
many 0
biosynthetic 0
and 0
structural 0
features 0
that 0
include 0
site 0
of 0
biosynthesis 0
in 0
the 0
endometrium 0
, 0
P4 0
- 0
responsiveness 0
, 0
the 0
presence 0
of 0
the 0
mannose 0
6 0
- 0
phosphate 0
lysosomal 0
recognition 0
marker 0
, 0
and 0
considerable 0
sequence 0
similarity 0
, 0
the 0
UfAP B-gene
and 0
the 0
UTMP B-gene
may 0
have 0
homologous 0
function 0
which 0
for 0
both 0
still 0
remains 0
obscure 0
. 0

Fifteen 0
light 0
for 0
dates 0
infants 0
and 0
their 0
placentae 0
were 0
compared 0
to 0
15 0
well 0
- 0
grown 0
infants 0
and 0
their 0
placentae 0
. 0

Treating 0
renal 0
anaemia 0
with 0
recombinant 0
human 0
erythropoietin B-gene
. 0

The 0
pseudolymphoma 0
syndrome 0
is 0
a 0
reversible 0
reactive 0
condition 0
consisting 0
of 0
fever 0
, 0
lymphadenopathy 0
and 0
generalized 0
rash 0
. 0

In 0
the 0
local 0
geomagnetic 0
field 0
, 0
the 0
animals 0
preferred 0
the 0
SE 0
- 0
sector 0
. 0

In 0
the 0
artificial 0
lung 0
, 0
like 0
in 0
the 0
natural 0
lung 0
and 0
peripheral 0
tissues 0
, 0
gas 0
exchanges 0
depend 0
on 0
several 0
parameters 0
: 0
blood 0
inlet 0
conditions 0
, 0
blood 0
flow 0
rate 0
, 0
temperature 0
, 0
composition 0
of 0
the 0
gas 0
mixture 0
used 0
for 0
ventilation 0
, 0
blood 0
tissue 0
perfusion 0
, 0
O2 0
consumption 0
, 0
etc 0
. 0

Mean 0
( 0
+/ 0
- 0
SE 0
) 0
measurements 0
of 0
clearance 0
( 0
24.5 0
+/ 0
- 0
2.06 0
v 0
26.5 0
+/ 0
- 0
2.05 0
mL/min/m2 0
) 0
, 0
half 0
- 0
life 0
( 0
5.7 0
+/ 0
- 0
0.5 0
v 0
6.4 0
+/ 0
- 0
0.5 0
hours 0
) 0
, 0
and 0
volume 0
of 0
distribution 0
( 0
12.4 0
+/ 0
- 0
1.1 0
v 0
13.7 0
+/ 0
- 0
1.6 0
L/m2 0
) 0
were 0
not 0
significantly 0
different 0
in 0
patients 0
with 0
jaundice 0
when 0
compared 0
with 0
controls 0
. 0

Attitudes 0
were 0
found 0
to 0
be 0
multidimensional 0
, 0
with 0
similar 0
dimensions 0
being 0
identified 0
in 0
both 0
samples 0
. 0

We 0
conclude 0
that 0
DNA 0
ploidy 0
is 0
a 0
major 0
objective 0
prognostic 0
factor 0
and 0
therapeutic 0
determinant 0
for 0
endometrial 0
carcinoma 0
. 0

A 0
semiautomatic 0
digital 0
system 0
( 0
Videoplan 0
2 0
) 0
was 0
used 0
. 0

Environmental 0
factors 0
were 0
more 0
important 0
in 0
the 0
older 0
cohorts 0
( 0
perhaps 0
because 0
of 0
less 0
reliable 0
recall 0
) 0
. 0

Dopamine 0
SERS 0
spectra 0
from 0
these 0
electrodes 0
are 0
similar 0
to 0
those 0
obtained 0
at 0
uncoated 0
electrodes 0
. 0

These 0
findings 0
indicate 0
that 0
hypergastrinemia 0
induced 0
by 0
surgical 0
removal 0
of 0
acid 0
- 0
producing 0
mucosa 0
in 0
the 0
rat 0
has 0
the 0
same 0
effects 0
on 0
oxyntical 0
mucosal B-gene
HDC I-gene
activity 0
, 0
histamine 0
concentration 0
and 0
ECL 0
cell 0
density 0
as 0
hypergastrinemia 0
induced 0
by 0
continuous 0
gastrin B-gene
infusion 0
or 0
by 0
long 0
- 0
term 0
treatment 0
with 0
effective 0
antisecretagogues 0
. 0

Basing 0
on 0
experimental 0
toxicity 0
research 0
it 0
was 0
established 0
that 0
, 0
out 0
of 0
50 0
atmosphere 0
metal 0
corrosion 0
inhibitors 0
, 0
some 0
14 0
per 0
cent 0
were 0
found 0
extremely 0
hazardous 0
, 0
42 0
per 0
cent 0
- 0
- 0
of 0
high 0
level 0
hazardous 0
, 0
33 0
percent 0
- 0
- 0
of 0
moderate 0
and 0
11 0
per 0
cent 0
- 0
- 0
of 0
low 0
hazardous 0
. 0

The 0
order 0
of 0
the 0
helicase B-gene
motif I-gene
and 0
the 0
nsP3 B-gene
homology I-gene
region I-gene
in 0
the 0
RUB 0
genome 0
is 0
reversed 0
with 0
respect 0
to 0
the 0
alphavirus 0
genome 0
indicating 0
that 0
a 0
genetic 0
rearrangement 0
has 0
occurred 0
during 0
the 0
evolution 0
of 0
these 0
viruses 0
. 0

The 0
results 0
suggest 0
followings 0
- 0
- 0
1 0
) 0
both 0
eosinophils 0
and 0
neutrophils 0
participate 0
in 0
hypersecretion 0
of 0
type 0
Ib 0
in 0
atopic 0
cases 0
, 0
and 0
only 0
eosinophils 0
in 0
non 0
- 0
atopic 0
cases 0
. 0

There 0
were 0
5 0
treatments 0
: 0
control 0
( 0
C 0
) 0
; 0
a 0
wooden 0
surround 0
in 0
one 0
rear 0
corner 0
of 0
the 0
cage 0
( 0
S 0
) 0
; 0
a 0
fiberglass 0
rollaway 0
hollow 0
in 0
one 0
rear 0
corner 0
of 0
the 0
cage 0
( 0
H 0
) 0
; 0
a 0
hollow 0
and 0
a 0
surround 0
( 0
H/S 0
) 0
; 0
a 0
nest 0
box 0
attached 0
to 0
the 0
back 0
of 0
the 0
cage 0
, 0
containing 0
a 0
hollow 0
( 0
N 0
) 0
. 0

While 0
no 0
significant 0
differences 0
in 0
the 0
tensile 0
responses 0
or 0
failure 0
characteristics 0
were 0
noted 0
for 0
irradiated 0
and 0
nonirradiated 0
grafts 0
in 0
the 0
drip 0
, 0
in 0
the 0
bath 0
environment 0
the 0
nonirradiated 0
tissues 0
had 0
greater 0
strength 0
and 0
modulus 0
. 0

The 0
patient 0
was 0
treated 0
with 0
benzathine 0
penicillin 0
, 0
2,400,000 0
U 0
weekly 0
for 0
three 0
weeks 0
. 0

A 0
consensus 0
binding 0
site 0
for 0
the 0
transcription 0
factor 0
SP1 B-gene
was 0
identified 0
in 0
intron 0
As 0
downstream 0
of 0
the 0
proenkephalin B-gene
germ I-gene
cell I-gene
cap I-gene
site I-gene
region I-gene
. 0

This 0
proposed 0
method 0
is 0
similar 0
in 0
principle 0
to 0
the 0
sets 0
technique 0
but 0
is 0
shown 0
to 0
have 0
much 0
better 0
expected 0
time 0
to 0
alarm 0
properties 0
. 0

The 0
effects 0
on 0
reflex 0
latencies 0
but 0
not 0
on 0
paCO2 0
or 0
pHa 0
were 0
blocked 0
by 0
naloxone 0
( 0
2 0
mg/kg 0
) 0
, 0
and 0
were 0
not 0
present 0
in 0
morphine 0
- 0
tolerant 0
animals 0
. 0

Of 0
the 0
remaining 0
seven 0
, 0
five 0
reacted 0
either 0
with 0
immediate 0
and 0
strong 0
symptoms 0
or 0
had 0
spontaneously 0
reduced 0
gluten B-gene
intake 0
, 0
or 0
had 0
an 0
acquired 0
IgA B-gene
deficiency 0
. 0

Drug 0
and 0
personnel 0
costs 0
were 0
reduced 0
when 0
batch 0
manufacturing 0
with 0
40 0
- 0
mL 0
multidose 0
vials 0
was 0
compared 0
with 0
extemporaneous 0
compounding 0
with 0
unit 0
- 0
dose 0
vials 0
. 0

Changes 0
in 0
prognosis 0
of 0
twin 0
births 0
over 0
20 0
years 0
. 0

Dermal 0
toxicity 0
and 0
carcinogenicity 0
of 0
4 0
- 0
vinyl 0
- 0
1 0
- 0
cyclohexene 0
diepoxide 0
in 0
Fischer 0
rats 0
and 0
B6C3F1 0
mice 0
. 0

Per 0
kg 0
FFM 0
SMR 0
was 0
almost 0
restored 0
to 0
baseline 0
values 0
for 0
the 0
EX 0
group 0
, 0
whereas 0
the 0
non 0
- 0
exercising 0
subjects 0
still 0
showed 0
depressed 0
values 0
( 0
EX 0
3.7 0
per 0
cent 0
and 0
D 0
+ 0
DE 0
15.8 0
per 0
cent 0
lower 0
than 0
before 0
treatment 0
; 0
P 0
less 0
than 0
0.05 0
) 0
. 0

MK 0
- 0
927 0
: 0
a 0
topically 0
active 0
ocular 0
hypotensive 0
carbonic B-gene
anhydrase I-gene
inhibitor 0
. 0

PCR 0
- 0
derived 0
fragments 0
were 0
used 0
as 0
probes 0
for 0
the 0
isolation 0
of 0
the 0
U3 B-gene
snRNA I-gene
genes I-gene
from 0
a 0
genomic 0
library 0
of 0
Arabidopsis 0
. 0

In 0
addition 0
serum B-gene
IgE I-gene
concentrations 0
were 0
not 0
statistically 0
different 0
. 0

The 0
findings 0
suggest 0
that 0
, 0
although 0
iodine 0
deficiency 0
is 0
the 0
most 0
probable 0
cause 0
of 0
goiter 0
among 0
immigrants 0
of 0
the 0
1928 0
cohort 0
, 0
where 0
the 0
native 0
population 0
is 0
concerned 0
( 0
both 0
men 0
and 0
women 0
) 0
, 0
some 0
other 0
goitrogenic 0
factor 0
( 0
s 0
) 0
must 0
be 0
involved 0
. 0

The 0
transcriptional 0
unit 0
spans 0
a 0
chromosomal 0
region 0
of 0
about 0
55 0
kilobase 0
pairs 0
( 0
kbp 0
) 0
. 0

100 0
of 0
the 0
patients 0
who 0
would 0
have 0
died 0
survive 0
. 0

Co 0
- 0
administration 0
of 0
5FU 0
, 0
angiotensin B-gene
II I-gene
and 0
microspheres 0
via 0
the 0
hepatic 0
artery 0
may 0
reduce 0
drug 0
exposure 0
in 0
the 0
systemic 0
compartment 0
and 0
therefore 0
may 0
increase 0
the 0
therapeutic 0
ratio 0
of 0
5FU 0
administration 0
via 0
the 0
hepatic 0
artery 0
. 0

The 0
effects 0
of 0
tap 0
( 0
TW 0
) 0
or 0
carbonated 0
( 0
CW 0
) 0
water 0
on 0
arterial 0
pH 0
, 0
partial 0
pressure 0
of 0
carbon 0
dioxide 0
( 0
PCO2 0
) 0
and 0
plasma 0
lactate 0
were 0
determined 0
in 0
heat 0
- 0
stressed 0
broilers 0
. 0

Transient 0
expression 0
of 0
human B-gene
and I-gene
chicken I-gene
progesterone I-gene
receptors I-gene
does 0
not 0
support 0
alternative 0
translational 0
initiation 0
from 0
a 0
single 0
mRNA 0
as 0
the 0
mechanism 0
generating 0
two 0
receptor 0
isoforms 0
. 0

In 0
contrast 0
, 0
2,397 0
( 0
74 0
% 0
) 0
had 0
one 0
or 0
more 0
risk 0
factors 0
( 0
not 0
low 0
risk 0
) 0
; 0
of 0
these 0
, 0
5.3 0
% 0
died 0
in 0
6 0
weeks 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

The 0
Community 0
Adjustment 0
Scale 0
provided 0
outcome 0
data 0
related 0
to 0
the 0
subjects 0
' 0
degree 0
of 0
productivity 0
, 0
ability 0
to 0
maintain 0
close 0
relationships 0
, 0
and 0
presence/absence 0
of 0
symptomatology 0
an 0
average 0
of 0
32 0
years 0
after 0
initial 0
admission 0
. 0

However 0
, 0
at 0
18 0
months 0
of 0
age 0
, 0
significantly 0
higher 0
levels 0
of 0
IgG1 B-gene
( 0
P 0
less 0
than 0
0.05 0
) 0
and 0
of 0
IgG4 B-gene
( 0
P 0
less 0
than 0
0.01 0
) 0
were 0
found 0
in 0
infants 0
with 0
an 0
elevated 0
IgE B-gene
( 0
greater 0
than 0
or 0
equal 0
to 0
8.0 0
kU/l 0
) 0
than 0
in 0
those 0
with 0
a 0
lower 0
level 0
. 0

The 0
protein 0
sequence 0
contains 0
seven 0
potential 0
N 0
- 0
linked 0
glycosylation 0
sites 0
and 0
a 0
threonine/serine 0
- 0
rich 0
region 0
which 0
is 0
a 0
potential 0
site 0
for 0
attachment 0
of 0
O 0
- 0
linked 0
carbohydrate 0
. 0

Thus 0
adaptation 0
to 0
continuous 0
mild 0
stress 0
has 0
a 0
potent 0
antiarrhythmic 0
effect 0
which 0
occurs 0
due 0
to 0
the 0
increased 0
vagal 0
tone 0
. 0

The 0
eluent 0
from 0
the 0
column 0
was 0
mixed 0
with 0
the 0
chemiluminescent 0
solution 0
containing 0
lucigenin B-gene
and 0
Triton 0
X 0
- 0
100 0
and 0
a 0
0.28 0
M 0
KOH 0
solution 0
by 0
pumps 0
and 0
monitored 0
by 0
a 0
chemiluminescence 0
detector 0
. 0

On 0
histologic 0
examination 0
the 0
cuboidal 0
epithelium 0
of 0
the 0
mucous 0
membrane 0
was 0
found 0
to 0
be 0
changed 0
into 0
columnar 0
epithelium 0
, 0
with 0
uneven 0
distribution 0
of 0
enlarged 0
nuclei 0
in 0
the 0
vacuolized 0
cytoplasm 0
. 0

These 0
results 0
suggest 0
an 0
increased 0
risk 0
of 0
developing 0
cancer 0
among 0
polyp 0
patients 0
and 0
the 0
possibility 0
of 0
prophylactic 0
effect 0
of 0
polypectomy 0
against 0
subsequent 0
cancer 0
. 0

The 0
same 0
trend 0
was 0
noted 0
between 0
YG 0
4.5 0
heifers 0
and 0
YG 0
5.5 0
steers 0
, 0
indicating 0
a 0
sex 0
- 0
related 0
deposition 0
of 0
seam 0
fat 0
in 0
fed 0
cattle 0
. 0

The 0
nucleotide 0
sequence 0
consists 0
of 0
48 0
bp 0
of 0
5' 0
- 0
end 0
non 0
- 0
coding 0
region 0
, 0
1695 0
bp 0
of 0
coding 0
region 0
and 0
212 0
bp 0
of 0
3' 0
- 0
end 0
non 0
- 0
coding 0
region 0
including 0
a 0
20 0
bp 0
poly 0
( 0
A 0
) 0
tail 0
. 0

Toxicities 0
included 0
: 0
nausea/vomiting 0
( 0
69 0
% 0
) 0
, 0
headache 0
( 0
25 0
% 0
) 0
, 0
chills 0
( 0
69 0
% 0
) 0
, 0
pain 0
at 0
tumor 0
sites 0
( 0
63 0
% 0
) 0
, 0
hypotension 0
( 0
31 0
% 0
) 0
, 0
and 0
hypertension 0
( 0
38 0
% 0
) 0
. 0

The 0
results 0
also 0
showed 0
that 0
although 0
oyster 0
shell 0
supplementation 0
generally 0
increased 0
alkaline B-gene
phosphatase I-gene
activity 0
, 0
bone 0
mineralization 0
was 0
relatively 0
uninfluenced 0
as 0
judged 0
by 0
the 0
low 0
coefficients 0
of 0
variation 0
( 0
CV 0
) 0
of 0
3.14 0
- 0
3.51 0
% 0
and 0
3.39 0
- 0
4.82 0
% 0
for 0
calcium 0
and 0
phosphorus 0
content 0
in 0
the 0
femur 0
and 0
tibia 0
respectively 0
. 0

In 0
6 0
of 0
24 0
infants 0
studied 0
( 0
27th 0
- 0
40th 0
weeks 0
of 0
gestation 0
) 0
, 0
acquired 0
and 0
congenital 0
structural 0
anomalies 0
of 0
the 0
airways 0
were 0
detected 0
with 0
an 0
ultrathin 0
flexible 0
fiberscope 0
( 0
Olympus 0
PF18 0
S 0
, 0
1.8 0
mm 0
) 0
. 0

Fatal 0
encephalitis 0
in 0
a 0
patient 0
with 0
chronic 0
graft 0
- 0
versus 0
- 0
host 0
disease 0
. 0

Compared 0
to 0
its 0
counterpart 0
in 0
the 0
GPB B-gene
gene I-gene
, 0
exon 0
3 0
of 0
the 0
GPE B-gene
gene I-gene
contains 0
several 0
point 0
mutations 0
, 0
an 0
insertion 0
of 0
24 0
bp 0
, 0
and 0
a 0
stop 0
codon 0
which 0
shortens 0
the 0
reading 0
frame 0
. 0

Molecular 0
cloning 0
of 0
a 0
cDNA 0
encoding 0
rat B-gene
NADH I-gene
- I-gene
cytochrome I-gene
b5 I-gene
reductase I-gene
and 0
the 0
corresponding 0
gene 0
. 0

The 0
results 0
corroborate 0
the 0
idea 0
that 0
the 0
structure 0
of 0
relaxation 0
curves 0
contains 0
information 0
on 0
the 0
distance 0
scale 0
and 0
on 0
the 0
architecture 0
of 0
the 0
pore 0
space 0
, 0
even 0
if 0
it 0
is 0
difficult 0
to 0
extract 0
it 0
without 0
ambiguities 0
. 0

Serotonin B-gene
5 I-gene
- I-gene
HT2 I-gene
receptor I-gene
binding 0
on 0
blood 0
platelets 0
as 0
a 0
state 0
dependent 0
marker 0
in 0
major 0
affective 0
disorder 0
. 0

Although 0
% 0
BF 0
was 0
correlated 0
with 0
all 0
the 0
BMIs 0
( 0
r 0
= 0
0.60 0
- 0
0.82 0
) 0
, 0
applying 0
objective 0
definitions 0
of 0
obesity 0
based 0
on 0
BMIs 0
or 0
% 0
BF 0
by 0
densitometry 0
often 0
produced 0
conflicting 0
results 0
. 0

The 0
RF 0
values 0
correlated 0
well 0
with 0
the 0
angiographic 0
semiquantitative 0
scale 0
of 0
severity 0
of 0
aortal 0
insufficiency 0
( 0
r 0
= 0
0.805 0
; 0
p 0
less 0
than 0
0.001 0
) 0
, 0
although 0
they 0
enabled 0
the 0
authors 0
only 0
to 0
make 0
a 0
partial 0
differentiation 0
of 0
haemodynamically 0
severe 0
regurgitations 0
and 0
mild 0
or 0
insignificant 0
ones 0
. 0

Promoter 0
elements 0
include 0
an 0
atypical 0
TATA 0
box 0
( 0
GTTA 0
) 0
, 0
one 0
CCAAT 0
box 0
much 0
further 0
from 0
the 0
initiation 0
site 0
, 0
three 0
reverse 0
compliments 0
of 0
CCAAT 0
( 0
ATTGG 0
) 0
, 0
and 0
two 0
pyrimidine 0
- 0
rich 0
nucleotide 0
stretches 0
. 0

The 0
cloned 0
genes 0
were 0
identified 0
in 0
genetic 0
libraries 0
by 0
hybridization 0
screening 0
using 0
four 0
deoxyoligonucleotide 0
probes 0
which 0
corresponded 0
to 0
the 0
partial 0
amino 0
acid 0
sequence 0
of 0
the 0
purified 0
enzyme 0
. 0

The 0
pattern 0
for 0
catalytic 0
zinc 0
sites 0
included 0
two 0
ligands 0
close 0
in 0
sequence 0
, 0
a 0
sequence 0
- 0
distant 0
ligand 0
, 0
and 0
a 0
main 0
- 0
chain 0
hydrogen 0
bond 0
joining 0
two 0
ligands 0
. 0

Results 0
of 0
the 0
long 0
- 0
term 0
observation 0
and 0
treatment 0
of 0
patients 0
with 0
arterial 0
hypertension 0

Eucaryotic 0
transcription 0
factors 0
that 0
stimulate 0
RNA B-gene
polymerase I-gene
II I-gene
by 0
increasing 0
the 0
efficiency 0
of 0
elongation 0
of 0
specifically 0
or 0
randomly 0
initiated 0
RNA 0
chains 0
have 0
been 0
isolated 0
and 0
characterized 0
. 0

Sprague 0
- 0
Dawley 0
newborn 0
rats 0
( 0
n 0
= 0
85 0
) 0
breathed 0
100 0
% 0
oxygen 0
( 0
O2 0
) 0
or 0
room 0
air 0
( 0
RA 0
) 0
during 0
the 0
first 0
8 0
days 0
of 0
life 0
, 0
and 0
then 0
RA 0
. 0

The 0
Lm 0
increased 0
and 0
the 0
alveoli/mm2 0
and 0
elastic 0
recoil 0
pressure 0
decreased 0
. 0

Comparison 0
of 0
propofol 0
and 0
thiopentone 0
as 0
anaesthetic 0
agents 0
for 0
electroconvulsive 0
therapy 0
. 0

In 0
Experiment 0
II 0
, 0
as 0
performing 0
moderate 0
supine 0
cycling 0
( 0
55 0
% 0
VO2 0
max 0
) 0
for 0
50 0
minutes 0
under 0
several 0
LBNP 0
conditions 0
in 0
5 0
sedentary 0
women 0
, 0
there 0
were 0
correspondingly 0
similar 0
changing 0
manners 0
of 0
the 0
cardiovascular 0
adjustments 0
to 0
each 0
of 0
the 0
phases 0
given 0
in 0
Experiment 0
I 0
. 0

Commercially 0
available 0
formulations 0
of 0
2.5 0
% 0
and 0
5 0
% 0
lambdacyhalothrin 0
can 0
be 0
diluted 0
either 0
with 0
water 0
for 0
ULV 0
cold 0
aerosol 0
space 0
- 0
spraying 0
or 0
with 0
diesel/kerosene 0
for 0
thermal 0
fogging 0
at 0
recommended 0
application 0
rates 0
of 0
0.5 0
- 0
1 0
g 0
ai/ha 0
for 0
mosquito 0
control 0
and 0
2 0
g 0
ai/ha 0
for 0
housefly 0
control 0
. 0

Thus 0
, 0
this 0
reading 0
frame 0
was 0
concluded 0
to 0
encode 0
the 0
precursor 0
of 0
mitochondrial B-gene
fumarase I-gene
. 0

Sequence 0
analysis 0
indicates 0
that 0
in 0
addition 0
to 0
an 0
ATA 0
and 0
GC 0
box 0
, 0
this 0
region 0
contains 0
domains 0
that 0
have 0
been 0
implicated 0
in 0
the 0
regulation 0
of 0
other 0
muscle 0
- 0
specific 0
genes 0
: 0
a 0
CArG 0
box 0
at 0
- 0
91 0
bp 0
; 0
myocyte B-gene
- I-gene
specific I-gene
enhancer I-gene
- I-gene
binding I-gene
nuclear I-gene
factor I-gene
1 I-gene
binding I-gene
site I-gene
homologies 0
at 0
- 0
58 0
, 0
- 0
535 0
, 0
and 0
- 0
583 0
bp 0
; 0
and 0
a 0
muscle 0
- 0
CAAT 0
consensus 0
sequence 0
at 0
- 0
394 0
bp 0
relative 0
to 0
the 0
cap 0
site 0
. 0

The 0
trk B-gene
- I-gene
2h I-gene
oncogene I-gene
, 0
isolated 0
from 0
the 0
human 0
breast 0
carcinoma 0
cell 0
line 0
MDA 0
- 0
MB 0
231 0
by 0
genomic 0
DNA 0
- 0
transfection 0
into 0
NIH3T3 0
cells 0
, 0
consists 0
of 0
the 0
trk B-gene
proto I-gene
- I-gene
oncogene I-gene
receptor I-gene
kinase I-gene
domain I-gene
fused 0
to 0
a 0
N 0
- 0
terminal 0
41 0
amino 0
acid 0
activating 0
sequence 0
( 0
Kozma 0
, 0
S.C. 0
, 0
Redmond 0
, 0
S.M.S. 0
, 0
Xiao 0
- 0
Chang 0
, 0
F. 0
, 0
Saurer 0
, 0
S.M. 0
, 0
Groner 0
, 0
B. 0
and 0
Hynes 0
, 0
N.E 0
. 0

Antibodies 0
raised 0
against 0
a 0
bacterially 0
produced 0
beta B-gene
gal I-gene
- 0
trk B-gene
receptor 0
kinase 0
fusion 0
protein 0
recognized 0
a 0
44 0
kd 0
phosphoprotein 0
phosphorylated 0
on 0
serine 0
, 0
threonine 0
and 0
tyrosine 0
in 0
extracts 0
of 0
trk B-gene
- I-gene
2h I-gene
transformed 0
NIH3T3 0
cells 0
. 0

Since 0
very 0
recent 0
scanning 0
- 0
deletion 0
analysis 0
indicates 0
that 0
there 0
is 0
a 0
critical 0
region 0
for 0
activity 0
near 0
Cys 0
- 0
118 0
and 0
that 0
Cys 0
- 0
118 0
is 0
necessary 0
for 0
maximal 0
activity 0
, 0
we 0
conclude 0
that 0
the 0
Cys 0
- 0
118 0
residue 0
is 0
necessary 0
for 0
proper 0
glycosylation 0
and 0
maximal 0
biologic 0
activity 0
of 0
GM B-gene
- I-gene
CSF I-gene
. 0

Molecular 0
and 0
functional 0
characterization 0
of 0
the 0
promoter 0
of 0
ETS2 B-gene
, 0
the 0
human 0
c B-gene
- I-gene
ets I-gene
- I-gene
2 I-gene
gene 0
. 0

Information 0
about 0
immunologic 0
drug 0
interactions 0
is 0
needed 0
by 0
pharmacists 0
to 0
make 0
rational 0
drug 0
- 0
use 0
decisions 0
. 0

Branch 0
occlusion 0
of 0
Heubner 0
's 0
artery 0
, 0
or 0
perforators 0
from 0
the 0
proximal 0
anterior 0
or 0
middle 0
cerebral 0
arteries 0
were 0
the 0
posited 0
mechanism 0
of 0
infarction 0
. 0

All 0
ABFI B-gene
- I-gene
binding I-gene
sites I-gene
, 0
regardless 0
of 0
origin 0
, 0
provided 0
weak 0
UAS 0
function 0
in 0
vivo 0
when 0
examined 0
in 0
test 0
plasmids 0
. 0

An 0
examination 0
of 0
the 0
properties 0
of 0
sequences 0
surrounding 0
ARS1 0
left 0
open 0
the 0
possibility 0
that 0
ABFI B-gene
enhances 0
the 0
initiation 0
of 0
DNA 0
replication 0
at 0
ARS1 0
by 0
transcriptional 0
activation 0
. 0

Nonvascular 0
ophthalmic 0
and 0
neurologic 0
disorders 0
that 0
can 0
be 0
confused 0
with 0
amaurosis 0
fugax 0
are 0
listed 0
, 0
and 0
an 0
algorithm 0
for 0
evaluation 0
( 0
which 0
includes 0
ophthalmic 0
examination 0
, 0
laboratory 0
studies 0
, 0
and 0
noninvasive 0
carotid 0
artery 0
studies 0
) 0
is 0
given 0
. 0

Likewise 0
, 0
whether 0
or 0
not 0
the 0
hypotensive 0
action 0
of 0
converting 0
enzyme 0
inhibitors 0
is 0
age 0
- 0
related 0
is 0
as 0
yet 0
unknown 0
. 0

Polyclonal 0
antiserum 0
generated 0
to 0
the 0
fusion 0
protein 0
was 0
capable 0
of 0
detecting 0
42 0
- 0
and 0
46 0
- 0
kilodalton 0
polypeptides 0
from 0
virus 0
particles 0
; 0
both 0
polypeptides 0
were 0
also 0
shown 0
to 0
contain 0
HBsAg B-gene
determinants I-gene
. 0

These 0
characteristics 0
of 0
N22/P22 0
indicate 0
that 0
it 0
is 0
a 0
localized 0
synaptically 0
dependent 0
event 0
conforming 0
to 0
a 0
transverse 0
dipole 0
with 0
dorsal 0
negativity 0
and 0
a 0
simultaneous 0
anterior 0
positivity 0
. 0

Role 0
of 0
superoxide B-gene
dismutase I-gene
in 0
cellular 0
oxidative 0
processes 0
and 0
method 0
of 0
its 0
determination 0
in 0
biological 0
materials 0

At 0
maximum 0
photosensitivity 0
the 0
inhibitory 0
amino 0
acids 0
gamma 0
- 0
aminobutyric 0
acid 0
and 0
taurine 0
were 0
lower 0
, 0
and 0
those 0
of 0
asparagine 0
( 0
metabolite 0
of 0
the 0
excitatory 0
amino 0
acid 0
aspartate 0
) 0
were 0
higher 0
, 0
than 0
when 0
the 0
animals 0
were 0
not 0
photosensitive 0
. 0

We 0
evaluated 0
the 0
likelihood 0
of 0
tissues 0
to 0
be 0
positive 0
for 0
carcinoembryonic B-gene
antigen I-gene
and 0
the 0
intensity 0
of 0
carcinoembryonic B-gene
antigen I-gene
staining 0
in 0
specimens 0
of 0
villous 0
adenomas 0
, 0
mixed 0
polypoid 0
villous 0
adenomas 0
, 0
polypoid 0
adenomas 0
, 0
and 0
diverticulitis 0
using 0
the 0
peroxidase B-gene
- 0
antiperoxidase B-gene
technique 0
. 0

The 0
priming 0
activity 0
of 0
DNA 0
incised 0
by 0
either 0
of 0
the 0
Drosophila 0
enzymes 0
can 0
be 0
enhanced 0
, 0
however 0
, 0
by 0
an 0
additional 0
incubation 0
with 0
E. B-gene
coli I-gene
endonuclease I-gene
IV I-gene
, 0
which 0
is 0
known 0
to 0
cleave 0
depurinated 0
DNA 0
on 0
the 0
5' 0
- 0
side 0
of 0
an 0
apurinic 0
site 0
. 0

A 0
. 0

Therefore 0
, 0
in 0
conjunction 0
with 0
a 0
positive 0
pregnancy 0
test 0
and 0
the 0
patient 0
's 0
clinical 0
history 0
, 0
a 0
severely 0
depressed 0
or 0
absent 0
serum 0
PAPP B-gene
- I-gene
A I-gene
level 0
may 0
aid 0
in 0
the 0
diagnosis 0
of 0
extrauterine 0
pregnancy 0
. 0

The 0
levels 0
of 0
both 0
MAP1 B-gene
- I-gene
specific I-gene
and I-gene
MAP2 I-gene
- I-gene
specific I-gene
mRNAs I-gene
decline 0
in 0
the 0
postnatal 0
developing 0
brain 0
; 0
the 0
level 0
of 0
MAP1 B-gene
- I-gene
specific I-gene
mRNA I-gene
also 0
increases 0
slightly 0
in 0
rat 0
PC12 0
cells 0
upon 0
exposure 0
to 0
nerve B-gene
growth I-gene
factor I-gene
. 0

The 0
cDNAs 0
cross 0
- 0
hybridize 0
with 0
genomic 0
sequences 0
in 0
rat 0
, 0
human 0
, 0
and 0
chicken 0
DNA 0
, 0
but 0
not 0
with 0
DNA 0
from 0
frog 0
, 0
Drosophila 0
, 0
or 0
sea 0
urchin 0
. 0

Colorimetric 0
method 0
of 0
determining 0
glycerin 0
in 0
the 0
blood 0

Deletion 0
analysis 0
was 0
carried 0
out 0
within 0
a 0
part 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
showing 0
homology 0
to 0
the 0
upstream 0
region 0
of 0
the 0
yeast B-gene
CYC1 I-gene
gene I-gene
. 0

The 0
N1 0
and 0
P2 0
were 0
comparable 0
in 0
amplitude 0
and 0
both 0
had 0
prolonged 0
refractory 0
periods 0
. 0

Tolerance 0
to 0
fenfluramine 0
anorexia 0
: 0
fact 0
or 0
fiction 0
? 0
Recent 0
findings 0
in 0
this 0
laboratory 0
with 0
regard 0
to 0
tolerance 0
to 0
fenfluramine 0
anorexia 0
are 0
reviewed 0
with 0
respect 0
to 0
generality 0
of 0
the 0
behavioural 0
phenomenon 0
. 0

In 0
30 0
dogs 0
the 0
left 0
limb 0
( 0
tail 0
) 0
of 0
the 0
pancreas 0
was 0
removed 0
but 0
left 0
in 0
the 0
abdominal 0
cavity 0
after 0
cessation 0
of 0
blood 0
flow 0
to 0
produce 0
warm 0
ischemia 0
for 0
30 0
, 0
60 0
, 0
and 0
120 0
min 0
( 0
10 0
dogs 0
at 0
each 0
time 0
point 0
) 0
, 0
and 0
then 0
was 0
flushed 0
with 0
cold 0
Ringers 0
' 0
lactate 0
and 0
transplanted 0
to 0
the 0
iliac 0
vessels 0
. 0

These 0
results 0
support 0
the 0
view 0
that 0
clonidine 0
and 0
6 0
- 0
OHDA 0
, 0
but 0
not 0
alpha 0
- 0
MD 0
, 0
have 0
central 0
pressor 0
actions 0
in 0
the 0
rat 0
that 0
oppose 0
their 0
antihypertensive 0
action 0
. 0

Furthermore 0
, 0
beta B-gene
2 I-gene
- I-gene
adrenoceptor I-gene
sensitivity 0
appears 0
to 0
be 0
unaltered 0
in 0
BHT 0
. 0

We 0
conclude 0
that 0
Hansel 0
's 0
stain 0
substantially 0
improves 0
the 0
recognition 0
of 0
eosinophiluria 0
as 0
compared 0
with 0
Wright 0
's 0
stain 0
. 0

These 0
results 0
suggest 0
that 0
the 0
negative 0
inotropic 0
action 0
of 0
nicorandil 0
is 0
caused 0
by 0
inhibition 0
of 0
Ca 0
influx 0
and 0
intracellular 0
mobilization 0
of 0
Ca 0
. 0

The 0
study 0
included 0
139 0
eyes 0
with 0
presumed 0
ocular 0
histoplasmosis 0
syndrome 0
( 0
POHS 0
) 0
and 0
age 0
- 0
related 0
macular 0
degeneration 0
( 0
AMD 0
) 0
. 0

Comparison 0
of 0
elastase B-gene
- I-gene
1 I-gene
with 0
amylase B-gene
, 0
lipase B-gene
, 0
and 0
trypsin B-gene
- 0
like 0
immunoreactivity 0
in 0
the 0
diagnosis 0
of 0
acute 0
pancreatitis 0
. 0

A 0
probe 0
evoked 0
potentials 0
procedure 0
was 0
used 0
to 0
assess 0
the 0
relative 0
engagement 0
of 0
both 0
cerebral 0
hemispheres 0
during 0
a 0
language 0
task 0
in 0
the 0
following 0
four 0
groups 0
of 0
dextral 0
adults 0
: 0
left 0
hemisphere 0
( 0
LH 0
) 0
- 0
damaged 0
aphasics 0
recovering 0
from 0
stroke 0
, 0
dysarthrics 0
, 0
right 0
hemisphere 0
( 0
RH 0
) 0
- 0
damaged 0
nonaphasic 0
patients 0
, 0
and 0
normal 0
control 0
subjects 0
. 0

Mucolipidosis 0
type 0
IV 0
: 0
clinical 0
spectrum 0
and 0
natural 0
history 0
. 0

Two 0
of 0
the 0
three 0
groups 0
were 0
administered 0
dauricine 0
, 0
as 0
a 0
new 0
calcium 0
channel 0
blocker 0
, 0
and 0
verapamil 0
, 0
as 0
a 0
generally 0
recognized 0
calcium 0
channel 0
blocker 0
, 0
respectively 0
, 0
from 0
15 0
minutes 0
pre 0
- 0
bypass 0
to 0
the 0
end 0
of 0
the 0
bypass 0
procedure 0
( 0
a 0
period 0
of 0
95 0
minutes 0
) 0
. 0

No 0
reflow 0
occurred 0
in 0
approximately 0
30 0
percent 0
of 0
the 0
muscle 0
microvasculature 0
upon 0
reperfusion 0
. 0

Rarely 0
, 0
patients 0
with 0
locally 0
advanced 0
, 0
uncontrollable 0
, 0
non 0
- 0
metastatic 0
prostatic 0
cancer 0
enjoy 0
prolonged 0
survival 0
. 0

Lysozyme B-gene
activity 0
was 0
evidently 0
increased 0
as 0
well 0
in 0
undiluted 0
as 0
in 0
diluted 0
sera 0
in 0
all 0
our 0
tested 0
patients 0
. 0

The 0
first 0
involved 0
measurements 0
of 0
the 0
steady 0
state 0
levels 0
of 0
mRNAs 0
for 0
subunit 0
5 0
of 0
cytochrome B-gene
oxidase I-gene
and 0
the 0
beta 0
subunit 0
of 0
F1 B-gene
ATPase I-gene
in 0
wild 0
type 0
and 0
in 0
a 0
hem2 B-gene
mutant I-gene
. 0

A 0
5.8S B-gene
- I-gene
like I-gene
structure I-gene
is 0
present 0
within 0
the 0
5' 0
- 0
terminal 0
region 0
of 0
all 0
three 0
fungal B-gene
mitochondrial I-gene
LSU I-gene
rRNAs I-gene
; 0
in 0
contrast 0
, 0
no 0
4.5S B-gene
- I-gene
like I-gene
structure I-gene
is 0
evident 0
at 0
the 0
3 0
' 0
end 0
of 0
these 0
molecules 0
. 0

ATP 0
gamma 0
S 0
inhibition 0
can 0
be 0
overcome 0
by 0
high 0
concentrations 0
of 0
ATP 0
, 0
dATP 0
, 0
araATP 0
, 0
or 0
ddATP 0
. 0

The 0
recovery 0
of 0
labelled 0
methoxydextrane 0
is 0
98 0
+/ 0
- 0
7 0
% 0
. 0

ASL 0
- 0
8123 0
demonstrated 0
weak 0
competitive 0
beta B-gene
- I-gene
adrenoreceptor I-gene
blocking 0
activity 0
in 0
isolated 0
guinea 0
pig 0
right 0
atria 0
with 0
a 0
pA2 0
of 0
3.73 0
+/ 0
- 0
0.07 0
; 0
no 0
agonist 0
- 0
like 0
activity 0
was 0
observed 0
in 0
this 0
tissue 0
at 0
concentrations 0
of 0
ASL 0
- 0
8123 0
from 0
3 0
X 0
10 0
( 0
- 0
5 0
) 0
to 0
1 0
X 0
10 0
( 0
- 0
2 0
) 0
M 0
. 0

Enhancer 0
and 0
promoter 0
elements 0
directing 0
activation 0
and 0
glucocorticoid 0
repression 0
of 0
the 0
alpha B-gene
1 I-gene
- I-gene
fetoprotein I-gene
gene I-gene
in 0
hepatocytes 0
. 0

We 0
discuss 0
the 0
results 0
in 0
relation 0
to 0
previous 0
systems 0
for 0
parcellating 0
the 0
posterior 0
ectosylvian 0
gyrus 0
of 0
the 0
cat 0
and 0
consider 0
the 0
possibility 0
that 0
divisions 0
of 0
the 0
feline 0
posterior 0
ectosylvian 0
gyrus 0
correspond 0
directly 0
to 0
areas 0
making 0
up 0
the 0
superior 0
temporal 0
gyrus 0
in 0
primates 0
. 0

The 0
gene 0
is 0
contained 0
within 0
a 0
1.8 0
- 0
kilobase 0
AccI B-gene
- 0
EcoRI B-gene
restriction 0
fragment 0
mapping 0
at 0
map 0
coordinates 0
0.136 0
to 0
0.148 0
in 0
the 0
UL 0
region 0
of 0
the 0
EHV 0
- 0
1 0
genome 0
and 0
is 0
transcribed 0
from 0
right 0
to 0
left 0
. 0

The 0
4 0
- 0
AP 0
( 0
4 0
- 0
20 0
mM 0
) 0
effect 0
resulted 0
in 0
a 0
decrease 0
of 0
the 0
sensory 0
activity 0
, 0
which 0
was 0
fully 0
restored 0
by 0
TEA 0
or 0
Ba2+ 0
. 0

Hybridization 0
of 0
a 0
probe 0
from 0
this 0
region 0
to 0
electrophoretic 0
blots 0
of 0
RNAs 0
from 0
different 0
human 0
tissues 0
showed 0
a 0
predominant 0
2.8 0
- 0
kilobase 0
( 0
kb 0
) 0
message 0
accompanied 0
by 0
weaker 0
bands 0
4.1 0
and 0
2.1 0
kb 0
in 0
size 0
. 0

Prognosis 0
of 0
asymptomatic 0
multiple 0
myeloma 0
. 0

A 0
new 0
method 0
for 0
the 0
quantitative 0
analysis 0
of 0
sleep 0
spindles 0
during 0
continuous 0
overnight 0
EEG 0
recordings 0
. 0

Svensson 0
et 0
al 0
. 0

Endogenous 0
release 0
of 0
neuronal 0
serotonin 0
and 0
5 0
- 0
hydroxyindoleacetic 0
acid 0
in 0
the 0
caudate 0
- 0
putamen 0
of 0
the 0
rat 0
as 0
revealed 0
by 0
intracerebral 0
dialysis 0
coupled 0
to 0
high 0
- 0
performance 0
liquid 0
chromatography 0
with 0
fluorimetric 0
detection 0
. 0

In 0
this 0
report 0
we 0
describe 0
for 0
the 0
first 0
time 0
the 0
complete 0
primary 0
structure 0
of 0
type B-gene
X I-gene
collagen I-gene
, 0
based 0
on 0
cloning 0
and 0
sequencing 0
of 0
cDNA 0
and 0
genomic 0
DNA 0
. 0

Viable 0
flap 0
areas 0
were 0
established 0
following 0
vascular 0
pedicle 0
ligation 0
( 0
both 0
vessels 0
or 0
only 0
artery 0
or 0
vein 0
) 0
, 0
on 0
the 0
third 0
day 0
after 0
flap 0
replantation 0
in 0
both 0
island 0
and 0
free 0
flaps 0
. 0

The 0
size 0
discrepancy 0
is 0
not 0
due 0
to 0
glycosylation 0
or 0
phosphorylation 0
of 0
Ag35 B-gene
but 0
may 0
result 0
from 0
a 0
proline 0
- 0
rich 0
sequence 0
which 0
occurs 0
in 0
this 0
polypeptide 0
. 0

A 0
9.5 0
- 0
kb 0
KpnI B-gene
- 0
SalI B-gene
fragment 0
, 0
where 0
all 0
the 0
DNA 0
changes 0
associated 0
with 0
su B-gene
( I-gene
Hw I-gene
) I-gene
mutations I-gene
were 0
mapped 0
, 0
was 0
able 0
to 0
rescue 0
the 0
su B-gene
( I-gene
Hw I-gene
) I-gene
mutant I-gene
phenotype 0
after 0
P 0
- 0
element 0
- 0
mediated 0
germ 0
- 0
line 0
transformation 0
. 0

The 0
corticosterone 0
synthesis 0
inhibitor 0
metyrapone 0
( 0
75 0
mg/kg 0
i.p 0
. 0
) 0
was 0
given 0
to 0
attenuate 0
the 0
rise 0
of 0
corticosterone 0
to 0
a 0
level 0
typical 0
of 0
stressed 0
males 0
. 0

The 0
effects 0
of 0
L655,240 0
, 0
a 0
selective 0
thromboxane 0
and 0
prostaglandin 0
endoperoxide 0
antagonist 0
, 0
on 0
ischemia 0
- 0
and 0
reperfusion 0
- 0
induced 0
cardiac 0
arrhythmias 0
. 0

In 0
10 0
pentobarbitalized 0
dogs 0
, 0
plasma 0
viscosity 0
( 0
Ep 0
) 0
was 0
raised 0
fourfold 0
while 0
apparent 0
blood 0
viscosity 0
( 0
Ea 0
) 0
increased 0
about 0
twofold 0
by 0
two 0
steps 0
of 0
exchange 0
transfusion 0
of 0
200 0
ml 0
of 0
plasma 0
with 0
plasma 0
containing 0
high 0
molecular 0
weight 0
dextran 0
( 0
mol 0
wt 0
500,000 0
, 0
20 0
% 0
wt/vol 0
) 0
. 0

The 0
small B-gene
IGF I-gene
- I-gene
binding I-gene
protein I-gene
is 0
abundant 0
in 0
human 0
amniotic 0
fluid 0
. 0

Serum 0
prostatic B-gene
acid I-gene
phosphatase I-gene
levels 0
showed 0
a 0
significantly 0
weaker 0
correlation 0
with 0
cancer 0
volume 0
( 0
r 0
equals 0
0.51 0
) 0
and 0
every 0
other 0
pathological 0
parameter 0
. 0

The 0
investigation 0
was 0
thereafter 0
continued 0
in 0
an 0
open 0
fashion 0
by 0
administering 0
a 0
single 0
10 0
mg 0
dose 0
of 0
the 0
MAO B-gene
- I-gene
B I-gene
inhibitor 0
deprenyl 0
to 0
the 0
same 0
subjects 0
. 0

Their 0
studies 0
have 0
revealed 0
a 0
considerable 0
increase 0
of 0
CSF B-gene
AP I-gene
activity 0
in 0
purulent 0
meningitides 0
whereas 0
in 0
serous 0
meningitides 0
it 0
grows 0
negligibly 0
. 0

A 0
cDNA 0
encoding 0
a 0
new 0
human 0
lymphocyte 0
cell 0
surface 0
molecule 0
has 0
been 0
isolated 0
and 0
shown 0
to 0
identify 0
a 0
fourth 0
member 0
of 0
a 0
recently 0
discovered 0
family 0
of 0
adhesion 0
proteins 0
. 0

Dopamine 0
caused 0
a 0
prominent 0
potassium 0
efflux 0
measured 0
as 0
86Rb+ 0
efflux 0
from 0
control 0
glands 0
, 0
but 0
was 0
without 0
effect 0
in 0
denervated 0
glands 0
. 0

Spontaneous 0
sensitization 0
to 0
cross 0
- 0
reacting 0
chemicals 0
in 0
a 0
proportion 0
of 0
control 0
animals 0
is 0
strongly 0
suggested 0
, 0
somewhat 0
akin 0
to 0
spontaneous 0
sensitization 0
in 0
patients 0
with 0
anaphylactoid 0
reactions 0
to 0
neuromuscular 0
blockers 0
on 0
first 0
exposure 0
, 0
and 0
in 0
whom 0
IgE B-gene
antibodies I-gene
are 0
detected 0
. 0

This 0
approach 0
was 0
examined 0
utilizing 0
the 0
fetal 0
protein 0
, 0
HGB B-gene
F I-gene
. 0

The 0
investigation 0
was 0
apt 0
at 0
studying 0
the 0
relationship 0
between 0
urinary 0
metabolites 0
of 0
serotonin 0
and 0
catecholamine 0
( 0
5 0
- 0
HIAA 0
and 0
VMA 0
) 0
, 0
T 0
- 0
cells 0
( 0
OKT3+ B-gene
) 0
, 0
T 0
- 0
helper 0
( 0
OKT4+ B-gene
) 0
, 0
T 0
- 0
suppressor 0
( 0
OKT8+ B-gene
) 0
and 0
B 0
- 0
cells 0
( 0
EAC 0
- 0
rosette 0
forming 0
cells 0
) 0
in 0
normal 0
( 0
10 0
subjects 0
, 0
1 0
female 0
, 0
9 0
male 0
, 0
age 0
21 0
+/ 0
- 0
5 0
years 0
) 0
and 0
stress 0
administered 0
subjects 0
( 0
20 0
subjects 0
, 0
3 0
female 0
, 0
17 0
male 0
, 0
age 0
20 0
+/ 0
- 0
4 0
years 0
) 0
. 0

The 0
84.1C B-gene
mAb I-gene
recognizes 0
a 0
site 0
on 0
IgE B-gene
which 0
is 0
identical 0
or 0
very 0
close 0
to 0
the 0
Fc B-gene
epsilon I-gene
R I-gene
binding I-gene
site I-gene
, 0
and 0
95.3 0
recognizes 0
a 0
site 0
on 0
IgE B-gene
which 0
is 0
related 0
, 0
but 0
not 0
identical 0
to 0
the 0
Fc B-gene
epsilon I-gene
R I-gene
binding I-gene
site I-gene
. 0

Their 0
hydropathic 0
plots 0
are 0
very 0
similar 0
and 0
both 0
possess 0
three 0
hydrophobic 0
segments 0
that 0
are 0
likely 0
alpha 0
- 0
helical 0
transmembrane 0
segments 0
. 0

Angiotensin B-gene
converting I-gene
enzyme I-gene
inhibitors 0
enhance 0
the 0
antihypertensive 0
efficacy 0
of 0
diuretics 0
and 0
blunt 0
or 0
prevent 0
adverse 0
metabolic 0
effects 0
. 0

In 0
addition 0
to 0
the 0
significant 0
reduction 0
in 0
blood 0
pressure 0
, 0
the 0
angiotensin B-gene
converting I-gene
enzyme I-gene
( 0
ACE B-gene
) 0
inhibitor 0
ramipril 0
caused 0
a 0
significant 0
regression 0
of 0
pathologic 0
left 0
ventricular 0
hypertrophy 0
demonstrated 0
by 0
magnetic 0
resonance 0
imaging 0
and 0
echocardiography 0
. 0

Endocrine 0
cells 0
were 0
studied 0
by 0
means 0
of 0
Grimelius 0
' 0
silver 0
staining 0
and 0
immunostaining 0
for 0
chromogranin B-gene
, 0
a 0
general 0
marker 0
of 0
endocrine 0
cells 0
. 0

The 0
ratio 0
of 0
radioactivity 0
in 0
tumour 0
compared 0
with 0
normal 0
tissue 0
( 0
T 0
: 0
N 0
ratio 0
) 0
was 0
determined 0
after 0
simultaneously 0
injecting 0
microspheres 0
into 0
the 0
portal 0
and 0
arterial 0
circulation 0
of 0
each 0
animal 0
. 0

The 0
mRNA 0
was 0
converted 0
to 0
cDNA 0
and 0
amplified 0
by 0
the 0
polymerase 0
chain 0
reaction 0
technique 0
. 0

Tissue 0
necrosis 0
was 0
evaluated 0
using 0
triphenyltetrazolium 0
staining 0
and 0
was 0
related 0
to 0
two 0
major 0
baseline 0
predictors 0
of 0
infarct 0
size 0
: 0
anatomic 0
risk 0
zone 0
size 0
and 0
coronary 0
collateral 0
flow 0
. 0

To 0
study 0
the 0
retinal 0
surface 0
in 0
the 0
human 0
eye 0
in 0
normal 0
and 0
diseased 0
states 0
we 0
used 0
laser 0
scanning 0
tomography 0
. 0

Previously 0
, 0
we 0
reported 0
the 0
sequence 0
of 0
the 0
gene B-gene
encoding I-gene
human I-gene
K14 I-gene
( 0
D 0
. 0

A 0
potential 0
TATA 0
box 0
is 0
located 0
29 0
base 0
pairs 0
upstream 0
of 0
the 0
first 0
transcription 0
initiation 0
site 0
. 0

Cotransfection 0
of 0
either 0
construct 0
with 0
plasmids 0
encoding 0
PKI B-gene
( I-gene
1 I-gene
- I-gene
31 I-gene
) I-gene
inhibits 0
cAMP 0
- 0
stimulated 0
but 0
not 0
basal 0
- 0
or 0
phorbol 0
ester 0
- 0
stimulated 0
expression 0
. 0

Sequence 0
analysis 0
of 0
the 0
5 0
' 0
flanking 0
region 0
revealed 0
several 0
GC 0
boxes 0
but 0
no 0
identifiable 0
TATA 0
box 0
. 0

The 0
underlying 0
cirrhosis 0
was 0
alcoholic 0
in 0
11 0
( 0
53.3 0
% 0
) 0
, 0
cryptogenic 0
in 0
5 0
( 0
23.8 0
% 0
) 0
, 0
and 0
hepatitis 0
B 0
chronic 0
infection 0
related 0
in 0
5 0
( 0
23.8 0
% 0
) 0
. 0

Once 0
P B-gene
- I-gene
450scc I-gene
mRNA I-gene
is 0
induced 0
as 0
a 0
consequence 0
of 0
the 0
LH/hCG B-gene
surge 0
it 0
is 0
constitutively 0
maintained 0
by 0
luteinized 0
cells 0
in 0
vivo 0
( 0
0 0
- 0
4 0
days 0
) 0
and 0
in 0
vitro 0
( 0
0 0
- 0
9 0
days 0
) 0
in 0
the 0
absence 0
of 0
LH/hCG I-gene

Similarly 0
, 0
a 0
human 0
but 0
not 0
a 0
bovine B-gene
alpha I-gene
transgene I-gene
was 0
expressed 0
in 0
placenta 0
in 0
transgenic 0
mice 0
. 0

A 0
rapid 0
staining 0
technique 0
for 0
Leishmania 0
parasites 0
in 0
splenic 0
aspirate 0
smears 0
. 0

NIK 0
- 0
244 0
suppressed 0
coronary 0
ligation 0
- 0
and 0
digitalis 0
- 0
induced 0
arrhythmias 0
, 0
and 0
the 0
minimum 0
effective 0
plasma 0
concentrations 0
for 0
arrhythmias 0
induced 0
by 0
24 0
- 0
h 0
and 0
48 0
- 0
h 0
coronary 0
ligation 0
and 0
digitalis 0
were 0
0.41 0
+/ 0
- 0
0.10 0
( 0
by 0
1 0
mg/kg 0
i.v 0
. 0
) 0
, 0
0.70 0
+/ 0
- 0
0.13 0
( 0
by 0
1 0
mg/kg 0
i.v 0
. 0
) 0
, 0
and 0
0.21 0
+/ 0
- 0
0.08 0
( 0
by 0
0.5 0
mg/kg 0
i.v 0
. 0
) 0
microgram/ml 0
, 0
respectively 0
( 0
mean 0
+/ 0
- 0
SD 0
of 0
the 0
mean 0
, 0
n 0
= 0
6 0
) 0
. 0

In 0
TNF B-gene
- 0
resistant 0
T24 0
bladder 0
carcinoma 0
cells 0
, 0
TNF B-gene
failed 0
to 0
alter 0
EGF B-gene
- I-gene
R I-gene
tyrosine B-gene
protein I-gene
kinase I-gene
activity 0
although 0
both 0
EGF B-gene
and 0
phorbol 0
ester 0
were 0
shown 0
to 0
modulate 0
the 0
enzymatic 0
activity 0
of 0
the 0
receptor 0
in 0
these 0
cells 0
. 0

Thus 0
, 0
phosphodiesterase 0
inhibitors 0
that 0
produce 0
an 0
opiate 0
quasi 0
- 0
withdrawal 0
syndrome 0
potentiate 0
interoceptive 0
stimuli 0
and 0
weight 0
loss 0
associated 0
with 0
the 0
withdrawal 0
syndrome 0
precipitated 0
by 0
naltrexone 0
in 0
morphine 0
- 0
dependent 0
rats 0
. 0

The 0
diagnostic 0
value 0
of 0
blood 0
serum 0
and 0
urinary B-gene
amylase I-gene
, 0
lipase B-gene
, 0
and 0
trypsin B-gene
in 0
exacerbations 0
of 0
chronic 0
relapsing 0
pancreatitis 0
is 0
discussed 0
. 0

On 0
the 0
basis 0
of 0
the 0
mechanism 0
of 0
action 0
, 0
two 0
groups 0
of 0
inodilators 0
are 0
distinguished 0
, 0
the 0
phosphodiesterase 0
inhibitors 0
and 0
the 0
dopaminergic 0
agents 0
. 0

Structural 0
organization 0
and 0
expression 0
of 0
the 0
mouse B-gene
estrogen I-gene
receptor I-gene
. 0

Intravenous 0
gamma B-gene
globulins I-gene

Following 0
chondroitinase B-gene
AC I-gene
and I-gene
ABC I-gene
digestion 0
, 0
staining 0
reactions 0
suggested 0
that 0
the 0
highest 0
levels 0
of 0
dermatan 0
sulfate 0
were 0
in 0
the 0
diabetes 0
resistant 0
group 0
( 0
p 0
less 0
than 0
0.001 0
compared 0
to 0
diabetic 0
, 0
p 0
less 0
than 0
0.001 0
compared 0
to 0
diabetes 0
prone 0
) 0
and 0
the 0
highest 0
levels 0
of 0
chondroitin 0
sulfates 0
were 0
in 0
the 0
diabetes 0
prone 0
group 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Myocardial 0
perfusion 0
was 0
evaluated 0
using 0
the 0
enhanced 0
gray 0
level 0
after 0
contrast 0
injection 0
, 0
and 0
the 0
level 0
was 0
compared 0
with 0
the 0
morphology 0
and 0
degree 0
of 0
collateral 0
development 0
. 0

Once 0
NGF B-gene
administration 0
is 0
proven 0
effective 0
it 0
will 0
be 0
possible 0
to 0
develop 0
alternative 0
ways 0
of 0
NGF B-gene
administration 0
. 0

During 0
the 0
program 0
's 0
use 0
at 0
the 0
RSNA 0
meeting 0
, 0
the 0
program 0
selected 0
the 0
correct 0
diagnosis 0
in 0
the 0
top 0
five 0
22 0
% 0
of 0
the 0
time 0
. 0

Immunoglobulin B-gene
light I-gene
chain I-gene
( 0
IgL B-gene
) 0
diversity 0
is 0
generated 0
in 0
the 0
chicken 0
by 0
recombination 0
between 0
the 0
single 0
functional 0
variable 0
( 0
VL B-gene
) 0
and 0
joining 0
( 0
JL B-gene
) 0
gene 0
segments 0
and 0
subsequent 0
somatic 0
diversification 0
of 0
the 0
rearranged 0
VL B-gene
region 0
. 0

The 0
results 0
were 0
as 0
follows 0
: 0
1 0
) 0
Total 0
integrated 0
EMG 0
activity 0
of 0
FB 0
group 0
was 0
approximately 0
equal 0
in 0
any 0
occluded 0
position 0
, 0
whereas 0
that 0
of 0
CG 0
and 0
GF 0
group 0
varied 0
from 0
position 0
to 0
position 0
. 0

Muscle 0
action 0
potential 0
and 0
masticatory 0
rhythm 0
of 0
anterior 0
temporal 0
and 0
masseter 0
muscles 0
in 0
children 0
and 0
adults 0

In 0
76 0
% 0
of 0
59 0
lead 0
- 0
toxic 0
children 0
, 0
bone 0
lead 0
values 0
measured 0
by 0
LXRF 0
were 0
equal 0
to 0
or 0
greater 0
than 0
those 0
measured 0
in 0
normal 0
and 0
industrially 0
exposed 0
adults 0
. 0

When 0
considered 0
with 0
the 0
known 0
neurotoxic 0
effects 0
on 0
children 0
of 0
`` 0
low 0
levels 0
'' 0
of 0
exposure 0
to 0
lead 0
, 0
these 0
results 0
also 0
suggest 0
that 0
either 0
an 0
excessively 0
narrow 0
margin 0
of 0
safety 0
or 0
insufficient 0
safety 0
is 0
provided 0
by 0
present 0
U.S. 0
guidelines 0
, 0
which 0
classify 0
an 0
elevated 0
blood 0
lead 0
concentration 0
as 0
25 0
micrograms/dl 0
or 0
greater 0
. 0

In 0
resting 0
3T3 0
cells 0
, 0
jun B-gene
- I-gene
D I-gene
is 0
expressed 0
at 0
a 0
higher 0
level 0
compared 0
to 0
c B-gene
- I-gene
jun I-gene
and 0
jun B-gene
- I-gene
B I-gene
, 0
and 0
its 0
transcription 0
is 0
stimulated 0
only 0
slightly 0
by 0
serum 0
growth 0
factors 0
. 0

The 0
thrombolytic 0
effects 0
of 0
native 0
tissue B-gene
- I-gene
type I-gene
plasminogen I-gene
activator I-gene
( 0
AK B-gene
- I-gene
124 I-gene
) 0
on 0
experimental 0
canine 0
coronary 0
thrombosis 0
. 0

O2 0
and 0
CO2 0
in 0
the 0
tracheostomy 0
tube 0
were 0
continuously 0
monitored 0
by 0
mass 0
spectrometry 0
using 0
a 0
special 0
sample 0
- 0
hold 0
phase 0
- 0
locked 0
sampling 0
technique 0
. 0

Enzyme 0
- 0
linked 0
immunosorbent 0
assay 0
for 0
screening 0
aflatoxin 0
B1 0
in 0
cottonseed 0
products 0
and 0
mixed 0
feed 0
: 0
collaborative 0
study 0
. 0

However 0
, 0
experiments 0
with 0
S1 B-gene
mapping 0
of 0
in 0
vivo 0
transcripts 0
, 0
gene 0
disruptions 0
in 0
the 0
alpha 0
region 0
, 0
and 0
a 0
single 0
- 0
copy 0
transcriptional 0
fusion 0
vector 0
all 0
suggested 0
that 0
these 0
possible 0
promoters 0
were 0
largely 0
inactive 0
during 0
logarithmic 0
growth 0
, 0
that 0
the 0
major 0
promoter 0
for 0
the 0
alpha 0
operon 0
lay 0
upstream 0
from 0
the 0
region 0
cloned 0
, 0
and 0
that 0
the 0
genes 0
in 0
the 0
IF1 B-gene
to 0
L17 B-gene
interval 0
were 0
cotranscribed 0
. 0

Functional 0
rearranged 0
antibody 0
genes 0
were 0
detected 0
with 0
JH B-gene
and 0
VH B-gene
heavy I-gene
chain I-gene
probes 0
and 0
with 0
Jk B-gene
and 0
Vk B-gene
light I-gene
chain I-gene
probes 0
. 0

Two 0
specific 0
DNA 0
- 0
protein 0
complexes 0
were 0
identified 0
in 0
gel 0
retardation 0
assays 0
using 0
HeLa 0
cell 0
nuclear 0
extracts 0
and 0
an 0
oligonucleotide 0
probe 0
spanning 0
the 0
footprinted 0
region 0
. 0

After 0
transfection 0
, 0
specific 0
TSH B-gene
beta I-gene
promoter I-gene
activity 0
was 0
evident 0
in 0
both 0
TRH B-gene
- 0
responsive 0
pituitary 0
- 0
derived 0
GH3 0
and 0
primary 0
pituitary 0
cell 0
cultures 0
. 0

In 0
transformed 0
E. 0
coli 0
, 0
constitutive B-gene
CAT I-gene
expression 0
is 0
maintained 0
when 0
as 0
little 0
as 0
0.3 0
kilobase 0
of 0
DNA 0
from 0
the 0
3 0
' 0
end 0
of 0
the 0
1.6 0
- 0
kilobase 0
segment 0
is 0
inserted 0
in 0
the 0
correct 0
orientation 0
in 0
front 0
of 0
the 0
CAT B-gene
gene I-gene
. 0

Lowering 0
of 0
the 0
renal 0
blood 0
flow 0
alters 0
the 0
glomerular 0
and 0
tubular 0
excretion 0
processes 0
. 0

Tonometry 0
of 0
blood 0
samples 0
from 0
patients 0
may 0
also 0
be 0
used 0
in 0
the 0
determination 0
of 0
acid 0
- 0
base 0
quantities 0
and 0
hemoglobin B-gene
- 0
oxygen 0
affinity 0
e.g 0
. 0
p50 0
. 0

100 0
and 0
14 0
p 0
. 0

Isolation 0
of 0
Weeksella 0
virosa 0
( 0
formerly 0
CDC 0
group 0
IIf 0
) 0
from 0
a 0
vaginal 0
sample 0
. 0

Here 0
, 0
we 0
alter 0
the 0
dimerization 0
specificity 0
of 0
Fos B-gene
by 0
precisely 0
replacing 0
its 0
leucine 0
zipper 0
with 0
that 0
from 0
GCN4 B-gene
. 0

Growth 0
of 0
tracheal 0
anastomoses 0
in 0
growing 0
animals 0

Fourth 0
, 0
sometime 0
between 0
4 0
and 0
24 0
hours 0
of 0
recovery 0
is 0
necessary 0
to 0
reverse 0
the 0
effect 0
of 0
chronic 0
hypoxia 0
on 0
cerebral 0
blood 0
flow 0
. 0

The 0
ORF1 0
product 0
was 0
required 0
for 0
competence 0
, 0
while 0
ORF2 0
, 0
which 0
was 0
cotranscribed 0
with 0
ORF1 0
and 0
encoded 0
a 0
predicted 0
protein 0
of 0
126 0
amino 0
acids 0
, 0
was 0
not 0
. 0

Kindling 0
of 0
the 0
primary 0
visual 0
cortex 0
( 0
VC 0
) 0
was 0
compared 0
with 0
that 0
of 0
the 0
amygdala 0
in 0
cats 0
. 0

Abundant 0
infiltration 0
of 0
lymphocytes 0
and 0
plasma 0
cells 0
was 0
also 0
wide 0
- 0
spread 0
beneath 0
the 0
carcinoma 0
in 0
situ 0
, 0
together 0
with 0
the 0
lymphoid 0
follicles 0
. 0

These 0
case 0
reports 0
provide 0
further 0
evidence 0
that 0
LiCO3 0
can 0
be 0
a 0
useful 0
medication 0
in 0
the 0
treatment 0
of 0
aggressive 0
behavior 0
and 0
affective 0
instability 0
after 0
brain 0
injury 0
, 0
but 0
that 0
it 0
has 0
significant 0
potential 0
for 0
neurotoxicity 0
in 0
this 0
population 0
, 0
particularly 0
when 0
used 0
in 0
conjunction 0
with 0
neuroleptic 0
agents 0
. 0

In 0
all 0
sessions 0
under 0
IFN B-gene
, 0
the 0
latency 0
of 0
the 0
P100 0
component 0
of 0
the 0
VEP 0
was 0
shortened 0
as 0
compared 0
to 0
baseline 0
conditions 0
. 0

Among 0
100 0
cases 0
of 0
post 0
- 0
transfusion 0
hepatitis 0
, 0
10 0
are 0
due 0
to 0
the 0
hepatitis 0
B 0
virus 0
( 0
despite 0
systematic 0
search 0
for 0
HBs B-gene
Ag I-gene
) 0
, 0
89 0
are 0
due 0
to 0
one 0
of 0
the 0
non 0
- 0
A 0
non 0
- 0
B 0
viruses 0
( 0
not 0
detectable 0
by 0
specific 0
serological 0
tests 0
) 0
and 0
1 0
to 0
several 0
viruses 0
, 0
specially 0
CMV 0
. 0

Recessive 0
lethal 0
mutations 0
were 0
isolated 0
based 0
upon 0
failure 0
to 0
complement 0
the 0
recessive 0
lethality 0
of 0
Df 0
( 0
3L 0
) 0
RR2 0
, 0
a 0
deletion 0
of 0
the 0
DRE 0
region 0
that 0
removes 0
16 0
- 0
18 0
polytene 0
chromosome 0
bands 0
. 0

Current 0
status 0
and 0
future 0
perspectives 0

K 0
. 0

A 0
215 0
- 0
base 0
- 0
pair 0
( 0
bp 0
) 0
region 0
of 0
the 0
mouse B-gene
MOPC I-gene
41 I-gene
kappa I-gene
light I-gene
- I-gene
chain I-gene
immunoglobulin I-gene
gene I-gene
enhancer I-gene
has 0
been 0
analyzed 0
for 0
specific 0
binding 0
of 0
lymphoid 0
and 0
nonlymphoid 0
nuclear 0
factors 0
. 0

This 0
paper 0
presents 0
the 0
reasons 0
why 0
countries 0
to 0
which 0
Chagas 0
disease 0
is 0
endemic 0
should 0
carry 0
out 0
the 0
relevant 0
research 0
themselves 0
. 0

The 0
PETCO2 0
measurement 0
during 0
precordial 0
compression 0
predicted 0
the 0
success 0
of 0
defibrillation 0
with 0
return 0
of 0
spontaneous 0
circulation 0
. 0

Gastric 0
CO2/HCO3 0
was 0
determined 0
in 0
absence 0
of 0
simultaneous 0
inhibition 0
of 0
acid 0
secretion 0
by 0
intra 0
- 0
and 0
extragastric 0
pCO2/pH 0
measurements 0
in 0
23 0
persons 0
and 0
calculated 0
using 0
the 0
equation 0
of 0
Henderson 0
- 0
Hasselbalch 0
. 0
pCO2 0
was 0
measured 0
with 0
use 0
of 0
a 0
new 0
electrode 0
. 0

Follow 0
- 0
up 0
study 0
showed 0
85 0
% 0
of 0
these 0
patients 0
with 0
effectiveness 0
. 0

The 0
other 0
patients 0
continued 0
the 0
trial 0
with 0
single 0
daily 0
doses 0
of 0
monotherapy 0
. 0

Neonatal 0
Chagas 0
disease 0
: 0
laboratory 0
diagnosis 0
during 0
the 0
first 0
year 0
of 0
life 0

Using 0
mutated B-gene
IL2R I-gene
alpha I-gene
promoter I-gene
constructs I-gene
in 0
transient 0
transfection 0
and 0
DNA 0
binding 0
assays 0
, 0
we 0
now 0
demonstrate 0
that 0
sequences 0
located 0
immediately 0
upstream 0
and 0
downstream 0
of 0
the 0
kappa B-gene
B I-gene
enhancer I-gene
also 0
contribute 0
to 0
the 0
regulation 0
of 0
IL2R B-gene
alpha I-gene
gene I-gene
expression 0
. 0

Palindromic 0
rheumatism 0

Inefficacy 0
of 0
phosphine 0
fumigation 0
against 0
ticks 0
. 0

Forty 0
patients 0
, 0
divided 0
according 0
to 0
their 0
initial 0
total 0
gastrointestinal 0
transit 0
times 0
and 0
presenting 0
symptoms 0
, 0
were 0
treated 0
with 0
cimetropium 0
bromide 0
50 0
mg 0
t.d.s 0
. 0
or 0
placebo 0
for 0
1 0
month 0
according 0
to 0
a 0
double 0
- 0
blind 0
, 0
parallel 0
group 0
design 0
. 0

An 0
immunologically 0
related 0
protein 0
was 0
detected 0
in 0
ribosome 0
and 0
membrane 0
fractions 0
of 0
mitochondria 0
from 0
Saccharomyces 0
cerevisiae 0
. 0

Mapping 0
of 0
RNA 0
- 0
temperature B-gene
- I-gene
sensitive I-gene
mutants I-gene
of I-gene
Sindbis I-gene
virus I-gene
: I-gene
complementation I-gene
group I-gene
F I-gene
mutants I-gene
have 0
lesions 0
in 0
nsP4 B-gene
. 0

The 0
effect 0
of 0
the 0
thromboxane B-gene
A2 I-gene
( I-gene
TXA2 I-gene
) I-gene
/prostaglandin I-gene
endoperoxide I-gene
receptor I-gene
antagonist 0
, 0
SQ 0
29,548 0
on 0
pacing 0
- 0
induced 0
ischemia 0
was 0
determined 0
in 0
anesthetized 0
open 0
- 0
chest 0
dogs 0
. 0

According 0
to 0
the 0
published 0
sequence 0
of 0
the 0
CHS1 B-gene
gene I-gene
, 0
this 0
fragment 0
contains 0
four 0
repeats 0
of 0
a 0
TGAAACA 0
consensus 0
sequence 0
previously 0
identified 0
in 0
the 0
alpha B-gene
- I-gene
factor I-gene
- 0
inducible 0
BAR1 B-gene
promoter I-gene
[ 0
Kronstad 0
, 0
J 0
. 0

The 0
recovery 0
index 0
( 0
T25 0
- 0
T75 0
) 0
after 0
the 0
infusion 0
stopped 0
was 0
similar 0
in 0
patients 0
who 0
received 0
mivacurium 0
and 0
those 0
who 0
received 0
suxamethonium 0
. 0

The 0
sign 0
of 0
Leser 0
- 0
Trelat 0
: 0
does 0
it 0
exist 0
? 0
The 0
sign 0
of 0
Leser 0
- 0
Trelat 0
is 0
usually 0
regarded 0
as 0
a 0
reliable 0
cutaneous 0
marker 0
of 0
internal 0
malignancy 0
. 0

Xenopus B-gene
homolog I-gene
of I-gene
the I-gene
mos I-gene
protooncogene I-gene
transforms 0
mammalian 0
fibroblasts 0
and 0
induces 0
maturation 0
of 0
Xenopus 0
oocytes 0
. 0

Southern 0
blot 0
analyses 0
demonstrated 0
a 0
low 0
, 0
if 0
not 0
single 0
, 0
copy 0
number 0
for 0
this 0
gene 0
and 0
conservation 0
of 0
this 0
domain 0
in 0
other 0
vertebrates 0
. 0

Three 0
missense 0
mutants 0
in 0
subunit 0
a 0
of 0
the 0
Escherichia B-gene
coli I-gene
F1F0 I-gene
- I-gene
ATPase I-gene
were 0
isolated 0
and 0
characterized 0
after 0
hydroxylamine 0
mutagenesis 0
of 0
a 0
plasmid 0
carrying 0
the 0
uncB B-gene
( I-gene
subunit I-gene
a I-gene
) I-gene
gene I-gene
. 0

Moreover 0
, 0
exons 0
2a 0
and 0
2b 0
share 0
the 0
same 0
5 0
' 0
sequence 0
but 0
differ 0
from 0
each 0
other 0
by 0
the 0
use 0
of 0
two 0
distinct 0
donor 0
splice 0
sites 0
171 0
bp 0
apart 0
in 0
the 0
gene 0
. 0

S1 B-gene
nuclease I-gene
analysis 0
of 0
RNA 0
prepared 0
after 0
transfection 0
of 0
these 0
HIV 0
constructs 0
into 0
HeLa 0
cells 0
infected 0
with 0
wild 0
- 0
type 0
adenovirus 0
indicated 0
that 0
the 0
enhancer 0
, 0
SP1 B-gene
, 0
TATA 0
, 0
and 0
a 0
portion 0
of 0
the 0
transactivation 0
- 0
responsive 0
element 0
were 0
each 0
required 0
for 0
complete 0
E1A/E1B B-gene
- 0
mediated 0
activation 0
of 0
the 0
E1A/E1B I-gene

In 0
supine 0
position 0
, 0
plasma 0
ANP B-gene
levels 0
ranged 0
from 0
12 0
pg/ml 0
to 0
51.5 0
pg/ml 0
, 0
with 0
an 0
average 0
level 0
of 0
35.3 0
+/ 0
- 0
11.5 0
pg/ml 0
. 0

The 0
overall 0
prevalence 0
of 0
HBV 0
markers 0
was 0
higher 0
among 0
staff 0
members 0
than 0
in 0
the 0
blood 0
donors 0
of 0
our 0
area 0
. 0

Quantitative 0
predictions 0
are 0
confirmed 0
for 0
the 0
positive 0
responses 0
, 0
but 0
not 0
for 0
the 0
negatives 0
, 0
suggesting 0
that 0
the 0
SSTS 0
model 0
is 0
incorrect 0
. 0

Plasma 0
concentrations 0
of 0
ANF B-gene
( 0
pANF B-gene
) 0
, 0
aldosterone 0
( 0
PAC 0
) 0
and 0
renin B-gene
( 0
PRC B-gene
) 0
were 0
measured 0
daily 0
, 0
as 0
were 0
hemodynamic 0
parameters 0
. 0

The 0
adenovirus B-gene
E1A I-gene
gene I-gene
encodes 0
a 0
protein 0
that 0
transcriptionally 0
activates 0
viral B-gene
early I-gene
genes I-gene
. 0

Administration 0
of 0
dexamethasone 0
was 0
associated 0
with 0
progressive 0
rises 0
in 0
plasma 0
17 0
alpha 0
OH 0
progesterone 0
, 0
11 0
beta 0
- 0
desoxycortisol 0
, 0
DHEA 0
sulphate 0
, 0
androstenedione 0
and 0
testosterone 0
, 0
together 0
with 0
increased 0
urinary 0
excretion 0
of 0
androsterone 0
, 0
11 0
beta 0
OH 0
androsterone 0
, 0
etiocholanolone 0
, 0
DHEA 0
, 0
and 0
16 0
alpha 0
OH 0
DHEA 0
. 0

RNA 0
transcripts 0
that 0
hybridize 0
to 0
the 0
introduced 0
foreign 0
gene 0
have 0
been 0
identified 0
. 0

In 0
HeLa 0
cells 0
, 0
it 0
activated 0
transcription 0
from 0
the 0
herpes B-gene
simplex I-gene
virus I-gene
type I-gene
1 I-gene
thymidine I-gene
kinase I-gene
promoter I-gene
linked 0
to 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
gene I-gene
when 0
located 0
in 0
inverted 0
orientation 0
upstream 0
of 0
the 0
thymidine B-gene
kinase I-gene
promoter I-gene
or 0
downstream 0
of 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
gene I-gene
coding I-gene
sequence I-gene
. 0

At 0
the 0
basal 0
unstimulated 0
condition 0
, 0
Ren1d B-gene
5 I-gene
' I-gene
flanking I-gene
sequence I-gene
in 0
the 0
sense 0
orientation 0
inhibited 0
basal 0
CAT B-gene
expression 0
from 0
the 0
TK B-gene
promoter I-gene
of 0
pUTKAT1 0
, 0
whereas 0
the 0
same 0
sequence 0
in 0
the 0
antisense 0
orientation 0
did 0
not 0
. 0

None 0
were 0
restricted 0
from 0
clinical 0
duties 0
, 0
were 0
given 0
varicella B-gene
- I-gene
zoster I-gene
immune I-gene
globulin I-gene
, 0
or 0
developed 0
disease 0
. 0

In 0
the 0
formalin 0
test 0
, 0
however 0
, 0
naloxone 0
attenuated 0
morphine 0
analgesia 0
at 0
the 0
lower 0
doses 0
( 0
0.1 0
and 0
0.3 0
mg/kg 0
) 0
and 0
potentiated 0
morphine 0
analgesia 0
at 0
the 0
highest 0
dose 0
( 0
10 0
mg/kg 0
) 0
. 0

We 0
have 0
isolated 0
cDNA 0
clones 0
from 0
rat 0
brain 0
and 0
human 0
liver 0
encoding 0
a 0
putative 0
isoform 0
of 0
the 0
Na B-gene
, I-gene
K I-gene
- I-gene
ATPase I-gene
beta I-gene
subunit I-gene
. 0

We 0
have 0
determined 0
that 0
several 0
E1 B-gene
mutants I-gene
mapping 0
in 0
both 0
the 0
M 0
and 0
R 0
regions 0
and 0
a 0
single 0
mutant 0
of 0
the 0
upstream 0
regulatory 0
region 0
have 0
a 0
higher 0
transforming 0
activity 0
on 0
mouse 0
C127 0
cells 0
than 0
the 0
wild 0
- 0
type 0
genome 0
does 0
. 0

UbiA B-gene
is 0
also 0
unique 0
among 0
known 0
polyubiquitin B-gene
genes I-gene
in 0
containing 0
four 0
cis 0
- 0
spliced 0
introns 0
within 0
its 0
coding 0
sequence 0
. 0

That 0
of 0
the 0
T2 B-gene
gene I-gene
contains 0
numerous 0
potential 0
sites 0
for 0
binding 0
the 0
mammalian B-gene
transcription I-gene
factor I-gene
SP1 I-gene
, 0
but 0
no 0
TATA 0
or 0
CCAAT 0
sequences 0
are 0
evident 0
near 0
to 0
its 0
5 0
' 0
end 0
, 0
although 0
these 0
latter 0
features 0
are 0
associated 0
with 0
the 0
human B-gene
T1 I-gene
gene I-gene
. 0

Radiation 0
therapy 0
was 0
effective 0
in 0
controlling 0
symptomatic 0
metastasis 0
in 0
all 0
three 0
patients 0
. 0

These 0
results 0
indicate 0
that 0
patients 0
who 0
undergo 0
postoperative 0
irradiation 0
for 0
low 0
grade 0
spinal 0
astrocytomas 0
and 0
localized 0
spinal 0
ependymomas 0
achieve 0
excellent 0
survival 0
. 0

The 0
methylation 0
of 0
nuclear 0
and 0
chloroplast 0
DNAs 0
has 0
been 0
examined 0
in 0
relation 0
to 0
the 0
known 0
differential 0
expression 0
of 0
C4 B-gene
photosynthesis I-gene
genes I-gene
in 0
the 0
bundle 0
sheath 0
and 0
mesophyll 0
cells 0
of 0
etiolated 0
, 0
greening 0
, 0
and 0
fully 0
green 0
maize 0
leaves 0
. 0

S1 B-gene
nuclease I-gene
analysis 0
of 0
RNA 0
from 0
chemically 0
induced 0
B95 0
- 0
8 0
cells 0
and 0
from 0
Vero 0
cells 0
cotransfected 0
with 0
NotI B-gene
repeat I-gene
promoter I-gene
- 0
CAT B-gene
and 0
Z B-gene
showed 0
that 0
Z B-gene
transactivation 0
increased 0
the 0
level 0
of 0
correctly 0
initiated 0
, 0
stable 0
RNA 0
transcripts 0
. 0

We 0
conclude 0
that 0
( 0
a 0
) 0
the 0
likelihood 0
of 0
detecting 0
carcinoma 0
or 0
atypical 0
hyperplasia 0
exclusively 0
in 0
the 0
adipose 0
tissue 0
component 0
of 0
grossly 0
benign 0
breast 0
biopsies 0
is 0
extremely 0
low 0
, 0
and 0
( 0
b 0
) 0
a 0
possible 0
cost 0
- 0
effective 0
method 0
of 0
sampling 0
grossly 0
benign 0
breast 0
biopsies 0
consists 0
of 0
initially 0
submitting 0
a 0
maximum 0
of 0
10 0
blocks 0
of 0
fibrous 0
parenchyma 0
for 0
each 0
case 0
, 0
then 0
examining 0
the 0
remaining 0
tissue 0
histologically 0
only 0
if 0
carcinoma 0
or 0
atypical 0
hyperplasia 0
is 0
found 0
among 0
these 0
blocks 0
. 0

Analysis 0
of 0
the 0
DNA 0
from 0
15 0
cases 0
of 0
sporadic 0
and 0
familial 0
Wilms 0
' 0
tumor 0
did 0
not 0
reveal 0
any 0
changes 0
, 0
indicating 0
that 0
the 0
translocation 0
breakpoint 0
does 0
not 0
reside 0
in 0
this 0
gene 0
. 0

We 0
also 0
provide 0
evidence 0
that 0
neither 0
the 0
lambda B-gene
O I-gene
and 0
P B-gene
initiators I-gene
nor 0
the 0
E. B-gene
coli I-gene
DnaJ I-gene
and 0
DnaK B-gene
heat 0
shock 0
proteins 0
play 0
a 0
direct 0
role 0
in 0
the 0
propagation 0
of 0
lambda 0
replication 0
forks 0
in 0
vitro 0
. 0

Synthetic 0
oligonucleotides 0
representing 0
the 0
19 0
bp 0
repeat 0
unit 0
strongly 0
reduced 0
the 0
activity 0
of 0
the 0
IE1/2 B-gene
enhancer/promoter I-gene
in 0
cotransfection 0
assays 0
after 0
transient 0
expression 0
. 0

Effects 0
of 0
nitrogen 0
( 0
PN2 0
: 0
5 0
and 0
14 0
MPa 0
) 0
and 0
helium 0
( 0
PHe 0
: 0
13 0
and 0
14 0
MPa 0
) 0
were 0
also 0
tested 0
. 0

The 0
mustard B-gene
chloroplast I-gene
gene I-gene
rps16 I-gene
is 0
split 0
by 0
an 0
887 0
bp 0
group 0
II 0
( 0
or 0
III 0
) 0
intron 0
. 0

Antibodies 0
raised 0
to 0
the 0
expressed 0
NS3 B-gene
by 0
immunization 0
of 0
mice 0
detected 0
both 0
NS3 B-gene
and 0
NS3A B-gene
in 0
BTV 0
- 0
10 0
- 0
infected 0
BHK 0
cells 0
but 0
not 0
in 0
purified 0
BTV 0
- 0
10 0
virus 0
particles 0
. 0

Similarly 0
, 0
supraventricular 0
tachycaydia 0
following 0
resuscitative 0
efforts 0
appeared 0
to 0
be 0
associated 0
with 0
a 0
negative 0
outcome 0
. 0

The 0
negative 0
calcium 0
balance 0
with 0
hyperparathyroidemia 0
occurred 0
after 0
continuous 0
oral 0
administration 0
of 0
Cd 0
and 0
developed 0
via 0
increased 0
urinary 0
excretion 0
of 0
calcium 0
. 0

Clone 0
4c 0
( 0
2681 0
bp 0
) 0
had 0
a 0
coding 0
region 0
identical 0
to 0
that 0
of 0
clone 0
22c 0
but 0
it 0
included 0
a 0
putative 0
intron 0
of 0
959 0
bp 0
. 0

The 0
application 0
of 0
ISH 0
and 0
IHC 0
did 0
not 0
change 0
significantly 0
the 0
routine 0
histologic 0
classification 0
of 0
pneumonias 0
into 0
CMV 0
- 0
IP 0
and 0
IIP 0
. 0

Validity 0
of 0
immunohistology 0
and 0
in 0
situ 0
hybridization 0
in 0
the 0
differential 0
diagnosis 0
of 0
cytomegalovirus 0
pneumonia 0
and 0
idiopathic 0
interstitial 0
pneumonia 0
after 0
allogenic 0
bone 0
marrow 0
transplantation 0

The 0
unique 0
nature 0
and 0
arrangement 0
of 0
the 0
ANT1 B-gene
transcriptional I-gene
control I-gene
elements I-gene
may 0
account 0
for 0
this 0
differential 0
expression 0
. 0

A 0
brief 0
account 0
of 0
the 0
1988 0
seminar 0
in 0
Shanghai 0
on 0
viral 0
hepatitis 0
A 0

The 0
Bacillus B-gene
subtilis I-gene
phage I-gene
phi I-gene
105 I-gene
repressor I-gene
, 0
a 0
lambda B-gene
repressor I-gene
- 0
like 0
transcriptional 0
regulatory 0
protein 0
, 0
was 0
overproduced 0
in 0
Escherichia 0
coli 0
and 0
purified 0
to 0
near 0
homogeneity 0
in 0
order 0
to 0
examine 0
its 0
in 0
vitro 0
DNA 0
- 0
binding 0
properties 0
. 0

In 0
consequence 0
, 0
the 0
gpI B-gene
derived 0
from 0
cells 0
infected 0
with 0
mO74 0
showed 0
antigenic 0
characteristics 0
similar 0
to 0
those 0
of 0
gpI B-gene
from 0
VZV 0
- 0
infected 0
cells 0
as 0
determined 0
from 0
the 0
immunoprecipitation 0
pattern 0
, 0
although 0
the 0
molecular 0
weight 0
of 0
each 0
polypeptide 0
was 0
different 0
, 0
and 0
antibody 0
produced 0
in 0
rabbits 0
infected 0
with 0
recombinant 0
virus 0
had 0
a 0
high 0
neutralizing 0
activity 0
, 0
when 0
the 0
reaction 0
was 0
performed 0
with 0
complement 0
. 0

Erythrocytic 0
stages 0
of 0
mammalian 0
malarial 0
parasites 0
contain 0
acristate 0
mitochondria 0
whose 0
functions 0
are 0
not 0
well 0
understood 0
. 0

However 0
, 0
bilateral 0
diffuse 0
pulmonary 0
infiltrations 0
developed 0
21 0
days 0
later 0
. 0

Grossly 0
, 0
the 0
incidence 0
of 0
a 0
type 0
IIc 0
carcinoma 0
was 0
46.5 0
% 0
and 0
that 0
of 0
a 0
IIc 0
+ 0
III 0
type 0
was 0
20.5 0
% 0
, 0
respectively 0
. 0

Restriction 0
maps 0
of 0
the 0
cloned 0
plasmids 0
revealed 0
that 0
their 0
chromosomal 0
inserts 0
consisted 0
of 0
overlapping 0
fragments 0
. 0

VP5 B-gene
, 0
which 0
encodes 0
the 0
major B-gene
capsid I-gene
protein I-gene
, 0
each 0
fused 0
to 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
gene I-gene
. 0

Of 0
202 0
initially 0
seronegative 0
caretakers 0
( 0
observed 0
for 0
an 0
average 0
of 0
305 0
days 0
per 0
woman 0
) 0
, 0
19 0
seroconverted 0
, 0
for 0
an 0
annual 0
seroconversion 0
rate 0
of 0
11 0
percent 0
. 0

In 0
contrast 0
, 0
a 0
similar 0
fragment 0
lacking 0
the 0
38 0
- 0
base 0
- 0
pair 0
region 0
had 0
no 0
such 0
stabilizing 0
effect 0
. 0

First 0
, 0
a 0
pet54 B-gene
: 0
:LEU2 B-gene
cytoductant 0
bearing 0
the 0
'short 0
' 0
mitochondrial 0
genome 0
that 0
lacks 0
both 0
COX1 B-gene
introns I-gene
aI5 B-gene
alpha I-gene
and 0
aI5 B-gene
beta I-gene
is 0
defective 0
only 0
in 0
COX3 B-gene
gene I-gene
expression 0
and 0
not 0
in 0
COX1 B-gene
mRNA I-gene
splicing 0
or 0
mRNA 0
translation 0
. 0

Insert2 0
contains 0
repetitive 0
non 0
- 0
Ig B-gene
- 0
related 0
sequences 0
and 0
a 0
small B-gene
Ig I-gene
- I-gene
related I-gene
sequence I-gene
. 0

Since 0
considerable 0
variations 0
in 0
length 0
and 0
primary 0
sequence 0
in 0
the 0
CDR3 B-gene
( 0
complementarity B-gene
determining I-gene
region I-gene
) 0
peptides 0
of 0
all 0
the 0
H B-gene
- I-gene
chains I-gene
are 0
evident 0
, 0
conservation 0
of 0
the 0
D B-gene
- I-gene
region I-gene
structure 0
does 0
not 0
appear 0
to 0
be 0
necessary 0
for 0
effective 0
hapten 0
binding 0
. 0

Tyrosine B-gene
kinase I-gene
oncogenes 0
abrogate 0
interleukin B-gene
- I-gene
3 I-gene
dependence 0
of 0
murine 0
myeloid 0
cells 0
through 0
signaling 0
pathways 0
involving 0
c B-gene
- I-gene
myc I-gene
: 0
conditional 0
regulation 0
of 0
c B-gene
- I-gene
myc I-gene
transcription 0
by 0
temperature 0
- 0
sensitive 0
v B-gene
- I-gene
abl I-gene
. 0

This 0
TC B-gene
- I-gene
II I-gene
enhanson I-gene
, 0
which 0
is 0
identical 0
to 0
the 0
kappa B-gene
B I-gene
motif I-gene
from 0
the 0
kappa B-gene
chain I-gene
enhancer I-gene
, 0
was 0
active 0
in 0
both 0
lymphoid 0
and 0
non 0
- 0
lymphoid 0
cells 0
, 0
which 0
contrasts 0
with 0
the 0
previously 0
reported 0
lymphoid 0
cell 0
specificity 0
of 0
the 0
kappa B-gene
B I-gene
motif I-gene
. 0

The 0
DNA 0
helix 0
at 0
the 0
tandemly 0
repeated 0
, 0
13mer 0
sequence 0
is 0
thermodynamically 0
unstable 0
, 0
as 0
evidenced 0
by 0
hypersensitivity 0
to 0
single B-gene
- I-gene
strand I-gene
- I-gene
specific I-gene
nuclease I-gene
in 0
a 0
negatively 0
supercoiled 0
plasmid 0
, 0
and 0
demonstrated 0
by 0
stable 0
DNA 0
unwinding 0
seen 0
after 0
two 0
- 0
dimensional 0
gel 0
electrophoresis 0
of 0
topoisomers 0
. 0

There 0
has 0
been 0
similar 0
improvement 0
in 0
treating 0
ampullary 0
and 0
periampullary 0
cancer 0
, 0
gallbladder 0
cancer 0
, 0
or 0
extrahepatic 0
bile 0
duct 0
cancer 0
. 0

Beta B-gene
- I-gene
endorphin I-gene
, 0
ACTH B-gene
and 0
cortisol 0
secretion 0
were 0
measured 0
in 0
twelve 0
healthy 0
adult 0
males 0
after 0
nasal 0
spray 0
administration 0
200 0
IU 0
salmon B-gene
calcitonin I-gene
. 0

The 0
data 0
indicate 0
that 0
calcitonin B-gene
induced 0
a 0
beta B-gene
- I-gene
endorphin I-gene
increase 0
independent 0
of 0
enhanced 0
corticotrophin B-gene
- 0
cortisol 0
release 0
. 0

The 0
DNA 0
sequences 0
predict 0
proteins 0
for 0
SRP54sc B-gene
and 0
SRP54sp B-gene
that 0
are 0
47 0
% 0
and 0
52 0
% 0
identical 0
to 0
SRP54mam B-gene
, 0
respectively 0
. 0

Other 0
hemostatic 0
values 0
evaluated 0
were 0
activated 0
partial 0
thromboplastin B-gene
times 0
, 0
prothrombin B-gene
times 0
, 0
thrombin B-gene
times 0
, 0
fibrinogen B-gene
, 0
platelet 0
counts 0
, 0
and 0
fibrin/fibrinogen B-gene
degradation 0
products 0
. 0

Rare 0
neurogenic 0
tumor 0
with 0
metastasis 0
to 0
mouth 0
, 0
jaw 0
and 0
face 0
regions 0

We 0
have 0
designated 0
the 0
protein 0
`` B-gene
cellular I-gene
NBP I-gene
'' B-gene
( I-gene
CNBP I-gene
) 0
. 0

Responsiveness 0
to 0
beta 0
- 0
2 0
agonist 0
therapy 0
was 0
retained 0
with 0
both 0
agents 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Drug 0
use 0
in 0
trauma 0
victims 0
. 0

A 0
critical 0
heart 0
rate 0
and/or 0
appropriate 0
sympathetic 0
state 0
was 0
found 0
to 0
provoke 0
all 0
instances 0
of 0
reentrant 0
or 0
automatic 0
atrial 0
tachycardia 0
and 0
atypical 0
junctional 0
tachycardia 0
. 0

In 0
contrast 0
, 0
the 0
neu B-gene
proto I-gene
- I-gene
oncogene I-gene
did 0
not 0
show 0
kinase 0
activity 0
or 0
transforming 0
properties 0
when 0
expressed 0
at 0
similar 0
levels 0
in 0
NIH 0
3T3 0
cells 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

The 0
65 0
- 0
bp 0
sequence 0
contains 0
the 0
octameric 0
cAMP 0
- 0
responsive 0
enhancer 0
( 0
CRE 0
) 0
TGACGTCA 0
( 0
nucleotides 0
- 0
48 0
to 0
- 0
41 0
) 0
. 0

Somatostatin B-gene
gene I-gene
expression 0
in 0
pancreatic 0
islet 0
cells 0
is 0
directed 0
by 0
cell 0
- 0
specific 0
DNA 0
control 0
elements 0
and 0
DNA 0
- 0
binding 0
proteins 0
. 0

In 0
contrast 0
, 0
the 0
full 0
mu 0
- 0
opioid 0
agonists 0
fentanyl 0
, 0
morphine 0
, 0
I 0
- 0
methadone 0
and 0
levorphanol 0
produced 0
50 0
% 0
fentanyl 0
- 0
appropriate 0
responding 0
at 0
doses 0
only 0
1.3 0
to 0
10.9 0
times 0
smaller 0
than 0
those 0
required 0
to 0
decrease 0
response 0
rates 0
by 0
50 0
% 0
. 0

After 0
overtraining 0
on 0
the 0
original 0
discrimination 0
, 0
the 0
controls 0
showed 0
the 0
normal 0
difficulty 0
in 0
learning 0
the 0
first 0
reversal 0
. 0

Isolation 0
and 0
characterization 0
of 0
a 0
cDNA 0
encoding 0
a 0
putative 0
cytokine 0
which 0
is 0
induced 0
by 0
stimulation 0
via 0
the 0
CD2 B-gene
structure I-gene
on 0
human 0
T 0
lymphocytes 0
. 0

After 0
termination 0
of 0
medication 0
the 0
animals 0
were 0
kindled 0
electrically 0
in 0
the 0
nucleus 0
amygdala 0
. 0

Haploid 0
cells 0
of 0
mating 0
type 0
A 0
of 0
the 0
basidiomycetous 0
yeast 0
Rhodosporidium 0
toruloides 0
secrete 0
a 0
mating 0
pheromone 0
, 0
rhodotorucine B-gene
A I-gene
, 0
which 0
is 0
an 0
undecapeptide 0
containing 0
S 0
- 0
farnesyl 0
cysteine 0
at 0
its 0
carboxy 0
terminus 0
. 0

Tumour B-gene
necrosis I-gene
factor I-gene
and 0
adult 0
respiratory 0
distress 0
syndrome 0
. 0

Monitoring 0
of 0
rheumatoid 0
arthritis 0
. 0

The 0
decrease 0
in 0
left 0
ventricular 0
( 0
LV 0
) 0
stroke 0
volume 0
during 0
positive 0
end 0
- 0
expiratory 0
pressure 0
( 0
PEEP 0
) 0
has 0
been 0
attributed 0
to 0
reduced 0
LV 0
filling 0
and 0
a 0
decreased 0
contractile 0
state 0
. 0

An 0
experiment 0
on 0
the 0
return 0
- 0
of 0
- 0
fear 0
( 0
ROF 0
) 0
was 0
carried 0
out 0
on 0
40 0
snake 0
- 0
or 0
spider 0
- 0
phobic 0
subjects 0
in 0
order 0
to 0
determine 0
whether 0
an 0
arousing 0
event 0
that 0
occurs 0
shortly 0
before 0
retest 0
influences 0
the 0
magnitude 0
of 0
the 0
ROF 0
. 0

Evolutionary 0
conservation 0
of 0
homeodomain B-gene
- 0
binding 0
sites 0
and 0
other 0
sequences 0
upstream 0
and 0
within 0
the 0
major 0
transcription 0
unit 0
of 0
the 0
Drosophila B-gene
segmentation I-gene
gene I-gene
engrailed I-gene
. 0

To 0
assess 0
the 0
functional 0
importance 0
of 0
these 0
NBS 0
in 0
the 0
overall 0
drug 0
resistance 0
phenotype 0
conferred 0
by 0
mdr1 B-gene
, 0
we 0
introduced 0
amino 0
acid 0
substitutions 0
in 0
the 0
core 0
consensus 0
sequence 0
for 0
nucleotide 0
binding 0
, 0
GXGKST 0
. 0

When 0
the 0
first 0
twitch 0
of 0
TOF 0
spontaneously 0
recovered 0
to 0
10 0
% 0
of 0
control 0
value 0
, 0
neostigmine 0
was 0
injected 0
( 0
40 0
micrograms/kg 0
in 0
adults 0
, 0
30 0
micrograms/kg 0
in 0
infants 0
and 0
children 0
) 0
. 0

No 0
significant 0
differences 0
were 0
found 0
in 0
relation 0
to 0
Type 0
A 0
behaviour 0
and 0
beta B-gene
- I-gene
adrenoceptor I-gene
blockade 0
. 0

Selection 0
of 0
the 0
22 0
items 0
of 0
the 0
Clinical 0
Institute 0
Withdrawal 0
Assessment 0
- 0
Benzodiazepines 0
( 0
CIWA 0
- 0
B 0
) 0
was 0
based 0
on 0
statistically 0
significant 0
differences 0
between 0
baseline 0
and 0
critical 0
withdrawal 0
periods 0
in 0
high 0
- 0
dose 0
subjects 0
and 0
between 0
symptoms 0
associated 0
with 0
placebo 0
and 0
diazepam 0
in 0
low 0
- 0
dose 0
subjects 0
, 0
using 0
contingency 0
tables 0
and 0
logistic 0
regression 0
analysis 0
. 0

Antihistamines 0
in 0
asthma 0
. 0

We 0
have 0
therefore 0
evaluated 0
the 0
efficacy 0
and 0
safety 0
of 0
doxazosin 0
, 0
a 0
new 0
orally 0
active 0
selective 0
alpha B-gene
1 I-gene
blocker 0
, 0
in 0
patients 0
with 0
systemic 0
hypertension 0
with 0
concomitant 0
airflow 0
limitation 0
. 0

Northern 0
blot 0
analysis 0
revealed 0
multiple 0
oIGF B-gene
- I-gene
I I-gene
transcripts I-gene
in 0
a 0
broad 0
band 0
at 0
800 0
- 0
1,100 0
nucleotides 0
and 0
other 0
transcripts 0
of 0
higher 0
molecular 0
weight 0
in 0
liver 0
. 0

Materials 0
science 0
studies 0
on 0
the 0
soldering 0
of 0
different 0
orthodontic 0
wires 0

The 0
latency 0
time 0
for 0
the 0
lactate 0
concentration 0
to 0
reach 0
the 0
top 0
values 0
was 0
reduced 0
by 0
aerobic 0
training 0
( 0
T2 0
) 0
. 0

In 0
patients 0
resistant 0
to 0
VAD 0
, 0
high 0
- 0
dose 0
therapies 0
with 0
intravenous 0
melphalan 0
, 0
a 0
CBV 0
combination 0
( 0
cyclophosphamide 0
- 0
BCNU 0
- 0
VP 0
- 0
16 0
) 0
or 0
an 0
EDAP 0
regimen 0
( 0
VP 0
- 0
16 0
- 0
platinum 0
) 0
produced 0
responses 0
in 0
about 0
40 0
% 0
of 0
patients 0
. 0

The 0
discussion 0
focuses 0
primarily 0
on 0
the 0
newer 0
drugs 0
like 0
angiotensin B-gene
converting I-gene
enzyme I-gene
inhibitors 0
, 0
alpha B-gene
- I-gene
adrenergic I-gene
receptor I-gene
blockers 0
, 0
and 0
calcium 0
antagonists 0
. 0

The 0
avian 0
cellular 0
homolog 0
of 0
the 0
oncogene B-gene
jun I-gene
. 0

A 0
736 0
- 0
bp 0
sequence 0
of 0
the 0
5 0
' 0
flanking 0
region 0
adjacent 0
to 0
the 0
cap 0
site 0
of 0
the 0
human B-gene
AFP I-gene
gene I-gene
shows 0
a 0
61 0
% 0
similarity 0
with 0
the 0
corresponding 0
region 0
of 0
the 0
mouse B-gene
AFP I-gene
gene I-gene
. 0

High 0
ATP/GTP 0
ratios 0
promoted 0
initiation 0
of 0
RNA 0
primer 0
synthesis 0
at 0
3' 0
- 0
dCTTT 0
sites 0
, 0
whereas 0
low 0
ATP/GTP 0
ratios 0
promoted 0
initiation 0
at 0
3' 0
- 0
dCCC 0
sites 0
. 0

After 0
hepatitis 0
B 0
vaccine 0
immunization 0
, 0
serum 0
antibody 0
response 0
was 0
of 0
primary 0
type 0
in 0
33 0
cases 0
with 0
anti B-gene
- I-gene
HBs I-gene
less 0
than 0
2.1 0
S/N 0
( 0
S/N 0
Ratio 0
Unit 0
) 0
at 0
T0 0
, 0
the 0
anti B-gene
- I-gene
HBs I-gene
positive 0
rate 0
was 0
39.4 0
% 0
, 0
84.8 0
% 0
, 0
96.7 0
% 0
and 0
96.7 0
% 0
in 0
T1 0
, 0
T2 0
, 0
T0 0
and 0
T12 0
respectively 0
. 0

The 0
experimental 0
design 0
incorporated 0
a 0
multiple 0
regression 0
model 0
, 0
sequential 0
treatments 0
and 0
a 0
proportional 0
end 0
point 0
( 0
95 0
% 0
) 0
for 0
protection 0
time 0
. 0

Interspecific 0
complementation 0
tests 0
showed 0
that 0
the 0
P7 B-gene
proteins I-gene
are 0
unable 0
to 0
complement 0
P1 B-gene
parA B-gene
or 0
parB B-gene
mutants I-gene
, 0
and 0
the 0
P1 B-gene
proteins I-gene
fail 0
to 0
complement 0
the 0
P7 B-gene
mutations I-gene
. 0

GN101 0
, 0
YC819 0
- 0
9 0
, 0
and 0
SB3 0
. 0

Analysis 0
of 0
the 0
inferred 0
1,859 B-gene
- I-gene
residue I-gene
ama I-gene
- I-gene
1 I-gene
product I-gene
showed 0
considerable 0
identity 0
with 0
the 0
largest 0
subunit 0
of 0
RNAP B-gene
II I-gene
from 0
other 0
organisms 0
, 0
including 0
the 0
presence 0
of 0
a 0
zinc 0
finger 0
motif 0
near 0
the 0
amino 0
terminus 0
, 0
and 0
a 0
carboxyl 0
- 0
terminal 0
domain 0
of 0
42 0
tandemly 0
reiterated 0
heptamers 0
with 0
the 0
consensus 0
Tyr 0
Ser 0
Pro 0
Thr 0
Ser 0
Pro 0
Ser 0
. 0

Nodular 0
involvement 0
of 0
the 0
left 0
lung 0
and 0
infiltration 0
of 0
the 0
mucosa 0
of 0
the 0
left 0
lower 0
lobe 0
bronchus 0
followed 0
very 0
gradually 0
and 0
a 0
monoclonal 0
gammopathy 0
( 0
IgA B-gene
- I-gene
- I-gene
Type I-gene
Kappa I-gene
) 0
was 0
demonstrated 0
. 0

5 0
. 0

None 0
of 0
the 0
measured 0
parameters 0
( 0
heart 0
contents 0
of 0
neutral 0
lipids 0
, 0
total 0
phospholipids 0
, 0
phosphatidylcholine 0
, 0
phosphatidylethanolamine 0
, 0
diphosphatidylglycerol 0
, 0
sphingomyelin 0
and 0
fatty 0
acid 0
composition 0
of 0
each 0
phospholipid 0
class 0
) 0
appeared 0
to 0
be 0
related 0
with 0
the 0
grading 0
of 0
the 0
lesions 0
. 0

Of 0
165 0
women 0
with 0
non 0
- 0
malignant 0
diagnoses 0
26 0
( 0
16 0
% 0
) 0
had 0
CA B-gene
125 I-gene
levels 0
in 0
excess 0
of 0
35 0
U/ml 0
and 0
8 0
( 0
5 0
% 0
) 0
greater 0
than 0
65 0
U/ml 0
. 0

We 0
conclude 0
that 0
at 0
steady 0
state 0
the 0
timing 0
of 0
a 0
light 0
meal 0
is 0
unlikely 0
to 0
alter 0
in 0
any 0
clinically 0
important 0
manner 0
the 0
pharmacokinetics 0
of 0
nifedipine 0
released 0
from 0
'biphasic 0
' 0
tablets 0
. 0

The 0
GALT 0
- 0
primed 0
calves 0
had 0
increased 0
serum 0
IgG B-gene
, 0
lavage 0
IgG B-gene
and 0
IgA B-gene
and 0
increased 0
LNA B-gene
titers 0
in 0
both 0
lavage 0
fluids 0
and 0
serum 0
following 0
the 0
SC 0
dose 0
of 0
killed 0
bacteria 0
. 0

Recent 0
investigations 0
have 0
shown 0
that 0
Grenz 0
rays 0
can 0
suppress 0
the 0
allergic 0
contact 0
dermatitis 0
reaction 0
completely 0
and 0
that 0
Langerhans 0
cells 0
, 0
identified 0
by 0
OKT6 B-gene
antibodies I-gene
and 0
electron 0
microscopy 0
, 0
disappear 0
from 0
the 0
epidermis 0
at 0
the 0
same 0
time 0
. 0

The 0
elements 0
responsible 0
for 0
glucocorticoid 0
stimulation 0
of 0
ADH B-gene
gene I-gene
transcription 0
appear 0
to 0
reside 0
outside 0
of 0
this 0
region 0
. 0

1 0
. 0

The 0
present 0
studies 0
compare 0
the 0
biochemical 0
characteristics 0
, 0
Kanagawa 0
hemolysin B-gene
reactions 0
, 0
and 0
plasmid 0
profiles 0
of 0
13 0
patient 0
and 0
221 0
environmental 0
isolates 0
of 0
the 0
organism 0
. 0

High 0
values 0
of 0
both 0
retinol 0
and 0
beta 0
- 0
carotene 0
were 0
found 0
in 0
full 0
fat 0
cheeses 0
and 0
whipping 0
cream 0
: 0
from 0
179.0 0
( 0
cheese 0
, 0
Edam 0
- 0
type 0
) 0
to 0
318.7 0
micrograms/100 0
g 0
( 0
whipping 0
cream 0
) 0
and 0
from 0
86.7 0
( 0
cheese 0
, 0
Edam 0
- 0
type 0
) 0
to 0
186.5 0
micrograms/100 0
g 0
( 0
whipping 0
cream 0
) 0
for 0
all 0
- 0
trans 0
retinol 0
and 0
total 0
beta 0
- 0
carotene 0
, 0
respectively 0
. 0

COGLAB 0
includes 0
measures 0
of 0
preattentional 0
, 0
attentional 0
, 0
conceptual 0
, 0
and 0
psychomotor 0
performance 0
. 0

These 0
data 0
locate 0
the 0
aniridia B-gene
gene I-gene
( 0
AN2 B-gene
) 0
and 0
a 0
recurrent 0
T B-gene
- I-gene
cell I-gene
leukemia I-gene
breakpoint I-gene
( 0
TCL2 B-gene
) 0
in 0
the 0
marker 0
sequence 0
, 0
on 0
opposite 0
sides 0
of 0
MIC1 B-gene
. 0

A 0
fine 0
- 0
structure 0
deletion 0
map 0
of 0
human 0
chromosome 0
11p 0
: 0
analysis 0
of 0
J1 0
series 0
hybrids 0
. 0

With 0
respect 0
to 0
effective 0
diffusivity 0
of 0
platelets 0
( 0
De 0
) 0
and 0
the 0
surface 0
reactivity 0
constant 0
( 0
K 0
) 0
, 0
less 0
significant 0
differences 0
were 0
found 0
among 0
artificial 0
materials 0
. 0

The 0
two 0
most 0
recent 0
patients 0
( 0
35 0
and 0
132 0
days 0
) 0
received 0
only 0
oral 0
dipyridamole 0
( 0
75 0
mg 0
X 0
3/day 0
) 0
and 0
aspirin 0
( 0
80 0
mg/day 0
) 0
after 0
the 0
early 0
recovery 0
period 0
( 0
four 0
- 0
six 0
days 0
) 0
, 0
resulting 0
in 0
normal 0
prothrombin B-gene
and 0
partial 0
thromboplastin B-gene
times 0
. 0

Middle 0
- 0
latency 0
auditory 0
evoked 0
potentials 0
( 0
MAEPs 0
) 0
were 0
recorded 0
in 0
controls 0
and 0
patients 0
with 0
focal 0
lesions 0
in 0
dorsolateral 0
prefrontal 0
cortex 0
. 0

Most 0
of 0
them 0
were 0
situated 0
at 0
Sylvius 0
fissure 0
( 0
13 0
cases 0
) 0
. 0

Intracellular 0
activity 0
studies 0
indicated 0
that 0
, 0
at 0
ten 0
times 0
MBC 0
, 0
only 0
penicillin 0
had 0
any 0
significant 0
activity 0
against 0
intracellular 0
staphylococci 0
, 0
reducing 0
survival 0
by 0
28 0
% 0
. 0

Specifically 0
, 0
they 0
were 0
performed 0
to 0
determine 0
whether 0
detection 0
of 0
envelope 0
phase 0
disparity 0
was 0
consistent 0
with 0
processing 0
within 0
a 0
single 0
channel 0
in 0
which 0
the 0
AM 0
tones 0
were 0
simply 0
added 0
. 0

Gel 0
retardation 0
assays 0
combined 0
with 0
DNase B-gene
I I-gene
footprinting 0
and 0
diethyl 0
pyrocarbonate 0
interference 0
showed 0
that 0
a 0
nuclear 0
factor 0
from 0
differentiated 0
C2 0
myotubes 0
and 0
BC3H1 0
myocytes 0
recognized 0
a 0
conserved 0
A 0
+ 0
T 0
- 0
rich 0
sequence 0
within 0
the 0
peripheral 0
activating 0
region 0
. 0

Such 0
transgenic 0
plants 0
should 0
enable 0
not 0
only 0
the 0
mutational 0
analysis 0
of 0
sequence 0
elements 0
within 0
the 0
replication 0
origin 0
region 0
, 0
but 0
also 0
the 0
construction 0
of 0
a 0
new 0
generation 0
of 0
vectors 0
for 0
gene 0
amplification 0
in 0
plants 0
, 0
based 0
on 0
a 0
minimal 0
virus 0
replicon 0
. 0

Ventral 0
rhinotomy 0
is 0
no 0
more 0
difficult 0
than 0
dorsal 0
rhinotomy 0
, 0
has 0
less 0
patient 0
morbidity 0
and 0
fewer 0
postoperative 0
complications 0
, 0
and 0
is 0
more 0
cosmetically 0
acceptable 0
. 0

Four 0
full 0
- 0
thickness 0
skin 0
incisions 0
were 0
made 0
in 0
the 0
back 0
of 0
10 0
female 0
pigs 0
that 0
treated 0
twice 0
a 0
day 0
for 0
14 0
days 0
with 0
2 0
ml 0
of 0
epidermal B-gene
growth I-gene
factor I-gene
( 0
300 0
ng/ml 0
) 0
or 0
2 0
ml 0
of 0
Ringer 0
's 0
lactate 0
solution 0
in 0
a 0
single 0
- 0
blind 0
, 0
randomized 0
fashion 0
. 0

During 0
challenge 0
, 0
rebiopsy 0
was 0
done 0
when 0
reticulin B-gene
antibodies I-gene
turned 0
positive 0
( 0
mean 0
0.6 0
years 0
, 0
range 0
0.2 0
- 0
2.0 0
) 0
or 0
at 0
the 0
end 0
of 0
the 0
two 0
year 0
study 0
. 0

The 0
effect 0
of 0
iron 0
intake 0
on 0
59Fe 0
absorption 0
throughout 0
pregnancy 0
, 0
and 0
on 0
maternal 0
and 0
fetal 0
Fe 0
status 0
towards 0
the 0
end 0
of 0
pregnancy 0
, 0
was 0
investigated 0
in 0
rats 0
. 0

The 0
deduced 0
protein 0
sequence 0
is 0
characterized 0
by 0
a 0
putative 0
16 0
- 0
residue 0
amino 0
- 0
terminal 0
signal 0
peptide 0
that 0
is 0
cleaved 0
, 0
resulting 0
in 0
a 0
239 0
- 0
residue 0
polypeptide 0
. 0

Analysis 0
of 0
the 0
rate 0
constants 0
indicated 0
that 0
the 0
isomerization 0
rate 0
k12 0
was 0
approximately 0
equal 0
to 0
the 0
apparent 0
degradation 0
rate 0
of 0
the 0
delta 0
3 0
ester 0
kdeg 0
, 0
and 0
slower 0
than 0
the 0
hydrolysis 0
rate 0
of 0
the 0
delta 0
2 0
ester 0
k24 0
. 0

A 0
protocol 0
is 0
elaborated 0
for 0
the 0
preparation 0
and 0
characterization 0
of 0
a 0
quality 0
control 0
material 0
( 0
QCM 0
) 0
containing 0
intrinsic 0
concentration 0
of 0
cadmium 0
( 0
Cd 0
) 0
( 0
0.8 0
microgram/L 0
) 0
and 0
lead 0
( 0
Pb 0
) 0
( 0
13.4 0
micrograms/dL 0
) 0
from 0
bovine 0
blood 0
and 0
an 0
elevated 0
QCM 0
containing 0
Cd 0
( 0
5.0 0
micrograms/L 0
) 0
, 0
mercury 0
( 0
Hg 0
) 0
( 0
11.2 0
micrograms/L 0
) 0
, 0
and 0
Pb 0
( 0
34.5 0
micrograms/dL 0
) 0
from 0
bovine 0
blood 0
spiked 0
with 0
aqueous 0
spiking 0
- 0
solutions 0
prepared 0
with 0
salts 0
of 0
Cd 0
, 0
Hg 0
, 0
and 0
Pb 0
. 0

Reagent 0
strips 0
are 0
frequently 0
used 0
in 0
the 0
practice 0
of 0
laboratory 0
medicine 0
as 0
well 0
as 0
outside 0
the 0
professional 0
laboratories 0
. 0

The 0
lowest 0
detectable 0
concentration 0
was 0
1.0 0
ng/ml 0
in 0
the 0
serum 0
. 0

Precipitating 0
antibodies 0
for 0
Thermophilic 0
actinomycetes 0
and 0
M.f 0
. 0
were 0
negative 0
. 0

LON 0
- 0
72 0
( 0
34 0
isolates 0
) 0
, 0
LON 0
- 0
73 0
( 0
1 0
) 0
, 0
LON 0
- 0
71 0
( 0
2 0
) 0
and 0
LON 0
- 0
10 0
( 0
2 0
) 0
were 0
found 0
at 0
altitudes 0
around 0
2000 0
m 0
, 0
3 0
of 0
them 0
in 0
a 0
single 0
village 0
. 0

Animal 0
experimental 0
and 0
clinical 0
applications 0
of 0
plates 0
, 0
screws 0
and 0
spinal 0
segmental 0
replacement 0
implants 0
made 0
of 0
this 0
composite 0
material 0
have 0
shown 0
good 0
results 0
so 0
far 0
. 0

Significance 0
of 0
delta 0
- 0
aminolevulinic 0
acid 0
analysis 0
in 0
clinical 0
tests 0

No 0
changes 0
were 0
evident 0
in 0
the 0
FR 0
- 0
task 0
performance 0
of 0
controls 0
that 0
received 0
daily 0
saline 0
injections 0
. 0

The 0
antigen B-gene
- I-gene
specific I-gene
IgG4 I-gene
antibody I-gene
seems 0
to 0
be 0
an 0
index 0
in 0
evaluating 0
immunotherapy 0
objectively 0
. 0

Although 0
the 0
fertility 0
decline 0
in 0
the 0
black 0
population 0
in 0
the 0
Mississippi 0
Delta 0
between 0
the 0
late 0
1870 0
's 0
and 0
early 0
1930 0
's 0
closely 0
paralleled 0
that 0
of 0
the 0
national 0
black 0
population 0
, 0
it 0
rose 0
much 0
more 0
dramatically 0
in 0
the 0
1940 0
's 0
and 0
1950 0
's 0
to 0
almost 0
1880 0
levels 0
. 0

According 0
to 0
their 0
staining 0
affinity 0
for 0
anti B-gene
- I-gene
T I-gene
antibodies I-gene
, 0
the 0
glandular 0
tissue 0
cells 0
were 0
classified 0
as 0
T B-gene
- 0
, 0
T+ B-gene
, 0
T++ B-gene
, 0
and 0
T B-gene
and 0
the 0
annual 0
changes 0
in 0
the 0
numbers 0
of 0
these 0
cell 0
populations 0
, 0
as 0
well 0
as 0
in 0
the 0
volume 0
occupied 0
by 0
the 0
glandular 0
tissue 0
, 0
were 0
calculated 0
. 0

Ampicillin 0
( 0
AMP 0
) 0
alone 0
or 0
with 0
an 0
aminoglycoside 0
( 0
AMI 0
) 0
was 0
the 0
treatment 0
in 0
9 0
and 0
16 0
cases 0
, 0
respectively 0
. 0

Alkoxymetgyl 0
- 0
3,4 0
- 0
dimethylpyridinium 0
chlorides 0
were 0
synthetized 0
by 0
reacting 0
3,4 0
- 0
dimethylpyridine 0
with 0
chloromethyl 0
alkyl 0
ethers 0
, 0
while 0
1 0
- 0
ethyloxymethyl 0
- 0
3 0
- 0
alkylthiomethylimidazolium 0
chlorides 0
were 0
obtained 0
in 0
reactions 0
of 0
1 0
- 0
ethyloxymethylimidazol 0
with 0
chloromethyl 0
alkyl 0
sulfides 0
. 0

We 0
investigated 0
the 0
incidence 0
of 0
congenital 0
color 0
deficiency 0
among 0
Koreans 0
by 0
the 0
use 0
of 0
H 0
- 0
R 0
- 0
R 0
pseudoisochromatic 0
plates 0
. 0

Eighty 0
patients 0
presenting 0
to 0
HGGM 0
with 0
non 0
- 0
Hodgkin 0
's 0
lymphomas 0
between 0
1962 0
and 0
1986 0
, 0
were 0
reviewed 0
. 0

The 0
relation 0
between 0
VE/VO2 0
and 0
Q/VO2 0
showed 0
a 0
significant 0
negative 0
correlation 0
( 0
r 0
= 0
- 0
0.93 0
, 0
p 0
less 0
than 0
0.01 0
) 0
. 0

The 0
differential 0
diagnosis 0
of 0
both 0
affections 0
is 0
based 0
on 0
the 0
clinical 0
course 0
, 0
sialography 0
and 0
CT 0
examination 0
which 0
along 0
with 0
modern 0
ATB 0
treatment 0
significantly 0
modify 0
hitherto 0
used 0
surgical 0
therapy 0
. 0

Retrograde 0
filling 0
consists 0
in 0
sealing 0
endodontics 0
system 0
directly 0
at 0
the 0
apical 0
zone 0
after 0
surgical 0
approach 0
. 0

Collaborative 0
study 0
of 0
Japanese 0
Pharmacopoeia 0
Heparin 0
Sodium 0
Reference 0
Standard 0

Serological 0
studies 0
at 0
the 0
early 0
relapse 0
stage 0
of 0
this 0
disease 0
showed 0
increased 0
serum B-gene
ANA I-gene
, 0
IgA B-gene
and 0
IgM B-gene
level 0
with 0
normal 0
IgG B-gene
and 0
decrease 0
of 0
C3 B-gene
and 0
C4 B-gene
. 0

The 0
maximum 0
stress 0
due 0
to 0
the 0
hygroscopic 0
examination 0
of 0
the 0
composite 0
was 0
0.74 0
kg/mm2 0
at 0
equilibrium 0
of 0
the 0
water 0
absorbed 0
of 0
the 0
composite 0
. 0

Ischemic 0
heart 0
disease 0
evaluated 0
by 0
exercise 0
stress 0
thallium 0
- 0
201 0
myocardial 0
scintigraphy 0
: 0
a 0
comparison 0
of 0
SPECT 0
and 0
bull 0
's 0
eye 0
display 0

Sequence 0
analysis 0
of 0
the 0
47 B-gene
- I-gene
kilodalton I-gene
major I-gene
integral I-gene
membrane I-gene
immunogen I-gene
of I-gene
Treponema I-gene
pallidum I-gene
. 0

Potential 0
consensus 0
sequences 0
for 0
early 0
and 0
late 0
regulatory 0
elements 0
were 0
identified 0
. 0

An 0
FP B-gene
mutant I-gene
, 0
AcFP875 B-gene
- I-gene
2 I-gene
, 0
had 0
a 0
1.6 0
- 0
kbp 0
insertion 0
of 0
S. 0
frugiperda 0
DNA 0
near 0
the 0
5 0
' 0
end 0
of 0
these 0
transcripts 0
which 0
by 0
S1 B-gene
analysis 0
were 0
shown 0
to 0
initiate 0
within 0
the 0
host 0
cell 0
sequence 0
. 0

Construction 0
of 0
a 0
RIP1 B-gene
deletion 0
strain 0
and 0
isolation 0
of 0
temperature 0
- 0
sensitive 0
mutants 0
. 0

These 0
data 0
suggest 0
that 0
hypocitraturia 0
in 0
type 0
I 0
renal 0
tubular 0
acidosis 0
may 0
be 0
due 0
to 0
a 0
defect 0
in 0
proximal 0
tubule 0
function 0
. 0

Concomitant 0
chronic 0
lymphocytic 0
leukemia 0
, 0
acute 0
myeloid 0
leukemia 0
, 0
and 0
thrombosis 0
with 0
protein B-gene
C I-gene
deficiency 0
. 0

Vivid 0
visual 0
hallucinations 0
without 0
other 0
psychopathology 0
have 0
been 0
reported 0
for 0
several 0
hundred 0
years 0
. 0

In 0
the 0
whole 0
group 0
, 0
basal 0
GH B-gene
and 0
somatomedin B-gene
- I-gene
C I-gene
levels 0
decreased 0
from 0
a 0
mean 0
( 0
+/ 0
- 0
standard 0
error 0
of 0
the 0
mean 0
) 0
of 0
52.3 0
+/ 0
- 0
12.7 0
to 0
11.1 0
+/ 0
- 0
6.3 0
ng/ml 0
and 0
from 0
7.6 0
+/ 0
- 0
0.7 0
to 0
2.5 0
+/ 0
- 0
0.5 0
U/ml 0
, 0
respectively 0
. 0

Application 0
of 0
different 0
criteria 0
of 0
cure 0
revealed 0
that 0
19 0
patients 0
( 0
66 0
% 0
) 0
had 0
basal 0
GH B-gene
levels 0
below 0
5 0
ng/ml 0
, 0
17 0
patients 0
( 0
59 0
% 0
) 0
had 0
normal 0
somatomedin B-gene
- I-gene
C I-gene
values 0
, 0
16 0
patients 0
( 0
55 0
% 0
) 0
had 0
complete 0
GH B-gene
suppression 0
( 0
less 0
than 0
1 0
ng/ml 0
) 0
during 0
OGTT 0
, 0
and 0
13 0
patients 0
( 0
45 0
% 0
) 0
met 0
the 0
above 0
- 0
mentioned 0
criteria 0
with 0
disappearance 0
of 0
the 0
paradoxical 0
GH B-gene
response 0
to 0
TRH/GnRH B-gene
test 0
. 0

It 0
suggests 0
a 0
sequence 0
of 0
surgical 0
planning 0
that 0
can 0
prevent 0
them 0
and 0
also 0
offers 0
ways 0
of 0
dealing 0
with 0
the 0
problems 0
should 0
they 0
occur 0
. 0

In 0
Rat 0
- 0
1a 0
cells 0
the 0
expression 0
of 0
human B-gene
c I-gene
- I-gene
jun I-gene
mRNA I-gene
was 0
associated 0
with 0
the 0
ability 0
to 0
clone 0
in 0
soft 0
agarose 0
and 0
form 0
tumors 0
in 0
nude 0
mice 0
. 0

Furthermore 0
, 0
formation 0
of 0
foci 0
of 0
transformed 0
RECs 0
by 0
the 0
c B-gene
- I-gene
jun/ras I-gene
combination 0
was 0
augmented 0
3 0
- 0
fold 0
by 0
the 0
tumor 0
promoter 0
phorbol 0
12 0
- 0
tetradecanoate 0
13 0
- 0
acetate 0
. 0

Platelet B-gene
activating I-gene
factor I-gene
was 0
given 0
in 0
six 0
doses 0
at 0
15 0
minute 0
intervals 0
and 0
airway 0
response 0
measured 0
as 0
change 0
in 0
partial 0
expiratory 0
flow 0
at 0
30 0
% 0
of 0
vital 0
capacity 0
( 0
Vp30 0
) 0
. 0

There 0
was 0
no 0
significant 0
correlation 0
between 0
baseline 0
PC40 0
methacholine 0
and 0
the 0
maximal 0
fall 0
in 0
Vp30 0
after 0
either 0
the 0
first 0
( 0
12 0
micrograms 0
) 0
or 0
the 0
second 0
dose 0
( 0
24 0
micrograms 0
) 0
of 0
platelet B-gene
activating I-gene
factor I-gene
. 0

Both 0
BG 0
and 0
IRI B-gene
concentrations 0
during 0
the 0
OGTT 0
were 0
the 0
lowest 0
in 0
body 0
builders 0
, 0
medium 0
in 0
controls 0
, 0
and 0
the 0
highest 0
in 0
obese 0
men 0
. 0

Postcoital 0
contraception 0
: 0
a 0
family 0
planning 0
study 0
. 0

A 0
0.5 0
rating 0
was 0
intended 0
to 0
characterize 0
subjects 0
in 0
whom 0
mild 0
cognitive 0
impairment 0
due 0
to 0
senile 0
dementia 0
of 0
the 0
Alzheimer 0
type 0
was 0
suspected 0
but 0
was 0
insufficient 0
in 0
degree 0
to 0
warrant 0
a 0
diagnosis 0
of 0
definite 0
dementia 0
. 0

An 0
implant 0
may 0
release 0
a 0
drug 0
either 0
by 0
diffusion 0
concurrent 0
with 0
dissolution 0
of 0
the 0
polymeric 0
implant 0
material 0
without 0
depolymerization 0
( 0
Type 0
A 0
) 0
or 0
by 0
bioerosion 0
involving 0
depolymerization 0
( 0
Type 0
B 0
) 0
. 0

Although 0
it 0
is 0
well 0
known 0
that 0
calcium 0
channel 0
blockers 0
can 0
influence 0
contraction 0
of 0
vascular 0
smooth 0
muscle 0
, 0
there 0
is 0
less 0
knowledge 0
on 0
its 0
effect 0
on 0
excitation 0
contraction 0
coupling 0
in 0
the 0
endocrine 0
glands 0
and 0
more 0
specifically 0
on 0
insulin B-gene
and 0
glucagon B-gene
release 0
. 0

Many 0
studies 0
have 0
pointed 0
out 0
the 0
possibility 0
of 0
`` 0
masked 0
'' 0
organic 0
factors 0
in 0
erectile 0
impotence 0
, 0
detectable 0
only 0
by 0
means 0
of 0
laboratory 0
investigations 0
: 0
mild 0
hypogonadism 0
, 0
hyperprolactinemia 0
, 0
occlusions 0
selectively 0
located 0
at 0
the 0
site 0
of 0
the 0
sexual 0
arteries 0
, 0
venous 0
incompetence 0
, 0
subclinical 0
neuropathies 0
. 0

The 0
site 0
- 0
specific 0
DNA 0
inversion 0
system 0
Cin B-gene
encoded 0
by 0
the 0
bacteriophage 0
P1 0
consists 0
of 0
a 0
recombinase B-gene
, 0
two 0
inverted 0
crossing 0
- 0
over 0
sites 0
and 0
a 0
recombinational 0
enhancer 0
. 0

The 0
terminator 0
region 0
supported 0
termination 0
of 0
transcripts 0
initiated 0
by 0
RNA B-gene
polymerase I-gene
I I-gene
in 0
vivo 0
. 0

US 0
- 0
Doppler 0
has 0
recently 0
gained 0
attention 0
as 0
a 0
noninvasive 0
method 0
for 0
the 0
functional 0
evaluation 0
of 0
arteriovenous 0
fistulas 0
( 0
FAV 0
) 0
. 0

Doppler 0
echo 0
in 0
evaluating 0
arteriovenous 0
fistulae 0
for 0
dialysis 0

Improved 0
cosmesis 0
, 0
extension 0
of 0
the 0
scope 0
of 0
the 0
problems 0
that 0
can 0
be 0
addressed 0
with 0
this 0
repair 0
( 0
including 0
treatment 0
of 0
a 0
distal 0
urethrocutaneous 0
fistula 0
) 0
and 0
the 0
ease 0
with 0
which 0
the 0
Arap 0
procedure 0
can 0
be 0
performed 0
are 0
the 0
advantages 0
that 0
this 0
operation 0
has 0
over 0
other 0
1 0
- 0
stage 0
distal 0
hypospadias 0
repairs 0
. 0

Following 0
the 0
patients 0
during 0
a 0
course 0
of 0
therapy 0
with 0
a 0
selective 0
vasodilator 0
calcium 0
antagonist 0
, 0
the 0
beta 0
- 0
adrenergic 0
reflex 0
vasodilation 0
became 0
substantially 0
attenuated 0
but 0
was 0
preserved 0
during 0
a 0
placebo 0
course 0
of 0
therapy 0
. 0

The 0
galactose B-gene
transporter I-gene
shows 0
both 0
sequence 0
and 0
structural 0
homology 0
with 0
a 0
superfamily 0
of 0
sugar B-gene
transporters I-gene
which 0
includes 0
the 0
human B-gene
HepG2 I-gene
- I-gene
erythrocyte I-gene
and I-gene
fetal I-gene
muscle I-gene
glucose I-gene
transporters I-gene
, 0
the 0
rat B-gene
brain I-gene
and I-gene
liver I-gene
glucose I-gene
transporters I-gene
, 0
the 0
Escherichia B-gene
coli I-gene
xylose I-gene
and I-gene
arabinose I-gene
permeases I-gene
, 0
and 0
the 0
S. B-gene
cerevisiae I-gene
glucose I-gene
, I-gene
maltose I-gene
, I-gene
and I-gene
galactose I-gene
transporters I-gene
. 0

Of 0
110 0
previously 0
untreated 0
patients 0
who 0
had 0
entered 0
the 0
study 0
of 0
protocol 0
TCL821 0
, 0
96 0
were 0
evaluable 0
. 0

There 0
were 0
3/32 0
( 0
9.4 0
per 0
cent 0
) 0
adverse 0
reactions 0
( 0
ADRs 0
) 0
, 0
and 0
one 0
case 0
each 0
of 0
nausea 0
, 0
dizziness 0
and 0
increased 0
menstrual 0
flow 0
. 0

More 0
mRNA 0
corresponding 0
to 0
nagB B-gene
and 0
nagA B-gene
is 0
detected 0
than 0
that 0
corresponding 0
to 0
the 0
distal 0
genes 0
, 0
nagC B-gene
and 0
nagD B-gene
. 0

Tumor B-gene
necrosis I-gene
factor I-gene
( 0
TNF B-gene
) 0
is 0
reported 0
to 0
cause 0
a 0
shock 0
syndrome 0
similar 0
to 0
that 0
produced 0
by 0
endotoxin 0
( 0
LPS 0
) 0
. 0

The 0
calcium 0
requirement 0
for 0
hypothermic 0
storage 0
of 0
the 0
cardiac 0
explant 0
. 0

The 0
seventh 0
cysteine 0
residue 0
of 0
CTSE B-gene
is 0
located 0
within 0
the 0
activation 0
peptide 0
region 0
of 0
the 0
proenzyme 0
. 0

The 0
p34.8 B-gene
gene I-gene
has 0
a 0
strong 0
codon 0
usage 0
bias 0
which 0
is 0
strikingly 0
different 0
from 0
that 0
of 0
the 0
polyhedrin B-gene
gene I-gene
. 0

Of 0
the 0
single 0
- 0
stranded 0
DNA 0
transformants 0
, 0
65 0
% 0
resulted 0
from 0
replacement 0
of 0
the 0
resident 0
met2 B-gene
mutation I-gene
by 0
the 0
exogenous 0
wild 0
- 0
type 0
allele 0
. 0

The 0
results 0
strongly 0
support 0
the 0
notion 0
that 0
the 0
OBF1 B-gene
- I-gene
binding I-gene
sites I-gene
and 0
the 0
OBF1 B-gene
protein I-gene
are 0
important 0
for 0
normal 0
ARS 0
function 0
as 0
an 0
origin 0
of 0
replication 0
. 0

On 0
the 0
basis 0
of 0
S1 B-gene
nuclease I-gene
protection 0
analysis 0
of 0
RNA 0
preparations 0
from 0
several 0
mouse 0
tissues 0
, 0
both 0
dhfr B-gene
and 0
divergent 0
genes 0
showed 0
similar 0
levels 0
of 0
expression 0
but 0
did 0
show 0
some 0
specificity 0
in 0
start 0
site 0
utilization 0
. 0

Four 0
out 0
of 0
10 0
patients 0
showed 0
clinical 0
improvement 0
according 0
to 0
Ritchie 0
- 0
Index 0
, 0
pain 0
score 0
, 0
ESR 0
and 0
CRP B-gene
. 0

62:2491 0
- 0
2499 0
, 0
1987 0
) 0
. 0

With 0
both 0
wild 0
- 0
type 0
and 0
the 0
mutant 0
enzymes 0
, 0
ATP 0
activates 0
both 0
[ 0
14C 0
] 0
Asp 0
in 0
equilibrium 0
N 0
- 0
carbamyl 0
- 0
L 0
- 0
aspartate 0
( 0
C 0
- 0
Asp 0
) 0
and 0
the 0
[ 0
32P 0
] 0
carbamyl 0
phosphate 0
( 0
C 0
- 0
P 0
) 0
in 0
equilibrium 0
Pi 0
exchanges 0
. 0

Survival 0
rates 0
for 0
the 0
original 0
treatment 0
group 0
were 0
84.5 0
% 0
and 0
57.6 0
% 0
at 0
12 0
and 0
21 0
months 0
, 0
respectively 0
; 0
for 0
the 0
delayed 0
treatment 0
group 0
, 0
78.8 0
% 0
and 0
64.6 0
% 0
at 0
12 0
and 0
21 0
months 0
, 0
respectively 0
, 0
and 0
78.8 0
% 0
and 0
47.5 0
% 0
at 0
12 0
and 0
21 0
months 0
, 0
respectively 0
, 0
for 0
77 0
subjects 0
with 0
AIDS 0
and 0
93.0 0
% 0
and 0
71.8 0
% 0
, 0
respectively 0
, 0
for 0
50 0
subjects 0
with 0
AIDS 0
- 0
related 0
complex 0
in 0
the 0
original 0
treatment 0
group 0
. 0

Mapping 0
results 0
suggested 0
that 0
the 0
complementation 0
group 0
identified 0
by 0
these 0
mutants 0
is 0
allelic 0
to 0
the 0
ag B-gene
alpha I-gene
1 I-gene
mutation 0
identified 0
previously 0
. 0

The 0
products 0
of 0
genes 0
ura10 B-gene
and 0
ura3 B-gene
are 0
proposed 0
to 0
participate 0
in 0
the 0
channeling 0
of 0
orotidine 0
monophosphate 0
. 0

After 0
the 0
application 0
of 0
RS 0
86 0
, 0
REM 0
latency 0
was 0
shortened 0
in 0
all 0
groups 0
under 0
investigation 0
. 0

Hybridization 0
analysis 0
showed 0
that 0
the 0
size 0
of 0
the 0
mRNA 0
is 0
about 0
1.4 0
kilobases 0
. 0

Agranulocytosis 0
treatment 0
with 0
rhGM B-gene
- I-gene
CSF I-gene

The 0
R. B-gene
meliloti I-gene
nifH I-gene
promoter I-gene
but 0
not 0
the 0
K. B-gene
pneumoniae I-gene
nifH I-gene
promoter I-gene
showed 0
sigma B-gene
54 I-gene
- 0
dependent 0
methylation 0
protection 0
of 0
guanine 0
residues 0
at 0
- 0
14 0
, 0
- 0
25 0
and 0
- 0
26 0
, 0
the 0
most 0
conserved 0
nucleotides 0
characteristic 0
of 0
sigma B-gene
54 I-gene
- I-gene
dependent I-gene
promoters I-gene
. 0

Major 0
clinical 0
symptoms 0
of 0
the 0
disease 0
were 0
defined 0
in 0
this 0
group 0
of 0
patients 0
. 0

Recently 0
, 0
an 0
alternatively 0
spliced 0
form 0
of 0
c B-gene
- I-gene
myb I-gene
- I-gene
encoded I-gene
mRNA I-gene
has 0
been 0
identified 0
in 0
murine 0
cells 0
containing 0
either 0
normal 0
or 0
rearranged 0
c B-gene
- I-gene
myb I-gene
genes I-gene
. 0

Routine 0
clinical 0
analysis 0
revealed 0
lower 0
hematocrit 0
and 0
hemoglobin B-gene
, 0
and 0
elevated 0
BUN 0
and 0
alkaline B-gene
phosphatase I-gene
in 0
the 0
treated 0
group 0
. 0

To 0
assess 0
the 0
health 0
significance 0
of 0
the 0
early 0
renal 0
changes 0
after 0
chronic 0
exposure 0
to 0
cadmium 0
, 0
23 0
workers 0
removed 0
from 0
exposure 0
because 0
of 0
the 0
discovery 0
of 0
an 0
increased 0
urinary 0
excretion 0
of 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
or 0
retinol B-gene
binding I-gene
protein I-gene
, 0
or 0
both 0
, 0
have 0
been 0
examined 0
once 0
a 0
year 0
for 0
five 0
years 0
. 0

In 0
order 0
to 0
study 0
the 0
structural 0
and 0
functional 0
organization 0
of 0
the 0
eukaryotic 0
nucleolus 0
, 0
we 0
have 0
started 0
to 0
isolate 0
and 0
characterize 0
nucleolar 0
components 0
of 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

A 0
transcription 0
factor 0
exclusion 0
assay 0
was 0
used 0
to 0
show 0
that 0
the 0
PCF1 B-gene
mutation I-gene
affects 0
two 0
distinct 0
stages 0
in 0
transcription 0
: 0
one 0
prior 0
to 0
and 0
one 0
after 0
stable 0
complex 0
formation 0
; 0
and 0
that 0
these 0
effects 0
are 0
mediated 0
by 0
a 0
component 0
of 0
the 0
stable 0
complex 0
. 0

Psychiatry 0
and 0
the 0
skin 0
. 0

These 0
adverse 0
effects 0
usually 0
abate 0
with 0
time 0
. 0

The 0
cytosolic 0
glutathione B-gene
S I-gene
- I-gene
transferases I-gene
( 0
GSTs B-gene
, 0
EC B-gene
2.5.1.18 I-gene
) 0
are 0
a 0
superfamily 0
of 0
dimeric 0
isoenzymes 0
which 0
catalyze 0
the 0
conjugation 0
of 0
electrophilic 0
substrates 0
with 0
glutathione 0
. 0

Furthermore 0
, 0
the 0
3' 0
- 0
untranslated 0
regions 0
of 0
pmGT10 B-gene
display 0
a 0
marked 0
degree 0
of 0
homology 0
to 0
the 0
3 0
' 0
region 0
of 0
the 0
rat B-gene
Yb1 I-gene
gene I-gene
, 0
while 0
this 0
region 0
of 0
pmGT2 B-gene
displays 0
marked 0
homology 0
to 0
the 0
corresponding 0
region 0
of 0
the 0
rat B-gene
Yb2 I-gene
gene I-gene
. 0

Model 0
IV 0
: 0
primary 0
abutments 0
with 0
the 0
lateral 0
incisor 0
and 0
the 0
second 0
molar 0
as 0
secondary 0
abutments 0
. 0

The 0
incidence 0
of 0
fetal 0
breathing 0
movements 0
( 0
06.00 0
- 0
10.00 0
h 0
) 0
decreased 0
with 0
increasing 0
gestational 0
age 0
while 0
fetal 0
arterial 0
concentrations 0
of 0
plasma 0
PGE 0
increased 0
significantly 0
over 0
the 0
same 0
period 0
of 0
gestation 0
. 0

During 0
the 0
first 0
3 0
min 0
of 0
recovery 0
, 0
plasma 0
potassium 0
fell 0
rapidly 0
in 0
spite 0
of 0
nearly 0
unchanged 0
blood 0
acidosis 0
and 0
significantly 0
decreasing 0
bicarbonate 0
concentration 0
. 0

The 0
present 0
data 0
also 0
suggest 0
that 0
when 0
compared 0
to 0
the 0
systemic 0
vascular 0
bed 0
, 0
the 0
pulmonary 0
vascular 0
bed 0
is 0
less 0
responsive 0
to 0
bolus 0
administration 0
of 0
ET B-gene
- I-gene
1 I-gene
. 0

In 0
comparison 0
with 0
normal 0
pregnant 0
women 0
and 0
normal 0
non 0
- 0
pregnant 0
women 0
, 0
women 0
with 0
PIH 0
showed 0
an 0
increase 0
in 0
heart 0
rate 0
, 0
suggesting 0
an 0
increased 0
peripheral 0
sympathetic 0
tone 0
, 0
and 0
an 0
initial 0
derangement 0
in 0
renal 0
function 0
as 0
shown 0
by 0
the 0
increase 0
in 0
serum 0
uric 0
acid 0
and 0
reduction 0
in 0
sodium 0
excretion 0
and 0
total 0
and 0
fractional 0
calcium 0
excretion 0
at 0
any 0
given 0
level 0
of 0
sodium 0
excretion 0
. 0

We 0
have 0
examined 0
the 0
role 0
of 0
two 0
recombination 0
- 0
and 0
repair 0
- 0
defective 0
mutations 0
, 0
rad1 B-gene
and 0
rad52 B-gene
, 0
on 0
direct 0
repeat 0
recombination 0
in 0
transcriptionally 0
active 0
and 0
inactive 0
sequences 0
. 0

The 0
encoded 0
protein 0
has 0
a 0
leader 0
sequence 0
of 0
27 0
amino 0
acids 0
. 0

On 0
the 0
other 0
hand 0
, 0
knowledge 0
of 0
the 0
epidemiology 0
of 0
Parkinson 0
's 0
disease 0
is 0
necessary 0
in 0
creating 0
etiological 0
hypotheses 0
, 0
since 0
only 0
hypotheses 0
consistent 0
with 0
the 0
epidemiological 0
profile 0
deserve 0
careful 0
testing 0
. 0

The 0
stereoselectivity 0
of 0
drug 0
action 0
. 0

Scotchbond 0
2 0
showed 0
the 0
least 0
dye 0
penetration 0
but 0
not 0
statistically 0
less 0
than 0
the 0
XR 0
bond/Silus 0
Plus 0
combination 0
. 0

A 0
combination 0
of 0
cisplatin 0
and 0
5 0
- 0
fluorouracil 0
, 0
both 0
administered 0
4 0
days 0
continuously 0
as 0
infusion 0
, 0
was 0
assessed 0
in 0
advanced 0
head 0
and 0
neck 0
cancer 0
. 0

Metformin 0
plasma 0
concentrations 0
remained 0
unchanged 0
except 0
for 0
patients 0
transferred 0
from 0
1.5 0
to 0
2.0 0
g 0
daily 0
to 0
850 0
mg 0
twice 0
daily 0
; 0
in 0
these 0
patients 0
plasma 0
concentrations 0
increased 0
from 0
1.83 0
+/ 0
- 0
0.87 0
to 0
2.50 0
+/ 0
- 0
0.89 0
micrograms/l 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Diagnosis 0
of 0
primary 0
sclerosing 0
cholangitis 0
in 0
a 0
blood 0
donor 0
with 0
elevated 0
serum B-gene
alanine I-gene
aminotransferase I-gene
. 0

When 0
statistically 0
analyzed 0
in 0
various 0
subgroupings 0
, 0
the 0
obtained 0
average 0
sedimentation 0
coefficients 0
and 0
polydispersity 0
profiles 0
supported 0
the 0
following 0
conclusions 0
: 0
( 0
a 0
) 0
loss 0
of 0
proteoglycan 0
aggregation 0
and 0
sedimentability 0
is 0
confirmed 0
to 0
be 0
a 0
primary 0
sign 0
of 0
cartilage 0
matrix 0
degradation 0
; 0
( 0
b 0
) 0
higher 0
S 0
values 0
for 0
proteoglycans 0
of 0
the 0
high 0
weight 0
( 0
HW 0
) 0
- 0
bearing 0
areas 0
and 0
lower 0
values 0
for 0
those 0
of 0
the 0
low 0
weight 0
( 0
LW 0
) 0
- 0
bearing 0
areas 0
were 0
a 0
typical 0
finding 0
in 0
normal 0
cartilage 0
samples 0
; 0
( 0
c 0
) 0
inversion 0
of 0
this 0
pattern 0
was 0
indicative 0
of 0
matrix 0
degradation 0
, 0
suggesting 0
that 0
the 0
HW 0
regions 0
are 0
more 0
affected 0
than 0
the 0
LW 0
- 0
bearing 0
areas 0
; 0
( 0
d 0
) 0
the 0
average 0
S 0
value 0
distribution 0
across 0
cartilage 0
thickness 0
tended 0
to 0
resemble 0
the 0
corresponding 0
proteoglycan 0
content 0
versus 0
distance 0
from 0
articular 0
surface 0
; 0
and 0
( 0
e 0
) 0
the 0
deepest 0
cartilage 0
layer 0
had 0
, 0
in 0
most 0
cases 0
, 0
the 0
smallest 0
amount 0
of 0
aggregates 0
while 0
the 0
highest 0
average 0
sedimentability 0
was 0
observed 0
at 0
the 0
middle 0
zone 0
of 0
the 0
normal 0
samples 0
. 0

A 0
significant 0
relationship 0
existed 0
during 0
the 0
evolution 0
of 0
the 0
disease 0
between 0
CRS/BW 0
and 0
gas 0
exchange 0
parameters 0
( 0
FIO2 0
and 0
a/AO2 0
ratio 0
) 0
( 0
P 0
less 0
than 0
0.01 0
) 0
, 0
but 0
gas 0
exchange 0
improved 0
earlier 0
than 0
lung 0
mechanics 0
. 0

End 0
points 0
measured 0
were 0
perioperative 0
( 0
30 0
- 0
day 0
) 0
myocardial 0
infarction 0
( 0
MI 0
) 0
rate 0
and 0
death 0
. 0

The 0
predicted 0
molecular 0
weight 0
of 0
the 0
polyprotein 0
encoded 0
by 0
ORF1 0
is 0
33 0
kilodaltons 0
( 0
kDa 0
) 0
. 0

Thus 0
RV 0
O2 0
demand 0
fell 0
when 0
RC 0
O2 0
supply 0
was 0
reduced 0
, 0
although 0
a 0
flow 0
reserve 0
was 0
available 0
. 0

An 0
alternative 0
method 0
of 0
UKM 0
is 0
proposed 0
based 0
on 0
collecting 0
a 0
small 0
fraction 0
of 0
spent 0
dialysate 0
flow 0
for 0
3 0
consecutive 0
dialyses 0
. 0

Liquid 0
chromatography 0
with 0
amperometric 0
detection 0
( 0
LC/AD 0
) 0
is 0
used 0
to 0
determine 0
fluazifop 0
acid 0
produced 0
from 0
the 0
metabolism 0
or 0
base 0
hydrolysis 0
of 0
fluazifop 0
- 0
butyl 0
in 0
soybeans 0
and 0
soybean 0
oil 0
. 0

The 0
dichloromethane 0
is 0
removed 0
, 0
mobile 0
phase 0
solvent 0
is 0
added 0
, 0
and 0
aliquots 0
are 0
injected 0
onto 0
a 0
PRP 0
- 0
1 0
liquid 0
chromatographic 0
column 0
; 0
fluazifop 0
acid 0
is 0
separated 0
from 0
coextracted 0
compounds 0
and 0
detected 0
at 0
an 0
applied 0
potential 0
of 0
+ 0
1.25 0
V 0
, 0
using 0
an 0
amperometric 0
electrochemical 0
detector 0
in 0
the 0
oxidation 0
mode 0
. 0

Primer 0
extension 0
experiments 0
indicated 0
that 0
the 0
transcription 0
initiation 0
site 0
mapped 0
to 0
a 0
position 0
on 0
gene B-gene
IV I-gene
that 0
was 0
analogous 0
to 0
that 0
reported 0
for 0
the 0
structurally 0
similar 0
P B-gene
- I-gene
450e I-gene
gene I-gene
. 0

Significantly 0
, 0
the 0
polymerase 0
chain 0
reaction 0
results 0
demonstrated 0
that 0
gene B-gene
IV I-gene
transcripts I-gene
were 0
associated 0
with 0
hepatic 0
polysome 0
fractions 0
, 0
indicating 0
their 0
active 0
utilization 0
in 0
this 0
tissue 0
. 0

Validation 0
of 0
the 0
survey 0
of 0
work 0
styles 0
: 0
a 0
profile 0
measure 0
of 0
the 0
type 0
A 0
behaviour 0
pattern 0
. 0

Only 0
one 0
ADR 0
was 0
related 0
definitely 0
to 0
ciprofloxacin 0
therapy 0
. 0

HIV 0
infectiousness 0
and 0
the 0
AIDS 0
epidemic 0
. 0

From 0
day 0
30 0
after 0
turnout 0
, 0
the 0
PFB 0
- 0
group 0
had 0
significantly 0
lower 0
serum B-gene
pepsinogen I-gene
levels 0
, 0
which 0
reflects 0
the 0
low 0
degree 0
of 0
abomasal 0
damage 0
in 0
these 0
animals 0
. 0

The 0
corresponding 0
inhibition 0
of 0
acid B-gene
phosphatase I-gene
activity 0
in 0
control 0
male 0
and 0
female 0
guinea 0
pigs 0
was 0
15.91 0
% 0
and 0
20.33 0
% 0
respectively 0
. 0

Its 0
clinical 0
and 0
histopathologic 0
characteristics 0
. 0

Normocapnic 0
( 0
PACO2 0
= 0
40 0
mm 0
Hg 0
) 0
ventilatory 0
drive 0
increased 0
significantly 0
( 0
p 0
less 0
than 0
0.05 0
) 0
in 0
six 0
subjects 0
( 0
Type 0
1 0
response 0
) 0
and 0
decreased 0
substantially 0
in 0
the 0
others 0
( 0
Type 0
2 0
response 0
) 0
; 0
with 0
hypercapnia 0
, 0
the 0
changes 0
in 0
drive 0
were 0
attenuated 0
in 0
both 0
groups 0
. 0

Fundus 0
changes 0
in 0
( 0
type 0
II 0
) 0
mesangiocapillary 0
glomerulonephritis 0
simulating 0
drusen 0
: 0
a 0
histopathological 0
report 0
. 0

Chronic 0
dose 0
effects 0
of 0
methyl 0
parathion 0
on 0
nuthatches 0
: 0
cholinesterase B-gene
and 0
ptilochronology 0
. 0

The 0
titer 0
of 0
anti B-gene
HSV I-gene
type I-gene
1 I-gene
and 0
anti B-gene
HSV I-gene
type I-gene
2 I-gene
antibodies I-gene
in 0
the 0
mothers 0
' 0
and 0
cord 0
blood 0
was 0
determined 0
and 0
compared 0
. 0

Kidney 0
weight 0
and 0
kidney 0
- 0
to 0
- 0
body 0
weight 0
ratio 0
were 0
significantly 0
elevated 0
at 0
the 0
highest 0
dose 0
level 0
after 0
10 0
weeks 0
and 0
at 0
the 0
two 0
higher 0
dose 0
levels 0
after 0
15 0
weeks 0
of 0
exposure 0
. 0

Allelic 0
variation 0
in 0
HLA B-gene
- I-gene
B I-gene
and 0
HLA B-gene
- I-gene
C I-gene
sequences I-gene
and 0
the 0
evolution 0
of 0
the 0
HLA B-gene
- I-gene
B I-gene
alleles I-gene
. 0

A 0
method 0
for 0
determining 0
optimal 0
development 0
conditions 0
by 0
summary 0
oxygen 0
consumption 0

Men 0
were 0
more 0
positive 0
about 0
their 0
physical 0
fitness 0
than 0
women 0
. 0

Handgrip 0
dynamometry 0
was 0
also 0
carried 0
out 0
in 0
249 0
of 0
the 0
patients 0
. 0

In 0
cerebrospinal 0
fluid 0
, 0
an 0
ADA B-gene
catalytic 0
concentration 0
above 0
0.15 0
mu 0
kat/L 0
strongly 0
suggests 0
tuberculous 0
meningitis 0
in 0
patients 0
older 0
than 0
7 0
years 0
( 0
sensitivity 0
1.00 0
, 0
specificity 0
0.99 0
and 0
efficiency 0
0.99 0
) 0
. 0

NERVTRACK 0
contains 0
4000 0
anatomical 0
data 0
items 0
arranged 0
in 0
a 0
tree 0
- 0
like 0
manner 0
reflecting 0
structural 0
and 0
functional 0
relationships 0
. 0

Swim 0
- 0
over 0
: 0
an 0
alternative 0
method 0
for 0
harvesting 0
motile 0
spermatozoa 0
. 0

Perfusion 0
washout 0
: 0
increasing 0
a 0
microvascular 0
free 0
flap 0
tolerance 0
to 0
ischemia 0
. 0

Similarly 0
, 0
the 0
sequence 0
of 0
the 0
U2 B-gene
RNA I-gene
region I-gene
shown 0
to 0
be 0
involved 0
in 0
pre 0
- 0
mRNA 0
branchpoint 0
recognition 0
in 0
yeast 0
, 0
and 0
exactly 0
conserved 0
in 0
metazoan B-gene
U2 I-gene
RNAs I-gene
, 0
was 0
totally 0
divergent 0
in 0
trypanosomes 0
. 0

It 0
is 0
striking 0
that 0
the 0
active 0
CHO 0
spacer 0
promoter 0
violated 0
the 0
otherwise 0
universal 0
rule 0
that 0
metazoan B-gene
RNA I-gene
polymerase I-gene
I I-gene
promoters I-gene
all 0
have 0
a 0
G 0
residue 0
at 0
position 0
- 0
16 0
. 0

A 0
raised 0
amplitude 0
of 0
the 0
aggregation 0
of 0
plates 0
and 0
a 0
decrease 0
in 0
the 0
threshold 0
of 0
their 0
sensitivity 0
to 0
ADP 0
were 0
established 0
in 0
the 0
persons 0
with 0
types 0
IIa 0
and 0
IIb 0
HLP 0
and 0
in 0
CHD 0
without 0
HLP 0
. 0

Significant 0
intergroup 0
differences 0
are 0
highlighted 0
for 0
both 0
selected 0
dentoskeletal 0
and 0
soft 0
tissue 0
profile 0
variables 0
. 0

The 0
author 0
provides 0
a 0
rationale 0
for 0
an 0
interactional 0
view 0
and 0
presents 0
a 0
case 0
in 0
which 0
post 0
- 0
surgical 0
hiccups 0
were 0
successfully 0
treated 0
, 0
using 0
principles 0
developed 0
by 0
the 0
Mental 0
Research 0
Institute 0
. 0

The 0
relative 0
toxicity 0
of 0
nickel 0
oxide 0
( 0
NiO 0
) 0
, 0
nickel 0
sulfate 0
hexahydrate 0
( 0
NiSO4.6H2O 0
) 0
, 0
and 0
nickel 0
subsulfide 0
( 0
Ni3S2 0
) 0
was 0
studied 0
in 0
F344/N 0
rats 0
and 0
B6C3F1 0
mice 0
after 0
inhalation 0
exposure 0
for 0
6 0
hr/day 0
, 0
5 0
days/week 0
, 0
for 0
13 0
weeks 0
. 0

Light 0
microscopical 0
and 0
routine 0
immunohistochemical 0
studies 0
of 0
a 0
cervical 0
neoplasm 0
in 0
a 0
32 0
year 0
old 0
woman 0
initially 0
suggested 0
a 0
histiocytic 0
lymphoma 0
, 0
but 0
histochemical 0
staining 0
for 0
chloroacetate B-gene
esterase I-gene
established 0
the 0
correct 0
diagnosis 0
. 0

From 0
the 0
National 0
Institutes 0
of 0
Health 0
. 0

Molecular 0
cloning 0
and 0
characterisation 0
of 0
the 0
two 0
homologous 0
genes 0
coding 0
for 0
nitrate B-gene
reductase I-gene
in I-gene
tobacco I-gene
. 0

In 0
the 0
final 0
model 0
, 0
grade 0
( 0
p 0
= 0
0.0002 0
) 0
, 0
peritoneal 0
cytologic 0
results 0
( 0
p 0
= 0
0.0002 0
) 0
, 0
progesterone B-gene
receptor I-gene
status 0
( 0
p 0
= 0
0.004 0
) 0
, 0
and 0
age 0
as 0
a 0
continuous 0
variable 0
( 0
p 0
= 0
0.008 0
) 0
were 0
most 0
closely 0
associated 0
with 0
disease 0
- 0
free 0
survival 0
. 0

In 0
contrast 0
, 0
despite 0
external 0
radiation 0
therapy 0
, 0
brain 0
metastases 0
proved 0
fatal 0
. 0

COUP B-gene
transcription I-gene
factor I-gene
is 0
a 0
member 0
of 0
the 0
steroid B-gene
receptor I-gene
superfamily I-gene
. 0

In 0
Experiment 0
2 0
, 0
we 0
again 0
used 0
classification 0
, 0
but 0
the 0
fixed 0
standard 0
75 0
was 0
not 0
at 0
the 0
center 0
of 0
the 0
range 0
of 0
target 0
numbers 0
( 0
20 0
, 0
21 0
, 0
... 0

Cosmid 0
clones 0
containing 0
both 0
VNTR 0
sequences 0
were 0
identified 0
, 0
and 0
restriction 0
mapping 0
showed 0
them 0
to 0
be 0
less 0
than 0
15 0
kb 0
apart 0
. 0

The 0
oxygen 0
uptake 0
( 0
VO2 0
) 0
, 0
carbon 0
dioxide 0
output 0
( 0
VCO2 0
) 0
, 0
respiratory 0
rate 0
( 0
fR 0
) 0
, 0
minute 0
ventilation 0
( 0
VE 0
) 0
, 0
alveolar 0
ventilation 0
( 0
VA 0
) 0
, 0
alveolar 0
oxygen 0
pressure 0
( 0
PAO2 0
) 0
, 0
and 0
VE/VO2 0
ratio 0
were 0
higher 0
in 0
the 0
cows 0
, 0
while 0
the 0
tidal 0
volume 0
( 0
VT 0
) 0
and 0
physiological 0
dead 0
space 0
( 0
VD 0
) 0
were 0
larger 0
in 0
the 0
horses 0
. 0

Epithelial 0
damage 0
was 0
not 0
observed 0
in 0
any 0
controls 0
but 0
was 0
in 0
all 0
tissues 0
exposed 0
to 0
SO2 0
. 0

Among 0
booked 0
patients 0
the 0
maternal 0
mortality 0
rate 0
was 0
0.32 0
and 0
among 0
unbooked 0
patients 0
11.13 0
per 0
1000 0
deliveries 0
. 0

The 0
present 0
study 0
investigates 0
whether 0
prostaglandins 0
`` 0
cytoprotect 0
'' 0
the 0
gastric 0
mucosa 0
against 0
hemorrhage 0
- 0
induced 0
stress 0
ulceration 0
by 0
assessing 0
the 0
influence 0
of 0
16,16 0
- 0
dimethyl 0
prostaglandin 0
E2 0
( 0
16,16 0
- 0
dm 0
PGE2 0
) 0
on 0
gross 0
and 0
microscopic 0
lesion 0
formation 0
, 0
intramucosal 0
tissue 0
pH 0
, 0
H+ 0
back 0
- 0
diffusion 0
, 0
and 0
mucosal 0
blood 0
flow 0
in 0
rat 0
gastric 0
mucosa 0
exposed 0
to 0
luminal 0
acid 0
( 0
100 0
mM 0
HCl 0
) 0
during 0
hemorrhagic 0
shock 0
( 0
13 0
ml/kg 0
for 0
20 0
min 0
) 0
. 0

Transcripts 0
characterized 0
include 0
( 0
i 0
) 0
abundant 0
monocistronic 0
L11e B-gene
and 0
tricistronic 0
L1e B-gene
- 0
L10e B-gene
- 0
L12e B-gene
transcripts 0
; 0
( 0
ii 0
) 0
less 0
abundant 0
bicistronic 0
NAB B-gene
- 0
L11e B-gene
and 0
monocistronic 0
NAB B-gene
transcripts I-gene
and 0
( 0
iii 0
) 0
a 0
very 0
rare 0
ORF 0
monocistronic 0
transcript 0
. 0

Qualitatively 0
, 0
the 0
results 0
are 0
similar 0
for 0
the 0
two 0
species 0
: 0
Both 0
rhesus 0
monkey 0
and 0
man 0
have 0
photopic 0
and 0
scotopic 0
branches 0
, 0
which 0
cross 0
at 0
approximately 0
the 0
same 0
time 0
in 0
the 0
dark 0
and 0
at 0
approximately 0
the 0
same 0
background 0
luminance 0
. 0

Evidence 0
from 0
the 0
structure 0
of 0
a 0
number 0
of 0
cDNA 0
clones 0
, 0
as 0
well 0
as 0
S1 B-gene
nuclease I-gene
and 0
primer 0
extension 0
studies 0
supports 0
the 0
hypothesis 0
that 0
the 0
PTHrP B-gene
gene I-gene
contains 0
at 0
least 0
two 0
mRNA 0
transcription 0
start 0
points 0
that 0
define 0
two 0
putative 0
regulatory 0
domains 0
. 0

At 0
each 0
level 0
of 0
PaO2 0
we 0
obtained 0
simultaneous 0
measures 0
of 0
arterial 0
and 0
venous 0
blood 0
gases 0
, 0
venous 0
lactate 0
concentration 0
, 0
and 0
changes 0
in 0
the 0
relative 0
concentrations 0
of 0
inorganic 0
phosphate 0
, 0
phosphocreatine 0
, 0
and 0
ATP 0
measured 0
with 0
31P 0
magnetic 0
resonance 0
spectroscopy 0
. 0

The 0
transcription 0
initiation 0
site 0
was 0
determined 0
by 0
S1 B-gene
nuclease I-gene
mapping 0
. 0

Endometrial 0
biopsies 0
and 0
plasma 0
oestradiol 0
( 0
E2 0
) 0
and 0
progesterone 0
( 0
P4 0
) 0
levels 0
in 0
23 0
patients 0
were 0
evaluated 0
during 0
26 0
replacement 0
therapy 0
cycles 0
for 0
premature 0
ovarian 0
failure 0
. 0

The 0
mobility 0
of 0
the 0
upper 0
and 0
lower 0
premolars 0
under 0
load 0
was 0
investigated 0
in 0
relation 0
to 0
the 0
interproximal 0
contact 0
and 0
occlusal 0
facets 0
. 0

A 0
larval B-gene
albumin I-gene
- I-gene
like I-gene
protein I-gene
was 0
not 0
detectable 0
by 0
silver 0
staining 0
in 0
serum 0
of 0
tadpoles 0
before 0
the 0
beginning 0
of 0
metamorphosis 0
at 0
stage 0
48 0
. 0

Behaviorally 0
, 0
a 0
pain 0
- 0
tolerant 0
group 0
( 0
PT 0
= 0
29 0
Ss 0
) 0
tolerated 0
the 0
entire 0
3 0
- 0
min 0
test 0
( 0
means 0
= 0
180 0
+/ 0
- 0
0 0
sec 0
) 0
, 0
while 0
a 0
pain 0
- 0
sensitive 0
group 0
( 0
PS 0
= 0
13 0
Ss 0
) 0
averaged 0
only 0
50.31 0
+/ 0
- 0
20.81 0
sec 0
of 0
the 0
cold 0
- 0
pressor 0
test 0
( 0
t 0
= 0
16.75 0
, 0
P 0
less 0
than 0
0.0001 0
) 0
, 0
replicating 0
our 0
earlier 0
studies 0
. 0

This 0
suggested 0
that 0
baboon B-gene
liver I-gene
class I-gene
I I-gene
ADH I-gene
is 0
of 0
the 0
same 0
ancestral 0
lineage 0
as 0
the 0
human B-gene
ADH I-gene
- I-gene
beta I-gene
. 0

Isolated 0
proteinuria 0
( 0
i.e 0
. 0
without 0
hematuria 0
and/or 0
pyuria 0
) 0
is 0
a 0
frequent 0
finding 0
. 0

Each 0
individual 0
shot 0
25 0
bullets 0
in 0
about 0
5 0
minutes 0
, 0
at 0
an 0
intensity 0
level 0
calculated 0
at 0
163 0
dB 0
. 0

Lithium 0
delays 0
the 0
circadian 0
rhythm 0
of 0
wheel 0
- 0
running 0
in 0
Syrian 0
hamsters 0
at 0
plasma 0
concentrations 0
( 0
0.59 0
- 0
0.74 0
mM 0
) 0
that 0
also 0
cause 0
toxic 0
weight 0
loss 0
. 0

Dynamic 0
and 0
static 0
scintigrams 0
, 0
using 0
99mtechnetium 0
methylene 0
diphosphonate 0
, 0
were 0
obtained 0
at 0
zero 0
, 0
six 0
, 0
and 0
12 0
weeks 0
after 0
fracture 0
. 0

On 0
admission 0
to 0
our 0
department 0
in 0
September 0
, 0
1987 0
, 0
the 0
patient 0
was 0
alert 0
and 0
had 0
spastic 0
paraparesis 0
, 0
the 0
impairment 0
of 0
all 0
sensory 0
modalities 0
below 0
the 0
level 0
of 0
Th 0
10 0
and 0
urinary 0
disturbance 0
. 0

Prostaglandins 0
and 0
gallstones 0

The 0
nature 0
of 0
the 0
process 0
formed 0
by 0
the 0
successive 0
occurrences 0
of 0
this 0
arrhythmia 0
was 0
studied 0
in 0
8 0
patients 0
with 0
a 0
history 0
of 0
symptomatic 0
paroxysmal 0
AF 0
. 0

This 0
would 0
have 0
had 0
the 0
effect 0
of 0
positioning 0
the 0
genes 0
currently 0
on 0
the 0
long 0
arm 0
adjacent 0
to 0
the 0
centromeric 0
heterochromatin 0
, 0
perhaps 0
resulting 0
in 0
a 0
`` 0
position 0
effect 0
'' 0
on 0
transcription 0
of 0
these 0
genes 0
. 0

Initial 0
experience 0
with 0
a 0
microprocessor 0
controlled 0
current 0
based 0
defibrillator 0
. 0

Obesity 0
was 0
strongly 0
associated 0
with 0
the 0
proportions 0
of 0
nonprotein 0
- 0
bound 0
and 0
albumin B-gene
- 0
bound 0
estradiol 0
, 0
and 0
inversely 0
associated 0
with 0
sex B-gene
hormone I-gene
binding I-gene
globulin I-gene
( 0
SHBG B-gene
) 0
levels 0
and 0
the 0
proportion 0
of 0
SHBG B-gene
- 0
bound 0
estradiol 0
. 0

Heterogeneous B-gene
nuclear I-gene
ribonucleoprotein I-gene
( I-gene
hnRNP I-gene
) I-gene
core I-gene
protein I-gene
A1 I-gene
is 0
a 0
major 0
component 0
of 0
mammalian B-gene
hnRNP I-gene
40 I-gene
S I-gene
particles I-gene
. 0

Brain B-gene
cholinesterase I-gene
activity 0
of 0
nestling 0
great 0
egrets 0
, 0
snowy 0
egrets 0
and 0
black 0
- 0
crowned 0
night 0
- 0
herons 0
. 0
inhibition 0
of 0
brain B-gene
cholinesterase I-gene
( 0
ChE B-gene
) 0
activity 0
in 0
birds 0
is 0
often 0
used 0
to 0
diagnose 0
exposure 0
or 0
death 0
from 0
organophosphorus 0
or 0
carbamate 0
pesticides 0
. 0

The 0
effect 0
of 0
zinc 0
deficiency 0
on 0
trace 0
metals 0
in 0
the 0
liver 0
, 0
spleen 0
, 0
kidney 0
, 0
pancreas 0
and 0
duodenum 0
was 0
investigated 0
in 0
the 0
control 0
and 0
zinc 0
- 0
deficient 0
rats 0
at 0
17 0
days 0
and 0
20 0
days 0
of 0
pregnancy 0
. 0

Our 0
findings 0
support 0
the 0
view 0
of 0
a 0
multifactorial 0
genesis 0
of 0
the 0
cardiac 0
involvement 0
in 0
uremic 0
patients 0
. 0

Heating 0
cells 0
to 0
43 0
degrees 0
C 0
decreased 0
the 0
amount 0
of 0
newly 0
synthesized 0
rRNA 0
to 0
less 0
than 0
5 0
% 0
of 0
the 0
control 0
level 0
and 0
led 0
to 0
greater 0
than 0
95 0
% 0
inhibition 0
of 0
transcription 0
termination 0
at 0
a 0
region 0
355 0
to 0
362 0
nucleotides 0
downstream 0
of 0
the 0
3 0
' 0
end 0
of 0
28S B-gene
rRNA I-gene
, 0
with 0
readthrough 0
continuing 0
into 0
the 0
next 0
transcription 0
unit 0
. 0

Deletion 0
analysis 0
showed 0
that 0
the 0
NF B-gene
- I-gene
4FA I-gene
, 0
NF B-gene
- I-gene
4FB I-gene
, 0
and 0
AP B-gene
- I-gene
1 I-gene
sequences 0
are 0
each 0
necessary 0
for 0
full 0
enhancer 0
activity 0
. 0

Cord 0
swelling 0
was 0
observed 0
in 0
2 0
patients 0
who 0
developed 0
complete 0
lesions 0
. 0

Reye 0
's 0
syndrome 0
: 0
reports 0
of 0
7 0
cases 0
in 0
the 0
period 0
1982 0
- 0
1987 0

When 0
two 0
- 0
dimensional 0
polyacrylamide 0
gel 0
electrophoretic 0
patterns 0
of 0
[ 0
35S 0
] 0
methionine 0
- 0
labeled 0
proteins 0
secreted 0
from 0
cells 0
infected 0
with 0
parental 0
and 0
recombinant 0
viruses 0
were 0
compared 0
, 0
a 0
spot 0
missing 0
from 0
the 0
latter 0
corresponded 0
in 0
molecular 0
weigh 0
and 0
isoelectric 0
point 0
with 0
that 0
predicted 0
from 0
the 0
N1L B-gene
ORF I-gene
. 0

PULSE 0
is 0
used 0
to 0
set 0
such 0
NMR 0
spectroscopic 0
parameters 0
as 0
the 0
delay 0
and 0
duration 0
of 0
rf 0
transmit 0
and 0
receive 0
gates 0
, 0
rf 0
phase 0
, 0
sampling 0
times 0
, 0
and 0
such 0
imaging 0
parameters 0
as 0
rf 0
pulse 0
shape 0
and 0
gradient 0
waveforms 0
. 0

Definite 0
JPsA 0
( 0
24 0
patients 0
) 0
was 0
defined 0
as 0
arthritis 0
associated 0
, 0
but 0
not 0
necessarily 0
coincident 0
, 0
with 0
a 0
typical 0
psoriatic 0
rash 0
, 0
or 0
arthritis 0
plus 0
at 0
least 0
3 0
of 0
4 0
minor 0
criteria 0
: 0
dactylitis 0
, 0
nail 0
pitting 0
, 0
psoriasis 0
- 0
like 0
rash 0
, 0
or 0
family 0
history 0
of 0
psoriasis 0
. 0

Hence 0
follows 0
Kurti 0
's 0
demand 0
to 0
mete 0
out 0
appropriate 0
importance 0
to 0
the 0
arguments 0
. 0

The 0
author 0
gives 0
an 0
account 0
of 0
antipsychotic 0
, 0
analgetic 0
, 0
myorelaxing 0
and 0
vasodilatating 0
effects 0
of 0
some 0
calcium 0
antagonists 0
, 0
and 0
their 0
clinical 0
application 0
is 0
discussed 0
. 0

A 0
correlation 0
coefficient 0
was 0
used 0
for 0
assessing 0
the 0
similarity 0
of 0
each 0
map 0
pattern 0
with 0
the 0
normal 0
mean 0
IQRST 0
map 0
. 0

A 0
hospital 0
- 0
based 0
study 0
of 0
the 0
relationship 0
between 0
retained 0
placenta 0
and 0
mastitis 0
in 0
dairy 0
cows 0
. 0

This 0
indicates 0
that 0
lipid 0
peroxidation 0
may 0
be 0
involved 0
in 0
the 0
development 0
of 0
senile 0
cataract 0
and 0
, 0
as 0
a 0
direct 0
consequence 0
of 0
retinal 0
damage 0
, 0
also 0
in 0
the 0
pathogenesis 0
of 0
cataract 0
in 0
diabetes 0
and 0
in 0
severe 0
myopia 0
. 0

The 0
histological 0
grading 0
was 0
certified 0
in 0
68 0
cases 0
: 0
12 0
G1 0
, 0
39 0
G2 0
, 0
17 0
G3 0
; 0
extracapsular 0
spread 0
was 0
found 0
in 0
20/54 0
cases 0
( 0
37 0
% 0
) 0
. 0

Asthma 0
was 0
significantly 0
more 0
often 0
associated 0
with 0
ASA 0
group 0
( 0
91 0
% 0
) 0
vs 0
46 0
% 0
at 0
AT 0
and 0
in 0
only 0
16 0
% 0
at 0
INTR 0
group 0
. 0

A 0
value 0
of 0
1.1 0
l/kg 0
was 0
used 0
for 0
V 0
in 0
calculating 0
all 0
single 0
sample 0
estimates 0
of 0
clearance 0
( 0
CL 0
) 0
, 0
and 0
a 0
value 0
of 0
4.3 0
l/kg 0
was 0
used 0
to 0
calculate 0
single 0
sample 0
estimates 0
of 0
clearance 0
of 0
plasma 0
unbound 0
drug 0
( 0
CLunb 0
) 0
. 0

The 0
solitary 0
kidney 0
: 0
a 0
model 0
of 0
chronic 0
hyperfiltration 0
in 0
humans 0
. 0

Halothane 0
is 0
metabolized 0
by 0
an 0
oxidative 0
pathway 0
to 0
stable 0
, 0
nonvolatile 0
end 0
products 0
, 0
trifluoroacetic 0
acid 0
( 0
TFAA 0
) 0
and 0
bromide 0
( 0
Br 0
- 0
) 0
, 0
and 0
by 0
reductive 0
pathways 0
to 0
Br 0
- 0
and 0
inorganic 0
fluoride 0
( 0
F 0
- 0
) 0
. 0

The 0
values 0
were 0
consistently 0
lower 0
( 0
P 0
less 0
than 0
0.01 0
) 0
during 0
summer 0
( 0
3.79 0
+/ 0
- 0
0.13 0
micrograms/100 0
ml 0
) 0
, 0
as 0
compared 0
to 0
winter 0
( 0
5.06 0
+/ 0
- 0
0.27 0
) 0
. 0

These 0
results 0
suggest 0
that 0
HAPE 0
- 0
S 0
- 0
S 0
are 0
prone 0
to 0
irregular 0
nocturnal 0
breathing 0
patterns 0
at 0
high 0
altitude 0
, 0
which 0
is 0
associated 0
with 0
the 0
development 0
of 0
AMS 0
, 0
but 0
it 0
was 0
not 0
possible 0
to 0
determine 0
whether 0
these 0
abnormal 0
breathing 0
patterns 0
are 0
a 0
cause 0
or 0
an 0
effect 0
of 0
AMS 0
. 0

Buflomedil 0
( 0
i.v 0
. 0
) 0
induced 0
a 0
dose 0
- 0
dependent 0
increase 0
of 0
cardiac 0
output 0
at 0
0.16 0
- 0
0.64 0
mg/kg 0
, 0
biphasic 0
changes 0
at 0
1.28 0
and 0
2.56 0
mg/kg 0
and 0
a 0
marked 0
decrease 0
and 0
subsequent 0
slight 0
increase 0
at 0
a 0
large 0
dose 0
of 0
5.12 0
mg/kg 0
. 0

It 0
was 0
possible 0
to 0
classify 0
the 0
animals 0
into 0
high 0
and 0
low 0
responders 0
according 0
to 0
the 0
pattern 0
of 0
humoral 0
immune 0
response 0
. 0

Heart 0
rate 0
( 0
HR 0
) 0
, 0
rectal 0
temperature 0
( 0
Tre 0
) 0
, 0
blood 0
pressure 0
, 0
temperature 0
and 0
relative 0
humidity 0
changes 0
inside 0
clothing 0
were 0
measured 0
on 0
18 0
professional 0
firemen 0
( 0
mean 0
age 0
29.4 0
+/ 0
- 0
7.4 0
yr 0
, 0
VO2 0
max 0
41.4 0
+ 0
8.8 0
ml 0
kg 0
- 0
1 0
min 0
- 0
1 0
) 0
wearing 0
fire 0
fighter 0
's 0
uniforms 0
( 0
SU 0
) 0
or 0
aluminized 0
, 0
fire 0
resistant 0
, 0
impermeable 0
clothing 0
with 0
self 0
contained 0
breathing 0
apparatus 0
( 0
FE 0
) 0
. 0

The 0
clinical 0
tolerance 0
and 0
pharmacokinetics 0
of 0
FCE 0
22101 0
( 0
sodium 0
( 0
5R 0
, 0
6S 0
) 0
- 0
6 0
- 0
[ 0
( 0
1R 0
) 0
- 0
hydroxyethyl 0
] 0
- 0
2 0
- 0
carbamoyloxymethyl 0
- 0
2 0
- 0
penem 0
- 0
3 0
- 0
carboxylate 0
) 0
, 0
a 0
new 0
penem 0
antibiotic 0
, 0
have 0
been 0
studied 0
after 0
giving 0
a 0
single 0
i.v 0
. 0
dose 0
of 0
4 0
mg.kg 0
- 0
1 0
to 0
ten 0
healthy 0
male 0
volunteers 0
. 0

DNA 0
blot 0
hybridization 0
suggests 0
that 0
the 0
rat 0
genome 0
may 0
contain 0
more 0
than 0
one 0
gene 0
encoding 0
PtdIns B-gene
transfer I-gene
protein I-gene
. 0

We 0
use 0
the 0
term 0
corticosteroid 0
- 0
dependent 0
IA 0
to 0
refer 0
to 0
the 0
serious 0
problem 0
of 0
chronic 0
IA 0
requiring 0
maintenance 0
prednisone 0
therapy 0
. 0

Another 0
segment 0
of 0
CRL3 B-gene
( 0
- 0
296 0
to 0
- 0
184 0
) 0
, 0
also 0
displaying 0
enhancer 0
function 0
, 0
contained 0
tandem 0
repeated 0
sequences 0
( 0
DR 0
- 0
A1 0
and 0
DR 0
- 0
A2 0
) 0
. 0

1 0
- 0
( 0
1 0
- 0
Naphthyl 0
) 0
piperazine 0
( 0
1 0
- 0
NP 0
) 0
has 0
been 0
reported 0
to 0
have 0
serotonin 0
antagonist 0
properties 0
at 0
the 0
5 B-gene
- I-gene
HT2 I-gene
subtype I-gene
of 0
receptor 0
, 0
and 0
it 0
has 0
been 0
suggested 0
that 0
it 0
may 0
have 0
agonist 0
actions 0
at 0
the 0
5 B-gene
- I-gene
HT1 I-gene
site I-gene
. 0

1 0
- 0
( 0
m 0
- 0
Chlorophenyl 0
) 0
piperazine 0
( 0
mCPP 0
, 0
0.1 0
- 0
3.0 0
mg/kg 0
) 0
and 0
1 0
- 0
( 0
m 0
- 0
trifluoromethylphenyl 0
) 0
piperazine 0
( 0
TFMPP 0
, 0
0.1 0
- 0
3.0 0
mg/kg 0
) 0
, 0
both 0
thought 0
to 0
act 0
primarily 0
at 0
5 B-gene
- I-gene
HT1 I-gene
sites I-gene
, 0
also 0
decreased 0
responding 0
and 0
this 0
effect 0
was 0
blocked 0
by 0
methysergide 0
and 0
by 0
1 0
- 0
NP 0
, 0
but 0
not 0
by 0
ketanserin 0
. 0

The 0
characteristic 0
feature 0
of 0
liver 0
and 0
spleen 0
MP 0
function 0
in 0
patients 0
with 0
VHA 0
associated 0
with 0
HBsAg B-gene
carriership 0
consisted 0
in 0
the 0
lack 0
of 0
the 0
compensatory 0
reaction 0
on 0
the 0
part 0
of 0
spleen 0
MP 0
, 0
which 0
was 0
likely 0
to 0
be 0
connected 0
with 0
overstrain 0
of 0
long 0
standing 0
and 0
depletion 0
of 0
the 0
MP 0
system 0
due 0
to 0
permanent 0
antigenic 0
stimulation 0
of 0
HBsAg B-gene
. 0

Changes 0
in 0
xanthine B-gene
oxidase I-gene
activity 0
in 0
patients 0
with 0
circulatory 0
failure 0

A 0
soap 0
and 0
water 0
( 0
1:1 0
, 0
v/v 0
) 0
solution 0
effectively 0
decontaminated 0
powdered 0
stratum 0
corneum 0
. 0

The 0
cytoprotective 0
and 0
antiulcer 0
activities 0
of 0
the 0
antacid 0
magaldrate 0
( 0
ES 0
Riopan 0
) 0
as 0
well 0
as 0
its 0
effects 0
on 0
gastric 0
mucosal 0
blood 0
flow 0
and 0
mucus 0
secretions 0
, 0
were 0
determined 0
in 0
the 0
rat 0
. 0

The 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
preferentially 0
infects 0
CD4+ B-gene
T 0
lymphocytes 0
and 0
may 0
exist 0
as 0
a 0
latent 0
provirus 0
within 0
these 0
cells 0
for 0
extended 0
periods 0
. 0

Histiocytic 0
panniculitis 0
was 0
observed 0
in 0
biopsy 0
specimens 0
with 0
cytophagocytosis 0
. 0

We 0
have 0
utilized 0
the 0
human B-gene
4F2 I-gene
heavy I-gene
chain I-gene
( 0
4F2HC B-gene
) 0
gene 0
as 0
a 0
model 0
system 0
in 0
studies 0
designed 0
to 0
elucidate 0
the 0
molecular 0
events 0
involved 0
in 0
regulating 0
inducible 0
gene 0
expression 0
during 0
normal 0
human 0
T 0
- 0
cell 0
activation 0
. 0

A 0
cDNA 0
encoding 0
the 0
NF B-gene
- I-gene
4FB I-gene
enhancer I-gene
binding I-gene
protein I-gene
has 0
been 0
cloned 0
by 0
screening 0
a 0
lambda 0
gt11 0
cDNA 0
library 0
with 0
a 0
rabiolabelled 0
oligonucleotide 0
corresponding 0
to 0
the 0
NF B-gene
- I-gene
4FB I-gene
recognition I-gene
sequence I-gene
. 0

Electrocardiographic 0
right 0
ventricular 0
hypertrophy 0
was 0
seen 0
in 0
4 0
, 0
and 0
biventricular 0
hypertrophy 0
in 0
5 0
patients 0
. 0

The 0
two 0
IL6 B-gene
mRNA I-gene
species 0
are 0
generated 0
by 0
alternative 0
polyadenylation 0
at 0
sites 0
separated 0
by 0
a 0
distance 0
of 0
1.2 0
kilobases 0
. 0

Sequencing 0
analysis 0
revealed 0
that 0
the 0
0.54 0
- 0
and 0
0.4 0
- 0
kb 0
fragments 0
are 0
identical 0
except 0
for 0
150 0
nucleotides 0
missing 0
at 0
the 0
5 0
' 0
region 0
of 0
the 0
0.4 0
- 0
kb 0
fragment 0
. 0

The 0
mature 0
protein 0
also 0
contains 0
a 0
cysteine 0
- 0
rich 0
, 0
highly 0
hydrophilic 0
region 0
homologous 0
to 0
the 0
ovomucoid B-gene
serine I-gene
protease I-gene
inhibitors I-gene
( 0
residues 0
76 0
- 0
132 0
) 0
. 0

Oligosynaptic 0
EPSP 0
components 0
were 0
consistently 0
modulated 0
only 0
in 0
the 0
superficial 0
peroneal 0
responses 0
in 0
flexor 0
motoneurons 0
, 0
which 0
exhibited 0
enhanced 0
amplitude 0
during 0
the 0
flexion 0
phase 0
. 0

Experiments 0
on 0
23 0
white 0
rats 0
and 0
10 0
guinea 0
pigs 0
have 0
shown 0
that 0
preliminarily 0
indomethacin 0
- 0
induced 0
inhibition 0
of 0
prostaglandins 0
synthesis 0
prevented 0
development 0
of 0
pulmonary 0
oedema 0
, 0
evoked 0
by 0
heterologous 0
serum 0
in 0
rats 0
and 0
by 0
vagotomy 0
in 0
guinea 0
pigs 0
. 0

On 0
the 0
other 0
hand 0
, 0
lack 0
of 0
conservation 0
of 0
the 0
membrane 0
attachment 0
sequence 0
arginine 0
- 0
glycine 0
- 0
aspartic 0
acid 0
argues 0
against 0
its 0
functional 0
importance 0
in 0
CgA B-gene
. 0

Third 0
- 0
and 0
later 0
- 0
parity 0
cows 0
were 0
randomly 0
assigned 0
after 0
each 0
parturition 0
to 0
Charolais 0
and 0
Red 0
Poll 0
bulls 0
in 0
multiple 0
- 0
sire 0
pastures 0
. 0

Within 0
each 0
lobe 0
, 0
the 0
PA 0
dispersion 0
was 0
up 0
to 0
10 0
cmH2O 0
at 0
CFV 0
of 0
90 0
l/min 0
; 0
when 0
flow 0
decreased 0
, 0
PA 0
at 0
all 0
sites 0
decreased 0
, 0
as 0
did 0
the 0
intralobar 0
dispersion 0
. 0

The 0
system 0
consisted 0
of 0
the 0
intact 0
canine 0
heart 0
connected 0
to 0
a 0
microcomputer 0
that 0
operated 0
as 0
the 0
modulated 0
parasystolic 0
pacemaker 0
. 0

In 0
order 0
to 0
identify 0
and 0
classify 0
the 0
basic 0
CT 0
appearances 0
of 0
interstitial 0
pneumonia 0
, 0
radiologic 0
- 0
pathologic 0
correlative 0
study 0
was 0
performed 0
using 0
inflated 0
and 0
fixed 0
lungs 0
from 0
autopsy 0
and 0
surgery 0
. 0

The 0
disease 0
ran 0
an 0
atypical 0
course 0
; 0
with 0
early 0
jaundice 0
syndrome 0
, 0
severe 0
enterorrhagia 0
and 0
late 0
appearance 0
of 0
roseola 0
. 0

The 0
transcription 0
factor 0
Sp1 B-gene
bound 0
to 0
eight 0
sites 0
, 0
as 0
demonstrated 0
by 0
footprinting 0
assays 0
and 0
gel 0
shift 0
analysis 0
with 0
purified 0
Sp1 B-gene
. 0

The 0
combination 0
PIP 0
64 0
micrograms 0
- 0
PEF 0
4 0
micrograms 0
prevents 0
the 0
frequent 0
secondary 0
regrowth 0
seen 0
after 0
6 0
hours 0
with 0
the 0
antibiotics 0
used 0
alone 0
. 0

With 0
a 0
sample 0
of 0
mothers 0
of 0
healthy 0
infants 0
, 0
all 0
three 0
subscales 0
of 0
the 0
revised 0
instrument 0
, 0
WPL 0
- 0
R 0
, 0
had 0
acceptable 0
levels 0
of 0
internal 0
consistency 0
at 0
7 0
, 0
30 0
, 0
and 0
90 0
days 0
postpartum 0
, 0
and 0
stability 0
across 0
administrations 0
. 0

Since 0
1948 0
, 0
the 0
use 0
of 0
saline 0
- 0
washed 0
red 0
cells 0
( 0
WRBCs 0
) 0
has 0
been 0
advocated 0
to 0
minimize 0
hemolysis 0
after 0
transfusion 0
to 0
patients 0
with 0
PNH 0
. 0

In 0
the 0
group 0
of 0
asthmatics 0
statistically 0
significant 0
correlation 0
was 0
found 0
between 0
PC20 0
PGF2 0
alpha 0
and 0
histamine 0
values 0
( 0
r 0
= 0
0.538 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Acute 0
experiments 0
on 0
nembutal 0
- 0
anesthetized 0
cats 0
( 0
50 0
mg/kg 0
) 0
were 0
employed 0
to 0
investigate 0
the 0
effect 0
of 0
1 0
T 0
pulsating 0
magnetic 0
field 0
( 0
PMF 0
) 0
on 0
neuromuscular 0
system 0
of 0
the 0
leg 0
. 0

No 0
significant 0
differences 0
were 0
found 0
between 0
the 0
TS 0
and 0
the 0
PTS 0
. 0

The 0
percentages 0
of 0
formed 0
cysts 0
and 0
growth 0
rates 0
were 0
monthly 0
estimated 0
and 0
analyzed 0
rhythmometrically 0
by 0
cosinor 0
for 0
5 0
clonal 0
cultures 0
of 0
Scripsiella 0
trochoidea 0
Stein 0
grown 0
for 0
2 0
years 0
under 0
laboratory 0
conditions 0
, 0
rended 0
as 0
constant 0
as 0
possible 0
from 0
the 0
view 0
point 0
of 0
environmental 0
temperature 0
( 0
24 0
+/ 0
- 0
1 0
degree 0
C 0
) 0
, 0
lighting 0
( 0
25 0
microEin 0
m 0
- 0
2 0
s 0
- 0
1 0
) 0
, 0
and 0
artificial 0
seawater 0
. 0

A 0
genomic 0
DNA 0
clone 0
encoding 0
oryzacystatin B-gene
( 0
Oc B-gene
) 0
, 0
a 0
cysteine B-gene
proteinase I-gene
inhibitor 0
( 0
cystatin B-gene
) 0
of 0
rice 0
, 0
was 0
isolated 0
from 0
a 0
lambda 0
EMBL3 0
phage 0
library 0
constructed 0
with 0
Sau3AI B-gene
partial 0
digests 0
of 0
rice 0
chromosomal 0
DNA 0
, 0
by 0
screening 0
with 0
an 0
oc B-gene
cDNA I-gene
as 0
a 0
probe 0
. 0

The 0
use 0
of 0
an 0
appropriate 0
solution 0
of 0
methylene 0
blue 0
( 0
0.2 0
% 0
in 0
0.9 0
M 0
NaCl 0
for 0
15 0
min 0
) 0
permits 0
the 0
staining 0
of 0
premalignant 0
areas 0
and 0
CIS 0
, 0
and 0
their 0
early 0
diagnosis 0
. 0

Lower 0
limits 0
( 0
to 0
10 0
micrograms/kg 0
) 0
were 0
detectable 0
, 0
but 0
with 0
lower 0
reliability 0
( 0
60 0
% 0
) 0
. 0

Instead 0
, 0
some 0
small 0
negative 0
effects 0
are 0
observed 0
, 0
particularly 0
involving 0
effects 0
of 0
husbands 0
' 0
retirement 0
on 0
the 0
marital 0
satisfaction 0
of 0
employed 0
wives 0
. 0

This 0
in 0
turn 0
will 0
further 0
enhance 0
the 0
role 0
of 0
meta 0
- 0
analysis 0
in 0
helping 0
clinicians 0
and 0
policy 0
makers 0
answer 0
clinical 0
questions 0
. 0

In 0
one 0
acromegalic 0
patient 0
visual 0
improvement 0
was 0
obtained 0
while 0
the 0
abnormal 0
GH B-gene
secretion 0
remained 0
unaltered 0
. 0

In 0
contrast 0
, 0
the 0
PPSF 0
+ 0
DBP 0
side 0
showed 0
large 0
amounts 0
of 0
bone 0
formation 0
, 0
and 0
bone 0
almost 0
covered 0
the 0
implant 0
. 0

The 0
accuracies 0
of 0
presence 0
or 0
absence 0
of 0
neuroblastoma 0
were 0
compared 0
between 0
131I 0
- 0
MIBG 0
imaging 0
and 0
several 0
tumor 0
markers 0
. 0

The 0
congenital 0
forms 0
( 0
7 0
cases 0
) 0
all 0
occurred 0
in 0
female 0
infants 0
and 0
involved 0
the 0
mucosa 0
overlying 0
either 0
the 0
anterior 0
ridge 0
of 0
the 0
maxilla 0
or 0
the 0
mandible 0
. 0

Immunohistochemical 0
studies 0
revealed 0
positive 0
staining 0
for 0
S100 B-gene
protein I-gene
in 0
all 0
the 0
granular 0
cell 0
tumors 0
of 0
the 0
adult 0
but 0
in 0
none 0
of 0
the 0
congenital 0
granular 0
cell 0
epulides 0
. 0

We 0
also 0
found 0
that 0
the 0
same 0
males 0
, 0
breeding 0
in 0
different 0
years 0
on 0
the 0
same 0
territories 0
, 0
had 0
significantly 0
larger 0
harems 0
in 0
the 0
years 0
they 0
had 0
familiar 0
neighbors 0
. 0

Male B-gene
- I-gene
enhanced I-gene
antigen I-gene
gene I-gene
is 0
phylogenetically 0
conserved 0
and 0
expressed 0
at 0
late 0
stages 0
of 0
spermatogenesis 0
. 0

In 0
rats 0
bearing 0
Walker 0
- 0
256 0
- 0
carcinosarcoma 0
4 0
- 0
EPI 0
was 0
effective 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Pacing 0
the 0
Roux 0
limb 0
abolished 0
the 0
ectopic 0
pacemakers 0
, 0
restored 0
the 0
slow 0
emptying 0
of 0
liquids 0
to 0
the 0
more 0
rapid 0
rate 0
found 0
in 0
the 0
Billroth 0
dogs 0
( 0
t1/2 0
: 0
paced 0
Roux 0
, 0
72 0
+/ 0
- 0
15 0
minutes 0
; 0
Billroth 0
, 0
43 0
+/ 0
- 0
9 0
minutes 0
; 0
p 0
greater 0
than 0
0.05 0
) 0
and 0
did 0
not 0
change 0
emptying 0
of 0
solids 0
. 0

The 0
treatments 0
were 0
60 0
mg 0
t.i.d 0
. 0
and 0
120 0
mg 0
t.i.d 0
. 0
during 0
14 0
days 0
' 0
treatment 0
, 0
with 0
the 0
last 0
dose 0
pulsed 0
with 0
1.85 0
MBq 0
[ 0
14C 0
] 0
diltiazem 0
. 0

The 0
subepicardial 0
lymphatic 0
capillaries 0
were 0
ramified 0
and 0
anastomosed 0
with 0
each 0
other 0
to 0
form 0
a 0
relatively 0
dense 0
network 0
which 0
extended 0
over 0
the 0
entire 0
surface 0
of 0
both 0
ventricles 0
. 0

The 0
examination 0
must 0
include 0
T1 0
and 0
T2 0
sequences 0
and 0
scans 0
in 0
three 0
planes 0
. 0

A 0
great 0
deal 0
of 0
information 0
is 0
available 0
on 0
the 0
morphology 0
of 0
the 0
claustrum 0
in 0
various 0
animal 0
species 0
, 0
as 0
well 0
as 0
on 0
its 0
neuronal 0
distribution 0
and 0
relationships 0
with 0
the 0
cerebral 0
cortex 0
and 0
other 0
nuclei 0
. 0

Low 0
- 0
grade 0
glioma 0
. 0

In 0
terms 0
of 0
sequence 0
repetitions 0
, 0
seven 0
tandemly 0
repeated 0
copies 0
of 0
the 0
hexanucleotide 0
ATTGTT 0
and 0
three 0
flanking 0
regions 0
of 0
dyad 0
symmetry 0
were 0
detected 0
, 0
all 0
in 0
ORF 0
T3C 0
. 0

The 0
significance 0
of 0
these 0
palindromic 0
domains 0
in 0
this 0
ORF 0
is 0
unclear 0
but 0
the 0
coincidence 0
of 0
the 0
end 0
of 0
one 0
larger 0
palindrome 0
with 0
the 0
end 0
of 0
the 0
translated 0
protein 0
sequence 0
that 0
has 0
homology 0
with 0
the 0
B 0
chain 0
of 0
insulin B-gene
suggests 0
that 0
the 0
palindromes 0
may 0
divide 0
the 0
T2 B-gene
protein I-gene
into 0
several 0
functional 0
units 0
. 0

During 0
sub 0
- 0
maximal 0
exercise 0
, 0
DCR 0
in 0
the 0
UT 0
dogs 0
decreased 0
from 0
a 0
resting 0
value 0
of 0
4.08 0
+/ 0
- 0
0.18 0
mm 0
Hg 0
X 0
ml 0
- 0
1 0
X 0
min 0
- 0
1 0
to 0
1.91 0
+/ 0
- 0
0.17 0
mm 0
Hg 0
X 0
ml 0
- 0
1 0
X 0
min 0
- 0
1 0
at 0
a 0
workload 0
of 0
6.4 0
kph 0
( 0
speed 0
) 0
/16 0
% 0
( 0
grade 0
) 0
. 0

7 0
. 0

These 0
data 0
suggest 0
that 0
the 0
G B-gene
- I-gene
protein I-gene
gene I-gene
family I-gene
may 0
be 0
distributed 0
over 0
at 0
least 0
two 0
human 0
chromosomes 0
. 0

The 0
major 0
inserted 0
DNA 0
has 0
no 0
significant 0
homology 0
to 0
published 0
human 0
nucleic 0
acid 0
sequences 0
. 0

In 0
44 0
evaluable 0
patients 0
the 0
response 0
rate 0
was 0
50 0
% 0
, 0
with 0
one 0
complete 0
response 0
. 0

We 0
have 0
also 0
found 0
that 0
the 0
in 0
vitro 0
interaction 0
between 0
the 0
SV40 0
octamer 0
motif 0
and 0
the 0
lymphoid B-gene
cell I-gene
- I-gene
specific I-gene
protein I-gene
oct I-gene
- I-gene
B2 I-gene
was 0
negatively 0
modulated 0
by 0
a 0
component 0
present 0
in 0
the 0
nuclear 0
extracts 0
from 0
several 0
lymphoid 0
cell 0
lines 0
. 0

Anoxia 0
was 0
introduced 0
by 0
perfusing 0
the 0
gill 0
with 0
water 0
deprived 0
of 0
oxygen 0
or 0
by 0
halting 0
the 0
water 0
flow 0
to 0
the 0
gill 0
. 0

Growth 0
, 0
4 0
- 0
PA 0
and 0
14C 0
turnover 0
data 0
indicated 0
that 0
WB 0
contributed 0
to 0
B 0
- 0
6 0
intake 0
of 0
these 0
rats 0
. 0

Thus 0
, 0
multiple 0
myogenic 0
factors 0
that 0
vary 0
qualitatively 0
and 0
quantitatively 0
may 0
be 0
responsible 0
for 0
the 0
different 0
and 0
complex 0
modulatory 0
programs 0
of 0
actin B-gene
gene I-gene
expression 0
observed 0
during 0
in 0
vivo 0
muscle 0
differentiation 0
. 0

DNA 0
sequence 0
analysis 0
revealed 0
that 0
these 0
clones 0
encode 0
two 0
distinct 0
forms 0
of 0
translocase B-gene
. 0

The 0
effect 0
of 0
acetazolamide 0
( 0
ACZ 0
) 0
on 0
HCO3 0
- 0
and 0
Cl 0
- 0
activities 0
in 0
inner 0
ear 0
fluid 0
was 0
investigated 0
by 0
ion 0
- 0
selective 0
microelectrode 0
methods 0
. 0

RPA190 B-gene
encodes 0
a 0
polypeptide 0
chain 0
of 0
186,270 0
daltons 0
in 0
a 0
large 0
uninterrupted 0
reading 0
frame 0
. 0

Both 0
the 0
intact B-gene
A1 I-gene
protein I-gene
and 0
its 0
proteolytic 0
fragment 0
, 0
the 0
UP1 B-gene
protein I-gene
, 0
can 0
be 0
cleaved 0
by 0
Staphylococcus B-gene
aureus I-gene
V I-gene
- I-gene
8 I-gene
protease I-gene
to 0
produce 0
two 0
polypeptides 0
of 0
92 0
amino 0
acids 0
. 0

Irmiere 0
, 0
and 0
W 0
. 0

These 0
offspring 0
of 0
the 0
alpha B-gene
- I-gene
MSH I-gene
treated 0
mothers 0
were 0
less 0
sensitive 0
to 0
pain 0
and 0
as 0
adults 0
showed 0
a 0
reduced 0
analgesic 0
response 0
to 0
morphine 0
. 0

Simian 0
immunodeficiency 0
virus 0
( 0
SIV 0
) 0
is 0
a 0
lentivirus 0
with 0
morphological 0
and 0
antigenic 0
similarities 0
to 0
human 0
immunodeficiency 0
virus 0
, 0
the 0
causative 0
agent 0
of 0
acquired 0
immunodeficiency 0
syndrome 0
( 0
AIDS 0
) 0
of 0
humans 0
. 0

The 0
lack 0
of 0
change 0
in 0
the 0
ratio 0
of 0
the 0
two 0
spliced 0
products 0
expressed 0
from 0
either 0
the 0
normal 0
or 0
the 0
5' B-gene
- I-gene
rearranged I-gene
myb I-gene
further 0
indicates 0
that 0
the 0
insertion 0
of 0
the 0
unique 0
121 0
amino 0
acids 0
in 0
the 0
larger 0
myb B-gene
transcripts I-gene
is 0
not 0
a 0
consequence 0
of 0
tumor 0
- 0
specific 0
activation 0
of 0
the 0
mouse B-gene
myb I-gene
oncogene I-gene
. 0

The 0
use 0
of 0
CRF B-gene
- I-gene
41 I-gene
in 0
the 0
differential 0
diagnosis 0
of 0
Cushing 0
's 0
syndrome 0
and 0
obesity 0
. 0

We 0
detected 0
mos B-gene
transcripts I-gene
by 0
Northern 0
( 0
RNA 0
) 0
analyses 0
in 0
RNA 0
prepared 0
from 0
chicken 0
and 0
quail 0
ovaries 0
and 0
testes 0
. 0

The 0
predicted 0
L B-gene
mRNA I-gene
was 0
6398 0
nucleotides 0
long 0
and 0
contained 0
a 0
single 0
open 0
reading 0
frame 0
corresponding 0
to 0
an 0
L B-gene
protein I-gene
encompassing I-gene
2109 I-gene
amino I-gene
acids I-gene
with 0
a 0
MW 0
of 0
241,546 0
. 0

The 0
results 0
suggest 0
that 0
the 0
organization 0
of 0
functional 0
units 0
of 0
the 0
72 0
- 0
bp 0
repeat 0
required 0
for 0
transcriptional 0
enhancement 0
of 0
the 0
early 0
promoter 0
is 0
different 0
from 0
that 0
required 0
for 0
late 0
promoter 0
function 0
. 0

Variations 0
in 0
the 0
5 0
' 0
half 0
of 0
U3 0
were 0
primarily 0
due 0
to 0
insertions 0
and 0
deletions 0
. 0

An 0
analysis 0
of 0
the 0
steady 0
state 0
RNA 0
levels 0
in 0
T 0
- 0
lymphoid 0
cell 0
lines 0
showed 0
that 0
at 0
least 0
three 0
different 0
incomplete 0
proviral 0
transcripts 0
and 0
their 0
spliced 0
products 0
made 0
up 0
the 0
majority 0
of 0
expressed 0
RD B-gene
- I-gene
114 I-gene
mRNA I-gene
, 0
and 0
further 0
demonstrated 0
that 0
partially 0
deleted 0
proviral 0
loci 0
have 0
the 0
potential 0
to 0
be 0
transcriptionally 0
vigorous 0
in 0
certain 0
feline 0
cell 0
types 0
. 0

Aplastic 0
crisis 0
in 0
sickle 0
cell 0
disorders 0
: 0
bone 0
marrow 0
necrosis 0
and 0
human 0
parvovirus 0
infection 0
. 0

Either 0
two 0
or 0
more 0
different 0
sequences 0
can 0
promote 0
cleavage 0
, 0
or 0
a 0
single 0
element 0
exists 0
which 0
is 0
long 0
and 0
diffuse 0
. 0

Low 0
molecular 0
weight 0
heparins 0
have 0
stimulated 0
much 0
interest 0
because 0
of 0
their 0
supposedly 0
more 0
selective 0
action 0
on 0
Xa B-gene
factor I-gene
. 0

The 0
bactericidal 0
activity 0
of 0
six 0
new 0
rifamycin 0
derivatives 0
- 0
- 0
rifabutin 0
( 0
RBU 0
) 0
, 0
FCE 0
22250 0
( 0
F22 0
) 0
, 0
rifapentine 0
( 0
RPE 0
) 0
, 0
CGP 0
29861 0
( 0
C29 0
) 0
, 0
CGP 0
7040 0
( 0
C70 0
) 0
and 0
CGP 0
27557 0
( 0
C27 0
) 0
and 0
rifampicin 0
( 0
RMP 0
) 0
- 0
- 0
have 0
been 0
measured 0
against 0
log 0
phase 0
and 0
, 0
as 0
a 0
better 0
test 0
of 0
sterilising 0
activity 0
, 0
against 0
stationary 0
phase 0
cultures 0
of 0
Mycobacterium 0
tuberculosis 0
, 0
H37Rv 0
. 0

Mo 0
+ 0
SV 0
M 0
- 0
MuLV 0
- 0
inoculated 0
animals 0
became 0
moribund 0
at 0
3 0
to 0
13 0
months 0
postinoculation 0
, 0
whereas 0
delta 0
Mo 0
+ 0
SV 0
M 0
- 0
MuLV 0
- 0
inoculated 0
animals 0
became 0
moribund 0
at 0
6 0
to 0
24 0
months 0
postinoculation 0
. 0

Sodium 0
dodecyl 0
sulphate 0
- 0
induced 0
cleavage 0
by 0
eukaryotic B-gene
topoisomerase I-gene
I I-gene
is 0
known 0
to 0
yield 0
enzyme 0
covalently 0
attached 0
to 0
the 0
3 0
' 0
cut 0
end 0
of 0
the 0
DNA 0
. 0

Amino 0
acid 0
sequence 0
of 0
one 0
human 0
liver 0
clone 0
( 0
HL 0
- 0
14 0
) 0
was 0
identical 0
to 0
the 0
rabbit B-gene
skeletal I-gene
muscle I-gene
phosphatase I-gene
2A I-gene
cDNA I-gene
( 0
with 0
97 0
% 0
nucleotide 0
identity 0
) 0
. 0

Herpes 0
virus 0
infection 0
was 0
characterized 0
by 0
inversion 0
of 0
the 0
T4/T8 0
ratio 0
below 0
1.0 0
( 0
sensitivity 0
90 0
% 0
, 0
specificity 0
88 0
% 0
) 0
, 0
caused 0
by 0
proliferation 0
of 0
the 0
T8 0
subpopulation 0
, 0
which 0
- 0
- 0
compared 0
with 0
the 0
findings 0
in 0
patients 0
with 0
rejection 0
crises 0
- 0
- 0
was 0
significantly 0
raised 0
( 0
P 0
less 0
than 0
0.001 0
) 0
. 0

RVEF 0
and 0
LVEF 0
both 0
increased 0
by 0
about 0
14 0
% 0
( 0
p 0
less 0
than 0
0.05 0
and 0
p 0
less 0
than 0
0.01 0
) 0
. 0

The 0
levels 0
of 0
NPY B-gene
- 0
ir 0
in 0
the 0
rat 0
vas 0
deferens 0
were 0
not 0
affected 0
by 0
either 0
surgical 0
or 0
pharmacological 0
treatment 0
. 0

Quantitative 0
assays 0
in 0
which 0
the 0
activity 0
of 0
the 0
synthetic B-gene
alpha I-gene
s I-gene
- I-gene
1 I-gene
was 0
compared 0
to 0
that 0
of 0
native 0
purified 0
human B-gene
erythrocyte I-gene
type I-gene
- I-gene
1 I-gene
Gs I-gene
, 0
indicated 0
that 0
the 0
two 0
products 0
are 0
equipotent 0
within 0
a 0
2 0
- 0
fold 0
margin 0
of 0
error 0
. 0

In 0
these 0
cells 0
, 0
E2 B-gene
proteins I-gene
had 0
little 0
or 0
no 0
stimulatory 0
effect 0
on 0
the 0
transcriptional 0
activity 0
of 0
the 0
HPV B-gene
- I-gene
11 I-gene
enhancer I-gene
- 0
SV40 B-gene
promoter I-gene
. 0

The 0
mechanism 0
by 0
which 0
E2 B-gene
- I-gene
C I-gene
represses 0
E2 B-gene
- I-gene
dependent I-gene
enhancer I-gene
activity 0
most 0
likely 0
involves 0
competition 0
with 0
E2 B-gene
for 0
binding 0
to 0
a 0
common 0
transcriptional 0
regulatory 0
site 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

Accurate 0
evaluation 0
of 0
the 0
treatment 0
results 0
in 0
unresectable 0
lung 0
cancer 0
patients 0
must 0
take 0
the 0
strong 0
prognostic 0
factors 0
into 0
account 0
. 0

( 0
anti B-gene
- I-gene
IIa I-gene
) 0
and 0
Holmer 0
et 0
al 0
. 0

Introduction 0
of 0
v B-gene
- I-gene
fms I-gene
into 0
a 0
CSF B-gene
- I-gene
1 I-gene
dependent 0
murine 0
macrophage 0
cell 0
line 0
induced 0
factor 0
independence 0
and 0
tumorigenicity 0
by 0
a 0
nonautocrine 0
mechanism 0
. 0

Chronic 0
E 0
- 0
B 0
virus 0
infection 0
terminated 0
in 0
malignant 0
lymphoma 0
: 0
a 0
case 0
report 0

The 0
primary 0
structure 0
and 0
cotranscription 0
of 0
the 0
petCA B-gene
genes I-gene
encoding 0
the 0
Rieske B-gene
- I-gene
FeS I-gene
( 0
nuclear B-gene
encoded I-gene
in I-gene
plants I-gene
) 0
and 0
apocytochrome B-gene
f I-gene
proteins I-gene
has 0
been 0
described 0
previously 0
( 0
Kallas 0
, 0
T. 0
, 0
Spiller 0
, 0
S. 0
, 0
and 0
Malkin 0
, 0
R 0
. 0

The 0
Nostoc 0
petBD B-gene
genes I-gene
are 0
not 0
closely 0
linked 0
to 0
the 0
psbB B-gene
gene I-gene
( 0
encoding 0
the 0
51 0
- 0
kDa 0
photosystem B-gene
II I-gene
polypeptide I-gene
) 0
and 0
do 0
not 0
contain 0
introns 0
as 0
do 0
the 0
closely 0
related 0
chloroplast 0
genes 0
. 0

RNA 0
blot 0
hybridizations 0
identified 0
an 0
1.8 0
- 0
kb 0
mRNA 0
common 0
to 0
cytochrome B-gene
b6 I-gene
and 0
subunit 0
IV 0
, 0
and 0
an 0
intensely 0
hybridizing 0
0.8 0
- 0
kb 0
mRNA 0
specific 0
to 0
the 0
subunit 0
IV 0
gene 0
probe 0
. 0

Whereas 0
the 0
muscle 0
isoform 0
consists 0
of 0
997 0
amino 0
acids 0
and 0
terminates 0
with 0
the 0
sequence 0
Ala 0
- 0
Ile 0
- 0
Leu 0
- 0
Glu 0
, 0
the 0
second 0
isoform 0
is 0
1043 0
amino 0
acids 0
in 0
length 0
due 0
to 0
the 0
replacement 0
of 0
these 0
last 0
4 0
amino 0
acids 0
with 0
a 0
50 0
- 0
amino 0
acid 0
sequence 0
that 0
contains 0
a 0
potential 0
transmembrane 0
domain 0
followed 0
by 0
a 0
consensus 0
sequence 0
for 0
an 0
N 0
- 0
linked 0
glycosylation 0
site 0
. 0

Substitution 0
of 0
a 0
threonine 0
residue 0
by 0
an 0
alanine 0
residue 0
at 0
position 0
- 0
2 0
( 0
P2 0
) 0
of 0
this 0
cleavage 0
site 0
abolished 0
cleavage 0
, 0
whereas 0
substitution 0
of 0
a 0
tyrosine 0
residue 0
by 0
a 0
phenylalanine 0
residue 0
at 0
amino 0
acid 0
position 0
- 0
1 0
( 0
P1 0
) 0
of 0
the 0
cleavage 0
site 0
did 0
not 0
influence 0
processing 0
. 0

All 0
of 0
the 0
indigo 0
- 0
producing 0
bacteria 0
had 0
an 0
indoxyl B-gene
phosphatase I-gene
with 0
a 0
pI 0
of 0
6.4 0
. 0

The 0
number 0
of 0
polymerases 0
active 0
in 0
vitro 0
at 0
the 0
E 0
strand 0
promoter 0
was 0
similar 0
to 0
the 0
number 0
of 0
polymerases 0
at 0
the 0
L 0
strand 0
promoter 0
. 0

A 0
family 0
of 0
RNA 0
molecules 0
in 0
the 0
2.0 0
- 0
2.2 0
- 0
kilobase 0
range 0
identified 0
with 0
a 0
probe 0
from 0
this 0
gene 0
was 0
overexpressed 0
in 0
the 0
resistant 0
cells 0
. 0

A 0
highly 0
hydrophobic 0
sequence 0
located 0
near 0
the 0
carboxyl 0
- 0
terminal 0
extremity 0
of 0
the 0
molecule 0
most 0
likely 0
constitutes 0
the 0
anchor 0
to 0
the 0
plasma 0
membrane 0
. 0

The 0
SV40 B-gene
enhancer I-gene
augmented 0
replication 0
1.5 0
- 0
10 0
fold 0
. 0

One 0
of 0
these 0
, 0
the 0
origin 0
core 0
, 0
is 0
required 0
only 0
for 0
DNA 0
replication 0
. 0

Induction 0
of 0
proto B-gene
- I-gene
oncogene I-gene
fos I-gene
transcription 0
through 0
the 0
adenylate B-gene
cyclase I-gene
pathway 0
: 0
characterization 0
of 0
a 0
cAMP 0
- 0
responsive 0
element 0
. 0

A 0
17 0
- 0
mer 0
oligodeoxynucleotide 0
, 0
corresponding 0
to 0
a 0
region 0
of 0
the 0
VtHb B-gene
amino I-gene
acid I-gene
sequence I-gene
was 0
used 0
as 0
a 0
hybridization 0
probe 0
to 0
screen 0
a 0
Vitreoscilla 0
genomic 0
library 0
constructed 0
in 0
broad 0
- 0
host 0
- 0
range 0
cosmid 0
vector 0
pVK102 0
. 0

( 0
total 0
soluble 0
solids 0
) 0
and 0
organoleptic 0
characteristics 0
under 0
the 0
influence 0
of 0
different 0
treatments 0
. 0

Causes 0
of 0
death 0
found 0
in 0
an 0
epidemiological 0
study 0
of 0
native 0
chickens 0
in 0
Thai 0
villages 0
. 0

The 0
progression 0
of 0
non 0
- 0
A 0
, 0
non 0
- 0
B 0
hepatitis 0
to 0
chronic 0
diseases 0
, 0
and 0
the 0
transformation 0
to 0
hepatocellular 0
carcinoma 0

Elevated 0
IOP 0
developed 0
in 0
35 0
patients 0
( 0
44 0
eyes 0
) 0
during 0
the 0
study 0
. 0

Use 0
of 0
serum 0
thyroglobulin B-gene
determination 0
in 0
the 0
follow 0
- 0
up 0
of 0
differentiated 0
carcinomas 0
of 0
the 0
thyroid 0

Poor 0
response 0
when 0
laboratory 0
recommended 0
range 0
for 0
serum 0
lithium 0
is 0
changed 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
investigate 0
the 0
effects 0
of 0
nebulized 0
ipratropium 0
in 0
patients 0
with 0
acute 0
asthma 0
in 0
order 0
to 0
determine 0
whether 0
it 0
augments 0
the 0
bronchodilator 0
effect 0
of 0
a 0
beta 0
agonist 0
drug 0
. 0

Further 0
analysis 0
of 0
this 0
DNA 0
fragment 0
showed 0
that 0
four 0
genes 0
are 0
present 0
encoding 0
proteins 0
of 0
16 0
, 0
18.5 0
, 0
21 0
and 0
89 0
kDal 0
. 0

Hantaan 0
virus 0
. 0

Changes 0
in 0
dopamine B-gene
receptor I-gene
sensitivity 0
in 0
humans 0
after 0
heavy 0
alcohol 0
intake 0
. 0

No 0
significant 0
differences 0
between 0
the 0
two 0
treatment 0
groups 0
were 0
found 0
, 0
but 0
rapid 0
responders 0
had 0
a 0
smaller 0
mean 0
initial 0
platelet B-gene
- I-gene
associated I-gene
IgG I-gene
index 0
which 0
returned 0
more 0
rapidly 0
and 0
more 0
permanently 0
to 0
normal 0
than 0
that 0
of 0
slow 0
responders 0
. 0

Replacement B-gene
variant I-gene
histone I-gene
genes I-gene
contain 0
intervening 0
sequences 0
. 0

Double 0
- 0
blind 0
randomised 0
trial 0
of 0
intravenous 0
tissue B-gene
- I-gene
type I-gene
plasminogen I-gene
activator I-gene
versus 0
placebo 0
in 0
acute 0
myocardial 0
infarction 0
. 0

The 0
C 0
- 0
terminal 0
domains 0
( 0
CTDs 0
) 0
of 0
the 0
RPase B-gene
beta I-gene
subunit I-gene
and 0
DNA B-gene
primase I-gene
( 0
dnaG B-gene
protein I-gene
) 0
were 0
not 0
only 0
strongly 0
homologous 0
to 0
each 0
other 0
but 0
also 0
considerably 0
homologous 0
to 0
the 0
RPase B-gene
alpha I-gene
, 0
suggesting 0
that 0
an 0
alpha 0
subunit 0
- 0
like 0
enzyme 0
must 0
have 0
been 0
commonly 0
ancestral 0
to 0
core B-gene
enzyme I-gene
subunits I-gene
and 0
primase B-gene
. 0

However 0
, 0
vancomycin 0
and 0
fosfomycin 0
, 0
which 0
revealed 0
suboptimal 0
in 0
vitro 0
bactericidal 0
activity 0
, 0
proved 0
as 0
efficacious 0
as 0
penicillin 0
G 0
and 0
imipenem 0
in 0
an 0
experimental 0
mode 0
of 0
murine 0
gas 0
gangrene 0
. 0

Fentanyl 0
, 0
a 0
prototypic 0
mu B-gene
- I-gene
opiate I-gene
receptor I-gene
agonist 0
, 0
has 0
been 0
previously 0
shown 0
to 0
produce 0
a 0
syndrome 0
characterized 0
by 0
marked 0
analgesia 0
and 0
locomotor 0
stimulation 0
as 0
well 0
as 0
tachycardia 0
, 0
tachypnoea 0
and 0
behavioural 0
arousal 0
. 0

Intravesical 0
chemotherapy 0
. 0

Bisoprolol 0
was 0
found 0
to 0
be 0
an 0
effective 0
beta B-gene
- I-gene
adrenoceptor I-gene
antagonist 0
, 0
the 0
pA2 0
values 0
determined 0
against 0
isoprenaline 0
in 0
guinea 0
pig 0
atria 0
and 0
tracheal 0
muscle 0
being 0
7.45 0
and 0
6.41 0
, 0
respectively 0
. 0

Output 0
of 0
99mTcO 0
- 0
4 0
by 0
the 0
parotid 0
gland 0
closely 0
mimicked 0
fluctuations 0
in 0
parotid 0
saliva 0
flow 0
rate 0
. 0

The 0
Hagen 0
- 0
Poiseuille 0
equation 0
is 0
used 0
to 0
assess 0
the 0
effects 0
of 0
attached 0
parasites 0
in 0
the 0
foregut 0
of 0
Leishmania 0
- 0
infected 0
sandflies 0
on 0
blood 0
flow 0
. 0

Moreover 0
, 0
in 0
rats 0
allowed 0
to 0
choose 0
in 0
a 0
T 0
- 0
maze 0
between 0
immediate 0
- 0
but 0
- 0
small 0
vs. 0
delayed 0
- 0
but 0
- 0
large 0
reward 0
, 0
BZP 0
significantly 0
decreased 0
the 0
frequency 0
with 0
which 0
the 0
delayed 0
reward 0
was 0
chosen 0
, 0
with 0
5 0
- 0
HT 0
uptake 0
blockers 0
producing 0
opposite 0
effects 0
. 0

An 0
endometrial 0
luteal 0
phase 0
deficiency 0
was 0
detected 0
in 0
15 0
( 0
30 0
% 0
) 0
of 0
aborting 0
patients 0
. 0

Prenatal 0
exposure 0
to 0
the 0
fungicide 0
dinocap 0
causes 0
behavioral 0
torticollis 0
, 0
ballooning 0
and 0
cleft 0
palate 0
in 0
mice 0
, 0
but 0
not 0
rats 0
or 0
hamsters 0
. 0

Reperfusion 0
with 0
normal 0
blood 0
in 0
the 0
beating 0
, 0
working 0
hearts 0
caused 0
extensive 0
structural 0
damage 0
, 0
reduced 0
reflow 0
, 0
and 0
failed 0
to 0
restore 0
contractility 0
in 0
any 0
instance 0
( 0
- 0
27 0
% 0
systolic 0
shortening 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

The 0
sensitivity 0
of 0
the 0
vas 0
deferens 0
to 0
adrenaline 0
was 0
also 0
reduced 0
in 0
scorbutic 0
guinea 0
pigs 0
, 0
thus 0
decreasing 0
their 0
fertility 0
rate 0
. 0

In 0
metabolic 0
acidosis 0
there 0
was 0
a 0
marked 0
stimulation 0
when 0
clamped 0
at 0
- 0
10 0
to 0
- 0
100 0
mV 0
. 0

On 0
Days 0
1 0
and 0
14 0
, 0
most 0
young 0
and 0
elderly 0
subjects 0
exhibited 0
monoexponential 0
decline 0
in 0
bevantolol 0
plasma 0
concentrations 0
after 0
absorption 0
phase 0
. 0

Mature 0
and 0
old 0
B6AF1 0
and 0
B6D2F1 0
mice 0
were 0
given 0
acidified 0
tap 0
water 0
or 0
promethazine 0
HCl 0
( 0
a 0
phenothiazine 0
with 0
H1 B-gene
receptor I-gene
blocking 0
activity 0
) 0
, 0
chlorpheniramine 0
( 0
an 0
H1 B-gene
blocker 0
) 0
or 0
trifluoperazine 0
( 0
a 0
phenothiazine 0
with 0
no 0
H1 B-gene
blocking 0
activity 0
) 0
in 0
their 0
drinking 0
water 0
, 0
and 0
the 0
effects 0
of 0
these 0
agents 0
on 0
bone 0
mineral 0
content 0
were 0
assessed 0
by 0
intermittently 0
measuring 0
the 0
24 0
- 0
h 0
whole 0
body 0
retention 0
of 0
Tc 0
99m 0
methylene 0
diphosphonate 0
( 0
Tc 0
99m 0
MDP 0
, 0
an 0
indicator 0
of 0
bone 0
metabolism 0
) 0
and 0
at 0
the 0
end 0
of 0
the 0
studies 0
by 0
determining 0
ash 0
weights 0
of 0
femur 0
, 0
ilium 0
and 0
sacrum 0
. 0

Present 0
results 0
reveal 0
a 0
frequency 0
- 0
dependent 0
inhibition 0
of 0
ganglionic 0
transmission 0
by 0
diltiazem 0
, 0
and 0
suggest 0
that 0
diltiazem 0
may 0
depress 0
excessive 0
sympathetic 0
activity 0
without 0
affecting 0
normal 0
ganglionic 0
transmission 0
. 0

Studies 0
were 0
performed 0
on 0
several 0
superficial 0
veins 0
from 0
the 0
rabbit 0
face 0
to 0
examine 0
the 0
relationship 0
between 0
beta B-gene
adrenoceptor I-gene
subtype I-gene
distribution 0
, 0
intrinsic 0
myogenic 0
tone 0
and 0
sympathetic 0
nerve 0
innervation 0
. 0

Effects 0
of 0
a 0
new 0
antihypertensive 0
agent 0
, 0
SGB 0
- 0
1534 0
, 0
on 0
rat 0
platelet 0
aggregation 0
. 0

Since 0
the 0
stability 0
of 0
TF1 B-gene
resides 0
in 0
its 0
primary 0
structure 0
, 0
we 0
cloned 0
a 0
gene 0
coding 0
for 0
TF1 B-gene
, 0
and 0
the 0
primary 0
structure 0
of 0
the 0
beta 0
subunit 0
was 0
deduced 0
from 0
the 0
nucleotide 0
sequence 0
of 0
the 0
gene 0
to 0
compare 0
the 0
sequence 0
with 0
those 0
of 0
beta 0
's 0
of 0
three 0
major 0
categories 0
of 0
F1 B-gene
's 0
; 0
prokaryotic 0
membranes 0
, 0
chloroplasts 0
, 0
and 0
mitochondria 0
. 0

Body 0
temperature 0
and 0
overall 0
conductance 0
in 0
the 0
cold 0
appear 0
to 0
be 0
more 0
variable 0
in 0
P. 0
s. 0
campbelli 0
than 0
in 0
nominative 0
sp 0
. 0

Two 0
polyadenylation 0
sites 0
were 0
used 0
, 0
one 0
at 0
the 0
end 0
of 0
the 0
early B-gene
( I-gene
E I-gene
) I-gene
region I-gene
of 0
the 0
viral 0
DNA 0
, 0
the 0
other 0
at 0
the 0
end 0
of 0
the 0
late B-gene
( I-gene
L I-gene
) I-gene
region I-gene
. 0

A 0
drug 0
with 0
ISA 0
`` 0
down 0
regulates 0
'' B-gene
beta I-gene
receptors I-gene
; 0
thus 0
, 0
when 0
the 0
drug 0
is 0
withdrawn 0
there 0
is 0
no 0
post 0
- 0
beta 0
- 0
blocking 0
drug 0
hypersensitivity 0
in 0
contrast 0
to 0
agents 0
without 0
ISA 0
. 0

Six 0
patients 0
with 0
human 0
T 0
- 0
cell 0
lymphotropic 0
virus 0
type 0
I 0
( 0
HTLV 0
- 0
I 0
) 0
- 0
associated 0
myelopathy 0
( 0
HAM 0
) 0
were 0
studied 0
by 0
electrophysiologic 0
methods 0
. 0

Terazosin 0
, 0
a 0
structural 0
analog 0
of 0
prazosin 0
, 0
also 0
inhibits 0
alpha B-gene
1 I-gene
adrenoceptors I-gene
and 0
is 0
recommended 0
as 0
once 0
or 0
twice 0
- 0
daily 0
therapy 0
. 0

Testing 0
blood 0
donors 0
for 0
non 0
- 0
A 0
, 0
non 0
- 0
B 0
hepatitis 0
: 0
irrational 0
, 0
perhaps 0
, 0
but 0
inescapable 0
. 0

Most 0
patients 0
with 0
high 0
blood 0
pressure 0
( 0
BP 0
) 0
can 0
be 0
managed 0
by 0
using 0
one 0
of 0
4 0
classes 0
of 0
compounds 0
: 0
a 0
diuretic 0
, 0
beta 0
blocker 0
, 0
converting 0
enzyme 0
inhibitor 0
or 0
calcium 0
antagonist 0
. 0

In 0
a 0
randomised 0
double 0
- 0
blind 0
study 0
, 0
46 0
first 0
episode 0
schizophrenics 0
were 0
given 0
pimozide 0
or 0
flupenthixol 0
for 0
up 0
to 0
5 0
weeks 0
; 0
the 0
mean 0
daily 0
dose 0
at 0
the 0
end 0
was 0
18.8 0
mg 0
pimozide 0
and 0
20 0
mg 0
flupenthixol 0
. 0

Somatostatin B-gene
- 0
producing 0
endocrine 0
pancreatic 0
tumor 0
in 0
Recklinghausen 0
's 0
neurofibromatosis 0
. 0

Direct 0
and 0
inverted 0
repeat 0
elements 0
of 0
10 0
, 0
11 0
, 0
16 0
, 0
19 0
, 0
and 0
22 0
nucleotides 0
( 0
nt 0
) 0
flank 0
the 0
promoter 0
site 0
. 0

We 0
have 0
been 0
able 0
to 0
map 0
specific 0
DNA 0
fragments 0
at 0
the 0
bases 0
of 0
chromatin 0
loops 0
with 0
the 0
help 0
of 0
a 0
novel 0
extraction 0
procedure 0
by 0
using 0
lithium 0
- 0
3',5' 0
- 0
diiodosalicylate 0
. 0

Seventy 0
- 0
one 0
supplementary 0
doses 0
of 0
vecuronium 0
were 0
used 0
for 0
muscle 0
relaxation 0
during 0
a 0
22 0
- 0
h 0
- 0
long 0
NLA 0
II 0
anaesthesia 0
. 0

Finally 0
, 0
the 0
recovery 0
indexes 0
represented 0
by 0
the 0
times 0
required 0
for 0
T1/T0 0
and 0
T4/T1 0
to 0
rise 0
from 0
25 0
% 0
to 0
75 0
% 0
respectively 0
were 0
studied 0
. 0

Transformed 0
bacterial 0
colonies 0
were 0
screened 0
for 0
recombinant 0
plasmids 0
containing 0
cDNA 0
coding 0
for 0
BiP B-gene
by 0
hybrid 0
- 0
selected 0
mRNA 0
translation 0
. 0

DPA 0
attenuated 0
the 0
increase 0
of 0
the 0
intensity 0
of 0
the 0
ischemic 0
and 0
pressure 0
pain 0
components 0
with 0
increasing 0
ischemia 0
duration 0
, 0
but 0
only 0
the 0
effect 0
on 0
the 0
pressure 0
pain 0
component 0
was 0
significant 0
. 0

Topical 0
1 0
percent 0
isoproterenol 0
in 0
the 0
presence 0
of 0
the 0
phosphodiesterase 0
inhibitor 0
theophylline 0
was 0
tested 0
for 0
its 0
ability 0
to 0
stimulate 0
the 0
rate 0
of 0
aqueous 0
humor 0
flow 0
through 0
the 0
anterior 0
chamber 0
of 0
the 0
normal 0
and 0
the 0
partially 0
adrenergically 0
denervated 0
human 0
eye 0
( 0
Horner 0
's 0
syndrome 0
) 0
. 0

Hyperthyroidism 0
is 0
one 0
of 0
the 0
numerous 0
causes 0
of 0
infertility 0
and 0
recurrent 0
abortion 0
. 0

A 0
strong 0
correlation 0
exists 0
between 0
the 0
numbers 0
of 0
CFU 0
- 0
GM 0
transfused 0
and 0
the 0
rate 0
of 0
granulocytes 0
and 0
platelets 0
recovery 0
. 0

We 0
propose 0
that 0
the 0
technique 0
of 0
low 0
- 0
frequency 0
kindling 0
is 0
a 0
useful 0
experimental 0
model 0
in 0
assessing 0
the 0
effects 0
of 0
antipsychotic 0
or 0
antiepileptic 0
drugs 0
on 0
the 0
excitability 0
of 0
the 0
limbic 0
regions 0
. 0

Oestrogen 0
implant 0
overdose 0
. 0

Three 0
sequence 0
elements 0
are 0
shown 0
to 0
be 0
required 0
for 0
accurate 0
and 0
efficient 0
transcription 0
termination 0
by 0
RNA B-gene
polymerase I-gene
I I-gene
( 0
pol B-gene
I I-gene
) 0
assayed 0
both 0
in 0
a 0
cell 0
- 0
free 0
transcription 0
system 0
and 0
in 0
vivo 0
after 0
transfection 0
of 0
rDNA 0
minigene 0
constructs 0
into 0
3T6 0
cells 0
. 0

The 0
biosynthesis 0
and 0
stability 0
of 0
the 0
three 0
mutant 0
proteins 0
were 0
similar 0
to 0
those 0
of 0
the 0
wild B-gene
- I-gene
type I-gene
erbB I-gene
protein I-gene
, 0
and 0
all 0
three 0
retained 0
the 0
ability 0
to 0
transform 0
chicken 0
embryo 0
fibroblasts 0
. 0

Codon 0
usage 0
in 0
C. 0
reinhardtii 0
mitochondria 0
is 0
highly 0
biased 0
, 0
with 0
eight 0
codons 0
entirely 0
absent 0
from 0
all 0
protein 0
- 0
coding 0
genes 0
; 0
however 0
, 0
even 0
though 0
codon 0
usage 0
is 0
restricted 0
, 0
it 0
appears 0
that 0
C. 0
reinhardtii 0
mtDNA 0
can 0
not 0
encode 0
the 0
minimum 0
number 0
of 0
tRNAs 0
needed 0
to 0
support 0
mitochondrial 0
protein 0
synthesis 0
. 0

A 0
new 0
physiopathological 0
treatment 0
of 0
HBV 0
- 0
related 0
polyarteritis 0
inspired 0
by 0
advances 0
in 0
the 0
treatment 0
of 0
chronic 0
active 0
hepatitis 0
B 0
was 0
tested 0
in 0
7 0
patients 0
. 0

Like 0
scrotal 0
testes 0
, 0
undescended 0
testes 0
were 0
hypointense 0
to 0
fat 0
on 0
sequences 0
with 0
a 0
short 0
repetition 0
time 0
( 0
TR 0
) 0
and 0
echo 0
time 0
( 0
TE 0
) 0
in 0
all 0
cases 0
, 0
and 0
hyperintense 0
or 0
isointense 0
to 0
fat 0
on 0
long 0
TR/TE 0
sequences 0
in 0
all 0
but 0
two 0
cases 0
. 0

The 0
subunit B-gene
- I-gene
a I-gene
gene I-gene
is 0
preceded 0
by 0
a 0
gene 0
coding 0
for 0
a 0
small 0
hydrophobic 0
protein 0
, 0
as 0
has 0
been 0
observed 0
previously 0
in 0
the 0
atp B-gene
operons I-gene
in 0
E. 0
coli 0
, 0
bacterium 0
PS3 0
and 0
cyanobacteria 0
. 0

Here 0
, 0
we 0
describe 0
the 0
isolation 0
of 0
bovine B-gene
and I-gene
rat I-gene
GHF I-gene
- I-gene
1 I-gene
cDNA I-gene
clones 0
. 0

To 0
explore 0
the 0
functional 0
properties 0
of 0
the 0
protein 0
encoded 0
by 0
neu B-gene
, 0
we 0
created 0
a 0
fusion 0
gene 0
that 0
joins 0
the 0
cytoplasmic 0
domain 0
of 0
neu B-gene
to 0
the 0
extracellular 0
portion 0
of 0
an 0
immunoglobulin B-gene
heavy I-gene
chain I-gene
. 0

The 0
East 0
African 0
dik 0
- 0
dik 0
antelope 0
represents 0
a 0
miniature 0
model 0
ruminant 0
for 0
comparative 0
studies 0
. 0

By 0
sequence 0
comparison 0
, 0
42 0
blocks 0
of 0
homology 0
are 0
defined 0
in 0
the 0
5' 0
- 0
terminal 0
region 0
, 0
of 0
which 0
36 0
appear 0
in 0
the 0
CpG 0
island 0
and 0
contain 0
numerous 0
conserved 0
CpG 0
dinucleotides 0
. 0

Among 0
unusual 0
features 0
, 0
we 0
report 0
numerous 0
large 0
G 0
+ 0
C 0
- 0
rich 0
conserved 0
sequences 0
located 0
in 0
the 0
first 0
intron 0
. 0

In 0
the 0
first 0
group 0
, 0
0.02 0
% 0
Prazosin 0
( 0
0.5 0
mg/kg 0
) 0
was 0
administered 0
intravenously 0
for 0
1.5 0
hours 0
before 0
the 0
application 0
of 0
Oxy 0
- 0
Hb 0
or 0
PGF2 0
alpha 0
. 0

Efficacy 0
and 0
field 0
evaluation 0
of 0
Bacillus 0
thuringiensis 0
( 0
H 0
- 0
14 0
) 0
and 0
B. 0
sphaericus 0
against 0
floodwater 0
mosquitoes 0
in 0
California 0
. 0

2 0
cases 0
of 0
type 0
II 0
tyrosinosis 0
( 0
Richner 0
- 0
Hanhart 0
syndrome 0
) 0

This 0
loss 0
was 0
independent 0
of 0
drug 0
concentration 0
and 0
a 0
correction 0
factor 0
was 0
employed 0
to 0
calculate 0
the 0
true 0
free 0
diazepam 0
concentration 0
. 0

Effects 0
of 0
a 0
perfluorochemical 0
blood 0
substitute 0
on 0
diazepam 0
binding 0
by 0
human B-gene
albumin I-gene
. 0

A 0
second 0
promoter 0
activity 0
was 0
identified 0
in 0
the 0
region 0
between 0
the 0
two 0
major 0
transcriptional 0
start 0
sites 0
. 0

A 0
decamer 0
sequence 0
, 0
5' 0
- 0
CGA 0
- 0
CCCCUCC 0
- 0
3 0
' 0
, 0
complementary 0
to 0
a 0
conserved 0
sequence 0
adjacent 0
to 0
the 0
enzymatic 0
cleavage 0
site 0
on 0
the 0
mitochondrial 0
RNA 0
substrate 0
, 0
is 0
present 0
in 0
the 0
RNAase B-gene
MRP I-gene
RNA I-gene
. 0

Effects 0
of 0
aging 0
and 0
beta 0
- 0
adrenergic 0
- 0
blockade 0
on 0
standing 0
- 0
induced 0
QT/QS2 0
changes 0
. 0

A 0
patient 0
with 0
an 0
infected 0
wound 0
or 0
one 0
on 0
a 0
primary 0
area 0
( 0
hands 0
, 0
feet 0
, 0
face 0
, 0
or 0
perineum 0
) 0
may 0
have 0
to 0
be 0
hospitalized 0
to 0
ensure 0
proper 0
care 0
. 0

Pharmacology 0
studies 0
with 0
potassium 0
chloride 0
and 0
acetylcholine 0
suggest 0
that 0
raveron 0
acts 0
as 0
a 0
calcium 0
antagonist 0
by 0
blocking 0
the 0
influx 0
of 0
extracellular 0
calcium 0
. 0

Computer 0
analysis 0
included 0
digital 0
averaging 0
, 0
followed 0
by 0
digital 0
filtering 0
in 0
different 0
frequency 0
bands 0
in 0
order 0
to 0
determine 0
the 0
frequency 0
range 0
corresponding 0
to 0
notches 0
and 0
slurs 0
. 0

On 0
admission 0
to 0
the 0
ICU 0
, 0
117 0
patients 0
( 0
61 0
percent 0
) 0
had 0
hypomagnesemia 0
( 0
serum 0
Mg 0
less 0
than 0
1.5 0
mEq/dl 0
) 0
, 0
66 0
patients 0
( 0
34 0
percent 0
) 0
had 0
normomagnesemia 0
( 0
1.5 0
to 0
2.0 0
mEq/dl 0
) 0
, 0
and 0
ten 0
patients 0
( 0
5 0
percent 0
) 0
had 0
hypermagnesemia 0
( 0
greater 0
than 0
2.0 0
mEq/dl 0
) 0
. 0

The 0
risk 0
factors 0
studied 0
were 0
male 0
sex 0
, 0
hypertension 0
, 0
diabetes 0
mellitus 0
, 0
hypercholesterolemia 0
, 0
cigarette 0
smoking 0
, 0
sedentary 0
life 0
- 0
style 0
, 0
and 0
family 0
history 0
. 0

Neither 0
verapamil 0
nor 0
nifedipine 0
changed 0
collateral 0
myocardial 0
blood 0
flow 0
from 0
0.10 0
+/ 0
- 0
0.02 0
in 0
the 0
subendocardium 0
and 0
0.17 0
+/ 0
- 0
0.03 0
ml/min/g 0
in 0
the 0
subepicardium 0
. 0

There 0
were 0
35 0
boys 0
and 0
15 0
girls 0
, 0
with 0
a 0
mean 0
age 0
of 0
five 0
and 0
a 0
half 0
years 0
. 0

Controlled 0
versus 0
uncontrolled 0
reperfusion 0
of 0
ischemic 0
myocardium 0
after 0
experimental 0
coronary 0
artery 0
occlusion 0
was 0
studied 0
to 0
determine 0
the 0
effect 0
on 0
regional 0
ventricular 0
wall 0
motion 0
and 0
associated 0
biochemical 0
alterations 0
. 0

Cardiac 0
disease 0
was 0
not 0
detected 0
with 0
M 0
- 0
mode 0
, 0
2 0
- 0
dimensional 0
real 0
- 0
time 0
or 0
pulsed 0
- 0
wave 0
Doppler 0
echocardiography 0
. 0

Hemodynamic 0
assessment 0
was 0
obtained 0
before 0
and 0
following 0
administration 0
of 0
digoxin 0
10 0
micrograms/kg 0
IV 0
or 0
dopamine 0
, 0
5 0
to 0
12 0
micrograms/kg/min 0
IV 0
. 0

We 0
also 0
examined 0
the 0
relationship 0
between 0
the 0
side 0
of 0
sinusitis 0
and 0
the 0
cleft 0
side 0
in 0
patients 0
with 0
unilateral 0
cleft 0
palate 0
. 0

We 0
conclude 0
that 0
at 0
these 0
low 0
levels 0
studied 0
, 0
aluminum 0
accumulates 0
in 0
intestinal 0
tissue 0
, 0
and 0
that 0
this 0
accumulation 0
is 0
enhanced 0
by 0
citrate 0
ligand 0
. 0

Thus 0
, 0
the 0
effects 0
of 0
father 0
absence 0
under 0
routine 0
conditions 0
in 0
relatively 0
healthy 0
samples 0
may 0
exert 0
no 0
significant 0
effects 0
independent 0
of 0
intervening 0
family 0
stressors 0
or 0
maternal 0
psychopathology 0
. 0

Recently 0
, 0
an 0
electrical 0
- 0
mechanical 0
analog 0
model 0
of 0
heat 0
flow 0
within 0
the 0
brain 0
has 0
been 0
developed 0
from 0
which 0
an 0
expression 0
for 0
CBF 0
has 0
been 0
derived 0
: 0
CBF 0
= 0
Cb/ 0
( 0
tau 0
rho 0
c 0
) 0
where 0
tau 0
is 0
the 0
thermal 0
decay 0
constant 0
, 0
rho 0
is 0
the 0
density 0
of 0
blood 0
, 0
and 0
c 0
is 0
its 0
specific 0
heat 0
. 0

All 0
of 0
the 0
newly 0
acquired 0
proviruses 0
identified 0
in 0
mosaic 0
founder 0
SWR/J 0
- 0
RF/J 0
mice 0
that 0
could 0
be 0
transmitted 0
through 0
the 0
germ 0
line 0
were 0
also 0
present 0
in 0
somatic 0
tissues 0
, 0
demonstrating 0
that 0
viral 0
integration 0
occurred 0
before 0
the 0
germ 0
line 0
was 0
set 0
aside 0
from 0
the 0
somatic 0
lineages 0
. 0

Molecular 0
cloning 0
of 0
the 0
cDNA 0
for 0
the 0
human B-gene
U2 I-gene
snRNA I-gene
- I-gene
specific I-gene
A I-gene
' I-gene
protein I-gene
. 0

For 0
the 0
present 0
work 0
we 0
used 0
water 0
saturated 0
with 0
a 0
50/50 0
mixture 0
of 0
H2 0
and 0
O2 0
gases 0
, 0
for 0
which 0
the 0
heat 0
defect 0
is 0
calculated 0
to 0
be 0
- 0
2.1 0
% 0
. 0

Successful 0
use 0
of 0
transureteroureterostomy 0
to 0
salvage 0
ureterosigmoidostomy 0
after 0
anastomotic 0
failure 0
. 0

During 0
flexion 0
whiplash 0
, 0
the 0
torque 0
at 0
the 0
occipital 0
condyle 0
reverses 0
its 0
direction 0
at 0
about 0
25 0
ms 0
after 0
impact 0
. 0

The 0
data 0
indicates 0
the 0
presence 0
of 0
5 B-gene
- I-gene
HT2 I-gene
serotonergic I-gene
receptors I-gene
in 0
the 0
bronchial 0
artery 0
of 0
these 0
species 0
. 0

Oxfendazole 0
, 0
which 0
was 0
active 0
for 0
the 0
shortest 0
time 0
( 0
about 0
65 0
days 0
) 0
from 0
the 0
start 0
of 0
grazing 0
( 0
May 0
1 0
) 0
, 0
produced 0
a 0
78.1 0
per 0
cent 0
reduction 0
in 0
Ostertagia 0
species 0
and 0
an 0
84.4 0
per 0
cent 0
reduction 0
in 0
D 0
viviparus 0
. 0

By 0
adapting 0
a 0
method 0
for 0
DNA 0
- 0
footprinting 0
using 0
impure 0
extracts 0
of 0
ner B-gene
overproducing 0
cells 0
, 0
we 0
were 0
able 0
to 0
determine 0
that 0
the 0
ner B-gene
- I-gene
binding I-gene
sites I-gene
are 0
located 0
between 0
nucleotides 0
1026 0
and 0
1058 0
from 0
the 0
Mu 0
left 0
end 0
. 0

We 0
have 0
identified 0
and 0
characterized 0
the 0
structure 0
of 0
the 0
Spec1 B-gene
gene I-gene
in 0
the 0
sea 0
urchin 0
Strongylocentrotus 0
purpuratus 0
. 0

Platelet 0
function 0
and 0
platelet 0
- 0
polymorphonuclear 0
- 0
neutrophil 0
interaction 0
in 0
patients 0
with 0
deficient 0
platelet B-gene
lipoxygenase I-gene
activity 0
. 0

Spontaneous 0
degradation 0
of 0
atracurium 0
in 0
plasma 0
is 0
the 0
major 0
route 0
of 0
elimination 0
in 0
man 0
and 0
contributes 0
to 0
a 0
short 0
elimination 0
half 0
- 0
life 0
( 0
approximatively 0
20 0
min 0
) 0
. 0

Transformed 0
cell 0
lines 0
expressing 0
solely 0
E1a B-gene
or 0
E1a B-gene
and 0
E1b B-gene
gene I-gene
products I-gene
derived 0
from 0
these 0
viruses 0
display 0
enhanced 0
anchorage 0
- 0
independent 0
growth 0
at 0
37 0
degrees 0
C 0
versus 0
32 0
degrees 0
C 0
and 0
display 0
a 0
cytoskeletal 0
architecture 0
resembling 0
untransformed 0
fibroblastic 0
CREF 0
cells 0
. 0

Partial 0
N 0
- 0
terminal 0
amino 0
acid 0
sequence 0
analysis 0
showed 0
that 0
the 0
43K B-gene
and I-gene
42K I-gene
T I-gene
antigens I-gene
contain 0
methionine 0
at 0
residues 0
1 0
and 0
5 0
, 0
as 0
predicted 0
from 0
the 0
DNA 0
sequence 0
, 0
whereas 0
no 0
methionine 0
was 0
released 0
from 0
the 0
39K B-gene
T I-gene
antigen I-gene
during 0
the 0
first 0
six 0
cycles 0
of 0
Edman 0
degradation 0
. 0

Group 0
A 0
was 0
treated 0
with 0
three 0
or 0
four 0
doses 0
of 0
hepatitis B-gene
B I-gene
immune I-gene
globulin I-gene
( 0
HBIG B-gene
) 0
in 0
one 0
of 0
three 0
different 0
schedules 0
. 0

In 0
the 0
former 0
instance 0
, 0
in 0
addition 0
to 0
serum 0
calcium 0
and 0
phosphorous 0
ion 0
concentrations 0
, 0
tissue 0
pH 0
, 0
blood 0
supply 0
, 0
hormones 0
, 0
i.e. 0
, 0
vitamin 0
D 0
, 0
vitamin 0
A 0
, 0
and 0
various 0
enzymes 0
( 0
e.g. 0
, 0
alkaline B-gene
phosphatase I-gene
and 0
pyrophosphatase B-gene
) 0
may 0
all 0
play 0
significant 0
, 0
ancillary 0
, 0
time 0
- 0
dependent 0
, 0
but 0
as 0
yet 0
undetermined 0
roles 0
. 0

Penicillinase B-gene
production 0
in 0
Staphylococcus 0
aureus 0
strains 0
of 0
clinical 0
importance 0
. 0

Thus 0
, 0
quantitative 0
analysis 0
of 0
thallium 0
- 0
201 0
uptake 0
and 0
washout 0
provided 0
objective 0
evidence 0
for 0
improved 0
myocardial 0
perfusion 0
after 0
coronary 0
angioplasty 0
. 0

This 0
study 0
reports 0
the 0
effects 0
of 0
a 0
preparation 0
with 0
50 0
micrograms 0
ethinyl 0
estradiol 0
and 0
2 0
mg 0
cyproterone 0
acetate 0
on 0
gonadotropins B-gene
, 0
prolactin B-gene
, 0
testosterone 0
, 0
sex B-gene
hormone I-gene
binding I-gene
globulin I-gene
( 0
SHBG B-gene
) 0
, 0
androstenedione 0
, 0
and 0
calculated 0
free 0
testosterone 0
index 0
before 0
and 0
after 0
six 0
months 0
of 0
treatment 0
. 0

Functional 0
flow 0
was 0
evaluated 0
using 0
laser 0
Doppler 0
flowmetry 0
( 0
LDF 0
) 0
, 0
for 0
which 0
the 0
output 0
signal 0
, 0
blood 0
cell 0
flux 0
( 0
BCF 0
) 0
, 0
is 0
expressed 0
in 0
terms 0
of 0
volts 0
. 0

In 0
nine 0
patients 0
with 0
renal 0
failure 0
routine 0
haemodialysis 0
was 0
accompanied 0
by 0
a 0
30 0
per 0
cent 0
reduction 0
in 0
plasma 0
ANP B-gene
concentration 0
. 0

To 0
investigate 0
the 0
effects 0
of 0
isotretinoin 0
on 0
HDL B-gene
, 0
we 0
measured 0
HDL B-gene
- I-gene
C I-gene
, 0
HDL B-gene
phospholipids 0
( 0
HDL B-gene
- I-gene
PL I-gene
) 0
, 0
apoprotein B-gene
A1 I-gene
( 0
apo B-gene
A I-gene
- I-gene
1 I-gene
) 0
, 0
and 0
HDL B-gene
- I-gene
C I-gene
subfractions 0
( 0
HDL2 B-gene
- I-gene
C I-gene
and 0
HDL3 B-gene
- I-gene
C I-gene
) 0
in 0
24 0
healthy 0
, 0
male 0
patients 0
receiving 0
a 0
16 0
- 0
week 0
course 0
of 0
isotretinoin 0
( 0
1.0 0
mg/kg/day 0
) 0
for 0
treatment 0
of 0
severe 0
acne 0
vulgaris 0
. 0

The 0
clinical 0
picture 0
and 0
laboratory 0
parameters 0
were 0
consistent 0
with 0
a 0
serum 0
sickness 0
reaction 0
. 0

Our 0
data 0
, 0
however 0
, 0
did 0
not 0
suggest 0
the 0
existence 0
of 0
a 0
conversion 0
factor 0
for 0
LDF 0
signal 0
to 0
absolute 0
flow 0
values 0
from 0
experiment 0
to 0
experiment 0
. 0

Preventive 0
effect 0
of 0
ONO 0
- 0
3708 0
on 0
thrombosis 0
and 0
vasospasms 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

The 0
frequency 0
of 0
PPNG 0
strains 0
increased 0
from 0
1.7 0
% 0
in 0
1981 0
to 0
6.7 0
% 0
in 0
1985 0
. 0

Monospecific 0
antibodies 0
, 0
eluted 0
from 0
the 0
beta B-gene
- I-gene
galactosidase I-gene
fusion 0
protein 0
of 0
either 0
clone 0
reacted 0
with 0
the 0
U1 B-gene
snRNP I-gene
- 0
specific 0
A B-gene
antigen I-gene
. 0

Quantitative 0
analysis 0
of 0
the 0
coronary 0
stenosis 0
was 0
assessed 0
before 0
and 0
after 0
PTCA 0
, 0
and 0
the 0
dilatation 0
resulted 0
in 0
an 0
increase 0
in 0
minimal 0
luminal 0
cross 0
- 0
sectional 0
area 0
from 0
1.1 0
+/ 0
- 0
0.8 0
to 0
2.7 0
+/ 0
- 0
1.2 0
mm2 0
. 0

The 0
pathogenesis 0
of 0
Limited 0
Joint 0
Mobility 0
( 0
LJM 0
) 0
in 0
diabetes 0
is 0
unknown 0
, 0
but 0
the 0
abnormality 0
is 0
said 0
to 0
be 0
associated 0
with 0
an 0
increased 0
incidence 0
of 0
microangiopathy 0
. 0

In 0
a 0
previous 0
study 0
( 0
Brandl 0
, 0
C 0
. 0

The 0
experimental 0
end 0
points 0
were 0
the 0
time 0
required 0
for 0
treated 0
tumors 0
to 0
reach 0
3 0
times 0
their 0
treatment 0
size 0
, 0
the 0
survival 0
of 0
stem 0
cells 0
in 0
the 0
duodenal 0
crypts 0
, 0
and 0
the 0
breathing 0
rate 0
measured 0
early 0
( 0
19 0
- 0
23 0
weeks 0
) 0
and 0
late 0
( 0
41 0
- 0
46 0
weeks 0
) 0
after 0
treatment 0
. 0

Schedule 0
2 0
, 0
in 0
which 0
2.4 0
mg/kg 0
c 0
- 0
DDP 0
was 0
administered 0
immediately 0
before 0
X 0
- 0
ray 0
on 0
5 0
consecutive 0
days 0
produced 0
the 0
highest 0
degree 0
of 0
enhancement 0
of 0
radiation 0
effect 0
( 0
expressed 0
as 0
dose 0
- 0
effect 0
factor 0
) 0
; 0
and 0
the 0
next 0
greatest 0
enhancement 0
was 0
produced 0
by 0
12 0
mg/kg 0
c 0
- 0
DDP 0
administered 0
24 0
h 0
before 0
the 0
start 0
of 0
fractionated 0
daily 0
radiotherapy 0
. 0

The 0
cpc B-gene
- I-gene
1 I-gene
- I-gene
encoded I-gene
transcript I-gene
contains 0
three 0
open 0
reading 0
frames 0
, 0
two 0
of 0
which 0
are 0
located 0
in 0
the 0
720 0
- 0
nucleotide 0
leader 0
segment 0
preceding 0
the 0
cpc B-gene
- I-gene
1 I-gene
coding I-gene
region I-gene
. 0

The 0
seco 0
- 0
steroid 0
hormone 0
1,25 0
- 0
dihydroxyvitamin 0
D3 0
is 0
known 0
to 0
induce 0
the 0
expression 0
of 0
a 0
calcium 0
binding 0
protein 0
termed 0
calbindin B-gene
- I-gene
D28K I-gene
in 0
a 0
variety 0
of 0
target 0
tissues 0
. 0

In 0
addition 0
, 0
the 0
calbindin B-gene
- I-gene
D28K I-gene
promoter I-gene
is 0
composed 0
of 0
a 0
variety 0
of 0
simple 0
repeated 0
sequences 0
, 0
some 0
of 0
which 0
are 0
components 0
of 0
putative 0
regulatory 0
signals 0
. 0

The 0
HOI 0
induced 0
a 0
nearly 0
fourfold 0
increase 0
in 0
ANF B-gene
in 0
the 0
elderly 0
, 0
whereas 0
that 0
for 0
the 0
young 0
was 0
threefold 0
. 0

To 0
assess 0
the 0
ability 0
of 0
the 0
atria 0
to 0
maintain 0
elevated 0
plasma 0
concentrations 0
of 0
atrial B-gene
natriuretic I-gene
peptide I-gene
( 0
ANP B-gene
) 0
, 0
the 0
temporal 0
changes 0
in 0
plasma B-gene
ANP I-gene
concentrations 0
were 0
studied 0
in 0
seven 0
chloralose 0
- 0
anaesthetized 0
dogs 0
during 0
4 0
h 0
of 0
sustained 0
rapid 0
cardiac 0
pacing 0
. 0

Ig B-gene
D I-gene
- 0
JH B-gene
recombinations 0
may 0
precede 0
TcR B-gene
gene I-gene
recombination 0
in 0
these 0
early 0
T 0
cell 0
lines 0
, 0
and 0
some 0
but 0
not 0
all 0
express 0
sterile 0
Cmu B-gene
transcripts I-gene
. 0

The 0
RAD18 B-gene
gene I-gene
open I-gene
reading I-gene
frame I-gene
encodes 0
a 0
protein 0
of 0
487 0
amino 0
acids 0
, 0
with 0
a 0
calculated 0
molecular 0
weight 0
of 0
55,512 0
. 0

Atomic 0
absorption 0
spectrophotometry 0
applied 0
to 0
bacterially 0
expressed 0
E1A B-gene
proteins I-gene
revealed 0
that 0
the 0
289 0
- 0
amino 0
acid 0
protein 0
binds 0
one 0
zinc 0
ion 0
, 0
whereas 0
the 0
243 0
- 0
amino 0
acid 0
protein 0
binds 0
no 0
zinc 0
. 0

Most 0
patients 0
preferred 0
tablets 0
to 0
injection 0
both 0
on 0
day 0
1 0
( 0
313 0
v 0
200 0
) 0
and 0
at 0
follow 0
up 0
( 0
373 0
v 0
104 0
) 0
. 0

Plots 0
of 0
RV 0
, 0
LV 0
+ 0
S 0
and 0
2A 0
weight 0
vs 0
real 0
hematocrit 0
showed 0
sharp 0
upward 0
inflections 0
at 0
real 0
hematocrit 0
65 0
% 0
, 0
suggesting 0
a 0
possible 0
role 0
of 0
increased 0
viscosity 0
in 0
CO 0
cardiomegaly 0
at 0
the 0
higher 0
hematocrit 0
. 0

The 0
absorbable 0
perisplenic 0
mesh 0
is 0
an 0
important 0
improvement 0
, 0
and 0
in 0
some 0
cases 0
it 0
may 0
replace 0
other 0
techniques 0
for 0
arresting 0
splenic 0
bleeding 0
. 0

A 0
rare 0
chronic 0
course 0
of 0
Budd 0
- 0
Chiari 0
syndrome 0
associated 0
with 0
thrombosis 0
of 0
the 0
portal 0
vein 0
was 0
observed 0
in 0
a 0
30 0
- 0
year 0
- 0
old 0
male 0
patient 0
suffering 0
from 0
postmyocarditic 0
cardiosclerosis 0
. 0

After 0
one 0
accommodation 0
night 0
, 0
sleep 0
EEG 0
recordings 0
were 0
performed 0
during 0
three 0
consecutive 0
nights 0
in 0
ten 0
drug 0
- 0
free 0
inpatients 0
presenting 0
generalized 0
anxiety 0
disorder 0
( 0
GAD 0
) 0
with 0
significant 0
depression 0
, 0
compared 0
with 0
a 0
age 0
- 0
and 0
sex 0
- 0
matched 0
group 0
of 0
patients 0
with 0
GAD 0
and 0
a 0
group 0
of 0
primary 0
major 0
depressive 0
disorder 0
( 0
MDD 0
) 0
patients 0
. 0

Oligonucleotide 0
mutagenesis 0
of 0
these 0
binding 0
domains 0
indicated 0
their 0
importance 0
in 0
the 0
transcriptional 0
regulation 0
of 0
the 0
E3 B-gene
promoter I-gene
in 0
yeast 0
cells 0
. 0

The 0
concentration 0
of 0
PGI2 0
on 0
the 0
newly 0
- 0
formed 0
luminal 0
surface 0
remained 0
low 0
. 0

Organ 0
transplantation 0
in 0
Denmark 0
. 0

Effects 0
of 0
single 0
and 0
combined 0
maltose 0
tetrapalmitate 0
immunotherapy 0
, 0
cyclophosphamide 0
chemotherapy 0
and 0
radiotherapy 0
on 0
ethyl 0
carbamate 0
accelerated 0
primary 0
lung 0
cancer 0
in 0
A/J 0
mice 0
. 0

D 0
. 0

A 0
114 0
- 0
base 0
pair 0
sequence 0
of 0
predominantly 0
repeating 0
purine 0
- 0
pyrimidine 0
nucleotides 0
separates 0
these 0
two 0
d 0
( 0
AC 0
) 0
repeats 0
. 0

Phase 0
II 0
study 0
of 0
VP 0
- 0
16 0
( 0
capsule 0
) 0
in 0
solid 0
tumors 0
. 0

When 0
the 0
coding 0
segments 0
, 0
including 0
both 0
framework 0
and 0
complementarity 0
- 0
determining 0
regions 0
, 0
of 0
these 0
genes 0
and 0
the 0
murine 0
probe 0
sequences 0
are 0
compared 0
by 0
metric 0
analysis 0
, 0
it 0
is 0
apparent 0
that 0
the 0
caiman 0
genes 0
are 0
only 0
slightly 0
more 0
related 0
to 0
each 0
other 0
than 0
to 0
the 0
mammalian 0
sequence 0
, 0
consistent 0
with 0
significant 0
preservation 0
of 0
nucleotide 0
sequence 0
over 0
an 0
extended 0
period 0
of 0
phylogenetic 0
time 0
. 0

Evidence 0
for 0
a 0
role 0
of 0
endogenous B-gene
corticotropin I-gene
- I-gene
releasing I-gene
factor I-gene
in 0
cold 0
, 0
ether 0
, 0
immobilization 0
, 0
and 0
traumatic 0
stress 0
. 0

An 0
unusual 0
feature 0
of 0
these 0
replicative 0
genes 0
is 0
that 0
the 0
smaller 0
mRNA 0
begins 0
within 0
a 0
long 0
open 0
reading 0
frame 0
of 0
the 0
larger 0
mRNA 0
. 0

Different 0
sequence 0
elements 0
of 0
both 0
the 0
retroviral 0
vectors 0
and 0
the 0
c B-gene
- I-gene
myc I-gene
gene I-gene
recombined 0
during 0
genesis 0
of 0
highly 0
oncogenic 0
retroviruses 0
CMII 0
, 0
MC29 0
, 0
or 0
MH2 0
. 0

81 0
milk 0
samples 0
collected 0
from 0
35 0
donors 0
3 0
days 0
to 0
7 0
months 0
after 0
delivery 0
were 0
examined 0
for 0
the 0
occurrence 0
of 0
cytomegalovirus 0
( 0
CMV 0
) 0
. 0

Subcloning 0
of 0
DNA 0
fragments 0
from 0
the 0
8.5 0
- 0
kilobase 0
( 0
kb 0
) 0
insert 0
of 0
pAVO4 0
defined 0
a 0
4 0
- 0
kb 0
DNA 0
fragment 0
which 0
contained 0
the 0
functional B-gene
FBP+ I-gene
gene I-gene
and 0
its 0
regulatory 0
region 0
. 0

Three 0
cases 0
of 0
primary 0
signet 0
- 0
ring 0
cell 0
carcinoma 0
of 0
the 0
rectum 0
are 0
described 0
. 0

The 0
data 0
obtained 0
up 0
to 0
now 0
only 0
suggest 0
the 0
future 0
potentiality 0
of 0
Bestatin 0
treatment 0
for 0
these 0
types 0
of 0
malignancy 0
. 0

These 0
data 0
suggest 0
that 0
dopaminergic 0
regulation 0
of 0
adrenal 0
zona 0
glomerulosa 0
corticosteroid 0
and 0
renal B-gene
renin I-gene
secretion 0
is 0
absent 0
in 0
patients 0
with 0
high 0
spinal 0
cord 0
transections 0
, 0
suggesting 0
that 0
intact 0
neural 0
pathways 0
from 0
the 0
central 0
nervous 0
system 0
are 0
necessary 0
for 0
metoclopramide 0
stimulation 0
of 0
aldosterone 0
and 0
renin B-gene
secretion 0
in 0
men 0
. 0

In 0
the 0
absence 0
of 0
enhancer 0
sequences 0
, 0
the 0
adenovirus B-gene
E1A I-gene
gene I-gene
can 0
not 0
stimulate 0
CATase B-gene
synthesis 0
. 0

These 0
IgG B-gene
antibodies I-gene
in 0
the 0
babies 0
diminished 0
rapidly 0
after 0
delivery 0
, 0
and 0
were 0
detectable 0
only 0
in 0
3 0
cases 0
at 0
2 0
, 0
3 0
, 0
and 0
5 0
months 0
of 0
ages 0
out 0
of 0
38 0
babies 0
up 0
to 0
21 0
months 0
. 0

Fine 0
analysis 0
at 0
the 0
nucleotide 0
level 0
of 0
the 0
early 0
events 0
in 0
the 0
digestion 0
with 0
nuclease B-gene
S1 I-gene
shows 0
that 0
the 0
enzyme 0
attacks 0
preferentially 0
the 0
sequence 0
( 0
G 0
- 0
A 0
) 0
12 0
on 0
the 0
message 0
complementary 0
strand 0
. 0

Those 0
dosages 0
that 0
inhibited 0
mean 0
NTE B-gene
activity 0
in 0
spinal 0
cord 0
greater 0
than 0
or 0
equal 0
to 0
72 0
% 0
and 0
brain 0
greater 0
than 0
or 0
equal 0
to 0
66 0
% 0
of 0
control 0
values 0
within 0
44 0
hr 0
postexposure 0
produced 0
marked 0
spinal 0
cord 0
pathology 0
14 0
days 0
postexposure 0
in 0
greater 0
than 0
or 0
equal 0
to 0
90 0
% 0
of 0
similarly 0
dosed 0
animals 0
. 0

FK 0
33 0
- 0
824 0
, 0
a 0
methionine 0
- 0
enkephalin B-gene
analogue 0
, 0
suppressed 0
plasma 0
ACTH B-gene
to 0
85 0
% 0
of 0
basal 0
level 0
, 0
while 0
bromocriptine 0
( 0
CB 0
- 0
154 0
) 0
caused 0
no 0
significant 0
change 0
. 0

A 0
v B-gene
- I-gene
erbB I-gene
- I-gene
related I-gene
protooncogene I-gene
, 0
c B-gene
- I-gene
erbB I-gene
- I-gene
2 I-gene
, 0
is 0
distinct 0
from 0
the 0
c B-gene
- I-gene
erbB I-gene
- I-gene
1/epidermal I-gene
1/epidermal I-gene
growth I-gene
factor I-gene
- I-gene
receptor I-gene
gene 0
and 0
is 0
amplified 0
in 0
a 0
human 0
salivary 0
gland 0
adenocarcinoma 0
. 0

The 0
sequence 0
analysis 0
of 0
both 0
products 0
of 0
individual 0
phi 0
80 0
site 0
- 0
specific 0
recombination 0
events 0
in 0
vivo 0
shows 0
that 0
recombination 0
with 0
a 0
secondary 0
attachment 0
( 0
att 0
) 0
site 0
generates 0
several 0
different 0
novel 0
joints 0
at 0
the 0
mismatched 0
position 0
: 0
one 0
recombination 0
event 0
resulted 0
in 0
a 0
single 0
base 0
- 0
pair 0
deletion 0
and 0
two 0
other 0
recombination 0
events 0
resulted 0
in 0
two 0
different 0
single 0
base 0
- 0
pair 0
substitutions 0
. 0

This 0
L B-gene
- I-gene
myc I-gene
sequence I-gene
is 0
amplified 0
10 0
- 0
20 0
- 0
fold 0
in 0
four 0
SCLC 0
cell 0
line 0
DNAs 0
and 0
in 0
one 0
SCLC 0
tumour 0
specimen 0
taken 0
directly 0
from 0
a 0
patient 0
. 0

Temperature 0
- 0
shift 0
experiments 0
using 0
synchronously 0
grown 0
cells 0
of 0
a 0
delta B-gene
top1 I-gene
top2 B-gene
temperature I-gene
- I-gene
sensitive I-gene
( I-gene
ts I-gene
) I-gene
double I-gene
mutant I-gene
and 0
its 0
isogenic 0
top2 B-gene
ts 0
strain 0
show 0
that 0
, 0
whereas 0
mitotic 0
blocks 0
can 0
prevent 0
killing 0
of 0
the 0
top2 B-gene
ts I-gene
mutant I-gene
at 0
a 0
nonpermissive 0
temperature 0
, 0
the 0
same 0
treatments 0
are 0
ineffective 0
in 0
preventing 0
cell 0
death 0
of 0
the 0
delta B-gene
top1 I-gene
top2 B-gene
ts I-gene
double I-gene
mutant I-gene
. 0

The 0
homology 0
to 0
v B-gene
- I-gene
mil I-gene
starts 0
within 0
the 0
coding 0
sequence 0
of 0
exon 0
1 0
and 0
ends 0
within 0
the 0
3 0
' 0
untranslated 0
region 0
of 0
exon 0
11 0
, 0
12 0
nucleotides 0
downstream 0
from 0
the 0
nonsense 0
codon 0
terminating 0
the 0
large 0
open 0
reading 0
frame 0
shared 0
between 0
c B-gene
- I-gene
mil I-gene
and 0
v B-gene
- I-gene
mil I-gene
. 0

Examination 0
of 0
the 0
sequence 0
of 0
the 0
Punta B-gene
Toro I-gene
M I-gene
gene I-gene
product I-gene
reveals 0
the 0
presence 0
of 0
multiple 0
hydrophobic 0
sequences 0
including 0
a 0
19 0
- 0
amino 0
acid 0
, 0
carboxy 0
- 0
proximal 0
, 0
hydrophobic 0
region 0
( 0
G2 0
) 0
. 0

Six 0
( 0
four 0
FAP 0
; 0
two 0
primary 0
amyloidosis 0
) 0
also 0
had 0
diffusely 0
positive 0
myocardial 0
uptakes 0
, 0
but 0
the 0
intensity 0
was 0
less 0
than 0
that 0
of 0
the 0
sternum 0
. 0

The 0
intensity 0
of 0
myocardial 0
uptake 0
of 0
Tc 0
- 0
99m 0
- 0
PYP 0
in 0
patients 0
with 0
echocardiographic 0
left 0
ventricular 0
hypertrophy 0
and/or 0
highly 0
refractile 0
myocardial 0
echoes 0
, 0
so 0
- 0
called 0
granular 0
sparkling 0
appearance 0
( 0
GS 0
) 0
was 0
slightly 0
greater 0
than 0
that 0
in 0
patients 0
with 0
neither 0
myocardial 0
hypertrophy 0
nor 0
GS 0
. 0

The 0
210 0
kDa 0
precursor 0
is 0
converted 0
slowly 0
( 0
t 0
1/2 0
= 0
2 0
h 0
) 0
by 0
proteolytic 0
processing 0
into 0
a 0
125 0
kDa 0
( 0
alpha 0
' 0
) 0
and 0
83 0
kDa 0
( 0
beta 0
' 0
) 0
species 0
. 0

Alveolar 0
lymphocytes 0
were 0
surprisingly 0
increased 0
in 0
most 0
patients 0
with 0
AIDS 0
( 0
mean 0
26.1 0
+/ 0
- 0
21.9 0
% 0
; 0
range 0
1 0
- 0
76 0
% 0
) 0
and 0
CGL 0
( 0
mean 0
26.6 0
+/ 0
- 0
22.6 0
% 0
; 0
range 0
3 0
- 0
76 0
% 0
) 0
with 0
criteria 0
of 0
activation 0
contrasting 0
with 0
the 0
blood 0
lymphopenia 0
. 0

We 0
have 0
determined 0
that 0
these 0
nicks 0
occur 0
in 0
both 0
the 0
wild 0
- 0
type 0
and 0
the 0
mutant 0
sites 0
. 0

The 0
sequence 0
was 0
determined 0
for 0
a 0
4024 0
- 0
base 0
pair 0
( 0
bp 0
) 0
segment 0
that 0
extends 0
from 0
149 0
bp 0
5 0
' 0
to 0
the 0
cap 0
site 0
of 0
alpha B-gene
1 I-gene
to 0
207 0
bp 0
3 0
' 0
to 0
psi B-gene
alpha I-gene
. 0

Its 0
predicted 0
amino 0
acid 0
sequence 0
shows 0
extensive 0
homology 0
to 0
those 0
of 0
Drosophila B-gene
hsp70 I-gene
, 0
trout B-gene
hsp70 I-gene
, 0
Xenopus B-gene
hsp70 I-gene
, 0
yeast B-gene
hsp70 I-gene
, 0
and 0
some 0
homology 0
to 0
the 0
heat B-gene
- I-gene
inducible I-gene
dnaK I-gene
gene I-gene
product I-gene
of 0
Escherichia 0
coli 0
. 0

When 0
phosphorylation 0
of 0
exogenous 0
peptide 0
substrates 0
was 0
measured 0
as 0
a 0
function 0
of 0
receptor 0
self 0
- 0
phosphorylation 0
, 0
tyrosine B-gene
kinase I-gene
activity 0
was 0
found 0
to 0
be 0
enhanced 0
two 0
to 0
threefold 0
at 0
1 0
- 0
2 0
mol 0
of 0
phosphate 0
per 0
mol 0
of 0
receptor 0
. 0

At 0
temperatures 0
permissive 0
for 0
transformation 0
, 0
6m2 0
cells 0
contain 0
P58gag B-gene
produced 0
from 0
the 0
4.0 0
- 0
kilobase 0
( 0
kb 0
) 0
viral 0
RNA 0
genome 0
and 0
P85gag B-gene
- 0
mos B-gene
translated 0
from 0
a 0
3.5 0
- 0
kb 0
spliced 0
mRNA 0
. 0

The 0
pet56 B-gene
and 0
his3 B-gene
genes I-gene
are 0
transcribed 0
divergently 0
from 0
initiation 0
sites 0
that 0
are 0
separated 0
by 0
only 0
192 0
bp 0
. 0

Multistep 0
transformation 0
by 0
defined 0
fragments 0
of 0
herpes 0
simplex 0
virus 0
type 0
2 0
DNA 0
: 0
oncogenic 0
region 0
and 0
its 0
gene 0
product 0
. 0

It 0
is 0
concluded 0
that 0
in 0
patients 0
with 0
first 0
- 0
attack 0
genital 0
herpes 0
, 0
the 0
type 0
of 0
HSV 0
is 0
the 0
most 0
important 0
determinant 0
of 0
subsequent 0
recurrences 0
and 0
that 0
intravenous 0
acyclovir 0
has 0
little 0
effect 0
on 0
subsequent 0
recurrences 0
. 0

Comparison 0
of 0
sequences 0
of 0
ovine 0
and 0
bovine 0
, 0
rat 0
and 0
guinea B-gene
- I-gene
pig I-gene
alpha I-gene
s1 I-gene
- I-gene
casein I-gene
mRNAs I-gene
has 0
revealed 0
a 0
greater 0
homology 0
in 0
the 0
3 0
' 0
and 0
especially 0
5 0
' 0
non 0
coding 0
regions 0
. 0

One 0
group 0
( 0
n 0
= 0
9 0
) 0
was 0
premedicated 0
with 0
midazolam 0
, 0
0.1 0
mg 0
kg 0
- 0
1 0
, 0
and 0
atropine 0
0.2 0
- 0
0.4 0
mg 0
i.m 0
. 0

Comparison 0
with 0
a 0
recently 0
described 0
c B-gene
- I-gene
sis I-gene
cDNA I-gene
clone I-gene
( 0
Collins 0
et 0
al. 0
, 0
Nature 0
316 0
, 0
748 0
- 0
750 0
( 0
1985 0
) 0
) 0
revealed 0
that 0
the 0
1.9 0
kbp 0
DNA 0
region 0
contained 0
a 0
large 0
5 B-gene
' I-gene
c I-gene
- I-gene
sis I-gene
exon I-gene
of 0
at 0
least 0
1050 0
bp 0
. 0

It 0
was 0
also 0
suggested 0
that 0
the 0
biological 0
activities 0
of 0
5 0
- 0
FU 0
, 0
ADM 0
and 0
MMC 0
in 0
FAMLIP 0
were 0
stable 0
in 0
FULIP 0
, 0
ADRLIP 0
and 0
MMCLIP 0
. 0

Surprisingly 0
, 0
a 0
C 0
to 0
G 0
transversion 0
at 0
the 0
first 0
residue 0
of 0
the 0
CAT B-gene
pentanucleotide I-gene
, 0
which 0
severely 0
impairs 0
the 0
activity 0
of 0
both 0
promoters 0
, 0
appears 0
to 0
increase 0
affinity 0
of 0
the 0
CAT B-gene
binding I-gene
protein I-gene
. 0

The 0
nucleotide 0
sequence 0
of 0
3874 0
bp 0
of 0
cloned 0
R. 0
sphaeroides 0
chromosomal 0
DNA 0
, 0
including 0
the 0
three 0
structural 0
genes 0
fbcF B-gene
, 0
fbcB B-gene
and 0
fbcC B-gene
has 0
been 0
determined 0
. 0

The 0
N 0
- 0
terminal 0
sequence 0
of 0
one 0
hydrophilic 0
peptide 0
of 0
the 0
FeS B-gene
protein I-gene
has 0
been 0
also 0
obtained 0
confirming 0
the 0
fbcF B-gene
reading 0
frame 0
. 0

The 0
5 0
' 0
and 0
3 0
' 0
untranslated 0
sequences 0
contain 0
characteristic 0
sequences 0
that 0
are 0
involved 0
in 0
the 0
initiation 0
and 0
termination 0
of 0
transcription 0
, 0
including 0
two 0
possible 0
promoters 0
, 0
one 0
of 0
which 0
may 0
contain 0
two 0
overlapping 0
- 0
10 0
sequences 0
. 0

Unlike 0
P135gag B-gene
- 0
myb B-gene
- 0
ets B-gene
and 0
the 0
Mr 0
75,000 0
translation 0
product 0
of 0
c B-gene
- I-gene
myb I-gene
( 0
P75c B-gene
- I-gene
myb I-gene
) 0
, 0
which 0
are 0
nuclear 0
proteins 0
, 0
P54c B-gene
- I-gene
ets I-gene
was 0
found 0
to 0
be 0
predominantly 0
cytoplasmic 0
. 0

The 0
Dox B-gene
- I-gene
A2 I-gene
locus I-gene
is 0
within 0
3.4 0
to 0
4.4 0
kb 0
of 0
the 0
Df B-gene
( I-gene
2L I-gene
) I-gene
OD15 I-gene
breakpoint I-gene
, 0
placing 0
four 0
of 0
the 0
vital 0
loci 0
within 0
a 0
maximum 0
of 0
15.5 0
kb 0
. 0

The 0
C 0
- 0
terminal 0
end 0
of 0
this 0
polypeptide 0
harbors 0
three 0
types 0
of 0
repeated 0
sequences 0
. 0

Further 0
outbreaks 0
of 0
ocular 0
disease 0
in 0
farmed 0
red 0
deer 0
calves 0
caused 0
by 0
HVC 0
- 0
1 0
were 0
investigated 0
. 0

From 0
our 0
ultrastructural 0
and 0
biochemical 0
studies 0
, 0
it 0
is 0
evident 0
that 0
Type 0
II 0
pneumocytes 0
are 0
an 0
early 0
target 0
of 0
radiation 0
and 0
the 0
release 0
of 0
surfactant 0
into 0
the 0
alveolus 0
shortly 0
after 0
exposure 0
persists 0
for 0
days 0
and 0
weeks 0
. 0

Thirty 0
of 0
the 0
clones 0
contained 0
a 0
complete 0
340 0
base 0
- 0
pair 0
dimer 0
unit 0
of 0
the 0
repeat 0
. 0

Two 0
copies 0
of 0
the 0
72 0
- 0
bp 0
repeat 0
provided 0
efficient 0
activation 0
of 0
gene 0
expression 0
. 0

The 0
open 0
reading 0
frames 0
of 0
rbsD B-gene
, 0
rbsA B-gene
, 0
and 0
rbsC B-gene
encode 0
proteins 0
of 0
139 0
, 0
501 0
, 0
and 0
321 0
amino 0
acid 0
residues 0
, 0
respectively 0
. 0

In 0
order 0
to 0
study 0
the 0
influence 0
of 0
iron 0
overload 0
on 0
the 0
polymorphonuclear 0
leucocyte 0
( 0
PMN 0
) 0
metabolism 0
of 0
patients 0
on 0
chronic 0
hemodialysis 0
, 0
generation 0
of 0
superoxide 0
anion 0
( 0
O2 0
- 0
) 0
by 0
PMN 0
in 0
whole 0
blood 0
was 0
compared 0
in 0
two 0
groups 0
of 0
hemodialyzed 0
patients 0
: 0
group 0
A 0
consisted 0
of 0
twenty 0
- 0
one 0
individuals 0
with 0
serum 0
ferritin B-gene
levels 0
above 0
1000 0
ng/ml 0
and 0
group 0
B 0
of 0
nineteen 0
individuals 0
with 0
serum 0
ferritin B-gene
levels 0
below 0
1000 0
ng/ml 0
. 0

Cattaneo 0
, 0
and 0
J 0
. 0

Human B-gene
alpha I-gene
- I-gene
galactosidase I-gene
A I-gene
: 0
nucleotide 0
sequence 0
of 0
a 0
cDNA 0
clone 0
encoding 0
the 0
mature 0
enzyme 0
. 0

Diazepam 0
( 0
3 0
mg/kg 0
) 0
generalized 0
to 0
Ro 0
11 0
- 0
6896 0
whereas 0
the 0
structurally 0
related 0
Ro 0
5 0
- 0
4864 0
( 0
3 0
mg/kg 0
and 0
30 0
mg/kg 0
) 0
did 0
not 0
. 0

The 0
amino 0
acid 0
sequence 0
was 0
determined 0
to 0
be 0
residues 0
716 0
- 0
724 0
and 0
hence 0
lysine 0
residue 0
721 0
is 0
located 0
within 0
the 0
ATP 0
- 0
binding 0
site 0
. 0

Osteocalcin B-gene
( 0
and 0
urinary 0
hydroxyproline 0
) 0
were 0
not 0
elevated 0
in 0
isolated 0
hyperphosphatasaemia 0
, 0
indicating 0
that 0
mechanisms 0
other 0
than 0
increased 0
bone 0
turnover 0
may 0
account 0
for 0
the 0
markedly 0
elevated 0
serum B-gene
alkaline I-gene
phosphatase I-gene
activity 0
in 0
these 0
subjects 0
. 0

Analysis 0
of 0
glucocorticoid 0
unresponsive 0
cell 0
variants 0
using 0
a 0
mouse B-gene
glucocorticoid I-gene
receptor I-gene
complementary 0
DNA 0
clone 0
. 0

Among 0
the 0
v B-gene
- I-gene
myc I-gene
codons 0
, 0
the 0
first 0
5 0
are 0
derived 0
from 0
the 0
noncoding 0
5 0
' 0
terminus 0
of 0
the 0
second 0
c B-gene
- I-gene
myc I-gene
exon 0
, 0
and 0
412 0
codons 0
correspond 0
to 0
the 0
c B-gene
- I-gene
myc I-gene
coding 0
region 0
. 0

A 0
recombinant 0
vector 0
, 0
p410+ 0
, 0
was 0
constructed 0
which 0
carried 0
the 0
BamHI B-gene
- I-gene
K I-gene
fragment I-gene
( 0
nucleotides 0
107565 0
to 0
112625 0
of 0
the 0
B95 0
- 0
8 0
strain 0
, 0
encoding 0
the 0
EBV 0
- 0
associated 0
nuclear 0
antigen 0
EBNA B-gene
- I-gene
1 I-gene
) 0
, 0
the 0
cis 0
- 0
acting 0
sequence 0
from 0
the 0
BamHI B-gene
- I-gene
C I-gene
fragment I-gene
, 0
and 0
a 0
dominant 0
selectable 0
marker 0
gene 0
encoding 0
G 0
- 0
418 0
resistance 0
in 0
animal 0
cells 0
. 0

13 0
men 0
with 0
a 0
history 0
of 0
recurrent 0
genital 0
herpes 0
simplex 0
virus 0
type 0
2 0
( 0
HSV 0
- 0
2 0
) 0
infection 0
were 0
followed 0
daily 0
for 0
4 0
weeks 0
with 0
samples 0
taken 0
from 0
the 0
urethra 0
for 0
virus 0
isolation 0
. 0

Next 0
, 0
with 0
carcinoma 0
presenting 0
a 0
leather 0
bottle 0
( 0
linitis 0
plastica 0
type 0
) 0
of 0
the 0
stomach 0
itself 0
, 0
the 0
II 0
c 0
portion 0
of 0
the 0
stomach 0
consisted 0
of 0
fundic 0
glands 0
( 0
undifferentiated 0
carcinoma 0
) 0
shall 0
become 0
the 0
primary 0
focus 0
supporting 0
Nakamura 0
's 0
theory 0
. 0

During 0
the 0
biosynthesis 0
of 0
all 0
three 0
mutant 0
polypeptides 0
, 0
the 0
signal 0
peptide 0
is 0
efficiently 0
and 0
accurately 0
cleaved 0
from 0
the 0
nascent 0
protein 0
, 0
even 0
though 0
in 0
mutants 0
X2 0
and 0
X3 0
the 0
cleavage 0
site 0
itself 0
has 0
been 0
altered 0
. 0

The 0
hexanucleotide 0
5' 0
- 0
TGTCCT 0
- 0
3 0
' 0
, 0
thought 0
to 0
be 0
important 0
for 0
GRE 0
activity 0
, 0
not 0
only 0
was 0
found 0
in 0
this 0
sequence 0
and 0
in 0
the 0
5' 0
- 0
flanking 0
region 0
, 0
but 0
also 0
was 0
present 0
twice 0
in 0
the 0
3 0
' 0
end 0
of 0
the 0
gene 0
that 0
did 0
not 0
show 0
specific 0
receptor 0
binding 0
. 0

Five 0
patients 0
developed 0
metastatic 0
spread 0
, 0
and 0
all 0
of 0
them 0
died 0
of 0
tumor 0
. 0

The 0
smallest 0
of 0
the 0
mini 0
- 0
Mu 0
elements 0
is 0
only 0
7.9 0
kilobase 0
pairs 0
long 0
, 0
allowing 0
the 0
cloning 0
of 0
DNA 0
fragments 0
of 0
up 0
to 0
31.1 0
kilobase 0
pairs 0
, 0
and 0
the 0
largest 0
of 0
them 0
is 0
21.7 0
kilobase 0
pairs 0
, 0
requiring 0
that 0
clones 0
carry 0
insertions 0
of 0
less 0
than 0
17.3 0
kilobase 0
pairs 0
. 0

The 0
52 0
- 0
protein 0
subunit 0
of 0
T4 B-gene
DNA I-gene
topoisomerase I-gene
is 0
homologous 0
to 0
the 0
gyrA B-gene
- I-gene
protein I-gene
of 0
gyrase B-gene
. 0

There 0
were 0
no 0
interfering 0
peaks 0
in 0
the 0
quantitation 0
of 0
sulbactam 0
. 0

The 0
latent 0
periods 0
from 0
the 0
antral 0
exclusion 0
to 0
the 0
occurrence 0
of 0
anastomotic 0
ulcers 0
after 0
a 0
subtotal 0
gastrectomy 0
with 0
Billroth 0
's 0
type 0
II 0
reconstruction 0
varied 0
from 0
a 0
few 0
days 0
to 0
19 0
years 0
, 0
with 0
an 0
average 0
of 0
2.8 0
years 0
. 0

The 0
nucleosomal 0
arrays 0
detected 0
by 0
MPE 0
X 0
Fe 0
( 0
II 0
) 0
were 0
characterized 0
by 0
a 0
considerable 0
loss 0
of 0
detail 0
and 0
significantly 0
enhanced 0
accessibility 0
, 0
the 0
extent 0
of 0
which 0
probably 0
reflected 0
the 0
relative 0
transcription 0
rate 0
of 0
each 0
gene 0
. 0

Translation 0
of 0
specific 0
cellular 0
genes 0
from 0
the 0
chimeric 0
viral 0
- 0
cellular 0
transcripts 0
seems 0
to 0
be 0
unlikely 0
. 0

The 0
molecular 0
weight 0
of 0
in 0
vivo 0
- 0
labeled 0
proteins 0
was 0
increased 0
relative 0
to 0
that 0
of 0
in 0
vitro 0
- 0
translated 0
proteins 0
, 0
indicating 0
that 0
a 0
posttranslational 0
modification 0
had 0
occurred 0
. 0

Insertion 0
of 0
4 0
bp 0
reduced 0
SV40 B-gene
early I-gene
promoter I-gene
- 0
dependent 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
expression 0
by 0
six 0
- 0
to 0
eightfold 0
. 0

In 0
the 0
DNAs 0
of 0
all 0
Ph1 0
- 0
positive 0
chronic 0
myelocytic 0
leukemia 0
patients 0
studied 0
to 0
date 0
, 0
a 0
breakpoint 0
on 0
chromosome 0
22 0
( 0
the 0
Ph1 0
chromosome 0
) 0
can 0
be 0
demonstrated 0
with 0
a 0
probe 0
from 0
the 0
bcr B-gene
( 0
breakpoint B-gene
cluster I-gene
region I-gene
) 0
. 0

Nuclease 0
footprinting 0
revealed 0
that 0
purified 0
glucocorticoid B-gene
receptor I-gene
bound 0
at 0
multiple 0
discrete 0
sites 0
within 0
and 0
at 0
the 0
borders 0
of 0
the 0
tandemly 0
repeated 0
sequence 0
motif 0
that 0
defines 0
Sa B-gene
. 0

The 0
96 0
- 0
bp 0
insert 0
contained 0
a 0
termination 0
signal 0
which 0
caused 0
the 0
premature 0
termination 0
of 0
the 0
protein 0
, 0
leading 0
to 0
the 0
generation 0
of 0
a 0
p53 B-gene
product I-gene
9 0
amino 0
acids 0
shorter 0
than 0
usual 0
. 0

All 0
tumors 0
proved 0
histologically 0
to 0
be 0
neuroendocrine 0
in 0
origin 0
. 0

The 0
coding 0
region 0
of 0
2385 0
nucleotides 0
corresponds 0
to 0
a 0
polypeptide 0
chain 0
of 0
795 0
amino 0
acids 0
, 0
giving 0
a 0
molecular 0
weight 0
of 0
91,555 0
for 0
the 0
hsp108 B-gene
protein I-gene
. 0

Transcriptional 0
control 0
signals 0
of 0
a 0
herpes B-gene
simplex I-gene
virus I-gene
type I-gene
1 I-gene
late I-gene
( I-gene
gamma I-gene
2 I-gene
) I-gene
gene I-gene
lie 0
within 0
bases 0
- 0
34 0
to 0
+124 0
relative 0
to 0
the 0
5 0
' 0
terminus 0
of 0
the 0
mRNA 0
. 0

A 0
noncatalytic 0
domain 0
conserved 0
among 0
cytoplasmic B-gene
protein I-gene
- I-gene
tyrosine I-gene
kinases I-gene
modifies 0
the 0
kinase 0
function 0
and 0
transforming 0
activity 0
of 0
Fujinami B-gene
sarcoma I-gene
virus I-gene
P130gag I-gene
- 0
fps B-gene
. 0

Gluzman 0
, 0
EMBO 0
J 0
. 0

A 0
single 0
exon 0
encodes 0
the 0
carboxyl 0
- 0
terminal 0
26 0
amino 0
acids 0
of 0
the 0
ssd B-gene
chain I-gene
and 0
the 0
3 0
' 0
untranslated 0
region 0
of 0
its 0
mRNA 0
, 0
ending 0
with 0
a 0
poly 0
( 0
A 0
) 0
- 0
addition 0
site 0
. 0

The 0
5' 0
- 0
nontranslated 0
sequences 0
and 0
parts 0
of 0
the 0
coding 0
sequences 0
of 0
various 0
yeast 0
genes 0
have 0
been 0
cloned 0
into 0
representative 0
lacZ B-gene
fusion 0
vectors 0
. 0

Two 0
activities 0
of 0
the 0
D B-gene
protein I-gene
of 0
the 0
miniF 0
plasmid 0
have 0
been 0
found 0
. 0

SPECT 0
examination 0
of 0
the 0
TMJ 0
using 0
99m 0
Tc 0
- 0
MDP 0
was 0
performed 0
in 0
43 0
patients 0
with 0
arthrographically 0
proven 0
anterior 0
dislocation 0
of 0
the 0
disc 0
and 0
in 0
30 0
normals 0
. 0

Plasma B-gene
renin I-gene
activity 0
rose 0
and 0
the 0
plasma 0
aldosterone 0
level 0
fell 0
after 0
taking 0
lisinopril 0
. 0

Two 0
mutants 0
, 0
each 0
representative 0
of 0
a 0
separate 0
pet B-gene
complementation 0
group 0
, 0
have 0
been 0
analyzed 0
. 0

The 0
second 0
group 0
of 0
homologous 0
elements 0
is 0
present 0
in 0
the 0
upstream 0
region 0
of 0
both 0
genes 0
. 0

A 0
centromere 0
in 0
S. 0
cerevisiae 0
consists 0
of 0
a 0
region 0
of 0
DNA 0
, 0
approximately 0
150 0
bp 0
in 0
length 0
, 0
containing 0
three 0
important 0
sequence 0
elements 0
, 0
which 0
are 0
folded 0
with 0
proteins 0
into 0
a 0
specific 0
conformation 0
in 0
the 0
chromatin 0
( 0
the 0
yeast 0
kinetochore 0
) 0
. 0

Constitutive 0
function 0
of 0
a 0
positively 0
regulated 0
promoter 0
reveals 0
new 0
sequences 0
essential 0
for 0
activity 0
. 0

Two 0
separate 0
NF1 B-gene
- I-gene
binding I-gene
loci I-gene
were 0
also 0
found 0
in 0
the 0
equivalent 0
IE68 B-gene
gene I-gene
of 0
HCMV 0
( 0
Towne 0
) 0
DNA 0
, 0
but 0
in 0
this 0
case 0
the 0
DNA 0
sequence 0
and 0
competition 0
filter 0
binding 0
experiments 0
indicated 0
a 0
maximum 0
of 0
only 0
four 0
to 0
five 0
consensus 0
binding 0
sites 0
encompassing 0
the 0
promoter 0
- 0
enhancer 0
region 0
. 0

The 0
previously 0
described 0
four 0
sets 0
of 0
13 0
- 0
to 0
18 0
- 0
base 0
- 0
pair 0
interspersed 0
repeat 0
elements 0
between 0
- 0
55 0
and 0
- 0
580 0
provide 0
most 0
of 0
the 0
high 0
basal 0
transcriptional 0
strength 0
, 0
whereas 0
the 0
arrangement 0
of 0
further 0
upstream 0
tandemly 0
repeated 0
NF1 B-gene
- I-gene
binding I-gene
sites I-gene
may 0
contribute 0
significantly 0
to 0
the 0
expanded 0
biological 0
host 0
range 0
for 0
expression 0
of 0
SCMV B-gene
IE94 I-gene
compared 0
with 0
HCMV B-gene
IE68 I-gene
. 0

We 0
inserted 0
genes 0
or 0
gene 0
segments 0
, 0
that 0
code 0
for 0
the 0
bacterial B-gene
chloramphenicol I-gene
acetyltransferase I-gene
, 0
the 0
bacterial 0
gene 0
conferring 0
resistance 0
against 0
hygromycin 0
, 0
and 0
the 0
ORF 0
E7 B-gene
of 0
the 0
human 0
papillomavirus 0
type 0
18 0
into 0
these 0
vectors 0
. 0

By 0
contrast 0
, 0
their 0
basal 0
adrenal 0
androgen 0
levels 0
were 0
significantly 0
decreased 0
compared 0
to 0
those 0
in 0
normal 0
subjects 0
on 0
both 0
the 0
day 0
on 0
and 0
the 0
day 0
off 0
prednisone 0
( 0
P 0
less 0
than 0
0.05 0
) 0
. 0

Active 0
lambda B-gene
and I-gene
kappa I-gene
antibody I-gene
gene I-gene
rearrangement 0
in 0
Abelson 0
murine 0
leukemia 0
virus 0
- 0
transformed 0
pre 0
- 0
B 0
cell 0
lines 0
. 0

Identification 0
of 0
p40x 0
- 0
responsive 0
regulatory 0
sequences 0
within 0
the 0
human 0
T 0
- 0
cell 0
leukemia 0
virus 0
type 0
I 0
long 0
terminal 0
repeat 0
. 0

During 0
pentobarbital 0
anesthesia 0
, 0
the 0
basal 0
VO2 0
was 0
5.26 0
ml/kg/min 0
and 0
was 0
increased 0
by 0
epinephrine 0
in 0
a 0
dose 0
dependent 0
manner 0
at 0
plasma 0
concentrations 0
between 0
3.9 0
ng/ml 0
( 0
VO2 0
= 0
5.68 0
ml/kg/min 0
) 0
and 0
36.5 0
ng/ml 0
( 0
VO2 0
= 0
6.47 0
ml/kg/min 0
) 0
. 0

Influence 0
of 0
cyclo B-gene
- I-gene
oxygenase I-gene
inhibition 0
and 0
of 0
leukotriene B-gene
receptor I-gene
blockade 0
on 0
pulmonary 0
vascular 0
pressure/cardiac 0
index 0
relationships 0
in 0
hyperoxic 0
and 0
in 0
hypoxic 0
dogs 0
. 0

Oligonucleotide 0
- 0
directed 0
mutagenesis 0
was 0
used 0
to 0
create 0
an 0
NdeI B-gene
restriction I-gene
site I-gene
at 0
the 0
natural 0
ATG 0
of 0
the 0
yeast 0
R 0
. 0

ACTH B-gene
release 0
is 0
transiently 0
suppressed 0
in 0
some 0
children 0
after 0
exogenous 0
ACTH B-gene
treatment 0
. 0

We 0
previously 0
showed 0
that 0
the 0
upstream 0
promoter 0
element 0
of 0
the 0
yeast B-gene
RP39A I-gene
gene I-gene
consists 0
of 0
these 0
identical 0
sequence 0
motifs 0
. 0

These 0
data 0
suggest 0
that 0
mammalian 0
erythroid 0
alpha B-gene
- I-gene
spectrin I-gene
evolved 0
by 0
duplication 0
and 0
rapid 0
divergence 0
from 0
an 0
ancestral 0
alpha B-gene
- I-gene
fodrin I-gene
- I-gene
like I-gene
gene I-gene
. 0

Northern 0
analyses 0
of 0
RNAs 0
from 0
mouse 0
tissues 0
and 0
cell 0
lines 0
indicated 0
that 0
p11 B-gene
mRNA I-gene
levels 0
vary 0
widely 0
. 0

One 0
group 0
of 0
six 0
cDNA 0
clones 0
was 0
derived 0
from 0
a 0
2.9 0
- 0
kilobase 0
early 0
transcript 0
encoded 0
by 0
the 0
IR2 0
repeat 0
element 0
and 0
showed 0
restriction 0
site 0
polymorphism 0
for 0
the 0
enzyme B-gene
SmaI I-gene
. 0

Combined 0
immunochemotherapy 0
with 0
cyclophosphamide 0
plus 0
BCG 0
gave 0
a 0
better 0
enhancement 0
of 0
the 0
antitumor 0
effect 0
of 0
the 0
cytostatic 0
than 0
that 0
of 0
the 0
combination 0
of 0
methotrexate 0
plus 0
BCG 0
and 0
cyclophosphamide 0
plus 0
levamisole 0
. 0

Morphine 0
produced 0
a 0
dose 0
- 0
dependent 0
bradycardia 0
followed 0
by 0
tachycardia 0
. 0

The 0
PSS B-gene
gene I-gene
was 0
subcloned 0
into 0
a 0
1.1 0
- 0
kb 0
fragment 0
of 0
the 0
yeast 0
DNA 0
on 0
the 0
YEp13 0
vector 0
. 0

Indeed 0
, 0
A 0
- 0
MuLV 0
pseudotyped 0
with 0
some 0
viruses 0
, 0
such 0
as 0
the 0
Moloney 0
MuLV 0
, 0
has 0
been 0
shown 0
to 0
be 0
highly 0
lymphogenic 0
, 0
whereas 0
A 0
- 0
MuLV 0
pseudotyped 0
with 0
other 0
viruses 0
, 0
such 0
as 0
the 0
BALB/c 0
endogenous 0
N 0
- 0
tropic 0
MuLV 0
, 0
has 0
been 0
shown 0
to 0
be 0
devoid 0
of 0
lymphogenic 0
potential 0
( 0
N 0
. 0

The 0
presence 0
of 0
circulating 0
platelet 0
aggregates 0
and 0
elevated 0
levels 0
of 0
fibrinopeptide B-gene
A I-gene
( 0
a 0
cleavage 0
product 0
of 0
fibrin B-gene
) 0
suggests 0
that 0
platelet 0
activation 0
and 0
fibrin B-gene
deposition 0
may 0
play 0
a 0
role 0
in 0
the 0
pathogenesis 0
of 0
this 0
disorder 0
. 0

The 0
gene 0
is 0
essential 0
for 0
yeast 0
vegetative 0
growth 0
. 0

4 0
. 0

In 0
general 0
, 0
the 0
values 0
obtained 0
by 0
the 0
two 0
methods 0
were 0
in 0
agreement 0
for 0
each 0
species 0
of 0
epidermal B-gene
growth I-gene
factor I-gene
and 0
followed 0
the 0
order 0
: 0
wild 0
type 0
greater 0
than 0
Glu24 0
- 0
- 0
- 0
- 0
Gly 0
greater 0
than 0
Asp27 0
- 0
- 0
- 0
- 0
Gly 0
much 0
greater 0
than 0
Pro7 0
- 0
- 0
- 0
- 0
Thr 0
greater 0
than 0
Tyr29 0
- 0
- 0
- 0
- 0
Gly 0
greater 0
than 0
Leu47 0
- 0
- 0
- 0
- 0
His 0
. 0

It 0
is 0
concluded 0
that 0
suppression 0
of 0
elevated 0
prolactin B-gene
levels 0
in 0
progressive 0
metastatic 0
breast 0
cancer 0
patients 0
is 0
not 0
effective 0
in 0
restoring 0
tumor 0
sensitivity 0
to 0
chemotherapy 0
. 0

We 0
report 0
a 0
prevalence 0
study 0
of 0
the 0
best 0
visual 0
acuity 0
in 0
the 0
affected 0
eye 0
of 0
100 0
selected 0
patients 0
with 0
herpetic 0
keratitis 0
seen 0
during 0
a 0
two 0
- 0
year 0
period 0
. 0

We 0
also 0
found 0
an 0
eIF B-gene
- I-gene
4A I-gene
intronless 0
retroposon 0
which 0
, 0
when 0
compared 0
to 0
the 0
cDNA 0
, 0
contains 0
a 0
single 0
nucleotide 0
difference 0
. 0

Bacteriologic 0
culture 0
of 0
pancreatic 0
tissue 0
was 0
positive 0
in 0
6/8 0
IB 0
and 0
3/17 0
NIB 0
rats 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

These 0
similarities 0
suggest 0
that 0
these 0
E2 B-gene
proteins I-gene
are 0
structurally 0
and 0
evolutionarily 0
related 0
. 0

After 0
infection 0
of 0
293 0
cells 0
( 0
which 0
provide 0
complementary 0
E1a B-gene
- 0
E1b B-gene
functions 0
) 0
, 0
both 0
viruses 0
directed 0
equal 0
amounts 0
of 0
P/C B-gene
- I-gene
specific I-gene
mRNA I-gene
transcription 0
. 0

This 0
observation 0
can 0
not 0
be 0
explained 0
by 0
the 0
scanning 0
model 0
for 0
ribosomal 0
initiation 0
and 0
suggests 0
that 0
ribosomes 0
may 0
be 0
binding 0
directly 0
at 0
an 0
internal 0
mRNA 0
site 0
at 0
or 0
near 0
the 0
initiator 0
AUG 0
codon 0
for 0
the 0
C B-gene
protein I-gene
. 0

In 0
view 0
of 0
these 0
results 0
, 0
simultaneous 0
pancreas 0
- 0
kidney 0
transplantation 0
appears 0
to 0
be 0
the 0
treatment 0
of 0
choice 0
for 0
Type 0
I 0
diabetic 0
patients 0
. 0

This 0
makes 0
these 0
compounds 0
attractive 0
as 0
vehicles 0
for 0
these 0
and 0
other 0
gases 0
in 0
- 0
vivo 0
and 0
in 0
- 0
vitro 0
. 0

DNA 0
sequencing 0
of 0
the 0
DPM1 B-gene
gene I-gene
revealed 0
an 0
open 0
reading 0
frame 0
of 0
801 0
bases 0
. 0

The 0
relationship 0
between 0
primary 0
malignant 0
lymphoma 0
of 0
the 0
thyroid 0
and 0
chronic 0
thyroiditis 0
is 0
discussed 0
. 0

Administration 0
of 0
anticoagulants 0
, 0
i.e. 0
, 0
heparin 0
, 0
prostaglandin 0
E1 0
and 0
ticlopidine 0
seems 0
to 0
be 0
effective 0
in 0
alleviating 0
symptoms 0
and 0
might 0
prevent 0
further 0
deterioration 0
. 0

Mutational 0
analysis 0
of 0
the 0
L1 B-gene
binding I-gene
site I-gene
of 0
23S B-gene
rRNA I-gene
in I-gene
Escherichia I-gene
coli I-gene
. 0

Animals 0
may 0
be 0
immunized 0
by 0
oral 0
vaccination 0
, 0
but 0
natural 0
mechanisms 0
that 0
also 0
can 0
terminate 0
outbreaks 0
are 0
discussed 0
. 0

Prostacyclin 0
formation 0
, 0
reflected 0
by 0
the 0
excretion 0
rate 0
of 0
its 0
stable 0
metabolite 0
6 0
- 0
keto 0
- 0
prostaglandin 0
F1 0
alpha 0
, 0
was 0
measured 0
by 0
means 0
of 0
radioimmunoassay 0
in 0
4 0
- 0
hour 0
urine 0
specimens 0
obtained 0
during 0
a 0
smoking 0
- 0
free 0
period 0
and 0
after 0
participants 0
had 0
inhaled 0
smoke 0
from 0
four 0
high 0
- 0
nicotine 0
cigarettes 0
. 0

However 0
, 0
excretion 0
of 0
6 0
- 0
keto 0
- 0
prostaglandin 0
F1 0
alpha 0
was 0
further 0
reduced 0
in 0
the 0
smokers 0
who 0
used 0
oral 0
contraceptives 0
( 0
133 0
+/ 0
- 0
20 0
to 0
86 0
+/ 0
- 0
9 0
ng/gm 0
of 0
creatinine 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

The 0
in 0
vitro 0
activity 0
of 0
mecillinam 0
and 0
amoxicillin/clavulanic 0
acid 0
against 0
Escherichia 0
coli 0
strains 0
producing 0
beta B-gene
- I-gene
lactamases I-gene
of 0
the 0
TEM B-gene
- I-gene
1 I-gene
, 0
Oxa B-gene
- I-gene
1 I-gene
and 0
chromosomal 0
type 0
were 0
studied 0
using 0
the 0
broth 0
and 0
agar 0
dilution 0
technique 0
. 0

GCN4 B-gene
encodes 0
a 0
transcriptional 0
activator 0
of 0
amino 0
acid 0
biosynthetic 0
genes 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

These 0
results 0
imply 0
that 0
the 0
GCN3 B-gene
product I-gene
can 0
promote 0
either 0
repression 0
or 0
activation 0
of 0
GCN4 B-gene
expression 0
depending 0
on 0
amino 0
acid 0
availability 0
. 0

The 0
efficacy 0
of 0
these 0
immunosuppressive 0
drugs 0
is 0
clinical 0
proven 0
. 0

The 0
amino 0
acid 0
sequence 0
of 0
the 0
S. 0
aureus 0
peptide 0
carrying 0
the 0
phosphoryl 0
group 0
was 0
found 0
to 0
be 0
Gln 0
- 0
Val 0
- 0
Val 0
- 0
Ser 0
- 0
Thr 0
- 0
Phe 0
- 0
Met 0
- 0
Gly 0
- 0
Asn 0
- 0
Gly 0
- 0
Leu 0
- 0
Ala 0
- 0
Ile 0
- 0
Pro 0
- 0
His 0
- 0
Gly 0
- 0
Thr 0
- 0
Asp 0
- 0
Asp 0
. 0

These 0
mutations 0
alter 0
two 0
regions 0
of 0
GAL4 B-gene
protein I-gene
: 0
the 0
DNA 0
binding 0
domain 0
, 0
and 0
the 0
transcription 0
activation 0
domain 0
. 0

The 0
results 0
indicated 0
that 0
two 0
genes 0
( 0
citA B-gene
and 0
citB B-gene
) 0
have 0
separate 0
promoters 0
, 0
and 0
the 0
location 0
of 0
the 0
promoter 0
for 0
the 0
citB B-gene
gene I-gene
in 0
the 0
Tn3411 B-gene
nucleotide 0
sequence 0
was 0
different 0
from 0
that 0
in 0
pMS185 0
. 0

The 0
rci B-gene
gene I-gene
was 0
fused 0
with 0
lacZ B-gene
and 0
its 0
gene 0
product 0
was 0
identified 0
by 0
Western 0
blot 0
analysis 0
. 0

Structure 0
and 0
regulation 0
of 0
a 0
nuclear 0
gene 0
in 0
Saccharomyces 0
cerevisiae 0
that 0
specifies 0
MRP13 B-gene
, 0
a 0
protein 0
of 0
the 0
small 0
subunit 0
of 0
the 0
mitochondrial 0
ribosome 0
. 0

After 0
a 0
survey 0
of 0
the 0
anatomical 0
and 0
physiological 0
basis 0
of 0
operative 0
treatment 0
of 0
behaviour 0
disorders 0
by 0
stereotactic 0
lesions 0
in 0
the 0
amygdala 0
and 0
the 0
posterior 0
medial 0
hypothalamus 0
the 0
author 0
describes 0
his 0
own 0
experiences 0
with 0
603 0
operations 0
for 0
control 0
of 0
conservatively 0
untreatable 0
aggressiveness 0
. 0

Histological 0
examination 0
revealed 0
a 0
small 0
simple 0
renal 0
cyst 0
associated 0
with 0
renal 0
cell 0
carcinoma 0
. 0

Although 0
large 0
epidemiologic 0
studies 0
are 0
best 0
able 0
to 0
identify 0
the 0
relative 0
contributions 0
of 0
specific 0
risk 0
factors 0
while 0
controlling 0
for 0
other 0
risk 0
factors 0
, 0
new 0
studies 0
need 0
to 0
focus 0
on 0
important 0
unresolved 0
questions 0
. 0

Thus 0
, 0
prostacyclin 0
enhanced 0
the 0
autoregulative 0
property 0
of 0
the 0
inner 0
ear 0
vessels 0
. 0

The 0
method 0
is 0
accurate 0
, 0
with 0
good 0
precision 0
and 0
adequate 0
sensitivity 0
. 0

Factors 0
influencing 0
the 0
bond 0
strength 0
between 0
glass 0
polyalkenoate 0
( 0
ionomer 0
) 0
cements 0
and 0
dentine 0
. 0

The 0
amino 0
acid 0
sequences 0
of 0
the 0
yeast 0
and 0
mammalian 0
mitochondrial 0
targeting 0
sequences 0
are 0
similar 0
but 0
less 0
related 0
than 0
the 0
mature 0
polypeptides 0
. 0

Van 0
der 0
Ende 0
, 0
R 0
. 0

During 0
insulin B-gene
infusion 0
, 0
a 0
20 0
% 0
dextrose 0
solution 0
was 0
infused 0
by 0
a 0
Biostator 0
in 0
order 0
to 0
maintain 0
the 0
patient 0
's 0
glycemia 0
at 0
90 0
mg/dl 0
. 0

Amounts 0
of 0
glucose 0
infused 0
during 0
the 0
last 0
20 0
min 0
of 0
each 0
2 0
hour 0
insulin B-gene
infusion 0
were 0
( 0
at 0
1 0
and 0
10 0
m/kg/min 0
respectively 0
) 0
: 0
before 0
treatment 0
( 0
K+ 0
= 0
2.7 0
mmol/l 0
) 0
: 0
2.4 0
and 0
8.4 0
mg/kg/min 0
; 0
after 0
spironolactone 0
( 0
K+ 0
= 0
3.9 0
mmol/l 0
) 0
: 0
3.3 0
and 0
15.4 0
mg/kg/min 0
; 0
after 0
indomethacine 0
( 0
K+ 0
= 0
3.7 0
mmol/l 0
) 0
: 0
5 0
and 0
19 0
mg/kg/min 0
after 0
stopping 0
drugs 0
( 0
K+ 0
= 0
2.9 0
mmol/l 0
) 0
: 0
2.5 0
and 0
5.3 0
mg/kg/min 0
. 0

Mycobacterium 0
avium 0
- 0
intracellulare 0
complex 0
infections 0
in 0
the 0
acquired 0
immunodeficiency 0
syndrome 0
. 0

Recurrence 0
of 0
oxalate 0
deposition 0
in 0
a 0
renal 0
transplant 0
during 0
ciclosporin 0
A 0
therapy 0
. 0

The 0
bile 0
acid 0
sequestrants 0
( 0
cholestyramine 0
and 0
colestipol 0
) 0
, 0
nicotinic 0
acid 0
, 0
fenofibrate 0
and 0
inhibitors 0
of 0
hydroxymethylglutaryl B-gene
coenzyme I-gene
A I-gene
( I-gene
HMG I-gene
CoA I-gene
) I-gene
reductase I-gene
( 0
e.g 0
. 0
lovastatin 0
or 0
simvastatin 0
) 0
are 0
the 0
most 0
effective 0
drugs 0
for 0
use 0
in 0
patients 0
with 0
primary 0
hypercholesterolaemia 0
; 0
these 0
agents 0
reduce 0
plasma 0
concentrations 0
of 0
total 0
and 0
LDL B-gene
- I-gene
cholesterol I-gene
by 0
15 0
to 0
45 0
% 0
. 0

Finally 0
, 0
the 0
pathophysiological 0
aspects 0
of 0
urinary 0
acidification 0
are 0
discussed 0
, 0
focusing 0
on 0
renal 0
tubular 0
acidosis 0
models 0
( 0
induced 0
by 0
maleate 0
and 0
amphotericin 0
B 0
treatment 0
) 0
and 0
their 0
cellular 0
mechanisms 0
, 0
as 0
well 0
as 0
the 0
role 0
of 0
adrenal 0
steroids 0
in 0
urinary 0
acidification 0
. 0

Analysis 0
in 0
3 0
groups 0
of 0
patients 0
suffering 0
from 0
simple 0
acute 0
and 0
pernicious 0
malarial 0
flare 0
- 0
ups 0

Statement 0
on 0
the 0
development 0
of 0
guidelines 0
for 0
the 0
prevention 0
of 0
AIDS 0
transmission 0
in 0
the 0
workplace 0
. 0

Modifications 0
of 0
the 0
involuntary 0
postcontraction 0
in 0
diseased 0
people 0
. 0

Cocaine 0
- 0
treated 0
rats 0
acquired 0
a 0
preference 0
for 0
cocaine 0
- 0
associated 0
contextual 0
stimuli 0
( 0
CS 0
) 0
relative 0
to 0
saline 0
- 0
injected 0
control 0
rats 0
. 0

Under 0
these 0
schedules 0
, 0
a 0
reinforced 0
response 0
run 0
consisted 0
of 0
responding 0
between 0
eight 0
and 0
12 0
times 0
on 0
one 0
response 0
key 0
( 0
work 0
key 0
) 0
and 0
then 0
responding 0
once 0
on 0
a 0
second 0
response 0
key 0
( 0
reinforced 0
key 0
) 0
. 0

Intravenous 0
glucose 0
tolerance 0
tests 0
were 0
performed 0
before 0
operation 0
, 0
before 0
starting 0
CyA 0
and 0
after 0
3 0
weeks 0
. 0

The 0
effects 0
of 0
glutaraldehyde 0
on 0
dimensions 0
and 0
ultrastructure 0
of 0
microvascular 0
beds 0
in 0
rat 0
mesentery 0
were 0
studied 0
in 0
two 0
kinds 0
of 0
experiment 0
, 0
administering 0
the 0
fixative 0
by 0
intra 0
- 0
arterial 0
perfusion 0
at 0
a 0
pressure 0
of 0
80 0
mm 0
Hg 0
and 0
by 0
superfusion 0
of 0
the 0
exteriorized 0
mesenteric 0
membrane 0
. 0

This 0
gave 0
rise 0
to 0
RNA 0
molecules 0
with 0
3' 0
- 0
untranslated 0
regions 0
of 0
roughly 0
375 0
, 0
655 0
, 0
and 0
945 0
base 0
pairs 0
. 0

Also 0
, 0
the 0
BALB/c B-gene
gene I-gene
contains 0
a 0
single 0
substitution 0
in 0
a 0
conserved 0
octamer 0
sequence 0
approximately 0
equal 0
to 0
100 0
nucleotides 0
upstream 0
of 0
the 0
coding 0
region 0
, 0
which 0
could 0
affect 0
its 0
expression 0
. 0

Clinical 0
findings 0
were 0
: 0
height 0
183 0
cm 0
, 0
weight 0
62 0
kg 0
, 0
increased 0
length 0
of 0
lower 0
limbs 0
, 0
P2 0
- 0
A2 0
pilosity 0
and 0
micropenis 0
. 0

Our 0
data 0
suggest 0
that 0
it 0
may 0
be 0
possible 0
to 0
individualize 0
hCG B-gene
administration 0
at 0
midcycle 0
by 0
determining 0
the 0
number 0
of 0
follicles 0
greater 0
than 0
1 0
cm 0
by 0
ultrasound 0
on 0
cycle 0
day 0
12 0
or 0
13 0
and 0
giving 0
hCG B-gene
when 0
serum 0
E2 0
levels 0
reach 0
1100 0
to 0
1200 0
pmol/l 0
per 0
follicle 0
. 0

The 0
8 0
patients 0
receiving 0
Ir192 0
implant 0
in 0
addition 0
to 0
external 0
radiation 0
showed 0
improved 0
( 0
p 0
= 0
0.06 0
) 0
survival 0
compared 0
to 0
the 0
9 0
receiving 0
external 0
only 0
: 0
median 0
15 0
months 0
( 0
range 0
1.5 0
- 0
34 0
+ 0
months 0
) 0
versus 0
7 0
months 0
( 0
range 0
2.5 0
- 0
21 0
months 0
) 0
. 0

Within 0
Stage 0
IA 0
, 0
141 0
patients 0
had 0
well 0
differentiated 0
tumor 0
( 0
G1 0
) 0
, 0
20 0
had 0
moderately 0
well 0
differentiated 0
tumor 0
( 0
G2 0
) 0
, 0
and 0
12 0
patients 0
had 0
poorly 0
differentiated 0
( 0
G3 0
) 0
. 0

Mechanism 0
of 0
the 0
t 0
( 0
14 0
; 0
18 0
) 0
chromosomal 0
translocation 0
: 0
structural 0
analysis 0
of 0
both 0
derivative 0
14 0
and 0
18 0
reciprocal 0
partners 0
. 0

After 0
age 0
30 0
, 0
mean 0
hemoglobin B-gene
levels 0
for 0
men 0
gradually 0
declined 0
, 0
while 0
those 0
in 0
women 0
rose 0
, 0
so 0
that 0
the 0
sex 0
difference 0
diminished 0
after 0
60 0
years 0
of 0
age 0
. 0

Ritanserin 0
is 0
a 0
new 0
substance 0
with 0
highly 0
selective 0
blocking 0
activity 0
on 0
S2 B-gene
receptors I-gene
for 0
5 0
- 0
HT 0
in 0
the 0
central 0
nervous 0
system 0
. 0

Ethylene 0
glycol 0
and 0
diethylene 0
glycol 0
were 0
each 0
administered 0
once 0
weekly 0
subcutaneously 0
to 0
groups 0
of 0
100 0
female 0
NMRI 0
mice 0
at 0
3 0
dosages 0
( 0
30 0
; 0
10 0
und 0
3 0
mg 0
single 0
dose 0
per 0
mouse 0
) 0
. 0

Research 0
on 0
ethylene 0
glycol 0
and 0
diethylene 0
glycol 0
for 0
carcinogenic 0
effects 0

The 0
results 0
suggest 0
that 0
the 0
greater 0
estrogenic 0
influence 0
associated 0
with 0
the 0
ethinyl 0
estradiol 0
- 0
containing 0
OC 0
resulted 0
in 0
inhibition 0
of 0
coronary 0
artery 0
atherosclerosis 0
despite 0
a 0
pronounced 0
progestin 0
- 0
induced 0
lowering 0
of 0
plasma 0
HDL B-gene
cholesterol I-gene
concentration 0
and 0
, 0
further 0
, 0
that 0
hormonal 0
balance 0
may 0
have 0
a 0
marked 0
influence 0
on 0
the 0
relationship 0
between 0
plasma 0
lipids 0
and 0
atherogenesis 0
. 0

During 0
BH 0
the 0
ventilator 0
was 0
disconnected 0
and 0
a 0
bias 0
flow 0
of 0
50 0
% 0
O2 0
at 0
4 0
- 0
5 0
l/min 0
was 0
delivered 0
through 0
the 0
side 0
ports 0
of 0
a 0
small 0
catheter 0
whose 0
tip 0
was 0
positioned 0
1 0
cm 0
cephalad 0
of 0
the 0
carina 0
. 0

Comparison 0
of 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
removal 0
using 0
the 0
same 0
polysulphone 0
membrane 0
for 0
haemodialysis 0
and 0
haemofiltration 0
shows 0
that 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
is 0
more 0
effectively 0
removed 0
by 0
convection 0
than 0
by 0
diffusion 0
when 0
both 0
treatment 0
modes 0
are 0
matched 0
for 0
blood 0
flow 0
and 0
urea 0
clearance 0
. 0

40.3 0
+/ 0
- 0
10.1 0
mg/l 0
( 0
SD 0
) 0
vs 0
31.2 0
+/ 0
- 0
8.0 0
, 0
P 0
less 0
than 0
0.01 0
) 0
. 0
beta B-gene
2m I-gene
was 0
not 0
significantly 0
higher 0
in 0
patients 0
with 0
bone 0
cysts 0
( 0
37.7 0
+/ 0
- 0
11.4 0
mg/l 0
vs 0
37.0 0
+/ 0
- 0
10.0 0
) 0
, 0
but 0
median 0
duration 0
of 0
dialysis 0
was 0
significantly 0
( 0
P 0
less 0
than 0
0.01 0
) 0
longer 0
in 0
patients 0
with 0
bone 0
cysts 0
( 0
90 0
vs 0
57 0
months 0
) 0
. 0
beta B-gene
2m I-gene
was 0
lower 0
in 0
patients 0
maintained 0
on 0
dialysis 0
for 0
less 0
than 0
1 0
year 0
and 0
whose 0
residual 0
urine 0
volume 0
was 0
greater 0
than 0
0.1 0
litre 0
per 0
day 0
. 0

The 0
mean 0
percentage 0
of 0
linoleic 0
acid 0
in 0
the 0
triglycerides 0
of 0
the 0
subcutaneous 0
adipose 0
tissue 0
( 0
PLASAT 0
) 0
of 0
these 0
subjects 0
was 0
substantially 0
higher 0
than 0
that 0
in 0
a 0
similar 0
group 0
examined 0
in 0
1975 0
- 0
1976 0
. 0

In 0
overdoses 0
up 0
to 0
2 0
g 0
fluvoxamine 0
no 0
lasting 0
toxic 0
effects 0
were 0
observed 0
. 0

It 0
is 0
concluded 0
that 0
the 0
plasma B-gene
prolactin I-gene
response 0
to 0
12.5 0
micrograms 0
i.v 0
. 0

No 0
effect 0
was 0
found 0
on 0
grooming 0
behavior 0
. 0

The 0
remaining 0
six 0
patients 0
had 0
slightly 0
decreased 0
( 0
n 0
= 0
3 0
) 0
or 0
normal 0
( 0
n 0
= 0
3 0
) 0
seminal 0
parameters 0
. 0

In 0
addition 0
, 0
a 0
wild 0
- 0
type 0
strain 0
containing 0
a 0
temperature B-gene
- I-gene
sensitive I-gene
threonyl I-gene
- I-gene
tRNA I-gene
synthetase I-gene
mutation I-gene
showed 0
increased 0
thr B-gene
operon I-gene
expression 0
at 0
the 0
non 0
- 0
permissive 0
temperature 0
, 0
whereas 0
none 0
of 0
the 0
mutants 0
showed 0
any 0
change 0
. 0

Significant 0
treatment 0
- 0
related 0
problems 0
appeared 0
during 0
the 0
second 0
decade 0
in 0
5 0
patients 0
, 0
including 0
one 0
chest 0
wall 0
sarcoma 0
; 0
all 0
of 0
these 0
patients 0
had 0
received 0
at 0
least 0
60 0
Gy 0
to 0
breast 0
and 0
regional 0
nodal 0
areas 0
. 0

Clinical 0
and 0
biological 0
correlates 0
of 0
panic 0
states 0
. 0

Effects 0
of 0
long 0
- 0
term 0
parenteral 0
nutrition 0
on 0
gastrin B-gene
release 0
in 0
dogs 0
. 0

The 0
mean 0
weight 0
and 0
height 0
velocities 0
were 0
148 0
% 0
and 0
122 0
% 0
of 0
the 0
standard 0
, 0
respectively 0
. 0

Of 0
7 0
patients 0
treated 0
with 0
cyclophosphamide 0
, 0
hexamethylmelamine 0
, 0
adriamycin 0
and 0
cisplatin 0
( 0
CHAP 0
- 0
5 0
) 0
, 0
6 0
had 0
measurable 0
disease 0
, 0
of 0
whom 0
5 0
yielded 0
a 0
response 0
( 0
2 0
complete 0
responses 0
for 0
19+ 0
and 0
40 0
months 0
and 0
3 0
partial 0
responses 0
for 0
4 0
, 0
7 0
and 0
8 0
months 0
) 0
. 0

Isolation 0
and 0
characterization 0
of 0
a 0
vinculin B-gene
cDNA I-gene
from I-gene
chick I-gene
- I-gene
embryo I-gene
fibroblasts I-gene
. 0

A 0
complementary 0
study 0
, 0
showing 0
a 0
good 0
agreement 0
between 0
surface 0
and 0
oesophageal 0
EMGd 0
seems 0
to 0
confirm 0
that 0
surface 0
EMGd 0
is 0
a 0
useful 0
and 0
promising 0
tool 0
for 0
clinical 0
investigation 0
. 0

No 0
differences 0
in 0
fixation 0
quality 0
were 0
observed 0
between 0
cochleas 0
fixed 0
by 0
intravascular 0
perfusion 0
and 0
cochleas 0
fixed 0
by 0
intralabyrinthine 0
perfusion 0
. 0

The 0
DNA 0
sequence 0
encodes 0
a 0
protein 0
of 0
1520 0
amino 0
acids 0
with 0
sequence 0
homology 0
to 0
the 0
human B-gene
c I-gene
- I-gene
abl I-gene
proto I-gene
- I-gene
oncogene I-gene
product I-gene
, 0
beginning 0
at 0
the 0
amino 0
terminus 0
and 0
extending 0
656 0
amino 0
acids 0
through 0
the 0
region 0
essential 0
for 0
tyrosine B-gene
kinase I-gene
activity 0
. 0

The 0
requirement 0
of 0
different 0
essential 0
fatty 0
acids 0
in 0
patients 0
with 0
total 0
parenteral 0
nutrition 0
after 0
heavy 0
injury 0
is 0
of 0
special 0
interest 0
with 0
respect 0
to 0
the 0
development 0
and 0
prognosis 0
of 0
shock 0
, 0
sepsis 0
or 0
adult 0
respiratory 0
distress 0
syndrome 0
. 0

In 0
64 0
% 0
a 0
small 0
cardiac 0
vein 0
does 0
not 0
exist 0
, 0
but 0
its 0
origin 0
, 0
the 0
right 0
marginal 0
vein 0
, 0
joins 0
the 0
system 0
of 0
anterior 0
cardiac 0
veins 0
. 0

The 0
Drosophila B-gene
melanogaster I-gene
Gart I-gene
gene I-gene
encodes 0
three 0
enzymatic 0
activities 0
in 0
the 0
pathway 0
for 0
purine 0
de 0
novo 0
synthesis 0
. 0

The 0
role 0
of 0
neuroplasticity 0
in 0
the 0
response 0
to 0
drugs 0
. 0

Biol 0
. 0

The 0
results 0
of 0
these 0
experiments 0
indicate 0
that 0
at 0
least 0
two 0
upstream 0
activator 0
sequences 0
( 0
UAS 0
) 0
mediate 0
maximum 0
induction 0
by 0
galactose 0
. 0

Reversal 0
of 0
the 0
increase 0
in 0
apomorphine 0
- 0
induced 0
stereotypy 0
and 0
aggression 0
in 0
REM 0
sleep 0
deprived 0
rats 0
by 0
dopamine 0
agonist 0
pretreatments 0
. 0

The 0
heart 0
rate 0
, 0
respiratory 0
rate 0
, 0
arterial 0
O2 0
and 0
systemic 0
vascular 0
resistance 0
were 0
not 0
significantly 0
altered 0
. 0

Human B-gene
rIL I-gene
- I-gene
3 I-gene
expressed 0
in 0
COS7 0
cells 0
has 0
multipotential 0
CSF B-gene
activity 0
in 0
semisolid 0
cultures 0
of 0
bone 0
marrow 0
cells 0
, 0
and 0
selectively 0
induced 0
the 0
proliferation 0
of 0
My 0
- 0
10+ 0
marrow 0
or 0
cord 0
blood 0
cells 0
in 0
liquid 0
cultures 0
. 0

In 0
14 0
patients 0
whose 0
PaCO2 0
was 0
greater 0
than 0
or 0
equal 0
to 0
39 0
torr 0
( 0
range 0
39 0
to 0
58 0
torr 0
) 0
and 0
clinical 0
asthma 0
score 0
was 0
6 0
or 0
greater 0
, 0
PaCO2 0
decreased 0
a 0
mean 0
of 0
11.7 0
torr 0
during 0
a 0
mean 0
of 0
8.1 0
hours 0
. 0

A 0
randomized 0
, 0
prospective 0
study 0
was 0
conducted 0
to 0
compare 0
ovarian 0
stimulation 0
with 0
human B-gene
menopausal I-gene
gonadotropin I-gene
( 0
hMG B-gene
) 0
and 0
human B-gene
follicle I-gene
- I-gene
stimulating I-gene
hormone I-gene
( 0
hFSH B-gene
) 0
in 0
an 0
in 0
vitro 0
fertilization 0
and 0
embryo 0
transfer 0
( 0
IVF 0
- 0
ET 0
) 0
program 0
. 0

Our 0
findings 0
suggest 0
that 0
the 0
mtr B-gene
product I-gene
causes 0
both 0
transcription 0
attenuation 0
and 0
inhibition 0
of 0
translation 0
of 0
trpE B-gene
mRNA I-gene
. 0

Apropos 0
of 0
a 0
case 0

A 0
prostaglandin 0
analogue 0
given 0
in 0
early 0
pregnancy 0
and 0
human B-gene
chorionic I-gene
gonadotropin I-gene
given 0
near 0
the 0
end 0
of 0
the 0
ensuing 0
follicular 0
phase 0
were 0
used 0
for 0
controlling 0
the 0
reproductive 0
cycle 0
, 0
timing 0
oocyte 0
collection 0
, 0
and 0
synchronizing 0
the 0
cycles 0
of 0
oocyte 0
donors 0
and 0
embryo 0
recipients 0
. 0

The 0
nucleolin B-gene
gene I-gene
extends 0
over 0
9000 0
base 0
- 0
pairs 0
and 0
is 0
split 0
into 0
14 0
exons 0
that 0
encode 0
the 0
706 0
amino 0
acid 0
residues 0
of 0
the 0
protein 0
. 0

Although 0
L 0
- 0
threo 0
- 0
dihydroxyphenylserine 0
( 0
DOPS 0
) 0
, 0
an 0
artificial 0
norepinephrine 0
( 0
NE 0
) 0
precursor 0
, 0
did 0
not 0
change 0
immobility 0
in 0
intact 0
mice 0
, 0
DOPS 0
significantly 0
reduced 0
immobility 0
in 0
mice 0
pretreated 0
with 0
the 0
selective 0
NE 0
neurotoxin 0
DSP4 0
. 0

Substantial 0
amounts 0
of 0
liposomal 0
ampicillin 0
were 0
recovered 0
from 0
isolated 0
Kupffer 0
cells 0
, 0
the 0
target 0
cells 0
of 0
L. 0
monocytogenes 0
after 0
intravenous 0
inoculation 0
. 0

This 0
suggested 0
that 0
delta 0
6 0
and 0
delta 0
5 0
desaturation 0
activities 0
are 0
normal 0
in 0
these 0
conditions 0
with 0
this 0
C18:2w6 0
supply 0
. 0

The 0
genetic 0
basis 0
for 0
the 0
expression 0
of 0
a 0
latent 0
VH B-gene
allotype I-gene
in 0
the 0
rabbit 0
was 0
investigated 0
. 0

Here 0
we 0
report 0
the 0
complete 0
6 0
- 0
kilobase 0
cDNA 0
sequence 0
coding 0
for 0
a 0
chain 0
of 0
1775 0
amino 0
acids 0
, 0
as 0
well 0
as 0
the 0
genomic 0
structure 0
. 0

HDL B-gene
- I-gene
cholesterol I-gene
( 0
+6 0
% 0
, 0
P 0
less 0
than 0
.01 0
) 0
and 0
apolipoprotein B-gene
A I-gene
- I-gene
I I-gene
( 0
+6 0
% 0
, 0
P 0
less 0
than 0
.01 0
) 0
concentrations 0
increased 0
significantly 0
only 0
in 0
the 0
young 0
. 0

The 0
Euglena B-gene
ribosomal I-gene
protein I-gene
gene I-gene
cluster I-gene
resembles 0
the 0
S B-gene
- I-gene
10 I-gene
ribosomal I-gene
protein I-gene
operon I-gene
of I-gene
Escherichia I-gene
coli I-gene
in 0
gene 0
organization 0
and 0
follows 0
the 0
exact 0
linear 0
order 0
of 0
the 0
analogous 0
genes 0
in 0
the 0
tobacco 0
and 0
liverwort 0
chloroplast 0
genomes 0
. 0

The 0
distribution 0
of 0
the 0
sites 0
of 0
recombinational 0
resolution 0
is 0
inversely 0
correlated 0
with 0
that 0
of 0
the 0
gradient 0
of 0
sequence 0
divergence 0
, 0
with 0
only 0
approximately 0
7 0
% 0
of 0
the 0
X 0
recombinants 0
resolved 0
within 0
the 0
3 0
' 0
third 0
of 0
the 0
X 0
blocks 0
where 0
two 0
diverged 0
Alu B-gene
family 0
repeats 0
reside 0
. 0

The 0
nucleotide 0
sequence 0
of 0
the 0
region 0
upstream 0
from 0
M. B-gene
voltae I-gene
ORFtrpA I-gene
was 0
determined 0
and 0
revealed 0
the 0
presence 0
of 0
an 0
ORF 0
of 0
1227 0
nucleotides 0
( 0
ORFtrpB B-gene
) 0
encoding 0
a 0
409 0
amino 0
acid 0
polypeptide 0
of 0
mol 0
. 0
wt 0
. 0

Potentiation 0
of 0
the 0
thrombolytic 0
efficacy 0
of 0
single B-gene
- I-gene
chain I-gene
urokinase I-gene
( 0
Pro B-gene
- I-gene
urokinase I-gene
) 0
by 0
heparin 0
. 0

Of 0
49 0
receptors 0
which 0
fired 0
in 0
phase 0
with 0
ventilation 0
, 0
13 0
behaved 0
like 0
mammalian 0
rapidly 0
adapting 0
pulmonary 0
stretch 0
receptors 0
, 0
19 0
like 0
mammalian 0
slowly 0
adapting 0
pulmonary 0
stretch 0
receptors 0
( 0
PSR 0
) 0
, 0
and 0
17 0
like 0
avian 0
intrapulmonary 0
CO2 0
- 0
sensitive 0
chemoreceptors 0
( 0
IPC 0
) 0
. 0

Symptomatic 0
hyperventilators 0
had 0
a 0
larger 0
number 0
of 0
sighs 0
and 0
abnormally 0
wide 0
fluctuations 0
in 0
baseline 0
for 0
inspiratory 0
time 0
, 0
expiratory 0
time 0
, 0
and 0
PETCO2 0
. 0

In 0
the 0
IA 0
task 0
, 0
post 0
- 0
training 0
intraperitoneal 0
injections 0
of 0
picrotoxin 0
and 0
bicuculline 0
induced 0
a 0
dose 0
- 0
dependent 0
enhancement 0
of 0
retention 0
measured 0
24 0
h 0
after 0
the 0
training 0
, 0
while 0
retention 0
was 0
not 0
affected 0
by 0
bicuculline 0
methiodide 0
( 0
a 0
GABA B-gene
receptor I-gene
antagonist 0
that 0
does 0
not 0
readily 0
cross 0
the 0
blood 0
- 0
brain 0
barrier 0
) 0
. 0

Clinical 0
research 0
of 0
non 0
- 0
A 0
, 0
non 0
- 0
B 0
post 0
- 0
transfusion 0
hepatitis 0

It 0
is 0
suggested 0
that 0
the 0
use 0
of 0
endogenous 0
creatinine 0
clearance 0
to 0
estimate 0
the 0
glomerular 0
filtration 0
rate 0
( 0
GFR 0
) 0
requires 0
caution 0
and 0
the 0
recognition 0
of 0
the 0
limitations 0
of 0
the 0
method 0
, 0
and 0
that 0
simpler 0
techniques 0
( 0
serum 0
creatinine 0
or 0
estimated 0
endogenous 0
creatinine 0
clearance 0
) 0
are 0
preferable 0
in 0
routine 0
practice 0
. 0

The 0
protein 0
mixtures 0
of 0
sesame 0
flour 0
and 0
soybean 0
flour 0
were 0
well 0
accepted 0
. 0

The 0
5 0
' 0
end 0
of 0
the 0
coding 0
region 0
was 0
located 0
precisely 0
by 0
comparing 0
the 0
deduced 0
amino 0
acid 0
sequence 0
to 0
the 0
actual 0
N 0
- 0
terminal 0
amino 0
acid 0
sequence 0
of 0
IHF B-gene
. 0

A 0
protein 0
footprint 0
also 0
was 0
identified 0
for 0
a 0
GC 0
box 0
element 0
at 0
nucleotides 0
- 0
59 0
to 0
- 0
45 0
. 0

Insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
II I-gene
( 0
IGFII B-gene
) 0
is 0
a 0
mitogenic 0
polypeptide 0
, 0
the 0
mRNAs 0
of 0
which 0
are 0
present 0
in 0
multiple 0
forms 0
, 0
despite 0
derivation 0
from 0
a 0
single 0
gene 0
. 0

The 0
central 0
visual 0
fields 0
of 0
2165 0
normal 0
and 0
106 0
glaucoma 0
eyes 0
were 0
measured 0
using 0
a 0
threshold 0
related 0
suprathreshold 0
strategy 0
. 0

The 0
variability 0
is 0
most 0
likely 0
a 0
result 0
of 0
alternative 0
splicing 0
of 0
exons 0
from 0
the 0
primary 0
elastin B-gene
transcripts I-gene
. 0

This 0
led 0
to 0
the 0
conclusion 0
that 0
the 0
metatarsal 0
artery 0
should 0
be 0
used 0
for 0
toe 0
MP 0
joint 0
grafts 0
, 0
while 0
the 0
unilateral 0
proper 0
digital 0
artery 0
is 0
suitable 0
for 0
toe 0
PIP 0
joint 0
grafts 0
, 0
together 0
with 0
concomitant 0
or 0
dorsal 0
cutaneous 0
vein 0
. 0

Effect 0
of 0
chronic 0
undernutrition 0
on 0
susceptibility 0
to 0
cold 0
stress 0
in 0
young 0
adult 0
and 0
aged 0
rats 0
. 0

This 0
effect 0
and 0
the 0
fact 0
that 0
all 0
three 0
doses 0
were 0
toxic 0
to 0
the 0
dams 0
dictated 0
that 0
a 0
second 0
experiment 0
be 0
carried 0
out 0
at 0
lower 0
doses 0
. 0

The 0
CHARGE 0
association 0
is 0
a 0
collection 0
of 0
multisystem 0
congenital 0
anomalies 0
including 0
choanal 0
atresia 0
. 0

Esophageal 0
brush 0
cytological 0
screening 0
was 0
undertaken 0
and 0
blood 0
concentrations 0
of 0
micronutrients 0
( 0
vitamin 0
A 0
, 0
E 0
, 0
B12 0
, 0
folic 0
acid 0
and 0
methionine 0
) 0
determined 0
from 0
adults 0
at 0
risk 0
for 0
esophageal 0
carcinoma 0
( 0
EC 0
) 0
in 0
Transkei 0
and 0
Ciskei 0
, 0
Southern 0
Africa 0
. 0

Aviators 0
from 0
the 0
Light 0
Attack 0
Wing 0
, 0
Pacific 0
were 0
surveyed 0
and 0
the 0
results 0
were 0
categorized 0
by 0
aircraft 0
type 0
. 0

Evaluation 0
of 0
human 0
and 0
bovine 0
modified 0
- 0
hemoglobin B-gene
solution 0
as 0
oxygen 0
- 0
carrying 0
fluid 0
for 0
blood 0
volume 0
replacement 0
. 0

Delayed 0
gallbladder 0
visualization 0
and 0
reduction 0
in 0
ejection 0
fraction 0
were 0
sensitive 0
but 0
nonspecific 0
indicators 0
of 0
biliary 0
disease 0
. 0

26 0
micrograms 0
PAF B-gene
or 0
placebo 0
was 0
sprayed 0
into 0
each 0
nasal 0
cavity 0
8 0
h 0
and 0
1 0
h 0
before 0
a 0
nasal 0
allergen 0
challenge 0
. 0

Sci 0
. 0

Chem 0
. 0

Sequential 0
MR 0
examinations 0
of 0
the 0
nasal 0
cavity 0
and 0
paranasal 0
sinuses 0
were 0
performed 0
within 0
a 0
6 0
- 0
8 0
h 0
period 0
in 0
five 0
normal 0
volunteers 0
. 0

Comparison 0
was 0
made 0
with 0
other 0
neuroradiological 0
imaging 0
modalities 0
including 0
CT 0
, 0
myelography 0
, 0
CT 0
ventriculography 0
, 0
and 0
CT 0
myelocisternography 0
. 0

The 0
feed 0
given 0
to 0
young 0
broiler 0
chickens 0
was 0
contaminated 0
artificially 0
with 0
Salmonella 0
kedougou 0
, 0
a 0
serotype 0
associated 0
with 0
both 0
subclinical 0
infections 0
in 0
commercially 0
reared 0
chickens 0
and 0
food 0
poisoning 0
in 0
humans 0
. 0

A 0
poor 0
correlation 0
was 0
found 0
between 0
a 0
mildly 0
- 0
atypical 0
( 0
inflammatory 0
) 0
cytological 0
result 0
( 0
class 0
2 0
) 0
and 0
a 0
benign 0
histological 0
diagnosis 0
: 0
48 0
% 0
of 0
class 0
- 0
2 0
smears 0
were 0
diagnosed 0
histologically 0
as 0
dysplasia 0
or 0
worse 0
. 0

Factors 0
involved 0
in 0
specific 0
transcription 0
by 0
mammalian 0
RNA B-gene
polymerase I-gene
II I-gene
: 0
purification 0
, 0
genetic 0
specificity 0
, 0
and 0
TATA 0
box 0
- 0
promoter 0
interactions 0
of 0
TFIID B-gene
. 0

Change 0
in 0
plasma B-gene
cystyl I-gene
aminopeptidase I-gene
( 0
oxytocinase B-gene
) 0
between 0
30 0
- 0
34 0
weeks 0
' 0
gestation 0
as 0
a 0
predictor 0
of 0
pregnancy 0
- 0
induced 0
hypertension 0
. 0

You 0
make 0
the 0
diagnosis 0
. 0

The 0
test 0
for 0
alpha B-gene
- I-gene
naphthyl I-gene
esterase I-gene
and 0
quantitation 0
of 0
macrophages 0
( 0
absolute 0
number 0
) 0
per 0
infiltration 0
area 0
unit 0
adjacent 0
to 0
the 0
abscess 0
suggest 0
a 0
direct 0
correlation 0
between 0
the 0
absolute 0
number 0
of 0
macrophages 0
and 0
the 0
width 0
of 0
the 0
capsule 0
. 0

Determined 0
as 0
migration 0
differentials 0
, 0
chemotactic 0
and 0
chemokinetic 0
responsiveness 0
tended 0
to 0
be 0
higher 0
in 0
the 0
neutropenic 0
group 0
. 0

The 0
deduced 0
96 0
- 0
residue 0
amino 0
acid 0
coding 0
sequence 0
of 0
the 0
murine 0
HMG B-gene
- I-gene
I I-gene
( I-gene
Y I-gene
) I-gene
cDNA 0
is 0
very 0
similar 0
to 0
the 0
reported 0
amino 0
acid 0
sequence 0
of 0
human 0
HMG B-gene
- I-gene
I I-gene
, 0
except 0
that 0
it 0
lacks 0
11 0
internal 0
amino 0
acids 0
reported 0
in 0
the 0
human 0
protein 0
. 0

Interpersonal 0
style 0
differences 0
among 0
drug 0
abusers 0
were 0
explored 0
using 0
Ryan 0
's 0
( 0
1977 0
) 0
typological 0
system 0
of 0
FIRO 0
- 0
B 0
interpretation 0
. 0

Statement 0
of 0
the 0
American 0
Academy 0
of 0
Implant 0
Dentistry 0
. 0

Sera 0
from 0
euthyroid 0
post 0
- 0
menopausal 0
or 0
pregnant 0
women 0
yielded 0
TSH B-gene
levels 0
within 0
the 0
normal 0
range 0
. 0

No 0
UOxase B-gene
mRNA I-gene
was 0
detected 0
in 0
11 0
nonhepatic 0
tissues 0
of 0
rat 0
, 0
suggesting 0
tissue 0
specificity 0
of 0
expression 0
of 0
this 0
UOxase B-gene
gene I-gene
. 0

The 0
platelet 0
adhesion 0
rate 0
on 0
these 0
layers 0
were 0
tested 0
concerning 0
the 0
valuation 0
of 0
the 0
haemocompatibility 0
of 0
the 0
basic 0
- 0
polymers 0
polyurethane 0
( 0
PUR 0
) 0
, 0
polyvinylchloride 0
( 0
PVC 0
) 0
, 0
and 0
polystyrene 0
( 0
PS 0
) 0
in 0
two 0
different 0
worked 0
test 0
chambers 0
. 0

Conservative 0
treatment 0
of 0
bladder 0
carcinoma 0
by 0
partial 0
cystectomy 0
and 0
interstitial 0
iridium 0
192 0
. 0

In 0
a 0
112 0
- 0
d 0
feedlot 0
trial 0
, 0
105 0
heifers 0
were 0
assigned 0
to 0
light 0
, 0
medium 0
and 0
heavy 0
weight 0
blocks 0
on 0
five 0
treatments 0
: 0
dietary 0
MGA 0
( 0
.5 0
mg.hd 0
- 0
1.d 0
- 0
1 0
) 0
, 0
control 0
( 0
no 0
MGA 0
) 0
or 0
DEPO 0
- 0
MGA 0
on 0
d 0
1 0
at 0
.5 0
, 0
1.0 0
or 0
1.5 0
ml/hd 0
( 0
30 0
, 0
60 0
or 0
90 0
mg 0
MGA/hd 0
, 0
respectively 0
) 0
. 0

Existence 0
and 0
uniqueness 0
of 0
solutions 0
of 0
the 0
appropriate 0
boundary 0
value 0
problems 0
are 0
established 0
, 0
in 0
the 0
case 0
of 0
small 0
permeability 0
coefficients 0
and 0
transport 0
rates 0
, 0
or 0
large 0
diffusion 0
coefficients 0
and 0
small 0
resistance 0
to 0
flow 0
constants 0
. 0

There 0
were 0
gene 0
clusters 0
encoding 0
photosynthesis 0
components 0
such 0
as 0
the 0
psbB B-gene
- 0
psbH B-gene
- 0
petB B-gene
- 0
petD B-gene
and 0
the 0
psbE 0
- 0
psbF 0
clusters 0
. 0

The 0
results 0
presented 0
suggest 0
that 0
TIQ 0
reduces 0
the 0
turnover 0
rate 0
of 0
the 0
nigrostriatal 0
dopamine 0
neurons 0
after 0
repeated 0
administration 0
for 0
a 0
long 0
period 0
in 0
mice 0
. 0

The 0
partial 0
sequence 0
of 0
the 0
62 B-gene
- I-gene
kDa I-gene
nuclear I-gene
pore I-gene
glycoprotein I-gene
shows 0
little 0
similarity 0
to 0
other 0
characterized 0
proteins 0
and 0
elucidates 0
structural 0
features 0
of 0
a 0
member 0
of 0
the 0
family 0
of 0
nuclear B-gene
pore I-gene
glycoproteins I-gene
. 0

Seventy 0
- 0
two 0
hours 0
after 0
administration 0
of 0
vitamin 0
K1 0
, 0
plasma 0
concentrations 0
of 0
the 0
vitamin 0
were 0
not 0
different 0
from 0
normal 0
. 0

The 0
glomerular 0
filtration 0
rate 0
did 0
not 0
change 0
but 0
lithium 0
clearance 0
fell 0
by 0
30 0
% 0
. 0

During 0
a 0
28 0
- 0
week 0
promotion 0
bioassay 0
, 0
groups 0
of 0
30 0
male 0
CD 0
- 0
1 0
mice 0
were 0
treated 0
once 0
with 0
50 0
microliter 0
of 0
either 0
DMBA 0
( 0
1.0 0
mg/ml 0
) 0
or 0
acetone 0
, 0
rested 0
for 0
2 0
weeks 0
, 0
and 0
then 0
treated 0
twice 0
per 0
week 0
with 0
test 0
material 0
for 0
the 0
remaining 0
25 0
weeks 0
. 0

The 0
pathogenesis 0
of 0
Dupuytren 0
's 0
contracture 0

An 0
ELISA 0
procedure 0
was 0
developed 0
for 0
monitoring 0
the 0
specific 0
IgE B-gene
response 0
in 0
dogs 0
to 0
Dirofilaria 0
immitis 0
infection 0
. 0

Fifty 0
min 0
after 0
release 0
from 0
stress 0
, 0
increases 0
in 0
plasma 0
corticosterone 0
levels 0
induced 0
by 0
stress 0
recovered 0
in 0
the 0
biting 0
group 0
but 0
remained 0
high 0
in 0
the 0
non 0
- 0
biting 0
group 0
. 0

The 0
only 0
isolate 0
of 0
Aeromonas 0
hydrophila 0
produced 0
cytotoxic 0
enterotoxin 0
and 0
was 0
invasive 0
. 0

An 0
11 0
- 0
month 0
- 0
old 0
girl 0
suffering 0
from 0
Dandy 0
- 0
Walker 0
malformation 0
( 0
DWM 0
) 0
associated 0
with 0
tetralogy 0
of 0
Fallot 0
( 0
TOF 0
) 0
is 0
presented 0
. 0

The 0
incidence 0
of 0
early 0
neonatal 0
convulsions 0
for 0
inborn 0
babies 0
was 0
3.0/1000 0
live 0
births 0
. 0

The 0
median 0
survival 0
is 0
not 0
reached 0
with 0
a 0
median 0
follow 0
- 0
up 0
time 0
of 0
9.6 0
years 0
. 0

Critical 0
evaluation 0
of 0
various 0
methods 0
of 0
determining 0
markers 0
of 0
fetal 0
maturity 0
in 0
amniotic 0
fluid 0

Of 0
the 0
43 0
infants 0
with 0
a 0
( 0
probable 0
) 0
loss 0
18 0
were 0
examined 0
again 0
at 0
3 0
months 0
corrected 0
age 0
. 0

Variety 0
of 0
cows 0
and 0
sires 0
according 0
to 0
types 0
of 0
dermatoglyphics 0
( 0
patterns 0
) 0
of 0
the 0
nose 0
- 0
labial 0
mirror 0
of 0
cattle 0

Although 0
not 0
consistently 0
identified 0
in 0
all 0
samples 0
, 0
secondary 0
Academic 0
, 0
Personal 0
Responsibility 0
, 0
and 0
Community/Vocational 0
dimensions 0
were 0
also 0
identified 0
. 0

Recovery 0
was 0
characterized 0
by 0
rapid 0
improvement 0
such 0
that 0
all 0
measured 0
parameters 0
normalized 0
by 0
1 0
week 0
, 0
except 0
for 0
cross 0
- 0
sectional 0
cardiac 0
area 0
which 0
remained 0
dilated 0
up 0
to 0
4 0
weeks 0
( 0
14 0
+/ 0
- 0
3 0
cm2 0
, 0
p 0
less 0
than 0
0.05 0
versus 0
control 0
) 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Not 0
even 0
extensive 0
pancreatic 0
resection 0
could 0
prevent 0
pancreatic 0
remnant 0
infection 0
. 0

It 0
has 0
been 0
calculated 0
that 0
600,000 0
new 0
cases 0
of 0
lung 0
cancer 0
occur 0
worldwide 0
every 0
year 0
, 0
most 0
of 0
them 0
due 0
to 0
smoking 0
. 0

Neuromyelitis 0
optica 0
( 0
Devic 0
's 0
syndrome 0
) 0
: 0
not 0
always 0
multiple 0
sclerosis 0
. 0

Effect 0
of 0
the 0
methods 0
of 0
cutaneous 0
administration 0
of 0
methyl 0
isobutyl 0
ketone 0
on 0
its 0
toxicity 0

Incorporation 0
of 0
0.1 0
or 0
0.2 0
M 0
sodium 0
dihydrogen 0
phosphate 0
in 0
the 0
sugar 0
solutions 0
resulted 0
in 0
a 0
decrease 0
in 0
the 0
shelf 0
- 0
life 0
of 0
diltiazem 0
. 0

None 0
had 0
a 0
past 0
history 0
of 0
opportunistic 0
infections 0
; 0
neither 0
did 0
any 0
have 0
lymphopenia 0
. 0

Increasing 0
the 0
phosphorus 0
content 0
of 0
the 0
diet 0
improved 0
the 0
reabsorption 0
of 0
calcium 0
and 0
magnesium 0
. 0

Post 0
- 0
transcriptional 0
regulation 0
of 0
ribosomal B-gene
protein I-gene
gene I-gene
expression 0
during 0
development 0
in 0
Dictyostelium 0
discoideum 0
. 0

The 0
temporal 0
and 0
static 0
plasma 0
concentration 0
- 0
effect 0
relationships 0
were 0
evaluated 0
by 0
pharmacodynamic 0
modeling 0
and 0
linear 0
regression 0
. 0

The 0
increase 0
in 0
amplitudes 0
of 0
the 0
b 0
- 0
wave 0
during 0
the 0
adaptation 0
period 0
was 0
more 0
prominent 0
in 0
lead 0
- 0
exposed 0
subjects 0
than 0
in 0
controls 0
. 0

Possible 0
factors 0
for 0
the 0
development 0
of 0
psychotic 0
symptomatology 0
during 0
group 0
activities 0
and 0
the 0
role 0
of 0
group 0
dynamics 0
acting 0
as 0
stress 0
factors 0
precipitating 0
functional 0
psychoses 0
, 0
especially 0
bipolar 0
manifestations 0
, 0
are 0
discussed 0
. 0

Baseline 0
measurements 0
of 0
forced 0
expiratory 0
volume 0
in 0
1 0
s 0
( 0
FEV1 0
) 0
, 0
specific 0
airway 0
conductance 0
( 0
SGaw 0
) 0
and 0
the 0
provocative 0
dose 0
of 0
carbachol 0
causing 0
a 0
35 0
% 0
reduction 0
in 0
SGaw 0
( 0
PD35 0
) 0
, 0
and 0
a 0
20 0
% 0
reduction 0
in 0
FEV1 0
( 0
PD20 0
) 0
were 0
established 0
on 0
entry 0
while 0
each 0
subject 0
was 0
still 0
smoking 0
. 0

Many 0
children 0
with 0
BGC 0
are 0
delayed 0
in 0
their 0
development 0
, 0
but 0
calcifications 0
are 0
not 0
directly 0
related 0
to 0
specific 0
forms 0
of 0
neurologic 0
dysfunction 0
. 0

R 0
- 0
wave 0
voltage 0
in 0
the 0
right 0
precordial 0
leads 0
in 0
anthracycline 0
cardiomyopathy 0
: 0
a 0
clinical 0
study 0
. 0

The 0
results 0
indicate 0
that 0
the 0
pooling 0
requirements 0
are 0
task 0
dependent 0
. 0

These 0
results 0
indicate 0
that 0
CSFHU B-gene
can 0
increase 0
neutrophil 0
counts 0
by 0
increasing 0
the 0
number 0
and 0
maturity 0
of 0
the 0
marrow 0
neutrophil 0
precursors 0
in 0
some 0
types 0
of 0
childhood 0
chronic 0
neutropenia 0
. 0

The 0
purposes 0
of 0
this 0
study 0
were 0
1 0
) 0
to 0
examine 0
the 0
effect 0
of 0
high 0
intensity 0
, 0
low 0
frequency 0
transcutaneous 0
electrical 0
nerve 0
stimulation 0
at 0
auricular 0
acupuncture 0
points 0
on 0
experimental 0
pain 0
threshold 0
measured 0
at 0
the 0
wrist 0
and 0
2 0
) 0
to 0
determine 0
the 0
changes 0
in 0
effect 0
over 0
time 0
. 0

In 0
the 0
infected 0
neonates 0
serum 0
alpha B-gene
- I-gene
amylase I-gene
value 0
, 0
as 0
determined 0
by 0
the 0
blue 0
starch 0
method 0
, 0
was 0
only 0
40 0
% 0
that 0
of 0
healthy 0
controls 0
; 0
the 0
mean 0
value 0
of 0
175.1 0
+/ 0
- 0
64.9 0
IU/l 0
for 0
healthy 0
neonates 0
was 0
significantly 0
higher 0
( 0
p 0
less 0
than 0
0.0010 0
) 0
than 0
the 0
value 0
of 0
82.8 0
+/ 0
- 0
44.4 0
IU/l 0
for 0
the 0
infected 0
neonates 0
. 0

Records 0
of 0
31 0
children 0
with 0
AIDS 0
or 0
AIDS 0
- 0
related 0
complex 0
admitted 0
to 0
the 0
pediatric 0
intensive 0
care 0
unit 0
for 0
acute 0
respiratory 0
failure 0
throughout 0
a 0
46 0
- 0
month 0
period 0
were 0
reviewed 0
. 0

Fourteen 0
patients 0
were 0
in 0
the 0
multifocal 0
disease 0
group 0
; 0
13 0
were 0
detected 0
by 0
SPECT 0
and 0
10 0
by 0
TCT 0
. 0

SPECT 0
is 0
an 0
important 0
aid 0
in 0
the 0
diagnosis 0
of 0
AIDS 0
dementia 0
complex 0
and 0
contributes 0
to 0
the 0
understanding 0
of 0
the 0
pathophysiological 0
mechanisms 0
of 0
this 0
disorder 0
. 0

We 0
were 0
interested 0
in 0
studying 0
the 0
relationship 0
between 0
the 0
circadian 0
rhythm 0
in 0
body 0
temperature 0
and 0
24 0
- 0
h 0
variations 0
in 0
plasma 0
concentrations 0
of 0
iron 0
, 0
zinc 0
, 0
circulating 0
leukocyte 0
counts 0
, 0
and 0
plasma 0
interleukin B-gene
1 I-gene
( 0
IL B-gene
- I-gene
1 I-gene
) 0
activity 0
. 0

The 0
murine B-gene
MHC I-gene
class I-gene
I I-gene
genes I-gene
, 0
H B-gene
- I-gene
2Dq I-gene
and 0
H B-gene
- I-gene
2Lq I-gene
, 0
are 0
strikingly 0
homologous 0
to 0
each 0
other 0
, 0
H B-gene
- I-gene
2Ld I-gene
, 0
and 0
two 0
genes 0
reported 0
to 0
encode 0
tumor 0
- 0
specific 0
antigens 0
. 0

The 0
active 0
derivatives 0
of 0
the 0
present 0
series 0
were 0
also 0
tested 0
for 0
their 0
analgesic 0
activity 0
against 0
aconitine 0
- 0
induced 0
writhing 0
in 0
albino 0
mice 0
and 0
ulcerogenic 0
activity 0
in 0
albino 0
rats 0
. 0

In 0
untreated 0
mice 0
, 0
bactericidal 0
activity 0
of 0
peritoneal 0
macrophages 0
decreased 0
from 0
one 0
day 0
to 0
3 0
days 0
after 0
ip 0
injection 0
of 0
killed 0
L. 0
monocytogenes 0
. 0

Among 0
a 0
population 0
of 0
18,175 0
children 0
below 0
7 0
years 0
of 0
age 0
in 0
medium 0
sized 0
towns 0
and 0
rural 0
areas 0
in 0
south 0
- 0
western 0
Germany 0
552 0
( 0
3.03 0
% 0
) 0
cases 0
of 0
croup 0
were 0
registered 0
during 0
a 0
12 0
months 0
period 0
in 0
1984 0
- 0
85 0
by 0
their 0
physicians 0
. 0

We 0
concluded 0
that 0
Ga 0
- 0
fbg 0
scintigraphy 0
is 0
a 0
very 0
simple 0
method 0
and 0
sufficiently 0
useful 0
for 0
detecting 0
active 0
left 0
ventricular 0
thrombi 0
and 0
for 0
monitoring 0
the 0
effect 0
of 0
anticoagulant 0
therapy 0
. 0

In 0
vitro 0
assessment 0
of 0
the 0
biocompatibility 0
of 0
dental 0
materials 0
- 0
- 0
the 0
millipore 0
filter 0
method 0
. 0

Hypomagnesemia 0
was 0
due 0
to 0
magnesium 0
wasting 0
by 0
the 0
kidney 0
. 0

Dentalplaque 0
was 0
controlled 0
by 0
the 0
oral 0
higienic 0
index 0
of 0
the 0
whole 0
dentition 0
daily 0
, 0
after 0
staining 0
with 0
1 0
per 0
cent 0
alkaline 0
fuxin 0
. 0

GRFI B-gene
bound 0
to 0
sequences 0
at 0
the 0
negative 0
regulatory 0
elements 0
( 0
silencers 0
) 0
of 0
the 0
silent B-gene
mating I-gene
type I-gene
loci I-gene
HML B-gene
E I-gene
and 0
HMR B-gene
E I-gene
and 0
to 0
the 0
upstream 0
activating 0
sequence 0
( 0
UAS 0
) 0
required 0
for 0
transcription 0
of 0
the 0
MAT B-gene
alpha I-gene
genes I-gene
. 0

The 0
effects 0
of 0
these 0
mutations 0
on 0
RNA B-gene
polymerase I-gene
II I-gene
activity 0
were 0
assayed 0
by 0
measuring 0
the 0
ability 0
of 0
mutant 0
genes 0
to 0
confer 0
alpha B-gene
- I-gene
amanitin I-gene
resistance 0
after 0
transfection 0
of 0
susceptible 0
rodent 0
cells 0
. 0

We 0
report 0
the 0
use 0
of 0
a 0
new 0
technetium 0
- 0
99m 0
- 0
albumin B-gene
colloid 0
white 0
blood 0
cell 0
( 0
TAC 0
- 0
WBC 0
) 0
scan 0
in 0
the 0
evaluation 0
of 0
appendicitis 0
. 0

In 0
one 0
of 0
these 0
tumors 0
the 0
observed 0
rearrangement 0
was 0
not 0
due 0
to 0
the 0
insertion 0
of 0
an 0
intact 0
MoMuLV 0
provirus 0
. 0

The 0
indications 0
for 0
its 0
use 0
include 0
every 0
primary 0
and 0
secondary 0
rhinoplasty 0
candidate 0
unless 0
tip 0
grafts 0
are 0
going 0
to 0
be 0
under 0
tension 0
or 0
if 0
the 0
deformity 0
is 0
minor 0
. 0

The 0
SSB B-gene
- 0
poly 0
( 0
dT 0
) 0
affinity 0
is 0
too 0
high 0
to 0
measure 0
in 0
buffers 0
containing 0
even 0
5 0
M 0
NaCl 0
; 0
however 0
, 0
in 0
1.8 0
- 0
2.5 0
M 0
NaBr 0
, 0
we 0
measure 0
alpha 0
log 0
Kobsd/alpha 0
log 0
[ 0
NaBr 0
] 0
= 0
- 0
5.7 0
+/ 0
- 0
0.7 0
, 0
with 0
a 0
lower 0
value 0
of 0
omega 0
T/O 0
= 0
130 0
+/ 0
- 0
70 0
. 0

Mutations 0
at 0
the 0
suf12 B-gene
locus I-gene
were 0
isolated 0
in 0
Saccharomyces 0
cerevisiae 0
as 0
extragenic 0
suppressors 0
of 0
+1 0
frameshift 0
mutations 0
in 0
glycine 0
( 0
GGX 0
) 0
and 0
proline 0
( 0
CCX 0
) 0
codons 0
, 0
as 0
well 0
as 0
UGA 0
and 0
UAG 0
nonsense 0
mutations 0
. 0

The 0
behavior 0
of 0
suf12 B-gene
- I-gene
null/SUF12+ I-gene
heterozygotes I-gene
indicates 0
that 0
suf12 B-gene
is 0
co 0
- 0
dominantly 0
expressed 0
and 0
suggests 0
that 0
suf12 B-gene
allele 0
- 0
specific 0
suppression 0
may 0
result 0
from 0
functionally 0
distinct 0
mutant 0
proteins 0
rather 0
than 0
variation 0
in 0
residual 0
wild B-gene
- I-gene
type I-gene
SUF12+ I-gene
activity 0
. 0

Antituberculosis 0
agents 0
. 0

The 0
putative 0
immunity 0
protein 0
was 0
detected 0
among 0
the 0
[ 0
35S 0
] 0
methionine 0
- 0
labelled 0
proteins 0
produced 0
by 0
minicells 0
carrying 0
cni B-gene
cloned 0
under 0
lac B-gene
promoter I-gene
control 0
, 0
and 0
when 0
the 0
gene 0
was 0
subcloned 0
into 0
expression 0
vectors 0
under 0
the 0
control 0
of 0
a 0
bacteriophage 0
T7 0
promoter 0
. 0

Antibodies 0
made 0
against 0
fusion 0
protein 0
produced 0
by 0
the 0
DP1A B-gene
clone 0
reacted 0
specifically 0
with 0
DP B-gene
- I-gene
I I-gene
and I-gene
- I-gene
II I-gene
on 0
immunoblots 0
. 0

Finally 0
, 0
over 0
a 0
similar 0
range 0
of 0
QO2 0
, 0
oxygen 0
extraction 0
was 0
greater 0
in 0
patients 0
with 0
ARDS 0
compared 0
to 0
patients 0
with 0
non 0
- 0
ARDS 0
respiratory 0
failure 0
( 0
r 0
= 0
- 0
0.67 0
and 0
slope 0
= 0
- 0
0.62 0
vs 0
r 0
= 0
- 0
0.45 0
and 0
slope 0
= 0
- 0
0.35 0
; 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Stable 0
patients 0
have 0
mucous 0
hypersecretion 0
and 0
little 0
evidence 0
of 0
acute 0
inflammation 0
. 0

Hyperprolactinaemia 0
, 0
moderate 0
hypogonadism 0
, 0
infraclinical 0
neuropathies 0
, 0
arterial 0
stenoses 0
and 0
moderate 0
venous 0
leakages 0
seem 0
to 0
play 0
a 0
partial 0
role 0
of 0
organic 0
starter 0
or 0
cofactor 0
, 0
the 0
sexual 0
consequences 0
of 0
which 0
are 0
amplified 0
by 0
psychological 0
factors 0
, 0
partly 0
secondary 0
to 0
the 0
initial 0
sexual 0
failures 0
. 0

Yang 0
and 0
H 0
. 0

Secretory 0
function 0
of 0
the 0
prostate 0
gland 0
. 0

Chronic 0
endotoxemia 0
appears 0
to 0
be 0
associated 0
with 0
an 0
elevated 0
pulmonary 0
microvascular 0
permeability 0
and 0
a 0
tendency 0
toward 0
a 0
hyperdynamic 0
circulation 0
but 0
with 0
an 0
appreciable 0
degree 0
of 0
refractoriness 0
associated 0
with 0
regional 0
hemodynamics 0
and 0
eicosanoid 0
biosynthesis 0
. 0

In 0
contrast 0
, 0
we 0
observed 0
high 0
concentrations 0
in 0
29 0
of 0
75 0
patients 0
with 0
tumors 0
of 0
the 0
central 0
nervous 0
system 0
, 0
especially 0
in 0
meningioma 0
( 0
6/9 0
) 0
, 0
glioblastoma 0
( 0
9/23 0
) 0
, 0
and 0
neurinoma 0
( 0
5/5 0
) 0
. 0

Diet 0
and 0
atopic 0
eczema 0
. 0

Time 0
delay 0
effects 0
on 0
the 0
tensile 0
bond 0
strength 0
developed 0
by 0
the 0
Silicoater 0
. 0

The 0
future 0
of 0
research 0
with 0
interferon B-gene
may 0
be 0
divided 0
into 0
three 0
areas 0
: 0
Efforts 0
must 0
be 0
made 0
to 0
determine 0
how 0
best 0
to 0
translate 0
the 0
in 0
vitro 0
synergy 0
into 0
clinically 0
meaningful 0
terms 0
; 0
in 0
order 0
to 0
exploit 0
the 0
fullest 0
potential 0
of 0
IFN B-gene
, 0
research 0
is 0
moving 0
toward 0
using 0
this 0
agent 0
earlier 0
in 0
disease 0
either 0
as 0
an 0
adjuvant 0
after 0
tumor 0
debulking 0
or 0
after 0
initial 0
diagnosis 0
; 0
the 0
medical 0
community 0
must 0
rethink 0
the 0
natural 0
history 0
of 0
some 0
diseases 0
, 0
because 0
the 0
fullest 0
potential 0
of 0
the 0
biologic 0
agents 0
will 0
most 0
likely 0
manifest 0
itself 0
when 0
these 0
agents 0
are 0
used 0
together 0
. 0

Minor 0
differences 0
were 0
noted 0
with 0
latamoxef 0
producing 0
mild 0
persistant 0
elevation 0
of 0
prothrombin B-gene
time 0
( 0
0.7 0
second 0
) 0
associated 0
with 0
depression 0
of 0
factor B-gene
II I-gene
and 0
factor B-gene
VII I-gene
. 0

Six 0
healthy 0
male 0
subjects 0
received 0
single 0
oral 0
doses 0
of 0
regular 0
release 0
( 0
RR 0
) 0
quinidine 0
sulfate 0
, 0
sustained 0
release 0
( 0
SR 0
) 0
quinidine 0
bisulfate 0
and 0
the 0
same 0
dose 0
of 0
the 0
SR 0
product 0
with 0
food 0
( 0
SR 0
- 0
F 0
) 0
. 0

This 0
report 0
expands 0
on 0
previous 0
work 0
with 0
interferon B-gene
alfa I-gene
- I-gene
2b I-gene
( I-gene
Intron I-gene
A I-gene
; I-gene
Schering I-gene
- I-gene
Plough I-gene
) I-gene
in 0
the 0
treatment 0
of 0
hairy 0
cell 0
leukemia 0
( 0
HCL 0
) 0
. 0

Oxygen 0
delivery 0
and 0
base 0
excess 0
decreased 0
significantly 0
and 0
four 0
pigs 0
died 0
. 0

Clinical 0
chemistry 0
. 0

Revascularization 0
after 0
anterior 0
maxillary 0
and 0
mandibular 0
osteotomy 0

Static 0
orthoses 0
for 0
the 0
management 0
of 0
microstomia 0
. 0

The 0
intrapancreatic 0
spread 0
of 0
the 0
carcinoma 0
correlated 0
with 0
portal 0
invasion 0
of 0
carcinoma 0
, 0
hardness 0
of 0
the 0
body 0
and 0
tail 0
, 0
obstruction 0
of 0
main 0
pancreatic 0
duct 0
and 0
irregular 0
pancreaticogram 0
. 0

Lysosomal 0
enzymes 0
that 0
degrade 0
cartilage 0
are 0
released 0
. 0

Contrary 0
to 0
the 0
observation 0
made 0
with 0
other 0
S. 0
pombe 0
genes 0
transcribed 0
in 0
the 0
budding 0
yeast 0
, 0
the 0
heterologous 0
actin B-gene
gene I-gene
transcript I-gene
is 0
initiated 0
39 0
nucleotides 0
upstream 0
of 0
the 0
initiation 0
start 0
site 0
used 0
in 0
the 0
homologous 0
yeast 0
. 0

A 0
multicentre 0
study 0
involving 0
9 0
Italian 0
institutions 0
was 0
carried 0
out 0
to 0
compare 0
the 0
efficacy 0
and 0
safety 0
of 0
ranitidine 0
150 0
mg 0
b.i.d 0
. 0
and 0
ranitidine 0
300 0
mg 0
nocte 0
in 0
the 0
treatment 0
of 0
reflux 0
oesophagitis 0
. 0

Monotherapy 0
with 0
ceftazidime 0
was 0
clinically 0
and 0
bacteriologically 0
as 0
effective 0
as 0
a 0
combination 0
therapy 0
with 0
cefazolin 0
and 0
tobramycin 0
. 0

The 0
N3 0
wave 0
of 0
the 0
SSEP 0
's 0
, 0
which 0
has 0
been 0
found 0
to 0
correlate 0
best 0
with 0
neurological 0
recovery 0
, 0
returned 0
to 0
65 0
% 0
+/ 0
- 0
48 0
% 0
of 0
the 0
preischemia 0
amplitude 0
in 0
the 0
insulin B-gene
- 0
treated 0
animals 0
, 0
compared 0
to 0
40 0
% 0
+/ 0
- 0
34 0
% 0
in 0
the 0
fasted 0
group 0
and 0
26 0
% 0
+/ 0
- 0
24 0
% 0
in 0
the 0
control 0
animals 0
. 0

Proctoscopy 0
and 0
roentgenographic 0
studies 0
may 0
be 0
an 0
important 0
part 0
of 0
evaluation 0
, 0
especially 0
in 0
patients 0
who 0
present 0
with 0
perianal 0
suppuration 0
, 0
masses 0
, 0
or 0
anal 0
fissures 0
. 0

In 0
the 0
control 0
group 0
the 0
histological 0
picture 0
resembled 0
osteoarthritis 0
. 0

In 0
contrast 0
to 0
this 0
mRNA 0
, 0
90 0
% 0
of 0
alpha B-gene
and I-gene
beta I-gene
actin I-gene
mRNAs I-gene
were 0
translated 0
in 0
both 0
myoblasts 0
and 0
myotubes 0
. 0

Plasma B-gene
renin I-gene
activity 0
does 0
not 0
predict 0
the 0
antihypertensive 0
efficacy 0
of 0
chlorthalidone 0
. 0

Cephradine 0
250 0
mg 0
at 0
night 0
for 0
12 0
months 0
was 0
given 0
as 0
a 0
prophylactic 0
measure 0
to 0
33 0
female 0
patients 0
of 0
mean 0
age 0
41.6 0
years 0
, 0
who 0
had 0
a 0
history 0
in 0
the 0
preceding 0
12 0
months 0
of 0
between 0
three 0
and 0
24 0
( 0
median 0
= 0
7 0
) 0
episodes 0
of 0
frequency 0
and/or 0
dysuria 0
. 0

If 0
this 0
is 0
unavailable 0
, 0
then 0
Supramid 0
has 0
a 0
proven 0
record 0
for 0
good 0
tissue 0
compatibility 0
and 0
resistance 0
to 0
infection 0
. 0

The 0
size 0
of 0
the 0
group 0
allocated 0
to 0
the 0
good 0
compliance 0
category 0
by 0
the 0
use 0
of 0
the 0
digoxin 0
marker 0
was 0
equivalent 0
in 0
size 0
to 0
a 0
group 0
of 0
patients 0
who 0
had 0
returned 0
less 0
than 0
15 0
% 0
of 0
their 0
prescribed 0
dose 0
or 0
reported 0
a 0
deviation 0
of 0
less 0
than 0
6 0
% 0
from 0
their 0
prescription 0
. 0

Bullous 0
keratopathy 0
was 0
usually 0
aphakic 0
in 0
origin 0
in 0
1982 0
, 0
but 0
after 0
1983 0
pseudophakic 0
bullous 0
keratopathy 0
( 0
PBK 0
) 0
was 0
the 0
most 0
common 0
cause 0
of 0
bullous 0
keratopathy 0
. 0

The 0
ultrastructural 0
findings 0
, 0
as 0
well 0
as 0
the 0
urinary 0
C B-gene
- I-gene
peptide I-gene
excretion 0
, 0
confirmed 0
that 0
the 0
glycemic 0
effects 0
should 0
not 0
be 0
thought 0
to 0
be 0
due 0
to 0
a 0
direct 0
action 0
of 0
the 0
drugs 0
used 0
on 0
the 0
endocrine 0
pancreas 0
. 0

The 0
activity 0
of 0
the 0
EGF B-gene
receptor I-gene
promoter I-gene
can 0
be 0
modulated 0
by 0
E1A B-gene
protein I-gene
and 0
receptor 0
RNA 0
levels 0
increased 0
by 0
stimulation 0
with 0
phorbol 0
ester 0
or 0
fetal 0
calf 0
serum 0
. 0

In 0
vitro 0
antimalarial 0
activity 0
of 0
neem 0
( 0
Azadirachta 0
indica 0
A 0
. 0

`` 0
In 0
vitro 0
'' 0
study 0
of 0
dentin 0
adhesion 0
to 0
adhesives 0
made 0
from 0
urethane 0
molecules 0
with 0
free 0
groups 0
of 0
isocyanate 0

By 0
Felix 0
Lagrange 0
, 0
1918 0
. 0

There 0
is 0
a 0
cysteine 0
clustering 0
region 0
in 0
an 0
N 0
- 0
terminal 0
region 0
of 0
the 0
c B-gene
- I-gene
raf I-gene
( I-gene
- I-gene
1 I-gene
) I-gene
product I-gene
deduced 0
from 0
the 0
nucleotide 0
sequence 0
, 0
and 0
this 0
cysteine 0
clustering 0
region 0
was 0
found 0
to 0
be 0
highly 0
homologous 0
to 0
that 0
present 0
in 0
an 0
N 0
- 0
terminal 0
region 0
of 0
protein B-gene
kinase I-gene
C I-gene
, 0
although 0
, 0
in 0
the 0
latter 0
cysteine 0
clusters 0
are 0
present 0
in 0
duplicate 0
. 0

Hand 0
- 0
held 0
, 0
continuous 0
- 0
wave 0
Doppler 0
probes 0
, 0
coupled 0
with 0
sound 0
spectral 0
analysis 0
, 0
can 0
successfully 0
predict 0
carotid 0
artery 0
stenosis 0
. 0

The 0
German 0
Society 0
of 0
Pediatric 0
Oncology 0
in 0
1981 0
initiated 0
the 0
Cooperative 0
Ewing 0
's 0
Sarcoma 0
Study 0
( 0
CESS 0
81 0
) 0
using 0
a 0
four 0
- 0
drug 0
combination 0
of 0
chemotherapy 0
prior 0
to 0
definitive 0
local 0
control 0
with 0
surgery 0
and/or 0
radiation 0
. 0

The 0
program 0
has 0
been 0
written 0
in 0
a 0
generic 0
BASIC 0
in 0
order 0
to 0
make 0
the 0
procedure 0
user 0
- 0
friendly 0
. 0

Since 0
high 0
levels 0
of 0
immunoglobulin B-gene
G I-gene
were 0
demonstrated 0
against 0
the 0
surface 0
of 0
the 0
NVS 0
after 0
immunization 0
, 0
passive 0
transfer 0
experiments 0
were 0
initiated 0
. 0

A 0
study 0
was 0
conducted 0
of 0
a 0
human 0
male 0
who 0
had 0
inhaled 0
a 0
mixture 0
of 0
241Am 0
and 0
Pu 0
. 0

An 0
analytic 0
method 0
for 0
comparative 0
parameter 0
weighting 0
in 0
magnetic 0
resonance 0
( 0
MR 0
) 0
imaging 0
has 0
been 0
developed 0
using 0
the 0
concept 0
of 0
`` 0
fractional 0
sensitivity 0
. 0
'' 0
This 0
new 0
approach 0
results 0
in 0
easily 0
calculated 0
indexes 0
for 0
T1 0
, 0
T2 0
, 0
and 0
hydrogen 0
weighting 0
. 0

Fifty 0
- 0
four 0
patients 0
were 0
divided 0
into 0
groups 0
according 0
to 0
their 0
clinical 0
presentation 0
; 0
seven 0
asymptomatic 0
volunteers 0
, 0
20 0
patients 0
with 0
duodenal 0
- 0
gastric 0
reflux 0
gastropathy 0
( 0
DRG 0
) 0
, 0
16 0
patients 0
with 0
recurrent 0
ulcers 0
of 0
the 0
duodenal 0
bulb 0
( 0
RUD 0
) 0
, 0
and 0
11 0
patients 0
with 0
Moynihan 0
's 0
disease 0
. 0

No 0
previous 0
studies 0
have 0
determined 0
the 0
pharmaco 0
- 0
dynamics 0
of 0
intravenous 0
procainamide 0
when 0
administered 0
in 0
a 0
dose 0
of 0
15 0
mg/kg 0
and 0
at 0
a 0
rate 0
of 0
50 0
mg/min 0
, 0
as 0
is 0
common 0
practice 0
during 0
electropharmacologic 0
testing 0
. 0

High 0
concentrations 0
of 0
tumor 0
- 0
associated 0
trypsin B-gene
inhibitor 0
in 0
hemodialyzed 0
patients 0
. 0

In 0
the 0
chicken 0
liver 0
, 0
levels 0
of 0
chicken B-gene
MT I-gene
mRNA I-gene
were 0
rapidly 0
induced 0
by 0
metals 0
( 0
Cd2+ 0
, 0
Zn2+ 0
, 0
Cu2+ 0
) 0
, 0
glucocorticoids 0
and 0
lipopolysaccharide 0
. 0

With 0
histology 0
and 0
Evans 0
blue 0
injections 0
, 0
blood 0
- 0
brain 0
barrier 0
alterations 0
were 0
seen 0
as 0
early 0
as 0
4 0
days 0
after 0
a 0
dose 0
of 0
50 0
Gy 0
. 0

Dosimetric 0
estimates 0
for 0
these 0
organs 0
were 0
2.3 0
+/ 0
- 0
1.1 0
and 0
2.3 0
+/ 0
- 0
1.4 0
rad 0
( 0
.02 0
+/ 0
- 0
.01 0
Gy 0
) 0
, 0
respectively 0
, 0
with 0
a 0
whole 0
- 0
body 0
estimate 0
of 0
0.28 0
rad 0
( 0
.003 0
Gy 0
) 0
. 0

A 0
significant 0
association 0
between 0
a 0
family 0
history 0
and 0
a 0
higher 0
urinary 0
pH 0
was 0
observed 0
among 0
the 0
female 0
calcium 0
stone 0
patients 0
. 0

New 0
technologies 0
in 0
diagnosis 0
and 0
classification 0
of 0
malignancy 0
. 0

Thus 0
the 0
present 0
data 0
also 0
suggest 0
that 0
BP 0
and 0
HR 0
measurements 0
are 0
influenced 0
not 0
only 0
by 0
state 0
- 0
dependent 0
factors 0
but 0
also 0
by 0
at 0
least 0
three 0
different 0
factors 0
that 0
are 0
each 0
independent 0
of 0
the 0
state 0
: 0
one 0
leads 0
to 0
BP 0
and 0
HR 0
values 0
that 0
are 0
influenced 0
by 0
the 0
cycle 0
the 0
animal 0
is 0
in 0
and 0
the 0
other 0
two 0
influence 0
, 0
respectively 0
, 0
the 0
ranking 0
of 0
the 0
individual 0
's 0
BP 0
and 0
HR 0
levels 0
within 0
the 0
population 0
. 0

The 0
correlation 0
between 0
PaCO2 0
and 0
PtcO2 0
in 0
RDS 0
was 0
insufficient 0
to 0
make 0
clinical 0
judgement 0
. 0

Since 0
1967 0
at 0
the 0
times 0
of 0
their 0
biennial 0
ABCC/RERF 0
radiological 0
examinations 0
, 0
all 0
Adult 0
Health 0
Study 0
( 0
AHS 0
) 0
subjects 0
have 0
been 0
interviewed 0
to 0
determine 0
the 0
exposures 0
to 0
medical 0
x 0
- 0
rays 0
they 0
experienced 0
in 0
institutions 0
other 0
than 0
RERF 0
in 0
order 0
to 0
estimate 0
the 0
numbers 0
of 0
examinations 0
and 0
corresponding 0
doses 0
which 0
they 0
received 0
. 0

The 0
epidermal B-gene
growth I-gene
factor I-gene
( I-gene
EGF I-gene
) I-gene
receptor I-gene
, 0
which 0
exhibits 0
intrinsic 0
protein B-gene
tyrosine I-gene
kinase I-gene
activity 0
, 0
undergoes 0
a 0
rapid 0
, 0
intramolecular 0
self 0
- 0
phosphorylation 0
reaction 0
following 0
EGF B-gene
activation 0
. 0

One 0
millimolar 0
ouabain 0
completely 0
inhibited 0
net 0
HCO3 0
- 0
secretion 0
. 0

There 0
are 0
regions 0
with 0
long 0
runs 0
of 0
up 0
to 0
45 0
% 0
C 0
or 0
35 0
% 0
G 0
residues 0
. 0

The 0
same 0
rhythmic 0
structure 0
enables 0
a 0
prediction 0
to 0
be 0
made 0
concerning 0
when 0
vowels 0
of 0
stressed 0
syllables 0
will 0
be 0
auditorily 0
perceived 0
. 0

Vocal 0
cord 0
abduction 0
rehabilitation 0
by 0
nervous 0
selective 0
anastomosis 0
. 0

UK 0
's 0
biotechnology 0
lacking 0
specialists 0
. 0

A 0
case 0
of 0
AIDS 0
- 0
related 0
complex 0
( 0
ARC/LAS 0
) 0
in 0
a 0
health 0
worker 0

Distant 0
spread 0
was 0
found 0
in 0
46 0
patients 0
( 0
34 0
% 0
) 0
, 0
42 0
of 0
whom 0
had 0
serum 0
Tg B-gene
greater 0
than 0
10 0
micrograms/l 0
. 0

The 0
glomerular 0
filtration 0
rate 0
and 0
effective 0
renal 0
plasma 0
flow 0
were 0
determined 0
by 0
a 0
standard 0
clearance 0
method 0
, 0
employing 0
continuous 0
infusion 0
of 0
inulin 0
and 0
para 0
- 0
aminohippuric 0
acid 0
. 0

After 0
the 0
meal 0
containing 0
potato 0
, 0
plasma 0
glucose 0
levels 0
rose 0
sharply 0
, 0
peaked 0
at 0
30 0
- 0
45 0
min 0
and 0
fell 0
below 0
initial 0
levels 0
2 0
to 0
3 0
h 0
later 0
. 0

The 0
relations 0
among 0
various 0
negative 0
emotional 0
and 0
behavioral 0
characteristics 0
( 0
e.g. 0
, 0
aggression 0
, 0
anxiety 0
, 0
undercompliance 0
, 0
depressive 0
mood 0
) 0
and 0
adjustment 0
were 0
examined 0
through 0
use 0
of 0
data 0
from 0
the 0
31 0
- 0
year 0
- 0
old 0
New 0
York 0
Longitudinal 0
Study 0
. 0

To 0
evaluate 0
the 0
effect 0
of 0
altitude 0
on 0
adolescent 0
growth 0
and 0
development 0
, 0
three 0
groups 0
of 0
healthy 0
, 0
well 0
- 0
nourished 0
youth 0
of 0
similar 0
socioeconomic 0
status 0
and 0
ethnic 0
grouping 0
who 0
resided 0
at 0
sea 0
level 0
( 0
n 0
= 0
1262 0
subjects 0
) 0
, 0
mid 0
- 0
altitude 0
( 0
n 0
= 0
1743 0
subjects 0
) 0
, 0
and 0
high 0
altitude 0
( 0
n 0
= 0
1137 0
subjects 0
) 0
were 0
studied 0
. 0

Because 0
the 0
CAP 0
measures 0
variables 0
predictive 0
of 0
abusive 0
behavior 0
, 0
a 0
substantial 0
relationship 0
was 0
expected 0
between 0
the 0
CAP 0
and 0
the 0
MHI 0
Loss 0
of 0
Behavioral/Emotional 0
Control 0
scale 0
. 0

We 0
have 0
improved 0
our 0
system 0
for 0
nuclear 0
contour 0
digitization 0
and 0
determined 0
its 0
theoretical 0
limitations 0
by 0
digitizing 0
standardized 0
objects 0
. 0

Such 0
a 0
change 0
may 0
involve 0
increased 0
mammary 0
utilization 0
of 0
pre 0
- 0
formed 0
long 0
- 0
chain 0
fatty 0
acid 0
and 0
increased 0
metabolism 0
of 0
glucose 0
via 0
glycolysis 0
. 0

The 0
skin 0
site 0
, 0
6 0
- 0
cm 0
- 0
distal 0
and 0
- 0
proximal 0
subcutaneous 0
segments 0
of 0
the 0
catheter 0
, 0
exudates 0
, 0
and 0
blood 0
were 0
cultured 0
. 0

Because 0
of 0
its 0
great 0
reliability 0
, 0
conventional 0
arteriography 0
occupies 0
a 0
place 0
of 0
choice 0
among 0
the 0
medical 0
imaging 0
techniques 0
. 0

Rapid 0
detection 0
of 0
radioisotopically 0
contaminated 0
test 0
serum 0
before 0
radioassay 0
of 0
vitamin 0
B12 0
. 0

The 0
former 0
group 0
did 0
excrete 0
less 0
dry 0
fecal 0
material 0
compared 0
to 0
both 0
other 0
groups 0
. 0

Electronic 0
data 0
processing 0
( 0
EDP 0
) 0
latex 0
immunoassay 0
using 0
anti B-gene
- I-gene
human I-gene
seminal I-gene
acid I-gene
phosphatase I-gene
( 0
anti B-gene
- I-gene
HSAP I-gene
) 0
immune 0
serum 0
was 0
applied 0
for 0
the 0
species 0
and 0
organ 0
identification 0
of 0
human 0
seminal 0
stains 0
. 0

Vimentin B-gene
positivity 0
was 0
noted 0
in 0
the 0
undifferentiated 0
and 0
fibroblastic 0
components 0
. 0

The 0
maximum 0
deflections 0
of 0
phase 0
IV 0
for 0
Ar 0
and 0
N2 0
from 0
extrapolated 0
phase 0
III 0
slopes 0
were 0
smaller 0
in 0
the 0
prone 0
position 0
, 0
suggesting 0
more 0
uniform 0
tracer 0
gas 0
concentrations 0
across 0
the 0
lungs 0
. 0

Recent 0
developments 0
in 0
drugs 0
antagonistic 0
to 0
factors 0
causing 0
peptic 0
ulcer 0
- 0
- 0
clinical 0
efficacy 0
and 0
problems 0
; 0
gastrin B-gene
receptor I-gene
blockaders 0

The 0
spermicide 0
nonoxynol 0
- 0
9 0
is 0
a 0
member 0
of 0
a 0
homologous 0
series 0
of 0
alkylphenol 0
- 0
ethoxylates 0
( 0
polyethoxyethanols 0
) 0
of 0
general 0
formula 0
C9H19 0
- 0
C6H6 0
- 0
O 0
- 0
( 0
CH2CH2O 0
) 0
n 0
- 0
1 0
CH2CH2OH 0
. 0

Static 0
magnetic 0
fields 0
affect 0
the 0
diffusion 0
of 0
biological 0
particles 0
in 0
solutions 0
through 0
the 0
Lorentz 0
force 0
and 0
Maxwell 0
stress 0
. 0

Psychological 0
disturbance 0
was 0
greater 0
in 0
the 0
high 0
life 0
stress 0
group 0
as 0
indicated 0
by 0
significant 0
elevations 0
on 0
the 0
global 0
severity 0
index 0
of 0
the 0
Symptom 0
Checklist 0
- 0
90 0
and 0
elevations 0
on 0
somatization 0
, 0
obsessive 0
compulsive 0
, 0
interpersonal 0
sensitivity 0
, 0
depression 0
, 0
anxiety 0
and 0
psychoticism 0
subscales 0
. 0

Chronic 0
administration 0
of 0
sodium 0
cyanate 0
decreases 0
O2 0
extraction 0
ratio 0
in 0
dogs 0
. 0

Nucleotide 0
sequencing 0
indicates 0
that 0
this 0
E1 B-gene
alpha I-gene
cDNA I-gene
clone 0
is 0
1821 0
base 0
pairs 0
( 0
bp 0
) 0
in 0
length 0
with 0
an 0
open 0
reading 0
frame 0
of 0
1365 0
bp 0
and 0
a 0
3' 0
- 0
untranslated 0
region 0
of 0
356 0
bp 0
. 0

SPA 0
from 0
PAG 0
sites 0
was 0
associated 0
with 0
aversion 0
. 0

In 0
contrast 0
, 0
the 0
MAN 0
showed 0
a 0
unimodal 0
, 0
skewed 0
distribution 0
, 0
with 0
a 0
range 0
from 0
approximately 0
1 0
to 0
14 0
micron 0
and 0
a 0
maximum 0
at 0
3 0
- 0
4 0
micron 0
. 0

Abnormal 0
technetium 0
Tc 0
99m 0
medronate 0
scans 0
in 0
patients 0
with 0
previously 0
undiagnosed 0
polyarthralgias 0
suggested 0
inflammatory 0
arthropathy 0
and 0
influenced 0
management 0
decisions 0
with 0
favorable 0
therapeutic 0
outcomes 0
. 0

Practical 0
interest 0
of 0
such 0
studies 0
is 0
limited 0
since 0
the 0
pharmacokinetic 0
parameters 0
are 0
systematically 0
evaluated 0
in 0
man 0
during 0
phase 0
I 0
trials 0
. 0

The 0
artery 0
cuff 0
was 0
slightly 0
superior 0
to 0
the 0
fat 0
wrap 0
, 0
particularly 0
in 0
having 0
fewer 0
adhesions 0
and 0
a 0
better 0
histological 0
picture 0
. 0

Lithium 0
- 0
carbonate 0
action 0
during 0
radiation 0
therapy 0
has 0
been 0
studied 0
, 0
valuing 0
the 0
positive 0
effect 0
on 0
leukopoiesis 0
and 0
the 0
consequent 0
better 0
clinical 0
conditions 0
of 0
the 0
patients 0
in 0
course 0
of 0
treatment 0
. 0

Of 0
the 0
53 0
units 0
tested 0
during 0
sinusoidal 0
motion 0
at 0
0.05 0
Hz 0
( 0
9.1 0
cm/s 0
) 0
, 0
1 0
( 0
1.9 0
% 0
) 0
was 0
responsive 0
to 0
the 0
otolith 0
input 0
only 0
, 0
13 0
( 0
24.5 0
% 0
) 0
were 0
influenced 0
by 0
the 0
visual 0
input 0
only 0
and 0
23 0
( 0
43.4 0
% 0
) 0
responded 0
to 0
both 0
modalities 0
. 0

Depending 0
on 0
the 0
location 0
and 0
size 0
of 0
the 0
mass 0
, 0
a 0
wide 0
range 0
of 0
clinical 0
presentations 0
is 0
associated 0
with 0
the 0
lesion 0
. 0

The 0
development 0
and 0
distribution 0
of 0
Trypanosoma 0
congolense 0
, 0
T 0
vivax 0
and 0
T 0
brucei 0
in 0
the 0
skin 0
of 0
goats 0
was 0
examined 0
after 0
the 0
animals 0
were 0
bitten 0
by 0
infected 0
Glossina 0
morsitans 0
centralis 0
. 0

Electroglottography 0
is 0
a 0
useful 0
, 0
non 0
- 0
invasive 0
technique 0
that 0
can 0
assist 0
in 0
the 0
assessment 0
of 0
vocal 0
fold 0
dysfunction 0
. 0

Statistical 0
analysis 0
of 0
the 0
degrees 0
of 0
secondary 0
spinal 0
cord 0
compression 0
was 0
performed 0
in 0
group 0
- 0
1 0
dogs 0
by 0
measuring 0
and 0
comparing 0
ratios 0
of 0
the 0
vertical 0
to 0
the 0
horizontal 0
diameters 0
of 0
the 0
transverse 0
spinal 0
cord 0
sections 0
from 0
locations 0
within 0
( 0
T12 0
to 0
L1 0
) 0
and 0
out 0
of 0
( 0
T11 0
, 0
T11 0
- 0
12 0
, 0
L1 0
- 0
2 0
, 0
and 0
L2 0
) 0
the 0
region 0
of 0
surgical 0
intervention 0
. 0

The 0
pharmacological 0
effects 0
of 0
the 0
novel 0
compound 0
WEB 0
1881 0
FU 0
( 0
4 0
- 0
amino 0
- 0
methyl 0
- 0
1 0
- 0
benzyl 0
- 0
pyrrolidine 0
- 0
2 0
- 0
one 0
- 0
fumarate 0
) 0
were 0
investigated 0
. 0

Histopathological 0
examination 0
revealed 0
dose 0
- 0
related 0
proliferation 0
of 0
type 0
II 0
pneumocytes 0
in 0
dams 0
and 0
proliferation 0
of 0
interstitial 0
cells 0
and 0
delayed 0
septal/capillary 0
development 0
in 0
neonates 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

So 0
far 0
no 0
problems 0
with 0
multiply 0
resistant 0
strains 0
have 0
developed 0
. 0

During 0
the 0
observation 0
period 0
of 0
0.4 0
- 0
30 0
weeks 0
, 0
cardiac 0
white 0
spots 0
on 0
the 0
right 0
ventricle 0
of 0
BALB/c 0
mice 0
were 0
first 0
detected 0
at 0
three 0
weeks 0
( 0
6 0
of 0
20 0
mice 0
; 0
30 0
% 0
) 0
, 0
and 0
the 0
maximal 0
incidence 0
of 0
cardiac 0
white 0
spots 0
was 0
obtained 0
at 0
nine 0
weeks 0
( 0
39 0
of 0
44 0
mice 0
; 0
88 0
% 0
) 0
. 0

The 0
state 0
of 0
the 0
liver 0
in 0
generalized 0
forms 0
of 0
meningococcal 0
infection 0

Increasing 0
the 0
RH 0
beyond 0
32 0
% 0
resulted 0
in 0
solvation 0
of 0
the 0
peroxy 0
radical 0
, 0
sterically 0
hindering 0
the 0
radical 0
from 0
entering 0
the 0
propagation 0
transition 0
state 0
. 0

The 0
effects 0
produced 0
by 0
oral 0
administration 0
of 0
500 0
mg/kg 0
p 0
- 0
xylene 0
or 0
toluene 0
lasted 0
at 0
least 0
8 0
hr 0
, 0
while 0
the 0
effect 0
of 0
inhaled 0
p 0
- 0
xylene 0
dissipated 0
within 0
75 0
min 0
of 0
removal 0
from 0
the 0
exposure 0
. 0

PATIENTS 0
and 0
METHODS 0
: 0
Thallium 0
- 0
201 0
myocardial 0
scintigraphy 0
was 0
performed 0
at 0
rest 0
and 0
after 0
0.56 0
mg/kg 0
intravenous 0
dipyridamole 0
during 0
four 0
minutes 0
in 0
16 0
patients 0
with 0
sarcoidosis 0
. 0

Thin 0
melanomas 0
can 0
metastasize 0
and 0
be 0
lethal 0
. 0

The 0
TA 0
muscle 0
was 0
fatigued 0
by 0
four 0
forms 0
of 0
repeated 0
isometric 0
contractions 0
: 0
( 0
1 0
) 0
maximal 0
voluntary 0
contractions 0
( 0
MVC 0
) 0
, 0
( 0
2 0
) 0
MVC 0
with 0
circulation 0
occluded 0
, 0
( 0
3 0
) 0
electrically 0
evoked 0
contractions 0
with 0
20 0
Hz 0
supramaximal 0
voltage 0
stimulation 0
and 0
( 0
4 0
) 0
electrically 0
evoked 0
contractions 0
with 0
circulation 0
occluded 0
. 0

The 0
actuarial 0
local 0
control 0
rates 0
at 0
10 0
years 0
for 0
the 0
three 0
treatment 0
groups 0
were 0
as 0
follows 0
: 0
subtotal 0
excision 0
alone 0
, 0
18 0
% 0
; 0
subtotal 0
excision 0
plus 0
postoperative 0
radiation 0
therapy 0
, 0
82 0
% 0
; 0
and 0
total 0
excision 0
alone 0
, 0
77 0
% 0
. 0

The 0
effects 0
of 0
anabolic 0
implants 0
on 0
rate 0
, 0
composition 0
and 0
energetic 0
efficiency 0
of 0
growth 0
were 0
determined 0
in 0
steers 0
fed 0
diets 0
varying 0
in 0
forage 0
and 0
grain 0
content 0
. 0

Prolonged 0
suspension 0
induced 0
a 0
significant 0
change 0
in 0
the 0
geometric 0
configuration 0
of 0
the 0
femur 0
middiaphysis 0
by 0
increasing 0
the 0
minimum 0
diameter 0
( 0
12 0
% 0
) 0
without 0
any 0
significant 0
alterations 0
in 0
cortical 0
area 0
, 0
density 0
, 0
mineral 0
, 0
and 0
collagen B-gene
concentrations 0
. 0

Which 0
cineangiographically 0
assessed 0
anatomic 0
variable 0
correlates 0
best 0
with 0
functional 0
measurements 0
of 0
stenosis 0
severity 0
? 0
A 0
comparison 0
of 0
quantitative 0
analysis 0
of 0
the 0
coronary 0
cineangiogram 0
with 0
measured 0
coronary 0
flow 0
reserve 0
and 0
exercise/redistribution 0
thallium 0
- 0
201 0
scintigraphy 0
. 0

Water 0
content 0
and 0
equilibrium 0
water 0
partition 0
in 0
immature 0
cartilage 0
. 0

Thyroid 0
function 0
tests 0
were 0
performed 0
on 0
300 0
admissions 0
, 0
leaving 0
707 0
untested 0
. 0

Data 0
on 0
the 0
line 0
spread 0
function 0
( 0
LSF 0
) 0
were 0
obtained 0
from 0
the 0
image 0
of 0
a 0
0.2 0
mm 0
wide 0
slit 0
between 0
tungsten 0
blocks 0
that 0
were 0
positioned 0
at 0
the 0
isocentre 0
in 0
front 0
of 0
a 0
polystyrene 0
phantom 0
. 0

Primary 0
infection 0
is 0
usually 0
managed 0
conservatively 0
. 0

Papers 0
of 0
the 0
Society 0
for 0
Clinical 0
Vascular 0
Surgery 0
. 0

Ischemic 0
heart 0
disease 0
, 0
age 0
of 0
more 0
than 0
75 0
years 0
, 0
and 0
the 0
fact 0
that 0
the 0
patient 0
was 0
a 0
woman 0
were 0
independent 0
predictors 0
of 0
poor 0
cardiac 0
function 0
. 0

Prognosis 0
in 0
Bowen 0
's 0
disease 0
localized 0
to 0
the 0
ano 0
- 0
genital 0
region 0
. 0

Taken 0
together 0
, 0
the 0
results 0
suggest 0
that 0
chlorphentermine 0
may 0
be 0
capable 0
of 0
producing 0
dual 0
stimulus 0
effects 0
in 0
animals 0
. 0

Liquid 0
chromatographic 0
method 0
for 0
determination 0
of 0
citreoviridin 0
in 0
corn 0
and 0
rice 0
. 0

These 0
findings 0
indicate 0
that 0
autophosphorylation 0
of 0
Thr286 0
( 0
alpha 0
subunit 0
) 0
and 0
Thr287 0
( 0
beta 0
subunit 0
) 0
is 0
responsible 0
for 0
transition 0
of 0
CaM B-gene
- I-gene
kinase I-gene
II I-gene
to 0
the 0
Ca2+ 0
- 0
independent 0
form 0
. 0

This 0
rapid 0
and 0
extensive 0
penetration 0
of 0
intrathecally 0
administered 0
chemotherapy 0
may 0
offer 0
insight 0
into 0
the 0
myelopathy 0
observed 0
with 0
these 0
treatments 0
. 0

The 0
interaction 0
of 0
radiation 0
and 0
hyperthermia 0
was 0
systematically 0
studied 0
in 0
the 0
Dunning 0
R3327G 0
prostatic 0
adenocarcinoma 0
, 0
the 0
preeminent 0
animal 0
model 0
for 0
human 0
prostatic 0
cancer 0
. 0

Pregnant 0
rats 0
were 0
exposed 0
to 0
one 0
of 0
the 0
following 0
: 0
( 0
1 0
) 0
10 0
% 0
O2 0
in 0
N2 0
or 0
100 0
% 0
O2 0
for 0
2 0
days 0
beginning 0
at 0
day 0
7 0
, 0
11 0
, 0
14 0
, 0
or 0
18 0
of 0
pregnancy 0
; 0
( 0
2 0
) 0
10 0
% 0
O2 0
in 0
N2 0
or 0
100 0
% 0
O2 0
for 0
10 0
h/day 0
beginning 0
at 0
day 0
7 0
; 0
or 0
( 0
3 0
) 0
14 0
- 0
11 0
% 0
O2 0
in 0
N2 0
continuously 0
beginning 0
at 0
day 0
14 0
till 0
day 0
21 0
when 0
they 0
were 0
sacrificed 0
. 0

The 0
incidence 0
of 0
cryptosporidiosis 0
in 0
young 0
children 0
was 0
determined 0
by 0
staining 0
of 0
faecal 0
specimens 0
with 0
a 0
modified 0
Kinyoun 0
stain 0
. 0

Seven 0
patients 0
( 0
8.3 0
percent 0
) 0
had 0
latent 0
hypothyroidism 0
only 0
discovered 0
by 0
hormonal 0
determinations 0
. 0

Addition 0
of 0
sucralfate 0
or 0
De 0
- 0
Nol 0
resulted 0
in 0
increments 0
of 0
gastric 0
HCO3 0
secretion 0
, 0
reaching 0
about 0
45 0
% 0
and 0
59 0
% 0
, 0
respectively 0
, 0
of 0
the 0
maximal 0
HCO3 0
response 0
to 0
16,16 0
- 0
dimethyl 0
PGE2 0
( 0
dmPGE2 0
) 0
. 0

Moreover 0
, 0
unlike 0
control 0
rats 0
operated 0
animals 0
did 0
not 0
show 0
aversion 0
to 0
the 0
highest 0
concentrations 0
of 0
saccharin 0
solutions 0
. 0

In 0
Salmo 0
gairdneri 0
, 0
no 0
specialized 0
system 0
of 0
portal 0
vessels 0
appears 0
to 0
exist 0
between 0
the 0
pineal 0
organ 0
and 0
other 0
portions 0
of 0
the 0
brain 0
. 0

The 0
4 0
degrees 0
stimuli 0
were 0
found 0
to 0
elicit 0
scalp 0
distributions 0
for 0
the 0
pattern 0
reversal 0
P100 0
and 0
the 0
pattern 0
onset 0
C1 0
consistent 0
with 0
striate 0
and 0
extrastriate 0
visual 0
cortical 0
origins 0
respectively 0
. 0

Nuclear B-gene
factor I-gene
III I-gene
( 0
NFIII B-gene
) 0
is 0
a 0
protein 0
from 0
HeLa 0
cells 0
that 0
stimulates 0
the 0
initiation 0
of 0
adenovirus 0
type 0
2 0
( 0
Ad2 0
) 0
DNA 0
replication 0
by 0
binding 0
to 0
a 0
specific 0
nucleotide 0
sequence 0
in 0
the 0
origin 0
, 0
adjacent 0
to 0
the 0
nuclear B-gene
factor I-gene
I I-gene
recognition I-gene
site I-gene
. 0

A 0
Golgi 0
study 0
of 0
the 0
sixth 0
layer 0
of 0
the 0
cerebral 0
cortex 0
. 0

We 0
conclude 0
that 0
cephalothin 0
clearance 0
of 0
S. 0
aureus 0
from 0
a 0
site 0
accessible 0
to 0
phagocytes 0
was 0
delayed 0
when 0
compared 0
to 0
a 0
phagocyte 0
- 0
inaccessible 0
site 0
. 0

The 0
findings 0
are 0
discussed 0
in 0
the 0
context 0
of 0
known 0
properties 0
of 0
cortical 0
- 0
bar 0
detectors 0
. 0

Mean 0
rCBF 0
increased 0
in 0
some 0
patients 0
4 0
- 0
8 0
weeks 0
after 0
surgery 0
on 0
the 0
ipsilateral 0
side 0
. 0

Quantitative 0
computed 0
tomography 0
for 0
measuring 0
vertebral 0
bone 0
mineral 0
content 0
offers 0
high 0
sensitivity 0
and 0
reproducibility 0
. 0

The 0
structure 0
of 0
the 0
enhancer 0
was 0
also 0
probed 0
by 0
inserting 0
a 0
pair 0
of 0
complementary 0
synthetic 0
oligodeoxynucleotides 0
which 0
represented 0
the 0
region 0
between 0
nt 0
positions 0
- 0
235 0
and 0
- 0
215 0
into 0
a 0
truncated 0
template 0
which 0
lacked 0
the 0
enhancer 0
. 0

Kf 0
, 0
c 0
and 0
CT 0
( 0
referenced 0
to 0
the 0
initial 0
lung 0
mass 0
) 0
decreased 0
linearly 0
with 0
reductions 0
in 0
lung 0
mass 0
% 0
delta 0
Kf 0
, 0
c 0
= 0
1.26 0
- 0
0.98 0
% 0
mass 0
removed 0
( 0
r 0
= 0
0.90 0
, 0
P 0
less 0
than 0
0.01 0
) 0
and 0
% 0
delta 0
CT 0
= 0
- 0
3.99 0
- 0
0.98 0
% 0
mass 0
removed 0
( 0
r 0
= 0
0.82 0
, 0
P 0
less 0
than 0
0.01 0
) 0
relationships 0
that 0
were 0
not 0
altered 0
by 0
blocker 0
pretreatment 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Two 0
scintigraphic 0
methods 0
, 0
resting 0
dipyridamole 0
and 0
exercise 0
thallium 0
- 0
201 0
myocardial 0
perfusion 0
imaging 0
, 0
to 0
detect 0
and 0
localize 0
coronary 0
artery 0
stenosis 0
were 0
compared 0
in 0
32 0
patients 0
suffering 0
from 0
coronary 0
artery 0
disease 0
. 0

From 0
these 0
results 0
, 0
it 0
is 0
concluded 0
that 0
EDLF 0
has 0
clear 0
vasoconstrictor 0
properties 0
which 0
are 0
not 0
due 0
to 0
adrenergic 0
or 0
calcium 0
entry 0
mechanisms 0
and 0
that 0
there 0
are 0
differences 0
in 0
the 0
vasoconstrictor 0
effects 0
of 0
EDLFs 0
with 0
respect 0
to 0
different 0
vascular 0
beds 0
. 0

Research 0
was 0
carried 0
out 0
on 0
the 0
rheumatoid B-gene
factors I-gene
in 0
the 0
serum 0
of 0
917 0
patients 0
by 0
means 0
of 0
two 0
tests 0
( 0
one 0
using 0
polystyrene 0
and 0
one 0
with 0
erythrocytes 0
) 0
and 0
the 0
results 0
obtained 0
were 0
compared 0
using 0
a 0
method 0
of 0
reference 0
. 0

A 0
low 0
aspirin B-gene
esterase I-gene
activity 0
may 0
be 0
a 0
contributory 0
factor 0
in 0
precipitating 0
these 0
aspirin 0
sensitive 0
reactions 0
. 0

In 0
both 0
experiments 0
, 0
average 0
daily 0
gain 0
and 0
gain 0
- 0
to 0
- 0
feed 0
ratio 0
were 0
similar 0
for 0
TR 0
and 0
CR 0
. 0

Overall 0
least 0
- 0
squares 0
means 0
for 0
uncooked 0
and 0
cooked 0
longissimus 0
muscle 0
and 0
subcutaneous 0
fat 0
were 0
63.32 0
, 0
80.27 0
and 0
98.90 0
mg 0
of 0
cholesterol/100 0
g 0
of 0
tissue 0
, 0
respectively 0
. 0

The 0
role 0
of 0
supercritical 0
fluid 0
chromatography 0
( 0
SFC 0
) 0
as 0
a 0
viable 0
technique 0
for 0
analyzing 0
agricultural 0
products 0
has 0
been 0
investigated 0
using 0
packed 0
and 0
capillary 0
column 0
methodology 0
. 0

Nitrofurazone 0
significantly 0
reduced 0
the 0
rise 0
in 0
LH B-gene
induced 0
by 0
LHRH B-gene
. 0

Ovarian 0
tumors 0
in 0
pregnancy 0
. 0

Ultrastructural 0
study 0
of 0
polyarteritis 0

X2 0
test 0
, 0
with 0
Yates 0
correction 0
if 0
need 0
, 0
was 0
used 0
as 0
statistical 0
. 0
method 0
. 0

After 0
a 0
baseline 0
study 0
, 0
WPW 0
syndrome 0
was 0
simulated 0
by 0
stimulation 0
at 0
seven 0
different 0
sites 0
around 0
the 0
base 0
of 0
the 0
ventricles 0
, 0
and 0
RNV 0
's 0
were 0
obtained 0
. 0

Man 0
and 0
insect 0
, 0
past 0
, 0
present 0
, 0
future 0

All 0
patients 0
had 0
the 0
CA B-gene
125 I-gene
assay 0
performed 0
within 0
one 0
week 0
before 0
their 0
second 0
- 0
look 0
operation 0
. 0

Allergy 0
and 0
Tourette 0
's 0
syndrome 0
. 0

The 0
criterion 0
was 0
reached 0
after 0
two 0
sessions 0
and 0
generalization 0
to 0
a 0
variety 0
of 0
pills 0
and 0
capsules 0
occurred 0
. 0

Clinical 0
method 0
for 0
the 0
treatment 0
of 0
Class 0
II 0
occlusal 0
anomalies 0
with 0
open 0
bite 0

Enoxacin 0
appears 0
to 0
be 0
well 0
suited 0
for 0
the 0
treatment 0
of 0
complicated 0
UTI 0
. 0

Mean 0
fluorosis 0
scores 0
, 0
however 0
, 0
were 0
similar 0
. 0

Autonomic 0
dysfunctions 0
were 0
restricted 0
to 0
tonic 0
pupils 0
. 0

An 0
industry 0
- 0
wide 0
retrospective 0
cohort 0
mortality 0
study 0
was 0
conducted 0
on 0
6,152 0
chemical 0
workers 0
( 0
2,460 0
exposed 0
and 0
3,692 0
nonexposed 0
) 0
engaged 0
in 0
chloromethyl 0
ether 0
manufacture 0
at 0
7 0
major 0
U.S. 0
companies 0
between 0
1948 0
and 0
1980 0
. 0

The 0
diagnosis 0
of 0
amyloidosis 0
was 0
determined 0
from 0
a 0
labial 0
salivary 0
gland 0
biopsy 0
. 0

Hair 0
and 0
blood 0
samples 0
were 0
taken 0
before 0
vitamin 0
C 0
or 0
placebo 0
supplementation 0
was 0
started 0
and 0
at 0
monthly 0
intervals 0
thereafter 0
for 0
three 0
months 0
. 0

In 0
treated 0
herds 0
, 0
cows 0
more 0
than 0
40 0
d 0
postpartum 0
with 0
a 0
corpus 0
luteum 0
received 0
prostaglandin 0
F2 0
alpha 0
. 0

On 0
the 0
other 0
hand 0
, 0
if 0
the 0
measured 0
angle 0
ANB 0
is 0
smaller 0
than 0
the 0
calculated 0
angle 0
, 0
the 0
skeletal 0
relation 0
is 0
Class 0
III 0
. 0

Emergency 0
treatment 0
of 0
facial 0
and 0
maxillary/mandibular 0
injuries 0

In 0
14 0
cases 0
, 0
isolates 0
were 0
biotyped 0
yielding 0
eight 0
with 0
biotype 0
II 0
, 0
four 0
with 0
biotype 0
III 0
, 0
and 0
one 0
each 0
with 0
biotypes 0
IV 0
and 0
V 0
. 0

A 0
total 0
of 0
117 0
EVS 0
treatments 0
were 0
performed 0
on 0
34 0
patients 0
. 0

Most 0
of 0
the 0
prepeptide 0
portion 0
of 0
the 0
precursor 0
polypeptide 0
is 0
encoded 0
by 0
the 0
next 0
three 0
exons 0
, 0
and 0
the 0
mature 0
form 0
of 0
IL B-gene
- I-gene
1 I-gene
alpha I-gene
is 0
encoded 0
by 0
the 0
remaining 0
three 0
exons 0
. 0

A 0
stochastic 0
version 0
of 0
Kernell 0
's 0
( 0
1968 0
, 0
1972 0
) 0
model 0
with 0
cumulative 0
afterhyperpolarization 0
( 0
AHP 0
) 0
was 0
simulated 0
. 0

In 0
a 0
previous 0
interim 0
report 0
we 0
noted 0
more 0
prompt 0
resolution 0
of 0
dermatomal 0
signs 0
and 0
symptoms 0
with 0
acyclovir 0
treatment 0
. 0

The 0
detectability 0
of 0
the 0
defects 0
in 0
RCA 0
or 0
LAD 0
region 0
was 0
80 0
% 0
in 0
single 0
- 0
position 0
scans 0
in 0
stress 0
studies 0
. 0

Pharmacologic 0
properties 0
of 0
serotonergic 0
agents 0
and 0
antidepressant 0
drugs 0
. 0

This 0
brief 0
hypercapnic 0
challenge 0
induced 0
a 0
rapid 0
increase 0
in 0
CBF 0
in 0
the 0
absence 0
of 0
any 0
change 0
in 0
MABP 0
. 0

These 0
data 0
should 0
be 0
useful 0
in 0
developing 0
reagents 0
for 0
heterozygote 0
detection 0
and 0
prenatal 0
diagnosis 0
of 0
11 B-gene
beta I-gene
- I-gene
hydroxylase I-gene
deficiency 0
, 0
the 0
second 0
most 0
frequent 0
cause 0
of 0
congenital 0
adrenal 0
hyperplasia 0
. 0

Osteocalcin B-gene
( 0
serum B-gene
bone I-gene
- I-gene
Gla I-gene
protein I-gene
, 0
sBGP B-gene
) 0
, 0
serum B-gene
alkaline I-gene
phosphatase I-gene
( 0
sAP B-gene
) 0
and 0
urinary 0
hydroxyproline/creatinine 0
ratio 0
( 0
uOH 0
- 0
Prol/creatinine 0
) 0
have 0
been 0
measured 0
in 0
21 0
patients 0
with 0
primary 0
hyperparathyroidism 0
( 0
PHPT 0
) 0
and 0
in 0
nine 0
patients 0
with 0
hypercalcaemia 0
of 0
malignancy 0
( 0
HM 0
) 0
. 0

Multivariate 0
logistic 0
regression 0
analysis 0
indicated 0
that 0
seropositivity 0
was 0
strongly 0
associated 0
with 0
the 0
prevalence 0
of 0
hepatitis 0
B 0
in 0
an 0
employee 0
's 0
country 0
of 0
birth 0
and 0
with 0
age 0
. 0

Hexsyn 0
is 0
the 0
Goodyear 0
Tire 0
and 0
Rubber 0
Company 0
tradename 0
for 0
a 0
polyolefin 0
rubber 0
synthesized 0
from 0
1 0
- 0
hexene 0
with 0
3 0
- 0
5 0
% 0
methylhexadiene 0
as 0
the 0
source 0
of 0
residual 0
double 0
bonds 0
for 0
vulcanization 0
. 0

Chimeric 0
phage 0
- 0
plasmid 0
expression 0
vectors 0
were 0
constructed 0
from 0
pUC18/19 0
plasmids 0
by 0
cloning 0
a 0
single 0
- 0
stranded 0
DNA 0
( 0
ssDNA 0
) 0
origin 0
of 0
replication 0
from 0
bacteriophage 0
f1 0
and 0
inserting 0
a 0
bacteriophage 0
T7 0
promoter 0
within 0
the 0
beta B-gene
- I-gene
galactosidase I-gene
gene I-gene
. 0

By 0
order 0
of 0
decreasing 0
rate 0
, 0
finger 0
flexors 0
, 0
jaw 0
, 0
crossed 0
adductors 0
, 0
and 0
triceps 0
reflexes 0
were 0
less 0
frequently 0
elicited 0
in 0
both 0
groups 0
. 0

Natl 0
. 0

Neither 0
ethanol 0
nor 0
estrogen 0
has 0
been 0
shown 0
to 0
cause 0
UROD B-gene
- 0
deficiency 0
in 0
animals 0
. 0

Although 0
not 0
common 0
, 0
the 0
disorder 0
is 0
the 0
most 0
frequently 0
diagnosed 0
disturbance 0
of 0
porphyrin 0
metabolism 0
in 0
many 0
countries 0
, 0
and 0
further 0
insight 0
into 0
its 0
unusual 0
pathogenesis 0
may 0
clarify 0
the 0
hepatotoxic 0
effects 0
of 0
the 0
4 0
etiologic 0
agents 0
. 0

Five 0
out 0
of 0
eight 0
consecutive 0
cases 0
with 0
initial 0
symptoms 0
of 0
a 0
'midline 0
granuloma 0
' 0
were 0
identified 0
as 0
malignant 0
histiocytosis 0
( 0
histiocytic 0
sarcoma 0
) 0
which 0
within 0
5 0
months 0
to 0
4 0
years 0
led 0
to 0
generalization 0
and 0
death 0
. 0

All 0
patients 0
then 0
received 0
suxamethonium 0
1.5 0
mg 0
kg 0
- 0
1 0
i.v 0
. 0

The 0
highest 0
postoperative 0
CK B-gene
- I-gene
MB I-gene
level 0
was 0
less 0
after 0
BC 0
( 0
BC 0
, 0
31 0
+/ 0
- 0
17 0
U/L 0
; 0
CC 0
, 0
56 0
+/ 0
- 0
13 0
U/L 0
; 0
p 0
less 0
than 0
0.05 0
) 0
. 0

No 0
relevant 0
changes 0
in 0
heart 0
rate 0
, 0
body 0
weight 0
, 0
and 0
plasma 0
levels 0
of 0
renin B-gene
activity 0
and 0
aldosterone 0
concentration 0
were 0
observed 0
. 0

High 0
trough 0
serum 0
TOB 0
concentrations 0
were 0
associated 0
with 0
death 0
and 0
very 0
low 0
levels 0
with 0
recovery 0
. 0

State 0
- 0
approved 0
schools 0
of 0
nursing 0
R.N 0
. 0

In 0
a 0
maxicell 0
system 0
a 0
protein 0
with 0
an 0
approximate 0
molecular 0
weight 0
of 0
36,000 0
was 0
synthesized 0
. 0

This 0
means 0
that 0
the 0
loss 0
of 0
recessives 0
must 0
be 0
calculated 0
by 0
using 0
a 0
hypergeometric 0
and 0
not 0
a 0
binomial 0
model 0
as 0
Fisher 0
did 0
. 0

The 0
incidence 0
of 0
second 0
malignant 0
neoplasms 0
was 0
lower 0
( 0
1.3 0
% 0
) 0
in 0
the 0
group 0
treated 0
with 0
5 0
- 0
fluorouracil 0
, 0
doxorubicin 0
, 0
and 0
cyclophosphamide 0
than 0
in 0
the 0
historical 0
control 0
group 0
( 0
4.8 0
% 0
) 0
. 0

Ovulation 0
was 0
induced 0
in 0
8 0
( 0
56.7 0
% 0
) 0
patients 0
who 0
conceived 0
. 0

In 0
previous 0
work 0
( 0
E 0
. 0

The 0
small 0
size 0
and 0
placement 0
of 0
the 0
mutagenesis 0
marker 0
( 0
the 0
supF B-gene
suppressor I-gene
tRNA I-gene
gene I-gene
from I-gene
Escherichia I-gene
coli I-gene
) 0
within 0
the 0
vector 0
substantially 0
reduced 0
the 0
frequency 0
of 0
spontaneous 0
mutations 0
normally 0
observed 0
after 0
transfection 0
of 0
mammalian 0
cells 0
with 0
plasmid 0
DNA 0
; 0
hence 0
, 0
UV 0
- 0
induced 0
mutations 0
were 0
easily 0
identified 0
above 0
the 0
spontaneous 0
background 0
. 0

W 0
. 0

Tetrad 0
analysis 0
and 0
mitotic 0
recombination 0
experiments 0
localized 0
the 0
PEP4 B-gene
gene I-gene
proximal 0
to 0
GAL4 B-gene
on 0
chromosome 0
XVI 0
. 0

Based 0
on 0
our 0
observations 0
, 0
we 0
propose 0
a 0
model 0
whereby 0
inactive 0
precursor 0
molecules 0
produced 0
from 0
the 0
PEP4 B-gene
gene I-gene
self 0
- 0
activate 0
within 0
the 0
yeast 0
vacuole 0
and 0
subsequently 0
activate 0
other 0
vacuolar B-gene
hydrolases I-gene
. 0

The 0
poly 0
( 0
A 0
) 0
segment 0
of 0
the 0
RNA 0
was 0
selectively 0
cross 0
- 0
linked 0
to 0
the 0
72,000 0
- 0
molecular 0
- 0
weight 0
protein 0
( 0
72K 0
protein 0
) 0
. 0

In 0
vitro 0
translation 0
of 0
RNA 0
synthesized 0
from 0
the 0
cloned 0
cDNAs 0
predicts 0
that 0
P0 B-gene
transcripts I-gene
are 0
translated 0
into 0
a 0
novel 0
12.5 0
- 0
kilodalton 0
protein 0
corresponding 0
to 0
the 0
first 0
open 0
reading 0
frame 0
. 0

The 0
N 0
- 0
terminal 0
amino 0
acid 0
sequence 0
of 0
Mop B-gene
has 0
sequence 0
homology 0
with 0
DNA 0
binding 0
proteins 0
. 0

Several 0
new 0
techniques 0
are 0
available 0
for 0
monitoring 0
control 0
of 0
diabetes 0
. 0

Ciprofloxacin 0
: 0
an 0
overview 0
of 0
adverse 0
experiences 0
. 0

Possible 0
pathogenetic 0
mechanisms 0
of 0
hemopoietic 0
changes 0
in 0
response 0
to 0
space 0
flight 0
effects 0
are 0
described 0
. 0

The 0
rho B-gene
genes I-gene
comprise 0
an 0
evolutionarily 0
conserved 0
family 0
with 0
significant 0
homology 0
to 0
the 0
ras B-gene
oncogene I-gene
family I-gene
. 0

Also 0
, 0
component 0
I 0
significantly 0
correlated 0
with 0
fasting 0
insulin B-gene
and 0
VO2 0
max 0
for 0
both 0
sexes 0
and 0
with 0
basal 0
metabolism 0
and 0
HDL B-gene
- I-gene
cholesterol I-gene
for 0
females 0
and 0
males 0
, 0
respectively 0
. 0

The 0
glucose 0
areas 0
following 0
the 0
ingestion 0
of 0
the 0
foods 0
were 0
: 0
Study 0
1 0
: 0
glucose 0
11.7 0
, 0
orange 0
juice 0
7.3 0
, 0
sucrose 0
5.2 0
, 0
glucose 0
+ 0
fructose 0
6.3 0
, 0
and 0
fructose 0
0.7 0
mmol 0
X 0
h/l 0
; 0
Study 0
2 0
: 0
glucose 0
14.6 0
, 0
orange 0
juice 0
7.3 0
, 0
apples 0
5.5 0
, 0
and 0
apple 0
juice 0
4.7 0
mmol 0
X 0
h/l 0
; 0
Study 0
3 0
: 0
glucose 0
12.6 0
, 0
ice 0
cream 0
8.1 0
, 0
milk 0
3.7 0
, 0
and 0
lactose 0
4.1 0
mmol 0
X 0
h/l 0
. 0

The 0
serum B-gene
insulin I-gene
response 0
can 0
not 0
. 0

SCL 0
prolonged 0
promptly 0
after 0
verapamil 0
, 0
and 0
sinus 0
arrest 0
developed 0
in 0
two 0
of 0
10 0
group 0
2 0
and 0
two 0
of 0
five 0
group 0
3 0
animals 0
. 0

Development 0
of 0
a 0
yeast 0
system 0
to 0
assay 0
mutational 0
specificity 0
. 0

Postglucose 0
serum B-gene
insulin I-gene
levels 0
showed 0
no 0
significant 0
correlations 0
with 0
systolic 0
or 0
diastolic 0
blood 0
pressure 0
levels 0
in 0
men 0
, 0
but 0
in 0
female 0
diabetic 0
and 0
non 0
- 0
diabetic 0
subjects 0
significant 0
correlations 0
were 0
found 0
in 0
particular 0
with 0
systolic 0
blood 0
pressure 0
level 0
. 0

We 0
used 0
oligonucleotide 0
- 0
directed 0
mutagenesis 0
to 0
alter 0
a 0
site 0
in 0
MucA B-gene
homologous 0
to 0
the 0
Ala 0
- 0
Gly 0
cleavage 0
site 0
of 0
LexA B-gene
. 0

The 0
latter 0
was 0
determined 0
as 0
follows 0
: 0
Type 0
I 0
- 0
solid 0
tumor 0
tissue 0
without 0
significant 0
peripheral 0
isolated 0
tumor 0
cells 0
; 0
Type 0
II 0
- 0
solid 0
tumor 0
tissue 0
associated 0
with 0
peripheral 0
isolated 0
tumor 0
cells 0
; 0
Type 0
III 0
- 0
isolated 0
tumor 0
cells 0
only 0
. 0

The 0
pharmacology 0
of 0
carnitine 0
. 0

Acute 0
inhalation 0
toxicity 0
of 0
T 0
- 0
2 0
mycotoxin 0
in 0
mice 0
. 0

The 0
present 0
investigation 0
sought 0
to 0
identify 0
the 0
principal 0
dimensions 0
of 0
the 0
Framingham 0
Type 0
A 0
scale 0
( 0
FTAS 0
) 0
and 0
then 0
to 0
examine 0
their 0
physiological 0
and 0
psychological 0
correlates 0
. 0

A 0
preliminary 0
study 0
on 0
pyogenic 0
arthritis 0
. 0

Legionella 0
, 0
microbial 0
ecology 0
, 0
and 0
inconspicuous 0
consumption 0
. 0

Lymphatics 0
in 0
the 0
aorta 0
of 0
rats 0
treated 0
with 0
a 0
soy 0
- 0
bean 0
oil 0
extract 0
( 0
lipofundin 0
) 0
. 0

As 0
a 0
last 0
resort 0
, 0
it 0
may 0
be 0
possible 0
to 0
maintain 0
a 0
patient 0
on 0
dialysis 0
in 0
reasonable 0
health 0
with 0
a 0
DiaTAP 0
button 0
graft 0
complex 0
infected 0
with 0
Staphylococcus 0
epidermidis 0
and 0
intermittent 0
positive 0
blood 0
cultures 0
using 0
long 0
term 0
vancomycin 0
therapy 0
. 0

For 0
signal 0
durations 0
less 0
than 0
10 0
ms 0
, 0
however 0
, 0
the 0
SoNo 0
and 0
S 0
pi 0
No 0
threshold 0
functions 0
converged 0
and 0
the 0
masking 0
- 0
level 0
difference 0
decreased 0
. 0

The 0
spleen 0
rate 0
of 0
about 0
600 0
villagers 0
of 0
RK 0
I 0
examined 0
was 0
54.3 0
% 0
and 0
the 0
parasite 0
rate 0
13.2 0
% 0
before 0
the 0
drug 0
intervention 0
. 0

Multiple 0
dosing 0
four 0
times 0
daily 0
for 0
7 0
days 0
of 0
indoprofen 0
200 0
mg 0
, 0
a 0
non 0
- 0
steroidal 0
anti 0
- 0
inflammatory 0
drug 0
with 0
a 0
short 0
half 0
- 0
life 0
( 0
t1/2 0
) 0
, 0
revealed 0
drug 0
accumulation 0
in 0
eight 0
elderly 0
subjects 0
. 0

In 0
10 0
patients 0
with 0
subacute 0
cardiac 0
tamponade 0
, 0
pulmonary 0
wedge 0
pressure 0
( 0
PWP 0
) 0
, 0
RAP 0
, 0
and 0
IPP 0
were 0
measured 0
along 0
with 0
indexes 0
of 0
systolic 0
function 0
. 0

Encompassing 0
tamponade 0
and 0
pericardiocentesis 0
data 0
, 0
left 0
ventricular 0
stroke 0
work 0
index 0
showed 0
positive 0
correlation 0
with 0
TMFP1 0
( 0
r 0
= 0
.59 0
) 0
and 0
TMFP2 0
( 0
r 0
= 0
.52 0
) 0
but 0
not 0
with 0
TMFP3 0
. 0

Rabbits 0
developed 0
profound 0
hypocalcemia 0
, 0
with 0
levels 0
falling 0
from 0
15.5 0
+/ 0
- 0
0.2 0
to 0
7.6 0
+/ 0
- 0
0.4 0
mg/dl 0
under 0
the 0
influence 0
of 0
TSST B-gene
- I-gene
1 I-gene
. 0

Reward 0
value 0
of 0
prosodic 0
features 0
of 0
language 0
for 0
autistic 0
, 0
mentally 0
retarded 0
, 0
and 0
normal 0
children 0
. 0

Similarly 0
, 0
actuarial 0
interpretations 0
for 0
the 0
second 0
protocols 0
were 0
not 0
more 0
frequently 0
selected 0
by 0
therapists 0
as 0
more 0
valid 0
, 0
regardless 0
of 0
treatment 0
condition 0
and 0
elevation 0
of 0
the 0
F 0
and 0
F 0
- 0
K 0
indices 0
on 0
the 0
first 0
MMPI 0
profile 0
. 0

Due 0
to 0
its 0
relatively 0
soluble 0
chemical 0
form 0
, 0
90Sr 0
was 0
rapidly 0
translocated 0
from 0
lung 0
to 0
bone 0
where 0
a 0
substantial 0
portion 0
was 0
retained 0
for 0
a 0
long 0
period 0
of 0
time 0
. 0

The 0
study 0
disclosed 0
generalized 0
atrophy 0
and 0
diffuse 0
symmetric 0
white 0
matter 0
hypodensities 0
. 0

The 0
diagnosis 0
of 0
metachromatic 0
leukodystrophy 0
( 0
MLD 0
) 0
was 0
confirmed 0
by 0
the 0
finding 0
of 0
low 0
arylsulfatase B-gene
A I-gene
( 0
ASA B-gene
) 0
levels 0
in 0
cultured 0
fibroblasts 0
in 0
both 0
sisters 0
. 0

Artificial 0
ventilation 0
was 0
conducted 0
using 0
a 0
tidal 0
volume 0
of 0
10 0
ml 0
X 0
kg 0
- 0
1 0
and 0
a 0
rate 0
of 0
10 0
to 0
12 0
c 0
X 0
min 0
- 0
1 0
. 0

Significantly 0
lower 0
heart 0
rate 0
reactivity 0
and 0
significantly 0
less 0
pronounced 0
left 0
temporal 0
artery 0
pulse 0
amplitude 0
responses 0
were 0
found 0
in 0
non 0
- 0
medicated 0
TH 0
subjects 0
than 0
in 0
controls 0
. 0

An 0
epidemiological 0
survey 0
of 0
rheumatic 0
valve 0
disease 0
and 0
rheumatic 0
fever 0
in 0
primary 0
and 0
secondary 0
school 0
students 0
in 0
Jiangxi 0
Province 0

Drugs 0
that 0
are 0
transformed 0
via 0
phase 0
II 0
reactions 0
usually 0
do 0
not 0
require 0
dosage 0
adjustment 0
. 0

A 0
study 0
of 0
human 0
genes 0
coding 0
for 0
U4 B-gene
small I-gene
nuclear I-gene
RNA I-gene
is 0
presented 0
. 0

Using 0
the 0
balloon 0
- 0
gas 0
procedure 0
with 0
a 0
single 0
gas 0
injection 0
, 0
a 0
bubble 0
was 0
obtained 0
that 0
was 0
large 0
enough 0
to 0
tamponade 0
a 0
giant 0
tear 0
without 0
prior 0
drainage 0
of 0
subretinal 0
fluid 0
or 0
vitrectomy 0
. 0

Heat 0
- 0
labile 0
- 0
like 0
enterotoxin 0
( 0
LT B-gene
) 0
was 0
produced 0
by 0
26 0
of 0
42 0
stool 0
isolates 0
( 0
62 0
% 0
) 0
, 0
while 0
only 0
1 0
of 0
the 0
42 0
isolates 0
( 0
2 0
% 0
) 0
produced 0
enterotoxinlike 0
activity 0
in 0
suckling 0
mice 0
; 0
65 0
% 0
of 0
the 0
cytotoxin 0
- 0
producing 0
strains 0
also 0
produced 0
an 0
LT B-gene
- I-gene
like I-gene
material 0
. 0

Development 0
of 0
a 0
provisional 0
information 0
- 0
retrieval 0
descriptor 0
language 0
for 0
`` 0
Roentgenology 0
and 0
Medical 0
Radiology 0
'' 0
for 0
use 0
in 0
the 0
Medinform 0
system 0

Persistent 0
acantholytic 0
dermatosis 0
with 0
increased 0
light 0
sensitivity 0

Thus 0
, 0
a 0
negative 0
test 0
is 0
compatible 0
with 0
low 0
disease 0
activity 0
and/or 0
efficacy 0
of 0
calcium 0
antagonist 0
treatment 0
. 0

Thus 0
, 0
a 0
negative 0
test 0
is 0
compatible 0
with 0
low 0
disease 0
activity 0
and/or 0
efficacy 0
of 0
calcium 0
antagonist 0
treatment 0
. 0

Dorsal 0
foot 0
TcpO2 0
was 0
measured 0
by 0
using 0
oxygen 0
- 0
sensing 0
electrodes 0
with 0
surface 0
temperatures 0
of 0
42 0
degrees 0
C 0
and 0
45 0
degrees 0
C 0
; 0
in 0
theory 0
, 0
changes 0
in 0
sympathetic 0
activity 0
should 0
affect 0
vasomotor 0
tone 0
and 0
TcpO2 0
in 0
skin 0
beneath 0
an 0
electrode 0
at 0
42 0
degrees 0
C 0
( 0
submaximal 0
vasodilation 0
) 0
, 0
but 0
not 0
at 0
45 0
degrees 0
C 0
( 0
maximal 0
vasodilation 0
) 0
. 0

In 0
subjects 0
( 0
n 0
= 0
5 0
) 0
with 0
quadriplegia 0
and 0
reduced 0
sympathetic 0
tone 0
secondary 0
to 0
cervical 0
cord 0
trauma 0
, 0
TcpO2 0
at 0
42 0
degrees 0
C 0
and 0
vasodilation 0
index 0
were 0
increased 0
( 0
45.0 0
mmHg 0
and 0
0.61 0
) 0
; 0
TcpO2 0
at 0
45 0
degrees 0
C 0
did 0
not 0
change 0
. 0

The 0
nucleotide 0
sequences 0
of 0
the 0
human B-gene
and I-gene
murine I-gene
ornithine I-gene
decarboxylase I-gene
mRNAs I-gene
share 0
an 0
85 0
% 0
homology 0
, 0
even 0
in 0
their 0
3' 0
- 0
noncoding 0
regions 0
. 0

The 0
absolute 0
concentrations 0
of 0
alpha B-gene
2 I-gene
- I-gene
plasmin I-gene
inhibitor 0
, 0
alpha B-gene
2 I-gene
- I-gene
macroglobulin I-gene
, 0
and 0
antithrombin B-gene
III I-gene
increased 0
with 0
exercise 0
( 0
all 0
P 0
less 0
than 0
0.005 0
) 0
, 0
but 0
when 0
concentrations 0
were 0
corrected 0
for 0
acute 0
shifts 0
of 0
plasma 0
water 0
during 0
exercise 0
, 0
the 0
quantity 0
of 0
these 0
inhibitors 0
actually 0
decreased 0
( 0
all 0
P 0
less 0
than 0
0.005 0
) 0
. 0

The 0
other 0
model 0
was 0
a 0
continuous 0
exponential 0
plus 0
constant 0
of 0
the 0
form 0
La 0
- 0
= 0
a 0
+ 0
b 0
[ 0
exp 0
( 0
cVO2 0
) 0
] 0
. 0

Cell 0
. 0

Timing 0
of 0
symptoms 0
and 0
oocyst 0
excretion 0
in 0
human 0
cryptosporidiosis 0
. 0

After 0
dopamine 0
infusion 0
in 0
women 0
with 0
polycystic 0
ovary 0
syndrome 0
and 0
in 0
matched 0
controls 0
, 0
steady 0
state 0
levels 0
of 0
plasma 0
dopamine 0
, 0
norepinephrine 0
, 0
and 0
the 0
ratio 0
of 0
dopamine/norepinephrine 0
were 0
similar 0
in 0
the 0
two 0
groups 0
. 0

Diagnostic 0
importance 0
of 0
determining 0
the 0
complement 0
constituents 0
in 0
children 0
with 0
autoimmune 0
thyroiditis 0

In 0
the 0
normal 0
, 0
basal 0
( 0
unstimulated 0
) 0
condition 0
there 0
were 0
no 0
significant 0
correlations 0
( 0
p 0
greater 0
than 0
0.05 0
) 0
between 0
the 0
systolic 0
blood 0
pressure 0
and 0
dopamine 0
( 0
r 0
= 0
0.09 0
) 0
, 0
norepinephrine 0
( 0
r 0
= 0
0.26 0
) 0
, 0
or 0
epinephrine 0
( 0
r 0
= 0
0.27 0
) 0
, 0
nor 0
were 0
there 0
significant 0
correlations 0
between 0
melatonin 0
and 0
dopamine 0
( 0
r 0
= 0
- 0
0.01 0
) 0
, 0
norepinephrine 0
( 0
r 0
= 0
- 0
0.26 0
) 0
, 0
or 0
growth B-gene
hormone I-gene
( 0
r 0
= 0
0.17 0
) 0
. 0

The 0
4 0
patients 0
with 0
carboxyhemoglobin B-gene
levels 0
in 0
excess 0
of 0
10 0
% 0
may 0
represent 0
occult 0
carbon 0
monoxide 0
poisoning 0
in 0
this 0
population 0
. 0

All 0
these 0
processes 0
were 0
fully 0
developed 0
during 0
the 0
last 0
month 0
of 0
pregnancy 0
, 0
offering 0
the 0
same 0
picture 0
as 0
the 0
controls 0
. 0

Hypoglycemic 0
action 0
of 0
`` 0
he 0
xiang 0
zhuang 0
qi 0
gong 0
'' 0
and 0
its 0
mechanism 0
on 0
diabetes 0
mellitus 0

In 0
cases 0
of 0
1 0
degrees 0
HPT 0
, 0
the 0
plasma 0
1,25 0
- 0
( 0
OH 0
) 0
2D 0
level 0
rose 0
significantly 0
in 0
all 0
cases 0
( 0
P 0
less 0
than 0
0.05 0
) 0
, 0
although 0
the 0
pattern 0
of 0
the 0
increase 0
was 0
not 0
uniform 0
. 0

This 0
region 0
of 0
60 0
amino 0
acids 0
may 0
be 0
involved 0
in 0
coiled 0
- 0
coil 0
interactions 0
similar 0
to 0
those 0
that 0
facilitate 0
the 0
filament 0
formation 0
in 0
the 0
rod 0
region 0
. 0

This 0
approach 0
enables 0
the 0
sources 0
of 0
error 0
in 0
the 0
calculation 0
of 0
nutrient 0
utilization 0
to 0
be 0
readily 0
identified 0
, 0
and 0
their 0
effect 0
on 0
precision 0
to 0
be 0
assessed 0
in 0
different 0
nutritional 0
and 0
metabolic 0
states 0
. 0

The 0
effect 0
of 0
dietary 0
zinc 0
deficiency 0
on 0
the 0
mossy 0
fiber 0
zinc 0
content 0
of 0
the 0
rat 0
hippocampus 0
. 0

Weaned 0
rats 0
were 0
fed 0
a 0
normal 0
diet 0
or 0
a 0
low 0
- 0
protein 0
, 0
low 0
- 0
energy 0
diet 0
, 0
and 0
injected 0
with 0
saline 0
or 0
thyroxine 0
( 0
5 0
micrograms/100 0
g 0
BW 0
) 0
for 0
22 0
days 0
. 0

It 0
is 0
largely 0
predicted 0
by 0
lupus 0
anticoagulant 0
( 0
estimated 0
by 0
activated 0
partial 0
thromboplastin B-gene
time 0
) 0
and/or 0
antibody 0
to 0
cardiolipin 0
. 0

The 0
effects 0
of 0
several 0
opioid 0
agonists 0
and 0
the 0
opioid 0
antagonist 0
naloxone 0
were 0
examined 0
in 0
rats 0
responding 0
under 0
a 0
fixed 0
- 0
consecutive 0
- 0
number 0
( 0
FCN 0
) 0
schedule 0
. 0

The 0
rate 0
- 0
decreasing 0
effects 0
of 0
morphine 0
and 0
U50488 0
were 0
reversed 0
completely 0
by 0
a 0
0.01 0
and 0
1.0 0
mg/kg 0
dose 0
of 0
naloxone 0
, 0
respectively 0
. 0

Data 0
from 0
119 0
men 0
and 0
40 0
women 0
undergoing 0
coronary 0
angiography 0
provide 0
an 0
opportunity 0
to 0
compare 0
these 0
associations 0
in 0
relation 0
to 0
a 0
direct 0
and 0
continuous 0
measure 0
of 0
atherosclerosis 0
while 0
controlling 0
for 0
age 0
, 0
sex 0
, 0
income 0
, 0
hypertension 0
, 0
serum 0
cholesterol 0
, 0
smoking 0
, 0
angina 0
, 0
diabetes 0
, 0
family 0
history 0
of 0
heart 0
disease 0
, 0
Type 0
A 0
behavior 0
pattern 0
, 0
and 0
hostility 0
. 0

An 0
intralobar 0
change 0
in 0
temperature 0
above 0
or 0
below 0
36 0
degrees 0
C 0
decreases 0
only 0
the 0
lobar 0
bronchial 0
blood 0
flow 0
and 0
does 0
not 0
influence 0
blood 0
flow 0
to 0
other 0
nearby 0
tissues 0
including 0
those 0
vascularized 0
by 0
the 0
bronchial 0
circulation 0
. 0

Convulsive 0
status 0
epilepticus 0
after 0
infusion 0
of 0
cisplatin 0

The 0
presence 0
in 0
such 0
patients 0
of 0
antibodies 0
to 0
adrenaline 0
and 0
noradrenaline 0
is 0
indicative 0
of 0
considerable 0
disruption 0
of 0
catecholamine 0
biotransformation 0
. 0

The 0
following 0
markers 0
were 0
looked 0
for 0
in 0
the 0
serum 0
, 0
skin 0
and 0
liver 0
of 0
all 0
patients 0
with 0
chronic 0
hepatitis 0
: 0
HBV 0
( 0
HBs B-gene
Ag I-gene
and 0
HBe B-gene
Ag I-gene
, 0
anti B-gene
- I-gene
HBs I-gene
, 0
anti B-gene
- I-gene
HBe I-gene
and 0
anti B-gene
- I-gene
HBc I-gene
in 0
the 0
serum 0
, 0
HBs B-gene
and I-gene
HBc I-gene
Ag I-gene
in 0
the 0
liver 0
) 0
; 0
non B-gene
- I-gene
A I-gene
non I-gene
- I-gene
B I-gene
( 0
non B-gene
- I-gene
A I-gene
, I-gene
non I-gene
- I-gene
B I-gene
Ag I-gene
and I-gene
antibody I-gene
, 0
anti B-gene
non I-gene
- I-gene
A I-gene
non I-gene
- I-gene
Bc I-gene
in 0
the 0
serum 0
, 0
non B-gene
- I-gene
A I-gene
, I-gene
non I-gene
- I-gene
Bc I-gene
Ag I-gene
in 0
the 0
liver 0
) 0
. 0

Groups 0
of 0
male 0
and 0
female 0
Fischer 0
344 0
rats 0
, 0
B6C3F1 0
mice 0
, 0
and 0
Hartley 0
guinea 0
pigs 0
were 0
exposed 0
once 0
for 0
6 0
hr 0
to 0
mean 0
concentrations 0
of 0
10.5 0
, 0
5.4 0
, 0
2.4 0
, 0
1.0 0
, 0
or 0
0 0
( 0
control 0
) 0
ppm 0
of 0
methyl 0
isocyanate 0
( 0
MIC 0
) 0
vapor 0
. 0

Radionuclide 0
study 0
and 0
endomyocardial 0
biopsy 0
revealed 0
remarkable 0
degeneration 0
of 0
myocardium 0
. 0

Immobilization 0
of 0
the 0
fracture 0
in 0
a 0
collar 0
and 0
cuff 0
sling 0
was 0
as 0
effective 0
as 0
more 0
elaborate 0
methods 0
. 0

Comparison 0
of 0
patients 0
receiving 0
phenytoin 0
and 0
those 0
who 0
were 0
not 0
showed 0
significantly 0
lower 0
serum 0
folate 0
in 0
the 0
sub 0
- 0
group 0
receiving 0
phenytoin 0
, 0
but 0
there 0
was 0
no 0
significant 0
difference 0
between 0
the 0
sub 0
- 0
groups 0
with 0
respect 0
to 0
vitamin 0
B12 0
or 0
behaviour 0
problem 0
rating 0
. 0

Effects 0
of 0
a 0
low 0
- 0
energy 0
laser 0
beam 0
on 0
the 0
cells 0
of 0
the 0
newt 0
embryo 0

Typical 0
and 0
atypical 0
clinical 0
features 0
of 0
this 0
lacrimal 0
sac 0
cyst 0
are 0
emphasized 0
. 0

The 0
role 0
of 0
saliva 0
in 0
sour 0
taste 0
perception 0
was 0
investigated 0
in 0
a 0
series 0
of 0
4 0
experiments 0
. 0

Samples 0
from 0
1415 0
neurological 0
patients 0
were 0
used 0
to 0
study 0
the 0
diagnostic 0
value 0
of 0
acid B-gene
alpha I-gene
1 I-gene
- I-gene
glycoprotein I-gene
in 0
the 0
lumbar 0
cerebrospinal 0
fluid 0
. 0

Separate 0
experiments 0
measured 0
AIB 0
and 0
86RbCl 0
uptake 0
in 0
36B 0
- 0
10 0
cells 0
in 0
vitro 0
1 0
and 0
2 0
days 0
following 0
20 0
Gy 0
irradiation 0
to 0
assess 0
whether 0
this 0
radiation 0
dose 0
reduced 0
the 0
capacity 0
of 0
tumor 0
cells 0
to 0
trap 0
AIB 0
or 0
Rb+ 0
. 0

For 0
patients 0
with 0
recurrent 0
or 0
metastatic 0
disease 0
, 0
the 0
data 0
suggest 0
that 0
I 0
- 0
131 0
MIBG 0
scintigraphy 0
is 0
the 0
examination 0
of 0
choice 0
. 0

W 0
. 0

Comparison 0
of 0
the 0
amino 0
acid 0
sequence 0
of 0
the 0
M B-gene
RNA I-gene
product I-gene
of I-gene
Uukuniemi I-gene
virus I-gene
with 0
that 0
of 0
Punta 0
Toro 0
and 0
Rift 0
Valley 0
fever 0
viruses 0
showed 0
in 0
both 0
cases 0
a 0
weak 0
homology 0
that 0
was 0
more 0
pronounced 0
for 0
the 0
proteins 0
located 0
at 0
the 0
COOH 0
- 0
terminal 0
end 0
of 0
the 0
precursor 0
. 0

Cyclosporine 0
treatment 0
for 0
intractable 0
polymyositis 0
. 0

In 0
addition 0
, 0
on 0
the 0
Cohler 0
's 0
maternal 0
scale 0
, 0
Korean 0
mothers 0
were 0
found 0
to 0
view 0
their 0
infants 0
as 0
more 0
passive 0
and 0
dependent 0
than 0
American 0
mothers 0
did 0
( 0
P 0
less 0
than 0
0.00 0
) 0
. 0

A 0
preoperative 0
teaching 0
booklet 0
for 0
pediatric 0
patients 0
. 0

Hyperthyroidism 0

We 0
conclude 0
that 0
for 0
mono 0
- 0
intronic 0
precursors 0
in 0
which 0
there 0
is 0
only 0
one 0
choice 0
of 0
splice 0
sites 0
, 0
most 0
of 0
the 0
exon 0
sequences 0
are 0
not 0
mechanistically 0
involved 0
in 0
the 0
splicing 0
process 0
. 0

UVA 0
- 0
induced 0
melanocytic 0
lesions 0
. 0

Ex 0
vivo 0
MAO B-gene
inhibition 0
data 0
indicated 0
DPGPEA 0
to 0
be 0
an 0
inhibitor 0
of 0
MAO B-gene
- I-gene
B I-gene
, 0
although 0
the 0
effect 0
was 0
much 0
weaker 0
than 0
seen 0
with 0
tranylcypromine 0
or 0
pargyline 0
. 0

Thus 0
in 0
this 0
region 0
of 0
the 0
vessel 0
pyridinoline 0
represents 0
the 0
major 0
stabilising 0
crosslink 0
of 0
collagen B-gene
. 0

A 0
careful 0
, 0
radiolabelled 0
tissue 0
- 0
distribution 0
study 0
is 0
warranted 0
to 0
elucidate 0
the 0
complicated 0
metabolic 0
fate 0
of 0
perhexiline 0
. 0

Systemic 0
lupus 0
erythematosus 0
was 0
diagnosed 0
. 0

In 0
the 0
evening 0
, 0
the 0
amplitude 0
of 0
the 0
responses 0
to 0
both 0
O2 0
and 0
CO2 0
increased 0
but 0
the 0
increase 0
in 0
CO2 0
sensitivity 0
was 0
proportionally 0
more 0
important 0
. 0

The 0
statistical 0
significance 0
of 0
the 0
prognosis 0
factors 0
was 0
studied 0
by 0
uni 0
- 0
and 0
multivariative 0
methods 0
, 0
according 0
to 0
the 0
model 0
of 0
Cox 0
, 0
with 0
the 0
help 0
of 0
an 0
IMB 0
computer 0
. 0

These 0
changes 0
at 0
the 0
site 0
of 0
injection 0
consist 0
of 0
a 0
focal 0
abnormality 0
characterized 0
by 0
a 0
slight 0
increase 0
in 0
signal 0
intensity 0
on 0
T1 0
weighted 0
images 0
and 0
markedly 0
increased 0
signal 0
intensity 0
on 0
T2 0
weighted 0
images 0
. 0

These 0
results 0
suggest 0
that 0
less 0
antidopaminergic 0
activity 0
of 0
RHAL 0
in 0
this 0
neuroleptic 0
test 0
might 0
be 0
explained 0
by 0
the 0
lesser 0
conversion 0
of 0
RHAL 0
to 0
HAL 0
. 0

The 0
purpose 0
of 0
this 0
study 0
is 0
twofold 0
: 0
( 0
1 0
) 0
to 0
present 0
a 0
parallel 0
form 0
of 0
the 0
Gudjonsson 0
Suggestibility 0
Scale 0
( 0
GSS 0
, 0
Form 0
1 0
) 0
; 0
( 0
2 0
) 0
to 0
study 0
test 0
- 0
retest 0
reliabilities 0
of 0
interrogative 0
suggestibility 0
. 0

Organisms 0
were 0
recovered 0
from 0
the 0
conjunctiva 0
for 0
several 0
weeks 0
, 0
and 0
persistent 0
genital 0
and 0
gastrointestinal 0
infection 0
also 0
resulted 0
from 0
the 0
ocular 0
infection 0
in 0
some 0
cats 0
. 0

In 0
vivo 0
epiluminescence 0
microscopy 0
of 0
pigmented 0
skin 0
lesions 0
. 0

These 0
equilibrium 0
solutions 0
are 0
then 0
shown 0
to 0
arise 0
from 0
the 0
vertices 0
of 0
a 0
particular 0
convex 0
polyhedron 0
. 0

The 0
average 0
deviations 0
in 0
the 0
X 0
- 0
ray 0
counts 0
of 0
the 0
constant 0
elements 0
from 0
the 0
series 0
means 0
were 0
used 0
to 0
correct 0
the 0
recorded 0
count 0
of 0
the 0
variable 0
element 0
in 0
each 0
block 0
. 0

Statistically 0
significant 0
effects 0
were 0
noted 0
at 0
doses 0
which 0
did 0
not 0
appear 0
to 0
be 0
maternally 0
toxic 0
. 0

Low 0
MAO B-gene
subjects 0
showed 0
a 0
pattern 0
of 0
higher 0
scores 0
in 0
KSP 0
Impulsiveness 0
, 0
EPQ 0
Neuroticism 0
, 0
and 0
KSP 0
Somatic 0
Anxiety 0
and 0
Irritability 0
and 0
lower 0
scores 0
in 0
KSP 0
Socialization 0
, 0
in 0
line 0
with 0
personality 0
profiles 0
found 0
in 0
alcoholics 0
, 0
psychopaths 0
, 0
and 0
suicide 0
attempters 0
who 0
also 0
tend 0
to 0
have 0
low 0
platelet 0
MAO B-gene
activity 0
. 0

To 0
evaluate 0
the 0
relative 0
accuracy 0
of 0
continuous 0
wave 0
( 0
CW 0
) 0
and 0
high 0
pulse 0
repetition 0
frequency 0
( 0
HPRF 0
) 0
Doppler 0
for 0
estimating 0
aortic 0
transvalvular 0
pressure 0
gradients 0
, 0
Doppler 0
examinations 0
with 0
both 0
devices 0
were 0
obtained 0
in 0
87 0
consecutive 0
patients 0
with 0
aortic 0
valve 0
disease 0
. 0

In 0
group 0
I 0
, 0
Paw 0
, 0
delta 0
V 0
, 0
PaO2 0
, 0
Vinj 0
and 0
VT 0
significantly 0
decreased 0
whereas 0
operating 0
pressure 0
and 0
E 0
significantly 0
increased 0
when 0
the 0
internal 0
diameter 0
of 0
the 0
injector 0
cannula 0
was 0
reduced 0
. 0

In 0
calves 0
receiving 0
milk 0
- 0
substitute 0
diets 0
containing 0
80 0
- 0
260 0
g 0
DM/kg 0
, 0
milk 0
intakes 0
were 0
reduced 0
by 0
up 0
to 0
30 0
% 0
on 0
the 0
1st 0
day 0
that 0
calves 0
were 0
fed 0
once 0
daily 0
instead 0
of 0
twice 0
daily 0
. 0

Today 0
there 0
is 0
no 0
doubt 0
that 0
elevated 0
plasma 0
cholesterol 0
levels 0
should 0
be 0
lowered 0
first 0
by 0
dietary 0
modification 0
even 0
in 0
early 0
childhood 0
, 0
beginning 0
at 0
the 0
age 0
of 0
two 0
years 0
. 0

The 0
number 0
of 0
fecal 0
pellets 0
ingested 0
peaked 0
at 0
5 0
to 0
6 0
weeks 0
old 0
( 0
13 0
pellets/day 0
) 0
and 0
gradually 0
decreased 0
, 0
thereafter 0
( 0
2.1 0
pellets 0
at 0
78 0
weeks 0
old 0
, 0
1.5 0
pellets 0
at 0
104 0
weeks 0
old 0
) 0
. 0

These 0
results 0
suggest 0
that 0
N 0
- 0
nitroso 0
compounds 0
can 0
be 0
formed 0
in 0
vivo 0
in 0
the 0
infected 0
bladder 0
, 0
which 0
could 0
explain 0
the 0
association 0
between 0
urinary 0
- 0
tract 0
infections 0
and 0
increased 0
risk 0
for 0
bladder 0
cancer 0
. 0

Epithelial 0
nerve 0
fiber 0
defects 0
included 0
absence 0
or 0
distorted 0
architecture 0
of 0
the 0
basal 0
epithelial 0
plexus 0
and 0
intra 0
- 0
epithelial 0
terminals 0
. 0

The 0
histologic 0
grade 0
for 0
the 0
same 0
anatomic 0
site 0
varied 0
among 0
hearts 0
and 0
among 0
different 0
anatomic 0
sites 0
in 0
the 0
same 0
heart 0
. 0

Serum 0
levels 0
of 0
albumin B-gene
, 0
globulin B-gene
, 0
and 0
coagulation B-gene
protein I-gene
activity 0
were 0
measured 0
preshock 0
, 0
postshock 0
, 0
and 0
daily 0
for 0
3 0
days 0
; 0
skin 0
lymph 0
levels 0
were 0
measured 0
on 0
Day 0
3 0
. 0

For 0
colostral 0
milk 0
there 0
was 0
a 0
significant 0
correlation 0
of 0
vitamin 0
K1 0
to 0
cholesterol 0
( 0
r 0
= 0
0.62 0
) 0
but 0
not 0
to 0
total 0
lipid 0
or 0
phospholipid 0
suggesting 0
a 0
role 0
for 0
cholesterol 0
in 0
the 0
secretion 0
of 0
vitamin 0
K1 0
into 0
colostral 0
milk 0
. 0

Endurance 0
training 0
resulted 0
in 0
an 0
increase 0
of 0
stiffness 0
associated 0
with 0
a 0
decrease 0
of 0
type 0
II 0
fibers 0
. 0

A 0
rate 0
- 0
decreasing 0
dose 0
of 0
physostigmine 0
, 0
an 0
acetylcholinesterase B-gene
inhibitor 0
, 0
was 0
studied 0
in 0
combination 0
with 0
the 0
range 0
of 0
atropine 0
doses 0
. 0

References 0
for 0
occupational 0
fitness 0
of 0
adolescents 0
with 0
diseases 0
of 0
the 0
respiratory 0
tract 0
and 0
lungs 0

Salzburg 0
, 0
9 0
- 0
12 0
September 0
1987 0
. 0

Two 0
new 0
glucosidase B-gene
inhibitors 0
( 0
BAY 0
m 0
1099 0
and 0
BAY 0
o 0
1248 0
) 0
were 0
studied 0
in 0
volunteers 0
and 0
type 0
II 0
diabetics 0
under 0
various 0
conditions 0
. 0

The 0
models 0
accurately 0
localized 0
the 0
common 0
boundaries 0
between 0
the 0
PBB 0
and 0
CN 0
. 0

Two 0
of 0
these 0
six 0
cases 0
showed 0
mucosal 0
spread 0
without 0
stromal 0
invasion 0
( 0
type 0
A 0
) 0
; 0
the 0
remaining 0
four 0
cases 0
presented 0
a 0
direct 0
extension 0
( 0
type 0
B 0
) 0
from 0
muscle 0
- 0
invasive 0
carcinomas 0
of 0
the 0
bladder 0
. 0

However 0
, 0
conversions 0
of 0
12 0
mm 0
or 0
more 0
from 0
a 0
documented 0
negative 0
result 0
indicated 0
spread 0
of 0
infection 0
. 0

The 0
maximum 0
amplitude 0
of 0
evoked 0
responses 0
in 0
the 0
cervical 0
sympathetic 0
trunk 0
was 0
obtained 0
when 0
the 0
T2 0
white 0
ramus 0
was 0
stimulated 0
and 0
decreased 0
gradually 0
when 0
followed 0
by 0
the 0
stimulation 0
of 0
T1 0
, 0
T3 0
, 0
T4 0
and 0
T5 0
white 0
rami 0
. 0

It 0
is 0
concluded 0
that 0
contact 0
allergy 0
to 0
K 0
- 0
CG 0
is 0
common 0
. 0

The 0
effect 0
of 0
a 0
beta B-gene
- I-gene
adrenoceptor I-gene
antagonist 0
, 0
pindolol 0
, 0
on 0
uterine 0
smooth 0
muscle 0
in 0
term 0
pregnant 0
women 0
was 0
studied 0
in 0
vitro 0
and 0
in 0
vivo 0
( 0
in 0
hypertensive 0
women 0
) 0
. 0

The 0
less 0
- 0
polar 0
mycolic 0
acid 0
- 0
containing 0
Rhodococcus 0
species 0
showed 0
chromatographic 0
patterns 0
that 0
partially 0
overlapped 0
( 0
in 0
elution 0
times 0
) 0
the 0
patterns 0
of 0
Nocardia 0
asteroides 0
, 0
N. 0
otitidiscaviarum 0
, 0
and 0
N. 0
brasiliensis 0
, 0
but 0
the 0
larger 0
number 0
of 0
peaks 0
in 0
the 0
last 0
species 0
made 0
separation 0
between 0
the 0
genera 0
possible 0
. 0

The 0
development 0
of 0
a 0
data 0
base 0
is 0
described 0
which 0
can 0
be 0
used 0
as 0
common 0
reference 0
for 0
ECG 0
computer 0
programs 0
analyzing 0
12 0
or 0
15 0
simultaneously 0
recorded 0
leads 0
. 0

Blood B-gene
serum I-gene
erythropoietin I-gene
level 0
and 0
basic 0
hematological 0
indices 0
during 0
the 0
adaptation 0
of 0
healthy 0
newborn 0
infants 0

49 0
, 0
XXXXY 0
chromosome 0
anomaly 0
: 0
an 0
unusual 0
variant 0
of 0
Klinefelter 0
's 0
syndrome 0
. 0

Contraction 0
of 0
the 0
tracheal 0
muscle 0
and 0
the 0
activity 0
of 0
stretch 0
receptors 0
in 0
the 0
trachea 0

The 0
selenium 0
level 0
and 0
glutathione B-gene
peroxidase I-gene
activity 0
in 0
the 0
blood 0
, 0
liver 0
, 0
and 0
stomach 0
mucosa 0
were 0
significantly 0
higher 0
in 0
the 0
high 0
- 0
selenium 0
diet 0
group 0
than 0
in 0
the 0
low 0
- 0
selenium 0
diet 0
group 0
. 0

Oxygen 0
delivery 0
and 0
consumption 0
and 0
P50 0
in 0
patients 0
with 0
acute 0
myocardial 0
infarction 0
. 0

Infants 0
of 0
this 0
sample 0
had 0
monocular 0
PL 0
visual 0
acuities 0
similar 0
to 0
those 0
established 0
by 0
McDonald 0
et 0
al 0
. 0
in 0
a 0
laboratory 0
setting 0
. 0

These 0
results 0
indicate 0
that 0
the 0
effect 0
of 0
the 0
isomers 0
of 0
pentobarbital 0
and 0
secobarbital 0
on 0
mult 0
FR30 0
FI600 0
responding 0
and 0
on 0
suppressed 0
responding 0
are 0
qualitatively 0
similar 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

The 0
number 0
of 0
crystalline 0
deposits 0
is 0
less 0
in 0
the 0
advanced 0
atrophic 0
areas 0
of 0
the 0
RPE 0
- 0
choriocapillaris 0
complex 0
. 0

All 0
33 0
subjects 0
were 0
given 0
psychometric 0
instruments 0
for 0
measuring 0
various 0
components 0
of 0
anger 0
and 0
anxiety 0
: 0
Spielberger 0
's 0
State 0
- 0
Trait 0
Personality 0
Inventory 0
, 0
the 0
Anger 0
Expression 0
Scale 0
, 0
and 0
the 0
State 0
Anger 0
Reaction 0
Scale 0
. 0

It 0
was 0
found 0
that 0
the 0
primary 0
visual 0
cortex 0
of 0
the 0
rat 0
is 0
asymmetrical 0
in 0
volume 0
, 0
and 0
that 0
the 0
asymmetry 0
reflects 0
side 0
differences 0
in 0
the 0
number 0
of 0
neurons 0
. 0

The 0
subjects 0
received 0
a 0
single 0
500 0
mg 0
dose 0
of 0
acetaminophen 0
i.v 0
. 0
and 0
concentrations 0
in 0
plasma 0
were 0
measured 0
for 0
360 0
minutes 0
and 0
in 0
urine 0
for 0
24 0
h 0
in 0
order 0
to 0
estimate 0
the 0
production 0
of 0
metabolites 0
. 0

Mean 0
weighted 0
skin 0
temperature 0
( 0
Tsk 0
) 0
was 0
lower 0
( 0
P 0
less 0
than 0
0.01 0
) 0
following 0
acclimation 0
than 0
before 0
, 0
and 0
acclimation 0
resulted 0
in 0
a 0
larger 0
( 0
P 0
less 0
than 0
0.02 0
) 0
Tre 0
- 0
to 0
- 0
Tsk 0
gradient 0
. 0

Indium 0
- 0
111 0
leukocyte 0
imaging 0
in 0
patients 0
with 0
rheumatoid 0
arthritis 0
. 0

The 0
effect 0
of 0
L 0
- 0
methionine 0
supplementation 0
on 0
the 0
utilization 0
of 0
a 0
soy 0
protein 0
isolate 0
( 0
SPI 0
) 0
was 0
evaluated 0
by 0
short 0
- 0
term 0
nitrogen 0
balance 0
studies 0
in 0
young 0
women 0
. 0

Primary 0
invasive 0
Haemophilus 0
influenzae 0
type 0
b 0
disease 0
: 0
a 0
population 0
- 0
based 0
assessment 0
of 0
risk 0
factors 0
. 0

Overall 0
, 0
lesions 0
infiltrating 0
the 0
deep 0
lamina 0
propria 0
do 0
not 0
exhibit 0
a 0
reduced 0
frequency 0
of 0
occurrence 0
compared 0
to 0
lesions 0
infiltrating 0
the 0
skeletal 0
muscle 0
; 0
however 0
, 0
carcinomas 0
affecting 0
other 0
oral 0
sites 0
showed 0
a 0
reduced 0
frequency 0
of 0
deeply 0
infiltrating 0
lesions 0
in 0
comparison 0
to 0
more 0
superficial 0
lesions 0
. 0

Factors 0
that 0
showed 0
significant 0
correlation 0
to 0
elevated 0
CIC 0
's 0
in 0
the 0
highly 0
elevated 0
portion 0
of 0
our 0
CIC 0
population 0
were 0
poor 0
NIH 0
score 0
, 0
increased 0
patient 0
age 0
, 0
low 0
peak 0
expiratory 0
flow 0
rate 0
, 0
and 0
elevated 0
total 0
serum B-gene
IgG I-gene
. 0

Induction 0
of 0
both 0
potential 0
transcripts 0
follows 0
heat 0
shock 0
in 0
vivo 0
. 0

New 0
and 0
successful 0
steps 0
have 0
been 0
made 0
in 0
immunodiagnostics 0
, 0
immunotherapy 0
, 0
and 0
immunoprophylaxis 0
of 0
immunologically 0
conditioned 0
infertility 0
. 0

Amikacin 0
was 0
the 0
most 0
stable 0
and 0
tobramycin 0
was 0
the 0
least 0
stable 0
aminoglycoside 0
under 0
the 0
conditions 0
tested 0
. 0

This 0
may 0
explain 0
in 0
part 0
a 0
secular 0
trend 0
towards 0
reduced 0
birthweight 0
for 0
gestation 0
in 0
preterm 0
infants 0
. 0

Estimated 0
nucleic 0
acid 0
N 0
absorption 0
is 0
7 0
- 0
8 0
% 0
of 0
N 0
intake 0
. 0

Adhesion 0
, 0
phagocytosis 0
, 0
chemotactic 0
and 0
random 0
migration 0
, 0
nitroblue 0
tetrazolium 0
dye 0
reduction 0
of 0
peritoneal 0
exudate 0
neutrophils 0
and 0
macrophages 0
, 0
fibrinogen B-gene
level 0
, 0
gelation 0
of 0
soluble 0
fibrin B-gene
and 0
serial 0
dilution 0
protamine 0
sulfate 0
test 0
were 0
investigated 0
in 0
115 0
New 0
Zealand 0
white 0
rabbits 0
with 0
experimentally 0
induced 0
Shwartzman 0
phenomenon 0
in 0
the 0
colon 0
, 0
and 0
in 0
control 0
animals 0
. 0

Nickel 0
is 0
the 0
most 0
common 0
cause 0
of 0
allergic 0
contact 0
dermatitis 0
in 0
Singapore 0
, 0
resulting 0
in 0
positive 0
reactions 0
in 0
patch 0
tests 0
between 0
7 0
and 0
14 0
% 0
. 0

The 0
FFA 0
levels 0
were 0
not 0
affected 0
( 0
P 0
greater 0
than 0
.1 0
) 0
by 0
meal 0
interval 0
. 0

He 0
visited 0
our 0
hospital 0
and 0
left 0
solitary 0
renal 0
cyst 0
was 0
suspected 0
. 0

However 0
, 0
further 0
analyses 0
of 0
the 0
data 0
indicate 0
that 0
increasing 0
VO2 0
AT 0
( 0
r 0
= 0
- 0
0.63 0
, 0
P 0
less 0
than 0
0.05 0
) 0
rather 0
than 0
VO2max 0
( 0
r 0
= 0
- 0
0.15 0
) 0
could 0
result 0
in 0
improving 0
the 0
10,000 0
m 0
race 0
performance 0
to 0
a 0
larger 0
extent 0
, 0
and 0
that 0
the 0
absolute 0
amount 0
of 0
change 0
( 0
delta 0
) 0
in 0
the 0
10,000 0
m 0
run 0
time 0
is 0
best 0
accounted 0
for 0
by 0
a 0
combination 0
of 0
delta 0
VO2 0
AT 0
and 0
delta 0
5,000 0
m 0
run 0
time 0
. 0

A 0
significant 0
herd 0
X 0
period 0
interaction 0
existed 0
for 0
liver 0
TG 0
and 0
serum 0
dextran 0
precipitable 0
cholesterol 0
concentrations 0
. 0

Liver 0
TG 0
and 0
serum 0
NEFA 0
concentrations 0
were 0
positively 0
correlated 0
. 0

The 0
results 0
show 0
that 0
nerve 0
and 0
roots 0
differ 0
considerably 0
both 0
in 0
the 0
force 0
they 0
sustain 0
before 0
failure 0
and 0
in 0
the 0
other 0
biomechanics 0
they 0
exhibit 0
. 0

When 0
the 0
coronary 0
sinus 0
pressure 0
reached 0
15 0
torr 0
, 0
there 0
was 0
a 0
significant 0
decrease 0
in 0
cardiac 0
index 0
( 0
3.60 0
+/ 0
- 0
0.5 0
to 0
2.70 0
+/ 0
- 0
0.6 0
L/min/m2 0
, 0
p 0
less 0
than 0
0.001 0
) 0
, 0
coronary 0
blood 0
flow 0
( 0
13.7 0
+/ 0
- 0
3.1 0
to 0
7.0 0
+/ 0
- 0
2.1 0
ml/min 0
, 0
p 0
less 0
than 0
0.001 0
) 0
, 0
rate 0
of 0
rise 0
of 0
left 0
ventricular 0
pressure 0
( 0
1,567 0
+/ 0
- 0
275 0
to 0
1,331 0
+/ 0
- 0
314 0
, 0
p 0
less 0
than 0
0.05 0
) 0
, 0
and 0
an 0
increase 0
in 0
coronary 0
arteriovenous 0
difference 0
( 0
62.8 0
% 0
+/ 0
- 0
9.3 0
% 0
to 0
70.5 0
% 0
+/ 0
- 0
5.4 0
% 0
saturation 0
, 0
p 0
less 0
than 0
0.03 0
) 0
. 0

Calcifications 0
in 0
the 0
thoracic 0
aorta 0
at 0
the 0
level 0
of 0
the 0
11th 0
and 0
the 0
12th 0
thoracic 0
vertebrae 0
in 0
592 0
men 0
and 0
333 0
women 0
were 0
studied 0
using 0
computed 0
tomography 0
. 0

In 0
a 0
series 0
of 0
402 0
consecutive 0
autopsies 0
, 0
parietal 0
pleural 0
plaques 0
( 0
PP 0
) 0
were 0
found 0
in 0
68 0
individuals 0
above 0
40 0
years 0
of 0
age 0
. 0

Approximately 0
60 0
% 0
of 0
cell 0
bodies 0
of 0
primary 0
neurons 0
innervating 0
the 0
intra 0
and 0
perioral 0
structures 0
through 0
the 0
inferior 0
alveolar 0
, 0
lingual 0
, 0
mental 0
, 0
and 0
buccal 0
nerves 0
were 0
in 0
the 0
range 0
between 0
300 0
and 0
600 0
micron 0
2 0
in 0
cross 0
- 0
sectional 0
area 0
: 0
mean 0
+/ 0
- 0
SD 0
509 0
+/ 0
- 0
243 0
micron 0
2 0
, 0
420 0
+/ 0
- 0
181 0
micron 0
2 0
, 0
469 0
+/ 0
- 0
200 0
micron 0
2 0
, 0
and 0
444 0
+/ 0
- 0
186 0
micron 0
2 0
, 0
respectively 0
. 0

Pharmacological 0
action 0
of 0
eptazocine 0
( 0
l 0
- 0
1,4 0
- 0
dimethyl 0
- 0
10 0
- 0
hydroxy 0
- 0
2,3,4,5,6,7 0
- 0
hexahydro 0
- 0
1,6 0
- 0
methano 0
- 0
1H 0
- 0
4 0
- 0
benz 0
azonine 0
) 0
. 0

On 0
transition 0
from 0
high 0
to 0
low 0
voltage 0
there 0
was 0
a 0
significant 0
fall 0
in 0
arterial 0
pressure 0
( 0
7 0
% 0
) 0
and 0
an 0
increase 0
in 0
flow 0
( 0
19 0
- 0
38 0
% 0
) 0
to 0
areas 0
of 0
the 0
brain 0
corresponding 0
to 0
the 0
arborization 0
of 0
the 0
reticular 0
formation 0
, 0
i.e 0
. 0
excluding 0
the 0
cerebrum 0
and 0
cerebellum 0
. 0

Findings 0
of 0
positive 0
potentials 0
showed 0
that 0
N1 0
originated 0
in 0
the 0
area 0
of 0
ventral 0
gray 0
matter 0
through 0
the 0
ventro 0
- 0
lateral 0
column 0
and 0
N2 0
through 0
the 0
dorsal 0
column 0
. 0

One 0
hundred 0
and 0
four 0
( 0
14 0
per 0
cent 0
) 0
second 0
primary 0
tumours 0
were 0
reported 0
. 0

Failures 0
of 0
colorimetric 0
additivity 0
under 0
these 0
experimental 0
conditions 0
are 0
discussed 0
. 0

There 0
have 0
been 0
five 0
problems 0
( 0
extravasation 0
2 0
, 0
suspected 0
sepsis 0
1 0
, 0
and 0
hematoma 0
2 0
) 0
during 0
a 0
total 0
of 0
2,927 0
days 0
of 0
exposure 0
. 0

It 0
is 0
suggested 0
that 0
these 0
results 0
may 0
raise 0
the 0
interesting 0
possibility 0
of 0
providing 0
a 0
means 0
of 0
identifying 0
greater 0
or 0
lesser 0
susceptibility 0
to 0
the 0
coronary 0
effects 0
of 0
Type 0
A 0
behavior 0
. 0

Two 0
studies 0
assessed 0
two 0
types 0
of 0
reliability 0
of 0
the 0
student 0
Jenkins 0
Activity 0
Survey 0
( 0
JAS 0
; 0
a 0
questionnaire 0
measure 0
of 0
Type 0
A 0
behavior 0
) 0
. 0

Splenectomized 0
patients 0
are 0
predisposed 0
toward 0
developing 0
overwhelming 0
bacterial 0
infections 0
. 0

When 0
phencyclidine 0
was 0
administered 0
alone 0
, 0
overall 0
response 0
rate 0
decreased 0
and 0
percent 0
errors 0
increased 0
with 0
increasing 0
doses 0
. 0

Possibilities 0
and 0
outlook 0
for 0
wrist 0
joint 0
endoprosthesis 0

Study 0
of 0
the 0
energy 0
metabolism 0
of 0
the 0
sensomotor 0
cortex 0
and 0
hippocampus 0
by 0
the 0
( 0
14C 0
) 0
2 0
- 0
deoxyglucose 0
method 0
during 0
the 0
development 0
of 0
dissociated 0
states 0

Malignant 0
lymphoma 0
is 0
very 0
heterogeneous 0
in 0
terms 0
of 0
its 0
biological 0
behavior 0
. 0

Further 0
investigations 0
are 0
necessary 0
to 0
elucidate 0
the 0
biochemical 0
and 0
physiological 0
properties 0
of 0
DLIS 0
. 0

Among 0
them 0
, 0
26 0
cases 0
were 0
benign 0
and 0
34 0
malignant 0
. 0

Of 0
the 0
cases 0
with 0
PLD 0
, 0
50 0
% 0
had 0
associated 0
renal 0
cysts 0
and 0
10 0
% 0
of 0
the 0
cases 0
with 0
APCD 0
had 0
associated 0
liver 0
cysts 0
. 0

Fast 0
goal 0
- 0
directed 0
voluntary 0
movements 0
of 0
the 0
human 0
upper 0
extremity 0
are 0
known 0
to 0
be 0
associated 0
with 0
three 0
distinct 0
bursts 0
of 0
EMG 0
activity 0
in 0
antagonistic 0
muscles 0
. 0

The 0
combination 0
of 0
F1 0
and 0
F2 0
which 0
was 0
the 0
best 0
predictor 0
of 0
CHD 0
in 0
this 0
population 0
( 0
G1 0
) 0
might 0
be 0
interpreted 0
as 0
reflecting 0
trunk 0
adiposity 0
mainly 0
abdominal 0
. 0

Renal 0
clearance 0
fell 0
from 0
19.0 0
+/ 0
- 0
4.9 0
ml/min/1.73 0
m2 0
( 0
group 0
I 0
) 0
to 0
1.0 0
+/ 0
- 0
0.4 0
ml/min/1.73 0
m2 0
( 0
group 0
IV 0
) 0
. 0

The 0
relations 0
between 0
type 0
A 0
behavior 0
, 0
clinically 0
relevant 0
behavior 0
, 0
academic 0
achievement 0
, 0
and 0
IQ 0
in 0
children 0
. 0

The 0
rats 0
were 0
used 0
for 0
the 0
study 0
of 0
the 0
effects 0
of 0
sepsis 0
on 0
the 0
utilization 0
of 0
exogenous 0
fat 0
emulsion 0
. 0

She 0
also 0
had 0
slight 0
weakness 0
of 0
the 0
upper 0
extremities 0
. 0

Results 0
of 0
electron 0
therapy 0
of 0
tumors 0
in 0
different 0
sites 0

The 0
mechanism 0
of 0
action 0
is 0
explored 0
in 0
some 0
detail 0
, 0
specifically 0
as 0
it 0
relates 0
to 0
reticuloendothelial 0
system 0
( 0
RES 0
) 0
Fc B-gene
receptor I-gene
blockade 0
and 0
suppression 0
of 0
antiplatelet 0
antibody 0
synthesis 0
. 0

Incidences 0
of 0
nonfatal 0
stroke 0
, 0
myocardial 0
infarction 0
, 0
angina 0
pectoris 0
und 0
left 0
ventricular 0
hypertrophy 0
could 0
also 0
be 0
lowered 0
. 0

High 0
radial 0
r 0
values 0
with 0
small 0
standard 0
deviations 0
were 0
observed 0
in 0
normal 0
LV 0
( 0
0.972 0
+/ 0
- 0
0.016 0
) 0
and 0
in 0
non 0
- 0
MI 0
regions 0
( 0
0.964 0
+/ 0
- 0
0.018 0
) 0
, 0
indicating 0
temporally 0
homogeneous 0
radial 0
shortening 0
. 0

These 0
results 0
indicate 0
that 0
during 0
pregnancy 0
there 0
are 0
increases 0
in 0
bone 0
formation 0
rates 0
contributing 0
to 0
the 0
increases 0
in 0
skeletal 0
mass 0
. 0

We 0
analyzed 0
data 0
from 0
56 0
patients 0
with 0
Systemic 0
Lupus 0
Erythematosus 0
( 0
SLE 0
) 0
in 0
whom 0
renal 0
biopsies 0
were 0
done 0
systematically 0
. 0

The 0
possibility 0
of 0
a 0
hereditary 0
disorder 0
leading 0
to 0
a 0
minor 0
defect 0
in 0
elastic 0
fibre 0
structure 0
which 0
could 0
be 0
responsible 0
for 0
the 0
spontaneous 0
lesions 0
is 0
discussed 0
. 0

Prevention 0
by 0
a 0
heparin 0
- 0
antithrombin B-gene
III I-gene
combination 0

N 0
- 0
Substituted 0
trimethylsilylcarbamates 0
were 0
tested 0
as 0
derivatizing 0
reagents 0
for 0
gas 0
chromatographic 0
analysis 0
. 0

MICs 0
of 0
four 0
antifungal 0
agents 0
( 0
5 0
- 0
fluorocytosine 0
, 0
miconazole 0
, 0
ketoconazole 0
, 0
and 0
amphotericin 0
B 0
) 0
for 0
84 0
clinical 0
isolates 0
of 0
various 0
Candida 0
species 0
were 0
then 0
determined 0
with 0
both 0
media 0
in 0
agar 0
dilution 0
and 0
microtiter 0
broth 0
dilution 0
systems 0
. 0

There 0
were 0
18 0
patients 0
with 0
Group 0
II 0
( 0
a 0
) 0
tumors 0
; 0
although 0
tumor 0
biopsy 0
was 0
attempted 0
on 0
eight 0
of 0
these 0
, 0
pathological 0
diagnosis 0
at 0
the 0
time 0
of 0
surgery 0
was 0
made 0
in 0
only 0
one 0
case 0
. 0

Evidence 0
that 0
opiate 0
addiction 0
is 0
in 0
part 0
an 0
immune 0
response 0
. 0

Parasitological 0
post 0
- 0
mortem 0
examination 0
of 0
all 0
seropositive 0
animals 0
showed 0
five 0
and 0
seven 0
false 0
- 0
positive 0
animals 0
when 0
E/S B-gene
and I-gene
CWE I-gene
antigens I-gene
were 0
used 0
, 0
respectively 0
. 0

Glucocorticoid 0
induced 0
hypertension 0
has 0
been 0
regarded 0
as 0
independent 0
of 0
sodium 0
( 0
Na 0
) 0
, 0
in 0
contrast 0
to 0
mineralocorticoid 0
induced 0
hypertension 0
, 0
which 0
is 0
Na+ 0
- 0
dependent 0
. 0

Seventeen 0
of 0
them 0
were 0
on 0
treatment 0
with 0
systemic 0
steroids 0
. 0

Examples 0
of 0
its 0
use 0
in 0
the 0
intensive 0
therapy 0
unit 0
are 0
described 0
. 0

The 0
growing 0
drug 0
problem 0
is 0
also 0
reflected 0
in 0
the 0
increasing 0
number 0
of 0
cases 0
of 0
hepatitis 0
B 0
and 0
of 0
drug 0
- 0
related 0
deaths 0
. 0

Only 0
seven 0
patients 0
, 0
five 0
of 0
whom 0
have 0
metastatic 0
disease 0
, 0
survive 0
more 0
than 0
10 0
years 0
after 0
first 0
presentation 0
; 0
nine 0
patients 0
, 0
one 0
of 0
whom 0
has 0
secondaries 0
, 0
survive 0
for 0
5 0
years 0
or 0
less 0
. 0

Although 0
differences 0
were 0
not 0
significant 0
, 0
infants 0
in 0
the 0
experimental 0
group 0
had 0
more 0
changes 0
in 0
the 0
intermittent 0
mandatory 0
ventilation 0
( 0
IMV 0
) 0
settings 0
during 0
transport 0
, 0
and 0
more 0
such 0
infants 0
arrived 0
at 0
the 0
receiving 0
hospital 0
with 0
acceptable 0
pH 0
and 0
PCO2 0
values 0
. 0

Repetitive 0
sequences 0
are 0
present 0
in 0
at 0
least 0
three 0
introns 0
of 0
the 0
cytochrome B-gene
P I-gene
- I-gene
450PBc2 I-gene
gene I-gene
, 0
but 0
not 0
in 0
exons 0
or 0
the 0
5' 0
- 0
flanking 0
region 0
. 0

A 0
large 0
increase 0
of 0
serum 0
ketones 0
occurred 0
under 0
all 0
conditions 0
, 0
and 0
the 0
exercise 0
respiratory 0
quotient 0
suggested 0
some 0
increase 0
of 0
fat 0
utilization 0
, 0
WW 0
( 0
0.85 0
) 0
through 0
CW 0
( 0
0.84 0
) 0
to 0
CC 0
( 0
0.83 0
) 0
. 0

This 0
lack 0
of 0
correlation 0
may 0
be 0
due 0
to 0
variations 0
in 0
the 0
metabolic 0
activity 0
of 0
the 0
endometriotic 0
implants 0
present 0
at 0
different 0
stages 0
of 0
the 0
disease 0
. 0

Respiratory 0
adaptation 0
to 0
chronic 0
hypoxia 0
in 0
newborn 0
rats 0
. 0

Compound 0
1 0
is 0
either 0
21 0
- 0
O 0
- 0
angeloyl 0
, 0
22 0
- 0
O 0
- 0
tigloyl 0
R1 0
- 0
barrigenol 0
, 0
or 0
21 0
- 0
O 0
- 0
tigloyl 0
, 0
22 0
- 0
O 0
- 0
angeloyl 0
R1 0
- 0
barrigenol 0
. 0

Human 0
and 0
Chinese B-gene
hamster I-gene
S14 I-gene
protein I-gene
sequences I-gene
deduced 0
from 0
the 0
cDNAs 0
are 0
identical 0
. 0

RPS14 B-gene
introns 0
3 0
and 0
4 0
both 0
contain 0
Alu B-gene
sequences 0
. 0

One 0
of 0
the 0
most 0
relevant 0
aspects 0
in 0
achieving 0
the 0
consistent 0
survival 0
of 0
an 0
animal 0
undergoing 0
the 0
experimental 0
implantation 0
of 0
a 0
total 0
artificial 0
heart 0
is 0
obviously 0
related 0
to 0
the 0
correct 0
anatomic 0
placement 0
of 0
prosthetic 0
ventricles 0
inside 0
the 0
chest 0
. 0

An 0
exaggerated 0
tissue 0
response 0
adjacent 0
to 0
the 0
cyanoacrylate 0
site 0
suggested 0
a 0
potential 0
toxic 0
chemical 0
or 0
thermal 0
reaction 0
, 0
or 0
both 0
, 0
to 0
the 0
tissue 0
adhesive 0
, 0
but 0
there 0
was 0
no 0
evidence 0
of 0
any 0
distant 0
ocular 0
effects 0
. 0

These 0
findings 0
suggest 0
that 0
there 0
may 0
be 0
a 0
relationship 0
between 0
the 0
pathogenesis 0
of 0
MAL 0
, 0
narcolepsy 0
, 0
and 0
OSA 0
. 0

Among 0
82 0
superficial 0
lesions 0
34 0
were 0
classified 0
as 0
showing 0
CR 0
and 0
another 0
23 0
as 0
showing 0
PR 0
, 0
with 0
a 0
response 0
rate 0
of 0
69.5 0
% 0
. 0

Under 0
the 0
same 0
hematocrit 0
and 0
flow 0
conditions 0
, 0
the 0
rate 0
of 0
oxygen 0
saturation 0
decrease 0
was 0
significantly 0
higher 0
for 0
the 0
sickle 0
cells 0
than 0
for 0
normal 0
cells 0
. 0

While 0
the 0
examiner 0
observed 0
the 0
interior 0
of 0
the 0
eye 0
with 0
indirect 0
ophthalmoscopy 0
, 0
the 0
point 0
source 0
of 0
light 0
from 0
the 0
fiberoptic 0
light 0
pipe 0
was 0
moved 0
along 0
the 0
margins 0
of 0
the 0
episcleral 0
plaque 0
. 0

These 0
fusion 0
proteins 0
also 0
allowed 0
the 0
localization 0
of 0
the 0
transcriptional 0
activation 0
and 0
DNA 0
binding 0
domains 0
of 0
the 0
ToxR B-gene
protein I-gene
to 0
its 0
cytoplasmically 0
located 0
N 0
- 0
terminal 0
portion 0
. 0

From 0
life 0
- 0
table 0
analyses 0
of 0
these 0
patients 0
, 0
we 0
estimated 0
that 0
the 0
incidence 0
of 0
secondary 0
chondrosarcoma 0
in 0
patients 0
who 0
have 0
Ollier 0
disease 0
is 0
about 0
25 0
per 0
cent 0
at 0
the 0
age 0
of 0
forty 0
years 0
, 0
and 0
that 0
malignant 0
degeneration 0
is 0
almost 0
a 0
certainty 0
in 0
patients 0
who 0
have 0
Maffucci 0
syndrome 0
. 0

The 0
lethal 0
toxicity 0
of 0
inorganic 0
( 0
HgCl2 0
) 0
and 0
organic 0
( 0
CH3HgCl 0
) 0
mercury 0
chloride 0
was 0
compared 0
for 0
Coturnix 0
( 0
Japanese 0
quail 0
, 0
Coturnix 0
japonica 0
) 0
of 0
different 0
ages 0
from 0
hatch 0
through 0
adulthood 0
by 0
single 0
- 0
dose 0
acute 0
oral 0
and 0
intramuscular 0
injections 0
and 0
by 0
a 0
5 0
- 0
d 0
dietary 0
trial 0
. 0

Since 0
the 0
integrated 0
13h00 0
- 0
16h00 0
plasma 0
cortisol 0
estimation 0
is 0
cheaper 0
and 0
simpler 0
than 0
the 0
mean 0
13h00 0
- 0
16h00 0
plasma 0
cortisol 0
estimation 0
, 0
we 0
recommend 0
it 0
as 0
an 0
adjunct 0
in 0
the 0
diagnosis 0
of 0
Cushing 0
's 0
syndrome 0
. 0

Most 0
of 0
the 0
patients 0
had 0
locally 0
advanced 0
lesions 0
( 0
63 0
T3 0
- 0
4 0
: 0
91.5 0
% 0
) 0
according 0
to 0
the 0
adopted 0
TNM 0
system 0
( 0
Lederman 0
- 0
Gadeberg 0
, 0
Sisson 0
- 0
Jesse 0
) 0
. 0

The 0
risk 0
for 0
these 0
complications 0
is 0
increased 0
by 0
the 0
following 0
factors 0
: 0
multiple 0
gestation 0
, 0
the 0
combination 0
of 0
magnesium 0
sulfate 0
and 0
beta 0
- 0
adrenergic 0
agonist 0
, 0
and 0
the 0
use 0
of 0
adrenocortico 0
- 0
steroids 0
to 0
hasten 0
fetal 0
pulmonary 0
maturity 0
. 0

Chlorambucil 0
and 0
interferon B-gene
for 0
low 0
grade 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
. 0

Selenium 0
( 0
.1 0
ppm 0
) 0
and 0
E 0
( 0
50 0
IU/kg 0
) 0
supplementation 0
of 0
the 0
diet 0
of 0
the 0
sow 0
increased 0
plasma 0
tocopherol 0
and 0
Se 0
concentrations 0
, 0
but 0
did 0
not 0
increase 0
plasma B-gene
glutathione I-gene
peroxidase I-gene
( 0
GSH B-gene
- I-gene
Px I-gene
) 0
activity 0
. 0

Framingham 0
Type 0
A 0
behavior 0
was 0
positively 0
associated 0
with 0
diastolic 0
blood 0
pressure 0
( 0
r 0
= 0
0.17 0
, 0
p 0
less 0
than 0
0.05 0
) 0
among 0
the 0
women 0
. 0

The 0
in 0
vitro 0
antibacterial 0
potency 0
is 0
greatest 0
when 0
the 0
1 0
- 0
substituent 0
is 0
2,4 0
- 0
difluorophenyl 0
and 0
the 0
7 0
- 0
substituent 0
is 0
a 0
3 0
- 0
amino 0
- 0
1 0
- 0
pyrrolidinyl 0
group 0
. 0

The 0
M B-gene
reading I-gene
frame I-gene
differed 0
from 0
the 0
reported 0
sequence 0
by 0
a 0
single 0
nucleotide 0
corresponding 0
to 0
a 0
conservative 0
lysine 0
to 0
arginine 0
amino 0
acid 0
substitution 0
near 0
the 0
carboxy 0
- 0
terminus 0
conserved 0
among 0
the 0
M B-gene
proteins I-gene
of 0
paramyxoviruses 0
. 0

An 0
ion 0
chromatographic 0
method 0
was 0
used 0
to 0
determine 0
Br 0
ion 0
in 0
the 0
urine 0
of 0
Greyhounds 0
. 0

II 0
. 0

Laryngographic 0
changes 0
following 0
endotracheal 0
intubation 0
in 0
adults 0
. 0

Intensification 0
of 0
human 0
myocardial 0
contractile 0
activity 0
as 0
affected 0
by 0
blood 0
serum 0

Autotransplantation 0
of 0
a 0
vein 0
segment 0
with 0
valve 0
in 0
the 0
treatment 0
of 0
deep 0
vein 0
valvular 0
insufficiency 0
of 0
the 0
lower 0
extremity 0

The 0
relationships 0
among 0
four 0
descriptors 0
of 0
lactate 0
increase 0
: 0
lactate 0
threshold 0
( 0
LT 0
) 0
( 0
the 0
VO2 0
at 0
which 0
blood 0
lactate 0
concentration 0
begins 0
to 0
increase 0
above 0
the 0
resting 0
level 0
during 0
an 0
incremental 0
exercise 0
test 0
) 0
, 0
LT1 0
( 0
the 0
VO2 0
at 0
which 0
blood 0
lactate 0
increases 0
1 0
mM 0
above 0
the 0
resting 0
level 0
) 0
, 0
LT2 0
( 0
the 0
VO2 0
at 0
which 0
blood 0
lactate 0
concentration 0
reaches 0
a 0
fixed 0
value 0
of 0
2 0
mM 0
) 0
, 0
onset 0
of 0
blood 0
lactate 0
accumulation 0
( 0
OBLA 0
; 0
the 0
VO2 0
at 0
which 0
blood 0
lactate 0
reaches 0
a 0
concentration 0
of 0
4 0
mM 0
) 0
, 0
were 0
compared 0
with 0
aerobic 0
capacity 0
( 0
VO2max 0
) 0
and 0
12 0
min 0
running 0
performance 0
in 0
19 0
untrained 0
female 0
students 0
. 0

This 0
is 0
based 0
on 0
partitioning 0
an 0
underlying 0
multivariate 0
normal 0
distribution 0
. 0

The 0
observation 0
of 0
late 0
effects 0
after 0
irradiations 0
or 0
after 0
space 0
flights 0
show 0
the 0
difficulties 0
encountered 0
in 0
assessing 0
radiative 0
risks 0
during 0
long 0
duration 0
space 0
flights 0
. 0

Practical 0
use 0
and 0
interpretation 0
of 0
viral 0
hepatitis 0
B 0
markers 0
and 0
hepatic 0
biopsy 0
in 0
HBs B-gene
Ag I-gene
carriers 0
and 0
at 0
the 0
chronic 0
hepatitis 0
stage 0

The 0
1 0
, 0
2 0
, 0
3 0
and 0
4 0
year 0
survival 0
rates 0
were 0
94 0
% 0
, 0
84 0
% 0
, 0
76 0
% 0
and 0
63 0
% 0
, 0
respectively 0
. 0

Inhibition 0
of 0
histalog 0
- 0
stimulated 0
gastric 0
secretion 0
by 0
40 0
749 0
RP 0
, 0
a 0
new 0
long 0
- 0
acting 0
gastric 0
antisecretory 0
agent 0
. 0

Five 0
- 0
year 0
prospective 0
study 0
of 0
peripheral 0
white 0
blood 0
cells 0
in 0
infectious 0
mononucleosis 0
. 0

Northern 0
blotting 0
with 0
a 0
unique 0
17 0
- 0
mer 0
oligonucleotide 0
demonstrated 0
the 0
absence 0
of 0
the 0
mutant 0
sequence 0
in 0
the 0
mRNA 0
from 0
which 0
the 0
cDNA 0
library 0
giving 0
rise 0
to 0
the 0
mutant 0
cDNA 0
was 0
constructed 0
. 0

Novel 0
multigene 0
families 0
encoding 0
highly 0
repetitive 0
peptide 0
sequences 0
. 0

Chemotherapy 0
of 0
metastasizing 0
breast 0
cancer 0

In 0
recent 0
years 0
, 0
successful 0
physiological 0
models 0
have 0
been 0
developed 0
for 0
a 0
variety 0
of 0
volatile 0
and 0
nonvolatile 0
chemicals 0
, 0
and 0
their 0
ability 0
to 0
perform 0
the 0
extrapolations 0
needed 0
in 0
risk 0
assessment 0
has 0
been 0
demonstrated 0
. 0

Linear 0
extrapolation 0
is 0
used 0
below 0
the 0
experimental 0
data 0
range 0
to 0
establish 0
an 0
upper 0
bound 0
on 0
carcinogenic 0
risk 0
at 0
low 0
doses 0
. 0

Hisako 0
Minowa 0
who 0
has 0
worked 0
as 0
a 0
psychiatric 0
counsellor 0
in 0
industry 0
for 0
the 0
past 0
20 0
years 0

Deletion 0
mapping 0
studies 0
revealed 0
that 0
the 0
upstream 0
DNA 0
sequences 0
up 0
to 0
- 0
86 0
were 0
sufficient 0
for 0
the 0
optimal 0
basal 0
level 0
transcription 0
in 0
HeLa 0
cells 0
and 0
also 0
for 0
the 0
EIA B-gene
- 0
induced 0
transcription 0
. 0

Incorporation 0
of 0
the 0
polyene 0
antibiotic 0
amphotericin 0
B 0
( 0
AMB 0
) 0
in 0
liposomes 0
results 0
in 0
a 0
marked 0
reduction 0
in 0
drug 0
toxicity 0
with 0
no 0
loss 0
of 0
antifungal 0
potency 0
. 0

Eleven 0
healthy 0
, 0
normotensive 0
males 0
undergoing 0
routine 0
restorative 0
dental 0
care 0
were 0
evaluated 0
during 0
treatment 0
for 0
possible 0
hemodynamic 0
alterations 0
in 0
response 0
to 0
potential 0
sympathetic 0
nervous 0
system 0
stimulation 0
. 0

Serum B-gene
IgM I-gene
and 0
IgE B-gene
concentrations 0
, 0
allergen B-gene
- I-gene
specific I-gene
IgE I-gene
scores 0
, 0
and 0
the 0
tumor 0
E2R B-gene
status 0
were 0
combined 0
to 0
construct 0
a 0
three 0
- 0
level 0
risk 0
classification 0
that 0
was 0
more 0
prognostic 0
than 0
any 0
of 0
the 0
individual 0
components 0
. 0

The 0
M 0
- 0
3 0
subtype 0
was 0
an 0
adverse 0
prognostic 0
factor 0
. 0

Within 0
the 0
Strep 0
. 0
mutans 0
group 0
there 0
was 0
a 0
highly 0
- 0
significant 0
difference 0
between 0
Strep 0
. 0
mutans/Strep 0
. 0
cricetus 0
( 0
p 0
less 0
than 0
0.01 0
) 0
with 0
respect 0
to 0
mean 0
clump 0
size 0
. 0

These 0
results 0
indicate 0
that 0
T.C. 0
, 0
LDL B-gene
- I-gene
C. I-gene
, 0
HDL B-gene
- I-gene
C. I-gene
, 0
HDL2 B-gene
- I-gene
C. I-gene
, 0
apo B-gene
B I-gene
, 0
apo B-gene
A I-gene
- I-gene
I/B I-gene
ratio 0
and 0
apo B-gene
A I-gene
- I-gene
II/B I-gene
ratio 0
are 0
predictive 0
risk 0
factors 0
of 0
the 0
coronary 0
heart 0
disease 0
. 0

It 0
is 0
concluded 0
that 0
the 0
unique 0
suppository 0
formulation 0
of 0
CZX 0
- 0
S 0
is 0
useful 0
in 0
the 0
treatment 0
of 0
infections 0
in 0
children 0
with 0
heavy 0
psychophysiologic 0
disorders 0
and 0
in 0
children 0
who 0
can 0
not 0
take 0
oral 0
drugs 0
because 0
of 0
severe 0
vomiting 0
. 0

In 0
addition 0
, 0
marked 0
hypertension 0
accompanied 0
this 0
disorder 0
and 0
all 0
abnormalities 0
, 0
including 0
the 0
hypertension 0
, 0
responded 0
to 0
1 B-gene
- I-gene
desamino I-gene
- I-gene
8 I-gene
- I-gene
D I-gene
- I-gene
arginine I-gene
vasopressin I-gene
therapy 0
. 0

Single 0
photon 0
emission 0
computerized 0
tomography 0
( 0
SPECT 0
) 0
, 0
by 0
providing 0
three 0
- 0
dimensional 0
representation 0
of 0
myocardial 0
Tl 0
- 0
201 0
, 0
offers 0
promise 0
for 0
improved 0
localization 0
of 0
CAD 0
. 0

Computer 0
assisted 0
mapping 0
in 0
quantitative 0
analysis 0
of 0
cerebral 0
positron 0
emission 0
tomograms 0
. 0

In 0
19 0
patients 0
vagotomy 0
not 0
only 0
curbed 0
the 0
bleeding 0
but 0
provided 0
definitive 0
therapy 0
( 0
Visick 0
I 0
- 0
II 0
) 0
; 0
4 0
patients 0
died 0
( 0
mortality 0
rate 0
16 0
% 0
) 0
. 0

Documentation 0
of 0
a 0
successful 0
intrauterine 0
fertilization 0
with 0
delivery 0
of 0
a 0
term 0
baby 0
supports 0
the 0
theoretical 0
feasibility 0
of 0
the 0
EP 0
; 0
however 0
, 0
anovulation 0
incurred 0
by 0
our 0
procedure 0
appears 0
to 0
be 0
the 0
major 0
drawback 0
. 0

MRI 0
disclosed 0
one 0
or 0
more 0
of 0
the 0
following 0
abnormalities 0
in 0
24 0
( 0
63 0
% 0
) 0
of 0
38 0
treated 0
kidneys 0
: 0
( 0
1 0
) 0
loss 0
of 0
corticomedullary 0
differentiation 0
, 0
( 0
2 0
) 0
perirenal 0
fluid 0
, 0
( 0
3 0
) 0
subcapsular 0
hematoma 0
, 0
( 0
4 0
) 0
hemorrhage 0
into 0
a 0
renal 0
cyst 0
, 0
and 0
( 0
5 0
) 0
unexplained 0
abnormalities 0
. 0

The 0
results 0
obtained 0
are 0
similar 0
to 0
those 0
described 0
with 0
the 0
previous 0
Cremophor 0
formulation 0
although 0
greater 0
variability 0
in 0
induction 0
and 0
recovery 0
times 0
was 0
noted 0
with 0
the 0
emulsion 0
formulation 0
. 0

The 0
percentage 0
RFR 0
reduction 0
at 0
the 0
end 0
of 0
CPB 0
showed 0
significant 0
correlation 0
with 0
1 0
) 0
CPB 0
duration 0
( 0
r 0
= 0
0.49 0
) 0
, 0
2 0
) 0
oxygen 0
flow 0
rate 0
index 0
( 0
OFRI 0
) 0
, 0
i.e 0
. 0
flow/min 0
in 0
the 0
bubble 0
oxygenator/m2 0
bsa 0
( 0
r 0
= 0
0.38 0
) 0
, 0
and 0
3 0
) 0
blood 0
flow 0
rate 0
index 0
( 0
BFRI 0
) 0
, 0
i.e 0
. 0
average 0
volume 0
of 0
blood 0
pumped 0
through 0
the 0
heart 0
- 0
lung 0
machine/min 0
CPB 0
time/m2 0
bsa 0
( 0
r 0
= 0
0.51 0
) 0
. 0

Diagnosis 0
of 0
unilateral 0
renal 0
artery 0
lesions 0
after 0
captopril 0
administration 0
. 0

A 0
yeast 0
DNA 0
fragment 0
carrying 0
the 0
gene B-gene
CP I-gene
A1 I-gene
encoding 0
the 0
small 0
subunit 0
of 0
the 0
arginine 0
pathway 0
carbamoyl B-gene
- I-gene
phosphate I-gene
synthetase I-gene
has 0
been 0
sequenced 0
. 0

A 0
retrospective 0
study 0
of 0
banked 0
sera 0
from 0
19 0
cats 0
with 0
the 0
eosinophilic 0
granuloma 0
complex 0
revealed 0
that 0
68 0
% 0
of 0
affected 0
cats 0
had 0
circulating 0
antibodies 0
to 0
components 0
of 0
normal 0
cat 0
epithelium 0
. 0

In 0
memory 0
of 0
Magdelaine 0
Comtesse 0

The 0
H2 B-gene
receptor I-gene
antagonists 0
and 0
sucralfate 0
cost 0
about 0
the 0
same 0
and 0
have 0
few 0
side 0
effects 0
. 0

These 0
results 0
suggest 0
that 0
indoramin 0
may 0
have 0
Class 0
III 0
antiarrhythmic 0
activity 0
. 0

A 0
high 0
efficacy 0
of 0
the 0
combined 0
use 0
of 0
nontoxic 0
doses 0
of 0
two 0
pharmaceuticals 0
: 0
cystamine 0
( 0
50 0
mg/kg 0
) 0
and 0
mexamine 0
( 0
25 0
mg/kg 0
) 0
under 0
the 0
conditions 0
of 0
short 0
- 0
term 0
exogenous 0
hypoxia 0
( 0
7.5 0
% 0
O2 0
) 0
was 0
found 0
in 0
( 0
CBA 0
X 0
C57Bl 0
) 0
F1 0
mice 0
. 0

The 0
Mean 0
was 0
74,3 0
+/ 0
- 0
53,6 0
micrograms 0
J/g 0
Cr 0
, 0
the 0
Median 0
61 0
micrograms 0
J/g 0
Cr 0
. 0

In 0
the 0
region 0
Walgau 0
with 0
mixed 0
industrial 0
- 0
rural 0
population 0
an 0
iodine 0
deficiency 0
I 0
was 0
found 0
in 0
81 0
% 0
and 0
an 0
iodine 0
deficiency 0
II 0
in 0
45 0
% 0
. 0

The 0
structural 0
gene 0
for 0
hydrogenase B-gene
encodes 0
a 0
protein 0
product 0
of 0
molecular 0
mass 0
45820 0
Da 0
. 0

Pancreaticoduodenal 0
lymph 0
node 0
enlargement 0
, 0
regardless 0
of 0
cause 0
, 0
has 0
been 0
a 0
source 0
of 0
imaging 0
confusion 0
because 0
of 0
its 0
propensity 0
to 0
mimic 0
pancreatic 0
malignancy 0
yet 0
not 0
cause 0
biliary 0
obstruction 0
. 0

Interference 0
with 0
rheumatoid B-gene
factor I-gene
was 0
only 0
observed 0
in 0
the 0
ELISA 0
enzygnost 0
if 0
sera 0
were 0
not 0
pretreated 0
with 0
latex 0
adsorbents 0
. 0

All 0
patients 0
had 0
elevated 0
levels 0
of 0
serum B-gene
IgE I-gene
antibodies I-gene
to 0
the 0
crude 0
soybean 0
extract 0
; 0
binding 0
values 0
ranged 0
from 0
2.3 0
to 0
28.1 0
times 0
that 0
of 0
a 0
negative 0
control 0
serum 0
. 0

New 0
techniques 0
for 0
the 0
mass 0
spectrometry 0
of 0
natural 0
products 0
. 0

Dual 0
radionuclide 0
subtraction 0
imaging 0
of 0
the 0
spleen 0
using 0
67Ga 0
citrate 0
and 0
99mTc 0
is 0
useful 0
in 0
further 0
delineating 0
lesions 0
that 0
are 0
identified 0
on 0
either 0
a 0
routine 0
radiogallium 0
survey 0
or 0
on 0
a 0
conventional 0
sulfur 0
colloid 0
liver 0
- 0
spleen 0
image 0
. 0

Such 0
studied 0
acquired 0
with 0
low 0
energy 0
or 0
medium 0
energy 0
collimation 0
and 0
a 0
window 0
centered 0
on 0
the 0
159 0
keV 0
123I 0
photopeak 0
contain 0
appreciable 0
septal 0
breakthrough 0
signals 0
originating 0
from 0
Compton 0
scatter 0
of 0
high 0
energy 0
photons 0
primarily 0
from 0
124I 0
. 0

Nursing 0
education 0
- 0
- 0
the 0
computer 0
obligation 0
. 0

Shear 0
bond 0
strength 0
of 0
a 0
composite 0
resin 0
to 0
an 0
etched 0
glass 0
ionomer 0
. 0

An 0
additional 0
advantage 0
is 0
that 0
the 0
resin 0
can 0
be 0
removed 0
and 0
the 0
immunoperoxidase B-gene
technique 0
carried 0
out 0
on 0
thin 0
sections 0
. 0

Such 0
a 0
concept 0
is 0
crucial 0
to 0
our 0
understanding 0
of 0
the 0
pathology 0
of 0
ageing 0
in 0
general 0
. 0

We 0
consider 0
that 0
DIL 0
- 0
CP 0
is 0
a 0
safe 0
and 0
excellent 0
CP 0
in 0
CABG 0
surgery 0
and 0
we 0
are 0
now 0
utilizing 0
this 0
CP 0
in 0
all 0
patients 0
requiring 0
CABG 0
surgery 0
. 0

We 0
have 0
earlier 0
evolved 0
an 0
experimental 0
model 0
by 0
means 0
of 0
which 0
changes 0
identical 0
to 0
the 0
microembolism 0
syndrome 0
can 0
be 0
induced 0
from 0
a 0
reproducible 0
musculo 0
- 0
skeletal 0
trauma 0
in 0
pigs 0
observed 0
under 0
long 0
- 0
term 0
anesthesia 0
under 0
standardized 0
conditions 0
. 0

Although 0
no 0
statistical 0
significance 0
was 0
achieved 0
, 0
it 0
is 0
remarkable 0
that 0
there 0
was 0
a 0
clear 0
trend 0
for 0
the 0
superiority 0
of 0
Galphimia 0
D6 0
while 0
the 0
Galphimia 0
dilution 0
10 0
( 0
- 0
6 0
) 0
was 0
about 0
equally 0
effective 0
compared 0
with 0
placebo 0
. 0

The 0
volume 0
of 0
blood 0
to 0
the 0
flap 0
ranges 0
from 0
1 0
to 0
2 0
ml/min 0
, 0
collateral 0
circulation 0
to 0
the 0
flap 0
exists 0
, 0
but 0
is 0
negligible 0
, 0
and 0
there 0
is 0
little 0
change 0
in 0
the 0
capillary 0
blood 0
flow 0
as 0
the 0
flap 0
ages 0
. 0

With 0
aging 0
, 0
many 0
aspects 0
of 0
immune 0
function 0
change 0
. 0

Oral 0
candidiasis 0

In 0
addition 0
, 0
the 0
gcd1 B-gene
- I-gene
101 I-gene
mutation I-gene
suppressed 0
the 0
low 0
translational 0
efficiency 0
of 0
GCN4 B-gene
- 0
lacZ B-gene
mRNA 0
observed 0
in 0
gcn2 B-gene
- I-gene
and 0
gcn3 B-gene
- I-gene
cells 0
. 0

This 0
suggests 0
that 0
alaproclate 0
acutely 0
increases 0
the 0
responsiveness 0
of 0
postsynaptic 0
muscarinic B-gene
and I-gene
alpha I-gene
1 I-gene
adrenoceptors I-gene
. 0

The 0
concentrations 0
of 0
apo B-gene
A I-gene
- I-gene
I I-gene
and 0
apo B-gene
A I-gene
- I-gene
II I-gene
of 0
abstainers 0
decreased 0
significantly 0
compared 0
with 0
the 0
corresponding 0
changes 0
in 0
controls 0
. 0

The 0
distribution 0
of 0
patients 0
was 0
as 0
follows 0
: 0
group 0
1 0
- 0
- 0
complex 0
gamma 0
- 0
therapy 0
( 0
55 0
cases 0
) 0
, 0
group 0
2 0
- 0
- 0
complex 0
gamma 0
- 0
therapy 0
plus 0
iliac 0
lymphadenectomy 0
( 0
50 0
cases 0
) 0
and 0
group 0
3 0
- 0
- 0
complex 0
radiation 0
treatment 0
with 0
megavolt 0
bremsstrahlung 0
beam 0
from 0
the 0
luc 0
type 0
installation 0
and 0
iliac 0
lymphadenectomy 0
( 0
50 0
cases 0
) 0
. 0

The 0
availability 0
of 0
cryoprecipitate 0
and 0
DDAVP 0
offers 0
an 0
alternative 0
and 0
effective 0
treatment 0
for 0
the 0
temporary 0
reversal 0
of 0
uremic 0
bleeding 0
in 0
patients 0
who 0
require 0
urgent 0
invasive 0
procedures 0
. 0

Thrombophlebitis 0
and 0
pulmonary 0
embolism 0
in 0
congenital 0
factor B-gene
XII I-gene
deficiency 0

Biopsies 0
of 0
the 0
jejunal 0
mucosa 0
have 0
shown 0
abnormal 0
enzyme 0
activity 0
or 0
deficiencies 0
in 0
transport 0
mechanisms 0
. 0

Laboratory 0
pyrolyses 0
have 0
indeed 0
shown 0
that 0
PCBs 0
give 0
significant 0
yields 0
of 0
PCDFs 0
, 0
and 0
chlorobenzenes 0
give 0
both 0
PCDFs 0
and 0
PCDDs 0
. 0

A 0
significant 0
degree 0
of 0
homology 0
was 0
also 0
found 0
among 0
these 0
genes 0
and 0
the 0
Mtase B-gene
gene I-gene
of 0
related 0
phage 0
SPR 0
, 0
which 0
codes 0
for 0
an 0
enzyme 0
with 0
different 0
modification 0
specificity 0
. 0

Thyrotropin B-gene
- I-gene
releasing I-gene
hormone I-gene
- 0
induced 0
contraction 0
of 0
urethral 0
and 0
vaginal 0
muscle 0
. 0

In 0
a 0
blind 0
controlled 0
trial 0
, 0
15 0
patients 0
with 0
COCM 0
( 0
NYHA 0
II 0
- 0
III 0
) 0
with 0
sinus 0
rhythm 0
and 0
a 0
left 0
ventricular 0
ejection 0
fraction 0
( 0
LV 0
- 0
EF 0
) 0
of 0
34.5 0
+/ 0
- 0
2.6 0
% 0
received 0
consecutively 0
D 0
( 0
0.25 0
- 0
0.5 0
mg/d 0
) 0
, 0
placebo 0
( 0
PLAC 0
) 0
, 0
P 0
( 0
slow 0
releases 0
= 0
SR 0
) 0
( 0
80 0
mg/d 0
SR 0
) 0
and 0
both 0
drugs 0
combined 0
in 0
respective 0
doses 0
. 0

Mild 0
orbital 0
discomfort 0
occurred 0
in 0
some 0
patients 0
. 0

The 0
sample 0
is 0
deproteinized 0
and 0
after 0
centrifugation 0
valproic 0
acid 0
in 0
the 0
supernatant 0
is 0
measured 0
in 0
the 0
free 0
form 0
by 0
direct 0
injection 0
into 0
the 0
gas 0
chromatograph 0
. 0

Changes 0
in 0
muscarinic B-gene
acetylcholine I-gene
receptors I-gene
in 0
guinea 0
- 0
pig 0
lung 0
: 0
effects 0
of 0
aging 0
, 0
inhalation 0
of 0
an 0
allergen 0
, 0
administration 0
of 0
drugs 0
, 0
and 0
vagotomy 0
. 0

In 0
the 0
absence 0
of 0
other 0
stabilizers 0
, 0
increased 0
sucrose 0
can 0
provide 0
increased 0
thermoresistance 0
to 0
the 0
virus 0
in 0
2.5 0
% 0
albumin B-gene
. 0

The 0
overall 0
prevalence 0
of 0
psoriasis 0
was 0
4.79 0
% 0
in 0
men 0
and 0
4.85 0
% 0
in 0
women 0
. 0

Greek 0
classicism 0
in 0
living 0
structure 0
? 0
Some 0
deductive 0
pathways 0
in 0
animal 0
morphology 0
. 0

The 0
possible 0
origin 0
and 0
role 0
of 0
CSF B-gene
prolactin I-gene
are 0
discussed 0
. 0

Three 0
chromosomal B-gene
crsA I-gene
mutations I-gene
, 0
crsA1 B-gene
, 0
crsA4 B-gene
, 0
and 0
crsA47 B-gene
, 0
were 0
transferred 0
by 0
the 0
`` 0
gene 0
conversion 0
'' 0
process 0
to 0
B. 0
subtilis 0
plasmid 0
pRPD11 0
, 0
which 0
consists 0
of 0
the 0
entire B-gene
wild I-gene
- I-gene
type I-gene
rpoD I-gene
coding I-gene
sequence I-gene
, 0
encoding 0
the B-gene
major I-gene
sigma I-gene
43 I-gene
factor I-gene
of I-gene
B. I-gene
subtilis I-gene
RNA I-gene
polymerase I-gene
, 0
and 0
pUB110 0
. 0

Selective 0
effect 0
of 0
pulmonary 0
oedema 0
on 0
prostaglandin 0
E2 0
pharmacokinetics 0
in 0
rat 0
lung 0
. 0

This 0
article 0
will 0
briefly 0
review 0
the 0
published 0
data 0
on 0
the 0
morphology 0
, 0
function 0
, 0
and 0
biochemistry 0
of 0
the 0
normal 0
renal 0
medulla 0
and 0
the 0
pathology 0
associated 0
with 0
RPN 0
, 0
together 0
with 0
the 0
secondary 0
changes 0
which 0
give 0
rise 0
to 0
cortical 0
degeneration 0
or 0
epithelial 0
carcinoma 0
. 0

The 0
data 0
indicate 0
that 0
the 0
five 0
different 0
( 0
and 0
partially 0
overlapping 0
) 0
sry B-gene
messenger I-gene
RNAs I-gene
detectable 0
in 0
early 0
embryos 0
are 0
initiated 0
at 0
three 0
separate 0
sites 0
, 0
each 0
directly 0
upstream 0
from 0
one 0
of 0
the 0
three 0
protein 0
- 0
coding 0
regions 0
, 0
designated 0
( 0
in 0
5 0
' 0
to 0
3 0
' 0
order 0
) 0
beta 0
, 0
alpha 0
and 0
delta 0
. 0

Chronic 0
thyroiditis 0
as 0
a 0
risk 0
factor 0
of 0
B 0
- 0
cell 0
lymphoma 0
in 0
the 0
thyroid 0
gland 0
. 0

Plasma B-gene
secretin I-gene
levels 0
also 0
augmented 0
after 0
the 0
administration 0
of 0
ethanol 0
solutions 0
, 0
with 0
a 0
delay 0
of 0
about 0
one 0
hour 0
after 0
the 0
onset 0
of 0
acid 0
secretion 0
. 0

Spectrophotometric 0
microanalysis 0
of 0
ethylenediaminotetracetic 0
acid 0
in 0
pharmaceutical 0
preparations 0

A 0
comparison 0
among 0
the 0
5 0
' 0
flanking 0
regions 0
encompassing 0
the 0
presumptive 0
HS B-gene
promoter I-gene
of 0
the 0
soybean B-gene
HS I-gene
- I-gene
protein I-gene
genes I-gene
demonstrated 0
this 0
region 0
to 0
be 0
extremely 0
homologous 0
. 0

Results 0
of 0
this 0
study 0
indicate 0
that 0
GLC 0
of 0
short 0
chain 0
fatty 0
acids 0
produced 0
on 0
agar 0
medium 0
by 0
anaerobes 0
, 0
combined 0
with 0
simple 0
tests 0
such 0
as 0
Gram 0
's 0
stain 0
and 0
colonial 0
morphology 0
, 0
may 0
allow 0
fir 0
direct 0
presumptive 0
genus 0
identification 0
from 0
an 0
initial 0
pure 0
agar 0
culture 0
. 0

Using 0
this 0
method 0
, 0
we 0
measured 0
absorption 0
of 0
low 0
doses 0
of 0
vitamin 0
A 0
, 0
which 0
may 0
provide 0
a 0
more 0
physiological 0
approach 0
to 0
assessment 0
of 0
fat 0
malabsorption 0
. 0

Fulminant 0
hepatitis 0
A 0
in 0
chronic 0
HBV 0
carrier 0
. 0

Tissue 0
pressure 0
, 0
rCBF 0
, 0
and 0
water 0
content 0
were 0
measured 0
from 0
gray 0
matter 0
in 0
the 0
central 0
core 0
and 0
the 0
peripheral 0
margin 0
of 0
the 0
MCA 0
territory 0
over 0
6 0
h 0
after 0
MCAO 0
. 0

During 0
this 0
time 0
, 0
the 0
patients 0
all 0
had 0
the 0
characteristic 0
plasma 0
thyroid 0
hormone 0
changes 0
associated 0
with 0
amiodarone 0
therapy 0
, 0
i.e 0
. 0
increased 0
T4 0
, 0
free 0
T4 0
, 0
and 0
rT3 0
and 0
decreased 0
T3 0
, 0
while 0
remaining 0
clinically 0
euthyroid 0
. 0

Drug 0
and 0
nutrient 0
interactions 0
. 0

In 0
each 0
compartment 0
O2 0
is 0
removed 0
by 0
the 0
tissues 0
as 0
a 0
chemical 0
reaction 0
takes 0
place 0
between 0
O2 0
and 0
oxyhemoglobin B-gene
( 0
HbO2 B-gene
) 0
. 0

To 0
evaluate 0
the 0
effects 0
of 0
propranolol 0
on 0
myocardial 0
metabolism 0
after 0
coronary 0
reperfusion 0
, 0
serial 0
measurements 0
of 0
myocardial B-gene
creatine I-gene
kinase I-gene
( 0
CK B-gene
) 0
and 0
calcium 0
( 0
Ca 0
) 0
contents 0
and 0
CK B-gene
and 0
lactic 0
acid 0
( 0
LA 0
) 0
concentrations 0
in 0
coronary 0
sinus 0
blood 0
were 0
carried 0
out 0
in 0
33 0
open 0
- 0
chest 0
dogs 0
. 0

Dissolution 0
of 0
the 0
Pt 0
- 0
30 0
% 0
Ir 0
microelectrode 0
tip 0
was 0
observed 0
by 0
scanning 0
electron 0
microscopy 0
at 0
charge 0
densities 0
as 0
low 0
as 0
200 0
microC/cm2 0
X 0
ph 0
( 0
1 0
A/cm2 0
) 0
, 0
whereas 0
erosion 0
of 0
activated 0
iridium 0
microelectrodes 0
occurred 0
only 0
at 0
the 0
highest 0
charge 0
and 0
current 0
densities 0
( 0
3200 0
microC/cm2 0
X 0
ph 0
, 0
16 0
A/cm2 0
) 0
. 0

Cortisol 0
excretion 0
, 0
appeared 0
to 0
be 0
markedly 0
affected 0
by 0
the 0
season 0
although 0
other 0
factors 0
such 0
as 0
social 0
and 0
environmental 0
stress 0
can 0
not 0
be 0
discounted 0
. 0

Two 0
studies 0
on 0
the 0
relationship 0
between 0
taking 0
a 0
commercial 0
coaching 0
course 0
and 0
performance 0
on 0
the 0
Medical 0
College 0
Admission 0
Test 0
( 0
MCAT 0
) 0
are 0
reported 0
. 0

A 0
total 0
of 0
90 0
patients 0
were 0
randomly 0
allocated 0
either 0
to 0
an 0
MY 0
- 0
1 0
treated 0
or 0
an 0
untreated 0
group 0
. 0

Below 0
50 0
% 0
decrease 0
of 0
PaO2 0
, 0
NADH 0
was 0
reduced 0
largely 0
. 0

Angiography 0
was 0
performed 0
following 0
the 0
rCBF 0
study 0
and 0
the 0
degree 0
of 0
vasospasm 0
was 0
measured 0
on 0
the 0
angiograms 0
. 0

The 0
results 0
from 0
the 0
first 0
five 0
years 0
of 0
follow 0
up 0
in 0
1972 0
showed 0
a 0
4.7 0
- 0
fold 0
excess 0
mortality 0
for 0
ischaemic 0
and 0
other 0
heart 0
diseases 0
( 0
ICD 0
A83 0
- 0
A84 0
) 0
compared 0
with 0
a 0
comparable 0
reference 0
cohort 0
of 0
paper 0
mill 0
workers 0
. 0

The 0
financial 0
impact 0
of 0
childhood 0
asthma 0
has 0
not 0
been 0
assessed 0
since 0
Vance 0
and 0
Taylor 0
reported 0
their 0
data 0
in 0
Annals 0
of 0
Allergy 0
13 0
years 0
ago 0
. 0

Hypersplenism 0

Electrical 0
activity 0
was 0
evaluated 0
by 0
monitoring 0
the 0
general 0
electrocorticogram 0
( 0
ECoG 0
) 0
as 0
well 0
as 0
local 0
DC 0
steady 0
potential 0
( 0
two 0
sites 0
) 0
. 0

The 0
topography 0
and 0
trajectories 0
of 0
the 0
commissural 0
fibers 0
of 0
the 0
superior 0
temporal 0
region 0
( 0
STR 0
) 0
are 0
studied 0
using 0
the 0
autoradiographic 0
technique 0
. 0

The 0
diabetic 0
state 0
was 0
characterized 0
by 0
mild 0
insulin B-gene
deficiency 0
, 0
plasma 0
levels 0
being 0
73 0
% 0
of 0
controls 0
, 0
and 0
mild 0
hyperglycemia 0
, 0
with 0
nonfasting 0
plasma 0
glucose 0
levels 0
of 0
1.5 0
times 0
normal 0
. 0

The 0
primary 0
CT 0
findings 0
were 0
misinterpreted 0
as 0
a 0
brain 0
infarct 0
or 0
possibly 0
a 0
tumour 0
. 0

No 0
consistent 0
correlation 0
between 0
blood 0
pressure 0
change 0
and 0
SCR 0
- 0
change 0
was 0
seen 0
. 0

Shoulder 0
forearm 0
support 0
for 0
the 0
subluxed 0
shoulder 0
. 0

Piroxicam 0
produced 0
a 0
lower 0
incidence 0
of 0
gastric 0
ulcers 0
than 0
equivalent 0
doses 0
of 0
indomethacin 0
. 0

These 0
findings 0
suggest 0
that 0
both 0
in 0
the 0
early 0
stages 0
( 0
0T 0
, 0
0N 0
) 0
and 0
in 0
more 0
severe 0
stages 0
of 0
VWF 0
( 0
stages 0
1 0
- 0
2 0
) 0
cold 0
induced 0
hyperreactivity 0
in 0
the 0
digital 0
vessels 0
and 0
Raynaud 0
's 0
syndrome 0
are 0
vascular 0
disorders 0
of 0
functional 0
origin 0
occurring 0
without 0
any 0
prethrombotic 0
alterations 0
. 0

In 0
MCCP 0
functions 0
of 0
the 0
source 0
emission 0
, 0
surface 0
reflection 0
, 0
photoacceptor 0
sensitivity 0
are 0
approximated 0
by 0
the 0
normal 0
distribution 0
curves 0
. 0

However 0
, 0
kidneys 0
perfused 0
for 0
72 0
hr 0
demonstrated 0
more 0
similar 0
renal 0
functions 0
when 0
tested 0
by 0
either 0
IMPK 0
or 0
IBPK 0
. 0

To 0
assess 0
the 0
effects 0
of 0
alveolar 0
hypoxia 0
and 0
angiotensin B-gene
II I-gene
infusion 0
on 0
distribution 0
of 0
blood 0
flow 0
to 0
the 0
lung 0
we 0
performed 0
perfusion 0
lung 0
scans 0
on 0
anesthetized 0
mechanically 0
ventilated 0
lambs 0
. 0

A 0
flow 0
rate 0
of 0
at 0
least 0
5 0
mL/h 0
is 0
required 0
through 0
the 0
receptor 0
( 0
volume 0
, 0
0.4 0
mL 0
) 0
for 0
accurate 0
results 0
. 0

We 0
have 0
now 0
located 0
the 0
5 0
' 0
ends 0
of 0
the 0
two 0
remaining 0
late 0
mRNAs 0
. 0

The 0
efficacy 0
of 0
quantitative 0
and 0
qualitative 0
chloride 0
titrators 0
in 0
the 0
estimation 0
of 0
human 0
salt 0
intake 0
. 0

Doctor 0
Berglund 0
warns 0
members 0
of 0
union 0
pitfalls 0
. 0

Acute 0
appearance 0
of 0
hemiparesis 0
or 0
hemiplegia 0
with 0
initial 0
marked 0
spasticity 0
was 0
observed 0
in 0
8 0
stroke 0
patients 0
. 0

Recurrent 0
acute 0
rhinosinusitis 0
was 0
common 0
in 0
both 0
groups 0
of 0
patients 0
, 0
but 0
the 0
development 0
of 0
chronic 0
rhinosinusitis 0
was 0
only 0
found 0
in 0
patients 0
with 0
CVID 0
, 0
indicating 0
the 0
more 0
severe 0
nature 0
of 0
this 0
condition 0
compared 0
with 0
selective 0
IgA B-gene
deficiency 0
. 0

These 0
data 0
suggest 0
that 0
AP B-gene
- I-gene
A I-gene
may 0
be 0
potentially 0
useful 0
in 0
the 0
management 0
of 0
heart 0
failure 0
. 0

The 0
various 0
muscles 0
of 0
the 0
pelvic 0
floor 0
region 0
could 0
be 0
reflexly 0
activated 0
either 0
individually 0
or 0
as 0
a 0
mass 0
unit 0
depending 0
on 0
the 0
intensity 0
of 0
stimulation 0
. 0

It 0
has 0
been 0
reported 0
that 0
rat 0
blood 0
chloroform 0
levels 0
were 0
significantly 0
decreased 0
after 0
treatment 0
with 0
ClO2 0
. 0

The 0
frequency 0
of 0
lactase B-gene
phenotypes I-gene
in 0
Aymara 0
children 0
. 0

Activities 0
of 0
hepatic 0
cytochrome B-gene
P I-gene
- I-gene
450 I-gene
- 0
dependent 0
metabolizing 0
enzymes 0
such 0
as 0
aminopyrine B-gene
- I-gene
and I-gene
TMO I-gene
N I-gene
- I-gene
demethylase I-gene
and 0
aniline B-gene
hydroxylase I-gene
activity 0
were 0
decreased 0
by 0
pretreatment 0
of 0
rats 0
with 0
cimetidine 0
, 0
whereas 0
in 0
the 0
rats 0
pretreated 0
with 0
ranitidine 0
, 0
these 0
enzyme 0
activities 0
were 0
not 0
changed 0
. 0

Doxorubicin 0
, 0
dacarbazine 0
, 0
vincristine 0
, 0
and 0
cyclophosphamide 0
in 0
the 0
treatment 0
of 0
advanced 0
gastrointestinal 0
leiomyosarcoma 0
. 0

The 0
effect 0
of 0
the 0
opiate 0
antagonist 0
naloxone 0
was 0
evaluated 0
in 0
11 0
unselected 0
patients 0
with 0
cerebral 0
ischemia 0
. 0

Electrochemical 0
detection 0
of 0
depressed 0
circulating 0
levels 0
of 0
vitamin 0
K1 0
in 0
osteoporosis 0
. 0

In 0
the 0
present 0
experiments 0
, 0
we 0
investigate 0
the 0
role 0
played 0
by 0
the 0
temporal 0
pattern 0
of 0
neural 0
activity 0
during 0
the 0
ontogeny 0
of 0
frequency 0
tuning 0
in 0
the 0
mouse 0
central 0
auditory 0
system 0
. 0

Ultrastructure 0
of 0
the 0
tumor 0
in 0
1 0
patient 0
in 0
whom 0
transurethral 0
resection 0
was 0
performed 0
2 0
weeks 0
after 0
alum 0
irrigation 0
revealed 0
well 0
preserved 0
nuclear 0
chromatin 0
, 0
thus 0
, 0
suggesting 0
that 0
whatever 0
changes 0
occur 0
after 0
alum 0
irrigation 0
are 0
short 0
- 0
lived 0
. 0

The 0
generally 0
adopted 0
criteria 0
enabling 0
to 0
classify 0
the 0
examined 0
persons 0
into 0
the 0
following 0
3 0
groups 0
have 0
been 0
used 0
: 0
( 0
a 0
) 0
diseased 0
of 0
BEN 0
; 0
( 0
b 0
) 0
suspect 0
to 0
be 0
diseased 0
of 0
BEN 0
, 0
and 0
( 0
c 0
) 0
individuals 0
without 0
signs 0
of 0
a 0
renal 0
disease 0
. 0

For 0
this 0
purpose 0
, 0
a 0
simple 0
respiration 0
- 0
control 0
device 0
has 0
been 0
developed 0
that 0
enables 0
the 0
patient 0
to 0
monitor 0
breath 0
- 0
holding 0
during 0
successive 0
scans 0
. 0

The 0
POEMS 0
syndrome 0
( 0
Polyneuropathy 0
, 0
Organomegaly 0
, 0
Endocrinopathy 0
, 0
Monoclonal 0
component 0
, 0
Skin 0
) 0
. 0

During 0
a 0
disease 0
remission 0
there 0
was 0
an 0
increase 0
in 0
GAG 0
secretion 0
with 0
urine 0
, 0
linked 0
with 0
hyperheparinuria 0
( 0
13.1 0
- 0
fold 0
, 0
P 0
less 0
than 0
0.001 0
) 0
. 0

In 0
metastasis 0
- 0
free 0
patients 0
, 0
the 0
best 0
results 0
were 0
obtained 0
with 0
tumor 0
diameters 0
under 0
2 0
cm 0
regardless 0
of 0
their 0
localization 0
in 0
lung 0
tissue 0
and 0
with 0
2 0
- 0
- 0
4.9 0
cm 0
tumors 0
embedded 0
in 0
lung 0
parenchyma 0
. 0

Two 0
siblings 0
with 0
hemolytic 0
anemia 0
caused 0
by 0
triosephosphate B-gene
isomerase I-gene
deficiency 0
developed 0
a 0
progressive 0
neurological 0
syndrome 0
featuring 0
dystonic 0
movements 0
, 0
tremor 0
, 0
pyramidal 0
tract 0
signs 0
, 0
and 0
evidence 0
of 0
spinal 0
motor 0
neuron 0
involvement 0
. 0

One 0
extract 0
with 0
the 0
lowest 0
PCA 0
content 0
was 0
non 0
- 0
carcinogenic 0
. 0

In 0
the 0
10 0
patients 0
with 0
a 0
more 0
severe 0
degree 0
of 0
steatorrhea 0
the 0
decrease 0
in 0
fat 0
loss 0
approached 0
20 0
% 0
and 0
a 0
close 0
relationship 0
was 0
found 0
( 0
r 0
= 0
0.84 0
, 0
p 0
less 0
than 0
0.01 0
) 0
between 0
the 0
extent 0
of 0
the 0
fatty 0
acid 0
loss 0
on 0
placebo 0
and 0
the 0
decrease 0
of 0
this 0
loss 0
on 0
taurine 0
. 0

Aortic 0
diameters 0
in 0
infants 0
and 0
young 0
children 0
: 0
normative 0
angiographic 0
data 0
. 0

The 0
present 0
investigation 0
has 0
revealed 0
that 0
the 0
distribution 0
of 0
the 0
main 0
fatty 0
acids 0
in 0
Leptospira 0
phospholipids 0
is 0
similar 0
to 0
their 0
distribution 0
in 0
Leptospira 0
neutral 0
lipids 0
with 0
the 0
exception 0
of 0
unsaturated 0
fatty 0
acid 0
with 0
14 0
carbon 0
atoms 0
, 0
occurring 0
mainly 0
in 0
phospholipids 0
. 0

Since 0
1970 0
the 0
frequency 0
of 0
potassium 0
- 0
induced 0
ulceration 0
has 0
been 0
low 0
- 0
- 0
3 0
cases 0
per 0
100 0
000 0
patient 0
- 0
years 0
of 0
slow 0
- 0
release 0
tablet 0
use 0
. 0

Hydrocortisone 0
caused 0
lymphopenia 0
and 0
inhibited 0
the 0
blastogenic 0
response 0
of 0
peripheral 0
blood 0
lymphocytes 0
to 0
phytohemagglutinin B-gene
and 0
concanavalin B-gene
A I-gene
mitogens 0
. 0

To 0
test 0
the 0
feasibility 0
of 0
using 0
liposomes 0
to 0
deliver 0
therapeutic 0
agents 0
to 0
the 0
lungs 0
, 0
the 0
effect 0
of 0
liposome 0
- 0
encapsulated 0
superoxide B-gene
dismutase I-gene
( 0
SOD B-gene
) 0
or 0
catalase B-gene
on 0
pulmonary 0
oxygen 0
toxicity 0
was 0
studied 0
in 0
rats 0
. 0

Marrow 0
cell 0
necrosis 0
in 0
anorexia 0
nervosa 0
and 0
involuntary 0
starvation 0
. 0

For 0
comparison 0
conventional 0
heparin 0
was 0
used 0
during 0
18 0
dialyses 0
in 0
the 0
same 0
patients 0
. 0

Chenodeoxycholic 0
acid 0
( 0
cheno 0
) 0
and 0
ursodeoxycholic 0
acid 0
( 0
urso 0
) 0
dissolve 0
cholesterol 0
gallstones 0
in 0
man 0
. 0

Sensory 0
evoked 0
field 0
potentials 0
were 0
recorded 0
from 0
the 0
mesencephalic 0
reticular 0
formation 0
( 0
MRF 0
) 0
, 0
central 0
gray 0
( 0
CG 0
) 0
and 0
somatosensory 0
cortex 0
( 0
SCX 0
) 0
, 0
following 0
incremental 0
doses 0
of 0
halothane 0
in 0
freely 0
- 0
moving 0
rats 0
. 0

Ultrastructure 0
of 0
the 0
heart 0
muscle 0
in 0
experimental 0
myocardial 0
infarct 0
following 0
physical 0
training 0

Pharmacological 0
desympathization 0
leads 0
to 0
the 0
development 0
of 0
hyper 0
- 0
reactivity 0
of 0
the 0
true 0
pacemakers 0
to 0
noradrenaline 0
and 0
dopamine 0
and 0
triggers 0
off 0
changes 0
in 0
the 0
regulation 0
of 0
the 0
electric 0
activity 0
of 0
these 0
cells 0
by 0
catecholamines 0
. 0

OODG 0
is 0
a 0
diagnostic 0
method 0
permitting 0
assessment 0
of 0
ocular 0
pulse 0
curves 0
and 0
objective 0
determination 0
of 0
blood 0
pressures 0
in 0
the 0
ophthalmic 0
circulatory 0
system 0
( 0
retinal 0
and 0
ciliary 0
arterial 0
blood 0
pressures 0
) 0
simultaneously 0
for 0
both 0
eyes 0
, 0
without 0
dilatation 0
of 0
the 0
pupils 0
. 0

Viral 0
infections 0
have 0
long 0
been 0
suspected 0
to 0
be 0
causative 0
agents 0
in 0
a 0
number 0
of 0
inner 0
ear 0
dysfunctions 0
. 0

55 0
+/ 0
- 0
11 0
% 0
) 0
, 0
all 0
other 0
parameters 0
showed 0
a 0
significant 0
increase 0
: 0
RS 0
index 0
5.4 0
+/ 0
- 0
1.4 0
mVolt 0
to 0
6.0 0
+/ 0
- 0
1.7 0
mVolt 0
( 0
p 0
less 0
than 0
0.01 0
) 0
; 0
EDD 0
6.3 0
+/ 0
- 0
0.7 0
to 0
6.8 0
+/ 0
- 0
0.9 0
cm 0
( 0
p 0
less 0
than 0
0.001 0
) 0
; 0
HV 0
1017 0
+/ 0
- 0
151 0
ml 0
to 0
1099 0
+/ 0
- 0
261 0
ml 0
( 0
p 0
less 0
than 0
0.01 0
) 0
; 0
EDV 0
371 0
+/ 0
- 0
131 0
ml 0
to 0
441 0
+/ 0
- 0
175 0
ml 0
( 0
p 0
less 0
than 0
0.001 0
) 0
; 0
RBV 0
117 0
+/ 0
- 0
57 0
ml 0
to 0
151 0
+/ 0
- 0
77 0
ml 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Retrospective 0
analyses 0
of 0
this 0
death 0
revealed 0
a 0
significant 0
decrease 0
of 0
the 0
left 0
ventricular 0
( 0
LV 0
) 0
end 0
- 0
diastolic 0
volume 0
index 0
( 0
EDVI 0
) 0
of 0
21 0
ml/m2 0
( 0
36 0
% 0
of 0
normal 0
) 0
. 0

In 0
group 0
I 0
adults 0
both 0
of 0
these 0
variables 0
increased 0
. 0

Polysorbate 0
80 0
did 0
not 0
have 0
a 0
direct 0
stimulant 0
or 0
relaxant 0
effect 0
on 0
either 0
guinea 0
pig 0
ileum 0
or 0
rat 0
uterus 0
, 0
however 0
, 0
it 0
antagonised 0
the 0
contractions 0
induced 0
by 0
acetylcholine 0
, 0
histamine 0
, 0
barium 0
, 0
5 0
- 0
hydroxytryptamine 0
and 0
carbachol 0
in 0
a 0
dose 0
- 0
dependent 0
manner 0
. 0

Individual 0
alcohol 0
reaction 0
profiles 0
. 0

Vitiligo 0
in 0
diabetes 0
mellitus 0
. 0

The 0
pharmacokinetics 0
of 0
each 0
tetracycline 0
in 0
serum 0
and 0
dermal 0
, 0
suction 0
blister 0
fluid 0
were 0
determined 0
after 0
oral 0
doses 0
of 0
300 0
mg 0
lymecycline 0
or 0
100 0
mg 0
doxycycline 0
on 0
the 0
3rd 0
day 0
. 0

A 0
high 0
degree 0
of 0
correlation 0
in 0
the 0
sense 0
of 0
the 0
classic 0
conception 0
of 0
brain 0
localization 0
of 0
neuropsychological 0
syndromes 0
was 0
found 0
. 0

Either 0
a 0
UV 0
detector 0
set 0
at 0
268 0
nm 0
or 0
an 0
electrochemical 0
( 0
EC 0
) 0
detector 0
set 0
at 0
a 0
potential 0
of 0
+0.9 0
V 0
( 0
versus 0
Ag/AgCl/3 0
M 0
NaCl 0
) 0
was 0
used 0
to 0
monitor 0
the 0
drug 0
. 0

35 0
patients 0
with 0
acute 0
arterial 0
occlusions 0
[ 0
27 0
] 0
and 0
graft 0
thromboses 0
[ 0
8 0
] 0
, 0
responsible 0
for 0
severe 0
and 0
recent 0
ischemia 0
, 0
were 0
treated 0
by 0
fibrinolytic 0
therapy 0
( 0
Urokinase B-gene
: 0
1 0
000 0
units/kg/hour 0
, 0
and 0
Lys 0
Plasminogen B-gene
) 0
. 0

The 0
mean 0
transfer 0
ratios 0
of 0
the 0
drug 0
into 0
the 0
genital 0
tissues 0
to 0
the 0
concentration 0
in 0
the 0
uterine 0
arterial 0
blood 0
were 0
such 0
that 0
the 0
transfer 0
ratio 0
into 0
the 0
portio 0
vaginalis 0
was 0
the 0
highest 0
, 0
followed 0
by 0
the 0
uterine 0
cervix 0
and 0
the 0
myometrium 0
, 0
and 0
that 0
into 0
the 0
oviduct 0
was 0
the 0
lowest 0
with 0
about 0
1/2 0
that 0
into 0
the 0
portio 0
vaginalis 0
. 0

We 0
conclude 0
that 0
androgenic 0
hormones 0
reduce 0
HDL B-gene
- I-gene
cholesterol I-gene
concentrations 0
and 0
the 0
HDL2 B-gene
- I-gene
cholesterol I-gene
subfraction 0
, 0
possibly 0
by 0
enhancing 0
hepatic B-gene
triglyceride I-gene
lipase I-gene
activity 0
. 0

Because 0
of 0
its 0
wide 0
spectrum 0
of 0
activity 0
particularly 0
against 0
ampicillin 0
resistant 0
strains 0
of 0
H. 0
influenzae 0
and 0
because 0
of 0
its 0
good 0
tolerance 0
Cefaclor 0
is 0
very 0
useful 0
in 0
treatment 0
of 0
respiratory 0
tract 0
infections 0
in 0
children 0
. 0

Lower 0
extremity 0
weight 0
bearing 0
under 0
various 0
standing 0
conditions 0
in 0
independently 0
ambulatory 0
patients 0
with 0
hemiparesis 0
. 0

Shape 0
factor 0
correlated 0
well 0
with 0
hemodynamic 0
data 0
for 0
RV/LV 0
systolic 0
pressure 0
ratios 0
( 0
r 0
= 0
0.93 0
, 0
p 0
less 0
than 0
0.001 0
) 0
for 0
normalized 0
interventricular 0
pressure 0
differences 0
( 0
r 0
= 0
- 0
0.95 0
, 0
p 0
less 0
than 0
0.001 0
) 0
. 0

The 0
effective 0
and 0
low 0
toxic 0
dose 0
schedules 0
of 0
KW 0
- 0
2083 0
should 0
be 0
investigated 0
further 0
. 0

Furthermore 0
, 0
the 0
initial 0
plasma 0
retinol 0
level 0
in 0
conjunction 0
with 0
RBP B-gene
was 0
found 0
to 0
be 0
even 0
lower 0
in 0
12 0
patients 0
( 0
35.1 0
micrograms 0
dl 0
- 0
1 0
, 0
3.7 0
mg 0
dl 0
- 0
1 0
) 0
who 0
subsequently 0
had 0
cancer 0
recurrence 0
than 0
in 0
those 0
who 0
remained 0
free 0
of 0
apparent 0
cancer 0
( 0
44.5 0
micrograms 0
dl 0
- 0
1 0
, 0
4.6 0
mg 0
dl 0
- 0
1 0
) 0
. 0

The 0
results 0
indicate 0
that 0
: 0
1 0
) 0
the 0
initial 0
response 0
to 0
tethering 0
varies 0
according 0
to 0
previous 0
penning 0
and 0
handling 0
experience 0
, 0
2 0
) 0
although 0
the 0
circadian 0
rhythm 0
of 0
cortisol 0
was 0
either 0
altered 0
or 0
disrupted 0
during 0
estrus 0
, 0
such 0
disruptions 0
were 0
not 0
influenced 0
by 0
type 0
of 0
penning 0
and 0
3 0
) 0
tether 0
stalls 0
may 0
chronically 0
increase 0
cortisol 0
concentrations 0
in 0
gilts 0
. 0

This 0
laser 0
provided 0
sufficient 0
power 0
in 0
an 0
amniotic 0
fluid 0
medium 0
to 0
occlude 0
placental 0
vessels 0
as 0
large 0
as 0
7 0
mm 0
in 0
diameter 0
within 0
6 0
seconds 0
at 0
a 0
power 0
density 0
of 0
2000 0
W/cm2 0
. 0

On 0
d 0
112 0
, 0
progesterone 0
was 0
higher 0
( 0
P 0
less 0
than 0
.05 0
) 0
in 0
hysterectomized 0
heifers 0
than 0
in 0
other 0
treatment 0
groups 0
. 0

Male 0
Japanese 0
quail 0
were 0
chronically 0
exposed 0
to 0
5000 0
ppm 0
manganese 0
( 0
Mn 0
) 0
as 0
particulate 0
manganese 0
oxide 0
( 0
Mn3O4 0
) 0
in 0
their 0
diet 0
from 0
hatching 0
to 0
75 0
days 0
of 0
age 0
. 0

This 0
study 0
indicated 0
that 0
the 0
Japanese 0
quail 0
was 0
less 0
sensitive 0
to 0
particulate 0
Mn3O4 0
exposure 0
than 0
rodents 0
treated 0
comparably 0
. 0

Plasma 0
and 0
bladder 0
platinum 0
concentration 0
were 0
measured 0
following 0
intravesical 0
DDP 0
, 0
and 0
also 0
histopathological 0
examination 0
, 0
urinalysis 0
, 0
complete 0
blood 0
count 0
and 0
blood 0
chemistry 0
were 0
performed 0
in 0
order 0
to 0
know 0
the 0
toxicity 0
of 0
intravesical 0
DDP 0
. 0

Scintigraphic 0
visualisation 0
of 0
Walker 0
carcinoma 0
- 0
256 0
in 0
Sprague 0
- 0
Dawley 0
rats 0
by 0
means 0
of 0
99mTc 0
- 0
labelled 0
monocytes 0
. 0

These 0
results 0
were 0
compared 0
with 0
those 0
obtained 0
in 0
- 0
D 0
mothers 0
and 0
pups 0
, 0
after 0
giving 0
the 0
mothers 0
an 0
oral 0
supplement 0
( 0
10 0
i.u 0
. 0
vitamin 0
D3/day 0
) 0
during 0
the 0
period 0
of 0
lactation 0
( 0
20 0
days 0
) 0
. 0

Rabbit 0
eyes 0
were 0
removed 0
and 0
held 0
in 0
temperature 0
- 0
regulated 0
chambers 0
and 0
irrigated 0
with 0
saline 0
. 0

Before 0
birth 0
, 0
there 0
were 0
a 0
few 0
perivascular 0
adrenergic 0
nerves 0
and 0
correspondingly 0
low 0
ovarian 0
NE 0
levels 0
. 0

Monitoring 0
changes 0
in 0
the 0
heart 0
rate 0
of 0
the 0
premature 0
fetus 0
during 0
tocolysis 0
with 0
the 0
beta 0
- 0
adrenomimetics 0
partusisten 0
and 0
Pre 0
- 0
par 0

Since 0
September 0
1980 0
to 0
June 0
1983 0
we 0
have 0
treated 0
32 0
patients 0
with 0
ovarian 0
cancer 0
. 0

The 0
results 0
suggest 0
that 0
the 0
calcium 0
antagonist 0
, 0
diltiazem 0
, 0
may 0
modify 0
the 0
effects 0
of 0
isoflurane 0
on 0
myocardial 0
function 0
. 0

Supraventricular 0
arrhythmias 0
- 0
- 0
digoxin 0
and 0
quinidine 0
revisited 0
. 0

Visidex 0
I 0
is 0
unsuitable 0
for 0
storage 0
and 0
re 0
- 0
reading 0
. 0

Treatment 0
with 0
oxyphenylbutazone 0
and 0
hydrocortisone 0
failed 0
to 0
inhibit 0
the 0
raised 0
serum B-gene
CPN I-gene
levels 0
. 0

40,000 0
) 0
. 0

The 0
Cox 0
proportional 0
hazards 0
model 0
was 0
applied 0
to 0
the 0
data 0
in 0
order 0
to 0
determine 0
the 0
prognostic 0
factors 0
for 0
long 0
- 0
term 0
survival 0
. 0

This 0
suggests 0
that 0
mechanisms 0
other 0
than 0
an 0
excessive 0
increase 0
in 0
myocardial 0
oxygen 0
demand 0
may 0
be 0
responsible 0
for 0
the 0
many 0
episodes 0
occurring 0
outside 0
the 0
hospital 0
. 0

Duration 0
of 0
remission 0
in 0
advanced 0
gastric 0
cancer 0
patients 0
responding 0
to 0
sequential 0
dose 0
of 0
MTX 0
and 0
5 0
- 0
FU 0

These 0
data 0
showed 0
: 0
that 0
progesterone 0
secretion 0
is 0
pulsatile 0
throughout 0
the 0
human 0
luteal 0
phase 0
, 0
with 0
maximum 0
frequency 0
in 0
the 0
mid 0
- 0
luteal 0
phase 0
; 0
that 0
during 0
the 0
mid 0
- 0
luteal 0
phase 0
most 0
subjects 0
had 0
progesterone 0
levels 0
both 0
above 0
and 0
below 0
currently 0
accepted 0
ovulatory 0
thresholds 0
; 0
the 0
use 0
of 0
a 0
single 0
measurement 0
of 0
progesterone 0
in 0
the 0
mid 0
- 0
luteal 0
phase 0
is 0
not 0
always 0
a 0
reliable 0
indicator 0
of 0
ovulation 0
; 0
a 0
threshold 0
greater 0
than 0
20 0
nmol/l 0
may 0
yield 0
an 0
unacceptable 0
number 0
of 0
false 0
negative 0
results 0
. 0

The 0
fast 0
real 0
- 0
time 0
digital 0
processing 0
of 0
the 0
N2 0
and 0
flow 0
signals 0
incorporated 0
filtering 0
, 0
delay 0
compensation 0
, 0
and 0
corrections 0
for 0
the 0
effects 0
of 0
changes 0
in 0
gas 0
composition 0
and 0
temperature 0
. 0

This 0
slope 0
tended 0
to 0
be 0
higher 0
( 0
approximately 0
1.6 0
dB/dB 0
) 0
for 0
L1 0
= 0
L2 0
greater 0
than 0
80 0
dB 0
. 0

Histamine 0
reactivity 0
was 0
significantly 0
reduced 0
after 0
the 0
nifedipine 0
aerosol 0
, 0
the 0
geometric 0
mean 0
provocative 0
concentration 0
causing 0
a 0
35 0
% 0
fall 0
in 0
specific 0
airway 0
conductance 0
, 0
rising 0
from 0
5.0 0
to 0
10.9 0
mg/ml 0
of 0
histamine 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Pharmacologic 0
doses 0
of 0
vitamin 0
B6 0
administered 0
to 0
lactating 0
women 0
have 0
been 0
reported 0
to 0
suppress 0
plasma B-gene
prolactin I-gene
. 0

There 0
was 0
a 0
significant 0
but 0
similar 0
elevation 0
of 0
mean 0
O2 0
uptake 0
during 0
40 0
min 0
postexercise 0
by 0
13.6 0
% 0
in 0
both 0
the 0
fasted 0
( 0
p 0
less 0
than 0
0.001 0
) 0
and 0
fed 0
state 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

National 0
Institutes 0
of 0
Health 0
Consensus 0
Development 0
Conference 0
Statement 0
. 0

In 0
controls 0
, 0
most 0
of 0
the 0
output 0
from 0
the 0
conduit 0
occurred 0
during 0
type 0
I 0
activity 0
( 0
73 0
+/ 0
- 0
14 0
% 0
) 0
. 0

Greater 0
attenuation 0
of 0
the 0
N1 0
- 0
P2 0
and 0
baseline 0
- 0
P2 0
amplitude 0
of 0
the 0
probe 0
EPs 0
was 0
observed 0
when 0
the 0
probe 0
stimulus 0
was 0
presented 0
to 0
the 0
right 0
ear 0
and 0
the 0
verbal 0
material 0
presented 0
to 0
the 0
left 0
ear 0
than 0
when 0
the 0
opposite 0
stimulation 0
arrangement 0
was 0
used 0
. 0

Twenty 0
- 0
five 0
patients 0
( 0
80,6 0
% 0
) 0
with 0
mixed 0
neoplasms 0
were 0
operated 0
on 0
by 0
total 0
conservative 0
parotidectomy 0
( 0
T.C.P 0
. 0
) 0
, 0
3 0
( 0
9,7 0
% 0
) 0
by 0
S.P 0
. 0
and 0
3 0
( 0
9,7 0
% 0
) 0
by 0
En 0
. 0

The 0
comparisons 0
revealed 0
that 0
female 0
homicide 0
- 0
suicide 0
perpetrators 0
were 0
more 0
likely 0
than 0
female 0
homicide 0
- 0
suicide 0
victims 0
to 0
live 0
in 0
mobile 0
homes 0
, 0
kill 0
their 0
lover 0
or 0
ex 0
- 0
lover 0
, 0
have 0
their 0
crime 0
accidentally 0
discovered 0
, 0
leave 0
a 0
suicide 0
note 0
, 0
kill 0
on 0
a 0
weekend 0
, 0
and 0
be 0
depressed 0
, 0
but 0
are 0
less 0
likely 0
than 0
female 0
homicide 0
- 0
suicide 0
victims 0
to 0
live 0
with 0
a 0
spouse 0
. 0

Germ 0
- 0
free 0
rabbits 0
given 0
mouse 0
CRF 0
- 0
flora 0
showed 0
values 0
quite 0
different 0
from 0
control 0
animals 0
for 0
most 0
parameters 0
, 0
indicating 0
unsuitability 0
of 0
mouse 0
CRF 0
flora 0
to 0
'normalize 0
' 0
rabbits 0
. 0

The 0
weak 0
relationships 0
between 0
F 0
and 0
Zn 0
to 0
Mg 0
clearly 0
have 0
no 0
significant 0
effect 0
on 0
the 0
contents 0
of 0
these 0
elements 0
in 0
bone 0
. 0

L3 0
- 0
L4 0
compressive 0
load 0
was 0
calculated 0
using 0
a 0
model 0
of 0
the 0
anatomy 0
of 0
the 0
trunk 0
musculoskeletal 0
system 0
. 0

Diagnosis 0
: 0
progressive 0
multifocal 0
leukoencephalopathy 0
. 0

Component 0
P100 0
was 0
associated 0
with 0
a 0
frontal 0
negativity 0
of 0
similar 0
latency 0
favoring 0
the 0
hypothesis 0
of 0
a 0
dipolar 0
occipital 0
generator 0
. 0

Although 0
no 0
differences 0
were 0
noted 0
in 0
the 0
decrease 0
in 0
platelet 0
counts 0
between 0
the 0
two 0
groups 0
, 0
fibrinogen B-gene
levels 0
and 0
alpha B-gene
2 I-gene
- I-gene
antiplasmin I-gene
levels 0
declined 0
less 0
drastically 0
in 0
the 0
antithrombin B-gene
- 0
treated 0
group 0
. 0

Failure 0
of 0
stapedius 0
reflexometry 0
in 0
the 0
diagnosis 0
of 0
myasthenia 0
gravis 0
. 0

Factors 0
influencing 0
semen 0
characteristics 0
in 0
young 0
boars 0
reared 0
in 0
a 0
subtropical 0
environment 0
were 0
studied 0
. 0

[ 0
14C 0
] 0
- 0
beta 0
- 0
phenethylamine 0
, 0
its 0
distribution 0
after 0
administration 0
by 0
various 0
routes 0
to 0
cats 0
, 0
and 0
the 0
effects 0
of 0
monoamine B-gene
oxidase I-gene
inhibitors 0
. 0

All 0
runners 0
drank 0
a 0
total 0
of 0
1.4 0
L 0
of 0
water 0
during 0
the 0
race 0
. 0

The 0
rates 0
of 0
total 0
energy 0
use 0
( 0
mean 0
+/ 0
- 0
SD 0
= 0
39.3 0
+/ 0
- 0
1.2 0
vs 0
35.7 0
+/ 0
- 0
1.3 0
kJ 0
X 0
min 0
- 0
1 0
; 0
P 0
less 0
than 0
0.05 0
) 0
were 0
significantly 0
higher 0
at 0
- 0
10 0
degrees 0
C 0
than 0
at 0
22 0
degrees 0
C 0
. 0

Clinical 0
aspects 0
and 0
therapy 0

Following 0
seven 0
days 0
' 0
incubation 0
both 0
at 0
20 0
degrees 0
C 0
and 0
28 0
degrees 0
C 0
, 0
Ae 0
. 0
vexans 0
nip 0
. 0
was 0
capable 0
of 0
transmitting 0
the 0
virus 0
. 0

Blood 0
eosinophils 0
in 0
patients 0
with 0
Taenia 0
saginata 0
taeniasis 0
. 0

The 0
imino 0
proton 0
of 0
T3 0
in 0
the 0
O6meG.T 0
12 0
- 0
mer 0
and 0
G3 0
in 0
the 0
O6meG.N 0
12 0
- 0
mer 0
helix 0
, 0
which 0
are 0
associated 0
with 0
the 0
modification 0
site 0
, 0
resonate 0
at 0
unusually 0
high 0
field 0
( 0
8.5 0
to 0
9.0 0
ppm 0
) 0
compared 0
to 0
imino 0
protons 0
in 0
Watson 0
- 0
Crick 0
base 0
pairs 0
( 0
12.5 0
to 0
14.5 0
ppm 0
) 0
. 0

The 0
recommendation 0
is 0
made 0
that 0
specific 0
sub 0
- 0
groups 0
of 0
attempters 0
need 0
to 0
be 0
identified 0
and 0
may 0
warrant 0
specialized 0
intervention 0
strategies 0
. 0

There 0
was 0
no 0
correlation 0
between 0
secretor 0
status 0
and 0
clinical 0
status 0
, 0
spirometry 0
measurements 0
, 0
salivary B-gene
and I-gene
serum I-gene
lysozyme I-gene
levels 0
or 0
rates 0
of 0
respiratory 0
tract 0
colonization 0
with 0
P. 0
aeruginosa 0
and 0
S. 0
aureus 0
. 0

There 0
was 0
no 0
correlation 0
between 0
secretor 0
status 0
and 0
clinical 0
status 0
, 0
spirometry 0
measurements 0
, 0
salivary 0
and 0
serum B-gene
lysozyme I-gene
levels 0
or 0
rates 0
of 0
respiratory 0
tract 0
colonization 0
with 0
P. 0
aeruginosa 0
and 0
S. 0
aureus 0
. 0

Gains 0
increased 0
3.5 0
% 0
( 0
P 0
less 0
than 0
.10 0
) 0
and 0
feed 0
conversion 0
improved 0
5.9 0
% 0
( 0
P 0
less 0
than 0
.07 0
) 0
in 0
steers 0
fed 0
.28 0
% 0
AS 0
- 0
VFA 0
compared 0
with 0
gain 0
and 0
feed 0
conversion 0
of 0
the 0
control 0
steers 0
. 0

Postnatal 0
volumetric 0
development 0
of 0
the 0
prefrontal 0
cortex 0
in 0
the 0
rat 0
. 0

Daily 0
and 0
seasonal 0
rhythmicity 0
in 0
the 0
methylation 0
of 0
pineal 0
indolic 0
compounds 0
in 0
adult 0
male 0
golden 0
hamsters 0
, 0
kept 0
under 0
natural 0
conditions 0
. 0

The 0
transit 0
time 0
was 0
significantly 0
shortened 0
. 0

Among 0
the 0
patients 0
grades 0
1 0
- 0
2 0
- 0
3 0
, 0
81 0
% 0
had 0
a 0
good 0
out 0
come 0
without 0
any 0
neurological 0
abnormality 0
, 0
among 0
the 0
patients 0
graded 0
4 0
- 0
5 0
, 0
only 0
27 0
% 0
had 0
a 0
fair 0
out 0
come 0
. 0

Activity 0
of 0
acid B-gene
hydrolases I-gene
of 0
peripheral 0
blood 0
leukocytes 0
in 0
focal 0
and 0
segmental 0
pneumonia 0
in 0
children 0

Comparative 0
studies 0
of 0
the 0
antithrombin B-gene
III I-gene
level 0
and 0
plasminogen B-gene
activator I-gene
activity 0
in 0
patients 0
with 0
thrombophlebitis 0

We 0
also 0
observed 0
that 0
the 0
predictive 0
ability 0
of 0
the 0
selected 0
attitudes 0
and 0
orientations 0
increased 0
considerably 0
from 0
1975 0
to 0
1982 0
. 0

Relations 0
between 0
cellular 0
electrical 0
activity 0
and 0
cardiac 0
mechanical 0
activity 0
in 0
man 0
, 0
the 0
dog 0
and 0
the 0
rabbit 0

Treatment 0
of 0
Paget 0
's 0
disease 0
. 0

Improvement 0
of 0
the 0
CRT 0
display 0
of 0
an 0
averager 0
. 0

Is 0
desensitization 0
' 0
for 0
ragweed 0
hay 0
fever 0
immunologically 0
specific 0
? 0

Renal 0
excretion 0
of 0
sulphadimidine 0
in 0
normal 0
and 0
uraemic 0
subjects 0
. 0

Experiences 0
with 0
the 0
clinical 0
and 0
experimental 0
use 0
of 0
Urat 0
- 0
I 0
lithotriptor 0
. 0

Formation 0
of 0
hyphae 0
and 0
chlamydospores 0
by 0
Cryptococcus 0
laurentii 0
. 0

Evaluation 0
of 0
thyroid 0
function 0
. 0

The 0
effect 0
of 0
a 0
tissue 0
emulsion 0
, 0
vitamin 0
A 0
and 0
nonspecific 0
gamma B-gene
- I-gene
globulin I-gene
on 0
the 0
blood 0
clearance 0
in 0
rabbits 0

HL B-gene
- I-gene
A I-gene
antibodies I-gene
in 0
polytransfused 0
patients 0

Demonstration 0
of 0
fine 0
structure 0
of 0
the 0
guinea 0
pig 0
organ 0
of 0
Corti 0
after 0
electron 0
microscopic 0
silver 0
staining 0

Histamine 0
metabolism 0
in 0
hemorrhagic 0
- 0
hypotensive 0
shock 0

They 0
also 0
discuss 0
the 0
existing 0
nomenclature 0
. 0

Relaxation 0
of 0
catch 0
in 0
a 0
molluscan 0
smooth 0
muscle 0
. 0

Studies 0
on 0
alcoholic 0
liver 0
injury 0
. 0

Hypothalamic 0
control 0
of 0
coronary 0
circulation 0
in 0
the 0
dog 0
. 0

Evidence 0
for 0
two 0
distinctive 0
clinical 0
, 0
epidemiological 0
, 0
and 0
immunological 0
types 0
of 0
infection 0
. 0

Ultraviolet 0
light 0
- 0
induced 0
kinin B-gene
formation 0
in 0
human 0
skin 0
. 0

Poliomyelitis 0
from 0
a 0
vaccine 0
. 0

To 0
the 0
problem 0
of 0
the 0
stimulation 0
of 0
the 0
growth 0
of 0
transplantable 0
tumors 0
of 0
animals 0
previously 0
treated 0
with 0
antineoplastic 0
antibiotics 0

Assessment 0
of 0
nutrient 0
media 0
in 0
the 0
diagnosis 0
of 0
diptheria 0

Aluminium 0
resin 0
for 0
the 0
treatment 0
of 0
the 0
hyperkalamia 0
of 0
renal 0
failure 0
. 0

Value 0
of 0
the 0
EMG 0
in 0
the 0
diagnosis 0
of 0
a 0
cardiomyopathy 0
associated 0
with 0
a 0
myotonic 0
myopathy 0
. 0

D 0
. 0

Prevention 0
of 0
maternal 0
Rh 0
sensitization 0
: 0
anti B-gene
- I-gene
Rh I-gene
immune I-gene
globulin I-gene
. 0

Serotonin 0
levels 0
in 0
infant 0
hypothyroidism 0
. 0

Cerebrospinal 0
fluid 0
transferrin B-gene
II I-gene
studies 0
in 0
ischemic 0
disorders 0
of 0
the 0
central 0
nervous 0
system 0
. 0

High 0
dosages 0
of 0
D 0
- 0
penicillamine 0
in 0
pulmonary 0
fibroses 0

Inverse 0
relation 0
between 0
serum 0
IgG B-gene
concentration 0
and 0
glucose 0
and 0
xylose 0
absorption 0
in 0
Zambian 0
African 0
adults 0
. 0

Disorders 0
of 0
platelet 0
function 0
in 0
chronic 0
myeloid 0
leukemias 0

The 0
effect 0
of 0
anticonvulsants 0
on 0
sodium B-gene
- I-gene
potassium I-gene
- I-gene
activated I-gene
ATPase I-gene
, 0
sodium 0
, 0
and 0
potassim 0
in 0
cortex 0
. 0

Effect 0
of 0
immune 0
lymphocytes 0
and 0
of 0
rabbit B-gene
- I-gene
anti I-gene
- I-gene
lymphocyte I-gene
globulin I-gene
( 0
RAMLG B-gene
) 0
on 0
infected 0
macrophages 0
exposed 0
to 0
increased 0
incubation 0
temperature 0
in 0
vitro 0
. 0

Estral 0
cycle 0
in 0
white 0
rats 0
in 0
the 0
low 0
and 0
high 0
mountains 0
of 0
Kirghizia 0

Lactation 0
of 0
baboons 0
fed 0
a 0
low 0
protein 0
maintenance 0
diet 0
. 0

Studies 0
on 0
the 0
organic 0
matrix 0
of 0
human 0
ear 0
ossicles 0

A 0
medical 0
- 0
geographical 0
review 0

Age 0
and 0
sex 0
structure 0
of 0
the 0
natural 0
population 0
of 0
Ornithodoros 0
tatarovski 0
Ol 0
. 0

Sensitization 0
to 0
hyperlactatemia 0
induced 0
by 0
phenformin 0
after 0
subtotal 0
ablation 0
of 0
the 0
pancreas 0
. 0

Vitamin 0
D3 0
and 0
calcium 0
absorption 0
in 0
the 0
chick 0
. 0

The 0
incidence 0
of 0
tumours 0
in 0
young 0
chickens 0
. 0

Laboratory 0
aspects 0
with 0
particular 0
reference 0
to 0
chemotherapy 0
and 0
control 0
. 0

Their 0
effect 0
on 0
the 0
guinea 0
pig 0
vas 0
deferens 0
. 0

Androgens 0
and 0
growth 0
. 0

Effect 0
of 0
variations 0
in 0
time 0
interval 0
between 0
treatment 0
with 0
BCG 0
and 0
quartz 0
dust 0
on 0
translocation 0
of 0
quartz 0
dust 0
from 0
the 0
lungs 0
to 0
their 0
regional 0
lymph 0
nodes 0
. 0

Therapeutic 0
action 0
of 0
a 0
new 0
antibiotic 0
- 0
corticoid 0
association 0
used 0
for 0
instillations 0
in 0
otology 0

Clinico 0
- 0
physiological 0
experiment 0

Enzyme 0
histochemical 0
findings 0
in 0
the 0
ultimobranchial 0
body 0
of 0
the 0
horse 0

Familial 0
glutathione B-gene
reductase I-gene
deficiency 0
and 0
disorder 0
of 0
glutathione 0
synthesis 0
in 0
the 0
erythrocyte 0

Studies 0
on 0
swine 0
enteroviruses 0
. 0

Serodiagnosis 0
of 0
ectromelia 0
in 0
laboratory 0
mice 0

Ultrasound 0
effect 0
on 0
the 0
cytochrome B-gene
oxidase I-gene
activity 0

Metastasis 0
of 0
colon 0
carcinoma 0
to 0
the 0
lip 0
. 0

Genesis 0
of 0
foam 0
cells 0
: 0
study 0
in 0
rats 0
after 0
administration 0
of 0
Cloforex 0
. 0

Pre B-gene
- I-gene
beta I-gene
- I-gene
1 I-gene
lipoprotein I-gene
and 0
early 0
detection 0
of 0
risk 0
factors 0
for 0
coronary 0
heart 0
disease 0
. 0

Conditions 0
influencing 0
inhibitors 0
of 0
the 0
colony B-gene
- I-gene
stimulating I-gene
factor I-gene
( 0
CSF B-gene
) 0
. 0

Absence 0
of 0
action 0
potentials 0
in 0
frog 0
slow 0
muscle 0
fibres 0
paralysed 0
by 0
botulinum B-gene
toxin I-gene
. 0

An 0
automated 0
method 0
for 0
the 0
quantitative 0
analysis 0
of 0
the 0
polyamines 0
putrescine 0
, 0
spermidine 0
and 0
spermine 0
in 0
cerebrospinal 0
fluid 0
( 0
CSF 0
) 0
was 0
used 0
to 0
analyze 0
CSF 0
samples 0
from 0
37 0
patients 0
with 0
central 0
nervous 0
system 0
( 0
CNS 0
) 0
tumors 0
and 0
from 0
13 0
patients 0
without 0
tumors 0
. 0

I 0
. 0

Disulfiram 0
and 0
the 0
drug 0
- 0
induced 0
effects 0
on 0
motility 0
. 0

Particles 0
resembling 0
microbodies 0
in 0
normal 0
and 0
neoplastic 0
perianal 0
glands 0
of 0
dogs 0
. 0

Natural 0
and 0
induced 0
malarias 0
in 0
western 0
hemisphere 0
monkeys 0
. 0

A 0
study 0
in 0
vivo 0
of 0
adrenergic B-gene
receptors I-gene
in 0
the 0
rectum 0
and 0
in 0
the 0
internal 0
and 0
sphincter 0
of 0
the 0
cat 0
. 0

Intracranial 0
arachnoid 0
cyst 0
of 0
the 0
middle 0
fossa 0
demonstrated 0
by 0
positive 0
99mTc 0
brainscintigraphy 0
. 0

Effects 0
of 0
estrogen 0
and 0
glucocorticoids 0
on 0
the 0
adrenal 0
development 0
of 0
the 0
fetus 0
. 0

Copper 0
and 0
ceruloplasmin B-gene
content 0
in 0
pregnant 0
women 0
and 0
in 0
women 0
with 0
certain 0
gynecological 0
diseases 0

Effect 0
of 0
noise 0
on 0
CO 0
- 0
induced 0
increases 0
of 0
LAP B-gene
and 0
GPT B-gene
activity 0
in 0
the 0
plasma 0
of 0
rats 0

Kinetics 0
of 0
calcium 0
metabolism 0
. 0

On 0
the 0
transport 0
of 0
mucus 0
and 0
its 0
rheologic 0
simulants 0
in 0
ciliated 0
systems 0
. 0

A 0
hydrodynamic 0
description 0
of 0
the 0
osmotic 0
reflection 0
coefficient 0
with 0
application 0
to 0
the 0
pore 0
theory 0
of 0
transcapillary 0
exchange 0
. 0

Pathology 0
of 0
neuritis 0
caudae 0
equinae 0
in 0
the 0
horse 0

Abnormal 0
characteristics 0
and 0
verticillation 0
in 0
Platynothrus 0
peltifer 0

Selected 0
topics 0
in 0
laboratory 0
animal 0
medicine 0
. 0

Problems 0
common 0
to 0
pediatrics 0
and 0
anesthesiology 0

Clinical 0
course 0
and 0
nursing 0
care 0
of 0
patients 0
with 0
decubitus 0
ulcer 0
- 0
- 0
use 0
of 0
pillows 0
stuffed 0
with 0
buckwheat 0
chaff 0

On 0
parents 0

From 0
the 0
Icelandic 0
Red 0
Cross 0
activities 0

Effects 0
of 0
alcoholism 0
on 0
the 0
family 0

Treatment 0
and 0
care 0
of 0
adult 0
diabetes 0
mellitus 0
without 0
coma 0

Re 0
- 0
examining 0
methylbenzene 0
( 0
toluene 0
) 0
as 0
a 0
treatment 0
for 0
Ancylostomum 0
caninum 0
. 0

Junctions 0
between 0
cells 0
of 0
the 0
human 0
enamel 0
organ 0
. 0

Electrocardiograms 0
of 0
the 0
month 0
. 0

Composites 0
as 0
restoration 0
materials 0

Hodgkin 0
's 0
disease 0
. 0

Value 0
of 0
Normotest 0
and 0
antithrombin B-gene
3 I-gene
in 0
the 0
assessment 0
of 0
liver 0
function 0
. 0

Glutathione B-gene
peroxidase I-gene
in 0
human 0
red 0
cells 0
in 0
health 0
and 0
disease 0
. 0

Histopathologic 0
response 0
of 0
gingival 0
tissues 0
to 0
hemodent 0
and 0
aluminum 0
chloride 0
solutions 0
as 0
tissue 0
displacement 0
materials 0
. 0

Changes 0
following 0
periodontal 0
surgery 0
. 0

Intracellular 0
pH 0
, 0
H 0
ion 0
flux 0
and 0
H 0
ion 0
permeability 0
coefficient 0
in 0
bullfrog 0
toe 0
muscle 0
. 0

Teratological 0
studies 0
on 0
SF 0
- 0
837 0
. 0

Directives 0
concerning 0
medical 0
care 0

Proceedings 0
: 0
Reversible 0
complete 0
heart 0
block 0
following 0
surgery 0
of 0
congenital 0
heart 0
defects 0

Method 0
of 0
synthesis 0
of 0
the 0
rheumatoid B-gene
factor I-gene
in 0
clinico 0
- 0
immunological 0
studies 0

Variations 0
of 0
the 0
timing 0
of 0
deflections 0
in 0
the 0
His 0
bundle 0
recordings 0
. 0

Extracellular 0
fibril 0
formation 0
by 0
neuroglial 0
cells 0
at 0
the 0
vitreoretinal 0
junction 0
of 0
the 0
human 0
eye 0
. 0

Blood 0
platelets 0
, 0
coagulation 0
factors 0
and 0
morphologic 0
organ 0
changes 0
following 0
scalding 0
shock 0
in 0
rhesus 0
monkeys 0

Cell 0
viability 0
and 0
lysosomal B-gene
enzymes I-gene

State 0
- 0
approved 0
schools 0
of 0
nursing 0
- 0
- 0
R.N. 0
, 0
1972 0
. 0

Further 0
investigation 0
on 0
the 0
chemotactic 0
influence 0
of 0
thymic B-gene
hormone I-gene
on 0
lymphocytes 0

1,3 0
- 0
bis 0
( 0
2 0
- 0
chloroethyl 0
) 0
- 0
1 0
- 0
nitrosourea 0
( 0
bcnu 0
) 0
and 0
other 0
nitrosoureas 0
in 0
cancer 0
treatment 0
: 0
a 0
review 0
. 0

Pneumothorax 0
following 0
lung 0
abscess 0
in 0
the 0
renal 0
transplant 0
patient 0
. 0

Taxonomically 0
significant 0
colour 0
changes 0
in 0
Brevibacterium 0
linens 0
probably 0
associated 0
with 0
a 0
carotenoid 0
- 0
like 0
pigment 0
. 0

Temporal 0
relationships 0
and 0
the 0
development 0
phase 0
affected 0
. 0

A 0
short 0
history 0
of 0
dermatology 0
in 0
Lagos 0
, 0
Nigeria 0
. 0

Local 0
graft 0
irradiation 0
as 0
an 0
adjunct 0
to 0
pharmacologic 0
immunosuppression 0
. 0

Letter 0
: 0
Salmonella 0
detection 0

Role 0
of 0
biocenosis 0
in 0
the 0
manifestation 0
of 0
Shigella 0
virulence 0

The 0
effect 0
of 0
antilymphocyte 0
sera 0
on 0
formation 0
of 0
transplantation 0
and 0
anti 0
- 0
infection 0
immunity 0
in 0
mice 0

60th 0
birthday 0
of 0
colonel 0
prof. 0
e.cerny 0
m.d 0
. 0

Morphology 0
of 0
bacteriophages 0
of 0
Klebsiella 0
bacilli 0
. 0

Cortical 0
afferents 0
to 0
the 0
entorhinal 0
cortex 0
of 0
the 0
Rhesus 0
monkey 0
. 0

Mechanism 0
of 0
immunogenesis 0
in 0
vaccination 0
with 0
streptomycin 0
- 0
dependent 0
mutants 0
of 0
salmonellae 0
and 0
shigellae 0
. 0

Resistance 0
pattern 0
of 0
Mycobacterium 0
tuberculosis 0
( 0
H 0
37 0
Rv 0
) 0
to 0
a 0
new 0
antibiotic 0
, 0
lividomycin 0

Pulmonary 0
arterial 0
pressure 0
and 0
structure 0
in 0
the 0
patas 0
monkey 0
after 0
prolonged 0
administration 0
of 0
aminorex 0
fumarate 0
. 0

Effect 0
of 0
triftazin 0
and 0
aminazin 0
on 0
hippocampal 0
bioelectric 0
activity 0

Sex 0
ratio 0
at 0
birth 0
. 0

Pathological 0
processes 0
in 0
the 0
cervix 0
uteri 0

Benign 0
intramural 0
tumors 0
of 0
the 0
esophagus 0

General 0
formulae 0
for 0
estimating 0
heritability 0
in 0
a 0
population 0
with 0
related 0
parents 0
. 0

Measurement 0
of 0
open 0
- 0
loop 0
responses 0
to 0
electrical 0
stimulation 0
in 0
olfactory 0
bulb 0
of 0
cat 0
. 0

Glucose 0
disappearance 0
rate 0
and 0
changes 0
in 0
plasma 0
nutrients 0
after 0
intravenouly 0
injected 0
glucose 0
in 0
normoglycaemic 0
and 0
hypoglycaemic 0
underweight 0
newborns 0
. 0

Normal 0
values 0
for 0
the 0
peripheral 0
blood 0
and 0
bone 0
marrow 0
of 0
the 0
grey 0
( 0
Armenian 0
) 0
hamster 0

The 0
relationship 0
of 0
human 0
umbilical 0
arterial 0
and 0
venous 0
plasma 0
levels 0
of 0
corticosteroids 0
to 0
gestational 0
age 0
. 0

Antibiotic 0
effect 0
of 0
the 0
mud 0
from 0
heviz 0

Sulfuric 0
acid 0
concentration 0
in 0
the 0
catalyzed 0
breathalyzer 0
ampules 0
. 0

Role 0
of 0
histoclinical 0
studies 0
in 0
the 0
prophylaxis 0
of 0
spontaneous 0
abortions 0

Range 0
behavior 0
of 0
Hereford 0
, 0
Hereford 0
x 0
Holstein 0
and 0
Holstein 0
non 0
- 0
lactating 0
heifers 0
. 0

Chemical 0
constituents 0
of 0
the 0
gentianaceae 0
V 0
: 0
tetraoxygenated 0
xanthones 0
of 0
Swertia 0
chirata 0
Buch. 0
- 0
Ham 0
. 0

Methyl 0
mercury 0
intoxication 0
in 0
rat 0
kidneys 0
. 0

Microdetermination 0
of 0
adrenocortical 0
steroids 0
by 0
double 0
isotope 0
method 0
. 0

Compensative 0
justice 0
and 0
moral 0
investment 0
among 0
Japanese 0
, 0
Chinese 0
, 0
and 0
Koreans 0
. 0

Effects 0
of 0
cortisone 0
, 0
starvation 0
, 0
and 0
rickets 0
on 0
oxidative 0
enzyme 0
activities 0
of 0
epiphyseal 0
cartilage 0
from 0
rats 0
. 0

Metal 0
coordination 0
compounds 0
of 0
thiabendazole 0
. 0

Estimation 0
of 0
renin B-gene
secretion 0
rate 0
and 0
renal 0
plasma 0
flow 0
from 0
peripheral 0
and 0
renal B-gene
vein I-gene
renin I-gene
levels 0
. 0

Disability 0
insurance 0
under 0
social 0
security 0
. 0

Choice 0
of 0
vessel 0
. 0

Suppression 0
of 0
food 0
intake 0
in 0
the 0
rat 0
by 0
tung 0
oil 0
. 0

Studies 0
of 0
lipoprotein B-gene
- I-gene
X I-gene
( 0
LP B-gene
- I-gene
X I-gene
) 0
and 0
bile 0
acids 0
in 0
familial 0
LCAT B-gene
deficiency 0
. 0

Pneumothorax 0
complicated 0
by 0
chronic 0
steroid 0
treatment 0
. 0

Polycythemia 0
- 0
1973 0
. 0

Manifest 0
anxiety 0
of 0
Vietnam 0
returnees 0
and 0
undergraduates 0
. 0

Familial 0
juvenile 0
nephronophthisis 0

Early 0
heparin 0
therapy 0
in 0
60 0
children 0
with 0
acute 0
meningococcemia 0
. 0

9,11 0
- 0
Seco 0
steroids 0
derived 0
from 0
estradiol 0
3 0
- 0
methyl 0
ether 0
. 0

Psychological 0
examinations 0
in 0
patients 0
with 0
chronic 0
kidney 0
insufficiency 0

Possibilities 0
of 0
needleless 0
administration 0
of 0
various 0
substances 0
to 0
animals 0

Change 0
in 0
the 0
makeup 0
of 0
the 0
blood 0
following 0
a 0
short 0
- 0
term 0
local 0
action 0
of 0
a 0
permanent 0
magnetic 0
field 0
on 0
the 0
human 0
body 0

Observations 0
on 0
the 0
flight 0
activities 0
of 0
Chrysops 0
caecutiens 0
L 0
. 0

Combination 0
of 0
3 0
multiple 0
primary 0
malignant 0
and 0
benign 0
tumors 0
of 0
the 0
breasts 0
and 0
uterus 0

Analysis 0
of 0
clearance 0
curve 0
of 0
rose 0
bengal 0
- 0
I 0
- 0
131 0

Proceedings 0
: 0
Barrels 0
and 0
somatotopy 0
in 0
S 0
I 0
neocortex 0
of 0
the 0
brush 0
- 0
tailed 0
possum 0
. 0

Antivitamin 0
K 0
agents 0

Canine 0
reproduction 0
: 0
effects 0
of 0
a 0
single 0
injection 0
of 0
medroxyprogesterone 0
acetate 0
on 0
the 0
reproductive 0
organs 0
of 0
the 0
bitch 0
. 0

3 0
. 0

Hypoglycemic 0
and 0
antidiabetic 0
properties 0

Hematopoietic 0
system 0
in 0
streptococcal 0
allergy 0
. 0

Letter 0
: 0
Aryl B-gene
hydrocarbon I-gene
hydroxylase I-gene
and 0
smoking 0
. 0

Evaluation 0
of 0
1,10 0
- 0
phenanthroline 0
as 0
a 0
reagent 0
for 0
sialic 0
acid 0
determinations 0
. 0

Delta 0
- 0
aminolevulinic 0
acid 0
in 0
physiological 0
conditions 0
and 0
some 0
diseases 0
in 0
children 0

Nonteratogenicity 0
in 0
rats 0
of 0
blighted 0
potatoes 0
and 0
compounds 0
contained 0
in 0
them 0
. 0

VII 0
. 0

Isolation 0
of 0
tha 0
avian 0
reticuloendothelial 0
virus 0
( 0
strain 0
T 0
) 0
. 0

Observations 0
on 0
saccules 0
of 0
rats 0
exposed 0
to 0
long 0
- 0
term 0
hypergravity 0
. 0

Effect 0
of 0
a 0
high 0
- 0
intensity 0
SHF 0
field 0
on 0
the 0
blood 0
coagulation 0
system 0

The 0
levels 0
of 0
galactosyltransferase B-gene
activity 0
in 0
sera 0
from 0
normal 0
children 0
and 0
patients 0
with 0
cystic 0
fibrosis 0
. 0

Lack 0
of 0
effect 0
of 0
the 0
appetite 0
stimulant 0
pizotifen 0
( 0
BC 0
105 0
) 0
on 0
the 0
absorption 0
of 0
isonicotinylhydrazine 0
. 0

Relationship 0
between 0
gross 0
lesions 0
and 0
Escherichia 0
coli 0
serotypes 0
in 0
chronic 0
respiratory 0
disease 0
( 0
CRD 0
) 0
of 0
poultry 0
. 0

Plastic 0
solution 0
of 0
elbow 0
joint 0
ankylosis 0
with 0
a 0
decorticated 0
cylindrical 0
flap 0

Effects 0
of 0
ionizing 0
radiation 0
in 0
the 0
human 0
oral 0
cavity 0
and 0
oropharynx 0
: 0
results 0
of 0
a 0
survey 0
. 0

The 0
Twentieth 0
Anniversary 0
of 0
the 0
Pomeranian 0
Medical 0
Academy 0
. 0

Immunelectrophoretic 0
pattern 0
of 0
Wassermann 0
reagin 0
and 0
comparison 0
of 0
the 0
appearance 0
time 0
between 0
RPCF B-gene
and 0
FTA B-gene
antibodies I-gene

Motile 0
nocardoid 0
Actinomycetales 0
. 0

Electrocardiographic 0
QRS 0
complexes 0
and 0
vectorcardiographic 0
QRS 0
loop 0

Study 0
of 0
antinuclear 0
autoantibodies 0
by 0
immunofluorescence 0
technic 0
in 0
collagen B-gene
diseases 0

Cardiac 0
preservation 0
. 0

Labial 0
bar 0
. 0

Yusuf 0
Dawood 0
Docrat 0
L.R.C.P 0
. 0

Dr 0
. 0

The 0
metabolism 0
and 0
pharmacology 0
of 0
5 0
- 0
fluorouracil 0
. 0

Spleen 0
weight 0
in 0
rats 0
during 0
tumour 0
growth 0
and 0
in 0
homograft 0
rejection 0
. 0

Isolation 0
of 0
Proteus 0
vulgaris 0
MC 0
- 0
63 0
from 0
carcinoma 0
63 0
and 0
its 0
antitumor 0
effect 0
on 0
Crocker 0
sarcoma 0
180 0
and 0
Ehrlich 0
carcinoma 0
. 0

Human 0
synovial 0
fluid 0
: 0
detection 0
of 0
a 0
new 0
component 0
. 0

Effects 0
of 0
temperature 0
and 0
moulting 0
cycle 0
on 0
melanin 0
synthesis 0
in 0
the 0
newt 0
, 0
Triturus 0
cristatus 0
. 0

Some 0
reflexions 0
apropos 0
of 0
a 0
personal 0
statistical 0
study 0
of 0
513 0
arterial 0
embolisms 0

LA 0
- 0
3848 0
- 0
MS 0
. 0

Immunochemical 0
studies 0
with 0
filarial 0
antigens 0
. 0

Morphological 0
and 0
functional 0
alterations 0
noted 0
after 0
baboon 0
renal 0
allotransplantation 0
. 0

Heterogeneity 0
of 0
human B-gene
serum I-gene
albumin I-gene
. 0

Analysis 0
of 0
corticosteroids 0
. 0

Reactivities 0
to 0
horse B-gene
anti I-gene
- I-gene
lymphocyte I-gene
globulin I-gene
. 0

Plasma B-gene
histaminase I-gene
in 0
patients 0
of 0
bronchial 0
asthma 0
and 0
the 0
effect 0
of 0
prednisolone 0
administration 0
on 0
it 0
. 0

A 0
comparative 0
study 0
of 0
the 0
cortical 0
end 0
of 0
the 0
auditory 0
analyzer 0
during 0
postnatal 0
ontogenesis 0
in 0
lower 0
monkeys 0
and 0
man 0

The 0
effect 0
of 0
osmotic 0
flow 0
on 0
the 0
distribution 0
of 0
horseradish B-gene
peroxidase I-gene
within 0
the 0
intercellular 0
spaces 0
of 0
toad 0
bladder 0
epithelium 0
. 0

Immunogenicity 0
of 0
various 0
mycobacteria 0
and 0
the 0
corresponding 0
levels 0
of 0
cross 0
- 0
protection 0
developed 0
between 0
species 0
. 0

Ten 0
- 0
year 0
experience 0
with 0
one 0
- 0
stage 0
proctocolectomy 0
and 0
anal 0
ileostomy 0
. 0

Nitrogen 0
- 0
hydrogen 0
tautomerism 0
in 0
porphyrins 0
and 0
chlorins 0
. 0

Factors 0
affecting 0
the 0
inhibition 0
of 0
phagocytosis 0
by 0
chlorpromazine 0
. 0

Photopic 0
spectral 0
sensitivity 0
determined 0
electroretinographically 0
for 0
the 0
pigeon 0
eye 0
. 0

Angiography 0
of 0
aneurysmal 0
bone 0
cyst 0
. 0

Cholinesterase B-gene

Sodium 0
restriction 0
in 0
cardiac 0
failure 0
. 0

Clinical 0
and 0
angiographic 0
examinations 0
in 0
occlusion 0
disease 0
of 0
the 0
great 0
intestinal 0
arteries 0

Serum 0
lipid 0
changes 0
during 0
pregnancy 0
due 0
to 0
oral 0
calcium 0
administration 0

Successful 0
treatment 0
of 0
candidiasis 0
with 0
transfer B-gene
factor I-gene
. 0

A 0
possible 0
role 0
for 0
the 0
mixed 0
function 0
oxidase B-gene
enzyme 0
system 0
in 0
the 0
requirement 0
for 0
selenium 0
in 0
the 0
rat 0
. 0

Periodic 0
breathing 0
and 0
apnea 0
in 0
preterm 0
infants 0
. 0

Working 0
session 0
report 0
: 0
in 0
vivo 0
- 0
in 0
vitro 0
screening 0
. 0

Clinicopathologic 0
studies 0
in 0
feminizing 0
tumors 0
of 0
the 0
ovary 0
. 0

On 0
the 0
constituents 0
of 0
Dryopteris 0
polylepis 0

Relation 0
between 0
mixing 0
ratio 0
of 0
raw 0
materials 0
and 0
composition 0
of 0
products 0
in 0
the 0
synthesis 0
of 0
aluminosilicates 0

Influence 0
of 0
diet 0
on 0
urinary 0
VMA 0
excretion 0
. 0

Oscilloscope 0
triggering 0
circuit 0
for 0
recording 0
long 0
transients 0
at 0
fast 0
sweep 0
speeds 0
. 0

Derivatives 0
of 0
boswellic 0
acids 0
. 0

The 0
status 0
of 0
education 0
and 0
training 0
programs 0
in 0
speech 0
pathology 0
and 0
audiology 0
- 0
- 0
1971 0
- 0
72 0
. 0

Coronary 0
arteries 0
- 0
- 0
old 0
and 0
new 0
. 0

Antiviral 0
agents 0
. 0

Separation 0
of 0
ninhydrin 0
- 0
positive 0
compounds 0
in 0
urine 0
by 0
the 0
combined 0
methods 0
of 0
medium 0
- 0
tension 0
intophoresis 0
and 0
partition 0
chromatography 0

Conservative 0
treatment 0
of 0
central 0
nervous 0
system 0
injuries 0

Spasmus 0
nutans 0
: 0
a 0
syndrome 0
of 0
auto 0
- 0
arousal 0
. 0

6 0
. 0

1st 0
data 0
on 0
the 0
immunosuppressive 0
therapy 0
of 0
scleroderma 0

Slowed 0
lysosomal B-gene
enzyme I-gene
release 0
and 0
its 0
normalization 0
by 0
drugs 0
in 0
adjuvant 0
- 0
induced 0
polyarthritis 0
. 0

Treatment 0
of 0
ovarian 0
neoplasms 0

Experimental 0
pancreatitis 0
in 0
pigs 0
. 0

Bacterial 0
metabolism 0
of 0
4 0
- 0
chlorophenoxyacetate 0
. 0

Dynamics 0
of 0
hospital 0
stay 0
in 0
peptic 0
ulcer 0
patients 0

I 0
. 0

Surgical 0
treatment 0
of 0
pathologic 0
scars 0
of 0
myocardial 0
infarct 0

The 0
interaction 0
of 0
caffeine 0
, 0
theophylline 0
and 0
theobromine 0
with 0
monoamine B-gene
oxidase I-gene
inhibitors 0
. 0

Effect 0
of 0
phenformin 0
on 0
gluconeogenesis 0
in 0
perfused 0
rat 0
liver 0
. 0

New 0
alkaloids 0
from 0
bark 0
of 0
Erythrophleum 0
ivorense 0
. 0

A 0
case 0
of 0
M 0
hemoglobinosis 0

Radiosensitive 0
nature 0
of 0
paravascular 0
infiltrate 0
- 0
producing 0
potential 0
of 0
parental 0
spleen 0
cells 0
. 0

Sinusoidal 0
oscillations 0
of 0
a 0
gas 0
dilution 0
indicator 0

The 0
value 0
of 0
different 0
sources 0
of 0
nitrogen 0
in 0
diets 0
for 0
the 0
early 0
- 0
weaned 0
calf 0
. 0

1 0
. 0

Abdominal 0
tumors 0
in 0
childhood 0
. 0

Results 0
of 0
the 0
official 0
inspection 0
of 0
the 0
commercial 0
anti 0
- 0
inflammatory 0
enzyme 0
preparations 0
containing 0
chymotrypsin B-gene
and 0
trypsin B-gene
by 0
means 0
of 0
modified 0
NF 0
13 0
methods 0

Studies 0
on 0
the 0
hereditary 0
nature 0
of 0
sole 0
prints 0
- 0
- 0
with 0
special 0
reference 0
to 0
interdigital 0
and 0
triradii 0

The 0
problem 0
of 0
disablement 0
due 0
to 0
pulmonary 0
tuberculosis 0
, 0
on 0
the 0
basis 0
of 0
an 0
analysis 0
of 0
the 0
history 0
of 0
395 0
cases 0
as 0
observed 0
in 0
Gdansk 0
in 0
the 0
years 0
1946 0
- 0
1965 0

Cleidocranial 0
dysostosis 0

Proposals 0
on 0
authorization 0
; 0
by 0
a 0
group 0
of 0
nurses 0
from 0
psychiatric 0
hospitals 0

Successive 0
abdominal 0
scintillation 0
with 0
131 0
- 0
I 0
- 0
tagged 0
BSP 0
- 0
- 0
description 0
of 0
the 0
thyroid 0
gland 0
, 0
kidney 0
and 0
spleen 0
( 0
comparison 0
with 0
131 0
- 0
I 0
- 0
RB 0
) 0

Pneumonia 0
in 0
children 0

Osteosarcoma 0
caused 0
by 0
3,4 0
- 0
benzopyrene 0

The 0
content 0
of 0
glucosamine 0
and 0
galactosamine 0
in 0
tartar 0

Relapse 0
of 0
leukemia 0
after 0
prolonged 0
remission 0
. 0

Influence 0
of 0
cigarette 0
smoking 0
on 0
some 0
blood 0
coagulation 0
tests 0
. 0

The 0
non 0
- 0
role 0
of 0
fluoride 0
in 0
the 0
control 0
of 0
plasma 0
calcium 0
in 0
the 0
parathyroidectomized 0
rat 0
. 0

Second 0
report 0
of 0
the 0
Norwegian 0
Cancer 0
Society 0
. 0

Modification 0
of 0
the 0
growth 0
of 0
Tetrahymena 0
by 0
compounds 0
which 0
affect 0
the 0
adrenergic 0
mechanism 0
. 0

SAM 0
- 0
TR 0
- 0
68 0
- 0
54 0
. 0

A 0
brief 0
discussion 0
of 0
color 0
deficiencies 0
. 0

BIM 0
130 0
. 0

Problems 0
in 0
the 0
determination 0
of 0
the 0
antigenic 0
content 0
of 0
influenza 0
vaccines 0
. 0

Aedes 0
aegypti 0
( 0
L. 0
) 0
and 0
Aedes 0
albopictus 0
( 0
Skuse 0
) 0
in 0
Singapore 0
City 0
. 0

Homograft 0
response 0
and 0
hemagglutinin B-gene
production 0
by 0
sensitized 0
thymectomized 0
irradiated 0
adult 0
mice 0
. 0

Comparative 0
study 0
on 0
acute 0
oral 0
overload 0
using 0
tolbutamide 0
and 0
tolazamide 0
in 0
normal 0
and 0
diabetic 0
subjects 0
. 0

Mycotoxins 0
in 0
feeds 0
and 0
foods 0
. 0

Factors 0
influencing 0
in 0
vitro 0
skin B-gene
permeability I-gene
factor I-gene
production 0
by 0
Vibrio 0
cholerae 0
. 0

Spinal 0
cord 0
representation 0
of 0
the 0
micturition 0
reflex 0
. 0

Biological 0
action 0
and 0
kinetics 0
of 0
the 0
elimination 0
of 0
tritium 0
oxide 0
in 0
dogs 0

Auto 0
- 0
and 0
isotopy 0
of 0
the 0
conjunctiva 0

IX 0
. 0

Pitfalls 0
in 0
the 0
use 0
of 0
chromosome 0
aberration 0
analysis 0
for 0
biological 0
radiation 0
dosimetry 0
. 0

Renin B-gene
secretion 0
in 0
essential 0
and 0
accelerated 0
hypertension 0
. 0

The 0
need 0
for 0
including 0
forensic 0
medical 0
expertise 0
in 0
the 0
list 0
of 0
urgent 0
criminal 0
investigative 0
actions 0

Histopathology 0
and 0
pathogenesis 0
of 0
exanthematous 0
viroses 0

CNS 0
effects 0
of 0
local 0
anesthetics 0
only 0
partially 0
dependent 0
on 0
biogenic 0
amine 0
mechanisms 0
. 0

Diethylene 0
benzene 0

Midge 0
control 0
in 0
flood 0
channels 0
. 0

The 0
effects 0
of 0
taloximine 0
and 0
aminophylline 0
on 0
isolated 0
human 0
smooth 0
muscle 0
. 0

The 0
exploratory 0
behaviour 0
in 0
normal 0
and 0
aggressive 0
mice 0
. 0

Genitography 0
in 0
intersexual 0
states 0
. 0

Tolerance 0
test 0
of 0
HB 0
419 0
in 0
animal 0
experiments 0

The 0
role 0
of 0
ascorbic 0
acid 0
in 0
the 0
prevention 0
of 0
bladder 0
tumor 0
formation 0
. 0

The 0
`` 0
28 0
percent 0
'' 0
Venturi 0
mask 0
in 0
obstructive 0
airway 0
disease 0
. 0

3' 0
- 0
Methyl 0
, 0
8 0
- 0
methyl 0
, 0
and 0
8 0
- 0
phenyl 0
derivatives 0
of 0
5,9 0
- 0
dimethyl 0
- 0
6,7 0
- 0
benzomorphans 0
. 0

Antidromic 0
invasion 0
of 0
impulses 0
and 0
recurrent 0
collateral 0
inhibition 0
in 0
pyramidal 0
tract 0
neurones 0
. 0

The 0
distribution 0
of 0
body 0
fluids 0
following 0
hemorrhage 0
and 0
resuscitation 0
in 0
combat 0
casualties 0
. 0

Once 0
more 0
Hong 0
Kong 0
influenza 0
in 0
the 0
Netherlands 0

Early 0
disagnosis 0
of 0
cancer 0
- 0
- 0
50 0
per 0
cent 0
of 0
all 0
patients 0
could 0
be 0
cured 0

Difficulties 0
bound 0
to 0
measuring 0
of 0
sputum 0
viscosity 0

Lipid 0
concentration 0
and 0
lipase B-gene
activity 0
in 0
the 0
epiphysis 0
of 0
adrenalectomized 0
rats 0
consuming 0
food 0
with 0
different 0
sodium 0
content 0

Behavior 0
of 0
aspartate B-gene
aminotransferase I-gene
( 0
EC B-gene
2.6.1.1 I-gene
) 0
and 0
alanine B-gene
aminotransferase I-gene
( 0
EC B-gene
2.6.1.2 I-gene
) 0
in 0
rat 0
serum 0
during 0
the 0
course 0
of 0
acute 0
radiation 0
syndrome 0
following 0
whole 0
body 0
X 0
- 0
irradiation 0

Diminished 0
forearm 0
arteriolar 0
dilator 0
capacity 0
produced 0
by 0
mineralocorticoid 0
- 0
induced 0
salt 0
retention 0
in 0
man 0
. 0

Studies 0
on 0
the 0
pathogenicity 0
of 0
ECHO 0
9 0
( 0
HILL 0
) 0
virus 0
and 0
its 0
mutants 0
for 0
suckling 0
mice 0

Counter 0
- 0
current 0
heat 0
exchange 0
in 0
the 0
respiratory 0
passages 0
: 0
effect 0
on 0
water 0
and 0
heat 0
balance 0
. 0

Calibration 0
and 0
a 0
correction 0
of 0
blood 0
O2 0
content 0
measured 0
by 0
Po2 0
and 0
CO 0
saturation 0
. 0

Mae 0
West 0
and 0
the 0
doctor 0
shortage 0
. 0

Elimination 0
of 0
gamma 0
- 0
irradiation 0
induced 0
oxidation 0
in 0
aqueous 0
drug 0
preparations 0

The 0
absolute 0
configuration 0
at 0
C 0
- 0
2 0
in 0
monocrotalic 0
acid 0
. 0

Teratogenic 0
effects 0
of 0
actinomycin 0
D 0
in 0
rats 0

The 0
plasma B-gene
growth I-gene
hormone I-gene
concentration 0
of 0
the 0
foetal 0
lamb 0
. 0

Bimodal 0
cochlear 0
response 0
curves 0
in 0
rodents 0
. 0

A 0
new 0
hemagglutination 0
test 0
for 0
the 0
on 0
- 0
slide 0
assay 0
of 0
rheumatoid B-gene
factor I-gene

CO2 0
assimilation 0
by 0
chloroplasts 0
illuminated 0
on 0
filter 0
paper 0
. 0

The 0
biology 0
of 0
Hyostrongylus 0
ruidus 0
. 0

Foreign 0
profiles 0
in 0
air 0
pollution 0
control 0
activities 0
. 0

Effects 0
of 0
chronic 0
metaraminol 0
treatment 0
on 0
the 0
sympathetic 0
activity 0
of 0
intact 0
and 0
adrenal 0
demedullated 0
rats 0
kept 0
in 0
warm 0
or 0
cold 0
environments 0
. 0

The 0
association 0
of 0
clopamide 0
and 0
hydergine 0
( 0
Brinedine 0
) 0
in 0
the 0
treatment 0
of 0
the 0
vasculo 0
- 0
renal 0
syndromes 0
of 0
pregnancy 0

The 0
effect 0
of 0
low 0
dosage 0
radiation 0
on 0
metabolism 0
and 0
function 0
of 0
the 0
rat 0
kidney 0
damaged 0
by 0
ischemia 0

Leukemia 0
in 0
twins 0
: 0
world 0
- 0
wide 0
review 0
of 0
clinical 0
cases 0
. 0

Preliminary 0
report 0
. 0

Quantitation 0
of 0
exocrine B-gene
IgA I-gene
in 0
human 0
serum 0
in 0
health 0
and 0
disease 0
. 0

Gastrointestinal 0
manifestations 0
of 0
systemic 0
sclerosis 0

Iodine 0
metabolism 0
in 0
chronic 0
thyroiditis 0
. 0

Total 0
body 0
water 0
, 0
rhodanide 0
space 0
and 0
I B-gene
- I-gene
131 I-gene
- I-gene
albumin I-gene
space 0
under 0
the 0
acute 0
effect 0
of 0
furosemide 0

V 0
. 0

18F 0
and 0
85Sr 0
scintimetry 0
in 0
the 0
study 0
of 0
primary 0
arthropathies 0
. 0

Propagation 0
and 0
hormone 0
production 0
by 0
human 0
normal 0
and 0
malignant 0
trophoblast 0
in 0
rats 0
. 0

Health 0
: 0
an 0
integrative 0
reticulum 0
. 0

Sensitive 0
fluorometric 0
method 0
of 0
determining 0
SH 0
- 0
and 0
S 0
- 0
S 0
- 0
groups 0
when 0
jointly 0
present 0

Morphogenesis 0
of 0
the 0
trochanter 0
produced 0
by 0
femoral 0
regeneration 0
in 0
the 0
phasmid 0
Carausius 0
morosus 0
Br 0

Behavioral 0
and 0
electrographic 0
expression 0
of 0
natural 0
sleep 0
and 0
wakefulness 0
in 0
reptiles 0

Sensitivities 0
of 0
thromboplastins B-gene
to 0
factor B-gene
VII I-gene
deficiency 0
. 0

3 0
. 0

Central 0
venous 0
catheter 0
used 0
for 0
recording 0
intracardiac 0
electrocardiogram 0
. 0

Two 0
Lab 0
8 0
computer 0
programmes 0
for 0
use 0
in 0
the 0
study 0
of 0
the 0
isometric 0
and 0
isotonic 0
contractile 0
characteristics 0
of 0
skeletal 0
muscle 0
. 0

Open 0
head 0
- 0
brain 0
injuries 0

The 0
modification 0
of 0
P32 0
uptake 0
into 0
the 0
Jensen 0
sarcoma 0
in 0
vitro 0
by 0
adding 0
of 0
peroxide 0
to 0
the 0
nutritive 0
medium 0

Students 0
, 0
parents 0
, 0
teachers 0
and 0
hearing 0
disorders 0

Changing 0
and 0
predicting 0
doses 0
of 0
Cs137 0
irradiation 0

Positive 0
shifts 0
of 0
basal 0
skin 0
potentials 0
during 0
human 0
sleep 0
. 0

Evaluating 0
dietary 0
department 0
management 0
. 0

5 0
- 0
( 0
Dimethylaminopropyl 0
) 0
- 0
19,11 0
- 0
dihydro 0
- 0
5H 0
- 0
benzo 0
[ 0
2,3 0
] 0
pyrido 0
[ 0
6,7 0
- 0
b 0
] 0
azepine 0
. 0

Osteogenesis 0
imperfecta 0

Investigation 0
on 0
the 0
exchange 0
of 0
Ca45 0
in 0
intact 0
and 0
burned 0
rats 0
by 0
the 0
kinetic 0
analysis 0
method 0

Effect 0
of 0
thrombotic 0
and 0
antithrombotic 0
drugs 0
on 0
the 0
surface 0
charge 0
characteristics 0
of 0
canine 0
blood 0
vessels 0
: 0
in 0
vivo 0
and 0
in 0
vitro 0
studies 0
. 0

Measurements 0
of 0
activity 0
with 0
the 0
radioprotective 0
chamber 0
VA 0
- 0
K 0
- 0
254 0
of 0
the 0
osimeter 0
VA 0
- 0
J18 0

3 0
- 0
( 0
N 0
- 0
Alkyl 0
- 0
N 0
- 0
2 0
- 0
chloroethylaminomethyl 0
) 0
- 0
5 0
- 0
or 0
7 0
- 0
halogenobenzo 0
[ 0
b 0
] 0
thiophen 0
hydrochlorides 0
. 0

Nephrectomy 0
applied 0
to 0
cattle 0

Evaluation 0
of 0
automatic 0
blood 0
cell 0
counters 0
. 0

Determination 0
of 0
transaminases 0
with 0
an 0
autoanalyzer 0

Sterols 0
in 0
pollen 0
. 0

Dermoid 0
cyst 0
in 0
a 0
free 0
skin 0
flap 0
as 0
the 0
complication 0
after 0
treatment 0
of 0
recurring 0
hernia 0

Histological 0
observations 0
on 0
the 0
decidua 0
in 0
the 0
second 0
half 0
of 0
pregnancy 0

Endocardial 0
fibro 0
- 0
elastosis 0
, 0
mitral 0
incompetence 0
, 0
and 0
coarctation 0
of 0
abdominal 0
aorta 0
. 0

Studies 0
on 0
the 0
method 0
of 0
size 0
reduction 0
of 0
medicinal 0
compounds 0
. 0

Children 0
with 0
defective 0
vision 0

Identification 0
and 0
estimation 0
of 0
monosaccharides 0
and 0
disaccharides 0
in 0
urine 0
by 0
gas 0
- 0
liquid 0
chromatography 0
. 0

Steroids 0
in 0
germfree 0
and 0
conventional 0
rats 0
. 0

The 0
effects 0
of 0
loading 0
the 0
respiratory 0
pumps 0
on 0
the 0
oxygen 0
consumption 0
of 0
Callionymus 0
lyra 0
. 0

Trials 0
of 0
sevine 0
activity 0
against 0
mosquito 0
larvae 0

The 0
significance 0
of 0
structural 0
integrity 0
of 0
lymphoid 0
tissue 0
for 0
antibody 0
production 0
in 0
culture 0
in 0
vivo 0

The 0
effect 0
of 0
a 0
constant 0
magnetic 0
field 0
on 0
the 0
phagocytic 0
activity 0
of 0
Paramecia 0

Studies 0
carried 0
out 0
with 0
the 0
Glossina 0
morsitans 0
colony 0
of 0
Lisbon 0
. 0

Relations 0
between 0
adrenergic 0
mechanisms 0
and 0
analgesic 0
effects 0

Transformations 0
in 0
the 0
morphine 0
series 0
. 0

Dissociative 0
anesthetics 0
2 0
- 0
( 0
o 0
- 0
chlorophenyl 0
) 0
- 0
2 0
- 0
methyl 0
- 0
amino 0
cyclohexane 0
HCL 0
( 0
CI 0
- 0
581 0
) 0

Estrus 0
and 0
copulative 0
abilities 0
of 0
androgen 0
- 0
sterilized 0
rats 0

The 0
bearing 0
of 0
season 0
and 0
sequence 0
of 0
calving 0
on 0
frequency 0
of 0
male 0
, 0
female 0
and 0
total 0
calvings 0
in 0
Hariana 0
cows 0
. 0

Hemodynamics 0
changes 0
in 0
man 0
during 0
flight 0

Caries 0
prevention 0
in 0
the 0
dental 0
office 0
. 0

I 0
. 0

Clinical 0
applications 0
of 0
inhibition 0
of 0
beta B-gene
- I-gene
adrenergic I-gene
receptors I-gene
with 0
propranolol 0
. 0

Automatic 0
view 0
box 0
. 0

Measurement 0
of 0
gastric 0
acid 0
secretion 0
by 0
conductivity 0
. 0

Effect 0
of 0
castration 0
on 0
pituitary B-gene
and I-gene
serum I-gene
LH I-gene
and 0
FSH B-gene
in 0
testosterone 0
- 0
sterilized 0
rats 0
. 0

The 0
significance 0
of 0
the 0
phenolphthalein B-gene
sulphatase I-gene
test 0
for 0
the 0
differentiation 0
and 0
identification 0
of 0
Nocardia 0
species 0
. 0

Relationship 0
of 0
mast 0
cells 0
to 0
sarcoidosis 0
granuloma 0
of 0
the 0
skin 0

Long 0
- 0
term 0
effects 0
of 0
clofibrate 0
( 0
Atromid 0
- 0
S 0
) 0
on 0
serum 0
lipids 0
in 0
man 0
. 0

Phosphate B-gene
glucose I-gene
dehydrogenase I-gene
deficiency 0
causing 0
hyperbilirubinemia 0
in 0
the 0
newborn 0

Evidence 0
forthe 0
electroosmosis 0
theory 0
of 0
transport 0
in 0
the 0
phloem 0
. 0

Effects 0
of 0
beta B-gene
- I-gene
adrenergic I-gene
receptor I-gene
blockade 0
on 0
airway 0
conductance 0
and 0
lung 0
volume 0
in 0
normal 0
and 0
asthmatic 0
subjects 0
. 0

Effect 0
of 0
heparin 0
on 0
the 0
inactivation 0
of 0
serum B-gene
lipoprotein I-gene
lipase I-gene
by 0
the 0
liver 0
in 0
unanesthetized 0
dogs 0
. 0

Experimental 0
chlorpromazine 0
cataracts 0
. 0

I 0
. 0

Specialist 0
in 0
family 0
practice 0
- 0
- 0
prototype 0
of 0
a 0
doctor 0
. 0

The 0
possibility 0
of 0
selective 0
chemotherapy 0
of 0
progressive 0
recurring 0
ovarian 0
carcinoma 0
with 0
the 0
aid 0
of 0
cytodiagnosis 0
and 0
incorporation 0
of 0
tagged 0
idoxuridine 0

Variation 0
in 0
the 0
temporal 0
- 0
spatial 0
distribution 0
of 0
228Ra 0
and 0
224Ra 0
in 0
the 0
RES 0
and 0
marrow 0
- 0
free 0
skeleton 0
after 0
incorporation 0
of 0
colloidal 0
ThO2 0

Oxidative 0
degradation 0
of 0
adrenaline 0
solutions 0
: 0
study 0
of 0
the 0
intermediate 0
stages 0
and 0
their 0
analytic 0
value 0
for 0
the 0
control 0
of 0
this 0
solute 0

Absorption 0
of 0
electrolytes 0
from 0
the 0
colon 0
in 0
cases 0
of 0
ulcerative 0
colitis 0
and 0
in 0
control 0
subjects 0
. 0

Ion 0
injection 0
. 0

Polyvinyl 0
alcohol 0
as 0
a 0
solution 0
mediator 0

Mining 0
the 0
diagnostic 0
iron 0
ore 0
. 0

The 0
structure 0
of 0
digiprogenin 0
. 0

The 0
need 0
in 0
the 0
small 0
hospital 0
. 0

I 0
. 0

On 0
the 0
character 0
of 0
changes 0
in 0
the 0
enzyme 0
activity 0
in 0
the 0
brain 0
tissue 0
during 0
reflex 0
epilepsy 0

A 0
malignant 0
true 0
teratoma 0
of 0
liver 0
in 0
childhood 0
. 0

Methoxyflurane 0
and 0
renal 0
function 0

Histochemistry 0
and 0
electron 0
microscopy 0
of 0
acute 0
liver 0
lesions 0
induced 0
by 0
Aflatoxin 0
B1 0
in 0
ducklings 0
. 0

Functional 0
disorders 0
of 0
the 0
ureter 0
following 0
gynecologic 0
surgery 0

Study 0
of 0
the 0
alterations 0
of 0
intestinal 0
absorption 0
, 0
by 0
means 0
of 0
I 0
- 0
131 0
- 0
triolein 0
, 0
in 0
the 0
whole 0
body 0
irradiated 0
rat 0

Chemical 0
histologic 0
and 0
immunologic 0
responses 0
in 0
rats 0
to 0
CC1 0
- 0
4 0
by 0
different 0
routes 0
of 0
administration 0
. 0

Clinical 0
trials 0
with 0
1,3 0
- 0
bis 0
( 0
2 0
- 0
chloroethyl 0
) 0
- 0
1 0
- 0
nitrosourea 0
, 0
NSC 0
- 0
409962 0
. 0

Hydroxypropyl 0
methacrylate 0
, 0
a 0
new 0
water 0
- 0
miscible 0
embedding 0
medium 0
for 0
electron 0
microscopy 0
. 0

Statistics 0
of 0
the 0
past 0
5 0
years 0

On 0
the 0
diagnosis 0
of 0
bovine 0
leucosis 0
and 0
its 0
control 0
in 0
southern 0
Lower 0
Saxony 0

Experience 0
with 0
the 0
restoration 0
of 0
agglutination 0
properties 0
of 0
non 0
- 0
agglutinating 0
dysenterial 0
cultures 0
with 0
the 0
use 0
of 0
Rzhaninov 0
's 0
method 0

Study 0
on 0
micromelias 0
in 0
the 0
mouse 0
fetus 0
caused 0
by 0
x 0
- 0
radiation 0
, 0
hypoxia 0
, 0
trypan 0
blue 0
injection 0
of 0
hypervitaminosis 0
- 0
A 0
upon 0
mother 0
animals 0
during 0
pregnancy 0
. 0

Human 0
antitetanus 0
serum 0
: 0
an 0
unused 0
wealth 0

( 0
3 0
) 0
. 0

Studies 0
on 0
the 0
intracutaneous 0
infection 0
of 0
rabbits 0
by 0
Staphylococcus 0
aureus 0
. 0

On 0
catabolism 0
of 0
aminoketones 0
in 0
climacteric 0
age 0

The 0
effect 0
of 0
feeding 0
patterns 0
on 0
fat 0
deposition 0
in 0
mice 0
. 0

Naphthalene 0
and 0
paradichlorobenzene 0
in 0
clinical 0
toxicology 0

IV 0
. 0

Studies 0
on 0
powdered 0
preparations 0
. 0

A 0
case 0
report 0
with 0
angiographic 0
follow 0
- 0
up 0
study 0
. 0

Interactions 0
between 0
adrenergics 0
, 0
adrenolytics 0
and 0
monoamine B-gene
oxidase I-gene
inhibitors 0

Further 0
studies 0
on 0
a 0
`` 0
new 0
'' 0
human B-gene
isoprecipitin I-gene
system 0
( 0
Australia 0
antigen 0
) 0
. 0

Pigmentary 0
rhythms 0
as 0
indicators 0
of 0
neurosecretion 0
. 0

Story 0
of 0
a 0
hospital 0
that 0
filmed 0
its 0
employee 0
orientation 0
program 0
. 0

When 0
the 0
cervical 0
Pap 0
smear 0
is 0
positive 0
. 0

I 0
. 0

The 0
3 0
- 0
hour 0
test 0
iodine 0
( 0
I 0
- 0
132 0
) 0
uptake 0
by 0
the 0
thyroid 0
in 0
children 0
with 0
growth 0
deficiency 0

Persistence 0
of 0
toxaphene 0
in 0
treated 0
lakes 0
. 0

Studies 0
on 0
Coxsackie 0
B 0
Type 0
5 0
virus 0
infections 0
. 0

Value 0
of 0
the 0
method 0
of 0
passive 0
hemagglutination 0
with 0
polysaccharide 0
C 0
in 0
detecting 0
C B-gene
- I-gene
reactive I-gene
protein I-gene
as 0
compared 0
to 0
precipitation 0
in 0
capillaries 0
and 0
slide 0
latex 0
test 0
with 0
anti B-gene
- I-gene
CRP I-gene
serum 0

Adrenergic 0
nerve 0
function 0
, 0
noradrenaline 0
level 0
and 0
noradrenaline 0
uptake 0
in 0
cat 0
nictitating 0
membrane 0
after 0
reserpine 0
treatment 0
. 0

Concussion 0
of 0
the 0
spinal 0
cord 0

Study 0
on 0
the 0
evagination 0
of 0
Cysticercus 0
pisiformis 0
. 0

Antimicrobial 0
substance 0
isolated 0
from 0
an 0
acorn 0
extract 0
. 0

The 0
pathogenicity 0
of 0
Achromobacter 0
puntatum 0
for 0
cold 0
blooded 0
and 0
warm 0
blooded 0
animals 0

Consanguinity 0
and 0
migration 0
in 0
the 0
marriages 0
of 0
the 0
region 0
of 0
Nunoa 0
, 0
Santiago 0
, 0
1850 0
- 0
1960 0

On 0
the 0
amount 0
and 0
significance 0
of 0
the 0
effective 0
glucose 0
level 0
in 0
tumors 0
. 0

Studies 0
of 0
lipogenesis 0
by 0
labelled 0
precursors 0
in 0
the 0
pregnant 0
rat 0
. 0

Pharmacodynamic 0
studies 0
on 0
the 0
cardiovascular 0
system 0
of 0
spontaneously 0
hypertensive 0
rats 0
. 0

Nuclear 0
spin 0
of 0
249Bk 0
from 0
the 0
hyperfine 0
structure 0
in 0
its 0
emission 0
spectrum 0
. 0

Further 0
observations 0
on 0
resorption 0
in 0
guinea 0
pigs 0
following 0
injections 0
of 0
trypan 0
blue 0
. 0

Derivatives 0
of 0
fluorene 0
. 0

Note 0
on 0
Slot 0
's 0
method 0
for 0
the 0
specific 0
determination 0
of 0
creatinine 0
. 0

Retention 0
behavior 0
of 0
steroids 0
in 0
gas 0
chromatography 0
with 0
a 0
series 0
of 0
combination 0
columns 0
. 0

Compensatory 0
renal 0
hypertrophy 0
in 0
parabiotic 0
rats 0
. 0

( 0
3 0
) 0
. 0

XXI 0
. 0

In 0
vitro 0
evaluation 0
of 0
the 0
mucolytic 0
action 0
of 0
urea 0
. 0

Electrophoretic 0
characteriaztion 0
of 0
virus 0
- 0
induced 0
interferon B-gene
of 0
the 0
blood 0
and 0
urine 0
in 0
rabbits 0

Iron 0
and 0
folate 0
deficiency 0
in 0
pregnancy 0

Symposium 0
on 0
presenile 0
spongy 0
encephalopathies 0
. 0

Twenty 0
- 0
two 0
of 0
the 0
24 0
patients 0
had 0
a 0
rise 0
in 0
the 0
total 0
serum 0
amylase B-gene
following 0
ERCP 0
. 0

The 0
immuno 0
- 0
purified 0
mRNA 0
in 0
the 0
polysome 0
complex 0
was 0
used 0
to 0
prepare 0
cDNA 0
with 0
which 0
to 0
probe 0
a 0
D. 0
melanogaster 0
genomic 0
library 0
. 0

Elevated 0
maternal B-gene
alpha I-gene
fetoproteins I-gene
and 0
oligoamnios 0
: 0
fetal 0
prognosis 0

Also 0
discussed 0
is 0
the 0
possibility 0
of 0
a 0
combined 0
genetic 0
and 0
environmental 0
etiology 0
. 0

Courses 0
were 0
repeated 0
monthly 0
upon 0
recovery 0
of 0
myelosuppression 0
. 0

Stimulation 0
with 0
MCh 0
produced 0
a 0
Ca 0
- 0
dependent 0
transient 0
elevation 0
of 0
cGMP 0
level 0
from 0
10 0
to 0
80 0
fmol/gland 0
, 0
peaking 0
at 0
1 0
- 0
2 0
min 0
but 0
returning 0
to 0
the 0
basal 0
level 0
by 0
5 0
min 0
. 0

Two 0
hundred 0
forty 0
- 0
three 0
patients 0
have 0
received 0
WR 0
- 0
2721 0
in 0
Phase 0
I 0
- 0
II 0
studies 0
. 0

The 0
PEPCK B-gene
promoter 0
fragment 0
was 0
introduced 0
either 0
in 0
the 0
proper 0
orientation 0
for 0
transcription 0
of 0
the 0
TK B-gene
gene I-gene
or 0
in 0
the 0
opposite 0
orientation 0
. 0

Many 0
mammary 0
tumors 0
induced 0
by 0
mouse 0
mammary 0
tumor 0
virus 0
( 0
MMTV 0
) 0
contain 0
a 0
provirus 0
in 0
the 0
same 0
region 0
of 0
the 0
host 0
- 0
cell 0
genome 0
, 0
leading 0
to 0
expression 0
of 0
a 0
putative 0
cellular 0
oncogene 0
called 0
int B-gene
- I-gene
1 I-gene
. 0

In 0
these 0
cases 0
, 0
asbestos 0
or 0
erionite 0
- 0
tissue 0
burden 0
followed 0
by 0
fibrosis 0
was 0
frequently 0
observed 0
. 0

Hepatitis 0
B 0
virus 0
and 0
hepatoma 0
. 0

Eight 0
recombinant 0
DNA 0
clones 0
of 0
endogenous 0
murine 0
leukemia 0
virus 0
( 0
MuLV 0
) 0
- 0
related 0
DNA 0
sequences 0
have 0
been 0
isolated 0
from 0
a 0
lambdaphage 0
genomic 0
library 0
of 0
Balb/c 0
mouse 0
DNA 0
. 0

USA 0
80 0
, 0
3618 0
- 0
3622 0
) 0
The 0
two 0
proteins 0
show 0
36 0
% 0
identities 0
in 0
their 0
amino 0
acid 0
sequence 0
, 0
in 0
an 0
alignment 0
requiring 0
six 0
gaps 0
. 0

The 0
envelope B-gene
glycoproteins I-gene
of I-gene
Rous I-gene
sarcoma I-gene
virus I-gene
( I-gene
RSV I-gene
) I-gene
, 0
gp85 B-gene
and 0
gp37 B-gene
, 0
are 0
anchored 0
in 0
the 0
membrane 0
by 0
a 0
27 0
- 0
amino 0
acid 0
, 0
hydrophobic 0
domain 0
that 0
lies 0
adjacent 0
to 0
a 0
22 0
- 0
amino 0
acid 0
, 0
cytoplasmic 0
domain 0
at 0
the 0
carboxy 0
terminus 0
of 0
gp37 B-gene
. 0

The 0
drug 0
was 0
given 0
in 0
a 0
daily 0
oral 0
dose 0
of 0
0.5 0
g/m2 0
, 0
3.5 0
h 0
prior 0
to 0
each 0
radiation 0
treatment 0
. 0

Histogenetic 0
aspects 0
of 0
mesoblastic 0
nephroma 0
. 0

Effect 0
of 0
acute 0
and 0
chronic 0
psychogenic 0
stress 0
on 0
corticoadrenal 0
and 0
pituitary B-gene
- I-gene
thyroid I-gene
hormones I-gene
in 0
male 0
rats 0
. 0

Mature 0
mRNA 0
for 0
cytosolic B-gene
phosphoenolpyruvate I-gene
carboxykinase I-gene
of I-gene
the I-gene
chicken I-gene
is 0
2.8 0
kilobases 0
in 0
length 0
, 0
similar 0
to 0
that 0
previously 0
noted 0
for 0
mRNA 0
coding 0
for 0
the 0
same 0
enzyme 0
in 0
the 0
rat 0
. 0

Upstream 0
activation 0
sites 0
of 0
the 0
CYC1 B-gene
gene I-gene
of 0
Saccharomyces 0
cerevisiae 0
are 0
active 0
when 0
inverted 0
but 0
not 0
when 0
placed 0
downstream 0
of 0
the 0
`` 0
TATA 0
box 0
'' 0
. 0

An 0
intact 0
5.7 0
- 0
kb 0
provirus 0
of 0
the 0
avian 0
erythroblastosis 0
virus 0
E26 0
has 0
been 0
molecularly 0
cloned 0
for 0
comparisons 0
with 0
avian 0
myeloblastosis 0
virus 0
( 0
AMV 0
) 0
and 0
other 0
avian 0
tumor 0
viruses 0
. 0

It 0
is 0
concluded 0
that 0
haloperidol 0
selectively 0
reduced 0
the 0
animal 0
's 0
capacity 0
to 0
'programme 0
non 0
- 0
stimulus 0
directed 0
motor 0
behaviour 0
' 0
. 0

Neither 0
side 0
effect 0
nor 0
abnormal 0
laboratory 0
findings 0
due 0
to 0
this 0
drug 0
were 0
observed 0
. 0

The 0
results 0
presented 0
in 0
this 0
report 0
suggest 0
that 0
the 0
SV40 0
G 0
- 0
C 0
- 0
rich 0
sequences 0
can 0
function 0
as 0
independent 0
RNA B-gene
polymerase I-gene
II I-gene
transcriptional 0
- 0
control 0
elements 0
. 0

Construction 0
of 0
human 0
cell 0
lines 0
which 0
contain 0
and 0
express 0
the 0
adenovirus 0
DNA 0
binding 0
protein 0
gene 0
by 0
cotransformation 0
with 0
the 0
HSV B-gene
- I-gene
1 I-gene
tk I-gene
gene I-gene
. 0

Diagnosis 0
and 0
treatment 0
of 0
insulin B-gene
- 0
secreting 0
tumours 0
. 0

Theories 0
proffered 0
to 0
account 0
for 0
the 0
modality 0
shift 0
effect 0
are 0
critically 0
evaluated 0
. 0

The 0
effects 0
of 0
cardioselective 0
beta 0
- 0
1 0
adrenergic 0
agonist 0
, 0
1 0
- 0
( 0
4 0
- 0
hydroxyphenoxy 0
) 0
- 0
isopropylamino 0
- 0
2 0
- 0
propanol 0
) 0
, 0
i.e. 0
, 0
prenalterol 0
, 0
were 0
examined 0
on 0
direct 0
and 0
continuous 0
measurements 0
of 0
left 0
ventricular 0
( 0
LV 0
) 0
pressure 0
, 0
diameter 0
, 0
dP/dt 0
, 0
velocity 0
of 0
shortening 0
, 0
arterial 0
pressure 0
, 0
iliac 0
blood 0
flow 0
and 0
heart 0
rate 0
in 0
10 0
conscious 0
dogs 0
. 0

Endorphins B-gene
at 0
the 0
approach 0
of 0
death 0
. 0

Trial 0
treatment 0
of 0
schizophrenia 0
with 0
des B-gene
- I-gene
Tyr I-gene
- I-gene
gamma I-gene
- I-gene
endorphin I-gene

Cardiac 0
taurine 0
levels 0
and 0
sarcolemmal 0
calcium 0
binding 0
activity 0
in 0
furazolidone 0
- 0
induced 0
cardiomyopathy 0
. 0

Separation 0
of 0
malaria 0
- 0
infected 0
erythrocytes 0
from 0
whole 0
blood 0
: 0
use 0
of 0
a 0
selective 0
high 0
- 0
gradient 0
magnetic 0
separation 0
technique 0
. 0

The 0
roll 0
- 0
over 0
test 0
to 0
predict 0
toxemia 0
in 0
pregnancy 0
. 0

Can 0
thyroglobulin B-gene
assay 0
really 0
supplant 0
radioiodine 0
scans 0
in 0
patients 0
with 0
differentiated 0
thyroid 0
cancer 0
? 0

3 0
Significant 0
reductions 0
in 0
lying 0
mean 0
arterial 0
blood 0
pressure 0
were 0
observed 0
with 0
daily 0
doses 0
of 0
200 0
mg 0
( 0
- 0
9 0
% 0
) 0
, 0
400 0
mg 0
( 0
- 0
10 0
% 0
) 0
and 0
800 0
mg 0
( 0
- 0
14 0
% 0
) 0
, 0
and 0
were 0
associated 0
with 0
significant 0
decreases 0
in 0
heart 0
rate 0
and 0
plasma B-gene
renin I-gene
activity 0
. 0

Isolation 0
of 0
Aeromonas 0
from 0
faeces 0
. 0

Plasma 0
and 0
erthrocyte 0
lipid 0
profile 0
and 0
lipoprotein B-gene
lipase I-gene
activity 0
in 0
postheparin 0
plasma 0
on 0
vasectomized 0
rabbits 0
were 0
studied 0
and 0
also 0
the 0
incidence 0
of 0
atherosclerosis 0
in 0
different 0
arterial 0
beds 0
. 0

( 0
iii 0
) 0
The 0
mRNA 0
is 0
not 0
efficiently 0
polyadenylated 0
at 0
sequences 0
in 0
the 0
3 0
' 0
end 0
of 0
the 0
DHFR B-gene
cDNA I-gene
but 0
rather 0
uses 0
polyadenylation 0
signals 0
downstream 0
from 0
the 0
DHFR B-gene
cDNA I-gene
. 0

At 0
both 0
water 0
temperatures 0
, 0
VO2 0
increased 0
linearly 0
with 0
increasing 0
swimming 0
velocity 0
. 0

Propranolol 0
also 0
effectively 0
controlled 0
her 0
familial 0
tremor 0
. 0

Brief 0
report 0
. 0

The 0
distribution 0
phase 0
is 0
followed 0
by 0
an 0
elimination 0
phase 0
with 0
a 0
much 0
longer 0
half 0
- 0
life 0
( 0
mean 0
value 0
375 0
min 0
) 0
and 0
a 0
volume 0
of 0
distribution 0
of 0
approximately 0
200 0
- 0
400 0
l 0
. 0

Hybrid 0
- 0
selection 0
experiments 0
against 0
total 0
PB 0
- 0
inducible 0
RNA 0
were 0
performed 0
with 0
plasmid 0
DNA 0
derived 0
from 0
clones 0
enriched 0
in 0
PB 0
- 0
inducible 0
information 0
. 0

Risk 0
of 0
HTLV 0
infection 0
in 0
patients 0
on 0
haemodialysis 0
. 0

In 0
vitro 0
metabolism 0
of 0
progesterone 0
by 0
the 0
human 0
undescended 0
testis 0
. 0

Two 0
patients 0
withdrew 0
from 0
therapy 0
, 0
one 0
for 0
personal 0
reasons 0
and 0
one 0
because 0
a 0
paraspinal 0
mass 0
developed 0
. 0

All 0
patients 0
received 0
VCR 0
1.0 0
mg/m2 0
weekly 0
for 0
6 0
weeks 0
with 0
dose 0
modification 0
for 0
neurotoxicity 0
. 0

Glutamic 0
acid 0
in 0
a 0
dose 0
of 0
1/100 0
of 0
the 0
LD50 0
was 0
injected 0
in 0
the 0
form 0
of 0
sodium 0
salt 0
into 0
male 0
and 0
female 0
Wistar 0
rats 0
for 0
7 0
days 0
after 0
8 0
- 0
and 0
12 0
- 0
day 0
injections 0
of 0
dexazone 0
. 0

Serum 0
ascorbic 0
acid 0
had 0
an 0
inverse 0
and 0
the 0
strongest 0
association 0
with 0
systolic 0
blood 0
pressure 0
among 0
the 0
risk 0
factors 0
including 0
blood 0
pressure 0
, 0
total 0
cholesterol 0
, 0
triglyceride 0
, 0
gamma B-gene
- I-gene
GTP I-gene
and 0
obesity 0
. 0

Plasma B-gene
secretin I-gene
, 0
pancreozymin B-gene
, 0
and 0
somatostatin B-gene
- I-gene
like I-gene
hormone I-gene
in 0
chronic 0
renal 0
failure 0
patients 0
. 0

Effect 0
of 0
bromazepam 0
on 0
growth B-gene
hormone I-gene
and 0
prolactin B-gene
secretion 0
in 0
normal 0
subjects 0
. 0

In 0
several 0
cases 0
of 0
definite 0
SjS 0
, 0
labial 0
salivary 0
gland 0
examinations 0
after 0
more 0
than 0
a 0
one 0
year 0
interval 0
were 0
performed 0
on 0
two 0
occasions 0
, 0
and 0
the 0
clinical 0
and 0
histopathological 0
changes 0
were 0
investigated 0
. 0

All 0
radiologists 0
using 0
the 0
machine 0
found 0
that 0
the 0
reporting 0
terminal 0
was 0
simple 0
to 0
operate 0
, 0
but 0
found 0
that 0
reporting 0
abnormalities 0
caused 0
an 0
increased 0
effort 0
and 0
took 0
a 0
longer 0
time 0
. 0

Thalamotomy 0
aiming 0
at 0
the 0
CM 0
- 0
Pf 0
complex 0
and 0
using 0
stereotactic 0
gamma 0
irradiation 0
has 0
been 0
performed 0
in 0
a 0
series 0
of 0
52 0
patients 0
with 0
severe 0
pain 0
due 0
to 0
malignancy 0
. 0

2 0
Silastic 0
capsules 0
, 0
each 0
containing 0
22 0
- 0
23 0
mg 0
of 0
ethinyl 0
estradiol 0
, 0
were 0
inserted 0
subcutaneously 0
in 0
5 0
men 0
with 0
benign 0
prostatic 0
hypertrophy 0
. 0

When 0
used 0
subcutaneously 0
or 0
intravenously 0
in 0
maximum 0
tolerated 0
doses 0
the 0
antibiotic 0
inhibited 0
the 0
development 0
of 0
lymphadenosis 0
NK/Li 0
by 0
90 0
and 0
70 0
per 0
cent 0
respectively 0
. 0

Effect 0
of 0
2 0
- 0
( 0
p 0
- 0
chlorophenyl 0
) 0
cyclopropylamine 0
on 0
5 0
- 0
hydroxyindole 0
concentration 0
and 0
monoamine B-gene
oxidase I-gene
activity 0
in 0
rat 0
brain 0
. 0

Then 0
, 0
pure 0
pancreatic 0
juice 0
was 0
infused 0
into 0
the 0
duodenum 0
. 0

An 0
experiment 0
was 0
carried 0
on 0
133 0
grown 0
up 0
fowls 0
and 0
broilers 0
from 0
4 0
industrial 0
farms 0
, 0
vaccinated 0
with 0
spray 0
lento 0
and 0
mesogenic 0
vaccines 0
for 0
straining 0
the 0
immunity 0
against 0
pseodopest 0
through 0
RIHA 0
and 0
provoking 0
pseudoplague 0
with 0
a 0
pathogenic 0
virus 0
. 0

( 0
2 0
) 0
The 0
inappropriateness 0
of 0
adaptive 0
segmentation 0
for 0
the 0
isolation 0
of 0
spikes 0
and 0
sharp 0
waves 0
, 0
which 0
had 0
been 0
anticipated 0
in 0
view 0
of 0
the 0
short 0
duration 0
of 0
such 0
transients 0
in 0
relation 0
to 0
the 0
length 0
of 0
the 0
window 0
( 0
1.2 0
sec 0
) 0
used 0
for 0
the 0
autocorrelation 0
functions 0
employed 0
in 0
the 0
segmentation 0
algorithm 0
, 0
was 0
confirmed 0
. 0

The 0
ability 0
of 0
chronic 0
UM 0
- 0
272 0
( 0
dimethylpropranolol 0
) 0
treatment 0
to 0
prevent 0
the 0
induction 0
of 0
reentrant 0
ventricular 0
tachyarrhythmias 0
was 0
assessed 0
in 0
the 0
conscious 0
dog 0
subjected 0
to 0
serial 0
programmed 0
electrical 0
stimulation 0
on 0
days 0
3 0
- 0
- 0
5 0
after 0
myocardial 0
infarction 0
. 0

The 0
effect 0
of 0
echothiophate 0
on 0
the 0
biphasic 0
response 0
of 0
rabbit 0
ocular 0
pressure 0
to 0
dipivefrin 0
. 0

In 0
most 0
cases 0
of 0
acute 0
transmural 0
infarction 0
, 0
the 0
reciprocal 0
ST 0
segment 0
depressions 0
observed 0
in 0
contralateral 0
leads 0
are 0
less 0
marked 0
than 0
the 0
primary 0
ST 0
segment 0
elevations 0
. 0

Bacillus 0
cereus 0
cross 0
- 0
infection 0
in 0
a 0
maternity 0
- 0
unit 0
. 0

We 0
have 0
followed 0
37 0
phenytoin 0
- 0
treated 0
patients 0
with 0
reduced 0
serum B-gene
IgA I-gene
concentrations 0
for 0
2 0
- 0
7 0
years 0
. 0

In 0
the 0
latter 0
category 0
particular 0
emphasis 0
is 0
being 0
placed 0
on 0
new 0
anthracycline 0
analogues 0
of 0
doxorubicin 0
and 0
analogues 0
of 0
cisplatinum 0
diammine 0
dichloride 0
. 0

Unusual 0
course 0
of 0
plasmocytosis 0
. 0

Late 0
mRNA 0
selected 0
by 0
a 0
cDNA 0
homologous 0
to 0
the 0
HindIII B-gene
- I-gene
P/EcoRI I-gene
P/EcoRI I-gene
- I-gene
B I-gene
region 0
of 0
the 0
AcNPV 0
map 0
directed 0
the 0
synthesis 0
of 0
31K 0
and 0
30K 0
proteins 0
which 0
comigrated 0
with 0
the 0
31K 0
and 0
30K 0
proteins 0
translated 0
from 0
RNA 0
selected 0
by 0
the 0
HindIII B-gene
- I-gene
A/EcoRI I-gene
A/EcoRI I-gene
- I-gene
C/SstI I-gene
C/SstI I-gene
- I-gene
G I-gene
cDNA 0
. 0

Intraoperatively 0
the 0
complement B-gene
factor I-gene
C3c I-gene
decreased 0
by 0
20 0
% 0
, 0
while 0
alpha B-gene
1 I-gene
- I-gene
antitrypsin I-gene
showed 0
postoperatively 0
an 0
increase 0
by 0
30 0
% 0
. 0

A 0
polypeptide 0
chain 0
of 0
34 0
residues 0
of 0
the 0
deduced 0
yeast 0
amino 0
acid 0
sequence 0
closely 0
resembles 0
a 0
peptide 0
sequence 0
at 0
the 0
ADP 0
binding 0
site 0
of 0
bovine B-gene
muscle I-gene
pyruvate I-gene
kinase I-gene
. 0

The 0
P165 0
component 0
, 0
however 0
, 0
could 0
be 0
differentiated 0
from 0
the 0
two 0
later 0
components 0
since 0
it 0
increased 0
in 0
amplitude 0
with 0
increased 0
task 0
demands 0
while 0
the 0
N2 0
and 0
P3 0
amplitudes 0
remained 0
constant 0
. 0

Differential 0
drawing 0
size 0
associated 0
with 0
unilateral 0
brain 0
damage 0
. 0

The 0
intracoronary 0
administration 0
of 0
both 0
drugs 0
markedly 0
reduced 0
the 0
incidence 0
of 0
VF 0
induced 0
by 0
the 0
release 0
of 0
a 0
40 0
- 0
min 0
coronary 0
artery 0
occlusion 0
. 0

These 0
fusions 0
are 0
contained 0
on 0
plasmids 0
which 0
have 0
both 0
yeast 0
and 0
E. 0
coli 0
replication 0
origins 0
and 0
selectable 0
markers 0
and 0
, 0
therefore 0
, 0
can 0
be 0
used 0
to 0
transform 0
either 0
yeast 0
or 0
E. 0
coli 0
cells 0
. 0

Therefore 0
, 0
it 0
was 0
concluded 0
that 0
thrombotic 0
tendency 0
certainly 0
existed 0
in 0
patients 0
with 0
MS 0
compared 0
to 0
those 0
with 0
non 0
RHD 0
and 0
that 0
it 0
was 0
one 0
of 0
the 0
causes 0
of 0
the 0
significantly 0
high 0
incidence 0
of 0
thromboembolism 0
in 0
comparison 0
with 0
non 0
RHD 0
. 0

Toxicity 0
was 0
significant 0
in 0
selected 0
cases 0
; 0
three 0
patients 0
developed 0
WBC 0
counts 0
less 0
than 0
1,000/mm3 0
and 0
one 0
of 0
these 0
patients 0
died 0
with 0
sepsis 0
. 0

Subdural 0
electrodes 0
may 0
yield 0
larger 0
VEP 0
amplitudes 0
than 0
skull 0
or 0
scalp 0
electrodes 0
. 0

Products 0
of 0
immune 0
cells 0
such 0
as 0
transfer B-gene
factor I-gene
and 0
lymphokines 0
form 0
the 0
third 0
and 0
possibly 0
most 0
important 0
group 0
of 0
immune 0
- 0
stimulating 0
agents 0
. 0

Use 0
of 0
the 0
immunofluorescence 0
method 0
for 0
identification 0
of 0
enteroviruses 0
in 0
cell 0
cultures 0

This 0
fraction 0
is 0
resistant 0
to 0
digestions 0
by 0
DNase B-gene
I I-gene
and 0
RNase B-gene
T1 I-gene
and 0
disappears 0
completely 0
upon 0
alkali 0
hydrolysis 0
. 0

The 0
construction 0
of 0
a 0
small 0
library 0
of 0
mouse 0
repetitive 0
DNA 0
has 0
been 0
previously 0
reported 0
( 0
Pietras 0
et 0
al. 0
, 0
Nucleic 0
Acids 0
Res 0
. 0

No 0
direct 0
repeats 0
flank 0
the 0
pseudogene 0
in 0
the 0
U2/4 B-gene
locus I-gene
. 0

The 0
direct 0
effects 0
of 0
transmitter 0
release 0
were 0
( 0
a 0
) 0
an 0
early 0
fall 0
in 0
MAP 0
followed 0
by 0
a 0
late 0
pressor 0
effect 0
; 0
and 0
( 0
b 0
) 0
an 0
early 0
bradycardia 0
followed 0
by 0
a 0
late 0
tachycardia 0
. 0

At 0
Cabras 0
( 0
Oristano 0
) 0
, 0
a 0
town 0
characterized 0
by 0
a 0
high 0
incidence 0
of 0
thalassaemia 0
and 0
G6PD B-gene
deficiency 0
less 0
than 0
half 0
the 0
people 0
between 0
18 0
and 0
35 0
have 0
a 0
fair 0
knowledge 0
of 0
genetic 0
diseases 0
and 0
of 0
their 0
prevention 0
. 0

The 0
number 0
of 0
elements 0
and 0
their 0
sizes 0
relative 0
to 0
the 0
configuration 0
were 0
varied 0
in 0
a 0
series 0
of 0
five 0
experiments 0
. 0

In 0
addition 0
, 0
the 0
overall 0
chance 0
that 0
a 0
patient 0
would 0
undergo 0
ET 0
was 0
greater 0
in 0
a 0
cycle 0
in 0
which 0
more 0
than 0
one 0
follicle 0
20 0
mm 0
or 0
larger 0
was 0
developing 0
than 0
in 0
a 0
cycle 0
in 0
which 0
a 0
single 0
large 0
follicle 0
was 0
developing 0
. 0

Experience 0
with 0
the 0
tensor 0
fasciae 0
latae 0
free 0
flap 0
. 0

Five 0
of 0
the 0
patients 0
with 0
increased 0
L 0
- 0
L 0
size 0
had 0
a 0
normal 0
A 0
- 0
P 0
diameter 0
. 0

Immunochemotherapy 0
with 0
schizophyllan 0
( 0
SPG 0
) 0
combined 0
with 0
chemotherapeutic 0
agents 0
was 0
evaluated 0
in 0
two 0
syngeneic 0
tumor 0
- 0
C3H/He 0
mouse 0
systems 0
. 0

However 0
, 0
when 0
combined 0
with 0
mitomycin 0
C 0
given 0
with 0
1 0
to 0
5 0
- 0
days 0
interval 0
, 0
the 0
concurrent 0
administration 0
of 0
SPG 0
prolonged 0
significantly 0
the 0
life 0
- 0
span 0
of 0
the 0
tumor 0
- 0
bearing 0
mice 0
. 0

Data 0
are 0
presented 0
hinting 0
that 0
the 0
15 0
beta 0
- 0
hydroxy 0
- 0
, 0
metabolite 0
of 0
CPA 0
may 0
actually 0
be 0
the 0
biologically 0
active 0
agent 0
. 0

The 0
abluminal 0
surface 0
is 0
often 0
almost 0
entirely 0
encircled 0
by 0
a 0
thick 0
layer 0
of 0
fibrillary 0
connective 0
tissue 0
. 0

In 0
contrast 0
, 0
in 0
LL 0
patients 0
during 0
ENL 0
the 0
ConA B-gene
- 0
induced 0
suppressor 0
response 0
was 0
markedly 0
reduced 0
. 0

Functional 0
characterization 0
of 0
a 0
fraction 0
identified 0
by 0
its 0
activity 0
in 0
a 0
second 0
template 0
rescue 0
assay 0
. 0

It 0
has 0
been 0
established 0
that 0
preoperative 0
irradiation 0
in 0
the 0
form 0
of 0
the 0
fractionation 0
of 0
a 0
single 0
focal 0
dose 0
of 0
6 0
Gy 0
every 0
other 0
day 0
, 0
the 0
summary 0
dose 0
of 0
24 0
Gy 0
within 0
8 0
- 0
10 0
days 0
followed 0
by 0
surgery 0
1 0
- 0
3 0
days 0
after 0
irradiation 0
does 0
not 0
either 0
complicate 0
its 0
performance 0
or 0
the 0
course 0
of 0
the 0
postoperative 0
period 0
, 0
and 0
by 0
the 0
short 0
- 0
and 0
long 0
- 0
term 0
results 0
it 0
is 0
no 0
worse 0
than 0
the 0
routine 0
dose 0
fractionation 0
. 0

Fibrin B-gene
gels 0
and 0
their 0
possible 0
implication 0
for 0
surface 0
hemorheology 0
in 0
health 0
and 0
disease 0
. 0

Hepatitis 0
- 0
B 0
vaccination 0
in 0
the 0
elderly 0
. 0

Radiogallium 0
imaging 0
is 0
thus 0
of 0
limited 0
use 0
in 0
evaluation 0
of 0
suspected 0
giant 0
cell 0
tumors 0
of 0
bone 0
. 0

The 0
customary 0
coupling 0
reagent 0
sulfanilic 0
acid 0
has 0
been 0
replaced 0
by 0
1,3 0
- 0
dimethylbarbituric 0
acid 0
; 0
CNCl 0
is 0
produced 0
in 0
the 0
flow 0
through 0
system 0
directly 0
from 0
KCN 0
and 0
chloramine 0
T 0
. 0

Ventricular 0
volume 0
stiffness 0
vs. 0
the 0
mean 0
wall 0
stress 0
relationship 0
of 0
LVH 0
shifted 0
upward 0
, 0
whereas 0
the 0
normalized 0
wall 0
muscle 0
stiffness 0
vs. 0
the 0
mean 0
wall 0
stress 0
relationship 0
of 0
LVH 0
showed 0
a 0
smaller 0
slope 0
. 0

Synthesis 0
of 0
( 0
+ 0
) 0
- 0
lysergic 0
acid 0
diethylamide 0
tartrate 0

Weight 0
loss 0
reduces 0
arterial 0
pressure 0
by 0
a 0
decrease 0
in 0
intravascular 0
volume 0
and 0
cardiac 0
output 0
associated 0
with 0
a 0
fall 0
in 0
sympathetic 0
activity 0
. 0

The 0
effect 0
of 0
treatment 0
may 0
thus 0
be 0
divided 0
into 0
two 0
main 0
phases 0
- 0
- 0
an 0
initial 0
phase 0
with 0
a 0
reduction 0
in 0
LV 0
mass 0
and 0
a 0
reduction 0
in 0
cardiac 0
output 0
and 0
no 0
change 0
in 0
total 0
peripheral 0
resistance 0
- 0
- 0
and 0
a 0
second 0
phase 0
with 0
a 0
constant 0
LV 0
mass 0
but 0
an 0
increase 0
in 0
cardiac 0
output 0
to 0
the 0
pretreatment 0
level 0
again 0
and 0
a 0
concomitant 0
decrease 0
in 0
total 0
peripheral 0
resistance 0
. 0

This 0
study 0
was 0
undertaken 0
to 0
assess 0
the 0
effects 0
of 0
hypothermia 0
and 0
chemical 0
cardioplegia 0
on 0
the 0
functional 0
recovery 0
of 0
hypertrophied 0
non 0
- 0
failing 0
rat 0
hearts 0
subjected 0
to 0
an 0
extended 0
period 0
of 0
global 0
ischaemia 0
. 0

Oxygen 0
profiles 0
calculated 0
for 0
the 0
Krogh 0
model 0
with 0
excentric 0
diffusion 0
were 0
similar 0
to 0
those 0
derived 0
for 0
the 0
two 0
models 0
of 0
concentric 0
diffusion 0
. 0

Cultivation 0
technics 0
for 0
Codonopsis 0
pilosula 0

Radioimmunoassay 0
of 0
serum 0
creatine B-gene
kinase I-gene
B I-gene
isoenzyme I-gene
in 0
the 0
diagnosis 0
of 0
acute 0
myocardial 0
infarction 0
. 0

Selective 0
macrophage 0
inhibition 0
abolishes 0
warfarin 0
- 0
induced 0
reduction 0
of 0
metastasis 0
. 0

Restriction 0
enzyme 0
and 0
heteroduplex 0
analyses 0
confirmed 0
that 0
sequences 0
unique 0
to 0
FeSV 0
( 0
src B-gene
sequences I-gene
) 0
are 0
located 0
at 0
the 0
center 0
of 0
the 0
FeSV 0
genome 0
and 0
are 0
approximately 0
1.5 0
kilobase 0
pairs 0
in 0
length 0
. 0

Among 0
six 0
different 0
library 0
isolates 0
containing 0
6.5 B-gene
- I-gene
to I-gene
7 I-gene
- I-gene
kb I-gene
IAP I-gene
units I-gene
, 0
some 0
restriction 0
sites 0
were 0
highly 0
conserved 0
whereas 0
others 0
varied 0
in 0
both 0
occurrence 0
and 0
position 0
. 0

Catecholamines 0
and 0
aversive 0
learning 0
: 0
a 0
review 0
. 0

A 0
haemolytic 0
enterotoxigenic 0
strain 0
of 0
E. 0
coli 0
( 0
O149 0
: 0
K88 0
: 0
H10 0
) 0
was 0
regularly 0
recovered 0
from 0
piglets 0
with 0
PWD 0
while 0
rotavirus 0
was 0
demonstrated 0
on 0
a 0
number 0
of 0
occasions 0
. 0

The 0
antibody 0
titer 0
of 0
202 0
chickens 0
to 0
SA 0
- 0
11 0
rotavirus 0
was 0
determined 0
by 0
enzyme 0
- 0
linked 0
immunosorbent 0
blocking 0
assay 0
. 0

Poly 0
( 0
dT 0
) 0
and 0
denatured 0
calf 0
thymus 0
DNA 0
were 0
more 0
effective 0
than 0
were 0
other 0
polynucleotides 0
tested 0
in 0
promoting 0
accumulation 0
of 0
19 0
HDP* B-gene
; 0
( 0
dT 0
) 0
8 0
was 0
as 0
effective 0
as 0
were 0
longer 0
molecules 0
of 0
( 0
dT 0
) 0
n 0
, 0
but 0
( 0
dT 0
) 0
4 0
and 0
( 0
dT 0
) 0
6 0
were 0
much 0
less 0
effective 0
, 0
indicating 0
that 0
the 0
binding 0
site 0
involved 0
in 0
19 0
HDP* B-gene
accumulation 0
covered 0
between 0
6 0
and 0
8 0
residues 0
of 0
( 0
dT 0
) 0
n 0
. 0

A 0
double 0
- 0
blind 0
trial 0
of 0
half 0
- 0
strength 0
Polybactrin 0
Soluble 0
GU 0
bladder 0
irrigation 0
in 0
cystoscopy 0
. 0

Thus 0
it 0
appears 0
that 0
insertion 0
of 0
a 0
transposable 0
element 0
near 0
the 0
5 0
' 0
terminus 0
of 0
the 0
structural 0
gene 0
can 0
produce 0
constitutive 0
expression 0
of 0
a 0
normally 0
glucose 0
- 0
repressed 0
enzyme 0
. 0

Five 0
experiments 0
examined 0
the 0
influence 0
of 0
opiate 0
antagonists 0
on 0
both 0
the 0
short 0
- 0
term 0
analgesic 0
reaction 0
resulting 0
30 0
min 0
after 0
exposure 0
to 0
inescapable 0
shock 0
and 0
the 0
long 0
- 0
term 0
analgesic 0
reaction 0
resulting 0
after 0
reexposure 0
to 0
shock 0
24 0
hr 0
after 0
inescapable 0
shock 0
exposure 0
. 0

Experiment 0
3 0
showed 0
that 0
the 0
long 0
- 0
term 0
analgesic 0
reaction 0
could 0
also 0
be 0
reduced 0
by 0
administration 0
of 0
naltrexone 0
prior 0
to 0
reexposure 0
to 0
shock 0
. 0

During 0
the 0
period 0
from 0
May 0
to 0
August 0
, 0
1978 0
, 0
an 0
epidemic 0
of 0
hand 0
, 0
foot 0
and 0
mouth 0
disease 0
( 0
HFMD 0
) 0
occurred 0
in 0
Gifu 0
prefecture 0
. 0

A 0
22K 0
polypeptide 0
was 0
detected 0
as 0
a 0
translation 0
product 0
of 0
late 0
RNA 0
that 0
hybridized 0
to 0
this 0
DNA 0
fragment 0
. 0

Replicating 0
simian 0
virus 0
40 0
( 0
SV40 0
) 0
chromosomes 0
were 0
found 0
to 0
be 0
similar 0
to 0
other 0
eukaryotic 0
chromosomes 0
in 0
that 0
the 0
rate 0
and 0
extent 0
of 0
micrococcal B-gene
nuclease I-gene
( 0
MNase B-gene
) 0
digestion 0
were 0
greater 0
with 0
replicating 0
than 0
with 0
nonreplicating 0
mature 0
SV40 0
chromatin 0
. 0

A 0
hypothesis 0
. 0

We 0
have 0
investigated 0
the 0
requirements 0
of 0
the 0
CH B-gene
gene I-gene
switch 0
by 0
characterizing 0
two 0
rearranged B-gene
gamma I-gene
2b I-gene
genes I-gene
from 0
a 0
gamma B-gene
2b I-gene
producing 0
mouse 0
myeloma 0
( 0
MPC 0
- 0
11 0
) 0
. 0

Physiology 0
and 0
Physiopathology 0

The 0
genome 0
of 0
avian 0
erythroblastosis 0
virus 0
contains 0
two 0
independently 0
expressed 0
genetic 0
loci 0
( 0
v B-gene
- I-gene
erbA I-gene
and 0
v B-gene
- I-gene
erbB I-gene
) 0
whose 0
activities 0
are 0
probably 0
responsible 0
for 0
oncogenesis 0
by 0
the 0
virus 0
. 0

Because 0
RNase B-gene
III I-gene
host I-gene
mutants I-gene
are 0
defective 0
in 0
sib B-gene
regulation 0
, 0
processing 0
of 0
the 0
PL B-gene
mRNA I-gene
at 0
sib B-gene
by 0
this 0
endoribonuclease 0
may 0
cause 0
int B-gene
mRNA I-gene
decay 0
and 0
decrease 0
int B-gene
synthesis 0
. 0

At 0
least 0
one 0
clone 0
, 0
lambda 0
HHG 0
41 0
, 0
contains 0
, 0
in 0
addition 0
to 0
the 0
histone B-gene
genes I-gene
, 0
a 0
region 0
that 0
hybridizes 0
with 0
a 0
cytoplasmic 0
RNA 0
approximately 0
330 0
nucleotides 0
in 0
length 0
. 0

Both 0
neural 0
and 0
hormonal 0
pathways 0
and 0
both 0
opiate 0
and 0
nonopiate 0
substances 0
play 0
roles 0
in 0
the 0
complex 0
modulation 0
of 0
pain 0
transmission 0
. 0

Restoration 0
of 0
impaired 0
immune 0
functions 0
in 0
aging 0
animals 0
. 0

Postoperative 0
serum 0
ACTH B-gene
levels 0
were 0
normal 0
. 0

WR 0
- 0
2721 0
( 0
S 0
- 0
2 0
- 0
( 0
3 0
aminopropylamino 0
) 0
ethylphosphorothioic 0
acid 0
) 0
has 0
been 0
investigated 0
for 0
its 0
ability 0
to 0
protect 0
gut 0
, 0
lung 0
, 0
and 0
testis 0
, 0
as 0
well 0
as 0
fibrosarcoma 0
( 0
FSa 0
) 0
tumor 0
nodules 0
, 0
in 0
the 0
lungs 0
of 0
mice 0
from 0
gamma 0
- 0
radiation 0
injury 0
. 0

In 0
fact 0
, 0
families 0
of 0
polypeptides 0
were 0
produced 0
by 0
initiation 0
of 0
translation 0
at 0
AUG 0
codons 0
within 0
sequences 0
coding 0
for 0
VP1 B-gene
and 0
T B-gene
, 0
presumably 0
as 0
a 0
result 0
of 0
transcription 0
initiation 0
events 0
that 0
generated 0
5 0
' 0
ends 0
immediately 0
upstream 0
from 0
these 0
AUGs 0
. 0

In 0
addition 0
, 0
TRP1 B-gene
RI 0
Circle 0
DNA 0
is 0
organized 0
into 0
nucleosomes 0
whose 0
size 0
and 0
spacing 0
are 0
indistinguishable 0
from 0
that 0
of 0
bulk 0
yeast 0
chromatin 0
. 0

The 0
frequency 0
of 0
previous 0
transfusion 0
in 0
chronic 0
hepatitis 0
, 0
cirrhosis 0
and 0
hepatocellular 0
carcinoma 0
of 0
type 0
NANB 0
was 0
42.8 0
, 0
37.1 0
and 0
15.1 0
% 0
, 0
respectively 0
, 0
whereas 0
the 0
incidence 0
of 0
early 0
posttransfusion 0
hepatitis 0
was 0
8.5 0
, 0
8.6 0
and 0
7.5 0
% 0
, 0
respectively 0
. 0
in 0
chronic 0
liver 0
diseases 0
with 0
a 0
history 0
of 0
jaundice 0
and/or 0
hepatitis 0
, 0
previous 0
transfusions 0
are 0
more 0
frequently 0
associated 0
with 0
type 0
NANB 0
than 0
with 0
type 0
B 0
disease 0
. 0

Of 0
115 0
hepatitis 0
B 0
patients 0
seen 0
at 0
12 0
months 0
, 0
6 0
% 0
had 0
chronic 0
hepatitis 0
Bs 0
antigenaemia 0
, 0
60 0
% 0
had 0
developed 0
anti B-gene
- I-gene
HBs I-gene
antibodies I-gene
, 0
and 0
7.3 0
% 0
still 0
had 0
abnormal 0
liver 0
function 0
. 0

Survey 0
on 0
antibody 0
against 0
egg 0
drop 0
syndrome 0
- 0
1976 0
virus 0
among 0
chicken 0
flocks 0
in 0
Japan 0
. 0

In 0
49 0
patients 0
in 0
whom 0
gated 0
equilibrium 0
ventriculography 0
and 0
cardiac 0
catheterization 0
were 0
performed 0
within 0
a 0
6 0
day 0
interval 0
, 0
total 0
and 0
fractional 0
portions 0
of 0
global 0
and 0
regional 0
right 0
ventricular 0
ejection 0
fraction 0
( 0
RVEF 0
) 0
were 0
correlated 0
with 0
pulmonary 0
arterial 0
systolic 0
pressure 0
. 0

74 0
, 0
193 0
- 0
197 0
) 0
. 0

The 0
combination 0
of 0
MISO 0
and 0
WR 0
- 0
2721 0
gave 0
an 0
intermediate 0
response 0
compared 0
with 0
either 0
drug 0
used 0
alone 0
, 0
resulting 0
in 0
some 0
sensitization 0
with 0
single 0
doses 0
and 0
an 0
overall 0
protection 0
with 0
repeated 0
small 0
doses 0
. 0

Two 0
mutations 0
that 0
affect 0
larval B-gene
cuticle I-gene
protein I-gene
gene I-gene
expression 0
in 0
the 0
2/3 0
variant 0
Drosophila 0
melanogaster 0
strain 0
were 0
investigated 0
. 0

The 0
ensembles 0
are 0
considered 0
to 0
be 0
one 0
of 0
the 0
forms 0
of 0
activity 0
of 0
the 0
structured 0
morphofunctional 0
cortical 0
units 0
, 0
i.e 0
. 0
the 0
columns 0
. 0

The 0
strong 0
conservation 0
of 0
the 0
inverted 0
terminal 0
repeat 0
sequence 0
may 0
reflect 0
a 0
common 0
integration 0
mechanism 0
for 0
VL30 B-gene
elements I-gene
and 0
MuLV 0
proviruses 0
. 0

A 0
cDNA 0
cloning 0
vector 0
that 0
permits 0
expression 0
of 0
cDNA 0
inserts 0
in 0
mammalian 0
cells 0
. 0

Hybridization 0
of 0
plasmid 0
- 0
transformed 0
Escherichia 0
coli 0
RR1 0
colonies 0
with 0
32P 0
- 0
labeled 0
viral 0
genome 0
RNAs 0
demonstrated 0
the 0
presence 0
of 0
DNA 0
clones 0
representative 0
of 0
each 0
of 0
the 0
10 0
reovirus 0
RNAs 0
and 0
10 0
of 0
the 0
11 0
constituent 0
segments 0
of 0
the 0
rotavirus 0
genome 0
. 0

Another 0
sequence 0
, 0
GGGXGGAG 0
, 0
which 0
is 0
repeated 0
several 0
times 0
in 0
many 0
polyomaviruses 0
and 0
adenoviruses 0
, 0
and 0
which 0
is 0
thought 0
to 0
play 0
a 0
role 0
in 0
DNA 0
replication 0
and/or 0
transcription 0
, 0
is 0
not 0
found 0
in 0
the 0
JCV 0
sequence 0
presented 0
. 0

In 0
conclusion 0
, 0
these 0
studies 0
indicate 0
that 0
LiCl 0
( 0
1 0
) 0
decreases 0
histamine 0
- 0
stimulated 0
gastric 0
acid 0
secretion 0
, 0
and 0
( 0
2 0
) 0
diminishes 0
bile 0
- 0
induced 0
disruption 0
of 0
the 0
gastric 0
mucosal 0
barrier 0
in 0
the 0
canine 0
Heidenhain 0
pouch 0
. 0

Lung 0
density 0
increased 0
in 0
quartz 0
- 0
exposed 0
, 0
but 0
not 0
in 0
volcanic 0
- 0
ash 0
- 0
exposed 0
animals 0
. 0

The 0
hepatitis B-gene
A I-gene
virus I-gene
antibody I-gene
( 0
anti B-gene
- I-gene
HAV I-gene
) 0
in 0
chronic 0
diffuse 0
liver 0
diseases 0

The 0
junctions 0
between 0
viral 0
and 0
cellular 0
sequences 0
were 0
determined 0
by 0
DNA 0
sequence 0
analysis 0
to 0
be 0
517 0
nucleotides 0
into 0
the 0
p30 B-gene
sequence I-gene
and 0
1,920 0
nucleotides 0
into 0
the 0
polymerase 0
sequence 0
. 0

Naloxone 0
( 0
2 0
mg/kg 0
bolus 0
+ 0
2 0
mg 0
X 0
kg 0
- 0
1 0
X 0
h 0
- 0
1 0
) 0
was 0
given 0
with 0
one 0
of 0
the 0
two 0
doses 0
of 0
the 0
lipopolysaccharide 0
. 0

Gel 0
route 0
preparation 0
of 0
low 0
fusing 0
dental 0
porcelain 0
frit 0
. 0

I 0
. 0

Viral 0
RNA 0
, 0
molecularly 0
cloned 0
proviral 0
DNA 0
, 0
and 0
virus 0
- 0
specific 0
protein 0
of 0
avian 0
retrovirus 0
MH2 0
were 0
analyzed 0
. 0

Intracellular 0
recordings 0
were 0
performed 0
on 0
the 0
optic 0
tectum 0
of 0
the 0
carp 0
in 0
vitro 0
. 0

Molecular 0
structure 0
and 0
evolutionary 0
origin 0
of 0
human B-gene
cardiac I-gene
muscle I-gene
actin I-gene
gene I-gene
. 0

The 0
mutants 0
were 0
obtained 0
by 0
substitution 0
into 0
a 0
molecular 0
clone 0
of 0
M 0
- 0
MuLV 0
DNA 0
by 0
DNA 0
from 0
two 0
acutely 0
transforming 0
viruses 0
, 0
Ableson 0
MuLV 0
( 0
Ab 0
- 0
MuLV 0
) 0
and 0
Moloney 0
murine 0
sarcoma 0
virus 0
( 0
M 0
- 0
MSV 0
) 0
. 0

Plasmids 0
for 0
the 0
cloning 0
and 0
expression 0
of 0
full 0
- 0
length 0
double 0
- 0
stranded 0
cDNAs 0
under 0
control 0
of 0
the 0
SV40 B-gene
early I-gene
or 0
late B-gene
gene I-gene
promoter 0
. 0

Supplementing 0
a 0
soybean 0
protein 0
and 0
sucrose 0
- 0
based 0
diet 0
with 0
levels 0
of 0
2.2 0
, 0
11 0
, 0
and 0
55 0
ppm 0
of 0
the 0
antibiotic 0
, 0
from 0
the 0
two 0
sources 0
each 0
with 0
two 0
different 0
purities 0
, 0
improved 0
weight 0
gain 0
of 0
chicks 0
an 0
average 0
of 0
23 0
% 0
and 0
improved 0
feed 0
efficiency 0
an 0
average 0
of 0
13 0
% 0
at 0
the 0
higher 0
levels 0
( 0
all 0
P 0
less 0
than 0
.01 0
) 0
. 0

The 0
dnaQ B-gene
- 0
lacZ B-gene
and 0
the 0
rnh B-gene
- 0
lacZ B-gene
fused 0
genes 0
were 0
constructed 0
and 0
hybrid 0
proteins 0
with 0
beta B-gene
- I-gene
galactosidase I-gene
activity 0
were 0
produced 0
. 0

Overall 0
prevalences 0
of 0
antibody 0
were 0
70 0
per 0
cent 0
in 0
cattle 0
, 0
67 0
per 0
cent 0
in 0
sheep 0
and 0
76 0
per 0
cent 0
in 0
goats 0
as 0
assessed 0
by 0
an 0
immunodiffusion 0
test 0
. 0

Expression 0
of 0
herpes 0
simplex 0
virus 0
beta 0
and 0
gamma 0
genes 0
integrated 0
in 0
mammalian 0
cells 0
and 0
their 0
induction 0
by 0
an 0
alpha 0
gene 0
product 0
. 0

The 0
splice 0
acceptor 0
site 0
is 0
ca 0
. 0

This 0
is 0
consistent 0
with 0
a 0
model 0
proposing 0
that 0
SSV 0
was 0
generated 0
by 0
recombination 0
between 0
proviral 0
DNA 0
of 0
a 0
simian 0
sarcoma 0
associated 0
virus 0
and 0
proto B-gene
- I-gene
sis I-gene
and 0
that 0
introns 0
were 0
spliced 0
out 0
subsequently 0
from 0
a 0
fused 0
viral B-gene
- I-gene
sis I-gene
messenger I-gene
RNA I-gene
. 0

We 0
conclude 0
that 0
, 0
with 0
autonomic 0
nervous 0
system 0
activity 0
intact 0
, 0
carotid 0
chemoreceptor 0
reflex 0
activation 0
can 0
elicit 0
an 0
absolute 0
reflexly 0
mediated 0
reduction 0
in 0
coronary 0
blood 0
flow 0
in 0
the 0
normal 0
, 0
conscious 0
dog 0
, 0
despite 0
an 0
increase 0
in 0
arterial 0
pressure 0
. 0

Female 0
subjects 0
, 0
including 0
both 0
normal 0
subjects 0
and 0
idiopathic 0
calcium 0
stone 0
- 0
formers 0
, 0
have 0
higher 0
urinary 0
cyclic 0
AMP 0
levels 0
than 0
their 0
male 0
counterparts 0
, 0
and 0
this 0
difference 0
is 0
significant 0
when 0
urinary 0
cyclic 0
AMP 0
is 0
expressed 0
in 0
the 0
units 0
mumol/g 0
of 0
creatinine 0
. 0

We 0
conclude 0
that 0
the 0
'morning 0
dip 0
' 0
observed 0
in 0
asthmatic 0
patients 0
can 0
not 0
simply 0
be 0
explained 0
by 0
changes 0
in 0
cell 0
receptor 0
number 0
or 0
affinity 0
, 0
as 0
our 0
results 0
suggest 0
that 0
both 0
groups 0
have 0
intact 0
beta B-gene
- I-gene
adrenoceptor I-gene
function 0
. 0

The 0
effect 0
of 0
desipramine 0
probably 0
represents 0
inhibition 0
of 0
neuronal 0
uptake 0
and 0
that 0
of 0
amitriptyline 0
and 0
mianserin 0
blockade 0
of 0
neuronal 0
uptake 0
and 0
prejunctional 0
alpha B-gene
2 I-gene
- I-gene
adrenoreceptors I-gene
. 0

We 0
conclude 0
that 0
the 0
gp54 B-gene
structural I-gene
gene I-gene
is 0
required 0
for 0
initiation 0
or 0
amplification 0
of 0
the 0
splenic 0
erythroblast 0
hyperplasia 0
which 0
characterizes 0
the 0
preleukemic 0
phase 0
of 0
Rauscher 0
disease 0
. 0

Surgical 0
treatment 0
of 0
pulmonary 0
metastases 0
. 0

A 0
promoter 0
sequence 0
( 0
Goldberg 0
- 0
Hogness 0
or 0
TATA 0
box 0
) 0
is 0
situated 0
28 0
base 0
pairs 0
upstream 0
from 0
the 0
point 0
of 0
initiation 0
of 0
transcription 0
which 0
was 0
found 0
by 0
S1 B-gene
nuclease I-gene
mapping 0
and 0
by 0
oligonucleotide 0
- 0
primed 0
reverse 0
transcription 0
of 0
rat B-gene
PTH I-gene
mRNA I-gene
. 0

Each 0
of 0
these 0
spliced 0
mRNAs 0
has 0
an 0
untranslated 0
leader 0
sequence 0
of 0
249 0
bases 0
and 0
a 0
single 0
intron 0
of 0
approximately 0
540 0
bases 0
which 0
are 0
contained 0
entirely 0
within 0
TRs/IRs 0
sequences 0
. 0

The 0
expression 0
of 0
chloramphenicol B-gene
acetyltransferase I-gene
was 0
detected 0
within 0
1 0
h 0
after 0
infection 0
of 0
cells 0
with 0
recombinant 0
virus 0
, 0
reflecting 0
the 0
early 0
nature 0
of 0
the 0
promoters 0
used 0
. 0

NPT B-gene
II I-gene
synthesis 0
, 0
measured 0
by 0
agar 0
plate 0
assays 0
of 0
kanamycin 0
resistance 0
and 0
by 0
immunoprecipitation 0
of 0
the 0
NPT B-gene
II I-gene
protein I-gene
, 0
was 0
repressed 0
in 0
the 0
presence 0
of 0
cysteine 0
and 0
derepressed 0
in 0
its 0
absence 0
. 0

A 0
computed 0
tomographic 0
scan 0
obtained 0
after 0
EOE 0
- 0
13 0
infusion 0
accurately 0
showed 0
the 0
perfusion 0
pattern 0
of 0
the 0
implanted 0
catheter 0
. 0

The 0
primary 0
structure 0
of 0
the 0
GAL7 B-gene
5 I-gene
' I-gene
flanking I-gene
region I-gene
has 0
many 0
features 0
common 0
to 0
those 0
of 0
multicellular 0
eukaryotic 0
genes 0
. 0

The 0
12,000 B-gene
MW I-gene
( I-gene
12K I-gene
) I-gene
IE I-gene
polypeptide I-gene
encoded 0
by 0
IEmRNA B-gene
- I-gene
5 I-gene
is 0
translated 0
from 0
an 0
88 0
codon 0
open 0
reading 0
frame 0
, 0
leaving 0
a 0
1200 0
base 0
3 0
' 0
non 0
- 0
translated 0
region 0
. 0

The 0
greatest 0
difference 0
between 0
the 0
Ad7 B-gene
and I-gene
Ad5 I-gene
DBPs I-gene
is 0
the 0
absence 0
, 0
in 0
the 0
Ad7 0
protein 0
, 0
of 0
12 0
amino 0
acids 0
located 0
between 0
the 0
two 0
functional 0
domains 0
in 0
the 0
Ad5 0
protein 0
( 0
amino 0
acids 0
151 0
- 0
162 0
) 0
. 0

No 0
significant 0
correlation 0
was 0
found 0
between 0
LVM 0
or 0
wall 0
thickness 0
and 0
body 0
surface 0
area 0
, 0
age 0
, 0
blood 0
pressure 0
, 0
heart 0
rate 0
, 0
cardiac 0
output 0
, 0
total 0
peripheral 0
resistance 0
and 0
left 0
ventricular 0
systolic 0
wall 0
stress 0
, 0
whereas 0
CD25 0
was 0
correlated 0
with 0
urinary 0
catecholamines 0
only 0
in 0
hypertensive 0
patients 0
( 0
r 0
= 0
0.606 0
, 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Furthermore 0
, 0
no 0
Shine 0
- 0
Dalgarno 0
sequences 0
are 0
present 0
upstream 0
of 0
the 0
presumed 0
translational 0
start 0
codons 0
. 0

The 0
gene B-gene
cat I-gene
- I-gene
86 I-gene
, 0
specifying 0
chloramphenicol B-gene
- I-gene
inducible I-gene
chloramphenicol I-gene
acetyltransferase I-gene
, 0
is 0
located 0
on 0
the 0
1.1 0
- 0
kilobase 0
cloned 0
DNA 0
. 0

The 0
myeloproliferative 0
sarcoma 0
virus 0
( 0
MPSV 0
) 0
was 0
derived 0
by 0
passage 0
of 0
Moloney 0
sarcoma 0
virus 0
( 0
Mo 0
- 0
MuSV 0
) 0
in 0
adult 0
mice 0
. 0

The 0
same 0
- 0
sized 0
EBNA B-gene
protein I-gene
( I-gene
approximately I-gene
78,000 I-gene
) I-gene
was 0
made 0
after 0
transfection 0
with 0
BamHI B-gene
- I-gene
K I-gene
( I-gene
5.2 I-gene
kilobase I-gene
pairs I-gene
[ I-gene
kbp I-gene
] I-gene
) I-gene
or 0
the 0
I1f 0
subfragment 0
( 0
2.9 0
kbp 0
) 0
. 0

They 0
generated 0
ca 0
. 0

Here 0
we 0
have 0
determined 0
the 0
nucleotide 0
sequence 0
of 0
3.5 0
kb 0
from 0
the 0
3 0
' 0
end 0
of 0
delta B-gene
gag I-gene
to 0
the 0
3 0
' 0
end 0
of 0
molecularly 0
cloned 0
proviral 0
MH2 0
DNA 0
, 0
in 0
order 0
to 0
elucidate 0
the 0
genetic 0
structure 0
of 0
the 0
virus 0
and 0
to 0
compare 0
it 0
with 0
other 0
mht B-gene
- 0
and 0
myc B-gene
- 0
containing 0
oncogenic 0
viruses 0
as 0
well 0
as 0
with 0
the 0
chicken B-gene
proto I-gene
- I-gene
myc I-gene
gene I-gene
. 0

USA 0
80 0
, 0
802 0
- 0
806 0
] 0
was 0
used 0
to 0
isolate 0
a 0
genomic 0
clone 0
lambda 0
PGK B-gene
- I-gene
1 I-gene
containing 0
a 0
portion 0
of 0
an 0
autosomal 0
locus 0
for 0
phosphoglycerate B-gene
kinase I-gene
( 0
PGK B-gene
) 0
. 0

A 0
. 0

188 0
patients 0
received 0
cimetidine 0
400 0
mg 0
q.i.d 0
. 0
intravenously 0
and 0
1,000 0
mg 0
daily 0
orally 0
in 0
divided 0
doses 0
. 0

An 0
immunologic 0
test 0
using 0
stomach 0
and 0
tumor 0
antigens 0
for 0
screening 0
of 0
those 0
at 0
high 0
risk 0
for 0
stomach 0
cancer 0
is 0
suggested 0
. 0

Thirty 0
isolates 0
of 0
Haemophilus 0
influenzae 0
type 0
b 0
were 0
obtained 0
during 0
an 0
outbreak 0
of 0
invasive 0
H. 0
influenzae 0
type 0
b 0
disease 0
and 0
were 0
classified 0
by 0
the 0
electrophoretic 0
profile 0
of 0
their 0
lipopolysaccharide 0
( 0
LPS 0
) 0
. 0

Tiaprofenic 0
acid 0
overdose 0
. 0

Frog 0
type 0
I 0
( 0
Ft 0
I 0
) 0
and 0
frog 0
type 0
II 0
( 0
Ft 0
II 0
) 0
slowly 0
adapting 0
( 0
SA 0
) 0
units 0
produced 0
spikes 0
only 0
at 0
the 0
indentation 0
phase 0
, 0
and 0
the 0
threshold 0
response 0
phase 0
( 0
TRP 0
) 0
, 0
i.e.. 0
the 0
phase 0
of 0
the 0
first 0
spike 0
was 0
for 0
ca 0
. 0

Frog 0
type 0
I 0
( 0
Ft 0
I 0
) 0
and 0
frog 0
type 0
II 0
( 0
Ft 0
II 0
) 0
slowly 0
adapting 0
( 0
SA 0
) 0
units 0
produced 0
spikes 0
only 0
at 0
the 0
indentation 0
phase 0
, 0
and 0
the 0
threshold 0
response 0
phase 0
( 0
TRP 0
) 0
, 0
i.e.. 0
the 0
phase 0
of 0
the 0
first 0
spike 0
was 0
for 0
ca 0
. 0

DMCM 0
also 0
permits 0
extension 0
of 0
the 0
possibilities 0
of 0
obtaining 0
and 0
transplanting 0
donor 0
organs 0
. 0

Grimelius 0
stain 0
was 0
positive 0
, 0
Masson 0
Fontana 0
stain 0
negative 0
. 0

Blood 0
glucose 0
and 0
plasma 0
insulin B-gene
were 0
measured 0
at 0
zero 0
time 0
and 0
then 0
at 0
15 0
, 0
30 0
, 0
60 0
, 0
90 0
and 0
120 0
min 0
after 0
ingestion 0
of 0
25 0
g 0
glucose 0
, 0
fructose 0
or 0
lactose 0
, 0
or 0
30 0
g 0
honey 0
, 0
50 0
g 0
white 0
bread 0
, 0
125 0
g 0
white 0
rice 0
or 0
potatoes 0
, 0
150 0
g 0
apples 0
or 0
260 0
g 0
carrots 0
. 0

Clinical 0
use 0
of 0
absorbable 0
polyglycolic 0
acid 0
suture 0
in 0
Blalock 0
- 0
Taussig 0
's 0
operation 0

Among 0
these 0
are 0
: 0
( 0
1 0
) 0
Is 0
there 0
sufficient 0
understanding 0
of 0
family 0
pathophysiology 0
, 0
of 0
the 0
sensitivity 0
and 0
specificity 0
of 0
diagnostic 0
techniques 0
and 0
of 0
the 0
safety 0
and 0
efficacy 0
of 0
therapeutic 0
modalities 0
to 0
make 0
true 0
family 0
health 0
care 0
possible 0
? 0
( 0
2 0
) 0
If 0
this 0
type 0
of 0
care 0
is 0
possible 0
, 0
how 0
are 0
the 0
needs 0
of 0
the 0
family 0
and 0
its 0
individual 0
members 0
met 0
, 0
or 0
value 0
judgements 0
made 0
about 0
their 0
relative 0
importance 0
? 0
and 0
( 0
3 0
) 0
What 0
are 0
the 0
consequences 0
for 0
the 0
health 0
care 0
delivery 0
system 0
of 0
this 0
type 0
of 0
care 0
? 0
An 0
extensive 0
literature 0
review 0
is 0
used 0
in 0
an 0
attempt 0
to 0
answer 0
these 0
queries 0
, 0
from 0
which 0
questions 0
for 0
further 0
study 0
are 0
posed 0
. 0

In 0
patients 0
in 0
group 0
A 0
( 0
`` 0
normal 0
'' 0
CI 0
) 0
, 0
the 0
CI 0
, 0
heart 0
rate 0
and 0
the 0
mean 0
circumferential 0
fiber 0
shortening 0
velocity 0
( 0
mVCF 0
) 0
were 0
normal 0
, 0
but 0
the 0
TPR 0
was 0
increased 0
significantly 0
. 0

Immunologically 0
reactive 0
insulin B-gene
levels 0
were 0
determined 0
in 0
freely 0
- 0
moving 0
normal 0
rats 0
offered 0
three 0
different 0
test 0
- 0
meals 0
. 0

These 0
results 0
indicate 0
that 0
both 0
naturally 0
acquired 0
and 0
passive 0
( 0
modified 0
immune B-gene
serum I-gene
globulin I-gene
) 0
antibodies 0
to 0
type B-gene
III I-gene
group I-gene
B I-gene
Streptococcus I-gene
antigen I-gene
are 0
partially 0
protective 0
against 0
intra 0
- 0
amniotic 0
infection 0
. 0

In 0
the 0
posthospital 0
phase 0
of 0
AMI 0
, 0
as 0
well 0
as 0
in 0
CCHD 0
, 0
the 0
occurrence 0
of 0
high 0
- 0
grade 0
VPBs 0
usually 0
indicates 0
more 0
advanced 0
degrees 0
of 0
both 0
coronary 0
and 0
left 0
ventricular 0
disease 0
as 0
well 0
as 0
the 0
possibility 0
of 0
cardiac 0
and/or 0
sudden 0
death 0
. 0

Sweet 0
oranges 0
, 0
mandarin 0
, 0
grapefruit 0
, 0
lemon 0
, 0
and 0
lime 0
are 0
generally 0
used 0
for 0
processing 0
. 0

The 0
genes 0
at 0
each 0
locus 0
are 0
divergently 0
transcribed 0
and 0
the 0
coding 0
sequences 0
are 0
separated 0
by 0
646 0
base 0
- 0
pairs 0
at 0
one 0
locus 0
and 0
676 0
base 0
- 0
pairs 0
at 0
the 0
other 0
. 0

The 0
enzymic 0
hydrolysis 0
of 0
urea 0
produces 0
ammonia 0
which 0
causes 0
a 0
vivid 0
yellow 0
to 0
purple 0
colour 0
change 0
in 0
the 0
pH 0
indicator 0
. 0

The 0
clinical 0
efficacy 0
rates 0
evaluated 0
in 0
151 0
cases 0
( 0
KS 0
- 0
R1 0
group 0
in 0
77 0
cases 0
, 0
oral 0
group 0
in 0
74 0
cases 0
) 0
on 0
standard 0
criteria 0
of 0
committee 0
members 0
were 0
88.3 0
% 0
for 0
the 0
KS 0
- 0
R1 0
group 0
and 0
86.5 0
% 0
for 0
the 0
oral 0
group 0
, 0
respectively 0
. 0

Side 0
effect 0
including 0
subjective 0
and 0
objective 0
symptoms 0
were 0
strictly 0
evaluated 0
in 0
163 0
cases 0
( 0
KS 0
- 0
R1 0
group 0
in 0
83 0
cases 0
, 0
oral 0
group 0
in 0
80 0
cases 0
) 0
, 0
but 0
the 0
incidence 0
rate 0
which 0
was 0
22.9 0
% 0
for 0
the 0
KS 0
- 0
R1 0
group 0
and 0
23.8 0
% 0
for 0
the 0
oral 0
group 0
showed 0
no 0
significant 0
difference 0
. 0

Plasma 0
renin B-gene
activity 0
did 0
not 0
change 0
in 0
response 0
to 0
head 0
- 0
up 0
tilt 0
or 0
isoprenaline 0
infusion 0
in 0
the 0
patients 0
. 0

Martin 0
Luther 0
and 0
his 0
physicians 0
. 0

Enhancement 0
of 0
the 0
immune 0
response 0
by 0
aspecific 0
action 0
of 0
vaccine 0
additives 0
in 0
the 0
aerogenic 0
immunization 0
of 0
swine 0
against 0
swine 0
plague 0

Induced 0
gamma 0
- 0
ray 0
spectroscopy 0

Bepridil 0
, 0
a 0
calcium 0
antagonist 0
with 0
a 0
half 0
- 0
life 0
of 0
approximately 0
42 0
hours 0
, 0
was 0
compared 0
with 0
placebo 0
in 0
a 0
double 0
- 0
blind 0
, 0
randomized 0
, 0
crossover 0
trial 0
. 0

Analysis 0
of 0
proteins 0
synthesized 0
by 0
plasmids 0
containing 0
deleted 0
forms 0
of 0
the 0
trfA B-gene
region I-gene
indicates 0
that 0
the 0
A2 B-gene
protein I-gene
is 0
the 0
essential 0
trfA B-gene
- I-gene
encoded I-gene
replication I-gene
protein I-gene
of 0
plasmid 0
RK2 0
. 0

Effects 0
of 0
negative 0
pleural 0
pressure 0
on 0
left 0
ventricular 0
hemodynamics 0
. 0

Resting 0
plasma 0
norepinephrine 0
( 0
NE 0
) 0
and 0
epinephrine 0
( 0
E 0
) 0
levels 0
were 0
lower 0
during 0
active 0
therapy 0
than 0
2 0
wk 0
after 0
withdrawal 0
( 0
guanfacine 0
and 0
control 0
: 0
plasma 0
NE 0
, 0
0.27 0
+/ 0
- 0
0.03/0.64 0
+/ 0
- 0
0.13 0
ng/ml 0
; 0
plasma 0
E 0
, 0
0.09 0
+/ 0
- 0
0.02/0.17 0
+/ 0
- 0
0.05 0
ng/ml 0
) 0
. 0

Renal 0
response 0
to 0
captopril 0
in 0
severe 0
heart 0
failure 0
: 0
role 0
of 0
furosemide 0
in 0
natriuresis 0
and 0
reversal 0
of 0
hyponatremia 0
. 0

Lauciello 0
describes 0
a 0
technique 0
for 0
the 0
placement 0
of 0
functionally 0
generated 0
amalgam 0
stops 0
as 0
restorations 0
within 0
mandibular 0
acrylic 0
teeth 0
. 0

Eleven 0
biopsy 0
specimens 0
( 0
five 0
papules 0
and 0
six 0
dusky 0
or 0
crusted 0
lesions 0
) 0
from 0
four 0
patients 0
with 0
pityriasis 0
lichenoides 0
et 0
varioliformis 0
acuta 0
( 0
PLEVA 0
) 0
were 0
studied 0
by 0
direct 0
immunofluorescence 0
and 0
immunoperoxidase B-gene
technics 0
. 0

These 0
data 0
suggest 0
that 0
a 0
major 0
part 0
of 0
the 0
reduction 0
in 0
food 0
intake 0
in 0
hyperphagic 0
rats 0
eating 0
a 0
quinine 0
- 0
adulterated 0
diet 0
is 0
due 0
to 0
postingestional 0
events 0
. 0

The 0
aspirate 0
from 0
a 0
parathyroid 0
cyst 0
was 0
watery 0
clear 0
and 0
contained 0
high 0
amount 0
of 0
parathyroid B-gene
hormone I-gene
. 0

EGV 0
had 0
no 0
detectable 0
effect 0
on 0
PP B-gene
secretion 0
under 0
basal 0
or 0
stimulated 0
conditions 0
. 0

The 0
numerous 0
tests 0
demonstrate 0
that 0
the 0
HDL 0
- 0
2M 0
can 0
be 0
extensively 0
and 0
successfully 0
used 0
for 0
therapy 0
of 0
insulin B-gene
- 0
dependent 0
diabetes 0
mellitus 0
in 0
clinical 0
practice 0
. 0

Lung 0
prostacyclin 0
production 0
may 0
be 0
related 0
to 0
flow 0
. 0

For 0
the 0
first 0
30 0
min 0
following 0
insulin B-gene
administration 0
, 0
the 0
rate 0
of 0
change 0
in 0
glucose 0
levels 0
was 0
significantly 0
less 0
among 0
the 0
patients 0
with 0
major 0
depressive 0
disorder 0
than 0
among 0
either 0
the 0
patients 0
with 0
dysthymic 0
disorder 0
or 0
the 0
normal 0
control 0
subjects 0
. 0

Management 0
of 0
hypertension 0
in 0
the 0
elderly 0
. 0

Climatic 0
treatment 0
of 0
children 0
with 0
respiratory 0
allergy 0

Transplantation 0
of 0
kidneys 0
of 0
juvenile 0
donors 0
in 0
adult 0
recipients 0
. 0

Ten 0
patients 0
with 0
advanced 0
, 0
diffuse 0
Hodgkin 0
's 0
and 0
non 0
- 0
Hodgkin 0
's 0
lymphomas 0
responding 0
poorly 0
to 0
the 0
most 0
widely 0
employed 0
primary 0
chemotherapy 0
regimens 0
were 0
treated 0
with 0
a 0
high 0
- 0
dose 0
chemotherapy 0
( 0
HDC 0
) 0
followed 0
by 0
rescue 0
with 0
non 0
- 0
frozen 0
autologous 0
bone 0
marrow 0
infusion 0
( 0
ABMT 0
) 0
. 0

Effect 0
of 0
proteolytic 0
enzymes 0
and 0
polypeptides 0
on 0
the 0
antacid 0
activity 0
of 0
almagate 0
and 0
other 0
antacids 0
. 0

Results 0
of 0
a 0
controlled 0
study 0

Hydrallazine 0
also 0
caused 0
a 0
slight 0
increase 0
in 0
plasma B-gene
renin I-gene
activity 0
and 0
urinary 0
excretion 0
of 0
noradrenaline 0
. 0

Urease B-gene
activity 0
of 0
97 0
% 0
of 0
these 0
organisms 0
became 0
evident 0
within 0
30 0
min 0
. 0

After 0
description 0
of 0
his 0
short 0
life 0
and 0
an 0
explanation 0
of 0
the 0
light 0
conductor 0
Bozzini 0
's 0
merit 0
is 0
emphasized 0
, 0
by 0
his 0
invention 0
as 0
first 0
physician 0
to 0
have 0
made 0
accessible 0
to 0
medicine 0
endoscopic 0
diagnostic 0
possibilities 0
. 0

The 0
effect 0
of 0
lithium 0
on 0
the 0
osmoregulation 0
of 0
arginine B-gene
vasopressin I-gene
secretion 0
. 0

The 0
susceptibility 0
of 0
the 0
PPNG 0
strains 0
to 0
clinically 0
relevant 0
antibiotics 0
varied 0
with 0
the 0
plasmid 0
pattern 0
; 0
this 0
stresses 0
the 0
necessity 0
of 0
permanent 0
surveillance 0
of 0
gonococcal 0
infections 0
and 0
of 0
regular 0
evaluation 0
of 0
the 0
recommendations 0
for 0
antimicrobial 0
treatment 0
. 0

Antithrombin B-gene
III I-gene
( 0
AT B-gene
III I-gene
) 0
is 0
a 0
plasma 0
protein 0
which 0
acts 0
as 0
the 0
principal 0
inhibitor 0
of 0
thrombin B-gene
and 0
is 0
a 0
major 0
modulator 0
of 0
intravascular 0
coagulation 0
. 0

Eighteen 0
patients 0
were 0
untreated 0
, 0
and 0
8 0
had 0
been 0
given 0
previous 0
treatment 0
with 0
depot 0
testosterone 0
100 0
mg 0
intramuscularly 0
every 0
2 0
- 0
3 0
weeks 0
for 0
an 0
average 0
duration 0
of 0
4.7 0
years 0
. 0

195mPt 0
- 0
labeled 0
cisplatin 0
was 0
administered 0
iv 0
and 0
ip 0
to 0
control 0
mice 0
and 0
to 0
mice 0
bearing 0
Sarcoma 0
180 0
. 0

New 0
beta 0
- 0
blocking 0
drugs 0
have 0
been 0
introduced 0
which 0
may 0
prove 0
beneficial 0
in 0
certain 0
clinical 0
situations 0
since 0
they 0
exert 0
more 0
selective 0
blockade 0
of 0
the 0
cardiac B-gene
receptors I-gene
( 0
beta1 B-gene
) 0
as 0
opposed 0
to 0
smooth B-gene
muscle I-gene
receptors I-gene
( 0
beta2 B-gene
) 0
. 0

If 0
facilities 0
for 0
measurements 0
of 0
O2 0
consumption 0
and 0
hence 0
metabolic 0
rate 0
are 0
available 0
, 0
these 0
should 0
be 0
utilized 0
. 0

This 0
generally 0
means 0
an 0
energy 0
intake 0
of 0
1.4 0
to 0
1.6 0
times 0
the 0
energy 0
expenditure 0
, 0
with 0
a 0
N 0
intake 0
of 0
250 0
to 0
400 0
mg/kg/day 0
. 0

In 0
the 0
37 0
patients 0
without 0
lung 0
disease 0
respiratory 0
muscle 0
weakness 0
was 0
accompanied 0
by 0
significant 0
decreases 0
in 0
vital 0
capacity 0
, 0
total 0
lung 0
capacity 0
, 0
and 0
maximum 0
voluntary 0
ventilation 0
; 0
by 0
significant 0
increases 0
in 0
residual 0
volume 0
and 0
arterial 0
carbon 0
dioxide 0
tension 0
( 0
PaCO2 0
) 0
; 0
and 0
greater 0
likelihood 0
of 0
dependence 0
on 0
ventilators 0
, 0
atelectasis 0
, 0
and 0
pneumonia 0
. 0

Commun 0
. 0

The 0
statistical 0
analysis 0
of 0
data 0
of 0
TRH B-gene
test 0
on 0
a 0
sample 0
of 0
57 0
healthy 0
volunteers 0
has 0
permitted 0
an 0
evaluation 0
of 0
the 0
upper 0
limits 0
of 0
the 0
normal 0
thyrotropin B-gene
response 0
; 0
the 0
secretory 0
area 0
( 0
As 0
) 0
was 0
shown 0
to 0
be 0
more 0
discriminating 0
. 0

Total 0
cumulative 0
doses 0
of 0
doxorubicin 0
ranged 0
from 0
145 0
to 0
625 0
mg./m.2 0
. 0

Movement 0
programming 0
depends 0
on 0
understanding 0
of 0
behavioral 0
requirements 0
. 0

Following 0
20 0
min 0
of 0
steady 0
state 0
anaesthesia 0
during 0
which 0
measurements 0
of 0
IOP 0
, 0
arterial 0
pressure 0
, 0
heart 0
rate 0
, 0
FIO2 0
, 0
FE'CO2 0
and 0
CVP 0
were 0
recorded 0
, 0
one 0
group 0
of 0
patients 0
received 0
atracurium 0
0.45 0
mg 0
kg 0
- 0
1 0
and 0
the 0
other 0
pancuronium 0
0.1 0
mg 0
kg 0
- 0
1 0
. 0

Transitory 0
subclinical 0
and 0
permanent 0
hypothyroidism 0
in 0
the 0
course 0
of 0
subacute 0
thyroiditis 0
( 0
de 0
Quervain 0
) 0
. 0

Gonadotropin B-gene
levels 0
in 0
mothers 0
who 0
have 0
had 0
two 0
sets 0
of 0
DZ 0
twins 0
. 0

Freezing 0
of 0
plasma 0
to 0
obtain 0
better 0
yield 0
of 0
factor B-gene
VIII I-gene
: 0
C 0
. 0

These 0
children 0
were 0
grouped 0
into 0
four 0
diagnostic 0
categories 0
: 0
1 0
) 0
idiopathic 0
GH B-gene
deficiency 0
( 0
n 0
= 0
10 0
) 0
; 0
2 0
) 0
organic 0
hypopituitarism 0
( 0
n 0
= 0
7 0
) 0
; 0
3 0
) 0
intrauterine 0
growth 0
retardation 0
( 0
n 0
= 0
5 0
) 0
; 0
and 0
4 0
) 0
constitutional 0
delay 0
of 0
growth 0
and/or 0
familial 0
short 0
stature 0
( 0
n 0
= 0
18 0
) 0
, 0
by 0
standard 0
clinical 0
criteria 0
and 0
physiological 0
and 0
pharmacological 0
tests 0
of 0
GH B-gene
reserve 0
. 0

Each 0
patient 0
had 0
measurable 0
LH B-gene
and 0
FSH B-gene
levels 0
, 0
with 0
pulsed 0
nocturnal 0
secretion 0
, 0
and 0
pubertal 0
LH B-gene
and 0
FSH B-gene
responses 0
to 0
LRH B-gene
. 0

These 0
changes 0
were 0
the 0
result 0
of 0
a 0
decrease 0
in 0
afterload 0
: 0
mean 0
aortic 0
pressure 0
fell 0
from 0
85 0
+/ 0
- 0
11.8 0
to 0
68 0
+/ 0
- 0
19.6 0
mmHg 0
( 0
p 0
less 0
than 0
0.01 0
) 0
and 0
systemic 0
arterial 0
resistance 0
fell 0
from 0
2 0
886 0
+/ 0
- 0
745 0
to 0
2 0
010 0
+/ 0
- 0
610 0
dynes/cm 0
- 0
5/sec/m 0
- 0
2 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Cimetidine 0
800 0
mg 0
given 0
at 0
night 0
is 0
as 0
effective 0
as 0
400 0
mg 0
twice 0
daily 0
; 0
the 0
single 0
dose 0
regimen 0
may 0
improve 0
patient 0
compliance 0
, 0
thus 0
facilitating 0
treatment 0
. 0

Ceftazidime 0
shows 0
promise 0
as 0
single 0
- 0
agent 0
therapy 0
for 0
serious 0
gram 0
- 0
negative 0
bacillary 0
infections 0
. 0

Regional 0
CBF 0
was 0
determined 0
by 0
clearance 0
of 0
xenon 0
133 0
in 0
67 0
patients 0
undergoing 0
coronary 0
bypass 0
grafting 0
procedures 0
. 0

Our 0
results 0
indicate 0
that 0
serum B-gene
BGP I-gene
is 0
a 0
valuable 0
measurement 0
of 0
bone 0
metabolism 0
. 0

The 0
management 0
of 0
the 0
`` 0
chronic 0
'' 0
patient 0
. 0

Study 0
of 0
bacterial 0
motility 0
and 0
rate 0
of 0
movement 0
using 0
a 0
closed 0
circuit 0
television 0

Finding 0
of 0
Rhodnius 0
prolixus 0
Stal 0
, 0
1859 0
, 0
in 0
babassu 0
palm 0
trees 0

Each 0
causative 0
organism 0
has 0
a 0
species 0
- 0
specific 0
preference 0
and 0
requirement 0
for 0
temperature 0
, 0
salinity 0
, 0
pH 0
, 0
the 0
basic 0
nutrients 0
, 0
and 0
growth 0
factors 0
, 0
and 0
the 0
toxin 0
formation 0
is 0
affected 0
by 0
these 0
environmental 0
factors 0
. 0

It 0
is 0
concluded 0
that 0
axillo 0
- 0
axillary 0
by 0
- 0
pass 0
is 0
a 0
simple 0
solution 0
for 0
a 0
complex 0
haemodynamic 0
, 0
clinical 0
and 0
therapeutic 0
problem 0
. 0

Deformities 0
of 0
the 0
tip 0
of 0
the 0
olecranon 0
and 0
of 0
the 0
coronoid 0
process 0
are 0
also 0
described 0
( 0
De 0
Palma 0
1956 0
, 0
Jordan 0
1958 0
, 0
Ahlberg 0
1965 0
, 0
Weseloh 0
1973 0
) 0
. 0

There 0
was 0
significant 0
correlation 0
of 0
LVM/M2 0
and 0
PWVn 0
for 0
pre 0
- 0
AVR 0
and 0
post 0
AVR 0
studies 0
. 0

Statokinesimetric 0
recording 0
in 0
Huntington 0
choreas 0

The 0
development 0
and 0
histostructural 0
organization 0
of 0
intrahepatic 0
biliary 0
ducts 0
were 0
studied 0
on 0
a 0
human 0
embryofetal 0
material 0
6 0
to 0
32 0
weeks 0
old 0
. 0

It 0
has 0
been 0
shown 0
in 0
an 0
animal 0
experiment 0
that 0
alterations 0
of 0
the 0
renal 0
vasculature 0
and 0
parenchyma 0
after 0
hemostasis 0
performed 0
by 0
Infrared 0
- 0
Contact 0
- 0
Coagulation 0
are 0
best 0
shown 0
by 0
intravital 0
magnification 0
angiography 0
( 0
magnification 0
factor 0
2.22 0
) 0
. 0

Cardiovascular 0
and 0
adrenal 0
medullo 0
- 0
sympathetic 0
reactions 0
to 0
acute 0
tobacco 0
poisoning 0

Intravenous 0
injections 0
of 0
SG 0
- 0
75 0
( 0
0.03 0
- 0
1 0
mg/kg 0
) 0
decreased 0
systemic 0
blood 0
pressure 0
( 0
SBP 0
) 0
and 0
increased 0
peripheral 0
( 0
coronary 0
, 0
renal 0
, 0
mesenteric 0
and 0
femoral 0
) 0
blood 0
flow 0
( 0
PBF 0
) 0
dose 0
- 0
dependently 0
. 0

In 0
doses 0
of 0
0.03 0
- 0
0.3 0
mg/kg 0
i.v. 0
, 0
SG 0
- 0
75 0
did 0
not 0
significantly 0
affect 0
pulse 0
pressure 0
, 0
heart 0
rate 0
, 0
aortic 0
blood 0
flow 0
, 0
left 0
ventricular 0
pressure 0
( 0
LVP 0
) 0
and 0
LVdP/dt 0
max 0
. 0

Resting 0
VE 0
in 0
the 0
luteal 0
phase 0
was 0
7.8 0
% 0
greater 0
than 0
that 0
in 0
the 0
follicular 0
phase 0
. 0

Exposure 0
of 0
endothelium 0
to 0
pulsatile 0
shear 0
stresses 0
that 0
followed 0
a 0
tape 0
recording 0
of 0
physiological 0
flow 0
waveforms 0
( 0
electromagnetic 0
flowmeter 0
) 0
did 0
not 0
cause 0
gross 0
injury 0
or 0
denudation 0
even 0
when 0
peak 0
shear 0
exceeded 0
1500 0
dyne/cm2 0
. 0

Modern 0
cancer 0
therapy 0
has 0
included 0
surgery 0
, 0
radiotherapy 0
, 0
chemotherapy 0
, 0
and 0
most 0
recently 0
, 0
immunotherapy 0
and 0
hyperthermia 0
. 0

There 0
was 0
a 0
close 0
correlation 0
between 0
plasma 0
clearance 0
of 0
NT 0
by 0
10 0
- 0
hydroxylation 0
and 0
the 0
D 0
metabolic 0
ratio 0
( 0
D/4 0
- 0
OH 0
- 0
D 0
in 0
urine 0
) 0
in 0
the 0
Ghanaians 0
( 0
rs 0
= 0
- 0
0.95 0
; 0
P 0
less 0
than 0
0.01 0
) 0
and 0
Swedes 0
( 0
rs 0
= 0
- 0
0.84 0
; 0
P 0
less 0
than 0
0.01 0
) 0
. 0

The 0
response 0
properties 0
of 0
cat 0
horizontal 0
canal 0
afferents 0
( 0
N 0
= 0
81 0
) 0
were 0
characterized 0
by 0
three 0
parameters 0
: 0
their 0
long 0
time 0
constants 0
( 0
tau 0
) 0
, 0
low 0
frequency 0
gain 0
constants 0
( 0
G1 0
) 0
, 0
and 0
middle 0
frequency 0
gain 0
constants 0
( 0
Gm 0
) 0
. 0

Endothelium 0
of 0
the 0
central 0
ear 0
artery 0
of 0
an 0
anesthetized 0
rabbit 0
is 0
damaged 0
by 0
placing 0
artery 0
forceps 0
on 0
the 0
ear 0
directly 0
over 0
the 0
vessel 0
. 0

Despite 0
supraphysiologic 0
E2 0
concentrations 0
, 0
however 0
, 0
cervical 0
mucus 0
scores 0
were 0
significantly 0
reduced 0
in 0
the 0
CC 0
- 0
treated 0
group 0
( 0
P 0
less 0
than 0
0.01 0
) 0
. 0

Stimulation 0
of 0
the 0
caudate 0
nucleus 0
' 0
dophamine 0
- 0
reactive 0
system 0
in 0
dogs 0
by 0
means 0
of 0
administration 0
of 0
dophamine 0
( 0
60 0
micrograms 0
) 0
and 0
phenamine 0
led 0
to 0
deterioration 0
of 0
conditioned 0
and 0
unconditioned 0
components 0
of 0
feeding 0
behaviour 0
. 0

Value 0
of 0
urine 0
glucose 0
tests 0
in 0
the 0
management 0
of 0
type 0
II 0
diabetes 0
mellitus 0
. 0

This 0
experiment 0
was 0
conducted 0
to 0
determine 0
if 0
the 0
sex 0
or 0
actual 0
egg 0
production 0
was 0
the 0
important 0
factor 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Hydrocortisone 0
seems 0
to 0
be 0
unable 0
to 0
hinder 0
the 0
postdenervation 0
changes 0
in 0
the 0
muscle 0
membrane 0
whereas 0
high 0
doses 0
of 0
the 0
hormone 0
are 0
able 0
to 0
induce 0
changes 0
in 0
the 0
muscle 0
membrane 0
. 0

Significant 0
clinical 0
differences 0
between 0
the 0
patients 0
treated 0
with 0
and 0
without 0
AMB 0
were 0
longer 0
survival 0
time 0
following 0
diagnosis 0
of 0
illness 0
( 0
P 0
less 0
than 0
0.05 0
) 0
and 0
more 0
frequent 0
cranial 0
nerve 0
signs 0
in 0
the 0
treated 0
patients 0
( 0
P 0
= 0
0.089 0
) 0
. 0

A 0
pharmacokinetic 0
study 0
of 0
apalcillin 0
was 0
performed 0
in 0
12 0
patients 0
in 0
an 0
intensive 0
- 0
care 0
unit 0
. 0

Catch 0
- 0
up 0
growth 0
was 0
observed 0
only 0
for 0
a 0
12 0
- 0
month 0
period 0
in 0
4 0
children 0
with 0
a 0
bone 0
age 0
of 0
7 0
to 0
8 0
years 0
. 0

Thrombocyte 0
function 0
was 0
impaired 0
in 0
all 0
patients 0
, 0
characterized 0
by 0
a 0
diminished 0
platelet 0
shape 0
change 0
. 0

The 0
findings 0
demonstrate 0
that 0
AMPH 0
administration 0
induces 0
a 0
significant 0
increase 0
in 0
the 0
height 0
of 0
a 0
major 0
electroactive 0
peak 0
in 0
the 0
caudate 0
nucleus 0
of 0
pigtail 0
monkeys 0
, 0
and 0
further 0
that 0
such 0
amphetamine 0
- 0
induced 0
increases 0
can 0
be 0
manipulated 0
by 0
altering 0
the 0
affective 0
and/or 0
emotional 0
state 0
of 0
the 0
animal 0
. 0

In 0
two 0
experiments 0
, 0
neonatal 0
female 0
BALB/cCrgl 0
or 0
BALB/cfC3HCrgl 0
mice 0
were 0
given 0
subcutaneous 0
injections 0
of 0
5 0
micrograms 0
17 0
beta 0
- 0
estradiol 0
or 0
sesame 0
oil 0
for 0
the 0
first 0
3 0
days 0
of 0
life 0
and 0
were 0
ovariectomized 0
at 0
60 0
days 0
of 0
age 0
, 0
at 0
which 0
time 0
vaginal 0
concretions 0
( 0
Experiments 0
I 0
and 0
II 0
) 0
or 0
silica 0
( 0
Experiment 0
II 0
) 0
were 0
implanted 0
intravaginally 0
. 0

For 0
228 0
of 0
425 0
deaths 0
( 0
54 0
% 0
) 0
occurring 0
among 0
26 0
100 0
people 0
of 0
known 0
age 0
in 0
the 0
Malumfashi 0
area 0
of 0
northern 0
Nigeria 0
, 0
data 0
were 0
collected 0
on 0
symptoms 0
present 0
prior 0
to 0
death 0
. 0

Salivary 0
estradiol 0
17 0
beta 0
( 0
E2 0
- 0
17 0
beta 0
) 0
and 0
progesterone 0
( 0
P 0
) 0
were 0
determined 0
by 0
using 0
radioimmunoassay 0
techniques 0
in 0
30 0
pregnant 0
females 0
in 0
the 0
first 0
, 0
second 0
and 0
third 0
trimesters 0
as 0
well 0
as 0
in 0
10 0
non 0
- 0
pregnant 0
controls 0
during 0
the 0
luteal 0
phase 0
of 0
the 0
menstrual 0
cycle 0
. 0

Other 0
than 0
d 0
7 0
, 0
there 0
was 0
no 0
significant 0
effect 0
on 0
the 0
number 0
of 0
implants 0
. 0

Variable 0
FHR 0
decelerations 0
or 0
bradycardias 0
were 0
encountered 0
on 0
95 0
nonstress 0
tests 0
( 0
18.8 0
% 0
) 0
in 0
80 0
( 0
33.5 0
% 0
) 0
postdate 0
patients 0
. 0

The 0
response 0
chain 0
in 0
each 0
component 0
was 0
maintained 0
by 0
food 0
presentation 0
under 0
a 0
fixed 0
- 0
ratio 0
schedule 0
. 0

The 0
results 0
imply 0
that 0
kindling 0
does 0
not 0
produce 0
its 0
facilitating 0
effect 0
on 0
acquisition 0
of 0
HPC 0
SS 0
by 0
removing 0
a 0
disruptive 0
effect 0
of 0
the 0
stimulation 0
. 0

The 0
persistent 0
fetal 0
dispersion 0
of 0
nodal 0
and 0
Hiss 0
bundle 0
fragments 0
within 0
the 0
ventricular 0
septum 0
is 0
proposed 0
as 0
a 0
possible 0
explanation 0
. 0

According 0
to 0
the 0
biochemical 0
tests 0
, 0
high 0
activity 0
( 0
over 0
200 0
U/l 0
) 0
of 0
alkaline B-gene
phosphatase I-gene
was 0
recorded 0
exclusively 0
in 0
patients 0
with 0
the 0
lymphogranulomatosis 0
- 0
induced 0
liver 0
damage 0
. 0

Changes 0
of 0
plasma 0
cortisol 0
level 0
in 0
late 0
asthmatic 0
responses 0

Significant 0
alterations 0
in 0
the 0
vasectomized 0
rats 0
from 0
sham 0
rats 0
included 0
: 0
testicular 0
and 0
epididymal 0
hypertrophy 0
, 0
formation 0
of 0
pathologic 0
vas 0
deferens 0
granulomas 0
, 0
decreased 0
total 0
serum 0
protein 0
, 0
lowered 0
alpha B-gene
- I-gene
globulin I-gene
levels 0
as 0
shown 0
by 0
serum 0
electrophoresis 0
, 0
and 0
increased 0
sperm 0
agglutinin B-gene
antibody 0
titers 0
. 0

SFP 0
was 0
significantly 0
elevated 0
in 0
Hn 0
( 0
s 0
) 0
. 0

The 0
average 0
birth 0
mass 0
of 0
these 0
newborns 0
was 0
3491.9 0
+/ 0
- 0
2 0
SD 0
780.5 0
g 0
and 0
that 0
in 0
the 0
control 0
group 0
3,767.5 0
+/ 0
- 0
2 0
SD 0
824.2 0
g 0
( 0
P 0
less 0
than 0
0.05 0
) 0
. 0

This 0
machine 0
drift 0
, 0
which 0
was 0
not 0
associated 0
with 0
a 0
rise 0
in 0
water 0
phantom 0
temperature 0
and 0
did 0
not 0
consistently 0
correlate 0
with 0
estimated 0
x 0
- 0
ray 0
tube 0
heat 0
, 0
could 0
result 0
in 0
a 0
significant 0
overestimation 0
of 0
regional 0
cerebral 0
blood 0
flow 0
( 0
rCBF 0
) 0
for 0
a 0
xenon/CT 0
rCBF 0
protocol 0
involving 0
5 0
- 0
7 0
sequential 0
scans 0
obtained 0
at 0
1 0
- 0
min 0
interscan 0
intervals 0
. 0

Other 0
uncertainties 0
in 0
the 0
dosimetry 0
at 0
Y 0
- 0
12 0
and 0
Vinca 0
are 0
unaltered 0
. 0

E2 0
treatments 0
elevated 0
hen 0
plasma 0
TG 0
7.2X 0
, 0
PL 0
5.1X 0
, 0
and 0
C 0
7.2X 0
; 0
and 0
pullet 0
plasma 0
TG 0
6.8X 0
, 0
PL 0
3.7X 0
, 0
and 0
C 0
2.5X 0
. 0

By 0
contrast 0
, 0
kidneys 0
from 0
rats 0
with 0
chronic 0
metabolic 0
acidosis 0
produced 0
significantly 0
more 0
NH3 0
than 0
both 0
these 0
groups 0
( 0
2.73 0
+/ 0
- 0
0.29 0
mumol 0
X 0
min 0
- 0
1 0
X 0
g 0
- 0
1 0
) 0
. 0

Serodiagnosis 0
of 0
trypanosomiasis 0
in 0
dromedary 0
camels 0
using 0
a 0
card 0
agglutination 0
test 0
set 0
( 0
Testryp 0
CATT 0
) 0
. 0

Adenyl B-gene
cyclase I-gene
activity 0
of 0
gastric 0
mucosa 0
in 0
patients 0
with 0
duodenal 0
ulcer 0
before 0
and 0
after 0
treatment 0

Proteinuria 0
- 0
- 0
selected 0
physiopathological 0
and 0
clinical 0
problems 0

However 0
, 0
subcutaneously 0
administered 0
pneumococci 0
gave 0
a 0
lower 0
mortality 0
than 0
pneumococci 0
given 0
intravenously 0
or 0
intraperitoneally 0
. 0

Reaction 0
of 0
human 0
organism 0
to 0
exercise 0
. 0

HA 0
resulted 0
in 0
decreased 0
( 0
p 0
less 0
than 0
0.05 0
) 0
Tre 0
( 0
0.4 0
degrees 0
C 0
) 0
and 0
HR 0
( 0
17 0
b 0
X 0
min 0
- 0
1 0
) 0
, 0
and 0
increased 0
( 0
p 0
less 0
than 0
0.05 0
) 0
Msw 0
( 0
16 0
g 0
X 0
m 0
- 0
2 0
X 0
h 0
- 0
1 0
) 0
during 0
the 0
saline 0
experiments 0
. 0

The 0
results 0
obtained 0
were 0
as 0
follows 0
: 0
The 0
mitral 0
valve 0
orifice 0
area 0
( 0
MVA 0
) 0
was 0
significantly 0
smaller 0
in 0
patients 0
with 0
type 0
III 0
of 0
the 0
LVIT 0
flow 0
velocity 0
pattern 0
than 0
in 0
patients 0
with 0
type 0
I 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Scientific 0
cooperation 0
of 0
CMEA 0
member 0
countries 0
has 0
been 0
carried 0
out 0
since 0
1974 0
under 0
the 0
sponsorship 0
of 0
the 0
Cancer 0
Research 0
Institute 0
, 0
Slovak 0
Academy 0
of 0
Sciences 0
( 0
Czechoslovakia 0
) 0
within 0
the 0
framework 0
of 0
CMEA 0
. 0

This 0
compares 0
favorably 0
to 0
results 0
of 0
similarly 0
sized 0
melanomas 0
treated 0
by 0
enucleation 0
. 0

A 0
new 0
variant 0
of 0
the 0
EMG 0
- 0
BFB 0
method 0
( 0
multichannel 0
) 0
is 0
offered 0
which 0
has 0
made 0
it 0
possible 0
to 0
use 0
the 0
method 0
not 0
only 0
for 0
training 0
weakened 0
muscles 0
and 0
reducing 0
spasticity 0
in 0
their 0
antagonists 0
but 0
also 0
for 0
improving 0
motor 0
coordination 0
. 0

Lymphocytes 0
from 0
all 0
3 0
species 0
yielded 0
maximum 0
responses 0
with 0
a 0
48 0
- 0
hour 0
prelabel 0
and 0
12 0
- 0
to 0
- 0
16 0
hour 0
postlabel 0
incubation 0
period 0
at 0
41 0
C 0
and 0
1:20 0
blood 0
dilution 0
. 0

However 0
, 0
there 0
was 0
a 0
difference 0
in 0
the 0
quality 0
of 0
immunity 0
: 0
fever 0
and 0
body 0
weight 0
loss 0
were 0
seen 0
in 0
hamsters 0
vaccinated 0
with 0
the 0
killed 0
- 0
toxoplasma 0
vaccine 0
after 0
they 0
were 0
challenge 0
exposed 0
with 0
T 0
- 0
1 0
strain 0
, 0
whereas 0
these 0
changes 0
were 0
rarely 0
seen 0
in 0
hamsters 0
given 0
the 0
live 0
- 0
toxoplasma 0
vaccine 0
and 0
then 0
challenge 0
exposed 0
with 0
RH 0
strain 0
. 0

Alternating 0
proline/alanine 0
sequence 0
of 0
beta B-gene
B1 I-gene
subunit I-gene
originates 0
from 0
a 0
repetitive 0
DNA 0
sequence 0
. 0

The 0
segmental 0
and 0
regional 0
projections 0
of 0
the 0
sciatic 0
, 0
tibial 0
and 0
common 0
peroneal 0
nerves 0
to 0
the 0
substantia 0
gelatinosa 0
of 0
the 0
spinal 0
cord 0
in 0
rats 0
- 0
- 0
an 0
experimental 0
study 0
by 0
means 0
of 0
an 0
acid B-gene
phosphatase I-gene
( 0
ACP B-gene
) 0
method 0
. 0

Removal 0
of 0
lipid 0
fractions 0
of 0
plant 0
extractions 0
with 0
hexane 0
is 0
recommended 0
to 0
avoid 0
damage 0
to 0
the 0
HPLC 0
column 0
. 0

In 0
the 0
Arithmetic 0
subtest 0
one 0
of 0
the 0
items 0
would 0
not 0
meet 0
the 0
difficulty 0
grading 0
shown 0
while 0
the 0
last 0
two 0
items 0
offer 0
very 0
little 0
possibility 0
of 0
success 0
for 0
all 0
subjects 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

The 0
toxicological 0
evaluation 0
of 0
chlorofluorocarbon 0
22 0
( 0
CFC 0
22 0
) 0
. 0

All 0
patients 0
were 0
evaluable 0
for 0
toxicity 0
and 0
9 0
for 0
response 0
. 0

Methods 0
of 0
clinical 0
and 0
experimental 0
algesimetry 0
are 0
described 0
that 0
have 0
been 0
used 0
to 0
evaluate 0
effects 0
of 0
peripherally 0
and 0
centrally 0
acting 0
analgesics 0
. 0

The 0
present 0
paper 0
elucidates 0
the 0
existing 0
discrepancies 0
, 0
and 0
offers 0
a 0
consistent 0
terminology 0
incorporating 0
also 0
such 0
terms 0
as 0
`` 0
additivity 0
'' 0
, 0
`` 0
potentiation 0
'' 0
, 0
and 0
`` 0
simple 0
similarity 0
'' 0
. 0

We 0
propose 0
that 0
the 0
ambiguous 0
discrimination 0
required 0
a 0
greater 0
time 0
for 0
simulus 0
evaluation 0
and 0
that 0
this 0
was 0
reflected 0
in 0
the 0
delayed 0
P3 0
latencies 0
. 0

Ammonia 0
concentration 0
dropped 0
significantly 0
in 0
all 0
treatments 0
, 0
a 0
finding 0
which 0
suggests 0
a 0
protective 0
effect 0
on 0
protein 0
nitrogen 0
degradation 0
to 0
non 0
- 0
protein 0
nitrogen 0
( 0
NH3 0
) 0
. 0

In 0
this 0
respect 0
C B-gene
reactive I-gene
protein I-gene
concentrations 0
are 0
superior 0
to 0
white 0
cell 0
count 0
, 0
erythrocyte 0
sedimentation 0
rate 0
, 0
and 0
temperature 0
and 0
the 0
concentrations 0
of 0
antiproteases 0
. 0

Human B-gene
thyroid I-gene
stimulator I-gene
( 0
HTS B-gene
) 0
in 0
thyroid 0
diseases 0

We 0
conclude 0
that 0
administration 0
of 0
the 0
calcium 0
antagonist 0
Verapamil 0
is 0
of 0
no 0
additional 0
value 0
in 0
tocolytic 0
treatment 0
with 0
beta 0
- 0
mimetics 0
. 0

Brainstem 0
auditory 0
evoked 0
responses 0
( 0
BAERs 0
) 0
and 0
quantitative 0
saccadic 0
eye 0
movement 0
studies 0
provide 0
information 0
on 0
the 0
integrity 0
of 0
pathways 0
traversing 0
the 0
brainstem 0
. 0

Effects 0
of 0
ketamine 0
on 0
the 0
circulatory 0
functions 0
and 0
body 0
tissue 0
oxygenation 0
in 0
dogs 0
under 0
normal 0
and 0
hypovolemic 0
conditions 0
. 0

The 0
salient 0
clinical 0
features 0
, 0
the 0
problems 0
of 0
management 0
and 0
the 0
modern 0
approaches 0
to 0
the 0
reconstruction 0
of 0
facial 0
deformities 0
seen 0
in 0
this 0
disease 0
are 0
described 0
. 0

Besides 0
, 0
it 0
was 0
considered 0
that 0
the 0
NPF 0
was 0
a 0
useful 0
tool 0
for 0
activation 0
of 0
velopharyngeal 0
activity 0
by 0
way 0
of 0
visual 0
feed 0
- 0
back 0
control 0
. 0

To 0
evaluate 0
the 0
comparative 0
safety 0
of 0
U 0
- 0
P 0
and 0
D 0
& 0
E 0
, 0
we 0
analyzed 0
2,805 0
U 0
- 0
P 0
and 0
9,572 0
D 0
& 0
E 0
abortions 0
at 0
13 0
to 0
24 0
menstrual 0
weeks 0
' 0
gestation 0
. 0

Three 0
radiologists 0
without 0
knowledge 0
of 0
patients 0
' 0
data 0
and 0
treatment 0
analyzed 0
30 0
angiograms 0
with 0
and 0
30 0
examinations 0
without 0
PGF 0
. 0

In 0
a 0
man 0
with 0
myelomonocytic 0
leukemia 0
, 0
the 0
association 0
of 0
increased 0
prostatic B-gene
acid I-gene
phosphatase I-gene
activity 0
in 0
serum 0
and 0
the 0
presence 0
of 0
typical 0
bone 0
lesions 0
on 0
roentgenography 0
suggested 0
the 0
existence 0
of 0
disseminated 0
prostatic 0
carcinoma 0
. 0

The 0
rational 0
for 0
the 0
prophylactic 0
treatment 0
, 0
the 0
therapy 0
of 0
the 0
meningopathy 0
and 0
AIL 0
- 0
AIEOP 0
protocols 0
are 0
exposed 0
. 0

An 0
experimental 0
long 0
- 0
term 0
study 0
. 0

No 0
anisotropism 0
was 0
recorded 0
in 0
a 0
tetrahydrofuran 0
solution 0
. 0

Hepatitis 0
B 0
vaccine 0

The 0
calculated 0
values 0
of 0
lambda 0
tb 0
at 0
37 0
degrees 0
C 0
and 0
50 0
per 0
cent 0
haematocrit 0
were 0
0.650 0
for 0
the 0
pulp 0
, 0
0.674 0
for 0
the 0
tongue 0
, 0
0.828 0
for 0
the 0
submandibular 0
gland 0
and 0
0.881 0
for 0
the 0
gingiva 0
of 0
the 0
dog 0
. 0
lambda 0
cp 0
increased 0
and 0
lambda 0
tp 0
decreased 0
as 0
the 0
temperature 0
was 0
reduced 0
from 0
37 0
to 0
4 0
degrees 0
C 0
. 0

As 0
pleural 0
thickening 0
is 0
seen 0
commonly 0
in 0
asbestosis 0
and 0
may 0
influence 0
lung 0
volumes 0
and 0
the 0
ratio 0
of 0
transfer B-gene
factor I-gene
to 0
effective 0
alveolar 0
volume 0
, 0
the 0
results 0
of 0
these 0
measurements 0
were 0
compared 0
only 0
in 0
the 0
cases 0
showing 0
absent 0
or 0
minimal 0
pleural 0
thickening 0
. 0

The 0
invasive 0
pattern 0
of 0
squamous 0
cell 0
carcinoma 0
in 0
the 0
mandibular 0
gingiva 0

Azygos 0
vein 0
abutting 0
the 0
posterior 0
wall 0
of 0
the 0
right 0
main 0
and 0
upper 0
lobe 0
bronchi 0
: 0
a 0
normal 0
CT 0
variant 0
. 0

However 0
, 0
the 0
history 0
of 0
acute 0
severe 0
complications 0
from 0
otitis 0
media 0
revealed 0
a 0
higher 0
frequency 0
in 0
those 0
individuals 0
with 0
alpha B-gene
1 I-gene
- I-gene
antitrypsin I-gene
deficiency 0
as 0
compared 0
to 0
normals 0
. 0

The 0
Sarns 0
51F 0
cavoatrial 0
cannula 0
decompressed 0
the 0
venous 0
system 0
as 0
efficiently 0
as 0
the 0
double 0
caval 0
cannulas 0
. 0

All 0
other 0
changes 0
at 0
the 0
3 0
- 0
, 0
5 0
- 0
, 0
and 0
6 0
- 0
positions 0
, 0
as 0
well 0
as 0
the 0
replacement 0
of 0
the 0
phenyl 0
group 0
at 0
position 0
2 0
, 0
caused 0
a 0
marked 0
decrease 0
of 0
activity 0
. 0

Three 0
experiments 0
contrasted 0
the 0
effects 0
of 0
6 0
- 0
hydroxydopamine 0
- 0
induced 0
lesions 0
of 0
the 0
ventral 0
noradrenergic 0
and 0
dorsal 0
noradrenergic 0
projections 0
, 0
predominantly 0
to 0
hypothalamus 0
and 0
cortex 0
, 0
respectively 0
, 0
upon 0
body 0
weight 0
changes 0
and 0
food 0
- 0
related 0
behaviour 0
in 0
the 0
rat 0
. 0

Limb 0
allografts 0
in 0
rats 0
immunosuppressed 0
with 0
cyclosporin 0
A 0
. 0

The 0
method 0
involved 0
deproteinizing 0
samples 0
with 0
two 0
volumes 0
of 0
acetonitrile 0
followed 0
by 0
injection 0
of 0
5 0
microliters 0
of 0
deproteinized 0
supernatant 0
onto 0
a 0
C18 0
reversed 0
- 0
phase 0
column 0
. 0

Refractory 0
periods 0
of 0
the 0
AV 0
junction 0
were 0
altered 0
in 0
a 0
comparable 0
fashion 0
to 0
conduction 0
through 0
the 0
AV 0
node 0
. 0

This 0
paper 0
brings 0
together 0
data 0
, 0
obtained 0
from 0
a 0
variety 0
of 0
sources 0
, 0
on 0
the 0
extent 0
of 0
prescription 0
and 0
use 0
of 0
psychotropic 0
drugs 0
in 0
the 0
late 0
1960s 0
and 0
early 0
1970s 0
. 0

Sixteen 0
patients 0
were 0
studied 0
within 0
24 0
hours 0
of 0
resuscitation 0
and 0
all 0
showed 0
depressed 0
right 0
ventricular 0
ejection 0
( 0
RVEF 0
) 0
and/or 0
an 0
increased 0
end 0
- 0
diastolic 0
volume 0
( 0
RVEDVI 0
) 0
. 0

During 0
a 0
single 0
LAD 0
occlusion 0
lasting 0
35 0
minutes 0
( 0
series 0
I 0
, 0
n 0
= 0
10 0
) 0
9 0
microns 0
TMs 0
were 0
infused 0
immediately 0
and 0
30 0
minutes 0
after 0
ligation 0
, 0
15 0
microns 0
TMs 0
being 0
infused 0
after 0
15 0
- 0
20 0
minutes 0
. 0

The 0
population 0
of 0
between 0
75,000 0
and 0
100,000 0
was 0
largely 0
unstable 0
, 0
and 0
cost 0
per 0
capita 0
was 0
$ 0
0.95 0
to 0
$ 0
1.21 0
. 0

Female 0
Wistar 0
rats 0
were 0
fed 0
a 0
liquid 0
diet 0
, 0
Sustacal 0
, 0
which 0
contained 0
ethanol 0
( 0
40 0
% 0
of 0
calories 0
) 0
or 0
isocaloric 0
sucrose 0
. 0

HL 0
02 0
type 0
oculomotor 0
stimulator 0
. 0

Four 0
patients 0
( 0
group 0
1 0
) 0
had 0
type 0
I 0
basement 0
membrane 0
nephropathy 0
, 0
characterized 0
by 0
marked 0
thickening 0
and 0
lamellation 0
of 0
the 0
basement 0
membrane 0
in 0
a 0
pattern 0
resembling 0
that 0
of 0
Alport 0
's 0
syndrome 0
. 0

Brain 0
pH 0
following 0
3 0
h 0
of 0
cerebral 0
focal 0
ischemia 0
changed 0
from 0
a 0
normal 0
value 0
of 0
7.0 0
to 0
6.5 0
and 0
6.2 0
in 0
animals 0
studied 0
under 0
barbiturate 0
and 0
halothane 0
anesthesia 0
, 0
respectively 0
. 0

Our 0
results 0
demonstrate 0
the 0
importance 0
of 0
phosphate 0
and 0
calcium 0
in 0
influencing 0
the 0
secretion 0
of 0
PTH B-gene
and 0
CT B-gene
in 0
uremia 0
. 0

Thin 0
- 0
layer 0
chromatographic 0
methods 0
were 0
up 0
- 0
dated 0
for 0
pharmacokinetic 0
studies 0
of 0
imipramine 0
in 0
plasma 0
and 0
urine 0
. 0

Introductory 0
remarks 0
. 0

Increasing 0
the 0
cut 0
- 0
off 0
point 0
to 0
3 0
positive 0
responses 0
decreased 0
the 0
sensitivity 0
to 0
81 0
% 0
and 0
increased 0
the 0
specificity 0
to 0
94 0
% 0
. 0

After 0
clofelin 0
administration 0
the 0
autoregulation 0
borders 0
shifted 0
to 0
the 0
right 0
i. 0
e. 0
towards 0
higher 0
AP 0
levels 0
. 0

This 0
phenomenon 0
may 0
be 0
regarded 0
as 0
a 0
variant 0
of 0
selective 0
individual 0
cell 0
death 0
, 0
currently 0
referred 0
to 0
as 0
apoptosis 0
, 0
which 0
has 0
not 0
been 0
previously 0
reported 0
in 0
a 0
case 0
of 0
embryonal 0
rhabdomyosarcoma 0
. 0

Combination 0
of 0
a 0
Shwachman 0
syndrome 0
and 0
a 0
complex 0
granulocyte 0
function 0
disorder 0
in 0
a 0
girl 0

A 0
combined 0
series 0
of 0
patients 0
experienced 0
a 0
TOL 0
after 0
two 0
or 0
more 0
previous 0
cesarean 0
deliveries 0
; 0
the 0
rate 0
of 0
vaginal 0
delivery 0
was 0
66 0
% 0
, 0
and 0
there 0
was 0
virtually 0
no 0
morbidity 0
. 0

Nursing 0
home 0
discharges 0
in 0
clinical 0
practice 0
. 0

Trial 0
3 0
broiler 0
chickens 0
were 0
maintained 0
on 0
control 0
feed 0
until 0
they 0
reached 0
3 0
weeks 0
of 0
age 0
at 0
which 0
time 0
they 0
were 0
taken 0
off 0
of 0
feed 0
for 0
2.5 0
hr 0
and 0
then 0
placed 0
on 0
either 0
control 0
feed 0
or 0
feed 0
containing 0
4.0 0
ppm 0
ochratoxin 0
A 0
, 0
and 0
heart 0
rate 0
and 0
blood 0
pressure 0
were 0
measured 0
every 0
half 0
hour 0
through 0
7 0
hr 0
. 0

The 0
carcinogen 0
bioassay 0
therefore 0
is 0
a 0
very 0
important 0
component 0
of 0
the 0
battery 0
of 0
toxicological 0
tests 0
used 0
in 0
hazard 0
evaluation 0
. 0

Harmful 0
effects 0
in 0
animals 0
and 0
man 0
may 0
result 0
from 0
both 0
deficient 0
or 0
excessive 0
amounts 0
of 0
intake 0
. 0

Angionephroscintigraphy 0
in 0
the 0
diagnosis 0
of 0
diseases 0
of 0
the 0
kidney 0

The 0
analysis 0
of 0
the 0
structure 0
of 0
the 0
sleep 0
period 0
as 0
a 0
whole 0
reveals 0
that 0
with 0
increasing 0
of 0
the 0
age 0
the 0
delta 0
- 0
wave 0
stage 0
( 0
DS 0
) 0
of 0
the 0
QS 0
( 0
determined 0
by 0
defined 0
polygraphic 0
parameters 0
) 0
increases 0
, 0
while 0
the 0
paradoxical 0
phase 0
of 0
sleep 0
( 0
PS 0
) 0
decreases 0
, 0
this 0
change 0
being 0
more 0
pronounced 0
during 0
the 0
first 0
six 0
months 0
than 0
during 0
the 0
second 0
ones 0
of 0
the 0
first 0
year 0
of 0
the 0
life 0
. 0

[ 0
82Br 0
] 0
MISO 0
was 0
prepared 0
by 0
irradiating 0
samples 0
of 0
Br 0
- 0
MISO 0
in 0
a 0
SLOWPOKE 0
reactor 0
for 0
2 0
h 0
at 0
a 0
thermal 0
neutron 0
flux 0
of 0
10 0
( 0
12 0
) 0
n 0
cm 0
- 0
2 0
s 0
- 0
1 0
. 0

While 0
these 0
findings 0
may 0
reflect 0
the 0
sensitivity 0
of 0
a 0
thick 0
myocardial 0
wall 0
to 0
ischaemia 0
during 0
surgery 0
, 0
the 0
postoperative 0
recovery 0
was 0
not 0
related 0
to 0
the 0
serum B-gene
CK I-gene
- I-gene
MB I-gene
level 0
. 0

Morphofunctional 0
status 0
of 0
the 0
formed 0
elements 0
of 0
the 0
blood 0
in 0
rats 0
subjected 0
to 0
different 0
variants 0
of 0
combined 0
and 0
isolated 0
exposure 0
to 0
BR 0
- 0
1 0
benzene 0

Using 0
a 0
MOS 0
- 0
Hypersil 0
reversed 0
- 0
phase 0
column 0
with 0
a 0
phosphate 0
buffer 0
- 0
- 0
acetonitrile 0
mobile 0
phase 0
, 0
baseline 0
separation 0
of 0
antipyrine 0
, 0
its 0
metabolites 0
3 0
- 0
hydroxymethylantipyrine 0
, 0
norantipyrine 0
and 0
4 0
- 0
hydroxyantipyrine 0
, 0
and 0
the 0
internal 0
standard 0
, 0
phenacetin 0
, 0
was 0
achieved 0
within 0
6 0
min 0
. 0

The 0
liver 0
in 0
the 0
severely 0
ill 0

In 0
a 0
randomized 0
study 0
on 0
150 0
patients 0
( 0
ASA 0
1 0
) 0
undergoing 0
induction 0
of 0
anaesthesia 0
, 0
the 0
effects 0
of 0
Fentanyl 0
( 0
0.1 0
mg 0
) 0
, 0
the 0
combination 0
of 0
Fentanyl 0
( 0
0.1 0
mg 0
) 0
and 0
Droperidol 0
( 0
5 0
mg 0
) 0
( 0
Innovar 0
, 0
Thalamonal 0
) 0
and 0
Atropine 0
( 0
0.01 0
mg/kg 0
b.w 0
. 0
) 0
alone 0
on 0
cardiocirculatory 0
parameters 0
were 0
studied 0
. 0

These 0
results 0
confirming 0
the 0
high 0
validity 0
of 0
NOM 0
inhibiting 0
test 0
in 0
the 0
diagnosis 0
of 0
tumoural 0
hyperprolactinemic 0
states 0
, 0
reveal 0
contradictory 0
responses 0
to 0
CD/LD 0
, 0
LD 0
and 0
DOM 0
, 0
with 0
sustain 0
the 0
existence 0
of 0
2 0
sub 0
- 0
group 0
of 0
Prolactinomas 0
: 0
with 0
or 0
without 0
a 0
maintained 0
DA 0
central 0
tonus 0
supporting 0
the 0
possibility 0
of 0
different 0
etiopathogenetical 0
factors 0
in 0
inducing 0
a 0
tumoural 0
hyperprolactinemic 0
states 0
. 0

Serum 0
lipids 0
and 0
lipoproteins 0
of 0
29 0
insulin B-gene
dependent 0
diabetic 0
children 0
have 0
been 0
determined 0
and 0
related 0
to 0
the 0
metabolic 0
status 0
of 0
the 0
patients 0
. 0

Low 0
NA 0
and 0
A 0
may 0
participate 0
in 0
lowering 0
the 0
plasma B-gene
renin I-gene
activity 0
which 0
in 0
PA 0
in 0
suppressed 0
, 0
sometimes 0
disproportionately 0
to 0
the 0
actual 0
body 0
sodium 0
content 0
. 0

Amikacin 0
concentrations 0
in 0
serum 0
and 0
blister 0
fluid 0
in 0
healthy 0
volunteers 0
and 0
in 0
patients 0
with 0
renal 0
impairment 0
. 0

The 0
subgroup 0
innervating 0
the 0
medial 0
rectus 0
lies 0
exclusively 0
along 0
the 0
medial 0
face 0
of 0
the 0
oculomotor 0
nucleus 0
, 0
with 0
no 0
aberrant 0
neurons 0
in 0
the 0
medial 0
longitudinal 0
fasciculus 0
, 0
as 0
have 0
been 0
found 0
in 0
other 0
mammals 0
. 0

Hepatitis 0
B 0
vaccination 0
strategy 0
for 0
health 0
- 0
care 0
workers 0
in 0
a 0
country 0
of 0
intermediate 0
hepatitis 0
B 0
endemicity 0
. 0

An 0
intravenous 0
drip 0
infusion 0
of 0
AMK 0
in 0
adequate 0
dosage 0
would 0
be 0
beneficial 0
to 0
use 0
against 0
some 0
infectious 0
diseases 0
of 0
otorhinolaryngologic 0
field 0
. 0

Out 0
of 0
these 0
families 0
74,3 0
% 0
planned 0
next 0
pregnancy 0
( 0
table 0
IX 0
) 0
, 0
57,6 0
% 0
wanted 0
to 0
have 0
prenatal 0
diagnosis 0
( 0
table 0
VI 0
) 0
. 0

The 0
authors 0
have 0
tested 0
the 0
interference 0
of 0
the 0
hemoglobin B-gene
by 0
two 0
routine 0
methods 0
( 0
Berthelot 0
classic 0
and 0
Berthelot 0
modified 0
) 0
for 0
the 0
determination 0
of 0
plasmatic 0
urea 0
. 0

Parkinsonian 0
patients 0
had 0
a 0
significantly 0
lower 0
prevalence 0
of 0
alcohol 0
use 0
. 0

These 0
cells 0
averaged 0
17 0
microns 0
in 0
diameter 0
and 0
reproduced 0
by 0
fission 0
, 0
forming 0
clusters 0
of 0
two 0
or 0
four 0
daughter 0
cells 0
. 0

Female 0
but 0
not 0
male 0
mortalities 0
were 0
significantly 0
higher 0
for 0
cake 0
- 0
fed 0
rats 0
than 0
for 0
those 0
fed 0
diet 0
41B 0
. 0

Urinary B-gene
N I-gene
- I-gene
acetylglucosaminidase I-gene
activity 0
per 0
mg 0
creatinine 0
did 0
not 0
differ 0
significantly 0
between 0
groups 0
. 0

The 0
associations 0
between 0
sex B-gene
- I-gene
hormone I-gene
- I-gene
binding I-gene
globulin I-gene
capacity 0
( 0
SHBG B-gene
) 0
, 0
age 0
, 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
, 0
and 0
physical 0
fitness 0
have 0
been 0
studied 0
in 0
34 0
men 0
and 0
36 0
women 0
. 0

Dipetalonema 0
( 0
Alafilaria 0
) 0
hydrochoerus 0
subgen 0
. 0
et 0
sp 0
. 0
n 0
. 0

After 0
1.5 0
years 0
of 0
such 0
photoperiodic 0
control 0
, 0
all 0
ewes 0
were 0
blinded 0
by 0
bilateral 0
orbital 0
enucleation 0
. 0

The 0
concentrations 0
of 0
C4 B-gene
and 0
C1 B-gene
- I-gene
INH I-gene
increased 0
with 0
advancing 0
stage 0
of 0
disease 0
and 0
were 0
above 0
normal 0
mean 0
values 0
in 0
all 0
stages 0
. 0

Less 0
antibacterial 0
activity 0
was 0
shown 0
toward 0
the 0
Gram 0
- 0
negative 0
bacilli 0
, 0
i.e. 0
, 0
Pseudomonas 0
, 0
Klebsiella 0
- 0
Enterobacter 0
, 0
Shigella 0
, 0
Escherichia 0
coli 0
, 0
Serratia 0
marcescens 0
and 0
Proteus 0
. 0

The 0
mucosal 0
defence 0
capacity 0
against 0
proteolytic 0
leukocyte 0
enzymes 0
. 0

The 0
apparatus 0
consists 0
of 0
an 0
Am 0
- 0
241 0
exciting 0
source 0
( 0
300 0
mCi 0
) 0
and 0
pure 0
Ge 0
detector 0
( 0
50 0
mm2 0
X 0
5 0
mm 0
) 0
for 0
measuring 0
K 0
alpha 0
fluorescent 0
x 0
- 0
rays 0
( 0
28.3 0
and 0
28.6 0
KeV 0
) 0
emitted 0
from 0
exited 0
iodine 0
. 0

Ultrastructural 0
studies 0
of 0
retinopathy 0
of 0
premature 0
infants 0

The 0
range 0
of 0
serum 0
concentrations 0
, 0
mean 0
values 0
, 0
median 0
values 0
, 0
and 0
standard 0
deviations 0
for 0
each 0
analyte 0
are 0
reported 0
for 0
males 0
and 0
females 0
and 0
for 0
three 0
age 0
groups 0
( 0
25 0
- 0
44 0
, 0
45 0
- 0
59 0
, 0
60 0
- 0
70 0
) 0
. 0

The 0
effects 0
of 0
antithrombotic 0
drugs 0
in 0
patients 0
with 0
left 0
ventricular 0
thrombi 0
: 0
assessment 0
with 0
indium 0
- 0
111 0
platelet 0
imaging 0
and 0
two 0
- 0
dimensional 0
echocardiography 0
. 0

A 0
stable 0
interface 0
depends 0
on 0
overall 0
stress 0
and 0
microstress 0
distribution 0
on 0
the 0
bone 0
, 0
particularly 0
trabecular 0
bone 0
. 0

Plasma 0
NE 0
was 0
also 0
low 0
in 0
the 0
anephric 0
group 0
( 0
289 0
mg/liter 0
+/ 0
- 0
126 0
( 0
1 0
SD 0
) 0
vs 0
612 0
+/ 0
- 0
189 0
, 0
P 0
= 0
0.033 0
, 0
resting 0
) 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

10 0
long 0
- 0
term 0
hemodialysis 0
patients 0
had 0
immediate 0
and 0
redistribution 0
thallium 0
- 0
201 0
myocardial 0
imaging 0
performed 0
after 0
a 0
course 0
of 0
hemodialysis 0
. 0

The 0
Prolactin B-gene
levels 0
were 0
within 0
the 0
physiological 0
norms 0
; 0
the 0
responses 0
to 0
TRH B-gene
were 0
normal 0
, 0
and 0
elevated 0
only 0
in 0
a 0
few 0
cases 0
. 0

Despite 0
total 0
tumor 0
resection 0
, 0
multiple 0
intraperitoneal 0
tumor 0
nodules 0
of 0
varying 0
sizes 0
were 0
found 0
and 0
resected 0
six 0
months 0
and 0
one 0
year 0
later 0
. 0

Private 0
hospital 0
accreditation 0
. 0

Antithrombin B-gene
III I-gene
in 0
hip 0
surgery 0

In 0
14 0
of 0
21 0
infant 0
hearts 0
( 0
66 0
% 0
) 0
with 0
aortic 0
arch 0
interruption 0
between 0
the 0
left 0
common 0
carotid 0
and 0
left 0
subclavian 0
arteries 0
( 0
type 0
B 0
of 0
Celoria 0
and 0
Patton 0
) 0
, 0
the 0
right 0
subclavian 0
artery 0
( 0
SA 0
) 0
arose 0
anomalously 0
. 0

We 0
suggest 0
that 0
sensitivity 0
to 0
photoperiod 0
in 0
pallid 0
bats 0
, 0
as 0
in 0
several 0
other 0
mammals 0
, 0
is 0
mediated 0
by 0
the 0
pineal 0
gland 0
. 0

Absorption 0
was 0
rapid 0
, 0
with 0
a 0
mean 0
time 0
to 0
peak 0
of 0
39 0
min 0
. 0

Additionally 0
, 0
observations 0
that 0
patients 0
with 0
mitral 0
versus 0
aortic 0
regurgitation 0
respond 0
differently 0
to 0
valve 0
replacement 0
suggest 0
that 0
differences 0
exist 0
preoperatively 0
between 0
these 0
two 0
types 0
of 0
volume 0
overload 0
. 0

A 0
case 0
of 0
manifest 0
latent 0
nystagmus 0
of 0
late 0
onset 0
in 0
a 0
13 0
- 0
year 0
- 0
old 0
girl 0
is 0
reported 0
. 0

Within 0
the 0
compartment 0
or 0
dimension 0
of 0
severity 0
of 0
depression 0
a 0
subscale 0
of 0
the 0
Hamilton 0
Depression 0
Scale 0
( 0
or 0
the 0
Melancholia 0
Scale 0
) 0
was 0
shown 0
to 0
have 0
reached 0
an 0
instrumental 0
perfection 0
, 0
e.g 0
. 0
as 0
an 0
outcome 0
measure 0
of 0
antidepressant 0
treatment 0
. 0

Significant 0
immunoglobulinuria 0
developed 0
prior 0
to 0
the 0
development 0
of 0
azotemia 0
, 0
significantly 0
decreased 0
creatinine 0
clearance 0
, 0
significant 0
proteinuria 0
( 0
greater 0
than 0
or 0
equal 0
to 0
3+ 0
dipstick 0
or 0
greater 0
than 0
or 0
equal 0
to 0
5 0
gm 0
per 0
24 0
- 0
hour 0
urine 0
collection 0
) 0
, 0
or 0
oliguria 0
. 0

A 0
total 0
number 0
of 0
1628 0
cases 0
were 0
collected 0
from 0
135 0
medical 0
institutions 0
. 0

Epileptiform 0
activity 0
recorded 0
from 0
superficial 0
laminae 0
bordering 0
layer 0
4 0
, 0
and 0
into 0
which 0
layer 0
4 0
's 0
primary 0
projections 0
terminate 0
, 0
is 0
suppressed 0
preferentially 0
by 0
phenytoin 0
. 0

The 0
AD 0
components 0
were 0
markedly 0
more 0
dependent 0
on 0
the 0
affective 0
state 0
of 0
the 0
rat 0
then 0
was 0
the 0
V1 0
component 0
. 0

Is 0
nisoldipine 0
capable 0
of 0
reducing 0
left 0
ventricular 0
preload 0
? 0
In 0
ten 0
anesthetized 0
pigs 0
, 0
nisoldipine 0
( 0
2 0
- 0
4 0
micrograms 0
X 0
kg 0
- 0
1 0
X 0
min 0
- 0
1 0
) 0
, 0
a 0
calcium 0
channel 0
blocker 0
structurally 0
related 0
to 0
nifedipine 0
, 0
reduced 0
left 0
ventricular 0
systolic 0
pressure 0
( 0
40 0
% 0
) 0
and 0
systemic 0
vascular 0
resistance 0
( 0
35 0
% 0
) 0
, 0
whereas 0
maxLVdP/dt 0
decreased 0
by 0
20 0
% 0
and 0
cardiac 0
output 0
was 0
unchanged 0
. 0

Monkeys 0
were 0
evaluated 0
before 0
and 0
after 0
unilateral 0
and 0
serial 0
bilateral 0
removal 0
of 0
superior 0
temporal 0
cortex 0
. 0

HBB 0
concentration 0
in 0
the 0
fetuses 0
indicated 0
little 0
, 0
if 0
any 0
accumulation 0
. 0

All 0
samples 0
exhibited 0
a 0
decline 0
in 0
ethanol 0
concentration 0
, 0
with 0
most 0
losses 0
falling 0
within 0
the 0
expected 0
20 0
to 0
40 0
mg 0
% 0
range 0
. 0

Plasma B-gene
lactoferrin I-gene
and 0
the 0
blood 0
count 0
of 0
polynuclear 0
neutrophils 0

The 0
importance 0
of 0
selective 0
renal 0
vein 0
phlebography 0
in 0
the 0
evaluation 0
of 0
unexplained 0
hematuria 0
and 0
filing 0
defects 0
in 0
the 0
excretory 0
urogram 0
is 0
illustrated 0
. 0

Pilot 0
study 0
of 0
blood 0
coagulation 0
in 0
gout 0
patients 0
. 0

The 0
statistical 0
analysis 0
consist 0
of 0
the 0
F 0
test 0
followed 0
by 0
Snedecor 0
's 0
contrast 0
test 0
. 0

The 0
pyramidal 0
tract 0
and 0
Mesencephalic 0
Reticular 0
Formation 0
( 0
MRF 0
) 0
were 0
stimulated 0
before 0
and 0
after 0
the 0
transection 0
. 0

Further 0
, 0
the 0
reduction 0
in 0
5 0
- 0
hydroxytryptophan 0
( 0
5 0
- 0
HTP 0
) 0
accumulation 0
by 0
LSD 0
showed 0
regional 0
differences 0
in 0
inhibition 0
by 0
methiothepin 0
( 0
hypothalamus 0
greater 0
than 0
cortex 0
greater 0
than 0
striatum 0
) 0
which 0
paralleled 0
the 0
autoreceptor 0
antagonist 0
activity 0
of 0
methiothepin 0
in 0
vitro 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Effects 0
of 0
methiothepin 0
and 0
lysergic 0
acid 0
diethylamide 0
on 0
serotonin 0
release 0
in 0
vitro 0
and 0
serotonin 0
synthesis 0
in 0
vivo 0
: 0
possible 0
relation 0
to 0
serotonin B-gene
autoreceptor I-gene
function 0
. 0

In 0
a 0
recent 0
measles 0
epidemic 0
in 0
El 0
Paso 0
, 0
TX 0
, 0
120,000 0
records 0
were 0
screened 0
using 0
these 0
criteria 0
, 0
and 0
as 0
a 0
result 0
13,000 0
students 0
were 0
vaccinated 0
. 0

No 0
patient 0
with 0
bradyarrhythmia 0
- 0
related 0
SCD 0
had 0
manifest 0
atrioventricular 0
block 0
or 0
bundle 0
branch 0
block 0
. 0

The 0
measurement 0
of 0
the 0
areas 0
of 0
fibrin B-gene
, 0
of 0
tissue 0
and 0
fibrinolysis 0
, 0
at 0
the 0
above 0
mentioned 0
times 0
, 0
has 0
been 0
effected 0
at 0
standard 0
magnification 0
( 0
15 0
X 0
) 0
by 0
an 0
image 0
analyser 0
( 0
Videoplan 0
) 0
scale 0
1:8 0
. 0

Diclofenac 0
sodium 0
- 0
chlormezanone 0
poisoning 0
. 0

Postprandial 0
plasma B-gene
enteroglucagon I-gene
concentration 0
after 0
90 0
minutes 0
in 0
untreated 0
patients 0
correlated 0
positively 0
to 0
the 0
faecal 0
fat 0
excretion 0
( 0
r 0
= 0
0.58 0
, 0
p 0
less 0
than 0
0.02 0
) 0
. 0

Blood 0
pressure 0
in 0
children 0
. 0

In 0
this 0
study 0
the 0
splenectomized 0
captive 0
born 0
cynomolgus 0
appeared 0
to 0
be 0
capable 0
of 0
supplementing 0
rhesus 0
as 0
an 0
antimalarial 0
drug 0
testing 0
model 0
. 0

The 0
results 0
showed 0
that 0
the 0
sensitivity 0
of 0
the 0
3 0
given 0
guinea 0
pig 0
strains 0
was 0
comparable 0
. 0

Adult 0
Amblyomma 0
lepidum 0
ticks 0
fed 0
as 0
nymphs 0
on 0
this 0
goat 0
transmitted 0
heartwater 0
to 0
a 0
Friesian 0
( 0
Bos 0
taurus 0
) 0
calf 0
. 0

Twenty 0
- 0
one 0
percent 0
of 0
these 0
patients 0
had 0
neurologic 0
disease 0
that 0
appeared 0
to 0
be 0
responsible 0
for 0
the 0
tinnitus 0
. 0

Morphine 0
injected 0
into 0
the 0
lateral 0
ventricle 0
of 0
the 0
rat 0
produced 0
unilateral 0
analgesia 0
in 0
the 0
formalin 0
test 0
, 0
which 0
involves 0
continuous 0
, 0
moderate 0
pain 0
. 0

The 0
maps 0
of 0
Case 0
2 0
showed 0
that 0
a 0
maximum 0
first 0
appeared 0
on 0
the 0
upper 0
right 0
back 0
and 0
then 0
moved 0
down 0
the 0
right 0
side 0
of 0
the 0
posterior 0
thorax 0
. 0

Urinary 0
urate 0
excretion 0
, 0
urate 0
clearance 0
, 0
and 0
fractional 0
excretion 0
of 0
urate 0
all 0
increased 0
significantly 0
during 0
water 0
immersion 0
, 0
and 0
decreased 0
in 0
the 0
hour 0
following 0
water 0
immersion 0
. 0

Mutations 0
in 0
seven 0
other 0
lts B-gene
genes I-gene
do 0
not 0
result 0
in 0
the 0
mak B-gene
- I-gene
phenotype I-gene
. 0

Twenty 0
- 0
eight 0
were 0
excluded 0
as 0
gallstones 0
were 0
not 0
proved 0
: 0
of 0
the 0
remainder 0
, 0
21 0
patients 0
received 0
glucagon B-gene
and 0
22 0
placebo 0
. 0

4 0
Five 0
patients 0
died 0
within 0
one 0
month 0
of 0
captopril 0
and 0
five 0
between 0
four 0
and 0
seven 0
months 0
, 0
three 0
of 0
whom 0
had 0
improved 0
to 0
class 0
IIM 0
and 0
one 0
to 0
IIS 0
before 0
death 0
. 0

Bullous 0
angiolymphoid 0
hyperplasia 0
with 0
eosinophilia 0

Regions 0
of 0
the 0
translated 0
open 0
reading 0
frames 0
of 0
cobA B-gene
and 0
the 0
third 0
intron 0
of 0
the 0
cob B-gene
gene I-gene
in I-gene
yeast I-gene
show 0
high 0
amino 0
acid 0
homology 0
. 0

Multiresistant 0
strains 0
isolated 0
from 0
humans 0
in 0
enteral 0
toxico 0
- 0
infections 0
kill 0
orally 0
infected 0
mice 0
more 0
frequently 0
than 0
strains 0
isolated 0
in 0
hospital 0
infections 0
. 0

Single 0
tooth 0
replacement 0
with 0
the 0
aid 0
of 0
the 0
ITI 0
( 0
International 0
Team 0
fur 0
Implantologie 0
) 0
type 0
F 0
hollow 0
- 0
cylinder 0
implant 0

The 0
13,14 0
- 0
dihydro 0
- 0
15 0
- 0
keto 0
- 0
metabolites 0
of 0
PGE2 0
and 0
PGF2 0
alpha 0
had 0
no 0
statistically 0
significant 0
antiarrhythmic 0
effect 0
. 0

Nucleotide 0
sequence 0
of 0
DNA 0
controlling 0
expression 0
of 0
genes 0
for 0
maltosaccharide 0
utilization 0
in 0
Streptococcus 0
pneumoniae 0
. 0

The 0
hypertension 0
with 0
elevated 0
PRA 0
, 0
however 0
, 0
was 0
resistant 0
to 0
the 0
angiotensin B-gene
II I-gene
( 0
AII B-gene
) 0
analog 0
[ 0
Sar1 0
, 0
Ile8 0
] 0
ALL 0
. 0

Colorimetric 0
determination 0
of 0
urinary 0
iron 0
, 0
chelated 0
with 0
deferoxamine 0
B 0
, 0
using 0
a 0
single 0
reagent 0

Measurements 0
of 0
perfusion 0
also 0
showed 0
significantly 0
higher 0
values 0
under 0
active 0
therapy 0
. 0

Volume 0
of 0
distribution 0
of 0
total 0
DMDZ 0
( 0
range 0
, 0
1.33 0
to 0
6.30 0
l/kg 0
) 0
and 0
of 0
unbound 0
DMDZ 0
after 0
correction 0
for 0
protein 0
binding 0
( 0
range 0
, 0
43 0
to 0
243 0
l/kg 0
) 0
was 0
larger 0
in 0
women 0
than 0
in 0
men 0
of 0
all 0
ages 0
, 0
and 0
in 0
the 0
elderly 0
as 0
opposed 0
to 0
the 0
young 0
. 0

Effects 0
of 0
dopamine 0
and 0
of 0
a 0
dopaminergic 0
blocker 0
, 0
haloperidol 0
, 0
on 0
the 0
responses 0
of 0
carotid 0
body 0
chemoreceptors 0
to 0
hypoxia 0
and 0
hypercapnia 0
were 0
investigated 0
in 0
16 0
anesthetized 0
cats 0
. 0

HLA B-gene
- I-gene
A I-gene
and I-gene
B I-gene
phenotypes 0
of 0
105 0
patients 0
suffering 0
from 0
malignant 0
melanomas 0
were 0
determined 0
, 0
with 0
special 0
regard 0
for 0
metastatic 0
form 0
or 0
relapse 0
. 0

Trypanosoma 0
cruzi 0
. 0

The 0
subjects 0
of 0
the 0
study 0
were 0
10 0
normal 0
subjects 0
and 0
64 0
patients 0
with 0
gastroduodenal 0
disease 0
. 0

1 0
. 0

This 0
study 0
represents 0
the 0
first 0
published 0
long 0
- 0
term 0
follow 0
- 0
up 0
regarding 0
this 0
mode 0
of 0
treatment 0
in 0
patients 0
with 0
alveolar 0
hypoventilation 0
. 0

The 0
alterations 0
in 0
differentiation 0
of 0
osteoprogenitor 0
cells 0
, 0
together 0
with 0
the 0
failure 0
of 0
mineralization 0
, 0
resulted 0
in 0
significantly 0
lower 0
rates 0
of 0
bone 0
formation 0
( 0
as 0
measured 0
by 0
fluorochrome 0
labeling 0
) 0
in 0
the 0
magnesium 0
- 0
deficient 0
rats 0
. 0

A 0
convenient 0
measure 0
of 0
this 0
impairment 0
may 0
be 0
obtained 0
using 0
the 0
ratio 0
of 0
urine 0
volume 0
( 0
V 0
) 0
divided 0
by 0
lithium 0
clearance 0
( 0
CLi 0
) 0
. 0

Nitrogen 0
balance 0
was 0
compared 0
, 0
and 0
metabolic 0
complications 0
were 0
monitored 0
by 0
evaluating 0
BUN 0
, 0
serum 0
creatinine 0
, 0
creatinine 0
clearance 0
, 0
serum 0
CO2 0
, 0
SGOT B-gene
, 0
SGPT B-gene
, 0
serum B-gene
LDH I-gene
, 0
and 0
serum B-gene
alkaline I-gene
phosphatase I-gene
. 0

Production 0
of 0
C B-gene
mu I-gene
RNAs I-gene
, 0
unlike 0
mu B-gene
mRNAs I-gene
, 0
does 0
not 0
require 0
recombination 0
with 0
the 0
joining B-gene
region I-gene
( 0
JH B-gene
) 0
locus 0
. 0

The 0
1.9 0
- 0
kb 0
C B-gene
mu I-gene
RNA 0
contains 0
the 0
3 0
' 0
sequence 0
characteristic 0
of 0
secreted 0
mu B-gene
chain I-gene
, 0
whereas 0
the 0
longer 0
species 0
bear 0
that 0
of 0
membrane 0
- 0
bound 0
mu B-gene
chin 0
. 0

Transcripts 0
of 0
the 0
immunoglobulin B-gene
C I-gene
mu I-gene
gene I-gene
vary 0
in 0
structure 0
and 0
splicing 0
during 0
lymphoid 0
development 0
. 0

Non 0
- 0
complement 0
- 0
dependent 0
sperm 0
- 0
immobilizing 0
activity 0
was 0
also 0
detected 0
in 0
the 0
cervical 0
mucus 0
of 0
several 0
patients 0
. 0

The 0
role 0
of 0
DNA 0
rearrangement 0
and 0
alternative 0
RNA 0
processing 0
in 0
the 0
expression 0
of 0
immunoglobulin B-gene
delta I-gene
genes I-gene
. 0

Although 0
the 0
mechanism 0
of 0
action 0
of 0
ICRF 0
- 0
159 0
and 0
187 0
has 0
not 0
been 0
clearly 0
defined 0
, 0
it 0
is 0
evident 0
from 0
both 0
preclinical 0
and 0
early 0
clinical 0
studies 0
that 0
these 0
compounds 0
are 0
of 0
interest 0
. 0

All 0
62 0
isolates 0
were 0
resistant 0
to 0
lincomycin 0
, 0
colistin 0
, 0
nystatin 0
, 0
amphotericin 0
B 0
, 0
trimethoprim 0
lactate 0
, 0
polymyxin 0
B 0
, 0
and 0
anisomycin 0
. 0

The 0
evaluation 0
of 0
amniotic 0
fluid 0
delta 0
OD450 0
is 0
considered 0
to 0
be 0
the 0
cornerstone 0
of 0
clinical 0
management 0
. 0

Host 0
lipids 0
in 0
tuberculous 0
infection 0
. 0

There 0
is 0
now 0
a 0
significative 0
difference 0
between 0
age 0
group 0
1 0
- 0
5 0
and 0
the 0
others 0
( 0
p 0
Less 0
Than 0
0,02 0
) 0
. 0

The 0
sympathetic 0
neuroeffector 0
influence 0
on 0
the 0
myocardium 0
with 0
ATCI 0
depends 0
to 0
a 0
large 0
measure 0
on 0
the 0
intensity 0
of 0
the 0
neurotransmitter 0
biosynthesis 0
and 0
function 0
of 0
cardiomyocyte 0
adrenoreceptors 0
. 0

Lens B-gene
aldose I-gene
reductase I-gene
in 0
diabetic 0
and 0
galactosemic 0
cataracts 0
. 0

Fenfluramine 0
( 0
in 0
doses 0
ranging 0
from 0
0.0625 0
- 0
4.0 0
mg/kg/infusion 0
) 0
did 0
not 0
maintain 0
self 0
- 0
administration 0
behavior 0
at 0
or 0
above 0
the 0
minimum 0
requirement 0
( 0
FR 0
30 0
) 0
. 0

In 0
the 0
course 0
of 0
Hepatitis B-gene
A I-gene
HBs I-gene
- I-gene
and I-gene
HBe I-gene
- I-gene
antigen I-gene
as 0
well 0
as 0
HBc B-gene
( I-gene
IgM I-gene
and I-gene
IgG I-gene
) I-gene
- I-gene
, I-gene
HBs I-gene
- I-gene
and I-gene
HBe I-gene
- I-gene
antibodies I-gene
can 0
be 0
detected 0
. 0

The 0
effect 0
of 0
the 0
fatty B-gene
acid I-gene
cyclo I-gene
- I-gene
oxygenase I-gene
inhibitor 0
indomethacin 0
on 0
cerebral 0
blood 0
flow 0
( 0
CBF 0
) 0
and 0
the 0
metabolic 0
rate 0
for 0
oxygen 0
( 0
CMRO2 0
) 0
was 0
studied 0
in 0
paralyzed 0
and 0
artificially 0
ventilated 0
rats 0
. 0

The 0
rat 0
incisor 0
is 0
an 0
excellent 0
model 0
system 0
in 0
which 0
to 0
study 0
amelgenesis 0
. 0

The 0
already 0
elevated 0
prolactin B-gene
levels 0
in 0
nursing 0
women 0
were 0
not 0
influenced 0
by 0
chronic 0
oestradiol 0
administration 0
. 0

Factor B-gene
VIII I-gene
procoagulant 0
activity 0
, 0
antigen 0
concentration 0
and 0
von B-gene
Willebrand I-gene
activity 0
as 0
ristocetin B-gene
cofactor I-gene
were 0
determined 0
several 0
times 0
in 0
10 0
patients 0
with 0
DIC 0
. 0

Morphine 0
- 0
dependent 0
and 0
control 0
rats 0
in 0
an 0
oral 0
free 0
- 0
choice 0
protocol 0
were 0
treated 0
with 0
gamma 0
- 0
vinyl 0
GABA 0
( 0
GVG 0
) 0
, 0
60 0
, 0
120 0
and 0
240 0
mg/kg 0
IP 0
, 0
for 0
3 0
days 0
over 0
three 0
successive 0
periods 0
. 0

Significance 0
of 0
the 0
pulmonary 0
gas 0
exchange 0
reaction 0
to 0
physical 0
loading 0
in 0
evaluating 0
the 0
effectiveness 0
of 0
mitral 0
commissurotomy 0

Thyreoliberin B-gene
VUFB 0
in 0
thyroid 0
gammagraphy 0

In 0
silicosis 0
, 0
significant 0
relationships 0
between 0
patients 0
and 0
sons 0
were 0
not 0
seen 0
with 0
respect 0
to 0
arterial 0
blood 0
gas 0
determinations 0
and 0
ventilatory 0
responses 0
except 0
for 0
Paco2 0
of 0
patients 0
and 0
hypercapnic 0
ventilatory 0
responses 0
of 0
sons 0
. 0

For 0
steers 0
the 0
urinary 0
N 0
values 0
were 0
403 0
and 0
295 0
mg/kg 0
W0.75 0
at 0
200 0
and 0
350 0
kg 0
live 0
weight 0
respectively 0
and 0
total 0
N 0
excretion 0
including 0
faecal 0
N 0
was 0
408 0
and 0
320 0
mg/kg 0
W0.75 0
. 0

Advances 0
in 0
hemophilia 0
treatment 0
: 0
a 0
hepatitis 0
- 0
safe 0
factor B-gene
VIII I-gene
concentrate 0

This 0
study 0
was 0
designed 0
to 0
assess 0
and 0
compare 0
the 0
ability 0
of 0
three 0
different 0
forms 0
of 0
DSG 0
to 0
block 0
EIB 0
. 0

Comparison 0
of 0
three 0
different 0
preparations 0
of 0
disodium 0
cromoglycate 0
in 0
the 0
prevention 0
of 0
exercise 0
- 0
induced 0
bronchospasm 0
: 0
a 0
double 0
- 0
blind 0
study 0
. 0

LCBF 0
in 0
normal 0
and 0
hypoxic 0
puppies 0
was 0
correlated 0
with 0
local 0
cerebral 0
glucose 0
utilization 0
( 0
LCGU 0
) 0
obtained 0
under 0
the 0
same 0
experimental 0
conditions 0
( 0
Duffy 0
et 0
al 0
, 0
1982 0
) 0
. 0

Phagocytosis 0
of 0
tubercle 0
bacilli 0
by 0
macrophages 0
. 0

Detection 0
of 0
hemophilia 0
A 0
carriers 0
. 0

The 0
stability 0
of 0
isoniazid 0
solutions 0
increases 0
markedly 0
with 0
increasing 0
NTA 0
or 0
EDTA 0
concentration 0
up 0
to 0
1 0
mmol/l 0
. 0

Bile 0
bilirubin 0
did 0
not 0
rise 0
within 0
12 0
h 0
after 0
haem 0
infusion 0
a 0
finding 0
which 0
warrants 0
further 0
investigation 0
. 0

Autoimmune 0
manipulation 0
aids 0
juvenile 0
diabetes 0
management 0
. 0

Other 0
properties 0
of 0
Hg 0
- 0
and 0
Cd 0
- 0
spores 0
were 0
similar 0
to 0
those 0
of 0
control 0
spores 0
. 0

The 0
decrease 0
in 0
HDL B-gene
- I-gene
cholesterol I-gene
with 0
increasing 0
VLDL B-gene
- I-gene
triglycerides I-gene
was 0
relatively 0
much 0
larger 0
than 0
the 0
concomitant 0
decrease 0
in 0
apo B-gene
A I-gene
- I-gene
I I-gene
. 0

Apo B-gene
A I-gene
- I-gene
I I-gene
level 0
was 0
unrelated 0
to 0
age 0
, 0
but 0
increased 0
with 0
ethanol 0
consumption 0
and 0
decreased 0
with 0
adiposity 0
. 0

TEMTU 0
and 0
DPTU 0
were 0
the 0
most 0
potent 0
teratogens 0
. 0

The 0
osmotic 0
diuretic 0
mannitol 0
was 0
administered 0
to 0
21 0
patients 0
. 0

Of 0
270 0
patients 0
with 0
well 0
- 0
defined 0
drug 0
reactions 0
, 0
190 0
( 0
70 0
per 0
cent 0
) 0
gave 0
a 0
positive 0
response 0
to 0
the 0
mast 0
cell 0
test 0
. 0

Selenium 0
, 0
as 0
a 0
constituent 0
of 0
glutathione B-gene
peroxidase I-gene
, 0
plays 0
a 0
role 0
in 0
the 0
antioxidant 0
defense 0
systems 0
of 0
the 0
body 0
, 0
but 0
other 0
metabolic 0
roles 0
for 0
selenium 0
may 0
yet 0
be 0
discovered 0
. 0

Diagnostic 0
value 0
of 0
serum B-gene
myoglobin I-gene
in 0
cases 0
of 0
neuromuscular 0
disease 0

At 0
43 0
% 0
blood 0
pressure 0
reduction 0
, 0
PCO2 0
fell 0
by 0
0.53 0
kPa 0
, 0
a 0
decrease 0
which 0
could 0
not 0
explain 0
the 0
observed 0
CBF 0
fall 0
of 0
27 0
% 0
. 0

During 0
the 0
last 0
6 0
months 0
of 0
the 0
study 0
a 0
striking 0
change 0
in 0
epidemiology 0
concerning 0
hepatitis 0
A 0
was 0
seen 0
, 0
apparently 0
caused 0
by 0
a 0
steep 0
increase 0
in 0
the 0
incidence 0
of 0
this 0
type 0
of 0
hepatitis 0
among 0
drug 0
addicts 0
. 0

Asthmatic 0
patients 0
showed 0
greater 0
responses 0
of 0
both 0
parameters 0
to 0
adrenaline 0
than 0
controls 0
indicating 0
that 0
long 0
- 0
term 0
corticosteroid 0
treatment 0
enhances 0
the 0
acute 0
responses 0
of 0
plasminogen B-gene
activator I-gene
and 0
clotting B-gene
factor I-gene
VIII I-gene
to 0
adrenaline 0
infusion 0
. 0

Sulphur 0
amino 0
acids 0
( 0
g/16 0
g 0
N 0
) 0
were 0
higher 0
in 0
the 0
isolates 0
than 0
in 0
the 0
flours 0
. 0

Time 0
shifts 0
increase 0
growth B-gene
hormone I-gene
release 0
. 0

It 0
then 0
merged 0
with 0
right 0
ventricular 0
wavefronts 0
ending 0
along 0
the 0
right 0
ventricular 0
anterior 0
atrioventricular 0
groove 0
and 0
outflow 0
tract 0
. 0

Many 0
of 0
these 0
landfill 0
operations 0
were 0
undertaken 0
in 0
the 0
early 0
1950s 0
and 0
1960s 0
, 0
when 0
knowledge 0
regarding 0
the 0
safe 0
and 0
prolonged 0
containment 0
of 0
the 0
waste 0
buried 0
was 0
nonexistent 0
or 0
minimal 0
at 0
best 0
. 0

Vesicles 0
could 0
be 0
induced 0
only 0
with 0
multiple 0
exposures 0
to 0
UVA 0
. 0

The 0
level 0
of 0
contamination 0
in 0
the 0
wound 0
can 0
be 0
determined 0
with 0
the 0
rapid 0
biopsy 0
fixation 0
technique 0
. 0

Self 0
- 0
heating 0
after 0
deep 0
hypothermia 0
( 0
20 0
degrees 0
C 0
) 0
causes 0
a 0
considerable 0
increase 0
in 0
the 0
brain 0
tissues 0
glutaminase B-gene
activity 0
at 0
all 0
studied 0
incubation 0
temperatures 0
( 0
37 0
, 0
30 0
, 0
20 0
and 0
10 0
degrees 0
C 0
) 0
as 0
compared 0
to 0
control 0
rats 0
and 0
rats 0
under 0
hypothermia 0
. 0

Similar 0
observations 0
were 0
made 0
with 0
unilateral 0
pneumothorax 0
of 0
15 0
cmH2O 0
for 0
30 0
min 0
. 0

According 0
to 0
Sugiura 0
's 0
classification 0
, 0
they 0
consisted 0
of 0
Type 0
Ia 0
in 0
63 0
% 0
, 0
Type 0
Ib 0
in 0
11 0
% 0
, 0
Type 0
II 0
in 0
11 0
% 0
, 0
and 0
Type 0
III 0
in 0
16 0
% 0
. 0

This 0
study 0
was 0
undertaken 0
to 0
define 0
the 0
mechanism 0
for 0
the 0
respiratory 0
inhibition 0
observed 0
during 0
high 0
- 0
frequency 0
oscillatory 0
ventilation 0
( 0
HFOV 0
) 0
. 0

Determination 0
of 0
20 0
alpha 0
- 0
hydroxy 0
- 0
9 0
beta,10 0
alpha 0
- 0
pregna 0
- 0
4,6 0
- 0
dien 0
- 0
3 0
- 0
one 0
in 0
plasma 0
by 0
selected 0
ion 0
monitoring 0
. 0

A 0
case 0
of 0
a 0
dense 0
epidermoid 0
cyst 0
of 0
the 0
suprasellar 0
cistern 0
is 0
presented 0
. 0

Copper 0
treatments 0
were 0
assigned 0
to 0
simulate 0
the 0
different 0
levels 0
of 0
copper 0
intake 0
that 0
might 0
result 0
from 0
differences 0
in 0
daily 0
feed 0
intake 0
similar 0
to 0
the 0
practice 0
followed 0
with 0
commercial 0
industry 0
. 0

Fibromuscular 0
intimal 0
thickening 0
was 0
seen 0
in 0
the 0
ascending 0
and 0
thoracic 0
aorta 0
of 0
the 0
swine 0
fed 0
62,500 0
IU 0
of 0
vitamin 0
D3/kg 0
of 0
diet 0
for 0
three 0
months 0
duration 0
; 0
and 0
after 0
3 0
months 0
of 0
vitamin 0
D3 0
withdrawal 0
, 0
atherosclerotic 0
lesions 0
were 0
found 0
. 0

Because 0
of 0
a 0
rapid 0
development 0
of 0
the 0
connective 0
tissue 0
scars 0
, 0
however 0
, 0
at 0
the 0
place 0
of 0
the 0
destroyed 0
glandular 0
parenchyma 0
areas 0
, 0
there 0
is 0
no 0
normalization 0
of 0
the 0
organ 0
's 0
structure 0
and 0
function 0
by 0
the 0
42d 0
day 0
. 0

Histological 0
signs 0
of 0
the 0
flare 0
- 0
up 0
reaction 0
were 0
already 0
present 0
at 0
6 0
hr 0
after 0
i.v 0
. 0
challenge 0
and 0
lasted 0
for 0
at 0
least 0
4 0
days 0
. 0

Significant 0
GMBF 0
reductions 0
occurred 0
in 0
early 0
shock 0
in 0
both 0
treatment 0
groups 0
. 0

Of 0
254 0
children 0
with 0
neuroblastoma 0
treated 0
at 0
St 0
. 0

Penicillin 0
- 0
G 0
degradation 0
products 0
inhibit 0
in 0
vitro 0
granulopoiesis 0
. 0

Plasma 0
fibrinogen B-gene
was 0
measured 0
by 0
the 0
turbidimetric 0
method 0
in 0
timol 0
turbidimetric 0
units 0
. 0

Five 0
patients 0
with 0
type 0
III 0
musculoskeletal 0
infection 0
from 0
nongonococcal 0
Neisseria 0
species 0
were 0
examined 0
during 0
a 0
13 0
- 0
month 0
period 0
. 0

Distal 0
tubular 0
acidification 0
and 0
the 0
threshold 0
for 0
proximal 0
tubular 0
bicarbonate 0
reabsorption 0
were 0
normal 0
, 0
as 0
was 0
urine 0
concentrating 0
capacity 0
. 0

Detection 0
of 0
exercise 0
- 0
induced 0
asynergy 0
by 0
M 0
- 0
mode 0
echocardiography 0
. 0

The 0
Tullio 0
phenomenon 0
, 0
fistula 0
test 0
, 0
and 0
Hennebert 0
's 0
sign 0
: 0
clinical 0
significance 0
. 0

These 0
results 0
indicate 0
that 0
significant 0
pulmonary 0
metabolism 0
of 0
5 0
- 0
HT 0
followed 0
by 0
efflux 0
of 0
5 0
- 0
HIAA 0
into 0
venous 0
output 0
occurs 0
during 0
single 0
- 0
pass 0
circulation 0
. 0

Disturbances 0
of 0
placental 0
maturation 0
, 0
2 0
. 0

On 0
the 0
basis 0
of 0
histopathological 0
findings 0
, 0
the 0
origin 0
of 0
amyloid 0
appeared 0
to 0
be 0
closely 0
related 0
to 0
the 0
fibroblasts 0
. 0

Both 0
groups 0
were 0
subjected 0
to 0
tests 0
of 0
delayed 0
hypersensitivity 0
with 0
Candidin B-gene
, 0
Trycophytin B-gene
and 0
Tuberculin B-gene
. 0

Serum 0
lactate B-gene
dehydrogenase I-gene
and 0
haptoglobin B-gene
levels 0
were 0
normal 0
, 0
and 0
total 0
bilirubin 0
was 0
only 0
slightly 0
elevated 0
. 0

Low 0
- 0
dose 0
D 0
( 0
0.4 0
- 0
0.8 0
mg 0
) 0
and 0
DB 0
( 0
1.0 0
- 0
5.0 0
mg 0
) 0
did 0
not 0
significantly 0
alter 0
any 0
parameter 0
from 0
control 0
. 0

Efficacy 0
of 0
cervical 0
spine 0
immobilization 0
methods 0
. 0

Leads 0
from 0
the 0
MMWR 0
. 0

The 0
presence 0
of 0
visna 0
- 0
maedi 0
in 0
Italy 0
is 0
reported 0
for 0
the 0
first 0
time 0
. 0

High 0
levels 0
of 0
IC 0
coincided 0
with 0
relative 0
hypocomplementemia 0
. 0

Circulating 0
platelets 0
may 0
be 0
activated 0
by 0
exposed 0
triple 0
- 0
helical 0
collagen B-gene
in 0
atherosclerotic 0
lesions 0
in 0
Mg 0
- 0
deficient 0
ruminants 0
. 0

Acute 0
type 0
A 0
hepatitis 0
in 0
three 0
patients 0
with 0
chronic 0
HBV 0
infection 0
. 0

Pathogenetic 0
relationships 0
between 0
renal 0
tubular 0
acidosis 0
and 0
sodium 0
metabolism 0
alterations 0
in 0
liver 0
cirrhosis 0
. 0

5 0
microU/l 0
thyrotropin B-gene
: 0
75 0
% 0
( 0
1974 0
) 0
, 0
45 0
% 0
( 0
1977 0
) 0
and 0
20 0
% 0
( 0
1980 0
) 0
. 0

Echosismography 0
enables 0
to 0
improve 0
the 0
diagnosis 0
when 0
compared 0
with 0
classical 0
sonography 0
in 0
about 0
20 0
% 0
of 0
cases 0
. 0

Relationships 0
with 0
the 0
acquired 0
immune 0
deficiency 0
syndrome 0
. 0

The 0
prevalence 0
of 0
CPAF 0
was 0
similar 0
in 0
type 0
1 0
and 0
type 0
2 0
diabetes 0
, 0
was 0
greater 0
in 0
women 0
than 0
in 0
men 0
, 0
and 0
was 0
significantly 0
greater 0
after 0
repeated 0
administrations 0
than 0
after 0
one 0
single 0
administration 0
of 0
chlorpropamide 0
. 0

A 0
reassessment 0
of 0
the 0
prevalence 0
data 0
was 0
carried 0
out 0
in 0
the 0
southern 0
province 0
of 0
Uusimaa 0
and 0
in 0
the 0
western 0
province 0
of 0
Vaasa 0
, 0
the 0
prevalence 0
day 0
being 0
January 0
1 0
, 0
1979 0
. 0

The 0
results 0
confirm 0
and 0
extend 0
previous 0
work 0
by 0
other 0
researchers 0
. 0

In 0
the 0
ultramarathon 0
runner 0
the 0
testosterone 0
levels 0
sharply 0
rose 0
at 0
the 0
beginning 0
of 0
the 0
training 0
session 0
( 0
from 0
the 0
7,20 0
ng/ml 0
to 0
11,50 0
ng/ml 0
after 0
20 0
' 0
training 0
) 0
, 0
and 0
subsequently 0
decrease 0
after 0
3 0
hours 0
( 0
9,20 0
ng/ml 0
) 0
and 0
at 0
the 0
end 0
of 0
the 0
6 0
hours 0
training 0
( 0
4,60 0
ng/ml 0
) 0
. 0

In 0
patients 0
with 0
complete 0
or 0
partial 0
remission 0
of 0
the 0
tumor 0
, 0
the 0
neopterine 0
excretion 0
dropped 0
to 0
normal 0
values 0
. 0

In 0
visible 0
tumours 0
the 0
best 0
results 0
were 0
obtained 0
with 0
FB 0
( 0
85 0
% 0
) 0
while 0
TBN 0
was 0
positive 0
in 0
65 0
% 0
. 0

Total 0
PGE 0
levels 0
in 0
synovial 0
fluid 0
remained 0
significantly 0
depressed 0
in 0
the 0
patient 0
group 0
for 0
24 0
hours 0
after 0
the 0
400 0
- 0
mg 0
test 0
dose 0
of 0
tolmetin 0
on 0
day 0
8 0
. 0

Normal 0
rates 0
of 0
weight 0
gain 0
were 0
seen 0
once 0
absorbed 0
energy 0
intakes 0
reached 0
100 0
- 0
110 0
% 0
of 0
requirements 0
. 0

Its 0
vasodilatory 0
, 0
anti 0
- 0
vasopressor 0
, 0
and 0
platelet 0
stabilizing 0
effects 0
could 0
be 0
expected 0
to 0
counteract 0
the 0
placental 0
ischemia 0
, 0
hypertension 0
and 0
excessive 0
coagulation 0
that 0
are 0
seen 0
in 0
pre 0
- 0
eclampsia 0
. 0

Behcet 0
's 0
syndrome 0

Survival 0
of 0
111 0
Indium 0
- 0
labelled 0
autologous 0
platelets 0
was 0
studied 0
in 0
2 0
patients 0
after 0
correction 0
of 0
platelet 0
count 0
and 0
was 0
still 0
found 0
shortened 0
. 0

The 0
effect 0
of 0
emotional 0
- 0
painful 0
stress 0
( 0
EPS 0
) 0
on 0
myocardial 0
extensibility 0
and 0
contractility 0
was 0
studied 0
on 0
an 0
isolated 0
rat 0
atrium 0
. 0

Terbutaline 0
; 0
a 0
beta2 0
- 0
adrenergic 0
agonist 0
, 0
and 0
aminophyllin 0
, 0
a 0
phosphodiesterase 0
inhibitor 0
, 0
were 0
given 0
separately 0
, 0
or 0
in 0
combination 0
, 0
to 0
rabbit 0
fetuses 0
on 0
the 0
28th 0
day 0
of 0
gestation 0
. 0

When 0
O2 0
therapy 0
was 0
controlled 0
for 0
, 0
the 0
association 0
between 0
RBT 0
and 0
RLF 0
did 0
not 0
achieve 0
statistical 0
significance 0
( 0
P 0
= 0
.07 0
) 0
. 0

This 0
two 0
- 0
helix 0
motif 0
is 0
thought 0
to 0
be 0
involved 0
in 0
specific 0
DNA 0
sequence 0
recognition 0
by 0
CAP B-gene
. 0

The 0
hyperacute 0
phase 0
of 0
posterolateral 0
myocardial 0
infarction 0
. 0

Statistics 0
for 0
nurse 0
managers 0
- 0
- 0
3 0
. 0

The 0
infection 0
rate 0
was 0
five 0
times 0
greater 0
in 0
patients 0
with 0
Hickman 0
catheters 0
than 0
in 0
those 0
with 0
Broviac 0
catheters 0
( 0
p 0
= 0
0.01 0
) 0
. 0

After 0
a 0
year 0
of 0
planning 0
in 0
the 0
Laboratory 0
Assistants 0
' 0
School 0
in 0
Stockholm 0
: 0
new 0
education 0
for 0
laboratory 0
assistants 0
is 0
now 0
arranged 0

The 0
electrocardiogram 0
. 0

Setting 0
takes 0
place 0
through 0
complex 0
formation 0
of 0
( 0
NH4Mg 0
PO4.6H2O 0
) 0
n 0
, 0
excess 0
reactants 0
, 0
and 0
water 0
. 0

The 0
Authors 0
have 0
proposed 0
to 0
develop 0
this 0
research 0
employing 0
a 0
preparation 0
containing 0
exclusively 0
a 0
cortisonic 0
, 0
the 0
desametazone 0
, 0
in 0
order 0
to 0
evaluate 0
the 0
alterations 0
of 0
the 0
dentinogenesis 0
to 0
be 0
attributed 0
to 0
such 0
component 0
. 0

Secretory B-gene
IgA I-gene
and 0
serum B-gene
immunoglobulins I-gene
as 0
indices 0
of 0
the 0
local 0
immunity 0
of 0
the 0
intestinal 0
mucosa 0
in 0
acute 0
leukemias 0

Serum B-gene
IgE I-gene
levels 0
in 0
Tauranga 0
children 0
. 0

Use 0
of 0
prostaglandin 0
F2 0
alpha 0
( 0
PGF2 0
alpha 0
) 0
in 0
cattle 0
breeding 0
. 0

Thus 0
it 0
appears 0
that 0
the 0
management 0
of 0
blood 0
, 0
including 0
washing 0
is 0
of 0
great 0
importance 0
. 0

Range 0
, 0
variations 0
and 0
neoplastic 0
potential 0
. 0

The 0
scores 0
are 0
dependent 0
in 0
part 0
on 0
the 0
reliability 0
of 0
faculty 0
evaluations 0
. 0

Study 0
on 0
distribution 0
of 0
metal 0
in 0
the 0
teeth 0
treated 0
by 0
iontophoresis 0
with 0
transparent 0
specimens 0

Whereas 0
creatine B-gene
kinase I-gene
activity 0
declined 0
exponentially 0
from 0
a 0
single 0
peak 0
, 0
myoglobin B-gene
appeared 0
in 0
multiple 0
episodes 0
inadequately 0
represented 0
by 0
a 0
single 0
peak 0
value 0
and 0
having 0
no 0
clear 0
clinical 0
correlation 0
. 0

Utero 0
- 0
placental 0
blood 0
flow 0
and 0
the 0
effect 0
of 0
beta B-gene
2 I-gene
- I-gene
adrenoceptor I-gene
stimulating 0
drugs 0
. 0

Development 0
of 0
basophilic 0
leukemia 0
with 0
trisomy 0
8 0
and 0
atypical 0
erythroblastosis 0
in 0
a 0
patient 0
with 0
a 0
history 0
of 0
aplastic 0
anemia 0
22 0
years 0
earlier 0

The 0
arginyl 0
peptide 0
bonds 0
that 0
are 0
cleaved 0
in 0
the 0
conversion 0
of 0
human B-gene
factor I-gene
IX I-gene
to 0
factor B-gene
IXa I-gene
by 0
factor B-gene
XIa I-gene
were 0
identified 0
as 0
Arg145 0
- 0
Ala146 0
and 0
Arg180 0
- 0
Val181 0
. 0

Alveolar 0
growth 0
, 0
contemporary 0
with 0
dental 0
eruption 0
, 0
is 0
sufficient 0
to 0
compensate 0
possible 0
hypotrophy 0
of 0
maxillary 0
bone 0
bases 0
. 0

Fluorometric 0
methods 0
can 0
also 0
provide 0
information 0
about 0
porphyrin 0
binding 0
sites 0
that 0
is 0
useful 0
in 0
understanding 0
porphyrin 0
transport 0
and 0
clearance 0
. 0

Renal 0
and 0
extrarenal 0
arterial 0
fibromuscular 0
hyperplasia 0
with 0
hypertension 0
. 0

The 0
monoexponential 0
rate 0
of 0
clearance 0
of 0
tracer 0
- 0
- 0
obtained 0
from 0
the 0
portion 0
of 0
the 0
residue 0
- 0
detection 0
curve 0
reflecting 0
metabolism 0
of 0
fatty 0
acid 0
incorporated 0
into 0
neutral 0
lipids 0
- 0
- 0
correlated 0
directly 0
with 0
induced 0
changes 0
in 0
tension 0
- 0
time 0
index 0
after 0
injections 0
into 0
the 0
left 0
atrium 0
( 0
r 0
= 0
0.96 0
, 0
n 0
= 0
12 0
) 0
, 0
right 0
atrium 0
( 0
r 0
= 0
0.86 0
, 0
n 0
= 0
14 0
) 0
, 0
and 0
ear 0
vein 0
( 0
r 0
= 0
0.93 0
, 0
n 0
= 0
14 0
) 0
. 0

Both 0
examinations 0
are 0
sensitive 0
indicators 0
of 0
CNS 0
abnormalities 0
associated 0
with 0
bacterial 0
meningeal 0
infections 0
and 0
are 0
important 0
determinants 0
of 0
the 0
therapy 0
and 0
ultimate 0
prognosis 0
of 0
such 0
complications 0
. 0

Specific 0
IgE B-gene
levels 0
decreased 0
slightly 0
, 0
but 0
always 0
remained 0
within 0
the 0
pathological 0
range 0
. 0

Similar 0
clinical 0
evaluation 0
of 0
an 0
obligate 0
carrier 0
revealed 0
no 0
ocular 0
abnormalities 0
. 0

Correlation 0
between 0
intraocular 0
involvement 0
and 0
systemic 0
outcome 0
was 0
poor 0
. 0

A 0
case 0
of 0
anterior 0
cleavage 0
syndrome 0
in 0
a 0
27 0
- 0
year 0
- 0
old 0
female 0
patient 0
is 0
described 0
. 0

The 0
daily 0
administration 0
of 0
betamethasone 0
for 0
three 0
weeks 0
markedly 0
reduced 0
the 0
absorption 0
of 0
calcium 0
and 0
phosphate 0
as 0
well 0
as 0
the 0
growth 0
rate 0
. 0

Endorphins B-gene
and 0
legal 0
issues 0
. 0

At 0
necropsy 0
28 0
days 0
post 0
- 0
inoculation 0
, 0
F344 0
rats 0
had 0
no 0
gross 0
lung 0
lesions 0
, 0
even 0
those 0
given 0
the 0
maximum 0
dose 0
of 0
1.4 0
X 0
10 0
( 0
9 0
) 0
colony 0
- 0
forming 0
units 0
of 0
M. 0
pulmonis 0
. 0

Aneurysmectomy 0
and 0
the 0
performance 0
of 0
CABG 0
were 0
not 0
significantly 0
associated 0
with 0
postoperative 0
ECG 0
changes 0
, 0
but 0
more 0
bypass 0
grafts 0
per 0
patient 0
grafted 0
appeared 0
in 0
the 0
group 0
with 0
postoperative 0
ECG 0
changes 0
, 0
suggesting 0
that 0
coronary 0
artery 0
disease 0
may 0
be 0
more 0
severe 0
in 0
that 0
group 0
. 0

REV 0
I 0
: 0
All 0
vessels 0
up 0
to 0
50 0
% 0
stenosed 0
have 0
a 0
patent 0
graft 0
. 0

Complete 0
sequences 0
were 0
obtained 0
for 0
the 0
three 0
large 0
thrombic 0
peptides 0
, 0
and 0
these 0
were 0
aligned 0
by 0
using 0
peptides 0
from 0
the 0
V8 B-gene
protease I-gene
digest 0
. 0

The 0
extraction 0
measurements 0
were 0
used 0
to 0
test 0
for 0
extracerebral 0
contamination 0
of 0
venous 0
outflow 0
. 0

Contractile 0
responses 0
to 0
norepinephrine 0
, 0
serotonin 0
and 0
potassium 0
( 0
K+ 0
) 0
and 0
relaxant 0
responses 0
to 0
isoproterenol 0
and 0
papaverine 0
were 0
studied 0
in 0
vitro 0
with 0
spirally 0
cut 0
thoracic 0
aortic 0
strips 0
from 0
aortic 0
coarcted 0
hypertensive 0
rats 0
( 0
AHR 0
) 0
2 0
, 0
6 0
, 0
14 0
and 0
28 0
days 0
postoperatively 0
and 0
compared 0
to 0
time 0
- 0
matched 0
, 0
sham 0
- 0
operated 0
normotensive 0
controls 0
. 0

On 0
line 0
calculation 0
of 0
steroid 0
concentrations 0
by 0
radioimmunoassay 0

Detection 0
of 0
congenital 0
hypothyroidism 0
in 0
26,282 0
newborn 0
infants 0

In 0
rubella 0
patients 0
with 0
serologic 0
confirmation 0
by 0
HI 0
, 0
the 0
IF 0
test 0
detected 0
significant 0
rises 0
in 0
219 0
( 0
99.1 0
% 0
) 0
of 0
221 0
patients 0
and 0
the 0
PHA B-gene
test 0
detected 0
antibody 0
conversion 0
in 0
68 0
( 0
93 0
% 0
) 0
of 0
73 0
patients 0
. 0

The 0
results 0
indicate 0
that 0
folate 0
compounds 0
decrease 0
formate 0
accumulation 0
after 0
methanol 0
by 0
stimulating 0
formate 0
oxidation 0
or 0
utilization 0
and 0
suggest 0
a 0
possible 0
use 0
for 0
folates 0
in 0
the 0
treatment 0
of 0
certain 0
cases 0
of 0
human 0
methanol 0
poisoning 0
. 0

The 0
effect 0
of 0
sodium 0
saccharin 0
in 0
the 0
diet 0
on 0
caecal 0
microflora 0
. 0

The 0
residue 0
functions 0
, 0
R 0
( 0
t 0
) 0
, 0
for 0
C 0
- 0
11 0
CPZ 0
and 0
In 0
- 0
113m 0
transferrin B-gene
were 0
plotted 0
against 0
time 0
for 0
selected 0
areas 0
of 0
interest 0
, 0
and 0
the 0
CPZ 0
area 0
- 0
weighted 0
extraction 0
, 0
E 0
( 0
t 0
) 0
, 0
was 0
computed 0
for 0
the 0
same 0
areas 0
every 0
250 0
msec 0
using 0
the 0
formula 0
: 0
E 0
( 0
t 0
) 0
= 0
[ 0
RT 0
( 0
t 0
) 0
- 0
RR 0
( 0
t 0
) 0
] 0
/ 0
[ 0
1 0
- 0
RR 0
( 0
t 0
) 0
] 0
, 0
where 0
RT 0
and 0
RR 0
are 0
the 0
normalized 0
residue 0
functions 0
for 0
CPZ 0
and 0
transferrin B-gene
, 0
respectively 0
. 0

Synchronous 0
extracts 0
showed 0
no 0
significant 0
migration 0
inhibition 0
in 0
allogeneic 0
assays 0
. 0

Ten 0
days 0
of 0
cefadroxil 0
therapy 0
was 0
used 0
to 0
treat 0
44 0
children 0
with 0
urinary 0
tract 0
infection 0
and 0
CRP B-gene
values 0
greater 0
than 0
or 0
equal 0
to 0
28 0
microgram/ml 0
( 0
CRP B-gene
- 0
positive 0
group 0
) 0
. 0

Both 0
resting 0
blood 0
flow 0
( 0
RBF 0
) 0
and 0
maximal 0
blood 0
flow 0
( 0
NBF 0
) 0
were 0
studied 0
by 0
Xenon 0
133 0
clearance 0
. 0

Plasma B-gene
renin I-gene
concentration 0
is 0
significantly 0
higher 0
in 0
the 0
subcapsular 0
venous 0
outflow 0
, 0
which 0
drains 0
the 0
superficial 0
cortex 0
, 0
than 0
in 0
the 0
deep 0
venous 0
outflow 0
, 0
which 0
drains 0
the 0
inner 0
half 0
of 0
the 0
cortex 0
and 0
medulla 0
of 0
the 0
cat 0
kidney 0
. 0

After 0
acclimation 0
, 0
resting 0
supine 0
and 0
sitting 0
DPB 0
decreased 0
( 0
P 0
less 0
than 0
0.05 0
) 0
by 0
6 0
and 0
9 0
mmHg 0
, 0
respectively 0
. 0

In 0
the 0
diabetics 0
, 0
Ca2+ 0
infusions 0
induced 0
a 0
rise 0
of 0
plasma 0
Ca2+ 0
up 0
to 0
3.2 0
+/ 0
- 0
0.1 0
mmol/1 0
and 0
a 0
fall 0
of 0
circulating 0
glucagon B-gene
( 0
- 0
26.4 0
+/ 0
- 0
5.7 0
% 0
; 0
p 0
less 0
than 0
0.001 0
) 0
and 0
glucose 0
( 0
- 0
23.3 0
+/ 0
- 0
3.6 0
% 0
; 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Fifty 0
- 0
eight 0
RMI 0
's 0
occurred 0
in 0
the 0
placebo 0
group 0
as 0
compared 0
to 0
only 0
twenty 0
in 0
the 0
AC 0
group 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

The 0
`` 0
cracked 0
- 0
tooth 0
'' 0
syndrome 0
. 0

The 0
foregoing 0
results 0
show 0
that 0
CXD 0
has 0
high 0
efficacy 0
and 0
safety 0
and 0
it 0
can 0
be 0
said 0
that 0
it 0
is 0
a 0
drug 0
required 0
in 0
the 0
pediatric 0
field 0
. 0

Based 0
on 0
peptide 0
map 0
similarities 0
, 0
partial 0
amino 0
- 0
terminal 0
sequence 0
data 0
, 0
and 0
common 0
genetic 0
origin 0
, 0
it 0
is 0
suggested 0
that 0
p60 B-gene
and 0
p62 B-gene
have 0
identical 0
amino 0
acid 0
sequences 0
carboxy 0
- 0
terminal 0
to 0
the 0
p60 B-gene
initiator 0
methionine 0
( 0
residue 0
21 0
of 0
p62 B-gene
) 0
. 0

All 0
patients 0
in 0
the 0
control 0
group 0
showed 0
a 0
significant 0
improvement 0
in 0
their 0
PEFR 0
while 0
only 0
3 0
patients 0
in 0
the 0
treated 0
group 0
showed 0
an 0
improvement 0
. 0

Facts 0
on 0
the 0
Economic 0
Recovery 0
Tax 0
Act 0
of 0
1981 0
for 0
speech 0
- 0
language 0
pathologists 0
and 0
audiologists 0
. 0

From 0
Pap 0
to 0
ApUp 0
. 0

The 0
relationship 0
between 0
the 0
rare 0
complications 0
mentioned 0
above 0
and 0
the 0
pathophysiology 0
of 0
Bartter 0
's 0
syndrome 0
is 0
still 0
obscure 0
. 0

Using 0
an 0
opsonophagocytic 0
bacterial 0
assay 0
and 0
a 0
suckling 0
rat 0
model 0
of 0
GBS 0
sepsis 0
, 0
we 0
analyzed 0
a 0
modified 0
human B-gene
immunoglobulin I-gene
for 0
opsonic 0
and 0
protective 0
antibody 0
. 0

Glomerular 0
lesions 0
in 0
renal 0
allografts 0
. 0

Commonly 0
observed 0
systemic 0
toxic 0
effects 0
( 0
bone 0
marrow 0
, 0
gastrointestinal 0
tract 0
, 0
and 0
heart 0
) 0
were 0
not 0
seen 0
in 0
this 0
study 0
. 0

2 0
. 0

When 0
vascular 0
pressure 0
( 0
Pvas 0
) 0
was 0
raised 0
abruptly 0
from 0
- 0
5 0
to 0
+25 0
cmH2O 0
by 0
air 0
inflation 0
for 0
60 0
min 0
, 0
Px 0
( 0
f 0
) 0
became 0
abruptly 0
less 0
negative 0
, 0
then 0
remained 0
stable 0
. 0

( 0
1980 0
) 0
: 0
Science 0
210 0
, 0
77 0
- 0
72 0
) 0
that 0
stimulating 0
the 0
crossed 0
olivocochlear 0
bundle 0
( 0
COCB 0
) 0
can 0
change 0
the 0
magnitude 0
of 0
the 0
distortion 0
product 0
( 0
f2 0
- 0
f1 0
) 0
in 0
the 0
ear 0
- 0
canal 0
sound 0
pressure 0
. 0

Rats 0
underwent 0
either 0
a 0
90 0
- 0
95 0
% 0
JIB 0
or 0
a 0
sham 0
operation 0
. 0

When 0
the 0
l 0
- 0
methadone 0
- 0
sensitive 0
, 0
opioid B-gene
receptor I-gene
is 0
blocked 0
by 0
naloxone 0
or 0
tolerance 0
has 0
developed 0
, 0
than 0
l 0
- 0
methadone 0
can 0
produce 0
behavioral 0
effects 0
by 0
a 0
nonopioid 0
mechanism 0
. 0

Microwave 0
hyperthermia 0
- 0
induced 0
blood 0
- 0
brain 0
barrier 0
alterations 0
. 0

Large 0
and 0
small 0
medullary 0
lesions 0
inhibited 0
the 0
occurrence 0
of 0
target 0
fibres 0
in 0
the 0
tenotomized 0
muscles 0
, 0
the 0
smallest 0
one 0
being 0
neurolysis 0
of 0
the 0
dorsal 0
roots 0
. 0

Diagnosis 0
of 0
phenylalanine B-gene
hydroxylase I-gene
deficiency 0
( 0
phenylketonuria 0
) 0
. 0

In 0
10 0
control 0
sheep 0
mean 0
plasma 0
TXB2 0
concentration 0
increased 0
from 0
0.39 0
ng/ml 0
prebypass 0
to 0
about 0
1.1 0
ng/ml 0
at 0
8 0
and 0
16 0
min 0
of 0
bypass 0
. 0

The 0
respiratory 0
rate 0
was 0
13 0
+/ 0
- 0
1 0
breaths/min 0
with 0
52 0
+/ 0
- 0
4 0
% 0
of 0
the 0
respiratory 0
cycle 0
spent 0
in 0
inspiration 0
; 0
end 0
- 0
tidal 0
CO2 0
pressure 0
increased 0
by 0
3.3 0
+/ 0
- 0
1.0 0
Torr 0
during 0
runs 0
at 0
SIP 0
. 0

There 0
was 0
no 0
further 0
increase 0
in 0
oxygen 0
consumption 0
when 0
these 0
subjects 0
breathed 0
with 0
inspiratory 0
pressures 0
above 0
SIP 0
. 0

We 0
compared 0
the 0
volume 0
of 0
the 0
pulmonary 0
extravascular 0
, 0
extracellular 0
water 0
space 0
using 0
sodium 0
and 0
sucrose 0
indicators 0
in 0
8 0
normal 0
and 0
11 0
edematous 0
rabbit 0
lungs 0
by 0
steady 0
- 0
state 0
techniques 0
. 0

Investigated 0
the 0
reliability 0
, 0
validity 0
and 0
dimensionality 0
of 0
scores 0
obtained 0
by 0
acute 0
psychiatric 0
inpatients 0
( 0
N 0
= 0
120 0
) 0
on 0
the 0
Michigan 0
Alcoholism 0
Screening 0
Test 0
adapted 0
to 0
assess 0
lifetime 0
and 0
current 0
symptomatology 0
. 0

A 0
simple 0
method 0
for 0
measuring 0
urinary 0
iron 0
following 0
the 0
administration 0
of 0
desferrioxamine 0
( 0
DF 0
) 0
is 0
described 0
. 0

During 0
conventional 0
hemofiltration 0
using 0
substitution 0
fluid 0
with 0
a 0
Na+ 0
concentration 0
of 0
140 0
mEq/L 0
, 0
a 0
decrease 0
in 0
extracellular 0
fluid 0
volume 0
was 0
noted 0
whereas 0
the 0
intracellular 0
fluid 0
volume 0
was 0
unaltered 0
. 0

The 0
uncomplicated 0
cases 0
of 0
typhoid 0
fever 0
were 0
found 0
to 0
have 0
an 0
intact 0
CMIR 0
as 0
compared 0
to 0
the 0
complicated 0
cases 0
. 0

Transvenous 0
serial 0
xeroradiography 0
. 0

Recommendations 0
to 0
deal 0
with 0
these 0
and 0
related 0
issues 0
are 0
presented 0
. 0

Use 0
of 0
subcutaneous 0
deferoxamine 0
in 0
a 0
child 0
with 0
hemochromatosis 0
associated 0
with 0
congenital 0
dyserythropoietic 0
anemia 0
, 0
type 0
I 0
. 0

There 0
was 0
a 0
significant 0
correlation 0
between 0
tubular 0
diameter 0
and 0
spg 0
( 0
r 0
= 0
0.68 0
, 0
P 0
less 0
than 0
0.001 0
) 0
suggesting 0
that 0
tubular 0
diameter 0
measurements 0
in 0
histological 0
sections 0
could 0
be 0
used 0
to 0
predict 0
sperm 0
production 0
. 0

The 0
differential 0
investigation 0
of 0
lipoproteins 0
, 0
however 0
, 0
showed 0
that 0
the 0
high B-gene
- I-gene
density I-gene
lipoprotein I-gene
( 0
HDL B-gene
) 0
fractions 0
are 0
absolutely 0
or 0
relatively 0
decreased 0
with 0
respect 0
to 0
low B-gene
- I-gene
density I-gene
lipoproteins I-gene
( 0
LDL B-gene
) 0
in 0
cerebral 0
infarcts 0
and 0
in 0
transient 0
ischaemic 0
attacks 0
. 0

Although 0
noninhibitory 0
fluid 0
had 0
higher 0
mean 0
concentrations 0
of 0
phosphorus 0
and 0
zinc 0
, 0
these 0
differences 0
did 0
not 0
hold 0
after 0
meconium 0
- 0
stained 0
samples 0
were 0
excluded 0
. 0

Selenium 0
status 0
of 0
thoroughbreds 0
in 0
the 0
United 0
Kingdom 0
. 0

During 0
an 0
8 0
- 0
wk 0
follow 0
- 0
up 0
, 0
parasites 0
reappeared 0
in 0
10 0
patients 0
, 0
5 0
after 0
each 0
drug 0
, 0
between 0
1 0
and 0
7 0
wk 0
after 0
treatment 0
. 0

Preparation 0
of 0
a 0
stable 0
phospholipid 0
reagent 0
for 0
coagulation 0
assays 0
. 0

A 0
note 0
on 0
some 0
consequences 0
of 0
UV 0
vision 0
in 0
birds 0
. 0

Before 0
turnout 0
, 0
a 0
morantel 0
sustained 0
release 0
bolus 0
( 0
MSRB 0
) 0
was 0
administered 0
to 0
each 0
animal 0
in 0
the 0
`` 0
treated 0
'' 0
category 0
. 0

In 0
a 0
longitudinal 0
study 0
, 0
14 0
low 0
- 0
risk 0
fetuses 0
were 0
studied 0
at 0
2 0
- 0
week 0
intervals 0
from 0
32 0
weeks 0
of 0
gestation 0
onward 0
. 0

Further 0
, 0
intracerebroventricular 0
injections 0
of 0
KA 0
resulted 0
in 0
the 0
substantial 0
loss 0
of 0
pyramidal 0
cells 0
in 0
the 0
whole 0
CA3 0
field 0
of 0
the 0
hippocampus 0
. 0

Seventeen 0
of 0
the 0
35 0
patients 0
were 0
randomly 0
chosen 0
to 0
receive 0
a 0
training 0
program 0
( 0
lasting 0
approximately 0
1 0
month 0
) 0
designed 0
to 0
establish 0
a 0
systematic 0
strategy 0
of 0
organizing 0
complex 0
visual 0
material 0
. 0

The 0
duration 0
and 0
the 0
amplitude 0
of 0
the 0
negative 0
potential 0
were 0
greatest 0
for 0
completely 0
regenerating 0
ears 0
with 0
overgrowth 0
, 0
smaller 0
for 0
partially 0
regenerating 0
ears 0
, 0
and 0
smallest 0
for 0
the 0
nonregenerating 0
ears 0
. 0

Samples 0
obtained 0
from 0
normal 0
volunteers 0
and 0
from 0
the 0
great 0
majority 0
of 0
the 0
patients 0
, 0
excluding 0
those 0
with 0
asthma 0
, 0
had 0
no 0
effect 0
on 0
ciliary 0
beating 0
. 0

These 0
results 0
suggested 0
the 0
possibility 0
that 0
the 0
fetus 0
played 0
some 0
role 0
in 0
the 0
production 0
of 0
E3 0
- 0
16 0
- 0
G 0
in 0
early 0
pregnancy 0
. 0

In 0
this 0
way 0
it 0
is 0
possible 0
to 0
simulate 0
the 0
growth 0
function 0
of 0
the 0
embryofetal 0
curve 0
of 0
the 0
length 0
' 0
increase 0
of 0
man 0
and 0
the 0
curve 0
of 0
the 0
mass 0
' 0
increase 0
of 0
rat 0
. 0

The 0
highest 0
doses 0
were 0
found 0
for 0
drivers 0
who 0
transported 0
large 0
numbers 0
of 0
99Mo 0
generators 0
. 0

The 0
steepness 0
of 0
the 0
standard 0
O2 0
dissociation 0
curve 0
becomes 0
greater 0
during 0
the 0
training 0
period 0
( 0
increase 0
in 0
Hill 0
's 0
n 0
from 0
2.68 0
+/ 0
- 0
0.10 0
to 0
2.96 0
+/ 0
- 0
0.15 0
) 0
. 0

Conjugated 0
and 0
unconjugated 0
phenylacetic 0
acid 0
and 0
m 0
- 0
and 0
p 0
- 0
hydroxyphenylacetic 0
acid 0
have 0
been 0
determined 0
in 0
the 0
plasma 0
of 0
normal 0
, 0
healthy 0
subjects 0
after 0
fasting 0
, 0
consumption 0
of 0
a 0
meal 0
and 0
ingestion 0
of 0
deuterium 0
labelled 0
amine 0
precursors 0
, 0
by 0
high 0
- 0
resolution 0
gas 0
chromatography 0
- 0
- 0
high 0
resolution 0
mass 0
spectrometry 0
with 0
selected 0
ion 0
monitoring 0
of 0
their 0
trifluoroethyl 0
- 0
pentafluoropropionyl 0
derivatives 0
. 0

In 0
concept 0
II 0
62 0
patients 0
were 0
treated 0
with 0
selective 0
vagotomy 0
and 0
pyloroplasty 0
. 0

They 0
consisted 0
of 0
behavioural 0
disorders 0
, 0
tetraparesis 0
, 0
incontinence 0
and 0
oculomotor 0
paralysis 0
. 0

CSF 0
adenosine B-gene
deaminase I-gene
activity 0
( 0
ADA 0
) 0
was 0
measured 0
at 0
the 0
same 0
time 0
. 0

Histamine 0
reactivity 0
had 0
returned 0
to 0
normal 0
in 0
half 0
the 0
workers 0
who 0
had 0
left 0
their 0
original 0
factories 0
, 0
but 0
in 0
only 0
one 0
worker 0
who 0
had 0
moved 0
within 0
her 0
original 0
factory 0
. 0

It 0
was 0
also 0
found 0
that 0
there 0
is 0
no 0
significant 0
difference 0
between 0
the 0
prevalence 0
of 0
nasal 0
carriage 0
of 0
S. 0
aureus 0
amongst 0
the 0
hospital 0
staff 0
and 0
the 0
patients 0
. 0

Ficat 0
and 0
Bizou 0
's 0
condylar 0
depth 0
index 0
and 0
the 0
condylar 0
- 0
joint 0
surface 0
angle 0
of 0
Brattstrom 0
are 0
recommended 0
as 0
especially 0
suitable 0
methods 0
of 0
measurement 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
EF 0
between 0
the 0
two 0
studies 0
, 0
both 0
at 0
rest 0
( 0
56.0 0
+/ 0
- 0
13.8 0
% 0
vs 0
58.2 0
+/ 0
- 0
11.7 0
% 0
, 0
p 0
= 0
NS 0
) 0
and 0
with 0
exercise 0
( 0
51.1 0
+/ 0
- 0
17.6 0
% 0
vs 0
54.3 0
+/ 0
- 0
17.6 0
% 0
, 0
p 0
= 0
NS 0
) 0
and 0
a 0
highly 0
significant 0
correlation 0
was 0
shown 0
between 0
the 0
two 0
groups 0
of 0
values 0
( 0
rest 0
r 0
= 0
0.90 0
, 0
exercise 0
r 0
= 0
0.93 0
, 0
p 0
less 0
than 0
0.001 0
) 0
. 0

After 0
MOPP 0
therapy 0
, 0
complete 0
remission 0
of 0
Hodgkin 0
's 0
disease 0
was 0
accompanied 0
by 0
normalization 0
of 0
the 0
glucocerebrosidase B-gene
level 0
and 0
disappearance 0
of 0
Gaucher 0
's 0
cells 0
. 0

Specifically 0
, 0
by 0
the 0
type 0
of 0
adjuvant 0
therapy 0
, 0
the 0
median 0
disease 0
- 0
free 0
interval 0
and 0
survival 0
from 0
stage 0
IVA 0
for 0
23 0
patients 0
receiving 0
Corynebacterium 0
parvum 0
were 0
6.9 0
and 0
19 0
months 0
; 0
for 0
39 0
patients 0
receiving 0
BCG 0
, 0
eight 0
months 0
and 0
26 0
months 0
; 0
for 0
24 0
patients 0
receiving 0
BCG 0
+ 0
DTIC 0
, 0
eight 0
and 0
17.4 0
months 0
; 0
and 0
for 0
all 0
51 0
DTIC 0
treated 0
patients 0
6.3 0
and 0
17.8 0
months 0
, 0
respectively 0
. 0

The 0
COP 0
- 0
PAWP 0
gradient 0
was 0
markedly 0
decreased 0
in 0
both 0
shock 0
and 0
non 0
- 0
shock 0
patients 0
with 0
pulmonary 0
edema 0
. 0

Re 0
: 0
A 0
modified 0
method 0
for 0
the 0
in 0
vivo 0
labeling 0
of 0
red 0
blood 0
cells 0
with 0
Tc 0
- 0
99m 0
. 0

A 0
limited 0
study 0
in 0
a 0
glassware 0
factory 0
( 0
As2O3 0
exposure 0
) 0
involving 0
the 0
measurement 0
of 0
total 0
airborne 0
arsenic 0
, 0
the 0
determination 0
of 0
urinary 0
arsenic 0
, 0
and 0
the 0
evaluation 0
of 0
hand 0
and 0
mouth 0
contamination 0
by 0
arsenic 0
before 0
and 0
after 0
the 0
workshift 0
suggests 0
that 0
the 0
high 0
urinary 0
arsenic 0
levels 0
( 0
300 0
microgram/g 0
creatinine 0
) 0
are 0
likely 0
to 0
be 0
more 0
related 0
to 0
an 0
increased 0
oral 0
intake 0
from 0
contaminated 0
hands 0
than 0
to 0
an 0
increased 0
absorption 0
from 0
the 0
lungs 0
. 0

Parasitological 0
and 0
pathological 0
findings 0
in 0
capuchin 0
monkeys 0
infected 0
with 0
Schistosoma 0
japonicum 0
or 0
Schistosoma 0
mansoni 0
. 0

The 0
pia 0
mater 0
at 0
the 0
site 0
of 0
the 0
entry 0
of 0
blood 0
vessels 0
into 0
the 0
central 0
nervous 0
system 0
. 0

Experimental 0
reproduction 0
of 0
malignant 0
catarrhal 0
fever 0
in 0
Bali 0
cattle 0

1 0
A 0
colonic 0
delivery 0
system 0
is 0
described 0
to 0
deliver 0
orally 0
ingested 0
drugs 0
to 0
the 0
colon 0
and 0
release 0
them 0
at 0
that 0
site 0
by 0
coating 0
with 0
an 0
acrylic 0
based 0
resin 0
( 0
Eudragit 0
S 0
) 0
. 0

Administration 0
of 0
the 0
dopamine 0
agonist 0
bromocriptine 0
( 0
2.5 0
mg 0
three 0
times 0
a 0
day 0
for 0
4 0
days 0
) 0
suppressed 0
( 0
P 0
less 0
than 0
0.01 0
) 0
mean 0
24 0
- 0
h 0
plasma 0
18 0
- 0
OHB 0
levels 0
from 0
21.9 0
+/ 0
- 0
2.0 0
to 0
14.8 0
+/ 0
- 0
1.4 0
ng/dl 0
. 0

Restarting 0
time 0
was 0
not 0
affected 0
by 0
magnesium 0
cardioplegia 0
. 0

The 0
most 0
common 0
types 0
of 0
malformations 0
were 0
eye 0
defects 0
and 0
open 0
coeloms 0
. 0

Repair 0
of 0
a 0
cosmetic 0
defect 0
of 0
the 0
lower 0
leg 0
with 0
a 0
myocutaneous 0
free 0
flap 0
. 0

According 0
to 0
the 0
literature 0
, 0
second 0
malignant 0
epithelial 0
tumours 0
are 0
, 0
in 0
contrast 0
to 0
mesenchymal 0
tumours 0
such 0
as 0
osteosarcoma 0
, 0
very 0
rare 0
in 0
retinoblastoma 0
survivors 0
. 0

In 0
Malmo 0
, 0
Sweden 0
, 0
17,181 0
school 0
children 0
born 0
in 0
the 0
years 0
1961 0
- 0
1965 0
were 0
screened 0
for 0
scoliosis 0
once 0
a 0
year 0
between 0
the 0
ages 0
of 0
7 0
and 0
16 0
years 0
, 0
during 0
1971 0
- 0
1980 0
. 0

In 0
the 0
past 0
, 0
immunology 0
in 0
Singapore 0
was 0
mainly 0
confined 0
to 0
serology 0
for 0
the 0
diagnosis 0
of 0
certain 0
infectious 0
diseases 0
. 0

Intra 0
- 0
articular 0
dislocation 0
of 0
the 0
patella 0
. 0

This 0
study 0
demonstrates 0
secretion 0
of 0
bicarbonate 0
by 0
the 0
human 0
stomach 0
in 0
vivo 0
at 0
a 0
rate 0
equivalent 0
to 0
10 0
- 0
- 0
20 0
% 0
of 0
basal 0
acid 0
secretion 0
. 0

Histological 0
evaluation 0
revealed 0
a 0
more 0
than 0
twofold 0
increase 0
in 0
the 0
number 0
of 0
interepithelial 0
mononuclear 0
cells 0
( 0
p 0
less 0
than 0
0.005 0
) 0
, 0
while 0
the 0
number 0
of 0
epithelial 0
cells/100 0
microns 0
of 0
villous 0
mucosa 0
and 0
the 0
mean 0
height 0
of 0
the 0
epithelial 0
cells 0
were 0
comparable 0
in 0
both 0
groups 0
. 0

Cramps 0
in 0
extrapyramidal 0
disorders 0
. 0

A 0
suspected 0
new 0
storage 0
disease 0
in 0
cattle 0
. 0

For 0
various 0
dog 0
vessels 0
in 0
vivo 0
, 0
Q/Dk 0
ranged 0
from 0
0.15 0
to 0
47 0
X 0
10 0
( 0
5 0
) 0
Torr/cm2 0
. 0

The 0
tetraphasic 0
action 0
of 0
lidocaine 0
on 0
CNS 0
electrical 0
activity 0
and 0
behavior 0
in 0
cats 0
. 0

Modification 0
of 0
enteral 0
resorption 0
by 0
cytostatic 0
therapy 0

Asymptomatic 0
bacteriospermia 0
and 0
fertility 0

Triumph 0
of 0
Leninist 0
national 0
policy 0

The 0
favourable 0
effect 0
of 0
thymic 0
shielding 0
was 0
also 0
reflected 0
in 0
a 0
significant 0
increase 0
of 0
LD50/30 0
, 0
and 0
the 0
dose 0
reduction 0
factor 0
was 0
equal 0
to 0
2 0
. 0

The 0
application 0
of 0
ultrafiltration 0
to 0
sample 0
preparation 0
in 0
the 0
detection 0
and 0
quantification 0
of 0
ethylene 0
glycol 0
in 0
plasma 0
by 0
gas 0
chromatography 0
is 0
described 0
. 0

Mastocytosis 0
. 0

A 0
new 0
Onchocerca 0
species 0
, 0
a 0
parasite 0
of 0
domestic 0
cattle 0
, 0
in 0
Senegal 0

It 0
was 0
suggested 0
that 0
the 0
absence 0
of 0
pronounced 0
differences 0
between 0
conditions 0
may 0
have 0
been 0
due 0
to 0
the 0
complexity 0
of 0
the 0
task 0
or 0
the 0
type 0
of 0
prompts 0
employed 0
. 0

A 0
limiting 0
factor 0
were 0
disturbances 0
in 0
the 0
system 0
of 0
energy 0
transport 0
( 0
creatine 0
phosphate 0
, 0
creatine B-gene
phosphokinase I-gene
) 0
and 0
of 0
the 0
calcium 0
pump 0
( 0
Ca++ B-gene
- I-gene
ATPase I-gene
of 0
the 0
sarcoplasmic 0
reticulum 0
, 0
SPR 0
) 0
, 0
which 0
evidently 0
led 0
to 0
a 0
decrease 0
of 0
the 0
inotropic 0
properties 0
of 0
the 0
myocardium 0
at 0
70 0
% 0
restriction 0
of 0
coronary 0
blood 0
flow 0
. 0

In 0
vitro 0
penetration 0
tests 0
of 0
human 0
sperm 0
into 0
cervical 0
mucus 0
were 0
introduced 0
in 0
order 0
to 0
study 0
the 0
interaction 0
between 0
sperm 0
and 0
cervical 0
mucus 0
. 0

Vibrio 0
fluvialis 0
( 0
group 0
F 0
vibrio 0
) 0
in 0
Maharashtra 0
. 0

Serum B-gene
creatine I-gene
kinase I-gene
( 0
SCK B-gene
) 0
was 0
measured 0
in 0
ten 0
subjects 0
in 0
the 0
laboratory 0
before 0
and 0
after 0
the 0
performance 0
of 0
bicycle 0
ergometry 0
and 0
a 0
lifting 0
task 0
. 0

Organisms 0
were 0
not 0
observed 0
in 0
the 0
5 0
bobcats 0
trapped 0
in 0
2 0
other 0
counties 0
. 0

The 0
cause 0
of 0
death 0
is 0
often 0
quite 0
apparent 0
from 0
the 0
pathological 0
and 0
toxicological 0
findings 0
; 0
however 0
, 0
the 0
manner 0
of 0
death 0
often 0
gives 0
the 0
examining 0
official 0
some 0
difficulty 0
. 0

The 0
average 0
annual 0
cost 0
per 0
head 0
of 0
population 0
was 0
US+0 0
X 0
46 0
. 0

It 0
is 0
postulated 0
that 0
altered 0
blood 0
flow 0
, 0
mediated 0
through 0
the 0
well 0
- 0
known 0
prostaglandin B-gene
synthetase I-gene
inhibitory 0
effects 0
of 0
ibuprofen 0
, 0
resulted 0
in 0
tubular 0
necrosis 0
. 0

Either 0
20 0
mg 0
mitomycin/20 0
ml 0
distilled 0
water 0
or 0
40 0
mg/40 0
ml 0
distilled 0
water 0
was 0
locally 0
instilled 0
into 0
the 0
bladder 0
with 0
a 0
catheter 0
after 0
emptying 0
it 0
and 0
was 0
left 0
for 0
about 0
25 0
- 0
l20 0
min 0
. 0

Both 0
groups 0
rejected 0
pops 0
with 0
added 0
SOA 0
, 0
decreasing 0
mouthing 0
times 0
as 0
SOA 0
concentration 0
increased 0
. 0

The 0
mean 0
extracted 0
concentration 0
of 0
flucloxacillin 0
obtained 0
at 0
operation 0
was 0
12.9 0
micrograms/ml 0
( 0
SD 0
5.25 0
) 0
in 0
synovial 0
fluid 0
; 0
2.9 0
micrograms/g 0
( 0
SD 0
3.59 0
) 0
in 0
synovium 0
; 0
2.0 0
micrograms/g 0
( 0
SD 0
1.48 0
) 0
in 0
cancellous 0
bone 0
and 0
1.3 0
micrograms/g 0
( 0
SD 0
1.25 0
) 0
in 0
cortical 0
bone 0
. 0

A 0
preliminary 0
study 0
of 0
vincristine 0
, 0
methotrexate 0
, 0
and 0
prednisolone 0
( 0
VM*P 0
) 0
combination 0
chemotherapy 0
for 0
advanced 0
adult 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0

Lacrimal 0
secretion 0
in 0
hyperthyroidism 0

Re 0
- 0
examination 0
of 0
the 0
ED01 0
study 0
. 0

Based 0
on 0
213 0
determinations 0
, 0
the 0
control 0
mean 0
serum B-gene
CPK I-gene
activity 0
was 0
262 0
+/ 0
- 0
113 0
I.U./liter 0
. 0

A 0
further 0
study 0
on 0
plasminogen B-gene
activator I-gene
release 0
by 0
vasoactive 0
agents 0
in 0
the 0
isolated 0
perfused 0
dog 0
leg 0
. 0

CDDP 0
is 0
active 0
as 0
a 0
single 0
agent 0
in 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
. 0

Treatment 0
of 0
meat 0
muscle 0
800 0
V 0
for 0
45 0
s 0
reduced 0
weeping 0
but 0
increased 0
slightly 0
the 0
rate 0
of 0
autoxidation 0
of 0
lipids 0
. 0

The 0
hormonal 0
response 0
to 0
a 0
standardized 0
bicycle 0
exercise 0
test 0
was 0
studied 0
in 0
11 0
male 0
cadets 0
exposed 0
to 0
a 0
course 0
of 0
107 0
h 0
of 0
continuous 0
activity 0
with 0
less 0
than 0
2 0
h 0
sleep 0
. 0

At 0
an 0
ambient 0
temperature 0
of 0
25 0
degrees 0
C 0
, 0
the 0
responses 0
to 0
spinal 0
cooling 0
are 0
reduced 0
during 0
the 0
dark 0
phase 0
. 0

A 0
method 0
for 0
determining 0
cumulative 0
behavioral 0
toxicity 0
after 0
chronic 0
oral 0
administration 0
of 0
l 0
- 0
alpha 0
- 0
acetylmethadol 0
to 0
female 0
rats 0
. 0

After 0
successful 0
subtotal 0
parathyroidectomy 0
, 0
evident 0
by 0
the 0
decrease 0
of 0
serum 0
iPTH B-gene
levels 0
, 0
both 0
the 0
CL 0
of 0
group 0
2 0
PMNs 0
and 0
the 0
ability 0
of 0
group 0
2 0
sera 0
to 0
induce 0
augmented 0
CL 0
in 0
normal 0
PMNs 0
decreased 0
( 0
p 0
< 0
0.025 0
) 0
. 0

TCZ 0
provides 0
quick 0
, 0
inexpensive 0
, 0
noninvasive 0
indication 0
of 0
tissue 0
necrosis 0
, 0
moderate 0
- 0
to 0
- 0
severe 0
intracranial 0
hemorrhage 0
, 0
and 0
delayed 0
brain 0
maturation 0
. 0

The 0
number 0
of 0
muricidal 0
rats 0
increased 0
with 0
increase 0
in 0
the 0
duration 0
of 0
Cd 0
administration 0
in 0
association 0
with 0
greater 0
accumulation 0
of 0
Cd 0
in 0
the 0
olfactory 0
bulb 0
than 0
in 0
any 0
other 0
region 0
of 0
the 0
brain 0
. 0

This 0
test 0
should 0
provide 0
another 0
practical 0
means 0
to 0
study 0
leprosy 0
. 0

The 0
preferences 0
were 0
for 0
intact 0
vis 0
- 0
a 0
- 0
vis 0
castrated 0
males 0
, 0
though 0
injections 0
of 0
TP 0
restored 0
the 0
castrates 0
' 0
attractiveness 0
to 0
the 0
females 0
. 0

Each 0
trial 0
consisted 0
of 0
light 0
and 0
buzzer 0
for 0
five 0
seconds 0
as 0
conditioned 0
stimuli 0
and 0
electric 0
shock 0
for 0
five 0
seconds 0
as 0
an 0
unconditioned 0
stimulus 0
. 0

Ulcer 0
appeared 0
on 0
the 0
angulus 0
of 0
the 0
stomach 0
at 0
the 0
28th 0
week 0
and 0
resulted 0
in 0
ulcer 0
scar 0
at 0
the 0
42nd 0
week 0
. 0

Family 0
visits 0
and 0
involvement 0
in 0
treatment 0
of 0
patients 0
at 0
a 0
state 0
hospital 0
. 0

A 0
transparent 0
overlay 0
for 0
assessing 0
amplitude 0
of 0
ECG 0
wave 0
forms 0
. 0

Adverse 0
reaction 0
of 0
the 0
apparently 0
healthy 0
partner 0
in 0
response 0
to 0
improvement 0
in 0
the 0
overtly 0
dysfunctional 0
partner 0
. 0

Brain 0
scan 0
with 0
99mTc 0
- 0
labelled 0
macroaggregated B-gene
albumin I-gene
( 0
MAA B-gene
brain 0
scan 0
) 0
and 0
computed 0
tomography 0
studies 0
( 0
CT 0
) 0
were 0
performed 0
on 0
78 0
patients 0
with 0
intracranial 0
diseases 0
. 0

Inhibition 0
of 0
Fusarium 0
moniliforme 0
var 0
. 0
subglutinans 0
, 0
the 0
causal 0
agent 0
of 0
pine 0
pitch 0
canker 0
, 0
by 0
the 0
soil 0
bacterium 0
Arthrobacter 0
sp 0
. 0

The 0
five 0
- 0
drug 0
combination 0
of 0
fluorouracil 0
imidazole 0
carboxamide 0
dimethyl 0
triazeno 0
, 0
vincristine 0
, 0
bis 0
- 0
chloroethyl 0
nitrosourea 0
, 0
and 0
prednisone 0
( 0
FIVB 0
+ 0
P 0
) 0
was 0
given 0
to 0
120 0
women 0
with 0
metastatic 0
breast 0
cancer 0
. 0

A 0
method 0
is 0
described 0
for 0
the 0
simultaneous 0
determination 0
of 0
1 0
, 0
alpha 0
- 0
acetylmethadol 0
( 0
LAAM 0
) 0
and 0
five 0
active 0
metabolites 0
- 0
- 0
noracetylmethadol 0
, 0
dinoracetylmethadol 0
, 0
methadol 0
, 0
normethadol 0
, 0
and 0
dinormethadol 0
- 0
- 0
in 0
biofluids 0
by 0
high 0
- 0
performance 0
liquid 0
chromatography 0
using 0
a 0
normal 0
- 0
phase 0
column 0
and 0
a 0
UV 0
detector 0
at 0
218 0
nm 0
. 0

Results 0
of 0
the 0
recognition 0
task 0
revealed 0
significant 0
effects 0
of 0
consonant 0
voicing 0
, 0
position 0
and 0
vowel 0
context 0
on 0
syllable 0
recognition 0
. 0

Visual 0
response 0
properties 0
of 0
neurons 0
in 0
four 0
extrastriate 0
visual 0
areas 0
of 0
the 0
owl 0
monkey 0
( 0
Aotus 0
trivirgatus 0
) 0
: 0
a 0
quantitative 0
comparison 0
of 0
medial 0
, 0
dorsomedial 0
, 0
dorsolateral 0
, 0
and 0
middle 0
temporal 0
areas 0
. 0

A 0
unified 0
approach 0
to 0
the 0
standardization 0
of 0
allergens 0
. 0

Clinical 0
and 0
anatomical 0
considerations 0

A 0
dose 0
- 0
dependent 0
fall 0
in 0
GABA 0
content 0
was 0
observed 0
; 0
GABA 0
decrease 0
was 0
evident 0
15 0
min 0
after 0
the 0
administration 0
, 0
reached 0
its 0
nadir 0
at 0
60 0
min 0
and 0
disappeared 0
at 0
120 0
minutes 0
. 0

Theory 0
and 0
applications 0
of 0
pulse 0
dosing 0
: 0
a 0
summary 0
of 0
the 0
symposium 0
. 0

These 0
results 0
show 0
that 0
the 0
neonate 0
differs 0
from 0
the 0
adult 0
in 0
respect 0
of 0
both 0
the 0
nature 0
of 0
effects 0
of 0
the 0
drug 0
and 0
sensitivity 0
to 0
it 0
. 0

To 0
evaluate 0
the 0
gas 0
chromatographic 0
electron 0
capture 0
detection 0
method 0
described 0
earlier 0
, 0
23 0
plasma 0
samples 0
have 0
been 0
analysed 0
by 0
both 0
techniques 0
. 0

The 0
hemodynamics 0
of 0
isoproterenol 0
- 0
induced 0
cardiac 0
failure 0
in 0
the 0
rat 0
. 0

Several 0
authors 0
have 0
recently 0
reported 0
interference 0
in 0
theophylline 0
analysis 0
by 0
paraxanthine 0
( 0
1,7 0
- 0
dimethylxanthine 0
) 0
, 0
an 0
important 0
metabolite 0
of 0
caffeine 0
. 0

Multi 0
drug 0
regimens 0
like 0
C 0
- 0
MOPP 0
, 0
CHOP 0
and 0
BACOP 0
led 0
to 0
high 0
remission 0
rates 0
and 0
in 0
some 0
cases 0
probably 0
also 0
to 0
a 0
cure 0
of 0
the 0
disease 0
. 0

For 0
monocytes 0
, 0
as 0
measured 0
on 0
the 0
Hematrak 0
, 0
it 0
was 0
13.4 0
% 0
. 0

Morphological 0
features 0
of 0
Jat 0
dentition 0
. 0

Clinical 0
accuracy 0
of 0
updated 0
version 0
of 0
the 0
Phadebas 0
RAST 0
test 0
. 0

Five 0
control 0
subjects 0
with 0
COPD 0
, 0
who 0
performed 0
the 0
same 0
sequence 0
of 0
tests 0
without 0
breathing 0
30 0
% 0
O2 0
, 0
showed 0
no 0
change 0
in 0
flow 0
rates 0
or 0
density 0
dependence 0
. 0

Following 0
extended 0
recovery 0
hippocampal 0
EEG 0
was 0
normal 0
despite 0
extensive 0
cellular 0
loss 0
in 0
areas 0
CA3 0
and 0
CA4 0
. 0

Evoked 0
potential 0
and 0
single 0
unit 0
responses 0
to 0
olfactory 0
nerve 0
volleys 0
in 0
the 0
isolated 0
turtle 0
olfactory 0
bulb 0
. 0

While 0
all 0
deletions 0
within 0
the 0
sequence 0
coding 0
for 0
the 0
mature 0
tRNA 0
led 0
to 0
inactivity 0
of 0
the 0
mutated 0
genes 0
, 0
substitution 0
of 0
the 0
central 0
portion 0
by 0
concatenated B-gene
Hind I-gene
III I-gene
linkers I-gene
produced 0
gene 0
units 0
active 0
in 0
transcription 0
. 0

Cross 0
reactivity 0
in 0
theophylline 0
RIA 0
kit 0
decreased 0
. 0

Strontium 0
- 0
90 0
was 0
inject 0
i.v 0
. 0
into 0
pregnant 0
rats 0
on 0
day 0
18 0
post 0
conception 0
( 0
p.c 0
. 0
) 0
. 0

Recording 0
of 0
the 0
digital 0
sphygmic 0
activity 0
in 0
the 0
lower 0
extremities 0
with 0
the 0
photoplethysmographic 0
and 0
strain 0
- 0
gauge 0
methods 0
. 0

Eight 0
hr 0
of 0
acidosis 0
caused 0
a 0
significant 0
( 0
P 0
less 0
than 0
0.01 0
) 0
decrease 0
in 0
P50 0
in 0
vitro 0
which 0
fell 0
from 0
29.0 0
to 0
24.4 0
torr 0
. 0

Catheter 0
transit 0
slows 0
the 0
response 0
to 0
a 0
step 0
increase 0
in 0
concentration 0
by 0
about 0
0.13 0
s 0
( 0
from 0
10 0
per 0
cent 0
- 0
90 0
per 0
cent 0
) 0
and 0
prolongs 0
the 0
transit 0
time 0
through 0
the 0
catheter 0
for 0
a 0
volatile 0
anesthetic 0
by 0
about 0
0.04 0
s 0
more 0
than 0
N2 0
. 0

These 0
women 0
should 0
not 0
be 0
given 0
the 0
current 0
estrogen 0
PPI 0
, 0
which 0
was 0
designed 0
to 0
warn 0
women 0
of 0
the 0
risks 0
of 0
long 0
- 0
term 0
estrogen 0
use 0
; 0
a 0
PPI 0
should 0
be 0
written 0
specifically 0
for 0
patients 0
receiving 0
short 0
courses 0
. 0

The 0
oral 0
temperature 0
rose 0
and 0
the 0
serum B-gene
creatine I-gene
kinase I-gene
levels 0
fell 0
only 0
in 0
those 0
patients 0
who 0
were 0
actively 0
warmed 0
. 0

Determination 0
of 0
aortic 0
distensibility 0
and 0
its 0
variations 0
in 0
arterial 0
hypertension 0
. 0

We 0
studied 0
the 0
role 0
of 0
prostaglandins 0
in 0
acid 0
- 0
induced 0
esophagitis 0
and 0
the 0
associated 0
LES 0
hypotension 0
by 0
simultaneous 0
treatment 0
of 0
some 0
animals 0
with 0
indomethacin 0
( 0
150 0
micrograms/kg 0
intravenous 0
) 0
, 0
a 0
specific 0
inhibitor 0
of 0
prostaglandin 0
synthesis 0
, 0
either 0
during 0
production 0
of 0
esophagitis 0
or 0
during 0
recovery 0
. 0

Since 0
only 0
58 0
% 0
of 0
our 0
sample 0
could 0
be 0
adequately 0
classified 0
with 0
one 0
diagnosis 0
, 0
we 0
expect 0
that 0
the 0
ASDC 0
nosology 0
will 0
need 0
to 0
evolve 0
further 0
. 0

A 0
surgical 0
technique 0
for 0
correcting 0
this 0
problem 0
is 0
described 0
. 0

Effects 0
of 0
prostaglandin 0
inhibitors 0
on 0
the 0
onset 0
of 0
proteinuria 0
and 0
stroke 0
in 0
stroke 0
- 0
prone 0
spontaneously 0
hypertensive 0
rats 0
. 0

In 0
this 0
study 0
, 0
the 0
general 0
clinical 0
criteria 0
for 0
inhalation 0
injury 0
- 0
- 0
presence 0
of 0
facial 0
or 0
oropharyngeal 0
burns 0
, 0
carboxyhemoglobin B-gene
levels 0
, 0
carbonaceous 0
sputum 0
, 0
or 0
closed 0
space 0
injury 0
- 0
- 0
did 0
not 0
differentiate 0
patients 0
with 0
airway 0
injury 0
only 0
from 0
those 0
with 0
parenchymal 0
injury 0
. 0

Survival 0
was 0
calculated 0
both 0
from 0
the 0
date 0
of 0
onset 0
and 0
from 0
the 0
date 0
of 0
diagnosis 0
. 0

Methisergide 0
( 0
0.5 0
mg/kg 0
, 0
i.p 0
. 0
) 0
, 0
a 0
blocker 0
of 0
serotonin B-gene
receptors I-gene
, 0
prevented 0
the 0
development 0
of 0
the 0
antinociceptive 0
effect 0
of 0
serotonin 0
. 0

The 0
plasma 0
half 0
- 0
life 0
of 0
slow 0
disposition 0
phase 0
t1/2 0
beta 0
, 0
increases 0
from 0
0.26 0
hour 0
in 0
rabbits 0
with 0
normal 0
renal 0
function 0
to 0
5.41 0
hours 0
in 0
rabbits 0
with 0
severe 0
renal 0
impairment 0
. 0

Effects 0
of 0
early 0
monocular 0
deprivation 0
on 0
development 0
of 0
cortico 0
- 0
geniculate 0
projections 0
in 0
the 0
cat 0
. 0

Corticosteroid 0
therapy 0
is 0
known 0
to 0
be 0
hazardous 0
in 0
patients 0
with 0
occult 0
infection 0
but 0
the 0
mechanism 0
by 0
which 0
the 0
host 0
parasite 0
relationship 0
is 0
altered 0
by 0
steroids 0
is 0
not 0
known.We 0
have 0
used 0
an 0
intestinal 0
protozoal 0
parasite 0
, 0
Giardia 0
muris 0
, 0
to 0
examine 0
the 0
effects 0
of 0
corticosteroids 0
on 0
the 0
number 0
of 0
parasites 0
in 0
the 0
intestine 0
in 0
the 0
course 0
of 0
a 0
primary 0
infection 0
. 0

Static 0
lung 0
function 0
in 0
puppies 0
after 0
pneumonectomy 0
. 0

With 0
Sair 0
and 0
So2 0
, 0
mean 0
vital 0
capacity 0
was 0
reduced 0
by 0
44 0
% 0
from 0
control 0
. 0

Bilateral 0
Charnley 0
arthroplasty 0
as 0
a 0
single 0
procedure 0
. 0

Of 0
the 0
117 0
patients 0
( 0
out 0
of 0
the 0
136 0
) 0
with 0
serologic 0
evidence 0
of 0
chronic 0
thyroiditis 0
who 0
could 0
be 0
studied 0
, 0
eight 0
( 0
7 0
% 0
) 0
had 0
hyperthyroidism 0
and 0
45 0
( 0
38 0
% 0
) 0
were 0
hypothyroid 0
. 0

The 0
relationship 0
between 0
estrogenic 0
properties 0
of 0
Tamoxifen 0
and 0
breast 0
cancer 0
management 0
is 0
discussed 0
. 0

The 0
new 0
semi 0
- 0
synthetic 0
oral 0
cephalosporin 0
, 0
CGP 0
9,000 0
, 0
has 0
been 0
evaluated 0
in 0
a 0
large 0
number 0
of 0
hospitalized 0
patients 0
with 0
urinary 0
infections 0
. 0

A 0
fluoroimmunoassay 0
for 0
the 0
determination 0
of 0
serum 0
of 0
plasma 0
levels 0
of 0
propranolol 0
was 0
developed 0
using 0
antibodies 0
to 0
propranolol 0
coupled 0
to 0
magnetizable 0
solid 0
- 0
phase 0
particles 0
and 0
fluorescein 0
- 0
labeled 0
propranolol 0
as 0
tracer 0
. 0

The 0
syncytial 0
microvillous 0
projections 0
seemed 0
to 0
be 0
more 0
numerous 0
and 0
longer 0
in 0
CNF 0
, 0
otherwise 0
the 0
structure 0
of 0
the 0
trophoblastic 0
layer 0
of 0
the 0
villi 0
and 0
the 0
lining 0
of 0
the 0
subtrophoblastic 0
vessels 0
were 0
identical 0
in 0
CNF 0
and 0
controls 0
. 0

When 0
pollen 0
allergen 0
from 0
three 0
grass 0
species 0
were 0
used 0
, 0
The 0
RAST 0
- 0
test 0
results 0
did 0
not 0
differ 0
from 0
duplicate 0
values 0
either 0
. 0

DMI 0
and 0
2 0
- 0
OH 0
- 0
DMI 0
concentrations 0
were 0
determined 0
in 0
a 0
similar 0
group 0
of 0
61 0
DMI 0
- 0
treated 0
patients 0
. 0

It 0
has 0
been 0
shown 0
in 0
experiments 0
in 0
vitro 0
that 0
the 0
hepatotrophic 0
organic 0
anions 0
, 0
the 0
radiographic 0
contrast 0
agent 0
( 0
RCA 0
) 0
bilignost 0
used 0
in 0
cholecystography 0
and 0
Bengal 0
pink 0
, 0
have 0
an 0
affinity 0
, 0
unlike 0
the 0
urographic 0
RCA 0
triombrin 0
and 0
renotrophic 0
dye 0
indigo 0
- 0
carmine 0
, 0
for 0
the 0
plasmatic 0
membranes 0
( 0
PM 0
) 0
of 0
liver 0
cells 0
. 0

33 0
out 0
of 0
90 0
neurons 0
of 0
the 0
cat 0
medial 0
geniculate 0
body 0
revealed 0
the 0
selectivity 0
of 0
their 0
afterdischarges 0
to 0
movement 0
of 0
sound 0
when 0
velocity 0
of 0
the 0
movement 0
changed 0
from 0
30 0
to 0
180 0
deg/s 0
. 0

In 0
controls 0
, 0
only 0
modest 0
differences 0
were 0
observed 0
. 0

Assay 0
of 0
serum B-gene
immunoreactive I-gene
trypsin I-gene
in 0
dried 0
blood 0
spots 0
and 0
the 0
early 0
detection 0
of 0
cystic 0
fibrosis 0
. 0

Similar 0
waves 0
were 0
seen 0
on 0
cross 0
- 0
correlating 0
a 0
motor 0
unit 0
with 0
an 0
electronic 0
oscillator 0
, 0
confirming 0
that 0
their 0
occurrence 0
does 0
not 0
necessarily 0
demonstrate 0
the 0
existence 0
of 0
active 0
neural 0
interactions 0
. 0

Leukocyte 0
enzyme 0
activity 0
and 0
blood 0
lymphocyte 0
blast 0
transformation 0
in 0
chronic 0
bronchitis 0

Current 0
status 0
of 0
chemotherapy 0
for 0
Hodgkin 0
's 0
disease 0

In 0
literature 0
, 0
the 0
HBE 0
has 0
been 0
displayed 0
by 0
application 0
of 0
the 0
averaging 0
method 0
. 0

Forty 0
- 0
five 0
cases 0
were 0
surgically 0
by 0
direct 0
approach 0
to 0
the 0
tumour 0
, 0
while 0
two 0
cases 0
were 0
treated 0
only 0
with 0
a 0
shunt 0
. 0

In 0
Group 0
V 0
, 0
the 0
salvaged 0
tissue 0
was 0
primarily 0
subepicardial 0
with 0
virtually 0
no 0
lateral 0
zone 0
of 0
salvaged 0
tissue 0
( 0
ratio 0
of 0
salvaged 0
subepicardium 0
to 0
salvaged 0
subendocardium 0
14.8 0
+/ 0
- 0
1.9 0
to 0
1 0
) 0
. 0

Progressive 0
100 0
- 0
mmHg 0
stepwise 0
decreases 0
in 0
superfusate 0
oxygen 0
partial 0
pressure 0
( 0
PO2 0
) 0
from 0
control 0
( 0
95 0
% 0
O2 0
aeration 0
, 0
PO2 0
, 0
620 0
- 0
650 0
mmHg 0
) 0
were 0
produced 0
, 0
and 0
subsequent 0
changes 0
in 0
isometric 0
active 0
and 0
resting 0
tension 0
were 0
measured 0
. 0

The 0
known 0
B1 0
- 0
deficiency 0
reaches 0
excessive 0
high 0
values 0
with 0
light 0
exercise 0
. 0

Based 0
on 0
AUC 0
infinity 0
analyses 0
, 0
the 0
pharmacokinetics 0
of 0
buflomedil 0
were 0
found 0
to 0
be 0
linear 0
within 0
the 0
dose 0
ranges 0
studied 0
( 0
50 0
to 0
200 0
mg 0
for 0
i. 0
v. 0
injection 0
and 0
150 0
to 0
450 0
mg 0
for 0
oral 0
administration 0
) 0
. 0

Gastrin B-gene
secretion 0
during 0
food 0
stimulation 0
in 0
digestive 0
system 0
diseases 0

Fibrinogen B-gene
determination 0
using 0
the 0
KZM 0
- 0
1 0
meter 0

Over 0
a 0
period 0
of 0
15 0
days 0
16 0
% 0
of 0
the 0
dose 0
administered 0
was 0
excreted 0
with 0
faeces 0
and 0
0.9 0
% 0
in 0
the 0
urine 0
. 0

Delayed 0
or 0
paradoxically 0
emptying 0
regions 0
of 0
the 0
left 0
ventricle 0
were 0
detected 0
by 0
a 0
relatively 0
new 0
nuclear 0
technique 0
- 0
- 0
phase 0
imaging 0
. 0

Responses 0
to 0
brainstem 0
of 0
nuclei 0
medialis 0
dorsalis 0
, 0
lateralis 0
posterior 0
were 0
of 0
considerably 0
longer 0
latency 0
. 0

Nineteen 0
patients 0
with 0
non 0
- 0
visualized 0
gallbladder 0
with 0
OCG 0
subsequently 0
had 0
Tc 0
- 0
99m 0
- 0
PyG 0
cholescintigraphy 0
performed 0
. 0

One 0
was 0
allowed 0
fresh 0
drinking 0
water 0
ad 0
libitum 0
whilst 0
the 0
other 0
received 0
Aludrox 0
in 0
their 0
drinking 0
water 0
. 0

Anamnestic 0
data 0
were 0
obtained 0
from 0
case 0
history 0
, 0
smoking 0
habits 0
were 0
not 0
known 0
in 0
collective 0
A 0
and 0
C 0
. 0

The 0
determination 0
of 0
physical 0
performance 0
capacity 0
was 0
based 0
on 0
W170 0
, 0
W85 0
% 0
and 0
on 0
predicted 0
VO2 0
max 0
measured 0
with 0
continuously 0
increasing 0
work 0
load 0
on 0
a 0
bicycle 0
ergometer 0
. 0

Determination 0
of 0
lead 0
in 0
blood 0
. 0

Effect 0
of 0
indomethacin 0
and 0
prostaglandin 0
F2 0
alpha 0
on 0
parturition 0
in 0
swine 0
. 0

LD50 0
values 0
of 0
terms 0
of 0
KP 0
were 0
84 0
mg/kg 0
in 0
male 0
rats 0
and 0
122 0
mg/kg 0
in 0
female 0
rats 0
when 0
KP 0
- 0
CMC 0
was 0
administered 0
intrarectally 0
, 0
and 0
117 0
mg/kg 0
in 0
male 0
and 0
92 0
mg/kg 0
in 0
female 0
when 0
KP 0
- 0
T10 0
was 0
administered 0
intrarectally. 0
, 0
while 0
peroral 0
administration 0
of 0
KP 0
- 0
CMC 0
showed 0
LD50 0
values 0
of 0
68 0
mg/kg 0
in 0
males 0
and 0
78 0
mg/kg 0
in 0
females 0
in 0
terms 0
of 0
KP 0
. 0

Autotransfusion 0
was 0
performed 0
as 0
follows 0
: 0
Heparin 0
- 0
ACD 0
- 0
B 0
- 0
Heparin 0
- 0
DPD 0
- 0
Heparin 0
- 0
ACD 0
- 0
B 0
etc 0
. 0

Electron 0
microscopic 0
picture 0
of 0
the 0
cerebral 0
cortex 0
in 0
rats 0
cooled 0
to 0
22 0
degrees 0
C 0

Generally 0
the 0
differences 0
between 0
short 0
gut 0
and 0
sham 0
operation 0
animals 0
disappeared 0
when 0
the 0
data 0
were 0
normalised 0
for 0
mucosal 0
weight 0
. 0

A 0
simplified 0
thin 0
- 0
layer 0
chromatographic 0
determination 0
of 0
hippuric 0
acid 0
and 0
methylhippuric 0
acids 0
. 0

The 0
architecture 0
of 0
microvasculature 0
in 0
these 0
two 0
regions 0
was 0
also 0
examined 0
by 0
scanning 0
electron 0
microscopy 0
, 0
using 0
the 0
resin 0
casting 0
method 0
. 0

MSMS 0
Council 0
hears 0
new 0
public 0
health 0
director 0
. 0

Chordoma 0
of 0
the 0
spinal 0
cord 0
in 0
a 0
F344 0
rat 0
. 0

Micro 0
high 0
- 0
performance 0
liquid 0
chromatographic 0
system 0
with 0
micro 0
precolumn 0
and 0
dual 0
electrochemical 0
detector 0
for 0
direct 0
injection 0
analysis 0
of 0
catecholamines 0
in 0
body 0
fluids 0
. 0

Thirty 0
- 0
one 0
age 0
- 0
matched 0
, 0
conscious 0
, 0
virgin 0
, 0
male 0
Sprague 0
- 0
Dawley 0
rats 0
and 0
spontaneously 0
hypertensive 0
rats 0
( 0
SHRs 0
) 0
were 0
individually 0
injected 0
with 0
a 0
single 0
subcutaneous 0
dose 0
of 0
85 0
mg/kg 0
dl 0
- 0
isoproterenol 0
to 0
determine 0
the 0
degree 0
and 0
time 0
course 0
of 0
drug 0
- 0
induced 0
cardiac 0
failure 0
and 0
functional 0
recovery 0
. 0

A 0
narrow 0
zone 0
of 0
myelin 0
- 0
axonal 0
dissociation 0
was 0
also 0
observed 0
. 0

The 0
IgA B-gene
deficiency 0
is 0
combined 0
with 0
the 0
IgE B-gene
one 0
. 0

In 0
PB 0
mice 0
, 0
there 0
was 0
only 0
a 0
small 0
deficit 0
in 0
the 0
number 0
of 0
the 0
hippocampal 0
pyramidal 0
neurons 0
compared 0
to 0
controls 0
( 0
15 0
% 0
, 0
p 0
less 0
than 0
0.01 0
) 0
, 0
and 0
no 0
deficit 0
in 0
the 0
granule 0
cells 0
. 0

Nutritional 0
cataracts 0
in 0
timber 0
wolves 0
. 0

Prevention 0
of 0
transfusion 0
reactions 0
by 0
the 0
use 0
of 0
saline 0
washed 0
red 0
blood 0
cells 0
. 0

The 0
geometric 0
mean 0
hemagglutination 0
- 0
inhibition 0
antibody 0
titers 0
( 0
GMT 0
) 0
of 0
non 0
- 0
immunized 0
, 0
once 0
- 0
immunized 0
, 0
and 0
twice 0
- 0
immunized 0
chickens 0
were 0
compared 0
at 0
2 0
- 0
week 0
intervals 0
following 0
primary 0
immunization 0
, 0
secondary 0
immunization 0
, 0
and 0
challenge 0
. 0

The 0
quantitative 0
determination 0
of 0
HBSAG B-gene
- 0
- 0
a 0
valuable 0
aid 0
in 0
evaluating 0
the 0
infectiousness 0
of 0
hepatitis 0
B 0
virus 0
carriers 0

2. 0
numerous 0
narrow 0
shunt 0
vessels 0
departing 0
continuously 0
from 0
the 0
primary 0
arteries 0
to 0
feed 0
a 0
secondary 0
arterial 0
system 0
which 0
parallels 0
the 0
primary 0
one 0
. 0

Urological 0
complications 0
are 0
frequent 0
during 0
and 0
after 0
the 0
treatment 0
of 0
gynecological 0
malignancy 0
. 0

Arachnoid 0
cyst 0
. 0

100 0
more 0
than 0
in 0
the 0
summer 0
coat 0
) 0
. 0

Hypotension 0
was 0
produced 0
by 0
head 0
up 0
tilt 0
. 0

Therefore 0
the 0
procedure 0
of 0
Lich 0
- 0
Gregoir 0
is 0
not 0
to 0
be 0
recommended 0
in 0
adults 0
. 0

Mucoepidermoid 0
and 0
acinous 0
cell 0
carcinomas 0
of 0
salivary 0
tissues 0
. 0

Twenty 0
patients 0
aged 0
45 0
or 0
older 0
with 0
the 0
diagnosis 0
of 0
endogenous 0
depression 0
were 0
evaluated 0
in 0
terms 0
of 0
safety 0
and 0
efficacy 0
in 0
their 0
response 0
to 0
multiple 0
monitored 0
electroconvulsive 0
therapy 0
( 0
MMECT 0
) 0
versus 0
single 0
electroconvulsive 0
therapy 0
( 0
SECT 0
) 0
. 0

Two 0
new 0
artifacts 0
in 0
automated 0
coagulation 0
testing 0
. 0

This 0
relatively 0
simple 0
and 0
easily 0
performed 0
technique 0
of 0
measuring 0
deep 0
muscle 0
temperature 0
appears 0
to 0
be 0
a 0
useful 0
adjunct 0
in 0
choosing 0
the 0
amputation 0
level 0
. 0

Longitudinal 0
force 0
- 0
length 0
relationships 0
of 0
guinea 0
pig 0
ureter 0
were 0
studied 0
in 0
vitro 0
in 0
animals 0
3 0
weeks 0
, 0
3 0
months 0
, 0
and 0
3 0
years 0
of 0
age 0
. 0

Tests 0
of 0
the 0
method 0
indicate 0
( 0
1 0
) 0
the 0
Mossbauer 0
source 0
can 0
be 0
placed 0
on 0
the 0
basilar 0
membrane 0
without 0
altering 0
the 0
signal 0
- 0
transmission 0
properties 0
of 0
the 0
cochlea 0
, 0
and 0
( 0
2 0
) 0
the 0
source 0
adheres 0
to 0
the 0
basilar 0
membrane 0
. 0

Angiographic 0
work 0
- 0
up 0
in 0
a 0
patient 0
with 0
late 0
vaginal 0
metastasis 0
from 0
a 0
renal 0
carcinoma 0
. 0

The 0
authors 0
conclude 0
that 0
nonspecificity 0
of 0
low 0
platelet B-gene
MAO I-gene
as 0
a 0
possible 0
correlate 0
of 0
bipolar 0
affective 0
disorder 0
, 0
as 0
well 0
as 0
schizophrenia 0
, 0
increases 0
the 0
burden 0
of 0
proof 0
necessary 0
before 0
findings 0
of 0
low 0
platelet B-gene
MAO I-gene
can 0
be 0
accepted 0
as 0
primary 0
. 0

Ecthyma 0
, 0
a 0
known 0
disease 0
, 0
of 0
which 0
little 0
is 0
known 0

Estrogen 0
replacement 0
, 0
either 0
as 0
17 0
beta 0
- 0
estradiol 0
or 0
beta 0
- 0
estradiol 0
- 0
3 0
- 0
benzoate 0
via 0
subcutaneous 0
Silastic 0
capsules 0
, 0
was 0
associated 0
with 0
elevated 0
rates 0
of 0
heat 0
production 0
and 0
dry 0
heat 0
loss 0
relative 0
to 0
untreated 0
ovariectomized 0
controls 0
. 0

The 0
following 0
aspects 0
were 0
assessed 0
: 0
( 0
1 0
) 0
The 0
effect 0
on 0
the 0
cardiovascular 0
system 0
in 0
terms 0
of 0
brachial 0
arterial 0
pressure 0
, 0
pulse 0
rate 0
, 0
and 0
oxygen 0
consumption 0
( 0
VO2 0
) 0
during 0
exercise 0
in 0
5 0
health 0
volunteers 0
; 0
( 0
2 0
) 0
emg 0
activity 0
of 0
the 0
tibialis 0
anterior 0
and 0
gastrocnemius 0
muscles 0
during 0
exercise 0
in 0
the 0
same 0
5 0
volunteers 0
; 0
and 0
( 0
3 0
) 0
postexercise 0
ankle 0
pressure 0
changes 0
in 0
10 0
subjects 0
with 0
angiographically 0
proven 0
occlusive 0
arterial 0
diseases 0
of 0
the 0
lower 0
extremities 0
. 0

Changes 0
in 0
immunologic 0
reactivity 0
in 0
subjects 0
receiving 0
transfer B-gene
factor I-gene
could 0
not 0
be 0
distinguished 0
from 0
those 0
in 0
subjects 0
receiving 0
placebo 0
. 0

It 0
was 0
argued 0
that 0
this 0
arose 0
from 0
the 0
possibility 0
that 0
the 0
nature 0
of 0
blue 0
collar 0
jobs 0
was 0
physical 0
, 0
and 0
that 0
loss 0
of 0
myocardial 0
tissue 0
might 0
be 0
expected 0
to 0
more 0
markedly 0
interfere 0
with 0
their 0
work 0
efficiency 0
( 0
on 0
returning 0
to 0
work 0
) 0
than 0
it 0
would 0
the 0
efficiency 0
of 0
the 0
more 0
sedentary 0
jobs 0
of 0
white 0
collar 0
workers 0
. 0

Importance 0
of 0
determining 0
the 0
blood 0
sulfhydryl 0
groups 0
in 0
fractures 0
of 0
the 0
long 0
tubular 0
bones 0
complicated 0
by 0
infection 0

The 0
results 0
revealed 0
increased 0
blood 0
lead 0
level 0
associated 0
with 0
decreased 0
blood B-gene
haemoglobin I-gene
and 0
increased 0
urinary 0
excretion 0
of 0
delta 0
amino 0
levulinic 0
acid 0
. 0

Following 0
iv 0
injection 0
of 0
0.5 0
g 0
galactose 0
per 0
kg 0
body 0
weight 0
, 0
together 0
with 0
2 0
mu 0
Ci 0
generally 0
14C 0
- 0
labelled 0
galactose 0
, 0
14CO2 0
is 0
collected 0
in 0
regular 0
intervals 0
during 0
one 0
hour 0
. 0

Specific 0
clotting 0
factor 0
assays 0
showed 0
an 0
isolated 0
deficiency 0
of 0
factor B-gene
X I-gene
ranging 0
from 0
7 0
to 0
12 0
per 0
cent 0
on 0
three 0
determinations 0
. 0

Charcoal 0
- 0
facilitated 0
dialysis 0
. 0

Blood 0
variables 0
measured 0
at 0
eight 0
intervals 0
before 0
, 0
during 0
, 0
and 0
after 0
operation 0
were 0
as 0
follows 0
: 0
seven 0
plasma 0
proteins 0
, 0
free 0
hemoglobin B-gene
, 0
formed 0
elements 0
, 0
and 0
clotting 0
functions 0
. 0

Retinal 0
changes 0
in 0
pigmentary 0
retinopathy 0
in 0
children 0

As 0
a 0
result 0
, 0
beta 0
- 0
apo 0
- 0
8' 0
- 0
carotenoic 0
acid 0
ethyl 0
ester 0
( 0
apo 0
- 0
EE 0
) 0
was 0
used 0
as 0
a 0
reference 0
standard 0
in 0
Experiments 0
4 0
to 0
6 0
. 0

The 0
ability 0
of 0
sodium 0
phenobarbital 0
( 0
60 0
mg/kg 0
) 0
and 0
sodium 0
barbital 0
( 0
80 0
mg/kg 0
) 0
to 0
produce 0
a 0
taste 0
aversion 0
in 0
23 0
hr 0
fluid 0
deprived 0
rats 0
was 0
examined 0
using 0
a 0
discrimination 0
or 0
two 0
bottle 0
taste 0
aversion 0
task 0
( 0
0.125 0
% 0
sodium 0
saccharin 0
solution 0
or 0
water 0
) 0
. 0

It 0
appears 0
that 0
the 0
pulmonary 0
gas 0
exchange 0
parenchyma 0
of 0
these 0
smallest 0
mammals 0
is 0
well 0
suited 0
to 0
supply 0
the 0
organism 0
with 0
the 0
comparatively 0
high 0
levels 0
of 0
O2 0
required 0
by 0
the 0
high 0
metabolic 0
rates 0
, 0
exhibiting 0
a 0
structural 0
adaptation 0
of 0
the 0
lung 0
to 0
higher 0
VO2 0
. 0

Underestimations 0
by 0
as 0
much 0
as 0
35 0
% 0
may 0
occur 0
due 0
to 0
the 0
problems 0
in 0
the 0
existing 0
methodologies 0
. 0

Chemotherapy 0
was 0
administered 0
without 0
altering 0
the 0
course 0
of 0
the 0
disorder 0
. 0

Drug 0
inhibition 0
of 0
whole 0
blood 0
aspirin B-gene
esterase I-gene
. 0

However 0
, 0
at 0
lower 0
temperature 0
the 0
positive 0
staircase 0
was 0
not 0
clear 0
and 0
rather 0
negative 0
staircase 0
appeared 0
( 0
1 0
- 0
- 0
3 0
Hz 0
) 0
. 0

Visual 0
averaged 0
evoked 0
responses 0
and 0
platelet B-gene
monoamine I-gene
oxidase I-gene
in 0
patients 0
suffering 0
from 0
alcoholism 0
. 0

At 0
the 0
end 0
of 0
the 0
experiment 0
the 0
urinary 0
porphyrin 0
excretion 0
and 0
the 0
porphyrin 0
content 0
in 0
lijver 0
and 0
skin 0
were 0
diminished 0
in 0
HCB 0
- 0
CQ 0
- 0
treated 0
animals 0
by 0
about 0
50 0
% 0
compared 0
to 0
the 0
HCB 0
controls 0
. 0

Six 0
hours 0
after 0
the 0
last 0
administration 0
, 0
uterus 0
of 0
Gf 0
and 0
Cv 0
mice 0
were 0
weight 0
337.6 0
mg 0
% 0
and 0
423.5 0
mg 0
% 0
respectively 0
, 0
the 0
difference 0
was 0
statistically 0
significant 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Although 0
stone 0
- 0
formers 0
were 0
not 0
found 0
to 0
display 0
any 0
features 0
of 0
magnesium 0
metabolism 0
that 0
were 0
different 0
from 0
those 0
in 0
the 0
control 0
group 0
, 0
their 0
lower 0
urinary 0
excretion 0
of 0
magnesium 0
in 0
relation 0
to 0
calcium 0
may 0
be 0
a 0
factor 0
in 0
their 0
increased 0
stone 0
- 0
forming 0
propensity 0
. 0

Analysis 0
of 0
an 0
autopsy 0
population 0
. 0

A 0
16 0
- 0
year 0
follow 0
- 0
up 0
study 0
of 0
69 0
paraplegics 0
with 0
complete 0
lesions 0
from 0
T1 0
- 0
L3 0
is 0
presented 0
. 0

Autoradiographic 0
localisation 0
of 0
its 0
cellular 0
distribution 0
in 0
the 0
kidney 0
. 0

Hippocampal 0
stimulation 0
overlapping 0
conditioned 0
stimulus 0
preexposure 0
produced 0
attenuation 0
of 0
latent 0
inhibition 0
, 0
as 0
did 0
stimulation 0
presented 0
during 0
conditioning 0
after 0
preexposure 0
. 0

The 0
centromedial 0
amygdala 0
and 0
gastric 0
pathology 0
in 0
rats 0
. 0

Cataract 0
extraction 0
in 0
primary 0
glaucoma 0

Number 0
and 0
size 0
of 0
the 0
myelin 0
structures 0
in 0
the 0
pneumocytes 0
typ 0
II 0
increased 0
simultaneously 0
. 0

In 0
the 0
intact 0
animal 0
, 0
postextrasystolic 0
potentiation 0
depended 0
on 0
the 0
basic 0
pacing 0
interval 0
, 0
t0 0
, 0
and 0
the 0
timing 0
of 0
the 0
extrasystole 0
, 0
t1 0
: 0
when 0
t0 0
was 0
held 0
constant 0
and 0
t1 0
was 0
increased 0
, 0
potentiation 0
decreased 0
; 0
when 0
t1 0
was 0
held 0
constant 0
and 0
t0 0
was 0
increased 0
, 0
potentiation 0
increased 0
. 0

In 0
spite 0
of 0
this 0
and 0
other 0
complications 0
of 0
corticosteroids 0
, 0
she 0
made 0
a 0
full 0
recovery 0
from 0
the 0
fungal 0
infection 0
following 0
treatment 0
with 0
amphotericin 0
B 0
and 0
surgical 0
excision 0
of 0
the 0
lung 0
abscess 0
. 0

Implications 0
of 0
this 0
observation 0
for 0
pediatrics 0
are 0
discussed 0
. 0

For 0
the 0
study 0
of 0
the 0
transition 0
of 0
long 0
to 0
short 0
waves 0
( 0
deep 0
- 0
water 0
waves 0
) 0
a 0
closed 0
- 0
form 0
solution 0
is 0
advantageous 0
; 0
this 0
can 0
, 0
however 0
, 0
only 0
be 0
obtained 0
at 0
the 0
cost 0
of 0
further 0
simplification 0
. 0

Treatment 0
of 0
suppurative 0
peritonitis 0

We 0
report 0
a 0
case 0
of 0
pheochromocytoma 0
manifesting 0
during 0
the 0
third 0
trimester 0
of 0
pregnancy 0
. 0

Fasting 0
plasma 0
and 0
lipoprotein 0
lipid 0
concentrations 0
, 0
adipose B-gene
tissue I-gene
lipoprotein I-gene
lipase I-gene
activity 0
, 0
anthropometric 0
data 0
, 0
alcohol 0
consumption 0
, 0
smoking 0
habits 0
, 0
weekly 0
mileage 0
run 0
and 0
performance 0
on 0
a 0
bicycle 0
ergometer 0
were 0
recorded 0
before 0
and 0
after 0
the 0
training 0
period 0
. 0

The 0
C18:1 0
: 0
C10 0
value 0
is 0
a 0
convenient 0
measure 0
of 0
these 0
changes 0
and 0
can 0
be 0
determined 0
more 0
rapidly 0
than 0
determining 0
all 0
the 0
lower 0
fatty 0
acids 0
. 0

A 0
progressive 0
growth 0
of 0
blood 0
erythrocyte 0
membrane 0
injury 0
has 0
been 0
demonstrated 0
after 0
rats 0
were 0
exposed 0
to 0
gamma 0
- 0
irradiaton 0
at 0
a 0
dose 0
of 0
100 0
to 0
500 0
Gy 0
. 0

Within 0
the 0
3 0
' 0
terminal 0
50 0
nucleotides 0
, 0
the 0
mouse B-gene
mt I-gene
12S I-gene
rRNA I-gene
contains 0
a 0
potential 0
10 0
bp 0
hairpin 0
structure 0
and 0
a 0
sequence 0
of 0
15 0
consecutive 0
nucleotides 0
common 0
to 0
the 0
RNA 0
of 0
the 0
small 0
ribosomal 0
subunit 0
in 0
all 0
systems 0
, 0
but 0
does 0
not 0
contain 0
the 0
mRNA 0
binding 0
site 0
( 0
ACCUCC 0
) 0
found 0
in 0
E. 0
coli 0
and 0
corn 0
chloroplast 0
rRNAs 0
. 0

Microscopic 0
anatomy 0
and 0
cell 0
population 0
dynamics 0
. 0

Thirty 0
cadaver 0
brains 0
were 0
examined 0
under 0
X 0
6 0
to 0
16 0
magnification 0
in 0
order 0
to 0
define 0
the 0
microsurgical 0
anatomy 0
of 0
the 0
pineal 0
region 0
, 0
particularly 0
the 0
relationship 0
of 0
the 0
pineal 0
body 0
, 0
posterior 0
cerebral 0
artery 0
, 0
superior 0
cerebellar 0
artery 0
, 0
vein 0
of 0
Galen 0
, 0
basal 0
vein 0
of 0
Rosenthal 0
, 0
internal 0
cerebral 0
vein 0
, 0
straight 0
sinus 0
, 0
bridging 0
vein 0
, 0
the 0
size 0
of 0
the 0
tentorial 0
notch 0
, 0
and 0
the 0
third 0
and 0
the 0
fourth 0
cranial 0
nerves 0
. 0

Serum 0
antibody 0
titre 0
was 0
not 0
significantly 0
associated 0
with 0
the 0
recurrence 0
rate 0
or 0
the 0
duration 0
of 0
infection 0
. 0

We 0
propose 0
that 0
refeeding 0
may 0
be 0
an 0
important 0
mechanism 0
for 0
activation 0
of 0
certain 0
viral 0
infections 0
previously 0
suppressed 0
by 0
famine 0
. 0

One 0
hundred 0
twenty 0
units 0
of 0
deglycerolized 0
red 0
blood 0
cells 0
, 0
some 0
with 0
glycerol 0
added 0
so 0
as 0
to 0
exceed 0
an 0
acceptable 0
1 0
% 0
glycerol 0
content 0
, 0
had 0
measurements 0
made 0
of 0
the 0
post 0
- 0
wash 0
supernatant 0
fluid 0
by 0
refractive 0
index 0
and 0
osmometry 0
. 0

The 0
symptoms 0
and 0
objective 0
findings 0
were 0
caused 0
by 0
a 0
malignant 0
lymphoma 0
, 0
and 0
the 0
diagnosis 0
was 0
established 0
from 0
a 0
drill 0
biopsy 0
. 0

Our 0
study 0
differs 0
from 0
previous 0
studies 0
in 0
that 0
it 0
is 0
limited 0
to 0
one 0
diagnostic 0
entity 0
, 0
yet 0
at 0
the 0
same 0
time 0
evaluates 0
a 0
broad 0
range 0
of 0
social 0
and 0
work 0
- 0
related 0
factors 0
in 0
disability 0
. 0

It 0
is 0
suggested 0
that 0
a 0
raised 0
hydroxykynurenine/hydroxyanthranilic 0
acid 0
ratio 0
does 0
not 0
necessarily 0
indicate 0
vitamin 0
B6 0
deficiency 0
but 0
may 0
represent 0
a 0
nonspecific 0
response 0
of 0
tryptophan 0
metabolism 0
to 0
stress 0
. 0

All 0
control 0
persons 0
had 0
a 0
normal 0
reaction 0
to 0
DNFB 0
. 0

In 0
a 0
control 0
group 0
both 0
common 0
carotid 0
arteries 0
( 0
CCA 0
) 0
were 0
ligated 0
. 0

At 0
pH 0
6.9 0
, 0
the 0
same 0
lidocaine 0
concentrations 0
significantly 0
reduced 0
resting 0
potential 0
( 0
3 0
- 0
10 0
% 0
) 0
, 0
action 0
potential 0
amplitude 0
( 0
3 0
- 0
8 0
% 0
) 0
and 0
Vmax 0
( 0
14 0
- 0
22 0
% 0
) 0
. 0

Simultaneous 0
right 0
and 0
left 0
adrenal 0
and 0
peripheral 0
blood 0
samples 0
were 0
collected 0
for 0
determination 0
of 0
oestrone 0
( 0
E1 0
) 0
and 0
oestradiol 0
( 0
E2 0
) 0
. 0

Arm 0
function 0
tests 0
. 0

All 0
lambs 0
with 0
B 0
breeding 0
had 0
significantly 0
higher 0
Hb B-gene
levels 0
at 0
the 0
end 0
of 0
the 0
experiment 0
than 0
did 0
NB 0
lambs 0
. 0
b 0
and 0
S 0
x 0
B 0
lambs 0
had 0
higher 0
( 0
P 0
< 0
.05 0
) 0
Hb B-gene
levels 0
than 0
the 0
D 0
x 0
B 0
lambs 0
, 0
and 0
B 0
lambs 0
had 0
the 0
highest 0
( 0
P 0
< 0
.05 0
) 0
mean 0
corpuscular 0
hemoglobin B-gene
concentrations 0
. 0

The 0
same 0
response 0
occurs 0
whether 0
acrylamide 0
is 0
given 0
immediately 0
after 0
nerve 0
ligation 0
or 0
1 0
week 0
later 0
. 0

The 0
operation 0
recommended 0
is 0
excision 0
of 0
3 0
mm 0
of 0
central 0
slip 0
followed 0
by 0
end 0
- 0
to 0
- 0
end 0
repair 0
of 0
the 0
tendon 0
. 0

In 0
the 0
unclipped 0
group 0
arterial 0
pressure 0
decreased 0
50 0
mmHg 0
to 0
normal 0
by 0
24 0
h 0
and 0
was 0
associated 0
with 0
increased 0
diuresis 0
and 0
a 0
small 0
decrease 0
in 0
blood 0
volume 0
( 0
9.8 0
% 0
) 0
. 0

Marked 0
sedative 0
activity 0
was 0
observed 0
with 0
9 0
- 0
methoxy 0
- 0
5 0
- 0
phenylpyrrolo 0
[ 0
2,1 0
- 0
d 0
] 0
[ 0
1,5 0
] 0
benzothiazepin 0
- 0
6,6 0
- 0
dioxide 0
( 0
NF19 0
) 0
and 0
9 0
- 0
chloro 0
- 0
5 0
- 0
p 0
- 0
nitrophenylpyrrolo 0
[ 0
2,1 0
- 0
d 0
] 0
[ 0
1,5 0
] 0
benzothiazepin 0
- 0
6,6 0
- 0
dioxide 0
( 0
NF20 0
) 0
. 0

In 0
patients 0
, 0
the 0
effect 0
of 0
CCK B-gene
- 0
PZ B-gene
on 0
the 0
movement 0
of 0
the 0
terminal 0
part 0
of 0
the 0
bile 0
duct 0
was 0
measured 0
with 0
a 0
pressure 0
sensor 0
using 0
a 0
duodenofiberscope 0
. 0

In 0
11 0
patients 0
with 0
Horton 0
's 0
headache 0
morphological 0
investigations 0
( 0
differential 0
white 0
blood 0
cell 0
count 0
) 0
, 0
cytoenzymatic 0
determinations 0
( 0
alkaline B-gene
and I-gene
acid I-gene
phosphatase I-gene
, 0
non B-gene
- I-gene
specific I-gene
esterase I-gene
) 0
and 0
cytoimmunological 0
tests 0
( 0
IgM B-gene
and 0
IgG B-gene
binding 0
) 0
were 0
carried 0
out 0
on 0
capillary 0
blood 0
neutrophils 0
obtained 0
from 0
the 0
area 0
of 0
pain 0
, 0
non 0
- 0
painful 0
area 0
of 0
the 0
skin 0
on 0
the 0
head 0
on 0
the 0
contralateral 0
side 0
, 0
and 0
from 0
the 0
finger 0
. 0

As 0
high 0
- 0
speed 0
, 0
volumetric 0
imaging 0
, 0
computed 0
tomographic 0
scan 0
machines 0
such 0
as 0
the 0
Dynamic 0
Spatial 0
Reconstructor 0
become 0
available 0
with 0
higher 0
density 0
resolution 0
, 0
perhaps 0
a 0
single 0
injection 0
of 0
contrast 0
agent 0
into 0
the 0
right 0
atrium 0
or 0
even 0
a 0
peripheral 0
vein 0
may 0
be 0
adequate 0
to 0
obtain 0
all 0
these 0
measurements 0
. 0

The 0
ESEG 0
's 0
are 0
a 0
direct 0
result 0
of 0
the 0
NEXT 0
study 0
. 0

The 0
potentially 0
SLE 0
- 0
inducing 0
drugs 0
are 0
reviewed 0
. 0

A 0
third 0
series 0
of 0
mice 0
were 0
given 0
a 0
single 0
injection 0
of 0
5 0
- 0
OH 0
- 0
DA 0
, 0
sacrificed 0
, 0
and 0
prepared 0
for 0
ultrastructural 0
study 0
. 0

Fourteen 0
different 0
species 0
( 0
eight 0
Platyhelmintha 0
, 0
one 0
Nematoda 0
and 0
five 0
Crustacea 0
) 0
have 0
been 0
inventorized 0
. 0

No 0
symptoms 0
other 0
than 0
hot 0
flush 0
showed 0
such 0
significant 0
correlation 0
with 0
plasma 0
epinephrine 0
or 0
norepinephrine 0
levels 0
. 0

The 0
mean 0
values 0
of 0
the 0
concentrations 0
of 0
the 0
components 0
due 0
to 0
tobacco 0
smoke 0
are 0
: 0
CO 0
= 0
1.1 0
ppm 0
, 0
NO 0
= 0
32 0
ppb 0
, 0
NO2 0
= 0
24 0
ppb 0
, 0
nicotine 0
= 0
0.9 0
micrograms/m3 0
, 0
particulate 0
matter 0
= 0
133 0
micrograms/m3 0
. 0

The 0
average 0
backscatter 0
coefficient 0
was 0
six 0
time 0
larger 0
in 0
regions 0
of 0
infarct 0
studied 0
8 0
- 0
- 0
10 0
weeks 0
after 0
occlusion 0
than 0
that 0
in 0
regions 0
of 0
infarct 0
studied 0
5 0
- 0
- 0
6 0
weeks 0
after 0
occlusion 0
. 0

At 0
4 0
wk 0
however 0
, 0
tumor 0
relapse 0
was 0
noted 0
in 0
6 0
of 0
7 0
group 0
4 0
responders 0
, 0
10 0
of 0
12 0
in 0
group 0
5 0
, 0
13 0
of 0
16 0
in 0
group 0
7 0
, 0
but 0
only 0
4 0
of 0
19 0
group 0
8 0
responders 0
( 0
p 0
less 0
than 0
.001 0
group 0
8 0
versus 0
4 0
, 0
5 0
, 0
7 0
) 0
. 0

Early 0
infection 0
was 0
detected 0
in 0
one 0
of 0
50 0
control 0
women 0
who 0
gave 0
birth 0
to 0
a 0
healthy 0
infant 0
. 0

Pentachlorophenol 0
accelerates 0
the 0
onset 0
of 0
HCB 0
porphyria 0
, 0
in 0
other 0
words 0
it 0
increases 0
the 0
total 0
urinary 0
porphyrin 0
excretion 0
and 0
causes 0
an 0
earlier 0
disturbance 0
of 0
the 0
porphyrin 0
pattern 0
. 0

Family 0
planning 0
continues 0
to 0
play 0
a 0
minor 0
role 0
, 0
and 0
only 0
25.3 0
per 0
cent 0
of 0
all 0
patients 0
reviewed 0
took 0
to 0
oral 0
contraceptives 0
for 0
shorter 0
or 0
longer 0
periods 0
of 0
time 0
. 0
- 0
The 0
percentages 0
of 0
primiparae 0
and 0
secundiparae 0
in 0
all 0
births 0
as 0
well 0
as 0
the 0
high 0
percentage 0
of 0
multigravidity 0
are 0
parameters 0
by 0
which 0
the 0
approach 0
to 0
reproduction 0
differs 0
substantively 0
from 0
behaviour 0
patterns 0
in 0
Europe 0
. 0

The 0
term 0
osteomesopycnosis 0
is 0
proposed 0
for 0
a 0
sclerosing 0
bone 0
disease 0
with 0
dominant 0
inheritance 0
that 0
has 0
been 0
discovered 0
in 0
five 0
members 0
of 0
four 0
different 0
families 0
. 0

The 0
87K 0
protein 0
, 0
together 0
with 0
proteins 0
of 0
105,000 0
and 0
75,000 0
daltons 0
, 0
are 0
translated 0
from 0
leftward 0
transcribed 0
( 0
1 0
- 0
strand 0
) 0
messenger 0
RNAs 0
that 0
are 0
complementary 0
to 0
the 0
viral 0
genome 0
between 0
positions 0
11.2 0
and 0
31.5 0
. 0

The 0
identification 0
of 0
viable 0
myocardium 0
with 0
both 0
99mTc 0
- 0
tetrofosmin 0
and 0
201Tl 0
can 0
be 0
greatly 0
enhanced 0
to 0
a 0
similar 0
degree 0
if 0
the 0
severity 0
of 0
reduction 0
in 0
activity 0
within 0
nonreversible 0
defects 0
is 0
considered 0
. 0

The 0
temporal 0
component 0
lacked 0
a 0
mandibular 0
fossa 0
as 0
well 0
as 0
articular 0
eminence 0
. 0

EUK 0
- 0
8 0
is 0
a 0
novel 0
, 0
synthetic 0
, 0
low 0
- 0
molecular 0
- 0
weight 0
salen 0
- 0
manganese 0
complex 0
that 0
exhibits 0
both 0
superoxide B-gene
dismutase I-gene
and 0
catalase B-gene
activities 0
in 0
vitro 0
. 0

The 0
protein B-gene
ELT I-gene
- I-gene
1 I-gene
, 0
encoded 0
by 0
a 0
single 0
- 0
copy 0
gene 0
homologous 0
to 0
the 0
GATA B-gene
family I-gene
of I-gene
vertebrate I-gene
transcription I-gene
factors I-gene
, 0
is 0
potentially 0
capable 0
of 0
interacting 0
with 0
this 0
element 0
. 0

However 0
, 0
in 0
contrast 0
with 0
previous 0
in 0
vitro 0
cell 0
- 0
free 0
integration 0
studies 0
, 0
alteration 0
of 0
the 0
highly 0
conserved 0
CA 0
dinucleotide 0
resulted 0
in 0
a 0
mutant 0
which 0
still 0
retained 0
40 0
% 0
of 0
wild 0
- 0
type 0
integration 0
activity 0
. 0

The 0
resulting 0
R B-gene
protein I-gene
terminates 0
five 0
codons 0
downstream 0
of 0
the 0
frameshift 0
site 0
at 0
the 0
V B-gene
protein I-gene
stop 0
codon 0
. 0

These 0
results 0
demonstrate 0
that 0
although 0
PI2 0
and 0
PI3 0
viruses 0
belong 0
to 0
the 0
same 0
parainfluenza 0
virus 0
genus 0
, 0
these 0
viruses 0
show 0
marked 0
differences 0
with 0
respect 0
to 0
functional 0
requirements 0
for 0
the 0
cytoplasmic 0
tail 0
of 0
the 0
F B-gene
glycoprotein I-gene
. 0

By 0
site 0
- 0
specific 0
mutagenesis 0
, 0
we 0
also 0
show 0
that 0
individual 0
ICP27 B-gene
C I-gene
- I-gene
terminal I-gene
amino I-gene
acid I-gene
residues I-gene
that 0
are 0
positionally 0
conserved 0
in 0
ICP27 B-gene
homologs I-gene
in 0
other 0
herpesviruses 0
( 0
D 0
- 0
357 0
, 0
E 0
- 0
358 0
, 0
H 0
- 0
479 0
, 0
C 0
- 0
400 0
, 0
C 0
- 0
483 0
, 0
and 0
C 0
- 0
488 0
) 0
are 0
critical 0
for 0
trans 0
- 0
regulatory 0
activity 0
. 0

Magnetic 0
resonance 0
imaging 0
( 0
MRI 0
) 0
has 0
enabled 0
us 0
to 0
see 0
the 0
spinal 0
intramedullary 0
pathology 0
as 0
differences 0
in 0
signal 0
intensity 0
. 0

Patients 0
with 0
psychotropic 0
drugs 0
showed 0
significantly 0
higher 0
PRL B-gene
levels 0
. 0

The 0
Laser 0
Scanning 0
Ophthalmoscope 0
enables 0
a 0
fundus 0
- 0
based 0
examination 0
and 0
therefore 0
allows 0
exact 0
comparison 0
between 0
morphologic 0
appearance 0
and 0
corresponding 0
function 0
. 0

Malaria 0
, 0
anaemia 0
, 0
and 0
HIV 0
- 0
1 0
transmission 0
in 0
central 0
Africa 0
. 0

BSE 0
and 0
farmworkers 0
. 0

In 0
addition 0
, 0
two 0
- 0
dimensional 0
nuclear 0
magnetic 0
resonance 0
studies 0
with 0
F17A 0
, 0
K13Q 0
, 0
F15Y 0
and 0
F27Y 0
revealed 0
that 0
the 0
mutants 0
have 0
the 0
same 0
overall 0
structure 0
as 0
the 0
wild B-gene
- I-gene
type I-gene
CspB I-gene
protein I-gene
. 0

Considerably 0
high 0
levels 0
of 0
IgE B-gene
antibodies I-gene
was 0
also 0
established 0
while 0
other 0
pollens 0
did 0
not 0
show 0
such 0
correspondence 0
. 0

Peroxisome B-gene
proliferator I-gene
- I-gene
activated I-gene
receptors I-gene
( 0
PPARs B-gene
) 0
and 0
retinoid B-gene
X I-gene
receptors I-gene
( 0
RXRs B-gene
) 0
are 0
nuclear B-gene
hormone I-gene
receptors I-gene
that 0
are 0
activated 0
by 0
fatty 0
acids 0
and 0
9 0
- 0
cis 0
- 0
retinoic 0
acid 0
, 0
respectively 0
. 0

This 0
is 0
particularly 0
intriguing 0
because 0
SKUT 0
- 0
1B 0
- 0
20 0
cells 0
lack 0
the 0
transcription 0
factor 0
Pit B-gene
- I-gene
1 I-gene
. 0

The 0
number 0
of 0
lactotropes 0
, 0
somatotropes 0
, 0
thyrotropes 0
, 0
and 0
gonadotropes 0
was 0
not 0
altered 0
compared 0
with 0
controls 0
, 0
indicating 0
that 0
in 0
the 0
adult 0
pituitary 0
, 0
POMC B-gene
products I-gene
are 0
not 0
required 0
to 0
maintain 0
the 0
distribution 0
of 0
cell 0
types 0
. 0

Some 0
strains 0
of 0
A. 0
parasiticus 0
produced 0
all 0
four 0
aflatoxins 0
B1 0
B2 0
G1 0
G2 0
, 0
while 0
the 0
other 0
ones 0
produced 0
AF 0
B1 0
+ 0
G1 0
only 0
, 0
with 0
concentrations 0
of 0
aflatoxins 0
from 0
0.1 0
to 0
450 0
mg/kg 0
. 0

We 0
have 0
isolated 0
a 0
new 0
, 0
larger 0
rat B-gene
B I-gene
- I-gene
myc I-gene
genomic I-gene
clone I-gene
. 0

In 0
addition 0
to 0
the 0
nine 0
and 0
51 0
terminal 0
amino 0
acid 0
forms 0
already 0
known 0
, 0
we 0
identified 0
a 0
third 0
with 0
43 0
terminal 0
amino 0
acids 0
predicted 0
to 0
encode 0
a 0
novel 0
RET B-gene
protein I-gene
isoform I-gene
. 0

Both 0
classes 0
of 0
MHBst B-gene
proteins I-gene
were 0
found 0
to 0
form 0
dimers 0
; 0
an 0
which 0
is 0
involved 0
in 0
mediating 0
the 0
dimerization 0
. 0

In 0
electrophoretic 0
mobility 0
shift 0
assays 0
, 0
the 0
PERE B-gene
formed 0
three 0
major 0
complexes 0
( 0
P1 0
, 0
P2 0
and 0
P3 0
) 0
with 0
proteins 0
in 0
nuclear 0
extracts 0
from 0
HeLa 0
or 0
293 0
cells 0
. 0

She 0
had 0
been 0
receiving 0
MTX 0
7.5 0
mg/week 0
for 0
2.5 0
months 0
because 0
of 0
her 0
vasculitis 0
symptoms 0
. 0

Analysis 0
of 0
the 0
sequence 0
identified 0
four 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
which 0
are 0
designated 0
UL1 B-gene
, 0
UL2 B-gene
, 0
UL3 B-gene
, 0
and 0
UL3.5 B-gene
based 0
on 0
their 0
homology 0
with 0
proteins 0
of 0
herpes 0
simplex 0
virus 0
- 0
1 0
( 0
HSV 0
- 0
1 0
) 0
, 0
pseudorabies 0
virus 0
( 0
PRV 0
) 0
, 0
equine 0
herpesvirus 0
- 0
1 0
, 0
and 0
varicella 0
- 0
zoster 0
virus 0
. 0

These 0
HPV16 0
E6/E7 B-gene
cDNAs 0
were 0
cloned 0
under 0
the 0
E6/E7 I-gene

Correlation 0
coefficients 0
between 0
the 0
reference 0
methods 0
and 0
NIT 0
were 0
> 0
or 0
= 0
0.95 0
for 0
water 0
, 0
fat 0
, 0
crude 0
protein 0
and 0
connective 0
- 0
tissue 0
- 0
protein 0
frei 0
meat 0
protein 0
, 0
and 0
> 0
or 0
= 0
0.86 0
for 0
connective 0
- 0
tissue 0
- 0
protein 0
. 0

The 0
translation 0
products 0
of 0
both 0
clones 0
are 0
highly 0
homologous 0
to 0
APS1 B-gene
( 0
66 0
and 0
86 0
% 0
identity 0
, 0
respectively 0
) 0
over 0
their 0
entire 0
lengths 0
, 0
including 0
amino 0
terminal 0
sequences 0
resembling 0
transit 0
peptides 0
for 0
plastid 0
localization 0
. 0

The 0
serum 0
levels 0
of 0
IgE B-gene
, 0
and 0
asIgE B-gene
and 0
IgG B-gene
- I-gene
4 I-gene
against 0
14 0
common 0
food 0
allergens 0
were 0
determined 0
. 0

Two 0
experiments 0
investigating 0
the 0
effects 0
of 0
short 0
- 0
term 0
spaceflight 0
on 0
cancellous 0
bone 0
turnover 0
were 0
carried 0
out 0
: 0
Physiological 0
Systems 0
Experiment 0
- 0
1 0
( 0
PSE 0
- 0
1 0
) 0
( 0
a 0
4 0
- 0
d 0
orbital 0
spaceflight 0
) 0
and 0
PSE 0
- 0
2 0
( 0
a 0
10 0
- 0
d 0
flight 0
) 0
. 0

That 0
sequence 0
strongly 0
promoted 0
the 0
transcription 0
of 0
the 0
promotorless 0
chloramphenicol B-gene
acetyltranferase I-gene
( 0
CAT B-gene
) 0
gene 0
in 0
cells 0
of 0
pancreatic 0
origin 0
( 0
AR 0
- 0
42J 0
) 0
but 0
not 0
in 0
cells 0
of 0
non 0
- 0
pancreatic 0
origin 0
( 0
Rat 0
2 0
and 0
IEC 0
6 0
) 0
. 0

Functional 0
analysis 0
of 0
aryl B-gene
hydrocarbon I-gene
receptor I-gene
nuclear I-gene
translocator I-gene
interactions 0
with 0
aryl B-gene
hydrocarbon I-gene
receptor I-gene
in 0
the 0
yeast 0
two 0
- 0
hybrid 0
system 0
. 0

Histopathologic 0
observations 0
showed 0
that 0
both 0
somatostatin B-gene
and 0
triamcinolone 0
acetonide 0
reduced 0
the 0
inflammatory 0
signs 0
in 0
the 0
joint 0
structures 0
, 0
although 0
triamcinolone 0
acetonide 0
appeared 0
to 0
be 0
more 0
effective 0
. 0

An 0
approach 0
to 0
a 0
biomathematical 0
model 0
of 0
lymphocytopoiesis 0
. 0

The 0
influenza 0
virus 0
NS1 B-gene
protein 0
is 0
a 0
unique 0
posttranscriptional 0
regulator 0
that 0
has 0
two 0
activities 0
: 0
inhibition 0
of 0
the 0
nuclear 0
export 0
of 0
poly 0
A 0
- 0
containing 0
mRNAs 0
and 0
inhibition 0
of 0
pre 0
- 0
mRNA 0
splicing 0
. 0

These 0
are 0
two 0
regions 0
of 0
known 0
conserved 0
synteny 0
, 0
providing 0
further 0
evidence 0
that 0
the 0
human B-gene
STEP I-gene
is 0
a 0
true 0
homolog 0
of 0
the 0
murine B-gene
STEP I-gene
gene I-gene
. 0

Molecular 0
cloning 0
of 0
the 0
human 0
homolog 0
of 0
a 0
striatum B-gene
- I-gene
enriched I-gene
phosphatase I-gene
( B-gene
STEP I-gene
) I-gene
gene I-gene
and 0
chromosomal 0
mapping 0
of 0
the 0
human 0
and 0
murine 0
loci 0
. 0

Carbonic B-gene
anhydrase I-gene
V I-gene
( 0
CA B-gene
V I-gene
) 0
is 0
expressed 0
in 0
mitochondrial 0
matrix 0
in 0
liver 0
and 0
several 0
other 0
tissues 0
. 0

Vitamin 0
D3 0
plus 0
nicotine 0
treatment 0
produced 0
parallel 0
increases 0
in 0
cardiac 0
mass 0
and 0
elastic 0
modulus 0
, 0
with 0
a 0
significant 0
correlation 0
between 0
the 0
two 0
. 0

The 0
latter 0
domain 0
appears 0
to 0
be 0
involved 0
in 0
targeting 0
Num1p B-gene
to 0
the 0
mother 0
cell 0
cortex 0
. 0

This 0
finding 0
is 0
consistent 0
with 0
the 0
notion 0
that 0
the 0
dsRNA 0
binding 0
domains 0
may 0
be 0
composed 0
of 0
two 0
separate 0
functional 0
subdomains 0
. 0

Preferential 0
heterodimeric 0
parallel 0
coiled 0
- 0
coil 0
formation 0
by 0
synthetic B-gene
Max I-gene
and 0
c B-gene
- I-gene
Myc I-gene
leucine I-gene
zippers I-gene
: 0
a 0
description 0
of 0
putative 0
electrostatic 0
interactions 0
responsible 0
for 0
the 0
specificity 0
of 0
heterodimerization 0
. 0

Comparison 0
to 0
other 0
coxI B-gene
genes I-gene
revealed 0
a 0
966 0
- 0
bp 0
group 0
I 0
intron 0
, 0
which 0
, 0
based 0
on 0
homology 0
with 0
the 0
related 0
yeast B-gene
coxI I-gene
intron I-gene
aI4 I-gene
, 0
potentially 0
encodes 0
a 0
279 0
- 0
amino 0
- 0
acid 0
site 0
- 0
specific 0
DNA B-gene
endonuclease I-gene
. 0

We 0
studied 0
the 0
GR B-gene
in 0
DMS 0
- 0
79 0
cells 0
derived 0
from 0
a 0
human 0
ACTH B-gene
- 0
secreting 0
small 0
cell 0
lung 0
cancer 0
. 0

This 0
study 0
analyzed 0
whether 0
the 0
localization 0
of 0
an 0
accessory 0
pathway 0
could 0
be 0
predicted 0
by 0
using 0
the 0
polarity 0
of 0
the 0
QRS 0
complex 0
during 0
sinus 0
rhythm 0
on 0
the 0
surface 0
ECG 0
, 0
instead 0
of 0
the 0
delta 0
wave 0
polarity 0
as 0
used 0
in 0
many 0
reports 0
. 0

The 0
promoter 0
mutation 0
is 0
complemented 0
in 0
trans 0
by 0
E1A B-gene
products 0
of 0
the 0
heterologous 0
helper 0
adenovirus 0
type 0
5 0
( 0
Ad5 0
) 0
. 0

Thus 0
, 0
as 0
expected 0
, 0
trans 0
- 0
splicing 0
depends 0
on 0
the 0
integrity 0
of 0
U2 B-gene
, 0
U4 B-gene
, 0
and 0
U6 B-gene
snRNAs I-gene
. 0

Treatment 0
of 0
PCC4.aza1R 0
cells 0
with 0
an 0
RAR B-gene
- 0
selective 0
agonist 0
also 0
repressed 0
the 0
expression 0
of 0
EC B-gene
- I-gene
1 I-gene
mRNA I-gene
while 0
treatment 0
with 0
an 0
RXR B-gene
- 0
selective 0
agonist 0
reduced 0
EC B-gene
- I-gene
1 I-gene
expression 0
slightly 0
. 0

In 0
the 0
absence 0
of 0
E1A243 B-gene
, 0
YY1 B-gene
represses 0
CRE 0
- 0
dependent 0
transcription 0
of 0
c B-gene
- I-gene
fos I-gene
by 0
physically 0
interacting 0
with 0
ATF/CREB B-gene
proteins 0
bound 0
to 0
the 0
- 0
67 0
CRE 0
. 0

Shift 0
- 0
down 0
experiments 0
indicated 0
that 0
the 0
10 0
( 0
4 0
) 0
- 0
to 0
10 0
( 0
5 0
) 0
- 0
fold 0
reduction 0
in 0
virus 0
yield 0
at 0
the 0
nonpermissive 0
temperature 0
was 0
due 0
to 0
the 0
disfunction 0
of 0
alpha B-gene
TIF I-gene
late 0
in 0
infection 0
, 0
presumably 0
in 0
virion 0
maturation 0
. 0

These 0
results 0
demonstrate 0
that 0
tip B-gene
acts 0
at 0
an 0
early 0
stage 0
of 0
the 0
T 0
- 0
cell 0
signal 0
transduction 0
cascade 0
by 0
associating 0
with 0
Lck B-gene
and 0
downregulating 0
Lck 0
- 0
mediated 0
activation 0
. 0

Human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
Vpr I-gene
is 0
a 0
virion 0
- 0
associated 0
, 0
regulatory 0
protein 0
that 0
is 0
required 0
for 0
efficient 0
viral 0
replication 0
in 0
monocytes/macrophages 0
. 0

Here 0
we 0
examine 0
the 0
potential 0
for 0
VP16 B-gene
protein 0
- 0
protein 0
interactions 0
specific 0
to 0
virus 0
- 0
infected 0
cells 0
and 0
show 0
that 0
VP16 B-gene
copurifies 0
in 0
a 0
highly 0
enriched 0
fraction 0
with 0
a 0
single 0
major 0
polypeptide 0
which 0
we 0
identify 0
as 0
the 0
virus 0
- 0
encoded 0
structural 0
protein 0
VP22 B-gene
. 0

Thus 0
, 0
transcriptional 0
regulation 0
, 0
splicing 0
, 0
kinase 0
interaction 0
sites 0
, 0
and 0
tyrosine 0
phosphorylation 0
of 0
the 0
LMP2A B-gene
homologs I-gene
have 0
been 0
conserved 0
despite 0
significant 0
sequences 0
heterogeneity 0
in 0
the 0
preterminal 0
repeat 0
regions 0
of 0
these 0
human 0
and 0
nonhuman 0
primate 0
EBVs 0
. 0

Results 0
of 0
the 0
ECAT 0
Angina 0
Pectoris 0
Study 0
Group 0
. 0

Therefore 0
, 0
a 0
prospective 0
Phase 0
II 0
trial 0
was 0
conducted 0
to 0
determine 0
the 0
safety 0
and 0
efficacy 0
of 0
cryosurgery 0
following 0
radiation 0
therapy 0
in 0
men 0
with 0
local 0
recurrence 0
. 0

These 0
motifs 0
include 0
a 0
Chi 0
motif 0
and 0
a 0
Chi 0
- 0
like 0
element 0
previously 0
found 0
in 0
the 0
recombination 0
hotspot 0
region 0
of 0
the 0
Bcl B-gene
- I-gene
2 I-gene
proto I-gene
- I-gene
oncogene I-gene
and 0
close 0
to 0
chromosomal 0
breakpoints 0
in 0
T 0
- 0
ALL 0
lines 0
. 0

Common 0
history 0
and 0
prospects 0
in 0
surgical 0
gynecology 0
of 0
the 0
Charite 0
and 0
the 0
Vienna 0
University 0
Clinic 0

In 0
contrast 0
with 0
the 0
previously 0
reported 0
HMGR1 B-gene
mRNA I-gene
( 0
HMGR1S B-gene
mRNA I-gene
) 0
, 0
which 0
is 0
detected 0
at 0
high 0
levels 0
in 0
all 0
tissues 0
of 0
the 0
plant 0
, 0
HMGR1L B-gene
mRNA I-gene
is 0
present 0
at 0
relatively 0
low 0
levels 0
and 0
its 0
expression 0
is 0
restricted 0
mostly 0
to 0
seedlings 0
, 0
roots 0
and 0
inflorescences 0
. 0

However 0
, 0
the 0
requirement 0
of 0
rev3 B-gene
for 0
the 0
production 0
of 0
G.C 0
- 0
- 0
> 0
T.A 0
transversions 0
by 0
the 0
rad18 B-gene
mutator I-gene
, 0
which 0
induces 0
only 0
these 0
substitutions 0
, 0
was 0
similar 0
to 0
that 0
for 0
rad6 B-gene
- 0
mediated 0
G.C 0
- 0
- 0
> 0
T.A 0
transversion 0
. 0

The 0
second 0
mutation 0
present 0
in 0
the 0
original 0
mutant 0
proved 0
to 0
be 0
an 0
allele 0
of 0
a 0
known 0
gene 0
, 0
PBS2 B-gene
, 0
which 0
encodes 0
a 0
putative 0
protein 0
kinase 0
that 0
functions 0
in 0
the 0
high 0
osmolarity 0
stress 0
pathway 0
. 0

In 0
adult 0
tissues 0
, 0
it 0
was 0
less 0
restricted 0
, 0
indicating 0
that 0
RAFTK B-gene
expression 0
is 0
developmentally 0
up 0
- 0
regulated 0
. 0

As 0
hGM B-gene
- I-gene
CSF I-gene
receptor I-gene
( 0
hGMR B-gene
) 0
does 0
not 0
contain 0
a 0
consensus 0
sequence 0
for 0
binding 0
of 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
, 0
hGMR B-gene
must 0
use 0
a 0
distinct 0
mechanism 0
for 0
its 0
association 0
with 0
and 0
activation 0
of 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
. 0

J 0
. 0

The 0
identity 0
between 0
hnRNPs B-gene
H I-gene
and 0
H B-gene
' I-gene
is 0
96 0
% 0
, 0
between 0
H B-gene
and 0
F B-gene
78 0
% 0
, 0
and 0
between 0
H B-gene
' I-gene
and 0
F B-gene
75 0
% 0
, 0
respectively 0
. 0

TPBF B-gene
has 0
two 0
potential 0
coiled 0
- 0
coil 0
regions 0
, 0
a 0
basic 0
region 0
, 0
a 0
proline 0
- 0
rich 0
region 0
, 0
a 0
histidine 0
- 0
rich 0
N 0
terminus 0
, 0
and 0
a 0
nuclear 0
targeting 0
sequence 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
transiently 0
expressed 0
in 0
primary 0
cultures 0
of 0
rat 0
hepatocytes 0
plasmids 0
consisting 0
of 0
CYP3A1 B-gene
5' I-gene
- I-gene
flanking I-gene
sequences I-gene
fused 0
to 0
a 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
plasmid 0
. 0

We 0
show 0
that 0
stimulation 0
of 0
resting 0
splenic 0
B 0
cells 0
with 0
CD40L B-gene
- 0
expressing 0
Sf9 0
cells 0
induces 0
germ 0
- 0
line 0
gamma 0
1 0
and 0
epsilon 0
transcripts 0
independently 0
of 0
cytokines 0
. 0

To 0
confirm 0
the 0
GapIII B-gene
protein I-gene
activity 0
, 0
constructs 0
containing 0
different 0
GapIII B-gene
- 0
GRD B-gene
domains 0
were 0
transformed 0
into 0
iral B-gene
mutant 0
yeast 0
to 0
determine 0
their 0
relative 0
ability 0
to 0
replace 0
IRA1 B-gene
functionally 0
. 0

At 0
the 0
time 0
of 0
the 0
13 0
latest 0
BPVs 0
, 0
age 0
ranged 0
from 0
three 0
days 0
to 0
13.1 0
years 0
( 0
mean 0
5.7 0
+/ 0
- 0
SD 0
4.8 0
years 0
) 0
. 0

A 0
tobacco 0
homologue 0
( 0
trolC B-gene
) 0
of 0
the 0
rolC B-gene
gene I-gene
of I-gene
the I-gene
Agrobacterium I-gene
rhizogenes I-gene
Ri I-gene
- I-gene
plasmid I-gene
was 0
cloned 0
and 0
sequenced 0
from 0
Nicotiana 0
tabacum 0
L. 0
cv 0
. 0

High 0
ADR1 B-gene
gene I-gene
dosage 0
increased 0
the 0
transcription 0
of 0
genes 0
encoding 0
peroxisomal 0
proteins 0
as 0
compared 0
to 0
one 0
copy 0
of 0
the 0
ADR1 B-gene
gene I-gene
. 0

A 0
water 0
- 0
vapour 0
giga 0
- 0
maser 0
in 0
the 0
active 0
galaxy 0
TXFS2226 0
- 0
184 0
. 0

Of 0
the 0
three 0
known 0
C/EBP B-gene
family I-gene
inhibitors 0
, 0
Ig/EBP B-gene
, 0
LIP B-gene
and 0
CHOP B-gene
- I-gene
10 I-gene
, 0
only 0
Ig/EBP B-gene
is 0
ubiquitously 0
expressed 0
. 0

The 0
effects 0
of 0
a 0
1 0
- 0
or 0
24 0
- 0
hour 0
pretreatment 0
regimen 0
with 0
monophosphoryl 0
lipid 0
A 0
( 0
MLA 0
, 0
35 0
micrograms/kg 0
i.v 0
. 0
) 0
on 0
myocardial 0
stunning 0
produced 0
by 0
repetitive 0
coronary 0
occlusions 0
were 0
studied 0
in 0
barbital 0
- 0
anesthetized 0
dogs 0
. 0

These 0
incisors 0
were 0
studied 0
by 0
scanning 0
electron 0
microscopy 0
- 0
energy 0
dispersive 0
spectroscopy 0
analysis 0
( 0
SEM 0
- 0
EDS 0
) 0
and 0
light 0
microscopy 0
to 0
examine 0
the 0
calciotraumatic 0
lines 0
of 0
strontium 0
in 0
the 0
rat 0
incisor 0
labial 0
dentin 0
. 0

A 0
platelet B-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
receptor I-gene
( 0
PDGF B-gene
- I-gene
R I-gene
) 0
phosphopeptide 0
containing 0
Tyr 0
- 0
857 0
does 0
not 0
bind 0
appreciably 0
to 0
the 0
Src B-gene
SH2 I-gene
domain I-gene
, 0
suggesting 0
it 0
is 0
not 0
the 0
PDGF B-gene
- I-gene
R I-gene
binding 0
site 0
for 0
Src B-gene
as 0
previously 0
reported 0
. 0

We 0
have 0
also 0
tested 0
Src B-gene
SH2 B-gene
mutants 0
for 0
their 0
binding 0
properties 0
and 0
have 0
interpreted 0
our 0
results 0
in 0
light 0
of 0
the 0
recent 0
crystal 0
structure 0
solution 0
for 0
the 0
Src B-gene
SH2 B-gene
domain 0
. 0

These 0
observations 0
link 0
actin B-gene
plaque 0
assembly 0
to 0
increased 0
cell 0
substrate 0
adhesion 0
. 0

The 0
early 0
lethality 0
of 0
the 0
left 0
- 0
sided 0
resectio 0
was 0
0 0
% 0
and 0
the 0
postoperative 0
survival 0
- 0
- 0
5 0
- 0
10 0
months 0
. 0

There 0
are 0
two 0
immunogenic 0
sites 0
on 0
the 0
type 0
A 0
influenza 0
A/Japan/57 0
( 0
H2N2 0
) 0
hemagglutinin B-gene
( 0
HA B-gene
) 0
that 0
can 0
be 0
recognized 0
by 0
class B-gene
I I-gene
major I-gene
histocompatibility I-gene
complex I-gene
( 0
MHC B-gene
) 0
, 0
H B-gene
- I-gene
2Kd I-gene
- 0
restricted 0
cytolytic 0
T 0
lymphocytes 0
( 0
CTLs 0
) 0
. 0

This 0
enhancer 0
activates 0
both 0
the 0
K19 B-gene
and 0
TK B-gene
basal I-gene
promoters I-gene
in 0
HeLa 0
cells 0
. 0

Mechanism 0
of 0
enhancement 0
of 0
DNA 0
expression 0
consequent 0
to 0
cointernalization 0
of 0
a 0
replication 0
- 0
deficient 0
adenovirus 0
and 0
unmodified 0
plasmid 0
DNA 0
. 0

Interestingly 0
, 0
one 0
IRF B-gene
binding I-gene
site I-gene
was 0
found 0
within 0
the 0
IRF B-gene
- I-gene
2 I-gene
promoter I-gene
, 0
and 0
expression 0
of 0
the 0
IRF B-gene
- I-gene
2 I-gene
gene I-gene
was 0
affected 0
by 0
both 0
transient 0
and 0
stable 0
IRF B-gene
- I-gene
1 I-gene
expression 0
. 0

Therefore 0
, 0
we 0
studied 0
ninety 0
coagulopathic 0
patients 0
with 0
the 0
aim 0
of 0
determining 0
the 0
prevalence 0
of 0
hepatitis B-gene
C I-gene
virus I-gene
( I-gene
HCV I-gene
) I-gene
antibodies I-gene
using 0
the 0
ELISA 0
and 0
RIBA 0
methods 0
. 0

The 0
highest 0
decrease 0
in 0
mutagenic 0
activity 0
was 0
observed 0
when 0
enzymatic 0
bleaching 0
was 0
used 0
together 0
with 0
chlorine 0
. 0

Hepatitis B-gene
B I-gene
surface I-gene
antigen I-gene
was 0
detected 0
in 0
2 0
patients 0
, 0
with 0
negative 0
hepatitis B-gene
C I-gene
virus I-gene
antibody I-gene
. 0

There 0
was 0
also 0
a 0
highly 0
significant 0
correlation 0
between 0
total 0
selenium 0
intake 0
and 0
liver 0
selenium 0
concentration 0
( 0
r 0
= 0
0.99 0
, 0
p 0
< 0
0.01 0
) 0
after 0
1 0
mo 0
of 0
treatment 0
, 0
but 0
this 0
time 0
liver 0
selenium 0
did 0
not 0
change 0
with 0
time 0
, 0
and 0
the 0
correlation 0
remained 0
highly 0
significant 0
throughout 0
the 0
investigation 0
. 0

Antibodies 0
affinity 0
- 0
purified 0
using 0
the 0
bacterially 0
expressed 0
recombinant 0
protein 0
recognized 0
the 0
56K B-gene
autoantigen I-gene
in 0
a 0
HeLa 0
cell 0
extract 0
. 0
cDNA 0
sequencing 0
revealed 0
that 0
the 0
56K B-gene
cDNA I-gene
shares 0
a 0
high 0
degree 0
of 0
homology 0
in 0
both 0
nucleotide 0
( 0
87 0
% 0
) 0
and 0
amino 0
acid 0
sequence 0
( 0
92.5 0
% 0
) 0
with 0
bovine B-gene
annexin I-gene
XI I-gene
, 0
indicating 0
that 0
the 0
56K B-gene
cDNA I-gene
encodes 0
the 0
human B-gene
homologue I-gene
of I-gene
annexin I-gene
XI I-gene
, 0
a 0
member 0
of 0
the 0
Ca B-gene
( I-gene
2+ I-gene
) I-gene
- I-gene
dependent I-gene
phospholipid I-gene
binding I-gene
protein I-gene
family I-gene
. 0

The 0
avidin B-gene
- I-gene
biotin I-gene
complex I-gene
peroxidase I-gene
( 0
ABC B-gene
- I-gene
P I-gene
) 0
method 0
was 0
used 0
to 0
detect 0
Mycobacterium 0
bovis 0
, 0
and 0
the 0
results 0
were 0
compared 0
with 0
those 0
obtained 0
by 0
the 0
Ziehl 0
- 0
Neelsen 0
( 0
ZN 0
) 0
technique 0
. 0

Its 0
role 0
in 0
these 0
processes 0
suggests 0
that 0
the 0
function 0
of 0
c B-gene
- I-gene
Myb I-gene
may 0
be 0
important 0
early 0
in 0
the 0
establishment 0
of 0
the 0
hematopoietic 0
lineage 0
. 0

The 0
transforming 0
gene 0
of 0
the 0
avian B-gene
sarcoma I-gene
virus I-gene
CT10 I-gene
encodes 0
a 0
fusion 0
protein 0
( 0
p47gag B-gene
- 0
crk B-gene
or 0
v B-gene
- I-gene
Crk I-gene
) 0
containing 0
viral B-gene
Gag I-gene
sequences I-gene
fused 0
to 0
cellular 0
sequences 0
consisting 0
primarily 0
of 0
Src B-gene
homology I-gene
regions I-gene
2 I-gene
and I-gene
3 I-gene
( 0
SH2 B-gene
and 0
SH3 B-gene
sequences I-gene
) 0
. 0

This 0
specific 0
methylation 0
pattern 0
caused 0
inactivation 0
of 0
the 0
HSV B-gene
tk I-gene
gene I-gene
, 0
while 0
methylation 0
of 0
the 0
cytosine 0
residues 0
within 0
the 0
nucleotide 0
sequence 0
from 0
+811 0
to 0
+1309 0
had 0
no 0
effect 0
on 0
HSV B-gene
tk I-gene
gene I-gene
activity 0
. 0

CONCLUSION 0
: 0
This 0
study 0
documents 0
that 0
regression 0
of 0
choroidal 0
neovascularization 0
that 0
occurred 0
with 0
alpha B-gene
interferon I-gene
treatment 0
was 0
minimal 0
. 0

Long 0
- 0
range 0
mapping 0
of 0
the 0
11q23 0
region 0
involved 0
in 0
chromosome 0
aberrations 0
in 0
human 0
tumors 0
by 0
pulsed 0
- 0
field 0
gel 0
electrophoresis 0
with 0
a 0
yeast 0
artificial 0
chromosome 0
. 0

GTRE 0
, 0
TRE 0
, 0
and 0
CRE 0
oligonucleotides 0
all 0
compete 0
more 0
efficiently 0
for 0
protein 0
binding 0
to 0
their 0
labeled 0
congeners 0
than 0
for 0
protein 0
binding 0
to 0
either 0
of 0
the 0
other 0
labeled 0
oligonucleotides 0
, 0
suggesting 0
that 0
the 0
GTRE 0
, 0
TRE 0
, 0
and 0
CRE 0
oligonucleotides 0
, 0
suggesting 0
that 0
the 0
GTRE 0
, 0
TRE 0
, 0
and 0
CRE 0
oligonucleotides 0
each 0
bind 0
unique 0
as 0
well 0
as 0
common 0
proteins 0
, 0
likely 0
to 0
be 0
members 0
of 0
the 0
Jun/Fos B-gene
and 0
Jun/Fos I-gene

One 0
patient 0
only 0
had 0
any 0
test 0
abnormalities 0
. 0

One 0
antibody 0
, 0
mAb1C2 B-gene
, 0
and 0
a 0
synthetic 0
peptide 0
comprising 0
its 0
epitope 0
selectively 0
inhibited 0
in 0
vitro 0
transcription 0
from 0
TATA 0
- 0
containing 0
, 0
but 0
not 0
from 0
TATA 0
- 0
less 0
promoters 0
, 0
irrespective 0
of 0
whether 0
they 0
were 0
transcribed 0
by 0
Pol B-gene
II I-gene
or 0
Pol B-gene
III I-gene
. 0

The 0
lymph 0
nodes 0
from 0
two 0
of 0
the 0
patients 0
with 0
rheumatoid 0
arthritis 0
contained 0
numerous 0
sarcoid 0
like 0
granulomata 0
, 0
further 0
indicating 0
a 0
possible 0
association 0
between 0
sarcoidosis 0
and 0
rheumatoid 0
arthritis 0
. 0

HCV 0
infection 0
acquired 0
during 0
or 0
after 0
BMT 0
caused 0
only 0
mild 0
acute 0
hepatitis 0
C 0
, 0
which 0
progressed 0
to 0
chronic 0
hepatitis 0
C 0
in 0
one 0
patient 0
surviving 0
10 0
years 0
after 0
BMT 0
. 0

Hepatitis 0
C 0
virus 0
infection 0
is 0
a 0
risk 0
factor 0
for 0
liver 0
failure 0
from 0
veno 0
- 0
occlusive 0
disease 0
after 0
bone 0
marrow 0
transplantation 0
. 0

High 0
plasma 0
concentrations 0
of 0
soluble 0
E B-gene
- I-gene
selectin I-gene
were 0
closely 0
associated 0
with 0
multiple 0
- 0
organ 0
dysfunction 0
and 0
death 0
. 0

These 0
human 0
IFN B-gene
- I-gene
beta I-gene
- 0
transformed 0
cell 0
populations 0
have 0
acquired 0
a 0
low 0
, 0
constitutive 0
production 0
of 0
human B-gene
IFN I-gene
, 0
while 0
replicating 0
at 0
a 0
rate 0
similar 0
to 0
that 0
of 0
untransformed 0
cells 0
and 0
of 0
cells 0
transformed 0
with 0
the 0
control 0
vector 0
carrying 0
a 0
human B-gene
IFN I-gene
- I-gene
beta I-gene
sequence I-gene
encoding 0
an 0
inactive 0
, 0
mutated 0
protein 0
. 0

Improvement 0
of 0
the 0
polypyrimidine 0
tract 0
also 0
increased 0
the 0
splicing 0
efficiency 0
, 0
but 0
to 0
a 0
degree 0
slightly 0
less 0
than 0
that 0
obtained 0
with 0
the 0
branchpoint 0
mutation 0
. 0

Liver 0
transplantation 0
in 0
one 0
patient 0
resolved 0
metabolic 0
complications 0
but 0
did 0
not 0
improve 0
PMN 0
count 0
or 0
the 0
infectious 0
status 0
, 0
while 0
neutropenia 0
was 0
corrected 0
by 0
G B-gene
- I-gene
CSF I-gene
. 0

Joys 0
and 0
F 0
. 0

Activation 0
of 0
the 0
SH2 B-gene
- I-gene
containing I-gene
protein I-gene
tyrosine I-gene
phosphatase I-gene
, 0
SH B-gene
- I-gene
PTP2 I-gene
, 0
by 0
phosphotyrosine 0
- 0
containing 0
peptides 0
derived 0
from 0
insulin B-gene
receptor I-gene
substrate I-gene
- I-gene
1 I-gene
. 0

Tyrosine 0
phosphorylation 0
of 0
cellular 0
proteins 0
is 0
the 0
earliest 0
identifiable 0
event 0
following 0
T B-gene
- I-gene
cell I-gene
antigen I-gene
receptor I-gene
( 0
TCR B-gene
) 0
stimulation 0
and 0
is 0
essential 0
for 0
activating 0
downstream 0
signaling 0
machinery 0
. 0

The 0
interferon B-gene
- 0
induced 0
RNA B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
PKR B-gene
) 0
is 0
considered 0
to 0
play 0
an 0
important 0
role 0
in 0
the 0
cellular 0
defense 0
against 0
viral 0
infection 0
and 0
, 0
in 0
addition 0
, 0
has 0
been 0
suggested 0
to 0
be 0
a 0
tumor 0
suppressor 0
gene 0
because 0
of 0
its 0
growth 0
- 0
suppressive 0
properties 0
. 0

Moreover 0
, 0
Lck B-gene
was 0
reversibly 0
co 0
- 0
immunoprecipitated 0
with 0
p95Vav B-gene
, 0
and 0
the 0
stoichiometry 0
of 0
binding 0
increased 0
in 0
anti B-gene
- I-gene
CD3 I-gene
- 0
treated 0
Jurkat 0
cells 0
. 0

In 0
contrast 0
, 0
injection 0
of 0
a 0
plasmid 0
encoding 0
simian B-gene
virus I-gene
40 I-gene
small I-gene
t I-gene
antigen I-gene
, 0
which 0
interacts 0
with 0
PP2A B-gene
to 0
inhibit 0
its 0
activity 0
towards 0
several 0
phosphoprotein 0
substrates 0
, 0
had 0
no 0
effect 0
on 0
the 0
phosphorylation 0
state 0
of 0
CREB B-gene
in 0
stimulated 0
or 0
unstimulated 0
NIH 0
3T3 0
cells 0
. 0

Several 0
Src B-gene
SH3 I-gene
- I-gene
binding I-gene
proteins I-gene
were 0
phosphorylated 0
in 0
Src B-gene
- 0
transformed 0
cells 0
. 0

We 0
also 0
examined 0
the 0
effect 0
of 0
proteolytic 0
processing 0
in 0
the 0
MVE 0
nonstructural 0
polyprotein 0
segment 0
mediated 0
by 0
the 0
viral B-gene
proteinase I-gene
NS3 I-gene
on 0
antigen 0
processing 0
and 0
presentation 0
of 0
the 0
MVE 0
H 0
- 0
2Kk 0
- 0
restricted 0
T 0
cell 0
determinant 0
. 0

A 0
full B-gene
- I-gene
length I-gene
PRL I-gene
receptor I-gene
( 0
PRLR B-gene
) 0
complementary 0
DNA 0
from 0
pigeons 0
was 0
obtained 0
by 0
screening 0
pigeon 0
crop 0
sac 0
libraries 0
and 0
by 0
reverse 0
transcription 0
coupled 0
with 0
polymerase 0
chain 0
reaction 0
. 0

After 0
7 0
days 0
, 0
a 0
spontaneous 0
regression 0
of 0
the 0
morphologic 0
alterations 0
caused 0
by 0
caerulein 0
- 0
induced 0
acute 0
pancreatitis 0
occurs 0
; 0
however 0
, 0
recovery 0
of 0
the 0
secretory 0
function 0
of 0
the 0
pancreas 0
was 0
only 0
reached 0
after 0
this 0
period 0
of 0
time 0
when 0
L 0
- 0
364,718 0
was 0
administered 0
therapeutically 0
( 0
0.1 0
mg/kg/day 0
) 0
. 0

We 0
observed 0
that 0
dephosphorylation 0
severely 0
inhibits 0
the 0
DNA 0
- 0
binding 0
ability 0
of 0
C/EBP B-gene
- I-gene
delta I-gene
and 0
its 0
transactivating 0
potential 0
increases 0
in 0
the 0
presence 0
of 0
cellular 0
phosphatase 0
inhibitors 0
, 0
such 0
as 0
okadaic 0
acid 0
and 0
sodium 0
orthovanadate 0
. 0

Two 0
promoters 0
were 0
identified 0
by 0
S1 B-gene
nuclease I-gene
mapping 0
: 0
P1 0
, 0
which 0
lies 0
about 0
72 0
bp 0
upstream 0
from 0
the 0
structural 0
gene 0
; 0
and 0
P2 0
, 0
which 0
lies 0
about 0
35 0
bp 0
upstream 0
. 0

Interleukin B-gene
- I-gene
8 I-gene
( 0
IL B-gene
- I-gene
8 I-gene
) 0
is 0
a 0
potent 0
inflammatory 0
mediator 0
that 0
belongs 0
to 0
the 0
family 0
of 0
C B-gene
- I-gene
X I-gene
- I-gene
C I-gene
chemokines I-gene
. 0

On 0
the 0
other 0
hand 0
, 0
cells 0
containing 0
a 0
PTP1C B-gene
in 0
which 0
the 0
catalytic 0
site 0
had 0
been 0
inactivated 0
through 0
mutagenesis 0
, 0
stably 0
phosphorylated 0
the 0
phosphatase 0
. 0

We 0
recently 0
found 0
that 0
the 0
p72syk B-gene
protein I-gene
tyrosine I-gene
kinase I-gene
is 0
physically 0
associated 0
with 0
the 0
TCR/CD3 B-gene
complex 0
and 0
is 0
rapidly 0
tyrosine 0
phosphorylated 0
and 0
activated 0
by 0
receptor 0
triggering 0
also 0
in 0
T 0
cells 0
lacking 0
TCR/CD3 I-gene

The 0
transforming 0
protein 0
of 0
Rous 0
sarcoma 0
virus 0
, 0
pp60v B-gene
- I-gene
src I-gene
, 0
and 0
its 0
normal 0
cellular 0
homolog 0
, 0
pp60c B-gene
- I-gene
src I-gene
, 0
differ 0
not 0
only 0
in 0
oncogenic 0
potential 0
but 0
also 0
in 0
their 0
subcellular 0
localization 0
and 0
cytoskeletal 0
binding 0
ability 0
. 0
pp60v B-gene
- I-gene
src I-gene
has 0
been 0
shown 0
to 0
stably 0
associate 0
with 0
a 0
detergent 0
- 0
insoluble 0
cytoskeletal 0
matrix 0
, 0
whereas 0
pp60c B-gene
- I-gene
src I-gene
does 0
not 0
. 0

Organization 0
of 0
the 0
bovine 0
gene 0
encoding 0
the 0
endothelial B-gene
nitric I-gene
oxide I-gene
synthase I-gene
. 0

We 0
determined 0
whether 0
regional 0
myocardial 0
work 0
efficiency 0
( 0
segment 0
work/regional 0
O2 0
consumption 0
) 0
would 0
be 0
elevated 0
by 0
surgically 0
- 0
augmented 0
inflow 0
. 0

In 0
female 0
Sl B-gene
( I-gene
pan I-gene
) I-gene
/Sl I-gene
( I-gene
pan I-gene
) I-gene
mice 0
, 0
ovarian 0
follicle 0
development 0
is 0
arrested 0
at 0
the 0
one 0
layered 0
cuboidal 0
stage 0
as 0
a 0
result 0
of 0
reduced 0
KL B-gene
expression 0
in 0
follicle 0
cells 0
, 0
indicating 0
a 0
role 0
for 0
c B-gene
- I-gene
kit I-gene
in 0
oocyte 0
growth 0
. 0

Anti B-gene
- I-gene
NPROSP I-gene
- I-gene
C I-gene
also 0
exclusively 0
detected 0
time 0
- 0
dependent 0
appearances 0
of 0
5 B-gene
- I-gene
10 I-gene
- I-gene
kDa I-gene
proSP I-gene
- I-gene
C I-gene
forms 0
in 0
lamellar 0
bodies 0
and 0
homogenates 0
. 0

In 0
the 0
B6 0
- 0
derived 0
Db B-gene
mutant I-gene
B6.CH I-gene
- I-gene
2bm13 I-gene
( I-gene
bm13 I-gene
) I-gene
strain 0
, 0
part 0
of 0
the 0
class B-gene
I I-gene
Db I-gene
antigen I-gene
- I-gene
presenting I-gene
groove I-gene
is 0
shaped 0
by 0
a 0
class B-gene
I I-gene
Kb I-gene
- I-gene
encoded I-gene
sequence I-gene
. 0

Three 0
mutants 0
( 0
pms1 B-gene
, 0
pms2 B-gene
and 0
pms3 B-gene
) 0
isolated 0
earlier 0
from 0
MW104 0
- 0
1B 0
were 0
shown 0
to 0
correct 0
in 0
vitro 0
constructed 0
plasmids 0
with 0
defined 0
DNA 0
mismatches 0
( 0
G/T 0
, 0
A/C 0
, 0
G/G 0
, 0
etc 0
. 0
) 0
poorly 0
( 0
Kramer 0
et 0
al. 0
, 0
1989a 0
) 0
. 0

Our 0
findings 0
confirm 0
the 0
high 0
frequency 0
of 0
proximal 0
nerve 0
lesions 0
in 0
early 0
GBS 0
and 0
CIDP 0
, 0
not 0
all 0
of 0
which 0
are 0
associated 0
with 0
distal 0
motor 0
conduction 0
abnormalities 0
, 0
and 0
suggest 0
that 0
assessment 0
of 0
multiple 0
F 0
wave 0
parameters 0
, 0
in 0
particular 0
chronodispersion 0
, 0
mean 0
latency 0
and 0
mean 0
amplitude 0
( 0
in 0
addition 0
to 0
absence 0
and 0
minimum 0
latency 0
) 0
, 0
increases 0
the 0
yield 0
of 0
F 0
wave 0
studies 0
. 0

Hematopoietic B-gene
growth I-gene
factors I-gene
are 0
being 0
used 0
to 0
accelerate 0
the 0
recovery 0
of 0
myelopoiesis 0
following 0
high 0
- 0
dose 0
chemotherapy 0
in 0
cancer 0
patients 0
. 0

Effects 0
of 0
alterations 0
of 0
primer 0
- 0
binding 0
site 0
sequences 0
on 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
replication 0
. 0

Presentation 0
of 0
a 0
horse B-gene
cytochrome I-gene
c I-gene
peptide I-gene
by 0
multiple 0
H B-gene
- I-gene
2b I-gene
class I-gene
I I-gene
major I-gene
histocompatibility I-gene
complex I-gene
( 0
MHC B-gene
) 0
molecules 0
to 0
C57BL/6 0
- 0
and 0
bm1 0
- 0
derived 0
cytotoxic 0
T 0
lymphocytes 0
: 0
presence 0
of 0
a 0
single 0
MHC B-gene
anchor I-gene
residue I-gene
may 0
confer 0
efficient 0
peptide 0
- 0
specific 0
CTL 0
recognition 0
. 0

A 0
particularly 0
striking 0
HpaII B-gene
tiny 0
fragment 0
island 0
, 0
extending 0
over 0
nearly 0
2,000 0
base 0
pairs 0
, 0
surrounds 0
the 0
USF2 B-gene
translation I-gene
initiation I-gene
site I-gene
. 0

Diagnosis 0
of 0
prostatic 0
carcinoma 0
: 0
the 0
yield 0
of 0
serum B-gene
prostate I-gene
specific I-gene
antigen I-gene
, 0
digital 0
rectal 0
examination 0
and 0
transrectal 0
ultrasonography 0
. 0

Increased 0
granulocyte B-gene
- I-gene
colony I-gene
stimulating I-gene
factor I-gene
( 0
G B-gene
- I-gene
CSF I-gene
) 0
levels 0
in 0
neonates 0
with 0
perinatal 0
complications 0
. 0

The 0
results 0
revealed 0
a 0
hierarchy 0
of 0
ligand 0
affinities 0
that 0
mirrored 0
their 0
adhesive 0
activity 0
( 0
rsVCAM B-gene
- I-gene
1 I-gene
> 0
fibronectin B-gene
variants I-gene
containing 0
CS1 B-gene
> 0
> 0
other 0
fibronectin B-gene
variants I-gene
) 0
. 0

When 0
expressed 0
in 0
and 0
purified 0
from 0
Escherichia 0
coli 0
, 0
both 0
full B-gene
- I-gene
length I-gene
Fpr3 I-gene
and 0
its 0
isolated 0
COOH 0
- 0
terminal 0
domain 0
exhibit 0
readily 0
detectable 0
PPIase B-gene
activity 0
. 0

Dilutions 0
of 0
H B-gene
- I-gene
2b I-gene
or I-gene
H I-gene
- I-gene
2d I-gene
NP I-gene
peptides I-gene
indicated 0
that 0
3 0
- 0
4 0
logs 0
less 0
H B-gene
- I-gene
2b I-gene
NP I-gene
peptide I-gene
was 0
required 0
to 0
sensitize 0
syngeneic 0
target 0
cells 0
for 0
CTL 0
- 0
specific 0
lysis 0
, 0
suggesting 0
that 0
the 0
differing 0
affinities 0
of 0
H 0
- 0
2b 0
and 0
H 0
- 0
2d 0
major B-gene
histocompatibility I-gene
complex I-gene
molecules I-gene
for 0
their 0
peptides 0
likely 0
account 0
for 0
the 0
total 0
removal 0
of 0
NP 0
CTL 0
in 0
the 0
H 0
- 0
2b 0
mice 0
but 0
only 0
partial 0
removal 0
in 0
H 0
- 0
2d 0
mice 0
made 0
to 0
express 0
thymic 0
NP 0
. 0

However 0
, 0
expression 0
of 0
sigma B-gene
3 I-gene
from 0
S4 B-gene
( 0
3'UTR/S1 B-gene
) 0
, 0
which 0
included 0
the 0
PKR B-gene
activator I-gene
sequence I-gene
from 0
S1 B-gene
within 0
the 0
3' B-gene
- I-gene
UTR I-gene
of I-gene
S4 I-gene
, 0
was 0
comparable 0
to 0
that 0
from 0
wild B-gene
- I-gene
type I-gene
S4 I-gene
. 0

Microvessels 0
were 0
counted 0
in 0
a 0
x200 0
field 0
( 0
0.754 0
mm2 0
) 0
in 0
the 0
area 0
of 0
maximal 0
angiogenesis 0
. 0

Although 0
both 0
transfected 0
cell 0
lines 0
contain 0
FGF B-gene
- I-gene
1 I-gene
cell I-gene
surface I-gene
receptors I-gene
as 0
judged 0
by 0
crosslinking 0
studies 0
, 0
the 0
wild 0
- 0
type 0
transfectants 0
are 0
refractory 0
to 0
exogenous 0
FGF B-gene
- I-gene
1 I-gene
, 0
whereas 0
the 0
mutant 0
transfectants 0
respond 0
normally 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Recent 0
studies 0
have 0
demonstrated 0
that 0
the 0
activated 0
GH B-gene
receptor I-gene
can 0
stimulate 0
Stat1 B-gene
, 0
a 0
cytoplasmic 0
transcription 0
factor 0
that 0
becomes 0
tyrosine 0
phosphorylated 0
and 0
translocates 0
to 0
the 0
nucleus 0
, 0
where 0
it 0
can 0
interact 0
with 0
specific 0
DNA 0
sequences 0
to 0
modulate 0
gene 0
expression 0
. 0

In 0
viral 0
infections 0
, 0
G B-gene
- I-gene
CSF I-gene
was 0
correlated 0
with 0
mononuclear 0
cells 0
( 0
rs 0
= 0
0.41 0
, 0
P 0
< 0
0.05 0
) 0
, 0
white 0
blood 0
cell 0
counts 0
( 0
rs 0
= 0
0.56 0
, 0
P 0
< 0
0.01 0
) 0
, 0
neutrophils 0
( 0
rs 0
= 0
0.41 0
, 0
P 0
< 0
0.05 0
) 0
and 0
CRP B-gene
( 0
rs 0
= 0
0.47 0
, 0
P 0
< 0
0.05 0
) 0
. 0

Minor 0
initiation 0
sites 0
were 0
found 0
at 0
positions 0
- 0
128 0
, 0
- 0
111 0
, 0
- 0
91 0
, 0
and 0
- 0
74 0
. 0

Phosphoamino 0
acid 0
analysis 0
of 0
radiolabeled 0
ASGPR B-gene
subunits I-gene
identified 0
Ser 0
( 0
P 0
) 0
as 0
the 0
predominant 0
( 0
approximately 0
95 0
% 0
) 0
and 0
Thr 0
( 0
P 0
) 0
as 0
a 0
minor 0
( 0
approximately 0
5 0
% 0
) 0
phosphoamino 0
acid 0
in 0
each 0
polypeptide 0
and 0
confirmed 0
the 0
presence 0
of 0
Tyr 0
( 0
P 0
) 0
( 0
approximately 0
1 0
% 0
) 0
in 0
RHL1 B-gene
. 0

To 0
further 0
define 0
the 0
structural 0
requirements 0
for 0
ZAP B-gene
- I-gene
70 I-gene
interaction 0
with 0
the 0
TCR B-gene
, 0
we 0
developed 0
a 0
binding 0
assay 0
using 0
immobilized 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
fusion I-gene
proteins I-gene
containing 0
the 0
NH2 0
- 0
and/or 0
COOH B-gene
- I-gene
terminal I-gene
SH2 I-gene
domains I-gene
of 0
ZAP B-gene
- I-gene
70 I-gene
, 0
and 0
soluble 0
synthetic 0
peptides 0
with 0
the 0
sequence 0
of 0
the 0
cytoplasmic 0
region 0
of 0
the 0
TCR B-gene
zeta I-gene
chain I-gene
( 0
TCR B-gene
zeta I-gene
cyt I-gene
) 0
or 0
individual 0
TCR B-gene
zeta I-gene
and 0
CD3 B-gene
epsilon I-gene
TAM I-gene
motifs I-gene
. 0

All 0
four 0
doubly 0
tyrosine 0
phosphorylated 0
TAM 0
peptides 0
cross 0
- 0
compete 0
with 0
each 0
other 0
for 0
binding 0
to 0
the 0
tandem 0
SH2 B-gene
domains I-gene
of 0
ZAP B-gene
- I-gene
70 I-gene
. 0

The 0
three 0
- 0
dimensional 0
structure 0
of 0
RT B-gene
shows 0
that 0
it 0
is 0
a 0
strikingly 0
asymmetric 0
heterodimer 0
consisting 0
of 0
two 0
differently 0
folded 0
subunits 0
( 0
molecular 0
weights 0
66 0
kDa 0
and 0
51 0
kDa 0
) 0
with 0
identical 0
amino 0
- 0
terminal 0
amino 0
acid 0
sequences 0
( 0
residues 0
1 0
- 0
428 0
) 0
. 0

Pharmacological 0
and 0
pharmacokinetic 0
characteristics 0
of 0
the 0
non 0
- 0
ionic 0
monomeric 0
X 0
- 0
ray 0
contrast 0
agent 0
iopromide 0
( 0
Ultravist 0
, 0
CAS 0
73334 0
- 0
07 0
- 0
3 0
) 0
were 0
evaluated 0
in 0
preclinical 0
studies 0
. 0

All 0
subsequent 0
patients 0
were 0
treated 0
at 0
the 0
maximal 0
tolerated 0
dose 0
of 0
EDXR 0
( 0
35 0
mg/m2/day 0
) 0
. 0

The 0
median 0
post 0
- 0
treatment 0
, 0
pre 0
- 0
operative 0
serum B-gene
PSA I-gene
was 0
0.4 0
ng/ml 0
. 0

Addition 0
of 0
soluble 0
recombinant B-gene
human I-gene
SLF I-gene
to 0
SI4 0
- 0
h220 0
cultures 0
enhanced 0
reduction 0
of 0
cell 0
- 0
surface 0
c B-gene
- I-gene
kit I-gene
expression 0
and 0
its 0
protein 0
degradation 0
. 0

Membrane 0
- 0
bound 0
Steel B-gene
factor I-gene
induces 0
more 0
persistent 0
tyrosine B-gene
kinase I-gene
activation 0
and 0
longer 0
life 0
span 0
of 0
c B-gene
- I-gene
kit I-gene
gene 0
- 0
encoded 0
protein 0
than 0
its 0
soluble 0
form 0
. 0

Analysis 0
of 0
the 0
sequences 0
with 0
the 0
BLAST 0
and 0
GRAIL 0
programs 0
provided 0
additional 0
independent 0
evidence 0
that 0
15 0
of 0
these 0
17 0
clones 0
contain 0
coding 0
sequences 0
and 0
that 0
nine 0
other 0
clones 0
are 0
likely 0
to 0
contain 0
sequences 0
coding 0
for 0
portions 0
of 0
new 0
genes 0
. 0

Patients 0
with 0
more 0
than 0
250 0
PVC/24 0
hours 0
were 0
selected 0
for 0
distribution 0
of 0
PVC 0
and 0
CI 0
evaluation 0
. 0

Horvath 0
, 0
I 0
. 0

Cell 0
lines 0
derived 0
from 0
the 0
tumors 0
were 0
examined 0
by 0
fluorescent 0
in 0
situ 0
hybridization 0
for 0
the 0
status 0
of 0
the 0
transferred 0
human 0
chromosome 0
and 0
by 0
PCR 0
for 0
marker 0
loss 0
. 0

The 0
amino 0
acid 0
sequences 0
of 0
the 0
predicted 0
RfbA B-gene
and 0
RfbB B-gene
homologs I-gene
showed 0
identities 0
of 0
75.7 0
% 0
( 0
87.9 0
% 0
total 0
similarity 0
) 0
and 0
78.0 0
% 0
( 0
86.5 0
% 0
total 0
similarity 0
) 0
, 0
respectively 0
. 0

However 0
, 0
multiple 0
alanine 0
substitutions 0
or 0
proline 0
( 0
helix 0
- 0
destabilizing 0
) 0
substitutions 0
disrupted 0
both 0
oligomerization 0
and 0
transport 0
of 0
GP64 B-gene
EFP I-gene
. 0

The 0
FinO B-gene
protein I-gene
of 0
IncF 0
plasmids 0
binds 0
FinP B-gene
antisense I-gene
RNA I-gene
and 0
its 0
target 0
, 0
traJ B-gene
mRNA I-gene
, 0
and 0
promotes 0
duplex 0
formation 0
. 0

In 0
this 0
paper 0
we 0
report 0
that 0
ligand 0
binding 0
induced 0
tyrosine 0
phosphorylation 0
in 0
BaF3 0
cells 0
engineered 0
to 0
express 0
the 0
murine B-gene
Mpl I-gene
receptor I-gene
( 0
BaF3/mMpl B-gene
) 0
. 0

A 0
chicken B-gene
paxillin I-gene
cDNA I-gene
was 0
also 0
cloned 0
and 0
is 0
predicted 0
to 0
encode 0
a 0
protein 0
approximately 0
90 0
% 0
identical 0
to 0
human B-gene
paxil I-gene
- I-gene
lin I-gene
. 0

We 0
linked 0
a 0
4.1 0
- 0
kilobase 0
pair 0
HindIII B-gene
DNA I-gene
fragment I-gene
from 0
the 0
region 0
upstream 0
of 0
the 0
human B-gene
AP I-gene
endonuclease I-gene
gene I-gene
( 0
APE B-gene
) 0
to 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
gene 0
. 0

The 0
overexpressed 0
His6 B-gene
- I-gene
tagged I-gene
GrsA I-gene
derivatives I-gene
were 0
affinity 0
- 0
purified 0
, 0
and 0
the 0
catalytic 0
properties 0
of 0
the 0
deletion 0
mutants 0
were 0
examined 0
by 0
biochemical 0
studies 0
including 0
ATP 0
- 0
dependent 0
amino 0
acid 0
activation 0
, 0
carboxyl 0
thioester 0
formation 0
, 0
and 0
the 0
ability 0
to 0
racemize 0
the 0
covalently 0
bound 0
phenylalanine 0
from 0
L 0
- 0
to 0
the 0
D 0
- 0
isomer 0
. 0

CD7+/CD3 B-gene
- 0
T 0
- 0
cell 0
precursors 0
exhibit 0
CD7+/CD3 I-gene

HVH2 B-gene
mRNA I-gene
showed 0
an 0
expression 0
pattern 0
distinct 0
from 0
CL100 B-gene
( 0
human B-gene
homologue I-gene
of I-gene
mouse I-gene
MKP1 I-gene
) 0
and 0
PAC1 B-gene
, 0
two 0
previously 0
identified 0
MAP B-gene
kinase I-gene
phosphatases I-gene
. 0

These 0
data 0
suggest 0
that 0
these 0
sequences 0
located 0
immediately 0
3 0
' 0
to 0
the 0
breakpoint 0
of 0
the 0
HPFH B-gene
- I-gene
3 I-gene
deletion I-gene
, 0
exhibit 0
both 0
the 0
structure 0
and 0
the 0
function 0
of 0
an 0
enhancer 0
, 0
and 0
can 0
modify 0
the 0
developmental 0
specificity 0
of 0
the 0
fetal B-gene
gamma I-gene
- I-gene
globin I-gene
genes I-gene
, 0
resulting 0
in 0
their 0
continued 0
expression 0
during 0
adult 0
life 0
. 0

In 0
vivo 0
association 0
between 0
Shb B-gene
- 0
SH3 B-gene
domain 0
proteins 0
v B-gene
- I-gene
Src I-gene
and 0
Eps8 B-gene
was 0
detected 0
by 0
coimmunoprecipitation 0
. 0

Our 0
results 0
indicate 0
that 0
interaction 0
between 0
Jak2 B-gene
and 0
PRLR B-gene
requires 0
a 0
proline 0
- 0
rich 0
sequence 0
in 0
the 0
membrane 0
proximal 0
region 0
of 0
the 0
receptor 0
, 0
which 0
is 0
conserved 0
among 0
the 0
different 0
members 0
of 0
the 0
cytokine B-gene
receptor I-gene
superfamily I-gene
. 0

Transcription 0
of 0
the 0
vascular B-gene
cell I-gene
adhesion I-gene
molecule I-gene
1 I-gene
( 0
VCAM B-gene
- I-gene
1 I-gene
) 0
gene 0
in 0
endothelial 0
cells 0
is 0
induced 0
by 0
lipopolysaccharide 0
and 0
the 0
inflammatory 0
cytokines B-gene
interleukin I-gene
- I-gene
1 I-gene
beta I-gene
and 0
tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
( 0
TNF B-gene
- I-gene
alpha I-gene
) 0
. 0

Experiments 0
with 0
recombinant 0
proteins 0
showed 0
that 0
p50/p65 B-gene
and 0
p50/p65 I-gene

Based 0
on 0
these 0
results 0
the 0
minimal 0
control 0
element 0
( 0
AX 0
470 0
) 0
specifying 0
the 0
anterior 0
boundary 0
of 0
Hox B-gene
expression 0
was 0
designated 0
as 0
Hoxa B-gene
- I-gene
7 I-gene
enhancer I-gene
. 0

In 0
this 0
report 0
we 0
describe 0
the 0
isolation 0
of 0
a 0
Fab B-gene
fragment I-gene
( 0
Fab B-gene
A8 I-gene
) 0
showing 0
a 0
high 0
relative 0
affinity 0
for 0
the 0
receptor 0
( 0
0.5 0
nM 0
) 0
. 0

MBP B-gene
- 0
Rep68 B-gene
delta I-gene
- 0
mediated 0
DNA 0
- 0
RNA 0
helicase 0
activity 0
required 0
ATP 0
hydrolysis 0
and 0
the 0
presence 0
of 0
Mg2+ 0
ions 0
and 0
was 0
inhibited 0
by 0
high 0
ionic 0
strength 0
. 0

To 0
identify 0
critical 0
regions 0
mediating 0
growth 0
signal 0
transduction 0
by 0
hG B-gene
- I-gene
CSFR I-gene
, 0
deletions 0
or 0
site 0
- 0
directed 0
amino 0
acid 0
substitutions 0
were 0
introduced 0
into 0
the 0
cytoplasmic 0
domain 0
of 0
hG B-gene
- I-gene
CSFR I-gene
, 0
and 0
the 0
mutant 0
cDNAs 0
were 0
transfected 0
into 0
the 0
murine B-gene
interleukin I-gene
- I-gene
3 I-gene
( 0
IL B-gene
- I-gene
3 I-gene
) 0
- 0
dependent 0
Ba/F3 0
and 0
FDCP 0
cell 0
lines 0
. 0

When 0
combined 0
with 0
independent 0
activating 0
mutations 0
in 0
the 0
c B-gene
- I-gene
abl I-gene
kinase I-gene
domain I-gene
or 0
NH2 0
- 0
terminus 0
, 0
the 0
G128R B-gene
mutation 0
blocked 0
transformation 0
by 0
the 0
double 0
mutant 0
, 0
suggesting 0
that 0
the 0
G128R B-gene
mutant I-gene
was 0
unable 0
to 0
transform 0
cells 0
for 0
trivial 0
reasons 0
. 0

Both 0
mutations 0
completely 0
abolished 0
binding 0
of 0
the 0
Abl B-gene
SH3 B-gene
domain 0
to 0
proline 0
- 0
rich 0
target 0
proteins 0
in 0
a 0
filter 0
- 0
binding 0
assay 0
. 0

Changes 0
induced 0
in 0
the 0
gills 0
of 0
milkfish 0
( 0
Chanos 0
chanos 0
Forsskal 0
) 0
fingerlings 0
after 0
acute 0
exposure 0
to 0
nifurpirinol 0
( 0
Furanace 0
; 0
P 0
- 0
7138 0
) 0
. 0

Retreatment 0
of 0
these 0
2 0
dogs 0
resulted 0
in 0
a 0
similar 0
, 0
but 0
blunted 0
, 0
response 0
to 0
human B-gene
immunoglobulin I-gene
. 0

The 0
levels 0
of 0
NSE B-gene
and 0
MBP B-gene
in 0
the 0
IJVB 0
were 0
compared 0
to 0
those 0
in 0
the 0
PVB 0
. 0

As 0
expected 0
, 0
the 0
insulin B-gene
effect 0
to 0
increase 0
ras B-gene
GTP I-gene
formation 0
and 0
MAP B-gene
kinase I-gene
activity 0
was 0
negligible 0
in 0
A/K1018 0
cells 0
but 0
normal 0
, 0
or 0
supernormal 0
, 0
in 0
Y/F2 0
cells 0
. 0

Morphologic 0
variables 0
included 0
cancer 0
volume 0
, 0
histologic 0
grade 0
, 0
capsular 0
penetration 0
, 0
seminal 0
vesicle 0
invasion 0
, 0
and 0
lymph 0
node 0
metastasis 0
. 0

Sequence 0
analysis 0
of 0
these 0
regions 0
showed 0
a 0
CAAT 0
box 0
upstream 0
of 0
exon 0
1a 0
and 0
high 0
G 0
- 0
C 0
content 0
regions 0
within 0
both 0
P1 0
and 0
P2 0
. 0

The 0
fusion 0
proteins 0
were 0
tested 0
by 0
ELISA 0
for 0
reactivity 0
with 0
a 0
panel 0
of 0
human B-gene
anti I-gene
- I-gene
La I-gene
sera I-gene
in 0
order 0
to 0
define 0
the 0
nature 0
of 0
the 0
epitopes 0
. 0

GCD10 B-gene
was 0
first 0
identified 0
genetically 0
as 0
a 0
translational 0
repressor 0
of 0
GCN4 B-gene
. 0

GCD10 B-gene
binds 0
RNA 0
in 0
vitro 0
and 0
we 0
present 0
strong 0
biochemical 0
evidence 0
that 0
it 0
is 0
identical 0
to 0
the 0
RNA 0
- 0
binding 0
subunit 0
of 0
yeast B-gene
initiation I-gene
factor I-gene
- I-gene
3 I-gene
( 0
eIF B-gene
- I-gene
3 I-gene
) 0
. 0
eIF B-gene
- I-gene
3 I-gene
is 0
a 0
multisubunit 0
complex 0
that 0
stimulates 0
translation 0
initiation 0
in 0
vitro 0
at 0
several 0
different 0
steps 0
. 0

Sources 0
of 0
noise 0
in 0
these 0
signals 0
were 0
evaluated 0
in 0
preparations 0
stained 0
with 0
the 0
potentiometric 0
probe 0
RH 0
- 0
414 0
. 0

1993 0
. 0

A 0
transformation 0
- 0
competent 0
mutant 0
, 0
like 0
the 0
wild B-gene
- I-gene
type I-gene
E5 I-gene
protein I-gene
, 0
bound 0
the 0
receptor 0
and 0
induced 0
receptor 0
tyrosine 0
phosphorylation 0
and 0
down 0
- 0
regulation 0
. 0

We 0
conclude 0
that 0
cAMP 0
, 0
acting 0
through 0
PKA B-gene
, 0
is 0
an 0
essential 0
regulator 0
of 0
basal 0
CFTR B-gene
gene I-gene
expression 0
and 0
may 0
mediate 0
an 0
induction 0
of 0
CFTR B-gene
in 0
responsive 0
cell 0
types 0
. 0

Appropriate 0
restriction 0
sites 0
allow 0
one 0
to 0
insert 0
virtually 0
any 0
desired 0
cDNA 0
fragment 0
directly 0
behind 0
the 0
epitope 0
- 0
specific 0
sequence 0
and 0
before 0
a 0
long 0
poly 0
( 0
A 0
) 0
tail 0
. 0

Both 0
PPC 0
- 0
1 0
and 0
ALVA 0
- 0
31 0
cells 0
display 0
tumorigenesis 0
and 0
invasiveness 0
in 0
nude 0
mice 0
, 0
whereas 0
LNCap 0
cells 0
exhibit 0
a 0
less 0
malignant 0
phenotype 0
, 0
suggesting 0
a 0
correlation 0
between 0
CD44 B-gene
variant I-gene
( 0
CD44v B-gene
) 0
expression 0
and 0
aggressive 0
prostate 0
tumor 0
behavior 0
. 0

The 0
gene 0
product 0
of 0
cotS B-gene
was 0
confirmed 0
to 0
be 0
identical 0
to 0
Cot40 B-gene
- I-gene
2 I-gene
by 0
SDS 0
- 0
PAGE 0
and 0
immunoblotting 0
from 0
Escherichia 0
coli 0
transformed 0
with 0
a 0
plasmid 0
containing 0
the 0
cotS B-gene
region I-gene
. 0

Two 0
such 0
genes 0
, 0
designated 0
hsiggll150 B-gene
and 0
hsiggll295 B-gene
, 0
were 0
cloned 0
and 0
sequenced 0
from 0
genomic 0
DNA 0
. 0

A 0
retrospective 0
epidemiological 0
study 0
is 0
reported 0
concerning 0
burn 0
injuries 0
in 0
775 0
children 0
hospitalized 0
at 0
the 0
unit 0
of 0
burn 0
care 0
of 0
Casablanca 0
between 0
1985 0
and 0
1993 0
. 0

Our 0
results 0
suggest 0
that 0
protein 0
binding 0
to 0
the 0
E2F B-gene
- I-gene
like I-gene
sequences I-gene
may 0
act 0
to 0
reduce 0
expression 0
. 0

The 0
RAD6/UBC2 B-gene
gene 0
from 0
Saccharomyces 0
cerevisiae 0
encodes 0
a 0
RAD6/UBC2 I-gene

Echocardiography 0
revealed 0
right 0
ventricular 0
diastolic 0
collapse 0
( 0
RVDC 0
) 0
without 0
physical 0
signs 0
of 0
cardiac 0
tamponade 0
. 0

In 0
on 0
- 0
going 0
screening 0
programmes 0
, 0
the 0
Haemoccult 0
test 0
consists 0
of 0
six 0
slides 0
and 0
a 0
test 0
is 0
considered 0
positive 0
if 0
at 0
least 0
one 0
slide 0
is 0
coloured 0
. 0

We 0
showed 0
previously 0
that 0
a 0
fusion 0
protein 0
( 0
GAL4 B-gene
- 0
p40 B-gene
) 0
containing 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
GAL4 B-gene
and 0
sequences 0
of 0
chicken B-gene
l I-gene
kappa I-gene
B I-gene
- I-gene
alpha I-gene
( 0
p40 B-gene
) 0
inhibits 0
growth 0
in 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

We 0
have 0
demonstrated 0
previously 0
that 0
two 0
binding 0
sites 0
in 0
the 0
- B-gene
184 I-gene
HNF I-gene
- I-gene
3 I-gene
beta I-gene
promoter I-gene
are 0
recognized 0
by 0
widely 0
distributed 0
factors 0
and 0
that 0
there 0
is 0
also 0
a 0
critical 0
autoregulatory 0
site 0
, 0
we 0
identified 0
a 0
binding 0
site 0
for 0
a 0
cell 0
- 0
specific 0
factor 0
, 0
LF B-gene
- I-gene
H3 I-gene
beta I-gene
, 0
that 0
may 0
function 0
in 0
restricting 0
HNF B-gene
- I-gene
3 I-gene
beta I-gene
gene I-gene
expression 0
to 0
hepatocytes 0
. 0

In 0
4 0
spinalized 0
cats 0
, 0
the 0
effects 0
of 0
afferent 0
inputs 0
from 0
hindlimb 0
cutaneous 0
nerves 0
( 0
sural 0
cutaneous 0
nerve 0
: 0
Sur 0
) 0
on 0
mono 0
- 0
and 0
poly 0
- 0
synaptic 0
reflex 0
recorded 0
from 0
tail 0
muscle 0
motoneurons 0
were 0
studied 0
before 0
and 0
after 0
spinal 0
lesioning 0
at 0
S2 0
- 0
3 0
level 0
. 0

The 0
flow 0
rate 0
of 0
phosphate 0
buffered 0
saline 0
through 0
dermis 0
was 0
measured 0
as 0
a 0
function 0
of 0
applied 0
pressure 0
. 0

However 0
, 0
parallax 0
measurements 0
showed 0
that 0
at 0
150K 0
, 0
collapse 0
of 0
Epon 0
sections 0
does 0
not 0
take 0
place 0
. 0

Although 0
within 0
normal 0
limits 0
, 0
latency 0
was 0
high 0
. 0

The 0
outcome 0
of 0
the 0
optimization 0
of 0
the 0
seven 0
- 0
field 0
plan 0
prompted 0
an 0
investigation 0
into 0
the 0
best 0
results 0
that 0
could 0
be 0
achieved 0
by 0
an 0
`` 0
ideal 0
'' 0
conformal 0
radiotherapy 0
technique 0
. 0

Specific 0
requirements 0
for 0
branched 0
- 0
chain 0
amino 0
acids 0
, 0
glutamine 0
, 0
and 0
arginine 0
are 0
evaluated 0
. 0

The 0
pea B-gene
rps10 I-gene
intron I-gene
is 0
homologous 0
to 0
introns 0
in 0
rrn26 B-gene
and 0
cox3 B-gene
in 0
the 0
Marchantia 0
mitochondrial 0
genome 0
, 0
while 0
the 0
Marchantia B-gene
rps10 I-gene
gene I-gene
lacks 0
an 0
intron 0
. 0

The 0
optimal 0
care 0
of 0
CHF 0
patient 0
includes 0
the 0
recognition 0
and 0
management 0
of 0
these 0
electrolyte 0
disturbances 0
. 0

Serum 0
magnesium 0
in 0
79 0
patients 0
of 0
gynecologic 0
neoplasms 0
treated 0
with 0
cisplatin 0
and 0
their 0
controls 0
was 0
measured 0
. 0

METHODS 0
: 0
rHb1.1 B-gene
or 0
human B-gene
serum I-gene
albumin I-gene
was 0
administered 0
intravenously 0
to 0
fasting 0
male 0
volunteers 0
. 0

Alanine B-gene
aminotransferase I-gene
( 0
ALT B-gene
) 0
levels 0
had 0
been 0
elevated 0
for 0
six 0
months 0
in 0
all 0
patients 0
and 0
hepatitis 0
B 0
viral 0
infection 0
was 0
replicative 0
. 0

In 0
this 0
study 0
we 0
have 0
investigated 0
the 0
role 0
of 0
C/EBP B-gene
beta I-gene
in 0
initiating 0
the 0
adipogenic 0
program 0
by 0
overexpressing 0
C/EBP B-gene
beta I-gene
in 0
multipotential 0
NIH 0
- 0
3T3 0
fibroblasts 0
. 0

XYL1 B-gene
was 0
isolated 0
as 0
a 0
highly 0
expressed 0
fusion 0
clone 0
from 0
a 0
'lacZ B-gene
translational 0
fusion 0
library 0
. 0

Various 0
transcripts 0
are 0
generated 0
from 0
the 0
VCSA1 B-gene
gene I-gene
by 0
alternative 0
splicing 0
and 0
poly 0
( 0
A 0
) 0
processing 0
in 0
the 0
rat 0
submandibular 0
gland 0
. 0

However 0
, 0
division 0
of 0
the 0
chest 0
wall 0
muscles 0
, 0
usually 0
with 0
diathermy 0
, 0
contributes 0
to 0
prolonged 0
pain 0
and 0
morbidity 0
. 0

Closure 0
of 0
an 0
open 0
high 0
below 0
- 0
knee 0
guillotine 0
amputation 0
wound 0
using 0
a 0
skin 0
- 0
stretching 0
device 0
. 0

Our 0
study 0
was 0
addressed 0
to 0
the 0
synthesis 0
of 0
some 0
derivatives 0
of 0
this 0
sequence 0
in 0
order 0
to 0
obtain 0
both 0
peptide 0
substrates 0
suitable 0
for 0
the 0
detection 0
of 0
the 0
Src B-gene
- 0
like 0
tyrosine B-gene
kinase I-gene
activity 0
and 0
active 0
site 0
- 0
directed 0
inhibitors 0
specific 0
for 0
this 0
class 0
of 0
enzymes 0
. 0

Citrate B-gene
synthase I-gene
activity 0
was 0
increased 0
in 0
the 0
medial 0
head 0
( 0
81 0
% 0
, 0
P 0
< 0
0.001 0
) 0
and 0
the 0
red 0
long 0
head 0
( 0
88 0
% 0
, 0
P 0
< 0
0.001 0
) 0
of 0
the 0
triceps 0
brachii 0
muscle 0
in 0
R 0
rats 0
but 0
not 0
in 0
the 0
white 0
long 0
head 0
( 0
25 0
% 0
, 0
P 0
= 0
0.06 0
) 0
. 0

The 0
expression 0
of 0
the 0
putative 0
operon 0
bglPH B-gene
of 0
Bacillus 0
subtilis 0
was 0
studied 0
by 0
using 0
bglP' B-gene
- 0
lacZ B-gene
transcriptional 0
fusions 0
. 0

Although 0
eight 0
contiguous 0
genes 0
necessary 0
for 0
urease B-gene
activity 0
have 0
been 0
cloned 0
and 0
sequenced 0
, 0
the 0
transcriptional 0
organization 0
and 0
regulation 0
of 0
specific 0
genes 0
within 0
the 0
Proteus B-gene
gene I-gene
cluster I-gene
has 0
not 0
been 0
investigated 0
in 0
detail 0
. 0

The 0
hypBFCDE B-gene
operon I-gene
from 0
Rhizobium 0
leguminosarum 0
biovar 0
viciae 0
is 0
expressed 0
from 0
an 0
Fnr B-gene
- I-gene
type I-gene
promoter I-gene
that 0
escapes 0
mutagenesis 0
of 0
the 0
fnrN B-gene
gene I-gene
. 0

We 0
demonstrate 0
that 0
a 0
VT+ 0
peptide 0
was 0
specifically 0
phosphorylated 0
by 0
protein B-gene
kinase I-gene
C I-gene
( 0
PKC B-gene
) 0
in 0
vitro 0
, 0
but 0
not 0
by 0
protein B-gene
kinase I-gene
A I-gene
( 0
PKA B-gene
) 0
. 0

R 0
. 0

15 0
, 0
2500 0
- 0
2508 0
; 0
O'Neill 0
, 0
T 0
. 0

Control 0
experiments 0
showed 0
that 0
each 0
fusion 0
protein 0
had 0
a 0
high 0
affinity 0
binding 0
site 0
for 0
estradiol 0
- 0
17 0
beta 0
and 0
could 0
transactivate 0
an 0
ERE 0
- 0
LacZ B-gene
reporter 0
gene 0
in 0
yeast 0
similar 0
to 0
the 0
wild B-gene
type I-gene
ER I-gene
. 0

Although 0
Micrococcus B-gene
luteus I-gene
UV I-gene
endonuclease I-gene
has 0
been 0
reported 0
to 0
be 0
an 0
18 0
- 0
kDa 0
enzyme 0
with 0
possible 0
homology 0
to 0
the 0
16 B-gene
- I-gene
kDa I-gene
endonuclease I-gene
V I-gene
from I-gene
bacteriophage I-gene
T4 I-gene
( 0
Gordon 0
, 0
L 0
. 0

Several 0
different 0
oncogenes 0
and 0
growth 0
factors 0
promote 0
G1 0
phase 0
progression 0
. 0

Cyclin B-gene
D1 I-gene
promoter I-gene
activity 0
was 0
stimulated 0
by 0
overexpression 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
p41MAPK B-gene
) 0
or 0
c B-gene
- I-gene
Ets I-gene
- I-gene
2 I-gene
through 0
the 0
proximal 0
22 0
base 0
pairs 0
. 0

Indeed 0
, 0
ERM B-gene
and 0
c B-gene
- I-gene
Jun I-gene
synergistically 0
activated 0
the 0
EBS 0
- 0
CRE 0
without 0
making 0
an 0
apparent 0
ternary 0
complex 0
. 0

A 0
mutant 0
( 0
residues 0
1 0
- 0
332 0
) 0
showed 0
complete 0
Ca2+/CaM B-gene
- 0
dependent 0
activity 0
. 0

In 0
addition 0
, 0
the 0
R206S B-gene
HSF I-gene
substitution 0
exhibits 0
constitutive 0
transcriptional 0
activation 0
from 0
a 0
consensus 0
HSE 0
( 0
HSE2 0
) 0
. 0

The 0
two 0
bases 0
immediately 0
flanking 0
the 0
5 0
' 0
end 0
of 0
the 0
element 0
proved 0
to 0
be 0
very 0
important 0
to 0
its 0
function 0
as 0
a 0
UAS 0
element 0
as 0
did 0
the 0
two 0
bases 0
immediately 0
3 0
' 0
of 0
the 0
bHLH 0
core 0
motif 0
. 0

These 0
results 0
indicate 0
that 0
the 0
PCNA B-gene
gene I-gene
is 0
a 0
likely 0
target 0
gene 0
of 0
E2F B-gene
. 0

Differential 0
sensitivity 0
of 0
the 0
MMPI 0
- 0
2 0
depression 0
scales 0
and 0
subscales 0
. 0

After 0
recovery 0
, 0
a 0
hypertonic 0
saline 0
challenge 0
was 0
performed 0
. 0

The 0
range 0
of 0
eosinophils 0
was 0
22 0
- 0
56 0
% 0
of 0
the 0
number 0
of 0
peripheral 0
white 0
blood 0
cells 0
( 0
mean 0
nadir 0
33 0
% 0
) 0
. 0

Comparisons 0
of 0
rrnB B-gene
P1 B-gene
- 0
lacZ B-gene
expression 0
at 0
different 0
ppGpp 0
levels 0
is 0
interpreted 0
for 0
the 0
rpoD B-gene
( I-gene
P504L I-gene
) I-gene
mutant I-gene
as 0
resulting 0
from 0
a 0
hypersensitivity 0
to 0
ppGpp 0
. 0

These 0
intron 0
chimeras 0
show 0
that 0
peripheral 0
sequences 0
and 0
the 0
elements 0
that 0
define 0
the 0
splice 0
sites 0
are 0
adequate 0
for 0
self 0
- 0
splicing 0
activity 0
but 0
that 0
the 0
central 0
portions 0
containing 0
the 0
catalytic 0
cores 0
of 0
ai4 B-gene
and 0
bi4 B-gene
are 0
deficient 0
; 0
these 0
cores 0
are 0
the 0
likely 0
targets 0
of 0
the 0
splicing 0
proteins 0
. 0

Here 0
we 0
demonstrate 0
genetically 0
that 0
plus 0
- 0
strand 0
DNA 0
synthesis 0
of 0
the 0
yeast B-gene
Ty1 I-gene
element I-gene
is 0
initiated 0
at 0
two 0
sites 0
located 0
at 0
the 0
5 0
' 0
boundary 0
of 0
the 0
3 0
' 0
long 0
terminal 0
repeat 0
( 0
PPT1 B-gene
) 0
and 0
near 0
the 0
middle 0
of 0
the 0
pol B-gene
gene I-gene
in 0
the 0
integrase B-gene
coding I-gene
sequence I-gene
( 0
PPT2 B-gene
) 0
. 0

Characterization 0
of 0
the 0
3 0
' 0
ends 0
of 0
the 0
plus 0
- 0
strand 0
DNA 0
fragments 0
reveals 0
( 0
1 0
) 0
that 0
the 0
upstream 0
fragment 0
is 0
elongated 0
beyond 0
PPT2 B-gene
creating 0
a 0
plus 0
- 0
strand 0
overlap 0
and 0
( 0
2 0
) 0
that 0
the 0
majority 0
of 0
plus 0
- 0
strand 0
strong 0
- 0
stop 0
DNA 0
fragments 0
bear 0
a 0
copy 0
of 0
the 0
minus 0
- 0
strand 0
primer 0
binding 0
site 0
in 0
agreement 0
with 0
the 0
accepted 0
model 0
of 0
retroviral 0
genomic 0
RNA 0
reverse 0
transcription 0
. 0

The 0
patients 0
undergoing 0
VTLB 0
had 0
significantly 0
shorter 0
operative 0
times 0
( 0
VTLB 0
, 0
100.2 0
+/ 0
- 0
27.2 0
min 0
. 0
vs 0
OLB 0
, 0
119.8 0
+/ 0
- 0
42.6 0
min 0
; 0
p 0
< 0
0.01 0
) 0
and 0
less 0
blood 0
loss 0
( 0
VTLB 0
, 0
4.7 0
+/ 0
- 0
14.6 0
ml 0
vs 0
OLB 0
, 0
65.7 0
+/ 0
- 0
77.0 0
ml 0
; 0
p 0
< 0
0.001 0
) 0
. 0

By 0
150 0
minutes 0
after 0
Cr2O3 0
inhalation 0
, 0
FEV1.0 0
had 0
decreased 0
by 0
32 0
% 0
. 0

This 0
combined 0
intravenous 0
anaesthetic 0
regimen 0
gave 0
good 0
anaesthesia 0
and 0
analgesia 0
to 0
pigs 0
for 0
up 0
to 0
2 0
h 0
as 0
monitored 0
by 0
clinical 0
signs 0
. 0

Twenty 0
food 0
products 0
were 0
contaminated 0
with 0
V. 0
cholerae 0
O1 0
, 0
Ogawa 0
, 0
toxigenic 0
and 0
not 0
toxigenic 0
strains 0
: 0
yoghurt 0
, 0
cream 0
cheese 0
, 0
apricot 0
marmelade 0
, 0
hip 0
rose 0
marmelade 0
, 0
mayonnaise 0
, 0
italian 0
pasta 0
for 0
`` 0
empanadas 0
'' 0
, 0
`` 0
dulce 0
de 0
leche 0
'' 0
, 0
meat 0
sausage 0
, 0
meat 0
and 0
spinach 0
ravioli 0
, 0
margarine 0
, 0
milk 0
dessert 0
( 0
made 0
with 0
cocoa 0
, 0
milk 0
confiture 0
, 0
starch 0
and 0
additives 0
) 0
, 0
lettuce 0
, 0
tuna 0
fish 0
, 0
ricotta 0
and 0
sterilized 0
milk 0
. 0

It 0
is 0
impossible 0
to 0
define 0
only 0
one 0
clinical 0
outline 0
because 0
both 0
symptomatic 0
and 0
asymptomatic 0
infected 0
NB 0
may 0
be 0
found 0
with 0
gestational 0
age 0
at 0
term 0
and 0
pre 0
- 0
term 0
and 0
when 0
born 0
with 0
a 0
weight 0
above 0
or 0
below 0
2000 0
g 0
. 0

The 0
expression 0
of 0
the 0
pilin B-gene
gene I-gene
, 0
tcpA B-gene
, 0
is 0
dependent 0
upon 0
ToxR B-gene
and 0
upon 0
ToxT B-gene
. 0

The 0
chloramphenicol B-gene
- I-gene
resistance I-gene
transposon I-gene
Tn4451 B-gene
undergoes 0
precise 0
conjugative 0
deletion 0
from 0
its 0
parent 0
plasmid 0
plP401 0
in 0
Clostridium 0
perfringens 0
and 0
precise 0
spontaneous 0
excision 0
from 0
multicopy 0
plasmids 0
in 0
Escherichia 0
coli 0
. 0

Ras B-gene
p21Val I-gene
inhibits 0
myogenesis 0
without 0
altering 0
the 0
DNA 0
binding 0
or 0
transcriptional 0
activities 0
of 0
the 0
myogenic B-gene
basic I-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
factors I-gene
. 0

In 0
cells 0
limited 0
for 0
His 0
, 0
increased 0
expression 0
of 0
arg B-gene
- I-gene
2 I-gene
and 0
cpc B-gene
- I-gene
1 I-gene
, 0
and 0
decreased 0
expression 0
of 0
cox B-gene
- I-gene
5 I-gene
, 0
also 0
had 0
translational 0
and 0
transcriptional 0
components 0
. 0

The 0
peptide 0
sequences 0
reveal 0
that 0
the 0
factor 0
consists 0
of 0
GABP B-gene
alpha I-gene
and 0
GABP B-gene
beta I-gene
1 I-gene
with 0
Ets B-gene
and 0
Notch B-gene
motifs I-gene
, 0
respectively 0
. 0

Immunofluorescence 0
microscopy 0
and 0
cell 0
fractionation 0
analyses 0
showed 0
that 0
the 0
110 0
- 0
kDa 0
protein 0
was 0
exclusively 0
nuclear 0
, 0
whereas 0
the 0
150 0
- 0
kDa 0
protein 0
was 0
present 0
in 0
both 0
the 0
cytoplasm 0
and 0
nucleus 0
of 0
human 0
cells 0
. 0

Expression 0
and 0
regulation 0
by 0
interferon B-gene
of 0
a 0
double B-gene
- I-gene
stranded I-gene
- I-gene
RNA I-gene
- I-gene
specific I-gene
adenosine I-gene
deaminase I-gene
from 0
human 0
cells 0
: 0
evidence 0
for 0
two 0
forms 0
of 0
the 0
deaminase 0
. 0

T 0
- 0
cell 0
hybridomas 0
, 0
thymocytes 0
, 0
and 0
T 0
cells 0
can 0
be 0
induced 0
to 0
undergo 0
apoptotic 0
cell 0
death 0
by 0
activation 0
through 0
the 0
T B-gene
- I-gene
cell I-gene
receptor I-gene
. 0

Deletions 0
were 0
examined 0
in 0
the 0
LYS2 B-gene
gene I-gene
, 0
using 0
a 0
set 0
of 0
31 0
- 0
to 0
156 0
- 0
bp 0
inserts 0
that 0
included 0
inserts 0
with 0
no 0
apparent 0
potential 0
for 0
secondary 0
structure 0
as 0
well 0
as 0
two 0
quasipalindromes 0
. 0

Overexpression 0
of 0
SCS1 B-gene
could 0
not 0
complement 0
an 0
HSP60 B-gene
- I-gene
null I-gene
allele I-gene
, 0
indicating 0
that 0
suppression 0
was 0
not 0
due 0
to 0
the 0
bypassing 0
of 0
Hsp60 B-gene
activity 0
. 0

The 0
DNA 0
binding 0
domain 0
of 0
NirA B-gene
was 0
expressed 0
as 0
a 0
fusion 0
protein 0
with 0
the 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
of 0
Schistosoma 0
japonicum 0
. 0

The 0
kinase 0
is 0
essential 0
in 0
vivo 0
for 0
normal 0
phosphorylation 0
of 0
the 0
CTD 0
and 0
for 0
normal 0
growth 0
and 0
differentiation 0
. 0

A 0
general 0
model 0
for 0
ARE 0
- 0
mediated 0
mRNA 0
degradation 0
involving 0
a 0
potential 0
role 0
for 0
certain 0
heterogeneous 0
nuclear 0
ribonucleoproteins 0
and 0
ARE B-gene
- I-gene
binding I-gene
proteins I-gene
is 0
proposed 0
. 0

Finally 0
, 0
we 0
demonstrate 0
that 0
C/EBP B-gene
alpha I-gene
can 0
also 0
active 0
the 0
GM B-gene
- I-gene
CSF I-gene
receptor I-gene
alpha I-gene
promoter 0
in 0
nonmyeloid 0
cells 0
. 0

Endocytosis 0
and 0
vacuolar 0
degradation 0
of 0
the 0
plasma 0
membrane 0
- 0
localized 0
Pdr5 B-gene
ATP I-gene
- I-gene
binding I-gene
cassette I-gene
multidrug I-gene
transporter I-gene
in 0
Saccharomyces 0
cerevisiae 0
. 0

Individual 0
mutations 0
in 0
motifs 0
III 0
, 0
IV 0
, 0
and 0
V 0
had 0
distinctive 0
effects 0
on 0
the 0
affinity 0
of 0
enzyme 0
for 0
GTP 0
, 0
the 0
rate 0
of 0
covalent 0
catalysis 0
( 0
EpG 0
formation 0
) 0
, 0
or 0
the 0
transfer 0
of 0
GMP 0
from 0
enzyme 0
to 0
RNA 0
. 0

Mutational 0
analysis 0
of 0
mRNA B-gene
capping I-gene
enzyme I-gene
identifies 0
amino 0
acids 0
involved 0
in 0
GTP 0
binding 0
, 0
enzyme 0
- 0
guanylate 0
formation 0
, 0
and 0
GMP 0
transfer 0
to 0
RNA 0
. 0

Disruption 0
of 0
the 0
HOG1 B-gene
and 0
PBS2 B-gene
genes I-gene
leads 0
to 0
a 0
dramatic 0
decrease 0
of 0
the 0
HSP12 B-gene
inducibility 0
in 0
osmostressed 0
cells 0
, 0
whereas 0
overproduction 0
of 0
Hog1 B-gene
produces 0
a 0
fivefold 0
increase 0
in 0
wild 0
- 0
type 0
induced 0
levels 0
upon 0
a 0
shift 0
to 0
a 0
high 0
salt 0
concentration 0
. 0

Deletion 0
or 0
inactivation 0
of 0
CRY1 B-gene
leads 0
to 0
5 0
- 0
to 0
10 0
- 0
fold 0
- 0
increased 0
levels 0
of 0
CRY2 B-gene
mRNA I-gene
. 0

( 0
1986 0
) 0
method 0
of 0
separation 0
of 0
Cryptosporidium 0
spp 0
. 0
oocysts 0
from 0
feces 0
by 0
using 0
a 0
percoll 0
discontinuous 0
density 0
gradient 0
appeared 0
a 0
method 0
of 0
choice 0
for 0
obtaining 0
large 0
numbers 0
of 0
oocysts 0
of 0
C. 0
parvum 0
free 0
of 0
fecal 0
contamination 0
. 0

Staphylococcal B-gene
enterotoxin I-gene
A I-gene
involvement 0
in 0
the 0
illness 0
of 0
a 0
20 0
- 0
month 0
- 0
old 0
burn 0
patient 0
. 0

METHODS 0
: 0
We 0
obtained 0
maximal 0
inspiratory 0
and 0
expiratory 0
flow 0
- 0
volume 0
curves 0
in 0
41 0
unselected 0
patients 0
with 0
essential 0
tremor 0
( 0
14 0
males 0
, 0
27 0
females 0
, 0
age 0
61.7 0
+/ 0
- 0
2.14 0
years 0
) 0
. 0

Our 0
findings 0
also 0
provide 0
the 0
basis 0
for 0
the 0
development 0
of 0
assays 0
to 0
screen 0
for 0
the 0
ligands 0
to 0
testis B-gene
receptor I-gene
2 I-gene
and 0
hERR1 B-gene
. 0

Four 0
p53 B-gene
DNA I-gene
- I-gene
binding I-gene
domain I-gene
peptides I-gene
bind 0
natural 0
p53 B-gene
- I-gene
response I-gene
elements I-gene
and 0
bend 0
the 0
DNA 0
. 0

The 0
Stat5b B-gene
mRNA I-gene
has 0
a 0
size 0
of 0
5.6 0
kb 0
and 0
encodes 0
a 0
protein 0
of 0
786 0
amino 0
acids 0
. 0

The 0
hydropathy 0
plot 0
revealed 0
a 0
rather 0
hydrophilic 0
N 0
- 0
terminal 0
region 0
and 0
the 0
absence 0
of 0
a 0
hydrophobic 0
signal 0
peptide 0
. 0

These 0
results 0
suggest 0
that 0
G B-gene
beta I-gene
gamma I-gene
- 0
stimulated 0
Shc B-gene
phosphorylation 0
represents 0
an 0
early 0
step 0
in 0
the 0
pathway 0
leading 0
to 0
p21ras B-gene
activation 0
, 0
similar 0
to 0
the 0
mechanism 0
utilized 0
by 0
growth B-gene
factor I-gene
tyrosine I-gene
kinase I-gene
receptors I-gene
. 0

This 0
report 0
focused 0
on 0
the 0
relationship 0
between 0
Type 0
A 0
behavior 0
and 0
eight 0
basic 0
emotion 0
dimensions 0
. 0

All 0
carcasses 0
resulted 0
in 0
contamination 0
with 0
aerobic 0
mesophilic 0
bacteria 0
in 0
the 0
range 0
from 0
6 0
x 0
10 0
( 0
3 0
) 0
to 0
1.2 0
x 0
10 0
( 0
6 0
) 0
CFU/ml 0
liquid 0
washed 0
, 0
and 0
94 0
% 0
them 0
with 0
sporulate 0
bacteria 0
, 0
the 0
threshold 0
being 0
under 0
100 0
CFU/ml 0
( 0
Figure 0
1 0
) 0
. 0

As 0
for 0
31 0
stage 0
I 0
- 0
II 0
lung 0
cancer 0
patients 0
, 0
CR 0
has 0
been 0
observed 0
in 0
82.8 0
% 0
of 0
them 0
and 0
PR 0
in 0
13.8 0
% 0
; 0
the 0
response 0
was 0
always 0
assessed 0
with 0
chest 0
radiography 0
, 0
CT 0
, 0
FBS 0
, 0
cytology 0
and/or 0
histology 0
. 0

Pediatric 0
medical 0
emergencies 0
in 0
a 0
regional 0
hospital 0
: 0
appropriate 0
locale 0
? 0

Protein 0
electrophoresis 0
showed 0
decreased 0
albumin B-gene
levels 0
in 0
both 0
groups 0
, 0
with 0
lower 0
values 0
in 0
G2 0
. 0

METHODS 0
: 0
All 0
these 0
30 0
non 0
- 0
responders 0
received 0
an 0
extra 0
dose 0
of 0
the 0
same 0
vaccine 0
2 0
months 0
after 0
primary 0
immunization 0
and 0
a 0
booster 0
dose 0
with 0
a 0
yeast 0
- 0
derived 0
vaccine 0
6 0
years 0
later 0
. 0

An 0
abnormally 0
high 0
percentage 0
of 0
hypertensive 0
patients 0
( 0
approximately 0
30 0
% 0
) 0
undergoing 0
cardiac 0
catheterization 0
because 0
of 0
anginal 0
pain 0
and/or 0
exercise 0
- 0
induced 0
ST 0
- 0
segment 0
depressions 0
has 0
angiographically 0
normal 0
coronary 0
arteries 0
. 0

Negative 0
- 0
staining 0
, 0
refractile 0
mycobacteria 0
in 0
Romanowsky 0
- 0
stained 0
smears 0
. 0

Mibefradil 0
( 0
Ro 0
40 0
- 0
5967 0
) 0
is 0
a 0
novel 0
calcium 0
antagonist 0
from 0
a 0
new 0
chemical 0
class 0
and 0
is 0
the 0
first 0
that 0
selectively 0
blocks 0
the 0
T 0
- 0
type 0
calcium 0
channel 0
. 0

However 0
, 0
2 0
minimum 0
alveolar 0
concentration 0
anesthesia 0
did 0
significantly 0
decrease 0
the 0
calculated 0
VE 0
at 0
a 0
PCO2 0
of 0
60 0
mmHg 0
( 0
from 0
7.4 0
+/ 0
- 0
1.2 0
to 0
4.0 0
+/ 0
- 0
0.6 0
l.min 0
- 0
1 0
) 0
, 0
indicating 0
a 0
rightward 0
shift 0
in 0
the 0
response 0
relationship 0
. 0

cDNA 0
encoding 0
a 0
functional 0
feline B-gene
liver/bone/kidney I-gene
- I-gene
type I-gene
alkaline I-gene
phosphatase I-gene
. 0

Protein B-gene
kinase I-gene
C I-gene
( 0
PKC B-gene
) 0
, 0
a 0
widely 0
- 0
distributed 0
enzyme 0
implicated 0
in 0
the 0
regulation 0
of 0
many 0
physiological 0
processes 0
, 0
consists 0
of 0
a 0
family 0
of 0
at 0
least 0
twelve 0
isoenzymes 0
which 0
differ 0
in 0
tissue 0
distribution 0
, 0
subcellular 0
localization 0
, 0
regulatory 0
properties 0
, 0
etc 0
. 0

This 0
work 0
, 0
therefore 0
, 0
also 0
emphasizes 0
the 0
importance 0
of 0
careful 0
choice 0
of 0
oligonucleotide 0
and 0
cDNA 0
probes 0
to 0
study 0
PKC B-gene
zeta I-gene
mRNA I-gene
. 0

This 0
action 0
is 0
dependent 0
on 0
helix B-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
factors I-gene
bound 0
to 0
the 0
E1 B-gene
element 0
. 0

The 0
debate 0
over 0
electives 0
- 0
- 0
1899 0
. 0

Polypeptide 0
growth 0
factors 0
and 0
cytokines 0
mediate 0
their 0
biochemical 0
functions 0
through 0
their 0
responsive 0
receptors 0
. 0

However 0
, 0
a 0
strongly 0
increased 0
frequency 0
of 0
CpG 0
dinucleotides 0
was 0
found 0
. 0

Here 0
we 0
focused 0
on 0
the 0
role 0
of 0
the 0
5 0
' 0
proximal 0
regulatory 0
cassette 0
( 0
- 0
190 0
; 0
+53 0
bp 0
) 0
of 0
the 0
rat B-gene
enkephalin I-gene
( 0
rENK B-gene
) 0
gene 0
in 0
the 0
developmental 0
regulation 0
of 0
the 0
enkephalin B-gene
phenotype 0
. 0

Unexpectedly 0
, 0
all 0
ENK B-gene
- I-gene
specific I-gene
motifs I-gene
formed 0
specific 0
and 0
highly 0
abundant 0
protein 0
- 0
DNA 0
complexes 0
when 0
nuclear 0
extracts 0
from 0
the 0
human 0
tumor 0
cell 0
line 0
( 0
HeLa 0
) 0
, 0
which 0
does 0
not 0
express 0
ENK B-gene
, 0
were 0
used 0
. 0

Infant 0
aged 0
3.5 0
years 0
presents 0
persistence 0
of 0
primordial 0
vitreous 0
body 0
with 0
crystalline 0
dislocation 0
in 0
the 0
camera 0
aquosa 0
and 0
secondary 0
buphthalmos 0
of 0
the 0
left 0
eye 0
and 0
microphthalmos 0
with 0
dislocation 0
of 0
the 0
crystalline 0
in 0
the 0
vitreous 0
body 0
of 0
the 0
right 0
eye 0
. 0

During 0
the 0
dose 0
- 0
finding 0
, 0
two 0
patients 0
were 0
temporarily 0
withdrawn 0
from 0
medication 0
and 0
one 0
patient 0
was 0
excluded 0
because 0
of 0
elevated 0
levels 0
of 0
liver 0
enzymes 0
. 0

In 0
comparison 0
of 0
cDNA 0
and 0
genomic 0
sequences 0
four 0
RNA 0
editing 0
events 0
were 0
found 0
in 0
both 0
atp9 B-gene
genes I-gene
. 0

MZF B-gene
- I-gene
1 I-gene
represses 0
CAT B-gene
reporter I-gene
gene I-gene
expression 0
via 0
GAL4 B-gene
binding I-gene
sites I-gene
in 0
the 0
nonhematopoietic 0
cell 0
lines 0
NIH 0
3T3 0
and 0
293 0
. 0

As 0
with 0
the 0
heterologous 0
DNA 0
binding 0
domain 0
, 0
MZF B-gene
- I-gene
1 I-gene
represses 0
reporter 0
gene 0
expression 0
in 0
nonhematopoietic 0
cell 0
lines 0
and 0
activates 0
expression 0
in 0
hematopoietic 0
cell 0
lines 0
. 0

Analyses 0
of 0
hGMR B-gene
beta I-gene
subunit I-gene
mutants I-gene
revealed 0
two 0
cytoplasmic 0
regions 0
involved 0
in 0
activation 0
of 0
the 0
c B-gene
- I-gene
myc I-gene
promoter I-gene
, 0
one 0
is 0
essential 0
and 0
the 0
other 0
is 0
dispensable 0
but 0
enhances 0
the 0
activity 0
. 0

Similarly 0
, 0
we 0
observed 0
synthetic 0
phenotypes 0
between 0
mutations 0
in 0
MIF2 B-gene
and 0
trans 0
- 0
acting 0
mutations 0
in 0
three 0
known 0
yeast 0
centromere 0
protein 0
genes 0
- 0
CEP1/CBF1/CPF1 B-gene
, 0
CEP1/CBF1/CPF1 I-gene

Taken 0
together 0
, 0
these 0
data 0
suggest 0
that 0
the 0
Mif2 B-gene
protein I-gene
interacts 0
with 0
Cep1p B-gene
at 0
the 0
centromere 0
and 0
that 0
the 0
yeast 0
centromere 0
indeed 0
exists 0
as 0
a 0
higher 0
order 0
protein 0
- 0
DNA 0
complex 0
. 0

To 0
accomplish 0
this 0
, 0
actin B-gene
cables 0
and 0
patches 0
are 0
redistributed 0
during 0
the 0
cell 0
cycle 0
to 0
direct 0
secretory 0
components 0
to 0
appropriate 0
sites 0
for 0
cell 0
growth 0
. 0

The 0
effects 0
of 0
Codonopsis 0
pilosula 0
oral 0
liquor 0
( 0
CPOL 0
) 0
on 0
tissue B-gene
- I-gene
type I-gene
plasminogen I-gene
activator I-gene
( 0
t B-gene
- I-gene
PA I-gene
) 0
and 0
plasminogen B-gene
activator I-gene
inhibitor I-gene
( 0
PAI B-gene
) 0
in 0
the 0
plasma 0
of 0
25 0
patients 0
of 0
coronary 0
heart 0
disease 0
with 0
blood 0
stasis 0
were 0
studied 0
. 0

Estimated 0
daily 0
intakes 0
( 0
EDIs 0
) 0
per 0
person 0
were 0
0.56 0
microgram 0
for 0
total 0
HCH 0
, 0
0.20 0
microgram 0
for 0
gamma 0
- 0
HCH 0
, 0
0.09 0
microgram 0
for 0
dieldrin 0
, 0
1.42 0
micrograms 0
for 0
total 0
DDT 0
, 0
and 0
0.15 0
microgram 0
for 0
HCB 0
. 0

Imaging 0
features 0
of 0
splenic 0
epidermoid 0
cyst 0
with 0
pathologic 0
correlation 0
. 0

In 0
two 0
further 0
cases 0
( 0
one 0
type 0
I 0
and 0
one 0
type 0
III 0
SMA 0
) 0
, 0
de 0
novo 0
deletions 0
of 0
only 0
one 0
copy 0
of 0
Ag1 B-gene
- I-gene
CA I-gene
and 0
C212 B-gene
were 0
found 0
. 0

With 0
each 0
of 0
the 0
three 0
pairs 0
of 0
isolates 0
( 0
case 0
and 0
suspicious 0
case 0
) 0
, 0
identical 0
IS6110 0
banding 0
patterns 0
were 0
found 0
suggesting 0
identical 0
MTB 0
strains 0
. 0

HRES 0
has 0
been 0
found 0
to 0
be 0
clinically 0
useful 0
in 0
assessing 0
histologic 0
damage 0
following 0
pneumatic 0
dilatation 0
and 0
in 0
localizing 0
the 0
LES 0
during 0
the 0
administration 0
of 0
intrasphincter 0
botulinum B-gene
toxin I-gene
injection 0
in 0
the 0
treatment 0
of 0
achalasia 0
. 0

These 0
early 0
structural 0
processes 0
are 0
assumed 0
to 0
be 0
subserved 0
by 0
the 0
anterior 0
parts 0
of 0
the 0
left 0
hemisphere 0
, 0
as 0
event 0
- 0
related 0
brain 0
potentials 0
show 0
this 0
area 0
to 0
be 0
maximally 0
activated 0
when 0
phrase 0
structure 0
violations 0
are 0
processed 0
and 0
as 0
circumscribed 0
lesions 0
in 0
this 0
area 0
lead 0
to 0
an 0
impairment 0
of 0
the 0
on 0
- 0
line 0
structural 0
assignment 0
. 0

In 0
men 0
with 0
BMI 0
< 0
30 0
, 0
the 0
OR 0
was 0
1.83 0
for 0
postprandial 0
TG 0
( 0
P 0
= 0
.041 0
) 0
and 0
2.77 0
for 0
postprandial 0
RP 0
( 0
P 0
= 0
.032 0
) 0
in 0
models 0
that 0
included 0
fasting 0
TG 0
, 0
LDL B-gene
- I-gene
C I-gene
, 0
and 0
hypertension 0
. 0

SL1 B-gene
trans 0
- 0
splicing 0
specified 0
by 0
AU 0
- 0
rich 0
synthetic 0
RNA 0
inserted 0
at 0
the 0
5 0
' 0
end 0
of 0
Caenorhabditis 0
elegans 0
pre 0
- 0
mRNA 0
. 0

A 0
pyrazolo 0
- 0
quinoline 0
compound 0
, 0
6 0
- 0
methoxy 0
- 0
4 0
- 0
[ 0
2 0
- 0
[ 0
( 0
2 0
- 0
hydroxyethoxyl 0
) 0
- 0
ethyl 0
] 0
amino 0
] 0
- 0
3 0
- 0
methyl 0
- 0
1M 0
- 0
pyrazo 0
lo 0
[ 0
3,4 0
- 0
b 0
] 0
quinoline 0
( 0
SCH 0
51344 0
) 0
, 0
was 0
identified 0
based 0
on 0
its 0
ability 0
to 0
derepress 0
human 0
smooth 0
muscle 0
alpha B-gene
- I-gene
actin I-gene
promoter I-gene
activity 0
in 0
ras B-gene
- 0
transformed 0
cells 0
. 0

On 0
the 0
basis 0
of 0
these 0
relations 0
, 0
a 0
risk 0
factor 0
- 0
selection 0
scale 0
( 0
RFSS 0
) 0
( 0
range 0
, 0
0 0
to 0
10 0
) 0
was 0
developed 0
by 0
computing 0
appropriate 0
weights 0
for 0
each 0
risk 0
factor 0
. 0

The 0
Caenorhabditis B-gene
elegans I-gene
death I-gene
susceptibility I-gene
gene I-gene
, 0
ced B-gene
- I-gene
3 I-gene
, 0
has 0
a 0
number 0
of 0
homologs 0
in 0
vertebrate 0
species 0
, 0
including 0
interleukin B-gene
- I-gene
1 I-gene
beta I-gene
( I-gene
IL I-gene
- I-gene
1 I-gene
beta I-gene
) I-gene
- I-gene
converting I-gene
enzyme I-gene
( 0
ICE B-gene
) 0
, 0
Ich B-gene
- I-gene
1long I-gene
, 0
and 0
CPP32 B-gene
. 0

Repression 0
of 0
glucocorticoid B-gene
receptor I-gene
- 0
mediated 0
transcriptional 0
activation 0
by 0
unliganded 0
thyroid B-gene
hormone I-gene
receptor I-gene
( 0
TR B-gene
) 0
is 0
TR B-gene
isoform 0
- 0
specific 0
. 0

The 0
results 0
indicate 0
considerable 0
flexibility 0
in 0
the 0
spacing 0
between 0
DH B-gene
regulatory 0
sites 0
. 0

Obstruction 0
of 0
the 0
ERF B-gene
repressor I-gene
function 0
by 0
the 0
transactivating 0
members 0
of 0
the 0
ets B-gene
family I-gene
of 0
genes 0
( 0
i.e.gag B-gene
- 0
myb B-gene
- 0
ets B-gene
) 0
may 0
be 0
essential 0
for 0
the 0
control 0
of 0
genes 0
involved 0
in 0
cell 0
proliferation 0
and 0
may 0
also 0
underlie 0
their 0
tumorigenic 0
effects 0
. 0

Overexpression 0
of 0
wild B-gene
- I-gene
type I-gene
p53 I-gene
also 0
induces 0
apoptosis 0
in 0
an 0
LCL 0
. 0

We 0
show 0
that 0
c B-gene
- I-gene
Fos I-gene
( 0
the 0
c B-gene
- I-gene
fos I-gene
protooncogene I-gene
product I-gene
) 0
, 0
which 0
is 0
an 0
intrinsically 0
unstable 0
nuclear 0
protein 0
, 0
is 0
metabolically 0
highly 0
stabilized 0
, 0
and 0
greatly 0
enhances 0
the 0
transforming 0
efficiency 0
of 0
NIH 0
3T3 0
cells 0
, 0
by 0
Mos B-gene
. 0

Cloning 0
, 0
sequencing 0
and 0
expression 0
of 0
the 0
3 B-gene
- I-gene
phosphoglycerate I-gene
kinase I-gene
gene I-gene
of 0
Pyrococcus 0
woesei 0
in 0
Escherichia 0
coli 0
and 0
characterization 0
of 0
the 0
protein 0
. 0

These 0
observations 0
lead 0
to 0
the 0
proposal 0
that 0
the 0
RNAP B-gene
II I-gene
CTD I-gene
might 0
be 0
an 0
in 0
vivo 0
target 0
for 0
the 0
activated 0
p42mapk B-gene
and 0
p44mapk B-gene
MAP I-gene
kinases I-gene
. 0

We 0
also 0
isolated 0
two 0
alternatively 0
spliced 0
forms 0
of 0
human B-gene
CD6 I-gene
cDNA I-gene
lacking 0
sequences 0
encoding 0
membrane 0
- 0
proximal 0
regions 0
of 0
the 0
cytoplasmic 0
domain 0
which 0
maintain 0
the 0
same 0
reading 0
frame 0
as 0
CD6 B-gene
- 0
PB1 B-gene
. 0

We 0
sought 0
to 0
determine 0
whether 0
such 0
differences 0
in 0
polyadenylation 0
affect 0
the 0
steady 0
- 0
state 0
levels 0
of 0
DHFR B-gene
and 0
mRNAs 0
expressed 0
from 0
either 0
allele 0
and 0
, 0
in 0
a 0
more 0
general 0
sense 0
, 0
to 0
ask 0
whether 0
differences 0
in 0
3 0
' 0
end 0
RNA 0
processing 0
in 0
a 0
gene 0
containing 0
multiple 0
poly 0
( 0
A 0
) 0
sites 0
affects 0
the 0
final 0
level 0
of 0
gene 0
expression 0
. 0

We 0
have 0
isolated 0
a 0
Drosophila 0
melanogaster 0
( 0
Dm 0
) 0
cDNA 0
encoding 0
a 0
polypeptide 0
that 0
has 0
extensive 0
sequence 0
similarity 0
to 0
the 0
mammalian B-gene
MAPKAPK I-gene
- I-gene
2 I-gene
. 0

A 0
2.4 B-gene
- I-gene
kb I-gene
MAPKAPK I-gene
- I-gene
2 I-gene
message I-gene
is 0
expressed 0
throughout 0
development 0
, 0
while 0
two 0
shorter 0
transcripts 0
of 0
2.3 0
and 0
1.8 0
kb 0
appear 0
to 0
be 0
specifically 0
expressed 0
in 0
the 0
germline 0
. 0

The 0
finding 0
that 0
the 0
chimeric B-gene
TdT I-gene
: 0
:Pol B-gene
beta I-gene
protein I-gene
possessed 0
significant 0
template 0
- 0
dependent 0
polymerase 0
activity 0
suggests 0
that 0
aa 0
1 0
- 0
60 0
of 0
Pol B-gene
beta I-gene
are 0
involved 0
in 0
template 0
utilization 0
during 0
the 0
polymerization 0
reaction 0
, 0
as 0
suggested 0
by 0
the 0
previous 0
finding 0
that 0
the 0
8 0
- 0
kDa 0
N 0
- 0
terminal 0
domain 0
of 0
Pol B-gene
beta I-gene
possesses 0
ssDNA 0
- 0
binding 0
activity 0
[ 0
Kumar 0
et 0
al. 0
, 0
J 0
. 0

The 0
average 0
values 0
were 0
199 0
and 0
424 0
revertants/g 0
for 0
the 0
hamburgers 0
and 0
hot 0
dogs 0
, 0
respectively 0
. 0

Cholangiography 0
was 0
performed 0
in 0
all 0
cases 0
and 0
classified 0
by 0
a 0
scoring 0
system 0
specifically 0
developed 0
for 0
pediatric 0
patients 0
. 0

The 0
integrity 0
of 0
the 0
cDNA 0
sequence 0
was 0
confirmed 0
by 0
analysis 0
of 0
several 0
overlapping 0
genomic 0
clones 0
that 0
span 0
the 0
GAR1 B-gene
gene I-gene
. 0

In 0
Trial 0
1 0
, 0
eight 0
sows 0
were 0
allowed 0
to 0
farrow 0
naturally 0
( 0
d 0
114 0
, 0
NF 0
sows 0
) 0
and 0
eight 0
sows 0
were 0
induced 0
to 0
farrow 0
( 0
IF 0
sows 0
) 0
prematurely 0
by 0
injection 0
of 0
prostaglandin 0
F2 0
alpha 0
on 0
d 0
112 0
of 0
gestation 0
. 0

End 0
- 0
tidal 0
PO2 0
and 0
the 0
ratio 0
of 0
minute 0
ventilation 0
to 0
oxygen 0
consumption 0
( 0
VE/VO2 0
) 0
were 0
lower 0
while 0
PETCO2 0
was 0
higher 0
for 0
Hyp 0
( 0
P 0
< 0
or 0
= 0
0.01 0
) 0
. 0

These 0
results 0
suggested 0
that 0
NfxB B-gene
negatively 0
autoregulates 0
the 0
expression 0
of 0
nfxB B-gene
itself 0
. 0

A511 0
is 0
a 0
broad 0
- 0
host 0
- 0
range 0
, 0
virulent 0
myovirus 0
for 0
Listeria 0
monocytogenes 0
. 0

The 0
mechanism 0
of 0
peroxisome 0
proliferation 0
is 0
poorly 0
understood 0
. 0

If 0
NCR 0
- 0
sensitive 0
gene 0
expression 0
occurs 0
exclusively 0
by 0
this 0
pathway 0
, 0
as 0
has 0
been 0
thought 0
to 0
be 0
the 0
case 0
, 0
then 0
the 0
NCR 0
sensitivity 0
of 0
a 0
gene 0
's 0
expression 0
should 0
be 0
abolished 0
by 0
a 0
ure2 B-gene
delta I-gene
mutation I-gene
. 0

The 0
single 0
- 0
stranded 0
DNA 0
Pur B-gene
alpha I-gene
recognition I-gene
element I-gene
disrupts 0
these 0
complexes 0
. 0

Association 0
of 0
human B-gene
Pur I-gene
alpha I-gene
with 0
the 0
retinoblastoma B-gene
protein I-gene
, 0
Rb B-gene
, 0
regulates 0
binding 0
to 0
the 0
single 0
- 0
stranded 0
DNA 0
Pur B-gene
alpha I-gene
recognition I-gene
element I-gene
. 0

The 0
insulin B-gene
- 0
induced 0
DNA 0
- 0
binding 0
complex 0
was 0
identified 0
as 0
the 0
p50/p65 B-gene
heterodimer 0
. 0

Using 0
varying 0
conditions 0
, 0
three 0
distinct 0
complexes 0
were 0
shown 0
to 0
interact 0
specifically 0
with 0
the 0
NIP B-gene
region I-gene
, 0
although 0
only 0
one 0
correlates 0
with 0
repressor 0
activity 0
. 0

Exchange 0
of 0
the 0
LPL B-gene
and 0
HL B-gene
lids 0
resulted 0
in 0
a 0
reversal 0
of 0
the 0
phospholipase/neutral B-gene
lipase B-gene
ratio 0
, 0
establishing 0
the 0
important 0
role 0
of 0
this 0
region 0
in 0
mediating 0
substrate 0
specificity 0
. 0

The 0
interferon B-gene
- 0
inducible 0
protein B-gene
kinase I-gene
PKR I-gene
modulates 0
the 0
transcriptional 0
activation 0
of 0
immunoglobulin B-gene
kappa I-gene
gene I-gene
. 0

Truncated 0
forms 0
of 0
a 0
novel 0
yeast 0
protein 0
suppress 0
the 0
lethality 0
of 0
a 0
G B-gene
protein I-gene
alpha I-gene
subunit I-gene
deficiency 0
by 0
interacting 0
with 0
the 0
beta 0
subunit 0
. 0

Another 0
common 0
mutation 0
involved 0
amino 0
acids 0
that 0
are 0
thought 0
to 0
make 0
specific 0
contacts 0
with 0
DNA 0
. 0

Phorbol 0
esters 0
stimulated 0
phosphorylation 0
of 0
CSK B-gene
35H I-gene
proteins I-gene
, 0
thus 0
emphasizing 0
that 0
sequences 0
isolated 0
according 0
to 0
PKC B-gene
binding 0
activity 0
in 0
vitro 0
are 0
also 0
PKC B-gene
substrates 0
in 0
vivo 0
. 0

Levels 0
of 0
TSG B-gene
- I-gene
14 I-gene
protein I-gene
( 0
also 0
termed 0
PTX B-gene
- I-gene
3 I-gene
) 0
become 0
elevated 0
in 0
the 0
serum 0
of 0
mice 0
and 0
humans 0
after 0
injection 0
with 0
bacterial 0
lipopolysaccharide 0
, 0
but 0
in 0
contrast 0
to 0
conventional 0
acute 0
phase 0
proteins 0
, 0
the 0
bulk 0
of 0
TSG B-gene
- I-gene
14 I-gene
synthesis 0
in 0
the 0
intact 0
organism 0
occurs 0
outside 0
the 0
liver 0
. 0

The 0
mouse B-gene
beta I-gene
2 I-gene
- I-gene
syntrophin I-gene
gene I-gene
( 0
> 0
33 0
kilobases 0
) 0
contains 0
seven 0
exons 0
, 0
all 0
of 0
which 0
have 0
homologues 0
at 0
the 0
corresponding 0
position 0
in 0
the 0
alpha B-gene
1 I-gene
- I-gene
syntrophin I-gene
gene I-gene
. 0

Altogether 0
our 0
data 0
indicate 0
that 0
PEDF B-gene
belongs 0
to 0
the 0
subgroup 0
of 0
noninhibitory 0
serpins B-gene
and 0
that 0
its 0
N 0
- 0
terminal 0
region 0
confers 0
a 0
neurite 0
- 0
promoting 0
activity 0
to 0
the 0
protein 0
. 0

We 0
report 0
here 0
the 0
cloning 0
of 0
the 0
murine 0
p44 B-gene
MAP B-gene
kinase I-gene
( 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
1 I-gene
) 0
gene 0
, 0
the 0
determination 0
of 0
its 0
intron/exon 0
boundaries 0
, 0
and 0
the 0
characterization 0
of 0
its 0
promoter 0
. 0

It 0
contains 0
three 0
putative 0
TATA 0
boxes 0
far 0
upstream 0
of 0
the 0
main 0
start 0
sites 0
region 0
, 0
one 0
AP B-gene
- I-gene
1 I-gene
box I-gene
, 0
one 0
AP B-gene
- I-gene
2 I-gene
box I-gene
, 0
one 0
Malt B-gene
box I-gene
, 0
one 0
GAGA 0
box 0
, 0
one 0
half 0
serum 0
- 0
responsive 0
element 0
, 0
and 0
putative 0
binding 0
sites 0
for 0
Sp1 B-gene
( 0
five 0
) 0
, 0
GC B-gene
- I-gene
rich I-gene
binding I-gene
factor I-gene
( 0
five 0
) 0
, 0
CTF B-gene
- I-gene
NF1 I-gene
( 0
one 0
) 0
, 0
Myb B-gene
( 0
one 0
) 0
, 0
p53 B-gene
( 0
two 0
) 0
, 0
Ets B-gene
- I-gene
1 I-gene
( 0
one 0
) 0
, 0
NF B-gene
- I-gene
IL6 I-gene
( 0
two 0
) 0
, 0
MyoD B-gene
( 0
two 0
) 0
, 0
Zeste B-gene
( 0
one 0
) 0
, 0
and 0
hepatocyte B-gene
nuclear I-gene
factor I-gene
- I-gene
5 I-gene
( 0
one 0
) 0
. 0

One 0
of 0
these 0
is 0
surrounded 0
by 0
an 0
adenine 0
- 0
uridine 0
rich 0
region 0
that 0
can 0
form 0
an 0
11 0
- 0
base 0
pair 0
stem 0
structure 0
. 0

We 0
conclude 0
that 0
this 0
new 0
measurement 0
technique 0
provides 0
an 0
easy 0
and 0
accurate 0
P0.1 0
measurement 0
using 0
standard 0
respiratory 0
equipment 0
when 0
tested 0
in 0
a 0
lung 0
model 0
. 0

Effects 0
of 0
verapamil 0
and 0
propranolol 0
on 0
early 0
afterdepolarizations 0
and 0
ventricular 0
arrhythmias 0
induced 0
by 0
epinephrine 0
in 0
congenital 0
long 0
QT 0
syndrome 0
. 0

Deletion 0
of 0
the 0
NF B-gene
- I-gene
IL6 I-gene
beta I-gene
leucine I-gene
zipper I-gene
domain I-gene
also 0
greatly 0
diminished 0
the 0
interaction 0
between 0
these 0
two 0
proteins 0
. 0

After 0
cells 0
were 0
stably 0
transfected 0
with 0
CIITA B-gene
, 0
endogenous 0
MHC B-gene
class I-gene
II I-gene
genes I-gene
were 0
constitutively 0
expressed 0
, 0
and 0
MHC B-gene
class I-gene
II I-gene
promoters I-gene
, 0
delivered 0
by 0
transfection 0
, 0
were 0
actively 0
transcribed 0
in 0
CIITA B-gene
- 0
expressing 0
cells 0
. 0

Two 0
domains 0
of 0
EBNA2 B-gene
defined 0
by 0
deletion 0
of 0
amino 0
acids 0
247 0
- 0
337 0
and 0
437 0
- 0
476 0
were 0
found 0
to 0
be 0
important 0
for 0
the 0
activation 0
of 0
both 0
promoters 0
, 0
while 0
two 0
different 0
domains 0
corresponding 0
to 0
residues 0
4 0
- 0
18 0
and 0
118 0
- 0
198 0
were 0
required 0
solely 0
for 0
the 0
LMP1 B-gene
promoter I-gene
. 0

The 0
peak 0
velocities 0
of 0
the 0
atrial 0
systolic 0
waves 0
of 0
the 0
transmitral 0
and 0
pulmonary 0
venous 0
flow 0
velocities 0
( 0
A 0
and 0
PVA 0
, 0
respectively 0
) 0
and 0
first 0
systolic 0
wave 0
( 0
PVS1 0
) 0
of 0
pulmonary 0
venous 0
flow 0
, 0
durations 0
of 0
both 0
atrial 0
systolic 0
waves 0
, 0
and 0
amplitude 0
of 0
interatrial 0
septal 0
motion 0
during 0
atrial 0
systole 0
increased 0
significantly 0
ten 0
days 0
after 0
cardioversion 0
compared 0
with 0
those 0
measured 0
within 0
a 0
day 0
of 0
cardioversion 0
in 0
all 0
patients 0
except 0
the 0
5 0
patients 0
with 0
dilated 0
cardiomyopathy 0
. 0

Additionally 0
, 0
the 0
enzyme 0
shows 0
activity 0
towards 0
triglycerides 0
such 0
as 0
olive 0
oil 0
and 0
tributyrin 0
and 0
towards 0
egg 0
- 0
yolk 0
emulsions 0
. 0

The 0
nucleotide 0
sequence 0
directly 0
upstream 0
of 0
fimA B-gene
contains 0
two 0
open 0
reading 0
frames 0
, 0
ORF5 0
and 0
ORF1 0
, 0
whose 0
deduced 0
protein 0
products 0
are 0
homologous 0
to 0
members 0
of 0
a 0
superfamily 0
of 0
ATP B-gene
- I-gene
binding I-gene
cassette I-gene
membrane I-gene
transport I-gene
proteins I-gene
, 0
including 0
both 0
prokaryotic 0
and 0
eukaryotic 0
uptake 0
and 0
export 0
systems 0
. 0

The 0
ORF3 0
probe 0
also 0
hybridized 0
to 0
a 0
540 0
bp 0
transcript 0
consistent 0
with 0
the 0
size 0
of 0
ORF3 0
alone 0
and 0
supportive 0
of 0
the 0
mutagenesis 0
data 0
of 0
non 0
- 0
linkage 0
. 0

These 0
results 0
suggest 0
that 0
low 0
concentrations 0
of 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
may 0
be 0
useful 0
for 0
nonsurgical 0
treatment 0
of 0
human 0
vitreous 0
hemorrhage 0
. 0

We 0
conclude 0
that 0
pancreatic 0
polypeptide 0
and 0
motilin B-gene
responses 0
to 0
a 0
meal 0
are 0
different 0
in 0
encopretic 0
children 0
than 0
in 0
children 0
in 0
the 0
control 0
group 0
. 0

Here 0
we 0
report 0
the 0
cloning 0
, 0
expression 0
, 0
and 0
biochemical 0
characterization 0
of 0
the 0
32 0
- 0
kDa 0
subunit 0
of 0
human 0
( 0
h 0
) 0
TFIID B-gene
, 0
termed 0
hTAFII32 B-gene
. 0

Hemolytic 0
jaundice 0
due 0
to 0
G6PD B-gene
deficiency 0
causing 0
kernicterus 0
in 0
a 0
female 0
newborn 0
. 0

Two 0
transcripts 0
of 0
1.6 0
kb 0
and 0
5.8 0
kb 0
are 0
5 0
' 0
coterminal 0
and 0
may 0
both 0
encode 0
the 0
novel 0
glycoprotein B-gene
gene I-gene
EUS4 I-gene
. 0

Mean 0
growth 0
changes 0
in 0
this 0
Class 0
II 0
sample 0
were 0
comparable 0
to 0
those 0
previously 0
reported 0
for 0
male 0
subjects 0
with 0
Class 0
I 0
malocclusions 0
over 0
the 0
same 0
age 0
period 0
, 0
suggesting 0
a 0
similarity 0
in 0
postpubertal 0
development 0
between 0
these 0
two 0
groups 0
. 0

However 0
, 0
the 0
few 0
studies 0
that 0
address 0
antimicrobial 0
prophylaxis 0
in 0
bone 0
marrow 0
transplantation 0
have 0
not 0
always 0
shown 0
a 0
survival 0
benefit 0
. 0

The 0
fracture 0
groups 0
were 0
significantly 0
older 0
and 0
had 0
more 0
years 0
since 0
menopause 0
than 0
the 0
control 0
groups 0
. 0

In 0
addition 0
, 0
we 0
found 0
differences 0
in 0
the 0
binding 0
of 0
nuclear 0
factors 0
from 0
shoots 0
versus 0
from 0
roots 0
, 0
in 0
agreement 0
with 0
the 0
different 0
activities 0
of 0
the 0
promoter 0
in 0
these 0
two 0
organs 0
. 0

The 0
prevalence 0
and 0
incidence 0
of 0
human 0
immunodeficiency 0
virus 0
types 0
1 0
and 0
2 0
( 0
HIV 0
- 0
1 0
, 0
HIV 0
- 0
2 0
) 0
, 0
human 0
T 0
- 0
lymphotropic 0
virus 0
types 0
I 0
and 0
II 0
( 0
HTLV 0
- 0
I/II 0
) 0
, 0
and 0
syphilitic 0
infections 0
and 0
the 0
association 0
between 0
these 0
infections 0
were 0
determined 0
in 0
a 0
cohort 0
of 0
police 0
officers 0
in 0
Guinea 0
- 0
Bissau 0
. 0

By 0
in 0
vitro 0
immunoprecipitations 0
and 0
gel 0
shift 0
assays 0
, 0
we 0
identified 0
two 0
classes 0
of 0
high 0
affinity 0
Engrailed B-gene
- I-gene
binding I-gene
sites I-gene
upstream 0
of 0
each 0
of 0
the 0
two 0
polyhomeotic 0
transcription 0
units 0
. 0

Subjects 0
with 0
a 0
short 0
postexposure 0
time 0
and 0
a 0
dioxin 0
burden 0
> 0
0.6 0
pg/m3 0
had 0
a 0
significantly 0
higher 0
risk 0
of 0
hypoergy 0
than 0
unexposed 0
subjects 0
( 0
hypoergy 0
I 0
: 0
OR 0
= 0
9.51 0
, 0
95 0
% 0
CI 0
= 0
1.96 0
- 0
42.02 0
; 0
hypoergy 0
II 0
: 0
OR 0
= 0
2.92 0
, 0
95 0
% 0
CI 0
= 0
1.14 0
- 0
7.5 0
) 0
. 0

Analysis 0
of 0
this 0
sequence 0
combined 0
with 0
that 0
previously 0
reported 0
for 0
the 0
5' 0
- 0
flanking 0
region 0
directly 0
proximal 0
to 0
the 0
start 0
of 0
transcription 0
revealed 0
several 0
putative 0
regulatory 0
sequences 0
. 0

We 0
now 0
show 0
that 0
the 0
BAT1 B-gene
translation I-gene
product I-gene
is 0
the 0
homolog 0
of 0
the 0
rat B-gene
p47 I-gene
nuclear I-gene
protein I-gene
, 0
the 0
WM6 B-gene
Drosophila I-gene
gene I-gene
product I-gene
, 0
and 0
probably 0
also 0
Ce08102 B-gene
of 0
Caenorhabditis 0
elegans 0
, 0
all 0
members 0
of 0
the 0
DEAD B-gene
protein I-gene
family I-gene
of 0
ATP B-gene
- I-gene
dependent I-gene
RNA I-gene
helicases I-gene
. 0

By 0
using 0
lacZ B-gene
fusions I-gene
, 0
it 0
was 0
possible 0
to 0
localize 0
the 0
DNA 0
sequences 0
required 0
to 0
mediate 0
nitrate 0
repression 0
to 0
the 0
pfl B-gene
promoter I-gene
- I-gene
regulatory I-gene
region I-gene
. 0

In 0
this 0
report 0
, 0
we 0
describe 0
the 0
characterization 0
of 0
two 0
early 0
class B-gene
II I-gene
flagellar I-gene
genes I-gene
contained 0
in 0
the 0
orfX 0
- 0
fliP B-gene
locus 0
. 0

Vestibular 0
adaptation 0
exercises 0
and 0
recovery 0
: 0
acute 0
stage 0
after 0
acoustic 0
neuroma 0
resection 0
. 0

The 0
experimental 0
design 0
represents 0
a 0
2 0
x 0
3 0
factorial 0
arrangement 0
of 0
treatments 0
with 0
three 0
dietary 0
levels 0
of 0
incorporation 0
of 0
RSB 0
( 0
0 0
, 0
50 0
, 0
and 0
100 0
% 0
) 0
, 0
and 0
chickens 0
either 0
infected 0
or 0
uninfected 0
. 0

A 0
cDNA 0
clone 0
corresponding 0
to 0
the 0
putative 0
GA B-gene
20 I-gene
- 0
oxidase B-gene
genomic 0
sequence 0
was 0
constructed 0
with 0
the 0
reverse 0
transcription 0
- 0
PCR 0
method 0
, 0
and 0
the 0
identity 0
of 0
the 0
cDNA 0
clone 0
was 0
confirmed 0
by 0
analyzing 0
the 0
capability 0
of 0
the 0
fusion 0
protein 0
expressed 0
in 0
Escherichia 0
coli 0
to 0
convert 0
GA53 B-gene
to 0
GA44 B-gene
and 0
GA19 B-gene
to 0
GA20 B-gene
. 0

There 0
were 0
no 0
significant 0
changes 0
in 0
either 0
the 0
fatty 0
acid 0
composition 0
of 0
biliary 0
lecithin 0
or 0
in 0
the 0
bile 0
acid 0
composition 0
of 0
bile 0
. 0

Total 0
cholesterol 0
was 0
also 0
reduced 0
at 0
week 0
12 0
by 0
17.0 0
% 0
( 0
20 0
mg/day 0
) 0
and 0
15.7 0
% 0
( 0
20 0
- 0
30 0
mg/day 0
) 0
, 0
and 0
at 0
week 0
52 0
by 0
20.4 0
% 0
( 0
< 0
or 0
= 0
20 0
mg/day 0
) 0
and 0
19.2 0
% 0
( 0
> 0
or 0
= 0
30 0
mg/day 0
) 0
. 0

Although 0
further 0
studies 0
are 0
required 0
to 0
determine 0
the 0
precise 0
role 0
of 0
PEBP2 B-gene
in 0
the 0
GM B-gene
- I-gene
CSF I-gene
promoter I-gene
activity 0
, 0
the 0
present 0
findings 0
suggested 0
the 0
importance 0
of 0
the 0
relative 0
ratio 0
of 0
different 0
PEBP2 B-gene
isoforms I-gene
in 0
regulating 0
the 0
levels 0
of 0
the 0
promoter 0
activity 0
. 0

Benefits 0
of 0
obtaining 0
board 0
certification 0
in 0
pharmacotherapy 0
. 0

Piperacillin 0
- 0
tazobactam 0
can 0
be 0
used 0
for 0
the 0
treatment 0
of 0
infections 0
caused 0
by 0
gram 0
- 0
negative 0
, 0
gram 0
- 0
positive 0
, 0
aerobic 0
, 0
and 0
anaerobic 0
bacteria 0
. 0

Basal 0
plasma 0
renin B-gene
activity 0
( 0
PRA 0
) 0
was 0
slightly 0
raised 0
prior 0
to 0
training 0
( 0
P 0
< 0
0.07 0
) 0
compared 0
to 0
the 0
controls 0
and 0
post 0
- 0
training 0
. 0

This 0
apparently 0
anomalous 0
structure/activity 0
relationship 0
raises 0
important 0
issues 0
for 0
understanding 0
the 0
evolution 0
of 0
regulatory 0
peptides 0
and 0
the 0
mechanisms 0
that 0
control 0
their 0
expression 0
. 0

The 0
structural 0
gene 0
encoding 0
the 0
novel 0
lantibiotic 0
epilancin B-gene
K7 I-gene
from 0
Staphylococcus 0
epidermidis 0
K7 0
was 0
cloned 0
and 0
its 0
nucleotide 0
sequence 0
was 0
determined 0
. 0

This 0
paper 0
summarises 0
the 0
experimental 0
evidence 0
upon 0
which 0
the 0
clinical 0
trials 0
of 0
aldose B-gene
reductase I-gene
inhibitors 0
in 0
diabetic 0
patients 0
have 0
been 0
initiated 0
and 0
the 0
results 0
of 0
published 0
drug 0
trials 0
in 0
these 0
patients 0
. 0

The 0
spectrum 0
of 0
phenotypes 0
caused 0
by 0
these 0
mutations 0
was 0
strikingly 0
different 0
than 0
mutations 0
in 0
the 0
adaptor 0
for 0
the 0
VP16 B-gene
activation I-gene
domain I-gene
. 0

Increase 0
in 0
urinary 0
calcium 0
and 0
oxalate 0
after 0
fructose 0
infusion 0
. 0

The 0
5'flanking 0
region 0
is 0
highly 0
GC 0
rich 0
, 0
with 0
multiple 0
CpG 0
doublets 0
, 0
and 0
contains 0
multiple 0
binding 0
sites 0
for 0
Sp1 B-gene
. 0

To 0
discern 0
whether 0
these 0
disorders 0
of 0
GnRH B-gene
deficiency 0
are 0
associated 0
with 0
altered 0
melatonin 0
secretion 0
profiles 0
, 0
we 0
compared 0
untreated 0
young 0
males 0
IGD 0
( 0
n 0
= 0
7 0
) 0
and 0
DP 0
( 0
n 0
= 0
7 0
) 0
to 0
normal 0
pubertal 0
male 0
controls 0
( 0
n 0
= 0
6 0
) 0
. 0

Increased 0
blood 0
pressure 0
during 0
CyA 0
treatment 0
was 0
independent 0
of 0
circulating 0
ET B-gene
- I-gene
1 I-gene
levels 0
. 0

Analysis 0
of 0
several 0
Tat B-gene
mutants I-gene
indicated 0
that 0
both 0
the 0
cysteine 0
- 0
rich 0
and 0
the 0
core 0
domains 0
of 0
this 0
transactivator 0
are 0
necessary 0
and 0
sufficient 0
to 0
activate 0
transcription 0
when 0
TBP B-gene
is 0
overexpressed 0
. 0

In 0
addition 0
, 0
depletion 0
of 0
Oct B-gene
- I-gene
1 I-gene
from 0
the 0
nuclear 0
extract 0
by 0
using 0
Oct B-gene
- I-gene
1 I-gene
- 0
specific 0
antiserum 0
or 0
a 0
sequence 0
- 0
specific 0
DNA 0
affinity 0
resin 0
decreased 0
in 0
vitro 0
transcription 0
from 0
the 0
wild 0
- 0
type 0
MMTV 0
promoter 0
to 0
a 0
level 0
identical 0
to 0
that 0
obtained 0
from 0
a 0
promoter 0
in 0
which 0
all 0
three 0
octamer 0
- 0
related 0
sequences 0
were 0
mutated 0
. 0

Transactivation 0
of 0
the 0
HIV B-gene
- I-gene
1 I-gene
LTR I-gene
by 0
T3R B-gene
alpha I-gene
and 0
several 0
receptor 0
mutants 0
revealed 0
that 0
the 0
50 0
- 0
amino 0
- 0
acid 0
N 0
- 0
terminal 0
A/B 0
region 0
of 0
T3R B-gene
alpha I-gene
, 0
known 0
to 0
interact 0
with 0
the 0
basal B-gene
transcription I-gene
factor I-gene
TFIIB I-gene
, 0
is 0
critical 0
for 0
activation 0
of 0
both 0
Tat B-gene
- 0
dependent 0
and 0
Tat B-gene
- 0
independent 0
responsive 0
sequences 0
of 0
the 0
LTR 0
. 0

M.M.C 0
. 0
was 0
used 0
for 0
2.5 0
minutes 0
in 0
44 0
cases 0
( 0
20 0
HR 0
patients 0
, 0
24 0
LR 0
patients 0
) 0
, 0
and 0
for 0
5 0
minutes 0
in 0
66 0
cases 0
( 0
46 0
HR 0
patients 0
, 0
20 0
LR 0
patients 0
) 0
. 0

Finally 0
, 0
we 0
show 0
that 0
complexes 0
similar 0
to 0
the 0
C25 B-gene
, 0
C30 B-gene
and 0
C35 B-gene
complexes I-gene
are 0
formed 0
by 0
rat 0
cortex 0
nuclear 0
extracts 0
and 0
the 0
SAA 0
element 0
in 0
EMSA 0
experiments 0
, 0
suggesting 0
the 0
relevance 0
of 0
our 0
in 0
vitro 0
observations 0
to 0
the 0
in 0
vivo 0
functioning 0
of 0
the 0
rat B-gene
APP I-gene
promoter I-gene
. 0

Oncological 0
, 0
clinical 0
and 0
psychological 0
aspects 0
are 0
evaluated 0
according 0
to 0
experience 0
accumulated 0
in 0
recent 0
years 0
, 0
with 0
immediate 0
and 0
delayed 0
reconstruction 0
, 0
carried 0
out 0
in 0
the 0
most 0
diverse 0
specialized 0
centers 0
. 0

The 0
analysis 0
of 0
the 0
prevalence 0
values 0
shows 0
clearly 0
that 0
the 0
global 0
MS 0
- 0
frequency 0
is 0
closer 0
related 0
to 0
the 0
geomagnetic 0
than 0
to 0
the 0
geographic 0
latitude 0
. 0

Diltiazem 0
caused 0
significant 0
decrease 0
in 0
the 0
ventricular 0
response 0
without 0
conversion 0
to 0
sinus 0
rhythm 0
. 0

Subhuman 0
primates 0
appear 0
to 0
be 0
more 0
sensitive 0
to 0
reproductive 0
and 0
other 0
adverse 0
effects 0
of 0
PCBs 0
than 0
humans 0
. 0

When 0
excluding 0
children 0
with 0
ocular 0
and 0
cerebral 0
pathology 0
, 0
32 0
matched 0
pairs 0
of 0
premature 0
and 0
control 0
children 0
remained 0
. 0

The 0
cryptococcal B-gene
antigen I-gene
test 0
was 0
positive 0
at 0
1:125 0
by 0
latex 0
agglutination 0
. 0

Functional 0
analysis 0
of 0
DNase B-gene
- I-gene
I I-gene
hypersensitive 0
sites 0
at 0
the 0
mouse B-gene
porphobilinogen I-gene
deaminase I-gene
gene I-gene
locus I-gene
. 0

These 0
transcripts 0
have 0
a 0
unique 0
5'untranslated 0
region 0
and 0
NH2 0
- 0
terminal 0
sequence 0
and 0
encode 0
a 0
predicted 0
protein 0
of 0
121 0
kD 0
. 0

Both 0
mu B-gene
and I-gene
gamma I-gene
2b I-gene
heavy I-gene
chain I-gene
genes I-gene
cause 0
this 0
feedback 0
inhibition 0
of 0
heavy 0
chain 0
gene 0
rearrangement 0
. 0

Purified 0
CarP B-gene
binds 0
in 0
vitro 0
to 0
the 0
carAB B-gene
control I-gene
region I-gene
and 0
protects 0
against 0
DNase B-gene
I I-gene
two 0
approximately 0
25 0
bp 0
long 0
stretches 0
, 0
one 0
of 0
which 0
is 0
located 0
just 0
downstream 0
of 0
the 0
GATC 0
sequence 0
. 0

They 0
include 0
genes 0
encoding 0
three 0
subunits 0
of 0
the 0
cytochrome B-gene
oxidase I-gene
( 0
cox1 B-gene
to I-gene
3 I-gene
) 0
, 0
apocytochrome B-gene
b I-gene
( 0
cob B-gene
) 0
, 0
seven 0
subunits 0
of 0
the 0
NADH B-gene
dehydrogenase I-gene
complex I-gene
( 0
nad1 B-gene
to I-gene
6 I-gene
, 0
nad4L B-gene
) 0
, 0
two 0
ATPase B-gene
subunits 0
( 0
atp6 B-gene
and 0
atp9 B-gene
) 0
, 0
three 0
ribosomal 0
RNAs 0
( 0
rrn5 B-gene
, 0
srn B-gene
and 0
lrn B-gene
) 0
, 0
23 0
tRNAs 0
and 0
four 0
ribosomal 0
proteins 0
( 0
rps3 B-gene
, 0
rps11 B-gene
, 0
rps12 B-gene
and 0
rpl16 B-gene
) 0
. 0

From 0
day 0
10 0
, 0
a 0
significant 0
increase 0
in 0
platelet 0
count 0
was 0
observed 0
in 0
eight 0
of 0
the 0
ten 0
patients 0
treated 0
with 0
heparin 0
( 0
p 0
< 0
0.05 0
) 0
, 0
with 0
return 0
to 0
the 0
initial 0
value 0
after 0
heparin 0
cessation 0
in 0
six 0
of 0
the 0
responders 0
. 0

These 0
`` 0
nucleocapsid 0
- 0
like 0
'' 0
structures 0
were 0
readily 0
purified 0
by 0
density 0
gradient 0
centrifugation 0
. 0

The 0
Babcock 0
Surgical 0
Clinic 0
. 0

Resources 0
for 0
helping 0
patients 0
to 0
quit 0
smoking 0
. 0

The 0
PEBP2 B-gene
alpha I-gene
proteins I-gene
contain 0
a 0
128 0
- 0
amino 0
- 0
acid 0
( 0
aa 0
) 0
region 0
highly 0
homologous 0
to 0
the 0
Drosophila B-gene
melanogaster I-gene
segmentation I-gene
gene I-gene
runt I-gene
. 0

In 0
human 0
proliferative 0
cells 0
, 0
the 0
NADP 0
- 0
dependent 0
ME B-gene
activity 0
is 0
poorly 0
expressed 0
and 0
barely 0
inducible 0
by 0
thyroid 0
hormones 0
. 0

Based 0
on 0
previous 0
mapping 0
of 0
the 0
G B-gene
beta I-gene
gamma I-gene
binding I-gene
region I-gene
of 0
beta B-gene
ARK I-gene
, 0
and 0
conserved 0
residues 0
within 0
the 0
PH B-gene
domain I-gene
, 0
we 0
have 0
constructed 0
a 0
series 0
of 0
mutants 0
in 0
the 0
carboxyl 0
terminus 0
of 0
beta B-gene
ARK I-gene
in 0
order 0
to 0
determine 0
important 0
residues 0
involved 0
in 0
G B-gene
beta I-gene
gamma I-gene
and 0
PIP2 0
binding 0
. 0

Histopathological 0
features 0
of 0
relapsed 0
leprosy 0
. 0

To 0
dissect 0
these 0
mechanisms 0
, 0
wild 0
- 0
type 0
and 0
mutant B-gene
Raf I-gene
- I-gene
1 I-gene
proteins I-gene
were 0
studied 0
in 0
an 0
in 0
vitro 0
system 0
with 0
purified 0
plasma 0
membranes 0
from 0
v B-gene
- I-gene
Ras I-gene
- 0
and 0
v B-gene
- I-gene
Src I-gene
- 0
transformed 0
cells 0
( 0
transformed 0
membranes 0
) 0
. 0

In 0
CV 0
- 0
1 0
cells 0
, 0
cotransfection 0
of 0
the 0
retinoid B-gene
and I-gene
estrogen I-gene
receptors I-gene
led 0
to 0
mutual 0
inhibition 0
of 0
the 0
other 0
's 0
activity 0
, 0
while 0
an 0
RA 0
- 0
dependent 0
inhibition 0
of 0
ER B-gene
activity 0
was 0
observed 0
in 0
breast 0
cancer 0
cells 0
. 0

One 0
of 0
these 0
factors 0
, 0
HRF B-gene
- I-gene
1 I-gene
, 0
recognizes 0
a 0
cis 0
element 0
consisting 0
of 0
an 0
inverted 0
palindromic 0
motif 0
. 0

Regulation 0
of 0
Gax B-gene
homeobox B-gene
gene I-gene
transcription 0
by 0
a 0
combination 0
of 0
positive 0
factors 0
including 0
myocyte B-gene
- I-gene
specific I-gene
enhancer I-gene
factor I-gene
2 I-gene
. 0

The 0
carboxyl 0
- 0
terminal 0
transactivation 0
domain 0
of 0
heat B-gene
shock I-gene
factor I-gene
1 I-gene
is 0
negatively 0
regulated 0
and 0
stress 0
responsive 0
. 0

D 0
. 0

It 0
was 0
proposed 0
that 0
the 0
synthetase 0
- 0
related 0
sequences 0
of 0
GCN2 B-gene
stimulate 0
the 0
activity 0
of 0
the 0
kinase 0
by 0
interacting 0
directly 0
with 0
uncharged 0
tRNA 0
that 0
accumulates 0
during 0
amino 0
acid 0
limitation 0
. 0

However 0
, 0
unlike 0
Bcl B-gene
- I-gene
2 I-gene
and 0
the 0
E1B B-gene
19K I-gene
proteins I-gene
, 0
which 0
completely 0
block 0
apoptosis 0
but 0
not 0
p53 B-gene
- 0
dependent 0
growth 0
arrest 0
, 0
H B-gene
- I-gene
ras I-gene
expression 0
permitted 0
DNA 0
synthesis 0
and 0
cell 0
proliferation 0
in 0
the 0
presence 0
of 0
high 0
levels 0
of 0
wild B-gene
- I-gene
type I-gene
p53 I-gene
. 0

To 0
compare 0
the 0
PAX3 B-gene
and 0
putative 0
PAX3 B-gene
- 0
FKHR B-gene
transactivation 0
domains 0
, 0
we 0
fused 0
C 0
- 0
terminal 0
test 0
fragments 0
to 0
the 0
heterologous 0
GAL4 B-gene
DNA I-gene
- I-gene
binding I-gene
domain I-gene
and 0
tested 0
activation 0
of 0
a 0
reporter 0
gene 0
co 0
- 0
transfected 0
into 0
four 0
cell 0
types 0
. 0

All 0
subjects 0
were 0
submitted 0
to 0
ECG 0
and 0
arterial 0
blood 0
pressure 0
determination 0
and 0
were 0
assayed 0
for 0
TSH B-gene
, 0
thyroid 0
hormone 0
, 0
PRL B-gene
, 0
glucose 0
, 0
creatinine 0
, 0
nitrogen 0
, 0
glutamine B-gene
transaminase I-gene
, 0
cholesterol 0
and 0
triglycerides 0
plasma 0
levels 0
before 0
therapy 0
( 0
T0 0
) 0
, 0
after 0
30 0
treatment 0
days 0
( 0
T30 0
) 0
and 0
after 0
a 0
15 0
days 0
washout 0
( 0
T45 0
) 0
. 0

Acute 0
decrease 0
in 0
body 0
temperature 0
( 0
TB 0
) 0
lowered 0
PaCO2 0
( 0
32.5 0
to 0
14.5 0
mmHg 0
) 0
and 0
[ 0
HCO3 0
- 0
] 0
a 0
( 0
24.20 0
mEq/L 0
to 0
17.56 0
mEq/L 0
) 0
, 0
increased 0
pHa 0
( 0
7.481 0
to 0
7.608 0
) 0
and 0
diminished 0
the 0
[ 0
OH 0
- 0
] 0
/ 0
[ 0
H+ 0
] 0
ratio 0
, 0
but 0
had 0
no 0
significant 0
effect 0
on 0
[ 0
SID 0
] 0
or 0
[ 0
Atot 0
] 0
, 0
although 0
both 0
total 0
phosphorus 0
[ 0
PT 0
] 0
and 0
inorganic 0
phosphate 0
[ 0
Pi 0
] 0
increased 0
. 0

Hepatitis 0
B 0
vaccine 0
: 0
still 0
has 0
its 0
problems 0
. 0

Basal 0
promoter 0
activity 0
is 0
enhanced 0
by 0
a 0
functional 0
M1 0
domain 0
in 0
LHR B-gene
- 0
expressing 0
mouse 0
Leydig 0
tumor 0
cells 0
( 0
MLTC 0
) 0
but 0
not 0
in 0
non 0
- 0
expressing 0
CHO 0
cells 0
. 0

The 0
RAT3 B-gene
gene I-gene
encodes 0
an 0
1157 0
- 0
amino 0
acid 0
protein 0
without 0
similarity 0
to 0
other 0
known 0
proteins 0
. 0

For 0
Al 0
, 0
the 0
exposure 0
to 0
1.36 0
mg/m3 0
during 0
the 0
shift 0
corresponded 0
to 0
a 0
urinary 0
concentration 0
at 0
the 0
end 0
of 0
the 0
shift 0
of 0
200 0
microgram/g 0
creatinine 0
. 0

Tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNF B-gene
alpha I-gene
) 0
, 0
a 0
proinflammatory 0
cytokine 0
, 0
inhibits 0
cAMP 0
- 0
stimulated 0
testosterone 0
production 0
in 0
mouse 0
Leydig 0
cells 0
. 0

The 0
Drosophila B-gene
insulin I-gene
receptor I-gene
homolog I-gene
: 0
a 0
gene 0
essential 0
for 0
embryonic 0
development 0
encodes 0
two 0
receptor 0
isoforms 0
with 0
different 0
signaling 0
potential 0
. 0

We 0
show 0
here 0
that 0
RA 0
and 0
E1A B-gene
induce 0
phosphorylation 0
of 0
the 0
E1A B-gene
- I-gene
associated I-gene
300 I-gene
kDa I-gene
protein I-gene
( 0
p300 B-gene
) 0
during 0
the 0
differentiation 0
of 0
F9 0
cells 0
. 0

The 0
double 0
- 0
stranded 0
RNA 0
binding 0
domain 0
( 0
dsRBD 0
) 0
is 0
an 0
approximately 0
65 0
amino 0
acid 0
motif 0
that 0
is 0
found 0
in 0
a 0
variety 0
of 0
proteins 0
that 0
interact 0
with 0
double 0
- 0
stranded 0
( 0
ds 0
) 0
RNA 0
, 0
such 0
as 0
Escherichia 0
coli 0
RNase B-gene
III I-gene
and 0
the 0
dsRNA B-gene
- I-gene
dependent I-gene
kinase I-gene
, 0
PKR B-gene
. 0

CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
isoforms I-gene
beta I-gene
and I-gene
delta I-gene
are 0
expressed 0
in 0
mammary 0
epithelial 0
cells 0
and 0
bind 0
to 0
multiple 0
sites 0
in 0
the 0
beta B-gene
- I-gene
casein I-gene
gene I-gene
promoter I-gene
. 0

SCA B-gene
was 0
resistant 0
to 0
inhibitors 0
of 0
serine 0
, 0
aspartyl 0
, 0
and 0
metalloproteases B-gene
, 0
but 0
it 0
was 0
sensitive 0
to 0
N 0
- 0
ethylmaleimide 0
. 0

Mutational 0
analysis 0
of 0
potential 0
activating 0
phosphorylation 0
sites 0
found 0
in 0
NIMA B-gene
, 0
NIM B-gene
- I-gene
1 I-gene
, 0
and 0
related 0
protein 0
kinases 0
was 0
performed 0
on 0
NIMA B-gene
. 0

However 0
, 0
a 0
similar 0
mutation 0
of 0
a 0
leucine 0
residue 0
to 0
arginine 0
at 0
position 0
422 0
showed 0
no 0
alteration 0
of 0
heterodimerization 0
, 0
DNA 0
binding 0
, 0
or 0
transcriptional 0
activation 0
. 0

Expression 0
of 0
the 0
CYP11A1 B-gene
gene I-gene
is 0
increased 0
by 0
hormones 0
, 0
such 0
as 0
adrenocorticotropin B-gene
and 0
luteinizing B-gene
hormone I-gene
, 0
as 0
well 0
as 0
by 0
a 0
number 0
of 0
growth 0
factors 0
, 0
suggesting 0
that 0
its 0
promoter 0
may 0
contain 0
regulatory 0
elements 0
that 0
respond 0
to 0
multiple 0
signal 0
transduction 0
pathways 0
. 0

NH2 0
- 0
and 0
COOH 0
- 0
terminal 0
deletion 0
analysis 0
revealed 0
that 0
both 0
the 0
PH B-gene
and 0
putative 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
domains I-gene
are 0
required 0
, 0
but 0
the 0
zinc 0
butterfly 0
is 0
dispensable 0
, 0
for 0
transformation 0
. 0

We 0
have 0
found 0
that 0
the 0
expression 0
of 0
GTPase B-gene
- 0
deficient 0
mutants 0
of 0
alpha B-gene
12 I-gene
( 0
alpha B-gene
12Q229L I-gene
) 0
or 0
alpha B-gene
13 I-gene
( 0
alpha B-gene
13Q226L I-gene
) 0
leads 0
to 0
robust 0
activation 0
of 0
the 0
Jun B-gene
kinase/stress I-gene
kinase/stress I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
JNK/SAPK B-gene
) 0
pathway 0
. 0

The 0
objective 0
of 0
our 0
study 0
was 0
to 0
evaluate 0
the 0
age 0
, 0
sex 0
, 0
clinical 0
conditions 0
, 0
family 0
history 0
, 0
site 0
, 0
catheter 0
association 0
, 0
means 0
of 0
radiologic 0
evaluation 0
, 0
development 0
of 0
pulmonary 0
involvement 0
, 0
prevalence 0
of 0
antithrombin B-gene
III I-gene
, 0
protein B-gene
C I-gene
and 0
protein B-gene
S I-gene
deficiencies 0
, 0
and 0
lupus 0
anticoagulants 0
in 0
children 0
who 0
suffered 0
a 0
thrombotic 0
event 0
. 0

Harel 0
, 0
E.M 0
. 0

Radiotherapy 0
and 0
early 0
orchiectomy 0
in 0
stage 0
D1 0
prostatic 0
carcinoma 0

Structural 0
organization 0
and 0
developmental 0
expression 0
pattern 0
of 0
the 0
mouse B-gene
WD I-gene
- I-gene
repeat I-gene
gene I-gene
DMR I-gene
- I-gene
N9 I-gene
immediately 0
upstream 0
of 0
the 0
myotonic B-gene
dystrophy I-gene
locus I-gene
. 0

The 0
ARX2 0
procedure 0
models 0
the 0
recorded 0
signal 0
as 0
the 0
sum 0
of 0
three 0
signals 0
: 0
( 0
a 0
) 0
the 0
background 0
EEG 0
activity 0
, 0
modelled 0
as 0
an 0
autoregressive 0
process 0
driven 0
by 0
a 0
white 0
noise 0
; 0
( 0
b 0
) 0
a 0
filtered 0
version 0
of 0
a 0
reference 0
signal 0
carrying 0
the 0
average 0
information 0
contained 0
in 0
each 0
sweep 0
; 0
( 0
c 0
) 0
a 0
signal 0
due 0
to 0
the 0
ocular 0
artefact 0
propagation 0
. 0

The 0
expression 0
of 0
the 0
gene 0
encoding 0
the 0
enzyme 0
( 0
CYP19 B-gene
) 0
is 0
regulated 0
, 0
in 0
part 0
, 0
by 0
tissue 0
- 0
specific 0
promoters 0
through 0
the 0
use 0
of 0
alternative 0
- 0
splicing 0
mechanisms 0
. 0

Using 0
mutagenesis 0
, 0
we 0
have 0
identified 0
two 0
mutations 0
of 0
the 0
second 0
actin B-gene
- I-gene
binding I-gene
domain I-gene
that 0
can 0
also 0
suppress 0
the 0
act1 B-gene
mutations 0
of 0
interest 0
. 0

CIITA B-gene
mRNA I-gene
is 0
normally 0
inducible 0
by 0
IFN B-gene
- I-gene
gamma I-gene
in 0
class 0
II 0
non 0
- 0
inducible 0
, 0
RB 0
- 0
defective 0
lines 0
, 0
and 0
in 0
one 0
line 0
, 0
re 0
- 0
expression 0
of 0
RB B-gene
has 0
no 0
effect 0
on 0
CIITA B-gene
mRNA I-gene
induction 0
levels 0
. 0

The 0
normal 0
cell 0
cycle 0
is 0
regulated 0
by 0
several 0
molecules 0
, 0
such 0
as 0
the 0
tumor B-gene
- I-gene
suppressor I-gene
protein I-gene
pRb I-gene
, 0
the 0
G1 B-gene
cyclins I-gene
, 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinases I-gene
, 0
and 0
their 0
inhibitors 0
. 0

Consistent 0
with 0
the 0
protein 0
expression 0
data 0
, 0
V B-gene
beta I-gene
8.3 I-gene
gene I-gene
transcripts I-gene
were 0
found 0
only 0
in 0
the 0
transgenic 0
lines 0
with 0
the 0
wild 0
- 0
type 0
promoter 0
. 0

These 0
results 0
are 0
very 0
useful 0
for 0
deciding 0
on 0
the 0
doses 0
of 0
hormones 0
and 0
the 0
expected 0
serum 0
estradiol 0
level 0
in 0
HRT 0
for 0
Japanese 0
women 0
. 0

Comparison 0
of 0
1.5 0
Tesla 0
and 0
0.35 0
Tesla 0
field 0
strength 0
magnetic 0
resonance 0
imaging 0
scans 0
in 0
the 0
morphometric 0
evaluation 0
of 0
the 0
lumbar 0
intervertebral 0
foramina 0
. 0

One 0
month 0
after 0
the 0
DTaP 0
booster 0
vaccination 0
, 0
both 0
groups 0
had 0
6 0
- 0
to 0
40 0
- 0
fold 0
increases 0
in 0
serum 0
antibody 0
concentrations 0
to 0
all 0
antigens 0
tested 0
; 0
the 0
concentrations 0
against 0
the 0
three 0
pertussis B-gene
antigens I-gene
were 0
higher 0
in 0
the 0
DTaP 0
- 0
primed 0
children 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Interestingly 0
, 0
this 0
amino 0
- 0
terminal 0
determinant 0
appears 0
not 0
to 0
reside 0
in 0
the 0
HSV 0
- 0
alpha B-gene
TIF I-gene
, 0
which 0
displays 0
no 0
independent 0
amino 0
- 0
terminal 0
activity 0
. 0

We 0
also 0
show 0
that 0
in 0
fusions 0
with 0
the 0
DNA 0
binding 0
domain 0
of 0
GAL4 B-gene
, 0
full 0
activity 0
requires 0
the 0
entire 0
BHV B-gene
- I-gene
alpha I-gene
TIF I-gene
, 0
although 0
both 0
amino 0
and 0
carboxyl 0
termini 0
display 0
some 0
activity 0
on 0
their 0
own 0
. 0

To 0
investigate 0
the 0
potential 0
role 0
of 0
SP1 B-gene
, 0
we 0
examined 0
nuclear 0
extracts 0
from 0
HCMV 0
- 0
infected 0
cells 0
. 0

Here 0
we 0
show 0
that 0
messenger 0
RNAs 0
encoding 0
trans 0
- 0
sialidases 0
containing 0
the 0
repeats 0
are 0
not 0
present 0
in 0
epimastigotes 0
but 0
are 0
abundant 0
in 0
trypomastigotes 0
. 0

From 0
May 0
1985 0
to 0
May 0
1989 0
, 0
126 0
necropsies 0
were 0
performed 0
at 0
the 0
Sao 0
Paulo 0
City 0
Morgue 0
on 0
cadavers 0
of 0
individuals 0
AIDS 0
victims 0
whose 0
unnatural 0
deaths 0
had 0
prompted 0
police 0
investigations 0
. 0

A 0
model 0
with 0
age 0
and 0
weight 0
described 0
the 0
best 0
fit 0
for 0
TBBMD 0
, 0
whereas 0
age 0
, 0
weight 0
, 0
and 0
height 0
described 0
the 0
best 0
fit 0
for 0
total 0
body 0
TBBMC 0
. 0

As 0
retinoic 0
acid 0
and 0
thyroid 0
hormone 0
are 0
frequently 0
involved 0
in 0
developmental 0
regulatory 0
processes 0
, 0
it 0
is 0
possible 0
that 0
this 0
element 0
may 0
be 0
important 0
in 0
the 0
process 0
of 0
islet 0
cell 0
differentiation 0
. 0

The 0
C 0
- 0
terminal 0
peptide 0
sequences 0
of 0
the 0
human B-gene
lymphocyte I-gene
- I-gene
specific I-gene
high I-gene
mobility I-gene
group I-gene
( I-gene
HMG I-gene
) I-gene
- I-gene
box I-gene
transcription I-gene
factor I-gene
TCF I-gene
- I-gene
1 I-gene
are 0
determined 0
by 0
alternative 0
splice 0
mechanisms 0
affecting 0
the 0
exons 0
VIII 0
to 0
X 0
. 0

Thromboxane 0
B2 0
increased 0
( 0
97 0
+/ 0
- 0
105 0
versus 0
40 0
+/ 0
- 0
26 0
pg/ml 0
) 0
and 0
was 0
significantly 0
higher 0
during 0
heparin 0
free 0
hemodialysis 0
than 0
during 0
hemodialysis 0
with 0
heparin 0
( 0
p 0
= 0
0.01 0
, 0
Wilcoxon 0
matched 0
pairs 0
signed 0
rank 0
test 0
) 0
. 0

A 0
new 0
vector 0
, 0
pHBK280 0
, 0
was 0
designed 0
to 0
facilitate 0
this 0
analysis 0
. 0

To 0
explore 0
the 0
mechanism 0
of 0
RSK B-gene
activation 0
, 0
a 0
cloned 0
human 0
RSK B-gene
cDNA 0
( 0
RSK3 B-gene
) 0
was 0
used 0
to 0
generate 0
and 0
characterize 0
several 0
site 0
- 0
directed 0
RSK B-gene
mutants I-gene
; 0
K91A 0
( 0
N 0
- 0
Lys 0
, 0
NH2 0
- 0
terminal 0
ATP 0
- 0
binding 0
mutant 0
) 0
, 0
K444A 0
( 0
C 0
- 0
Lys 0
, 0
COOH 0
- 0
terminal 0
ATP 0
- 0
binding 0
mutant 0
) 0
, 0
N/C 0
- 0
Lys 0
( 0
double 0
ATP 0
- 0
binding 0
mutant 0
) 0
T570A 0
( 0
C 0
- 0
Thr 0
, 0
mutant 0
of 0
the 0
putative 0
MAPK B-gene
phosphorylation 0
site 0
in 0
subdomain 0
VIII 0
of 0
the 0
C 0
- 0
domain 0
) 0
, 0
S218A 0
( 0
N 0
- 0
Ser 0
, 0
mutant 0
of 0
the 0
corresponding 0
NH2 0
- 0
terminal 0
residue 0
) 0
. 0

In 0
contrast 0
, 0
both 0
C 0
- 0
Lys 0
and 0
C 0
- 0
Thr 0
retained 0
high 0
levels 0
of 0
kinase 0
activity 0
and 0
were 0
capable 0
of 0
responding 0
to 0
stimulation 0
. 0

Conversely 0
, 0
treatment 0
of 0
human B-gene
protein I-gene
- I-gene
tyrosine I-gene
phosphatase I-gene
alpha I-gene
- 0
overexpressing 0
cells 0
with 0
phenylarsine 0
oxide 0
led 0
to 0
a 0
loss 0
of 0
the 0
constitutive 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
activity 0
. 0

A 0
TATA 0
- 0
less 0
promoter 0
containing 0
binding 0
sites 0
for 0
ubiquitous 0
transcription 0
factors 0
mediates 0
cell 0
type 0
- 0
specific 0
regulation 0
of 0
the 0
gene 0
for 0
transcription B-gene
enhancer I-gene
factor I-gene
- I-gene
1 I-gene
( 0
TEF B-gene
- I-gene
1 I-gene
) 0
. 0

Since 0
electrical 0
stimulation 0
of 0
neurones 0
may 0
activate 0
not 0
only 0
cell 0
bodies 0
but 0
also 0
neuronal 0
fibres 0
, 0
this 0
study 0
aimed 0
to 0
test 0
a 0
selectively 0
cholinergic 0
neurochemical 0
stimulation 0
of 0
the 0
rat 0
substantia 0
innominata 0
( 0
SI 0
) 0
by 0
the 0
local 0
microinjection 0
of 0
carbachol 0
; 0
the 0
effects 0
of 0
this 0
acetylcholine 0
agonist 0
were 0
compared 0
with 0
glutamate 0
. 0

Here 0
we 0
describe 0
an 0
in 0
vitro 0
assay 0
where 0
the 0
NS3 B-gene
- I-gene
4A I-gene
polyprotein I-gene
, 0
NS3 B-gene
, 0
the 0
serine B-gene
proteinase I-gene
domain I-gene
( I-gene
the I-gene
N I-gene
- I-gene
terminal I-gene
181 I-gene
residues I-gene
of I-gene
NS3 I-gene
) I-gene
, 0
and 0
the 0
NS4A B-gene
cofactor I-gene
were 0
produced 0
by 0
cell 0
- 0
free 0
translation 0
and 0
tested 0
for 0
trans 0
- 0
processing 0
of 0
radiolabeled 0
substrates 0
. 0

In 0
contrast 0
, 0
over 0
- 0
expression 0
of 0
RAR B-gene
beta I-gene
only 0
poorly 0
restored 0
differentiation 0
, 0
although 0
it 0
could 0
replace 0
RAR B-gene
gamma I-gene
for 0
the 0
activation 0
of 0
target 0
genes 0
. 0

We 0
purified 0
both 0
proteins 0
from 0
human 0
platelet 0
membranes 0
using 0
DEAE 0
- 0
Sepharose 0
chromatography 0
followed 0
by 0
mAb B-gene
F11 I-gene
affinity 0
chromatography 0
. 0

The 0
homeobox B-gene
gene I-gene
ATK1 I-gene
of 0
Arabidopsis 0
thaliana 0
is 0
expressed 0
in 0
the 0
shoot 0
apex 0
of 0
the 0
seedling 0
and 0
in 0
flowers 0
and 0
inflorescence 0
stems 0
of 0
mature 0
plants 0
. 0

The 0
most 0
likely 0
explanation 0
for 0
this 0
is 0
that 0
gold 0
principally 0
accumulates 0
in 0
the 0
Kupffer 0
cells 0
and 0
renal 0
cortex 0
and 0
these 0
cells 0
do 0
not 0
express 0
Type B-gene
I I-gene
deiodinase I-gene
. 0

These 0
results 0
suggest 0
that 0
different 0
models 0
of 0
intestinal 0
ischemia 0
have 0
different 0
cytokine 0
profiles 0
and 0
that 0
the 0
early 0
TNF B-gene
response 0
associated 0
with 0
SMA 0
occlusion 0
model 0
is 0
primarily 0
due 0
to 0
the 0
laparotomy 0
. 0

Our 0
evidence 0
derives 0
from 0
three 0
principal 0
observations 0
: 0
1 0
) 0
a 0
transfection 0
construct 0
containing 0
only 0
122 0
nucleotides 0
( 0
nt 0
) 0
of 0
promoter 0
1 0
and 0
328 0
nt 0
of 0
the 0
5' 0
- 0
UTR 0
retained 0
full 0
PGE2 0
- 0
stimulated 0
reporter 0
expression 0
; 0
2 0
) 0
maximal 0
PGE2 0
- 0
driven 0
reporter 0
expression 0
required 0
the 0
presence 0
of 0
nt 0
196 0
to 0
328 0
of 0
exon 0
1 0
when 0
tested 0
within 0
the 0
context 0
of 0
IGF B-gene
- I-gene
I I-gene
promoter I-gene
1 I-gene
; 0
3 0
) 0
cotransfection 0
of 0
IGF B-gene
- I-gene
I I-gene
promoter I-gene
- 0
luciferase B-gene
- 0
reporter 0
constructs 0
with 0
a 0
plasmid 0
encoding 0
the 0
alpha 0
- 0
isoform 0
of 0
the 0
catalytic 0
subunit 0
of 0
murine B-gene
cAMP I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
PKA B-gene
) 0
produced 0
results 0
comparable 0
to 0
those 0
seen 0
with 0
PGE2 0
treatment 0
, 0
whereas 0
cotransfection 0
with 0
a 0
plasmid 0
encoding 0
a 0
mutant 0
regulatory 0
subunit 0
of 0
PKA B-gene
that 0
can 0
not 0
bind 0
cAMP 0
blocked 0
PGE2 0
- 0
induced 0
reporter 0
expression 0
. 0

The 0
changes 0
after 0
treatment 0
were 0
observed 0
chiefly 0
by 0
electromyography 0
while 0
sensory 0
and 0
motor 0
improvement 0
were 0
also 0
recorded 0
as 0
auxiliary 0
indicators 0
. 0

Band 0
- 0
shift 0
assays 0
and 0
DNase B-gene
I I-gene
footprinting 0
experiments 0
using 0
purified 0
42 0
kDa 0
repressor 0
isoform 0
confirmed 0
that 0
CIRs B-gene
5 I-gene
and I-gene
6 I-gene
were 0
indeed 0
the 0
targets 0
for 0
binding 0
of 0
this 0
protein 0
. 0

The 0
5' 0
- 0
terminus 0
of 0
the 0
p B-gene
- I-gene
gvpF I-gene
- I-gene
M I-gene
mRNA I-gene
was 0
located 0
169 0
nucleotides 0
upstream 0
of 0
p B-gene
- I-gene
gvpF I-gene
within 0
p B-gene
- I-gene
gvpE I-gene
. 0

Retransformation 0
of 0
uvsH77 B-gene
mutants I-gene
with 0
the 0
rescued 0
cosmids 0
from 0
the 0
MMS 0
- 0
resistant 0
transformants 0
resulted 0
in 0
restoration 0
of 0
both 0
UV 0
and 0
MMS 0
resistance 0
to 0
wild 0
- 0
type 0
levels 0
. 0

Furthermore 0
, 0
this 0
element 0
confers 0
p53 B-gene
induction 0
to 0
the 0
otherwise 0
nonresponsive 0
adenovirus 0
major 0
late 0
promoter 0
. 0

In 0
flies 0
, 0
the 0
dShc B-gene
protein I-gene
physically 0
associates 0
with 0
the 0
activated 0
Drosophila B-gene
epidermal I-gene
growth I-gene
factor I-gene
receptor I-gene
homolog I-gene
( 0
DER B-gene
) 0
and 0
is 0
inducibly 0
phosphorylated 0
on 0
tyrosine 0
by 0
DER B-gene
. 0

A 0
potential 0
binding 0
site 0
for 0
the 0
dShc B-gene
PTB 0
domain 0
is 0
located 0
at 0
Tyr 0
- 0
1228 0
of 0
DER B-gene
. 0

A 0
Drosophila B-gene
shc I-gene
gene I-gene
product I-gene
is 0
implicated 0
in 0
signaling 0
by 0
the 0
DER B-gene
receptor I-gene
tyrosine I-gene
kinase I-gene
. 0

This 0
inhibition 0
can 0
be 0
overcome 0
by 0
mutating 0
either 0
the 0
exon 0
's 0
5 0
' 0
or 0
3 0
' 0
splice 0
site 0
to 0
make 0
it 0
correspond 0
more 0
closely 0
to 0
the 0
relevant 0
consensus 0
sequence 0
. 0

Biochemical 0
analysis 0
shows 0
that 0
Ssm1p B-gene
is 0
a 0
structural 0
protein 0
that 0
forms 0
part 0
of 0
the 0
largest 0
60S B-gene
ribosomal I-gene
subunit I-gene
, 0
which 0
does 0
not 0
exist 0
in 0
a 0
pool 0
of 0
free 0
proteins 0
. 0

In 0
wild 0
- 0
type 0
cells 0
, 0
SSM1b B-gene
transcripts I-gene
accumulate 0
to 0
twice 0
the 0
level 0
of 0
SSM1a B-gene
transcripts I-gene
, 0
suggesting 0
that 0
SSM1b B-gene
is 0
responsible 0
for 0
the 0
majority 0
of 0
the 0
Ssm1p B-gene
pool 0
. 0

Northern 0
blot 0
analysis 0
revealed 0
the 0
expression 0
of 0
LIMK B-gene
- I-gene
1 I-gene
mRNA I-gene
predominantly 0
in 0
the 0
brain 0
and 0
the 0
expression 0
of 0
LIMK B-gene
- I-gene
2 I-gene
mRNA I-gene
in 0
various 0
tissues 0
in 0
the 0
rat 0
. 0

However 0
, 0
the 0
relative 0
binding 0
affinity 0
for 0
the 0
motifs 0
is 0
different 0
. 0

On 0
the 0
basis 0
of 0
this 0
anatomic 0
concept 0
, 0
the 0
brachioplasty 0
procedure 0
was 0
modified 0
to 0
provide 0
secure 0
anchoring 0
of 0
the 0
arm 0
flap 0
to 0
the 0
axillary 0
fascia 0
along 0
with 0
strong 0
superficial 0
fascial 0
system 0
repair 0
of 0
incisions 0
, 0
reducing 0
the 0
risk 0
of 0
widening 0
or 0
migration 0
of 0
scars 0
and 0
unnatural 0
contours 0
. 0

Furthermore 0
, 0
microinjection 0
of 0
dominant 0
negative 0
forms 0
of 0
Rac B-gene
and 0
Cdc42 B-gene
or 0
of 0
the 0
Rho B-gene
inhibitor 0
C3 B-gene
transferase I-gene
blocked 0
serum 0
- 0
induced 0
DNA 0
synthesis 0
. 0

INF B-gene
- I-gene
alpha I-gene
therapy 0
has 0
been 0
a 0
major 0
development 0
in 0
the 0
treatment 0
of 0
CML 0
. 0

A 0
series 0
of 0
amino 0
terminal 0
deletion 0
mutants 0
( 0
d10 0
, 0
d20 0
, 0
d27 0
, 0
d31 0
, 0
d40 0
, 0
d44 0
, 0
and 0
d73 0
) 0
were 0
compared 0
for 0
processing 0
, 0
cell 0
surface 0
expression 0
, 0
and 0
maintenance 0
of 0
their 0
biological 0
attributes 0
by 0
recombinant 0
expression 0
of 0
mutant 0
genes 0
using 0
a 0
plasmid 0
vector 0
( 0
pcDL 0
- 0
SR 0
alpha 0
- 0
296 0
) 0
in 0
CV 0
- 0
1 0
and 0
HeLa 0
cells 0
. 0

Intrathecal 0
acetyl B-gene
cholinesterase I-gene
inhibitors 0
produce 0
analgesia 0
that 0
is 0
synergistic 0
with 0
morphine 0
and 0
clonidine 0
in 0
rats 0
. 0

After 0
determining 0
isoflurane 0
MAC 0
in 0
triplicate 0
, 0
birds 0
were 0
given 0
a 0
mu 0
- 0
opioid 0
agonist 0
( 0
morphine 0
, 0
n 0
= 0
9 0
) 0
or 0
a 0
kappa 0
- 0
opioid 0
agonist 0
( 0
U50488H 0
, 0
n 0
= 0
9 0
) 0
. 0

Max B-gene
was 0
constantly 0
transcribed 0
at 0
a 0
relatively 0
low 0
level 0
during 0
cell 0
cycle 0
progression 0
. 0

The 0
yeast 0
enzyme 0
was 0
6 0
- 0
fold 0
slower 0
than 0
the 0
mammalian 0
enzymes 0
, 0
which 0
made 0
it 0
amenable 0
to 0
pre 0
- 0
steady 0
- 0
state 0
stopped 0
- 0
flow 0
spectroscopic 0
kinetic 0
analysis 0
at 0
30 0
degrees 0
C 0
and 0
pH 0
6.0 0
. 0

Key 0
areas 0
of 0
the 0
selection 0
process 0
including 0
medical 0
and 0
surgical 0
alternatives 0
to 0
transplantation 0
, 0
the 0
composition 0
of 0
the 0
transplant 0
work 0
- 0
up 0
, 0
specific 0
inclusion 0
criteria 0
as 0
well 0
as 0
specific 0
psychosocial 0
factors 0
and 0
specific 0
disease 0
etiologies 0
and 0
co 0
- 0
morbidities 0
that 0
might 0
represent 0
contraindications 0
were 0
extensively 0
reviewed 0
. 0

The 0
transport 0
of 0
a 0
genetically 0
engineered 0
chimeric 0
transmembrane 0
protein 0
connected 0
to 0
this 0
ER 0
leader 0
sequence 0
was 0
as 0
efficient 0
as 0
that 0
of 0
the 0
original 0
protein 0
from 0
which 0
the 0
ER 0
sequence 0
has 0
been 0
derived 0
. 0

In 0
both 0
shoots 0
and 0
roots 0
, 0
GT B-gene
- I-gene
2 I-gene
protein I-gene
is 0
undetectable 0
in 0
meristematic 0
tissue 0
but 0
becomes 0
expressed 0
at 0
later 0
stages 0
of 0
cellular 0
development 0
, 0
consistent 0
with 0
a 0
role 0
in 0
contributing 0
to 0
the 0
pattern 0
of 0
phytochrome B-gene
A I-gene
gene I-gene
expression 0
. 0

A 0
polymorphic 0
bipartite 0
motif 0
signals 0
nuclear 0
targeting 0
of 0
early 0
auxin 0
- 0
inducible 0
proteins 0
related 0
to 0
PS B-gene
- I-gene
IAA4 I-gene
from I-gene
pea I-gene
( I-gene
Pisum I-gene
sativum I-gene
) I-gene
. 0

Comparative 0
DNA 0
sequence 0
analysis 0
showed 0
the 0
Genethon 0
microsatellite B-gene
D19S596 I-gene
lies 0
2.2 0
kb 0
downstream 0
of 0
the 0
coding 0
region 0
of 0
FUT1 B-gene
, 0
indicating 0
that 0
the 0
cluster 0
comprising 0
the 0
closely 0
linked 0
FUT1 B-gene
and 0
FUT2 B-gene
genes I-gene
is 0
located 0
4 0
cM 0
distal 0
to 0
D19S412 B-gene
( 0
lod 0
score 0
13.7 0
) 0
and 0
9 0
cM 0
proximal 0
to 0
D19S571 B-gene
( 0
lod 0
score 0
11.7 0
) 0
. 0

We 0
conclude 0
that 0
transcription 0
activation 0
by 0
LEF B-gene
- I-gene
1 I-gene
in 0
vitro 0
is 0
a 0
chromatin 0
- 0
dependent 0
process 0
that 0
requires 0
a 0
functional 0
trans 0
- 0
activation 0
domain 0
in 0
addition 0
to 0
the 0
HMG B-gene
domain I-gene
. 0

TH B-gene
- 0
SH3 B-gene
binding 0
in 0
vitro 0
is 0
abolished 0
by 0
specific 0
, 0
single 0
amino 0
acid 0
substitutions 0
within 0
the 0
Btk B-gene
TH B-gene
domain I-gene
or 0
the 0
Fyn B-gene
SH3 B-gene
domain I-gene
. 0

These 0
results 0
indicate 0
that 0
K B-gene
- I-gene
glypican I-gene
is 0
a 0
novel 0
GPI B-gene
- I-gene
anchored I-gene
HSPG I-gene
involved 0
in 0
embryonic 0
development 0
. 0

Protein B-gene
S I-gene
levels 0
were 0
virtually 0
undetectable 0
at 0
the 0
time 0
of 0
admission 0
and 0
failed 0
to 0
respond 0
to 0
infusions 0
of 0
fresh 0
frozen 0
plasma 0
, 0
despite 0
correction 0
of 0
other 0
procoagulant 0
and 0
anticoagulant 0
factors 0
. 0

The 0
plant 0
hormone 0
auxin 0
transcriptionally 0
activates 0
early B-gene
genes I-gene
. 0

The 0
test 0
was 0
not 0
performed 0
in 0
3923 0
patients 0
because 0
of 0
contraindications 0
. 0

The 0
ubiquitous 0
transcription 0
factor 0
Oct B-gene
- I-gene
1 I-gene
forms 0
complexes 0
with 0
an 0
octamer 0
motif 0
present 0
within 0
FPIV 0
by 0
gel 0
shift 0
analysis 0
with 0
liver 0
and 0
kidney 0
extracts 0
, 0
making 0
Oct B-gene
- I-gene
1 I-gene
an 0
intriguing 0
candidate 0
for 0
partnership 0
in 0
androgen 0
regulation 0
. 0

A 0
new 0
non 0
- 0
LTR 0
retrotransposon 0
provides 0
evidence 0
for 0
multiple 0
distinct 0
site 0
- 0
specific 0
elements 0
in 0
Crithidia 0
fasciculata 0
miniexon 0
arrays 0
. 0

We 0
used 0
deletion 0
analysis 0
and 0
transfection 0
assays 0
with 0
reporter 0
gene 0
constructs 0
to 0
examine 0
the 0
transcription 0
control 0
elements 0
in 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
human B-gene
EpoR I-gene
gene I-gene
. 0

The 0
CVA16.4 B-gene
proteolipid I-gene
transcript I-gene
is 0
the 0
most 0
prevalent 0
of 0
the 0
two 0
proteolipid 0
messages 0
in 0
expanding 0
ovules 0
harvested 0
10 0
d 0
post 0
- 0
anthesis 0
. 0

Incubation 0
of 0
the 0
purified 0
fusion 0
proteins 0
with 0
[ 0
gamma 0
- 0
32P 0
] 0
ATP 0
in 0
an 0
in 0
vitro 0
assay 0
showed 0
that 0
both 0
proteins 0
were 0
capable 0
of 0
autophosphorylation 0
. 0

The 0
character 0
of 0
specific 0
immune 0
response 0
in 0
101 0
immunized 0
children 0
and 0
in 0
12 0
adults 0
belonging 0
to 0
a 0
high 0
risk 0
group 0
with 0
respect 0
to 0
VHB 0
. 0

After 0
nadolol 0
, 0
heart 0
rate 0
decreased 0
( 0
- 0
22 0
+/ 0
- 0
8 0
% 0
) 0
, 0
and 0
so 0
did 0
PBV 0
and 0
PBF 0
( 0
8.8 0
+/ 0
- 0
3.4 0
vs 0
. 0

The 0
synthetic 0
DNA 0
sequence 0
was 0
constructed 0
to 0
achieve 0
efficient 0
base 0
pairing 0
with 0
Escherichia B-gene
coli I-gene
16S I-gene
ribosomal I-gene
RNA I-gene
, 0
avoidance 0
of 0
internal 0
secondary 0
structure 0
, 0
and 0
optimal 0
codon 0
usage 0
for 0
high 0
- 0
level 0
protein 0
expression 0
in 0
accord 0
with 0
the 0
known 0
preferences 0
in 0
E. 0
coli 0
. 0

Adrenergic 0
system 0
activation 0
, 0
indicated 0
by 0
metanephrine/epinephrine 0
ratio 0
, 0
increased 0
with 0
time 0
in 0
losing 0
males 0
, 0
except 0
that 0
after 0
one 0
month 0
of 0
cohabitation 0
, 0
turnover 0
returned 0
to 0
levels 0
that 0
equaled 0
those 0
of 0
control 0
animals 0
. 0

Transabdominal 0
repair 0
of 0
type 0
IV 0
thoraco 0
- 0
abdominal 0
aortic 0
aneurysms 0
. 0

A 0
. 0

Transcription 0
factors 0
containing 0
a 0
basic 0
helix 0
- 0
loop 0
- 0
helix 0
( 0
bHLH 0
) 0
motif 0
regulate 0
the 0
expression 0
of 0
tissue 0
- 0
specific 0
genes 0
in 0
a 0
number 0
of 0
mammalian 0
and 0
insect 0
systems 0
. 0

Primer 0
extension 0
and 0
cDNA 0
cloning 0
were 0
used 0
to 0
isolate 0
the 0
complete 0
5 0
' 0
end 0
of 0
the 0
Nramp1 B-gene
mRNA I-gene
. 0

Primer 0
extension 0
and 0
S1 B-gene
nuclease I-gene
mapping 0
experiments 0
were 0
used 0
to 0
locate 0
the 0
transcription 0
initiation 0
site 0
of 0
Nramp1 B-gene
and 0
revealed 0
the 0
presence 0
of 0
one 0
major 0
and 0
several 0
minor 0
initiation 0
sites 0
. 0

EsaR B-gene
can 0
repress 0
its 0
own 0
expression 0
but 0
seems 0
not 0
to 0
regulate 0
the 0
expression 0
of 0
esaI B-gene
. 0

Sequence 0
analysis 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
CD69 B-gene
gene I-gene
revealed 0
the 0
presence 0
of 0
a 0
potential 0
TATA 0
element 0
30 0
base 0
pairs 0
upstream 0
of 0
the 0
major 0
transcription 0
initiation 0
site 0
and 0
several 0
putative 0
binding 0
sequences 0
for 0
inducible 0
transcription 0
factors 0
( 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
, 0
Egr B-gene
- I-gene
1 I-gene
, 0
AP B-gene
- I-gene
1 I-gene
) 0
, 0
which 0
might 0
mediate 0
the 0
inducible 0
expression 0
of 0
this 0
gene 0
. 0

The 0
plasmin B-gene
- I-gene
derived I-gene
D I-gene
( I-gene
approximately I-gene
105 I-gene
- I-gene
kDa I-gene
) I-gene
product I-gene
, 0
however 0
, 0
could 0
be 0
cross 0
- 0
linked 0
into 0
DD 0
dimers 0
. 0

All 0
clinical 0
isolates 0
were 0
concomitantly 0
tested 0
by 0
disk 0
diffusion 0
and 0
agar 0
dilution 0
procedures 0
as 0
outlined 0
by 0
the 0
National 0
Committee 0
for 0
Clinical 0
Laboratory 0
Standards 0
. 0

IgE B-gene
levels 0
showed 0
higher 0
values 0
compared 0
to 0
normal 0
individuals 0
and 0
IgE B-gene
levels 0
were 0
higher 0
in 0
children 0
groups 0
than 0
in 0
adults 0
regardless 0
of 0
the 0
intensity 0
of 0
infection 0
. 0

Tissue 0
- 0
specific 0
expression 0
of 0
the 0
tmy B-gene
- I-gene
1 I-gene
gene I-gene
was 0
determined 0
by 0
microinjection 0
of 0
a 0
promoter/lacZ B-gene
fusion I-gene
gene I-gene
and 0
with 0
immunohistochemistry 0
by 0
using 0
affinity 0
- 0
purified 0
tissue B-gene
- I-gene
specific I-gene
anti I-gene
- I-gene
tropomyosins I-gene
. 0

The 0
nucleotide 0
sequence 0
of 0
the 0
chloroplast 0
( 0
cp 0
) 0
DNA 0
from 0
maize 0
( 0
Zea 0
mays 0
) 0
has 0
been 0
completed 0
. 0

Investigation 0
of 0
the 0
control 0
of 0
coronavirus 0
subgenomic 0
mRNA 0
transcription 0
by 0
using 0
T7 0
- 0
generated 0
negative 0
- 0
sense 0
RNA 0
transcripts 0
. 0

Initiation 0
of 0
translation 0
of 0
the 0
human 0
hepatitis 0
C 0
virus 0
( 0
HCV 0
) 0
RNA 0
genome 0
occurs 0
by 0
internal 0
ribosome 0
entry 0
into 0
the 0
5 0
' 0
noncoding 0
region 0
( 0
5'NCR 0
) 0
in 0
a 0
cap 0
- 0
independent 0
manner 0
. 0

Mean 0
longitudinal 0
extension 0
of 0
the 0
epidural 0
lesion 0
was 0
2.6 0
vertebral 0
segments 0
. 0

The 0
association 0
of 0
p255 B-gene
with 0
splicing 0
complexes 0
is 0
suggested 0
by 0
the 0
finding 0
that 0
mAb B-gene
CC3 I-gene
can 0
inhibit 0
in 0
vitro 0
splicing 0
and 0
immunoprecipitate 0
pre 0
- 0
messenger 0
RNA 0
and 0
splicing 0
products 0
. 0

L 0
- 0
735,524 0
free 0
base 0
or 0
sulfate 0
salt 0
was 0
administered 0
orally 0
as 0
suspension 0
, 0
solution 0
or 0
in 0
solid 0
dosage 0
forms 0
to 0
fasted 0
or 0
fed 0
Beagle 0
dogs 0
. 0

Doppler 0
ultrasound 0
studies 0
of 0
long 0
- 0
term 0
follow 0
- 0
up 0
of 0
children 0
with 0
hemolytic 0
- 0
uremic 0
syndrome 0

Thus 0
, 0
endemic 0
cumlations 0
of 0
hepatitis 0
A 0
diseases 0
are 0
possible 0
. 0

( 0
1991 0
) 0
. 0

The 0
properties 0
of 0
the 0
phi 0
29 0
SSB B-gene
- I-gene
ssDNA I-gene
complex 0
are 0
described 0
. 0

This 0
shows 0
that 0
the 0
characteristically 0
diffuse 0
banding 0
pattern 0
of 0
plant 0
nuclear 0
proteins 0
interacting 0
with 0
the 0
G 0
- 0
box 0
is 0
also 0
observed 0
in 0
a 0
binding 0
assay 0
using 0
only 0
one 0
recombinant B-gene
GBF I-gene
. 0

We 0
studied 0
120 0
male 0
and 0
42 0
female 0
patients 0
with 0
early 0
CAD 0
who 0
were 0
unrelated 0
to 0
each 0
other 0
but 0
were 0
from 0
families 0
in 0
which 0
at 0
least 0
one 0
other 0
sibling 0
had 0
early 0
CAD 0
. 0

The 0
physical 0
linkage 0
of 0
the 0
FHR2 B-gene
and 0
the 0
factor B-gene
H I-gene
genes I-gene
provides 0
additional 0
evidence 0
for 0
a 0
close 0
relatedness 0
of 0
complement B-gene
factor I-gene
H I-gene
and 0
the 0
factor B-gene
H I-gene
- I-gene
related I-gene
proteins I-gene
. 0

Genomic 0
structure 0
and 0
chromosomal 0
location 0
of 0
the 0
mouse B-gene
pre I-gene
- I-gene
T I-gene
- I-gene
cell I-gene
receptor I-gene
alpha I-gene
gene I-gene
. 0

The 0
third 0
domain 0
had 0
the 0
motif 0
of 0
a 0
cAMP 0
response 0
element 0
( 0
CRE 0
) 0
. 0

The 0
tyrosine 0
- 0
phosphorylated 0
state 0
of 0
CAK B-gene
beta I-gene
was 0
not 0
reduced 0
on 0
trypsinization 0
, 0
nor 0
enhanced 0
in 0
response 0
to 0
plating 0
3Y1 0
cells 0
onto 0
fibronectin B-gene
. 0

Our 0
results 0
suggest 0
that 0
while 0
many 0
muscle 0
gene 0
E 0
- 0
boxes 0
are 0
capable 0
of 0
binding 0
the 0
previously 0
characterized 0
spectrum 0
of 0
MDF/bH B-gene
- I-gene
L I-gene
- I-gene
H I-gene
heterodimers I-gene
in 0
vitro 0
, 0
MCK B-gene
- I-gene
L I-gene
type 0
E 0
- 0
boxes 0
probably 0
bind 0
qualitatively 0
different 0
factors 0
in 0
vivo 0
. 0

A 0
single 0
- 0
case 0
experimental 0
ABAB 0
multiple 0
baseline 0
design 0
was 0
employed 0
to 0
test 0
for 0
treatment 0
effectiveness 0
. 0

These 0
clones 0
were 0
found 0
to 0
share 0
a 0
common 0
domain 0
encoded 0
by 0
p 0
( 0
CA 0
) 0
n 0
repeats 0
; 0
a 0
simple 0
sequence 0
length 0
polymorphism 0
( 0
SSLP 0
) 0
. 0

In 0
one 0
glioblastoma 0
cell 0
line 0
, 0
a 0
Shc B-gene
- 0
associated 0
p190 B-gene
was 0
identified 0
as 0
the 0
activated 0
PDGFR B-gene
. 0

We 0
conclude 0
that 0
, 0
in 0
comparison 0
to 0
reports 0
from 0
other 0
regions 0
, 0
Scandinavian 0
renal 0
transplant 0
recipients 0
are 0
at 0
high 0
risk 0
of 0
dying 0
of 0
IHD 0
. 0

Veterinary 0
certification 0
for 0
livestock 0
export 0
. 0

The 0
serum 0
concentration 0
of 0
iP 0
before 0
dialysis 0
( 0
HD 0
) 0
was 0
on 0
average 0
3.06 0
( 0
+/ 0
- 0
0.81 0
) 0
mmol/l 0
and 0
D 0
was 0
on 0
average 0
55.6 0
( 0
+/ 0
- 0
10.0 0
) 0
mmol 0
. 0

A 0
significant 0
correlation 0
between 0
a 0
number 0
of 0
functional 0
parameters 0
of 0
gastric 0
secretion 0
, 0
incretion 0
and 0
histological 0
changes 0
of 0
gastric 0
mucosa 0
was 0
found 0
in 0
patients 0
with 0
chronic 0
gastritis 0
. 0

The 0
TAF 0
factor 0
appears 0
to 0
be 0
particularly 0
significant 0
in 0
OCD 0
. 0

Diffuse 0
white 0
matter 0
injury 0
can 0
be 0
attributed 0
to 0
radiation 0
and 0
associated 0
with 0
neurological 0
deficits 0
, 0
but 0
leukoencephalopathy 0
is 0
rarely 0
observed 0
in 0
the 0
absence 0
of 0
chemotherapy 0
. 0

RNase B-gene
protection 0
analyses 0
indicate 0
that 0
either 0
61 B-gene
- I-gene
kDa I-gene
CaM I-gene
PDE I-gene
mRNA I-gene
or 0
structurally 0
related 0
transcripts 0
encoding 0
different 0
CaM B-gene
PDE I-gene
isoforms I-gene
are 0
expressed 0
in 0
a 0
tissue 0
- 0
specific 0
manner 0
. 0

Little 0
or 0
no 0
protection 0
was 0
detected 0
using 0
adrenal 0
cortex 0
, 0
adrenal 0
medulla 0
, 0
liver 0
, 0
kidney 0
cortex 0
, 0
spleen 0
, 0
or 0
T 0
- 0
lymphocyte 0
total 0
RNA 0
. 0

The 0
PDGFR B-gene
mutants I-gene
that 0
failed 0
to 0
associate 0
with 0
PLC B-gene
gamma I-gene
were 0
not 0
able 0
to 0
mediate 0
the 0
PDGF B-gene
- 0
dependent 0
production 0
of 0
inositol 0
phosphates 0
. 0

We 0
found 0
a 0
direct 0
correlation 0
between 0
the 0
levels 0
of 0
transcription 0
of 0
the 0
acc B-gene
genes I-gene
and 0
the 0
rate 0
of 0
cellular 0
growth 0
. 0

The 0
hybridizing 0
clone 0
of 0
V. 0
vulnificus 0
chromosomal 0
DNA 0
complemented 0
a 0
V. B-gene
cholerae I-gene
fur I-gene
mutant I-gene
. 0

We 0
generated 0
transformed 0
B 0
lymphoblast 0
cell 0
lines 0
from 0
controls 0
, 0
from 0
four 0
patients 0
with 0
p47 B-gene
- 0
phox B-gene
- 0
deficient 0
chronic 0
granulomatous 0
disease 0
, 0
and 0
from 0
three 0
parents 0
. 0

The 0
ectopic 0
expression 0
of 0
Oct B-gene
- I-gene
3/4 I-gene
in 0
hybrid 0
cells 0
under 0
a 0
constitutive 0
promoter 0
is 0
sufficient 0
for 0
transcriptional 0
activation 0
of 0
an 0
octamer 0
- 0
dependent 0
promoter 0
. 0

RNase B-gene
protection 0
and 0
primer 0
extension 0
assays 0
confirmed 0
that 0
the 0
5 0
' 0
non 0
- 0
coding 0
exon 0
is 0
included 0
in 0
the 0
DDT1 0
aFGF B-gene
mRNA I-gene
and 0
that 0
a 0
major 0
transcription 0
start 0
site 0
is 0
approximately 0
136 0
bp 0
upstream 0
of 0
the 0
5 0
' 0
non 0
- 0
coding 0
splice 0
junction 0
of 0
this 0
exon 0
. 0

These 0
results 0
suggest 0
that 0
FK 0
506 0
is 0
a 0
useful 0
immunosuppressive 0
agent 0
in 0
kidney 0
transplantation 0
. 0

The 0
roles 0
of 0
phorbol 0
esters 0
and 0
cyclic 0
AMP 0
in 0
mediating 0
the 0
GnRH B-gene
response 0
were 0
also 0
investigated 0
. 0

RT 0
- 0
PCR 0
using 0
1.D 0
- 0
specific 0
primers 0
showed 0
that 0
kidney 0
, 0
brain 0
and 0
prostate 0
do 0
not 0
express 0
1.D 0
mRNA 0
even 0
though 0
kidney 0
and 0
brain 0
are 0
the 0
most 0
abundant 0
source 0
for 0
aFGF B-gene
protein I-gene
. 0

Molecular 0
cloning 0
and 0
characterization 0
of 0
two 0
genes B-gene
encoding I-gene
gp138 I-gene
, 0
a 0
cell 0
surface 0
glycoprotein 0
involved 0
in 0
the 0
sexual 0
cell 0
fusion 0
of 0
Dictyostelium 0
discoideum 0
. 0

Two 0
- 0
dimensional 0
phosphotryptic 0
analyses 0
indicate 0
that 0
phosphorylation 0
on 0
Ser 0
- 0
12 0
and 0
Ser 0
- 0
48 0
in 0
unstimulated 0
cells 0
is 0
associated 0
with 0
the 0
ability 0
of 0
overexpressed 0
pp60c B-gene
- I-gene
src I-gene
to 0
potentiate 0
beta 0
- 0
adrenergic 0
signalling 0
. 0

Piroximone 0
is 0
a 0
new 0
phosphodiesterase B-gene
III I-gene
inhibitor 0
that 0
combines 0
inotropic 0
and 0
vasodilator 0
properties 0
. 0

Cytogenetic 0
studies 0
were 0
performed 0
in 0
lymphocytes 0
from 0
hospital 0
workers 0
exposed 0
to 0
low 0
doses 0
of 0
radiation 0
( 0
1.6 0
- 0
42.71 0
mSv 0
) 0
. 0

To 0
study 0
the 0
origin 0
of 0
different 0
fMLF B-gene
- I-gene
R I-gene
transcripts I-gene
, 0
the 0
genetic 0
linkage 0
of 0
chemotactic 0
receptor 0
genes 0
, 0
and 0
the 0
regulation 0
of 0
fMLF B-gene
- I-gene
R I-gene
gene I-gene
expression 0
, 0
we 0
determined 0
the 0
copy 0
number 0
, 0
chromosomal 0
location 0
, 0
structural 0
organization 0
, 0
and 0
5' 0
- 0
flanking 0
sequence 0
of 0
the 0
human B-gene
fMLF I-gene
- I-gene
R I-gene
gene I-gene
. 0

The 0
first 0
exon 0
encodes 0
66 0
bp 0
of 0
the 0
5' 0
- 0
untranslated 0
sequence 0
, 0
while 0
exon 0
2 0
encodes 0
the 0
coding 0
and 0
3' 0
- 0
untranslated 0
sequences 0
. 0

The 0
genomic 0
structure 0
of 0
four 0
members 0
of 0
the 0
SRC B-gene
- I-gene
family I-gene
revealed 0
nearly 0
identical 0
exon/intron 0
boundaries 0
within 0
the 0
catalytic 0
domain 0
of 0
this 0
family 0
. 0

Since 0
we 0
have 0
observed 0
effects 0
of 0
growth 0
factors 0
and 0
cAMP 0
as 0
well 0
as 0
estradiol 0
( 0
E2 0
) 0
on 0
regulation 0
of 0
expression 0
of 0
some 0
genes 0
stimulated 0
by 0
the 0
estrogen B-gene
receptor I-gene
( 0
ER B-gene
) 0
, 0
we 0
have 0
undertaken 0
studies 0
to 0
examine 0
directly 0
whether 0
activators 0
of 0
protein 0
kinases 0
can 0
modulate 0
transcriptional 0
activity 0
of 0
the 0
ER B-gene
. 0

Using 0
the 0
polymerase 0
chain 0
reaction 0
, 0
Whipple 0
- 0
specific 0
DNA 0
fragments 0
of 0
284 0
base 0
pairs 0
from 0
the 0
genome 0
of 0
the 0
Whipple 0
bacterium 0
( 0
Tropheryma 0
whippelii 0
) 0
were 0
demonstrated 0
. 0

RNA B-gene
polymerase I-gene
bound 0
to 0
the 0
+10A 0
promoter 0
partially 0
protects 0
a 0
20 0
base 0
- 0
pair 0
sequence 0
from 0
DNase B-gene
I I-gene
digestion 0
upstream 0
of 0
the 0
start 0
site 0
. 0

Salivary 0
sodium 0
, 0
calcium 0
, 0
and 0
magnesium 0
concentrations 0
were 0
significantly 0
higher 0
in 0
the 0
SLE 0
patients 0
with 0
systemic 0
lupus 0
erythematosus 0
, 0
whereas 0
potassium 0
and 0
total 0
protein 0
concentrations 0
and 0
amylase B-gene
activity 0
did 0
not 0
differ 0
significantly 0
from 0
the 0
controls 0
. 0

Chem 0
. 0

Recombinant 0
plasmid 0
pFV100 0
was 0
subsequently 0
isolated 0
by 0
its 0
ability 0
to 0
complement 0
B 0
- 0
band 0
expression 0
in 0
ge6 B-gene
. 0

We 0
here 0
demonstrate 0
that 0
a 0
temperature 0
- 0
sensitive 0
fission 0
yeast 0
mutant 0
which 0
has 0
a 0
mutation 0
in 0
a 0
homologous 0
gene 0
, 0
and 0
two 0
of 0
three 0
additional 0
( 0
mtr1/prp20/srm1 B-gene
) 0
mutants 0
accumulate 0
nuclear 0
poly 0
( 0
A 0
) 0
+ 0
RNA 0
at 0
37 0
degrees 0
C 0
. 0

Since 0
RCC1p B-gene
acts 0
as 0
GNRP B-gene
for 0
Ran B-gene
, 0
a 0
small B-gene
nuclear I-gene
GTPase I-gene
of 0
the 0
ras B-gene
superfamily I-gene
, 0
we 0
have 0
identified 0
two 0
homologs 0
of 0
Ran B-gene
in 0
S.cerevisiae 0
( 0
CNR1 B-gene
and 0
CNR2 B-gene
) 0
. 0

The 0
immunosuppressant 0
FK506 0
inhibits 0
amino 0
acid 0
import 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Prostate B-gene
specific I-gene
antigen I-gene
shows 0
the 0
metastatic 0
cases 0
better 0
[ 0
correction 0
of 0
worse 0
] 0
than 0
prostatic B-gene
acid I-gene
phosphatase I-gene
. 0

Protein 0
phosphorylation 0
appears 0
to 0
play 0
a 0
critical 0
role 0
in 0
uPA B-gene
gene I-gene
expression 0
in 0
these 0
cells 0
; 0
protein B-gene
kinase I-gene
C I-gene
- 0
activating 0
phorbol 0
esters 0
cooperate 0
with 0
pp60v B-gene
- I-gene
src I-gene
to 0
synergistically 0
increase 0
uPA B-gene
mRNA I-gene
, 0
whereas 0
cyclic B-gene
AMP I-gene
( I-gene
cAMP I-gene
) I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
- 0
activating 0
agents 0
( 0
e.g. 0
, 0
8 0
- 0
bromo 0
cAMP 0
) 0
repress 0
uPA B-gene
mRNA I-gene
levels 0
. 0

Of 0
these 0
carriers 0
149 0
were 0
diagnosed 0
to 0
be 0
asymptomatic 0
clinically 0
, 0
biochemically 0
and 0
echographically 0
. 0

This 0
300 0
bp 0
5' 0
- 0
upstream 0
sequence 0
of 0
K3 B-gene
keratin I-gene
gene I-gene
, 0
which 0
can 0
function 0
in 0
vitro 0
as 0
a 0
keratinocyte 0
- 0
specific 0
promoter 0
, 0
contains 0
two 0
clusters 0
of 0
partially 0
overlapping 0
motifs 0
, 0
one 0
with 0
an 0
NFkB B-gene
consensus 0
sequence 0
and 0
another 0
with 0
a 0
GC 0
box 0
. 0

Identification 0
of 0
mutations 0
in 0
the 0
coding 0
sequence 0
of 0
the 0
proto B-gene
- I-gene
oncogene I-gene
c I-gene
- I-gene
kit I-gene
in 0
a 0
human 0
mast 0
cell 0
leukemia 0
cell 0
line 0
causing 0
ligand 0
- 0
independent 0
activation 0
of 0
c B-gene
- I-gene
kit I-gene
product I-gene
. 0

BACKGROUND 0
: 0
Delineation 0
of 0
the 0
morphologic 0
aspects 0
of 0
age 0
- 0
related 0
macular 0
degeneration 0
( 0
ARMD 0
) 0
is 0
helpful 0
in 0
correlation 0
with 0
the 0
clinical 0
features 0
and 0
may 0
contribute 0
to 0
understanding 0
the 0
pathogenesis 0
. 0

An 0
abundant 0
1.1 0
- 0
kb 0
virion 0
- 0
sense 0
polyadenylated 0
RNA 0
and 0
four 0
complementary 0
- 0
sense 0
polyadenylated 0
RNAs 0
of 0
1.7 0
, 0
1.5 0
, 0
1.3 0
, 0
and 0
0.7 0
kb 0
have 0
been 0
identified 0
by 0
northern 0
blot 0
hybridization 0
, 0
confirming 0
the 0
bidirectional 0
transcription 0
strategy 0
implied 0
by 0
the 0
arrangement 0
of 0
ORFs 0
. 0

Risk 0
factors 0
associated 0
with 0
a 0
high 0
seroprevalence 0
of 0
hepatitis 0
C 0
virus 0
infection 0
in 0
Egyptian 0
blood 0
donors 0
. 0

Here 0
the 0
cloning 0
and 0
molecular 0
analysis 0
of 0
the 0
Zm B-gene
- I-gene
ERabp1 I-gene
, 0
Zm B-gene
- I-gene
ERabp4 I-gene
, 0
and 0
Zm B-gene
- I-gene
ERabp5 I-gene
genes I-gene
is 0
presented 0
. 0

This 0
agent 0
, 0
isolated 0
from 0
the 0
fungus 0
Streptomyces 0
tsukubaensis 0
, 0
has 0
a 0
mechanism 0
of 0
action 0
similar 0
to 0
that 0
of 0
cyclosporine 0
. 0

DNase B-gene
I I-gene
footprinting 0
of 0
the 0
proximal 0
promoter 0
revealed 0
four 0
regions 0
of 0
protection 0
. 0

Finally 0
, 0
the 0
stability 0
of 0
the 0
nucleotide 0
binding 0
function 0
of 0
the 0
two 0
proteins 0
is 0
similar 0
as 0
assessed 0
by 0
sensitivity 0
to 0
urea 0
. 0

Insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
- I-gene
binding I-gene
protein I-gene
- I-gene
2 I-gene
( 0
IGF B-gene
- I-gene
BP I-gene
- I-gene
2 I-gene
) 0
transcription 0
in 0
rat 0
liver 0
varies 0
with 0
developmental 0
age 0
and 0
fasting 0
. 0

The 0
presence 0
of 0
the 0
RV 0
5 0
' 0
( 0
+ 0
) 0
SL 0
sequence 0
had 0
the 0
primary 0
enhancing 0
effect 0
on 0
translation 0
. 0

By 0
contrast 0
, 0
all 0
proteins 0
initiated 0
with 0
a 0
methionine 0
placed 0
one 0
residue 0
upstream 0
of 0
the 0
natural 0
N 0
terminus 0
of 0
PR B-gene
failed 0
to 0
show 0
specific 0
proteolysis 0
. 0

Reverse B-gene
transcriptase I-gene
and 0
protease 0
activities 0
of 0
avian 0
leukosis 0
virus 0
Gag B-gene
- 0
Pol B-gene
fusion 0
proteins 0
expressed 0
in 0
insect 0
cells 0
. 0

In 0
addition 0
, 0
an 0
mck1 B-gene
mds1 B-gene
mrk1 B-gene
triple 0
disruptant 0
was 0
viable 0
. 0

However 0
, 0
there 0
were 0
some 0
properties 0
of 0
Rak B-gene
that 0
are 0
distinct 0
from 0
Src B-gene
- I-gene
like I-gene
kinases I-gene
: 0
( 0
a 0
) 0
expression 0
of 0
Rak B-gene
was 0
predominantly 0
in 0
epithelial 0
- 0
derived 0
cell 0
lines 0
and 0
tissues 0
, 0
especially 0
normal 0
liver 0
and 0
kidney 0
, 0
and 0
cell 0
lines 0
of 0
breast 0
and 0
colon 0
origin 0
; 0
( 0
b 0
) 0
Rak B-gene
does 0
not 0
harbor 0
the 0
NH2 0
- 0
terminal 0
glycine 0
essential 0
for 0
myristylation 0
and 0
membrane 0
localization 0
; 0
and 0
( 0
c 0
) 0
Rak B-gene
possesses 0
a 0
putative 0
bipartite 0
nuclear 0
localization 0
signal 0
in 0
the 0
SH2 B-gene
domain I-gene
, 0
and 0
subcellular 0
fractionation 0
studies 0
revealed 0
that 0
p54rak B-gene
resides 0
predominantly 0
in 0
the 0
nucleus 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
We 0
report 0
our 0
experience 0
with 0
seven 0
children 0
with 0
active 0
small 0
bowel 0
Crohn 0
's 0
disease 0
given 0
a 0
casein B-gene
- 0
based 0
, 0
polymeric 0
feed 0
rich 0
in 0
TGF B-gene
- I-gene
beta I-gene
2 I-gene
( 0
Specific 0
Polymeric 0
Diet 0
; 0
Nestle 0
- 0
Clintec 0
; 0
Vevey 0
, 0
Switzerland 0
) 0
as 0
complete 0
nutrition 0
for 0
8 0
weeks 0
. 0

The 0
leader 0
sequence 0
of 0
the 0
isolated 0
cDNA 0
clone 0
contains 0
several 0
small 0
open 0
reading 0
frames 0
upstream 0
of 0
the 0
initiation 0
codon 0
of 0
the 0
largest 0
open 0
reading 0
frame 0
coding 0
for 0
the 0
homeodomain B-gene
protein I-gene
. 0

A 0
small 0
amount 0
of 0
HSP81 B-gene
- I-gene
1 I-gene
mRNA I-gene
was 0
detected 0
only 0
in 0
roots 0
. 0

Cell 0
adhesion 0
and 0
migration 0
assays 0
demonstrate 0
that 0
alpha B-gene
6 I-gene
beta I-gene
1 I-gene
is 0
the 0
major 0
laminin B-gene
receptor I-gene
in 0
undifferentiated 0
F9 0
cells 0
as 0
well 0
as 0
F9 0
- 0
derived 0
PE 0
cells 0
. 0

No 0
local 0
destruction 0
by 0
tumor 0
or 0
infection 0
could 0
be 0
demonstrated 0
apart 0
from 0
HIV 0
infection 0
. 0

Among 0
the 0
mixed 0
race 0
persons 0
one 0
Chukcha 0
- 0
Eskimo 0
had 0
AS 0
, 0
one 0
Eskimo 0
- 0
Russian 0
had 0
psoriatic 0
arthritis 0
( 0
PsA 0
) 0
. 0

Our 0
data 0
complement 0
other 0
studies 0
of 0
circumpolar 0
populations 0
and 0
reinforce 0
the 0
reported 0
high 0
prevalences 0
of 0
SPA 0
and 0
HLA B-gene
- I-gene
B27 I-gene
among 0
those 0
populations 0
. 0

Clinical 0
studies 0
SY5555 0
was 0
administered 0
to 0
45 0
patients 0
with 0
various 0
infectious 0
diseases 0
( 0
2 0
with 0
acute 0
pharyngitis 0
, 0
8 0
with 0
acute 0
tonsillitis 0
, 0
4 0
with 0
lacunar 0
tonsillitis 0
, 0
3 0
each 0
with 0
acute 0
bronchitis 0
, 0
pneumonia 0
and 0
pertussis 0
, 0
7 0
with 0
scarlet 0
fever 0
, 0
3 0
with 0
impetigo 0
contagiosa 0
, 0
6 0
with 0
acute 0
urinary 0
tract 0
infections 0
, 0
2 0
with 0
balanoposthitis 0
and 0
1 0
each 0
with 0
cervical 0
lymphadenitis 0
, 0
S.S.S.S. 0
, 0
vulvitis 0
and 0
acute 0
colitis 0
) 0
at 0
daily 0
doses 0
between 0
3.4 0
- 0
10 0
mg/kg 0
, 0
t.i.d. 0
, 0
for 0
3 0
- 0
14 0
days 0
. 0

Although 0
most 0
SH2 B-gene
- 0
pTyr B-gene
interactions 0
occur 0
between 0
two 0
different 0
types 0
of 0
molecules 0
, 0
some 0
appear 0
to 0
involve 0
only 0
a 0
single 0
molecular 0
type 0
. 0

RESULTS 0
: 0
Closure 0
time 0
of 0
fistulas 0
in 0
patients 0
receiving 0
TPN 0
+ 0
somatostatin B-gene
was 0
significantly 0
shorter 0
( 0
13.86 0
+/ 0
- 0
1.84 0
versus 0
20.4 0
+/ 0
- 0
2.89 0
days 0
) 0
than 0
in 0
those 0
receiving 0
TPN 0
alone 0
. 0

Experimental 0
adhesion 0
prophylaxis 0
with 0
recombinant B-gene
tissue I-gene
plasminogen I-gene
activator I-gene
. 0

Scratching 0
during 0
sleep 0
in 0
children 0
with 0
atopic 0
dermatitis 0
is 0
associated 0
with 0
increased 0
VO2 0
. 0

To 0
determine 0
which 0
sequences 0
in 0
the 0
rat B-gene
P450c17 I-gene
promoter I-gene
may 0
be 0
responsible 0
for 0
basal 0
and 0
cAMP 0
- 0
stimulated 0
gene 0
transcription 0
, 0
deletion 0
constructs 0
containing 0
between 0
- 0
1,560 0
and 0
- 0
53 0
base 0
pairs 0
of 0
5' 0
- 0
flanking 0
DNA 0
from 0
the 0
rat B-gene
P450c17 I-gene
gene I-gene
were 0
ligated 0
to 0
plasmids 0
expressing 0
the 0
reporter 0
gene 0
luciferase B-gene
and 0
transfected 0
into 0
two 0
mouse 0
cell 0
lines 0
, 0
adrenal 0
Y 0
- 0
1 0
cells 0
, 0
and 0
testicular 0
Leydig 0
MA 0
- 0
10 0
cells 0
. 0

Within 0
- 0
subject 0
BP 0
differences 0
between 0
fish 0
oil 0
and 0
corn 0
oil 0
treatment 0
were 0
similar 0
for 0
Dinamap 0
( 0
3.2 0
+/ 0
- 0
1.8/2.5 0
+/ 0
- 0
1.0 0
mm 0
Hg 0
) 0
and 0
for 0
24 0
- 0
h 0
ABP 0
( 0
2.5 0
+/ 0
- 0
1.0/2.3 0
+/ 0
- 0
0.8 0
mm 0
Hg 0
) 0
, 0
but 0
were 0
more 0
significant 0
with 0
the 0
latter 0
. 0

We 0
have 0
cloned 0
and 0
sequenced 0
the 0
mouse B-gene
NMO1 I-gene
cDNA I-gene
, 0
which 0
encodes 0
the 0
NAD B-gene
( I-gene
P I-gene
) I-gene
H I-gene
: I-gene
menadione I-gene
oxidoreductase I-gene
[ 0
also 0
called 0
NAD B-gene
( I-gene
P I-gene
) I-gene
H I-gene
: I-gene
( I-gene
quinone I-gene
acceptor I-gene
) I-gene
oxidoreductase I-gene
; 0
quinone B-gene
reductase I-gene
; 0
azo B-gene
dye I-gene
reductase I-gene
; 0
DT B-gene
diaphorase I-gene
; 0
EC B-gene
1.6.99.2 I-gene
] 0
. 0

Escherichia 0
coli 0
JRG582 0
is 0
an 0
ampD B-gene
ampE B-gene
deletion 0
derivative 0
of 0
strain 0
HfrH 0
and 0
accordingly 0
it 0
is 0
derepressed 0
for 0
expression 0
of 0
the 0
cloned 0
inducible 0
beta B-gene
- I-gene
lactamase I-gene
gene I-gene
of 0
Citrobacter 0
freundii 0
, 0
carried 0
on 0
plasmid 0
pNU305 0
. 0

Such 0
a 0
mechanism 0
may 0
allow 0
acceleration 0
of 0
degenerative 0
joint 0
conditions 0
, 0
and 0
may 0
account 0
for 0
the 0
increased 0
prevalence 0
of 0
such 0
conditions 0
seen 0
with 0
HMS 0
subjects 0
. 0

Solitary 0
thyroid 0
nodule 0
. 0

Male 0
contraception 0
: 0
ideas 0
for 0
the 0
future 0
. 0

While 0
daily 0
food 0
intake 0
was 0
almost 0
constant 0
regardless 0
of 0
the 0
dietary 0
protein 0
level 0
, 0
water 0
intake 0
and 0
urine 0
volume 0
increased 0
with 0
increasing 0
the 0
dietary 0
protein 0
. 0

We 0
propose 0
that 0
Mad B-gene
and 0
Medea B-gene
encode 0
rate 0
- 0
limiting 0
components 0
integral 0
to 0
dpp B-gene
pathways 0
throughout 0
development 0
. 0

Transcriptional 0
regulation 0
of 0
the 0
vacuolar B-gene
H I-gene
( I-gene
+ I-gene
) I-gene
- I-gene
ATPase I-gene
B2 I-gene
subunit I-gene
gene I-gene
in 0
differentiating 0
THP 0
- 0
1 0
cells 0
. 0

However 0
, 0
the 0
inability 0
to 0
export 0
RNA 0
from 0
the 0
nucleus 0
to 0
the 0
cytoplasm 0
was 0
not 0
limited 0
to 0
a 0
particular 0
phase 0
of 0
the 0
cell 0
division 0
cycle 0
. 0

An 0
E 0
box 0
element 0
is 0
required 0
for 0
the 0
expression 0
of 0
the 0
ad4bp B-gene
gene I-gene
, 0
a 0
mammalian B-gene
homologue I-gene
of I-gene
ftz I-gene
- I-gene
f1 I-gene
gene I-gene
, 0
which 0
is 0
essential 0
for 0
adrenal 0
and 0
gonadal 0
development 0
. 0

Inhibition 0
assays 0
performed 0
with 0
over 0
30 0
different 0
natural 0
and 0
synthetic 0
sialylated 0
and/or 0
sulfated 0
compounds 0
are 0
utilized 0
to 0
define 0
in 0
greater 0
detail 0
specific 0
structural 0
features 0
involved 0
in 0
oligosaccharide 0
- 0
protein 0
binding 0
. 0

The 0
amino 0
acid 0
sequence 0
of 0
the 0
protein 0
in 0
the 0
region 0
of 0
the 0
specificity 0
pocket 0
is 0
similar 0
to 0
that 0
of 0
S. B-gene
griseus I-gene
proteases I-gene
A I-gene
, I-gene
B I-gene
, I-gene
and I-gene
C I-gene
. 0

Mutations 0
in 0
the 0
VPS45 B-gene
gene I-gene
, 0
a 0
SEC1 B-gene
homologue 0
, 0
result 0
in 0
vacuolar 0
protein 0
sorting 0
defects 0
and 0
accumulation 0
of 0
membrane 0
vesicles 0
. 0

In 0
293 0
cells 0
, 0
expression 0
of 0
the 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
inhibitor 0
, 0
I B-gene
kappa I-gene
B I-gene
- I-gene
alpha I-gene
, 0
reduced 0
the 0
stimulatory 0
activity 0
of 0
LMP B-gene
. 0

This 0
experimental 0
design 0
was 0
used 0
to 0
determine 0
the 0
effect 0
of 0
displacement 0
of 0
the 0
alpha B-gene
4 I-gene
- I-gene
2 I-gene
binding I-gene
site I-gene
on 0
the 0
repression 0
of 0
alpha B-gene
4 I-gene
gene I-gene
transcription 0
by 0
ICP4 B-gene
. 0

Immediate 0
- 0
early 0
transcription 0
from 0
the 0
channel 0
catfish 0
virus 0
genome 0
: 0
characterization 0
of 0
two 0
immediate B-gene
- I-gene
early I-gene
transcripts I-gene
. 0

The 0
GRE 0
at 0
nucleotide 0
7640 0
is 0
a 0
composite 0
GRE 0
( 0
cGRE 0
) 0
containing 0
an 0
overlapping 0
activator B-gene
protein I-gene
- I-gene
1 I-gene
( 0
AP B-gene
- I-gene
1 I-gene
) 0
motif 0
for 0
the 0
c B-gene
- I-gene
jun I-gene
homodimer I-gene
and 0
c B-gene
- I-gene
jun/c I-gene
jun/c I-gene
- I-gene
fos I-gene
heterodimer 0
. 0

In 0
contrast 0
to 0
some 0
results 0
previously 0
published 0
for 0
a 0
very 0
close 0
sequence 0
variant 0
( 0
see 0
ref 0
. 0

Transcriptional 0
activation 0
by 0
thyroid 0
hormone 0
( 0
T3 0
) 0
requires 0
interactions 0
between 0
the 0
T3 B-gene
receptor I-gene
( 0
TR B-gene
) 0
and 0
T3 0
response 0
elements 0
( 0
TREs 0
) 0
composed 0
of 0
two 0
copies 0
of 0
sequences 0
related 0
to 0
AGGTCA 0
. 0

A 0
multivariate 0
analysis 0
of 0
risk 0
factors 0
for 0
relapse 0
examined 0
age 0
, 0
WBC 0
at 0
diagnosis 0
, 0
blast 0
count 0
at 0
diagnosis 0
, 0
percentage 0
of 0
marrow 0
blasts 0
, 0
FAB B-gene
subtype 0
, 0
the 0
number 0
of 0
remission 0
induction 0
courses 0
to 0
achieve 0
a 0
remission 0
, 0
maintenance 0
therapy 0
, 0
consolidation 0
therapy 0
, 0
marrow 0
cell 0
dose 0
, 0
donor 0
- 0
recipient 0
sex 0
, 0
GVHD 0
prophylaxis 0
regimen 0
and 0
isolation 0
and 0
decontamination 0
in 0
laminar 0
airflow 0
rooms 0
. 0

Carnitine B-gene
palmitoyltransferase I-gene
( I-gene
CPT I-gene
) I-gene
II I-gene
deficiency 0
is 0
the 0
most 0
common 0
inherited 0
disorder 0
of 0
lipid 0
metabolism 0
affecting 0
skeletal 0
muscle 0
. 0

We 0
show 0
that 0
these 0
three 0
gain 0
- 0
of 0
- 0
function 0
mutants 0
differ 0
considerably 0
in 0
their 0
ability 0
to 0
bypass 0
the 0
sex 0
determination 0
signal 0
, 0
with 0
SxlM4 B-gene
being 0
the 0
strongest 0
and 0
SxlM1 B-gene
the 0
weakest 0
. 0

We 0
show 0
that 0
these 0
three 0
gain 0
- 0
of 0
- 0
function 0
mutants 0
differ 0
considerably 0
in 0
their 0
ability 0
to 0
bypass 0
the 0
sex 0
determination 0
signal 0
, 0
with 0
SxlM4 B-gene
being 0
the 0
strongest 0
and 0
SxlM1 B-gene
the 0
weakest 0
. 0

Binding 0
of 0
meAda B-gene
is 0
necessary 0
to 0
activate 0
transcription 0
of 0
the 0
adaptive 0
response 0
genes 0
; 0
accordingly 0
, 0
in 0
vitro 0
transcription 0
of 0
aidB B-gene
is 0
dependent 0
on 0
the 0
presence 0
of 0
meAda B-gene
. 0

No 0
significant 0
differences 0
were 0
identified 0
between 0
groups 0
for 0
pH 0
, 0
PaCO2 0
, 0
intracranial 0
pressure 0
, 0
heart 0
rate 0
, 0
brain 0
temperature 0
, 0
or 0
glucose 0
levels 0
. 0

Blood 0
pressure 0
also 0
was 0
increased 0
by 0
lidocaine 0
( 0
6 0
mg 0
kg 0
- 0
1 0
) 0
. 0

Anesthesiologists 0
often 0
use 0
more 0
than 0
one 0
drug 0
in 0
a 0
patient 0
to 0
achieve 0
a 0
target 0
response 0
, 0
such 0
as 0
a 0
desired 0
blood 0
pressure 0
. 0

We 0
suggest 0
that 0
this 0
gene 0
cluster 0
codes 0
for 0
( 0
parts 0
of 0
) 0
a 0
multisubunit B-gene
cytochrome I-gene
c I-gene
haem I-gene
lyase I-gene
. 0

In 0
this 0
paper 0
, 0
a 0
comparison 0
between 0
the 0
number 0
and 0
shape 0
of 0
corneal 0
endothelial 0
cells 0
has 0
been 0
performed 0
in 0
25 0
patients 0
before 0
and 0
6 0
months 0
after 0
PRK 0
. 0

Standard 0
reference 0
sources 0
indicate 0
that 0
an 0
able 0
- 0
bodied 0
11 0
- 0
year 0
- 0
old 0
child 0
of 0
comparable 0
height 0
requires 0
1,493 0
kcal/d 0
for 0
support 0
of 0
basal 0
metabolic 0
functions 0
. 0

Weak 0
allergenicity 0
of 0
recombinant B-gene
hirudin I-gene
CGP I-gene
39393 I-gene
( 0
REVASC 0
) 0
in 0
immunocompetent 0
volunteers 0
. 0

In 0
contrast 0
to 0
the 0
myoD B-gene
promoter I-gene
, 0
the 0
myoD B-gene
enhancer I-gene
shows 0
striking 0
conservation 0
between 0
humans 0
and 0
mice 0
both 0
in 0
its 0
sequence 0
and 0
its 0
distal 0
position 0
. 0

However 0
, 0
a 0
clear 0
difference 0
exists 0
between 0
myoblasts 0
and 0
10T1/2 0
cells 0
( 0
and 0
other 0
non 0
- 0
muscle 0
cell 0
types 0
) 0
in 0
the 0
chromatin 0
structure 0
of 0
the 0
chromosomal 0
myoD B-gene
core I-gene
enhancer I-gene
, 0
suggesting 0
that 0
the 0
myoD B-gene
enhancer I-gene
is 0
repressed 0
by 0
epigenetic 0
mechanisms 0
in 0
10T1/2 0
cells 0
. 0

Using 0
Ki B-gene
- I-gene
ras I-gene
- 0
transformed 0
3T3 0
cells 0
as 0
a 0
model 0
system 0
, 0
we 0
show 0
that 0
both 0
RA 0
and 0
the 0
'dissociating 0
' 0
retinoids 0
inhibit 0
anchorage 0
- 0
independent 0
cell 0
proliferation 0
, 0
suggesting 0
that 0
retinoid 0
- 0
induced 0
growth 0
inhibition 0
may 0
be 0
related 0
to 0
AP1 B-gene
transrepression 0
. 0

The 0
Oct B-gene
and 0
HMG2 B-gene
proteins I-gene
also 0
interact 0
in 0
vivo 0
. 0

Atopic 0
dermatitis 0
is 0
an 0
`` 0
itch 0
which 0
rashes 0
and 0
not 0
a 0
rash 0
which 0
itches 0
'' 0
and 0
therefore 0
, 0
any 0
patient 0
treatment 0
program 0
should 0
address 0
the 0
multiplicity 0
of 0
potential 0
trigger 0
factors 0
that 0
provoke 0
this 0
itching 0
. 0

Primer 0
extension 0
experiments 0
showed 0
that 0
there 0
are 0
two 0
transcription 0
initiation 0
sites 0
16 0
bp 0
apart 0
in 0
the 0
mouse B-gene
type I-gene
2 I-gene
receptor I-gene
gene I-gene
. 0

The 0
beta 0
subunit 0
of 0
the 0
Fc B-gene
epsilon I-gene
R1 I-gene
is 0
a 0
33 0
- 0
kDa 0
tyrosine 0
phosphoprotein 0
, 0
but 0
the 0
p33 B-gene
Grb2 B-gene
- I-gene
binding I-gene
protein I-gene
described 0
in 0
the 0
present 0
report 0
is 0
not 0
the 0
Fc B-gene
epsilon I-gene
R1 I-gene
beta I-gene
chain I-gene
and 0
its 0
identity 0
is 0
unknown 0
. 0

To 0
study 0
the 0
mechanisms 0
as 0
well 0
as 0
magnitude 0
of 0
the 0
transmembrane 0
transfer 0
of 0
bacterial 0
products 0
from 0
the 0
dialysate 0
, 0
we 0
developed 0
a 0
computerized 0
in 0
vitro 0
dialysis 0
model 0
which 0
provides 0
continuous 0
pressure 0
recording 0
from 0
the 0
arterial 0
, 0
venous 0
, 0
dialysate 0
inflow 0
and 0
outflow 0
ports 0
. 0

After 0
24 0
hour 0
incubation 0
, 0
total 0
cell 0
- 0
associated 0
IL B-gene
- I-gene
1Ra I-gene
and 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
were 0
measured 0
by 0
specific 0
radioimmunoassay 0
. 0

Each 0
dietary 0
treatment 0
was 0
fed 0
to 0
six 0
pen 0
replicates 0
of 0
five 0
chicks 0
per 0
pen 0
for 0
21 0
d 0
. 0

1972 0
. 0

In 0
contrast 0
, 0
recent 0
evidence 0
suggests 0
that 0
children 0
with 0
sickle B-gene
- I-gene
hemoglobin I-gene
C I-gene
disease 0
do 0
not 0
develop 0
functional 0
asplenia 0
before 0
3 0
to 0
4 0
years 0
of 0
age 0
and 0
thus 0
may 0
not 0
benefit 0
from 0
penicillin 0
prophylaxis 0
. 0

Deletion 0
analysis 0
indicates 0
that 0
TBP B-gene
and 0
hTAFII18 B-gene
bind 0
to 0
distinct 0
domains 0
of 0
hTAFII28 B-gene
. 0
hTAFII18 B-gene
also 0
interacts 0
with 0
TBP B-gene
, 0
but 0
it 0
interacts 0
more 0
strongly 0
with 0
hTAFII28 B-gene
and 0
hTAFII30 B-gene
. 0

The 0
NarX B-gene
and 0
NarQ B-gene
proteins I-gene
with 0
amino 0
acid 0
substitutions 0
at 0
the 0
first 0
conserved 0
histidine 0
position 0
were 0
also 0
unable 0
to 0
dephosphorylate 0
NarL B-gene
- 0
phosphate 0
in 0
vitro 0
. 0

Vascular 0
endothelial 0
cells 0
undergo 0
profound 0
changes 0
upon 0
cellular 0
activation 0
including 0
expression 0
of 0
a 0
spectrum 0
of 0
cell 0
activation 0
- 0
associated 0
genes 0
. 0

Because 0
ATF B-gene
- I-gene
1 I-gene
and 0
CREM B-gene
are 0
known 0
to 0
bind 0
to 0
cAMP 0
response 0
elements 0
( 0
CRE 0
) 0
, 0
this 0
functional 0
sequence 0
was 0
named 0
the 0
kappa B-gene
E3' I-gene
- 0
CRE 0
. 0

The 0
Ng/RC3 B-gene
and 0
PKC B-gene
- I-gene
gamma I-gene
genes I-gene
have 0
a 0
similar 0
expression 0
pattern 0
in 0
the 0
brain 0
during 0
development 0
. 0

Structure 0
and 0
regulation 0
of 0
the 0
gene 0
encoding 0
the 0
neuron 0
- 0
specific 0
protein B-gene
kinase I-gene
C I-gene
substrate 0
neurogranin B-gene
( 0
RC3 B-gene
protein I-gene
) 0
. 0

The 0
amino 0
acid 0
sequences 0
of 0
the 0
known 0
largest 0
subunits 0
of 0
DdRPs B-gene
from 0
different 0
species 0
contain 0
highly 0
conserved 0
regions 0
. 0

The 0
TTG B-gene
- I-gene
2 I-gene
gene I-gene
has 0
been 0
identified 0
at 0
the 0
site 0
of 0
chromosomal 0
translocations 0
in 0
acute 0
T 0
- 0
cell 0
leukemia 0
's 0
( 0
T 0
- 0
ALL 0
) 0
. 0

In 0
vitro 0
studies 0
with 0
blood 0
cells 0
incubated 0
with 0
acetate 0
or 0
bicarbonate 0
ions 0
in 0
concentrations 0
, 0
which 0
are 0
observed 0
in 0
vivo 0
during 0
hemodialysis 0
, 0
suggest 0
that 0
probably 0
these 0
ions 0
do 0
not 0
directly 0
affect 0
superoxide 0
anions 0
generation 0
, 0
erythrocyte 0
SOD B-gene
- I-gene
1 I-gene
and 0
catalase B-gene
activities 0
and 0
erythrocyte 0
membrane 0
lipid 0
peroxidation 0
. 0

Short 0
therapy 0
with 0
omeprazole 0
20 0
mg/b.i.d. 0
, 0
clarithromycin 0
500 0
mg/b.i.d. 0
, 0
and 0
CBS 0
120 0
mg/q.i.d 0
. 0
is 0
a 0
safe 0
, 0
well 0
tolerated 0
combination 0
that 0
achieves 0
a 0
80.6 0
% 0
eradication 0
rate 0
of 0
H. 0
pylori 0
and 0
duodenal 0
ulcer 0
healing 0
rates 0
as 0
good 0
as 0
those 0
achieved 0
by 0
omeprazole 0
20 0
mg/d 0
when 0
given 0
for 0
4 0
wk 0
. 0

The 0
concentration 0
of 0
mite 0
allergen 0
was 0
very 0
low 0
( 0
mean 0
0.18 0
micrograms 0
Der 0
p 0
milligrams 0
sieved 0
house 0
dust 0
) 0
, 0
whereas 0
that 0
of 0
cat 0
allergen 0
was 0
high 0
in 0
homes 0
with 0
a 0
cat 0
( 0
80.8 0
micrograms 0
Fel 0
d 0
milligrams 0
) 0
but 0
also 0
in 0
homes 0
with 0
no 0
cat 0
( 0
3.2 0
micrograms 0
Fel 0
d 0
milligrams 0
) 0
. 0

CONCLUSIONS 0
: 0
A 0
comparison 0
of 0
the 0
LysU B-gene
crystal 0
structure 0
with 0
the 0
structures 0
of 0
seryl B-gene
- I-gene
and I-gene
aspartyl I-gene
- I-gene
tRNA I-gene
synthetases I-gene
enables 0
a 0
conserved 0
core 0
to 0
be 0
identified 0
. 0

Whole 0
bowel 0
irrigation 0
is 0
a 0
recently 0
described 0
technique 0
to 0
enhance 0
the 0
passage 0
of 0
drugs 0
already 0
beyond 0
the 0
pylorus 0
. 0

The 0
MPS1 B-gene
open I-gene
reading I-gene
frame I-gene
has 0
been 0
fused 0
to 0
those 0
that 0
encode 0
the 0
LexA B-gene
protein I-gene
or 0
the 0
GST B-gene
protein I-gene
and 0
both 0
of 0
these 0
constructs 0
function 0
in 0
yeast 0
. 0

As 0
in 0
Tb 0
, 0
U6 B-gene
is 0
a 0
single 0
- 0
copy 0
gene 0
and 0
two 0
tRNA 0
genes 0
, 0
tRNAGln B-gene
and 0
tRNAIle B-gene
, 0
are 0
found 0
upstream 0
to 0
the 0
gene 0
. 0

Hematopoietic B-gene
growth I-gene
factors I-gene
have 0
already 0
had 0
an 0
enormous 0
impact 0
on 0
transfusion 0
practice 0
by 0
eliminating 0
or 0
reducing 0
the 0
need 0
for 0
red 0
blood 0
cell 0
transfusions 0
in 0
a 0
variety 0
of 0
anemic 0
states 0
characterized 0
by 0
an 0
absolute 0
or 0
relative 0
decrease 0
in 0
erythropoietin B-gene
. 0

However 0
, 0
the 0
mouse 0
has 0
previously 0
been 0
shown 0
to 0
possess 0
only 0
three 0
forms 0
of 0
ADH B-gene
. 0

During 0
IC 0
breaths 0
and 0
following 0
EC 0
and 0
VC 0
breaths 0
at 0
rest 0
, 0
end 0
- 0
tidal 0
CO2 0
pressure 0
( 0
PET 0
, 0
CO2 0
) 0
fell 0
by 0
7.5 0
, 0
8.5 0
and 0
9.5 0
mmHg 0
, 0
respectively 0
. 0

2 0
. 0

Phylogenetic 0
analyses 0
of 0
19 0
amino 0
acid 0
sequences 0
of 0
6 0
related 0
protein 0
types 0
indicate 0
that 0
actin B-gene
- 0
associated 0
proteins 0
related 0
to 0
gelsolin B-gene
are 0
monophyletic 0
to 0
a 0
common 0
ancestor 0
and 0
include 0
flightless B-gene
proteins I-gene
. 0

No 0
homologs 0
of 0
other 0
members 0
of 0
the 0
Surfeit B-gene
gene I-gene
cluster I-gene
were 0
detected 0
in 0
close 0
proximity 0
to 0
the 0
D. 0
melanogaster 0
Surf B-gene
- I-gene
3/rpL7a I-gene
gene 0
. 0

Moreover 0
, 0
we 0
found 0
that 0
cyclin B-gene
E I-gene
, 0
in 0
contrast 0
to 0
cyclin B-gene
D1 I-gene
, 0
was 0
required 0
for 0
the 0
G1/S 0
transition 0
even 0
in 0
cells 0
lacking 0
retinoblastoma B-gene
protein I-gene
function 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
of 0
the 0
SGC1 B-gene
gene I-gene
product I-gene
includes 0
a 0
region 0
with 0
substantial 0
similarity 0
to 0
the 0
basic 0
- 0
helix 0
- 0
loop 0
- 0
helix 0
domain 0
of 0
the 0
Myc B-gene
family I-gene
of 0
DNA 0
- 0
binding 0
proteins 0
. 0

By 0
creating 0
Pax B-gene
- I-gene
6 I-gene
- 0
BSAP B-gene
fusion 0
proteins 0
, 0
we 0
were 0
able 0
to 0
identify 0
a 0
short 0
amino 0
acid 0
stretch 0
in 0
the 0
N 0
- 0
terminal 0
part 0
of 0
the 0
paired B-gene
domain 0
which 0
is 0
responsible 0
for 0
these 0
differences 0
in 0
DNA 0
- 0
binding 0
specificity 0
. 0

To 0
establish 0
a 0
possible 0
association 0
between 0
familial 0
dysfibrinogenemia 0
and 0
thrombophilia 0
, 0
data 0
on 0
cases 0
with 0
both 0
affections 0
were 0
collected 0
in 0
a 0
study 0
within 0
the 0
framework 0
of 0
the 0
SSC 0
Subcommittee 0
on 0
Fibrinogen B-gene
of 0
the 0
International 0
Society 0
on 0
Thrombosis 0
and 0
Haemostasis 0
. 0

Conjugated 0
estrogens 0
shorten 0
bleeding 0
time 0
in 0
uraemia 0
: 0
a 0
possible 0
role 0
of 0
serotonin 0
? 0

These 0
six 0
districts 0
have 0
an 0
area 0
of 0
34,000 0
km2 0
and 0
hold 0
a 0
population 0
of 0
30 0
million 0
. 0

According 0
to 0
symptoms 0
, 0
signs 0
, 0
imaging 0
features 0
, 0
operation 0
findings 0
, 0
the 0
original 0
places 0
and 0
the 0
expansive 0
directions 0
of 0
the 0
tumor 0
, 0
they 0
were 0
divided 0
into 0
four 0
clinical 0
types 0
: 0
sellar 0
, 0
clival 0
, 0
occipito 0
- 0
temporal 0
and 0
extent 0
. 0

Two 0
mammalian 0
enzymes 0
, 0
the 0
haem B-gene
- I-gene
controlled I-gene
repressor I-gene
( 0
HCR B-gene
) 0
and 0
the 0
double B-gene
- I-gene
stranded I-gene
RNA I-gene
- I-gene
activated I-gene
inhibitor I-gene
( 0
dsI B-gene
) 0
, 0
phosphorylate 0
Ser 0
- 0
51 0
of 0
the 0
alpha 0
subunit 0
, 0
thereby 0
inhibiting 0
the 0
exchange 0
of 0
bound 0
nucleotides 0
on 0
, 0
and 0
thus 0
the 0
recycling 0
of 0
, 0
eIF B-gene
- I-gene
2 I-gene
. 0

A 0
triple 0
Ser 0
- 0
- 0
> 0
Ala 0
mutant 0
form 0
of 0
yeast 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
was 0
found 0
to 0
be 0
no 0
longer 0
phosphorylated 0
by 0
either 0
of 0
the 0
yeast 0
( 0
or 0
mammalian 0
) 0
casein B-gene
kinase I-gene
activities 0
in 0
vitro 0
. 0

The 0
cases 0
included 0
35 0
de 0
novo 0
diffuse 0
aggressive 0
lymphomas 0
( 0
DAL 0
; 0
19 0
large 0
- 0
cell 0
, 0
4 0
mixed 0
- 0
cell 0
, 0
and 0
12 0
large 0
- 0
cell 0
immunoblastic 0
) 0
, 0
52 0
transformed 0
aggressive 0
lymphomas 0
derived 0
from 0
follicular 0
lymphomas 0
( 0
TFL 0
) 0
, 0
42 0
indolent 0
follicular 0
lymphomas 0
( 0
FL 0
) 0
, 0
14 0
mantle 0
cell 0
lymphomas 0
( 0
MCL 0
) 0
, 0
and 0
27 0
small 0
noncleaved 0
cell 0
lymphomas 0
( 0
SNCL 0
) 0
. 0

Icterus 0
and 0
beta 0
- 0
thalassemia 0
in 0
Congolese 0
children 0
in 0
Brazzaville 0

Female 0
patients 0
with 0
breast 0
cancer 0
diagnosed 0
between 0
1982 0
and 0
1991 0
at 0
Roswell 0
Park 0
Cancer 0
Institute 0
( 0
RPCI 0
) 0
in 0
Buffalo 0
, 0
New 0
York 0
, 0
who 0
provided 0
information 0
on 0
their 0
cigarette 0
smoking 0
history 0
at 0
the 0
time 0
of 0
their 0
diagnosis 0
were 0
included 0
. 0

Upon 0
analysis 0
of 0
the 0
tissue 0
distribution 0
of 0
AAMP B-gene
, 0
it 0
was 0
found 0
to 0
be 0
expressed 0
strongly 0
in 0
endothelial 0
cells 0
, 0
cytotrophoblasts 0
, 0
and 0
poorly 0
differentiated 0
colon 0
adenocarcinoma 0
cells 0
found 0
in 0
lymphatics 0
. 0

Data 0
from 0
the 0
V 0
- 0
HeFT 0
II 0
show 0
that 0
at 0
2 0
- 0
year 0
follow 0
- 0
up 0
, 0
a 0
progressive 0
rise 0
of 0
plasma 0
norepinephrine 0
was 0
observed 0
in 0
both 0
treatment 0
arms 0
, 0
suggesting 0
that 0
disease 0
progresses 0
despite 0
treatment 0
with 0
either 0
an 0
angiotensin B-gene
- I-gene
converting I-gene
enzyme I-gene
inhibitor 0
, 0
enalapril 0
, 0
or 0
vasodilator 0
therapy 0
with 0
hydralazine/isosorbide 0
dinitrate 0
. 0

Binding 0
activity 0
in 0
rat 0
liver 0
nuclear 0
extracts 0
includes 0
these 0
orphan 0
receptors 0
as 0
judged 0
from 0
electromobility 0
supershift 0
experiments 0
and 0
from 0
results 0
obtained 0
with 0
expressed 0
receptors 0
, 0
although 0
the 0
element 0
in 0
CYP2C11 B-gene
did 0
not 0
bind 0
HNF B-gene
- I-gene
4 I-gene
. 0

Transcript 0
analysis 0
reveals 0
that 0
lethal 0
B B-gene
block I-gene
substitutions 0
reduce 0
U6 B-gene
RNA I-gene
synthesis 0
at 0
least 0
10 0
- 0
fold 0
in 0
vivo 0
and 0
20 0
- 0
fold 0
in 0
vitro 0
. 0

Analysis 0
of 0
Bcl B-gene
- I-gene
2/Bcl I-gene
2/Bcl I-gene
- I-gene
2 I-gene
homodimerization 0
using 0
both 0
in 0
vitro 0
binding 0
assays 0
as 0
well 0
as 0
a 0
yeast 0
two 0
- 0
hybrid 0
method 0
provided 0
evidence 0
in 0
support 0
of 0
a 0
head 0
- 0
to 0
- 0
tail 0
model 0
for 0
Bcl B-gene
- I-gene
2/Bcl I-gene
2/Bcl I-gene
- I-gene
2 I-gene
homodimerization 0
and 0
revealed 0
that 0
sequences 0
within 0
the 0
NH2 0
- 0
terminal 0
A 0
domain 0
interact 0
with 0
a 0
structure 0
that 0
requires 0
the 0
presence 0
of 0
both 0
the 0
carboxyl 0
B 0
and 0
C 0
domains 0
in 0
combination 0
. 0

The 0
protein 0
is 0
composed 0
of 0
a 0
central 0
alpha 0
- 0
helical 0
portion 0
with 0
globular 0
domains 0
at 0
both 0
NH2 0
and 0
COOH 0
termini 0
, 0
and 0
the 0
epitope 0
to 0
the 0
monoclonal 0
antibody 0
resides 0
in 0
the 0
central 0
alpha 0
- 0
helical 0
stalk 0
. 0

Radioligand 0
binding 0
was 0
indistinguishable 0
for 0
both 0
transiently 0
expressed 0
constructs 0
. 0

Diagnosis 0
of 0
FHCS 0
has 0
been 0
weighed 0
upon 0
laparoscopic 0
findings 0
. 0

Human B-gene
papillomavirus I-gene
type I-gene
31b I-gene
late I-gene
gene I-gene
expression 0
is 0
regulated 0
through 0
protein B-gene
kinase I-gene
C I-gene
- 0
mediated 0
changes 0
in 0
RNA 0
processing 0
. 0

Interestingly 0
, 0
virions 0
also 0
contained 0
smaller 0
proteins 0
that 0
reacted 0
with 0
antibodies 0
specific 0
for 0
the 0
accessory 0
proteins 0
as 0
well 0
as 0
SN B-gene
and 0
CAT B-gene
fusion I-gene
partners 0
. 0

Studies 0
using 0
an 0
inhibitor 0
or 0
a 0
mutant B-gene
Lb I-gene
proteinase I-gene
indicated 0
that 0
stimulation 0
of 0
IRES 0
- 0
driven 0
translation 0
is 0
mediated 0
via 0
proteolysis 0
of 0
some 0
cellular 0
component 0
( 0
s 0
) 0
. 0

Restriction 0
mapping 0
analysis 0
localized 0
this 0
cDNA 0
to 0
the 0
HHV B-gene
- I-gene
6A I-gene
( I-gene
U1102 I-gene
) I-gene
genomic I-gene
BamHI I-gene
G I-gene
fragment I-gene
, 0
at 0
the 0
right 0
end 0
of 0
the 0
unique 0
long 0
segment 0
of 0
the 0
genome 0
and 0
to 0
the 0
SalI B-gene
L I-gene
and 0
SalI B-gene
O I-gene
fragments I-gene
within 0
the 0
left 0
and 0
right 0
terminal 0
direct 0
repeat 0
regions 0
, 0
respectively 0
. 0

For 0
replication 0
reporter 0
constructs 0
where 0
E1 B-gene
and 0
E2 B-gene
are 0
supplied 0
in 0
trans 0
by 0
the 0
respective 0
expression 0
vectors 0
, 0
distance 0
between 0
the 0
half 0
sites 0
seems 0
to 0
play 0
a 0
major 0
role 0
, 0
yet 0
the 0
phasing 0
relationships 0
are 0
measurable 0
. 0

As 0
it 0
had 0
been 0
previously 0
reported 0
that 0
the 0
18 0
- 0
bp 0
palindrome 0
contains 0
sufficient 0
nucleotide 0
sequence 0
information 0
for 0
E1 B-gene
binding 0
, 0
we 0
speculate 0
that 0
a 0
minimal 0
E1 B-gene
recognition 0
motif 0
is 0
presented 0
in 0
each 0
half 0
site 0
. 0

METHODS 0
: 0
Out 0
of 0
171 0
patients 0
receiving 0
anticoagulation 0
between 0
July 0
1992 0
and 0
December 0
1993 0
, 0
83 0
patients 0
with 0
hemispheric 0
embolisms 0
received 0
heparin 0
within 0
72 0
hours 0
from 0
onset 0
( 0
activated 0
partial 0
thromboplastin B-gene
time 0
[ 0
aPTT 0
] 0
1.5 0
times 0
control 0
value 0
) 0
. 0

In 0
the 0
commercially 0
available 0
intravenous 0
formulation 0
of 0
Cyclosporin 0
A 0
( 0
Sandimmun 0
) 0
, 0
polyoxyethylated 0
castor 0
oil 0
( 0
Cremophor 0
EL 0
) 0
is 0
used 0
as 0
a 0
solubilizing 0
agent 0
. 0

Lung 0
function 0
tests 0
( 0
EFR 0
) 0
were 0
performed 0
on 0
these 0
patients 0
for 0
a 0
period 0
of 0
19.2 0
+/ 0
- 0
3.4 0
months 0
. 0

Sequence 0
comparisons 0
of 0
prokaryotic B-gene
RCR I-gene
initiators I-gene
has 0
revealed 0
a 0
set 0
of 0
three 0
common 0
motifs 0
, 0
two 0
of 0
which 0
, 0
a 0
putative 0
metal 0
coordination 0
site 0
and 0
a 0
downstream 0
active 0
- 0
site 0
tyrosine 0
motif 0
, 0
could 0
be 0
tentatively 0
identified 0
in 0
parvoviral B-gene
replicator I-gene
proteins I-gene
. 0

The 0
mean 0
marginal 0
discrepancy 0
of 0
provisional 0
restorations 0
was 0
compared 0
for 0
restorations 0
fabricated 0
from 0
stone 0
, 0
low 0
- 0
viscosity 0
poly 0
( 0
vinyl 0
siloxane 0
) 0
, 0
and 0
medium 0
- 0
viscosity 0
poly 0
( 0
vinyl 0
siloxane 0
) 0
. 0

The 0
characterized 0
Aplysia B-gene
Afurin2 I-gene
is 0
a 0
candidate 0
PC B-gene
that 0
may 0
play 0
an 0
important 0
role 0
in 0
the 0
processing 0
of 0
egg B-gene
- I-gene
laying I-gene
hormone I-gene
( 0
ELH B-gene
) 0
- 0
related 0
precursors 0
in 0
the 0
secretory 0
cells 0
of 0
the 0
atrial 0
gland 0
. 0

Rats 0
treated 0
with 0
8 0
- 0
OH 0
- 0
DPAT 0
were 0
not 0
impaired 0
in 0
their 0
ability 0
to 0
learn 0
a 0
visual 0
discrimination 0
in 0
a 0
water 0
maze 0
. 0

The 0
term 0
endovascular 0
papillary 0
haemangioma 0
is 0
suggested 0
. 0

In 0
addition 0
, 0
two 0
internal 0
promoters 0
, 0
PmiaA B-gene
and 0
P1hfq B-gene
were 0
identified 0
and 0
mapped 0
to 0
201 0
and 0
837 0
nucleotides 0
upstream 0
from 0
the 0
respective 0
translation 0
start 0
sites 0
. 0

These 0
results 0
indicate 0
that 0
mutL B-gene
, 0
miaA B-gene
, 0
and 0
hfq B-gene
expression 0
could 0
be 0
regulated 0
by 0
multiple 0
mechanisms 0
, 0
including 0
degree 0
of 0
cotranscription 0
from 0
upstream 0
genes 0
, 0
modulation 0
of 0
internal 0
promoter 0
strength 0
, 0
and 0
by 0
RNase B-gene
E I-gene
activity 0
. 0

Coronary 0
T1 0
and 0
T2 0
weighted 0
images 0
were 0
obtained 0
. 0

The 0
2 0
kb 0
of 0
5' 0
- 0
flanking 0
region 0
and 0
the 0
1.1 0
kb 0
of 0
the 0
entire 0
sGTH B-gene
alpha I-gene
subunit I-gene
coding 0
region 0
were 0
sequenced 0
from 0
the 0
genomic 0
clone 0
, 0
sGTH B-gene
alpha I-gene
- I-gene
G1 I-gene
. 0

Functional 0
analysis 0
of 0
the 0
sGTH B-gene
alpha I-gene
subunit I-gene
promoter I-gene
by 0
the 0
transient 0
transfection 0
of 0
several 0
sGTH B-gene
alpha/CAT I-gene
chimeric 0
plasmids 0
into 0
rainbow 0
trout 0
pituitary 0
cells 0
suggests 0
that 0
its 0
pituitary 0
- 0
specific 0
expression 0
is 0
alpha/CAT I-gene

Indium 0
- 0
111 0
OncoScint 0
CR/OV 0
and 0
F 0
- 0
18 0
FDG 0
in 0
colorectal 0
and 0
ovarian 0
carcinoma 0
recurrences 0
. 0

His 0
carnitine B-gene
palmitoyltransferase I-gene
( I-gene
CPT I-gene
) I-gene
I I-gene
and I-gene
II I-gene
activities 0
were 0
0.06 0
and 0
0.12 0
nmol/min/mg 0
protein 0
, 0
as 0
compared 0
with 0
a 0
mean 0
value 0
of 0
0.22 0
+/ 0
- 0
0.14 0
and 0
0.27 0
+/ 0
- 0
0.07 0
nmol/min/mg 0
protein 0
, 0
respectively 0
, 0
in 0
control 0
subjects 0
. 0

The 0
Myc B-gene
LZ I-gene
was 0
found 0
to 0
prevent 0
homodimeric 0
interactions 0
, 0
thus 0
explaining 0
Myc B-gene
inability 0
to 0
homodimerize 0
efficiently 0
. 0

Staphylococcus 0
aureus 0
and 0
CNS 0
showed 0
high 0
or 0
moderate 0
resistance 0
rates 0
to 0
methicillin 0
( 0
DMPPC 0
) 0
. 0

Thus 0
, 0
VF 0
resistant 0
to 0
defibrillation 0
is 0
not 0
necessarily 0
associated 0
with 0
both 0
toxic 0
plasma 0
drug 0
level 0
and 0
remarkably 0
decreased 0
conduction 0
. 0

The 0
smallest 0
active B-gene
FecR I-gene
derivative I-gene
contained 0
59 0
amino 0
acid 0
residues 0
as 0
compared 0
to 0
the 0
317 0
residues 0
of 0
wild B-gene
- I-gene
type I-gene
FecR I-gene
. 0

The 0
gene 0
pairs 0
psbB B-gene
- 0
psbT B-gene
and 0
psbH B-gene
- 0
psbN B-gene
are 0
cotranscribed 0
from 0
opposite 0
strands 0
. 0

Hybridization 0
signals 0
were 0
also 0
detected 0
with 0
total 0
DNAs 0
of 0
Rhizobium 0
leguminosarum 0
bv 0
. 0
phaseoli 0
, 0
Rhodobacter 0
capsulatus 0
and 0
Escherichia 0
coli 0
, 0
but 0
not 0
those 0
of 0
Xanthomonas 0
campestris 0
pv 0
. 0
campestris 0
and 0
Pseudomonas 0
putida 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
contains 0
regions 0
identical 0
to 0
the 0
sequences 0
of 0
peptides 0
derived 0
from 0
bovine B-gene
liver I-gene
eIF I-gene
- I-gene
2B I-gene
alpha I-gene
subunit I-gene
. 0

Expression 0
of 0
this 0
cDNA 0
in 0
vitro 0
yields 0
a 0
peptide 0
which 0
comigrates 0
with 0
natural B-gene
eIF I-gene
- I-gene
2B I-gene
alpha I-gene
in 0
SDS/polyacrylamide 0
gels 0
. 0

When 0
RNA 0
encoding 0
the 0
tail 0
domain 0
of 0
desmoglein B-gene
was 0
coinjected 0
with 0
plakoglobin B-gene
RNA I-gene
, 0
both 0
the 0
dorsalizing 0
effect 0
and 0
nuclear 0
accumulation 0
of 0
plakoglobin B-gene
were 0
suppressed 0
. 0

Six 0
of 0
them 0
, 0
NUC1 B-gene
, 0
PRP21 B-gene
( 0
also 0
called 0
SPP91 B-gene
) 0
, 0
CDC6 B-gene
, 0
CRY2 B-gene
, 0
the 0
gene 0
encoding 0
the 0
ribosomal B-gene
protein I-gene
S24 I-gene
and 0
the 0
gene 0
coding 0
for 0
a 0
hypothetical 0
protein 0
of 0
599 0
amino 0
acids 0
, 0
have 0
been 0
sequenced 0
previously 0
. 0

Intrastriatal 0
grafts 0
of 0
nigral 0
and 0
adrenal 0
tissues 0
have 0
been 0
found 0
to 0
be 0
effective 0
in 0
alleviating 0
many 0
of 0
the 0
simple 0
motor 0
and 0
sensorimotor 0
deficits 0
associated 0
with 0
lesions 0
of 0
the 0
nigrostriatal 0
dopamine 0
system 0
. 0

OBJECTIVE 0
: 0
To 0
determine 0
the 0
impact 0
of 0
the 0
introduction 0
of 0
clarithromycin 0
and 0
azithromycin 0
on 0
the 0
treatment 0
and 0
survival 0
of 0
patients 0
with 0
AIDS 0
and 0
disseminated 0
Mycobacterium 0
avium 0
complex 0
( 0
DMAC 0
) 0
. 0

Thereafter 0
, 0
the 0
aggregation 0
rose 0
to 0
the 0
initial 0
100 0
% 0
value 0
4 0
h 0
after 0
drug 0
application 0
and 0
remained 0
at 0
this 0
level 0
during 0
the 0
observation 0
period 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Growth 0
curves 0
indicated 0
that 0
proliferation 0
of 0
clone 0
CA9 0
in 0
the 0
presence 0
of 0
10 0
% 0
serum 0
was 0
reduced 0
by 0
60 0
% 0
compared 0
with 0
clone 0
ME10 0
. 0

The 0
protein 0
coding 0
region 0
, 0
1,696 0
bps 0
long 0
, 0
is 0
divided 0
by 0
an 0
intron 0
into 0
two 0
exons 0
. 0

The 0
UAS 0
of 0
the 0
AAC2 B-gene
gene I-gene
contains 0
at 0
least 0
two 0
distinct 0
motifs 0
for 0
DNA 0
- 0
binding 0
transcriptional 0
activators 0
, 0
including 0
one 0
which 0
is 0
identical 0
with 0
the 0
core 0
HAP2/3/4 B-gene
binding I-gene
motif I-gene
, 0
and 0
a 0
second 0
one 0
with 0
the 0
ABF1 B-gene
consensus I-gene
binding I-gene
sequence I-gene
. 0

The 0
emerging 0
complexity 0
of 0
the 0
5 0
' 0
regulatory 0
region 0
of 0
the 0
GH B-gene
receptor I-gene
gene I-gene
was 0
emphasised 0
by 0
the 0
observation 0
that 0
probes 0
derived 0
from 0
exon 0
1B 0
and 0
the 0
distal 0
3 0
' 0
intron 0
boundary 0
do 0
not 0
hybridise 0
with 0
previously 0
cloned 0
genomic 0
sequences 0
that 0
span 0
the 0
liver 0
- 0
specific 0
P1 0
promoter 0
and 0
exon 0
2 0
. 0

A 0
polymorphic 0
dinucleotide 0
( 0
GT/CA 0
) 0
n 0
repeat 0
contained 0
in 0
the 0
NHE5 0
cosmid 0
was 0
identified 0
and 0
developed 0
into 0
a 0
microsatellite 0
PCR 0
marker 0
. 0

The 0
proteins 0
are 0
more 0
than 0
90 0
% 0
identical 0
to 0
each 0
other 0
within 0
the 0
protein 0
kinase 0
domain 0
but 0
only 0
51 0
- 0
59 0
% 0
identical 0
to 0
other 0
casein B-gene
kinase I-gene
I I-gene
isoforms I-gene
within 0
this 0
region 0
. 0

We 0
used 0
two 0
approaches 0
to 0
ascertain 0
whether 0
CDP/cut B-gene
serves 0
as 0
a 0
repressor 0
of 0
CDP/cut I-gene

Serum 0
induction 0
of 0
a 0
MEF2 B-gene
reporter I-gene
gene I-gene
was 0
not 0
observed 0
in 0
a 0
line 0
of 0
NIH 0
3T3 0
cells 0
which 0
contain 0
low 0
MEF2 B-gene
site I-gene
binding 0
activity 0
. 0

Despite 0
the 0
activation 0
of 0
these 0
intracellular 0
signaling 0
molecules 0
, 0
PDGF B-gene
beta I-gene
receptor I-gene
activation 0
elicited 0
no 0
detectable 0
effect 0
on 0
cell 0
proliferation 0
or 0
differentiation 0
. 0

UAS1 0
is 0
the 0
binding 0
site 0
for 0
the 0
transcriptional 0
regulator 0
Adr1p B-gene
. 0

In 0
the 0
context 0
of 0
the 0
ADH2 B-gene
upstream I-gene
regulatory I-gene
region I-gene
, 0
including 0
UAS1 0
, 0
working 0
in 0
concert 0
with 0
the 0
ADH2 B-gene
basal I-gene
promoter I-gene
elements I-gene
, 0
UAS2 0
- 0
dependent 0
gene 0
activation 0
was 0
dependent 0
on 0
orientation 0
, 0
copy 0
number 0
, 0
and 0
helix 0
phase 0
. 0

Induction 0
in 0
AP B-gene
- I-gene
1 I-gene
DNA 0
binding 0
correlates 0
with 0
a 0
concomitant 0
GH B-gene
trans 0
- 0
activation 0
of 0
c B-gene
- I-gene
jun I-gene
and 0
c B-gene
- I-gene
fos I-gene
genes I-gene
described 0
previously 0
. 0

Inactivation 0
of 0
MAP B-gene
kinases I-gene
occurs 0
via 0
a 0
specific 0
phosphatase 0
, 0
MKP B-gene
- I-gene
1 I-gene
. 0

Short 0
- 0
course 0
amphotericin 0
B 0
therapy 0
for 0
candidemia 0
in 0
pediatric 0
patients 0
. 0

Furthermore 0
, 0
45Ca 0
- 0
binding 0
assays 0
revealed 0
that 0
CCaMK B-gene
directly 0
binds 0
Ca2+ 0
. 0

Since 0
AP B-gene
- I-gene
1 I-gene
is 0
an 0
important 0
mediator 0
of 0
tumor 0
promoter 0
action 0
, 0
these 0
findings 0
may 0
explain 0
the 0
anti 0
- 0
tumor 0
- 0
promoting 0
activity 0
of 0
phenolic 0
antioxidants 0
. 0

The 0
second 0
complex 0
, 0
when 0
purified 0
, 0
contained 0
four 0
protein 0
components 0
including 0
the 0
36 0
- 0
kDa 0
protein 0
. 0

The 0
protein 0
expressed 0
from 0
the 0
cloned 0
cDNA 0
is 0
secreted 0
into 0
the 0
culture 0
medium 0
and 0
yields 0
of 0
up 0
to 0
40 0
mg 0
per 0
litre 0
have 0
been 0
obtained 0
. 0

The 0
study 0
was 0
repeated 0
after 0
administration 0
of 0
oral 0
amiodarone 0
, 0
50 0
mg/kg/day 0
for 0
2 0
days 0
in 0
8 0
divided 0
doses 0
( 0
mean 0
dose 0
6.9 0
+/ 0
- 0
0.4 0
g 0
) 0
. 0

Plasmids 0
pAMS12 0
, 0
pAMS13 0
and 0
pAMS14 0
were 0
transformed 0
into 0
a 0
laboratory 0
strain 0
of 0
Saccharomyces 0
cerevisiae 0
, 0
whereas 0
pAMS15 0
was 0
stably 0
introduced 0
into 0
two 0
commercial 0
wine 0
yeast 0
strains 0
. 0

The 0
maximum 0
induction 0
of 0
ACC B-gene
- I-gene
oxidase I-gene
transcripts I-gene
occurred 0
at 0
about 0
6 0
h 0
after 0
excision 0
, 0
while 0
the 0
maximum 0
enzyme 0
activity 0
was 0
observed 0
at 0
24 0
h 0
. 0

Within 0
their 0
polypeptide 0
chain 0
, 0
they 0
all 0
contain 0
those 0
conserved 0
features 0
that 0
define 0
a 0
plant 0
CDPK B-gene
; 0
kinase 0
catalytic 0
sequences 0
are 0
linked 0
to 0
a 0
calmodulin B-gene
- I-gene
like I-gene
regulatory I-gene
domain I-gene
through 0
a 0
junction 0
region 0
. 0

Repair 0
of 0
this 0
insertion 0
by 0
homologous 0
recombination 0
restores 0
the 0
activity 0
of 0
the 0
hprt B-gene
locus I-gene
, 0
thus 0
confirming 0
the 0
site 0
of 0
mutation 0
. 0

The 0
timing 0
of 0
fla B-gene
gene I-gene
expression 0
in 0
the 0
cell 0
cycle 0
is 0
determined 0
by 0
specialized 0
forms 0
of 0
RNA B-gene
polymerase I-gene
and 0
the 0
appearance 0
and/or 0
activation 0
of 0
regulatory 0
proteins 0
. 0

Primer 0
extension 0
experiments 0
revealed 0
a 0
strong 0
transcription 0
initiation 0
site 0
102 0
bp 0
upstream 0
of 0
the 0
translational 0
start 0
site 0
. 0

Polypeptides 0
of 0
the 0
same 0
apparent 0
sizes 0
are 0
detected 0
in 0
spores 0
of 0
a 0
cotE B-gene
null 0
mutant 0
, 0
on 0
which 0
basis 0
we 0
infer 0
that 0
the 0
products 0
of 0
the 0
cotJ B-gene
operon I-gene
are 0
required 0
for 0
the 0
normal 0
formation 0
of 0
the 0
inner 0
layers 0
of 0
the 0
coat 0
or 0
are 0
themselves 0
structural 0
components 0
of 0
the 0
coat 0
. 0

Based 0
on 0
the 0
estimated 0
values 0
of 0
divergence 0
of 0
apobec1 B-gene
sequences I-gene
in 0
terms 0
of 0
the 0
numbers 0
of 0
synonymous 0
and 0
non 0
- 0
synonymous 0
suhstitutions 0
per 0
site 0
, 0
we 0
found 0
that 0
apobec1 B-gene
is 0
a 0
fairly 0
rapidly 0
evolving 0
protein 0
. 0

EEA1 B-gene
is 0
a 0
conserved 0
alpha 0
- 0
helical 0
peripheral 0
membrane 0
protein 0
flanked 0
by 0
cysteine 0
`` 0
fingers 0
'' 0
and 0
contains B-gene
a I-gene
calmodulin I-gene
- I-gene
binding I-gene
IQ I-gene
motif I-gene
. 0

Nucleotide 0
sequences 0
of 0
the 0
clones 0
revealed 0
that 0
one 0
clone 0
, 0
cap3 B-gene
, 0
contained 0
an 0
open 0
reading 0
frame 0
( 0
ORF 0
) 0
that 0
would 0
code 0
for 0
a 0
26 0
- 0
amino 0
acid 0
, 0
cysteine 0
- 0
rich 0
peptide 0
with 0
significant 0
homology 0
to 0
Neurospora B-gene
crassa I-gene
copper I-gene
metallothionein I-gene
. 0

Sensing 0
with 0
chemically 0
and 0
biologically 0
modified 0
carbon 0
electrodes 0
. 0

Elevation 0
of 0
the 0
tissues 0
of 0
the 0
face 0
is 0
essentially 0
vertical 0
and 0
acts 0
on 0
the 0
forehead 0
, 0
temporal 0
region 0
, 0
gaze 0
and 0
cheekbones 0
. 0

This 0
region 0
binds 0
two 0
ubiquitous 0
nuclear 0
factors 0
, 0
USF/MLTF B-gene
and 0
the 0
USF/MLTF I-gene

The 0
potential 0
impact 0
of 0
using 0
a 0
rapid 0
diagnostic 0
test 0
( 0
Strep 0
A 0
OIA 0
) 0
on 0
detection 0
and 0
treatment 0
of 0
group 0
A 0
beta 0
- 0
hemolytic 0
streptococcal 0
( 0
GABHS 0
) 0
pharyngitis 0
in 0
a 0
large 0
- 0
volume 0
pediatric 0
and 0
adolescent 0
clinic 0
was 0
examined 0
. 0

The 0
bHLH B-gene
proteins I-gene
function 0
as 0
potent 0
transcriptional 0
activators 0
of 0
tissue 0
- 0
specific 0
genes 0
by 0
forming 0
heterodimers 0
between 0
ubiquitous 0
and 0
cell 0
- 0
restricted 0
family 0
members 0
. 0

YAC 0
and 0
cosmid 0
contigs 0
spanning 0
the 0
BRCA1 B-gene
region I-gene
were 0
used 0
to 0
select 0
cDNA 0
clones 0
from 0
pools 0
of 0
cDNAs 0
derived 0
from 0
human 0
placenta 0
, 0
HeLa 0
cells 0
, 0
activated 0
T 0
cells 0
, 0
and 0
fetal 0
head 0
. 0

The 0
other 0
two 0
clones 0
, 0
Ash B-gene
- I-gene
m I-gene
and I-gene
- I-gene
s I-gene
, 0
had 0
nucleotide 0
sequences 0
identical 0
with 0
Ash B-gene
- I-gene
l I-gene
cDNA 0
in 0
the 0
amino 0
- 0
terminal 0
region 0
. 0

This 0
study 0
assesses 0
the 0
feasibility 0
and 0
toxicity 0
of 0
adoptive 0
immunotherapy 0
with 0
tumor 0
infiltrating 0
lymphocytes 0
and 0
recombinant B-gene
interleukin I-gene
- I-gene
2 I-gene
in 0
29 0
patients 0
who 0
underwent 0
resection 0
for 0
stage 0
III 0
non 0
- 0
small 0
- 0
cell 0
lung 0
cancer 0
. 0

MATERIAL 0
AND 0
METHODS 0
: 0
Of 0
the 0
17 0
men 0
and 0
17 0
women 0
, 0
who 0
were 0
21 0
to 0
80 0
years 0
of 0
age 0
, 0
27 0
had 0
hereditary 0
motor 0
and 0
sensory 0
neuropathy 0
type 0
I 0
and 0
7 0
had 0
acquired 0
demyelinating 0
polyneuropathy 0
. 0

The 0
present 0
study 0
describes 0
the 0
cell 0
volume 0
dynamics 0
in 0
intact 0
rat 0
hearts 0
, 0
during 0
ischemia 0
and 0
after 0
reperfusion 0
. 0

In 0
contrast 0
, 0
COUP B-gene
- I-gene
TF I-gene
alone 0
had 0
no 0
effect 0
on 0
repCRS2 0
- 0
dependent 0
reporter 0
gene 0
activity 0
. 0

DNA 0
sequencing 0
and 0
Southern 0
blot 0
analyses 0
established 0
that 0
the 0
cDNA 0
clones 0
are 0
derived 0
from 0
two 0
different 0
genes 0
. 0

Muscle B-gene
GSH I-gene
- I-gene
Px I-gene
activity 0
after 0
prolonged 0
exercise 0
, 0
training 0
, 0
and 0
selenium 0
supplementation 0
. 0

Mutation 0
of 0
the 0
Sp1 B-gene
element I-gene
, 0
which 0
abolishes 0
Sp1 B-gene
binding 0
, 0
results 0
in 0
a 0
6 0
- 0
10 0
- 0
fold 0
reduction 0
in 0
reporter 0
activity 0
. 0

The 0
c B-gene
- I-gene
myc I-gene
gene I-gene
is 0
overexpressed 0
in 0
a 0
variety 0
of 0
tumor 0
types 0
and 0
appears 0
to 0
play 0
an 0
important 0
role 0
in 0
the 0
abnormal 0
growth 0
of 0
a 0
number 0
of 0
cell 0
types 0
. 0

We 0
found 0
that 0
PML B-gene
was 0
expressed 0
at 0
a 0
lower 0
level 0
in 0
S 0
, 0
G2 0
, 0
and 0
M 0
phases 0
and 0
at 0
a 0
significantly 0
higher 0
level 0
in 0
G1 0
phase 0
. 0

Schooling 0
is 0
found 0
to 0
be 0
related 0
to 0
good 0
health 0
even 0
after 0
controlling 0
for 0
differences 0
in 0
observable 0
health 0
inputs 0
. 0

With 0
this 0
bisected 0
diastolic 0
driving 0
, 0
the 0
abnormal 0
echo 0
disappeared 0
completely 0
. 0

It 0
acts 0
on 0
Cdks B-gene
in 0
the 0
G1 0
and 0
S 0
phases 0
of 0
the 0
cell 0
cycle 0
, 0
and 0
also 0
binds 0
to 0
proliferating B-gene
cell I-gene
nuclear I-gene
antigen I-gene
( 0
PCNA B-gene
) 0
, 0
blocking 0
DNA 0
replication 0
in 0
vitro 0
. 0

Two 0
major 0
and 0
one 0
minor 0
transcription 0
initiation 0
sites 0
were 0
assigned 0
to 0
positions 0
+1 0
and 0
+24 0
and 0
position 0
+14 0
, 0
respectively 0
, 0
by 0
a 0
combination 0
of 0
ribonuclease 0
protection 0
, 0
primer 0
extension 0
, 0
and 0
5 0
' 0
RACE 0
analyses 0
. 0

The 0
roxithromycin 0
doses 0
that 0
were 0
chosen 0
for 0
these 0
studies 0
were 0
less 0
than 0
achievable 0
blood 0
levels 0
. 0

We 0
demonstrate 0
here 0
that 0
the 0
- 0
DEDDDL 0
sequence 0
stabilizes 0
GDP 0
binding 0
to 0
Ran B-gene
, 0
and 0
that 0
the 0
domain 0
is 0
required 0
for 0
high 0
affinity 0
interaction 0
with 0
a 0
Ran B-gene
- I-gene
binding I-gene
protein I-gene
, 0
HTF9A/RanBP1 B-gene
. 0

Further 0
, 0
the 0
ORFs 0
of 0
components 0
3 0
and 0
5 0
potentially 0
encoded 0
proteins 0
of 0
about 0
20 0
kDa 0
, 0
the 0
size 0
of 0
the 0
BBTV B-gene
coat I-gene
protein I-gene
. 0

Serial 0
followup 0
strength 0
data 0
for 0
2 0
patients 0
were 0
compared 0
to 0
change 0
in 0
creatinine B-gene
kinase I-gene
( 0
CK B-gene
) 0
levels 0
. 0

CodY B-gene
does 0
not 0
have 0
any 0
homologues 0
in 0
the 0
data 0
- 0
bases 0
. 0

OBJECTIVE 0
: 0
To 0
investigate 0
the 0
incidence 0
and 0
presentation 0
of 0
acute 0
pernicious 0
or 0
fulminating 0
beriberi 0
in 0
a 0
general 0
district 0
hospital 0
. 0

Unlike 0
most 0
other 0
small B-gene
G I-gene
proteins I-gene
which 0
are 0
expressed 0
ubiquitously 0
, 0
TTF B-gene
was 0
transcribed 0
only 0
in 0
hemopoietic 0
cells 0
as 0
a 0
2.2 0
kb 0
transcript 0
. 0

An 0
explanation 0
explored 0
for 0
this 0
lack 0
of 0
gene 0
expression 0
was 0
that 0
increased 0
levels 0
of 0
RAR B-gene
alpha I-gene
or 0
PML B-gene
might 0
suppress 0
APL 0
cell 0
growth 0
. 0

Transfection 0
of 0
non 0
- 0
deleted 0
expression 0
vector 0
into 0
NIH3T3 0
cells 0
results 0
in 0
acquisition 0
of 0
focus 0
- 0
forming 0
activity 0
while 0
a 0
deleted 0
form 0
of 0
expression 0
vector 0
fails 0
to 0
show 0
this 0
activity 0
even 0
in 0
the 0
presence 0
of 0
basic B-gene
FGF I-gene
. 0

Cytosolic 0
extracts 0
from 0
a 0
variety 0
of 0
mammalian 0
cell 0
lines 0
( 0
monkey 0
Cos7 0
, 0
several 0
mouse 0
fibrosarcomas 0
and 0
human 0
HeLa 0
S3 0
) 0
demonstrated 0
similar 0
TGF B-gene
- I-gene
beta I-gene
1 I-gene
dependent 0
RNA 0
- 0
protein 0
band 0
shifts 0
as 0
cell 0
extract 0
from 0
BALB/c 0
3T3 0
mouse 0
fibroblasts 0
. 0

All 0
ribosomal B-gene
protein I-gene
( 0
rp B-gene
) 0
gene 0
promoters 0
from 0
Saccharomyces 0
cerevisiae 0
studied 0
so 0
far 0
contain 0
either 0
( 0
usually 0
two 0
) 0
binding 0
sites 0
for 0
the 0
global 0
gene 0
regulator 0
Rap1p B-gene
or 0
one 0
binding 0
site 0
for 0
another 0
global 0
factor 0
, 0
Abf1p B-gene
. 0

The 0
provisional 0
reports 0
are 0
based 0
mainly 0
upon 0
macroscopic 0
findings 0
, 0
whereas 0
the 0
final 0
reports 0
include 0
the 0
information 0
provided 0
by 0
supplementary 0
investigations 0
such 0
as 0
microscopy 0
, 0
histochemistry 0
, 0
more 0
rarely 0
electron 0
microscopy 0
, 0
immunohistochemistry 0
and/or 0
microbiology 0
. 0

Circulating 0
thrombomodulin B-gene
: 0
current 0
knowledge 0
and 0
future 0
prospects 0

CPT 0
- 0
11 0
was 0
administered 0
as 0
a 0
30 0
- 0
minute 0
i.v 0
. 0
infusion 0
at 0
a 0
dose 0
of 0
350 0
mg/m2 0
diluted 0
in 0
250 0
ml 0
normal 0
saline 0
every 0
3 0
weeks 0
. 0

CONCLUSION 0
: 0
The 0
MTD 0
for 0
CPT 0
- 0
11 0
administered 0
in 0
a 0
3 0
consecutive 0
- 0
days 0
- 0
every 0
- 0
3 0
weeks 0
schedule 0
in 0
this 0
patient 0
population 0
is 0
115 0
mg/m2/day 0
. 0

A 0
73 0
bp 0
fragment 0
( 0
X1 0
region 0
) 0
of 0
the 0
PRB B-gene
- I-gene
1b I-gene
promoter I-gene
, 0
located 0
between 0
positions 0
- 0
213 0
and 0
- 0
141 0
, 0
was 0
sufficient 0
to 0
confer 0
ethylene 0
responsiveness 0
to 0
the 0
reporter 0
gene 0
. 0

To 0
assess 0
the 0
function 0
( 0
s 0
) 0
of 0
E74 B-gene
during 0
metamorphosis 0
, 0
we 0
have 0
isolated 0
and 0
characterized 0
recessive 0
loss 0
- 0
of 0
- 0
function 0
mutations 0
specific 0
to 0
each 0
transcription 0
unit 0
. 0

Although 0
the 0
extracellular 0
domain 0
of 0
the 0
TSH B-gene
- I-gene
R I-gene
is 0
sufficient 0
for 0
high 0
affinity 0
binding 0
of 0
TSH B-gene
, 0
we 0
conclude 0
that 0
the 0
hyt 0
mutation 0
in 0
the 0
fourth 0
transmembrane 0
domain 0
eliminates 0
TSH B-gene
binding 0
. 0

Lipiodol 0
was 0
covalently 0
conjugated 0
with 0
EDTB 0
. 0

Moreover 0
, 0
Western 0
blots 0
demonstrated 0
at 0
least 0
six 0
types 0
of 0
Ypt B-gene
in 0
both 0
Cr 0
and 0
Vc 0
, 0
suggesting 0
that 0
these 0
Ypt B-gene
are 0
used 0
for 0
household 0
functions 0
responsible 0
for 0
vesicle 0
transport 0
rather 0
than 0
for 0
cellular 0
differentiation 0
. 0

The 0
absence 0
of 0
other 0
regions 0
of 0
hybridization 0
suggests 0
that 0
there 0
are 0
no 0
closely 0
related 0
sequences 0
( 0
e.g. 0
, 0
reverse 0
transcribed 0
pseudogenes 0
) 0
scattered 0
throughout 0
the 0
genome 0
and 0
that 0
if 0
there 0
are 0
closely 0
related 0
genes 0
, 0
they 0
must 0
be 0
clustered 0
near 0
GSTT2 B-gene
. 0

However 0
, 0
the 0
lens 0
dose 0
( 0
3.6 0
Gy/25 0
fractions 0
) 0
was 0
higher 0
compared 0
to 0
the 0
other 0
techniques 0
. 0

Antibodies 0
to 0
the 0
human B-gene
PTS1R I-gene
recognize 0
this 0
protein 0
in 0
human 0
, 0
monkey 0
, 0
rat 0
, 0
and 0
hamster 0
cells 0
. 0

There 0
is 0
a 0
national 0
effort 0
to 0
begin 0
to 0
ask 0
all 0
female 0
patients 0
about 0
family 0
violence 0
. 0

GnRH B-gene
treatment 0
was 0
found 0
to 0
increase 0
the 0
phosphorylation 0
of 0
tyrosine 0
residues 0
of 0
MAPK B-gene
and 0
to 0
increase 0
MAPK B-gene
activity 0
, 0
as 0
determined 0
by 0
an 0
immune 0
complex 0
kinase 0
assay 0
. 0

Molecular 0
cloning 0
of 0
an 0
amphibian B-gene
insulin I-gene
receptor I-gene
substrate I-gene
1 I-gene
- I-gene
like I-gene
cDNA I-gene
and 0
involvement 0
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
in 0
insulin B-gene
- 0
induced 0
Xenopus 0
oocyte 0
maturation 0
. 0

We 0
report 0
here 0
that 0
in 0
cultured 0
Jurkat 0
T 0
cells 0
, 0
Cbl B-gene
is 0
coprecipitated 0
with 0
antibody 0
against 0
the 0
adapter B-gene
protein I-gene
Grb2 I-gene
. 0

The 0
effect 0
of 0
these 0
cell 0
cycle 0
regulators 0
is 0
not 0
specific 0
to 0
the 0
rap1s B-gene
or 0
hmr B-gene
delta I-gene
A I-gene
mutation I-gene
, 0
since 0
swi6 B-gene
, 0
swi4 B-gene
, 0
and 0
clb5 B-gene
mutations I-gene
also 0
suppress 0
mutations 0
in 0
SIR1 B-gene
, 0
another 0
gene 0
implicated 0
in 0
the 0
establishment 0
of 0
silencing 0
. 0

ICP4 B-gene
has 0
been 0
shown 0
to 0
form 0
tripartite 0
complexes 0
cooperatively 0
with 0
the 0
TATA B-gene
box I-gene
- I-gene
binding I-gene
protein I-gene
and 0
TFIIB B-gene
on 0
DNA 0
containing 0
an 0
ICP4 B-gene
binding I-gene
site I-gene
and 0
a 0
TATA 0
box 0
( 0
C 0
. 0

Otte 0
, 0
Mol 0
. 0

Characterization 0
of 0
fus1 B-gene
of 0
Schizosaccharomyces 0
pombe 0
: 0
a 0
developmentally 0
controlled 0
function 0
needed 0
for 0
conjugation 0
. 0

SRY B-gene
- I-gene
related I-gene
cDNA I-gene
encoding 0
a 0
protein 0
with 0
a 0
high B-gene
- I-gene
mobility I-gene
- I-gene
group I-gene
( 0
HMG B-gene
) 0
box 0
and 0
a 0
leucine 0
zipper 0
motif 0
, 0
which 0
was 0
designated 0
SOX B-gene
- I-gene
LZ I-gene
, 0
was 0
isolated 0
from 0
a 0
rainbow 0
trout 0
testis 0
cDNA 0
library 0
. 0

Scalp 0
flaps 0
can 0
be 0
expanded 0
just 0
to 0
the 0
point 0
of 0
becoming 0
noticeable 0
over 0
4 0
to 0
6 0
weeks 0
followed 0
by 0
scalp 0
flap 0
transposition 0
and 0
easy 0
closure 0
of 0
the 0
donor 0
site 0
. 0

In 0
the 0
Center 0
for 0
Human 0
Genetics 0
in 0
Leuven 0
, 0
predictive 0
DNA 0
- 0
testing 0
for 0
Huntington 0
's 0
disease 0
is 0
available 0
as 0
a 0
clinical 0
service 0
since 0
November 0
1987 0
, 0
initially 0
by 0
DNA 0
- 0
linkage 0
and 0
since 0
mid 0
1993 0
by 0
direct 0
mutation 0
analysis 0
. 0

Risks 0
of 0
chronicity 0
following 0
acute 0
hepatitis 0
B 0
virus 0
infection 0
: 0
a 0
review 0
. 0

Examination 0
of 0
neurohumoral 0
factors 0
revealed 0
a 0
hyperactive 0
sympathetic 0
nervous 0
system 0
and 0
an 0
increase 0
in 0
plasma 0
renin B-gene
activity 0
. 0

We 0
compared 0
the 0
inhibitory 0
effect 0
of 0
naturally 0
occurring 0
mutant B-gene
hTR I-gene
beta I-gene
1 I-gene
, 0
artificially 0
created 0
hTR B-gene
alpha I-gene
1 I-gene
mutants I-gene
, 0
c B-gene
- I-gene
erbA I-gene
alpha I-gene
2 I-gene
and 0
the 0
human B-gene
peroxisome I-gene
proliferator I-gene
- I-gene
activated I-gene
receptor I-gene
( 0
hPPAR B-gene
) 0
on 0
three 0
prototypic 0
T3 0
- 0
response 0
elements 0
( 0
TREs 0
) 0
, 0
TRE 0
- 0
PAL 0
, 0
DR 0
+ 0
4 0
and 0
TRE 0
- 0
LAP 0
. 0

The 0
amino 0
- 0
terminal 0
DNA 0
- 0
binding 0
domain 0
of 0
Pip B-gene
exhibits 0
a 0
high 0
degree 0
of 0
homology 0
to 0
the 0
DNA 0
- 0
binding 0
domains 0
of 0
members 0
of 0
the 0
interferon B-gene
regulatory I-gene
factor I-gene
( 0
IRF B-gene
) 0
family 0
, 0
which 0
includes 0
IRF B-gene
- I-gene
1 I-gene
, 0
IRF B-gene
- I-gene
2 I-gene
, 0
ICSBP B-gene
, 0
and 0
ISGF3 B-gene
gamma I-gene
. 0

An 0
outbreak 0
of 0
hepatitis 0
A 0
among 0
homosexual 0
men 0
in 0
Amsterdam 0
, 0
1991 0
- 0
1993 0
. 0

The 0
RAP74 B-gene
subunit I-gene
of 0
TFIIF B-gene
alone 0
contained 0
the 0
stimulatory 0
activity 0
and 0
the 0
minimal 0
region 0
sufficient 0
for 0
stimulation 0
corresponds 0
to 0
COOH 0
- 0
terminal 0
residues 0
358 0
- 0
517 0
. 0

We 0
have 0
generated 0
various 0
base 0
substitutions 0
and 0
internal 0
deletions 0
in 0
and 0
around 0
DRE 0
( 0
nucleotide 0
positions 0
- 0
93 0
to 0
- 0
100 0
with 0
respect 0
to 0
the 0
transcription 0
initiation 0
site 0
) 0
of 0
the 0
PCNA B-gene
gene I-gene
in 0
vitro 0
and 0
subsequently 0
examined 0
their 0
effects 0
on 0
the 0
binding 0
to 0
DREF B-gene
( 0
DRE B-gene
- I-gene
binding I-gene
factor I-gene
) 0
and 0
PCNA B-gene
gene I-gene
promote 0
activity 0
in 0
cultured 0
Drosophila 0
Kc 0
cells 0
as 0
well 0
as 0
in 0
living 0
flies 0
. 0

The 0
hsp70 B-gene
gene I-gene
family I-gene
of 0
Neurospora 0
crassa 0
: 0
cloning 0
, 0
sequence 0
analysis 0
, 0
expression 0
, 0
and 0
genetic 0
mapping 0
of 0
the 0
major 0
stress 0
- 0
inducible 0
member 0
. 0

The 0
deduced 0
amino 0
acid 0
sequences 0
of 0
each 0
of 0
the 0
W3A1 B-gene
ETF I-gene
subunits I-gene
exhibit 0
only 0
approximately 0
30 0
% 0
identity 0
with 0
the 0
corresponding 0
subunits 0
of 0
the 0
ETF B-gene
from 0
human 0
, 0
rat 0
, 0
and 0
Paracoccus 0
denitrificans 0
, 0
which 0
as 0
a 0
group 0
are 0
greater 0
than 0
50 0
% 0
identical 0
. 0

A 0
secondary 0
phosphorylation 0
of 0
CREB341 B-gene
at 0
Ser129 0
is 0
required 0
for 0
the 0
cAMP 0
- 0
mediated 0
control 0
of 0
gene 0
expression 0
. 0

A 0
role 0
for 0
glycogen B-gene
synthase I-gene
kinase I-gene
- I-gene
3 I-gene
in 0
the 0
control 0
of 0
gene 0
expression 0
. 0

This 0
last 0
region 0
contains 0
two 0
sites 0
that 0
bind 0
Ets B-gene
- I-gene
related I-gene
proteins I-gene
present 0
in 0
liver 0
nuclear 0
extracts 0
as 0
well 0
as 0
recombinant B-gene
purified I-gene
Ets I-gene
- I-gene
1 I-gene
protein I-gene
. 0

Other 0
assays 0
also 0
distinguished 0
the 0
processive 0
replication 0
of 0
pNeo.Myc 0
- 0
2.4 0
from 0
the 0
dispersive 0
labeling 0
of 0
control 0
plasmids 0
. 0

Reconstitution 0
of 0
complexes 0
containing 0
p62 B-gene
and 0
the 0
src B-gene
family I-gene
kinase I-gene
p59fyn B-gene
in 0
HeLa 0
cells 0
demonstrated 0
that 0
complex 0
formation 0
resulted 0
in 0
tyrosine 0
phosphorylation 0
of 0
p62 B-gene
and 0
was 0
mediated 0
by 0
both 0
the 0
SH3 B-gene
and 0
SH2 B-gene
domains I-gene
of 0
p59fyn B-gene
. 0

Therefore 0
, 0
it 0
is 0
hoped 0
that 0
by 0
defining 0
the 0
transcriptional 0
control 0
of 0
the 0
L7 B-gene
gene I-gene
insights 0
into 0
the 0
mechanisms 0
that 0
control 0
functional 0
fate 0
and 0
organization 0
in 0
the 0
nervous 0
system 0
can 0
be 0
gained 0
. 0

In 0
contrast 0
, 0
a 0
Maf B-gene
- I-gene
related I-gene
protein I-gene
, 0
Nrl B-gene
, 0
completely 0
mimicked 0
c B-gene
- I-gene
Maf I-gene
actions 0
. 0

The 0
27 0
- 0
base 0
element 0
interacts 0
with 0
a 0
PDGF B-gene
- 0
activated 0
serine/threonine 0
phosphoprotein 0
that 0
is 0
detected 0
only 0
within 0
the 0
nucleus 0
of 0
PDGF 0
- 0
treated 0
3T3 0
cells 0
. 0

By 0
contrast 0
, 0
deletion 0
of 0
this 0
Ras B-gene
- I-gene
binding I-gene
site I-gene
did 0
not 0
diminish 0
activation 0
of 0
Raf B-gene
- I-gene
1 I-gene
kinase I-gene
by 0
Src B-gene
, 0
implying 0
that 0
Src B-gene
and 0
Ras B-gene
can 0
activate 0
Raf B-gene
- I-gene
1 I-gene
through 0
independent 0
mechanisms 0
. 0

In 0
studies 0
of 0
many 0
different 0
phenotypically 0
distinct 0
cells 0
, 0
the 0
CRE 0
of 0
the 0
somatostatin B-gene
gene I-gene
promoter I-gene
is 0
a 0
prototype 0
of 0
a 0
highly 0
cAMP 0
- 0
responsive 0
element 0
regulated 0
by 0
CREB B-gene
. 0

The 0
first 0
gene 0
, 0
NSR1 B-gene
, 0
a 0
previously 0
identified 0
gene 0
, 0
encodes 0
a 0
protein 0
involved 0
in 0
ribosomal 0
RNA 0
maturation 0
and 0
possibly 0
in 0
transport 0
of 0
proteins 0
into 0
the 0
nucleus 0
. 0

Characterization 0
of 0
the 0
promoter 0
for 0
the 0
human B-gene
85 I-gene
kDa I-gene
cytosolic I-gene
phospholipase I-gene
A2 I-gene
gene I-gene
. 0

This 0
paper 0
describes 0
the 0
advantages 0
and 0
limitations 0
of 0
the 0
main 0
study 0
approaches 0
used 0
. 0

Comparative 0
study 0
of 0
the 0
differential 0
white 0
blood 0
cell 0
count 0
using 0
three 0
automated 0
analyzers 0
: 0
Coulter 0
STKS 0
, 0
Sysmex 0
NE 0
8000 0
and 0
Technicon 0
H 0
- 0
1 0
. 0

Characterization 0
of 0
FIII/YY1 B-gene
, 0
a 0
FIII/YY1 I-gene

Further 0
studies 0
established 0
that 0
the 0
Ep B-gene
- 0
induced 0
increase 0
in 0
beta B-gene
- I-gene
globin I-gene
mRNA I-gene
could 0
be 0
inhibited 0
by 0
the 0
tyrosine B-gene
kinase I-gene
inhibitor 0
genistein 0
and 0
the 0
protein B-gene
kinase I-gene
C I-gene
inhibitor 0
Compound 0
3 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

This 0
structure 0
of 0
cucumisin B-gene
suggests 0
that 0
it 0
is 0
probably 0
synthesized 0
as 0
an 0
inactive 0
precursor 0
. 0

Molecular 0
dissection 0
of 0
the 0
multimeric 0
CD3 B-gene
- 0
TCR B-gene
complex 0
revealed 0
that 0
at 0
least 0
two 0
associated 0
polypeptides 0
, 0
CD3 B-gene
zeta I-gene
and 0
CD3 B-gene
epsilon I-gene
, 0
autonomously 0
couple 0
antigenic 0
recognition 0
event 0
to 0
early 0
and 0
late 0
events 0
of 0
the 0
intracytoplasmic 0
activation 0
cascade 0
. 0

Protein B-gene
cHMGI I-gene
binds 0
preferentially 0
to 0
AT 0
- 0
rich 0
DNA 0
with 0
a 0
half 0
- 0
saturation 0
value 0
of 0
1.1 0
nM 0
. 0

This 0
study 0
investigated 0
the 0
degree 0
to 0
which 0
racial 0
identity 0
influences 0
Mexican 0
- 0
Americans 0
' 0
performance 0
on 0
the 0
L 0
, 0
K 0
, 0
and 0
MF 0
scales 0
of 0
the 0
MMPI 0
- 0
2 0
. 0

Both 0
can 0
be 0
elevated 0
on 0
a 0
single 0
vascular 0
pedicle 0
based 0
on 0
the 0
superficial 0
temporal 0
artery 0
, 0
the 0
double 0
- 0
layered 0
temporal 0
fascia 0
flap 0
. 0

To 0
do 0
this 0
, 0
segments 0
of 0
DNA 0
from 0
the 0
5 0
' 0
flank 0
of 0
the 0
initiation 0
sites 0
for 0
germline 0
epsilon 0
RNA 0
were 0
ligated 0
to 0
a 0
luciferase B-gene
reporter I-gene
gene I-gene
and 0
transfected 0
into 0
two 0
mouse 0
B 0
cell 0
lines 0
, 0
one 0
of 0
which 0
can 0
be 0
induced 0
to 0
switch 0
to 0
IgE B-gene
. 0

The 0
negative 0
predictive 0
value 0
is 0
92 0
% 0
, 0
vs 0
80 0
% 0
for 0
the 0
NCEP 0
I 0
. 0

Oncogenic 0
capacity 0
of 0
the 0
E2F1 B-gene
gene I-gene
. 0

In 0
some 0
of 0
the 0
cases 0
of 0
solitary 0
lesion 0
, 0
serum B-gene
TSH I-gene
levels 0
, 0
serum B-gene
thyroglobulin I-gene
values 0
, 0
and 0
131I 0
protein 0
bounded 0
iodine 0
( 0
131I 0
- 0
PBI 0
) 0
were 0
measured 0
, 0
but 0
there 0
were 0
no 0
significant 0
differences 0
between 0
successful 0
and 0
unsuccessful 0
therapy 0
. 0

Endo16 B-gene
transcripts I-gene
are 0
confined 0
to 0
the 0
definitive 0
vegetal 0
plate 0
in 0
blastula 0
stage 0
embryos 0
; 0
at 0
gastrula 0
stage 0
this 0
gene 0
is 0
expressed 0
throughout 0
the 0
archenteron 0
, 0
but 0
later 0
only 0
in 0
the 0
midgut 0
. 0

A 0
unique 0
leucine 0
- 0
proline 0
repeat 0
element 0
found 0
N 0
- 0
terminal 0
to 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
EmBP B-gene
- I-gene
1 I-gene
does 0
not 0
appear 0
to 0
play 0
a 0
role 0
in 0
DNA 0
- 0
binding 0
or 0
dimerization 0
. 0

Another 0
full 0
ORF 0
was 0
found 0
on 0
the 0
opposite 0
strand 0
downstream 0
from 0
the 0
nspC B-gene
gene I-gene
. 0

The 0
U14 B-gene
genes I-gene
of 0
mouse 0
as 0
well 0
as 0
rat 0
, 0
hamster 0
, 0
human 0
, 0
Xenopus 0
and 0
trout 0
are 0
encoded 0
within 0
introns 0
of 0
the 0
constitutively 0
expressed 0
70 B-gene
- I-gene
kDa I-gene
- I-gene
cognate I-gene
- I-gene
heat I-gene
- I-gene
shock I-gene
protein I-gene
gene I-gene
( 0
hsc70 B-gene
) 0
. 0

Two 0
related 0
cDNAs 0
were 0
isolated 0
that 0
encode 0
proteins 0
that 0
recognize 0
the 0
XMyoDa B-gene
TATA I-gene
motif I-gene
. 0

Deletion 0
of 0
both 0
prfA B-gene
and 0
ponA B-gene
resulted 0
in 0
extremely 0
slow 0
growth 0
and 0
a 0
reduction 0
in 0
sporulation 0
efficiency 0
. 0

Inclusion 0
in 0
this 0
family 0
of 0
proteins 0
suggests 0
that 0
FliQ B-gene
and 0
FliR B-gene
may 0
participate 0
in 0
an 0
export 0
pathway 0
required 0
for 0
flagellum 0
assembly 0
. 0

In 0
broken 0
L 0
- 0
cell 0
membranes 0
expressing 0
wild 0
type 0
or 0
mutant B-gene
M6P/IGF I-gene
II I-gene
receptors I-gene
, 0
30 0
nM 0
IGF B-gene
II I-gene
also 0
failed 0
to 0
affect 0
the 0
pertussis B-gene
toxin I-gene
substrate 0
activity 0
. 0

Chem 0
. 0

For 0
the 0
first 0
time 0
we 0
describe 0
deletion 0
and 0
point 0
mutations 0
within 0
the 0
plasma B-gene
membrane I-gene
family I-gene
of I-gene
guanylyl I-gene
cyclase I-gene
receptors I-gene
that 0
result 0
in 0
the 0
formation 0
of 0
effective 0
dominant 0
negative 0
proteins 0
. 0

Increase 0
in 0
blood 0
NEFA 0
was 0
further 0
augmented 0
by 0
fat 0
plus 0
AA 0
supplementation 0
, 0
but 0
no 0
changes 0
in 0
concentrations 0
of 0
Lys 0
or 0
Met 0
in 0
blood 0
were 0
found 0
. 0

Virol 0
. 0

Coronary 0
vasoconstriction 0
caused 0
by 0
endothelin B-gene
- I-gene
1 I-gene
is 0
enhanced 0
by 0
ischemia 0
- 0
reperfusion 0
and 0
by 0
norepinephrine 0
present 0
in 0
concentrations 0
typically 0
observed 0
after 0
neonatal 0
cardiopulmonary 0
bypass 0
. 0

Comparison 0
of 0
the 0
deduced 0
amino B-gene
acid I-gene
sequence I-gene
of I-gene
gamma I-gene
- I-gene
kafirin I-gene
with 0
the 0
published 0
sequences B-gene
of I-gene
gamma I-gene
- I-gene
prolamins I-gene
of I-gene
maize I-gene
, I-gene
and I-gene
Coix I-gene
revealed 0
highly 0
conserved 0
domains 0
. 0

Atcys1 B-gene
, 0
Athyp1 B-gene
, 0
AKin10 B-gene
and 0
the 0
ORF 0
are 0
very 0
close 0
to 0
each 0
other 0
and 0
organized 0
in 0
the 0
same 0
polarity 0
; 0
hence 0
, 0
the 0
intergenic 0
regions 0
probably 0
contain 0
, 0
within 0
less 0
than 0
0.5 0
kb 0
, 0
all 0
the 0
regulatory 0
elements 0
necessary 0
to 0
govern 0
initiation 0
and 0
termination 0
of 0
transcription 0
. 0

Southern 0
blot 0
hybridization 0
experiments 0
suggest 0
the 0
presence 0
of 0
one 0
copy 0
of 0
Atcys1 B-gene
, 0
Athyp1 B-gene
and 0
AKin10 B-gene
per 0
haploid 0
genome 0
, 0
and 0
Northern 0
blot 0
analysis 0
demonstrates 0
that 0
the 0
three 0
genes 0
are 0
differentially 0
expressed 0
in 0
roots 0
, 0
shoots 0
and 0
leaves 0
. 0

These 0
results 0
suggest 0
that 0
HAC1 B-gene
may 0
also 0
be 0
one 0
of 0
the 0
meiotic 0
genes 0
. 0

We 0
characterized 0
three 0
Arabidopsis 0
thaliana 0
cDNA 0
clones 0
that 0
could 0
rescue 0
the 0
sterile 0
phenotype 0
of 0
the 0
Schizosaccharomyces B-gene
pombe I-gene
pde1 I-gene
mutant I-gene
, 0
which 0
is 0
defective 0
in 0
cAMP B-gene
phosphodiesterase I-gene
. 0

Furthermore 0
, 0
the 0
identification 0
of 0
a 0
Dr1 B-gene
- I-gene
like I-gene
protein I-gene
in 0
A.thaliana 0
strongly 0
argues 0
for 0
the 0
ubiquity 0
of 0
this 0
protein 0
among 0
eukaryotic 0
genera 0
and 0
for 0
a 0
conserved 0
mechanism 0
to 0
regulate 0
transcription 0
initiation 0
that 0
involves 0
Dr1 B-gene
. 0

Similarly 0
approximately 0
300 0
bp 0
of 0
sequence 0
downstream 0
of 0
the 0
translation 0
terminator 0
TGA 0
of 0
the 0
beta B-gene
- I-gene
tubulin I-gene
2 I-gene
( 0
BTU2 B-gene
) 0
gene 0
could 0
substitute 0
for 0
the 0
3 0
' 0
region 0
of 0
the 0
H4 B-gene
- I-gene
I I-gene
gene I-gene
. 0

These 0
data 0
demonstrate 0
that 0
the 0
STR B-gene
family I-gene
of 0
genes 0
is 0
represented 0
in 0
a 0
nematode 0
whose 0
ancestor 0
appeared 0
well 0
before 0
the 0
branching 0
that 0
gave 0
rise 0
to 0
the 0
Arthropoda 0
and 0
Chordata 0
. 0

The 0
pre 0
- 0
and 0
postoperative 0
haemoglobin B-gene
concentrations 0
in 0
the 0
autologous 0
group 0
were 0
lower 0
by 0
15 0
and 0
10 0
g/L 0
, 0
respectively 0
, 0
after 0
primary 0
THR 0
and 0
by 0
10 0
g/L 0
in 0
both 0
instances 0
after 0
revision 0
THR 0
. 0

The 0
introduction 0
of 0
an 0
acidic 0
residue 0
at 0
the 0
second 0
site 0
was 0
essential 0
for 0
suppression 0
of 0
the 0
Asn 0
- 0
285 0
mutation 0
because 0
Lys 0
- 0
220 0
and 0
Gln 0
- 0
220 0
second 0
- 0
site 0
mutants 0
of 0
the 0
Asn 0
- 0
285 0
mutant 0
showed 0
very 0
low 0
tetracycline 0
resistance 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
, 0
the 0
cytokine 0
that 0
participates 0
in 0
the 0
autocrine 0
growth 0
control 0
of 0
hairy 0
cell 0
leukemia 0
has 0
strong 0
bone 0
resorptive 0
properties 0
. 0

( 0
iv 0
) 0
Although 0
UCRBP B-gene
has 0
been 0
previously 0
shown 0
to 0
act 0
as 0
a 0
transcriptional 0
repressor 0
, 0
we 0
show 0
here 0
that 0
UCRBP B-gene
can 0
also 0
act 0
as 0
a 0
positive 0
transactivator 0
of 0
a 0
reporter 0
driven 0
by 0
UCR 0
elements 0
when 0
used 0
in 0
co 0
- 0
transfection 0
assays 0
. 0

The 0
sequence 0
of 0
monkey B-gene
opsin I-gene
closely 0
resembles 0
the 0
human 0
sequence 0
at 0
the 0
nucleotide 0
and 0
the 0
amino 0
acid 0
levels 0
, 0
with 0
the 0
latter 0
having 0
only 0
7 0
differences 0
out 0
of 0
348 0
residues 0
. 0

One 0
complex 0
appears 0
to 0
be 0
ubiquitous 0
but 0
enriched 0
in 0
lymphoid 0
cells 0
and 0
represents 0
the 0
binding 0
of 0
a 0
potentially 0
novel 0
factor 0
with 0
an 0
apparent 0
molecular 0
mass 0
of 0
approximately 0
50 0
kDa 0
. 0

Chem 0
. 0

Conversely 0
, 0
activation 0
of 0
Oct B-gene
- I-gene
3/4 I-gene
promoter I-gene
by 0
RAR B-gene
: 0
RXR B-gene
heterodimers I-gene
was 0
completely 0
abolished 0
by 0
EAR B-gene
- I-gene
3/COUP I-gene
3/COUP I-gene
- I-gene
TFI I-gene
and 0
by 0
ARP B-gene
- I-gene
1/COUP I-gene
1/COUP I-gene
- I-gene
TFII I-gene
. 0

These 0
results 0
demonstrate 0
that 0
EKLF B-gene
provides 0
a 0
crucial 0
transactivation 0
function 0
for 0
globin B-gene
expression 0
and 0
further 0
reinforce 0
the 0
idea 0
that 0
EKLF B-gene
is 0
an 0
important 0
regulator 0
of 0
CACCC 0
element 0
- 0
directed 0
transcription 0
in 0
erythroid 0
cells 0
. 0

Using 0
a 0
battery 0
of 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
mutants I-gene
, 0
we 0
show 0
that 0
( 0
i 0
) 0
a 0
dimer 0
binds 0
a 0
single 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
molecule I-gene
, 0
( 0
ii 0
) 0
the 0
acidic 0
C 0
- 0
terminal 0
region 0
of 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
is 0
not 0
required 0
for 0
protein 0
- 0
protein 0
binding 0
and 0
does 0
not 0
mask 0
the 0
nuclear 0
localization 0
signal 0
of 0
the 0
dimer 0
, 0
( 0
iii 0
) 0
the 0
same 0
C 0
- 0
terminal 0
region 0
is 0
required 0
for 0
inhibition 0
of 0
DNA 0
binding 0
, 0
and 0
( 0
iv 0
) 0
this 0
inhibition 0
may 0
be 0
accomplished 0
by 0
direct 0
interaction 0
between 0
the 0
PEST 0
- 0
like 0
region 0
and 0
the 0
DNA 0
- 0
binding 0
region 0
of 0
one 0
of 0
the 0
subunits 0
of 0
the 0
dimer 0
. 0

The 0
negative 0
regulatory 0
activity 0
of 0
the 0
N 0
- 0
terminal 0
domain 0
was 0
antagonized 0
by 0
a 0
C 0
- 0
terminal 0
segment 0
of 0
Pho81p B-gene
supplied 0
in 0
trans 0
. 0

At 0
different 0
times 0
of 0
the 0
surgical 0
procedures 0
( 0
thorax 0
opening 0
and 0
closure 0
, 0
period 0
of 0
cardiopulmonary 0
bypass 0
) 0
67 0
to 0
100 0
% 0
of 0
the 0
patients 0
in 0
group 0
1 0
had 0
vancomycin 0
concentrations 0
in 0
the 0
studied 0
tissues 0
above 0
the 0
MIC 0
90 0
for 0
Staphylococcus 0
aureus 0
( 0
1 0
microgram/g 0
) 0
and 0
Staphylococcus 0
epidermidis 0
( 0
2 0
micrograms/g 0
) 0
. 0

On 0
- 0
line 0
angioscopic 0
images 0
of 0
tissue 0
flaps 0
floating 0
in 0
the 0
lumen 0
, 0
recent 0
or 0
structured 0
thrombi 0
, 0
artery 0
wall 0
dissections 0
, 0
plaque 0
ruptures 0
, 0
deep 0
fissurations 0
and 0
sub 0
- 0
intimal 0
haemorrhages 0
demonstrate 0
, 0
in 0
live 0
colour 0
, 0
the 0
pathophysiological 0
mechanisms 0
of 0
coronary 0
artery 0
stenosis 0
. 0

The 0
enhanced 0
cysteine 0
formation 0
in 0
a 0
pCSK4F 0
plant 0
responding 0
to 0
sulfite 0
was 0
also 0
observed 0
in 0
leaf 0
discs 0
. 0

Each 0
type 0
was 0
divided 0
into 0
two 0
subgroups 0
on 0
the 0
basis 0
of 0
whether 0
the 0
body 0
and 0
tail 0
of 0
the 0
pancreas 0
showed 0
intense 0
fatty 0
replacement 0
( 0
type 0
a 0
= 0
negative 0
for 0
intense 0
fatty 0
replacement 0
, 0
type 0
b 0
= 0
positive 0
for 0
intense 0
fatty 0
replacement 0
) 0
. 0

Between 0
the 0
subgroups 0
of 0
dementia 0
disorders 0
there 0
were 0
no 0
significant 0
differences 0
in 0
basal 0
cortisol 0
levels 0
. 0

A 0
new 0
hypothesis 0
on 0
mechanisms 0
for 0
inhibiting 0
catalytic 0
subunits 0
by 0
gamma 0
- 0
subunits 0
and 0
activation 0
of 0
a 0
holoenzyme 0
by 0
transducin B-gene

Basal 0
components 0
of 0
the 0
transcription 0
apparatus 0
( 0
RNA B-gene
polymerase I-gene
II I-gene
, 0
TATA B-gene
- I-gene
binding I-gene
protein I-gene
) 0
contain 0
activation 0
domains 0
: 0
is 0
the 0
repetitive 0
C 0
- 0
terminal 0
domain 0
( 0
CTD 0
) 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
a 0
`` 0
portable 0
enhancer 0
domain 0
'' 0
? 0
Regions 0
rich 0
in 0
serine 0
, 0
threonine 0
, 0
and 0
proline 0
residues 0
can 0
be 0
found 0
in 0
transcriptional 0
activation 0
domains 0
, 0
as 0
well 0
as 0
in 0
the 0
N 0
- 0
terminal 0
parts 0
of B-gene
mammalian I-gene
TATA I-gene
- I-gene
binding I-gene
proteins I-gene
, 0
where 0
they 0
are 0
interrupted 0
by 0
polyglutamine 0
stretches 0
. 0

Mutagenesis 0
of 0
IM1 B-gene
enhances 0
the 0
ability 0
of 0
c B-gene
- I-gene
Fos I-gene
to 0
activate 0
an 0
AP1 B-gene
bearing I-gene
promoter I-gene
. 0

Binding 0
of 0
SSP B-gene
to 0
the 0
stage B-gene
selector I-gene
element I-gene
( 0
SSE B-gene
) 0
in 0
the 0
proximal 0
gamma B-gene
- I-gene
globin I-gene
promoter I-gene
is 0
integral 0
to 0
the 0
competitive 0
silencing 0
of 0
a 0
linked 0
beta B-gene
- I-gene
promoter I-gene
in 0
embryonic/fetal 0
stage 0
erythroleukemia 0
( 0
K562 0
) 0
cells 0
. 0

This 0
failure 0
to 0
execute 0
regulated 0
G1/S 0
arrest 0
is 0
correlated 0
with 0
enhanced 0
thermosensitivity 0
of 0
colony 0
- 0
forming 0
ability 0
. 0

Mutations 0
that 0
alter 0
photoreceptor 0
cell 0
structure 0
and 0
development 0
were 0
isolated 0
that 0
fail 0
to 0
complement 0
these 0
deletions 0
. 0

It 0
is 0
possible 0
that 0
the 0
telomeres 0
of 0
the 0
two 0
nuclei 0
have 0
different 0
functions 0
. 0

The 0
marker 0
orders 0
from 0
the 0
genetic 0
and 0
RH 0
maps 0
were 0
consistent 0
. 0

Integrated 0
mapping 0
analysis 0
of 0
the 0
Werner 0
syndrome 0
region 0
of 0
chromosome 0
8 0
. 0

The 0
region 0
between 0
DXS52 B-gene
and 0
Factor B-gene
VIII I-gene
gene I-gene
in 0
the 0
human 0
Xq28 0
chromosomal 0
band 0
contains 0
a 0
G+C 0
- 0
rich 0
isochore 0
to 0
which 0
many 0
genes 0
have 0
been 0
mapped 0
. 0

Haplotype 0
mapping 0
and 0
sequence 0
analysis 0
of 0
the 0
mouse 0
Nramp B-gene
gene I-gene
predict 0
susceptibility 0
to 0
infection 0
with 0
intracellular 0
parasites 0
. 0

This 0
utilization 0
of 0
an 0
intronic 0
polyadenylation 0
site 0
without 0
alternative 0
exon 0
usage 0
is 0
comparable 0
to 0
the 0
mechanism 0
whereby 0
both 0
secreted 0
and 0
membrane 0
- 0
bound 0
forms 0
of 0
the 0
immunoglobulin B-gene
mu I-gene
heavy I-gene
chain I-gene
are 0
made 0
from 0
a 0
single 0
genetic 0
locus 0
. 0

To 0
further 0
our 0
knowledge 0
about 0
the 0
systemic 0
humoral 0
immune 0
system 0
response 0
to 0
weak 0
hapten 0
- 0
syngeneic 0
or 0
allogeneic 0
protein 0
conjugates 0
( 0
corrosion 0
and 0
wear 0
products 0
of 0
metallic 0
orthopedic 0
devices 0
) 0
, 0
a 0
sensitive 0
enzyme 0
- 0
linked 0
immunosorbent 0
assay 0
( 0
ELISA 0
) 0
method 0
for 0
testing 0
for 0
antibody 0
( 0
humoral 0
immunity 0
) 0
to 0
metals 0
was 0
developed 0
. 0

In 0
contrast 0
, 0
peak 0
filling 0
rate 0
( 0
PFR 0
) 0
, 0
normalized 0
to 0
end 0
diastolic 0
volume 0
( 0
EDV 0
) 0
, 0
or 0
stroke 0
volume 0
( 0
SV 0
) 0
, 0
or 0
expressed 0
as 0
the 0
ratio 0
of 0
PFR 0
- 0
to 0
- 0
PER 0
was 0
reduced 0
( 0
p 0
< 0
0.01 0
) 0
, 0
time 0
to 0
PFR 0
( 0
TPFR 0
) 0
was 0
prolonged 0
( 0
p 0
< 0
0.01 0
) 0
, 0
and 0
echocardiographic 0
left 0
ventricular 0
mass 0
index 0
was 0
higher 0
( 0
p 0
< 0
0.001 0
) 0
in 0
patients 0
with 0
acromegaly 0
compared 0
to 0
normals 0
. 0

A 0
genetic 0
complementation 0
system 0
was 0
developed 0
in 0
which 0
tobacco B-gene
etch I-gene
virus I-gene
( I-gene
TEV I-gene
) I-gene
polymerase I-gene
( 0
NIb B-gene
) 0
- 0
expressing 0
transgenic 0
plants 0
or 0
protoplasts 0
were 0
inoculated 0
with 0
NIb B-gene
- 0
defective 0
TEV B-gene
mutants I-gene
. 0

Nucleotide 0
sequence 0
and 0
transcriptional 0
analysis 0
of 0
the 0
DNA B-gene
polymerase I-gene
gene I-gene
of I-gene
Bombyx I-gene
mori I-gene
nuclear I-gene
polyhedrosis I-gene
virus I-gene
. 0

Comparison 0
of 0
the 0
genomes 0
of 0
PMTV 0
, 0
BNYVV 0
, 0
and 0
SBWMV 0
shows 0
that 0
furoviruses 0
exhibit 0
considerable 0
heterogeneity 0
in 0
genome 0
organization 0
. 0

The 0
drug 0
sensitivity 0
was 0
100 0
% 0
for 0
vancomycin 0
( 0
VCM 0
) 0
, 0
30 0
% 0
for 0
imipenam 0
( 0
IMP 0
) 0
, 0
31 0
% 0
for 0
minomycin 0
( 0
MINO 0
) 0
, 0
31 0
% 0
for 0
amikacin 0
( 0
AMK 0
) 0
, 0
and 0
7 0
% 0
for 0
fosfomycin 0
( 0
FOM 0
) 0
. 0

Deglycosylation 0
with 0
endoglycosidase B-gene
H I-gene
showed 0
that 0
the 0
mutant 0
receptors 0
had 0
mainly 0
high 0
- 0
mannose 0
oligosaccharide 0
chains 0
. 0

Dietary 0
supplement 0
with 0
fish 0
oil 0
and 0
related 0
n 0
- 0
3 0
EFAs 0
has 0
been 0
used 0
to 0
study 0
their 0
antihypertensive 0
property 0
in 0
animals 0
and 0
humans 0
with 0
borderline 0
and 0
essential 0
hypertension 0
. 0

The 0
HSD3B1 B-gene
and 0
HSD3B2 B-gene
genes I-gene
encoding 0
the 0
types B-gene
I I-gene
and I-gene
II I-gene
3 I-gene
beta I-gene
- I-gene
HSD I-gene
isoenzymes I-gene
, 0
respectively 0
, 0
have 0
been 0
previously 0
assigned 0
by 0
in 0
situ 0
hybridization 0
to 0
the 0
chromosome 0
1p13.1 0
region 0
. 0

Therefore 0
the 0
prevalences 0
of 0
total 0
diabetes 0
and 0
GDM 0
were 0
1.19 0
% 0
and 0
0.56 0
% 0
, 0
respectively 0
. 0

Insulin B-gene
- 0
stimulated 0
glucose 0
transport 0
in 0
adipocytes 0
is 0
mediated 0
by 0
the 0
insulin B-gene
receptor I-gene
. 0

After 0
selection 0
and 0
conversion 0
to 0
adipocytes 0
, 0
the 0
level 0
of 0
EGFR B-gene
expression 0
was 0
retained 0
in 0
infectant 0
adipocytes 0
( 0
150,000 0
and 0
250,000/cell 0
, 0
respectively 0
) 0
, 0
but 0
not 0
in 0
the 0
parental 0
3T3 0
- 0
L1 0
adipocytes 0
( 0
< 0
5000/cell 0
) 0
. 0

Intron 0
- 0
exon 0
structure 0
of 0
the 0
porcine B-gene
I I-gene
kappa I-gene
B I-gene
alpha I-gene
- I-gene
encoding I-gene
gene I-gene
. 0

Fraction 0
2 0
contains 0
1,25 0
( 0
OH 0
) 0
2 0
- 0
vitamin 0
D3 0
, 0
vitamin 0
D3 0
, 0
25 0
( 0
OH 0
) 0
- 0
vitamin 0
D3 0
and 0
1,24,25 0
( 0
OH 0
) 0
3 0
- 0
vitamin 0
D3 0
. 0

The 0
kallistatin B-gene
gene I-gene
was 0
localized 0
by 0
in 0
situ 0
hybridization 0
to 0
human 0
chromosome 0
14q31 0
- 0
q32.1 0
, 0
close 0
to 0
the 0
serpin B-gene
genes I-gene
encoding 0
alpha B-gene
1 I-gene
- I-gene
antichymotrypsin I-gene
, 0
protein B-gene
C I-gene
inhibitor I-gene
, 0
alpha B-gene
1 I-gene
- I-gene
antitrypsin I-gene
, 0
and 0
corticosteroid B-gene
- I-gene
binding I-gene
globulin I-gene
. 0

The 0
locus 0
encoding 0
the 0
XD B-gene
gene I-gene
( 0
designated 0
Xd B-gene
) 0
was 0
mapped 0
to 0
the 0
distal 0
part 0
of 0
mouse 0
chromosome 0
17 0
by 0
haplotype 0
analysis 0
of 0
114 0
interspecific 0
backcross 0
mice 0
. 0

Some 0
studies 0
of 0
exercise 0
have 0
associated 0
beta B-gene
- I-gene
endorphin I-gene
release 0
with 0
increased 0
exertion 0
levels 0
, 0
but 0
other 0
evidence 0
suggests 0
that 0
acidosis 0
may 0
stimulate 0
the 0
release 0
of 0
beta B-gene
- I-gene
endorphin I-gene
. 0

An 0
interatrial 0
communication 0
mitigates 0
the 0
impairment 0
of 0
LV 0
function 0
after 0
an 0
acute 0
and 0
sustained 0
drop 0
of 0
intrathoracic 0
pressure 0
. 0

Self 0
or 0
foreign 0
cellular 0
proteins 0
provide 0
peptides 0
for 0
presentation 0
by 0
major B-gene
histocompatibility I-gene
complex I-gene
( I-gene
MHC I-gene
) I-gene
class I-gene
I I-gene
molecules I-gene
on 0
the 0
surface 0
of 0
antigen 0
presenting 0
cells 0
( 0
APC 0
) 0
. 0

The 0
characteristics 0
of 0
the 0
VirD1/VirD2 B-gene
- 0
mediated 0
cleavage 0
reaction 0
strongly 0
resemble 0
those 0
observed 0
with 0
relaxosomes 0
of 0
IncP 0
plasmids 0
involved 0
in 0
initiation 0
of 0
transfer 0
DNA 0
replication 0
during 0
bacterial 0
conjugation 0
. 0

Isoelectric 0
focusing 0
of 0
tryptic 0
peptides 0
generated 0
from 0
MHC B-gene
- I-gene
B I-gene
phosphorylated 0
with 0
cdc2 B-gene
kinase I-gene
revealed 0
one 0
major 0
phosphopeptide 0
that 0
was 0
purified 0
by 0
reverse 0
- 0
phase 0
high 0
performance 0
liquid 0
chromatography 0
and 0
sequenced 0
. 0

The 0
deduced 0
protein 0
sequence 0
was 0
88 0
% 0
homologous 0
to 0
that 0
of 0
hNUC B-gene
I I-gene
, 0
isolated 0
from 0
human 0
osteosarcoma 0
cells 0
. 0

However 0
, 0
cotransfection 0
studies 0
indicate 0
that 0
RVR B-gene
does 0
not 0
activate 0
transcription 0
when 0
this 0
hormone 0
response 0
element 0
is 0
linked 0
to 0
a 0
reporter 0
gene 0
but 0
rather 0
acts 0
as 0
a 0
potent 0
competitive 0
repressor 0
of 0
ROR B-gene
alpha I-gene
function 0
. 0

A 0
comparison 0
of 0
the 0
Flavobacterium 0
glycosylasparaginase B-gene
with 0
a 0
mammalian 0
glycosylasparaginase B-gene
revealed 0
30 0
% 0
structural 0
identity 0
and 0
60 0
% 0
overall 0
similarity 0
between 0
the 0
prokaryotic 0
and 0
eukaryotic 0
forms 0
of 0
the 0
enzyme 0
. 0

Dissociation 0
and 0
complexation 0
of 0
the 0
fluoroquinolone 0
antimicrobials 0
- 0
- 0
an 0
update 0
. 0

Superoxide B-gene
dismutase I-gene
( 0
SOD B-gene
) 0
activity 0
decreased 0
significantly 0
in 0
sperm 0
subjected 0
to 0
direct 0
electric 0
current 0
in 0
comparison 0
to 0
the 0
control 0
or 0
the 0
sample 0
incubated 0
with 0
electrolyzed 0
medium 0
. 0

These 0
studies 0
indicate 0
that 0
in 0
vitro 0
and 0
in 0
vivo 0
electrical 0
stimulation 0
generate 0
reactive 0
oxygen 0
species 0
and 0
affect 0
SOD B-gene
activity 0
, 0
which 0
in 0
part 0
are 0
responsible 0
for 0
decreased 0
sperm 0
motion 0
and 0
viability 0
. 0

Molecular 0
cloning 0
and 0
sequencing 0
of 0
a 0
cDNA 0
encoding 0
SR B-gene
beta I-gene
revealed 0
that 0
SR B-gene
beta I-gene
is 0
a 0
transmembrane 0
protein 0
and 0
, 0
like 0
SR B-gene
alpha I-gene
and 0
SRP54 B-gene
, 0
is 0
a 0
member 0
of 0
the 0
GTPase B-gene
superfamily I-gene
. 0

To 0
understand 0
the 0
function 0
of 0
receptor B-gene
- I-gene
linked I-gene
tyrosine I-gene
phosphatases I-gene
in 0
neural 0
development 0
, 0
we 0
sought 0
to 0
identify 0
LAR B-gene
isoforms I-gene
preferentially 0
expressed 0
in 0
the 0
nervous 0
system 0
and 0
cellular 0
processes 0
regulating 0
LAR B-gene
alternative 0
splicing 0
. 0

Sex 0
selection 0
via 0
albumin B-gene
columns 0
: 0
20 0
years 0
of 0
results 0
. 0

135 0
students 0
had 0
a 0
count 0
of 0
less 0
than 0
50 0
eggs/10 0
ml 0
. 0
urine 0
and 0
56 0
had 0
more 0
than 0
50 0
eggs/10ml 0
. 0

They 0
also 0
reported 0
that 0
E B-gene
mu I-gene
pim I-gene
- I-gene
1 I-gene
transgenic 0
mice 0
show 0
greatly 0
accelerated 0
lymphoma 0
development 0
when 0
infected 0
with 0
wild 0
- 0
type 0
M 0
- 0
MuLV 0
at 0
birth 0
. 0

Comparison 0
of 0
human B-gene
and I-gene
murine I-gene
blk I-gene
sequences I-gene
indicated 0
that 0
they 0
share 0
86 0
% 0
amino 0
acid 0
identity 0
, 0
the 0
most 0
conserved 0
region 0
being 0
the 0
catalytic 0
domain 0
( 0
93 0
% 0
identity 0
) 0
. 0

Chrispeels 0
[ 0
1993 0
] 0
EMBO 0
J 0
12 0
: 0
2241 0
- 0
2247 0
) 0
. 0

The 0
mRNAs 0
of 0
the 0
GRF B-gene
genes I-gene
are 0
encoded 0
by 0
six 0
exons 0
interrupted 0
by 0
five 0
introns 0
. 0

The 0
effect 0
of 0
ethanol 0
on 0
human 0
sensorimotor 0
reactivity 0
was 0
assessed 0
by 0
examining 0
the 0
acoustic 0
startle 0
response 0
. 0

Digitalis 0
glycosides 0
or 0
beta B-gene
- I-gene
receptor I-gene
antagonists 0
are 0
not 0
helpful 0
in 0
the 0
therapy 0
of 0
this 0
form 0
of 0
atrial 0
fibrillation 0
whereas 0
class 0
I 0
antiarrhythmic 0
drugs 0
have 0
been 0
shown 0
to 0
be 0
more 0
effective 0
. 0

Atrial 0
fibrillation 0
and 0
the 0
autonomic 0
nervous 0
system 0

VIII 0
in 0
doses 0
2 0
- 0
3 0
times 0
higher 0
than 0
usually 0
used 0
in 0
haemophiliacs 0
without 0
inhibitor 0
were 0
successful 0
. 0

A 0
reduction 0
of 0
the 0
aspartate B-gene
aminotransferase I-gene
activity 0
was 0
observed 0
from 0
800 0
mg/kg 0
b.w./d 0
onwards 0
. 0

Thus 0
, 0
these 0
studies 0
indicate 0
that 0
the 0
104 0
- 0
kDa 0
isoform 0
is 0
required 0
for 0
normal 0
proliferation 0
of 0
female 0
germline 0
cells 0
and 0
perhaps 0
for 0
oocyte 0
differentiation 0
. 0

Physical 0
analysis 0
maps 0
SAL6 B-gene
to 0
chromosome 0
XVI 0
between 0
TPK2 B-gene
and 0
spt14 B-gene
. 0

The 0
newly 0
devised 0
DCT 0
method 0
yields 0
reliable 0
data 0
in 0
measuring 0
TBF 0
. 0

Removal 0
of 0
PDMP 0
from 0
the 0
cell 0
medium 0
resulted 0
in 0
reversal 0
of 0
the 0
cell 0
cycle 0
changes 0
, 0
with 0
cells 0
re 0
- 0
entering 0
the 0
S 0
phase 0
. 0

Rho B-gene
GDP/GTP I-gene
exchange I-gene
inhibitor I-gene
, 0
Rho B-gene
GDI I-gene
, 0
comigrated 0
with 0
Rac2 B-gene
and 0
RhoA B-gene
, 0
but 0
not 0
Rac1 B-gene
. 0

A 0
major 0
task 0
for 0
sports 0
scientists 0
may 0
be 0
to 0
verify 0
empirically 0
the 0
nature 0
of 0
an 0
integrated 0
model 0
of 0
the 0
sport 0
performer 0
. 0

Schnell 0
, 0
J 0
. 0

Encapsidation 0
of 0
poliovirus 0
replicons 0
encoding 0
the 0
complete 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
gag I-gene
gene I-gene
by 0
using 0
a 0
complementation 0
system 0
which 0
provides 0
the 0
P1 B-gene
capsid I-gene
protein I-gene
in 0
trans 0
. 0

Removal 0
of 0
the 0
GST B-gene
domain I-gene
from 0
GST B-gene
- 0
Tax B-gene
by 0
thrombin B-gene
restores 0
Tax B-gene
's 0
ability 0
to 0
assemble 0
a 0
ternary 0
Tax B-gene
- 0
CREB B-gene
- 0
21 0
- 0
bp 0
- 0
repeat 0
complex 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

The 0
requirement 0
of 0
PilE B-gene
in 0
pilus 0
biogenesis 0
was 0
confirmed 0
by 0
demonstrating 0
that 0
chromosomal B-gene
pilE I-gene
insertion I-gene
mutants I-gene
were 0
pilus 0
- 0
and 0
twitching 0
- 0
motility 0
deficient 0
. 0

The 0
pilE B-gene
gene I-gene
product I-gene
of I-gene
Pseudomonas I-gene
aeruginosa I-gene
, 0
required 0
for 0
pilus 0
biogenesis 0
, 0
shares 0
amino 0
acid 0
sequence 0
identity 0
with 0
the 0
N 0
- 0
termini 0
of 0
type B-gene
4 I-gene
prepilin I-gene
proteins I-gene
. 0

Because 0
of 0
the 0
functional 0
conservation 0
of 0
cell 0
cycle 0
control 0
elements 0
, 0
the 0
expression 0
of 0
a 0
vertebrate B-gene
wee1 I-gene
or 0
mik1 B-gene
homolog I-gene
would 0
be 0
expected 0
to 0
rescue 0
such 0
lethal 0
mutations 0
in 0
yeast 0
. 0

The 0
expression 0
of 0
this 0
clone 0
in 0
a 0
wee1/mik1 B-gene
- 0
deficient 0
mutant 0
causes 0
an 0
elongated 0
cell 0
phenotype 0
under 0
non 0
- 0
permissive 0
growth 0
conditions 0
. 0

These 0
data 0
indicate 0
that 0
phosphorylation 0
of 0
M B-gene
protein I-gene
at 0
the 0
major 0
in 0
vivo 0
sites 0
is 0
not 0
essential 0
for 0
virus 0
assembly 0
. 0

Near 0
a 0
third 0
( 0
31.6 0
% 0
) 0
of 0
Insulin B-gene
Dependent 0
and 0
a 0
third 0
( 0
33.41 0
% 0
) 0
for 0
Non 0
Insulin B-gene
Dependent 0
were 0
of 0
D 0
, 0
F 0
, 0
H 0
White 0
's 0
Class 0
. 0

The 0
activity 0
of 0
6 0
- 0
fluoroquinolones 0
and 0
their 0
nonfluorinated 0
derivatives 0
is 0
compared 0
in 0
general 0
. 0

As 0
the 0
half 0
- 0
life 0
of 0
the 0
compound 0
did 0
never 0
exceed 0
8 0
- 0
9 0
h 0
, 0
the 0
data 0
do 0
not 0
support 0
any 0
change 0
of 0
pidotimod 0
administration 0
schedule 0
( 0
every 0
24 0
- 0
12 0
h 0
) 0
. 0

The 0
MAP B-gene
kinase I-gene
cascade 0
is 0
highly 0
conserved 0
in 0
all 0
eukaryotes 0
and 0
involved 0
in 0
numerous 0
cellular 0
responses 0
. 0

A 0
comparative 0
study 0
by 0
holographic 0
interferometry 0
of 0
ten 0
porcine 0
bioprosthetic 0
valves 0
( 0
seven 0
Carpentier 0
- 0
Edwards 0
SAV 0
, 0
two 0
BioImplant 0
and 0
one 0
Valcor 0
) 0
with 0
five 0
human 0
aortic 0
valves 0
before 0
and 0
after 0
glutaraldehyde 0
treatment 0
is 0
presented 0
. 0

No 0
serious 0
side 0
effects 0
were 0
observed 0
. 0

This 0
region 0
constitutes 0
the 0
DNA 0
- 0
binding 0
domain 0
with 0
basic 0
- 0
helix 0
- 0
loop 0
- 0
helix 0
and 0
leucine 0
- 0
zipper 0
motifs 0
, 0
features 0
common 0
to 0
the 0
myc B-gene
- I-gene
related I-gene
transcription I-gene
factor I-gene
family I-gene
. 0

Specific 0
binding 0
was 0
not 0
observed 0
with 0
either 0
the 0
orthologous 0
rat 0
or 0
mouse 0
fragments 0
using 0
human 0
or 0
rodent 0
extracts 0
. 0

The 0
mean 0
jitter 0
and 0
the 0
fiber 0
density 0
did 0
not 0
change 0
significantly 0
from 0
day 0
0 0
( 0
30.1 0
+/ 0
- 0
3.6 0
microseconds 0
; 0
1.4 0
+/ 0
- 0
0.07 0
) 0
to 0
day 0
30 0
( 0
34.5 0
+/ 0
- 0
2.7 0
microseconds 0
; 0
1.6 0
+/ 0
- 0
0.13 0
) 0
. 0

Lack 0
of 0
cyclin B-gene
D I-gene
- 0
Cdk B-gene
complexes 0
in 0
Rb B-gene
- 0
negative 0
cells 0
correlates 0
with 0
high 0
levels 0
of 0
p16INK4/MTS1 B-gene
tumour 0
suppressor 0
gene 0
product 0
. 0

Recombinant B-gene
human I-gene
serum I-gene
albumin I-gene
( 0
rHSA B-gene
) 0
produced 0
by 0
cultured 0
fermentation 0
has 0
been 0
prepared 0
in 0
the 0
form 0
of 0
microcapsules 0
nominally 0
3 0
- 0
5 0
microns 0
in 0
diameter 0
and 0
radiolabelled 0
with 0
technetium 0
- 0
99m 0
following 0
reduction 0
with 0
stannous 0
chloride 0
. 0

We 0
have 0
measured 0
the 0
release 0
of 0
interleukin B-gene
- I-gene
1 I-gene
beta I-gene
( 0
IL B-gene
- I-gene
1 I-gene
) 0
and 0
tumour B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNF B-gene
) 0
by 0
unstimulated 0
monocytes 0
and 0
monocytes 0
stimulated 0
with 0
lipopolysaccharide 0
( 0
LPS 0
) 0
isolated 0
from 0
the 0
peripheral 0
blood 0
of 0
two 0
patients 0
with 0
acute 0
poststreptococcal 0
glomerulonephritis 0
( 0
AGN 0
) 0
and 0
16 0
healthy 0
controls 0
. 0

Such 0
an 0
intervention 0
may 0
be 0
of 0
considerable 0
use 0
for 0
the 0
treatment 0
of 0
angiogenesis 0
- 0
dependent 0
diseases 0
involving 0
FGF B-gene
- I-gene
2 I-gene
. 0

We 0
have 0
attempted 0
to 0
clone 0
two 0
recessive 0
extragenic 0
suppressors 0
of 0
such 0
ts 0
mutants 0
( 0
sdp1 B-gene
for 0
mutation B-gene
pol3 I-gene
- I-gene
14 I-gene
and 0
sdp5 B-gene
- I-gene
1 I-gene
for 0
mutation B-gene
pol3 I-gene
- I-gene
11 I-gene
) 0
by 0
transforming 0
thermoresistant 0
haploid 0
strains 0
pol3 B-gene
- I-gene
14 I-gene
sdp1 I-gene
and 0
pol3 B-gene
- I-gene
11 I-gene
sdp5 I-gene
- I-gene
1 I-gene
with 0
wild 0
- 0
type 0
genomic 0
libraries 0
in 0
singlecopy 0
or 0
multicopy 0
vectors 0
. 0

UV 0
cross 0
- 0
linking 0
experiments 0
show 0
that 0
TEP B-gene
has 0
an 0
apparent 0
molecular 0
mass 0
of 0
approximately 0
65 0
kDa 0
. 0

In 0
acute 0
- 0
phase 0
livers 0
, 0
we 0
observed 0
a 0
dramatic 0
reduction 0
in 0
HNF B-gene
- I-gene
3 I-gene
alpha I-gene
expression 0
which 0
correlates 0
with 0
a 0
decrease 0
in 0
the 0
expression 0
of 0
its 0
target 0
gene 0
, 0
the 0
TTR B-gene
gene I-gene
. 0

Alternatively 0
, 0
loss 0
- 0
of 0
- 0
function 0
alleles 0
of 0
genes 0
that 0
inhibit 0
cAPK B-gene
lead 0
to 0
the 0
inability 0
to 0
undergo 0
sexual 0
differentiation 0
. 0

One 0
member 0
of 0
this 0
family 0
, 0
RFX1 B-gene
, 0
is 0
a 0
transcription 0
factor 0
for 0
a 0
variety 0
of 0
viral 0
and 0
cellular 0
genes 0
. 0

This 0
mutant 0
was 0
identified 0
by 0
screening 0
with 0
a 0
TGF B-gene
- I-gene
beta I-gene
- 0
inducible 0
vector 0
a 0
series 0
of 0
mink 0
lung 0
epithelial 0
cell 0
clones 0
that 0
have 0
normal 0
TGF B-gene
- I-gene
beta I-gene
binding 0
activity 0
but 0
have 0
lost 0
antiproliferative 0
and 0
transcriptional 0
responses 0
to 0
TGF B-gene
- I-gene
beta I-gene
. 0

Cloning 0
by 0
complementation 0
and 0
subsequent 0
physical 0
and 0
genetic 0
analysis 0
revealed 0
that 0
it 0
maps 0
to 0
RAF1 B-gene
. 0

In 0
the 0
presence 0
of 0
inositol 0
and 0
choline 0
( 0
repressing 0
) 0
, 0
the 0
product 0
of 0
the 0
OPI1 B-gene
gene I-gene
represses 0
transcription 0
dictated 0
by 0
the 0
UASINO 0
element 0
. 0

By 0
treating 0
monkey 0
COS 0
cells 0
with 0
oligonucleotides 0
linked 0
to 0
psoralen 0
, 0
we 0
have 0
generated 0
targeted 0
mutations 0
in 0
a 0
simian 0
virus 0
40 0
( 0
SV40 0
) 0
vector 0
contained 0
within 0
the 0
cells 0
via 0
intracellular 0
triple 0
helix 0
formation 0
. 0

The 0
interleukin B-gene
2 I-gene
receptor I-gene
alpha I-gene
- I-gene
chain I-gene
( 0
IL B-gene
- I-gene
2R I-gene
alpha I-gene
) 0
gene 0
is 0
rapidly 0
and 0
potently 0
induced 0
in 0
T 0
cells 0
in 0
response 0
to 0
mitogenic 0
stimuli 0
. 0

The 0
Wilms B-gene
' I-gene
tumour I-gene
suppressor I-gene
protein I-gene
( 0
WT1 B-gene
) 0
is 0
a 0
putative 0
transcriptional 0
regulatory 0
protein 0
with 0
four 0
zinc 0
fingers 0
, 0
the 0
last 0
three 0
of 0
which 0
have 0
extensive 0
sequence 0
homology 0
to 0
the 0
early B-gene
growth I-gene
response I-gene
- I-gene
1 I-gene
( 0
EGR B-gene
- I-gene
1 I-gene
) 0
protein 0
. 0

OBJECTIVES 0
: 0
1 0
) 0
to 0
determine 0
serum B-gene
ACE I-gene
activity 0
in 0
patients 0
with 0
COPD 0
treated 0
with 0
and 0
without 0
continuous 0
ambulatory 0
oxygen 0
therapy 0
( 0
CAOT 0
) 0
; 0
2 0
) 0
to 0
verify 0
whether 0
there 0
is 0
a 0
correlation 0
between 0
ACE B-gene
and 0
any 0
hematological 0
, 0
spirometric 0
or 0
gasometric 0
parameter 0
. 0

In 0
order 0
to 0
infer 0
shape 0
from 0
contour 0
, 0
the 0
human 0
visual 0
system 0
must 0
selectively 0
integrate 0
fragments 0
projecting 0
from 0
a 0
common 0
object 0
while 0
keeping 0
fragments 0
from 0
different 0
objects 0
separate 0
. 0

Among 0
9 0
group 0
I 0
patients 0
with 0
a 0
positive 0
result 0
on 0
head 0
- 0
up 0
tilt 0
- 0
table 0
testing 0
and 0
no 0
evidence 0
of 0
structural 0
heart 0
disease 0
( 0
mean 0
follow 0
- 0
up 0
4.3 0
years 0
) 0
, 0
7 0
are 0
without 0
further 0
episodes 0
of 0
syncope 0
; 0
3 0
have 0
discontinued 0
medication 0
and 0
5 0
have 0
resumed 0
at 0
least 0
limited 0
exercise 0
. 0

Constructs 0
designed 0
and 0
expressed 0
were 0
E2L1 B-gene
( I-gene
1 I-gene
- I-gene
98 I-gene
) I-gene
, 0
E2L1.H1 B-gene
( I-gene
1 I-gene
- I-gene
128 I-gene
) I-gene
, 0
E2L2 B-gene
( I-gene
120 I-gene
- I-gene
233 I-gene
) I-gene
, 0
E2H1.L2 B-gene
( I-gene
98 I-gene
- I-gene
233 I-gene
) I-gene
, 0
and 0
E2L1.H1.L2 B-gene
( I-gene
1 I-gene
- I-gene
233 I-gene
) I-gene
, 0
where 0
numbers 0
in 0
parentheses 0
give 0
the 0
amino 0
acid 0
sequence 0
for 0
the 0
portions 0
of 0
the 0
E2 B-gene
component 0
incorporated 0
into 0
a 0
construct 0
. 0

Thus 0
, 0
we 0
have 0
produced 0
lipoyl 0
domain 0
constructs 0
that 0
can 0
be 0
employed 0
in 0
sorting 0
the 0
specific 0
roles 0
of 0
E2L1 B-gene
and 0
E2L2 B-gene
in 0
facilitating 0
catalytic 0
and 0
regulatory 0
processes 0
. 0

METHODS 0
: 0
Ten 0
influenza 0
A 0
( 0
H3N2 0
) 0
viruses 0
isolated 0
during 0
the 0
outbreaks 0
were 0
examined 0
for 0
resistance 0
to 0
amantadine 0
and 0
rimantadine 0
by 0
means 0
of 0
an 0
enzyme 0
immunoassay 0
and 0
by 0
sequencing 0
of 0
the 0
viral 0
nucleic 0
acid 0
that 0
encodes 0
the 0
transmembrane 0
domain 0
of 0
the 0
M2 B-gene
protein I-gene
. 0

The 0
first 0
contains 0
ATF/CRE B-gene
and 0
TBP/TATA B-gene
sequence 0
motifs 0
within 0
an 0
87 0
- 0
bp 0
region 0
. 0

Gene 0
expression 0
occurs 0
in 0
a 0
circadian 0
rhythm 0
and 0
induced 0
by 0
light 0
in 0
leaves 0
of 0
dark 0
- 0
adapted 0
plants 0
. 0

Our 0
results 0
suggested 0
that 0
the 0
hexamer 0
and 0
the 0
octamer 0
motifs 0
may 0
play 0
important 0
role 0
( 0
s 0
) 0
in 0
regulation 0
of 0
replication 0
- 0
dependent 0
but 0
not 0
of 0
replication 0
- 0
independent 0
expression 0
of 0
the 0
wheat B-gene
histone I-gene
H3 I-gene
gene I-gene
. 0

The 0
tissue 0
- 0
specific 0
expression 0
of 0
DP B-gene
family I-gene
members I-gene
suggests 0
that 0
the 0
combination 0
of 0
DP/E2F B-gene
heterodimers 0
that 0
constitute 0
DP/E2F I-gene

Similarly 0
, 0
in 0
mammalian 0
cells 0
PBP74 B-gene
is 0
synthesized 0
as 0
a 0
pre 0
- 0
protein 0
that 0
requires 0
membrane 0
potential 0
- 0
dependent 0
import 0
into 0
mitochondria 0
for 0
its 0
maturation 0
. 0

In 0
a 0
second 0
experiment 0
involving 0
an 0
18 0
- 0
h 0
lung 0
clearance 0
assay 0
, 0
we 0
used 0
the 0
mAb B-gene
3.2.3 I-gene
to 0
deplete 0
rats 0
of 0
LGL/NK 0
cells 0
with 0
the 0
following 0
rationale 0
: 0
if 0
LGL/NK 0
cells 0
are 0
necessary 0
to 0
mediate 0
an 0
event 0
, 0
then 0
in 0
their 0
absence 0
, 0
that 0
event 0
should 0
not 0
occur 0
. 0

Treatment 0
of 0
recurrent 0
FSGS 0
has 0
included 0
high 0
- 0
dose 0
steroids 0
, 0
high 0
- 0
dose 0
cyclosporine 0
( 0
CSA 0
) 0
, 0
plasmapheresis 0
, 0
and 0
ACE B-gene
inhibitors 0
with 0
mixed 0
results 0
. 0

Our 0
results 0
concluded 0
that 0
1 0
) 0
the 0
two 0
inhibin/activin B-gene
beta 0
B 0
- 0
subunit 0
mRNAs 0
were 0
transcribed 0
from 0
different 0
initiation 0
sites 0
; 0
2 0
) 0
both 0
promoters 0
may 0
be 0
controlled 0
by 0
up 0
- 0
stream 0
negative 0
regulatory 0
elements 0
; 0
and 0
3 0
) 0
neither 0
of 0
these 0
promoters 0
is 0
responsive 0
to 0
cAMP 0
and/or 0
phorbol 0
esters 0
under 0
the 0
conditions 0
employed 0
. 0

Promoter 0
region 0
of 0
the 0
transcriptional 0
unit 0
for 0
human B-gene
alpha I-gene
1 I-gene
- I-gene
chimaerin I-gene
, 0
a 0
neuron B-gene
- I-gene
specific I-gene
GTPase I-gene
- I-gene
activating I-gene
protein I-gene
for 0
p21rac B-gene
. 0
alpha B-gene
1 I-gene
- I-gene
chimaerin I-gene
is 0
a 0
neuron B-gene
- I-gene
specific I-gene
GTPase I-gene
- I-gene
activating I-gene
protein I-gene
for 0
p21rac B-gene
, 0
a 0
protein 0
involved 0
in 0
morphological 0
events 0
. 0

Upstream 0
from 0
the 0
transcription 0
start 0
point 0
( 0
tsp 0
) 0
, 0
a 0
nucleotide 0
sequence 0
highly 0
homologous 0
to 0
the 0
consensus B-gene
sequence I-gene
motif I-gene
for I-gene
the I-gene
sigma I-gene
35 I-gene
- I-gene
recognized I-gene
promoters I-gene
was 0
found 0
. 0

In 0
this 0
paper 0
, 0
an 0
analysis 0
of 0
the 0
dynamics 0
in 0
the 0
closing 0
phase 0
of 0
the 0
occluder 0
of 0
a 0
mechanical 0
monoleaflet 0
heart 0
valve 0
prosthesis 0
is 0
presented 0
. 0

During 0
ISO+AT 0
infusion 0
, 0
abdominal 0
fat 0
blood 0
flow 0
was 0
still 0
significantly 0
increased 0
as 0
compared 0
with 0
control 0
values 0
in 0
lean 0
and 0
obese 0
subjects 0
. 0

When 0
expressed 0
per 0
kilogram 0
body 0
weight 0
, 0
mean 0
GIT 0
increased 0
in 0
the 0
dF 0
group 0
from 0
0.14 0
% 0
to 0
0.16 0
% 0
above 0
RMR 0
, 0
with 0
a 0
significant 0
decrease 0
from 0
0.15 0
% 0
to 0
0.13 0
% 0
in 0
the 0
P 0
group 0
. 0

In 0
nucleus 0
ventralis 0
anterior 0
thalami 0
- 0
nucleus 0
ventralis 0
lateralis 0
thalami 0
neurons 0
with 0
an 0
inhibitory 0
input 0
from 0
nucleus 0
entopeduncularis 0
, 0
a 0
shortening 0
of 0
inhibition 0
from 0
17.5 0
+/ 0
- 0
3.6 0
to 0
9.1 0
+/ 0
- 0
1.8 0
ms 0
( 0
P 0
< 0
0.05 0
) 0
under 0
the 0
haloperidol 0
influence 0
was 0
evident 0
. 0

However 0
, 0
inclusion 0
of 0
the 0
neighboring 0
CGGAAR 0
motifs 0
from 0
the 0
ICP4 B-gene
promoter I-gene
, 0
which 0
bind 0
factors 0
GABP B-gene
alpha I-gene
and I-gene
beta I-gene
, 0
results 0
in 0
a 0
strong 0
synergistic 0
activation 0
. 0

The 0
first 0
open 0
reading 0
frame 0
of 0
the 0
blueberry 0
scorch 0
carlavirus 0
( 0
BBScV 0
) 0
genome 0
encodes 0
a 0
putative 0
replication 0
- 0
associated 0
protein 0
of 0
223 0
kDa 0
( 0
p223 B-gene
) 0
. 0

From 0
sequence 0
alignments 0
with 0
phylogenetically 0
related 0
viruses 0
, 0
including 0
tymoviruses 0
, 0
we 0
predicted 0
that 0
p223 B-gene
contained 0
a 0
papain B-gene
- I-gene
like I-gene
proteinase I-gene
domain I-gene
with 0
a 0
putative 0
catalytic 0
cysteine994 0
and 0
histidine1075 0
. 0

This 0
finding 0
represents 0
both 0
a 0
potentially 0
important 0
mechanism 0
by 0
which 0
HPV 0
gene 0
expression 0
can 0
be 0
regulated 0
and 0
an 0
interesting 0
model 0
for 0
the 0
study 0
of 0
transcriptional 0
cooperativity 0
. 0

Using 0
this 0
method 0
, 0
VLPs 0
were 0
obtained 0
in 0
quantities 0
sufficient 0
for 0
further 0
characterization 0
. 0

Analysis 0
of 0
the 0
sequence 0
upstream 0
of 0
this 0
initiation 0
codon 0
reveals 0
the 0
presence 0
of 0
a 0
promotor 0
sequence 0
. 0

SUP46 B-gene
is 0
implicated 0
in 0
translation 0
fidelity 0
and 0
encodes 0
the 0
ribosomal B-gene
protein I-gene
S13 I-gene
. 0

To 0
explore 0
the 0
functional 0
relationship 0
between 0
c B-gene
- I-gene
fos I-gene
and 0
Rb B-gene
, 0
a 0
eukaryotic 0
expression 0
plasmid 0
was 0
constructed 0
containing 0
the 0
c B-gene
- I-gene
fos I-gene
gene I-gene
under 0
control 0
of 0
the 0
SV40 B-gene
promoter I-gene
complex 0
. 0

The 0
high 0
degree 0
of 0
sequence 0
identity 0
( 0
96 0
% 0
) 0
between 0
hydrolase B-gene
B I-gene
and I-gene
C I-gene
, 0
particularly 0
in 0
the 0
3 0
' 0
untranslated 0
region 0
, 0
suggests 0
that 0
the 0
genes 0
encoding 0
these 0
two 0
carboxylesterases B-gene
evolved 0
by 0
duplication 0
and 0
divergence 0
of 0
a 0
common 0
ancestral 0
gene 0
. 0

The 0
regions 0
of 0
the 0
tooth 0
fracture 0
are 0
determined 0
. 0

Secondary 0
pancreatic 0
involvement 0
of 0
mycosis 0
fungoides 0
detected 0
by 0
a 0
clinically 0
palpable 0
mass 0
. 0

The 0
NR2 0
hybrid 0
is 0
a 0
powerful 0
tool 0
for 0
the 0
mapping 0
of 0
new 0
probes 0
of 0
this 0
region 0
, 0
as 0
well 0
as 0
for 0
obtaining 0
new 0
informative 0
probes 0
specific 0
for 0
the 0
deletion 0
by 0
subtractive 0
cloning 0
of 0
the 0
region 0
. 0

TDEYA 0
at 0
doses 0
of 0
200 0
to 0
500 0
mg/kg 0
significantly 0
suppressed 0
xanthine B-gene
oxidase I-gene
( 0
XO B-gene
) 0
activity 0
in 0
the 0
stomach 0
tissue 0
following 0
its 0
oral 0
administration 0
. 0

Like 0
humans 0
, 0
the 0
PITSLRE B-gene
PK I-gene
genes I-gene
in I-gene
chickens I-gene
must 0
be 0
closely 0
linked 0
, 0
based 0
on 0
fluorescent 0
in 0
situ 0
hybridization 0
( 0
FISH 0
) 0
localization 0
of 0
these 0
genes 0
to 0
a 0
single 0
chicken 0
microchromosome 0
. 0

Here 0
, 0
we 0
report 0
the 0
characterization 0
of 0
an 0
alternatively 0
processed 0
form 0
of 0
AFAP B-gene
- I-gene
110 I-gene
that 0
encodes 0
an 0
additional 0
258 0
base 0
pair 0
( 0
bp 0
) 0
of 0
open 0
reading 0
frame 0
. 0

Expression 0
of 0
class B-gene
IV I-gene
ADH I-gene
mRNA I-gene
was 0
detected 0
in 0
human 0
stomach 0
but 0
not 0
liver 0
. 0

In 0
ICE B-gene
gamma I-gene
, 0
most 0
of 0
the 0
propeptide 0
( 0
amino 0
acids 0
20 0
- 0
112 0
) 0
is 0
deleted 0
, 0
which 0
suggests 0
that 0
it 0
may 0
function 0
as 0
a 0
catalyst 0
for 0
ICE B-gene
autoprocessing 0
in 0
vivo 0
. 0

Endocytosis 0
and 0
lysosomal 0
targeting 0
of 0
epidermal B-gene
growth I-gene
factor I-gene
receptors I-gene
are 0
mediated 0
by 0
distinct 0
sequences 0
independent 0
of 0
the 0
tyrosine B-gene
kinase I-gene
domain I-gene
. 0

It 0
is 0
now 0
recognized 0
that 0
essentially 0
all 0
eukaryotic 0
and 0
prokaryotic 0
genes 0
whose 0
5' 0
- 0
flanking 0
regions 0
are 0
known 0
and 0
that 0
encode 0
barbiturate 0
- 0
inducible 0
proteins 0
contain 0
the 0
Barbie 0
box 0
element 0
. 0

Mutation 0
of 0
the 0
P450BM B-gene
- I-gene
3 I-gene
Barbie I-gene
box I-gene
significantly 0
increased 0
the 0
expression 0
of 0
both 0
P450BM B-gene
- I-gene
3 I-gene
and 0
Bm3P1 B-gene
( 0
another 0
small 0
gene 0
located 0
upstream 0
of 0
the 0
P450BM B-gene
- I-gene
3 I-gene
gene I-gene
that 0
encodes 0
a 0
second 0
putative 0
regulatory 0
protein 0
) 0
in 0
response 0
to 0
pentobarbital 0
induction 0
but 0
left 0
the 0
basal 0
levels 0
unaffected 0
. 0

The 0
p97 B-gene
- 0
depleted 0
nuclei 0
remained 0
largely 0
competent 0
for 0
nuclear 0
protein 0
import 0
. 0

A 0
potential 0
outcome 0
of 0
these 0
biochemical 0
effects 0
may 0
include 0
the 0
limited 0
responsiveness 0
of 0
infected 0
T 0
cells 0
to 0
antigenic 0
stimulation 0
observed 0
during 0
HIV 0
- 0
1 0
infection 0
. 0

The 0
full 0
protocol 0
was 0
completed 0
by 0
33 0
patients 0
( 0
45 0
% 0
of 0
original 0
cohort 0
) 0
. 0

In 0
addition 0
, 0
we 0
found 0
that 0
cell 0
- 0
specific 0
suppression 0
of 0
RA 0
- 0
stimulated 0
zif268 B-gene
gene I-gene
expression 0
can 0
be 0
attributed 0
to 0
a 0
29 0
base 0
pair 0
nucleotide 0
sequence 0
, 0
located 0
downstream 0
of 0
the 0
RA 0
- 0
responsive 0
region 0
in 0
the 0
zif268 B-gene
gene I-gene
. 0

We 0
show 0
that 0
CBF B-gene
- I-gene
A I-gene
and 0
CBF B-gene
- I-gene
C I-gene
interact 0
with 0
each 0
other 0
to 0
form 0
a 0
CBF B-gene
- I-gene
A I-gene
- 0
CBF B-gene
- I-gene
C I-gene
complex 0
and 0
that 0
CBF B-gene
- I-gene
B I-gene
does 0
not 0
interact 0
with 0
CBF B-gene
- I-gene
A I-gene
or 0
CBF B-gene
- I-gene
C I-gene
individually 0
but 0
that 0
it 0
associates 0
with 0
the 0
CBF B-gene
- I-gene
A I-gene
- 0
CBF B-gene
- I-gene
C I-gene
complex 0
. 0

In 0
the 0
first 0
, 0
homologous 0
sequences 0
were 0
deleted 0
from 0
a 0
mouse 0
enhancer 0
, 0
resulting 0
in 0
a 0
tissue 0
- 0
specific 0
loss 0
of 0
activity 0
when 0
assayed 0
in 0
transgenic 0
mice 0
. 0

OKT3 B-gene
prophylaxis 0
improves 0
long 0
- 0
term 0
renal 0
graft 0
survival 0
in 0
high 0
- 0
risk 0
patients 0
as 0
compared 0
to 0
cyclosporine 0
: 0
combined 0
results 0
from 0
the 0
prospective 0
, 0
randomized 0
Belgian 0
and 0
US 0
studies 0
. 0

The 0
major 0
PKC B-gene
beta I-gene
transcription 0
initiation 0
site 0
was 0
identified 0
by 0
primer 0
extension 0
and 0
S1 B-gene
nuclease I-gene
protection 0
. 0

In 0
the 0
course 0
of 0
a 0
study 0
of 0
low 0
dose 0
X 0
- 0
rays 0
effects 0
, 0
we 0
found 0
that 0
male 0
ICR 0
white 0
Swiss 0
mice 0
showed 0
remarkable 0
suppression 0
of 0
mounting 0
behavior 0
after 0
whole 0
body 0
irradiation 0
by 0
5 0
to 0
15 0
cGy 0
X 0
- 0
rays 0
. 0

A 0
quantitative 0
analysis 0
of 0
the 0
diffraction 0
intensity 0
as 0
function 0
of 0
the 0
accumulated 0
electron 0
dose 0
suggests 0
the 0
possibility 0
of 0
recording 0
up 0
to 0
250 0
diffraction 0
patterns 0
with 0
3.5 0
A 0
resolution 0
from 0
a 0
single 0
crotoxin 0
complex 0
crystal 0
128 0
A 0
thick 0
. 0

Supplementary 0
Phase 0
Contraste 0
RSE 0
( 0
`` 0
Rapid 0
Sequential 0
Excitation 0
'' 0
) 0
sequences 0
were 0
carried 0
out 0
in 0
29 0
patients 0
. 0

In 0
yeast 0
, 0
the 0
products 0
of 0
the 0
UPF1 B-gene
and 0
UPF3 B-gene
genes I-gene
are 0
required 0
for 0
this 0
decay 0
pathway 0
, 0
and 0
in 0
this 0
report 0
we 0
focus 0
on 0
the 0
identification 0
and 0
characterization 0
of 0
additional 0
factors 0
required 0
for 0
rapid 0
decay 0
of 0
nonsense 0
- 0
containing 0
mRNAs 0
. 0

Mutations 0
in 0
UPF1 B-gene
lead 0
to 0
the 0
selective 0
stabilization 0
of 0
mRNAs 0
containing 0
early 0
nonsense 0
mutations 0
without 0
affecting 0
the 0
decay 0
rates 0
of 0
most 0
other 0
mRNAs 0
. 0

A 0
DNA 0
fragment 0
encoding 0
the 0
DNA 0
- 0
binding 0
domain 0
( 0
amino 0
acids 0
1 0
- 0
60 0
) 0
of 0
the 0
Escherichia B-gene
coli I-gene
fru I-gene
transcriptional I-gene
regulator I-gene
was 0
cloned 0
into 0
the 0
pGEX 0
- 0
KT 0
vector 0
and 0
expressed 0
in 0
frame 0
with 0
the 0
fused 0
gene 0
encoding 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
. 0

Using 0
gel 0
retardation 0
assays 0
with 0
HepG2 0
nuclear 0
extract 0
, 0
we 0
demonstrated 0
the 0
presence 0
of 0
a 0
specific 0
protein 0
which 0
bound 0
to 0
the 0
NRE 0
fragment 0
. 0

0.61 0
+/ 0
- 0
0.04 0
) 0
. 0

Several 0
nuclear 0
factors 0
that 0
interact 0
with 0
sequences 0
in 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
mouse B-gene
tyrosinase I-gene
gene I-gene
were 0
identified 0
using 0
band 0
shift 0
and 0
methylation 0
interference 0
assays 0
. 0

With 0
a 0
population 0
of 0
853 0
million 0
there 0
should 0
be 0
51,204 0
patients 0
with 0
hemophilia 0
A 0
in 0
India 0
assuming 0
a 0
prevalence 0
of 0
6/100,000 0
population 0
. 0

When 0
combined 0
with 0
serum 0
ferritin B-gene
and 0
hemoglobin B-gene
determinations 0
, 0
the 0
serum 0
transferrin B-gene
receptor I-gene
assay 0
is 0
a 0
valuable 0
addition 0
in 0
epidemiologic 0
surveys 0
because 0
it 0
provides 0
a 0
quantitative 0
measure 0
of 0
functional 0
iron 0
deficiency 0
and 0
it 0
distinguishes 0
true 0
IDA 0
from 0
the 0
anemia 0
of 0
chronic 0
disease 0
. 0

Twenty 0
- 0
two 0
consecutive 0
patients 0
with 0
ischaemic 0
ulcers 0
had 0
tcPO2 0
measured 0
and 0
the 0
ankle/brachial 0
( 0
ABI 0
) 0
and 0
toe/brachial 0
( 0
TBI 0
) 0
indices 0
calculated 0
. 0

TcPO2 0
measurement 0
appears 0
to 0
be 0
a 0
reliable 0
technique 0
that 0
can 0
influence 0
ischaemic 0
ulcer 0
management 0
. 0

Since 0
1990 0
the 0
University 0
Hospital 0
of 0
Tromso 0
has 0
provided 0
local 0
hospitals 0
in 0
northern 0
Norway 0
with 0
a 0
remote 0
frozen 0
section 0
service 0
and 0
with 0
access 0
to 0
video 0
conferences 0
for 0
the 0
review 0
of 0
microscopic 0
findings 0
and 0
for 0
the 0
discussion 0
of 0
major 0
diagnostic 0
issues 0
. 0

Current 0
status 0
of 0
telepathology 0
. 0

Expression 0
of 0
h6.1 0
in 0
COS 0
- 0
1 0
cells 0
led 0
to 0
the 0
production 0
of 0
a 0
typical 0
type B-gene
IV I-gene
PDE I-gene
activity 0
in 0
that 0
cAMP 0
, 0
but 0
not 0
cGMP 0
, 0
served 0
as 0
substrate 0
and 0
its 0
activity 0
was 0
insensitive 0
to 0
either 0
Ca2+/CaM B-gene
or 0
cGMP 0
but 0
was 0
inhibited 0
by 0
low 0
concentrations 0
of 0
rolipram 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

PMEK1 B-gene
displays 0
96 0
and 0
80 0
% 0
identity 0
respectively 0
with 0
the 0
tobacco B-gene
NTF3 I-gene
and 0
Arabidopsis B-gene
ATMPK1 I-gene
kinases I-gene
, 0
and 0
only 0
50 0
% 0
to 0
the 0
more 0
distantly 0
related 0
plant 0
MAP 0
kinase 0
MsERK1 B-gene
from 0
alfalfa 0
. 0

Translation 0
of 0
the 0
coding 0
segment 0
, 0
which 0
was 0
designated 0
MsPRP2 B-gene
, 0
suggested 0
it 0
encodes 0
a 0
chimeric 0
40,569 0
Da 0
cell 0
wall 0
protein 0
with 0
an 0
amino 0
- 0
terminal 0
signal 0
sequence 0
, 0
a 0
repetitive 0
proline 0
- 0
rich 0
sequence 0
, 0
and 0
a 0
cysteine 0
- 0
rich 0
carboxyl 0
- 0
terminal 0
sequence 0
homologous 0
to 0
nonspecific 0
lipid 0
transfer 0
proteins 0
. 0

The 0
presence 0
of 0
type 0
I 0
hypersensitivity 0
in 0
a 0
subgroup 0
of 0
aspergillomas 0
suggests 0
an 0
immunoallergic 0
component 0
to 0
this 0
disease 0
which 0
could 0
contribute 0
to 0
a 0
chronic 0
inflammatory 0
response 0
to 0
Aspergillus 0
in 0
some 0
aspergillomas 0
. 0

This 0
concept 0
is 0
supported 0
by 0
the 0
identification 0
of 0
RH B-gene
- I-gene
like I-gene
genes I-gene
in 0
non 0
human 0
primates 0
. 0

With 0
steady 0
illumination 0
, 0
outer 0
retinal 0
( 0
photoreceptor 0
) 0
QO2 0
decreased 0
to 0
1.4 0
+/ 0
- 0
0.9 0
ml 0
O2/ 0
( 0
100 0
g.min 0
) 0
, 0
but 0
inner 0
retinal 0
QO2 0
remained 0
unchanged 0
at 0
3.7 0
+/ 0
- 0
1.5 0
ml 0
O2/ 0
( 0
100 0
g.min 0
) 0
( 0
5 0
cats 0
) 0
. 0

We 0
have 0
screened 0
the 0
mouse 0
cDNA 0
library 0
of 0
an 0
MIN6 0
cell 0
line 0
, 0
derived 0
from 0
pancreatic 0
beta 0
cells 0
, 0
for 0
its 0
novel 0
isoform 0
and 0
have 0
identified 0
a 0
cDNA 0
encoding 0
a 0
593 0
- 0
amino 0
acid 0
protein 0
having 0
63 0
, 0
53 0
, 0
and 0
30 0
% 0
identity 0
with 0
munc B-gene
- I-gene
18/n I-gene
- I-gene
Sec1/rbSec1 I-gene
, 0
Caenorhabditis B-gene
elegans I-gene
unc18 I-gene
, 0
and 0
Saccharomyces B-gene
cerevisiae I-gene
Sec1p I-gene
, 0
respectively 0
. 0

The 0
catenins B-gene
bind 0
to 0
APC B-gene
and 0
E B-gene
- I-gene
cadherin I-gene
in 0
a 0
similar 0
fashion 0
, 0
but 0
APC B-gene
and 0
E B-gene
- I-gene
cadherin I-gene
do 0
not 0
associate 0
with 0
each 0
other 0
either 0
in 0
the 0
presence 0
or 0
absence 0
of 0
catenins B-gene
. 0

However 0
, 0
addition 0
of 0
core B-gene
DNA I-gene
polymerase I-gene
III I-gene
to 0
preinitiation 0
complex 0
, 0
fully 0
reconstituting 0
holoenzyme 0
resulted 0
in 0
replacement 0
of 0
gamma 0
by 0
alpha 0
at 0
the 0
primer 0
terminus 0
. 0

The 0
PSD2 B-gene
gene I-gene
was 0
heterologously 0
expressed 0
by 0
infection 0
of 0
Sf 0
- 0
9 0
insect 0
cells 0
with 0
recombinant 0
baculovirus 0
, 0
resulting 0
in 0
a 0
10 0
- 0
fold 0
increase 0
in 0
PSD B-gene
activity 0
. 0

Computerized 0
detection 0
of 0
abnormal 0
asymmetry 0
in 0
digital 0
chest 0
radiographs 0
. 0

These 0
results 0
suggest 0
that 0
gluconeogenic 0
genes 0
are 0
derepressed 0
upon 0
binding 0
of 0
Cat8p B-gene
, 0
whose 0
synthesis 0
depends 0
on 0
the 0
release 0
of 0
Cat4p B-gene
( 0
Mig1p B-gene
) 0
from 0
the 0
CAT8 B-gene
promoter I-gene
. 0

Like 0
Epo B-gene
, 0
HNF B-gene
- I-gene
4 I-gene
is 0
expressed 0
in 0
kidney 0
, 0
liver 0
, 0
and 0
Hep3B 0
cells 0
but 0
not 0
in 0
HeLa 0
cells 0
. 0

Moreover 0
, 0
the 0
hypoxia 0
- 0
induced 0
expression 0
of 0
the 0
endogenous 0
Epo B-gene
gene I-gene
was 0
significantly 0
inhibited 0
in 0
Hep3B 0
cells 0
stably 0
transfected 0
with 0
HNF B-gene
- I-gene
4 I-gene
delta I-gene
C I-gene
. 0

These 0
observations 0
indicate 0
that 0
there 0
are 0
multiple 0
mechanisms 0
by 0
which 0
an 0
individual 0
transcript 0
can 0
be 0
degraded 0
following 0
deadenylation 0
. 0

Small B-gene
Maf I-gene
proteins I-gene
heterodimerize 0
with 0
Fos B-gene
and 0
may 0
act 0
as 0
competitive 0
repressors 0
of 0
the 0
NF B-gene
- I-gene
E2 I-gene
transcription I-gene
factor I-gene
. 0

We 0
show 0
here 0
that 0
the 0
binding 0
of 0
C1F B-gene
in 0
vitro 0
is 0
sensitive 0
to 0
the 0
concentration 0
of 0
calcium 0
ions 0
. 0

Survival 0
after 0
development 0
of 0
symptomatic 0
infection 0
( 0
P 0
- 0
2 0
) 0
did 0
not 0
differ 0
by 0
transmission 0
mode 0
. 0

Both 0
factors 0
demonstrated 0
significant 0
correlations 0
with 0
rCBF 0
in 0
the 0
medial 0
prefrontal 0
cortex 0
and 0
frontal 0
polar 0
cortex 0
while 0
for 0
each 0
factor 0
there 0
were 0
also 0
unique 0
patterns 0
of 0
correlations 0
with 0
posterior 0
brain 0
regions 0
. 0

These 0
data 0
suggest 0
that 0
the 0
function 0
of 0
the 0
DS2 B-gene
may 0
be 0
the 0
protection 0
of 0
the 0
nuclear 0
DNA 0
from 0
desiccation 0
. 0

Glomerular 0
hemodynamics 0
during 0
abortion 0
induced 0
by 0
RU 0
486 0
and 0
sepsis 0
in 0
rats 0
. 0

The 0
aim 0
of 0
this 0
retrospective 0
study 0
was 0
to 0
demonstrate 0
that 0
in 0
certain 0
cases 0
of 0
expulsive 0
choroidal 0
hemorrhage 0
( 0
ECH 0
) 0
anatomical 0
success 0
and 0
useful 0
vision 0
can 0
be 0
obtained 0
with 0
repeated 0
vitreoretinal 0
surgery 0
. 0

The 0
function 0
of 0
the 0
C 0
- 0
terminal 0
tail 0
in 0
telomere 0
maintenance 0
is 0
not 0
mediated 0
through 0
the 0
RAP1 B-gene
interacting I-gene
factor I-gene
RIF1 B-gene
: 0
rap1 B-gene
alleles I-gene
defective 0
in 0
both 0
the 0
C 0
- 0
terminal 0
tail 0
and 0
RIF1 B-gene
interaction I-gene
domains I-gene
have 0
additive 0
effects 0
on 0
telomere 0
length 0
. 0

The 0
resulting 0
integrated 0
physical 0
, 0
genetic 0
, 0
and 0
cytogenetic 0
map 0
constitutes 0
a 0
resource 0
for 0
the 0
characterization 0
of 0
genes 0
that 0
may 0
be 0
involved 0
in 0
the 0
WAGR 0
syndrome 0
. 0

The 0
contribution 0
of 0
skin 0
flow 0
to 0
the 0
changes 0
in 0
760 0
- 0
800 0
nm 0
absorption 0
was 0
investigated 0
by 0
simultaneous 0
measurement 0
of 0
skin 0
flow 0
by 0
laser 0
flow 0
Doppler 0
and 0
NIR 0
recordings 0
during 0
hot 0
water 0
immersion 0
. 0

Proteins 0
immunoprecipitated 0
from 0
lysates 0
of 0
control 0
- 0
and 0
VEGF B-gene
- 0
stimulated 0
BAEC 0
with 0
antisera 0
to 0
phospholipase B-gene
C I-gene
- I-gene
gamma I-gene
( 0
PLC B-gene
- I-gene
gamma I-gene
) 0
were 0
fractionated 0
by 0
SDS 0
- 0
polyacrylamide 0
gel 0
electrophoresis 0
and 0
transferred 0
to 0
Immobilon 0
- 0
P 0
. 0

Alternatively 0
processed 0
isoforms 0
of 0
cellular B-gene
nucleic I-gene
acid I-gene
- I-gene
binding I-gene
protein I-gene
interact 0
with 0
a 0
suppressor 0
region 0
of 0
the 0
human B-gene
beta I-gene
- I-gene
myosin I-gene
heavy I-gene
chain I-gene
gene I-gene
. 0

Involvement 0
of 0
early B-gene
growth I-gene
response I-gene
factor I-gene
Egr I-gene
- I-gene
1 I-gene
in 0
apolipoprotein B-gene
AI I-gene
gene I-gene
transcription 0
. 0

The 0
wild 0
- 0
type 0
and 0
altered 0
forms 0
of 0
the 0
F B-gene
protein I-gene
were 0
expressed 0
in 0
BHK 0
- 0
21 0
and 0
HeLa 0
T4 0
cells 0
by 0
use 0
of 0
the 0
recombinant B-gene
vaccinia I-gene
virus I-gene
- I-gene
encoding I-gene
T7 I-gene
polymerase I-gene
system 0
. 0

Erythrocyte B-gene
delta I-gene
- I-gene
aminolevulinic I-gene
acid I-gene
dehydratase I-gene
( 0
ALAD B-gene
) 0
activity 0
, 0
erythrocyte 0
zinc 0
protoporphyrin 0
( 0
ZPP 0
) 0
/heme 0
ratio 0
, 0
and 0
urinary 0
coproporphyrin 0
( 0
UC 0
) 0
concentration 0
have 0
been 0
employed 0
as 0
biological 0
indicators 0
of 0
moderate 0
- 0
to 0
high 0
- 0
level 0
lead 0
exposure 0
, 0
corresponding 0
to 0
blood 0
levels 0
in 0
excess 0
of 0
50 0
micrograms/dl 0
, 0
in 0
human 0
subjects 0
. 0

The 0
relative 0
risk 0
of 0
graft 0
loss 0
after 0
conversion 0
to 0
azathioprine 0
compared 0
with 0
graft 0
loss 0
after 0
conversion 0
to 0
azathioprine 0
compared 0
with 0
cyclosporin 0
maintenance 0
was 0
0.71 0
( 0
0.37 0
- 0
1.38 0
) 0
and 0
the 0
relative 0
risk 0
of 0
patient 0
death 0
was 0
0.57 0
( 0
0.23 0
- 0
1.41 0
) 0
. 0

Three 0
classes 0
of 0
test 0
objects 0
were 0
considered 0
: 0
( 0
1 0
) 0
a 0
multicompartment 0
test 0
object 0
for 0
31P 0
MRS 0
measurements 0
performed 0
with 0
slice 0
- 0
selective 0
sequences 0
; 0
( 0
2 0
) 0
a 0
two 0
- 0
compartment 0
test 0
object 0
for 0
volume 0
- 0
selection 0
1H 0
MRS 0
; 0
and 0
( 0
3 0
) 0
two 0
- 0
compartment 0
test 0
objects 0
for 0
assessing 0
the 0
performance 0
of 0
experimental 0
systems 0
using 0
ISIS 0
as 0
volume 0
localization 0
sequence 0
in 0
31P 0
MRS 0
. 0

The 0
`` 0
tobacco 0
issue 0
'' 0
. 0

Pregnancy 0
screening 0
by 0
uterine 0
artery 0
Doppler 0
velocimetry 0
- 0
- 0
which 0
criterion 0
performs 0
best 0
? 0
OBJECTIVE 0
: 0
To 0
test 0
whether 0
repeating 0
Doppler 0
studies 0
of 0
the 0
uteroplacental 0
circulation 0
late 0
in 0
gestation 0
will 0
improve 0
the 0
test 0
's 0
power 0
for 0
predicting 0
pregnancy 0
- 0
induced 0
hypertension 0
and 0
fetal 0
growth 0
restriction 0
( 0
FGR 0
) 0
, 0
and 0
whether 0
analysis 0
based 0
on 0
a 0
combination 0
of 0
quantitative 0
and 0
qualitative 0
assessments 0
of 0
the 0
uterine 0
arterial 0
waveforms 0
will 0
yield 0
better 0
results 0
than 0
analysis 0
based 0
on 0
either 0
alone 0
. 0

The 0
effect 0
of 0
the 0
Ca 0
entry 0
blocker 0
nitrendipine 0
, 0
the 0
antioxidant 0
superoxide B-gene
dismutase I-gene
( 0
SOD B-gene
) 0
, 0
and 0
a 0
combination 0
of 0
nitrendipine 0
and 0
superoxide B-gene
dismutase I-gene
on 0
postischemic 0
renal 0
function 0
was 0
studied 0
in 0
four 0
groups 0
( 0
n 0
= 0
24 0
) 0
of 0
rats 0
. 0

PURPOSE 0
: 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
bony 0
anchorage 0
of 0
a 0
new 0
implant 0
( 0
orderly 0
wired 0
surface 0
effect 0
with 0
alloy 0
Ti 0
Al 0
Va 0
and 0
ordered 0
pores 0
of 0
488 0
mu 0
) 0
. 0

To 0
determine 0
whether 0
food 0
and/or 0
water 0
in 0
the 0
gastrointestinal 0
tract 0
affects 0
restitution 0
of 0
blood 0
volume 0
and 0
plasma 0
protein 0
after 0
hemorrhage 0
, 0
fed 0
and 0
24 0
- 0
h 0
- 0
fasted 0
awake 0
rats 0
received 0
a 0
20 0
ml.kg 0
- 0
1 0
x 0
3 0
min 0
- 0
1 0
hemorrhage 0
, 0
and 0
restitution 0
of 0
blood 0
volume 0
was 0
measured 0
by 0
Evans 0
blue 0
dye 0
and 0
dilution 0
of 0
hematocrit 0
. 0

Cooperative 0
dimerization 0
of 0
paired B-gene
class 0
homeo 0
domains 0
on 0
DNA 0
. 0

We 0
took 0
advantage 0
of 0
the 0
high 0
degree 0
of 0
aa 0
sequence 0
homology 0
between 0
DAHPSs B-gene
from 0
several 0
species 0
to 0
isolate 0
ARO3 B-gene
homologues I-gene
from 0
the 0
pathogenic 0
yeast 0
Candida 0
albicans 0
. 0

In 0
this 0
study 0
, 0
we 0
demonstrate 0
that 0
BOX 0
DNA 0
enhances 0
transcription 0
from 0
the 0
thymidine B-gene
kinase I-gene
( 0
TK B-gene
) 0
promoter 0
in 0
various 0
EC 0
cells 0
. 0

Deletion 0
analyses 0
of 0
the 0
construct 0
revealed 0
that 0
the 0
transcription 0
of 0
BOXF1 B-gene
gene I-gene
is 0
regulated 0
by 0
BOX 0
DNA 0
, 0
preferentially 0
in 0
undifferentiated 0
EC 0
cells 0
versus 0
differentiated 0
cells 0
. 0

Analysis 0
of 0
disassociation 0
rates 0
indicates 0
that 0
the 0
Grf10 B-gene
- 0
Swi5 B-gene
- 0
DNA 0
complex 0
has 0
a 0
longer 0
half 0
- 0
life 0
than 0
protein 0
- 0
DNA 0
complexes 0
that 0
contain 0
only 0
Swi5 B-gene
or 0
Grf10 B-gene
. 0

The 0
presence 0
of 0
an 0
unusual 0
transcript 0
possessing 0
IVS2C B-gene
beta I-gene
1 I-gene
at 0
the 0
5 0
' 0
terminus 0
suggests 0
that 0
cleavage 0
of 0
its 0
splice 0
acceptor 0
is 0
inefficient 0
or 0
negatively 0
regulated 0
. 0

The 0
mutant 0
allele 0
of 0
the 0
alpha B-gene
1 I-gene
- I-gene
tubulin I-gene
gene I-gene
was 0
designated 0
tua1 B-gene
- I-gene
1 I-gene
. 0

During 0
chronic 0
treatment 0
, 0
when 0
plasma 0
concentrations 0
fluctuated 0
between 0
23.5 0
ng.ml 0
- 0
1 0
at 0
8 0
h 0
and 0
14 0
ng.ml 0
- 0
1 0
at 0
24 0
h 0
post 0
- 0
dosing 0
, 0
ST 0
segment 0
depression 0
at 0
an 0
individually 0
comparable 0
workload 0
was 0
significantly 0
decreased 0
by 0
28 0
% 0
compared 0
with 0
placebo 0
( 0
P 0
< 0
0.005 0
) 0
at 0
both 0
points 0
in 0
time 0
. 0

Results 0
from 0
in 0
vitro 0
transcription 0
- 0
translation 0
analysis 0
and 0
maxicell 0
experiments 0
suggested 0
that 0
the 0
447 0
- 0
bp 0
ORF 0
was 0
the 0
one 0
being 0
actively 0
expressed 0
. 0

Preliminary 0
experiments 0
demonstrated 0
that 0
it 0
was 0
possible 0
to 0
produce 0
fasD B-gene
mutants I-gene
, 0
whose 0
products 0
remain 0
functional 0
for 0
fimbrial 0
export 0
and 0
assembly 0
. 0

Evoked 0
electromyographic 0
response 0
to 0
indirect 0
supramaximal 0
stimulation 0
at 0
1 0
Hz 0
was 0
monitored 0
in 0
ten 0
adult 0
goats 0
under 0
thiopentone 0
- 0
halothane 0
anaesthesia 0
. 0

313 0
, 0
98 0
- 0
102 0
) 0
. 0

Group 0
6 0
was 0
given 0
physostigmine 0
, 0
0.1 0
mg/kg 0
i.v. 0
, 0
known 0
to 0
inhibit 0
cholinesterase B-gene
degradation 0
, 0
5 0
min 0
before 0
bupivacaine 0
administration 0
, 0
and 0
Group 0
7 0
received 0
a 0
combination 0
of 0
physostigmine 0
pretreatment 0
and 0
electrical 0
vagal 0
stimulation 0
. 0

To 0
examine 0
the 0
possibility 0
that 0
LNNB 0
performance 0
of 0
the 0
schizophrenic 0
groups 0
may 0
have 0
been 0
related 0
to 0
neuroleptic 0
medication 0
, 0
analyses 0
were 0
completed 0
on 0
the 0
relationship 0
between 0
medication 0
levels 0
and 0
LNNB 0
scores 0
. 0

ISIS 0
5 0
possibilities 0
. 0

The 0
use 0
of 0
specific 0
antibodies 0
allowed 0
the 0
identification 0
of 0
at 0
least 0
RAR B-gene
beta I-gene
in 0
some 0
of 0
the 0
DNA 0
- 0
protein 0
complexes 0
, 0
although 0
the 0
four 0
sequences 0
bind 0
single 0
RARs B-gene
transfected 0
in 0
COS 0
cells 0
much 0
less 0
efficiently 0
, 0
or 0
not 0
at 0
all 0
, 0
when 0
compared 0
to 0
a 0
canonical 0
RAR B-gene
responsive I-gene
element I-gene
. 0

The 0
present 0
treatment 0
strategy 0
in 0
progressive 0
disorders 0
is 0
mainly 0
based 0
on 0
the 0
complementary 0
effect 0
of 0
intensive 0
radiochemotherapy 0
, 0
autologous 0
stem 0
- 0
cell 0
transplantation 0
and 0
the 0
rational 0
use 0
of 0
cytokines 0
, 0
mostly 0
colony B-gene
- I-gene
stimulating I-gene
factors I-gene
. 0

Our 0
study 0
cohorts 0
consisted 0
of 0
15 0
patients 0
who 0
received 0
SC 0
rIL B-gene
- I-gene
2 I-gene
at 0
doses 0
of 0
4.8 0
- 0
14.4 0
million 0
IU/m2/day 0
on 0
5 0
days 0
per 0
week 0
for 0
a 0
total 0
of 0
8 0
weeks 0
, 0
20 0
patients 0
who 0
received 0
rIFN B-gene
- I-gene
alpha I-gene
2b I-gene
at 0
3.0 0
- 0
6.0 0
million 0
U/m2/day 0
thrice 0
weekly 0
for 0
a 0
total 0
of 0
6 0
weeks 0
, 0
and 0
72 0
patients 0
who 0
were 0
given 0
SC 0
rIFN B-gene
- I-gene
alpha I-gene
2b I-gene
at 0
6.0 0
million 0
U/m2/day 0
thrice 0
weekly 0
plus 0
SC 0
rIL B-gene
- I-gene
2 I-gene
at 0
14.4 0
- 0
18.0 0
million 0
IU/m2/day 0
on 0
days 0
1 0
and 0
2 0
, 0
followed 0
by 0
4.8 0
million 0
IU/m2/day 0
, 0
5 0
days 0
per 0
week 0
for 0
6 0
consecutive 0
weeks 0
. 0

Analysis 0
of 0
a 0
set 0
of 0
deletion 0
constructs 0
in 0
transient 0
transfection 0
assays 0
measuring 0
heterologous 0
reporter 0
gene 0
( 0
luciferase B-gene
) 0
activity 0
demonstrated 0
that 0
the 0
182 0
- 0
bp 0
5' 0
- 0
flanking 0
region 0
provides 0
full 0
promoter 0
activity 0
in 0
IL B-gene
- I-gene
2 I-gene
- 0
stimulated 0
L2 0
cells 0
. 0

At 0
the 0
MTD 0
( 0
8 0
mg/m2/day 0
) 0
, 0
the 0
dose 0
- 0
limiting 0
toxicity 0
of 0
this 0
agent 0
is 0
myelosuppression 0
. 0

Mitogen 0
- 0
induced 0
lymphocyte 0
proliferation 0
was 0
diminished 0
. 0

A 0
decanucleotide 0
promoter 0
sequence 0
homologous 0
to 0
those 0
found 0
in 0
humans 0
and 0
mice 0
was 0
located 0
in 0
the 0
5 0
' 0
untranslated 0
region 0
of 0
one 0
horse 0
gene 0
. 0

Some 0
of 0
these 0
targets 0
were 0
reported 0
to 0
code 0
for 0
molecules 0
involved 0
in 0
cell 0
- 0
cell 0
interactions 0
, 0
whereas 0
no 0
relationship 0
has 0
yet 0
been 0
demonstrated 0
between 0
Hox B-gene
genes I-gene
and 0
other 0
transcription 0
factors 0
involved 0
in 0
determining 0
and/or 0
maintaining 0
tissue 0
specificity 0
. 0

Northern 0
analysis 0
of 0
RNA 0
samples 0
isolated 0
from 0
ammonium 0
- 0
grown 0
cultures 0
of 0
the 0
ntcA B-gene
mutant I-gene
showed 0
reduced 0
amounts 0
of 0
glnA B-gene
message I-gene
and 0
the 0
absence 0
of 0
a 0
1.7 0
- 0
kb 0
transcript 0
. 0

HER2 B-gene
overexpressing 0
cells 0
showed 0
a 0
single 0
prominent 0
DNase B-gene
I I-gene
hypersensitive 0
site 0
near 0
a 0
conserved 0
and 0
hitherto 0
unrecognized 0
ets B-gene
response 0
element 0
( 0
GAGGAA 0
) 0
, 0
located 0
38 0
bases 0
down 0
- 0
stream 0
from 0
the 0
CAAT 0
box 0
and 0
directly 0
5 0
' 0
of 0
the 0
TATA 0
box 0
in 0
the 0
human B-gene
HER2 I-gene
promoter I-gene
. 0

Gel 0
- 0
shift 0
assays 0
with 0
nuclear 0
extracts 0
and 0
oligonucleotide 0
sequences 0
spanning 0
the 0
0.125 0
- 0
kb 0
promoter 0
region 0
detected 0
an 0
ETS B-gene
- 0
immunoreactive 0
complex 0
, 0
present 0
most 0
abundantly 0
in 0
cells 0
overexpressing 0
HER2 B-gene
, 0
whose 0
high 0
- 0
affinity 0
binding 0
depended 0
on 0
the 0
GAGGAA 0
response 0
element 0
. 0

Comparison 0
of 0
cDNA 0
sequences 0
revealed 0
that 0
the 0
two 0
mRNA 0
species 0
arise 0
as 0
a 0
result 0
of 0
alternate 0
use 0
of 0
poly 0
( 0
A 0
) 0
- 0
addition 0
sites 0
. 0

The 0
gene 0
for 0
the 0
RNA B-gene
- I-gene
dependent I-gene
eIF I-gene
- I-gene
2 I-gene
alpha I-gene
protein I-gene
kinase I-gene
( 0
PKR B-gene
) 0
was 0
isolated 0
from 0
mouse 0
genomic 0
DNA 0
and 0
characterized 0
. 0

High 0
- 0
frequency 0
electrical 0
stimulation 0
in 0
the 0
hippocampus 0
leads 0
to 0
an 0
increase 0
in 0
synaptic 0
efficacy 0
that 0
lasts 0
for 0
many 0
hours 0
. 0

Similar 0
to 0
the 0
mouse 0
gene 0
, 0
the 0
5 0
' 0
flanking 0
region 0
of 0
human B-gene
CD79 I-gene
alpha I-gene
lacks 0
a 0
TATA 0
box 0
; 0
however 0
, 0
unlike 0
mouse B-gene
CD79 I-gene
alpha I-gene
, 0
a 0
classical 0
octamer 0
motif 0
could 0
not 0
be 0
identified 0
in 0
the 0
human 0
gene 0
. 0

Detailed 0
molecular 0
organization 0
of 0
the 0
coding 0
and 0
upstream 0
regulatory 0
regions 0
of 0
the 0
murine 0
homeodomain B-gene
- I-gene
containing I-gene
gene I-gene
, 0
Msx B-gene
- I-gene
1 I-gene
, 0
is 0
reported 0
. 0

We 0
report 0
here 0
the 0
cloning 0
of 0
the 0
human B-gene
goosecoid I-gene
gene I-gene
( 0
GSC B-gene
) 0
from 0
a 0
genomic 0
library 0
and 0
the 0
sequence 0
of 0
its 0
encoded 0
protein 0
. 0

In 0
order 0
to 0
define 0
potential 0
candidate 0
genes 0
for 0
inherited 0
disorders 0
characterized 0
by 0
aberrant 0
gene 0
expression 0
, 0
we 0
utilized 0
Kruppel B-gene
- I-gene
related I-gene
sequences I-gene
to 0
isolate 0
zinc 0
finger 0
- 0
containing 0
cDNAs 0
. 0

This 0
virus 0
is 0
not 0
merely 0
a 0
South 0
African 0
strain 0
of 0
passion 0
fruit 0
woodiness 0
virus 0
( 0
PWV 0
) 0
: 0
the 0
deduced 0
CP B-gene
sequence I-gene
is 0
only 0
distantly 0
related 0
to 0
CPs B-gene
of 0
other 0
sequenced 0
strains 0
of 0
PWV 0
, 0
although 0
it 0
is 0
part 0
of 0
a 0
distinct 0
subgroup 0
of 0
potyviruses 0
related 0
to 0
PWV 0
. 0

The 0
ratio 0
of 0
the 0
activity 0
of 0
arogenate B-gene
dehydrogenase I-gene
to 0
that 0
of 0
prephenate B-gene
dehydrogenase I-gene
( 0
approximately 0
3:1 0
) 0
remained 0
constant 0
throughout 0
purification 0
, 0
and 0
the 0
two 0
activities 0
were 0
therefore 0
inseparable 0
. 0

The 0
isolated 0
POT1 B-gene
clones 0
hybridized 0
to 0
a 0
1.4 0
kb 0
RNA 0
species 0
, 0
which 0
was 0
induced 0
approximately 0
30 0
- 0
fold 0
when 0
oleate 0
was 0
the 0
carbon 0
source 0
. 0

The 0
Y. 0
lipolytica 0
genomic 0
POT1 B-gene
gene 0
was 0
disrupted 0
by 0
replacing 0
120 0
bp 0
of 0
its 0
coding 0
sequence 0
with 0
2.7 0
kbp 0
of 0
DNA 0
including 0
the 0
Y. 0
lipolytica 0
LEU2 B-gene
gene I-gene
. 0

A 0
leucine 0
zipper 0
domain 0
of 0
the 0
suppressor B-gene
of I-gene
Hairy I-gene
- I-gene
wing I-gene
protein I-gene
mediates 0
its 0
repressive 0
effect 0
on 0
enhancer 0
function 0
. 0

It 0
is 0
concluded 0
that 0
CT 0
should 0
be 0
routinely 0
employed 0
in 0
patients 0
with 0
N1 0
- 0
N3 0
neck 0
disease 0
to 0
determine 0
the 0
proper 0
electron 0
- 0
energy 0
prescription 0
. 0

The 0
predicted 0
DNA 0
- 0
binding 0
, 0
zinc B-gene
finger I-gene
domain I-gene
protein I-gene
sequence 0
was 0
strictly 0
conserved 0
. 0

60 0
patients 0
were 0
entered 0
into 0
a 0
randomised 0
study 0
comparing 0
vindesine 0
( 0
3 0
mg/m2/week 0
) 0
plus 0
interferon B-gene
- I-gene
alpha I-gene
2b I-gene
( 0
6 0
U/m2 0
3 0
times 0
per 0
week 0
) 0
to 0
vindesine 0
alone 0
or 0
to 0
interferon B-gene
alone 0
for 0
the 0
treatment 0
of 0
metastatic 0
malignant 0
melanoma 0
. 0

The 0
novel 0
Notch B-gene
homologue I-gene
mouse B-gene
Notch I-gene
3 I-gene
lacks 0
specific 0
epidermal B-gene
growth I-gene
factor I-gene
- I-gene
repeats I-gene
and 0
is 0
expressed 0
in 0
proliferating 0
neuroepithelium 0
. 0

BACKGROUND 0
: 0
We 0
conducted 0
a 0
phase 0
I 0
study 0
with 0
MDL 0
73,147EF 0
, 0
a 0
new 0
5 B-gene
hydroxytryptamine I-gene
3 I-gene
( I-gene
5 I-gene
- I-gene
HT3 I-gene
) I-gene
receptor I-gene
antagonist 0
, 0
in 0
25 0
patients 0
requiring 0
emetogenic 0
chemotherapy 0
. 0

In 0
the 0
presence 0
of 0
the 0
in 0
vivo 0
reducing 0
system 0
( 0
thioredoxin B-gene
, 0
thioredoxin B-gene
reductase I-gene
, 0
and 0
NADPH 0
) 0
, 0
however 0
, 0
each 0
of 0
these 0
mutants 0
catalyzed 0
the 0
formation 0
of 0
only 0
0.6 0
- 0
0.8 0
dCTPs 0
per 0
mole 0
of 0
enzyme 0
. 0

These 0
genetic 0
alterations 0
do 0
not 0
affect 0
synthesis 0
of 0
the 0
major 0
c B-gene
- I-gene
myc I-gene
protein I-gene
, 0
p64 B-gene
, 0
which 0
is 0
initiated 0
from 0
the 0
first 0
AUG 0
codon 0
in 0
exon 0
2 0
. 0

In 0
addition 0
, 0
both 0
the 0
exon 0
1 0
- 0
and 0
exon 0
2 0
- 0
initiated 0
forms 0
of 0
the 0
c B-gene
- I-gene
Myc I-gene
protein I-gene
stimulated 0
transcription 0
of 0
a 0
Myc/Max B-gene
- 0
responsive 0
reporter 0
construct 0
to 0
a 0
similar 0
level 0
. 0

Biological 0
activities 0
of 0
hematopoietic B-gene
growth I-gene
factors I-gene
that 0
lead 0
to 0
future 0
clinical 0
application 0
. 0

Expression 0
is 0
exclusively 0
limited 0
to 0
the 0
CNS 0
at 0
this 0
and 0
later 0
stages 0
. 0

Immunoreactive 0
AR B-gene
content 0
in 0
transfected 0
COS 0
- 0
1 0
cells 0
was 0
not 0
influenced 0
by 0
exposure 0
to 0
8 0
- 0
Br 0
- 0
cAMP 0
. 0

Disruption 0
of 0
any 0
one 0
of 0
the 0
four 0
genes 0
encoding 0
the 0
newly 0
identified 0
SRP B-gene
proteins I-gene
results 0
in 0
slow 0
cell 0
growth 0
and 0
inefficient 0
protein 0
translocation 0
across 0
the 0
ER 0
membrane 0
. 0

Genetic 0
alterations 0
in 0
elements 0
of 0
normal 0
signal 0
transduction 0
mechanisms 0
are 0
known 0
to 0
be 0
oncogenic 0
events 0
often 0
resulting 0
in 0
aberrant 0
activation 0
of 0
programs 0
of 0
gene 0
transcription 0
. 0

The 0
expression 0
pattern 0
of 0
GL2 B-gene
, 0
as 0
demonstrated 0
by 0
in 0
situ 0
hybridization 0
, 0
indicated 0
that 0
the 0
gene 0
is 0
expressed 0
in 0
trichome 0
progenitor 0
cells 0
and 0
at 0
stages 0
associated 0
with 0
trichome 0
development 0
. 0

NOT4 B-gene
interacts 0
with 0
NOT1 B-gene
and 0
NOT3 B-gene
in 0
the 0
two 0
- 0
hybrid 0
assay 0
, 0
and 0
overexpression 0
of 0
NOT3 B-gene
or 0
NOT4 B-gene
suppresses 0
not1 B-gene
and 0
not2 B-gene
mutations 0
. 0

Binding 0
site 0
selection 0
using 0
in 0
vitro 0
- 0
synthesized 0
proteins 0
reveals 0
that 0
the 0
ROR B-gene
alpha I-gene
1 I-gene
and 0
ROR B-gene
alpha I-gene
2 I-gene
isoforms I-gene
bind 0
DNA 0
as 0
monomers 0
to 0
hormone 0
response 0
elements 0
composed 0
of 0
a 0
6 0
- 0
bp 0
AT 0
- 0
rich 0
sequence 0
preceding 0
a 0
half 0
- 0
site 0
core 0
motif 0
PuGGTCA 0
( 0
RORE B-gene
) 0
. 0

The 0
p73pct1/p85cdc10 B-gene
complex 0
binds 0
both 0
in 0
vitro 0
and 0
in 0
vivo 0
to 0
p73pct1/p85cdc10 I-gene

We 0
show 0
that 0
the 0
en B-gene
stripes 0
expand 0
anteriorly 0
in 0
slp B-gene
mutant 0
embryos 0
and 0
that 0
slp B-gene
activity 0
is 0
an 0
absolute 0
requirement 0
for 0
maintenance 0
of 0
wg B-gene
expression 0
at 0
the 0
same 0
time 0
that 0
wg B-gene
transcription 0
is 0
dependent 0
on 0
hh B-gene
. 0

The 0
DNA 0
sequence 0
adjacent 0
to 0
the 0
lacZ B-gene
gene I-gene
has 0
been 0
determined 0
for 0
91 0
vegetative 0
fusion 0
genes 0
whose 0
products 0
have 0
been 0
localized 0
and 0
for 0
43 0
meiotically 0
induced 0
fusions 0
. 0

CMV 0
hyperimmunoglobulin B-gene
treatment 0
( 0
Cytotect 0
, 0
Biotest 0
) 0
was 0
started 0
( 0
2 0
ml/kg 0
bw 0
on 0
day 0
1 0
and 0
3 0
, 0
and 0
1 0
ml/kg 0
on 0
days 0
5 0
, 0
7 0
and 0
9 0
) 0
, 0
which 0
led 0
to 0
the 0
eradication 0
of 0
the 0
residual 0
infiltrate 0
and 0
CMV 0
- 0
DNA 0
in 0
the 0
myocardium 0
. 0

Internal 0
biliary 0
drainage 0
, 0
unlike 0
external 0
drainage 0
, 0
does 0
not 0
suppress 0
the 0
regeneration 0
of 0
cholestatic 0
rat 0
liver 0
after 0
partial 0
hepatectomy 0
. 0

ORF 0
2 0
potentially 0
encoded 0
a 0
hydrophobic 0
protein 0
of 0
29,705 0
Da 0
with 0
six 0
potential 0
membrane 0
- 0
spanning 0
regions 0
. 0

In 0
eight 0
groups 0
of 0
subjects 0
operating 0
various 0
hand 0
- 0
held 0
vibrating 0
tools 0
and 0
aged 0
from 0
30 0
to 0
59 0
years 0
, 0
the 0
prevalence 0
rates 0
of 0
vibration 0
- 0
induced 0
white 0
finger 0
( 0
VWF 0
) 0
and 0
numbness 0
, 0
pain 0
, 0
or 0
stiffness 0
in 0
the 0
upper 0
and 0
lower 0
extremities 0
were 0
investigated 0
. 0

DNA 0
sequence 0
analysis 0
showed 0
that 0
the 0
gene 0
was 0
525 0
bp 0
long 0
and 0
encoded 0
a 0
175 0
- 0
amino 0
- 0
acid 0
protein 0
with 0
a 0
molecular 0
weight 0
of 0
19,094 0
containing 0
a 0
21 0
- 0
residue 0
typical 0
lipoprotein 0
signal 0
peptide 0
and 0
consensus 0
prolipoprotein 0
processing 0
site 0
. 0

DNA 0
sequence 0
and 0
functions 0
of 0
the 0
actVI B-gene
region I-gene
of 0
the 0
actinorhodin B-gene
biosynthetic I-gene
gene I-gene
cluster I-gene
of I-gene
Streptomyces I-gene
coelicolor I-gene
A3 I-gene
( I-gene
2 I-gene
) I-gene
. 0

( 0
1992 0
) 0
Genomics 0
12 0
, 0
58 0
- 0
62 0
) 0
. 0

A 0
comparison 0
of 0
the 0
predicted 0
polypeptide 0
sequence 0
of 0
the 0
Drosophila 0
protein 0
with 0
the 0
equivalent 0
subunits 0
from 0
mouse 0
and 0
yeast 0
suggests 0
that 0
they 0
are 0
closely 0
related 0
and 0
defines 0
three 0
conserved 0
regions 0
which 0
are 0
likely 0
to 0
be 0
important 0
for 0
enzyme 0
activity 0
. 0

Plasmids 0
were 0
constructed 0
with 0
the 0
mouse 0
promoter 0
region 0
linked 0
to 0
the 0
reporter B-gene
gene I-gene
chloramphenicol I-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
, 0
and 0
transiently 0
and 0
stably 0
transfected 0
in 0
the 0
INS 0
- 0
1 0
cells 0
. 0

Cytoplasmic B-gene
dynein I-gene
is 0
a 0
multisubunit 0
, 0
microtubule 0
- 0
dependent 0
mechanochemical 0
enzyme 0
that 0
has 0
been 0
proposed 0
to 0
function 0
in 0
a 0
variety 0
of 0
intracellular 0
movements 0
, 0
including 0
minus 0
- 0
end 0
- 0
directed 0
transport 0
of 0
organelles 0
. 0

Identification 0
of 0
the 0
plakoglobin B-gene
- 0
binding 0
domain 0
in 0
desmoglein B-gene
and 0
its 0
role 0
in 0
plaque 0
assembly 0
and 0
intermediate 0
filament 0
anchorage 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
One 0
hundred 0
eighty 0
- 0
four 0
chemotherapy 0
- 0
naive 0
patients 0
receiving 0
high 0
- 0
dose 0
cisplatin 0
( 0
81 0
to 0
120 0
mg/m2 0
) 0
were 0
randomized 0
to 0
receive 0
one 0
of 0
four 0
granisetron 0
doses 0
( 0
5 0
, 0
10 0
, 0
20 0
, 0
or 0
40 0
micrograms/kg 0
) 0
administered 0
before 0
chemotherapy 0
. 0

Nine 0
new 0
naphthalene 0
related 0
compounds 0
( 0
I 0
, 0
IV 0
, 0
V 0
, 0
VII 0
- 0
XII 0
) 0
together 0
with 0
four 0
known 0
compounds 0
( 0
II 0
, 0
III 0
, 0
VI 0
, 0
XIII 0
) 0
were 0
isolated 0
from 0
the 0
root 0
bark 0
of 0
Oroxylum 0
indicum 0
Vent 0
. 0

Specifically 0
, 0
this 0
study 0
determined 0
the 0
influence 0
of 0
: 0
( 0
1 0
) 0
an 0
awareness 0
strategy 0
, 0
( 0
2 0
) 0
a 0
non 0
- 0
awareness 0
strategy 0
, 0
( 0
3 0
) 0
a 0
Five 0
- 0
Step 0
Approach 0
strategy 0
and 0
( 0
4 0
) 0
a 0
control 0
condition 0
. 0

Mutually 0
exclusive 0
interaction 0
of 0
the 0
adenovirus B-gene
E4 I-gene
- I-gene
6/7 I-gene
protein I-gene
and 0
the 0
retinoblastoma B-gene
gene I-gene
product I-gene
with 0
internal 0
domains 0
of 0
E2F B-gene
- I-gene
1 I-gene
and 0
DP B-gene
- I-gene
1 I-gene
. 0

As 0
shown 0
previously 0
, 0
EBNA2 B-gene
transactivates 0
the 0
promoters 0
of 0
the 0
viral B-gene
latent I-gene
membrane I-gene
proteins I-gene
. 0

We 0
previously 0
showed 0
that 0
v B-gene
- I-gene
Rel I-gene
, 0
the 0
oncoprotein 0
of 0
the 0
avian 0
retrovirus 0
Rev 0
- 0
T 0
, 0
can 0
increase 0
expression 0
from 0
promoters 0
containing 0
binding 0
sites 0
for 0
the 0
cellular 0
transcription 0
factor 0
Sp1 B-gene
in 0
chicken 0
embryo 0
fibroblasts 0
( 0
S 0
. 0

Previous 0
studies 0
have 0
demonstrated 0
that 0
the 0
TATA 0
element 0
is 0
critical 0
for 0
basal 0
and 0
Tat B-gene
- 0
induced 0
HIV 0
- 0
1 0
gene 0
expression 0
. 0

A 0
comparison 0
of 0
the 0
nucleotide 0
sequence 0
of 0
the 0
p54 B-gene
gene I-gene
carried 0
by 0
two 0
virulent 0
ASFV 0
strains 0
( 0
E70 0
and 0
E75 0
) 0
with 0
that 0
obtained 0
from 0
virus 0
Ba71V 0
showed 0
100 0
% 0
similarity 0
. 0

The 0
p55 B-gene
mRNA I-gene
is 0
undetectable 0
in 0
non 0
- 0
EBV 0
- 0
infected 0
B 0
- 0
and 0
T 0
- 0
cell 0
lines 0
or 0
in 0
a 0
myelomonocytic 0
cell 0
line 0
( 0
U937 0
) 0
. 0

A 0
simple 0
registration 0
as 0
an 0
incentive 0
for 0
improvement 0

The 0
transverse 0
magnetization 0
decays 0
mentioned 0
above 0
exhibited 0
two 0
components 0
, 0
a 0
T2 0
fast 0
( 0
T2f 0
) 0
and 0
a 0
T2 0
slow 0
( 0
T2s 0
) 0
component 0
. 0

RESULTS 0
: 0
The 0
diagnostic 0
quality 0
of 0
FDG 0
images 0
was 0
at 0
least 0
as 0
good 0
as 0
that 0
of 0
their 0
Tl 0
- 0
201 0
counterparts 0
, 0
with 0
less 0
liver 0
background 0
in 0
all 0
but 0
one 0
FDG 0
study 0
. 0

The 0
coordinated 0
expression 0
of 0
CD4 B-gene
and 0
CD8 B-gene
during 0
T 0
- 0
cell 0
development 0
is 0
tightly 0
coupled 0
with 0
the 0
maturation 0
state 0
of 0
the 0
T 0
cell 0
. 0

Expression 0
of 0
a 0
dominant B-gene
- I-gene
negative I-gene
ras I-gene
gene I-gene
also 0
blocks 0
TIS10/PGS2 B-gene
induction 0
by 0
TIS10/PGS2 I-gene

The 0
dying 0
tTG B-gene
- 0
transfected 0
cells 0
exhibit 0
both 0
cytoplasmic 0
and 0
nuclear 0
changes 0
characteristic 0
of 0
cells 0
undergoing 0
apoptosis 0
. 0

Using 0
an 0
RNase B-gene
H I-gene
- 0
mediated 0
mapping 0
technique 0
, 0
we 0
show 0
that 0
the 0
64 0
- 0
kDa 0
subunit 0
of 0
CstF B-gene
can 0
be 0
photo 0
cross 0
- 0
linked 0
to 0
pre 0
- 0
mRNAs 0
at 0
U 0
- 0
rich 0
regions 0
located 0
downstream 0
of 0
the 0
cleavage 0
site 0
of 0
the 0
simian 0
virus 0
40 0
late 0
and 0
adenovirus B-gene
L3 I-gene
pre I-gene
- I-gene
mRNAs I-gene
. 0

The 0
protein 0
encoded 0
is 0
114 0
kDa 0
and 0
contains 0
eight 0
zinc 0
finger 0
motifs 0
, 0
seven 0
of 0
which 0
are 0
present 0
in 0
two 0
clusters 0
at 0
opposite 0
ends 0
of 0
the 0
molecule 0
. 0

Tissue 0
- 0
specific 0
expression 0
of 0
the 0
diazepam B-gene
- I-gene
binding I-gene
inhibitor I-gene
in 0
Drosophila 0
melanogaster 0
: 0
cloning 0
, 0
structure 0
, 0
and 0
localization 0
of 0
the 0
gene 0
. 0

Using 0
a 0
v B-gene
- I-gene
erbA I-gene
probe 0
, 0
we 0
obtained 0
a 0
cDNA 0
which 0
encodes 0
a 0
novel 0
445 0
- 0
amino 0
- 0
acid 0
protein 0
, 0
RLD B-gene
- I-gene
1 I-gene
, 0
that 0
contains 0
the 0
characteristic 0
domains 0
of 0
nuclear 0
receptors 0
. 0

Only 0
two 0
of 0
the 0
isoforms 0
possess 0
the 0
N 0
- 0
terminal 0
zinc 0
finger 0
domain 0
that 0
is 0
necessary 0
and 0
sufficient 0
for 0
TdT B-gene
promoter I-gene
binding 0
. 0

This 0
study 0
provides 0
direct 0
evidence 0
that 0
USF B-gene
, 0
a 0
member 0
of 0
the 0
basic B-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
leucine I-gene
zipper I-gene
family I-gene
, 0
binds 0
to 0
MLE1 B-gene
, 0
HF B-gene
- I-gene
1a I-gene
, 0
and 0
PRE B-gene
B I-gene
sites I-gene
and 0
suggests 0
that 0
it 0
is 0
a 0
component 0
of 0
protein 0
complexes 0
that 0
may 0
coordinately 0
control 0
the 0
expression 0
of 0
MLC B-gene
- I-gene
2v I-gene
and 0
alpha B-gene
- I-gene
myosin I-gene
heavy I-gene
- I-gene
chain I-gene
genes I-gene
. 0

Human 0
T 0
- 0
cell 0
leukemia 0
virus 0
type 0
I 0
Tax B-gene
activation 0
of 0
NF B-gene
- I-gene
kappa I-gene
B/Rel I-gene
involves 0
phosphorylation 0
and 0
degradation 0
of 0
B/Rel I-gene

Activation 0
of 0
c B-gene
- I-gene
fos I-gene
gene I-gene
expression 0
by 0
a 0
kinase 0
- 0
deficient 0
epidermal B-gene
growth I-gene
factor I-gene
receptor I-gene
. 0

Because 0
endogenous 0
HSF B-gene
DNA 0
- 0
binding 0
activity 0
is 0
low 0
and 0
anti B-gene
- I-gene
hHSF1 I-gene
antibody I-gene
does 0
not 0
recognize 0
Xenopus B-gene
HSF I-gene
, 0
we 0
employed 0
this 0
system 0
for 0
mapping 0
regions 0
in 0
hHSF1 B-gene
that 0
are 0
required 0
for 0
the 0
maintenance 0
of 0
the 0
monomeric 0
state 0
. 0

Enhancers 0
containing 0
disrupted 0
Ets B-gene
- I-gene
1 I-gene
binding I-gene
sites I-gene
were 0
tested 0
in 0
transient 0
expression 0
assays 0
in 0
the 0
murine 0
T 0
- 0
cell 0
line 0
EL4.E1 0
; 0
alterations 0
in 0
the 0
LVb 0
element 0
affected 0
constitutive 0
enhancer 0
activity 0
, 0
while 0
mutation 0
of 0
either 0
the 0
LVb 0
or 0
LVc 0
element 0
disrupted 0
phorbol 0
ester 0
- 0
induced 0
enhancer 0
activity 0
. 0

The 0
predominant 0
binding 0
activity 0
was 0
not 0
Ets B-gene
- I-gene
1 I-gene
but 0
rather 0
two 0
independent 0
DNA 0
- 0
protein 0
complexes 0
that 0
comigrated 0
in 0
mobility 0
shift 0
assays 0
. 0

These 0
RZR B-gene
subtypes 0
represent 0
members 0
of 0
a 0
new 0
family 0
of 0
orphan B-gene
nuclear I-gene
receptors I-gene
that 0
most 0
likely 0
regulate 0
specific 0
gene 0
expression 0
. 0

Interestingly 0
, 0
these 0
response 0
elements 0
display 0
dramatically 0
reduced 0
affinity 0
for 0
retinoic B-gene
acid I-gene
receptor I-gene
- 0
retinoid B-gene
- I-gene
X I-gene
receptor I-gene
heterodimers 0
. 0

Treatment 0
with 0
amphotericin 0
B 0
and 0
flucytosine 0
led 0
to 0
improvement 0
of 0
the 0
symptoms 0
but 0
did 0
not 0
eradicate 0
the 0
micro 0
- 0
organisms 0
from 0
the 0
cerebrospinal 0
fluid 0
( 0
CSF 0
) 0
. 0

The 0
unexpected 0
presence 0
of 0
the 0
tRNA B-gene
( I-gene
trp I-gene
) I-gene
( I-gene
CCA I-gene
) I-gene
- I-gene
gene I-gene
transcript I-gene
in I-gene
mitochondria I-gene
is 0
also 0
reported 0
. 0

The 0
parameters 0
of 0
nonspecific 0
humoral 0
immunity 0
- 0
- 0
serum B-gene
immunoglobulins I-gene
and 0
immune 0
complexes 0
- 0
- 0
were 0
evaluated 0
in 0
irradiated 0
group 0
of 0
patients 0
with 0
uterine 0
cervix 0
carcinoma 0
( 0
Stages 0
IIB 0
and 0
IIIB 0
) 0
, 0
during 0
one 0
year 0
follow 0
up 0
. 0

Mutation 0
of 0
KRKR 0
to 0
NGER 0
retains 0
MO15 B-gene
in 0
the 0
cytoplasmic 0
compartment 0
, 0
whilst 0
the 0
wild 0
- 0
type 0
protein 0
is 0
detected 0
exclusively 0
in 0
the 0
nucleus 0
. 0

To 0
confirm 0
the 0
binding 0
of 0
protein 0
to 0
these 0
sites 0
in 0
cells 0
, 0
we 0
carried 0
out 0
an 0
in 0
vivo 0
genomic 0
footprinting 0
analysis 0
of 0
this 0
portion 0
of 0
the 0
TGF B-gene
alpha I-gene
promoter I-gene
in 0
normal 0
and 0
transformed 0
rat 0
liver 0
epithelial 0
cell 0
lines 0
that 0
express 0
the 0
endogenous 0
gene 0
at 0
varying 0
levels 0
. 0

Strikingly 0
, 0
this 0
subdomain 0
is 0
also 0
present 0
in 0
the 0
otherwise 0
unrelated 0
N 0
- 0
terminal 0
activating 0
region 0
of 0
p58c B-gene
- I-gene
ets I-gene
- I-gene
2 I-gene
and 0
was 0
thus 0
named 0
BEC B-gene
for 0
Ets B-gene
- I-gene
1 I-gene
- I-gene
beta/Ets I-gene
beta/Ets I-gene
- I-gene
2 I-gene
- I-gene
Conserved I-gene
sequence I-gene
. 0

This 0
work 0
unravels 0
a 0
new 0
model 0
for 0
the 0
ets B-gene
- I-gene
1/ets I-gene
1/ets I-gene
- I-gene
2 I-gene
gene I-gene
's 0
evolution 0
, 0
based 0
for 0
the 0
first 0
time 0
on 0
both 0
structural 0
and 0
functional 0
evidences 0
. 0

The 0
v B-gene
- I-gene
ets I-gene
oncogene I-gene
of 0
the 0
avian 0
retrovirus 0
E26 0
differs 0
from 0
its 0
cellular 0
progenitor 0
p68c B-gene
- I-gene
ets I-gene
- I-gene
1 I-gene
by 0
two 0
amino 0
acid 0
substitutions 0
( 0
alanine 0
285 0
and 0
isoleucine 0
445 0
in 0
c B-gene
- I-gene
ets I-gene
- I-gene
1 I-gene
both 0
substituted 0
by 0
valine 0
in 0
v B-gene
- I-gene
ets I-gene
, 0
mutations 0
A 0
and 0
B 0
respectively 0
) 0
and 0
its 0
carboxy 0
- 0
terminal 0
end 0
( 0
mutation 0
C 0
) 0
. 0

Consequently 0
functional 0
mRNAs 0
can 0
be 0
produced 0
by 0
endogenous B-gene
RNA I-gene
polymerase I-gene
I 0
. 0

The 0
individual 0
subunits 0
of 0
Ku B-gene
have 0
been 0
difficult 0
to 0
isolate 0
from 0
human 0
cells 0
without 0
denaturation 0
and 0
attempts 0
to 0
produce 0
functional B-gene
recombinant I-gene
Ku I-gene
have 0
been 0
largely 0
unsuccessful 0
. 0

Using 0
this 0
method 0
, 0
we 0
were 0
able 0
to 0
select 0
strong 0
enhancer 0
- 0
type 0
activation 0
domains 0
from 0
the 0
immediate B-gene
early I-gene
regions I-gene
of 0
two 0
herpesviruses 0
, 0
namely 0
pseudorabies 0
virus 0
and 0
bovine 0
herpesvirus 0
1 0
. 0

Remarkably 0
, 0
U21 B-gene
contains 0
a 0
long 0
stretch 0
( 0
13 0
nt 0
. 0
) 0
of 0
complementarity 0
to 0
a 0
highly 0
conserved 0
sequence 0
in 0
28S B-gene
rRNA I-gene
. 0

A 0
genetic 0
system 0
was 0
devised 0
to 0
select 0
for 0
pi B-gene
protein I-gene
mutants I-gene
which 0
discriminate 0
between 0
IR 0
and 0
DR 0
( 0
York 0
et 0
al. 0
, 0
Gene 0
( 0
Amst 0
. 0
) 0
116 0
, 0
7 0
- 0
12 0
, 0
1992 0
; 0
York 0
and 0
Filutowicz 0
, 0
J 0
. 0

Univariate 0
statistical 0
analysis 0
based 0
on 0
Kaplan 0
- 0
Meier 0
- 0
estimates 0
and 0
Log 0
- 0
Rank 0
- 0
Test 0
showed 0
the 0
following 0
prognostically 0
beneficial 0
factors 0
: 0
Limited 0
disease 0
stage 0
( 0
p 0
= 0
0.009 0
) 0
, 0
NSE B-gene
serum 0
level 0
less 0
than 0
25 0
micrograms/l 0
( 0
p 0
= 0
0.016 0
) 0
, 0
serum 0
alkaline B-gene
phosphatase I-gene
less 0
than 0
200 0
U/l 0
( 0
p 0
= 0
0.035 0
) 0
, 0
normal 0
serum 0
albumin B-gene
( 0
p 0
= 0
0.003 0
) 0
and 0
activity 0
index 0
of 0
minimum 0
of 0
70 0
( 0
p 0
< 0
0.001 0
) 0
. 0

These 0
results 0
provide 0
evidence 0
of 0
a 0
bypass 0
of 0
p53 B-gene
- 0
induced 0
Waf1/Cip1 B-gene
- 0
mediated 0
cell 0
cycle 0
regulatory 0
pathways 0
by 0
a 0
member 0
of 0
the 0
Waf1/Cip1 I-gene

HBx B-gene
strongly 0
elevates 0
levels 0
of 0
GTP 0
- 0
bound 0
Ras B-gene
, 0
activated 0
and 0
phosphorylated 0
Raf B-gene
, 0
and 0
tyrosine 0
- 0
phosphorylated 0
and 0
activated 0
MAP B-gene
kinase I-gene
. 0

Role 0
of 0
c B-gene
- I-gene
myc I-gene
in 0
simian B-gene
virus I-gene
40 I-gene
large I-gene
tumor I-gene
antigen I-gene
- 0
induced 0
DNA 0
synthesis 0
in 0
quiescent 0
3T3 0
- 0
L1 0
mouse 0
fibroblasts 0
. 0

All 0
groups 0
were 0
challenged 0
subsequently 0
with 0
naloxone 0
( 0
0.4 0
mg/kg 0
) 0
in 0
the 0
distinctive 0
environment 0
and 0
then 0
observed 0
for 0
signs 0
of 0
opiate 0
withdrawal 0
. 0

Laser 0
therapy 0
of 0
penile 0
carcinoma 0

A 0
15.1 0
kb 0
fragment 0
of 0
the 0
yeast 0
genome 0
was 0
allocated 0
to 0
the 0
centromeric 0
region 0
of 0
chromosome 0
XIV 0
by 0
genetic 0
mapping 0
. 0

A 0
third 0
one 0
is 0
homologous 0
in 0
half 0
of 0
its 0
length 0
to 0
the 0
prokaryotic B-gene
hydantoinase I-gene
HyuA B-gene
and 0
in 0
the 0
other 0
half 0
to 0
hydatoinase B-gene
HyuB B-gene
. 0

It 0
was 0
shown 0
that 0
estradiol 0
concentrations 0
obtained 0
after 0
estradiol 0
valerate 0
and 0
micronized 0
estradiol 0
ingestion 0
were 0
dependent 0
on 0
the 0
patient 0
's 0
age 0
as 0
well 0
as 0
on 0
the 0
constitutional 0
type 0
. 0

There 0
were 0
9 0
patients 0
in 0
NYHA 0
class 0
III 0
and 0
8 0
in 0
class 0
IV 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Constipation 0
is 0
not 0
a 0
risk 0
factor 0
for 0
hemorrhoids 0
: 0
a 0
case 0
- 0
control 0
study 0
of 0
potential 0
etiological 0
agents 0
. 0

Of 0
419 0
persons 0
surveyed 0
, 0
207 0
( 0
49.4 0
% 0
) 0
were 0
antigen 0
- 0
positive 0
with 0
the 0
Og4C3 B-gene
assay 0
. 0

TG 0
- 0
day 0
and 0
TG 0
- 0
night 0
were 0
19.4 0
+/ 0
- 0
6.1 0
% 0
, 0
26.6 0
+/ 0
- 0
5.3 0
% 0
, 0
( 0
750 0
mm3 0
< 0
T 0
. 0

Vibrio 0
cholerae 0
O139 0
in 0
Calcutta 0
. 0

Ten 0
volunteers 0
were 0
tested 0
at 0
18,000 0
ft 0
( 0
5,486 0
m 0
) 0
, 0
and 0
through 0
12,000 0
, 0
8,000 0
, 0
and 0
5,000 0
ft 0
( 0
3,657 0
, 0
2,438 0
, 0
and 0
1,524 0
m 0
) 0
with 0
directional 0
sounds 0
recorded 0
via 0
a 0
dummy 0
head 0
microphone 0
and 0
presented 0
binaurally 0
. 0

Upon 0
differentiation 0
with 0
retinoic 0
acid 0
( 0
RA 0
) 0
, 0
transcription 0
of 0
the 0
Rex B-gene
- I-gene
1 I-gene
gene I-gene
decreases 0
rapidly 0
. 0

Sequence 0
analysis 0
of 0
the 0
zebrafish B-gene
egr1 I-gene
coding I-gene
region I-gene
revealed 0
a 0
high 0
level 0
of 0
homology 0
to 0
the 0
mouse 0
, 0
rat 0
, 0
and 0
human B-gene
Egr1 I-gene
genes I-gene
with 0
the 0
notable 0
exception 0
of 0
a 0
polymorphic 0
, 0
triplet 0
nucleotide 0
repeat 0
sequence 0
in 0
the 0
region 0
coding 0
for 0
the 0
amino 0
terminus 0
of 0
the 0
Egr1 B-gene
protein I-gene
. 0

The 0
fibrinogen B-gene
, 0
serum 0
proteins 0
, 0
sodium 0
heparin 0
and 0
membrane 0
contributed 0
to 0
Cm 0
by 0
20 0
% 0
, 0
14 0
% 0
, 0
2 0
% 0
and 0
64 0
% 0
, 0
respectively 0
. 0

In 0
these 0
vectors 0
the 0
chimeric B-gene
long I-gene
terminal I-gene
repeat I-gene
( 0
chLTR B-gene
) 0
drives 0
the 0
expression 0
of 0
the 0
chloramphenicol B-gene
acetyl I-gene
transferase I-gene
( 0
CAT B-gene
) 0
reporter 0
gene 0
that 0
is 0
followed 0
by 0
an 0
internal 0
SV40 B-gene
virus I-gene
early I-gene
region I-gene
promoter I-gene
linked 0
to 0
the 0
neomycin B-gene
phosphotransferase I-gene
II I-gene
( 0
NEO B-gene
) 0
gene 0
. 0

Optima 0
) 0
genomic 0
library 0
by 0
hybridizing 0
with 0
elicitor 0
- 0
induced 0
stilbene B-gene
synthase I-gene
cDNA I-gene
as 0
a 0
probe 0
. 0

A 0
total 0
of 0
125 0
acute 0
leukemia 0
adult 0
patients 0
were 0
autografted 0
with 0
bone 0
marrow 0
( 0
BM 0
) 0
purged 0
by 0
mafosfamide 0
( 0
ASTA 0
Z 0
) 0
during 0
the 0
period 0
of 0
January 0
1983 0
to 0
January 0
1993 0
. 0

The 0
pretransplant 0
regimen 0
consisted 0
of 0
cyclophosphamide 0
( 0
120 0
mg/kg 0
) 0
and 0
total 0
body 0
irradiation 0
. 0

The 0
site 0
- 0
directed 0
mutation 0
of 0
the 0
kappa B-gene
B I-gene
motif I-gene
in 0
IL B-gene
- I-gene
6/CAT I-gene
plasmid 0
resulted 0
in 0
the 0
complete 0
abrogation 0
of 0
6/CAT I-gene

Curiously 0
, 0
testololactone 0
was 0
earlier 0
and 0
more 0
widely 0
used 0
than 0
aminoglutethimide 0
in 0
treating 0
advanced 0
breast 0
carcinoma 0
. 0

Use 0
of 0
the 0
vena 0
cava 0
to 0
extend 0
the 0
right 0
renal 0
vein 0
for 0
cadaver 0
transplantation 0
is 0
controversial 0
. 0

Enhanced 0
hepatic 0
portal 0
blood 0
flow 0
induced 0
by 0
prostaglandin 0
E1 0
following 0
liver 0
transplantation 0
in 0
pigs 0
. 0

One 0
gene 0
appears 0
ubiquitously 0
expressed 0
while 0
the 0
other 0
is 0
prominently 0
expressed 0
in 0
muscle 0
. 0

For 0
HeLa 0
, 0
293 0
, 0
U937 0
, 0
and 0
A549 0
cells 0
, 0
participation 0
of 0
E2F B-gene
- I-gene
1 I-gene
, 0
DP B-gene
- I-gene
1 I-gene
, 0
cyclin B-gene
A I-gene
, 0
and 0
RB B-gene
was 0
involved 0
in 0
formation 0
of 0
some 0
complexes 0
only 0
, 0
assuming 0
participation 0
of 0
factors 0
different 0
from 0
E2F B-gene
- I-gene
1 I-gene
or 0
DP B-gene
- I-gene
1 I-gene
in 0
others 0
. 0

E1A B-gene
autoactivation 0
mediated 0
by 0
these 0
sites 0
was 0
about 0
twofold 0
compared 0
with 0
a 0
ninefold 0
activation 0
described 0
for 0
the 0
complete 0
E1A B-gene
promoter I-gene
. 0

Cestode 0
invasion 0
in 0
irradiated 0
host 0
organism 0
increases 0
the 0
negative 0
effect 0
of 0
ionizing 0
radiation 0
on 0
the 0
hamster 0
immune 0
system 0
. 0

During 0
heat 0
exposure 0
, 0
chicks 0
that 0
had 0
been 0
subjected 0
to 0
early 0
60 0
% 0
restriction 0
with 0
non 0
- 0
metyrapone 0
- 0
treated 0
food 0
had 0
lower 0
H/L 0
ratios 0
and 0
improved 0
resistance 0
to 0
marble 0
spleen 0
disease 0
infection 0
. 0

Analyses 0
of 0
additional 0
tumors 0
induced 0
in 0
mice 0
from 0
two 0
reciprocal 0
crosses 0
, 0
A/J 0
x 0
C3H/HeJ 0
F1 0
( 0
hereafter 0
called 0
AC3F1 0
) 0
and 0
C3H/HeJ 0
x 0
A/J 0
F1 0
( 0
hereafter 0
called 0
C3AF1 0
) 0
, 0
provided 0
evidence 0
for 0
the 0
inactivation 0
of 0
one 0
allele 0
of 0
the 0
putative 0
chromosome 0
4 0
tumor 0
suppressor 0
gene 0
by 0
parental 0
imprinting 0
. 0

ERV1 B-gene
is 0
involved 0
in 0
the 0
cell 0
- 0
division 0
cycle 0
and 0
the 0
maintenance 0
of 0
mitochondrial 0
genomes 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Lesion 0
diameters 0
of 0
greater 0
than 0
20 0
mm 0
and 0
the 0
large 0
sessile 0
- 0
type 0
configurations 0
were 0
factors 0
that 0
were 0
associated 0
with 0
incomplete 0
removal 0
. 0

Routinely 0
collected 0
, 0
processed 0
and 0
stored 0
breast 0
cancer 0
tissue 0
blocks 0
recovered 0
from 0
the 0
archives 0
of 0
the 0
Pathology 0
laboratory 0
in 0
Dar 0
es 0
Salaam 0
after 0
storage 0
of 0
up 0
to 0
3 0
years 0
were 0
analysed 0
by 0
a 0
flow 0
cytometry 0
for 0
DNA 0
ploidy 0
and 0
S 0
- 0
phase 0
fraction 0
. 0

Cbf3 B-gene
contains 0
three 0
proteins 0
, 0
Cbf3a B-gene
, 0
Cbf3b B-gene
and 0
Cbf3c B-gene
. 0

Such 0
an 0
interaction 0
could 0
be 0
detected 0
using 0
a 0
GST B-gene
- 0
POU B-gene
fusion 0
protein 0
bound 0
to 0
glutathione 0
- 0
agarose 0
beads 0
. 0

These 0
mutations 0
are 0
localized 0
in 0
the 0
same 0
region 0
where 0
the 0
HSV B-gene
transactivator I-gene
VP16 I-gene
binds 0
, 0
but 0
did 0
not 0
coincide 0
with 0
the 0
VP16 B-gene
contacts 0
. 0

In 0
general 0
, 0
the 0
filtration 0
rate 0
in 0
relevant 0
areas 0
appears 0
to 0
be 0
an 0
integrative 0
and 0
easily 0
determined 0
parameter 0
, 0
reflecting 0
hormonal 0
and 0
neurogenic 0
vascular 0
as 0
well 0
as 0
local 0
interstitial 0
control 0
of 0
the 0
Starling 0
forces 0
. 0

Notably 0
, 0
these 0
residues 0
are 0
located 0
in 0
different 0
domains 0
. 0

However 0
, 0
rapamycin 0
inhibited 0
proliferation 0
of 0
Ba/F3 0
- 0
EpoRgp55 0
but 0
not 0
of 0
MEL 0
cells 0
despite 0
inhibition 0
of 0
p70 B-gene
S6 I-gene
kinase I-gene
activity 0
in 0
both 0
cells 0
. 0

Intraventricular 0
injection 0
of 0
( 0
2S,1'R,2'R,3'R 0
) 0
- 0
2 0
- 0
( 0
2,3 0
- 0
dicarboxycyclopropyl 0
) 0
glycine 0
( 0
DCG 0
- 0
IV 0
) 0
, 0
a 0
potent 0
agonist 0
for 0
metabotropic 0
glutamate B-gene
receptors I-gene
, 0
to 0
rats 0
retarded 0
dose 0
- 0
dependently 0
the 0
recovery 0
from 0
halothane 0
anesthesia 0
at 0
a 0
dose 0
range 0
from 0
30 0
to 0
300 0
pmol/rat 0
. 0

The 0
hepatocyte B-gene
nuclear I-gene
factor I-gene
- I-gene
3 I-gene
( 0
HNF B-gene
- I-gene
3 I-gene
) 0
/forkhead B-gene
( 0
fkh B-gene
) 0
proteins 0
consist 0
of 0
an 0
extensive 0
family 0
of 0
tissue 0
- 0
specific 0
and 0
developmental 0
gene 0
regulators 0
which 0
share 0
homology 0
within 0
the 0
winged 0
helix 0
DNA 0
binding 0
motif 0
. 0

Homozygous 0
null 0
embryos 0
also 0
displayed 0
abnormalities 0
in 0
heart 0
development 0
, 0
consistent 0
with 0
the 0
conclusion 0
that 0
Tek B-gene
is 0
necessary 0
for 0
endocardial/myocardial 0
interactions 0
during 0
development 0
. 0

Interestingly 0
, 0
dTFIIA B-gene
- I-gene
L/S I-gene
is 0
also 0
able 0
to 0
significantly 0
enhance 0
transcriptional 0
activation 0
by 0
upstream 0
transcription 0
factors 0
including 0
Sp1 B-gene
, 0
VP16 B-gene
, 0
and 0
NTF B-gene
- I-gene
1 I-gene
. 0

A 0
strong 0
trithorax B-gene
binding I-gene
site I-gene
was 0
found 0
at 0
the 0
cytological 0
location 0
of 0
the 0
fork B-gene
head I-gene
gene I-gene
, 0
a 0
region 0
- 0
specific 0
homeotic B-gene
gene I-gene
not 0
located 0
within 0
a 0
homeotic B-gene
complex I-gene
. 0

In 0
particular 0
, 0
changes 0
in 0
intracellular 0
Ca2+ 0
have 0
the 0
potential 0
to 0
either 0
inhibit 0
or 0
augment 0
the 0
ability 0
of 0
cAMP 0
to 0
stimulate 0
transcription 0
, 0
depending 0
on 0
the 0
presence 0
of 0
specific 0
forms 0
of 0
Ca2+/calmodulin B-gene
- I-gene
dependent I-gene
protein I-gene
kinases I-gene
. 0

Antibodies 0
directed 0
against 0
the 0
SNM1 B-gene
protein I-gene
immunoprecipitated 0
RNase B-gene
MRP I-gene
RNA I-gene
from 0
whole 0
- 0
cell 0
extracts 0
without 0
precipitating 0
the 0
structurally 0
and 0
functionally 0
related 0
RNase B-gene
P I-gene
RNA I-gene
. 0

C/EBP B-gene
alpha I-gene
also 0
activates 0
the 0
promoter 0
of 0
the 0
rat B-gene
class I-gene
- I-gene
I I-gene
ADH I-gene
gene I-gene
in 0
a 0
sequence 0
- 0
specific 0
manner 0
[ 0
Potter 0
et 0
al. 0
, 0
Arch 0
. 0

C/EBP B-gene
alpha I-gene
also 0
activates 0
the 0
promoter 0
of 0
the 0
rat B-gene
class I-gene
- I-gene
I I-gene
ADH I-gene
gene I-gene
in 0
a 0
sequence 0
- 0
specific 0
manner 0
[ 0
Potter 0
et 0
al. 0
, 0
Arch 0
. 0

Our 0
results 0
show 0
that 0
the 0
ORF 0
of 0
hAMPK B-gene
encodes 0
552 0
amino 0
acids 0
( 0
aa 0
) 0
( 0
62.250 0
kDa 0
) 0
and 0
is 0
highly 0
conserved 0
with 0
rAMPK B-gene
with 0
identities 0
of 0
97.3 0
and 0
90 0
% 0
at 0
the 0
aa 0
and 0
nt 0
levels 0
, 0
respectively 0
. 0

In 0
human 0
brain 0
, 0
contactin B-gene
was 0
first 0
identified 0
by 0
amino 0
terminal 0
and 0
peptide 0
sequencing 0
of 0
the 0
lentil B-gene
- I-gene
lectin I-gene
- I-gene
binding I-gene
glycoprotein I-gene
Gp135 I-gene
. 0

The 0
centromeric 0
YAC 0
contig 0
, 0
which 0
consists 0
of 0
23 0
overlapping 0
YACs 0
and 0
orders 0
19 0
sequence 0
- 0
tagged 0
sites 0
( 0
STSs 0
) 0
, 0
covers 0
a 0
minimum 0
of 0
2.2 0
Mb 0
and 0
spans 0
the 0
Ewing 0
sarcoma 0
breakpoint 0
. 0
c B-gene
- I-gene
ets I-gene
1 I-gene
and 0
Fli B-gene
- I-gene
1 I-gene
, 0
two 0
members 0
of 0
the 0
ets B-gene
family I-gene
, 0
have 0
been 0
linked 0
within 0
400 0
kb 0
of 0
intervening 0
DNA 0
within 0
this 0
contig 0
, 0
which 0
also 0
comprises 0
a 0
polymorphic 0
microsatellite 0
, 0
D11S912 B-gene
( 0
CA 0
) 0
n 0
, 0
which 0
we 0
have 0
localized 0
within 0
the 0
Fli B-gene
- I-gene
1 I-gene
gene I-gene
. 0

A 0
cDNA 0
for 0
a 0
newly 0
discovered 0
pseudogene 0
, 0
closely 0
related 0
to 0
the 0
mouse B-gene
mast I-gene
cell I-gene
chymases I-gene
was 0
isolated 0
by 0
polymerase 0
chain 0
reaction 0
amplification 0
from 0
a 0
mouse 0
connective 0
tissue 0
- 0
like 0
mast 0
cell 0
line 0
. 0

IFI16 B-gene
consists 0
of 0
ten 0
exons 0
and 0
nine 0
intervening 0
introns 0
spanning 0
at 0
least 0
28 0
kilobases 0
( 0
kb 0
) 0
of 0
DNA 0
. 0

Courses 0
were 0
repeated 0
every 0
four 0
weeks 0
. 0

Peter 0
Elfer 0
explores 0
the 0
implications 0
of 0
the 0
ruling 0
. 0

Other 0
adverse 0
events 0
with 0
incidences 0
significantly 0
higher 0
than 0
with 0
placebo 0
were 0
dizziness 0
, 0
constipation 0
, 0
sweating 0
, 0
nervousness 0
, 0
and 0
abnormal 0
ejaculation 0
. 0

Homology 0
was 0
also 0
detected 0
between 0
the 0
putative 0
transit 0
peptide 0
sequence 0
of 0
cysteine B-gene
synthase I-gene
C I-gene
and 0
other 0
mitochondrion 0
- 0
targeting 0
leader 0
sequences 0
. 0

Furthermore 0
, 0
our 0
data 0
also 0
show 0
that 0
, 0
in 0
addition 0
to 0
TEF B-gene
- I-gene
1 I-gene
, 0
another 0
HF B-gene
- I-gene
1a I-gene
- I-gene
related I-gene
factor I-gene
may 0
be 0
recognized 0
by 0
the 0
alpha B-gene
- I-gene
MHC I-gene
gene I-gene
EM 0
element 0
. 0

Rat B-gene
kidney I-gene
carboxylesterase I-gene
. 0

Recombinant B-gene
I I-gene
- I-gene
kappa I-gene
B I-gene
alpha I-gene
inhibited 0
kappa B-gene
B I-gene
motif I-gene
binding 0
by 0
nuclear B-gene
factor I-gene
- I-gene
kappa I-gene
B1 I-gene
, 0
RelA B-gene
, 0
and 0
c B-gene
- I-gene
Rel I-gene
as 0
indicated 0
by 0
studies 0
using 0
UV 0
radiation 0
- 0
induced 0
covalent 0
cross 0
- 0
linking 0
to 0
a 0
bromodeoxyuridine 0
- 0
substituted 0
kappa B-gene
B I-gene
oligonucleotide I-gene
. 0

The 0
physical 0
and 0
chemical 0
stability 0
of 0
a 0
combination 0
of 0
drugs 0
commonly 0
administered 0
into 0
the 0
epidural 0
or 0
intrathecal 0
space 0
for 0
the 0
treatment 0
of 0
chronic 0
pain 0
was 0
investigated 0
. 0

Therefore 0
, 0
mechanisms 0
that 0
control 0
activation 0
of 0
the 0
MAP B-gene
kinase I-gene
cascade 0
temporally 0
and 0
spatially 0
may 0
be 0
important 0
for 0
specification 0
of 0
cellular 0
responses 0
. 0

A 0
candidate 0
gene 0
for 0
Bcg B-gene
, 0
designated 0
natural B-gene
resistance I-gene
- I-gene
associated I-gene
macrophage I-gene
protein I-gene
( 0
Nramp B-gene
) 0
, 0
has 0
been 0
isolated 0
and 0
shown 0
to 0
encode 0
a 0
novel 0
macrophage 0
- 0
specific 0
membrane 0
protein 0
, 0
which 0
is 0
altered 0
in 0
susceptible 0
animals 0
. 0

This 0
motif 0
is 0
similar 0
to 0
but 0
distinct 0
from 0
the 0
LIM B-gene
domain I-gene
and 0
the 0
RING B-gene
finger I-gene
family I-gene
, 0
and 0
is 0
reminiscent 0
of 0
known 0
metal 0
- 0
binding 0
regions 0
. 0

The 0
P131 0
ORF 0
is 0
followed 0
in 0
- 0
frame 0
by 0
a 0
second 0
ORF 0
which 0
is 0
probably 0
expressed 0
by 0
partial 0
readthrough 0
of 0
the 0
UGA 0
termination 0
codon 0
of 0
the 0
P131 0
ORF 0
to 0
produce 0
a 0
polypeptide 0
of 0
M 0
( 0
r 0
) 0
191044 0
( 0
P191 0
) 0
. 0

One 0
hundred 0
fifty 0
patients 0
were 0
reviewed 0
at 0
1 0
year 0
after 0
arthroplasty 0
. 0

Elementary 0
visual 0
hallucinations 0
in 0
migraine 0
and 0
epilepsy 0
. 0

The 0
influence 0
of 0
patient 0
- 0
related 0
factors 0
on 0
inter 0
- 0
observer 0
variability 0
in 0
the 0
evaluation 0
of 0
neurological 0
signs 0
was 0
investigated 0
. 0

Segments 0
with 0
more 0
reduced 0
BMIPP 0
uptake 0
than 0
MIBI 0
uptake 0
( 0
mismatching 0
) 0
showed 0
either 0
normal 0
wall 0
motion 0
or 0
demonstrated 0
inotropic 0
reserve 0
during 0
dobutamine 0
stimulation 0
. 0

The 0
defined 0
length 0
of 0
the 0
mRNA 0
, 0
1,838 0
nucleotides 0
, 0
was 0
in 0
agreement 0
with 0
that 0
of 0
a 0
1.9 0
- 0
kb 0
RNA 0
expressed 0
throughout 0
the 0
replication 0
cycle 0
, 0
starting 0
at 0
the 0
early 0
stages 0
of 0
infection 0
. 0

Infect 0
. 0

Transient 0
transfections 0
of 0
a 0
construct 0
expressing 0
the 0
RNA 0
transcript 0
defined 0
by 0
clone 0
B1.1 0
into 0
D17 0
cells 0
led 0
to 0
the 0
expression 0
of 0
an 0
Env/Mlvi B-gene
Env/Mlvi I-gene
- I-gene
4 I-gene
fusion 0
protein 0
with 0
an 0
apparent 0
molecular 0
mass 0
of 0
33 0
kDa 0
. 0

Roizman 0
, 0
J 0
. 0

Articles 0
addressing 0
valvular 0
heart 0
disease 0
or 0
heart 0
failure 0
secondary 0
to 0
acute 0
myocardial 0
infarction 0
or 0
Chagas 0
' 0
disease 0
were 0
excluded 0
. 0

The 0
present 0
data 0
also 0
indicate 0
that 0
patients 0
with 0
TGBM 0
nephropathy 0
often 0
have 0
concomitant 0
IgA B-gene
nephropathy 0
and 0
mesangial 0
proliferative 0
glomerulonephritis 0
. 0

All 0
nuclear 0
receptors 0
have 0
several 0
well 0
- 0
characterized 0
structural 0
domains 0
, 0
including 0
a 0
conserved 0
DNA 0
- 0
binding 0
domain 0
, 0
and 0
a 0
ligand 0
binding 0
domain 0
at 0
the 0
carboxyl 0
terminus 0
of 0
the 0
receptor 0
. 0

The 0
sample 0
includes 0
all 0
the 0
HIV 0
- 0
infected 0
- 0
patients 0
continuously 0
referred 0
to 0
the 0
Outpatient 0
Service 0
of 0
the 0
Infectious 0
Diseases 0
dept 0
. 0
of 0
Bologna 0
's 0
`` 0
Ospedale 0
Maggiore 0
'' 0
General 0
Hospital 0
during 0
some 0
five 0
days 0
( 0
19 0
- 0
23rd 0
, 0
July 0
1993 0
) 0
. 0

Using 0
in 0
organello 0
footprint 0
analysis 0
, 0
we 0
demonstrate 0
that 0
within 0
human 0
placental 0
mitochondria 0
there 0
is 0
a 0
high 0
level 0
of 0
protein 0
- 0
DNA 0
binding 0
at 0
regularly 0
phased 0
intervals 0
throughout 0
a 0
500 0
- 0
bp 0
region 0
encompassing 0
the 0
D 0
- 0
loop 0
DNA 0
origins 0
and 0
two 0
promoter 0
regions 0
. 0

The 0
Nur77 B-gene
protein I-gene
can 0
act 0
as 0
a 0
potent 0
transcription 0
activator 0
and 0
may 0
function 0
to 0
regulate 0
the 0
expression 0
of 0
downstream 0
genes 0
in 0
response 0
to 0
extracellular 0
stimuli 0
. 0

One 0
class 0
of 0
plasmids 0
contained 0
tRNA B-gene
( I-gene
His I-gene
) I-gene
genes I-gene
and 0
conferred 0
efficient 0
suppression 0
only 0
when 0
cells 0
were 0
starved 0
for 0
histidine 0
; 0
these 0
plasmids 0
suppressed 0
a 0
gcn2 B-gene
deletion 0
much 0
less 0
efficiently 0
than 0
they 0
suppressed 0
gcn2 B-gene
- I-gene
507 I-gene
. 0

Thus 0
, 0
the 0
presence 0
of 0
the 0
Cln2 B-gene
PEST I-gene
domain I-gene
was 0
sufficient 0
to 0
destabilize 0
a 0
heterologous 0
protein 0
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
with 0
each 0
of 0
these 0
sequences 0
demonstrated 0
complexes 0
with 0
mobilities 0
identical 0
to 0
those 0
of 0
the 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
site I-gene
from 0
the 0
kappa B-gene
light I-gene
- I-gene
chain I-gene
gene I-gene
. 0

Although 0
a 0
carboxyl 0
- 0
terminal 0
HSF B-gene
transcriptional 0
activation 0
domain 0
is 0
critical 0
for 0
the 0
activation 0
of 0
CUP1 B-gene
transcription 0
in 0
response 0
to 0
both 0
heat 0
shock 0
stress 0
and 0
glucose 0
starvation 0
, 0
this 0
region 0
is 0
dispensable 0
for 0
transient 0
heat 0
shock 0
activation 0
of 0
at 0
least 0
two 0
genes 0
encoding 0
members 0
of 0
the 0
S. 0
cerevisiae 0
hsp70 B-gene
family I-gene
. 0

We 0
have 0
recently 0
detected 0
high 0
levels 0
of 0
CKB B-gene
mRNA I-gene
in 0
HeLa 0
cells 0
and 0
, 0
in 0
this 0
study 0
, 0
have 0
tested 0
whether 0
this 0
may 0
be 0
due 0
to 0
the 0
extremely 0
low 0
amounts 0
of 0
p53 B-gene
protein I-gene
present 0
in 0
HeLa 0
cells 0
. 0

Distal 0
lower 0
motor 0
neuron 0
syndrome 0
with 0
high 0
- 0
titer 0
serum B-gene
IgM I-gene
anti I-gene
- I-gene
GM1 I-gene
antibodies I-gene
: 0
improvement 0
following 0
immunotherapy 0
with 0
monthly 0
plasma 0
exchange 0
and 0
intravenous 0
cyclophosphamide 0
. 0

Regulators 0
responsible 0
for 0
the 0
pervasive 0
, 0
nonsex 0
- 0
specific 0
alternative 0
pre 0
- 0
mRNA 0
splicing 0
characteristic 0
of 0
metazoans 0
are 0
almost 0
entirely 0
unknown 0
or 0
uncertain 0
. 0

A 0
normal 0
systemic 0
response 0
was 0
obtained 0
after 0
IF 0
, 0
indicating 0
that 0
rhG B-gene
- I-gene
CSF I-gene
retains 0
activity 0
in 0
the 0
solid 0
state 0
. 0

A 0
full 0
- 0
length 0
cDNA 0
clone 0
isolated 0
from 0
a 0
rat 0
lung 0
library 0
was 0
predicted 0
to 0
encode 0
a 0
55 0
- 0
kDa 0
protein 0
containing 0
at 0
its 0
amino 0
terminus 0
a 0
targeting 0
domain 0
that 0
binds 0
to 0
the 0
ANP B-gene
- I-gene
receptor I-gene
kinase I-gene
- I-gene
like I-gene
domain I-gene
and 0
containing 0
at 0
its 0
carboxyl 0
terminus 0
a 0
putative 0
protein B-gene
- I-gene
serine I-gene
phosphatase I-gene
domain 0
. 0

A 0
high 0
- 0
resolution 0
restriction 0
map 0
of 0
over 0
200 0
kb 0
of 0
contiguous 0
DNA 0
containing 0
N B-gene
- I-gene
myc I-gene
has 0
been 0
generated 0
by 0
subcloning 0
YACs 0
into 0
cosmids 0
. 0

PAI B-gene
- I-gene
1 I-gene
levels 0
increased 0
significantly 0
in 0
patients 0
who 0
received 0
iohexol 0
but 0
not 0
in 0
those 0
who 0
received 0
ioxaglate 0
. 0

In 0
the 0
present 0
article 0
, 0
the 0
causes 0
of 0
death 0
or 0
ill 0
- 0
being 0
as 0
found 0
in 0
10 0
consecutive 0
carcinogenicity 0
studies 0
- 0
- 0
5 0
studies 0
with 0
2400 0
OFA 0
( 0
Sprague 0
- 0
Dawley 0
- 0
derived 0
) 0
and 0
Wistar 0
rats 0
and 0
5 0
studies 0
with 0
2400 0
OF1 0
and 0
NMRI 0
mice 0
- 0
- 0
were 0
re 0
- 0
examined 0
. 0

Determination 0
of 0
potassium 0
iodide 0
in 0
Polish 0
edible 0
salt 0

The 0
recovery 0
value 0
of 0
systolic 0
pressure 0
was 0
higher 0
than 0
diastolic 0
pressure 0
and 0
pulse 0
pressure 0
increased 0
. 0

The 0
importance 0
of 0
hepatitis 0
C 0
virus 0
( 0
HCV 0
) 0
infection 0
as 0
a 0
cause 0
of 0
chronic 0
liver 0
disease 0
has 0
become 0
clear 0
with 0
the 0
introduction 0
of 0
serologic 0
detection 0
methods 0
. 0

Human 0
adenovirus 0
type 0
41 0
contains 0
two 0
fibers 0
. 0

Outflow 0
obstruction 0
of 0
pancreatic 0
juice 0
, 0
i.e. 0
, 0
`` 0
relative 0
stenosis 0
of 0
the 0
minor 0
papilla 0
, 0
'' 0
was 0
considered 0
to 0
be 0
present 0
in 0
the 0
patients 0
with 0
type 0
II 0
papilla 0
, 0
and 0
, 0
therefore 0
, 0
the 0
patients 0
with 0
type 0
II 0
papilla 0
might 0
suffer 0
from 0
acute 0
pancreatitis 0
resulting 0
from 0
poor 0
drainage 0
of 0
pancreatic 0
juice 0
and 0
excessive 0
pressure 0
in 0
the 0
dorsal 0
duct 0
. 0

Sequencing 0
of 0
the 0
TP53 B-gene
transcripts I-gene
from 0
exons 0
2 0
to 0
10 0
, 0
however 0
, 0
did 0
not 0
reveal 0
mutations 0
of 0
the 0
remaining 0
allele 0
in 0
any 0
of 0
these 0
tumors 0
. 0

An 0
unusual 0
complication 0
in 0
an 0
unsuitable 0
patient 0
. 0

In 0
the 0
ISO 0
group 0
, 0
at 0
pre 0
- 0
DEX 0
, 0
CBF 0
increased 0
from 0
86 0
+/ 0
- 0
8 0
to 0
166 0
+/ 0
- 0
19 0
mL.min 0
- 0
1.100 0
g 0
- 0
1 0
in 0
response 0
to 0
hypercapnia 0
( 0
PCO2 0
approximately 0
90 0
mmHg 0
) 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

All 0
other 0
ejaculate 0
parameters 0
( 0
density 0
, 0
motility 0
, 0
swelling 0
test 0
, 0
penetration 0
test 0
) 0
remained 0
unchanged 0
, 0
and 0
there 0
was 0
only 0
one 0
post 0
- 0
therapeutic 0
pregnancy 0
. 0

KRN2391 0
and 0
cromakalim 0
produced 0
a 0
dose 0
- 0
dependent 0
increase 0
in 0
aortic 0
and 0
coronary 0
blood 0
flow 0
. 0

In 0
H4IIE 0
rat 0
hepatoma 0
cells 0
, 0
glucocorticoids 0
, 0
retinoic 0
acid 0
and 0
cyclic 0
AMP 0
( 0
cAMP 0
) 0
increase 0
PEPCK B-gene
gene I-gene
transcription 0
whereas 0
insulin B-gene
and 0
phorbol 0
esters 0
have 0
the 0
opposite 0
effect 0
. 0

Acta 0
572 0
, 0
113 0
- 0
120 0
] 0
. 0

Basal 0
plasma 0
AVP B-gene
levels 0
and 0
AVP B-gene
release 0
after 0
postural 0
change 0
were 0
assessed 0
, 0
and 0
plasma 0
NPY B-gene
levels 0
were 0
measured 0
in 0
the 0
same 0
samples 0
. 0

A 0
stretch 0
of 0
16 0
nucleotides 0
just 0
upstream 0
of 0
the 0
IL B-gene
- I-gene
4RE I-gene
contributed 0
to 0
IL B-gene
- I-gene
4 I-gene
inducibility 0
and 0
formed 0
nucleoprotein 0
complexes 0
with 0
constitutive 0
factors 0
. 0

Our 0
previous 0
study 0
suggested 0
that 0
pertussis B-gene
toxin I-gene
( 0
IAP B-gene
) 0
- 0
sensitive 0
GTP B-gene
- I-gene
binding I-gene
protein I-gene
( I-gene
s I-gene
) I-gene
( 0
G B-gene
- I-gene
protein I-gene
) 0
is 0
involved 0
in 0
the 0
process 0
of 0
differentiation 0
by 0
hormones/IBMX 0
, 0
accompanied 0
by 0
c B-gene
- I-gene
fos I-gene
induction 0
. 0

ATX B-gene
, 0
like 0
PC B-gene
- I-gene
1 I-gene
, 0
was 0
found 0
to 0
hydrolyze 0
the 0
type B-gene
I I-gene
phosphodiesterase I-gene
substrate 0
p 0
- 0
nitrophenyl 0
thymidine 0
- 0
5' 0
- 0
monophosphate 0
. 0

The 0
effect 0
of 0
site 0
- 0
specific 0
mutations 0
in 0
the 0
mouse B-gene
platelet I-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
( I-gene
PDGF I-gene
) I-gene
beta I-gene
- I-gene
receptor I-gene
on 0
activation 0
of 0
the 0
Na+/H+ B-gene
exchanger I-gene
was 0
examined 0
in 0
normal 0
murine 0
mammary 0
gland 0
epithelial 0
( 0
NMuMG 0
) 0
and 0
Chinese 0
hamster 0
ovary 0
( 0
CHO 0
) 0
cells 0
. 0

Sequence 0
analysis 0
revealed 0
: 0
1 0
) 0
a 0
kinase 0
catalytic 0
domain 0
most 0
characteristic 0
of 0
serine/threonine B-gene
kinases I-gene
but 0
hybrid 0
between 0
members 0
of 0
the 0
family 0
of 0
microtubule B-gene
- I-gene
associated I-gene
protein I-gene
kinase I-gene
kinase I-gene
kinases I-gene
and 0
the 0
fibroblast B-gene
growth I-gene
factor I-gene
receptor I-gene
family I-gene
; 0
2 0
) 0
two 0
putative 0
alpha 0
- 0
helical 0
leucine 0
zipper 0
motifs 0
separated 0
by 0
a 0
25 0
- 0
amino 0
acid 0
charged 0
intermediate 0
segment 0
but 0
lacking 0
an 0
NH2 0
- 0
terminal 0
basic 0
domain 0
; 0
and 0
3 0
) 0
COOH 0
- 0
terminal 0
and 0
NH2 0
- 0
terminal 0
proline 0
- 0
rich 0
domains 0
suggestive 0
of 0
src B-gene
homology I-gene
3 I-gene
( 0
SH3 B-gene
) 0
domain 0
binding 0
regions 0
. 0

Type 0
2 0
genomes 0
containing 0
this 0
sequence 0
presumably 0
more 0
closely 0
reflect 0
the 0
structure 0
of 0
the 0
infectious 0
, 0
replication 0
- 0
competent 0
retrovirus 0
ancestors 0
of 0
the 0
HERV 0
- 0
K 0
family 0
than 0
do 0
type 0
1 0
genomes 0
that 0
lack 0
the 0
sequence 0
. 0

However 0
, 0
when 0
domain 0
I 0
and 0
domain 0
II 0
were 0
linked 0
on 0
the 0
same 0
plasmid 0
, 0
high 0
levels 0
of 0
replication 0
were 0
observed 0
. 0

Point 0
mutations 0
that 0
suppressed 0
the 0
in 0
vitro 0
binding 0
of 0
NF B-gene
- I-gene
Y I-gene
to 0
the 0
internal 0
palindromic 0
arm 0
reduced 0
the 0
activity 0
of 0
the 0
resident 0
P4 0
promoter 0
, 0
while 0
those 0
preventing 0
complex 0
formation 0
with 0
USF B-gene
did 0
not 0
, 0
as 0
determined 0
by 0
transient 0
expression 0
assays 0
using 0
the 0
luciferase B-gene
reporter 0
gene 0
. 0

Surprisingly 0
, 0
Northern 0
( 0
RNA 0
) 0
blot 0
analysis 0
and 0
reverse B-gene
transcriptase I-gene
- 0
PCRs 0
performed 0
after 0
transfection 0
of 0
COS 0
- 0
7 0
or 0
HeLa 0
cells 0
with 0
these 0
viral 0
RNAs 0
revealed 0
that 0
Y88S B-gene
and 0
Y88L B-gene
RNAs I-gene
replicated 0
at 0
only 0
very 0
low 0
levels 0
. 0

Surprisingly 0
, 0
nuclear 0
forms 0
of 0
IE110 B-gene
were 0
found 0
to 0
move 0
a 0
cytoplasmic 0
form 0
of 0
IE175 B-gene
into 0
nuclear 0
punctate 0
structures 0
, 0
and 0
a 0
cytoplasmic 0
form 0
of 0
IE110 B-gene
was 0
able 0
to 0
retain 0
nuclear 0
forms 0
of 0
IE175 B-gene
in 0
cytoplasmic 0
punctate 0
structures 0
. 0

Transcription 0
of 0
the 0
gene 0
for 0
ivanolysin B-gene
O I-gene
and 0
expression 0
of 0
other 0
genes 0
of 0
the 0
virulence B-gene
gene I-gene
cluster I-gene
in I-gene
L. I-gene
ivanovii I-gene
were 0
dependent 0
on 0
PrfA B-gene
. 0

Moreover 0
, 0
by 0
complementation 0
of 0
the 0
WA B-gene
fyuA I-gene
mutant I-gene
by 0
the 0
cloned 0
fyuA B-gene
gene I-gene
, 0
yersiniabactin 0
uptake 0
and 0
mouse 0
virulence 0
were 0
restored 0
. 0

The 0
ICBF 0
in 0
the 0
ischaemic 0
cortex 0
revealed 0
a 0
graded 0
reduction 0
from 0
the 0
ischaemic 0
centre 0
to 0
the 0
surrounding 0
tissues 0
. 0

The 0
treatment 0
of 0
hydronephrosis 0
in 0
children 0

The 0
inflation 0
hub 0
of 0
the 0
probe 0
is 0
recreated 0
by 0
modifying 0
a 0
standard 0
USCI 0
Tuohy 0
- 0
Borst 0
Y 0
adaptor 0
and 0
attaching 0
this 0
to 0
the 0
transected 0
probe 0
hypotube 0
. 0

The 0
other 0
element 0
bound 0
RBP B-gene
- I-gene
J I-gene
kappa I-gene
with 0
low 0
affinity 0
. 0

The 0
basal 0
promoter 0
strength 0
of 0
constructs 0
that 0
contained 0
deletions 0
in 0
the 0
U5 B-gene
region I-gene
of 0
the 0
LTR 0
was 0
analyzed 0
by 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
assays 0
following 0
transfection 0
of 0
HeLa 0
cells 0
or 0
Jurkat 0
T 0
- 0
cells 0
in 0
the 0
presence 0
or 0
absence 0
of 0
viral 0
transactivator 0
tax B-gene
protein 0
. 0

In 0
reviewing 0
a 0
number 0
of 0
the 0
most 0
intensely 0
studied 0
environmentally 0
inducible 0
promoters 0
it 0
becomes 0
clear 0
that 0
the 0
presence 0
of 0
two 0
cis 0
- 0
acting 0
elements 0
are 0
critical 0
for 0
promoter 0
activity 0
, 0
one 0
of 0
which 0
is 0
the 0
G 0
- 0
box 0
( 0
CCACGTGG 0
) 0
. 0

Recently 0
, 0
a 0
protein 0
designated 0
GF14 B-gene
has 0
been 0
isolated 0
that 0
is 0
associated 0
with 0
the 0
GBF B-gene
protein I-gene
complex I-gene
. 0

New 0
diagnostic 0
strategies 0
for 0
lupus 0
anticoagulants 0
and 0
antiphospholipid 0
antibodies 0
. 0

Moreover 0
, 0
the 0
ability 0
to 0
selectivity 0
arrest 0
elongation 0
by 0
polIII B-gene
at 0
defined 0
positions 0
within 0
the 0
tRNA 0
gene 0
transcription 0
unit 0
has 0
permitted 0
the 0
identification 0
of 0
discrete 0
functional 0
properties 0
of 0
paused 0
mammalian B-gene
polIII I-gene
ternary I-gene
complexes I-gene
. 0

Propafenone 0
is 0
well 0
tolerated 0
in 0
the 0
majority 0
of 0
young 0
patients 0
. 0

Mutational 0
analysis 0
of 0
yeast B-gene
CEG1 I-gene
demonstrated 0
that 0
four 0
of 0
the 0
five 0
conserved 0
motifs 0
are 0
essential 0
for 0
capping B-gene
enzyme I-gene
function 0
in 0
vivo 0
. 0

2 0
patients 0
( 0
11 0
% 0
) 0
had 0
significant 0
morbidity 0
502 0
and 0
529 0
days 0
respectively 0
after 0
transplantation 0
. 0

A 0
recent 0
index 0
( 0
Fluorosis 0
Risk 0
Index 0
) 0
developed 0
by 0
Pendrys 0
( 0
1990 0
) 0
is 0
also 0
included 0
in 0
this 0
review 0
. 0

Alternative 0
splicing 0
of 0
the 0
cytoplasmic 0
tail 0
appears 0
to 0
generate 0
multiple 0
PECAM B-gene
- I-gene
1 I-gene
isoforms I-gene
that 0
may 0
regulate 0
phosphorylation 0
, 0
cytoskeletal 0
association 0
, 0
and 0
affinity 0
modulation 0
of 0
the 0
mature 0
protein 0
. 0

Transfer 0
also 0
correlated 0
inversely 0
with 0
gastric 0
juice 0
pH 0
( 0
r 0
= 0
- 0
0.619 0
, 0
P 0
< 0
0.02 0
) 0
. 0

This 0
technique 0
has 0
a 0
sensitivity 0
and 0
a 0
specificity 0
of 0
almost 0
100 0
% 0
, 0
and 0
is 0
currently 0
the 0
best 0
way 0
to 0
diagnose 0
nodal 0
involvement 0
, 0
apart 0
from 0
laparotomy 0
. 0

The 0
data 0
show 0
conclusively 0
that 0
phosphorylation 0
of 0
His 0
- 0
304 0
is 0
not 0
essential 0
for 0
any 0
of 0
the 0
known 0
functions 0
of 0
A. B-gene
vinelandii I-gene
NifL I-gene
. 0

The 0
role 0
of 0
HIV B-gene
tat I-gene
, 0
which 0
is 0
the 0
main 0
enhancing 0
factor 0
for 0
viral B-gene
LTR I-gene
, 0
in 0
the 0
regulation 0
of 0
IL B-gene
- I-gene
2 I-gene
gene I-gene
transcription 0
has 0
been 0
studied 0
following 0
transient 0
expression 0
of 0
the 0
tat B-gene
gene I-gene
in 0
phorbol 0
ester 0
and 0
calcium 0
ionophore 0
- 0
activated 0
Jurkat 0
cells 0
transfected 0
with 0
IL B-gene
- I-gene
2 I-gene
promoter 0
- 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter 0
constructs 0
. 0

Splice 0
variations 0
in 0
genes 0
coding 0
for 0
the 0
transmembrane B-gene
FGF I-gene
receptor I-gene
( 0
FGFR B-gene
) 0
result 0
in 0
isoforms 0
that 0
vary 0
in 0
the 0
ectodomain 0
, 0
intracellular 0
juxtamembrane 0
domain 0
, 0
and 0
the 0
intracellular 0
kinase 0
domain 0
. 0

If 0
this 0
is 0
present 0
, 0
such 0
patients 0
should 0
be 0
closely 0
monitored 0
, 0
and 0
any 0
atypical 0
lesions 0
biopsied 0
. 0

Cumulated 0
maximum 0
lod 0
scores 0
between 0
FRDA B-gene
and 0
D9S5 B-gene
and 0
between 0
FRDA B-gene
and 0
D9S15 B-gene
are 0
above 0
36 0
and 0
61 0
, 0
respectively 0
, 0
at 0
a 0
recombination 0
fraction 0
of 0
0 0
, 0
indicating 0
that 0
recombination 0
events 0
needed 0
to 0
orient 0
the 0
search 0
of 0
the 0
gene 0
are 0
very 0
difficult 0
to 0
identify 0
and 0
ascertain 0
. 0

A 0
receptor B-gene
- I-gene
like I-gene
protein I-gene
kinase I-gene
, 0
OsPK10 B-gene
, 0
has 0
been 0
cloned 0
from 0
rice 0
( 0
Oryza 0
sativa 0
) 0
. 0

A 0
sequence 0
representing 0
about 0
50 0
% 0
of 0
the 0
expected 0
complete 0
sequence 0
was 0
obtained 0
by 0
translation 0
of 0
the 0
two 0
open 0
reading 0
frames 0
present 0
on 0
a 0
1.6 0
kb 0
DNA 0
genomic 0
fragment 0
. 0

Goodpasture's 0
- 0
like 0
syndrome 0
and 0
effect 0
of 0
extracorporeal 0
membrane 0
oxygenator 0
support 0
. 0

A 0
cDNA 0
clone 0
pCZ1 0
, 0
with 0
a 0
1.1 0
kb 0
insert 0
, 0
was 0
isolated 0
from 0
a 0
NaCl 0
- 0
adapted 0
tobacco 0
cell 0
cDNA 0
library 0
that 0
encodes 0
an 0
apparently 0
full 0
- 0
length 0
29 0
kDa 0
protein 0
( 0
251 0
amino 0
acids 0
) 0
with 0
a 0
calculated 0
pI 0
of 0
5.7 0
. 0

METHODS 0
- 0
- 0
16 0
volunteered 0
for 0
spirometry 0
with 0
methacholine 0
provocation 0
test 0
including 0
a 0
test 0
for 0
small 0
airways 0
function 0
by 0
volume 0
of 0
trapped 0
gas 0
( 0
VTG 0
) 0
. 0

Relationship 0
of 0
CDK B-gene
- I-gene
activating I-gene
kinase I-gene
and 0
RNA B-gene
polymerase I-gene
II I-gene
CTD 0
kinase 0
TFIIH/TFIIK B-gene
. 0

The 0
git1 B-gene
, 0
git3 B-gene
, 0
git5 B-gene
, 0
git7 B-gene
, 0
git8 B-gene
and 0
git10 B-gene
genes I-gene
act 0
upstream 0
of 0
adenylate B-gene
cyclase I-gene
, 0
presumably 0
encoding 0
an 0
adenylate B-gene
cyclase I-gene
activation 0
pathway 0
. 0

These 0
same 0
regions 0
showed 0
remarkable 0
homology 0
to 0
two 0
invertebrate 0
proteins 0
, 0
CNC B-gene
and 0
skin B-gene
- I-gene
1 I-gene
, 0
postulated 0
to 0
regulate 0
embryonic 0
development 0
in 0
Drosophila 0
melanogaster 0
and 0
Caenorhabditis 0
elegans 0
, 0
respectively 0
. 0

DNA 0
sequence 0
analysis 0
has 0
confirmed 0
that 0
this 0
mutation 0
affects 0
the 0
C 0
- 0
terminal 0
region 0
of 0
the 0
alpha 0
subunit 0
, 0
changing 0
a 0
leucine 0
residue 0
at 0
position 0
290 0
to 0
a 0
histidine 0
( 0
rpoAL290H B-gene
) 0
. 0

CONCLUSIONS 0
: 0
These 0
findings 0
indicate 0
a 0
physical 0
barrier 0
of 0
oesophageal 0
surfactant 0
which 0
could 0
offer 0
some 0
degree 0
of 0
protection 0
against 0
gastro 0
- 0
oesophageal 0
reflux 0
but 0
one 0
which 0
is 0
particularly 0
prone 0
to 0
attack 0
by 0
bile 0
. 0

Differential 0
screening 0
of 0
mitochondrial 0
cDNA 0
libraries 0
from 0
male 0
- 0
fertile 0
and 0
cytoplasmic 0
male 0
- 0
sterile 0
sugar 0
- 0
beet 0
reveals 0
genome 0
rearrangements 0
at 0
atp6 B-gene
and 0
atpA B-gene
loci I-gene
. 0

The 0
effects 0
of 0
social 0
isolation 0
on 0
morphine 0
- 0
induced 0
locomotor 0
activity 0
were 0
compared 0
in 0
: 0
( 0
i 0
) 0
animals 0
with 0
an 0
intact 0
hypothalamo 0
- 0
pituitary 0
- 0
adrenal 0
( 0
HPA 0
) 0
axis 0
; 0
( 0
ii 0
) 0
animals 0
in 0
which 0
stress 0
- 0
induced 0
corticosterone 0
secretion 0
was 0
blocked 0
by 0
adrenalectomy 0
. 0

Using 0
this 0
reporter 0
gene 0
system 0
, 0
we 0
previously 0
showed 0
that 0
EPO B-gene
- 0
induced 0
activation 0
of 0
the 0
c B-gene
- I-gene
fos I-gene
promoter I-gene
can 0
be 0
detected 0
rapidly 0
and 0
sensitively 0
as 0
an 0
elevation 0
of 0
cellular B-gene
luciferase I-gene
activity 0
. 0

I 0
hypothesize 0
that 0
white B-gene
gene I-gene
expression 0
from 0
P B-gene
[ I-gene
en I-gene
] I-gene
is 0
repressed 0
by 0
the 0
formation 0
of 0
a 0
protein 0
complex 0
which 0
is 0
initiated 0
at 0
the 0
engrailed B-gene
PS I-gene
sites I-gene
and 0
also 0
requires 0
interactions 0
with 0
flanking 0
genomic 0
DNA 0
. 0

SPP41 B-gene
was 0
cloned 0
and 0
sequenced 0
and 0
found 0
to 0
be 0
essential 0
. 0
spp43 B-gene
is 0
allelic 0
to 0
the 0
previously 0
identified 0
suppressor B-gene
srn1 I-gene
, 0
which 0
encodes 0
a 0
negative 0
regulator 0
of 0
gene 0
expression 0
. 0

Standard 0
curve 0
correlation 0
coefficients 0
of 0
0.995 0
or 0
greater 0
were 0
obtained 0
during 0
validation 0
experiments 0
and 0
analysis 0
of 0
study 0
samples 0
. 0

To 0
see 0
if 0
a 0
pulse 0
oximeter 0
can 0
monitor 0
the 0
fetus 0
during 0
labour 0
we 0
recruited 0
100 0
Caucasian 0
women 0
in 0
normal 0
uncomplicated 0
labour 0
. 0

There 0
was 0
no 0
difference 0
in 0
plasma 0
concentrations 0
of 0
PGI2 0
( 0
figure 0
4 0
) 0
and 0
TxA2 0
in 0
patients 0
with 0
normal 0
blood 0
pressure 0
, 0
mild 0
preeclampsia 0
and 0
hypotension 0
, 0
whereas 0
in 0
severe 0
preeclampsia 0
, 0
the 0
plasma 0
concentration 0
of 0
PGI2 0
was 0
significantly 0
lower 0
( 0
p 0
< 0
0.001 0
) 0
and 0
of 0
TxA2 0
significantly 0
higher 0
( 0
p 0
< 0
0.001 0
) 0
. 0

A 0
causal 0
analysis 0
of 0
secondary 0
variables 0
showed 0
that 0
the 0
formation 0
of 0
FB 0
memories 0
was 0
primarily 0
associated 0
with 0
the 0
level 0
of 0
importance 0
attached 0
to 0
the 0
event 0
and 0
level 0
of 0
affective 0
response 0
to 0
the 0
news 0
. 0

Deletion 0
studies 0
identified 0
a 0
distal 0
response 0
element 0
that 0
is 0
responsible 0
for 0
the 0
cytokine 0
response 0
and 0
has 0
properties 0
of 0
an 0
inducible 0
transcriptional 0
enhancer 0
. 0

The 0
IPL1 B-gene
gene I-gene
is 0
required 0
for 0
high 0
- 0
fidelity 0
chromosome 0
segregation 0
in 0
the 0
budding 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

2 0
. 0

No 0
drop 0
in 0
oxygen 0
saturation 0
( 0
SaO2 0
) 0
or 0
visual 0
evidence 0
of 0
transient 0
electroencephalographic 0
( 0
EEG 0
) 0
arousals 0
can 0
be 0
found 0
at 0
repeat 0
polysomnography 0
. 0

The 0
complete 0
gene 0
organization 0
was 0
obtained 0
by 0
combining 0
the 0
results 0
of 0
the 0
sequence 0
of 0
these 0
clones 0
and 0
those 0
of 0
the 0
characterization 0
of 0
polymerase 0
chain 0
reaction 0
- 0
amplified 0
genomic 0
segments 0
. 0

INO2 B-gene
, 0
a 0
regulatory 0
gene 0
in 0
yeast 0
phospholipid 0
biosynthesis 0
, 0
affects 0
nuclear 0
segregation 0
and 0
bud 0
pattern 0
formation 0
. 0

The 0
pentafluorobenzyl 0
derivative 0
of 0
clonidine 0
yields 0
an 0
intense 0
ion 0
fragment 0
at 0
m/z 0
354 0
, 0
and 0
the 0
lower 0
limit 0
of 0
detection 0
is 0
0.025 0
ng/ml 0
for 0
a 0
1 0
- 0
ml 0
plasma 0
sample 0
. 0

Mammalian B-gene
ABPs I-gene
and 0
SHBGs B-gene
bind 0
sex 0
steroids 0
with 0
high 0
affinity 0
, 0
but 0
some 0
binding 0
properties 0
differ 0
among 0
species 0
. 0

Src B-gene
homology I-gene
( 0
SH B-gene
) 0
domain 0
dependent 0
protein 0
- 0
protein 0
interactions 0
are 0
important 0
to 0
tyrosine B-gene
kinase I-gene
receptor I-gene
signal 0
transduction 0
. 0

Sample 0
treatment 0
was 0
optimized 0
in 0
order 0
to 0
achieve 0
a 0
complete 0
extraction 0
of 0
labetalol 0
diastereoisomers 0
and 0
to 0
avoid 0
racemization 0
during 0
extraction 0
. 0

Under 0
resting 0
conditions 0
, 0
activity 0
levels 0
of 0
cardiac 0
vagal 0
and 0
sympathetic 0
outflows 0
are 0
not 0
related 0
across 0
young 0
, 0
healthy 0
human 0
subjects 0
and 0
peripheral 0
interaction 0
is 0
not 0
manifest 0
between 0
the 0
autonomic 0
divisions 0
. 0

Both 0
proprioceptive 0
and 0
electroreceptive 0
units 0
showed 0
a 0
progression 0
of 0
receptive 0
fields 0
from 0
anterior 0
to 0
posterior 0
body 0
in 0
the 0
rostral 0
to 0
caudal 0
direction 0
along 0
the 0
length 0
of 0
DGR 0
. 0

In 0
control 0
patients 0
, 0
baseline 0
images 0
presented 0
Type 0
I 0
in 0
25 0
, 0
Type 0
II 0
in 0
7 0
, 0
and 0
the 0
Type 0
III 0
& 0
IV 0
in 0
0 0
, 0
and 0
the 0
Type 0
after 0
loading 0
was 0
the 0
same 0
as 0
the 0
Type 0
at 0
baseline 0
. 0

A 0
more 0
complete 0
analysis 0
of 0
dose 0
response 0
, 0
time 0
and 0
mode 0
of 0
Ga 0
administration 0
( 0
preinjury 0
or 0
postinjury 0
) 0
, 0
and 0
availability 0
of 0
Ga 0
across 0
the 0
blood 0
- 0
brain 0
barrier 0
is 0
needed 0
to 0
further 0
evaluate 0
the 0
efficacy 0
of 0
this 0
compound 0
. 0

The 0
presence 0
of 0
regulatory 0
sequences 0
for 0
the 0
binding 0
of 0
transcription 0
factors 0
such 0
as 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
and 0
AP B-gene
- I-gene
2 I-gene
, 0
whose 0
activation 0
is 0
associated 0
with 0
the 0
immediate 0
response 0
of 0
the 0
cell 0
to 0
an 0
injury 0
, 0
may 0
be 0
an 0
indication 0
of 0
the 0
important 0
role 0
which 0
HO B-gene
- I-gene
1 I-gene
may 0
play 0
in 0
defense 0
mechanisms 0
against 0
tissue 0
injury 0
. 0

Granisetron 0
, 0
but 0
not 0
saline 0
, 0
abolished 0
vomiting 0
and 0
nausea 0
when 0
given 0
as 0
intervention 0
after 0
this 0
combined 0
emetic 0
regimen 0
. 0

The 0
femoroarterial 0
coronary 0
sinus 0
difference 0
in 0
lactate 0
turned 0
negative 0
, 0
and 0
pH 0
, 0
PCO2 0
and 0
potassium 0
differences 0
increased 0
in 0
group 0
2 0
during 0
pacing 0
. 0

This 0
was 0
obtained 0
with 0
the 0
thermal 0
neutron 0
fluency 0
2.0 0
x 0
10 0
( 0
10 0
) 0
n/cm2 0
. 0

Endotoxemia 0
induced 0
by 0
gram 0
- 0
negative 0
bacteria 0
leads 0
to 0
endotoxic 0
shock 0
pathogenetically 0
stemming 0
from 0
the 0
integral 0
component 0
of 0
the 0
bacterial 0
wall 0
- 0
- 0
lipid 0
A 0
. 0

The 0
study 0
made 0
to 0
define 0
the 0
ability 0
of 0
lipid B-gene
A I-gene
monoclonal I-gene
antibodies I-gene
to 0
correct 0
hemodynamic 0
disturbances 0
due 0
to 0
endotoxemia 0
in 0
dog 0
experiments 0
showed 0
the 0
efficacy 0
of 0
the 0
antibodies 0
administration 0
. 0

A 0
randomised 0
, 0
controlled 0
trial 0
was 0
undertaken 0
in 0
40 0
patients 0
with 0
active 0
Crohn 0
's 0
disease 0
to 0
evaluate 0
clinical 0
and 0
nutritional 0
outcomes 0
after 0
an 0
amino 0
acid 0
based 0
diet 0
containing 0
3 0
% 0
fat 0
was 0
given 0
by 0
a 0
feeding 0
tube 0
compared 0
with 0
a 0
peptide 0
based 0
diet 0
containing 0
33 0
% 0
fat 0
. 0

This 0
sequenced 0
region 0
of 0
the 0
V 0
beta 0
locus 0
contains 0
an 0
average 0
number 0
of 0
repetitive 0
DNA 0
elements 0
( 0
21 0
Alu B-gene
, 0
three 0
L1 B-gene
, 0
three 0
MER 0
, 0
and 0
three 0
retrovirus 0
- 0
related 0
elements 0
. 0

The 0
sequenced 0
genomic 0
region 0
thus 0
accounts 0
for 0
essentially 0
all 0
of 0
the 0
longest 0
known 0
transcript 0
( 0
4.5 0
kb 0
) 0
, 0
although 0
the 0
precise 0
ends 0
of 0
this 0
transcript 0
have 0
not 0
been 0
defined 0
. 0

The 0
pexB B-gene
upstream I-gene
region I-gene
contained 0
245 0
nucleotides 0
within 0
which 0
sequences 0
approximating 0
the 0
consensus 0
for 0
cyclic B-gene
AMP I-gene
receptor I-gene
protein I-gene
and 0
integration B-gene
host I-gene
factor I-gene
binding 0
sites 0
were 0
discernible 0
. 0

The 0
fepA B-gene
- 0
entD B-gene
and 0
fes B-gene
- 0
entF B-gene
operons 0
in 0
the 0
enterobactin 0
synthesis 0
and 0
transport 0
system 0
are 0
divergently 0
transcribed 0
from 0
overlapping 0
promoters 0
, 0
and 0
both 0
are 0
inhibited 0
by 0
the 0
Fur B-gene
repressor I-gene
protein I-gene
under 0
iron 0
- 0
replete 0
conditions 0
. 0

Sequence 0
analysis 0
of 0
a 0
6.3 0
- 0
kbp 0
genomic 0
EcoRI B-gene
- 0
fragment 0
of 0
Alcaligenes 0
eutrophus 0
, 0
which 0
was 0
recently 0
identified 0
by 0
using 0
a 0
dihydrolipoamide B-gene
dehydrogenase I-gene
- 0
specific 0
DNA 0
probe 0
( 0
A 0
. 0

Using 0
a 0
previously 0
published 0
two 0
- 0
frequency 0
( 0
AC 0
excitation 0
) 0
three 0
- 0
electrode 0
method 0
, 0
the 0
admittance 0
locus 0
plot 0
( 0
ALP 0
) 0
in 0
the 0
low 0
- 0
frequency 0
region 0
( 0
< 0
1000 0
Hz 0
) 0
has 0
been 0
shown 0
to 0
be 0
very 0
well 0
approximated 0
by 0
a 0
straight 0
line 0
and 0
can 0
be 0
described 0
with 0
frequency 0
- 0
independent 0
parameters 0
; 0
phase 0
angle 0
alpha 0
pi/2 0
, 0
conductance 0
at 0
extrapolated 0
zero 0
frequency 0
G0 0
= 0
1/R0 0
, 0
and 0
ion 0
relaxation 0
time 0
tau 0
. 0

Intraoperative 0
measurement 0
of 0
activated 0
partial 0
thromboplastin B-gene
time 0
and 0
prothrombin B-gene
time 0
with 0
a 0
new 0
compact 0
monitor 0
. 0

In 0
addition 0
, 0
we 0
sought 0
to 0
test 0
the 0
hypothesis 0
that 0
, 0
when 0
equal 0
volumes 0
are 0
administered 0
intrathecally 0
, 0
significant 0
differences 0
exist 0
in 0
the 0
potential 0
to 0
three 0
commonly 0
used 0
anesthetic 0
solutions 0
to 0
induce 0
sensory 0
impairment 0
. 0

In 0
an 0
in 0
vitro 0
study 0
, 0
10/0 0
nylon 0
was 0
found 0
to 0
require 0
a 0
significantly 0
lower 0
laser 0
energy 0
density 0
to 0
produce 0
suture 0
lysis 0
following 0
a 0
single 0
shot 0
than 0
either 0
10/0 0
Dacron 0
or 0
10/0 0
prolene 0
. 0

The 0
proteins 0
encoded 0
downstream 0
of 0
rpoN B-gene
are 0
known 0
to 0
negatively 0
regulate 0
sigma B-gene
54 I-gene
activity 0
. 0

We 0
report 0
here 0
that 0
microinjection 0
of 0
an 0
anti B-gene
- I-gene
CBP I-gene
antiserum I-gene
into 0
fibroblasts 0
can 0
inhibit 0
transcription 0
from 0
a 0
cAMP 0
responsive 0
promoter 0
. 0

These 0
results 0
demonstrate 0
that 0
a 0
class 0
of 0
proline 0
- 0
rich 0
activator 0
proteins 0
and 0
RNA B-gene
polymerase I-gene
II I-gene
possess 0
a 0
common 0
structural 0
and 0
functional 0
component 0
which 0
can 0
interact 0
with 0
the 0
same 0
target 0
in 0
the 0
general 0
transcription 0
machinery 0
. 0

Cloning 0
of 0
higher B-gene
plant I-gene
omega I-gene
- I-gene
3 I-gene
fatty I-gene
acid I-gene
desaturases I-gene
. 0

65 0
, 0
3829 0
- 0
3838 0
, 0
1991 0
) 0
, 0
a 0
truncated 0
form 0
of 0
the 0
IE B-gene
polypeptide I-gene
lacking 0
IE B-gene
amino I-gene
acid I-gene
residues I-gene
1 I-gene
- I-gene
322 I-gene
( 0
and 0
, 0
therefore 0
lacks 0
the 0
deduced 0
transcriptional 0
activation 0
domain 0
) 0
, 0
fails 0
to 0
transactivate 0
the 0
EHV B-gene
- I-gene
1 I-gene
tk I-gene
promoter I-gene
, 0
but 0
retains 0
the 0
ability 0
to 0
down 0
- 0
regulate 0
the 0
EHV B-gene
- I-gene
1 I-gene
IE I-gene
promoter I-gene
. 0

However 0
, 0
by 0
an 0
NS35 B-gene
- I-gene
specific I-gene
RNA I-gene
capture 0
assay 0
, 0
the 0
multimers 0
were 0
shown 0
to 0
possess 0
the 0
RNA 0
- 0
binding 0
activity 0
previously 0
demonstrated 0
for 0
NS35 B-gene
. 0

CONCLUSION 0
: 0
Human 0
preterm 0
birth 0
is 0
associated 0
with 0
significantly 0
lower 0
progesterone/17 0
beta 0
- 0
estradiol 0
ratios 0
than 0
those 0
of 0
women 0
with 0
preterm 0
labor 0
delivered 0
at 0
term 0
. 0

Ketamine 0
in 0
the 0
treatment 0
of 0
bronchospasm 0
during 0
mechanical 0
ventilation 0
. 0

In 0
conclusion 0
, 0
the 0
disposition 0
of 0
venlafaxine 0
and 0
O 0
- 0
desmethylvenlafaxine 0
is 0
markedly 0
altered 0
in 0
renal 0
disease 0
; 0
therefore 0
dosage 0
adjustment 0
is 0
warranted 0
for 0
patients 0
with 0
creatinine 0
clearance 0
values 0
below 0
30 0
ml/min 0
. 0

The 0
availability 0
of 0
sequence 0
from 0
multiple 0
species 0
has 0
permitted 0
us 0
to 0
determine 0
that 0
the 0
UBE 0
site 0
has 0
close 0
similarity 0
to 0
motifs 0
that 0
bind 0
members 0
of 0
the 0
NF B-gene
- I-gene
1 I-gene
family I-gene
of I-gene
transcription I-gene
factors I-gene
. 0

The 0
incidence 0
of 0
HSV 0
- 0
2 0
positive 0
subjects 0
( 0
HSV B-gene
- I-gene
2/HSV I-gene
- I-gene
1 I-gene
antibody I-gene
ratio 0
> 0
or 0
= 0
1 0
) 0
was 0
low 0
in 0
the 0
Jewish 0
Israeli 0
population 0
, 0
compared 0
to 0
other 0
demographic 0
areas 0
. 0

The 0
mechanism 0
whereby 0
zeta B-gene
PKC I-gene
regulates 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
most 0
probably 0
involves 0
the 0
activation 0
of 0
a 0
putative 0
I B-gene
kappa I-gene
B I-gene
kinase I-gene
of 0
molecular 0
mass 0
approximately 0
50 0
kDa 0
, 0
which 0
phosphorylates 0
and 0
inactivates 0
I B-gene
kappa I-gene
B I-gene
. 0

Stable 0
expression 0
of 0
truncated B-gene
inositol I-gene
1,4,5 I-gene
- I-gene
trisphosphate I-gene
receptor I-gene
subunits I-gene
in 0
3T3 0
fibroblasts 0
. 0

The 0
molecular 0
basis 0
for 0
commitment 0
of 0
progenitors 0
to 0
the 0
eosinophil 0
lineage 0
and 0
mechanisms 0
by 0
which 0
eosinophil 0
- 0
specific 0
genes 0
are 0
expressed 0
and 0
regulated 0
during 0
differentiation 0
is 0
unknown 0
. 0

We 0
report 0
the 0
identification 0
and 0
characterization 0
of 0
myr B-gene
4 I-gene
( 0
myosin B-gene
from I-gene
rat I-gene
) 0
, 0
the 0
first 0
mammalian B-gene
myosin I-gene
I I-gene
that 0
is 0
not 0
closely 0
related 0
to 0
brush 0
border 0
myosin B-gene
I I-gene
. 0

M. 0
, 0
and 0
D 0
. 0

In 0
addition 0
, 0
computer 0
analysis 0
suggests 0
that 0
sequences 0
similar 0
to 0
the 0
A 0
stem 0
element 0
are 0
present 0
within 0
the 0
three 0
AAV B-gene
promoter I-gene
regions 0
. 0

At 0
least 0
some 0
of 0
the 0
difference 0
in 0
stability 0
of 0
the 0
two 0
kinds 0
of 0
complexes 0
was 0
due 0
to 0
the 0
fact 0
that 0
the 0
dissociation 0
rate 0
of 0
the 0
A 0
stem 0
substrate 0
from 0
the 0
protein 0
- 0
DNA 0
complexes 0
was 0
approximately 0
fourfold 0
faster 0
than 0
that 0
of 0
the 0
complete 0
TR B-gene
. 0

Processing 0
of 0
the 0
NS3' B-gene
- 0
5B B-gene
polyprotein 0
was 0
complex 0
and 0
occurred 0
rapidly 0
. 0

However 0
, 0
each 0
promoter 0
activated 0
by 0
IEP86 B-gene
was 0
synergistically 0
affected 0
by 0
the 0
addition 0
of 0
IEP72 B-gene
. 0

32Pi 0
labeling 0
or 0
isoelectric 0
focusing 0
analysis 0
of 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
from 0
conditional 0
casein B-gene
kinase I-gene
II I-gene
mutants I-gene
indicated 0
that 0
phosphorylation 0
of 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
is 0
abolished 0
or 0
dephosphorylated 0
forms 0
of 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
are 0
detected 0
when 0
these 0
strains 0
are 0
grown 0
at 0
the 0
restrictive 0
growth 0
conditions 0
. 0

Thus 0
, 0
YMIP B-gene
is 0
a 0
functional 0
homolog 0
of 0
RMIP B-gene
and 0
represents 0
a 0
new 0
component 0
of 0
the 0
yeast 0
mitochondrial 0
import 0
machinery 0
. 0

The 0
R2 0
region 0
within 0
the 0
class 0
I 0
enhancer 0
acts 0
as 0
a 0
negative 0
element 0
in 0
Ad12 0
- 0
transformed 0
cells 0
and 0
exhibits 0
a 0
stronger 0
binding 0
activity 0
than 0
is 0
observed 0
in 0
nontumorigenic 0
Ad5 0
- 0
transformed 0
cells 0
, 0
which 0
are 0
not 0
reduced 0
in 0
class 0
I 0
expression 0
. 0

PURPOSE 0
: 0
To 0
evaluate 0
the 0
kinetics 0
of 0
erythropoietin B-gene
( 0
EPO B-gene
) 0
production 0
and 0
address 0
the 0
pathogenesis 0
of 0
anemia 0
of 0
prematurity 0
, 0
we 0
measured 0
EPO B-gene
levels 0
in 0
infants 0
during 0
the 0
first 0
year 0
of 0
life 0
. 0

The 0
nerve B-gene
growth I-gene
factor I-gene
beta I-gene
gene I-gene
( 0
NGFB B-gene
) 0
belongs 0
to 0
a 0
conserved 0
syntenic 0
group 0
on 0
human 0
chromosome 0
1 0
and 0
mouse 0
Chromosome 0
3 0
. 0

Furthermore 0
, 0
an 0
upstream 0
element 0
, 0
collagen B-gene
element I-gene
I I-gene
( I-gene
- I-gene
370/ I-gene
- I-gene
344 I-gene
) I-gene
, 0
which 0
shares 0
homology 0
with 0
the 0
LAP B-gene
binding 0
cis 0
- 0
element 0
of 0
the 0
albumin B-gene
promoter I-gene
( 0
9 0
of 0
13 0
bp 0
) 0
is 0
described 0
. 0

Number 0
and 0
size 0
of 0
silver 0
- 0
stained 0
nucleoli 0
( 0
Ag 0
- 0
NOR 0
clusters 0
) 0
in 0
canine 0
seminomas 0
: 0
correlation 0
with 0
histological 0
features 0
and 0
tumour 0
behaviour 0
. 0

We 0
speculate 0
that 0
mast 0
cell 0
degranulation 0
may 0
be 0
involved 0
in 0
the 0
pathogenesis 0
of 0
necrobiosis 0
by 0
altering 0
fibroblast 0
enzyme 0
activity 0
and/or 0
producing 0
prolonged 0
inflammatory 0
reactions 0
. 0

Molecular 0
cloning 0
of 0
a 0
cysteine B-gene
synthase I-gene
cDNA I-gene
from 0
Citrullus 0
vulgaris 0
( 0
watermelon 0
) 0
by 0
genetic 0
complementation 0
in 0
an 0
Escherichia 0
coli 0
Cys 0
- 0
auxotroph 0
. 0

In 0
earlier 0
studies 0
we 0
identified 0
several 0
regulatory 0
elements 0
that 0
control 0
transcriptional 0
activation 0
and 0
aerobic 0
repression 0
of 0
one 0
of 0
these 0
genes 0
, 0
COX5b B-gene
. 0

Although 0
elevated 0
serum 0
levels 0
of 0
antibodies 0
to 0
the 0
nicotinic B-gene
acetylcholine I-gene
receptor I-gene
( 0
nAChR B-gene
) 0
have 0
been 0
reported 0
in 0
neuroleptic 0
treated 0
patients 0
with 0
tardive 0
dyskinesia 0
, 0
such 0
antibodies 0
have 0
not 0
been 0
determined 0
in 0
comparable 0
nondyskinetic 0
patients 0
. 0

The 0
tumor 0
suppressor 0
and 0
transcriptional 0
factor 0
p53 B-gene
is 0
a 0
phosphorylated 0
protein 0
. 0

This 0
DNA 0
containing 0
promoter 0
activity 0
has 0
been 0
sequenced 0
in 0
its 0
entirety 0
and 0
found 0
to 0
contain 0
multiple 0
putative 0
regulatory 0
sites 0
. 0

However 0
, 0
Southern 0
blot 0
and 0
karyotype 0
analyses 0
did 0
not 0
reveal 0
any 0
significant 0
changes 0
in 0
copy 0
number 0
or 0
gross 0
rearrangements 0
of 0
the 0
p53 B-gene
gene I-gene
in 0
any 0
of 0
the 0
p53 B-gene
- I-gene
cell 0
lines 0
. 0

HupI B-gene
showed 0
strong 0
identity 0
to 0
rubredoxin B-gene
and 0
rubredoxin B-gene
- I-gene
like I-gene
proteins I-gene
from 0
many 0
other 0
bacteria 0
. 0

The 0
PCr 0
resynthesis 0
rate 0
( 0
P 0
< 0
0.01 0
) 0
and 0
the 0
effective 0
maximal 0
rate 0
of 0
mitochondrial 0
ATP 0
synthesis 0
( 0
P 0
< 0
0.05 0
) 0
also 0
improved 0
. 0

An 0
examination 0
was 0
performed 0
in 0
15 0
patients 0
who 0
had 0
developed 0
pronounced 0
osteomalacia 0
following 0
gastric 0
resection 0
. 0

However 0
, 0
regional 0
MVO2 0
increased 0
to 0
about 0
the 0
same 0
extent 0
in 0
the 0
CFX 0
( 0
from 0
6.0 0
+/ 0
- 0
0.7 0
to 0
12.4 0
+/ 0
- 0
0.9 0
ml 0
O2.min 0
- 0
1 0
times 0
100 0
g 0
- 0
1 0
) 0
and 0
the 0
LAD 0
region 0
( 0
from 0
7.0 0
+/ 0
- 0
0.6 0
to 0
14.5 0
+/ 0
- 0
1.3 0
ml 0
O2.min 0
- 0
1 0
times 0
100 0
g 0
- 0
1 0
) 0
. 0

IGF B-gene
I I-gene
and 0
insulin B-gene
receptors I-gene
are 0
homologous 0
proteins 0
that 0
function 0
in 0
distinct 0
physiological 0
pathways 0
. 0

Immunodepression 0
was 0
combined 0
with 0
the 0
increase 0
of 0
glucocorticoid 0
activity 0
of 0
adrenal 0
cortex 0
, 0
while 0
no 0
significant 0
changes 0
in 0
thyroid 0
hormones 0
were 0
registered 0
. 0

Tryptic 0
cleavage 0
and 0
peptide 0
sequence 0
analysis 0
demonstrated 0
that 0
the 0
98 0
- 0
kD 0
protein 0
is 0
identical 0
to 0
a 0
recently 0
cloned 0
protein 0
, 0
special B-gene
A I-gene
- I-gene
T I-gene
- I-gene
rich I-gene
binding I-gene
protein I-gene
1 I-gene
( 0
SATB1 B-gene
) 0
, 0
that 0
binds 0
selectively 0
to 0
nuclear 0
matrix/scaffold 0
- 0
associated 0
regions 0
of 0
DNA 0
( 0
MARs/SARs 0
) 0
. 0

Aberrant 0
protein 0
phosphorylation 0
at 0
tyrosine 0
is 0
responsible 0
for 0
the 0
growth 0
- 0
inhibitory 0
action 0
of 0
pp60v B-gene
- I-gene
src I-gene
expressed 0
in 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

Acute 0
pancreatitis 0
: 0
a 0
multisystem 0
disease 0
. 0

Alginate 0
biosynthesis 0
is 0
controlled 0
by 0
a 0
complex 0
regulatory 0
mechanism 0
. 0

The 0
sequence 0
upstream 0
of 0
the 0
rhlA B-gene
promoter I-gene
contains 0
two 0
inverted 0
repeats 0
which 0
define 0
putative 0
binding 0
sites 0
for 0
the 0
RhlR B-gene
regulator I-gene
. 0

We 0
have 0
examined 0
by 0
in 0
vitro 0
footprinting 0
a 0
region 0
located 0
downstream 0
of 0
the 0
human 0
immunodeficiency 0
virus 0
, 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
promoter 0
found 0
to 0
be 0
hypersensitive 0
to 0
DNase B-gene
I I-gene
digestion 0
in 0
vivo 0
. 0

Heparin 0
had 0
no 0
effect 0
on 0
rAC B-gene
- I-gene
st I-gene
myosin I-gene
light I-gene
chain I-gene
phosphatase I-gene
activity 0
, 0
while 0
the 0
B 0
subunit 0
- 0
containing 0
forms 0
were 0
stimulated 0
2 0
- 0
3 0
- 0
fold 0
. 0

The 0
relative 0
abundance 0
of 0
each 0
alternatively 0
spliced 0
mRNA 0
was 0
determined 0
by 0
reverse 0
transcription 0
- 0
polymerase 0
chain 0
reaction 0
in 0
various 0
human 0
tissues 0
and 0
cell 0
lines 0
. 0

BACKGROUND 0
AND 0
DESIGN 0
: 0
Fifty 0
- 0
nine 0
melanocytic 0
nevi 0
with 0
eccentric 0
foci 0
of 0
hyperpigmentation 0
( 0
`` 0
small 0
dark 0
dots 0
'' 0
) 0
that 0
measured 0
primarily 0
1 0
to 0
2 0
mm 0
in 0
diameter 0
were 0
prospectively 0
examined 0
to 0
determine 0
the 0
histologic 0
correlates 0
of 0
the 0
dark 0
dots 0
. 0

The 0
retention 0
index 0
of 0
201Tl 0
SPECT 0
is 0
a 0
useful 0
indicator 0
of 0
metastatic 0
potential 0
, 0
thereby 0
facilitating 0
the 0
prediction 0
of 0
prognosis 0
, 0
and 0
provides 0
insight 0
into 0
the 0
relationship 0
between 0
201Tl 0
uptake 0
and 0
malignancy 0
. 0

The 0
central 0
globular 0
domain 0
is 0
highly 0
similar 0
to 0
those 0
regions 0
from 0
other 0
H1 B-gene
molecules I-gene
, 0
and 0
the 0
carboxyl 0
- 0
terminal 0
domain 0
contains 0
a 0
repeating 0
hexapeptide 0
motif 0
, 0
variants 0
of 0
which 0
are 0
conserved 0
among 0
H1 B-gene
molecules I-gene
. 0

The 0
location 0
and 0
approximate 0
length 0
of 0
the 0
intron 0
are 0
conserved 0
in 0
both 0
the 0
tomato 0
and 0
Arabidopsis 0
genes 0
, 0
with 0
the 0
intron 0
separating 0
the 0
'nose 0
' 0
region 0
( 0
encoded 0
by 0
exon 0
1 0
) 0
from 0
the 0
central 0
globular 0
domain 0
( 0
exon 0
2 0
) 0
. 0

The 0
topology 0
and 0
chain 0
folding 0
of 0
the 0
beta 0
subunits 0
in 0
the 0
artifactual 0
beta 0
60 0
capsid 0
are 0
similar 0
to 0
the 0
native B-gene
alpha I-gene
3 I-gene
beta I-gene
60 I-gene
enzyme I-gene
. 0

A 0
single 0
NMSC 0
was 0
present 0
in 0
69.4 0
% 0
, 0
two 0
in 0
16 0
% 0
, 0
three 0
in 0
6.4 0
% 0
, 0
four 0
in 0
3.5 0
% 0
, 0
five 0
to 0
nine 0
in 0
4.2 0
% 0
, 0
and 0
0.5 0
% 0
had 0
ten 0
or 0
more 0
. 0

A 0
constitutive 0
mutant 0
form 0
with 0
a 0
single 0
substitution 0
( 0
V88A 0
) 0
in 0
the 0
amino 0
- 0
terminal 0
( 0
response 0
regulator 0
) 0
region 0
was 0
used 0
. 0

Comparisons 0
of 0
the 0
four 0
operon 0
control 0
regions 0
studied 0
indicate 0
that 0
the 0
NarL B-gene
heptamers I-gene
are 0
arranged 0
with 0
diverse 0
orientations 0
and 0
spacing 0
. 0

Direct 0
binding 0
and 0
competition 0
assays 0
using 0
30 0
- 0
mer 0
oligonucleotide 0
probes 0
representing 0
the 0
individual 0
CBF1 B-gene
binding I-gene
sites I-gene
indicated 0
that 0
CBF1 B-gene
bound 0
less 0
efficiently 0
to 0
the 0
CD23 B-gene
promoter I-gene
and 0
the 0
EBV B-gene
LMP I-gene
- I-gene
1 I-gene
promoter I-gene
sites I-gene
than 0
to 0
the 0
Cp B-gene
site I-gene
. 0

We 0
have 0
found 0
a 0
satisfactory 0
reproducibility 0
in 0
vitro 0
( 0
T1 0
: 0
1.9 0
% 0
; 0
T2 0
: 0
6.2 0
% 0
) 0
, 0
while 0
the 0
reproducibility 0
was 0
less 0
satisfactory 0
in 0
vivo 0
( 0
T1 0
: 0
16.4 0
% 0
; 0
T2 0
: 0
13.4 0
% 0
) 0
. 0

The 0
two 0
ParA B-gene
proteins I-gene
that 0
are 0
produced 0
as 0
a 0
result 0
of 0
independent 0
translation 0
initiation 0
at 0
two 0
different 0
start 0
codons 0
within 0
the 0
same 0
open 0
reading 0
frame 0
were 0
overexpressed 0
in 0
Escherichia 0
coli 0
and 0
partially 0
purified 0
. 0

To 0
get 0
further 0
insights 0
into 0
the 0
molecular 0
mechanisms 0
that 0
control 0
tal B-gene
- I-gene
1 I-gene
expression 0
, 0
we 0
have 0
isolated 0
5 0
' 0
sequences 0
of 0
the 0
murine 0
gene 0
and 0
compared 0
them 0
to 0
their 0
human 0
counterparts 0
. 0

CONCLUSION 0
: 0
Sonographic 0
angiography 0
has 0
a 0
possible 0
role 0
in 0
the 0
detection 0
of 0
small 0
nodules 0
in 0
patients 0
with 0
CRF 0
. 0

Each 0
expressed 0
domain 0
, 0
as 0
well 0
as 0
FKBP B-gene
- I-gene
33 I-gene
itself 0
, 0
possesses 0
peptidyl B-gene
- I-gene
prolyl I-gene
cis I-gene
- I-gene
trans I-gene
isomerase I-gene
activity 0
, 0
though 0
with 0
much 0
lower 0
specific 0
activities 0
than 0
FKBP B-gene
- I-gene
12 I-gene
. 0

The 0
first 0
85 0
nt 0
upstream 0
of 0
the 0
transcription 0
initiation 0
site 0
of 0
the 0
mouse B-gene
desmin I-gene
gene I-gene
, 0
which 0
contain 0
an 0
E 0
box 0
( 0
E1 0
) 0
, 0
the 0
binding 0
site 0
of 0
the 0
helix B-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
myogenic I-gene
regulators I-gene
, 0
are 0
sufficient 0
to 0
confer 0
low 0
level 0
muscle 0
- 0
specific 0
expression 0
. 0

The 0
acfD B-gene
gene I-gene
encompasses 0
254 0
nt 0
that 0
are 0
predicted 0
to 0
encode 0
an 0
88 0
- 0
amino 0
- 0
acid 0
( 0
aa 0
) 0
protein 0
. 0

We 0
find 0
that 0
beta B-gene
II I-gene
PKC I-gene
phosphorylates 0
nuclear B-gene
envelope I-gene
lamin I-gene
B I-gene
at 0
10 0
- 0
20 0
times 0
the 0
rate 0
of 0
alpha B-gene
PKC I-gene
, 0
whereas 0
both 0
kinases 0
phosphorylate 0
soluble B-gene
lamin I-gene
B I-gene
at 0
similar 0
rates 0
. 0

Regulation 0
of 0
parathyroid B-gene
hormone I-gene
- I-gene
related I-gene
protein I-gene
( 0
PTHrP B-gene
) 0
gene 0
expression 0
. 0

These 0
results 0
demonstrate 0
that 0
a 0
diverse 0
set 0
of 0
carboxyl 0
- 0
terminal 0
sequence 0
motifs 0
and 0
posttranslational 0
modifications 0
lead 0
to 0
functional 0
Ras B-gene
proteins I-gene
in 0
yeast 0
. 0

We 0
conclude 0
that 0
c B-gene
- I-gene
Abl I-gene
activates 0
c B-gene
- I-gene
myc I-gene
transcription 0
indirectly 0
with 0
no 0
requirement 0
for 0
DNA 0
binding 0
by 0
c B-gene
- I-gene
Abl I-gene
. 0

Long 0
- 0
latency 0
: 0
locked 0
units 0
responded 0
to 0
shocks 0
with 0
little 0
jitter 0
and 0
long 0
latency 0
( 0
4 0
- 0
11 0
ms 0
) 0
. 0

The 0
highly 0
conserved 0
ninth 0
heptad 0
, 0
which 0
is 0
involved 0
in 0
heterodimerization 0
, 0
appears 0
to 0
participate 0
in 0
the 0
receptor 0
- 0
inhibitor 0
interaction 0
, 0
suggesting 0
that 0
the 0
inhibitor 0
is 0
a 0
related 0
member 0
of 0
the 0
receptor 0
gene 0
family 0
. 0

Here 0
we 0
show 0
that 0
for 0
expression 0
of 0
snRNA 0
genes 0
in 0
maize 0
, 0
a 0
monocotyledonous 0
plant 0
, 0
the 0
USE 0
and 0
TATA 0
elements 0
are 0
essential 0
, 0
but 0
not 0
sufficient 0
, 0
for 0
transcription 0
. 0

Extensive 0
DNA 0
rearrangement 0
occurs 0
during 0
the 0
development 0
of 0
the 0
somatic 0
macronucleus 0
from 0
the 0
germ 0
line 0
micronucleus 0
in 0
ciliated 0
protozoans 0
. 0

An 0
in 0
vitro 0
binding 0
site 0
selection 0
procedure 0
was 0
used 0
to 0
determine 0
DNA 0
sequences 0
preferentially 0
bound 0
by 0
wild B-gene
- I-gene
type I-gene
HLF I-gene
and 0
chimeric 0
E2A B-gene
- 0
HLF B-gene
proteins 0
isolated 0
from 0
various 0
t 0
( 0
17 0
; 0
19 0
) 0
- 0
bearing 0
leukemias 0
. 0

The 0
Oct B-gene
- I-gene
2 I-gene
glutamine 0
- 0
rich 0
and 0
proline 0
- 0
rich 0
activation 0
domains 0
can 0
synergize 0
with 0
each 0
other 0
or 0
duplicates 0
of 0
themselves 0
to 0
activate 0
transcription 0
. 0

Binding 0
of 0
U2 B-gene
small I-gene
nuclear I-gene
ribonucleoprotein I-gene
( 0
snRNP 0
) 0
to 0
the 0
pre 0
- 0
mRNA 0
is 0
an 0
early 0
and 0
important 0
step 0
in 0
spliceosome 0
assembly 0
. 0

Taken 0
together 0
, 0
our 0
data 0
suggest 0
that 0
Dbf8p B-gene
plays 0
an 0
essential 0
role 0
in 0
chromosome 0
segregation 0
. 0

Ariga 0
, 0
Biochem 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
KRAB B-gene
domain I-gene
present 0
in 0
the 0
non 0
- 0
finger 0
region 0
of 0
many 0
ZFP B-gene
genes I-gene
quenches 0
transcription 0
possibly 0
due 0
to 0
specific 0
protein 0
- 0
protein 0
interactions 0
between 0
the 0
KRAB B-gene
- I-gene
A I-gene
domain I-gene
and 0
components 0
of 0
the 0
proximal 0
transcriptional 0
apparatus 0
. 0

Marine 0
oils 0
and 0
cardiovascular 0
reactivity 0
. 0

The 0
diagnostic 0
significance 0
of 0
creatine B-gene
phosphokinase I-gene
antibodies 0
in 0
the 0
cardiac 0
muscle 0
in 0
non 0
- 0
coronarogenic 0
myocardial 0
diseases 0

According 0
to 0
the 0
results 0
of 0
assays 0
obtained 0
with 0
the 0
use 0
of 0
assay 0
systems 0
ORTHO 0
ELISA 0
and 0
ABBOTT 0
HCV 0
EIA 0
( 0
USA 0
) 0
, 0
the 0
detection 0
rate 0
of 0
anti B-gene
- I-gene
HCV I-gene
- I-gene
C100 I-gene
- I-gene
3 I-gene
among 0
primary 0
blood 0
donors 0
in 0
Moscow 0
was 0
1.37 0
% 0
and 0
was 0
not 0
different 0
from 0
that 0
among 0
HBsAg B-gene
carriers 0
( 0
1.8 0
% 0
) 0
and 0
among 0
donors 0
with 0
anti B-gene
- I-gene
HCV I-gene
- I-gene
C100 I-gene
- I-gene
3 I-gene
in 0
the 0
blood 0
( 0
1.6 0
% 0
) 0
( 0
p 0
< 0
0.01 0
) 0
. 0

We 0
examined 0
the 0
hypothesis 0
that 0
the 0
coronary 0
vasomotor 0
responses 0
to 0
etomidate 0
( 0
ETO 0
) 0
, 0
propofol 0
( 0
PRO 0
) 0
, 0
and 0
sodium 0
thiopental 0
( 0
STP 0
) 0
are 0
mediated 0
through 0
contrasting 0
effects 0
on 0
the 0
resting 0
nitric 0
oxide 0
( 0
NO 0
) 0
- 0
dependent 0
vasodilator 0
tone 0
that 0
opposes 0
adrenergic 0
vasoconstrictor 0
activity 0
in 0
the 0
intact 0
dog 0
. 0

Significant 0
alterations 0
in 0
CBC 0
results 0
and 0
serum B-gene
CRP I-gene
concentration 0
, 0
compared 0
with 0
baseline 0
values 0
, 0
were 0
lacking 0
in 0
dogs 0
of 0
the 0
control 0
group 0
. 0

These 0
alternative 0
splice 0
variants 0
were 0
detected 0
in 0
RNA 0
isolated 0
from 0
several 0
sources 0
, 0
including 0
primary 0
leptomeningeal 0
tissue 0
and 0
an 0
established 0
line 0
of 0
leptomeningeal 0
cells 0
( 0
LMC 0
) 0
. 0

Roux 0
- 0
en 0
- 0
Y 0
gastroenterostomy 0
severely 0
disturbs 0
emptying 0
of 0
the 0
gallbladder 0
. 0

Surface 0
- 0
coil 0
experiments 0
on 0
phantoms 0
and 0
on 0
human 0
calf 0
muscles 0
in 0
vivo 0
are 0
presented 0
. 0

Large 0
interpatient 0
variation 0
in 0
peak 0
PCZ 0
plasma 0
levels 0
( 0
91 0
- 0
3215 0
ng/ml 0
) 0
was 0
seen 0
, 0
with 0
the 0
plasma 0
half 0
- 0
life 0
( 0
t1/2 0
alpha 0
) 0
being 0
approximately 0
57 0
min 0
in 0
patients 0
given 0
135 0
- 0
180 0
mg/m2 0
PCZ 0
. 0

The 0
maximal 0
effect 0
was 0
seen 0
at 0
100 0
ng/ml 0
EGF B-gene
, 0
with 0
a 0
time 0
lag 0
of 0
about 0
5 0
h 0
. 0

KAR1 B-gene
encodes 0
an 0
essential 0
component 0
of 0
the 0
yeast 0
spindle 0
pole 0
body 0
( 0
SPB 0
) 0
that 0
is 0
required 0
for 0
karyogamy 0
and 0
SPB 0
duplication 0
. 0

CDC31 B-gene
is 0
required 0
for 0
SPB 0
duplication 0
and 0
encodes 0
a 0
calmodulin B-gene
- I-gene
like I-gene
protein I-gene
that 0
is 0
most 0
closely 0
related 0
to 0
caltractin/centrin B-gene
, 0
a 0
protein 0
associated 0
with 0
the 0
Chlamydomonas 0
basal 0
body 0
. 0

During 0
transcript 0
elongation 0
, 0
the 0
sizes 0
of 0
the 0
DNA 0
footprint 0
and 0
the 0
single 0
- 0
stranded 0
transcription 0
bubble 0
vary 0
markedly 0
among 0
transcription 0
complexes 0
halted 0
at 0
different 0
template 0
positions 0
. 0

The 0
newly 0
recognised 0
skeletogenital 0
syndrome 0
. 0

All 0
our 0
patients 0
had 0
polyps 0
, 0
23 0
( 0
54 0
% 0
) 0
had 0
asthma 0
, 0
12 0
( 0
27 0
% 0
) 0
had 0
aspirin 0
sensitivity 0
, 0
20 0
( 0
65 0
% 0
) 0
had 0
eosinophilia 0
, 0
and 0
9 0
( 0
69 0
% 0
) 0
had 0
increased 0
total 0
IgE B-gene
levels 0
. 0

Ras B-gene
- I-gene
and I-gene
ultra I-gene
- I-gene
violet I-gene
- I-gene
responsive I-gene
protein I-gene
kinases I-gene
that 0
phosphorylate 0
c B-gene
- I-gene
Jun I-gene
on 0
serine 0
residues 0
at 0
positions 0
63 0
and 0
73 0
and 0
stimulate 0
its 0
transcriptional 0
activity 0
have 0
been 0
identified 0
. 0

A 0
short 0
sequence 0
surrounding 0
the 0
major 0
JNK B-gene
phosphorylation 0
site 0
of 0
c B-gene
- I-gene
Jun I-gene
is 0
conserved 0
in 0
c B-gene
- I-gene
Fos I-gene
and 0
is 0
part 0
of 0
its 0
activation 0
domain 0
, 0
suggesting 0
that 0
c B-gene
- I-gene
Fos I-gene
may 0
be 0
similarly 0
regulated 0
. 0

c B-gene
- I-gene
Fos I-gene
transcriptional 0
activity 0
stimulated 0
by 0
H B-gene
- I-gene
Ras I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
distinct 0
from 0
JNK B-gene
and 0
ERK B-gene
. 0

A 0
new 0
generation 0
of 0
information 0
retrieval 0
tools 0
for 0
biologists 0
: 0
the 0
example 0
of 0
the 0
ExPASy 0
WWW 0
server 0
. 0

Essential 0
features 0
of 0
this 0
model 0
are 0
bending 0
of 0
the 0
DNA 0
double 0
helix 0
and 0
contact 0
of 0
operator 0
sites 0
with 0
repressor 0
domains 0
bearing 0
sequence 0
homologies 0
with 0
the 0
helix 0
- 0
turn 0
- 0
helix 0
( 0
HTH 0
) 0
motifs 0
of 0
other 0
DNA 0
- 0
binding 0
proteins 0
. 0

The 0
partial 0
ORF 0
was 0
found 0
to 0
be 0
identical 0
to 0
the 0
C 0
terminus 0
of 0
HrpJ2 B-gene
. 0

The 0
partial 0
ORF 0
was 0
found 0
to 0
be 0
identical 0
to 0
the 0
C 0
terminus 0
of 0
HrpJ2 B-gene
. 0

The 0
binding 0
of 0
transcription 0
factor 0
AP B-gene
- I-gene
1 I-gene
and 0
vitamin B-gene
D I-gene
receptor I-gene
( 0
VDR B-gene
) 0
to 0
the 0
composite 0
AP B-gene
- I-gene
1 I-gene
plus I-gene
vitamin I-gene
- I-gene
D I-gene
- I-gene
responsive I-gene
promoter I-gene
region 0
( 0
AP B-gene
- I-gene
1 I-gene
+ I-gene
VDRE I-gene
) 0
of 0
the 0
human B-gene
osteocalcin I-gene
gene I-gene
was 0
characterized 0
in 0
osteocalcin B-gene
- 0
producing 0
( 0
MG 0
- 0
63 0
) 0
and 0
non 0
- 0
producing 0
( 0
U2 0
- 0
Os 0
, 0
SaOs 0
- 0
2 0
) 0
human 0
osteosarcoma 0
cell 0
lines 0
. 0

Rapid 0
detection 0
of 0
this 0
mutation 0
is 0
achieved 0
by 0
restriction 0
digestion 0
of 0
PCR 0
- 0
amplified 0
genomic 0
DNA 0
; 0
a 0
mismatch 0
primer 0
combined 0
with 0
the 0
point 0
mutation 0
creates 0
a 0
Tru9I B-gene
restriction I-gene
site I-gene
. 0

Wild B-gene
type I-gene
and I-gene
mutant I-gene
Epo I-gene
cDNAs I-gene
were 0
transiently 0
expressed 0
at 0
high 0
levels 0
in 0
COS1 0
and 0
COS7 0
cells 0
. 0

OBJECTIVE 0
- 0
- 0
To 0
assess 0
the 0
risk 0
of 0
hepatitis 0
A 0
in 0
international 0
travelers 0
and 0
to 0
recommend 0
preventive 0
measures 0
. 0

The 0
bactericidal 0
effect 0
of 0
disinfectants 0
against 0
biofilm 0
cells 0
was 0
found 0
to 0
be 0
considerably 0
enhanced 0
by 0
increasing 0
the 0
concentrations 0
of 0
the 0
disinfectants 0
. 0

Expression 0
of 0
ME31B B-gene
cDNA I-gene
in 0
S. 0
pombe 0
suppresses 0
the 0
ste13 B-gene
mutation 0
. 0

Use 0
of 0
Medi 0
- 0
Jector 0
EZ 0
dermojet 0
for 0
anesthesia 0
in 0
minor 0
surgery 0

2 0
. 0

The 0
immune 0
response 0
of 0
past 0
- 0
infection 0
of 0
cytomegalovirus 0
in 0
the 0
patients 0
of 0
RTID 0
is 0
rather 0
remarkable 0
. 0

Acupuncture 0
effect 0
on 0
deep 0
receptors 0
was 0
not 0
limited 0
to 0
one 0
point 0
but 0
within 0
a 0
certain 0
area 0
, 0
namely 0
distant 0
effect 0
existed 0
. 0

Reduced 0
NK 0
activity 0
correlates 0
with 0
active 0
disease 0
in 0
HIV 0
- 0
patients 0
with 0
multidrug 0
- 0
resistant 0
pulmonary 0
tuberculosis 0
. 0

Smoking 0
history 0
and 0
awake 0
oxygen 0
saturation 0
( 0
SaO2 0
) 0
was 0
recorded 0
in 0
all 0
of 0
them 0
. 0

( 0
LH B-gene
P 0
< 0
0.05 0
, 0
LH/FSH B-gene
P 0
< 0
0.01 0
) 0
. 0

The 0
relative 0
R 0
- 0
and 0
L 0
- 0
brain 0
weights 0
were 0
found 0
to 0
be 0
inversely 0
related 0
to 0
the 0
relative 0
R 0
- 0
L 0
brain 0
weight 0
only 0
in 0
the 0
RH 0
female 0
cats 0
with 0
R 0
- 0
L 0
brain 0
weight 0
smaller 0
than 0
zero 0
( 0
testosterone 0
in 0
males 0
, 0
estrogen 0
in 0
females 0
) 0
. 0

This 0
mode 0
of 0
ternary 0
complex 0
formation 0
is 0
in 0
contrast 0
to 0
the 0
one 0
seen 0
in 0
the 0
promoter 0
of 0
the 0
c B-gene
- I-gene
fos I-gene
protooncogene I-gene
, 0
where 0
formation 0
of 0
the 0
ternary 0
complex 0
is 0
dependent 0
on 0
the 0
prior 0
assembly 0
of 0
the 0
serum B-gene
response I-gene
factor I-gene
- I-gene
DNA I-gene
binary I-gene
complex I-gene
. 0

The 0
LTR 0
- 0
binding 0
activities 0
of 0
VBP B-gene
, 0
a1/EBP B-gene
, 0
and 0
B B-gene
- I-gene
cell I-gene
nuclear I-gene
extract I-gene
protein I-gene
were 0
compared 0
and 0
mapped 0
by 0
gel 0
shift 0
, 0
DNase B-gene
I I-gene
footprinting 0
, 0
and 0
methylation 0
interference 0
assays 0
. 0

These 0
results 0
suggest 0
that 0
leader 0
- 0
mRNA 0
fusion 0
in 0
coronavirus 0
transcription 0
does 0
not 0
require 0
direct 0
RNA 0
- 0
RNA 0
interaction 0
between 0
complementary 0
sequences 0
. 0

These 0
results 0
suggest 0
that 0
leader 0
- 0
mRNA 0
fusion 0
in 0
coronavirus 0
transcription 0
does 0
not 0
require 0
direct 0
RNA 0
- 0
RNA 0
interaction 0
between 0
complementary 0
sequences 0
. 0

Vaccinia 0
virus 0
- 0
expressed 0
, 0
purified 0
full B-gene
- I-gene
length I-gene
HPV I-gene
- I-gene
16 I-gene
and I-gene
BPV I-gene
- I-gene
1 I-gene
E2 I-gene
proteins I-gene
bound 0
a 0
consensus 0
E2 B-gene
site I-gene
with 0
high 0
specific 0
affinities 0
( 0
Kd 0
= 0
approximately 0
10 0
( 0
- 0
9 0
) 0
M 0
) 0
and 0
stimulated 0
in 0
vitro 0
transcription 0
up 0
to 0
six 0
- 0
to 0
eightfold 0
. 0

This 0
alternatively 0
spliced 0
transcript 0
contained 0
an 0
open 0
reading 0
frame 0
extending 0
from 0
the 0
upstream 0
J 0
alpha 0
11 0
- 0
2 0
region 0
to 0
82 0
nucleotides 0
downstream 0
of 0
the 0
beginning 0
of 0
the 0
TCR B-gene
C I-gene
alpha I-gene
region I-gene
, 0
and 0
potentially 0
encoded 0
a 0
36 0
amino 0
acid 0
polypeptide 0
. 0

In 0
HeLa 0
x 0
fibroblast 0
cell 0
hybrids 0
its 0
expression 0
correlates 0
with 0
tumorigenicity 0
. 0

Demographic 0
characteristics 0
and 0
risk 0
factor 0
data 0
for 0
76,672 0
clients 0
were 0
studied 0
to 0
characterize 0
the 0
distribution 0
of 0
infection 0
with 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
and 0
the 0
use 0
of 0
counseling 0
and 0
testing 0
facilities 0
in 0
Houston 0
, 0
Tex 0
. 0

Results 0
indicate 0
that 0
KNM 0
- 0
LU 0
335 0
differs 0
from 0
both 0
human 0
and 0
chimpanzee 0
M1s 0
in 0
relative 0
distances 0
( 0
measured 0
in 0
three 0
dimensions 0
) 0
between 0
crown 0
fissure 0
termini 0
. 0

We 0
describe 0
49 0
cases 0
with 0
papillary 0
tumor 0
< 0
1 0
cm 0
. 0

Comparison 0
with 0
the 0
bovine 0
gene 0
showed 0
that 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
hATP1 B-gene
gene I-gene
has 0
an 0
unconserved 0
guanine 0
- 0
cytosine 0
( 0
GC 0
) 0
rich 0
region 0
, 0
including 0
several 0
binding 0
motifs 0
of 0
transcriptional 0
factors 0
, 0
such 0
as 0
Sp1 B-gene
, 0
AP B-gene
- I-gene
2 I-gene
, 0
and 0
GCF B-gene
. 0

Structure 0
, 0
promoter 0
analysis 0
and 0
chromosomal 0
assignment 0
of 0
the 0
human B-gene
APEX I-gene
gene I-gene
. 0

The 0
polyubiquitin B-gene
gene I-gene
was 0
transcribed 0
throughout 0
the 0
Volvox 0
life 0
cycle 0
with 0
peaks 0
in 0
the 0
1.6 0
- 0
kb 0
mRNA 0
levels 0
during 0
pre 0
- 0
cleavage 0
, 0
cleavage 0
, 0
and 0
post 0
- 0
inversion 0
. 0

Thus 0
, 0
in 0
stress 0
- 0
induced 0
arrhythmic 0
disease 0
as 0
well 0
as 0
in 0
ischemic 0
heart 0
disease 0
, 0
the 0
main 0
pathogenetic 0
links 0
are 0
outside 0
the 0
heart 0
, 0
but 0
they 0
differ 0
from 0
those 0
observed 0
in 0
ischemia 0
. 0

Here 0
, 0
we 0
present 0
genetic 0
evidence 0
in 0
Saccharomyces 0
cerevisiae 0
for 0
a 0
functional 0
interaction 0
between 0
the 0
DEAH B-gene
protein I-gene
Prp16 B-gene
, 0
and 0
the 0
U6 B-gene
and 0
U2 B-gene
spliceosomal I-gene
snRNAs I-gene
. 0

The 0
consensus 0
gene 0
order 0
deduced 0
by 0
combining 0
data 0
from 0
both 0
crosses 0
is 0
D2Mit1 B-gene
- 0
( 0
Dbh B-gene
, 0
Notch1 B-gene
) 0
- 0
( 0
Col5a1 B-gene
, 0
Rxra B-gene
) 0
- 0
Spna2 B-gene
- 0
Ab B-gene
l I-gene
- 0
( 0
Ak1 B-gene
, 0
Fpgs B-gene
) 0
- 0
( 0
Grp78 B-gene
, 0
Pbx3 B-gene
) 0
- 0
( 0
Epb7.2 B-gene
, I-gene
Hc I-gene
, I-gene
Gsn I-gene
) 0
- 0
Acra B-gene
. 0

The 0
high 0
level 0
of 0
transformation 0
- 0
associated 0
deletions 0
in 0
the 0
human 0
YACs 0
was 0
reduced 0
over 0
10 0
- 0
fold 0
when 0
the 0
host 0
was 0
a 0
recombination 0
- 0
deficient 0
strain 0
deleted 0
for 0
the 0
RAD52 B-gene
gene I-gene
. 0

In 0
addition 0
, 0
the 0
megabase 0
region 0
surrounding 0
the 0
dagA B-gene
locus I-gene
was 0
mapped 0
. 0

These 0
mutants 0
had 0
deletions 0
of 0
the 0
extreme 0
amino 0
- 0
terminal 0
residues 0
as 0
far 0
as 0
amino 0
acid 0
residue 0
30 0
. 0

SECONDARY 0
OUTCOME 0
MEASURE 0
- 0
- 0
Double 0
- 0
blind 0
caffeine 0
- 0
withdrawal 0
evaluation 0
. 0

Elimination 0
of 0
natural 0
antibodies 0
in 0
discordant 0
xenografts 0

An 0
8 0
- 0
bp 0
sequence 0
( 0
ATTTCAAA 0
) 0
within 0
the 0
protected 0
region 0
shares 0
significant 0
homology 0
with 0
promoter 0
sequences 0
required 0
for 0
ethylene 0
responsiveness 0
from 0
the 0
tomato 0
fruit 0
- 0
ripening 0
E4 B-gene
gene I-gene
. 0

We 0
present 0
evidence 0
that 0
DNA B-gene
polymerase I-gene
delta I-gene
of I-gene
Saccharomyces I-gene
cerevisiae I-gene
, 0
an 0
enzyme 0
that 0
is 0
essential 0
for 0
viability 0
and 0
chromosomal 0
replication 0
, 0
is 0
also 0
required 0
for 0
base 0
excision 0
repair 0
of 0
exogenous 0
DNA 0
methylation 0
damage 0
. 0

We 0
have 0
identified 0
two 0
Marek 0
's 0
Disease 0
Virus 0
( 0
MDV 0
) 0
genes 0
within 0
the 0
EcoRI B-gene
- I-gene
B I-gene
fragment I-gene
of 0
MDV 0
- 0
GA 0
genomic 0
DNA 0
. 0

Cowpox 0
virus 0
contains 0
two 0
copies 0
of 0
an 0
early B-gene
gene I-gene
encoding 0
a 0
soluble 0
secreted 0
form 0
of 0
the 0
type B-gene
II I-gene
TNF I-gene
receptor I-gene
. 0

To 0
determine 0
whether 0
P35 B-gene
could 0
activate 0
the 0
39k 0
promoter 0
in 0
the 0
absence 0
of 0
IE1 B-gene
, 0
the 0
p35 B-gene
open 0
reading 0
frame 0
was 0
cloned 0
under 0
the 0
control 0
of 0
the 0
ie1 B-gene
promoter I-gene
. 0

Mutagenesis 0
of 0
each 0
NRF B-gene
- I-gene
1 I-gene
motif I-gene
in 0
the 0
ALAS B-gene
promoter I-gene
gave 0
substantially 0
lowered 0
levels 0
of 0
chloramphenicol B-gene
acetyltransferase I-gene
expression 0
, 0
whereas 0
mutagenesis 0
of 0
both 0
NRF B-gene
- I-gene
1 I-gene
motifs I-gene
resulted 0
in 0
the 0
almost 0
complete 0
loss 0
of 0
expression 0
. 0

DNase B-gene
I I-gene
footprinting 0
analysis 0
indicated 0
that 0
DREF B-gene
binds 0
to 0
the 0
24 0
- 0
bp 0
DRE 0
region 0
of 0
the 0
DNA B-gene
polymerase I-gene
alpha I-gene
gene I-gene
in 0
which 0
8 0
- 0
bp 0
palindromic 0
sequences 0
are 0
centered 0
. 0

Novel 0
8 0
- 0
base 0
pair 0
sequence 0
( 0
Drosophila 0
DNA 0
replication 0
- 0
related 0
element 0
) 0
and 0
specific 0
binding 0
factor 0
involved 0
in 0
the 0
expression 0
of 0
Drosophila 0
genes 0
for 0
DNA B-gene
polymerase I-gene
alpha I-gene
and 0
proliferating B-gene
cell I-gene
nuclear I-gene
antigen I-gene
. 0

In 0
addition 0
, 0
a 0
microsatellite 0
repeat 0
polymorphism 0
with 0
a 0
heterozygosity 0
of 0
71 0
% 0
at 0
the 0
RET B-gene
locus I-gene
and 0
a 0
restriction 0
fragment 0
length 0
polymorphism 0
with 0
a 0
heterozygosity 0
of 0
42 0
% 0
detected 0
by 0
a 0
lambda 0
clone 0
from 0
the 0
D10S94 B-gene
locus I-gene
have 0
been 0
developed 0
for 0
high 0
- 0
resolution 0
genetic 0
linkage 0
mapping 0
and 0
predictive 0
diagnostic 0
testing 0
. 0

However 0
, 0
tyrA B-gene
can 0
be 0
expressed 0
efficiently 0
from 0
an 0
internal 0
promoter 0
which 0
appears 0
to 0
lie 0
within 0
the 0
3 0
' 0
portion 0
of 0
aroF B-gene
. 0

Within 0
the 0
span 0
of 0
attenuator 0
region 0
encoding 0
the 0
three 0
stem 0
- 0
loop 0
structures 0
of 0
mRNA 0
secondary 0
configuration 0
, 0
hot 0
spots 0
of 0
base 0
- 0
residue 0
divergence 0
were 0
localized 0
to 0
looped 0
- 0
out 0
regions 0
. 0

Most 0
, 0
however 0
, 0
would 0
tell 0
the 0
spouse 0
the 0
full 0
truth 0
about 0
both 0
diagnosis 0
and 0
prognosis 0
. 0

Previous 0
studies 0
showed 0
that 0
mutations 0
in 0
the 0
6K 0
protein 0
led 0
to 0
the 0
slow 0
release 0
of 0
aberrant 0
, 0
multi 0
- 0
cored 0
infectious 0
virions 0
. 0

Metabolism 0
of 0
calcium 0
and 0
vitamin 0
D3 0
in 0
patients 0
with 0
acute 0
tubulointerstitial 0
nephritis 0
: 0
a 0
study 0
of 0
41 0
patients 0
with 0
nephropathia 0
epidemica 0
. 0

Furthermore 0
, 0
this 0
study 0
demonstrates 0
that 0
reduced 0
inotropy 0
with 0
timolol 0
helped 0
uniform 0
local 0
contraction 0
as 0
estimated 0
by 0
the 0
increased 0
LONG/CIRC 0
ratio 0
, 0
a 0
transition 0
that 0
could 0
improve 0
contraction 0
efficacy 0
. 0

Effects 0
of 0
moderate 0
hypercapnia 0
on 0
hypothermia 0
induced 0
by 0
cold 0
He 0
- 0
O2 0
in 0
rats 0
. 0

The 0
RFLP 0
patterns 0
of 0
the 0
isolates 0
from 0
six 0
of 0
these 0
patients 0
remained 0
essentially 0
unchanged 0
( 0
two 0
strains 0
showed 0
one 0
additional 0
band 0
) 0
despite 0
the 0
development 0
of 0
drug 0
resistance 0
. 0

We 0
recommend 0
that 0
ovarian 0
stimulation 0
is 0
done 0
only 0
if 0
there 0
is 0
a 0
valid 0
indication 0
after 0
proper 0
assessment 0
of 0
the 0
ovaries 0
, 0
and 0
that 0
women 0
who 0
have 0
had 0
ovarian 0
stimulation 0
are 0
followed 0
for 0
longer 0
than 0
at 0
present 0
. 0

A23187 0
did 0
not 0
induce 0
any 0
modifications 0
of 0
the 0
endolymphatic 0
potential 0
, 0
the 0
ampullar 0
direct 0
current 0
or 0
the 0
frequency 0
of 0
the 0
evoked 0
afferent 0
spikes 0
. 0

Activation 0
of 0
the 0
aboral 0
ectoderm B-gene
- I-gene
specific I-gene
Spec2a I-gene
gene I-gene
in 0
blastula 0
- 0
stage 0
sea 0
urchin 0
embryos 0
requires 0
an 0
upstream 0
regulatory 0
region 0
that 0
is 0
part 0
of 0
a 0
repetitive 0
sequence 0
element 0
( 0
RSR 0
) 0
associated 0
with 0
all 0
Spec1/Spec2 B-gene
genes 0
. 0

A 0
transcript 0
of 0
about 0
2 0
kb 0
is 0
expected 0
for 0
each 0
PPO B-gene
. 0

Mutations 0
in 0
a 0
region 0
located 0
15 0
to 0
30 0
bp 0
downstream 0
from 0
the 0
major 0
transcription 0
start 0
site 0
that 0
shows 0
good 0
homology 0
to 0
a 0
sequence 0
in 0
the 0
first 0
exon 0
of 0
c B-gene
- I-gene
fos I-gene
implicated 0
as 0
a 0
negative 0
regulatory 0
element 0
resulted 0
in 0
a 0
significant 0
increase 0
in 0
basal 0
gene 0
expression 0
but 0
did 0
not 0
affect 0
regulation 0
. 0

Salazopyrine 0
desensitization 0

During 0
exercise 0
, 0
the 0
Pes 0
- 0
Ves 0
relation 0
was 0
shifted 0
toward 0
the 0
left 0
and 0
the 0
slope 0
[ 0
end 0
- 0
systolic 0
elastance 0
( 0
Ees 0
) 0
] 0
increased 0
from 0
7.7 0
+/ 0
- 0
2.8 0
to 0
12.7 0
+/ 0
- 0
4.2 0
( 0
SD 0
) 0
mmHg/ml 0
( 0
P 0
< 0
0.05 0
) 0
. 0

We 0
show 0
that 0
HRI B-gene
and 0
dsRNA B-gene
- I-gene
PK I-gene
phosphorylate 0
yeast B-gene
eIF I-gene
- I-gene
2 I-gene
alpha I-gene
in 0
vitro 0
and 0
in 0
vivo 0
and 0
functionally 0
substitute 0
for 0
GCN2 B-gene
protein I-gene
to 0
stimulate 0
GCN4 B-gene
translation 0
in 0
yeast 0
. 0

Double 0
- 0
staining 0
confirmed 0
that 0
there 0
were 0
separate 0
populations 0
of 0
CD68 B-gene
- 0
positive 0
macrophages 0
and 0
XIIIa B-gene
- 0
positive 0
dendrocytes 0
. 0

Interestingly 0
, 0
in 0
the 0
adult 0
, 0
transgene 0
expression 0
patterns 0
within 0
the 0
cerebellum 0
in 0
two 0
lines 0
appeared 0
to 0
mark 0
distinct 0
anterior 0
- 0
posterior 0
compartments 0
. 0

Southern 0
analysis 0
on 0
genomic 0
DNA 0
isolated 0
from 0
tissues 0
and 0
cell 0
lines 0
from 0
several 0
mouse 0
strains 0
using 0
mCD22 B-gene
cDNA I-gene
demonstrated 0
that 0
the 0
Cd22 B-gene
locus I-gene
encoding 0
mCD22 B-gene
is 0
a 0
single 0
copy 0
gene 0
of 0
< 0
or 0
= 0
30 0
kb 0
. 0

The 0
concentrations 0
of 0
plasma 0
ACTH B-gene
and 0
cortisol 0
increased 0
by 0
40 0
% 0
and 0
60 0
% 0
after 0
MPTP 0
treatment 0
, 0
respectively 0
. 0

Instead 0
, 0
the 0
results 0
support 0
the 0
idea 0
that 0
Pc B-gene
group I-gene
products I-gene
provide 0
stable 0
memory 0
or 0
imprinting 0
of 0
boundaries 0
which 0
are 0
initially 0
specified 0
by 0
gap 0
and 0
pair 0
- 0
rule 0
regulators 0
. 0

To 0
investigate 0
the 0
regulation 0
of 0
expression 0
of 0
the 0
human B-gene
mdr1 I-gene
gene I-gene
, 0
the 0
response 0
of 0
the 0
mdr1 B-gene
promoter I-gene
to 0
signals 0
involved 0
in 0
cell 0
proliferation 0
was 0
examined 0
. 0

The 0
tyrosine B-gene
hydroxylase I-gene
gene I-gene
( 0
TH B-gene
) 0
contains 0
a 0
single 0
copy 0
of 0
a 0
consensus 0
CRE 0
at 0
- 0
45 0
to 0
- 0
38 0
base 0
pair 0
( 0
bp 0
) 0
upstream 0
of 0
the 0
transcription 0
initiation 0
site 0
. 0

Tobacco 0
mosaic 0
virus 0
- 0
infected 0
tobacco 0
( 0
Nicotiana 0
tabacum 0
var 0
. 0

Through 0
a 0
stretch 0
of 0
56 0
amino 0
acids 0
, 0
constituting 0
the 0
MADS B-gene
domain I-gene
, 0
the 0
two 0
proteins 0
are 0
identical 0
except 0
for 0
two 0
conservative 0
amino 0
acid 0
substitutions 0
. 0

Isolation 0
and 0
characterization 0
of 0
SRF B-gene
accessory I-gene
proteins I-gene
. 0

These 0
data 0
suggest 0
that 0
: 0
( 0
a 0
) 0
proSRIF B-gene
cleavage 0
is 0
initiated 0
in 0
the 0
TGN 0
, 0
and 0
( 0
b 0
) 0
this 0
reaction 0
requires 0
an 0
acidic 0
pH 0
which 0
is 0
facilitated 0
by 0
a 0
Golgi B-gene
- I-gene
associated I-gene
vacuolar I-gene
- I-gene
type I-gene
ATPase I-gene
. 0

Fenoldopam 0
, 0
a 0
dopamine B-gene
receptor I-gene
agonist 0
, 0
has 0
been 0
shown 0
, 0
in 0
animal 0
experiments 0
, 0
to 0
improve 0
renal 0
perfusion 0
. 0

Clinical 0
aspects 0
of 0
early 0
increase 0
in 0
serum 0
gamma B-gene
- I-gene
glutamyl I-gene
transferase I-gene
in 0
cerebral 0
infarction 0
. 0

In 0
the 0
3 0
' 0
flanking 0
region 0
of 0
the 0
27 B-gene
kDa I-gene
zein I-gene
gene I-gene
, 0
several 0
AATAAA 0
- 0
like 0
sequences 0
and 0
a 0
sequence 0
resembling 0
the 0
mammalian 0
GT 0
- 0
rich 0
sequence 0
are 0
present 0
around 0
the 0
polyadenylation 0
sites 0
. 0

The 0
indoor 0
radon 0
concentration 0
in 0
the 0
summer 0
( 0
1990 0
) 0
period 0
ranged 0
between 0
8 0
and 0
81 0
Bq 0
m 0
- 0
3 0
, 0
while 0
in 0
the 0
winter 0
( 0
1989 0
- 0
1990 0
) 0
it 0
ranged 0
between 0
20 0
and 0
143 0
Bq 0
m 0
- 0
3 0
for 0
the 0
first 0
year 0
of 0
measurements 0
or 0
between 0
8 0
and 0
92 0
Bq 0
m 0
- 0
3 0
in 0
the 0
summer 0
( 0
1991 0
) 0
period 0
and 0
between 0
12 0
and 0
119 0
Bq 0
m 0
- 0
3 0
in 0
the 0
winter 0
( 0
1990 0
- 0
1991 0
) 0
for 0
the 0
second 0
year 0
of 0
measurements 0
. 0

The 0
results 0
indicate 0
that 0
hrpRS B-gene
and 0
hrpL B-gene
are 0
part 0
of 0
a 0
regulatory 0
cascade 0
in 0
which 0
HrpR B-gene
and 0
HrpS B-gene
activate 0
expression 0
of 0
hrpL B-gene
and 0
HrpL B-gene
, 0
a 0
putative 0
sigma B-gene
factor I-gene
, 0
induces 0
expression 0
of 0
HrpL B-gene
- I-gene
responsive I-gene
genes I-gene
. 0

DtxR B-gene
is 0
an 0
iron 0
- 0
dependent 0
sequence 0
- 0
specific 0
DNA 0
- 0
binding 0
protein 0
that 0
binds 0
to 0
the 0
tox B-gene
operator I-gene
, 0
an 0
inverted 0
- 0
repeat 0
nucleotide 0
sequence 0
located 0
upstream 0
from 0
the 0
diphtheria B-gene
toxin I-gene
gene I-gene
. 0

Vasopressin B-gene
( 0
AVP B-gene
) 0
, 0
the 0
antidiuretic 0
hormone 0
, 0
is 0
a 0
cyclic 0
nonapeptide 0
that 0
acts 0
through 0
binding 0
to 0
G B-gene
protein I-gene
- I-gene
coupled I-gene
specific I-gene
membrane I-gene
receptors I-gene
pharmacologically 0
divided 0
into 0
three 0
subtypes 0
( 0
V1a B-gene
, 0
V1b B-gene
, 0
and 0
V2 B-gene
) 0
linked 0
to 0
distinct 0
second 0
messengers 0
. 0

These 0
results 0
confirmed 0
that 0
cleavage 0
of 0
the 0
leader 0
peptide 0
is 0
the 0
last 0
step 0
in 0
nisin B-gene
maturation 0
and 0
is 0
necessary 0
to 0
generate 0
a 0
biologically 0
active 0
peptide 0
. 0

When 0
the 0
promoter 0
region 0
was 0
linked 0
with 0
a 0
heterologous 0
reporter 0
gene 0
, 0
we 0
found 0
that 0
the 0
promoter 0
region 0
is 0
inducible 0
by 0
both 0
interferons B-gene
( 0
interferon B-gene
- I-gene
alpha I-gene
and I-gene
- I-gene
gamma I-gene
) 0
and 0
interferon B-gene
regulatory I-gene
factor I-gene
1 I-gene
. 0

Anti B-gene
- I-gene
B I-gene
. I-gene
burgdorferi I-gene
, 0
anti B-gene
- I-gene
B I-gene
. I-gene
turicatae I-gene
and 0
anti B-gene
- I-gene
B I-gene
. I-gene
parkeri I-gene
antibodies I-gene
, 0
tested 0
by 0
the 0
indirect 0
immunofluorescent 0
assay 0
( 0
IFA 0
) 0
, 0
were 0
detected 0
in 0
10.8 0
, 0
16.1 0
and 0
8.2 0
% 0
of 0
the 0
serum 0
samples 0
tested 0
, 0
and 0
confirmed 0
by 0
IFA 0
- 0
ABS 0
in 0
1.3 0
, 0
1.3 0
and 0
1.0 0
% 0
, 0
respectively 0
. 0

The 0
approach 0
derives 0
from 0
a 0
recently 0
described 0
strategy 0
for 0
making 0
recombinants 0
from 0
five 0
overlapping 0
EBV 0
cosmid 0
- 0
cloned 0
DNAs 0
( 0
B 0
. 0

Evaluation 0
of 0
desmopressin 0
for 0
dental 0
extractions 0
in 0
patients 0
with 0
hemostatic 0
disorders 0
. 0

Comparative 0
analysis 0
with 0
an 0
antiandrogen 0
niftolid 0
and 0
synthetic B-gene
GnRH I-gene
was 0
carried 0
out 0
in 0
22 0
normal 0
subjects 0
, 0
14 0
patients 0
with 0
primary 0
and 0
20 0
ones 0
with 0
secondary 0
hypogonadism 0
, 0
and 0
in 0
5 0
patients 0
with 0
clinical 0
signs 0
of 0
gonadal 0
insufficiency 0
and 0
obscure 0
diagnosis 0
in 0
order 0
to 0
elucidate 0
the 0
pituitary B-gene
gonadotropin I-gene
reserves 0
. 0

All 0
other 0
normal 0
and 0
transformed 0
lymphoid 0
and 0
nonlymphoid 0
cell 0
lines 0
and 0
normal 0
tissues 0
were 0
negative 0
for 0
PANG B-gene
expression 0
except 0
for 0
the 0
brain 0
, 0
wherein 0
unique 0
4.0 0
- 0
and 0
6.1 0
- 0
kb 0
transcripts 0
were 0
detected 0
. 0

The 0
cis 0
- 0
acting 0
regulatory 0
properties 0
of 0
an 0
872 0
bp 0
promoter 0
fragment 0
of 0
a 0
B. 0
napus 0
oleosin B-gene
gene I-gene
were 0
examined 0
by 0
analysis 0
of 0
beta B-gene
- I-gene
glucuronidase I-gene
( 0
GUS B-gene
) 0
expression 0
in 0
transgenic 0
tobacco 0
plants 0
containing 0
an 0
oleosin B-gene
promoter I-gene
- 0
GUS B-gene
transcriptional 0
fusion 0
. 0

This 0
indicates 0
that 0
the 0
mechanism 0
by 0
which 0
CX 0
blocks 0
rapid 0
degradation 0
of 0
tubulin B-gene
mRNA I-gene
in 0
vivo 0
is 0
not 0
simply 0
by 0
preventing 0
its 0
translation 0
and 0
suggests 0
the 0
involvement 0
of 0
an 0
altered 0
trans 0
- 0
factor 0
. 0

L. 0
, 0
Greer 0
, 0
J 0
. 0
& 0
Carter 0
, 0
G 0
. 0

Increasing 0
the 0
extracellular 0
calcium 0
concentration 0
enhanced 0
detrusor 0
contractility 0
in 0
a 0
dose 0
- 0
dependent 0
manner 0
in 0
both 0
control 0
and 0
obstructed 0
bladders 0
. 0

Structural 0
organization 0
of 0
the 0
gene 0
encoding 0
the 0
human B-gene
lipocalin I-gene
tear I-gene
prealbumin I-gene
and 0
synthesis 0
of 0
the 0
recombinant 0
protein 0
in 0
Escherichia 0
coli 0
. 0

The 0
sequence 0
has 0
a 0
1092 0
- 0
bp 0
open 0
reading 0
frame 0
encoding 0
a 0
protein 0
of 0
364 0
amino 0
acids 0
. 0

Western 0
blotting 0
( 0
immunoblotting 0
) 0
with 0
an 0
antiserum 0
to 0
a 0
partial 0
SOD B-gene
expressed 0
in 0
Escherichia 0
coli 0
revealed 0
two 0
proteins 0
with 0
estimated 0
molecular 0
masses 0
of 0
19 0
and 0
29 0
kDa 0
. 0

The 0
gene 0
organization 0
of 0
CRSV B-gene
RNA I-gene
- I-gene
1 I-gene
is 0
similar 0
to 0
those 0
of 0
red 0
clover 0
necrotic 0
mosaic 0
( 0
RCNMV 0
) 0
and 0
sweet 0
clover 0
necrotic 0
mosaic 0
( 0
SCNMV 0
) 0
dianthoviruses 0
with 0
the 0
exception 0
that 0
CRSV B-gene
RNA I-gene
- I-gene
1 I-gene
contains 0
the 0
additional 0
3' 0
- 0
terminal 0
ORF 0
. 0

Members 0
of 0
the 0
myocyte B-gene
- I-gene
specific I-gene
enhancer I-gene
- I-gene
binding I-gene
factor I-gene
2 I-gene
( 0
MEF2 B-gene
) 0
family 0
of 0
transcription 0
factors 0
bind 0
a 0
conserved 0
A/T 0
- 0
rich 0
sequence 0
in 0
the 0
control 0
regions 0
of 0
numerous 0
muscle 0
- 0
specific 0
genes 0
. 0

We 0
have 0
previously 0
shown 0
that 0
LBP B-gene
- I-gene
1 I-gene
represses 0
HIV 0
- 0
1 0
transcription 0
by 0
inhibiting 0
the 0
binding 0
of 0
TFIID B-gene
to 0
the 0
TATA 0
box 0
. 0

These 0
results 0
illustrate 0
an 0
important 0
role 0
for 0
La B-gene
in 0
RNA 0
production 0
by 0
demonstrating 0
its 0
ability 0
to 0
clear 0
the 0
termination 0
sites 0
of 0
class 0
III 0
templates 0
, 0
thereby 0
promoting 0
efficient 0
use 0
of 0
transcription 0
complexes 0
by 0
pol B-gene
III I-gene
. 0

The 0
films 0
were 0
analyzed 0
using 0
a 0
scanning 0
helium 0
- 0
neon 0
laser 0
densitometer 0
with 0
a 0
small 0
aperture 0
of 0
5 0
- 0
10 0
microns 0
. 0

The 0
GafChromic 0
method 0
has 0
proven 0
to 0
be 0
an 0
accurate 0
and 0
rapid 0
method 0
of 0
analysis 0
and 0
could 0
be 0
easily 0
incorporated 0
into 0
a 0
quality 0
assurance 0
program 0
. 0

Viral 0
genomic 0
RNA 0
for 0
these 0
reactions 0
was 0
obtained 0
directly 0
from 0
fecal 0
specimens 0
of 0
infected 0
infant 0
rats 0
. 0

GATA B-gene
- I-gene
1 I-gene
mRNA I-gene
was 0
present 0
in 0
equivalent 0
levels 0
in 0
both 0
erythroid 0
cell 0
lines 0
, 0
but 0
at 0
a 0
low 0
level 0
in 0
FDC 0
- 0
P1 0
cells 0
. 0

Tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNF B-gene
alpha I-gene
) 0
is 0
one 0
of 0
several 0
autocrine/paracrine 0
factors 0
known 0
to 0
exert 0
potent 0
inhibitory 0
effects 0
on 0
bone 0
. 0

We 0
have 0
investigated 0
the 0
role 0
of 0
cellular B-gene
p21ras I-gene
protein I-gene
in 0
insulin B-gene
and 0
insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
- I-gene
I I-gene
( 0
IGF B-gene
- I-gene
I I-gene
) 0
signaling 0
pathways 0
. 0

The 0
lack 0
of 0
the 0
C2 B-gene
domain 0
of 0
the 0
Ca B-gene
( I-gene
2+ I-gene
) I-gene
- I-gene
dependent I-gene
PKCs I-gene
and 0
the 0
presence 0
of 0
a 0
unique 0
NH2 0
- 0
terminal 0
sequence 0
with 0
a 0
potential 0
signal 0
peptide 0
and 0
a 0
transmembrane 0
domain 0
suggest 0
that 0
PKC B-gene
mu I-gene
is 0
a 0
novel 0
member 0
of 0
the 0
subgroup 0
of 0
atypical 0
PKCs B-gene
. 0

Moreover 0
, 0
we 0
observed 0
that 0
the 0
function 0
of 0
T3R B-gene
- 0
RXR B-gene
heterodimers 0
on 0
response 0
elements 0
composed 0
of 0
two 0
half 0
- 0
sites 0
in 0
a 0
directly 0
repeated 0
orientation 0
spaced 0
by 0
4 0
nucleotides 0
is 0
determined 0
in 0
major 0
parts 0
by 0
the 0
5' 0
- 0
flanking 0
sequence 0
of 0
the 0
upstream 0
half 0
- 0
site 0
. 0

However 0
, 0
three 0
Hm1 B-gene
mutants I-gene
that 0
were 0
moderately 0
deficient 0
in 0
stimulating 0
PI 0
turnover 0
displayed 0
normal 0
sequestration 0
, 0
suggesting 0
distinct 0
mechanisms 0
. 0

Furthermore 0
, 0
in 0
vitro 0
decay 0
reaction 0
mixtures 0
supplemented 0
with 0
the 0
20 0
- 0
nt 0
sense 0
RNA 0
transcript 0
resulted 0
in 0
stabilization 0
of 0
R2 B-gene
message I-gene
. 0

Deletion 0
analyses 0
of 0
the 0
pCD41 B-gene
ORF I-gene
- I-gene
A I-gene
and 0
the 0
use 0
of 0
promoter 0
constructs 0
further 0
mapped 0
an 0
internal 0
functional 0
promoter 0
within 0
the 0
pCD41 B-gene
sequence I-gene
that 0
can 0
direct 0
the 0
synthesis 0
of 0
the 0
trans 0
- 0
activating 0
protein 0
. 0

Seven 0
of 0
these 0
had 0
counterparts 0
in 0
the 0
US 0
of 0
herpes 0
simplex 0
type 0
1 0
( 0
HSV 0
- 0
1 0
) 0
, 0
pseudorabies 0
virus 0
( 0
PRV 0
) 0
, 0
and 0
equine 0
herpesvirus 0
type 0
1 0
( 0
EHV 0
- 0
1 0
) 0
. 0

The 0
inferred 0
amino 0
acid 0
sequence 0
of 0
the 0
cyanobacterial B-gene
HemB I-gene
protein I-gene
indicates 0
a 0
significant 0
difference 0
in 0
the 0
metal 0
cofactor 0
requirement 0
from 0
the 0
higher 0
- 0
plant 0
enzymes 0
, 0
which 0
was 0
confirmed 0
by 0
overexpression 0
and 0
biochemical 0
analysis 0
. 0

METHODS 0
AND 0
RESULTS 0
: 0
In 0
25 0
open 0
- 0
chest 0
, 0
anesthetized 0
dogs 0
, 0
progressive 0
circumflex 0
artery 0
stenosis 0
led 0
to 0
a 0
concordant 0
decrease 0
of 0
circumflex 0
artery 0
resting 0
and 0
hyperemic 0
flow 0
, 0
coronary 0
flow 0
reserve 0
, 0
and 0
inverse 0
angiographic 0
mean 0
transit 0
time 0
Tmicro 0
- 0
1 0
( 0
P 0
< 0
.01 0
) 0
. 0

However 0
, 0
a 0
correlation 0
was 0
observed 0
between 0
SF 0
levels 0
of 0
IL B-gene
- I-gene
8 I-gene
with 0
those 0
of 0
lactate 0
, 0
LDH B-gene
, 0
beta B-gene
2 I-gene
- I-gene
microglobulin I-gene
and 0
glucose 0
. 0

Sodium 0
- 0
taurocholate 0
- 0
induced 0
acute 0
necrotizing 0
pancreatitis 0
does 0
not 0
affect 0
jejunal 0
oxygenation 0
in 0
pigs 0
. 0

Although 0
inactive 0
in 0
cells 0
under 0
normal 0
conditions 0
, 0
the 0
CHOP B-gene
gene I-gene
is 0
markedly 0
induced 0
by 0
a 0
variety 0
of 0
cellular 0
stresses 0
, 0
including 0
nutrient 0
deprivation 0
and 0
metabolic 0
perturbations 0
. 0

The 0
ipiO B-gene
genes I-gene
code 0
for 0
two 0
almost 0
identical 0
152 0
- 0
aa 0
proteins 0
which 0
do 0
not 0
have 0
any 0
homology 0
with 0
sequences 0
present 0
in 0
data 0
libraries 0
. 0

Sterol 0
analysis 0
of 0
the 0
disrupted 0
mutant 0
demonstrated 0
the 0
accumulation 0
of 0
ignosterol 0
, 0
indicating 0
a 0
loss 0
of 0
Erg24p B-gene
activity 0
. 0

The 0
previously 0
described 0
enhanced 0
translation 0
of 0
spinach 0
L12 B-gene
mRNA I-gene
from 0
its 0
two 0
tandem 0
AUG 0
codons 0
and 0
the 0
two 0
functional 0
rpl12 B-gene
genes I-gene
in 0
Arabidopsis 0
probably 0
provide 0
two 0
mechanisms 0
for 0
generating 0
the 0
four 0
copies 0
of 0
L12/chloroplast B-gene
ribosome I-gene
, 0
qualitatively 0
different 0
from 0
those 0
attempted 0
in 0
eubacteria 0
. 0

In 0
these 0
experiments 0
we 0
begin 0
to 0
study 0
the 0
potential 0
functions 0
of 0
the 0
alpha B-gene
7 I-gene
cytoplasmic I-gene
domain I-gene
by 0
analyzing 0
homologies 0
between 0
the 0
rat 0
and 0
human 0
sequences 0
, 0
by 0
immunologic 0
studies 0
using 0
an 0
anti 0
- 0
cytoplasmic 0
domain 0
antiserum 0
, 0
and 0
by 0
identifying 0
two 0
alternate 0
forms 0
. 0

The 0
alpha 0
7A 0
form 0
RNA 0
contains 0
an 0
additional 0
113 0
nucleotides 0
compared 0
to 0
the 0
B 0
form 0
, 0
and 0
a 0
common 0
coding 0
region 0
in 0
the 0
A 0
and 0
B 0
form 0
RNAs 0
is 0
used 0
in 0
alternate 0
reading 0
frames 0
. 0

In 0
order 0
to 0
evaluate 0
the 0
function 0
of 0
the 0
hypothalamic 0
- 0
pituitary 0
- 0
thyroid 0
( 0
HPT 0
) 0
- 0
axis 0
in 0
unipolar 0
depression 0
, 0
the 0
authors 0
measured 0
basal 0
0800h 0
plasma 0
levels 0
of 0
free 0
thyroxine 0
( 0
FT4 0
) 0
, 0
free 0
triiodothyronine 0
( 0
FT3 0
) 0
, 0
and 0
thyroid B-gene
stimulating I-gene
hormone I-gene
( 0
TSH B-gene
) 0
by 0
means 0
of 0
the 0
new 0
, 0
ultrasensitive 0
assays 0
( 0
TSH 0
- 0
IRMA 0
) 0
in 0
69 0
healthy 0
controls 0
, 0
62 0
minor 0
, 0
101 0
simple 0
major 0
, 0
and 0
57 0
melancholic 0
depressed 0
subjects 0
. 0

CRS B-gene
function 0
in 0
a 0
5 0
' 0
LTR 0
- 0
linked 0
gene 0
expression 0
assay 0
correlates 0
with 0
the 0
ability 0
of 0
both 0
p60CRS B-gene
and 0
p40CRS B-gene
to 0
interact 0
with 0
5 0
' 0
LTR 0
RNA 0
in 0
vitro 0
. 0

Serial 0
levels 0
of 0
troponin B-gene
T I-gene
and 0
the 0
activity 0
of 0
CK B-gene
- I-gene
MB I-gene
were 0
measured 0
6 0
, 0
12 0
, 0
24 0
and 0
48 0
h 0
after 0
aortic 0
unclamping 0
. 0

Regionalization 0
of 0
drug 0
delivery 0
is 0
a 0
potential 0
method 0
to 0
avoid 0
this 0
problem 0
. 0

The 0
epidemic 0
occurred 0
in 0
a 0
group 0
of 0
26 0
community 0
members 0
( 0
23 0
men 0
and 0
3 0
women 0
, 0
mean 0
age 0
, 0
28.9 0
- 0
- 0
3 0
years 0
) 0
living 0
and 0
working 0
together 0
, 0
who 0
underwent 0
acute 0
and 0
convalescent 0
serologic 0
tests 0
for 0
Mycoplasma 0
pneumoniae 0
, 0
Legionella 0
pneumophila 0
, 0
cytomegalovirus 0
, 0
adenovirus 0
, 0
Coxiella 0
burnetii 0
, 0
and 0
Chlamydia 0
pneumoniae 0
. 0

MEK B-gene
itself 0
is 0
activated 0
via 0
serine 0
phosphorylation 0
by 0
upstream B-gene
activator I-gene
kinases I-gene
, 0
including 0
c B-gene
- I-gene
raf I-gene
, 0
mos B-gene
and 0
MEK B-gene
kinase I-gene
. 0

Genomic 0
DNA 0
clones 0
containing 0
the 0
T B-gene
- I-gene
cell I-gene
- I-gene
specific I-gene
human I-gene
MAL I-gene
gene I-gene
were 0
isolated 0
. 0

Members 0
of 0
SVA B-gene
are 0
also 0
present 0
in 0
the 0
complement B-gene
C2 I-gene
gene I-gene
located 0
about 0
20 0
kilobases 0
upstream 0
of 0
RP1 B-gene
in 0
the 0
HLA B-gene
and 0
in 0
the 0
cytochrome B-gene
CYP1A1 I-gene
gene I-gene
. 0

Expression 0
of 0
the 0
dibasic 0
proprotein 0
processing 0
enzyme 0
furin B-gene
is 0
directed 0
by 0
multiple 0
promoters 0
. 0

European 0
Community 0
Huntington 0
's 0
Disease 0
Collaborative 0
Study 0
Group 0
. 0

The 0
c B-gene
- I-gene
myc I-gene
and 0
skeletal B-gene
alpha I-gene
- I-gene
actin I-gene
gene I-gene
promoters I-gene
contain 0
YY1 B-gene
binding I-gene
sites I-gene
thought 0
to 0
act 0
either 0
as 0
positive 0
or 0
negative 0
cis 0
- 0
acting 0
elements 0
. 0

MSSP B-gene
- I-gene
1 I-gene
produced 0
in 0
E. 0
coli 0
as 0
a 0
fusion 0
protein 0
with 0
GST B-gene
specifically 0
interacted 0
with 0
single 0
- 0
stranded 0
TCTTAT 0
( 0
plus 0
myc B-gene
( 0
H 0
- 0
P 0
) 0
21 0
) 0
and 0
ACT 0
- 0
ATT 0
( 0
in 0
minus 0
myc B-gene
( 0
H 0
- 0
P 0
) 0
21 0
) 0
, 0
the 0
consensus 0
of 0
which 0
can 0
be 0
referred 0
to 0
as 0
A/TCTA/TA/TT 0
. 0

Within 0
12 0
hours 0
after 0
MR 0
tomography 0
the 0
patients 0
were 0
surgically 0
explored 0
, 0
biopsied 0
and 0
if 0
necessary 0
orchiectomised 0
. 0

Certain 0
spt10 B-gene
spontaneous 0
alleles 0
are 0
good 0
suppressors 0
but 0
have 0
a 0
normal 0
growth 0
rate 0
, 0
suggesting 0
that 0
the 0
SPT10 B-gene
protein I-gene
may 0
have 0
two 0
distinct 0
functions 0
. 0

Varieties 0
of 0
envious 0
experience 0
. 0

The 0
results 0
show 0
that 0
both 0
the 0
amino 0
and 0
carboxy 0
termini 0
of 0
the 0
NS1 B-gene
protein I-gene
molecule I-gene
and 0
the 0
cysteines 0
at 0
residues 0
337 0
and 0
340 0
are 0
essential 0
for 0
tubule 0
formation 0
. 0

The 0
3 0
' 0
UTR 0
has 0
several 0
stable 0
hairpins 0
that 0
are 0
flanked 0
by 0
single 0
- 0
stranded 0
( 0
A/U 0
) 0
UGC 0
sequences 0
. 0

Moreover 0
, 0
the 0
major 0
site 0
of 0
transcriptional 0
initiation 0
, 0
which 0
was 0
localized 0
by 0
primer 0
extension 0
250 0
bp 0
upstream 0
of 0
the 0
5 0
' 0
end 0
of 0
the 0
Ets B-gene
- I-gene
1 I-gene
cDNA I-gene
clone I-gene
, 0
was 0
shown 0
to 0
be 0
identical 0
in 0
normal 0
cells 0
and 0
tumors 0
carrying 0
a 0
provirus 0
in 0
the 0
Tpl B-gene
- I-gene
1 I-gene
locus I-gene
. 0

Specifically 0
, 0
by 0
oligonucleotide 0
- 0
directed 0
site 0
- 0
specific 0
mutagenesis 0
, 0
we 0
demonstrate 0
that 0
of 0
10 0
cysteine 0
residues 0
in 0
the 0
ORF4 0
polypeptide 0
, 0
only 0
C 0
- 0
421 0
and 0
C 0
- 0
426 0
are 0
essential 0
for 0
transactivator 0
function 0
and 0
suggest 0
that 0
these 0
cysteine 0
residues 0
may 0
participate 0
in 0
critical 0
protein 0
- 0
protein 0
interactions 0
rather 0
than 0
protein 0
- 0
nucleic 0
acid 0
interactions 0
to 0
mediate 0
ORF4 0
inducibility 0
. 0

In 0
Rat 0
1a 0
cells 0
, 0
m1R B-gene
stimulation 0
of 0
phospholipase B-gene
C I-gene
beta I-gene
and 0
the 0
marked 0
rise 0
in 0
intracellular 0
calcium 0
stimulated 0
cyclic 0
AMP 0
( 0
cAMP 0
) 0
synthesis 0
, 0
resulting 0
in 0
the 0
activation 0
of 0
protein B-gene
kinase I-gene
A I-gene
. 0

The 0
mutations 0
did 0
not 0
affect 0
the 0
repression 0
of 0
CPA1 B-gene
by 0
arginine 0
. 0

A 0
segment 0
of 0
mRNA 0
encoding 0
the 0
leader 0
peptide 0
of 0
the 0
CPA1 B-gene
gene I-gene
confers 0
repression 0
by 0
arginine 0
on 0
a 0
heterologous 0
yeast 0
gene 0
transcript 0
. 0

To 0
search 0
for 0
genes 0
that 0
interact 0
with 0
the 0
SLK1 B-gene
- 0
SLT2 B-gene
pathway 0
, 0
a 0
synthetic 0
lethal 0
suppression 0
screen 0
was 0
carried 0
out 0
. 0

Genetic 0
and 0
phenotypic 0
analysis 0
indicates 0
that 0
NHP6A B-gene
and 0
NHP6B B-gene
function 0
downstream 0
of 0
SLT2 B-gene
. 0

In 0
this 0
report 0
, 0
we 0
present 0
two 0
lines 0
of 0
evidence 0
that 0
all 0
ribosomes 0
which 0
synthesize 0
GCN4 B-gene
have 0
previously 0
translated 0
uORF1 0
, 0
resumed 0
scanning 0
, 0
and 0
reinitiated 0
at 0
the 0
GCN4 B-gene
start 0
site 0
. 0

Identical 0
components 0
of 0
yeast 0
transcription B-gene
factor I-gene
IIIB I-gene
are 0
required 0
and 0
sufficient 0
for 0
transcription 0
of 0
TATA 0
box 0
- 0
containing 0
and 0
TATA 0
- 0
less 0
genes 0
. 0

Concordantly 0
, 0
it 0
was 0
shown 0
that 0
the 0
dnHLH B-gene
protein I-gene
Id1 B-gene
inhibits 0
differentiation 0
of 0
muscle 0
and 0
myeloid 0
cells 0
in 0
vitro 0
. 0

RNP1 B-gene
, 0
a 0
new 0
ribonucleoprotein 0
gene 0
of 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

Crohn 0
's 0
disease 0
in 0
prolonged 0
remission 0
: 0
should 0
one 0
augment 0
protein 0
- 0
calorie 0
intake 0
as 0
compared 0
to 0
healthy 0
subjects 0
? 0
] 0
The 0
aim 0
of 0
our 0
two 0
year 0
prospective 0
study 0
was 0
to 0
evaluate 0
whether 0
adult 0
Crohn 0
's 0
disease 0
patients 0
in 0
prolonged 0
remission 0
( 0
CDAI 0
< 0
150 0
) 0
, 0
in 0
order 0
to 0
maintain 0
their 0
body 0
weight 0
as 0
close 0
as 0
possible 0
to 0
the 0
ideal 0
one 0
, 0
need 0
a 0
protein 0
- 0
calorie 0
intake 0
higher 0
than 0
the 0
predicted 0
one 0
and 0
that 0
of 0
healthy 0
controls 0
. 0

To 0
achieve 0
complete 0
dissection 0
of 0
the 0
anterior 0
vitreous 0
, 0
we 0
remove 0
even 0
a 0
clear 0
lens 0
during 0
the 0
first 0
surgical 0
intervention 0
in 0
selected 0
cases 0
. 0

Restoration 0
of 0
opponens 0
function 0
with 0
transplantation 0
of 0
free 0
composites 0
dorsal 0
pedal 0
skin 0
flap 0
containing 0
m. 0
extensor 0
hallucis 0
brevis 0

Neither 0
ethanol 0
regimen 0
impaired 0
spontaneous 0
alternation 0
, 0
but 0
the 0
4 0
g 0
ethanol.kg 0
- 0
1 0
x 0
day 0
- 0
1 0
regimen 0
increased 0
the 0
percent 0
completed 0
trials 0
. 0

The 0
mean 0
( 0
+/ 0
- 0
sd 0
) 0
intra 0
- 0
vesicular 0
pressure 0
( 0
IVP 0
) 0
and 0
maximal 0
urethral 0
closure 0
pressures 0
( 0
MUCP 0
) 0
were 0
10.3 0
( 0
+/ 0
- 0
1.7 0
) 0
and 0
129.8 0
( 0
+/ 0
- 0
19.6 0
) 0
cmH2O 0
, 0
respectively 0
, 0
and 0
the 0
ratio 0
between 0
MUCP 0
and 0
IVP 0
was 0
13.2 0
( 0
+/ 0
- 0
2.5 0
) 0
. 0

Several 0
highly 0
conserved 0
regions 0
were 0
identified 0
at 0
the 0
near 0
N 0
terminus 0
, 0
middle 0
and 0
C 0
terminus 0
. 0

Thioredoxin B-gene
( 0
TR B-gene
) 0
is 0
a 0
small 0
ubiquitous 0
dithiol B-gene
- I-gene
reductase I-gene
enzyme I-gene
first 0
identified 0
in 0
bacteria 0
and 0
plants 0
. 0

The 0
mutation 0
within 0
the 0
asgB480 B-gene
allele I-gene
was 0
identified 0
as 0
an 0
A 0
- 0
to 0
- 0
G 0
transition 0
that 0
results 0
in 0
a 0
threonine 0
- 0
to 0
- 0
alanine 0
substitution 0
in 0
the 0
predicted 0
protein 0
product 0
. 0

The 0
cysteine 0
- 0
rich 0
region 0
of 0
raf B-gene
- I-gene
1 I-gene
kinase I-gene
contains 0
zinc 0
, 0
translocates 0
to 0
liposomes 0
, 0
and 0
is 0
adjacent 0
to 0
a 0
segment 0
that 0
binds 0
GTP B-gene
- I-gene
ras I-gene
. 0

Kinetic 0
coupling 0
and 0
requirement 0
for 0
ATP 0
hydrolysis 0
. 0

ATP 0
by 0
itself 0
also 0
reduced 0
polypeptide 0
binding 0
to 0
Ssb1/2p B-gene
to 0
a 0
level 0
that 0
was 0
intermediate 0
between 0
that 0
observed 0
for 0
the 0
Ssa B-gene
Hsp70 B-gene
proteins I-gene
tested 0
and 0
BiP B-gene
and 0
DnaK B-gene
. 0

Digestion 0
of 0
NF B-gene
- I-gene
IL6 I-gene
with 0
endoprotease B-gene
Asp I-gene
- I-gene
N I-gene
produced 0
a 0
domain 0
smaller 0
than 0
the 0
TCD B-gene
( 0
NF B-gene
- I-gene
IL6 I-gene
bZIP I-gene
domains I-gene
( 0
NFBD B-gene
) 0
( 0
272 0
- 0
345 0
) 0
) 0
, 0
a 0
domain 0
identified 0
either 0
in 0
the 0
absence 0
or 0
the 0
presence 0
of 0
DNA 0
. 0

Signaling 0
by 0
tyrosine B-gene
kinases I-gene
involves 0
direct 0
associations 0
between 0
proteins 0
with 0
Src B-gene
homology I-gene
2 I-gene
( 0
SH2 B-gene
) 0
domains 0
and 0
sites 0
of 0
tyrosine 0
phosphorylation 0
. 0

Rather 0
, 0
complete 0
skipping 0
of 0
exon 0
V 0
and 0
subsequent 0
joining 0
of 0
exon 0
IV 0
to 0
exon 0
VI 0
caused 0
a 0
shift 0
in 0
the 0
open 0
reading 0
frame 0
, 0
which 0
remodeled 0
GPHe B-gene
( I-gene
P2 I-gene
) I-gene
with 0
an 0
elongated 0
new 0
hydrophobic 0
sequence 0
for 0
membrane 0
anchoring 0
. 0

The 0
responses 0
of 0
the 0
`` 0
stress 0
hormones 0
'' 0
cortisol 0
, 0
11 0
- 0
deoxycortisol B-gene
, I-gene
ACTH I-gene
ACTH I-gene
, I-gene
vasopressin I-gene
vasopressin I-gene
( I-gene
AVP I-gene
) 0
, 0
and B-gene
corticotropin I-gene
releasing I-gene
factor I-gene
factor I-gene
( I-gene
CRF I-gene
) 0
were 0
studied 0
in 0
6 0
normal 0
males 0
in 0
response 0
to 0
acute 0
cortisol 0
deficiency 0
induced 0
by 0
the B-gene
11 I-gene
- I-gene
beta I-gene
- I-gene
hydroxylase I-gene
inhibitor 0
, 0
metyrapone 0
. 0

Structure 0
and 0
expression 0
of 0
the 0
alternative 0
sigma B-gene
factor I-gene
, 0
RpoN B-gene
, 0
in 0
Rhodobacter 0
capsulatus 0
; 0
physiological 0
relevance 0
of 0
an 0
autoactivated 0
nifU2 B-gene
- 0
rpoN B-gene
superoperon 0
. 0

Thus 0
our 0
observations 0
establish 0
a 0
functional 0
link 0
between 0
the 0
PKC B-gene
and 0
retinoid 0
pathways 0
, 0
which 0
are 0
generally 0
considered 0
to 0
have 0
antagonistic 0
activities 0
on 0
differentiation 0
processes 0
. 0

The 0
colony B-gene
- I-gene
stimulating I-gene
factors I-gene
( 0
CSFs B-gene
) 0
principally 0
involved 0
in 0
the 0
production 0
of 0
neutrophils 0
and 0
monocytes 0
are 0
granulocyte B-gene
CSF I-gene
, 0
granulocyte B-gene
- I-gene
macrophage I-gene
CSF I-gene
, 0
macrophage B-gene
CSF I-gene
, 0
and 0
interleukin B-gene
3 I-gene
( 0
sometimes 0
called 0
multi B-gene
- I-gene
CSF I-gene
) 0
. 0

The 0
degree 0
of 0
lung 0
destruction 0
, 0
reflected 0
by 0
interstitial 0
hemorrhage 0
was 0
assessed 0
by 0
measuring 0
hemoglobin B-gene
content 0
in 0
the 0
fluid 0
of 0
the 0
lavaged 0
lungs 0
. 0

Expression 0
plasmids 0
harboring 0
full 0
- 0
length 0
or 0
kinase 0
domain 0
of 0
PKC B-gene
alpha I-gene
and 0
PKC B-gene
delta I-gene
( 0
PKC B-gene
alpha I-gene
K I-gene
and 0
PKC B-gene
delta I-gene
K I-gene
) 0
were 0
constructed 0
. 0

These 0
results 0
indicate 0
that 0
both 0
PKC B-gene
alpha I-gene
( 0
calcium 0
dependent 0
) 0
and 0
PKC B-gene
delta I-gene
( 0
calcium 0
independent 0
) 0
may 0
mediate 0
the 0
transcription 0
of 0
TPA 0
- 0
inducible 0
genes 0
through 0
both 0
AP B-gene
- I-gene
1 I-gene
and 0
non 0
- 0
AP B-gene
- I-gene
1 I-gene
sequences 0
. 0

With 0
a 0
cutoff 0
level 0
for 0
TSST B-gene
- I-gene
1 I-gene
of 0
less 0
than 0
100 0
pg/ml 0
, 0
28 0
samples 0
obtained 0
from 0
12 0
patients 0
were 0
positive 0
for 0
TSST B-gene
- I-gene
1 I-gene
. 0

Insertion 0
of 0
short 0
oligonucleotides 0
encoding 0
the 0
basic 0
amino 0
acid 0
motifs 0
726 0
- 0
GRKRKSP 0
- 0
732 0
from 0
IE175 B-gene
and 0
500 0
- 0
VRPRKRR 0
- 0
506 0
from 0
IE110 B-gene
into 0
deleted 0
cytoplasmic 0
forms 0
of 0
the 0
two 0
proteins 0
restored 0
the 0
karyophilic 0
phenotype 0
and 0
confirmed 0
that 0
these 0
motifs 0
are 0
both 0
necessary 0
and 0
sufficient 0
for 0
proper 0
nuclear 0
localization 0
. 0

Mapping 0
of 0
intracellular 0
localization 0
domains 0
and 0
evidence 0
for 0
colocalization 0
interactions 0
between 0
the 0
IE110 B-gene
and 0
IE175 B-gene
nuclear 0
transactivator 0
proteins 0
of 0
herpes 0
simplex 0
virus 0
. 0

The 0
revertant 0
TATA 0
boxes 0
accelerated 0
the 0
kinetics 0
of 0
HIV 0
replication 0
when 0
present 0
in 0
the 0
context 0
of 0
an 0
LTR 0
containing 0
a 0
Sp1 B-gene
mutation 0
( 0
deletion 0
or 0
site 0
specific 0
) 0
; 0
no 0
effect 0
was 0
observed 0
on 0
the 0
infectivity 0
of 0
wild 0
- 0
type 0
HIV 0
. 0

Panlobular 0
emphysema 0

Since 0
the 0
ETS B-gene
domain I-gene
, 0
which 0
is 0
localized 0
in 0
the 0
carboxy 0
terminal 0
region 0
of 0
the 0
encoded 0
protein 0
, 0
is 0
95 0
% 0
and 0
96 0
% 0
identical 0
to 0
that 0
of 0
PEA3 B-gene
and 0
ER81 B-gene
, 0
respectively 0
, 0
we 0
named 0
this 0
new 0
member 0
'Ets B-gene
Related I-gene
Molecule I-gene
PEA3 I-gene
- I-gene
like I-gene
' I-gene
( 0
ERM B-gene
) 0
. 0

Gel 0
shift 0
analysis 0
indicates 0
that 0
the 0
full B-gene
- I-gene
length I-gene
ERM I-gene
protein I-gene
is 0
able 0
to 0
bind 0
specifically 0
to 0
an 0
oligonucleotide 0
containing 0
the 0
consensus 0
nucleotide 0
core 0
sequence 0
GGAA 0
recognized 0
by 0
the 0
Ets B-gene
proteins 0
. 0

Effects 0
of 0
estradiol 0
on 0
worm 0
burden 0
and 0
peripheral 0
leukocytes 0
in 0
Parastrongylus 0
malaysiensis 0
- 0
infected 0
rats 0
. 0

Dotarizine 0
produced 0
arterial 0
dilation 0
in 0
both 0
systemic 0
and 0
pulmonary 0
circulation 0
: 0
the 0
total 0
peripheral 0
resistance 0
dropped 0
, 0
and 0
femoral 0
artery 0
flow 0
rose 0
; 0
aortic 0
and 0
pulmonary 0
artery 0
mean 0
and 0
diastolic 0
pressures 0
declined 0
, 0
and 0
systolic 0
pressures 0
remained 0
almost 0
stable 0
. 0

These 0
issues 0
include 0
the 0
use 0
of 0
LMWHs 0
in 0
patients 0
with 0
arterial 0
thrombosis 0
or 0
myocardial 0
infarction 0
( 0
e.g 0
. 0
in 0
conjunction 0
with 0
thrombolytic 0
treatment 0
) 0
, 0
and 0
in 0
patients 0
with 0
pulmonary 0
embolism 0
. 0

The 0
usefulness 0
of 0
the 0
lambda 0
PG15 0
and 0
the 0
lambda 0
AD5 0
cloning 0
vectors 0
was 0
demonstrated 0
by 0
constructing 0
large 0
Neurospora 0
crassa 0
cDNA 0
libraries 0
. 0

Endoscopic 0
transthoracic 0
sympathectomy 0
as 0
adjuvant 0
treatment 0
for 0
critical 0
upper 0
- 0
limb 0
ischaemia 0
. 0

Sequence 0
comparisons 0
have 0
shown 0
that 0
Aps1p B-gene
is 0
more 0
similar 0
to 0
the 0
sigma 0
subunit 0
of 0
the 0
Golgi 0
- 0
localized 0
mammalian 0
AP B-gene
- I-gene
1 I-gene
complex I-gene
than 0
Aps2p B-gene
, 0
which 0
is 0
more 0
related 0
to 0
the 0
plasma 0
membrane 0
AP B-gene
- I-gene
2 I-gene
sigma I-gene
subunit 0
. 0

The 0
Saccharomyces B-gene
cerevisiae I-gene
APS1 I-gene
gene I-gene
encodes 0
a 0
homolog 0
of 0
the 0
small 0
subunit 0
of 0
the 0
mammalian B-gene
clathrin I-gene
AP B-gene
- I-gene
1 I-gene
complex I-gene
: 0
evidence 0
for 0
functional 0
interaction 0
with 0
clathrin B-gene
at 0
the 0
Golgi 0
complex 0
. 0

These 0
results 0
are 0
the 0
first 0
to 0
demonstrate 0
the 0
structural 0
organization 0
of 0
a 0
vertebrate 0
gene 0
encoding 0
an 0
integral 0
membrane 0
protein 0
of 0
the 0
nuclear 0
envelope 0
that 0
may 0
be 0
a 0
member 0
of 0
a 0
family 0
of 0
polypeptides 0
conserved 0
in 0
evolution 0
. 0

Biochemical 0
characterization 0
of 0
valosin B-gene
- I-gene
containing I-gene
protein I-gene
, 0
a 0
protein B-gene
tyrosine I-gene
kinase I-gene
substrate 0
in 0
hematopoietic 0
cells 0
. 0

The 0
presence 0
of 0
the 0
foreign 0
gene 0
was 0
confirmed 0
by 0
Southern 0
analysis 0
. 0

All 0
patients 0
with 0
deterioriation 0
in 0
mental 0
status 0
showed 0
a 0
marked 0
increase 0
in 0
liver 0
enzymes 0
( 0
aspartate B-gene
and I-gene
alanine I-gene
aminotransaminases I-gene
) 0
and 0
severe 0
coagulopathy 0
. 0

Functional 0
postnatal 0
development 0
of 0
the 0
rat 0
primary 0
visual 0
cortex 0
and 0
the 0
role 0
of 0
visual 0
experience 0
: 0
dark 0
rearing 0
and 0
monocular 0
deprivation 0
. 0

Eleven 0
patients 0
tested 0
positive 0
for 0
the 0
hepatitis B-gene
B I-gene
surface I-gene
antigen I-gene
( 0
HBsAg B-gene
) 0
. 0

The 0
xylose B-gene
isomerase I-gene
- I-gene
encoding I-gene
gene I-gene
( 0
xylA B-gene
) 0
of 0
Clostridium 0
thermosaccharolyticum 0
: 0
cloning 0
, 0
sequencing 0
and 0
phylogeny 0
of 0
XylA B-gene
enzymes I-gene
. 0

Two 0
phosphopeptides 0
, 0
identified 0
as 0
RS 0
- 0
[ 0
32P 0
] 0
SGASGLLTSEHHSR 0
and 0
S 0
- 0
[ 0
32P 0
] 0
SGASGLLTSEHHSR 0
, 0
were 0
obtained 0
after 0
stoichiometric 0
phosphorylation 0
and 0
trypsinization 0
of 0
the 0
peptide 0
. 0

Mitochondrial B-gene
Mas70p I-gene
signal I-gene
anchor I-gene
sequence I-gene
. 0

Altogether 0
, 0
these 0
data 0
suggest 0
that 0
Ypt51p B-gene
, 0
Ypt52p B-gene
, 0
and 0
Ypt53p B-gene
are 0
required 0
for 0
transport 0
in 0
the 0
endocytic 0
pathway 0
and 0
for 0
correct 0
sorting 0
of 0
vacuolar B-gene
hydrolases I-gene
suggesting 0
a 0
possible 0
intersection 0
of 0
the 0
endocytic 0
with 0
the 0
vacuolar 0
sorting 0
pathway 0
. 0

All 0
of 0
the 0
basal 0
TPN 0
solutions 0
were 0
isonitrogenous 0
and 0
identical 0
in 0
nutrient 0
composition 0
, 0
except 0
for 0
the 0
difference 0
in 0
energy 0
level 0
, 0
which 0
was 0
adjusted 0
with 0
glucose 0
. 0

Surprisingly 0
, 0
TFIIIC B-gene
alpha I-gene
has 0
no 0
homology 0
to 0
any 0
of 0
the 0
yeast B-gene
TFIIIC I-gene
subunits I-gene
already 0
cloned 0
, 0
suggesting 0
a 0
significant 0
degree 0
of 0
evolutionary 0
divergence 0
for 0
RNA B-gene
polymerase I-gene
III I-gene
factors I-gene
. 0

Transactivation 0
domain 0
is 0
located 0
downstream 0
of 0
the 0
128 B-gene
- I-gene
amino I-gene
- I-gene
acid I-gene
runt I-gene
homology I-gene
region I-gene
, 0
referred 0
to 0
as 0
the 0
Runt B-gene
domain I-gene
. 0

We 0
estimate 0
that 0
the 0
protease 0
activity 0
is 0
at 0
least 0
35 0
- 0
fold 0
greater 0
in 0
mature 0
B 0
cells 0
than 0
in 0
pre 0
- 0
B 0
cells 0
. 0

The 0
ligand 0
for 0
RXR B-gene
, 0
9 0
- 0
cis 0
retinoic 0
acid 0
, 0
has 0
the 0
opposite 0
effect 0
of 0
destabilizing 0
the 0
heterodimeric 0
- 0
DNA 0
complex 0
. 0

Cerebral125 B-gene
albumin I-gene
was 0
increased 0
to 0
similar 0
proportions 0
in 0
those 0
groups 0
submitted 0
to 0
hyperosmolality 0
. 0

Retrogradely 0
labelled 0
neurons 0
significantly 0
prevailed 0
in 0
the 0
ipsilateral 0
substantia 0
nigra 0
pars 0
compacta 0
. 0

Response 0
to 0
treatment 0
was 0
better 0
in 0
patients 0
with 0
less 0
pretreatment 0
( 0
one 0
- 0
two 0
prior 0
treatments 0
) 0
than 0
in 0
heavily 0
pretreated 0
ones 0
( 0
more 0
than 0
three 0
) 0
and 0
this 0
relation 0
was 0
found 0
to 0
be 0
statistically 0
significant 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Therefore 0
, 0
the 0
amino 0
- 0
terminal 0
sequence 0
of 0
the 0
purified 0
carA B-gene
product I-gene
is 0
identical 0
to 0
that 0
derived 0
from 0
the 0
nucleotide 0
sequence 0
in 0
both 0
organisms 0
, 0
P. 0
stutzeri 0
having 0
four 0
additional 0
amino 0
acids 0
. 0

Aneurysmal 0
bone 0
cyst 0
of 0
the 0
jaws 0
: 0
analysis 0
of 0
11 0
cases 0
. 0

Location 0
and 0
orientation 0
of 0
an 0
activating 0
region 0
in 0
the 0
Escherichia 0
coli 0
transcription 0
factor 0
, 0
FNR B-gene
. 0

Moxidectin 0
( 0
at 0
3 0
times 0
the 0
therapeutic 0
dose 0
) 0
did 0
not 0
have 0
deleterious 0
effects 0
on 0
cow 0
reproductive 0
performance 0
as 0
examined 0
( 0
eg 0
, 0
at 0
folliculogenesis 0
, 0
ovulation 0
, 0
and 0
the 0
early 0
embryonic 0
phase 0
of 0
development 0
) 0
. 0

Northern 0
- 0
blot 0
analysis 0
of 0
mRNA 0
from 0
Avicel 0
- 0
grown 0
N. 0
patriciarum 0
showed 0
that 0
xynB B-gene
hybridized 0
to 0
a 0
3.4 0
kb 0
mRNA 0
species 0
. 0

The 0
variable 0
regions 0
of 0
vertebrate 0
striated 0
TnT B-gene
isoforms I-gene
reflect 0
the 0
subsequent 0
addition 0
and 0
modification 0
of 0
genomic 0
sequences 0
to 0
give 0
rise 0
to 0
members 0
of 0
the 0
TnT B-gene
multigene I-gene
family I-gene
. 0

The 0
class B-gene
II I-gene
Escherichia I-gene
coli I-gene
alanine I-gene
tRNA I-gene
synthetase I-gene
aminoacylates I-gene
RNA I-gene
miniduplexes I-gene
, 0
which 0
reconstruct 0
the 0
acceptor 0
end 0
of 0
alanine B-gene
tRNA I-gene
with 0
the 0
critical 0
G3 0
: 0
U70 0
base 0
pair 0
. 0

Simple 0
reaction 0
time 0
( 0
RT 0
) 0
to 0
a 0
peripheral 0
visual 0
target 0
( 0
S2 0
) 0
is 0
shortened 0
when 0
a 0
non 0
- 0
informative 0
cue 0
( 0
S1 0
) 0
is 0
flashed 0
at 0
the 0
S2 0
location 0
100 0
- 0
150 0
ms 0
before 0
target 0
onset 0
( 0
early 0
facilitation 0
) 0
. 0

A 0
second 0
study 0
group 0
, 0
with 0
intact 0
cardiac 0
innervation 0
, 0
consisted 0
of 0
19 0
patients 0
with 0
stable 0
angina 0
pectoris 0
class 0
I 0
to 0
III 0
. 0

These 0
viruses 0
depend 0
on 0
the 0
host 0
cell 0
machinery 0
for 0
their 0
existence 0
, 0
and 0
interference 0
with 0
these 0
processes 0
typically 0
interferes 0
with 0
other 0
important 0
host 0
physiology 0
. 0

Treatment 0
was 0
well 0
- 0
tolerated 0
. 0

A 0
concentration 0
of 0
12.5 0
ppm 0
SO2 0
induced 0
a 0
decrease 0
from 0
baseline 0
values 0
of 0
approximately 0
80 0
% 0
in 0
mean 0
MCA 0
and 0
of 0
roughly 0
70 0
% 0
in 0
mean 0
CBF 0
. 0

We 0
have 0
used 0
these 0
modified 0
assay 0
conditions 0
to 0
extend 0
studies 0
on 0
the 0
transposition 0
pathway 0
. 0

Renal 0
cell 0
carcinoma 0
in 0
children 0
: 0
a 0
single 0
institution 0
's 0
experience 0
. 0

The 0
data 0
suggest 0
that 0
ICP10 B-gene
constitutively 0
increases 0
ras B-gene
activity 0
, 0
and 0
its 0
TM 0
segment 0
plays 0
a 0
critical 0
role 0
in 0
transformation 0
- 0
related 0
signaling 0
pathways 0
. 0

Thus 0
, 0
we 0
have 0
separated 0
the 0
signal 0
function 0
from 0
the 0
anchor 0
function 0
of 0
the 0
6.7K 0
SA 0
domain 0
. 0

Five 0
concensus 0
poly 0
A 0
addition 0
sites 0
are 0
located 0
in 0
the 0
350 0
base 0
pairs 0
immediately 0
following 0
the 0
protein B-gene
IX I-gene
coding 0
region 0
. 0

Factors 0
associated 0
with 0
intrafamilial 0
transmission 0
of 0
hepatitis 0
B 0
virus 0
infection 0
in 0
Korea 0
. 0

Exposure 0
to 0
higher 0
TPA 0
concentrations 0
decreased 0
the 0
content 0
of 0
these 0
transcripts 0
. 0

Northern 0
analysis 0
, 0
to 0
search 0
for 0
a 0
pcbAB B-gene
transcript I-gene
, 0
showed 0
no 0
distinct 0
transcript 0
and 0
indicated 0
severely 0
degraded 0
mRNA 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
minimal 0
requirements 0
for 0
induction 0
of 0
PEPCK B-gene
by 0
PKA B-gene
and 0
inhibition 0
by 0
insulin B-gene
include 0
: 0
1 0
) 0
the 0
CREB B-gene
activation I-gene
domain I-gene
, 0
2 0
) 0
the 0
PEPCK B-gene
TATA I-gene
sequence I-gene
, 0
and 0
3 0
) 0
insulin B-gene
- 0
responsive 0
hepatoma 0
cells 0
. 0

The 0
high 0
degree 0
of 0
conservation 0
between 0
NQO2 B-gene
and 0
NQO1 B-gene
gene I-gene
organization 0
and 0
sequence 0
confirmed 0
that 0
NQO2 B-gene
gene I-gene
encodes 0
for 0
a 0
second 0
member 0
of 0
the 0
NQO B-gene
gene I-gene
family I-gene
in 0
human 0
. 0

The 0
efficacy 0
of 0
a 0
Propionibacterium 0
acnes 0
product 0
for 0
treatment 0
of 0
coliform 0
mastitis 0
was 0
evaluated 0
following 0
intramammary 0
infusion 0
of 0
Escherichia 0
coli 0
. 0

The 0
human B-gene
eps15 I-gene
gene I-gene
, 0
encoding 0
a 0
tyrosine B-gene
kinase I-gene
substrate 0
, 0
is 0
conserved 0
in 0
evolution 0
and 0
maps 0
to 0
1p31 0
- 0
p32 0
. 0

The 0
gene 0
encoding 0
the 0
105 B-gene
- I-gene
kDa I-gene
protein I-gene
( I-gene
p105 I-gene
) I-gene
precursor I-gene
of 0
the 0
p50 B-gene
subunit I-gene
of 0
transcription 0
factor 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
also 0
encodes 0
a 0
p70 B-gene
I I-gene
kappa I-gene
B I-gene
protein I-gene
, 0
I B-gene
kappa I-gene
B I-gene
gamma I-gene
, 0
which 0
is 0
identical 0
to 0
the 0
C 0
- 0
terminal 0
607 0
amino 0
acids 0
of 0
p105 B-gene
. 0

Alternative 0
splicing 0
of 0
RNA 0
transcripts 0
encoded 0
by 0
the 0
murine 0
p105 B-gene
NF B-gene
- I-gene
kappa I-gene
B I-gene
gene 0
generates 0
I B-gene
kappa I-gene
B I-gene
gamma I-gene
isoforms I-gene
with 0
different 0
inhibitory 0
activities 0
. 0

Topical 0
L 0
- 0
NNA 0
attenuated 0
the 0
hypercapnic 0
increase 0
of 0
CoBF 0
by 0
52 0
+/ 0
- 0
6 0
% 0
and 0
CeBF 0
by 0
29 0
+/ 0
- 0
5 0
% 0
after 0
45 0
- 0
min 0
exposure 0
. 0

The 0
experiment 0
included 0
6 0
male 0
and 0
4 0
female 0
healthy 0
subjects 0
who 0
, 0
during 0
a 0
24 0
- 0
hour 0
stay 0
in 0
the 0
respiration 0
chambers 0
, 0
performed 0
, 0
in 0
the 0
morning 0
and 0
afternoon 0
, 0
15 0
min 0
cycling 0
with 0
the 0
total 0
work 0
of 0
6,750 0
kg 0
m 0
. 0

These 0
rearrangements 0
result 0
in 0
the 0
formation 0
of 0
chimeric 0
genes 0
showing 0
the 0
tyrosine B-gene
kinase I-gene
domain I-gene
of 0
ret B-gene
fused 0
with 0
the 0
5 0
' 0
end 0
sequences 0
of 0
different 0
genes 0
. 0

Frequent 0
loss 0
of 0
heterozygosity 0
( 0
LOH 0
) 0
of 0
> 0
30 0
% 0
of 0
the 0
informative 0
cases 0
was 0
observed 0
on 0
chromosomes 0
3p 0
( 0
41.1 0
% 0
) 0
, 0
5q 0
( 0
52.6 0
% 0
) 0
, 0
6p 0
( 0
30.4 0
% 0
) 0
, 0
8p 0
( 0
33.3 0
% 0
) 0
, 0
9p 0
( 0
35.7 0
% 0
) 0
, 0
9q 0
( 0
30.8 0
% 0
) 0
, 0
11p 0
( 0
32.4 0
% 0
) 0
, 0
13q 0
( 0
52.7 0
% 0
) 0
, 0
17p 0
( 0
55.2 0
% 0
) 0
, 0
17q 0
( 0
33.3 0
% 0
) 0
, 0
18q 0
( 0
45.7 0
% 0
) 0
, 0
and 0
19q 0
( 0
30.4 0
% 0
) 0
. 0

A 0
single 0
amino 0
acid 0
change 0
in 0
the 0
CPY B-gene
vacuolar I-gene
sorting I-gene
signal I-gene
prevents 0
this 0
interaction 0
. 0

Glutamyl B-gene
- I-gene
tRNA I-gene
synthetase I-gene
and 0
prolyl B-gene
- I-gene
tRNA I-gene
synthetase I-gene
belong 0
to 0
different 0
classes 0
of 0
aminoacyl B-gene
- I-gene
tRNA I-gene
synthetases I-gene
that 0
are 0
thought 0
to 0
have 0
evolved 0
along 0
independent 0
evolutionary 0
pathways 0
. 0

Using 0
the 0
sequence 0
data 0
obtained 0
from 0
the 0
human 0
TCRAC/TCRDC B-gene
region 0
, 0
we 0
have 0
extended 0
a 0
polymerase 0
chain 0
reaction 0
- 0
based 0
assay 0
to 0
test 0
for 0
the 0
expression 0
of 0
the 0
individual 0
TCRAC/TCRDC I-gene

This 0
analysis 0
revealed 0
an 0
intact 0
gene 0
( 0
arg4 B-gene
) 0
showing 0
a 0
high 0
degree 0
of 0
homology 0
with 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
CPA2 I-gene
gene I-gene
encoding 0
the 0
large 0
subunit 0
of 0
carbamoyl B-gene
- I-gene
phosphate I-gene
synthetase I-gene
( 0
CPS B-gene
- I-gene
A I-gene
) 0
. 0

Restriction 0
analysis 0
and 0
Southern 0
hybridization 0
revealed 0
the 0
presence 0
of 0
Tn5422 B-gene
in 0
all 0
the 0
plasmid 0
- 0
mediated 0
cadmium 0
- 0
resistant 0
L. 0
monocytogenes 0
strains 0
tested 0
but 0
not 0
in 0
strains 0
encoding 0
cadmium 0
resistance 0
on 0
the 0
chromosome 0
. 0

The 0
baroreflex 0
latency 0
( 0
from 0
the 0
ECG 0
R 0
- 0
wave 0
to 0
the 0
integrated 0
MSNA 0
burst 0
peak 0
) 0
was 0
constant 0
at 0
approximately 0
1.20 0
s 0
during 0
sleep 0
, 0
suggesting 0
that 0
pulse 0
- 0
synchronicity 0
was 0
maintained 0
. 0

DESIGN 0
- 0
- 0
A 0
randomised 0
study 0
was 0
conducted 0
in 0
all 0
women 0
aged 0
50 0
- 0
70 0
years 0
who 0
were 0
eligible 0
for 0
breast 0
cancer 0
screening 0
and 0
living 0
in 0
the 0
city 0
of 0
Utrecht 0
. 0

Identification 0
of 0
an 0
immediate B-gene
- I-gene
early I-gene
gene I-gene
in 0
the 0
Marek 0
's 0
disease 0
virus 0
long 0
internal 0
repeat 0
region 0
which 0
encodes 0
a 0
unique 0
14 0
- 0
kilodalton 0
polypeptide 0
. 0

We 0
have 0
used 0
a 0
full 0
- 0
length 0
cDNA 0
clone 0
of 0
a 0
mouse 0
hepatitis 0
virus 0
strain 0
A59 0
defective 0
interfering 0
( 0
DI 0
) 0
RNA 0
, 0
pMIDI B-gene
- I-gene
C I-gene
, 0
and 0
cassette 0
mutagenesis 0
to 0
study 0
the 0
mechanism 0
of 0
coronavirus 0
subgenomic 0
mRNA 0
synthesis 0
. 0

To 0
study 0
the 0
structure 0
- 0
function 0
of 0
the 0
gene B-gene
5 I-gene
product I-gene
, 0
wild 0
- 0
type 0
and 0
mutant 0
forms 0
of 0
NS53 B-gene
were 0
produced 0
by 0
using 0
a 0
recombinant 0
baculovirus 0
expression 0
system 0
and 0
a 0
recombinant 0
vaccinia 0
virus/T7 0
( 0
vTF7 0
- 0
3 0
) 0
expression 0
system 0
. 0

Gel 0
electrophoresis 0
and 0
Western 0
immunoblot 0
analyses 0
of 0
intracellular 0
fractions 0
derived 0
from 0
infected 0
cells 0
revealed 0
that 0
large 0
amounts 0
of 0
NS53 B-gene
were 0
present 0
in 0
the 0
cytosol 0
and 0
in 0
association 0
with 0
the 0
cytoskeletal 0
matrix 0
. 0

The 0
transcription B-gene
factor I-gene
AP I-gene
- I-gene
2 I-gene
is 0
encoded 0
by 0
a 0
gene 0
located 0
on 0
chromosome 0
6 0
near 0
the 0
HLA B-gene
locus I-gene
. 0

The 0
mature 0
AP B-gene
- I-gene
2 I-gene
mRNA I-gene
is 0
spliced 0
from 0
7 0
exons 0
distributed 0
over 0
a 0
region 0
of 0
18 0
kb 0
genomic 0
DNA 0
. 0

San 0
Martin 0
's 0
psychological 0
traits 0
coupled 0
to 0
his 0
work 0
with 0
masonic 0
lodges 0
that 0
allowed 0
him 0
to 0
display 0
his 0
abilities 0
as 0
strategist 0
and 0
political 0
ruler 0
. 0

The 0
participants 0
were 0
homosexual 0
men 0
in 0
hepatitis 0
B 0
vaccine 0
trials 0
in 0
Amsterdam 0
( 0
n 0
= 0
74 0
) 0
, 0
New 0
York 0
City 0
( 0
n 0
= 0
120 0
) 0
, 0
and 0
San 0
Francisco 0
( 0
n 0
= 0
168 0
) 0
. 0

The 0
7 0
- 0
day 0
treatment 0
resulted 0
in 0
a 0
decrease 0
in 0
mitochondrial 0
uptake 0
of 0
Rh123 0
and 0
an 0
increase 0
in 0
NAO 0
uptake 0
. 0

Thrombotic 0
thrombocytopenic 0
purpura 0
in 0
systemic 0
lupus 0
erythematosus 0
. 0

Comparison 0
with 0
the 0
crystal 0
structure 0
of 0
Desulfovibrio 0
gigas 0
, 0
Dg 0
, 0
Fd B-gene
( 0
Kissinger 0
et 0
al. 0
, 0
1991 0
) 0
reveals 0
a 0
very 0
similar 0
folding 0
topology 0
, 0
although 0
several 0
secondary 0
structural 0
elements 0
are 0
extended 0
in 0
Pf 0
relative 0
to 0
Dg 0
Fd B-gene
. 0

CONCLUSIONS 0
: 0
Serum B-gene
prolactin I-gene
concentrations 0
show 0
age 0
related 0
variations 0
in 0
presumably 0
fertile 0
men 0
. 0

Eight 0
highly 0
trained 0
male 0
kayakers 0
were 0
studied 0
to 0
determine 0
the 0
relationship 0
between 0
critical 0
power 0
( 0
CP 0
) 0
and 0
the 0
onset 0
of 0
blood 0
lactate 0
accumulation 0
( 0
OBLA 0
) 0
. 0

As 0
in 0
S. 0
cerevisiae 0
, 0
the 0
sequence 0
of 0
rhp51+ B-gene
showed 0
two 0
MluI B-gene
cell I-gene
- I-gene
cycle I-gene
boxes I-gene
and 0
a 0
putative 0
DNA 0
damage 0
- 0
responsive 0
element 0
in 0
its 0
upstream 0
region 0
. 0

Women 0
's 0
opportunities 0
for 0
paid 0
work 0
outside 0
the 0
home 0
are 0
constrained 0
by 0
their 0
role 0
as 0
primary 0
carer 0
within 0
the 0
family 0
, 0
writes 0
Trudy 0
Wynne 0
. 0

A 0
partial 0
cDNA 0
sequence 0
indicated 0
that 0
the 0
T B-gene
lymphocyte I-gene
early I-gene
- I-gene
activation I-gene
gene I-gene
( 0
Tea B-gene
) 0
encodes 0
a 0
protein 0
related 0
to 0
the 0
dual 0
- 0
function 0
ecotropic B-gene
retrovirus I-gene
receptor/cationic I-gene
receptor/cationic I-gene
amino I-gene
acid I-gene
transporter I-gene
( 0
ecoR/CAT1 B-gene
) 0
, 0
and 0
RNA 0
blots 0
suggested 0
highest 0
ecoR/CAT1 I-gene

Furthermore 0
, 0
unlike 0
the 0
case 0
for 0
HIS3 B-gene
where 0
only 0
a 0
limited 0
subset 0
of 0
TATA 0
- 0
like 0
sequences 0
can 0
activate 0
transcription 0
in 0
conjunction 0
with 0
GCN4p B-gene
, 0
many 0
divergent 0
TATA 0
- 0
like 0
sequences 0
allowed 0
GCN4p B-gene
activation 0
of 0
TRP3 B-gene
. 0

Bacterially 0
expressed 0
protein 0
, 0
as 0
well 0
as 0
the 0
in 0
vitro 0
reticulocyte 0
lysate 0
translation 0
product 0
, 0
comigrated 0
with 0
the 0
purified 0
37 0
- 0
kDa 0
protein 0
on 0
sodium 0
dodecyl 0
sulfate 0
- 0
polyacrylamide 0
gels 0
. 0

In 0
addition 0
, 0
this 0
kinase 0
is 0
well 0
conserved 0
evolutionarily 0
, 0
ubiquitously 0
expressed 0
, 0
and 0
its 0
genes 0
map 0
to 0
a 0
position 0
on 0
human 0
chromosome 0
1 0
frequently 0
deleted 0
in 0
the 0
late 0
stages 0
of 0
tumorigenesis 0
. 0

Deletion 0
analysis 0
of 0
the 0
ICL1 B-gene
promoter I-gene
led 0
to 0
the 0
identification 0
of 0
an 0
upstream 0
activating 0
sequence 0
element 0
, 0
UASICL1 0
( 0
5 0
' 0
CATTCATCCG 0
3 0
' 0
) 0
, 0
necessary 0
and 0
sufficient 0
for 0
conferring 0
carbon 0
source 0
- 0
dependent 0
regulation 0
on 0
a 0
heterologous 0
reporter 0
gene 0
. 0

Interestingly 0
, 0
the 0
interaction 0
of 0
ZAP B-gene
- I-gene
70 I-gene
with 0
the 0
motif 0
was 0
dependent 0
on 0
the 0
presence 0
of 0
both 0
ZAP B-gene
- I-gene
70 I-gene
SH2 B-gene
domains I-gene
and 0
both 0
of 0
the 0
tyrosine 0
residues 0
in 0
the 0
motif 0
, 0
suggesting 0
that 0
ZAP B-gene
- I-gene
70 I-gene
interacts 0
with 0
two 0
phosphotyrosine 0
residues 0
and 0
that 0
the 0
binding 0
of 0
the 0
two 0
SH2 B-gene
domains I-gene
is 0
cooperative 0
. 0

PRL B-gene
- I-gene
1 I-gene
is 0
able 0
to 0
dephosphorylate 0
phosphotyrosine 0
substrates 0
, 0
and 0
mutation 0
of 0
the 0
active 0
- 0
site 0
cysteine 0
residue 0
abolishes 0
this 0
activity 0
. 0

In 0
Mv1Lu 0
lung 0
epithelial 0
cells 0
, 0
ActR B-gene
- I-gene
IB I-gene
and 0
T B-gene
beta I-gene
R I-gene
- I-gene
I I-gene
signal 0
a 0
common 0
set 0
of 0
growth 0
- 0
inhibitory 0
and 0
transcriptional 0
responses 0
in 0
association 0
with 0
their 0
corresponding 0
ligands 0
and 0
type B-gene
II I-gene
receptors I-gene
. 0

50 0
kDa 0
and 0
130 0
- 0
170 0
kDa 0
were 0
detected 0
. 0

H 0
- 0
7 0
, 0
which 0
specifically 0
, 0
although 0
weakly 0
, 0
inhibited 0
PKC B-gene
activation 0
, 0
had 0
no 0
effect 0
on 0
tyrosine 0
phosphorylation 0
and 0
PtdIns 0
( 0
3,4 0
) 0
P2 0
production 0
. 0

The 0
effects 0
of 0
systemic 0
glucose 0
concentration 0
on 0
brain 0
metabolism 0
following 0
repeated 0
brain 0
ischemia 0
. 0

This 0
strategy 0
was 0
used 0
to 0
place 0
both 0
the 0
Tn903 B-gene
neo I-gene
gene I-gene
and 0
the 0
Rhodosporidium B-gene
toruloides I-gene
phenylalanine I-gene
ammonia I-gene
lyase I-gene
( 0
PAL B-gene
) 0
- 0
encoding 0
gene 0
under 0
the 0
transcriptional 0
control 0
of 0
pPGK B-gene
: 0
:REP2 B-gene
. 0

In 0
the 0
case 0
of 0
congenital 0
protein B-gene
C I-gene
deficiency 0
, 0
vitamin 0
K 0
antagonists 0
must 0
be 0
started 0
cautiously 0
due 0
to 0
the 0
risk 0
of 0
skin 0
necrosis 0
. 0

A 0
- 0
69 0
- 0
year 0
- 0
old 0
patient 0
with 0
postoperative 0
small 0
- 0
bowel 0
obstruction 0
underwent 0
laparotomy 0
three 0
times 0
. 0

On 0
physical 0
examination 0
a 0
mild 0
symmetrical 0
polyarthritis 0
of 0
small 0
and 0
large 0
joints 0
was 0
seen 0
. 0

In 0
addition 0
, 0
we 0
observe 0
that 0
the 0
hUBF B-gene
- I-gene
promoter I-gene
interaction 0
is 0
highly 0
sensitive 0
to 0
the 0
antagonistic 0
effects 0
of 0
cisplatin 0
- 0
DNA 0
adducts 0
. 0

We 0
conclude 0
that 0
the 0
SIMV 0
is 0
useful 0
in 0
weaning 0
neonates 0
from 0
the 0
ventilator 0
. 0

VP 0
- 0
16 0
, 0
ifosfamide 0
and 0
cisplatin 0
( 0
VIP 0
) 0
for 0
extensive 0
small 0
cell 0
lung 0
cancer 0
. 0

A 0
total 0
of 0
7 0
( 0
4 0
males 0
and 0
3 0
females 0
) 0
patients 0
were 0
included 0
in 0
this 0
retrospective 0
study 0
to 0
determine 0
the 0
sensitivity 0
of 0
radioimmunoscintigraphy 0
with 0
I 0
- 0
131 0
labeled 0
anti B-gene
CEA/CA I-gene
CEA/CA I-gene
19 I-gene
- I-gene
9 I-gene
monoclonal 0
antibodies 0
. 0

Simultaneous 0
, 0
bilateral 0
and 0
permanent 0
ventilation 0
with 0
a 0
diaphragm 0
pacing 0
in 0
childhood 0
: 0
the 0
implantation 0
technique 0
and 0
indications 0

A 0
genomic 0
clone 0
for 0
the 0
cyc07 B-gene
gene I-gene
, 0
which 0
is 0
expressed 0
specifically 0
at 0
the 0
S 0
phase 0
during 0
the 0
cell 0
cycle 0
in 0
synchronous 0
cultures 0
of 0
periwinkle 0
( 0
Catharanthus 0
roseus 0
) 0
cells 0
, 0
was 0
isolated 0
. 0

CONCLUSIONS 0
: 0
Translocation 0
of 0
bacteria 0
or 0
endotoxin 0
from 0
the 0
gastrointestinal 0
tract 0
into 0
the 0
bloodstream 0
has 0
been 0
noted 0
in 0
animal 0
experiments 0
; 0
however 0
, 0
translocation 0
was 0
not 0
detected 0
in 0
our 0
patients 0
with 0
hemorrhagic 0
shock 0
. 0

The 0
pyrR B-gene
and 0
pyrP B-gene
genes I-gene
encoded 0
polypeptides 0
with 0
calculated 0
molecular 0
masses 0
of 0
19.9 0
and 0
45.2 0
kDa 0
, 0
respectively 0
. 0

Southern 0
blotting 0
analysis 0
implied 0
the 0
occurrence 0
of 0
multiple 0
COXVb B-gene
genes I-gene
in 0
the 0
rat 0
genome 0
. 0

Acylation 0
with 0
the 0
palmitate 0
analog 0
was 0
prevented 0
when 0
Gly 0
- 0
2 0
was 0
mutated 0
to 0
alanine 0
, 0
implying 0
that 0
N 0
- 0
myristylation 0
is 0
required 0
for 0
palmitylation 0
, 0
and 0
when 0
either 0
Cys 0
- 0
3 0
or 0
Cys 0
- 0
6 0
was 0
mutated 0
to 0
serine 0
. 0

Subunit 0
composition 0
and 0
domain 0
structure 0
of 0
the 0
Spo0A B-gene
sporulation I-gene
transcription I-gene
factor I-gene
of I-gene
Bacillus I-gene
subtilis I-gene
. 0

Electrophoretic 0
mobility 0
shift 0
analysis 0
indicates 0
that 0
NF B-gene
- I-gene
IL I-gene
- I-gene
6 I-gene
, 0
as 0
well 0
as 0
other 0
related 0
members 0
of 0
this 0
family 0
, 0
bind 0
specifically 0
to 0
the 0
NF B-gene
- I-gene
IL I-gene
- I-gene
6 I-gene
site 0
in 0
the 0
IL B-gene
- I-gene
8 I-gene
promoter I-gene
. 0

BYV 0
, 0
citrus 0
tristeza 0
virus 0
( 0
CTV 0
) 0
, 0
beet 0
yellow 0
stunt 0
virus 0
( 0
BYSV 0
) 0
and 0
carnation 0
necrotic 0
fleck 0
virus 0
templates 0
produced 0
1 0
kb 0
amplification 0
products 0
, 0
which 0
were 0
shown 0
by 0
sequencing 0
to 0
represent 0
fragments 0
of 0
the 0
respective 0
HSP70 B-gene
genes I-gene
. 0

To 0
identify 0
the 0
precise 0
location 0
of 0
the 0
phosphorylation 0
site 0
on 0
the 0
64 0
- 0
kDa 0
protein 0
, 0
a 0
step 0
- 0
by 0
- 0
step 0
mutagenesis 0
procedures 0
was 0
followed 0
. 0

The 0
p53 B-gene
tumor I-gene
suppressor I-gene
gene I-gene
product I-gene
, 0
a 0
sequence 0
- 0
specific 0
DNA 0
- 0
binding 0
protein 0
, 0
has 0
been 0
shown 0
to 0
act 0
as 0
a 0
transcriptional 0
activator 0
and 0
repressor 0
both 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

Mutational 0
analysis 0
of 0
chromosomal 0
segment 0
64AB 0
, 0
a 0
region 0
containing 0
the 0
glutamic B-gene
acid I-gene
decarboxylase I-gene
gene I-gene
. 0

Rearrangements 0
of 0
the 0
NFKB2 B-gene
gene I-gene
are 0
associated 0
with 0
lymphoid 0
malignancies 0
, 0
but 0
the 0
functional 0
significance 0
of 0
these 0
alterations 0
is 0
not 0
known 0
. 0

Cloning 0
and 0
sequencing 0
of 0
the 0
corresponding 0
cDNAs 0
indicates 0
that 0
, 0
via 0
alternative 0
splicing 0
, 0
the 0
rearranged 0
gene 0
codes 0
for 0
two 0
proteins 0
of 0
84 0
and 0
85 0
kD 0
( 0
p84/85 B-gene
) 0
which 0
retain 0
the 0
DNA 0
- 0
binding 0
rel B-gene
domain I-gene
and 0
the 0
first 0
five 0
ankyrin B-gene
repeats 0
, 0
but 0
have 0
lost 0
their 0
carboxy 0
- 0
terminus 0
including 0
the 0
seventh 0
ankyrin B-gene
repeat 0
. 0

Transient 0
co 0
- 0
transfection 0
assays 0
involving 0
NFKB2 B-gene
expression 0
vectors 0
and 0
kappa B-gene
B I-gene
- 0
driven 0
reporter 0
plasmids 0
indicate 0
that 0
NFKB2 B-gene
p85 B-gene
has 0
lost 0
the 0
transcriptional 0
repressor 0
functions 0
typical 0
of 0
normal 0
NFKB2 B-gene
p52 B-gene
. 0

Also 0
, 0
HR21ap B-gene
as 0
well 0
as 0
HR21Xap B-gene
are 0
specific 0
in 0
their 0
inhibition 0
of 0
Sp1 B-gene
binding 0
. 0

Intravenous 0
antibiotic 0
therapy 0
in 0
cystic 0
fibrosis 0
: 0
in 0
hospital 0
or 0
at 0
home 0
? 0

Open 0
reading 0
frames 0
in 0
a 0
4556 0
nucleotide 0
sequence 0
within 0
MDV B-gene
- I-gene
1 I-gene
BamHI I-gene
- I-gene
D I-gene
DNA I-gene
fragment I-gene
: 0
evidence 0
for 0
splicing 0
of 0
mRNA 0
from 0
a 0
new 0
viral 0
glycoprotein 0
gene 0
. 0

The 0
ns2 B-gene
gene I-gene
comprises 0
an 0
open 0
reading 0
frame 0
( 0
ORF 0
) 0
encoding 0
a 0
putative 0
nonstructural 0
( 0
ns 0
) 0
protein 0
of 0
279 0
amino 0
acids 0
with 0
a 0
predicted 0
molecular 0
mass 0
of 0
32 0
- 0
kDa 0
. 0

Co 0
- 0
transfection 0
of 0
a 0
tat B-gene
expressing 0
plasmid 0
with 0
these 0
viruses 0
containing 0
the 0
tat B-gene
ORF I-gene
mutations 0
resulted 0
in 0
higher 0
levels 0
of 0
virus 0
production 0
demonstrating 0
that 0
the 0
effects 0
of 0
both 0
mutants 0
are 0
tat B-gene
specific 0
. 0

Analysis 0
of 0
the 0
gag B-gene
and 0
rev B-gene
proteins I-gene
in 0
the 0
transfected 0
cells 0
demonstrated 0
that 0
these 0
proteins 0
were 0
not 0
detectable 0
in 0
cells 0
transfected 0
with 0
the 0
tat B-gene
mutants I-gene
but 0
could 0
be 0
readily 0
detected 0
when 0
the 0
mutations 0
were 0
complemented 0
in 0
trans 0
with 0
a 0
tat B-gene
expression 0
vector 0
. 0

The 0
hydrophobicity 0
profile 0
of 0
the 0
methyltransferase 0
reveals 0
the 0
presence 0
of 0
at 0
least 0
five 0
potential 0
transmembrane 0
domains 0
. 0

Measurement 0
of 0
SaO2 0
at 0
moderate 0
altitude 0
can 0
be 0
helpful 0
in 0
the 0
care 0
of 0
both 0
healthy 0
and 0
ill 0
newborns 0
or 0
infants 0
. 0

To 0
determine 0
whether 0
the 0
excess 0
prevalence 0
of 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
infection 0
in 0
US 0
black 0
and 0
Hispanic 0
homosexual 0
men 0
relative 0
to 0
white 0
men 0
can 0
be 0
explained 0
by 0
differences 0
in 0
sociodemographic 0
factors 0
, 0
history 0
of 0
sexually 0
transmitted 0
diseases 0
, 0
or 0
sexual 0
and 0
drug 0
- 0
use 0
behaviors 0
, 0
the 0
authors 0
conducted 0
a 0
cross 0
- 0
sectional 0
analysis 0
of 0
baseline 0
HIV 0
- 0
1 0
seroprevalence 0
and 0
HIV 0
- 0
1 0
risk 0
factors 0
among 0
4,475 0
non 0
- 0
Hispanic 0
white 0
, 0
234 0
Hispanic 0
white 0
, 0
and 0
194 0
black 0
homosexual 0
men 0
from 0
four 0
centers 0
in 0
the 0
United 0
States 0
( 0
Baltimore/Washington 0
, 0
DC 0
, 0
Pittsburgh 0
, 0
Chicago 0
, 0
and 0
Los 0
Angeles 0
) 0
. 0

The 0
patients 0
in 0
one 0
group 0
had 0
intrauterine 0
catheters 0
inserted 0
and 0
oxytocin B-gene
was 0
titrated 0
to 0
achieve 0
the 0
75th 0
percentile 0
of 0
uterine 0
activity 0
observed 0
in 0
spontaneous 0
normal 0
labour 0
according 0
to 0
parity 0
. 0

Continued 0
development 0
of 0
the 0
rat 0
conditioning 0
paradigm 0
is 0
especially 0
warranted 0
because 0
of 0
the 0
ability 0
to 0
record 0
sympathetic 0
nerve 0
activity 0
in 0
intact 0
, 0
awake 0
subjects 0
and 0
the 0
large 0
number 0
of 0
readily 0
available 0
genetic 0
strains 0
, 0
which 0
model 0
human 0
pathological 0
states 0
. 0

The 0
ultrastructure 0
of 0
retinal 0
vessels 0
was 0
examined 0
in 0
three 0
eyes 0
from 0
diabetic 0
patients 0
and 0
two 0
eyes 0
from 0
control 0
subjects 0
. 0

The 0
regulatory 0
region 0
also 0
has 0
a 0
sequence 0
similar 0
to 0
the 0
binding 0
site 0
for 0
a 0
liver 0
- 0
specific 0
transcription 0
factor 0
, 0
hepatocyte B-gene
nuclear I-gene
factor I-gene
1 I-gene
( 0
HNF B-gene
- I-gene
1 I-gene
) 0
, 0
at 0
positions 0
- 0
120 0
to 0
- 0
132 0
. 0

Thus 0
, 0
we 0
have 0
identified 0
a 0
GRE 0
sufficient 0
to 0
account 0
for 0
full 0
glucocorticoid 0
inducibility 0
and 0
an 0
HNF B-gene
- I-gene
1 I-gene
site I-gene
close 0
to 0
the 0
promoter 0
that 0
are 0
major 0
determinants 0
of 0
transcriptional 0
control 0
of 0
the 0
Xenopus B-gene
fibrinogen I-gene
B I-gene
beta I-gene
subunit I-gene
gene I-gene
in 0
cells 0
from 0
normal 0
liver 0
tissue 0
. 0

Acad 0
. 0

The 0
PRB B-gene
- I-gene
1b I-gene
gene I-gene
encodes 0
for 0
a 0
basic 0
- 0
type 0
component 0
of 0
the 0
pathogenesis 0
- 0
related 0
PR B-gene
- I-gene
1 I-gene
protein I-gene
family I-gene
. 0

Replacement 0
of 0
the 0
CRE 0
with 0
a 0
second 0
copy 0
of 0
the 0
AP B-gene
- I-gene
1 I-gene
site I-gene
results 0
in 0
a 0
level 0
of 0
transcriptional 0
activity 0
comparable 0
with 0
that 0
of 0
the 0
wild 0
- 0
type 0
sequence 0
, 0
but 0
replacement 0
of 0
the 0
AP B-gene
- I-gene
1 I-gene
site I-gene
with 0
a 0
CRE 0
abolishes 0
activity 0
. 0

The 0
T B-gene
- I-gene
cyt I-gene
promoter I-gene
, 0
although 0
of 0
bacterial 0
origin 0
is 0
active 0
in 0
planta 0
and 0
the 0
30 B-gene
bp I-gene
cyt I-gene
- I-gene
1 I-gene
element I-gene
is 0
located 0
within 0
a 0
region 0
that 0
is 0
essential 0
for 0
T B-gene
- I-gene
cyt I-gene
promotor I-gene
activity 0
in 0
leaf 0
, 0
stem 0
and 0
root 0
cells 0
of 0
tobacco 0
plants 0
. 0

Reviewing 0
manuscripts 0
: 0
developing 0
an 0
efficient 0
system 0
. 0

We 0
suggest 0
that 0
CT 0
scan 0
be 0
preferable 0
in 0
diagnosis 0
of 0
tumors 0
in 0
that 0
area 0
. 0

SIN 0
- 0
1 0
had 0
no 0
influence 0
on 0
either 0
the 0
ischemic 0
parameters 0
in 0
the 0
surface 0
electrocardiogram 0
( 0
ECG 0
) 0
or 0
the 0
intracoronary 0
ECG 0
. 0

Effect 0
of 0
aging 0
on 0
respiratory 0
skeletal 0
muscles 0
. 0

Two 0
BASIC 0
computer 0
programs 0
using 0
logit 0
transformation 0
for 0
the 0
analysis 0
of 0
S 0
- 0
shaped 0
curves 0
are 0
presented 0
. 0

The 0
yeast B-gene
SSS1 I-gene
gene I-gene
is 0
essential 0
for 0
secretory 0
protein 0
translocation 0
and 0
encodes 0
a 0
conserved 0
protein 0
of 0
the 0
endoplasmic 0
reticulum 0
. 0

The 0
lengths 0
of 0
the 0
complete 0
polypeptide 0
chain 0
of 0
the 0
recombinant 0
enzyme 0
and 0
its 0
transit 0
peptide 0
are 0
388 0
and 0
53 0
residues 0
, 0
respectively 0
. 0

The 0
absence 0
of 0
H4PteGlun 0
bound 0
to 0
the 0
T B-gene
protein I-gene
in 0
our 0
experimental 0
conditions 0
demonstrates 0
that 0
H4PteGlun 0
is 0
not 0
covalently 0
linked 0
to 0
the 0
T B-gene
protein I-gene
. 0

TATA 0
and 0
CCAAT 0
boxes 0
are 0
located 0
34 0
- 0
bp 0
and 0
68 0
- 0
bp 0
, 0
respectively 0
, 0
upstream 0
of 0
the 0
transcription 0
start 0
site 0
, 0
the 0
5' 0
- 0
untranslated 0
leader 0
is 0
78 0
nucleotides 0
long 0
, 0
and 0
the 0
intronless 0
gene 0
has 0
at 0
least 0
two 0
different 0
polyadenylation 0
sites 0
. 0

GGS1 B-gene
is 0
the 0
same 0
gene 0
as 0
TPS1 B-gene
which 0
was 0
identified 0
as 0
encoding 0
a 0
subunit 0
of 0
the 0
trehalose B-gene
- I-gene
6 I-gene
- I-gene
phosphate I-gene
synthase/phosphatase I-gene
complex I-gene
and 0
it 0
is 0
allelic 0
to 0
the 0
fdp1 B-gene
, 0
byp1 B-gene
, 0
glc6 B-gene
and 0
cif1 0
mutations 0
. 0

We 0
also 0
compared 0
the 0
sequence 0
with 0
the 0
partly 0
homologous 0
products 0
of 0
the 0
S. 0
cerevisiae 0
genes 0
TPS2 B-gene
and 0
TSL1 B-gene
which 0
code 0
for 0
the 0
larger 0
subunits 0
of 0
the 0
trehalose B-gene
synthase I-gene
complex I-gene
and 0
with 0
a 0
TSL1 B-gene
homologue I-gene
, 0
TPS3 B-gene
, 0
of 0
unknown 0
function 0
. 0

Stroop 0
interference 0
: 0
aging 0
effects 0
assessed 0
with 0
the 0
Stroop 0
Color 0
- 0
Word 0
Test 0
. 0

Stimulation 0
of 0
[ 0
3H 0
] 0
PA 0
production 0
upon 0
CD3 B-gene
cross 0
- 0
linking 0
was 0
77 0
% 0
lower 0
in 0
permeabilized 0
CD45 B-gene
- I-gene
cells 0
than 0
in 0
CD45+ B-gene
cells 0
, 0
consistent 0
with 0
the 0
reduced 0
activity 0
of 0
p59fyn B-gene
in 0
CD45 B-gene
- I-gene
cells 0
. 0

CONCLUSION 0
: 0
The 0
study 0
demonstrates 0
that 0
transvaginal 0
ultrasonography 0
has 0
an 0
efficiency 0
of 0
88 0
% 0
in 0
differentiating 0
endometriomas 0
from 0
other 0
ovarian 0
masses 0
with 0
a 0
specificity 0
of 0
90 0
% 0
. 0

Genomic 0
Southern 0
blot 0
analysis 0
of 0
rat B-gene
EFIA I-gene
( 0
gene 0
encoding 0
enhancer B-gene
factor I-gene
I I-gene
subunit I-gene
A I-gene
) 0
reveals 0
a 0
complex 0
band 0
pattern 0
when 0
cDNA 0
subfragment 0
probes 0
are 0
used 0
. 0

The 0
effect 0
of 0
ibopamine 0
and 0
furosemide 0
in 0
130 0
patients 0
with 0
NYHA 0
Class 0
I 0
and 0
II 0
heart 0
failure 0
were 0
studied 0
in 0
a 0
parallel 0
, 0
double 0
- 0
blind 0
, 0
randomized 0
placebo 0
- 0
controlled 0
multi 0
- 0
centre 0
trial 0
. 0

The 0
nit B-gene
- I-gene
3 I-gene
gene I-gene
of I-gene
the I-gene
filamentous I-gene
fungus I-gene
Neurospora I-gene
crassa I-gene
encodes 0
nitrate B-gene
reductase I-gene
, 0
the 0
enzyme 0
which 0
catalyzes 0
the 0
first 0
step 0
in 0
nitrate 0
assimilation 0
. 0

Unfolding 0
can 0
be 0
described 0
by 0
a 0
two 0
- 0
state 0
process 0
since 0
a 0
ratio 0
of 0
delta 0
Hcalorimetric 0
to 0
delta 0
Hva 0
n't 0
Hoff 0
equals 0
0.96 0
. 0

A 0
Dictyostelium 0
transformant 0
overexpressing 0
DdPTPa B-gene
does 0
not 0
develop 0
normally 0
. 0

This 0
motif 0
has 0
been 0
shown 0
to 0
mediate 0
protein 0
interactions 0
in 0
the 0
case 0
of 0
ankyrin B-gene
as 0
well 0
as 0
several 0
other 0
repeat 0
- 0
bearing 0
proteins 0
. 0

[ B-gene
Ala85 I-gene
] I-gene
Dk I-gene
( I-gene
69 I-gene
- I-gene
85 I-gene
) I-gene
retains 0
full 0
biological 0
activity 0
. 0

We 0
postulate 0
that 0
CaM B-gene
binding 0
by 0
HIV B-gene
envelope I-gene
proteins I-gene
is 0
likely 0
to 0
exert 0
diverse 0
modulatory 0
effects 0
, 0
and 0
the 0
mechanism 0
for 0
HIV 0
- 0
induced 0
cytotoxicity 0
may 0
involve 0
, 0
in 0
part 0
, 0
inhibition 0
of 0
CaM B-gene
- 0
regulated 0
cellular 0
functions 0
. 0

There 0
was 0
no 0
apparent 0
effect 0
of 0
growth 0
temperature 0
on 0
the 0
steady 0
- 0
state 0
levels 0
of 0
fad7 B-gene
mRNA I-gene
in 0
wild 0
type 0
plants 0
. 0

The 0
major 0
myosin B-gene
- I-gene
binding I-gene
domain I-gene
of 0
skeletal B-gene
muscle I-gene
MyBP I-gene
- I-gene
C I-gene
( 0
C B-gene
protein I-gene
) 0
resides 0
in 0
the 0
COOH 0
- 0
terminal 0
, 0
immunoglobulin B-gene
C2 B-gene
motif I-gene
. 0

A 0
second 0
important 0
molecule 0
in 0
TCR B-gene
signal 0
transduction 0
is 0
the 0
guanine B-gene
nucleotide I-gene
binding I-gene
protein I-gene
, 0
p21ras B-gene
, 0
which 0
is 0
coupled 0
to 0
the 0
TCR B-gene
by 0
a 0
protein B-gene
tyrosine I-gene
kinase I-gene
dependent 0
mechanism 0
. 0

Our 0
results 0
indicate 0
that 0
periseizure 0
lipid 0
accumulation 0
is 0
related 0
to 0
cortical 0
oxygenation 0
. 0

We 0
conclude 0
that 0
the 0
QLMI 0
questionnaire 0
has 0
good 0
potential 0
as 0
an 0
instrument 0
for 0
assessing 0
QL 0
in 0
post 0
- 0
AMI 0
patients 0
and 0
that 0
it 0
can 0
be 0
successfully 0
self 0
- 0
administered 0
. 0

Most 0
smokers 0
would 0
prefer 0
to 0
quit 0
smoking 0
on 0
their 0
own 0
. 0

The 0
inhibitory 0
response 0
to 0
taps 0
is 0
essentially 0
a 0
protective 0
reflex 0
which 0
probably 0
serves 0
to 0
reduce 0
the 0
activity 0
of 0
the 0
jaw 0
- 0
closing 0
muscles 0
when 0
one 0
bites 0
unexpectedly 0
on 0
hard 0
objects 0
. 0

The 0
action 0
of 0
nef B-gene
was 0
specific 0
to 0
the 0
LTR 0
, 0
as 0
expression 0
of 0
nef B-gene
had 0
no 0
effect 0
on 0
the 0
activity 0
of 0
the 0
simian 0
virus 0
40 0
, 0
c B-gene
- I-gene
fms I-gene
, 0
urokinase B-gene
plasminogen I-gene
activator I-gene
, 0
or 0
type B-gene
5 I-gene
acid I-gene
phosphatase I-gene
promoter I-gene
. 0
trans 0
- 0
activating 0
activity 0
was 0
also 0
manifested 0
by 0
a 0
frameshift 0
mutant 0
expressing 0
only 0
the 0
first 0
35 0
amino 0
acids 0
of 0
the 0
protein 0
. 0

The 0
product 0
of 0
the 0
vpr B-gene
open I-gene
reading I-gene
frame I-gene
of I-gene
human I-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
is 0
a 0
15 0
- 0
kDa 0
, 0
arginine 0
- 0
rich 0
protein 0
that 0
is 0
present 0
in 0
virions 0
in 0
molar 0
quantities 0
equivalent 0
to 0
that 0
of 0
Gag B-gene
. 0

The 0
recombinant B-gene
vaccinia I-gene
virus I-gene
- I-gene
expressed I-gene
mutant I-gene
P1 I-gene
polyproteins I-gene
were 0
analyzed 0
for 0
proteolytic 0
processing 0
defects 0
in 0
cells 0
coinfected 0
with 0
a 0
recombinant 0
vaccinia 0
virus 0
( 0
VVP3 0
) 0
that 0
expresses 0
the 0
poliovirus B-gene
3CD I-gene
protease I-gene
and 0
for 0
processing 0
and 0
assembly 0
defects 0
by 0
using 0
a 0
trans 0
complementation 0
system 0
in 0
which 0
P1 B-gene
- 0
expressing 0
recombinant 0
vaccinia 0
viruses 0
provide 0
capsid B-gene
precursor I-gene
to 0
a 0
defective 0
poliovirus 0
genome 0
that 0
does 0
not 0
express 0
functional 0
capsid B-gene
proteins I-gene
( 0
D 0
. 0

In 0
contrast 0
, 0
capsid B-gene
proteins I-gene
derived 0
from 0
the 0
P1 B-gene
precursor I-gene
with 0
a 0
valine 0
substitution 0
at 0
the 0
amino 0
terminus 0
of 0
VP1 B-gene
( 0
VP1 B-gene
- I-gene
G001V I-gene
) 0
assembled 0
empty 0
capsid 0
particles 0
but 0
were 0
deficient 0
in 0
assembling 0
RNA 0
- 0
containing 0
virions 0
. 0

RESULTS 0
: 0
In 0
an 0
18 0
moth 0
period 0
and 0
out 0
of 0
a 0
total 0
of 0
284 0
positive 0
blood 0
cultures 0
( 0
154 0
significant 0
isolations 0
) 0
14 0
episodes 0
of 0
bacteremia 0
by 0
M. 0
tuberculosis 0
were 0
studied 0
in 0
12 0
prison 0
patients 0
coinfected 0
by 0
the 0
human 0
immunodeficiency 0
virus 0
with 0
associated 0
severe 0
immunosuppression 0
( 0
mean 0
of 0
CD4 B-gene
= 0
0.068 0
x 0
10 0
( 0
9 0
) 0
/l 0
) 0
. 0

Acid 0
instilled 0
on 0
the 0
larynx 0
of 0
maturing 0
rabbits 0
resulted 0
in 0
significant 0
obstructive 0
, 0
central 0
, 0
and 0
mixed 0
apnea 0
. 0

By 0
using 0
total 0
- 0
protein 0
extracts 0
from 0
mycelia 0
grown 0
under 0
penicillin 0
producing 0
conditions 0
we 0
have 0
detected 0
a 0
DNA 0
- 0
binding 0
activity 0
that 0
specifically 0
shifts 0
a 0
promoter 0
fragment 0
located 0
between 0
- 0
654 0
and 0
- 0
455 0
( 0
relative 0
to 0
IPNS B-gene
tsp I-gene
) 0
. 0

A 0
series 0
of 0
5' 0
- 0
deletions 0
revealed 0
that 0
the 0
fragment 0
- 0
218 0
to 0
+4 0
from 0
the 0
TSS 0
had 0
the 0
highest 0
promoter 0
activity 0
, 0
nearly 0
1000 0
- 0
fold 0
greater 0
than 0
the 0
promoterless 0
chloramphenicol B-gene
acetyltransferase I-gene
construct I-gene
. 0

The 0
lemdr1 B-gene
gene I-gene
was 0
cloned 0
in 0
the 0
expression 0
vector 0
pALTNEO 0
and 0
transfected 0
into 0
wild 0
- 0
type 0
L. 0
enriettii 0
and 0
the 0
resulting 0
transfected 0
cells 0
were 0
resistant 0
to 0
vinblastine 0
but 0
at 0
lower 0
levels 0
than 0
in 0
the 0
selected 0
mutant 0
cells 0
. 0

The 0
bioavailability 0
of 0
etodolac 0
from 0
capsules 0
exposed 0
to 0
stressed 0
conditions 0
was 0
compared 0
in 0
both 0
dogs 0
and 0
humans 0
to 0
capsules 0
stored 0
at 0
RT 0
conditions 0
. 0

Similar 0
synergistic 0
activation 0
was 0
observed 0
in 0
the 0
IL B-gene
- I-gene
8 I-gene
promoter I-gene
, 0
which 0
also 0
contains 0
both 0
NF B-gene
- I-gene
IL6 I-gene
and 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
binding I-gene
sites I-gene
. 0

Notice 0
of 0
retraction 0
. 0

No 0
homology 0
was 0
found 0
between 0
the 0
36K 0
protein 0
and 0
known 0
structures 0
of 0
proteins 0
. 0

We 0
report 0
an 0
odd 0
case 0
of 0
marked 0
enlargement 0
of 0
suprapineal 0
recess 0
in 0
a 0
patient 0
with 0
triventricular 0
hydrocephalus 0
. 0

As 0
regards 0
lipid 0
metabolism 0
, 0
the 0
mean 0
values 0
for 0
total 0
triglycerides 0
, 0
cholesterol 0
, 0
LDL B-gene
- I-gene
cholesterol I-gene
and 0
HDL B-gene
- I-gene
cholesterol I-gene
seen 0
at 0
the 0
end 0
of 0
five 0
years 0
of 0
Norplant 0
- 0
2 0
rod 0
use 0
and 0
six 0
months 0
postremoval 0
were 0
similar 0
to 0
the 0
preinsertion 0
mean 0
. 0

At 0
a 0
PaCO2 0
of 0
40 0
mmHg 0
, 0
baseline 0
brain 0
pHi 0
measured 0
7.03 0
+/ 0
- 0
0.04 0
, 0
while 0
regional 0
cortical 0
blood 0
flow 0
was 0
47.0 0
+/ 0
- 0
4.3 0
ml.100 0
g 0
- 0
1.min 0
- 0
1 0
. 0

CPAP 0
reduced 0
isotime 0
( 0
defined 0
as 0
the 0
last 0
common 0
minute 0
of 0
exercise 0
) 0
VO2 0
and 0
dyspnea 0
in 0
those 0
patients 0
with 0
more 0
severe 0
lung 0
disease 0
, 0
but 0
these 0
values 0
tended 0
to 0
increase 0
slightly 0
in 0
the 0
patients 0
with 0
only 0
mild 0
lung 0
disease 0
. 0

Effects 0
of 0
diltiazem 0
on 0
netilmicin 0
- 0
induced 0
nephrotoxicity 0
in 0
rabbits 0
. 0

Four 0
forms 0
of 0
salmonellosis 0
were 0
recognised 0
in 0
feedlots 0
and 0
during 0
transport 0
by 0
sea 0
: 0
septicaemic 0
, 0
and 0
acute 0
, 0
subacute 0
and 0
chronic 0
enteric 0
. 0

About 0
20 0
% 0
of 0
single 0
- 0
stranded 0
DNA 0
binding 0
was 0
observed 0
in 0
the 0
presence 0
of 0
MgdTDP 0
, 0
but 0
none 0
was 0
detectable 0
in 0
the 0
absence 0
of 0
nucleotides 0
. 0

To 0
our 0
knowledge 0
this 0
is 0
the 0
first 0
case 0
in 0
which 0
a 0
probable 0
association 0
between 0
cholelithiasis 0
and 0
Wildervanck 0
's 0
syndrome 0
has 0
been 0
recorded 0
. 0

Both 0
4,8 0
- 0
DiMeIQx 0
and 0
A 0
alpha 0
C 0
were 0
found 0
at 0
< 0
1 0
p.p.b 0
. 0

Three 0
cysteine 0
and 0
four 0
tryptophan 0
residues 0
, 0
previously 0
identified 0
as 0
conserved 0
amongst 0
nitrous B-gene
- I-gene
oxide I-gene
reductases I-gene
, 0
are 0
found 0
in 0
the 0
Paracoccus 0
enzyme 0
. 0

Recombinant B-gene
Leishmania I-gene
surface I-gene
glycoprotein I-gene
GP63 I-gene
is 0
secreted 0
in 0
the 0
baculovirus 0
expression 0
system 0
as 0
a 0
latent 0
metalloproteinase B-gene
. 0

Delineating 0
the 0
molecular 0
basis 0
for 0
agonist 0
- 0
induced 0
destabilization 0
of 0
mRNA 0
of 0
G B-gene
- I-gene
protein I-gene
- I-gene
linked I-gene
receptors I-gene
that 0
contributes 0
to 0
receptor 0
down 0
- 0
regulation 0
is 0
fundamental 0
to 0
our 0
understanding 0
of 0
long 0
- 0
term 0
regulation 0
of 0
receptors 0
by 0
agonist 0
. 0

Addition 0
of 0
phalloidin 0
- 0
stabilized 0
F B-gene
- I-gene
actin I-gene
nuclei 0
and 0
phalloidin 0
restored 0
L266D 0
actin B-gene
's 0
ability 0
to 0
polymerize 0
at 0
4 0
degrees 0
C 0
. 0

These 0
cells 0
produce 0
a 0
low 0
level 0
of 0
IL B-gene
- I-gene
5 I-gene
when 0
stimulated 0
with 0
PMA 0
alone 0
; 0
however 0
, 0
N6 0
, 0
O2 0
- 0
dibutyryl 0
cAMP 0
( 0
Bt2cAMP 0
) 0
, 0
in 0
combination 0
with 0
PMA 0
, 0
augmented 0
by 0
more 0
than 0
tenfold 0
the 0
IL B-gene
- I-gene
5 I-gene
production 0
at 0
the 0
mRNA 0
and 0
the 0
protein 0
levels 0
. 0

Hu B-gene
- I-gene
Met I-gene
- I-gene
1 I-gene
mRNA I-gene
expression 0
in 0
a 0
small 0
number 0
of 0
human 0
T 0
cell 0
tumor 0
lines 0
did 0
not 0
correlate 0
with 0
any 0
particular 0
phenotype 0
or 0
stage 0
of 0
development 0
. 0

Partial 0
engorgement 0
was 0
higher 0
in 0
the 0
treatments 0
. 0

Northern 0
( 0
RNA 0
) 0
analysis 0
demonstrated 0
expression 0
of 0
human 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
in 0
all 0
tissues 0
and 0
cell 0
lines 0
tested 0
. 0

These 0
results 0
demonstrate 0
the 0
existence 0
of 0
different 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
isoforms I-gene
and 0
define 0
a 0
family 0
of 0
genes 0
encoding 0
distinct 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
catalytic I-gene
subunits I-gene
that 0
can 0
associate 0
with 0
p85 B-gene
. 0

In 0
addition 0
to 0
the 0
protein B-gene
- I-gene
tyrosine I-gene
kinase I-gene
domain I-gene
, 0
p56lck B-gene
possesses 0
Src B-gene
homology I-gene
2 I-gene
and I-gene
3 I-gene
( 0
SH2 B-gene
and 0
SH3 B-gene
) 0
domains 0
as 0
well 0
as 0
a 0
unique 0
N 0
- 0
terminal 0
region 0
. 0

Strains 0
bearing 0
the 0
drs2 B-gene
mutation I-gene
process 0
the 0
20S B-gene
precursor I-gene
of 0
the 0
mature B-gene
18S I-gene
rRNA I-gene
slowly 0
and 0
are 0
deficient 0
in 0
40S B-gene
ribosomal I-gene
subunits I-gene
. 0

Hepatitis 0
B 0
and 0
liver 0
transplantation 0
. 0

One 0
complex 0
most 0
likely 0
contained 0
Sp1 B-gene
, 0
and 0
another 0
complex 0
showed 0
S 0
- 0
phase 0
- 0
specific 0
binding 0
, 0
suggesting 0
a 0
direct 0
role 0
in 0
the 0
cell 0
- 0
cycle 0
- 0
dependent 0
R1 B-gene
gene I-gene
expression 0
. 0

These 0
combined 0
observations 0
define 0
a 0
promoter 0
and 0
an 0
enhancer 0
for 0
the 0
chicken B-gene
L I-gene
- I-gene
CAM I-gene
gene I-gene
. 0

The 0
rate 0
of 0
enzymic 0
stimulation 0
induced 0
by 0
a 0
given 0
nitrate 0
correlates 0
closely 0
with 0
the 0
rate 0
of 0
measured 0
NO 0
production 0
from 0
the 0
nitrate 0
molecule 0
. 0

Clipping 0
resulted 0
in 0
a 0
serious 0
mislocalization 0
of 0
the 0
position 0
of 0
the 0
peak 0
of 0
the 0
epicortical 0
potential 0
field 0
. 0

The 0
duration 0
of 0
diabetes 0
mellitus 0
in 0
these 0
patients 0
was 0
from 0
5 0
months 0
to 0
6 0
years 0
, 0
and 0
in 0
all 0
patients 0
this 0
was 0
the 0
first 0
myocardial 0
infarction 0
. 0

The 0
247 0
- 0
kDa 0
complex 0
appears 0
to 0
contain 0
two 0
distinct 0
protein 0
- 0
DNA 0
complexes 0
of 0
approximately 0
232 0
and 0
256 0
kDa 0
and 0
represents 0
two 0
proteins 0
covalently 0
cross 0
- 0
linked 0
to 0
a 0
single 0
DRE 0
oligonucleotide 0
, 0
while 0
the 0
97 0
, 0
105 0
, 0
and 0
115 0
- 0
kDa 0
complexes 0
represent 0
single 0
protein 0
- 0
DRE 0
cross 0
- 0
links 0
. 0

The 0
promoter 0
and 0
upstream 0
region 0
of 0
the 0
Brassica B-gene
napus I-gene
2S I-gene
storage I-gene
protein I-gene
napA I-gene
gene I-gene
were 0
studied 0
to 0
identify 0
cis 0
- 0
acting 0
sequences 0
involved 0
in 0
developmental 0
seed 0
- 0
specific 0
expression 0
. 0

However 0
, 0
limited 0
comparisons 0
reveal 0
domains 0
in 0
the 0
NH2 0
and 0
COOH 0
termini 0
that 0
have 0
a 0
high 0
degree 0
of 0
similarity 0
suggesting 0
functional 0
conservation 0
. 0

Rinit 0
reflects 0
the 0
Newtonian 0
resistances 0
and 0
Rdiff 0
represents 0
the 0
viscoelastic/inhomogeneous 0
pressure 0
dissipations 0
in 0
the 0
system 0
. 0

We 0
have 0
explored 0
the 0
mechanism 0
of 0
action 0
of 0
the 0
fibronectin B-gene
splicing I-gene
enhancer I-gene
and 0
found 0
that 0
the 0
SE 0
element 0
is 0
required 0
for 0
efficient 0
assembly 0
of 0
early 0
splicing 0
complexes 0
, 0
allowing 0
a 0
more 0
efficient 0
interaction 0
of 0
the 0
U2 B-gene
snRNP I-gene
with 0
branch 0
site 0
sequences 0
. 0

Inspection 0
of 0
enhancer 0
mutants 0
suggests 0
that 0
trans 0
- 0
activation 0
by 0
hLEF/GAL4 B-gene
is 0
especially 0
dependent 0
on 0
hLEF/GAL4 I-gene

We 0
conclude 0
that 0
sequences 0
outside 0
of 0
the 0
hLEF B-gene
HMG I-gene
box I-gene
mediate 0
cell 0
- 0
and 0
context 0
- 0
specific 0
activation 0
of 0
the 0
TCR B-gene
alpha I-gene
enhancer I-gene
and 0
may 0
facilitate 0
interactions 0
between 0
hLEF B-gene
and 0
other 0
T 0
- 0
cell 0
- 0
specific 0
factors 0
recruited 0
to 0
the 0
enhancer 0
. 0

A 0
cAMP 0
response 0
element 0
( 0
CRE 0
) 0
consensus 0
signal 0
was 0
identified 0
in 0
the 0
5' 0
- 0
noncoding 0
region 0
. 0
cAMP 0
regulates 0
the 0
expression 0
of 0
Kv1.5 B-gene
gene I-gene
in 0
a 0
cell 0
- 0
specific 0
manner 0
. 0

A 0
number 0
of 0
serological 0
tests 0
measuring 0
the 0
presence 0
of 0
Helicobacter 0
pylori 0
- 0
specific 0
serum 0
immunoglobulin B-gene
G I-gene
( 0
IgG B-gene
) 0
are 0
now 0
commercially 0
available 0
. 0

Using 0
a 0
series 0
of 0
mutant B-gene
T I-gene
antigens I-gene
expressed 0
by 0
recombinant 0
baculoviruses 0
in 0
Sf9 0
cells 0
, 0
we 0
find 0
that 0
the 0
origin 0
unwinding 0
activities 0
of 0
both 0
TS677 0
- 0
- 0
> 0
A 0
and 0
TS677,679 0
- 0
- 0
> 0
A 0
are 0
inhibited 0
by 0
the 0
T B-gene
- I-gene
antigen I-gene
kinase I-gene
, 0
as 0
is 0
wild B-gene
- I-gene
type I-gene
T I-gene
antigen I-gene
. 0

The 0
degree 0
of 0
hypoperfusion 0
was 0
slightly 0
related 0
to 0
decrease 0
in 0
FEV1.0 0
% 0
, 0
V25 0
and 0
PaO2 0
and 0
increase 0
in 0
circulating 0
blood 0
volume 0
and 0
peripheral 0
red 0
blood 0
cell 0
counts 0
. 0

Two 0
patients 0
were 0
treated 0
successfully 0
with 0
a 0
combination 0
of 0
metronidazole 0
( 0
a 0
tissue 0
amoebicide 0
) 0
and 0
diloxanide 0
( 0
a 0
lumenal 0
amoebicide 0
) 0
. 0

We 0
have 0
identified 0
in 0
the 0
5 0
' 0
untranslated 0
region 0
of 0
the 0
Drosophila B-gene
copia I-gene
retrotransposon I-gene
, 0
3 0
' 0
to 0
the 0
left 0
LTR 0
, 0
a 0
sequence 0
for 0
transcriptional 0
regulation 0
by 0
homeoproteins 0
. 0

In 0
the 0
present 0
study 0
, 0
lesions 0
of 0
the 0
OPT 0
complex 0
( 0
the 0
thalamic 0
source 0
of 0
afferents 0
to 0
IHA 0
and 0
HD 0
) 0
were 0
found 0
to 0
have 0
no 0
effect 0
on 0
color 0
- 0
reversal 0
learning 0
performance 0
. 0

The 0
fourth 0
dose 0
produced 0
favorable 0
results 0
( 0
66.7 0
% 0
) 0
in 0
individuals 0
with 0
HB B-gene
antibodies I-gene
between 0
10 0
and 0
100 0
IU/ml 0
and 0
unfavorable 0
ones 0
( 0
3.8 0
% 0
) 0
where 0
the 0
HB B-gene
antibodies I-gene
were 0
below 0
10 0
IU/ml 0
. 0

CONCLUSIONS 0
: 0
In 0
our 0
patients 0
and 0
within 0
the 0
range 0
of 0
treatment 0
variables 0
studied 0
, 0
age 0
, 0
Karnofsky 0
index 0
, 0
and 0
graft 0
- 0
versus 0
- 0
host 0
disease 0
are 0
the 0
most 0
important 0
factors 0
related 0
with 0
early 0
mortality 0
. 0

Nucleotide 0
sequence 0
analysis 0
of 0
the 0
HA B-gene
gene I-gene
in 0
these 0
two 0
mutants 0
confirmed 0
the 0
HA B-gene
- I-gene
phenotype 0
. 0

This 0
intron 0
occupies 0
a 0
conserved 0
position 0
corresponding 0
to 0
that 0
of 0
intron 0
1 0
in 0
the 0
transit 0
peptide 0
region 0
of 0
chloroplast B-gene
GAPDH I-gene
genes I-gene
( 0
GapA B-gene
and 0
GapB B-gene
) 0
of 0
higher 0
plants 0
. 0

The 0
drug 0
- 0
resistant 0
cell 0
lines 0
P388/ADR/3 0
and 0
P388/ADR/7 0
express 0
a 0
shortened 0
topo B-gene
II I-gene
alpha I-gene
mRNA I-gene
transcript I-gene
in 0
addition 0
to 0
the 0
native 0
transcript 0
present 0
in 0
the 0
drug 0
- 0
sensitive 0
P388/4 0
cell 0
line 0
. 0

Using 0
a 0
3' 0
- 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
strategy 0
, 0
we 0
have 0
cloned 0
cDNAs 0
representing 0
the 0
3' 0
- 0
termini 0
of 0
both 0
the 0
native 0
and 0
mutant 0
transcripts 0
from 0
both 0
P388/ADR/3 0
and 0
P388/ADR/7 0
cells 0
. 0

The 0
phi B-gene
AP3 I-gene
factor I-gene
is 0
a 0
nuclear 0
phosphoprotein 0
; 0
the 0
extent 0
of 0
its 0
phosphorylation 0
is 0
regulated 0
during 0
the 0
cell 0
cycle 0
. 0

Similarly 0
, 0
the 0
N 0
- 0
terminal 0
cytoplasmic 0
domain 0
of 0
the 0
latent B-gene
membrane I-gene
protein I-gene
2A I-gene
( 0
LMP2A B-gene
) 0
of 0
the 0
Epstein 0
- 0
Barr 0
virus 0
( 0
EBV 0
) 0
contains 0
a 0
single 0
copy 0
of 0
the 0
Tyr 0
- 0
X 0
- 0
X 0
- 0
Leu/Ile 0
- 0
containing 0
motif 0
which 0
could 0
play 0
a 0
critical 0
role 0
in 0
B 0
cell 0
transformation 0
. 0

The 0
functional 0
homology 0
of 0
Cwg2 B-gene
with 0
Cdc43 B-gene
, 0
which 0
has 0
been 0
implicated 0
in 0
the 0
control 0
of 0
cell 0
polarity 0
, 0
suggests 0
a 0
link 0
between 0
two 0
morphogenetic 0
events 0
such 0
as 0
establishment 0
of 0
cell 0
polarity 0
and 0
cell 0
wall 0
biosynthesis 0
. 0

Molecular 0
cloning 0
of 0
a 0
P B-gene
- I-gene
type I-gene
ATPase I-gene
gene I-gene
from 0
the 0
cyanobacterium 0
Synechocystis 0
sp 0
. 0

The 0
cloning 0
of 0
PTR2 B-gene
represents 0
the 0
first 0
example 0
of 0
the 0
molecular 0
genetic 0
characterization 0
of 0
a 0
eucaryotic 0
peptide 0
transport 0
gene 0
. 0

By 0
using 0
the 0
full 0
- 0
length 0
cytoplasmic 0
domain 0
and 0
mutants 0
with 0
progressive 0
carboxy 0
- 0
terminal 0
deletions 0
, 0
internal 0
deletions 0
, 0
or 0
point 0
mutations 0
, 0
we 0
identified 0
the 0
first 0
150 0
amino 0
acid 0
residues 0
of 0
LIFR B-gene
as 0
the 0
minimal 0
region 0
necessary 0
for 0
signaling 0
. 0

To 0
examine 0
the 0
biochemical 0
basis 0
of 0
the 0
end 0
joining 0
, 0
nuclear 0
extracts 0
were 0
prepared 0
from 0
a 0
wide 0
variety 0
of 0
mammalian 0
cell 0
lines 0
and 0
tested 0
for 0
their 0
ability 0
to 0
join 0
test 0
plasmid 0
substrates 0
. 0

These 0
data 0
indicate 0
that 0
the 0
largest 0
subunit 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
and 0
TFIIB B-gene
are 0
important 0
determinants 0
of 0
transcription 0
start 0
site 0
selection 0
in 0
S. 0
cerevisiae 0
and 0
suggest 0
that 0
this 0
function 0
might 0
be 0
conferred 0
by 0
interaction 0
between 0
these 0
two 0
proteins 0
. 0

Recombinant 0
expression 0
of 0
a 0
chimeric 0
EGFR/ErbB B-gene
EGFR/ErbB I-gene
- I-gene
3 I-gene
receptor I-gene
in 0
NIH 0
3T3 0
fibroblasts 0
allowed 0
us 0
to 0
investigate 0
cytoplasmic 0
events 0
associated 0
with 0
ErbB B-gene
- I-gene
3 I-gene
signal 0
transduction 0
upon 0
ligand 0
activation 0
. 0

Oligonucleotide 0
competitors 0
were 0
used 0
to 0
evaluate 0
the 0
accessibility 0
of 0
the 0
TATA 0
- 0
binding 0
site 0
in 0
TIF B-gene
- I-gene
IB I-gene
, 0
TFIID B-gene
, 0
and 0
TFIIIB B-gene
. 0

The 0
227 0
- 0
to 0
- 0
239 0
region 0
blocked 0
ADR1 B-gene
activity 0
independently 0
of 0
the 0
TAD B-gene
present 0
on 0
ADR1 B-gene
, 0
ADR1 B-gene
DNA 0
binding 0
, 0
and 0
specific 0
ADH2 B-gene
promoter I-gene
sequences I-gene
. 0

Analysis 0
of 0
strains 0
harboring 0
an 0
mds1 B-gene
null I-gene
mutation I-gene
demonstrates 0
that 0
MDS1 B-gene
is 0
not 0
essential 0
during 0
normal 0
vegetative 0
growth 0
but 0
appears 0
to 0
be 0
required 0
for 0
meiosis 0
. 0

TGF B-gene
beta I-gene
1 I-gene
expression 0
is 0
largely 0
governed 0
by 0
three 0
AP B-gene
- I-gene
1 I-gene
binding I-gene
sites I-gene
located 0
in 0
two 0
different 0
promoters 0
of 0
this 0
gene 0
. 0

Val 0
- 0
- 0
> 0
Ala 0
mutations 0
selectively 0
alter 0
helix 0
- 0
helix 0
packing 0
in 0
the 0
transmembrane 0
segment 0
of 0
phage B-gene
M13 I-gene
coat I-gene
protein I-gene
. 0

Strategic 0
change 0
in 0
the 0
NHS 0
. 0

A 0
much 0
less 0
expensive 0
solution 0
than 0
UW 0
, 0
containing 0
only 0
K 0
( 0
+ 0
) 0
- 0
lactobionate 0
, 0
KH2PO4 0
, 0
MgSO4 0
and 0
raffinose 0
, 0
can 0
be 0
used 0
successfully 0
for 0
preservation 0
of 0
rat 0
hepatocytes 0
for 0
24 0
hr 0
for 0
drug 0
transport 0
studies 0
. 0

Repeated 0
administration 0
of 0
GRg2 0
20 0
mg/kg 0
i.p 0
. 0
significantly 0
improved 0
the 0
CYP 0
- 0
induced 0
recognitional 0
deficits 0
by 0
increasing 0
the 0
CYP 0
- 0
decreased 0
rate 0
from 0
55.8 0
+/ 0
- 0
9.6 0
to 0
80.8 0
+/ 0
- 0
4.2 0
in 0
d 0
3 0
learning 0
acquisition 0
( 0
F 0
( 0
1,14 0
) 0
= 0
5.6 0
, 0
p 0
< 0
0.05 0
) 0
, 0
from 0
53.4 0
+/ 0
- 0
8.4 0
to 0
60.0 0
+/ 0
- 0
8.2 0
in 0
48 0
h 0
memory 0
acquisition 0
( 0
F 0
( 0
1,14 0
) 0
= 0
7.5 0
, 0
p 0
< 0
0.05 0
) 0
and 0
from 0
55.0 0
+/ 0
- 0
5.5 0
to 0
88.3 0
+/ 0
- 0
2.5 0
in 0
24 0
h 0
memory 0
retention 0
( 0
F 0
( 0
1,12 0
) 0
27.5 0
, 0
p 0
< 0
0.01 0
) 0
as 0
well 0
as 0
from 0
60.0 0
+/ 0
- 0
6.8 0
to 0
85.6 0
+/ 0
- 0
6.9 0
in 0
48 0
h 0
memory 0
retrieval 0
( 0
F 0
( 0
1,12 0
) 0
= 0
5.2 0
, 0
p 0
< 0
0.05 0
) 0
, 0
respectively 0
. 0

Human B-gene
bcl3 I-gene
protein I-gene
specifically 0
displaces 0
( B-gene
p50 I-gene
) I-gene
2 I-gene
- I-gene
DNA I-gene
complexes I-gene
. 0

The 0
therapeutic 0
action 0
of 0
cyclosporin 0
A 0
( 0
Sandimmun 0
) 0
: 0
its 0
application 0
in 0
rheumatoid 0
arthritis 0
. 0

In 0
vitro 0
translation 0
experiments 0
show 0
that 0
human 0
cDNA 0
derived 0
RNA 0
translates 0
into 0
a 0
protein 0
with 0
a 0
mobility 0
of 0
44 0
- 0
46 0
kD 0
on 0
SDS 0
polyacrylamide 0
gels 0
. 0

After 0
peripheral 0
administration 0
of 0
both 0
CRF B-gene
and 0
TRH B-gene
, 0
ACTH B-gene
levels 0
were 0
significantly 0
higher 0
on 0
the 0
tumor 0
side 0
in 0
all 0
patients 0
. 0

Pentazocine 0
analgesia 0
: 0
is 0
there 0
a 0
niche 0
for 0
Talwin 0
Nx 0
? 0
Pentazocine 0
can 0
be 0
a 0
useful 0
analgesic 0
agent 0
for 0
the 0
management 0
of 0
acute 0
dental 0
pain 0
. 0

A 0
sequence 0
homology 0
analysis 0
between 0
human B-gene
nm23 I-gene
- I-gene
H1 I-gene
and 0
the 0
homolog 0
gene 0
of 0
the 0
rat 0
( 0
NDP B-gene
- I-gene
K I-gene
beta I-gene
) 0
shows 0
that 0
exon 0
- 0
intron 0
boundaries 0
are 0
well 0
conserved 0
between 0
these 0
two 0
species 0
. 0

A 0
favourable 0
response 0
was 0
achieved 0
with 0
a 0
combination 0
of 0
amphotericin 0
B 0
and 0
cotrimoxazole 0
. 0

Response 0
durations 0
were 0
short 0
. 0

RESULTS 0
: 0
At 0
the 0
beginning 0
of 0
the 0
QA/QI 0
process 0
, 0
monitoring 0
of 0
blood 0
administration 0
practices 0
revealed 0
that 0
a 0
variance 0
from 0
institutional 0
blood 0
administration 0
policy 0
occurred 0
during 0
50 0
percent 0
of 0
blood 0
and 0
component 0
transfusions 0
. 0

In 0
addition 0
, 0
REP21 0
plants 0
were 0
resistant 0
to 0
an 0
unusually 0
broad 0
range 0
of 0
tobamoviruses 0
including 0
tomato 0
mosaic 0
virus 0
, 0
tobacco 0
mild 0
green 0
mosaic 0
virus 0
, 0
TMV 0
- 0
U5 0
, 0
green 0
tomato 0
atypical 0
mosaic 0
virus 0
, 0
and 0
ribgrass 0
mosaic 0
virus 0
. 0

Drug 0
effect 0
, 0
measured 0
as 0
postural 0
sway 0
, 0
was 0
also 0
similar 0
in 0
the 0
patients 0
with 0
cirrhosis 0
and 0
control 0
subjects 0
; 0
therefore 0
the 0
ratio 0
of 0
effect 0
area 0
under 0
the 0
curve 0
to 0
concentration 0
area 0
under 0
the 0
curve 0
, 0
a 0
measure 0
of 0
sensitivity 0
, 0
did 0
not 0
differ 0
significantly 0
between 0
the 0
patients 0
with 0
cirrhosis 0
and 0
the 0
control 0
subjects 0
. 0

We 0
present 0
evidence 0
that 0
YY1 B-gene
, 0
a 0
ubiquitously 0
expressed 0
DNA 0
- 0
binding 0
protein 0
, 0
regulates 0
the 0
activity 0
of 0
the 0
c B-gene
- I-gene
fos I-gene
promoter I-gene
primarily 0
through 0
an 0
effect 0
on 0
DNA 0
structure 0
. 0

In 0
a 0
retrospective 0
analysis 0
of 0
first 0
- 0
time 0
total 0
colonoscopies 0
in 0
685 0
patients 0
, 0
we 0
investigated 0
the 0
relationship 0
between 0
hyperplastic 0
and 0
adenomatous 0
polyps 0
. 0

The 0
rate 0
of 0
decrement 0
in 0
DPOAE 0
amplitude 0
over 0
a 0
prescribed 0
time 0
period 0
was 0
utilized 0
as 0
a 0
measure 0
of 0
susceptibility 0
to 0
the 0
acoustic 0
trauma 0
. 0

Effect 0
of 0
single 0
base 0
substitutions 0
at 0
glycine 0
- 0
870 0
codon 0
of 0
gramicidin B-gene
S I-gene
synthetase I-gene
2 I-gene
gene I-gene
on 0
proline 0
activation 0
. 0

The 0
predicted 0
Pay4p B-gene
sequence I-gene
contains 0
two 0
putative 0
ATP 0
- 0
binding 0
domains 0
and 0
shows 0
structural 0
relationships 0
to 0
other 0
potential 0
ATP B-gene
- I-gene
binding I-gene
proteins I-gene
involved 0
in 0
biological 0
processes 0
as 0
diverse 0
as 0
peroxisome 0
biogenesis 0
, 0
vesicle 0
- 0
mediated 0
protein 0
transport 0
, 0
cell 0
cycle 0
control 0
, 0
and 0
transcriptional 0
regulation 0
. 0

The 0
results 0
show 0
that 0
the 0
structure 0
of 0
the 0
decorin B-gene
gene I-gene
promoter I-gene
is 0
different 0
from 0
that 0
of 0
any 0
other 0
proteoglycan 0
promoter 0
characterized 0
so 0
far 0
and 0
indicate 0
that 0
the 0
pur/pyr 0
segment 0
plays 0
a 0
role 0
in 0
the 0
regulation 0
of 0
gene 0
transcription 0
. 0

The 0
kinase 0
inhibitor 0
staurosporine 0
( 0
1 0
microM 0
) 0
blocks 0
LPA 0
- 0
induced 0
, 0
but 0
not 0
epidermal 0
growth 0
factor 0
- 0
induced 0
, 0
activation 0
of 0
p21ras B-gene
and 0
MAP B-gene
kinase I-gene
, 0
consistent 0
with 0
an 0
intermediate 0
protein 0
kinase 0
linking 0
the 0
LPA B-gene
receptor I-gene
to 0
p21ras B-gene
activation 0
. 0

267 0
, 0
4870 0
- 0
4877 0
) 0
) 0
indicates 0
an 0
overall 0
identity 0
of 0
58 0
and 0
56 0
% 0
, 0
respectively 0
, 0
with 0
a 0
91 0
and 0
92 0
% 0
identity 0
in 0
the 0
highly 0
conserved 0
transmembrane 0
and 0
cytoplasmic 0
domains 0
. 0

S. 0
, 0
K 0
. 0

The 0
survival 0
rate 0
at 0
forty 0
months 0
in 0
15 0
patients 0
with 0
N2 0
disease 0
who 0
underwent 0
R2b 0
operation 0
was 0
51 0
% 0
. 0

Mothers 0
with 0
severe 0
anatomical 0
abnormalities 0
, 0
who 0
are 0
HIV 0
positive 0
, 0
have 0
active 0
TB 0
or 0
whose 0
children 0
have 0
inherited 0
mono 0
- 0
or 0
disaccharide 0
intolerances 0
should 0
not 0
breastfeed 0
. 0

G 0
. 0

The 0
psaD B-gene
, 0
psaF B-gene
, 0
psaH B-gene
, 0
and 0
psaL B-gene
products I-gene
have 0
two 0
isoforms 0
each 0
that 0
are 0
distinguished 0
by 0
different 0
mobilities 0
in 0
polyacrylamide 0
gel 0
electrophoresis 0
, 0
and 0
the 0
psaE B-gene
product I-gene
has 0
four 0
isoforms 0
. 0

When 0
Hy 0
- 0
Vac 0
SPF 0
type 0
V 0
embryos 0
were 0
exposed 0
to 0
either 0
0.20 0
ml 0
50 0
% 0
ethanol 0
in 0
CRS 0
or 0
to 0
0.20 0
ml 0
CRS 0
( 0
controls 0
) 0
, 0
ethanol 0
- 0
treated 0
embryos 0
showed 0
a 0
VSD 0
incidence 0
of 0
34.1 0
% 0
compared 0
with 0
a 0
3.6 0
% 0
incidence 0
in 0
the 0
controls 0
( 0
P 0
= 0
0.0017 0
) 0
. 0

Peripheral 0
vitreochorioretinal 0
dystrophies 0
in 0
myopia 0
patients 0

In 0
our 0
studies 0
, 0
we 0
utilized 0
HIV 0
- 0
1 0
HXB2 B-gene
and 0
HIV 0
- 0
1 0
Z2Z6 B-gene
core I-gene
enhancers I-gene
because 0
the 0
Z2Z6 B-gene
strain 0
has 0
a 0
single 0
point 0
mutation 0
flanking 0
the 0
right 0
ETS B-gene
- I-gene
binding I-gene
site I-gene
. 0

The 0
secondary 0
, 0
but 0
not 0
the 0
primary 0
, 0
antibody 0
responses 0
of 0
male 0
C57Bl/6 0
mice 0
were 0
higher 0
among 0
mice 0
housed 0
alone 0
compared 0
to 0
mice 0
housed 0
in 0
groups 0
; 0
differences 0
were 0
observed 0
for 0
both 0
IgM B-gene
and 0
IgG B-gene
anti I-gene
- I-gene
KLH I-gene
antibodies I-gene
. 0

However 0
, 0
a 0
surprisingly 0
high 0
degree 0
of 0
conservation 0
of 0
intron 0
sequences 0
was 0
observed 0
between 0
both 0
species 0
. 0

Interleukin B-gene
- I-gene
6 I-gene
may 0
possibly 0
potentiate 0
metastasis 0
of 0
cardiac 0
myxoma 0
. 0

Other 0
parameters 0
of 0
iron 0
metabolism 0
, 0
including 0
ferritin B-gene
, 0
were 0
not 0
found 0
to 0
contribute 0
to 0
the 0
risk 0
. 0

Responses 0
to 0
the 0
Plowright 0
Rinderpest 0
vaccine 0
by 0
43 0
calves 0
and 0
70 0
adult 0
cattle 0
in 0
Uganda 0
in 0
1990 0
, 0
through 0
the 0
production 0
of 0
IgG B-gene
antibodies I-gene
, 0
were 0
monitored 0
for 0
4 0
weeks 0
using 0
the 0
ELISA 0
assay 0
. 0

Because 0
of 0
the 0
small 0
number 0
of 0
visceral 0
angiography 0
procedures 0
performed 0
( 0
38 0
) 0
, 0
no 0
definitive 0
conclusions 0
could 0
be 0
drawn 0
as 0
to 0
the 0
differences 0
between 0
ionic 0
and 0
nonionic 0
agents 0
regarding 0
grade 0
- 0
2 0
and 0
grade 0
- 0
3 0
adverse 0
events 0
. 0

Tumours 0
of 0
the 0
cavum 0
oris 0
and 0
oropharynx 0
of 0
T1 0
- 0
stage 0
are 0
possible 0
only 0
in 0
1 0
of 0
3 0
cases 0
. 0

Thomas 0
' 0
Hospital 0
solution 0
( 0
with 0
95 0
% 0
O2:5 0
% 0
CO2 0
) 0
can 0
meet 0
the 0
metabolic 0
demand 0
of 0
the 0
ischaemic 0
myocardium 0
and 0
thus 0
increase 0
the 0
safe 0
duration 0
of 0
cardiac 0
arrest 0
. 0

Plasma 0
, 0
LDL B-gene
and 0
liver 0
cholesterol 0
concentrations 0
were 0
higher 0
in 0
the 0
hyperlipidemic 0
control 0
than 0
the 0
nonhyperlipidemic 0
control 0
and 0
lower 0
in 0
the 0
groups 0
fed 0
diets 0
containing 0
pectin B-gene
or 0
prune 0
fiber 0
than 0
in 0
the 0
hyperlipidemic 0
control 0
group 0
. 0

The 0
Stryker 0
frame 0
modification 0
to 0
the 0
standard 0
Dornier 0
HM3 0
lithotriptor 0
allows 0
for 0
improved 0
visualization 0
and 0
easier 0
localization 0
of 0
distal 0
ureteral 0
calculi 0
compared 0
to 0
the 0
standard 0
gantry 0
. 0

Glomerular 0
mesangial 0
cells 0
expressed 0
an 0
abundant 0
1.1 0
kb 0
mRNA 0
transcript 0
for 0
Id1 B-gene
, 0
but 0
in 0
contrast 0
to 0
other 0
cell 0
types 0
Id1 B-gene
mRNA I-gene
was 0
expressed 0
in 0
both 0
randomly 0
cycling 0
cells 0
and 0
in 0
serum 0
- 0
deprived 0
, 0
quiescent 0
cultures 0
. 0

Routine 0
psychometric 0
screening 0
of 0
IHD 0
patients 0
may 0
provide 0
a 0
cost 0
- 0
effective 0
means 0
of 0
alerting 0
cardiologists 0
and 0
internists 0
to 0
the 0
relatively 0
high 0
levels 0
of 0
distress 0
among 0
their 0
patients 0
. 0

A 0
single 0
1.8 0
- 0
kb 0
transcript 0
mRNA 0
was 0
detected 0
by 0
Northern 0
( 0
RNA 0
) 0
blot 0
analysis 0
, 0
and 0
its 0
5 0
' 0
end 0
maps 0
to 0
a 0
position 0
51 0
bp 0
upstream 0
from 0
the 0
site 0
of 0
initiation 0
of 0
protein 0
synthesis 0
. 0

Employing 0
this 0
sequence 0
information 0
from 0
c11/1 0
, 0
the 0
c11/1 0
- 0
specific 0
cDNA 0
was 0
generated 0
from 0
poly 0
( 0
A 0
) 0
+RNA 0
of 0
bovine 0
PMNLs 0
by 0
reverse 0
transcription 0
and 0
a 0
combination 0
of 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
methods 0
. 0

The 0
sequence 0
similarity 0
has 0
suggested 0
that 0
SCG10 B-gene
and 0
stathmin B-gene
have 0
been 0
derived 0
from 0
structurally 0
and 0
evolutionarily 0
related 0
genes 0
. 0

These 0
data 0
are 0
consistent 0
with 0
the 0
idea 0
that 0
the 0
neuron B-gene
- I-gene
specific I-gene
SCG10 I-gene
gene I-gene
evolved 0
by 0
duplication 0
and 0
modification 0
of 0
the 0
more 0
broadly 0
expressed 0
stathmin/Lap18 B-gene
gene 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
of 0
the 0
mouse B-gene
HO I-gene
- I-gene
1 I-gene
gene I-gene
is 0
identical 0
to 0
that 0
of 0
p32 B-gene
, 0
initially 0
identified 0
as 0
a 0
stress 0
- 0
induced 0
protein 0
in 0
mouse 0
BALBc/3T3 0
cells 0
. 0

We 0
found 0
that 0
T3 0
( 0
10 0
( 0
- 0
8 0
) 0
M 0
) 0
selectively 0
stimulates 0
transcription 0
from 0
rGH B-gene
- 0
TRE 0
- 0
and 0
TREpal 0
- 0
, 0
but 0
not 0
ME 0
- 0
TRE 0
- 0
and 0
F2 0
- 0
TRE 0
- 0
, 0
containing 0
templates 0
in 0
which 0
these 0
TREs 0
are 0
linked 0
in 0
front 0
of 0
the 0
rGH B-gene
minimal I-gene
promoter I-gene
containing 0
only 0
the 0
TATA B-gene
box I-gene
binding I-gene
protein I-gene
, 0
but 0
not 0
any 0
other 0
proximal 0
binding 0
protein 0
, 0
sequence 0
. 0

Using 0
a 0
polymerase 0
chain 0
reaction 0
- 0
based 0
approach 0
, 0
we 0
cloned 0
a 0
150 0
- 0
base 0
pair 0
fragment 0
of 0
a 0
new 0
sialymotif 0
from 0
human 0
placenta 0
mRNA 0
, 0
which 0
was 0
then 0
used 0
as 0
a 0
probe 0
to 0
clone 0
the 0
complete 0
coding 0
sequence 0
of 0
the 0
corresponding 0
gene 0
from 0
a 0
cDNA 0
library 0
. 0

The 0
structural 0
analysis 0
also 0
demonstrated 0
that 0
the 0
heterogeneity 0
of 0
the 0
HDC B-gene
mRNA I-gene
is 0
caused 0
by 0
an 0
insertion 0
of 0
the 0
seventh 0
intron 0
sequence 0
and 0
alternative 0
use 0
of 0
the 0
splicing 0
acceptor 0
site 0
at 0
the 0
12th 0
exon 0
. 0

A 0
complementary 0
DNA 0
was 0
isolated 0
from 0
Caenorhabditis 0
elegans 0
that 0
encoded 0
a 0
polypeptide 0
of 0
1438 0
amino 0
acid 0
residues 0
, 0
CeGAP B-gene
, 0
which 0
contains 0
a 0
domain 0
with 0
sequence 0
similarity 0
to 0
the 0
COOH B-gene
- I-gene
terminal I-gene
segment I-gene
( I-gene
GTPase I-gene
- I-gene
activating I-gene
protein I-gene
region I-gene
) I-gene
of 0
Bcr B-gene
and 0
other 0
known 0
GTPase B-gene
- I-gene
activating I-gene
proteins I-gene
of 0
the 0
Rho B-gene
subfamily I-gene
. 0

Additional 0
exonuclease B-gene
III I-gene
protection 0
was 0
observed 0
beyond 0
the 0
core 0
region 0
on 0
both 0
the 0
5 0
' 0
and 0
3 0
' 0
sides 0
, 0
suggesting 0
that 0
E1 B-gene
interacted 0
with 0
more 0
distal 0
sequences 0
as 0
well 0
. 0

Repression 0
is 0
alleviated 0
when 0
the 0
two 0
( 0
for 0
E2 B-gene
) 0
or 0
three 0
( 0
for 0
E2 B-gene
- I-gene
C I-gene
) 0
promoter 0
- 0
proximal 0
copies 0
of 0
E2 B-gene
- 0
RS 0
are 0
mutated 0
. 0

A 0
mutant 0
in 0
the 0
AAV 0
terminal 0
resolution 0
site 0
( 0
trs 0
) 0
was 0
defective 0
for 0
DNA 0
replication 0
in 0
the 0
in 0
vitro 0
assay 0
. 0

The 0
results 0
indicate 0
that 0
rep B-gene
strongly 0
enhances 0
the 0
function 0
of 0
negative 0
regulatory 0
elements 0
of 0
the 0
LTR 0
. 0

However 0
, 0
artificially 0
ventilated 0
rats 0
, 0
pretreated 0
with 0
MK 0
- 0
801 0
, 0
were 0
more 0
sensitive 0
( 0
lethal 0
cocaine 0
dose 0
, 0
76.6 0
+/ 0
- 0
8.0 0
mg/kg 0
, 0
n 0
= 0
5 0
) 0
than 0
vehicle 0
pretreated 0
rats 0
( 0
129.4 0
+/ 0
- 0
15.8 0
mg/kg 0
, 0
n 0
= 0
6 0
) 0
, 0
indicating 0
that 0
MK 0
- 0
801 0
may 0
increase 0
both 0
the 0
respiratory 0
and 0
the 0
cardiac 0
toxicity 0
of 0
cocaine 0
in 0
urethane 0
anesthetized 0
rats 0
. 0

The 0
Oct B-gene
- I-gene
3/4 I-gene
gene I-gene
product I-gene
, 0
which 0
belongs 0
to 0
the 0
POU B-gene
family I-gene
of I-gene
transcription I-gene
factors I-gene
, 0
is 0
a 0
good 0
candidate 0
for 0
regulating 0
initial 0
differentiation 0
decisions 0
. 0

Using 0
site 0
- 0
directed 0
mutagenesis 0
, 0
we 0
show 0
that 0
the 0
RAREoct B-gene
contributes 0
to 0
the 0
transcriptional 0
activation 0
of 0
Oct B-gene
- I-gene
3/4 I-gene
promoter I-gene
in 0
P19 0
cells 0
and 0
, 0
most 0
interestingly 0
, 0
mediates 0
the 0
RA 0
- 0
induced 0
repression 0
in 0
RA 0
- 0
differentiated 0
EC 0
cells 0
. 0

176:787 0
- 0
792 0
, 0
1992 0
; 0
M 0
. 0

Furthermore 0
, 0
the 0
negative 0
transcriptional 0
effect 0
of 0
COUP B-gene
- I-gene
TFs I-gene
is 0
dominant 0
over 0
the 0
activating 0
effect 0
of 0
the 0
Oct4 B-gene
embryonic I-gene
stem I-gene
cell I-gene
- I-gene
specific I-gene
enhancer I-gene
. 0

Analysis 0
of 0
mig/CAT B-gene
chimeric 0
constructs 0
transiently 0
transfected 0
into 0
the 0
RAW 0
264.7 0
mouse 0
monocytic 0
cell 0
line 0
revealed 0
a 0
unique 0
mig/CAT I-gene

When 0
expressed 0
alone 0
in 0
test 0
cells 0
, 0
Atr B-gene
- I-gene
I I-gene
is 0
unable 0
to 0
bind 0
TGF B-gene
- I-gene
beta I-gene
, 0
activin B-gene
, 0
or 0
bone B-gene
morphogenetic I-gene
protein I-gene
2 I-gene
. 0

Therefore 0
, 0
Mxi1 B-gene
and 0
Mad B-gene
might 0
antagonize 0
Myc B-gene
function 0
and 0
are 0
candidate 0
tumor 0
suppressor 0
genes 0
. 0

To 0
our 0
knowledge 0
, 0
type 0
IV 0
renal 0
tubular 0
acidosis 0
has 0
not 0
been 0
reported 0
previously 0
in 0
association 0
with 0
Alport 0
's 0
syndrome 0
in 0
an 0
adult 0
patient 0
. 0

A 0
cDNA 0
clone 0
was 0
isolated 0
from 0
a 0
chicken 0
embryo 0
cDNA 0
library 0
employing 0
a 0
PCR 0
- 0
generated 0
radiolabeled 0
probe 0
specific 0
for 0
the 0
U3 B-gene
region I-gene
of 0
the 0
Rous B-gene
sarcoma I-gene
virus I-gene
LTR I-gene
. 0

Two 0
basic 0
patterns 0
of 0
locomotor 0
behavior 0
and 0
corresponding 0
torso 0
morphology 0
exist 0
among 0
extant 0
anthropoids 0
. 0

Animal 0
age 0
and 0
sex 0
had 0
no 0
significant 0
effects 0
on 0
CSF 0
composition 0
, 0
but 0
serum 0
IgG B-gene
concentration 0
increased 0
with 0
age 0
. 0

Fast 0
continuous 0
expansion 0
. 0

A 0
randomized 0
, 0
multicenter 0
study 0
comparing 0
the 0
efficacy 0
and 0
tolerability 0
of 0
tropisetron 0
, 0
a 0
new 0
5 B-gene
- I-gene
HT3 I-gene
receptor I-gene
antagonist 0
, 0
with 0
a 0
metoclopramide 0
- 0
containing 0
antiemetic 0
cocktail 0
in 0
the 0
prevention 0
of 0
cisplatin 0
- 0
induced 0
emesis 0
. 0

Each 0
repeat 0
consists 0
of 0
12 0
nt 0
, 0
coding 0
for 0
the 0
reiterated 0
sequence 0
, 0
K/NPAG 0
. 0

ENV B-gene
also 0
was 0
secreted 0
from 0
P. 0
pastoris 0
using 0
the 0
S. B-gene
cerevisiae I-gene
alpha I-gene
- I-gene
factor I-gene
prepro I-gene
secretion I-gene
leader I-gene
and 0
the 0
S. B-gene
cerevisiae I-gene
invertase I-gene
signal I-gene
sequence I-gene
. 0

BACKGROUND 0
: 0
To 0
determine 0
the 0
predictors 0
of 0
desipramine 0
- 0
refractory 0
depression 0
, 0
the 0
authors 0
examined 0
the 0
outcome 0
in 0
patients 0
with 0
major 0
depression 0
who 0
were 0
admitted 0
to 0
a 0
general 0
hospital 0
and 0
treated 0
with 0
desipramine 0
adjusted 0
to 0
an 0
adequate 0
blood 0
level 0
. 0

Analysis 0
of 0
the 0
intact 0
hGH B-gene
gene I-gene
or 0
hGH B-gene
5' I-gene
- I-gene
flanking I-gene
DNA I-gene
( I-gene
5' I-gene
- I-gene
FR I-gene
) I-gene
coupled 0
to 0
the 0
hGh B-gene
cDNA I-gene
or 0
chloramphenicol B-gene
acetyltransferase I-gene
or 0
luciferase B-gene
genes I-gene
, 0
indicated 0
that 0
cAMP 0
primarily 0
stimulated 0
hGH B-gene
promoter I-gene
activity 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
of 0
the 0
SAP B-gene
- I-gene
1 I-gene
cDNA I-gene
showed 0
that 0
mature B-gene
SAP I-gene
- I-gene
1 I-gene
consisted 0
of 0
1093 0
amino 0
acids 0
and 0
a 0
transmembrane B-gene
- I-gene
type I-gene
PTP I-gene
, 0
which 0
possessed 0
a 0
single 0
PTP B-gene
- I-gene
conserved I-gene
domain I-gene
in 0
the 0
cytoplasmic 0
region 0
. 0

The 0
following 0
evidence 0
indicates 0
that 0
the 0
69 0
- 0
kD 0
protein 0
is 0
a 0
common 0
, 0
rather 0
than 0
a 0
U1 B-gene
- 0
specific 0
, 0
protein 0
, 0
possibly 0
associating 0
with 0
the 0
snRNP 0
core 0
particles 0
by 0
protein 0
- 0
protein 0
interaction 0
. 0

Several 0
features 0
of 0
10.24.6 0
cells 0
suggest 0
that 0
the 0
mutation 0
disrupts 0
normal 0
intracellular 0
formation 0
of 0
peptide/DR B-gene
complexes I-gene
. 0

This 0
distribution 0
parallels 0
that 0
of 0
the 0
neurotransmitters 0
glutamate 0
and 0
aspartate 0
; 0
however 0
, 0
neither 0
of 0
these 0
excitatory 0
amino 0
acids 0
is 0
a 0
substrate 0
for 0
transport 0
. 0

The 0
Harleco 0
apparatus 0
is 0
a 0
simple 0
, 0
useful 0
, 0
cost 0
- 0
effective 0
adjunct 0
to 0
the 0
diagnosis 0
and 0
treatment 0
of 0
this 0
life 0
- 0
threatening 0
condition 0
. 0

Co 0
- 0
transfection 0
of 0
expression 0
vectors 0
for 0
CCAAT/enhancer B-gene
binding I-gene
protein I-gene
( I-gene
C/EBP I-gene
) I-gene
alpha I-gene
and 0
C/EBP B-gene
beta I-gene
trans 0
- 0
activated 0
the 0
rat B-gene
uncoupling I-gene
protein I-gene
gene I-gene
promoter I-gene
due 0
to 0
sequences 0
in 0
the 0
5 0
' 0
proximal 0
region 0
. 0

It 0
was 0
not 0
possible 0
to 0
study 0
the 0
basis 0
for 0
tissue 0
- 0
specific 0
expression 0
of 0
this 0
gene 0
, 0
because 0
the 0
beta B-gene
3 I-gene
gene I-gene
promoter I-gene
had 0
not 0
been 0
isolated 0
previously 0
. 0

Isolation 0
and 0
characterization 0
of 0
a 0
TATA 0
- 0
less 0
promoter 0
for 0
the 0
human B-gene
beta I-gene
3 I-gene
integrin I-gene
gene I-gene
. 0

Subretinal 0
fluid 0
was 0
punctured 0
on 0
the 0
poorer 0
eye 0
in 0
19 0
eyes 0
( 0
52.7 0
% 0
) 0
and 0
on 0
the 0
better 0
eye 0
in 0
7 0
eyes 0
( 0
19.4 0
% 0
) 0
. 0

These 0
data 0
indicate 0
that 0
activation 0
of 0
these 0
enzymes 0
is 0
not 0
sufficient 0
for 0
the 0
acute 0
stimulation 0
of 0
glucose 0
transport 0
. 0

The 0
inserted 0
region 0
, 0
which 0
represents 0
an 0
intron 0
in 0
brain 0
and 0
muscle 0
, 0
is 0
expressed 0
in 0
the 0
tumor 0
cell 0
lines 0
either 0
as 0
a 0
`` 0
readthrough 0
'' 0
form 0
or 0
with 0
78 0
residues 0
deleted 0
from 0
its 0
5 0
' 0
end 0
. 0

Concordance 0
of 0
IBDQ 0
scores 0
was 0
tested 0
in 0
280 0
stable 0
subjects 0
. 0

Regression 0
line 0
slopes 0
of 0
IBDQ 0
scores 0
were 0
significantly 0
different 0
in 0
patients 0
who 0
deteriorated 0
from 0
those 0
who 0
remained 0
stable 0
( 0
[ 0
b 0
] 0
< 0
0.15 0
; 0
P 0
< 0
0.0001 0
) 0
. 0

Praziquantel 0
and 0
Albendazole 0
were 0
found 0
effective 0
in 0
the 0
treatment 0
of 0
neurocysticercosis 0
, 0
but 0
because 0
of 0
serious 0
side 0
effects 0
encountered 0
in 0
some 0
cases 0
, 0
the 0
drugs 0
should 0
be 0
used 0
cautiously 0
in 0
selected 0
cases 0
only 0
. 0

Inhibition 0
of 0
erythromycin 0
synthesis 0
by 0
disruption 0
of 0
malonyl B-gene
- I-gene
coenzyme I-gene
A I-gene
decarboxylase I-gene
gene I-gene
eryM B-gene
in 0
Saccharopolyspora 0
erythraea 0
. 0

This 0
region 0
is 0
required 0
for 0
activation 0
of 0
DNA 0
binding 0
of 0
MyoD B-gene
and 0
E12 B-gene
homodimers I-gene
and 0
E12/MyoD B-gene
heterodimers 0
. 0

Transcriptional 0
analysis 0
of 0
a 0
series 0
of 0
deletion 0
mutants 0
of 0
the 0
gene 0
in 0
the 0
nuclear 0
extracts 0
prepared 0
from 0
the 0
middle 0
silk 0
gland 0
of 0
2 0
- 0
day 0
- 0
old 0
fifth 0
instar 0
larvae 0
revealed 0
the 0
presence 0
of 0
multiple 0
cis 0
- 0
regulatory 0
elements 0
located 0
both 0
upstream 0
and 0
downstream 0
of 0
the 0
initiation 0
site 0
. 0

One 0
of 0
these 0
elements 0
, 0
the 0
homeodomain B-gene
- I-gene
binding I-gene
element I-gene
, 0
was 0
identified 0
to 0
mediate 0
negative 0
regulation 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
of 0
the 0
traI B-gene
structural I-gene
gene I-gene
and 0
application 0
of 0
purified 0
mutant 0
TraI B-gene
proteins I-gene
for 0
in 0
vitro 0
assays 0
served 0
to 0
evaluate 0
the 0
functional 0
importance 0
of 0
conserved 0
amino 0
acid 0
residues 0
. 0

Concerted 0
action 0
of 0
three 0
distinct 0
domains 0
in 0
the 0
DNA 0
cleaving 0
- 0
joining 0
reaction 0
catalyzed 0
by 0
relaxase B-gene
( 0
TraI B-gene
) 0
of 0
conjugative 0
plasmid 0
RP4 0
. 0

The 0
COOH 0
- 0
terminal 0
46 0
codons 0
of 0
slyD B-gene
encode 0
a 0
remarkable 0
histidine 0
- 0
rich 0
peptide 0
sequence 0
which 0
is 0
at 0
least 0
partly 0
dispensable 0
for 0
slyD B-gene
function 0
in 0
E B-gene
- 0
mediated 0
lysis 0
. 0

Monospecific 0
antibodies 0
raised 0
against 0
rat B-gene
cytochrome I-gene
P I-gene
- I-gene
450 I-gene
1A1 I-gene
recognized 0
a 0
protein 0
in 0
the 0
hepatic 0
microsomes 0
of 0
the 0
double 0
- 0
crested 0
cormorant 0
, 0
and 0
also 0
in 0
those 0
of 0
the 0
great 0
blue 0
heron 0
( 0
Ardea 0
herodias 0
) 0
, 0
using 0
immunoblotting 0
. 0

We 0
studied 0
GSH 0
- 0
Px 0
enzyme 0
activity 0
in 0
serum 0
after 0
acute 0
myocardial 0
infarction 0
( 0
AMI 0
) 0
and 0
unstable 0
angina 0
pectoris 0
( 0
UAP 0
) 0
. 0

The 0
HGF B-gene
- 0
induced 0
cell 0
motility 0
was 0
mimicked 0
by 0
12 0
- 0
0 0
- 0
tetradecanoyl 0
- 0
phorbol 0
- 0
13 0
- 0
acetate 0
, 0
a 0
protein B-gene
kinase I-gene
C I-gene
- 0
activating 0
phorbol 0
ester 0
, 0
but 0
not 0
by 0
Ca2+ 0
ionophore 0
. 0

In 0
addition 0
, 0
lexical 0
priming 0
was 0
examined 0
by 0
presenting 0
an 0
identity 0
prime 0
earlier 0
in 0
the 0
text 0
. 0

METHODS 0
: 0
Forty 0
- 0
nine 0
cases 0
with 0
intrahepatic 0
multiple 0
nodules 0
of 0
HCC 0
, 0
by 0
gross 0
examination 0
, 0
among 0
184 0
consecutive 0
resected 0
HCCs 0
were 0
examined 0
clinicopathologically 0
. 0

In 0
the 0
present 0
report 0
, 0
66 0
hemochromatosis 0
families 0
yielding 0
151 0
hemochromatosis 0
chromosomes 0
and 0
182 0
normal 0
chromosomes 0
were 0
RFLP 0
- 0
typed 0
with 0
a 0
battery 0
of 0
probes 0
, 0
including 0
two 0
newly 0
derived 0
polymorphic 0
markers 0
from 0
the 0
6.7 0
and 0
HLA B-gene
- I-gene
F I-gene
loci I-gene
located 0
150 0
and 0
250 0
kb 0
telomeric 0
to 0
HLA B-gene
- I-gene
A I-gene
, 0
respectively 0
. 0

Pneumothorax 0
during 0
laparoscopic 0
dissection 0
of 0
the 0
diaphragmatic 0
hiatus 0
. 0

Different 0
cortical 0
malformations 0
were 0
produced 0
in 0
rats 0
by 0
a 0
single 0
dose 0
of 0
X 0
- 0
rays 0
( 0
200 0
cGy 0
) 0
given 0
on 0
different 0
days 0
during 0
gestation 0
. 0

T2 0
cancers 0
should 0
not 0
be 0
excluded 0
from 0
the 0
benefit 0
of 0
preoperative 0
irradiation 0
. 0

IFN B-gene
alpha I-gene
and 0
IFN B-gene
gamma I-gene
inducibility 0
is 0
mediated 0
by 0
a 0
single 0
element 0
: 0
a 0
high 0
affinity 0
, 0
nearly 0
palindromic 0
version 0
of 0
the 0
IFN B-gene
gamma I-gene
activation I-gene
site I-gene
( 0
GAS B-gene
) 0
. 0

Mutations 0
in 0
the 0
nuclear B-gene
gene I-gene
CBP1 I-gene
of I-gene
Saccharomyces I-gene
cerevisiae I-gene
result 0
in 0
degradation 0
of 0
mitochondrially B-gene
encoded I-gene
cytochrome I-gene
b I-gene
( 0
cob B-gene
) 0
RNA 0
; 0
thus 0
, 0
the 0
cells 0
are 0
unable 0
to 0
respire 0
. 0

Twenty 0
- 0
three 0
sequence 0
- 0
tagged 0
sites 0
( 0
STSs 0
) 0
were 0
mapped 0
within 0
the 0
contig 0
, 0
a 0
density 0
of 0
approximately 0
1 0
per 0
200 0
kb 0
. 0

In 0
this 0
paper 0
, 0
we 0
demonstrate 0
that 0
binding 0
of 0
the 0
GA B-gene
- I-gene
binding I-gene
protein I-gene
( 0
GABP B-gene
) 0
to 0
ets B-gene
sequence I-gene
motifs I-gene
within 0
each 0
repeated 0
unit 0
is 0
required 0
for 0
transcriptional 0
activation 0
of 0
the 0
COXIV B-gene
promoter I-gene
. 0

To 0
gain 0
further 0
insight 0
into 0
the 0
pathogenesis 0
of 0
the 0
adult 0
respiratory 0
distress 0
syndrome 0
( 0
ARDS 0
) 0
, 0
the 0
authors 0
studied 0
possible 0
relationships 0
among 0
the 0
activation 0
status 0
of 0
circulating 0
polymorphonuclear 0
neutrophils 0
( 0
PMN 0
) 0
, 0
cytokine 0
levels 0
, 0
and 0
the 0
severity 0
of 0
lung 0
injury 0
in 0
31 0
patients 0
: 0
15 0
with 0
ARDS 0
, 0
9 0
with 0
severe 0
pneumonia 0
uncomplicated 0
by 0
ARDS 0
, 0
and 0
7 0
mechanically 0
ventilated 0
patients 0
with 0
neither 0
ARDS 0
nor 0
pneumonia 0
. 0

Amiodarone 0
, 0
seldom 0
used 0
as 0
first 0
- 0
line 0
treatment 0
, 0
appears 0
to 0
be 0
the 0
most 0
effective 0
drug 0
. 0

These 0
results 0
demonstrate 0
that 0
dopamine B-gene
receptor I-gene
stimulation 0
by 0
different 0
dopamine 0
agonists 0
produces 0
a 0
different 0
pattern 0
of 0
effects 0
on 0
the 0
characteristics 0
of 0
the 0
reaction 0
time 0
response 0
. 0

Two 0
experiments 0
were 0
conducted 0
to 0
study 0
the 0
vacuous 0
jaw 0
movements 0
induced 0
in 0
rats 0
by 0
acute 0
administration 0
of 0
the 0
monoamine 0
- 0
depleting 0
agent 0
reserpine 0
. 0

Depletion 0
of 0
dopamine 0
in 0
the 0
nucleus 0
accumbens 0
led 0
to 0
a 0
dramatic 0
shift 0
in 0
behavior 0
in 0
which 0
there 0
was 0
a 0
significant 0
decrease 0
in 0
lever 0
pressing 0
but 0
a 0
significant 0
increase 0
in 0
consumption 0
of 0
lab 0
chow 0
. 0

We 0
have 0
investigated 0
the 0
influence 0
of 0
NaFe3+EDTA 0
, 0
and 0
of 0
increasing 0
dietary 0
levels 0
of 0
Na2EDTA 0
, 0
on 0
Zn 0
, 0
Cu 0
and 0
Ca 0
metabolism 0
in 0
rats 0
fed 0
on 0
Zn 0
- 0
sufficient 0
and 0
Zn 0
- 0
deficient 0
soya 0
- 0
bean 0
- 0
isolate 0
- 0
based 0
diets 0
. 0

Recovery 0
of 0
carbimazole 0
- 0
induced 0
agranulocytosis 0
following 0
recombinant B-gene
granulocyte I-gene
- I-gene
macrophage I-gene
colony I-gene
stimulating I-gene
factor I-gene
( 0
rhGM B-gene
- I-gene
CSF I-gene
) 0
administration 0
. 0

Thus 0
, 0
the 0
system 0
can 0
be 0
used 0
to 0
detect 0
and 0
study 0
dynamic 0
perfusion 0
changes 0
from 0
the 0
brain 0
surface 0
with 0
minimal 0
tissue 0
damage 0
. 0

The 0
neglect 0
of 0
Richards 0
's 0
theory 0
demonstrates 0
the 0
range 0
of 0
factors 0
, 0
other 0
than 0
the 0
strictly 0
scientific 0
, 0
which 0
can 0
be 0
important 0
in 0
determining 0
the 0
influence 0
or 0
otherwise 0
of 0
a 0
psychological 0
theory 0
. 0

The 0
positive 0
- 0
acting 0
global 0
sulfur 0
regulatory 0
protein 0
, 0
CYS3 B-gene
, 0
of 0
Neurospora 0
crassa 0
turns 0
on 0
the 0
expression 0
of 0
a 0
family 0
of 0
unlinked 0
structural 0
genes 0
that 0
encode 0
enzymes 0
of 0
sulfur 0
catabolism 0
. 0

Analysis 0
of 0
the 0
upstream 0
untranslated 0
region 0
of 0
CHL15 B-gene
revealed 0
the 0
presence 0
of 0
the 0
hexamer 0
element 0
, 0
ACGCGT 0
( 0
an 0
MluI B-gene
restriction I-gene
site I-gene
) 0
controlling 0
both 0
the 0
periodic 0
expression 0
and 0
coordinate 0
regulation 0
of 0
the 0
DNA 0
synthesis 0
genes 0
in 0
budding 0
yeast 0
. 0

The 0
C 0
- 0
terminal 0
region 0
of 0
the 0
150 0
- 0
kDa 0
protein 0
contains 0
an 0
NTP 0
- 0
binding 0
helicase B-gene
motif I-gene
and 0
the 0
readthrough 0
region 0
, 0
an 0
RNA B-gene
polymerase I-gene
motif I-gene
, 0
indicating 0
that 0
these 0
two 0
overlapping 0
proteins 0
may 0
form 0
an 0
RNA 0
replication 0
complex 0
similar 0
to 0
those 0
of 0
tobamo 0
- 0
and 0
tobraviruses 0
. 0

The 0
5 0
' 0
ends 0
of 0
F3R B-gene
late 0
transcripts 0
were 0
located 0
to 0
an 0
A 0
within 0
the 0
sequence 0
5' 0
- 0
TAAAG 0
, 0
41 0
nt 0
downstream 0
from 0
the 0
early 0
promoter 0
and 0
17 0
nt 0
upstream 0
from 0
the 0
initiation 0
codon 0
. 0

On 0
T2 0
weighted 0
images 0
, 0
low 0
intensity 0
areas 0
in 0
the 0
thalamus 0
, 0
the 0
striatum 0
, 0
the 0
anterior 0
limb 0
of 0
the 0
internal 0
capsule 0
, 0
the 0
tegmentum 0
of 0
midbrain 0
, 0
high 0
intensity 0
areas 0
in 0
middle 0
cerebellar 0
peduncle 0
, 0
the 0
posterior 0
limb 0
of 0
the 0
internal 0
capsule 0
, 0
the 0
lateral 0
part 0
of 0
the 0
cerebral 0
peduncle 0
, 0
and 0
the 0
cerebral 0
white 0
matter 0
were 0
noted 0
. 0

Using 0
the 0
rap1t B-gene
alleles I-gene
to 0
generate 0
wild 0
- 0
type 0
cells 0
differing 0
only 0
in 0
telomere 0
tract 0
lengths 0
, 0
we 0
also 0
show 0
that 0
telomere 0
position 0
effects 0
are 0
highly 0
sensitive 0
to 0
changes 0
in 0
the 0
size 0
( 0
or 0
structure 0
) 0
of 0
the 0
telomeric 0
tract 0
. 0

Pronounced 0
microangiopathy 0
characterized 0
by 0
avascular 0
fields 0
, 0
enlarged 0
and 0
tortuous 0
capillaries 0
and 0
increased 0
transcapillary 0
diffusion 0
of 0
sodium 0
fluorescein 0
, 0
was 0
clearly 0
demonstrable 0
in 0
the 0
area 0
of 0
the 0
nodules 0
. 0

Epigenetic 0
switching 0
of 0
transcriptional 0
states 0
: 0
cis 0
- 0
and 0
trans 0
- 0
acting 0
factors 0
affecting 0
establishment 0
of 0
silencing 0
at 0
the 0
HMR B-gene
locus I-gene
in 0
Saccharomyces 0
cerevisiae 0
. 0

NF B-gene
- I-gene
kappa I-gene
B I-gene
p65 B-gene
, 0
p50 B-gene
, 0
and 0
Rel B-gene
functionally 0
synergize 0
with 0
C/EBP B-gene
alpha I-gene
, 0
C/EBP B-gene
beta I-gene
, 0
and 0
C/EBP B-gene
delta I-gene
. 0

It 0
could 0
be 0
detected 0
exclusively 0
in 0
the 0
culture 0
medium 0
of 0
cDNA 0
- 0
transfected 0
COS 0
cells 0
. 0

The 0
first 0
group 0
of 0
sequential 0
BMB 0
showed 0
a 0
significant 0
progress 0
to 0
myelofibrosis 0
in 0
so 0
- 0
called 0
`` 0
Chronic 0
Megakaryocytic 0
- 0
Granulocytic 0
Myelosis 0
'' 0
- 0
- 0
CMGM 0
- 0
, 0
which 0
corresponds 0
to 0
Agnogenic 0
Myeloid 0
Metaplasia 0
- 0
AMM 0
- 0
in 0
72.4 0
% 0
( 0
21/29 0
patients 0
) 0
, 0
as 0
well 0
as 0
in 0
CML 0
with 0
megakaryocytic 0
increase 0
- 0
CML.MI 0
- 0
in 0
39.2 0
% 0
( 0
20/51 0
) 0
. 0

The 0
two 0
methods 0
identify 0
the 0
same 0
patients 0
only 0
if 0
micturitional 0
pressures 0
are 0
normal 0
( 0
40 0
to 0
60 0
cmH2O 0
) 0
to 0
high 0
( 0
over 0
60 0
cmH2O 0
) 0
and 0
the 0
Sussett 0
formula 0
is 0
used 0
with 0
a 0
higher 0
( 0
95th 0
centile 0
) 0
cutoff 0
. 0

There 0
was 0
no 0
clear 0
correlation 0
between 0
the 0
MFA 0
and 0
the 0
severity 0
of 0
the 0
UTS 0
phenotype 0
. 0

Chicken 0
sterol B-gene
carrier I-gene
protein I-gene
2/sterol I-gene
2/sterol I-gene
carrier I-gene
protein I-gene
x I-gene
: 0
cDNA 0
cloning 0
reveals 0
evolutionary 0
conservation 0
of 0
structure 0
and 0
regulated 0
expression 0
. 0

The 0
plasmatic B-gene
albumin I-gene
concentration 0
( 0
3.5 0
- 0
4.5 0
g/dl 0
) 0
represents 0
about 0
60 0
% 0
of 0
the 0
total 0
plasma 0
protein 0
. 0

These 0
lesions 0
were 0
asymptomatic 0
, 0
but 0
both 0
were 0
characterized 0
clinically 0
by 0
central 0
ulceration 0
. 0

A 0
single 0
five 0
minute 0
period 0
of 0
rapid 0
atrial 0
pacing 0
fails 0
to 0
limit 0
infarct 0
size 0
in 0
the 0
in 0
situ 0
rabbit 0
heart 0
. 0

Neither 0
RD19 B-gene
nor 0
RD21 B-gene
mRNA I-gene
synthesis 0
was 0
responsive 0
to 0
cold 0
or 0
to 0
heat 0
stress 0
. 0

Previous 0
studies 0
indicated 0
that 0
the 0
20S B-gene
proteasome I-gene
is 0
a 0
catalytic 0
core 0
of 0
the 0
26S B-gene
proteolytic I-gene
complex I-gene
that 0
possesses 0
a 0
latent 0
multicatalytic 0
proteinase 0
activity 0
and 0
catalyzes 0
an 0
ATP 0
- 0
dependent 0
, 0
selective 0
breakdown 0
of 0
proteins 0
ligated 0
to 0
ubiquitin B-gene
. 0

The 0
O2 0
deficit 0
was 0
not 0
related 0
to 0
blood 0
lactate 0
during 0
submaximal 0
exercise 0
, 0
muscle 0
enzyme 0
activity 0
( 0
citrate B-gene
synthase I-gene
, 0
3 B-gene
- I-gene
hydroxyacyl I-gene
- I-gene
CoA I-gene
- I-gene
dehydrogenase I-gene
, 0
lactate B-gene
dehydrogenase I-gene
) 0
, 0
number 0
of 0
muscle 0
capillaries 0
, 0
% 0
ST 0
fibres 0
or 0
muscle 0
buffer 0
capacity 0
. 0

The 0
sequence 0
of 0
the 0
putative 0
RBP1 B-gene
protein I-gene
contains 0
two 0
copies 0
of 0
an 0
RNA 0
recognition 0
motif 0
, 0
two 0
glutamine 0
stretches 0
, 0
an 0
asparagine 0
- 0
rich 0
region 0
, 0
a 0
methionine 0
- 0
rich 0
region 0
, 0
and 0
two 0
long 0
potential 0
alpha 0
- 0
helixes 0
. 0

One 0
defective 0
RNA 0
with 0
a 0
large 0
deletion 0
in 0
the 0
p70 B-gene
coding I-gene
region I-gene
was 0
able 0
to 0
replicate 0
efficiently 0
, 0
both 0
when 0
inoculated 0
with 0
the 0
helper 0
genome 0
and 0
when 0
inoculated 0
with 0
a 0
second 0
complementing 0
defective 0
RNA 0
that 0
supplied 0
a 0
wild B-gene
- I-gene
type I-gene
p70 I-gene
. 0

Release 0
of 0
this 0
selective 0
pressure 0
, 0
however 0
, 0
gave 0
way 0
to 0
homologous 0
resolution 0
of 0
the 0
cointegrate 0
structures 0
. 0

Complete 0
nucleotide 0
sequence 0
of 0
the 0
bacteriophage B-gene
K1F I-gene
tail I-gene
gene I-gene
encoding 0
endo B-gene
- I-gene
N I-gene
- I-gene
acylneuraminidase I-gene
( 0
endo B-gene
- I-gene
N I-gene
) 0
and 0
comparison 0
to 0
an 0
endo B-gene
- I-gene
N I-gene
homolog I-gene
in 0
bacteriophage 0
PK1E 0
. 0

Binding 0
of 0
U2 B-gene
small I-gene
nuclear I-gene
ribonucleoprotein I-gene
was 0
partially 0
inhibited 0
. 0

Morphometrical 0
quantification 0
of 0
brain 0
edema 0
related 0
to 0
experimental 0
multiple 0
micro 0
- 0
infarcts 0
in 0
mice 0
: 0
assessment 0
of 0
neurotropin B-gene
effect 0
. 0

One 0
member 0
of 0
this 0
multigene 0
family 0
, 0
GATA B-gene
- I-gene
3 I-gene
, 0
is 0
most 0
abundantly 0
expressed 0
in 0
T 0
lymphocytes 0
, 0
a 0
cellular 0
target 0
for 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
infection 0
and 0
replication 0
. 0

Indeed 0
, 0
significant 0
level 0
of 0
CAT B-gene
activity 0
was 0
observed 0
in 0
human 0
lung 0
adenocarcinoma 0
( 0
A549 0
- 0
1 0
) 0
cells 0
which 0
had 0
been 0
incubated 0
with 0
a 0
complex 0
of 0
T7 B-gene
RNA I-gene
polymerase I-gene
, 0
pT7 B-gene
- I-gene
EMC I-gene
- I-gene
CAT I-gene
DNA I-gene
and 0
DC 0
- 0
chol 0
cationic 0
liposomes 0
. 0

Pneumoscrotum 0
is 0
a 0
rare 0
condition 0
that 0
receives 0
little 0
discussion 0
in 0
standard 0
texts 0
of 0
urology 0
. 0

The 0
first 0
gene 0
codes 0
for 0
a 0
protein 0
containing 0
11 0
cystein 0
residues 0
in 0
an 0
arrangement 0
typical 0
for 0
Fe/S B-gene
proteins I-gene
. 0

Triton 0
- 0
disrupted 0
cells 0
retained 0
capacity 0
for 0
activation 0
of 0
the 0
pathway 0
by 0
both 0
peptide 0
growth 0
factors 0
and 0
by 0
addition 0
of 0
GTP 0
- 0
loaded 0
p21 B-gene
rasVal12 B-gene
. 0

To 0
begin 0
to 0
examine 0
the 0
mechanism 0
controlling 0
expression 0
of 0
this 0
gene 0
during 0
the 0
cell 0
- 0
cycle 0
, 0
a 0
mouse B-gene
B I-gene
- I-gene
myb I-gene
5 I-gene
' I-gene
flanking I-gene
sequence I-gene
was 0
isolated 0
from 0
a 0
cosmid 0
library 0
and 0
shown 0
to 0
promote 0
efficiently 0
the 0
transcription 0
of 0
a 0
luciferase B-gene
reporter I-gene
gene I-gene
when 0
transfected 0
into 0
NIH3T3 0
fibroblasts 0
. 0

The 0
influence 0
of 0
a 0
high 0
ionic 0
strength 0
on 0
the 0
resolution 0
was 0
clearly 0
shown 0
. 0

The 0
number 0
of 0
bacteria 0
in 0
the 0
lung 0
, 0
peripheral 0
white 0
blood 0
cell 0
and 0
BAL 0
fluid 0
cell 0
also 0
decreased 0
by 0
the 0
administration 0
of 0
FN B-gene
. 0

In 0
mice 0
, 0
three 0
major 0
families 0
of 0
L1 0
elements 0
, 0
termed 0
`` 0
A 0
, 0
'' 0
`` 0
F 0
, 0
'' 0
and 0
`` 0
V 0
, 0
'' 0
have 0
been 0
defined 0
on 0
the 0
basis 0
of 0
the 0
sequence 0
found 0
at 0
the 0
5 0
' 0
terminus 0
. 0

TFEC B-gene
, 0
a 0
basic B-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
protein I-gene
, 0
forms 0
heterodimers 0
with 0
TFE3 B-gene
and 0
inhibits 0
TFE3 B-gene
- 0
dependent 0
transcription 0
activation 0
. 0

The 0
equivalent 0
of 0
the 0
third 0
ligand 0
, 0
H 0
- 0
87 0
, 0
is 0
T 0
- 0
47 0
in 0
the 0
PSTAIRE 0
sequence 0
motif 0
. 0

Similar 0
results 0
were 0
seen 0
on 0
Western 0
blots 0
of 0
Autographa 0
californica 0
MNPV 0
( 0
AcMNPV 0
) 0
- 0
infected 0
Spodoptera 0
frugiperda 0
cells 0
. 0

In 0
infected 0
mammalian 0
cells 0
, 0
the 0
ARV B-gene
G I-gene
and 0
GNS B-gene
genes I-gene
are 0
transcribed 0
primarily 0
as 0
a 0
polycistronic 0
mRNA 0
which 0
appears 0
to 0
extend 0
from 0
the 0
consensus 0
sequence 0
( 0
AACAG 0
) 0
at 0
the 0
start 0
of 0
the 0
G B-gene
gene I-gene
to 0
the 0
next 0
recognized 0
polyadenylation 0
signal 0
( 0
CATG 0
[ 0
A 0
] 0
7 0
) 0
located 0
697 0
nucleotides 0
downstream 0
of 0
the 0
GNS B-gene
protein I-gene
termination 0
codon 0
. 0

Molecular 0
cloning 0
and 0
expression 0
of 0
RPE65 B-gene
, 0
a 0
novel 0
retinal 0
pigment 0
epithelium 0
- 0
specific 0
microsomal 0
protein 0
that 0
is 0
post 0
- 0
transcriptionally 0
regulated 0
in 0
vitro 0
. 0

The 0
mean 0
power 0
( 0
in 0
mu 0
W 0
) 0
required 0
to 0
produce 0
the 0
observed 0
flow 0
rate 0
was 0
estimated 0
at 0
each 0
outflow 0
pressure 0
as 0
the 0
product 0
of 0
the 0
flow 0
rate 0
and 0
the 0
pressure 0
across 0
the 0
lymphatic 0
vessel 0
. 0

Although 0
antisperm 0
antibodies 0
are 0
associated 0
with 0
infertility 0
, 0
many 0
hospital 0
laboratories 0
do 0
not 0
test 0
for 0
these 0
antibodies 0
. 0

PPD B-gene
- 0
specific 0
IgG B-gene
subclass 0
responses 0
were 0
evident 0
to 0
all 0
four 0
IgG B-gene
subclasses 0
. 0

Anterior 0
body 0
pattern 0
in 0
Drosophila 0
is 0
specified 0
by 0
the 0
graded 0
distribution 0
of 0
the 0
bicoid B-gene
protein I-gene
( 0
bcd B-gene
) 0
, 0
which 0
activates 0
subordinate 0
genes 0
in 0
distinct 0
anterior 0
domains 0
. 0

GAP B-gene
- I-gene
N I-gene
bound 0
constitutively 0
to 0
p190 B-gene
in 0
both 0
serum 0
- 0
deprived 0
and 0
growth 0
factor 0
- 0
stimulated 0
cells 0
. 0

The 0
peptide 0
sequence 0
contains 0
a 0
region 0
of 0
80 0
amino 0
acids 0
that 0
shows 0
similarity 0
to 0
bcl B-gene
- I-gene
2 I-gene
and 0
to 0
the 0
recently 0
described 0
bcl B-gene
- I-gene
2 I-gene
- I-gene
related I-gene
gene I-gene
, 0
MCL1 B-gene
. 0

The 0
phosphorylation 0
efficiency 0
is 0
improved 0
by 0
increasing 0
the 0
number 0
of 0
N 0
- 0
terminal 0
arginine 0
residues 0
and 0
by 0
moving 0
the 0
arginyl 0
cluster 0
one 0
residue 0
further 0
away 0
from 0
the 0
serine 0
, 0
the 0
nonapeptide 0
( 0
Arg 0
) 0
4 0
- 0
Ala 0
- 0
Ala 0
- 0
Ser 0
- 0
Val 0
- 0
Ala 0
being 0
the 0
best 0
substrate 0
among 0
all 0
the 0
short 0
peptides 0
tested 0
( 0
Km 0
= 0
15 0
microM 0
) 0
. 0

Botulinum B-gene
toxin I-gene
: 0
preferred 0
treatment 0
for 0
hemifacial 0
spasm 0
. 0

The 0
Saccharomyces B-gene
cerevisiae I-gene
GAL1 I-gene
and 0
GAL10 B-gene
genes I-gene
are 0
controlled 0
in 0
response 0
to 0
the 0
availability 0
of 0
galactose 0
and 0
glucose 0
by 0
multiple 0
activating 0
and 0
repressing 0
proteins 0
bound 0
at 0
adjacent 0
or 0
overlapping 0
sites 0
in 0
UASG 0
. 0

Surprisingly 0
, 0
the 0
results 0
of 0
several 0
experiments 0
suggest 0
that 0
the 0
TSF B-gene
genes I-gene
encode 0
global 0
regulatory 0
factors 0
. 0
tsf1 B-gene
to 0
tsf6 B-gene
mutations 0
derepressed 0
expression 0
from 0
yeast 0
CYC B-gene
- 0
GAL B-gene
hybrid 0
promoters 0
( 0
fused 0
to 0
lacZ B-gene
) 0
that 0
harbor 0
a 0
variety 0
of 0
operator 0
sequences 0
, 0
and 0
caused 0
pleiotropic 0
defects 0
in 0
cell 0
growth 0
, 0
mating 0
, 0
and 0
sporulation 0
. 0

Sex 0
of 0
calf 0
( 0
variate 0
2 0
) 0
was 0
associated 0
most 0
closely 0
with 0
width 0
of 0
muzzle 0
and 0
head 0
. 0

Sequence 0
comparison 0
indicates 0
that 0
exons 0
5'/L 0
and 0
L/N 0
in 0
PSG12 B-gene
and 0
PSG12 B-gene
psi I-gene
are 0
99 0
% 0
identical 0
, 0
except 0
that 0
the 0
L/N 0
exon 0
in 0
the 0
PSG12 B-gene
psi I-gene
gene I-gene
contains 0
a 0
stop 0
codon 0
. 0

The 0
mechanisms 0
that 0
govern 0
the 0
activation 0
or 0
suppression 0
of 0
the 0
CD8 B-gene
gene I-gene
are 0
likely 0
to 0
be 0
central 0
to 0
the 0
T 0
cell 0
development 0
program 0
. 0

We 0
suggest 0
that 0
the 0
ER 0
lumenal 0
variable 0
domain 0
of 0
gp19K B-gene
has 0
a 0
specific 0
tertiary 0
structure 0
that 0
is 0
important 0
for 0
binding 0
to 0
the 0
polymorphic 0
alpha 0
1 0
and 0
alpha 0
2 0
domains 0
of 0
class B-gene
I I-gene
heavy I-gene
( I-gene
alpha I-gene
) I-gene
chains I-gene
. 0

We 0
recently 0
found 0
that 0
17 0
beta 0
- 0
estradiol 0
( 0
E2 0
) 0
not 0
only 0
suppresses 0
bone 0
resorption 0
but 0
also 0
stimulates 0
bone 0
formation 0
in 0
the 0
cancellous 0
bone 0
of 0
female 0
rats 0
. 0

Recombinant B-gene
human I-gene
erythropoietin I-gene
( 0
epoetin B-gene
) 0
is 0
approved 0
to 0
be 0
administered 0
by 0
the 0
intravenous 0
( 0
i.v 0
. 0
) 0
or 0
subcutaneous 0
( 0
SC 0
) 0
route 0
. 0

Single 0
- 0
photon 0
emission 0
computed 0
tomography 0
( 0
SPECT 0
) 0
with 0
99mTc 0
- 0
hexamethylpropyleneamine 0
oxime 0
( 0
HMPAO 0
) 0
was 0
used 0
to 0
investigate 0
changes 0
in 0
cerebral 0
blood 0
flow 0
in 0
seven 0
patients 0
with 0
cortical 0
visual 0
impairment 0
. 0

The 0
rCBF 0
ratio 0
was 0
mainly 0
reduced 0
in 0
frontal 0
lobes 0
( 0
65 0
% 0
) 0
. 0

METHODS 0
: 0
Twenty 0
- 0
two 0
patients 0
were 0
grouped 0
according 0
to 0
their 0
etiology 0
based 0
on 0
the 0
study 0
of 0
antiadrenal 0
antibodies 0
at 0
diagnosis 0
of 0
the 0
disease 0
: 0
7 0
were 0
positive 0
( 0
autoimmune 0
etiology 0
or 0
EAA 0
) 0
, 0
11 0
were 0
negative 0
( 0
tuberculous 0
etiology 0
or 0
EAT 0
) 0
and 0
in 0
four 0
serologic 0
study 0
was 0
not 0
available 0
( 0
undetermined 0
etiology 0
or 0
EAI 0
) 0
. 0

2 0
- 0
AP 0
induced 0
marked 0
, 0
steady 0
rises 0
in 0
mRNA 0
accumulation 0
from 0
both 0
transfected 0
and 0
chromosomally 0
integrated 0
HIV 0
- 0
1 0
constructs 0
but 0
no 0
increases 0
from 0
an 0
endogenous 0
gene 0
encoding 0
gamma B-gene
- I-gene
actin I-gene
or 0
glucose B-gene
6 I-gene
- I-gene
phosphate I-gene
dehydrogenase I-gene
. 0

The 0
UV 0
induction 0
of 0
c B-gene
- I-gene
jun I-gene
is 0
mediated 0
by 0
two 0
UV 0
response 0
elements 0
consisting 0
of 0
AP B-gene
- I-gene
1 I-gene
- I-gene
like I-gene
sequences I-gene
within 0
its 0
5 0
' 0
control 0
region 0
. 0

Protein B-gene
tyrosine I-gene
phosphatases I-gene
( 0
PTPs B-gene
) 0
, 0
together 0
with 0
protein B-gene
tyrosine I-gene
kinases I-gene
( 0
PTKs B-gene
) 0
, 0
are 0
involved 0
in 0
the 0
regulation 0
of 0
cell 0
activation 0
, 0
growth 0
, 0
and 0
differentiation 0
. 0

ST 0
elevation 0
occurs 0
in 0
5 0
patients 0
( 0
55.5 0
% 0
) 0
of 0
subgroup 0
A 0
and 0
in 0
no 0
patient 0
of 0
the 0
subgroup 0
B 0
. 0

Furthermore 0
, 0
a 0
p21X B-gene
protein I-gene
lacking 0
the 0
N 0
- 0
terminus 0
of 0
Rex1 B-gene
was 0
expressed 0
at 0
high 0
levels 0
; 0
our 0
data 0
indicate 0
that 0
p21X B-gene
is 0
translated 0
from 0
the 0
1.6 0
- 0
kb 0
mRNA 0
which 0
is 0
derived 0
primarily 0
from 0
deleted 0
proviruses 0
. 0

HTLV 0
- 0
1 0
gene 0
expression 0
by 0
defective 0
proviruses 0
in 0
an 0
infected 0
T 0
- 0
cell 0
line 0
. 0

Thus 0
, 0
it 0
was 0
confirmed 0
that 0
the 0
sodium 0
lauryl 0
sulfate 0
method 0
of 0
estimating 0
hemoglobin B-gene
concentration 0
is 0
an 0
appropriate 0
alternative 0
to 0
the 0
cyanmethemoglobin B-gene
method 0
and 0
avoids 0
the 0
generation 0
of 0
toxic 0
wastes 0
. 0

A 0
comparison 0
of 0
the 0
predicted 0
amino 0
acid 0
sequences 0
of 0
the 0
two 0
human B-gene
PKC I-gene
- I-gene
delta I-gene
clones 0
with 0
the 0
rat 0
and 0
mouse 0
homologues 0
indicated 0
a 0
greater 0
degree 0
of 0
sequence 0
divergence 0
( 0
89 0
- 0
90 0
% 0
homology 0
) 0
compared 0
to 0
the 0
high 0
degree 0
of 0
sequence 0
conservation 0
observed 0
with 0
other 0
human B-gene
PKC I-gene
family I-gene
members I-gene
and 0
their 0
mammalian 0
counterparts 0
. 0

XII 0
. 0

When 0
comparing 0
the 0
barley B-gene
PSI I-gene
- I-gene
K I-gene
and 0
PSI B-gene
- I-gene
G I-gene
with 0
the 0
reported 0
PSI B-gene
- I-gene
K I-gene
sequence I-gene
from I-gene
Synechococcus I-gene
vulcanus I-gene
, 0
the 0
degree 0
of 0
similarity 0
is 0
equal 0
, 0
suggesting 0
that 0
an 0
ancestral 0
gene 0
has 0
been 0
duplicated 0
in 0
a 0
chloroplast 0
progenitor 0
but 0
not 0
in 0
a 0
cyanobacterial 0
. 0

On 0
the 0
other 0
hand 0
, 0
the 0
structures 0
of 0
the 0
b 0
- 0
Zip 0
domain 0
are 0
well 0
conserved 0
among 0
these 0
Maf B-gene
- I-gene
related I-gene
proteins I-gene
. 0

Under 0
these 0
conditions 0
, 0
transfections 0
with 0
cDNAs 0
of 0
the 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
p50 B-gene
and 0
serum B-gene
response I-gene
factor I-gene
( 0
SRF B-gene
) 0
produced 0
a 0
factor 0
( 0
s 0
) 0
that 0
mediated 0
Tax B-gene
binding 0
to 0
the 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
site I-gene
and 0
the 0
CArG 0
box 0
respectively 0
. 0

We 0
show 0
here 0
that 0
v B-gene
- I-gene
Rel I-gene
specifically 0
increased 0
expression 0
from 0
a 0
reporter 0
plasmid 0
containing 0
multiple 0
Sp1 B-gene
binding I-gene
sites I-gene
approximately 0
sixfold 0
in 0
chicken 0
embryo 0
fibroblasts 0
( 0
CEFs 0
) 0
, 0
even 0
though 0
v B-gene
- I-gene
Rel I-gene
did 0
not 0
bind 0
directly 0
to 0
these 0
sites 0
. 0
v B-gene
- I-gene
Rel I-gene
also 0
increased 0
expression 0
from 0
a 0
reporter 0
plasmid 0
containing 0
a 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
long I-gene
terminal I-gene
repeat I-gene
( 0
LTR 0
) 0
in 0
which 0
the 0
kappa B-gene
B I-gene
binding I-gene
sites I-gene
were 0
mutated 0
but 0
which 0
still 0
contained 0
intact 0
Sp1 B-gene
binding I-gene
sites I-gene
. 0

The 0
simultaneous 0
recording 0
of 0
electrical 0
activity 0
from 0
the 0
surface 0
electrocardiogram 0
, 0
right 0
ventricular 0
apex 0
, 0
His 0
bundle 0
, 0
high 0
right 0
atrium 0
, 0
coronary 0
sinus 0
, 0
with 0
or 0
without 0
a 0
roving 0
mapping 0
catheter 0
, 0
enables 0
us 0
to 0
precisely 0
map 0
the 0
electrical 0
activation 0
sequence 0
in 0
the 0
heart 0
. 0

CONCLUSION 0
: 0
This 0
retrospective 0
analysis 0
does 0
not 0
confirm 0
the 0
efficacy 0
of 0
one 0
course 0
of 0
simultaneous 0
Mitomycin 0
- 0
C 0
and 0
5 0
- 0
fluorouracil 0
, 0
at 0
least 0
in 0
association 0
with 0
full 0
- 0
dose 0
radiotherapy 0
incorporating 0
Iridium 0
- 0
192 0
boost 0
. 0

Despite 0
the 0
existence 0
of 0
30 0
cysteine 0
residues 0
, 0
carboxymethylation 0
prevented 0
the 0
formation 0
of 0
most 0
if 0
not 0
all 0
disulfide 0
bonds 0
that 0
otherwise 0
occurred 0
when 0
the 0
cells 0
were 0
sonicated 0
. 0

Cerebro 0
- 0
oculo 0
- 0
facioskeletal 0
syndrome 0
( 0
Pena 0
- 0
Shokeir 0
syndrome 0
II 0
) 0

Most 0
importantly 0
, 0
the 0
addition 0
of 0
purified 0
17S B-gene
U2 I-gene
snRNPs I-gene
, 0
but 0
not 0
of 0
12S B-gene
U2 I-gene
snRNPs I-gene
, 0
to 0
HeLa 0
splicing 0
extracts 0
in 0
which 0
the 0
endogeneous B-gene
U2 I-gene
snRNPs I-gene
have 0
been 0
functionally 0
neutralized 0
with 0
anti B-gene
- I-gene
PRP9 I-gene
antibodies I-gene
fully 0
restores 0
the 0
mRNA 0
- 0
splicing 0
activity 0
of 0
the 0
extracts 0
. 0

Differences 0
in 0
profiles 0
of 0
viscosity 0
variables 0
between 0
subgroups 0
of 0
EAD 0
in 0
RA 0
patients 0
were 0
observed 0
. 0

These 0
contain 0
a 0
single 0
1977 0
- 0
bp 0
exon 0
that 0
encodes 0
900 0
bp 0
of 0
the 0
5 0
' 0
and 0
3 0
' 0
untranslated 0
sequences 0
in 0
addition 0
to 0
a 0
1077 0
- 0
bp 0
open 0
reading 0
frame 0
identical 0
to 0
that 0
found 0
in 0
vascular B-gene
smooth I-gene
muscle I-gene
cell I-gene
AT1a I-gene
receptor I-gene
cDNAs I-gene
. 0

Deletion 0
of 0
a 0
53 0
- 0
bp 0
early 0
promoter 0
region 0
containing 0
the 0
transcription 0
start 0
site 0
and 0
a 0
putative 0
TATA 0
box 0
completely 0
abolishes 0
the 0
ability 0
of 0
upstream 0
elements 0
to 0
drive 0
transcription 0
of 0
the 0
luciferase B-gene
cDNA I-gene
. 0

One 0
chimpanzee 0
reliably 0
selected 0
the 0
larger 0
numeral 0
4 0
during 0
testing 0
with 0
a 0
nonadjacent 0
pair 0
( 0
2 0
- 0
4 0
) 0
, 0
and 0
2 0
chimps 0
showed 0
no 0
preference 0
. 0

Dissipation 0
of 0
claudication 0
pain 0
after 0
walking 0
: 0
implications 0
for 0
endurance 0
training 0
. 0

Alternative 0
transcript 0
of 0
the 0
nonselective 0
- 0
type 0
endothelin B-gene
receptor I-gene
from 0
rat 0
brain 0
. 0

The 0
Functional 0
Independence 0
Measure 0
: 0
a 0
comparative 0
study 0
of 0
clinician 0
and 0
self 0
ratings 0
. 0

Polymyxin 0
B 0
was 0
given 0
intravenously 0
for 0
1 0
week 0
postburn 0
in 0
doses 0
designed 0
to 0
neutralize 0
circulating 0
endotoxemia 0
. 0

SvO2 0
can 0
be 0
determined 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

The 0
transverse 0
relaxation 0
time 0
( 0
T2 0
) 0
and 0
apparent 0
diffusion 0
coefficient 0
of 0
water 0
were 0
determined 0
. 0

The 0
Drosophila 0
clathrin B-gene
heavy I-gene
chain I-gene
gene 0
: 0
clathrin B-gene
function 0
is 0
essential 0
in 0
a 0
multicellular 0
organism 0
. 0

The 0
binding 0
specificity 0
of 0
this 0
protein 0
was 0
compared 0
to 0
that 0
of 0
human B-gene
E2F I-gene
using 0
a 0
number 0
of 0
mutant B-gene
E2F I-gene
sites I-gene
as 0
competitors 0
. 0

To 0
analyze 0
the 0
VH 0
regions 0
of 0
polyreactive 0
antibodies 0
, 0
with 0
particular 0
attention 0
at 0
their 0
somatically 0
mutated 0
status 0
, 0
we 0
generated 0
five 0
IgG B-gene
( 0
three 0
IgG1 B-gene
and 0
two 0
IgG3 B-gene
) 0
mAb 0
( 0
using 0
B 0
cells 0
from 0
a 0
healthy 0
subject 0
, 0
a 0
patient 0
with 0
insulin B-gene
- 0
dependent 0
diabetes 0
mellitus 0
and 0
a 0
patient 0
with 0
SLE 0
) 0
, 0
which 0
bound 0
with 0
various 0
efficiencies 0
a 0
number 0
of 0
different 0
self 0
and 0
foreign 0
Ag 0
. 0

It 0
is 0
possible 0
that 0
the 0
patch 0
determines 0
the 0
proper 0
conformation 0
of 0
the 0
site 0
and 0
thereby 0
contributes 0
to 0
recognition 0
indirectly 0
. 0

These 0
findings 0
suggest 0
a 0
functional 0
cross 0
- 0
talk 0
between 0
RB B-gene
protein I-gene
and 0
p21ras B-gene
, 0
which 0
balances 0
the 0
cell 0
phenotype 0
between 0
normal 0
and 0
transformed 0
states 0
. 0

The 0
7 0
- 0
kb 0
mRNA 0
differs 0
by 0
alternative 0
splicing 0
such 0
that 0
it 0
encodes 0
a 0
protein 0
with 0
a 0
distinct 0
amino 0
terminus 0
. 0

Kinetics 0
of 0
the 0
inhibition 0
indicated 0
that 0
this 0
polymerase 0
domain 0
can 0
inhibit 0
viral 0
replication 0
only 0
during 0
the 0
preinitiation 0
stage 0
. 0

The 0
other 0
transmembrane 0
regions 0
as 0
well 0
as 0
the 0
nucleoplasmic 0
domain 0
are 0
not 0
required 0
for 0
sorting 0
. 0

3 0
. 0

McCann 0
III 0
, 0
F 0
. 0

These 0
cell 0
lines 0
, 0
selected 0
for 0
the 0
ability 0
to 0
support 0
the 0
replication 0
of 0
a 0
temperature 0
- 0
sensitive 0
VP5 B-gene
mutant I-gene
, 0
were 0
used 0
to 0
isolate 0
VP5 B-gene
and 0
VP23 B-gene
null 0
mutants 0
. 0

The 0
E1 B-gene
nuclear I-gene
transport I-gene
motif I-gene
is 0
highly 0
conserved 0
in 0
the 0
animal 0
and 0
human 0
papillomaviruses 0
and 0
is 0
encoded 0
in 0
a 0
similar 0
region 0
in 0
the 0
related 0
E1 B-gene
genes I-gene
. 0

The 0
E1 B-gene
replication I-gene
protein I-gene
of 0
bovine 0
papillomavirus 0
type 0
1 0
contains 0
an 0
extended 0
nuclear 0
localization 0
signal 0
that 0
includes 0
a 0
p34cdc2 B-gene
phosphorylation 0
site 0
. 0

In 0
order 0
to 0
investigate 0
to 0
what 0
extent 0
this 0
interaction 0
might 0
contribute 0
to 0
tumor 0
induction 0
by 0
the 0
virus 0
, 0
we 0
have 0
introduced 0
two 0
different 0
point 0
mutations 0
within 0
the 0
putative 0
pRb B-gene
- I-gene
binding I-gene
sequence I-gene
of 0
large B-gene
T I-gene
antigen I-gene
, 0
and 0
as 0
a 0
preliminary 0
to 0
in 0
vivo 0
experiments 0
we 0
have 0
studied 0
their 0
effects 0
in 0
vitro 0
on 0
some 0
biological 0
activities 0
relevant 0
to 0
tumor 0
induction 0
. 0

We 0
conclude 0
that 0
the 0
conservation 0
of 0
nucleotides 0
154 0
to 0
156 0
is 0
likely 0
to 0
be 0
a 0
consequence 0
of 0
their 0
role 0
as 0
a 0
sequence 0
- 0
specific 0
recognition 0
element 0
for 0
the 0
SRP54 B-gene
protein I-gene
. 0

A 0
region 0
of 0
the 0
deduced 0
protein 0
shares 0
extensive 0
homology 0
with 0
a 0
catalytic 0
region 0
of 0
Raf B-gene
kinases I-gene
, 0
a 0
feature 0
shared 0
only 0
with 0
TFIIE B-gene
among 0
transcription 0
factors 0
. 0

The 0
low 0
molecular 0
mass 0
polypeptide 0
complex 0
is 0
assumed 0
to 0
be 0
involved 0
in 0
antigen 0
presentation 0
, 0
generating 0
peptides 0
from 0
cytosolic 0
protein 0
antigens 0
, 0
which 0
are 0
subsequently 0
presented 0
to 0
cytotoxic 0
T 0
- 0
lymphocytes 0
on 0
the 0
cell 0
surface 0
. 0

Secondary 0
cleavage 0
of 0
RT B-gene
at 0
Trp 0
- 0
595 0
- 0
Tyr 0
- 0
596 0
of 0
Pol B-gene
yields 0
a 0
truncated 0
form 0
lacking 0
the 0
C B-gene
- I-gene
terminal I-gene
RNase I-gene
H I-gene
domain I-gene
. 0

The 0
C 0
- 0
terminal 0
approximately 0
50 0
amino 0
acids 0
of 0
Bel B-gene
- I-gene
1 I-gene
are 0
shown 0
to 0
be 0
essential 0
for 0
Bel B-gene
- I-gene
1 I-gene
activity 0
but 0
can 0
be 0
effectively 0
substituted 0
by 0
the 0
C 0
- 0
terminal 0
activation 0
domain 0
of 0
VP16 B-gene
. 0

Since 0
the 0
- 0
172/ 0
- 0
148 0
element 0
also 0
conferred 0
estrogen 0
and 0
thyroid 0
hormone 0
responsiveness 0
, 0
it 0
can 0
be 0
considered 0
a 0
composite 0
hormone 0
response 0
element 0
. 0

Optimal 0
activation 0
of 0
T 0
cells 0
requires 0
at 0
least 0
two 0
signals 0
. 0

Together 0
with 0
a 0
considerably 0
shortened 0
and 0
interrupted 0
aromatic 0
aa 0
stretch 0
in 0
this 0
region 0
, 0
these 0
differences 0
are 0
discussed 0
in 0
terms 0
of 0
the 0
peculiar 0
affinity 0
of 0
cyanobacterial B-gene
cytochrome I-gene
oxidases I-gene
for 0
acidic 0
c B-gene
- I-gene
type I-gene
cytochromes I-gene
. 0

All 0
four 0
of 0
the 0
genes 0
have 0
a 0
similar 0
structure 0
, 0
with 0
the 0
receptor 0
protein 0
encoded 0
in 0
a 0
single 0
exon 0
. 0

Identity 0
of 0
GABP B-gene
with 0
NRF B-gene
- I-gene
2 I-gene
, 0
a 0
multisubunit 0
activator 0
of 0
cytochrome B-gene
oxidase I-gene
expression 0
, 0
reveals 0
a 0
cellular 0
role 0
for 0
an 0
ETS B-gene
domain I-gene
activator 0
of 0
viral 0
promoters 0
. 0

In 0
the 0
present 0
study 0
, 0
beta 0
- 0
funaltrexamine 0
( 0
beta 0
- 0
FNA 0
) 0
and 0
naltrindole 0
( 0
NTI 0
) 0
( 0
nonequilibrium 0
mu 0
- 0
and 0
delta 0
- 0
antagonist 0
, 0
respectively 0
) 0
were 0
used 0
to 0
precipitate 0
withdrawal 0
in 0
butorphanol 0
- 0
dependent 0
rats 0
. 0

The 0
intracellular 0
basic B-gene
region/helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
( I-gene
bHLH I-gene
) I-gene
dioxin I-gene
receptor I-gene
mediates 0
signal 0
transduction 0
by 0
dioxin 0
( 0
2,3,7,8 0
- 0
tetrachlorodibenzo 0
- 0
p 0
- 0
dioxin 0
) 0
and 0
functions 0
as 0
a 0
ligand 0
- 0
activated 0
DNA 0
binding 0
protein 0
directly 0
interacting 0
with 0
target 0
genes 0
by 0
binding 0
to 0
dioxin 0
response 0
elements 0
. 0

The 0
alpha B-gene
2A I-gene
- I-gene
adrenergic I-gene
receptor I-gene
( 0
alpha B-gene
2AAR I-gene
) 0
is 0
coupled 0
to 0
a 0
variety 0
of 0
effectors 0
via 0
pertussis B-gene
toxin I-gene
- 0
sensitive 0
GTP B-gene
- I-gene
binding I-gene
proteins I-gene
. 0

A 0
sequence 0
comparison 0
reveals 0
two 0
CCAAT/enhancer B-gene
binding I-gene
protein I-gene
( 0
C/EBP B-gene
) 0
consensus 0
sequences 0
, 0
basic 0
DNA 0
binding 0
region 0
and 0
leucine 0
zippers 0
1 0
and 0
2 0
( 0
bZIP1 0
and 0
bZIP2 0
) 0
, 0
within 0
this 0
region 0
. 0

One 0
of 0
these 0
genes 0
, 0
REC114 B-gene
, 0
is 0
described 0
here 0
, 0
and 0
the 0
data 0
confirm 0
that 0
REC114 B-gene
is 0
a 0
meiosis 0
- 0
specific 0
recombination 0
gene 0
with 0
no 0
detectable 0
function 0
in 0
mitosis 0
. 0

The 0
transactivation 0
function 0
of 0
EBNA2 B-gene
was 0
also 0
observed 0
in 0
the 0
HeLa 0
epithelial 0
cell 0
line 0
, 0
which 0
suggests 0
that 0
EBV 0
and 0
HIV 0
- 0
1 0
infection 0
of 0
non 0
- 0
B 0
cells 0
may 0
result 0
in 0
HIV B-gene
- I-gene
1 I-gene
promoter I-gene
activation 0
. 0

Mutation 0
of 0
the 0
C/EBP B-gene
binding I-gene
sites I-gene
in 0
the 0
Rous B-gene
sarcoma I-gene
virus I-gene
long I-gene
terminal I-gene
repeat I-gene
and 0
gag B-gene
enhancers I-gene
. 0

Nuclear B-gene
protein I-gene
phosphatase I-gene
2A I-gene
dephosphorylates 0
protein B-gene
kinase I-gene
A I-gene
- 0
phosphorylated 0
CREB B-gene
and 0
regulates 0
CREB B-gene
transcriptional 0
stimulation 0
. 0

We 0
show 0
that 0
IL B-gene
- I-gene
6 I-gene
activates 0
JRE B-gene
- I-gene
IL6 I-gene
through 0
an 0
H7 0
- 0
sensitive 0
pathway 0
that 0
does 0
not 0
involve 0
protein B-gene
kinase I-gene
C I-gene
, 0
cyclic B-gene
AMP I-gene
- I-gene
dependent I-gene
kinase I-gene
, 0
Ca B-gene
( I-gene
2+ I-gene
) I-gene
- I-gene
or I-gene
calmodulin I-gene
- I-gene
dependent I-gene
kinases I-gene
, 0
Ras B-gene
, 0
Raf B-gene
- I-gene
1 I-gene
, 0
or 0
NF B-gene
- I-gene
IL6 I-gene
( 0
C/EBP B-gene
beta I-gene
) 0
. 0

Mutation 0
of 0
the 0
presumptive 0
phosphorylated 0
tyrosine 0
and 0
threonine 0
residues 0
of 0
Mpk1p B-gene
individually 0
to 0
phenylalanine 0
and 0
alanine 0
, 0
respectively 0
, 0
severely 0
impaired 0
Mpk1p B-gene
function 0
. 0

Growth 0
factor 0
stimulation 0
rapidly 0
induces 0
a 0
reversible 0
change 0
in 0
the 0
electrophoretic 0
mobility 0
of 0
the 0
ternary 0
complex 0
, 0
accompanied 0
by 0
increased 0
phosphorylation 0
of 0
the 0
Elk B-gene
- I-gene
1 I-gene
C I-gene
- I-gene
terminal I-gene
region I-gene
and 0
by 0
the 0
activation 0
of 0
a 0
42 B-gene
kd I-gene
cellular I-gene
Elk I-gene
- I-gene
1 I-gene
kinase I-gene
. 0

In 0
contrast 0
to 0
the 0
situation 0
in 0
mammalian 0
cells 0
, 0
prolonged 0
exposure 0
of 0
the 0
agonist 0
( 0
24 0
h 0
) 0
does 0
not 0
result 0
in 0
down 0
regulation 0
of 0
the 0
remaining 0
70 0
% 0
of 0
the 0
receptors 0
. 0

This 0
stimulatory 0
effect 0
could 0
also 0
be 0
elicited 0
by 0
c B-gene
- I-gene
Jun I-gene
, 0
which 0
interacts 0
with 0
topo B-gene
II I-gene
, 0
but 0
not 0
by 0
c B-gene
- I-gene
Fos I-gene
, 0
which 0
does 0
not 0
bind 0
topo B-gene
II I-gene
in 0
our 0
in 0
vitro 0
assay 0
. 0

The 0
regulation 0
of 0
Myf B-gene
- I-gene
5 I-gene
and 0
MyoD B-gene
function 0
by 0
a 0
cAMP 0
- 0
dependent 0
pathway 0
may 0
partly 0
explain 0
how 0
external 0
signals 0
generated 0
by 0
serum 0
and 0
certain 0
peptide 0
growth 0
factors 0
can 0
be 0
transduced 0
to 0
the 0
nucleus 0
and 0
inhibit 0
dominant 0
- 0
acting 0
factors 0
that 0
are 0
responsible 0
for 0
myoblast 0
differentiation 0
. 0

16 0
, 0
99 0
- 0
104 0
) 0
. 0

We 0
have 0
previously 0
reported 0
that 0
high 0
level 0
human B-gene
desmin I-gene
expression 0
depends 0
on 0
a 0
280 0
- 0
base 0
pair 0
muscle 0
- 0
specific 0
enhancer 0
which 0
can 0
function 0
not 0
only 0
in 0
myotubes 0
, 0
but 0
can 0
also 0
activate 0
gene 0
expression 0
in 0
myoblasts 0
. 0

After 0
surgery 0
, 0
patients 0
self 0
administered 0
one 0
of 0
three 0
possible 0
postsurgical 0
medications 0
, 0
which 0
included 0
placebo 0
, 0
codeine 0
60 0
mg 0
, 0
and 0
ibuprofen 0
400 0
mg 0
, 0
when 0
their 0
pain 0
reached 0
a 0
moderate 0
or 0
severe 0
intensity 0
. 0

Replacement 0
of 0
the 0
wild 0
- 0
type 0
5' 0
- 0
regulatory 0
region 0
with 0
either 0
of 0
the 0
mutants 0
' 0
cis 0
- 0
acting 0
regulatory 0
element 0
resulted 0
in 0
the 0
anaerobic 0
expression 0
of 0
active B-gene
Mn I-gene
- I-gene
superoxide I-gene
dismutase I-gene
. 0

The 0
orf61 B-gene
gene I-gene
product I-gene
, 0
when 0
expressed 0
from 0
an 0
exogenous 0
promoter 0
, 0
inhibited 0
int B-gene
- 0
mediated 0
integration 0
at 0
the 0
chromosomal B-gene
attB I-gene
site I-gene
. 0

Expression 0
in 0
established 0
LCLs 0
, 0
occurring 0
irrespective 0
of 0
virus 0
producer 0
status 0
, 0
was 0
not 0
a 0
consequence 0
of 0
continued 0
in 0
vitro 0
passage 0
; 0
thus 0
, 0
appropriately 0
spliced 0
BamHI B-gene
- I-gene
A I-gene
transcripts I-gene
could 0
be 0
amplified 0
from 0
normal 0
B 0
cells 0
within 0
1 0
day 0
of 0
their 0
experimental 0
infection 0
in 0
vitro 0
, 0
along 0
with 0
BamHI B-gene
- I-gene
C/W I-gene
promoter 0
- 0
initiated 0
but 0
not 0
BamHI B-gene
- I-gene
F I-gene
promoter I-gene
- I-gene
initiated I-gene
mRNAs I-gene
. 0

Analysis 0
by 0
cell 0
surface 0
immunofluorescence 0
showed 0
that 0
the 0
UL28 B-gene
gene I-gene
is 0
not 0
required 0
for 0
expression 0
of 0
viral 0
glycoproteins 0
on 0
the 0
surface 0
of 0
infected 0
cells 0
. 0

Furthermore 0
, 0
a 0
mutant 0
receptor 0
( 0
Y977F/Y989F 0
[ 0
PLC B-gene
gamma I-gene
- 0
binding 0
sites 0
] 0
) 0
could 0
fully 0
activate 0
Ras B-gene
, 0
and 0
the 0
direct 0
activation 0
of 0
protein B-gene
kinase I-gene
C I-gene
and 0
calcium 0
mobilization 0
had 0
almost 0
no 0
effect 0
on 0
the 0
GDP/GTP 0
state 0
of 0
Ras B-gene
in 0
this 0
cell 0
line 0
. 0

Estrogen 0
treatment 0
in 0
high 0
doses 0
is 0
effective 0
in 0
reducing 0
adult 0
stature 0
in 0
constitutionally 0
tall 0
girls 0
. 0

Mutations 0
at 0
the 0
extreme 0
C 0
- 0
terminus 0
of 0
EIAV B-gene
Tat I-gene
impaired 0
both 0
RNA 0
binding 0
and 0
activation 0
domain 0
functions 0
, 0
suggesting 0
effects 0
on 0
secondary 0
or 0
tertiary 0
structure 0
. 0

This 0
observation 0
suggests 0
that 0
the 0
methyl 0
- 0
directed 0
repair 0
system 0
utilizes 0
the 0
proximal 0
d 0
( 0
GATC 0
) 0
sequence 0
to 0
direct 0
correction 0
. 0

Uracil B-gene
DNA I-gene
glycosylase I-gene
catalyzes 0
the 0
initial 0
step 0
in 0
the 0
repair 0
pathway 0
that 0
removes 0
potentially 0
mutagenic 0
uracil 0
from 0
duplex 0
DNA 0
. 0

Current 0
clinical 0
trials 0
should 0
answer 0
the 0
question 0
of 0
which 0
of 0
the 0
therapeutic 0
options 0
impairs 0
quality 0
of 0
life 0
less 0
. 0

Lithium 0
phthalocyanine 0
( 0
LiPc 0
) 0
is 0
a 0
prototype 0
of 0
another 0
generation 0
of 0
synthetic 0
, 0
metallic 0
- 0
organic 0
, 0
paramagnetic 0
crystallites 0
that 0
appear 0
very 0
useful 0
for 0
in 0
vitro 0
and 0
in 0
vivo 0
electron 0
paramagnetic 0
resonance 0
oximetry 0
. 0

In 0
this 0
report 0
, 0
we 0
focus 0
on 0
the 0
genetics 0
of 0
the 0
region 0
of 0
the 0
17 B-gene
hep I-gene
syn I-gene
gB I-gene
gene I-gene
that 0
conferred 0
both 0
the 0
syncytial 0
and 0
pathogenic 0
phenotypes 0
to 0
17 B-gene
syn+ I-gene
. 0

Recipients 0
with 0
acute 0
leukaemia 0
in 0
first 0
remission 0
or 0
chronic 0
myeloid 0
leukaemia 0
in 0
first 0
chronic 0
phase 0
were 0
analysed 0
as 0
good 0
risk 0
, 0
and 0
those 0
beyond 0
these 0
stages 0
, 0
as 0
poor 0
risk 0
patients 0
. 0

Elledge 0
, 0
P 0
. 0

Drugs 0
suppressed 0
> 0
or 0
= 0
75 0
% 0
of 0
the 0
total 0
premature 0
ventricular 0
contractions 0
in 0
all 0
patients 0
who 0
had 0
both 0
use 0
- 0
dependent 0
QRS 0
prolongation 0
and 0
reverse 0
use 0
- 0
dependent 0
QT 0
prolongation 0
, 0
in 0
79 0
% 0
of 0
patients 0
with 0
use 0
- 0
dependent 0
QRS 0
prolongation 0
alone 0
, 0
in 0
70 0
% 0
with 0
reverse 0
use 0
- 0
dependent 0
QT 0
prolongation 0
alone 0
, 0
and 0
in 0
11 0
% 0
with 0
neither 0
use 0
- 0
dependent 0
QRS 0
prolongation 0
nor 0
reverse 0
use 0
- 0
dependent 0
QT 0
prolongation 0
. 0

Losses 0
during 0
the 0
complete 0
procedure 0
are 0
corrected 0
for 0
using 0
radioactive 0
estrogen 0
conjugates 0
during 0
the 0
first 0
steps 0
and 0
later 0
by 0
adding 0
deuterated 0
internal 0
standards 0
of 0
all 0
compounds 0
measured 0
( 0
matairesinol 0
, 0
enterodiol 0
, 0
enterolactone 0
, 0
daidzein 0
, 0
O 0
- 0
desmethylangolensin 0
, 0
equol 0
, 0
and 0
genistein 0
) 0
. 0

IE2 B-gene
- 0
IE2 B-gene
interactions 0
were 0
mapped 0
to 0
a 0
domain 0
containing 0
a 0
putative 0
helix 0
- 0
turn 0
- 0
helix 0
motif 0
located 0
near 0
the 0
C 0
terminus 0
of 0
IE2 B-gene
, 0
between 0
amino 0
acids 0
456 0
and 0
539 0
. 0

The 0
Sp1 B-gene
region I-gene
, 0
however 0
, 0
is 0
converted 0
to 0
a 0
functionally 0
strong 0
TRE 0
by 0
the 0
viral B-gene
tat I-gene
factor I-gene
. 0

Precipitation 0
using 0
GST B-gene
fusion I-gene
proteins I-gene
containing 0
Fyn B-gene
SH2 B-gene
, 0
SH3 B-gene
, 0
and 0
SH2/SH3 B-gene
domains 0
revealed 0
that 0
SH2/SH3 I-gene

A 0
sheep 0
testicular 0
cDNA 0
library 0
constructed 0
in 0
pcDNA1 0
vector 0
was 0
screened 0
with 0
a 0
probe 0
generated 0
by 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
and 0
corresponding 0
to 0
a 0
1.6 0
kb 0
fragment 0
of 0
the 0
rat B-gene
luteinizing I-gene
hormone I-gene
receptor I-gene
cDNA I-gene
. 0

Two 0
putative 0
Rev B-gene
proteins I-gene
with 0
apparent 0
molecular 0
masses 0
of 0
18 0
and 0
16 0
kDa 0
were 0
expressed 0
by 0
p2/2 B-gene
and 0
p176 B-gene
, 0
while 0
p20 B-gene
expressed 0
only 0
a 0
16 0
- 0
kDa 0
species 0
. 0

Three 0
group 0
1 0
patients 0
developed 0
CMV 0
disease 0
; 0
1 0
group 0
2 0
patient 0
developed 0
CMV 0
hepatitis 0
. 0

The 0
ability 0
of 0
spt2 B-gene
mutations I-gene
to 0
suppress 0
the 0
transcriptional 0
interference 0
caused 0
by 0
the 0
delta B-gene
promoter I-gene
insertion I-gene
his I-gene
- I-gene
4 I-gene
- I-gene
912 I-gene
delta I-gene
correlates 0
with 0
an 0
increase 0
in 0
wild B-gene
- I-gene
type I-gene
HIS4 I-gene
mRNA I-gene
levels 0
. 0

Nuclear 0
localization 0
and 0
protein 0
sequence 0
similarities 0
suggested 0
that 0
the 0
SPT2/SIN1 B-gene
protein 0
may 0
be 0
related 0
to 0
the 0
SPT2/SIN1 I-gene

The 0
conserved 0
ninth 0
C 0
- 0
terminal 0
heptad 0
in 0
thyroid 0
hormone 0
and 0
retinoic B-gene
acid I-gene
receptors I-gene
mediates 0
diverse 0
responses 0
by 0
affecting 0
heterodimer 0
but 0
not 0
homodimer 0
formation 0
. 0

Genetic 0
interactions 0
between 0
BCK2 B-gene
and 0
other 0
pathway 0
components 0
suggested 0
that 0
BCK2 B-gene
functions 0
on 0
a 0
common 0
pathway 0
branch 0
with 0
PPZ1 B-gene
and 0
PPZ2 B-gene
. 0

Steroidogenic B-gene
factor I-gene
1 I-gene
, 0
an 0
orphan B-gene
nuclear I-gene
receptor I-gene
, 0
regulates 0
the 0
expression 0
of 0
the 0
rat B-gene
aromatase I-gene
gene I-gene
in 0
gonadal 0
tissues 0
. 0

To 0
study 0
the 0
functional 0
differences 0
between 0
cutaneous 0
HPV5 0
and 0
HPV8 0
E7s B-gene
and 0
genital B-gene
HPV16 I-gene
E7 I-gene
, 0
we 0
cloned 0
each 0
of 0
the 0
E7 B-gene
open 0
reading 0
frames 0
and 0
tested 0
their 0
immortalizing 0
and 0
transforming 0
activities 0
, 0
the 0
binding 0
ability 0
of 0
their 0
products 0
with 0
retinoblastoma B-gene
protein I-gene
( 0
RB B-gene
) 0
and 0
their 0
complementation 0
activity 0
of 0
a 0
RB B-gene
- I-gene
nonbinding I-gene
adenovirus I-gene
E1A I-gene
mutant I-gene
. 0

The 0
rhaB B-gene
transcription I-gene
start I-gene
site I-gene
was 0
mapped 0
to 0
- 0
24 0
relative 0
to 0
the 0
start 0
of 0
translation 0
. 0

Several 0
lines 0
of 0
evidence 0
demonstrate 0
that 0
this 0
growth 0
inhibition 0
requires 0
active 0
PKA B-gene
subunits I-gene
and 0
cAMP 0
: 0
( 0
i 0
) 0
this 0
phenotype 0
is 0
dependent 0
on 0
cAMP 0
since 0
it 0
is 0
not 0
seen 0
in 0
a 0
strain 0
lacking 0
adenylyl B-gene
cyclase I-gene
activity 0
, 0
but 0
the 0
growth 0
rate 0
of 0
these 0
transformants 0
is 0
slower 0
when 0
exogenous 0
cAMP 0
is 0
added 0
; 0
( 0
ii 0
) 0
normal 0
growth 0
occurs 0
when 0
wild 0
- 0
type 0
RI B-gene
cDNA 0
is 0
replaced 0
by 0
a 0
mutant B-gene
RI I-gene
cDNA I-gene
encoding 0
a 0
RI B-gene
protein I-gene
with 0
reduced 0
cAMP 0
binding 0
; 0
and 0
( 0
iii 0
) 0
the 0
growth 0
- 0
inhibited 0
phenotype 0
of 0
the 0
transformed 0
BL21 0
( 0
DE3 0
) 0
cells 0
requires 0
soluble 0
, 0
active 0
C B-gene
alpha I-gene
protein I-gene
. 0

Liu 0
, 0
B 0
. 0

BCR B-gene
- 0
ABL B-gene
and 0
v B-gene
- I-gene
abl I-gene
oncogenes I-gene
induce 0
distinct 0
patterns 0
of 0
thymic 0
lymphoma 0
involving 0
different 0
lymphocyte 0
subsets 0
. 0

These 0
experiments 0
confirm 0
that 0
the 0
6 0
- 0
S 0
liganded 0
form 0
of 0
the 0
receptor 0
identified 0
in 0
nuclear 0
extracts 0
of 0
cells 0
treated 0
with 0
2,3,7,8 0
- 0
tetrachlorodibenzo 0
- 0
p 0
- 0
dioxin 0
( 0
TCDD 0
) 0
contains 0
the 0
Ah B-gene
receptor I-gene
protein I-gene
and 0
ARNT B-gene
but 0
not 0
the 0
90 B-gene
- I-gene
kDa I-gene
heat I-gene
shock I-gene
protein I-gene
. 0

LDL B-gene
cholesterol I-gene
decreased 0
from 0
4.74 0
+/ 0
- 0
0.87 0
to 0
3.78 0
+/ 0
- 0
0.78 0
mmol/l 0
after 0
8 0
weeks 0
on 0
simvastatin 0
( 0
P 0
< 0
0.001 0
) 0
, 0
and 0
apo B-gene
B I-gene
fell 0
from 0
142 0
+/ 0
- 0
31 0
to 0
112 0
+/ 0
- 0
22 0
mg/dl 0
( 0
P 0
< 0
0.001 0
) 0
. 0

LDL B-gene
cholesterol I-gene
decreased 0
from 0
4.74 0
+/ 0
- 0
0.87 0
to 0
3.78 0
+/ 0
- 0
0.78 0
mmol/l 0
after 0
8 0
weeks 0
on 0
simvastatin 0
( 0
P 0
< 0
0.001 0
) 0
, 0
and 0
apo B-gene
B I-gene
fell 0
from 0
142 0
+/ 0
- 0
31 0
to 0
112 0
+/ 0
- 0
22 0
mg/dl 0
( 0
P 0
< 0
0.001 0
) 0
. 0

This 0
negative 0
element 0
may 0
, 0
at 0
least 0
in 0
part 0
, 0
be 0
responsible 0
for 0
the 0
cell 0
type 0
- 0
specific 0
expression 0
of 0
the 0
DGK B-gene
gene I-gene
. 0

Regulated 0
activity 0
of 0
the 0
distal 0
promoter 0
- 0
like 0
element 0
of 0
the 0
human B-gene
corticotropin I-gene
- I-gene
releasing I-gene
hormone I-gene
gene I-gene
and 0
secondary 0
structural 0
features 0
of 0
its 0
corresponding 0
transcripts 0
. 0

A 0
new 0
bioencapsulation 0
technology 0
for 0
microbial 0
inoculants 0
. 0

We 0
linked 0
hypersensitivity 0
site 0
2 0
( 0
HS2 0
) 0
from 0
the 0
locus 0
control 0
region 0
( 0
LCR 0
) 0
to 0
a 0
A B-gene
gamma I-gene
- I-gene
globin I-gene
gene 0
( 0
A B-gene
gamma* I-gene
) 0
mutationally 0
marked 0
to 0
allow 0
its 0
transcript 0
to 0
be 0
distinguished 0
from 0
endogenous 0
gamma B-gene
- I-gene
globin I-gene
mRNA 0
. 0

INTERVENTIONS 0
- 0
- 0
Patients 0
allocated 0
to 0
treatment 0
with 0
levodopa/dopa B-gene
decarboxylase I-gene
inhibitor 0
alone 0
( 0
arm 0
1 0
) 0
, 0
levodopa/decarboxylase B-gene
inhibitor/selegiline 0
in 0
combination 0
( 0
arm 0
2 0
) 0
, 0
or 0
bromocriptine 0
( 0
arm 0
3 0
) 0
. 0

It 0
contains 0
three 0
putative 0
binding 0
sites 0
for 0
transcription B-gene
factor I-gene
Sp1 I-gene
as 0
well 0
as 0
several 0
short 0
sequences 0
that 0
are 0
similar 0
to 0
known 0
cis 0
- 0
acting 0
enhancers 0
or 0
binding 0
sites 0
for 0
transcription 0
factors 0
. 0

French 0
bean 0
contains 0
a 0
small 0
family 0
of 0
genes B-gene
encoding I-gene
PAL I-gene
and 0
two 0
of 0
these 0
genes 0
, 0
PAL2 B-gene
and 0
PAL3 B-gene
, 0
have 0
been 0
shown 0
to 0
be 0
differentially 0
expressed 0
at 0
the 0
mRNA 0
level 0
in 0
bean 0
tissues 0
. 0

Plasma 0
thromboxane 0
B2 0
levels 0
in 0
the 0
older 0
group 0
were 0
about 0
double 0
those 0
in 0
younger 0
piglets 0
. 0

By 0
stepwise 0
linear 0
multiple 0
regression 0
analysis 0
, 0
ionized 0
magnesium 0
was 0
significantly 0
related 0
to 0
cyclosporin 0
trough 0
level 0
and 0
total 0
cholesterol 0
but 0
not 0
to 0
serum 0
creatinine 0
, 0
time 0
after 0
transplant 0
or 0
the 0
dose 0
of 0
cyclosporin 0
. 0

The 0
human B-gene
insulin I-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
II I-gene
( 0
IGF B-gene
- I-gene
II I-gene
) 0
gene 0
contains 0
four 0
promoters 0
( 0
P1 0
, 0
P2 0
, 0
P3 0
and 0
P4 0
) 0
. 0

Moreover 0
, 0
in 0
transient 0
transfection 0
assays 0
, 0
PU.1 B-gene
alone 0
activated 0
reporter 0
constructs 0
containing 0
the 0
JB 0
cis 0
- 0
element 0
, 0
and 0
the 0
activation 0
was 0
shown 0
to 0
be 0
dependent 0
on 0
a 0
glutamine 0
- 0
rich 0
sequence 0
in 0
the 0
amino 0
- 0
terminal 0
portion 0
of 0
PU.1 B-gene
. 0

Army 0
veterans 0
given 0
yellow 0
fever 0
vaccine 0
contaminated 0
with 0
hepatitis 0
B 0
virus 0
in 0
1942 0
and 0
controls 0
and 0
( 0
b 0
) 0
a 0
case 0
- 0
control 0
study 0
comparing 0
veterans 0
with 0
hepatocellular 0
carcinoma 0
in 0
Veterans 0
Affairs 0
hospitals 0
with 0
matched 0
controls 0
with 0
respect 0
to 0
receipt 0
of 0
contaminated 0
vaccine 0
in 0
1942 0
. 0

They 0
were 0
found 0
to 0
be 0
seropositive 0
for 0
antibodies 0
to 0
hepatitis 0
C 0
virus 0
by 0
second 0
- 0
generation 0
testing 0
( 0
RIBA 0
2 0
, 0
Ortho 0
Diagnostic 0
Systems 0
Inc 0
, 0
Westwood 0
, 0
MA 0
) 0
. 0

Defects 0
of 0
fibrillin B-gene
( 0
FBN1 B-gene
) 0
, 0
a 0
glycoprotein 0
component 0
of 0
the 0
extracellular 0
microfibril 0
, 0
cause 0
Marfan 0
syndrome 0
. 0

When 0
introduced 0
into 0
recJ+ B-gene
strains 0
, 0
srjA B-gene
mutations 0
conferred 0
hyperrecombinational 0
and 0
hyper B-gene
- I-gene
UVr I-gene
phenotypes 0
. 0

Distinguishing 0
roles 0
of 0
the 0
membrane 0
- 0
cytoskeleton 0
and 0
cadherin B-gene
mediated 0
cell 0
- 0
cell 0
adhesion 0
in 0
generating 0
different 0
Na+ B-gene
, I-gene
K I-gene
( I-gene
+ I-gene
) I-gene
- I-gene
ATPase I-gene
distributions 0
in 0
polarized 0
epithelia 0
. 0

Neonatal 0
lupus 0
erythematosus 0
is 0
most 0
often 0
associated 0
with 0
autoantibodies 0
against 0
Ro B-gene
and 0
La B-gene
antigens 0
. 0

Genetic 0
abnormalities 0
that 0
could 0
lead 0
to 0
mutagenesis 0
include 0
chromosomal 0
abnormalities 0
and 0
single 0
- 0
gene 0
mutations 0
. 0

Hops 0
, 0
and 0
L 0
. 0

Continued 0
absorption 0
of 0
amino 0
acids 0
by 0
the 0
NBB 0
carrier 0
( 0
for 0
neutral 0
amino 0
acids 0
) 0
, 0
the 0
Y+ 0
system 0
( 0
for 0
dibasic 0
amino 0
acids 0
) 0
, 0
and 0
the 0
PHE 0
carrier 0
were 0
operative 0
even 0
during 0
the 0
actively 0
purging 0
stage 0
of 0
watery 0
diarrhoea 0
due 0
to 0
cholera 0
. 0

1 0
) 0
CFDN 0
, 0
AMPC 0
and 0
MNZ 0
showed 0
a 0
potent 0
antimicrobial 0
activity 0
against 0
H. 0
pylori 0
, 0
and 0
especially 0
, 0
AMPC 0
showed 0
a 0
marked 0
bactericidal 0
activity 0
in 0
a 0
short 0
time 0
. 0

Creutzfeldt 0
- 0
Jakob 0
disease 0
and 0
lyophilised 0
dura 0
mater 0
grafts 0
: 0
report 0
of 0
two 0
cases 0
. 0

A 0
high 0
mean 0
intensity 0
of 0
CLTPA 0
( 0
standardized 0
multivariate 0
regression 0
coefficient 0
beta 0
- 0
0.059 0
, 0
p 0
= 0
0.020 0
) 0
and 0
a 0
high 0
maximal 0
oxygen 0
uptake 0
( 0
beta 0
- 0
0.163 0
, 0
p 0
< 0
0.001 0
) 0
were 0
associated 0
with 0
reduced 0
plasma B-gene
fibrinogen I-gene
when 0
adjusting 0
for 0
the 0
strongest 0
covariates 0
. 0

What 0
young 0
people 0
think 0
and 0
do 0
when 0
the 0
option 0
for 0
cystic 0
fibrosis 0
carrier 0
testing 0
is 0
available 0
. 0

A 0
patient 0
matches 0
a 0
PIC 0
patient 0
if 0
both 0
have 0
the 0
same 0
mechanism 0
of 0
injury 0
, 0
the 0
same 0
coding 0
of 0
Revised 0
Trauma 0
Score 0
variables 0
( 0
Glascow 0
Coma 0
Scale 0
score 0
, 0
systolic 0
blood 0
pressure 0
, 0
respiratory 0
rate 0
) 0
, 0
the 0
same 0
coded 0
age 0
per 0
A 0
Severity 0
Characterization 0
of 0
Trauma 0
) 0
( 0
ASCOT 0
) 0
, 0
and 0
if 0
they 0
differ 0
by 0
no 0
more 0
than 0
0.5 0
for 0
A 0
, 0
B 0
, 0
and 0
C 0
( 0
the 0
ASCOT 0
components 0
for 0
serious 0
injuries 0
) 0
. 0

Skin 0
and 0
bowel 0
TPO2 0
varied 0
with 0
DO2 0
and 0
each 0
other 0
( 0
P 0
< 0
0.05 0
) 0
. 0

A 0
region 0
approximately 0
100 0
bp 0
upstream 0
from 0
the 0
transcription 0
start 0
point 0
of 0
virB B-gene
was 0
identified 0
as 0
being 0
necessary 0
for 0
full 0
activation 0
of 0
this 0
promoter 0
by 0
VirF B-gene
. 0

We 0
have 0
isolated 0
a 0
cosmid 0
containing 0
DNA 0
that 0
corresponds 0
to 0
the 0
site 0
of 0
transposon 0
insertion 0
in 0
257DH4 0
and 0
have 0
localized 0
Tn5 B-gene
on 0
an 0
8.0 B-gene
kb I-gene
EcoRI I-gene
fragment I-gene
. 0

The 0
scr B-gene
regulon I-gene
of 0
pUR400 0
and 0
the 0
chromosomally B-gene
encoded I-gene
scr I-gene
regulon I-gene
of I-gene
Klebsiella I-gene
pneumoniae I-gene
KAY2026 I-gene
are 0
both 0
negatively 0
controlled 0
by 0
a 0
specific 0
repressor 0
( 0
ScrR B-gene
) 0
. 0

Although 0
the 0
molecular 0
mechanisms 0
involved 0
in 0
this 0
regulation 0
are 0
currently 0
being 0
elucidated 0
, 0
very 0
little 0
is 0
known 0
about 0
the 0
trans 0
- 0
acting 0
factors 0
that 0
allow 0
expression 0
of 0
the 0
nitrate B-gene
and I-gene
nitrite I-gene
reductase I-gene
genes I-gene
which 0
code 0
for 0
the 0
first 0
enzymes 0
in 0
the 0
pathway 0
. 0

The 0
Ntl1 B-gene
gene I-gene
is 0
present 0
as 0
a 0
unique 0
copy 0
in 0
the 0
diploid 0
N. 0
plumbaginifolia 0
species 0
. 0

Transient 0
transfection 0
experiments 0
revealed 0
that 0
Pax B-gene
- I-gene
8 I-gene
isoforms I-gene
a I-gene
and I-gene
b I-gene
, 0
but 0
not 0
c 0
and 0
d 0
, 0
strongly 0
stimulate 0
transcription 0
from 0
a 0
promoter 0
containing 0
six 0
copies 0
of 0
a 0
paired B-gene
- I-gene
domain I-gene
recognition I-gene
sequence I-gene
. 0

The 0
amino 0
- 0
terminal 0
third 0
of 0
the 0
protein 0
contains 0
a 0
high B-gene
- I-gene
mobility I-gene
- I-gene
group I-gene
motif I-gene
characteristic 0
of 0
DNA 0
- 0
binding 0
proteins 0
. 0

We 0
have 0
examined 0
the 0
ability 0
of 0
various 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
subunits I-gene
to 0
bind 0
to 0
, 0
and 0
activate 0
transcription 0
from 0
, 0
the 0
IL B-gene
- I-gene
8 I-gene
promoter I-gene
. 0

When 0
multiple 0
copies 0
of 0
the 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
NF B-gene
- I-gene
kappa I-gene
B I-gene
site I-gene
were 0
linked 0
to 0
an 0
enhancerless 0
simian B-gene
virus I-gene
40 I-gene
promoter I-gene
, 0
this 0
element 0
was 0
able 0
to 0
mediate 0
phorbol 0
ester 0
- 0
or 0
lipopolysaccharide 0
- 0
inducible 0
gene 0
expression 0
. 0

We 0
found 0
that 0
the 0
3' 0
- 0
end 0
- 0
adjacent 0
sequence 0
CA 0
( 0
N 0
) 0
3 0
- 0
10AGTNNAA 0
, 0
conserved 0
in 0
plant 0
Pol B-gene
II I-gene
- 0
specific 0
U B-gene
snRNA I-gene
genes I-gene
, 0
is 0
essential 0
for 0
the 0
3' 0
- 0
end 0
formation 0
of 0
U2 B-gene
transcripts I-gene
and 0
, 0
similar 0
to 0
the 0
vertebrate 0
3 0
' 0
box 0
, 0
is 0
highly 0
tolerant 0
to 0
mutation 0
. 0

These 0
results 0
indicate 0
that 0
Rb B-gene
protein I-gene
is 0
interacting 0
with 0
some 0
component 0
( 0
s 0
) 0
of 0
the 0
cell 0
cycle 0
- 0
regulatory 0
machinery 0
during 0
G2 0
phase 0
. 0

MDBP B-gene
from 0
HeLa 0
and 0
Raji 0
cells 0
formed 0
DNA 0
- 0
protein 0
complexes 0
with 0
X 0
- 0
box 0
oligonucleotides 0
that 0
coelectrophoresed 0
with 0
those 0
containing 0
standard 0
MDBP B-gene
sites I-gene
. 0

Transgenic 0
mice 0
harboring 0
the 0
rat 0
TnI B-gene
- 0
CAT B-gene
fusion 0
gene 0
expressed 0
the 0
reporter 0
specifically 0
in 0
the 0
skeletal 0
muscle 0
. 0

METHODS 0
: 0
Fifty 0
- 0
one 0
healthy 0
eyes 0
, 0
169 0
ocular 0
hypertensive 0
eyes 0
with 0
normal 0
visual 0
fields 0
, 0
and 0
132 0
glaucomatous 0
eyes 0
with 0
early 0
visual 0
field 0
defects 0
were 0
evaluated 0
with 0
qualitative 0
and 0
quantitative 0
measures 0
of 0
structural 0
damage 0
to 0
the 0
optic 0
nerve 0
and 0
nerve 0
fiber 0
layer 0
. 0

Consistent 0
with 0
the 0
hypothesis 0
that 0
it 0
acts 0
as 0
transcriptional 0
regulator 0
, 0
wild B-gene
- I-gene
type I-gene
p53 I-gene
protein I-gene
binds 0
DNA 0
and 0
activates 0
transcription 0
of 0
several 0
promoters 0
. 0

The 0
ADP B-gene
- I-gene
ribosylation I-gene
factor I-gene
( 0
ARF B-gene
) 0
family 0
is 0
one 0
of 0
four 0
subfamilies 0
of 0
the 0
RAS B-gene
superfamily I-gene
of 0
low B-gene
molecular I-gene
weight I-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
( 0
G B-gene
proteins I-gene
) 0
. 0

The 0
E1 B-gene
gene I-gene
is 0
located 0
within 0
the 0
first 0
intron 0
of 0
the 0
gene 0
for 0
RCC1 B-gene
, 0
a 0
protein 0
that 0
regulates 0
onset 0
of 0
mitosis 0
. 0

Genomic 0
Southern 0
blot 0
analysis 0
and 0
chromosome 0
mapping 0
showed 0
that 0
GPRK6 B-gene
hybridizes 0
to 0
two 0
closely 0
related 0
genes 0
located 0
on 0
chromosomes 0
5 0
and 0
13 0
and 0
are 0
, 0
therefore 0
, 0
distinct 0
from 0
the 0
GPRK B-gene
located 0
near 0
the 0
Huntington B-gene
disease I-gene
locus I-gene
on 0
chromosome 0
4 0
. 0

Metabolic 0
labeling 0
studies 0
in 0
S. 0
cerevisiae 0
and 0
co 0
- 0
expression 0
of 0
nmt72p B-gene
with 0
several 0
protein 0
substrates 0
of 0
Nmt1p B-gene
in 0
Escherichia 0
coli 0
indicate 0
that 0
the 0
Leu99 0
- 0
- 0
> 0
Pro 0
substitution 0
causes 0
a 0
reduction 0
in 0
the 0
acylation 0
of 0
some 0
but 0
not 0
all 0
protein 0
substrates 0
. 0

These 0
CTD B-gene
kinases I-gene
, 0
designated 0
CTDK1 B-gene
and 0
CTDK2 B-gene
, 0
are 0
fractionated 0
by 0
chromatography 0
on 0
Mono 0
Q 0
. 0

Instead 0
, 0
mRNA 0
of 0
2.0 0
and 0
2.8 0
kb 0
are 0
detected 0
in 0
varying 0
abundance 0
. 0

Previously 0
, 0
we 0
identified 0
a 0
51 0
- 0
bp 0
promoter 0
fragment 0
, 0
oligo31/32 0
, 0
which 0
conferred 0
heat 0
shock 0
inducibility 0
on 0
the 0
heterologous 0
CYC1 B-gene
- 0
lacZ B-gene
reporter 0
gene 0
in 0
S. 0
cerevisiae 0
( 0
N 0
. 0

The 0
sequence 0
of 0
the 0
HIR1 B-gene
gene I-gene
predicts 0
an 0
88 0
- 0
kDa 0
protein 0
with 0
three 0
repeats 0
of 0
a 0
motif 0
found 0
in 0
the 0
G B-gene
beta I-gene
subunit I-gene
of 0
retinal B-gene
transducin I-gene
and 0
in 0
a 0
yeast 0
transcriptional 0
repressor 0
, 0
Tup1 B-gene
. 0

All 0
of 0
these 0
data 0
suggest 0
that 0
replication 0
of 0
UV 0
- 0
damaged 0
templates 0
occurs 0
in 0
vitro 0
as 0
it 0
does 0
in 0
vivo 0
and 0
that 0
this 0
replication 0
results 0
in 0
mutation 0
fixation 0
. 0

To 0
identify 0
factors 0
that 0
may 0
modify 0
the 0
heterosexual 0
transmission 0
of 0
human 0
T 0
cell 0
leukemia/lymphoma 0
virus 0
type 0
I 0
( 0
HTLV 0
- 0
I 0
) 0
, 0
534 0
married 0
couples 0
enrolled 0
in 0
the 0
Miyazaki 0
Cohort 0
Study 0
between 0
November 0
1984 0
and 0
April 0
1989 0
were 0
studied 0
: 0
95 0
husband 0
HTLV 0
- 0
I 0
- 0
seropositive 0
( 0
H+ 0
) 0
/wife 0
seropositive 0
( 0
W+ 0
) 0
, 0
33 0
H+/W 0
- 0
, 0
64 0
H 0
- 0
/W+ 0
, 0
and 0
342 0
H 0
- 0
/W 0
- 0
. 0

Biol 0
. 0

To 0
characterize 0
the 0
expression 0
of 0
this 0
DNA B-gene
repair I-gene
enzyme I-gene
, 0
we 0
have 0
isolated 0
the 0
corresponding 0
genomic 0
clone 0
. 0

L. 0
, 0
Stange 0
, 0
G. 0
, 0
Markovich 0
, 0
D. 0
, 0
Biber 0
, 0
J. 0
, 0
Testar 0
, 0
X. 0
, 0
Zorzano 0
, 0
A. 0
, 0
Palacin 0
, 0
M. 0
, 0
and 0
Murer 0
, 0
H 0
. 0

The 0
nucleotide 0
sequence 0
of 0
the 0
gene 0
predicts 0
a 0
polypeptide 0
of 0
215 0
amino 0
acids 0
( 0
25.2 0
kDa 0
) 0
with 0
two 0
putative 0
membrane 0
- 0
spanning 0
domains 0
. 0

SAECG 0
, 0
echocardiography 0
and 0
thallium 0
- 0
201 0
imaging 0
were 0
performed 0
before 0
and 0
1 0
month 0
after 0
attempted 0
angioplasty 0
. 0

They 0
were 0
called 0
PACE4 B-gene
and 0
PC4 B-gene
. 0

265 0
, 0
1102 0
- 0
1110 0
) 0
. 0

Both 0
fusion 0
proteins 0
form 0
stable 0
specific 0
complexes 0
with 0
a 0
short 0
DNA 0
duplex 0
harboring 0
the 0
CTGT 0
( 0
at 0
) 0
4ACAG 0
consensus 0
sequence 0
of 0
the 0
LexA B-gene
repressor I-gene
. 0

Ten 0
selenocysteine 0
residues 0
( 0
deduced 0
) 0
are 0
present 0
. 0

CONCLUSIONS 0
: 0
Free 0
protein B-gene
S I-gene
deficiency 0
is 0
common 0
among 0
hospitalized 0
patients 0
, 0
even 0
in 0
the 0
absence 0
of 0
a 0
recognized 0
predisposing 0
condition 0
. 0

During 0
the 0
past 0
decade 0
, 0
different 0
types 0
of 0
endogenous 0
retroviral 0
sequences 0
have 0
been 0
defined 0
in 0
the 0
human 0
genome 0
usually 0
by 0
low 0
stringency 0
hybridization 0
employing 0
DNA 0
probes 0
of 0
evolutionary 0
conserved 0
animal 0
retrovirus 0
genes 0
. 0

As 0
the 0
components 0
of 0
these 0
complexes 0
, 0
at 0
least 0
five 0
TRBPs B-gene
( 0
p30 B-gene
, 0
p37 B-gene
, 0
p46 B-gene
, 0
p50 B-gene
, 0
and 0
p56 B-gene
) 0
showing 0
specific 0
binding 0
to 0
the 0
TAR 0
RNA 0
were 0
detected 0
in 0
the 0
uv 0
cross 0
- 0
linking 0
assay 0
. 0

The 0
obvious 0
functional 0
necessity 0
for 0
editing 0
in 0
kinetoplastid 0
mitochondria 0
is 0
the 0
formation 0
of 0
translatable 0
mRNAs 0
. 0

The 0
use 0
of 0
this 0
model 0
for 0
investigating 0
pathophysiologically 0
significant 0
issues 0
in 0
denervating 0
diseases 0
is 0
illustrated 0
with 0
five 0
different 0
sets 0
of 0
parameters 0
. 0

An 0
extensive 0
inverted 0
repeat 0
is 0
present 0
3 0
' 0
of 0
rpeA B-gene
; 0
inverted 0
repeats 0
are 0
found 0
downstream 0
of 0
all 0
PE B-gene
operons I-gene
sequenced 0
to 0
date 0
, 0
although 0
the 0
sequence 0
is 0
not 0
conserved 0
. 0

We 0
describe 0
a 0
novel 0
cytoplasmic B-gene
tyrosine I-gene
kinase I-gene
, 0
termed 0
BPK B-gene
( 0
B B-gene
cell I-gene
progenitor I-gene
kinase I-gene
) 0
, 0
which 0
is 0
expressed 0
in 0
all 0
stages 0
of 0
the 0
B 0
lineage 0
and 0
in 0
myeloid 0
cells 0
. 0

Large 0
differences 0
between 0
the 0
groups 0
were 0
not 0
observed 0
in 0
HA B-gene
- I-gene
synthesizing I-gene
enzyme I-gene
activity 0
, 0
but 0
degradative 0
enzyme 0
activity 0
was 0
much 0
higher 0
in 0
aspirin 0
- 0
induced 0
asthma 0
- 0
related 0
polyps 0
than 0
in 0
other 0
types 0
of 0
nasal 0
polyps 0
tested 0
. 0

In 0
the 0
multivariate 0
analysis 0
, 0
six 0
variables 0
were 0
independently 0
correlated 0
with 0
survival 0
: 0
blood 0
urea 0
nitrogen 0
level 0
, 0
serum B-gene
aspartate I-gene
aminotransferase I-gene
level 0
, 0
community 0
- 0
acquired 0
vs. 0
hospital 0
- 0
acquired 0
peritonitis 0
, 0
age 0
, 0
Child 0
- 0
Pugh 0
score 0
and 0
ileus 0
. 0

Localization 0
of 0
the 0
intronless 0
gene 0
coding 0
for 0
calmodulin B-gene
- I-gene
like I-gene
protein I-gene
CLP B-gene
to 0
human 0
chromosome 0
10p13 0
- 0
ter 0
. 0

In 0
wandering 0
stage 0
larvae 0
, 0
the 0
OBP B-gene
transcript I-gene
appeared 0
to 0
be 0
at 0
least 0
250 0
- 0
fold 0
less 0
abundant 0
than 0
ribosomal 0
RNA 0
. 0

One 0
such 0
mutant 0
also 0
affects 0
the 0
overlapping 0
- 0
10 0
hexamer 0
of 0
PR 0
and 0
results 0
in 0
reduced 0
occupancy 0
by 0
both 0
MerR B-gene
and 0
RNA B-gene
polymerase I-gene
, 0
likely 0
as 0
a 0
result 0
of 0
inefficient 0
transcriptional 0
initiation 0
of 0
merR B-gene
mRNA I-gene
. 0

However 0
, 0
L B-gene
- I-gene
plastin I-gene
has 0
been 0
found 0
in 0
many 0
types 0
of 0
malignant 0
human 0
cells 0
of 0
non 0
- 0
hemopoietic 0
origin 0
suggesting 0
that 0
its 0
expression 0
is 0
induced 0
accompanying 0
tumorigenesis 0
in 0
solid 0
tissues 0
. 0

Finally 0
, 0
we 0
present 0
evidence 0
that 0
fimbrin B-gene
is 0
a 0
third 0
distinct 0
plastin B-gene
isoform I-gene
which 0
is 0
specifically 0
expressed 0
at 0
high 0
levels 0
in 0
the 0
small 0
intestine 0
. 0

This 0
promoter 0
could 0
direct 0
the 0
constitutive 0
expression 0
of 0
the 0
reporter 0
beta B-gene
- I-gene
galactosidase I-gene
at 0
high 0
frequency 0
in 0
transfected 0
colonies 0
of 0
transformed 0
cells 0
that 0
express 0
L B-gene
- I-gene
plastin I-gene
constitutively 0
; 0
by 0
contrast 0
, 0
this 0
promoter 0
was 0
virtually 0
inactive 0
in 0
transfected 0
colonies 0
of 0
normal 0
fibroblasts 0
and 0
it 0
exhibited 0
a 0
low 0
frequency 0
of 0
constitutive 0
activation 0
in 0
transfected 0
colonies 0
of 0
in 0
vitro 0
SV40 0
- 0
transformed 0
fibroblasts 0
which 0
did 0
not 0
exhibit 0
L B-gene
- I-gene
plastin I-gene
expression 0
. 0

The 0
half 0
- 0
life 0
of 0
the 0
serum 0
- 0
induced 0
CBP/tk B-gene
binding 0
activity 0
was 0
estimated 0
to 0
be 0
less 0
than 0
1 0
h. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

The 0
DNase B-gene
I I-gene
footprint 0
extended 0
5 0
' 0
in 0
the 0
silencer 0
region 0
to 0
include 0
an 0
inverted 0
repeat 0
of 0
a 0
six 0
- 0
nucleotide 0
motif 0
( 0
epsilon 0
- 0
267 0
to 0
- 0
278 0
bp 0
) 0
which 0
shares 0
5 0
of 0
6 0
bases 0
with 0
the 0
GATA B-gene
- I-gene
1 I-gene
consensus I-gene
sequence I-gene
. 0

Furthermore 0
, 0
competitor 0
containing 0
the 0
YY1 B-gene
consensus I-gene
sequence I-gene
competed 0
for 0
protein B-gene
B I-gene
binding 0
, 0
whereas 0
competitor 0
containing 0
a 0
perfect 0
yeast B-gene
ABF I-gene
- I-gene
1 I-gene
consensus I-gene
sequence I-gene
did 0
not 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

The 0
gene 0
includes 0
three 0
exons 0
and 0
two 0
introns 0
within 0
1.6 0
kilobases 0
of 0
DNA 0
, 0
and 0
the 0
entire 0
open 0
reading 0
frame 0
for 0
glycoprotein B-gene
IX I-gene
is 0
included 0
within 0
the 0
third 0
exon 0
. 0

Rhizobium 0
meliloti 0
large 0
plasmid 0
pRmeGR4b 0
carries 0
the 0
nodulation 0
competitiveness 0
locus 0
nfe B-gene
responsible 0
for 0
the 0
nodulation 0
efficiency 0
and 0
competitive 0
ability 0
of 0
strain 0
GR4 0
on 0
alfalfa 0
roots 0
. 0

Further 0
, 0
the 0
ability 0
of 0
recombinant 0
beta 0
and/or 0
gamma 0
chains 0
to 0
function 0
in 0
defined 0
biochemical 0
assays 0
of 0
beta 0
gamma 0
activity 0
was 0
assessed 0
for 0
membrane 0
extracts 0
and 0
supernatant 0
fractions 0
from 0
infected 0
Sf9 0
cells 0
. 0

This 0
report 0
describes 0
the 0
identification 0
of 0
a 0
gene 0
of 0
related 0
function 0
, 0
SMD1 B-gene
, 0
located 0
immediately 0
3 0
' 0
to 0
PRP38 B-gene
. 0

These 0
data 0
establish 0
Smd1p B-gene
as 0
a 0
required 0
component 0
of 0
the 0
cellular 0
splicing 0
apparatus 0
and 0
a 0
factor 0
in 0
snRNA 0
maturation 0
and 0
stability 0
. 0

This 0
study 0
compared 0
the 0
gross 0
and 0
fine 0
motor 0
performance 0
of 0
14 0
traumatically 0
brain 0
- 0
injured 0
children 0
( 0
five 0
to 0
15 0
years 0
old 0
, 0
with 0
loss 0
of 0
consciousness 0
for 0
at 0
least 0
24 0
hours 0
) 0
to 0
14 0
normal 0
children 0
group 0
matched 0
for 0
age 0
and 0
sex 0
. 0

We 0
compared 0
the 0
parameters 0
pleural B-gene
adenosine I-gene
deaminase I-gene
( 0
PADA B-gene
, 0
determined 0
in 0
405 0
patients 0
) 0
, 0
the 0
PADA/serum B-gene
PADA/serum I-gene
ADA I-gene
ratio 0
( 0
P/SADA B-gene
; 0
276 0
cases 0
) 0
, 0
P/SADA I-gene

These 0
exons 0
were 0
identified 0
by 0
cloning 0
and 0
sequencing 0
cDNAs 0
obtained 0
by 0
polymerase 0
chain 0
reaction 0
amplification 0
of 0
a 0
fibroblast 0
cDNA 0
library 0
. 0

Deletion 0
of 0
the 0
apeA B-gene
gene I-gene
, 0
either 0
with 0
or 0
without 0
deletion 0
of 0
other 0
proteinases 0
( 0
protease B-gene
IV I-gene
and 0
aminopeptidase B-gene
N I-gene
) 0
, 0
did 0
not 0
have 0
any 0
effect 0
on 0
cell 0
growth 0
in 0
the 0
various 0
media 0
tested 0
. 0

In 0
Experiment 0
2 0
scopolamine 0
hydrobromide 0
, 0
0.5 0
and 0
1.0 0
mg/kg 0
i.p. 0
, 0
was 0
administered 0
1 0
h 0
before 0
each 0
electrical 0
stimulation 0
until 0
each 0
rat 0
showed 0
the 0
stage 0
- 0
3 0
seizure 0
. 0

PNT 0
, 0
ADD 0
and 0
BSS 0
in 0
the 0
initial 0
stage 0
of 0
kindling 0
, 0
kindling 0
rate 0
for 0
the 0
stage 0
- 0
3 0
and 0
- 0
5 0
seizures 0
, 0
seizure 0
parameters 0
at 0
the 0
first 0
stage 0
- 0
3 0
and 0
- 0
5 0
were 0
recorded 0
and 0
compared 0
to 0
the 0
values 0
of 0
saline 0
- 0
treated 0
, 0
control 0
group 0
. 0

CONCLUSIONS 0
. 0

There 0
was 0
a 0
positive 0
correlation 0
between 0
pyridinium 0
cross 0
- 0
link 0
excretion 0
and 0
thyroid 0
hormone 0
concentrations 0
. 0

Mutations 0
truncating 0
as 0
many 0
as 0
143 0
C 0
- 0
terminal 0
residues 0
from 0
the 0
transcriptional 0
activator 0
encoded 0
by 0
the 0
areA B-gene
gene I-gene
, 0
mediating 0
nitrogen 0
metabolite 0
repression 0
in 0
Aspergillus 0
nidulans 0
, 0
do 0
not 0
significantly 0
reduce 0
the 0
ability 0
of 0
the 0
areA B-gene
product I-gene
to 0
activate 0
expression 0
of 0
most 0
genes 0
under 0
areA B-gene
control 0
. 0

Naval 0
personnel 0
who 0
exceed 0
standards 0
for 0
% 0
BF 0
can 0
be 0
separated 0
from 0
active 0
duty 0
. 0

Weak 0
promoter 0
activity 0
was 0
observed 0
for 0
the 0
promoter 0
of 0
the 0
C1 B-gene
and 0
C2 B-gene
ORFs 0
( 0
C1 B-gene
- 0
C2 B-gene
gene 0
) 0
and 0
for 0
the 0
promoter 0
of 0
the 0
V1 B-gene
ORF I-gene
. 0

The 0
activity 0
of 0
the 0
coat B-gene
protein I-gene
promoter I-gene
of 0
chloris 0
striate 0
mosaic 0
virus 0
is 0
enhanced 0
by 0
its 0
own 0
and 0
C1 B-gene
- 0
C2 B-gene
gene 0
products 0
. 0

The 0
amino 0
acid 0
sequence 0
alignment 0
of 0
TC B-gene
II I-gene
with 0
that 0
of 0
other 0
Cbl B-gene
binding I-gene
proteins I-gene
( 0
rat B-gene
intrinsic I-gene
factor I-gene
, 0
human B-gene
transcobalamin I-gene
I I-gene
and 0
porcine B-gene
haptocorrin I-gene
) 0
revealed 0
only 0
33 0
% 0
overall 0
homology 0
. 0

This 0
short 0
communication 0
compares 0
a 0
novel 0
fluorimetric 0
microplate 0
enzyme 0
immunoassay 0
( 0
FEIA 0
) 0
with 0
a 0
commercial 0
time 0
- 0
resolved 0
fluoroimmunoassay 0
for 0
the 0
determination 0
of 0
thyrotropin B-gene
in 0
dried 0
blood 0
spots 0
. 0

The 0
evaluation 0
was 0
performed 0
using 0
a 0
retrospective 0
study 0
design 0
with 0
newborn 0
blood 0
samples 0
from 0
three 0
screening 0
centres 0
. 0

A 0
region 0
in 0
the 0
C 0
- 0
terminus 0
of 0
adenovirus B-gene
2/5 I-gene
E1a I-gene
protein I-gene
is 0
required 0
for 0
association 0
with 0
a 0
cellular 0
phosphoprotein 0
and 0
important 0
for 0
the 0
negative 0
modulation 0
of 0
T24 0
- 0
ras B-gene
mediated 0
transformation 0
, 0
tumorigenesis 0
and 0
metastasis 0
. 0

These 0
studies 0
demonstrate 0
that 0
both 0
G B-gene
alpha I-gene
i I-gene
genes I-gene
are 0
dynamically 0
regulated 0
in 0
LLC 0
- 0
PK1 0
cells 0
by 0
both 0
growth 0
, 0
differentiation 0
, 0
and 0
hormone 0
signals 0
. 0

Constructs 0
containing 0
the 0
full B-gene
- I-gene
length I-gene
PfCPK I-gene
cDNA I-gene
have 0
been 0
expressed 0
in 0
Escherichia 0
coli 0
at 0
a 0
high 0
level 0
to 0
generate 0
a 0
60 0
- 0
kDa 0
recombinant 0
protein 0
. 0

When 0
ligated 0
to 0
the 0
proIL B-gene
- I-gene
1 I-gene
beta I-gene
cap I-gene
site I-gene
- I-gene
proximal I-gene
region I-gene
( 0
located 0
between 0
- 0
131 0
to 0
+12 0
) 0
, 0
both 0
the 0
proIL B-gene
- I-gene
1 I-gene
beta I-gene
and 0
the 0
simian B-gene
virus I-gene
40 I-gene
enhancer I-gene
elements I-gene
functioned 0
more 0
efficiently 0
in 0
monocytes 0
than 0
in 0
HeLa 0
cells 0
, 0
which 0
are 0
not 0
normally 0
competent 0
for 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
expression 0
. 0

Therefore 0
, 0
PC B-gene
- I-gene
PLC I-gene
is 0
a 0
component 0
of 0
a 0
signal 0
transduction 0
pathway 0
leading 0
to 0
transcription 0
of 0
c B-gene
- I-gene
fos I-gene
and 0
junB B-gene
that 0
collaborates 0
with 0
c B-gene
- I-gene
myc I-gene
and 0
is 0
independent 0
of 0
PKC B-gene
- I-gene
delta I-gene
and 0
Ras B-gene
activation 0
. 0

In 0
mitogen 0
- 0
stimulated 0
splenocytes 0
, 0
Gfi B-gene
- I-gene
1 I-gene
expression 0
begins 0
to 0
rise 0
at 0
12 0
h 0
after 0
stimulation 0
and 0
reaches 0
very 0
high 0
levels 0
after 0
50 0
h 0
, 0
suggesting 0
that 0
it 0
may 0
be 0
functionally 0
involved 0
in 0
events 0
occurring 0
after 0
the 0
interaction 0
of 0
IL B-gene
- I-gene
2 I-gene
with 0
its 0
receptor 0
, 0
perhaps 0
during 0
the 0
transition 0
from 0
the 0
G1 0
to 0
the 0
S 0
phase 0
of 0
the 0
cell 0
cycle 0
. 0

We 0
have 0
isolated 0
and 0
characterized 0
the 0
GCD6 B-gene
and 0
GCD7 B-gene
genes I-gene
and 0
shown 0
that 0
their 0
products 0
are 0
required 0
to 0
repress 0
GCN4 B-gene
translation 0
under 0
nonstarvation 0
conditions 0
. 0

The 0
plateau 0
MO2 0
value 0
was 0
that 0
predicted 0
by 0
allometric 0
relation 0
. 0

While 0
the 0
latter 0
corresponded 0
to 0
a 0
protein 0
of 0
824 0
amino 0
acids 0
, 0
an 0
upstream 0
open 0
reading 0
frame 0
( 0
uORF 0
) 0
within 0
the 0
5 0
' 0
leader 0
could 0
potentially 0
encode 0
a 0
54 0
amino 0
acid 0
peptide 0
. 0

The 0
SCH9 B-gene
protein I-gene
kinase I-gene
mRNA I-gene
contains 0
a 0
long 0
5 0
' 0
leader 0
with 0
a 0
small 0
open 0
reading 0
frame 0
. 0

In 0
contrast 0
to 0
T 0
cells 0
, 0
in 0
fibroblasts 0
PILOT B-gene
gene I-gene
expression 0
requires 0
only 0
one 0
signal 0
( 0
PMA 0
) 0
and 0
is 0
not 0
affected 0
by 0
CyA 0
. 0

Histochemical 0
localization 0
of 0
GUS B-gene
revealed 0
promoter 0
function 0
in 0
leaf 0
epidermis 0
, 0
mesophyll 0
and 0
vascular 0
bundles 0
, 0
in 0
the 0
cortex 0
and 0
vascular 0
cylinder 0
of 0
the 0
root 0
. 0

In 0
order 0
to 0
investigate 0
how 0
these 0
expression 0
patterns 0
are 0
established 0
, 0
we 0
fused 0
promoter 0
regions 0
of 0
an 0
acidic 0
and 0
a 0
basic 0
glucanase B-gene
gene I-gene
to 0
the 0
beta B-gene
- I-gene
glucuronidase I-gene
( 0
GUS B-gene
) 0
reporter 0
gene 0
and 0
examined 0
expression 0
of 0
these 0
constructs 0
in 0
transgenic 0
tobacco 0
plants 0
. 0

Southern 0
blot 0
analysis 0
using 0
probes 0
from 0
the 0
3 0
' 0
portions 0
of 0
the 0
genomic 0
and 0
B. B-gene
napus I-gene
MA I-gene
and 0
MB B-gene
cDNA I-gene
clones 0
showed 0
that 0
MA B-gene
type I-gene
myrosinases B-gene
are 0
encoded 0
by 0
approximately 0
4 0
genes 0
, 0
while 0
MB B-gene
type I-gene
myrosinases B-gene
are 0
encoded 0
by 0
more 0
than 0
10 0
genes 0
in 0
B. 0
napus 0
. 0

Sudomoina 0
, 0
A 0
. 0

Zinc 0
fingers 0
( 0
Zf 0
) 0
are 0
a 0
common 0
structural 0
motif 0
found 0
in 0
many 0
nucleic 0
acid 0
- 0
binding 0
proteins 0
. 0

The 0
deduced 0
bovine 0
EFIA B-gene
# I-gene
1 I-gene
amino 0
acid 0
( 0
aa 0
) 0
sequence 0
is 0
98 0
% 0
identical 0
to 0
rat 0
EFIA B-gene
and 0
100 0
% 0
identical 0
to 0
human 0
EFIA/DbpB/YB B-gene
EFIA/DbpB/YB I-gene

Effect 0
of 0
tracheal 0
insufflation 0
of 0
deferoxamine 0
on 0
acute 0
ozone 0
toxicity 0
in 0
rats 0
. 0

Localization 0
of 0
the 0
insertion 0
locus 0
in 0
the 0
yeast 0
genome 0
and 0
complementation 0
studies 0
with 0
the 0
temperature 0
- 0
sensitive 0
mutant 0
indicate 0
that 0
the 0
two 0
mutations 0
are 0
allelic 0
. 0

Replacement 0
of 0
the 0
spacer 0
sequence 0
between 0
the 0
two 0
ARMs 0
with 0
a 0
shorter 0
stretch 0
of 0
sequence 0
also 0
reduced 0
RNA 0
binding 0
in 0
vitro 0
. 0

Type 0
II 0
could 0
be 0
divided 0
further 0
into 0
two 0
forms 0
( 0
IIA 0
and 0
IIB 0
) 0
that 0
may 0
represent 0
two 0
underscribed 0
species 0
or 0
developmental 0
stages 0
of 0
the 0
same 0
species 0
. 0

Second 0
, 0
the 0
transcription B-gene
factor I-gene
Gal I-gene
- I-gene
ER I-gene
was 0
rendered 0
more 0
potent 0
and 0
less 0
susceptible 0
to 0
cell 0
type 0
- 0
specific 0
variation 0
by 0
fusing 0
the 0
strong 0
activating 0
domain 0
of 0
the 0
herpesvirus B-gene
protein I-gene
VP16 I-gene
onto 0
its 0
C 0
terminus 0
. 0

The 0
exogenous 0
fos B-gene
gene I-gene
was 0
rapidly 0
induced 0
to 0
maximal 0
levels 0
within 0
1 0
- 0
2 0
hr 0
of 0
estrogen 0
addition 0
. 0

Elimination 0
of 0
Haemophilus 0
influenzae 0
type 0
b 0
meningitis 0
after 0
introduction 0
of 0
vaccination 0

Endosonography 0
accurately 0
assessed 0
tumor 0
extension 0
in 0
two 0
T2 0
tumors 0
, 0
14 0
T3 0
tumors 0
, 0
and 0
seven 0
T4 0
tumors 0
. 0

In 0
the 0
present 0
study 0
we 0
demonstrated 0
a 0
unique 0
mechanism 0
of 0
action 0
of 0
8 0
- 0
Cl 0
- 0
cAMP 0
in 0
the 0
regulation 0
of 0
these 0
kinase 0
isozymes 0
in 0
HL 0
- 0
60 0
human 0
promyelocytic 0
leukemia 0
cells 0
. 0

Analysis 0
of 0
cell 0
cycle 0
regulation 0
in 0
the 0
budding 0
yeast 0
Saccharomyces 0
cerevisiae 0
has 0
shown 0
that 0
a 0
central 0
regulatory 0
protein 0
kinase 0
, 0
Cdc28 B-gene
, 0
undergoes 0
changes 0
in 0
activity 0
through 0
the 0
cell 0
cycle 0
by 0
associating 0
with 0
distinct 0
groups 0
of 0
cyclins B-gene
that 0
accumulate 0
at 0
different 0
times 0
. 0

Overlapping 0
clones 0
representing 0
full 0
- 0
length 0
cDNAs 0
for 0
MMI B-gene
alpha I-gene
were 0
obtained 0
from 0
mouse 0
brain 0
. 0

The 0
method 0
involves 0
preliminary 0
isolation 0
of 0
oxiracetam 0
and 0
internal 0
standard 0
from 0
plasma 0
by 0
solid 0
- 0
phase 0
extraction 0
prior 0
to 0
the 0
formation 0
of 0
their 0
n 0
- 0
propyl 0
carbamate 0
derivatives 0
. 0

There 0
are 0
, 0
however 0
, 0
several 0
differences 0
between 0
the 0
two 0
new 0
ars 0
sequences 0
. 0

Pathways 0
linking 0
the 0
olfactory 0
bulbs 0
with 0
the 0
medial 0
preoptic 0
anterior 0
hypothalamus 0
are 0
important 0
for 0
intermale 0
aggression 0
in 0
mice 0
. 0

Pokeweed B-gene
mitogen I-gene
( 0
PWM B-gene
) 0
or 0
anti B-gene
- I-gene
CD3 I-gene
significantly 0
increases 0
c B-gene
- I-gene
jun I-gene
messenger I-gene
RNA I-gene
( I-gene
mRNA I-gene
) I-gene
levels 0
in 0
T 0
cells 0
. 0

Following 0
seizure 0
induction 0
, 0
MABP 0
increased 0
to 0
105 0
mm 0
Hg 0
and 0
brain 0
pHi 0
fell 0
to 0
6.79 0
+/ 0
- 0
0.03 0
within 0
15 0
min 0
and 0
remained 0
at 0
this 0
level 0
for 0
1 0
h 0
( 0
P 0
< 0
0.001 0
) 0
. 0

In 0
contrast 0
, 0
rats 0
receiving 0
U74500A 0
( 0
2 0
mg/kg 0
i.v 0
. 0
infusion 0
commencing 0
30 0
min 0
prior 0
to 0
revascularisation 0
) 0
exhibited 0
enhanced 0
GMBF 0
throughout 0
reperfusion 0
[ 0
PI 0
10 0
min 0
: 0
3.26 0
( 0
2.56 0
- 0
3.63 0
) 0
; 0
120 0
min 0
: 0
2.03 0
( 0
1.73 0
- 0
2.25 0
) 0
; 0
240 0
min 0
: 0
2.13 0
( 0
1.75 0
- 0
2.44 0
) 0
, 0
p 0
< 0
0.01 0
vs. 0
controls 0
and 0
normals 0
] 0
with 0
complete 0
muscle 0
salvage 0
[ 0
GMV 0
100 0
% 0
in 0
all 0
reperfused 0
muscles 0
, 0
p 0
< 0
0.01 0
vs. 0
controls 0
, 0
not 0
significant 0
( 0
NS 0
) 0
vs. 0
normals 0
and 0
6 0
h 0
ischaemia 0
] 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Sequencing 0
of 0
a 0
1.3 0
- 0
kilobase 0
fragment 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
TSG6 B-gene
gene I-gene
identified 0
TATA 0
- 0
like 0
and 0
CAAT 0
sequences 0
near 0
the 0
transcription 0
start 0
site 0
. 0

The 0
region 0
that 0
imparts 0
inducibility 0
by 0
IL B-gene
- I-gene
1 I-gene
or 0
TNF B-gene
( 0
positions 0
- 0
165 0
to 0
- 0
58 0
) 0
contains 0
potential 0
binding 0
sites 0
for 0
IRF B-gene
- I-gene
1 I-gene
and I-gene
- I-gene
2 I-gene
, 0
AP B-gene
- I-gene
1 I-gene
, 0
and 0
NF B-gene
- I-gene
IL I-gene
- I-gene
6 I-gene
. 0

Ig B-gene
- I-gene
alpha I-gene
and 0
Ig B-gene
- I-gene
beta I-gene
contain 0
extended 0
cytoplasmic 0
structure 0
( 0
61 0
and 0
48 0
amino 0
acids 0
, 0
respectively 0
) 0
and 0
associate 0
with 0
cytoplasmic 0
effectors 0
indicating 0
that 0
they 0
are 0
directly 0
involved 0
in 0
signal 0
transduction 0
. 0

Sterile 0
mutants 0
of 0
Saccharomyces 0
cerevisiae 0
were 0
isolated 0
from 0
alpha 0
* 0
cells 0
having 0
the 0
a/alpha B-gene
aar1 I-gene
- I-gene
6 I-gene
genotype 0
( 0
exhibiting 0
alpha 0
mating 0
ability 0
and 0
weak 0
a 0
mating 0
ability 0
as 0
a 0
result 0
of 0
a 0
defect 0
in 0
a1 B-gene
- I-gene
alpha I-gene
2 I-gene
repression 0
) 0
. 0

We 0
studied 0
the 0
functional 0
interaction 0
between 0
human 0
embryonic 0
zeta B-gene
2 I-gene
globin I-gene
promoter 0
and 0
the 0
alpha B-gene
globin I-gene
regulatory I-gene
element I-gene
( 0
HS B-gene
- I-gene
40 I-gene
) 0
located 0
40 0
kb 0
upstream 0
of 0
the 0
zeta B-gene
2 I-gene
globin I-gene
gene I-gene
. 0

It 0
was 0
shown 0
by 0
transient 0
expression 0
assay 0
that 0
HS B-gene
- I-gene
40 I-gene
behaved 0
as 0
an 0
authentic 0
enhancer 0
for 0
high 0
- 0
level 0
zeta B-gene
2 I-gene
globin I-gene
promoter I-gene
activity 0
in 0
K562 0
cells 0
, 0
an 0
erythroid 0
cell 0
line 0
of 0
embryonic 0
and/or 0
fetal 0
origin 0
. 0

Initial 0
results 0
indicate 0
that 0
this 0
23S B-gene
pre I-gene
- I-gene
rRNA I-gene
is 0
the 0
same 0
as 0
the 0
species 0
detected 0
on 0
depletion 0
of 0
the 0
small B-gene
nucleolar I-gene
RNA I-gene
- I-gene
associated I-gene
proteins I-gene
NOP1 B-gene
and 0
GAR1 B-gene
and 0
in 0
an 0
snr10 B-gene
mutant I-gene
strain 0
. 0

Breitbart 0
, 0
L 0
. 0

This 0
study 0
evaluates 0
the 0
feasibility 0
of 0
indirect 0
mesenteric 0
lymphangiography 0
as 0
a 0
colonoscopic 0
technique 0
in 0
a 0
canine 0
model 0
. 0

OBJECTIVE 0
: 0
Our 0
purpose 0
was 0
to 0
determine 0
the 0
simultaneous 0
concentrations 0
of 0
serum 0
cotinine 0
in 0
both 0
fetal 0
and 0
maternal 0
blood 0
. 0

Internal 0
amino 0
acid 0
sequence 0
has 0
now 0
been 0
obtained 0
from 0
this 0
protein 0
which 0
shares 0
50 0
- 0
100 0
% 0
sequence 0
identity 0
with 0
sequences 0
encoded 0
by 0
mammalian B-gene
G I-gene
alpha I-gene
11 I-gene
and 0
G B-gene
alpha I-gene
q I-gene
cDNAs I-gene
. 0

Estradiol 0
is 0
known 0
to 0
induce 0
expression 0
of 0
certain 0
proto 0
- 0
oncogenes 0
, 0
and 0
this 0
led 0
us 0
to 0
examine 0
potential 0
regulatory 0
regions 0
of 0
the 0
cellular B-gene
c I-gene
- I-gene
fos I-gene
oncogene I-gene
. 0

Air 0
lead 0
was 0
not 0
a 0
significant 0
explanatory 0
variable 0
. 0

We 0
now 0
show 0
that 0
regulation 0
of 0
flaN B-gene
transcription 0
in 0
vivo 0
depends 0
on 0
a 0
sigma B-gene
54 I-gene
promoter I-gene
and 0
two 0
ftr 0
elements 0
located 0
downstream 0
of 0
the 0
transcription 0
start 0
site 0
at 0
+86 0
( 0
ftr2 0
) 0
and 0
+120 0
( 0
ftr3 0
) 0
. 0

5 0
micrograms/l 0
was 0
detected 0
in 0
urine 0
from 0
some 0
non 0
- 0
occupationally 0
exposed 0
persons 0
. 0

Fibular 0
dimelia 0
with 0
deficiency 0
of 0
the 0
tibia 0
. 0

This 0
prospective 0
study 0
compared 0
the 0
measured 0
energy 0
expenditures 0
of 0
30 0
patients 0
using 0
indirect 0
calorimetry 0
with 0
their 0
predicted 0
basal 0
energy 0
expenditure 0
according 0
to 0
the 0
Harris 0
- 0
Benedict 0
equation 0
, 0
or 0
their 0
calculated 0
energy 0
expenditure 0
derived 0
from 0
basal 0
energy 0
expenditure 0
times 0
, 0
an 0
activity 0
factor 0
, 0
and 0
a 0
stress 0
factor 0
. 0

However 0
, 0
after 0
repeated 0
infections 0
, 0
hypobiotic 0
larvae 0
were 0
numerous 0
. 0

This 0
was 0
performed 0
in 0
a 0
double 0
blinded 0
, 0
randomized 0
, 0
placebo 0
- 0
controlled 0
study 0
. 0

Group 0
I 0
consisted 0
of 0
six 0
noncholestatic 0
patients 0
; 0
group 0
II 0
consisted 0
of 0
nine 0
mildly 0
cholestatic 0
patients 0
with 0
mild 0
hepatic 0
impairment 0
( 0
conjugated 0
bilirubin 0
, 0
47 0
mumol 0
liter 0
- 0
1 0
; 0
alkaline B-gene
phosphatase I-gene
, 0
280 0
IU 0
liter 0
- 0
1 0
; 0
gamma B-gene
- I-gene
glutamyltranspeptidase I-gene
, 0
190 0
IU 0
liter 0
- 0
1 0
) 0
; 0
group 0
III 0
consisted 0
of 0
six 0
benign 0
intrahepatic 0
cholestatic 0
patients 0
with 0
high 0
isolated 0
conjugated 0
hyperbilirubinemia 0
( 0
98.1 0
mumol 0
liter 0
- 0
1 0
) 0
. 0

There 0
was 0
either 0
no 0
change 0
or 0
an 0
improvement 0
in 0
renographic 0
findings 0
( 0
t1/2 0
time 0
and/or 0
split 0
function 0
) 0
in 0
40 0
patients 0
( 0
93 0
% 0
) 0
. 0

We 0
discuss 0
the 0
need 0
to 0
use 0
animals 0
older 0
than 0
3 0
months 0
for 0
the 0
study 0
of 0
'adult 0
' 0
regeneration 0
phenomena 0
since 0
3 0
- 0
month 0
- 0
old 0
rats 0
may 0
be 0
somewhat 0
immature 0
. 0

Nuclear B-gene
beta I-gene
II I-gene
PKC I-gene
, 0
like 0
p34cdc2 B-gene
kinase I-gene
, 0
may 0
function 0
to 0
regulate 0
nuclear 0
lamina 0
structural 0
stability 0
during 0
cell 0
cycle 0
. 0

In 0
situ 0
copper 0
- 0
phenanthroline 0
footprinting 0
of 0
individual 0
gel 0
shift 0
assembly 0
intermediates 0
shows 0
that 0
on 0
the 0
302 0
- 0
nucleotide 0
G4oric 0
, 0
the 0
first 0
two 0
SSB B-gene
tetramers I-gene
assemble 0
at 0
random 0
, 0
but 0
the 0
addition 0
of 0
more 0
SSB B-gene
tetramers I-gene
results 0
in 0
formation 0
of 0
a 0
unique 0
structure 0
. 0

Effects 0
of 0
intramammary 0
endotoxin 0
infusion 0
on 0
milking 0
- 0
induced 0
oxytocin B-gene
release 0
. 0

Finger B-gene
associated I-gene
box I-gene
- I-gene
zinc I-gene
finger I-gene
proteins I-gene
( 0
FAX B-gene
- I-gene
ZFPs I-gene
) 0
constitute 0
a 0
subfamily 0
of 0
the 0
many 0
C2H2 B-gene
type I-gene
ZFPs I-gene
in 0
Xenopus 0
laevis 0
. 0

Further 0
evidence 0
for 0
a 0
clustered 0
organization 0
of 0
FAX B-gene
- 0
ZFP B-gene
transcription 0
units 0
is 0
provided 0
by 0
Southern 0
blot 0
analysis 0
of 0
large 0
genomic 0
restriction 0
fragments 0
separated 0
by 0
transverse 0
field 0
gel 0
electrophoresis 0
, 0
and 0
by 0
in 0
situ 0
hybridization 0
on 0
intact 0
chromosomes 0
. 0

A 0
rat 0
cDNA 0
that 0
encodes 0
eIF B-gene
- I-gene
5 I-gene
has 0
been 0
isolated 0
and 0
expressed 0
in 0
Escherichia 0
coli 0
to 0
yield 0
a 0
catalytically 0
active 0
eIF B-gene
- I-gene
5 I-gene
protein I-gene
. 0

Mutational 0
analyses 0
have 0
demonstrated 0
the 0
importance 0
of 0
sequences 0
within 0
the 0
327 0
bp 0
segment 0
that 0
contain 0
a 0
putative 0
cyclic B-gene
AMP I-gene
responsive I-gene
element I-gene
binding I-gene
protein I-gene
( 0
CREB B-gene
) 0
binding 0
site 0
for 0
TGF B-gene
- I-gene
beta I-gene
1 I-gene
and 0
PMA 0
responsiveness 0
and 0
putative 0
PU B-gene
- I-gene
1 I-gene
and 0
Sp1 B-gene
binding I-gene
sites I-gene
for 0
basal 0
promoter 0
activity 0
. 0

( 0
1992 0
) 0
J 0
. 0

In 0
F42A 0
- 0
stimulated 0
internalization 0
assays 0
on 0
forskolin 0
- 0
induced 0
YT 0
- 0
1 0
cells 0
, 0
the 0
IL B-gene
- I-gene
2R I-gene
alpha I-gene
chain I-gene
is 0
consistently 0
endocytosed 0
together 0
with 0
the 0
IL B-gene
- I-gene
2R I-gene
beta I-gene
subunit I-gene
indicating 0
that 0
IL B-gene
- I-gene
2R I-gene
alpha I-gene
is 0
stably 0
associated 0
with 0
the 0
F42A B-gene
- I-gene
IL I-gene
- I-gene
2R I-gene
beta I-gene
complex I-gene
even 0
though 0
the 0
alpha 0
- 0
subunit 0
contributes 0
little 0
if 0
any 0
affinity 0
to 0
the 0
F42A 0
binding 0
reaction 0
. 0

The 0
microcirculatory 0
dynamics 0
of 0
prostaglandin 0
E1 0
and/or 0
nicardipine 0
and 0
their 0
different 0
reactions 0
in 0
the 0
hyper 0
- 0
and 0
hypodynamic 0
state 0
of 0
septic 0
shock 0
in 0
a 0
rat 0
model 0

We 0
obtained 0
the 0
prevalence 0
of 0
IgG B-gene
antibodies I-gene
against 0
Trypanosoma 0
cruzi 0
among 0
1076 0
blood 0
donors 0
at 0
the 0
Instituto 0
Nacional 0
de 0
Cardiologia 0
`` 0
Ignacio 0
Chavez 0
'' 0
in 0
Mexico 0
City 0
. 0

Examination 0
of 0
the 0
immediate 0
sequence 0
5 0
' 0
to 0
the 0
mRNA 0
start 0
site 0
reveals 0
no 0
TATA 0
box 0
and 0
multiple 0
known 0
enhancer 0
sequences 0
. 0

The 0
short 0
- 0
term 0
synthesis 0
and 0
infant 0
- 0
regulated 0
removal 0
of 0
milk 0
in 0
lactating 0
women 0
. 0

Pseudosubstrate 0
( 0
19 0
- 0
36 0
) 0
, 0
derived 0
from 0
the 0
C 0
- 0
terminus 0
of 0
Ca B-gene
- I-gene
dependent I-gene
PKC I-gene
isotypes I-gene
, 0
inhibited 0
beta B-gene
- I-gene
PKC I-gene
but 0
not 0
nPKC B-gene
activity 0
using 0
either 0
Histone B-gene
IIIS I-gene
or 0
peptide 0
( 0
19 0
- 0
31 0
) 0
as 0
substrate 0
. 0

Based 0
on 0
these 0
results 0
, 0
a 0
new 0
model 0
for 0
the 0
regulation 0
of 0
nif/fix B-gene
gene 0
expression 0
in 0
A. 0
caulinodans 0
is 0
proposed 0
. 0

Nitric 0
oxide 0
inhalation 0
selectively 0
reduces 0
pulmonary 0
hypertension 0
in 0
porcine 0
endotoxin 0
shock 0
and 0
improves 0
arterial 0
oxygenation 0
and 0
pH 0
with 0
a 0
marked 0
attenuation 0
of 0
sympathetic 0
activation 0
. 0

B 0
cell 0
- 0
specific 0
mb B-gene
- I-gene
1 I-gene
and 0
B29 B-gene
genes I-gene
encode 0
the 0
alpha/beta 0
components 0
of 0
the 0
BCR B-gene
- I-gene
associated I-gene
complex I-gene
in 0
mature 0
sIgM+ B-gene
B 0
cells 0
. 0

Bipolarity 0
in 0
Jungian 0
type 0
theory 0
and 0
the 0
Myers 0
- 0
Briggs 0
Type 0
Indicator 0
. 0

A 0
variety 0
of 0
nuclear 0
ribonucleoproteins 0
are 0
believed 0
to 0
associate 0
directly 0
with 0
nascent 0
RNA B-gene
polymerase I-gene
II I-gene
transcripts I-gene
and 0
remain 0
associated 0
during 0
subsequent 0
nuclear 0
RNA 0
processing 0
reactions 0
, 0
including 0
pre 0
- 0
mRNA 0
polyadenylation 0
and 0
splicing 0
as 0
well 0
as 0
nucleocytoplasmic 0
mRNA 0
transport 0
. 0

Mutations 0
at 0
three 0
sites 0
have 0
larger 0
effects 0
in 0
muscle 0
than 0
nonmuscle 0
cells 0
; 0
an 0
A/T 0
- 0
rich 0
site 0
mutation 0
has 0
a 0
pronounced 0
effect 0
in 0
both 0
striated 0
muscle 0
types 0
, 0
mutations 0
at 0
the 0
MEF1 B-gene
( I-gene
Right I-gene
E I-gene
- I-gene
box I-gene
) I-gene
site I-gene
are 0
relatively 0
specific 0
to 0
expression 0
in 0
skeletal 0
muscle 0
, 0
and 0
mutations 0
at 0
the 0
CArG 0
site 0
are 0
relatively 0
specific 0
to 0
expression 0
in 0
cardiac 0
muscle 0
. 0

Transient 0
transfection 0
analysis 0
with 0
these 0
mutations 0
revealed 0
that 0
only 0
a 0
10 0
- 0
bp 0
region 0
, 0
containing 0
precisely 0
the 0
Ets B-gene
and 0
proximal 0
LyF B-gene
- I-gene
1 I-gene
binding I-gene
sites I-gene
, 0
was 0
needed 0
for 0
D 0
' 0
activity 0
. 0

However 0
, 0
despite 0
its 0
relationship 0
to 0
the 0
TR B-gene
, 0
Rev B-gene
- 0
Erb B-gene
bound 0
poorly 0
to 0
TR B-gene
binding I-gene
sites I-gene
. 0

We 0
report 0
here 0
that 0
a 0
25 0
- 0
bp 0
promoter 0
element 0
previously 0
shown 0
to 0
be 0
important 0
for 0
the 0
G1 0
- 0
S 0
activation 0
of 0
the 0
human B-gene
thymidine I-gene
kinase I-gene
( 0
htk B-gene
) 0
promoter 0
in 0
growth 0
- 0
stimulated 0
cells 0
is 0
a 0
cellular 0
target 0
of 0
cyclin B-gene
A I-gene
and 0
the 0
p33cdk2 B-gene
complexes I-gene
. 0

These 0
protective 0
influences 0
were 0
observed 0
throughout 0
the 0
range 0
of 0
filling 0
pressures 0
measured 0
, 0
from 0
0 0
to 0
30 0
mmHg 0
. 0

DNase B-gene
I I-gene
footprinting 0
with 0
rat 0
liver 0
nuclear 0
extracts 0
identified 0
7 0
major 0
protein 0
- 0
binding 0
domains 0
termed 0
P1 0
through 0
P7 0
in 0
a 0
796 0
base 0
pair 0
DNA 0
fragment 0
( 0
base 0
pairs 0
- 0
763 0
to 0
+33 0
) 0
. 0

This 0
may 0
account 0
, 0
at 0
least 0
in 0
part 0
, 0
for 0
the 0
ability 0
of 0
excess 0
wt B-gene
p53 I-gene
to 0
inhibit 0
cell 0
proliferation 0
and 0
to 0
interfere 0
with 0
neoplastic 0
processes 0
. 0

Neither 0
clone 0
encoded 0
the 0
cognate 0
endonuclease 0
. 0

Northern 0
blot 0
analysis 0
of 0
total 0
cellular 0
RNA 0
indicated 0
that 0
xylP B-gene
encodes 0
a 0
1.3 0
- 0
kb 0
transcript 0
which 0
is 0
induced 0
by 0
xylan 0
. 0

The 0
nifJ B-gene
and 0
nifH B-gene
promoters I-gene
of I-gene
Klebsiella I-gene
pneumoniae I-gene
are 0
divergently 0
transcribed 0
sigma B-gene
54 I-gene
- I-gene
dependent I-gene
promoters I-gene
that 0
are 0
positively 0
activated 0
by 0
the 0
NifA B-gene
protein I-gene
. 0

These 0
data 0
show 0
that 0
PTH B-gene
and 0
cAMP 0
can 0
repress 0
collagen B-gene
promoter I-gene
activity 0
in 0
calvariae 0
from 0
transgenic 0
mice 0
, 0
suggesting 0
that 0
the 0
alpha B-gene
1 I-gene
( I-gene
I I-gene
) I-gene
collagen I-gene
promoter I-gene
may 0
contain 0
cis 0
elements 0
down 0
- 0
stream 0
of 0
- 0
2.3 0
kilobases 0
that 0
mediate 0
PTH B-gene
and 0
cAMP 0
repression 0
of 0
collagen B-gene
gene I-gene
expression 0
in 0
bone 0
. 0

Both 0
inhaled 0
and 0
superfused 0
isoflurane 0
dilated 0
the 0
baseline 0
vein 0
diameter 0
before 0
stimulation 0
. 0

Prevalence 0
of 0
rheumatoid 0
arthritis 0
and 0
rheumatoid B-gene
factor I-gene
in 0
women 0
: 0
evidence 0
for 0
a 0
secular 0
decline 0
. 0

Although 0
olfactory 0
associative 0
conditioning 0
in 0
newborn 0
rats 0
produces 0
marked 0
structural 0
and 0
functional 0
changes 0
in 0
the 0
olfactory 0
bulb 0
, 0
recent 0
evidence 0
suggests 0
that 0
extrabulbar 0
circuits 0
must 0
be 0
involved 0
in 0
storing 0
these 0
early 0
memories 0
. 0

The 0
fission B-gene
yeast I-gene
dsk1+ I-gene
gene I-gene
, 0
a 0
multicopy 0
suppressor 0
for 0
cold 0
- 0
sensitive 0
dis1 B-gene
mutants I-gene
, 0
encodes 0
a 0
novel 0
61 0
- 0
kd 0
protein 0
kinase 0
. 0

Closure 0
of 0
the 0
patent 0
ductus 0
arteriosus 0
with 0
a 0
Ligaclip 0
through 0
a 0
minithoracotomy 0
. 0

Sequence 0
comparison 0
between 0
the 0
translated 0
ORF 0
and 0
a 0
protein 0
database 0
reveal 0
between 0
26.5 0
and 0
23.4 0
% 0
aa 0
sequence 0
homology 0
to 0
bacterial B-gene
transmembrane I-gene
( I-gene
TM I-gene
) I-gene
proteins I-gene
including 0
those 0
mediating 0
chloramphenicol 0
( 0
Cm 0
) 0
and 0
tetracycline 0
( 0
Tc 0
) 0
resistance 0
and 0
an 0
arabinose 0
- 0
proton 0
symport 0
protein 0
. 0

The 0
yeast 0
gene 0
that 0
encodes 0
eIF B-gene
- I-gene
5 I-gene
, 0
designated 0
TIF5 B-gene
, 0
has 0
been 0
isolated 0
and 0
expressed 0
in 0
Escherichia 0
coli 0
to 0
yield 0
a 0
catalytically 0
active 0
eIF B-gene
- I-gene
5 I-gene
protein I-gene
. 0

The 0
strategies 0
by 0
which 0
hepatitis 0
B 0
and 0
hepatitis 0
D 0
can 0
be 0
diminished 0
and 0
eventually 0
eliminated 0
are 0
: 0
immunization 0
, 0
measures 0
to 0
prevent 0
exposure 0
to 0
infective 0
blood 0
or 0
blood 0
derivatives 0
and 0
education 0
( 0
in 0
particular 0
awareness 0
that 0
hepatitis 0
B 0
is 0
a 0
sexually 0
transmitted 0
disease 0
) 0
. 0

Xylose 0
- 0
and 0
arabinose 0
- 0
containing 0
polymers 0
were 0
better 0
digested 0
than 0
was 0
cellulose 0
for 0
both 0
breads 0
. 0

The 0
technical 0
construction 0
of 0
the 0
mouth 0
protectors 0
is 0
illustrated 0
, 0
as 0
is 0
the 0
need 0
for 0
instrumentation 0
and 0
its 0
costs 0
and 0
the 0
materials 0
required 0
to 0
manufacture 0
these 0
mouth 0
protectors 0
. 0

The 0
alpha 0
- 0
subunit 0
by 0
itself 0
binds 0
to 0
telomeric 0
DNA 0
. 0

We 0
conclude 0
that 0
the 0
alpha 0
- 0
subunit 0
of 0
the 0
telomere B-gene
- I-gene
binding I-gene
protein I-gene
, 0
like 0
many 0
transcription 0
factors 0
, 0
has 0
separable 0
DNA 0
- 0
binding 0
and 0
protein 0
- 0
protein 0
interaction 0
domains 0
. 0

Three 0
patients 0
had 0
well 0
- 0
, 0
6 0
patients 0
had 0
moderately 0
- 0
, 0
and 0
5 0
patients 0
had 0
poorly 0
- 0
differentiated 0
adenocarcinoma 0
of 0
the 0
prostate 0
. 0

Spontaneous 0
burst 0
firing 0
in 0
cat 0
primary 0
auditory 0
cortex 0
: 0
age 0
and 0
depth 0
dependence 0
and 0
its 0
effect 0
on 0
neural 0
interaction 0
measures 0
. 0

By 0
applying 0
the 0
potentiometric 0
method 0
, 0
in 0
aqueous 0
medium 0
of 0
ionic 0
strength 0
mu 0
= 0
0.2 0
, 0
the 0
stability 0
constants 0
, 0
log 0
beta 0
1 0
= 0
4.42 0
and 0
log 0
beta 0
2 0
= 0
8.57 0
were 0
obtained 0
. 0

Cryopreservation 0
straws 0
filled 0
with 0
media 0
plus 0
additive 0
are 0
emersed 0
below 0
the 0
surface 0
of 0
an 0
unprocessed 0
donor 0
ejaculate 0
. 0

The 0
bcl B-gene
- I-gene
2 I-gene
gene I-gene
can 0
potentially 0
encode 0
26 0
- 0
and 0
22 0
- 0
kDa 0
proteins 0
that 0
differ 0
only 0
in 0
their 0
carboxyl 0
tails 0
because 0
of 0
an 0
alternative 0
splicing 0
mechanism 0
. 0

The 0
active 0
open 0
reading 0
frame 0
in 0
the 0
clone 0
maps 0
at 0
27 0
min 0
on 0
the 0
E. 0
coli 0
chromosome 0
and 0
is 0
identical 0
in 0
sequence 0
to 0
a 0
wild 0
type 0
counterpart 0
. 0

Subsequent 0
cloning 0
and 0
nucleotide 0
sequence 0
analysis 0
of 0
the 0
S. B-gene
pombe I-gene
adenylate I-gene
kinase I-gene
gene I-gene
, 0
adk1 B-gene
, 0
revealed 0
a 0
coding 0
region 0
of 0
660 0
nucleotides 0
. 0

Calcification 0
of 0
a 0
cariogenic 0
Streptococcus 0
and 0
of 0
Corynebacterium 0
( 0
Bacterionema 0
) 0
matruchotii 0
. 0

As 0
a 0
result 0
of 0
alternative 0
splicing 0
, 0
the 0
BGP B-gene
gene I-gene
is 0
transcribed 0
into 0
at 0
least 0
seven 0
distinct 0
mRNA 0
species 0
. 0

A 0
comparison 0
of 0
the 0
promoters 0
for 0
muMIP B-gene
- I-gene
1 I-gene
beta I-gene
and 0
muMIP B-gene
- I-gene
1 I-gene
alpha I-gene
reveals 0
a 0
conserved 0
CK 0
- 0
1 0
element 0
, 0
but 0
transient 0
expression 0
studies 0
in 0
RAW 0
264.7 0
macrophages 0
with 0
proximal 0
fragments 0
of 0
either 0
the 0
muMIP B-gene
- I-gene
1 I-gene
beta I-gene
or 0
the 0
muMIP B-gene
- I-gene
1 I-gene
alpha I-gene
5 I-gene
' I-gene
promoter I-gene
fused 0
to 0
a 0
human B-gene
growth I-gene
hormone I-gene
reporter I-gene
gene I-gene
link 0
LPS 0
- 0
inducibility 0
in 0
both 0
to 0
promoter 0
segments 0
near 0
to 0
, 0
but 0
not 0
identical 0
with 0
, 0
the 0
consensus 0
CK 0
- 0
1 0
sequence 0
. 0

However 0
, 0
essential 0
contrast 0
differences 0
existing 0
between 0
the 0
FSE 0
sequences 0
and 0
their 0
routine 0
asymmetric 0
dual 0
SE 0
counterpart 0
can 0
be 0
identified 0
. 0

Sequence 0
analysis 0
and 0
identification 0
of 0
two 0
hyp B-gene
regulatory I-gene
mutants I-gene
. 0

The 0
gene 0
encoding 0
the 0
receptor 0
for 0
macrophage B-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
1 I-gene
( 0
CSF B-gene
- I-gene
1 I-gene
) 0
, 0
the 0
c B-gene
- I-gene
fms I-gene
protooncogene I-gene
, 0
is 0
selectively 0
expressed 0
in 0
immature 0
and 0
mature 0
mononuclear 0
phagocytes 0
and 0
trophoblasts 0
. 0

The 0
level 0
of 0
the 0
SUP4A53T61 B-gene
transcript I-gene
was 0
threefold 0
higher 0
in 0
the 0
tap1 B-gene
- I-gene
1 I-gene
mutant I-gene
than 0
in 0
the 0
wild 0
type 0
. 0

This 0
sequence 0
similarity 0
raises 0
the 0
possibility 0
that 0
GCN1 B-gene
interacts 0
with 0
ribosomes 0
or 0
tRNA 0
molecules 0
and 0
functions 0
in 0
conjunction 0
with 0
GCN2 B-gene
in 0
monitoring 0
uncharged 0
tRNA 0
levels 0
during 0
the 0
process 0
of 0
translation 0
elongation 0
. 0

NF B-gene
- I-gene
HB I-gene
( 0
BSAP B-gene
) 0
is 0
a 0
repressor 0
of 0
the 0
murine B-gene
immunoglobulin I-gene
heavy I-gene
- I-gene
chain I-gene
3 I-gene
' I-gene
alpha I-gene
enhancer I-gene
at 0
early 0
stages 0
of 0
B 0
- 0
cell 0
differentiation 0
. 0

Since 0
the 0
regulation 0
of 0
SWI4 B-gene
is 0
required 0
for 0
normal 0
cell 0
cycle 0
progression 0
, 0
we 0
have 0
characterized 0
cis 0
- 0
and 0
trans 0
- 0
acting 0
regulators 0
of 0
SWI4 B-gene
transcription 0
. 0

It 0
also 0
suggests 0
that 0
there 0
is 0
another 0
pathway 0
which 0
can 0
activate 0
SWI4 B-gene
transcription 0
in 0
the 0
absence 0
of 0
SWI6 B-gene
. 0

Multiple 0
SWI6 B-gene
- 0
dependent 0
cis 0
- 0
acting 0
elements 0
control 0
SWI4 B-gene
transcription 0
through 0
the 0
cell 0
cycle 0
. 0

In 0
conclusion 0
, 0
changes 0
in 0
carotid 0
sinus 0
stimulation 0
alters 0
blood 0
flow 0
to 0
the 0
hindlimb 0
through 0
changes 0
in 0
both 0
Pcrit 0
and 0
Ra 0
. 0

Multizone 0
PRK 0
has 0
been 0
suggested 0
to 0
increase 0
the 0
predictability 0
of 0
higher 0
myopic 0
corrections 0
. 0

In 0
17 0
patients 0
with 0
deletions 0
, 0
the 0
parental 0
origin 0
of 0
deletion 0
was 0
determined 0
. 0

The 0
COL7A1 B-gene
gene I-gene
, 0
which 0
encodes 0
type B-gene
VII I-gene
collagen I-gene
, 0
has 0
been 0
implicated 0
as 0
a 0
candidate 0
gene 0
for 0
dominantly 0
and 0
recessively 0
inherited 0
forms 0
of 0
dystrophic 0
epidermolysis 0
bullosa 0
. 0

However 0
, 0
study 0
of 0
the 0
productive 0
gamma 0
gene 0
showed 0
that 0
the 0
skipped 0
variable 0
exon 0
was 0
bounded 0
by 0
normal 0
splicing 0
signals 0
and 0
that 0
the 0
adjacent 0
intron 0
organization 0
was 0
not 0
altered 0
. 0

We 0
conclude 0
that 0
grade 0
III 0
BGCT 0
can 0
be 0
treated 0
by 0
modified 0
intralesional 0
excision 0
provided 0
the 0
articular 0
surfaces 0
and 0
part 0
of 0
the 0
metaphysis 0
are 0
intact 0
. 0

Second 0
, 0
nitrate 0
induction 0
of 0
aeg B-gene
- I-gene
46.5 I-gene
operon I-gene
expression 0
is 0
substantially 0
enhanced 0
in 0
narL B-gene
null 0
strains 0
( 0
M.H 0
. 0

This 0
new 0
knowledge 0
has 0
contributed 0
to 0
the 0
development 0
of 0
a 0
successful 0
immunoprophylactic 0
strategy 0
for 0
eliminating 0
Hib 0
disease 0
. 0

The 0
HMG B-gene
CoA I-gene
reductase I-gene
inhibitors 0
are 0
the 0
most 0
effective 0
cholesterol 0
- 0
lowering 0
agents 0
currently 0
available 0
. 0

The 0
etiology 0
, 0
pathology 0
, 0
brain 0
CT 0
scan 0
features 0
, 0
clinical 0
manifestations 0
and 0
treatment 0
of 0
these 0
accidents 0
were 0
discussed 0
. 0

Drosophila 0
230 0
- 0
kD 0
TFIID B-gene
subunit 0
, 0
a 0
functional 0
homolog 0
of 0
the 0
human 0
cell 0
cycle 0
gene 0
product 0
, 0
negatively 0
regulates 0
DNA 0
binding 0
of 0
the 0
TATA B-gene
box I-gene
- I-gene
binding I-gene
subunit I-gene
of I-gene
TFIID I-gene
. 0

One 0
enigmatic 0
aspect 0
of 0
GATA B-gene
factor I-gene
expression 0
is 0
that 0
several 0
GATA B-gene
proteins I-gene
, 0
which 0
ostensibly 0
share 0
the 0
same 0
DNA 0
- 0
binding 0
site 0
specificity 0
, 0
are 0
coexpressed 0
in 0
erythroid 0
cells 0
. 0

Pit B-gene
- I-gene
1 I-gene
is 0
a 0
tissue 0
- 0
specific 0
POU B-gene
domain I-gene
factor I-gene
obligatory 0
for 0
the 0
appearance 0
of 0
three 0
cell 0
phenotypes 0
in 0
the 0
anterior 0
pituitary 0
gland 0
. 0

Maximum 0
number 0
of 0
strains 0
( 0
39.1 0
% 0
) 0
were 0
resistant 0
in 0
S. 0
bareilly 0
serotype 0
, 0
followed 0
by 0
S. 0
typhimurium 0
( 0
21.7 0
% 0
) 0
and 0
least 0
in 0
S. 0
typhi 0
( 0
17.4 0
% 0
) 0
. 0

Biol 0
. 0

Characterization 0
and 0
hormonal 0
regulation 0
of 0
the 0
promoter 0
of 0
the 0
rat B-gene
prostaglandin I-gene
endoperoxide I-gene
synthase I-gene
2 I-gene
gene I-gene
in 0
granulosa 0
cells 0
. 0

The 0
retention 0
of 0
75SeHCAT 0
was 0
low 0
. 0

Patient 0
characteristics 0
associated 0
with 0
deep 0
wounds 0
as 0
well 0
as 0
patient 0
and 0
wound 0
characteristics 0
predictive 0
of 0
the 0
extent 0
of 0
healing 0
and 0
time 0
required 0
for 0
healing 0
were 0
identified 0
. 0

Members 0
of 0
the 0
C/EBP B-gene
family I-gene
of 0
basic B-gene
- I-gene
leucine I-gene
zipper I-gene
( I-gene
bZip I-gene
) I-gene
transcription I-gene
factors I-gene
form 0
heterodimers 0
and 0
bind 0
to 0
the 0
CAAT 0
box 0
and 0
other 0
sequence 0
- 0
related 0
enhancer 0
motifs 0
. 0

In 0
mammalian 0
cells 0
, 0
phosphorylation 0
of 0
eIF B-gene
- I-gene
2 I-gene
alpha I-gene
inhibits 0
the 0
activity 0
of 0
eIF B-gene
- I-gene
2B I-gene
, 0
the 0
GDP B-gene
- I-gene
GTP I-gene
exchange I-gene
factor I-gene
for 0
eIF B-gene
- I-gene
2 I-gene
. 0

In 0
conclusion 0
, 0
these 0
observations 0
demonstrated 0
that 0
stratification 0
of 0
acute 0
MI 0
patients 0
by 0
plasma 0
ANF B-gene
level 0
is 0
a 0
useful 0
non 0
- 0
invasive 0
method 0
for 0
predicting 0
prognosis 0
and 0
for 0
identifying 0
individuals 0
at 0
high 0
risk 0
of 0
cardiac 0
death 0
. 0

Analysis 0
of 0
the 0
binding 0
of 0
Lrp B-gene
to 0
a 0
set 0
of 0
circularly 0
permuted 0
DNA 0
fragments 0
from 0
this 0
region 0
indicates 0
that 0
Lrp B-gene
induces 0
DNA 0
bending 0
. 0

Yeast 0
mutants 0
lacking 0
a 0
functional 0
NOP1 B-gene
gene I-gene
can 0
be 0
complemented 0
by 0
human B-gene
fibrillarin I-gene
but 0
are 0
temperature 0
sensitive 0
for 0
growth 0
and 0
impaired 0
in 0
pre 0
- 0
rRNA 0
processing 0
. 0

The 0
patients 0
were 0
divided 0
into 0
ischaemia 0
and 0
non 0
- 0
ischaemia 0
groups 0
on 0
the 0
basis 0
of 0
the 0
change 0
in 0
lactate 0
extraction 0
ratio 0
during 0
balloon 0
inflation 0
. 0

Seven 0
out 0
of 0
34 0
patients 0
died 0
, 0
giving 0
a 0
mortality 0
rate 0
of 0
21 0
% 0
. 0

A 0
36 0
- 0
kDa 0
protein 0
that 0
was 0
localized 0
to 0
the 0
membrane 0
fraction 0
was 0
detected 0
in 0
minicells 0
containing 0
plasmids 0
with 0
the 0
ftsN B-gene
gene I-gene
, 0
confirming 0
that 0
FtsN B-gene
was 0
a 0
membrane 0
protein 0
. 0

SSG1 B-gene
, 0
a 0
gene 0
encoding 0
a 0
sporulation B-gene
- I-gene
specific I-gene
1,3 I-gene
- I-gene
beta I-gene
- I-gene
glucanase I-gene
in 0
Saccharomyces 0
cerevisiae 0
. 0

Expression 0
of 0
this 0
protein 0
in 0
E. 0
coli 0
demonstrated 0
that 0
tyrosine 0
was 0
incorporated 0
during 0
suppression 0
and 0
that 0
yeast B-gene
cytoplasmic I-gene
TyrRS I-gene
activity 0
was 0
produced 0
. 0

The 0
first 0
involved 0
complementation 0
of 0
a 0
nonphotosynthetic 0
mutant 0
of 0
Chlamydomonas 0
, 0
CC 0
- 0
2341 0
( 0
ac 0
- 0
u 0
- 0
g 0
- 0
2.3 0
) 0
, 0
which 0
has 0
a 0
frameshift 0
mutation 0
in 0
the 0
psaB B-gene
gene I-gene
, 0
and 0
selection 0
of 0
photosynthetic 0
transformants 0
on 0
minimal 0
medium 0
. 0

Against 0
200 0
strains 0
of 0
methicillin 0
- 0
resistant 0
Staphylococcus 0
aureus 0
( 0
MRSA 0
) 0
isolated 0
from 0
1990 0
to 0
1991 0
, 0
minimum 0
inhibitory 0
concentrations 0
( 0
MICs 0
) 0
of 0
a 0
total 0
of 0
15 0
antibacterial 0
agents 0
including 0
arbekacin 0
( 0
ABK 0
) 0
were 0
determined 0
. 0

It 0
is 0
reported 0
that 0
, 0
at 0
present 0
, 0
most 0
of 0
the 0
MRSAs 0
spreading 0
in 0
Japan 0
are 0
acceleratedly 0
acquiring 0
resistance 0
to 0
many 0
drugs 0
, 0
and 0
especially 0
, 0
they 0
are 0
developing 0
high 0
resistance 0
against 0
beta 0
- 0
lactams 0
. 0

Beg2 B-gene
and 0
Beg1 B-gene
are 0
regulated 0
differently 0
which 0
may 0
indicate 0
variation 0
in 0
storage 0
or 0
utilization 0
properties 0
among 0
the 0
barley B-gene
globulins I-gene
. 0

Here 0
, 0
we 0
have 0
more 0
closely 0
investigated 0
transactivation 0
of 0
the 0
human B-gene
HSP70 I-gene
promoter I-gene
by 0
Myb B-gene
proteins I-gene
. 0

We 0
have 0
found 0
out 0
that 0
one 0
- 0
year 0
- 0
old 0
carps 0
are 0
extremely 0
sensitive 0
to 0
ichthiomycin 0
in 0
concentrations 0
between 0
25 0
- 0
125 0
micrograms/dm3 0
. 0

RESULTS 0
: 0
Statistically 0
significant 0
differences 0
were 0
obtained 0
between 0
group 0
I 0
and 0
II 0
concerning 0
the 0
number 0
of 0
patients 0
in 0
whom 0
induced 0
atrial 0
fibrillation 0
with 0
conduction 0
by 0
the 0
accessory 0
pathway 0
and 0
RR 0
< 0
or 0
= 0
250 0
msec 0
was 0
found 0
( 0
0 0
vs 0
6 0
, 0
p 0
= 0
0.0045 0
) 0
. 0

We 0
studied 0
the 0
effect 0
of 0
skinfold 0
thickness 0
on 0
the 0
correlation 0
between 0
serum 0
total 0
bilirubin 0
level 0
and 0
transcutaneous 0
bilirubin 0
( 0
TcB 0
) 0
readings 0
. 0

Both 0
immunophilins B-gene
may 0
have 0
important 0
roles 0
in 0
receptor 0
assembly 0
and 0
may 0
represent 0
a 0
new 0
category 0
of 0
ligand 0
- 0
and 0
calcium 0
- 0
dependent 0
modulators 0
of 0
protein 0
function 0
. 0

The 0
GTPase B-gene
activity 0
of 0
CDC42Ce B-gene
is 0
moderately 0
stimulated 0
by 0
human B-gene
n I-gene
- I-gene
chimaerin I-gene
, 0
a 0
GTPase B-gene
- I-gene
activating I-gene
protein I-gene
for 0
the 0
related 0
p21 B-gene
rac1 B-gene
. 0

Tl 0
- 0
201 0
uptake 0
ratio 0
of 0
the 0
right 0
ventricle 0
, 0
which 0
represents 0
the 0
ratio 0
of 0
total 0
counts 0
of 0
the 0
right 0
ventricle 0
to 0
counts 0
of 0
the 0
administered 0
dose 0
of 0
Tl 0
- 0
201 0
, 0
was 0
higher 0
in 0
COPD 0
, 0
especially 0
in 0
pulmonary 0
emphysema 0
and 0
B 0
type 0
COPD 0
by 0
Burrows 0
classification 0
than 0
in 0
controls 0
. 0

A 0
second 0
hydrophobic 0
domain 0
, 0
bordered 0
by 0
two 0
hydrophilic 0
regions 0
strongly 0
suggests 0
a 0
transmembrane 0
region 0
. 0

This 0
gene 0
spans 0
23 0
kb 0
and 0
is 0
composed 0
of 0
five 0
exons 0
and 0
four 0
introns 0
. 0

The 0
remaining 0
RAD+ B-gene
cells 0
progressed 0
to 0
form 0
microcolonies 0
( 0
< 0
30 0
cells 0
) 0
containing 0
aberrantly 0
shaped 0
inviable 0
cells 0
. 0

The 0
11 0
; 0
22 0
chromosomal 0
translocation 0
specifically 0
linked 0
to 0
Ewing 0
sarcoma 0
and 0
primitive 0
neuroectodermal 0
tumor 0
results 0
in 0
a 0
chimeric 0
molecule 0
fusing 0
the 0
amino 0
- 0
terminal 0
- 0
encoding 0
portion 0
of 0
the 0
EWS B-gene
gene I-gene
to 0
the 0
carboxyl 0
- 0
terminal 0
DNA 0
- 0
binding 0
domain 0
encoded 0
by 0
the 0
FLI1 B-gene
gene I-gene
. 0

These 0
findings 0
suggest 0
that 0
a 0
range 0
of 0
microenvironmental 0
conditions 0
exist 0
within 0
purified 0
water 0
systems 0
, 0
leading 0
to 0
variable 0
populations 0
of 0
bacteria 0
. 0

X 0
- 0
linked 0
liver 0
glycogenosis 0
: 0
localization 0
and 0
isolation 0
of 0
a 0
candidate 0
gene 0
. 0

This 0
conclusion 0
is 0
based 0
on 0
the 0
observations 0
of 0
the 0
immunologic 0
changes 0
that 0
characterize 0
the 0
acute 0
stages 0
of 0
illness 0
as 0
well 0
as 0
on 0
the 0
demonstrated 0
association 0
with 0
toxin 0
- 0
producing 0
bacteria 0
in 0
the 0
pharynx 0
and 0
gastrointestinal 0
tract 0
. 0

Measurement 0
of 0
anti B-gene
- I-gene
HCV I-gene
IgM I-gene
antibodies I-gene
with 0
an 0
experimental 0
kit 0

Embryo 0
coculture 0
system 0
may 0
contribute 0
to 0
understand 0
the 0
mechanisms 0
underlying 0
the 0
decrease 0
of 0
fertility 0
with 0
aging 0
. 0

These 0
cell 0
lines 0
displayed 0
methylation 0
of 0
the 0
CpG 0
island 0
surrounding 0
the 0
first 0
exon 0
of 0
p16INK4A B-gene
and 0
expressed 0
abundant 0
levels 0
of 0
a 0
nontranslated 0
mRNA 0
containing 0
an 0
alternative 0
first 0
exon 0
( 0
E1 0
beta 0
) 0
, 0
as 0
did 0
all 0
other 0
cell 0
lines 0
in 0
which 0
the 0
p16INK4A B-gene
locus I-gene
was 0
not 0
deleted 0
. 0

An 0
immunoperoxidase B-gene
reaction 0
, 0
PAP B-gene
method 0
, 0
with 0
the 0
antiserum 0
of 0
Factor B-gene
VIII I-gene
as 0
the 0
primary 0
antibody 0
, 0
was 0
carried 0
out 0
in 0
the 0
endometrial 0
biopsies 0
to 0
detect 0
the 0
Factor B-gene
VIII I-gene
activity 0
in 0
the 0
endometrial 0
endothelium 0
before 0
and 0
after 0
insertion 0
of 0
LNG 0
- 0
IUD 0
- 0
20 0
. 0

Umweltchem 0
. 0

Egd1p B-gene
is 0
homologous 0
to 0
human B-gene
BTF3b I-gene
, 0
recently 0
identified 0
as 0
the 0
beta 0
subunit 0
of 0
the 0
heterodimeric B-gene
nascent I-gene
- I-gene
polypeptide I-gene
- I-gene
associated I-gene
complex I-gene
( 0
NAC B-gene
) 0
involved 0
in 0
ensuring 0
signal 0
- 0
sequence 0
- 0
specific 0
protein 0
sorting 0
and 0
translocation 0
[ 0
Wiedmann 0
et 0
al. 0
, 0
Nature 0
370 0
( 0
1994 0
) 0
434 0
- 0
440 0
] 0
. 0

Purified 0
PLB B-gene
showed 0
optimal 0
lyase B-gene
activity 0
at 0
pH 0
10.0 0
. 0

The 0
5 0
' 0
flanking 0
regions 0
of 0
both 0
pelA B-gene
and 0
pelB B-gene
were 0
translationally 0
fused 0
to 0
the 0
beta B-gene
- I-gene
glucuronidase I-gene
gene I-gene
and 0
introduced 0
into 0
F. 0
solani 0
f. 0
sp 0
. 0
pisi 0
, 0
and 0
beta B-gene
- I-gene
glucuronidase I-gene
activities 0
of 0
the 0
transformants 0
were 0
measured 0
. 0

When 0
nifA B-gene
mRNA I-gene
5 0
' 0
start 0
points 0
were 0
mapped 0
by 0
primer 0
extension 0
, 0
both 0
a 0
minor 0
upstream 0
transcript 0
( 0
s 0
) 0
starting 0
45 0
bp 0
distal 0
to 0
the 0
anaerobox 0
and 0
a 0
major 0
downstream 0
transcript 0
starting 0
10 0
bp 0
distal 0
to 0
the 0
sigma B-gene
54 I-gene
box 0
were 0
observed 0
. 0

We 0
failed 0
to 0
find 0
these 0
data 0
to 0
be 0
useful 0
in 0
predicting 0
the 0
time 0
of 0
onset 0
of 0
initial 0
seizures 0
after 0
acute 0
ischemic 0
stroke 0
and 0
recurrence 0
. 0

The 0
human B-gene
papillomavirus I-gene
type I-gene
16 I-gene
E7 I-gene
protein I-gene
complements 0
adenovirus B-gene
type I-gene
5 I-gene
E1A I-gene
amino 0
- 0
terminus 0
- 0
dependent 0
transactivation 0
of 0
adenovirus B-gene
type I-gene
5 I-gene
early I-gene
genes I-gene
and 0
increases 0
ATF B-gene
and 0
Oct B-gene
- I-gene
1 I-gene
DNA 0
binding 0
activity 0
. 0

A 0
chaotropic 0
detergent 0
, 0
0.1 0
% 0
Nonidet 0
P 0
- 0
40 0
, 0
also 0
abolished 0
the 0
interaction 0
, 0
further 0
supporting 0
the 0
hydrophobic 0
nature 0
of 0
the 0
interaction 0
. 0

Contrary 0
to 0
expectations 0
, 0
we 0
find 0
a 0
relatively 0
high 0
level 0
of 0
variation 0
in 0
the 0
stripe B-gene
2 I-gene
enhancer 0
region 0
, 0
including 0
point 0
substitutions 0
and 0
insertion/deletions 0
in 0
binding 0
sites 0
, 0
and 0
a 0
comparable 0
level 0
of 0
variation 0
in 0
the 0
other 0
noncoding 0
regions 0
. 0

Degradation 0
of 0
the 0
soybean B-gene
ribulose I-gene
- I-gene
1,5 I-gene
- I-gene
bisphosphate I-gene
carboxylase I-gene
small I-gene
- I-gene
subunit I-gene
mRNA I-gene
, 0
SRS4 B-gene
, 0
initiates 0
with 0
endonucleolytic 0
cleavage 0
. 0

Cloning 0
and 0
sequencing 0
revealed 0
that 0
dMax B-gene
contains 0
a 0
deletion 0
spanning 0
the 0
basic 0
region 0
and 0
helix 0
1 0
and 0
the 0
loop 0
of 0
the 0
helix 0
- 0
loop 0
- 0
helix 0
region 0
, 0
presumably 0
as 0
a 0
result 0
of 0
alternative 0
splicing 0
of 0
max B-gene
RNA I-gene
. 0

I 0
report 0
here 0
that 0
induction 0
of 0
HSP82 B-gene
is 0
regulated 0
by 0
the 0
early 0
meiotic 0
IME1 B-gene
- 0
IME2 B-gene
transcriptional 0
cascade 0
. 0

The 0
domain 0
structure 0
of 0
bovine B-gene
LTBP I-gene
- I-gene
2 I-gene
is 0
very 0
similar 0
to 0
that 0
of 0
the 0
human B-gene
LTBP I-gene
- I-gene
2 I-gene
, 0
containing 0
20 0
examples 0
of 0
6 0
- 0
cysteine 0
epidermal B-gene
growth I-gene
factor I-gene
- I-gene
like I-gene
repeats I-gene
, 0
16 0
of 0
which 0
have 0
the 0
consensus 0
sequence 0
for 0
calcium 0
binding 0
, 0
together 0
with 0
4 0
examples 0
of 0
8 0
- 0
cysteine 0
motifs 0
characteristic 0
of 0
fibrillins B-gene
and 0
LTBP B-gene
- I-gene
1 I-gene
. 0

Similarly 0
, 0
expression 0
of 0
a 0
transiently 0
transfected 0
wild B-gene
- I-gene
type I-gene
prothymosin I-gene
alpha I-gene
gene I-gene
as 0
the 0
reporter 0
was 0
not 0
affected 0
by 0
a 0
repertoire 0
of 0
myc B-gene
- I-gene
derived I-gene
genes I-gene
, 0
including 0
myc B-gene
itself 0
and 0
dominant 0
or 0
recessive 0
negative 0
myc B-gene
mutants I-gene
. 0

Differential 0
regulation 0
of 0
the 0
alpha/beta B-gene
interferon I-gene
- 0
stimulated 0
Jak/Stat B-gene
pathway 0
by 0
the 0
Jak/Stat I-gene

We 0
now 0
report 0
the 0
isolation 0
and 0
expression 0
of 0
cDNAs 0
encoding 0
PTF B-gene
gamma I-gene
and 0
PTF B-gene
delta I-gene
, 0
as 0
well 0
as 0
functional 0
studies 0
with 0
cognate 0
antibodies 0
that 0
recognize 0
the 0
native 0
PTF B-gene
complex I-gene
in 0
HeLa 0
extracts 0
. 0

Results 0
from 0
the 0
mechanism 0
study 0
have 0
revealed 0
that 0
YY1 B-gene
is 0
able 0
to 0
inhibit 0
transactivation 0
mediated 0
by 0
either 0
AP1 B-gene
or 0
the 0
Sp1 B-gene
- I-gene
related I-gene
protein I-gene
, 0
and 0
YY1 B-gene
suppressive 0
activity 0
is 0
DNA 0
binding 0
dependent 0
. 0

The 0
skp1+ B-gene
gene I-gene
is 0
not 0
essential 0
. 0

The 0
TEA1 B-gene
( 0
Ty B-gene
enhancer I-gene
activator I-gene
) 0
gene 0
sequence 0
predicts 0
a 0
protein 0
of 0
86.9 0
kDa 0
whose 0
N 0
terminus 0
contains 0
a 0
zinc 0
cluster 0
and 0
dimerization 0
motif 0
typical 0
of 0
the 0
Gal4 B-gene
- I-gene
type I-gene
family I-gene
of 0
DNA 0
- 0
binding 0
proteins 0
. 0

Refugees 0
living 0
in 0
Lund 0
and 0
repatriated 0
to 0
Chile 0
considered 0
their 0
health 0
as 0
bad 0
in 0
a 0
higher 0
proportion 0
than 0
their 0
Swedish 0
counterparts 0
, 0
with 0
an 0
odds 0
ratio 0
of 0
3.48 0
( 0
2.03 0
- 0
5.66 0
) 0
and 0
4.78 0
( 0
2.1 0
- 0
10.25 0
) 0
respectively 0
. 0

This 0
study 0
underlines 0
the 0
importance 0
of 0
terminal 0
SC5b B-gene
- I-gene
9 I-gene
complement I-gene
complex I-gene
as 0
a 0
suitable 0
marker 0
in 0
the 0
evaluation 0
of 0
complement 0
activation 0
during 0
cardiopulmonary 0
bypass 0
. 0

Videonystagmoscopy 0
has 0
been 0
used 0
to 0
subjectively 0
observe 0
the 0
responses 0
of 0
the 0
vestibular 0
system 0
in 0
a 0
population 0
of 0
patients 0
with 0
vestibular 0
deficits 0
. 0

The 0
MCA 0
and 0
UA 0
PI 0
values 0
showed 0
the 0
greatest 0
deviation 0
for 0
any 0
single 0
- 0
vessel 0
parameter 0
. 0

Striking 0
sequence 0
similarities 0
( 0
57 0
and 0
53 0
% 0
) 0
were 0
observed 0
with 0
yeast 0
mitochondrial 0
proteins 0
, 0
SMF1 B-gene
and 0
SMF2 B-gene
, 0
especially 0
within 0
putative 0
functional 0
domains 0
: 0
exon 0
6 0
encoding 0
the 0
second 0
transmembrane 0
spanning 0
domain 0
, 0
site 0
of 0
the 0
murine B-gene
susceptibility I-gene
mutation 0
; 0
and 0
exon 0
11 0
encoding 0
a 0
conserved 0
transport 0
motif 0
. 0

Stems 0
contain 0
distinctly 0
less 0
P B-gene
protein I-gene
mRNA I-gene
and 0
the 0
relative 0
level 0
in 0
roots 0
is 0
very 0
low 0
but 0
still 0
clearly 0
detectable 0
. 0

The 0
B. B-gene
germanica I-gene
cyclophilin I-gene
amino I-gene
acid I-gene
sequence I-gene
shares 0
83 0
% 0
identity 0
with 0
the 0
cytosolic B-gene
cyclophilin I-gene
isoform I-gene
from I-gene
Drosophila I-gene
melanogaster I-gene
( 0
Cyp B-gene
- I-gene
1 I-gene
) 0
. 0

Furthermore 0
, 0
we 0
have 0
identified 0
a 0
soluble 0
form 0
of 0
ERp57/GRP58 B-gene
by 0
Western 0
blotting 0
and 0
biosynthetic 0
labeling 0
. 0

The 0
minimal 0
region 0
of 0
overlap 0
of 0
Langer 0
- 0
Giedion 0
syndrome 0
deletions 0
, 0
previously 0
identified 0
by 0
analysis 0
of 0
15 0
patients 0
, 0
was 0
placed 0
on 0
the 0
map 0
by 0
analysis 0
of 0
2 0
patients 0
whose 0
deletions 0
define 0
the 0
endpoints 0
. 0

Consistent 0
with 0
the 0
hepatic 0
and 0
epidermal 0
expression 0
of 0
histidase B-gene
, 0
this 0
finding 0
suggests 0
that 0
histidase B-gene
transcription 0
may 0
be 0
regulated 0
by 0
these 0
factors 0
. 0

Comparison 0
of 0
promoters 0
repressed 0
by 0
c B-gene
- I-gene
myc I-gene
reveals 0
a 0
weak 0
consensus 0
sequence 0
of 0
the 0
initiator 0
( 0
Inr 0
) 0
element 0
: 0
TCA 0
( 0
+1 0
) 0
YYYNY 0
. 0

The 0
human B-gene
gp39 I-gene
promoter I-gene
. 0

Transfection 0
analyses 0
indicate 0
that 0
mutation 0
of 0
any 0
one 0
of 0
these 0
TGACCT 0
motifs 0
or 0
truncation 0
of 0
the 0
entire 0
HD B-gene
PPRE 0
into 0
a 0
separate 0
DR1 0
and 0
DR2 0
element 0
significantly 0
reduced 0
the 0
transcriptional 0
response 0
of 0
HD B-gene
PPRE 0
to 0
peroxisome 0
proliferators 0
. 0

The 0
site 0
of 0
autophosphorylation 0
is 0
Tyr397 0
which 0
corresponds 0
to 0
the 0
consensus 0
autophosphorylation 0
site 0
of 0
other 0
Src B-gene
family I-gene
tyrosine B-gene
kinases I-gene
. 0

This 0
protein 0
- 0
protein 0
interaction 0
does 0
not 0
require 0
the 0
simultaneous 0
binding 0
of 0
Oct B-gene
proteins I-gene
to 0
DNA 0
, 0
and 0
high 0
resolution 0
footprinting 0
of 0
the 0
Oct B-gene
- I-gene
DNA I-gene
interaction 0
reveals 0
that 0
binding 0
of 0
BOB.1/OBF.1 B-gene
to 0
BOB.1/OBF.1 I-gene

Together 0
, 0
our 0
data 0
suggest 0
that 0
the 0
TR2 B-gene
orphan I-gene
receptor I-gene
may 0
be 0
a 0
master 0
regulator 0
in 0
modulating 0
the 0
activation 0
of 0
two 0
key 0
HREs 0
, 0
RARE 0
beta 0
and 0
CRBPIIp 0
, 0
involved 0
in 0
the 0
retinoic 0
acid 0
signal 0
transduction 0
pathway 0
. 0

Using 0
a 0
series 0
of 0
mutant 0
proteins 0
, 0
we 0
have 0
characterized 0
domains 0
responsible 0
for 0
activation 0
or 0
repression 0
. 0

Unlike 0
ARF B-gene
, 0
the 0
ARP B-gene
immunoreactivity 0
was 0
detected 0
in 0
plasma 0
membranes 0
but 0
not 0
in 0
cytosol 0
of 0
fractionated 0
3T3 0
- 0
L1 0
cells 0
. 0

It 0
is 0
considered 0
that 0
the 0
recurrent 0
annular 0
erythema 0
is 0
a 0
specific 0
skin 0
manifestation 0
of 0
SjS 0
with 0
anti B-gene
SS I-gene
- I-gene
A/SS I-gene
A/SS I-gene
- I-gene
B I-gene
antibodies I-gene
. 0

Competition 0
needs 0
to 0
be 0
better 0
studied 0
, 0
since 0
in 0
Central 0
America 0
and 0
Caribean 0
islands 0
this 0
kind 0
of 0
study 0
has 0
favored 0
the 0
biological 0
control 0
of 0
planorbid 0
species 0
. 0

In 0
this 0
paper 0
we 0
describe 0
properties 0
of 0
the 0
cdc10 B-gene
- 0
C4 0
mutant 0
of 0
the 0
fission 0
yeast 0
Schizosaccharomyces 0
pombe 0
. 0

TIEG B-gene
expression 0
in 0
hFOB 0
cells 0
was 0
highly 0
induced 0
by 0
TGF B-gene
- I-gene
beta I-gene
and 0
bone B-gene
morphogenetic I-gene
protein I-gene
- I-gene
2 I-gene
( 0
BMP B-gene
- I-gene
2 I-gene
) 0
, 0
with 0
a 0
moderate 0
induction 0
by 0
epidermal B-gene
growth I-gene
factor I-gene
( 0
EGF B-gene
) 0
, 0
but 0
no 0
induction 0
by 0
other 0
growth 0
factors/cytokines 0
was 0
observed 0
. 0

An 0
infectious 0
origin 0
should 0
always 0
be 0
excluded 0
since 0
specific 0
etiologic 0
therapy 0
may 0
be 0
implemented 0
. 0

The 0
predicted 0
protein 0
products 0
of 0
ORFs B-gene
N2417 I-gene
and 0
N2403 B-gene
present 0
similarities 0
with 0
domains 0
from 0
proteins 0
of 0
other 0
organisms 0
: 0
the 0
Candida 0
maltosa 0
cycloheximide B-gene
- I-gene
resistance I-gene
protein I-gene
, 0
the 0
human 0
interleukin B-gene
enhancer I-gene
- I-gene
binding I-gene
factor I-gene
( 0
ILF B-gene
- I-gene
2 I-gene
) 0
. 0

In 0
particular 0
, 0
the 0
highly 0
expressed 0
ADH1 B-gene
gene I-gene
is 0
represented 0
in 0
this 0
database 0
by 0
no 0
less 0
than 0
20 0
EST 0
sequences 0
. 0

Five 0
families 0
of 0
Ashkenazi 0
Jewish 0
descent 0
carried 0
the 0
185delAG 0
mutation 0
and 0
shared 0
the 0
same 0
haplotype 0
at 0
eight 0
polymorphic 0
markers 0
spanning 0
approximately 0
850 0
kb 0
at 0
BRCA1 B-gene
. 0

The 0
subjects 0
from 0
the 0
two 0
regions 0
with 0
a 0
higher 0
pollution 0
level 0
had 0
lower 0
FVC 0
and 0
FEV1 0
values 0
than 0
those 0
from 0
the 0
Viskovo 0
region 0
. 0

PTP B-gene
- I-gene
S3 I-gene
differs 0
from 0
PTP B-gene
- I-gene
S4 I-gene
in 0
having 0
a 0
deletion 0
of 0
19 0
amino 0
acids 0
corresponding 0
to 0
exon 0
E1 0
. 0

All 0
three 0
NR B-gene
isoforms I-gene
are 0
expressed 0
in 0
cv 0
. 0

All 0
three 0
NR B-gene
isoforms 0
are 0
expressed 0
in 0
cv 0
. 0

The 0
Arabidopsis B-gene
FAD7 I-gene
gene I-gene
encodes 0
a 0
chloroplast B-gene
omega I-gene
- I-gene
3 I-gene
fatty I-gene
acid I-gene
desaturase I-gene
that 0
catalyzes 0
the 0
desaturation 0
of 0
lipid 0
- 0
linked 0
dienoic 0
fatty 0
acids 0
( 0
18:2 0
and 0
16:2 0
) 0
. 0

When 0
differentiated 0
G0 0
- 0
arrested 0
leaf 0
cells 0
were 0
induced 0
to 0
resume 0
cell 0
division 0
by 0
treatment 0
with 0
plant 0
hormones 0
, 0
cycMs4 B-gene
transcription 0
was 0
induced 0
before 0
the 0
onset 0
of 0
DNA 0
synthesis 0
. 0

A 0
survey 0
is 0
given 0
of 0
the 0
pharmacological 0
backgrounds 0
that 0
are 0
relevant 0
for 0
the 0
drug 0
treatment 0
of 0
essential 0
hypertension 0
in 0
the 0
elderly 0
. 0

Protein 0
kinases 0
play 0
pivotal 0
roles 0
in 0
the 0
control 0
of 0
many 0
cellular 0
processes 0
. 0

Interestingly 0
, 0
internal 0
and 0
5 0
' 0
deletions 0
revealed 0
tha 0
the 0
distal 0
promoter 0
was 0
not 0
required 0
for 0
full 0
transcriptional 0
activity 0
and 0
that 0
the 0
first 0
631 0
base 0
pairs 0
of 0
WNT B-gene
- I-gene
5A I-gene
harbored 0
the 0
strongest 0
promoter 0
activity 0
. 0

The 0
protein 0
kinase 0
domains 0
of 0
LIMK1 B-gene
and 0
LIMK2 B-gene
are 0
unique 0
in 0
that 0
they 0
contain 0
an 0
unusual 0
sequence 0
motif 0
Asp 0
- 0
Leu 0
- 0
Asn 0
- 0
Ser 0
- 0
His 0
- 0
Asn 0
in 0
subdomain 0
VIB 0
and 0
a 0
highly 0
basic 0
insert 0
between 0
subdomains 0
VII 0
and 0
VIII 0
. 0

A 0
human 0
recombinant 0
cDNA 0
clone 0
that 0
encoded 0
253 0
amino 0
acids 0
residues 0
of 0
a 0
zinc B-gene
- I-gene
finger I-gene
protein I-gene
( 0
THZif B-gene
- I-gene
1 I-gene
) 0
was 0
cloned 0
by 0
screening 0
a 0
cDNA 0
library 0
prepared 0
from 0
human 0
promyelocytic 0
leukemia 0
HL60 0
cells 0
with 0
synthetic 0
oligodeoxynucleotide 0
probes 0
that 0
corresponded 0
to 0
the 0
amino 0
acid 0
sequences 0
of 0
tryptic 0
peptides 0
derived 0
from 0
the 0
DNA 0
- 0
binding 0
protein 0
specific 0
for 0
the 0
nuclease B-gene
- I-gene
hypersensitive I-gene
element I-gene
( 0
NHE B-gene
) 0
of 0
the 0
human B-gene
c I-gene
- I-gene
myc I-gene
gene I-gene
. 0

Erythrocyte 0
AA 0
in 0
FO+EPO B-gene
- 0
supplemented 0
infants 0
remained 0
low 0
and 0
below 0
breast 0
- 0
and 0
placebo 0
formula 0
- 0
fed 0
levels 0
. 0

Taking 0
into 0
consideration 0
weight 0
and 0
seasonal 0
changes 0
in 0
bone 0
mass 0
, 0
total 0
( 0
TBBMC 0
) 0
and 0
regional 0
body 0
bone 0
mineral 0
content 0
were 0
measured 0
in 0
38 0
women 0
treated 0
with 0
GnRH B-gene
agonists 0
for 0
6 0
months 0
for 0
endometriosis 0
or 0
leiomyomata 0
. 0

The 0
encoded 0
polypeptide 0
is 0
similar 0
in 0
sequence 0
to 0
the 0
ABA B-gene
- I-gene
1 I-gene
allergen I-gene
of I-gene
Ascaris I-gene
, 0
the 0
gp15/400 B-gene
'ladder I-gene
' I-gene
protein I-gene
of I-gene
Brugia I-gene
malayi I-gene
, I-gene
Brugia I-gene
pahangi I-gene
and I-gene
Wuchereria I-gene
bancrofti I-gene
, 0
and 0
a 0
15 B-gene
- I-gene
kDa I-gene
antigen I-gene
of I-gene
Dirofilaria I-gene
immitis I-gene
. 0

Certain 0
transcript 0
patterns 0
in 0
Epifagus 0
plastids 0
are 0
highly 0
complex 0
and 0
similar 0
to 0
those 0
of 0
tobacco 0
operons 0
. 0

Spontaneous 0
recovery 0
occurs 0
within 0
30 0
min 0
to 0
2 0
hrs 0
. 0

DAF B-gene
is 0
a 0
70 0
kD 0
glycoprotein 0
containing 0
complement 0
regulatory 0
short 0
consensus 0
repeats 0
( 0
SCRs 0
) 0
; 0
its 0
gene 0
is 0
located 0
in 0
the 0
regulation B-gene
of I-gene
complement I-gene
activation I-gene
( 0
RCA B-gene
) 0
gene 0
cluster 0
on 0
chromosome 0
1 0
and 0
is 0
about 0
40 0
kb 0
in 0
size 0
. 0

The 0
XS2 B-gene
gene I-gene
down 0
- 0
regulates 0
but 0
does 0
not 0
abolish 0
expression 0
of 0
LU B-gene
genes I-gene
and 0
does 0
not 0
affect 0
expression 0
of 0
CD44 B-gene
. 0

Diabetes 0
care 0
: 0
a 0
guideline 0
to 0
the 0
facilities 0
needed 0
to 0
support 0
internationally 0
endorsed 0
standards 0
. 0

There 0
is 0
no 0
TATA 0
box 0
around 0
the 0
transcriptional 0
start 0
points 0
( 0
tsp 0
) 0
, 0
as 0
determined 0
by 0
primer 0
extension 0
analysis 0
. 0

According 0
to 0
the 0
investigation 0
, 0
the 0
recent 0
burst 0
of 0
pseudoterranovosis 0
in 0
this 0
area 0
can 0
be 0
attributed 0
to 0
the 0
increased 0
presence 0
of 0
sea 0
lions 0
, 0
which 0
proliferate 0
in 0
the 0
Arctic 0
region 0
, 0
then 0
migrate 0
to 0
the 0
northern 0
Japan 0
Sea 0
and 0
eat 0
the 0
intermediate 0
host 0
fish 0
. 0

In 0
summary 0
, 0
the 0
efficacies 0
of 0
adjuvant 0
carboplatin 0
and 0
of 0
abdominal 0
radiotherapy 0
seem 0
to 0
be 0
identical 0
. 0

To 0
identify 0
some 0
of 0
the 0
genes 0
expressed 0
in 0
LPS 0
- 0
activated 0
coelomocytes 0
, 0
we 0
sequenced 0
randomly 0
chosen 0
clones 0
from 0
a 0
directionally 0
constructed 0
cDNA 0
library 0
to 0
produce 0
a 0
set 0
of 0
expressed 0
sequence 0
tags 0
( 0
ESTs 0
) 0
. 0

Characterization 0
of 0
an 0
EcR/USP B-gene
heterodimer 0
target 0
site 0
that 0
mediates 0
ecdysone 0
responsiveness 0
of 0
the 0
EcR/USP I-gene

Thus 0
, 0
SPECT 0
was 0
not 0
as 0
sensitive 0
as 0
PET 0
in 0
this 0
activation 0
task 0
. 0

Transcriptional 0
activation 0
of 0
the 0
chicken B-gene
lysozyme I-gene
gene I-gene
by 0
NF B-gene
- I-gene
kappa I-gene
Bp65 I-gene
( 0
RelA B-gene
) 0
and 0
c B-gene
- I-gene
Rel I-gene
, 0
but 0
not 0
by 0
NF B-gene
- I-gene
kappa I-gene
Bp50 I-gene
. 0

The 0
results 0
indicate 0
that 0
the 0
bradycardic 0
agents 0
alinidine 0
and 0
zatebradine 0
do 0
not 0
exert 0
antiarrhythmic 0
efficacy 0
against 0
SVT 0
induced 0
during 0
subacute 0
myocardial 0
infarction 0
in 0
conscious 0
dogs 0
. 0

In 0
vivo 0
, 0
selective 0
activation 0
of 0
SAPKs B-gene
stimulates 0
formation 0
of 0
the 0
ternary 0
complex 0
containing 0
Elk B-gene
- I-gene
1 I-gene
, 0
serum B-gene
response I-gene
factor I-gene
and 0
the 0
serum 0
response 0
element 0
, 0
and 0
enhances 0
Elk B-gene
- I-gene
1 I-gene
- 0
dependent 0
transcription 0
. 0

An 0
epidemic 0
of 0
hepatitis 0
B 0
virus 0
infection 0
among 0
intravenous 0
drug 0
users 0
in 0
Iceland 0
. 0

The 0
gene 0
was 0
uniquely 0
mapped 0
with 0
odds 0
> 0
1,000:1 0
on 0
chromosome 0
3p 0
in 0
Centre 0
d'Etude 0
du 0
Polymorphisme 0
Humain 0
pedigrees 0
. 0

Three 0
of 0
these 0
subunits 0
are 0
also 0
homologous 0
to 0
the 0
dimeric 0
POR B-gene
from 0
a 0
mesophilic 0
archaeon 0
, 0
Halobacterium 0
halobium 0
( 0
21 0
% 0
identity 0
) 0
. 0

The 0
transposon 0
- 0
inactivated 0
gene 0
, 0
designated 0
pilP B-gene
, 0
is 0
525 0
bp 0
long 0
, 0
potentially 0
encoding 0
a 0
19.1 0
- 0
kDa 0
protein 0
precursor 0
that 0
contains 0
a 0
typical 0
membrane 0
lipoprotein 0
leader 0
sequence 0
. 0

Cheung 0
and 0
S 0
. 0

Upstream 0
of 0
the 0
dra B-gene
gene I-gene
an 0
open 0
reading 0
frame 0
of 0
313 0
amino 0
acids 0
was 0
identified 0
. 0

Sucrose 0
- 0
specific 0
regulation 0
of 0
scrB B-gene
was 0
also 0
lost 0
upon 0
deletion 0
of 0
4 0
bp 0
of 0
a 0
palindromic 0
sequence 0
( 0
OB 0
) 0
covering 0
positions 0
+6 0
to 0
+21 0
downstream 0
of 0
the 0
scrB B-gene
transcriptional 0
start 0
site 0
. 0

In 0
E. 0
coli 0
, 0
CheW B-gene
mediates 0
the 0
physical 0
coupling 0
of 0
the 0
receptors 0
to 0
the 0
kinase 0
CheA B-gene
. 0

The 0
promoter 0
of 0
the 0
first 0
gene 0
, 0
epiF B-gene
, 0
responded 0
to 0
the 0
activator B-gene
protein I-gene
EpiQ I-gene
and 0
contained 0
a 0
palindromic 0
sequence 0
similar 0
to 0
the 0
EpiQ B-gene
binding I-gene
site I-gene
of 0
the 0
epiA B-gene
promoter I-gene
, 0
which 0
is 0
also 0
activated 0
by 0
EpiQ B-gene
. 0

CXC 0
chemokines 0
bind 0
to 0
unique 0
sets 0
of 0
selectivity 0
determinants 0
that 0
can 0
function 0
independently 0
and 0
are 0
broadly 0
distributed 0
on 0
multiple 0
domains 0
of 0
human 0
interleukin B-gene
- I-gene
8 I-gene
receptor I-gene
B I-gene
. 0

Oligodeoxynucleotides 0
antisense 0
to 0
the 0
predicted 0
translation 0
initiation 0
regions 0
of 0
ICP4 B-gene
and 0
pp38 B-gene
mRNAs I-gene
inhibited 0
proliferation 0
of 0
MSB1 0
cells 0
but 0
not 0
MDCC 0
- 0
CU91 0
( 0
CU91 0
) 0
reticuloendotheliosis 0
virus 0
- 0
transformed 0
cells 0
. 0

Retroviral 0
replication 0
requires 0
that 0
a 0
portion 0
of 0
the 0
primary 0
transcripts 0
generated 0
from 0
proviral 0
DNA 0
be 0
spliced 0
to 0
serve 0
as 0
mRNA 0
for 0
the 0
envelope B-gene
protein I-gene
and 0
in 0
Rous 0
sarcoma 0
virus 0
as 0
src B-gene
mRNA I-gene
. 0

In 0
this 0
case 0
the 0
degree 0
of 0
promoter 0
methylation 0
, 0
which 0
could 0
extend 0
beyond 0
the 0
T 0
- 0
DNA 0
borders 0
, 0
was 0
not 0
correlated 0
with 0
the 0
reduction 0
in 0
steady 0
- 0
state 0
poly 0
( 0
A 0
) 0
+ 0
mRNA 0
levels 0
, 0
the 0
silenced 0
state 0
was 0
transmitted 0
through 0
meiosis 0
and 0
reactivation 0
lasted 0
several 0
generations 0
. 0

Thus 0
, 0
the 0
consensus 0
sequences 0
for 0
phosphatase 0
regulation 0
are 0
5' 0
- 0
GCACGTGGG 0
- 0
3 0
' 0
and 0
5' 0
- 0
GCACGTTTT 0
- 0
3 0
' 0
which 0
differ 0
from 0
the 0
binding 0
sequences 0
for 0
the 0
Cpflp B-gene
protein 0
required 0
for 0
transcription 0
of 0
the 0
genes 0
in 0
methionine 0
biosynthesis 0
and 0
for 0
centromere 0
function 0
. 0

Here 0
we 0
report 0
that 0
the 0
proline 0
- 0
rich 0
region 0
of 0
CAP B-gene
is 0
recognized 0
by 0
the 0
SH3 B-gene
domains I-gene
of 0
several 0
proteins 0
, 0
including 0
the 0
yeast B-gene
actin I-gene
- I-gene
associated I-gene
protein I-gene
Abp1p I-gene
. 0

We 0
have 0
identified 0
and 0
characterized 0
a 0
vitamin 0
D 0
response 0
element 0
( 0
VDRE 0
) 0
in 0
the 0
promoter 0
of 0
c B-gene
- I-gene
fos I-gene
. 0

In 0
addition 0
to 0
protein 0
binding 0
at 0
sequences 0
known 0
to 0
be 0
involved 0
in 0
the 0
regulation 0
of 0
transcription 0
, 0
genomic 0
footprinting 0
of 0
the 0
entire 0
promoter 0
region 0
also 0
showed 0
that 0
a 0
protein 0
factor 0
is 0
constitutively 0
bound 0
to 0
the 0
first 0
intron 0
of 0
the 0
rep3 B-gene
gene I-gene
. 0

Differentiation 0
was 0
not 0
observed 0
after 0
cellular 0
expression 0
of 0
GTPase B-gene
- 0
deficient 0
forms 0
of 0
alpha B-gene
i2 I-gene
or 0
alpha B-gene
0 I-gene
, 0
indicating 0
selectivity 0
for 0
the 0
Gq B-gene
family I-gene
of 0
G B-gene
proteins I-gene
. 0

Consistent 0
with 0
a 0
possible 0
role 0
in 0
transcription 0
, 0
Paf1p B-gene
is 0
localized 0
to 0
the 0
nucleus 0
. 0

By 0
comparing 0
the 0
abundances 0
of 0
many 0
yeast 0
transcripts 0
in 0
isogenic 0
wild 0
- 0
type 0
and 0
paf1 B-gene
mutant I-gene
strains 0
, 0
we 0
have 0
identified 0
genes 0
whose 0
expression 0
is 0
affected 0
by 0
PAF1 B-gene
. 0

Paf1p B-gene
may 0
therefore 0
be 0
required 0
for 0
both 0
positive 0
and 0
negative 0
regulation 0
of 0
subsets 0
of 0
yeast 0
genes 0
. 0

Using 0
a 0
high 0
- 0
copy 0
suppression 0
strategy 0
, 0
we 0
have 0
identified 0
a 0
yeast 0
gene 0
( 0
UBS1 B-gene
) 0
whose 0
elevated 0
expression 0
suppresses 0
the 0
conditional 0
cell 0
cycle 0
defects 0
associated 0
with 0
cdc34 B-gene
mutations 0
. 0

Molecular 0
characterization 0
of 0
malignant 0
melanoma 0
of 0
soft 0
parts 0
or 0
soft 0
tissue 0
clear 0
cell 0
sarcoma 0
which 0
shares 0
t 0
( 0
12 0
; 0
22 0
) 0
chromosome 0
translocation 0
revealed 0
fusion 0
of 0
EWS B-gene
with 0
a 0
transcriptional 0
factor 0
gene B-gene
ATF I-gene
- I-gene
1 I-gene
. 0

Clones 0
that 0
expressed 0
DBD 0
exhibited 0
a 0
dominant 0
negative 0
phenotype 0
and 0
did 0
not 0
elicit 0
antiviral 0
activity 0
against 0
vesicular 0
stomatitis 0
virus 0
( 0
VSV 0
) 0
infection 0
upon 0
IFN B-gene
treatment 0
. 0

Abp1 B-gene
preferentially 0
binds 0
to 0
multiple 0
sites 0
in 0
ARS B-gene
3002 I-gene
and 0
to 0
the 0
DNA 0
polymer 0
poly 0
[ 0
d 0
( 0
A.T 0
) 0
] 0
. 0

Identification 0
, 0
purification 0
, 0
and 0
molecular 0
cloning 0
of 0
autonomously B-gene
replicating I-gene
sequence I-gene
- I-gene
binding I-gene
protein I-gene
1 I-gene
from I-gene
fission I-gene
yeast I-gene
Schizosaccharomyces I-gene
pombe I-gene
. 0

A 0
short 0
open 0
reading 0
frame 0
( 0
ORF2 0
) 0
, 0
of 0
unknown 0
function 0
, 0
is 0
present 0
in 0
all 0
FIV 0
isolates 0
. 0

The 0
patient 0
was 0
homozygous 0
for 0
the 0
underlying 0
mutation 0
, 0
which 0
was 0
found 0
to 0
be 0
a 0
G 0
- 0
- 0
> 0
T 0
transversion 0
within 0
the 0
acceptor 0
splice 0
site 0
between 0
intron 0
e 0
and 0
exon 0
6 0
, 0
abolishing 0
normal 0
RNA 0
splicing 0
. 0

These 0
regions 0
overlap 0
with 0
the 0
HIT B-gene
protein I-gene
similarity I-gene
regions I-gene
. 0

We 0
tested 0
10 0
rats 0
with 0
electrophysiologically 0
guided 0
, 0
ibotenic 0
acid 0
lesions 0
of 0
the 0
PBN 0
( 0
PBNx 0
) 0
to 0
determine 0
whether 0
they 0
could 0
acquire 0
a 0
LiCl 0
- 0
induced 0
CTA 0
to 0
l 0
- 0
alanine 0
( 0
0.3 0
M 0
) 0
or 0
demonstrate 0
a 0
sodium 0
appetite 0
following 0
furosemide 0
treatment 0
and 0
overnight 0
access 0
to 0
sodium 0
deficient 0
chow 0
. 0

Liposomal 0
Amphotericin 0
- 0
B 0
failed 0
in 0
6/7 0
patients 0
with 0
culture 0
- 0
proven 0
mycosis 0
who 0
died 0
from 0
infection 0
with 0
Aspergillus 0
( 0
n 0
= 0
2 0
) 0
and 0
Candida 0
( 0
n 0
= 0
4 0
) 0
, 0
respectively 0
. 0

Mg2+ 0
and 0
Mn2+ 0
compete 0
for 0
binding 0
sites 0
, 0
with 0
the 0
former 0
having 0
lower 0
affinity 0
. 0

Magnetic 0
storm 0
indicators 0
could 0
be 0
used 0
in 0
medicine 0
, 0
in 0
geophysics 0
and 0
for 0
special 0
purposes 0
. 0

Transgenic 0
tobacco 0
plants 0
( 0
ppa B-gene
- I-gene
1 I-gene
) 0
constitutively 0
expressing 0
Escherichia B-gene
coli I-gene
pyrophosphatase I-gene
behind 0
the 0
35S B-gene
CaMV I-gene
promoter I-gene
accumulate 0
high 0
levels 0
of 0
soluble 0
sugars 0
in 0
their 0
leaves 0
[ 0
27 0
] 0
. 0

Human B-gene
LAF I-gene
- I-gene
4 I-gene
readily 0
hybridized 0
with 0
genes 0
in 0
mouse 0
and 0
chicken 0
, 0
thus 0
showing 0
that 0
this 0
gene 0
family 0
has 0
been 0
highly 0
conserved 0
during 0
vertebrate 0
evolution 0
. 0

Hb B-gene
levels 0
remained 0
adequate 0
( 0
Hb B-gene
= 0
10.68 0
+/ 0
- 0
0.77 0
g/dl 0
) 0
after 0
14.6 0
+/ 0
- 0
7.64 0
months 0
. 0

CBT 0
is 0
discussed 0
in 0
comparison 0
with 0
the 0
Wisconsin 0
Card 0
Sorting 0
Test 0
as 0
a 0
potential 0
cognitive 0
activation 0
task 0
for 0
functional 0
neuroimaging 0
of 0
the 0
frontal 0
lobes 0
. 0

These 0
data 0
indicate 0
that 0
although 0
218leu 0
retains 0
normal 0
transactivation 0
activity 0
on 0
a 0
p53 B-gene
promoter I-gene
in 0
yeast 0
at 0
physiological 0
temperatures 0
, 0
it 0
is 0
not 0
capable 0
of 0
normal 0
p53 B-gene
function 0
in 0
the 0
presence 0
of 0
a 0
248trp B-gene
allele I-gene
in 0
SNU 0
- 0
C5 0
cells 0
. 0

Cycles 0
were 0
repeated 0
every 0
3 0
weeks 0
. 0

Neither 0
class 0
II 0
nor 0
IV 0
infections 0
precluded 0
transplantation 0
. 0

Although 0
a 0
great 0
deal 0
is 0
understood 0
about 0
how 0
bHLH B-gene
factors I-gene
activate 0
gene 0
transcription 0
via 0
E 0
- 0
box 0
DNA 0
consensus 0
sequences 0
, 0
studies 0
of 0
bHLH B-gene
factor I-gene
function 0
in 0
higher 0
eukaryotes 0
often 0
have 0
been 0
hindered 0
by 0
the 0
presence 0
of 0
multiple 0
family 0
members 0
. 0

Mobility 0
and 0
supershift 0
assays 0
demonstrated 0
that 0
upstream B-gene
stimulatory I-gene
factor I-gene
( 0
USF B-gene
) 0
and 0
Sp1 B-gene
bind 0
to 0
the 0
former 0
elements 0
and 0
competition 0
experiments 0
confirmed 0
that 0
CREB/ATF B-gene
and 0
CREB/ATF I-gene

Upstream 0
of 0
- 0
37 0
, 0
the 0
5 0
' 0
untranslated 0
sequences 0
of 0
the 0
isolates 0
differ 0
in 0
both 0
length 0
and 0
sequence 0
. 0

In 0
these 0
cases 0
, 0
greatly 0
increased 0
human B-gene
chorionic I-gene
gonadotropin I-gene
( 0
hCG B-gene
) 0
levels 0
and 0
suppressed 0
TSH B-gene
levels 0
suggest 0
that 0
hCG B-gene
has 0
thyrotropic 0
activity 0
. 0

High 0
fibrinogen B-gene
levels 0
could 0
thus 0
be 0
a 0
risk 0
for 0
perioperative 0
thrombosis 0
. 0

Strontium 0
chloride 0
Sr 0
89 0
is 0
costly 0
, 0
but 0
preliminary 0
analysis 0
indicates 0
that 0
it 0
may 0
reduce 0
management 0
expenditures 0
overall 0
. 0
( 0
ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

We 0
propose 0
that 0
epigenetic 0
features 0
of 0
tissue 0
- 0
specific 0
control 0
and 0
of 0
the 0
control 0
of 0
allelic 0
expression 0
are 0
intricately 0
linked 0
. 0

This 0
study 0
determined 0
the 0
arthritogenic 0
potential 0
of 0
silicone 0
gel 0
by 0
either 0
mixing 0
it 0
with 0
bovine B-gene
collagen I-gene
II I-gene
( 0
BII B-gene
) 0
or 0
by 0
injecting 0
silicone 0
gel 0
alone 0
in 0
DA 0
rats 0
. 0

SBF B-gene
binds 0
to 0
the 0
promoter 0
prior 0
to 0
the 0
activation 0
of 0
transcription 0
in 0
late 0
G1 0
, 0
suggesting 0
that 0
Cln/Cdc28 B-gene
kinase 0
regulates 0
the 0
ability 0
of 0
previously 0
bound 0
Cln/Cdc28 I-gene

However 0
, 0
it 0
remains 0
an 0
open 0
question 0
whether 0
vertebrate B-gene
Hox I-gene
genes I-gene
expressed 0
under 0
the 0
control 0
of 0
Drosophila 0
regulatory 0
sequences 0
can 0
substitute 0
the 0
function 0
of 0
Drosophila B-gene
Hox I-gene
genes I-gene
. 0

This 0
approach 0
places 0
gHoxb B-gene
- I-gene
1 I-gene
into 0
the 0
normal 0
embryonic 0
spatiotemporal 0
context 0
in 0
which 0
lab 0
acts 0
. 0

This 0
5 0
' 0
splice 0
site 0
sequence 0
was 0
required 0
for 0
enhanced 0
polyadenylation 0
and 0
was 0
recognized 0
by 0
both 0
U1 B-gene
small I-gene
nuclear I-gene
ribonucleoproteins I-gene
( 0
snRNPs 0
) 0
and 0
alternative B-gene
splicing I-gene
factor/splicing I-gene
factor/splicing I-gene
factor I-gene
2 I-gene
( 0
ASF/SF2 B-gene
) 0
. 0

This 0
analysis 0
revealed 0
that 0
SAP B-gene
145 I-gene
, 0
together 0
with 0
four 0
other 0
SF3a/SF3b B-gene
subunits 0
, 0
UV 0
cross 0
- 0
links 0
to 0
pre 0
- 0
mRNA 0
in 0
a 0
20 0
- 0
nucleotide 0
region 0
upstream 0
of 0
the 0
BPS 0
. 0

We 0
propose 0
that 0
CTS1 B-gene
and I-gene
CTS2 I-gene
of I-gene
Ci I-gene
are 0
members 0
of 0
two 0
distinct 0
classes 0
of 0
fungal B-gene
chitinases I-gene
, 0
an 0
observation 0
not 0
previously 0
reported 0
for 0
a 0
single 0
fungus 0
. 0

Although 0
the 0
consumption 0
of 0
myoglobin B-gene
- 0
bound 0
O2 0
( 0
MbO2 0
) 0
stores 0
in 0
seal 0
muscles 0
has 0
been 0
demonstrated 0
in 0
seal 0
muscles 0
during 0
laboratory 0
simulations 0
of 0
diving 0
, 0
this 0
may 0
not 0
be 0
a 0
feature 0
of 0
normal 0
field 0
diving 0
in 0
which 0
measurements 0
of 0
heart 0
rate 0
and 0
lactate 0
production 0
show 0
marked 0
differences 0
from 0
the 0
profound 0
diving 0
response 0
induced 0
by 0
forced 0
immersion 0
. 0

The 0
human B-gene
purH I-gene
cDNA I-gene
is 0
1776 0
base 0
pairs 0
in 0
length 0
encoding 0
for 0
a 0
591 0
- 0
amino 0
acid 0
polypeptic 0
( 0
Mr 0
= 0
64,425 0
) 0
. 0

The 0
Saccharomyces 0
cerevisiae 0
spindle 0
pole 0
body 0
duplication 0
gene B-gene
MPS1 I-gene
is 0
part 0
of 0
a 0
mitotic 0
checkpoint 0
. 0

In 0
our 0
opinion 0
, 0
the 0
SM 0
- 0
CMA 0
system 0
is 0
, 0
despite 0
some 0
shortcomings 0
in 0
its 0
user 0
- 0
interface 0
, 0
a 0
useful 0
and 0
versatile 0
instrument 0
for 0
examination 0
of 0
human 0
semen 0
samples 0
, 0
with 0
desirable 0
features 0
. 0

The 0
purpose 0
of 0
the 0
study 0
reported 0
here 0
was 0
to 0
investigate 0
whether 0
differences 0
in 0
T1 0
and 0
T2 0
between 0
tumors 0
are 0
mainly 0
a 0
consequence 0
of 0
differences 0
in 0
the 0
fractional 0
volume 0
of 0
the 0
extracellular 0
compartment 0
. 0

A 0
mutant B-gene
areA I-gene
product I-gene
truncated 0
immediately 0
after 0
the 0
last 0
residue 0
of 0
the 0
highly 0
conserved 0
GATA B-gene
( I-gene
DNA I-gene
- I-gene
binding I-gene
) I-gene
domain I-gene
retains 0
partial 0
function 0
. 0

Oligonucleotides 0
, 0
designed 0
on 0
the 0
basis 0
of 0
conserved 0
flanking 0
amino 0
acid 0
sequence 0
segments 0
within 0
the 0
catalytic 0
domain 0
of 0
eukaryotic B-gene
protein I-gene
kinase I-gene
C I-gene
( 0
PKC B-gene
) 0
proteins 0
, 0
were 0
used 0
as 0
primers 0
for 0
polymerase 0
chain 0
reactions 0
to 0
amplify 0
a 0
427 0
- 0
bp 0
chromosomal 0
DNA 0
fragment 0
from 0
the 0
filamentous 0
fungus 0
Trichoderma 0
reesei 0
. 0

Disruption 0
of 0
RB/E2F B-gene
RB/E2F I-gene
- I-gene
1 I-gene
interaction 0
by 0
single 0
point 0
mutations 0
in 0
E2F B-gene
- I-gene
1 I-gene
enhances 0
S 0
- 0
phase 0
entry 0
and 0
apoptosis 0
. 0

Apparent 0
loss 0
of 0
differentiation 0
markers 0
characterizes 0
advanced 0
malignant 0
neoplasms 0
. 0

This 0
region 0
contains 0
a 0
motif 0
with 0
partial 0
identity 0
with 0
the 0
binding 0
site 0
for 0
the 0
ubiquitous 0
transcription 0
factor 0
upstream B-gene
stimulatory I-gene
factor I-gene
( 0
USF B-gene
) 0
, 0
which 0
binds 0
to 0
the 0
human B-gene
insulin I-gene
promoter I-gene
. 0

The 0
method 0
has 0
been 0
satisfactorily 0
applied 0
to 0
the 0
determination 0
of 0
paracetamol 0
in 0
pharmaceutical 0
formulations 0
and 0
biological 0
fluids 0
. 0

These 0
primers 0
yielded 0
a 0
PCR 0
product 0
of 0
a 0
characteristic 0
length 0
within 0
most 0
Xanthomonas 0
species 0
and 0
pathovars 0
tested 0
. 0

The 0
Clb5 B-gene
kinase I-gene
, 0
which 0
promotes 0
S 0
phase 0
, 0
remains 0
active 0
during 0
the 0
G2 0
- 0
phase 0
arrest 0
of 0
cells 0
of 0
the 0
parental 0
strain 0
, 0
but 0
its 0
activity 0
declines 0
rapidly 0
in 0
sim B-gene
mutants I-gene
. 0

The 0
C/D 0
ratio 0
was 0
equal 0
to 0
or 0
over 0
0.6 0
in 0
9 0
cases 0
( 0
16 0
eyes 0
) 0
, 0
and 0
the 0
values 0
were 0
inconsistent 0
between 0
both 0
eyes 0
in 0
55 0
% 0
of 0
the 0
patients 0
. 0

Rad6 B-gene
mutants I-gene
display 0
a 0
remarkably 0
pleiotropic 0
phenotype 0
, 0
implicating 0
the 0
protein 0
in 0
DNA 0
damage 0
- 0
induced 0
mutagenesis 0
, 0
postreplication 0
repair 0
, 0
repression 0
of 0
retrotransposition 0
, 0
and 0
sporulation 0
. 0

RNase B-gene
protection 0
assays 0
revealed 0
a 0
correlation 0
between 0
the 0
levels 0
of 0
dorsal 0
and 0
ventral 0
skin 0
expression 0
with 0
pigmentation/phaeomelanin 0
phenotypes 0
. 0

Molecular 0
cloning 0
, 0
expression 0
pattern 0
, 0
and 0
chromosomal 0
localization 0
of 0
human 0
CDKN2D/INK4d B-gene
, 0
an 0
inhibitor 0
of 0
CDKN2D/INK4d I-gene

Overproduction 0
of 0
HrcA B-gene
protein I-gene
from 0
a 0
second 0
copy 0
of 0
hrcA B-gene
derived 0
from 0
a 0
plasmid 0
( 0
phrcA+ B-gene
) 0
in 0
B. 0
subtilis 0
wild 0
- 0
type 0
and 0
delta 0
hrcA B-gene
strains 0
prevented 0
heat 0
shock 0
induction 0
of 0
the 0
dnaK B-gene
and 0
groE B-gene
operons I-gene
at 0
the 0
level 0
of 0
transcription 0
almost 0
completely 0
and 0
strongly 0
reduced 0
the 0
amounts 0
of 0
mRNA 0
at 0
a 0
low 0
temperature 0
as 0
well 0
. 0

We 0
report 0
the 0
molecular 0
cloning 0
and 0
functional 0
characterization 0
of 0
USF2 B-gene
isoforms I-gene
, 0
corresponding 0
to 0
a 0
44 0
- 0
kDa 0
subunit 0
, 0
USF2a B-gene
, 0
and 0
a 0
new 0
38 0
- 0
kDa 0
subunit 0
, 0
USF2b B-gene
, 0
generated 0
by 0
differential 0
splicing 0
. 0

The 0
preferential 0
heterodimerization 0
of 0
USF B-gene
subunits I-gene
was 0
reproduced 0
ex 0
vivo 0
, 0
while 0
the 0
in 0
vitro 0
association 0
of 0
cotranslated 0
subunits 0
, 0
or 0
recombinant B-gene
USF I-gene
proteins I-gene
, 0
appeared 0
to 0
be 0
random 0
. 0

Activated 0
PKR B-gene
may 0
exist 0
as 0
a 0
dimer 0
and 0
phosphorylates 0
the 0
eukaryotic B-gene
translation I-gene
initiation I-gene
factor I-gene
2 I-gene
alpha I-gene
subunit I-gene
( 0
cIF B-gene
- I-gene
2 I-gene
alpha I-gene
) 0
to 0
inhibit 0
polypeptide 0
chain 0
initiation 0
. 0

GRP78 B-gene
, 0
a 0
molecular 0
chaperone 0
expressed 0
in 0
the 0
endoplasmic 0
reticulum 0
, 0
is 0
a 0
`` 0
glucose 0
- 0
regulated 0
protein 0
'' 0
induced 0
by 0
stress 0
responses 0
that 0
deplete 0
glucose 0
or 0
intracisternal 0
calcium 0
or 0
otherwise 0
disrupt 0
glycoprotein 0
trafficking 0
. 0

The 0
IL B-gene
- I-gene
8 I-gene
receptor I-gene
is 0
a 0
seven 0
- 0
transmembrane 0
spanning 0
receptor 0
coupled 0
to 0
specific 0
heterotrimeric B-gene
G I-gene
proteins I-gene
including 0
Gi B-gene
and 0
G16 B-gene
. 0

In 0
a 0
second 0
series 0
of 0
experiments 0
, 0
the 0
efficacy 0
of 0
PDC/HDC 0
Ac 0
was 0
evaluated 0
in 0
both 0
single 0
and 0
multiple 0
dose 0
regiments 0
. 0

To 0
elucidate 0
the 0
functional 0
significance 0
of 0
Fyn B-gene
in 0
the 0
expression 0
of 0
viral 0
promoters 0
, 0
we 0
transfected 0
a 0
Fyn B-gene
- 0
expression 0
vector 0
together 0
with 0
a 0
reporter 0
plasmid 0
containing 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
gene I-gene
driven 0
by 0
HIV B-gene
LTR I-gene
into 0
a 0
human 0
T 0
cell 0
line 0
, 0
Jurkat 0
. 0

We 0
conducted 0
a 0
prospective 0
, 0
randomized 0
controlled 0
trial 0
of 0
metoprolol 0
, 0
a 0
selective 0
beta 0
- 0
blocker 0
for 0
prevention 0
of 0
gastrointestinal 0
bleeding 0
from 0
portal 0
hypertension 0
in 0
29 0
non 0
- 0
selected 0
patients 0
with 0
liver 0
disease 0
and 0
previous 0
gastrointestinal 0
bleeding 0
. 0

A 0
genetic 0
and 0
molecular 0
analysis 0
of 0
non 0
- 0
inducible 0
qutA B-gene
mutants I-gene
showed 0
that 0
all 0
23 0
mutations 0
analysed 0
map 0
within 0
the 0
N 0
- 0
terminal 0
half 0
of 0
the 0
encoded 0
QUTA B-gene
protein I-gene
. 0

These 0
studies 0
indicate 0
that 0
the 0
acidimetric 0
test 0
was 0
less 0
sensitive 0
than 0
the 0
chromogenic 0
cephalosporin 0
substrates 0
and 0
that 0
nitrocefin 0
and 0
S1 0
could 0
be 0
used 0
to 0
screen 0
for 0
beta B-gene
- I-gene
lactamase I-gene
production 0
in 0
these 0
tested 0
species 0
. 0

Suppressors 0
of 0
defective 0
silencing 0
in 0
yeast 0
: 0
effects 0
on 0
transcriptional 0
repression 0
at 0
the 0
HMR B-gene
locus I-gene
, 0
cell 0
growth 0
and 0
telomere 0
structure 0
. 0

Although 0
ANP B-gene
induced 0
systemic 0
capillary 0
filtration 0
, 0
in 0
the 0
calf 0
, 0
filtration 0
was 0
reduced 0
with 0
ANP B-gene
. 0

Recent 0
literature 0
has 0
suggested 0
that 0
beta B-gene
- I-gene
2 I-gene
transferrin I-gene
can 0
also 0
be 0
used 0
as 0
a 0
clinical 0
marker 0
for 0
perilymph 0
. 0

With 0
current 0
methodology 0
beta B-gene
- I-gene
2 I-gene
transferrin I-gene
does 0
not 0
appear 0
to 0
be 0
a 0
reliable 0
clinical 0
marker 0
for 0
perilymph 0
in 0
the 0
operative 0
setting 0
. 0

The 0
hIGF B-gene
- I-gene
I I-gene
gene I-gene
has 0
two 0
promoters 0
, 0
P1 0
and 0
P2 0
. 0

Gel 0
mobility 0
shift 0
assays 0
indicated 0
that 0
at 0
least 0
four 0
nuclear 0
proteins 0
with 0
distinct 0
biochemical 0
and 0
binding 0
properties 0
possess 0
the 0
ability 0
to 0
bind 0
the 0
3 0
beta 0
I 0
- 0
A 0
element 0
to 0
produce 0
four 0
DNA 0
- 0
protein 0
complexes 0
( 0
R1 0
to 0
R4 0
) 0
. 0

Sixty 0
- 0
five 0
patients 0
( 0
aged 0
between 0
3 0
years 0
5 0
months 0
and 0
60 0
years 0
) 0
suffering 0
from 0
medically 0
resistant 0
temporal 0
lobe 0
epilepsy 0
( 0
TLE 0
) 0
were 0
operated 0
on 0
over 0
a 0
period 0
of 0
33 0
months 0
in 0
Bethel 0
Epilepsy 0
Center 0
. 0

Significant 0
correlations 0
existed 0
between 0
FEV1 0
and 0
the 0
corresponding 0
values 0
of 0
Raw 0
, 0
MEF50 0
and 0
MEF25 0
, 0
although 0
there 0
were 0
considerable 0
individual 0
differences 0
between 0
test 0
results 0
. 0

( 0
1989 0
) 0
, 0
which 0
is 0
identical 0
to 0
the 0
SSC1 B-gene
gene I-gene
( 0
Smith 0
et 0
al. 0
, 0
1988 0
) 0
. 0

This 0
region 0
also 0
contains 0
a 0
gene 0
specifying 0
a 0
Leu B-gene
- I-gene
tRNA I-gene
precursor I-gene
and 0
a 0
remnant 0
of 0
a 0
tau 0
element 0
. 0

Occupational 0
exposure 0
to 0
hepatitis 0
B 0
virus 0
and 0
human 0
immunodeficiency 0
virus 0
: 0
a 0
comparative 0
risk 0
analysis 0
. 0

Hybrid 0
female 0
mice 0
( 0
C57BL 0
x 0
CBA 0
) 0
were 0
paired 0
with 0
breeder 0
males 0
( 0
CD 0
- 0
1 0
) 0
and 0
LNG 0
pellets 0
were 0
implanted 0
on 0
day 0
0 0
, 0
the 0
day 0
on 0
which 0
copulation 0
plugs 0
were 0
found 0
, 0
or 0
on 0
day 0
2 0
or 0
day 0
3 0
in 0
the 0
postcoital 0
period 0
. 0

This 0
gene 0
encodes 0
a 0
putative 0
transcription 0
factor 0
with 0
regions 0
of 0
homology 0
to 0
several 0
other 0
proteins 0
including 0
the 0
zinc 0
fingers 0
and 0
other 0
domains 0
of 0
the 0
Drosophila B-gene
trithorax I-gene
gene I-gene
product I-gene
, 0
and 0
the 0
`` 0
AT 0
- 0
hook 0
'' 0
DNA 0
- 0
binding 0
motif 0
of B-gene
high I-gene
mobility I-gene
group I-gene
proteins I-gene
. 0

Using 0
reference 0
probes 0
as 0
internal 0
standards 0
, 0
we 0
show 0
that 0
the 0
ost B-gene
transcription I-gene
unit I-gene
is 0
located 0
within 0
the 0
cytogenetic 0
band 0
interval 0
89A1,2 0
on 0
the 0
right 0
arm 0
of 0
the 0
third 0
chromosome 0
, 0
and 0
that 0
it 0
exerts 0
diagnostic 0
segmentation 0
gene 0
expression 0
patterns 0
in 0
the 0
embryo 0
. 0

The 0
purified 0
recombinant 0
enzyme 0
catalyzed 0
specific 0
phosphoryl 0
transfer 0
from 0
ATP 0
to 0
UMP 0
and 0
CMP 0
. 0

Studies 0
on 0
the 0
life 0
cycle 0
of 0
Haplorchis 0
pumilio 0
( 0
Looss 0
, 0
1896 0
) 0
Looss 0
, 0
1899 0
with 0
morphological 0
redescription 0
of 0
larval 0
and 0
adult 0
stages 0
. 0

Regressing 0
microaneurysms 0
in 0
5 0
cases 0
of 0
hepatitis 0
B 0
virus 0
related 0
polyarteritis 0
nodosa 0
. 0

During 0
the 0
following 0
pregnancy 0
ultrasonographic 0
studies 0
of 0
the 0
male 0
fetus 0
in 0
the 0
16th 0
week 0
of 0
gestation 0
revealed 0
severe 0
micrognathia 0
, 0
short 0
and 0
wide 0
thumbs 0
, 0
and 0
big 0
toes 0
, 0
and 0
bowed 0
tibiae 0
. 0

Despite 0
an 0
overall 0
survival 0
rate 0
of 0
43 0
% 0
, 0
survival 0
to 0
discharge 0
varied 0
greatly 0
( 0
0 0
to 0
100 0
% 0
) 0
among 0
the 0
24 0
diagnostic 0
groups 0
: 0
tumor 0
lysis 0
syndrome 0
and 0
systemic 0
lupus 0
erythematosus 0
( 0
3/3 0
patients 0
each 0
, 0
100 0
% 0
) 0
, 0
hemolytic 0
uremic 0
syndrome 0
( 0
8/9 0
patients 0
, 0
89 0
% 0
) 0
. 0

One 0
hundred 0
units/kg 0
of 0
recombinant B-gene
human I-gene
erythropoietin I-gene
( 0
rhEPO B-gene
) 0
was 0
given 0
subcutaneously 0
3 0
times 0
a 0
week 0
for 0
3 0
weeks 0
. 0

A 0
3 0
- 0
week 0
regimen 0
of 0
erythropoietin B-gene
may 0
help 0
prevent 0
the 0
donor 0
's 0
need 0
to 0
receive 0
allogeneic 0
blood 0
transfusion 0
, 0
when 0
the 0
initial 0
Hb B-gene
levels 0
were 0
below 0
130 0
milligrams 0
. 0

In 0
these 0
constructs 0
, 0
GUS B-gene
expression 0
was 0
driven 0
by 0
promoter 0
regions 0
derived 0
from 0
the 0
Arabidopsis B-gene
alcohol I-gene
dehydrogenase I-gene
( 0
Adh1 B-gene
) 0
, 0
maize B-gene
ubiquitin I-gene
( 0
Ubi1 B-gene
) 0
, 0
rice B-gene
actin I-gene
( 0
Act1 B-gene
) 0
and 0
CaMV B-gene
35S I-gene
genes I-gene
. 0

Its 0
organization 0
and 0
regulation 0
indicate 0
that 0
the 0
S. B-gene
pombe I-gene
URA1 I-gene
gene I-gene
product I-gene
appears 0
very 0
similar 0
to 0
the 0
S. B-gene
cerevisiae I-gene
URA2 I-gene
gene I-gene
product I-gene
. 0

The 0
mean 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
was 0
31.8 0
+/ 0
- 0
6.3 0
kg/m2 0
and 0
28.5 0
+/ 0
- 0
6.3 0
kg/m2 0
in 0
women 0
and 0
men 0
, 0
respectively 0
. 0

These 0
findings 0
demonstrate 0
that 0
haemodialysis 0
patients 0
with 0
chronic 0
hepatitis 0
C 0
respond 0
well 0
to 0
interferon B-gene
treatment 0
and 0
that 0
a 0
long 0
- 0
term 0
response 0
is 0
achieved 0
in 0
a 0
high 0
proportion 0
of 0
patients 0
. 0

Synthetic 0
enantiomers 0
of 0
drugs 0

Polysome 0
analysis 0
further 0
indicated 0
that 0
these 0
germ B-gene
cell I-gene
- I-gene
specific I-gene
Sp1 I-gene
mRNAs I-gene
are 0
translated 0
, 0
albeit 0
with 0
a 0
lower 0
efficiency 0
than 0
the 0
somatic 0
transcript 0
. 0

In 0
nondiabetics 0
the 0
response 0
of 0
tcPO2 0
but 0
not 0
of 0
LDF 0
was 0
influenced 0
by 0
the 0
values 0
at 0
rest 0
. 0

This 0
study 0
proposes 0
an 0
estimator 0
for 0
such 0
global 0
synchronizing 0
effects 0
upon 0
unit 0
- 0
pair 0
correlations 0
based 0
on 0
local 0
field 0
potentials 0
( 0
LFPs 0
) 0
. 0

The 0
assembly 0
of 0
sequence 0
ready 0
, 0
high 0
- 0
resolution 0
physical 0
maps 0
and 0
construction 0
of 0
minimally 0
overlapping 0
contigs 0
for 0
the 0
human 0
as 0
well 0
as 0
model 0
genomes 0
requires 0
accurate 0
determination 0
of 0
the 0
extent 0
of 0
overlap 0
between 0
adjacent 0
clones 0
as 0
well 0
as 0
their 0
relative 0
orientation 0
. 0

( 0
ii 0
) 0
opening 0
of 0
KATP 0
attenuates 0
, 0
inhibition 0
of 0
the 0
channel 0
exacerbates 0
functional 0
consequences 0
of 0
coronary 0
occlusion 0
, 0
and 0
( 0
iii 0
) 0
KATP 0
opening 0
attenuates 0
reperfusion 0
- 0
induced 0
VF 0
, 0
but 0
it 0
triggers 0
ischemia 0
- 0
induced 0
VF 0
. 0

The 0
DNA 0
sequences 0
upstream 0
of 0
these 0
termini 0
exhibit 0
homology 0
to 0
plant 0
mitochondrial 0
- 0
processing 0
sites 0
, 0
therefore 0
the 0
proximal 0
5 0
' 0
ends 0
are 0
most 0
probably 0
generated 0
by 0
RNA 0
processing 0
. 0

Curing 0
shrinkage 0
and 0
volumetric 0
changes 0
of 0
resin 0
- 0
modified 0
glass 0
ionomer 0
restorative 0
materials 0
. 0

Here 0
we 0
present 0
genetic 0
evidence 0
suggesting 0
that 0
PP2A B-gene
functions 0
downstream 0
of 0
Ras1 B-gene
in 0
the 0
Sevenless B-gene
receptor B-gene
tyrosine I-gene
kinase I-gene
( 0
RTK B-gene
) 0
signal 0
transduction 0
pathway 0
that 0
specifies 0
R7 0
photoreceptor 0
cell 0
fate 0
in 0
the 0
developing 0
Drosophila 0
eye 0
. 0

QBMDs 0
for 0
a 0
5 0
% 0
change 0
in 0
response 0
( 0
QBMD05 0
) 0
were 0
6 0
- 0
fold 0
lower 0
, 0
on 0
average 0
, 0
than 0
the 0
corresponding 0
NOAEL 0
. 0

Effects 0
of 0
repeated 0
exposures 0
of 0
hydrogen 0
sulphide 0
on 0
rat 0
hippocampal 0
EEG 0
. 0

The 0
gene 0
encodes 0
an 0
ATP B-gene
- I-gene
binding I-gene
cassette I-gene
, 0
ABC B-gene
transporter I-gene
. 0

The 0
T 0
- 0
box 0
motif 0
is 0
present 0
in 0
a 0
family 0
of 0
genes 0
whose 0
structural 0
features 0
and 0
expression 0
patterns 0
support 0
their 0
involvement 0
in 0
developmental 0
gene 0
regulation 0
. 0

Molecular 0
analysis 0
of 0
a 0
novel 0
schizosaccharomyces 0
pombe 0
gene 0
containing 0
two 0
RNP 0
consensus 0
- 0
sequence 0
RNA 0
- 0
binding 0
domains 0
. 0

Do 0
overall 0
treatment 0
time 0
, 0
field 0
size 0
, 0
and 0
treatment 0
energy 0
influence 0
local 0
control 0
of 0
T1 0
- 0
T2 0
squamous 0
cell 0
carcinomas 0
of 0
the 0
glottic 0
larynx 0
? 0
PURPOSE 0
: 0
To 0
evaluate 0
treatment 0
and 0
patient 0
related 0
prognostic 0
factors 0
that 0
may 0
influence 0
local 0
control 0
in 0
the 0
treatment 0
of 0
T1 0
- 0
T2 0
squamous 0
cell 0
carcinoma 0
of 0
the 0
glottic 0
larynx 0
. 0

In 0
contrast 0
to 0
the 0
signaling 0
triggered 0
by 0
surface 0
Ig B-gene
engagement 0
in 0
B 0
lymphocytes 0
, 0
CD38 B-gene
ligation 0
did 0
not 0
appear 0
to 0
induce 0
tyrosine 0
phosphorylation 0
of 0
the 0
src B-gene
- I-gene
like I-gene
protein I-gene
tyrosine I-gene
kinases I-gene
lyn B-gene
, 0
fyn B-gene
, 0
and 0
btk B-gene
, 0
or 0
of 0
vav B-gene
- I-gene
and I-gene
ras I-gene
- I-gene
GTPase I-gene
- I-gene
activating I-gene
protein I-gene
, 0
nor 0
did 0
it 0
induce 0
detectable 0
changes 0
in 0
cytosolic 0
CA2+ 0
concentrations 0
. 0

Mutations 0
in 0
the 0
alpha B-gene
- I-gene
amanitin I-gene
conserved 0
domain 0
of 0
the 0
largest 0
subunit 0
of 0
yeast B-gene
RNA I-gene
polymerase I-gene
III I-gene
affect 0
pausing 0
, 0
RNA 0
cleavage 0
and 0
transcriptional 0
transitions 0
. 0

The 0
evidence 0
presented 0
here 0
suggests 0
that 0
the 0
p40 B-gene
complex I-gene
is 0
a 0
ribonucleoprotein 0
complex 0
containing 0
L1Hs B-gene
RNA I-gene
( I-gene
s I-gene
) I-gene
and 0
that 0
protein 0
- 0
protein 0
interactions 0
in 0
which 0
alpha 0
- 0
helix 0
structures 0
participate 0
, 0
for 0
example 0
coiled 0
- 0
coils 0
, 0
may 0
occur 0
in 0
the 0
complex 0
. 0

Our 0
data 0
suggest 0
that 0
trans 0
- 0
activation 0
from 0
the 0
prothymosin B-gene
intron I-gene
enhancer I-gene
is 0
a 0
faithful 0
reflection 0
of 0
the 0
transforming 0
properties 0
of 0
the 0
Myc B-gene
protein I-gene
. 0

Pseudomembranous 0
conjunctivitis 0
following 0
bone 0
marrow 0
transplantation 0
: 0
immunopathological 0
and 0
ultrastructural 0
study 0
of 0
one 0
case 0
. 0

In 0
view 0
of 0
the 0
presence 0
of 0
SECIS 0
elements 0
in 0
the 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
of 0
bacterial B-gene
selenoproteins I-gene
, 0
we 0
examine 0
the 0
effects 0
in 0
the 0
type B-gene
1 I-gene
deiodinase I-gene
of 0
extending 0
the 0
ORF 0
into 0
the 0
SECIS 0
element 0
, 0
and 0
find 0
that 0
this 0
dramatically 0
inhibits 0
SECIS 0
function 0
. 0

The 0
5 0
' 0
external 0
transcribed 0
spacer 0
( 0
ETS 0
) 0
region 0
of 0
the 0
pre 0
- 0
rRNA 0
in 0
Saccharomyces 0
cerevisiae 0
contains 0
a 0
sequence 0
with 0
10 0
bp 0
of 0
perfect 0
complementarity 0
to 0
the 0
U3 B-gene
snoRNA I-gene
. 0

These 0
animals 0
were 0
viable 0
and 0
fertile 0
. 0

This 0
spindle 0
defect 0
of 0
pds1 B-gene
mutants I-gene
results 0
from 0
a 0
temperature 0
- 0
sensitive 0
step 0
that 0
occurs 0
around 0
the 0
G1/S 0
boundary 0
about 0
the 0
time 0
of 0
spindle 0
assembly 0
. 0

These 0
data 0
suggest 0
that 0
RPF B-gene
- I-gene
1 I-gene
is 0
likely 0
to 0
be 0
involved 0
in 0
early 0
steps 0
in 0
the 0
differentiation 0
of 0
amacrine 0
and 0
ganglion 0
cells 0
. 0

In 0
the 0
point 0
mutant 0
we 0
observed 0
normal 0
repair 0
of 0
endonuclease B-gene
III I-gene
site I-gene
( 0
i.e 0
. 0
as 0
wild 0
type 0
) 0
, 0
but 0
no 0
removal 0
of 0
CPDs 0
at 0
the 0
MAT B-gene
alpha I-gene
and 0
HML B-gene
alpha I-gene
loci I-gene
. 0

However 0
, 0
for 0
the 0
evaluable 0
cases 0
, 0
the 0
performances 0
of 0
the 0
CD3500 0
and 0
the 0
STKS 0
were 0
broadly 0
similar 0
and 0
generally 0
correlated 0
well 0
with 0
the 0
manual 0
reference 0
procedure 0
. 0

Carboxy 0
- 0
terminal 0
Spc110p B-gene
truncations 0
lacking 0
the 0
calmodulin B-gene
binding 0
site 0
can 0
support 0
growth 0
and 0
are 0
also 0
phosphorylated 0
in 0
a 0
cell 0
cycle 0
- 0
specific 0
manner 0
. 0

Both 0
EWS B-gene
- 0
FLI B-gene
- I-gene
1 I-gene
and 0
FLI B-gene
- I-gene
1 I-gene
proteins I-gene
function 0
as 0
transcription 0
factors 0
that 0
bind 0
specifically 0
to 0
ets B-gene
sequences 0
( 0
the 0
ets B-gene
boxes 0
) 0
present 0
in 0
promoter 0
elements 0
. 0

In 0
electromobility 0
shift 0
assays 0
, 0
EWS B-gene
- 0
FLI B-gene
- I-gene
1 I-gene
binding 0
to 0
the 0
SRE 0
is 0
detectable 0
in 0
the 0
absence 0
of 0
SRF B-gene
whereas 0
the 0
binding 0
of 0
FLI B-gene
- I-gene
1 I-gene
is 0
not 0
, 0
suggesting 0
that 0
the 0
interaction 0
with 0
DNA 0
is 0
the 0
step 0
which 0
limits 0
ternary 0
complex 0
formation 0
by 0
FLI B-gene
- I-gene
1 I-gene
. 0

Additional 0
studies 0
with 0
new 0
and 0
reprocessed 0
regenerated 0
cellulose 0
dialyzers 0
comparing 0
450 0
and 0
220 0
mL/min 0
blood 0
flow 0
rates 0
at 0
10 0
minutes 0
showed 0
no 0
change 0
in 0
BTG 0
. 0

DNA 0
methylation 0
, 0
especially 0
of 0
either 0
one 0
or 0
both 0
of 0
the 0
deoxyadenosines 0
at 0
the 0
two 0
GATC 0
motifs 0
( 0
one 0
in 0
the 0
first 0
exon 0
and 0
the 0
other 0
in 0
the 0
first 0
intron 0
of 0
the 0
rice 0
CatA B-gene
gene I-gene
) 0
, 0
appeared 0
to 0
be 0
responsible 0
for 0
the 0
CatA B-gene
promoter I-gene
activity 0
identified 0
in 0
the 0
transient 0
assay 0
. 0

The 0
viral B-gene
LTR I-gene
was 0
used 0
as 0
the 0
promoter 0
. 0

Overlapping 0
cDNA 0
clones 0
were 0
isolated 0
and 0
sequenced 0
. 0

In 0
conclusion 0
, 0
IgM B-gene
class 0
CIC 0
is 0
the 0
predominant 0
CIC 0
in 0
acute 0
hepatitis 0
A 0
and 0
correlated 0
with 0
disease 0
activity 0
. 0

Epitope 0
mapping 0
revealed 0
that 0
these 0
three 0
clones 0
appear 0
to 0
recognize 0
an 0
identical 0
epitope 0
domain 0
present 0
on 0
the 0
C 0
- 0
terminal 0
RNP 0
motif 0
of 0
the 0
U1A B-gene
protein I-gene
. 0

Variables 0
evaluated 0
were 0
number 0
of 0
weekly 0
anginal 0
events 0
, 0
data 0
from 0
ergometric 0
exercise 0
testing 0
with 0
simultaneous 0
electrocardiographic 0
registration 0
, 0
semiquantitative 0
evaluation 0
of 0
Tc 0
- 0
99m 0
2 0
- 0
methoxy 0
isobutyl 0
isonitrile 0
( 0
MIBI 0
) 0
scans 0
and 0
rheologic 0
variables 0
. 0

As 0
the 0
length 0
of 0
the 0
fatty 0
acid 0
decreased 0
, 0
the 0
binding 0
affinity 0
was 0
reduced 0
; 0
myristic 0
acid 0
( 0
14:0 0
) 0
bound 0
with 0
a 0
K 0
( 0
d 0
) 0
of 0
1409 0
+/ 0
- 0
423 0
nM 0
, 0
but 0
medium 0
- 0
chain 0
( 0
decanoic 0
acid 0
, 0
10:0 0
) 0
and 0
short 0
- 0
chain 0
( 0
octanoic 0
acid 0
, 0
8:0 0
) 0
lipids 0
were 0
not 0
bound 0
at 0
all 0
. 0

The 0
membrane 0
- 0
distal 0
cytoplasmic 0
region 0
of 0
human B-gene
granulocyte I-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
receptor I-gene
is 0
required 0
for 0
STAT3 B-gene
but 0
not 0
STAT1 B-gene
homodimer I-gene
formation 0
. 0

However 0
, 0
whether 0
or 0
not 0
nonsense 0
codon 0
recognition 0
within 0
TPI B-gene
transcripts I-gene
takes 0
place 0
prior 0
to 0
or 0
after 0
splicing 0
remained 0
unresolved 0
. 0

Although 0
some 0
residues 0
are 0
found 0
reactive 0
toward 0
dimethylsulphate 0
and 0
kethoxal 0
in 0
regions 0
predicted 0
to 0
be 0
unpaired 0
by 0
the 0
phylogenetic 0
secondary 0
structure 0
model 0
of 0
4.5S B-gene
RNA I-gene
, 0
generally 0
the 0
reactivity 0
is 0
low 0
, 0
and 0
some 0
residues 0
in 0
internal 0
loops 0
are 0
not 0
reactive 0
at 0
all 0
. 0

Ongoing 0
and 0
future 0
investigations 0
may 0
better 0
define 0
the 0
optimal 0
approach 0
for 0
local 0
control 0
, 0
the 0
optimal 0
duration 0
of 0
maintenance 0
chemotherapy 0
, 0
and 0
the 0
possible 0
role 0
of 0
biologic 0
response 0
modifiers 0
and 0
growth 0
factors 0
in 0
further 0
improving 0
the 0
outcome 0
for 0
patients 0
with 0
this 0
disease 0
. 0

SUMMARY 0
OF 0
REVIEW 0
: 0
We 0
discuss 0
the 0
criteria 0
that 0
make 0
such 0
studies 0
comparable 0
, 0
drawing 0
on 0
the 0
experiences 0
of 0
recent 0
studies 0
performed 0
around 0
the 0
world 0
. 0

Forty 0
- 0
five 0
patients 0
with 0
pleural 0
lesions 0
identified 0
on 0
CT 0
scans 0
were 0
subsequently 0
examined 0
by 0
MR 0
imaging 0
at 0
0.5 0
T 0
. 0

Left 0
atrial 0
volumes 0
were 0
greater 0
in 0
old 0
compared 0
with 0
young 0
subjects 0
( 0
maximal 0
: 0
31 0
+/ 0
- 0
10 0
cm3/m2 0
vs 0
24 0
+/ 0
- 0
8 0
cm3/m2 0
, 0
p 0
= 0
0.02 0
; 0
at 0
onset 0
of 0
atrial 0
systole 0
: 0
23 0
+/ 0
- 0
8 0
cm3/m2 0
vs 0
15 0
+/ 0
- 0
5 0
cm3/m2 0
, 0
p 0
= 0
0.0002 0
; 0
minimal 0
: 0
13 0
+/ 0
- 0
5 0
cm3/m2 0
vs 0
9 0
+/ 0
- 0
4 0
cm3/m2 0
, 0
p 0
= 0
0.001 0
) 0
. 0

RESULTS 0
: 0
Basal 0
plasma B-gene
IGF I-gene
- I-gene
I I-gene
levels 0
as 0
well 0
as 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
were 0
lower 0
in 0
amenorrheic 0
patients 0
than 0
in 0
healthy 0
controls 0
. 0

We 0
observed 0
abundant 0
levels 0
of 0
Rev B-gene
- 0
erbA B-gene
alpha I-gene
mRNA 0
in 0
dividing 0
C2C12 0
myoblasts 0
, 0
which 0
were 0
suppressed 0
when 0
the 0
cells 0
differentiated 0
into 0
postmitotic 0
multinucleated 0
myotubes 0
. 0

We 0
then 0
demonstrated 0
that 0
1 0
) 0
GAL4 B-gene
- 0
REV B-gene
- 0
erbA B-gene
alpha I-gene
chimeras 0
that 0
contain 0
the 0
'AB 0
' 0
region 0
and 0
lack 0
the 0
'E 0
' 0
region 0
activated 0
transcription 0
of 0
GAL4 B-gene
response I-gene
elements I-gene
in 0
the 0
presence 0
of 0
8 0
- 0
Br 0
- 0
cAMP 0
and 0
2 0
) 0
the 0
ligand 0
- 0
binding 0
domain 0
( 0
LBD 0
) 0
contains 0
an 0
active 0
transcriptional 0
silencer 0
. 0

The 0
alpha 0
T3 0
- 0
1 0
cell 0
line 0
, 0
a 0
GnRH B-gene
- 0
responsive 0
gonadotroph 0
cell 0
line 0
developed 0
by 0
targeted 0
oncogenesis 0
in 0
transgenic 0
mice 0
, 0
was 0
used 0
to 0
study 0
regulation 0
of 0
the 0
glycoprotein B-gene
hormone I-gene
alpha I-gene
- I-gene
subunit I-gene
by 0
activin B-gene
. 0

Cotransfection 0
with 0
the 0
ie1 B-gene
gene I-gene
resulted 0
in 0
a 0
dramatic 0
increase 0
in 0
the 0
amount 0
of 0
the 0
two 0
enzymes 0
expressed 0
in 0
the 0
transfected 0
cells 0
. 0

As 0
expected 0
, 0
glycosylation 0
of 0
Env B-gene
produced 0
from 0
mutants 0
was 0
affected 0
but 0
, 0
irrespective 0
of 0
the 0
glycosylation 0
phenotype 0
, 0
( 0
i 0
) 0
similar 0
quantities 0
of 0
Env B-gene
were 0
synthesized 0
, 0
( 0
ii 0
) 0
the 0
immunoreactivity 0
of 0
V3 B-gene
was 0
similar 0
, 0
( 0
iii 0
) 0
gp160 B-gene
was 0
efficiently 0
cleaved 0
into 0
gp120 B-gene
and 0
gp41 B-gene
, 0
( 0
vi 0
) 0
Env B-gene
was 0
exposed 0
at 0
the 0
cell 0
membrane 0
, 0
( 0
v 0
) 0
secreted 0
gp120 B-gene
bound 0
CD4 B-gene
, 0
and 0
( 0
vi 0
) 0
membrane 0
gp41 B-gene
was 0
able 0
to 0
induce 0
membrane 0
fusion 0
with 0
CD4+ B-gene
cells 0
. 0

Effects 0
of 0
posteroventral 0
pallidotomy 0
on 0
Parkinson 0
's 0
disease 0
. 0

On 0
the 0
trail 0
of 0
Dr 0
. 0

However 0
, 0
only 0
complete B-gene
DnaJ I-gene
can 0
cooperate 0
with 0
DnaK B-gene
and 0
a 0
third 0
protein 0
, 0
GrpE B-gene
, 0
in 0
refolding 0
denatured B-gene
firefly I-gene
luciferase I-gene
. 0

The 0
two 0
different 0
phosphoforms 0
of 0
STAT5 B-gene
have 0
identical 0
in 0
vitro 0
DNA 0
binding 0
specificity 0
and 0
reactivity 0
with 0
tyrosine 0
phosphopeptides 0
, 0
but 0
differ 0
in 0
their 0
cellular 0
localization 0
. 0

TNF B-gene
Treatment 0
of 0
cell 0
activated 0
the 0
p38 B-gene
MAP I-gene
kinase I-gene
pathway 0
, 0
as 0
revealed 0
by 0
increased 0
phosphorylation 0
of 0
p38 B-gene
MAP I-gene
kinase I-gene
itself 0
, 0
activation 0
of 0
the 0
substrate 0
protein 0
MAPKAP B-gene
kinase I-gene
- I-gene
2 I-gene
, 0
and 0
culminating 0
in 0
the 0
phosphorylation 0
of 0
the 0
heat B-gene
shock I-gene
protein I-gene
27 I-gene
( 0
hsp27 B-gene
) 0
. 0

We 0
have 0
isolated 0
a 0
novel 0
protein 0
from 0
Drosophila 0
nuclear 0
extracts 0
which 0
binds 0
specifically 0
to 0
a 0
site 0
in 0
this 0
second 0
region 0
. 0

However 0
, 0
while 0
the 0
sequence 0
similarity 0
between 0
the 0
membrane 0
exons 0
of 0
avian B-gene
mIgY I-gene
and 0
mammalian B-gene
mIgG I-gene
and I-gene
IgE I-gene
is 0
striking 0
, 0
the 0
overall 0
similarity 0
with 0
Xenopus B-gene
mIgY I-gene
is 0
very 0
low 0
. 0

Control 0
of 0
transcription 0
of 0
the 0
erbB B-gene
- I-gene
2 I-gene
gene I-gene
is 0
an 0
important 0
determinant 0
of 0
receptor 0
expression 0
. 0

DNase B-gene
I I-gene
footprinting 0
and 0
electrophoretic 0
mobility 0
shift 0
assays 0
indicate 0
that 0
PBP B-gene
binds 0
to 0
the 0
half 0
- 0
site 0
of 0
each 0
palindrome 0
with 0
the 0
core 0
recognition 0
sequence 0
TGGGAG 0
. 0

These 0
results 0
demonstrate 0
that 0
sequences 0
in 0
the 0
SH2/SH3/SH2 B-gene
region 0
of 0
SH2/SH3/SH2 I-gene

The 0
novel 0
hematopoietic B-gene
growth I-gene
factor I-gene
FLT3 I-gene
ligand I-gene
( 0
FL B-gene
) 0
is 0
the 0
cognate 0
ligand 0
for 0
the 0
FLT3 B-gene
, 0
tyrosine B-gene
kinase I-gene
receptor I-gene
( 0
R B-gene
) 0
, 0
also 0
referred 0
to 0
as 0
FLK B-gene
- I-gene
2 I-gene
and 0
STK B-gene
- I-gene
1 I-gene
. 0

In 0
contrast 0
to 0
the 0
selective 0
expression 0
of 0
the 0
receptor 0
, 0
FL B-gene
expression 0
was 0
detected 0
in 0
90 0
- 0
100 0
% 0
of 0
the 0
various 0
cell 0
types 0
of 0
leukemia 0
cell 0
lines 0
from 0
all 0
hematopoietic 0
cell 0
lineages 0
. 0

Further 0
analysis 0
of 0
this 0
domain 0
by 0
in 0
vitro 0
mutagenesis 0
pointed 0
to 0
a 0
core 0
of 0
hydrophobic 0
and 0
acidic 0
residues 0
as 0
critical 0
for 0
the 0
activity 0
. 0

Analysis 0
of 0
RAR B-gene
alpha I-gene
mutants I-gene
in 0
transfection 0
studies 0
reveals 0
that 0
the 0
DNA 0
binding 0
domain 0
is 0
sufficient 0
for 0
inhibition 0
of 0
BZLF1 B-gene
activity 0
. 0

We 0
measured 0
serum B-gene
hepatocyte I-gene
growth I-gene
factor I-gene
( 0
HGF B-gene
) 0
in 0
patients 0
with 0
acute 0
myocardial 0
infarction 0
, 0
angina 0
pectoris 0
, 0
and 0
other 0
heart 0
diseases 0
. 0

The 0
neural 0
mechanism 0
of 0
parkinsonian 0
motor 0
symptoms 0
, 0
i.e. 0
, 0
rigidity 0
, 0
tremor 0
and 0
akinesia 0
, 0
which 0
are 0
the 0
result 0
of 0
nigrostriatal 0
dopamine 0
deficiency 0
, 0
is 0
interpreted 0
from 0
long 0
- 0
term 0
observations 0
on 0
the 0
effect 0
of 0
surgical 0
and 0
pharmacological 0
treatment 0
of 0
the 0
disease 0
in 0
relation 0
to 0
the 0
neuropathological 0
findings 0
within 0
the 0
substantia 0
nigra 0
zona 0
compacta 0
( 0
SNc 0
) 0
. 0

Protein 0
splicing 0
: 0
evidence 0
for 0
an 0
N 0
- 0
O 0
acyl 0
rearrangement 0
as 0
the 0
initial 0
step 0
in 0
the 0
splicing 0
process 0
. 0

In 0
agreement 0
with 0
these 0
data 0
, 0
western 0
blot 0
experiments 0
using 0
an 0
antibody 0
directed 0
against 0
the 0
carboxy 0
- 0
terminal 0
portion 0
of 0
the 0
mouse 0
c B-gene
- I-gene
kit I-gene
protein I-gene
showed 0
that 0
a 0
polypeptide 0
, 0
of 0
the 0
size 0
predicted 0
by 0
the 0
open 0
reading 0
frame 0
of 0
the 0
spermatid B-gene
- I-gene
specific I-gene
c I-gene
- I-gene
kit I-gene
cDNA I-gene
, 0
accumulates 0
in 0
the 0
latest 0
stages 0
of 0
spermatogenesis 0
and 0
in 0
epididymal 0
spermatozoa 0
. 0

It 0
is 0
shown 0
that 0
the 0
( 0
G+C 0
) 0
- 0
rich 0
element 0
of 0
the 0
aldolase B-gene
C I-gene
promoter I-gene
directs 0
transcription 0
in 0
neuronal 0
as 0
well 0
as 0
in 0
nonneuronal 0
cells 0
. 0

LY290181 0
appears 0
to 0
inhibit 0
uPA B-gene
promoter I-gene
activation 0
by 0
blocking 0
phorbol 0
ester 0
- 0
stimulated 0
binding 0
of 0
nuclear 0
proteins 0
to 0
the 0
uPA B-gene
PEA3/12 B-gene
- 0
0 0
- 0
tetradecanoylphorbol 0
13 0
- 0
acetate 0
responsive 0
element 0
( 0
TRE 0
) 0
. 0

Treatment 0
of 0
keratinocytes 0
expressing 0
a 0
normal 0
epidermal B-gene
growth I-gene
factor I-gene
receptor I-gene
( 0
EGFR B-gene
) 0
with 0
TGFalpha B-gene
or 0
epidermal B-gene
growth I-gene
factor I-gene
for 0
5 0
min 0
induced 0
PKCdelta B-gene
tyrosine 0
phosphorylation 0
. 0

Only 0
one 0
of 0
these 0
bands 0
was 0
supershifted 0
by 0
antibody 0
to 0
p50 B-gene
, 0
whereas 0
antibodies 0
to 0
p65 B-gene
or 0
other 0
NF B-gene
- I-gene
kappaB I-gene
proteins I-gene
had 0
no 0
effect 0
. 0

We 0
isolated 0
a 0
complementary 0
DNA 0
( 0
cDNA 0
) 0
clone 0
from 0
an 0
RL95 0
- 0
2 0
expression 0
library 0
that 0
encodes 0
the 0
C1 B-gene
site I-gene
- I-gene
binding I-gene
protein I-gene
. 0

Biol 0
. 0

In 0
addition 0
, 0
anti B-gene
- I-gene
phosphotyrosine I-gene
antibodies I-gene
immunoprecipitated 0
80K B-gene
- I-gene
H I-gene
from 0
cell 0
lysates 0
of 0
FGF B-gene
- 0
stimulated 0
but 0
not 0
from 0
control 0
fibroblasts 0
. 0

The 0
novel 0
protein 0
kinases 0
, 0
c B-gene
- I-gene
Jun I-gene
NH2 I-gene
- I-gene
terminal I-gene
kinases I-gene
( 0
JNKs B-gene
) 0
/stress B-gene
- I-gene
activated I-gene
protein I-gene
kinases I-gene
, 0
are 0
also 0
activated 0
by 0
TNF B-gene
- I-gene
alpha I-gene
, 0
IL B-gene
- I-gene
1 I-gene
, 0
and 0
CD28 B-gene
costimulation 0
. 0

Thus 0
, 0
hGRbeta B-gene
potentially 0
functions 0
as 0
a 0
dominant 0
negative 0
inhibitor 0
of 0
hGRalpha B-gene
activity 0
. 0

Gas6 B-gene
contains 0
an 0
NH2 0
- 0
terminal 0
Gla 0
domain 0
followed 0
by 0
four 0
epidermal B-gene
growth I-gene
factor I-gene
- I-gene
like I-gene
repeats I-gene
and 0
tandem 0
globular 0
( 0
G 0
) 0
domains 0
. 0

Both 0
P5CDh B-gene
cDNA I-gene
clones 0
detect 0
a 0
single 0
3.2 0
- 0
kb 0
transcript 0
on 0
Northern 0
blots 0
of 0
multiple 0
human 0
tissues 0
, 0
indicating 0
the 0
long 0
cDNA 0
containing 0
the 0
3' 0
- 0
untranslated 0
intron 0
represents 0
the 0
predominant 0
transcript 0
. 0

Polymerization 0
of 0
neurofilament B-gene
L I-gene
protein I-gene
in 0
vitro 0
was 0
inhibited 0
by 0
phosphorylation 0
of 0
neurofilament B-gene
L I-gene
protein I-gene
by 0
PKN B-gene
. 0

The 0
protein 0
folds 0
correctly 0
with 0
two 0
disulfide 0
bonds 0
and 0
a 0
free 0
thiol 0
group 0
at 0
Cys25 0
. 0

We 0
and 0
others 0
have 0
demonstrated 0
that 0
the 0
c B-gene
- I-gene
cbl I-gene
proto I-gene
- I-gene
oncogene I-gene
product I-gene
is 0
one 0
of 0
the 0
earliest 0
targets 0
of 0
tyrosine 0
phosphorylation 0
upon 0
T B-gene
cell I-gene
receptor I-gene
stimulation 0
. 0

A 0
substantial 0
fraction 0
of 0
Cbl B-gene
was 0
constitutively 0
associated 0
with 0
Grb2 B-gene
and 0
this 0
interaction 0
was 0
mediated 0
by 0
Grb2 B-gene
SH3 B-gene
domains 0
. 0

An 0
AP B-gene
- I-gene
1 I-gene
binding I-gene
sequence I-gene
is 0
essential 0
for 0
regulation 0
of 0
the 0
human B-gene
alpha2 I-gene
( I-gene
I I-gene
) I-gene
collagen I-gene
( 0
COL1A2 B-gene
) 0
promoter 0
activity 0
by 0
transforming B-gene
growth I-gene
factor I-gene
- I-gene
beta I-gene
. 0

No 0
significant 0
differences 0
existed 0
between 0
the 0
two 0
age 0
groups 0
in 0
baseline 0
characteristics 0
, 0
including 0
treatment 0
protocol 0
, 0
performance 0
status 0
, 0
and 0
serum B-gene
lactate I-gene
dehydrogenase I-gene
( 0
LDH B-gene
) 0
level 0
. 0

Only 0
two 0
patients 0
( 0
0.3 0
% 0
) 0
had 0
a 0
CA B-gene
125 I-gene
response 0
at 0
the 0
time 0
of 0
clinical 0
progression 0
. 0

The 0
men 0
self 0
- 0
selected 0
a 0
prescribed 0
diet 0
at 0
home 0
emphasizing 0
saturated 0
fat 0
as 0
the 0
visible 0
fat 0
for 0
1 0
week 0
. 0

Conversely 0
, 0
when 0
VDR B-gene
is 0
overexpressed 0
, 0
vitamin 0
D3 0
attenuates 0
9 0
- 0
cis 0
RA 0
induction 0
from 0
an 0
RXR B-gene
- 0
responsive 0
element 0
. 0

These 0
results 0
illuminate 0
a 0
hitherto 0
unanticipated 0
function 0
of 0
U6 B-gene
RNA I-gene
: 0
the 0
modulation 0
of 0
a 0
phosphorylation 0
- 0
dephosphorylation 0
cycle 0
of 0
C1 B-gene
hnRNP I-gene
protein I-gene
that 0
influences 0
the 0
binding 0
affinity 0
of 0
this 0
protein 0
for 0
pre 0
- 0
mRNA 0
. 0

Inclusion 0
of 0
the 0
extended 0
N 0
terminus 0
into 0
the 0
originally 0
reported 0
protein 0
resulted 0
in 0
a 0
striking 0
similarity 0
to 0
the 0
lymphoid B-gene
factor I-gene
Lef I-gene
- I-gene
1 I-gene
. 0

Truncated 0
mammalian B-gene
Notch1 I-gene
activates 0
CBF1/RBPJk B-gene
- 0
repressed 0
genes 0
by 0
a 0
mechanism 0
resembling 0
that 0
of 0
CBF1/RBPJk I-gene

Electrophoretic 0
mobility 0
shift 0
assays 0
( 0
EMSAs 0
) 0
using 0
purified 0
glucocorticoid B-gene
receptor I-gene
DNA I-gene
binding I-gene
domain I-gene
( 0
DBD 0
) 0
demonstrated 0
that 0
both 0
GRE B-gene
- I-gene
2 I-gene
and I-gene
- I-gene
3 I-gene
motifs I-gene
interact 0
with 0
DBD 0
and 0
oligonucleotide 0
competition 0
experiments 0
established 0
that 0
these 0
have 0
different 0
affinities 0
for 0
DBD 0
. 0

The 0
large 0
subfamily 0
of 0
receptor B-gene
tyrosine I-gene
kinases I-gene
( 0
RTKs B-gene
) 0
for 0
which 0
EPH B-gene
is 0
the 0
prototype 0
have 0
likely 0
roles 0
in 0
intercellular 0
communication 0
during 0
normal 0
mammalian 0
development 0
, 0
but 0
the 0
biochemical 0
signalling 0
pathways 0
utilised 0
by 0
this 0
family 0
are 0
poorly 0
characterised 0
. 0

The 0
17 0
- 0
kDa 0
protein 0
is 0
required 0
for 0
the 0
systemic 0
infection 0
of 0
plants 0
. 0

We 0
present 0
here 0
a 0
detailed 0
genomic 0
sequencing 0
analysis 0
of 0
the 0
cytosine 0
methylation 0
patterns 0
of 0
the 0
transposase B-gene
binding 0
sites 0
within 0
both 0
Ac B-gene
ends 0
in 0
the 0
wx B-gene
- I-gene
m9 I-gene
: 0
:Ac B-gene
allele I-gene
, 0
where 0
Ac B-gene
is 0
inserted 0
into 0
the 0
tenth 0
exon 0
of 0
the 0
Waxy B-gene
gene I-gene
. 0

Krox B-gene
- I-gene
20 I-gene
, 0
a 0
zinc B-gene
finger I-gene
gene I-gene
, 0
has 0
a 0
highly 0
conserved 0
pattern 0
of 0
expression 0
in 0
r3 0
and 0
r5 0
and 0
is 0
functionally 0
required 0
for 0
their 0
maintenance 0
in 0
mouse 0
embryos 0
. 0

Pituitary 0
adenylate B-gene
cyclase I-gene
- I-gene
activating I-gene
polypeptide I-gene
regulates 0
prolactin B-gene
promoter I-gene
activity 0
via 0
a 0
protein B-gene
kinase I-gene
A I-gene
- 0
mediated 0
pathway 0
that 0
is 0
independent 0
of 0
the 0
transcriptional 0
pathway 0
employed 0
by 0
thyrotropin B-gene
- I-gene
releasing I-gene
hormone I-gene
. 0

Clones 0
33F 0
and 0
34B 0
encoded 0
identical 0
aromatase B-gene
proteins I-gene
of 0
503 0
amino 0
acids 0
, 0
but 0
differed 0
in 0
size 0
due 0
to 0
alternative 0
polyadenylation 0
signal 0
usage 0
for 0
the 0
corresponding 0
mRNAs 0
. 0

In 0
sorted 0
bone 0
marrow 0
cells 0
expression 0
of 0
both 0
VpreB B-gene
genes I-gene
was 0
detected 0
in 0
pro 0
- 0
B/pre 0
- 0
BI 0
and 0
large 0
pre 0
- 0
BII 0
cells 0
, 0
while 0
the 0
RNA 0
steady 0
state 0
levels 0
were 0
at 0
least 0
100 0
- 0
fold 0
lower 0
in 0
small 0
pre 0
- 0
BII 0
and 0
immature/mature 0
B 0
cells 0
. 0

We 0
have 0
cloned 0
and 0
sequenced 0
a 0
3574 0
- 0
bp 0
Bacillus 0
subtilis 0
( 0
Bs 0
) 0
DNA 0
fragment 0
located 0
between 0
the 0
nrdA B-gene
and 0
citB B-gene
genes I-gene
at 0
about 0
169 0
degrees 0
on 0
the 0
chromosome 0
. 0

Aeromonas 0
salmonicida 0
possesses 0
two 0
genes 0
encoding 0
homologs 0
of 0
the 0
major B-gene
outer I-gene
membrane I-gene
protein I-gene
, 0
OmpA B-gene
. 0

Expression 0
of 0
Msp B-gene
was 0
toxic 0
to 0
E. 0
coli 0
when 0
the 0
entire 0
msp B-gene
gene I-gene
was 0
present 0
. 0

In 0
agreement 0
with 0
previous 0
in 0
vitro 0
data 0
, 0
we 0
have 0
shown 0
that 0
UmuD B-gene
and 0
UmuD B-gene
' I-gene
are 0
able 0
to 0
form 0
both 0
homodimers 0
( 0
UmuD B-gene
- 0
UmuD B-gene
and 0
UmuD' B-gene
- 0
UmuD B-gene
' I-gene
) 0
and 0
a 0
heterodimer 0
( 0
UmuD B-gene
- 0
UmuD B-gene
' I-gene
) 0
. 0

Lyn B-gene
kinase I-gene
immunoprecipitated 0
from 0
lysates 0
of 0
irradiated 0
BCP 0
as 0
well 0
as 0
a 0
full 0
- 0
length 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
- 0
Lyn B-gene
fusion 0
protein 0
- 0
phosphorylated 0
recombinant B-gene
human I-gene
p34cdc2 I-gene
on 0
tyrosine 0
15 0
. 0

Mutations 0
within 0
conserved 0
region 0
2 0
( 0
CR2 0
) 0
of 0
E1A B-gene
that 0
inhibit 0
the 0
binding 0
of 0
E1A B-gene
to 0
the 0
retinoblastoma B-gene
gene I-gene
product I-gene
( 0
pRb B-gene
) 0
further 0
enhanced 0
the 0
stimulation 0
of 0
transcription 0
from 0
the 0
PEPCK B-gene
promoter I-gene
by 0
2 0
3 0
- 0
fold 0
compared 0
with 0
wild B-gene
type I-gene
E1A I-gene
. 0

Using 0
autoantibodies 0
from 0
a 0
Sjogren 0
's 0
syndrome 0
patient 0
, 0
we 0
have 0
previously 0
identified 0
a 0
230 0
- 0
kDa 0
peripheral 0
membrane 0
protein 0
associated 0
with 0
the 0
cytosolic 0
face 0
of 0
the 0
trans 0
- 0
Golgi 0
( 0
Kooy 0
, 0
J. 0
, 0
Toh 0
, 0
B 0
. 0

Apart 0
from 0
two 0
proline 0
- 0
rich 0
regions 0
( 0
amino 0
acids 0
1 0
- 0
117 0
and 0
239 0
- 0
270 0
) 0
, 0
p230 B-gene
contains 0
a 0
very 0
high 0
frequency 0
of 0
heptad 0
repeats 0
, 0
characteristic 0
of 0
alpha 0
- 0
helices 0
that 0
form 0
dimeric 0
coiled 0
- 0
coil 0
structures 0
. 0
p230 B-gene
also 0
includes 0
the 0
sequence 0
ESLALEELEL 0
( 0
amino 0
acids 0
538 0
- 0
546 0
) 0
, 0
a 0
motif 0
found 0
in 0
the 0
granin B-gene
family I-gene
of 0
acidic 0
proteins 0
present 0
in 0
secretory 0
granules 0
of 0
neuroendocrine 0
cells 0
. 0

Binding 0
specificity 0
and 0
modulation 0
of 0
the 0
ApoA B-gene
- I-gene
I I-gene
promoter I-gene
activity 0
by 0
homo 0
- 0
and 0
heterodimers 0
of 0
nuclear 0
receptors 0
. 0

They 0
were 0
found 0
to 0
stimulate 0
at 0
nanomolar 0
concentrations 0
the 0
turnover 0
of 0
biosynthetically 0
labeled 0
ceramide 0
, 0
glucosylceramide 0
, 0
and 0
lactosylceramide 0
. 0

There 0
is 0
growing 0
evidence 0
that 0
mammalian B-gene
AMP I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
AMPK B-gene
) 0
plays 0
a 0
role 0
in 0
protecting 0
cells 0
from 0
stresses 0
that 0
cause 0
ATP 0
depletion 0
by 0
switching 0
off 0
ATP 0
- 0
consuming 0
biosynthetic 0
pathways 0
. 0

Sterol 0
- 0
mediated 0
suppression 0
of 0
cleavage 0
of 0
SREBP B-gene
- I-gene
1 I-gene
was 0
found 0
to 0
be 0
dependent 0
on 0
the 0
extreme 0
COOH 0
- 0
terminal 0
region 0
( 0
residue 0
1034 0
to 0
the 0
COOH 0
terminus 0
) 0
, 0
which 0
exists 0
in 0
two 0
forms 0
as 0
a 0
result 0
of 0
alternative 0
splicing 0
. 0

Am 0
. 0

EMSA 0
competition 0
experiments 0
showed 0
that 0
mutations 0
within 0
the 0
direct 0
repeats 0
failed 0
to 0
compete 0
for 0
binding 0
of 0
the 0
nuclear 0
proteins 0
to 0
labeled 0
wild 0
type 0
oligonucleotide 0
. 0

Transcription 0
from 0
the 0
promoter 0
containing 0
the 0
mutated 0
direct 0
repeats 0
was 0
increased 0
greatly 0
, 0
consistent 0
with 0
the 0
conclusion 0
that 0
these 0
motifs 0
functions 0
in 0
vivo 0
to 0
repress 0
GPT B-gene
gene I-gene
expression 0
. 0

However 0
, 0
a 0
> 0
10 0
- 0
fold 0
increase 0
in 0
ERK3 B-gene
activity 0
in 0
each 0
PKC B-gene
beta I-gene
transfectant 0
was 0
shown 0
by 0
immunoprecipitation 0
with 0
anti B-gene
- I-gene
ERK3 I-gene
monoclonal I-gene
antibody I-gene
followed 0
by 0
either 0
immune 0
complex 0
kinase 0
assay 0
or 0
by 0
in 0
gel 0
kinase 0
assay 0
. 0

Sequence 0
analysis 0
of 0
this 0
100 0
- 0
bp 0
Col2a1 B-gene
enhancer I-gene
revealed 0
several 0
sequence 0
motifs 0
similar 0
to 0
motifs 0
present 0
within 0
the 0
regulatory 0
region 0
of 0
the 0
link B-gene
protein I-gene
gene I-gene
, 0
another 0
cartilage 0
gene 0
. 0

Retinoid 0
- 0
dependent 0
activation 0
of 0
the 0
tissue B-gene
transglutaminase I-gene
promoter I-gene
depends 0
on 0
both 0
a 0
proximal 0
regulatory 0
region 0
containing 0
sequences 0
highly 0
conserved 0
between 0
the 0
human 0
and 0
the 0
mouse B-gene
tissue I-gene
transglutaminase I-gene
promoters I-gene
and 0
a 0
distal 0
region 0
that 0
includes 0
a 0
30 0
- 0
base 0
pair 0
retinoid 0
response 0
element 0
( 0
mTGRRE1 0
) 0
. 0
mTGRRE1 0
contains 0
three 0
hexanucleotide 0
half 0
- 0
sites 0
( 0
two 0
canonical 0
and 0
one 0
non 0
- 0
canonical 0
) 0
in 0
a 0
DR7/DR5 B-gene
motif 0
that 0
bind 0
both 0
DR7/DR5 I-gene

Significantly 0
, 0
pPKR B-gene
is 0
capable 0
of 0
specifically 0
phosphorylating 0
Ser51 0
in 0
a 0
synthetic B-gene
eIF I-gene
- I-gene
2alpha I-gene
peptide I-gene
, 0
a 0
key 0
characteristic 0
of 0
the 0
eIF B-gene
- I-gene
2alpha I-gene
kinase I-gene
family I-gene
. 0

Vertebrate B-gene
synapsins I-gene
constitute 0
a 0
family 0
of 0
synaptic 0
proteins 0
that 0
participate 0
in 0
the 0
regulation 0
of 0
neurotransmitter 0
release 0
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
using 0
crude 0
extracts 0
from 0
FREJ4 0
cells 0
revealed 0
the 0
binding 0
of 0
a 0
member 0
( 0
s 0
) 0
of 0
the 0
Ets B-gene
family I-gene
of I-gene
transcription I-gene
factors I-gene
to 0
the 0
P4 B-gene
EBS I-gene
, 0
as 0
well 0
as 0
the 0
interaction 0
of 0
two 0
members 0
of 0
the 0
Sp1 B-gene
family I-gene
, 0
Sp1 B-gene
and 0
Sp3 B-gene
, 0
with 0
the 0
adjacent 0
GC 0
box 0
. 0

ZEBRA B-gene
and 0
cellular 0
AP B-gene
- I-gene
1 I-gene
bZip I-gene
activators I-gene
, 0
such 0
as 0
c B-gene
- I-gene
Fos I-gene
, 0
have 0
homologous 0
DNA 0
- 0
binding 0
domains 0
, 0
and 0
their 0
DNA 0
- 0
binding 0
specificities 0
overlap 0
. 0

This 0
result 0
suggested 0
that 0
mutant 0
I299 0
has 0
diminished 0
cap 0
- 0
binding 0
activity 0
. 0

UV 0
cross 0
- 0
linking 0
experiments 0
demonstrated 0
that 0
HSV 0
infection 0
caused 0
enhanced 0
binding 0
of 0
protein 0
factors 0
, 0
including 0
the 0
64 B-gene
- I-gene
kDa I-gene
component I-gene
of I-gene
cleavage I-gene
stimulation I-gene
factor I-gene
( 0
CstF B-gene
) 0
, 0
to 0
poly 0
( 0
A 0
) 0
site 0
RNAs 0
from 0
virus 0
genes 0
of 0
all 0
temporal 0
classes 0
and 0
that 0
this 0
enhanced 0
binding 0
required 0
expression 0
of 0
IE63 B-gene
. 0

CM B-gene
- I-gene
ACO3 I-gene
is 0
expressed 0
in 0
flowers 0
and 0
is 0
not 0
induced 0
by 0
any 0
of 0
the 0
stimuli 0
tested 0
. 0

We 0
show 0
here 0
that 0
these 0
Jun/eb1 B-gene
chimeras 0
are 0
potent 0
transactivators 0
of 0
Jun/eb1 I-gene

In 0
synchronized 0
HeLa 0
cells 0
, 0
expression 0
of 0
luciferase B-gene
activity 0
was 0
induced 0
at 0
the 0
beginning 0
of 0
DNA 0
synthesis 0
and 0
was 0
dependent 0
on 0
the 0
presence 0
of 0
an 0
E2F B-gene
- I-gene
binding I-gene
site I-gene
in 0
the 0
H2A.1 B-gene
promoter I-gene
. 0

Utilizing 0
transient 0
transfection 0
studies 0
in 0
HepG2 0
cells 0
, 0
we 0
have 0
shown 0
that 0
deletion 0
of 0
the 0
factor B-gene
VIII I-gene
promoter I-gene
sequences I-gene
distal 0
to 0
nucleotide 0
- 0
44 0
results 0
in 0
a 0
significant 0
but 0
small 0
increase 0
in 0
promoter 0
activity 0
. 0

We 0
constructed 0
a 0
yeast 0
reporter 0
strain 0
containing 0
the 0
lacZ B-gene
gene I-gene
under 0
the 0
control 0
of 0
the 0
CYC1 B-gene
promoter I-gene
associated 0
with 0
three 0
copies 0
of 0
TRE B-gene
- I-gene
1 I-gene
. 0

If 0
hnRNP B-gene
K I-gene
is 0
a 0
transcription 0
factor 0
, 0
then 0
interactions 0
with 0
the 0
RNA B-gene
polymerase I-gene
II I-gene
transcription 0
apparatus 0
are 0
predicted 0
. 0

A 0
developmentally 0
regulated 0
4.6 0
kb 0
mRNA 0
is 0
recognized 0
on 0
Northern 0
blots 0
of 0
oocyte 0
RNA 0
using 0
the 0
X.laevis 0
cDNA 0
. 0

Sequence 0
conservation 0
is 0
greatest 0
for 0
residues 0
located 0
near 0
the 0
active 0
centers 0
of 0
the 0
exo B-gene
and 0
pol B-gene
domains I-gene
of 0
the 0
E.coli B-gene
DNA I-gene
polymerase I-gene
I I-gene
structure 0
. 0

Despite 0
the 0
favourable 0
natural 0
history 0
of 0
acute 0
BI 0
, 0
mild 0
, 0
moderate 0
, 0
and 0
severe 0
posttraumatic 0
changes 0
were 0
shown 0
to 0
appear 0
as 0
cicatricial 0
- 0
adhesive 0
and 0
atrophic 0
processes 0
, 0
intracerebral 0
cysts 0
, 0
porencephaly 0
, 0
which 0
result 0
in 0
posttraumatic 0
epilepsy 0
, 0
hydrocephalus 0
, 0
etc 0
. 0

These 0
findings 0
suggest 0
that 0
the 0
increase 0
in 0
V 0
O2 0
may 0
have 0
been 0
a 0
consequence 0
of 0
the 0
increase 0
in 0
Q 0
O2 0
rather 0
than 0
a 0
response 0
to 0
the 0
procedure 0
itself 0
. 0

Several 0
cytokines 0
exhibit 0
a 0
high 0
degree 0
of 0
temporal 0
regulation 0
as 0
well 0
as 0
somnogenic 0
potency 0
( 0
e.g. 0
, 0
interleukin B-gene
- I-gene
1 I-gene
[ 0
IL B-gene
- I-gene
1 I-gene
] 0
, 0
tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
[ 0
TNF B-gene
- I-gene
alpha I-gene
] 0
) 0
. 0

As 0
pH 0
and 0
Hb B-gene
can 0
also 0
affect 0
mixed 0
venous 0
CO2 0
content 0
, 0
the 0
effect 0
on 0
Q 0
was 0
also 0
assessed 0
. 0

No 0
difference 0
in 0
elastin B-gene
peptide I-gene
concentration 0
was 0
observed 0
between 0
emphysematous 0
patients 0
and 0
control 0
subjects 0
( 0
mean 0
+/ 0
- 0
SD 0
= 0
2.39 0
+/ 0
- 0
1.18 0
micrograms/ml 0
in 0
patients 0
versus 0
2.55 0
+/ 0
- 0
1.34 0
micrograms/ml 0
in 0
policemen 0
and 0
2.59 0
+/ 0
- 0
1.20 0
micrograms/ml 0
in 0
coal 0
miners 0
) 0
. 0

Identification 0
of 0
this 0
region 0
as 0
the 0
E. B-gene
coli I-gene
tmk I-gene
gene I-gene
was 0
confirmed 0
by 0
functional 0
complementation 0
of 0
a 0
yeast B-gene
dTMP I-gene
kinase I-gene
temperature 0
- 0
sensitive 0
mutant 0
and 0
by 0
in 0
vitro 0
enzyme 0
assay 0
of 0
the 0
thymidylate B-gene
kinase I-gene
activity 0
in 0
cell 0
extracts 0
of 0
E. 0
coli 0
by 0
use 0
of 0
tmk B-gene
- 0
overproducing 0
plasmids 0
. 0

The 0
structural 0
gene 0
for 0
copper B-gene
- I-gene
and I-gene
topa I-gene
quinone I-gene
- I-gene
containing I-gene
monoamine I-gene
oxidase I-gene
( 0
maoA B-gene
) 0
and 0
an 0
unknown 0
amine B-gene
oxidase I-gene
gene I-gene
have 0
been 0
located 0
at 0
30.9 0
min 0
on 0
the 0
Escherichia 0
coli 0
chromosome 0
. 0

This 0
interaction 0
is 0
mediated 0
by 0
the 0
SH2 B-gene
domain I-gene
of 0
Crk B-gene
and 0
can 0
be 0
inhibited 0
with 0
a 0
phosphopeptide 0
containing 0
the 0
Crk B-gene
- 0
SH2 B-gene
binding 0
motif 0
. 0

Consistent 0
with 0
ErbB B-gene
- I-gene
2 I-gene
being 0
a 0
shared 0
receptor 0
subunit 0
, 0
its 0
tyrosine 0
phosphorylation 0
was 0
increased 0
by 0
both 0
heterologous 0
ligands 0
and 0
it 0
mediated 0
a 0
trans 0
- 0
inhibitory 0
effect 0
of 0
NDF B-gene
on 0
EGF B-gene
binding 0
. 0

Identification 0
of 0
a 0
consensus 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
phosphorylation I-gene
site I-gene
unique 0
to 0
the 0
nuclear 0
form 0
of 0
human B-gene
deoxyuridine I-gene
triphosphate I-gene
nucleotidohydrolase I-gene
. 0

The 0
cDNA 0
corresponding 0
to 0
the 0
FPS1 B-gene
gene I-gene
was 0
isolated 0
by 0
functional 0
complementation 0
of 0
a 0
mutant 0
yeast 0
strain 0
defective 0
in 0
FPS B-gene
activity 0
( 0
Delourme 0
, 0
D. 0
, 0
Lacroute 0
, 0
F. 0
, 0
and 0
Karst 0
, 0
F 0
. 0

The 0
isolated 0
plasmin B-gene
fragments 0
of 0
VEGF B-gene
were 0
compared 0
with 0
respect 0
to 0
heparin 0
binding 0
, 0
interaction 0
with 0
soluble 0
VEGF B-gene
receptors I-gene
, 0
and 0
ability 0
to 0
promote 0
endothelial 0
cell 0
mitogenesis 0
. 0

VDR/RXR B-gene
bound 0
well 0
to 0
the 0
VDREs 0
and 0
to 0
DR4 0
and 0
DR5 0
using 0
the 0
electrophoretic 0
mobility 0
shift 0
assay 0
. 0

The 0
members 0
of 0
the 0
Myb B-gene
family I-gene
of I-gene
transcription I-gene
factors I-gene
are 0
defined 0
by 0
homology 0
in 0
the 0
DNA 0
- 0
binding 0
domain 0
; 0
all 0
bind 0
the 0
Myb B-gene
- I-gene
binding I-gene
site I-gene
( 0
MBS B-gene
) 0
sequence 0
( 0
YG 0
( 0
A/G 0
) 0
C 0
( 0
A/C/G 0
) 0
GTT 0
( 0
G/A 0
) 0
) 0
. 0

In 0
contrast 0
, 0
when 0
the 0
isoform 0
containing 0
the 0
C 0
epsilon4 0
domain 0
joined 0
directly 0
to 0
the 0
M2 0
exon 0
( 0
IgE B-gene
grande I-gene
) 0
is 0
expressed 0
in 0
the 0
J558L 0
cell 0
line 0
, 0
it 0
is 0
degraded 0
intracellularly 0
, 0
suggesting 0
a 0
cell 0
line 0
- 0
dependent 0
regulation 0
of 0
secretion 0
. 0

Human B-gene
cytomegalovirus I-gene
immediate I-gene
- I-gene
early I-gene
protein I-gene
IE2 I-gene
tethers 0
a 0
transcriptional 0
repression 0
domain 0
to 0
p53 B-gene
. 0

The 0
specificity 0
of 0
action 0
of 0
C/EBP B-gene
family I-gene
members I-gene
may 0
be 0
derived 0
from 0
the 0
characteristics 0
of 0
each 0
factor 0
, 0
including 0
the 0
expression 0
profiles 0
, 0
the 0
DNA 0
binding 0
affinities 0
, 0
the 0
cofactors 0
, 0
and 0
so 0
on 0
, 0
in 0
addition 0
to 0
the 0
DNA 0
binding 0
specificities 0
. 0

The 0
antibodies 0
inhibited 0
specifically 0
the 0
transcription 0
of 0
DNA B-gene
polymerase I-gene
alpha I-gene
promoter 0
in 0
vitro 0
. 0

Immunocytochemical 0
analysis 0
demonstrated 0
the 0
presence 0
of 0
DREF B-gene
polypeptide I-gene
in 0
nuclei 0
after 0
the 0
eighth 0
nuclear 0
division 0
cycle 0
, 0
suggesting 0
that 0
nuclear 0
accumulation 0
of 0
DREF B-gene
is 0
important 0
for 0
the 0
coordinate 0
zygotic 0
expression 0
of 0
DNA 0
replication 0
- 0
related 0
genes 0
carrying 0
DRE 0
sequences 0
. 0

A 0
DNA 0
fragment 0
carrying 0
1,100 0
nucleotides 0
derived 0
from 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
UGT1A1 B-gene
gene I-gene
was 0
enough 0
for 0
MC 0
induction 0
. 0

This 0
result 0
supports 0
the 0
argument 0
that 0
the 0
beta 0
' 0
subunit 0
plays 0
an 0
essential 0
role 0
in 0
determining 0
the 0
progress 0
of 0
transcription 0
elongation 0
. 0

Two 0
XPG B-gene
regions I-gene
with 0
putative 0
NLS 0
[ 0
amino 0
acid 0
( 0
AA 0
) 0
coordinates 0
: 0
NLS 0
- 0
B 0
( 0
AA 0
1057 0
- 0
1074 0
) 0
and 0
NLS 0
- 0
C 0
( 0
AA 0
1171 0
- 0
1185 0
) 0
] 0
were 0
each 0
shown 0
to 0
independently 0
localize 0
the 0
beta B-gene
- I-gene
gal I-gene
extensively 0
( 0
> 0
80 0
% 0
) 0
to 0
the 0
nucleus 0
of 0
HeLa 0
cells 0
. 0

The 0
lacS B-gene
gene I-gene
was 0
cloned 0
in 0
an 0
E. 0
coli 0
- 0
Streptococcus 0
shuttle 0
vector 0
and 0
was 0
expressed 0
both 0
in 0
a 0
lacS B-gene
deletion 0
derivative 0
of 0
S. 0
thermophilus 0
and 0
in 0
a 0
pNZ63 0
- 0
cured 0
strain 0
, 0
L. 0
lactis 0
NZ6091 0
. 0

The 0
genome 0
of 0
all 0
retroviruses 0
consists 0
of 0
two 0
identical 0
RNAs 0
noncovalently 0
linked 0
near 0
their 0
5 0
' 0
end 0
. 0

The 0
extraction 0
recovery 0
of 0
Amphotericin 0
B 0
from 0
the 0
cerebrospinal 0
fluid 0
is 0
higher 0
than 0
90 0
% 0
over 0
the 0
entire 0
linear 0
range 0
. 0

HuEpo B-gene
- I-gene
R I-gene
Ab I-gene
inhibited 0
Epo B-gene
- 0
induced 0
parental 0
UT 0
- 0
7 0
cell 0
growth 0
, 0
but 0
not 0
that 0
of 0
cells 0
of 0
clone 0
12 0
, 0
suggesting 0
that 0
the 0
muEpo B-gene
- I-gene
R I-gene
is 0
able 0
to 0
induce 0
human 0
UT 0
- 0
7 0
cell 0
proliferation 0
. 0

The 0
frequency 0
of 0
integrations 0
that 0
led 0
to 0
transcription 0
of 0
the 0
lacZ B-gene
gene I-gene
was 0
estimated 0
to 0
be 0
0.5 0
% 0
of 0
all 0
integrations 0
, 0
of 0
which 0
14 0
% 0
were 0
downregulated 0
on 0
differentiation 0
of 0
32D 0
cells 0
towards 0
neutrophils 0
. 0

The 0
sequence 0
and 0
isolated 0
cDNAs 0
will 0
provide 0
useful 0
reagents 0
for 0
studying 0
the 0
expression 0
of 0
Brca1 B-gene
in 0
the 0
mouse 0
, 0
and 0
for 0
testing 0
the 0
importance 0
of 0
the 0
evolutionarily 0
conserved 0
domains 0
. 0

A 0
study 0
was 0
performed 0
to 0
compare 0
the 0
ONLINE 0
and 0
EMIT 0
II 0
immunoassays 0
with 0
gas 0
chromatographic/mass 0
spectrometric 0
( 0
GC/MS 0
) 0
analysis 0
of 0
methaqualone 0
metabolites 0
on 0
urine 0
using 0
samples 0
obtained 0
from 0
a 0
clinical 0
study 0
. 0

Interaction 0
of 0
the 0
Fur B-gene
repressor I-gene
with 0
a 0
150 0
- 0
bp 0
fragment 0
encompassing 0
the 0
pvdS B-gene
promoter I-gene
was 0
demonstrated 0
in 0
vivo 0
by 0
the 0
Fur B-gene
titration 0
assay 0
and 0
confirmed 0
in 0
vitro 0
by 0
gel 0
retardation 0
experiments 0
with 0
a 0
partially 0
purified 0
Fur B-gene
preparation 0
. 0

This 0
protein 0
encoded 0
by 0
this 0
cDNA 0
, 0
which 0
we 0
have 0
termed 0
p150TSP B-gene
( 0
for 0
TPR 0
- 0
containing 0
, 0
SH2 B-gene
- I-gene
binding I-gene
phosphoprotein I-gene
) 0
, 0
is 0
located 0
predominantly 0
in 0
the 0
nucleus 0
and 0
is 0
highly 0
conserved 0
in 0
evolution 0
. 0

Both 0
mutant 0
receptors 0
were 0
expressed 0
on 0
the 0
cell 0
surface 0
and 0
bound 0
insulin B-gene
normally 0
, 0
but 0
showed 0
markedly 0
impaired 0
autophosphorylation 0
in 0
response 0
to 0
insulin B-gene
. 0

EMBO 0
J 0
. 0

Taken 0
together 0
, 0
our 0
results 0
indicate 0
that 0
thrombin B-gene
- 0
stimulated 0
vascular 0
smooth 0
muscle 0
proliferation 0
is 0
delayed 0
and 0
requires 0
the 0
de 0
novo 0
expression 0
of 0
one 0
or 0
more 0
autocrine 0
mitogens 0
. 0

Transcription 0
from 0
adenovirus B-gene
E2 I-gene
- I-gene
early I-gene
promoter I-gene
is 0
controlled 0
by 0
a 0
unique 0
array 0
of 0
four 0
cis 0
- 0
acting 0
elements 0
which 0
include 0
an 0
atypical 0
TBP B-gene
site I-gene
, 0
two 0
E2F B-gene
sites I-gene
present 0
in 0
an 0
inverted 0
orientation 0
relative 0
to 0
each 0
other 0
, 0
and 0
an 0
ATF B-gene
site I-gene
. 0

Furthermore 0
, 0
we 0
showed 0
that 0
the 0
IL B-gene
- I-gene
6/interferon I-gene
6/interferon I-gene
gamma I-gene
( 0
IFN B-gene
gamma I-gene
) 0
response 0
element 0
in 0
the 0
IRF B-gene
- I-gene
1 I-gene
promoter I-gene
( 0
IR/IRF B-gene
IR/IRF I-gene
- I-gene
1 I-gene
) 0
, 0
which 0
contains 0
a 0
Stat B-gene
- I-gene
binding I-gene
site I-gene
and 0
an 0
adjacent 0
CRE 0
- 0
like 0
site 0
, 0
also 0
makes 0
IL B-gene
- I-gene
6 I-gene
- 0
induced 0
binding 0
complexes 0
similar 0
to 0
JRE 0
- 0
IL6 B-gene
- 0
BCs 0
. 0

A 0
second 0
peptide 0
( 0
amino 0
acids 0
58 0
- 0
77 0
) 0
also 0
antagonized 0
p21 B-gene
- 0
activity 0
, 0
but 0
this 0
peptide 0
did 0
not 0
affect 0
the 0
ability 0
of 0
p21 B-gene
to 0
interact 0
with 0
cyclin B-gene
E/Cdk2 I-gene
. 0

A 0
p21 B-gene
peptide I-gene
spanning 0
amino 0
acids 0
139 0
- 0
164 0
was 0
found 0
to 0
bind 0
PCNA B-gene
in 0
a 0
filter 0
binding 0
assay 0
and 0
this 0
peptide 0
suppressed 0
recombinant 0
p21 B-gene
- 0
PCNA B-gene
interaction 0
. 0

Results 0
were 0
supported 0
by 0
the 0
agar 0
diffusion 0
method 0
for 0
Y. 0
enterocolitica 0
, 0
whereas 0
inhibition 0
activity 0
was 0
not 0
found 0
for 0
A. 0
hydrophila 0
. 0

OND 0
8 0
mg 0
tid 0
days 0
2 0
- 0
3 0
, 0
and 0
8 0
mg 0
tid 0
prn 0
days 0
4 0
- 0
5 0
and 0
prednisolone 0
75 0
- 0
100 0
mg 0
qds 0
days 0
2 0
- 0
5 0
and 0
2 0
) 0
MCP 0
30 0
mg/metylprednisolone 0
80 0
mg 0
i.v 0
. 0
before 0
CT 0
and 0
MCP 0
20 0
mg 0
p.r 0
. 0
after 0
4 0
and 0
8 0
h 0
respectively 0
. 0

The 0
dynamic 0
properties 0
of 0
this 0
protein 0
fragment 0
were 0
measured 0
and 0
analyzed 0
using 0
both 0
isotropic 0
and 0
anisotropic 0
models 0
of 0
molecular 0
motion 0
. 0

Adduction 0
of 0
the 0
human B-gene
N I-gene
- I-gene
ras I-gene
codon I-gene
61 I-gene
sequence I-gene
with 0
( 0
- 0
) 0
- 0
( 0
7S,8R,9R,10S 0
) 0
- 0
7,8 0
- 0
dihydroxy 0
- 0
9,10 0
- 0
epoxy 0
- 0
7,8,9,10 0
- 0
tetrahydrobenzo 0
[ 0
a 0
] 0
pyrene 0
: 0
structural 0
refinement 0
of 0
the 0
intercalated 0
SRSR 0
( 0
61,2 0
) 0
( 0
- 0
) 0
- 0
( 0
7S,8R,9S,10R 0
) 0
- 0
N6 0
- 0
[ 0
10 0
- 0
( 0
7,8,9,10 0
- 0
tetrahydrobenzo 0
[ 0
a 0
] 0
pyrenyl 0
) 0
] 0
- 0
2' 0
- 0
deoxyadenosyl 0
adduct 0
from 0
1H 0
NMR 0
. 0

Isolation 0
by 0
PCR 0
of 0
a 0
cDNA 0
clone 0
from 0
pea 0
petals 0
with 0
similarity 0
to 0
petunia 0
and 0
wheat B-gene
zinc I-gene
finger I-gene
proteins I-gene
. 0

This 0
fragment 0
can 0
bind 0
several 0
trans 0
- 0
acting 0
factors 0
in 0
vitro 0
, 0
including 0
GATA B-gene
- I-gene
1 I-gene
and 0
members 0
of 0
the 0
Ets B-gene
family I-gene
. 0

Exposure 0
of 0
peripheral 0
blood 0
T 0
cells 0
from 0
young 0
subjects 0
to 0
PHA B-gene
or 0
cross 0
- 0
linked 0
anti B-gene
- I-gene
CD3 I-gene
monoclonal I-gene
antibodies I-gene
stimulated 0
rapid 0
increases 0
in 0
MAPK B-gene
and 0
MEK B-gene
enzymatic 0
activity 0
. 0

These 0
different 0
observations 0
exclude 0
a 0
heterozygosity 0
of 0
the 0
A 0
- 0
- 0
> 0
G 0
mutation 0
at 0
codon 0
beta 0
77 0
, 0
as 0
well 0
as 0
a 0
deletion 0
comparable 0
to 0
that 0
of 0
Hbs B-gene
Lepore I-gene
or I-gene
Kenya I-gene
, 0
or 0
a 0
beta B-gene
- I-gene
globin I-gene
gene I-gene
duplication 0
, 0
and 0
point 0
to 0
a 0
nontraditional 0
inheritance 0
of 0
Hb B-gene
Costa I-gene
Rica I-gene
. 0

This 0
is 0
the 0
first 0
description 0
, 0
to 0
our 0
knowledge 0
, 0
of 0
regulatory 0
elements 0
that 0
control 0
expression 0
of 0
a 0
gene 0
encoding 0
a 0
B7 B-gene
costimulatory I-gene
molecule I-gene
. 0

DNA B-gene
- I-gene
STAT I-gene
complexes I-gene
were 0
detected 0
in 0
all 0
Bcr/Abl B-gene
- 0
transformed 0
cell 0
lines 0
and 0
they 0
were 0
supershifted 0
by 0
antibodies 0
against 0
Bcr/Abl I-gene

When 0
overexpressed 0
in 0
an 0
appropriate 0
cell 0
line 0
, 0
TAN B-gene
- I-gene
1C I-gene
prevented 0
kappa B-gene
B I-gene
- 0
dependent 0
transactivation 0
in 0
transient 0
reporter 0
gene 0
assays 0
in 0
a 0
fashion 0
similar 0
to 0
the 0
structurally 0
related 0
protein 0
, 0
Bcl B-gene
- I-gene
3 I-gene
. 0

T 0
cell 0
leukemia 0
- 0
associated 0
human 0
Notch/translocation B-gene
- 0
associated 0
Notch B-gene
homologue 0
has 0
I B-gene
kappa I-gene
B I-gene
- 0
like 0
activity 0
and 0
physically 0
interacts 0
with 0
nuclear B-gene
factor I-gene
- I-gene
kappa I-gene
B I-gene
proteins 0
in 0
T 0
cells 0
. 0

Polyprotein 0
processing 0
in 0
Southampton 0
virus 0
: 0
identification 0
of 0
3C B-gene
- I-gene
like I-gene
protease I-gene
cleavage 0
sites 0
by 0
in 0
vitro 0
mutagenesis 0
. 0

The 0
humanized B-gene
LL2 I-gene
( 0
hLL2 B-gene
) 0
, 0
lacking 0
light B-gene
chain I-gene
variable I-gene
region I-gene
glycosylation 0
, 0
exhibited 0
immunoreactivities 0
that 0
were 0
comparable 0
to 0
that 0
of 0
chimeric B-gene
LL2 I-gene
( 0
cLL2 B-gene
) 0
, 0
which 0
was 0
shown 0
previously 0
to 0
have 0
antigen 0
- 0
binding 0
properties 0
similar 0
to 0
its 0
murine 0
counterpart 0
, 0
suggesting 0
that 0
the 0
VK 0
- 0
appended 0
oligosaccharides 0
found 0
in 0
mLL2 B-gene
are 0
not 0
necessary 0
for 0
antigen 0
binding 0
. 0

An 0
apparent 0
N 0
- 0
terminal 0
transit 0
peptide 0
in 0
the 0
coding 0
region 0
and 0
a 0
3 0
' 0
poly 0
( 0
A 0
) 0
tail 0
exist 0
in 0
the 0
cDNA 0
clone 0
indicated 0
that 0
this 0
chloroplast 0
protein 0
as 0
nuclear 0
encoded 0
. 0

Deletion 0
analysis 0
of 0
rOC B-gene
promoter I-gene
- 0
chloramphenicol B-gene
acetyltransferase I-gene
constructs 0
demonstrates 0
that 0
an 0
AML B-gene
- I-gene
1 I-gene
- I-gene
binding I-gene
sequence I-gene
within 0
the 0
proximal 0
promoter 0
( 0
- 0
138 0
to 0
- 0
130 0
nt 0
) 0
contributes 0
to 0
75 0
% 0
of 0
the 0
level 0
of 0
osteocalcin B-gene
gene I-gene
expression 0
. 0

Thus 0
, 0
a 0
critical 0
question 0
is 0
how 0
HOX B-gene
proteins I-gene
select 0
the 0
correct 0
sets 0
of 0
target 0
genes 0
in 0
vivo 0
. 0

RAS2val19 B-gene
, 0
a 0
dominant 0
activated 0
form 0
of 0
Saccharomyces B-gene
cerevisiae I-gene
Ras2 I-gene
, 0
stimulates 0
both 0
filamentous 0
growth 0
and 0
expression 0
of 0
a 0
transcriptional 0
reporter 0
FG B-gene
( 0
TyA B-gene
) 0
: 0
:lacZ B-gene
but 0
does 0
not 0
induce 0
the 0
mating B-gene
pathway I-gene
reporter I-gene
FUS1 I-gene
: 0
:lacZ B-gene
. 0

Moreover 0
, 0
the 0
Rho B-gene
family I-gene
protein I-gene
Cdc42 B-gene
, 0
a 0
conserved 0
morphogenetic B-gene
G I-gene
protein I-gene
, 0
is 0
also 0
a 0
potent 0
regulator 0
of 0
filamentous 0
growth 0
and 0
FG B-gene
( 0
TyA B-gene
) 0
: 0
:lacZ B-gene
expression 0
in 0
S. 0
cerevisiae 0
. 0

Each 0
immunoprecipitate 0
contained 0
a 0
complex 0
of 0
N1 B-gene
( I-gene
deltaEC I-gene
) I-gene
and 0
CBF1 B-gene
. 0

This 0
region 0
includes 0
verA B-gene
, 0
a 0
structural 0
gene 0
previously 0
shown 0
to 0
be 0
required 0
for 0
ST 0
biosynthesis 0
, 0
and 0
24 0
additional 0
closely 0
spaced 0
transcripts 0
ranging 0
in 0
size 0
from 0
0.6 0
to 0
7.2 0
kb 0
that 0
are 0
coordinately 0
induced 0
only 0
under 0
ST 0
- 0
producing 0
conditions 0
. 0

Subcellular 0
localizations 0
of 0
the 0
wild B-gene
- I-gene
type I-gene
CBFbeta I-gene
and 0
the 0
CBFbeta B-gene
- 0
SMMHC B-gene
fusion 0
protein 0
were 0
determined 0
by 0
immunofluorescence 0
of 0
NIH 0
3T3 0
cells 0
that 0
overexpress 0
wild 0
- 0
type 0
or 0
fusion 0
protein 0
. 0

Menstrual 0
- 0
cycle 0
phase 0
did 0
not 0
significantly 0
affect 0
personality 0
variables 0
in 0
either 0
group 0
. 0

We 0
report 0
the 0
isolation 0
of 0
human 0
cDNAs 0
homologous 0
to 0
the 0
Drosophila B-gene
dishevelled I-gene
( 0
dsh B-gene
) 0
segment 0
- 0
polarity 0
gene 0
. 0

Escherichia 0
coli 0
BL21 0
( 0
DE3 0
) 0
plysS 0
, 0
harbouring 0
a 0
recombinant 0
plasmid 0
containing 0
the 0
catalase B-gene
- 0
peroxidase B-gene
gene 0
, 0
produced 0
a 0
large 0
amount 0
of 0
proteins 0
that 0
co 0
- 0
migrated 0
on 0
SDS/PAGE 0
with 0
the 0
native 0
enzyme 0
. 0

Ca2+ 0
decreased 0
Zn2+ 0
binding 0
in 0
S100 B-gene
beta I-gene
but 0
it 0
did 0
not 0
influence 0
binding 0
to 0
MRP14 B-gene
, 0
suggesting 0
that 0
the 0
Zn2+ 0
binding 0
site 0
was 0
distinct 0
from 0
and 0
independent 0
of 0
the 0
two 0
Ca2+ 0
binding 0
domains 0
. 0

Cdk2 B-gene
formed 0
a 0
complex 0
with 0
cyclin B-gene
D1 I-gene
in 0
this 0
system 0
. 0

The 0
Cdk2 B-gene
- 0
cyclin B-gene
- I-gene
D1 I-gene
complex 0
did 0
not 0
phosphorylate 0
any 0
tested 0
substrates 0
, 0
such 0
as 0
H1 B-gene
histone I-gene
, 0
pRB B-gene
, 0
SV40 B-gene
large I-gene
T I-gene
antigen I-gene
, 0
p53 B-gene
, 0
E2F B-gene
- I-gene
1 I-gene
or 0
a 0
preparation 0
of 0
nuclear 0
proteins 0
from 0
HeLa 0
cells 0
; 0
in 0
contrast 0
, 0
Cdk2 B-gene
- 0
cyclin B-gene
- I-gene
E I-gene
and 0
Cdk2 B-gene
- 0
cyclin B-gene
- I-gene
A I-gene
phosphorylated 0
these 0
proteins 0
. 0

Cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
- I-gene
2 I-gene
( 0
Cdk2 B-gene
) 0
forms 0
an 0
inactive 0
complex 0
with 0
cyclin B-gene
D1 I-gene
since 0
Cdk2 B-gene
associated 0
with 0
cyclin B-gene
D1 I-gene
is 0
not 0
phosphorylated 0
by 0
Cdk7 B-gene
- 0
cyclin B-gene
- I-gene
H I-gene
. 0

Two 0
overlapping 0
clones 0
contained 0
the 0
complete 0
Adh B-gene
- I-gene
2 I-gene
gene I-gene
composed 0
of 0
nine 0
exons 0
in 0
a 0
12 0
- 0
kb 0
region 0
, 0
with 0
the 0
placement 0
of 0
introns 0
matching 0
that 0
observed 0
in 0
other 0
mammalian B-gene
ADH I-gene
genes I-gene
. 0

Ligation 0
of 0
CD40 B-gene
rescues 0
Ramos 0
- 0
Burkitt 0
lymphoma 0
B 0
cells 0
from 0
calcium 0
ionophore 0
- 0
and 0
antigen 0
receptor 0
- 0
triggered 0
apoptosis 0
by 0
inhibiting 0
activation 0
of 0
the 0
cysteine B-gene
protease I-gene
CPP32/Yama B-gene
and 0
cleavage 0
of 0
its 0
substrate 0
CPP32/Yama I-gene

Large B-gene
T I-gene
antigen I-gene
was 0
coimmunoprecipitated 0
by 0
antibodies 0
to 0
epitope 0
- 0
tagged 0
TBP B-gene
, 0
endogenous 0
TBP B-gene
, 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
100 I-gene
, 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
130 I-gene
, 0
and 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
250 I-gene
, 0
under 0
conditions 0
where 0
holo B-gene
- I-gene
TFIID I-gene
would 0
be 0
precipitated 0
. 0

Northern 0
blot 0
hybridization 0
demonstrated 0
that 0
HEP B-gene
- 0
COP B-gene
was 0
expressed 0
in 0
a 0
wide 0
range 0
of 0
human 0
adult 0
and 0
fetal 0
tissues 0
. 0

A 0
human 0
cytoplasmic 0
signaling 0
protein 0
has 0
been 0
cloned 0
that 0
possesses 0
the 0
same 0
structural 0
arrangement 0
of 0
SH3 B-gene
- 0
SH2 B-gene
- 0
SH3 B-gene
domains 0
as 0
Grb2 B-gene
. 0

A 0
direct 0
role 0
for 0
sterol B-gene
regulatory I-gene
element I-gene
binding I-gene
protein I-gene
in 0
activation 0
of 0
3 B-gene
- I-gene
hydroxy I-gene
- I-gene
3 I-gene
- I-gene
methylglutaryl I-gene
coenzyme I-gene
A I-gene
reductase I-gene
gene I-gene
. 0

E3/19K B-gene
resides 0
in 0
the 0
endoplasmic 0
reticulum 0
where 0
it 0
binds 0
to 0
MHC B-gene
class I-gene
I I-gene
molecules I-gene
, 0
thereby 0
preventing 0
their 0
transport 0
to 0
the 0
cell 0
surface 0
. 0

When 0
the 0
PHT 0
and 0
CSA 0
groups 0
were 0
compared 0
, 0
Hyp 0
levels 0
were 0
significantly 0
higher 0
in 0
the 0
PHT 0
- 0
GO+ 0
group 0
than 0
in 0
the 0
CSA 0
- 0
GO+ 0
group 0
. 0

Among 0
the 0
LE6 B-gene
deletions 0
, 0
only 0
one 0
had 0
a 0
reduced 0
transformation 0
efficiency 0
, 0
while 0
seven 0
transformed 0
cells 0
at 0
least 0
as 0
efficiently 0
as 0
wild B-gene
- I-gene
type I-gene
LE6 I-gene
. 0

ORF B-gene
E8 I-gene
colinear 0
with 0
ORF B-gene
E6 I-gene
, 0
which 0
could 0
generate 0
a 0
50 0
- 0
amino 0
- 0
acid 0
protein 0
with 0
a 0
hydrophobic 0
segment 0
, 0
did 0
not 0
transform 0
cells 0
when 0
cloned 0
into 0
the 0
pZipNeo 0
vector 0
. 0

Cloning 0
of 0
individual 0
ZI 0
domains 0
upstream 0
of 0
a 0
minimal 0
promoter 0
demonstrated 0
that 0
the 0
ZIA 0
, 0
ZIC 0
, 0
and 0
ZID 0
domains 0
, 0
but 0
not 0
the 0
ZIB 0
domain 0
, 0
are 0
TPA 0
responsive 0
. 0

Clb2/Cdc28 B-gene
kinase 0
is 0
not 0
required 0
for 0
the 0
repression 0
of 0
Clb2/Cdc28 I-gene

The 0
carboxy 0
terminus 0
of 0
Mbp1 B-gene
is 0
sufficient 0
for 0
interaction 0
with 0
Swi6 B-gene
, 0
and 0
the 0
carboxy 0
terminus 0
of 0
Swi6 B-gene
is 0
required 0
for 0
interaction 0
with 0
Mbp1 B-gene
. 0

Multiple 0
single 0
- 0
stranded 0
cis 0
elements 0
are 0
associated 0
with 0
activated 0
chromatin 0
of 0
the 0
human B-gene
c I-gene
- I-gene
myc I-gene
gene I-gene
in 0
vivo 0
. 0

A 0
new 0
UASH 0
consensus 0
sequence 0
derived 0
from 0
this 0
mutational 0
analysis 0
closely 0
matches 0
a 0
consensus 0
Abf1 B-gene
binding I-gene
site I-gene
. 0

We 0
have 0
isolated 0
and 0
analyzed 0
human B-gene
CTCF I-gene
cDNA I-gene
clones 0
and 0
show 0
here 0
that 0
the 0
ubiquitously 0
expressed 0
11 B-gene
- I-gene
zinc I-gene
- I-gene
finger I-gene
factor I-gene
CTCF I-gene
is 0
an 0
exceptionally 0
highly 0
conserved 0
protein 0
displaying 0
93 0
% 0
identity 0
between 0
avian 0
and 0
human 0
amino 0
acid 0
sequences 0
. 0

Mutational 0
analysis 0
of 0
the 0
P2 B-gene
- I-gene
proximal I-gene
CTCF I-gene
binding I-gene
site I-gene
and 0
transient 0
- 0
cotransfection 0
experiments 0
demonstrate 0
that 0
CTCF B-gene
is 0
a 0
transcriptional 0
repressor 0
of 0
the 0
human B-gene
c I-gene
- I-gene
myc I-gene
gene I-gene
. 0

A 0
chromosome B-gene
transmission I-gene
fidelity I-gene
( 0
ctf B-gene
) 0
mutant 0
, 0
s138 0
, 0
of 0
Saccharomyces 0
cerevisiae 0
was 0
identified 0
by 0
its 0
centromere 0
( 0
CEN 0
) 0
transcriptional 0
readthrough 0
phenotype 0
, 0
suggesting 0
perturbed 0
kinetochore 0
integrity 0
in 0
vivo 0
. 0

The 0
growth 0
defect 0
of 0
a 0
reg1 B-gene
reg2 B-gene
double I-gene
mutant I-gene
is 0
alleviated 0
by 0
a 0
loss 0
- 0
of 0
- 0
function 0
mutation 0
in 0
the 0
SNF1 B-gene
- I-gene
encoded I-gene
protein I-gene
kinase I-gene
. 0

Sp1 B-gene
binds 0
two 0
sites 0
in 0
the 0
CD11c B-gene
promoter I-gene
in 0
vivo 0
specifically 0
in 0
myeloid 0
cells 0
and 0
cooperates 0
with 0
AP1 B-gene
to 0
activate 0
transcription 0
. 0

Expression 0
of 0
the 0
phenylalanine B-gene
hydroxylase I-gene
gene I-gene
in 0
livers 0
and 0
kidneys 0
of 0
rodents 0
is 0
activated 0
at 0
birth 0
and 0
is 0
induced 0
by 0
glucocorticoids 0
and 0
cyclic 0
AMP 0
in 0
the 0
liver 0
. 0

We 0
found 0
that 0
120 0
bp 0
of 0
the 0
enhancer 0
's 0
transcriptional 0
core 0
becomes 0
DNase B-gene
I I-gene
hypersensitive 0
early 0
in 0
B 0
- 0
cell 0
development 0
. 0

A 0
developmentally 0
modulated 0
chromatin 0
structure 0
at 0
the 0
mouse B-gene
immunoglobulin I-gene
kappa I-gene
3 I-gene
' I-gene
enhancer I-gene
. 0

We 0
report 0
here 0
the 0
identification 0
of 0
a 0
cDNA 0
that 0
encodes 0
a 0
new 0
member 0
of 0
the 0
GTPase B-gene
- I-gene
activating I-gene
protein I-gene
( 0
GAP B-gene
) 0
family 0
of 0
GTPase B-gene
regulators 0
. 0

In 0
this 0
study 0
, 0
we 0
further 0
investigated 0
the 0
regulation 0
of 0
the 0
synthesis 0
of 0
the 0
c B-gene
- I-gene
mos I-gene
oncogene I-gene
product I-gene
, 0
which 0
is 0
necessary 0
for 0
the 0
activation 0
of 0
Cdc2 B-gene
. 0

The 0
heterogeneity 0
of 0
bovine B-gene
IgG2 I-gene
- I-gene
- I-gene
VIII I-gene
. 0

The 0
ability 0
of 0
BCL B-gene
- I-gene
6 I-gene
to 0
function 0
as 0
a 0
transcriptional 0
repressor 0
may 0
contribute 0
to 0
its 0
ability 0
to 0
transform 0
B 0
lymphocytes 0
in 0
diffuse 0
large 0
cell 0
lymphoma 0
. 0

Positioning 0
this 0
uORF 0
, 0
together 0
with 0
its 0
accompanying 0
Kozak 0
sequences 0
, 0
between 0
a 0
heterologous 0
promoter 0
from 0
SV40 0
and 0
a 0
CAT B-gene
reporter I-gene
gene I-gene
resulted 0
in 0
marked 0
inhibition 0
of 0
CAT B-gene
protein I-gene
production 0
without 0
a 0
decrease 0
in 0
CAT B-gene
mRNA I-gene
. 0

A 0
secondary 0
spread 0
of 0
an 0
imported 0
methicillin 0
- 0
resistant 0
Staphylococcus 0
aureus 0
strain 0
( 0
MRSA 0
) 0
to 0
two 0
other 0
patients 0
occurred 0
within 0
a 0
Danish 0
surgical 0
ward 0
in 0
spite 0
of 0
isolation 0
of 0
a 0
multitraumatized 0
index 0
- 0
patient 0
immediately 0
after 0
arrival 0
from 0
a 0
hospital 0
in 0
the 0
Mediterranean 0
area 0
. 0

Mesial 0
temporal 0
sclerosis 0
was 0
characterized 0
by 0
severe 0
neuronal 0
loss 0
accompanied 0
by 0
gliosis 0
occurring 0
in 0
the 0
CA1/prosubiculum 0
( 0
27 0
patients 0
, 0
100 0
% 0
) 0
, 0
focally 0
in 0
the 0
dentate 0
gyrus 0
( 0
12 0
patients 0
, 0
44 0
% 0
) 0
, 0
and 0
in 0
the 0
CA4 0
region 0
( 0
11 0
patients 0
, 0
41 0
% 0
) 0
. 0

Mesial 0
temporal 0
sclerosis 0
. 0

More 0
specific 0
adverse 0
events 0
, 0
also 0
frequently 0
considered 0
as 0
dose 0
- 0
limiting 0
toxicities 0
, 0
include 0
hypotension 0
with 0
IL B-gene
- I-gene
1 I-gene
, 0
severe 0
headache 0
or 0
skin 0
rash 0
with 0
IL B-gene
- I-gene
3 I-gene
, 0
and 0
nasal 0
congestion 0
and 0
gastroduodenal 0
lesions 0
with 0
IL B-gene
- I-gene
4 I-gene
. 0

Therefore 0
, 0
magnetic 0
resonance 0
imaging 0
was 0
used 0
to 0
determine 0
liver 0
volume 0
in 0
pediatric 0
and 0
adolescent 0
patients 0
, 0
in 0
whom 0
systemic 0
clearance 0
of 0
three 0
model 0
substrates 0
[ 0
lorazepam 0
( 0
0.03 0
mg/kg 0
) 0
, 0
antipyrine 0
( 0
10 0
mg/kg 0
) 0
, 0
and 0
indocyanine 0
green 0
( 0
ICG 0
; 0
0.5 0
mg/kg 0
) 0
] 0
was 0
also 0
determined 0
. 0

A 0
mutational 0
analysis 0
has 0
resolved 0
a 0
region 0
of 0
seven 0
amino 0
acids 0
( 0
amino 0
acids 0
26 0
- 0
32 0
) 0
in 0
the 0
N 0
- 0
terminus 0
of 0
Bob1 B-gene
that 0
are 0
important 0
for 0
contacting 0
the 0
DNA B-gene
binding I-gene
POU I-gene
domain I-gene
of 0
Oct B-gene
- I-gene
1 I-gene
or 0
Oct B-gene
- I-gene
2 I-gene
. 0

Heme B-gene
oxygenase I-gene
1 I-gene
is 0
an 0
essential 0
enzyme 0
in 0
heme 0
catabolism 0
that 0
cleaves 0
heme 0
to 0
form 0
biliverdin 0
, 0
iron 0
, 0
and 0
carbon 0
monoxide 0
. 0

An 0
inactive 0
analog 0
of 0
wortmannin 0
, 0
WM12 0
, 0
did 0
not 0
affect 0
TCR/CD3 B-gene
- 0
induced 0
TCR/CD3 I-gene

155 0
aa 0
, 0
shares 0
78 0
% 0
identity 0
with 0
the 0
analogous 0
region 0
of 0
Xenopus 0
laevis 0
FGF3 B-gene
and 0
72 0
% 0
identity 0
with 0
the 0
product 0
of 0
the 0
more 0
distantly 0
related 0
human 0
gene 0
. 0

The 0
transcription 0
start 0
point 0
of 0
the 0
proximal 0
promoter 0
aligns 0
to 0
that 0
of 0
mouse 0
promoter 0
P3 0
and 0
lies 0
within 0
a 0
conserved 0
region 0
of 0
sequence 0
. 0

Defects 0
in 0
the 0
Schizosaccharomyces 0
pombe 0
( 0
Sp 0
) 0
cell 0
cycle 0
- 0
controlling 0
genes 0
prevent 0
the 0
cell 0
cycle 0
progression 0
. 0

To 0
determine 0
the 0
signal B-gene
recognition I-gene
particle I-gene
( 0
SRP B-gene
) 0
- 0
SRP B-gene
receptor I-gene
( 0
Srb B-gene
) 0
system 0
in 0
Bacillus 0
subtilis 0
( 0
Bs 0
) 0
, 0
we 0
cloned 0
the 0
Bs B-gene
srb I-gene
gene I-gene
, 0
which 0
encodes 0
a 0
homologue 0
of 0
the 0
mammalian B-gene
SRP I-gene
receptor I-gene
alpha I-gene
- I-gene
subunit I-gene
[ 0
Oguro 0
et 0
al. 0
, 0
DNA 0
Res 0
. 0

A 0
novel 0
gene 0
designated 0
cmr B-gene
, 0
which 0
mapped 0
to 0
18.8 0
min 0
of 0
the 0
Escherichia 0
coli 0
K 0
- 0
12 0
genome 0
, 0
was 0
shown 0
to 0
mediate 0
resistance 0
to 0
chloramphenicol 0
when 0
it 0
was 0
expressed 0
from 0
a 0
multicopy 0
vector 0
. 0

In 0
addition 0
, 0
5 0
' 0
deletions 0
removing 0
all 0
but 0
34 0
bp 0
upstream 0
of 0
the 0
transcription 0
start 0
point 0
retained 0
greater 0
than 0
90 0
% 0
promoter 0
activity 0
, 0
suggesting 0
that 0
the 0
- 0
35 0
hexamer 0
was 0
not 0
essential 0
for 0
promoter 0
activity 0
. 0

The 0
DNA 0
sequence 0
immediately 0
upstream 0
from 0
the 0
- 0
10 0
hexamer 0
contained 0
the 0
TGn 0
motif 0
described 0
as 0
an 0
extended 0
- 0
10 0
region 0
in 0
prokaryotic 0
promoters 0
. 0

An 0
apparent 0
ufo B-gene
mRNA I-gene
overexpression 0
was 0
not 0
found 0
in 0
any 0
of 0
the 0
positive 0
leukemia 0
cell 0
lines 0
, 0
but 0
was 0
identified 0
in 0
the 0
drug 0
- 0
resistant 0
subclones 0
of 0
the 0
cervix 0
carcinoma 0
cell 0
line 0
HeLa 0
. 0

We 0
conclude 0
from 0
these 0
studies 0
that 0
CKII B-gene
may 0
act 0
as 0
a 0
positive 0
regulator 0
of 0
myogenesis 0
by 0
preventing 0
E B-gene
protein I-gene
homodimers I-gene
from 0
binding 0
to 0
muscle 0
gene 0
regulatory 0
elements 0
. 0

The 0
role 0
of 0
negative 0
regulators 0
such 0
as 0
NCE3 B-gene
, 0
as 0
well 0
as 0
the 0
previously 0
described 0
SIN5 B-gene
gene I-gene
, 0
in 0
determining 0
the 0
promoter 0
specificity 0
of 0
homologous 0
activators 0
is 0
discussed 0
. 0

Transcriptional 0
regulators 0
utilizing 0
the 0
POU B-gene
domain I-gene
DNA I-gene
- I-gene
binding I-gene
motif I-gene
have 0
been 0
shown 0
to 0
form 0
multi 0
- 0
protein 0
complexes 0
dependent 0
on 0
the 0
POU B-gene
domain I-gene
itself 0
and 0
its 0
flexible 0
recognition 0
of 0
various 0
octamer 0
sequence 0
elements 0
. 0

We 0
found 0
strand 0
selective 0
repair 0
in 0
DNA 0
fragments 0
within 0
two 0
active 0
genes 0
, 0
DHFR B-gene
and 0
an 0
unknown 0
gene 0
adjacent 0
to 0
DHFR B-gene
. 0

MATERIALS 0
AND 0
METHODS 0
: 0
Coronal 0
3D 0
GRE 0
imaging 0
was 0
used 0
to 0
study 0
the 0
volar 0
, 0
middle 0
, 0
and 0
dorsal 0
portions 0
of 0
the 0
SLL 0
in 0
14 0
patients 0
with 0
an 0
arthroscopically 0
normal 0
SLL 0
and 0
in 0
five 0
cadaveric 0
wrists 0
that 0
had 0
a 0
normal 0
SLL 0
proved 0
with 0
dissection 0
. 0

In 0
an 0
effort 0
to 0
contribute 0
to 0
the 0
transcript 0
map 0
of 0
human 0
chromosome 0
21 0
and 0
the 0
understanding 0
of 0
the 0
pathophysiology 0
of 0
trisomy 0
21 0
, 0
we 0
have 0
used 0
exon 0
trapping 0
to 0
identify 0
fragments 0
of 0
chromosome 0
21 0
genes 0
. 0

Reproducing 0
populations 0
of 0
this 0
aphid 0
were 0
first 0
detected 0
in 0
Puerto 0
Rico 0
in 0
April 0
1992 0
. 0

The 0
model 0
captures 0
the 0
essence 0
of 0
predator 0
- 0
prey 0
dynamics 0
to 0
provide 0
reasonable 0
predictions 0
of 0
population 0
patterns 0
. 0

At 0
cuticular 0
positions 0
exhibiting 0
the 0
Brd B-gene
bristle I-gene
loss I-gene
phenotype I-gene
, 0
we 0
have 0
found 0
that 0
the 0
progeny 0
of 0
the 0
multiplied 0
SOPs 0
develop 0
aberrantly 0
, 0
in 0
that 0
neurons 0
and 0
thecogen 0
( 0
sheath 0
) 0
cells 0
appear 0
but 0
not 0
trichogen 0
( 0
shaft 0
) 0
and 0
tormogen 0
( 0
socket 0
) 0
cells 0
. 0

Transcriptional 0
blockade 0
was 0
reversed 0
by 0
co 0
- 0
transfections 0
of 0
a 0
wild B-gene
- I-gene
type I-gene
SRF I-gene
expression 0
vector 0
, 0
but 0
was 0
not 0
rescued 0
by 0
the 0
expression 0
of 0
other 0
myogenic 0
factors 0
, 0
such 0
as 0
MyoD B-gene
and 0
Mef B-gene
- I-gene
2C I-gene
. 0

The 0
mMIWC1 B-gene
promoter I-gene
was 0
identified 0
and 0
contained 0
TATA 0
, 0
CAAT 0
, 0
GATA 0
, 0
and 0
AP B-gene
- I-gene
2 I-gene
elements I-gene
; 0
primer 0
extension 0
revealed 0
mMIWC B-gene
transcription 0
initiation 0
at 0
621 0
bp 0
upstream 0
from 0
the 0
mMIWC1 B-gene
translational 0
initiation 0
site 0
. 0

Human B-gene
MN/CA9 I-gene
gene I-gene
, 0
a 0
novel 0
member 0
of 0
the 0
carbonic B-gene
anhydrase I-gene
family I-gene
: 0
structure 0
and 0
exon 0
to 0
protein 0
domain 0
relationships 0
. 0

The 0
exon 0
- 0
intron 0
distribution 0
of 0
Cdebp B-gene
appears 0
strikingly 0
similar 0
to 0
that 0
of 0
the 0
App B-gene
gene I-gene
in 0
the 0
regions 0
encoding 0
the 0
conserved 0
domains 0
, 0
with 0
a 0
divergent 0
structure 0
in 0
the 0
other 0
parts 0
. 0

DNA 0
sequence 0
analysis 0
reveals 0
that 0
the 0
gene 0
encodes 0
a 0
protein 0
highly 0
homologous 0
to 0
rat B-gene
CRP1 I-gene
. 0

The 0
gene 0
was 0
expressed 0
as 0
an 0
approximately 0
1.5 0
- 0
kb 0
mRNA 0
in 0
most 0
nonlymphoid 0
human 0
cells/tissues 0
including 0
prostate 0
, 0
lung 0
, 0
liver 0
, 0
and 0
colon 0
. 0

Both 0
of 0
these 0
domains 0
have 0
striking 0
sequence 0
homology 0
with 0
human 0
SIM B-gene
and 0
Drosophila 0
SIM B-gene
proteins 0
. 0

Promoter 0
activity 0
was 0
high 0
in 0
cell 0
lines 0
that 0
expressed 0
high 0
levels 0
of 0
endogenous 0
D3 B-gene
mRNA I-gene
, 0
as 0
indicated 0
by 0
Northern 0
blot 0
analyses 0
, 0
and 0
was 0
significantly 0
reduced 0
when 0
the 0
promoter 0
was 0
truncated 0
to 0
- 0
122 0
bp 0
. 0

We 0
have 0
obtained 0
the 0
human B-gene
EP4 I-gene
receptor I-gene
gene I-gene
sequence I-gene
and 0
determined 0
its 0
structure 0
relative 0
to 0
EP4R B-gene
cDNA I-gene
synthesized 0
from 0
peripheral 0
blood 0
lymphocytes 0
. 0

Some 0
users 0
will 0
willingly 0
comply 0
with 0
management 0
measures 0
, 0
other 0
users 0
will 0
comply 0
in 0
response 0
to 0
education 0
, 0
but 0
there 0
will 0
be 0
another 0
group 0
who 0
will 0
only 0
respond 0
to 0
enforcement 0
activities 0
. 0

Three 0
separate 0
activation 0
subdomains 0
, 0
and 0
one 0
negative 0
- 0
acting 0
region 0
, 0
which 0
function 0
in 0
yeast 0
were 0
located 0
in 0
the 0
carboxyl 0
- 0
terminal 0
region 0
of 0
NIT4 B-gene
. 0

The 0
front 0
( 0
F 0
) 0
interaction 0
occurs 0
ahead 0
of 0
the 0
growing 0
end 0
of 0
RNA 0
. 0

Collectively 0
, 0
these 0
data 0
indicate 0
that 0
HIP B-gene
is 0
a 0
membrane 0
- 0
associated 0
HP B-gene
- I-gene
binding I-gene
protein I-gene
expressed 0
on 0
the 0
surface 0
of 0
normal 0
human 0
uterine 0
epithelia 0
and 0
uterine 0
epithelial 0
cell 0
lines 0
. 0

The 0
corresponding 0
gene 0
was 0
identified 0
in 0
the 0
GenBankTM 0
data 0
base 0
by 0
sequence 0
alignment 0
and 0
termed 0
RPS30A B-gene
. 0

The 0
location 0
of 0
multiple 0
GRK2 B-gene
and 0
GRK5 B-gene
phosphoacceptor I-gene
sites I-gene
at 0
the 0
extreme 0
carboxyl 0
terminus 0
of 0
the 0
beta2AR B-gene
is 0
highly 0
reminiscent 0
of 0
GRK1 B-gene
- 0
mediated 0
phosphorylation 0
of 0
rhodopsin B-gene
. 0

This 0
regulation 0
could 0
not 0
be 0
appreciably 0
modified 0
by 0
enhanced 0
expression 0
of 0
STAT B-gene
proteins I-gene
. 0

Receptors 0
for 0
interleukin B-gene
( I-gene
IL I-gene
) I-gene
- I-gene
10 I-gene
and 0
IL B-gene
- I-gene
6 I-gene
- I-gene
type I-gene
cytokines I-gene
use 0
similar 0
signaling 0
mechanisms 0
for 0
inducing 0
transcription 0
through 0
IL B-gene
- I-gene
6 I-gene
response 0
elements 0
. 0

Specifically 0
, 0
the 0
deduced 0
FR B-gene
- I-gene
19 I-gene
amino I-gene
acid I-gene
sequence I-gene
has 0
approximately89 0
, 0
77 0
, 0
and 0
68 0
% 0
overall 0
identity 0
to 0
chicken B-gene
TEF I-gene
- I-gene
1A I-gene
, 0
mouse B-gene
TEF I-gene
- I-gene
1 I-gene
, 0
and 0
mouse B-gene
embryonic I-gene
TEA I-gene
domain I-gene
- I-gene
containing I-gene
factor I-gene
, 0
respectively 0
. 0

This 0
phenomenon 0
did 0
not 0
require 0
DNA 0
binding 0
by 0
the 0
`` 0
interfering 0
'' 0
receptor 0
but 0
required 0
it 0
to 0
be 0
hormone 0
- 0
bound 0
, 0
indicating 0
that 0
a 0
transcriptionally 0
active 0
form 0
of 0
the 0
interfering 0
receptor 0
is 0
essential 0
for 0
the 0
interfering 0
effect 0
. 0

The 0
receptor B-gene
for I-gene
hyaluronan I-gene
mediated I-gene
motility I-gene
( B-gene
RHAMM I-gene
) I-gene
gene I-gene
expression 0
is 0
markedly 0
elevated 0
in 0
fibrosarcomas 0
exposed 0
to 0
transforming B-gene
growth I-gene
factor I-gene
- I-gene
beta1 I-gene
( 0
TGF B-gene
- I-gene
beta1 I-gene
) 0
. 0

Oncogenic B-gene
Raf I-gene
- I-gene
1 I-gene
activates 0
p70 B-gene
S6 I-gene
kinase I-gene
via 0
a 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
- 0
independent 0
pathway 0
. 0

Hydropathy 0
analysis 0
of 0
KCC1 B-gene
indicates 0
structural 0
homology 0
to 0
NKCC B-gene
, 0
including 0
12 0
transmembrane 0
domains 0
, 0
a 0
large 0
extracellular 0
loop 0
with 0
potential 0
N 0
- 0
linked 0
glycosylation 0
sites 0
, 0
and 0
cytoplasmic 0
N 0
- 0
and 0
C 0
- 0
terminal 0
regions 0
. 0

A 0
cis 0
- 0
acting 0
DNA 0
element 0
located 0
between 0
TATA 0
box 0
and 0
transcription 0
initiation 0
site 0
is 0
critical 0
in 0
response 0
to 0
regulatory 0
sequences 0
in 0
human 0
angiotensinogen B-gene
gene I-gene
. 0

This 0
protein 0
with 0
a 0
hydrophobic 0
amino 0
terminus 0
appears 0
to 0
be 0
a 0
secreted 0
protein 0
. 0

The 0
promoter 0
of 0
the 0
rat B-gene
PGS I-gene
- I-gene
2 I-gene
gene I-gene
contains 0
a 0
CAAT B-gene
enhancer I-gene
- I-gene
binding I-gene
protein I-gene
consensus I-gene
site I-gene
( I-gene
CAAT I-gene
box I-gene
) I-gene
which 0
can 0
confer 0
hormone 0
inducibility 0
to 0
a 0
PGS B-gene
- I-gene
2.CAT I-gene
reporter 0
gene 0
, 0
as 0
well 0
as 0
a 0
putative 0
E 0
- 0
box 0
region 0
. 0

Notably 0
, 0
SRF B-gene
has 0
been 0
found 0
to 0
be 0
a 0
key 0
regulator 0
of 0
members 0
of 0
a 0
class 0
of 0
cellular 0
response 0
genes 0
termed 0
immediate B-gene
- I-gene
early I-gene
genes I-gene
( 0
IEGs B-gene
) 0
, 0
many 0
of 0
which 0
are 0
believed 0
to 0
be 0
involved 0
in 0
regulating 0
cell 0
growth 0
and 0
differentiation 0
. 0

The 0
final 0
sigma54 B-gene
- I-gene
dependent I-gene
DmpR I-gene
activator I-gene
regulates 0
transcription 0
of 0
the 0
dmp B-gene
operon I-gene
that 0
encodes 0
the 0
enzymes 0
for 0
catabolism 0
of 0
( 0
methyl 0
) 0
phenols 0
. 0

In 0
this 0
study 0
, 0
we 0
have 0
cloned 0
the 0
human B-gene
DSG3 I-gene
gene I-gene
and 0
examined 0
the 0
transcriptional 0
regulation 0
of 0
its 0
expression 0
. 0

Clinical 0
evaluation 0
of 0
the 0
Allergan 0
Humphrey 0
500 0
autorefractor 0
and 0
the 0
Nidek 0
AR 0
- 0
1000 0
autorefractor 0
. 0

None 0
of 0
the 0
five 0
proprotein 0
processing 0
proteases 0
tested 0
were 0
capable 0
of 0
cleaving 0
human B-gene
pro I-gene
- I-gene
LPH I-gene
, 0
strongly 0
suggesting 0
that 0
they 0
are 0
not 0
involved 0
in 0
the 0
maturation 0
of 0
this 0
enzyme 0
. 0

These 0
changes 0
may 0
be 0
the 0
result 0
of 0
, 0
on 0
the 0
one 0
hand 0
, 0
an 0
increased 0
sensitivity 0
of 0
the 0
neuromuscular 0
transmission 0
and/or 0
decreased 0
muscle 0
contractility 0
and 0
, 0
on 0
the 0
other 0
hand 0
, 0
the 0
result 0
of 0
a 0
reduced 0
plasma 0
clearance 0
during 0
hypothermia 0
. 0

SETTING 0
- 0
- 0
Delhi 0
, 0
urban 0
India 0
, 0
1985 0
- 0
6 0
. 0

By 0
using 0
interleukin B-gene
- I-gene
3 I-gene
- 0
dependent 0
cells 0
that 0
ectopically 0
express 0
the 0
three 0
ErbB B-gene
proteins I-gene
or 0
their 0
combinations 0
, 0
we 0
found 0
that 0
ErbB B-gene
- I-gene
3 I-gene
is 0
devoid 0
of 0
any 0
biological 0
activity 0
but 0
both 0
ErbB B-gene
- I-gene
1 I-gene
and 0
ErbB B-gene
- I-gene
2 I-gene
can 0
reconstitute 0
its 0
extremely 0
potent 0
mitogenic 0
activity 0
. 0

ZIOS 0
was 0
significantly 0
more 0
sensitive 0
than 0
all 0
subsequent 0
methods 0
, 0
and 0
Ptc 0
, 0
O2 0
was 0
significantly 0
more 0
sensitive 0
than 0
FEV1 0
. 0

Selective 0
translation 0
initiation 0
by 0
ribosome 0
jumping 0
in 0
adenovirus 0
- 0
infected 0
and 0
heat 0
- 0
shocked 0
cells 0
. 0

Furthermore 0
, 0
we 0
have 0
identified 0
a 0
43 0
- 0
bp 0
region 0
of 0
the 0
24p3 B-gene
promoter I-gene
required 0
for 0
the 0
Dex 0
responsiveness 0
. 0

These 0
findings 0
suggest 0
that 0
direct 0
cDNA 0
mapping 0
using 0
fluorescence 0
in 0
situ 0
hybridization 0
provides 0
an 0
accurate 0
and 0
rapid 0
approach 0
to 0
the 0
definition 0
of 0
a 0
transcribed 0
map 0
of 0
the 0
human 0
genome 0
. 0

YAC 0
and 0
cosmid 0
contigs 0
spanning 0
the 0
Batten B-gene
disease I-gene
( 0
CLN3 B-gene
) 0
region 0
at 0
16p12.1 0
- 0
p11.2 0
. 0

Isolation 0
of 0
a 0
near 0
full 0
- 0
length 0
cDNA 0
from 0
a 0
human 0
fetal 0
brain 0
cDNA 0
library 0
revealed 0
a 0
protein B-gene
serine I-gene
- I-gene
threonine I-gene
phosphatase I-gene
with 0
a 0
tetratricopeptide 0
motif 0
, 0
almost 0
identical 0
to 0
human B-gene
PPP5C I-gene
( 0
PP5 B-gene
) 0
and 0
highly 0
homologous 0
to 0
rat B-gene
PPT I-gene
. 0

Ly B-gene
- I-gene
49 I-gene
is 0
a 0
family B-gene
type I-gene
II I-gene
transmembrane I-gene
proteins I-gene
encoded 0
by 0
a 0
gene 0
cluster 0
on 0
murine 0
chromosome 0
6 0
. 0

The 0
Dox B-gene
- I-gene
A2 I-gene
ORF I-gene
driven 0
by 0
the 0
TDH3 B-gene
promoter I-gene
complemented 0
the 0
phenotype 0
of 0
a 0
strain 0
deleted 0
for 0
sun2 B-gene
. 0

The 0
introduction 0
of 0
hARF4 B-gene
to 0
the 0
cells 0
maintained 0
the 0
balance 0
between 0
cytosolic 0
and 0
membrane 0
- 0
associated 0
Sec7p B-gene
pools 0
. 0

Our 0
data 0
demonstrate 0
directly 0
that 0
Rpm1r B-gene
is 0
transcribed 0
with 0
its 0
substrates 0
, 0
tRNA B-gene
met I-gene
f I-gene
and 0
tRNAPro B-gene
, 0
from 0
a 0
promoter 0
located 0
upstream 0
of 0
the 0
tRNA B-gene
met I-gene
f I-gene
gene I-gene
and 0
suggest 0
that 0
a 0
portion 0
also 0
originates 0
from 0
a 0
second 0
promoter 0
, 0
located 0
between 0
the 0
tRNA B-gene
met I-gene
f I-gene
gene I-gene
and 0
RPM1 B-gene
. 0

Furthermore 0
, 0
strains 0
with 0
mutant B-gene
RPM1 I-gene
genes I-gene
also 0
accumulate 0
precursor B-gene
Rpm1r I-gene
, 0
suggesting 0
that 0
mutations 0
in 0
either 0
gene 0
can 0
lead 0
to 0
similar 0
biogenesis 0
defects 0
. 0

Vacuolar 0
membrane 0
vesicles 0
from 0
hum1 B-gene
mutants I-gene
lack 0
all 0
Ca2+/H+ 0
antiport 0
activity 0
, 0
demonstrating 0
that 0
Hum1p B-gene
catalyzes 0
the 0
exchange 0
of 0
Ca2+ 0
for 0
H+ 0
across 0
the 0
yeast 0
vacuolar 0
membrane 0
. 0

Detailed 0
mutagenesis 0
of 0
the 0
element 0
's 0
rare 0
- 0
codon/AU 0
- 0
rich 0
sequence 0
boundary 0
revealed 0
that 0
the 0
destabilizing 0
activity 0
of 0
the 0
MATalpha1 B-gene
IE I-gene
is 0
observed 0
when 0
the 0
terminal 0
codon 0
of 0
the 0
element 0
's 0
rare 0
- 0
codon 0
interval 0
is 0
translated 0
. 0

FTF B-gene
is 0
also 0
abundantly 0
expressed 0
in 0
the 0
pancreas 0
and 0
may 0
exert 0
differentiation 0
functions 0
in 0
endodermal 0
sublineages 0
, 0
similar 0
to 0
SF B-gene
- I-gene
1 I-gene
in 0
steroidogenic 0
tissues 0
. 0

Merlie 0
, 0
Cold 0
Spring 0
Harbor 0
Symp 0
. 0

Substantial 0
evidence 0
supports 0
a 0
critical 0
role 0
for 0
the 0
activation 0
of 0
the 0
Raf B-gene
- I-gene
1/MEK/mitogen I-gene
1/MEK/mitogen I-gene

Stylohyoid 0
chain 0
ossification 0
: 0
choice 0
of 0
the 0
surgical 0
approach 0
. 0

The 0
incidence 0
of 0
cardiac 0
death 0
( 0
one 0
per 0
group 0
) 0
, 0
Q 0
wave 0
MI 0
( 0
propofol 0
, 0
n 0
= 0
7 0
; 0
midazolam 0
, 0
n 0
= 0
3 0
; 0
P 0
= 0
0.27 0
) 0
, 0
or 0
non 0
Q 0
wave 0
MI 0
( 0
propofol 0
, 0
n 0
= 0
16 0
; 0
midazolam 0
, 0
n 0
= 0
18 0
; 0
P 0
= 0
0.81 0
) 0
did 0
not 0
differ 0
between 0
treatment 0
groups 0
. 0

63.3 0
micromol/1 0
, 0
p 0
< 0
0.01 0
) 0
and 0
area 0
under 0
the 0
plasma 0
concentration 0
- 0
time 0
curve 0
extrapolated 0
to 0
infinity 0
AUC 0
9 0
( 0
0 0
- 0
infinity 0
) 0
( 0
518.7 0
vs 0
. 0

Cluster 0
formation 0
of 0
E B-gene
- I-gene
cadherin I-gene
on 0
the 0
cell 0
surface 0
is 0
believed 0
to 0
be 0
of 0
major 0
importance 0
for 0
cell 0
- 0
cell 0
adhesion 0
. 0

DNA B-gene
polymerase I-gene
E I-gene
, 0
DNA B-gene
ligase I-gene
III I-gene
and 0
a 0
DNA 0
structure 0
- 0
specific 0
endonuclease 0
co 0
- 0
purify 0
with 0
the 0
five 0
polypeptide 0
complex 0
. 0

By 0
using 0
reporter 0
gene 0
constructs 0
, 0
it 0
is 0
shown 0
that 0
upstream 0
sequences 0
of 0
the 0
P1 0
promoter 0
contain 0
several 0
regions 0
that 0
modulate 0
the 0
expression 0
either 0
positively 0
or 0
negatively 0
. 0

The 0
factor 0
structure 0
of 0
`` 0
schizotypal 0
' 0
traits 0
: 0
a 0
large 0
replication 0
study 0
. 0

Interestingly 0
, 0
however 0
, 0
it 0
is 0
homologous 0
to 0
several 0
expressed 0
sequence 0
tags 0
( 0
EST 0
) 0
of 0
unknown 0
function 0
from 0
Caenorhabditis 0
elegans 0
, 0
Oryza 0
sativa 0
and 0
Homo 0
sapiens 0
. 0

RESULTS 0
: 0
The 0
bilinear 0
model 0
provided 0
a 0
significantly 0
better 0
fit 0
to 0
the 0
acuity 0
outcome 0
data 0
. 0

Outcome 0
of 0
severe 0
congenital 0
hypothyroidism 0
. 0

Mean 0
increase 0
of 0
milk 0
protein 0
yield 0
was 0
46 0
g/d 0
with 0
Met 0
plus 0
Lys 0
, 0
and 0
mean 0
increase 0
of 0
true 0
protein 0
content 0
was 0
1.1 0
g/kg 0
of 0
milk 0
. 0

Nonreturn 0
rates 0
can 0
be 0
used 0
to 0
derive 0
more 0
elementary 0
biological 0
measures 0
for 0
reproductive 0
efficiency 0
, 0
such 0
as 0
conception 0
rate 0
and 0
calving 0
rate 0
, 0
which 0
separately 0
might 0
be 0
more 0
reliable 0
than 0
nonreturn 0
rate 0
itself 0
to 0
evaluate 0
the 0
fertility 0
of 0
a 0
bull 0
or 0
the 0
performance 0
of 0
an 0
AI 0
technician 0
. 0

However 0
, 0
if 0
EMPD 0
involves 0
the 0
glans 0
penis 0
or 0
perianal 0
area 0
, 0
a 0
search 0
for 0
internal 0
malignancy 0
is 0
still 0
warranted 0
. 0

The 0
mean 0
values 0
of 0
protease 0
activity 0
were 0
significantly 0
higher 0
in 0
the 0
test 0
groups 0
than 0
in 0
the 0
control 0
group 0
at 0
baseline 0
. 0

Each 0
half 0
molecule 0
contains 0
four 0
disulfide 0
linkages 0
and 0
four 0
cis 0
peptides 0
. 0

Only 0
fully 0
processed 0
Pra B-gene
( 0
N0 0
and 0
Nb 0
) 0
and 0
ICP35 B-gene
( 0
ICP35 B-gene
e I-gene
, I-gene
f I-gene
) 0
are 0
present 0
in 0
B 0
capsids 0
, 0
which 0
are 0
believed 0
to 0
be 0
precursors 0
of 0
mature 0
virions 0
. 0

A 0
chimeric 0
VP16 B-gene
- 0
Tat B-gene
construct 0
containing 0
the 0
leucine 0
mutations 0
showed 0
no 0
increased 0
AP B-gene
- I-gene
1 I-gene
responsiveness 0
in 0
comparison 0
with 0
that 0
of 0
the 0
VP16 B-gene
activation I-gene
domain I-gene
alone 0
. 0

However 0
, 0
one 0
3 0
' 0
splice 0
site 0
, 0
located 0
at 0
nucleotide 0
( 0
nt 0
) 0
3225 0
, 0
is 0
used 0
for 0
the 0
processing 0
of 0
most 0
BPV 0
- 0
1 0
pre 0
- 0
mRNAs 0
in 0
BPV 0
- 0
1 0
- 0
transformed 0
C127 0
cells 0
and 0
at 0
early 0
to 0
intermediate 0
times 0
in 0
productively 0
infected 0
warts 0
. 0

Here 0
, 0
the 0
cloning 0
and 0
characterization 0
of 0
S B-gene
- I-gene
RNase I-gene
genes I-gene
from 0
two 0
species 0
of 0
Rosaceae 0
, 0
apple 0
( 0
Malus 0
x 0
domestica 0
) 0
and 0
Japanese 0
pear 0
( 0
Pyrus 0
serotina 0
) 0
is 0
described 0
and 0
these 0
sequences 0
are 0
compared 0
with 0
those 0
of 0
other 0
T2 B-gene
- I-gene
type I-gene
RNases I-gene
. 0

A 0
phylogenetic 0
tree 0
of 0
members 0
of 0
the 0
T2/S B-gene
- I-gene
RNase I-gene
superfamily I-gene
in 0
plants 0
was 0
obtained 0
. 0

In 0
a 0
Hoosier 0
Oncology 0
Group 0
randomized 0
study 0
involving 0
extensive 0
- 0
disease 0
SCLC 0
patients 0
, 0
VIP 0
was 0
superior 0
to 0
etoposide/cisplatin 0
with 0
regard 0
to 0
median 0
time 0
to 0
progression 0
( 0
6.6 0
v 0
5.8 0
months 0
) 0
, 0
median 0
survival 0
times 0
( 0
9.1 0
v 0
7.3 0
months 0
) 0
, 0
and 0
2 0
- 0
and 0
3 0
- 0
year 0
survival 0
rates 0
( 0
13 0
% 0
v 0
5 0
% 0
and 0
5 0
% 0
v 0
0 0
% 0
, 0
respectively 0
) 0
. 0

It 0
was 0
shown 0
that 0
administration 0
of 0
immunomodulator 0
neurotropin B-gene
( 0
NSP B-gene
) 0
results 0
in 0
more 0
steady 0
consolidation 0
and 0
retention 0
of 0
feeding 0
and 0
avoidance 0
behavior 0
, 0
and 0
some 0
neurophysiological 0
mechanisms 0
of 0
that 0
phenomena 0
were 0
revealed 0
. 0

Sestamibi 0
scintigraphy 0
, 0
performed 0
in 0
70 0
patients 0
, 0
was 0
less 0
sensitive 0
than 0
ultrasonography 0
( 0
80 0
% 0
) 0
. 0

Atopic 0
allergy 0
and 0
other 0
hypersensitivities 0
. 0

Despite 0
significant 0
lethality 0
and 0
cardiovascular 0
dysfunction 0
, 0
in 0
the 0
septic 0
group 0
on 0
Days 0
1 0
and 0
2 0
, 0
septic 0
versus 0
control 0
animals 0
had 0
no 0
significant 0
differences 0
in 0
mean 0
metabolic 0
cart 0
measured 0
( 0
Vo2DIR 0
, 0
ml/kg/min 0
; 0
Day 0
1 0
: 0
11.9 0
versus 0
12.4 0
, 0
p 0
= 0
0.81 0
; 0
Day 0
2 0
: 0
14.2 0
versus 0
13.5 0
, 0
p 0
= 0
0.72 0
, 0
respectively 0
) 0
and 0
intravascular 0
catheter 0
calculated 0
( 0
Vo2INDIR 0
, 0
ml/kg/min 0
; 0
Day 0
1 0
: 0
11.2 0
versus 0
11.2 0
, 0
p 0
= 0
0.99 0
; 0
Day 0
2 0
: 0
12.8 0
versus 0
15.4 0
, 0
p 0
= 0
0.49 0
, 0
respectively 0
) 0
. 0

After 0
6 0
h 0
of 0
reperfusion 0
, 0
PO2/FlO2 0
ratio 0
was 0
significantly 0
better 0
after 0
Combined 0
Therapy 0
( 0
372 0
+/ 0
- 0
52 0
mm 0
Hg 0
) 0
than 0
in 0
the 0
Recipient 0
Instilled 0
( 0
117 0
+/ 0
- 0
47 0
mm 0
Hg 0
) 0
and 0
Control 0
groups 0
( 0
87 0
+/ 0
- 0
26 0
mm 0
Hg 0
) 0
, 0
with 0
intermediate 0
values 0
in 0
Donor 0
Aerosol 0
dogs 0
( 0
232 0
+/ 0
- 0
64 0
mm 0
Hg 0
) 0
. 0

The 0
euglobulin B-gene
clot 0
lysis 0
time 0
was 0
slightly 0
longer 0
in 0
the 0
smokers 0
than 0
in 0
the 0
non 0
- 0
smokers 0
in 0
all 0
three 0
experimental 0
situations 0
, 0
but 0
the 0
differences 0
were 0
not 0
significant 0
. 0

HS 0
inducibility 0
required 0
the 0
HSE 0
which 0
was 0
bound 0
by 0
HS B-gene
transcription I-gene
factor I-gene
- I-gene
1 I-gene
( 0
HSF B-gene
- I-gene
1 I-gene
) 0
present 0
in 0
extracts 0
prepared 0
from 0
cells 0
exposed 0
to 0
HS 0
. 0

Although 0
the 0
DSK2 B-gene
- I-gene
1 I-gene
mutation I-gene
alters 0
a 0
conserved 0
residue 0
in 0
the 0
Dsk2p B-gene
ubiquitin B-gene
- I-gene
like I-gene
domain I-gene
, 0
we 0
detect 0
no 0
differences 0
in 0
Dsk2p B-gene
or 0
Cdc31p B-gene
stability 0
. 0

Although 0
IL B-gene
- I-gene
2 I-gene
and 0
IFN B-gene
- I-gene
alpha I-gene
activated 0
STAT1 B-gene
alpha I-gene
and 0
STAT5 B-gene
, 0
IL B-gene
- I-gene
2 I-gene
predominantly 0
activated 0
STAT5 B-gene
, 0
while 0
IFN B-gene
- I-gene
alpha I-gene
predominantly 0
activated 0
STAT1 B-gene
alpha I-gene
. 0

Consistent 0
with 0
this 0
interpretation 0
, 0
recombinant B-gene
CREB I-gene
and 0
activating B-gene
transcription I-gene
factor I-gene
proteins I-gene
bound 0
the 0
junB B-gene
CRE 0
- 0
like 0
site 0
, 0
but 0
did 0
not 0
interact 0
with 0
a 0
mutant 0
CRE 0
- 0
like 0
site 0
. 0

Collectively 0
, 0
these 0
results 0
suggest 0
that 0
components 0
of 0
the 0
protein B-gene
kinase I-gene
A I-gene
signaling 0
pathway 0
are 0
recruited 0
by 0
mIg B-gene
to 0
induce 0
junB B-gene
transcription 0
. 0

One 0
complex 0
containing 0
a 0
70 0
D 0
protein 0
was 0
found 0
to 0
be 0
associated 0
specifically 0
with 0
transcriptionally 0
active 0
leukemia 0
cells 0
. 0

Our 0
results 0
confirm 0
the 0
participation 0
of 0
intron 0
1 0
in 0
transcriptional 0
regulation 0
of 0
the 0
c B-gene
- I-gene
myb I-gene
gene I-gene
( 0
in 0
mouse 0
and 0
human 0
) 0
and 0
implicate 0
multiple 0
and 0
complex 0
regulatory 0
mechanisms 0
of 0
activation 0
during 0
myelomonocytic 0
differentiation 0
and 0
leukemic 0
cell 0
growth 0
control 0
. 0

Immunofluorescence 0
microscopy 0
revealed 0
extensive 0
deposition 0
of 0
such 0
extracellular 0
matrices 0
as 0
type B-gene
IV I-gene
collagen I-gene
and 0
laminin B-gene
in 0
the 0
vascular 0
wall 0
. 0

OBJECTIVE 0
: 0
To 0
compare 0
pregnancy 0
complications 0
in 0
women 0
having 0
genetic 0
amniocentesis 0
at 0
11 0
- 0
14 0
weeks 0
versus 0
those 0
undergoing 0
amniocentesis 0
at 0
16 0
- 0
19 0
weeks 0
' 0
gestation 0
. 0

Three 0
ORFs 0
( 0
9765orfR002 0
, 0
9765orfR011 0
and 0
9765orfR013 0
) 0
were 0
found 0
to 0
be 0
homologous 0
with 0
Schizosaccharomyces 0
pombe 0
polyadenylate B-gene
binding I-gene
protein I-gene
, 0
Escherichia 0
coli 0
hypothetical 0
38.1 0
- 0
kDa 0
protein 0
in 0
the 0
BCR B-gene
5 0
' 0
region 0
, 0
and 0
transcription 0
regulatory 0
protein 0
Swi3 B-gene
, 0
respectively 0
. 0

Two 0
new 0
flavone 0
glucosides 0
, 0
nevadensin 0
5 0
- 0
O 0
- 0
beta 0
- 0
D 0
- 0
glucoside 0
and 0
nevadensin 0
5 0
- 0
O 0
- 0
beta 0
- 0
D 0
- 0
glucosyl 0
( 0
1 0
- 0
- 0
> 0
6 0
) 0
beta 0
- 0
D 0
- 0
glucoside 0
, 0
have 0
been 0
isolated 0
from 0
the 0
aerial 0
parts 0
of 0
Lysionotus 0
pauciflorus 0
. 0

Recently 0
, 0
our 0
laboratory 0
developed 0
a 0
screen 0
that 0
identified 0
five 0
multicopy 0
suppressors 0
that 0
can 0
rescue 0
lethal 0
strains 0
of 0
clathrin B-gene
heavy 0
chain 0
- 0
deficient 0
yeast 0
( 0
Chc B-gene
- 0
scd1 B-gene
- I-gene
i I-gene
) 0
to 0
viability 0
. 0

Reproductive 0
period 0
affects 0
water 0
intake 0
in 0
heat 0
- 0
stressed 0
dehydrated 0
goats 0
. 0

The 0
logistic 0
regression 0
analysis 0
of 0
the 0
manual 0
method 0
( 0
percentage 0
normal 0
morphology 0
) 0
and 0
IVOS 0
indicated 0
that 0
both 0
were 0
predictors 0
of 0
fertilization 0
. 0

METHODS 0
: 0
Rats 0
received 0
continuous 0
intragastric 0
infusion 0
of 0
elemental 0
diet 0
or 0
with 0
supplementation 0
of 0
oatbase 0
, 0
Lactobacillus 0
reuteri 0
R2LC 0
, 0
and 0
Lactobacillus 0
plantarum 0
DSM 0
9843 0
, 0
with 0
and 0
without 0
fermentation 0
, 0
from 0
the 0
beginning 0
of 0
the 0
study 0
. 0

However 0
, 0
D8 B-gene
binding 0
was 0
observed 0
by 0
nuclease 0
protection 0
with 0
lactotroph B-gene
- I-gene
as I-gene
well I-gene
as I-gene
somatotroph I-gene
- I-gene
like I-gene
cell I-gene
nuclear I-gene
protein I-gene
. 0

Limited 0
role 0
for 0
PCR 0
- 0
based 0
diagnosis 0
of 0
Whipple 0
's 0
disease 0
from 0
peripheral 0
blood 0
mononuclear 0
cells 0
. 0

The 0
ability 0
of 0
A20 B-gene
to 0
block 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
was 0
mapped 0
to 0
its 0
C 0
- 0
terminal 0
zinc 0
finger 0
domain 0
. 0

The 0
Pro 0
- 0
258 0
- 0
- 0
> 0
Leu 0
( 0
P258L 0
) 0
mutation 0
caused 0
constitutive 0
receptor 0
signaling 0
that 0
was 0
equivalent 0
to 0
about 0
45 0
% 0
of 0
the 0
maximum 0
level 0
observed 0
in 0
wild 0
- 0
type 0
cells 0
stimulated 0
with 0
alpha B-gene
- I-gene
factor I-gene
. 0

By 0
using 0
a 0
DNA 0
sequence 0
selected 0
for 0
its 0
ability 0
to 0
bind 0
recombinant B-gene
BCL I-gene
- I-gene
6 I-gene
in 0
vitro 0
, 0
we 0
show 0
here 0
that 0
BCL B-gene
- I-gene
6 I-gene
is 0
present 0
in 0
DNA 0
- 0
binding 0
complexes 0
in 0
nuclear 0
extracts 0
from 0
various 0
B 0
- 0
cell 0
lines 0
. 0

The 0
predictive 0
value 0
of 0
a 0
positive 0
flag 0
was 0
77.7 0
% 0
. 0

CONCLUSIONS 0
: 0
Our 0
findings 0
suggest 0
that 0
pre 0
- 0
treatment 0
with 0
coenzyme 0
Q10 0
may 0
play 0
a 0
protective 0
role 0
during 0
routine 0
vascular 0
procedures 0
requiring 0
abdominal 0
aortic 0
cross 0
clamping 0
by 0
attenuating 0
the 0
degree 0
of 0
peroxidative 0
damage 0
. 0

Because 0
chromosome 0
X 0
is 0
frequently 0
involved 0
in 0
structural 0
alterations 0
in 0
neoplastic 0
Syrian 0
hamster 0
cells 0
transformed 0
by 0
chemical 0
carcinogens 0
and 0
oncogenic 0
viruses 0
, 0
the 0
localization 0
of 0
the 0
cph B-gene
locus I-gene
on 0
this 0
chromosome 0
supports 0
the 0
notion 0
that 0
the 0
cph B-gene
oncogene I-gene
plays 0
a 0
role 0
in 0
the 0
malignant 0
conversion 0
of 0
chemically 0
transformed 0
hamster 0
fibroblasts 0
. 0

In 0
a 0
screen 0
for 0
genes 0
with 0
oncogenic 0
potential 0
expressed 0
by 0
the 0
murine 0
B6SUtA1 0
myeloid 0
progenitor 0
cell 0
line 0
, 0
we 0
isolated 0
a 0
2 0
. 0

Gap1 B-gene
( I-gene
IP4BP I-gene
) I-gene
, 0
one 0
of 0
a 0
member 0
of 0
Ras B-gene
GTPase I-gene
- I-gene
activating I-gene
proteins I-gene
, 0
has 0
been 0
identified 0
as 0
a 0
specific 0
inositol B-gene
1,3,4,5 I-gene
- I-gene
tetrakisphosphate I-gene
( I-gene
IP4 I-gene
) I-gene
- I-gene
binding I-gene
protein I-gene
( 0
Cullen 0
, 0
P 0
. 0

We 0
previously 0
described 0
the 0
purification 0
of 0
an 0
83 B-gene
- I-gene
kDa I-gene
phosphatidic I-gene
acid I-gene
phosphatase I-gene
( 0
PAP B-gene
) 0
from 0
the 0
porcine 0
thymus 0
membranes 0
( 0
Kanoh 0
, 0
H. 0
, 0
Imai 0
, 0
S. 0
- 0
i. 0
, 0
Yamada 0
, 0
K. 0
and 0
Sakane 0
, 0
F. 0
( 0
1992 0
) 0
J 0
. 0

The 0
mechanism 0
involves 0
Gbetagamma B-gene
subunit 0
- 0
mediated 0
increases 0
in 0
tyrosine 0
phosphorylation 0
of 0
the 0
Shc B-gene
adapter I-gene
protein I-gene
, 0
Shc*Grb2 B-gene
complex 0
formation 0
, 0
and 0
recruitment 0
of 0
Shc*Grb2 I-gene

A 0
cDNA 0
encoding 0
the 0
amino 0
- 0
terminal 0
17 0
% 0
of 0
apoB B-gene
( 0
apoB17 B-gene
) 0
was 0
fused 0
to 0
a 0
cDNA 0
coding 0
for 0
the 0
last 0
37 0
amino 0
acids 0
of 0
decay B-gene
- I-gene
accelerating I-gene
factor I-gene
( 0
DAF B-gene
) 0
, 0
which 0
contains 0
the 0
signal 0
for 0
glycosylphosphatidylinositol 0
anchor 0
attachment 0
. 0

Next 0
, 0
we 0
stably 0
overexpressed 0
wild B-gene
- I-gene
type I-gene
Shc I-gene
or 0
Y317F B-gene
mutant I-gene
Shc I-gene
into 0
HIRc 0
cells 0
. 0

The 0
small B-gene
GTPase I-gene
Rho B-gene
is 0
implicated 0
in 0
physiological 0
functions 0
associated 0
with 0
actin B-gene
- 0
myosin B-gene
filaments 0
such 0
as 0
cytokinesis 0
, 0
cell 0
motility 0
, 0
and 0
smooth 0
muscle 0
contraction 0
. 0

Conversely 0
, 0
activation 0
of 0
this 0
signaling 0
pathway 0
by 0
expression 0
of 0
a 0
constitutively 0
active 0
MKK1 B-gene
mutant I-gene
dramatically 0
increased 0
cyclin B-gene
D1 I-gene
promoter 0
activity 0
and 0
cyclin B-gene
D1 I-gene
protein I-gene
expression 0
, 0
in 0
a 0
growth 0
factor 0
- 0
independent 0
manner 0
. 0

Furthermore 0
, 0
upstream 0
insertion 0
of 0
the 0
GSTP1 B-gene
silencer I-gene
element I-gene
failed 0
to 0
inhibit 0
activity 0
of 0
a 0
heterologous 0
promoter 0
in 0
MCF7 0
cells 0
. 0

In 0
order 0
to 0
delineate 0
structural 0
motifs 0
regulating 0
substrate 0
affinity 0
and 0
recognition 0
for 0
the 0
human B-gene
dopamine I-gene
transporter I-gene
( 0
DAT B-gene
) 0
, 0
we 0
assessed 0
[ 0
3H 0
] 0
dopamine 0
uptake 0
kinetics 0
and 0
[ 0
3H 0
] 0
CFT 0
binding 0
characteristics 0
of 0
COS 0
- 0
7 0
cells 0
transiently 0
expressing 0
mutant B-gene
DATs I-gene
in 0
which 0
the 0
COOH 0
terminus 0
was 0
truncated 0
or 0
substituted 0
. 0

An 0
expression 0
library 0
was 0
constructed 0
by 0
inserting 0
5 0
' 0
portion 0
- 0
enriched 0
cDNAs 0
from 0
phytohemagglutinin B-gene
- 0
stimulated 0
peripheral 0
blood 0
mononuclear 0
cells 0
into 0
upstream 0
of 0
signal B-gene
sequence I-gene
- I-gene
deleted I-gene
CD4 I-gene
cDNA I-gene
in 0
an 0
Epstein 0
- 0
Barr 0
virus 0
shuttle 0
vector 0
. 0

Radiolabeled 0
recombinant B-gene
TARC I-gene
specifically 0
bound 0
to 0
T 0
cell 0
lines 0
and 0
peripheral 0
T 0
cells 0
but 0
not 0
to 0
monocytes 0
or 0
granulocytes 0
. 0

The 0
cis 0
- 0
acting 0
elements 0
that 0
control 0
promoter 0
activity 0
include 0
binding 0
sites 0
for 0
transcription 0
factors 0
Sp1 B-gene
and 0
alphaCbf B-gene
, 0
a 0
60 B-gene
- I-gene
kDa I-gene
CCAAT I-gene
box I-gene
- I-gene
binding I-gene
protein I-gene
. 0

Therefore 0
, 0
we 0
have 0
identified 0
a 0
cis 0
- 0
acting 0
element 0
, 0
the 0
E1 0
E 0
- 0
box 0
, 0
located 0
in 0
the 0
GAP B-gene
- I-gene
43 I-gene
promoter 0
region 0
that 0
modulates 0
either 0
positively 0
or 0
negatively 0
the 0
expression 0
of 0
the 0
GAP B-gene
- I-gene
43 I-gene
gene I-gene
depending 0
on 0
which 0
E B-gene
- I-gene
box I-gene
- I-gene
binding I-gene
proteins I-gene
occupy 0
this 0
site 0
. 0

Collectively 0
, 0
our 0
findings 0
demonstrate 0
that 0
SF B-gene
- I-gene
1 I-gene
plays 0
a 0
key 0
role 0
in 0
controlling 0
the 0
basal 0
and 0
cAMP 0
- 0
stimulated 0
expression 0
of 0
the 0
StAR B-gene
gene I-gene
. 0

There 0
was 0
a 0
general 0
broadening 0
of 0
proton 0
resonances 0
for 0
a 0
three 0
- 0
nucleotide 0
segment 0
centered 0
about 0
the 0
lesion 0
site 0
which 0
resulted 0
in 0
a 0
tentative 0
assignment 0
for 0
the 0
sugar 0
protons 0
of 0
the 0
C7 0
residue 0
in 0
the 0
spectrum 0
of 0
the 0
adduct 0
duplex 0
. 0

Using 0
one 0
of 0
the 0
six 0
fragments 0
( 0
CPK3 B-gene
- I-gene
8 I-gene
) 0
, 0
we 0
isolated 0
a 0
2022 B-gene
bp I-gene
cDNA I-gene
( I-gene
VrCDPK I-gene
- I-gene
1 I-gene
) I-gene
from 0
a 0
Vigna 0
radiata 0
lambda 0
gt11 0
library 0
. 0

However 0
, 0
in 0
TF 0
- 0
1 0
cells 0
grown 0
on 0
GM B-gene
- I-gene
CSF I-gene
before 0
starvation 0
, 0
CREB B-gene
phosphorylation 0
was 0
observed 0
10 0
minutes 0
after 0
PIXY321 B-gene
stimulation 0
. 0

Workplace 0
violence 0
- 0
- 0
nurses 0
at 0
risk 0
. 0

RESULTS 0
: 0
The 0
LV 0
maximum 0
brightness 0
and 0
area 0
under 0
the 0
curve 0
showed 0
significant 0
negative 0
correlations 0
( 0
p 0
= 0
< 0
0.004 0
) 0
with 0
the 0
FIO2 0
, 0
while 0
the 0
minimum 0
brightness 0
showed 0
a 0
significant 0
positive 0
correlation 0
( 0
p 0
= 0
< 0
0.002 0
) 0
. 0

The 0
results 0
also 0
imply 0
that 0
the 0
absence 0
of 0
perforin B-gene
expression 0
in 0
non 0
- 0
cytotoxic 0
cells 0
may 0
be 0
due 0
to 0
the 0
suppression 0
of 0
the 0
induction 0
of 0
the 0
killer 0
- 0
cell 0
- 0
specific 0
trans 0
- 0
acting 0
factor 0
NF B-gene
- I-gene
P2 I-gene
. 0

We 0
identify 0
considerable 0
spatio 0
- 0
temporal 0
similarities 0
between 0
reported 0
expression 0
patterns 0
of 0
Ypr10 B-gene
genes I-gene
and 0
ribonuclease 0
genes 0
, 0
which 0
, 0
together 0
with 0
the 0
significant 0
sequence 0
similarity 0
to 0
the 0
ginseng B-gene
ribonuclease I-gene
, 0
support 0
the 0
hypothesis 0
of 0
a 0
ribonuclease 0
function 0
for 0
PR B-gene
- I-gene
10 I-gene
proteins I-gene
and 0
allow 0
the 0
prediction 0
of 0
possible 0
biological 0
roles 0
. 0

The 0
expression 0
of 0
ERV3 B-gene
env I-gene
mRNA I-gene
was 0
found 0
to 0
be 0
differentiation 0
- 0
associated 0
, 0
with 0
high 0
expression 0
detected 0
in 0
the 0
late 0
stages 0
of 0
monocytic 0
development 0
. 0

Initial 0
estimates 0
indicate 0
that 0
27,193 0
people 0
are 0
either 0
in 0
receipt 0
of 0
or 0
in 0
need 0
of 0
mental 0
handicap 0
services 0
. 0

It 0
is 0
exclusively 0
observed 0
in 0
smooth 0
muscle 0
cells 0
by 0
Northern 0
blotting 0
and 0
immunohistochemical 0
analysis 0
and 0
therefore 0
designated 0
`` B-gene
smoothelin I-gene
. I-gene
'' 0
A 0
human 0
smooth 0
muscle 0
cDNA 0
library 0
was 0
screened 0
with 0
the B-gene
monoclonal I-gene
antibody I-gene
R4A I-gene
, 0
and 0
a 0
full 0
- 0
size 0
cDNA 0
of 0
the 0
protein 0
was 0
selected 0
. 0

Using 0
immunogold 0
electron 0
microscopy 0
, 0
we 0
found 0
that 0
p58/p45 B-gene
and 0
p58/p45 I-gene

Concurrent 0
with 0
ligand 0
- 0
dependent 0
uptake 0
, 0
we 0
now 0
show 0
that 0
the 0
receptor 0
undergoes 0
ligand 0
- 0
induced 0
ubiquitination 0
, 0
suggesting 0
that 0
receptor 0
ubiquitination 0
may 0
function 0
in 0
the 0
ligand 0
- 0
dependent 0
endocytosis 0
of 0
the 0
a B-gene
- I-gene
factor I-gene
receptor I-gene
as 0
well 0
as 0
in 0
its 0
constitutive 0
endocytosis 0
. 0

Transcription 0
initiation 0
sites 0
of 0
the 0
rat 0
II B-gene
beta I-gene
- I-gene
, I-gene
III I-gene
beta I-gene
, I-gene
and I-gene
O I-gene
beta I-gene
- I-gene
globin I-gene
genes 0
were 0
determined 0
to 0
be 0
52 0
base 0
pairs 0
( 0
bp 0
) 0
5' 0
- 0
upstream 0
of 0
the 0
translation 0
initiation 0
codon 0
( 0
ATG 0
) 0
, 0
in 0
each 0
gene 0
by 0
primer 0
extension 0
analysis 0
. 0

Aggravating 0
process 0
induced 0
by 0
indomethacin 0
on 0
chronic 0
gastric 0
lesion 0
in 0
rat 0
. 0

Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
nuclear I-gene
protein I-gene
2 I-gene
( 0
EBNA2 B-gene
) 0
binds 0
to 0
a 0
component 0
of 0
the 0
human 0
SNF B-gene
- 0
SWI B-gene
complex 0
, 0
hSNF5/Ini1 B-gene
. 0

Our 0
studies 0
also 0
excluded 0
the 0
possibility 0
that 0
the 0
phosphorylation 0
of 0
Ser 0
- 0
2 0
, 0
Ser 0
- 0
123 0
, 0
or 0
Ser 0
- 0
210 0
, 0
had 0
roles 0
in 0
the 0
trans 0
- 0
suppression 0
activity 0
of 0
the 0
large B-gene
HDAg I-gene
, 0
in 0
the 0
assembly 0
of 0
empty 0
virus B-gene
- I-gene
like I-gene
HDAg I-gene
particle I-gene
, 0
and 0
in 0
the 0
nuclear 0
transport 0
of 0
HDAgs B-gene
. 0

Homologous 0
recombination 0
between 0
the 0
Autographa 0
californica 0
nuclear 0
polyhedrosis 0
virus 0
( 0
AcNPV 0
) 0
genome 0
and 0
a 0
0.6 0
- 0
kbp 0
- 0
long 0
DNA 0
fragment 0
derived 0
from 0
the 0
putative 0
DNA B-gene
helicase I-gene
gene I-gene
of I-gene
Bombyx I-gene
mori I-gene
nuclear I-gene
polyhedrosis I-gene
virus I-gene
generates 0
eh2 0
- 0
AcNPV 0
, 0
an 0
expanded 0
- 0
host 0
- 0
range 0
AcNPV 0
mutant 0
( 0
S 0
. 0

The 0
data 0
further 0
indicate 0
that 0
the 0
IL B-gene
- I-gene
7R I-gene
alpha I-gene
chains I-gene
are 0
directly 0
involved 0
in 0
the 0
activation 0
of 0
JAKs B-gene
and 0
STATs B-gene
and 0
have 0
a 0
major 0
role 0
in 0
proliferative 0
signaling 0
in 0
precursor 0
B 0
cells 0
. 0

Furthermore 0
, 0
the 0
potency 0
of 0
Dacarbacine 0
in 0
the 0
treatment 0
of 0
carcinoid 0
tumors 0
seems 0
to 0
be 0
underestimated 0
up 0
to 0
now 0
. 0

5 0
) 0
We 0
've 0
noticed 0
that 0
the 0
mean 0
value 0
of 0
the 0
cost 0
for 0
episode 0
of 0
pnx 0
s. 0
in 0
class 0
A 0
was 0
more 0
than 0
15 0
% 0
compared 0
to 0
class 0
B 0
and 0
the 0
cost 0
for 0
patient 0
in 0
class 0
A 0
was 0
nearly 0
double 0
than 0
in 0
class 0
B 0
. 0

We 0
have 0
been 0
studying 0
the 0
interaction 0
of 0
the 0
oncogenic 0
human 0
polyomavirus 0
BK 0
( 0
BKV 0
) 0
with 0
the 0
tumor B-gene
- I-gene
suppressor I-gene
protein I-gene
p53 I-gene
to 0
understand 0
the 0
biology 0
of 0
this 0
virus 0
as 0
well 0
as 0
to 0
understand 0
the 0
basic 0
mechanisms 0
of 0
p53 B-gene
transactivation 0
. 0

Site 0
S 0
- 0
II 0
also 0
spans 0
a 0
23 0
bp 0
sequence 0
containing 0
two 0
tandem 0
consensus 0
binding 0
sites 0
with 0
three 0
base 0
pair 0
mismatches 0
in 0
each 0
and 0
a 0
one 0
base 0
pair 0
deletion 0
. 0

Cbl B-gene
constitutively 0
interacts 0
with 0
the 0
SH3 B-gene
domains I-gene
of 0
Grb2 B-gene
, 0
with 0
a 0
preference 0
for 0
the 0
amino 0
- 0
terminal 0
domain 0
, 0
and 0
is 0
in 0
this 0
way 0
recruited 0
to 0
Shc B-gene
upon 0
BCR B-gene
stimulation 0
. 0

Activation 0
mediated 0
by 0
Cat8p B-gene
was 0
no 0
longer 0
detectable 0
in 0
a 0
cat1 B-gene
mutant I-gene
. 0

Treatment 0
is 0
instituted 0
with 0
prednisone 0
and 0
cyclophosphamide 0
. 0

Unaided 0
attempts 0
to 0
quit 0
smoking 0
are 0
generally 0
unsuccessful 0
. 0

Laboratory 0
evaluation 0
was 0
normal 0
, 0
and 0
neuroimaging 0
failed 0
to 0
confirm 0
obstruction 0
of 0
venous 0
or 0
lymphatic 0
drainage 0
. 0

Microcomputer 0
management 0
of 0
chronic 0
hepatitis 0
B 0
virus 0
asymptomatic 0
patients 0

While 0
fusion 0
to 0
the 0
N 0
- 0
terminus 0
required 0
a 0
linker 0
to 0
become 0
surface 0
accessible 0
, 0
both 0
fusion 0
to 0
the 0
N 0
- 0
terminus 0
and 0
to 0
the 0
C 0
- 0
terminus 0
was 0
compatible 0
with 0
particle 0
assembly 0
and 0
preserved 0
the 0
native 0
antigenicity 0
and 0
immunogenicity 0
of 0
HBcAg B-gene
. 0

The 0
standard 0
dosage 0
of 0
anti B-gene
- I-gene
D I-gene
currently 0
given 0
at 0
all 0
gestational 0
ages 0
is 0
1 0
ampoule 0
containing 0
125 0
micrograms 0
of 0
anti B-gene
- I-gene
D I-gene
. 0

We 0
report 0
here 0
the 0
molecular 0
cloning 0
of 0
a 0
putative 0
adhesive 0
molecule 0
from 0
P. 0
falciparum 0
that 0
shares 0
both 0
sequence 0
and 0
structural 0
similarities 0
with 0
a 0
sporozoite 0
surface 0
molecule 0
from 0
Plasmodium 0
termed 0
the 0
thrombospondin B-gene
- I-gene
related I-gene
anonymous I-gene
protein I-gene
( 0
TRAP B-gene
) 0
and 0
, 0
to 0
a 0
lesser 0
extent 0
, 0
with 0
the 0
circumsporozoite B-gene
( I-gene
CS I-gene
) I-gene
protein I-gene
. 0

There 0
are 0
no 0
introns 0
within 0
the 0
gene 0
, 0
which 0
contains 0
a 0
9360 0
- 0
bp 0
open 0
reading 0
frame 0
and 0
encodes 0
a 0
377 0
- 0
kDa 0
protein 0
. 0

METHODS 0
: 0
DSF 0
was 0
instilled 0
in 0
one 0
eye 0
chosen 0
at 0
random 0
and 0
CF 0
in 0
the 0
fellow 0
eye 0
of 0
13 0
normal 0
subjects 0
and 0
in 0
13 0
patients 0
with 0
KCS 0
. 0

The 0
experience 0
of 0
the 0
lateral 0
rhinotomy 0
approach 0
in 0
transsphenoidal 0
surgery 0
of 0
acromegaly 0
has 0
been 0
favourable 0
. 0

CONCLUSION 0
: 0
The 0
results 0
demonstrate 0
that 0
at 0
the 0
site 0
of 0
lumbar 0
disc 0
herniation 0
, 0
inflammatory 0
cytokines 0
such 0
as 0
interleukin B-gene
- I-gene
1 I-gene
alpha I-gene
are 0
produced 0
, 0
which 0
increases 0
prostaglandin 0
E2 0
production 0
. 0

The 0
predominant 0
sensitizing 0
allergens 0
in 0
Swedish 0
asthmatic 0
children 0
are 0
furred 0
pet 0
animals 0
. 0

Our 0
results 0
demonstrate 0
that 0
distinct 0
cytoplasmic 0
domains 0
of 0
these 0
cytokine 0
receptors 0
elicit 0
convergent 0
signaling 0
pathways 0
and 0
provide 0
evidence 0
that 0
beta B-gene
c I-gene
and 0
IL B-gene
- I-gene
2R I-gene
beta I-gene
function 0
as 0
a 0
complete 0
signal 0
transducer 0
. 0

In 0
addition 0
, 0
they 0
display 0
common 0
features 0
that 0
make 0
them 0
strikingly 0
related 0
to 0
snoRNA B-gene
U14 I-gene
. 0

U24 B-gene
has 0
two 0
separate 0
12 0
nt 0
long 0
complementarities 0
to 0
a 0
highly 0
conserved 0
tract 0
of 0
28S B-gene
rRNA I-gene
. 0

This 0
complex 0
interacts 0
at 0
the 0
GTPase B-gene
domain I-gene
in 0
the 0
large 0
subunit 0
rRNA 0
, 0
overlapping 0
the 0
binding 0
site 0
of 0
the 0
protein B-gene
L11 I-gene
- I-gene
like I-gene
eukaryotic I-gene
counterpart I-gene
( 0
Saccharomyces B-gene
cerevisiae I-gene
protein I-gene
L15 I-gene
and 0
mammalian B-gene
protein I-gene
L12 I-gene
) 0
. 0

Chromatin 0
repression 0
of 0
these 0
replacement 0
genes 0
would 0
be 0
avoided 0
, 0
consistent 0
with 0
the 0
high 0
, 0
constitutive 0
expression 0
of 0
replacement 0
H3 B-gene
histone I-gene
genes I-gene
in 0
plants 0
. 0

This 0
transition 0
is 0
regulated 0
positively 0
by 0
G1 B-gene
- I-gene
specific I-gene
cyclin I-gene
- I-gene
dependent I-gene
kinases I-gene
( 0
cdks B-gene
) 0
and 0
negatively 0
by 0
the 0
product 0
of 0
the 0
retinoblastoma B-gene
tumour I-gene
suppressor I-gene
gene I-gene
, 0
pRb B-gene
. 0

Possible 0
relationship 0
between 0
hyperinsulinemia 0
and 0
glomerular 0
hypertrophy 0
in 0
nephrosclerosis 0
. 0

Blood 0
GSH B-gene
- I-gene
Px I-gene
activity 0
was 0
measured 0
with 0
a 0
spectrophotometer 0
, 0
using 0
a 0
modification 0
of 0
a 0
previously 0
described 0
assay 0
. 0

The 0
concentrations 0
of 0
vitamin 0
A 0
precursors 0
and 0
vitamin 0
E 0
in 0
the 0
hay 0
were 0
below 0
currently 0
recommended 0
dietary 0
levels 0
for 0
llamas 0
, 0
and 0
alfalfa 0
hay 0
appears 0
to 0
provide 0
an 0
unreliable 0
source 0
of 0
vitamins 0
A 0
and 0
E 0
in 0
this 0
species 0
. 0

Eight 0
cats 0
infected 0
with 0
H. 0
pylori 0
were 0
used 0
in 0
the 0
study 0
. 0

However 0
, 0
as 0
determined 0
by 0
PCR 0
with 0
primers 0
specific 0
for 0
the 0
26 0
- 0
kDa 0
product 0
, 0
the 0
majority 0
of 0
cats 0
at 0
2 0
and 0
4 0
weeks 0
p.t 0
. 0
had 0
gastric 0
fluid 0
samples 0
which 0
were 0
positive 0
for 0
H. 0
pylori 0
and 0
three 0
of 0
three 0
cats 0
at 0
2 0
weeks 0
p.t 0
. 0
had 0
dental 0
plaque 0
which 0
was 0
positive 0
for 0
H. 0
pylori 0
. 0

To 0
derive 0
quantitative 0
concentration 0
changes 0
from 0
measurements 0
of 0
light 0
attenuation 0
, 0
the 0
optical 0
path 0
length 0
must 0
be 0
known 0
. 0

STUDY 0
DESIGN 0
. 0

Following 0
the 0
injection 0
of 0
PGF2 0
alpha 0
, 0
heifers 0
were 0
observed 0
visually 0
for 0
signs 0
of 0
estrus 0
at 0
0730 0
and 0
1630 0
( 0
45 0
min 0
each 0
) 0
. 0

Differential 0
activation 0
of 0
the 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
, 0
Jun B-gene
kinase I-gene
and 0
Janus B-gene
kinase I-gene
- 0
Stat B-gene
pathways 0
by 0
oncostatin B-gene
M I-gene
and 0
basic B-gene
fibroblast I-gene
growth I-gene
factor I-gene
in 0
AIDS 0
- 0
derived 0
Kaposi 0
's 0
sarcoma 0
cells 0
. 0

There 0
is 0
general 0
agreement 0
that 0
the 0
hepatitis 0
C 0
virus 0
is 0
efficiently 0
transmitted 0
parenterally 0
, 0
while 0
data 0
on 0
viral 0
transmission 0
from 0
mothers 0
to 0
babies 0
or 0
by 0
sexual 0
or 0
non 0
- 0
sexual 0
household 0
contact 0
are 0
conflicting 0
. 0

Ten 0
weeks 0
after 0
reconstruction 0
, 0
the 0
regenerating 0
nerves 0
already 0
resembled 0
normal 0
nerves 0
. 0

The 0
distribution 0
and 0
organization 0
of 0
projections 0
from 0
the 0
spinal 0
cervical 0
enlargement 0
to 0
subnucleus 0
reticularis 0
dorsalis 0
( 0
SRD 0
) 0
and 0
the 0
neighbouring 0
Cuneate 0
nucleus 0
( 0
Cu 0
) 0
area 0
was 0
studied 0
in 0
the 0
rat 0
by 0
using 0
microinjections 0
of 0
Phaseolus B-gene
vulgaris I-gene
leucoagglutinin I-gene
( 0
PHA B-gene
- I-gene
L I-gene
) 0
into 0
different 0
laminae 0
around 0
the 0
C7 0
level 0
. 0

The 0
levels 0
of 0
fibrinogen B-gene
as 0
well 0
as 0
antithrombin B-gene
III I-gene
( 0
ATIII B-gene
) 0
and 0
heparin B-gene
cofactor I-gene
II I-gene
( 0
HCII B-gene
) 0
activities 0
were 0
steadily 0
increased 0
in 0
loop 0
- 0
bearing 0
animals 0
. 0

Amplification 0
and 0
overexpression 0
of 0
the 0
c B-gene
- I-gene
erbB I-gene
- I-gene
2 I-gene
gene I-gene
in 0
21MT 0
- 0
2 0
and 0
21MT 0
- 0
1 0
human 0
breast 0
carcinoma 0
cells 0
results 0
in 0
progressively 0
elevated 0
levels 0
of 0
constitutively 0
tyrosine B-gene
- I-gene
phosphorylated I-gene
p185erbB I-gene
- I-gene
2 I-gene
and 0
is 0
associated 0
with 0
progressive 0
insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
( 0
IGF B-gene
) 0
and 0
combined 0
IGF/epidermal B-gene
IGF/epidermal I-gene
growth I-gene
factor I-gene
( 0
EGF B-gene
) 0
independence 0
in 0
culture 0
. 0

Facioscapulohumeral 0
muscular 0
dystrophy 0
( 0
FSHD 0
) 0
is 0
an 0
autosomal 0
dominant 0
, 0
neuromuscular 0
disorder 0
characterized 0
by 0
progressive 0
weakness 0
of 0
muscles 0
in 0
the 0
face 0
, 0
shoulder 0
and 0
upper 0
arm 0
. 0

The 0
mature 0
chromosome 0
4 0
FRG1 B-gene
transcript I-gene
is 0
1042 0
bp 0
in 0
length 0
and 0
contains 0
nine 0
exons 0
which 0
encode 0
a 0
putative 0
protein 0
of 0
258 0
amino 0
acid 0
residues 0
. 0

Patients 0
who 0
have 0
undergone 0
thyroidectomy 0
for 0
thyroid 0
carcinoma 0
are 0
frequently 0
subjected 0
to 0
periods 0
of 0
induced 0
severe 0
hypothyroidism 0
in 0
preparation 0
for 0
131I 0
whole 0
body 0
scanning 0
and 0
measurement 0
of 0
serum 0
TG B-gene
. 0

Full 0
thyroid 0
function 0
testing 0
was 0
performed 0
on 0
600 0
randomly 0
selected 0
samples 0
with 0
normal 0
TSH B-gene
values 0
and 0
also 0
on 0
subjects 0
with 0
abnormal 0
TSH B-gene
levels 0
. 0

In 0
a 0
third 0
experiment 0
, 0
crossover 0
AM 0
between 0
dissimilar 0
textures 0
was 0
investigated 0
, 0
and 0
it 0
was 0
found 0
that 0
the 0
more 0
salient 0
textures 0
carried 0
the 0
AM 0
. 0

The 0
relative 0
tumor 0
FDG 0
- 0
uptake 0
( 0
Q 0
- 0
MRGlu 0
) 0
( 0
tumor/contralateral 0
cortex 0
) 0
of 0
all 0
meningiomas 0
was 0
calculated 0
with 0
0.73 0
+/ 0
- 0
0.37 0
( 0
0.24 0
- 0
1.79 0
) 0
. 0

Zatebradine 0
weakly 0
depressed 0
the 0
ectopic 0
ventricular 0
rate 0
but 0
not 0
the 0
arrhythmic 0
ratio 0
of 0
the 0
ventricular 0
arrhythmias 0
induced 0
by 0
two 0
- 0
stage 0
coronary 0
ligation 0
24 0
h 0
after 0
the 0
ligation 0
in 0
conscious 0
dogs 0
. 0

Catha 0
edulis 0
, 0
a 0
plant 0
that 0
has 0
amphetamine 0
effects 0
. 0

The 0
predicted 0
protein 0
, 0
Seb1p B-gene
, 0
consists 0
of 0
82 0
amino 0
acids 0
and 0
contains 0
one 0
potential 0
membrane 0
- 0
spanning 0
region 0
at 0
the 0
C 0
- 0
terminus 0
but 0
no 0
N 0
- 0
terminal 0
signal 0
sequence 0
. 0

The 0
SEB1 B-gene
homologue 0
thus 0
isolated 0
, 0
SEB2 B-gene
, 0
encodes 0
a 0
protein 0
53 0
% 0
identical 0
to 0
Seb1p B-gene
. 0

Nonetheless 0
, 0
that 0
ventricular 0
afferents 0
, 0
in 0
certain 0
special 0
settings 0
, 0
are 0
able 0
to 0
induce 0
e.g 0
. 0
generalised 0
vasodilation 0
and 0
hypotension 0
can 0
not 0
be 0
excluded 0
. 0

Large 0
ones 0
were 0
similar 0
in 0
size 0
to 0
the 0
main 0
lobe 0
and 0
small 0
ones 0
were 0
approximately 0
1/4 0
of 0
the 0
length 0
of 0
the 0
main 0
lobe 0
. 0

Fragments 0
and 0
analogs 0
of 0
the 0
hormone 0
ACTH B-gene
were 0
previously 0
shown 0
to 0
have 0
beneficial 0
effect 0
on 0
the 0
outcome 0
of 0
head 0
injury 0
, 0
while 0
elevated 0
levels 0
of 0
corticosterone 0
( 0
CS 0
) 0
exacerbate 0
it 0
. 0

The 0
most 0
frequent 0
causes 0
of 0
the 0
meningitis 0
was 0
the 0
external 0
ventricular 0
drainage 0
( 0
14.8 0
% 0
) 0
, 0
post 0
- 0
neurosurgical 0
( 0
0.8 0
% 0
) 0
and 0
head 0
injury 0
( 0
0.0007 0
% 0
) 0
. 0

Fifty 0
- 0
one 0
patients 0
with 0
primary 0
refractory 0
or 0
relapsed 0
malignant 0
lymphoma 0
( 0
47 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
and 0
four 0
Hodgkin 0
's 0
disease 0
) 0
were 0
treated 0
with 0
a 0
new 0
chemotherapeutic 0
regimen 0
( 0
cisplatinum 0
, 0
methyl 0
GAG 0
, 0
bleomocyin 0
, 0
methyl 0
prednisolon 0
) 0
. 0

With 0
the 0
increasing 0
use 0
of 0
ACE B-gene
inhibitors 0
, 0
the 0
incidence 0
of 0
rare 0
adverse 0
effects 0
such 0
as 0
potentially 0
lethal 0
pancreatitis 0
is 0
likely 0
to 0
increase 0
. 0

In 0
3 0
treatments 0
the 0
diet 0
was 0
supplemented 0
with 0
0 0
, 0
100 0
and 0
150 0
mg 0
probiotic/kg 0
food 0
. 0

Low 0
- 0
dose 0
aspirin 0
and 0
recurrent 0
miscarriage 0
. 0

Protein 0
films 0
are 0
distinctly 0
different 0
in 0
mechanical 0
profiles 0
from 0
those 0
films 0
made 0
of 0
other 0
materials 0
. 0

Furthermore 0
, 0
cpxA* B-gene
mutations 0
suppress 0
the 0
toxicity 0
conferred 0
by 0
the 0
LamB B-gene
- 0
LacZ B-gene
hybrid 0
protein 0
, 0
which 0
exerts 0
its 0
effects 0
in 0
the 0
cytoplasm 0
, 0
sequestered 0
from 0
DegP B-gene
. 0

The 0
PI3K_68D B-gene
cDNA I-gene
encodes 0
a 0
protein 0
of 0
210 0
kDa 0
, 0
which 0
lacks 0
sequences 0
implicated 0
in 0
linking 0
p110 B-gene
PI B-gene
3 I-gene
- I-gene
kinases I-gene
to 0
p85 B-gene
adaptor I-gene
proteins I-gene
, 0
but 0
contains 0
an 0
amino 0
- 0
terminal 0
proline 0
- 0
rich 0
sequence 0
, 0
which 0
could 0
bind 0
to 0
SH3 B-gene
domains I-gene
, 0
and 0
a 0
carboxy 0
- 0
terminal 0
C2 B-gene
domain 0
. 0

In 0
vitro 0
interaction 0
studies 0
, 0
using 0
proteins 0
fused 0
to 0
glutathione B-gene
- I-gene
S I-gene
- I-gene
transferase I-gene
, 0
showed 0
that 0
RBP B-gene
- I-gene
J I-gene
kappa I-gene
and 0
Su B-gene
( I-gene
H I-gene
) I-gene
bind 0
directly 0
to 0
the 0
RAM23 B-gene
regions I-gene
of 0
mouse B-gene
Notch1 I-gene
and 0
Drosophila B-gene
Notch I-gene
, 0
respectively 0
. 0

AIMS/METHODS 0
: 0
Reticuloendothelial 0
system 0
function 0
, 0
as 0
assessed 0
by 0
clearance 0
of 0
radiolabelled 0
bacteria 0
, 0
was 0
evaluated 0
in 0
acute 0
liver 0
injury 0
induced 0
by 0
D 0
- 0
galactosamine 0
in 0
rats 0
, 0
and 0
compared 0
with 0
that 0
after 0
70 0
% 0
liver 0
resection 0
model 0
. 0

Our 0
laboratory 0
and 0
others 0
have 0
shown 0
alternative 0
splicing 0
of 0
up 0
to 0
ten 0
exons 0
at 0
a 0
discrete 0
extracellular 0
site 0
to 0
be 0
primarily 0
responsible 0
for 0
the 0
generation 0
of 0
CD44 B-gene
variant I-gene
( 0
CD44v B-gene
) 0
isoforms 0
. 0

Study 0
groups 0
were 0
control 0
, 0
and 0
those 0
treated 0
with 0
the 0
alpha1 B-gene
- I-gene
adrenoceptor I-gene
- I-gene
subtype I-gene
blockers 0
WB4101 0
( 0
0.5 0
mg/kg 0
i.v 0
. 0
) 0
or 0
chloroethylclonidine 0
( 0
1.9 0
mg/kg 0
i.v 0
. 0
) 0
. 0

This 0
caused 0
severe 0
cortical 0
damage 0
and 0
neuronal 0
loss 0
in 0
hippocampus 0
subfields 0
CA1 0
, 0
CA3 0
, 0
and 0
hilus 0
. 0

The 0
occurrence 0
of 0
multiple 0
malignancy 0
was 0
studied 0
in 0
674 0
patients 0
with 0
hematologic 0
malignancies 0
who 0
were 0
admitted 0
to 0
this 0
department 0
during 0
the 0
past 0
10 0
years 0
. 0

The 0
upTRE 0
binds 0
more 0
T3R B-gene
homodimers I-gene
and 0
less 0
T3R B-gene
- 0
RXR B-gene
heterodimers 0
than 0
the 0
dnTRE 0
, 0
and 0
T3 0
more 0
readily 0
facilitates 0
heterodimer 0
binding 0
to 0
the 0
dn 0
- 0
than 0
to 0
the 0
upTRE 0
. 0

Transcriptional 0
control 0
of 0
a 0
nuclear 0
gene 0
encoding 0
a 0
mitochondrial 0
fatty 0
acid 0
oxidation 0
enzyme 0
in 0
transgenic 0
mice 0
: 0
role 0
for 0
nuclear 0
receptors 0
in 0
cardiac 0
and 0
brown 0
adipose 0
expression 0
. 0

Hoeben 0
, 0
F.J 0
. 0

Twelve 0
genomic 0
fragments 0
containing 0
novel 0
response 0
elements 0
are 0
described 0
, 0
and 0
the 0
transcription 0
unit 0
associated 0
with 0
one 0
of 0
them 0
, 0
NN B-gene
- I-gene
84AG I-gene
, 0
was 0
characterized 0
in 0
detail 0
. 0

Moreover 0
, 0
glucan B-gene
synthase I-gene
activity 0
, 0
which 0
is 0
activated 0
by 0
Rho1p B-gene
, 0
was 0
significantly 0
reduced 0
in 0
the 0
deltabem4 B-gene
mutant I-gene
. 0

In 0
gel 0
retardation 0
assays 0
, 0
an 0
RCS 0
cell 0
- 0
specific 0
protein 0
and 0
another 0
closely 0
related 0
protein 0
expressed 0
only 0
in 0
RCS 0
cells 0
and 0
primary 0
chondrocytes 0
bound 0
to 0
a 0
10 0
- 0
bp 0
sequence 0
within 0
the 0
18 0
- 0
mer 0
. 0

Two 0
classes 0
of 0
Xanthomonas 0
pathogens 0
evading 0
Bs2 0
host 0
resistance 0
and 0
displaying 0
reduced 0
fitness 0
were 0
found 0
to 0
be 0
specifically 0
mutated 0
in 0
avrBs2 B-gene
. 0

Members 0
of 0
the 0
Ras B-gene
subfamily I-gene
of 0
small B-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
have 0
been 0
shown 0
to 0
be 0
promiscuous 0
towards 0
a 0
variety 0
of 0
putative 0
effector 0
molecules 0
such 0
as 0
the 0
protein B-gene
kinase I-gene
c I-gene
- I-gene
Raf I-gene
and 0
the 0
Ral B-gene
- I-gene
specific I-gene
guanine I-gene
nucleotide I-gene
exchange I-gene
factor I-gene
( 0
Ral B-gene
- I-gene
GEF I-gene
) 0
. 0

Thus 0
, 0
the 0
characterization 0
of 0
the 0
promoter 0
region 0
should 0
help 0
to 0
define 0
regulatory 0
elements 0
that 0
control 0
neuron 0
- 0
specific 0
and 0
developmental 0
expression 0
of 0
the 0
MAP1B B-gene
gene I-gene
. 0

The 0
cDNA 0
encoded 0
a 0
mature 0
protein 0
of 0
240 0
amino 0
acids 0
, 0
including 0
a 0
29 0
- 0
amino 0
acid 0
signal 0
sequence 0
. 0

Mutants 0
lacking 0
the 0
3 0
' 0
stem 0
- 0
loop 0
exhibited 0
a 0
75 0
% 0
reduction 0
in 0
the 0
level 0
of 0
psaB B-gene
mRNA 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
was 0
highly 0
conserved 0
across 0
the 0
wide 0
range 0
of 0
eukaryotes 0
( 0
vertebrates 0
, 0
invertebrates 0
, 0
fungi 0
, 0
plants 0
and 0
protozoa 0
) 0
in 0
which 0
this 0
gene 0
has 0
now 0
been 0
identified 0
. 0

Biol 0
. 0

Semidominant 0
mutations 0
in 0
the 0
yeast B-gene
Rad51 I-gene
protein I-gene
and 0
their 0
relationships 0
with 0
the 0
Srs2 B-gene
helicase I-gene
. 0

Alterations 0
of 0
the 0
5q23 0
- 0
q31 0
interval 0
are 0
frequently 0
observed 0
in 0
myelodysplasia 0
and 0
myeloid 0
leukemia 0
. 0

Previous 0
studies 0
have 0
suggested 0
that 0
the 0
616 0
amino 0
acid 0
, 0
70 B-gene
- I-gene
kDa I-gene
subunit I-gene
of I-gene
RPA I-gene
( 0
RPA B-gene
70 I-gene
) 0
is 0
composed 0
of 0
multiple 0
structural/functional 0
domains 0
. 0

Neurons 0
were 0
held 0
at 0
- 0
67 0
mV 0
to 0
equate 0
voltage 0
- 0
dependent 0
effects 0
. 0

This 0
site 0
acts 0
as 0
a 0
negative 0
element 0
when 0
transferred 0
to 0
the 0
thymidine B-gene
kinase I-gene
promoter I-gene
, 0
but 0
does 0
not 0
confer 0
inducibility 0
. 0

The 0
extent 0
of 0
the 0
fbpA B-gene
operator I-gene
sequence I-gene
( I-gene
42 I-gene
bp I-gene
) I-gene
, 0
as 0
defined 0
by 0
our 0
footprinting 0
analysis 0
, 0
would 0
suggest 0
the 0
binding 0
of 0
two 0
Fur B-gene
repressor I-gene
dimers I-gene
. 0

The 0
structural 0
similarity 0
between 0
Vav B-gene
and 0
other 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factors I-gene
for 0
small B-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
, 0
together 0
with 0
the 0
recent 0
identification 0
of 0
biochemical 0
routes 0
specific 0
for 0
members 0
of 0
the 0
Ras B-gene
and 0
Rho B-gene
family I-gene
of 0
GTPases B-gene
, 0
prompted 0
us 0
to 0
explore 0
whether 0
MAPK B-gene
or 0
JNK B-gene
are 0
downstream 0
components 0
of 0
the 0
Vav B-gene
signaling 0
pathways 0
. 0

CONCLUSION 0
: 0
Twice 0
daily 0
treatment 0
with 0
inhaled 0
fluticasone 0
propionate 0
50 0
micrograms 0
or 0
100 0
micrograms 0
was 0
significantly 0
more 0
effective 0
than 0
theophylline 0
in 0
the 0
treatment 0
of 0
mild 0
- 0
to 0
- 0
moderate 0
asthma 0
. 0

Our 0
results 0
support 0
a 0
model 0
where 0
both 0
E2F B-gene
- 0
and 0
CDE 0
- 0
mediated 0
repression 0
, 0
acting 0
at 0
different 0
stages 0
in 0
the 0
cell 0
cycle 0
, 0
are 0
dependent 0
on 0
promoter 0
- 0
specific 0
CHR 0
elements 0
. 0

The 0
cDNA 0
clone 0
was 0
used 0
as 0
a 0
homologous 0
probe 0
to 0
isolate 0
a 0
truncated 0
genomic 0
clone 0
encoding 0
H2A1 B-gene
. 0

Comparison 0
of 0
the 0
deduced 0
amino 0
acid 0
sequences 0
with 0
protein 0
sequences 0
of 0
T. 0
pyriformis 0
H2As B-gene
showed 0
only 0
two 0
and 0
three 0
differences 0
respectively 0
, 0
in 0
a 0
total 0
of 0
137 0
amino 0
acids 0
for 0
H2A1 B-gene
, 0
and 0
132 0
amino 0
acids 0
for 0
H2A2 B-gene
, 0
indicating 0
the 0
two 0
genes 0
arose 0
before 0
the 0
divergence 0
of 0
these 0
two 0
species 0
. 0

Cognitive 0
visual 0
dysfunction 0
in 0
a 0
child 0
with 0
cerebral 0
damage 0
. 0

Interaction 0
was 0
apparently 0
determined 0
by 0
the 0
N 0
- 0
terminal 0
splice 0
region 0
of 0
RPDE B-gene
- I-gene
6 I-gene
, 0
as 0
the 0
PDE4A B-gene
splice 0
variant 0
RPDE B-gene
- I-gene
39 I-gene
, 0
which 0
differs 0
from 0
RPDE B-gene
- I-gene
6 I-gene
at 0
the 0
extreme 0
N 0
- 0
terminus 0
, 0
failed 0
to 0
associate 0
with 0
v B-gene
- I-gene
Src I-gene
- 0
SH3 B-gene
; 0
met26RD1 B-gene
( 0
where 0
RD1 B-gene
is 0
rat B-gene
'dunc I-gene
- I-gene
like I-gene
' I-gene
PDE I-gene
) 0
, 0
which 0
has 0
the 0
N 0
- 0
terminal 0
splice 0
region 0
deleted 0
, 0
failed 0
to 0
associate 0
with 0
v B-gene
- I-gene
Src I-gene
- 0
SH3 B-gene
, 0
and 0
the 0
association 0
of 0
RPDE B-gene
- I-gene
6 I-gene
and 0
v B-gene
- I-gene
Src I-gene
- 0
SH3 B-gene
was 0
blocked 0
by 0
a 0
fusion 0
protein 0
formed 0
from 0
the 0
N 0
- 0
terminal 0
splice 0
region 0
. 0

Potentially 0
load 0
- 0
insensitive 0
measures 0
of 0
ventricular 0
performance 0
were 0
therefore 0
evaluated 0
in 0
10 0
open 0
- 0
and 0
closed 0
- 0
chested 0
, 0
anesthetized 0
rabbits 0
. 0

Large 0
strain 0
differences 0
were 0
found 0
for 0
all 0
variables 0
recorded 0
, 0
i.e. 0
, 0
the 0
proportion 0
of 0
attacking 0
males 0
, 0
the 0
time 0
spent 0
in 0
the 0
brightly 0
lit 0
box 0
, 0
and 0
the 0
number 0
of 0
transitions 0
between 0
the 0
lit 0
and 0
the 0
dark 0
boxes 0
. 0

The 0
effect 0
of 0
ligustrazine 0
hydrochloride 0
( 0
LTH 0
) 0
on 0
depressing 0
pulmonary 0
artery 0
hypertension 0
has 0
been 0
proved 0
in 0
recent 0
studies 0
. 0

It 0
is 0
the 0
oxidation 0
peak 0
of 0
this 0
product 0
, 0
arising 0
in 0
acidic 0
media 0
at 0
0.42 0
V 0
, 0
which 0
was 0
analysed 0
using 0
DPV 0
, 0
again 0
following 0
the 0
accumulation 0
of 0
clenbuterol 0
at 0
the 0
Nafion 0
- 0
modified 0
CPE 0
. 0

Phenylephrine 0
is 0
a 0
pure 0
alpha B-gene
- I-gene
1 I-gene
adrenoreceptor I-gene
agonist 0
known 0
to 0
produce 0
marked 0
systemic 0
vasoconstriction 0
and 0
associated 0
hypertension 0
with 0
occasional 0
profound 0
reflex 0
bradycardia 0
. 0

The 0
expression 0
of 0
the 0
first 0
two 0
genes 0
located 0
in 0
this 0
unit 0
( 0
c B-gene
- I-gene
gvpD I-gene
and 0
c B-gene
- I-gene
gvpE I-gene
) 0
was 0
also 0
monitored 0
by 0
Western 0
blot 0
( 0
immunoblot 0
) 0
analyses 0
using 0
antisera 0
raised 0
against 0
these 0
proteins 0
synthesized 0
in 0
Escherichia 0
coli 0
. 0

One 0
unit 0
encodes 0
traA B-gene
, 0
traF B-gene
, 0
and 0
traB B-gene
, 0
while 0
the 0
second 0
encodes 0
traC B-gene
, 0
traD B-gene
, 0
and 0
traG B-gene
. 0

A 0
. 0

In 0
an 0
effort 0
to 0
isolate 0
genes 0
with 0
down 0
- 0
regulated 0
expression 0
at 0
the 0
mRNA 0
level 0
during 0
oncogenic 0
transformation 0
of 0
human 0
mammary 0
epithelial 0
cells 0
( 0
MECs 0
) 0
, 0
we 0
performed 0
subtractive 0
hybridization 0
between 0
normal 0
MEC 0
strain 0
76N 0
and 0
its 0
radiation 0
- 0
transformed 0
tumorigenic 0
derivative 0
76R 0
- 0
30 0
. 0

CASE 0
REPORT 0
: 0
Referred 0
because 0
of 0
a 0
right 0
corneal 0
perforation 0
with 0
cellular 0
reaction 0
in 0
anterior 0
chamber 0
, 0
a 0
patient 0
was 0
sutured 0
and 0
treated 0
with 0
a 0
single 0
intravitreal 0
injection 0
of 0
0.2 0
ml 0
( 0
1 0
mg 0
) 0
Amikacin 0
and 0
0.2 0
ml 0
( 0
1 0
mg 0
) 0
Vancomycin 0
. 0

In 0
the 0
same 0
period 0
we 0
pointed 0
out 0
an 0
increase 0
of 0
hematocrit 0
( 0
from 0
29 0
% 0
to 0
35 0
% 0
) 0
and 0
of 0
the 0
Hb B-gene
( 0
from 0
9.3 0
to 0
11.2 0
g/dl 0
) 0
. 0

The 0
P B-gene
- I-gene
wr I-gene
and 0
P B-gene
- I-gene
rr I-gene
cDNA I-gene
sequences I-gene
are 0
very 0
similar 0
in 0
their 0
5 0
' 0
regions 0
. 0

Because 0
the 0
hcf109 B-gene
locus I-gene
was 0
mapped 0
at 0
a 0
distance 0
< 0
0.1 0
centimorgans 0
from 0
the 0
phytochrome B-gene
C I-gene
gene I-gene
, 0
its 0
molecular 0
characterization 0
by 0
positional 0
cloning 0
is 0
possible 0
. 0

The 0
human B-gene
MSH I-gene
- I-gene
2 I-gene
gene I-gene
product I-gene
is 0
a 0
member 0
of 0
a 0
highly 0
conserved 0
family 0
of 0
proteins 0
which 0
are 0
involved 0
in 0
post 0
- 0
replication 0
mismatch 0
repair 0
. 0
hMSH B-gene
- I-gene
2 I-gene
is 0
homologous 0
to 0
Escherichia 0
coli 0
( 0
E. 0
coli 0
) 0
MutS B-gene
and 0
Sacchromyces B-gene
cerevisiae I-gene
MSH I-gene
- I-gene
1 I-gene
and 0
MSH B-gene
- I-gene
2 I-gene
proteins I-gene
, 0
which 0
recognise 0
heteroduplex 0
DNA 0
at 0
the 0
sites 0
of 0
all 0
single 0
base 0
mismatches 0
and 0
deletions 0
or 0
insertions 0
up 0
to 0
4 0
base 0
pairs 0
. 0
hMSH B-gene
- I-gene
2 I-gene
is 0
one 0
of 0
the 0
hereditary B-gene
non I-gene
- I-gene
polyposis I-gene
colorectal I-gene
cancer I-gene
( I-gene
HNPCC I-gene
) I-gene
tumor I-gene
suppressor I-gene
genes I-gene
, 0
and 0
maps 0
to 0
human 0
chromosome 0
2p16 0
. 0

We 0
have 0
recently 0
shown 0
that 0
the 0
tissue 0
- 0
specific 0
expression 0
of 0
the 0
RAR B-gene
beta I-gene
2 I-gene
gene I-gene
in I-gene
mouse I-gene
embryos I-gene
is 0
regulated 0
at 0
the 0
translational 0
level 0
by 0
short 0
upstream 0
open 0
reading 0
frames 0
( 0
uORFs 0
) 0
In 0
the 0
5' 0
- 0
untranslated 0
region 0
( 0
Zimmer 0
, 0
A. 0
, 0
A.M 0
. 0

We 0
have 0
previously 0
isolated 0
a 0
cDNA 0
for 0
a 0
transcription 0
factor 0
referred 0
to 0
as 0
Zfhep B-gene
( 0
zinc B-gene
finger I-gene
homeodomain I-gene
enhancer I-gene
- I-gene
binding I-gene
protein I-gene
) 0
containing 0
two 0
separate 0
zinc 0
finger 0
domains 0
, 0
ZD1 B-gene
and 0
ZD2 B-gene
, 0
each 0
of 0
which 0
binds 0
DNA 0
, 0
and 0
a 0
homeodomain 0
. 0

The 0
structure 0
of 0
these 0
genes 0
suggests 0
a 0
common 0
ancestor 0
for 0
all 0
viperid B-gene
PLA2 I-gene
genes I-gene
. 0

Increased 0
PTHRP B-gene
production 0
by 0
a 0
tyrosine B-gene
kinase I-gene
oncogene I-gene
, 0
Tpr B-gene
- I-gene
Met I-gene
: 0
role 0
of 0
the 0
Ras B-gene
signaling 0
pathway 0
. 0

Subsequent 0
to 0
their 0
secretion 0
, 0
the 0
IGF B-gene
- I-gene
II I-gene
in 0
xz97 0
and 0
G11 0
cells 0
accumulated 0
in 0
the 0
conditioned 0
medium 0
mostly 0
as 0
two 0
partially 0
processed 0
species 0
with 0
appMr 0
, 0
of 0
17K 0
and 0
14K 0
, 0
respectively 0
. 0

Paradoxically 0
, 0
coexpression 0
of 0
the 0
transcriptionally 0
inactive 0
, 0
amino 0
- 0
terminally 0
deleted 0
IDX B-gene
- I-gene
1 I-gene
mutant I-gene
proteins I-gene
, 0
either 0
with 0
the 0
wild B-gene
- I-gene
type I-gene
IDX I-gene
- I-gene
1 I-gene
or 0
with 0
themselves 0
, 0
results 0
in 0
a 0
marked 0
enhancement 0
of 0
transactivation 0
of 0
the 0
transcriptional 0
TAAT B-gene
- I-gene
1 I-gene
element I-gene
reporter I-gene
. 0

All 0
patients 0
had 0
abnormal 0
von B-gene
Willebrand I-gene
factor I-gene
( 0
vWF B-gene
) 0
fragmentation 0
as 0
reflected 0
by 0
decreased 0
high 0
molecular 0
weight 0
and 0
increased 0
low 0
molecular 0
weight 0
vWF B-gene
multimers I-gene
in 0
the 0
circulation 0
. 0

In 0
an 0
attempt 0
to 0
investigate 0
whether 0
the 0
intergenic 0
region 0
between 0
the 0
oleosin B-gene
and 0
a 0
second 0
open 0
reading 0
frame 0
( 0
ORFII 0
) 0
in 0
Brassica 0
napus 0
( 0
L. 0
) 0
is 0
a 0
divergent 0
promoter 0
, 0
and 0
also 0
to 0
characterize 0
the 0
ORFII B-gene
, 0
cDNA B-gene
clones I-gene
homologous I-gene
to I-gene
ORFII I-gene
were 0
isolated 0
from 0
a 0
leaf 0
cDNA 0
library 0
. 0

The 0
ORFII B-gene
gene I-gene
product I-gene
is 0
targeted 0
to 0
the 0
chloroplast 0
, 0
which 0
is 0
consistent 0
with 0
previous 0
data 0
indicating 0
the 0
presence 0
of 0
PMSR B-gene
activity 0
in 0
the 0
chloroplast 0
. 0

Characterization 0
of 0
LRP B-gene
, 0
a 0
leucine B-gene
- I-gene
rich I-gene
repeat I-gene
( I-gene
LRR I-gene
) I-gene
protein I-gene
from I-gene
tomato I-gene
plants I-gene
that 0
is 0
processed 0
during 0
pathogenesis 0
. 0

To 0
test 0
whether 0
Sp1 B-gene
and 0
zif268/egr B-gene
zif268/egr I-gene
- I-gene
1 I-gene
interact 0
with 0
this 0
motif 0
, 0
gel 0
retardation 0
assays 0
were 0
performed 0
. 0

OBJECTIVES 0
: 0
The 0
aim 0
of 0
the 0
study 0
was 0
to 0
analyze 0
the 0
clinical 0
characteristics 0
, 0
treatment 0
and 0
outcome 0
of 0
310 0
patients 0
with 0
hydatidiform 0
mole 0
. 0

Stably 0
transfected 0
human 0
kidney 0
293 0
cells 0
expressing 0
the 0
wild B-gene
type I-gene
rat I-gene
LH/CG I-gene
receptor I-gene
( 0
rLHR B-gene
) 0
or 0
receptors 0
with 0
C 0
- 0
terminal 0
tails 0
truncated 0
at 0
residues 0
653 0
, 0
631 0
, 0
or 0
628 0
( 0
designated 0
rLHR B-gene
- I-gene
t653 I-gene
, 0
rLHR B-gene
- I-gene
t631 I-gene
, 0
and 0
rLHR B-gene
- I-gene
t628 I-gene
) 0
were 0
used 0
to 0
probe 0
the 0
importance 0
of 0
this 0
region 0
on 0
the 0
regulation 0
of 0
hormonal 0
responsiveness 0
. 0

Are 0
low 0
P300 0
amplitudes 0
a 0
marker 0
for 0
schizophrenia 0
. 0

Sleep 0
was 0
determined 0
again 0
for 0
an 0
additional 0
3 0
days 0
and 0
6 0
hours 0
. 0

The 0
patients 0
are 0
two 0
healthy 0
adult 0
males 0
. 0

Chloroplast B-gene
mutator I-gene
( 0
chm B-gene
) 0
of 0
Arabidopsis 0
is 0
a 0
recessive 0
nuclear 0
mutation 0
that 0
causes 0
green 0
and 0
white 0
variegation 0
in 0
leaves 0
and 0
is 0
inherited 0
in 0
a 0
non 0
- 0
Mendelian 0
fashion 0
. 0

Indoor 0
concentrations 0
were 0
only 0
weakly 0
correlated 0
with 0
outdoor 0
concentrations 0
, 0
however 0
, 0
and 0
personal 0
exposures 0
were 0
even 0
more 0
poorly 0
correlated 0
with 0
outdoor 0
concentrations 0
. 0

A 0
neuropsychological 0
test 0
battery 0
was 0
used 0
that 0
contained 0
the 0
Wisconsin 0
card 0
sorting 0
test 0
, 0
Street 0
completion 0
test 0
, 0
Stroop 0
test 0
, 0
a 0
dichotic 0
memory 0
listening 0
test 0
, 0
and 0
a 0
facial 0
recognition 0
test 0
. 0

We 0
present 0
this 0
case 0
because 0
of 0
the 0
rarity 0
of 0
left 0
ventricular 0
involvement 0
associated 0
with 0
ARVD 0
. 0

In 0
a 0
randomized 0
single 0
- 0
blind 0
3 0
x 0
3 0
Latin 0
- 0
square 0
study 0
with 0
corrections 0
for 0
any 0
carryover 0
effects 0
, 0
27 0
males 0
and 0
30 0
females 0
consumed 0
supplements 0
containing 0
glucose 0
or 0
resistant 0
starch 0
( 0
RS 0
) 0
from 0
raw 0
high 0
- 0
amylose 0
cornstarch 0
( 0
RS2 0
) 0
or 0
from 0
retrograded 0
high 0
- 0
amylose 0
cornstarch 0
( 0
RS3 0
) 0
. 0

The 0
5 0
' 0
flanking 0
region 0
of 0
the 0
mouse B-gene
Met I-gene
- I-gene
ase I-gene
- I-gene
1 I-gene
gene I-gene
also 0
shares 0
considerable 0
regions 0
of 0
identity 0
with 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
rat B-gene
Met I-gene
- I-gene
ase I-gene
- I-gene
1 I-gene
gene I-gene
. 0

The 0
[ 0
18F 0
] 0
FMISO 0
TMRR 0
is 0
a 0
simple 0
and 0
clinically 0
useful 0
index 0
for 0
detecting 0
tumour 0
hypoxia 0
in 0
NPC 0
. 0

Improved 0
methods 0
have 0
been 0
developed 0
for 0
maintaining 0
and 0
breeding 0
the 0
neotropical 0
short 0
- 0
tailed 0
fruit 0
bat 0
, 0
Carollia 0
perspicillata 0
, 0
in 0
an 0
easily 0
- 0
reproduced 0
, 0
laboratory 0
setting 0
. 0

In 0
addition 0
, 0
the 0
time 0
to 0
engraftment 0
was 0
significantly 0
shorter 0
in 0
the 0
amifostine 0
arm 0
in 0
both 0
cohorts 0
. 0

Also 0
like 0
the 0
thrombin B-gene
receptor I-gene
, 0
PAR2 B-gene
can 0
be 0
activated 0
by 0
the 0
hexapeptide 0
corresponding 0
to 0
its 0
tethered 0
ligand 0
sequence 0
independent 0
of 0
receptor 0
cleavage 0
. 0

We 0
conclude 0
that 0
CPET 0
is 0
a 0
useful 0
investigation 0
in 0
the 0
management 0
of 0
patients 0
with 0
cardiopulmonary 0
disease 0
and 0
complements 0
the 0
various 0
other 0
investigations 0
offered 0
by 0
a 0
pulmonary 0
function 0
laboratory 0
. 0

Using 0
fluorescence 0
in 0
situ 0
hybridization 0
, 0
we 0
mapped 0
the 0
chromosome 0
- 0
17 0
breakpoint 0
in 0
a 0
patient 0
with 0
acampomelic 0
CMPD 0
and 0
sex 0
reversal 0
, 0
who 0
carries 0
a 0
de 0
novo 0
constitutional 0
t 0
( 0
12 0
; 0
17 0
) 0
translocation 0
, 0
between 0
two 0
known 0
cosmid 0
markers 0
in 0
the 0
17q24 0
- 0
q25 0
region 0
. 0

This 0
is 0
concluded 0
from 0
the 0
isolation 0
of 0
cDNAs 0
from 0
spinach 0
( 0
Spinacia 0
oleracea 0
) 0
and 0
barley 0
( 0
Hordeum 0
vulgare 0
cv 0
. 0

The 0
data 0
presented 0
in 0
this 0
work 0
indicate 0
that 0
thi1 B-gene
may 0
also 0
be 0
involved 0
in 0
DNA 0
damage 0
tolerance 0
in 0
plant 0
cells 0
. 0

In 0
the 0
rat B-gene
rnu I-gene
allele I-gene
described 0
here 0
, 0
a 0
nonsense 0
mutation 0
in 0
exon 0
8 0
of 0
the 0
whn B-gene
gene I-gene
was 0
identified 0
. 0

Such 0
an 0
increase 0
in 0
the 0
steady 0
- 0
state 0
testicular B-gene
TIMP I-gene
- I-gene
2 I-gene
mRNA I-gene
level 0
apparently 0
is 0
not 0
the 0
result 0
of 0
an 0
up 0
- 0
regulation 0
by 0
germ 0
cells 0
because 0
germ 0
cells 0
cocultured 0
with 0
Sertoli 0
cells 0
failed 0
to 0
elicit 0
an 0
increase 0
in 0
the 0
Sertoli 0
cell 0
steady 0
- 0
state 0
TIMP B-gene
- I-gene
2 I-gene
mRNA I-gene
level 0
. 0

Control 0
intact 0
rats 0
were 0
age 0
- 0
matched 0
to 0
the 0
different 0
treated 0
groups 0
. 0

DESIGN 0
: 0
A 0
cross 0
- 0
sectional 0
study 0
. 0

In 0
the 0
SPK 0
and 0
PTA 0
category 0
, 0
anti 0
- 0
T 0
- 0
cell 0
therapy 0
significantly 0
lowered 0
the 0
risk 0
of 0
graft 0
loss 0
. 0

We 0
have 0
identified 0
a 0
strong 0
Tas B-gene
- I-gene
responsive I-gene
element I-gene
, 0
designated 0
TRE B-gene
( 0
GP B-gene
) 0
, 0
near 0
the 0
3 0
' 0
end 0
of 0
the 0
gag B-gene
gene I-gene
and 0
preceding 0
the 0
pol B-gene
gene I-gene
of 0
SFV 0
- 0
1 0
. 0

Although 0
the 0
binding 0
of 0
IE2 B-gene
86 I-gene
to 0
nonphosphorylated 0
full B-gene
- I-gene
length I-gene
CREB I-gene
or 0
deltaCREB B-gene
is 0
minimal 0
, 0
IE2 B-gene
86 I-gene
does 0
form 0
complexes 0
with 0
p300 B-gene
and 0
the 0
CREB B-gene
- I-gene
binding I-gene
protein I-gene
( 0
CBP B-gene
) 0
, 0
which 0
in 0
turn 0
bind 0
to 0
CREB B-gene
and 0
can 0
serve 0
as 0
adaptor 0
proteins 0
for 0
CREB B-gene
function 0
. 0

A 0
transgenic 0
complementation 0
assay 0
was 0
used 0
to 0
test 0
whether 0
NIa B-gene
supplied 0
in 0
trans 0
could 0
rescue 0
amplification 0
- 0
defective 0
viral 0
genomes 0
encoding 0
altered 0
NIa B-gene
proteins I-gene
. 0

On 0
the 0
basis 0
of 0
its 0
bZIP 0
structural 0
homology 0
, 0
meq B-gene
is 0
perhaps 0
the 0
only 0
member 0
of 0
the 0
jun B-gene
- 0
fos B-gene
gene 0
family 0
completely 0
viral 0
in 0
origin 0
. 0

The 0
rCBF 0
and 0
vasomotion 0
were 0
recorded 0
by 0
laser 0
- 0
doppler 0
fluxmetry 0
. 0

Although 0
basal 0
vessels 0
may 0
constrict 0
distal 0
parenchymal 0
vessels 0
tend 0
to 0
dilate 0
after 0
SAH 0
. 0

The 0
triple 0
combination 0
of 0
nizatidine 0
, 0
clarithromycin 0
, 0
and 0
bismuth 0
subcitrate 0
resulted 0
in 0
an 0
ulcer 0
healing 0
rate 0
of 0
98 0
% 0
and 0
an 0
H. 0
pylori 0
eradication 0
rate 0
of 0
90 0
% 0
. 0

Several 0
lines 0
of 0
evidence 0
presented 0
here 0
suggest 0
that 0
PKC B-gene
- I-gene
zeta I-gene
plays 0
a 0
role 0
in 0
alpha B-gene
2 I-gene
integrin I-gene
gene I-gene
expression 0
. 0

Plasma 0
thrombomodulin B-gene
: 0
a 0
marker 0
for 0
microvascular 0
complications 0
in 0
diabetes 0
mellitus 0
. 0

Update 0
: 0
diphtheria 0
epidemic 0
in 0
the 0
newly 0
independent 0
states 0
of 0
the 0
former 0
USSR 0
, 0
January 0
1995 0
- 0
March 0
1996 0
. 0

The 0
characterization 0
of 0
the 0
promoter 0
region 0
indicated 0
that 0
three 0
distinct 0
regulatory 0
elements 0
corresponding 0
to 0
an 0
AP B-gene
- I-gene
1 I-gene
binding I-gene
site I-gene
( 0
or 0
TRE 0
) 0
, 0
a 0
PRDII/kappaB B-gene
domain 0
, 0
and 0
a 0
CAAT 0
box 0
are 0
involved 0
in 0
the 0
activation 0
by 0
PRDII/kappaB I-gene

Serine 0
528 0
is 0
phosphorylated 0
in 0
vivo 0
in 0
several 0
cell 0
lines 0
, 0
and 0
substitution 0
of 0
serine 0
528 0
to 0
alanine 0
( 0
S528A 0
) 0
resulted 0
in 0
an 0
increased 0
ability 0
of 0
Myb B-gene
to 0
transactivate 0
a 0
synthetic 0
promoter 0
containing 0
five 0
copies 0
of 0
the 0
mim B-gene
- I-gene
1A I-gene
Myb B-gene
- 0
responsive 0
element 0
and 0
a 0
minimal 0
herpes B-gene
tk I-gene
promoter I-gene
. 0

The 0
DNA 0
binding 0
and 0
multimerization 0
activities 0
of 0
c B-gene
- I-gene
Myb I-gene
appear 0
to 0
be 0
unaffected 0
by 0
the 0
S528A 0
substitution 0
, 0
suggesting 0
that 0
phosphorylation 0
of 0
serine 0
528 0
may 0
mediate 0
its 0
effect 0
on 0
the 0
transcription 0
transactivating 0
activity 0
of 0
c B-gene
- I-gene
Myb I-gene
by 0
regulating 0
interactions 0
with 0
other 0
proteins 0
. 0

The 0
amount 0
of 0
these 0
factors 0
was 0
reduced 0
in 0
GEO 0
cells 0
in 0
which 0
the 0
u B-gene
- I-gene
PAR I-gene
gene I-gene
is 0
only 0
weakly 0
transcriptionally 0
activated 0
. 0

PIP2 0
, 0
when 0
incorporated 0
into 0
phosphatidylcholine 0
carrier 0
vesicles 0
, 0
binds 0
tightly 0
to 0
the 0
guanine 0
nucleotide 0
- 0
depleted 0
form 0
of 0
Cdc42Hs B-gene
and 0
weakly 0
to 0
the 0
GDP 0
- 0
bound 0
form 0
of 0
the 0
GTP B-gene
- I-gene
binding I-gene
protein I-gene
but 0
does 0
not 0
bind 0
to 0
GTP 0
- 0
bound 0
Cdc42Hs B-gene
, 0
similar 0
to 0
what 0
was 0
observed 0
for 0
the 0
Dbl B-gene
oncoprotein I-gene
. 0

Purified 0
spleen 0
GAP B-gene
accelerated 0
hydrolysis 0
of 0
GTP 0
bound 0
to 0
recombinant B-gene
ARF1 I-gene
, 0
ARF3 B-gene
, 0
ARF5 B-gene
, 0
and 0
ARF6 B-gene
; 0
no 0
effect 0
of 0
NH2 0
- 0
terminal 0
myristoylation 0
was 0
observed 0
. 0

Biol 0
. 0

A 0
novel 0
phosphotyrosine 0
- 0
binding 0
domain 0
in 0
the 0
N 0
- 0
terminal 0
transforming 0
region 0
of 0
Cbl B-gene
interacts 0
directly 0
and 0
selectively 0
with 0
ZAP B-gene
- I-gene
70 I-gene
in 0
T 0
cells 0
. 0

Cys 0
- 0
757 0
within 0
the 0
( 0
Fe4S4 0
) 0
- 0
siroheme 0
- 0
binding 0
domain 0
was 0
essential 0
for 0
native 0
enzyme 0
activity 0
. 0

Its 0
transcription 0
has 0
been 0
shown 0
to 0
be 0
induced 0
40 0
- 0
50 0
- 0
fold 0
in 0
response 0
to 0
oxygen 0
or 0
heme 0
deficiency 0
, 0
in 0
part 0
through 0
relief 0
of 0
repression 0
exerted 0
by 0
Rox1p B-gene
and 0
in 0
part 0
by 0
activation 0
mediated 0
by 0
an 0
upstream 0
activation 0
sequence 0
( 0
UAS 0
) 0
. 0

Altogether 0
, 0
our 0
results 0
indicate 0
that 0
the 0
transcriptional 0
activity 0
of 0
Cut B-gene
proteins I-gene
is 0
modulated 0
by 0
PKC B-gene
. 0

Lck B-gene
has 0
been 0
postulated 0
to 0
dimerize 0
through 0
the 0
SH2 B-gene
and 0
SH3 B-gene
domains I-gene
. 0

Furthermore 0
, 0
freezing 0
in 0
the 0
presence 0
of 0
bovine B-gene
lactalbumin I-gene
resulted 0
in 0
a 0
good 0
maintenance 0
of 0
the 0
cellular 0
viability 0
and 0
of 0
the 0
CCCD 0
heterogeneity 0
in 0
respect 0
to 0
fresh 0
cells 0
. 0

Myelomatous 0
pleural 0
effusion 0
as 0
presentation 0
form 0
of 0
multiple 0
myeloma 0

Five 0
- 0
year 0
survivals 0
amounted 0
to 0
100 0
% 0
, 0
86.2 0
% 0
, 0
59.4 0
% 0
, 0
29.8 0
% 0
, 0
and 0
20 0
% 0
for 0
stages 0
I 0
, 0
II 0
, 0
III 0
, 0
IVA 0
and 0
IVB 0
respectively 0
. 0

The 0
presence 0
of 0
unidentified 0
macroscopic 0
or 0
microscopic 0
clusters 0
of 0
neoplastic 0
cells 0
, 0
lying 0
around 0
, 0
more 0
or 0
less 0
close 0
to 0
, 0
the 0
line 0
of 0
insertion 0
of 0
lesion 0
, 0
could 0
render 0
any 0
attempt 0
to 0
gain 0
a 0
`` 0
radical 0
'' 0
excision 0
useless 0
. 0

The 0
partial 0
categories 0
of 0
the 0
SIP 0
that 0
were 0
more 0
affected 0
were 0
work 0
, 0
recreation 0
and 0
pastimes 0
, 0
home 0
management 0
, 0
and 0
sleep 0
and 0
rest 0
. 0

Northern 0
blot 0
analysis 0
, 0
using 0
the 0
Ltp4 B-gene
- 0
specific 0
probe 0
, 0
indicated 0
that 0
Xanthomonas 0
campestris 0
pv 0
. 0
translucens 0
induced 0
an 0
increase 0
over 0
basal 0
levels 0
of 0
Ltp4 B-gene
mRNA I-gene
, 0
while 0
Pseudomonas 0
syringae 0
pv 0
. 0
japonica 0
caused 0
a 0
decrease 0
. 0

Targeted 0
disruption 0
of 0
the 0
OGG1 B-gene
gene I-gene
in 0
yeast 0
revealed 0
a 0
second 0
OG B-gene
glycosylase/lyase I-gene
protein I-gene
, 0
tentatively 0
named 0
Ogg2 B-gene
, 0
which 0
differs 0
from 0
Ogg1 B-gene
in 0
that 0
it 0
preferentially 0
acts 0
on 0
OG 0
: 0
G 0
. 0

Furthermore 0
, 0
the 0
use 0
of 0
zero 0
- 0
loss 0
filtering 0
in 0
combination 0
with 0
exit 0
wavefront 0
reconstruction 0
is 0
considerably 0
more 0
effective 0
at 0
removing 0
the 0
effects 0
of 0
multiple 0
elastic 0
and 0
inelastic 0
scattering 0
and 0
microscope 0
objective 0
lens 0
aberrations 0
than 0
either 0
technique 0
by 0
itself 0
. 0

Transcripts 0
for 0
both 0
ODV B-gene
- I-gene
E18 I-gene
and 0
ODV B-gene
- I-gene
EC27 I-gene
initiate 0
from 0
conserved 0
TAAG 0
motifs 0
, 0
and 0
transcripts 0
are 0
detected 0
from 0
16 0
through 0
72 0
hr 0
p.i 0
. 0

In 0
order 0
to 0
determine 0
which 0
sequences 0
in 0
the 0
GATA B-gene
- I-gene
1 I-gene
promoter I-gene
are 0
crucial 0
for 0
activation 0
by 0
the 0
ME26 B-gene
viral I-gene
protein I-gene
, 0
we 0
made 0
deletions 0
of 0
the 0
promoter 0
, 0
cloned 0
them 0
into 0
a 0
luciferase B-gene
expression 0
vector 0
and 0
tested 0
their 0
activity 0
in 0
mouse 0
fibroblasts 0
, 0
which 0
do 0
not 0
express 0
GATA B-gene
- I-gene
1 I-gene
. 0

Sequence 0
analysis 0
of 0
the 0
isolated 0
genomic 0
clone 0
revealed 0
that 0
the 0
DNA 0
binding 0
domain 0
of 0
this 0
orphan 0
receptor 0
is 0
most 0
homologous 0
to 0
the 0
human B-gene
TR2 I-gene
receptor I-gene
. 0

Genomic 0
DNA 0
hybridization 0
suggests 0
that 0
SpSHR2 B-gene
is 0
a 0
single 0
- 0
copy 0
gene 0
in 0
the 0
S. 0
purpuratus 0
genome 0
. 0

A 0
3 0
- 0
yr 0
retrospective 0
review 0
is 0
effective 0
and 0
detects 0
94 0
% 0
of 0
the 0
undercalls 0
. 0

Isolation 0
and 0
identification 0
of 0
genes 0
activating 0
UAS2 B-gene
- I-gene
dependent I-gene
ADH2 I-gene
expression 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

METHODS 0
AND 0
RESULTS 0
: 0
A 0
64 0
- 0
year 0
- 0
old 0
woman 0
with 0
confirmed 0
AV 0
nodal 0
reentrant 0
tachycardia 0
underwent 0
a 0
successful 0
`` 0
slow 0
pathway 0
'' 0
AV 0
modification 0
with 0
a 0
single 0
radiofrequency 0
application 0
. 0

Patients 0
with 0
low 0
probability 0
of 0
having 0
aluminum 0
overload 0
( 0
serum 0
iron 0
levels 0
< 0
40 0
micrograms/L 0
and 0
DAI 0
< 0
150 0
micrograms/L 0
) 0
had 0
significantly 0
higher 0
values 0
of 0
serum 0
iron 0
, 0
iron 0
transferrin B-gene
saturation 0
, 0
and 0
serum B-gene
ferritin I-gene
levels 0
compared 0
with 0
those 0
patients 0
with 0
a 0
high 0
probability 0
of 0
having 0
aluminum 0
overload 0
( 0
serum 0
aluminum 0
levels 0
> 0
40 0
micrograms/L 0
and 0
DAI 0
> 0
150 0
micrograms/L 0
) 0
. 0

Although 0
the 0
RAD23 B-gene
equivalents 0
are 0
well 0
conserved 0
during 0
evolution 0
, 0
the 0
mammalian 0
genes 0
did 0
not 0
express 0
the 0
UV 0
- 0
inducible 0
phenotype 0
of 0
their 0
yeast 0
counterpart 0
. 0

Ha B-gene
- I-gene
RasV12 I-gene
and 0
activated 0
proteins 0
in 0
both 0
the 0
extra B-gene
- I-gene
cellular I-gene
regulated I-gene
kinase I-gene
( 0
ERK B-gene
) 0
and 0
the 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
SAPK B-gene
) 0
or 0
Jun B-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
( 0
JNK B-gene
) 0
cascades 0
independently 0
stimulated 0
PEA3 B-gene
- 0
mediated 0
gene 0
expression 0
. 0

Sequence 0
analysis 0
of 0
reverse 0
transcribed 0
, 0
amplified 0
cDNA 0
generated 0
from 0
total 0
RNA 0
isolated 0
from 0
transfected 0
cells 0
demonstrated 0
the 0
presence 0
of 0
abnormally 0
spliced 0
products 0
containing 0
13 0
and 0
78 0
additional 0
bases 0
as 0
well 0
as 0
the 0
accumulation 0
of 0
unspliced 0
mRNA 0
. 0

Its 0
hydropathy 0
profile 0
predicts 0
seven 0
transmembrane 0
spans 0
and 0
a 0
hydrophilic 0
amino 0
terminus 0
of 0
approximately 0
100 0
residues 0
, 0
and 0
it 0
suggests 0
the 0
presence 0
of 0
an 0
amphiphilic 0
alpha 0
- 0
helix 0
( 0
L 0
- 0
61 0
to 0
F 0
- 0
97 0
) 0
in 0
close 0
proximity 0
to 0
the 0
first 0
strongly 0
hydrophobic 0
segment 0
of 0
ProW B-gene
. 0

A 0
1.5 0
- 0
kb 0
HindIII B-gene
genomic 0
fragment 0
carrying 0
the 0
vspA B-gene
gene 0
from 0
M. 0
bovis 0
PG45 0
was 0
cloned 0
and 0
sequenced 0
. 0

Carbon 0
catabolite 0
repression 0
of 0
the 0
gnt B-gene
operon I-gene
of I-gene
Bacillus I-gene
subtilis I-gene
is 0
mediated 0
by 0
the 0
catabolite 0
control 0
protein 0
CcpA B-gene
and 0
by 0
HPr B-gene
, 0
a 0
phosphocarrier 0
protein 0
of 0
the 0
phosphotransferase 0
system 0
. 0

Melatonin 0
and 0
seasonality 0
: 0
filling 0
the 0
gap 0
. 0

A 0
subsequent 0
screen 0
for 0
the 0
loss 0
of 0
the 0
positively 0
selectable 0
target 0
locus 0
marker 0
detects 0
the 0
desired 0
replacement 0
at 0
modest 0
frequency 0
( 0
> 0
2 0
% 0
) 0
. 0

Here 0
we 0
demonstrate 0
that 0
another 0
cellular 0
protein 0
linked 0
to 0
BCR/ABL B-gene
through 0
the 0
BCR/ABL I-gene

There 0
are 0
four 0
polyglutamine 0
motifs 0
interspersed 0
with 0
histidine 0
- 0
rich 0
regions 0
. 0

The 0
effects 0
of 0
procedural 0
variations 0
on 0
lateralized 0
Stroop 0
effects 0
. 0

In 0
a 0
third 0
experiment 0
, 0
a 0
Chessmaster 0
gradually 0
increases 0
the 0
number 0
of 0
boards 0
he 0
can 0
reproduce 0
with 0
higher 0
than 0
70 0
% 0
average 0
accuracy 0
to 0
nine 0
, 0
replacing 0
as 0
many 0
as 0
160 0
pieces 0
correctly 0
. 0

PCNA B-gene
mRNA I-gene
has 0
a 0
3'UTR 0
antisense 0
to 0
yellow 0
crescent 0
RNA 0
and 0
is 0
localized 0
in 0
ascidian 0
eggs 0
and 0
embryos 0
. 0

A 0
1.8 0
- 0
kb 0
cDNA 0
clone 0
( 0
designed 0
hKID B-gene
, 0
gene B-gene
symbol I-gene
AQP2L I-gene
) 0
with 0
homology 0
to 0
the 0
aquaporins B-gene
was 0
isolated 0
from 0
a 0
human 0
kidney 0
cDNA 0
library 0
. 0

PCR/Southern 0
blot 0
analysis 0
of 0
human 0
kidney 0
cDNA 0
using 0
primers 0
flanking 0
the 0
hKID B-gene
coding I-gene
sequence I-gene
revealed 0
expression 0
of 0
a 0
full 0
- 0
length 0
mRNA 0
and 0
short 0
transcripts 0
with 0
partial 0
exon 0
1 0
and 0
partial 0
exon 0
4 0
deletions 0
. 0

The 0
high 0
sequence 0
homology 0
, 0
similar 0
genomic 0
structure 0
, 0
and 0
identical 0
chromosomal 0
loci 0
of 0
hKID B-gene
, 0
MIP B-gene
, 0
and 0
AQP B-gene
- I-gene
2 I-gene
suggest 0
a 0
MIP B-gene
family I-gene
gene I-gene
cluster I-gene
at 0
chromosome 0
locus 0
12q13 0
. 0

The 0
third 0
ORF 0
generates 0
a 0
transcript 0
of 0
1.6 0
kb 0
and 0
encodes 0
a 0
protein 0
of 0
382 0
residues 0
including 0
a 0
perfect 0
match 0
to 0
the 0
consensus 0
sequence 0
of 0
a 0
C2H2 0
zinc 0
finger 0
domain 0
; 0
it 0
shares 0
a 0
strong 0
homology 0
with 0
yeast B-gene
Mig1p I-gene
and 0
Cre B-gene
- I-gene
A I-gene
from I-gene
Aspergillus I-gene
, I-gene
Emericella I-gene
and I-gene
E. I-gene
coli I-gene
. 0

Adding 0
phytase B-gene
and 0
nP 0
improved 0
the 0
orderliness 0
of 0
development 0
, 0
mineralization 0
and 0
arrangement 0
of 0
cartilage 0
and 0
bone 0
cells 0
, 0
and 0
alleviated 0
the 0
effects 0
of 0
P 0
deficiency 0
on 0
the 0
histological 0
and 0
gross 0
structure 0
of 0
the 0
tibias 0
. 0

The 0
importance 0
of 0
temporal 0
factors 0
on 0
the 0
presence 0
and 0
severity 0
of 0
ethanol 0
withdrawal 0
signs 0
in 0
the 0
rat 0
was 0
quantified 0
using 0
rating 0
scale 0
, 0
tremor 0
, 0
and 0
acoustic 0
startle 0
paradigms 0
. 0

Data 0
supported 0
the 0
brevity 0
of 0
the 0
WISC 0
- 0
III 0
short 0
form 0
and 0
the 0
criterion 0
- 0
related 0
validity 0
of 0
both 0
the 0
K 0
- 0
FAST 0
and 0
and 0
Kaufman 0
Short 0
Neuropsychological 0
Assessment 0
Procedure 0
( 0
K 0
- 0
SNAP 0
) 0
. 0

Quantitative 0
analysis 0
of 0
plasmid 0
loss 0
rates 0
in 0
cdc28 B-gene
- I-gene
1N I-gene
strains 0
carrying 0
plasmids 0
with 0
multiple 0
replication 0
origins 0
suggests 0
that 0
a 0
defect 0
in 0
initiating 0
DNA 0
replication 0
probably 0
causes 0
this 0
plasmid 0
loss 0
phenotype 0
. 0

Thus 0
, 0
the 0
multidomained 0
ROK B-gene
alpha I-gene
appears 0
to 0
be 0
involved 0
in 0
reorganization 0
of 0
the 0
cytoskeleton 0
, 0
with 0
the 0
N 0
and 0
C 0
termini 0
acting 0
as 0
positive 0
and 0
negative 0
regulators 0
, 0
respectively 0
, 0
of 0
the 0
kinase 0
domain 0
whose 0
activity 0
is 0
crucial 0
for 0
formation 0
of 0
stress 0
fibers 0
and 0
focal 0
adhesion 0
complexes 0
. 0

These 0
findings 0
and 0
the 0
differential 0
tissue 0
distribution 0
of 0
p54 B-gene
suggest 0
that 0
this 0
novel 0
SR B-gene
protein I-gene
may 0
participate 0
in 0
regulation 0
of 0
alternative 0
splicing 0
in 0
a 0
tissue 0
- 0
and 0
substrate 0
- 0
dependent 0
manner 0
. 0

The 0
elevation 0
of 0
cyclic 0
AMP 0
( 0
cAMP 0
) 0
levels 0
in 0
the 0
cell 0
downregulates 0
the 0
activity 0
of 0
the 0
Raf B-gene
- I-gene
1 I-gene
kinase I-gene
. 0

An 0
interaction 0
screen 0
with 0
the 0
repression 0
domain 0
of 0
the 0
orphan B-gene
receptor I-gene
RevErb I-gene
identified 0
N B-gene
- I-gene
CoR I-gene
, 0
the 0
corepressor 0
for 0
thyroid B-gene
hormone I-gene
receptor I-gene
( 0
TR B-gene
) 0
and 0
retinoic B-gene
acid I-gene
receptor I-gene
( 0
RAR B-gene
) 0
. 0

These 0
results 0
indicate 0
that 0
inhibition 0
of 0
Jun B-gene
kinase I-gene
activation 0
was 0
sufficient 0
to 0
inhibit 0
Ras B-gene
transformation 0
even 0
in 0
the 0
presence 0
of 0
activated 0
Erk B-gene
- I-gene
2 I-gene
. 0

Our 0
analysis 0
suggests 0
that 0
Upf1p B-gene
is 0
a 0
multifunctional 0
protein 0
with 0
separable 0
activities 0
that 0
can 0
affect 0
mRNA 0
turnover 0
and 0
nonsense 0
suppression 0
. 0

Identification 0
of 0
Ste4 B-gene
as 0
a 0
potential 0
regulator 0
of 0
Byr2 B-gene
in 0
the 0
sexual 0
response 0
pathway 0
of 0
Schizosaccharomyces 0
pombe 0
. 0

Two 0
closely 0
related 0
variants 0
of 0
Stat5 B-gene
, 0
Stat5a B-gene
and 0
Stat5b B-gene
, 0
are 0
encoded 0
by 0
distinct 0
genes 0
. 0

Mutations 0
in 0
three 0
loci 0
( 0
SIC1 B-gene
, 0
SWI5 B-gene
, 0
and 0
RIC3 B-gene
) 0
were 0
identified 0
. 0

The 0
serine/threonine B-gene
kinase I-gene
Raf B-gene
- I-gene
1 I-gene
functions 0
downstream 0
of 0
Rats B-gene
in 0
a 0
signal 0
transduction 0
cascade 0
which 0
transmits 0
mitogenic 0
stimuli 0
from 0
the 0
plasma 0
membrane 0
to 0
the 0
nucleus 0
. 0

Platelet B-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
- 0
dependent 0
activation 0
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
is 0
regulated 0
by 0
receptor 0
binding 0
of 0
SH2 B-gene
- I-gene
domain I-gene
- I-gene
containing I-gene
proteins I-gene
which 0
influence 0
Ras B-gene
activity 0
. 0

In 0
transient 0
cotransfections 0
E1A B-gene
could 0
induce 0
the 0
activity 0
of 0
the 0
p53 B-gene
promoter I-gene
to 0
a 0
high 0
level 0
; 0
12S B-gene
E1A I-gene
was 0
threefold 0
as 0
efficient 0
as 0
13S B-gene
E1A I-gene
in 0
this 0
activity 0
, 0
and 0
YY1 B-gene
bound 0
to 0
the 0
composite 0
element 0
was 0
shown 0
to 0
mediate 0
55 0
% 0
of 0
this 0
induction 0
. 0

The 0
retinoid B-gene
Z I-gene
receptor I-gene
beta I-gene
( 0
RZR B-gene
beta I-gene
) 0
, 0
an 0
orphan 0
receptor 0
, 0
is 0
a 0
member 0
of 0
the 0
retinoic B-gene
acid I-gene
receptor I-gene
( 0
RAR B-gene
) 0
/thyroid B-gene
hormone I-gene
receptor I-gene
( 0
TR B-gene
) 0
subfamily 0
of 0
nuclear 0
receptors 0
. 0

DNA B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
DNA B-gene
- I-gene
PK I-gene
) 0
consists 0
of 0
a 0
heterodimeric 0
protein 0
( 0
Ku B-gene
) 0
and 0
a 0
large 0
catalytic 0
subunit 0
( 0
DNA B-gene
- I-gene
PKcs I-gene
) 0
. 0

Almost 0
complete 0
sequence 0
identity 0
was 0
found 0
between 0
the 0
3 0
' 0
end 0
of 0
the 0
DXS6673E B-gene
gene I-gene
and 0
two 0
expressed 0
sequence 0
tags 0
( 0
ESTs 0
) 0
and 0
between 0
the 0
5 0
' 0
end 0
of 0
the 0
DXS6673E B-gene
gene I-gene
and 0
a 0
third 0
EST 0
. 0

Sequencing 0
of 0
the 0
16p 0
11.1/Xq28 0
duplication 0
breakpoints 0
has 0
revealed 0
the 0
presence 0
of 0
repetitive 0
immunoglobulin B-gene
- I-gene
like I-gene
CAGGG I-gene
pentamer I-gene
sequences I-gene
at 0
or 0
near 0
the 0
paralogy 0
boundaries 0
. 0

However 0
, 0
in 0
a 0
multivariate 0
analysis 0
considering 0
age 0
, 0
gender 0
, 0
and 0
a 0
previous 0
history 0
of 0
cardiovascular 0
diseases 0
, 0
female 0
gender 0
was 0
not 0
independently 0
associated 0
with 0
death 0
. 0

Moreover 0
, 0
following 0
a 0
single 0
intravenous 0
injection 0
of 0
the 0
bicistronic 0
vector 0
complexed 0
to 0
cationic 0
liposomes 0
into 0
recipient 0
mice 0
, 0
delivery 0
of 0
MDR1 B-gene
and 0
GC B-gene
cDNAs I-gene
was 0
achieved 0
in 0
all 0
the 0
organs 0
we 0
tested 0
. 0

The 0
limits 0
of 0
agreement 0
between 0
DBS 0
and 0
TOF 0
responses 0
were 0
so 0
wide 0
that 0
they 0
can 0
not 0
be 0
used 0
interchangeably 0
. 0

The 0
harpin B-gene
- 0
encoding 0
hrpZ B-gene
gene I-gene
is 0
located 0
in 0
an 0
operon 0
that 0
also 0
encodes 0
Hrp B-gene
secretion I-gene
pathway I-gene
components I-gene
and 0
is 0
part 0
of 0
the 0
functional 0
cluster 0
of 0
hrp B-gene
genes I-gene
carried 0
on 0
cosmid 0
pHIR11 0
that 0
enables 0
saprophytic 0
bacteria 0
like 0
Escherichia 0
coli 0
and 0
Pseudomonas 0
fluorescens 0
to 0
elicit 0
the 0
HR 0
in 0
tobacco 0
leaves 0
. 0

Despite 0
the 0
presence 0
of 0
one 0
additional 0
ribonucleotide B-gene
reductase I-gene
, 0
the 0
nrdAB B-gene
- I-gene
encoded I-gene
enzyme I-gene
is 0
essential 0
to 0
the 0
aerobic 0
growth 0
of 0
the 0
cell 0
because 0
nrdAB B-gene
- I-gene
defective I-gene
mutants I-gene
of 0
both 0
species 0
are 0
not 0
viable 0
in 0
the 0
presence 0
of 0
oxygen 0
. 0

Altogether 0
, 0
the 0
results 0
demonstrate 0
that 0
the 0
two 0
isoforms 0
elicit 0
similar 0
responses 0
in 0
vivo 0
despite 0
differences 0
in 0
their 0
regulation 0
. 0

Motivational 0
factors 0
focusing 0
on 0
attitudes 0
, 0
perceived 0
susceptibility 0
to 0
pregnancy 0
, 0
and 0
normative 0
factors 0
were 0
also 0
relevant 0
. 0

High 0
- 0
resolution 0
structure 0
of 0
the 0
diphtheria B-gene
toxin I-gene
repressor I-gene
complexed 0
with 0
cobalt 0
and 0
manganese 0
reveals 0
an 0
SH3 B-gene
- I-gene
like I-gene
third 0
domain 0
and 0
suggests 0
a 0
possible 0
role 0
of 0
phosphate 0
as 0
co 0
- 0
corepressor 0
. 0

Titration 0
of 0
the 0
human 0
and 0
porcine 0
proteins 0
with 0
2 0
- 0
nitro 0
- 0
5 0
- 0
thiosulfabenzoate 0
indicates 0
that 0
membrane B-gene
dipeptidase I-gene
additionally 0
possesses 0
two 0
intrachain 0
disulfide 0
bonds 0
. 0

FEV1 0
did 0
not 0
fall 0
significantly 0
in 0
patients 0
without 0
acute 0
or 0
chronic 0
GVHD 0
and 0
recovered 0
earlier 0
than 0
in 0
patients 0
without 0
posttransplant 0
pulmonary 0
infection 0
. 0

Administration 0
of 0
adrenaline 0
resulted 0
in 0
a 0
large 0
overestimation 0
of 0
the 0
SaO2 0
in 0
6 0
of 0
the 0
7 0
measurements 0
. 0

Therapy 0
with 0
dietary 0
modification 0
and 0
triglyceride 0
lowering 0
drugs 0
resulted 0
in 0
resolution 0
of 0
symptoms 0
and 0
parotid 0
swelling 0
in 0
one 0
patient 0
. 0

Chernoff 0
, 0
submitted 0
for 0
publication 0
) 0
. 0

We 0
have 0
cloned 0
a 0
novel 0
protein 0
kinase 0
, 0
termed 0
hematopoietic B-gene
progenitor I-gene
kinase I-gene
1 I-gene
( 0
HPK1 B-gene
) 0
, 0
that 0
is 0
expressed 0
predominantly 0
in 0
hematopoietic 0
cells 0
, 0
including 0
early 0
progenitor 0
cells 0
. 0

Human 0
ESP1/CRP2 B-gene
protein 0
has 0
two 0
ESP1/CRP2 I-gene

The 0
fragments 0
are 0
separated 0
and 0
directly 0
sized 0
by 0
agarose 0
gel 0
electrophoresis 0
. 0

Several 0
of 0
the 0
exon 0
boundaries 0
correspond 0
to 0
the 0
boundaries 0
of 0
functional 0
domains 0
in 0
the 0
p55 B-gene
protein I-gene
. 0

Linkage 0
studies 0
have 0
shown 0
locus 0
heterogeneity 0
with 0
one 0
TSC B-gene
gene I-gene
mapped 0
to 0
chromosome 0
9q34 0
and 0
a 0
second 0
to 0
16p13.3 0
. 0

The 0
cytogenetic 0
expression 0
of 0
the 0
folate 0
sensitive 0
fragile 0
site 0
, 0
FRAXE B-gene
, 0
is 0
due 0
to 0
the 0
expansion 0
of 0
a 0
GCC 0
repeat 0
in 0
proximal 0
Xq28 0
of 0
the 0
human 0
X 0
chromosome 0
and 0
is 0
associated 0
with 0
a 0
mild 0
form 0
of 0
mental 0
handicap 0
. 0

DNA 0
sequence 0
analysis 0
of 0
a 0
3213 0
bp 0
BamHI B-gene
- 0
ClaI B-gene
fragment 0
revealed 0
that 0
three 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
were 0
encoded 0
in 0
the 0
same 0
orientation 0
. 0

The 0
initial 0
inpatient 0
experience 0
for 0
individuals 0
with 0
HIV 0
- 0
related 0
TB 0
may 0
be 0
pivotal 0
to 0
the 0
acceptance 0
of 0
and 0
participation 0
in 0
ongoing 0
TB 0
care 0
. 0

Tristetraprolin B-gene
( 0
TTP B-gene
) 0
is 0
the 0
prototype 0
of 0
a 0
group 0
of 0
potential 0
transcription 0
factors 0
that 0
contain 0
two 0
or 0
more 0
unusual 0
CCCH 0
zinc 0
fingers 0
. 0

This 0
element 0
, 0
termed 0
CREsp 0
- 0
a 0
( 0
TGACCTCA 0
) 0
, 0
differs 0
by 0
one 0
nucleotide 0
from 0
a 0
palindromic 0
CRE 0
( 0
CREpal 0
, 0
TGACGTCA 0
) 0
, 0
which 0
is 0
known 0
to 0
bind 0
CREB B-gene
as 0
a 0
homodimer 0
. 0

Analysis 0
of 0
human 0
genomic 0
DNA 0
reveals 0
an 0
intronless 0
sequence 0
with 0
strong 0
homology 0
to 0
human B-gene
G I-gene
alpha I-gene
q I-gene
cDNA I-gene
. 0

The 0
complete 0
exon 0
- 0
intron 0
structure 0
of 0
the 0
156 B-gene
- I-gene
kb I-gene
human I-gene
gene I-gene
NFKB1 I-gene
, 0
which 0
encodes 0
the 0
p105 B-gene
and 0
p50 B-gene
proteins I-gene
of 0
transcription 0
factors 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
and 0
I B-gene
kappa I-gene
B I-gene
- I-gene
gamma I-gene
: 0
implications 0
for 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
- 0
mediated 0
signal 0
transduction 0
. 0

An 0
inverted 0
Alu B-gene
repeat 0
element 0
, 0
flanked 0
by 0
nonamer 0
direct 0
repeats 0
, 0
was 0
identified 0
within 0
the 0
region 0
- 0
913/ 0
- 0
620 0
, 0
relative 0
to 0
the 0
cap 0
site 0
. 0

The 0
ewes 0
were 0
returned 0
to 0
normoxia 0
, 0
and 0
monitoring 0
was 0
continued 0
for 0
1 0
h 0
. 0

Feline 0
leukemia 0
viruses 0
( 0
FeLVs 0
) 0
, 0
which 0
are 0
replication 0
- 0
competent 0
oncoretroviruses 0
of 0
the 0
domestic 0
cat 0
species 0
, 0
are 0
contagiously 0
transmitted 0
in 0
natural 0
environments 0
. 0

Comparison 0
of 0
the 0
amino 0
acid 0
sequences 0
of 0
the 0
RPO1 B-gene
polypeptides I-gene
of I-gene
IIV6 I-gene
, I-gene
LCDV I-gene
, I-gene
and I-gene
MCV I-gene
- I-gene
1 I-gene
with 0
the 0
corresponding 0
prokaryotic 0
, 0
eukaryotic 0
, 0
and 0
viral 0
proteins 0
revealed 0
differences 0
in 0
amino 0
acid 0
similarity 0
and 0
phylogenetic 0
relationships 0
. 0

The 0
RPO1 B-gene
of 0
LCDV 0
shows 0
the 0
highest 0
similarity 0
to 0
the 0
RPO1 B-gene
of 0
IIV6 0
and 0
significant 0
lower 0
similarity 0
to 0
the 0
eukaryotic B-gene
polymerases I-gene
II I-gene
and I-gene
III I-gene
as 0
well 0
as 0
to 0
the 0
archaebacteral 0
subunit 0
. 0

The 0
use 0
of 0
primary 0
GE 0
cells 0
thus 0
provides 0
a 0
convenient 0
in 0
vitro 0
system 0
for 0
further 0
study 0
of 0
the 0
endocrine 0
, 0
paracrine 0
, 0
and 0
autocrine 0
factors 0
regulating 0
endometrial 0
gene 0
expression 0
during 0
pregnancy 0
. 0

We 0
performed 0
dipole 0
estimation 0
of 0
spikes 0
and 0
SEP 0
components 0
in 0
identical 0
patients 0
. 0

Both 0
verapamil 0
and 0
propranolol 0
can 0
exhibit 0
additive 0
effects 0
with 0
adenosine 0
in 0
prolonging 0
AV 0
nodal 0
conduction 0
time 0
; 0
however 0
, 0
only 0
verapamil 0
can 0
reduce 0
the 0
dose 0
of 0
adenosine 0
required 0
to 0
produce 0
AV 0
nodal 0
block 0
. 0

Proximal 0
CBD 0
was 0
inversely 0
correlated 0
with 0
bone B-gene
alkaline I-gene
phosphatase I-gene
( 0
r 0
= 0
- 0
0.71 0
, 0
p 0
< 0
0.01 0
) 0
and 0
intact 0
PTH B-gene
( 0
r 0
= 0
- 0
0.59 0
, 0
p 0
< 0
0.05 0
) 0
. 0

In 0
addition 0
, 0
a 0
comparison 0
of 0
the 0
hCHLR B-gene
gene I-gene
sequences I-gene
with 0
available 0
databases 0
indicates 0
that 0
a 0
large 0
portion 0
of 0
these 0
genes 0
, 0
including 0
exons 0
encoding 0
two 0
functional 0
domains 0
of 0
the 0
carboxyl 0
- 0
terminal 0
region 0
of 0
these 0
proteins 0
, 0
has 0
been 0
duplicated 0
as 0
part 0
of 0
a 0
larger 0
human 0
telomeric 0
repeat 0
sequence 0
found 0
on 0
many 0
human 0
chromosomes 0
. 0

We 0
show 0
here 0
that 0
the 0
LIM B-gene
domain I-gene
homeobox B-gene
protein I-gene
isl B-gene
- I-gene
1 I-gene
activates 0
the 0
rat B-gene
amylin I-gene
promoter I-gene
in 0
both 0
fibroblast 0
and 0
islet 0
cell 0
lines 0
. 0

Although 0
isl B-gene
- I-gene
1 I-gene
binds 0
to 0
both 0
the 0
insulin B-gene
and 0
amylin B-gene
gene I-gene
promoter I-gene
elements I-gene
in 0
vitro 0
, 0
these 0
sequences 0
display 0
marked 0
differences 0
in 0
their 0
relative 0
transcriptional 0
properties 0
when 0
ligated 0
adjacent 0
to 0
a 0
heterologous 0
promoter 0
and 0
transfected 0
into 0
InR1 0
- 0
G9 0
islet 0
cells 0
. 0

It 0
is 0
likely 0
that 0
other 0
pathways 0
involve 0
alternate 0
signal 0
transduction 0
events 0
( 0
e.g. 0
, 0
calcium 0
mobilization 0
) 0
and 0
promoter 0
response 0
elements 0
( 0
e.g. 0
, 0
SRE 0
) 0
. 0

The 0
CD4 B-gene
count 0
at 0
which 0
remission 0
occurs 0
may 0
reflect 0
severe 0
immunodeficiency 0
such 0
that 0
risk 0
for 0
AIDS 0
- 0
related 0
infection 0
is 0
high 0
. 0

Although 0
diagnostic 0
laparoscopy 0
is 0
still 0
considered 0
the 0
standard 0
reference 0
in 0
the 0
diagnosis 0
of 0
ectopic 0
pregnancy 0
( 0
EP 0
) 0
, 0
use 0
of 0
high 0
- 0
resolution 0
endovaginal 0
sonography 0
, 0
in 0
conjunction 0
with 0
qualitative 0
serum 0
assays 0
of 0
the 0
beta 0
subunit 0
of 0
human B-gene
chorionic I-gene
gonadotropin I-gene
( 0
beta B-gene
- I-gene
hCG I-gene
) 0
, 0
allows 0
detection 0
of 0
earlier 0
and 0
smaller 0
EPs 0
. 0

Bifunctionality 0
of 0
the 0
AcMNPV B-gene
homologous I-gene
region I-gene
sequence I-gene
( 0
hr1 B-gene
) 0
: 0
enhancer 0
and 0
ori 0
functions 0
have 0
different 0
sequence 0
requirements 0
. 0

RVR B-gene
'loss 0
of 0
function 0
' 0
studies 0
by 0
constitutive 0
over 0
- 0
expression 0
of 0
a 0
dominant 0
negative 0
RVR B-gene
delta I-gene
E I-gene
resulted 0
in 0
increased 0
levels 0
of 0
p21Cip1/Waf1 B-gene
and 0
p21Cip1/Waf1 I-gene

Neither 0
CES1 B-gene
nor 0
CES4 B-gene
is 0
essential 0
for 0
cell 0
growth 0
, 0
and 0
a 0
double 0
deletion 0
mutant 0
is 0
viable 0
. 0

These 0
two 0
repeat 0
motifs 0
are 0
organized 0
in 0
an 0
extremely 0
well 0
- 0
ordered 0
pattern 0
in 0
each 0
domain 0
, 0
which 0
suggests 0
that 0
SbHRGP3 B-gene
belongs 0
to 0
a 0
new 0
group 0
of 0
proteins 0
having 0
the 0
repeat 0
motifs 0
of 0
two 0
distinct 0
groups 0
of 0
dicot B-gene
extensins I-gene
. 0

Their 0
use 0
established 0
that 0
the 0
BrAAP 0
activity 0
catalyzed 0
both 0
a 0
postproline 0
and 0
a 0
postglutamate 0
cleavage 0
and 0
therefore 0
has 0
a 0
broader 0
specificity 0
than 0
previously 0
recognized 0
. 0

To 0
explore 0
the 0
functional 0
significance 0
of 0
these 0
subdomains 0
in 0
PRL B-gene
binding 0
and 0
signal 0
transduction 0
, 0
deletion 0
mutants 0
of 0
S1 0
or/and 0
S2 0
subdomains 0
were 0
constructed 0
. 0

A 0
stable 0
heterologous 0
cell 0
line 0
containing 0
the 0
mouse B-gene
TRH I-gene
receptor I-gene
was 0
constructed 0
by 0
transfection 0
of 0
nonexcitable 0
293 0
cells 0
, 0
which 0
lack 0
L 0
channel 0
activity 0
. 0

To 0
understand 0
further 0
the 0
expression 0
and 0
regulation 0
of 0
the 0
V1aR B-gene
, 0
we 0
now 0
describe 0
the 0
genomic 0
characteristics 0
, 0
tissue 0
expression 0
, 0
chromosomal 0
localization 0
, 0
and 0
regional 0
mapping 0
of 0
the 0
human B-gene
V1aR I-gene
gene I-gene
, 0
AVPR1A B-gene
. 0

The 0
final 0
predicted 0
structure 0
has 0
an 0
overall 0
backbone 0
deviation 0
of 0
0.7 0
A 0
from 0
that 0
of 0
ras B-gene
- 0
p21 B-gene
. 0

Genomic 0
organization 0
of 0
the 0
human B-gene
beta I-gene
- I-gene
catenin I-gene
gene I-gene
( 0
CTNNB1 B-gene
) 0
. 0

Furthermore 0
, 0
although 0
the 0
regional 0
distribution 0
of 0
lean 0
tissue 0
mass 0
in 0
the 0
trunk 0
and 0
legs 0
remained 0
fairly 0
constant 0
at 0
different 0
pubertal 0
stages 0
, 0
the 0
regional 0
distribution 0
of 0
fat 0
was 0
altered 0
significantly 0
, 0
becoming 0
more 0
central 0
and 0
less 0
peripheral 0
. 0

Thus 0
, 0
the 0
predicted 0
CD30v B-gene
protein I-gene
retains 0
most 0
of 0
the 0
cytoplasmic 0
region 0
, 0
but 0
lacks 0
the 0
extracellular 0
and 0
transmembrane 0
domains 0
. 0

Constitutive 0
phosphorylation 0
of 0
the 0
CD30v B-gene
protein I-gene
was 0
demonstrated 0
by 0
in 0
vitro 0
labeling 0
with 0
[ 0
32P 0
] 0
. 0

17.5 0
% 0
of 0
cycles 0
) 0
. 0

We 0
report 0
here 0
the 0
discovery 0
of 0
a 0
new 0
actin B-gene
- I-gene
related I-gene
gene I-gene
in 0
this 0
organism 0
, 0
which 0
we 0
have 0
named 0
ACT4 B-gene
. 0

Two 0
of 0
the 0
ORFs 0
are 0
completely 0
internal 0
to 0
longer 0
ones 0
and 0
a 0
third 0
is 0
partially 0
embedded 0
in 0
G2850 B-gene
. 0

MVR 0
typing 0
of 0
rare 0
- 0
length 0
alleles 0
indicates 0
that 0
they 0
are 0
comprised 0
of 0
disorganized 0
sequences 0
, 0
although 0
they 0
usually 0
bear 0
a 0
resemblance 0
to 0
one 0
of 0
the 0
common 0
alleles 0
at 0
the 0
5' 0
- 0
most 0
end 0
. 0

Plasmid 0
pAL618 0
contains 0
the 0
genetic 0
determinants 0
for 0
H2 0
uptake 0
( 0
hup B-gene
) 0
from 0
Rhizobium 0
leguminosarum 0
bv 0
. 0
viciae 0
, 0
including 0
a 0
cluster 0
of 0
17 0
genes 0
named 0
hupSLCDEFGHIJK B-gene
- I-gene
hypABFCDE I-gene
. 0

Two 0
classes 0
of 0
inactive 0
receptors 0
were 0
identified 0
: 0
one 0
in 0
which 0
both 0
transcriptional 0
activation 0
and 0
dimerization 0
were 0
compromised 0
and 0
a 0
second 0
in 0
which 0
only 0
transcriptional 0
activation 0
was 0
abolished 0
. 0

Here 0
we 0
localize 0
a 0
transferable 0
40 0
- 0
amino 0
acid 0
region 0
within 0
the 0
LBDs B-gene
of 0
RXR B-gene
, 0
RAR B-gene
, 0
TR B-gene
, 0
and 0
chicken B-gene
ovalbumin I-gene
upstream I-gene
promoter I-gene
transcription I-gene
factor I-gene
that 0
is 0
critical 0
for 0
determining 0
identity 0
in 0
the 0
heterodimeric 0
interaction 0
and 0
for 0
high 0
- 0
affinity 0
DNA 0
binding 0
. 0

OKA 0
and 0
calyculin 0
A 0
do 0
not 0
decrease 0
OCFRE B-gene
DNA 0
- 0
protein 0
interactions 0
, 0
suggesting 0
that 0
important 0
protein 0
- 0
protein 0
interactions 0
are 0
phosphatase 0
regulated 0
. 0

An 0
open 0
- 0
label 0
, 0
placebo 0
- 0
controlled 0
, 0
randomized 0
, 0
two 0
- 0
way 0
crossover 0
study 0
was 0
performed 0
in 0
12 0
healthy 0
volunteers 0
( 0
between 0
20 0
and 0
44 0
years 0
of 0
age 0
) 0
to 0
assess 0
the 0
effect 0
of 0
orlistat 0
, 0
a 0
gastrointestinal B-gene
lipase I-gene
inhibitor 0
that 0
reduces 0
dietary 0
fat 0
absorption 0
and 0
is 0
being 0
developed 0
for 0
weight 0
control 0
in 0
obesity 0
, 0
on 0
the 0
absorption 0
of 0
vitamins 0
A 0
and 0
E 0
. 0

Tilmicosin 0
is 0
a 0
novel 0
macrolide 0
antibiotic 0
developed 0
for 0
exclusive 0
use 0
in 0
veterinary 0
medicine 0
. 0

Effect 0
of 0
nitrous 0
oxide 0
( 0
N2O 0
) 0
on 0
the 0
somatosympathetic 0
A 0
- 0
and 0
C 0
- 0
reflexes 0
was 0
investigated 0
using 0
artificially 0
ventilated 0
rats 0
anesthetized 0
with 0
alpha 0
- 0
chloralose 0
and 0
urethane 0
. 0

Restriction 0
enzyme 0
mapping 0
and 0
Southern 0
analysis 0
indicated 0
further 0
that 0
the 0
human B-gene
MZF I-gene
- I-gene
1 I-gene
gene I-gene
is 0
a 0
single 0
- 0
copy 0
gene 0
. 0

In 0
the 0
absence 0
of 0
Swi4 B-gene
and 0
Swi6 B-gene
cell 0
viability 0
is 0
lost 0
, 0
but 0
can 0
be 0
regained 0
by 0
ectopic 0
expression 0
of 0
the 0
G1 B-gene
cyclin I-gene
encoding I-gene
genes I-gene
, 0
CLN1 B-gene
or 0
CLN2 B-gene
. 0

The 0
detection 0
ratio 0
peaked 0
at 0
ages 0
30 0
to 0
34 0
and 0
decreased 0
heavily 0
during 0
the 0
next 0
15 0
years 0
of 0
age 0
. 0

How 0
many 0
embryos 0
to 0
transfer 0
in 0
patients 0
undergoing 0
IVF 0
? 0

IMPLICATIONS 0
: 0
Given 0
the 0
small 0
size 0
of 0
this 0
study 0
and 0
the 0
inconsistency 0
of 0
results 0
among 0
the 0
few 0
prospective 0
studies 0
of 0
ovarian 0
cancer 0
conducted 0
to 0
test 0
these 0
associations 0
, 0
replications 0
of 0
these 0
findings 0
are 0
highly 0
desirable 0
. 0

The 0
nonconsensus 0
TATA 0
box 0
in 0
promoter 0
B 0
plays 0
a 0
more 0
important 0
role 0
in 0
promoter 0
activity 0
than 0
the 0
TATA 0
box 0
in 0
promoter 0
A 0
. 0

These 0
properties 0
indicate 0
that 0
Gle1 B-gene
is 0
an 0
RNA 0
- 0
export 0
factor 0
and 0
that 0
Rev B-gene
may 0
mediate 0
viral 0
RNA 0
export 0
by 0
mimicking 0
the 0
function 0
of 0
Gle1 B-gene
. 0

Demispan 0
is 0
a 0
reliable 0
and 0
reproducible 0
measure 0
of 0
stature 0
in 0
the 0
elderly 0
. 0

Two 0
techniques 0
based 0
on 0
assay 0
coefficients 0
of 0
variation 0
were 0
employed 0
to 0
characterize 0
a 0
normal 0
circadian 0
pattern 0
of 0
cortisol 0
. 0

We 0
have 0
performed 0
toeprinting 0
analyses 0
on 0
repA B-gene
mRNA I-gene
of 0
plasmid 0
R1 0
, 0
both 0
free 0
and 0
in 0
duplex 0
with 0
the 0
antisense 0
RNA 0
, 0
CopA B-gene
. 0

Previous 0
work 0
showed 0
that 0
repA B-gene
( 0
initiator 0
protein 0
) 0
expression 0
requires 0
tap B-gene
( 0
leader 0
peptide 0
) 0
translation 0
. 0

A 0
system 0
is 0
described 0
in 0
which 0
the 0
volume 0
flow 0
rate 0
of 0
blood 0
in 0
a 0
vessel 0
is 0
determined 0
using 0
transverse 0
colour 0
Doppler 0
ultrasound 0
imaging 0
. 0

The 0
enzyme 0
activities 0
studied 0
are 0
important 0
elements 0
in 0
the 0
pathophysiology 0
of 0
dental 0
caries 0
and 0
may 0
even 0
be 0
addressed 0
as 0
virulence 0
factors 0
. 0

Tonsillectomy 0
is 0
an 0
effective 0
means 0
of 0
prophylaxis 0
for 0
upper 0
respiratory 0
infection 0
in 0
habitual 0
angina 0
patients 0
. 0

In 0
lean 0
mice 0
, 0
the 0
fat/water 0
intensity 0
ratio 0
was 0
about 0
1:4 0
, 0
about 0
half 0
that 0
in 0
normal 0
mice 0
. 0

Pharmacokinetic 0
parameters 0
were 0
similar 0
to 0
values 0
given 0
in 0
the 0
literature 0
for 0
intravenous 0
( 0
IV 0
) 0
or 0
intraarterial 0
( 0
IA 0
) 0
bolus 0
MMC 0
injections 0
( 0
Tmax 0
= 0
7.0 0
min 0
following 0
the 0
beginning 0
of 0
MMC 0
infusion 0
, 0
Vss 0
= 0
0.57 0
1/kg 0
, 0
C1 0
= 0
8.9 0
ml/min.kg 0
, 0
T1/2 0
alpha 0
= 0
8.3 0
min 0
, 0
T1/2 0
beta 0
= 0
58.6 0
min 0
) 0
. 0

In 0
this 0
study 0
, 0
we 0
identified 0
four 0
distinct 0
E2F B-gene
complexes I-gene
present 0
in 0
aged 0
and 0
senescent 0
normal 0
, 0
human 0
diploid 0
fibroblasts 0
. 0

This 0
paper 0
gives 0
an 0
overview 0
of 0
the 0
global 0
pattern 0
of 0
casualties 0
in 0
earthquakes 0
which 0
occurred 0
during 0
the 0
30 0
- 0
month 0
period 0
from 0
1 0
September 0
1993 0
to 0
29 0
February 0
1996 0
. 0

If 0
we 0
apply 0
the 0
finding 0
of 0
non 0
- 0
visualization 0
of 0
the 0
GB 0
at 0
4 0
h 0
post 0
injection 0
as 0
the 0
criterion 0
for 0
the 0
diagnosis 0
of 0
AC 0
, 0
the 0
diagnostic 0
accuracy 0
was 0
only 0
40.7 0
% 0
( 0
11/27 0
) 0
. 0

These 0
results 0
were 0
corroborated 0
in 0
a 0
subsequent 0
study 0
in 0
which 0
30 0
hypogonadal 0
men 0
were 0
supplemented 0
with 0
SLT 0
5 0
mg 0
three 0
times 0
daily 0
for 0
6 0
months 0
. 0

Alternative 0
processing 0
of 0
the 0
tryptophanyl B-gene
- I-gene
tRNA I-gene
synthetase I-gene
mRNA I-gene
from 0
interferon B-gene
- 0
treated 0
human 0
cells 0
. 0

Evidence 0
for 0
the 0
promoting 0
role 0
of 0
the 0
intra B-gene
- I-gene
uterine I-gene
kinin I-gene
release 0
in 0
the 0
development 0
of 0
late 0
hypertonic 0
saline 0
- 0
induced 0
abortion 0
. 0

This 0
GAP B-gene
activity 0
was 0
observed 0
in 0
3T3 0
- 0
L1 0
adipocyte 0
lysates 0
, 0
and 0
was 0
able 0
to 0
accelerate 0
the 0
hydrolysis 0
of 0
the 0
[ 0
alpha 0
- 0
32P 0
] 0
GTP 0
bound 0
to 0
GST B-gene
- 0
Rab4 B-gene
into 0
[ 0
alpha 0
- 0
32P 0
] 0
GDP 0
. 0

CONCLUSION 0
: 0
During 0
chronic 0
treatment 0
, 0
the 0
haemodynamic 0
response 0
to 0
oral 0
cilazapril 0
was 0
attenuated 0
, 0
indicating 0
that 0
continued 0
clinical 0
improvement 0
in 0
patients 0
with 0
CHF 0
on 0
CLZ 0
is 0
independent 0
of 0
to 0
its 0
acute 0
haemodynamic 0
effects 0
. 0

We 0
conclude 0
that 0
, 0
in 0
AIDS 0
patients 0
with 0
cryptococcosis 0
, 0
tolerance 0
to 0
ILd 0
- 0
AmB 0
was 0
acceptable 0
when 0
the 0
daily 0
dosage 0
did 0
not 0
exceed 0
1 0
mg/kg 0
, 0
but 0
the 0
higher 0
1.5 0
mg/kg 0
daily 0
dosage 0
was 0
associated 0
with 0
an 0
unacceptable 0
rate 0
of 0
nephrotoxicity 0
. 0

Moreover 0
, 0
the 0
second 0
RCC1 B-gene
- I-gene
like I-gene
motif I-gene
located 0
at 0
the 0
amino 0
- 0
terminus 0
of 0
p619 B-gene
stimulates 0
guanine 0
nucleotide 0
exchange 0
on 0
ARF1 B-gene
and 0
on 0
members 0
of 0
the 0
related 0
Rab B-gene
proteins I-gene
, 0
but 0
not 0
on 0
other 0
small B-gene
GTP I-gene
binding I-gene
proteins I-gene
such 0
as 0
Ran B-gene
or 0
R B-gene
- I-gene
Ras2/TC21 I-gene
. 0

The 0
reconstituted 0
RNA B-gene
polymerases I-gene
containing 0
the 0
mutant 0
alpha 0
subunits 0
were 0
examined 0
for 0
their 0
response 0
to 0
transcription 0
activation 0
by 0
cAMP B-gene
- I-gene
CRP I-gene
and 0
the 0
rrnBP1 B-gene
UP I-gene
element I-gene
. 0

Transcription 0
factor 0
recognition 0
surface 0
on 0
the 0
RNA B-gene
polymerase I-gene
alpha I-gene
subunit I-gene
is 0
involved 0
in 0
contact 0
with 0
the 0
DNA 0
enhancer 0
element 0
. 0

Consistent 0
with 0
this 0
similarity 0
, 0
the 0
cdc28 B-gene
- 0
P8 0
mutant 0
accumulates 0
unspliced 0
precursors 0
at 0
the 0
restrictive 0
temperature 0
. 0

A 0
decrease 0
of 0
erythrocyte 0
Mn 0
with 0
age 0
, 0
expressed 0
in 0
nmol/L 0
, 0
was 0
noted 0
( 0
p 0
< 0
0.02 0
) 0
. 0

Cloning 0
and 0
sequence 0
analyses 0
revealed 0
a 0
second 0
cDNA 0
with 0
a 0
95 0
- 0
nt 0
deletion 0
in 0
the 0
region 0
coding 0
for 0
the 0
putative 0
second 0
intracellular 0
loop 0
and 0
the 0
fourth 0
transmembrane 0
domain 0
of 0
the 0
5 B-gene
- I-gene
HT2C I-gene
- I-gene
R I-gene
. 0

Expression 0
of 0
thymidine B-gene
kinase I-gene
gene I-gene
in 0
normal 0
human 0
diploid 0
cells 0
is 0
both 0
cell 0
cycle 0
- 0
and 0
age 0
- 0
dependent 0
and 0
appears 0
to 0
be 0
transcriptionally 0
regulated 0
. 0

The 0
minimum 0
inhibitory 0
concentrations 0
( 0
MICs 0
) 0
of 0
ketoconazole 0
, 0
miconazole 0
, 0
itraconazole 0
, 0
fluconazole 0
, 0
and 0
amphotericin 0
B 0
were 0
significantly 0
influenced 0
by 0
the 0
inoculum 0
size 0
, 0
regardless 0
of 0
the 0
techniques 0
used 0
. 0

These 0
bacteria 0
produce 0
and 0
export 0
proteins 0
capable 0
of 0
specific 0
interactions 0
with 0
key 0
mammalian 0
cell 0
regulatory 0
molecules 0
in 0
order 0
to 0
derail 0
the 0
normal 0
functions 0
of 0
the 0
cells 0
. 0

The 0
elevations 0
achieved 0
by 0
LDEE 0
given 0
s.c. 0
were 0
higher 0
than 0
those 0
achieved 0
after 0
i.p 0
. 0
administration 0
and 0
lasted 0
for 0
longer 0
periods 0
. 0

Thus 0
, 0
although 0
p28 B-gene
may 0
play 0
only 0
a 0
limited 0
role 0
during 0
the 0
early 0
embryonic 0
cleavages 0
, 0
it 0
may 0
function 0
later 0
in 0
development 0
to 0
establish 0
a 0
somatic 0
type 0
of 0
cell 0
cycle 0
. 0

The 0
main 0
aim 0
of 0
the 0
contribution 0
, 0
which 0
opens 0
an 0
arena 0
for 0
discussion 0
on 0
the 0
Rivista 0
dell'Infermiere 0
is 0
to 0
critically 0
appraise 0
published 0
research 0
works 0
focusing 0
both 0
on 0
strengths 0
and 0
novelty 0
and 0
weaknesses 0
in 0
the 0
hypothesis 0
formulation 0
, 0
methods 0
and 0
instruments 0
used 0
, 0
discussion 0
of 0
results 0
. 0

Moreover 0
, 0
it 0
also 0
discusses 0
the 0
effects 0
of 0
antihypertensive 0
drugs 0
currently 0
regarded 0
as 0
first 0
- 0
choice 0
agents 0
, 0
i.e 0
. 0
calcium 0
antagonists 0
and 0
the 0
angiotensin B-gene
converting I-gene
enzyme I-gene
inhibitors 0
, 0
on 0
intrarenal 0
hemodynamics 0
. 0

Many 0
human 0
viruses 0
are 0
able 0
to 0
develop 0
suitable 0
strategies 0
for 0
modifying 0
apoptosis 0
in 0
virus 0
- 0
infected 0
cells 0
and 0
in 0
virus 0
- 0
primed 0
T 0
cells 0
. 0

It 0
is 0
suggested 0
that 0
the 0
observed 0
clinical 0
phenomena 0
in 0
response 0
to 0
morphine 0
can 0
be 0
explained 0
by 0
differences 0
in 0
expression 0
and 0
sensitivity 0
of 0
some 0
opioid B-gene
receptor I-gene
subtypes 0
in 0
migraine 0
. 0

Previous 0
studies 0
demonstrated 0
that 0
the 0
flavin B-gene
- I-gene
containing I-gene
monooxygenases I-gene
( 0
FMO B-gene
) 0
are 0
expressed 0
in 0
a 0
tissue 0
- 0
specific 0
manner 0
. 0

Taken 0
together 0
, 0
these 0
observations 0
indicate 0
that 0
the 0
C 0
- 0
terminal 0
24 0
amino 0
acids 0
are 0
sufficient 0
for 0
NodO B-gene
secretion 0
although 0
the 0
region 0
adjacent 0
to 0
this 0
domain 0
appears 0
to 0
affect 0
secretion 0
efficiency 0
. 0

Thus 0
, 0
despite 0
the 0
potential 0
for 0
common 0
regulatory 0
mechanisms 0
, 0
the 0
available 0
evidence 0
indicates 0
that 0
the 0
Mtx B-gene
minimal I-gene
promoter I-gene
does 0
not 0
significantly 0
affect 0
Thbs3 B-gene
gene I-gene
expression 0
. 0

MSSP B-gene
proteins I-gene
have 0
been 0
identified 0
by 0
their 0
binding 0
to 0
an 0
upstream 0
element 0
of 0
c B-gene
- I-gene
myc I-gene
. 0

Gene B-gene
1 I-gene
has 0
been 0
completely 0
sequenced 0
. 0

B B-gene
cell I-gene
antigen I-gene
receptor I-gene
( 0
BCR B-gene
) 0
- 0
induced 0
apoptosis 0
in 0
the 0
WEHI 0
- 0
231 0
B 0
lymphoma 0
cell 0
line 0
can 0
be 0
prevented 0
by 0
engaging 0
CD40 B-gene
. 0

Both 0
alleles 0
are 0
functionally 0
expressed 0
and 0
are 0
distributed 0
within 0
CD4+/CD8+ B-gene
T 0
cell 0
subsets 0
. 0

The 0
model 0
also 0
predicts 0
that 0
blood 0
flow 0
shunt 0
fraction 0
( 0
Qs/QT 0
) 0
is 0
directly 0
related 0
to 0
the 0
oxygen 0
sine 0
- 0
wave 0
amplitude 0
perturbations 0
transmitted 0
to 0
end 0
- 0
expired 0
air 0
and 0
arterial 0
and 0
mixed 0
- 0
venous 0
blood 0
through 0
two 0
simple 0
equations 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
of 0
LvUSF2 B-gene
is 0
nearly 0
identical 0
to 0
LvUSF1 B-gene
except 0
at 0
the 0
amino 0
end 0
, 0
where 0
they 0
are 0
sharply 0
divergent 0
. 0

ECM 0
disruption 0
in 0
Lytechinus 0
embryos 0
caused 0
a 0
relative 0
drop 0
in 0
USF B-gene
RNA I-gene
accumulation 0
levels 0
to 0
approximately 0
60 0
% 0
of 0
control 0
embryos 0
, 0
while 0
LpS1 B-gene
RNA I-gene
accumulation 0
levels 0
dropped 0
to 0
less 0
than 0
5 0
% 0
. 0

Five 0
of 0
these 0
eight 0
patients 0
in 0
group 0
II 0
also 0
received 0
8 0
- 0
in 0
- 0
1 0
chemotherapy 0
. 0

Sixty 0
days 0
after 0
the 0
intervention 0
, 0
twitch 0
and 0
tetanic 0
tensions 0
remained 0
dependent 0
upon 0
the 0
extracellular 0
Ca2+ 0
concentration 0
( 0
[ 0
Ca 0
] 0
o 0
) 0
both 0
in 0
groups 0
A 0
and 0
B 0
. 0

Discrimination 0
between 0
HIV 0
- 0
1 0
and 0
HIV 0
- 0
2 0
showed 0
evidence 0
for 0
the 0
presence 0
of 0
HIV 0
- 0
1 0
only 0
. 0

However 0
, 0
an 0
intrinsic 0
DNA 0
- 0
binding 0
subunit 0
for 0
HiNF B-gene
- I-gene
D I-gene
was 0
not 0
identified 0
. 0

The 0
HiNF B-gene
- I-gene
D I-gene
( 0
CDP/cut B-gene
) 0
complex 0
with 0
the 0
CDP/cut I-gene

Recently 0
, 0
a 0
distantly 0
related 0
UmuC B-gene
- I-gene
homolog I-gene
, 0
DinB B-gene
, 0
has 0
also 0
been 0
identified 0
in 0
E. 0
coli 0
. 0

To 0
study 0
the 0
regulation 0
of 0
mdr2 B-gene
expression 0
, 0
the 0
promoter 0
of 0
the 0
mdr2 B-gene
gene I-gene
has 0
been 0
isolated 0
from 0
a 0
murine 0
vinblastine 0
- 0
resistant 0
cell 0
line 0
, 0
J7.V2 0
- 0
1 0
, 0
and 0
characterized 0
. 0

The 0
amplification 0
was 0
achieved 0
using 0
two 0
primers 0
which 0
correspond 0
to 0
TRH B-gene
progenitor I-gene
sequence I-gene
( 0
Lys/Arg 0
- 0
Arg 0
- 0
Gln 0
- 0
His 0
- 0
Pro 0
- 0
Gly 0
- 0
Lys/Arg 0
- 0
Arg 0
) 0
. 0

The 0
intranodal 0
mesothelial 0
cells 0
occupied 0
the 0
sinusoids 0
of 0
the 0
lymph 0
nodes 0
and 0
were 0
initially 0
suspected 0
of 0
being 0
metastatic 0
from 0
the 0
ovarian 0
tumor 0
in 0
each 0
case 0
. 0

The 0
gene B-gene
ccpA I-gene
encoding 0
the 0
catabolite B-gene
control I-gene
protein I-gene
CcpA I-gene
of 0
Staphylococcus 0
xylosus 0
has 0
been 0
cloned 0
and 0
characterized 0
. 0

An 0
InlC B-gene
deletion I-gene
mutant I-gene
shows 0
reduced 0
virulence 0
when 0
tested 0
in 0
an 0
intravenous 0
mouse 0
model 0
, 0
but 0
intracellular 0
replication 0
of 0
the 0
mutant 0
in 0
Caco 0
- 0
2 0
and 0
J774 0
cells 0
appears 0
to 0
be 0
comparable 0
with 0
that 0
of 0
the 0
wild 0
- 0
type 0
strain 0
. 0

Thus 0
, 0
the 0
N B-gene
- 0
Nus B-gene
complex 0
may 0
be 0
affected 0
through 0
contacts 0
with 0
the 0
CTD 0
of 0
the 0
alpha 0
subunit 0
of 0
RNA B-gene
polymerase I-gene
, 0
as 0
is 0
a 0
group 0
of 0
regulatory 0
proteins 0
that 0
influences 0
initiation 0
of 0
transcription 0
. 0

Administration 0
of 0
RIFA 0
at 0
200 0
mg/kg/day 0
in 0
combination 0
with 0
ATO 0
at 0
100 0
mg/kg/day 0
resulted 0
in 0
a 0
marked 0
prolongation 0
of 0
survival 0
compared 0
with 0
that 0
for 0
mice 0
that 0
received 0
ATO 0
or 0
RIFA 0
alone 0
. 0

Eight 0
- 0
four 0
ACOAs 0
were 0
tested 0
in 0
order 0
to 0
examine 0
the 0
fit 0
of 0
the 0
model 0
to 0
the 0
data 0
by 0
path 0
analysis 0
with 0
LISREL 0
VII 0
. 0

Two 0
of 0
seven 0
initiation 0
sites 0
were 0
flanked 0
by 0
a 0
sequence 0
homologous 0
to 0
the 0
consensus 0
promoter 0
motif 0
that 0
includes 0
the 0
CRTA 0
motif 0
( 0
where 0
R 0
is 0
A 0
or 0
G 0
) 0
of 0
the 0
rice 0
mitochondrion 0
. 0

Selection 0
using 0
SC 0
EPD 0
was 0
more 0
effective 0
than 0
phenotypic 0
selection 0
in 0
reducing 0
age 0
at 0
puberty 0
in 0
daughters 0
. 0

Using 0
anchored 0
PCR 0
, 0
a 0
VL B-gene
element I-gene
rearranged 0
to 0
CL2 B-gene
was 0
isolated 0
. 0

Sodium 0
polystyrene 0
sulfonate 0
treatment 0
for 0
lithium 0
toxicity 0
: 0
effects 0
on 0
serum 0
potassium 0
concentrations 0
. 0

The 0
mammalian B-gene
homeodomain I-gene
proteins I-gene
encoded 0
by 0
Hox B-gene
genes I-gene
play 0
an 0
important 0
role 0
in 0
embryonic 0
development 0
by 0
providing 0
positional 0
queues 0
which 0
define 0
developmental 0
identities 0
along 0
the 0
anteroposterior 0
axis 0
of 0
developing 0
organisms 0
. 0

Interferon B-gene
stimulated I-gene
gene I-gene
factor I-gene
3 I-gene
( 0
ISGF3 B-gene
) 0
is 0
a 0
trimeric 0
transcription 0
factor 0
activated 0
on 0
treatment 0
of 0
cells 0
with 0
interferon B-gene
- I-gene
alpha I-gene
and I-gene
beta I-gene
( 0
type B-gene
I I-gene
IFNs I-gene
) 0
. 0

The 0
TYAC/P1 0
resource 0
, 0
derivative 0
STSs 0
, 0
and 0
polymorphisms 0
constitute 0
an 0
enabling 0
resource 0
to 0
further 0
studies 0
of 0
telomere 0
structure 0
and 0
function 0
and 0
a 0
means 0
for 0
physical 0
and 0
genetic 0
map 0
integration 0
and 0
closure 0
. 0

Confirmatory 0
statistics 0
included 0
item 0
2 0
of 0
the 0
Clinical 0
Global 0
Impression 0
( 0
CGI 0
) 0
, 0
the 0
total 0
score 0
of 0
the 0
Sandoz 0
Clinical 0
Assessment 0
Geriatric 0
( 0
SCAG 0
) 0
scale 0
, 0
the 0
subscale 0
'need 0
for 0
help 0
' 0
of 0
the 0
nurse 0
's 0
rating 0
of 0
geriatric 0
patients 0
( 0
Beurteilungsskala 0
fur 0
geriatrische 0
Patienten 0
; 0
BGP 0
) 0
and 0
the 0
total 0
score 0
of 0
the 0
Short 0
Cognitive 0
Performance 0
Test 0
( 0
Syndrom 0
- 0
Kurztest 0
; 0
SKT 0
) 0
. 0

Three 0
mutants 0
were 0
isolated 0
from 0
the 0
widely 0
used 0
strain 0
, 0
PAO1 0
. 0

As 0
extensively 0
examined 0
with 0
the 0
myogenin B-gene
promoter I-gene
, 0
presence 0
of 0
one 0
or 0
multiple 0
copies 0
of 0
Me B-gene
in 0
the 0
vectors 0
elevated 0
the 0
expression 0
activity 0
in 0
myotubes 0
by 0
4.5 0
- 0
to 0
19 0
- 0
fold 0
over 0
those 0
without 0
Me B-gene
, 0
but 0
not 0
significantly 0
in 0
myoblasts 0
. 0

We 0
conclude 0
that 0
common 0
upstream 0
signals 0
cause 0
activation 0
of 0
Ras B-gene
and 0
TC21 B-gene
, 0
but 0
activated 0
TC21 B-gene
controls 0
cell 0
growth 0
via 0
distinct 0
Raf B-gene
- 0
independent 0
downstream 0
signaling 0
pathways 0
. 0

Fission B-gene
yeast I-gene
mal2+ I-gene
is 0
required 0
for 0
chromosome 0
segregation 0
. 0

Selection 0
was 0
based 0
on 0
expression 0
of 0
an 0
integrated 0
DNA 0
fragment 0
containing 0
the 0
con B-gene
- I-gene
10 I-gene
promoter I-gene
- I-gene
regulatory I-gene
region I-gene
followed 0
by 0
the 0
initial 0
segment 0
of 0
the 0
con B-gene
- I-gene
10 I-gene
open I-gene
reading I-gene
frame I-gene
fused 0
in 0
frame 0
with 0
the 0
bacterial B-gene
hygromycin I-gene
B I-gene
phosphotransferase I-gene
structural I-gene
gene I-gene
( 0
con10' B-gene
- I-gene
'hph I-gene
) 0
. 0

Mutations 0
at 0
two 0
neighboring 0
sites 0
, 0
serine 0
242 0
and 0
threonine 0
255 0
, 0
exacerbated 0
the 0
effect 0
. 0

IRF B-gene
- I-gene
1 I-gene
acts 0
as 0
a 0
transcriptional 0
activator 0
, 0
while 0
IRF B-gene
- I-gene
2 I-gene
acts 0
as 0
a 0
repressor 0
. 0

In 0
contrast 0
, 0
cotransfection 0
of 0
TFIIB B-gene
and 0
IRF B-gene
- I-gene
1 I-gene
into 0
NIH 0
3T3 0
cells 0
resulted 0
in 0
a 0
dose 0
- 0
dependent 0
repression 0
of 0
promoter 0
activation 0
which 0
occurred 0
in 0
a 0
TATA 0
- 0
dependent 0
manner 0
. 0

The 0
requirement 0
of 0
Tyr 0
- 0
19 0
dephosphorylation 0
for 0
spindle 0
assembly 0
is 0
also 0
observed 0
under 0
conditions 0
in 0
which 0
spindle 0
formation 0
is 0
independent 0
of 0
mitosis 0
, 0
suggesting 0
that 0
the 0
involvement 0
of 0
Cdc28/Clb B-gene
kinase 0
in 0
SPB 0
separation 0
is 0
direct 0
. 0

A 0
subset 0
of 0
these 0
DMP1 B-gene
recognition I-gene
sequences I-gene
containing 0
a 0
GGA 0
trinucleotide 0
core 0
can 0
also 0
function 0
as 0
Ets B-gene
- I-gene
responsive I-gene
elements I-gene
. 0

In 0
both 0
settings 0
, 0
it 0
can 0
be 0
phosphorylated 0
by 0
cyclin B-gene
D I-gene
- I-gene
dependent I-gene
kinases I-gene
, 0
suggesting 0
that 0
its 0
transcriptional 0
activity 0
may 0
normally 0
be 0
regulated 0
through 0
such 0
mechanisms 0
. 0

Expression 0
of 0
the 0
proapoptotic B-gene
protein I-gene
Bax I-gene
under 0
the 0
control 0
of 0
a 0
GAL10 B-gene
promoter I-gene
in 0
Saccharomyces 0
cerevisiae 0
resulted 0
in 0
galactose 0
- 0
inducible 0
cell 0
death 0
. 0

This 0
technique 0
was 0
employed 0
in 0
12 0
patients 0
with 0
a 0
unicameral 0
bone 0
cyst 0
. 0

Enterococcus 0
faecium 0
strains 0
with 0
vanA 0
- 0
mediated 0
glycopeptide 0
resistance 0
were 0
isolated 0
by 0
enrichment 0
culture 0
from 0
the 0
intestines 0
and 0
feces 0
of 0
several 0
animal 0
species 0
, 0
mainly 0
horses 0
and 0
dogs 0
( 0
8 0
% 0
positive 0
) 0
, 0
chickens 0
( 0
7 0
% 0
positive 0
) 0
, 0
and 0
pigs 0
( 0
6 0
% 0
positive 0
) 0
. 0

The 0
amino 0
- 0
terminal 0
region 0
of 0
E1A B-gene
binds 0
several 0
high 0
molecular 0
weight 0
proteins 0
and 0
inhibits 0
the 0
transcriptional 0
coactivator 0
function 0
of 0
p300 B-gene
and 0
the 0
homologous 0
cAMP B-gene
response I-gene
element I-gene
( I-gene
CRE I-gene
) I-gene
- I-gene
binding I-gene
protein I-gene
. 0

Transient 0
transfection 0
assays 0
using 0
reporter 0
gene 0
constructs 0
containing 0
various 0
lengths 0
of 0
the 0
5 B-gene
' I-gene
mdr1b I-gene
sequences I-gene
revealed 0
that 0
the 0
sequence 0
located 0
between 0
- 0
247 0
to 0
- 0
126 0
bp 0
was 0
important 0
for 0
the 0
expression 0
of 0
the 0
reporter 0
gene 0
in 0
many 0
different 0
cell 0
lines 0
. 0

We 0
show 0
that 0
the 0
5'UTR 0
characteristic 0
of 0
testis B-gene
- I-gene
specific I-gene
c I-gene
- I-gene
mos I-gene
mRNA I-gene
strongly 0
represses 0
translation 0
relative 0
to 0
the 0
translation 0
of 0
transcripts 0
that 0
contain 0
a 0
5'UTR 0
derived 0
from 0
beta B-gene
- I-gene
globin I-gene
mRNA I-gene
, 0
and 0
this 0
is 0
mainly 0
due 0
to 0
the 0
four 0
uORFs 0
. 0

To 0
address 0
the 0
biological 0
effect 0
of 0
specific 0
isoform 0
expression 0
, 0
NIH3T3 0
cells 0
were 0
transfected 0
with 0
a 0
eukaryotic 0
expression 0
vector 0
containing 0
cDNA 0
for 0
FGF8a B-gene
, 0
FGF8b B-gene
, 0
or 0
FGF8e B-gene
. 0

These 0
findings 0
suggest 0
that 0
the 0
F 0
- 0
wave 0
may 0
be 0
elicited 0
in 0
motoneuron 0
of 0
different 0
depolarization 0
threshold 0
but 0
primarily 0
in 0
larger 0
and 0
faster 0
nerve 0
fibers 0
, 0
with 0
a 0
lower 0
threshold 0
of 0
depolarization 0
. 0

In 0
addition 0
, 0
carp B-gene
JAK1 I-gene
shows 0
higher 0
sequence 0
homology 0
to 0
mammalian B-gene
JAK1 I-gene
in 0
both 0
the 0
kinase 0
- 0
like 0
( 0
JH2 B-gene
) 0
and 0
kinase 0
( 0
JH1 B-gene
) 0
domains 0
( 0
approximately 0
70 0
% 0
identity 0
) 0
. 0

When 0
this 0
DNA 0
fragment 0
was 0
placed 0
upstream 0
of 0
the 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
reporter 0
gene 0
and 0
transfected 0
into 0
a 0
carp 0
CF 0
cell 0
line 0
, 0
it 0
could 0
drive 0
the 0
synthesis 0
of 0
CAT B-gene
enzyme I-gene
16 0
times 0
more 0
efficiently 0
than 0
the 0
promoterless 0
pCAT B-gene
- I-gene
Basic I-gene
. 0

Molecular 0
cloning 0
of 0
Elk B-gene
- I-gene
3 I-gene
, 0
a 0
new 0
member 0
of 0
the 0
Ets B-gene
family I-gene
expressed 0
during 0
mouse 0
embryogenesis 0
and 0
analysis 0
of 0
its 0
transcriptional 0
repression 0
activity 0
. 0

We 0
report 0
an 0
example 0
of 0
an 0
MDV 0
- 0
transformed 0
T 0
- 0
lymphoblastoid 0
cell 0
line 0
( 0
T9 0
) 0
expressing 0
high 0
levels 0
of 0
a 0
truncated B-gene
C I-gene
- I-gene
MYB I-gene
protein I-gene
as 0
a 0
result 0
of 0
RAV 0
integration 0
within 0
one 0
c B-gene
- I-gene
myb I-gene
allele I-gene
. 0

Frozen/thawed 0
extensor 0
digitorum 0
longus 0
muscle 0
tendon 0
units 0
had 0
significantly 0
lower 0
values 0
for 0
load 0
to 0
failure 0
( 0
p 0
< 0
0.01 0
) 0
, 0
energy 0
absorbed 0
to 0
failure 0
( 0
p 0
< 0
0.01 0
) 0
, 0
and 0
strain 0
at 0
failure 0
( 0
p 0
< 0
0.01 0
) 0
, 0
and 0
they 0
tended 0
to 0
fail 0
at 0
a 0
different 0
anatomic 0
location 0
( 0
p 0
< 0
0.01 0
) 0
( 0
broadly 0
at 0
the 0
fascia 0
- 0
muscle 0
interface 0
as 0
compared 0
with 0
horizontally 0
at 0
the 0
musculotendinous 0
junction 0
) 0
than 0
fresh 0
units 0
. 0

Northern 0
analysis 0
of 0
the 0
3.1 B-gene
- I-gene
kb I-gene
PWP2H I-gene
cDNA I-gene
revealed 0
that 0
a 0
3.3 0
- 0
kb 0
major 0
transcript 0
is 0
ubiquitously 0
expressed 0
in 0
human 0
adult 0
tissues 0
. 0

Forty 0
- 0
eight 0
10 0
- 0
12 0
- 0
week 0
- 0
old 0
male 0
Sprague 0
- 0
Dawley 0
rats 0
were 0
randomized 0
to 0
receive 0
, 0
daily 0
for 0
28 0
days 0
: 0
( 0
1 0
) 0
CsA 0
vehicle 0
p.o 0
. 0
plus 0
FB 0
vehicle 0
sc 0
; 0
( 0
2 0
) 0
CsA 0
( 0
15 0
mg/kg 0
) 0
p.o 0
. 0
plus 0
FB 0
vehicle 0
sc 0
, 0
( 0
3 0
) 0
CsA 0
vehicle 0
p.o 0
. 0
plus 0
FB 0
( 0
1.5 0
mg/kg 0
) 0
sc 0
; 0
and 0
( 0
4 0
) 0
CsA 0
( 0
15 0
mg/kg 0
) 0
p.o 0
. 0
plus 0
FB 0
( 0
1.5 0
mg/kg 0
) 0
sc 0
. 0

CsA 0
alone 0
resulted 0
in 0
elevated 0
bone 0
turnover 0
. 0

Individuals 0
attending 0
the 0
GUM 0
Department 0
in 0
the 0
Royal 0
Infirmary 0
of 0
Edinburgh 0
between 0
1990 0
and 0
1994 0
with 0
the 0
diagnosis 0
of 0
HIV 0
infection 0
, 0
genital 0
warts 0
, 0
genital 0
herpes 0
, 0
non 0
- 0
specific 0
genital 0
infection 0
( 0
NSGI 0
) 0
, 0
gonorrhoea 0
and 0
syphilis 0
were 0
included 0
in 0
the 0
study 0
. 0

Oncogenic 0
activation 0
of 0
the 0
tyrosine B-gene
kinase I-gene
domain I-gene
of 0
the 0
human B-gene
trk I-gene
proto I-gene
- I-gene
oncogene I-gene
by 0
fusion 0
to 0
a 0
cell 0
adhesion 0
molecule 0
. 0

Northern 0
blotting 0
showed 0
that 0
MDMX B-gene
, 0
like 0
MDM2 B-gene
, 0
is 0
expressed 0
in 0
all 0
tissues 0
tested 0
, 0
and 0
that 0
several 0
mRNAs 0
for 0
MDMX B-gene
can 0
be 0
detected 0
. 0

Physiol 0
. 0

The 0
nucleotide 0
sequence 0
of 0
22,846 0
bp 0
of 0
the 0
left 0
arm 0
of 0
chromosome 0
IV 0
is 0
described 0
. 0

They 0
suggest 0
that 0
decreased 0
steady 0
- 0
state 0
levels 0
of 0
IME1 B-gene
and 0
IME2 B-gene
mRNA I-gene
were 0
not 0
merely 0
the 0
result 0
of 0
non 0
- 0
specific 0
adverse 0
affects 0
on 0
nucleic 0
acid 0
metabolism 0
caused 0
by 0
the 0
yvh1 B-gene
disruption 0
. 0

Natural 0
FL B-gene
protein I-gene
has 0
been 0
purified 0
from 0
a 0
stromal 0
cell 0
line 0
and 0
shown 0
to 0
be 0
a 0
65 0
kD 0
nondisulfide 0
- 0
linked 0
homodimeric 0
glycoprotein 0
comprised 0
of 0
30 0
kD 0
subunits 0
, 0
each 0
containing 0
12 0
kD 0
of 0
N 0
- 0
and 0
O 0
- 0
linked 0
sugars 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
influence 0
of 0
HHCA 0
and 0
other 0
serological 0
factors 0
upon 0
the 0
development 0
of 0
VGS 0
. 0

Spliced 0
exons 0
of 0
adenovirus 0
late 0
RNAs 0
colocalize 0
with 0
snRNP 0
in 0
a 0
specific 0
nuclear 0
domain 0
. 0

Using 0
Spurr 0
's 0
resin 0
as 0
a 0
mounting 0
medium 0
, 0
we 0
could 0
observe 0
thick 0
specimens 0
with 0
oil 0
immersion 0
objective 0
lens 0
without 0
the 0
use 0
of 0
coverslips 0
, 0
then 0
avoid 0
air 0
bubbles 0
near 0
the 0
specimen 0
. 0

The 0
present 0
study 0
investigated 0
dose 0
dependence 0
and 0
time 0
course 0
effects 0
of 0
the 0
benzodiazepine 0
( 0
BDZ 0
) 0
partial 0
inverse 0
agonist 0
, 0
RO19 0
- 0
4603 0
( 0
0.005 0
- 0
0.30 0
mg/kg 0
) 0
alone 0
, 0
and 0
in 0
combination 0
with 0
the 0
BDZ B-gene
receptor I-gene
antagonists 0
flumazenil 0
, 0
ZK 0
93426 0
, 0
and 0
CGS 0
8216 0
( 0
20 0
mg/kg 0
) 0
in 0
selectively 0
bred 0
alcohol 0
- 0
preferring 0
( 0
P 0
) 0
rats 0
provided 0
a 0
two 0
- 0
bottle 0
choice 0
test 0
between 0
ethanol 0
( 0
EtOH 0
) 0
( 0
10 0
% 0
v/v 0
) 0
, 0
and 0
a 0
palatable 0
saccharin 0
( 0
0.0125 0
% 0
g/v 0
) 0
solution 0
. 0

Beyond 0
the 0
Tower 0
of 0
Babel 0
: 0
a 0
nomenclature 0
for 0
suicidology 0
. 0

Infection 0
with 0
Neisseria 0
meningitidis 0
group 0
B 0
has 0
been 0
difficult 0
to 0
detect 0
, 0
partly 0
because 0
this 0
bacterial 0
group 0
's 0
polysaccharide 0
is 0
a 0
weak 0
immunogen 0
. 0

RNase B-gene
protection 0
analysis 0
of 0
two 0
rRNA 0
fragments 0
whose 0
genes 0
are 0
adjacent 0
provided 0
evidence 0
for 0
a 0
polycistronic 0
transcript 0
containing 0
sequences 0
from 0
both 0
, 0
as 0
well 0
as 0
separate 0
small 0
RNAs 0
. 0

Rss1p B-gene
encodes 0
a 0
novel 0
essential 0
protein 0
of 0
538 0
amino 0
acids 0
, 0
which 0
contains 0
an 0
extended 0
predicted 0
coiled 0
- 0
coil 0
domain 0
and 0
is 0
located 0
both 0
at 0
nuclear 0
pore 0
complexes 0
( 0
NPCs 0
) 0
and 0
in 0
the 0
cytoplasm 0
. 0

To 0
map 0
this 0
regulatory 0
serine 0
phosphorylation 0
site 0
we 0
developed 0
a 0
baculovirus 0
- 0
mediated 0
expression 0
system 0
for 0
wild B-gene
- I-gene
type I-gene
annexin I-gene
II I-gene
and 0
for 0
a 0
series 0
of 0
annexin B-gene
II I-gene
mutants I-gene
which 0
contained 0
substitutions 0
in 0
one 0
or 0
more 0
serine 0
residues 0
present 0
in 0
the 0
N 0
- 0
terminal 0
domain 0
. 0

The 0
PAI B-gene
- I-gene
2 I-gene
gene I-gene
is 0
one 0
of 0
the 0
most 0
TNF B-gene
- I-gene
responsive I-gene
genes I-gene
known 0
and 0
is 0
also 0
highly 0
induced 0
by 0
the 0
phorbol 0
ester 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
( 0
PMA 0
) 0
and 0
the 0
phosphatase 0
inhibitor 0
, 0
okadaic 0
acid 0
, 0
in 0
both 0
HT 0
- 0
1080 0
fibrosarcoma 0
and 0
U 0
- 0
937 0
histiocytic 0
cells 0
. 0

220 0
, 0
263 0
- 0
273 0
) 0
. 0

These 0
two 0
contigs 0
contain 0
a 0
total 0
of 0
163 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
in 0
26 0
- 0
29 0
putative 0
operons 0
; 0
56 0
ORFs 0
could 0
be 0
identified 0
with 0
reasonable 0
certainty 0
. 0

T. 0
, 0
Patel 0
, 0
S 0
. 0

Growth 0
factors 0
induce 0
the 0
expression 0
of 0
the 0
immediate B-gene
early I-gene
gene I-gene
products I-gene
MAP B-gene
kinase I-gene
phosphatase I-gene
- I-gene
1 I-gene
( 0
MKP B-gene
- I-gene
1 I-gene
) 0
, 0
c B-gene
- I-gene
Fos I-gene
and 0
c B-gene
- I-gene
Jun I-gene
. 0

The 0
up 0
- 0
regulation 0
of 0
E B-gene
- I-gene
selectin I-gene
, 0
one 0
of 0
the 0
adhesion 0
molecules 0
on 0
the 0
endothelium 0
, 0
is 0
an 0
important 0
event 0
in 0
the 0
mediation 0
of 0
the 0
inflammatory 0
response 0
. 0

The 0
NIT2 B-gene
protein I-gene
is 0
localised 0
in 0
nuclei 0
and 0
could 0
not 0
be 0
detected 0
in 0
the 0
cytoplasmic 0
fraction 0
of 0
cells 0
subjected 0
to 0
nitrogen 0
derepression 0
or 0
nitrogen 0
repression 0
, 0
indicating 0
that 0
the 0
nuclear 0
import 0
of 0
NIT2 B-gene
is 0
not 0
regulated 0
. 0

In 0
spite 0
of 0
much 0
effort 0
, 0
no 0
one 0
has 0
succeeded 0
in 0
isolating 0
and 0
characterizing 0
the 0
enzyme 0
( 0
s 0
) 0
responsible 0
for 0
synthesis 0
of 0
cellulose 0
, 0
the 0
major 0
cell 0
wall 0
polymer 0
of 0
plants 0
. 0

Vascular 0
responses 0
to 0
reactive 0
hyperemia 0
( 0
with 0
flow 0
increase 0
leading 0
to 0
endothelium 0
- 0
dependent 0
dilation 0
) 0
and 0
to 0
sublingual 0
glyceryl 0
trinitrate 0
( 0
GTN 0
; 0
endothelium 0
- 0
independent 0
dilation 0
) 0
were 0
recorded 0
. 0

During 0
this 0
period 0
, 0
administration 0
of 0
additional 0
exogenous B-gene
PRL I-gene
did 0
not 0
stimulate 0
further 0
activation 0
( 0
binding 0
) 0
of 0
the 0
Stat B-gene
factors I-gene
. 0

Intraperitoneal 0
administration 0
of 0
L 0
- 0
5 0
- 0
hydroxytryptophan 0
( 0
L 0
- 0
5 0
- 0
HTP 0
) 0
at 0
doses 0
of 0
25 0
to 0
100 0
mg/kg 0
dramatically 0
increase 0
defecation 0
in 0
mice 0
. 0

In 0
the 0
VA 0
- 0
SMV 0
mode 0
, 0
the 0
connection 0
was 0
made 0
with 0
valved 0
conduits 0
from 0
the 0
LV 0
apex 0
( 0
inflow 0
) 0
to 0
the 0
ascending 0
aorta 0
( 0
outflow 0
) 0
( 0
n 0
= 0
11 0
) 0
or 0
to 0
the 0
DAo 0
( 0
n 0
= 0
12 0
) 0
. 0

The 0
evidence 0
in 0
support 0
of 0
this 0
was 0
derived 0
from 0
the 0
fact 0
that 0
the 0
affinity 0
or 0
interaction 0
between 0
the 0
two 0
subunits 0
was 0
impaired 0
as 0
indicated 0
by 0
the 0
first 0
order 0
rate 0
constant 0
of 0
hCG B-gene
alpha I-gene
1 I-gene
beta I-gene
( 0
km 0
= 0
4.1 0
x 0
10 0
( 0
- 0
2 0
) 0
min 0
- 0
1 0
) 0
at 0
pH 0
3.0 0
at 0
23 0
degrees 0
C 0
which 0
is 0
one 0
order 0
of 0
magnitude 0
greater 0
relative 0
to 0
rehCG B-gene
( 0
kw 0
= 0
4.6 0
x 0
10 0
( 0
- 0
3 0
) 0
min 0
- 0
1 0
) 0
. 0

Factor 0
V 0
Leiden 0
is 0
a 0
genetic 0
disorder 0
associated 0
with 0
an 0
increased 0
risk 0
of 0
venous 0
thrombosis 0
. 0

This 0
is 0
the 0
first 0
determination 0
of 0
the 0
complete 0
secondary 0
structure 0
of 0
an 0
RNA 0
spliced 0
in 0
a 0
spliceosome 0
. 0

The 0
majority 0
of 0
the 0
cases 0
with 0
0 0
- 0
I 0
or 0
0 0
- 0
III 0
components 0
were 0
sm 0
. 0
cancer 0
. 0

These 0
patients 0
appear 0
to 0
have 0
slightly 0
better 0
pulmonary 0
function 0
and 0
nutritional 0
status 0
; 0
yet 0
, 0
they 0
seem 0
to 0
have 0
a 0
higher 0
degree 0
of 0
health 0
care 0
utilization 0
. 0

This 0
observation 0
calls 0
for 0
careful 0
monitoring 0
of 0
calcium 0
and 0
alkaline B-gene
phosphatase I-gene
values 0
and 0
possible 0
adjustments 0
of 0
vitamin 0
D 0
intake 0
when 0
fortifiers 0
are 0
used 0
for 0
extended 0
periods 0
. 0

We 0
have 0
found 0
that 0
PEA2 B-gene
is 0
also 0
required 0
for 0
the 0
bipolar 0
budding 0
pattern 0
and 0
that 0
it 0
encodes 0
a 0
novel 0
protein 0
with 0
a 0
predicted 0
coiled 0
- 0
coil 0
domain 0
. 0

Signaling 0
from 0
the 0
small B-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
Rac1 I-gene
and 0
Cdc42 B-gene
to 0
the 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase/stress I-gene
kinase/stress I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
pathway 0
. 0

Percent 0
identities 0
of 0
the 0
mouse B-gene
PP2 I-gene
to 0
mouse B-gene
Y1 I-gene
, 0
mouse 0
Y4/PP1 B-gene
and 0
Y4/PP1 I-gene

Correlating 0
with 0
the 0
previous 0
observation 0
that 0
CBF B-gene
binding 0
to 0
the 0
78C1 0
site 0
is 0
enhanced 0
by 0
EGTA 0
and 0
EDTA 0
, 0
these 0
divalent 0
cation 0
chelators 0
specifically 0
stimulate 0
78C1 0
- 0
directed 0
transcription 0
. 0

The 0
human 0
gene 0
fragment 0
ligated 0
to 0
the 0
minimal 0
rat 0
liver 0
glucokinase B-gene
promoter 0
was 0
shown 0
to 0
work 0
as 0
an 0
enhancer 0
in 0
the 0
hepatocyte 0
transfection 0
system 0
. 0

To 0
test 0
the 0
role 0
of 0
ML 0
in 0
human 0
reproductive 0
axis 0
, 0
128 0
healthy 0
children 0
, 0
68 0
boys 0
and 0
60 0
girls 0
, 0
were 0
studied 0
. 0

However 0
, 0
the 0
truncated 0
deer B-gene
receptor I-gene
lacks 0
the 0
most 0
C 0
- 0
terminal 0
tyrosine 0
residue 0
in 0
the 0
intracellular 0
domain 0
which 0
is 0
believed 0
to 0
be 0
essential 0
for 0
activation 0
of 0
the 0
beta B-gene
- I-gene
casein I-gene
promoter I-gene
. 0

This 0
report 0
provides 0
further 0
evidence 0
for 0
the 0
riMLF 0
in 0
the 0
control 0
of 0
downgaze 0
, 0
and 0
a 0
synkinesis 0
is 0
postulated 0
for 0
the 0
development 0
of 0
the 0
convergence 0
retraction 0
nystagmus 0
. 0

Rifabutin 0
has 0
substantial 0
efficacy 0
when 0
combined 0
with 0
other 0
agents 0
. 0

Ninety 0
- 0
four 0
percent 0
of 0
the 0
EPs 0
were 0
tubal 0
, 0
and 0
90 0
% 0
of 0
the 0
tubes 0
exhibited 0
some 0
pathologic 0
changes 0
, 0
including 0
chronic 0
salpingitis 0
( 0
49.5 0
% 0
) 0
and 0
follicular 0
salpingitis 0
( 0
10 0
% 0
) 0
, 0
among 0
others 0
. 0

The 0
assessment 0
using 0
7 0
H 0
9 0
liquid 0
medium 0
by 0
the 0
former 0
author 0
demonstrated 0
the 0
potent 0
activities 0
of 0
both 0
CS 0
- 0
940* 0
and 0
sparfloxacin 0
( 0
SPFX 0
) 0
, 0
followed 0
by 0
AM 0
- 0
1155* 0
, 0
ciprofloxacin 0
( 0
CPFX 0
) 0
, 0
levofloxacin 0
( 0
LVFX 0
) 0
, 0
OPC 0
- 0
17116* 0
, 0
NM 0
- 0
394* 0
in 0
sequence 0
. 0

The 0
STE20 B-gene
gene I-gene
, 0
encoding 0
a 0
protein 0
kinase 0
required 0
for 0
pheromone 0
signal 0
transduction 0
, 0
has 0
recently 0
been 0
identified 0
in 0
a 0
genetic 0
screen 0
for 0
high 0
- 0
gene 0
- 0
dosage 0
suppressors 0
of 0
a 0
partly 0
defective 0
G B-gene
beta I-gene
mutation 0
. 0

This 0
enzyme 0
is 0
designated 0
( B-gene
1 I-gene
- I-gene
- I-gene
> I-gene
4 I-gene
) I-gene
- I-gene
beta I-gene
- I-gene
xylan I-gene
endohydrolase I-gene
isoenzyme I-gene
X I-gene
- I-gene
I I-gene
. 0

Magnetic 0
resonance 0
imaging 0
in 0
coccidioidal 0
arthritis 0
. 0

Moloney 0
murine 0
leukemia 0
virus 0
( 0
MMLV 0
) 0
- 0
derived 0
pUCMoTiN 0
- 0
based 0
retroviral 0
vectors 0
were 0
engineered 0
to 0
allow 0
constitutive 0
and 0
Tat B-gene
( 0
trans B-gene
- I-gene
activator I-gene
of I-gene
transcription I-gene
) 0
- 0
inducible 0
expression 0
of 0
five 0
hammerhead 0
ribozymes 0
targeted 0
against 0
highly 0
conserved 0
sequences 0
within 0
the 0
group B-gene
antigen I-gene
( 0
Gag B-gene
) 0
, 0
protease B-gene
( 0
Pro B-gene
) 0
, 0
reverse B-gene
transcriptase I-gene
( 0
RT B-gene
) 0
, 0
tat B-gene
, 0
and 0
envelope B-gene
( 0
Env B-gene
) 0
coding 0
regions 0
of 0
human 0
immunodeficiency 0
virus 0
type 0
- 0
1 0
( 0
HIV 0
- 0
1 0
) 0
RNA 0
. 0

REM 0
sleep 0
deprivation 0
was 0
performed 0
using 0
the 0
platform 0
technique 0
. 0

The 0
same 0
ligands 0
also 0
exhibit 0
a 0
similar 0
inhibitory 0
effect 0
on 0
PDGF B-gene
- I-gene
BB I-gene
- 0
dependent 0
[ 0
3H 0
] 0
thymidine 0
incorporation 0
in 0
PAE 0
cells 0
expressing 0
the 0
PDGF B-gene
beta I-gene
- I-gene
receptors I-gene
. 0

We 0
analyzed 0
serial 0
biopsy 0
specimens 0
from 0
eight 0
patients 0
with 0
FL 0
for 0
secondary 0
alterations 0
of 0
the 0
rearranged B-gene
bcl I-gene
- I-gene
2 I-gene
gene I-gene
in 0
the 0
breakpoint 0
and 0
open 0
reading 0
frame 0
( 0
ORF 0
) 0
regions 0
. 0

In 0
all 0
eight 0
cases 0
, 0
neither 0
FL 0
nor 0
DLL 0
cells 0
showed 0
alterations 0
of 0
bcl B-gene
- I-gene
2 I-gene
gene I-gene
sequences I-gene
in 0
the 0
breakpoint 0
region 0
, 0
suggesting 0
high 0
conservation 0
of 0
the 0
bcl B-gene
- I-gene
2 I-gene
gene I-gene
during 0
both 0
t 0
( 0
14 0
; 0
18 0
) 0
translocation 0
and 0
morphologic 0
transformation 0
of 0
the 0
FL 0
cells 0
. 0

BACKGROUND 0
: 0
The 0
Bazett 0
- 0
corrected 0
QT 0
( 0
QTc 0
) 0
interval 0
during 0
exercise 0
has 0
been 0
used 0
as 0
a 0
marker 0
for 0
ischemic 0
disease 0
, 0
arrhythmogenic 0
substrate 0
and 0
the 0
long 0
QT 0
syndrome 0
. 0

An 0
essential 0
role 0
of 0
c B-gene
- I-gene
Jun I-gene
and 0
c B-gene
- I-gene
Fos I-gene
in 0
basal 0
and 0
PMA 0
- 0
stimulated 0
transcription 0
of 0
the 0
PAI B-gene
- I-gene
1 I-gene
gene I-gene
is 0
demonstrated 0
by 0
our 0
finding 0
that 0
antisense 0
c B-gene
- I-gene
jun I-gene
and 0
c B-gene
- I-gene
fos I-gene
oligodeoxynucleotides 0
both 0
strongly 0
reduced 0
basal 0
and 0
PMA 0
- 0
stimulated 0
PAI B-gene
- I-gene
1 I-gene
synthesis 0
. 0

Leukemia B-gene
- I-gene
inhibitory I-gene
factor I-gene
( 0
LIF B-gene
) 0
is 0
a 0
neuropoietin B-gene
able 0
to 0
regulate 0
the 0
differentiation 0
and 0
the 0
survival 0
of 0
many 0
cell 0
types 0
, 0
which 0
include 0
some 0
neuronal 0
populations 0
. 0

To 0
analyze 0
the 0
mechanism 0
of 0
fos/jun B-gene
activation 0
by 0
TCDD 0
we 0
have 0
used 0
electrophoretic 0
mobility 0
shift 0
and 0
transient 0
expression 0
assays 0
of 0
reporter 0
gene 0
constructs 0
containing 0
response 0
elements 0
for 0
12 0
- 0
O 0
- 0
tetradecanoyl 0
- 0
phorbol 0
- 0
13 0
- 0
acetate 0
( 0
TRE 0
) 0
, 0
serum 0
( 0
SRE 0
) 0
, 0
cAMP 0
( 0
CRE 0
) 0
, 0
and 0
aromatic 0
hydrocarbons 0
( 0
AhRE 0
) 0
from 0
the 0
fos/jun I-gene

The 0
optimal 0
sequence 0
for 0
interaction 0
with 0
mu B-gene
2 I-gene
and 0
with 0
AP B-gene
- I-gene
2 I-gene
has 0
tyrosine 0
as 0
an 0
anchor 0
and 0
prefers 0
arginine 0
at 0
position 0
Y 0
+ 0
2 0
and 0
leucine 0
at 0
position 0
Y 0
+ 0
3 0
. 0

STK/RON B-gene
- 0
expressing 0
Ba/F3 0
pro 0
- 0
B 0
cells 0
( 0
STK/RON I-gene

In 0
vitro 0
DNase B-gene
I I-gene
footprinting 0
showed 0
that 0
OxyR B-gene
- I-gene
C199S I-gene
protected 0
Pmom B-gene
from 0
- 0
104 0
to 0
- 0
46 0
on 0
the 0
top 0
strand 0
and 0
produced 0
a 0
protection 0
pattern 0
characteristic 0
of 0
reduced B-gene
wild I-gene
- I-gene
type I-gene
OxyR I-gene
. 0

Kss1 B-gene
binds 0
specifically 0
to 0
a 0
GST B-gene
- 0
Dig1 B-gene
fusion 0
in 0
the 0
absence 0
of 0
any 0
other 0
yeast 0
protein 0
. 0

In 0
contrast 0
, 0
dig1 B-gene
dig2 B-gene
cells 0
constitutively 0
invade 0
agar 0
medium 0
, 0
whereas 0
a 0
dig1 B-gene
dig2 B-gene
ste12 B-gene
triple 0
mutant 0
does 0
not 0
, 0
indicating 0
that 0
Dig1 B-gene
and 0
Dig2 B-gene
share 0
a 0
role 0
in 0
negatively 0
regulating 0
the 0
invasive 0
growth 0
pathway 0
. 0

Paracrine 0
activation 0
of 0
the 0
HIV B-gene
- I-gene
1 I-gene
LTR I-gene
promoter I-gene
by 0
the 0
viral B-gene
Tat I-gene
protein I-gene
is 0
mechanistically 0
similar 0
to 0
trans 0
- 0
activation 0
within 0
a 0
cell 0
. 0

Comparison 0
of 0
the 0
sequences 0
of 0
the 0
xFxFG 0
repeat 0
regions 0
of 0
p62 B-gene
and 0
Nsplp B-gene
indicated 0
that 0
NTF2 B-gene
was 0
probably 0
interacting 0
with 0
the 0
phenylalanine 0
- 0
containing 0
core 0
of 0
these 0
repeats 0
and 0
not 0
the 0
intervening 0
hydrophilic 0
linkers 0
. 0

This 0
is 0
the 0
first 0
report 0
of 0
the 0
successful 0
resection 0
of 0
a 0
MFH 0
originating 0
in 0
the 0
renal 0
capsular 0
tissue 0
and 0
extending 0
into 0
the 0
inferior 0
vena 0
cava 0
. 0

Transient 0
expression 0
of 0
VSF B-gene
- I-gene
1 I-gene
in 0
protoplasts 0
stimulated 0
vs B-gene
- I-gene
1 I-gene
dependent 0
activation 0
of 0
the 0
- B-gene
76/grp1.8 I-gene
minimal I-gene
promoter I-gene
. 0

Keeping 0
in 0
mind 0
the 0
limited 0
range 0
of 0
age 0
and 0
dosages 0
, 0
advantages 0
and 0
disadvantages 0
of 0
the 0
drug 0
are 0
discussed 0
, 0
comparing 0
the 0
experimental 0
results 0
with 0
those 0
derived 0
from 0
the 0
literature 0
. 0

Blood 0
sampling 0
procedures 0
were 0
videotaped 0
. 0

Analysis 0
of 0
one 0
cDNA 0
revealed 0
an 0
unusual 0
splicing 0
event 0
involving 0
EZH1 B-gene
and 0
a 0
tandemly 0
linked 0
gene 0
GPR2 B-gene
and 0
suggests 0
a 0
potential 0
mechanism 0
for 0
modifying 0
the 0
EZH1 B-gene
protein I-gene
in 0
the 0
conserved 0
C 0
- 0
terminal 0
domain 0
. 0

A 0
given 0
standard 0
input 0
function 0
and 0
a 0
given 0
value 0
of 0
distribution 0
volume 0
( 0
Vd 0
) 0
used 0
for 0
the 0
rCBF 0
measurement 0
of 0
this 0
method 0
were 0
calculated 0
from 0
the 0
dynamic 0
study 0
by 0
six 0
normal 0
volunteers 0
. 0

They 0
lack 0
a 0
predicted 0
single 0
stranded 0
( 0
ss 0
) 0
DNA 0
binding 0
motif 0
that 0
is 0
unique 0
the 0
large 0
terminase B-gene
proteins I-gene
in 0
T4 B-gene
gp17 I-gene
, 0
and 0
that 0
has 0
been 0
implicated 0
in 0
recognizing 0
ssDNA 0
regions 0
in 0
replicating 0
and 0
recombining 0
T4DNA 0
destined 0
to 0
be 0
packaged 0
. 0

It 0
can 0
be 0
concluded 0
that 0
in 0
normotensive 0
subjects 0
, 0
uric 0
acid 0
and 0
xanthine B-gene
oxidase I-gene
have 0
significant 0
association 0
with 0
blood 0
pressure 0
and 0
thus 0
are 0
one 0
of 0
the 0
many 0
factors 0
which 0
are 0
involved 0
in 0
the 0
cause 0
or 0
effect 0
of 0
hypertension 0
. 0

Immunoblotting 0
of 0
expressed 0
recombinant 0
proteins 0
with 0
the 0
monoclonal B-gene
08L I-gene
antibody I-gene
localized 0
the 0
08L B-gene
epitope 0
to 0
the 0
carboxyl 0
end 0
of 0
the 0
protein 0
. 0

We 0
infer 0
that 0
the 0
dominant 0
negative 0
inhibition 0
results 0
from 0
both 0
direct 0
proteolysis 0
of 0
the 0
beta B-gene
- I-gene
galactosidase I-gene
tetramer I-gene
by 0
the 0
fusion 0
subunit 0
and 0
detour 0
of 0
the 0
tetramer 0
to 0
the 0
lysosome 0
. 0

The 0
current 0
study 0
defines 0
the 0
vinculin B-gene
- 0
and 0
FAK B-gene
- I-gene
interaction I-gene
domains I-gene
on 0
paxillin B-gene
and 0
identifies 0
the 0
principal 0
paxillin B-gene
focal 0
adhesion 0
targeting 0
motif 0
. 0

These 0
data 0
demonstrate 0
the 0
presence 0
of 0
a 0
single 0
binding 0
site 0
for 0
vinculin B-gene
, 0
and 0
at 0
least 0
two 0
binding 0
sites 0
for 0
FAK B-gene
that 0
are 0
separated 0
by 0
an 0
intervening 0
stretch 0
of 0
100 0
amino 0
acids 0
. 0

These 0
data 0
demonstrate 0
that 0
paxillin B-gene
localizes 0
to 0
focal 0
adhesions 0
independent 0
of 0
interactions 0
with 0
vinculin B-gene
and/or 0
FAK B-gene
, 0
and 0
represents 0
the 0
first 0
definitive 0
demonstration 0
of 0
LIM B-gene
domains I-gene
functioning 0
as 0
a 0
primary 0
determinant 0
of 0
protein 0
subcellular 0
localization 0
to 0
focal 0
adhesions 0
. 0

A 0
single 0
protease 0
- 0
resistant 0
structure 0
formed 0
by 0
the 0
entirety 0
of 0
both 0
PDZ B-gene
repeats I-gene
1 I-gene
and I-gene
2 I-gene
( 0
PDZ1 B-gene
- I-gene
2 I-gene
) 0
contains 0
the 0
protein B-gene
4.1 I-gene
- I-gene
binding I-gene
site I-gene
. 0

Several 0
agents 0
have 0
been 0
tried 0
for 0
treatment 0
, 0
often 0
limited 0
by 0
toxic 0
side 0
effects 0
. 0

Jerseys 0
had 0
higher 0
hepatic 0
Cu 0
concentrations 0
than 0
did 0
Holsteins 0
on 0
d 0
60 0
( 0
346 0
vs 0
. 0

RUSH B-gene
- I-gene
1 I-gene
beta I-gene
is 0
a 0
95 0
- 0
kDa 0
truncated 0
version 0
of 0
RUSH B-gene
- I-gene
1 I-gene
alpha I-gene
that 0
results 0
from 0
alternative 0
splicing 0
of 0
a 0
57 0
- 0
bp 0
exon 0
as 0
confirmed 0
by 0
genomic 0
cloning 0
. 0

These 0
results 0
are 0
consistent 0
with 0
the 0
well 0
established 0
polarity 0
of 0
RXR B-gene
heterodimer 0
binding 0
to 0
bipartite 0
hormone 0
response 0
elements 0
, 0
with 0
the 0
VDR B-gene
recognizing 0
the 0
3' 0
- 0
half 0
- 0
element 0
. 0

PPAR B-gene
gamma I-gene
mRNA I-gene
levels 0
were 0
reduced 0
by 0
95 0
% 0
with 0
3 0
nM 0
TNF B-gene
alpha I-gene
treatment 0
for 0
24 0
h 0
. 0

Exons 0
III 0
to 0
VIII 0
, 0
which 0
cover 0
the 0
coding 0
region 0
and 0
the 0
3 0
' 0
untranslated 0
region 0
, 0
are 0
almost 0
identical 0
in 0
all 0
types 0
of 0
PST B-gene
or 0
AST B-gene
cDNAs I-gene
. 0

Growth 0
factor 0
allows 0
effective 0
dose 0
- 0
intensive 0
regimen 0
in 0
advanced 0
breast 0
cancer 0
patients 0
. 0

Recombinant B-gene
erythropoietin I-gene
( 0
r B-gene
- I-gene
HuEPO I-gene
) 0
in 0
the 0
treatment 0
of 0
anemia 0
in 0
multiple 0
myeloma 0

In 0
1993 0
and 0
1994 0
and 0
infection 0
with 0
body 0
lice 0
was 0
registered 0
41 0
times 0
in 0
31 0
patients 0
at 0
the 0
clinic 0
for 0
homeless 0
of 0
the 0
Community 0
Health 0
Service 0
of 0
Utrecht 0
. 0

Ki B-gene
- I-gene
ras I-gene
and 0
p53 B-gene
mutations I-gene
in 0
pancreatic 0
ductal 0
adenocarcinoma 0
. 0

Epidemiological 0
data 0
are 0
quite 0
controversial 0
but 0
sudden 0
death 0
occurring 0
during 0
sporting 0
activity 0
is 0
probably 0
not 0
a 0
rare 0
occurrence 0
. 0

However 0
, 0
the 0
ratio 0
M/Pc 0
provides 0
a 0
useful 0
index 0
that 0
seems 0
to 0
be 0
independent 0
of 0
the 0
metabolic 0
demand 0
. 0

Rat B-gene
liver I-gene
catalase I-gene
is 0
sorted 0
to 0
peroxisomes 0
by 0
its 0
C 0
- 0
terminal 0
tripeptide 0
Ala 0
- 0
Asn 0
- 0
Leu 0
, 0
not 0
by 0
the 0
internal 0
Ser 0
- 0
Lys 0
- 0
Leu 0
motif 0
. 0

The 0
mobility 0
shift 0
assay 0
of 0
the 0
65 0
bp 0
( 0
- 0
318/ 0
- 0
254 0
) 0
fragment 0
with 0
nuclear 0
extract 0
from 0
the 0
dark 0
- 0
adapted 0
sample 0
showed 0
an 0
additional 0
band 0
, 0
not 0
seen 0
with 0
the 0
light 0
- 0
grown 0
sample 0
. 0

These 0
data 0
provide 0
strong 0
evidence 0
that 0
E2F B-gene
or 0
an 0
E2F B-gene
- I-gene
related I-gene
transcription I-gene
factor I-gene
is 0
involved 0
in 0
the 0
regulation 0
of 0
nonmuscle B-gene
myosin I-gene
expression 0
. 0

When 0
the 0
E1A B-gene
N I-gene
- I-gene
terminus I-gene
is 0
used 0
as 0
a 0
competitor 0
in 0
squelshing 0
experiments 0
it 0
abolishes 0
CBP B-gene
- 0
induced 0
activation 0
of 0
E2F1/DP1 B-gene
, 0
whereas 0
an 0
E2F1/DP1 I-gene

Small 0
Maf B-gene
proteins I-gene
interact 0
with 0
the 0
human 0
transcription 0
factor 0
TCF11/Nrf1/LCR B-gene
TCF11/Nrf1/LCR I-gene

On 0
the 0
third 0
occasion 0
water 0
( 0
W 0
) 0
was 0
ingested 0
throughout 0
the 0
run 0
. 0

The 0
effect 0
of 0
maternal 0
ingestion 0
of 0
the 0
reduced 0
energy 0
sweetener 0
erythritol 0
was 0
investigated 0
in 0
KBL 0
: 0
JW 0
strain 0
pregnant 0
rabbits 0
. 0

Moreover 0
, 0
the 0
same 0
mutations 0
alter 0
the 0
structure 0
of 0
junB B-gene
5 0
' 0
flanking 0
DNA 0
within 0
chromatin 0
. 0

The 0
nm23 B-gene
- I-gene
H1/nm23 I-gene
H1/nm23 I-gene
- I-gene
H2 I-gene
gene 0
transcriptional 0
activity 0
ratio 0
varied 0
depending 0
on 0
the 0
cell 0
line 0
. 0

CONCLUSION 0
: 0
Intravenous 0
diazepam 0
administration 0
before 0
EGD 0
produces 0
a 0
significant 0
fall 0
in 0
SpO2 0
during 0
the 0
procedure 0
, 0
and 0
so 0
should 0
be 0
avoided 0
; 0
continuous 0
monitoring 0
of 0
SpO2 0
should 0
be 0
done 0
during 0
EGD 0
. 0

The 0
nucleotide 0
sequence 0
alignment 0
between 0
mouse 0
and 0
human B-gene
CA I-gene
IV I-gene
shows 0
69 0
% 0
identity 0
in 0
the 0
coding 0
region 0
and 0
all 0
of 0
the 0
exon 0
- 0
intron 0
boundaries 0
are 0
conserved 0
, 0
as 0
are 0
the 0
sizes 0
of 0
the 0
introns 0
. 0

Discordance 0
on 0
the 0
cost 0
dimension 0
correlated 0
negatively 0
with 0
G B-gene
Hb I-gene
, 0
suggesting 0
better 0
glycemic 0
control 0
with 0
greater 0
disagreement 0
. 0

DATA 0
SOURCES 0
: 0
Epidemiologic 0
studies 0
, 0
research 0
studies 0
, 0
review 0
articles 0
, 0
and 0
government 0
reports 0
pertaining 0
to 0
epidemiology 0
of 0
lung 0
cancer 0
. 0

RESULTS 0
: 0
The 0
age 0
distribution 0
was 0
28 0
to 0
83 0
years 0
old 0
( 0
mean 0
was 0
54.1 0
years 0
) 0
. 0

Histological 0
changes 0
, 0
including 0
cortical 0
cell 0
involution 0
and 0
hemorrhage 0
occurring 0
during 0
the 0
neonatal 0
period 0
, 0
would 0
seem 0
to 0
have 0
crucial 0
relevance 0
to 0
the 0
remodeling 0
of 0
the 0
adrenal 0
vasculature 0
. 0

Furthermore 0
, 0
co 0
- 0
expression 0
of 0
both 0
p46 B-gene
and 0
p54 B-gene
subunits I-gene
markedly 0
altered 0
the 0
subcellular 0
distribution 0
of 0
p46 B-gene
; 0
co 0
- 0
expressed 0
p46 B-gene
was 0
transported 0
into 0
the 0
nucleus 0
as 0
efficiently 0
as 0
p54 B-gene
. 0

The 0
results 0
suggest 0
that 0
, 0
although 0
both 0
the 0
N 0
- 0
and 0
C 0
- 0
terminal 0
regions 0
of 0
talin B-gene
bind 0
actin B-gene
, 0
the 0
properties 0
of 0
these 0
two 0
regions 0
of 0
the 0
protein 0
are 0
distinct 0
. 0

Merr 0
. 0
) 0
embryo 0
library 0
. 0

The 0
accumulation 0
of 0
both 0
LHA4 B-gene
and 0
LHA2 B-gene
mRNAs I-gene
is 0
induced 0
by 0
the 0
addition 0
of 0
exogenous 0
sugars 0
and 0
this 0
induction 0
appears 0
to 0
be 0
dependent 0
on 0
sugar 0
uptake 0
and 0
metabolism 0
, 0
because 0
mannitol 0
and 0
3 0
- 0
O 0
- 0
methylglucose 0
do 0
not 0
stimulate 0
mRNA 0
accumulation 0
. 0

Using 0
the 0
yeast 0
one 0
- 0
hybrid 0
screen 0
with 0
integrated 0
NRE 0
and 0
flanking 0
DNA 0
as 0
bait 0
, 0
the 0
predominant 0
clone 0
obtained 0
was 0
bovine B-gene
Nrl I-gene
. 0

As 0
the 0
rate 0
of 0
protein 0
synthesis 0
decreases 0
during 0
late 0
embryogenesis 0
, 0
levels 0
of 0
SEC B-gene
- I-gene
1 I-gene
and 0
its 0
cognate 0
mRNA 0
decline 0
precipitously 0
. 0

These 0
findings 0
suggest 0
that 0
fodrin B-gene
proteolysis 0
in 0
vivo 0
may 0
reflect 0
the 0
activity 0
of 0
multiple 0
ICE/Ced B-gene
ICE/Ced I-gene
- I-gene
3 I-gene
proteases 0
whose 0
partial 0
sensitivity 0
to 0
DEVD 0
- 0
CHO 0
reflects 0
a 0
limited 0
contribution 0
from 0
CPP32 B-gene
, 0
or 0
an 0
ICE/Ced B-gene
ICE/Ced I-gene
- I-gene
3 I-gene
protease 0
less 0
sensitive 0
than 0
CPP32 B-gene
to 0
DEVD 0
- 0
CHO 0
inhibition 0
. 0

In 0
3Y1 0
and 0
3Y1 0
v B-gene
- I-gene
crk I-gene
- 0
transformed 0
fibroblasts 0
, 0
almost 0
all 0
of 0
the 0
total 0
PTP1B B-gene
and 0
about 0
40 0
% 0
of 0
total 0
p130 B-gene
( 0
Cas B-gene
) 0
co 0
- 0
sediment 0
with 0
membranes 0
composed 0
primarily 0
of 0
endoplasmic 0
reticulum 0
. 0

Replacing 0
residues 0
405 0
- 0
419 0
on 0
delta419 0
with 0
the 0
conserved 0
AF 0
- 0
2 0
domain 0
from 0
the 0
vitamin B-gene
D3 I-gene
receptor I-gene
or 0
the 0
estrogen B-gene
receptor I-gene
results 0
in 0
a 0
receptor 0
with 0
wild 0
- 0
type 0
or 0
low 0
transcriptional 0
activity 0
, 0
respectively 0
. 0

Recurrent 0
G 0
- 0
to 0
- 0
A 0
substitution 0
in 0
a 0
single 0
codon 0
of 0
SREBP B-gene
cleavage I-gene
- I-gene
activating I-gene
protein I-gene
causes 0
sterol 0
resistance 0
in 0
three 0
mutant 0
Chinese 0
hamster 0
ovary 0
cell 0
lines 0
. 0

The 0
Escherichia B-gene
coli I-gene
tet I-gene
- I-gene
repressor I-gene
( 0
TetR B-gene
) 0
operator 0
system 0
was 0
used 0
to 0
develop 0
a 0
variation 0
of 0
the 0
yeast 0
two 0
- 0
hybrid 0
assay 0
in 0
which 0
disruptions 0
of 0
protein 0
- 0
protein 0
interactions 0
can 0
be 0
identified 0
by 0
a 0
positive 0
selection 0
. 0

Recent 0
studies 0
have 0
suggested 0
that 0
SHP B-gene
- I-gene
1 I-gene
regulates 0
the 0
function 0
of 0
Jak B-gene
family 0
tyrosine B-gene
kinases I-gene
, 0
as 0
shown 0
by 0
its 0
constitutive 0
association 0
with 0
the 0
Tyk2 B-gene
kinase I-gene
and 0
the 0
hyperphosphorylation 0
of 0
Jak B-gene
kinases I-gene
in 0
the 0
motheaten 0
cells 0
that 0
lack 0
functional 0
SHP B-gene
- I-gene
1 I-gene
. 0

Administration 0
of 0
a 0
second 0
dose 0
of 0
vaccine 0
during 0
the 0
outbreak 0
was 0
not 0
protective 0
. 0

But 0
, 0
as 0
Theriault 0
explains 0
, 0
improvements 0
in 0
assessing 0
exposure 0
have 0
not 0
yet 0
translated 0
into 0
clear 0
and 0
consistent 0
findings 0
. 0

Biol 0
. 0

Structural 0
basis 0
for 0
activation 0
of 0
human B-gene
lymphocyte I-gene
kinase I-gene
Lck B-gene
upon 0
tyrosine 0
phosphorylation 0
. 0

Evolutive 0
morphology 0
of 0
the 0
olfactory 0
bulb 0
in 0
man 0
and 0
certain 0
non 0
- 0
human 0
mammals 0

From 0
these 0
results 0
, 0
we 0
concluded 0
that 0
this 0
ORF 0
is 0
the 0
FRDS B-gene
gene I-gene
. 0

FK506 0
is 0
10 0
- 0
to 0
100 0
- 0
fold 0
more 0
potent 0
than 0
cyclosporin 0
A 0
in 0
preventing 0
organ 0
rejection 0
and 0
in 0
toxicity 0
. 0

These 0
results 0
suggest 0
that 0
Rho1p B-gene
regulates 0
cytoskeletal 0
reorganization 0
at 0
least 0
through 0
Bni1p B-gene
and 0
Pkc1p B-gene
. 0

The 0
ERH B-gene
expression 0
profile 0
is 0
similar 0
, 0
to 0
that 0
of 0
An3 B-gene
, 0
which 0
localizes 0
to 0
the 0
animal 0
hemisphere 0
of 0
oocytes 0
and 0
is 0
abundantly 0
expressed 0
in 0
the 0
embryo 0
. 0

Waves 0
N1 0
, 0
P3 0
and 0
CNV 0
were 0
recorded 0
during 0
a 0
CNV 0
paradigm 0
in 0
a 0
simple 0
reaction 0
time 0
task 0
with 0
a 0
constant 0
interstimulus 0
interval 0
( 0
ISI 0
) 0
of 0
1 0
sec 0
. 0

Therefore 0
, 0
both 0
the 0
Chilean 0
and 0
the 0
Japanese 0
samples 0
collected 0
in 0
high 0
- 0
risk 0
areas 0
showed 0
higher 0
mutagenic 0
rates 0
than 0
the 0
Japanese 0
ones 0
in 0
a 0
low 0
- 0
risk 0
area 0
, 0
with 0
a 0
statistical 0
significance 0
( 0
p 0
< 0
0.001 0
) 0
, 0
chi 0
- 0
square 0
test 0
) 0
. 0

Regulation 0
of 0
ASN1 B-gene
and 0
ASN2 B-gene
expression 0
was 0
studied 0
using 0
lacZ B-gene
fusions I-gene
and 0
both 0
genes 0
were 0
found 0
to 0
be 0
several 0
times 0
less 0
expressed 0
in 0
the 0
absence 0
of 0
the 0
transcription 0
activator 0
Gcn4p B-gene
. 0

Several 0
particular 0
features 0
of 0
this 0
polypeptide 0
fragment 0
from 0
the 0
hamster B-gene
lysyl I-gene
- I-gene
tRNA I-gene
synthetase I-gene
suggest 0
that 0
it 0
is 0
implicated 0
in 0
the 0
assembly 0
of 0
that 0
enzyme 0
within 0
the 0
multisynthetase 0
complex 0
. 0

He 0
is 0
well 0
, 0
five 0
years 0
after 0
relapse 0
. 0

Comparison 0
of 0
the 0
proportion 0
of 0
nonsynonymous 0
( 0
pN 0
) 0
and 0
synonymous 0
( 0
pS 0
) 0
substitutions 0
occurring 0
per 0
site 0
within 0
tamarin B-gene
variable I-gene
region I-gene
genes I-gene
demonstrated 0
a 0
reduction 0
in 0
pN 0
in 0
the 0
framework 0
regions 0
compared 0
with 0
pN 0
in 0
the 0
presumed 0
MHC B-gene
contact I-gene
regions I-gene
( 0
CDR1 B-gene
and 0
CDR2 B-gene
) 0
. 0

The 0
effects 0
of 0
oral 0
vanadyl 0
sulfate 0
( 0
VOSO4 0
) 0
( 0
0.5 0
mg/kg/day 0
) 0
on 0
anthropometry 0
, 0
body 0
composition 0
, 0
and 0
performance 0
were 0
investigated 0
in 0
a 0
12 0
- 0
week 0
, 0
double 0
- 0
blind 0
, 0
placebo 0
- 0
controlled 0
trial 0
involving 0
weight 0
- 0
training 0
volunteers 0
. 0

Later 0
in 0
development 0
, 0
Tbx6 B-gene
expression 0
is 0
restricted 0
to 0
presomitic 0
, 0
paraxial 0
mesoderm 0
and 0
to 0
the 0
tail 0
bud 0
, 0
which 0
replaces 0
the 0
streak 0
as 0
the 0
source 0
of 0
mesoderm 0
. 0

Disruption 0
of 0
re 0
- 0
replication 0
control 0
by 0
overexpression 0
of 0
human B-gene
ORC1 I-gene
in 0
fission 0
yeast 0
. 0

Our 0
results 0
demonstrate 0
that 0
the 0
promoter 0
and 0
enhancer 0
regions 0
identified 0
here 0
are 0
essential 0
for 0
maintaining 0
the 0
efficient 0
promoter 0
activity 0
of 0
the 0
human B-gene
activin I-gene
betaA I-gene
subunit I-gene
gene I-gene
. 0

Recombinant 0
, 0
bacterially 0
expressed 0
PIP5KIalpha B-gene
possessed 0
PIP5K B-gene
activity 0
and 0
was 0
immunoreactive 0
with 0
erythroid B-gene
PIP5KI I-gene
antibodies I-gene
. 0

Human B-gene
acid I-gene
ceramidase I-gene
( 0
( B-gene
AC I-gene
) I-gene
N I-gene
- I-gene
acylsphingosine I-gene
amidohydrolase I-gene
, 0
EC B-gene
3.5 I-gene
. 0

The 0
0.22 0
- 0
kb 0
NheI/BglII B-gene
promoter 0
exhibited 0
PMA 0
inducibility 0
in 0
myeloid 0
cells 0
and 0
contained 0
a 0
PMA 0
- 0
responsive 0
element 0
recognized 0
by 0
NheI/BglII I-gene

Northern 0
( 0
RNA 0
) 0
blot 0
analyses 0
indicated 0
that 0
the 0
cdh B-gene
genes I-gene
encoding 0
the 0
five 0
subunits 0
and 0
an 0
open 0
reading 0
frame 0
( 0
ORF1 0
) 0
with 0
unknown 0
function 0
are 0
cotranscribed 0
during 0
growth 0
on 0
acetate 0
. 0

Two 0
classes 0
of 0
mutations 0
were 0
obtained 0
: 0
( 0
i 0
) 0
those 0
that 0
altered 0
the 0
coding 0
region 0
of 0
HOL1 B-gene
, 0
conferring 0
the 0
ability 0
to 0
take 0
up 0
histidinol 0
; 0
and 0
( 0
ii 0
) 0
cis 0
- 0
acting 0
mutations 0
( 0
selected 0
in 0
a 0
mutant 0
HOL1 B-gene
- I-gene
1 I-gene
background 0
) 0
that 0
increased 0
expression 0
of 0
the 0
Hol1 B-gene
protein I-gene
. 0

Damage 0
to 0
the 0
BBB 0
was 0
judged 0
by 0
extravasation 0
of 0
Evans 0
Blue 0
( 0
EB 0
) 0
dye 0
, 0
which 0
was 0
administered 0
either 0
2 0
, 0
3 0
, 0
24 0
or 0
48 0
h 0
after 0
onset 0
of 0
MCAo 0
. 0

Lipid 0
hydroperoxide 0
levels 0
in 0
plasma 0
and 0
LDL B-gene
remained 0
unchanged 0
throughout 0
the 0
study 0
. 0

When 0
the 0
degree 0
of 0
exercise 0
was 0
maximal 0
, 0
mPAP 0
was 0
maintained 0
, 0
SVI 0
decreased 0
, 0
HR 0
was 0
unchanged 0
, 0
and 0
CO 0
and 0
VO2 0
decreased 0
. 0

We 0
report 0
a 0
case 0
of 0
vasculitis 0
( 0
cutaneous 0
and 0
neurologic 0
) 0
which 0
led 0
to 0
the 0
discovery 0
of 0
a 0
selective 0
immunodeficit 0
towards 0
EBV 0
, 0
similar 0
to 0
Purtilo 0
's 0
syndrome 0
. 0

To 0
elucidate 0
whether 0
potential 0
endocrine 0
changes 0
resulted 0
from 0
acute 0
hypoxaemia 0
alone 0
, 0
the 0
underlying 0
disease 0
, 0
or 0
unspecific 0
influences 0
connected 0
with 0
the 0
ICU 0
setting 0
, 0
all 0
measurements 0
were 0
compared 0
to 0
those 0
of 0
a 0
completely 0
healthy 0
reference 0
group 0
( 0
REF 0
) 0
with 0
comparable 0
acute 0
experimental 0
hypoxaemia 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
graft 0
survival 0
between 0
groups 0
with 0
early 0
graft 0
function 0
( 0
EGF 0
) 0
and 0
DGF 0
, 0
either 0
in 0
first 0
transplantations 0
or 0
retransplantations 0
. 0

These 0
results 0
suggested 0
that 0
the 0
GG 0
motifs 0
contributed 0
to 0
the 0
cell 0
- 0
specific 0
transcription 0
of 0
the 0
human B-gene
insulin I-gene
gene I-gene
in 0
association 0
with 0
the 0
binding 0
of 0
the 0
sequence 0
- 0
specific 0
nuclear 0
factor 0
. 0

Abnormal 0
urinary 0
coproporphyrin 0
levels 0
in 0
patients 0
infected 0
by 0
hepatitis 0
C 0
virus 0
with 0
or 0
without 0
human 0
immunodeficiency 0
virus 0
. 0

The 0
determination 0
of 0
immunoglobulin B-gene
E I-gene
( 0
IgE B-gene
) 0
antibodies 0
by 0
one 0
of 0
several 0
laboratory 0
tests 0
, 0
by 0
skin 0
- 0
prick 0
tests 0
or 0
by 0
appropriate 0
challenge 0
procedures 0
is 0
useful 0
either 0
to 0
identify 0
atopic 0
individuals 0
or 0
as 0
outcome 0
predictors 0
in 0
wheezy 0
children 0
. 0

Thrombosis 0
of 0
the 0
renal 0
vein 0
may 0
be 0
dramatic 0
and 0
include 0
renal 0
failure 0
. 0

Filter 0
and 0
cytocentrifuge 0
preparations 0
of 0
the 0
urine 0
were 0
studied 0
and 0
all 0
cases 0
displayed 0
numerous 0
scattered 0
aggregates 0
or 0
single 0
tumor 0
cells 0
in 0
an 0
inflammatory 0
background 0
. 0

327 0
and 0
736 0
protocols 0
of 0
postmortem 0
examinations 0
from 0
Moscow 0
hospitals 0
N 0
31 0
and 0
57 0
, 0
respectively 0
, 0
were 0
evaluated 0
statistically 0
. 0

The 0
promoter 0
segment 0
was 0
inactive 0
when 0
introduced 0
into 0
the 0
rat 0
glioma 0
cell 0
line 0
C6B4 0
, 0
the 0
rat 0
submandibular 0
cell 0
line 0
RSMT 0
- 0
A5 0
, 0
and 0
the 0
rat 0
pancreatic 0
beta 0
cell 0
line 0
RIN 0
- 0
5AH 0
, 0
all 0
of 0
which 0
do 0
not 0
express 0
the 0
endogenous 0
alpha2c B-gene
- I-gene
AR I-gene
gene I-gene
. 0

The 0
sequencing 0
of 0
the 0
conditional 0
lethal 0
mutation 0
ts 0
- 0
A13 0
, 0
localized 0
in 0
the 0
nrdE B-gene
cistron I-gene
, 0
and 0
the 0
lethality 0
of 0
insertional 0
mutations 0
targeted 0
in 0
the 0
internal 0
region 0
of 0
nrdE B-gene
and 0
nrdF B-gene
, 0
demonstrated 0
the 0
essential 0
role 0
of 0
this 0
locus 0
. 0

The 0
microdensitometric 0
scores 0
and 0
their 0
side 0
- 0
to 0
- 0
side 0
differences 0
in 0
patients 0
correlated 0
negatively 0
with 0
the 0
serum 0
25 0
- 0
OHD 0
concentration 0
and 0
positively 0
with 0
the 0
degree 0
of 0
paralysis 0
. 0

These 0
data 0
do 0
not 0
support 0
the 0
use 0
of 0
LDD 0
to 0
reduce 0
risk 0
of 0
progression 0
to 0
MSOF 0
in 0
sepsis 0
. 0

This 0
correlated 0
with 0
reduced 0
levels 0
of 0
secreted 0
hepatitis B-gene
B I-gene
e I-gene
antigen I-gene
and 0
increased 0
intracellular 0
levels 0
of 0
core B-gene
and 0
Pol B-gene
proteins I-gene
and 0
replicative 0
HBV 0
DNA 0
intermediates 0
. 0

In 0
contrast 0
, 0
extracts 0
of 0
the 0
mutant 0
virions 0
catalyze 0
the 0
wild 0
- 0
type 0
level 0
of 0
transcription 0
from 0
an 0
exogenous 0
template 0
containing 0
an 0
early 0
promoter 0
. 0

The 0
SCMV B-gene
SNE I-gene
sites I-gene
contain 0
potential 0
overlapping 0
core 0
recognition 0
binding 0
motifs 0
for 0
SRF B-gene
, 0
Rel/NFkappaB B-gene
, 0
Rel/NFkappaB I-gene

Upon 0
serum 0
withdrawal 0
at 0
the 0
permissive 0
temperature 0
, 0
p53 B-gene
- 0
mediated 0
apoptosis 0
was 0
induced 0
in 0
50 0
to 0
60 0
% 0
of 0
the 0
cells 0
. 0

To 0
circumvent 0
this 0
problem 0
, 0
a 0
simple 0
two 0
- 0
step 0
strategy 0
was 0
devised 0
by 0
which 0
essential 0
cis 0
- 0
acting 0
sites 0
like 0
the 0
a 0
sequence 0
can 0
be 0
readily 0
deleted 0
from 0
their 0
natural 0
loci 0
in 0
large 0
viral 0
DNA 0
genomes 0
. 0

On 0
the 0
basis 0
of 0
serological 0
studies 0
, 0
the 0
highly 0
conserved 0
A 0
domain 0
of 0
HspA B-gene
was 0
found 0
to 0
be 0
the 0
immunodominant 0
domain 0
. 0

In 0
Group 0
IV 0
dogs 0
that 0
received 0
alpha B-gene
- I-gene
MSH I-gene
only 0
during 0
reperfusion 0
, 0
BAEPs 0
were 0
increased 0
approximately 0
10 0
to 0
14 0
% 0
more 0
than 0
in 0
Group 0
II 0
during 0
the 0
late 0
reperfusion 0
period 0
. 0

The 0
Fas B-gene
receptor I-gene
mediates 0
a 0
signalling 0
cascade 0
resulting 0
in 0
programmed 0
cell 0
death 0
( 0
apoptosis 0
) 0
within 0
hours 0
of 0
receptor 0
cross 0
- 0
linking 0
. 0

Fas B-gene
has 0
been 0
shown 0
to 0
require 0
ICE B-gene
( 0
interleukin B-gene
- I-gene
1 I-gene
beta I-gene
- I-gene
converting I-gene
enzyme I-gene
) 0
family 0
proteases 0
to 0
induce 0
apoptosis 0
from 0
studies 0
utilizing 0
the 0
cowpox 0
ICE B-gene
inhibitor I-gene
protein I-gene
CrmA B-gene
, 0
the 0
synthetic 0
tetrapeptide 0
ICE B-gene
inhibitor 0
YVAD B-gene
- I-gene
CMK I-gene
, 0
and 0
the 0
tripeptide 0
pan 0
- 0
ICE B-gene
inhibitor 0
Z B-gene
- I-gene
VAD I-gene
- I-gene
FMK I-gene
. 0

The 0
imprinted 0
expression 0
of 0
the 0
endogenous 0
gene 0
can 0
be 0
recapitulated 0
in 0
mice 0
by 0
using 0
a 0
14 0
- 0
kb 0
transgene 0
encompassing 0
4 0
kb 0
of 0
5' 0
- 0
flanking 0
sequence 0
, 0
8 0
kb 0
of 0
3' 0
- 0
flanking 0
sequence 0
, 0
which 0
includes 0
the 0
two 0
endoderm 0
- 0
specific 0
enhancers 0
, 0
and 0
an 0
internally 0
deleted 0
structural 0
gene 0
. 0

In 0
this 0
report 0
, 0
we 0
demonstrate 0
that 0
hGCN5 B-gene
is 0
also 0
an 0
HAT B-gene
and 0
has 0
the 0
same 0
substrate 0
specificity 0
as 0
yGCN5 B-gene
. 0

The 0
effect 0
of 0
six 0
arginine 0
mutations 0
of 0
oxidative 0
phosphorylation 0
and 0
AAC B-gene
expression 0
. 0

Complementary 0
DNAs 0
encompassing 0
the 0
coat B-gene
protein I-gene
coding 0
and 0
adjacent 0
regions 0
of 0
Agropyron 0
mosaic 0
virus 0
( 0
AgMV 0
) 0
and 0
Hordeum 0
mosaic 0
virus 0
( 0
HoMV 0
) 0
were 0
cloned 0
and 0
sequenced 0
. 0

In 0
some 0
cases 0
, 0
factor 0
- 0
induced 0
Rac B-gene
activation 0
results 0
in 0
Rho B-gene
activation 0
, 0
and 0
factor 0
- 0
induced 0
Cdc42 B-gene
activation 0
leads 0
to 0
Rac B-gene
activation 0
, 0
as 0
determined 0
by 0
specific 0
morphological 0
changes 0
. 0

Several 0
cDNAs 0
corresponding 0
to 0
the 0
human B-gene
PWP2 I-gene
gene I-gene
were 0
identified 0
and 0
partially 0
sequenced 0
. 0

Isolation 0
and 0
genomic 0
structure 0
of 0
a 0
human 0
homolog 0
of 0
the 0
yeast B-gene
periodic I-gene
tryptophan I-gene
protein I-gene
2 I-gene
( 0
PWP2 B-gene
) 0
gene 0
mapping 0
to 0
21q22.3 0
. 0

Patterns 0
defined 0
by 0
combinations 0
of 0
normal 0
and 0
abnormal 0
laboratory 0
results 0
had 0
decreased 0
the 0
likelihood 0
of 0
PEM 0
from 0
an 0
all 0
- 0
2 0
to 0
all 0
- 0
0 0
pattern 0
. 0

To 0
examine 0
whether 0
thiamine 0
( 0
vitamin 0
B1 0
) 0
deficiency 0
is 0
associated 0
with 0
recurrent 0
aphthous 0
stomatitis 0
, 0
we 0
studied 0
vitamin 0
B1 0
levels 0
in 0
70 0
patients 0
with 0
recurrent 0
aphthous 0
stomatitis 0
and 0
in 0
50 0
members 0
of 0
a 0
control 0
group 0
. 0

Liver 0
injuries 0

By 0
screening 0
a 0
cDNA 0
library 0
with 0
a 0
probe 0
derived 0
from 0
sequences 0
downstream 0
of 0
the 0
p53p2 B-gene
start 0
site 0
, 0
we 0
have 0
cloned 0
and 0
characterized 0
a 0
cDNA 0
that 0
represents 0
a 0
mRNA 0
that 0
appears 0
to 0
have 0
been 0
initiated 0
from 0
the 0
p53p2 B-gene
promoter I-gene
. 0

However 0
, 0
we 0
did 0
not 0
observe 0
a 0
correlation 0
between 0
serum 0
and 0
seminal B-gene
plasma I-gene
PSA I-gene
levels 0
. 0

The 0
implications 0
for 0
estimates 0
of 0
cortical 0
magnification 0
and 0
possible 0
differences 0
in 0
the 0
specializations 0
of 0
foveal 0
and 0
peripheral 0
vision 0
are 0
discussed 0
. 0

G B-gene
- I-gene
CSF I-gene
activates 0
multiple 0
signaling 0
molecules 0
, 0
including 0
the 0
JAK1 B-gene
and 0
JAK2 B-gene
kinases I-gene
and 0
the 0
STAT B-gene
transcription 0
factors 0
. 0

Mutants 0
lacking 0
any 0
tyrosine 0
residues 0
in 0
the 0
cytoplasmic 0
domain 0
maintain 0
their 0
ability 0
to 0
activate 0
STAT5 B-gene
and 0
STAT1 B-gene
but 0
can 0
not 0
activate 0
STAT3 B-gene
, 0
implying 0
that 0
STAT5 B-gene
and 0
STAT1 B-gene
activation 0
does 0
not 0
require 0
receptor 0
tyrosine 0
phosphorylation 0
. 0

The 0
RI B-gene
alpha I-gene
gene I-gene
is 0
composed 0
of 0
nine 0
coding 0
exons 0
of 0
varying 0
lengths 0
, 0
separated 0
by 0
introns 0
, 0
giving 0
the 0
gene 0
a 0
total 0
length 0
of 0
at 0
least 0
21 0
kb 0
. 0
our 0
recent 0
cloning 0
of 0
a 0
processed 0
RI B-gene
alpha I-gene
pseudogene I-gene
with 0
a 0
5' 0
- 0
noncoding 0
region 0
different 0
from 0
the 0
previously 0
reported 0
RI B-gene
alpha I-gene
complementary I-gene
RNA I-gene
indicated 0
that 0
the 0
RI B-gene
alpha I-gene
gene I-gene
may 0
have 0
multiple 0
leader 0
exons 0
giving 0
rise 0
to 0
alternately 0
spliced 0
messenger 0
RNAs 0
( 0
mRNAs 0
) 0
. 0

This 0
establishes 0
Rad3/Mec1 B-gene
as 0
the 0
only 0
conserved 0
protein 0
which 0
is 0
required 0
for 0
all 0
the 0
DNA 0
structure 0
checkpoints 0
in 0
both 0
yeast 0
model 0
systems 0
. 0

In 0
addition 0
, 0
double 0
mutants 0
with 0
either 0
dim1 B-gene
- I-gene
delta I-gene
or 0
dim2 B-gene
- I-gene
1 I-gene
and 0
the 0
endocytosis 0
mutants B-gene
end4 I-gene
- I-gene
1 I-gene
or 0
act1 B-gene
- I-gene
1 I-gene
displayed 0
synthetic 0
growth 0
defects 0
, 0
indicating 0
that 0
the 0
DIM B-gene
gene I-gene
products I-gene
function 0
in 0
a 0
common 0
or 0
parallel 0
endocytic 0
pathway 0
. 0

The 0
identification 0
of 0
the 0
hepatitis 0
C 0
virus 0
as 0
the 0
major 0
cause 0
of 0
liver 0
disease 0
both 0
in 0
dialysis 0
patients 0
and 0
in 0
transplant 0
patients 0
has 0
focused 0
attention 0
on 0
the 0
epidemiology 0
and 0
the 0
impact 0
of 0
continuing 0
infection 0
in 0
these 0
patient 0
groups 0
. 0

Stable 0
transfection 0
of 0
the 0
BL 0
cell 0
line 0
Raji 0
with 0
constructs 0
containing 0
core 0
promoter 0
mutations 0
confirmed 0
that 0
the 0
proximal 0
Sp1 B-gene
site I-gene
and 0
the 0
TATA 0
box 0
are 0
essential 0
for 0
the 0
activation 0
of 0
promoter 0
P1 0
by 0
the 0
Ig B-gene
kappa I-gene
enhancers I-gene
. 0

Such 0
multisensory 0
interactions 0
can 0
be 0
significant 0
for 0
behavior 0
. 0

The 0
P13 0
and 0
N22 0
of 0
ppSEPs 0
had 0
phase 0
reversal 0
relationship 0
with 0
the 0
P2 0
and 0
N2 0
recorded 0
from 0
the 0
PES 0
, 0
respectively 0
. 0

The 0
cDNA 0
of 0
cpm7 B-gene
encodes 0
a 0
closely 0
related 0
protein 0
of 0
36.8 0
kDa 0
. 0

Finally 0
, 0
the 0
C 0
- 0
terminal 0
region 0
of 0
ENBP1 B-gene
shows 0
strong 0
homology 0
to 0
a 0
protein 0
from 0
rat 0
that 0
is 0
specifically 0
expressed 0
in 0
testis 0
tissue 0
. 0

The 0
conservation 0
of 0
both 0
the 0
G 0
- 0
box 0
and 0
H 0
- 0
box 0
in 0
different 0
CHS B-gene
promoters I-gene
emphasizes 0
their 0
importance 0
as 0
regulatory 0
motifs 0
. 0

Mortality 0
on 0
the 0
last 0
ranch 0
was 0
particularly 0
severe 0
among 0
certain 0
segregated 0
groups 0
of 0
turkeys 0
that 0
included 0
toms 0
, 0
heavier 0
birds 0
, 0
and 0
birds 0
undergoing 0
a 0
stressful 0
event 0
such 0
as 0
artificial 0
insemination 0
. 0

Further 0
, 0
the 0
PIP2 0
content 0
of 0
the 0
85 0
- 0
90 0
kDa 0
protein 0
appeared 0
to 0
decrease 0
with 0
CSF B-gene
- I-gene
1 I-gene
treatment 0
. 0

Further 0
, 0
the 0
PIP2 0
content 0
of 0
the 0
85 0
- 0
90 0
kDa 0
protein 0
appeared 0
to 0
decrease 0
with 0
CSF B-gene
- I-gene
1 I-gene
treatment 0
. 0

Just 0
before 0
inserting 0
on 0
the 0
anterior 0
margin 0
and 0
apex 0
of 0
the 0
iliac 0
crest 0
it 0
widens 0
, 0
assuming 0
the 0
aspect 0
of 0
a 0
small 0
cone 0
. 0

The 0
first 0
identification 0
of 0
the 0
active 0
37LRP/p40 B-gene
gene 0
presented 0
in 0
this 0
study 0
is 0
a 0
critical 0
step 0
toward 0
the 0
isolation 0
of 0
the 0
corresponding 0
human 0
gene 0
and 0
the 0
understanding 0
of 0
the 0
molecular 0
mechanisms 0
involved 0
in 0
the 0
up 0
- 0
regulation 0
of 0
its 0
expression 0
during 0
tumor 0
invasion 0
and 0
metastasis 0
. 0

The 0
promoter 0
region 0
( 0
P1 0
) 0
corresponding 0
to 0
the 0
main 0
group 0
of 0
transcription 0
initiation 0
sites 0
is 0
devoid 0
of 0
TATA 0
and 0
CAAT 0
boxes 0
but 0
has 0
putative 0
binding 0
sites 0
for 0
the 0
transcription B-gene
factor I-gene
SP1 I-gene
and 0
is 0
embedded 0
in 0
a 0
large 0
G 0
+ 0
C 0
- 0
rich 0
domain 0
of 0
a 0
CpG 0
island 0
, 0
features 0
shared 0
by 0
the 0
promoters 0
of 0
constitutively 0
expressed 0
housekeeping 0
genes 0
. 0

The 0
STAT B-gene
- I-gene
1 I-gene
signaling 0
pathway 0
provides 0
at 0
least 0
one 0
mechanism 0
for 0
activation 0
of 0
the 0
CAEV B-gene
LTR I-gene
by 0
IFN B-gene
- I-gene
gamma I-gene
in 0
monocytes 0
. 0

Reperfusion 0
caused 0
a 0
transient 0
reduction 0
in 0
lactate 0
production 0
and 0
a 0
significant 0
increase 0
in 0
LDH B-gene
release 0
. 0

To 0
evaluate 0
the 0
hepatic 0
regenerative 0
response 0
in 0
patients 0
with 0
alcoholic 0
liver 0
disease 0
, 0
sera 0
from 0
263 0
patients 0
with 0
severe 0
alcoholic 0
hepatitis 0
and/or 0
cirrhosis 0
were 0
analyzed 0
for 0
hepatocyte B-gene
growth I-gene
factor I-gene
( 0
HGF B-gene
) 0
and 0
alpha B-gene
- I-gene
fetoprotein I-gene
( 0
AFP B-gene
) 0
. 0

Children 0
born 0
from 0
chronic 0
alcoholic 0
mothers 0
have 0
shown 0
behavioral 0
teratogenic 0
effects 0
more 0
frequently 0
than 0
morphological 0
malformations 0
. 0

INTERVENTION 0
( 0
S 0
) 0
: 0
Twenty 0
- 0
six 0
hemostasis 0
parameters 0
evaluated 0
repeatedly 0
in 0
patients 0
undergoing 0
IVF 0
- 0
ET 0
. 0

Here 0
we 0
report 0
that 0
expression 0
of 0
the 0
I B-gene
- I-gene
POU/tI I-gene
POU/tI I-gene
- I-gene
POU I-gene
message 0
is 0
maximal 0
late 0
in 0
the 0
embryonic 0
phase 0
of 0
Drosophila 0
development 0
, 0
and 0
I B-gene
- I-gene
POU I-gene
is 0
the 0
preferred 0
splice 0
variant 0
. 0

Unlike 0
wild B-gene
- I-gene
type I-gene
p53 I-gene
, 0
the 0
delta B-gene
proAE I-gene
mutant I-gene
cDNA I-gene
can 0
be 0
stably 0
expressed 0
in 0
tumor 0
derived 0
cell 0
lines 0
with 0
few 0
immediate 0
detrimental 0
effects 0
. 0

The 0
patient 0
's 0
role 0
, 0
organized 0
by 0
the 0
prerequisites 0
of 0
expressive 0
freedom 0
, 0
is 0
counter 0
posed 0
with 0
the 0
psychoanalyst 0
's 0
, 0
which 0
is 0
structured 0
to 0
empower 0
listening 0
and 0
understanding 0
. 0

The 0
most 0
common 0
risk 0
factor 0
reported 0
for 0
both 0
recent 0
and 0
all 0
other 0
hepatitis 0
C 0
cases 0
was 0
a 0
history 0
of 0
injecting 0
drug 0
use 0
, 0
although 0
the 0
proportion 0
of 0
cases 0
with 0
that 0
history 0
was 0
different 0
in 0
NT 0
from 0
ACT 0
and 0
Queensland 0
. 0

Silencing 0
can 0
be 0
restored 0
by 0
creation 0
of 0
a 0
telomere 0
at 0
13 0
kb 0
from 0
the 0
reporter 0
construct 0
, 0
or 0
by 0
insertion 0
of 0
340 0
bp 0
of 0
yeast 0
telomeric 0
repeat 0
sequence 0
at 0
this 0
site 0
without 0
chromosomal 0
truncation 0
. 0

In 0
contrast 0
with 0
previous 0
two 0
- 0
pool 0
models 0
, 0
provisions 0
were 0
made 0
for 0
folate 0
turnover 0
by 0
urinary 0
folate 0
excretion 0
( 0
as 0
measured 0
here 0
) 0
and 0
by 0
fecal 0
excretion 0
and 0
catabolic 0
processes 0
. 0

When 0
voltage 0
- 0
operated 0
Ca2+ 0
channels 0
( 0
VOC 0
) 0
were 0
blocked 0
by 0
nifedipine 0
, 0
midazolam 0
, 0
in 0
concentrations 0
more 0
than 0
1 0
microM 0
, 0
attenuated 0
both 0
phasic 0
and 0
tonic 0
responses 0
. 0

Several 0
artifacts 0
occurred 0
that 0
interfered 0
with 0
visualization 0
of 0
the 0
diaphragm 0
. 0

Although 0
p48 B-gene
gene I-gene
induction 0
is 0
dependent 0
on 0
STAT1 B-gene
and 0
JAK1 B-gene
, 0
activated 0
STAT1 B-gene
does 0
not 0
bind 0
to 0
GATE B-gene
. 0

The 0
syndrome 0
of 0
resistance 0
to 0
thyroid 0
hormone 0
is 0
characterized 0
by 0
elevated 0
serum 0
free 0
thyroid 0
hormones 0
, 0
failure 0
to 0
suppress 0
pituitary B-gene
thyrotropin I-gene
secretion 0
, 0
and 0
variable 0
peripheral 0
refractoriness 0
to 0
hormone 0
action 0
. 0

Finally 0
, 0
nonphotosynthetic 0
mutants 0
, 0
including 0
the 0
tscA B-gene
- I-gene
lacking I-gene
photosystem I-gene
I I-gene
mutant I-gene
, 0
H13 0
, 0
did 0
not 0
show 0
evidence 0
of 0
light 0
- 0
stimulated 0
RNA 0
processing 0
. 0

The 0
progression 0
of 0
acute 0
bronchitis 0
is 0
associated 0
with 0
elevated 0
blood 0
concentrations 0
of 0
acute 0
- 0
phase 0
proteins 0
, 0
KKS B-gene
activation 0
in 0
the 0
blood 0
and 0
high 0
serotonin 0
and 0
lactic 0
acid 0
content 0
in 0
the 0
humor 0
condensated 0
from 0
the 0
exhaled 0
air 0
. 0

Because 0
of 0
the 0
potential 0
implications 0
of 0
these 0
findings 0
in 0
human 0
physiology 0
, 0
we 0
cloned 0
the 0
hPACAP B-gene
- I-gene
R I-gene
gene I-gene
. 0

Differential 0
signaling 0
and 0
immediate B-gene
- I-gene
early I-gene
gene I-gene
activation 0
by 0
four 0
splice 0
variants 0
of 0
the 0
human B-gene
pituitary I-gene
adenylate I-gene
cyclase I-gene
- I-gene
activating I-gene
polypeptide I-gene
receptor I-gene
( 0
hPACAP B-gene
- I-gene
R I-gene
) 0
. 0

During 0
skeletal 0
muscle 0
development 0
, 0
different 0
types 0
of 0
muscle 0
fibers 0
are 0
generated 0
, 0
which 0
express 0
different 0
combinations 0
of 0
muscle 0
- 0
specific 0
gene 0
products 0
. 0

We 0
discuss 0
these 0
results 0
with 0
respect 0
to 0
the 0
transcriptional 0
induction 0
of 0
the 0
HNF B-gene
- I-gene
3 I-gene
alpha I-gene
gene I-gene
in 0
respiratory 0
epithelium 0
during 0
embryogenesis 0
. 0

BACKGROUND 0
: 0
Mitosis 0
is 0
regulated 0
by 0
MPF B-gene
( 0
maturation B-gene
promoting I-gene
factor I-gene
) 0
, 0
the 0
active 0
form 0
of 0
Cdc2/28 B-gene
- 0
cyclin B-gene
B I-gene
complexes 0
. 0

Ectopic 0
expression 0
of 0
Apo B-gene
- I-gene
3 I-gene
in 0
HEK293 0
or 0
HeLa 0
cells 0
induced 0
marked 0
apoptosis 0
. 0

An 0
N 0
- 0
terminal 0
arm 0
from 0
each 0
subunit 0
wraps 0
around 0
the 0
dinucleotide 0
- 0
binding 0
domain 0
of 0
an 0
adjacent 0
subunit 0
, 0
covering 0
the 0
adenine 0
ring 0
of 0
NADP 0
. 0

Similarity 0
is 0
most 0
striking 0
in 0
the 0
zinc 0
knuckle 0
region 0
, 0
a 0
region 0
characteristic 0
of 0
gag B-gene
genes I-gene
of 0
most 0
replication 0
- 0
competent 0
retroelements 0
. 0

D. 0
melanogaster 0
HeT B-gene
- I-gene
A I-gene
coding 0
sequences 0
have 0
a 0
polymorphic 0
region 0
with 0
insertions/deletions 0
of 0
1 0
- 0
31 0
codons 0
and 0
many 0
nucleotide 0
changes 0
. 0

Eukaryotic B-gene
initiation I-gene
factor I-gene
3 I-gene
( 0
eIF3 B-gene
) 0
is 0
a 0
large 0
multisubunit 0
complex 0
that 0
stabilizes 0
the 0
ternary 0
complex 0
, 0
eIF2 B-gene
x 0
GTP 0
x 0
tRNA B-gene
( I-gene
Met I-gene
) I-gene
i I-gene
and 0
promotes 0
mRNA 0
binding 0
to 0
the 0
40 B-gene
S I-gene
ribosomal I-gene
subunit I-gene
. 0
eIF3 B-gene
also 0
functions 0
as 0
a 0
ribosome 0
subunit 0
anti 0
- 0
association 0
factor 0
. 0

Our 0
data 0
, 0
combined 0
with 0
those 0
of 0
Hershey 0
and 0
co 0
- 0
workers 0
, 0
suggest 0
that 0
mammalian B-gene
eIF3 I-gene
is 0
composed 0
of 0
at 0
least 0
10 0
subunits 0
: 0
p170 B-gene
, 0
p116 B-gene
( 0
hPrt1 B-gene
) 0
, 0
p110 B-gene
, 0
p66 B-gene
, 0
p48 B-gene
, 0
p47 B-gene
, 0
p44 B-gene
, 0
p40 B-gene
, 0
p36 B-gene
, 0
and 0
p35 B-gene
. 0

Identification 0
of 0
a 0
cis 0
- 0
acting 0
element 0
in 0
the 0
class B-gene
I I-gene
major I-gene
histocompatibility I-gene
complex I-gene
gene I-gene
promoter I-gene
responsive 0
to 0
activation 0
by 0
retroviral 0
sequences 0
. 0

The 0
results 0
demonstrate 0
that 0
( 0
i 0
) 0
no 0
intact 0
capsids 0
were 0
assembled 0
when 0
the 0
full 0
- 0
length 0
or 0
a 0
truncated 0
( 0
missing 0
the 0
C 0
- 0
terminal 0
65 0
amino 0
acids 0
) 0
UL80.5 B-gene
protein I-gene
was 0
tested 0
; 0
( 0
ii 0
) 0
when 0
the 0
C 0
- 0
terminal 0
65 0
amino 0
acids 0
of 0
the 0
UL80.5 B-gene
protein I-gene
were 0
replaced 0
with 0
the 0
C 0
- 0
terminal 0
25 0
amino 0
acids 0
of 0
the 0
UL26.5 B-gene
protein I-gene
, 0
intact 0
capsids 0
were 0
made 0
and 0
direct 0
interaction 0
of 0
the 0
UL80.5 B-gene
protein I-gene
with 0
VP5 B-gene
was 0
detected 0
; 0
( 0
iii 0
) 0
assembly 0
of 0
intact 0
capsids 0
was 0
demonstrated 0
when 0
the 0
sequence 0
of 0
the 0
last 0
12 0
amino 0
acids 0
of 0
the 0
UL80.5 B-gene
protein I-gene
was 0
changed 0
from 0
RRIFVA 0
ALNKLE 0
to 0
RRIFVAAMMKLE 0
; 0
( 0
iv 0
) 0
self 0
- 0
interaction 0
of 0
the 0
scaffold 0
proteins 0
is 0
mediated 0
by 0
sequences 0
N 0
terminal 0
to 0
the 0
maturation 0
cleavage 0
site 0
; 0
and 0
( 0
v 0
) 0
the 0
UL26.5 B-gene
and 0
UL80.5 B-gene
proteins I-gene
will 0
not 0
coassemble 0
into 0
scaffold 0
structures 0
. 0

Fourth 0
, 0
the 0
3' 0
- 0
region 0
splice 0
junctions 0
of 0
the 0
MSRs B-gene
during 0
latent 0
and 0
productive 0
infection 0
were 0
determined 0
by 0
sequencing 0
RNA 0
- 0
PCR 0
products 0
generated 0
with 0
primers 0
that 0
flank 0
the 0
3 0
' 0
splice 0
region 0
. 0

( 0
ii 0
) 0
ICP27 B-gene
binds 0
preferentially 0
to 0
less 0
modified 0
forms 0
of 0
ICP4 B-gene
, 0
a 0
protein 0
that 0
is 0
extensively 0
modified 0
posttranslationally 0
. 0

Lack 0
of 0
sufficient 0
data 0
on 0
vibration 0
measurements 0
and 0
employment 0
durations 0
add 0
to 0
the 0
uncertainty 0
, 0
as 0
do 0
variations 0
in 0
tool 0
conditions 0
( 0
grinder 0
wheels 0
, 0
etc 0
) 0
and 0
inherent 0
difficulties 0
in 0
measurement 0
. 0

C/EBP B-gene
beta I-gene
V I-gene
> 0
A 0
selectively 0
binds 0
only 0
the 0
subset 0
of 0
C/EBP B-gene
sites I-gene
that 0
are 0
also 0
DBP B-gene
sites I-gene
, 0
both 0
as 0
oligonucleotides 0
and 0
within 0
the 0
natural 0
contexts 0
of 0
the 0
albumin B-gene
and 0
cholesterol B-gene
hydroxylase I-gene
promoters I-gene
. 0

Specific 0
IgG B-gene
, 0
specific 0
IgE B-gene
and 0
total 0
IgE B-gene
immunoglobulins I-gene
against 0
Toxocara B-gene
canis I-gene
excretory/secretory I-gene
antigens I-gene
( 0
TES B-gene
) 0
were 0
detected 0
by 0
using 0
ELISA 0
technique 0
. 0

SUMMARY 0
BACKGROUND 0
DATA 0
: 0
Melanoma 0
care 0
has 0
not 0
changed 0
significantly 0
in 0
the 0
last 0
20 0
years 0
, 0
and 0
the 0
controversy 0
of 0
elective 0
lymph 0
node 0
dissections 0
in 0
this 0
disease 0
continues 0
to 0
be 0
discussed 0
. 0

The 0
differences 0
among 0
subgenera 0
of 0
the 0
genus 0
Dermacentor 0
are 0
more 0
significant 0
. 0

Mutating 0
the 0
E 0
- 0
box 0
in 0
the 0
context 0
of 0
the 0
3' 0
- 0
flanking 0
region 0
confirmed 0
that 0
it 0
contributes 0
to 0
the 0
enhancement 0
of 0
transcriptional 0
activity 0
of 0
the 0
alpha1 B-gene
( I-gene
I I-gene
) I-gene
collagen I-gene
gene I-gene
promoter I-gene
. 0

Expression 0
of 0
neuronal 0
traits 0
in 0
pancreatic 0
beta 0
cells 0
. 0

We 0
propose 0
that 0
Mnt B-gene
: 0
Max B-gene
: 0
Sin3 B-gene
complexes 0
normally 0
function 0
to 0
restrict 0
Myc B-gene
: 0
Max B-gene
activities 0
associated 0
with 0
cell 0
proliferation 0
. 0

Its 0
transcription 0
product 0
, 0
a 0
1.3 0
kb 0
mRNA 0
, 0
is 0
polyadenylated 0
at 0
a 0
site 0
containing 0
consensus 0
eukaryotic 0
polyadenylation 0
signals 0
and 0
mapping 0
87 0
bp 0
downstream 0
of 0
the 0
translation 0
termination 0
codon 0
for 0
CG30 B-gene
. 0

Phenotypic 0
changes 0
induced 0
by 0
wild B-gene
type I-gene
and I-gene
variant I-gene
c I-gene
- I-gene
src I-gene
genes I-gene
carrying 0
C 0
- 0
terminal 0
sequence 0
alterations 0
. 0

The 0
resurgence 0
of 0
drug 0
- 0
resistant 0
malaria 0
makes 0
urgent 0
the 0
evaluation 0
of 0
new 0
antimalarial 0
agents 0
. 0

In 0
the 0
p51 B-gene
subunit I-gene
, 0
the 0
Cys181 0
side 0
- 0
chain 0
is 0
oriented 0
in 0
a 0
similar 0
direction 0
to 0
the 0
Tyr181 0
side 0
- 0
chain 0
in 0
the 0
wild 0
- 0
type 0
complex 0
. 0

The 0
relatively 0
high 0
level 0
transcription 0
from 0
this 0
gene 0
shows 0
that 0
the 0
polymorphic 0
chromosome 0
ends 0
of 0
P. 0
falciparum 0
, 0
which 0
have 0
been 0
proposed 0
to 0
be 0
transcriptionally 0
silent 0
, 0
can 0
be 0
active 0
expression 0
sites 0
for 0
var B-gene
genes I-gene
. 0

NUP145 B-gene
was 0
previously 0
identified 0
by 0
using 0
a 0
genetic 0
synthetic 0
lethal 0
screen 0
( 0
E 0
. 0

Prevalence 0
of 0
sleep 0
- 0
disordered 0
breathing 0
( 0
SDB 0
) 0
is 0
reported 0
to 0
increase 0
in 0
menopausal 0
women 0
. 0

In 0
all 0
cases 0
the 0
antigenemia 0
was 0
transient 0
and 0
cleared 0
by 0
28th 0
day 0
post 0
- 0
vaccination 0
. 0

A 0
total 0
of 0
1459 0
men 0
aged 0
48 0
to 0
84 0
years 0
, 0
who 0
were 0
diagnosed 0
for 0
the 0
first 0
time 0
by 0
physicians 0
as 0
having 0
BPH 0
in 0
1994 0
and 0
who 0
had 0
not 0
received 0
treatment 0
, 0
participated 0
in 0
the 0
study 0
. 0

BCL B-gene
- I-gene
2 I-gene
, 0
an 0
inhibitor 0
of 0
apoptosis 0
in 0
a 0
wide 0
variety 0
of 0
cell 0
types 0
, 0
has 0
been 0
reported 0
to 0
prevent 0
oxidative 0
stress 0
- 0
induced 0
cell 0
death 0
. 0

In 0
vitro 0
translation 0
of 0
the 0
mTRF1 B-gene
cDNA I-gene
resulted 0
in 0
a 0
56 0
kDa 0
protein 0
that 0
binds 0
to 0
TTAGGG 0
repeat 0
arrays 0
. 0
mTRF1 B-gene
displayed 0
the 0
same 0
sequence 0
specificity 0
as 0
hTRF1 B-gene
, 0
preferring 0
arrays 0
of 0
TTAGGG 0
repeats 0
as 0
a 0
binding 0
substrate 0
over 0
TTAGGC 0
and 0
TTGGGG 0
repeats 0
. 0

The 0
ubiquitously 0
expressed 0
E12 B-gene
bHLH I-gene
protein I-gene
dimerizes 0
with 0
numerous 0
cell 0
- 0
specific 0
bHLH B-gene
factors I-gene
. 0

The 0
E 0
- 0
box 0
sequence 0
in 0
the 0
SE2 B-gene
fragment I-gene
of 0
the 0
transferrin B-gene
promoter I-gene
was 0
CATCTG 0
and 0
was 0
similar 0
in 0
gel 0
shifts 0
to 0
the 0
consensus 0
E 0
- 0
box 0
elements 0
( 0
CANNTG 0
) 0
previously 0
characterized 0
. 0

A 0
5.3 0
- 0
kb 0
DNA 0
fragment 0
, 0
which 0
included 0
the 0
entire 0
structural 0
porin B-gene
gene I-gene
( 0
named 0
porCa B-gene
) 0
and 0
its 0
flanking 0
regions 0
, 0
was 0
identified 0
. 0

Full B-gene
- I-gene
length I-gene
AT I-gene
- I-gene
PHH1 I-gene
, 0
and 0
both 0
AT B-gene
- I-gene
PHH1 I-gene
and 0
AT B-gene
- I-gene
PHH1 I-gene
delta I-gene
C I-gene
- I-gene
513 I-gene
( 0
truncated 0
to 0
be 0
approximately 0
the 0
size 0
of 0
microbial B-gene
photolyase I-gene
genes I-gene
) 0
cDNAs 0
, 0
were 0
overexpressed 0
, 0
respectively 0
, 0
in 0
yeast 0
and 0
Escherichia 0
coli 0
mutants 0
hypersensitive 0
to 0
ultraviolet 0
light 0
. 0

The 0
human B-gene
p100 I-gene
protein I-gene
was 0
recently 0
identified 0
as 0
a 0
coactivator 0
of 0
the 0
Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
nuclear I-gene
antigen I-gene
2 I-gene
. 0

However 0
, 0
five 0
new 0
mutation 0
sites 0
( 0
S61 B-gene
, 0
SL1 B-gene
, 0
S29 B-gene
, 0
SL11 B-gene
, 0
SL196 B-gene
and 0
SL126 B-gene
) 0
are 0
unique 0
to 0
the 0
nrdB B-gene
intron 0
and 0
disrupt 0
self 0
- 0
splicing 0
. 0

This 0
report 0
presents 0
the 0
isolation 0
and 0
characterization 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
( 0
1.2 0
kb 0
) 0
and 0
exon 0
1 0
of 0
the 0
human B-gene
RII I-gene
alpha I-gene
gene I-gene
. 0

A 0
cohort 0
of 0
Swedish 0
children 0
was 0
monitored 0
from 0
6 0
months 0
to 0
11 0
years 0
of 0
age 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
assess 0
the 0
reproducibility 0
of 0
a 0
number 0
of 0
simplified 0
clearance 0
methods 0
using 0
chromium 0
- 0
51 0
ethylenediamine 0
tetraacetic 0
acid 0
( 0
51Cr 0
- 0
EDTA 0
) 0
and 0
to 0
compare 0
these 0
with 0
the 0
multiple 0
blood 0
sample 0
technique 0
. 0

The 0
primary 0
structure 0
of 0
a 0
2671 0
bp 0
DNA 0
fragment 0
between 0
the 0
pla B-gene
gene I-gene
( 0
encoding 0
plasminogen B-gene
activator I-gene
) 0
and 0
the 0
origin 0
of 0
replication 0
of 0
the 0
wild 0
- 0
type 0
Yersinia 0
pestis 0
plasmid 0
pYP358 0
was 0
determined 0
. 0

Serotonin 0
concentration 0
in 0
the 0
blood 0
of 0
patients 0
with 0
hemorrhagic 0
fever 0
with 0
renal 0
syndrome 0

MAIN 0
OUTCOME 0
MEASURES 0
: 0
Associations 0
of 0
factor 0
analysis 0
- 0
derived 0
syndromes 0
with 0
risk 0
factors 0
for 0
chemical 0
interactions 0
that 0
inhibit 0
butyrylcholinesterase B-gene
and 0
neuropathy 0
target 0
esterase B-gene
. 0

CONCLUSION 0
: 0
Some 0
Gulf 0
War 0
veterans 0
may 0
have 0
delayed 0
, 0
chronic 0
neurotoxic 0
syndromes 0
from 0
wartime 0
exposure 0
to 0
combinations 0
of 0
chemicals 0
that 0
inhibit 0
butyrylcholinesterase B-gene
and 0
neuropathy B-gene
target I-gene
esterase I-gene
. 0

Control 0
examination 0
was 0
performed 0
at 0
the 0
end 0
of 0
each 0
period 0
. 0

No 0
correlation 0
between 0
the 0
age 0
of 0
the 0
horses 0
and 0
the 0
antibody 0
level 0
could 0
be 0
found 0
. 0

The 0
GHR B-gene
mRNA I-gene
: 0
GHBP B-gene
mRNA I-gene
ratio 0
was 0
1.1 0
+/ 0
- 0
0.12 0
and 0
remained 0
unchanged 0
during 0
differentiation 0
. 0

The 0
results 0
demonstrate 0
( 0
i 0
) 0
that 0
the 0
selenocysteine 0
- 0
specific 0
UGA 0
codon 0
is 0
readily 0
suppressed 0
under 0
conditions 0
where 0
the 0
homologous B-gene
SelB I-gene
protein I-gene
is 0
absent 0
and 0
( 0
ii 0
) 0
that 0
apart 0
from 0
the 0
specificity 0
of 0
the 0
SelB B-gene
- I-gene
mRNA I-gene
interaction 0
, 0
a 0
structural 0
compatibility 0
of 0
the 0
quaternary 0
complex 0
with 0
the 0
ribosome 0
is 0
required 0
. 0

One 0
linker 0
- 0
peptide 0
insertion 0
in 0
the 0
RsaA B-gene
C I-gene
terminus I-gene
( I-gene
amino I-gene
acid I-gene
784 I-gene
) I-gene
had 0
no 0
effect 0
on 0
S 0
- 0
layer 0
biogenesis 0
, 0
while 0
another 0
( 0
amino 0
acid 0
907 0
) 0
disrupted 0
secretion 0
of 0
the 0
protein 0
, 0
suggesting 0
that 0
RsaA B-gene
possesses 0
a 0
secretion 0
signal 0
lying 0
C 0
terminal 0
to 0
amino 0
acid 0
784 0
, 0
near 0
or 0
including 0
amino 0
acid 0
907 0
. 0

To 0
characterize 0
the 0
gene 0
products 0
, 0
the 0
cvaA B-gene
gene I-gene
was 0
subcloned 0
and 0
expressed 0
under 0
the 0
control 0
of 0
T7 B-gene
RNA I-gene
polymerase I-gene
promoter I-gene
. 0

PrpB B-gene
showed 0
homology 0
to 0
carboxyphosphonoenolpyruvate B-gene
phosphonomutase I-gene
of I-gene
Streptomyces I-gene
hygroscopicus I-gene
and 0
to 0
its 0
homolog 0
in 0
the 0
carnation 0
Dianthus 0
caryophyllus 0
; 0
PrpC B-gene
was 0
homologous 0
to 0
both 0
archaeal B-gene
and I-gene
bacterial I-gene
citrate I-gene
synthases I-gene
; 0
PrpD B-gene
showed 0
homology 0
to 0
yeast 0
and 0
Bacillus 0
subtilis 0
proteins 0
of 0
unknown 0
function 0
; 0
PrpE B-gene
showed 0
homology 0
to 0
acetyl B-gene
coenzyme I-gene
A I-gene
synthetases I-gene
. 0

MAIN 0
OUTCOME 0
MEASURES 0
: 0
Systemic 0
and 0
pulmonary 0
hemodynamics 0
, 0
arterial 0
blood 0
gas 0
determination 0
, 0
bronchoalveolar 0
lavage 0
protein 0
and 0
neutrophil 0
content 0
, 0
neutrophil 0
oxidant 0
burst 0
, 0
lung B-gene
myeloperoxidase I-gene
content 0
, 0
and 0
scanning 0
electron 0
micrographic 0
studies 0
. 0

We 0
have 0
isolated 0
a 0
cDNA 0
encoding 0
human B-gene
MEKK3 I-gene
. 0

To 0
investigate 0
the 0
mechanisms 0
involved 0
in 0
the 0
transcriptional 0
control 0
of 0
retinoid B-gene
X I-gene
receptor I-gene
( 0
RXR B-gene
) 0
gene 0
expression 0
, 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
RXRgamma2 I-gene
isoform I-gene
was 0
characterized 0
. 0

JNK B-gene
and 0
p38 B-gene
are 0
constitutively 0
present 0
in 0
the 0
nucleus 0
, 0
and 0
DNA 0
- 0
bound 0
c B-gene
- I-gene
JUN I-gene
and 0
ATF B-gene
- I-gene
2 I-gene
are 0
stably 0
contacted 0
by 0
JNK B-gene
and 0
p38 B-gene
, 0
respectively 0
. 0

The 0
effects 0
of 0
dominant 0
interfering 0
forms 0
of 0
the 0
JNK/p38 B-gene
signaling 0
pathway 0
demonstrate 0
that 0
activation 0
of 0
these 0
kinases 0
is 0
critical 0
for 0
cytokine 0
- 0
induced 0
JNK/p38 I-gene

Sp1 B-gene
binds 0
the 0
CTC 0
repeat 0
with 0
an 0
affinity 0
, 0
KD 0
= 0
0.37 0
nM 0
, 0
at 0
least 0
as 0
high 0
as 0
the 0
consensus 0
GC 0
box 0
. 0

Identification 0
of 0
the 0
region 0
in 0
actin B-gene
- I-gene
binding I-gene
protein I-gene
that 0
binds 0
to 0
the 0
cytoplasmic 0
domain 0
of 0
glycoprotein B-gene
IBalpha I-gene
. 0

Mutant 0
enzyme 0
forms 0
were 0
prepared 0
to 0
eliminate 0
the 0
initial 0
autoprocessing 0
site 0
and 0
thus 0
form 0
an 0
active 0
single 0
- 0
chain 0
protein 0
for 0
structure 0
- 0
function 0
studies 0
. 0

The 0
primer 0
is 0
generated 0
by 0
a 0
cleavage 0
that 0
occurs 0
between 0
bases 0
11 0
and 0
12 0
of 0
the 0
Tf1 B-gene
mRNA I-gene
. 0

Similarly 0
, 0
we 0
examined 0
whether 0
the 0
ELK1 B-gene
, 0
SAP1a B-gene
, 0
FLI1 B-gene
, 0
EWS B-gene
- 0
FLI1 B-gene
, 0
ETS1 B-gene
, 0
ETS2 B-gene
, 0
PEA3 B-gene
and 0
PU.1 B-gene
proteins I-gene
can 0
form 0
ternary 0
complexes 0
with 0
SRF B-gene
on 0
the 0
Egr1 B-gene
SREI B-gene
and I-gene
II I-gene
. 0

This 0
R 0
- 0
domain 0
may 0
modulate 0
the 0
interaction 0
with 0
SRF B-gene
, 0
providing 0
a 0
mechanism 0
that 0
would 0
be 0
unique 0
to 0
FLI1 B-gene
and 0
EWS B-gene
- 0
FLI1 B-gene
, 0
thus 0
implicating 0
a 0
novel 0
function 0
for 0
these 0
ETS B-gene
transcription I-gene
factors I-gene
in 0
the 0
regulation 0
of 0
the 0
Egr1 B-gene
gene I-gene
. 0

The 0
total 0
number 0
of 0
specimens 0
was 0
131 0
with 0
78 0
nonsmokers 0
and 0
53 0
smokers 0
. 0

The 0
murine 0
chromosomal 0
locations 0
of 0
the 0
five 0
NMDA B-gene
receptor I-gene
channel I-gene
subunits I-gene
, 0
the 0
epsilon B-gene
1 I-gene
( 0
Grin2a B-gene
) 0
, 0
epsilon B-gene
2 I-gene
( 0
Grin2b B-gene
) 0
, 0
epsilon B-gene
3 I-gene
( 0
Grin2c B-gene
) 0
, 0
epsilon B-gene
4 I-gene
( 0
Grin2d B-gene
) 0
and 0
zeta B-gene
1 I-gene
( 0
Grinl B-gene
) 0
subunits 0
, 0
were 0
determined 0
using 0
an 0
interspecific 0
backcross 0
mapping 0
panel 0
derived 0
from 0
crosses 0
of 0
[ 0
( 0
C57BL/6JxM 0
. 0
spretus 0
) 0
F1xC57BL/6J 0
] 0
mice 0
. 0

CDNA 0
cloning 0
of 0
chick B-gene
brain I-gene
alpha I-gene
- I-gene
amino I-gene
- I-gene
3 I-gene
- I-gene
hydroxy I-gene
- I-gene
5 I-gene
- I-gene
methyl I-gene
- I-gene
4 I-gene
- I-gene
isoxazolepropionic I-gene
acid I-gene
receptors I-gene
reveals 0
conservation 0
of 0
structure 0
, 0
function 0
and 0
post 0
- 0
transcriptional 0
processes 0
with 0
mammalian 0
receptors 0
. 0

Remarkably 0
, 0
both 0
TTD 0
- 0
A 0
and 0
XP 0
- 0
D 0
defects 0
are 0
associated 0
with 0
subunits 0
of 0
TFIIH B-gene
, 0
a 0
basal 0
transcription 0
factor 0
with 0
a 0
second 0
function 0
in 0
DNA 0
repair 0
. 0

Adjustment 0
for 0
age 0
, 0
total 0
cholesterol 0
, 0
HDL B-gene
cholesterol I-gene
, 0
triglycerides 0
, 0
current 0
smoking 0
, 0
and 0
systolic 0
pressure 0
slightly 0
reduced 0
the 0
association 0
between 0
fibrinogen B-gene
and 0
atherosclerosis 0
. 0

In 0
Experiment 0
1 0
, 0
pups 0
that 0
had 0
received 0
an 0
injection 0
of 0
the 0
noncompetitive 0
N B-gene
- I-gene
methyl I-gene
- I-gene
D I-gene
- I-gene
aspartate I-gene
receptor I-gene
antagonist 0
MK 0
- 0
801 0
( 0
0.1 0
mg/kg 0
, 0
i.p 0
. 0
) 0
either 0
30 0
min 0
before 0
or 0
immediately 0
after 0
conditioning 0
spent 0
less 0
time 0
over 0
the 0
conditioned 0
odor 0
than 0
saline 0
- 0
treated 0
controls 0
. 0

Cholesterol B-gene
side I-gene
- I-gene
chain I-gene
cleavage I-gene
cytochrome I-gene
P450 I-gene
( 0
CYP11A B-gene
; 0
P450scc B-gene
) 0
gene 0
expression 0
is 0
regulated 0
by 0
gonadotropins B-gene
via 0
cAMP 0
in 0
the 0
ovary 0
and 0
by 0
ACTH B-gene
via 0
cAMP 0
in 0
adrenal 0
cortical 0
cells 0
. 0

One 0
possible 0
solution 0
is 0
a 0
thin 0
radial 0
forearm 0
free 0
flap 0
. 0

Structural 0
analysis 0
and 0
characterization 0
of 0
tissue 0
and 0
hormonal 0
responsive 0
expression 0
of 0
the 0
avian B-gene
bone I-gene
sialoprotein I-gene
( 0
BSP B-gene
) 0
gene 0
. 0

Serotonin B-gene
receptors I-gene
in 0
suicide 0
victims 0
with 0
major 0
depression 0
. 0

The 0
Y 0
- 0
type 0
structural 0
motif 0
is 0
also 0
conserved 0
among 0
a 0
number 0
of 0
divergent 0
BiP B-gene
mRNAs I-gene
. 0

A 0
false 0
positive 0
marker 0
screen 0
was 0
associated 0
with 0
the 0
occurrence 0
of 0
hand 0
- 0
foot 0
syndrome 0
even 0
when 0
the 0
effect 0
of 0
regimen 0
was 0
accounted 0
for 0
by 0
stratification 0
( 0
p 0
= 0
.01 0
) 0
. 0

The 0
detection 0
of 0
ORF B-gene
- I-gene
1 I-gene
sequences 0
in 0
human 0
tumors 0
, 0
while 0
not 0
proof 0
per 0
se 0
, 0
is 0
a 0
prerequisite 0
for 0
establishing 0
its 0
role 0
in 0
tumor 0
development 0
. 0

Phylogenetic 0
analysis 0
gave 0
evidence 0
for 0
a 0
close 0
evolutionary 0
relationship 0
between 0
PhHV 0
- 0
1 0
and 0
members 0
of 0
the 0
Varicellovirus 0
genus 0
of 0
the 0
alpha 0
- 0
Herpesvirinae 0
and 0
canid 0
herpesvirus 0
in 0
particular 0
. 0

In 0
this 0
method 0
, 0
PLP 0
in 0
plasma 0
can 0
be 0
determined 0
with 0
high 0
sensitivity 0
using 0
derivatization 0
with 0
sodium 0
bisulfite 0
in 0
the 0
mobile 0
phase 0
. 0

Both 0
HEF1 B-gene
and 0
Cas B-gene
were 0
found 0
to 0
complex 0
with 0
the 0
related B-gene
adhesion I-gene
focal I-gene
tyrosine I-gene
kinase I-gene
( 0
RAFTK B-gene
) 0
, 0
and 0
when 0
tyrosine 0
phosphorylated 0
, 0
with 0
the 0
adapter 0
molecule 0
CrkL B-gene
. 0

SIM1 B-gene
and 0
SIM2 B-gene
do 0
not 0
form 0
homodimers 0
, 0
and 0
they 0
do 0
not 0
interact 0
with 0
AHR B-gene
. 0

Complexes 0
of 0
qTBP42 B-gene
with 0
each 0
complementary 0
strand 0
of 0
telomeric 0
DNA 0
and 0
with 0
quadruplex 0
forms 0
of 0
the 0
guanine 0
- 0
rich 0
strand 0
had 0
3.7 0
- 0
14.6 0
nM 0
dissociation 0
constants 0
, 0
Kd 0
, 0
whereas 0
complexes 0
with 0
double 0
- 0
stranded 0
telomeric 0
DNA 0
had 0
up 0
to 0
100 0
- 0
fold 0
higher 0
Kd 0
values 0
. 0

Moreover 0
, 0
the 0
effect 0
exerted 0
by 0
TIS1 B-gene
appeared 0
to 0
be 0
selective 0
for 0
the 0
MCK B-gene
promoter I-gene
. 0

Experimental 0
data 0
showed 0
that 0
these 0
abnormal 0
proteins 0
are 0
constitutively 0
localized 0
in 0
the 0
nucleus 0
, 0
have 0
lost 0
the 0
transcriptional 0
repressor 0
functions 0
typical 0
of 0
normal 0
NF B-gene
- I-gene
kappa I-gene
B2p52 I-gene
and 0
may 0
be 0
capable 0
of 0
transactivation 0
activity 0
. 0

Because 0
L B-gene
- I-gene
plastin I-gene
expression 0
in 0
tissue 0
- 0
specifically 0
regulated 0
in 0
both 0
humans 0
and 0
rodents 0
, 0
it 0
is 0
likely 0
that 0
similar 0
mechanisms 0
regulate 0
L B-gene
- I-gene
plastin I-gene
gene I-gene
expression 0
in 0
human 0
and 0
rodent 0
cells 0
and 0
that 0
they 0
could 0
be 0
identified 0
by 0
comparing 0
the 0
function 0
and 0
nucleotide 0
sequences 0
of 0
the 0
human 0
and 0
murine 0
L B-gene
- I-gene
plastin I-gene
gene 0
promoters 0
. 0

What 0
's 0
new 0
in 0
gynecologic 0
and 0
obstetrical 0
surgery 0
. 0

The 0
dnaK B-gene
operon I-gene
of I-gene
Bacillus I-gene
subtilis I-gene
is 0
heptacistronic 0
. 0

Moreover 0
, 0
expression 0
of 0
CBF1 B-gene
in 0
yeast 0
was 0
found 0
to 0
activate 0
transcription 0
of 0
reporter 0
genes 0
containing 0
the 0
C 0
- 0
repeat/DRE 0
as 0
an 0
upstream 0
activator 0
sequence 0
but 0
not 0
mutant 0
versions 0
of 0
the 0
DNA 0
element 0
. 0

Forty 0
- 0
one 0
ASA 0
physical 0
status 0
I 0
or 0
II 0
adult 0
patients 0
undergoing 0
a 0
variety 0
of 0
1 0
- 0
1.5 0
h 0
surgical 0
procedures 0
were 0
randomly 0
allocated 0
to 0
receive 0
CCA 0
with 0
desflurane 0
or 0
isoflurane 0
with 0
ventilation 0
being 0
either 0
spontaneous 0
or 0
controlled 0
. 0

OBJECTIVE 0
: 0
Our 0
goal 0
was 0
to 0
determine 0
whether 0
chlamydia 0
- 0
infected 0
women 0
have 0
a 0
higher 0
rate 0
of 0
febrile 0
complications 0
after 0
postpartum 0
tubal 0
ligation 0
. 0

In 0
the 0
electrophoresis 0
mobility 0
shift 0
assay 0
using 0
nuclear 0
extracts 0
of 0
the 0
myogenic 0
cells 0
, 0
MyoD B-gene
and 0
myogenin B-gene
bound 0
to 0
the 0
right 0
E 0
- 0
box 0
in 0
the 0
enhancer 0
region 0
of 0
the 0
MCK B-gene
gene I-gene
even 0
in 0
the 0
presence 0
of 0
BMP B-gene
- I-gene
2 I-gene
. 0

A 0
heterologous 0
promoter 0
construct 0
containing 0
three 0
repeats 0
of 0
a 0
consensus 0
Sp1 B-gene
site I-gene
, 0
cloned 0
upstream 0
of 0
a 0
single 0
copy 0
of 0
the 0
ZII B-gene
( 0
CREB/ B-gene
AP1 I-gene
) 0
element 0
from 0
the 0
BZLF1 B-gene
promoter I-gene
linked 0
to 0
the 0
beta B-gene
- I-gene
globin I-gene
TATA 0
box 0
, 0
exhibited 0
phorbol 0
ester 0
inducibility 0
. 0

Subsequent 0
experiments 0
showed 0
that 0
motoric 0
tasks 0
rather 0
than 0
cognitive 0
aspects 0
of 0
the 0
COWA 0
task 0
were 0
critical 0
in 0
potentiating 0
finger 0
- 0
tapping 0
performance 0
. 0

How 0
does 0
a 0
nurse 0
go 0
about 0
maintaining 0
her 0
level 0
of 0
competence 0
when 0
she 0
is 0
one 0
of 0
the 0
few 0
local 0
practitioners 0
in 0
her 0
field 0
? 0
Vancouver 0
sex 0
therapist 0
Bianca 0
Rucker 0
is 0
doing 0
it 0
by 0
cultivating 0
a 0
network 0
of 0
colleagues 0
and 0
mentors 0
in 0
related 0
fields 0
both 0
at 0
home 0
and 0
across 0
the 0
continent 0
. 0

Finally 0
, 0
antibody 0
binding 0
to 0
site 0
IIIa 0
on 0
the 0
hCG B-gene
- I-gene
ectodomain I-gene
complex I-gene
was 0
also 0
hindered 0
by 0
an 0
anti 0
- 0
peptide 0
mAb 0
directed 0
against 0
a 0
peptide 0
encoded 0
by 0
the 0
eighth 0
exon 0
( 0
pE 0
x 0
8 0
) 0
of 0
the 0
LHR B-gene
. 0

cDNA 0
cloning 0
, 0
expression 0
analysis 0
, 0
and 0
chromosomal 0
localization 0
of 0
a 0
gene 0
with 0
high 0
homology 0
to 0
wheat B-gene
eIF I-gene
- I-gene
( I-gene
iso I-gene
) I-gene
4F I-gene
and 0
mammalian B-gene
eIF I-gene
- I-gene
4G I-gene
. 0

Therefore 0
, 0
it 0
is 0
important 0
to 0
control 0
hypertension 0
and 0
keep 0
appropriate 0
renal 0
blood 0
flow 0
during 0
living 0
renal 0
transplantation 0
surgery 0
. 0

The 0
initial 0
patients 0
treated 0
with 0
AZQ 0
and 0
mitroxantrone 0
experienced 0
prolonged 0
bone 0
marrow 0
suppression 0
and 0
, 0
therefore 0
, 0
subsequent 0
cohorts 0
were 0
treated 0
with 0
G B-gene
- I-gene
CSF I-gene
, 0
5 0
micrograms/kg 0
, 0
beginning 0
the 0
day 0
after 0
completion 0
of 0
the 0
third 0
cycle 0
of 0
chemotherapy 0
. 0

Human B-gene
granulocyte I-gene
- I-gene
macrophage I-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
( 0
hGM B-gene
- I-gene
CSF I-gene
) 0
activates 0
a 0
set 0
of 0
genes 0
such 0
as 0
c B-gene
- I-gene
fos I-gene
, 0
jun B-gene
, 0
myc B-gene
, 0
and 0
early B-gene
growth I-gene
response I-gene
gene I-gene
1 I-gene
( 0
egr B-gene
- I-gene
1 I-gene
) 0
. 0

In 0
order 0
to 0
provide 0
adequate 0
local 0
control 0
without 0
compromising 0
cosmetic 0
outcome 0
, 0
the 0
amount 0
of 0
breast 0
tissue 0
that 0
must 0
be 0
excised 0
in 0
BCT 0
needs 0
to 0
be 0
individualized 0
. 0

Surprisingly 0
, 0
however 0
, 0
TCR B-gene
- 0
mediated 0
tyrosine 0
phosphorylation 0
of 0
phospholipase B-gene
C I-gene
gamma I-gene
1 I-gene
remains 0
intact 0
in 0
the 0
Jurkat 0
cells 0
expressing 0
the 0
A2/HCP B-gene
chimera 0
. 0

The 0
14.1 B-gene
( I-gene
IGLL1 I-gene
) I-gene
gene I-gene
is 0
expressed 0
in 0
a 0
lineage 0
- 0
and 0
stage 0
- 0
restricted 0
manner 0
. 0

The 0
interferon B-gene
( 0
IFN B-gene
) 0
- 0
induced 0
double B-gene
- I-gene
stranded I-gene
RNA I-gene
( I-gene
dsRNA I-gene
) I-gene
- I-gene
activated I-gene
Ser/Thr I-gene
protein I-gene
kinase I-gene
( 0
PKR B-gene
) 0
plays 0
a 0
role 0
in 0
the 0
antiviral 0
and 0
antiproliferative 0
effects 0
of 0
IFN B-gene
. 0

Together 0
, 0
the 0
data 0
suggest 0
that 0
cAMP 0
- 0
dependent 0
control 0
of 0
the 0
amounts 0
of 0
the 0
activator 0
SF B-gene
- I-gene
1 I-gene
vs. 0
the 0
repressor 0
COUP B-gene
- I-gene
TF I-gene
could 0
influence 0
CRS2 0
- 0
dependent 0
transcription 0
. 0

Object 0
relations 0
, 0
affect 0
management 0
, 0
and 0
psychic 0
structure 0
formation 0
. 0

When 0
expressed 0
in 0
COS 0
- 0
7 0
cells 0
, 0
MKP B-gene
- I-gene
4 I-gene
blocks 0
activation 0
of 0
MAP B-gene
kinases I-gene
with 0
the 0
selectivity 0
ERK B-gene
> 0
p38 B-gene
= 0
JNK/SAPK B-gene
. 0

In 0
rlf2 B-gene
mutants I-gene
, 0
telomeric 0
chromatin 0
is 0
perturbed 0
: 0
Telomeric 0
silencing 0
is 0
reduced 0
and 0
Rap1p B-gene
localization 0
is 0
altered 0
. 0

Most 0
kinases 0
are 0
not 0
significantly 0
inhibited 0
by 0
roscovitine 0
. 0
cdc2/cyclin B-gene
cdc2/cyclin I-gene
B I-gene
, 0
cdk2/cyclin B-gene
cdk2/cyclin I-gene
A I-gene
, 0
cdk2/cyclin B-gene
cdk2/cyclin I-gene
E I-gene
and 0
cdk5/p35 B-gene
only 0
are 0
substantially 0
inhibited 0
( 0
IC50 0
values 0
of 0
0.65 0
, 0
0.7 0
, 0
0.7 0
and 0
0.2 0
microM 0
, 0
respectively 0
) 0
. 0
cdk5/p35 I-gene

This 0
0.74 0
kb 0
cDNA 0
contains 0
an 0
open 0
reading 0
frame 0
( 0
ORF 0
) 0
of 0
477 0
bp 0
encoding 0
a 0
polypeptide 0
of 0
159 0
amino 0
acids 0
( 0
aa 0
) 0
which 0
differs 0
at 0
only 0
one 0
position 0
( 0
position 0
65 0
) 0
from 0
the 0
human B-gene
U1 I-gene
- I-gene
C I-gene
protein I-gene
. 0

Interaction 0
of 0
Ets B-gene
- I-gene
1 I-gene
and 0
the 0
POU B-gene
- I-gene
homeodomain I-gene
protein I-gene
GHF B-gene
- I-gene
1/Pit I-gene
1/Pit I-gene
- I-gene
1 I-gene
reconstitutes 0
pituitary 0
- 0
specific 0
gene 0
expression 0
. 0

Although 0
Pho85 B-gene
is 0
not 0
essential 0
for 0
viability 0
, 0
Pcl1,2 B-gene
- 0
Pho85 B-gene
kinase 0
complexes 0
become 0
essential 0
for 0
Start 0
in 0
the 0
absence 0
of 0
Cln1,2 B-gene
- 0
Cdc28 B-gene
kinases 0
. 0

Using 0
the 0
yeast 0
two 0
- 0
hybrid 0
system 0
to 0
screen 0
for 0
proteins 0
which 0
interact 0
with 0
Tax1 B-gene
, 0
we 0
isolated 0
the 0
B 0
subunit 0
of 0
the 0
CCAAT 0
binding 0
protein 0
NF B-gene
- I-gene
Y I-gene
from 0
a 0
HeLa 0
cDNA 0
library 0
. 0

Enhancer 0
activity 0
requires 0
both 0
the 0
AP B-gene
- I-gene
1 I-gene
site I-gene
and 0
these 0
adjacent 0
sequences 0
. 0

Studies 0
using 0
HLA B-gene
- I-gene
DR I-gene
- 0
B7 B-gene
- I-gene
1 I-gene
- 0
LFA B-gene
- I-gene
3 I-gene
triple 0
transfectants 0
showed 0
that 0
the 0
LFA B-gene
- I-gene
3 I-gene
- 0
induced 0
NF B-gene
- I-gene
AT I-gene
DNA 0
binding 0
activity 0
was 0
negatively 0
regulated 0
by 0
B7 B-gene
- I-gene
1 I-gene
costimulation 0
. 0

Constitutive 0
activation 0
of 0
Rac1 B-gene
and 0
RhoA B-gene
causes 0
tumorigenic 0
transformation 0
of 0
NIH 0
3T3 0
cells 0
, 0
and 0
their 0
functions 0
may 0
be 0
required 0
for 0
full 0
Ras B-gene
transformation 0
. 0

Furthermore 0
, 0
Rac1 B-gene
activation 0
of 0
JNK B-gene
or 0
SRF B-gene
, 0
or 0
induction 0
of 0
lamellipodia 0
, 0
was 0
neither 0
necessary 0
nor 0
sufficient 0
for 0
Rac1 B-gene
transforming 0
activity 0
. 0

Overexpression 0
of 0
the 0
bZip 0
interaction 0
domain 0
of 0
CBP B-gene
specifically 0
abolishes 0
the 0
positive 0
cross 0
talk 0
between 0
TR B-gene
and 0
p45/NF B-gene
p45/NF I-gene
- I-gene
E2 I-gene
. 0

This 0
inhibitory 0
domain 0
has 0
been 0
deleted 0
in 0
all 0
naturally 0
occurring 0
AHC B-gene
deletion I-gene
mutants I-gene
described 0
to 0
date 0
. 0

Identification 0
of 0
a 0
promoter 0
- 0
specific 0
transactivation 0
domain 0
in 0
the 0
herpes B-gene
simplex I-gene
virus I-gene
regulatory I-gene
protein I-gene
ICP4 I-gene
. 0

DNA 0
sequencing 0
of 0
a 0
17 0
- 0
kb 0
segment 0
encompassing 0
a 0
gammaherpesvirus 0
divergent 0
locus 0
( 0
DL 0
- 0
B 0
) 0
between 0
ORF11 0
and 0
ORF17 0
revealed 0
the 0
presence 0
of 0
nine 0
viral 0
ORFs 0
with 0
predicted 0
gene 0
products 0
related 0
to 0
cellular 0
proteins 0
. 0

Studies 0
in 0
mammalian 0
cells 0
have 0
correlated 0
induction 0
of 0
inhibitory 0
tyrosine 0
15 0
( 0
Y15 0
) 0
phosphorylation 0
on 0
p34cdc2 B-gene
with 0
the 0
response 0
to 0
DNA 0
damage 0
. 0

We 0
report 0
herein 0
the 0
case 0
of 0
a 0
30 0
- 0
year 0
- 0
old 0
man 0
in 0
whom 0
ectopic 0
mediastinal 0
parathyroid 0
adenoma 0
was 0
detected 0
by 0
99mTc 0
- 0
methoxyisobutylisonitrile 0
scintigraphy 0
( 0
99mTc 0
- 0
MIBI 0
) 0
. 0

Cardiac B-gene
endothelin I-gene
release 0
and 0
infarct 0
size 0
, 0
myocardial 0
blood 0
flow 0
, 0
and 0
ventricular 0
function 0
in 0
canine 0
infarction 0
and 0
reperfusion 0
. 0

The 0
workup 0
included 0
skin 0
tests 0
( 0
up 0
to 0
1 0
microgram/ml 0
, 0
Pharmacia 0
) 0
, 0
measurement 0
of 0
specific 0
serum 0
IgE B-gene
with 0
RAST 0
- 0
CAP 0
( 0
Pharmacia 0
) 0
, 0
and 0
CAST 0
with 0
three 0
concentrations 0
of 0
bee 0
( 0
Apis 0
mellifera 0
) 0
and 0
wasp 0
( 0
Vespula 0
spec 0
. 0
) 0
venom 0
( 0
Aquagen 0
ALK 0
) 0
. 0

The 0
proliferation B-gene
potential I-gene
protein I-gene
- I-gene
related I-gene
( 0
P2P B-gene
- I-gene
R I-gene
) 0
gene 0
with 0
domains 0
encoding 0
heterogeneous 0
nuclear 0
ribonucleoprotein 0
association 0
and 0
Rb1 B-gene
binding 0
shows 0
repressed 0
expression 0
during 0
terminal 0
differentiation 0
. 0

Recent 0
application 0
of 0
recombinant 0
canarypox 0
ALVAC/HIV 0
- 0
1 0
vectors 0
as 0
vaccine 0
immunogens 0
in 0
HIV 0
- 0
1 0
, 0
- 0
noninfected 0
volunteers 0
has 0
produced 0
CTL 0
responses 0
in 0
a 0
significant 0
number 0
of 0
vaccinees 0
. 0

The 0
relevance 0
of 0
these 0
elements 0
in 0
conferring 0
anaerobic 0
induction 0
of 0
gpc4 B-gene
gene I-gene
expression 0
is 0
discussed 0
. 0

Exons 0
A1a 0
and 0
A1b 0
are 0
separated 0
from 0
each 0
other 0
by 0
a 0
124 0
- 0
nucleotide 0
intron 0
. 0

A 0
MEK B-gene
- 0
specific 0
inhibitor 0
( 0
PD098059 0
) 0
( 0
Dudley 0
, 0
D 0
. 0

These 0
data 0
support 0
the 0
idea 0
that 0
the 0
repression 0
activity 0
of 0
NRSF/REST B-gene
depends 0
upon 0
the 0
species 0
of 0
promoter 0
to 0
which 0
it 0
is 0
linked 0
and 0
upon 0
the 0
proteins 0
that 0
bind 0
to 0
those 0
promoters 0
. 0

Enhanced 0
period 0
- 0
peak 0
analysis 0
of 0
electro 0
- 0
encephalograms 0
using 0
a 0
fast 0
sinc 0
function 0
. 0

In 0
summary 0
, 0
p56 B-gene
( 0
lck B-gene
) 0
activity 0
stimulates 0
G1/S 0
transition 0
in 0
immature 0
thymoblasts 0
and 0
maintains 0
cell 0
viability 0
via 0
transduction 0
of 0
constitutive 0
activation 0
signals 0
downstream 0
to 0
components 0
of 0
the 0
Ras/Raf/MAPK B-gene
pathway 0
. 0

However 0
, 0
the 0
action 0
of 0
each 0
cognate 0
ligand 0
and 0
the 0
accessory 0
cellular 0
factors 0
that 0
can 0
differentially 0
regulate 0
the 0
transcriptional 0
responses 0
of 0
a 0
heterodimer 0
- 0
DNA 0
complex 0
are 0
not 0
well 0
understood 0
. 0

We 0
have 0
measured 0
the 0
MBF 0
on 0
incisors 0
and 0
its 0
direction 0
in 0
three 0
dimensions 0
for 0
different 0
jaw 0
openings 0
in 0
ten 0
subjects 0
. 0

These 0
findings 0
suggest 0
that 0
intraarterial 0
neoadjuvant 0
chemotherapy 0
should 0
be 0
effective 0
on 0
advanced 0
cervical 0
cancer 0
. 0

The 0
FBF 0
questionnaire 0
did 0
not 0
highlight 0
a 0
characteristic 0
basic 0
symptoms 0
profile 0
of 0
schizoaffective 0
disorder 0
, 0
when 0
compared 0
with 0
bipolar 0
affective 0
disorder 0
and 0
schizophrenia 0
. 0

The 0
alternative 0
sigma B-gene
factor I-gene
sigmaB I-gene
in I-gene
Staphylococcus I-gene
aureus I-gene
: 0
regulation 0
of 0
the 0
sigB B-gene
operon I-gene
in 0
response 0
to 0
growth 0
phase 0
and 0
heat 0
shock 0

Cognate 0
promoter 0
elements 0
implicated 0
in 0
glucocorticoid 0
- 0
and 0
cAMP 0
- 0
mediated 0
regulation 0
as 0
well 0
as 0
in 0
liver 0
- 0
, 0
myeloid 0
- 0
, 0
and 0
lymphocyte 0
- 0
specific 0
expression 0
are 0
located 0
within 0
the 0
5 0
' 0
flanking 0
sequence 0
. 0

Clinically 0
meaningful 0
decreases 0
due 0
to 0
alkalinization 0
alone 0
within 0
30 0
minutes 0
are 0
unlikely 0
. 0

We 0
have 0
studied 0
the 0
biokinetics 0
of 0
BLM 0
labeled 0
with 0
indium 0
- 0
111 0
( 0
In 0
- 0
111 0
) 0
. 0

CD3 B-gene
cross 0
- 0
linking 0
induced 0
tyrosine 0
phosphorylation 0
of 0
Sam68 B-gene
in 0
uninfected 0
T 0
cells 0
. 0

Acetoin 0
- 0
dependent 0
expression 0
of 0
the 0
acoABCD B-gene
operon I-gene
could 0
be 0
restored 0
in 0
the 0
E. B-gene
coli I-gene
acoK I-gene
mutants I-gene
by 0
supplying 0
a 0
plasmid 0
carrying 0
an 0
intact 0
acoK B-gene
, 0
suggesting 0
a 0
transactivating 0
function 0
of 0
the 0
gene 0
product 0
. 0

Mutations 0
in 0
the 0
alpha B-gene
and I-gene
sigma I-gene
- I-gene
70 I-gene
subunits I-gene
of I-gene
RNA I-gene
polymerase I-gene
affect 0
expression 0
of 0
the 0
mer B-gene
operon I-gene
. 0

Taken 0
together 0
, 0
we 0
provide 0
evidence 0
for 0
the 0
existence 0
of 0
an 0
activator 0
, 0
NFE B-gene
, 0
which 0
in 0
combination 0
with 0
the 0
p50 B-gene
and 0
c B-gene
- I-gene
Rel I-gene
proteins I-gene
, 0
are 0
part 0
of 0
the 0
transcription 0
factor 0
machinery 0
that 0
regulates 0
3 0
' 0
enhancer 0
activity 0
, 0
and 0
thus 0
the 0
control 0
of 0
the 0
IgH B-gene
locus I-gene
in 0
late 0
B 0
lymphocyte 0
development 0
. 0

The 0
neuroprotective 0
efficacy 0
of 0
the 0
selective 0
N 0
- 0
type 0
voltage 0
- 0
sensitive 0
calcium 0
channel 0
blocker 0
, 0
SNX 0
- 0
111 0
, 0
was 0
evaluated 0
in 0
spontaneously 0
hypertensive 0
rats 0
subjected 0
to 0
60 0
min 0
of 0
focal 0
cerebral 0
ischemia 0
by 0
permanent 0
ligation 0
of 0
the 0
right 0
common 0
carotid 0
artery 0
and 0
temporary 0
occlusion 0
of 0
the 0
right 0
middle 0
cerebral 0
artery 0
. 0

The 0
genes 0
encoding 0
the 0
transcription B-gene
factor I-gene
yTAFII60 I-gene
, 0
the 0
G4p1 B-gene
protein I-gene
and 0
a 0
putative 0
glucose 0
transporter 0
are 0
contained 0
in 0
a 0
12.3 0
kb 0
DNA 0
fragment 0
on 0
the 0
left 0
arm 0
of 0
Saccharomyces 0
cerevisiae 0
chromosome 0
VII 0
. 0

The 0
protector 0
doubled 0
the 0
estimated 0
fall 0
distance 0
for 0
fracture 0
of 0
the 0
trochanter 0
. 0

Marinol/marijuana 0
usage 0
was 0
associated 0
with 0
depressed 0
CD4+ B-gene
counts 0
and 0
elevated 0
amylase B-gene
levels 0
within 0
the 0
DDI 0
subgroup 0
. 0

METHODS 0
: 0
Fifty 0
- 0
eight 0
patients 0
who 0
underwent 0
a 0
curative 0
hepatic 0
resection 0
for 0
HCC 0
and 0
whose 0
preoperative 0
AFP B-gene
levels 0
were 0
> 0
100 0
ng/ml 0
, 0
were 0
selected 0
for 0
this 0
study 0
. 0

Calmodulin B-gene
- I-gene
binding I-gene
peptide I-gene
( 0
CBP B-gene
) 0
, 0
a 0
peptide 0
of 0
26 0
amino 0
acids 0
derived 0
from 0
muscle B-gene
myosin I-gene
light I-gene
chain I-gene
kinase I-gene
( 0
MLCK B-gene
) 0
, 0
binds 0
to 0
calmodulin B-gene
with 0
nanomolar 0
affinity 0
. 0

Here 0
we 0
show 0
that 0
the 0
type 0
of 0
tyrosine B-gene
kinase I-gene
receptor I-gene
stimulated 0
also 0
participates 0
in 0
the 0
nature 0
of 0
the 0
cAMP 0
effect 0
. 0

To 0
gain 0
insight 0
into 0
the 0
possible 0
involvement 0
of 0
p21 B-gene
in 0
liver 0
cell 0
growth 0
, 0
the 0
expression 0
and 0
regulation 0
of 0
the 0
p21 B-gene
gene I-gene
was 0
evaluated 0
in 0
rodent 0
models 0
of 0
liver 0
regeneration 0
and 0
specimens 0
of 0
human 0
liver 0
diseases 0
. 0

Northern 0
blot 0
analysis 0
of 0
LeMT B-gene
( I-gene
A I-gene
) I-gene
and 0
LeMT B-gene
( I-gene
B I-gene
) I-gene
showed 0
that 0
transcripts 0
of 0
both 0
MT B-gene
- I-gene
like I-gene
genes I-gene
were 0
more 0
abundant 0
in 0
leaves 0
than 0
roots 0
in 0
tomato 0
plants 0
grown 0
without 0
addition 0
of 0
extra 0
metal 0
ions 0
, 0
a 0
characteristic 0
of 0
type B-gene
II I-gene
MTs I-gene
. 0

In 0
co 0
- 0
transfection 0
studies 0
, 0
an 0
AP B-gene
- I-gene
2 I-gene
but 0
not 0
an 0
Egr B-gene
- I-gene
1 I-gene
expression 0
vector 0
activated 0
VPF/VEGF B-gene
transcription 0
, 0
thus 0
indicating 0
that 0
VPF/VEGF I-gene

The 0
HBP B-gene
gene I-gene
is 0
composed 0
of 0
eight 0
exons 0
covering 0
19.5 0
kb 0
on 0
the 0
short 0
arm 0
of 0
chromosome 0
4 0
. 0

In 0
some 0
instances 0
, 0
this 0
is 0
partly 0
mediated 0
by 0
the 0
expression 0
of 0
virally 0
encoded 0
proteases 0
which 0
lead 0
to 0
the 0
cleavage 0
of 0
initiation B-gene
factor I-gene
eIF4G I-gene
. 0

The 0
best 0
endometrial 0
ablation 0
was 0
seen 0
when 0
SnET2 0
was 0
given 0
by 0
intrauterine 0
administration 0
with 0
light 0
treatment 0
at 0
150 0
J/cm 0
24 0
hours 0
later 0
. 0

Unlike 0
class 0
II 0
- 0
and 0
III 0
- 0
specific 0
TBP B-gene
- 0
TAF B-gene
complexes 0
, 0
the 0
corresponding 0
murine 0
and 0
human 0
class 0
I 0
- 0
specific 0
transcription 0
initiation 0
factor 0
TIF B-gene
- I-gene
IB/SL1 I-gene
exhibits 0
a 0
pronounced 0
selectivity 0
for 0
its 0
homologous 0
promoter 0
. 0

Cytohesin B-gene
- I-gene
1 I-gene
, 0
a 0
protein 0
abundant 0
in 0
cells 0
of 0
the 0
immune 0
system 0
, 0
has 0
been 0
proposed 0
to 0
be 0
a 0
human 0
homolog 0
of 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
Sec7 I-gene
gene I-gene
product I-gene
, 0
which 0
is 0
crucial 0
in 0
protein 0
transport 0
. 0

In 0
this 0
regard 0
, 0
it 0
differs 0
from 0
a 0
recently 0
reported 0
BFA 0
- 0
sensitive 0
ARF B-gene
- 0
GEP B-gene
that 0
contains 0
a 0
Sec7 B-gene
domain I-gene
. 0

We 0
now 0
describe 0
the 0
identification 0
of 0
DEK B-gene
as 0
this 0
43 B-gene
- I-gene
kDa I-gene
pets I-gene
factor I-gene
. 0

These 0
elements 0
comprise 0
a 0
binding 0
site 0
for 0
Krox B-gene
proteins I-gene
, 0
one 0
for 0
nuclear B-gene
factor I-gene
1 I-gene
, 0
an 0
octamer 0
motif 0
that 0
binds 0
POU B-gene
- I-gene
homeodomain I-gene
proteins I-gene
, 0
and 0
a 0
novel 0
TN B-gene
control I-gene
element I-gene
. 0

Tissue 0
samples 0
were 0
obtained 0
either 0
from 0
rats 0
that 0
had 0
been 0
exposed 0
to 0
opiate 0
withdrawal 0
following 0
a 0
seven 0
day 0
morphine 0
infusion 0
or 0
sham 0
treated 0
control 0
subjects 0
. 0

Therefore 0
, 0
the 0
impaired 0
floor 0
plate 0
development 0
in 0
oep B-gene
mutants I-gene
is 0
not 0
caused 0
by 0
the 0
absence 0
of 0
the 0
floor B-gene
plate I-gene
inducer I-gene
shh I-gene
. 0

RESULTS 0
: 0
The 0
medians 0
of 0
average 0
daily 0
CD34+ B-gene
cell 0
yields 0
for 0
patients 0
who 0
received 0
paclitaxel 0
plus 0
CY 0
, 0
CE 0
, 0
and 0
CEP 0
with 0
G B-gene
- I-gene
CSF I-gene
were 0
12.9 0
, 0
11.03 0
, 0
and 0
5.37 0
x 0
10 0
( 0
6 0
) 0
/kg 0
, 0
respectively 0
, 0
compared 0
with 0
2.02 0
x 0
10 0
( 0
6 0
) 0
/kg 0
in 0
the 0
reference 0
group 0
that 0
received 0
CY 0
with 0
G B-gene
- I-gene
CSF I-gene
( 0
P 0
= 0
< 0
.0001 0
, 0
.002 0
, 0
and 0
.09 0
, 0
respectively 0
) 0
. 0

Increased 0
p53 B-gene
activity 0
induced 0
by 0
OP 0
is 0
not 0
due 0
to 0
elevated 0
p53 B-gene
mRNA I-gene
nor 0
to 0
protein 0
levels 0
. 0

CONCLUSION 0
: 0
Chronic 0
administration 0
of 0
misoprostol 0
may 0
have 0
caused 0
a 0
negative 0
natriuretic 0
effect 0
in 0
cirrhotic 0
patients 0
with 0
ascites 0
. 0

The 0
intensity 0
of 0
the 0
SSTEs 0
is 0
an 0
order 0
of 0
magnitude 0
larger 0
than 0
that 0
of 0
the 0
MSEs 0
and 0
determines 0
the 0
signal 0
contrast 0
if 0
both 0
effects 0
are 0
selected 0
simultaneously 0
. 0

In 0
eukaryotic 0
cells 0
, 0
premature 0
termination 0
of 0
translation 0
at 0
nonsense 0
codons 0
has 0
been 0
implicated 0
as 0
the 0
cause 0
of 0
a 0
variety 0
of 0
posttranscriptional 0
events 0
, 0
including 0
rapid 0
mRNA 0
decay 0
in 0
the 0
cytoplasm 0
or 0
the 0
nucleus 0
, 0
altered 0
splice 0
site 0
selection 0
, 0
and 0
exon 0
skipping 0
. 0

The 0
region 0
of 0
plasmid 0
pCM2 0
encoding 0
the 0
pathogenicity B-gene
locus I-gene
pat I-gene
- I-gene
1 I-gene
was 0
mapped 0
by 0
deletion 0
analysis 0
and 0
complementation 0
studies 0
to 0
a 0
1.5 0
- 0
kb 0
Bg/II/SmaI B-gene
DNA 0
fragment 0
. 0

Transient 0
cotransfection 0
of 0
tat B-gene
cDNA I-gene
in 0
sense 0
orientation 0
( 0
tat/S B-gene
) 0
, 0
together 0
with 0
a 0
plasmid 0
containing 0
the 0
c B-gene
- I-gene
fos I-gene
promoter I-gene
( 0
FC3 B-gene
, 0
from 0
- 0
711 0
to 0
+42 0
) 0
in 0
front 0
of 0
the 0
bacterial B-gene
chloramphenicol I-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
gene 0
significantly 0
enhanced 0
CAT B-gene
activity 0
in 0
Jurkat 0
cells 0
activated 0
by 0
the 0
addition 0
of 0
15 0
% 0
fetal 0
calf 0
serum 0
( 0
FCS 0
) 0
or 0
5 0
micrograms/mL 0
phytohemagglutinin B-gene
plus 0
10 0
( 0
- 0
7 0
) 0
mol/L 0
phorbol 0
myristate 0
acetate 0
( 0
PMA 0
) 0
and 0
U937 0
cells 0
activated 0
by 0
15 0
% 0
FCS 0
or 0
10 0
( 0
- 0
7 0
) 0
mol/L 0
PMA 0
. 0

Snail 0
mortality 0
did 0
not 0
differ 0
among 0
the 0
various 0
treatment 0
conditions 0
. 0

The 0
recombinant 0
protein 0
was 0
purified 0
to 0
homogeneity 0
by 0
( 0
NH4 0
) 0
2SO4 0
- 0
precipitation 0
and 0
affinity 0
chromatography 0
on 0
5 0
' 0
AMP 0
- 0
Sepharose 0
. 0

Derepression 0
of 0
gene 0
expression 0
mediated 0
by 0
the 0
5 0
' 0
upstream 0
region 0
of 0
the 0
isocitrate B-gene
lyase I-gene
gene I-gene
of I-gene
Candida I-gene
tropicalis I-gene
is 0
controlled 0
by 0
two 0
distinct 0
regulatory 0
pathways 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Exploratory 0
- 0
motor 0
task 0
to 0
evaluate 0
right 0
frontal 0
lobe 0
damage 0
. 0

To 0
avoid 0
complications 0
, 0
accurate 0
quantitative 0
analysis 0
of 0
NO 0
and 0
NO2 0
is 0
necessary 0
during 0
this 0
therapy 0
. 0

Our 0
results 0
demonstrate 0
that 0
cis 0
elements 0
positioned 0
between 0
the 0
alpha B-gene
3 I-gene
and 0
beta B-gene
4 I-gene
coding 0
regions 0
are 0
important 0
for 0
establishing 0
part 0
of 0
the 0
restricted 0
CNS 0
patterns 0
of 0
beta B-gene
4 I-gene
, 0
alpha B-gene
3 I-gene
, 0
and 0
alpha B-gene
5 I-gene
gene I-gene
transcription 0
. 0

RNase B-gene
protection 0
experiments 0
confirmed 0
the 0
presence 0
of 0
the 0
GHR1 B-gene
- I-gene
279 I-gene
variant I-gene
in 0
IM 0
- 0
9 0
cells 0
and 0
human 0
liver 0
. 0

Functional 0
tests 0
using 0
a 0
reporter 0
gene 0
, 0
containing 0
Stat5 B-gene
- I-gene
binding I-gene
elements I-gene
, 0
confirmed 0
that 0
while 0
the 0
variant 0
form 0
was 0
inactive 0
by 0
itself 0
, 0
it 0
could 0
inhibit 0
the 0
function 0
of 0
the 0
full 0
- 0
length 0
receptor 0
. 0

Conversely 0
, 0
activated 0
glucocorticoid B-gene
receptors I-gene
suppressed 0
the 0
transactivation 0
function 0
of 0
p53 B-gene
, 0
while 0
transrepression 0
by 0
p53 B-gene
was 0
largely 0
unaffected 0
. 0

99mTc 0
- 0
HMPAO 0
was 0
distributed 0
in 0
the 0
territories 0
of 0
the 0
ACA 0
and 0
MCA 0
in 0
the 0
two 0
patients 0
who 0
were 0
treated 0
with 0
intraarterial 0
infusion 0
of 0
papaverine 0
from 0
the 0
C4 0
segment 0
, 0
but 0
was 0
distributed 0
only 0
to 0
the 0
territory 0
of 0
the 0
ACA 0
in 0
four 0
patients 0
who 0
were 0
treated 0
with 0
intraarterial 0
infusion 0
of 0
papaverine 0
from 0
the 0
C1 0
segment 0
at 0
1 0
ml/min 0
. 0

This 0
brief 0
review 0
analyses 0
these 0
interactions 0
and 0
defines 0
clinical 0
settings 0
where 0
antibiotic 0
- 0
induced 0
endotoxin 0
release 0
may 0
prove 0
to 0
be 0
clinically 0
relevant 0
. 0

This 0
promoter 0
segment 0
could 0
drive 0
expression 0
of 0
a 0
luciferase B-gene
reporter I-gene
gene I-gene
, 0
could 0
confer 0
correct 0
transcriptional 0
initiation 0
to 0
the 0
reporter 0
and 0
could 0
confer 0
the 0
EGF B-gene
- 0
responsiveness 0
previously 0
observed 0
in 0
the 0
native 0
gene 0
. 0

This 0
is 0
the 0
first 0
report 0
that 0
an 0
in 0
vitro 0
- 0
synthesized 0
alphavirus 0
RNA 0
lacking 0
a 0
poly 0
( 0
A 0
) 0
tail 0
can 0
initiate 0
infection 0
and 0
produce 0
3 0
' 0
polyadenylated 0
viral 0
genome 0
in 0
vivo 0
. 0

The 0
human 0
coreceptor 0
was 0
as 0
active 0
as 0
the 0
simian 0
for 0
SIV 0
entry 0
. 0

These 0
changes 0
in 0
virus 0
entry 0
features 0
may 0
result 0
in 0
coronaviruses 0
with 0
novel 0
pathogenic 0
properties 0
. 0

RESULTS 0
: 0
Among 0
women 0
, 0
the 0
age 0
- 0
related 0
decline 0
in 0
BMD 0
at 0
all 0
non 0
- 0
spine 0
skeletal 0
sites 0
was 0
significantly 0
different 0
from 0
zero 0
, 0
with 0
the 0
largest 0
decline 0
seen 0
at 0
the 0
femoral 0
neck 0
( 0
- 0
.0038 0
g/cm2/y 0
, 0
p 0
< 0
.001 0
) 0
and 0
the 0
smallest 0
at 0
the 0
trochanter 0
of 0
the 0
hip 0
( 0
- 0
.0023 0
g/cm2/y 0
, 0
p 0
= 0
.03 0
) 0
. 0

Sixty 0
- 0
nine 0
( 0
44 0
% 0
) 0
patients 0
were 0
administered 0
250 0
MBq 0
( 0
7 0
mCi 0
) 0
99Tcm 0
- 0
tetrofosmin 0
at 0
rest 0
followed 0
4 0
h 0
later 0
by 0
750 0
MBq 0
( 0
21 0
mCi 0
) 0
during 0
stress 0
( 0
the 0
1 0
day 0
protocol 0
) 0
, 0
whereas 0
88 0
( 0
56 0
% 0
) 0
patients 0
had 0
rest 0
and 0
stress 0
imaging 0
studies 0
on 0
two 0
separate 0
days 0
, 0
receiving 0
a 0
500 0
MBq 0
( 0
14 0
mCi 0
) 0
dose 0
of 0
99Tcm 0
- 0
tetrofosmin 0
on 0
each 0
occasion 0
( 0
the 0
2 0
day 0
protocol 0
) 0
. 0

Myocardial 0
SPET 0
imaging 0
with 0
99Tcm 0
- 0
tetrofosmin 0
in 0
clinical 0
practice 0
: 0
comparison 0
of 0
a 0
1 0
day 0
and 0
a 0
2 0
day 0
imaging 0
protocol 0
. 0

99Tcm 0
- 0
DMP 0
- 0
HSA 0
showed 0
an 0
almost 0
identical 0
behaviour 0
to 0
in 0
vitro 0
labelled 0
red 0
blood 0
cells 0
( 0
RBCs 0
) 0
, 0
which 0
are 0
generally 0
considered 0
the 0
reference 0
standard 0
for 0
blood 0
pool 0
agents 0
. 0

Relief 0
from 0
autoinhibition 0
and 0
a 0
subsequent 0
10 0
- 0
60 0
- 0
fold 0
increase 0
in 0
V 0
( 0
max 0
) 0
have 0
been 0
observed 0
upon 0
N B-gene
- I-gene
SH2 I-gene
domain I-gene
engagement 0
by 0
a 0
specific 0
phosphotyrosyl 0
ligand 0
or 0
upon 0
deletion 0
of 0
the 0
SH2 B-gene
domains I-gene
to 0
yield 0
the 0
catalytic 0
PTPase B-gene
domain I-gene
. 0

We 0
have 0
thus 0
identified 0
the 0
first 0
mammalian B-gene
homolog I-gene
of I-gene
yeast I-gene
UPF1 I-gene
, 0
a 0
protein 0
that 0
regulates 0
levels 0
of 0
nonsense 0
mRNA 0
, 0
and 0
we 0
tentatively 0
name 0
this 0
protein 0
human B-gene
HUPF1 I-gene
( 0
for 0
human B-gene
homolog I-gene
of I-gene
UPF1 I-gene
) 0
. 0

A 0
miracle 0
cure 0
and 0
its 0
solution 0

The 0
addition 0
of 0
zidovudine 0
did 0
not 0
influence 0
this 0
transfer 0
. 0

DNA 0
strand 0
exchange 0
catalyzed 0
by 0
Rad51 B-gene
protein I-gene
is 0
also 0
greatly 0
stimulated 0
by 0
RPA B-gene
. 0

Ume6p B-gene
, 0
which 0
also 0
controls 0
the 0
expression 0
of 0
early 0
meiotic 0
genes 0
, 0
represses 0
CAR1 B-gene
expression 0
through 0
a 0
sequence 0
called 0
URS 0
, 0
as 0
a 0
function 0
of 0
nitrogen 0
availability 0
. 0

The 0
second 0
class 0
of 0
cDNA 0
hybridized 0
to 0
a 0
13 0
kb 0
transcript 0
, 0
which 0
was 0
approximately 0
twice 0
as 0
large 0
as 0
the 0
mammalian B-gene
lactase I-gene
mRNA I-gene
. 0

In 0
cell 0
lines 0
transformed 0
by 0
BCR/ABL B-gene
, 0
BCR/ABL I-gene

In 0
untransformed 0
cells 0
, 0
three 0
major 0
proteins 0
coprecipitated 0
with 0
CRKL B-gene
, 0
identified 0
as 0
C3G B-gene
, 0
SOS B-gene
and 0
c B-gene
- I-gene
ABL I-gene
. 0

Effect 0
of 0
Azadirachta 0
indica 0
hydroalcoholic 0
leaf 0
extract 0
on 0
the 0
cardiovascular 0
system 0
. 0

RESULTS 0
: 0
Nodular 0
opacities 0
, 0
mainly 0
centrilobular 0
in 0
distribution 0
, 0
were 0
the 0
most 0
common 0
finding 0
, 0
seen 0
in 0
21 0
( 0
72 0
% 0
) 0
and 0
15 0
( 0
65 0
% 0
) 0
of 0
patients 0
with 0
MTB 0
and 0
NTMB 0
, 0
respectively 0
. 0

Circulating 0
oxytocin B-gene
in 0
male 0
guinea 0
pigs 0
affected 0
by 0
the 0
female 0
cohabitation 0
and 0
reproductive 0
condition 0
. 0

In 0
cellular 0
supernatant 0
fraction 0
, 0
SHRSP 0
showed 0
a 0
decrease 0
of 0
magnesium 0
in 0
many 0
tissues 0
and 0
an 0
elevation 0
of 0
the 0
calcium 0
to 0
magnesium 0
ratio 0
when 0
compared 0
to 0
age 0
- 0
matched 0
WKY 0
and 0
SHRSR 0
. 0

Antisense 0
transcription 0
of 0
a 0
murine B-gene
FGFR I-gene
- I-gene
3 I-gene
psuedogene I-gene
during 0
fetal 0
developement 0
. 0

A 0
previous 0
report 0
described 0
that 0
a 0
548 0
- 0
bp 0
BglII B-gene
- 0
SmaI B-gene
fragment 0
has 0
an 0
SSO 0
activity 0
( 0
ori2 0
; 0
Kataoka 0
et 0
al. 0
, 0
Mol 0
. 0

The 0
human B-gene
CD38 I-gene
gene I-gene
consists 0
of 0
8 0
exons 0
that 0
extend 0
more 0
than 0
77 0
kb 0
on 0
the 0
human 0
genome 0
. 0

Type 0
IV 0
splice 0
pattern 0
, 0
containing 0
exon 0
U3 0
and 0
S 0
was 0
found 0
both 0
in 0
kidney 0
and 0
ovary 0
. 0

GH B-gene
deficiency 0
may 0
be 0
absolute 0
, 0
but 0
often 0
is 0
not 0
and 0
the 0
diagnosis 0
may 0
be 0
complicated 0
by 0
a 0
constellation 0
of 0
physical 0
and 0
hormonal 0
findings 0
that 0
are 0
along 0
a 0
spectrum 0
from 0
low 0
normal 0
GH B-gene
sufficiency 0
to 0
absent 0
GH B-gene
secretion 0
. 0

Positive 0
CRP B-gene
test 0
were 0
seen 0
. 0

During 0
the 0
febrile 0
period 0
, 0
pleocytosis 0
was 0
associated 0
with 0
high 0
levels 0
of 0
IgG B-gene
, 0
IL B-gene
- I-gene
6 I-gene
, 0
TNF B-gene
- I-gene
alpha I-gene
, 0
and 0
PGE2 0
in 0
the 0
cerebrospinal 0
fluid 0
. 0

Recognition 0
mechanisms 0
of 0
the 0
minus 0
- 0
strand 0
origin 0
of 0
phage 0
f1 0
by 0
Escherichia B-gene
coli I-gene
RNA I-gene
polymerase I-gene
. 0

The 0
minimum 0
and 0
essential 0
subunits 0
for 0
RNA 0
synthesis 0
have 0
not 0
yet 0
been 0
identified 0
. 0

Syndecan B-gene
- I-gene
4 I-gene
is 0
a 0
focal 0
adhesion 0
component 0
, 0
and 0
this 0
interaction 0
may 0
both 0
localize 0
PKC B-gene
and 0
amplify 0
its 0
activity 0
at 0
sites 0
of 0
forming 0
adhesions 0
. 0

The 0
3ASubE 0
cells 0
expressing 0
CXCR2 B-gene
with 0
mutation 0
of 0
Ser 0
- 0
346 0
, 0
- 0
347 0
, 0
and 0
- 0
348 0
to 0
alanine 0
, 0
or 0
with 0
mutation 0
of 0
only 0
one 0
serine 0
in 0
this 0
domain 0
, 0
continue 0
to 0
be 0
phosphorylated 0
in 0
response 0
to 0
ligand 0
and 0
are 0
60 0
- 0
70 0
% 0
desensitized 0
following 0
the 0
initial 0
ligand 0
challenge 0
. 0

Members 0
of 0
the 0
MAPK B-gene
family I-gene
include 0
the 0
extracellular B-gene
response I-gene
kinases I-gene
( 0
ERKs B-gene
or 0
p42/44 B-gene
( 0
MAPK B-gene
) 0
) 0
, 0
the 0
c B-gene
- I-gene
Jun I-gene
amino I-gene
- I-gene
terminal I-gene
kinases I-gene
( 0
JNKs B-gene
) 0
, 0
and 0
the 0
p38/Hog B-gene
p38/Hog I-gene
1 I-gene
protein 0
kinases 0
. 0

MOP5 B-gene
contained 0
the 0
characteristic 0
PAS B-gene
domain 0
and 0
a 0
variable 0
C 0
terminus 0
; 0
it 0
is 0
possible 0
that 0
the 0
cDNA 0
contains 0
a 0
bHLH 0
domain 0
, 0
but 0
the 0
entire 0
open 0
reading 0
frame 0
has 0
yet 0
to 0
be 0
completed 0
. 0

The 0
reduced 0
NO 0
production 0
in 0
these 0
cells 0
was 0
associated 0
with 0
low 0
levels 0
of 0
mRNA 0
of 0
inducible B-gene
NO I-gene
synthetase I-gene
. 0

Some 0
8.8 0
kb 0
of 0
the 0
Lactobacillus 0
sake 0
plasmid 0
pCIM1 0
was 0
sequenced 0
, 0
revealing 0
eight 0
tightly 0
clustered 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
downstream 0
from 0
lasA B-gene
, 0
which 0
encodes 0
pre B-gene
- I-gene
lactocin I-gene
S I-gene
. 0

Purified B-gene
Pra I-gene
was 0
also 0
shown 0
to 0
physically 0
interact 0
with 0
pyruvate B-gene
kinase I-gene
( 0
Pk B-gene
) 0
; 0
Pk B-gene
and 0
Pra B-gene
can 0
form 0
a 0
complex 0
, 0
but 0
when 0
the 0
12 B-gene
- I-gene
kDa I-gene
Ndk I-gene
, 0
Pk B-gene
, 0
and 0
Pra B-gene
are 0
all 0
present 0
, 0
Pk B-gene
has 0
a 0
higher 0
affinity 0
than 0
Pra B-gene
for 0
forming 0
a 0
complex 0
with 0
the 0
12 B-gene
- I-gene
kDa I-gene
Ndk I-gene
. 0

Apart 0
from 0
iron 0
regulation 0
, 0
sodA B-gene
expression 0
was 0
affected 0
by 0
changes 0
in 0
DNA 0
topology 0
induced 0
by 0
coumermycin 0
A 0
but 0
not 0
by 0
the 0
global 0
virulence 0
regulatory 0
Bvg B-gene
system I-gene
. 0

Molecular 0
characterization 0
of 0
a 0
large 0
Borrelia 0
burgdorferi 0
motility 0
operon 0
which 0
is 0
initiated 0
by 0
a 0
consensus 0
sigma70 B-gene
promoter I-gene
. 0

M. B-gene
leprae I-gene
OxyR I-gene
was 0
overproduced 0
and 0
purified 0
, 0
and 0
its 0
binding 0
to 0
the 0
oxyR B-gene
- 0
ahpC B-gene
intergenic 0
region 0
of 0
M. 0
leprae 0
was 0
demonstrated 0
. 0

The 0
binding 0
site 0
for 0
OxyR B-gene
overlapped 0
P1oxyR B-gene
, 0
reminiscent 0
of 0
the 0
autoregulatory 0
loops 0
controlling 0
expression 0
of 0
oxyR B-gene
in 0
enteric 0
bacteria 0
and 0
characteristic 0
of 0
the 0
LysR B-gene
superfamily I-gene
in 0
general 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
have 0
isolated 0
and 0
sequenced 0
several 0
p15E B-gene
cDNA I-gene
gene I-gene
fragments I-gene
amplified 0
by 0
means 0
of 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
from 0
parental 0
( 0
P815 0
) 0
and 0
xenogenized 0
( 0
P815/DTIC 0
) 0
tumour 0
cells 0
. 0

Thirty 0
- 0
five 0
patients 0
were 0
included 0
. 0

Grade 0
3 0
- 0
4 0
mucositis 0
was 0
present 0
in 0
13 0
% 0
of 0
the 0
cycles 0
. 0

Therefore 0
more 0
active 0
and 0
tolerable 0
salvage 0
regimens 0
are 0
needed 0
. 0

None 0
of 0
these 0
organic 0
manifestations 0
was 0
discovered 0
by 0
scintigraphic 0
means 0
. 0

While 0
TGF B-gene
- I-gene
beta1 I-gene
does 0
not 0
alter 0
the 0
mitogen 0
- 0
induced 0
expression 0
and 0
abundance 0
of 0
G1 0
phase 0
cyclin B-gene
D1 I-gene
and 0
cdks B-gene
4 I-gene
and I-gene
2 I-gene
in 0
MCs 0
, 0
it 0
inhibits 0
cyclin B-gene
E I-gene
- 0
cdk B-gene
2 I-gene
activity 0
, 0
thus 0
preventing 0
mitogen 0
- 0
elicited 0
phosphorylation 0
and 0
inactivation 0
of 0
pRb B-gene
in 0
G1 0
phase 0
and 0
transition 0
to 0
S 0
phase 0
. 0

However 0
, 0
the 0
range 0
of 0
values 0
observed 0
is 0
suggestive 0
of 0
the 0
need 0
to 0
investigate 0
districts 0
with 0
contrasting 0
values 0
of 0
SYPLR 0
with 0
respect 0
to 0
the 0
inter 0
- 0
relationships 0
between 0
sociodemographic 0
characteristics 0
, 0
duration 0
of 0
symptoms 0
, 0
clinical 0
presentation 0
and 0
treatment 0
efficacy 0
. 0

The 0
prominent 0
lesions 0
were 0
confined 0
to 0
the 0
cerebral 0
surface 0
layer 0
and 0
leptomeningeal 0
tissue 0
including 0
the 0
arachnoid 0
vessels 0
, 0
which 0
were 0
all 0
bathed 0
in 0
the 0
cerebrospinal 0
fluid 0
, 0
suggesting 0
that 0
some 0
necrotizing 0
toxins 0
had 0
been 0
secreted 0
into 0
the 0
fluid 0
by 0
the 0
B. 0
cereus 0
. 0

This 0
fragment 0
contained 0
the 0
C 0
- 0
terminal 0
47 0
nucleotides 0
of 0
leuB B-gene
, 0
encoding 0
3 B-gene
- I-gene
isopropylmalate I-gene
dehydrogenase I-gene
; 0
asd B-gene
, 0
encoding 0
aspartate B-gene
- I-gene
beta I-gene
- I-gene
semialdehyde I-gene
dehydrogenase I-gene
( 0
Asd B-gene
) 0
; 0
and 0
orfA 0
, 0
whose 0
product 0
showed 0
similarity 0
to 0
the 0
Asd B-gene
proteins I-gene
from I-gene
Vibrio I-gene
spp I-gene
. 0

Transcriptional 0
activity 0
was 0
measured 0
by 0
slot 0
- 0
blot 0
hybridization 0
with 0
steady 0
- 0
state 0
RNA 0
isolated 0
from 0
lacZ+ B-gene
M. I-gene
smegmatis I-gene
clones 0
. 0

Hovenitin 0
I 0
and 0
( 0
+ 0
) 0
- 0
ampelopsin 0
, 0
both 0
of 0
which 0
were 0
principal 0
ingredients 0
of 0
the 0
active 0
fractions 0
from 0
this 0
natural 0
medicine 0
, 0
were 0
found 0
to 0
show 0
an 0
inhibitory 0
activity 0
on 0
the 0
ethanol 0
- 0
induced 0
muscle 0
relaxation 0
in 0
rats 0
. 0

Movement 0
time 0
and 0
kinematic 0
characteristics 0
were 0
analyzed 0
together 0
with 0
the 0
magnitude 0
of 0
cerebral 0
blood 0
flow 0
to 0
identify 0
areas 0
of 0
brain 0
activity 0
proportionate 0
to 0
task 0
and 0
movement 0
variables 0
. 0

Areas 0
with 0
significantly 0
greater 0
rCBF 0
for 0
targeting 0
were 0
the 0
left 0
motor 0
cortex 0
, 0
left 0
intraparietal 0
sulcus 0
, 0
and 0
left 0
caudate 0
. 0

Recent 0
studies 0
have 0
demonstrated 0
that 0
the 0
U1 B-gene
snRNP I-gene
is 0
recruited 0
to 0
the 0
5 0
' 0
splice 0
site 0
by 0
protein/protein 0
interactions 0
involving 0
the 0
SR B-gene
domains 0
of 0
the 0
U1 B-gene
- I-gene
70K I-gene
protein I-gene
and 0
SF2/ASF B-gene
. 0

Thus 0
, 0
the 0
tri 0
- 0
snRNP 0
- 0
specific 0
27K 0
protein 0
could 0
potentially 0
be 0
involved 0
in 0
SR B-gene
protein 0
- 0
mediated 0
protein/protein 0
interactions 0
and 0
, 0
additionally 0
, 0
its 0
phosphorylation 0
state 0
could 0
modulate 0
pre 0
- 0
mRNA 0
splicing 0
. 0

Purified B-gene
P7 I-gene
could 0
be 0
assembled 0
onto 0
particles 0
lacking 0
P7 B-gene
and 0
particles 0
lacking 0
both 0
P2 B-gene
( 0
RNA B-gene
polymerase I-gene
) 0
and 0
P7 B-gene
. 0

However 0
, 0
the 0
same 0
U1A B-gene
peptide I-gene
, 0
when 0
conjugated 0
to 0
BSA B-gene
, 0
inhibits 0
vertebrate B-gene
PAP I-gene
. 0

Plasma 0
levels 0
of 0
protein B-gene
C I-gene
, 0
protein B-gene
S I-gene
, 0
and 0
antithrombin B-gene
III I-gene
in 0
patients 0
with 0
subarachnoid 0
haemorrhage 0
. 0

Idiopathic 0
bilateral 0
recurrent 0
branch 0
retinal 0
arterial 0
occlusion 0
( 0
IBRBRAO 0
) 0
is 0
a 0
rare 0
syndrome 0
characterized 0
by 0
migraine 0
headaches 0
, 0
tinnitus 0
, 0
vertigo 0
, 0
hearing 0
loss 0
, 0
and 0
recurrent 0
branch 0
retinal 0
artery 0
occlusion 0
of 0
unknown 0
etiology 0
. 0

Epithelial 0
and 0
corneal 0
thickness 0
measurements 0
by 0
in 0
vivo 0
confocal 0
microscopy 0
through 0
focusing 0
( 0
CMTF 0
) 0
. 0

Sequences 0
downstream 0
of 0
the 0
two 0
human B-gene
CA I-gene
genes I-gene
, 0
possibly 0
containing 0
homologous 0
enhancer 0
elements 0
, 0
have 0
not 0
yet 0
been 0
reported 0
. 0

Recombinant 0
plasmids 0
containing 0
the 0
entire 0
322 0
nt 0
5 0
' 0
UTR 0
of 0
exon 0
1 0
and 0
a 0
1630 0
nt 0
segment 0
of 0
5 0
' 0
flanking 0
sequence 0
stimulated 0
luciferase B-gene
activity 0
nearly 0
70 0
times 0
higher 0
than 0
a 0
promoterless 0
control 0
plasmid 0
. 0

Analysis 0
for 0
DNA 0
- 0
protein 0
interactions 0
by 0
in 0
vitro 0
DNase B-gene
- I-gene
I I-gene
footprinting 0
identified 0
a 0
broad 0
region 0
of 0
protection 0
extending 0
from 0
nt 0
- 0
12 0
to 0
+38 0
. 0

It 0
is 0
also 0
homologous 0
to 0
other 0
sugar 0
carriers 0
from 0
human 0
, 0
mouse 0
and 0
Escherichia 0
coli 0
. 0

Until 0
now 0
, 0
each 0
of 0
these 0
loci 0
was 0
considered 0
to 0
contain 0
three 0
genes 0
( 0
for 0
regulator B-gene
, 0
permease B-gene
and 0
alpha B-gene
- I-gene
glucosidase I-gene
) 0
, 0
but 0
a 0
fourth 0
gene 0
, 0
presumably 0
an 0
extra 0
alpha B-gene
- I-gene
glucosidase I-gene
gene I-gene
, 0
was 0
found 0
at 0
MAL1 B-gene
adjacent 0
to 0
the 0
usual 0
cluster 0
of 0
three 0
genes 0
. 0

Although 0
methods 0
to 0
align 0
the 0
control 0
and 0
activation 0
fMR 0
images 0
may 0
correct 0
for 0
some 0
of 0
this 0
motional 0
error 0
, 0
they 0
will 0
be 0
incomplete 0
in 0
correcting 0
for 0
those 0
that 0
depend 0
on 0
spatial 0
orientation 0
. 0

Three 0
women 0
have 0
had 0
abnormal 0
endocervical 0
follow 0
up 0
cytology 0
suggestive 0
of 0
residual 0
disease 0
. 0

Autorosette 0
- 0
forming 0
cells 0
are 0
characterized 0
by 0
a 0
high 0
activity 0
of 0
alkaline B-gene
and I-gene
acid I-gene
phosphatases I-gene
and 0
low 0
NBT 0
- 0
test 0
values 0
. 0

Analysis 0
of 0
homologous 0
DNA 0
sequences 0
within 0
the 0
first 0
intron 0
of 0
the 0
mouse B-gene
and I-gene
human I-gene
mts1 I-gene
genes I-gene
: 0
kB B-gene
- I-gene
like I-gene
site I-gene
and 0
microsatellite 0
DNA 0

The 0
integration 0
at 0
the 0
VIP B-gene
CyRE B-gene
of 0
the 0
Jak B-gene
- 0
Stat B-gene
and 0
AP B-gene
- I-gene
1 I-gene
signaling 0
pathways 0
with 0
other 0
pre 0
- 0
existing 0
proteins 0
provides 0
a 0
cellular 0
mechanism 0
for 0
cell 0
- 0
and 0
cytokine 0
- 0
specific 0
signaling 0
. 0

These 0
studies 0
point 0
to 0
the 0
involvement 0
of 0
the 0
MAP B-gene
kinase I-gene
pathway 0
in 0
the 0
activation 0
of 0
monocytic 0
cells 0
during 0
transmigration 0
to 0
inflammatory 0
sites 0
. 0

Our 0
results 0
show 0
that 0
the 0
temperature B-gene
- I-gene
sensitive I-gene
rad54 I-gene
- I-gene
3 I-gene
allele I-gene
blocks 0
mitotic 0
recombination 0
between 0
tandemly 0
repeated 0
DYZ3 B-gene
satellite I-gene
sequences I-gene
and 0
significantly 0
stabilizes 0
a 0
human B-gene
DYZ5 I-gene
satellite 0
- 0
containing 0
YAC 0
clone 0
. 0

A 0
P22 0
R17 0
derivative 0
with 0
an 0
OcRNA 0
site 0
( 0
P22 0
R17 0
[ 0
A 0
( 0
- 0
10 0
) 0
U 0
] 0
) 0
develops 0
lytically 0
following 0
infection 0
of 0
these 0
strains 0
. 0

Circularized 0
Ac/Ds B-gene
transposons 0
: 0
formation 0
, 0
structure 0
and 0
fate 0
. 0

This 0
site 0
is 0
upstream 0
from 0
the 0
TATA 0
box 0
used 0
in 0
somatic 0
cells 0
. 0

In 0
this 0
study 0
, 0
we 0
have 0
examined 0
the 0
regulation 0
of 0
B B-gene
- I-gene
Myb I-gene
activity 0
by 0
cyclin B-gene
- 0
Cdks B-gene
. 0

Candidate 0
tumor 0
suppressor 0
genes 0
, 0
Mts1 B-gene
( 0
p16INK4a B-gene
) 0
and 0
Mts2 B-gene
( 0
p15INK4b B-gene
) 0
, 0
have 0
been 0
mapped 0
to 0
this 0
region 0
, 0
but 0
by 0
Southern 0
blot 0
analysis 0
, 0
no 0
homozygous 0
deletions 0
were 0
detected 0
in 0
either 0
gene 0
. 0

Excision 0
repair 0
at 0
the 0
level 0
of 0
the 0
nucleotide 0
in 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
MFA2 I-gene
gene I-gene
: 0
mapping 0
of 0
where 0
enhanced 0
repair 0
in 0
the 0
transcribed 0
strand 0
begins 0
or 0
ends 0
and 0
identification 0
of 0
only 0
a 0
partial 0
rad16 B-gene
requisite 0
for 0
repairing 0
upstream 0
control 0
sequences 0
. 0

An 0
aromatic 0
stacking 0
interaction 0
between 0
subunits 0
helps 0
mediate 0
DNA 0
sequence 0
specificity 0
: 0
operator 0
site 0
discrimination 0
by 0
phage B-gene
lambda I-gene
cI I-gene
repressor I-gene
. 0

We 0
have 0
characterized 0
a 0
panel 0
of 0
6 0
monoclonal 0
antibodies 0
raised 0
against 0
human B-gene
platelet I-gene
talin I-gene
by 0
Western 0
blotting 0
, 0
immune 0
precipitation 0
, 0
and 0
immunofluorescence 0
, 0
and 0
shown 0
that 0
antibodies B-gene
TA205 I-gene
and 0
TD77 B-gene
disrupt 0
actin B-gene
stress 0
fibers 0
and 0
focal 0
adhesions 0
, 0
and 0
inhibit 0
cell 0
motility 0
when 0
microinjected 0
into 0
human 0
fibroblasts 0
. 0

This 0
locus 0
maps 0
approximately 0
160 0
kbp 0
from 0
the 0
genes 0
encoding 0
cytadherence 0
- 0
associated 0
proteins 0
HMW1 B-gene
and 0
HMW3 B-gene
, 0
and 0
yet 0
insertions 0
therein 0
result 0
in 0
loss 0
of 0
these 0
proteins 0
and 0
a 0
hemadsorption 0
- 0
negative 0
( 0
HA 0
- 0
) 0
phenotype 0
, 0
prompting 0
the 0
designation 0
cytadherence B-gene
- I-gene
regulatory I-gene
locus I-gene
( 0
crl B-gene
) 0
. 0

Coliphage B-gene
186 I-gene
B I-gene
is 0
a 0
72 0
- 0
amino 0
acid 0
protein 0
belonging 0
to 0
the 0
Ogr B-gene
family 0
of 0
analogous 0
transcription 0
factors 0
present 0
in 0
P2 0
- 0
like 0
phage 0
, 0
which 0
contain 0
a 0
Cys 0
- 0
X2 0
- 0
Cys 0
- 0
X22 0
- 0
Cys 0
- 0
X4 0
- 0
Cys 0
presumptive 0
zinc 0
- 0
finger 0
motif 0
. 0

The 0
UV 0
absorption 0
spectrum 0
revealed 0
a 0
shoulder 0
at 0
250 0
nm 0
, 0
characteristic 0
of 0
CysS 0
- 0
Cd 0
( 0
II 0
) 0
ligand 0
- 0
to 0
- 0
metal 0
charge 0
- 0
transfer 0
transitions 0
, 0
and 0
the 0
difference 0
absorption 0
coefficient 0
after 0
acidification 0
( 0
delta 0
epsilon 0
248 0
, 0
24 0
mM 0
- 0
1 0
cm 0
- 0
1 0
) 0
indicated 0
the 0
presence 0
of 0
a 0
Cd 0
( 0
Cys 0
- 0
S 0
) 0
4 0
center 0
. 0

Diacylglycerol B-gene
kinase I-gene
( 0
DGK B-gene
) 0
attenuates 0
levels 0
of 0
second 0
messenger 0
diacylglycerol 0
in 0
cells 0
and 0
produces 0
another 0
( 0
putative 0
) 0
messenger 0
, 0
phosphatidic 0
acid 0
. 0

Recently 0
, 0
we 0
have 0
reported 0
the 0
cloning 0
of 0
the 0
germ 0
cell 0
- 0
specific 0
, 0
nuclear 0
orphan 0
receptor 0
germ B-gene
cell I-gene
nuclear I-gene
factor I-gene
( 0
GCNF B-gene
) 0
/RTR B-gene
. 0

Based 0
on 0
the 0
sequence 0
of 0
the 0
conRTRE B-gene
, 0
we 0
located 0
a 0
putative 0
RTRE B-gene
, 0
referred 0
to 0
as 0
P2 B-gene
- I-gene
RE I-gene
, 0
in 0
the 0
5 0
' 0
promoter 0
- 0
flanking 0
region 0
of 0
the 0
mouse B-gene
protamine I-gene
2 I-gene
gene I-gene
, 0
which 0
is 0
induced 0
during 0
the 0
same 0
stage 0
of 0
spermatogenesis 0
as 0
RTR B-gene
. 0

Here 0
we 0
report 0
the 0
purification 0
of 0
this 0
larger 0
form 0
as 0
an 0
approximately 0
320 0
- 0
kDa 0
particle 0
that 0
contains 0
mRNP3+4 B-gene
and 0
nine 0
additional 0
polypeptides 0
, 0
including 0
mRNA 0
- 0
binding 0
polypeptides 0
of 0
34 0
and 0
36 0
kDa 0
and 0
a 0
doublet 0
of 0
110/105 0
kDa 0
that 0
proved 0
to 0
be 0
nucleolin B-gene
. 0

Active 0
complexes 0
eluted 0
at 0
a 0
higher 0
molecular 0
weight 0
than 0
inactive 0
complexes 0
, 0
were 0
relatively 0
deficient 0
in 0
both 0
p21 B-gene
and 0
p27 B-gene
, 0
and 0
contained 0
Cdk2 B-gene
with 0
increased 0
threonine 0
160 0
phosphorylation 0
, 0
consistent 0
with 0
a 0
mechanism 0
of 0
activation 0
of 0
cyclin B-gene
E I-gene
- 0
Cdk2 B-gene
involving 0
both 0
reduced 0
CDK B-gene
inhibitor 0
association 0
and 0
CDK B-gene
- I-gene
activating I-gene
kinase I-gene
- 0
mediated 0
phosphorylation 0
of 0
Cdk2 B-gene
. 0

Thirty 0
Class 0
I 0
and 0
Class 0
II 0
recessions 0
in 0
30 0
patients 0
were 0
treated 0
with 0
a 0
modified 0
subepithelial 0
connective 0
tissue 0
graft 0
procedure 0
. 0

The 0
derivatives 0
of 0
the 0
latter 0
two 0
cell 0
lines 0
showed 0
increased 0
expression 0
of 0
the 0
p27Kip1 B-gene
protein I-gene
and 0
inhibition 0
of 0
cell 0
growth 0
. 0

The 0
perioperative 0
mortality 0
of 0
all 0
patients 0
was 0
1.9 0
% 0
, 0
the 0
mortality 0
of 0
patients 0
older 0
than 0
70 0
years 0
was 0
4.3 0
% 0
. 0

Chronic 0
renal 0
failure 0
patients 0
essentially 0
die 0
from 0
cardiovascular 0
causes 0
, 0
and 0
the 0
frequency 0
of 0
malignant 0
disease 0
responsible 0
for 0
death 0
is 0
estimated 0
to 0
be 0
10 0
% 0
. 0

The 0
new 0
FIGO 0
definition 0
of 0
cervical 0
cancer 0
stage 0
IA 0
: 0
a 0
critique 0
. 0

The 0
effect 0
of 0
Vpu B-gene
on 0
class 0
I 0
biogenesis 0
was 0
analyzed 0
in 0
more 0
detail 0
using 0
a 0
Vpu B-gene
- 0
expressing 0
recombinant 0
vaccinia 0
virus 0
( 0
VV 0
) 0
. 0

This 0
study 0
indicates 0
that 0
the 0
phenotype 0
of 0
myofibrillar 0
disarray 0
seen 0
in 0
HCM 0
patients 0
which 0
harbor 0
either 0
of 0
these 0
two 0
mutations 0
may 0
not 0
be 0
directly 0
due 0
to 0
the 0
failure 0
of 0
the 0
mutant B-gene
myosin I-gene
heavy I-gene
chain I-gene
protein I-gene
to 0
assemble 0
and 0
form 0
normal 0
sarcomeres 0
, 0
but 0
may 0
rather 0
be 0
a 0
secondary 0
effect 0
possibly 0
resulting 0
from 0
the 0
chronic 0
stress 0
of 0
decreased 0
beta B-gene
MHC I-gene
function 0
. 0

Inductively 0
coupled 0
plasma 0
atomic 0
emission 0
spectroscopy 0
was 0
employed 0
to 0
obtain 0
the 0
tissue 0
silicon 0
measurements 0
. 0

An 0
egg 0
protein 0
, 0
lysozyme B-gene
, 0
is 0
a 0
still 0
unlabeled 0
additive 0
currently 0
used 0
in 0
cheese 0
preparation 0
. 0

A 0
method 0
for 0
the 0
simultaneous 0
determination 0
of 0
de 0
( 0
N 0
- 0
methyl 0
) 0
- 0
N 0
- 0
ethyl 0
- 0
8,9 0
- 0
anhydroerythromycin 0
A 0
6,9 0
- 0
hemiacetal 0
( 0
EM523 0
, 0
I 0
) 0
and 0
its 0
three 0
metabolites 0
in 0
human 0
plasma 0
and 0
urine 0
has 0
been 0
developed 0
using 0
high 0
- 0
performance 0
liquid 0
chromatography 0
( 0
HPLC 0
) 0
with 0
chemiluminescence 0
( 0
CL 0
) 0
detection 0
. 0

Similarly 0
, 0
the 0
DNA 0
- 0
binding 0
activity 0
of 0
activator B-gene
protein I-gene
1 I-gene
( 0
AP B-gene
- I-gene
1 I-gene
) 0
is 0
modified 0
by 0
a 0
DNA B-gene
repair I-gene
enzyme I-gene
, 0
redox B-gene
factor I-gene
1 I-gene
( 0
Ref B-gene
- I-gene
1 I-gene
) 0
, 0
which 0
is 0
identical 0
to 0
a 0
DNA B-gene
repair I-gene
enzyme I-gene
, 0
AP B-gene
endonuclease I-gene
. 0

Having 0
an 0
LRR B-gene
domain I-gene
and 0
an 0
SH3 B-gene
- I-gene
binding I-gene
domain I-gene
, 0
Acan125 B-gene
and 0
the 0
C. 0
elegans 0
homologue 0
define 0
a 0
novel 0
family 0
of 0
bifunctional 0
binding 0
proteins 0
. 0

However 0
, 0
its 0
participation 0
in 0
gagging 0
induced 0
by 0
oropharyngeal 0
irritation 0
is 0
unclear 0
. 0

The 0
capacity 0
to 0
repair 0
8 0
- 0
OxoG 0
has 0
been 0
measured 0
in 0
cell 0
- 0
free 0
extracts 0
of 0
wild 0
- 0
type 0
and 0
ogg1 B-gene
strains 0
using 0
a 0
34mer 0
DNA 0
fragment 0
containing 0
a 0
single 0
8 0
- 0
OxoG 0
residue 0
paired 0
with 0
a 0
cytosine 0
( 0
8 0
- 0
OxoG/C 0
) 0
as 0
a 0
substrate 0
. 0

Results 0
from 0
our 0
and 0
other 0
laboratories 0
have 0
suggested 0
that 0
UCN 0
- 0
01 0
induces 0
preferential 0
G1 0
- 0
phase 0
accumulation 0
in 0
several 0
human 0
tumor 0
cell 0
lines 0
tested 0
. 0

Northern 0
and 0
RT 0
- 0
PCR 0
analysis 0
of 0
Ube3a B-gene
expression 0
in 0
mouse 0
tissues 0
from 0
animals 0
with 0
segmental 0
, 0
paternal 0
uniparental 0
disomy 0
failed 0
to 0
detect 0
substantially 0
reduced 0
or 0
absent 0
expression 0
compared 0
to 0
control 0
animals 0
, 0
failing 0
to 0
provide 0
any 0
evidence 0
for 0
maternal 0
- 0
specific 0
expression 0
from 0
this 0
locus 0
. 0

Two 0
predominant 0
effects 0
were 0
noted 0
: 0
( 0
i 0
) 0
the 0
Xaa 0
residue 0
in 0
the 0
dual 0
phosphorylation 0
motif 0
Thr 0
- 0
Xaa 0
- 0
Tyr 0
as 0
well 0
as 0
the 0
length 0
of 0
L12 0
influence 0
p38 B-gene
substrate 0
specificity 0
, 0
and 0
( 0
ii 0
) 0
the 0
length 0
of 0
L12 0
plays 0
a 0
major 0
role 0
in 0
controlling 0
autophosphorylation 0
. 0

A 0
novel 0
, 0
testis B-gene
- I-gene
specific I-gene
mRNA I-gene
transcript I-gene
encoding 0
an 0
NH2 B-gene
- I-gene
terminal I-gene
truncated I-gene
nitric I-gene
- I-gene
oxide I-gene
synthase I-gene
. 0
mRNA 0
diversity 0
represents 0
a 0
major 0
theme 0
of 0
neuronal B-gene
nitric I-gene
- I-gene
oxide I-gene
synthase I-gene
( 0
nNOS B-gene
) 0
gene 0
expression 0
in 0
somatic 0
cells/tissues 0
. 0

Unlike 0
the 0
MAR 0
- 0
binding 0
domain 0
, 0
the 0
homeodomain B-gene
when 0
isolated 0
binds 0
poorly 0
and 0
with 0
low 0
specificity 0
to 0
DNA 0
. 0

Cotransfection 0
of 0
Ets B-gene
- I-gene
2 I-gene
and 0
p44 B-gene
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinase I-gene
expression 0
vectors 0
strongly 0
potentiated 0
HB B-gene
- 0
EGF B-gene
promoter 0
activation 0
in 0
response 0
to 0
deltaRaf B-gene
- I-gene
1 I-gene
: 0
ER B-gene
. 0

Cyclin B-gene
D1 I-gene
could 0
not 0
be 0
displaced 0
from 0
cdk4 B-gene
in 0
the 0
resistant 0
184A1L5R 0
cell 0
lysates 0
. 0

The 0
importance 0
of 0
posttranslational 0
regulation 0
of 0
p15INK4B B-gene
by 0
TGF B-gene
- I-gene
beta I-gene
is 0
underlined 0
by 0
the 0
observation 0
that 0
in 0
TGF B-gene
- I-gene
beta I-gene
- 0
resistant 0
184A1L5R 0
, 0
although 0
the 0
p15 B-gene
transcript I-gene
increased 0
, 0
p15INK4B B-gene
protein I-gene
was 0
not 0
stabilized 0
and 0
did 0
not 0
accumulate 0
, 0
and 0
cyclin B-gene
D1 I-gene
- 0
cdk B-gene
association 0
and 0
kinase 0
activation 0
were 0
not 0
inhibited 0
. 0

The 0
Rlm1 B-gene
protein I-gene
, 0
a 0
member 0
of 0
the 0
MADS B-gene
box I-gene
family I-gene
of 0
transcription 0
factors 0
, 0
functions 0
downstream 0
of 0
Mpk1 B-gene
in 0
the 0
pathway 0
. 0

To 0
identify 0
cis 0
- 0
acting 0
elements 0
that 0
target 0
c B-gene
- I-gene
myc I-gene
mRNA I-gene
for 0
downregulation 0
during 0
myogenesis 0
, 0
we 0
stably 0
transfected 0
C2C12 0
cells 0
with 0
mutant B-gene
myc I-gene
genes I-gene
or 0
chimeric 0
genes 0
in 0
which 0
various 0
myc B-gene
sequences I-gene
were 0
fused 0
to 0
the 0
human B-gene
beta I-gene
- I-gene
globin I-gene
gene I-gene
or 0
to 0
the 0
bacterial B-gene
chloramphenicol I-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
gene 0
. 0

Furthermore 0
, 0
experiments 0
with 0
32D 0
temperature 0
- 0
sensitive 0
p53 B-gene
cells 0
indicate 0
that 0
aberrant 0
tal B-gene
- I-gene
1 I-gene
expression 0
at 0
the 0
permissive 0
temperature 0
does 0
not 0
exert 0
a 0
proliferative 0
effect 0
but 0
causes 0
p53 B-gene
- 0
mediated 0
apoptosis 0
, 0
i.e. 0
, 0
the 0
tal B-gene
- I-gene
1 I-gene
proliferative 0
effect 0
depends 0
on 0
the 0
integrity 0
of 0
the 0
cell 0
cycle 0
checkpoints 0
of 0
the 0
host 0
cell 0
, 0
as 0
observed 0
for 0
c B-gene
- I-gene
myc I-gene
and 0
other 0
oncogenes 0
. 0
tal B-gene
- I-gene
1 I-gene
mutant I-gene
experiments 0
indicate 0
that 0
ectopic 0
tal B-gene
- I-gene
1 I-gene
effects 0
are 0
mediated 0
by 0
both 0
the 0
DNA 0
- 0
binding 0
and 0
the 0
heterodimerization 0
domains 0
, 0
while 0
the 0
N B-gene
- I-gene
terminally I-gene
truncated I-gene
tal I-gene
- I-gene
1 I-gene
variant I-gene
( 0
M3 B-gene
) 0
expressed 0
in 0
T 0
- 0
ALL 0
malignant 0
cells 0
mimics 0
the 0
effects 0
of 0
the 0
wild 0
- 0
type 0
protein 0
. 0

The 0
likelihood 0
that 0
a 0
common 0
region 0
of 0
deletions 0
would 0
contain 0
a 0
tumor 0
suppressor 0
is 0
strongly 0
enhanced 0
by 0
coincidence 0
of 0
that 0
region 0
with 0
a 0
chromosome 0
fragment 0
suppressing 0
tumorigenicity 0
upon 0
introduction 0
in 0
tumor 0
cells 0
. 0

DNA 0
- 0
binding 0
activity 0
was 0
not 0
increased 0
by 0
the 0
addition 0
of 0
forskolin 0
to 0
thecal 0
or 0
luteal 0
cells 0
. 0

However 0
, 0
in 0
some 0
of 0
them 0
either 0
pattern 0
may 0
predominate 0
or 0
be 0
exclusively 0
present 0
. 0

Upon 0
induction 0
of 0
SOS 0
, 0
viability 0
increased 0
2 0
- 0
6 0
- 0
fold 0
. 0

In 0
particular 0
, 0
Western 0
, 0
supershift 0
, 0
and 0
promoter 0
deletion 0
analyses 0
suggested 0
a 0
role 0
for 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
- I-gene
beta I-gene
( 0
C/EBP B-gene
- I-gene
beta I-gene
) 0
binding 0
site 0
between 0
- 0
2010 0
and 0
- 0
1954 0
in 0
regulating 0
transcription 0
of 0
collagenase B-gene
- I-gene
1 I-gene
in 0
monocytic 0
cells 0
. 0

11 0
- 0
Aminoundecanoyl 0
- 0
SK 0
- 0
NH2 0
and 0
11 0
- 0
aminoundecanoyl 0
- 0
SH 0
- 0
NH2 0
establish 0
that 0
a 0
simple 0
alkyl 0
backbone 0
can 0
maintain 0
an 0
appropriate 0
distance 0
between 0
three 0
elements 0
critical 0
for 0
recognition 0
by 0
the 0
fungal 0
enzyme 0
's 0
peptide 0
- 0
binding 0
site 0
: 0
a 0
simple 0
omega 0
- 0
terminal 0
amino 0
group 0
, 0
a 0
beta 0
- 0
hydroxyl 0
, 0
and 0
an 0
epsilon 0
- 0
amino 0
group 0
or 0
an 0
imidazole 0
. 0

The 0
carboxyl 0
- 0
terminal 0
CCCC 0
module 0
is 0
structurally 0
related 0
to 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
the 0
erythroid B-gene
transcription I-gene
factor I-gene
GATA I-gene
- I-gene
1 I-gene
. 0

Cdc2 B-gene
co 0
- 0
precipitates 0
with 0
Pch1 B-gene
in 0
S. 0
pombe 0
cell 0
lysates 0
, 0
although 0
Cdc2 B-gene
may 0
not 0
be 0
the 0
major 0
catalytic 0
partner 0
of 0
a 0
Pch1 B-gene
kinase I-gene
in 0
vivo 0
. 0

Little 0
is 0
known 0
about 0
the 0
mechanism 0
, 0
but 0
the 0
availability 0
of 0
rapid 0
facile 0
assays 0
for 0
monitoring 0
immunoglobulin B-gene
hypermutation 0
would 0
greatly 0
aid 0
the 0
development 0
of 0
culture 0
systems 0
for 0
hypermutating 0
B 0
cells 0
as 0
well 0
as 0
the 0
screening 0
for 0
individuals 0
deficient 0
in 0
the 0
process 0
. 0

Expression 0
of 0
the 0
human B-gene
heat I-gene
shock I-gene
protein I-gene
70 I-gene
gene I-gene
( 0
hsp70 B-gene
) 0
is 0
induced 0
by 0
various 0
kinds 0
of 0
stress 0
and 0
by 0
oncogenes 0
. 0

Of 0
these 0
proteins 0
, 0
five 0
have 0
previously 0
been 0
shown 0
to 0
be 0
phosphorylated 0
during 0
mitosis 0
( 0
epithelial B-gene
- I-gene
microtubule I-gene
associated I-gene
protein I-gene
- I-gene
115 I-gene
, 0
Oct91 B-gene
, 0
Elongation B-gene
factor I-gene
1gamma I-gene
, 0
BRG1 B-gene
and 0
Ribosomal B-gene
protein I-gene
L18A I-gene
) 0
, 0
five 0
are 0
related 0
to 0
proteins 0
postulated 0
to 0
have 0
roles 0
in 0
mitosis 0
( 0
epithelial B-gene
- I-gene
microtubule I-gene
associated I-gene
protein I-gene
- I-gene
115 I-gene
, 0
Schizosaccharomyces B-gene
pombe I-gene
Cdc5 I-gene
, 0
innercentrosome B-gene
protein I-gene
, 0
BRG1 B-gene
and 0
the 0
RNA B-gene
helicase I-gene
WM6 I-gene
) 0
, 0
and 0
nine 0
are 0
related 0
to 0
transcription 0
factors 0
( 0
BRG1 B-gene
, 0
negative B-gene
co I-gene
- I-gene
factor I-gene
2alpha I-gene
, 0
Oct91 B-gene
, 0
S. 0
pombe 0
Cdc5 B-gene
, 0
HoxD1 B-gene
, 0
Sox3 B-gene
, 0
Vent2 B-gene
, 0
and 0
two 0
isoforms 0
of 0
Xbr1b B-gene
) 0
. 0

Thus 0
, 0
depending 0
on 0
their 0
location 0
, 0
psoralen 0
cross 0
- 0
links 0
affected 0
different 0
steps 0
in 0
the 0
initiation 0
process 0
. 0

Activation 0
of 0
alpha B-gene
4 I-gene
beta I-gene
1 I-gene
with 0
TS2/16 B-gene
inhibited 0
the 0
cytoplasmic 0
protrusions 0
and 0
cell 0
migration 0
but 0
did 0
not 0
affect 0
the 0
pattern 0
of 0
phosphorylation 0
. 0

Performance 0
on 0
two 0
verbal 0
measures 0
- 0
the 0
National 0
Adult 0
Reading 0
Test 0
- 0
Revised 0
( 0
NART 0
- 0
R 0
) 0
and 0
the 0
Vocabulary 0
subtest 0
from 0
the 0
Wechsler 0
Adult 0
Intelligence 0
Scale 0
- 0
Revised 0
( 0
WAIS 0
- 0
R 0
) 0
- 0
showed 0
strong 0
correlations 0
with 0
level 0
of 0
education 0
. 0

L 0
- 0
canavanine 0
, 0
a 0
selective 0
inhibitor 0
of 0
the 0
inducible 0
nitric B-gene
oxide I-gene
synthase I-gene
, 0
increases 0
the 0
mean 0
systemic 0
filling 0
pressure 0
, 0
thereby 0
improving 0
venous 0
return 0
, 0
under 0
these 0
conditions 0
. 0

RESULTS 0
: 0
Of 0
the 0
29 0
patients 0
who 0
received 0
concurrent 0
chemotherapy 0
and 0
G B-gene
- I-gene
CSF I-gene
, 0
ten 0
( 0
34 0
% 0
; 0
95 0
% 0
confidence 0
interval 0
[ 0
CI 0
] 0
, 0
17.9 0
to 0
54.3 0
% 0
) 0
were 0
believed 0
to 0
have 0
clinically 0
significant 0
bleomycin 0
toxicity 0
. 0

The 0
different 0
holoenzyme B-gene
RNA I-gene
polymerases I-gene
generated 0
upon 0
reconstituting 0
these 0
mutants 0
independently 0
with 0
core B-gene
RNA I-gene
polymerase I-gene
( 0
alpha2beta B-gene
beta I-gene
' I-gene
) 0
have 0
shown 0
reduced 0
transcriptional 0
activity 0
in 0
comparison 0
to 0
the 0
enzyme 0
containing 0
wild B-gene
- I-gene
type I-gene
sigma I-gene
factor I-gene
. 0

These 0
data 0
are 0
consistent 0
with 0
a 0
model 0
in 0
which 0
GATA B-gene
- I-gene
5 I-gene
performs 0
a 0
unique 0
temporally 0
and 0
spatially 0
restricted 0
function 0
in 0
the 0
embryonic 0
heart 0
and 0
lung 0
. 0

The 0
exonic 0
sequence 0
encodes 0
a 0
protein 0
of 0
495 0
amino 0
acids 0
that 0
is 0
nearly 0
identical 0
to 0
the 0
previously 0
reported 0
protein 0
sequence 0
of 0
human B-gene
GPT I-gene
- I-gene
1 I-gene
. 0

Here 0
we 0
characterize 0
an 0
S. B-gene
cerevisiae I-gene
Swi3 I-gene
homolog I-gene
( 0
Swh3 B-gene
) 0
and 0
present 0
evidence 0
that 0
it 0
associates 0
in 0
a 0
complex 0
with 0
a 0
Snf2 B-gene
homolog I-gene
, 0
Sthl B-gene
. 0

Shc B-gene
stimulates 0
Ras/mitogen B-gene
Ras/mitogen I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
MAPK B-gene
) 0
through 0
forming 0
a 0
complex 0
with 0
Grb2 B-gene
at 0
the 0
phosphorylated 0
tyrosine 0
( 0
Y 0
) 0
residue 0
317 0
. 0

In 0
contrast 0
, 0
Y239/240F B-gene
Shc I-gene
, 0
but 0
not 0
Y317F B-gene
Shc I-gene
, 0
reduced 0
the 0
EGF B-gene
- 0
induced 0
c B-gene
- I-gene
myc I-gene
message 0
. 0

The 0
Ras B-gene
guanine I-gene
nucleotide I-gene
- I-gene
binding I-gene
protein I-gene
functions 0
as 0
a 0
molecular 0
switch 0
in 0
signalling 0
downstream 0
of 0
protein B-gene
- I-gene
tyrosine I-gene
kinases I-gene
. 0

We 0
show 0
that 0
Rlm1 B-gene
and 0
Smp1 B-gene
have 0
MEF2 B-gene
- 0
related 0
DNA 0
- 0
binding 0
specificities 0
: 0
Rlm1 B-gene
binds 0
with 0
the 0
same 0
specificity 0
as 0
MEF2 B-gene
, 0
CTA B-gene
( I-gene
T/A I-gene
) I-gene
4TAG I-gene
, 0
while 0
SMP1 B-gene
binds 0
a 0
more 0
extended 0
consensus 0
sequence 0
, 0
ACTACTA 0
( 0
T/A 0
) 0
4TAG 0
. 0

Domains 0
I 0
and 0
II 0
of 0
B B-gene
'' I-gene
are 0
buried 0
upon 0
assembly 0
of 0
the B-gene
TFIIIB I-gene
- I-gene
DNA I-gene
complex I-gene
, 0
as 0
determined 0
by 0
protein 0
footprinting 0
. 0

Domain 0
switch 0
experiments 0
reveal 0
that 0
C/EBP B-gene
beta I-gene
proteins I-gene
containing 0
either 0
the 0
leucine 0
zipper 0
or 0
the 0
activation 0
domain 0
of 0
C/EBP B-gene
alpha I-gene
are 0
unable 0
to 0
stimulate 0
the 0
2D5 B-gene
promoter I-gene
yet 0
are 0
fully 0
capable 0
of 0
transactivating 0
an 0
artificial 0
promoter 0
bearing 0
a 0
high 0
- 0
affinity 0
C/EBP B-gene
site I-gene
. 0

The 0
similar 0
phenotypes 0
of 0
bur6 B-gene
and 0
bur3 B-gene
( 0
mot1 B-gene
) 0
mutations 0
suggest 0
that 0
Bur6p B-gene
and 0
Mot1p B-gene
have 0
related 0
, 0
but 0
not 0
identical 0
, 0
functions 0
in 0
modulating 0
the 0
activity 0
of 0
the 0
general 0
transcription 0
machinery 0
in 0
vivo 0
. 0

PRH75 B-gene
, 0
a 0
new 0
nucleus 0
- 0
localized 0
member 0
of 0
the 0
DEAD B-gene
- I-gene
box I-gene
protein I-gene
family I-gene
from 0
higher 0
plants 0
. 0

These 0
activities 0
are 0
all 0
required 0
for 0
stimulation 0
of 0
cell 0
growth 0
by 0
middle B-gene
- I-gene
T I-gene
and 0
activate 0
members 0
of 0
the 0
MAP B-gene
kinase I-gene
family I-gene
. 0

A 0
role 0
for 0
the 0
small B-gene
GTPase I-gene
Rac I-gene
in 0
polyomavirus B-gene
middle I-gene
- I-gene
T I-gene
antigen I-gene
- 0
mediated 0
activation 0
of 0
the 0
serum 0
response 0
element 0
and 0
in 0
cell 0
transformation 0
. 0

Time 0
- 0
activity 0
curves 0
from 0
the 0
gastric 0
region 0
of 0
interest 0
were 0
used 0
, 0
after 0
subjection 0
to 0
appropriate 0
corrective 0
procedures 0
, 0
to 0
calculate 0
the 0
mean 0
gastric 0
transit 0
time 0
( 0
MTT 0
90 0
) 0
and 0
the 0
fraction 0
of 0
the 0
test 0
meal 0
retained 0
in 0
the 0
stomach 0
after 0
90 0
min 0
( 0
F90 0
) 0
. 0

This 0
study 0
provides 0
a 0
direct 0
demonstration 0
of 0
a 0
role 0
for 0
G B-gene
betagamma I-gene
in 0
mediating 0
the 0
agonist 0
- 0
stimulated 0
translocation 0
of 0
GRK2 B-gene
and 0
GRK3 B-gene
in 0
an 0
intact 0
cellular 0
system 0
and 0
demonstrates 0
isoform 0
specificity 0
in 0
the 0
interaction 0
of 0
these 0
components 0
. 0

Our 0
results 0
indicate 0
that 0
RA 0
- 0
mediated 0
repression 0
of 0
the 0
hMGP B-gene
gene I-gene
is 0
due 0
to 0
binding 0
of 0
liganded 0
RAR/RXR B-gene
to 0
a 0
novel 0
negative 0
RA 0
response 0
element 0
. 0

Point 0
mutations 0
of 0
the 0
five 0
tyrosine 0
residues 0
in 0
the 0
cytoplasmic 0
domain 0
of 0
the 0
receptor 0
were 0
subsequently 0
used 0
to 0
confirm 0
our 0
conclusions 0
. 0

We 0
describe 0
a 0
novel 0
method 0
using 0
Saccharomyces 0
cerevisiae 0
for 0
detecting 0
protein 0
- 0
truncating 0
mutations 0
in 0
any 0
gene 0
of 0
interest 0
. 0

Hepatocellular 0
injury 0
during 0
preservation 0
of 0
human 0
livers 0
with 0
UW 0
and 0
HTK 0
solution 0
. 0

The 0
electromyographically 0
recorded 0
responses 0
consisted 0
of 0
an 0
early 0
R1 0
response 0
in 0
the 0
orbicularis 0
oculi 0
muscle 0
ipsilateral 0
to 0
the 0
side 0
of 0
stimulation 0
, 0
a 0
bilateral 0
late 0
response 0
( 0
ipsilateral 0
R2 0
and 0
contralateral 0
Rc 0
) 0
and 0
a 0
third 0
, 0
R3 0
response 0
, 0
in 0
the 0
ipsilateral 0
orbicularis 0
oculi 0
muscle 0
. 0

The 0
prognosis 0
of 0
seven 0
patients 0
who 0
received 0
ABSCT 0
was 0
significantly 0
better 0
than 0
that 0
of 0
13 0
patients 0
who 0
received 0
conventional 0
therapy 0
alone 0
. 0

( 0
1994 0
, 0
Hum 0
. 0

The 0
pigment 0
intensity 0
of 0
both 0
melanized 0
colonies 0
and 0
appressoria 0
of 0
CAL 0
transformants 0
was 0
weaker 0
than 0
that 0
of 0
the 0
wild 0
type 0
. 0

Malonate 0
decarboxylation 0
in 0
Malonomonas 0
rubra 0
involves 0
the 0
formation 0
of 0
malonyl B-gene
- I-gene
S I-gene
- I-gene
[ I-gene
acyl I-gene
- I-gene
carrier I-gene
protein I-gene
] I-gene
from 0
acetyl B-gene
- I-gene
S I-gene
- I-gene
[ I-gene
acyl I-gene
- I-gene
carrier I-gene
protein I-gene
] I-gene
and 0
malonate 0
, 0
carboxyltransfer 0
to 0
a 0
biotin B-gene
protein I-gene
and 0
its 0
decarboxylation 0
that 0
is 0
coupled 0
to 0
delta 0
mu 0
Na+ 0
generation 0
. 0

The 0
Jem B-gene
peptide 0
sequence 0
shows 0
a 0
'leucine 0
- 0
zipper 0
' 0
dimerisation 0
motif 0
with 0
limited 0
homology 0
to 0
Fos/Jun B-gene
and 0
Fos/Jun I-gene

Here 0
we 0
report 0
the 0
cloning 0
of 0
the 0
protein 0
that 0
binds 0
to 0
enhancer 0
site 0
III 0
. 0

Further 0
support 0
for 0
a 0
direct 0
interaction 0
of 0
Tub4p B-gene
, 0
Spc98p B-gene
and 0
Spc97p B-gene
comes 0
from 0
the 0
toxicity 0
of 0
strong 0
SPC97 B-gene
overexpression 0
which 0
is 0
suppressed 0
by 0
co 0
- 0
overexpression 0
of 0
TUB4 B-gene
or 0
SPC98 B-gene
. 0

Sequences 0
needed 0
for 0
iron 0
- 0
regulated 0
expression 0
of 0
sid1 B-gene
were 0
localized 0
to 0
a 0
306 0
bp 0
region 0
mapping 0
2.3 0
and 0
2.6 0
kb 0
upstream 0
of 0
the 0
ATG 0
. 0

A 0
genetic 0
screen 0
applied 0
to 0
mutants 0
in 0
the 0
branch 0
site 0
region 0
shows 0
that 0
all 0
positions 0
in 0
the 0
conserved 0
TACTAAC 0
sequence 0
are 0
important 0
for 0
intron 0
recognition 0
. 0

Implication 0
of 0
PAF B-gene
and 0
acetylhydrolase B-gene
( 0
PAF B-gene
- I-gene
AH I-gene
) 0
activity 0
in 0
periodontal 0
disease 0
. 0

Comparison 0
of 0
the 0
p50 B-gene
sequence I-gene
to 0
other 0
cloned 0
proteins 0
revealed 0
89 0
% 0
homology 0
with 0
a 0
glycosaminoglycan 0
- 0
binding 0
protein 0
and 0
54 0
% 0
homology 0
with 0
Drosophila B-gene
cell I-gene
cycle I-gene
control I-gene
protein I-gene
( I-gene
cdc I-gene
) I-gene
37 0
. 0

A 0
polypeptide 0
encoded 0
by 0
the 0
NTS 0
16 0
open 0
reading 0
frame 0
has 0
sequence 0
similarity 0
to 0
the 0
catalytic 0
domain 0
of 0
several 0
receptor B-gene
protein I-gene
kinases I-gene
from I-gene
plants I-gene
including 0
the 0
S B-gene
- I-gene
receptor I-gene
kinases I-gene
implicated 0
in 0
the 0
rejection 0
of 0
self 0
- 0
pollen 0
in 0
Brassica 0
species 0
and 0
the 0
Pto B-gene
gene I-gene
product I-gene
of I-gene
tomato I-gene
which 0
confers 0
resistance 0
to 0
a 0
bacterial 0
pathogen 0
. 0

The 0
atp B-gene
1 I-gene
and 0
atp B-gene
2 I-gene
types 0
of 0
cDNA 0
sequences 0
were 0
the 0
most 0
redundant 0
among 0
the 0
28 0
different 0
isoperoxidases B-gene
identified 0
among 0
about 0
200 0
peroxidase B-gene
encoding I-gene
ESTs I-gene
. 0

Additional 0
information 0
including 0
echocardiographic 0
sequences 0
, 0
perioperative 0
video 0
sequences 0
, 0
x 0
- 0
ray 0
analysis 0
, 0
angiograms 0
, 0
etc 0
. 0
is 0
represented 0
in 0
the 0
program 0
. 0

We 0
report 0
here 0
that 0
constitutively 0
active 0
Mek1 B-gene
could 0
activate 0
p96h2bk B-gene
in 0
the 0
absence 0
of 0
oncogenic B-gene
Ras I-gene
. 0

In 0
Schizosaccharomyces 0
pombe 0
, 0
the 0
activity 0
of 0
the 0
M 0
- 0
phase 0
- 0
inducing 0
Cdc2/Cdc13 B-gene
cyclin 0
- 0
dependent 0
kinase 0
is 0
inhibited 0
by 0
Cdc2/Cdc13 I-gene

Glycemic 0
response 0
to 0
malted 0
, 0
popped 0
and 0
roller 0
dried 0
wheat 0
- 0
legume 0
based 0
foods 0
in 0
normal 0
subjects 0
. 0

4.26 0
+/ 0
- 0
1.54 0
mmol/l 0
, 0
P 0
< 0
0.01 0
) 0
, 0
and 0
systolic 0
BP 0
responses 0
to 0
intravenous 0
norepinephrine 0
and 0
angiotensin B-gene
II I-gene
were 0
significantly 0
higher 0
on 0
glibenclamide 0
than 0
on 0
metformin 0
( 0
P 0
< 0
0.02 0
and 0
P 0
< 0
0.05 0
, 0
respectively 0
) 0
. 0

The 0
sequencing 0
of 0
Stellate B-gene
copies 0
located 0
along 0
the 0
discontinuous 0
cluster 0
revealed 0
a 0
complex 0
pattern 0
of 0
diversification 0
. 0

The 0
results 0
indicate 0
that 0
DNA 0
methylation 0
, 0
chromatin 0
structure 0
, 0
and 0
transactivation 0
at 0
an 0
Sp1 B-gene
site I-gene
contribute 0
to 0
the 0
highly 0
restricted 0
expression 0
of 0
this 0
myelomonocytic 0
lineage 0
specific 0
gene 0
. 0

In 0
gel 0
mobility 0
shift 0
assays 0
, 0
factors 0
present 0
in 0
nuclear 0
extracts 0
derived 0
from 0
differentiated 0
osteoblast 0
bound 0
to 0
oligonucleotide 0
probes 0
containing 0
the 0
E 0
- 0
box 0
1 0
and 0
E 0
- 0
box 0
2 0
elements 0
. 0

Laboratory 0
exam 0
: 0
IDR 0
of 0
the 0
tuberculin B-gene
was 0
high 0
positive 0
, 0
chest 0
radiography 0
shows 0
hilar 0
bilateral 0
calcifications 0
, 0
ORL 0
exam 0
shows 0
a 0
tumor 0
at 0
the 0
foot 0
of 0
the 0
epiglottis 0
and 0
anatomopathological 0
exam 0
shows 0
low 0
differentiated 0
epidermoid 0
carcinoma 0
. 0

Finally 0
, 0
we 0
show 0
that 0
PhLP B-gene
complexes 0
, 0
at 0
least 0
partially 0
, 0
with 0
Gbetagamma B-gene
in 0
vivo 0
. 0

CTF1alpha B-gene
, 0
expressed 0
in 0
Escherichia 0
coli 0
, 0
showed 0
specific 0
binding 0
to 0
the 0
palindrome 0
2 0
DNA 0
fragment 0
but 0
not 0
to 0
palindrome 0
1 0
or 0
mutant 0
palindrome 0
2 0
DNA 0
fragments 0
, 0
suggesting 0
specific 0
binding 0
of 0
CTF1alpha B-gene
to 0
palindrome 0
2 0
. 0

Cyclin B-gene
G2 I-gene
is 0
highly 0
expressed 0
in 0
the 0
immune 0
system 0
where 0
immunologic 0
tolerance 0
subjects 0
self 0
- 0
reactive 0
lymphocytes 0
to 0
negative 0
selection 0
and 0
clonal 0
deletion 0
via 0
apoptosis 0
. 0

A 0
sterol 0
- 0
regulated 0
protease 0
initiates 0
release 0
of 0
the 0
NH2 0
- 0
terminal 0
segments 0
of 0
sterol B-gene
regulatory I-gene
element I-gene
- I-gene
binding I-gene
proteins I-gene
( 0
SREBPs B-gene
) 0
from 0
cell 0
membranes 0
, 0
thereby 0
allowing 0
them 0
to 0
enter 0
the 0
nucleus 0
and 0
to 0
stimulate 0
transcription 0
of 0
genes 0
involved 0
in 0
the 0
uptake 0
and 0
synthesis 0
of 0
cholesterol 0
and 0
fatty 0
acids 0
. 0

Thus 0
, 0
the 0
P. 0
aeruginosa 0
orfX 0
and 0
vfr B-gene
promoters I-gene
are 0
arranged 0
in 0
a 0
back 0
- 0
to 0
- 0
back 0
orientation 0
rather 0
than 0
the 0
face 0
- 0
to 0
- 0
face 0
orientation 0
of 0
the 0
dorf 0
and 0
crp B-gene
promoters I-gene
. 0

Sequence 0
analysis 0
of 0
cloned 0
PCR 0
products 0
confirmed 0
the 0
presence 0
of 0
two 0
different 0
nifV B-gene
- I-gene
like I-gene
DNA I-gene
fragments I-gene
, 0
which 0
were 0
subsequently 0
used 0
as 0
nifV B-gene
- 0
and 0
leuA B-gene
- I-gene
specific I-gene
probes I-gene
, 0
respectively 0
, 0
to 0
clone 0
XbaI B-gene
fragments I-gene
of 0
2.1 0
kbp 0
( 0
pOST4 0
) 0
and 0
2.6 0
kbp 0
( 0
pOST2 0
) 0
. 0

In 0
contrast 0
, 0
the 0
Anabaena 0
strain 0
7120 0
leuA B-gene
gene 0
did 0
not 0
complement 0
the 0
nifV B-gene
mutation I-gene
of 0
R229I 0
efficiently 0
. 0

( 0
3 0
) 0
This 0
effect 0
occurs 0
without 0
removing 0
TRs B-gene
from 0
the 0
TRE 0
. 0

Is 0
leishmaniasis 0
endemic 0
on 0
the 0
island 0
of 0
Minorca 0
( 0
Spain 0
) 0
? 0
A 0
human 0
visceral 0
case 0
after 0
living 0
13 0
years 0
in 0
Minorca 0
. 0

RESULTS 0
: 0
Surprisingly 0
, 0
PAF B-gene
blockade 0
increased 0
mortality 0
after 0
trauma 0
( 0
5 0
of 0
11 0
WEB 0
- 0
2086 0
animals 0
versus 0
1 0
of 0
9 0
vehicle 0
animals 0
; 0
p 0
= 0
0.15 0
) 0
and 0
depressed 0
cardiac 0
index 0
and 0
O2 0
delivery 0
at 0
72 0
hours 0
( 0
p 0
< 0
0.05 0
) 0
. 0

This 0
finding 0
is 0
the 0
first 0
example 0
of 0
utilization 0
of 0
noncomplementary 0
dinucleotide 0
primer 0
by 0
an 0
RNA B-gene
polymerase I-gene
. 0

Pure 0
T1 0
and 0
dual 0
- 0
T1 0
images 0
were 0
visually 0
evaluated 0
for 0
image 0
quality 0
( 0
IQ 0
) 0
on 0
a 0
five 0
- 0
point 0
scale 0
( 0
0 0
= 0
unacceptable 0
to 0
4 0
= 0
excellent 0
) 0
. 0

In 0
a 0
model 0
of 0
the 0
ternary 0
complex 0
, 0
the 0
segment 0
of 0
NFAT B-gene
nearest 0
AP B-gene
- I-gene
1 I-gene
is 0
the 0
Rel B-gene
insert 0
region 0
( 0
RIR 0
) 0
, 0
a 0
feature 0
that 0
is 0
notable 0
for 0
its 0
hypervariability 0
in 0
size 0
and 0
in 0
sequence 0
amongst 0
members 0
of 0
the 0
Rel B-gene
transcription I-gene
factor I-gene
family I-gene
. 0

We 0
thus 0
conclude 0
that 0
the 0
NFAT B-gene
RIR I-gene
plays 0
an 0
essential 0
dual 0
role 0
in 0
DNA 0
recognition 0
and 0
cooperative 0
binding 0
to 0
AP B-gene
- I-gene
1 I-gene
family I-gene
transcription I-gene
factors I-gene
. 0

Thus 0
, 0
the 0
association 0
of 0
PS1 B-gene
fragments I-gene
may 0
be 0
maintained 0
during 0
cycles 0
of 0
phosphorylation/dephosphorylation 0
of 0
the 0
PS1 B-gene
CTF I-gene
. 0

This 0
conformer 0
features 0
a 0
Type 0
I 0
beta 0
- 0
turn 0
and 0
has 0
extensive 0
hydrophobic 0
contacts 0
with 0
the 0
FKBP12 B-gene
binding 0
surface 0
. 0

This 0
protein 0
can 0
bind 0
to 0
a 0
region 0
of 0
the 0
promoter 0
of 0
an 0
Arabidopsis B-gene
light I-gene
- I-gene
harvesting I-gene
chlorophyll I-gene
a/b I-gene
protein I-gene
gene I-gene
, 0
Lhcb1*3 B-gene
, 0
which 0
is 0
necessary 0
for 0
its 0
regulation 0
by 0
phytochrome B-gene
. 0

A 0
patient 0
of 0
Group 0
B 0
had 0
severe 0
athetoid 0
CP 0
with 0
spasticity 0
, 0
being 0
unable 0
to 0
right 0
his 0
trunk 0
and 0
neck 0
. 0

Dystonic 0
movement 0
of 0
the 0
left 0
upper 0
limb 0
in 0
a 0
case 0
of 0
the 0
right 0
pontine 0
hemorrhage 0

It 0
has 0
repeatedly 0
been 0
shown 0
that 0
HCMV 0
IE1/IE2 B-gene
can 0
independently 0
transactivate 0
IE1/IE2 I-gene

TAR B-gene
and 0
Sp1 B-gene
- 0
independent 0
transactivation 0
of 0
HIV B-gene
long I-gene
terminal I-gene
repeat I-gene
by 0
the 0
Tat B-gene
protein I-gene
in 0
the 0
presence 0
of 0
human 0
cytomegalovirus 0
IE1/IE2 B-gene
. 0

Respiratory 0
chain 0
enzyme 0
activity 0
was 0
normal 0
. 0

Children 0
's 0
temperament 0
and 0
maternal 0
socialization 0
at 0
Time 0
1 0
( 0
n 0
= 0
103 0
, 0
aged 0
2 0
- 0
3 0
years 0
) 0
were 0
considered 0
predictors 0
of 0
future 0
conscience 0
, 0
assessed 0
using 0
new 0
observational 0
and 0
narrative 0
measures 0
. 0

Cellular B-gene
Csk I-gene
was 0
associated 0
with 0
several 0
phosphoproteins 0
, 0
some 0
of 0
which 0
were 0
interacting 0
with 0
the 0
Csk B-gene
SH2 B-gene
domain I-gene
. 0

Thus 0
, 0
our 0
studies 0
suggest 0
that 0
pV 0
- 0
mediated 0
activation 0
of 0
HIV B-gene
- I-gene
1 I-gene
LTR I-gene
activity 0
is 0
controlled 0
by 0
the 0
nuclear 0
translocation 0
of 0
the 0
NF B-gene
- I-gene
kappaB I-gene
transcription I-gene
factor I-gene
, 0
which 0
is 0
mediated 0
by 0
IkappaBalpha B-gene
serine 0
phosphorylation 0
and 0
degradation 0
, 0
but 0
also 0
by 0
a 0
still 0
undefined 0
NF B-gene
- I-gene
kappaB I-gene
- 0
independent 0
pathway 0
. 0

One 0
P1 0
genomic 0
clone 0
and 0
six 0
subsequent 0
plasmid 0
subclones 0
were 0
isolated 0
and 0
analyzed 0
for 0
the 0
exon 0
- 0
intron 0
organization 0
of 0
the 0
Ctpct B-gene
gene I-gene
. 0

FN B-gene
- 0
stimulated 0
c B-gene
- I-gene
Src I-gene
PTK B-gene
activity 0
was 0
enhanced 0
by 0
wild 0
type 0
FAK B-gene
expression 0
, 0
whereas 0
FN B-gene
- 0
stimulated 0
activation 0
of 0
ERK2 B-gene
was 0
blocked 0
by 0
expression 0
of 0
the 0
c B-gene
- I-gene
Src I-gene
binding I-gene
site I-gene
Phe I-gene
- I-gene
397 I-gene
mutant I-gene
of 0
FAK B-gene
. 0

A 0
promising 0
new 0
cement 0
, 0
4 0
- 0
META/MMA 0
- 0
TBB 0
opaque 0
resin 0
, 0
has 0
shown 0
remarkable 0
adhesive 0
properties 0
as 0
a 0
bone 0
cement 0
in 0
vivo 0
. 0

Congruent 0
with 0
empirical 0
predictions 0
, 0
the 0
most 0
homesick 0
children 0
perceived 0
low 0
control 0
over 0
homesickness 0
and 0
separation 0
, 0
and 0
coped 0
by 0
relinquishing 0
control 0
. 0

Each 0
sample 0
was 0
analysed 0
as 0
soon 0
as 0
possible 0
, 0
and 0
repeated 0
15 0
, 0
30 0
, 0
60 0
and 0
120 0
min 0
after 0
sampling 0
. 0

We 0
also 0
review 0
the 0
role 0
of 0
grains 0
in 0
the 0
formation 0
of 0
complex 0
molecules 0
in 0
interstellar 0
molecular 0
clouds 0
. 0

Like 0
the 0
elicitors 0
of 0
the 0
hypersensitive 0
reaction 0
( 0
HR 0
) 0
produced 0
by 0
E. 0
chrysanthemi 0
( 0
HarpinEch 0
) 0
and 0
E. 0
amylovora 0
( 0
HarpinEa 0
) 0
, 0
the 0
deduced 0
36 0
- 0
kDa 0
protein 0
does 0
not 0
possess 0
a 0
typical 0
signal 0
sequence 0
, 0
but 0
it 0
contains 0
a 0
putative 0
membrane 0
- 0
spanning 0
domain 0
. 0

Molecular 0
characterization 0
and 0
expression 0
of 0
the 0
Erwinia B-gene
carotovora I-gene
hrpNEcc I-gene
gene I-gene
, 0
which 0
encodes 0
an 0
elicitor 0
of 0
the 0
hypersensitive 0
reaction 0
. 0

The 0
mRNA 0
from 0
this 0
gene 0
, 0
termed 0
HES1 B-gene
, 0
is 0
ubiquitously 0
expressed 0
, 0
but 0
strongly 0
so 0
in 0
heart 0
and 0
skeletal 0
muscle 0
. 0

Anesthesia 0
was 0
maintained 0
with 0
isoflurane 0
( 0
ISO 0
) 0
/N2O/ 0
O2 0
inhalation 0
. 0

They 0
observed 0
depressed 0
protein B-gene
C I-gene
activity 0
that 0
significantly 0
( 0
p 0
< 0
0.005 0
) 0
increased 0
and 0
became 0
normal 0
immediately 0
after 0
hemodialysis 0
while 0
factor B-gene
X I-gene
and 0
factor B-gene
VII I-gene
increased 0
( 0
p 0
< 0
0.01 0
; 0
p 0
< 0
0.05 0
) 0
despite 0
heparinization 0
together 0
with 0
amount 0
of 0
serum B-gene
lipoprotein I-gene
( I-gene
a I-gene
) I-gene
. 0

We 0
present 0
a 0
case 0
of 0
type 0
II 0
hyperbetalipoproteinemia 0
in 0
a 0
patient 0
whose 0
diagnosis 0
had 0
been 0
previously 0
unrecognized 0
, 0
and 0
who 0
had 0
previously 0
been 0
misdiagnosed 0
with 0
rheumatoid 0
arthritis 0
and 0
later 0
gout 0
. 0

These 0
data 0
provide 0
evidence 0
that 0
the 0
2.0 B-gene
- I-gene
kb I-gene
LAT I-gene
is 0
an 0
intron 0
of 0
the 0
mLAT B-gene
pre I-gene
- I-gene
mRNA I-gene
with 0
a 0
unique 0
branch 0
point 0
. 0

The 0
altered 0
amino 0
acid 0
residues 0
of 0
the 0
seven 0
mutant B-gene
9ORF1 I-gene
polypeptides I-gene
clustered 0
within 0
three 0
separate 0
regions 0
referred 0
to 0
as 0
region 0
I 0
( 0
residues 0
34 0
to 0
41 0
) 0
, 0
region 0
II 0
( 0
residues 0
89 0
to 0
91 0
) 0
, 0
and 0
C 0
- 0
terminal 0
region 0
III 0
( 0
residues 0
122 0
to 0
125 0
) 0
. 0

Rep B-gene
- 0
Rep B-gene
protein 0
interaction 0
was 0
confirmed 0
in 0
vitro 0
through 0
coimmunoprecipitation 0
experiments 0
with 0
a 0
bacterially 0
expressed 0
maltose B-gene
- I-gene
binding I-gene
protein I-gene
- 0
Rep78 B-gene
fusion 0
protein 0
in 0
combination 0
with 0
[ 0
35S 0
] 0
methionine 0
- 0
labeled 0
Rep78 B-gene
synthesized 0
in 0
a 0
coupled 0
in 0
vitro 0
transcription 0
- 0
translation 0
system 0
. 0

The 0
C 0
- 0
LIP 0
also 0
was 0
compared 0
with 0
transcather 0
arterial 0
embolization 0
( 0
TAE 0
; 0
C 0
- 0
LIP 0
followed 0
by 0
gelatin 0
sponge 0
) 0
and 0
percutaneous 0
ethanol 0
injection 0
therapy 0
( 0
PEIT 0
) 0
. 0

Fourteen 0
patients 0
with 0
New 0
York 0
Heart 0
Association 0
class 0
II 0
congestive 0
heart 0
failure 0
were 0
enrolled 0
in 0
a 0
double 0
- 0
blind 0
, 0
cross 0
- 0
over 0
study 0
. 0

The 0
main 0
advantages 0
of 0
Multi 0
- 0
MUP 0
analysis 0
are 0
: 0
( 0
1 0
) 0
quick 0
acquisition 0
of 0
many 0
MUPs 0
; 0
( 0
2 0
) 0
simultaneous 0
collection 0
of 0
several 0
MUPs 0
at 0
one 0
recording 0
site 0
; 0
( 0
3 0
) 0
possibility 0
to 0
analyze 0
not 0
only 0
low 0
threshold 0
MUPs 0
; 0
( 0
4 0
) 0
less 0
bias 0
in 0
the 0
selection 0
of 0
MUPs 0
and 0
( 0
5 0
) 0
the 0
reproducibility 0
of 0
the 0
results 0
that 0
allow 0
the 0
same 0
reference 0
values 0
to 0
be 0
used 0
in 0
different 0
laboratories 0
. 0

We 0
also 0
demonstrate 0
that 0
preformed 0
triplexes 0
are 0
quite 0
stable 0
when 0
precipitated 0
with 0
ethanol 0
and 0
resuspended 0
in 0
water 0
. 0

Transfection 0
experiments 0
using 0
preformed 0
triplexes 0
with 0
a 0
reporter 0
plasmid 0
containing 0
the 0
collagen B-gene
promoter I-gene
sequence I-gene
showed 0
significant 0
inhibition 0
of 0
transcription 0
when 0
compared 0
with 0
a 0
control 0
phosphorothioate 0
ODN 0
. 0

Thus 0
, 0
an 0
increase 0
in 0
plasma B-gene
TBG I-gene
and 0
a 0
shift 0
from 0
adrenal 0
androgen 0
and 0
mineralocorticoid 0
steroid 0
secretion 0
towards 0
cortisol 0
secretion 0
may 0
be 0
endocrine 0
markers 0
for 0
progression 0
of 0
the 0
disease 0
in 0
patients 0
with 0
HIV 0
- 0
infection 0
. 0

In 0
several 0
studies 0
the 0
RDFS 0
has 0
shown 0
evidence 0
of 0
reliability 0
and 0
validity 0
. 0

Latanoprost 0
produces 0
an 0
additional 0
reduction 0
of 0
intraocular 0
pressure 0
( 0
IOP 0
) 0
when 0
used 0
in 0
combination 0
with 0
timolol 0
, 0
pilocarpine 0
, 0
acetazolamide 0
and 0
dipivefrin 0
. 0

These 0
results 0
suggest 0
that 0
dietary 0
safflower 0
phospholipids 0
may 0
be 0
a 0
valuable 0
ingredient 0
to 0
layers 0
for 0
reducing 0
liver 0
triglycerides 0
and 0
serum 0
cholesterol 0
without 0
any 0
adverse 0
effects 0
. 0

Using 0
various 0
techniques 0
, 0
we 0
have 0
undertaken 0
a 0
systematic 0
analysis 0
of 0
the 0
natural 0
TATA 0
- 0
less 0
human B-gene
DNA I-gene
polymerase I-gene
beta I-gene
( 0
beta B-gene
- I-gene
pol I-gene
) 0
gene 0
promoter 0
. 0

Saturable 0
spermidine 0
transport 0
in 0
stk2 B-gene
: 0
:lacZ B-gene
mutants I-gene
had 0
an 0
approximately 0
fivefold 0
- 0
lower 0
affinity 0
and 0
twofold 0
- 0
lower 0
Vmax 0
than 0
in 0
the 0
parental 0
strain 0
. 0

Transient 0
overexpression 0
of 0
c B-gene
- I-gene
Jun I-gene
induced 0
tenascin B-gene
- I-gene
C I-gene
expression 0
in 0
primary 0
REF 0
and 0
in 0
FR3T3 0
, 0
an 0
established 0
fibroblast 0
cell 0
line 0
. 0

Inhibition 0
of 0
the 0
Raf B-gene
- I-gene
1 I-gene
kinase I-gene
by 0
cyclic 0
AMP 0
agonists 0
causes 0
apoptosis 0
of 0
v B-gene
- I-gene
abl I-gene
- 0
transformed 0
cells 0
. 0

Previous 0
studies 0
have 0
indicated 0
that 0
a 0
hamster 0
cell 0
line 0
( 0
ts13 0
) 0
with 0
a 0
point 0
mutation 0
in 0
the 0
TAF B-gene
( I-gene
II I-gene
) I-gene
250/CCG1 I-gene
( 0
250/CCG1 I-gene

We 0
show 0
here 0
that 0
the 0
protein 0
kinase 0
MEKK1 B-gene
can 0
induce 0
reporter 0
gene 0
expression 0
from 0
the 0
atrial B-gene
natriuretic I-gene
factor I-gene
( 0
ANF B-gene
) 0
promoter 0
, 0
a 0
genetic 0
marker 0
that 0
is 0
activated 0
during 0
in 0
vivo 0
hypertrophy 0
. 0

Overexpression 0
of 0
EFG1 B-gene
in 0
C. 0
albicans 0
leads 0
to 0
enhanced 0
filamentous 0
growth 0
in 0
the 0
form 0
of 0
extended 0
pseudohyphae 0
in 0
liquid 0
and 0
on 0
solid 0
media 0
. 0

Selected 0
parameters 0
: 0
heart 0
rate 0
( 0
HR 0
) 0
, 0
arterial 0
blood 0
pressure 0
( 0
ABP 0
) 0
and 0
arterial 0
O2 0
saturation 0
( 0
SaO2 0
) 0
monitored 0
by 0
pulsoximetry 0
were 0
measured 0
during 0
the 0
procedure 0
. 0

To 0
determine 0
if 0
signing 0
, 0
when 0
established 0
, 0
would 0
compete 0
with 0
SIB 0
when 0
both 0
were 0
reinforced 0
, 0
extinction 0
was 0
then 0
withdrawn 0
. 0

The 0
husband 0
in 0
one 0
of 0
the 0
married 0
couples 0
was 0
treated 0
for 0
hepatitis 0
of 0
unidentified 0
etiology 0
in 0
an 0
Infectology 0
Department 0
four 0
years 0
ago 0
. 0

Both 0
quantitative 0
and 0
qualitative 0
analysis 0
of 0
individual 0
cytoarchitectonic 0
peculiarities 0
of 0
Meynart 0
's 0
nucleus 0
as 0
well 0
as 0
of 0
external 0
part 0
of 0
dorsomedial 0
nucleus 0
of 0
thalamus 0
was 0
performed 0
in 0
mentally 0
normal 0
individuals 0
. 0

We 0
have 0
tested 0
this 0
proposal 0
by 0
carrying 0
out 0
circular 0
dichroism 0
( 0
CD 0
) 0
and 0
NMR 0
experiments 0
on 0
the 0
Skn B-gene
domain I-gene
and 0
five 0
truncated 0
proteins 0
. 0

Positional 0
cloning 0
has 0
already 0
produced 0
the 0
sequences 0
of 0
more 0
than 0
70 0
human 0
genes 0
associated 0
with 0
specific 0
diseases 0
. 0

Genes 0
for 0
ocs B-gene
element I-gene
binding I-gene
factors I-gene
( 0
OBFs B-gene
) 0
, 0
belonging 0
to 0
a 0
specific 0
class 0
of 0
basic B-gene
- I-gene
region I-gene
leucine I-gene
zipper I-gene
( I-gene
bZIP I-gene
) I-gene
transcription I-gene
factors I-gene
, 0
have 0
been 0
isolated 0
in 0
a 0
number 0
of 0
plants 0
. 0

The 0
30 0
- 0
day 0
mortality 0
in 0
the 0
CPB 0
group 0
and 0
the 0
non 0
- 0
CPB 0
group 0
were 0
20 0
% 0
and 0
4.6 0
% 0
, 0
respectively 0
which 0
was 0
not 0
statistically 0
significant 0
( 0
p 0
= 0
0.06 0
) 0
. 0

As 0
opposed 0
to 0
in 0
vitro 0
co 0
- 0
precipitation 0
studies 0
, 0
the 0
yeast 0
two 0
- 0
hybrid 0
screen 0
reveals 0
in 0
vivo 0
protein 0
- 0
protein 0
interactions 0
. 0

This 0
association 0
appears 0
to 0
be 0
mediated 0
by 0
Src B-gene
- 0
SH2 B-gene
domain 0
, 0
because 0
PECAM B-gene
- I-gene
1 I-gene
can 0
be 0
precipitated 0
by 0
a 0
GST B-gene
- 0
Src B-gene
- 0
SH2 B-gene
affinity 0
matrix 0
. 0

MKK3 B-gene
autophosphorylation 0
and 0
activation 0
of 0
p38 B-gene
was 0
also 0
observed 0
following 0
coexpression 0
of 0
MKK3 B-gene
with 0
MEKK3 B-gene
, 0
but 0
not 0
with 0
MEKK2 B-gene
. 0

An 0
alternatively 0
spliced 0
MAdCAM B-gene
- I-gene
1 I-gene
variant 0
was 0
identified 0
that 0
lacks 0
exon 0
4 0
encoding 0
the 0
mucin B-gene
domain 0
, 0
and 0
may 0
mediate 0
leukocyte 0
adhesion 0
to 0
LPAM B-gene
- I-gene
1 I-gene
without 0
adhesion 0
to 0
the 0
alternate 0
receptor 0
, 0
L B-gene
- I-gene
selectin I-gene
. 0

In 0
summary 0
, 0
the 0
data 0
establish 0
that 0
the 0
previously 0
reported 0
human B-gene
MAdCAM I-gene
- I-gene
1 I-gene
cDNA I-gene
does 0
indeed 0
encode 0
the 0
human 0
homologue 0
of 0
mouse B-gene
MAdCAM I-gene
- I-gene
1 I-gene
, 0
despite 0
gross 0
dissimilarities 0
in 0
the 0
MAdCAM B-gene
- I-gene
1 I-gene
C 0
- 0
terminal 0
structures 0
. 0

We 0
have 0
used 0
a 0
site 0
- 0
directed 0
mutagenesis 0
approach 0
to 0
examine 0
how 0
the 0
Xaa 0
and 0
hydroxy 0
( 0
Ser/Thr 0
) 0
amino 0
acid 0
residues 0
in 0
sequons 0
influence 0
core 0
- 0
glycosylation 0
efficiency 0
. 0

MATERIAL 0
AND 0
METHODS 0
: 0
The 0
authors 0
analyzed 0
41 0
persons 0
formerly 0
submitted 0
to 0
surgery 0
( 0
after 0
8 0
years 0
and 0
4 0
months 0
, 0
as 0
a 0
mean 0
) 0
, 0
31 0
to 0
highly 0
selective 0
vagotomy 0
, 0
and 0
10 0
to 0
truncal 0
or 0
selective 0
vagotomy 0
plus 0
gastroduodenal 0
drainage 0
. 0

This 0
region 0
does 0
not 0
contain 0
an 0
identifiable 0
TATA 0
element 0
, 0
indicating 0
that 0
transcription 0
of 0
the 0
glutaminase B-gene
gene I-gene
is 0
driven 0
by 0
a 0
TATA 0
- 0
less 0
promoter 0
. 0

SRE 0
activity 0
is 0
dependent 0
upon 0
the 0
activation 0
by 0
phosphorylation 0
of 0
a 0
ternary 0
complex 0
factor 0
; 0
included 0
among 0
the 0
ternary 0
complex 0
factors 0
is 0
Elk B-gene
- I-gene
1 I-gene
. 0

Serum B-gene
alkaline I-gene
phosphatase I-gene
activity 0
, 0
bone 0
mass 0
measurements 0
, 0
dual 0
energy 0
x 0
- 0
ray 0
absortiometric 0
analysis 0
of 0
mineral 0
density 0
, 0
and 0
mechanical 0
testing 0
values 0
in 0
vertebrae 0
and 0
femora 0
of 0
the 0
- 0
D 0
Sal 0
animals 0
did 0
not 0
significantly 0
differ 0
from 0
those 0
in 0
+D 0
Sal 0
animals 0
. 0

The 0
monkey B-gene
LHR I-gene
cDNA I-gene
displayed 0
83 0
- 0
94 0
% 0
overall 0
sequence 0
homology 0
with 0
the 0
other 0
mammalian B-gene
LHR I-gene
cDNAs I-gene
. 0

In 0
conclusion 0
, 0
marmoset B-gene
monkey I-gene
LHR I-gene
seems 0
to 0
lack 0
the 0
sequence 0
corresponding 0
to 0
exon 0
10 0
of 0
the 0
LHR B-gene
gene I-gene
in 0
other 0
mammalian 0
species 0
. 0

In 0
unc B-gene
- I-gene
4 I-gene
mutants I-gene
, 0
VA 0
motor 0
neurons 0
assume 0
the 0
pattern 0
of 0
synaptic 0
input 0
normally 0
reserved 0
for 0
their 0
lineal 0
sister 0
cells 0
, 0
the 0
VB 0
motor 0
neurons 0
; 0
the 0
loss 0
of 0
normal 0
input 0
to 0
the 0
VAs 0
produces 0
a 0
distinctive 0
backward 0
movement 0
defect 0
. 0

Intracavitary 0
irradiation 0
was 0
carried 0
out 0
with 0
a 0
microSelectron 0
HDR 0
afterloading 0
device 0
and 0
usually 0
22.5 0
Gy 0
was 0
given 0
in 0
three 0
fractions 0
repeated 0
weekly 0
. 0

No 0
patient 0
in 0
group 0
2 0
developed 0
HAT 0
( 0
P 0
= 0
0.006 0
versus 0
group 0
1 0
) 0
. 0

Sequence 0
comparison 0
of 0
the 0
0.38 0
kb 0
promoter 0
sequence 0
with 0
the 0
promoters 0
of 0
the 0
Sm B-gene
- I-gene
E I-gene
gene 0
and 0
U1 B-gene
snRNA I-gene
genes I-gene
revealed 0
several 0
homologous 0
motifs 0
, 0
suggesting 0
that 0
genes 0
encoding 0
the 0
snRNP 0
components 0
may 0
be 0
coordinately 0
regulated 0
. 0

METHODS 0
: 0
The 0
responses 0
of 0
a 0
31 0
- 0
year 0
- 0
old 0
woman 0
with 0
complex 0
regional 0
pain 0
syndrome 0
type 0
I 0
( 0
reflex 0
sympathetic 0
dystrophy 0
) 0
to 0
a 0
thermal 0
grill 0
were 0
evaluated 0
before 0
and 0
after 0
stellate 0
ganglion 0
block 0
. 0

More 0
recently 0
, 0
however 0
, 0
a 0
number 0
of 0
developments 0
such 0
as 0
the 0
successful 0
use 0
of 0
the 0
inhaled 0
steroid 0
budesonide 0
and 0
oral 0
dexamethasone 0
have 0
reinforced 0
the 0
argument 0
for 0
using 0
steroids 0
. 0

A 0
xylE B-gene
transcriptional I-gene
fusion I-gene
to 0
the 0
putative 0
mxbD B-gene
promoter I-gene
showed 0
low 0
- 0
level 0
expression 0
in 0
wild 0
- 0
type 0
cells 0
grown 0
on 0
one 0
- 0
carbon 0
( 0
C1 0
) 0
compounds 0
and 0
no 0
detectable 0
expression 0
in 0
cells 0
grown 0
on 0
succinate 0
. 0

In 0
AcMNPV 0
- 0
infected 0
Sf9 0
cells 0
, 0
late 0
transcription 0
initiation 0
is 0
detected 0
from 0
only 0
two 0
upstream 0
TAAG 0
sites 0
and 0
not 0
from 0
three 0
downstream 0
TAAG 0
sites 0
. 0

Mutation 0
of 0
nucleotides 0
adjacent 0
to 0
the 0
AP B-gene
- I-gene
1 I-gene
cis I-gene
- I-gene
response I-gene
elements I-gene
had 0
no 0
effect 0
on 0
trans 0
- 0
activation 0
. 0

The 0
close 0
proximity 0
of 0
the 0
two 0
neuropeptide B-gene
Y I-gene
receptor I-gene
genes I-gene
suggests 0
that 0
they 0
have 0
evolved 0
from 0
a 0
gene 0
duplication 0
event 0
with 0
the 0
small 0
intron 0
interrupting 0
the 0
coding 0
sequence 0
of 0
the 0
y1 B-gene
gene I-gene
being 0
converted 0
into 0
a 0
functional 0
sequence 0
within 0
the 0
y5 B-gene
gene I-gene
, 0
while 0
the 0
reverse 0
complementary 0
sequence 0
was 0
utilized 0
as 0
an 0
alternatively 0
spliced 0
5 0
' 0
exon 0
for 0
the 0
y1 B-gene
gene I-gene
. 0

The 0
mammalian B-gene
phosphoinositide I-gene
3 I-gene
- I-gene
kinases I-gene
( 0
PI3Ks B-gene
) 0
p110alpha B-gene
, I-gene
beta I-gene
, I-gene
and I-gene
delta I-gene
form 0
heterodimers 0
with 0
Src B-gene
homology I-gene
2 I-gene
( 0
SH2 B-gene
) 0
domain 0
- 0
containing 0
adaptors 0
such 0
as 0
p85alpha B-gene
or 0
p55 B-gene
( 0
PIK B-gene
) 0
. 0

In 0
the 0
studies 0
reported 0
here 0
, 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
gp130 I-gene
gene I-gene
was 0
isolated 0
and 0
the 0
transcription 0
initiation 0
sites 0
were 0
mapped 0
. 0

Localization 0
of 0
the 0
cytokine 0
response 0
element 0
by 0
5' 0
- 0
deletion 0
analysis 0
and 0
site 0
- 0
directed 0
mutagenesis 0
revealed 0
a 0
cis 0
- 0
acting 0
binding 0
site 0
for 0
activated 0
STAT B-gene
complexes 0
. 0

Insulin B-gene
regulation 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
kinase I-gene
( 0
MEK B-gene
) 0
, 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
and 0
casein B-gene
kinase I-gene
in 0
the 0
cell 0
nucleus 0
: 0
a 0
possible 0
role 0
in 0
the 0
regulation 0
of 0
gene 0
expression 0
. 0

Sequencing 0
of 0
the 0
three 0
pag B-gene
- I-gene
3 I-gene
alleles I-gene
showed 0
that 0
two 0
apparent 0
null 0
alleles 0
encode 0
a 0
nonsense 0
mutation 0
before 0
the 0
zinc 0
fingers 0
and 0
a 0
missense 0
mutation 0
in 0
the 0
fourth 0
zinc 0
finger 0
that 0
changes 0
a 0
coordinating 0
histidine 0
to 0
a 0
tyrosine 0
. 0

Pax B-gene
- I-gene
3 I-gene
is 0
a 0
paired B-gene
- I-gene
type I-gene
homeobox I-gene
gene I-gene
that 0
is 0
specifically 0
expressed 0
in 0
the 0
dorsal 0
and 0
posterior 0
neural 0
tube 0
. 0

Instead 0
, 0
they 0
contained 0
dendritic 0
cells 0
that 0
express 0
melanogenic 0
marker 0
proteins 0
such 0
as 0
tyrosinase B-gene
and 0
tyrosinase B-gene
- I-gene
related I-gene
protein I-gene
1 I-gene
. 0

These 0
mutations 0
create 0
stop 0
codons 0
in 0
exon 0
7 0
and 0
8 0
, 0
respectively 0
, 0
and 0
probably 0
result 0
in 0
truncated 0
proteins 0
lacking 0
HLH 0
- 0
Zip 0
or 0
Zip 0
structure 0
. 0

Here 0
, 0
a 0
case 0
of 0
Sjogren 0
's 0
syndrome 0
is 0
presented 0
that 0
was 0
initially 0
diagnosed 0
because 0
of 0
dental 0
complaints 0
, 0
and 0
long 0
- 0
term 0
treatment 0
of 0
Sjogren 0
's 0
patients 0
is 0
discussed 0
. 0

Cloning 0
and 0
characterization 0
of 0
a 0
cDNA 0
encoding 0
a 0
bacteriophage B-gene
- I-gene
type I-gene
RNA I-gene
polymerase I-gene
from 0
the 0
higher 0
plant 0
Chenopodium 0
album 0
. 0

Similarly 0
, 0
overexpression 0
of 0
increasing 0
concentration 0
of 0
COUP B-gene
- I-gene
TFI I-gene
, 0
but 0
not 0
COUP B-gene
- I-gene
TFI I-gene
delta35 I-gene
, 0
can 0
squelch 0
the 0
silencing 0
activity 0
of 0
the 0
unliganded 0
TRbeta B-gene
. 0

These 0
six 0
amino 0
acids 0
are 0
part 0
of 0
an 0
amphipathic 0
helix 0
that 0
is 0
highly 0
conserved 0
among 0
nuclear B-gene
hormone I-gene
receptors I-gene
and 0
contains 0
the 0
core 0
domain 0
of 0
the 0
ligand 0
- 0
dependent 0
transactivation 0
function 0
, 0
AF 0
- 0
2 0
. 0

Surprisingly 0
, 0
the 0
RXR B-gene
- 0
specific 0
ligand 0
9 0
- 0
cis 0
- 0
retinoic 0
acid 0
induced 0
binding 0
of 0
SRC B-gene
- I-gene
1 I-gene
to 0
the 0
RXR B-gene
component I-gene
of 0
the 0
TRE 0
- 0
bound 0
heterodimer 0
. 0

In 0
ciliates 0
, 0
both 0
mechanisms 0
are 0
readily 0
observed 0
. 0

Based 0
on 0
the 0
occurrence 0
of 0
several 0
transcription 0
signals 0
in 0
the 0
Thermus B-gene
pyr I-gene
promoter I-gene
region I-gene
and 0
strong 0
amino 0
acid 0
sequence 0
identities 0
( 0
about 0
60 0
% 0
) 0
between 0
Thermus B-gene
PyrR I-gene
and 0
the 0
PyrR B-gene
attenuation I-gene
proteins I-gene
of 0
two 0
Bacillus 0
sp. 0
, 0
we 0
propose 0
a 0
regulatory 0
mechanism 0
involving 0
transcriptional 0
attenuation 0
to 0
control 0
pyr B-gene
gene I-gene
expression 0
in 0
Thermus 0
. 0

Diver 0
respiratory 0
responses 0
to 0
a 0
tunable 0
closed 0
- 0
circuit 0
breathing 0
apparatus 0
. 0

Measurement 0
of 0
the 0
time 0
constant 0
of 0
VO2 0
and 0
oxygen 0
pulse 0
during 0
constant 0
work 0
rate 0
exercise 0
are 0
useful 0
for 0
the 0
objective 0
evaluation 0
of 0
the 0
training 0
effect 0
of 0
patients 0
with 0
COPD 0
. 0

Characterization 0
of 0
CR1 B-gene
repeat 0
random 0
PCR 0
markers 0
for 0
mapping 0
the 0
chicken 0
genome 0
. 0

A 0
reversed 0
- 0
phase 0
high 0
- 0
performance 0
liquid 0
chromatographic 0
( 0
HPLC 0
) 0
method 0
for 0
the 0
determination 0
of 0
cocaine 0
metabolites 0
produced 0
in 0
vitro 0
by 0
serum B-gene
and I-gene
liver I-gene
esterases I-gene
is 0
described 0
. 0

Mutational 0
studies 0
provide 0
evidence 0
to 0
this 0
end 0
and 0
indicate 0
that 0
the 0
side 0
chains 0
of 0
subdomain 0
4.2 0
make 0
specific 0
contacts 0
with 0
the 0
nucleotides 0
at 0
- 0
35 0
. 0

It 0
is 0
concluded 0
that 0
fludarabine 0
is 0
a 0
highly 0
useful 0
agent 0
in 0
CLL 0
. 0

Three 0
different 0
techniques 0
of 0
EA 0
analysis 0
were 0
used 0
in 0
the 0
study 0
: 0
1 0
) 0
fast 0
Fourier 0
transformation 0
( 0
FFT 0
) 0
of 0
EA 0
in 0
a 0
broad 0
band 0
, 0
2 0
) 0
developed 0
by 0
us 0
alternative 0
method 0
of 0
non 0
- 0
harmonic 0
expansion 0
of 0
the 0
EEG 0
curves 0
taking 0
into 0
account 0
their 0
shape 0
, 0
3 0
) 0
factor 0
analysis 0
of 0
the 0
EA 0
spectral 0
densities 0
. 0

Concomitantly 0
, 0
p34CDC2 B-gene
histone B-gene
H1 I-gene
kinase 0
activity 0
increases 0
in 0
the 0
former 0
, 0
but 0
not 0
in 0
the 0
latter 0
cell 0
lines 0
, 0
hence 0
suggesting 0
a 0
role 0
for 0
this 0
protein 0
in 0
radiation 0
- 0
induced 0
cell 0
death 0
. 0

Using 0
PRL B-gene
- I-gene
R I-gene
tagged 0
both 0
in 0
the 0
N 0
- 0
terminal 0
or 0
C 0
- 0
terminal 0
regions 0
of 0
the 0
mature 0
receptor 0
excludes 0
the 0
possibility 0
of 0
a 0
cleaved 0
fragment 0
which 0
could 0
have 0
been 0
subsequently 0
imported 0
into 0
the 0
nucleus 0
. 0

Thus 0
, 0
the 0
B 0
- 0
S 0
mutant 0
does 0
not 0
mimic 0
efficiently 0
the 0
chloroplastic B-gene
GAPDHs I-gene
, 0
and 0
long 0
- 0
range 0
and/or 0
second 0
- 0
layer 0
effects 0
, 0
not 0
easily 0
predictable 0
from 0
visual 0
inspection 0
of 0
three 0
- 0
dimensional 0
structures 0
, 0
need 0
to 0
be 0
taken 0
into 0
account 0
for 0
designing 0
a 0
true 0
`` 0
chloroplastic 0
- 0
like 0
'' 0
mutant 0
of B-gene
cytosolic I-gene
GAPDH I-gene
. 0

Transcription 0
of 0
these 0
genes 0
was 0
also 0
elevated 0
in 0
gut 0
and 0
lung 0
during 0
freezing 0
, 0
but 0
mRNA 0
levels 0
in 0
these 0
tissues 0
were 0
lower 0
than 0
in 0
liver 0
. 0

Computer 0
software 0
assisted 0
ordering 0
( 0
CSAO 0
) 0
was 0
developed 0
to 0
integrate 0
PN 0
Ca 0
: 0
P 0
solubility 0
with 0
clinical 0
data 0
to 0
improve 0
parenteral 0
Ca 0
and 0
P 0
administration 0
. 0

A 0
similar 0
chimera 0
was 0
assembled 0
from 0
the 0
two 0
halves 0
of 0
the 0
molecule 0
expressed 0
separately 0
in 0
different 0
bacteria 0
and 0
refolded 0
together 0
. 0

The 0
conditions 0
for 0
obtaining 0
titanium 0
dioxide 0
from 0
the 0
substrates 0
titanium 0
tetrachloride 0
and 0
oxygen 0
and 0
applying 0
this 0
to 0
a 0
surgical 0
stainless 0
steel 0
of 0
the 0
type 0
316L 0
by 0
the 0
plasma 0
assisted 0
chemical 0
vapour 0
deposition 0
method 0
have 0
been 0
determined 0
. 0

All 0
six 0
genes 0
were 0
cloned 0
and 0
characterised 0
. 0

We 0
analysed 0
two 0
regions 0
involved 0
in 0
preS2/S B-gene
preS2/S I-gene
gene I-gene
transcription 0
of 0
the 0
HBV 0
adw 0
subtype 0
: 0
the 0
diverged 0
TATA 0
box 0
and 0
a 0
putative 0
initiator 0
element 0
. 0

Indeed 0
the 0
predicted 0
folding 0
of 0
the 0
5 0
' 0
and 0
3' 0
- 0
untranslated 0
regions 0
revealed 0
patterns 0
of 0
stem 0
and 0
loop 0
structures 0
conserved 0
for 0
all 0
tick 0
- 0
borne 0
flaviviruses 0
suggesting 0
a 0
purifying 0
selection 0
for 0
preservation 0
of 0
essential 0
RNA 0
secondary 0
structures 0
which 0
could 0
be 0
involved 0
in 0
translational 0
control 0
and 0
replication 0
. 0

EGF B-gene
acts 0
primarily 0
by 0
means 0
of 0
transactivation 0
domain 0
AF 0
- 0
1 0
, 0
whereas 0
cAMP 0
acts 0
via 0
transactivation 0
domain 0
AF 0
- 0
2 0
of 0
the 0
ER B-gene
. 0

To 0
determine 0
which 0
region 0
of 0
SulA B-gene
is 0
essential 0
for 0
the 0
inhibition 0
of 0
cell 0
division 0
, 0
we 0
constructed 0
a 0
series 0
of 0
N 0
- 0
terminal 0
and 0
C 0
- 0
terminal 0
deletions 0
of 0
SulA B-gene
and 0
a 0
series 0
of 0
alanine 0
substitution 0
mutants 0
. 0

We 0
have 0
inactivated 0
Krox B-gene
- I-gene
20 I-gene
by 0
homologous 0
recombination 0
in 0
ES 0
cells 0
and 0
demonstrated 0
that 0
the 0
mutation 0
leads 0
to 0
the 0
deletion 0
of 0
r3 0
and 0
r5 0
. 0

Recently 0
we 0
have 0
performed 0
a 0
detailed 0
analysis 0
of 0
specific 0
neuronal 0
populations 0
affected 0
by 0
the 0
mutation 0
which 0
shed 0
new 0
light 0
on 0
the 0
role 0
of 0
Krox B-gene
- I-gene
20 I-gene
in 0
the 0
segmentation 0
and 0
on 0
the 0
physiological 0
consequences 0
of 0
its 0
inactivation 0
. 0

The 0
most 0
important 0
one 0
among 0
them 0
is 0
Cyclosporin 0
A 0
, 0
which 0
is 0
a 0
selective 0
immunosuppressive 0
drug 0
. 0

Consistent 0
with 0
its 0
role 0
in 0
p53 B-gene
ubiquitination 0
, 0
mE6 B-gene
- I-gene
AP I-gene
was 0
found 0
both 0
in 0
the 0
nucleus 0
and 0
cytosol 0
, 0
while 0
Nedd B-gene
- I-gene
4 I-gene
was 0
found 0
only 0
in 0
the 0
cytosol 0
. 0

SPP B-gene
also 0
induced 0
transient 0
tyrosine 0
phosphorylation 0
of 0
focal B-gene
adhesion I-gene
kinase I-gene
( 0
p125 B-gene
( 0
FAK B-gene
) 0
) 0
, 0
a 0
cytosolic B-gene
tyrosine I-gene
kinase I-gene
that 0
localizes 0
in 0
focal 0
adhesions 0
, 0
and 0
of 0
the 0
cytoskeleton B-gene
- I-gene
associated I-gene
protein I-gene
paxillin I-gene
. 0

Using 0
a 0
conditional 0
- 0
lethal 0
mutant 0
allele 0
of 0
SUP45 B-gene
( 0
sup45 B-gene
- I-gene
2 I-gene
) 0
and 0
a 0
combination 0
of 0
in 0
vivo 0
and 0
in 0
vitro 0
approaches 0
, 0
we 0
demonstrate 0
that 0
the 0
product 0
of 0
the 0
SUP45 B-gene
gene I-gene
( 0
Sup45p B-gene
or 0
eRF1 B-gene
) 0
is 0
a 0
factor 0
required 0
for 0
translation 0
termination 0
in 0
yeast 0
. 0

Evaluation 0
of 0
myocardial 0
perfusion 0
by 0
99mTc 0
- 0
tetrofosmin 0
SPECT 0
before 0
and 0
after 0
emergent 0
percutaneous 0
transluminal 0
coronary 0
angioplasty 0
for 0
acute 0
myocardial 0
infarction 0

A 0
neonatal 0
alloimmune 0
thrombocytopenia 0
with 0
an 0
HPA B-gene
- I-gene
3a I-gene
( 0
Baka 0
) 0
incompatibility 0
was 0
confirmed 0
. 0

She 0
was 0
able 0
to 0
stand 0
unaided 0
by 0
3 0
years 0
of 0
age 0
with 0
then 0
progressive 0
worsening 0
of 0
motor 0
abilities 0
. 0

Merosin B-gene
positive 0
congenital 0
muscular 0
dystrophy 0
with 0
mental 0
deficiency 0
, 0
epilepsy 0
and 0
MRI 0
changes 0
in 0
the 0
cerebral 0
white 0
matter 0
. 0

Most 0
eukaryotic 0
mRNAs 0
are 0
translated 0
by 0
a 0
`` 0
scanning 0
ribosome 0
'' 0
mechanism 0
. 0

Comparison 0
of 0
Tc 0
- 0
99m 0
sestamibi 0
perfusion 0
imaging 0
and 0
echocardiography 0
using 0
an 0
arbutamine 0
infusion 0
for 0
the 0
detection 0
of 0
coronary 0
artery 0
disease 0
. 0

Also 0
, 0
transient 0
overexpression 0
of 0
this 0
protein 0
in 0
C2C12 0
cells 0
reduced 0
the 0
transcription 0
of 0
a 0
CAT B-gene
- 0
reporter 0
regulated 0
by 0
an 0
E12/MyoD B-gene
driven 0
enhancer 0
. 0

Five 0
of 0
these 0
have 0
ocular 0
or 0
oculocutaneous 0
albinism 0
. 0

Comprising 0
a 0
126 0
- 0
nucleotide 0
5 0
' 0
untranscribed 0
genomic 0
sequence 0
and 0
a 0
466 0
- 0
nucleotide 0
5 0
' 0
noncoding 0
cDNA 0
sequence 0
, 0
the 0
592 0
- 0
nucleotide 0
5 0
' 0
CpG 0
island 0
lacked 0
TATA 0
and 0
CAAT 0
boxes 0
but 0
displayed 0
a 0
high 0
G+C 0
content 0
, 0
was 0
enriched 0
for 0
CpG 0
dinucleotides 0
, 0
and 0
contained 0
a 0
potential 0
Sp1 B-gene
- I-gene
binding I-gene
site I-gene
, 0
i.e. 0
, 0
features 0
compatible 0
with 0
a 0
housekeeping 0
gene 0
. 0

SSeCKS B-gene
( 0
pronounced 0
essex 0
) 0
encodes 0
a 0
major 0
protein B-gene
kinase I-gene
C I-gene
substrate 0
, 0
the 0
expression 0
of 0
which 0
is 0
down 0
- 0
regulated 0
in 0
src B-gene
- 0
and 0
ras B-gene
- 0
transformed 0
rodent 0
fibroblasts 0
but 0
not 0
in 0
raf 0
- 0
transformed 0
rodent 0
fibroblasts 0
( 0
X 0
. 0

Type 0
I 0
position 0
- 0
vestibular 0
- 0
pause 0
( 0
PVP 0
I 0
) 0
and 0
vestibular 0
- 0
only 0
( 0
V 0
I 0
) 0
neurons 0
, 0
as 0
well 0
as 0
a 0
smaller 0
number 0
of 0
other 0
type 0
I 0
and 0
type 0
II 0
eye 0
- 0
plus 0
- 0
vestibular 0
neurons 0
were 0
studied 0
. 0

The 0
1.1 0
- 0
and 0
1.3 0
- 0
kb 0
mRNA 0
species 0
were 0
found 0
only 0
in 0
the 0
heart 0
, 0
and 0
the 0
2.6 0
- 0
kb 0
species 0
was 0
found 0
in 0
the 0
heart 0
, 0
kidney 0
and 0
brain 0
, 0
but 0
not 0
in 0
skeletal 0
muscle 0
or 0
liver 0
. 0

Taurine 0
deficiency 0
significantly 0
depressed 0
the 0
amplitude 0
of 0
OP1 0
and 0
OP4 0
. 0

We 0
have 0
found 0
that 0
mcs4 B-gene
- 0
cells 0
are 0
defective 0
at 0
activation 0
of 0
Spc1 B-gene
in 0
response 0
to 0
various 0
forms 0
of 0
stress 0
. 0

The 0
extended 0
rat B-gene
SP I-gene
- I-gene
A I-gene
isoforms I-gene
were 0
enriched 0
in 0
the 0
more 0
fully 0
glycosylated 0
and 0
multimeric 0
SP B-gene
- I-gene
A I-gene
species 0
separated 0
on 0
SDS 0
- 0
PAGE 0
gels 0
. 0

Alternative 0
splicing 0
of 0
CDC25B B-gene
may 0
therefore 0
contribute 0
to 0
the 0
control 0
of 0
cell 0
proliferation 0
. 0

This 0
investigation 0
was 0
undertaken 0
to 0
determine 0
whether 0
consuming 0
several 0
small 0
feedings 0
of 0
preexercise 0
carbohydrate 0
( 0
CHO 0
) 0
, 0
rather 0
than 0
a 0
single 0
bolus 0
, 0
would 0
affect 0
blood 0
glucose 0
and 0
insulin B-gene
responses 0
during 0
rest 0
and 0
exercise 0
. 0

The 0
findings 0
suggest 0
that 0
ERP 0
effects 0
of 0
distinct 0
memory 0
processes 0
are 0
differentially 0
influenced 0
by 0
the 0
encoding 0
instructions 0
. 0

This 0
coat B-gene
protein I-gene
consists 0
of 0
Sar1p B-gene
, 0
the 0
Sec23p B-gene
protein I-gene
complex I-gene
containing 0
Sec23p B-gene
and 0
Sec24p B-gene
, 0
and 0
the 0
Sec13p B-gene
protein I-gene
complex I-gene
containing 0
Sec13p B-gene
and 0
a 0
novel 0
150 B-gene
- I-gene
kDa I-gene
protein I-gene
, I-gene
p150 I-gene
. 0

The 0
second 0
primary 0
mutant 0
contained 0
a 0
proline 0
- 0
to 0
- 0
leucine 0
change 0
at 0
position 0
243 0
( 0
P243L 0
) 0
. 0

Induction 0
of 0
correctly 0
spliced 0
germline 0
transcripts 0
is 0
necessary 0
to 0
target 0
a 0
switch 0
region 0
for 0
recombination 0
and 0
switching 0
. 0

Thus 0
, 0
the 0
PCE B-gene
binds 0
a 0
Pbx B-gene
dimer I-gene
partner I-gene
that 0
behaves 0
unlike 0
Class B-gene
I I-gene
Hox I-gene
proteins I-gene
. 0

Furthermore 0
, 0
the 0
NH2 0
- 0
terminal 0
portion 0
of 0
the 0
homologue 0
was 0
not 0
translocated 0
into 0
the 0
outer 0
membrane 0
without 0
its 0
COOH 0
- 0
terminal 0
part 0
. 0

Molecular 0
cloning 0
and 0
characterization 0
of 0
a 0
cDNA 0
, 0
CHEMR1 B-gene
, 0
encoding 0
a 0
chemokine 0
receptor 0
with 0
a 0
homology 0
to 0
the 0
human B-gene
C I-gene
- I-gene
C I-gene
chemokine I-gene
receptor I-gene
, 0
CCR B-gene
- I-gene
4 I-gene
. 0

Organization 0
of 0
the 0
human B-gene
LU I-gene
gene I-gene
and 0
molecular 0
basis 0
of 0
the 0
Lu B-gene
( I-gene
a I-gene
) I-gene
/Lu B-gene
( I-gene
b I-gene
) I-gene
blood 0
group 0
polymorphism 0
. 0

Using 0
mouse 0
- 0
human 0
somatic 0
hybrids 0
and 0
FISH 0
analysis 0
, 0
the 0
PE B-gene
- I-gene
2 I-gene
gene I-gene
is 0
localized 0
to 0
human 0
chromosome 0
19q13.2 0
, 0
a 0
region 0
involved 0
in 0
translocations 0
and 0
deletions 0
in 0
leukemias 0
and 0
several 0
solid 0
tumors 0
, 0
suggesting 0
that 0
this 0
novel 0
ETS B-gene
factor I-gene
may 0
play 0
a 0
role 0
in 0
carcinogenesis 0
. 0

Whereas 0
the 0
mutant 0
enzymes 0
terminate 0
normally 0
at 0
the 0
late 0
terminator 0
in 0
T7 0
DNA 0
( 0
T 0
( 0
phi 0
) 0
) 0
and 0
rrnB B-gene
T2 0
, 0
they 0
fail 0
to 0
terminate 0
at 0
one 0
of 0
the 0
termination 0
sites 0
of 0
rrnB B-gene
T1 0
, 0
and 0
also 0
fail 0
to 0
recognize 0
the 0
PTH B-gene
and 0
CJ 0
signals 0
. 0

Cytological 0
data 0
suggest 0
that 0
the 0
transgenes 0
associate 0
with 0
a 0
nucleolus 0
. 0

Light B-gene
regulatory I-gene
unit I-gene
1 I-gene
( 0
LRU1 B-gene
) 0
is 0
necessary 0
for 0
and 0
sufficient 0
to 0
mediate 0
light 0
- 0
dependent 0
activation 0
of 0
the 0
chalcone B-gene
synthase I-gene
( I-gene
CHS I-gene
) I-gene
minimal I-gene
promoter I-gene
in 0
Petroselinum 0
crispum 0
. 0

Sequence 0
divergence 0
is 0
observed 0
in 0
untranslated 0
regions 0
which 0
allows 0
the 0
definition 0
of 0
gene 0
- 0
specific 0
probes 0
. 0

The 0
active 0
state 0
is 0
terminated 0
by 0
hydrolysis 0
of 0
bound 0
GTP 0
, 0
producing 0
inactive 0
ARF B-gene
- I-gene
GDP I-gene
. 0

We 0
suggest 0
that 0
apart 0
from 0
the 0
World 0
Summit 0
for 0
Children 0
's 0
under 0
- 0
five 0
mortality 0
target 0
for 0
the 0
year 0
2000 0
, 0
intraregional 0
targets 0
to 0
reduce 0
geographical 0
inequalities 0
in 0
under 0
- 0
five 0
mortality 0
should 0
be 0
specified 0
. 0

The 0
immunophilin B-gene
, 0
which 0
can 0
be 0
of 0
the 0
FK506 0
- 0
or 0
cyclosporin 0
A 0
- 0
binding 0
class 0
, 0
binds 0
to 0
hsp90 B-gene
via 0
its 0
tetratricopeptide 0
repeat 0
( 0
TPR 0
) 0
domain 0
, 0
and 0
different 0
receptor 0
heterocomplexes 0
exist 0
depending 0
upon 0
which 0
immunophilin B-gene
occupies 0
the 0
TPR 0
- 0
binding 0
region 0
of 0
hsp90 B-gene
. 0

In 0
adherent 0
macrophages 0
, 0
absence 0
of 0
CD45 B-gene
led 0
to 0
the 0
hyperphosphorylation 0
and 0
hyperactivation 0
of 0
p56/59 B-gene
( 0
hck B-gene
) 0
and 0
p53/56 B-gene
( 0
lyn B-gene
) 0
, 0
but 0
not 0
of 0
p58 B-gene
( 0
c B-gene
- I-gene
fgr I-gene
) 0
. 0

Secretion 0
in 0
milk 0
and 0
transplacental 0
transfer 0
of 0
two 0
iodized 0
oils 0
, 0
Lipiodol 0
UF 0
and 0
Oriodol 0
, 0
in 0
rabbits 0
. 0

Sequencing 0
of 0
the 0
facB B-gene
gene I-gene
revealed 0
that 0
it 0
encodes 0
a 0
protein 0
that 0
contains 0
an 0
N 0
- 0
terminal 0
GAL4 B-gene
- 0
like 0
Zn 0
( 0
II 0
) 0
2Cys6 0
( 0
or 0
C6 0
zinc 0
) 0
binuclear 0
cluster 0
for 0
DNA 0
binding 0
, 0
leucine 0
zipper 0
- 0
like 0
heptad 0
repeat 0
motifs 0
and 0
central 0
and 0
C 0
- 0
terminal 0
acidic 0
alpha 0
- 0
helical 0
regions 0
, 0
consistent 0
with 0
a 0
function 0
as 0
a 0
DNA 0
- 0
binding 0
transcriptional 0
activator 0
. 0

Overexpression 0
of 0
Sed5p B-gene
allowed 0
growth 0
in 0
the 0
absence 0
of 0
Vti1p B-gene
. 0

The 0
coding 0
region 0
of 0
mkh1 B-gene
is 0
contained 0
within 0
a 0
single 0
exon 0
encoding 0
a 0
1,116 0
- 0
amino 0
- 0
acid 0
protein 0
. 0

Strikingly 0
, 0
stoichiometric 0
association 0
of 0
p107 B-gene
or 0
p130 B-gene
with 0
either 0
cyclin B-gene
E I-gene
- 0
cdk2 B-gene
or 0
cyclin B-gene
A I-gene
- 0
cdk2 B-gene
negated 0
the 0
activities 0
of 0
these 0
kinases 0
. 0

Furthermore 0
, 0
p150 B-gene
suppresses 0
actin B-gene
gelation 0
, 0
which 0
is 0
induced 0
by 0
smooth B-gene
muscle I-gene
alpha I-gene
- I-gene
actinin I-gene
. 0

Denaturation 0
of 0
the 0
simian 0
virus 0
40 0
origin 0
of 0
replication 0
mediated 0
by 0
human B-gene
replication I-gene
protein I-gene
A I-gene
. 0

This 0
effect 0
was 0
abolished 0
once 0
the 0
EM 0
motif 0
in 0
the 0
promoter 0
- 0
reporter 0
construct 0
was 0
mutated 0
, 0
thus 0
suggesting 0
that 0
the 0
synergistic 0
transactivation 0
function 0
of 0
the 0
TEF B-gene
- I-gene
1 I-gene
- 0
Max B-gene
heterotypic 0
complex 0
is 0
mediated 0
through 0
binding 0
of 0
the 0
complex 0
to 0
the 0
EM 0
motif 0
. 0

Interdigitated 0
residues 0
within 0
a 0
small 0
region 0
of 0
VP16 B-gene
interact 0
with 0
Oct B-gene
- I-gene
1 I-gene
, 0
HCF B-gene
, 0
and 0
DNA 0
. 0

With 0
a 0
view 0
to 0
identifying 0
other 0
important 0
U14 B-gene
interactions 0
, 0
a 0
stem 0
- 0
loop 0
domain 0
required 0
for 0
activity 0
of 0
Saccharomyces B-gene
cerevisiae I-gene
U14 I-gene
RNAs I-gene
( 0
the 0
Y 0
domain 0
) 0
was 0
first 0
subjected 0
to 0
detailed 0
mutational 0
analysis 0
. 0

Based 0
on 0
these 0
results 0
and 0
because 0
Cdc68 B-gene
has 0
been 0
implicated 0
as 0
a 0
regulator 0
of 0
chromatin 0
structure 0
, 0
we 0
postulate 0
that 0
polymerase B-gene
alpha I-gene
may 0
interact 0
with 0
these 0
proteins 0
to 0
gain 0
access 0
to 0
its 0
template 0
or 0
to 0
origins 0
of 0
replication 0
in 0
vivo 0
. 0

Even 0
when 0
the 0
inoculum 0
size 0
was 0
reduced 0
sixfold 0
( 0
i.e. 0
, 0
6 0
x 0
10 0
( 0
6 0
) 0
CFU/mouse 0
) 0
, 0
50 0
% 0
of 0
the 0
RB6 B-gene
- I-gene
8C5 I-gene
- 0
treated 0
animals 0
died 0
within 0
6 0
days 0
. 0

In 0
12 0
cases 0
( 0
3.1 0
% 0
) 0
, 0
a 0
change 0
in 0
stage 0
resulted 0
. 0

Promoter 0
recognition 0
algorithms 0
identified 0
divergent 0
promoter 0
elements 0
within 0
the 0
CpG 0
island 0
, 0
which 0
lies 0
between 0
the 0
ATM B-gene
and 0
E14/NPAT B-gene
genes 0
, 0
and 0
provide 0
evidence 0
for 0
a 0
putative 0
second 0
E14/NPAT I-gene

Recombinant B-gene
soluble I-gene
pMCP I-gene
that 0
lacked 0
transmembrane 0
and 0
cytoplasmic 0
domains 0
had 0
factor B-gene
I I-gene
cofactor I-gene
activity 0
in 0
C3b B-gene
cleavage 0
, 0
indicating 0
that 0
it 0
is 0
functionally 0
, 0
as 0
well 0
as 0
structurally 0
homologous 0
to 0
MCP B-gene
. 0

Clinical 0
and 0
haematological 0
signs 0
are 0
not 0
specific 0
in 0
this 0
setting 0
, 0
and 0
the 0
diagnosis 0
relies 0
on 0
histological 0
features 0
, 0
mainly 0
bone 0
marrow 0
examination 0
. 0

Spatial 0
zones 0
for 0
muscle 0
coactivation 0
and 0
the 0
control 0
of 0
postural 0
stability 0
. 0

Liquid 0
chromatographic 0
separation 0
was 0
achieved 0
on 0
a 0
Zorbax 0
RX 0
C8 0
analytical 0
column 0
using 0
gradient 0
elution 0
. 0

The 0
linear 0
plasmid 0
pDHL1 0
from 0
Debaryomyces 0
hansenii 0
encodes 0
a 0
protein 0
highly 0
homologous 0
to 0
the 0
pGKL1 B-gene
- I-gene
plasmid I-gene
DNA I-gene
polymerase I-gene
. 0

The 0
RNA 0
- 0
binding 0
and 0
RNA B-gene
- I-gene
DNA I-gene
helicase I-gene
activities 0
of 0
the 0
Escherichia B-gene
coli I-gene
transcription I-gene
termination I-gene
factor I-gene
rho I-gene
have 0
been 0
investigated 0
using 0
natural 0
RNA 0
molecules 0
that 0
are 0
255 0
and 0
391 0
nucleotide 0
residues 0
in 0
length 0
and 0
that 0
contain 0
the 0
trp B-gene
t I-gene
' I-gene
rho I-gene
- I-gene
dependent I-gene
termination I-gene
sequence I-gene
of 0
E. 0
coli 0
. 0

The 0
p20 B-gene
- I-gene
CGGBP I-gene
gene I-gene
is 0
conserved 0
among 0
mammals 0
but 0
shows 0
no 0
homology 0
to 0
non 0
- 0
vertebrate 0
species 0
. 0

The 0
data 0
suggest 0
that 0
like 0
in 0
yeast 0
, 0
in 0
plants 0
a 0
certain 0
subfamily 0
of 0
UBC B-gene
is 0
specifically 0
involved 0
in 0
the 0
proteolytic 0
degradation 0
of 0
abnormal 0
proteins 0
as 0
result 0
of 0
stress 0
. 0

The 0
pWP B-gene
- I-gene
19 I-gene
also 0
encodes 0
the 0
AAV 0
inverted 0
terminal 0
repeats 0
for 0
integration 0
and 0
replication 0
and 0
the 0
herpes 0
virus 0
thymidine B-gene
kinase I-gene
promoter 0
- 0
driven 0
gene 0
for 0
neomycin 0
resistance 0
( 0
neoR B-gene
) 0
. 0

We 0
have 0
developed 0
a 0
rAAV 0
- 0
mediated 0
gene 0
transfer 0
system 0
for 0
the 0
rat B-gene
preproinsulin I-gene
II I-gene
gene I-gene
. 0

The 0
serum 0
levels 0
of 0
beta B-gene
- I-gene
human I-gene
chorionic I-gene
gonadotropin I-gene
( 0
HCG B-gene
) 0
and 0
placental B-gene
alkaline I-gene
phosphatase I-gene
( 0
PLAP B-gene
) 0
were 0
not 0
elevated 0
. 0

A 0
striking 0
feature 0
of 0
the 0
recombinant B-gene
H19 I-gene
allele I-gene
is 0
the 0
occurrence 0
of 0
a 0
parental 0
imprint 0
set 0
on 0
the 0
neo B-gene
replacement I-gene
cassette I-gene
. 0

This 0
indicates 0
that 0
recruitment 0
of 0
large B-gene
T I-gene
antigen I-gene
to 0
the 0
rRNA 0
promoter 0
by 0
SL1 B-gene
constitutes 0
a 0
crucial 0
step 0
in 0
the 0
activation 0
process 0
. 0

In 0
1990 0
, 0
an 0
International 0
Commission 0
for 0
the 0
Certification 0
of 0
Eradication 0
of 0
Poliomyelitis 0
Eradication 0
( 0
ICCPE 0
) 0
was 0
established 0
by 0
the 0
Pan 0
American 0
Health 0
Organization 0
to 0
eventually 0
determine 0
if 0
transmission 0
was 0
interrupted 0
. 0

Functional 0
and 0
regulatory 0
analysis 0
of 0
the 0
two 0
copies 0
of 0
the 0
fixNOQP B-gene
operon I-gene
of 0
Rhizobium 0
leguminosarum 0
strain 0
VF39 0
. 0

This 0
study 0
describes 0
a 0
new 0
MADS B-gene
box I-gene
gene I-gene
, 0
nmhC5 B-gene
, 0
which 0
along 0
with 0
nmh7 B-gene
( 0
J 0
. 0

Thus 0
E14.1TG3B1 0
is 0
a 0
useful 0
ES 0
cell 0
line 0
for 0
modifying 0
the 0
mouse 0
genome 0
using 0
the 0
HPRT B-gene
gene I-gene
as 0
a 0
selection 0
marker 0
and 0
for 0
transmission 0
at 0
a 0
high 0
frequency 0
into 0
the 0
mouse 0
germ 0
line 0
. 0

Lung 0
and 0
multi 0
- 0
system 0
damage 0
were 0
early 0
indicators 0
of 0
poor 0
outcome 0
in 0
severe 0
non 0
- 0
fatal 0
disease 0
. 0

The 0
results 0
suggest 0
that 0
the 0
bulbospinal 0
micturition 0
reflex 0
evoked 0
by 0
bladder 0
filling 0
and 0
L 0
- 0
dopa 0
involves 0
a 0
descending 0
pathway 0
where 0
transmission 0
is 0
partly 0
mediated 0
by 0
spinal B-gene
alpha I-gene
1 I-gene
- I-gene
adrenoceptors I-gene
. 0

OBJECTIVE 0
: 0
This 0
study 0
was 0
designed 0
to 0
analyze 0
the 0
common 0
cause 0
of 0
asthenopia 0
, 0
mixed 0
astigmatism 0
. 0

Disturbance 0
of 0
regeneration 0
in 0
the 0
above 0
pathological 0
condition 0
results 0
from 0
the 0
damage 0
to 0
tunica 0
propria 0
and 0
loss 0
of 0
its 0
function 0
for 0
the 0
support 0
of 0
structural 0
homeostasis 0
. 0

Sternocleidomastoid 0
, 0
neck 0
or 0
facial 0
muscles 0
wasting 0
were 0
also 0
found 0
in 0
three 0
cases 0
. 0

Identification 0
of 0
five 0
new 0
genes 0
, 0
closely 0
related 0
to 0
the 0
interleukin B-gene
- I-gene
1beta I-gene
converting I-gene
enzyme I-gene
gene I-gene
, 0
that 0
do 0
not 0
encode 0
functional 0
proteases 0
. 0

The 0
C 0
- 0
terminal 0
mature 0
region 0
is 0
highly 0
conserved 0
in 0
other 0
serine B-gene
carboxypeptidases I-gene
. 0

One 0
RNA 0
construct 0
which 0
consisted 0
of 0
112 0
nucleotides 0
( 0
nt 0
) 0
from 0
nt 0
639 0
to 0
nt 0
750 0
formed 0
a 0
heterodimeric 0
complex 0
with 0
the 0
RNA 0
which 0
consisted 0
of 0
200 0
nucleotides 0
from 0
nt 0
551 0
to 0
nt 0
750 0
. 0

Here 0
we 0
demonstrate 0
that 0
AML1a B-gene
, 0
which 0
solely 0
has 0
no 0
effects 0
as 0
a 0
transcriptional 0
regulator 0
, 0
dominantly 0
suppresses 0
transcriptional 0
activation 0
by 0
AML1b B-gene
, 0
and 0
that 0
AML1a B-gene
exhibits 0
the 0
higher 0
affinity 0
for 0
DNA 0
- 0
binding 0
than 0
AML1b B-gene
. 0

However 0
, 0
we 0
could 0
not 0
find 0
the 0
homologous 0
regions 0
with 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factors I-gene
or 0
GTPase B-gene
- I-gene
activating I-gene
proteins I-gene
in 0
the 0
c B-gene
- I-gene
cbl I-gene
gene I-gene
. 0

However 0
, 0
using 0
ATL 0
- 0
16T 0
nuclear 0
extract 0
, 0
we 0
demonstrated 0
that 0
GATA B-gene
- I-gene
4 I-gene
is 0
the 0
only 0
GATA B-gene
- I-gene
binding I-gene
protein I-gene
that 0
forms 0
specific 0
DNA 0
- 0
protein 0
complex 0
with 0
the 0
- 0
70 0
GATA 0
site 0
. 0

The 0
impact 0
of 0
social 0
support 0
on 0
the 0
relationships 0
of 0
gay 0
male 0
couples 0
is 0
examined 0
. 0

The 0
ubiquitously 0
expressed 0
hypoxia B-gene
- I-gene
inducible I-gene
factor I-gene
- I-gene
1 I-gene
( 0
HIF B-gene
- I-gene
1 I-gene
) 0
is 0
involved 0
in 0
expression 0
of 0
a 0
large 0
number 0
of 0
oxygen 0
- 0
regulated 0
genes 0
. 0

Stromelysin B-gene
- I-gene
1 I-gene
, 0
matrix B-gene
metalloproteinase I-gene
- I-gene
3 I-gene
( 0
MMP B-gene
- I-gene
3 I-gene
) 0
, 0
is 0
an 0
important 0
endopeptidase 0
selectively 0
expressed 0
by 0
somatic 0
cells 0
in 0
organ 0
tissues 0
. 0

Tendon 0
also 0
shows 0
a 0
degree 0
of 0
extensibility 0
. 0

Surveillance 0
for 0
preeclampsia 0
was 0
conducted 0
by 0
personnel 0
unaware 0
of 0
treatment 0
- 0
group 0
assignments 0
, 0
using 0
standardized 0
measurements 0
of 0
blood 0
pressure 0
and 0
urinary 0
protein 0
excretion 0
at 0
uniformly 0
scheduled 0
prenatal 0
visits 0
, 0
protocols 0
for 0
monitoring 0
these 0
measurements 0
during 0
the 0
hospitalization 0
for 0
delivery 0
, 0
and 0
reviews 0
of 0
medical 0
records 0
of 0
unscheduled 0
outpatient 0
visits 0
and 0
all 0
hospitalizations 0
. 0

Aryl B-gene
hydrocarbon I-gene
receptor I-gene
nuclear I-gene
translocator I-gene
( 0
ARNT B-gene
) 0
is 0
a 0
component 0
of 0
the 0
transcription 0
factors 0
, 0
aryl B-gene
hydrocarbon I-gene
receptor I-gene
( 0
AhR B-gene
) 0
and 0
hypoxia B-gene
- I-gene
inducible I-gene
factor I-gene
1 I-gene
, 0
which 0
transactivate 0
their 0
target 0
genes 0
, 0
such 0
as 0
CYP1A1 B-gene
and 0
erythropoietin B-gene
, 0
in 0
response 0
to 0
xenobiotic 0
aromatic 0
hydrocarbons 0
and 0
to 0
low 0
O2 0
concentration 0
, 0
respectively 0
. 0

DNase B-gene
I I-gene
footprint 0
analysis 0
identified 0
a 0
protected 0
region 0
from 0
- 0
37 0
to 0
- 0
53 0
. 0

We 0
also 0
provide 0
evidence 0
that 0
gar2 B-gene
is 0
phosphorylated 0
in 0
vitro 0
by 0
a 0
p13 B-gene
( 0
suc1 B-gene
) 0
- 0
Sepharose 0
- 0
bound 0
kinase 0
from 0
Schizosaccharomyces 0
pombe 0
extracts 0
that 0
displays 0
cell 0
cycle 0
- 0
regulated 0
activity 0
similar 0
to 0
that 0
of 0
the 0
p34 B-gene
( 0
cdc2 B-gene
( 0
kinase 0
. 0

However 0
, 0
by 0
immobilized 0
metal 0
affinity 0
chromatography 0
assay 0
, 0
self 0
- 0
association 0
of 0
PR B-gene
- I-gene
A I-gene
was 0
3.5 0
- 0
fold 0
more 0
efficient 0
than 0
that 0
of 0
either 0
the 0
DhLBD 0
or 0
hLBD 0
constructs 0
. 0

The 0
overall 0
results 0
of 0
this 0
paper 0
are 0
consistent 0
with 0
the 0
conclusion 0
that 0
the 0
carboxyl 0
- 0
terminal 0
LBD 0
is 0
not 0
sufficient 0
for 0
mediating 0
PR B-gene
dimerization 0
and 0
that 0
multiple 0
regions 0
, 0
including 0
the 0
hinge 0
and 0
amino 0
- 0
terminal 0
sequences 0
, 0
contribute 0
either 0
directly 0
or 0
indirectly 0
to 0
homodimerization 0
of 0
PR B-gene
. 0

We 0
isolated 0
several 0
overlapping 0
A 0
- 0
phage 0
and 0
cosmid 0
clones 0
that 0
cover 0
more 0
than 0
100 0
kb 0
of 0
human 0
DNA 0
and 0
contained 0
the 0
entire 0
VDR B-gene
gene I-gene
. 0

Colorectal 0
carcinoma 0
: 0
therapeutic 0
approach 0
in 0
patients 0
already 0
treated 0
with 0
metastasis 0
resection 0

Here 0
, 0
we 0
correlate 0
Dox 0
effects 0
on 0
cell 0
cycle 0
with 0
changes 0
of 0
E2F/DP B-gene
complexes 0
and 0
activity 0
in 0
differentiating 0
C2C12 0
myocytes 0
. 0

The 0
products 0
of 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
CIN1 I-gene
, 0
CIN2 B-gene
and 0
CIN4 B-gene
genes I-gene
participate 0
in 0
a 0
nonessential 0
pathway 0
required 0
for 0
normal 0
microtubule 0
function 0
. 0

Vitrectomy 0
was 0
still 0
a 0
significant 0
risk 0
factor 0
when 0
macular 0
holes 0
were 0
excluded 0
. 0

Invited 0
editorial 0
on 0
`` 0
Acute 0
and 0
chronic 0
effects 0
of 0
exercise 0
on B-gene
leptin I-gene
levels 0
in 0
humans 0
'' 0
. 0

Both 0
promoters 0
lack 0
a 0
TATA 0
box 0
, 0
and 0
Pint B-gene
belongs 0
to 0
the 0
MED B-gene
- I-gene
1 I-gene
class 0
of 0
promoters 0
, 0
which 0
initiate 0
transcription 0
at 0
multiple 0
sites 0
. 0

Serum B-gene
response I-gene
factor I-gene
( 0
SRF B-gene
) 0
, 0
a 0
member 0
of 0
an 0
ancient 0
family 0
of 0
DNA 0
- 0
binding 0
proteins 0
, 0
is 0
generally 0
assumed 0
to 0
be 0
a 0
ubiquitous 0
transcription 0
factor 0
involved 0
in 0
regulating 0
growth 0
factor 0
- 0
responsive 0
genes 0
. 0

We 0
have 0
initiated 0
studies 0
to 0
identify 0
candidate 0
signal 0
transducers 0
that 0
associate 0
with 0
the 0
cytosolic 0
domain 0
( 0
cd 0
) 0
of 0
the 0
IL B-gene
- I-gene
1R I-gene
. 0

In 0
this 0
study 0
, 0
we 0
sought 0
to 0
identify 0
mechanisms 0
that 0
could 0
account 0
for 0
the 0
antimitogenic 0
effects 0
of 0
IL B-gene
- I-gene
4 I-gene
. 0

Pseudomonas 0
aeruginosa 0
strains 0
infecting 0
patients 0
with 0
cystic 0
fibrosis 0
( 0
CF 0
) 0
acquire 0
a 0
mucoid 0
phenotype 0
due 0
to 0
overproduction 0
of 0
alginate 0
. 0

Activity 0
of 0
palgD B-gene
in 0
the 0
cysB B-gene
mutant I-gene
, 0
in 0
CHA 0
and 0
in 0
the 0
non 0
- 0
mucoid 0
strain 0
PAO 0
was 0
assessed 0
by 0
the 0
use 0
of 0
a 0
transcriptional 0
algD B-gene
- 0
xylE B-gene
fusion 0
. 0

The 0
Man9 B-gene
- I-gene
mannosidase I-gene
specificity 0
of 0
the 0
cDNA 0
construct 0
was 0
verified 0
by 0
the 0
observation 0
that 0
all 0
peptide 0
sequences 0
derived 0
from 0
a 0
previously 0
purified 0
, 0
catalytically 0
active 0
49 0
- 0
kDa 0
fragment 0
were 0
found 0
within 0
the 0
coding 0
region 0
. 0

A 0
soluble 0
62 0
- 0
kDa 0
protein 0
was 0
produced 0
without 0
the 0
proteolytic 0
processing 0
by 0
inserting 0
the 0
coding 0
sequence 0
of 0
amino 0
acids 0
112 0
to 0
660 0
of 0
ORF 0
- 0
2 0
in 0
a 0
baculovirus 0
expression 0
vector 0
and 0
using 0
the 0
corresponding 0
virus 0
to 0
infect 0
Sf9 0
cells 0
. 0

The 0
CPK B-gene
- I-gene
MB I-gene
isoenzyme 0
showed 0
no 0
percentage 0
increase 0
of 0
total 0
CPK B-gene
higher 0
than 0
5 0
% 0
, 0
measured 0
at 0
6 0
, 0
12 0
, 0
and 0
24 0
h 0
after 0
the 0
shock 0
, 0
independent 0
of 0
the 0
number 0
of 0
attempts 0
of 0
cardioversion 0
. 0

Serum 0
and 0
peritoneal 0
dialysis 0
fluid 0
( 0
PDF 0
) 0
were 0
collected 0
for 0
assay 0
throughout 0
the 0
course 0
of 0
the 0
study 0
and 0
for 0
5 0
days 0
thereafter 0
. 0

Results 0
support 0
the 0
hypothesis 0
that 0
endogenous B-gene
corticotropin I-gene
- I-gene
releasing I-gene
factor I-gene
, 0
perhaps 0
acting 0
at 0
a 0
peripheral 0
binding 0
site 0
, 0
suppresses 0
the 0
active 0
behavioral 0
response 0
characteristic 0
of 0
pups 0
during 0
the 0
early 0
phase 0
of 0
isolation 0
in 0
novel 0
surroundings 0
. 0

Liver 0
regional 0
blood 0
volume 0
( 0
LRBV 0
) 0
is 0
altered 0
by 0
several 0
disease 0
states 0
and 0
various 0
drugs 0
. 0

The 0
gray 0
matter 0
NAA/mI 0
ratio 0
clearly 0
separated 0
the 0
two 0
groups 0
. 0

As 0
with 0
the 0
murine B-gene
and I-gene
human I-gene
mb I-gene
- I-gene
1 I-gene
genes I-gene
, 0
the 0
5 0
' 0
region 0
of 0
the 0
bovine B-gene
mb I-gene
- I-gene
1 I-gene
gene I-gene
lacked 0
a 0
TATA 0
box 0
. 0

Chloramphenicol B-gene
acetyltransferase I-gene
assays 0
examining 0
the 0
ability 0
of 0
IE86 B-gene
to 0
repress 0
activity 0
from 0
the 0
HCMV 0
major 0
IE B-gene
promoter I-gene
or 0
activate 0
the 0
HCMV B-gene
early I-gene
promoter I-gene
for 0
the 0
2.2 0
- 0
kb 0
class 0
of 0
RNAs 0
demonstrated 0
the 0
functional 0
integrity 0
of 0
the 0
IE86 B-gene
protein I-gene
. 0

ORF 0
M1 0
has 0
striking 0
homology 0
to 0
poxvirus 0
serpins B-gene
, 0
while 0
ORF 0
M11 0
encodes 0
a 0
potential 0
homolog 0
of 0
Bcl B-gene
- I-gene
2 I-gene
- I-gene
like I-gene
molecules I-gene
encoded 0
by 0
other 0
gammaherpesviruses 0
( 0
gene B-gene
16 I-gene
of 0
HVS 0
and 0
KSHV 0
and 0
the 0
BHRF1 B-gene
gene I-gene
of 0
EBV 0
) 0
. 0

Transcription 0
factor 0
binding 0
sites 0
downstream 0
of 0
the 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
transcription 0
start 0
site 0
are 0
important 0
for 0
virus 0
infectivity 0
. 0

Crystal 0
structure 0
of 0
an 0
oligomer 0
of 0
proteolytic 0
zymogens 0
: 0
detailed 0
conformational 0
analysis 0
of 0
the 0
bovine 0
ternary 0
complex 0
and 0
implications 0
for 0
their 0
activation 0
. 0

Through 0
transient 0
transfection 0
of 0
NIH3T3 0
fibroblast 0
cells 0
and 0
gel 0
mobility 0
shift 0
assays 0
, 0
the 0
functional 0
binding 0
site 0
was 0
localized 0
to 0
a 0
short 0
region 0
( 0
- 0
318 0
to 0
- 0
303 0
bp 0
from 0
the 0
transcription 0
start 0
site 0
) 0
which 0
has 0
a 0
CTCCC 0
sequence 0
. 0

We 0
suppose 0
that 0
this 0
injection 0
speed 0
( 0
0.1 0
- 0
0.2 0
ml.s 0
- 0
1 0
) 0
is 0
suitable 0
for 0
spinal 0
anesthesia 0
. 0

Alternative 0
splicing 0
of 0
ClC B-gene
- I-gene
6 I-gene
( 0
a 0
member 0
of 0
the 0
CIC B-gene
chloride I-gene
- I-gene
channel I-gene
family I-gene
) 0
transcripts 0
generates 0
three 0
truncated 0
isoforms 0
one 0
of 0
which 0
, 0
ClC B-gene
- I-gene
6c I-gene
, 0
is 0
kidney 0
- 0
specific 0
. 0

The 0
current 0
study 0
demonstrates 0
that 0
T3 0
- 0
activated 0
transcription 0
of 0
the 0
NADPH B-gene
: I-gene
cytochrome I-gene
P450 I-gene
oxidoreductase I-gene
( 0
P450R B-gene
) 0
gene 0
is 0
dependent 0
on 0
the 0
thyroid 0
hormonal 0
status 0
of 0
the 0
animal 0
, 0
with 0
both 0
transcriptional 0
and 0
post 0
- 0
transcriptional 0
pathways 0
being 0
important 0
in 0
regulating 0
the 0
cellular 0
P450R B-gene
mRNA 0
level 0
. 0

The 0
behavior 0
of 0
different 0
types 0
of 0
polytetrafluoroethylene 0
( 0
PTFE 0
) 0
prostheses 0
in 0
the 0
reparative 0
scarring 0
process 0
of 0
abdominal 0
wall 0
defects 0
. 0

The 0
control 0
group 0
revealed 0
significantly 0
higher 0
levels 0
of 0
coagulation B-gene
factors I-gene
II I-gene
, I-gene
V I-gene
and I-gene
VIII I-gene
, 0
compared 0
to 0
the 0
index 0
group 0
. 0

The 0
frequency 0
of 0
positive 0
anti B-gene
- I-gene
GM1 I-gene
antibody I-gene
titers 0
in 0
the 0
Guillain 0
- 0
Barre 0
syndrome 0
patients 0
with 0
PEN 0
19 0
isolates 0
was 0
higher 0
than 0
that 0
in 0
the 0
Guillain 0
- 0
Barre 0
syndrome 0
and 0
Fisher 0
's 0
syndrome 0
patients 0
without 0
PEN 0
19 0
isolates 0
. 0

Stereotactic 0
radiofrequency 0
lesioning 0
of 0
the 0
hamartoma 0
resulted 0
in 0
seizure 0
remission 0
without 0
complications 0
20 0
months 0
after 0
surgery 0
. 0

NF B-gene
- I-gene
kappa I-gene
B/Rel I-gene
transcription 0
factors 0
participate 0
in 0
the 0
activation 0
of 0
numerous 0
genes 0
involved 0
in 0
immune 0
regulation/inflammation 0
including 0
cytokines 0
, 0
cell 0
surface 0
receptors 0
, 0
adhesion 0
molecules 0
, 0
and 0
acute 0
phase 0
proteins 0
. 0

If 0
E. 0
coli 0
is 0
present 0
in 0
any 0
source 0
water 0
sample 0
, 0
the 0
borehole 0
and 0
any 0
directly 0
connected 0
borehole 0
should 0
be 0
embargoed 0
. 0

However 0
, 0
mean 0
food 0
intake 0
in 0
the 0
40 0
% 0
group 0
was 0
half 0
that 0
of 0
the 0
ACT 0
group 0
( 0
p 0
< 0
0.001 0
) 0
and 0
significantly 0
less 0
( 0
p 0
< 0
0.01 0
) 0
than 0
the 0
SEP 0
group 0
, 0
which 0
consumed 0
amounts 0
equivalent 0
to 0
65 0
% 0
of 0
daily 0
requirement 0
. 0

The 0
following 0
technique 0
describes 0
a 0
modification 0
to 0
a 0
bar 0
superstructure 0
that 0
provided 0
the 0
advantages 0
of 0
convenience 0
, 0
security 0
, 0
and 0
consistent 0
positioning 0
even 0
though 0
one 0
implant 0
was 0
lost 0
and 0
the 0
angulation 0
of 0
implants 0
limited 0
accuracy 0
. 0

In 0
summary 0
, 0
DDC 0
express 0
receptors 0
for 0
a 0
broad 0
panel 0
of 0
cytokines 0
, 0
even 0
receptors 0
for 0
cytokines 0
whose 0
effects 0
on 0
DC 0
are 0
still 0
unknown 0
( 0
i.e 0
. 0

Its 0
potential 0
as 0
a 0
diagnostic 0
tool 0
for 0
epidemiological 0
surveillance 0
was 0
assessed 0
in 0
comparison 0
with 0
three 0
other 0
diagnostic 0
tests 0
: 0
stool 0
examination 0
, 0
ELISA 0
with 0
soluble B-gene
egg I-gene
antigen I-gene
( 0
SEA B-gene
) 0
and 0
the 0
circumoval 0
precipitin B-gene
test 0
( 0
COPT 0
) 0
. 0

We 0
have 0
separated 0
a 0
dermatan 0
sulfate 0
proteoglycan 0
, 0
epiphycan 0
, 0
from 0
decorin B-gene
and 0
biglycan 0
by 0
using 0
dissociative 0
extraction 0
of 0
bovine 0
fetal 0
epiphyseal 0
cartilage 0
, 0
followed 0
by 0
sequential 0
ion 0
- 0
exchange 0
, 0
gel 0
permeation 0
, 0
hydrophobic 0
, 0
and 0
Zn2+ 0
chelate 0
chromatographic 0
steps 0
. 0

These 0
analyses 0
demonstrate 0
that 0
the 0
dUTPase B-gene
isoforms 0
are 0
encoded 0
by 0
the 0
same 0
gene 0
with 0
isoform 0
- 0
specific 0
transcripts 0
arising 0
through 0
the 0
use 0
of 0
alternative 0
5 0
' 0
exons 0
. 0

The 0
selective 0
5 B-gene
- I-gene
HT3 I-gene
receptor I-gene
antagonists 0
ramosetron 0
( 0
YM060 0
) 0
, 0
YM114 0
( 0
KAE 0
- 0
393 0
) 0
, 0
granisetron 0
and 0
ondansetron 0
, 0
and 0
the 0
substituted 0
benzamides 0
( 0
5 B-gene
- I-gene
HT4 I-gene
receptor I-gene
agonist/5 B-gene
- I-gene
HT3 I-gene
receptor I-gene
antagonists 0
) 0
cisapride 0
mosapride 0
and 0
SC 0
- 0
53116 0
dose 0
- 0
dependently 0
enhanced 0
gastric 0
emptying 0
in 0
normal 0
rats 0
. 0

Re 0
- 0
evaluation 0
of 0
the 0
biopsy 0
specimen 0
from 0
the 0
right 0
hip 0
taken 0
at 0
the 0
time 0
of 0
the 0
initial 0
operation 0
showed 0
areas 0
of 0
chondrosarcoma 0
arising 0
in 0
the 0
background 0
of 0
synovial 0
chondromatosis 0
. 0

All 0
corneal 0
buttons 0
were 0
processed 0
for 0
histopathologic 0
and 0
electron 0
microscopic 0
studies 0
. 0

3600 0
- 0
fold 0
to 0
apparent 0
homogeneity 0
with 0
a 0
41 0
% 0
yield 0
by 0
affinity 0
chromatography 0
utilizing 0
DNA 0
- 0
cellulose 0
; 0
the 0
purity 0
of 0
the 0
final 0
preparation 0
was 0
assessed 0
by 0
SDS/PAGE 0
, 0
lack 0
of 0
contamination 0
by 0
other 0
nucleases 0
and 0
production 0
of 0
a 0
monospecific 0
antibody 0
against 0
the 0
enzyme 0
. 0

Human B-gene
thymine I-gene
- I-gene
DNA I-gene
glycosylase I-gene
maps 0
at 0
chromosome 0
12q22 0
- 0
q24.1 0
: 0
a 0
region 0
of 0
high 0
loss 0
of 0
heterozygosity 0
in 0
gastric 0
cancer 0
. 0

FOG B-gene
is 0
coexpressed 0
with 0
GATA B-gene
- I-gene
1 I-gene
during 0
embryonic 0
development 0
and 0
in 0
erythroid 0
and 0
megakaryocytic 0
cells 0
. 0

The 0
mean 0
times 0
to 0
detection 0
of 0
all 0
mycobacteria 0
with 0
BACTEC 0
9000 0
MB 0
and 0
BACTEC 0
460 0
TB 0
were 0
similar 0
( 0
10.3 0
and 0
10.0 0
days 0
, 0
respectively 0
) 0
. 0

Though 0
the 0
BACTEC 0
9000 0
MB 0
system 0
is 0
recommended 0
for 0
respiratory 0
specimens 0
, 0
we 0
demonstrated 0
that 0
it 0
can 0
be 0
successfully 0
used 0
also 0
for 0
recovery 0
of 0
mycobacteria 0
from 0
clinical 0
specimens 0
from 0
various 0
extrapulmonary 0
sites 0
. 0

We 0
further 0
found 0
that 0
KmMig1p B-gene
is 0
fully 0
functional 0
when 0
expressed 0
in 0
S. 0
cerevisiae 0
. 0

A 0
pre 0
- 0
boutonniere 0
deformity 0
was 0
simulated 0
by 0
dividing 0
the 0
central 0
slip 0
. 0

Autoimmune 0
neutropenia 0
( 0
AIN 0
) 0
is 0
a 0
frequent 0
cause 0
of 0
chronic 0
neutropenia 0
especially 0
in 0
youngest 0
children 0
. 0

With 0
regard 0
to 0
the 0
characteristic 0
expression 0
pattern 0
of 0
DJ B-gene
protein I-gene
and 0
its 0
conspicuous 0
repeat 0
units 0
possible 0
functional 0
roles 0
are 0
discussed 0
. 0

Future 0
analysis 0
of 0
long 0
- 0
term 0
outcome 0
measures 0
of 0
performance 0
with 0
the 0
implant 0
will 0
confirm 0
or 0
dispute 0
the 0
benefit 0
of 0
ear 0
selection 0
using 0
the 0
Prom 0
- 0
EABR 0
. 0

This 0
protein 0
, 0
designated 0
p532 B-gene
based 0
on 0
its 0
predicted 0
molecular 0
weight 0
( 0
EMBO 0
J 0
15 0
: 0
5738 0
, 0
1996 0
) 0
, 0
contains 0
multiple 0
structural 0
domains 0
including 0
two 0
regions 0
of 0
seven 0
internal 0
repeats 0
highly 0
related 0
to 0
the 0
cell 0
cycle 0
regulator 0
RCC1 B-gene
, 0
a 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
for 0
the 0
small B-gene
GTP I-gene
- I-gene
binding I-gene
protein I-gene
Ran B-gene
, 0
seven 0
beta 0
- 0
repeat 0
domains 0
characteristic 0
of 0
the 0
beta 0
subunit 0
of 0
heterotrimeric B-gene
G I-gene
proteins I-gene
, 0
three 0
putative 0
SH3 B-gene
binding I-gene
sites I-gene
, 0
a 0
putative 0
leucine 0
- 0
zipper 0
and 0
a 0
carboxy B-gene
- I-gene
terminal I-gene
HECT I-gene
domain I-gene
characteristic 0
of 0
E3 B-gene
ubiquitin I-gene
- I-gene
protein I-gene
ligases I-gene
. 0

Thus 0
, 0
the 0
L45 0
sequence 0
between 0
kinase 0
subdomains 0
IV 0
and 0
V 0
specifies 0
TGF B-gene
- I-gene
beta I-gene
responsiveness 0
of 0
the 0
type B-gene
I I-gene
receptor I-gene
. 0

The 0
two 0
mouse 0
lines 0
carrying 0
the 0
unfragmented 0
Hnf3g B-gene
- 0
lacZ B-gene
YAC 0
showed 0
tissue 0
- 0
specific 0
, 0
copy 0
number 0
- 0
dependent 0
and 0
position 0
- 0
independent 0
expression 0
, 0
proving 0
that 0
170 0
kb 0
of 0
the 0
Hnf3g B-gene
locus 0
contain 0
all 0
elements 0
important 0
in 0
the 0
regulation 0
of 0
Hnf3g B-gene
. 0

Second 0
, 0
plasmid 0
- 0
derived 0
transgenes 0
and 0
gene 0
targeting 0
of 0
the 0
endogenous B-gene
Hnf3g I-gene
gene I-gene
locus I-gene
were 0
used 0
to 0
demonstrate 0
that 0
the 0
3' 0
- 0
flanking 0
region 0
of 0
the 0
gene 0
is 0
necessary 0
and 0
sufficient 0
to 0
direct 0
reporter 0
gene 0
expression 0
in 0
liver 0
, 0
pancreas 0
, 0
stomach 0
and 0
small 0
intestine 0
. 0

This 0
regulation 0
requires 0
two 0
HMG B-gene
- I-gene
box I-gene
proteins I-gene
: 0
the 0
ubiquitous 0
Ste11 B-gene
transcription I-gene
factor I-gene
and 0
the 0
M 0
cell 0
- 0
controlling 0
protein 0
Mat1 B-gene
- I-gene
Mc I-gene
. 0

Here 0
we 0
have 0
tested 0
the 0
hypothesis 0
that 0
the 0
short 0
transcripts 0
, 0
or 0
proteins 0
translated 0
from 0
the 0
short 0
transcripts 0
, 0
are 0
also 0
required 0
for 0
respiration 0
. 0

Upstream 0
activating 0
sequences 0
( 0
UASs 0
) 0
derived 0
from 0
known 0
Ste12p B-gene
- 0
dependent 0
genes 0
have 0
previously 0
been 0
characterized 0
to 0
require 0
either 0
multiple 0
PREs 0
or 0
a 0
single 0
PRE 0
coupled 0
to 0
a 0
binding 0
site 0
for 0
a 0
second 0
protein 0
. 0

Prominent 0
protein 0
kinase 0
cascades 0
are 0
those 0
that 0
activate 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinases I-gene
. 0

JNK B-gene
is 0
additionally 0
regulated 0
by 0
the 0
Ras B-gene
- 0
related 0
G B-gene
proteins I-gene
Rac B-gene
and 0
Cdc42 B-gene
. 0

In 0
this 0
study 0
, 0
we 0
tested 0
this 0
notion 0
by 0
using 0
ligation 0
- 0
mediated 0
PCR 0
to 0
assess 0
the 0
formation 0
of 0
recombination B-gene
- I-gene
activating I-gene
gene I-gene
( 0
RAG B-gene
) 0
- 0
dependent 0
double 0
- 0
strand 0
breaks 0
( 0
DSBs 0
) 0
at 0
RSSs 0
3 0
' 0
of 0
Ddelta3 B-gene
and 0
5 0
' 0
of 0
Jdelta1 B-gene
. 0

Recent 0
studies 0
have 0
demonstrated 0
that 0
Cbl B-gene
, 0
the 0
120 0
- 0
kDa 0
protein 0
product 0
of 0
the 0
c B-gene
- I-gene
cbl I-gene
proto I-gene
- I-gene
oncogene I-gene
, 0
serves 0
as 0
a 0
substrate 0
of 0
a 0
number 0
of 0
receptor B-gene
- I-gene
coupled I-gene
tyrosine I-gene
kinases I-gene
and 0
forms 0
complexes 0
with 0
SH3 B-gene
and 0
SH2 B-gene
domain 0
- 0
containing 0
proteins 0
, 0
pointing 0
to 0
its 0
role 0
in 0
signal 0
transduction 0
. 0

Although 0
neither 0
constitutively 0
activated 0
MEK B-gene
( 0
MEK B-gene
- I-gene
2E I-gene
) 0
nor 0
v B-gene
- I-gene
Src I-gene
was 0
sufficient 0
individually 0
to 0
differentiate 0
the 0
H19 0
- 0
7 0
cells 0
, 0
coexpression 0
of 0
constitutively 0
activated 0
MEK B-gene
and 0
v B-gene
- I-gene
Src I-gene
induced 0
neurite 0
outgrowth 0
. 0

This 0
mechanism 0
is 0
in 0
contrast 0
to 0
other 0
cases 0
of 0
splicing 0
regulation 0
by 0
PTB B-gene
, 0
in 0
which 0
the 0
protein 0
represses 0
the 0
splice 0
site 0
to 0
which 0
it 0
binds 0
. 0

While 0
important 0
for 0
ligand 0
- 0
dependent 0
transactivation 0
, 0
this 0
interaction 0
surface 0
is 0
not 0
directly 0
involved 0
in 0
transrepression 0
of 0
AP B-gene
- I-gene
1 I-gene
activity 0
. 0

Gal4 B-gene
- 0
Eed B-gene
fusion 0
protein 0
represses 0
transcription 0
of 0
a 0
reporter 0
gene 0
driven 0
by 0
a 0
promoter 0
that 0
contains 0
Gal4 B-gene
- I-gene
binding I-gene
DNA I-gene
elements I-gene
. 0

In 0
situ 0
hybridization 0
analysis 0
in 0
adult 0
rat 0
tissue 0
reveals 0
good 0
correlation 0
with 0
this 0
pattern 0
and 0
indicates 0
that 0
drm B-gene
mRNA I-gene
is 0
most 0
highly 0
expressed 0
in 0
nondividing 0
and 0
terminally 0
differentiated 0
cells 0
, 0
such 0
as 0
neurons 0
, 0
type 0
1 0
lung 0
cells 0
, 0
and 0
goblet 0
cells 0
. 0

Neither 0
of 0
these 0
proteins 0
, 0
individually 0
or 0
as 0
a 0
pair 0
, 0
can 0
bind 0
the 0
alpha B-gene
- I-gene
globin I-gene
3'UTR I-gene
unless 0
they 0
are 0
complexed 0
with 0
the 0
remaining 0
non 0
- 0
poly 0
( 0
C 0
) 0
binding 0
proteins 0
of 0
the 0
alpha B-gene
- I-gene
complex I-gene
. 0

A 0
2 0
years 0
and 0
9 0
months 0
old 0
female 0
patient 0
, 0
with 0
the 0
diagnosis 0
of 0
Weaver 0
syndrome 0
is 0
reported 0
. 0

Confirming 0
measures 0
made 0
by 0
nurses 0
and 0
additionally 0
, 0
ABPM 0
for 0
women 0
, 0
seem 0
to 0
lessen 0
this 0
effect 0
. 0

In 0
a 0
series 0
of 0
patients 0
with 0
neuroinfection 0
, 0
Lyme 0
disease 0
, 0
Guillain 0
Barre 0
syndrome 0
, 0
demyelinization 0
, 0
partial 0
or 0
generalized 0
, 0
epilepsy 0
, 0
we 0
have 0
investigated 0
antiphospholipid 0
antibodies 0
of 0
IgG B-gene
and 0
IgM B-gene
subtypes 0
, 0
together 0
with 0
anticoagulant 0
factors 0
, 0
member 0
of 0
thrombocytes 0
, 0
sedimentation 0
rate 0
of 0
erythrocytes 0
. 0

( 0
1996a 0
) 0
Biochemistry 0
35 0
, 0
1589 0
- 0
1598 0
] 0
. 0

Second 0
, 0
the 0
membrane 0
expression 0
of 0
alpha 0
and 0
beta 0
subunits 0
was 0
mimicked 0
by 0
cholesterol 0
and 0
17 0
- 0
ketocholesterol 0
, 0
both 0
of 0
which 0
inhibit 0
HMG B-gene
- I-gene
CoA I-gene
reductase I-gene
. 0

Our 0
results 0
suggest 0
that 0
Lrp B-gene
binds 0
a 0
central 0
palindromic 0
site 0
, 0
interacting 0
predominantly 0
with 0
the 0
major 0
groove 0
of 0
its 0
DNA 0
target 0
, 0
and 0
that 0
additional 0
dimers 0
bind 0
to 0
flanking 0
sites 0
to 0
form 0
a 0
nucleoprotein 0
activation 0
complex 0
. 0

Sustained 0
activation 0
of 0
p21 B-gene
expression 0
is 0
proposed 0
to 0
be 0
a 0
distinguishing 0
feature 0
of 0
the 0
activity 0
of 0
NGF B-gene
that 0
contributes 0
to 0
PC12 0
growth 0
arrest 0
during 0
differentiation 0

The 0
remaining 0
80 0
patients 0
underwent 0
recordings 0
of 0
ECG 0
, 0
beat 0
- 0
to 0
- 0
beat 0
arterial 0
oxygen 0
saturation 0
( 0
SaO2 0
) 0
, 0
and 0
respiration 0
during 0
both 0
spontaneous 0
and 0
controlled 0
breathing 0
. 0

The 0
mean 0
total 0
white 0
cell 0
count 0
increased 0
from 0
a 0
baseline 0
of 0
11.3 0
x 0
10 0
( 0
9 0
) 0
/L 0
( 0
SD 0
2.3 0
) 0
to 0
16.2 0
x 0
10 0
( 0
9 0
) 0
/L 0
( 0
SD 0
4.6 0
) 0
on 0
day 0
1 0
, 0
normalising 0
thereafter 0
. 0

A 0
prospective 0
observational 0
study 0
was 0
conducted 0
to 0
identify 0
early 0
indicators 0
of 0
acute 0
dengue 0
virus 0
infection 0
. 0

In 0
all 0
experimental 0
eyes 0
, 0
there 0
was 0
a 0
marked 0
reduction 0
, 0
but 0
never 0
a 0
complete 0
absence 0
of 0
adrenergic 0
nerves 0
in 0
the 0
iris 0
. 0

These 0
lesions 0
may 0
be 0
treated 0
by 0
propranolol 0
or 0
phentolamine 0
. 0

Furthermore 0
, 0
ICER B-gene
negatively 0
autoregulates 0
the 0
alternative 0
promoter 0
, 0
thus 0
generating 0
a 0
feedback 0
loop 0
. 0

This 0
night 0
- 0
day 0
oscillation 0
is 0
driven 0
by 0
the 0
endogenous 0
clock 0
( 0
located 0
in 0
the 0
suprachiasmatic 0
nucleus 0
, 0
SCN 0
) 0
. 0

It 0
is 0
present 0
in 0
the 0
nucleus 0
of 0
the 0
cells 0
in 0
which 0
it 0
is 0
expressed 0
and 0
can 0
phosphorylate 0
and 0
activate 0
the 0
cyclic B-gene
AMP I-gene
response I-gene
element I-gene
binding I-gene
proteins I-gene
CREB B-gene
and 0
CREM B-gene
tau I-gene
in 0
a 0
manner 0
analogous 0
to 0
protein B-gene
kinase I-gene
A I-gene
. 0

These 0
cells 0
fail 0
to 0
generate 0
the 0
signals 0
to 0
phosphorylate 0
CREB B-gene
and 0
produce 0
significantly 0
less 0
of 0
the 0
cytokine 0
Interleukin B-gene
- I-gene
2 I-gene
( 0
IL B-gene
- I-gene
2 I-gene
) 0
in 0
response 0
to 0
agents 0
that 0
either 0
increase 0
intracellular 0
Ca2+ 0
and/or 0
activate 0
protein B-gene
kinase I-gene
C I-gene
. 0

Both 0
of 0
these 0
dogs 0
had 0
low 0
serum 0
IgG B-gene
( 0
3.5 0
to 0
7.2 0
mg/ml 0
) 0
and 0
the 0
second 0
littermate 0
also 0
had 0
reduced 0
serum 0
IgA B-gene
( 0
< 0
0.1 0
to 0
0.15 0
mg/ml 0
) 0
. 0

CONCLUSIONS 0
: 0
Valproate 0
appears 0
to 0
inhibit 0
the 0
glucuronidation 0
of 0
carbamazepine 0
- 0
10,11 0
- 0
trans 0
- 0
diol 0
, 0
and 0
probably 0
also 0
inhibits 0
the 0
conversion 0
of 0
carbamazepine 0
- 0
10,11 0
- 0
epoxide 0
to 0
this 0
trans 0
- 0
diol 0
derivative 0
, 0
rather 0
than 0
simply 0
inhibiting 0
the 0
latter 0
reaction 0
only 0
. 0

The 0
Ogg1 B-gene
protein I-gene
efficiently 0
cleaves 0
a 0
DNA 0
duplex 0
where 0
a 0
preformed 0
AP B-gene
site I-gene
is 0
placed 0
opposite 0
a 0
cytosine 0
( 0
AP/C 0
) 0
. 0

A 0
consensus 0
sequence 0
indicates 0
a 0
highly 0
conserved 0
lysine 0
residue 0
, 0
K120 0
of 0
endonuclease B-gene
III I-gene
or 0
K241 0
of 0
Ogg1 B-gene
, 0
respectively 0
. 0

Overall 0
, 0
these 0
findings 0
demonstrate 0
that 0
mutations 0
E768D 0
and 0
V804L 0
are 0
gain 0
- 0
of 0
- 0
function 0
mutations 0
that 0
confer 0
to 0
the 0
long B-gene
RET I-gene
isoform I-gene
the 0
capacity 0
to 0
exert 0
a 0
biological 0
effect 0
, 0
although 0
these 0
mutations 0
are 0
more 0
weakly 0
activating 0
than 0
the 0
MEN2A B-gene
and 0
MEN2B B-gene
mutations 0
. 0

Volunteers 0
were 0
irradiated 0
on 0
their 0
backs 0
with 0
suberythemal 0
UV 0
daily 0
for 0
5 0
d 0
after 0
application 0
of 0
the 0
sunscreens 0
and 0
their 0
base 0
lotion 0
to 0
different 0
sites 0
. 0

E2F B-gene
is 0
a 0
heterodimeric 0
complex 0
consisting 0
of 0
E2F B-gene
family I-gene
members I-gene
( I-gene
1 I-gene
- I-gene
5 I-gene
) I-gene
and 0
DP B-gene
proteins I-gene
( I-gene
1 I-gene
- I-gene
3 I-gene
) I-gene
. 0

EBER1 B-gene
mRNA I-gene
, 0
a 0
consistent 0
marker 0
of 0
viral 0
latency 0
, 0
was 0
positive 0
in 0
all 0
PEL 0
cases 0
, 0
although 0
at 0
lower 0
levels 0
than 0
in 0
the 0
non 0
- 0
PEL 0
controls 0
due 0
to 0
EBER1 B-gene
expression 0
by 0
only 0
a 0
variable 0
subset 0
of 0
lymphoma 0
cells 0
. 0

METHODS 0
: 0
Four 0
hundred 0
fifty 0
patients 0
with 0
the 0
diagnosis 0
of 0
squamous 0
cell 0
carcinoma 0
of 0
the 0
oral 0
cavity 0
received 0
their 0
primary 0
treatment 0
at 0
Roswell 0
Park 0
Cancer 0
Center 0
( 0
RPCI 0
) 0
from 0
1971 0
to 0
1991 0
. 0

Therefore 0
, 0
use 0
of 0
presaturation 0
is 0
recommended 0
for 0
myocardial 0
motion 0
studies 0
using 0
cine 0
PC 0
velocity 0
data 0
. 0

In 0
addition 0
, 0
the 0
DNA 0
- 0
binding 0
experiments 0
show 0
that 0
either 0
one 0
of 0
the 0
two 0
MADS B-gene
domains I-gene
of 0
a 0
dimer 0
can 0
be 0
sufficient 0
to 0
confer 0
a 0
particular 0
DNA 0
- 0
binding 0
specificity 0
to 0
the 0
complex 0
and 0
that 0
sequences 0
outside 0
the 0
amino 0
- 0
terminal 0
basic 0
region 0
of 0
the 0
MADS B-gene
domain 0
can 0
, 0
in 0
some 0
cases 0
, 0
contribute 0
to 0
the 0
DNA 0
- 0
binding 0
specificity 0
of 0
the 0
proteins 0
. 0

PURPOSE/OBJECTIVES 0
: 0
To 0
examine 0
the 0
question 0
of 0
whether 0
an 0
early 0
first 0
full 0
- 0
term 0
pregnancy 0
( 0
FFTP 0
) 0
protects 0
against 0
breast 0
cancer 0
and 0
whether 0
interruption 0
of 0
the 0
pregnancy 0
with 0
an 0
induced 0
abortion 0
increases 0
breast 0
cancer 0
risk 0
. 0

Two 0
related 0
studies 0
conducted 0
over 0
a 0
five 0
week 0
period 0
measured 0
and 0
typed 0
HLA B-gene
- I-gene
DQA1 I-gene
from 0
accumulated 0
DNA 0
on 0
autopsy 0
room 0
and 0
Forensic 0
DNA 0
Laboratory 0
structures 0
. 0

Thirty 0
- 0
two 0
rats 0
were 0
divided 0
into 0
four 0
groups 0
. 0

Mutagenesis 0
of 0
the 0
pecT B-gene
regulatory 0
region 0
revealed 0
the 0
presence 0
of 0
two 0
sites 0
in 0
which 0
insertions 0
reproduced 0
the 0
pec B-gene
- I-gene
1 I-gene
phenotype 0
. 0

BRCA1 B-gene
, 0
a 0
familial 0
breast 0
and 0
ovarian 0
cancer 0
susceptibility 0
gene 0
encodes 0
nuclear 0
phosphoproteins 0
that 0
function 0
as 0
tumor 0
suppressors 0
in 0
human 0
breast 0
cancer 0
cells 0
. 0

The 0
alternative 0
splice 0
sites 0
for 0
the 0
smallest 0
adducin B-gene
isoform 0
, 0
beta B-gene
- I-gene
3 I-gene
, 0
are 0
alternative 0
donor 0
and 0
acceptor 0
sites 0
within 0
exons 0
7 0
and 0
12 0
. 0

Proteinuria 0
in 0
a 0
young 0
man 0
. 0

Neural 0
blockade 0
in 0
chronic 0
and 0
cancer 0
pain 0
. 0

Two 0
new 0
temperature 0
- 0
sensitive 0
alleles 0
of 0
SEC3 B-gene
, 0
1 0
of 0
10 0
late 0
- 0
acting 0
SEC B-gene
genes I-gene
required 0
for 0
targeting 0
or 0
fusion 0
of 0
post 0
- 0
Golgi 0
secretory 0
vesicles 0
to 0
the 0
plasma 0
membrane 0
in 0
Saccharomyces 0
cerevisiae 0
, 0
were 0
isolated 0
in 0
a 0
screen 0
for 0
temperature 0
- 0
sensitive 0
secretory 0
mutants 0
that 0
are 0
synthetically 0
lethal 0
with 0
sec4 B-gene
- I-gene
8 I-gene
. 0

Five 0
cell 0
strains 0
of 0
human 0
dermal 0
fibroblasts 0
were 0
each 0
treated 0
with 0
three 0
samples 0
of 0
burn 0
blister 0
fluid 0
and 0
the 0
effect 0
compared 0
with 0
the 0
rate 0
of 0
contraction 0
of 0
free 0
floating 0
fibroblast 0
populated 0
collagen B-gene
lattices 0
( 0
FPCL 0
) 0
. 0

It 0
is 0
thus 0
one 0
of 0
the 0
key 0
enzymes 0
involved 0
in 0
the 0
triiodothyronine 0
- 0
mediated 0
control 0
of 0
growth 0
, 0
differentiation 0
and 0
basal 0
metabolism 0
in 0
vertebrates 0
. 0

Cell 0
49 0
, 0
753 0
- 0
761 0
] 0
. 0

Twenty 0
- 0
one 0
ELISA 0
- 0
positive 0
sera 0
were 0
tested 0
and 0
confirmed 0
positive 0
by 0
plaque 0
reduction 0
neutralization 0
testing 0
. 0

Patients 0
received 0
either 0
diltiazem 0
CD 0
180 0
mg 0
or 0
placebo 0
once/day 0
in 0
combination 0
with 0
existing 0
antianginal 0
therapy 0
. 0

Reactive 0
lymphoid 0
hyperplasia 0
was 0
found 0
in 0
15 0
cases 0
, 0
2 0
cases 0
had 0
angiofollicular 0
lymphoid 0
hyperplasia 0
or 0
Castleman 0
's 0
disease 0
, 0
atypical 0
lymphoid 0
hyperplasia 0
suggestive 0
of 0
malignant 0
lymphoma 0
was 0
observed 0
in 0
3 0
cases 0
, 0
and 0
malignant 0
lymphoma 0
was 0
diagnosed 0
in 0
the 0
remaining 0
4 0
cases 0
. 0

We 0
had 0
previously 0
analyzed 0
repair 0
rates 0
of 0
cyclobutane 0
pyrimidine 0
dimers 0
at 0
nucleotide 0
resolution 0
along 0
the 0
human B-gene
JUN I-gene
gene I-gene
in 0
normal 0
fibroblasts 0
and 0
found 0
very 0
efficient 0
repair 0
of 0
sequences 0
near 0
the 0
transcription 0
initiation 0
site 0
but 0
slow 0
repair 0
along 0
the 0
promoter 0
. 0

Tyrosine 0
1356 0
forms 0
a 0
multisubstrate 0
binding 0
site 0
for 0
the 0
Grb2 B-gene
and 0
Shc B-gene
adaptor I-gene
proteins I-gene
, 0
the 0
p85 B-gene
subunit I-gene
of 0
phosphatidylinositol B-gene
3' I-gene
- I-gene
kinase I-gene
, 0
phospholipase B-gene
Cgamma I-gene
, 0
and 0
a 0
phosphatase 0
, 0
SHP2 B-gene
. 0

Then 0
we 0
correlated 0
HRCT 0
findings 0
with 0
the 0
clinical 0
features 0
, 0
pulmonary 0
functions 0
and 0
methacholine 0
PC20 0
( 0
PC20M 0
) 0
and 0
studied 0
their 0
clinical 0
significance 0
. 0

Gtx B-gene
mRNA I-gene
accumulates 0
in 0
parallel 0
with 0
the 0
RNAs 0
encoding 0
the 0
major 0
structural 0
proteins 0
of 0
myelin 0
, 0
myelin B-gene
basic I-gene
protein I-gene
( 0
MBP B-gene
) 0
, 0
and 0
proteolipid B-gene
protein I-gene
( 0
PLP B-gene
) 0
during 0
postnatal 0
brain 0
development 0
; 0
Gtx B-gene
mRNA I-gene
decreases 0
in 0
parallel 0
with 0
MBP B-gene
and 0
PLP B-gene
mRNAs I-gene
in 0
the 0
brains 0
of 0
myelin 0
- 0
deficient 0
rats 0
, 0
which 0
have 0
a 0
point 0
mutation 0
in 0
the 0
PLP B-gene
gene I-gene
. 0

Contacts 0
between 0
Bacillus 0
subtilis 0
catabolite 0
regulatory 0
protein 0
CcpA B-gene
and 0
amyO B-gene
target 0
site 0
. 0

They 0
also 0
interact 0
with 0
GTPase B-gene
activating I-gene
proteins I-gene
encoded 0
by 0
IRA1 B-gene
and 0
IRA2 B-gene
. 0

For 0
E2 0
, 0
each 0
cat 0
was 0
given 0
either 0
5 0
( 0
group 0
[ 0
G 0
] 0
1 0
) 0
or 0
10 0
( 0
G2 0
) 0
mg 0
of 0
itraconazole/kg 0
( 0
capsules 0
) 0
twice 0
daily 0
for 0
6 0
weeks 0
. 0

RESULTS 0
: 0
For 0
E1 0
, 0
itraconazole 0
plasma 0
drug 0
concentration 0
extrapolated 0
to 0
time 0
zero 0
( 0
IV 0
dose 0
) 0
was 0
5.2 0
+/ 0
- 0
1.4 0
micrograms/ml 0
, 0
and 0
mean 0
residence 0
time 0
( 0
MRT 0
) 0
was 0
37 0
+/ 0
- 0
16 0
hours 0
. 0

The 0
human 0
U4/U6 B-gene
snRNP 0
contains 0
60 0
and 0
90kD 0
proteins 0
that 0
are 0
structurally 0
homologous 0
to 0
the 0
yeast 0
splicing 0
factors 0
U4/U6 I-gene

G B-gene
- I-gene
CSF I-gene
was 0
started 0
on 0
day 0
3 0
of 0
each 0
cycle 0
( 0
5 0
microg/kg/day 0
) 0
and 0
was 0
stopped 0
the 0
day 0
before 0
the 0
last 0
apheresis 0
or 0
when 0
absolute 0
neutrophil 0
count 0
was 0
above 0
0.5 0
x 0
10 0
( 0
9 0
) 0
/l 0
. 0

The 0
used 0
expression 0
system 0
could 0
allow 0
to 0
produce 0
mutated 0
forms 0
of 0
SsEF B-gene
- I-gene
2 I-gene
obtained 0
by 0
mutagenesis 0
of 0
the 0
corresponding 0
gene 0
. 0

Crosstalk 0
among 0
the 0
pathways 0
may 0
explain 0
how 0
some 0
forms 0
of 0
stress 0
can 0
contribute 0
to 0
the 0
development 0
of 0
a 0
malignancy 0
. 0

Supershift 0
assays 0
, 0
using 0
Jun B-gene
and I-gene
Fos I-gene
family I-gene
member I-gene
- I-gene
specific I-gene
antibodies I-gene
, 0
showed 0
that 0
protein 0
complexes 0
formed 0
by 0
AtT 0
- 0
20 0
cell 0
nuclear 0
extracts 0
bound 0
to 0
the 0
c B-gene
- I-gene
jun I-gene
AP B-gene
- I-gene
1 I-gene
site I-gene
were 0
comprised 0
of 0
Jun B-gene
family 0
members 0
, 0
JunD B-gene
, 0
JunB B-gene
, 0
and 0
cJun B-gene
. 0

The 0
majority 0
of 0
PI B-gene
kinase I-gene
activity 0
appeared 0
to 0
be 0
cbl B-gene
- 0
associated 0
after 0
PRL B-gene
stimulation 0
. 0

Mutation 0
of 0
Enh4 B-gene
, 0
an 0
essential 0
GT B-gene
- I-gene
IIC I-gene
- I-gene
like I-gene
enhanson I-gene
in 0
the 0
context 0
of 0
the 0
intact 0
enhancer 0
, 0
abolishes 0
silencer 0
activity 0
, 0
and 0
multimerized 0
GT B-gene
- I-gene
IIC I-gene
enhansons I-gene
mimic 0
the 0
intact 0
CSEn B-gene
enhancer/silencer I-gene
activities 0
in 0
BeWo 0
and 0
GC 0
cells 0
, 0
respectively 0
. 0

Using 0
lectin B-gene
- 0
affinity 0
chromatography 0
, 0
discordance 0
between 0
the 0
pattern 0
of 0
O 0
- 0
glycosylation 0
of 0
SSBP B-gene
and 0
DSBP B-gene
was 0
demonstrated 0
. 0

Deletion 0
mapping 0
experiments 0
determined 0
that 0
the 0
sequences 0
required 0
for 0
full 0
activity 0
in 0
MSC 0
- 0
1 0
cells 0
were 0
included 0
within 0
619 0
bp 0
of 0
the 0
start 0
site 0
and 0
identified 0
several 0
regions 0
that 0
demonstrated 0
increased 0
luciferase B-gene
activity 0
: 0
the 0
- 0
583 0
bp 0
to 0
- 0
564 0
bp 0
, 0
- 0
503 0
bp 0
to 0
- 0
484 0
bp 0
, 0
and 0
- 0
114 0
bp 0
to 0
- 0
65 0
regions 0
. 0

Furthermore 0
, 0
the 0
PH B-gene
and 0
PTB 0
domains 0
are 0
highly 0
homologous 0
( 0
at 0
least 0
40 0
% 0
identical 0
) 0
to 0
those 0
found 0
in 0
insulin B-gene
receptor I-gene
substrates I-gene
1 I-gene
, I-gene
2 I-gene
, I-gene
and I-gene
3 I-gene
( 0
IRS B-gene
- I-gene
1 I-gene
, 0
IRS B-gene
- I-gene
2 I-gene
, 0
and 0
IRS B-gene
- I-gene
3 I-gene
) 0
. 0

The 0
mouse 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
2 I-gene
gene I-gene
. 0

As 0
demonstrated 0
by 0
gel 0
mobility 0
shift 0
analysis 0
and 0
supershift 0
experiments 0
, 0
FIRE1 B-gene
, 0
located 0
between 0
- 0
516 0
and 0
- 0
498 0
, 0
is 0
responsible 0
for 0
binding 0
NF B-gene
- I-gene
Y I-gene
. 0

MR 0
imaging 0
of 0
traumatic 0
head 0
injuries 0
using 0
FLAIR 0
technique 0

Gag B-gene
protein 0
sequence 0
motifs 0
of 0
the 0
NC B-gene
domain I-gene
of 0
primate 0
foamy 0
viruses 0
assumed 0
to 0
be 0
involved 0
in 0
genome 0
encapsidation 0
are 0
not 0
conserved 0
in 0
FeFV 0
. 0

Induction 0
of 0
B 0
cell 0
apoptosis 0
by 0
co 0
- 0
cross 0
- 0
linking 0
CD23 B-gene
and 0
sIg B-gene
involves 0
aberrant 0
regulation 0
of 0
c B-gene
- I-gene
myc I-gene
and 0
is 0
inhibited 0
by 0
bcl B-gene
- I-gene
2 I-gene
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
: 0
Lung 0
elastance 0
( 0
EL 0
) 0
and 0
resistance 0
( 0
RL 0
) 0
were 0
calculated 0
from 0
measurements 0
of 0
airway 0
pressure 0
, 0
esophageal 0
pressure 0
, 0
and 0
airway 0
flow 0
in 0
five 0
anesthetized 0
, 0
paralyzed 0
dogs 0
during 0
sinusoidal 0
forcing 0
at 0
a 0
constant 0
mean 0
airway 0
pressure 0
of 0
10 0
cmH2O 0
in 0
a 0
wide 0
range 0
of 0
breathing 0
frequencies 0
( 0
0.2 0
to 0
1.0 0
Hz 0
in 0
intervals 0
of 0
0.2 0
) 0
and 0
tidal 0
volumes 0
( 0
50 0
, 0
100 0
, 0
200 0
, 0
and 0
to 0
300 0
mL 0
) 0
. 0

Here 0
, 0
we 0
report 0
theoretical 0
models 0
for 0
the 0
Gla 0
and 0
EGF B-gene
- I-gene
1 I-gene
modules I-gene
of 0
human B-gene
PS I-gene
constructed 0
using 0
prothrombin B-gene
and 0
factor B-gene
X I-gene
experimental 0
structures 0
. 0

The 0
Cut9 B-gene
subunit I-gene
is 0
likely 0
to 0
be 0
a 0
target 0
for 0
regulating 0
APC/ B-gene
cyclosome I-gene
function 0
through 0
protein 0
- 0
protein 0
interactions 0
and 0
phosphorylation 0
. 0

The 0
dose 0
was 0
50 0
Gy/20 0
fractions/5 0
weeks 0
. 0

Because 0
the 0
biosynthetic 0
pathway 0
to 0
the 0
vacuole 0
intersects 0
with 0
the 0
endocytic 0
pathway 0
, 0
internalization 0
of 0
a 0
bulk 0
membrane 0
endocytic 0
marker 0
FM 0
4 0
- 0
64 0
was 0
assayed 0
in 0
the 0
sop B-gene
mutants I-gene
. 0

All 0
the 0
women 0
received 0
13.5 0
mg 0
plain 0
bupivacaine 0
via 0
subarachnoid 0
injection 0
at 0
the 0
L2 0
- 0
3 0
interspace 0
. 0

Far 0
from 0
this 0
being 0
the 0
case 0
, 0
however 0
, 0
the 0
measurement 0
of 0
apo B-gene
B I-gene
has 0
met 0
every 0
reasonable 0
standard 0
of 0
laboratory 0
precision 0
and 0
reliability 0
to 0
allow 0
its 0
widespread 0
introduction 0
in 0
clinical 0
laboratories 0
. 0

Two 0
soybean 0
cDNA 0
clones 0
, 0
SPK B-gene
- I-gene
3 I-gene
and 0
SPK B-gene
- I-gene
4 I-gene
, 0
encoding 0
putative 0
protein 0
kinases 0
were 0
isolated 0
and 0
characterized 0
. 0

Genes 0
belonging 0
to 0
the 0
ras B-gene
superfamily I-gene
encode 0
low B-gene
- I-gene
molecular I-gene
- I-gene
weight I-gene
GTP/GDP I-gene
- I-gene
binding I-gene
proteins I-gene
that 0
are 0
highly 0
conserved 0
in 0
wide 0
variety 0
of 0
organisms 0
. 0

Naltrexone 0
has 0
been 0
recently 0
approved 0
by 0
the 0
Food 0
and 0
Drug 0
Administration 0
for 0
the 0
treatment 0
of 0
alcohol 0
dependence 0
. 0

Ent B-gene
- I-gene
kaurene I-gene
synthase I-gene
from I-gene
the I-gene
fungus I-gene
Phaeosphaeria I-gene
sp 0
. 0

In 0
this 0
report 0
, 0
we 0
identify 0
and 0
characterize 0
two 0
overlapping 0
ELL B-gene
functional I-gene
domains I-gene
that 0
govern 0
its 0
interaction 0
with 0
RNA B-gene
polymerase I-gene
II I-gene
and 0
the 0
ternary 0
elongation 0
complex 0
. 0

Eight 0
induced 0
cDNA 0
sequences 0
were 0
identified 0
and 0
designated 0
message B-gene
up I-gene
- I-gene
regulated I-gene
during I-gene
death I-gene
( B-gene
mud I-gene
) I-gene
- I-gene
1 I-gene
- I-gene
8 I-gene
. 0

The 0
position 0
, 0
transcription 0
orientation 0
, 0
and 0
imprinted 0
status 0
of 0
the 0
genes 0
immediately 0
flanking 0
Igf2r B-gene
have 0
been 0
assessed 0
. 0

Here 0
, 0
we 0
describe 0
directional 0
chromosome 0
walking 0
studies 0
starting 0
from 0
D8S260 B-gene
as 0
well 0
as 0
D8S285 B-gene
. 0

We 0
describe 0
a 0
novel 0
zinc B-gene
finger I-gene
protein I-gene
, 0
dsRBP B-gene
- I-gene
ZFa I-gene
, 0
isolated 0
by 0
screening 0
an 0
expression 0
library 0
with 0
dsRNA 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
retroplasmid 0
reverse B-gene
transcriptase I-gene
is 0
uniquely 0
adapted 0
to 0
initiate 0
cDNA 0
synthesis 0
by 0
recognizing 0
a 0
3 0
' 0
CCA 0
sequence 0
. 0

Nasal 0
absorption 0
was 0
rapid 0
, 0
nasal 0
bioavailability 0
was 0
43 0
% 0
, 0
and 0
the 0
iv 0
and 0
nasal 0
elimination 0
profiles 0
were 0
similar 0
. 0

Together 0
, 0
these 0
results 0
suggest 0
that 0
EGF/Ras/Raf B-gene
induces 0
transcription 0
via 0
combined 0
activation 0
of 0
EGF/Ras/Raf I-gene

Together 0
, 0
these 0
data 0
support 0
a 0
model 0
in 0
which 0
Tax B-gene
anchors 0
CBP B-gene
to 0
the 0
HTLV B-gene
- I-gene
1 I-gene
promoter I-gene
, 0
with 0
strong 0
transcriptional 0
activation 0
resulting 0
from 0
the 0
CBP B-gene
- 0
associated 0
activities 0
of 0
nucleosome 0
remodeling 0
and 0
recruitment 0
of 0
the 0
general 0
transcription 0
machinery 0
. 0

DNase B-gene
I I-gene
and 0
1,10 0
- 0
phenanthroline 0
- 0
copper 0
footprinting 0
of 0
MURA B-gene
- 0
Mu1 B-gene
TIR 0
complexes 0
indicate 0
that 0
MURA B-gene
binds 0
to 0
a 0
conserved 0
approximately 0
32 0
- 0
bp 0
region 0
in 0
the 0
TIR 0
of 0
Mu1 B-gene
. 0

Consistent 0
with 0
this 0
model 0
, 0
a 0
synthetic 0
construct 0
containing 0
three 0
tandem 0
copies 0
of 0
the 0
native 0
LDL B-gene
receptor I-gene
SREBP B-gene
site 0
linked 0
to 0
a 0
single 0
Sp1 B-gene
site I-gene
was 0
also 0
significantly 0
activated 0
in 0
a 0
buttonhead B-gene
- 0
independent 0
fashion 0
. 0

Various 0
assays 0
demonstrate 0
promoter 0
activity 0
in 0
this 0
sequence 0
that 0
reproduces 0
the 0
normal 0
control 0
of 0
E2F2 B-gene
expression 0
during 0
a 0
growth 0
stimulation 0
. 0

In 0
the 0
adult 0
mouse 0
, 0
ERR B-gene
alpha I-gene
is 0
most 0
highly 0
expressed 0
in 0
kidney 0
, 0
heart 0
, 0
and 0
brown 0
adipocytes 0
, 0
tissues 0
which 0
preferentially 0
metabolize 0
fatty 0
acids 0
. 0

The 0
MCAD B-gene
nuclear I-gene
receptor I-gene
response I-gene
element I-gene
1 I-gene
( 0
NRRE B-gene
- I-gene
1 I-gene
) 0
interacts 0
in 0
vitro 0
with 0
ERR B-gene
alpha I-gene
expressed 0
in 0
COS 0
- 0
7 0
cells 0
. 0

Mapping 0
features 0
of 0
HIV B-gene
- I-gene
1 I-gene
integrase I-gene
near 0
selected 0
sites 0
on 0
viral 0
and 0
target 0
DNA 0
molecules 0
in 0
an 0
active 0
enzyme 0
- 0
DNA 0
complex 0
by 0
photo 0
- 0
cross 0
- 0
linking 0
. 0

Analysis 0
of 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
gene 0
also 0
revealed 0
the 0
presence 0
of 0
multiple 0
TATA 0
and 0
CAAT 0
sequences 0
. 0

Analysis 0
of 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
gene 0
also 0
revealed 0
the 0
presence 0
of 0
multiple 0
TATA 0
and 0
CAAT 0
sequences 0
. 0

The 0
complete 0
response 0
( 0
CR 0
) 0
rate 0
was 0
34 0
% 0
in 0
the 0
CODE 0
with 0
rhG B-gene
- I-gene
CSF I-gene
group 0
and 0
23 0
% 0
in 0
the 0
CODE 0
alone 0
group 0
; 0
the 0
median 0
survival 0
was 0
59 0
and 0
32 0
weeks 0
, 0
respectively 0
, 0
in 0
these 0
groups 0
( 0
P 0
= 0
0.004 0
) 0
. 0

Heterogeneous B-gene
nuclear I-gene
ribonucleoprotein I-gene
A1 I-gene
binds 0
to 0
the 0
transcription 0
- 0
regulatory 0
region 0
of 0
mouse 0
hepatitis 0
virus 0
RNA 0
. 0

The 0
m7GpppN 0
cap 0
structure 0
of 0
eukaryotic 0
mRNA 0
is 0
formed 0
cotranscriptionally 0
by 0
the 0
sequential 0
action 0
of 0
three 0
enzymes 0
: 0
RNA B-gene
triphosphatase I-gene
, 0
RNA B-gene
guanylyltransferase I-gene
, 0
and 0
RNA B-gene
( I-gene
guanine I-gene
- I-gene
7 I-gene
) I-gene
- I-gene
methyltransferase I-gene
. 0

In 0
the 0
first 0
part 0
of 0
our 0
study 0
, 0
the 0
highest 0
mutagenicity 0
was 0
revealed 0
by 0
TA98 0
strain 0
without 0
enzymatic 0
activation 0
, 0
suggesting 0
a 0
direct 0
- 0
acting 0
mutagenicity 0
prevalence 0
in 0
diesel 0
particulate 0
. 0

The 0
addition 0
of 0
culture 0
to 0
the 0
CC 0
and 0
CC 0
: 0
SW 0
by 0
- 0
products 0
resulted 0
in 0
pH 0
values 0
lower 0
( 0
P 0
< 0
0.05 0
) 0
than 0
those 0
without 0
culture 0
on 0
Day 0
21 0
, 0
and 0
the 0
15 0
% 0
carbohydrate 0
treatment 0
significantly 0
reduced 0
pH 0
beyond 0
the 0
5 0
% 0
carbohydrate 0
. 0

Myocardial 0
interstitial 0
edema 0
is 0
more 0
likely 0
a 0
potential 0
mechanism 0
of 0
diastolic 0
dysfunction 0
after 0
DC 0
shocks 0
. 0

Two 0
experiments 0
( 0
N 0
= 0
20 0
each 0
) 0
were 0
carried 0
out 0
to 0
explore 0
the 0
nature 0
of 0
ERP 0
negativities 0
in 0
a 0
visuospatial 0
memory 0
task 0
and 0
in 0
an 0
auditory 0
spatial 0
memory 0
task 0
, 0
respectively 0
. 0

Biol 0
. 0

The 0
pattern 0
and 0
timing 0
of 0
CARP B-gene
mRNA I-gene
expression 0
, 0
including 0
transient 0
expression 0
in 0
the 0
tongue 0
at 0
14.5 0
days 0
p.c. 0
, 0
coincides 0
with 0
that 0
of 0
Nkx2.5/Csx B-gene
( 0
a 0
putative 0
homolog 0
of 0
Nkx2.5/Csx I-gene

Overexpression 0
of 0
CARP B-gene
in 0
cardiomyocytes 0
suppresses 0
cardiac B-gene
troponin I-gene
C I-gene
and 0
atrial B-gene
natriuretic I-gene
factor I-gene
transcription 0
. 0

Substrate 0
specificity 0
of 0
the 0
RNase B-gene
activity 0
of 0
yeast B-gene
RNA I-gene
polymerase I-gene
III I-gene
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
and 0
competition 0
experiments 0
showed 0
that 0
site 0
A 0
is 0
recognized 0
by 0
an 0
NF1 B-gene
protein I-gene
. 0

Examination 0
of 0
the 0
MMP B-gene
- I-gene
2 I-gene
RE1 I-gene
sequence I-gene
revealed 0
an 0
incomplete 0
Y 0
- 0
box 0
sequence 0
( 0
CTGCTGGGCAAG 0
) 0
, 0
which 0
specifically 0
interacted 0
with 0
recombinant B-gene
YB I-gene
- I-gene
1 I-gene
on 0
DMS 0
protection 0
footprinting 0
analysis 0
. 0

Hence 0
, 0
scs32 B-gene
only 0
partially 0
suppressed 0
the 0
ts 0
phenotype 0
and 0
was 0
unable 0
to 0
suppress 0
the 0
Ino 0
- 0
phenotype 0
of 0
rpo26 B-gene
- I-gene
31 I-gene
. 0

In 0
contrast 0
, 0
both 0
Sp1 B-gene
and 0
ETS B-gene
proteins I-gene
are 0
required 0
to 0
bring 0
about 0
full 0
promoter 0
activity 0
in 0
the 0
Surf B-gene
- I-gene
1 I-gene
direction 0
. 0

CONCLUSION 0
: 0
Patients 0
wit 0
clinically 0
palpable 0
neck 0
disease 0
( 0
N1 0
- 0
3 0
) 0
, 0
histological 0
evidence 0
of 0
metastatic 0
nodal 0
disease 0
, 0
extracapsular 0
spread 0
, 0
and 0
three 0
or 0
more 0
positive 0
lymph 0
nodes 0
are 0
at 0
greater 0
risk 0
of 0
developing 0
failure 0
at 0
distant 0
sites 0
. 0

We 0
have 0
subcloned 0
into 0
pBR322 0
deoxyribonucleic 0
acid 0
( 0
DNA 0
) 0
sequences 0
mapping 0
either 0
in 0
the 0
coding 0
region 0
, 0
the 0
5 0
' 0
spacer 0
, 0
or 0
the 0
3 0
' 0
spacer 0
of 0
the 0
H2B B-gene
histone I-gene
gene I-gene
. 0

4 0
. 0

Area 0
under 0
the 0
drug 0
concentration 0
- 0
time 0
curves 0
( 0
AUC0 0
- 0
24 0
hr 0
) 0
for 0
MTX 0
were 0
2379 0
and 0
3534 0
ng*hr/ml 0
from 0
PG 0
- 0
2.5 0
% 0
Azone 0
and 0
PG 0
- 0
7.5 0
% 0
Azone 0
systems 0
respectively 0
. 0

The 0
combination 0
of 0
hydralazine 0
hydrochloride 0
and 0
isosorbide 0
dinitrate 0
also 0
improves 0
survival 0
, 0
but 0
direct 0
comparison 0
of 0
both 0
regimens 0
provided 0
evidence 0
for 0
a 0
less 0
favourable 0
effect 0
than 0
that 0
of 0
the 0
ACE B-gene
inhibitors 0
. 0

To 0
address 0
mechanisms 0
that 0
define 0
interactions 0
of 0
Site B-gene
II I-gene
regulatory I-gene
factors I-gene
with 0
this 0
cell 0
cycle 0
control 0
element 0
, 0
we 0
have 0
investigated 0
these 0
determinants 0
of 0
transcriptional 0
regulation 0
at 0
the 0
G1/S 0
phase 0
transition 0
in 0
FDC 0
- 0
P1 0
hematopoietic 0
progenitor 0
cells 0
. 0

The 0
goal 0
of 0
this 0
study 0
was 0
to 0
identify 0
neuronal 0
cell 0
cultures 0
that 0
express 0
RC3/neurogranin B-gene
, 0
to 0
check 0
whether 0
they 0
are 0
sensitive 0
to 0
T3 0
, 0
and 0
to 0
examine 0
the 0
mechanism 0
of 0
regulation 0
. 0

There 0
were 0
differences 0
between 0
males 0
( 0
p 0
< 0
0.05 0
) 0
for 0
most 0
of 0
the 0
characteristics 0
studied 0
. 0

Their 0
circadian 0
responses 0
to 0
both 0
photic 0
and 0
non 0
- 0
photic 0
cues 0
were 0
then 0
tested 0
. 0

Although 0
previous 0
data 0
have 0
suggested 0
that 0
Rev B-gene
uses 0
the 0
same 0
export 0
pathway 0
as 0
uracil 0
- 0
rich 0
small 0
nuclear 0
RNAs 0
and 0
5S B-gene
ribosomal I-gene
RNA I-gene
, 0
the 0
CTE 0
seems 0
to 0
interact 0
with 0
evolutionarily 0
conserved 0
factors 0
that 0
are 0
essential 0
for 0
cellular 0
mRNA 0
export 0
. 0

Human B-gene
Duo I-gene
contains 0
a 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
( 0
GEF B-gene
) 0
domain 0
that 0
is 0
likely 0
to 0
be 0
rac1 B-gene
- 0
specific 0
, 0
a 0
pleckstrin B-gene
homology I-gene
( 0
PH B-gene
) 0
domain 0
and 0
spectrin B-gene
- I-gene
like I-gene
repeat I-gene
units I-gene
. 0

S2F B-gene
, 0
a 0
leaf 0
- 0
specific 0
trans 0
- 0
acting 0
factor 0
, 0
binds 0
to 0
a 0
novel 0
cis 0
- 0
acting 0
element 0
and 0
differentially 0
activates 0
the 0
RPL21 B-gene
gene I-gene
. 0

ArgR B-gene
was 0
shown 0
to 0
be 0
a 0
dimer 0
of 0
two 0
equal 0
subunits 0
, 0
each 0
with 0
a 0
molecular 0
mass 0
of 0
37,000 0
Da 0
. 0

Plasma B-gene
leptin I-gene
concentrations 0
were 0
higher 0
in 0
women 0
than 0
men 0
, 0
even 0
after 0
the 0
adjustment 0
for 0
differences 0
in 0
fat 0
mass 0
( 0
28 0
+/ 0
- 0
3 0
ng/ml 0
for 0
women 0
vs 0
. 0

Consistent 0
with 0
effects 0
on 0
STAT B-gene
activation 0
, 0
altered 0
SHP B-gene
- I-gene
1 I-gene
expression 0
also 0
affected 0
EGF B-gene
- 0
induced 0
activation 0
of 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
pathway 0
; 0
expression 0
of 0
SHP B-gene
- I-gene
1 I-gene
- I-gene
( I-gene
Cys I-gene
- I-gene
- I-gene
> I-gene
Ser I-gene
) I-gene
inhibited 0
activity 0
of 0
MEK B-gene
by 0
approximately 0
25 0
% 0
, 0
whereas 0
expression 0
of 0
SHP B-gene
- I-gene
1 I-gene
resulted 0
in 0
a 0
approximately 0
25 0
% 0
increase 0
. 0

This 0
interaction 0
involved 0
the 0
SH3 B-gene
region I-gene
of 0
p50 B-gene
( 0
csk B-gene
) 0
and 0
a 0
proline 0
- 0
rich 0
region 0
( 0
PPPLPERTPESFVLADM 0
) 0
outside 0
the 0
catalytic 0
region 0
of 0
PTP B-gene
- 0
PEST 0
. 0

Following 0
2.5 0
Gy 0
, 0
HbO2 B-gene
changes 0
were 0
minimal 0
. 0

Polarised 0
expression 0
of 0
human 0
intestinal 0
N B-gene
- I-gene
benzoyl I-gene
- I-gene
L I-gene
- I-gene
tyrosyl I-gene
- I-gene
p I-gene
- I-gene
aminobenzoic I-gene
acid I-gene
hydrolase I-gene
( 0
human B-gene
meprin I-gene
) 0
alpha 0
and 0
beta 0
subunits 0
in 0
Madin 0
- 0
Darby 0
canine 0
kidney 0
cells 0
. 0

Neither 0
mutant 0
exhibited 0
derepression 0
of 0
the 0
silent B-gene
mating I-gene
type I-gene
loci I-gene
. 0

Among 0
38 0
patients 0
with 0
inducible 0
reentrant 0
VTs 0
who 0
underwent 0
electrophysiologic 0
study 0
( 0
EPS 0
) 0
, 0
10 0
VTs 0
of 0
six 0
patients 0
were 0
selected 0
. 0

The 0
cycle 0
length 0
of 0
induced 0
VT 0
( 0
n 0
= 0
10 0
VTs 0
) 0
was 0
380 0
+/ 0
- 0
41 0
msec 0
. 0

Transient 0
hyperammonaemia 0
in 0
an 0
adult 0
German 0
shepherd 0
dog 0
. 0

We 0
established 0
that 0
the 0
2.6 0
kb 0
mRNA 0
V 0
- 0
1 0
and 0
the 0
2.3 0
kb 0
GGT B-gene
mRNA 0
V 0
- 0
2 0
derive 0
, 0
by 0
alternate 0
splicing 0
, 0
from 0
a 0
primary 0
transcript 0
initiated 0
on 0
a 0
distal 0
promoter 0
on 0
the 0
rat B-gene
GGT I-gene
gene I-gene
. 0

A 0
specific 0
distal 0
promoter 0
controls 0
gamma B-gene
- I-gene
glutamyl I-gene
transpeptidase I-gene
gene I-gene
expression 0
in 0
undifferentiated 0
rat 0
transformed 0
liver 0
cells 0
. 0

These 0
repressor 0
sites 0
are 0
pyrimidine 0
rich 0
and 0
bind 0
avidly 0
to 0
the 0
polypyrimidine B-gene
tract I-gene
binding I-gene
protein I-gene
( 0
PTB B-gene
) 0
in 0
HeLa 0
nuclear 0
extracts 0
as 0
determined 0
by 0
UV 0
crosslinking/competition 0
assays 0
. 0

For 0
higher 0
expression 0
of 0
lipA B-gene
in 0
S. 0
lividans 0
, 0
the 0
gene 0
was 0
cloned 0
next 0
to 0
the 0
strong 0
aphII B-gene
promoter I-gene
. 0

Within 0
a 0
135 0
- 0
bp 0
core 0
homology 0
region 0
, 0
the 0
human B-gene
HS12 I-gene
enhancers I-gene
are 0
approximately 0
90 0
% 0
identical 0
to 0
the 0
murine 0
homolog 0
and 0
include 0
several 0
motifs 0
previously 0
demonstrated 0
to 0
be 0
important 0
for 0
function 0
of 0
the 0
murine 0
enhancer 0
; 0
additional 0
segments 0
of 0
high 0
sequence 0
conservation 0
suggest 0
the 0
possibility 0
of 0
previously 0
unrecognized 0
functional 0
motifs 0
. 0

In 0
contrast 0
to 0
the 0
wild 0
- 0
type 0
protein 0
, 0
expression 0
of 0
p45 B-gene
NF B-gene
- I-gene
E2 I-gene
lacking 0
this 0
activation 0
domain 0
in 0
an 0
NF B-gene
- I-gene
E2 I-gene
null 0
cell 0
line 0
fails 0
to 0
support 0
enhancer 0
- 0
dependent 0
transcription 0
in 0
transient 0
assays 0
. 0

These 0
findings 0
suggest 0
one 0
potential 0
mechanism 0
for 0
direct 0
recruitment 0
of 0
distal 0
regulatory 0
regions 0
of 0
the 0
globin B-gene
loci I-gene
to 0
the 0
individual 0
promoters 0
. 0

The 0
promoter 0
region 0
showed 0
no 0
consensus 0
TATA 0
box 0
but 0
it 0
contains 0
CCAAT 0
and 0
CreA B-gene
boxes 0
known 0
to 0
be 0
involved 0
in 0
both 0
stress 0
and 0
carbon 0
- 0
catabolite 0
regulation 0
of 0
fungal 0
promoters 0
. 0

The 0
two 0
cysteine 0
residues 0
located 0
in 0
this 0
additional 0
region 0
may 0
be 0
involved 0
in 0
the 0
formation 0
of 0
a 0
disulfide 0
bridge 0
associated 0
with 0
the 0
activation 0
process 0
of 0
the 0
catalytic 0
activity 0
. 0

The 0
por B-gene
gene I-gene
has 0
been 0
expressed 0
, 0
for 0
the 0
first 0
time 0
, 0
in 0
anaerobically 0
grown 0
Escherichia 0
coli 0
behind 0
the 0
isopropyl 0
- 0
beta 0
- 0
D 0
- 0
thiogalactopyranoside 0
- 0
inducible 0
tac B-gene
promoter I-gene
, 0
resulting 0
in 0
the 0
production 0
of 0
POR B-gene
in 0
its 0
active 0
form 0
. 0

When 0
the 0
downstream 0
operator 0
was 0
altered 0
, 0
there 0
was 0
a 0
fourfold 0
reduction 0
in 0
reporter 0
enzyme 0
levels 0
. 0

The 0
ORF3 0
mutant 0
produced 0
reduced 0
levels 0
of 0
tabtoxin B-gene
, 0
indicating 0
that 0
ORF3 0
may 0
have 0
a 0
role 0
in 0
T B-gene
beta I-gene
L I-gene
biosynthesis 0
. 0

Refined 0
Cox 0
models 0
using 0
a 0
CD4 B-gene
count 0
of 0
150/microL 0
rather 0
than 0
200/microL 0
to 0
distinguish 0
I0 0
and 0
I1 0
yielded 0
a 0
simplified 0
model 0
with 0
better 0
fit 0
to 0
the 0
observed 0
data 0
. 0

However 0
, 0
the 0
published 0
reports 0
consist 0
of 0
a 0
small 0
number 0
of 0
patients 0
and 0
limited 0
data 0
. 0

These 0
transcripts 0
contain 0
the 0
5 0
' 0
ends 0
of 0
mature 0
UbCRBP B-gene
mRNAs I-gene
; 0
extend 0
through 0
UbCRBP B-gene
, 0
across 0
the 0
intergenic 0
region 0
, 0
and 0
a 0
significant 0
distance 0
3 0
' 0
into 0
the 0
enolase B-gene
gene I-gene
. 0

The 0
distribution 0
of 0
cryptosporidia 0
in 0
the 0
intestine 0
and 0
number 0
of 0
cryptosporidia 0
per 0
ileal 0
villus 0
on 0
different 0
DPI 0
were 0
also 0
estimated 0
for 0
detailed 0
characterization 0
of 0
the 0
infection 0
in 0
kids 0
as 0
a 0
model 0
for 0
experimental 0
cryptosporidiosis 0
. 0

As 0
a 0
result 0
, 0
the 0
subendocardial/subepicardial 0
blood 0
flow 0
ratio 0
( 0
ENDO/EPI 0
) 0
increased 0
from 0
0.44 0
+/ 0
- 0
0.09 0
during 0
control 0
stenosis 0
to 0
0.85 0
+/ 0
- 0
0.13 0
after 0
ITF 0
1129 0
( 0
10 0
micrograms/kg/min 0
i.v 0
. 0
) 0
and 0
to 0
0.81 0
+/ 0
- 0
0.12 0
after 0
NTG 0
. 0

Proteasomes 0
are 0
the 0
multisubunit 0
protease 0
involved 0
in 0
the 0
generation 0
of 0
peptides 0
presented 0
by 0
MHC B-gene
class I-gene
I I-gene
molecules I-gene
. 0

In 0
support 0
of 0
this 0
interpretation 0
we 0
demonstrate 0
that 0
MQ9b B-gene
binds 0
strongly 0
5 0
of 0
17 0
motif 0
- 0
positive 0
, 0
pathogen 0
- 0
derived 0
synthetic 0
peptides 0
. 0

Takahashi 0
, 0
H 0
. 0

For 0
sputum B-gene
interleukin I-gene
- I-gene
8 I-gene
there 0
was 0
an 0
estimated 0
true 0
treatment 0
median 0
difference 0
of 0
142 0
pg/ml 0
( 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
8 0
to 0
2866 0
pg/ml 0
) 0
in 0
favour 0
of 0
placebo 0
; 0
while 0
for 0
maximal 0
expiratory 0
flow 0
at 0
25 0
% 0
( 0
MEF25 0
% 0
) 0
remaining 0
forced 0
vital 0
capacity 0
predicted 0
for 0
sex 0
and 0
height 0
there 0
was 0
a 0
15 0
percentage 0
points 0
( 0
pp 0
) 0
( 0
95 0
% 0
CI 0
4 0
to 0
26 0
pp 0
) 0
mean 0
treatment 0
difference 0
in 0
favour 0
of 0
placebo 0
. 0

However 0
, 0
although 0
deletion 0
of 0
Fp1 B-gene
in 0
the 0
hCRBP1 B-gene
gene I-gene
yielded 0
increased 0
CAT B-gene
activity 0
, 0
pointing 0
toward 0
a 0
negative 0
regulatory 0
function 0
exerted 0
by 0
this 0
element 0
, 0
its 0
insertion 0
upstream 0
of 0
the 0
p12 B-gene
basal I-gene
promoter I-gene
results 0
in 0
an 0
impressive 0
positive 0
stimulation 0
of 0
CAT B-gene
gene I-gene
expression 0
. 0

Gaucher 0
's 0
disease 0
is 0
a 0
rare 0
metabolic 0
disorder 0
characterized 0
by 0
the 0
lack 0
of 0
beta B-gene
- I-gene
glucocerebrosidase I-gene
enzyme I-gene
. 0

These 0
discoloration 0
's 0
can 0
be 0
treated 0
in 0
several 0
ways 0
but 0
up 0
to 0
lately 0
tooth 0
structure 0
had 0
to 0
be 0
removed 0
in 0
an 0
irreversible 0
manner 0
in 0
order 0
to 0
provide 0
sufficient 0
bulk 0
for 0
the 0
new 0
restorative 0
material 0
. 0

The 0
9 0
; 0
22 0
chromosomal 0
translocation 0
characteristic 0
of 0
CML 0
results 0
in 0
a 0
fused 0
bcr/abl B-gene
gene 0
and 0
an 0
abnormal 0
fusion 0
protein 0
, 0
bcr/abl I-gene

Overexpression 0
of 0
BAG B-gene
- I-gene
1 I-gene
also 0
protected 0
certain 0
cell 0
lines 0
from 0
heat 0
shock 0
- 0
induced 0
cell 0
death 0
. 0

The 0
5 0
' 0
flanking 0
region 0
contains 0
potential 0
binding 0
sites 0
for 0
TATA B-gene
- I-gene
binding I-gene
protein I-gene
, 0
Sp1 B-gene
, 0
nuclear B-gene
factor I-gene
1 I-gene
( 0
NF1 B-gene
) 0
, 0
CAAT B-gene
- I-gene
box I-gene
binding I-gene
protein I-gene
( 0
C/EBP B-gene
) 0
, 0
hepatocyte B-gene
nuclear I-gene
factors I-gene
1 I-gene
and I-gene
5 I-gene
( 0
HNF1 B-gene
, 0
HNF5 B-gene
) 0
and 0
activator B-gene
proteins I-gene
1 I-gene
and I-gene
2 I-gene
( 0
AP1 B-gene
, 0
AP2 B-gene
) 0
. 0

The 0
recognition 0
specificity 0
of 0
the 0
p55 B-gene
PDZ B-gene
domain I-gene
appears 0
to 0
be 0
unique 0
, 0
since 0
the 0
three 0
PDZ B-gene
domains I-gene
of 0
hDlg B-gene
( 0
human 0
lymphocyte 0
homologue 0
of 0
the 0
Drosophila B-gene
discs I-gene
large I-gene
tumor I-gene
suppressor I-gene
) 0
do 0
not 0
bind 0
the 0
cytoplasmic 0
domain 0
of 0
glycophorin B-gene
C I-gene
. 0

By 0
analyzing 0
the 0
RanGAP B-gene
activity 0
of 0
a 0
series 0
of 0
recombinantly 0
expressed 0
rna1p B-gene
mutant I-gene
derivatives 0
, 0
we 0
show 0
that 0
the 0
highly 0
acidic 0
sequence 0
in 0
the 0
C 0
- 0
terminal 0
domain 0
of 0
both 0
yeast 0
proteins 0
is 0
indispensable 0
for 0
activating 0
Ran B-gene
- 0
mediated 0
GTP 0
hydrolysis 0
. 0

In 0
the 0
absence 0
of 0
MHC B-gene
class I-gene
II I-gene
, 0
purified B-gene
soluble I-gene
D10 I-gene
TCR I-gene
bound 0
to 0
Staphylococcus B-gene
aureus I-gene
enterotoxin I-gene
C2 I-gene
with 0
an 0
association 0
rate 0
of 0
1.69+/ 0
- 0
0.12 0
x 0
10 0
( 0
4 0
) 0
M 0
( 0
- 0
1 0
) 0
sec 0
( 0
- 0
1 0
) 0
and 0
a 0
dissociation 0
rate 0
of 0
1.9+/ 0
- 0
0.47 0
x 0
10 0
( 0
- 0
2 0
) 0
sec 0
( 0
- 0
1 0
) 0
, 0
giving 0
a 0
dissociation 0
constant 0
of 0
1.1 0
microM 0
. 0

Evidence 0
for 0
such 0
peak 0
shifts 0
has 0
been 0
found 0
in 0
the 0
responses 0
of 0
auditory 0
nerve 0
fibers 0
, 0
cochlear 0
microphonics 0
, 0
and 0
the 0
responses 0
of 0
outer 0
hair 0
cells 0
and 0
supporting 0
cells 0
in 0
the 0
cochlea 0
, 0
as 0
well 0
as 0
in 0
basilar 0
membrane 0
vibration 0
measurements 0
, 0
and 0
indirectly 0
, 0
in 0
psychophysical 0
data 0
. 0

Mnt B-gene
: 0
Max B-gene
complexes 0
also 0
efficiently 0
suppress 0
Myc B-gene
- 0
dependent 0
activation 0
from 0
the 0
same 0
promoter 0
. 0

In 0
the 0
United 0
States 0
high 0
- 0
MW 0
HES 0
480 0
which 0
is 0
difficult 0
to 0
degrade 0
is 0
most 0
frequently 0
used 0
and 0
results 0
in 0
a 0
larger 0
in 0
vivo 0
MW 0
and 0
subsequent 0
decrease 0
in 0
factor B-gene
VIII/von I-gene
VIII/von I-gene
Willebrand I-gene
factor I-gene
levels 0
. 0

Assays 0
of 0
total 0
cholesterol 0
as 0
well 0
as 0
the 0
HDL B-gene
, 0
HDL2 B-gene
, 0
LDL B-gene
, 0
triglycerides 0
, 0
endothelin B-gene
- I-gene
1 I-gene
, 0
lipoprotein B-gene
( I-gene
a I-gene
) I-gene
, 0
estradiol 0
and 0
FSH B-gene
were 0
also 0
obtained 0
at 0
baseline 0
before 0
receiving 0
ERT 0
and 0
after 0
3 0
months 0
of 0
ERT 0
. 0

Six 0
tandem 0
repeats 0
of 0
the 0
P B-gene
element I-gene
linked 0
to 0
the 0
SV40 B-gene
promoter I-gene
responded 0
to 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
, 0
while 0
that 0
of 0
other 0
elements 0
did 0
not 0
. 0

The 0
distributed 0
current 0
density 0
J 0
is 0
calculated 0
within 0
the 0
volume 0
defined 0
by 0
the 0
motor 0
unit 0
. 0

The 0
cleavage 0
dipeptides 0
of 0
C1YVV B-gene
NIa I-gene
protease I-gene
are 0
Q 0
( 0
E 0
) 0
/S 0
( 0
A 0
, 0
G 0
) 0
. 0

In 0
our 0
previous 0
studies 0
, 0
transcriptional 0
activation 0
was 0
shown 0
to 0
correlate 0
with 0
IEP86 B-gene
binding 0
to 0
both 0
the 0
TATA B-gene
- I-gene
box I-gene
binding I-gene
protein I-gene
( 0
TBP B-gene
) 0
and 0
the 0
transcription 0
factor 0
bound 0
upstream 0
. 0

However 0
, 0
we 0
were 0
unable 0
to 0
identify 0
a 0
p4 B-gene
molecule 0
. 0

( 0
iv 0
) 0
The 0
accumulation 0
of 0
cyclin B-gene
D3 I-gene
protein I-gene
in 0
Vero 0
cells 0
infected 0
with 0
an 0
alpha0 B-gene
deletion I-gene
mutant I-gene
was 0
reduced 0
relative 0
to 0
that 0
of 0
cells 0
infected 0
with 0
wild 0
- 0
type 0
virus 0
or 0
a 0
recombinant 0
virus 0
in 0
which 0
the 0
deleted 0
alpha0 B-gene
sequences I-gene
were 0
restored 0
. 0

We 0
report 0
the 0
preliminary 0
biochemical 0
characterization 0
of 0
the 0
T B-gene
antigens I-gene
encoded 0
by 0
three 0
SV40 0
mutants 0
, 0
5030 0
, 0
5031 0
, 0
and 0
5061 0
, 0
each 0
of 0
which 0
have 0
altered 0
residues 0
within 0
or 0
near 0
the 0
ATP 0
binding 0
pocket 0
. 0

These 0
effects 0
were 0
abrogated 0
by 0
co 0
- 0
expression 0
of 0
kinase B-gene
- I-gene
deficient I-gene
PKC I-gene
zeta I-gene
and 0
inhibition 0
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
p85alpha B-gene
- 0
p110 B-gene
by 0
wortmannin 0
, 0
LY294002 0
and 0
a 0
dominant 0
- 0
negative 0
mutant 0
of 0
p85alpha B-gene
. 0

Protein B-gene
phosphatase I-gene
2A I-gene
is 0
a 0
critical 0
regulator 0
of 0
protein B-gene
kinase I-gene
C I-gene
zeta I-gene
signaling 0
targeted 0
by 0
SV40 B-gene
small I-gene
t I-gene
to 0
promote 0
cell 0
growth 0
and 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
. 0

Interestingly 0
, 0
the 0
RXRalphaF318A B-gene
constitutive 0
activity 0
generated 0
within 0
heterodimers 0
in 0
the 0
presence 0
of 0
BMS614 0
requires 0
the 0
integrity 0
of 0
both 0
RXR B-gene
and 0
RAR B-gene
AF 0
- 0
2 0
domains 0
. 0

These 0
introns 0
contain 0
only 0
single 0
snoRNA B-gene
genes I-gene
and 0
their 0
processing 0
involves 0
exonucleolytic 0
release 0
of 0
the 0
snoRNA 0
from 0
debranched 0
intron 0
lariats 0
. 0

Recent 0
studies 0
have 0
shown 0
that 0
the 0
Src B-gene
homology I-gene
- I-gene
2 I-gene
( 0
SH2 B-gene
) 0
domain 0
- 0
containing 0
protein B-gene
- I-gene
tyrosine I-gene
phosphatase I-gene
, 0
SHP B-gene
- I-gene
2 I-gene
, 0
associates 0
with 0
the 0
cytoplasmic 0
domain 0
of 0
PECAM B-gene
- I-gene
1 I-gene
as 0
it 0
becomes 0
tyrosine 0
- 0
phosphorylated 0
during 0
platelet 0
aggregation 0
: 0
a 0
process 0
that 0
can 0
be 0
mimicked 0
in 0
part 0
by 0
small 0
synthetic 0
phosphopeptides 0
corresponding 0
to 0
the 0
cytoplasmic 0
domain 0
of 0
PECAM B-gene
- I-gene
1 I-gene
encompassing 0
tyrosine 0
residues 0
Tyr 0
- 0
663 0
or 0
Tyr 0
- 0
686 0
. 0

Underlying 0
the 0
clustering 0
of 0
these 0
risk 0
variables 0
were 0
three 0
factors 0
. 0

Supplementation 0
was 0
stopped 0
when 0
pl B-gene
- I-gene
ALB I-gene
reached 0
2.0 0
g/dL 0
. 0

Detection 0
of 0
airborne 0
Mycobacterium 0
tuberculosis 0
by 0
air 0
filtration 0
and 0
polymerase 0
chain 0
reaction 0
. 0

These 0
findings 0
show 0
that 0
EBP50 B-gene
is 0
a 0
physiologically 0
relevant 0
ezrin B-gene
binding I-gene
protein I-gene
. 0

Previously 0
, 0
we 0
reported 0
that 0
scanthrough 0
translation 0
, 0
where 0
the 0
initiating 0
AUG 0
of 0
a 0
primary 0
open 0
reading 0
frame 0
is 0
bypassed 0
, 0
is 0
most 0
likely 0
to 0
account 0
for 0
the 0
presentation 0
of 0
cryptic 0
epitopes 0
from 0
alternative 0
reading 0
frames 0
within 0
the 0
influenza B-gene
A I-gene
PR/8/34 I-gene
nucleoprotein I-gene
gene I-gene
. 0

This 0
family 0
of 0
proteins 0
binds 0
GC 0
- 0
rich 0
motifs 0
widely 0
distributed 0
in 0
gene 0
promoters 0
, 0
resulting 0
in 0
distinct 0
activation 0
or 0
repression 0
of 0
transcriptional 0
activities 0
. 0

Deletion 0
of 0
the 0
POR2 B-gene
gene I-gene
alone 0
had 0
no 0
detectable 0
phenotype 0
, 0
while 0
yeasts 0
with 0
deletions 0
of 0
both 0
the 0
POR1 B-gene
and 0
POR2 B-gene
genes I-gene
were 0
viable 0
and 0
able 0
to 0
grow 0
on 0
glycerol 0
at 0
30 0
degrees 0
C 0
, 0
albeit 0
more 0
slowly 0
than 0
delta B-gene
por1 I-gene
single I-gene
mutants I-gene
. 0

Furthermore 0
, 0
our 0
novel 0
observation 0
that 0
expression 0
of 0
a 0
highly 0
activated 0
FGFR3 B-gene
kinase I-gene
domain I-gene
is 0
able 0
to 0
morphologically 0
transform 0
fibroblasts 0
suggests 0
that 0
dysregulation 0
of 0
FGFR3 B-gene
has 0
the 0
potential 0
to 0
play 0
a 0
role 0
in 0
human 0
neoplasia 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
of 0
the 0
gene 0
has 0
significant 0
homology 0
to 0
the 0
interferon B-gene
regulatory I-gene
factors I-gene
( 0
IRFs B-gene
) 0
. 0

Involvement 0
of 0
AP B-gene
- I-gene
2 I-gene
in 0
regulation 0
of 0
the 0
R B-gene
- I-gene
FABP I-gene
gene I-gene
in 0
the 0
developing 0
chick 0
retina 0
. 0

However 0
, 0
Cbf5p B-gene
was 0
found 0
to 0
be 0
nucleolar 0
and 0
is 0
highly 0
homologous 0
to 0
the 0
rat B-gene
nucleolar I-gene
protein I-gene
NAP57 I-gene
, 0
which 0
coimmunoprecipitates 0
with 0
Nopp140 B-gene
and 0
which 0
is 0
postulated 0
to 0
be 0
involved 0
in 0
nucleolar 0
- 0
cytoplasmic 0
shuttling 0
( 0
U 0
. 0

This 0
newly 0
described 0
organism 0
was 0
difficult 0
to 0
identify 0
due 0
to 0
discrepancies 0
between 0
the 0
Vitek 0
and 0
API 0
20E 0
identification 0
systems 0
. 0

Ig B-gene
heavy I-gene
chain I-gene
class 0
switching 0
is 0
directed 0
by 0
cytokines 0
inducing 0
transcription 0
from 0
unrearranged 0
CH B-gene
genes I-gene
. 0

The 0
available 0
data 0
suggest 0
that 0
the 0
NF B-gene
kappa I-gene
B2 I-gene
nucleoprotein I-gene
complex I-gene
may 0
cooperate 0
with 0
DNA 0
- 0
bound 0
STAT6 B-gene
to 0
achieve 0
IL B-gene
- I-gene
4 I-gene
- 0
dependent 0
activation 0
of 0
the 0
human B-gene
IgE I-gene
germline I-gene
gene I-gene
. 0

EXERCISE 0
IN 0
THE 0
TERRESTRIAL 0
CHRISTMAS 0
ISLAND 0
RED 0
CRAB 0
GECARCOIDEA 0
NATALIS 0
- 0
ENERGETICS 0
OF 0
LOCOMOTION 0

THE 0
SCALING 0
OF 0
SONG 0
FREQUENCY 0
IN 0
CICADAS 0

The 0
pheromone 0
response 0
pathway 0
activates 0
transcription 0
of 0
Ty5 B-gene
retrotransposons I-gene
located 0
within 0
silent 0
chromatin 0
of 0
Saccharomyces 0
cerevisiae 0
. 0

In 0
this 0
study 0
we 0
have 0
introduced 0
mutations 0
into 0
the 0
corresponding 0
elements 0
of 0
two 0
cox3 B-gene
promoters I-gene
and 0
show 0
that 0
while 0
the 0
core 0
element 0
is 0
essential 0
for 0
cox3 B-gene
promoter I-gene
activity 0
, 0
upstream 0
element 0
mutations 0
have 0
little 0
or 0
no 0
effect 0
. 0

We 0
found 0
that 0
multiple 0
tumor 0
suppressor 0
genes 0
( 0
e.g. 0
, 0
p53 B-gene
, 0
DCC B-gene
, 0
APC B-gene
, 0
MCC B-gene
, 0
BRCA1 B-gene
, 0
and 0
WAF1/CIP1 B-gene
) 0
were 0
inactivated 0
at 0
different 0
frequencies 0
via 0
various 0
mechanisms 0
[ 0
e.g. 0
, 0
loss 0
of 0
heterozygosity 0
( 0
LOH 0
) 0
, 0
loss 0
of 0
expression 0
( 0
LOE 0
) 0
, 0
mutation 0
, 0
and 0
inactivation 0
by 0
cellular 0
binding 0
protein 0
] 0
. 0

The 0
histidine 0
- 0
tagged 0
gene 0
, 0
rpoCHIS B-gene
, 0
was 0
used 0
to 0
replace 0
the 0
wild 0
- 0
type 0
allele 0
in 0
the 0
chromosome 0
of 0
S. 0
coelicolor 0
and 0
S. 0
lividans 0
. 0

Because 0
the 0
deletion 0
included 0
the 0
TK B-gene
gene I-gene
, 0
selection 0
with 0
gancyclovir 0
against 0
cells 0
not 0
having 0
undergone 0
recombination 0
was 0
possible 0
. 0

The 0
malate B-gene
synthase I-gene
gene I-gene
, 0
MLS1 B-gene
, 0
of 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
is 0
transcriptionally 0
regulated 0
by 0
the 0
carbon 0
source 0
in 0
the 0
growth 0
medium 0
. 0

By 0
deletion 0
analysis 0
of 0
the 0
MLS1 B-gene
control 0
region 0
, 0
we 0
identified 0
two 0
sites 0
, 0
UAS1 0
and 0
UAS2 0
, 0
as 0
important 0
for 0
efficient 0
derepression 0
of 0
the 0
gene 0
. 0

Lack 0
of 0
controlled 0
prospective 0
studies 0
of 0
sleep 0
electroencephalograms 0
( 0
EEG 0
) 0
, 0
and 0
the 0
use 0
of 0
medication 0
, 0
in 0
children 0
with 0
developmental 0
dysphasia 0
, 0
may 0
deny 0
appropriate 0
treatment 0
strategies 0
to 0
children 0
with 0
severe 0
developmental 0
speech 0
and 0
language 0
disorders 0
. 0

Prior 0
to 0
meals 0
2 0
to 0
3 0
times 0
daily 0
, 0
1 0
- 0
2 0
tablespoons 0
of 0
Alzoon 0
are 0
recommended 0
. 0

Widening 0
of 0
the 0
abdominal 0
aortic 0
wall 0
on 0
an 0
ultrasound 0
examination 0
was 0
the 0
key 0
to 0
the 0
incidental 0
diagnosis 0
of 0
a 0
clinically 0
unsuspected 0
type 0
B 0
dissection 0
. 0

Fermentation 0
process 0
after 0
supplementation 0
of 0
nitrate 0
, 0
nitrite 0
, 0
lactic 0
acid 0
bacteria 0
and 0
formic 0
acid 0

Substrates 0
include 0
the 0
p21 B-gene
( 0
ras B-gene
) 0
proteins 0
, 0
nuclear B-gene
lamins I-gene
, 0
and 0
a 0
series 0
of 0
retinal 0
proteins 0
. 0

Ovaries 0
of 0
10 0
animals 0
per 0
group 0
from 0
16 0
studies 0
in 0
CD 0
- 0
1 0
mice 0
and 0
1 0
study 0
each 0
in 0
C3H 0
and 0
C57BL/6 0
mice 0
were 0
sectioned 0
serially 0
at 0
6 0
microm 0
. 0

The 0
Trx B-gene
- 0
CT B-gene
fusion 0
protein 0
was 0
produced 0
less 0
efficiently 0
( 0
20 0
% 0
of 0
total 0
soluble 0
cellular 0
protein 0
) 0
. 0

These 0
results 0
suggest 0
that 0
UBP41 B-gene
may 0
play 0
an 0
important 0
role 0
in 0
the 0
recycling 0
of 0
ubiquitin B-gene
by 0
hydrolysis 0
of 0
branched B-gene
poly I-gene
- I-gene
ubiquitin I-gene
chains I-gene
generated 0
by 0
the 0
action 0
of 0
26 B-gene
S I-gene
proteasome I-gene
on 0
poly 0
- 0
ubiquitinated 0
protein 0
substrates 0
, 0
as 0
well 0
as 0
in 0
the 0
production 0
of 0
free 0
ubiquitin B-gene
from 0
linear B-gene
poly I-gene
- I-gene
ubiquitin I-gene
chains I-gene
and 0
of 0
certain 0
ribosomal 0
proteins 0
from 0
ubiquitin B-gene
fusion I-gene
proteins I-gene
. 0

A 0
data 0
base 0
homology 0
search 0
revealed 0
that 0
the 0
predicted 0
ER1 B-gene
amino 0
acid 0
sequence 0
contains 0
three 0
regions 0
of 0
similarity 0
to 0
the 0
rat 0
and 0
human 0
proteins 0
encoded 0
by 0
the 0
metastasis 0
- 0
associated 0
gene 0
, 0
mta1 B-gene
, 0
and 0
two 0
regions 0
of 0
similarity 0
to 0
the 0
Caenorhabditis 0
elegans 0
sequence 0
that 0
is 0
similar 0
to 0
mta1 B-gene
. 0

The 0
sequenced 0
cDNA 0
predicts 0
a 0
704 0
- 0
amino 0
acid 0
protein 0
80 0
% 0
identical 0
to 0
human B-gene
progelatinase I-gene
B I-gene
. 0

The 0
inhibition 0
by 0
cytosolic 0
Ca2+ 0
was 0
caused 0
by 0
a 0
decrease 0
in 0
cooperativity 0
and 0
by 0
a 0
shift 0
in 0
EC50 0
toward 0
higher 0
InsP3 0
concentrations 0
. 0

RESULTS 0
: 0
The 0
standardised 0
mortality 0
ratio 0
( 0
SMR 0
) 0
for 0
all 0
malignant 0
neoplasms 0
was 0
94 0
( 0
95 0
% 0
CI 0
74 0
to 0
118 0
) 0
. 0

Sequence 0
analysis 0
of 0
this 0
region 0
revealed 0
three 0
eight 0
- 0
bp 0
repetitive 0
elements 0
, 0
the 0
deletion 0
of 0
which 0
restored 0
wild 0
- 0
type 0
levels 0
of 0
luciferase B-gene
activity 0
to 0
the 0
- 0
916 0
- 0
bp 0
reporter 0
plasmid 0
. 0

Using 0
5'RACE 0
and 0
reverse 0
transcription 0
- 0
PCR 0
( 0
RT 0
- 0
PCR 0
) 0
methodologies 0
, 0
we 0
cloned 0
these 0
sequences 0
from 0
brain 0
and 0
placenta 0
and 0
found 0
this 0
material 0
to 0
be 0
composed 0
of 0
alternatively 0
spliced 0
exons 0
using 0
a 0
previously 0
reported 0
noncoding 0
exon 0
( 0
1A 0
) 0
and 0
a 0
novel 0
97 0
- 0
bp 0
noncoding 0
exon 0
( 0
1B 0
) 0
. 0

This 0
is 0
the 0
first 0
study 0
in 0
which 0
mutation 0
screening 0
has 0
been 0
performed 0
for 0
both 0
the 0
EXT1 B-gene
and 0
EXT2 B-gene
genes I-gene
prior 0
to 0
any 0
linkage 0
analysis 0
. 0

The 0
regurgitation 0
of 0
large 0
vitreous 0
injections 0
. 0

Positron 0
emission 0
tomography 0
radioligands 0
for 0
dopamine B-gene
transporters I-gene
and 0
studies 0
in 0
human 0
and 0
nonhuman 0
primates 0
. 0

Attenuation 0
from 0
the 0
vit B-gene
A2 I-gene
consensus 0
ERE 0
is 0
not 0
necessarily 0
dependent 0
on 0
DNA 0
binding 0
as 0
the 0
TR B-gene
alpha I-gene
DNA 0
binding 0
mutant 0
was 0
still 0
able 0
to 0
inhibit 0
E 0
- 0
dependent 0
transactivation 0
. 0

Expression 0
from 0
this 0
element 0
is 0
regulated 0
by 0
a 0
heteromeric 0
protein 0
complex 0
containing 0
ubiquitous 0
( 0
i.e 0
. 0
the 0
E2A B-gene
- 0
and 0
HEB B-gene
- I-gene
encoded I-gene
proteins I-gene
) 0
and 0
islet 0
- 0
enriched 0
members 0
of 0
the 0
bHLH B-gene
family I-gene
. 0

Thus 0
, 0
the 0
CCAAT 0
box 0
also 0
has 0
tissue 0
- 0
specific 0
characteristics 0
that 0
assist 0
in 0
targeting 0
expression 0
of 0
the 0
alpha B-gene
- I-gene
subunit I-gene
gene I-gene
to 0
trophoblasts 0
. 0

U4/U6 B-gene
snRNP 0
is 0
one 0
of 0
four 0
essential 0
small 0
nuclear 0
ribonucleoprotein 0
( 0
snRNP 0
) 0
particles 0
( 0
U4/U6 I-gene

Hprp3p B-gene
is 0
a 0
77 0
kDa 0
protein 0
, 0
which 0
is 0
homologous 0
to 0
the 0
Saccharomyces B-gene
cerevisiae I-gene
splicing I-gene
factor I-gene
Prp3p I-gene
. 0

The 0
growth 0
- 0
promoting 0
properties 0
of 0
the 0
retroviral B-gene
v I-gene
- I-gene
erbA I-gene
oncogene I-gene
, 0
a 0
highly 0
mutated 0
version 0
of 0
the 0
chicken B-gene
thyroid I-gene
hormone I-gene
receptor I-gene
( I-gene
TR I-gene
) I-gene
alpha I-gene
, 0
have 0
so 0
far 0
exclusively 0
been 0
linked 0
to 0
dominant 0
repression 0
of 0
the 0
antimitogenic 0
roles 0
of 0
TR B-gene
and 0
retinoic B-gene
acid I-gene
receptors I-gene
. 0

We 0
cloned 0
a 0
complete 0
cDNA 0
( 0
2.9 0
kb 0
) 0
for 0
HET B-gene
from 0
an 0
MCF 0
- 0
7 0
cDNA 0
library 0
. 0

The 0
most 0
common 0
grade 0
3 0
toxicity 0
was 0
neutropenia 0
, 0
thrombocytopenia 0
, 0
and 0
parasthesias 0
( 0
observed 0
in 0
< 0
10 0
% 0
of 0
cycles 0
) 0
. 0

Serum 0
concentrations 0
of 0
E2 0
and 0
TBOH 0
were 0
measured 0
on 0
d 0
0 0
, 0
1 0
, 0
3 0
, 0
5 0
, 0
7 0
, 0
13 0
, 0
21 0
, 0
28 0
, 0
42 0
, 0
56 0
, 0
84 0
, 0
112 0
, 0
and 0
140 0
in 0
finishing 0
heifers 0
administered 0
the 0
following 0
treatments 0
: 0
1 0
) 0
control 0
; 0
2 0
) 0
MGA 0
, 0
.5 0
mg 0
per 0
heifer 0
daily 0
; 0
3 0
) 0
Revalor 0
- 0
H 0
( 0
140 0
mg 0
TBA 0
+ 0
14 0
mg 0
E2 0
) 0
; 0
4 0
) 0
Revalor 0
- 0
H 0
+ 0
MGA 0
; 0
5 0
) 0
Finaplix 0
- 0
H 0
( 0
200 0
mg 0
TBA 0
) 0
; 0
and 0
6 0
) 0
Finaplix 0
- 0
H 0
+ 0
MGA 0
. 0

Serum 0
E2 0
concentrations 0
increased 0
numerically 0
two 0
- 0
to 0
threefold 0
from 0
d 0
56 0
to 0
140 0
in 0
controls 0
fed 0
MGA 0
, 0
compared 0
with 0
controls 0
not 0
fed 0
MGA 0
. 0

Interferon B-gene
Regulatory I-gene
Factor I-gene
( I-gene
IRF I-gene
) I-gene
- I-gene
1 I-gene
has 0
been 0
characterized 0
as 0
an 0
important 0
growth 0
regulatory 0
and 0
immunomodulatory 0
transcription 0
factor 0
. 0

The 0
genomic 0
structure 0
of 0
brk B-gene
consists 0
of 0
8 0
exons 0
, 0
whose 0
boundaries 0
are 0
distinct 0
from 0
other 0
non 0
- 0
receptor 0
PTK B-gene
family I-gene
members 0
, 0
again 0
indicating 0
a 0
structural 0
and 0
functional 0
divergence 0
. 0

We 0
have 0
previously 0
reported 0
that 0
expression 0
of 0
a 0
tumour 0
derived 0
brk B-gene
cDNA I-gene
in 0
mouse 0
embryonic 0
fibroblasts 0
and 0
human 0
mammary 0
epithelial 0
cells 0
supports 0
anchorage 0
independent 0
growth 0
, 0
and 0
in 0
the 0
latter 0
potentiates 0
the 0
mitogenic 0
response 0
to 0
epidermal B-gene
growth I-gene
factor I-gene
. 0

Anti B-gene
- I-gene
hepatitis I-gene
A I-gene
virus 0
( 0
HAV 0
) 0
titer 0
after 0
vaccination 0
was 0
measured 0
in 0
83 0
HIV 0
- 0
positive 0
and 0
39 0
HIV 0
- 0
negative 0
men 0
. 0

One 0
skull 0
does 0
not 0
a 0
species 0
make 0
. 0

Surprisingly 0
, 0
calf B-gene
thymus I-gene
CstF I-gene
contained 0
an 0
additional 0
, 0
novel 0
form 0
of 0
the 0
64 0
- 0
kDa 0
subunit 0
with 0
a 0
molecular 0
mass 0
of 0
70 0
kDa 0
. 0

Null 0
mutations 0
in 0
daf B-gene
- I-gene
3 I-gene
suppress 0
mutations 0
in 0
genes 0
encoding 0
this 0
TGF B-gene
- I-gene
beta I-gene
signal 0
, 0
its 0
receptors 0
, 0
and 0
associated 0
Smad B-gene
signal I-gene
transduction I-gene
proteins I-gene
. 0
daf B-gene
- I-gene
3 I-gene
encodes 0
a 0
Smad B-gene
protein I-gene
that 0
is 0
most 0
closely 0
related 0
to 0
mammalian B-gene
DPC4 I-gene
, 0
and 0
is 0
expressed 0
throughout 0
development 0
in 0
many 0
of 0
the 0
tissues 0
that 0
are 0
remodeled 0
during 0
dauer 0
development 0
. 0

Our 0
results 0
favor 0
the 0
possibility 0
that 0
the 0
Drosophila B-gene
EGF I-gene
receptor I-gene
DER/Egfr B-gene
expressed 0
by 0
the 0
EMA 0
cells 0
functions 0
as 0
a 0
receptor 0
for 0
DER/Egfr I-gene

PATIENTS 0
AND 0
METHODS 0
: 0
In 0
807 0
consecutive 0
patients 0
from 0
the 0
Chilean 0
National 0
Registry 0
of 0
Acute 0
Myocardial 0
Infarction 0
we 0
analyzed 0
the 0
resolution 0
of 0
chest 0
pain 0
and 0
ST 0
segment 0
elevation 0
over 0
50 0
% 0
within 0
the 0
first 0
90 0
min 0
, 0
abrupt 0
CK B-gene
rise 0
within 0
8 0
h 0
and 0
T 0
wave 0
inversion 0
in 0
infarct 0
related 0
EKG 0
leads 0
within 0
the 0
first 0
24 0
h 0
after 0
thrombolysis 0
. 0

Because 0
of 0
the 0
operon 0
structure 0
of 0
this 0
organism 0
, 0
traditional 0
methods 0
such 0
as 0
insertional 0
mutagenesis 0
run 0
the 0
risk 0
of 0
introducing 0
polar 0
effects 0
on 0
downstream 0
genes 0
or 0
creating 0
secondary 0
mutations 0
elsewhere 0
in 0
the 0
genome 0
. 0

It 0
has 0
been 0
proposed 0
that 0
the 0
parCBA B-gene
operon I-gene
encodes 0
a 0
plasmid 0
partitioning 0
system 0
( 0
M 0
. 0

Furthermore 0
, 0
the 0
insertion 0
of 0
the 0
ColE1 B-gene
cer I-gene
site I-gene
into 0
the 0
RK2 0
plasmid 0
deleted 0
for 0
the 0
par 0
region 0
failed 0
to 0
stabilize 0
the 0
plasmid 0
in 0
the 0
MC1061K 0
strain 0
, 0
indicating 0
that 0
the 0
multimer 0
resolution 0
activity 0
encoded 0
by 0
parCBA B-gene
is 0
not 0
by 0
itself 0
responsible 0
for 0
the 0
stabilization 0
activity 0
observed 0
for 0
this 0
operon 0
. 0

To 0
examine 0
the 0
basis 0
for 0
the 0
apparent 0
differences 0
in 0
postsegregational 0
killing 0
between 0
the 0
two 0
E. 0
coli 0
strains 0
, 0
transformation 0
assays 0
were 0
carried 0
out 0
to 0
determine 0
the 0
relative 0
sensitivities 0
of 0
the 0
strains 0
to 0
the 0
ParE B-gene
toxin I-gene
protein I-gene
. 0

Splice 0
- 0
junction 0
elements 0
and 0
intronic 0
sequences 0
regulate 0
alternative 0
splicing 0
of 0
the 0
Drosophila 0
myosin B-gene
heavy I-gene
chain I-gene
gene I-gene
transcript 0
. 0

Nucleotide 0
sequence 0
analysis 0
of 0
R 0
has 0
revealed 0
similarities 0
to 0
the 0
R1 0
plasmid 0
found 0
in 0
some 0
South 0
American 0
maize 0
races 0
with 0
RU 0
cytoplasm 0
, 0
to 0
the 0
M1 0
plasmid 0
found 0
in 0
one 0
source 0
of 0
Zea 0
luxurians 0
teosinte 0
, 0
to 0
the 0
atp9 B-gene
mitochondrial I-gene
gene I-gene
and 0
its 0
3 0
' 0
flanking 0
sequence 0
, 0
and 0
also 0
to 0
a 0
region 0
3 0
' 0
to 0
the 0
orf221 B-gene
gene I-gene
. 0

We 0
have 0
measured 0
the 0
kinetics 0
of 0
the 0
recovery 0
of 0
mRNA 0
synthesis 0
in 0
the 0
inducible 0
GAL10 B-gene
and 0
RNR3 B-gene
genes I-gene
after 0
exposure 0
of 0
yeast 0
cells 0
to 0
ultraviolet 0
( 0
UV 0
) 0
radiation 0
. 0

Cloning 0
of 0
a 0
human B-gene
phosphoinositide I-gene
3 I-gene
- I-gene
kinase I-gene
with 0
a 0
C2 B-gene
domain 0
that 0
displays 0
reduced 0
sensitivity 0
to 0
the 0
inhibitor 0
wortmannin 0
. 0

Ea 0
value 0
was 0
calculated 0
as 0
the 0
ratio 0
of 0
the 0
steady 0
- 0
state 0
end 0
- 0
systolic 0
aortic 0
pressure 0
( 0
ESAP 0
) 0
to 0
stroke 0
volume 0
( 0
thermodilution 0
) 0
. 0

Functional 0
analysis 0
of 0
promoter 0
activity 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
cyclin B-gene
D2 I-gene
suggested 0
that 0
the 0
region 0
- 0
1,100 0
to 0
- 0
805 0
including 0
C/EBP B-gene
, 0
PEA3 B-gene
, 0
AP2 B-gene
, 0
NF B-gene
- I-gene
Y I-gene
, 0
c B-gene
- I-gene
Myc I-gene
, 0
and 0
Sp1 B-gene
may 0
have 0
a 0
major 0
positive 0
regulatory 0
activity 0
for 0
expression 0
of 0
cyclin B-gene
D2 I-gene
. 0

Effect 0
of 0
alcohol 0
on 0
minimal 0
effective 0
nCPAP 0
pressure 0

In 0
contrast 0
, 0
resensitization 0
of 0
a 0
sequestration 0
- 0
impaired 0
beta2AR B-gene
mutant 0
( 0
Y326A 0
) 0
was 0
reestablished 0
following 0
the 0
overexpression 0
of 0
either 0
GRK2 B-gene
or 0
beta B-gene
- I-gene
arrestin I-gene
1 I-gene
. 0

The 0
medium 0
chains 0
of 0
these 0
complexes 0
, 0
mu1 B-gene
and 0
mu2 B-gene
, 0
have 0
been 0
implicated 0
in 0
two 0
types 0
of 0
interaction 0
: 0
assembly 0
with 0
the 0
beta1 B-gene
and I-gene
beta2 I-gene
chains I-gene
of 0
the 0
corresponding 0
complexes 0
and 0
recognition 0
of 0
tyrosine 0
- 0
based 0
sorting 0
signals 0
. 0

We 0
have 0
overexpressed 0
, 0
purified 0
, 0
characterized 0
, 0
and 0
crystallized 0
the 0
BTB/POZ B-gene
domain 0
from 0
PLZF B-gene
( 0
PLZF B-gene
- 0
BTB/POZ B-gene
) 0
. 0

Osmotic 0
shock 0
stimulates 0
GLUT4 B-gene
translocation 0
in 0
3T3L1 0
adipocytes 0
by 0
a 0
novel 0
tyrosine B-gene
kinase I-gene
pathway 0
. 0

We 0
also 0
identified 0
Sp1 B-gene
, 0
Sp3 B-gene
, 0
and 0
NGFI B-gene
- I-gene
A/Egr I-gene
A/Egr I-gene
- I-gene
1 I-gene
as 0
the 0
primary 0
nuclear 0
transcription 0
factors 0
binding 0
to 0
TRE1 B-gene
which 0
mediate 0
Tax B-gene
responsiveness 0
. 0

Interestingly 0
, 0
segment 0
nesting 0
differentially 0
increases 0
the 0
copy 0
number 0
of 0
genes 0
encoded 0
by 0
segment 0
W 0
, 0
suggesting 0
that 0
the 0
unusual 0
genomic 0
organization 0
of 0
PDVs 0
may 0
be 0
directly 0
linked 0
to 0
the 0
unique 0
functions 0
of 0
this 0
virus 0
in 0
its 0
obligate 0
mutualistic 0
association 0
with 0
parasitic 0
wasps 0
. 0

Furthermore 0
, 0
deletion 0
and 0
mutation 0
analyses 0
of 0
the 0
VCAM B-gene
- I-gene
1 I-gene
promoter I-gene
performed 0
with 0
chloramphenicol B-gene
acetyltransferase I-gene
constructs I-gene
revealed 0
that 0
Tax B-gene
was 0
trans 0
activating 0
the 0
VCAM B-gene
- I-gene
1 I-gene
promoter I-gene
via 0
two 0
NF B-gene
- I-gene
kappaB I-gene
sites I-gene
present 0
at 0
bp 0
- 0
72 0
and 0
- 0
57 0
in 0
the 0
VCAM B-gene
- I-gene
1 I-gene
gene I-gene
promoter I-gene
, 0
with 0
both 0
of 0
them 0
being 0
required 0
for 0
the 0
Tax B-gene
- 0
induced 0
expression 0
of 0
this 0
adhesion 0
molecule 0
. 0

The 0
AGM B-gene
and I-gene
NIH/Swiss I-gene
mouse I-gene
CCR5 I-gene
proteins I-gene
are 0
97.7 0
to 0
98.3 0
% 0
and 0
79.8 0
% 0
identical 0
to 0
the 0
human 0
protein 0
, 0
respectively 0
. 0

Processivity 0
of 0
DNA 0
synthesis 0
by 0
the 0
mutant 0
holoenzyme 0
containing 0
pcna B-gene
- I-gene
79 I-gene
was 0
unaffected 0
on 0
poly 0
( 0
dA 0
) 0
x 0
oligo 0
( 0
dT 0
) 0
but 0
was 0
dramatically 0
reduced 0
on 0
a 0
natural 0
template 0
with 0
secondary 0
structure 0
. 0

Alanine 0
substitution 0
mutations 0
in 0
the 0
Zta B-gene
activation I-gene
domain I-gene
which 0
eliminate 0
the 0
ability 0
of 0
Zta B-gene
to 0
stimulate 0
the 0
D B-gene
- I-gene
A I-gene
complex I-gene
were 0
examined 0
. 0

The 0
Scm B-gene
and 0
ph B-gene
proteins 0
share 0
a 0
homology 0
domain 0
with 0
38 0
% 0
identity 0
over 0
a 0
length 0
of 0
65 0
amino 0
acids 0
, 0
termed 0
the 0
SPM 0
domain 0
, 0
that 0
is 0
located 0
at 0
their 0
respective 0
C 0
termini 0
. 0

It 0
has 0
been 0
previously 0
shown 0
that 0
genes 0
transcribed 0
by 0
RNA B-gene
polymerase I-gene
II I-gene
( 0
RNAP B-gene
II I-gene
) 0
are 0
subject 0
to 0
position 0
effect 0
variegation 0
when 0
located 0
near 0
yeast 0
telomeres 0
. 0

Likewise 0
, 0
rad6 B-gene
- I-gene
delta I-gene
reduces 0
silencing 0
of 0
the 0
telomere B-gene
- I-gene
located I-gene
RNAP I-gene
II I-gene
- I-gene
transcribed I-gene
genes I-gene
URA3 I-gene
and 0
ADE2 B-gene
. 0

The 0
amplitude 0
of 0
detrusor 0
contractions 0
at 0
6 0
, 0
12 0
, 0
and 0
24 0
hours 0
showed 0
no 0
significant 0
difference 0
from 0
that 0
in 0
the 0
controls 0
. 0

In 0
the 0
predicted 0
transmembrane 0
domain 0
, 0
Casr B-gene
- I-gene
rs2 I-gene
and 0
Casr B-gene
- I-gene
rs3 I-gene
are 0
95 0
% 0
identical 0
to 0
Casr B-gene
- I-gene
rs1 I-gene
. 0

Recently 0
, 0
roles 0
also 0
have 0
been 0
suggested 0
for 0
the 0
nuclear 0
trans 0
- 0
factor 0
GATA B-gene
- I-gene
1 I-gene
in 0
regulating 0
progenitor 0
cell 0
proliferation 0
. 0

PET 0
activation 0
studies 0
are 0
performed 0
widely 0
to 0
study 0
human 0
brain 0
function 0
. 0

F B-gene
- I-gene
box I-gene
proteins I-gene
are 0
receptors 0
that 0
recruit 0
phosphorylated 0
substrates 0
to 0
the 0
SCF B-gene
ubiquitin B-gene
- 0
ligase B-gene
complex 0
. 0

In 0
the 0
context 0
of 0
liver 0
allograft 0
shortage 0
, 0
our 0
results 0
suggest 0
that 0
an 0
ELT 0
should 0
not 0
be 0
performed 0
in 0
patients 0
with 0
cardiac 0
failure 0
, 0
more 0
than 0
two 0
OSF 0
, 0
or 0
an 0
APACHE 0
II 0
score 0
higher 0
than 0
30 0
. 0

The 0
SH3 B-gene
domains I-gene
of 0
Grb2 B-gene
bound 0
in 0
vitro 0
to 0
specific 0
proline 0
- 0
rich 0
motifs 0
in 0
the 0
HPK1 B-gene
tail 0
and 0
functioned 0
synergistically 0
to 0
direct 0
the 0
stable 0
binding 0
of 0
Grb2 B-gene
to 0
HPK1 B-gene
in 0
transfected 0
Cos1 0
cells 0
. 0

By 0
far 0
- 0
Western 0
analysis 0
and 0
coimmunoprecipitation 0
studies 0
, 0
we 0
demonstrate 0
that 0
ZNF74 B-gene
interacts 0
, 0
via 0
its 0
zinc 0
finger 0
domain 0
, 0
with 0
the 0
hyperphosphorylated 0
largest 0
subunit 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
( 0
pol B-gene
IIo I-gene
) 0
but 0
not 0
with 0
the 0
hypophosphorylated 0
form 0
. 0

Thus 0
, 0
ZNF74 B-gene
sublocalization 0
in 0
nuclear 0
domains 0
enriched 0
in 0
pre 0
- 0
mRNA 0
maturating 0
factors 0
, 0
its 0
RNA 0
binding 0
activity 0
, 0
and 0
its 0
direct 0
phosphodependent 0
interaction 0
with 0
the 0
pol B-gene
IIo I-gene
, 0
a 0
form 0
of 0
the 0
RNA B-gene
polymerase I-gene
functionally 0
associated 0
with 0
pre 0
- 0
mRNA 0
processing 0
, 0
suggest 0
a 0
role 0
for 0
this 0
member 0
of 0
the 0
KRAB B-gene
multifinger I-gene
protein I-gene
family I-gene
in 0
RNA 0
processing 0
. 0

Ki B-gene
- I-gene
ras4BVal I-gene
- I-gene
12 I-gene
transfectant 0
cells 0
expressed 0
2 0
- 0
fold 0
elevated 0
protein 0
levels 0
of 0
the 0
lysosomal B-gene
cysteine I-gene
protease I-gene
cathepsin B-gene
B I-gene
but 0
did 0
not 0
up 0
- 0
regulate 0
cathepsin B-gene
B I-gene
mRNA I-gene
expression 0
. 0

The 0
cellular 0
rate 0
of 0
anticoagulant B-gene
heparan I-gene
sulfate I-gene
proteoglycan I-gene
( 0
HSPGact B-gene
) 0
generation 0
is 0
determined 0
by 0
the 0
level 0
of 0
a 0
kinetically 0
limiting 0
microsomal 0
activity 0
, 0
HSact 0
conversion 0
activity 0
, 0
which 0
is 0
predominantly 0
composed 0
of 0
the 0
long 0
sought 0
heparan B-gene
sulfate I-gene
D I-gene
- I-gene
glucosaminyl I-gene
3 I-gene
- I-gene
O I-gene
- I-gene
sulfotransferase I-gene
( 0
3 B-gene
- I-gene
OST I-gene
) 0
( 0
Shworak 0
, 0
N 0
. 0

Interestingly 0
, 0
EGF B-gene
, 0
but 0
not 0
insulin B-gene
, 0
stimulated 0
tyrosine 0
phosphorylation 0
of 0
c B-gene
- I-gene
cbl I-gene
and 0
its 0
association 0
with 0
Crk B-gene
- I-gene
II I-gene
. 0

An 0
end 0
to 0
the 0
lottery 0
. 0

We 0
previously 0
showed 0
that 0
the 0
N 0
- 0
terminal 0
portion 0
common 0
to 0
various 0
chimeric B-gene
MLL I-gene
products I-gene
, 0
as 0
well 0
as 0
to 0
MLL B-gene
- I-gene
LTG9 I-gene
and 0
MLL B-gene
- I-gene
LTG19 I-gene
, 0
localizes 0
in 0
the 0
nuclei 0
, 0
and 0
therefore 0
suggested 0
that 0
it 0
might 0
play 0
an 0
important 0
role 0
in 0
leukemogenesis 0
. 0

Our 0
results 0
suggest 0
that 0
the 0
pattern 0
of 0
blood 0
supply 0
is 0
relevant 0
to 0
the 0
structural 0
organisation 0
of 0
mature 0
lamellar 0
bone 0
around 0
the 0
implant 0
. 0

Induction 0
of 0
AtP5CS1 B-gene
mRNA I-gene
accumulation 0
in 0
salt 0
- 0
treated 0
seedlings 0
involves 0
an 0
immediate 0
early 0
transcriptional 0
response 0
regulated 0
by 0
ABA 0
signalling 0
that 0
is 0
not 0
inhibited 0
by 0
cycloheximide 0
, 0
but 0
abolished 0
by 0
the 0
deficiency 0
of 0
ABA 0
biosynthesis 0
in 0
the 0
aba1 B-gene
Arabidopsis I-gene
mutant I-gene
. 0

It 0
thus 0
appears 0
that 0
MAPK B-gene
functions 0
in 0
meiotic 0
maturation 0
by 0
preventing 0
unfertilized 0
eggs 0
from 0
proceeding 0
into 0
parthenogenetic 0
development 0
. 0

( 0
ii 0
) 0
An 0
AF 0
G B-gene
- I-gene
CSF I-gene
level 0
> 0
2000 0
pg/ 0
ml 0
is 0
a 0
strong 0
positive 0
predictor 0
of 0
CAM 0
. 0

A 0
positive 0
correlation 0
between 0
serum B-gene
myoglobin I-gene
and 0
CA B-gene
III I-gene
concentrations 0
( 0
rs 0
= 0
0.933 0
, 0
P 0
< 0
0.001 0
) 0
was 0
observed 0
in 0
hemodialyzed 0
patients 0
with 0
chronic 0
renal 0
failure 0
. 0

Furthermore 0
, 0
the 0
over 0
- 0
replication 0
phenotype 0
produced 0
by 0
this 0
mutant B-gene
p65cdc18 I-gene
is 0
resistant 0
to 0
increased 0
mitotic 0
cyclin/CDK B-gene
activity 0
, 0
a 0
known 0
inhibitor 0
of 0
over 0
- 0
replication 0
. 0

Rip1p B-gene
is 0
inessential 0
, 0
associated 0
with 0
nuclear 0
pore 0
complexes 0
, 0
and 0
structurally 0
related 0
to 0
the 0
FG B-gene
- I-gene
nucleoporin I-gene
family I-gene
of 0
pore 0
proteins 0
. 0

The 0
CNXA 0
domain 0
is 0
similar 0
at 0
the 0
amino 0
acid 0
level 0
to 0
the 0
Escherichia B-gene
coli I-gene
moaA I-gene
gene I-gene
product I-gene
, 0
while 0
CNXC 0
is 0
similar 0
to 0
the 0
E. B-gene
coli I-gene
moaC I-gene
product I-gene
, 0
with 0
both 0
E. 0
coli 0
products 0
encoded 0
by 0
different 0
cistrons 0
. 0

Deletions 0
in 0
each 0
of 0
these 0
regions 0
abolish 0
membrane 0
localization 0
of 0
Tiam1 B-gene
and 0
membrane 0
ruffling 0
, 0
suggesting 0
that 0
they 0
function 0
cooperatively 0
. 0

However 0
, 0
besides 0
the 0
kinase 0
catalytic 0
domain 0
and 0
double 0
leucine/isoleucine 0
zippers 0
, 0
there 0
was 0
no 0
significant 0
homology 0
with 0
known 0
proteins 0
. 0

RNA B-gene
polymerase I-gene
II I-gene
inhibition 0
increased 0
the 0
binding 0
of 0
ARE 0
( 0
AUBP 0
activity 0
) 0
and 0
poly 0
( 0
U 0
) 0
- 0
Sepharose 0
by 0
cytoplasmic B-gene
hnRNP I-gene
A1 I-gene
, 0
while 0
nuclear B-gene
hnRNP I-gene
A1 I-gene
binding 0
was 0
unaffected 0
. 0

Modulation 0
of 0
AUUUA 0
response 0
element 0
binding 0
by 0
heterogeneous B-gene
nuclear I-gene
ribonucleoprotein I-gene
A1 I-gene
in 0
human 0
T 0
lymphocytes 0
. 0

Histological 0
slides 0
of 0
one 0
biopsy 0
of 0
each 0
patient 0
( 0
formalin 0
- 0
fixed 0
and 0
paraffin 0
- 0
embedded 0
) 0
were 0
stained 0
with 0
a 0
Modified 0
Giemsa 0
( 0
MG 0
) 0
, 0
the 0
Warthin 0
- 0
Starry 0
( 0
WS 0
) 0
, 0
and 0
an 0
immunohistochemical 0
method 0
( 0
IMM 0
) 0
using 0
purified 0
polyclonal 0
H. 0
pylori 0
antiserum 0
( 0
DAKO 0
B471 0
) 0
. 0

Their 0
biosynthesis 0
proceeds 0
via 0
linear 0
precursors 0
that 0
become 0
branched 0
by 0
beta1,6 B-gene
- I-gene
GlcNAc I-gene
transferases I-gene
( 0
IGnT6 0
, 0
GlcNAc 0
to 0
Gal 0
) 0
. 0

These 0
findings 0
indicate 0
that 0
the 0
t 0
( 0
4 0
; 0
14 0
) 0
( 0
p16.3 0
; 0
q32 0
) 0
represents 0
a 0
novel 0
, 0
recurrent 0
chromosomal 0
translocation 0
in 0
MM 0
, 0
and 0
suggest 0
that 0
the 0
FGFR3 B-gene
gene I-gene
may 0
be 0
the 0
target 0
of 0
this 0
abnormality 0
and 0
thus 0
contribute 0
to 0
tumorigenesis 0
in 0
MM 0
. 0

In 0
addition 0
, 0
mutation 0
of 0
the 0
Sp1 B-gene
site I-gene
also 0
significantly 0
reduced 0
promoter 0
activity 0
. 0

Amino 0
acid 0
residues 0
of 0
beta 0
1 0
' 0
, 0
alpha 0
A 0
' 0
, 0
alpha 0
B 0
' 0
, 0
and 0
the 0
loop 0
containing 0
His539 0
of 0
the 0
RNase B-gene
H I-gene
domain I-gene
interact 0
with 0
the 0
primer 0
strand 0
of 0
the 0
dsDNA 0
. 0

Moreover 0
, 0
in 0
one 0
patient 0
with 0
a 0
sarcoma 0
who 0
underwent 0
a 0
leg 0
- 0
sparing 0
procedure 0
, 0
no 0
sciatic 0
nerve 0
enlargement 0
was 0
seen 0
postoperatively 0
. 0

The 0
full 0
length 0
cDNA 0
sequence 0
of 0
a 0
Type B-gene
I I-gene
transforming I-gene
growth I-gene
factor I-gene
- I-gene
beta I-gene
( I-gene
TGF I-gene
- I-gene
beta I-gene
) I-gene
receptor I-gene
has 0
been 0
isolated 0
from 0
the 0
filarial 0
parasitic 0
nematode 0
Brugia 0
pahangi 0
. 0

This 0
sequence 0
possessed 0
homology 0
with 0
a 0
methylation 0
- 0
sensitive 0
promoter 0
element 0
, 0
Enh2 0
, 0
present 0
in 0
the 0
LTR 0
of 0
mouse 0
intractisternal 0
A 0
- 0
particles 0
. 0

Codon 0
optimization 0
for 0
high 0
- 0
level 0
expression 0
of 0
human B-gene
erythropoietin I-gene
( 0
EPO B-gene
) 0
in 0
mammalian 0
cells 0
. 0

Parodoxical 0
rise 0
in 0
urinary B-gene
albumin I-gene
levels 0
after 0
treatment 0
of 0
essential 0
hypertension 0
. 0

20 0
% 0
of 0
total 0
HSL B-gene
transcripts I-gene
in 0
human 0
subcutaneous 0
adipocytes 0
. 0

Taken 0
together 0
, 0
our 0
data 0
suggest 0
that 0
Rat7p/Nup159p B-gene
is 0
anchored 0
within 0
the 0
NPC 0
through 0
its 0
coiled 0
- 0
coil 0
region 0
and 0
adjacent 0
sequences 0
. 0

In 0
a 0
group 0
of 0
13 0
patients 0
with 0
obliterative 0
arteriopathies 0
of 0
the 0
lower 0
limbs 0
the 0
plasma 0
levels 0
of 0
thrombomodulin B-gene
( 0
TM B-gene
) 0
, 0
betathromboglobulin B-gene
( 0
beta B-gene
- I-gene
TG I-gene
) 0
, 0
D 0
- 0
dimer 0
( 0
DD 0
) 0
and 0
plasminogen B-gene
activator I-gene
- I-gene
inhibitor I-gene
( 0
pAI B-gene
- I-gene
1 I-gene
) 0
were 0
measured 0
, 0
and 0
compared 0
to 0
the 0
values 0
obtained 0
from 0
10 0
healthy 0
volunteers 0
. 0

These 0
residues 0
, 0
Ile244 0
at 0
the 0
extracellular 0
end 0
of 0
transmembrane 0
helix 0
3 0
, 0
and 0
Tyr318 0
at 0
the 0
COOH 0
- 0
terminal 0
portion 0
of 0
extracellular 0
loop 0
2 0
, 0
are 0
replaced 0
by 0
Leu 0
and 0
Ile 0
in 0
the 0
PTH B-gene
- I-gene
1 I-gene
receptor I-gene
, 0
respectively 0
. 0

We 0
have 0
now 0
shown 0
that 0
in 0
vivo 0
phosphorylation 0
of 0
14 B-gene
- I-gene
3 I-gene
- I-gene
3 I-gene
zeta I-gene
at 0
the 0
CKIalpha B-gene
site I-gene
( I-gene
Thr I-gene
- I-gene
233 I-gene
) I-gene
negatively 0
regulates 0
its 0
binding 0
to 0
c B-gene
- I-gene
Raf I-gene
, 0
and 0
may 0
be 0
important 0
in 0
Raf B-gene
- 0
mediated 0
signal 0
transduction 0
. 0

Mouse B-gene
mast I-gene
cell I-gene
protease I-gene
9 I-gene
, 0
a 0
novel 0
member 0
of 0
the 0
chromosome 0
14 0
family 0
of 0
serine B-gene
proteases I-gene
that 0
is 0
selectively 0
expressed 0
in 0
uterine 0
mast 0
cells 0
. 0

A 0
DNase B-gene
I I-gene
- I-gene
hypersensitive I-gene
site I-gene
has 0
also 0
been 0
mapped 0
in 0
the 0
258 0
- 0
base 0
pair 0
enhancer 0
region 0
. 0

[ 0
Pulmonary 0
vascular 0
resistance 0
( 0
PVR 0
) 0
during 0
10 0
% 0
O2 0
- 0
PVR 0
during 0
21 0
% 0
O2/PVR 0
during 0
21 0
% 0
O2 0
] 0
x 0
100 0
was 0
termed 0
as 0
hypoxic 0
pulmonary 0
vasoconstriction 0
( 0
HPV 0
) 0
. 0

Together 0
, 0
our 0
results 0
show 0
that 0
tinman B-gene
is 0
controlled 0
by 0
an 0
array 0
of 0
discrete 0
enhancer 0
elements 0
that 0
are 0
activated 0
successively 0
by 0
differential 0
genetic 0
inputs 0
, 0
as 0
well 0
as 0
by 0
closely 0
linked 0
activator 0
and 0
repressor 0
binding 0
sites 0
within 0
an 0
early 0
- 0
acting 0
enhancer 0
, 0
which 0
restrict 0
twist B-gene
activity 0
to 0
specific 0
areas 0
within 0
the 0
twist B-gene
expression I-gene
domain I-gene
. 0

An 0
unusual 0
cysteine 0
triplet 0
conserved 0
in 0
the 0
sequences 0
of 0
TB B-gene
domains I-gene
is 0
localized 0
to 0
the 0
hydrophobic 0
core 0
, 0
at 0
the 0
C 0
- 0
terminus 0
of 0
an 0
alpha 0
- 0
helix 0
. 0

The 0
Fis B-gene
protein I-gene
regulates 0
site 0
- 0
specific 0
DNA 0
inversion 0
catalyzed 0
by 0
a 0
family 0
of 0
DNA B-gene
invertases I-gene
when 0
bound 0
to 0
a 0
cis 0
- 0
acting 0
recombinational 0
enhancer 0
. 0

Protein 0
phosphatases 0
play 0
a 0
critical 0
role 0
in 0
the 0
regulation 0
of 0
the 0
eukaryotic 0
cell 0
cycle 0
and 0
signal 0
transduction 0
. 0

The 0
cell 0
cycle 0
- 0
regulated 0
transcription 0
factor 0
E2F B-gene
is 0
also 0
known 0
to 0
bend 0
DNA 0
upon 0
binding 0
. 0

Our 0
study 0
reveals 0
that 0
the 0
modular 0
structure 0
of 0
the 0
FSH B-gene
receptor I-gene
gene 0
generates 0
motifs 0
that 0
allows 0
coupling 0
to 0
different 0
effectors 0
. 0

Transcriptional 0
regulation 0
of 0
SUP35 B-gene
and 0
SUP45 B-gene
in I-gene
Saccharomyces I-gene
cerevisiae I-gene
. 0

These 0
studies 0
serve 0
as 0
the 0
basis 0
for 0
the 0
further 0
characterization 0
of 0
the 0
regulatory 0
mechanism 0
of 0
aromatase B-gene
expression 0
in 0
human 0
breast 0
cancer 0
and 0
ASCs 0
. 0

Xenopus B-gene
Ran I-gene
- I-gene
binding I-gene
protein I-gene
1 I-gene
: 0
molecular 0
interactions 0
and 0
effects 0
on 0
nuclear 0
assembly 0
in 0
Xenopus 0
egg 0
extracts 0
. 0

She 0
improved 0
with 0
a 0
combination 0
of 0
benzodiazepines 0
and 0
the 0
acetylcholinesterase B-gene
inhibitor 0
physostigmine 0
. 0

METHODS 0
: 0
Total 0
muscle 0
paralysis 0
was 0
induced 0
under 0
general 0
anesthesia 0
in 0
a 0
group 0
of 0
obese 0
persons 0
( 0
n 0
= 0
9 0
; 0
body 0
mass 0
index 0
, 0
32 0
+/ 0
- 0
3 0
kg 0
[ 0
- 0
2 0
] 0
) 0
and 0
in 0
a 0
group 0
of 0
nonobese 0
persons 0
( 0
n 0
= 0
9 0
; 0
body 0
mas 0
index 0
, 0
21 0
+/ 0
- 0
2 0
kg 0
[ 0
- 0
2 0
] 0
) 0
. 0

PKA B-gene
phosphorylated 0
WT1 B-gene
at 0
Ser 0
- 0
365 0
and 0
Ser 0
- 0
393 0
in 0
vitro 0
, 0
as 0
well 0
as 0
at 0
additional 0
sites 0
, 0
and 0
this 0
phosphorylation 0
abolished 0
the 0
DNA 0
- 0
binding 0
activity 0
of 0
WT1 B-gene
in 0
vitro 0
. 0

Our 0
findings 0
provide 0
the 0
first 0
evidence 0
that 0
the 0
function 0
of 0
WT1 B-gene
can 0
be 0
modulated 0
by 0
its 0
phosphorylation 0
in 0
vivo 0
. 0

Re 0
: 0
`` 0
Assessing 0
the 0
direction 0
of 0
causality 0
in 0
cross 0
- 0
sectional 0
studies 0
'' 0
. 0

A 0
second 0
aim 0
was 0
to 0
determine 0
whether 0
the 0
decrease 0
in 0
muscle 0
- 0
tendon 0
unit 0
rest 0
length 0
produced 0
by 0
prolonged 0
immobilisation 0
in 0
a 0
shortened 0
position 0
is 0
mediated 0
primarily 0
by 0
adaptations 0
of 0
the 0
muscle 0
or 0
tendon 0
. 0

The 0
presence 0
of 0
an 0
additional 0
sequence 0
of 0
nucleotides 0
145 0
- 0
165 0
from 0
the 0
3 0
' 0
end 0
of 0
RNA3 B-gene
enhanced 0
template 0
recognition 0
by 0
RdRp B-gene
in 0
vitro 0
and 0
accumulation 0
of 0
RNA3 B-gene
in 0
vivo 0
to 0
wild 0
- 0
type 0
levels 0
. 0

We 0
argue 0
that 0
the 0
primary 0
role 0
of 0
hh B-gene
in 0
controlling 0
polarity 0
is 0
to 0
cause 0
anterior 0
compartment 0
cells 0
to 0
reverse 0
their 0
interpretation 0
of 0
an 0
underlying 0
symmetric 0
polarization 0
. 0

Restriction 0
enzyme 0
mapping 0
, 0
subcloning 0
, 0
and 0
DNA 0
sequencing 0
analysis 0
of 0
recombinant 0
phage 0
lambda 0
and 0
P1 0
clones 0
revealed 0
that 0
exons 0
encoding 0
the 0
1.9 0
- 0
kb 0
mouse B-gene
TS I-gene
mRNA I-gene
are 0
dispersed 0
over 0
> 0
150 0
kb 0
genomic 0
DNA 0
. 0

Transfection 0
analyses 0
indicated 0
that 0
the 0
expression 0
of 0
Tbxas1 B-gene
is 0
controlled 0
by 0
a 0
short 0
( 0
70 0
- 0
bp 0
) 0
positive 0
regulatory 0
sequence 0
and 0
several 0
upstream 0
repressive 0
elements 0
. 0

The 0
results 0
of 0
this 0
study 0
suggest 0
that 0
NF B-gene
- I-gene
kappaB I-gene
activity 0
may 0
be 0
regulated 0
by 0
its 0
interaction 0
with 0
the 0
cell 0
cycle 0
regulatory 0
protein 0
, 0
E2F B-gene
- I-gene
1 I-gene
. 0

The 0
lysozyme B-gene
FEF B-gene
site 0
is 0
immediately 0
5 0
' 0
to 0
a 0
PU B-gene
. 0

Osteocalcin B-gene
( 0
OC B-gene
) 0
is 0
a 0
matrix B-gene
calcium I-gene
- I-gene
binding I-gene
protein I-gene
expressed 0
in 0
osteoblasts 0
and 0
odontoblasts 0
undergoing 0
mineralization 0
. 0

In 0
this 0
study 0
, 0
we 0
examine 0
the 0
effects 0
of 0
Msx2 B-gene
expression 0
on 0
OC B-gene
promoter I-gene
activation 0
( 0
luciferase B-gene
reporter I-gene
) 0
by 0
FGF2/FSK B-gene
and 0
calcitriol 0
in 0
MC3T3 0
- 0
E1 0
osteoblasts 0
. 0

Thus 0
, 0
unlike 0
other 0
proteins 0
reported 0
to 0
inhibit 0
SRF B-gene
activity 0
, 0
the 0
repressor 0
activity 0
associated 0
with 0
the 0
GC 0
- 0
rich 0
element 0
does 0
not 0
appear 0
to 0
function 0
through 0
direct 0
inhibition 0
of 0
SRF B-gene
binding 0
. 0

However 0
, 0
one 0
CAK B-gene
- 0
phosphorylated 0
phosphopeptide 0
comigrates 0
with 0
a 0
Cdc2 B-gene
- 0
phosphorylated 0
phosphopeptide 0
previously 0
shown 0
to 0
be 0
mitosis 0
- 0
specific 0
, 0
suggesting 0
that 0
, 0
in 0
vitro 0
, 0
CAK B-gene
is 0
able 0
to 0
phosphorylate 0
at 0
least 0
one 0
site 0
that 0
is 0
also 0
phosphorylated 0
in 0
vivo 0
. 0

The 0
pen 0
can 0
heal 0
. 0

The 0
mHIF B-gene
- I-gene
1 I-gene
alpha I-gene
structural I-gene
gene I-gene
is 0
composed 0
of 0
15 0
exons 0
. 0

However 0
, 0
when 0
a 0
second 0
, 0
upstream B-gene
IRE I-gene
- I-gene
like I-gene
sequence I-gene
was 0
evaluated 0
by 0
EMSA 0
, 0
a 0
DNA 0
binding 0
pattern 0
distinct 0
from 0
that 0
seen 0
following 0
exposure 0
to 0
IFN B-gene
- I-gene
gamma I-gene
alone 0
was 0
observed 0
after 0
prolonged 0
stimulation 0
with 0
both 0
IFN B-gene
- I-gene
alpha I-gene
and 0
IFN B-gene
- I-gene
gamma I-gene
. 0

In 0
Arabidopsis 0
, 0
the 0
induction 0
of 0
a 0
dehydration 0
- 0
responsive 0
gene 0
, 0
rd22 B-gene
, 0
is 0
mediated 0
by 0
abscisic 0
acid 0
( 0
ABA 0
) 0
and 0
requires 0
protein 0
biosynthesis 0
for 0
ABA 0
- 0
dependent 0
gene 0
expression 0
. 0

A 0
cDNA 0
encoding 0
a 0
MYC B-gene
- I-gene
related I-gene
DNA I-gene
binding I-gene
protein I-gene
was 0
isolated 0
by 0
DNA 0
- 0
ligand 0
binding 0
screening 0
, 0
using 0
the 0
67 0
- 0
bp 0
region 0
as 0
a 0
probe 0
, 0
and 0
designated 0
rd22BP1 B-gene
. 0

Human B-gene
PDK1 I-gene
is 0
homologous 0
to 0
the 0
Drosophila B-gene
protein I-gene
kinase I-gene
DSTPK61 I-gene
, 0
which 0
has 0
been 0
implicated 0
in 0
the 0
regulation 0
of 0
sex 0
differentiation 0
, 0
oogenesis 0
and 0
spermatogenesis 0
. 0

Thus 0
, 0
the 0
synergistic 0
effects 0
of 0
HNF B-gene
- I-gene
1beta I-gene
and 0
the 0
GR B-gene
on 0
dexamethasone 0
- 0
stimulated 0
promoter 0
activity 0
require 0
that 0
they 0
are 0
bound 0
to 0
the 0
HNF B-gene
- I-gene
1 I-gene
site I-gene
and 0
the 0
GRE 0
, 0
respectively 0
, 0
and 0
may 0
involve 0
protein 0
- 0
protein 0
interactions 0
between 0
the 0
transcription 0
factors 0
, 0
or 0
between 0
them 0
and 0
the 0
basal 0
transcription 0
machinery 0
or 0
a 0
steroid B-gene
receptor I-gene
coactivator I-gene
. 0

Mutational 0
analysis 0
shows 0
that 0
both 0
an 0
AP B-gene
- I-gene
1 I-gene
like I-gene
sequence I-gene
( 0
- 0
294/ 0
- 0
285 0
, 0
TGAATCATCA 0
) 0
and 0
an 0
A/T 0
- 0
rich 0
myocyte B-gene
enhancer I-gene
factor I-gene
( I-gene
MEF I-gene
) I-gene
- I-gene
2 I-gene
like I-gene
sequence I-gene
( 0
- 0
310/ 0
- 0
298 0
, 0
TTAAAAATAAAAA 0
) 0
in 0
the 0
33 0
- 0
bp 0
region 0
are 0
necessary 0
for 0
the 0
OP B-gene
- I-gene
1 I-gene
effect 0
. 0

Unlike 0
most 0
other 0
members 0
of 0
the 0
Bcl B-gene
- I-gene
2 I-gene
family I-gene
, 0
BAD B-gene
( 0
Bcl B-gene
- I-gene
xL/Bcl I-gene
- I-gene
2 I-gene
associated I-gene
death I-gene
promoter I-gene
) 0
, 0
a 0
death B-gene
enhancer I-gene
, 0
has 0
no 0
C 0
- 0
terminal 0
transmembrane 0
domain 0
for 0
targeting 0
to 0
the 0
outer 0
mitochondrial 0
membrane 0
and 0
nuclear 0
envelope 0
. 0

Electromobility 0
shift 0
and 0
cotransfection 0
assays 0
demonstrated 0
that 0
HNF1alpha B-gene
, 0
but 0
not 0
HNF4 B-gene
, 0
bound 0
to 0
its 0
cognate 0
site 0
and 0
transactivated 0
G6Pase B-gene
gene I-gene
expression 0
. 0

An 0
open 0
reading 0
frame 0
of 0
2862 0
bp 0
encoding 0
a 0
954 0
amino 0
acid 0
protein 0
was 0
identified 0
. 0

One 0
of 0
these 0
, 0
an 0
AACA 0
motif 0
, 0
has 0
been 0
shown 0
to 0
be 0
a 0
negative 0
regulator 0
in 0
non 0
- 0
seed 0
tissues 0
and 0
has 0
a 0
similarity 0
to 0
the 0
barley 0
gibberellin 0
responsive 0
element 0
recognized 0
by 0
MYB B-gene
- I-gene
like I-gene
DNA I-gene
binding I-gene
proteins I-gene
. 0

Strain 0
CFN037 0
is 0
an 0
R. 0
etli 0
mutant 0
induced 0
by 0
a 0
single 0
Tn5mob B-gene
insertion 0
in 0
the 0
promoter 0
region 0
of 0
the 0
thiCOGE B-gene
gene I-gene
cluster I-gene
. 0

Expression 0
of 0
thiamin 0
biosynthetic 0
genes 0
( 0
thiCOGE B-gene
) 0
and 0
production 0
of 0
symbiotic B-gene
terminal I-gene
oxidase I-gene
cbb3 I-gene
in 0
Rhizobium 0
etli 0
. 0

We 0
have 0
cloned 0
and 0
sequenced 0
a 0
region 0
encoding 0
a 0
lipase B-gene
operon I-gene
and 0
a 0
putative 0
, 0
previously 0
uncharacterized 0
metalloprotease B-gene
of I-gene
Vibrio I-gene
cholerae I-gene
O1 I-gene
. 0

Furthermore 0
, 0
the 0
amount 0
of 0
tRNA B-gene
( I-gene
3Lys I-gene
) I-gene
that 0
was 0
placed 0
onto 0
viral 0
RNA 0
in 0
mutated 0
viruses 0
was 0
significantly 0
less 0
than 0
that 0
placed 0
in 0
the 0
wild 0
- 0
type 0
virus 0
. 0

This 0
protein 0
is 0
present 0
in 0
both 0
HeLa 0
nuclear 0
extracts 0
and 0
S100 B-gene
extracts 0
but 0
absent 0
from 0
SR B-gene
protein I-gene
preparations 0
, 0
suggesting 0
that 0
it 0
is 0
not 0
a 0
classical 0
SR B-gene
protein I-gene
. 0

Differential 0
regulation 0
of 0
the 0
pre B-gene
- I-gene
C I-gene
and 0
pregenomic 0
promoters 0
of 0
human 0
hepatitis 0
B 0
virus 0
by 0
members 0
of 0
the 0
nuclear B-gene
receptor I-gene
superfamily I-gene
. 0

Acad 0
. 0

Chimeras 0
containing 0
IE1 B-gene
peptides I-gene
dramatically 0
activated 0
transcription 0
of 0
the 0
basal 0
promoter 0
only 0
when 0
lac B-gene
operator I-gene
sequences I-gene
were 0
present 0
. 0

The 0
results 0
of 0
replicase B-gene
assays 0
performed 0
with 0
mutant B-gene
VP2 I-gene
containing 0
a 0
deletion 0
in 0
its 0
RNA 0
- 0
binding 0
domain 0
suggests 0
that 0
the 0
essential 0
role 0
for 0
VP2 B-gene
in 0
replication 0
is 0
linked 0
to 0
the 0
protein 0
's 0
ability 0
to 0
bind 0
the 0
mRNA 0
template 0
for 0
minus 0
- 0
strand 0
synthesis 0
. 0

We 0
previously 0
described 0
two 0
alanine 0
cluster 0
mutations 0
, 0
R77 0
to 0
A 0
( 0
R77A 0
) 0
- 0
K79A 0
and 0
E192A 0
- 0
E194A 0
, 0
which 0
selectively 0
inactivated 0
the 0
triphosphatase 0
component 0
. 0

Transfection 0
of 0
HepG2 0
and 0
SK 0
- 0
N 0
- 0
MC 0
cells 0
with 0
constructs 0
deleted 0
of 0
additional 0
5' 0
- 0
flanking 0
fragments 0
permitted 0
the 0
definition 0
of 0
a 0
minimal 0
200 0
bp 0
promoter 0
fragment 0
containing 0
the 0
pseudo 0
- 0
TATA 0
box 0
and 0
two 0
putative 0
SP1 B-gene
- I-gene
binding I-gene
sites I-gene
. 0

Both 0
inserts 0
are 0
larger 0
than 0
their 0
homologues 0
in 0
eIF B-gene
- I-gene
2alpha I-gene
kinases I-gene
. 0

Three 0
monopolar 0
electrodes 0
were 0
inserted 0
into 0
the 0
left 0
and 0
right 0
lateral 0
vestibulospinal 0
tract 0
( 0
LVST 0
) 0
and 0
medial 0
vestibulospinal 0
tract 0
( 0
MVST 0
) 0
of 0
the 0
C1 0
segment 0
, 0
to 0
determine 0
the 0
pathway 0
of 0
axons 0
. 0

Epitopes 0
of 0
adhesion 0
- 0
perturbing 0
monoclonal 0
antibodies 0
map 0
within 0
a 0
predicted 0
alpha 0
- 0
helical 0
domain 0
of 0
the 0
integrin B-gene
beta I-gene
1 I-gene
subunit I-gene
. 0

Polyhomeotic B-gene
and I-gene
Posterior I-gene
Sex I-gene
Combs I-gene
may 0
participate 0
in 0
a 0
more 0
general 0
transcriptional 0
mechanism 0
that 0
causes 0
modulated 0
gene 0
repression 0
, 0
whereas 0
the 0
inclusion 0
of 0
Polycomb B-gene
protein I-gene
in 0
the 0
complex 0
at 0
PREs B-gene
leads 0
to 0
stable 0
silencing 0
. 0

Furthermore 0
, 0
both 0
rhHR23 B-gene
proteins I-gene
function 0
in 0
a 0
defined 0
NER 0
system 0
reconstituted 0
with 0
purified 0
proteins 0
, 0
indicating 0
direct 0
involvement 0
of 0
hHR23 B-gene
proteins I-gene
in 0
the 0
DNA 0
repair 0
reaction 0
via 0
interaction 0
with 0
XPC B-gene
. 0

The 0
yeast 0
silent B-gene
information I-gene
regulator I-gene
Sir4p I-gene
anchors 0
and 0
partitions 0
plasmids 0
. 0

These 0
results 0
implicate 0
a 0
precursor 0
- 0
specific 0
base 0
- 0
paired 0
structure 0
involving 0
sequences 0
on 0
both 0
sides 0
of 0
the 0
mature 0
cleavage 0
site 0
in 0
the 0
3 0
' 0
processing 0
of 0
human B-gene
U2 I-gene
RNA I-gene
. 0

Polysome 0
analyses 0
in 0
a 0
temperature 0
- 0
sensitive 0
fal1 B-gene
- I-gene
1 I-gene
mutant I-gene
and 0
a 0
Fal1p B-gene
- 0
depleted 0
strain 0
reveal 0
a 0
decrease 0
in 0
the 0
number 0
of 0
40S B-gene
ribosomal I-gene
subunits I-gene
. 0

Sequence 0
analysis 0
identified 0
some 0
of 0
these 0
cDNA 0
clones 0
as 0
Dlc B-gene
- I-gene
1 I-gene
, 0
a 0
sequence 0
encoding 0
a 0
small 0
, 0
9 B-gene
- I-gene
kDa I-gene
human I-gene
homolog I-gene
of I-gene
the I-gene
outer I-gene
- I-gene
arm I-gene
dynein I-gene
light I-gene
- I-gene
chain I-gene
protein 0
. 0

Importantly 0
, 0
in 0
HeLa 0
and 0
293 0
cells 0
, 0
endogenous 0
and 0
transfected 0
I B-gene
kappaB I-gene
alpha I-gene
coimmunoprecipitated 0
with 0
Myc B-gene
- 0
tagged 0
or 0
endogenous 0
Dlc B-gene
- I-gene
1 I-gene
. 0

The 0
mouse B-gene
M I-gene
- I-gene
lysozyme I-gene
downstream I-gene
enhancer I-gene
has 0
been 0
previously 0
characterized 0
on 0
several 0
levels 0
of 0
gene 0
regulation 0
. 0

Identification 0
of 0
dynein B-gene
heavy I-gene
chain I-gene
genes I-gene
expressed 0
in 0
human 0
and 0
mouse 0
testis 0
: 0
chromosomal 0
localization 0
of 0
an 0
axonemal B-gene
dynein I-gene
gene I-gene
. 0

Bitter 0
cassava 0
contains 0
cyanogenic 0
glycosides 0
; 0
processing 0
breaks 0
them 0
down 0
to 0
acetone 0
cyanohydrin 0
and 0
hydrogen 0
cyanide 0
. 0

The 0
proposed 0
mechanism 0
of 0
effect 0
states 0
that 0
mono 0
( 0
2 0
- 0
ethylhexyl 0
) 0
phthalate 0
( 0
MEHP 0
) 0
, 0
the 0
primary 0
hydrolysis 0
product 0
of 0
DEHP 0
, 0
mimics 0
the 0
inducing 0
prostaglandins 0
( 0
PG 0
) 0
PGD 0
( 0
2 0
) 0
, 0
9alpha,11betaPGF2 0
, 0
and 0
PGF2alpha 0
, 0
and 0
thromboxanes 0
in 0
the 0
lungs 0
, 0
thereby 0
increasing 0
the 0
risk 0
of 0
inducing 0
inflammation 0
in 0
the 0
airways 0
, 0
which 0
is 0
a 0
characteristic 0
of 0
asthma 0
. 0

We 0
found 0
14 0
protein 0
binding 0
sites 0
that 0
were 0
occupied 0
in 0
vivo 0
. 0

Constitutive 0
protection 0
of 0
E2F B-gene
recognition I-gene
sequences I-gene
in 0
the 0
human B-gene
thymidine I-gene
kinase I-gene
promoter I-gene
during 0
cell 0
cycle 0
progression 0
. 0

Comparison 0
of 0
genomic 0
sequence 0
shows 0
that 0
the 0
ph B-gene
locus I-gene
has 0
been 0
duplicated 0
, 0
and 0
that 0
it 0
contains 0
proximal 0
and 0
distal 0
transcription 0
units 0
. 0

Radiation 0
decreased 0
the 0
levels 0
of 0
T4 0
and 0
T3 0
6 0
h 0
and 0
72 0
h 0
in 0
group 0
C 0
, 0
in 0
group 0
A 0
at 0
72 0
h 0
, 0
in 0
group 0
B 0
at 0
24 0
h 0
postexposure 0
. 0

We 0
have 0
reviewed 0
the 0
experience 0
of 0
a 0
major 0
MMT 0
general 0
practice 0
with 0
hepatitis 0
C 0
virus 0
( 0
HCV 0
) 0
infection 0
from 0
1991 0
to 0
1995 0
. 0

The 0
author 0
analyzes 0
extensive 0
own 0
data 0
based 0
on 0
study 0
into 0
particular 0
features 0
of 0
cardiovascular 0
disorders 0
in 0
chronic 0
renal 0
impairement 0
with 0
making 0
use 0
of 0
modern 0
diagnostic 0
tools 0
. 0

In 0
this 0
paper 0
, 0
characterization 0
is 0
given 0
of 0
clinical 0
and 0
biochemical 0
features 0
of 0
VH 0
B 0
course 0
against 0
the 0
background 0
of 0
narcomania 0
. 0

447 0
microns 0
for 0
A. 0
microcephalum 0
and 0
350 0
microns 0
for 0
A. 0
wedli 0
) 0
, 0
and 0
fewer 0
testes 0
per 0
proglottis 0
( 0
44 0
- 0
73 0
vs 0
. 0

The 0
ZnF20 B-gene
cDNA I-gene
hybridized 0
to 0
multiple 0
transcripts 0
in 0
a 0
thyroid 0
cancer 0
cell 0
line 0
( 0
8.0 0
, 0
4.5 0
and 0
2 0
kb 0
) 0
that 0
increased 0
after 0
cycloheximide 0
treatment 0
and 0
decayed 0
< 0
2 0
h 0
after 0
addition 0
of 0
actinomycin 0
D 0
. 0

Glutathione B-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
- 0
E2F B-gene
and 0
GST B-gene
- 0
DP B-gene
fusion 0
proteins 0
were 0
found 0
to 0
cooperate 0
in 0
binding 0
to 0
the 0
three 0
E2F B-gene
sites I-gene
in 0
the 0
DNA B-gene
polymerase I-gene
alpha I-gene
gene I-gene
promoter I-gene
in 0
vitro 0
. 0

Two 0
sterol 0
regulatory 0
element 0
- 0
like 0
sequences 0
mediate 0
up 0
- 0
regulation 0
of 0
caveolin B-gene
gene I-gene
transcription 0
in 0
response 0
to 0
low B-gene
density I-gene
lipoprotein I-gene
free 0
cholesterol 0
. 0

Furthermore 0
, 0
DNA 0
- 0
bound 0
LAZ3/BCL6 B-gene
recruits 0
LAZ3/BCL6 I-gene

CONCLUSIONS 0
: 0
We 0
obtained 0
normal 0
EPO B-gene
levels 0
for 0
mothers 0
and 0
newborns 0
for 0
our 0
area 0
, 0
similarly 0
to 0
the 0
previously 0
described 0
ones 0
. 0

Ischaemia 0
was 0
induced 0
by 0
a 0
low 0
flow 0
rate 0
of 0
0.8 0
mL 0
min 0
- 0
1 0
for 0
30 0
min 0
, 0
and 0
was 0
followed 0
by 0
a 0
40 0
- 0
minute 0
reperfusion 0
. 0

First 0
, 0
two 0
MCTs 0
using 0
a 0
long 0
electrode 0
, 0
3 0
cm 0
in 0
size 0
, 0
were 0
performed 0
in 0
the 0
central 0
area 0
of 0
the 0
tumor 0
, 0
and 0
eight 0
MCTs 0
by 0
a 0
short 0
electrode 0
, 0
2 0
cm 0
in 0
size 0
, 0
were 0
done 0
in 0
the 0
peripheral 0
and 0
surrounding 0
area 0
of 0
the 0
tumor 0
. 0

BACKGROUND 0
: 0
Checkpoint 0
pathways 0
prevent 0
cell 0
- 0
cycle 0
progression 0
in 0
the 0
event 0
of 0
DNA 0
lesions 0
. 0

Direct 0
proof 0
that 0
the 0
heightened 0
renal 0
cellular 0
apoptosis 0
in 0
PKD 0
is 0
not 0
occurring 0
through 0
p53 B-gene
was 0
obtained 0
by 0
successive 0
matings 0
between 0
SBM 0
and 0
p53 B-gene
( 0
- 0
/ 0
- 0
) 0
mice 0
. 0

Accumulated 0
evidence 0
indicates 0
that 0
, 0
upon 0
stimulation 0
with 0
interferon B-gene
- I-gene
gamma I-gene
( 0
IFN B-gene
- I-gene
gamma I-gene
) 0
, 0
three 0
beta 0
- 0
type 0
subunits 0
, 0
designated 0
LMP2 B-gene
, 0
LMP7 B-gene
, 0
and 0
PSMB10 B-gene
, 0
are 0
incorporated 0
into 0
the 0
20S B-gene
proteasome I-gene
by 0
displacing 0
the 0
housekeeping 0
beta 0
- 0
type 0
subunits 0
designated 0
PSMB6 B-gene
, 0
PSMB5 B-gene
, 0
and 0
PSMB7 B-gene
, 0
respectively 0
. 0

The 0
major 0
RNase B-gene
E I-gene
cleavage 0
product 0
( 0
denoted 0
pSok B-gene
- I-gene
6 I-gene
) 0
is 0
rapidly 0
degraded 0
by 0
polynucleotide B-gene
phosphorylase I-gene
( 0
PNPase B-gene
) 0
. 0

This 0
difference 0
may 0
result 0
from 0
the 0
lower 0
match 0
to 0
the 0
ARG 0
box 0
consensus 0
of 0
the 0
O B-gene
( I-gene
rocD I-gene
) I-gene
site I-gene
. 0

Ask 0
AONE 0
's 0
experts 0
... 0
about 0
productivity 0
indicators 0
. 0

All 0
pigs 0
had 0
significant 0
regional 0
LV 0
dysfunction 0
and 0
reduced 0
LV 0
ejection 0
fraction 0
( 0
41+/ 0
- 0
11 0
% 0
) 0
. 0

The 0
progress 0
of 0
morphological 0
research 0
on 0
the 0
parabrachial 0
nucleus 0

The 0
amplitudes 0
of 0
DPOAE 0
also 0
recovered 0
to 0
a 0
greater 0
extent 0
and 0
outer 0
hair 0
cell 0
losses 0
were 0
less 0
severe 0
in 0
the 0
R 0
- 0
PIA 0
- 0
treated 0
ears 0
. 0

The 0
data 0
provide 0
evidence 0
both 0
for 0
a 0
signal 0
transduction 0
pathway 0
independent 0
of 0
JNK B-gene
, 0
ERK B-gene
, 0
and 0
p38 B-gene
MAP B-gene
kinase I-gene
to 0
be 0
involved 0
in 0
the 0
induction 0
of 0
rhoB B-gene
by 0
genotoxic 0
stress 0
, 0
and 0
furthermore 0
, 0
indicate 0
autoregulation 0
of 0
rhoB B-gene
. 0

In 0
an 0
effort 0
to 0
separate 0
domains 0
of 0
FadR B-gene
required 0
for 0
DNA 0
binding 0
, 0
dimerization 0
, 0
and 0
ligand 0
binding 0
, 0
chimeric 0
protein 0
fusions 0
between 0
the 0
DNA 0
binding 0
domain 0
of 0
LexA B-gene
and 0
different 0
regions 0
of 0
FadR B-gene
were 0
constructed 0
. 0

Inhibition 0
appears 0
to 0
result 0
from 0
titration 0
of 0
general 0
transcription 0
factors 0
because 0
MDM2 B-gene
overexpression 0
inhibits 0
c B-gene
- I-gene
fos I-gene
as 0
well 0
as 0
other 0
promoters 0
in 0
vivo 0
and 0
basal 0
transcription 0
in 0
vitro 0
. 0

4 0
) 0
PU B-gene
and 0
PD B-gene
lacked 0
the 0
canonical 0
TATA 0
or 0
CAAT 0
motifs 0
, 0
and 0
are 0
AT 0
- 0
rich 0
. 0

We 0
also 0
show 0
by 0
immunogold 0
electron 0
microscopy 0
immunocytochemistry 0
that 0
amphiphysin B-gene
I I-gene
is 0
localized 0
in 0
the 0
nerve 0
terminal 0
cytomatrix 0
and 0
is 0
partially 0
associated 0
with 0
endocytic 0
intermediates 0
. 0

The 0
mobility 0
shift 0
of 0
both 0
of 0
these 0
proteins 0
is 0
abolished 0
by 0
treatment 0
with 0
inhibitors 0
of 0
PKC B-gene
or 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase/extracellular I-gene
kinase/extracellular I-gene
signal I-gene
- I-gene
related I-gene
kinase I-gene
kinase I-gene
. 0

The 0
prescription 0
for 0
apoplexy 0
includes 0
C1 0
- 0
7 0
, 0
T1 0
- 0
9 0
and 0
L2 0
- 0
4 0
. 0

During 0
the 0
aftermath 0
of 0
excitation 0
of 0
the 0
skin 0
sympathetic 0
nerve 0
by 0
mental 0
arithmetics 0
, 0
3/12 0
A 0
delta 0
units 0
were 0
turned 0
to 0
the 0
active 0
state 0
with 0
decreased 0
mechanical 0
threshold 0
. 0

In 0
a 0
similar 0
fashion 0
to 0
adipose 0
stromal 0
cells 0
, 0
serum 0
potentiated 0
the 0
response 0
to 0
dexamethasone 0
but 0
had 0
no 0
effect 0
on 0
phorbol 0
ester 0
- 0
stimulated 0
activity 0
. 0

Thus 0
, 0
Hex B-gene
expression 0
marks 0
the 0
earliest 0
unequivocal 0
molecular 0
anteroposterior 0
asymmetry 0
in 0
the 0
mouse 0
embryo 0
and 0
indicates 0
that 0
the 0
anteroposterior 0
axis 0
of 0
the 0
embryo 0
develops 0
from 0
conversion 0
of 0
a 0
proximodistal 0
asymmetry 0
established 0
in 0
the 0
primitive 0
endoderm 0
lineage 0
. 0

Thus 0
, 0
dpp B-gene
and 0
omb B-gene
promote 0
both 0
dorsal 0
leg 0
cell 0
fate 0
as 0
well 0
as 0
transdetermination 0
- 0
competent 0
leg 0
disc 0
cells 0
. 0

CONCLUSIONS 0
: 0
While 0
INR 0
correction 0
may 0
be 0
achieved 0
by 0
all 0
the 0
above 0
methods 0
, 0
that 0
relating 0
log 0
reference 0
INR 0
to 0
log 0
local 0
prothrombin B-gene
time 0
by 0
linear 0
regression 0
analysis 0
is 0
the 0
simplest 0
to 0
perform 0
. 0

RESULTS 0
: 0
The 0
overall 0
FNF 0
for 0
1992 0
was 0
12.3 0
% 0
and 0
was 0
19.1 0
% 0
, 0
22.2 0
% 0
, 0
3.8 0
% 0
and 0
6.1 0
% 0
per 0
successive 0
quarters 0
in 0
1992 0
. 0

Western 0
blot 0
analysis 0
of 0
various 0
bovine 0
tissues 0
with 0
human 0
NMT B-gene
peptide I-gene
antibody I-gene
indicated 0
a 0
common 0
prominent 0
immunoreactive 0
band 0
with 0
an 0
apparent 0
molecular 0
mass 0
of 0
48.5 0
- 0
50 0
kDa 0
in 0
all 0
tissues 0
. 0

Transcription 0
start 0
sites 0
of 0
the 0
plastid 0
ACCase B-gene
genes I-gene
were 0
estimated 0
from 0
the 0
longest 0
cDNA 0
clones 0
obtained 0
by 0
5' 0
- 0
RACE 0
( 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
) 0
. 0

AIDS 0
- 0
related 0
disseminated 0
histoplasmosis 0
in 0
San 0
Francisco 0
, 0
California 0
. 0

Thus 0
, 0
Fis B-gene
acts 0
as 0
an 0
accessory 0
transcriptional 0
activator 0
at 0
the 0
mar B-gene
promoter I-gene
. 0

These 0
observations 0
provide 0
strong 0
support 0
for 0
the 0
idea 0
that 0
expression 0
of 0
mutant 0
tRNA 0
can 0
confer 0
a 0
mutator 0
phenotype 0
, 0
including 0
the 0
UVM 0
- 0
constitutive 0
phenotype 0
observed 0
in 0
mutA B-gene
and 0
mutC B-gene
cells 0
. 0

TNF B-gene
- I-gene
alpha I-gene
exposure 0
markedly 0
increased 0
activity 0
of 0
several 0
RNA 0
- 0
binding 0
proteins 0
, 0
especially 0
a 0
novel 0
Mr 0
50,000 0
- 0
55,000 0
RNA 0
- 0
binding 0
protein 0
. 0

We 0
speculate 0
that 0
the 0
human 0
papillomavirus 0
late 0
mRNAs 0
, 0
produced 0
from 0
several 0
hundred 0
copies 0
of 0
the 0
virus 0
genome 0
present 0
in 0
infected 0
cells 0
, 0
compete 0
with 0
the 0
c B-gene
- I-gene
fos I-gene
mRNAs I-gene
for 0
destabilizing 0
cellular 0
factors 0
and 0
that 0
this 0
may 0
lead 0
to 0
elevated 0
Fos B-gene
protein I-gene
levels 0
in 0
human 0
papillomavirus 0
infected 0
cells 0
. 0

Two 0
closely 0
related 0
IgH B-gene
constant 0
region 0
genes 0
, 0
CHA B-gene
and 0
CHB B-gene
, 0
have 0
been 0
sequenced 0
completely 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
find 0
out 0
whether 0
it 0
was 0
possible 0
to 0
detect 0
normal 0
lymph 0
nodes 0
by 0
high 0
- 0
resolution 0
mediastinal 0
US 0
. 0

To 0
study 0
the 0
role 0
of 0
heavy 0
chain 0
motifs 0
in 0
substrate 0
recognition 0
, 0
secreted 0
variants 0
of 0
recombinant B-gene
bovine I-gene
proenteropeptidase I-gene
were 0
constructed 0
by 0
replacing 0
the 0
transmembrane 0
domain 0
with 0
a 0
signal 0
peptide 0
. 0

CKbeta4GT B-gene
- I-gene
II I-gene
is 0
predicted 0
to 0
encode 0
a 0
type B-gene
II I-gene
transmembrane I-gene
glycoprotein I-gene
of 0
43 0
kDa 0
with 0
five 0
potential 0
N 0
- 0
linked 0
glycosylation 0
sites 0
. 0

We 0
now 0
demonstrate 0
that 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
( I-gene
C/EBP I-gene
) I-gene
delta I-gene
is 0
a 0
major 0
component 0
of 0
a 0
PGE2 0
- 0
stimulated 0
DNA 0
- 0
protein 0
complex 0
involving 0
HS3D B-gene
and 0
find 0
that 0
C/EBPdelta B-gene
transactivates 0
IGF B-gene
- I-gene
I I-gene
promoter I-gene
1 I-gene
through 0
this 0
site 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
Semen 0
analyses 0
were 0
performed 0
on 0
58 0
patients 0
with 0
stages 0
I 0
- 0
III 0
HD 0
before 0
, 0
during 0
, 0
and 0
after 0
chemotherapy 0
and 0
after 0
the 0
sperm 0
count 0
recovered 0
from 0
the 0
effects 0
of 0
abdominal 0
radiotherapy 0
that 0
was 0
given 0
after 0
chemotherapy 0
. 0

Thus 0
, 0
the 0
absence 0
of 0
residual 0
infarct 0
- 0
zone 0
viability 0
discriminates 0
patients 0
who 0
develop 0
progressive 0
left 0
ventricular 0
dilation 0
after 0
reperfused 0
AMI 0
from 0
those 0
who 0
maintain 0
normal 0
left 0
ventricular 0
geometry 0
. 0

With 0
a 0
BMI 0
cutoff 0
of 0
27 0
, 0
mean 0
cardiac 0
NE 0
spillover 0
was 0
46 0
% 0
lower 0
in 0
the 0
obese 0
subjects 0
when 0
compared 0
with 0
the 0
lean 0
subjects 0
( 0
P=.017 0
) 0
. 0

The 0
gene 0
( 0
ApxII B-gene
) 0
encoding 0
both 0
chloroplastic B-gene
ascorbate I-gene
peroxidase I-gene
isoenzymes I-gene
was 0
isolated 0
and 0
the 0
organization 0
of 0
the 0
gene 0
was 0
determined 0
. 0

This 0
emphasizes 0
the 0
conclusion 0
that 0
CDF B-gene
- I-gene
1 I-gene
is 0
not 0
an 0
E2F B-gene
family I-gene
member I-gene
and 0
points 0
to 0
profound 0
differences 0
in 0
the 0
cell 0
cycle 0
regulation 0
of 0
CDF B-gene
- I-gene
1 I-gene
and 0
E2F B-gene
. 0

The 0
proofreading 0
domain 0
of 0
Escherichia B-gene
coli I-gene
DNA I-gene
polymerase I-gene
I I-gene
and 0
other 0
DNA B-gene
and/or I-gene
RNA I-gene
exonuclease I-gene
domains I-gene
. 0

Interleukin B-gene
- I-gene
1 I-gene
levels 0
remained 0
low 0
throughout 0
the 0
course 0
. 0

Responsibility 0
matters 0
- 0
- 0
this 0
is 0
a 0
scientific 0
council 0

Southern 0
blot 0
analysis 0
of 0
endonuclease 0
- 0
digested 0
genomic 0
DNA 0
from 0
primary 0
chick 0
embryo 0
fibroblasts 0
( 0
CEF 0
) 0
suggested 0
that 0
MEK2 B-gene
is 0
a 0
single 0
- 0
copy 0
gene 0
in 0
this 0
vertebrate 0
species 0
. 0

Sequences 0
required 0
for 0
interaction 0
of 0
mu2 B-gene
and 0
CTLA B-gene
- I-gene
4 I-gene
were 0
localized 0
to 0
residues 0
, 0
161TTGVY 0
in 0
CTLA B-gene
- I-gene
4 I-gene
; 0
this 0
sequence 0
is 0
N 0
- 0
terminal 0
to 0
, 0
but 0
overlaps 0
with 0
, 0
a 0
previously 0
identified 0
SH2 B-gene
binding I-gene
motif I-gene
, 0
165YVKM 0
, 0
involved 0
in 0
CTLA B-gene
- I-gene
4 I-gene
signaling 0
. 0

Here 0
, 0
we 0
report 0
that 0
a 0
transfected 0
Chinese 0
hamster 0
ovary 0
( 0
CHO 0
) 0
cell 0
line 0
expressing 0
a 0
murine B-gene
CD4 I-gene
fragment I-gene
containing 0
the 0
first 0
two 0
N 0
- 0
terminal 0
domains 0
secretes 0
both 0
monomeric 0
molecules 0
and 0
disulfide 0
- 0
linked 0
multimers 0
. 0

SCID 0
V B-gene
( 0
D B-gene
) 0
J B-gene
recombination 0
can 0
be 0
partly 0
rescued 0
in 0
T 0
- 0
lymphocytes 0
by 0
either 0
DNA 0
- 0
damaging 0
agents 0
( 0
gamma 0
- 0
irradiation 0
and 0
bieomycin 0
) 0
or 0
a 0
null 0
mutation 0
of 0
the 0
p53 B-gene
gene I-gene
, 0
possibly 0
because 0
of 0
transiently 0
elevated 0
DNA 0
repair 0
activity 0
in 0
response 0
to 0
DNA 0
damage 0
or 0
to 0
delayed 0
apoptosis 0
in 0
the 0
absence 0
of 0
p53 B-gene
. 0

Coexpression 0
of 0
mouse 0
PKR B-gene
( I-gene
1 I-gene
- I-gene
515 I-gene
) I-gene
WT I-gene
as 0
a 0
Gal4 B-gene
DNA 0
- 0
binding 0
domain 0
fusion 0
with 0
either 0
the 0
catalytic 0
- 0
deficient 0
human 0
PKR B-gene
( I-gene
1 I-gene
- I-gene
551 I-gene
) I-gene
K296R 0
mutant 0
, 0
the 0
RNA 0
- 0
binding 0
- 0
deficient 0
human 0
PKR B-gene
( I-gene
1 I-gene
- I-gene
551 I-gene
) I-gene
K64E/K296R I-gene
double 0
mutant 0
, 0
or 0
wild 0
- 0
type 0
mouse 0
PKR B-gene
( I-gene
1 I-gene
- I-gene
515 I-gene
) I-gene
WT I-gene
as 0
full 0
- 0
length 0
PKR B-gene
- 0
Gal4 B-gene
activation 0
domain 0
fusions 0
resulted 0
in 0
activation 0
of 0
the 0
HIS3 B-gene
and 0
lacZ B-gene
reporters 0
. 0

Using 0
GST B-gene
- 0
PKR B-gene
fusion 0
chromatography 0
, 0
direct 0
physical 0
interaction 0
between 0
the 0
mouse 0
and 0
human B-gene
PKR I-gene
homologs I-gene
was 0
established 0
. 0

An 0
even 0
greater 0
inflammatory 0
response 0
was 0
observed 0
after 0
intratracheal 0
instillation 0
of 0
ufCB 0
, 0
but 0
not 0
after 0
CB 0
instillation 0
. 0

Interestingly 0
, 0
the 0
avirulent 0
strain 0
H37Ra 0
showed 0
weak 0
hybridization 0
with 0
these 0
two 0
probes 0
, 0
suggesting 0
that 0
these 0
genes 0
might 0
have 0
been 0
deleted 0
in 0
the 0
avirulent 0
strain 0
or 0
are 0
present 0
in 0
limited 0
copy 0
numbers 0
as 0
opposed 0
to 0
those 0
in 0
the 0
virulent 0
strain 0
H37Rv 0
. 0

These 0
defects 0
no 0
doubt 0
impair 0
the 0
folding 0
and 0
configuration 0
necessary 0
for 0
normal 0
processing 0
of 0
the 0
AVP B-gene
gene I-gene
precursor I-gene
. 0

Similarities 0
between 0
the 0
hIGFBP B-gene
- I-gene
1 I-gene
and 0
phosphoenolpyruvate B-gene
kinase I-gene
( 0
PEPCK B-gene
) 0
promoters 0
, 0
including 0
regions 0
conferring 0
insulin B-gene
, 0
glucocorticoid 0
, 0
and 0
cyclic 0
adenosine 0
- 0
monophosphate 0
responses 0
, 0
are 0
consistent 0
with 0
our 0
previous 0
hypothesis 0
that 0
IGFBP B-gene
- I-gene
1 I-gene
is 0
involved 0
in 0
regulation 0
of 0
glucose 0
metabolism 0
. 0

This 0
binary 0
repeat 0
contains 0
repetitive 0
DNA 0
elements 0
that 0
include 0
LINES 0
, 0
SINES 0
, 0
medium 0
reiteration 0
frequency 0
repeats 0
, 0
and 0
a 0
transposon 0
- 0
like 0
element 0
. 0

At 0
60 0
days 0
the 0
amount 0
of 0
gangliosides 0
was 0
on 0
average 0
lower 0
in 0
females 0
than 0
in 0
males 0
, 0
even 0
if 0
with 0
some 0
exception 0
. 0

Large 0
genomic 0
constructs 0
integrate 0
at 0
the 0
endogenous 0
locus 0
by 0
homologous 0
recombination 0
, 0
but 0
cDNA 0
- 0
derived 0
sequences 0
lacking 0
long 0
stretches 0
of 0
contiguous 0
genomic 0
DNA 0
( 0
due 0
to 0
intron 0
excision 0
) 0
typically 0
integrate 0
into 0
chromosomal 0
DNA 0
by 0
nonhomologous 0
recombination 0
. 0

The 0
existence 0
of 0
these 0
two 0
categories 0
of 0
strains 0
offers 0
a 0
new 0
genetic 0
system 0
in 0
which 0
the 0
properties 0
of 0
a 0
potential 0
invertebrate 0
retrovirus 0
can 0
be 0
tested 0
. 0

During 0
the 0
conditioning 0
procedure 0
, 0
the 0
C 0
- 0
fiber 0
reflex 0
was 0
facilitated 0
( 0
wind 0
- 0
up 0
) 0
in 0
a 0
stimulus 0
- 0
dependent 0
fashion 0
in 0
intact 0
, 0
anesthetized 0
animals 0
during 0
the 0
application 0
of 0
the 0
first 0
seven 0
conditioning 0
stimuli 0
; 0
thereafter 0
, 0
the 0
magnitude 0
of 0
the 0
responses 0
reached 0
a 0
plateau 0
and 0
then 0
decreased 0
. 0

As 0
a 0
sequence 0
- 0
specific 0
DNA 0
binding 0
transcription 0
factor 0
, 0
p53 B-gene
specifically 0
binds 0
to 0
a 0
20 0
- 0
bp 0
consensus 0
motif 0
5' 0
- 0
PuPuPuC 0
( 0
A/T 0
) 0
( 0
T/A 0
) 0
GPyPyPyPuPuPuC 0
( 0
A/T 0
) 0
( 0
T/A 0
) 0
GPyPyPy 0
- 0
3 0
' 0
. 0

TSA 0
treatment 0
, 0
however 0
, 0
did 0
not 0
detectably 0
alter 0
enhancer 0
factor 0
binding 0
or 0
the 0
positioning 0
of 0
nuc B-gene
- I-gene
1 I-gene
on 0
the 0
majority 0
of 0
the 0
chromatin 0
templates 0
indicating 0
that 0
protein 0
acetylation 0
and 0
chromatin 0
remodeling 0
may 0
be 0
limiting 0
steps 0
that 0
occur 0
only 0
on 0
transcriptionally 0
competent 0
templates 0
, 0
or 0
that 0
remodeling 0
of 0
nuc B-gene
- I-gene
1 I-gene
requires 0
additional 0
factors 0
. 0

Upon 0
UV 0
damage 0
, 0
Crb2 B-gene
is 0
transiently 0
modified 0
, 0
probably 0
phosphorylated 0
, 0
with 0
a 0
similar 0
timing 0
of 0
phosphorylation 0
in 0
Chk1 B-gene
kinase I-gene
, 0
which 0
is 0
reported 0
to 0
restrain 0
Cdc2 B-gene
activation 0
. 0

Moreover 0
, 0
moderate 0
overexpression 0
of 0
Chk1 B-gene
suppresses 0
the 0
phenotypes 0
of 0
cut5 B-gene
and 0
crb2 B-gene
mutants I-gene
. 0

Tcn1p/Crz1p B-gene
, 0
a 0
calcineurin 0
- 0
dependent 0
transcription 0
factor 0
that 0
differentially 0
regulates 0
gene 0
expression 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Structure 0
and 0
localization 0
of 0
the 0
human 0
gene 0
encoding 0
SR B-gene
- I-gene
BI/CLA I-gene
BI/CLA I-gene
- I-gene
1 I-gene
. 0

We 0
introduced 0
the 0
gel 0
technique 0
as 0
a 0
routine 0
assay 0
for 0
antibody 0
detection 0
and 0
identification 0
in 0
1993 0
. 0

Stability 0
of 0
pyrimethamine 0
in 0
a 0
liquid 0
dosage 0
formulation 0
stored 0
for 0
three 0
months 0
. 0

Multiple 0
regression 0
analyses 0
revealed 0
that 0
WAIS 0
- 0
R 0
factor 0
scores 0
Verbal 0
Comprehension 0
and 0
Freedom 0
from 0
Distractibility 0
accounted 0
for 0
up 0
to 0
42 0
% 0
of 0
the 0
variance 0
in 0
WMS 0
- 0
R 0
and 0
CVLT 0
indices 0
. 0

Bilateral 0
basal 0
arteries 0
were 0
measured 0
by 0
the 0
transtemporal 0
approach 0
with 0
a 0
2 0
MHz 0
pulsed 0
Doppler 0
instrument 0
( 0
TC 0
- 0
2 0
64B 0
EME 0
) 0
. 0

At 0
the 0
genomic 0
level 0
, 0
the 0
sequences 0
of 0
two 0
members 0
of 0
this 0
family 0
are 0
known 0
in 0
the 0
rat 0
Rattus 0
norvegicus 0
: 0
the 0
VCSA1 B-gene
gene I-gene
, 0
encoding 0
the 0
prohormone B-gene
- I-gene
like I-gene
polypeptide I-gene
SMR1 I-gene
, 0
and 0
the 0
VCSB1 B-gene
gene I-gene
, 0
encoding 0
a 0
salivary 0
Pro 0
- 0
rich 0
polypeptide 0
. 0

The 0
Saccharomyces B-gene
cerevisiae I-gene
RAD30 I-gene
gene I-gene
, 0
a 0
homologue B-gene
of I-gene
Escherichia I-gene
coli I-gene
dinB I-gene
and 0
umuC B-gene
, 0
is 0
DNA 0
damage 0
inducible 0
and 0
functions 0
in 0
a 0
novel 0
error 0
- 0
free 0
postreplication 0
repair 0
mechanism 0
. 0

However 0
, 0
in 0
a 0
new 0
experiment 0
in 0
which 0
the 0
deletion 0
task 0
was 0
presented 0
as 0
a 0
puppet 0
game 0
, 0
and 0
with 0
pretraining 0
and 0
selection 0
on 0
vowel 0
deletion 0
, 0
a 0
significantly 0
higher 0
level 0
of 0
success 0
was 0
achieved 0
by 0
the 0
children 0
working 0
with 0
the 0
CVCC 0
material 0
. 0

Diet 0
therapy 0
with 0
soy 0
proteins 0
for 0
chronic 0
stomach 0
ulcers 0

In 0
ICU 0
patients 0
, 0
the 0
LIS 0
related 0
to 0
the 0
postoperative 0
rise 0
in 0
IL B-gene
- I-gene
6 I-gene
level 0
only 0
, 0
even 0
though 0
the 0
rise 0
in 0
plasma 0
concentrations 0
of 0
cytokines 0
interrelated 0
. 0

Resistance 0
training 0
shifts 0
the 0
power 0
curve 0
in 0
a 0
positive 0
direction 0
when 0
the 0
measurements 0
are 0
determined 0
with 0
absolute 0
loads 0
, 0
but 0
the 0
increased 0
power 0
may 0
not 0
be 0
transferred 0
to 0
an 0
absolute 0
performance 0
task 0
like 0
the 0
SSP 0
. 0

Gel 0
- 0
shift 0
assays 0
identified 0
two 0
Sp1 B-gene
binding I-gene
sites I-gene
within 0
this 0
element 0
. 0

Y15170 B-gene
( 0
Surf B-gene
- I-gene
2 I-gene
, 0
Surf B-gene
- I-gene
4 I-gene
) 0
, 0
Y15171 B-gene
( 0
Surf B-gene
- I-gene
3 I-gene
, 0
Surf B-gene
- I-gene
1 I-gene
, 0
Surf B-gene
- I-gene
6 I-gene
) 0
, 0
and 0
Y15172 B-gene
( 0
Surf B-gene
- I-gene
5 I-gene
. 0
) 0
] 0

Gel 0
mobility 0
shift 0
and 0
super 0
- 0
shift 0
assays 0
using 0
liver 0
nuclear 0
extracts 0
from 0
either 0
rat 0
liver 0
or 0
DDT1MF 0
- 0
2 0
cells 0
demonstrated 0
that 0
the 0
CRE 0
in 0
the 0
alpha B-gene
1B I-gene
- I-gene
AR I-gene
gene I-gene
bound 0
CRE B-gene
binding I-gene
protein I-gene
. 0

These 0
results 0
suggest 0
that 0
, 0
in 0
this 0
experimental 0
model 0
, 0
ACE B-gene
inhibitors 0
limit 0
the 0
arrhythmias 0
following 0
ischemia 0
- 0
reperfusion 0
and 0
free 0
radical 0
scavenging 0
action 0
of 0
these 0
drugs 0
does 0
not 0
have 0
a 0
major 0
contributory 0
role 0
in 0
their 0
protective 0
effect 0
. 0

The 0
mean 0
values 0
of 0
the 0
first 0
three 0
components 0
were 0
not 0
significantly 0
different 0
in 0
ARVD 0
patients 0
and 0
control 0
subjects 0
. 0

However 0
, 0
the 0
signaling 0
cascade 0
utilized 0
by 0
the 0
urokinase B-gene
receptor I-gene
is 0
only 0
incompletely 0
understood 0
. 0

The 0
murine 0
Htf9 B-gene
- I-gene
a/RanBP1 I-gene
and 0
a/RanBP1 I-gene

In 0
accordance 0
with 0
clinical 0
improvement 0
we 0
found 0
a 0
decrease 0
of 0
laboratory 0
indicators 0
of 0
inflammation 0
( 0
C B-gene
- I-gene
reactive I-gene
protein I-gene
, 0
alpha B-gene
2 I-gene
- I-gene
globuline I-gene
, 0
prostaglandin 0
E2 0
) 0
. 0

We 0
have 0
previously 0
reported 0
that 0
depletion 0
of 0
protein B-gene
kinase I-gene
C I-gene
by 0
long 0
- 0
term 0
treatment 0
of 0
B16 0
mouse 0
melanoma 0
cells 0
with 0
phorbol 0
dibutyrate 0
( 0
PDBu 0
) 0
prevented 0
cell 0
density 0
- 0
dependent 0
melanogenesis 0
. 0

Replacement 0
of 0
residues 0
in 0
positions 0
+3 0
( 0
His128Asn 0
) 0
and 0
+2 0
( 0
Gln155Lys 0
) 0
of 0
the 0
reading 0
helices 0
of 0
fingers 0
2 0
and 0
3 0
, 0
respectively 0
, 0
prevented 0
binding 0
. 0

Two 0
disulphide 0
bridges 0
, 0
which 0
are 0
conserved 0
in 0
all 0
spermadhesin 0
molecules 0
and 0
many 0
CUB 0
domains 0
, 0
crosslink 0
loop 0
LA 0
and 0
strand 0
beta 0
4 0
and 0
loops 0
LE 0
and 0
LG 0
, 0
respectively 0
, 0
at 0
opposite 0
edges 0
of 0
the 0
same 0
face 0
of 0
the 0
domain 0
. 0

Mg B-gene
- I-gene
chelatase I-gene
of 0
tobacco 0
: 0
identification 0
of 0
a 0
Chl B-gene
D I-gene
cDNA I-gene
sequence I-gene
encoding 0
a 0
third 0
subunit 0
, 0
analysis 0
of 0
the 0
interaction 0
of 0
the 0
three 0
subunits 0
with 0
the 0
yeast 0
two 0
- 0
hybrid 0
system 0
, 0
and 0
reconstitution 0
of 0
the 0
enzyme 0
activity 0
by 0
co 0
- 0
expression 0
of 0
recombinant B-gene
CHL I-gene
D I-gene
, 0
CHL B-gene
H I-gene
and 0
CHL B-gene
I I-gene
. 0

One 0
R 0
- 0
EST 0
and 0
one 0
Pto B-gene
- I-gene
like I-gene
sequence I-gene
each 0
mapped 0
to 0
two 0
locations 0
. 0

The 0
multidomain 0
structure 0
includes 0
a 0
cysteine 0
- 0
rich 0
motif 0
resembling 0
those 0
of 0
protein B-gene
kinase I-gene
C I-gene
and 0
n B-gene
- I-gene
chimaerin I-gene
and 0
a 0
putative 0
pleckstrin B-gene
homology I-gene
domain I-gene
. 0

The 0
interaction 0
between 0
DDB B-gene
and 0
E2F1 B-gene
can 0
also 0
be 0
detected 0
by 0
coimmunoprecipitation 0
experiments 0
. 0

271:31290 0
- 0
31295 0
, 0
1996 0
) 0
. 0

Nevertheless 0
, 0
antibodies 0
directed 0
against 0
an 0
epitope 0
- 0
tagged 0
version 0
of 0
Prp42p B-gene
specifically 0
precipitate 0
U1 B-gene
snRNA I-gene
from 0
yeast 0
extracts 0
. 0

These 0
results 0
indicate 0
that 0
in 0
addition 0
to 0
Grb2 B-gene
- 0
mediated 0
activation 0
of 0
Ras B-gene
, 0
PLC B-gene
- I-gene
gamma1 I-gene
- 0
mediated 0
DAG 0
production 0
is 0
required 0
for 0
EGF B-gene
- 0
and 0
PDGF B-gene
- 0
induced 0
S 0
- 0
phase 0
entry 0
and 0
gene 0
expression 0
, 0
possibly 0
through 0
activation 0
of 0
PKC B-gene
. 0

In 0
this 0
study 0
, 0
we 0
investigated 0
STAT B-gene
activation 0
in 0
a 0
panel 0
of 0
rodent 0
fibroblast 0
cell 0
lines 0
stably 0
transformed 0
by 0
diverse 0
viral 0
oncoproteins 0
. 0

In 0
serum 0
- 0
stimulated 0
cells 0
, 0
the 0
binding 0
of 0
NF B-gene
- I-gene
Y/CBF I-gene
to 0
Y/CBF I-gene

CONCLUSION 0
: 0
In 0
our 0
animal 0
model 0
, 0
blood 0
- 0
brain 0
barrier 0
disruption 0
was 0
a 0
reproducible 0
, 0
integral 0
finding 0
of 0
single 0
- 0
fraction 0
, 0
high 0
- 0
dose 0
irradiation 0
injury 0
. 0

To 0
facilitate 0
the 0
investigation 0
of 0
parameters 0
that 0
govern 0
selective 0
export 0
in 0
adenovirus 0
- 0
infected 0
cells 0
, 0
we 0
constructed 0
a 0
marked 0
human 0
beta B-gene
- I-gene
actin I-gene
minigene I-gene
under 0
the 0
control 0
of 0
the 0
glucocorticoid B-gene
- I-gene
inducible I-gene
enhancer I-gene
- I-gene
promoter I-gene
of 0
mouse 0
mammary 0
tumor 0
virus 0
and 0
introduced 0
it 0
into 0
the 0
left 0
end 0
of 0
the 0
adenovirus 0
type 0
5 0
( 0
Ad5 0
) 0
genome 0
. 0

Cell 0
factor 0
- 0
mediated 0
regulatory 0
interactions 0
are 0
involved 0
in 0
regulating 0
the 0
restricted 0
expression 0
of 0
the 0
HCMV B-gene
major I-gene
immediate I-gene
- I-gene
early I-gene
HCMV I-gene
major I-gene
immediate I-gene
- I-gene
early I-gene
( I-gene
IE I-gene
) I-gene
gene I-gene
( 0
J 0
. 0

MpB B-gene
GroEL I-gene
has 0
extensive 0
sequence 0
similarity 0
( 0
92 0
% 0
) 0
with 0
Escherichia B-gene
coli I-gene
GroEL I-gene
and 0
other 0
members 0
of 0
the 0
chaperonin B-gene
- I-gene
60 I-gene
family I-gene
. 0

The 0
critical 0
mutations 0
were 0
likely 0
to 0
have 0
been 0
multiple 0
and 0
dispersed 0
, 0
including 0
elongation 0
of 0
the 0
TM 0
and 0
Nef B-gene
coding I-gene
sequences I-gene
; 0
changes 0
in 0
RNA 0
splice 0
donor 0
and 0
acceptor 0
sites 0
, 0
TATA 0
box 0
sites 0
, 0
and 0
Sp1 B-gene
sites I-gene
; 0
multiple 0
changes 0
in 0
the 0
V2 B-gene
region 0
of 0
SU B-gene
, 0
including 0
a 0
consensus 0
neutralization 0
epitope 0
; 0
and 0
five 0
new 0
N 0
- 0
linked 0
glycosylation 0
sites 0
in 0
SU B-gene
. 0

C 0
. 0

These 0
are 0
the 0
long 0
terminal 0
repeat 0
( 0
LTR 0
) 0
promoter 0
, 0
which 0
regulates 0
expression 0
of 0
the 0
viral 0
structural 0
proteins 0
, 0
and 0
a 0
second 0
internal 0
promoter 0
, 0
located 0
towards 0
the 0
3 0
' 0
end 0
of 0
the 0
env B-gene
gene I-gene
, 0
that 0
directs 0
expression 0
of 0
the 0
viral 0
auxiliary 0
proteins 0
. 0

The 0
5 0
' 0
end 0
of 0
the 0
genomic 0
RNA 0
of 0
rubella 0
virus 0
( 0
RUB 0
) 0
contains 0
a 0
14 0
- 0
nucleotide 0
( 0
nt 0
) 0
single 0
- 0
stranded 0
leader 0
( 0
ss 0
- 0
leader 0
) 0
followed 0
by 0
a 0
stem 0
- 0
and 0
- 0
loop 0
structure 0
[ 0
5 0
' 0
( 0
+ 0
) 0
SL 0
] 0
( 0
nt 0
15 0
to 0
65 0
) 0
, 0
the 0
complement 0
of 0
which 0
at 0
the 0
3 0
' 0
end 0
of 0
the 0
minus 0
- 0
strand 0
RNA 0
[ 0
3 0
' 0
( 0
- 0
) 0
SL 0
] 0
has 0
been 0
proposed 0
to 0
function 0
as 0
a 0
promoter 0
for 0
synthesis 0
of 0
genomic 0
plus 0
strands 0
. 0

To 0
investigate 0
the 0
requirements 0
for 0
CBF2 B-gene
binding 0
, 0
we 0
synthesized 0
a 0
series 0
of 0
oligonucleotides 0
carrying 0
double 0
transversion 0
mutations 0
spanning 0
both 0
the 0
conserved 0
core 0
sequence 0
and 0
outside 0
flanking 0
sequences 0
. 0

In 0
addition 0
, 0
the 0
affinities 0
of 0
CBF2 B-gene
for 0
binding 0
to 0
the 0
LMP B-gene
- I-gene
1 I-gene
, 0
LMP B-gene
- I-gene
2 I-gene
, 0
and 0
CD23 B-gene
promoters I-gene
were 0
also 0
measured 0
. 0

CONCLUSIONS 0
: 0
The 0
myocardial 0
uptake 0
of 0
99mTc 0
sestamibi 0
in 0
normal 0
subjects 0
and 0
patients 0
with 0
coronary 0
artery 0
disease 0
is 0
comparable 0
after 0
exercise 0
, 0
dipyridamole 0
, 0
and 0
adenosine 0
stress 0
. 0

The 0
SR B-gene
protein I-gene
family I-gene
is 0
involved 0
in 0
constitutive 0
and 0
regulated 0
pre 0
- 0
mRNA 0
splicing 0
and 0
has 0
been 0
found 0
to 0
be 0
evolutionarily 0
conserved 0
in 0
metazoan 0
organisms 0
. 0

To 0
investigate 0
the 0
activity 0
of 0
TCF11 B-gene
through 0
this 0
selected 0
site 0
, 0
both 0
alone 0
and 0
in 0
the 0
presence 0
of 0
MafG B-gene
, 0
we 0
have 0
used 0
a 0
transient 0
transfection 0
assay 0
. 0

These 0
and 0
other 0
comparisons 0
suggest 0
that 0
, 0
during 0
evolution 0
, 0
both 0
the 0
RNA B-gene
- I-gene
polymerase I-gene
specificity 0
of 0
telomerase B-gene
RNA I-gene
- I-gene
gene I-gene
promoters I-gene
and 0
, 0
more 0
recently 0
, 0
the 0
position 0
of 0
the 0
template 0
sequence 0
in 0
the 0
telomerase B-gene
RNA I-gene
changed 0
. 0

Deadenylation 0
and 0
decay 0
of 0
beta B-gene
- I-gene
globin I-gene
mRNA I-gene
in 0
K562 0
cells 0
is 0
extraordinarily 0
slow 0
compared 0
with 0
NIH 0
3T3 0
cells 0
, 0
suggesting 0
that 0
the 0
increased 0
stability 0
gained 0
by 0
beta B-gene
- I-gene
globin I-gene
mRNA I-gene
in 0
K562 0
cells 0
is 0
mainly 0
controlled 0
at 0
the 0
deadenylation 0
step 0
. 0

Holliday B-gene
junction I-gene
resolvase I-gene
in 0
Schizosaccharomyces 0
pombe 0
has 0
identical 0
endonuclease 0
activity 0
to 0
the 0
CCE1 B-gene
homologue 0
YDC2 B-gene
. 0

Ca2+/calmodulin B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
II I-gene
( 0
CaMK B-gene
II I-gene
) 0
is 0
a 0
multifunctional 0
serine/threonine B-gene
protein I-gene
kinase I-gene
that 0
regulates 0
ion 0
channels 0
, 0
metabolic 0
enzymes 0
, 0
cytoskeletal 0
proteins 0
, 0
and 0
possibly 0
transcription 0
factors 0
. 0

A 0
cAMP 0
- 0
responsive 0
element 0
- 0
like 0
( 0
CRE 0
- 0
like 0
, 0
TGACGTGA 0
) 0
promoter 0
sequence 0
and 0
a 0
protein B-gene
kinase I-gene
A I-gene
signaling 0
pathway 0
are 0
involved 0
in 0
this 0
induction 0
, 0
and 0
activation 0
of 0
both 0
CRE B-gene
binding I-gene
protein I-gene
( 0
CREB B-gene
) 0
and 0
activating B-gene
transcription I-gene
factor I-gene
- I-gene
2 I-gene
( 0
ATF B-gene
- I-gene
2 I-gene
) 0
is 0
required 0
in 0
the 0
above 0
process 0
. 0

IVOX 0
was 0
named 0
as 0
an 0
acronym 0
for 0
intravascular 0
oxygenator 0
. 0

Histopathologically 0
, 0
a 0
cystic 0
lymphangioma 0
was 0
diagnosed 0
because 0
of 0
the 0
morphological 0
features 0
and 0
the 0
immunohistochemical 0
stainings 0
of 0
CD34 B-gene
and 0
Factor B-gene
VIII I-gene
related I-gene
antigen I-gene
which 0
were 0
observed 0
positive 0
reactions 0
in 0
endothelial 0
cells 0
of 0
the 0
cysts 0
. 0

Protease 0
activities 0
in 0
cultures 0
of 0
the 0
streptococcal 0
strains 0
were 0
associated 0
with 0
species 0
of 0
different 0
molecular 0
masses 0
ranging 0
from 0
130 0
to 0
200 0
kDa 0
, 0
suggesting 0
posttranslational 0
processing 0
possibly 0
as 0
a 0
result 0
of 0
autoproteolysis 0
at 0
post 0
- 0
proline 0
peptide 0
bonds 0
in 0
the 0
N 0
- 0
terminal 0
parts 0
of 0
the 0
molecules 0
. 0

The 0
mechanism 0
underlying 0
such 0
analgesia 0
has 0
been 0
suggested 0
to 0
involve 0
the 0
interaction 0
between 0
the 0
two 0
separate 0
but 0
interconnected 0
motivational 0
systems 0
`` 0
defense 0
'' 0
and 0
`` 0
pain 0
. 0
'' 0
To 0
determine 0
the 0
developmental 0
course 0
of 0
defense 0
and 0
nociception 0
, 0
these 0
processes 0
were 0
analyzed 0
during 0
early 0
ontogeny 0
in 0
rats 0
. 0

Three 0
large 0
field 0
placement 0
errors 0
( 0
two 0
patients 0
with 0
11.5 0
and 0
16.0 0
mm 0
distances 0
of 0
the 0
planned 0
versus 0
simulated 0
isocenter 0
, 0
respectively 0
and 0
one 0
patient 0
with 0
a 0
7 0
degree 0
rotational 0
error 0
) 0
were 0
detected 0
and 0
, 0
as 0
with 0
the 0
smaller 0
errors 0
, 0
were 0
immediately 0
corrected 0
. 0

In 0
addition 0
, 0
a 0
catalytically 0
inactive 0
version 0
of 0
the 0
Src B-gene
family I-gene
member 0
, 0
Lck B-gene
( 0
lymphoid B-gene
cell I-gene
kinase I-gene
) 0
, 0
was 0
expressed 0
, 0
purified 0
, 0
and 0
evaluated 0
as 0
a 0
Csk B-gene
substrate 0
. 0

A. 0
, 0
Swift 0
, 0
A 0
. 0

Neuronal 0
mechanisms 0
underlying 0
stimulus 0
- 0
response 0
( 0
S 0
- 0
R 0
) 0
associations 0
in 0
S 0
- 0
R 0
compatibility 0
tasks 0
were 0
identified 0
in 0
2 0
experiments 0
with 0
monkeys 0
. 0

The 0
c B-gene
- I-gene
myc/TGF I-gene
myc/TGF I-gene
- I-gene
alpha I-gene
HCCs 0
were 0
also 0
characterized 0
by 0
a 0
particularly 0
strong 0
expression 0
of 0
TGF B-gene
- I-gene
alpha I-gene
and 0
very 0
low 0
apoptotic 0
index 0
in 0
contrast 0
to 0
high 0
levels 0
of 0
apoptosis 0
in 0
peritumorous 0
tissues 0
and 0
c B-gene
- I-gene
myc I-gene
HCCs 0
. 0

Taken 0
together 0
, 0
our 0
data 0
suggest 0
that 0
the 0
antagonistic 0
effects 0
of 0
CRP B-gene
and 0
KdgR B-gene
on 0
the 0
expression 0
of 0
the 0
pectinolysis B-gene
genes I-gene
occur 0
by 0
different 0
mechanisms 0
, 0
including 0
direct 0
competition 0
between 0
the 0
two 0
regulators 0
or 0
between 0
the 0
repressor 0
and 0
RNA B-gene
polymerase I-gene
for 0
the 0
occupation 0
of 0
a 0
common 0
DNA 0
region 0
on 0
the 0
target 0
genes 0
. 0

The 0
well 0
- 0
known 0
Rel/NF B-gene
Rel/NF I-gene
- I-gene
kappaB I-gene
family 0
of 0
vertebrate 0
transcription 0
factors 0
comprises 0
a 0
number 0
of 0
structurally 0
related 0
, 0
interacting 0
proteins 0
that 0
bind 0
DNA 0
as 0
dimers 0
and 0
whose 0
activity 0
is 0
regulated 0
by 0
subcellular 0
location 0
. 0

The 0
cglIM B-gene
gene I-gene
is 0
organized 0
in 0
an 0
unusual 0
operon 0
which 0
contains 0
, 0
in 0
addition 0
, 0
two 0
genes 0
encoding 0
stress 0
- 0
sensitive 0
restriction 0
enzymes 0
. 0

Lysine B-gene
- I-gene
ketoglutarate I-gene
reductase I-gene
and 0
saccharopine B-gene
dehydrogenase I-gene
from 0
Arabidopsis 0
thaliana 0
: 0
nucleotide 0
sequence 0
and 0
characterization 0
. 0

The 0
purpose 0
of 0
this 0
investigation 0
was 0
to 0
describe 0
a 0
new 0
formulation 0
of 0
silver 0
sulfadiazine 0
in 0
a 0
water 0
soluble 0
gel 0
, 0
poloxamer 0
188 0
. 0

The 0
study 0
goals 0
were 0
to 0
isolate 0
a 0
full 0
- 0
length 0
clone 0
encoding 0
CO B-gene
- I-gene
Ag I-gene
from 0
a 0
bovine 0
corneal 0
cDNA 0
library 0
and 0
to 0
express 0
this 0
clone 0
in 0
Escherichia 0
coli 0
( 0
E. 0
coli 0
) 0
. 0

The 0
pel B-gene
gene I-gene
from 0
an 0
Amycolata 0
sp 0
. 0
encoding 0
a 0
pectate B-gene
lyase I-gene
( 0
EC B-gene
4.2.2.2 I-gene
) 0
was 0
isolated 0
by 0
activity 0
screening 0
a 0
genomic 0
DNA 0
library 0
in 0
Streptomyces 0
lividans 0
TK24 0
. 0

The 0
gene 0
contains 0
six 0
exons 0
separated 0
by 0
1.1 0
- 0
5.8 0
kb 0
introns 0
and 0
has 0
been 0
localized 0
to 0
the 0
murine 0
chromosome 0
2 0
by 0
linkage 0
analysis 0
. 0

In 0
Xenopus 0
embryos 0
, 0
the 0
engineered B-gene
PDGF I-gene
receptor I-gene
protein I-gene
induced 0
the 0
formation 0
of 0
mesoderm 0
from 0
animal 0
- 0
pole 0
explants 0
in 0
an 0
FK1012 0
- 0
dependent 0
manner 0
. 0

A 0
cytosolic 0
variant 0
of 0
the 0
protein 0
underwent 0
efficient 0
transphosphorylation 0
, 0
yet 0
failed 0
to 0
activate 0
appreciably 0
either 0
p70 B-gene
( 0
S6k B-gene
) 0
or 0
MAP B-gene
kinase I-gene
following 0
treatment 0
with 0
FK1012 0
. 0

Small 0
- 0
molecule 0
control 0
of 0
insulin B-gene
and 0
PDGF B-gene
receptor I-gene
signaling 0
and 0
the 0
role 0
of 0
membrane 0
attachment 0
. 0

Conversely 0
, 0
the 0
inactive 0
dAK B-gene
subunit I-gene
is 0
progressively 0
activated 0
by 0
1 0
) 0
association 0
with 0
a 0
dGK B-gene
or 0
dCK B-gene
subunit I-gene
and 0
2 0
) 0
the 0
conformationally 0
driven 0
heterotropic 0
affect 0
of 0
dGuo B-gene
or 0
dCyd B-gene
bound 0
to 0
the 0
opposing 0
subunit 0
. 0

CONCLUSIONS 0
: 0
A 0
50 0
- 0
mg 0
daily 0
dose 0
of 0
bicalutamide 0
is 0
sufficient 0
when 0
given 0
in 0
combination 0
with 0
an 0
agent 0
, 0
such 0
as 0
a 0
LHRH B-gene
- 0
A 0
, 0
that 0
lowers 0
serum 0
testosterone 0
, 0
but 0
higher 0
doses 0
of 0
bicalutamide 0
may 0
be 0
needed 0
when 0
the 0
drug 0
is 0
given 0
as 0
monotherapy 0
. 0

A 0
genomic 0
clone 0
was 0
isolated 0
that 0
contained 0
12.5 0
kb 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
and 0
the 0
first 0
exon 0
of 0
the 0
p69/71 B-gene
2 I-gene
- I-gene
5A I-gene
synthetase I-gene
gene I-gene
. 0

Although 0
the 0
gene 0
is 0
substantially 0
smaller 0
than 0
the 0
human 0
genes 0
for 0
other 0
mitochondrial 0
enzymes 0
, 0
its 0
intron/exon 0
organization 0
is 0
very 0
similar 0
, 0
especially 0
to 0
that 0
of 0
P450scc B-gene
. 0

RESULTS 0
: 0
Looking 0
at 0
the 0
question 0
of 0
its 0
benefits 0
, 0
we 0
were 0
unable 0
to 0
find 0
any 0
methodologically 0
sound 0
studies 0
that 0
have 0
shown 0
efficacy 0
for 0
EMDR 0
in 0
eating 0
disorders 0
, 0
or 0
, 0
indeed 0
, 0
any 0
psychiatric 0
disorder 0
. 0

In 0
the 0
clinical 0
study 0
, 0
the 0
defect 0
size 0
shown 0
by 0
BMIPP 0
imaging 0
was 0
greater 0
in 0
anterior 0
than 0
in 0
inferior 0
infarcts 0
( 0
p 0
< 0
0.001 0
) 0
and 0
correlated 0
well 0
with 0
the 0
risk 0
area 0
revealed 0
by 0
contrast 0
ventriculography 0
( 0
r 0
= 0
0.80 0
, 0
p 0
< 0
0.0001 0
) 0
CONCLUSION 0
: 0
The 0
above 0
preliminary 0
data 0
, 0
admittedly 0
from 0
a 0
small 0
group 0
of 0
patients 0
, 0
suggest 0
that 0
tomographic 0
BMIPP 0
imaging 0
provides 0
an 0
accurate 0
quantification 0
of 0
defect 0
size 0
by 0
means 0
of 0
a 0
simple 0
threshold 0
technique 0
and 0
, 0
in 0
the 0
subacute 0
phase 0
, 0
permits 0
determination 0
of 0
the 0
amount 0
of 0
myocardium 0
at 0
risk 0
after 0
acute 0
myocardial 0
infarction 0
. 0

Transient 0
overexpression 0
of 0
mutant B-gene
EphB1 I-gene
receptors I-gene
( 0
Y594F 0
) 0
blocked 0
Nck B-gene
recruitment 0
to 0
EphB1 B-gene
, 0
attenuated 0
downstream 0
JNK B-gene
activation 0
, 0
and 0
blocked 0
cell 0
attachment 0
responses 0
. 0

The 0
promoter 0
for 0
HMG B-gene
- I-gene
CoA I-gene
synthase I-gene
contains 0
two 0
binding 0
sites 0
for 0
the 0
sterol B-gene
regulatory I-gene
element I-gene
- I-gene
binding I-gene
proteins I-gene
( 0
SREBPs B-gene
) 0
. 0

S. 0
, 0
and 0
Walter 0
, 0
P 0
. 0

Here 0
we 0
demonstrate 0
that 0
Hh B-gene
and 0
Patched B-gene
( 0
Ptc B-gene
) 0
act 0
through 0
those 0
Ci B-gene
binding 0
sites 0
to 0
modulate 0
the 0
level 0
of 0
Ci B-gene
- 0
dependent 0
transcriptional 0
activation 0
in 0
S2 0
cells 0
. 0

Furthermore 0
the 0
median 0
increase 0
in 0
cyclosporine 0
DR/C 0
( 0
SS 0
trough 0
) 0
was 0
18 0
l 0
h 0
- 0
1 0
( 0
- 0
3.1 0
to 0
42.1 0
l 0
h 0
- 0
1 0
, 0
interquartile 0
range 0
) 0
. 0

Patients 0
and 0
their 0
relatives 0
must 0
be 0
informed 0
about 0
the 0
available 0
effective 0
treatment 0
possibilities 0
and 0
about 0
the 0
right 0
moment 0
for 0
their 0
application 0
in 0
an 0
individual 0
patient 0
. 0

Several 0
PTPases B-gene
were 0
expressed 0
abundantly 0
in 0
the 0
5 0
- 0
FU 0
- 0
treated 0
bone 0
marrow 0
stem 0
cells 0
. 0

Expression 0
of 0
PTPRO B-gene
was 0
also 0
observed 0
in 0
human B-gene
CD34+ I-gene
bone 0
marrow 0
cells 0
and 0
5 0
- 0
FU 0
- 0
treated 0
murine 0
primitive 0
stem 0
cells 0
. 0

The 0
organization 0
of 0
SPP1 B-gene
genes I-gene
involved 0
in 0
the 0
replication 0
, 0
DNA 0
packaging 0
and 0
phage 0
assembly 0
proteins 0
resembles 0
the 0
organization 0
of 0
genes 0
of 0
equivalent 0
regions 0
of 0
different 0
E. 0
coli 0
double 0
- 0
stranded 0
DNA 0
phages 0
. 0

Our 0
results 0
showed 0
that 0
compared 0
to 0
the 0
primary 0
photon 0
fluence 0
, 0
the 0
extra 0
- 0
focal 0
photon 0
fluence 0
from 0
the 0
primary 0
collimator 0
and 0
the 0
flattening 0
filter 0
was 0
11 0
% 0
- 0
16 0
% 0
at 0
the 0
isocenter 0
, 0
among 0
which 0
70 0
% 0
was 0
contributed 0
by 0
the 0
flattening 0
filter 0
. 0

The 0
functional 0
mature 0
domain 0
of 0
pediocin B-gene
AcH I-gene
( I-gene
Lys+1 I-gene
to I-gene
Cys+44 I-gene
) I-gene
is 0
targeted 0
into 0
the 0
E. 0
coli 0
sec 0
machinery 0
and 0
secreted 0
to 0
the 0
periplasm 0
in 0
active 0
form 0
when 0
fused 0
in 0
frame 0
to 0
the 0
COOH 0
terminus 0
of 0
the 0
secretory B-gene
protein I-gene
maltose I-gene
- I-gene
binding I-gene
protein I-gene
( 0
MBP B-gene
) 0
. 0

Isomers 0
were 0
differentiated 0
based 0
on 0
the 0
MS 0
- 0
MS 0
data 0
of 0
the 0
trofluoroacetyl 0
- 0
biphenylol 0
derivatives 0
. 0

Although 0
RAD17 B-gene
, 0
RAD24 B-gene
and 0
MEC3 B-gene
are 0
not 0
required 0
for 0
cell 0
cycle 0
arrest 0
when 0
S 0
phase 0
is 0
inhibited 0
by 0
hydroxyurea 0
( 0
HU 0
) 0
, 0
they 0
do 0
contribute 0
to 0
the 0
viability 0
of 0
yeast 0
cells 0
grown 0
in 0
the 0
presence 0
of 0
HU 0
, 0
possibly 0
because 0
they 0
are 0
required 0
for 0
the 0
repair 0
of 0
HU 0
- 0
induced 0
DNA 0
damage 0
. 0

Clinical 0
value 0
of 0
the 0
estimation 0
of 0
growth 0
kinetics 0
of 0
primary 0
ovarian 0
cancer 0
recurrences 0
by 0
CA125 B-gene
doubling 0
time 0

This 0
review 0
seeks 0
to 0
summarize 0
the 0
disease 0
, 0
to 0
propose 0
pathways 0
of 0
carcinogenesis 0
and 0
to 0
suggest 0
ways 0
in 0
which 0
the 0
`` 0
traditional 0
'' 0
risk 0
factors 0
may 0
be 0
interpreted 0
on 0
the 0
basis 0
of 0
evolving 0
knowledge 0
. 0

The 0
patient 0
underwent 0
two 0
intracytoplasmic 0
sperm 0
injection 0
cycles 0
with 0
thawed 0
epididymal 0
spermatozoa 0
, 0
in 0
which 0
, 0
due 0
to 0
a 0
pharmacist 0
's 0
mistake 0
, 0
ovarian 0
stimulation 0
was 0
carried 0
out 0
by 0
a 0
combination 0
of 0
long 0
- 0
acting 0
gonadotrophin B-gene
- I-gene
releasing I-gene
hormone I-gene
agonist 0
( 0
leuprolide 0
depot 0
) 0
and 0
gonadotrophins B-gene
. 0

Protein B-gene
C I-gene
deficiency 0
or 0
protein B-gene
S I-gene
deficiency 0
was 0
the 0
only 0
identified 0
risk 0
factor 0
for 0
5.4 0
% 0
( 0
2 0
patients 0
) 0
and 0
13.5 0
% 0
( 0
5 0
patients 0
) 0
, 0
respectively 0
, 0
of 0
these 0
37 0
children 0
. 0

Perhaps 0
in 0
addition 0
to 0
, 0
or 0
as 0
part 0
of 0
, 0
its 0
essential 0
function 0
in 0
late 0
mitosis 0
, 0
MOB1 B-gene
is 0
required 0
for 0
a 0
cell 0
cycle 0
reset 0
function 0
necessary 0
for 0
the 0
initiation 0
of 0
the 0
spindle 0
pole 0
body 0
duplication 0
. 0

In 0
contrast 0
, 0
overproduction 0
of 0
Der3p B-gene
is 0
lethal 0
in 0
a 0
sec61 B-gene
- I-gene
2 I-gene
strain 0
at 0
the 0
permissive 0
temperature 0
of 0
25 0
degrees 0
C 0
. 0

Normal 0
baseline 0
( 0
day 0
- 0
8 0
) 0
PC 0
levels 0
( 0
86 0
and 0
89 0
% 0
) 0
were 0
markedly 0
reduced 0
in 0
both 0
patients 0
at 0
the 0
time 0
of 0
VOD 0
manifestation 0
on 0
day 0
20 0
and 0
40 0
, 0
respectively 0
( 0
26 0
and 0
31 0
% 0
) 0
. 0

To 0
examine 0
the 0
role 0
of 0
this 0
CE2 0
element 0
in 0
regulating 0
Hoxa1 B-gene
expression 0
in 0
vivo 0
, 0
transgenic 0
mice 0
were 0
generated 0
which 0
express 0
a 0
Hoxa1 B-gene
beta B-gene
- I-gene
galactosidase I-gene
reporter 0
gene 0
that 0
contains 0
a 0
mutation 0
in 0
the 0
CE2 0
element 0
. 0

An 0
evolutionary 0
conserved 0
element 0
is 0
essential 0
for 0
somite 0
and 0
adjacent 0
mesenchymal 0
expression 0
of 0
the 0
Hoxa1 B-gene
gene I-gene
. 0

RESULTS 0
: 0
The 0
bovine 0
cDNA 0
insert 0
sequence 0
was 0
273 0
nucleotides 0
in 0
length 0
for 0
the 0
entire 0
mRNA 0
coding 0
region 0
, 0
212 0
nucleotides 0
in 0
the 0
5 0
' 0
untranslated 0
region 0
, 0
83 0
nucleotides 0
in 0
the 0
3 0
' 0
untranslated 0
region 0
and 0
a 0
poly 0
( 0
A 0
) 0
tail 0
. 0

Altogether 0
46 0
phase 0
III 0
activities 0
were 0
recorded 0
. 0

We 0
have 0
previously 0
identified 0
a 0
liver 0
- 0
enriched 0
transcription 0
factor 0
, 0
HNF B-gene
- I-gene
6 I-gene
, 0
which 0
is 0
required 0
for 0
HNF B-gene
- I-gene
3 I-gene
beta I-gene
promoter I-gene
activity 0
and 0
also 0
recognizes 0
the 0
regulatory 0
region 0
of 0
numerous 0
hepatocyte 0
- 0
specific 0
genes 0
. 0

A 0
cDNA 0
clone 0
was 0
identified 0
encoding 0
a 0
second 0
GHS B-gene
- I-gene
R I-gene
- I-gene
related I-gene
gene I-gene
( 0
GPR39 B-gene
) 0
. 0

( 0
1997 0
) 0
Science 0
275 0
, 0
1927 0
- 0
1930 0
) 0
. 0

P. 0
, 0
Peyron 0
, 0
J 0
. 0

A 0
hybridoma 0
clone 0
( 0
7H1 0
) 0
resulting 0
from 0
the 0
fusion 0
between 0
CEMLAI/NP 0
and 0
human 0
embryonic 0
fibroblasts 0
MRC5 0
cells 0
produced 0
very 0
large 0
amounts 0
of 0
P47 B-gene
that 0
was 0
purified 0
using 0
Jacalin B-gene
lectin I-gene
( 0
specific 0
for 0
O 0
- 0
glycans 0
) 0
and 0
microsequenced 0
. 0

This 0
information 0
, 0
together 0
with 0
estimation 0
of 0
the 0
size 0
of 0
the 0
deglycosylated 0
A 0
subunit 0
relative 0
to 0
a 0
series 0
of 0
C B-gene
- I-gene
terminal I-gene
truncated I-gene
TSHR I-gene
ectodomain I-gene
variants I-gene
, 0
places 0
cleavage 0
Site 0
1 0
in 0
the 0
vicinity 0
of 0
, 0
or 0
closely 0
upstream 0
to 0
, 0
residue 0
317 0
. 0

In 0
vitro 0
DNase B-gene
I I-gene
footprinting 0
of 0
the 0
200 0
- 0
bp 0
proximal 0
region 0
of 0
the 0
promoter 0
with 0
a 0
murine 0
Hepa 0
1 0
- 0
6 0
cell 0
nuclear 0
extract 0
revealed 0
a 0
clear 0
footprint 0
of 0
a 0
region 0
corresponding 0
to 0
- 0
80 0
to 0
- 0
28 0
bp 0
of 0
the 0
murine B-gene
fVII I-gene
gene I-gene
, 0
suggesting 0
that 0
liver 0
factors 0
interact 0
with 0
this 0
region 0
of 0
the 0
DNA 0
. 0

A 0
reciprocal 0
binding 0
assay 0
using 0
IM 0
- 0
9 0
cells 0
as 0
a 0
source 0
of 0
SHP B-gene
- I-gene
1 I-gene
and 0
SHP B-gene
- I-gene
2 I-gene
revealed 0
specific 0
association 0
of 0
SHP B-gene
- I-gene
2 I-gene
( 0
but 0
not 0
SHP B-gene
- I-gene
1 I-gene
) 0
with 0
a 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
fusion I-gene
incorporating 0
GHR B-gene
cytoplasmic I-gene
domain I-gene
residues I-gene
485 I-gene
- I-gene
620 I-gene
, 0
but 0
only 0
if 0
the 0
fusion 0
was 0
first 0
rendered 0
tyrosine 0
- 0
phosphorylated 0
. 0

Both 0
increasing 0
basal 0
FSH B-gene
and 0
age 0
were 0
associated 0
significantly 0
with 0
increased 0
total 0
gonadotrophin B-gene
dose 0
, 0
and 0
reduced 0
number 0
of 0
oocytes 0
collected 0
and 0
pregnancy 0
rate 0
. 0

A 0
comparative 0
study 0
was 0
undertaken 0
between 0
an 0
enzymatic 0
immunohistochemical 0
technique 0
( 0
EIT 0
) 0
developed 0
for 0
the 0
diagnosis 0
of 0
human 0
trichinellosis 0
and 0
the 0
indirect 0
immunofluorescence 0
test 0
( 0
IIF 0
) 0
, 0
analysing 0
sera 0
from 0
outbreaks 0
of 0
human 0
trichinellosis 0
in 0
Argentina 0
. 0

Our 0
results 0
establish 0
GKLF B-gene
as 0
a 0
sequence 0
- 0
specific 0
transcription 0
factor 0
likely 0
involved 0
in 0
regulation 0
of 0
expression 0
of 0
endogenous 0
genes 0
. 0

CES4 B-gene
on 0
a 0
multicopy 0
plasmid 0
was 0
unable 0
to 0
suppress 0
tif1 B-gene
- I-gene
A79V I-gene
. 0

Here 0
we 0
report 0
that 0
in 0
cultured 0
cells 0
from 0
Drosophila 0
melanogaster 0
human B-gene
Sp1 I-gene
efficiently 0
activates 0
transcription 0
from 0
synthetic 0
promoters 0
containing 0
TATA 0
boxes 0
, 0
but 0
not 0
from 0
promoters 0
that 0
contain 0
an 0
initiator 0
instead 0
of 0
a 0
TATA 0
box 0
. 0

No 0
apparent 0
clinical 0
signs 0
indicative 0
of 0
systemic 0
toxicity 0
were 0
observed 0
in 0
the 0
F0 0
and 0
F1 0
animals 0
of 0
either 0
sex 0
. 0

We 0
have 0
used 0
mutation 0
- 0
directed 0
chemical 0
cross 0
- 0
linking 0
with 0
bis 0
( 0
sulfosuccinimidyl 0
) 0
suberate 0
( 0
BS3 0
) 0
to 0
investigate 0
the 0
architecture 0
of 0
the 0
gp41 B-gene
oligomer I-gene
. 0

In 0
an 0
effort 0
to 0
identify 0
the 0
USH1C B-gene
disease I-gene
gene I-gene
we 0
have 0
isolated 0
the 0
region 0
between 0
these 0
markers 0
in 0
yeast 0
artificial 0
chromosomes 0
( 0
YACs 0
) 0
using 0
a 0
combination 0
of 0
STS 0
content 0
mapping 0
and 0
Alu B-gene
- 0
PCR 0
hybridization 0
. 0

PowerBLAST 0
analysis 0
identified 0
six 0
clusters 0
of 0
expressed 0
sequence 0
tags 0
( 0
ESTs 0
) 0
, 0
two 0
known 0
genes 0
( 0
BIR B-gene
, 0
SUR1 B-gene
) 0
mapped 0
previously 0
to 0
this 0
region 0
, 0
and 0
a 0
previously 0
characterized 0
but 0
unmapped 0
gene B-gene
NEFA I-gene
( 0
DNA B-gene
binding/EF I-gene
hand/acidic I-gene
amino I-gene
- I-gene
acid I-gene
- I-gene
rich I-gene
) 0
. 0

A 0
fusion 0
protein 0
composed 0
of 0
beta B-gene
- I-gene
galactosidase I-gene
and 0
full B-gene
- I-gene
length I-gene
Ahr I-gene
translocates 0
from 0
the 0
cytoplasm 0
to 0
the 0
nucleus 0
in 0
a 0
ligand 0
- 0
dependent 0
manner 0
. 0

Reconstitution 0
of 0
Raf B-gene
- I-gene
1 I-gene
activity 0
was 0
observed 0
only 0
with 0
kinase 0
active 0
Jak1 B-gene
in 0
both 0
cell 0
lines 0
. 0

In 0
addition 0
, 0
negatively 0
regulatory 0
region 0
may 0
exist 0
from 0
- 0
1782 0
to 0
- 0
1295 0
bp 0
. 0

The 0
hypothesis 0
of 0
Geisler 0
( 0
Brain 0
Res 0
. 0

The 0
second 0
transcript 0
, 0
rhis4l B-gene
, 0
is 0
bicistronic 0
. 0

Consistent 0
with 0
this 0
interpretation 0
, 0
a 0
mutant 0
form 0
of 0
XRN1 B-gene
, 0
which 0
encodes 0
a 0
5' 0
- 0
3 0
' 0
exonuclease 0
, 0
was 0
identified 0
as 0
an 0
extragenic 0
suppressor 0
that 0
increases 0
the 0
half 0
- 0
life 0
of 0
rhis4 B-gene
mRNA I-gene
, 0
leading 0
to 0
a 0
10 0
- 0
fold 0
increase 0
in 0
steady 0
- 0
state 0
mRNA 0
levels 0
compared 0
to 0
the 0
wild B-gene
- I-gene
type I-gene
HIS4 I-gene
mRNA I-gene
level 0
. 0

Sip1 B-gene
was 0
initially 0
identified 0
by 0
virtue 0
of 0
its 0
interaction 0
with 0
SC35 B-gene
, 0
a 0
splicing 0
factor 0
of 0
the 0
SR B-gene
family I-gene
. 0

Consistent 0
with 0
previous 0
reports 0
, 0
addition 0
of 0
a 0
myristoylation 0
signal 0
to 0
mSos1 B-gene
( 0
MyrSos1 B-gene
) 0
rendered 0
it 0
transforming 0
for 0
NIH 0
3T3 0
cells 0
and 0
deletion 0
of 0
the 0
mSos B-gene
C I-gene
terminus I-gene
( 0
MyrSos1 B-gene
- I-gene
deltaC I-gene
) 0
did 0
not 0
interfere 0
with 0
this 0
activity 0
. 0

Such 0
mutations 0
are 0
thought 0
to 0
exert 0
their 0
dominant 0
phenotype 0
by 0
sequestration 0
of 0
the 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
( 0
GNEF B-gene
) 0
. 0

Several 0
studies 0
have 0
characterized 0
the 0
upstream 0
regulatory 0
region 0
of 0
c B-gene
- I-gene
fos I-gene
, 0
and 0
identified 0
cis 0
- 0
acting 0
elements 0
termed 0
the 0
cyclic 0
AMP 0
( 0
cAMP 0
) 0
response 0
elements 0
( 0
CREs 0
) 0
that 0
are 0
critical 0
for 0
c B-gene
- I-gene
fos I-gene
transcription 0
in 0
response 0
to 0
a 0
variety 0
of 0
extracellular 0
stimuli 0
. 0

We 0
have 0
cloned 0
a 0
kinase 0
, 0
Nlk B-gene
, 0
that 0
is 0
a 0
murine B-gene
homolog I-gene
of I-gene
the I-gene
Drosophila I-gene
nemo I-gene
( 0
nmo B-gene
) 0
gene 0
. 0

Our 0
findings 0
suggest 0
that 0
striatal 0
FDG 0
and 0
particularly 0
RACLO 0
are 0
sensitive 0
and 0
effective 0
measures 0
of 0
striatal 0
function 0
and 0
may 0
help 0
characterizing 0
patients 0
with 0
multiple 0
system 0
atrophy 0
. 0

Childhood 0
misbehavior 0
and 0
the 0
risk 0
of 0
injecting 0
drug 0
use 0
. 0

Genetic 0
analysis 0
has 0
subsequently 0
identified 0
subpathways 0
of 0
the 0
DNA 0
structure 0
checkpoints 0
, 0
including 0
the 0
reversible 0
arrest 0
of 0
DNA 0
synthesis 0
. 0

Thus 0
, 0
Esigma54 B-gene
promoters I-gene
are 0
responsive 0
to 0
CRP B-gene
, 0
a 0
protein 0
unrelated 0
to 0
sigma54 B-gene
activators I-gene
, 0
and 0
the 0
repression 0
exerted 0
is 0
the 0
direct 0
result 0
of 0
an 0
interaction 0
between 0
Esigma54 B-gene
and 0
the 0
CRP B-gene
- I-gene
cAMP I-gene
complex I-gene
. 0

GlcNAc 0
- 0
and 0
GlcNAc2 0
- 0
PP 0
- 0
Dolichol 0
biosynthesis 0
could 0
be 0
shown 0
with 0
isolated 0
S.cerevisiae 0
membranes 0
from 0
cells 0
harboring 0
the 0
recombinant 0
plasmid 0
and 0
grown 0
on 0
glucose 0
thus 0
suppressing 0
transcription 0
of 0
the 0
endogenous 0
gene 0
. 0

Demonstration 0
of 0
tissue 0
lesions 0
after 0
intramuscular 0
injection 0
by 0
determination 0
of 0
creatine B-gene
kinase I-gene
in 0
blood 0

Antibodies 0
raised 0
against 0
GST B-gene
mSH2 I-gene
- I-gene
B I-gene
identified 0
a 0
cellular 0
protein 0
of 0
92 0
kDa 0
that 0
was 0
not 0
found 0
to 0
be 0
phosphorylated 0
on 0
Tyr 0
. 0

Interleukin B-gene
- I-gene
6 I-gene
( 0
IL B-gene
- I-gene
6 I-gene
) 0
is 0
a 0
pleiotropic 0
cytokine 0
, 0
which 0
is 0
involved 0
in 0
inflammatory 0
and 0
immune 0
responses 0
, 0
acute 0
phase 0
reactions 0
, 0
and 0
hematopoiesis 0
. 0

Upon 0
analysis 0
of 0
various 0
deletion 0
and 0
point 0
- 0
mutated 0
variants 0
of 0
the 0
human B-gene
IL I-gene
- I-gene
6 I-gene
gene I-gene
promoter I-gene
coupled 0
to 0
a 0
reporter 0
gene 0
, 0
we 0
screened 0
for 0
possible 0
cooperating 0
transcription 0
factors 0
. 0

This 0
region 0
, 0
however 0
, 0
contains 0
a 0
CCAATC 0
box 0
in 0
the 0
reverse 0
complement 0
and 0
several 0
GC 0
boxes 0
that 0
are 0
recognition 0
sites 0
for 0
SP1 B-gene
. 0

Our 0
purpose 0
was 0
to 0
determine 0
if 0
intact 0
perianal 0
( 0
S4 0
- 0
5 0
) 0
pin 0
sensation 0
( 0
PPS 0
) 0
and 0
bulbocavernosus 0
( 0
S2 0
- 0
4 0
) 0
reflex 0
( 0
BCR 0
) 0
shortly 0
after 0
spinal 0
cord 0
injury 0
( 0
SCI 0
) 0
are 0
predictive 0
of 0
bladder 0
function 0
recovery 0
. 0

The 0
correct 0
termination 0
of 0
retroviral 0
transcripts 0
at 0
the 0
3 0
' 0
LTR 0
R/U5 0
junction 0
is 0
primarily 0
dependent 0
on 0
the 0
canonical 0
AAUAAA 0
polyadenylation 0
signal 0
, 0
so 0
we 0
have 0
analyzed 0
the 0
effect 0
of 0
mutating 0
the 0
polyadenylation 0
signal 0
sequences 0
on 0
the 0
properties 0
of 0
a 0
selectable 0
murine 0
retroviral 0
vector 0
. 0

Levels 0
of 0
the 0
MEK B-gene
inhibitor 0
PD98059 0
that 0
block 0
EGF B-gene
- 0
induced 0
mitogenesis 0
and 0
MAP B-gene
kinase I-gene
phosphorylation 0
also 0
abrogate 0
EGF B-gene
- 0
induced 0
focal 0
adhesion 0
disassembly 0
and 0
cell 0
motility 0
. 0

ALT B-gene
levels 0
in 0
responders 0
were 0
lowered 0
by 0
46 0
% 0
and 0
AST B-gene
levels 0
were 0
lowered 0
by 0
35 0
% 0
after 0
12 0
weeks 0
of 0
vitamin 0
E 0
treatment 0
. 0

Surprisingly 0
, 0
the 0
COOH 0
- 0
terminal 0
domain 0
of 0
RanGAP1 B-gene
was 0
also 0
found 0
to 0
harbor 0
a 0
nuclear 0
localization 0
signal 0
. 0

51.9 0
% 0
( 0
P=0.0006 0
) 0
in 0
the 0
MMF 0
versus 0
the 0
AZA 0
groups 0
, 0
respectively 0
. 0

Our 0
study 0
was 0
designed 0
to 0
investigate 0
the 0
effect 0
of 0
MMF 0
on 0
in 0
vivo 0
bone 0
mineral 0
metabolism 0
. 0

Pao2 0
increased 0
from 0
15.5 0
+/ 0
- 0
5.6 0
kPa 0
( 0
116 0
+/ 0
- 0
42 0
mm 0
Hg 0
) 0
to 0
17.3 0
+/ 0
- 0
6.3 0
kPa 0
( 0
130 0
+/ 0
- 0
47 0
mm 0
Hg 0
) 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Typical 0
configurations 0
of 0
psychosocial 0
stress 0
factors 0
of 0
psychiatrically 0
conspicuous 0
children 0
and 0
adolescents 0

Nine 0
cats 0
received 0
PMEA 0
at 0
a 0
dosage 0
of 0
10 0
mg/kg 0
body 0
weight 0
, 0
nine 0
cats 0
received 0
FPMPA 0
at 0
a 0
dosage 0
of 0
25 0
mg/kg 0
body 0
weight 0
. 0

Resistance 0
to 0
thyroid 0
hormone 0
: 0
implications 0
for 0
neurodevelopmental 0
research 0
on 0
the 0
effects 0
of 0
thyroid 0
hormone 0
disruptors 0
. 0

Here 0
, 0
we 0
present 0
evidence 0
that 0
exposure 0
of 0
DT40 0
lymphoma 0
B 0
cells 0
to 0
low 0
energy 0
electromagnetic 0
field 0
( 0
EMF 0
) 0
results 0
in 0
a 0
tyrosine B-gene
kinase I-gene
- 0
dependent 0
activation 0
of 0
phospholipase B-gene
Cgamma2 I-gene
( 0
PLC B-gene
- I-gene
gamma2 I-gene
) 0
leading 0
to 0
increased 0
inositol 0
phospholipid 0
turnover 0
. 0

We 0
present 0
the 0
preliminary 0
results 0
obtained 0
on 0
36 0
patients 0
which 0
were 0
followed 0
for 0
a 0
mean 0
period 0
of 0
12 0
months 0
. 0

Moreover 0
, 0
xTAK1KN B-gene
could 0
block 0
the 0
expression 0
of 0
ventral 0
mesoderm 0
marker 0
genes 0
induced 0
by 0
Smad1 B-gene
or I-gene
5 I-gene
. 0

PATIENTS 0
AND 0
METHOD 0
: 0
Since 0
1986 0
, 0
62 0
patients 0
were 0
irradiated 0
stereotactically 0
. 0

The 0
assay 0
exhibits 0
a 0
dynamic 0
range 0
of 0
0.1 0
- 0
100 0
micrograms 0
l 0
- 0
1 0
using 0
a 0
monoclonal 0
antibody 0
or 0
alternatively 0
10 0
micrograms 0
l 0
- 0
1 0
to 0
10 0
mg 0
l 0
- 0
1 0
using 0
commercially 0
available 0
antiserum 0
. 0

Training 0
for 0
audit 0
. 0

A 0
canonical 0
TATA 0
box 0
was 0
not 0
detected 0
. 0

Expression 0
and 0
characterization 0
of 0
recombinant B-gene
single I-gene
- I-gene
chain I-gene
Fv I-gene
and 0
Fv B-gene
fragments I-gene
derived 0
from 0
a 0
set 0
of 0
catalytic 0
antibodies 0
. 0

A 0
putative 0
inhibitor 0
( 0
s 0
) 0
appears 0
to 0
co 0
- 0
elute 0
in 0
the 0
inactive 0
fraction 0
that 0
blocked 0
the 0
L B-gene
( I-gene
alpha I-gene
) I-gene
activity 0
. 0

Platelet 0
aggregation 0
in 0
response 0
to 0
10 0
micrograms 0
collagen/ml B-gene
was 0
decreased 0
in 0
parallel 0
after 0
treatment 0
with 0
ASA 0
. 0

Using 0
himA B-gene
mutants I-gene
, 0
we 0
confirmed 0
that 0
IHF B-gene
plays 0
a 0
role 0
in 0
the 0
molybdate 0
- 0
dependent 0
regulation 0
of 0
dmsA B-gene
- 0
lacZ B-gene
expression 0
in 0
vivo 0
. 0

Cross 0
- 0
talking 0
among 0
Drosophila 0
nuclear 0
receptors 0
at 0
the 0
promiscuous 0
response 0
element 0
of 0
the 0
ng B-gene
- I-gene
1 I-gene
and 0
ng B-gene
- I-gene
2 I-gene
intermolt I-gene
genes I-gene
. 0

The 0
ipsilateral 0
breast 0
tumor 0
relapse 0
rate 0
was 0
similar 0
between 0
the 0
PALP 0
and 0
MGDET 0
groups 0
. 0

Sibling 0
aggregation 0
of 0
low B-gene
- I-gene
and I-gene
high I-gene
- I-gene
density I-gene
lipoprotein I-gene
cholesterol I-gene
and 0
apolipoproteins B-gene
B I-gene
and I-gene
A I-gene
- I-gene
I I-gene
levels 0
in 0
black 0
and 0
white 0
children 0
: 0
the 0
Bogalusa 0
Heart 0
Study 0
. 0

The 0
CAPLC1 B-gene
protein I-gene
also 0
exhibited 0
several 0
unique 0
features 0
, 0
including 0
a 0
novel 0
stretch 0
of 0
18 0
- 0
19 0
amino 0
acid 0
residues 0
within 0
the 0
X 0
domain 0
and 0
an 0
unusually 0
long 0
N 0
- 0
terminus 0
which 0
did 0
not 0
contain 0
a 0
recognizable 0
EF 0
- 0
hand 0
Ca 0
( 0
2+ 0
) 0
- 0
binding 0
domain 0
. 0

This 0
hypothesis 0
is 0
consistent 0
with 0
the 0
occurrence 0
of 0
PEA3 B-gene
binding I-gene
sites I-gene
in 0
the 0
PEA3 B-gene
promoter I-gene
and 0
with 0
the 0
ability 0
of 0
PEA3 B-gene
to 0
transactivate 0
this 0
promoter 0
. 0

Pet B-gene
- I-gene
1 I-gene
can 0
bind 0
specifically 0
to 0
a 0
PEA3 B-gene
ETS B-gene
DNA 0
- 0
binding 0
motif 0
and 0
can 0
modulate 0
transcription 0
of 0
synthetic 0
promoter 0
constructs 0
in 0
a 0
sequence 0
- 0
specific 0
manner 0
. 0

The 0
protein 0
expressed 0
by 0
F2771 B-gene
cDNA I-gene
in 0
transfected 0
COS 0
cells 0
is 0
localized 0
in 0
the 0
cytoplasm 0
. 0

Northern 0
analysis 0
indicated 0
differential 0
expression 0
by 0
tissue 0
with 0
highest 0
expression 0
in 0
the 0
heart 0
. 0

As 0
well 0
, 0
further 0
deletion 0
of 0
the 0
promoter 0
region 0
to 0
nucleotide 0
- 0
110 0
, 0
which 0
contains 0
only 0
one 0
SF B-gene
- I-gene
1 I-gene
binding I-gene
site I-gene
, 0
still 0
retained 0
the 0
ability 0
to 0
respond 0
to 0
exogenous 0
SF B-gene
- I-gene
1 I-gene
. 0

The 0
observation 0
that 0
beta B-gene
2m I-gene
with 0
covalently 0
attached 0
peptide 0
can 0
effectively 0
create 0
CTL 0
target 0
structures 0
in 0
vitro 0
offers 0
new 0
possibilities 0
for 0
the 0
in 0
vivo 0
induction 0
of 0
epitope 0
- 0
specific 0
CTL 0
responses 0
by 0
either 0
DNA 0
immunization 0
or 0
injection 0
of 0
the 0
purified 0
epitope 0
- 0
linked 0
beta B-gene
2m I-gene
. 0

The 0
mRNAs 0
of 0
these 0
genes 0
contain 0
respectively 0
one 0
( 0
YAP1 B-gene
uORF I-gene
) 0
and 0
two 0
( 0
YAP2 B-gene
uORF1 I-gene
and 0
uORF2 0
) 0
upstream 0
open 0
reading 0
frames 0
. 0
uORF 0
- 0
mediated 0
modulation 0
of 0
post 0
- 0
termination 0
events 0
on 0
the 0
5' 0
- 0
untranslated 0
region 0
( 0
5' 0
- 0
UTR 0
) 0
directs 0
differential 0
control 0
not 0
only 0
of 0
translation 0
but 0
also 0
of 0
mRNA 0
decay 0
. 0

To 0
further 0
investigate 0
the 0
nature 0
of 0
the 0
site 0
specificity 0
a 0
set 0
of 0
deletion 0
mutants 0
of 0
the 0
160 0
bp 0
sequence 0
were 0
analysed 0
. 0

In 0
the 0
tissues 0
tested 0
, 0
except 0
brain 0
, 0
the 0
message 0
for 0
CLIP B-gene
- I-gene
170 I-gene
was 0
more 0
abundant 0
than 0
that 0
for 0
Restin B-gene
. 0

BACKGROUND 0
: 0
Chemicals 0
vary 0
considerably 0
in 0
their 0
intrinsic 0
ability 0
to 0
cause 0
allergic 0
contact 0
dermatitis 0
. 0

Cytoskeletal 0
polarization 0
of 0
T 0
cells 0
is 0
regulated 0
by 0
an 0
immunoreceptor 0
tyrosine 0
- 0
based 0
activation 0
motif 0
- 0
dependent 0
mechanism 0
. 0

Here 0
we 0
have 0
examined 0
the 0
ability 0
of 0
the 0
cellular 0
protein 0
YB B-gene
- I-gene
1 I-gene
to 0
modulate 0
transcription 0
of 0
the 0
HIV B-gene
- I-gene
1 I-gene
promoter I-gene
in 0
a 0
human 0
astrocytic 0
cell 0
line 0
( 0
U 0
- 0
87MG 0
) 0
, 0
a 0
neuronal 0
cell 0
line 0
( 0
SK 0
- 0
N 0
- 0
MC 0
) 0
and 0
lymphoid 0
cells 0
( 0
Jurkat 0
) 0
by 0
transfection 0
assay 0
. 0

Also 0
, 0
the 0
deduced 0
amino 0
acids 0
of 0
the 0
antigenic B-gene
regions I-gene
A I-gene
, I-gene
B I-gene
and I-gene
C I-gene
of I-gene
VP7 I-gene
were 0
nearly 0
conserved 0
within 0
the 0
phylogenetic 0
lineages 0
. 0

The 0
cloned 0
alcR B-gene
gene I-gene
provided 0
in 0
trans 0
restored 0
these 0
siderophore 0
system 0
activities 0
to 0
the 0
mutants 0
. 0

The 0
cloned 0
alcR B-gene
gene I-gene
provided 0
in 0
trans 0
restored 0
these 0
siderophore 0
system 0
activities 0
to 0
the 0
mutants 0
. 0

Copyright 0
1998 0
Academic 0
Press 0
. 0

It 0
may 0
also 0
be 0
suggested 0
that 0
particular 0
care 0
should 0
be 0
taken 0
when 0
such 0
a 0
trans 0
- 0
dominant 0
Rev B-gene
mutant I-gene
is 0
considered 0
to 0
be 0
used 0
as 0
a 0
genetic 0
therapy 0
against 0
HIV 0
- 0
I 0
infection 0
, 0
in 0
individuals 0
infected 0
with 0
both 0
HIV 0
- 0
I 0
and 0
HTLV 0
- 0
1 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
Between 0
January 0
1992 0
and 0
June 0
1994 0
at 0
St 0
. 0

The 0
frequency 0
of 0
SPs 0
for 0
both 0
the 0
moderate 0
and 0
severe 0
groups 0
was 0
significantly 0
higher 0
than 0
that 0
in 0
patients 0
with 0
a 0
normal 0
MMFCV 0
( 0
p 0
< 0
.01 0
) 0
; 0
of 0
154 0
arms 0
with 0
a 0
normal 0
MMFCV 0
, 0
only 0
9 0
( 0
6 0
% 0
) 0
had 0
an 0
SP 0
. 0

We 0
analyzed 0
the 0
P 0
- 0
SAECG 0
in 0
the 0
time 0
and 0
frequency 0
domain 0
in 0
23 0
patients 0
with 0
Paf 0
and 0
19 0
controls 0
. 0

Competitive 0
reverse 0
transcription 0
- 0
polymerase 0
chain 0
reaction 0
and 0
HPLC 0
analysis 0
showed 0
that 0
RUSH B-gene
- I-gene
1alpha I-gene
is 0
the 0
progesterone 0
- 0
dependent 0
splice 0
variant 0
. 0

TOR2 B-gene
is 0
part 0
of 0
two 0
related 0
signaling 0
pathways 0
coordinating 0
cell 0
growth 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

Transcervical 0
amnioinfusion 0
. 0

SETTING 0
: 0
A 0
division 0
of 0
a 0
large 0
tea 0
plantation 0
in 0
Kandy 0
. 0

Simple 0
models 0
of 0
bimolecular 0
interaction 0
did 0
not 0
fully 0
account 0
for 0
the 0
kinetic 0
profiles 0
obtained 0
with 0
the 0
parental 0
antibodies 0
and 0
the 0
hybrids 0
, 0
and 0
this 0
complexity 0
suggested 0
the 0
existence 0
of 0
a 0
conformational 0
heterogeneity 0
in 0
these 0
molecules 0
. 0

In 0
order 0
to 0
decipher 0
the 0
pathway 0
that 0
leads 0
to 0
Hox B-gene
gene I-gene
induction 0
, 0
we 0
have 0
investigated 0
whether 0
a 0
Hox B-gene
gene I-gene
regulator 0
, 0
the 0
leucine 0
zipper 0
transcription 0
factor 0
MafB/Kr B-gene
, 0
is 0
itself 0
transcriptionally 0
regulated 0
by 0
the 0
environmental 0
signals 0
. 0

Substrates 0
for 0
p210 B-gene
( 0
bcr B-gene
- 0
abl B-gene
) 0
are 0
likely 0
to 0
be 0
involved 0
in 0
the 0
pathogenesis 0
of 0
CML 0
. 0

Reporter 0
constructs 0
function 0
in 0
a 0
parallel 0
manner 0
, 0
demonstrating 0
the 0
key 0
role 0
of 0
the 0
AhR B-gene
in 0
constitutive 0
as 0
well 0
as 0
TCDD 0
- 0
induced 0
expression 0
of 0
Cyp1B1 B-gene
in 0
mouse 0
embryo 0
fibroblasts 0
. 0

Transfection 0
studies 0
also 0
showed 0
that 0
3' 0
- 0
deletion 0
of 0
sequences 0
downstream 0
of 0
the 0
transcriptional 0
start 0
site 0
( 0
+1/+47 0
) 0
markedly 0
reduced 0
OSM B-gene
- 0
fold 0
induction 0
. 0

Oncostatin B-gene
M I-gene
stimulates 0
c B-gene
- I-gene
Fos I-gene
to 0
bind 0
a 0
transcriptionally 0
responsive 0
AP B-gene
- I-gene
1 I-gene
element I-gene
within 0
the 0
tissue B-gene
inhibitor I-gene
of I-gene
metalloproteinase I-gene
- I-gene
1 I-gene
promoter I-gene
. 0

We 0
have 0
isolated 0
a 0
new 0
human B-gene
RING I-gene
- I-gene
finger I-gene
gene I-gene
( 0
RNF4 B-gene
) 0
that 0
encodes 0
a 0
190 0
- 0
amino 0
- 0
acid 0
protein 0
. 0

To 0
elucidate 0
the 0
regulatory 0
mechanism 0
of 0
human B-gene
AM I-gene
gene I-gene
expression 0
, 0
functional 0
elements 0
of 0
5' 0
- 0
flanking 0
region 0
of 0
AM B-gene
gene I-gene
were 0
studied 0
in 0
human 0
aortic 0
endothelial 0
cells 0
( 0
HAEC 0
) 0
. 0

The 0
COOH 0
- 0
terminal 0
region 0
of 0
the 0
transcripts 0
contained 0
fifteen 0
triplet 0
repeats 0
( 0
GCT 0
; 0
alanine 0
) 0
at 0
nucleotide 0
465 0
to 0
509 0
, 0
which 0
is 0
significantly 0
expanded 0
compared 0
to 0
the 0
rat B-gene
RL14 I-gene
. 0

Soluble 0
FasR B-gene
ligand 0
- 0
binding 0
domain 0
: 0
high 0
- 0
yield 0
production 0
of 0
active 0
fusion 0
and 0
non 0
- 0
fusion 0
recombinant 0
proteins 0
using 0
the 0
baculovirus/insect 0
cell 0
system 0
. 0

Control 0
of 0
fatty 0
liver 0
syndrome 0
in 0
a 0
Jersey 0
herd 0
by 0
a 0
change 0
of 0
diet 0
and 0
the 0
use 0
of 0
recombinant 0
bovine 0
somatotrophin B-gene
. 0

The 0
inhibition 0
of 0
focus 0
formation 0
observed 0
in 0
the 0
presence 0
of 0
C3G B-gene
was 0
not 0
due 0
to 0
toxic 0
effects 0
on 0
cell 0
viability 0
, 0
since 0
transfected 0
C3G B-gene
cells 0
exhibited 0
the 0
same 0
survival 0
and 0
growth 0
rates 0
as 0
untransfected 0
NIH3T3 0
cells 0
or 0
cells 0
transfected 0
with 0
plasmid 0
vector 0
alone 0
. 0

C.D2 0
- 0
Chr 0
4 0
congenic 0
strains 0
harboring 0
DBA/2 0
alleles 0
associated 0
with 0
the 0
Pctr1 B-gene
locus I-gene
contained 0
DBA/2 0
`` 0
resistant 0
'' 0
alleles 0
of 0
the B-gene
CDK4/CDK6 I-gene
CDK4/CDK6 I-gene

When 0
tested 0
with 0
wild 0
- 0
type 0
( 0
DBA/2 0
) 0
p16 B-gene
, 0
both 0
A134C 0
and 0
G232A 0
BALB/c 0
- 0
specific 0
variants 0
of 0
p16 B-gene
were 0
inefficient 0
in 0
their 0
ability 0
to 0
inhibit 0
the 0
activity 0
of 0
cyclin B-gene
D2/CDK4 I-gene
in 0
kinase 0
assays 0
with 0
D2/CDK4 I-gene

Despite 0
this 0
there 0
was 0
no 0
difference 0
in 0
the 0
intubating 0
conditions 0
at 0
one 0
minute 0
with 0
25 0
excellent/5 0
good 0
in 0
the 0
suxamethonium 0
group 0
and 0
27 0
excellent/3 0
good 0
in 0
the 0
rocuronium 0
group 0
. 0

Cloning 0
and 0
expression 0
of 0
two 0
genes 0
encoding 0
auxin B-gene
- I-gene
binding I-gene
proteins I-gene
from 0
tobacco 0
. 0

Furthermore 0
, 0
direct 0
association 0
with 0
D3 0
phosphatidylinositides 0
seems 0
to 0
be 0
essential 0
for 0
activation 0
of 0
PKB/Akt B-gene
. 0

The 0
FMN 0
moiety 0
but 0
not 0
the 0
[ 0
3Fe 0
- 0
4S 0
] 0
cluster 0
of 0
the 0
subunit 0
appears 0
to 0
participate 0
in 0
this 0
reaction 0
. 0

Alison 0
Bell 0
Memorial 0
Award 0
. 0

METHODS 0
: 0
A 0
population 0
survey 0
was 0
undertaken 0
in 0
10,148 0
individuals 0
to 0
measure 0
the 0
prevalence 0
and 0
identify 0
the 0
causes 0
of 0
blindness 0
in 0
Lebanon 0
. 0

During 0
organogenesis 0
, 0
HFH B-gene
- I-gene
8 I-gene
expression 0
is 0
found 0
in 0
the 0
splanchnic 0
mesoderm 0
in 0
close 0
apposition 0
of 0
the 0
gut 0
endoderm 0
, 0
suggesting 0
a 0
role 0
in 0
mesenchymal 0
- 0
epithelial 0
induction 0
of 0
lung 0
and 0
gut 0
morphogenesis 0
. 0

However 0
, 0
laparoscopy 0
failed 0
to 0
establish 0
inoperability 0
in 0
any 0
cases 0
of 0
carcinoma 0
spread 0
to 0
areas 0
not 0
accessible 0
to 0
laparoscopic 0
visualization 0
. 0

No 0
difference 0
in 0
telomere 0
length 0
was 0
seen 0
in 0
mutants 0
affected 0
in 0
the 0
regulation 0
of 0
Cdc2 B-gene
, 0
whereas 0
some 0
of 0
the 0
DNA 0
repair 0
mutants 0
examined 0
had 0
slightly 0
longer 0
telomeres 0
than 0
did 0
the 0
wild 0
type 0
. 0

The 0
mean 0
duration 0
of 0
pain 0
relief 0
was 0
4 0
- 0
6 0
weeks 0
. 0

The 0
ESEM 0
differs 0
from 0
conventional 0
SEM 0
in 0
that 0
no 0
sample 0
preparation 0
is 0
needed 0
, 0
eliminating 0
artifactual 0
changes 0
. 0

Sp1 B-gene
can 0
activate 0
transcription 0
through 0
immunoglobulin B-gene
kappa I-gene
- I-gene
chain I-gene
enhancer I-gene
or 0
P B-gene
- I-gene
selectin I-gene
promoter I-gene
NF B-gene
- I-gene
kappaB I-gene
sites I-gene
. 0
p50 B-gene
homodimers I-gene
replace 0
Sp1 B-gene
from 0
the 0
P B-gene
- I-gene
selectin I-gene
promoter I-gene
by 0
binding 0
site 0
competition 0
and 0
thereby 0
either 0
inhibit 0
basal 0
Sp1 B-gene
- 0
driven 0
expression 0
or 0
, 0
in 0
concert 0
with 0
Bcl B-gene
- I-gene
3 I-gene
, 0
stimulate 0
expression 0
. 0

The 0
3 0
' 0
fragment 0
was 0
shown 0
to 0
accumulate 0
as 0
full 0
- 0
length 0
mRNA 0
disappeared 0
in 0
actinomycin 0
D 0
- 0
treated 0
cells 0
, 0
indicating 0
a 0
precursor 0
- 0
product 0
relationship 0
. 0

The 0
TATA B-gene
box I-gene
- I-gene
binding I-gene
protein I-gene
( 0
TBP B-gene
) 0
plays 0
an 0
essential 0
role 0
in 0
transcription 0
by 0
all 0
three 0
eukaryotic 0
nuclear B-gene
RNA I-gene
polymerases I-gene
, 0
polymerases B-gene
( I-gene
Pol I-gene
) I-gene
I I-gene
, I-gene
II I-gene
, I-gene
and I-gene
III I-gene
. 0

A 0
triple B-gene
- I-gene
mutant I-gene
TBP I-gene
( 0
R231E 0
+ 0
R235E 0
+ 0
R239S 0
) 0
had 0
greatly 0
reduced 0
activity 0
for 0
yeast B-gene
U6 I-gene
snRNA I-gene
gene I-gene
transcription 0
while 0
remaining 0
active 0
for 0
Pol B-gene
II I-gene
basal 0
transcription 0
. 0

E2F B-gene
activity 0
is 0
regulated 0
in 0
part 0
by 0
the 0
retinoblastoma B-gene
family I-gene
of I-gene
tumor I-gene
suppressor I-gene
proteins I-gene
. 0

This 0
resulted 0
in 0
a 0
complete 0
inhibition 0
of 0
Site 0
- 0
1 0
cleavage 0
that 0
was 0
restored 0
by 0
concomitant 0
overexpression 0
of 0
full 0
- 0
length 0
SCAP B-gene
. 0

To 0
determine 0
the 0
true 0
molecular 0
identity 0
of 0
SFD B-gene
, 0
both 0
the 0
50 0
- 0
and 0
57 0
- 0
kDa 0
polypeptides 0
were 0
directly 0
sequenced 0
. 0

Molecular 0
characterization 0
of 0
the 0
50 0
- 0
and 0
57 0
- 0
kDa 0
subunits 0
of 0
the 0
bovine B-gene
vacuolar I-gene
proton I-gene
pump I-gene
. 0

In 0
C. 0
albicans 0
, 0
HST6 B-gene
is 0
expressed 0
constitutively 0
at 0
high 0
levels 0
in 0
the 0
different 0
cell 0
types 0
analysed 0
( 0
yeast 0
, 0
hyphae 0
, 0
white 0
and 0
opaque 0
) 0
, 0
demonstrating 0
that 0
HST6 B-gene
transcription 0
is 0
not 0
repressed 0
in 0
this 0
diploid 0
yeast 0
, 0
unlike 0
in 0
diploid 0
S. 0
cerevisiae 0
, 0
and 0
suggesting 0
a 0
basic 0
biological 0
function 0
for 0
the 0
Hst6p B-gene
transporter 0
in 0
C. 0
albicans 0
. 0

Furthermore 0
, 0
binding 0
of 0
recombinant B-gene
Myb I-gene
and 0
Ets B-gene
- I-gene
2 I-gene
protein I-gene
to 0
these 0
fragments 0
could 0
be 0
competed 0
with 0
an 0
excess 0
of 0
double 0
stranded 0
oligodeoxynucleotides 0
containing 0
canonical 0
, 0
but 0
not 0
mutated 0
, 0
Myb B-gene
- 0
or 0
Ets B-gene
- I-gene
binding I-gene
sites I-gene
. 0

This 0
structure 0
interconnects 0
specific 0
triplets 0
of 0
the 0
basal 0
bodies 0
with 0
the 0
microtubular 0
bundles 0
that 0
emerge 0
from 0
the 0
basal 0
apparatus 0
. 0

To 0
understand 0
the 0
regulatory 0
mechanism 0
controlling 0
its 0
expression 0
at 0
low 0
temperature 0
, 0
the 0
promoter 0
region 0
has 0
been 0
characterized 0
. 0

In 0
the 0
current 0
study 0
, 0
the 0
roles 0
of 0
two 0
putative 0
cis 0
- 0
acting 0
elements 0
within 0
the 0
- 0
73 0
to 0
+44 0
region 0
in 0
basal 0
exon 0
2 0
promoter 0
activity 0
were 0
evaluated 0
using 0
mutagenesis 0
and 0
nuclear 0
protein 0
- 0
DNA 0
binding 0
assays 0
. 0

For 0
the 0
5HT5A B-gene
receptor I-gene
the 0
addition 0
of 0
yohimbine 0
resulted 0
in 0
a 0
similar 0
but 0
smaller 0
effect 0
. 0

We 0
have 0
examined 0
reporter 0
gene 0
( 0
beta B-gene
- I-gene
gal I-gene
) 0
expression 0
directed 0
by 0
human B-gene
heat I-gene
shock I-gene
transcription I-gene
factors I-gene
1 I-gene
and I-gene
2 I-gene
( 0
HSF1 B-gene
and 0
HSF2 B-gene
) 0
in 0
HeLa 0
cells 0
and 0
in 0
yeast 0
( 0
Saccharomyces 0
cerevisiae 0
) 0
. 0

Localized 0
fluorescence 0
was 0
detectable 0
only 0
in 0
cells 0
containing 0
a 0
visible 0
midcell 0
constriction 0
, 0
suggesting 0
that 0
FtsK B-gene
targeting 0
normally 0
occurs 0
only 0
at 0
a 0
late 0
stage 0
of 0
septation 0
. 0

No 0
TATA 0
box 0
was 0
found 0
in 0
the 0
putative 0
promoter 0
region 0
, 0
but 0
multiple 0
GC 0
boxes 0
were 0
found 0
around 0
the 0
cap 0
sites 0
, 0
supporting 0
the 0
previously 0
inferred 0
housekeeping 0
nature 0
of 0
CYP51 B-gene
gene I-gene
and 0
the 0
existence 0
of 0
the 0
multiple 0
transcription 0
initiation 0
sites 0
. 0

Structural 0
and 0
evolutionary 0
studies 0
on 0
sterol B-gene
14 I-gene
- I-gene
demethylase I-gene
P450 I-gene
( 0
CYP51 B-gene
) 0
, 0
the 0
most 0
conserved 0
P450 B-gene
monooxygenase I-gene
: 0
I 0
. 0

Its 0
expression 0
pattern 0
is 0
representative 0
of 0
many 0
B 0
cell 0
- 0
specific 0
proteins 0
, 0
which 0
are 0
essential 0
for 0
B 0
cell 0
development 0
and 0
activation 0
but 0
are 0
down 0
- 0
regulated 0
after 0
B 0
cells 0
become 0
terminally 0
differentiated 0
plasma 0
cells 0
. 0

The 0
intercistronic 0
gene 0
junctions 0
of 0
vesicular 0
stomatitis 0
virus 0
( 0
VSV 0
) 0
contain 0
conserved 0
sequence 0
elements 0
that 0
are 0
important 0
for 0
polyadenylation 0
and 0
transcription 0
termination 0
of 0
upstream 0
transcript 0
as 0
well 0
as 0
reinitiation 0
of 0
transcription 0
of 0
downstream 0
transcript 0
. 0

Infectious 0
mutant 0
virus 0
progeny 0
was 0
obtained 0
only 0
on 0
complementing 0
gK B-gene
- 0
expressing 0
cells 0
, 0
suggesting 0
that 0
gK B-gene
has 0
an 0
important 0
function 0
in 0
the 0
replication 0
cycle 0
. 0

Cleavage 0
and 0
DNA 0
joining 0
reactions 0
, 0
carried 0
out 0
by 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
integrase I-gene
, 0
are 0
necessary 0
to 0
effect 0
the 0
covalent 0
insertion 0
of 0
HIV 0
- 0
1 0
DNA 0
into 0
the 0
host 0
genome 0
. 0

The 0
DSF 0
regimen 0
appears 0
to 0
have 0
significant 0
activity 0
in 0
patients 0
who 0
have 0
metastatic 0
pancreatic 0
islet 0
- 0
cell 0
carcinoma 0
, 0
and 0
patient 0
tolerance 0
of 0
the 0
regimen 0
is 0
excellent 0
, 0
thus 0
warranting 0
further 0
investigation 0
. 0

Activation 0
of 0
the 0
mitogen B-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinase I-gene
is 0
a 0
primary 0
consequence 0
of 0
Ras B-gene
activation 0
and 0
plays 0
a 0
key 0
role 0
in 0
mediating 0
Ras B-gene
signal 0
transduction 0
. 0

Histone B-gene
acetylation 0
levels 0
in 0
cells 0
result 0
from 0
a 0
dynamic 0
equilibrium 0
between 0
competing 0
histone B-gene
acetylases I-gene
and I-gene
deacetylases I-gene
. 0

CONCLUSIONS 0
: 0
XCoe2 B-gene
may 0
play 0
a 0
pivotal 0
role 0
in 0
the 0
transcriptional 0
cascade 0
that 0
specifies 0
primary 0
neurons 0
in 0
Xenopus 0
embryos 0
: 0
by 0
maintaining 0
Delta B-gene
- 0
Notch B-gene
signalling 0
, 0
XCoe2 B-gene
stabilises 0
the 0
higher 0
neural 0
potential 0
of 0
selected 0
progenitor 0
cells 0
that 0
express 0
X B-gene
- I-gene
ngnr I-gene
- I-gene
1 I-gene
, 0
ensuring 0
the 0
transition 0
between 0
neural 0
competence 0
and 0
irreversible 0
commitment 0
to 0
a 0
neural 0
fate 0
; 0
and 0
it 0
promotes 0
neuronal 0
differentiation 0
by 0
activating 0
XNeuroD B-gene
expression 0
, 0
directly 0
or 0
indirectly 0
. 0

RESULTS 0
: 0
Patients 0
in 0
Group 0
A 0
had 0
a 0
higher 0
incidence 0
of 0
posterolateral 0
wall 0
motion 0
abnormalities 0
( 0
p 0
< 0
0.001 0
) 0
on 0
radionuclide 0
ventriculography 0
, 0
a 0
larger 0
infarct 0
area 0
( 0
as 0
evidenced 0
by 0
higher 0
peak 0
creatine B-gene
kinase I-gene
levels 0
) 0
( 0
p 0
< 0
0.02 0
) 0
and 0
a 0
lower 0
left 0
ventricular 0
ejection 0
fraction 0
( 0
LVEF 0
) 0
at 0
hospital 0
discharge 0
( 0
p 0
< 0
0.008 0
) 0
than 0
those 0
in 0
Group 0
B 0
. 0

CyIIa B-gene
transcription 0
follows 0
, 0
and 0
is 0
therefore 0
downstream 0
of 0
, 0
the 0
initial 0
specification 0
of 0
these 0
embryonic 0
domains 0
. 0

Cis 0
- 0
regulation 0
downstream 0
of 0
cell 0
type 0
specification 0
: 0
a 0
single 0
compact 0
element 0
controls 0
the 0
complex 0
expression 0
of 0
the 0
CyIIa B-gene
gene I-gene
in 0
sea 0
urchin 0
embryos 0
. 0

We 0
also 0
present 0
evidence 0
that 0
human B-gene
HYAL1 I-gene
is 0
identical 0
to 0
an 0
uncharacterized 0
gene 0
positionally 0
cloned 0
by 0
others 0
from 0
chromosome 0
3p21.3 0
that 0
is 0
homozygously 0
deleted 0
in 0
several 0
small 0
- 0
cell 0
lung 0
carcinoma 0
cell 0
lines 0
. 0

In 0
patients 0
with 0
myalgia 0
, 0
Raynaud 0
's 0
syndrome 0
, 0
skin 0
vasculitis 0
and 0
vascular 0
diseases 0
WFAg B-gene
concentrations 0
were 0
higher 0
than 0
in 0
patients 0
without 0
them 0
. 0

Although 0
the 0
expression 0
of 0
the 0
4E B-gene
- I-gene
BP1 I-gene
gene I-gene
alone 0
has 0
not 0
yet 0
been 0
accomplished 0
, 0
the 0
gene 0
was 0
expressed 0
in 0
Escherichia 0
coli 0
[ 0
BL21 0
( 0
DE3 0
) 0
] 0
as 0
a 0
fusion 0
gene 0
with 0
the 0
glutathione B-gene
- I-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
gene 0
using 0
a 0
prokaryotic 0
gene 0
fusion 0
vector 0
( 0
pGEX 0
- 0
4T 0
- 0
2 0
) 0
, 0
which 0
contains 0
a 0
gene 0
sequence 0
coding 0
the 0
cleavage 0
site 0
for 0
a 0
specific 0
protease 0
, 0
alpha B-gene
- I-gene
thrombin I-gene
. 0

Randomised 0
comparison 0
of 0
addition 0
of 0
autologous 0
bone 0
- 0
marrow 0
transplantation 0
to 0
intensive 0
chemotherapy 0
for 0
acute 0
myeloid 0
leukaemia 0
in 0
first 0
remission 0
: 0
results 0
of 0
MRC 0
AML 0
10 0
trial 0
. 0

Therapeutic 0
use 0
of 0
cannabis 0
. 0

Analysis 0
of 0
intragenic 0
revertants 0
shows 0
that 0
this 0
function 0
depends 0
on 0
the 0
amino 0
acid 0
preceding 0
the 0
first 0
cysteine 0
residue 0
of 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
Hap1p B-gene
. 0

Peripheral 0
visual 0
stimuli 0
and 0
monoaural 0
auditory 0
stimuli 0
were 0
used 0
as 0
targets 0
. 0

A 0
review 0
of 0
studies 0
published 0
between 0
1983 0
and 0
1995 0
shows 0
that 0
there 0
are 0
some 0
common 0
factors 0
as 0
regards 0
the 0
psychological 0
distress 0
and 0
social 0
and 0
functional 0
limitations 0
this 0
group 0
of 0
patients 0
has 0
to 0
deal 0
with 0
. 0

PKC B-gene
- I-gene
gamma I-gene
, 0
which 0
is 0
not 0
present 0
in 0
keratinocytes 0
, 0
also 0
induces 0
involucrin B-gene
gene I-gene
expression 0
in 0
a 0
TPA 0
- 0
independent 0
manner 0
, 0
when 0
introduced 0
into 0
SVHK 0
cells 0
. 0

Identification 0
and 0
characterization 0
of 0
specific 0
DNA 0
- 0
binding 0
complexes 0
containing 0
members 0
of 0
the 0
Myc/Max/Mad B-gene
network 0
of 0
transcriptional 0
regulators 0
. 0

We 0
further 0
show 0
that 0
proteolytic 0
targeting 0
by 0
calpain B-gene
II I-gene
and 0
the 0
proteasome 0
involves 0
different 0
structural 0
elements 0
of 0
YY1 B-gene
. 0

Primers 0
for 0
subsequent 0
rounds 0
of 0
RACE 0
were 0
designed 0
from 0
the 0
5' 0
- 0
ends 0
of 0
amplified 0
RACE 0
products 0
. 0

Human 0
ZFM1 B-gene
protein I-gene
is 0
a 0
transcriptional 0
repressor 0
that 0
interacts 0
with 0
the 0
transcription B-gene
activation I-gene
domain I-gene
of I-gene
stage I-gene
- I-gene
specific I-gene
activator I-gene
protein I-gene
. 0

Surprisingly 0
, 0
the 0
CSF1R/IRDelta960 B-gene
was 0
as 0
effective 0
as 0
the 0
CSF1R/IRDelta960 I-gene

CONCLUSIONS 0
: 0
The 0
special 0
clinical 0
presentation 0
of 0
our 0
case 0
of 0
possible 0
Gardner 0
's 0
syndrome 0
is 0
discussed 0
. 0

These 0
results 0
would 0
suggest 0
that 0
a 0
high 0
UV 0
sensitivity 0
is 0
associated 0
with 0
high 0
phaeomelanin 0
and 0
low 0
eumelanin 0
levels 0
, 0
and 0
point 0
to 0
the 0
eumelanin/phaeomelanin 0
ratio 0
as 0
a 0
novel 0
chemical 0
parameter 0
that 0
could 0
be 0
used 0
for 0
predicting 0
individuals 0
at 0
high 0
risk 0
for 0
skin 0
cancer 0
and 0
melanoma 0
. 0

In 0
ferrets 0
naturally 0
infected 0
with 0
H. 0
mustelae 0
, 0
a 0
single 0
dose 0
( 0
50 0
mg/kg 0
, 0
per 0
os 0
) 0
of 0
fluorofamide 0
completely 0
inhibited 0
bacterial B-gene
urease I-gene
. 0

The 0
cAMP 0
- 0
dependent 0
mitogenic 0
pathway 0
is 0
unique 0
as 0
it 0
is 0
independent 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
activation 0
and 0
differs 0
from 0
growth 0
factor 0
- 0
dependent 0
pathways 0
at 0
the 0
level 0
of 0
the 0
expression 0
of 0
several 0
protooncogenes/transcription 0
factors 0
. 0

CONCLUSIONS 0
: 0
Use 0
of 0
the 0
first 0
method 0
was 0
associated 0
with 0
a 0
reduction 0
in 0
the 0
time 0
patients 0
remained 0
in 0
the 0
ICU 0
before 0
transfer 0
to 0
another 0
unit 0
and 0
savings 0
in 0
nursing 0
time 0
, 0
but 0
the 0
two 0
methods 0
did 0
not 0
differ 0
according 0
to 0
clinical 0
outcomes 0
. 0

We 0
have 0
elucidated 0
the 0
exon 0
- 0
intron 0
organization 0
of 0
the 0
entire 0
human 0
CD58 B-gene
gene I-gene
, 0
including 0
approximately 0
2.5 0
kilobases 0
( 0
kb 0
) 0
of 0
5' 0
- 0
flanking 0
DNA 0
. 0

The 0
risk 0
factors 0
for 0
hematuria 0
in 0
patients 0
with 0
renal 0
hypouricemia 0
are 0
the 0
elevation 0
of 0
urinary 0
urate 0
concentration 0
and 0
the 0
subtypes 0
of 0
Post 0
and 0
Secretion 0
. 0

Two 0
hundred 0
sixty 0
- 0
four 0
patients 0
scheduled 0
for 0
DCBM 0
were 0
randomized 0
to 0
receive 0
intravenously 0
geG 0
0.25 0
mg 0
( 0
geG 0
- 0
25 0
) 0
, 0
or 0
geG 0
0.5 0
mg 0
( 0
geG 0
- 0
50 0
) 0
, 0
or 0
HBB 0
20 0
mg 0
as 0
hypotonic 0
agent 0
. 0

If 0
the 0
haemoglobin B-gene
concentration 0
( 0
Hb B-gene
) 0
was 0
less 0
than 0
12 0
g 0
dL 0
- 0
1 0
they 0
were 0
given 0
a 0
four 0
week 0
course 0
of 0
ferrous 0
sulphate 0
. 0

In 0
all 0
cells 0
, 0
the 0
accumulation 0
of 0
high 0
Dsg B-gene
protein I-gene
levels 0
required 0
calcium 0
and 0
was 0
not 0
observed 0
in 0
low 0
calcium 0
( 0
0.05 0
- 0
0.07 0
mM 0
) 0
media 0
. 0

Based 0
on 0
restriction 0
enzyme 0
analysis 0
, 0
Southern 0
blots 0
, 0
polymerase 0
chain 0
reaction 0
analysis 0
and 0
DNA 0
sequencing 0
, 0
it 0
was 0
confirmed 0
that 0
the 0
three 0
overlapping 0
clones 0
isolated 0
cover 0
the 0
entire 0
cHO B-gene
- I-gene
1 I-gene
gene I-gene
, 0
as 0
well 0
as 0
approximately 0
10 0
kb 0
of 0
the 0
flanking 0
regions 0
on 0
both 0
ends 0
. 0

RESULTS 0
: 0
Using 0
information 0
in 0
the 0
dbEST 0
database 0
of 0
expressed 0
sequence 0
tags 0
, 0
we 0
isolated 0
an 0
Arabidopsis 0
thaliana 0
gene 0
( 0
GCR1 B-gene
) 0
that 0
encodes 0
a 0
protein 0
with 0
seven 0
predicted 0
membrane 0
- 0
spanning 0
domains 0
and 0
other 0
features 0
characteristic 0
of 0
7TM B-gene
receptors I-gene
. 0

E1A B-gene
represses 0
apolipoprotein B-gene
AI I-gene
enhancer I-gene
activity 0
in 0
liver 0
cells 0
through 0
a 0
pRb B-gene
- 0
and 0
CBP B-gene
- 0
independent 0
pathway 0
. 0

Position 0
- 0
independent 0
expression 0
of 0
a 0
human 0
nerve B-gene
growth I-gene
factor I-gene
- 0
luciferase B-gene
reporter 0
gene 0
cloned 0
on 0
a 0
yeast 0
artificial 0
chromosome 0
vector 0
. 0

Calcitriol 0
therapy 0
was 0
associated 0
with 0
a 0
decrease 0
in 0
serum 0
iPTH B-gene
levels 0
( 0
701 0
+/ 0
- 0
103.9 0
vs 0
. 0

Alterations 0
in 0
DNase B-gene
I I-gene
reactivity 0
of 0
the 0
GC 0
- 0
response 0
element 0
region 0
suggest 0
that 0
GC B-gene
receptor I-gene
- I-gene
GC I-gene
complexes I-gene
may 0
associate 0
, 0
in 0
a 0
transient 0
manner 0
, 0
with 0
the 0
promoter 0
in 0
the 0
actively 0
transcribing 0
control 0
state 0
. 0

Most 0
pituitary 0
hormone 0
- 0
coding 0
gene 0
promoters 0
are 0
activated 0
by 0
Ptx1 B-gene
. 0

One 0
of 0
these 0
small B-gene
inteins I-gene
might 0
be 0
inactive 0
or 0
a 0
`` B-gene
pseudo I-gene
intein I-gene
. I-gene
'' 0
The 0
results 0
suggest 0
a 0
modular 0
architecture 0
for B-gene
inteins I-gene
, 0
clarify 0
their 0
origin 0
and 0
relationship 0
to 0
other 0
protein 0
families 0
, 0
and 0
extend 0
recent 0
experimental 0
findings 0
on 0
the 0
functional 0
roles 0
of B-gene
intein I-gene
N I-gene
, I-gene
C I-gene
, I-gene
and I-gene
EN I-gene
motifs I-gene
. 0

Purification 0
of 0
MvaT B-gene
enriched 0
for 0
two 0
polypeptides 0
of 0
approximate 0
molecular 0
mass 0
15 0
kDa 0
and 0
16 0
kDa 0
, 0
designated 0
P15 B-gene
and 0
P16 B-gene
. 0

M B-gene
- I-gene
66 I-gene
identified 0
the 0
14 0
- 0
kDa 0
protein 0
in 0
another 0
MMTV 0
bearing 0
T 0
- 0
cell 0
lymphoma 0
, 0
EL 0
- 0
4 0
. 0

These 0
results 0
indicate 0
that 0
TGF B-gene
- I-gene
betaf I-gene
potentiates 0
the 0
c B-gene
- I-gene
fos I-gene
SRE 0
activated 0
by 0
PKC B-gene
through 0
the 0
SRF B-gene
binding I-gene
site I-gene
. 0

RT 0
- 0
PCR 0
indicated 0
that 0
p21 B-gene
mRNA I-gene
was 0
induced 0
1.4 0
- 0
, 0
2.0 0
- 0
, 0
and 0
3.1 0
- 0
fold 0
in 0
the 0
2 0
- 0
day 0
neonatal 0
, 0
7 0
- 0
day 0
neonatal 0
, 0
and 0
adult 0
stages 0
, 0
respectively 0
, 0
compared 0
to 0
the 0
17 0
- 0
day 0
fetal 0
stage 0
. 0

Ganciclovir 0
and 0
foscarnet 0
efficacy 0
in 0
AIDS 0
- 0
related 0
CMV 0
polyradiculopathy 0
. 0

BACKGROUND 0
: 0
Defensins B-gene
, 0
also 0
known 0
as 0
human B-gene
neutrophil I-gene
peptides I-gene
, 0
are 0
antimicrobial 0
peptides 0
present 0
in 0
the 0
azurophil 0
granules 0
of 0
neutrophils 0
. 0

The 0
spontaneous 0
mutation 0
blocking 0
pca B-gene
gene I-gene
expression 0
was 0
located 0
in 0
the 0
promoter 0
for 0
the 0
pca B-gene
operon I-gene
. 0

From 0
250 0
g 0
of 0
cells 0
, 0
we 0
isolated 0
1 0
mg 0
of 0
PDH B-gene
complex I-gene
with 0
a 0
specific 0
activity 0
of 0
12.6 0
U/mg 0
of 0
protein 0
. 0

The 0
PDH B-gene
complex I-gene
- I-gene
encoding I-gene
genes I-gene
were 0
identified 0
by 0
hybridization 0
experiments 0
and 0
sequence 0
analysis 0
in 0
two 0
separate 0
gene 0
regions 0
in 0
the 0
genome 0
of 0
Z. 0
mobilis 0
. 0

We 0
have 0
identified 0
two 0
functional 0
elements 0
, 0
both 0
located 0
downstream 0
from 0
the 0
TATA 0
motif 0
, 0
that 0
control 0
Id4 B-gene
promoter I-gene
activity 0
. 0

Azithromycin 0
is 0
a 0
new 0
generation 0
macrolide 0
antibiotic 0
with 0
unusual 0
and 0
favorable 0
pharmacokinetics 0
, 0
and 0
seems 0
to 0
be 0
a 0
very 0
promising 0
agent 0
for 0
innovative 0
anti 0
- 0
H. 0
pylori 0
regimens 0
. 0

The 0
study 0
enrolled 0
994 0
people 0
co 0
- 0
infected 0
with 0
CMV 0
and 0
HIV 0
, 0
with 0
at 0
least 0
one 0
CD4 B-gene
count 0
recorded 0
< 0
100 0
x 0
10 0
( 0
6 0
) 0
cells/l 0
. 0

BACKGROUND 0
AND 0
OBJECTIVES 0
: 0
The 0
sexually 0
transmitted 0
diseases 0
( 0
STD 0
) 0
control 0
program 0
for 0
female 0
sex 0
workers 0
( 0
FSW 0
) 0
in 0
Lima 0
, 0
Peru 0
, 0
provided 0
periodic 0
serological 0
tests 0
for 0
syphilis 0
and 0
cervical 0
smears 0
for 0
gonococci 0
, 0
but 0
not 0
medication 0
for 0
STD 0
or 0
condoms 0
. 0

National 0
certification 0
: 0
a 0
vital 0
component 0
of 0
quality 0
assurance 0
. 0

Two 0
rare 0
novel 0
mutations 0
, 0
D811N 0
in 0
exon 0
20 0
and 0
R835C 0
in 0
exon 0
21 0
, 0
were 0
identified 0
in 0
the 0
first 0
nucleotide 0
- 0
binding 0
fold 0
( 0
NBF 0
) 0
, 0
a 0
functionally 0
important 0
region 0
of 0
SUR1 B-gene
, 0
in 0
one 0
patient 0
each 0
, 0
both 0
heterozygotes 0
. 0

Chimaeric 0
VP16 B-gene
- 0
E2 B-gene
molecules 0
suggest 0
that 0
the 0
epithelial 0
specific 0
transcriptional 0
activation 0
of 0
the 0
BPV B-gene
- I-gene
4 I-gene
LCR I-gene
promoter I-gene
is 0
mediated 0
by 0
the 0
E2 B-gene
transactivation I-gene
domain I-gene
. 0

In 0
order 0
to 0
examine 0
the 0
potential 0
role 0
of 0
transcriptional 0
silencing 0
during 0
productive 0
HSV 0
- 0
1 0
infection 0
, 0
recombinant 0
viruses 0
were 0
generated 0
in 0
which 0
wild B-gene
- I-gene
type I-gene
or I-gene
mutant I-gene
ICP34.5 I-gene
promoters I-gene
controlling 0
the 0
expression 0
of 0
a 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
gene I-gene
were 0
inserted 0
into 0
the 0
thymidine B-gene
kinase I-gene
gene I-gene
of 0
the 0
viral 0
genome 0
. 0

These 0
changes 0
correlate 0
directly 0
with 0
an 0
increase 0
in 0
the 0
acetylation 0
levels 0
of 0
all 0
four 0
core B-gene
histones I-gene
in 0
vivo 0
. 0

Drosophila B-gene
orthodenticle I-gene
( 0
otd B-gene
) 0
and 0
murine B-gene
Otx I-gene
genes I-gene
exemplify 0
this 0
, 0
both 0
in 0
terms 0
of 0
expression 0
patterns 0
and 0
mutant 0
phenotypes 0
. 0

APETALA3 B-gene
transcripts I-gene
are 0
first 0
detected 0
in 0
a 0
meristematic 0
region 0
that 0
will 0
give 0
rise 0
to 0
the 0
petal 0
and 0
stamen 0
primordia 0
, 0
and 0
expression 0
is 0
maintained 0
in 0
this 0
region 0
during 0
subsequent 0
development 0
of 0
these 0
organs 0
. 0

We 0
also 0
recovered 0
mutations 0
in 0
the 0
60A B-gene
gene I-gene
which 0
encodes 0
another 0
TGF B-gene
- I-gene
beta I-gene
- I-gene
related I-gene
factor I-gene
in 0
Drosophila 0
. 0

Cell 0
lines 0
are 0
checked 0
to 0
find 0
out 0
whether 0
they 0
develop 0
tumors 0
in 0
nude 0
mice 0
followed 0
by 0
an 0
analysis 0
of 0
the 0
karyotype 0
. 0

Cervicovaginal 0
foetal B-gene
fibronectin I-gene
in 0
the 0
prediction 0
of 0
preterm 0
labour 0
in 0
a 0
low 0
- 0
risk 0
population 0
. 0

In 0
addition 0
, 0
IgM B-gene
can 0
be 0
absent 0
in 0
children 0
with 0
congenital 0
toxoplasmosis 0
or 0
subjects 0
with 0
secondary 0
reactivation 0
. 0

Both 0
variants 0
display 0
the 0
seven 0
- 0
transmembrane 0
topology 0
that 0
is 0
typical 0
for 0
G B-gene
protein I-gene
- I-gene
coupled I-gene
receptors I-gene
. 0

A 0
constitutive 0
allele 0
of 0
GPA2 B-gene
could 0
stimulate 0
growth 0
of 0
a 0
strain 0
lacking 0
both 0
RAS B-gene
genes I-gene
. 0

The 0
COOH 0
- 0
terminus 0
of 0
this 0
new 0
isoform 0
, 0
which 0
we 0
designate 0
beta B-gene
4 I-gene
, 0
lacks 0
a 0
22 0
amino 0
acid 0
lysine 0
- 0
rich 0
sequence 0
common 0
to 0
both 0
the 0
human B-gene
red I-gene
cell I-gene
alpha I-gene
- I-gene
and I-gene
beta I-gene
- I-gene
adducin I-gene
subunits I-gene
and 0
homologous 0
to 0
a 0
highly 0
conserved 0
region 0
in 0
MARCKS B-gene
, 0
a 0
filamentous 0
actin B-gene
- 0
cross 0
linking 0
protein 0
regulated 0
by 0
protein B-gene
kinase I-gene
C I-gene
and 0
calcium/calmodulin B-gene
. 0
beta B-gene
4 I-gene
- I-gene
adducin I-gene
preserves 0
a 0
previously 0
identified 0
calmodulin B-gene
binding I-gene
domain I-gene
. 0

PCR 0
analysis 0
indicates 0
that 0
this 0
new 0
beta B-gene
- I-gene
adducin I-gene
isoform I-gene
is 0
expressed 0
in 0
fetal 0
brain 0
and 0
liver 0
, 0
bone 0
marrow 0
, 0
and 0
NT 0
- 0
2 0
( 0
neuroepithelial 0
) 0
cells 0
, 0
but 0
is 0
not 0
detected 0
in 0
several 0
other 0
tissues 0
. 0

The 0
gene B-gene
lac I-gene
- I-gene
1 I-gene
, 0
encoding 0
the 0
enzyme 0
laccase B-gene
, 0
is 0
the 0
best 0
characterized 0
of 0
a 0
number 0
of 0
genes 0
in 0
the 0
chestnut 0
blight 0
fungus 0
, 0
Cryphonectria 0
parasitica 0
, 0
that 0
are 0
repressed 0
by 0
hypoviruses 0
, 0
a 0
group 0
of 0
virulence 0
- 0
attenuating 0
mycoviruses 0
. 0
lac B-gene
- I-gene
1 I-gene
has 0
also 0
been 0
shown 0
to 0
be 0
transcriptionally 0
activated 0
by 0
low 0
concentrations 0
of 0
the 0
translational 0
inhibitor 0
cycloheximide 0
( 0
CHX 0
) 0
and 0
by 0
the 0
immunosuppressant 0
cyclosporin 0
A 0
. 0

Both 0
TRE 0
- 0
like 0
elements 0
were 0
capable 0
of 0
binding 0
AP1 B-gene
. 0

The 0
hp55 B-gene
gamma I-gene
protein I-gene
interacts 0
strongly 0
with 0
the 0
activated 0
IGFIR B-gene
but 0
not 0
with 0
the 0
kinase 0
- 0
negative 0
mutant 0
receptor 0
. 0
hp55 B-gene
gamma I-gene
also 0
interacts 0
with 0
the 0
insulin B-gene
receptor I-gene
( 0
IR B-gene
) 0
in 0
the 0
yeast 0
two 0
- 0
hybrid 0
system 0
. 0

The 0
plant 0
protein 0
maintains 0
all 0
the 0
functional 0
domains 0
found 0
in 0
the 0
other 0
proteins 0
, 0
including 0
nuclear 0
localization 0
signal 0
, 0
DNA 0
- 0
binding 0
domain 0
and 0
helicase B-gene
motifs I-gene
, 0
suggesting 0
that 0
it 0
might 0
also 0
act 0
as 0
part 0
of 0
the 0
RNA 0
transcription 0
apparatus 0
, 0
as 0
well 0
as 0
nucleotide 0
excision 0
repair 0
in 0
plant 0
cells 0
. 0

This 0
paper 0
describes 0
the 0
genomic 0
organization 0
of 0
mouse 0
gC1qBP B-gene
and 0
the 0
characterization 0
of 0
its 0
5 0
' 0
flanking 0
region 0
. 0

LysR B-gene
proteins I-gene
have 0
been 0
shown 0
to 0
regulate 0
urease B-gene
in I-gene
Klebsiella I-gene
aerogenes I-gene
( 0
NAC B-gene
) 0
, 0
and 0
catalase B-gene
in I-gene
Escherichia I-gene
coli I-gene
( 0
OxyR B-gene
) 0
, 0
which 0
offers 0
the 0
intracellular 0
bacterium 0
protection 0
from 0
phagolysosome 0
damage 0
. 0

Also 0
, 0
the 0
anti 0
- 0
inflammatory 0
activities 0
of 0
an 0
aqueous 0
extract 0
of 0
Buddleia 0
cordata 0
and 0
its 0
principal 0
glycoside 0
linarin 0
were 0
evaluated 0
. 0

Regulation 0
of 0
the 0
Raf B-gene
kinase I-gene
in 0
T 0
cells 0
differs 0
from 0
findings 0
with 0
a 0
variety 0
of 0
cell 0
lines 0
that 0
the 0
catalytic B-gene
domain I-gene
of I-gene
Raf I-gene
( 0
Raf B-gene
( 0
delta26 0
- 0
303 0
) 0
) 0
shows 0
no 0
activity 0
. 0

Full B-gene
- I-gene
length I-gene
FLAP I-gene
clones 0
were 0
isolated 0
from 0
a 0
mouse 0
skeletal 0
muscle 0
cDNA 0
library 0
. 0

Members 0
of 0
the 0
meis1 B-gene
and 0
pbx B-gene
homeodomain I-gene
protein I-gene
families I-gene
cooperatively 0
bind 0
a 0
cAMP 0
- 0
responsive 0
sequence 0
( 0
CRS1 0
) 0
from 0
bovine B-gene
CYP17 I-gene
. 0

We 0
have 0
visualized 0
DNA 0
- 0
protein 0
complexes 0
by 0
electron 0
microscopy 0
and 0
a 0
high 0
- 0
affinity 0
binding 0
site 0
of 0
WDV B-gene
Rep I-gene
protein I-gene
within 0
the 0
core 0
element 0
has 0
been 0
mapped 0
to 0
approximately 0
144 0
+/ 0
- 0
18 0
bp 0
upstream 0
from 0
the 0
initiation 0
site 0
, 0
between 0
the 0
start 0
site 0
for 0
complementary 0
- 0
sense 0
transcription 0
and 0
the 0
TATA 0
box 0
. 0

Rex B-gene
- I-gene
1 I-gene
, 0
a 0
gene 0
encoding 0
a 0
transcription 0
factor 0
expressed 0
in 0
the 0
early 0
embryo 0
, 0
is 0
regulated 0
via 0
Oct B-gene
- I-gene
3/4 I-gene
and 0
Oct B-gene
- I-gene
6 I-gene
binding 0
to 0
an 0
octamer 0
site 0
and 0
a 0
novel 0
protein 0
, 0
Rox B-gene
- I-gene
1 I-gene
, 0
binding 0
to 0
an 0
adjacent 0
site 0
. 0

However 0
, 0
inhibition 0
of 0
both 0
the 0
ERK/RSK B-gene
and 0
the 0
ERK/RSK I-gene

Cells 0
respond 0
to 0
the 0
accumulation 0
of 0
unfolded 0
proteins 0
in 0
the 0
endoplasmic 0
reticulum 0
( 0
ER 0
) 0
by 0
increasing 0
the 0
transcription 0
of 0
the 0
genes 0
encoding 0
ER B-gene
- I-gene
resident I-gene
chaperone I-gene
proteins I-gene
. 0

The 0
RAS B-gene
- 0
cyclic B-gene
AMP I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
cAPK B-gene
pathway 0
prevents 0
the 0
UAS 0
activity 0
of 0
IREu B-gene
in 0
the 0
presence 0
of 0
glucose 0
as 0
the 0
sole 0
carbon 0
source 0
, 0
while 0
the 0
transcriptional 0
activators 0
Msn2p B-gene
and 0
Msn4p B-gene
promote 0
the 0
UAS 0
activity 0
of 0
this 0
repeat 0
in 0
the 0
presence 0
of 0
acetate 0
. 0

The 0
mei4+ B-gene
gene I-gene
of 0
the 0
fission 0
yeast 0
Schizosaccharomyces 0
pombe 0
was 0
cloned 0
by 0
functional 0
complementation 0
. 0

Alternative 0
splicing 0
of 0
fibroblast B-gene
growth I-gene
factor I-gene
receptor I-gene
2 I-gene
( 0
FGF B-gene
- I-gene
R2 I-gene
) 0
is 0
an 0
example 0
of 0
highly 0
regulated 0
alternative 0
splicing 0
in 0
which 0
exons 0
IIIb 0
and 0
IIIc 0
are 0
utilized 0
in 0
a 0
mutually 0
exclusive 0
manner 0
in 0
different 0
cell 0
types 0
. 0

In 0
some 0
cases 0
, 0
the 0
aberrant 0
methylation 0
of 0
CpGs 0
within 0
5 0
' 0
regulatory 0
regions 0
has 0
led 0
to 0
suppression 0
of 0
gene 0
activity 0
. 0

The 0
genomic 0
fragments 0
were 0
fused 0
upstream 0
of 0
the 0
luciferase B-gene
reporter I-gene
gene I-gene
. 0

Cotransfection 0
analyses 0
of 0
the 0
T/EBP B-gene
promoter I-gene
- I-gene
reporter I-gene
constructs I-gene
with 0
a 0
T/EBP B-gene
expression 0
vector 0
into 0
human 0
HepG2 0
cells 0
, 0
which 0
do 0
not 0
express 0
T/EBP B-gene
, 0
suggested 0
that 0
autoregulation 0
may 0
be 0
involved 0
in 0
controlling 0
both 0
rat 0
and 0
human B-gene
T/EBP I-gene
gene I-gene
expression 0
. 0

Deletion 0
of 0
the 0
last 0
two 0
Ser 0
residues 0
, 0
including 0
one 0
PKC B-gene
consensus 0
site 0
in 0
the 0
receptor 0
tail 0
, 0
prevented 0
only 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
- 0
induced 0
desensitization 0
by 0
30 0
% 0
. 0

Flap 0
survival 0
depends 0
on 0
the 0
development 0
of 0
a 0
small 0
number 0
of 0
vascular 0
connections 0
between 0
vessels 0
arising 0
from 0
the 0
pedicle 0
and 0
preexisting 0
dermal 0
vessels 0
. 0

Jean 0
Klig 0
reviews 0
recent 0
literature 0
about 0
lower 0
respiratory 0
tract 0
infection 0
in 0
children 0
. 0

Potential 0
indicators 0
were 0
assessed 0
for 0
the 0
two 0
classifications 0
of 0
protein 0
- 0
energy 0
malnutrition 0
in 0
the 0
guidelines 0
for 0
integrated 0
management 0
of 0
childhood 0
illness 0
: 0
severe 0
malnutrition 0
, 0
which 0
requires 0
immediate 0
referral 0
to 0
hospital 0
, 0
and 0
very 0
low 0
weight 0
, 0
which 0
calls 0
for 0
feeding 0
assessment 0
, 0
nutritional 0
counselling 0
and 0
follow 0
- 0
up 0
. 0

SNAC 0
or 0
PBS 0
was 0
infused 0
for 0
6.5 0
h 0
, 0
beginning 0
30 0
min 0
before 0
ischemia 0
and 0
continuing 0
throughout 0
the 0
duration 0
of 0
reperfusion 0
. 0

Despite 0
its 0
requirement 0
for 0
enhancer 0
- 0
dependent 0
splicing 0
activity 0
in 0
vitro 0
, 0
the 0
dU2AF38 B-gene
RS I-gene
domain I-gene
was 0
also 0
inessential 0
in 0
vivo 0
. 0

In 0
vitro 0
binding 0
studies 0
using 0
GST B-gene
fusion 0
proteins 0
and 0
yeast 0
extracts 0
defined 0
distinct 0
binding 0
sites 0
on 0
yAP180A B-gene
for 0
Pan1p B-gene
and 0
clathrin B-gene
. 0
yAP180 B-gene
proteins I-gene
and 0
Pan1p B-gene
, 0
like 0
actin B-gene
, 0
localize 0
to 0
peripheral 0
patches 0
along 0
the 0
plasma 0
membrane 0
. 0

In 0
vitro 0
affinity 0
analyses 0
demonstrated 0
that 0
recombinant 0
130 0
- 0
kD 0
protein 0
directly 0
interacts 0
with 0
ZO B-gene
- I-gene
1 I-gene
and 0
the 0
cytoplasmic 0
domain 0
of 0
occludin B-gene
, 0
but 0
not 0
with 0
ZO B-gene
- I-gene
2 I-gene
. 0

Cytochrome B-gene
b I-gene
in 0
human B-gene
complex I-gene
II I-gene
( 0
succinate B-gene
- I-gene
ubiquinone I-gene
oxidoreductase I-gene
) 0
: 0
cDNA 0
cloning 0
of 0
the 0
components 0
in 0
liver 0
mitochondria 0
and 0
chromosome 0
assignment 0
of 0
the 0
genes 0
for 0
the 0
large 0
( 0
SDHC B-gene
) 0
and 0
small 0
( 0
SDHD B-gene
) 0
subunits 0
to 0
1q21 0
and 0
11q23 0
. 0

A 0
possible 0
decrease 0
in 0
theophylline 0
's 0
volume 0
of 0
distribution 0
at 0
4 0
days 0
, 0
but 0
not 0
immediately 0
, 0
after 0
administration 0
of 0
chloroquine 0
was 0
suggested 0
, 0
although 0
this 0
just 0
failed 0
to 0
achieve 0
statistical 0
significance 0
( 0
p 0
= 0
0.055 0
) 0
. 0

The 0
addition 0
of 0
a 0
Paf B-gene
- 0
containing 0
extract 0
does 0
not 0
lead 0
to 0
significant 0
protein 0
binding 0
to 0
these 0
two 0
hly B-gene
target I-gene
sequences I-gene
in 0
the 0
absence 0
of 0
PrfA B-gene
but 0
converts 0
the 0
complex 0
( 0
CIII 0
) 0
consisting 0
of 0
PrfA B-gene
and 0
the 0
109 B-gene
bp I-gene
hly I-gene
DNA I-gene
fragment I-gene
to 0
a 0
slower 0
migrating 0
PrfA B-gene
- 0
Paf B-gene
- 0
DNA 0
complex 0
( 0
CI 0
) 0
. 0

Moreover 0
, 0
it 0
is 0
the 0
assumptions 0
behind 0
steady 0
- 0
state 0
O2 0
uptake 0
that 0
do 0
not 0
permit 0
proper 0
interpretation 0
of 0
energy 0
expenditure 0
during 0
EPOC 0
; 0
1 0
l 0
O2 0
not 0
= 0
20.9 0
kJ 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
of 0
m B-gene
- I-gene
Staf I-gene
is 0
highly 0
homologous 0
to 0
that 0
of 0
Staf B-gene
, 0
another 0
selenocysteine B-gene
tRNA I-gene
gene I-gene
transcription I-gene
activating I-gene
factor I-gene
of 0
Xenopus 0
laevis 0
. 0

ROCK B-gene
- I-gene
I I-gene
, 0
Kinectin B-gene
, 0
and 0
mDia2 B-gene
can 0
bind 0
the 0
wild 0
type 0
forms 0
of 0
both 0
RhoA B-gene
and 0
Cdc42 B-gene
in 0
a 0
GTP 0
- 0
dependent 0
manner 0
in 0
vitro 0
. 0

Among 0
three 0
isoforms 0
, 0
the 0
beta 0
isoform 0
has 0
the 0
greatest 0
Vmax 0
value 0
for 0
the 0
PtdIns B-gene
( I-gene
4 I-gene
) I-gene
P I-gene
kinase I-gene
activity 0
and 0
the 0
gamma 0
isoform 0
is 0
most 0
markedly 0
stimulated 0
by 0
phosphatidic 0
acid 0
. 0

The 0
beta 0
subunit 0
of 0
the 0
heterotrimeric B-gene
G I-gene
proteins I-gene
that 0
transduce 0
signals 0
across 0
the 0
plasma 0
membrane 0
is 0
made 0
up 0
of 0
an 0
amino 0
- 0
terminal 0
alpha 0
- 0
helical 0
segment 0
followed 0
by 0
seven 0
repeating 0
units 0
called 0
WD 0
( 0
Trp 0
- 0
Asp 0
) 0
repeats 0
that 0
occur 0
in 0
about 0
140 0
different 0
proteins 0
. 0

Two 0
differentially 0
expressed 0
LNX B-gene
messages I-gene
encode 0
overlapping 0
proteins 0
with 0
predicted 0
molecular 0
masses 0
of 0
80 B-gene
kDa I-gene
( I-gene
LNX I-gene
) I-gene
and 0
70 B-gene
kDa I-gene
( I-gene
LNX I-gene
- I-gene
b I-gene
) I-gene
. 0

In 0
contrast 0
, 0
the 0
contractile 0
action 0
of 0
arachidonic 0
acid 0
, 0
via 0
a 0
presumed 0
cyclooxygenase B-gene
product 0
that 0
mediated 0
the 0
contractions 0
caused 0
by 0
both 0
TF B-gene
and 0
EGF B-gene
, 0
was 0
not 0
blocked 0
by 0
any 0
of 0
the 0
signal 0
pathway 0
probe 0
inhibitors 0
. 0

Recent 0
studies 0
have 0
revealed 0
unconventional 0
myosin B-gene
V I-gene
to 0
be 0
an 0
important 0
actin B-gene
- 0
based 0
molecular 0
motor 0
involved 0
in 0
vesicular 0
movement 0
. 0

On 0
a 0
separate 0
occasion 0
the 0
T1 0
weighted 0
and 0
T2 0
weighted 0
sagittal 0
and 0
T2 0
weighted 0
axial 0
sequences 0
were 0
reported 0
blind 0
in 0
relation 0
to 0
the 0
initial 0
assessment 0
. 0

Furthermore 0
, 0
a 0
minor 0
start 0
site 0
was 0
localized 0
179 0
bp 0
upstream 0
of 0
the 0
major 0
site 0
using 0
reverse B-gene
transcriptase I-gene
- 0
polymerase 0
chain 0
reaction 0
with 0
various 0
P1 0
primers 0
( 0
primer 0
walking 0
) 0
, 0
primer 0
extension 0
, 0
and 0
cDNA 0
cloning 0
. 0

Analysis 0
of 0
promoter 0
and 0
androgen 0
regulatory 0
sequences 0
required 0
for 0
optimal 0
transcription 0
of 0
the 0
rat 0
androgen B-gene
- I-gene
binding I-gene
protein I-gene
gene 0
. 0

The 0
iron 0
dependence 0
of 0
transcription 0
and 0
expression 0
of 0
cvaA B-gene
, 0
which 0
encodes 0
a 0
transporter 0
accessory 0
protein 0
, 0
and 0
cvi B-gene
, 0
encoding 0
the 0
colicin B-gene
V I-gene
immunity I-gene
protein I-gene
, 0
was 0
assessed 0
under 0
conditions 0
of 0
iron 0
excess 0
or 0
depletion 0
. 0

In 0
a 0
gntR B-gene
deletion I-gene
mutant I-gene
, 0
the 0
expression 0
of 0
a 0
chromosomal 0
gntT B-gene
: 0
:lacZ B-gene
fusion 0
is 0
both 0
high 0
and 0
constitutive 0
, 0
confirming 0
that 0
GntR B-gene
is 0
the 0
negative 0
regulator 0
of 0
gntT B-gene
. 0

Furthermore 0
, 0
the 0
deletion 0
of 0
bcp B-gene
from 0
the 0
chromosome 0
had 0
no 0
effect 0
on 0
gcv B-gene
- 0
lacZ B-gene
expression 0
. 0

Of 0
these 0
sites 0
, 0
PEA3 B-gene
and 0
STAT B-gene
contributed 0
specifically 0
to 0
induction 0
by 0
v B-gene
- I-gene
src I-gene
, 0
whereas 0
the 0
remaining 0
elements 0
were 0
also 0
involved 0
in 0
induction 0
by 0
the 0
phorbol 0
ester 0
phorbol 0
myristate 0
acetate 0
( 0
PMA 0
) 0
. 0

BRCA1 B-gene
protein I-gene
contains 0
an 0
amino 0
- 0
terminal 0
zinc 0
finger 0
motif 0
and 0
a 0
carboxy 0
- 0
terminal 0
acidic 0
region 0
. 0

The 0
mitochondrial B-gene
regulatory I-gene
region I-gene
( 0
mrr B-gene
) 0
located 0
between 0
the 0
tRNAPhe B-gene
and 0
tRNAPro B-gene
genes I-gene
of 0
mitochondrial 0
DNA 0
( 0
mtDNA 0
) 0
is 0
essential 0
for 0
regulation 0
of 0
replication 0
and 0
transcription 0
of 0
the 0
mitochondrial 0
genome 0
. 0

In 0
this 0
report 0
, 0
we 0
investigate 0
the 0
mechanism 0
underlying 0
Ras B-gene
activation 0
upon 0
stimulation 0
of 0
these 0
two 0
types 0
of 0
receptors 0
in 0
hematopoietic 0
cells 0
. 0

Thus 0
, 0
Sir B-gene
proteins I-gene
from 0
K. 0
lactis 0
have 0
roles 0
in 0
both 0
silencing 0
and 0
telomere 0
length 0
maintenance 0
, 0
reflecting 0
conserved 0
functional 0
themes 0
. 0

Therefore 0
, 0
we 0
conclude 0
that 0
DnaA B-gene
may 0
contact 0
the 0
beta 0
subunit 0
of 0
RNA B-gene
polymerase I-gene
during 0
activation 0
of 0
the 0
pR B-gene
promoter I-gene
. 0

Expression 0
of 0
Bcl B-gene
- I-gene
XL I-gene
inhibited 0
the 0
association 0
of 0
Apaf B-gene
- I-gene
1 I-gene
with 0
caspase B-gene
- I-gene
9 I-gene
in 0
mammalian 0
cells 0
. 0

Whole 0
- 0
mount 0
in 0
situ 0
hybridization 0
to 0
early 0
mouse 0
embryos 0
of 0
9.5 0
- 0
10.5 0
days 0
indicated 0
a 0
complex 0
pattern 0
of 0
Arp1 B-gene
expression 0
spatially 0
overlapping 0
with 0
the 0
expression 0
of 0
All1 B-gene
. 0

These 0
mutants 0
were 0
tested 0
for 0
ability 0
to 0
bind 0
each 0
of 0
the 0
Site B-gene
II I-gene
cognate I-gene
proteins I-gene
, 0
and 0
subsequently 0
evaluated 0
for 0
ability 0
to 0
confer 0
H4 B-gene
transcriptional 0
activity 0
using 0
chimeric 0
H4 B-gene
promoter/CAT B-gene
fusion 0
constructs 0
in 0
different 0
cell 0
types 0
. 0

Increased 0
plasma 0
IgE B-gene
was 0
also 0
confirmed 0
in 0
the 0
NC 0
mice 0
, 0
and 0
treatment 0
with 0
FK506 0
ointment 0
reduced 0
the 0
plasma 0
IgE B-gene
level 0
. 0

Creatine B-gene
kinase I-gene
release 0
after 0
hepatic 0
artery 0
embolization 0
in 0
patients 0
with 0
carcinoid 0
tumors 0
. 0

Furthermore 0
, 0
in 0
the 0
ischemia/angiotension B-gene
II I-gene
- 0
induced 0
AHF 0
model 0
, 0
NIC 0
decreased 0
left 0
ventricular 0
end 0
- 0
diastolic 0
pressure 0
( 0
LVEDP 0
) 0
. 0

Group 0
A 0
( 0
68.7+/ 0
- 0
2.7 0
years 0
) 0
consisted 0
of 0
patients 0
with 0
0 0
or 0
1 0
risk 0
factors 0
; 0
B 0
( 0
68.3+/ 0
- 0
4.2 0
years 0
) 0
those 0
with 0
2 0
risk 0
factors 0
; 0
and 0
C 0
( 0
69.2+/ 0
- 0
3.6 0
years 0
) 0
those 0
with 0
3 0
or 0
more 0
risk 0
factors 0
. 0

We 0
further 0
demonstrate 0
that 0
RU486 0
- 0
PR B-gene
- I-gene
B I-gene
interacts 0
physically 0
with 0
NCoR B-gene
in 0
vitro 0
. 0

PRL B-gene
receptor I-gene
also 0
activates 0
SHP B-gene
- I-gene
2 I-gene
, 0
a 0
cytosolic B-gene
tyrosine I-gene
phosphatase I-gene
. 0

The 0
dominant 0
negative 0
mutant 0
of 0
SHP B-gene
- I-gene
2 I-gene
was 0
found 0
to 0
inhibit 0
the 0
induction 0
of 0
tyrosine 0
phosphorylation 0
and 0
DNA 0
- 0
binding 0
activity 0
of 0
m B-gene
- I-gene
Stat5a I-gene
, 0
m B-gene
- I-gene
Stat5b I-gene
, 0
and 0
the 0
carboxyl 0
- 0
terminal 0
deletion 0
variant 0
m B-gene
- I-gene
Stat5adelta749 I-gene
, 0
as 0
well 0
as 0
the 0
transactivation 0
potential 0
of 0
m B-gene
- I-gene
Stat5a I-gene
and 0
m B-gene
- I-gene
Stat5b I-gene
. 0

CONCLUSIONS 0
: 0
These 0
routinely 0
collected 0
data 0
provided 0
quantitative 0
estimates 0
of 0
changes 0
in 0
CBZ 0
Cl/F 0
due 0
to 0
comedication 0
and 0
an 0
age 0
- 0
related 0
decrease 0
in 0
Cl/F 0
The 0
derived 0
regression 0
equations 0
reasonably 0
predicted 0
concentrations 0
in 0
a 0
separate 0
validation 0
set 0
. 0

Sites 0
1 0
and 0
4 0
in 0
lumican B-gene
and 0
keratocan B-gene
are 0
in 0
a 0
homologous 0
location 0
. 0

Our 0
observations 0
suggest 0
that 0
members 0
of 0
the 0
HMG B-gene
- I-gene
I I-gene
family I-gene
play 0
an 0
important 0
role 0
in 0
SRF B-gene
- 0
dependent 0
transcription 0
and 0
that 0
their 0
effect 0
is 0
mediated 0
primarily 0
by 0
a 0
protein 0
- 0
protein 0
interaction 0
. 0

ATP 0
- 0
dependent 0
assembly 0
of 0
a 0
ternary 0
complex 0
consisting 0
of 0
a 0
DNA 0
mismatch 0
and 0
the 0
yeast 0
MSH2 B-gene
- 0
MSH6 B-gene
and 0
MLH1 B-gene
- 0
PMS1 B-gene
protein 0
complexes 0
. 0

Mutation 0
of 0
the 0
central 0
Tyr497 0
to 0
Phe 0
blocks 0
the 0
tyrosine 0
phosphorylation 0
of 0
the 0
insulin B-gene
receptor I-gene
substrate I-gene
1 I-gene
( 0
IRS1 B-gene
) 0
and 0
diminishes 0
proliferation 0
in 0
response 0
to 0
IL B-gene
- I-gene
4 I-gene
. 0

Instead 0
, 0
it 0
contained 0
two 0
tandem 0
kappaB B-gene
elements I-gene
and 0
a 0
variant 0
activating B-gene
transcription I-gene
factor/cAMP I-gene
response I-gene
element I-gene
site 0
, 0
which 0
closely 0
resembled 0
sites 0
in 0
the 0
E B-gene
- I-gene
selectin I-gene
gene I-gene
that 0
are 0
required 0
for 0
TNF B-gene
- I-gene
alpha I-gene
- 0
or 0
LPS 0
- 0
inducible 0
expression 0
. 0

We 0
recently 0
characterized 0
a 0
single 0
yeast B-gene
hnRNP I-gene
methyltransferase I-gene
( 0
HMT1 B-gene
) 0
. 0

We 0
recently 0
characterized 0
a 0
single 0
yeast B-gene
hnRNP I-gene
methyltransferase I-gene
( 0
HMT1 B-gene
) 0
. 0

Recombinant B-gene
HRMT1L2 I-gene
protein I-gene
encoded 0
by 0
the 0
most 0
common 0
5' 0
- 0
variant 0
exhibited 0
methyltransferase 0
activity 0
in 0
vitro 0
. 0

The 0
possible 0
roles 0
of 0
HRMT1L1 B-gene
and 0
HRMT1L2 B-gene
in 0
human 0
disease 0
are 0
currently 0
unknown 0
. 0

Identification 0
and 0
characterization 0
of 0
two 0
putative 0
human B-gene
arginine I-gene
methyltransferases I-gene
( 0
HRMT1L1 B-gene
and 0
HRMT1L2 B-gene
) 0
. 0

Interestingly 0
, 0
the 0
activated 0
PDGF B-gene
beta I-gene
- I-gene
receptor I-gene
was 0
found 0
not 0
to 0
bind 0
Crk B-gene
proteins I-gene
. 0

Furthermore 0
, 0
interactions 0
were 0
identified 0
between 0
endogenous B-gene
E I-gene
- I-gene
cadherin I-gene
and 0
the 0
chimera 0
containing 0
the 0
E B-gene
- I-gene
cadherin I-gene
extracellular I-gene
domain I-gene
and 0
the 0
desmoglein B-gene
1 I-gene
intracellular I-gene
domain I-gene
providing 0
in 0
vivo 0
evidence 0
for 0
previously 0
predicted 0
lateral 0
interactions 0
of 0
E B-gene
- I-gene
cadherin I-gene
extracellular I-gene
domains I-gene
. 0

The 0
ether 0
phospholipid 0
1 0
- 0
O 0
- 0
octadecyl 0
- 0
2 0
- 0
O 0
- 0
methyl 0
- 0
rac 0
- 0
glycero 0
- 0
3 0
- 0
phosphocholine 0
( 0
ET 0
- 0
18 0
- 0
OCH3 0
; 0
edelfosine 0
) 0
is 0
a 0
potent 0
inducer 0
of 0
apoptosis 0
in 0
human 0
tumor 0
cells 0
. 0

In 0
addition 0
to 0
a 0
previously 0
characterized 0
promoter 0
( 0
P1 0
) 0
, 0
we 0
now 0
show 0
the 0
existence 0
of 0
a 0
second 0
promoter 0
for 0
the 0
human B-gene
IL I-gene
- I-gene
5Ralpha I-gene
gene I-gene
. 0

Serum 0
levels 0
of 0
testosterone 0
also 0
showed 0
no 0
significant 0
changes 0
by 0
exposure 0
to 0
p 0
, 0
p' 0
- 0
DDE 0
under 0
the 0
conditions 0
of 0
this 0
study 0
. 0

Overall 0
agreement 0
between 0
rest/postnitroglycerin 0
technetium 0
- 0
99m 0
tetrofosmin 0
SPET 0
studies 0
and 0
rest/redistribution 0
or 0
rest/reinjection 0
thallium 0
- 0
201 0
SPET 0
studies 0
, 0
regarding 0
the 0
presence 0
of 0
myocardial 0
viability 0
, 0
was 0
87 0
% 0
and 0
90 0
% 0
, 0
respectively 0
. 0

Their 0
use 0
resulted 0
in 0
a 0
sensitivity 0
of 0
73 0
% 0
and 0
a 0
specificity 0
of 0
74 0
% 0
with 0
regard 0
to 0
predictability 0
of 0
ALT B-gene
levels 0
increasing 0
during 0
the 0
trial 0
. 0

One 0
hundred 0
replicate 0
data 0
sets 0
of 0
100 0
subjects 0
each 0
were 0
simulated 0
for 0
each 0
missing 0
data 0
scenario 0
. 0

Spatial 0
accuracy 0
of 0
primary 0
and 0
secondary 0
memory 0
- 0
guided 0
saccades 0
in 0
schizophrenic 0
patients 0
. 0

Successful 0
treatment 0
with 0
nasal 0
continuous 0
positive 0
airway 0
pressure 0
( 0
8.3 0
+/ 0
- 0
1.5 0
cmH2O 0
) 0
for 0
3 0
days 0
caused 0
a 0
significant 0
decrease 0
in 0
mean 0
blood 0
pressure 0
in 0
OSAS 0
. 0

When 0
data 0
were 0
expressed 0
in 0
a 0
cumulative 0
manner 0
, 0
the 0
response 0
to 0
intravenous 0
adenosine 0
3 0
mg 0
, 0
6 0
mg 0
, 0
9 0
mg 0
and 0
12 0
mg 0
in 0
the 0
24 0
episodes 0
of 0
PSVT 0
were 0
5 0
episodes 0
( 0
21 0
% 0
) 0
, 0
16 0
episodes 0
( 0
67 0
% 0
) 0
, 0
20 0
episodes 0
( 0
83 0
% 0
) 0
and 0
20 0
episodes 0
( 0
83 0
% 0
) 0
respectively 0
. 0

RNAs 0
are 0
not 0
only 0
essential 0
components 0
of 0
both 0
ribosomal 0
subunits 0
but 0
also 0
transiently 0
interacting 0
factors 0
during 0
particle 0
formation 0
. 0

To 0
study 0
retinoid 0
signalling 0
in 0
zebrafish 0
embryos 0
, 0
we 0
developed 0
a 0
novel 0
method 0
to 0
detect 0
endogenous 0
retinoids 0
in 0
situ 0
in 0
embryos 0
, 0
using 0
a 0
fusion 0
protein 0
of 0
the 0
ligand 0
inducible 0
transactivation 0
domain 0
of 0
a 0
retinoic B-gene
acid I-gene
receptor I-gene
and 0
a 0
heterologous 0
DNA 0
binding 0
domain 0
. 0

To 0
identify 0
nuclear 0
regulatory 0
factors 0
, 0
we 0
have 0
located 0
and 0
functionally 0
characterized 0
the 0
CCR5 B-gene
gene I-gene
promoter I-gene
. 0

Fluorescence 0
in 0
situ 0
hybridization 0
of 0
metaphase 0
spreads 0
of 0
chromosome 0
8 0
, 0
containing 0
hybrid 0
cell 0
line 0
706 0
- 0
B6 0
clone 0
17 0
( 0
CL 0
- 0
17 0
) 0
with 0
cosmid 0
c101F1 0
, 0
placed 0
the 0
9804 B-gene
gene I-gene
close 0
to 0
the 0
telomere 0
at 0
8q24.3 0
. 0

The 0
interaction 0
between 0
piroxicam 0
and 0
poloxamer 0
was 0
studied 0
by 0
x 0
- 0
ray 0
diffractometry 0
( 0
XRD 0
) 0
, 0
infrared 0
( 0
IR 0
) 0
spectroscopy 0
and 0
differential 0
thermal 0
analysis 0
( 0
DTA 0
) 0
with 0
a 0
solid 0
dispersion 0
, 0
coprecipitate 0
, 0
or 0
physical 0
mixture 0
. 0

Cell 0
survival 0
by 0
Epo B-gene
did 0
not 0
require 0
activation 0
of 0
other 0
known 0
signaling 0
pathways 0
including 0
PI B-gene
- I-gene
3 I-gene
kinase I-gene
, 0
PLC B-gene
- I-gene
gamma I-gene
, 0
Ras B-gene
or 0
Stats B-gene
. 0

The 0
N 0
- 0
syndecan 0
- 0
dependent 0
neurite 0
outgrowth 0
is 0
inhibited 0
by 0
the 0
tyrosine B-gene
kinase I-gene
inhibitors 0
herbimycin 0
A 0
and 0
PP1 B-gene
. 0

An 0
in 0
vivo 0
ZAP B-gene
- I-gene
70 I-gene
substrate 0
, 0
SLP B-gene
- I-gene
76 I-gene
, 0
implicated 0
in 0
Erk B-gene
activation 0
, 0
also 0
became 0
rapidly 0
tyrosine 0
- 0
phosphorylated 0
in 0
Jurkat 0
cells 0
, 0
but 0
not 0
in 0
P116 0
cells 0
, 0
upon 0
treatment 0
with 0
H2O2 0
. 0

The 0
pharmacokinetic 0
patterns 0
of 0
estradiol 0
( 0
CAS 0
50 0
- 0
28 0
- 0
2 0
) 0
and 0
of 0
estrone 0
( 0
CAS 0
53 0
- 0
16 0
- 0
7 0
) 0
were 0
investigated 0
in 0
18 0
women 0
in 0
natural 0
or 0
surgical 0
menopause 0
during 0
the 0
application 0
of 0
a 0
new 0
estradiol 0
transdermal 0
patch 0
with 0
active 0
matrix 0
and 0
without 0
absorption 0
enhancers 0
designed 0
for 0
epicutaneous 0
applications 0
of 0
7 0
days 0
( 0
hereinafter 0
called 0
`` 0
patch 0
7D 0
'' 0
) 0
. 0

The 0
results 0
confirm 0
that 0
a 0
single 0
base 0
change 0
in 0
the 0
branchpoint 0
consensus 0
sequence 0
of 0
an 0
intron 0
can 0
cause 0
human 0
disease 0
although 0
this 0
sequence 0
is 0
poorly 0
conserved 0
in 0
mammals 0
. 0

Conversely 0
, 0
the 0
central 0
regions 0
are 0
highly 0
variable 0
. 0

Among 0
the 0
H/ACA B-gene
snoRNAs I-gene
associated 0
with 0
Gar1p B-gene
, 0
one 0
can 0
distinguish 0
a 0
large 0
group 0
of 0
snoRNAs 0
that 0
are 0
not 0
essential 0
in 0
yeast 0
and 0
serve 0
as 0
guides 0
for 0
pseudouridine 0
synthesis 0
onto 0
the 0
pre 0
- 0
rRNA 0
molecule 0
. 0

It 0
bound 0
to 0
vitamin B-gene
D I-gene
receptor I-gene
( 0
VDR B-gene
) 0
but 0
not 0
retinoic B-gene
acid I-gene
Xalpha I-gene
receptor I-gene
( 0
RXRalpha B-gene
) 0
in 0
the 0
human 0
T 0
cell 0
line 0
MT2 0
cells 0
. 0

Further 0
studies 0
demonstrated 0
that 0
the 0
PPARalpha B-gene
ligand 0
8 0
( 0
S 0
) 0
- 0
hydroxyeicosatetraenoic 0
acid 0
strongly 0
promotes 0
the 0
interaction 0
of 0
PPARalpha B-gene
with 0
the 0
co 0
- 0
activator 0
RIP B-gene
- I-gene
140 I-gene
but 0
decreases 0
the 0
interaction 0
of 0
PPARalpha B-gene
with 0
the 0
co 0
- 0
repressor 0
SMRT B-gene
. 0

Based 0
on 0
the 0
current 0
literature 0
, 0
the 0
mechanisms 0
involved 0
in 0
the 0
toxicity 0
of 0
OA B-gene
indicate 0
three 0
major 0
effects 0
: 0
( 0
1 0
) 0
inhibition 0
of 0
mitochondrial 0
respiration 0
correlated 0
with 0
a 0
depletion 0
of 0
ATP 0
; 0
( 0
2 0
) 0
inhibition 0
of 0
tRNA B-gene
- I-gene
synthetase I-gene
accompanied 0
by 0
a 0
reduced 0
protein 0
synthesis 0
; 0
and 0
( 0
3 0
) 0
enhanced 0
lipid 0
peroxidation 0
. 0

We 0
previously 0
demonstrated 0
that 0
acute 0
expression 0
of 0
the 0
bovine 0
papillomavirus 0
type 0
1 0
( 0
BPV1 0
) 0
E2 B-gene
protein I-gene
in 0
HeLa 0
and 0
HT 0
- 0
3 0
cervical 0
carcinoma 0
cell 0
lines 0
greatly 0
reduced 0
cellular 0
proliferation 0
by 0
imposing 0
a 0
specific 0
G1/S 0
phase 0
growth 0
arrest 0
. 0

Four 0
possible 0
isoforms 0
( 0
hGli2 B-gene
alpha I-gene
, I-gene
beta I-gene
, I-gene
gamma I-gene
, I-gene
and I-gene
delta I-gene
) 0
are 0
formed 0
by 0
combinations 0
of 0
two 0
independent 0
alternative 0
splicings 0
, 0
and 0
all 0
the 0
isoforms 0
could 0
bind 0
to 0
a 0
DNA 0
motif 0
, 0
TRE2S 0
, 0
in 0
the 0
LTR 0
. 0

Specialized 0
actin B-gene
tails 0
that 0
propel 0
IEV 0
particles 0
to 0
the 0
periphery 0
and 0
virus 0
- 0
tipped 0
microvilli 0
( 0
both 0
common 0
in 0
wild 0
- 0
type 0
- 0
infected 0
cells 0
) 0
were 0
absent 0
in 0
cells 0
infected 0
with 0
vA33delta 0
. 0

Their 0
mean 0
IOP 0
was 0
15.3 0
( 0
SD 0
3.7 0
) 0
mmHg 0
prior 0
to 0
induction 0
of 0
anesthesia 0
, 0
13.5 0
( 0
SD 0
3.5 0
) 0
mmHg 0
after 0
loss 0
of 0
eyelash 0
reflex 0
following 0
injection 0
of 0
methohexitone 0
, 0
16.1 0
( 0
SD 0
2.4 0
) 0
mmHg 0
after 0
cessation 0
of 0
muscle 0
fasciculations 0
induced 0
by 0
suxamethonium 0
, 0
19.2 0
( 0
SD 0
5.6 0
) 0
mmHg 0
after 0
cessation 0
of 0
convulsion 0
and 0
15.5 0
( 0
SD 0
4.4 0
) 0
mmHg 0
following 0
resumption 0
of 0
regular 0
spontaneous 0
respiration 0
. 0

A 0
cDNA 0
, 0
cak1At B-gene
, 0
was 0
isolated 0
that 0
suppressed 0
the 0
CAK B-gene
mutation I-gene
in 0
budding 0
yeast 0
, 0
and 0
it 0
also 0
complemented 0
a 0
fission B-gene
yeast I-gene
CAK I-gene
mutant I-gene
. 0
cak1At B-gene
encodes 0
a 0
protein 0
related 0
to 0
animal B-gene
CAKs I-gene
. 0

Post 0
- 0
translational 0
modifications 0
such 0
as 0
glycosylation 0
and 0
phosphorylation 0
could 0
be 0
excluded 0
as 0
potential 0
explanations 0
for 0
the 0
protein 0
heterogeneity 0
. 0

In 0
addition 0
to 0
restoring 0
checkpoint 0
control 0
, 0
overexpression 0
of 0
sum1+ B-gene
inhibits 0
the 0
normal 0
cell 0
cycle 0
response 0
to 0
osmotic 0
stress 0
. 0

Ime1 B-gene
plays 0
a 0
pivotal 0
role 0
in 0
the 0
initiation 0
of 0
meiosis 0
in 0
a/alpha 0
diploid 0
cells 0
of 0
Saccharomyces 0
cerevisiae 0
. 0

Rhesus 0
macaques 0
and 0
BALB/c 0
mice 0
inoculated 0
with 0
the 0
Mengo 0
virus 0
SIV 0
recombinants 0
failed 0
to 0
develop 0
CTL 0
responses 0
against 0
the 0
SIV 0
gene 0
products 0
, 0
while 0
one 0
of 0
the 0
HIV B-gene
- I-gene
Nef I-gene
recombinants I-gene
induced 0
a 0
weak 0
CTL 0
response 0
in 0
mice 0
directed 0
to 0
an 0
HIV1 B-gene
Nef I-gene
peptide I-gene
spanning 0
positions 0
182 0
- 0
198 0
. 0

Deltamethrin 0
was 0
most 0
effective 0
on 0
the 0
thatched 0
surface 0
and 0
produced 0
100 0
% 0
mortality 0
of 0
An 0
. 0
culicifacies 0
adults 0
up 0
to 0
12 0
weeks 0
, 0
even 0
when 0
exposed 0
at 0
the 0
lowest 0
dose 0
/12.5 0
mg/m2 0
. 0

Trichloroethylene 0
, 0
in 0
turn 0
, 0
increased 0
the 0
AUC 0
5.0 0
( 0
1.9 0
- 0
13.4 0
) 0
, 0
25.8 0
( 0
8.2 0
- 0
80.8 0
) 0
and 0
2.9 0
( 0
1.6 0
- 0
5.4 0
) 0
, 0
respectively 0
, 0
whereas 0
the 0
corresponding 0
values 0
for 0
n 0
- 0
hexane 0
were 0
1.9 0
( 0
0.7 0
- 0
5.1 0
) 0
, 0
1.5 0
( 0
0.5 0
- 0
4.6 0
) 0
, 0
and 0
3.2 0
( 0
1.8 0
- 0
5.9 0
) 0
. 0

Solution 0
structure 0
of 0
the 0
IRF B-gene
- I-gene
2 I-gene
DNA I-gene
- I-gene
binding I-gene
domain I-gene
: 0
a 0
novel 0
subgroup 0
of 0
the 0
winged B-gene
helix I-gene
- I-gene
turn I-gene
- I-gene
helix I-gene
family I-gene
. 0

In 0
contrast 0
, 0
receptor/G B-gene
protein I-gene
coupling 0
appeared 0
unaffected 0
by 0
expression 0
of 0
loop 0
3i 0
domains 0
derived 0
from 0
two 0
receptors 0
coupled 0
to 0
G B-gene
( I-gene
i/o I-gene
) I-gene
proteins I-gene
( 0
M2Ach B-gene
- I-gene
muscarinic I-gene
and I-gene
alpha2A I-gene
- I-gene
adrenergic I-gene
receptors I-gene
) 0
. 0

These 0
data 0
indicate 0
that 0
the 0
third 0
intracellular 0
loop 0
of 0
the 0
rat B-gene
GnRH I-gene
- I-gene
R I-gene
is 0
involved 0
in 0
receptor B-gene
G I-gene
( I-gene
q/11 I-gene
) I-gene
protein I-gene
coupling 0
and/or 0
selectivity 0
, 0
and 0
in 0
the 0
GGH 0
( 0
3 0
) 0
1 0
' 0
cell 0
line 0
, 0
this 0
loop 0
is 0
also 0
involved 0
in 0
signal 0
transduction 0
mediated 0
through 0
the 0
Gs B-gene
protein 0
pathway 0
. 0

Decreased 0
levels 0
of 0
alpha2 B-gene
- I-gene
antiplasmin I-gene
were 0
also 0
observed 0
in 0
the 0
mediastinum 0
( 0
0.50 0
versus 0
0.61 0
U/mL 0
; 0
p 0
< 0
0.05 0
) 0
. 0

A 0
catalytic 0
domain 0
of 0
eukaryotic B-gene
DNA I-gene
topoisomerase I-gene
I I-gene
. 0

A 0
cluster 0
of 0
basic 0
amino 0
acids 0
, 0
KKKR 0
, 0
generated 0
by 0
joining 0
of 0
the 0
sequences 0
encoded 0
by 0
the 0
constitutive 0
exon 0
13 0
and 0
the 0
alternative 0
exon 0
16 0
, 0
is 0
necessary 0
for 0
the 0
nuclear 0
targeting 0
of 0
4.1H B-gene
, 0
as 0
demonstrated 0
by 0
site 0
- 0
directed 0
mutagenesis 0
analysis 0
. 0

Another 0
stem 0
- 0
loop 0
called 0
structure 0
III 0
near 0
the 0
3' 0
- 0
end 0
of 0
repY B-gene
sequesters 0
both 0
the 0
5' 0
- 0
rCGCC 0
- 0
3 0
' 0
sequence 0
and 0
the 0
repZ B-gene
ribosome I-gene
- I-gene
binding I-gene
site I-gene
. 0

All 0
three 0
genes 0
have 0
been 0
mapped 0
precisely 0
to 0
a 0
small 0
region 0
on 0
human 0
chromosome 0
16p12.1 0
- 0
p11.2 0
( 0
homologous 0
to 0
mouse 0
chromosome 0
7 0
) 0
, 0
using 0
somatic 0
cell 0
hybrids 0
and 0
cosmid 0
clones 0
. 0

In 0
fus3 B-gene
mutants I-gene
, 0
the 0
levels 0
of 0
Ty1 B-gene
RNA I-gene
, 0
protein 0
synthesis 0
, 0
and 0
proteolytic 0
processing 0
were 0
not 0
altered 0
relative 0
to 0
those 0
in 0
FUS3 B-gene
strains 0
but 0
steady 0
- 0
state 0
levels 0
of 0
TyA B-gene
, 0
integrase B-gene
, 0
and 0
reverse B-gene
transcriptase I-gene
proteins 0
and 0
Ty1 B-gene
cDNA I-gene
were 0
all 0
increased 0
. 0

Posttranslational 0
regulation 0
of 0
Ty1 B-gene
retrotransposition 0
by 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
Fus3 I-gene
. 0

The 0
general 0
transcription B-gene
factor I-gene
IIA I-gene
( 0
TFIIA B-gene
) 0
interacts 0
with 0
the 0
TATA B-gene
binding I-gene
protein I-gene
( 0
TBP B-gene
) 0
and 0
promoter 0
DNA 0
to 0
mediate 0
transcription 0
activation 0
in 0
vitro 0
. 0

Their 0
function 0
is 0
not 0
only 0
to 0
recruit 0
Pho2 B-gene
to 0
the 0
promoter 0
but 0
to 0
allow 0
cooperative 0
binding 0
of 0
Pho4 B-gene
together 0
with 0
Pho2 B-gene
. 0

Substitution 0
of 0
the 0
Ser 0
- 0
Thr 0
sites 0
with 0
the 0
phosphomimetic 0
Asp 0
generated 0
a 0
constitutively 0
active 0
form 0
of 0
IRF B-gene
- I-gene
3 I-gene
that 0
functioned 0
as 0
a 0
very 0
strong 0
activator 0
of 0
promoters 0
containing 0
PRDI B-gene
- 0
PRDIII B-gene
or 0
ISRE B-gene
regulatory I-gene
elements I-gene
. 0

New 0
- 0
onset 0
angina 0
preceding 0
acute 0
myocardial 0
infarction 0
is 0
associated 0
with 0
improved 0
contractile 0
recovery 0
after 0
thrombolysis 0
. 0

In 0
this 0
study 0
, 0
the 0
effect 0
of 0
acute 0
administration 0
of 0
various 0
doses 0
of 0
malathion 0
via 0
oral 0
and 0
dermal 0
routes 0
to 0
mice 0
and 0
rats 0
on 0
serum 0
levels 0
of 0
histamine 0
was 0
evaluated 0
. 0

Fetal 0
growth 0
retardation 0
as 0
a 0
cause 0
of 0
impaired 0
ovarian 0
development 0
. 0

Similarly 0
, 0
PCDFs/PCDDs 0
ratio 0
in 0
ESP 0
ash 0
was 0
lower 0
than 0
that 0
in 0
boiler 0
ash 0
. 0

In 0
addition 0
to 0
DNA 0
- 0
protein 0
interactions 0
, 0
protein 0
- 0
protein 0
interactions 0
with 0
partner 0
proteins 0
often 0
play 0
major 0
roles 0
in 0
targeting 0
ETS B-gene
- I-gene
domain I-gene
proteins I-gene
to 0
specific 0
promoters 0
. 0

Localization 0
of 0
67 0
exons 0
on 0
a 0
YAC 0
contig 0
spanning 0
1.5 0
Mb 0
around 0
the 0
multidrug B-gene
resistance I-gene
gene I-gene
region I-gene
of 0
human 0
chromosome 0
7q21.1 0
. 0

The 0
complete 0
exon 0
- 0
intron 0
organization 0
of 0
the 0
murine 0
gene 0
encoding 0
M B-gene
- I-gene
protein I-gene
, 0
a 0
structural 0
protein 0
of 0
sarcomeric 0
myofibrils 0
, 0
was 0
determined 0
. 0

PURPOSE 0
: 0
To 0
introduce 0
an 0
image 0
analysis 0
of 0
the 0
cornea 0
in 0
photorefractive 0
keratectomy 0
( 0
PRK 0
) 0
for 0
preoperative 0
and 0
early 0
postoperative 0
determination 0
of 0
changes 0
in 0
the 0
condition 0
of 0
the 0
cornea 0
. 0

Mean+/ 0
- 0
SD 0
serum B-gene
VEGF I-gene
concentrations 0
were 0
significantly 0
higher 0
( 0
P 0
< 0
0.001 0
) 0
in 0
women 0
with 0
PCO 0
and 0
PCOS 0
( 0
3.4+/ 0
- 0
0.7 0
and 0
3.2+/ 0
- 0
0.66 0
ng/ml 0
respectively 0
) 0
compared 0
with 0
women 0
with 0
normal 0
ovaries 0
( 0
2.3+/ 0
- 0
0.5 0
ng/ml 0
) 0
. 0

Strikingly 0
, 0
these 0
cells 0
contain 0
a 0
missense 0
mutation 0
of 0
the 0
p53 B-gene
gene I-gene
at 0
codon 0
242 0
( 0
p53 B-gene
( 0
242 0
) 0
) 0
, 0
which 0
substitutes 0
alanine 0
for 0
glycine 0
. 0

The 0
new 0
algorithm 0
, 0
called 0
RBI 0
- 0
MAP 0
, 0
is 0
based 0
on 0
the 0
rescaled 0
block 0
iterative 0
EM 0
( 0
RBI 0
- 0
EM 0
) 0
algorithm 0
. 0

A 0
third 0
ORF 0
, 0
ORF5 0
, 0
shows 0
homology 0
with 0
gene B-gene
agrB I-gene
from 0
Staphylococcus 0
aureus 0
, 0
which 0
is 0
involved 0
in 0
the 0
mechanism 0
of 0
regulation 0
of 0
the 0
virulence 0
phenotype 0
in 0
this 0
species 0
. 0

An 0
association 0
between 0
hSIE B-gene
and 0
Stat B-gene
- I-gene
3 I-gene
after 0
MHC B-gene
- I-gene
I I-gene
ligation 0
was 0
directly 0
demonstrated 0
by 0
precipitating 0
Stat B-gene
- I-gene
3 I-gene
from 0
nuclear 0
extracts 0
with 0
biotinylated 0
hSIE B-gene
probe 0
and 0
avidin B-gene
- 0
coupled 0
agarose 0
. 0

Transcriptional 0
repression 0
mediated 0
by 0
LysR B-gene
- I-gene
type I-gene
regulator I-gene
CatR I-gene
bound 0
at 0
multiple 0
binding 0
sites 0
. 0

Two 0
of 0
these 0
resulted 0
in 0
increased 0
levels 0
of 0
the 0
alpha 0
subunit 0
, 0
and 0
one 0
caused 0
a 0
substitution 0
of 0
glycine 0
for 0
the 0
aspartic 0
acid 0
residue 0
at 0
position 0
171 0
, 0
in 0
the 0
N 0
- 0
terminal 0
domain 0
. 0

These 0
two 0
mRNA 0
species 0
are 0
produced 0
by 0
differential 0
polyadenylation 0
site 0
usage 0
. 0

Using 0
Southern 0
blot 0
analysis 0
and 0
restriction 0
mapping 0
of 0
genomic 0
YAC 0
( 0
yeast 0
artificial 0
chromosome 0
) 0
and 0
cosmid 0
clones 0
, 0
we 0
located 0
the 0
human B-gene
RIL I-gene
gene I-gene
240 0
- 0
260 0
kb 0
telomeric 0
to 0
the 0
IRF1 B-gene
gene I-gene
and 0
characterized 0
its 0
genomic 0
structure 0
. 0

U73 B-gene
contains 0
C 0
, 0
D 0
and 0
D 0
' 0
boxes 0
and 0
a 0
12 0
- 0
nucleotide 0
antisense 0
complementarity 0
to 0
the 0
28S B-gene
ribosomal I-gene
RNA I-gene
. 0

However 0
, 0
mandibular 0
position 0
( 0
S 0
- 0
N 0
- 0
B 0
and 0
S 0
- 0
N 0
- 0
Pog 0
) 0
was 0
found 0
to 0
be 0
significantly 0
more 0
retrusive 0
in 0
Class 0
II 0
when 0
compared 0
with 0
Class 0
I 0
subjects 0
. 0

Echinostomiasis 0
is 0
aggravated 0
by 0
socioeconomic 0
factors 0
such 0
as 0
poverty 0
, 0
malnutrition 0
, 0
an 0
explosively 0
growing 0
free 0
- 0
food 0
market 0
, 0
a 0
lack 0
of 0
supervised 0
food 0
inspection 0
, 0
poor 0
or 0
insufficient 0
sanitation 0
, 0
other 0
helminthiases 0
, 0
and 0
declining 0
economic 0
conditions 0
. 0

The 0
localization 0
of 0
ZAP B-gene
- I-gene
70 I-gene
to 0
the 0
cell 0
cortex 0
is 0
, 0
therefore 0
, 0
regulated 0
by 0
the 0
activity 0
of 0
SRC B-gene
- I-gene
family I-gene
kinases I-gene
, 0
independently 0
of 0
their 0
ability 0
to 0
phosphorylate 0
immunoreceptor 0
tyrosine 0
- 0
based 0
activation 0
motifs 0
of 0
the 0
TCR B-gene
. 0

Finally 0
, 0
a 0
role 0
for 0
NF B-gene
- I-gene
kappaB I-gene
in 0
preventing 0
apoptosis 0
induced 0
by 0
ER 0
calcium 0
release 0
was 0
demonstrated 0
by 0
data 0
showing 0
that 0
sAPPalpha B-gene
prevents 0
thapsigargin 0
- 0
induced 0
apoptosis 0
, 0
an 0
effect 0
blocked 0
by 0
kappaB B-gene
decoy 0
DNA 0
. 0

Many 0
cytokine 0
receptors 0
employ 0
Janus B-gene
protein I-gene
tyrosine I-gene
kinases I-gene
( 0
Jaks B-gene
) 0
and 0
signal B-gene
transducers I-gene
and I-gene
activators I-gene
of I-gene
transcription I-gene
( 0
Stats B-gene
) 0
for 0
nuclear 0
signaling 0
. 0

A 0
site 0
- 0
directed 0
R618K 0
mutation 0
in 0
the 0
Stat5 B-gene
SH2 B-gene
domain I-gene
abolished 0
the 0
phosphorylation 0
by 0
Jak2 B-gene
, 0
while 0
deletion 0
of 0
the 0
C 0
terminus 0
led 0
to 0
Stat5 B-gene
hyperphosphorylation 0
. 0

The 0
effect 0
of 0
nitric B-gene
oxide I-gene
synthase I-gene
inhibitor 0
on 0
reperfusion 0
injury 0
of 0
the 0
brain 0
under 0
hypothermic 0
circulatory 0
arrest 0
. 0

Specifically 0
, 0
recombination 0
at 0
HMR B-gene
was 0
used 0
to 0
produce 0
rings 0
that 0
lacked 0
the 0
E 0
and 0
I 0
silencers 0
. 0

In 0
angiodysplasia 0
, 0
ectatic 0
vessels 0
in 0
the 0
mucosa 0
appeared 0
to 0
contain 0
less 0
collagen B-gene
type I-gene
IV I-gene
than 0
similarly 0
sized 0
vessels 0
in 0
the 0
submucosa 0
, 0
and 0
perforating 0
vessels 0
appeared 0
in 0
many 0
cases 0
to 0
lose 0
staining 0
at 0
the 0
level 0
of 0
the 0
muscularis 0
mucosae 0
. 0

We 0
studied 0
the 0
human 0
vestibulo 0
- 0
ocular 0
reflex 0
( 0
VOR 0
) 0
in 0
response 0
to 0
head 0
'impulses 0
' 0
: 0
brief 0
, 0
unpredictable 0
, 0
passive 0
, 0
high 0
- 0
acceleration 0
( 0
up 0
to 0
4000 0
degrees/s2 0
) 0
, 0
low 0
- 0
amplitude 0
( 0
20 0
- 0
30 0
degrees 0
) 0
head 0
rotations 0
. 0

To 0
clarify 0
whether 0
seizure 0
- 0
offset 0
patterns 0
are 0
reliable 0
in 0
predicting 0
seizure 0
outcome 0
, 0
we 0
studied 0
SEEG/ECoG 0
in 0
a 0
similar 0
group 0
of 0
patients 0
with 0
temporal 0
lobe 0
epilepsy 0
( 0
TLE 0
) 0
. 0

In 0
this 0
study 0
, 0
to 0
characterize 0
the 0
gene 0
for 0
protein B-gene
Z I-gene
, 0
its 0
organization 0
and 0
structure 0
were 0
determined 0
by 0
a 0
combination 0
of 0
PCR 0
amplification 0
of 0
leukocyte 0
DNA 0
and 0
isolation 0
of 0
phage 0
clones 0
from 0
a 0
human 0
genomic 0
library 0
. 0

These 0
modifications 0
may 0
improve 0
the 0
interlaboratory 0
reproducibility 0
of 0
CD34 B-gene
determinations 0
due 0
to 0
the 0
reduction 0
in 0
sample 0
handling 0
and 0
calculation 0
of 0
results 0
. 0

The 0
present 0
results 0
demonstrate 0
that 0
rats 0
with 0
relatively 0
small 0
remnants 0
of 0
one 0
olfactory 0
bulb 0
can 0
perform 0
a 0
variety 0
of 0
odor 0
detection 0
and 0
discrimination 0
tasks 0
as 0
well 0
or 0
nearly 0
as 0
well 0
as 0
controls 0
. 0

UDP B-gene
- I-gene
GlcNAc I-gene
: 0
alpha B-gene
- I-gene
6 I-gene
- I-gene
D I-gene
- I-gene
mannoside I-gene
beta I-gene
- I-gene
1,2 I-gene
- I-gene
N I-gene
- I-gene
acetylglucosaminyltransferase I-gene
II I-gene
( 0
GnT B-gene
II I-gene
; 0
EC B-gene
2.4.1.143 I-gene
) 0
is 0
essential 0
for 0
the 0
normal 0
assembly 0
of 0
complex 0
Asn 0
- 0
linked 0
glycans 0
. 0

These 0
patients 0
failed 0
to 0
respond 0
to 0
intravenous 0
cyclophosphamide 0
and 0
steroids 0
and 0
were 0
then 0
changed 0
to 0
receive 0
oral 0
cyclosporine 0
A 0
, 0
at 0
a 0
dose 0
of 0
5 0
mg/kg/day 0
. 0

The 0
predicted 0
amino 0
acid 0
sequence 0
is 0
78.0 0
% 0
identical 0
to 0
the 0
cytoplasmic B-gene
dynein I-gene
heavy I-gene
chain I-gene
of I-gene
Neurospora I-gene
crassa I-gene
, 0
70.2 0
% 0
identical 0
to 0
that 0
of 0
Aspergillus 0
nidulans 0
and 0
24.8 0
% 0
identical 0
to 0
that 0
of 0
Saccharomyces 0
cerevisiae 0
. 0

The 0
DNA 0
binding 0
activities 0
of 0
the 0
three 0
repressor 0
preparations 0
were 0
studied 0
using 0
fragments 0
containing 0
CIRs 0
( 0
CIR3 0
- 0
CIR6 0
) 0
from 0
the 0
essential 0
early 0
region 0
as 0
templates 0
for 0
DNase B-gene
I I-gene
footprinting 0
. 0

Molecular 0
modelling 0
suggested 0
that 0
the 0
tetramerization 0
domain 0
was 0
a 0
four 0
- 0
helix 0
bundle 0
, 0
stabilized 0
by 0
interactions 0
of 0
seven 0
conserved 0
aromatic 0
amino 0
acids 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
sought 0
to 0
investigate 0
whether 0
constitutive 0
NF B-gene
- I-gene
kappaB I-gene
activity 0
in 0
chronically 0
HIV 0
- 0
1 0
- 0
infected 0
promonocytic 0
U937 0
( 0
U9 0
- 0
IIIB 0
) 0
and 0
myeloblastic 0
PLB 0
- 0
985 0
( 0
PLB 0
- 0
IIIB 0
) 0
cells 0
affects 0
apoptotic 0
signaling 0
. 0

Taken 0
together 0
, 0
these 0
results 0
suggest 0
that 0
silymarin 0
may 0
exert 0
a 0
strong 0
anticarcinogenic 0
effect 0
against 0
PCA 0
and 0
that 0
this 0
effect 0
is 0
likely 0
to 0
involve 0
impairment 0
of 0
erbB1 B-gene
- 0
SHC B-gene
- 0
mediated 0
signaling 0
pathway 0
, 0
induction 0
of 0
CDKIs B-gene
, 0
and 0
a 0
resultant 0
G1 0
arrest 0
. 0

In 0
connective 0
tissue 0
, 0
cell 0
structure 0
contributes 0
to 0
type B-gene
I I-gene
collagen I-gene
expression 0
. 0

To 0
explore 0
the 0
function 0
of 0
human 0
SINA B-gene
- I-gene
homologous I-gene
( I-gene
Siah I-gene
) I-gene
proteins I-gene
, 0
expression 0
plasmids 0
encoding 0
Siah B-gene
- I-gene
1A I-gene
were 0
transiently 0
transfected 0
into 0
293 0
epithelial 0
cells 0
and 0
GM701 0
fibroblast 0
cells 0
, 0
resulting 0
in 0
growth 0
arrest 0
without 0
induction 0
of 0
apoptosis 0
. 0

A 0
point 0
mutation 0
in 0
Galphao B-gene
and 0
Galphai1 B-gene
blocks 0
interaction 0
with 0
regulator 0
of 0
G B-gene
protein I-gene
signaling 0
proteins 0
. 0

Indeed 0
, 0
it 0
is 0
shown 0
that 0
it 0
mediates 0
the 0
formation 0
of 0
disulfide 0
- 0
linked 0
homodimers 0
and 0
that 0
the 0
formation 0
of 0
homo 0
- 0
and 0
heterodimers 0
are 0
mutually 0
excluded 0
. 0

N. 0
, 0
and 0
Fanning 0
, 0
E 0
. 0

We 0
have 0
shown 0
previously 0
that 0
GH3 0
cells 0
transfected 0
with 0
the 0
rat B-gene
GnRH I-gene
receptor I-gene
cDNA I-gene
( 0
GGH3 0
- 0
1 0
' 0
cells 0
) 0
support 0
the 0
expression 0
of 0
a 0
cotransfected 0
fusion 0
gene 0
composed 0
of 0
797 0
base 0
pairs 0
of 0
rat B-gene
LHbeta I-gene
gene I-gene
5' I-gene
- I-gene
flanking I-gene
sequence I-gene
and 0
the 0
first 0
5 0
base 0
pairs 0
of 0
the 0
5' 0
- 0
untranslated 0
region 0
fused 0
to 0
a 0
luciferase B-gene
reporter I-gene
( I-gene
- I-gene
797/+5LHbetaLUC I-gene
) I-gene
and 0
respond 0
to 0
a 0
GnRH B-gene
agonist 0
with 0
a 0
10 0
- 0
fold 0
stimulation 0
of 0
activity 0
. 0

The 0
5' 0
- 0
flanking 0
region 0
, 0
from 0
nucleotide 0
- 0
837 0
to 0
- 0
336 0
, 0
contains 0
TATA 0
and 0
inverted 0
CAAT 0
boxes 0
as 0
well 0
as 0
GATA B-gene
- I-gene
1/SP1 I-gene
erythroid 0
- 0
specific 0
cis 0
- 0
acting 0
regulatory 0
elements 0
. 0

We 0
established 0
the 0
radiosensitive 0
cell 0
line 0
SX9 0
from 0
mammary 0
carcinoma 0
cell 0
line 0
FM3A 0
. 0

In 0
patients 0
with 0
type 0
IA 0
maple 0
syrup 0
urine 0
disease 0
, 0
the 0
E1alpha B-gene
subunit I-gene
is 0
affected 0
, 0
resulting 0
in 0
the 0
loss 0
of 0
E1 B-gene
and 0
branched B-gene
- I-gene
chain I-gene
ketoacid I-gene
dehydrogenase I-gene
catalytic 0
activities 0
. 0

Results 0
showed 0
that 0
the 0
mean 0
bond 0
strength 0
of 0
H.T.V 0
. 0
specimens 0
ranged 0
from 0
9.6 0
to 0
13.12 0
kg/cm2 0
, 0
while 0
the 0
mean 0
bond 0
strength 0
of 0
R.T.V 0
. 0
specimens 0
ranged 0
from 0
0.36 0
to 0
1.75 0
kg/cm2 0
. 0

OBJECTIVES 0
: 0
To 0
measure 0
coagulation B-gene
factor I-gene
VIII I-gene
: I-gene
coagulant I-gene
( 0
F.VIII B-gene
: I-gene
C I-gene
) 0
and 0
C1 B-gene
- I-gene
esterase I-gene
inhibitor I-gene
( 0
C1 B-gene
- I-gene
INH I-gene
) 0
, 0
hemostasis 0
- 0
associated 0
acute 0
- 0
phase 0
reactant 0
proteins 0
and 0
coagulation B-gene
factors I-gene
VII I-gene
( 0
F.VII B-gene
) 0
, 0
IX 0
( 0
F.IX B-gene
) 0
, 0
and 0
X 0
( 0
F.X B-gene
) 0
, 0
hemostasis 0
proteins 0
not 0
associated 0
with 0
an 0
acute 0
- 0
phase 0
response 0
, 0
in 0
a 0
select 0
population 0
of 0
horses 0
with 0
colic 0
and 0
hemostasis 0
abnormalities 0
, 0
and 0
presumed 0
to 0
have 0
acute 0
- 0
phase 0
changes 0
. 0

RESULTS 0
: 0
Horses 0
with 0
colic 0
had 0
significantly 0
higher 0
fibrinogen B-gene
concentration 0
, 0
greater 0
alpha B-gene
2AP I-gene
and 0
protein B-gene
C I-gene
activities 0
, 0
and 0
longer 0
PT 0
and 0
APTT 0
than 0
did 0
healthy 0
horses 0
. 0

The 0
data 0
suggest 0
that 0
plasminogen B-gene
, 0
alpha B-gene
2AP I-gene
, 0
and 0
C1 B-gene
- I-gene
INH I-gene
, 0
should 0
be 0
considered 0
equine 0
acute 0
- 0
phase 0
proteins 0
. 0

None 0
of 0
the 0
patients 0
was 0
obese 0
. 0

Marked 0
elevation 0
of 0
creatine B-gene
kinase I-gene
was 0
observed 0
while 0
serum 0
albumin B-gene
, 0
immunoglobulin B-gene
, 0
and 0
complement 0
were 0
decreased 0
. 0

DESIGN 0
AND 0
METHODS 0
: 0
Case 0
study 0
. 0

METHODS 0
: 0
A 0
total 0
of 0
15 0
pigs 0
were 0
randomised 0
to 0
ligation 0
of 0
left 0
marginal 0
arteries 0
( 0
infarction 0
group 0
, 0
n 0
= 0
5 0
) 0
, 0
to 0
TMLR 0
of 0
the 0
left 0
lateral 0
wall 0
using 0
a 0
holmium 0
: 0
yttrium 0
- 0
aluminium 0
garnet 0
( 0
Ho 0
: 0
YAG 0
) 0
laser 0
( 0
laser 0
group 0
, 0
n 0
= 0
5 0
) 0
, 0
and 0
to 0
both 0
( 0
laser 0
- 0
infarction 0
group 0
, 0
n 0
= 0
5 0
) 0
. 0

RACK1 B-gene
, 0
a 0
receptor 0
for 0
activated B-gene
C I-gene
kinase I-gene
and 0
a 0
homolog 0
of 0
the 0
beta 0
subunit 0
of 0
G B-gene
proteins I-gene
, 0
inhibits 0
activity 0
of 0
src B-gene
tyrosine I-gene
kinases I-gene
and 0
growth 0
of 0
NIH 0
3T3 0
cells 0
. 0

Peptide 0
sequences 0
of 0
the 0
zinc B-gene
finger I-gene
protein I-gene
Ttk I-gene
and 0
the 0
transcription B-gene
factor I-gene
Adf I-gene
- I-gene
1 I-gene
were 0
obtained 0
. 0

The 0
same 0
IL B-gene
- I-gene
4 I-gene
- 0
inducible 0
reporter 0
gene 0
is 0
also 0
synergistically 0
activated 0
by 0
the 0
endogenous B-gene
Stat6 I-gene
and 0
NF B-gene
- I-gene
kappaB I-gene
proteins I-gene
in 0
IL B-gene
- I-gene
4 I-gene
- 0
stimulated 0
I.29mu 0
B 0
lymphoma 0
cells 0
. 0

HEF1 B-gene
, 0
p130 B-gene
( 0
Cas B-gene
) 0
, 0
and 0
Efs/Sin B-gene
constitute 0
a 0
family 0
of 0
multidomain 0
docking 0
proteins 0
that 0
have 0
been 0
implicated 0
in 0
coordinating 0
the 0
regulation 0
of 0
cell 0
adhesion 0
. 0

In 0
support 0
of 0
a 0
role 0
at 0
the 0
spindle 0
, 0
two 0
- 0
hybrid 0
library 0
screening 0
with 0
HEF1 B-gene
identifies 0
the 0
human 0
homolog 0
of 0
the 0
G2/M B-gene
spindle I-gene
- I-gene
regulatory I-gene
protein I-gene
Dim1p I-gene
as 0
a 0
specific 0
interactor 0
with 0
a 0
region 0
of 0
HEF1 B-gene
encompassed 0
in 0
p55 B-gene
( 0
HEF1 B-gene
) 0
. 0

Our 0
data 0
showed 0
that 0
activation 0
of 0
the 0
raf B-gene
- 0
ERK B-gene
pathway 0
led 0
to 0
activation 0
of 0
TF B-gene
expression 0
in 0
breast 0
carcinoma 0
cells 0
and 0
suggested 0
that 0
constitutive 0
activation 0
of 0
this 0
pathway 0
leads 0
to 0
high 0
TF B-gene
expression 0
in 0
MDA 0
- 0
MB 0
- 0
231 0
cells 0
. 0

However 0
, 0
a 0
zinc 0
- 0
depleted 0
enzyme 0
was 0
obtained 0
after 0
prolonged 0
dialysis 0
against 0
the 0
specific 0
chelating 0
agent 0
1,10 0
- 0
phenanthroline 0
. 0

All 0
patients 0
diagnosed 0
of 0
H. 0
influenza 0
type 0
b 0
meningitis 0
were 0
less 0
than 0
3 0
years 0
old 0
. 0

The 0
lines 0
also 0
differed 0
in 0
postsynaptic 0
, 0
but 0
not 0
presynaptic 0
, 0
5 B-gene
- I-gene
HT1A I-gene
receptors I-gene
. 0

Convulsive 0
seizure 0
during 0
a 0
treatment 0
with 0
interferon B-gene
alpha I-gene
for 0
chronic 0
viral 0
hepatitis 0
C 0

Immunohistochemically 0
, 0
anticytokeratin B-gene
19 I-gene
antibody I-gene
revealed 0
strong 0
staining 0
in 0
both 0
epithelial 0
and 0
sarcomatous 0
MPM 0
tissues 0
. 0

Genetic 0
studies 0
in 0
Drosophila 0
have 0
led 0
to 0
the 0
identification 0
of 0
several 0
components 0
of 0
the 0
Notch B-gene
pathway 0
. 0

The 0
bZP2 B-gene
cDNA I-gene
( I-gene
115 I-gene
- I-gene
1914 I-gene
nt I-gene
, I-gene
1.8 I-gene
kb I-gene
) I-gene
, 0
excluding 0
sequences 0
coding 0
for 0
N 0
- 0
terminal 0
signal 0
sequence 0
and 0
C 0
- 0
terminal 0
transmembranelike 0
domain 0
, 0
was 0
PCR 0
amplified 0
and 0
Sac1 B-gene
- 0
Sal1 B-gene
restricted 0
fragment 0
cloned 0
in 0
frame 0
downstream 0
of 0
the 0
T5 0
promoter 0
under 0
the 0
lac B-gene
operator I-gene
control 0
in 0
a 0
pQE 0
- 0
30 0
vector 0
. 0

Control 0
subjects 0
' 0
evoked 0
potentials 0
( 0
EPs 0
) 0
were 0
characterized 0
by 0
an 0
initial 0
positivity 0
in 0
the 0
90 0
- 0
140 0
ms 0
range 0
( 0
P1 0
) 0
at 0
the 0
temporo 0
- 0
occipital 0
site 0
. 0

Class B-gene
I I-gene
alpha1,2 I-gene
- I-gene
mannosidases I-gene
play 0
an 0
essential 0
role 0
in 0
the 0
elaboration 0
of 0
complex 0
and 0
hybrid 0
N 0
- 0
glycans 0
in 0
mammalian 0
cells 0
. 0

Structural 0
features 0
of 0
the 0
minimal 0
DNA 0
binding 0
domain 0
( 0
M98 0
- 0
F219 0
) 0
of 0
human B-gene
nucleotide I-gene
excision I-gene
repair I-gene
protein I-gene
XPA I-gene
. 0

Amongst 0
other 0
qualities 0
, 0
the 0
book 0
's 0
importance 0
lies 0
in 0
the 0
fact 0
that 0
it 0
associates 0
an 0
elaborate 0
theoretical 0
construction 0
with 0
the 0
empirical 0
data 0
, 0
working 0
within 0
the 0
possibilities 0
provided 0
by 0
late 0
19th 0
- 0
century 0
moral 0
statistics 0
. 0

The 0
results 0
point 0
to 0
the 0
effectiveness 0
of 0
the 0
educational 0
intervention 0
. 0

The 0
mechanistic 0
implications 0
of 0
aromatic 0
non 0
- 0
responsiveness 0
of 0
autonomously 0
expressed 0
A 0
- 0
domain 0
, 0
despite 0
its 0
demonstrated 0
ability 0
to 0
bind 0
phenol 0
, 0
are 0
discussed 0
. 0

RESULTS 0
: 0
Acetabular 0
index 0
returned 0
to 0
normal 0
gradually 0
as 0
the 0
time 0
went 0
by 0
and 0
significantly 0
within 0
one 0
year 0
after 0
the 0
reduction 0
of 0
developmental 0
dislocation 0
of 0
the 0
hip 0
. 0

Recently 0
, 0
extremely 0
high 0
levels 0
of 0
endothelin B-gene
- I-gene
1 I-gene
( 0
ET B-gene
- I-gene
1 I-gene
) 0
were 0
detected 0
in 0
the 0
pericardial 0
fluid 0
of 0
patients 0
undergoing 0
cardiac 0
surgery 0
. 0

Consequently 0
, 0
it 0
is 0
not 0
known 0
how 0
knee 0
loading 0
changes 0
following 0
ACL 0
transection 0
, 0
and 0
how 0
it 0
contributes 0
to 0
cartilage 0
degeneration 0
. 0

We 0
show 0
that 0
the 0
surfaces 0
of 0
tracheal 0
cartilage 0
matrix 0
are 0
collagen B-gene
- 0
rich 0
and 0
surround 0
a 0
proteoglycan 0
- 0
rich 0
core 0
. 0

Comparative 0
mapping 0
of 0
the 0
Brassica B-gene
S I-gene
locus I-gene
region I-gene
and 0
its 0
homeolog 0
in 0
Arabidopsis 0
. 0

Roles 0
of 0
the 0
Candida B-gene
albicans I-gene
mitogen I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
homolog I-gene
, 0
Cek1p B-gene
, 0
in 0
hyphal 0
development 0
and 0
systemic 0
candidiasis 0
. 0

Neither 0
the 0
reaction 0
of 0
monosaccharides 0
nor 0
the 0
disaccharides 0
with 0
beta 0
- 0
alanine 0
resulted 0
in 0
the 0
formation 0
of 0
maltol 0
. 0

In 0
most 0
subjects 0
, 0
markers 0
of 0
bone 0
formation 0
and 0
resorption 0
were 0
normal 0
. 0

Analysis 0
of 0
a 0
Mac1p B-gene
mutant I-gene
, 0
refractile 0
for 0
copper 0
- 0
dependent 0
repression 0
of 0
the 0
Cu B-gene
( I-gene
I I-gene
) I-gene
transport I-gene
genes I-gene
, 0
showed 0
an 0
aberrant 0
pattern 0
of 0
CUP1 B-gene
expression 0
and 0
copper 0
sensitivity 0
. 0

The 0
DNA 0
sequencing 0
of 0
the 0
recombinant 0
clones 0
revealed 0
the 0
expression 0
of 0
RXR B-gene
alpha I-gene
and 0
RXR B-gene
beta I-gene
. 0

A 0
stratified 0
random 0
sample 0
of 0
20 0
active 0
employees 0
from 0
a 0
cohort 0
of 0
phenoxy 0
herbicide 0
workers 0
was 0
selected 0
in 0
1995 0
for 0
determining 0
PCDD 0
and 0
PCDF 0
congeners 0
in 0
blood 0
lipids 0
to 0
assess 0
the 0
extent 0
of 0
past 0
PCDD 0
and 0
PCDF 0
exposure 0
in 0
this 0
cohort 0
and 0
whether 0
that 0
exposure 0
might 0
explain 0
site 0
- 0
specific 0
cancer 0
findings 0
in 0
the 0
total 0
cohort 0
. 0

The 0
clinical 0
and 0
laboratory 0
features 0
of 0
72 0
children 0
with 0
Henoch 0
- 0
Schonlein 0
purpura 0
( 0
HSP 0
) 0
were 0
examined 0
to 0
determine 0
if 0
there 0
were 0
associations 0
between 0
the 0
laboratory 0
indices 0
- 0
- 0
including 0
white 0
blood 0
cell 0
( 0
WBC 0
) 0
counts 0
, 0
serum B-gene
C I-gene
- I-gene
reactive I-gene
protein I-gene
( 0
CRP B-gene
) 0
levels 0
, 0
platelet 0
( 0
PLT 0
) 0
counts 0
- 0
- 0
and 0
the 0
clinical 0
manifestations 0
of 0
acute 0
HSP 0
. 0

We 0
provide 0
community 0
metabolic 0
data 0
that 0
indicate 0
that 0
large 0
changes 0
in 0
CO2 0
concentration 0
can 0
occur 0
in 0
coral 0
reef 0
waters 0
via 0
biogeochemical 0
processes 0
not 0
directly 0
associated 0
with 0
photosynthesis 0
, 0
respiration 0
, 0
calcification 0
, 0
and 0
CaCO3 0
dissolution 0
. 0

In 0
contrast 0
to 0
other 0
known 0
retroviruses 0
, 0
the 0
FV B-gene
pol I-gene
genes I-gene
are 0
expressed 0
via 0
spliced 0
transcripts 0
. 0

Substitution 0
of 0
bulky 0
hydrophobic 0
residues 0
with 0
charged 0
residues 0
within 0
PEP1 B-gene
affects 0
the 0
fusion 0
activity 0
of 0
the 0
S B-gene
protein I-gene
without 0
affecting 0
processing 0
and 0
surface 0
expression 0
. 0

Tributyltin 0
and 0
its 0
breakdown 0
products 0
, 0
mono 0
- 0
and 0
di 0
- 0
butyltin 0
, 0
were 0
determined 0
in 0
water 0
birds 0
collected 0
from 0
Lake 0
Huron 0
( 0
the 0
Great 0
Lakes 0
) 0
, 0
marine 0
coastal 0
United 0
States 0
, 0
and 0
the 0
west 0
coast 0
of 0
British 0
Columbia 0
, 0
Canada 0
. 0

The 0
5 0
' 0
flanking 0
region 0
of 0
the 0
CD1 B-gene
gene I-gene
contained 0
the 0
binding 0
motifs 0
for 0
two 0
cytokine 0
- 0
inducible 0
transcription 0
factors 0
, 0
NF B-gene
- I-gene
IL2 I-gene
- I-gene
A I-gene
and 0
NF B-gene
- I-gene
IL6 I-gene
. 0

Fregnac 0
, 0
M 0
. 0

GLRaV 0
- 0
2 0
is 0
the 0
only 0
closterovirus 0
, 0
so 0
far 0
, 0
that 0
matches 0
the 0
genome 0
organization 0
of 0
the 0
type 0
member 0
of 0
the 0
group 0
, 0
BYV 0
, 0
and 0
thus 0
can 0
be 0
unambiguously 0
classified 0
as 0
a 0
definitive 0
member 0
of 0
the 0
genus 0
Closterovirus 0
. 0

Demographic 0
and 0
clinical 0
data 0
were 0
compared 0
with 0
a 0
control 0
group 0
of 0
339 0
healthy 0
age 0
- 0
matched 0
women 0
and 0
with 0
a 0
sample 0
of 0
224 0
women 0
with 0
wrist 0
fracture 0
. 0

Combined 0
expression 0
of 0
c B-gene
- I-gene
Jun I-gene
and 0
p65 B-gene
induced 0
vigorous 0
transcription 0
of 0
IL B-gene
- I-gene
2 I-gene
promoter 0
- 0
and 0
CD28RE B-gene
- I-gene
driven I-gene
reporter I-gene
constructs I-gene
in 0
both 0
LFA B-gene
- I-gene
3 I-gene
- 0
and 0
B7 B-gene
- I-gene
1 I-gene
- 0
costimulated 0
Jurkat 0
cells 0
. 0

Identical 0
results 0
were 0
obtained 0
when 0
transfections 0
and 0
mobility 0
shift 0
assays 0
were 0
performed 0
in 0
primary 0
rat 0
hepatocytes 0
in 0
which 0
the 0
endogenous 0
ALS B-gene
gene I-gene
is 0
expressed 0
. 0

This 0
E 0
box 0
sequence 0
( 0
CACGTG 0
) 0
is 0
identical 0
to 0
the 0
binding 0
element 0
for 0
USF B-gene
( 0
upstream B-gene
stimulatory I-gene
factor I-gene
) 0
, 0
a 0
member 0
of 0
the 0
helix B-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
family I-gene
of I-gene
transcription I-gene
factors I-gene
. 0

Interferon B-gene
beta I-gene
therapy 0
was 0
discontinued 0
for 0
4 0
weeks 0
. 0

Liquid 0
chromatographic 0
method 0
for 0
analysis 0
of 0
all 0
- 0
rac 0
- 0
alpha 0
- 0
tocopheryl 0
acetate 0
and 0
retinyl 0
palmitate 0
in 0
milk 0
- 0
based 0
infant 0
formula 0
using 0
matrix 0
solid 0
- 0
phase 0
dispersion 0
. 0

We 0
specially 0
devised 0
3 0
types 0
of 0
turbo 0
pumps 0
, 0
a 0
centrifugal 0
pump 0
( 0
CFP 0
) 0
, 0
a 0
mixed 0
flow 0
pump 0
( 0
MFP 0
) 0
, 0
and 0
an 0
axial 0
flow 0
pump 0
( 0
AFP 0
) 0
, 0
and 0
analyzed 0
their 0
in 0
vitro 0
performance 0
. 0

Examination 0
of 0
the 0
mitochondrial B-gene
bc1 I-gene
complex I-gene
crystal I-gene
structure I-gene
[ 0
Zhang 0
, 0
Z. 0
, 0
Huang 0
, 0
L. 0
, 0
Shulmeister 0
, 0
V 0
. 0

Two 0
protease 0
- 0
resistant 0
fragments 0
spanning 0
the 0
N 0
- 0
and 0
C 0
- 0
terminal 0
halves 0
of 0
the 0
nuclease 0
were 0
identified 0
using 0
different 0
proteases 0
which 0
cleave 0
the 0
protein 0
in 0
the 0
same 0
region 0
. 0

The 0
side 0
- 0
to 0
- 0
side 0
difference 0
was 0
statistically 0
significant 0
at 0
EXT 0
30 0
degrees/s 0
and 0
60 0
degrees/s 0
( 0
p 0
< 0
0.05 0
) 0
. 0

CONCLUSION 0
: 0
In 0
women 0
who 0
want 0
or 0
require 0
conservative 0
management 0
of 0
grade 0
4 0
prolapse 0
and 0
are 0
unable 0
to 0
retain 0
a 0
single 0
pessary 0
, 0
the 0
placement 0
of 0
two 0
pessaries 0
often 0
will 0
be 0
successful 0
. 0

The 0
ability 0
to 0
maintain 0
expression 0
of 0
FAS1 B-gene
in 0
nmt1 B-gene
- 0
451Dino2 B-gene
Delta 0
cells 0
suggests 0
the 0
existence 0
of 0
another 0
transcription 0
factor 0
, 0
or 0
factors 0
, 0
whose 0
expression/activity 0
is 0
inversely 0
related 0
to 0
overall 0
levels 0
of 0
cellular 0
protein 0
N 0
- 0
myristoy 0
- 0
lation 0
. 0

Rev B-gene
- 0
erbAalpha/beta B-gene
) 0
, 0
Mxi B-gene
- I-gene
1 I-gene
and 0
Mad B-gene
bHLH 0
- 0
zip 0
proteins 0
and 0
the 0
oncoproteins 0
PLZF B-gene
and 0
LAZ3/BCL6 B-gene
is 0
mediated 0
by 0
the 0
corepressors 0
LAZ3/BCL6 I-gene

The 0
identified 0
isolates 0
of 0
CSF 0
( 0
20 0
of 0
29 0
) 0
were 0
: 0
ECHO 0
30 0
( 0
9 0
) 0
, 0
ECHO 0
11 0
( 0
7 0
) 0
, 0
ECHO 0
9 0
( 0
3 0
) 0
and 0
ECHO 0
7 0
( 0
1 0
) 0
. 0

There 0
was 0
no 0
evidence 0
of 0
any 0
persistent 0
oscillation 0
within 0
the 0
ULF 0
band 0
. 0

The 0
ParaSight 0
- 0
F 0
test 0
alone 0
was 0
used 0
to 0
monitor 0
serum 0
antigen 0
levels 0
after 0
treatment 0
in 0
24 0
patients 0
. 0

The 0
purified 0
recombinant 0
protein 0
was 0
assayed 0
for 0
its 0
enzyme 0
activity 0
by 0
monitoring 0
transfer 0
of 0
[ 0
3H 0
] 0
methyl 0
groups 0
from 0
the 0
substrate 0
DNA 0
to 0
the 0
MGMT B-gene
protein I-gene
; 0
the 0
activity 0
was 0
found 0
to 0
be 0
stable 0
at 0
90 0
degrees 0
C 0
for 0
at 0
least 0
30 0
min 0
. 0

A 0
deproteinization 0
procedure 0
was 0
coupled 0
with 0
a 0
reversed 0
- 0
phase 0
HPLC 0
separation 0
using 0
a 0
250x4.6 0
mm 0
I.D 0
. 0

Elimination 0
of 0
the 0
inducible 0
response 0
requires 0
simultaneous 0
mutation 0
of 0
both 0
sequences 0
, 0
however 0
, 0
in 0
the 0
presence 0
of 0
an 0
intact 0
EpRE 0
the 0
upstream 0
AP B-gene
- I-gene
1 I-gene
site I-gene
is 0
irrelevant 0
to 0
induction 0
. 0

Three 0
high B-gene
mobility I-gene
group I-gene
- I-gene
like I-gene
sequences I-gene
within 0
a 0
48 0
- 0
base 0
pair 0
enhancer 0
of 0
the 0
Col2a1 B-gene
gene I-gene
are 0
required 0
for 0
cartilage 0
- 0
specific 0
expression 0
in 0
vivo 0
. 0

The 0
sequence 0
contains 0
an 0
open 0
reading 0
frame 0
of 0
1744 0
nt 0
in 0
the 0
virus 0
- 0
sense 0
strand 0
, 0
a 0
3 0
' 0
untranslated 0
region 0
of 0
1360 0
nt 0
and 0
a 0
3 0
' 0
poly 0
( 0
A 0
) 0
tail 0
. 0

A 0
phylogenetic 0
analysis 0
of 0
the 0
reverse B-gene
transcriptase I-gene
domain I-gene
confirms 0
our 0
differential 0
genetic 0
assessment 0
that 0
Cyclops B-gene
from 0
pea 0
is 0
a 0
novel 0
element 0
with 0
no 0
specific 0
relationship 0
to 0
the 0
previously 0
described 0
Gypsy B-gene
- I-gene
like I-gene
elements I-gene
from 0
plants 0
. 0

At 0
physiological 0
doses 0
, 0
either 0
insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
I I-gene
( 0
IGF B-gene
- I-gene
I I-gene
) 0
or 0
insulin B-gene
turned 0
out 0
to 0
be 0
as 0
potent 0
as 0
dibutyryl 0
cAMP 0
( 0
dbcAMP 0
) 0
in 0
increasing 0
UCP1 B-gene
gene I-gene
transcription 0
rate 0
( 0
1 0
h 0
) 0
and 0
also 0
UCP1 B-gene
mRNA I-gene
accumulation 0
( 0
3 0
h 0
) 0
, 0
their 0
maximal 0
effect 0
( 0
15 0
- 0
fold 0
increase 0
) 0
reached 0
upon 0
treatment 0
for 0
24 0
h 0
. 0

In 0
addition 0
, 0
insulin B-gene
induced 0
AP B-gene
- I-gene
1 I-gene
DNA 0
binding 0
activity 0
, 0
this 0
effect 0
being 0
totally 0
prevented 0
in 0
the 0
presence 0
of 0
MEK B-gene
- I-gene
1 I-gene
inhibitor 0
. 0

Essentially 0
, 0
2' 0
- 0
O 0
- 0
methyl 0
oligoribonucleotides 0
( 0
2'OMeRNA 0
) 0
were 0
delivered 0
to 0
the 0
nuclei 0
of 0
primary 0
mdx 0
myoblasts 0
in 0
culture 0
. 0

A 0
large 0
deletion 0
in 0
the 0
CTD B-gene
- I-gene
binding I-gene
motif I-gene
blocks 0
down 0
- 0
regulation 0
but 0
does 0
not 0
affect 0
the 0
essential 0
function 0
of 0
Nrd1 B-gene
. 0

Regulation 0
of 0
the 0
human 0
p21/WAF1/Cip1 B-gene
promoter 0
in 0
hepatic 0
cells 0
by 0
functional 0
interactions 0
between 0
p21/WAF1/Cip1 I-gene

RESULTS 0
: 0
We 0
isolated 0
a 0
C. 0
elegans 0
cDNA 0
that 0
encoded 0
a 0
protein 0
which 0
was 0
similar 0
to 0
, 0
but 0
not 0
exactly 0
homologous 0
with 0
mammalian 0
p120 B-gene
Ras B-gene
- 0
GAP B-gene
. 0

The 0
weak 0
base 0
ketoconazole 0
showed 0
complete 0
dissolution 0
from 0
a 0
tablet 0
formulation 0
in 0
Simulated 0
Gastric 0
Fluid 0
without 0
pepsin B-gene
( 0
SGFsp 0
) 0
within 0
30 0
minutes 0
, 0
70 0
% 0
dissolution 0
in 0
2 0
hours 0
under 0
fed 0
state 0
simulated 0
upper 0
jejunal 0
conditions 0
but 0
only 0
6 0
% 0
dissolution 0
in 0
2 0
hours 0
under 0
fasted 0
state 0
conditions 0
. 0

In 0
mammals 0
, 0
the 0
Rb B-gene
protein I-gene
interacts 0
specifically 0
with 0
D B-gene
- I-gene
type I-gene
cyclins I-gene
and 0
regulates 0
cell 0
proliferation 0
by 0
binding 0
and 0
inhibiting 0
E2F B-gene
transcription I-gene
factors I-gene
. 0

In 0
addition 0
to 0
the 0
signals 0
obtained 0
by 0
ligation 0
of 0
the 0
TCR B-gene
, 0
T 0
cells 0
need 0
additional 0
, 0
co 0
- 0
stimulatory 0
signals 0
to 0
be 0
activated 0
. 0

Moreover 0
, 0
the 0
observation 0
of 0
enhanced 0
luteal B-gene
HSP I-gene
- I-gene
27 I-gene
phosphorylation 0
in 0
vivo 0
, 0
in 0
late 0
pregnancy 0
, 0
when 0
PKC B-gene
- I-gene
delta I-gene
is 0
abundant 0
and 0
active 0
, 0
suggests 0
that 0
select 0
PKC B-gene
family I-gene
members I-gene
contribute 0
to 0
sHSP B-gene
phosphorylation 0
events 0
in 0
vivo 0
. 0

We 0
characterized 0
the 0
structure 0
of 0
this 0
leader 0
mRNA 0
by 0
using 0
the 0
program 0
Mfold 0
and 0
a 0
combination 0
of 0
nested 0
and 0
internal 0
deletions 0
transcriptionally 0
fused 0
to 0
a 0
promoterless 0
lac B-gene
operon I-gene
. 0

The 0
importance 0
of 0
these 0
sites 0
for 0
transcriptional 0
activation 0
was 0
studied 0
by 0
site 0
- 0
directed 0
mutagenesis 0
followed 0
by 0
promoter 0
function 0
analysis 0
of 0
the 0
mutants 0
with 0
a 0
chloramphenicol B-gene
acetyltransferase I-gene
reporter I-gene
system 0
. 0

Routine 0
blood 0
examination 0
showed 0
leukocytosis 0
, 0
thrombocytopenia 0
, 0
positive 0
CRP B-gene
, 0
and 0
elevated 0
myocardial 0
enzymes 0
. 0

Previous 0
studies 0
have 0
suggested 0
that 0
moderate 0
cooling 0
increases 0
the 0
responsiveness 0
of 0
vascular B-gene
alpha2 I-gene
- I-gene
adrenoceptors I-gene
. 0

Two 0
members 0
of 0
the 0
Cbl B-gene
family I-gene
have 0
since 0
been 0
defined 0
in 0
mammals 0
( 0
c B-gene
- I-gene
Cbl I-gene
and 0
Cbl B-gene
- I-gene
b I-gene
) 0
, 0
one 0
in 0
C. 0
elegans 0
( 0
Sli B-gene
- I-gene
1 I-gene
) 0
and 0
one 0
in 0
Drosophila 0
( 0
D B-gene
- I-gene
Cbl I-gene
) 0
. 0

Anti B-gene
- I-gene
PTB I-gene
antibodies I-gene
did 0
not 0
inhibit 0
the 0
binding 0
of 0
PTB B-gene
to 0
RNA 0
because 0
they 0
were 0
able 0
to 0
supershift 0
RNA B-gene
- I-gene
PTB I-gene
complexes I-gene
. 0

The 0
use 0
of 0
antibodies 0
to 0
the 0
polypyrimidine B-gene
tract I-gene
binding I-gene
protein I-gene
( 0
PTB B-gene
) 0
to 0
analyze 0
the 0
protein 0
components 0
that 0
assemble 0
on 0
alternatively 0
spliced 0
pre 0
- 0
mRNAs 0
that 0
use 0
distant 0
branch 0
points 0
. 0

The 0
therapeutic 0
use 0
of 0
botulinum B-gene
toxin I-gene
( 0
Botox B-gene
) 0
is 0
increasing 0
in 0
popularity 0
. 0

The 0
viral B-gene
oncoprotein I-gene
E1A I-gene
inhibits 0
NFAT B-gene
- 0
dependent 0
transactivation 0
in 0
a 0
p300 B-gene
- 0
dependent 0
manner 0
. 0

We 0
have 0
applied 0
the 0
mRNA 0
differential 0
display 0
method 0
to 0
compare 0
and 0
analyze 0
mRNAs 0
prepared 0
from 0
five 0
normal 0
nasopharyngeal 0
epithelial 0
cell 0
cultures 0
and 0
five 0
nasopharyngeal 0
carcinoma 0
cell 0
lines 0
. 0

Similar 0
experiments 0
with 0
TR B-gene
support 0
the 0
high 0
affinity 0
of 0
RIP140 B-gene
to 0
the 0
RXR B-gene
subunit I-gene
and 0
also 0
suggest 0
that 0
either 0
partner 0
in 0
the 0
TR/RXR B-gene
heterodimer 0
can 0
independently 0
respond 0
to 0
ligand 0
. 0

SETTING 0
: 0
University 0
hospital 0
- 0
based 0
, 0
tertiary 0
care 0
infertility 0
center 0
. 0

RESULT 0
( 0
S 0
) 0
: 0
In 0
patients 0
with 0
elevated 0
FSH B-gene
levels 0
on 0
cycle 0
day 0
3 0
, 0
a 0
low 0
oocyte 0
yield 0
was 0
achieved 0
( 0
7 0
versus 0
11 0
) 0
and 0
a 0
high 0
number 0
of 0
ampules 0
of 0
hMG B-gene
was 0
necessary 0
( 0
56 0
versus 0
33 0
) 0
. 0

RESULTS 0
: 0
Of 0
the 0
patients 0
with 0
IS 0
, 0
67 0
% 0
had 0
significantly 0
greater 0
values 0
of 0
directional 0
preponderance 0
on 0
the 0
OVAR 0
test 0
( 0
a 0
measure 0
of 0
otolith 0
system 0
imbalance 0
) 0
compared 0
with 0
control 0
subjects 0
. 0

In 0
the 0
ePTFE 0
specimens 0
, 0
tissue 0
coverage 0
had 0
increased 0
. 0

As 0
predicted 0
by 0
the 0
Wing 0
and 0
Kristofferson 0
model 0
, 0
the 0
durations 0
of 0
successive 0
ISIs 0
tended 0
to 0
be 0
negatively 0
correlated 0
. 0

Thus 0
, 0
included 0
in 0
the 0
KG1a 0
EST 0
dataset 0
are 0
candidates 0
for 0
new 0
human 0
genes 0
that 0
may 0
play 0
roles 0
in 0
hematopoietic 0
differentiative 0
progression 0
and 0
lineage 0
commitment 0
. 0

We 0
found 0
the 0
following 0
: 0
Specific 0
mutations 0
affected 0
the 0
precise 0
carbohydrate 0
structure 0
and 0
folding 0
of 0
the 0
HA B-gene
trimer I-gene
. 0

The 0
results 0
show 0
that 0
ROS 0
production 0
by 0
viable 0
spermatozoa 0
is 0
highly 0
correlated 0
with 0
the 0
concentration 0
of 0
PMN B-gene
elastase I-gene
and 0
the 0
number 0
of 0
both 0
peroxidase B-gene
- 0
positive 0
and 0
round 0
cells 0
. 0

Yeast B-gene
U1 I-gene
snRNP I-gene
is 0
considerably 0
more 0
complex 0
than 0
its 0
metazoan 0
counterpart 0
, 0
which 0
suggests 0
possible 0
differences 0
between 0
yeast 0
and 0
metazoa 0
in 0
early 0
splicing 0
events 0
. 0

Yeast B-gene
U1 I-gene
snRNP I-gene
therefore 0
contains 0
16 0
different 0
proteins 0
, 0
including 0
seven 0
snRNP B-gene
core I-gene
proteins I-gene
, 0
three 0
homologues 0
of 0
the 0
metazoan B-gene
U1 I-gene
snRNP I-gene
- I-gene
specific I-gene
proteins I-gene
, 0
and 0
six 0
yeast B-gene
- I-gene
specific I-gene
U1 I-gene
snRNP I-gene
proteins I-gene
. 0

After 0
the 0
first 0
cycle 0
, 0
18 0
cases 0
were 0
treated 0
at 0
dose 0
level 0
1 0
, 0
after 0
a 0
second 0
cycle 0
, 0
13 0
cases 0
were 0
treated 0
at 0
dose 0
level 0
2 0
. 0

The 0
opioid 0
antagonist 0
naltrexone 0
( 0
0.01 0
- 0
1.0 0
mg/kg 0
) 0
antagonized 0
the 0
discriminative 0
stimulus 0
effects 0
of 0
heroin 0
, 0
but 0
naltrexone 0
at 0
doses 0
up 0
to 0
10 0
mg/kg 0
had 0
no 0
effect 0
on 0
the 0
discriminative 0
stimulus 0
effects 0
of 0
cocaine 0
. 0

In 0
this 0
study 0
we 0
examined 0
hepatic 0
stellate 0
cell 0
regulation 0
of 0
M6P/IGFIIR B-gene
expression 0
and 0
found 0
that 0
M6P/IGFIIR I-gene

One 0
cDNA 0
clone 0
designated 0
NCoA 0
- 0
62 0
, 0
encoded 0
a 0
62 0
, 0
000 0
- 0
Da 0
protein 0
that 0
is 0
highly 0
related 0
to 0
BX42 B-gene
, 0
a 0
Drosophila 0
melanogaster 0
nuclear 0
protein 0
involved 0
in 0
ecdysone 0
- 0
stimulated 0
gene 0
expression 0
. 0

These 0
widely 0
expressed 0
proteins 0
share 0
a 0
C 0
- 0
terminal 0
region 0
that 0
bears 0
significant 0
sequence 0
homology 0
to 0
a 0
group 0
of 0
GDP/GTP B-gene
exchange I-gene
proteins I-gene
for 0
the 0
Rab3 B-gene
family I-gene
of 0
small B-gene
GTP I-gene
binding I-gene
proteins I-gene
. 0

Whereas 0
p82 B-gene
expression 0
had 0
no 0
effect 0
on 0
ERK2 B-gene
activation 0
by 0
p126 B-gene
, 0
p70 B-gene
completely 0
abrogated 0
this 0
activity 0
. 0

The 0
pre 0
- 0
mRNA 0
splicing 0
factor 0
U2AF B-gene
( 0
U2 B-gene
small I-gene
nuclear I-gene
ribonucleoprotein I-gene
particle I-gene
[ I-gene
snRNP I-gene
] I-gene
auxiliary I-gene
factor I-gene
) 0
plays 0
a 0
critical 0
role 0
in 0
3 0
' 0
splice 0
site 0
selection 0
. 0

The 0
brackets 0
were 0
bonded 0
to 0
100 0
freshly 0
extracted 0
bovine 0
incisors 0
, 0
and 0
, 0
after 0
storage 0
in 0
tap 0
water 0
at 0
room 0
temperature 0
for 0
24 0
hours 0
, 0
they 0
were 0
subsequently 0
tested 0
in 0
a 0
shear 0
mode 0
using 0
a 0
universal 0
testing 0
machine 0
. 0

Exercise 0
training 0
has 0
become 0
increasingly 0
important 0
in 0
the 0
treatment 0
of 0
heart 0
failure 0
patients 0
. 0

The 0
growth 0
of 0
Aer 0
. 0
hydrophila 0
in 0
filter 0
- 0
sterilized 0
lettuce 0
extract 0
was 0
completely 0
inhibited 0
by 0
0.1 0
% 0
( 0
v/v 0
) 0
BMC 0
whereas 0
that 0
of 0
Ps 0
. 0
fluorescens 0
was 0
not 0
significantly 0
affected 0
by 0
1 0
% 0
( 0
v/v 0
) 0
BMC 0
. 0

Despite 0
continuous 0
compliance 0
, 0
unexplained 0
resurgence 0
of 0
serum 0
ferritin B-gene
levels 0
occurred 0
in 0
4/7 0
patients 0
of 0
the 0
'veteran 0
' 0
group 0
after 0
4 0
- 0
5 0
years 0
on 0
L1 0
. 0

Hematocrit 0
and 0
PaO2 0
did 0
not 0
change 0
. 0

Regulation 0
of 0
myosin B-gene
phosphatase I-gene
activity 0
involves 0
changes 0
in 0
subunit 0
interactions 0
, 0
although 0
molecular 0
mechanisms 0
are 0
not 0
defined 0
. 0

Commutative 0
saccadic 0
generator 0
is 0
sufficient 0
to 0
control 0
a 0
3 0
- 0
D 0
ocular 0
plant 0
with 0
pulleys 0
. 0

The 0
virus 0
- 0
associated 0
VAI B-gene
RNA 0
of 0
adenovirus 0
is 0
a 0
small 0
highly 0
structured 0
RNA 0
that 0
is 0
required 0
for 0
the 0
efficient 0
translation 0
of 0
cellular 0
and 0
viral 0
mRNAs 0
at 0
late 0
times 0
after 0
infection 0
. 0

Structure 0
of 0
the 0
gene 0
encoding 0
the 0
human 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
inhibitor 0
p18 B-gene
and 0
mutational 0
analysis 0
in 0
breast 0
cancer 0
. 0

The 0
YccA B-gene
protein I-gene
was 0
found 0
to 0
be 0
degraded 0
in 0
an 0
FtsH B-gene
- 0
dependent 0
manner 0
in 0
vivo 0
and 0
in 0
vitro 0
, 0
whereas 0
the 0
YccA11 B-gene
mutant I-gene
protein I-gene
, 0
lacking 0
eight 0
amino 0
acid 0
residues 0
within 0
the 0
amino 0
- 0
terminal 0
cytoplasmic 0
domain 0
, 0
was 0
refractory 0
to 0
the 0
degradation 0
. 0

The 0
major 0
type 0
involves 0
activator 0
proteins 0
that 0
bind 0
to 0
DNA 0
adjacent 0
to 0
where 0
the 0
RNA B-gene
polymerase I-gene
( 0
RNAP B-gene
) 0
holoenzyme 0
binds 0
, 0
usually 0
assisting 0
in 0
recruitment 0
of 0
the 0
RNAP B-gene
to 0
the 0
promoter 0
. 0

A 0
conserved 0
role 0
for 0
L1 B-gene
as 0
a 0
transmembrane 0
link 0
between 0
neuronal 0
adhesion 0
and 0
membrane 0
cytoskeleton 0
assembly 0
. 0

Atmospheric 0
benzene 0
, 0
urinary 0
muconic 0
acid 0
( 0
tt 0
- 0
MA 0
) 0
and 0
leukocyte B-gene
alkaline I-gene
phosphatase I-gene
activity 0
( 0
LAPA 0
) 0
were 0
evaluated 0
among 0
66 0
car 0
mechanics 0
, 0
34 0
road 0
tanker 0
drivers 0
, 0
and 0
28 0
nonexposed 0
workers 0
. 0

It 0
contains 0
a 0
5' 0
- 0
noncoding 0
region 0
( 0
NCR 0
) 0
of 0
73 0
nucleotides 0
, 0
five 0
open 0
reading 0
frames 0
( 0
ORFs 0
1 0
to 0
5 0
) 0
which 0
encode 0
proteins 0
with 0
M 0
( 0
r 0
) 0
160 B-gene
kDa I-gene
RNA I-gene
- I-gene
dependent I-gene
RNA I-gene
polymerase I-gene
( I-gene
ORF1 I-gene
) I-gene
, 0
26 B-gene
kDa I-gene
movement I-gene
protein I-gene
1 I-gene
( I-gene
ORF2 I-gene
) I-gene
, 0
13 B-gene
kDa I-gene
movement I-gene
protein I-gene
2 I-gene
( I-gene
ORF3 I-gene
) I-gene
, 0
10 B-gene
kDa I-gene
movement I-gene
protein I-gene
3 I-gene
( I-gene
ORF4 I-gene
) I-gene
, 0
24 B-gene
kDa I-gene
coat I-gene
protein I-gene
( I-gene
OFR5 I-gene
) I-gene
, 0
and 0
a 0
3 0
' 0
NCR 0
of 0
76 0
nucleotides 0
. 0

After 0
profound 0
normovolemic 0
hemodilution 0
( 0
Hct 0
9 0
% 0
) 0
superiority 0
of 0
LV 0
MC 0
and 0
LV 0
diastolic 0
properties 0
was 0
found 0
, 0
when 0
myocardial 0
oxygenation 0
was 0
supported 0
by 0
i.v 0
. 0
perflubron 0
emulsion 0
, 0
a 0
temporary 0
O2 0
carrier 0
. 0

Sp1 B-gene
and 0
two 0
Sp3 B-gene
isoforms I-gene
were 0
detected 0
as 0
the 0
primary 0
cellular 0
constituents 0
of 0
DNA 0
- 0
protein 0
complexes 0
formed 0
with 0
the 0
NF B-gene
- I-gene
kappaB I-gene
- I-gene
proximal I-gene
site I-gene
. 0

These 0
genes 0
may 0
represent 0
interesting 0
targets 0
for 0
new 0
therapeutic 0
strategies 0
. 0

It 0
could 0
also 0
inhibit 0
C1q B-gene
- 0
dependent 0
haemolysis 0
of 0
both 0
IgG B-gene
- 0
and 0
IgM B-gene
- 0
sensitized 0
erythrocytes 0
. 0

3 0
) 0
and 0
one 0
distal 0
( 0
- 0
11.8/ 0
- 0
10.9 0
) 0
, 0
presented 0
an 0
enhancer 0
activity 0
in 0
pituitary 0
cells 0
when 0
placed 0
upstream 0
of 0
the 0
SV40 B-gene
promoter I-gene
. 0

The 0
second 0
patient 0
had 0
received 0
pituitary B-gene
- I-gene
derived I-gene
growth I-gene
hormone I-gene
for 0
treatment 0
of 0
growth B-gene
hormone I-gene
deficiency 0
, 0
secondary 0
to 0
a 0
third 0
ventricle 0
teratoma 0
, 0
exised 0
13 0
yr 0
earlier 0
. 0

3 0
- 0
- 0
It 0
is 0
necessary 0
to 0
think 0
about 0
cosmetic 0
consequences 0
of 0
the 0
chinese 0
flap 0
and 0
consider 0
other 0
possibilities 0
of 0
the 0
flap 0
choice 0
. 0

CONCLUSION 0
: 0
TNF B-gene
alpha I-gene
, 0
TGF B-gene
beta I-gene
, 0
PDGF B-gene
and 0
IL B-gene
- I-gene
1beta I-gene
increased 0
LDLr B-gene
gene I-gene
expression 0
by 0
increasing 0
sterol 0
- 0
independent 0
and 0
mitogenesis 0
- 0
independent 0
gene 0
transcription 0
. 0

Binding 0
affinities 0
of 0
different 0
nucleotide 0
mono 0
- 0
, 0
di 0
- 0
and 0
triphosphates 0
and 0
non 0
- 0
hydrolyzable 0
analogs 0
indicate 0
that 0
the 0
beta 0
- 0
phosphate 0
moiety 0
is 0
required 0
for 0
substrate 0
binding 0
. 0

However 0
, 0
it 0
is 0
only 0
one 0
- 0
half 0
and 0
one 0
- 0
third 0
the 0
size 0
of 0
the 0
proteolipids 0
from 0
M. 0
thermoautotrophicum 0
and 0
M. 0
jannaschii 0
, 0
respectively 0
. 0
ahaK B-gene
is 0
expressed 0
in 0
Escherichia 0
coli 0
, 0
and 0
it 0
is 0
incorporated 0
into 0
the 0
cytoplasmic 0
membrane 0
despite 0
the 0
different 0
chemical 0
natures 0
of 0
lipids 0
from 0
archaea 0
and 0
bacteria 0
. 0

In 0
this 0
report 0
we 0
studied 0
the 0
role 0
of 0
protein B-gene
- I-gene
tyrosine I-gene
phosphatase I-gene
SHP B-gene
- I-gene
2 I-gene
in 0
ErbB B-gene
- 0
mediated 0
activation 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
MAPK B-gene
) 0
by 0
overexpressing 0
SHP B-gene
- I-gene
2 I-gene
mutants I-gene
in 0
COS 0
- 0
7 0
cells 0
. 0

Osteoadherin B-gene
is 0
a 0
recently 0
described 0
bone 0
proteoglycan 0
containing 0
keratan 0
sulfate 0
. 0

Intron 0
8 0
harbored 0
a 0
strong 0
erythroid 0
- 0
specific 0
enhancer 0
activity 0
which 0
was 0
orientation 0
- 0
dependent 0
. 0

The 0
intron 0
8 0
enhancer 0
region 0
was 0
not 0
activated 0
by 0
GATA B-gene
- I-gene
1 I-gene
together 0
with 0
Sp1 B-gene
in 0
transactivation 0
experiments 0
in 0
COS 0
- 0
1 0
cells 0
indicating 0
the 0
involvement 0
of 0
a 0
related 0
Sp1 B-gene
protein I-gene
or 0
of 0
another 0
unidentified 0
erythroid 0
factor 0
. 0

The 0
cleavage 0
of 0
Fak B-gene
by 0
caspases B-gene
may 0
thus 0
play 0
an 0
important 0
role 0
in 0
the 0
execution 0
of 0
the 0
suicide 0
program 0
by 0
disabling 0
the 0
anti 0
- 0
apoptotic 0
function 0
of 0
Fak B-gene
. 0

Moreover 0
, 0
the 0
mass 0
estimated 0
with 0
the 0
QCM 0
response 0
through 0
the 0
Sauerbrey 0
equation 0
and 0
the 0
mass 0
which 0
can 0
be 0
measured 0
thanks 0
to 0
other 0
analytical 0
techniques 0
, 0
in 0
our 0
case 0
an 0
enzymatic 0
assay 0
, 0
are 0
different 0
: 0
the 0
deposited 0
mass 0
is 0
generally 0
overestimated 0
by 0
the 0
QCM 0
. 0

[ 0
Treatment 0
of 0
early 0
T1 0
small 0
T2N 0
breast 0
cancers 0
. 0

Transcription 0
initiation 0
occurred 0
predominantly 0
at 0
the 0
putative 0
sigmaA B-gene
- I-gene
dependent I-gene
promoter I-gene
in 0
exponentially 0
growing 0
cells 0
and 0
was 0
induced 0
under 0
stress 0
conditions 0
. 0

The 0
genes 0
encoding 0
( B-gene
2Fe I-gene
- I-gene
2S I-gene
) I-gene
plant I-gene
- I-gene
like I-gene
ferredoxins I-gene
were 0
studied 0
in 0
the 0
widely 0
used 0
cyanobacterium 0
Synechocystis 0
PCC6803 0
. 0

RNA 0
of 0
GBV 0
- 0
C 0
was 0
detected 0
in 0
14 0
( 0
18 0
% 0
) 0
patients 0
before 0
BMT 0
. 0

A 0
major 0
pool 0
of 0
Dsg B-gene
- 0
plakoglobin B-gene
complexes 0
sedimented 0
at 0
8S 0
and 0
exhibited 0
a 0
1:1 0
stoichiometry 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
binding 0
of 0
CBF/NF B-gene
CBF/NF I-gene
- I-gene
Y I-gene
to 0
the 0
inverted 0
CCAAT 0
box 0
is 0
responsible 0
for 0
transcriptional 0
activation 0
of 0
the 0
nTPH B-gene
gene I-gene
. 0

In 0
macrophages 0
, 0
LPS 0
- 0
inducible 0
HIV 0
- 0
1 0
gene 0
expression 0
is 0
mediated 0
in 0
part 0
by 0
binding 0
of 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
to 0
identical 0
tandem 0
binding 0
sites 0
located 0
within 0
the 0
long 0
terminal 0
repeat 0
( 0
LTR 0
) 0
. 0

The 0
influence 0
of 0
p53 B-gene
on 0
cytokine 0
- 0
triggered 0
Janus B-gene
kinase I-gene
- 0
STAT B-gene
signaling 0
was 0
investigated 0
in 0
human 0
hepatoma 0
Hep3B 0
cell 0
lines 0
engineered 0
to 0
constitutively 0
express 0
the 0
temperature 0
- 0
sensitive 0
Val135 B-gene
mutant I-gene
of I-gene
p53 I-gene
. 0

It 0
can 0
also 0
be 0
used 0
to 0
examine 0
various 0
laryngeal 0
parameters 0
obtained 0
from 0
videotaped 0
endoscopic 0
and 0
stroboscopic 0
examinations 0
. 0

CONCLUSIONS 0
: 0
Two 0
consecutive 0
sets 0
of 0
transrectal 0
ultrasound 0
guided 0
sextant 0
biopsies 0
of 0
the 0
prostate 0
performed 0
in 0
a 0
single 0
office 0
visit 0
represent 0
a 0
cost 0
- 0
effective 0
biopsy 0
strategy 0
for 0
men 0
presenting 0
with 0
an 0
abnormal 0
digital 0
rectal 0
examination 0
and/or 0
elevated 0
serum B-gene
PSA I-gene
. 0

Examination 0
of 0
nuclear 0
magnetic 0
resonance 0
( 0
NMR 0
) 0
spectra 0
of 0
a 0
series 0
of 0
N B-gene
- I-gene
terminally I-gene
truncated I-gene
MIP I-gene
- I-gene
1 I-gene
beta I-gene
variants I-gene
reveals 0
that 0
these 0
proteins 0
possess 0
a 0
range 0
of 0
ability 0
to 0
dimerize 0
. 0

Interestingly 0
, 0
PKA B-gene
activity 0
is 0
dispensable 0
in 0
a 0
strain 0
lacking 0
Msn2p B-gene
and 0
Msn4p B-gene
activity 0
. 0

They 0
also 0
indicate 0
that 0
direct 0
interactions 0
between 0
C/EBPs B-gene
and 0
specific 0
Ets B-gene
family 0
members 0
, 0
together 0
with 0
GATA B-gene
- I-gene
1 I-gene
, 0
are 0
important 0
for 0
eosinophil 0
lineage 0
determination 0
. 0

Recently 0
, 0
a 0
human B-gene
transcription I-gene
elongation I-gene
factor I-gene
P I-gene
- I-gene
TEFb I-gene
, 0
consisting 0
of 0
CDK9 B-gene
kinase I-gene
, 0
cyclin B-gene
T I-gene
and 0
other 0
associated 0
factors 0
, 0
has 0
been 0
shown 0
to 0
interact 0
with 0
Tat B-gene
to 0
restore 0
Tat B-gene
activation 0
in 0
HeLa 0
nuclear 0
extract 0
depleted 0
of 0
P B-gene
- I-gene
TEFb I-gene
. 0

We 0
have 0
used 0
the 0
hydrophobic 0
repeats 0
of 0
the 0
HSF1 B-gene
trimerization I-gene
domain I-gene
in 0
the 0
yeast 0
two 0
- 0
hybrid 0
protein 0
interaction 0
assay 0
to 0
identify 0
heat B-gene
shock I-gene
factor I-gene
binding I-gene
protein I-gene
1 I-gene
( 0
HSBP1 B-gene
) 0
, 0
a 0
novel 0
, 0
conserved 0
, 0
76 0
- 0
amino 0
- 0
acid 0
protein 0
that 0
contains 0
two 0
extended 0
arrays 0
of 0
hydrophobic 0
repeats 0
that 0
interact 0
with 0
the 0
HSF1 B-gene
heptad I-gene
repeats I-gene
. 0

Genomic 0
and 0
cDNA 0
clones 0
homologous 0
to 0
the 0
yeast 0
GCN2 B-gene
eIF B-gene
- I-gene
2alpha I-gene
kinase 0
( 0
yGCN2 0
) 0
were 0
isolated 0
from 0
Drosophila 0
melanogaster 0
. 0

The 0
general 0
recombination 0
at 0
a 0
polarizing 0
voltage 0
of 0
300 0
V 0
is 0
less 0
than 0
2 0
% 0
for 0
dose 0
- 0
rates 0
up 0
to 0
about 0
100 0
mGy 0
min 0
- 0
1 0
. 0

The 0
low 0
number 0
of 0
false 0
positives 0
indicates 0
that 0
our 0
scheme 0
would 0
not 0
confuse 0
the 0
radiologist 0
by 0
suggesting 0
normal 0
regions 0
as 0
suspicious 0
. 0

Strengthening 0
the 0
biological 0
weapons 0
convention 0
and 0
implications 0
on 0
the 0
pharmaceutical 0
and 0
biotechnology 0
industry 0
. 0

VirD2 B-gene
is 0
one 0
of 0
the 0
key 0
Agrobacterium 0
tumefaciens 0
proteins 0
involved 0
in 0
T 0
- 0
DNA 0
processing 0
and 0
transfer 0
. 0

Taken 0
together 0
, 0
these 0
data 0
indicate 0
that 0
the 0
VirD2 B-gene
omega I-gene
domain I-gene
is 0
important 0
for 0
efficient 0
T 0
- 0
DNA 0
integration 0
. 0

The 0
DHEAS 0
levels 0
in 0
all 0
stages 0
of 0
decreased 0
BMD 0
were 0
significantly 0
lower 0
than 0
those 0
in 0
the 0
group 0
with 0
normal 0
BMD 0
. 0

Orientation 0
of 0
the 0
nuclear 0
spin 0
system 0
by 0
optical 0
pumping 0
causes 0
an 0
Overhauser 0
shift 0
of 0
the 0
excitonic 0
energy 0
levels 0
proportional 0
to 0
the 0
degree 0
of 0
nuclear 0
orientation 0
. 0

Cystatin B-gene
A I-gene
, 0
a 0
cysteine B-gene
proteinase I-gene
inhibitor 0
, 0
is 0
one 0
of 0
the 0
precursor 0
proteins 0
of 0
cornified B-gene
cell I-gene
envelope I-gene
of 0
keratinocytes 0
and 0
is 0
expressed 0
during 0
the 0
late 0
stage 0
of 0
keratinocyte 0
differentiation 0
. 0

A 0
role 0
for 0
RalGDS B-gene
and 0
a 0
novel 0
Ras B-gene
effector 0
in 0
the 0
Ras B-gene
- 0
mediated 0
inhibition 0
of 0
skeletal 0
myogenesis 0
. 0

GTPase B-gene
activating 0
specificity 0
of 0
RGS12 B-gene
and 0
binding 0
specificity 0
of 0
an 0
alternatively 0
spliced 0
PDZ B-gene
( 0
PSD B-gene
- I-gene
95/Dlg/ZO I-gene
95/Dlg/ZO I-gene

However 0
, 0
mutations 0
in 0
the 0
HNF B-gene
- I-gene
4 I-gene
binding I-gene
site I-gene
on 0
element B-gene
CIIB I-gene
and 0
inhibition 0
of 0
HNF B-gene
- I-gene
4 I-gene
synthesis 0
in 0
HepG2 0
cells 0
by 0
antisense 0
HNF B-gene
- I-gene
4 I-gene
constructs I-gene
decreased 0
the 0
apoCII B-gene
promoter I-gene
activity 0
to 0
25 0
- 0
40 0
% 0
of 0
the 0
control 0
, 0
indicating 0
that 0
HNF B-gene
- I-gene
4 I-gene
is 0
a 0
positive 0
regulator 0
of 0
the 0
apoCII B-gene
gene I-gene
. 0

272 0
, 0
19107 0
- 0
19110 0
) 0
. 0

In 0
addition 0
, 0
we 0
find 0
that 0
E2F B-gene
- I-gene
1 I-gene
can 0
cause 0
apoptosis 0
in 0
p53 B-gene
- I-gene
/ I-gene
- I-gene
tumour 0
cells 0
and 0
further 0
p300 B-gene
, 0
which 0
also 0
functions 0
as 0
a 0
co 0
- 0
activator 0
for 0
the 0
E2F/DP B-gene
heterodimer 0
, 0
enhances 0
the 0
apoptotic 0
activity 0
of 0
E2F/DP I-gene

Blocked 0
shift/supershift 0
analysis 0
indicates 0
that 0
Fos B-gene
family I-gene
member 0
proteins 0
especially 0
Fra B-gene
- I-gene
1 I-gene
and 0
Fra B-gene
- I-gene
2 I-gene
are 0
related 0
to 0
progression 0
and 0
no 0
changes 0
found 0
in 0
the 0
Jun B-gene
family I-gene
member 0
proteins 0
although 0
they 0
are 0
present 0
in 0
the 0
AP B-gene
- I-gene
1/DNA I-gene
binding I-gene
complex I-gene
. 0

Initially 0
, 0
we 0
observed 0
that 0
unmutated 0
p53 B-gene
is 0
strongly 0
expressed 0
in 0
premalignant 0
mammary 0
glands 0
and 0
in 0
mammary 0
tumors 0
derived 0
from 0
the 0
MMTV 0
- 0
c B-gene
- I-gene
myc I-gene
strain 0
. 0

These 0
data 0
show 0
that 0
heterologous 0
virus 0
RNAs 0
( 0
BSMV 0
) 0
can 0
serve 0
as 0
primer 0
donors 0
for 0
MStV 0
mRNA 0
capped 0
RNA 0
- 0
primed 0
transcription 0
in 0
doubly 0
infected 0
plants 0
. 0

Human 0
isoforms 0
, 0
designated 0
1 0
to 0
4 0
, 0
differ 0
from 0
each 0
other 0
by 0
the 0
start 0
codon 0
used 0
. 0

Comparison 0
of 0
cDNA 0
and 0
genomic 0
sequences 0
shows 0
that 0
the 0
ZNF189 B-gene
gene I-gene
spans 0
approximately 0
11 0
kb 0
and 0
is 0
organized 0
into 0
at 0
least 0
four 0
exons 0
, 0
the 0
large 0
3' 0
- 0
end 0
exon 0
coding 0
for 0
the 0
complete 0
zinc 0
finger 0
domain 0
and 0
the 0
3 0
' 0
untranslated 0
region 0
. 0

Malaria 0
had 0
diminished 0
significantly 0
by 0
the 0
early 0
1940s 0
, 0
and 0
this 0
paper 0
queries 0
whether 0
that 0
reduction 0
was 0
due 0
to 0
the 0
control 0
projects 0
of 0
the 0
thirties 0
, 0
and 0
, 0
if 0
so 0
, 0
whether 0
such 0
projects 0
should 0
be 0
a 0
model 0
for 0
the 0
current 0
developing 0
world 0
, 0
where 0
malaria 0
is 0
a 0
growing 0
problem 0
today 0
. 0

The 0
gp330/Megalin/LRP B-gene
gp330/Megalin/LRP I-gene

In 0
the 0
DNA 0
recognition 0
helix 0
of 0
finger 0
II 0
, 0
the 0
conserved 0
Arg 0
at 0
position 0
62 0
( 0
N 0
- 0
terminal 0
side 0
of 0
the 0
first 0
zinc 0
- 0
coordinating 0
histidine 0
) 0
was 0
changed 0
to 0
a 0
Leu 0
or 0
Gln 0
. 0

Dosage 0
in 0
both 0
cases 0
was 0
0.2 0
g/m2 0
. 0

Five 0
additional 0
copies 0
of 0
Lian B-gene
elements I-gene
were 0
isolated 0
, 0
mapped 0
by 0
restriction 0
digestion 0
, 0
and 0
partially 0
sequenced 0
. 0

Evolutionary 0
relationships 0
among 0
putative 0
RNA B-gene
- I-gene
dependent I-gene
RNA I-gene
polymerases I-gene
encoded 0
by 0
a 0
mitochondrial 0
virus 0
- 0
like 0
RNA 0
in 0
the 0
Dutch 0
elm 0
disease 0
fungus 0
, 0
Ophiostoma 0
novo 0
- 0
ulmi 0
, 0
by 0
other 0
viruses 0
and 0
virus 0
- 0
like 0
RNAs 0
and 0
by 0
the 0
Arabidopsis 0
mitochondrial 0
genome 0
. 0

Role 0
of 0
the 0
transcription 0
start 0
site 0
core 0
region 0
and 0
transcription B-gene
factor I-gene
YY1 I-gene
in 0
Rous B-gene
sarcoma I-gene
virus I-gene
long I-gene
terminal I-gene
repeat I-gene
promoter I-gene
activity 0
. 0

Fowlpox 0
virus 0
encodes 0
nonessential 0
homologs 0
of 0
cellular B-gene
alpha I-gene
- I-gene
SNAP I-gene
, 0
PC B-gene
- I-gene
1 I-gene
, 0
and 0
an 0
orphan 0
human 0
homolog 0
of 0
a 0
secreted 0
nematode 0
protein 0
. 0

Addition 0
of 0
Rap 0
or 0
KN62 0
after 0
exposure 0
of 0
cells 0
to 0
progesterone 0
agonist 0
Org 0
2058 0
had 0
no 0
effect 0
on 0
induction 0
of 0
CAT B-gene
activity 0
. 0

The 0
Dax B-gene
- I-gene
1 I-gene
gene I-gene
encodes 0
a 0
protein 0
that 0
is 0
structurally 0
related 0
to 0
members 0
of 0
the 0
orphan B-gene
nuclear I-gene
receptor I-gene
superfamily I-gene
. 0

He 0
was 0
administered 0
recombinant B-gene
IFN I-gene
alpha I-gene
- I-gene
2b I-gene
under 0
the 0
diagnosis 0
of 0
chronic 0
hepatitis 0
C 0
. 0

Further 0
, 0
Ser/Thr 0
phosphorylation 0
of 0
downstream 0
molecules 0
Akt B-gene
and 0
p70 B-gene
S6 I-gene
kinase I-gene
was 0
inhibited 0
. 0

Quantitative 0
evaluation 0
of 0
the 0
steady 0
state 0
kinetics 0
of 0
MEK B-gene
inhibition 0
by 0
these 0
compounds 0
reveals 0
that 0
U0126 0
has 0
approximately 0
100 0
- 0
fold 0
higher 0
affinity 0
for 0
deltaN3 B-gene
- I-gene
S218E/S222D I-gene
MEK I-gene
than 0
does 0
PD098059 0
. 0

Regulation 0
at 0
37 0
degrees 0
C 0
, 0
therefore 0
, 0
involves 0
the 0
action 0
of 0
three 0
protein 0
kinase 0
cascades 0
that 0
repress 0
HSF1 B-gene
through 0
phosphorylation 0
of 0
serine 0
residues 0
303 0
, 0
307 0
, 0
and 0
363 0
and 0
may 0
promote 0
growth 0
by 0
suppressing 0
the 0
heat 0
shock 0
response 0
. 0

Clinical 0
implication 0
of 0
protein 0
levels 0
of 0
IL B-gene
- I-gene
5 I-gene
in 0
induced 0
sputum 0
in 0
asthmatic 0
patients 0
. 0

In 0
these 0
cells 0
, 0
ras B-gene
- 0
induced 0
transition 0
is 0
accompanied 0
by 0
a 0
strong 0
induction 0
of 0
AP B-gene
- I-gene
1 I-gene
- 0
binding 0
activity 0
along 0
with 0
increased 0
expression 0
of 0
CD44 B-gene
mRNA I-gene
and 0
protein 0
. 0

However 0
, 0
little 0
is 0
known 0
regarding 0
the 0
genomic 0
organization 0
and 0
developmental 0
expression 0
of 0
the 0
caveolin B-gene
gene I-gene
family I-gene
. 0

Tensile 0
bond 0
strengths 0
between 0
resin 0
composite 0
and 0
bovine 0
dentin 0
using 0
dentin 0
adhesive 0
systems 0
( 0
Clearfil 0
Liner 0
Bond 0
II 0
: 0
LB 0
II 0
; 0
Scotchbond 0
Multi 0
- 0
Purpose 0
: 0
MP 0
) 0
bonding 0
systems 0
showed 0
a 0
large 0
scatter 0
among 0
students 0
and 0
dentists 0
. 0

This 0
distribution 0
implies 0
that 0
the 0
polycistronic 0
precursor 0
is 0
imported 0
into 0
the 0
nucleolus 0
for 0
processing 0
to 0
the 0
mature 0
snoRNAs 0
, 0
and 0
that 0
the 0
import 0
or 0
processing 0
pathway 0
involves 0
coiled 0
bodies 0
. 0

Suppressive 0
therapy 0
for 0
thyroid 0
nodules 0
. 0

Fourteen 0
healthy 0
male 0
volunteers 0
completed 0
the 0
study 0
. 0

In 0
the 0
absence 0
of 0
Mg2+ 0
, 0
a 0
hydrophobic 0
exonuclease 0
site 0
dominates 0
over 0
the 0
polymerase 0
site 0
for 0
possession 0
of 0
the 0
primer 0
terminus 0
. 0

As 0
the 0
high 0
- 0
affinity 0
Mg2+ 0
binding 0
sites 0
are 0
filled 0
, 0
the 0
primer 0
terminus 0
migrates 0
from 0
the 0
exonuclease 0
site 0
to 0
a 0
highly 0
based 0
stacked 0
polymerase 0
active 0
site 0
. 0

One 0
missense 0
allele 0
( 0
P236S 0
) 0
with 0
complete 0
loss 0
of 0
function 0
at 0
30 0
degreesC 0
and 0
four 0
missense 0
alleles 0
( 0
L173F 0
, 0
E225K 0
, 0
S269L 0
and 0
E274K 0
) 0
that 0
conferred 0
a 0
temperature 0
sensitive 0
phenotype 0
were 0
identified 0
. 0

Structural 0
analysis 0
of 0
the 0
5' 0
- 0
regulatory 0
region 0
reveals 0
that 0
the 0
c B-gene
- I-gene
met I-gene
promoter I-gene
lacks 0
TATA 0
or 0
CAAT 0
elements 0
but 0
has 0
an 0
extremely 0
high 0
G 0
- 0
C 0
content 0
and 0
multiple 0
Sp1 B-gene
binding I-gene
sites I-gene
. 0

The 0
report 0
highlights 0
the 0
possible 0
contribution 0
of 0
stress 0
factors 0
in 0
the 0
context 0
of 0
therapy 0
resistant 0
periodontal 0
disease 0
, 0
and 0
the 0
results 0
seem 0
to 0
be 0
understandable 0
within 0
the 0
context 0
of 0
a 0
stress 0
system 0
disorder 0
perspective 0
. 0

Acute 0
pancreatitis 0
is 0
a 0
rather 0
common 0
abdominal 0
disorder 0
. 0

To 0
better 0
understand 0
the 0
role 0
of 0
Ets B-gene
proteins I-gene
in 0
Ras B-gene
transformation 0
, 0
we 0
have 0
now 0
analyzed 0
the 0
effects 0
of 0
stably 0
expressing 0
a 0
variety 0
of 0
Ets2 B-gene
constructs I-gene
in 0
Ras B-gene
- 0
transformed 0
NIH3T3 0
( 0
DT 0
) 0
cells 0
. 0

Each 0
binding 0
site 0
, 0
however 0
, 0
was 0
different 0
in 0
its 0
preference 0
for 0
binding 0
partners 0
. 0

We 0
isolated 0
the 0
human B-gene
FGF I-gene
- I-gene
BP I-gene
promoter I-gene
and 0
determined 0
by 0
deletion 0
analysis 0
that 0
TPA 0
regulatory 0
elements 0
were 0
all 0
contained 0
in 0
the 0
first 0
118 0
base 0
pairs 0
upstream 0
of 0
the 0
transcription 0
start 0
site 0
. 0

Manipulation 0
of 0
the 0
checkpoint 0
regulators 0
involved 0
in 0
cell 0
cycle 0
arrest 0
and 0
apoptosis 0
may 0
thus 0
provide 0
a 0
novel 0
strategy 0
to 0
cancer 0
therapy 0
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
demonstrated 0
specific 0
nuclear 0
protein 0
binding 0
to 0
- 0
85/ 0
- 0
64 0
, 0
and 0
single 0
point 0
mutations 0
suggested 0
important 0
binding 0
nucleotides 0
between 0
- 0
79/ 0
- 0
68 0
with 0
five 0
critical 0
bases 0
between 0
- 0
74/ 0
- 0
70 0
( 0
5' 0
- 0
CTCCT 0
- 0
3 0
' 0
) 0
. 0

The 0
diagnostic 0
accuracy 0
of 0
serum 0
PE B-gene
- I-gene
1 I-gene
was 0
0.80 0
, 0
and 0
that 0
of 0
amylase B-gene
0.97 0
. 0

We 0
demonstrate 0
that 0
Ddc1p B-gene
interacts 0
physically 0
in 0
vivo 0
with 0
Mec3p B-gene
, 0
and 0
this 0
interaction 0
requires 0
Rad17p B-gene
. 0

`` 0
Complex 0
partial 0
'' 0
seizures 0
. 0

B B-gene
cell I-gene
antigen I-gene
receptor I-gene
( 0
BCR B-gene
) 0
- 0
mediated 0
formation 0
of 0
a 0
SHP B-gene
- I-gene
2 I-gene
- 0
pp120 B-gene
complex 0
and 0
its 0
inhibition 0
by 0
Fc B-gene
gamma I-gene
RIIB1 I-gene
- 0
BCR B-gene
coligation 0
. 0

Chem. 0
, 0
270 0
: 0
7117 0
- 0
7124 0
, 0
1995 0
; 0
and 0
MT 0
Hartsough 0
et 0
al. 0
, 0
J 0
. 0

Deleting 0
SNF1 B-gene
repressed 0
meiosis 0
at 0
the 0
same 0
three 0
steps 0
that 0
were 0
inhibited 0
by 0
glucose 0
, 0
suggesting 0
that 0
glucose 0
blocks 0
meiosis 0
by 0
inhibiting 0
Snf1 B-gene
. 0

Here 0
we 0
investigate 0
the 0
role 0
of 0
c B-gene
- I-gene
Cbl I-gene
in 0
development 0
and 0
homeostasis 0
in 0
mice 0
by 0
targeted 0
disruption 0
of 0
the 0
c B-gene
- I-gene
Cbl I-gene
locus I-gene
. 0
c B-gene
- I-gene
Cbl I-gene
- 0
deficient 0
mice 0
were 0
viable 0
, 0
fertile 0
, 0
and 0
outwardly 0
normal 0
in 0
appearance 0
. 0

One 0
is 0
to 0
act 0
within 0
the 0
visceral 0
endoderm 0
to 0
promote 0
proper 0
streak 0
morphogenesis 0
. 0

We 0
propose 0
that 0
noi/pax2.1 B-gene
participates 0
in 0
sequential 0
signaling 0
processes 0
as 0
a 0
key 0
integrator 0
of 0
midbrain 0
- 0
hindbrain 0
boundary 0
development 0
. 0

Ligand 0
- 0
independent 0
activation 0
of 0
platelet B-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
receptor I-gene
is 0
a 0
necessary 0
intermediate 0
in 0
lysophosphatidic 0
, 0
acid 0
- 0
stimulated 0
mitogenic 0
activity 0
in 0
L 0
cells 0
. 0

METHODS 0
: 0
Fibrotic 0
changes 0
involving 0
bone 0
marrow 0
were 0
evaluated 0
histologically 0
semiquantitatively 0
using 0
reticulin B-gene
fiber 0
impregnation 0
( 0
method 0
of 0
Gomori 0
) 0
. 0

In 0
canrenoate 0
- 0
treated 0
rats 0
, 0
ANP B-gene
infusion 0
caused 0
greater 0
increases 0
in 0
sodium 0
excretion 0
( 0
FENA 0
from 0
3.05 0
+/ 0
- 0
0.71 0
to 0
7.21 0
+/ 0
- 0
0.45 0
% 0
; 0
P 0
< 0
0.05 0
; 0
n 0
= 0
8 0
) 0
than 0
saline 0
infusion 0
( 0
FENA 0
from 0
4.16 0
+/ 0
- 0
1.11 0
to 0
5.47 0
+/ 0
- 0
0.66 0
% 0
; 0
n 0
= 0
6 0
) 0
, 0
despite 0
the 0
hypocapnia 0
. 0

We 0
then 0
studied 0
four 0
unrelated 0
Japanese 0
families 0
with 0
GSD 0
- 0
Ib 0
, 0
and 0
found 0
three 0
novel 0
mutations 0
: 0
a 0
four 0
- 0
base 0
deletion/two 0
- 0
base 0
insertion 0
, 0
a 0
point 0
mutation 0
within 0
a 0
consensus 0
splicing 0
donor 0
site 0
, 0
and 0
a 0
missense 0
mutation 0
( 0
W118R 0
) 0
. 0

Removal 0
of 0
the 0
carboxyl 0
region 0
severely 0
reduced 0
transcriptional 0
activation 0
. 0

A 0
`` 0
Level 0
A 0
'' 0
in 0
vitro/in 0
vivo 0
correlation 0
was 0
established 0
for 0
a 0
sustained 0
release 0
theophylline 0
( 0
CAS 0
58 0
- 0
55 0
- 0
9 0
) 0
preparation 0
( 0
Bronchoretard 0
) 0
under 0
investigation 0
. 0

METHOD 0
: 0
50 0
consecutive 0
children 0
aged 0
from 0
6 0
months 0
to 0
17 0
years 0
were 0
included 0
into 0
the 0
study 0
which 0
comprised 0
questionnaires 0
of 0
patient 0
and 0
family 0
histories 0
, 0
serological 0
screening 0
tests 0
for 0
common 0
inhalational 0
allergens 0
( 0
CAP 0
SX1 0
) 0
, 0
and 0
determination 0
of 0
total 0
serum B-gene
immunoglobulin I-gene
E I-gene
( 0
IgE B-gene
) 0
and 0
of 0
latex 0
- 0
specific 0
serum B-gene
IgE I-gene
by 0
solid 0
- 0
phase 0
immunoassays 0
. 0

The 0
PDE4A B-gene
- I-gene
subfamily I-gene
- I-gene
specific I-gene
linker I-gene
region I-gene
LR1 0
, 0
which 0
joins 0
UCR1 0
and 0
UCR2 0
, 0
is 0
encoded 0
by 0
two 0
exons 0
, 0
whereas 0
LR2 0
, 0
which 0
joins 0
UCR2 0
to 0
the 0
catalytic 0
unit 0
, 0
is 0
encoded 0
by 0
a 0
single 0
exon 0
. 0

Pol32Delta B-gene
strains 0
are 0
weak 0
antimutators 0
and 0
are 0
defective 0
for 0
damage 0
- 0
induced 0
mutagenesis 0
. 0

At 0
the 0
same 0
time 0
, 0
the 0
results 0
indicate 0
that 0
p53 B-gene
plays 0
a 0
defensive 0
role 0
against 0
HBV 0
by 0
transcriptionally 0
repressing 0
the 0
HBV B-gene
core I-gene
promoter I-gene
through 0
liver B-gene
- I-gene
specific I-gene
enhancer I-gene
II I-gene
and 0
HBx B-gene
is 0
required 0
to 0
counteract 0
this 0
inhibitory 0
function 0
of 0
p53 B-gene
. 0

To 0
gain 0
insight 0
into 0
the 0
expression 0
of 0
the 0
AtCP1 B-gene
gene I-gene
, 0
northern 0
blot 0
analysis 0
was 0
carried 0
out 0
. 0

The 0
aim 0
of 0
the 0
study 0
was 0
to 0
correlate 0
the 0
responsiveness 0
to 0
bronchoprovocation 0
with 0
methacholine 0
in 0
subjects 0
a 0
with 0
allergic 0
rhinitis 0
during 0
and 0
out 0
of 0
the 0
pollen 0
season 0
with 0
total 0
serum 0
IgE B-gene
and 0
blood 0
eosinophils 0
. 0

These 0
results 0
provide 0
the 0
first 0
demonstration 0
that 0
an 0
SR B-gene
protein I-gene
can 0
influence 0
splicing 0
of 0
specific 0
pre 0
- 0
mRNAs 0
in 0
vivo 0
. 0

In 0
particular 0
, 0
the 0
potential 0
for 0
prostate 0
cancer 0
chemoprevention 0
using 0
nonsteroidal 0
anti 0
- 0
inflammatory 0
drugs 0
( 0
cyclo B-gene
- I-gene
oxygenase I-gene
inhibitors 0
; 0
NSAIDs 0
) 0
has 0
received 0
little 0
attention 0
. 0

This 0
study 0
reports 0
the 0
isolation 0
of 0
a 0
P. 0
hybrida 0
gene 0
, 0
jaf13 B-gene
, 0
encoding 0
a 0
basic B-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
protein I-gene
that 0
, 0
on 0
the 0
basis 0
of 0
sequence 0
homology 0
and 0
intron/exon 0
structure 0
, 0
represents 0
the 0
P. 0
hybrida 0
orthologue 0
of 0
the 0
Z. B-gene
mays I-gene
r I-gene
genes I-gene
. 0

Identical 0
c B-gene
- I-gene
erbB3 I-gene
transcripts I-gene
are 0
expressed 0
in 0
normal 0
human 0
placental 0
tissues 0
. 0

During 0
the 0
past 0
4 0
years 0
, 0
a 0
purposeful 0
search 0
was 0
made 0
for 0
electrocardiograms 0
with 0
documented 0
reversible 0
QRS 0
changes 0
associated 0
with 0
all 0
acute 0
injury 0
pattern 0
. 0

Mutating 0
a 0
potential 0
cleavage 0
site 0
located 0
N 0
- 0
terminal 0
to 0
the 0
protease 0
domain 0
, 0
Gln2526 0
- 0
Asp2527 0
, 0
diminished 0
processing 0
. 0

METHODS 0
: 0
Millipore 0
ultrafiltration 0
membranes 0
of 0
three 0
different 0
pore 0
sizes 0
were 0
used 0
as 0
model 0
lenticule 0
materials.The 0
nominal 0
membrane 0
pore 0
sizes 0
were 0
0.1 0
microm 0
, 0
0.45 0
microm 0
, 0
and 0
3 0
microm 0
; 0
the 0
surface 0
roughness 0
increased 0
in 0
the 0
same 0
order 0
The 0
membranes 0
were 0
coated 0
with 0
a 0
thin 0
layer 0
of 0
collagen B-gene
I I-gene
and 0
implanted 0
in 0
a 0
circular 0
pocket 0
of 0
the 0
anterior 0
cornea 0
of 0
adult 0
cats 0
, 0
and 0
were 0
clinically 0
evaluated 0
for 0
the 0
extent 0
of 0
epithelialization 0
and 0
the 0
persistence 0
of 0
epithelial 0
attachment 0
. 0

The 0
role 0
of 0
calcitonin B-gene
, 0
and 0
other 0
agonists 0
which 0
activate 0
the 0
cAMP 0
pathway 0
, 0
in 0
regulating 0
transcription 0
of 0
the 0
human B-gene
parathyroid I-gene
hormone I-gene
- I-gene
related I-gene
protein I-gene
( 0
PTHrP B-gene
) 0
gene 0
was 0
investigated 0
in 0
a 0
human 0
lung 0
cancer 0
cell 0
line 0
( 0
BEN 0
) 0
. 0

The 0
combination 0
of 0
Pitx2 B-gene
and 0
another 0
homeodomain B-gene
protein I-gene
, 0
Pit B-gene
- I-gene
1 I-gene
, 0
yielded 0
a 0
synergistic 0
55 0
- 0
fold 0
activation 0
of 0
the 0
prolactin B-gene
promoter I-gene
in 0
transfection 0
assays 0
. 0

The 0
biochemical 0
and 0
molecular 0
spectrum 0
of 0
ornithine B-gene
transcarbamylase I-gene
deficiency 0
. 0

To 0
further 0
understand 0
the 0
role 0
of 0
cis 0
- 0
acting 0
elements 0
in 0
these 0
regulatory 0
mechanisms 0
, 0
we 0
have 0
characterized 0
a 0
transcriptional 0
promoter 0
that 0
drives 0
germline 0
expression 0
of 0
TCR B-gene
beta I-gene
gene I-gene
segments I-gene
in 0
vivo 0
. 0

Our 0
results 0
suggest 0
that 0
the 0
crucial 0
role 0
of 0
the 0
mutations 0
activating 0
v B-gene
- I-gene
erbA I-gene
as 0
an 0
oncogene 0
is 0
to 0
'freeze 0
' 0
c B-gene
- I-gene
ErbA/ I-gene
TRalpha B-gene
in 0
its 0
non 0
- 0
liganded 0
, 0
repressive 0
conformation 0
and 0
to 0
facilitate 0
its 0
overexpression 0
. 0

Downregulation 0
of 0
FUS B-gene
expression 0
in 0
BCR/ABL B-gene
- 0
expressing 0
32Dcl3 0
cells 0
was 0
associated 0
with 0
suppression 0
of 0
growth 0
factor 0
- 0
independent 0
colony 0
formation 0
, 0
restoration 0
of 0
BCR/ABL I-gene

In 0
this 0
study 0
, 0
we 0
describe 0
a 0
mammalian 0
cell 0
- 0
free 0
transcription 0
system 0
reconstituted 0
with 0
only 0
recombinant 0
proteins 0
and 0
epitope 0
- 0
tagged 0
multiprotein 0
complexes 0
. 0

This 0
repressor 0
is 0
however 0
unlikely 0
to 0
mediate 0
spi B-gene
2.3 I-gene
3 I-gene
' I-gene
UTR I-gene
silencer I-gene
action 0
since 0
it 0
was 0
not 0
detected 0
in 0
rat 0
hepatocytes 0
. 0

A 0
prerequisite 0
for 0
the 0
synthesis 0
of 0
sialylated 0
glycoconjugates 0
is 0
the 0
activated 0
sugar 0
- 0
nucleotide 0
cytidine 0
5' 0
- 0
monophosphate 0
N 0
- 0
acetylneuraminic 0
acid 0
( 0
CMP 0
- 0
Neu5Ac 0
) 0
, 0
which 0
provides 0
a 0
substrate 0
for 0
Golgi B-gene
sialyltransferases I-gene
. 0

Thus 0
, 0
the 0
bovine B-gene
PEDF I-gene
cDNA I-gene
isolated 0
here 0
codes 0
for 0
a 0
functional 0
soluble 0
secreted B-gene
PEDF I-gene
glycoprotein I-gene
. 0

We 0
propose 0
a 0
model 0
in 0
which 0
Sro7 B-gene
function 0
is 0
involved 0
in 0
the 0
targeting 0
of 0
the 0
myosin B-gene
proteins I-gene
to 0
their 0
intrinsic 0
pathways 0
. 0

We 0
found 0
sequences 0
related 0
to 0
this 0
insertion 0
in 0
wild 0
- 0
type 0
strains 0
of 0
N. 0
crassa 0
and 0
other 0
Neurospora 0
species 0
. 0

When 0
cysteine 0
is 0
scanned 0
through 0
the 0
helices 0
, 0
characteristic 0
repeating 0
patterns 0
of 0
solvent 0
exposure 0
and 0
burial 0
are 0
observed 0
. 0

Human B-gene
ULK1 I-gene
, 0
a 0
novel 0
serine/threonine B-gene
kinase I-gene
related 0
to 0
UNC B-gene
- I-gene
51 I-gene
kinase I-gene
of 0
Caenorhabditis 0
elegans 0
: 0
cDNA 0
cloning 0
, 0
expression 0
, 0
and 0
chromosomal 0
assignment 0
. 0

Specifically 0
, 0
I 0
use 0
molecular 0
markers 0
that 0
identify 0
particular 0
neuroectodermal 0
domains 0
, 0
all 0
neuroblasts 0
or 0
individual 0
neuroblasts 0
, 0
to 0
show 0
that 0
in 0
DER B-gene
mutant I-gene
embryos 0
( 0
1 0
) 0
intermediate 0
column 0
neuroblasts 0
do 0
not 0
form 0
, 0
( 0
2 0
) 0
medial 0
column 0
neuroblasts 0
often 0
acquire 0
identities 0
inappropriate 0
for 0
their 0
position 0
, 0
while 0
( 0
3 0
) 0
lateral 0
neuroblasts 0
develop 0
normally 0
. 0

Cochlear 0
microphonic 0
potentials 0
in 0
patients 0
with 0
vestibular 0
schwannomas 0
. 0

These 0
results 0
with 0
clozapine 0
illustrate 0
that 0
LI 0
is 0
sensitive 0
to 0
antipsychotics 0
which 0
differ 0
in 0
their 0
mode 0
of 0
action 0
and 0
furthermore 0
emphasize 0
the 0
value 0
of 0
LI 0
as 0
a 0
test 0
model 0
for 0
detecting 0
the 0
antipsychotic 0
potential 0
of 0
novel 0
drugs 0
. 0

The 0
complement B-gene
C3a I-gene
anaphylatoxin I-gene
receptor I-gene
( 0
C3aR B-gene
) 0
is 0
a 0
seven B-gene
- I-gene
transmembrane I-gene
G I-gene
- I-gene
protein I-gene
coupled I-gene
chemoattractant I-gene
receptor I-gene
that 0
on 0
binding 0
the 0
C3a B-gene
peptide I-gene
ligand I-gene
mediates 0
numerous 0
cellular 0
responses 0
, 0
including 0
histamine 0
release 0
from 0
mast 0
cells 0
. 0
smooth 0
muscle 0
contraction 0
, 0
and 0
the 0
directed 0
migration 0
of 0
eosinophils 0
. 0

CONCLUSIONS 0
: 0
Significant 0
elevations 0
of 0
IL B-gene
- I-gene
1alpha I-gene
and 0
IL B-gene
- I-gene
1beta I-gene
occur 0
in 0
patients 0
with 0
bacterial 0
cystitis 0
and 0
microscopic 0
hematuria 0
. 0

Band 0
- 0
shift 0
assays 0
were 0
performed 0
using 0
the 0
LPS B-gene
- I-gene
and I-gene
IL I-gene
- I-gene
1 I-gene
- I-gene
responsive I-gene
element I-gene
( 0
LILRE B-gene
) 0
oligonucleotide 0
, 0
a 0
gamma B-gene
interferon I-gene
activation I-gene
site I-gene
- I-gene
like I-gene
site I-gene
that 0
is 0
present 0
in 0
the 0
human B-gene
IL I-gene
- I-gene
1beta I-gene
promoter I-gene
. 0

The 0
C 0
- 0
terminal 0
region 0
contains 0
the 0
PTP B-gene
- I-gene
like I-gene
domain I-gene
, 0
whereas 0
the 0
N 0
- 0
terminal 0
region 0
shows 0
no 0
homology 0
to 0
any 0
known 0
mammalian 0
protein 0
. 0

In 0
addition 0
, 0
and 0
in 0
support 0
of 0
a 0
mediating 0
role 0
of 0
STATs B-gene
in 0
the 0
activation 0
of 0
the 0
p21 B-gene
promoter I-gene
, 0
overexpression 0
of 0
Stat3 B-gene
potentiated 0
the 0
cytokine 0
effect 0
on 0
the 0
p21 B-gene
promoter I-gene
; 0
whereas 0
a 0
dominant B-gene
negative I-gene
Stat3 I-gene
, 0
or 0
a 0
mutation 0
of 0
the 0
STAT B-gene
response I-gene
element I-gene
on 0
the 0
promoter 0
, 0
significantly 0
reduced 0
the 0
cytokine 0
effect 0
. 0

The 0
heterogeneous 0
nuclear B-gene
ribonucleoprotein I-gene
C I-gene
protein I-gene
tetramer I-gene
binds 0
U1 B-gene
, 0
U2 B-gene
, 0
and 0
U6 B-gene
snRNAs I-gene
through 0
its 0
high 0
affinity 0
RNA 0
binding 0
domain 0
( 0
the 0
bZIP 0
- 0
like 0
motif 0
) 0
. 0

On 0
the 0
comparison 0
of 0
correlated 0
proportions 0
for 0
clustered 0
data 0
. 0

A 0
safe 0
and 0
simple 0
system 0
for 0
the 0
detection 0
of 0
sudden 0
infant 0
death 0
syndrome 0
( 0
SIDS 0
) 0
is 0
proposed 0
. 0

The 0
resulting 0
mutants 0
were 0
coexpressed 0
with 0
gE B-gene
in 0
the 0
vaccinia 0
virus 0
- 0
based 0
vTF7 0
- 0
3 0
system 0
, 0
and 0
the 0
formation 0
and 0
endoplasmic 0
reticulum 0
( 0
ER 0
) 0
- 0
to 0
- 0
Golgi 0
transport 0
of 0
the 0
hetero 0
- 0
oligomeric 0
complex 0
were 0
monitored 0
. 0

Homozygous 0
mutant 0
mice 0
, 0
designated 0
Cux/CDPDeltaCR1 B-gene
, 0
display 0
a 0
phenotype 0
characterized 0
by 0
curly 0
vibrissae 0
and 0
wavy 0
hair 0
. 0

The 0
mutant 0
protein 0
is 0
present 0
at 0
levels 0
slightly 0
greater 0
than 0
wild 0
- 0
type 0
, 0
but 0
exhibits 0
the 0
same 0
tissue 0
distribution 0
as 0
wild 0
- 0
type 0
protein 0
, 0
and 0
has 0
approximately 0
normal 0
affinity 0
for 0
known 0
target 0
sequences 0
( 0
though 0
no 0
DNA 0
targets 0
identified 0
to 0
date 0
require 0
the 0
first 0
cut 0
repeat 0
for 0
binding 0
) 0
. 0

METHODS 0
: 0
We 0
retrospectively 0
reviewed 0
242 0
adult 0
cadaveric 0
renal 0
transplant 0
recipients 0
treated 0
between 0
11/91 0
and 0
5/97 0
. 0

The 0
spectrum 0
of 0
age 0
- 0
associated 0
brain 0
abnormalities 0
: 0
their 0
measurement 0
and 0
histopathological 0
correlates 0
. 0

Our 0
laboratory 0
has 0
recently 0
identified 0
two 0
phosducin B-gene
- I-gene
like I-gene
orphan I-gene
proteins I-gene
( 0
PhLOP1 B-gene
and 0
PhLOP2 B-gene
) 0
that 0
lack 0
the 0
ability 0
to 0
interact 0
with 0
Gbetagamma B-gene
. 0

Reverse B-gene
transcriptase I-gene
- 0
polymerase 0
chain 0
reaction 0
( 0
RT B-gene
- 0
PCR 0
) 0
was 0
performed 0
using 0
eyestalk 0
complementary 0
DNA 0
of 0
the 0
sand 0
shrimp 0
Metapenaeus 0
ensis 0
. 0

In 0
contrast 0
, 0
transcription 0
initiating 0
from 0
opuE B-gene
P I-gene
- I-gene
1 I-gene
( 0
sigma B-gene
A I-gene
) 0
rose 0
in 0
proportion 0
to 0
the 0
external 0
osmolarity 0
and 0
was 0
maintained 0
at 0
high 0
levels 0
. 0

Randomly 0
selected 0
300 0
children 0
aged 0
3 0
months 0
- 0
3 0
yr 0
were 0
analysed 0
over 0
a 0
period 0
of 0
one 0
year 0
for 0
estimating 0
prevalence 0
of 0
nutritional 0
anaemia 0
. 0

In 0
insects 0
, 0
arylalkylamine B-gene
N I-gene
- I-gene
acetyltransferases I-gene
( 0
AANATs B-gene
) 0
have 0
been 0
implicated 0
in 0
several 0
physiological 0
processes 0
, 0
including 0
sclerotization 0
, 0
inactivation 0
of 0
certain 0
neurotransmitters 0
, 0
and 0
, 0
similar 0
to 0
the 0
function 0
in 0
vertebrates 0
, 0
catalysis 0
of 0
the 0
rate 0
- 0
limiting 0
step 0
in 0
melatonin 0
biosynthesis 0
. 0

In 0
experiments 0
with 0
the 0
D1 0
antagonist 0
SCH 0
23390 0
, 0
buprenorphine 0
- 0
induced 0
depression 0
was 0
consistently 0
blocked 0
, 0
but 0
facilitation 0
was 0
unaffected 0
. 0

These 0
results 0
establish 0
that 0
hydroquinones 0
lead 0
to 0
mutagenicity 0
and 0
carcinogenicity 0
. 0

IA 0
- 0
CT 0
with 0
cisplatin 0
50 0
mg 0
and 0
doxorubicin 0
30 0
mg 0
was 0
administered 0
by 0
one 0
shot 0
method 0
in 0
bilateral 0
internal 0
iliac 0
arteries 0
. 0

Arnt3 B-gene
mRNA I-gene
was 0
expressed 0
in 0
brain 0
, 0
skeletal 0
muscle 0
, 0
13.5 0
- 0
day 0
embryos 0
, 0
and 0
P19 0
cells 0
treated 0
with 0
retinoic 0
acid 0
. 0

Acute 0
idiopathic 0
thrombocytopenic 0
purpura 0
presenting 0
a 0
high 0
serum 0
level 0
of 0
immunoglobulin B-gene
E I-gene
and 0
eosinophilia 0
in 0
an 0
elderly 0
patient 0
. 0

The 0
genomic 0
structure 0
and 0
chromosomal 0
location 0
of 0
the 0
human B-gene
TR2 I-gene
orphan I-gene
receptor I-gene
, 0
a 0
member 0
of 0
the 0
steroid B-gene
receptor I-gene
superfamily I-gene
. 0

Correlation 0
of 0
skin 0
disorders 0
with 0
CD4 B-gene
lymphocyte 0
counts 0
in 0
patients 0
with 0
HIV/AIDS 0
. 0

E2F B-gene
- I-gene
6 I-gene
shares 0
significant 0
homology 0
with 0
E2Fs B-gene
1 I-gene
- I-gene
5 I-gene
, 0
especially 0
within 0
the 0
DNA 0
binding 0
, 0
heterodimerization 0
and 0
marked 0
box 0
domains 0
. 0

The 0
IE13.1 0
cell 0
line 0
was 0
able 0
to 0
complement 0
a 0
recombinant 0
virus 0
in 0
which 0
both 0
copies 0
of 0
the 0
IE B-gene
gene I-gene
were 0
replaced 0
by 0
insertion 0
of 0
the 0
Escherichia B-gene
coli I-gene
lacZ I-gene
gene I-gene
. 0

DNase B-gene
I I-gene
footprinting 0
and 0
electrophoretic 0
mobility 0
shift 0
analyses 0
revealed 0
two 0
hepatocyte B-gene
nuclear I-gene
factor I-gene
- I-gene
1 I-gene
( 0
HNF1 B-gene
) 0
, 0
three 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
( 0
C/EBP B-gene
) 0
, 0
and 0
one 0
consensus 0
palindromic 0
thyroid 0
hormone 0
response 0
elements 0
within 0
the 0
first 0
215 0
base 0
pairs 0
( 0
bp 0
) 0
of 0
the 0
promoter 0
sequence 0
of 0
rat B-gene
Std I-gene
. 0

Thus 0
, 0
these 0
studies 0
on 0
rat B-gene
Std I-gene
promoter I-gene
function 0
indicate 0
that 0
( 0
i 0
) 0
HNF1 B-gene
and 0
C/EBP B-gene
are 0
responsible 0
for 0
liver 0
specificity 0
of 0
the 0
rat B-gene
Std I-gene
gene I-gene
; 0
( 0
ii 0
) 0
androgenic 0
repression 0
of 0
the 0
gene 0
requires 0
the 0
presence 0
of 0
all 0
of 0
the 0
OCT B-gene
- I-gene
1 I-gene
and 0
C/EBP B-gene
elements I-gene
between 0
positions 0
- 0
231 0
and 0
- 0
292 0
; 0
and 0
( 0
iii 0
) 0
AR B-gene
may 0
exert 0
its 0
negative 0
regulatory 0
effect 0
indirectly 0
through 0
transcriptional 0
interference 0
of 0
OCT B-gene
- I-gene
1 I-gene
and 0
C/EBP B-gene
rather 0
than 0
through 0
a 0
direct 0
DNA B-gene
- I-gene
AR I-gene
interaction 0
. 0

Purified 0
Hsk1 B-gene
phosphorylates 0
the 0
Cdc19 B-gene
( 0
Mcm2 B-gene
) 0
subunit 0
of 0
the 0
six B-gene
- I-gene
member I-gene
minichromosome I-gene
maintenance I-gene
protein I-gene
complex I-gene
purified 0
from 0
fission 0
yeast 0
. 0

The 0
yeast B-gene
MMS2 I-gene
gene I-gene
was 0
cloned 0
by 0
its 0
ability 0
to 0
complement 0
the 0
methyl 0
methanesulfonate 0
sensitivity 0
of 0
the 0
mms2 B-gene
- I-gene
1 I-gene
mutant I-gene
and 0
was 0
later 0
shown 0
to 0
be 0
involved 0
in 0
DNA 0
post 0
- 0
replication 0
repair 0
. 0

Expression 0
of 0
the 0
human B-gene
papillomavirus I-gene
type I-gene
11 I-gene
E5A I-gene
protein I-gene
from 0
the 0
E1E4 B-gene
, I-gene
E5 I-gene
transcript I-gene
. 0

Anesthesia 0
with 0
M/K 0
was 0
reversed 0
after 0
41.6 0
min 0
of 0
immobilization 0
with 0
atipamezole 0
. 0

There 0
was 0
no 0
evident 0
inciting 0
agent 0
of 0
the 0
disease 0
. 0

MK 0
- 0
801 0
administration 0
resulted 0
in 0
a 0
biphasic 0
response 0
in 0
seizure 0
latency 0
. 0

In 0
contrast 0
, 0
the 0
distribution 0
of 0
endocytic 0
markers 0
is 0
not 0
affected 0
. 0

Toxicity 0
during 0
the 0
therapeutic 0
period 0
was 0
not 0
significant 0
in 0
the 0
study 0
group 0
compared 0
with 0
the 0
historical 0
control 0
, 0
treated 0
with 0
the 0
same 0
regimen 0
without 0
G B-gene
- I-gene
CSF I-gene
. 0

The 0
purpose 0
of 0
this 0
article 0
is 0
to 0
discuss 0
the 0
factors 0
involved 0
in 0
the 0
selection 0
of 0
antibodies 0
, 0
radionuclides 0
and 0
labeling 0
methods 0
in 0
the 0
development 0
of 0
radioimmunotherapy 0
( 0
RIT 0
) 0
for 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
( 0
NHL 0
) 0
from 0
a 0
single 0
clinical 0
study 0
site 0
through 0
multicenter 0
trials 0
and 0
commercialization 0
. 0

Both 0
methods 0
were 0
employed 0
for 0
various 0
focal 0
- 0
film 0
distances 0
, 0
image 0
intensifier 0
tube 0
modes 0
and 0
laser 0
printer 0
formats 0
. 0

The 0
effect 0
of 0
Rho B-gene
on 0
AP B-gene
- I-gene
1 I-gene
is 0
independent 0
of 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
pathway 0
, 0
as 0
a 0
dominant B-gene
- I-gene
negative I-gene
MEK I-gene
and 0
a 0
MEK B-gene
inhibitor 0
( 0
PD98059 0
) 0
did 0
not 0
affect 0
Rho B-gene
- 0
induced 0
AP B-gene
- I-gene
1 I-gene
activity 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
of 0
residues 0
in 0
this 0
domain 0
( 0
R82A 0
, 0
K85A 0
, 0
K88A 0
, 0
and 0
V89A 0
) 0
resulted 0
in 0
proteins 0
which 0
failed 0
to 0
transactivate 0
from 0
the 0
HTLV B-gene
- I-gene
1 I-gene
LTR I-gene
in 0
vivo 0
. 0

Mutations 0
within 0
the 0
C 0
terminus 0
of 0
c B-gene
- I-gene
fos I-gene
at 0
serine 0
residues 0
that 0
are 0
phosphorylation 0
targets 0
for 0
growth 0
factors 0
and 0
MAP B-gene
kinase I-gene
completely 0
abrogate 0
transactivation 0
and 0
block 0
potentiation 0
by 0
MAP B-gene
kinase I-gene
. 0

In 0
the 0
former 0
cells 0
, 0
ets B-gene
- I-gene
2 I-gene
was 0
a 0
CSF B-gene
- I-gene
1 I-gene
immediate 0
- 0
early 0
response 0
gene 0
, 0
and 0
phosphorylated 0
ets B-gene
- I-gene
2 I-gene
was 0
detected 0
after 0
2 0
to 0
4 0
h 0
, 0
coincident 0
with 0
expression 0
of 0
ets B-gene
- I-gene
2 I-gene
protein I-gene
. 0

Persistent 0
activation 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinases I-gene
p42 I-gene
and 0
p44 B-gene
and 0
ets B-gene
- I-gene
2 I-gene
phosphorylation 0
in 0
response 0
to 0
colony B-gene
- I-gene
stimulating I-gene
factor I-gene
1/c I-gene
1/c I-gene
- I-gene
fms I-gene
signaling 0
. 0

Identification 0
of 0
a 0
proline 0
- 0
rich 0
sequence 0
in 0
the 0
CD2 B-gene
cytoplasmic I-gene
domain I-gene
critical 0
for 0
regulation 0
of 0
integrin B-gene
- 0
mediated 0
adhesion 0
and 0
activation 0
of 0
phosphoinositide B-gene
3 I-gene
- I-gene
kinase I-gene
. 0

Vam7p B-gene
, 0
a 0
SNAP B-gene
- I-gene
25 I-gene
- I-gene
like I-gene
molecule I-gene
, 0
and 0
Vam3p B-gene
, 0
a 0
syntaxin B-gene
homolog I-gene
, 0
function 0
together 0
in 0
yeast 0
vacuolar 0
protein 0
trafficking 0
. 0

We 0
have 0
tested 0
this 0
possibility 0
by 0
constructing 0
a 0
consecutive 0
series 0
of 0
cysteine 0
substitutions 0
in 0
the 0
Neu B-gene
juxtamembrane I-gene
domain I-gene
in 0
order 0
to 0
force 0
dimerization 0
along 0
a 0
series 0
of 0
interreceptor 0
faces 0
. 0

It 0
has 0
been 0
demonstrated 0
previously 0
that 0
Pax B-gene
- I-gene
6 I-gene
, 0
a 0
paired B-gene
domain I-gene
( 0
PD B-gene
) 0
/homeodomain B-gene
( 0
HD B-gene
) 0
transcription 0
factor 0
critical 0
for 0
eye 0
development 0
, 0
contributes 0
to 0
the 0
activation 0
of 0
the 0
alphaB B-gene
- I-gene
, I-gene
alphaA I-gene
- I-gene
, I-gene
delta1 I-gene
- I-gene
, I-gene
and I-gene
zeta I-gene
- I-gene
crystallin I-gene
genes 0
in 0
the 0
lens 0
. 0

Tctex B-gene
- I-gene
1 I-gene
binding 0
required 0
the 0
first 0
19 0
amino 0
acids 0
of 0
Fyn B-gene
and 0
integrity 0
of 0
two 0
lysine 0
residues 0
within 0
this 0
sequence 0
that 0
were 0
previously 0
shown 0
to 0
be 0
important 0
for 0
Fyn B-gene
interactions 0
with 0
the 0
immunoreceptor 0
tyrosine 0
- 0
based 0
activation 0
motifs 0
( 0
ITAMs 0
) 0
of 0
lymphocyte B-gene
Ag I-gene
receptors I-gene
. 0

The 0
prothrombin B-gene
gene I-gene
G20210A I-gene
mutation I-gene
is 0
not 0
found 0
among 0
Japanese 0
patients 0
with 0
deep 0
vein 0
thrombosis 0
and 0
healthy 0
individuals 0
. 0

Transcriptional 0
regulation 0
of 0
the 0
GluR2 B-gene
gene I-gene
: 0
neural 0
- 0
specific 0
expression 0
, 0
multiple 0
promoters 0
, 0
and 0
regulatory 0
elements 0
. 0

The 0
binding 0
of 0
NF B-gene
- I-gene
ATp I-gene
, 0
although 0
not 0
NF B-gene
- I-gene
AT4 I-gene
, 0
to 0
this 0
enhancer 0
also 0
occurs 0
along 0
with 0
HTLV 0
- 0
I 0
- 0
mediated 0
infection 0
of 0
human 0
peripheral 0
blood 0
T 0
- 0
cells 0
. 0

Thus 0
, 0
TRAF2 B-gene
initiates 0
SAPK B-gene
and 0
p38 B-gene
activation 0
by 0
binding 0
two 0
proximal 0
protein 0
kinases 0
: 0
GCK B-gene
and 0
RIP B-gene
. 0

Tumor B-gene
necrosis I-gene
factor I-gene
signaling 0
to 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
SAPK B-gene
) 0
/Jun B-gene
NH2 I-gene
- I-gene
terminal I-gene
kinase I-gene
( 0
JNK B-gene
) 0
and 0
p38 B-gene
. 0

The 0
activity 0
of 0
the 0
minimal 0
promoter 0
was 0
found 0
to 0
be 0
controlled 0
by 0
a 0
combination 0
of 0
the 0
activities 0
of 0
the 0
transcription 0
factors 0
Sp1 B-gene
, 0
Sp3 B-gene
, 0
and 0
NF B-gene
- I-gene
Y I-gene
. 0

In 0
the 0
studies 0
described 0
in 0
this 0
report 0
, 0
we 0
have 0
investigated 0
the 0
signaling 0
pathway 0
( 0
s 0
) 0
that 0
are 0
responsible 0
for 0
CREB B-gene
activation 0
in 0
normal 0
T 0
cells 0
. 0

Respondents 0
who 0
lived 0
with 0
a 0
spouse/partner 0
only 0
were 0
less 0
likely 0
to 0
have 0
an 0
unfavorable 0
BMI 0
status 0
than 0
people 0
in 0
the 0
other 0
two 0
groups 0
. 0

Isolation 0
of 0
a 0
novel 0
TP53 B-gene
target I-gene
gene I-gene
from 0
a 0
colon 0
cancer 0
cell 0
line 0
carrying 0
a 0
highly 0
regulated 0
wild B-gene
- I-gene
type I-gene
TP53 I-gene
expression 0
system 0
. 0

Overexpression 0
of 0
MDR1 B-gene
has 0
been 0
demonstrated 0
in 0
many 0
cancers 0
, 0
both 0
in 0
patient 0
tumors 0
and 0
in 0
cell 0
lines 0
selected 0
with 0
a 0
variety 0
of 0
chemotherapeutic 0
agents 0
. 0

Cytogenetic 0
and 0
molecular 0
characterization 0
of 0
random 0
chromosomal 0
rearrangements 0
activating 0
the 0
drug 0
resistance 0
gene 0
, 0
MDR1/P B-gene
MDR1/P I-gene
- I-gene
glycoprotein I-gene
, 0
in 0
drug 0
- 0
selected 0
cell 0
lines 0
and 0
patients 0
with 0
drug 0
refractory 0
ALL 0
. 0

BACKGROUND 0
: 0
It 0
is 0
generally 0
accepted 0
that 0
smoking 0
increases 0
blood 0
pressure 0
and 0
inhibits 0
muscle 0
sympathetic 0
nerve 0
activity 0
( 0
SNA 0
) 0
. 0

When 0
the 0
blood 0
pressure 0
increase 0
in 0
response 0
to 0
smoking 0
was 0
blunted 0
by 0
nitroprusside 0
infusion 0
, 0
there 0
was 0
a 0
striking 0
increase 0
in 0
muscle 0
SNA 0
. 0

After 0
that 0
report 0
, 0
carboxypeptidase B-gene
D I-gene
( 0
CPD B-gene
) 0
was 0
subsequently 0
purified 0
from 0
bovine 0
pituitary 0
and 0
characterized 0
as 0
a 0
novel 0
carboxypeptidase B-gene
E I-gene
( 0
CPE B-gene
) 0
- 0
like 0
enzyme 0
, 0
with 0
many 0
characteristics 0
in 0
common 0
with 0
duck 0
gp180 B-gene
( 0
Song 0
, 0
L. 0
, 0
Fricker 0
, 0
L.D. 0
, 0
1995 0
. 0

RA 0
- 0
treatment 0
of 0
these 0
transfectants 0
induced 0
morphologic 0
and 0
immunophenotypic 0
maturation 0
, 0
changes 0
in 0
RA 0
- 0
regulated 0
genes 0
, 0
and 0
a 0
G1 0
cell 0
cycle 0
arrest 0
in 0
a 0
manner 0
similar 0
to 0
parental 0
NT2/D1 0
cells 0
. 0

The 0
histopathology 0
and 0
neovascularization 0
did 0
not 0
appreciably 0
differ 0
between 0
xenograft 0
tumors 0
derived 0
from 0
FGF4 B-gene
over 0
- 0
expressing 0
versus 0
control 0
transfectants 0
. 0

For 0
smaller 0
vessels 0
up 0
to 0
a 0
diameter 0
of 0
0.5 0
mm 0
, 0
treatments 0
at 0
16 0
and 0
18 0
J/cm2 0
showed 0
good 0
results 0
in 0
60 0
and 0
82 0
% 0
respectively 0
; 0
for 0
vessels 0
up 0
to 0
1 0
mm 0
in 0
27 0
and 0
33 0
% 0
. 0

Pressure 0
ulcers 0
. 0

RXR B-gene
- I-gene
gamma I-gene
expression 0
produced 0
significant 0
reduction 0
in 0
levels 0
of 0
RA 0
- 0
responsive 0
genes 0
including 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
inhibitors 0
p21Cip1/WAF1 B-gene
and 0
p21Cip1/WAF1 I-gene

TBP B-gene
can 0
be 0
phosphorylated 0
in 0
vitro 0
by 0
extracts 0
of 0
U937 0
cells 0
or 0
by 0
bacterially 0
expressed 0
activated 0
ERK2 B-gene
; 0
the 0
phosphorylation 0
sites 0
were 0
mapped 0
to 0
ERK B-gene
kinase I-gene
consensus I-gene
sites I-gene
in 0
the 0
TBP B-gene
amino I-gene
- I-gene
terminal I-gene
domain I-gene
. 0

During 0
the 0
CR/PP 0
diet 0
only 0
the 0
HS 0
subjects 0
did 0
not 0
show 0
the 0
stress 0
- 0
induced 0
rise 0
in 0
depression 0
, 0
decline 0
in 0
vigour 0
and 0
cortisol 0
elevation 0
that 0
they 0
showed 0
after 0
the 0
PR/CP 0
diet 0
. 0

Generally 0
ILC 0
and 0
ILVF 0
values 0
decreased 0
with 0
increasing 0
exposure 0
time 0
with 0
rate 0
constants 0
ranging 0
from 0
0.03 0
to 0
0.33 0
day 0
- 0
1 0
( 0
wet 0
and 0
lipid 0
weight 0
) 0
for 0
ILC 0
and 0
0.03 0
to 0
0.31 0
day 0
- 0
1 0
for 0
ILVF 0
. 0

These 0
sequence 0
analyses 0
suggest 0
that 0
xIRS B-gene
- I-gene
u I-gene
is 0
a 0
novel 0
member 0
of 0
the 0
IRS B-gene
family I-gene
rather 0
than 0
a 0
Xenopus 0
homolog 0
of 0
an 0
existing 0
member 0
. 0

The 0
present 0
study 0
sought 0
to 0
develop 0
an 0
equation 0
to 0
estimate 0
VO2peak 0
in 0
peripheral 0
arterial 0
occlusive 0
disease 0
( 0
PAOD 0
) 0
patients 0
with 0
intermittent 0
claudication 0
and 0
to 0
determine 0
independent 0
predictors 0
of 0
VO2peak 0
in 0
this 0
population 0
. 0

Evidence 0
for 0
a 0
novel 0
MAPKKK B-gene
- 0
independent 0
pathway 0
controlling 0
the 0
stress 0
activated 0
Sty1/Spc1 B-gene
MAP 0
kinase 0
in 0
fission 0
yeast 0
. 0

The 0
Abbreviated 0
Injury 0
Scale 0
( 0
AIS 0
) 0
, 0
Injury 0
Severity 0
Scale 0
and 0
TRISS 0
methodology 0
comprise 0
a 0
mathematically 0
sound 0
system 0
for 0
the 0
analysis 0
of 0
injuries 0
and 0
injured 0
patients 0
. 0

This 0
hypothesis 0
was 0
tested 0
by 0
introducing 0
mutations 0
at 0
each 0
of 0
the 0
three 0
histidine 0
pairs 0
, 0
the 0
H382 0
- 0
X2 0
- 0
H385 0
pair 0
, 0
the 0
H411 0
- 0
X2 0
- 0
H414 0
pair 0
and 0
the 0
H430 0
- 0
X5 0
- 0
H436 0
pair 0
, 0
which 0
constitute 0
the 0
histidine 0
- 0
rich 0
region 0
near 0
the 0
C 0
terminus 0
of 0
gp17 B-gene
. 0

Using 0
backcross 0
analysis 0
, 0
both 0
exons 0
1 0
and 0
4 0
mapped 0
to 0
a 0
proximal 0
region 0
of 0
murine 0
Chromosome 0
4 0
indistinguishable 0
from 0
the 0
vacillans B-gene
gene I-gene
. 0

Seventy 0
- 0
five 0
percent 0
of 0
children 0
who 0
received 0
a 0
second 0
transplant 0
for 0
HCV 0
hepatitis 0
had 0
early 0
histologic 0
recurrence 0
that 0
led 0
to 0
liver 0
failure 0
and 0
death 0
. 0

However 0
, 0
both 0
TPN 0
groups 0
showed 0
a 0
marked 0
increase 0
in 0
activities 0
of 0
liver 0
lysosomal B-gene
enzymes I-gene
. 0

Regulation 0
of 0
embryonic 0
growth 0
and 0
lysosomal 0
targeting 0
by 0
the 0
imprinted 0
Igf2/Mpr B-gene
gene 0
. 0

Furthermore 0
, 0
we 0
demonstrated 0
that 0
Galpha11 B-gene
Q209L I-gene
stimulated 0
Src B-gene
family I-gene
kinase 0
activity 0
and 0
induced 0
tyrosine 0
phosphorylation 0
of 0
several 0
proteins 0
in 0
HEK 0
- 0
293 0
cells 0
. 0

The 0
micturition 0
pressure 0
was 0
significantly 0
decreased 0
only 0
after 0
injection 0
with 0
BUP 0
- 0
4 0
in 0
both 0
normal 0
and 0
obstructed 0
rats 0
. 0

Peroxisome B-gene
proliferator I-gene
- I-gene
activated I-gene
receptors I-gene
( 0
PPAR B-gene
) 0
modulate 0
transcription 0
by 0
binding 0
to 0
specific 0
peroxisome 0
proliferator 0
- 0
response 0
elements 0
( 0
PPRE 0
) 0
through 0
heterodimerization 0
with 0
the 0
9 B-gene
- I-gene
cis I-gene
retinoic I-gene
acid I-gene
receptor I-gene
( 0
RXR B-gene
) 0
. 0

Furthermore 0
, 0
early 0
- 0
and 0
late 0
- 0
firing 0
origins 0
differ 0
not 0
in 0
the 0
timing 0
of 0
their 0
recruitment 0
of 0
an 0
Mcm B-gene
protein I-gene
, 0
but 0
in 0
the 0
timing 0
of 0
RPA B-gene
's I-gene
recruitment 0
. 0

Thus 0
, 0
in 0
the 0
presence 0
of 0
active B-gene
S I-gene
- I-gene
CDKs I-gene
and 0
Dbf4/Cdc7 B-gene
, 0
Dbf4/Cdc7 I-gene

Tyrosine 0
phosphorylated 0
STATs B-gene
dimerize 0
and 0
translocate 0
into 0
the 0
nucleus 0
to 0
activate 0
specific 0
genes 0
. 0

Nonsynonymous 0
substitution 0
in 0
abalone 0
sperm 0
fertilization 0
genes 0
exceeds 0
substitution 0
in 0
introns 0
and 0
mitochondrial 0
DNA 0
. 0

Gel 0
retardation 0
assays 0
detected 0
ZiaR B-gene
- 0
dependent 0
complexes 0
forming 0
with 0
the 0
zia B-gene
operator I-gene
- I-gene
promoter I-gene
and 0
ZiaR B-gene
- 0
DNA 0
binding 0
was 0
enhanced 0
by 0
treatment 0
with 0
a 0
metal 0
- 0
chelator 0
in 0
vitro 0
. 0

CONCLUSION 0
: 0
Although 0
quantitative 0
and 0
qualitative 0
criteria 0
for 0
diagnosing 0
fatty 0
liver 0
on 0
helical 0
CT 0
can 0
be 0
determined 0
, 0
they 0
are 0
protocol 0
- 0
specific 0
. 0

The 0
PC 0
- 0
based 0
RTPS 0
is 0
designed 0
to 0
run 0
in 0
the 0
Microsoft 0
Windows 0
3.11 0
environment 0
( 0
and 0
later 0
versions 0
) 0
, 0
for 0
computers 0
equipped 0
with 0
486 0
or 0
Pentium 0
processors 0
. 0

Alternatively 0
, 0
the 0
similarity 0
in 0
apparent 0
regulatory 0
action 0
of 0
the 0
genes 0
may 0
indicate 0
allelic 0
differences 0
wherein 0
the 0
IS1112C B-gene
Rf3 B-gene
allele I-gene
may 0
differ 0
from 0
alleles 0
of 0
maintainer 0
lines 0
by 0
the 0
capability 0
to 0
regulate 0
both 0
orf107 B-gene
and 0
urf209 B-gene
processing 0
activities 0
. 0

JCAHO 0
revised 0
interpretation 0

Molecular 0
cloning 0
and 0
functional 0
characterization 0
of 0
murine B-gene
sphingosine I-gene
kinase I-gene
. 0

A 0
human 0
SPT3 B-gene
- 0
TAFII31 B-gene
- 0
GCN5 B-gene
- 0
L B-gene
acetylase I-gene
complex 0
distinct 0
from 0
transcription B-gene
factor I-gene
IID I-gene
. 0

Oleate 0
induced 0
steady 0
- 0
state 0
levels 0
of 0
M B-gene
- I-gene
CPT I-gene
I I-gene
mRNA I-gene
4.5 0
- 0
fold 0
. 0

Mapping 0
of 0
the 0
DNA 0
binding 0
domain 0
of 0
the 0
copper 0
- 0
responsive 0
transcription 0
factor 0
Mac1 B-gene
from I-gene
Saccharomyces I-gene
cerevisiae I-gene
. 0

A 0
further 0
mechanism 0
increasing 0
specific 0
activation 0
was 0
cooperation 0
of 0
receptors 0
at 0
multiple 0
and 0
weak 0
HREs 0
, 0
which 0
was 0
accentuated 0
in 0
the 0
presence 0
of 0
both 0
the 0
AR B-gene
N 0
terminus 0
and 0
ligand 0
binding 0
domain 0
. 0

Previously 0
, 0
we 0
characterized 0
a 0
DNA 0
- 0
binding 0
protein 0
, 0
HS2NF5 B-gene
, 0
that 0
bound 0
tightly 0
to 0
a 0
conserved 0
region 0
within 0
hypersensitive 0
site 0
2 0
( 0
HS2 0
) 0
of 0
the 0
human B-gene
beta I-gene
- I-gene
globin I-gene
locus I-gene
control I-gene
region I-gene
( 0
LCR 0
) 0
( 0
Lam 0
, 0
L 0
. 0

The 0
CBF1 B-gene
site I-gene
within 0
HS2 0
resides 0
near 0
sites 0
for 0
hematopoietic 0
regulators 0
such 0
as 0
GATA B-gene
- I-gene
1 I-gene
, 0
NF B-gene
- I-gene
E2 I-gene
, 0
and 0
TAL1 B-gene
. 0

The 0
rat B-gene
branched I-gene
- I-gene
chain I-gene
- I-gene
2 I-gene
- I-gene
oxo I-gene
- I-gene
acid I-gene
dehydrogenase I-gene
( I-gene
BCOD I-gene
) I-gene
kinase I-gene
mRNA I-gene
is 0
transcribed 0
from 0
a 0
TATA 0
- 0
less 0
promoter 0
that 0
has 0
GC 0
- 0
rich 0
sequences 0
and 0
two 0
putative 0
Sp1 B-gene
binding I-gene
sites I-gene
near 0
the 0
transcription 0
start 0
site 0
. 0

Co 0
- 0
transfection 0
of 0
the 0
Sp1 B-gene
expression 0
plasmid 0
and 0
the 0
- 0
58 0
promoter 0
construct 0
into 0
Drosophila 0
Schneider 0
cells 0
revealed 0
that 0
Sp1 B-gene
contributed 0
to 0
the 0
kinase 0
basal 0
promoter 0
activity 0
by 0
binding 0
to 0
the 0
non 0
- 0
consensus 0
site 0
in 0
the 0
- 0
58 0
region 0
. 0

Until 0
such 0
investigations 0
are 0
performed 0
, 0
we 0
conclude 0
that 0
the 0
role 0
for 0
adjuvant 0
treatment 0
is 0
questionable 0
and 0
that 0
TME 0
surgery 0
is 0
preferred 0
as 0
the 0
treatment 0
option 0
for 0
Stage 0
T1 0
- 0
T3 0
rectal 0
cancers 0
. 0

Likewise 0
, 0
at 0
150 0
degrees 0
C 0
with 0
2 0
% 0
APS 0
the 0
surface 0
density 0
of 0
NH2 0
groups 0
reached 0
a 0
maximum 0
at 0
24 0
hr 0
and 0
remained 0
relatively 0
constant 0
up 0
to 0
96 0
hr 0
. 0

Taken 0
together 0
, 0
these 0
results 0
suggest 0
that 0
the 0
cooperation 0
of 0
transcription B-gene
factors I-gene
NF I-gene
- I-gene
kappaB I-gene
and 0
AP B-gene
- I-gene
1 I-gene
is 0
essential 0
for 0
transactivation 0
of 0
IL B-gene
- I-gene
8 I-gene
gene I-gene
by 0
HTLV B-gene
- I-gene
I I-gene
Tax I-gene
. 0

This 0
study 0
examines 0
the 0
cooperative 0
effects 0
of 0
a 0
human 0
estrogen B-gene
receptor I-gene
- I-gene
alpha I-gene
( 0
ERalpha B-gene
) 0
isoform 0
on 0
estrogen 0
( 0
E2 0
) 0
- 0
mediated 0
gene 0
activation 0
in 0
U2 0
- 0
OS 0
osteosarcoma 0
cells 0
. 0

Transfection 0
of 0
increasing 0
amounts 0
of 0
delta5ERalpha B-gene
expression 0
vector 0
into 0
[ 0
ERalpha+ B-gene
] 0
OS 0
cells 0
resulted 0
in 0
potentiation 0
of 0
E2 0
- 0
stimulated 0
ERELuc B-gene
activity 0
in 0
a 0
synergistic 0
, 0
dose 0
- 0
dependent 0
manner 0
. 0

Studies 0
using 0
the 0
yeast 0
two 0
- 0
hybrid 0
system 0
also 0
did 0
not 0
provide 0
evidence 0
for 0
the 0
formation 0
of 0
a 0
VDR B-gene
- 0
TR B-gene
protein 0
- 0
protein 0
interaction 0
. 0

Our 0
results 0
show 0
that 0
, 0
from 0
a 0
thermodynamical 0
standpoint 0
, 0
melatonin 0
may 0
directly 0
scavenge 0
hydroxyl 0
radicals 0
both 0
in 0
vacuum 0
and 0
in 0
aqueous 0
solution 0
. 0

This 0
sequence 0
, 0
Thr 0
- 0
Gly 0
- 0
X 0
- 0
X 0
- 0
Gly 0
- 0
Asp 0
- 0
Gly 0
- 0
Lys 0
- 0
Ile 0
- 0
Phe 0
, 0
forms 0
part 0
of 0
the 0
B 0
- 0
loop 0
and 0
is 0
conserved 0
in 0
a 0
wide 0
variety 0
of 0
organisms 0
that 0
include 0
bacteria 0
, 0
algae 0
and 0
archeabacteria 0
. 0

We 0
did 0
not 0
observe 0
any 0
changes 0
in 0
Bcl B-gene
- I-gene
2 I-gene
or 0
Bcl B-gene
- I-gene
2 I-gene
- I-gene
related I-gene
proteins I-gene
( 0
Bcl B-gene
- I-gene
x I-gene
, 0
Bax B-gene
, 0
and 0
Bad B-gene
) 0
in 0
control 0
or 0
KCREB B-gene
- 0
transfected 0
cells 0
before 0
or 0
after 0
treatment 0
with 0
Tg 0
. 0

Tyrosine 0
112 0
of 0
latent B-gene
membrane I-gene
protein I-gene
2A I-gene
is 0
essential 0
for 0
protein B-gene
tyrosine I-gene
kinase I-gene
loading 0
and 0
regulation 0
of 0
Epstein 0
- 0
Barr 0
virus 0
latency 0
. 0

The 0
only 0
abundant 0
viral 0
transcript 0
expressed 0
during 0
latency 0
is 0
the 0
latency B-gene
- I-gene
related I-gene
( 0
LR B-gene
) 0
RNA 0
. 0

To 0
improve 0
test 0
efficiency 0
, 0
we 0
modified 0
our 0
previously 0
introduced 0
contrast/color 0
card 0
test 0
by 0
including 0
a 0
patterned 0
test 0
stimulus 0
and 0
reducing 0
the 0
number 0
of 0
stimuli 0
in 0
both 0
experimental 0
phases 0
. 0

The 0
defect 0
in 0
these 0
proteins 0
was 0
also 0
uniformly 0
suppressed 0
by 0
either 0
Mn2+ 0
, 0
or 0
the 0
Mu B-gene
B I-gene
protein I-gene
in 0
the 0
presence 0
of 0
ATP 0
and 0
target 0
DNA 0
. 0

Using 0
homology 0
cloning 0
techniques 0
, 0
we 0
identified 0
a 0
mouse 0
homologue 0
of 0
E B-gene
( I-gene
Pc I-gene
) I-gene
, 0
termed 0
Epc1 B-gene
, 0
a 0
yeast 0
protein 0
that 0
we 0
name 0
EPL1 B-gene
, 0
and 0
as 0
well 0
as 0
additional 0
ESTs 0
from 0
Caenorhabditis 0
elegans 0
, 0
mice 0
and 0
humans 0
. 0

Second 0
, 0
the 0
wild B-gene
- I-gene
type I-gene
m8 I-gene
3 I-gene
' I-gene
UTR I-gene
strongly 0
reduces 0
accumulation 0
of 0
heterologous 0
transcripts 0
in 0
vivo 0
, 0
an 0
activity 0
that 0
requires 0
its 0
K 0
box 0
sequences 0
. 0

In 0
particular 0
, 0
unc B-gene
- I-gene
86 I-gene
encodes 0
a 0
POU B-gene
- I-gene
type I-gene
homeodomain I-gene
protein I-gene
needed 0
for 0
the 0
production 0
of 0
the 0
touch 0
cells 0
, 0
while 0
mec B-gene
- I-gene
3 I-gene
encodes 0
a 0
LIM B-gene
- I-gene
type I-gene
homeodomain I-gene
protein I-gene
needed 0
for 0
the 0
differentiation 0
of 0
the 0
touch 0
cells 0
. 0

During 0
the 0
2h 0
resuscitation 0
period 0
, 0
extracellular 0
aspartate 0
and 0
glutamate 0
concentrations 0
in 0
the 0
cerebral 0
striatum 0
were 0
higher 0
during 0
hypoxaemic 0
resuscitation 0
( 0
p 0
= 0
0.044 0
and 0
p 0
= 0
0.055 0
, 0
respectively 0
) 0
than 0
during 0
resuscitation 0
with 0
21 0
% 0
O2 0
or 0
100 0
% 0
O2 0
, 0
suggesting 0
an 0
unfavourable 0
accumulation 0
of 0
potent 0
excitotoxins 0
during 0
hypoxaemic 0
resuscitation 0
. 0

Expression 0
of 0
constitutively 0
active 0
MEK1 B-gene
, 0
the 0
kinase 0
that 0
activates 0
ERKs B-gene
, 0
or 0
overexpression 0
of 0
ERK2 B-gene
, 0
but 0
not 0
JNK1 B-gene
, 0
inhibited 0
Stat3 B-gene
activation 0
. 0

MEKs B-gene
and 0
ERKs B-gene
inhibited 0
IL B-gene
- I-gene
6 I-gene
activation 0
of 0
Stat3 B-gene
harboring 0
a 0
mutation 0
at 0
serine 0
- 0
727 0
, 0
the 0
major 0
site 0
for 0
serine 0
phosphorylation 0
, 0
similar 0
to 0
inhibition 0
of 0
wild B-gene
- I-gene
type I-gene
Stat3 I-gene
, 0
and 0
inhibited 0
Janus B-gene
kinases I-gene
Jak1 B-gene
and 0
Jak2 B-gene
upstream 0
of 0
Stat3 B-gene
in 0
the 0
Jak B-gene
- 0
STAT B-gene
- 0
signaling 0
pathway 0
. 0

Furthermore 0
, 0
phosphatidylinositol 0
( 0
3,4,5 0
) 0
trisphosphate 0
specifically 0
stimulates 0
the 0
activity 0
of 0
ILK B-gene
in 0
vitro 0
, 0
and 0
in 0
addition 0
, 0
membrane 0
targetted 0
constitutively 0
active 0
Pi B-gene
( I-gene
3 I-gene
) I-gene
K I-gene
activates 0
ILK B-gene
in 0
vivo 0
. 0

Transfection 0
and 0
in 0
vitro 0
binding 0
studies 0
identified 0
within 0
HEFT1 B-gene
a I-gene
promoter I-gene
whose 0
basal 0
activity 0
required 0
a 0
GC 0
box 0
activated 0
by 0
Sp1 B-gene
or 0
Sp3 B-gene
. 0

Plasma 0
was 0
tested 0
before 0
and 0
after 0
( 0
14 0
+/ 0
- 0
7.5 0
[ 0
SD 0
] 0
days 0
) 0
surgery 0
for 0
IgG B-gene
antibodies I-gene
to 0
the 0
complex 0
of 0
heparin/platelet B-gene
factor I-gene
4 I-gene
, 0
using 0
a 0
standardized 0
, 0
validated 0
enzyme 0
- 0
linked 0
immunosorbent 0
assay 0
( 0
ELISA 0
) 0
. 0

Genome 0
plasticity 0
in 0
the 0
distal 0
tail 0
fiber 0
locus 0
of 0
the 0
T 0
- 0
even 0
bacteriophage 0
: 0
recombination 0
between 0
conserved 0
motifs 0
swaps 0
adhesin B-gene
specificity 0
. 0

The 0
FAS B-gene
promoter I-gene
was 0
up 0
- 0
regulated 0
by 0
insulin B-gene
through 0
the 0
proximal 0
insulin B-gene
response I-gene
sequence I-gene
containing 0
an 0
E 0
- 0
box 0
motif 0
at 0
the 0
- 0
65 0
- 0
base 0
pair 0
position 0
. 0

The 0
effect 0
of 0
independent 0
predictors 0
on 0
survival 0
was 0
examined 0
in 0
a 0
Cox 0
regression 0
model 0
with 0
adjustment 0
for 0
existing 0
illnesses 0
. 0

Effects 0
of 0
rhG B-gene
- I-gene
CSF I-gene
on 0
neutrophil 0
functions 0
and 0
survival 0
in 0
sepsis 0
induced 0
diabetic 0
rats 0
. 0

OBJECTIVE 0
: 0
The 0
purpose 0
of 0
this 0
article 0
is 0
to 0
review 0
balance 0
instruments 0
developed 0
within 0
the 0
past 0
10 0
years 0
that 0
can 0
be 0
used 0
in 0
the 0
clinic 0
or 0
home 0
environment 0
. 0

CASE 0
REPORT 0
: 0
We 0
observed 0
a 0
congenital 0
skin 0
defect 0
located 0
exclusively 0
on 0
the 0
trunk 0
. 0

Whereas 0
, 0
in 0
the 0
single 0
- 0
chambered 0
body 0
box 0
, 0
PenH 0
units 0
( 0
Enhanced 0
Pause 0
) 0
reflect 0
`` 0
effort 0
of 0
breathing 0
. 0
'' 0
This 0
is 0
measured 0
as 0
the 0
pause 0
between 0
inspiration 0
and 0
expiration 0
. 0

Anastrozole 0
is 0
the 0
first 0
aromatase B-gene
inhibitor 0
to 0
show 0
a 0
significant 0
survival 0
advantage 0
over 0
megestrol 0
acetate 0
in 0
post 0
- 0
menopausal 0
women 0
with 0
advanced 0
breast 0
cancer 0
. 0

W 0
. 0

Moritta 0
) 0
and 0
contains 0
Bis 0
- 0
GMA 0
. 0

Mutation 0
of 0
either 0
the 0
AP B-gene
- I-gene
1 I-gene
or 0
the 0
ets B-gene
component 0
of 0
this 0
site 0
also 0
prevented 0
promoter 0
activity 0
in 0
SMCs 0
. 0

ANIMALS 0
: 0
Fifty 0
dogs 0
with 0
naturally 0
developing 0
DM 0
. 0

Surprisingly 0
, 0
double 0
mutants 0
of 0
the 0
shy2 B-gene
- I-gene
1D I-gene
mutant I-gene
with 0
the 0
phytochrome B-gene
- 0
deficient 0
mutants 0
hy2 B-gene
, 0
hy3 B-gene
( 0
phyB B-gene
- I-gene
1 I-gene
) 0
and 0
fre1 B-gene
- I-gene
1 I-gene
( 0
phyA B-gene
- I-gene
201 I-gene
) 0
showed 0
reduced 0
photomorphogenic 0
response 0
in 0
darkness 0
with 0
a 0
longer 0
hypocotyl 0
, 0
a 0
longer 0
inflorescence 0
stem 0
, 0
and 0
a 0
lower 0
level 0
expression 0
of 0
the 0
CAB B-gene
gene I-gene
than 0
the 0
shy2 B-gene
- I-gene
1D I-gene
single I-gene
mutant I-gene
. 0

This 0
suggests 0
that 0
while 0
underpredictions 0
of 0
pain 0
do 0
not 0
hurt 0
more 0
, 0
disruption 0
on 0
primary 0
tasks 0
and 0
physiological 0
impact 0
are 0
higher 0
. 0

Laser 0
ablation 0
has 0
been 0
employed 0
as 0
a 0
therapeutic 0
measure 0
for 0
chronic 0
pulmonary 0
emphysema 0
. 0

The 0
SH2 0
- 0
containing 0
adapter 0
protein 0
GRB10 B-gene
interacts 0
with 0
BCR B-gene
- 0
ABL B-gene
. 0

Saccharomyces 0
cerevisiae 0
contains 0
four 0
known 0
acyl B-gene
- I-gene
CoA I-gene
synthetases I-gene
( 0
fatty B-gene
acid I-gene
activation I-gene
proteins I-gene
, 0
Faaps B-gene
) 0
. 0

We 0
recently 0
reported 0
a 0
placenta 0
- 0
specific 0
enhancer 0
in 0
the 0
human B-gene
leukemia I-gene
inhibitory I-gene
factor I-gene
receptor I-gene
( 0
LIFR B-gene
) 0
gene 0
and 0
now 0
show 0
detailed 0
characterization 0
of 0
the 0
226 0
- 0
base 0
pair 0
enhancer 0
( 0
- 0
4625/ 0
- 0
4400 0
nucleotides 0
) 0
. 0

Copyright 0
1998 0
Elsevier 0
Science 0
B.V 0
. 0

It 0
may 0
be 0
time 0
to 0
reevaluate 0
the 0
dichotomy 0
between 0
AD 0
and 0
VaD 0
. 0

Clone 0
39 0
was 0
a 0
homolog 0
of 0
CONSTANS B-gene
, 0
which 0
is 0
a 0
gene 0
involved 0
in 0
controlling 0
the 0
flowering 0
time 0
in 0
Arabidopsis 0
. 0

Badcock 0
and 0
Westheimer 0
( 0
Spatial 0
Vision 0
1 0
( 0
1 0
) 0
, 0
3 0
- 0
11 0
, 0
1985 0
) 0
showed 0
that 0
a 0
thin 0
vertical 0
line 0
induces 0
nearby 0
zones 0
of 0
attraction 0
and 0
repulsion 0
; 0
this 0
study 0
extends 0
those 0
results 0
by 0
more 0
closely 0
examining 0
the 0
horizontal 0
and 0
vertical 0
extents 0
of 0
the 0
repulsion 0
zone 0
and 0
by 0
using 0
an 0
illusory 0
contour 0
to 0
induce 0
repulsion 0
. 0

The 0
effects 0
of 0
high 0
intensity 0
light 0
emissions 0
, 0
produced 0
by 0
a 0
novel 0
pulsed 0
power 0
energization 0
technique 0
( 0
PPET 0
) 0
, 0
on 0
the 0
survival 0
of 0
bacterial 0
populations 0
of 0
verocytotoxigenic 0
Escherichia 0
coli 0
( 0
serotype 0
0157 0
: 0
H7 0
) 0
and 0
Listeria 0
monocytogenes 0
( 0
serotype 0
4b 0
) 0
were 0
investigated 0
. 0

Multiple 0
chemical 0
sensitivity 0
( 0
MCS 0
) 0
is 0
a 0
syndrome 0
in 0
which 0
multiple 0
symptoms 0
reportedly 0
occur 0
with 0
low 0
- 0
level 0
chemical 0
exposure 0
. 0

POU B-gene
- I-gene
domain I-gene
proteins I-gene
, 0
such 0
as 0
the 0
pituitary B-gene
- I-gene
specific I-gene
factor I-gene
Pit I-gene
- I-gene
1 I-gene
, 0
are 0
members 0
of 0
the 0
homeodomain B-gene
family I-gene
of 0
proteins 0
which 0
are 0
important 0
in 0
development 0
and 0
homeostasis 0
, 0
acting 0
constitutively 0
or 0
in 0
response 0
to 0
signal 0
- 0
transduction 0
pathways 0
to 0
either 0
repress 0
or 0
activate 0
the 0
expression 0
of 0
specific 0
genes 0
. 0

Wild 0
- 0
type 0
and 0
mutant 0
MyoD B-gene
were 0
introduced 0
into 0
cells 0
using 0
an 0
E1 B-gene
, 0
E3 B-gene
- 0
deleted 0
adenoviral 0
vector 0
. 0

These 0
results 0
suggest 0
that 0
Thr115 0
may 0
play 0
an 0
important 0
role 0
in 0
the 0
regulation 0
of 0
MyoD B-gene
function 0
under 0
conditions 0
of 0
high 0
mitogenesis 0
. 0

This 0
and 0
previous 0
results 0
suggest 0
that 0
the 0
CRE 0
and 0
Sp1 B-gene
site I-gene
may 0
synergistically 0
activate 0
TH B-gene
transcription 0
in 0
a 0
promoter 0
context 0
- 0
dependent 0
manner 0
. 0

desmethyltrimebutine 0
was 0
inactive 0
. 0

Endoscopic 0
examinations 0
, 0
peripheral 0
white 0
blood 0
cell 0
( 0
WBC 0
) 0
counts 0
, 0
and 0
assays 0
of 0
myeloperoxidase B-gene
activity 0
( 0
MPO B-gene
) 0
in 0
homogenates 0
of 0
colon 0
mucosa 0
were 0
performed 0
after 0
one 0
week 0
( 0
4 0
% 0
DSS 0
model 0
) 0
and 0
eight 0
weeks 0
( 0
1 0
% 0
DSS 0
model 0
) 0
. 0

T7 0
transcription 0
could 0
be 0
manipulated 0
to 0
achieve 0
different 0
levels 0
of 0
constitutive 0
expression 0
, 0
through 0
the 0
use 0
of 0
promoter 0
mutations 0
. 0

The 0
primers 0
were 0
degenerate 0
sets 0
of 0
oligonucleotides 0
derived 0
from 0
known 0
amino 0
acid 0
sequences 0
of 0
the 0
PBAN B-gene
precursor I-gene
. 0

Plants 0
transformed 0
with 0
the 0
35S B-gene
- 0
1 B-gene
- I-gene
sst I-gene
construct 0
accumulated 0
the 0
oligofructans 0
1 0
- 0
kestose 0
( 0
GF2 0
) 0
, 0
1,1 0
- 0
nystose 0
( 0
GF3 0
) 0
and 0
1,1,1 0
- 0
fructosylnystose 0
( 0
GF4 0
) 0
. 0

Based 0
on 0
the 0
comparison 0
of 0
the 0
predicted 0
amino 0
acid 0
sequences 0
of 0
1 B-gene
- I-gene
sst I-gene
and 0
1 B-gene
- I-gene
fft I-gene
with 0
those 0
of 0
other 0
plant 0
fructosyl B-gene
transferase I-gene
genes I-gene
, 0
we 0
postulate 0
that 0
both 0
plant 0
fructan B-gene
genes I-gene
have 0
evolved 0
from 0
plant 0
invertase B-gene
genes 0
. 0

However 0
, 0
ICK1 B-gene
was 0
induced 0
by 0
ABA 0
, 0
and 0
along 0
with 0
ICK1 B-gene
induction 0
there 0
was 0
a 0
decrease 0
in 0
Cdc2 B-gene
- I-gene
like I-gene
histone B-gene
H1 I-gene
kinase I-gene
activity 0
. 0

A 0
5.0 0
- 0
kb 0
transcript 0
detected 0
by 0
the 0
differential 0
display 0
amplicon 0
3G1 0
was 0
found 0
to 0
correlate 0
strongly 0
with 0
RAG1 B-gene
mRNA I-gene
expression 0
in 0
various 0
human 0
cell 0
lines 0
. 0

The 0
hBRAG B-gene
gene I-gene
was 0
localized 0
to 0
the 0
long 0
arm 0
of 0
chromosome 0
10 0
( 0
10q26 0
) 0
. 0

Here 0
, 0
we 0
report 0
that 0
swa5 B-gene
- I-gene
1 I-gene
is 0
a 0
new 0
temperature 0
- 0
sensitive 0
allele 0
of 0
the 0
clathrin B-gene
heavy I-gene
chain I-gene
gene I-gene
( 0
chc1 B-gene
- I-gene
5 I-gene
) 0
, 0
which 0
carries 0
a 0
frameshift 0
mutation 0
near 0
the 0
3 0
' 0
end 0
of 0
the 0
CHC1 B-gene
open 0
reading 0
frame 0
. 0

We 0
have 0
determined 0
the 0
molecular 0
lesions 0
of 0
nine 0
Scm B-gene
mutant I-gene
alleles I-gene
, 0
which 0
identify 0
functional 0
requirements 0
for 0
specific 0
domains 0
. 0

Intriguingly 0
, 0
three 0
hypomorphic 0
Scm B-gene
mutations 0
, 0
which 0
map 0
within 0
an 0
mbt B-gene
repeat I-gene
, 0
interact 0
with 0
PcG B-gene
mutations I-gene
more 0
strongly 0
than 0
do 0
Scm B-gene
null 0
alleles 0
. 0

Northern 0
analysis 0
revealed 0
no 0
detectable 0
expression 0
of 0
the 0
transcript 0
in 0
diapause 0
- 0
or 0
nondiapause 0
- 0
programmed 0
wandering 0
larvae 0
, 0
and 0
only 0
trace 0
expression 0
in 0
nondiapausing 0
pupae 0
. 0

Besides 0
the 0
characterization 0
and 0
discussion 0
of 0
the 0
experimental 0
setup 0
used 0
, 0
the 0
rate 0
constants 0
obtained 0
are 0
discussed 0
and 0
compared 0
with 0
estimated 0
values 0
. 0

Genomic 0
locus 0
of 0
chCTCF B-gene
contains 0
a 0
GC 0
- 0
rich 0
untranslated 0
exon 0
separated 0
from 0
seven 0
coding 0
exons 0
by 0
a 0
long 0
intron 0
. 0

The 0
presence 0
of 0
PDZ B-gene
and 0
SAM 0
domains 0
in 0
the 0
KS5 B-gene
protein I-gene
suggests 0
that 0
it 0
may 0
act 0
as 0
a 0
molecular 0
adaptor 0
, 0
promoting 0
and 0
relaying 0
information 0
in 0
a 0
signal 0
transduction 0
pathway 0
. 0

BACKGROUND 0
: 0
Fluoroquinolones 0
( 0
FQ 0
) 0
are 0
contraindicated 0
in 0
children 0
because 0
of 0
the 0
risk 0
of 0
cartilage 0
damage 0
. 0

In 0
analyses 0
with 0
control 0
for 0
multiple 0
variables 0
, 0
relative 0
risk 0
for 0
microalbuminuria 0
( 0
urinary 0
albumin B-gene
excretion 0
, 0
20 0
- 0
199 0
microg/min 0
) 0
in 0
men 0
and 0
women 0
was 0
2.51 0
and 0
1.62 0
, 0
respectively 0
, 0
with 0
18 0
mm 0
Hg 0
higher 0
( 0
1 0
SD 0
) 0
systolic 0
blood 0
pressure 0
; 0
2.25 0
and 0
2.10 0
, 0
respectively 0
, 0
with 0
1.0 0
- 0
mmol/L 0
( 0
40 0
mg/dL 0
) 0
higher 0
plasma 0
cholesterol 0
level 0
; 0
1.99 0
and 0
1.91 0
, 0
respectively 0
, 0
for 0
smokers 0
vs 0
nonsmokers 0
; 0
and 0
1.83 0
and 0
1.33 0
, 0
respectively 0
, 0
with 0
4 0
kg/m2 0
higher 0
body 0
mass 0
index 0
. 0

However 0
, 0
while 0
IL B-gene
- I-gene
1beta I-gene
and 0
TNF B-gene
- I-gene
alpha I-gene
both 0
induced 0
nuclear 0
binding 0
of 0
the 0
Rel B-gene
proteins I-gene
p50 B-gene
and 0
p65 B-gene
to 0
an 0
NF B-gene
- I-gene
kappaB I-gene
consensus I-gene
oligonucleotide I-gene
in 0
gel 0
shift 0
assays 0
and 0
caused 0
transient 0
degradation 0
of 0
inhibitor B-gene
of I-gene
NF I-gene
- I-gene
kappaB I-gene
- I-gene
alpha I-gene
( 0
IkappaB B-gene
- I-gene
alpha I-gene
) 0
in 0
the 0
cytoplasm 0
of 0
myofibroblasts 0
, 0
only 0
IL B-gene
- I-gene
1beta I-gene
upregulated 0
PDGF B-gene
- I-gene
Ralpha I-gene
. 0

Cotransfections 0
with 0
ATF B-gene
- I-gene
2 I-gene
and 0
HNF B-gene
- I-gene
4 I-gene
expression 0
plasmids 0
resulted 0
in 0
additive 0
transactivation 0
of 0
the 0
apoCIII B-gene
promoter I-gene
. 0

Phosphocreatine 0
hydrolysis 0
during 0
submaximal 0
exercise 0
: 0
the 0
effect 0
of 0
FIO2 0
. 0

Pseudocontact 0
shifts 0
arise 0
from 0
the 0
isotropic 0
reorientational 0
average 0
of 0
the 0
dipolar 0
coupling 0
between 0
unpaired 0
electron 0
and 0
nuclei 0
, 0
in 0
the 0
presence 0
of 0
magnetic 0
susceptibility 0
anisotropy 0
. 0

GETS B-gene
- I-gene
1 I-gene
is 0
expressed 0
in 0
many 0
tissues 0
, 0
but 0
is 0
enriched 0
in 0
retina 0
and 0
brain 0
. 0

The 0
interaction 0
of 0
U1 B-gene
- I-gene
70K I-gene
with 0
the 0
SRZ B-gene
proteins I-gene
is 0
confirmed 0
further 0
in 0
vitro 0
using 0
a 0
blot 0
overlay 0
assay 0
. 0

The 0
major 0
phenotypes 0
resulting 0
from 0
Fab1p B-gene
kinase I-gene
inactivation 0
include 0
temperature 0
- 0
sensitive 0
growth 0
, 0
vacuolar 0
acidification 0
defects 0
, 0
and 0
dramatic 0
increases 0
in 0
vacuolar 0
size 0
. 0

Small B-gene
GTPases I-gene
of 0
the 0
Ypt/Rab B-gene
family 0
are 0
involved 0
in 0
the 0
regulation 0
of 0
vesicular 0
transport 0
. 0

The 0
GEF B-gene
and 0
GAP B-gene
activities 0
for 0
Ypt1p B-gene
localize 0
to 0
particulate 0
cellular 0
fractions 0
. 0

Dopamine B-gene
beta I-gene
- I-gene
hydroxylase I-gene
( 0
DBH B-gene
) 0
catalyzes 0
the 0
conversion 0
of 0
dopamine 0
to 0
noradrenaline 0
and 0
is 0
selectively 0
expressed 0
in 0
noradrenergic 0
and 0
adrenergic 0
neurons 0
and 0
neuroendocrine 0
cells 0
. 0

Collectively 0
, 0
this 0
study 0
emphasizes 0
a 0
critical 0
role 0
of 0
Phox2a B-gene
as 0
well 0
as 0
its 0
functional 0
synergism 0
with 0
other 0
transcription 0
factors 0
( 0
e.g. 0
, 0
CREB B-gene
, 0
AP2 B-gene
, 0
and 0
Sp1 B-gene
) 0
in 0
transcriptional 0
activation 0
of 0
the 0
DBH B-gene
gene I-gene
. 0

Interestingly 0
, 0
an 0
antibody 0
against 0
N B-gene
- I-gene
SMase I-gene
can 0
abrogate 0
Ox B-gene
- I-gene
LDL I-gene
- 0
and 0
TNF B-gene
- I-gene
alpha I-gene
- 0
induced 0
apoptosis 0
and 0
therefore 0
may 0
be 0
useful 0
for 0
in 0
vivo 0
studies 0
of 0
apoptosis 0
in 0
experimental 0
animals 0
. 0

We 0
found 0
that 0
virulent 0
Ngo 0
strains 0
induce 0
phosphorylation 0
and 0
activation 0
of 0
JNK B-gene
but 0
not 0
of 0
p38 B-gene
kinase 0
. 0

Focused 0
beams 0
of 0
classical 0
light 0
ablate 0
elements 0
of 0
the 0
cell 0
division 0
machinery 0
and 0
switch 0
the 0
beating 0
of 0
hearts 0
on 0
a 0
cellular 0
basis 0
. 0

The 0
human 0
T 0
cell 0
lymphotropic 0
retrovirus 0
type 0
I 0
( 0
HTLV 0
- 0
I 0
) 0
trans 0
- 0
activator 0
, 0
Tax B-gene
, 0
interacts 0
specifically 0
with 0
the 0
basic B-gene
- I-gene
domain/leucine I-gene
- I-gene
zipper I-gene
( I-gene
bZip I-gene
) I-gene
protein I-gene
, 0
cAMP B-gene
response I-gene
element I-gene
binding I-gene
protein I-gene
( 0
CREB B-gene
) 0
, 0
bound 0
to 0
the 0
viral B-gene
Tax I-gene
- I-gene
responsive I-gene
element I-gene
consisting 0
of 0
three 0
imperfect 0
21 0
- 0
base 0
pair 0
repeats 0
, 0
each 0
with 0
a 0
cAMP 0
response 0
element 0
core 0
flanked 0
by 0
G/C 0
- 0
rich 0
sequences 0
. 0

This 0
sequence 0
is 0
very 0
similar 0
to 0
the 0
insulin B-gene
response I-gene
sequence I-gene
found 0
in 0
the 0
regulatory 0
region 0
of 0
other 0
genes 0
negatively 0
regulated 0
by 0
insulin B-gene
such 0
as 0
those 0
encoding 0
phosphoenolpyruvate B-gene
carboxykinase I-gene
, 0
tyrosine B-gene
aminotransferase I-gene
, 0
and 0
insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
- I-gene
binding I-gene
protein I-gene
1 I-gene
. 0

The 0
murine B-gene
facilitative I-gene
glucose I-gene
transporter I-gene
isoform I-gene
3 I-gene
( 0
Glut B-gene
3 I-gene
) 0
is 0
developmentally 0
regulated 0
and 0
is 0
predominantly 0
expressed 0
in 0
neurons 0
and 0
trophoblasts 0
. 0

However 0
, 0
changing 0
the 0
half 0
- 0
site 0
to 0
the 0
consensus 0
sequence 0
AGGTCA 0
( 0
IRper 0
- 0
1 0
) 0
increased 0
binding 0
of 0
AaEcR.AaUSP B-gene
10 0
- 0
fold 0
over 0
IRhsp 0
- 0
1 0
and 0
, 0
at 0
the 0
same 0
time 0
, 0
reduced 0
the 0
stringency 0
of 0
the 0
spacer 0
length 0
requirement 0
, 0
with 0
IRper 0
- 0
0 0
to 0
IRper 0
- 0
5 0
showing 0
detectable 0
binding 0
. 0

The 0
levels 0
of 0
transactivation 0
are 0
correlated 0
with 0
the 0
respective 0
binding 0
affinities 0
of 0
the 0
response 0
elements 0
( 0
IRper 0
- 0
1 0
> 0
DR 0
- 0
4 0
> 0
IRhsp 0
- 0
1 0
) 0
. 0

The 0
high 0
density 0
of 0
tegumental 0
spines 0
on 0
posterior 0
half 0
of 0
the 0
body 0
and 0
the 0
distribution 0
of 0
type 0
II 0
papillae 0
on 0
dorsal 0
surface 0
are 0
considered 0
to 0
be 0
characteristic 0
of 0
C. 0
armatus 0
. 0

Inactivation 0
of 0
p53 B-gene
but 0
not 0
p73 B-gene
by 0
adenovirus B-gene
type I-gene
5 I-gene
E1B I-gene
55 I-gene
- I-gene
kilodalton I-gene
and I-gene
E4 I-gene
34 I-gene
- I-gene
kilodalton I-gene
oncoproteins I-gene
. 0

The 0
Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
transactivator I-gene
Zta I-gene
triggers 0
lytic 0
gene 0
expression 0
and 0
is 0
essential 0
for 0
replication 0
of 0
the 0
lytic 0
origin 0
, 0
oriLyt 0
. 0

Cotransfection 0
of 0
the 0
helicase B-gene
- 0
primase B-gene
proteins 0
, 0
one 0
of 0
which 0
was 0
fused 0
to 0
a 0
heterologous 0
activation 0
domain 0
, 0
led 0
to 0
Zta B-gene
- 0
dependent 0
superactivation 0
of 0
CAT B-gene
expression 0
. 0

Sequence 0
comparisons 0
strongly 0
suggest 0
that 0
the 0
S27a B-gene
and 0
the 0
ubiquitin B-gene
coding 0
sequences 0
found 0
in 0
the 0
genome 0
of 0
CP 0
Rit 0
were 0
both 0
derived 0
from 0
a 0
bovine 0
mRNA 0
encoding 0
a 0
hybrid 0
protein 0
with 0
the 0
structure 0
NH2 0
- 0
ubiquitin B-gene
- 0
S27a B-gene
- 0
COOH 0
. 0

J 0
. 0

There 0
was 0
a 0
trend 0
in 0
all 0
studies 0
favouring 0
PVI 0
. 0

A 0
single 0
rectal 0
dose 0
of 0
25 0
mg/kg 0
will 0
obtain 0
this 0
lower 0
concentration 0
within 0
1 0
h 0
of 0
administration 0
and 0
maintain 0
it 0
for 0
up 0
to 0
6 0
h 0
. 0

This 0
domain 0
, 0
although 0
adjacent 0
to 0
the 0
5 0
' 0
edge 0
of 0
the 0
SD 0
sequence 0
, 0
does 0
not 0
inhibit 0
ribosome 0
binding 0
as 0
long 0
as 0
the 0
single 0
- 0
stranded 0
region 0
of 0
domain 0
3 0
is 0
present 0
. 0

Although 0
YopH B-gene
is 0
a 0
highly 0
active 0
PTP B-gene
, 0
it 0
preferentially 0
targets 0
a 0
subset 0
of 0
tyrosine 0
- 0
phosphorylated 0
proteins 0
in 0
host 0
cells 0
, 0
including 0
p130Cas B-gene
. 0

Phylogenetic 0
position 0
of 0
the 0
Phacotaceae 0
within 0
the 0
Chlamydophyceaeas 0
revealed 0
by 0
analysis 0
of 0
18S B-gene
rDNA I-gene
and 0
rbcL B-gene
sequences I-gene
. 0

Previous 0
genetic 0
studies 0
led 0
to 0
the 0
conclusion 0
that 0
nitrate 0
and 0
nitrite 0
induction 0
of 0
nasF B-gene
operon I-gene
expression 0
is 0
determined 0
by 0
a 0
transcriptional 0
antitermination 0
mechanism 0
. 0

The 0
activation 0
and 0
injury 0
of 0
endothelial 0
cells 0
induced 0
by 0
TNF B-gene
and 0
other 0
proinflammatory 0
cytokines 0
may 0
underlie 0
the 0
local 0
effects 0
of 0
these 0
mediators 0
in 0
vivo 0
. 0

A 0
technique 0
for 0
thermal 0
imaging 0
of 0
the 0
animal 0
and 0
human 0
brain 0
cortex 0
using 0
an 0
infrared 0
optical 0
system 0
is 0
described 0
. 0

EGFR B-gene
levels 0
were 0
found 0
to 0
be 0
elevated 0
5 0
- 0
, 0
3 0
. 0

Here 0
we 0
demonstrate 0
that 0
THOV B-gene
NP I-gene
contains 0
a 0
motif 0
( 0
KRxxxxxxxxxKTKK 0
) 0
at 0
amino 0
acid 0
positions 0
179 0
- 0
193 0
that 0
represents 0
a 0
classical 0
bipartite 0
nuclear 0
localization 0
signal 0
( 0
NLS 0
) 0
. 0

As 0
PP2A B-gene
exerts 0
a 0
range 0
of 0
cellular 0
functions 0
including 0
cell 0
cycle 0
regulation 0
and 0
cell 0
fate 0
determination 0
, 0
we 0
were 0
surprised 0
to 0
find 0
that 0
these 0
embryos 0
develop 0
normally 0
until 0
postimplantation 0
, 0
around 0
embryonic 0
day 0
5.5/6.0 0
. 0

The 0
most 0
frequent 0
risk 0
factor 0
for 0
ischaemic 0
was 0
hypertension 0
. 0

The 0
results 0
indicate 0
that 0
anthraquinone 0
sennoside 0
B 0
and 0
rhein 0
are 0
weakly 0
genotoxic 0
. 0

Furthermore 0
, 0
LB1 B-gene
gene I-gene
mapped 0
to 0
chromosome 0
13q14 0
, 0
a 0
region 0
that 0
has 0
been 0
involved 0
as 0
a 0
chromosomal 0
breakpoint 0
in 0
DLBL 0
. 0

16 0
subjects 0
were 0
repatch 0
tested 0
to 0
ethylmercury 0
chloride 0
( 0
EtHgCl 0
) 0
and 0
to 0
solutions 0
containing 0
EtHgCl 0
mixed 0
with 0
L 0
- 0
cysteine 0
and 0
glutathione 0
, 0
respectively 0
. 0

Wild B-gene
- I-gene
type I-gene
AT1A I-gene
receptors I-gene
, 0
expressed 0
in 0
Chinese 0
hamster 0
ovary 0
cells 0
, 0
rapidly 0
internalized 0
after 0
Ang B-gene
II I-gene
stimulation 0
[ 0
t1/2 0
2.3 0
min 0
; 0
maximal 0
level 0
of 0
internalization 0
( 0
Ymax 0
) 0
78.2 0
% 0
] 0
, 0
as 0
did 0
mutant 0
receptors 0
carrying 0
single 0
acidic 0
substitutions 0
( 0
T332E 0
, 0
t1/2 0
2.7 0
min 0
, 0
Ymax 0
76.3 0
% 0
; 0
S335D 0
, 0
t1/2 0
2.4 0
min 0
, 0
Ymax 0
76.7 0
% 0
; 0
T336E 0
, 0
t1/2 0
2.5 0
min 0
, 0
Ymax 0
78.2 0
% 0
; 0
S338D 0
, 0
t1/2 0
2.6 0
min 0
, 0
Ymax 0
78.4 0
% 0
) 0
. 0

The 0
activated 0
glucocorticoid B-gene
receptor I-gene
forms 0
a 0
complex 0
with 0
Stat5 B-gene
and 0
enhances 0
Stat5 B-gene
- 0
mediated 0
transcriptional 0
induction 0
. 0

T. 0
, 0
Mahasneh 0
, 0
A. 0
, 0
and 0
Cote 0
, 0
G 0
. 0

The 0
carboxyl 0
- 0
terminal 0
portion 0
of 0
UKLF B-gene
contains 0
three 0
zinc 0
fingers 0
of 0
the 0
Cys2 0
- 0
His2 0
type 0
and 0
binds 0
in 0
vitro 0
to 0
the 0
CACCC 0
motif 0
of 0
the 0
beta B-gene
- I-gene
globin I-gene
promoter I-gene
and 0
to 0
the 0
Sp1 B-gene
recognition I-gene
sequence I-gene
. 0

We 0
have 0
recently 0
identified 0
a 0
mouse 0
enzyme 0
termed 0
gamma B-gene
- I-gene
glutamyl I-gene
leukotrienase I-gene
( 0
GGL B-gene
) 0
that 0
converts 0
leukotriene 0
C4 0
( 0
LTC4 0
) 0
to 0
leukotriene 0
D4 0
( 0
LTD4 0
) 0
. 0

UGA 0
codon 0
position 0
affects 0
the 0
efficiency 0
of 0
selenocysteine 0
incorporation 0
into 0
glutathione B-gene
peroxidase I-gene
- I-gene
1 I-gene
. 0

Forskolin 0
significantly 0
enhanced 0
heregulin B-gene
- 0
stimulated 0
expression 0
of 0
cyclin B-gene
D I-gene
and 0
phosphorylation 0
of 0
the 0
retinoblastoma B-gene
gene I-gene
product I-gene
. 0

The 0
ARF B-gene
promoter I-gene
was 0
also 0
found 0
to 0
be 0
highly 0
responsive 0
to 0
E2F1 B-gene
expression 0
, 0
in 0
keeping 0
with 0
previous 0
results 0
at 0
the 0
RNA 0
level 0
. 0

RESULTS 0
: 0
The 0
binding 0
of 0
99mTc 0
d 0
, 0
1 0
- 0
HMPAO 0
to 0
human 0
placenta 0
ranged 0
from 0
2.95 0
% 0
+/ 0
- 0
1.5 0
% 0
to 0
5.82 0
% 0
+/ 0
- 0
0.3 0
% 0
per 0
1 0
ml 0
standard 0
solution 0
. 0

CM 0
reduced 0
the 0
nuclear 0
binding 0
activity 0
of 0
transcription B-gene
factor I-gene
AP I-gene
- I-gene
1 I-gene
. 0

NF B-gene
- I-gene
kappaB I-gene
, 0
which 0
is 0
probably 0
important 0
for 0
basal 0
activity 0
of 0
the 0
human B-gene
NOS I-gene
II I-gene
promoter I-gene
, 0
is 0
unlikely 0
to 0
function 0
as 0
a 0
major 0
effector 0
of 0
CM 0
in 0
DLD 0
- 0
1 0
cells 0
. 0

Observers 0
with 0
brain 0
injury 0
and 0
control 0
participants 0
performed 0
a 0
vigilance 0
task 0
during 0
which 0
they 0
received 0
periodic 0
whiffs 0
of 0
unscented 0
air 0
or 0
air 0
scented 0
with 0
peppermint 0
. 0

A 0
simple 0
analytical 0
method 0
for 0
l 0
- 0
menthol 0
by 0
high 0
- 0
performance 0
liquid 0
chromatography 0
with 0
a 0
polarized 0
photometric 0
detector 0
was 0
established 0
. 0

RESULTS 0
: 0
The 0
cardiac 0
index 0
significantly 0
changed 0
with 0
varying 0
PaCO2 0
levels 0
( 0
hypocapnia 0
, 0
- 0
9 0
% 0
; 0
hypercapnia 0
, 0
13 0
% 0
) 0
. 0

After 0
measuring 0
baseline 0
Vmca 0
at 0
a 0
partial 0
pressure 0
of 0
carbon 0
dioxide 0
in 0
arterial 0
blood 0
( 0
PaCO2 0
) 0
of 0
37.7 0
+/ 0
- 0
4.5 0
mmHg 0
( 0
mean 0
+/ 0
- 0
SD 0
) 0
, 0
measurements 0
were 0
repeated 0
at 0
a 0
PaCO 0
of 0
44.2 0
+/ 0
- 0
3.8 0
mmHg 0
, 0
and 0
the 0
carbon 0
dioxide 0
reactivity 0
( 0
absolute 0
value 0
: 0
cm 0
x 0
s 0
( 0
- 0
1 0
) 0
x 0
mmHg 0
( 0
- 0
1 0
) 0
; 0
relative 0
value 0
: 0
percentage 0
of 0
baseline 0
Vmca/mmHg 0
) 0
was 0
calculated 0
. 0

Multivariate 0
Cox 0
survival 0
analysis 0
identified 0
baseline 0
EF 0
< 0
or 0
= 0
30 0
% 0
, 0
presence 0
of 0
significant 0
mitral 0
regurgitation 0
( 0
> 0
2+ 0
) 0
before 0
ablation 0
, 0
and 0
failure 0
to 0
exhibit 0
improved 0
cardiac 0
performance 0
by 0
1 0
month 0
after 0
ablation 0
as 0
the 0
only 0
independent 0
predictors 0
of 0
death 0
. 0

We 0
have 0
developed 0
a 0
new 0
method 0
for 0
estimation 0
of 0
regional 0
CBF 0
( 0
rCBF 0
) 0
and 0
cerebrovascular 0
reserve 0
capacity 0
on 0
a 0
pixel 0
- 0
by 0
- 0
pixel 0
basis 0
by 0
means 0
of 0
dynamic 0
magnetic 0
resonance 0
imaging 0
( 0
MRI 0
) 0
. 0

Cost 0
- 0
effectiveness 0
analysis 0
provides 0
a 0
rational 0
means 0
of 0
allocating 0
limited 0
health 0
care 0
resources 0
by 0
allowing 0
the 0
comparison 0
of 0
the 0
costs 0
of 0
lipid 0
- 0
lowering 0
therapy 0
, 0
in 0
particular 0
, 0
therapy 0
with 0
beta B-gene
- I-gene
hydroxy I-gene
- I-gene
beta I-gene
- I-gene
methylglutaryl I-gene
- I-gene
CoA I-gene
( I-gene
coenzyme I-gene
A I-gene
) I-gene
reductase I-gene
inhibitors 0
( 0
statins 0
) 0
, 0
with 0
the 0
costs 0
of 0
atherosclerosis 0
that 0
could 0
be 0
prevented 0
by 0
lowering 0
cholesterol 0
. 0

Although 0
E2FBP1 B-gene
lacks 0
the 0
transactivation 0
domain 0
, 0
it 0
stimulates 0
E2F B-gene
site 0
- 0
dependent 0
transcription 0
in 0
cooperation 0
with 0
E2F B-gene
- I-gene
1 I-gene
. 0

Sequencing 0
of 0
a 0
40 0
- 0
kb 0
DNA 0
segment 0
of 0
the 0
FK506 0
gene 0
cluster 0
from 0
Streptomyces 0
sp 0
. 0

The 0
predicted 0
domain 0
structures 0
of 0
FkbB B-gene
and 0
FkbC B-gene
are 0
analogous 0
to 0
that 0
of 0
FkbA B-gene
and 0
comprise 0
30 0
fatty B-gene
- I-gene
acid I-gene
- I-gene
synthase I-gene
( 0
FAS B-gene
) 0
- 0
like 0
domains 0
arranged 0
in 0
6 0
modules 0
. 0

Analysis 0
of 0
Msy2 B-gene
mRNA I-gene
expression 0
in 0
prepubertal 0
and 0
adult 0
mouse 0
testes 0
, 0
and 0
in 0
isolated 0
populations 0
of 0
germ 0
cells 0
, 0
reveals 0
maximal 0
expression 0
in 0
postmeiotic 0
round 0
spermatids 0
, 0
a 0
cell 0
type 0
with 0
abundant 0
amounts 0
of 0
stored 0
messenger 0
ribonucleoproteins 0
. 0

1 0
in 0
Ho 0
Chi 0
Minh 0
City 0
was 0
studied 0
by 0
culture 0
and 0
latex 0
agglutination 0
of 0
blood 0
, 0
cerebrospinal 0
fluid 0
, 0
urine 0
and 0
pleural 0
fluid 0
. 0

Glycogen 0
synthesis 0
and 0
catabolism 0
, 0
gluconeogenesis 0
, 0
glycolysis 0
, 0
motility 0
, 0
cell 0
surface 0
properties 0
and 0
adherence 0
are 0
modulated 0
by 0
csrA B-gene
in I-gene
Escherichia I-gene
coli I-gene
, 0
while 0
the 0
production 0
of 0
several 0
secreted 0
virulence 0
factors 0
, 0
the 0
plant 0
hypersensitive 0
response 0
elicitor 0
HrpN B-gene
( 0
Ecc B-gene
) 0
and 0
, 0
potentially 0
, 0
other 0
secondary 0
metabolites 0
are 0
regulated 0
by 0
rsmA B-gene
in I-gene
Erwinia I-gene
carotovora I-gene
. 0

The 0
cwg2 B-gene
- I-gene
1 I-gene
mutation I-gene
was 0
identified 0
as 0
a 0
guanine 0
to 0
adenine 0
substitution 0
at 0
nucleotide 0
604 0
of 0
the 0
coding 0
region 0
, 0
originating 0
the 0
change 0
A202T 0
in 0
the 0
cwg2p B-gene
. 0

Deletion 0
analysis 0
revealed 0
that 0
the 0
essential 0
domain 0
of 0
this 0
promoter 0
, 0
termed 0
the 0
ORF5/deltaX B-gene
transcript I-gene
promoter I-gene
, 0
mapped 0
to 0
nucleotides 0
1525 0
- 0
1625 0
. 0

Some 0
of 0
the 0
peptide B-gene
: I-gene
MBP I-gene
fusions I-gene
were 0
also 0
analyzed 0
using 0
surface 0
plasmon 0
resonance 0
. 0

Cardiac B-gene
myosin I-gene
- I-gene
binding I-gene
protein I-gene
C I-gene
( 0
MyBP B-gene
- I-gene
C I-gene
) 0
: 0
identification 0
of 0
protein B-gene
kinase I-gene
A I-gene
and 0
protein B-gene
kinase I-gene
C I-gene
phosphorylation 0
sites 0
. 0

Handling 0
on 0
PND 0
9 0
did 0
not 0
result 0
in 0
elevated 0
CORT 0
levels 0
in 0
any 0
of 0
the 0
groups 0
. 0

Analysis 0
of 0
chromosomal 0
DNA 0
sequence 0
immediately 0
downstream 0
of 0
the 0
transposon 0
insertion 0
identified 0
two 0
open 0
reading 0
frames 0
, 0
designated 0
csrR B-gene
and 0
csrS B-gene
, 0
which 0
exhibited 0
sequence 0
similarity 0
to 0
bacterial 0
two 0
- 0
component 0
regulatory 0
systems 0
. 0

633+/ 0
- 0
258 0
aggregates/ml 0
at 0
0 0
rpm 0
; 0
P 0
< 0
0.001 0
) 0
. 0

We 0
previously 0
delineated 0
a 0
region 0
in 0
the 0
fatty B-gene
- I-gene
acid I-gene
synthase I-gene
promoter I-gene
, 0
which 0
was 0
responsible 0
for 0
obesity 0
- 0
related 0
overexpression 0
of 0
the 0
fatty B-gene
- I-gene
acid I-gene
synthase I-gene
( 0
FAS B-gene
) 0
gene 0
, 0
by 0
negatively 0
regulating 0
the 0
activity 0
of 0
the 0
downstream 0
promoter 0
in 0
lean 0
but 0
not 0
obese 0
rat 0
fat 0
cells 0
. 0

Finally 0
, 0
using 0
in 0
vitro 0
binding 0
studies 0
, 0
we 0
showed 0
that 0
SREBP2 B-gene
was 0
able 0
to 0
displace 0
ADD1/SREBP1 B-gene
binding 0
from 0
the 0
sterol 0
regulatory 0
element 0
( 0
SRE 0
) 0
site 0
. 0

Thus 0
, 0
IRF B-gene
- I-gene
7 I-gene
exhibits 0
functional 0
similarity 0
to 0
IRF B-gene
- I-gene
3 I-gene
; 0
however 0
, 0
the 0
preferential 0
expression 0
of 0
IRF B-gene
- I-gene
7 I-gene
in 0
lymphoid 0
cells 0
( 0
the 0
cell 0
type 0
that 0
expresses 0
IFNA B-gene
) 0
suggests 0
that 0
IRF B-gene
- I-gene
7 I-gene
may 0
play 0
a 0
critical 0
role 0
in 0
regulating 0
the 0
IFNA B-gene
gene I-gene
expression 0
. 0

J 0
. 0

PURPOSE 0
: 0
The 0
role 0
interleukin B-gene
- I-gene
6 I-gene
( 0
IL B-gene
- I-gene
6 I-gene
) 0
in 0
the 0
treatment 0
of 0
congenital 0
thrombocytopenias 0
is 0
unknown 0
. 0

CKII B-gene
as 0
a 0
CD44 B-gene
- I-gene
associated I-gene
serine I-gene
kinase I-gene
therefore 0
may 0
serve 0
as 0
an 0
important 0
molecule 0
in 0
a 0
signaling 0
cascade 0
that 0
produces 0
a 0
variety 0
of 0
cellular 0
responses 0
in 0
MDA231 0
breast 0
cancer 0
cells 0
. 0

Galphaq B-gene
, 0
Galpha12 B-gene
, 0
and 0
Galpha13 B-gene
, 0
but 0
not 0
Galphai B-gene
, 0
activate 0
SRF B-gene
through 0
RhoA B-gene
. 0

Additionally 0
in 0
seven 0
subjects 0
adrenaline 0
( 0
A 0
) 0
and 0
noradrenaline 0
( 0
NA 0
) 0
concentrations 0
were 0
determined 0
. 0

Northern 0
blot 0
analyses 0
show 0
that 0
the 0
hBub1 B-gene
mRNA I-gene
level 0
is 0
abundantly 0
expressed 0
in 0
tissues 0
or 0
cells 0
with 0
a 0
high 0
mitotic 0
index 0
. 0

We 0
mapped 0
two 0
overlapping 0
expressed 0
sequence 0
tag 0
clones 0
within 0
a 0
genomic 0
contig 0
on 0
human 0
chromosome 0
5 0
, 0
band 0
q31 0
. 0

Htra2 B-gene
- I-gene
beta3 I-gene
is 0
developmentally 0
regulated 0
and 0
expressed 0
predominantly 0
in 0
brain 0
, 0
liver 0
testis 0
, 0
and 0
weakly 0
in 0
kidney 0
. 0

Gng3lg B-gene
transcripts I-gene
are 0
expressed 0
in 0
a 0
variety 0
of 0
tissues 0
including 0
both 0
brain 0
and 0
testes 0
. 0

Using 0
an 0
interspecific 0
backcross 0
panel 0
, 0
we 0
localized 0
both 0
Gng3 B-gene
and 0
Gng3lg B-gene
to 0
the 0
same 0
locus 0
on 0
chromosome 0
19 0
. 0

We 0
also 0
raised 0
a 0
polyclonal 0
antibody 0
against 0
the 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
fusion I-gene
protein I-gene
containing 0
the 0
NH2 0
- 0
terminal 0
86 0
amino 0
acids 0
of 0
human B-gene
NRAMP2 I-gene
. 0

Inhibition 0
of 0
the 0
apolipoprotein B-gene
B I-gene
mRNA I-gene
editing 0
enzyme 0
- 0
complex 0
by 0
hnRNP B-gene
C1 I-gene
protein I-gene
and 0
40S B-gene
hnRNP I-gene
complexes I-gene
. 0

SRC B-gene
- I-gene
1 I-gene
can 0
relieve 0
the 0
NF B-gene
- I-gene
kappaB I-gene
- 0
mediated 0
repression 0
of 0
GR B-gene
activity 0
. 0

However 0
the 0
sequence 0
surrounding 0
the 0
transcription 0
start 0
site 0
CTCA 0
( 0
+1 0
) 0
TTCC 0
was 0
similar 0
to 0
the 0
consensus 0
CTCA 0
( 0
+1 0
) 0
NTCT 0
( 0
N 0
is 0
any 0
nucleoside 0
) 0
for 0
an 0
initiator 0
element 0
found 0
in 0
terminal B-gene
deoxynucleotidyltransferase I-gene
and 0
a 0
number 0
of 0
other 0
highly 0
regulated 0
genes 0
. 0

These 0
results 0
indicate 0
that 0
the 0
total 0
number 0
of 0
subunit 0
c 0
in 0
F0 B-gene
should 0
be 0
a 0
multiple 0
of 0
2 0
and 0
3 0
. 0

Expression 0
of 0
a 0
dominant 0
- 0
negative 0
mutant 0
of 0
JNK1 B-gene
also 0
suppressed 0
glucose 0
deprivation 0
- 0
induced 0
JNK1 B-gene
activation 0
as 0
well 0
as 0
HSP70 B-gene
gene I-gene
expression 0
. 0

The 0
interaction 0
of 0
AF 0
- 0
1 0
with 0
proteins 0
that 0
regulate 0
distinct 0
steps 0
of 0
transcription 0
may 0
provide 0
a 0
mechanism 0
for 0
synergistic 0
activation 0
of 0
gene 0
expression 0
by 0
AF 0
- 0
1 0
. 0

The 0
role 0
of 0
protein B-gene
kinase I-gene
C I-gene
signaling 0
in 0
activated 0
DRA B-gene
transcription 0
. 0

Ligand 0
binding 0
to 0
the 0
receptor 0
complex 0
leads 0
to 0
tyrosine 0
phosphorylation 0
and 0
activation 0
of 0
Janus B-gene
kinases I-gene
( 0
Jak B-gene
) 0
, 0
phosphorylation 0
of 0
the 0
signal B-gene
transducing I-gene
subunit I-gene
gp130 I-gene
, 0
followed 0
by 0
recruitment 0
and 0
phosphorylation 0
of 0
the 0
signal B-gene
transducer I-gene
and I-gene
activator I-gene
of I-gene
transcription I-gene
factors I-gene
STAT3 B-gene
and 0
STAT1 B-gene
and 0
the 0
src B-gene
homology I-gene
domain I-gene
( 0
SH2 B-gene
) 0
- 0
containing 0
protein B-gene
tyrosine I-gene
phosphatase I-gene
( 0
SHP2 B-gene
) 0
. 0

Interestingly 0
, 0
an 0
increase 0
of 0
distance 0
per 0
se 0
did 0
not 0
have 0
a 0
deleterious 0
effect 0
on 0
translation 0
efficiency 0
. 0

We 0
also 0
mapped 0
a 0
3' 0
- 0
polyadenylation 0
site 0
504bp 0
downstream 0
of 0
the 0
TGA 0
stop 0
codon 0
, 0
consistent 0
with 0
the 0
2.5kb 0
transcript 0
size 0
. 0

RBP56 B-gene
protein I-gene
turned 0
out 0
to 0
be 0
hTAFII68 B-gene
which 0
was 0
isolated 0
as 0
a 0
TATA B-gene
- I-gene
binding I-gene
protein I-gene
associated I-gene
factor I-gene
( 0
TAF B-gene
) 0
from 0
a 0
sub 0
- 0
population 0
of 0
TFIID B-gene
complexes I-gene
( 0
Bertolotti 0
A. 0
, 0
Lutz 0
, 0
Y. 0
, 0
Heard 0
, 0
D.J. 0
, 0
Chambon 0
, 0
P. 0
, 0
Tora 0
, 0
L. 0
, 0
1996. 0
hTAFII68 B-gene
, 0
a 0
novel 0
RNA/ssDNA 0
- 0
binding 0
protein 0
with 0
homology 0
to 0
the 0
proto 0
- 0
oncoproteins 0
TLS/FUS B-gene
and 0
TLS/FUS I-gene

An 0
electrophoretic 0
mobility 0
shift 0
assay 0
was 0
performed 0
to 0
characterize 0
the 0
binding 0
property 0
of 0
TR2 B-gene
and 0
its 0
truncated 0
isoform 0
. 0

Gel 0
- 0
mobility 0
shift 0
analysis 0
was 0
also 0
performed 0
for 0
the 0
CCAAT 0
motif 0
at 0
- 0
67 0
. 0

BACKGROUND 0
: 0
The 0
c B-gene
- I-gene
myc I-gene
proto I-gene
- I-gene
oncogene I-gene
has 0
been 0
suggested 0
to 0
play 0
key 0
roles 0
in 0
cell 0
proliferation 0
, 0
differentiation 0
, 0
transformation 0
and 0
apoptosis 0
. 0

AMY B-gene
- I-gene
1 I-gene
was 0
localized 0
in 0
the 0
cytoplasm 0
in 0
cells 0
expressing 0
c B-gene
- I-gene
myc I-gene
at 0
low 0
levels 0
, 0
but 0
in 0
the 0
nucleus 0
in 0
the 0
cells 0
of 0
a 0
high 0
c B-gene
- I-gene
myc I-gene
expression 0
in 0
transiently 0
transfected 0
cells 0
. 0

RESULTS 0
: 0
We 0
identified 0
a 0
full 0
- 0
length 0
cDNA 0
with 0
an 0
open 0
reading 0
frame 0
of 0
2883 0
bp 0
corresponding 0
to 0
a 0
predicted 0
protein 0
of 0
961 0
amino 0
acids 0
that 0
shares 0
greater 0
than 0
95 0
% 0
homology 0
with 0
the 0
rat B-gene
gamma I-gene
- I-gene
aminobutyric I-gene
acid I-gene
B I-gene
( I-gene
GABAB I-gene
) I-gene
receptor I-gene
. 0

On 0
Day 0
8 0
, 0
the 0
CIDR 0
- 0
B 0
was 0
removed 0
and 0
500 0
micrograms 0
cloprostenol 0
injected 0
, 0
IM 0
. 0

Antidepressant 0
- 0
like 0
properties 0
of 0
some 0
serotonin B-gene
receptor I-gene
ligands 0
and 0
calcium 0
channel 0
antagonists 0
measured 0
with 0
the 0
forced 0
swimming 0
test 0
in 0
mice 0
. 0

Another 0
tentative 0
hotspot 0
mutation 0
in 0
the 0
third 0
patient 0
, 0
a 0
frame 0
shift 0
caused 0
by 0
a 0
G 0
nucleotide 0
insertion 0
in 0
a 0
monotonous 0
repeat 0
of 0
six 0
Gs 0
in 0
HPRT B-gene
exon I-gene
3 I-gene
, 0
has 0
been 0
reported 0
previously 0
in 0
three 0
other 0
LN 0
patients 0
. 0

SRF B-gene
- 0
deficient 0
embryos 0
( 0
Srf B-gene
- 0
/ 0
- 0
) 0
have 0
a 0
severe 0
gastrulation 0
defect 0
and 0
do 0
not 0
develop 0
to 0
term 0
. 0

These 0
characteristic 0
structural 0
features 0
were 0
used 0
to 0
create 0
the 0
abbreviation 0
AZF1 B-gene
( 0
Asparagine B-gene
- I-gene
rich I-gene
Zinc I-gene
Finger I-gene
protein I-gene
) 0
. 0

Over 0
- 0
expression 0
of 0
Azf1p B-gene
in 0
the 0
yeast 0
cell 0
does 0
not 0
influence 0
the 0
expression 0
level 0
of 0
the 0
mitochondrial B-gene
transcription I-gene
factor I-gene
Mtf1p I-gene
, 0
indicating 0
that 0
the 0
influence 0
of 0
Azf1p B-gene
on 0
the 0
suppression 0
of 0
the 0
special 0
mitochondrial B-gene
RNA I-gene
polymerase I-gene
mutant I-gene
is 0
an 0
indirect 0
one 0
. 0

We 0
have 0
generated 0
a 0
computer 0
model 0
of 0
the 0
C 0
- 0
terminal 0
domain 0
of 0
the 0
434 0
repressor 0
based 0
on 0
the 0
crystal 0
structure 0
of 0
the 0
homologous B-gene
UmuD I-gene
' I-gene
protein I-gene
. 0

Large 0
- 0
scale 0
sequencing 0
of 0
two 0
regions 0
in 0
human 0
chromosome 0
7q22 0
: 0
analysis 0
of 0
650 0
kb 0
of 0
genomic 0
sequence 0
around 0
the 0
EPO B-gene
and 0
CUTL1 B-gene
loci I-gene
reveals 0
17 0
genes 0
. 0

Because 0
Trp53 B-gene
( 0
the 0
mouse B-gene
homolog I-gene
of I-gene
human I-gene
TP53 I-gene
) 0
is 0
located 0
with 0
Tk1 B-gene
on 0
chromosome 0
11 0
and 0
is 0
critical 0
in 0
regulating 0
cellular 0
responses 0
following 0
exposure 0
to 0
DNA 0
damaging 0
agents 0
, 0
we 0
wanted 0
to 0
determine 0
if 0
these 0
mouse 0
lymphoma 0
cells 0
harbor 0
mutations 0
in 0
Trp53 B-gene
. 0

One 0
of 0
these 0
fragments 0
shows 0
the 0
highest 0
amino 0
acid 0
sequence 0
homology 0
to 0
the 0
insect 0
ecdysone 0
inducible 0
gene B-gene
E75 I-gene
. 0

The 0
full 0
- 0
length 0
N B-gene
gene I-gene
, 0
encoded 0
by 0
open 0
reading 0
frame 0
7 0
, 0
was 0
cloned 0
from 0
the 0
Canadian 0
PRRS 0
virus 0
, 0
PA 0
- 0
8 0
. 0

Based 0
on 0
sequence 0
homology 0
, 0
the 0
genes 0
were 0
identified 0
as 0
TEF B-gene
, 0
encoding 0
translation B-gene
elongation I-gene
factor I-gene
- I-gene
1 I-gene
alpha I-gene
and 0
RPS7 B-gene
, 0
encoding 0
ribosomal 0
protein 0
S7 B-gene
. 0

We 0
have 0
previously 0
shown 0
that 0
ARNO B-gene
localizes 0
to 0
the 0
plasma 0
membrane 0
in 0
vivo 0
and 0
efficiently 0
catalyzes 0
ARF6 B-gene
nucleotide 0
exchange 0
in 0
vitro 0
. 0

Renal 0
pathology 0
and 0
long 0
- 0
term 0
outcome 0
in 0
childhood 0
SLE 0
. 0

Transcription 0
factors 0
of 0
the 0
Stat B-gene
family I-gene
are 0
controlled 0
by 0
protein 0
kinases 0
. 0

We 0
propose 0
that 0
two 0
pathways 0
regulate 0
Stat5 B-gene
serine 0
phosphorylation 0
, 0
one 0
that 0
is 0
prolactin B-gene
- 0
activated 0
and 0
PD98059 0
- 0
resistant 0
and 0
one 0
that 0
is 0
constitutively 0
active 0
and 0
PD98059 0
- 0
sensitive 0
and 0
preferentially 0
targets 0
Stat5a B-gene
. 0

An 0
approximately 0
37 0
- 0
kDa 0
cytoplasmic 0
protein 0
is 0
rapidly 0
tyrosine 0
- 0
phosphorylated 0
in 0
the 0
response 0
of 0
mouse 0
BAC1.2F5 0
macrophages 0
to 0
colony B-gene
stimulating I-gene
factor I-gene
- I-gene
1 I-gene
( 0
CSF B-gene
- I-gene
1 I-gene
) 0
. 0
pp37 B-gene
was 0
purified 0
from 0
the 0
cytosolic 0
fraction 0
by 0
anti B-gene
- I-gene
Tyr I-gene
( I-gene
P I-gene
) I-gene
affinity 0
chromatography 0
, 0
size 0
exclusion 0
chromatography 0
, 0
and 0
C4 0
reverse 0
phase 0
high 0
pressure 0
liquid 0
chromatography 0
. 0

Dose 0
of 0
20 0
ig 0
were 0
administered 0
within 0
a 0
scheme 0
from 0
0.1 0
to 0
6 0
months 0
in 0
order 0
to 0
study 0
its 0
immunogenicity 0
, 0
which 0
was 0
evaluated 0
at 0
2 0
, 0
7 0
, 0
and 0
12 0
months 0
after 0
the 0
first 0
dose 0
. 0

The 0
various 0
available 0
data 0
strongly 0
suggesting 0
an 0
environmental 0
toxic 0
origin 0
for 0
the 0
`` 0
sperm 0
fall 0
'' 0
will 0
be 0
presented 0
as 0
well 0
as 0
the 0
most 0
frequently 0
suspected 0
class 0
of 0
substances 0
, 0
the 0
xenoestrogens 0
. 0

This 0
association 0
was 0
independently 0
significant 0
for 0
patients 0
treated 0
primarily 0
( 0
not 0
for 0
recurrence 0
) 0
. 0

CONCLUSION 0
: 0
Local 0
control 0
was 0
highest 0
with 0
Preop 0
in 0
patients 0
presenting 0
primarily 0
with 0
gross 0
disease 0
, 0
and 0
with 0
Postop 0
in 0
patients 0
presenting 0
primarily 0
following 0
gross 0
total 0
excision 0
. 0

Its 0
interaction 0
with 0
RFX5 B-gene
and 0
RFXAP B-gene
is 0
essential 0
for 0
binding 0
of 0
the 0
RFX B-gene
complex I-gene
to 0
MHC B-gene
- I-gene
II I-gene
promoters I-gene
. 0

We 0
have 0
previously 0
mapped 0
the 0
defect 0
in 0
RIIIS/J 0
to 0
distal 0
mouse 0
Chr 0
11 0
, 0
distinct 0
from 0
the 0
Vwf B-gene
locus I-gene
on 0
Chr 0
6 0
. 0

These 0
data 0
may 0
also 0
aid 0
in 0
the 0
localization 0
of 0
other 0
disease 0
loci 0
mapped 0
to 0
this 0
region 0
, 0
including 0
the 0
gene 0
for 0
tricho 0
- 0
dento 0
- 0
osseous 0
syndrome 0
and 0
a 0
murine 0
locus 0
for 0
susceptibility 0
to 0
ozone 0
- 0
induced 0
acute 0
lung 0
injury 0
. 0

Copyright 0
1998 0
Academic 0
Press 0
. 0

An 0
open 0
reading 0
frame 0
encoding 0
a 0
protein 0
which 0
shows 0
significant 0
similarity 0
to 0
invertases B-gene
and 0
resolvases B-gene
was 0
located 0
immediately 0
upstream 0
of 0
the 0
Pac25I B-gene
R B-gene
- I-gene
M I-gene
operon I-gene
. 0

Identification 0
of 0
a 0
new 0
gene 0
in 0
the 0
streptococcal 0
plasmid 0
pLS1 0
: 0
the 0
rnaI B-gene
gene I-gene
. 0

Rather 0
, 0
usp B-gene
is 0
required 0
in 0
late 0
third 0
instar 0
larvae 0
for 0
appropriate 0
developmental 0
and 0
transcriptional 0
responses 0
to 0
the 0
ecdysone 0
pulse 0
that 0
triggers 0
puparium 0
formation 0
. 0

An 0
intact 0
neurovascular 0
supply 0
is 0
essential 0
for 0
the 0
viability 0
of 0
a 0
muscle 0
flap 0
. 0

Examination 0
of 0
DNA 0
: 0
protein 0
binding 0
complexes 0
by 0
gel 0
- 0
shift 0
analysis 0
indicated 0
that 0
nuclear 0
factors 0
from 0
both 0
proliferative 0
and 0
growth 0
- 0
arrested 0
cells 0
bound 0
to 0
the 0
DNA 0
fragment 0
spanning 0
- 0
949 0
- 0
- 0
722 0
bp 0
. 0

BACKGROUND 0
: 0
Studies 0
in 0
lean 0
men 0
show 0
poor 0
regulation 0
of 0
energy 0
( 0
EB 0
) 0
and 0
fat 0
balance 0
( 0
FB 0
) 0
during 0
manipulation 0
of 0
dietary 0
ratios 0
of 0
fat 0
to 0
carbohydrate 0
. 0

Fatal 0
apneusis 0
was 0
observed 0
under 0
following 0
conditions 0
: 0
( 0
1 0
) 0
Persistent 0
apnea 0
was 0
produced 0
after 0
a 0
single 0
KA 0
microinjection 0
in 0
one 0
side 0
of 0
the 0
VRG 0
- 0
Apa 0
( 0
5 0
animals 0
) 0
. 0

A 0
comparative 0
analysis 0
of 0
the 0
reported 0
MOCT 0
- 0
associated 0
malignant 0
melanomas 0
emphasizes 0
the 0
singularity 0
of 0
our 0
case 0
in 0
the 0
amelanotic 0
character 0
of 0
the 0
melanoma 0
, 0
its 0
lymphotropism 0
and 0
the 0
coexistence 0
of 0
invasive 0
squamous 0
cell 0
carcinoma 0
. 0

RESULTS 0
: 0
An 0
herpetic 0
seroconversion 0
is 0
observed 0
with 0
presence 0
of 0
type 0
I 0
herpes 0
simplex 0
virus 0
( 0
HSV 0
I 0
) 0
nucleic 0
acids 0
in 0
the 0
recipient 0
's 0
aqueous 0
humor 0
. 0

These 0
results 0
indicate 0
that 0
HIV 0
- 0
1 0
Gag B-gene
sequences I-gene
can 0
influence 0
the 0
viral B-gene
PR I-gene
- 0
mediated 0
processing 0
of 0
the 0
MuLV 0
TM B-gene
Env I-gene
protein I-gene
p15 B-gene
( I-gene
E I-gene
) I-gene
. 0

These 0
results 0
demonstrate 0
a 0
specific 0
association 0
of 0
SIV 0
and 0
HIV B-gene
- I-gene
2 I-gene
nef I-gene
, 0
but 0
not 0
HIV B-gene
- I-gene
1 I-gene
nef I-gene
, 0
with 0
TCRzeta B-gene
. 0

Competition 0
EMSA 0
established 0
that 0
constitutively 0
expressed 0
nuclear 0
proteins 0
bound 0
the 0
KCS B-gene
element I-gene
selectively 0
; 0
KCS B-gene
protein I-gene
binding 0
activity 0
correlated 0
with 0
promoter 0
activity 0
in 0
the 0
transient 0
transfection 0
reporter 0
assay 0
. 0

Mechanism 0
of 0
interferon B-gene
action 0
: 0
identification 0
of 0
essential 0
positions 0
within 0
the 0
novel 0
15 B-gene
- I-gene
base I-gene
- I-gene
pair I-gene
KCS I-gene
element I-gene
required 0
for 0
transcriptional 0
activation 0
of 0
the 0
RNA B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
pkr I-gene
gene I-gene
. 0

GH B-gene
failed 0
to 0
stimulate 0
phosphorylation 0
or 0
activation 0
of 0
Jun B-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
under 0
the 0
conditions 0
used 0
. 0

Expression 0
of 0
a 0
novel 0
murine B-gene
phospholipase I-gene
D I-gene
homolog I-gene
coincides 0
with 0
late 0
neuronal 0
development 0
in 0
the 0
forebrain 0
. 0

We 0
detected 0
no 0
effect 0
of 0
deleting 0
YCL024W B-gene
, 0
either 0
alone 0
or 0
in 0
combination 0
with 0
deletion 0
of 0
GIN4 B-gene
. 0

Paralemmin B-gene
is 0
also 0
phosphorylated 0
, 0
and 0
its 0
mRNA 0
is 0
differentially 0
spliced 0
in 0
a 0
tissue 0
- 0
specific 0
and 0
developmentally 0
regulated 0
manner 0
. 0

The 0
deduced 0
amino 0
acid 0
sequence 0
of 0
CBP90 B-gene
had 0
no 0
significant 0
similarity 0
to 0
any 0
other 0
protein 0
, 0
but 0
it 0
had 0
a 0
proline 0
- 0
rich 0
domain 0
at 0
the 0
C 0
- 0
terminal 0
region 0
. 0

The 0
effect 0
of 0
low 0
- 0
profile 0
serine 0
substitutions 0
in 0
the 0
V3 B-gene
loop 0
of 0
HIV 0
- 0
1 0
gp120 B-gene
IIIB/LAI I-gene
on 0
the 0
immunogenicity 0
of 0
the 0
IIIB/LAI I-gene

Transcription 0
start 0
site 0
mapping 0
identified 0
the 0
presence 0
of 0
an 0
aphidicolin 0
- 0
sensitive 0
late 0
transcript 0
arising 0
from 0
a 0
TAAG 0
motif 0
located 0
at 0
- 0
352 0
nucleotides 0
and 0
an 0
aphidicolin 0
- 0
insensitive 0
early 0
transcript 0
originating 0
from 0
a 0
TTGT 0
motif 0
located 0
35 0
nucleotides 0
downstream 0
to 0
a 0
TATA 0
box 0
at 0
- 0
312 0
nucleotides 0
, 0
with 0
respect 0
to 0
the 0
+1 0
ATG 0
of 0
lef2 B-gene
. 0

The 0
human B-gene
2 I-gene
' I-gene
, I-gene
5' I-gene
- I-gene
oligoadenylate I-gene
( I-gene
2 I-gene
- I-gene
5A I-gene
) I-gene
synthetases I-gene
are 0
members 0
of 0
a 0
family 0
interferon B-gene
( 0
IFN B-gene
) 0
- 0
inducible 0
anti B-gene
- I-gene
viral I-gene
proteins I-gene
. 0

Our 0
findings 0
demonstrate 0
a 0
dose 0
- 0
dependent 0
blockade 0
of 0
the 0
mechanical 0
sensitivity 0
caused 0
by 0
a 0
mild 0
thermal 0
injury 0
by 0
both 0
GBP 0
and 0
IBG 0
. 0

These 0
striations 0
were 0
caused 0
by 0
contact 0
between 0
the 0
sharp 0
edge 0
of 0
the 0
upper 0
canine 0
and 0
the 0
P3 0
during 0
honing 0
( 0
canine/premolar 0
complex 0
) 0
. 0

Low 0
PbrO2 0
readings 0
, 0
however 0
, 0
could 0
be 0
caused 0
by 0
local 0
microhemorrhages 0
, 0
undetectable 0
on 0
CT 0
or 0
MRI 0
. 0

The 0
consequences 0
of 0
intensive 0
swine 0
production 0
on 0
the 0
environment 0
and 0
possible 0
solutions 0
by 0
means 0
of 0
nutrition 0
are 0
outlined 0
. 0

This 0
study 0
demonstrates 0
that 0
alteration 0
of 0
CDKN2 B-gene
is 0
one 0
of 0
the 0
most 0
frequent 0
genetic 0
abnormalities 0
in 0
prostate 0
cancer 0
and 0
may 0
contribute 0
to 0
prostate 0
carcinogenesis 0
. 0

The 0
pharmacokinetic 0
parameters 0
which 0
helped 0
predict 0
these 0
toxicities 0
included 0
area 0
under 0
the 0
curve 0
and 0
peak 0
plasma 0
level 0
. 0

A 0
Chinese 0
( 0
HK 0
) 0
SF 0
- 0
36 0
survey 0
form 0
was 0
developed 0
by 0
an 0
iterative 0
translation 0
process 0
. 0

However 0
, 0
the 0
use 0
of 0
cyclosporin 0
A 0
is 0
associated 0
with 0
an 0
increased 0
prevalence 0
of 0
hypertension 0
in 0
kidney 0
transplant 0
recipients 0
. 0

PURPOSE 0
: 0
To 0
determine 0
the 0
effects 0
of 0
hypercholesterolemia 0
and 0
atherosclerosis 0
- 0
induced 0
chronic 0
cavernosal 0
arterial 0
insufficiency 0
on 0
cavernosal 0
smooth 0
muscle 0
tone 0
, 0
nitric B-gene
oxide I-gene
synthase I-gene
( 0
NOS B-gene
) 0
activity 0
and 0
cavernosal 0
tissue 0
synthesis 0
of 0
constrictor 0
eicosanoids 0
. 0

Characterization 0
of 0
the 0
regulatory 0
regions 0
of 0
the 0
human B-gene
aromatase I-gene
( 0
P450arom B-gene
) 0
gene 0
involved 0
in 0
placenta 0
- 0
specific 0
expression 0
. 0

Recombinant B-gene
FVIIa I-gene
was 0
stable 0
in 0
the 0
infusion 0
pump 0
for 0
several 0
days 0
at 0
room 0
temperature 0
and 0
for 0
24 0
h 0
at 0
body 0
temperature 0
. 0

CD4 B-gene
lymphocyte 0
and 0
viral 0
load 0
levels 0
suggested 0
an 0
optimal 0
response 0
to 0
ARV 0
therapy 0
at 0
the 0
time 0
LD 0
developed 0
. 0

( 0
1992 0
) 0
Biochemistry 0
31 0
, 0
3351 0
- 0
3358 0
] 0
. 0

Levels 0
of 0
serum 0
IgE B-gene
were 0
measured 0
monthly 0
, 0
and 0
nasal 0
IgE B-gene
was 0
measured 0
at 0
the 0
height 0
and 0
end 0
of 0
the 0
season 0
. 0

A 0
mutation 0
in 0
the 0
5 0
' 0
C2U4 0
repeat 0
causes 0
underaccumulation 0
of 0
snR13F B-gene
, 0
whereas 0
mutations 0
in 0
the 0
3 0
' 0
C2U4 0
repeat 0
cause 0
the 0
accumulation 0
of 0
two 0
novel 0
RNAs 0
that 0
migrate 0
in 0
the 0
500 0
- 0
nt 0
range 0
. 0

By 0
directly 0
interacting 0
with 0
both 0
Arfs B-gene
and 0
tyrosine B-gene
kinases I-gene
involved 0
in 0
regulating 0
cell 0
growth 0
and 0
cytoskeletal 0
organization 0
, 0
ASAP1 B-gene
could 0
coordinate 0
membrane 0
remodeling 0
events 0
with 0
these 0
processes 0
. 0

By 0
DNase B-gene
I I-gene
footprint 0
analysis 0
of 0
the 0
PNR 0
element 0
, 0
a 0
palindrome 0
of 0
two 0
high 0
- 0
affinity 0
Ets B-gene
- I-gene
binding I-gene
sites I-gene
( 0
CTTCCCTGGAAG 0
) 0
was 0
identified 0
. 0

These 0
sorting B-gene
nexins I-gene
also 0
associated 0
with 0
the 0
long 0
isoform 0
of 0
the 0
leptin B-gene
receptor I-gene
but 0
not 0
with 0
the 0
short 0
and 0
medium 0
isoforms 0
. 0

Cyclophilins B-gene
are 0
cis B-gene
- I-gene
trans I-gene
- I-gene
peptidyl I-gene
- I-gene
prolyl I-gene
isomerases I-gene
that 0
bind 0
to 0
and 0
are 0
inhibited 0
by 0
the 0
immunosuppressant 0
cyclosporin 0
A 0
( 0
CsA 0
) 0
. 0

In 0
vitro 0
protein 0
retention 0
experiments 0
in 0
which 0
Hsp90 B-gene
heterocomplexes I-gene
were 0
precipitated 0
resulted 0
in 0
coprecipitation 0
of 0
Cns1 B-gene
. 0

The 0
Ras B-gene
- I-gene
related I-gene
GTPases I-gene
are 0
small 0
, 0
20 0
- 0
to 0
25 0
- 0
kDa 0
proteins 0
which 0
cycle 0
between 0
an 0
inactive 0
GDP 0
- 0
bound 0
form 0
and 0
an 0
active 0
GTP 0
- 0
bound 0
state 0
. 0

To 0
modulate 0
transcription 0
, 0
regulatory 0
factors 0
communicate 0
with 0
basal 0
transcription 0
factors 0
and/or 0
RNA B-gene
polymerases I-gene
in 0
a 0
variety 0
of 0
ways 0
. 0

Endogenous 0
RMP B-gene
was 0
immunologically 0
detected 0
interacting 0
with 0
assembled 0
RPB5 B-gene
in 0
RNA B-gene
polymerase I-gene
in 0
mammalian 0
cells 0
. 0

In 0
this 0
study 0
, 0
rabbits 0
were 0
used 0
to 0
evaluate 0
the 0
sutured 0
wound 0
reaction 0
with 0
Dexon 0
or 0
nylon 0
in 0
the 0
conjunctival 0
flap 0
1 0
, 0
4 0
, 0
7 0
, 0
14 0
and 0
28 0
days 0
after 0
trabeculectomy 0
surgery 0
with 0
or 0
without 0
the 0
use 0
of 0
mitomycin 0
- 0
C 0
. 0

The 0
mapping 0
was 0
completed 0
with 0
Southern 0
blotting 0
and 0
restriction 0
analysis 0
. 0

The 0
zona 0
pellucida 0
( 0
ZP 0
) 0
, 0
the 0
extracellular 0
glycocalyx 0
that 0
surrounds 0
the 0
oocyte 0
, 0
is 0
well 0
known 0
to 0
mediate 0
homologous 0
gamete 0
interaction 0
. 0

Therapeutic 0
use 0
of 0
continuous 0
subcutaneous 0
infusion 0
of 0
recombinant B-gene
human I-gene
erythropoietin I-gene
in 0
malnourished 0
predialysis 0
anemic 0
patients 0
with 0
diabetic 0
nephropathy 0
. 0

Although 0
pathological 0
thyroid 0
function 0
is 0
related 0
to 0
changes 0
in 0
energy 0
expenditure 0
and 0
body 0
composition 0
, 0
its 0
possible 0
influence 0
on 0
leptin B-gene
levels 0
remains 0
to 0
be 0
determined 0
. 0

These 0
cognitive 0
deficits 0
were 0
prevented 0
in 0
animals 0
treated 0
with 0
MK 0
- 0
801 0
during 0
SE 0
. 0

Here 0
we 0
demonstrate 0
that 0
the 0
mechanism 0
of 0
activation 0
of 0
HIF B-gene
- I-gene
1alpha I-gene
is 0
a 0
multi 0
- 0
step 0
process 0
which 0
includes 0
hypoxia 0
- 0
dependent 0
nuclear 0
import 0
and 0
activation 0
( 0
derepression 0
) 0
of 0
the 0
transactivation 0
domain 0
, 0
resulting 0
in 0
recruitment 0
of 0
the 0
CREB B-gene
- I-gene
binding I-gene
protein I-gene
( 0
CBP B-gene
) 0
/p300 B-gene
coactivator I-gene
. 0

Thus 0
, 0
hypoxia 0
- 0
inducible 0
nuclear 0
import 0
and 0
transactivation 0
by 0
recruitment 0
of 0
CBP B-gene
can 0
be 0
functionally 0
separated 0
from 0
one 0
another 0
and 0
play 0
critical 0
roles 0
in 0
signal 0
transduction 0
by 0
HIF B-gene
- I-gene
1alpha I-gene
. 0

The 0
rat B-gene
aldolase I-gene
C I-gene
gene I-gene
encodes 0
a 0
glycolytic 0
enzyme 0
strongly 0
expressed 0
in 0
adult 0
brain 0
. 0

A 0
synergistic 0
effect 0
on 0
HCK B-gene
promoter I-gene
activity 0
was 0
observed 0
at 0
high 0
concentrations 0
of 0
Sp1 B-gene
. 0

Quinone 0
- 0
binding 0
domain 0
and 0
amino 0
acid 0
residues 0
involved 0
in 0
quinone 0
binding 0
. 0

Western 0
analyses 0
with 0
antisera 0
raised 0
against 0
Lu B-gene
- I-gene
ECAM I-gene
- I-gene
1 I-gene
peptides I-gene
show 0
that 0
the 0
N 0
- 0
terminal 0
region 0
of 0
the 0
predicted 0
open 0
reading 0
frame 0
is 0
present 0
only 0
in 0
the 0
larger 0
size 0
proteins 0
( 0
i.e 0
. 0

Mammalian 0
sperm 0
motility 0
is 0
regulated 0
by 0
a 0
cascade 0
of 0
cAMP 0
- 0
dependent 0
protein 0
phosphorylation 0
events 0
mediated 0
by 0
protein B-gene
kinase I-gene
A I-gene
. 0

In 0
this 0
paper 0
, 0
we 0
show 0
that 0
, 0
like 0
BAP2 B-gene
, 0
the 0
expression 0
of 0
the 0
BAP3 B-gene
gene I-gene
in 0
S. 0
cerevisiae 0
is 0
induced 0
by 0
the 0
addition 0
of 0
branched 0
- 0
chain 0
amino 0
acids 0
to 0
the 0
medium 0
. 0

Effect 0
of 0
enteral 0
nutritional 0
products 0
differing 0
in 0
carbohydrate 0
and 0
fat 0
on 0
indices 0
of 0
carbohydrate 0
and 0
lipid 0
metabolism 0
in 0
patients 0
with 0
NIDDM 0
. 0

Low 0
- 0
grade 0
gastric 0
MALT 0
lymphoma 0
and 0
helicobacter 0
heilmannii 0
( 0
Gastrospirillum 0
hominis 0

These 0
studies 0
support 0
the 0
view 0
that 0
HMG B-gene
I I-gene
( I-gene
Y I-gene
) I-gene
is 0
an 0
important 0
cofactor 0
for 0
HLA B-gene
- I-gene
DRA I-gene
gene I-gene
activation 0
by 0
Oct B-gene
- I-gene
2A I-gene
and 0
provide 0
insights 0
into 0
its 0
mechanism 0
of 0
action 0
. 0

In 0
contrast 0
to 0
hemodynamic 0
and 0
histopathological 0
predictors 0
of 0
survival 0
, 0
vWF B-gene
: 0
Ag 0
does 0
not 0
require 0
invasive 0
techniques 0
to 0
be 0
determined 0
. 0

CONCLUSION 0
: 0
We 0
were 0
unable 0
to 0
identify 0
features 0
of 0
disease 0
likely 0
to 0
be 0
associated 0
with 0
a 0
clinically 0
useful 0
response 0
to 0
inhaled 0
NO 0
therapy 0
using 0
the 0
parameters 0
studied 0
. 0

We 0
find 0
that 0
BCL B-gene
- I-gene
6 I-gene
POZ 0
domain 0
mutations 0
that 0
disrupt 0
the 0
interaction 0
with 0
N B-gene
- I-gene
CoR I-gene
and 0
SMRT B-gene
no 0
longer 0
repress 0
transcription 0
. 0

Partial 0
characterization 0
of 0
the 0
active 0
site 0
human B-gene
platelet I-gene
cAMP I-gene
phosphodiesterase I-gene
, 0
PDE3A B-gene
, 0
by 0
site 0
- 0
directed 0
mutagenesis 0
. 0

This 0
core 0
sequence 0
, 0
along 0
with 0
additional 0
nonspecific 0
downstream 0
nucleotides 0
, 0
is 0
sufficient 0
for 0
partial 0
suppression 0
of 0
spliceosome 0
assembly 0
and 0
splicing 0
of 0
BPV 0
- 0
1 0
pre 0
- 0
mRNAs 0
. 0

Over 0
- 0
expression 0
of 0
the 0
cofactor 0
p300 B-gene
, 0
which 0
functions 0
as 0
a 0
coactivator 0
of 0
myoD B-gene
- 0
mediated 0
transcription 0
, 0
alleviated 0
repression 0
by 0
COUP B-gene
- I-gene
TF I-gene
II I-gene
. 0

Familial 0
autoimmune 0
hepatitis 0
and 0
C4 B-gene
deficiency 0

No 0
mutations 0
were 0
found 0
in 0
follicular 0
adenomas 0
. 0

Since 0
glutathione B-gene
peroxidase I-gene
( 0
GPX B-gene
) 0
and 0
superoxide B-gene
dismutase I-gene
( 0
SOD B-gene
) 0
play 0
a 0
significant 0
role 0
in 0
erythrocyte 0
antioxidative 0
defence 0
, 0
it 0
is 0
very 0
important 0
to 0
determine 0
their 0
activity 0
in 0
occupationally 0
exposed 0
workers 0
. 0

Retroviral B-gene
nucleocapsid I-gene
proteins I-gene
( 0
NCPs B-gene
) 0
are 0
CCHC B-gene
- I-gene
type I-gene
zinc I-gene
finger I-gene
proteins I-gene
that 0
mediate 0
virion 0
RNA 0
binding 0
activities 0
associated 0
with 0
retrovirus 0
assembly 0
and 0
genomic 0
RNA 0
encapsidation 0
. 0

The 0
Schizosaccharomyces B-gene
pombe I-gene
rad1+ I-gene
cell I-gene
cycle I-gene
checkpoint I-gene
control I-gene
gene I-gene
is 0
required 0
for 0
S 0
- 0
phase 0
and 0
G2/M 0
arrest 0
in 0
response 0
to 0
both 0
DNA 0
damage 0
and 0
incomplete 0
DNA 0
replication 0
. 0

It 0
is 0
now 0
well 0
established 0
that 0
progression 0
through 0
the 0
eukaryotic 0
cell 0
cycle 0
is 0
controlled 0
by 0
oscillations 0
in 0
the 0
activity 0
of 0
cyclin B-gene
- I-gene
dependent I-gene
kinases I-gene
( 0
CDKs B-gene
) 0
. 0

Positive 0
genetic 0
selections 0
for 0
inhibition 0
of 0
cyclin/CDK B-gene
function 0
were 0
characterized 0
using 0
the 0
cyclin/CDK I-gene

The 0
hematopoietic B-gene
colony I-gene
- I-gene
stimulating I-gene
factors I-gene
( 0
CSF B-gene
) 0
have 0
been 0
introduced 0
into 0
clinical 0
practice 0
as 0
additional 0
supportive 0
measures 0
that 0
can 0
reduce 0
the 0
incidence 0
of 0
infectious 0
complications 0
in 0
patients 0
with 0
cancer 0
and 0
neutropenia 0
. 0

All 0
injections 0
of 0
CSF B-gene
were 0
given 0
after 0
the 0
initiation 0
of 0
neutropenia 0
and 0
continued 0
until 0
the 0
occurrence 0
of 0
an 0
absolute 0
neutrophil 0
recovery 0
. 0
rHu B-gene
GM I-gene
- I-gene
CSF I-gene
and 0
rHu B-gene
G I-gene
- I-gene
CSF I-gene
, 0
administered 0
once 0
daily 0
at 0
the 0
250 0
microg 0
m 0
( 0
- 0
2 0
) 0
day 0
( 0
- 0
1 0
) 0
and 0
5 0
microg 0
kg 0
( 0
- 0
1 0
) 0
day 0
( 0
- 0
1 0
) 0
level 0
, 0
were 0
effective 0
in 0
increasing 0
the 0
absolute 0
neutrophil 0
count 0
and 0
neutrophil 0
function 0
, 0
as 0
measured 0
by 0
an 0
automated 0
chemiluminescence 0
system 0
. 0

Expression 0
of 0
lacZ B-gene
from 0
the 0
promoter 0
of 0
the 0
Escherichia B-gene
coli I-gene
spc I-gene
operon I-gene
cloned 0
into 0
vectors 0
carrying 0
the 0
W205 0
trp B-gene
- 0
lac B-gene
fusion 0
. 0

We 0
evaluated 0
regional 0
right 0
ventricular 0
wall 0
motion 0
during 0
systole 0
in 0
patients 0
with 0
surgically 0
repaired 0
tetralogy 0
of 0
Fallot 0
( 0
TOF 0
) 0
using 0
color 0
kinesis 0
imaging 0
. 0

RT 0
- 0
PCR 0
analysis 0
showed 0
that 0
PLP B-gene
- I-gene
H I-gene
as 0
well 0
as 0
PLP B-gene
- I-gene
C I-gene
and 0
PLP B-gene
- I-gene
D I-gene
are 0
expressed 0
in 0
all 0
rat 0
strains 0
examined 0
, 0
confirming 0
that 0
PLP B-gene
diversity 0
is 0
not 0
due 0
to 0
strain 0
differences 0
. 0

Molecular 0
cloning 0
and 0
characterization 0
of 0
a 0
new 0
member 0
of 0
the 0
rat B-gene
placental I-gene
prolactin I-gene
( 0
PRL B-gene
) 0
family 0
, 0
PRL B-gene
- 0
like 0
protein B-gene
H I-gene
. 0

Interestingly 0
, 0
we 0
find 0
that 0
the 0
interaction 0
between 0
Tat B-gene
and 0
hCycT1 B-gene
requires 0
zinc 0
as 0
well 0
as 0
essential 0
cysteine 0
residues 0
in 0
both 0
proteins 0
. 0

Thus 0
, 0
we 0
have 0
identified 0
an 0
activation 0
target 0
of 0
a 0
human 0
activator 0
, 0
Oct B-gene
- I-gene
1 I-gene
, 0
within 0
its 0
cognate 0
basal 0
transcription 0
complex 0
. 0

During 0
early 0
neurogenesis 0
, 0
Vnd B-gene
protein I-gene
is 0
restricted 0
to 0
ventral 0
column 0
neuroectoderm 0
and 0
neuroblasts 0
; 0
later 0
it 0
is 0
detected 0
in 0
a 0
complex 0
pattern 0
of 0
neurons 0
. 0

The 0
repression 0
domain 0
, 0
and 0
indeed 0
the 0
entire 0
Cdc68 B-gene
protein I-gene
, 0
is 0
highly 0
conserved 0
, 0
as 0
shown 0
by 0
the 0
sequence 0
of 0
the 0
Cdc68 B-gene
functional I-gene
homolog I-gene
from 0
the 0
yeast 0
Kluyveromyces 0
lactis 0
and 0
by 0
database 0
searches 0
. 0

The 0
exodomain 0
alone 0
has 0
the 0
high 0
affinity 0
hormone 0
binding 0
site 0
but 0
is 0
not 0
capable 0
of 0
generating 0
hormonal 0
signal 0
. 0

Pyrrolidine 0
dithiocarbamate 0
, 0
a 0
potent 0
transcriptional 0
inhibitor 0
of 0
the 0
viral B-gene
LTR I-gene
, 0
abrogated 0
the 0
cytokine 0
responses 0
in 0
both 0
U1 0
and 0
ACH 0
- 0
2 0
cells 0
, 0
suggesting 0
a 0
common 0
TNF B-gene
- I-gene
alpha I-gene
- 0
mediated 0
transcriptional 0
mechanism 0
in 0
these 0
cell 0
types 0
despite 0
their 0
different 0
modes 0
of 0
provirus 0
latency 0
. 0

Furthermore 0
, 0
synergistic 0
activation 0
of 0
ERK2 B-gene
occurred 0
in 0
the 0
absence 0
of 0
changes 0
in 0
intracellular 0
Ca2+ 0
, 0
and 0
was 0
not 0
blocked 0
by 0
inhibition 0
of 0
protein B-gene
kinase I-gene
C I-gene
activity 0
and 0
represents 0
a 0
separate 0
pathway 0
by 0
which 0
CD19 B-gene
regulates 0
B 0
cell 0
function 0
. 0

The 0
retrovesical 0
hydatid 0
cyst 0
is 0
a 0
very 0
rare 0
site 0
. 0

Biochemical 0
analysis 0
reveals 0
that 0
KS1 B-gene
is 0
a 0
nuclear 0
protein 0
containing 0
two 0
transcriptional 0
repressor 0
domains 0
, 0
R1 0
and 0
R2 0
. 0

However 0
, 0
the 0
BCH 0
group 0
showed 0
inferior 0
gross 0
motor 0
performance 0
on 0
the 0
Bruininks 0
- 0
Oseretsky 0
Test 0
of 0
Motor 0
Proficiency 0
( 0
Bruininks 0
1978 0
) 0
. 0

The 0
results 0
raise 0
the 0
possibility 0
that 0
pH 0
induced 0
post 0
- 0
translational 0
modifications 0
of 0
DdRPA B-gene
are 0
involved 0
in 0
events 0
that 0
halt 0
cell 0
proliferation 0
and 0
induce 0
differentiation 0
in 0
Dictyostelium 0
. 0

We 0
report 0
here 0
that 0
, 0
for 0
a 0
constant 0
amount 0
of 0
transfected 0
DNA 0
, 0
the 0
level 0
of 0
chloramphenicol B-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
mRNA 0
is 0
increased 0
in 0
Vpr B-gene
- 0
expressing 0
cells 0
using 0
either 0
HIV 0
- 0
1 0
or 0
a 0
murine 0
leukemia B-gene
virus I-gene
( I-gene
MLV I-gene
) I-gene
SL3 I-gene
- I-gene
3 I-gene
LTR I-gene
- 0
SL3 I-gene
- I-gene
3 I-gene

We 0
identified 0
telSMN B-gene
mutations 0
in 0
11 0
of 0
these 0
unrelated 0
SMA 0
- 0
like 0
individuals 0
who 0
carry 0
a 0
single 0
copy 0
of 0
telSMN B-gene
: 0
these 0
include 0
two 0
frameshift 0
mutations 0
( 0
800ins11 0
and 0
542delGT 0
) 0
and 0
three 0
missense 0
mutations 0
( 0
A2G 0
, 0
S262I 0
, 0
and 0
T274I 0
) 0
. 0

The 0
decrease 0
of 0
TNF B-gene
receptors I-gene
by 0
IL B-gene
- I-gene
4 I-gene
was 0
accompanied 0
by 0
down 0
- 0
regulation 0
of 0
TNF B-gene
- 0
induced 0
activities 0
, 0
including 0
cytotoxicity 0
, 0
caspase B-gene
- I-gene
3 I-gene
activation 0
, 0
NF B-gene
- I-gene
kappaB I-gene
and 0
AP B-gene
- I-gene
1 I-gene
activation 0
, 0
and 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
induction 0
. 0

Type B-gene
2 I-gene
deiodinase I-gene
( 0
D2 B-gene
) 0
catalyzes 0
the 0
5' 0
- 0
deiodination 0
of 0
thyroxine 0
to 0
form 0
3,5,3' 0
- 0
triiodothyronine 0
. 0

We 0
have 0
identified 0
two 0
overlapping 0
expressed 0
sequence 0
tag 0
clones 0
, 0
which 0
contain 0
the 0
missing 0
4.4 0
- 0
kb 0
3' 0
- 0
UTR 0
of 0
the 0
human B-gene
D2 I-gene
( 0
hD2 B-gene
) 0
cDNA 0
. 0

Biol 0
. 0

Here 0
we 0
have 0
investigated 0
the 0
structural 0
requirements 0
and 0
consequences 0
of 0
regulatory 0
phosphorylation 0
for 0
the 0
interaction 0
between 0
c B-gene
- I-gene
Jun I-gene
and 0
JNK B-gene
in 0
vivo 0
. 0

P B-gene
- I-gene
CIP1 I-gene
, 0
a 0
novel 0
protein 0
that 0
interacts 0
with 0
the 0
cytosolic 0
domain 0
of 0
peptidylglycine B-gene
alpha I-gene
- I-gene
amidating I-gene
monooxygenase I-gene
, 0
is 0
associated 0
with 0
endosomes 0
. 0

Immunolocalization 0
of 0
Sop1p B-gene
revealed 0
a 0
cytoplasmic 0
distribution 0
and 0
cell 0
fractionation 0
studies 0
showed 0
that 0
a 0
significant 0
fraction 0
of 0
Sop1p B-gene
was 0
recovered 0
in 0
a 0
sedimentable 0
fraction 0
of 0
the 0
cytosolic 0
material 0
. 0

Resultant 0
activation 0
of 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase/stress I-gene
kinase/stress I-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
JNK/SAPK B-gene
) 0
. 0

Here 0
we 0
report 0
the 0
full 0
- 0
length 0
coding 0
cDNA 0
sequence 0
of 0
the 0
mouse B-gene
homologue I-gene
of I-gene
MPP3 I-gene
. 0

The 0
method 0
also 0
eliminates 0
tagging 0
of 0
venous 0
spins 0
and 0
concern 0
about 0
asymmetric 0
magnetization 0
transfer 0
effects 0
. 0

Consistent 0
with 0
this 0
, 0
purified 0
Dlk B-gene
phosphorylated 0
core 0
histones B-gene
H3 I-gene
, 0
H2A B-gene
and 0
H4 B-gene
as 0
exogenous 0
substrates 0
and 0
endogenous 0
histone B-gene
H3 I-gene
in 0
kinase 0
assays 0
with 0
nuclear 0
extracts 0
. 0

In 0
this 0
study 0
we 0
provide 0
evidence 0
that 0
B B-gene
- I-gene
Myb I-gene
is 0
a 0
direct 0
physiological 0
target 0
for 0
cyclin B-gene
A/Cdk2 I-gene
. 0

Neither 0
Ha B-gene
- I-gene
Ras I-gene
( 0
G12V 0
, 0
T35S 0
) 0
( 0
Ha B-gene
- I-gene
RasV12S35 I-gene
) 0
, 0
which 0
activates 0
the 0
Rafl B-gene
signaling 0
pathway 0
, 0
nor 0
Ha B-gene
- I-gene
Ras I-gene
( I-gene
G12V I-gene
, I-gene
E37G I-gene
) I-gene
( 0
Ha B-gene
- I-gene
RasV12G37 I-gene
) 0
, 0
which 0
stimulates 0
the 0
RalGDS B-gene
pathway 0
, 0
did 0
not 0
have 0
significant 0
effects 0
on 0
factor 0
- 0
withdrawal 0
apoptosis 0
of 0
myeloid 0
cells 0
. 0

We 0
have 0
isolated 0
a 0
novel 0
human B-gene
cyclin I-gene
, 0
cyclin B-gene
E2 I-gene
, 0
that 0
contains 0
significant 0
homology 0
to 0
cyclin B-gene
E I-gene
. 0

Initial 0
experience 0
with 0
the 0
new 0
technology 0
indicates 0
that 0
SieScape 0
is 0
an 0
alternative 0
to 0
other 0
methods 0
such 0
as 0
CT 0
and 0
MRI 0
. 0

The 0
dopamine B-gene
D4 I-gene
receptor I-gene
as 0
well 0
as 0
many 0
other 0
catecholaminergic B-gene
receptors I-gene
contain 0
several 0
putative 0
SH3 B-gene
binding I-gene
domains I-gene
. 0

The 0
highly 0
amyloidogenic 0
42 0
- 0
residue 0
form 0
of 0
Abeta B-gene
( 0
Abeta42 B-gene
) 0
is 0
the 0
first 0
species 0
to 0
be 0
deposited 0
in 0
both 0
sporadic 0
and 0
familial 0
AD 0
. 0

This 0
model 0
is 0
supported 0
by 0
experiments 0
showing 0
that 0
Cdr2 B-gene
associates 0
with 0
the 0
N B-gene
- I-gene
terminal I-gene
regulatory I-gene
domain I-gene
of I-gene
Wee1 I-gene
in 0
cell 0
lysates 0
and 0
phosphorylates 0
Wee1 B-gene
in 0
vitro 0
. 0

Schizosaccharomyces 0
pombe 0
cells 0
respond 0
to 0
nutrient 0
deprivation 0
by 0
altering 0
G2/M 0
cell 0
size 0
control 0
. 0

A 0
- 0
tracts 0
functioned 0
best 0
when 0
positioned 0
close 0
to 0
the 0
- 0
35 0
hexamer 0
rather 0
than 0
one 0
helical 0
turn 0
farther 0
upstream 0
, 0
similar 0
to 0
the 0
positioning 0
optimal 0
for 0
UP 0
element 0
function 0
. 0

Pyk2 B-gene
phosphorylation 0
increased 0
upon 0
adherence 0
of 0
FLG 0
29.1 0
cells 0
to 0
fibronectin B-gene
and 0
to 0
ST2 0
stromal 0
cells 0
. 0

Raf B-gene
is 0
a 0
key 0
serine B-gene
- I-gene
threonine I-gene
protein I-gene
kinase I-gene
which 0
participates 0
in 0
the 0
transmission 0
of 0
growth 0
, 0
anti 0
- 0
apoptotic 0
and 0
differentiation 0
messages 0
. 0

The 0
US 0
National 0
Institute 0
on 0
Alcohol 0
Abuse 0
and 0
Alcoholism 0
( 0
NIAAA 0
) 0
recognizes 0
two 0
forms 0
of 0
problematic 0
drinking 0
: 0
'willful 0
alcohol 0
abuse 0
' 0
, 0
a 0
behavioural 0
problem 0
, 0
and 0
'alcohol 0
dependence 0
' 0
, 0
a 0
true 0
medical 0
disorder 0
, 0
which 0
includes 0
a 0
genetic 0
component 0
, 0
that 0
can 0
be 0
scientifically 0
understood 0
and 0
medically 0
treated 0
. 0

Collagen B-gene
was 0
extracted 0
from 0
the 0
skin 0
, 0
and 0
the 0
lack 0
of 0
type B-gene
III I-gene
collagen I-gene
was 0
determined 0
by 0
means 0
of 0
sodium 0
dodecyl 0
sulfate 0
- 0
polyacrylamide 0
gel 0
electrophoresis 0
( 0
SDS 0
- 0
PAGE 0
) 0
. 0

RESULTS 0
: 0
During 0
the 0
7 0
- 0
year 0
period 0
, 0
10,331 0
symptomatic 0
duodenal 0
ulcer 0
diseases 0
were 0
diagnosed 0
. 0

RESULTS 0
: 0
Significant 0
changes 0
from 0
pretreatment 0
to 0
posttreatment 0
were 0
observed 0
( 0
p 0
< 0
0.001 0
) 0
. 0

In 0
turn 0
, 0
assembly 0
of 0
this 0
complex 0
mediates 0
the 0
enzymatic 0
activation 0
of 0
the 0
p21 B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
1 I-gene
and 0
facilitates 0
actin B-gene
polymerization 0
. 0

The 0
tip 0
of 0
the 0
button 0
caused 0
a 0
perforation 0
of 0
the 0
posterior 0
stomach 0
wall 0
, 0
leading 0
to 0
death 0
. 0

Jembrana 0
disease 0
virus 0
( 0
JDV 0
) 0
is 0
a 0
newly 0
identified 0
bovine 0
lentivirus 0
that 0
is 0
closely 0
related 0
to 0
the 0
bovine 0
immunodeficiency 0
virus 0
( 0
BIV 0
) 0
. 0

Approximately 0
50 0
% 0
of 0
the 0
residues 0
are 0
conserved 0
among 0
all 0
three 0
sequences 0
, 0
yet 0
all 0
three 0
viruses 0
have 0
retained 0
response 0
elements 0
for 0
glucocorticoids 0
, 0
two 0
positionally 0
conserved 0
CCAAT 0
boxes 0
, 0
and 0
positionally 0
conserved 0
TATA 0
boxes 0
. 0

Nhp2p B-gene
is 0
a 0
highly 0
basic 0
protein 0
that 0
belongs 0
to 0
a 0
family 0
of 0
putative 0
RNA 0
- 0
binding 0
proteins 0
. 0

This 0
survey 0
included 0
3000 0
randomly 0
selected 0
Norwegians 0
above 0
18 0
years 0
of 0
age 0
who 0
received 0
the 0
European 0
Organization 0
for 0
Research 0
and 0
Treatment 0
of 0
Cancer 0
Core 0
Quality 0
of 0
Life 0
Questionnaire 0
( 0
EORTC 0
QLQ 0
- 0
C30 0
( 0
+3 0
) 0
by 0
mail 0
. 0

During 0
presentation 0
of 0
happy 0
facial 0
expressions 0
, 0
we 0
detected 0
a 0
signal 0
increase 0
predominantly 0
in 0
the 0
left 0
anterior 0
cingulate 0
gyrus 0
, 0
bilateral 0
posterior 0
cingulate 0
gyri 0
, 0
medial 0
frontal 0
cortex 0
and 0
right 0
supramarginal 0
gyrus 0
, 0
brain 0
regions 0
previously 0
implicated 0
in 0
visuospatial 0
and 0
emotion 0
processing 0
tasks 0
. 0

Down 0
- 0
regulation 0
of 0
IRS B-gene
- I-gene
1 I-gene
is 0
linked 0
to 0
its 0
serine 0
phosphorylation 0
dependent 0
on 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
activity 0
and 0
appears 0
required 0
for 0
differentiation 0
to 0
occur 0
, 0
as 0
IRS B-gene
- I-gene
1 I-gene
is 0
not 0
modified 0
and 0
continues 0
to 0
accumulate 0
in 0
a 0
nondifferentiating 0
myoblast 0
cell 0
line 0
. 0

This 0
study 0
utilizes 0
the 0
mammalian 0
two 0
- 0
hybrid 0
system 0
to 0
examine 0
the 0
role 0
of 0
ligand 0
in 0
the 0
dimerization 0
of 0
human B-gene
progesterone I-gene
receptor I-gene
( 0
hPR B-gene
) 0
. 0

One 0
of 0
its 0
unique 0
features 0
appears 0
to 0
be 0
the 0
unusually 0
short 0
5' 0
- 0
untranslated 0
regions 0
( 0
UTR 0
) 0
( 0
1 0
- 0
6 0
nucleotides 0
( 0
nts 0
) 0
) 0
and 0
the 0
apparent 0
absence 0
of 0
5' 0
- 0
cap 0
structures 0
from 0
its 0
mRNAs 0
. 0

The 0
gene B-gene
encoding I-gene
human I-gene
tissue I-gene
- I-gene
type I-gene
plasminogen I-gene
activator I-gene
( 0
t B-gene
- I-gene
PA I-gene
) 0
is 0
regulated 0
in 0
a 0
cell 0
- 0
type 0
- 0
specific 0
manner 0
. 0

Both 0
the 0
presence 0
of 0
arginine 0
and 0
anaerobiosis 0
are 0
needed 0
to 0
trigger 0
induction 0
of 0
the 0
pathway 0
. 0

Competition 0
with 0
a 0
putative 0
MADS B-gene
box I-gene
consensus 0
binding 0
site 0
from 0
the 0
promoter 0
of 0
the 0
coordinately 0
regulated 0
opaque B-gene
- I-gene
phase I-gene
- I-gene
specific I-gene
gene I-gene
PEP1 I-gene
( 0
SAP1 B-gene
) 0
and 0
the 0
human B-gene
MADS I-gene
box I-gene
consensus I-gene
binding I-gene
site I-gene
for 0
serum B-gene
response I-gene
factor I-gene
demonstrated 0
that 0
one 0
of 0
the 0
three 0
complexes 0
formed 0
was 0
specific 0
to 0
the 0
OP4 B-gene
sequence I-gene
. 0

The 0
human B-gene
SHBG I-gene
proximal I-gene
promoter I-gene
was 0
analyzed 0
by 0
DNase B-gene
I I-gene
footprinting 0
, 0
and 0
the 0
functional 0
significance 0
of 0
6 0
footprinted 0
regions 0
( 0
FP1 0
- 0
FP6 0
) 0
within 0
the 0
proximal 0
promoter 0
was 0
studied 0
in 0
human 0
HepG2 0
hepatoblastoma 0
cells 0
. 0

In 0
vitro 0
translation 0
and 0
in 0
vivo 0
polysome 0
profile 0
analysis 0
indicated 0
that 0
transcripts B-gene
C I-gene
and I-gene
E I-gene
were 0
translated 0
with 0
similar 0
translational 0
efficiencies 0
that 0
are 0
substantially 0
greater 0
than 0
that 0
of 0
transcript B-gene
D I-gene
, 0
suggesting 0
that 0
5' 0
- 0
untranslated 0
regions 0
play 0
a 0
role 0
in 0
translational 0
control 0
. 0

We 0
have 0
introduced 0
a 0
mutation 0
( 0
Ser36 0
- 0
- 0
> 0
Asn 0
) 0
into 0
this 0
domain 0
of 0
p190 B-gene
that 0
decreased 0
its 0
ability 0
to 0
bind 0
guanine 0
nucleotide 0
when 0
expressed 0
as 0
a 0
hemagglutinin B-gene
( 0
HA B-gene
) 0
- 0
tagged 0
protein 0
in 0
COS 0
cells 0
. 0

Wild 0
type 0
HA B-gene
- 0
p190 B-gene
induced 0
a 0
phenotype 0
of 0
rounded 0
cells 0
with 0
long 0
, 0
beaded 0
extensions 0
similar 0
to 0
that 0
seen 0
when 0
Rho B-gene
function 0
is 0
disrupted 0
by 0
ADP 0
- 0
ribosylation 0
. 0

We 0
emphasize 0
that 0
ANCA B-gene
- 0
associated 0
vasculitis 0
is 0
another 0
important 0
complication 0
of 0
RA 0
. 0

The 0
downstream 0
, 0
TATA 0
- 0
less 0
promoter 0
has 0
high 0
G+C 0
content 0
, 0
and 0
exon 0
1b 0
predominates 0
among 0
abundantly 0
expressed 0
mRNA 0
species 0
. 0

Although 0
we 0
predicted 0
that 0
overexpression 0
of 0
the 0
COOH 0
- 0
terminal 0
domains 0
, 0
which 0
were 0
thought 0
to 0
be 0
involved 0
in 0
the 0
regulation 0
of 0
SREBP B-gene
processing 0
, 0
would 0
result 0
in 0
disruption 0
of 0
the 0
SREBP B-gene
- 0
dependent 0
transcriptional 0
regulation 0
of 0
several 0
genes 0
, 0
the 0
mRNA 0
levels 0
for 0
3 B-gene
- I-gene
hydroxy I-gene
- I-gene
3 I-gene
- I-gene
methylglutaryl I-gene
coenzyme I-gene
A I-gene
( I-gene
HMG I-gene
CoA I-gene
) I-gene
synthase I-gene
in 0
these 0
two 0
cell 0
lines 0
were 0
regulated 0
in 0
a 0
sterol 0
- 0
dependent 0
manner 0
. 0

Dry 0
matter 0
intake 0
, 0
apparent 0
nutrient 0
digestibilities 0
, 0
serum 0
chemistry 0
profiles 0
, 0
sphingolipid 0
concentrations 0
, 0
and 0
persistency 0
of 0
FB1 0
in 0
tissues 0
were 0
evaluated 0
. 0

However 0
, 0
no 0
studies 0
have 0
been 0
conducted 0
to 0
further 0
investigate 0
this 0
potentially 0
hazardous 0
effect 0
of 0
lidocaine 0
. 0

E. 0
, 0
Scott 0
, 0
J 0
. 0

Yap1p B-gene
is 0
constitutively 0
nuclear 0
in 0
a 0
crm1 B-gene
mutant I-gene
, 0
and 0
Crm1p B-gene
binds 0
to 0
a 0
nuclear 0
export 0
sequence 0
( 0
NES 0
) 0
- 0
like 0
sequence 0
in 0
Yap1p B-gene
in 0
the 0
presence 0
of 0
RanGTP B-gene
. 0

Mean 0
intake 0
of 0
vitamin 0
A 0
amounted 0
to 0
1.1 0
and 0
0.9 0
mg 0
RE/day 0
for 0
men 0
and 0
women 0
, 0
respectively 0
; 0
the 0
contributions 0
of 0
meat 0
, 0
fats 0
and 0
oils 0
, 0
vegetables 0
and 0
dairy 0
products 0
to 0
total 0
intake 0
were 0
35 0
% 0
, 0
24 0
% 0
, 0
16 0
% 0
, 0
and 0
16 0
% 0
, 0
respectively 0
. 0

Also 0
, 0
the 0
amplitude 0
of 0
the 0
oscillatory 0
potentials 0
( 0
O1+O2+O3+O4 0
) 0
was 0
significantly 0
reduced 0
in 0
the 0
early 0
postoperative 0
period 0
. 0

Furthermore 0
, 0
RING1 B-gene
overexpression 0
results 0
in 0
enhanced 0
expression 0
of 0
the 0
proto 0
- 0
oncogenes 0
c B-gene
- I-gene
jun I-gene
and 0
c B-gene
- I-gene
fos I-gene
. 0

The 0
yeast B-gene
RER2 I-gene
gene I-gene
, 0
identified 0
by 0
endoplasmic 0
reticulum 0
protein 0
localization 0
mutations 0
, 0
encodes 0
cis B-gene
- I-gene
prenyltransferase I-gene
, 0
a 0
key 0
enzyme 0
in 0
dolichol 0
synthesis 0
. 0

The 0
yeast 0
retrotransposon B-gene
Ty5 I-gene
preferentially 0
integrates 0
into 0
regions 0
of 0
silent 0
chromatin 0
. 0

The 0
loss 0
of 0
SKO1 B-gene
completely 0
restored 0
ENA1 B-gene
expression 0
in 0
a 0
hog1 B-gene
mutant I-gene
and 0
partially 0
suppressed 0
the 0
osmotic 0
stress 0
sensitivity 0
, 0
qualifying 0
Sko1p B-gene
as 0
a 0
downstream 0
effector 0
of 0
the 0
HOG B-gene
pathway 0
. 0

Elevated 0
expression 0
of 0
a 0
previously 0
uncharacterized 0
gene 0
, 0
SPP381 B-gene
, 0
efficiently 0
suppresses 0
the 0
growth 0
and 0
splicing 0
defects 0
of 0
a 0
temperature 0
- 0
sensitive 0
( 0
Ts 0
) 0
mutant B-gene
prp38 I-gene
- I-gene
1 I-gene
. 0

The 0
slower 0
- 0
electrophoretic 0
- 0
mobility 0
form 0
of 0
p68 B-gene
was 0
absent 0
in 0
human 0
cells 0
in 0
G1/S 0
and 0
appeared 0
as 0
the 0
cells 0
entered 0
G2/M 0
. 0

We 0
have 0
identified 0
amino 0
acid 0
sequences 0
in 0
mammalian 0
and 0
Xenopus 0
NeuroD1/BETA2 B-gene
that 0
are 0
necessary 0
for 0
NeuroD1/BETA2 I-gene

Both 0
NUP98 B-gene
- 0
HOXA9 B-gene
chimeras 0
transformed 0
NIH 0
3T3 0
fibroblasts 0
, 0
and 0
this 0
transformation 0
required 0
the 0
HOXA9 B-gene
domains I-gene
for 0
DNA 0
binding 0
and 0
PBX B-gene
interaction 0
. 0

Recent 0
studies 0
have 0
suggested 0
that 0
Y319 0
also 0
positively 0
regulate 0
ZAP B-gene
- I-gene
70 I-gene
function 0
. 0

Genetic 0
and 0
molecular 0
data 0
indicate 0
that 0
wild B-gene
- I-gene
type I-gene
Pan I-gene
and 0
CiD B-gene
compete 0
for 0
binding 0
to 0
Arm B-gene
, 0
leading 0
to 0
a 0
compromised 0
transduction 0
of 0
the 0
Wg B-gene
signal 0
in 0
heterozygous 0
ciD/+ B-gene
animals 0
and 0
to 0
a 0
dramatic 0
enhancement 0
of 0
the 0
gain 0
- 0
of 0
- 0
function 0
activity 0
of 0
CiD B-gene
in 0
homozygous 0
mutants 0
. 0

Another 0
ORF 0
, 0
dda.2 B-gene
located 0
between 0
modA B-gene
and 0
dda B-gene
, 0
shares 0
sequence 0
similarity 0
with 0
sigma70 B-gene
, 0
and 0
we 0
call 0
it 0
srd B-gene
. 0

The 0
location 0
of 0
the 0
IBS 0
within 0
the 0
catB B-gene
structural I-gene
gene I-gene
, 0
the 0
cooperativity 0
observed 0
in 0
footprinting 0
studies 0
and 0
phasing 0
studies 0
suggest 0
that 0
the 0
IBS 0
participates 0
in 0
the 0
interaction 0
of 0
CatR B-gene
with 0
the 0
upstream 0
binding 0
sites 0
by 0
looping 0
out 0
the 0
intervening 0
DNA 0
. 0

In 0
vitro 0
transcription 0
assays 0
demonstrate 0
that 0
the 0
TCA 0
- 0
cycle 0
intermediate 0
, 0
fumarate 0
, 0
directly 0
and 0
specifically 0
inhibits 0
the 0
formation 0
of 0
the 0
clcA B-gene
transcript I-gene
. 0

BIAcore 0
analysis 0
gave 0
a 0
Kaff 0
of 0
4.4 0
x 0
10 0
( 0
10 0
) 0
M 0
- 0
1 0
for 0
the 0
binding 0
of 0
N B-gene
- I-gene
A3 I-gene
to 0
T84.1 B-gene
and 0
2.2 0
x 0
10 0
( 0
10 0
) 0
M 0
- 0
1 0
for 0
the 0
binding 0
of 0
N B-gene
- I-gene
A3 I-gene
to 0
T84.66 B-gene
. 0

Expression 0
of 0
p130 B-gene
( 0
Cas B-gene
) 0
( 0
Cas B-gene
) 0
, 0
a 0
major 0
binding 0
protein 0
for 0
the 0
Crk B-gene
SH2 B-gene
- I-gene
domain I-gene
, 0
also 0
induced 0
JNK B-gene
activation 0
, 0
which 0
was 0
blocked 0
by 0
the 0
SH2 B-gene
- I-gene
mutant I-gene
of 0
Crk B-gene
. 0

Positive 0
correlations 0
were 0
seen 0
between 0
the 0
measurements 0
for 0
protein 0
intake 0
( 0
r 0
=.58 0
, 0
P 0
=.0026 0
) 0
energy 0
intake 0
( 0
r 0
=.78 0
, 0
P 0
< 0
.00001 0
) 0
, 0
with 0
mean 0
differences 0
of.066 0
g/kg/d 0
( 0
SD.38 0
) 0
2.04 0
kcal/kg/day 0
( 0
SD 0
6.67 0
) 0
, 0
respectively 0
. 0

The 0
Og4C3 B-gene
enzyme 0
- 0
linked 0
immunosorbent 0
assay 0
( 0
ELISA 0
) 0
to 0
detect 0
circulating 0
Wuchereria B-gene
bancrofti I-gene
antigen I-gene
uses 0
50 0
microL 0
of 0
serum 0
. 0

We 0
now 0
show 0
that 0
gp200 B-gene
- 0
MR6 B-gene
ligation 0
can 0
also 0
mimic 0
IL B-gene
- I-gene
4 I-gene
and 0
have 0
an 0
anti 0
- 0
proliferative 0
pro 0
- 0
maturational 0
influence 0
within 0
the 0
immune 0
system 0
, 0
causing 0
up 0
- 0
regulation 0
of 0
co 0
- 0
stimulatory 0
molecules 0
on 0
B 0
lymphocytes 0
. 0

The 0
Mig1 B-gene
repressor I-gene
is 0
a 0
zinc B-gene
finger I-gene
protein I-gene
that 0
mediates 0
glucose 0
repression 0
in 0
yeast 0
. 0

Ethylene 0
is 0
involved 0
in 0
endosperm 0
rupture 0
and 0
high 0
- 0
level 0
betaGLU B-gene
I I-gene
expression 0
; 0
but 0
, 0
it 0
does 0
not 0
affect 0
the 0
spatial 0
and 0
temporal 0
pattern 0
of 0
betaGLU B-gene
I I-gene
expression 0
. 0

The 0
divergence 0
in 0
primary 0
structure 0
between 0
the 0
sheep 0
CRF1 B-gene
and 0
the 0
other 0
mammalian B-gene
CRF1s I-gene
is 0
primarily 0
localized 0
to 0
the 0
extracellular 0
amino 0
terminal 0
domain 0
of 0
the 0
receptor 0
( 0
18 0
of 0
22 0
divergent 0
residues 0
, 0
ovine 0
vs 0
human B-gene
CRF1 I-gene
) 0
. 0

Agonist 0
- 0
induced 0
receptor 0
internalization 0
, 0
determined 0
as 0
the 0
percent 0
of 0
total 0
[ 0
125I 0
] 0
Tyr0 B-gene
- I-gene
oCRF I-gene
bound 0
located 0
in 0
the 0
acid 0
- 0
resistant 0
fraction 0
of 0
transfected 0
Cos 0
7 0
cells 0
, 0
increased 0
with 0
time 0
( 0
0 0
- 0
60 0
min 0
at 0
37 0
degrees 0
C 0
) 0
for 0
both 0
wild 0
- 0
type 0
and 0
variant 0
oCRF1 B-gene
. 0

Recurrent 0
arterial 0
thrombotic 0
disease 0
on 0
young 0
onset 0
and 0
protein B-gene
S I-gene
deficiency 0
. 0

We 0
showed 0
that 0
Stat3 B-gene
and 0
Stat3beta B-gene
were 0
affinity 0
purified 0
using 0
phosphopeptides 0
containing 0
Y704 0
and 0
Y744 0
but 0
not 0
by 0
nonphosphorylated 0
peptide 0
analogues 0
or 0
by 0
phosphopeptides 0
containing 0
Y729 0
and 0
Y764 0
. 0

Taken 0
together 0
, 0
our 0
results 0
indicate 0
that 0
the 0
FCR1 B-gene
gene I-gene
behaves 0
as 0
a 0
negative 0
regulator 0
of 0
drug 0
resistance 0
in 0
C. 0
albicans 0
and 0
constitute 0
the 0
first 0
evidence 0
that 0
FCZ 0
resistance 0
can 0
result 0
from 0
the 0
inactivation 0
of 0
a 0
regulatory 0
factor 0
such 0
as 0
Fcr1p B-gene
. 0

These 0
findings 0
suggest 0
that 0
late 0
MYO/M 0
is 0
more 0
useful 0
than 0
washout 0
rate 0
to 0
assess 0
the 0
effect 0
of 0
treatment 0
on 0
heart 0
failure 0
due 0
to 0
DCM 0
. 0

This 0
study 0
was 0
undertaken 0
to 0
evaluate 0
how 0
couplers 0
and 0
their 0
placement 0
affect 0
the 0
ALGO2 0
click 0
spectral 0
properties 0
. 0

CONCLUSIONS 0
: 0
Pretreatment 0
with 0
OCs 0
prior 0
to 0
pituitary 0
suppression 0
in 0
the 0
early 0
follicular 0
phase 0
decreases 0
ovarian 0
cyst 0
formation 0
, 0
without 0
an 0
apparent 0
effect 0
on 0
subsequent 0
follicular 0
recruitment 0
or 0
pregnancy 0
rates 0
. 0

With 0
regard 0
to 0
the 0
optimal 0
threshold 0
values 0
, 0
sensitivity 0
and 0
specificity 0
were 0
100 0
% 0
/97 0
% 0
and 0
95 0
% 0
/95 0
% 0
with 0
FDG 0
PET 0
, 0
compared 0
to 0
86 0
% 0
/92 0
% 0
and 0
77 0
% 0
/82 0
% 0
with 0
IS 0
, 0
respectively 0
. 0

This 0
c B-gene
- I-gene
Jun I-gene
activity 0
is 0
inhibited 0
by 0
c B-gene
- I-gene
Fos I-gene
, 0
another 0
protooncoprotein 0
that 0
can 0
dimerize 0
with 0
c B-gene
- I-gene
Jun I-gene
to 0
form 0
the 0
transcription 0
factor 0
AP B-gene
- I-gene
1 I-gene
. 0

Dorsal 0
root 0
ganglia 0
neuron 0
- 0
specific 0
promoter 0
activity 0
of 0
the 0
rabbit B-gene
beta I-gene
- I-gene
galactoside I-gene
alpha1,2 I-gene
- I-gene
fucosyltransferase I-gene
gene I-gene
. 0

CONCLUSION 0
: 0
Our 0
study 0
shows 0
that 0
( 0
1 0
) 0
total 0
body 0
BMD 0
and 0
femoral 0
neck 0
BMD 0
were 0
significantly 0
higher 0
in 0
the 0
study 0
group 0
that 0
performed 0
weight 0
- 0
bearing 0
exercises 0
than 0
in 0
control 0
subjects 0
, 0
( 0
2 0
) 0
swimming 0
exercise 0
had 0
no 0
effect 0
on 0
BMD 0
, 0
and 0
( 0
3 0
) 0
although 0
swimming 0
is 0
not 0
a 0
bone 0
- 0
building 0
exercise 0
, 0
it 0
can 0
significantly 0
improve 0
shoulder 0
, 0
back 0
, 0
and 0
grip 0
muscle 0
strength 0
. 0

This 0
suggests 0
roles 0
for 0
both 0
the 0
CE1 0
and 0
CE2 0
elements 0
in 0
regulating 0
Hoxb1 B-gene
gene I-gene
expression 0
during 0
development 0
. 0

CAL 0
gain 0
amounted 0
to 0
4.2+/ 0
- 0
1.3 0
mm 0
, 0
60 0
% 0
of 0
the 0
defects 0
showing 0
CAL 0
gain 0
> 0
or 0
=4 0
mm 0
. 0

Comparisons 0
with 0
other 0
known 0
germins B-gene
and 0
germin B-gene
- I-gene
like I-gene
proteins I-gene
indicate 0
that 0
these 0
Arabidopsis 0
GLP B-gene
subfamilies 0
are 0
unique 0
from 0
wheat 0
germin B-gene
. 0

Lead 0
fixation 0
in 0
dogs 0
achieved 0
with 0
RF 0
energy 0
. 0

However 0
, 0
there 0
has 0
not 0
been 0
any 0
evidence 0
of 0
A. 0
salmonicida 0
infections 0
, 0
specifically 0
furunculosis 0
, 0
associated 0
with 0
the 0
fish 0
in 0
this 0
loch 0
. 0

Further 0
, 0
we 0
show 0
that 0
this 0
EIA B-gene
- 0
inducible 0
CBF/cdc2 B-gene
is 0
related 0
to 0
the 0
CBF B-gene
which 0
was 0
shown 0
to 0
activate 0
the 0
heat B-gene
shock I-gene
protein I-gene
70 I-gene
promoter I-gene
. 0

The 0
percutaneous 0
absorption 0
of 0
clindamycin 0
was 0
studied 0
in 0
healthy 0
male 0
volunteers 0
, 0
comparing 0
two 0
investigative 0
clindamycin 0
( 0
% 0
w/v 0
) 0
/tretinoin 0
( 0
0.025 0
% 0
w/v 0
) 0
gels 0
, 0
containing 0
clindamycin 0
phosphate 0
ester 0
and 0
clindamycin 0
HCl 0
, 0
respectively 0
, 0
relative 0
to 0
a 0
clindamycin 0
phosphate 0
lotion 0
( 0
1 0
% 0
clindamycin 0
; 0
Dalacin 0
T 0
) 0
. 0

The 0
BAL 0
concentrations 0
of 0
the 0
nine 0
cytokines 0
evaluated 0
for 0
the 0
more 0
and 0
less 0
affected 0
lungs 0
were 0
compared 0
: 0
interleukin B-gene
- I-gene
6 I-gene
( 0
IL B-gene
- I-gene
6 I-gene
) 0
, 0
IL B-gene
- I-gene
8 I-gene
, 0
IL B-gene
- I-gene
12 I-gene
, 0
tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNF B-gene
- I-gene
alpha I-gene
) 0
, 0
and 0
interferon B-gene
gamma I-gene
( 0
IFN B-gene
- I-gene
gamma I-gene
) 0
showed 0
significant 0
differences 0
( 0
p 0
ranged 0
between 0
0 0
. 0

Phosphorylation 0
analyses 0
indicated 0
that 0
inhibition 0
of 0
ERK B-gene
- I-gene
1/2 I-gene
decreased 0
okadaic 0
acid 0
- 0
elevated 0
phosphorylation 0
of 0
JunD B-gene
and 0
FosB B-gene
. 0

Two 0
- 0
way 0
analysis 0
of 0
variance 0
was 0
used 0
to 0
determine 0
whether 0
composite 0
knowledge 0
score 0
differed 0
among 0
patient 0
groups 0
. 0

The 0
human 0
pathogenic 0
bacterium 0
group 0
A 0
Streptococcus 0
produces 0
an 0
extracellular 0
cysteine B-gene
protease I-gene
[ 0
streptococcal B-gene
pyrogenic I-gene
exotoxin I-gene
B I-gene
( 0
SpeB B-gene
) 0
] 0
that 0
is 0
a 0
critical 0
virulence 0
factor 0
for 0
invasive 0
disease 0
episodes 0
. 0

The 0
orbitofrontal 0
, 0
cingulate 0
, 0
and 0
anteromedial 0
part 0
of 0
the 0
dorsal 0
premotor 0
areas 0
were 0
preferentially 0
activated 0
by 0
the 0
self 0
- 0
initiated 0
hand 0
movement 0
task 0
( 0
SELF 0
) 0
. 0

Improving 0
the 0
evidence 0
base 0
for 0
anaesthesia 0
. 0

Plasma 0
CCK B-gene
levels 0
were 0
determined 0
at 0
regular 0
intervals 0
. 0

The 0
peroxisome 0
biogenesis 0
disorders 0
( 0
PBDs 0
) 0
are 0
a 0
set 0
of 0
lethal 0
genetic 0
diseases 0
characterized 0
by 0
peroxisomal 0
metabolic 0
deficiencies 0
, 0
multisystem 0
abnormalities 0
, 0
mental 0
retardation 0
, 0
and 0
premature 0
death 0
. 0

The 0
active 0
site 0
includes 0
the 0
acidic 0
triad 0
Asp53 0
( 0
the 0
site 0
of 0
phosphorylation 0
) 0
, 0
Asp10 0
and 0
Glu9 0
. 0

Consistent 0
with 0
these 0
findings 0
, 0
relatively 0
weak 0
transcriptional 0
silencing 0
by 0
the 0
native 0
VDR B-gene
was 0
observed 0
using 0
the 0
osteopontin B-gene
VDRE 0
. 0

In 0
PAV 0
- 0
3 0
, 0
the 0
E1A B-gene
region I-gene
is 0
located 0
between 0
1.5 0
and 0
3.8 0
map 0
units 0
. 0

Six 0
putative 0
MDV 0
genome 0
products 0
, 0
including 0
one 0
Rep B-gene
and 0
five 0
non 0
- 0
Rep B-gene
proteins 0
, 0
show 0
high 0
( 0
70.4 0
- 0
90.9 0
% 0
) 0
amino 0
acid 0
identity 0
to 0
the 0
corresponding 0
six 0
FBNYV B-gene
proteins I-gene
, 0
whereas 0
two 0
other 0
Rep B-gene
proteins I-gene
encoded 0
by 0
MDV B-gene
- I-gene
C2 I-gene
and 0
C3 B-gene
are 0
82.3 0
% 0
and 0
73.0 0
% 0
identical 0
to 0
those 0
encoded 0
by 0
SCSV B-gene
- I-gene
C2 I-gene
and 0
C6 B-gene
, 0
respectively 0
. 0

MPO B-gene
was 0
labeled 0
with 0
1 0
mCi 0
125I 0
by 0
a 0
technique 0
of 0
self 0
- 0
labeling 0
in 0
the 0
presence 0
of 0
10 0
( 0
- 0
4 0
) 0
M 0
hydrogen 0
peroxide 0
. 0

It 0
is 0
related 0
to 0
a 0
variety 0
of 0
mammalian 0
Golgi 0
- 0
associated 0
proteins 0
and 0
to 0
the 0
yeast 0
Uso1p B-gene
, 0
an 0
essential 0
protein 0
involved 0
in 0
docking 0
of 0
endoplasmic 0
reticulum 0
- 0
derived 0
vesicles 0
to 0
the 0
cis 0
- 0
Golgi 0
. 0

The 0
data 0
indicate 0
that 0
Bmp2 B-gene
is 0
directly 0
regulated 0
by 0
retinoic 0
acid 0
- 0
bound 0
receptors 0
and 0
Sp1 B-gene
. 0

Both 0
proteins 0
were 0
shown 0
to 0
be 0
constitutively 0
associated 0
with 0
tubulin B-gene
. 0

HEED B-gene
was 0
found 0
to 0
bind 0
to 0
MA B-gene
protein I-gene
in 0
vitro 0
, 0
as 0
efficiently 0
as 0
in 0
vivo 0
in 0
yeast 0
cells 0
. 0

Fas B-gene
- 0
resistant 0
DT 0
- 0
40 0
lymphoma 0
B 0
- 0
cells 0
rendered 0
BTK B-gene
- 0
deficient 0
through 0
targeted 0
disruption 0
of 0
the 0
btk B-gene
gene I-gene
by 0
homologous 0
recombination 0
knockout 0
underwent 0
apoptosis 0
after 0
Fas B-gene
ligation 0
, 0
but 0
wild 0
- 0
type 0
DT 0
- 0
40 0
cells 0
or 0
BTK B-gene
- 0
deficient 0
DT 0
- 0
40 0
cells 0
reconstituted 0
with 0
wild B-gene
- I-gene
type I-gene
human I-gene
btk I-gene
gene I-gene
did 0
not 0
. 0

A 0
motif 0
( 0
TGATGTCA 0
) 0
which 0
matches 0
a 0
CREB B-gene
site I-gene
and 0
is 0
similar 0
to 0
an 0
AP B-gene
- I-gene
1 I-gene
site I-gene
is 0
embedded 0
within 0
ER2 B-gene
. 0

Conventionally 0
, 0
four 0
nominal 0
allotypic 0
variants 0
, 0
b4 0
, 0
b5 0
, 0
b6 0
and 0
b9 0
have 0
been 0
shown 0
to 0
be 0
co 0
- 0
dominantly 0
expressed 0
at 0
the 0
Ckappa1 B-gene
gene I-gene
locus I-gene
. 0

Therefore 0
, 0
in 0
order 0
to 0
search 0
for 0
the 0
latent 0
genes 0
, 0
we 0
used 0
allotype 0
- 0
specific 0
oligonucleotides 0
for 0
b5 0
, 0
b6 0
and 0
b9 0
to 0
probe 0
DNAs 0
from 0
both 0
normal 0
and 0
T. 0
brucei 0
- 0
infected 0
rabbits 0
by 0
Southern 0
blotting 0
. 0

TRAF2 B-gene
is 0
known 0
to 0
associate 0
with 0
TRADD B-gene
, 0
and 0
expression 0
of 0
a 0
dominant 0
- 0
negative 0
N 0
- 0
terminal 0
deletion 0
TRAF2 B-gene
mutant I-gene
was 0
found 0
to 0
partially 0
inhibit 0
LMP1 B-gene
- 0
induced 0
JNK B-gene
activation 0
in 0
293 0
cells 0
. 0

These 0
data 0
further 0
define 0
a 0
role 0
for 0
TRADD B-gene
and 0
TRAF2 B-gene
in 0
JNK B-gene
activation 0
and 0
confirm 0
that 0
LMP1 B-gene
utilizes 0
signalling 0
mechanisms 0
used 0
by 0
the 0
TNF B-gene
receptor/CD40 I-gene
family 0
to 0
elicit 0
its 0
pleiotropic 0
activities 0
. 0

Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
- I-gene
encoded I-gene
latent I-gene
membrane I-gene
protein I-gene
1 I-gene
activates 0
the 0
JNK B-gene
pathway 0
through 0
its 0
extreme 0
C 0
terminus 0
via 0
a 0
mechanism 0
involving 0
TRADD B-gene
and 0
TRAF2 B-gene
. 0

In 0
contrast 0
, 0
transiently 0
transfected 0
cells 0
expressing 0
EBNA B-gene
- I-gene
3 I-gene
revealed 0
a 0
sixfold 0
increase 0
in 0
EBNA B-gene
- I-gene
3 I-gene
protein I-gene
expression 0
from 0
the 0
genomic 0
EBNA B-gene
- I-gene
3 I-gene
gene I-gene
compared 0
to 0
EBNA B-gene
- I-gene
3 I-gene
cDNA I-gene
. 0

However 0
, 0
serial 0
passages 0
of 0
fetal 0
lamb 0
kidney 0
( 0
FLK 0
) 0
cells 0
, 0
which 0
are 0
sensitive 0
to 0
infection 0
with 0
BLV 0
, 0
after 0
transient 0
transfection 0
revealed 0
that 0
mutation 0
of 0
a 0
second 0
tyrosine 0
residue 0
in 0
the 0
N 0
- 0
terminal 0
motif 0
completely 0
prevented 0
the 0
propagation 0
of 0
the 0
virus 0
. 0

Varicella B-gene
- I-gene
zoster I-gene
virus I-gene
( I-gene
VZV I-gene
) I-gene
glycoprotein I-gene
gI I-gene
is 0
a 0
type B-gene
1 I-gene
transmembrane I-gene
glycoprotein I-gene
which 0
is 0
one 0
component 0
of 0
the 0
heterodimeric 0
gE B-gene
: 0
gI B-gene
Fc I-gene
receptor I-gene
complex 0
. 0

To 0
this 0
end 0
, 0
we 0
analyzed 0
the 0
phosphorylation 0
status 0
of 0
a 0
universal 0
tyrosine B-gene
kinase I-gene
substrate 0
, 0
the 0
transforming 0
Shc B-gene
adapter I-gene
protein I-gene
, 0
in 0
fibroblasts 0
expressing 0
the 0
viral 0
oncogene 0
. 0

These 0
genes 0
were 0
expressed 0
in 0
a 0
Saccharomyces 0
cerevisiae 0
mutant 0
in 0
which 0
the 0
endogenous B-gene
ferrochelatase I-gene
gene I-gene
( 0
HEM15 B-gene
) 0
had 0
been 0
deleted 0
, 0
and 0
the 0
phenotypes 0
of 0
the 0
transformants 0
were 0
characterized 0
. 0

In 0
this 0
study 0
, 0
evidence 0
is 0
presented 0
that 0
temporally 0
and 0
spatially 0
specific 0
mef2 B-gene
expression 0
is 0
controlled 0
by 0
a 0
complex 0
array 0
of 0
cis 0
- 0
acting 0
regulatory 0
modules 0
that 0
are 0
responsive 0
to 0
different 0
genetic 0
signals 0
. 0

Furthermore 0
, 0
using 0
transgenic 0
mouse 0
technology 0
we 0
localized 0
independent 0
cis 0
- 0
regulatory 0
elements 0
controlling 0
the 0
tissue 0
- 0
specific 0
expression 0
of 0
Pax6 B-gene
. 0

In 0
the 0
second 0
experiment 0
, 0
a 0
stable 0
nickel 0
isotope 0
, 0
61Ni 0
, 0
was 0
given 0
in 0
drinking 0
water 0
to 0
20 0
nickel 0
- 0
sensitized 0
women 0
and 0
20 0
age 0
- 0
matched 0
controls 0
, 0
both 0
groups 0
having 0
vesicular 0
hand 0
eczema 0
of 0
the 0
pompholyx 0
type 0
. 0

Folded 0
tissue 0
and 0
crimped 0
collagen B-gene
fibers 0
in 0
the 0
tunica 0
albuginea 0
permit 0
its 0
expansion 0
during 0
erection 0
. 0

Number 0
of 0
patients 0
infected 0
with 0
nontuberculous 0
mycobacteria 0
( 0
NTM 0
) 0
is 0
increasing 0
world 0
- 0
wide 0
in 0
recent 0
years 0
. 0

Comparison 0
of 0
the 0
sequences 0
of 0
attP B-gene
, 0
attB B-gene
and 0
bacteria 0
- 0
prophage 0
junctions 0
attL B-gene
and 0
attR B-gene
showed 0
a 0
26 0
bp 0
common 0
core 0
sequence 0
, 0
where 0
recombination 0
takes 0
place 0
, 0
near 0
the 0
5 0
' 0
end 0
of 0
the 0
integrase B-gene
gene I-gene
. 0

Interferon B-gene
- I-gene
alpha I-gene
treatment 0
of 0
posttransplant 0
lymphoproliferative 0
disorder 0
in 0
recipients 0
of 0
solid 0
organ 0
transplants 0
. 0

Immunological 0
testing 0
was 0
performed 0
on 0
all 0
brewery 0
workers 0
and 0
some 0
control 0
volunteers 0
using 0
skin 0
prick 0
testing 0
with 0
hops 0
, 0
barley 0
, 0
and 0
yeast 0
antigens 0
as 0
well 0
as 0
other 0
nonoccupational 0
allergens 0
, 0
and 0
by 0
determining 0
total 0
serum B-gene
IgE I-gene
levels 0
. 0

OBJECTIVE 0
: 0
To 0
evaluate 0
the 0
accuracy 0
of 0
working 0
casts 0
for 0
crown 0
and 0
bridge 0
restorations 0
made 0
from 0
twin 0
mix 0
putty/wash 0
silicone 0
elastomeric 0
impression 0
materials 0
using 0
different 0
types 0
of 0
stock 0
tray 0
. 0

OBJECTIVES 0
: 0
To 0
assess 0
the 0
ability 0
of 0
pretreatment 0
and 0
post 0
- 0
treatment 0
prostate B-gene
- I-gene
specific I-gene
antigen I-gene
( 0
PSA B-gene
) 0
measurements 0
, 0
clinical 0
tumor 0
stage 0
, 0
tumor 0
grade 0
, 0
Gleason 0
sum 0
, 0
race 0
, 0
age 0
, 0
and 0
radiation 0
dose 0
to 0
predict 0
the 0
recurrence 0
of 0
prostate 0
cancer 0
following 0
external 0
beam 0
radiation 0
therapy 0
( 0
XRT 0
) 0
since 0
the 0
introduction 0
of 0
PSA B-gene
as 0
a 0
tumor 0
marker 0
at 0
one 0
tertiary 0
care 0
center 0
. 0

To 0
evaluate 0
whether 0
the 0
human 0
gene 0
is 0
also 0
a 0
target 0
of 0
thyroid 0
hormone 0
we 0
have 0
searched 0
for 0
T3 0
- 0
responsive 0
elements 0
in 0
NRGN B-gene
cloned 0
genomic 0
fragments 0
spanning 0
the 0
whole 0
gene 0
. 0

The 0
transcriptional 0
activity 0
of 0
PPARgamma B-gene
is 0
positively 0
modulated 0
by 0
ligand 0
binding 0
and 0
negatively 0
regulated 0
by 0
phosphorylation 0
mediated 0
by 0
the 0
MEK/ERK B-gene
signaling 0
pathway 0
. 0

BACKGROUND 0
: 0
Diazepam 0
, 0
one 0
of 0
the 0
benzodiazepine 0
group 0
of 0
tranquilizers 0
, 0
is 0
used 0
as 0
an 0
adjunctive 0
drug 0
for 0
sedation 0
and 0
for 0
relief 0
of 0
anxiety 0
in 0
the 0
treatment 0
of 0
epilepsy 0
. 0

Bioplastique 0
granuloma 0
presents 0
with 0
irregularly 0
shaped 0
cystic 0
spaces 0
of 0
varying 0
size 0
containing 0
jagged 0
, 0
translucent 0
, 0
nonbirefringent 0
foreign 0
bodies 0
whereas 0
Artecoll 0
granuloma 0
shows 0
numerous 0
round 0
vacuoles 0
nearly 0
identical 0
in 0
size 0
and 0
shape 0
enclosing 0
round 0
and 0
sharply 0
circumscribed 0
, 0
translucent 0
, 0
nonbirefringent 0
foreign 0
bodies 0
. 0

This 0
Tbx6 B-gene
- I-gene
subfamily I-gene
gene I-gene
is 0
likely 0
to 0
participate 0
in 0
paraxial 0
mesoderm 0
formation 0
and 0
somitogenesis 0
in 0
human 0
embryo 0
. 0

Structure 0
- 0
function 0
analysis 0
of 0
the 0
Z 0
- 0
DNA 0
- 0
binding 0
domain 0
Zalpha 0
of 0
dsRNA B-gene
adenosine I-gene
deaminase I-gene
type I-gene
I I-gene
reveals 0
similarity 0
to 0
the 0
( B-gene
alpha I-gene
+ I-gene
beta I-gene
) I-gene
family I-gene
of 0
helix B-gene
- I-gene
turn I-gene
- I-gene
helix I-gene
proteins I-gene
. 0

In 0
addition 0
, 0
the 0
regulation 0
of 0
Glvr B-gene
- I-gene
1 I-gene
gene I-gene
expression 0
also 0
has 0
potential 0
applications 0
to 0
gene 0
therapy 0
, 0
since 0
retroviral 0
vectors 0
carrying 0
gibbon B-gene
ape I-gene
leukemia I-gene
virus I-gene
envelope I-gene
proteins I-gene
are 0
used 0
for 0
gene 0
delivery 0
into 0
different 0
cell 0
types 0
. 0

Carbohydrates 0
and 0
glycoconjugates 0
biophysical 0
methods 0
. 0

Molecular 0
cloning 0
of 0
mouse B-gene
glycolate I-gene
oxidase I-gene
. 0

In 0
such 0
a 0
manner 0
, 0
activated 0
PKR B-gene
inhibits 0
cell 0
growth 0
and 0
induces 0
apoptosis 0
, 0
whereas 0
disruption 0
of 0
normal 0
PKR B-gene
signaling 0
results 0
in 0
unregulated 0
cell 0
growth 0
. 0

We 0
isolated 0
a 0
ribosomal B-gene
protein I-gene
L18 I-gene
by 0
interaction 0
with 0
PKR B-gene
. 0

Processing 0
of 0
the 0
polycistronic 0
precursor 0
requires 0
nucleases 0
also 0
involved 0
in 0
rRNA 0
processing 0
, 0
i.e. 0
, 0
Rnt1p B-gene
and 0
Rat1p B-gene
. 0

To 0
search 0
for 0
transcriptional 0
regulators 0
, 0
we 0
used 0
a 0
fragment 0
of 0
the 0
SpHE B-gene
promoter I-gene
containing 0
several 0
individual 0
elements 0
instead 0
of 0
the 0
conventional 0
bait 0
that 0
contains 0
a 0
multimerized 0
cis 0
element 0
. 0

As 0
expected 0
for 0
a 0
positive 0
SpHE B-gene
transcriptional I-gene
regulator I-gene
, 0
the 0
timing 0
of 0
SpEts4 B-gene
gene I-gene
expression 0
precedes 0
the 0
transient 0
expression 0
of 0
SpHE B-gene
in 0
the 0
very 0
early 0
sea 0
urchin 0
blastula 0
. 0

Furthermore 0
, 0
rhoA B-gene
- 0
mediated 0
SRE 0
activation 0
was 0
blocked 0
by 0
dominant 0
negative 0
mutants 0
of 0
PKC B-gene
- I-gene
alpha I-gene
or 0
PKC B-gene
- I-gene
epsilon I-gene
. 0

Nip7p B-gene
- 0
depleted 0
cells 0
exhibited 0
the 0
same 0
defects 0
as 0
Nop8p B-gene
- 0
depleted 0
cells 0
, 0
except 0
that 0
they 0
accumulated 0
27S B-gene
precursors I-gene
. 0

We 0
show 0
that 0
the 0
Sm B-gene
- I-gene
binding I-gene
site I-gene
and 0
stem 0
- 0
loop 0
III 0
structures 0
are 0
necessary 0
for 0
correct 0
3' 0
- 0
end 0
formation 0
. 0

Five 0
different 0
subtypes 0
of 0
spondyloarthropathy 0
( 0
SpA 0
) 0
are 0
now 0
recognized 0
. 0

Further 0
experiments 0
will 0
be 0
required 0
to 0
highlight 0
the 0
in 0
vivo 0
role 0
of 0
ELE1 B-gene
in 0
nuclear 0
receptor 0
functioning 0
. 0

Overexpression 0
of 0
PTTG B-gene
in 0
transfected 0
NIH 0
3T3 0
cells 0
also 0
stimulated 0
expression 0
and 0
secretion 0
of 0
basic B-gene
fibroblast I-gene
growth I-gene
factor I-gene
, 0
a 0
human B-gene
pituitary I-gene
tumor I-gene
growth I-gene
- I-gene
regulating I-gene
factor I-gene
. 0

The 0
perifascicular 0
connective 0
tissue 0
sheath 0
is 0
important 0
in 0
organising 0
the 0
contraction 0
of 0
the 0
myocardium 0
by 0
preventing 0
lateral 0
spread 0
of 0
conduction 0
and 0
by 0
permitting 0
transmission 0
of 0
the 0
impulse 0
only 0
at 0
the 0
termination 0
of 0
the 0
purkinje 0
fibre 0
. 0

E1 B-gene
, 0
a 0
DNA B-gene
helicase I-gene
, 0
collaborates 0
with 0
the 0
HPV B-gene
E2 I-gene
protein I-gene
in 0
ori 0
- 0
dependent 0
replication 0
. 0

Here 0
we 0
describe 0
a 0
mutant 0
alpha 0
subunit 0
designed 0
to 0
inhibit 0
receptor 0
- 0
mediated 0
hormonal 0
activation 0
of 0
Gs B-gene
, 0
the 0
stimulatory 0
regulator 0
of 0
adenylyl B-gene
cyclase I-gene
. 0

A 0
gapped 0
search 0
with 0
the 0
C 0
- 0
terminal 0
region 0
of 0
CDED/LIOR B-gene
revealed 0
a 0
36 0
- 0
41 0
% 0
similarity 0
to 0
several 0
proteins 0
related 0
to 0
signal 0
transduction 0
and 0
cell 0
replication 0
, 0
such 0
as 0
CDED/LIOR I-gene

Northern 0
blot 0
analysis 0
demonstrated 0
the 0
ubiquitous 0
expression 0
of 0
2.9 0
kb 0
and 0
3 0
. 0

Additionally 0
, 0
a 0
variety 0
of 0
regulatory 0
schemes 0
contribute 0
temporal 0
and/or 0
spatial 0
restriction 0
to 0
TGF B-gene
- I-gene
beta I-gene
responses 0
. 0

Induction 0
of 0
anaesthesia 0
was 0
standardised 0
: 0
fentanyl 0
( 0
3 0
micrograms/kg 0
) 0
, 0
thiopentone 0
( 0
5 0
mg/kg 0
) 0
, 0
atracurium 0
( 0
0.4 0
mg/kg 0
) 0
. 0

A 0
comparison 0
of 0
the 0
clinical 0
profile 0
of 0
cavernous 0
malformations 0
with 0
and 0
without 0
associated 0
venous 0
malformations 0
. 0

Conserved 0
and 0
distinct 0
roles 0
of 0
kreisler B-gene
in 0
regulation 0
of 0
the 0
paralogous 0
Hoxa3 B-gene
and 0
Hoxb3 B-gene
genes I-gene
. 0

Magnetically 0
induced 0
optical 0
self 0
- 0
pulsing 0
in 0
a 0
nonlinear 0
resonator 0
. 0

Wave 0
cybernetics 0
: 0
A 0
simple 0
model 0
of 0
wave 0
- 0
controlled 0
nonlinear 0
and 0
nonlocal 0
cooperative 0
phenomena 0
. 0

Autoionization 0
rates 0
and 0
energy 0
levels 0
of 0
triplet 0
nf 0
, 0
v=1 0
Rydberg 0
states 0
of 0
H2 0
. 0

Unitary 0
- 0
group 0
approach 0
to 0
spin 0
- 0
dependent 0
operators 0
. 0

Nonlocal 0
approach 0
to 0
scattering 0
in 0
a 0
one 0
- 0
dimensional 0
problem 0
. 0

Soft 0
- 0
x 0
- 0
ray 0
lasing 0
at 0
32.6 0
nm 0
in 0
Ne 0
- 0
like 0
Ti 0
ions 0
driven 0
by 0
40 0
J 0
of 0
energy 0
from 0
two 0
650 0
- 0
ps 0
laser 0
pulses 0
. 0

Next 0
, 0
to 0
identify 0
regions 0
of 0
the 0
promoter 0
involved 0
, 0
we 0
examined 0
a 0
series 0
of 0
tenascin B-gene
- I-gene
C I-gene
promoter I-gene
constructs I-gene
with 0
5 0
' 0
deletions 0
and 0
showed 0
that 0
denatured 0
collagen B-gene
- I-gene
dependent I-gene
promoter I-gene
activity 0
was 0
retained 0
by 0
a 0
122 0
- 0
base 0
pair 0
element 0
, 0
located 0
- 0
43 0
to 0
- 0
165 0
bp 0
upstream 0
of 0
the 0
RNA 0
start 0
site 0
. 0

Nuclear B-gene
factor I-gene
kappa I-gene
B I-gene
( 0
NF B-gene
- I-gene
kappaB I-gene
) 0
is 0
an 0
important 0
transcription 0
factor 0
for 0
the 0
genes 0
of 0
many 0
pro 0
- 0
inflammatory 0
proteins 0
and 0
is 0
strongly 0
activated 0
by 0
the 0
cytokines 0
interleukin B-gene
- I-gene
1 I-gene
and 0
tumor B-gene
necrosis I-gene
factor I-gene
( I-gene
TNF I-gene
) I-gene
alpha I-gene
under 0
various 0
pathological 0
conditions 0
. 0

Moreover 0
, 0
this 0
enhancement 0
of 0
transcriptional 0
activation 0
by 0
COUP B-gene
- I-gene
TFI I-gene
requires 0
specifically 0
the 0
AF 0
- 0
1 0
transactivation 0
function 0
of 0
ER B-gene
and 0
can 0
be 0
observed 0
in 0
the 0
presence 0
of 0
E2 0
or 0
4 0
- 0
hydroxytamoxifen 0
but 0
not 0
ICI 0
164384 0
. 0

Recombinant B-gene
Ffh I-gene
has 0
a 0
melting 0
point 0
of 0
tm 0
= 0
89 0
degreesC 0
. 0

Unilateral 0
naris 0
occlusion 0
and 0
the 0
rat 0
accessory 0
olfactory 0
bulb 0
. 0

This 0
region 0
of 0
hsp90 B-gene
mediates 0
ATP 0
- 0
independent 0
chaperone 0
activity 0
, 0
overlaps 0
the 0
hsp90 B-gene
dimerization I-gene
domain I-gene
, 0
and 0
includes 0
structural 0
elements 0
important 0
for 0
steroid B-gene
receptor I-gene
interaction 0
. 0

The 0
promoter 0
of 0
the 0
rat 0
pgp2/mdr1b B-gene
gene 0
has 0
a 0
GC 0
- 0
rich 0
region 0
( 0
pgp2/mdr1b I-gene

Sp1 B-gene
's 0
role 0
in 0
transactivation 0
of 0
the 0
pgp2/mdr1b B-gene
promoter 0
was 0
tested 0
in 0
Drosophila 0
Schneider 0
cells 0
. 0

Measurements 0
included 0
bone 0
mineral 0
density 0
of 0
the 0
lumbar 0
spine 0
and 0
proximal 0
femur 0
( 0
by 0
dual 0
- 0
energy 0
X 0
- 0
ray 0
absorptiometry 0
) 0
and 0
biochemical 0
markers 0
of 0
bone 0
remodeling 0
( 0
serum 0
bone 0
- 0
specific 0
alkaline B-gene
phosphatase I-gene
by 0
immunoassay 0
and 0
urine 0
deoxypyridinoline 0
by 0
high 0
- 0
pressure 0
liquid 0
chromatography 0
) 0
. 0

Human B-gene
MGP I-gene
is 0
a 0
10 B-gene
- I-gene
kD I-gene
skeletal I-gene
extracellular I-gene
matrix I-gene
( I-gene
ECM I-gene
) I-gene
protein I-gene
that 0
consists 0
of 0
an 0
84 0
- 0
aa 0
mature 0
protein 0
and 0
a 0
19 0
- 0
aa 0
transmembrane 0
signal 0
peptide 0
. 0

Dual 0
roles 0
of 0
p82 B-gene
, 0
the 0
clam 0
CPEB B-gene
homolog I-gene
, 0
in 0
cytoplasmic 0
polyadenylation 0
and 0
translational 0
masking 0
. 0

The 0
RNA B-gene
polymerase I-gene
III I-gene
- I-gene
recruiting I-gene
factor I-gene
TFIIIB I-gene
induces 0
a 0
DNA 0
bend 0
between 0
the 0
TATA 0
box 0
and 0
the 0
transcriptional 0
start 0
site 0
. 0

The 0
pattern 0
of 0
RNase B-gene
E I-gene
digestion 0
of 0
finP305 B-gene
RNA I-gene
differed 0
from 0
FinP B-gene
, 0
and 0
GST B-gene
- 0
FinO B-gene
did 0
not 0
protect 0
finP305 B-gene
RNA I-gene
from 0
cleavage 0
in 0
vitro 0
. 0

Transcription 0
readthrough 0
into 0
the 0
inverted 0
repeats 0
has 0
little 0
effect 0
on 0
this 0
event 0
. 0

Analysis 0
of 0
hematopoietic B-gene
growth I-gene
factor I-gene
prescriptions 0
in 0
19 0
french 0
cancer 0
centers 0

In 0
the 0
second 0
case 0
, 0
an 0
epidermal 0
cyst 0
was 0
diagnosed 0
. 0

MotA B-gene
also 0
binds 0
a 0
DNA 0
sequence 0
( 0
a 0
MotA B-gene
box I-gene
) 0
, 0
centered 0
at 0
position 0
- 0
30 0
. 0

We 0
suggest 0
that 0
MotA B-gene
and 0
AsiA B-gene
may 0
function 0
like 0
certain 0
eukaryotic B-gene
TAFs I-gene
( 0
TATA B-gene
binding I-gene
protein I-gene
( I-gene
TBP I-gene
) I-gene
associated I-gene
factors I-gene
) 0
whose 0
binding 0
to 0
TBP B-gene
results 0
in 0
transcription 0
from 0
new 0
core 0
promoter 0
sequences 0
. 0

The 0
S229A 0
variant 0
can 0
better 0
flip 0
modified 0
bases 0
but 0
does 0
not 0
tightly 0
lock 0
the 0
flipped 0
base 0
into 0
the 0
adenine 0
- 0
binding 0
pocket 0
, 0
suggesting 0
that 0
Ser229 0
could 0
form 0
a 0
contact 0
to 0
the 0
flipped 0
adenine 0
. 0

The 0
high 0
conservation 0
of 0
the 0
3 0
' 0
terminus 0
suggests 0
that 0
this 0
region 0
directs 0
the 0
assembly 0
of 0
proteins 0
required 0
for 0
the 0
initiation 0
of 0
RNA 0
replication 0
. 0

All 0
stimulations 0
were 0
down 0
- 0
regulated 0
with 0
GnRH B-gene
- I-gene
a I-gene
commenced 0
on 0
day 0
21 0
in 0
a 0
long 0
protocol 0
before 0
gonadotropin B-gene
stimulation 0
. 0

The 0
sequence 0
up 0
to 0
- 0
267 0
bp 0
relative 0
to 0
the 0
transcription 0
start 0
site 0
was 0
sufficient 0
to 0
enhance 0
reporter 0
gene 0
expression 0
depending 0
on 0
the 0
mesodermal 0
differentiation 0
of 0
P19 0
cells 0
. 0

Chem 0
. 0

No 0
significant 0
differences 0
between 0
the 0
substituted 0
and 0
wild 0
type 0
peptides 0
were 0
observed 0
, 0
suggesting 0
that 0
this 0
substitution 0
in 0
the 0
intact 0
protein 0
may 0
cause 0
disruption 0
of 0
global 0
rather 0
than 0
local 0
structures 0
. 0

These 0
results 0
suggest 0
that 0
the 0
c B-gene
- I-gene
met I-gene
gene I-gene
is 0
also 0
a 0
target 0
of 0
p53 B-gene
gene I-gene
regulation 0
. 0

C3 B-gene
toxin I-gene
completely 0
inhibited 0
RhoA B-gene
function 0
, 0
partially 0
inhibited 0
SRE 0
: 0
Luc B-gene
activity 0
, 0
but 0
had 0
no 0
effect 0
on 0
LPA 0
- 0
stimulated 0
c B-gene
- I-gene
Fos I-gene
expression 0
. 0

However 0
, 0
C3 B-gene
toxin I-gene
alone 0
or 0
in 0
combination 0
with 0
growth 0
factors 0
did 0
not 0
stimulate 0
AP B-gene
- I-gene
1 I-gene
: 0
Luc B-gene
activity 0
and 0
actually 0
antagonized 0
the 0
synergistic 0
activation 0
of 0
AP B-gene
- I-gene
1 I-gene
: 0
Luc B-gene
observed 0
in 0
response 0
to 0
co 0
- 0
stimulation 0
with 0
growth 0
factors 0
and 0
Ro 0
- 0
31 0
- 0
8220 0
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
examine 0
the 0
antimicrobial 0
susceptibility 0
to 0
10 0
currently 0
used 0
antimicrobial 0
agents 0
of 0
50 0
strains 0
of 0
P. 0
acnes 0
isolated 0
from 0
acne 0
lesions 0
and 0
identified 0
using 0
a 0
Rap 0
ID 0
ANA 0
II 0
panel 0
. 0

The 0
role 0
of 0
intraoperative 0
echocardiography 0
in 0
surgery 0
of 0
the 0
heart 0
and 0
large 0
vessels 0

Taken 0
together 0
, 0
our 0
results 0
demonstrate 0
that 0
CAP1 B-gene
is 0
involved 0
in 0
multidrug 0
resistance 0
and 0
oxidative 0
stress 0
response 0
in 0
C. 0
albicans 0
. 0

Trinipatch 0
is 0
a 0
small 0
, 0
transparent 0
, 0
matricial 0
, 0
monolayer 0
patch 0
with 0
an 0
absorption 0
promoter 0
, 0
marketed 0
in 0
two 0
dose 0
- 0
strengths 0
( 0
5 0
mg/24 0
h 0
and 0
10 0
mg/24 0
h 0
) 0
by 0
Laboratoires 0
Synthelabo 0
. 0

The 0
RMRI 0
was 0
tested 0
for 0
interrater 0
reliability 0
using 0
three 0
simulated 0
and 0
10 0
actual 0
patients 0
. 0

The 0
starting 0
point 0
is 0
the 0
consideration 0
that 0
the 0
conceptions 0
underlying 0
the 0
ICIDH 0
are 0
not 0
suitable 0
to 0
serve 0
as 0
a 0
mainstay 0
of 0
a 0
model 0
for 0
diagnostics 0
in 0
rehabilitation 0
because 0
they 0
do 0
not 0
reflect 0
essential 0
characteristics 0
of 0
the 0
diagnostic 0
process 0
which 0
is 0
the 0
basis 0
for 0
intervention 0
. 0

Pokeweed B-gene
antiviral I-gene
protein I-gene
( 0
PAP B-gene
) 0
from 0
Phytolacca 0
americana 0
is 0
a 0
highly 0
specific 0
N B-gene
- I-gene
glycosidase I-gene
removing 0
adenine 0
residues 0
( 0
A4324 0
in 0
28S B-gene
rRNA I-gene
and 0
A2660 0
in 0
23S B-gene
rRNA I-gene
) 0
from 0
intact 0
ribosomes 0
of 0
both 0
eukaryotes 0
and 0
prokaryotes 0
. 0

OBJECTIVE 0
: 0
This 0
meta 0
- 0
analysis 0
of 0
67 0
controlled 0
trials 0
was 0
performed 0
to 0
quantify 0
the 0
cholesterol 0
- 0
lowering 0
effect 0
of 0
major 0
dietary 0
fibers 0
. 0

Among 0
these 0
360 0
ZFPs B-gene
, 0
a 0
novel 0
ZFP B-gene
cDNA I-gene
named 0
HFHZ B-gene
( 0
human B-gene
fetal I-gene
heart I-gene
ZFP I-gene
) 0
with 0
sequence 0
homology 0
to 0
a 0
Kruppel B-gene
- I-gene
associated I-gene
box I-gene
( 0
KRAB B-gene
) 0
was 0
identified 0
. 0

The 0
3.3 0
- 0
fold 0
higher 0
expression 0
in 0
the 0
fetal 0
heart 0
than 0
in 0
the 0
adult 0
heart 0
suggests 0
that 0
HFHZ B-gene
mRNA I-gene
is 0
downregulated 0
in 0
the 0
process 0
of 0
development 0
. 0

When 0
the 0
high 0
affinity 0
hnRNP B-gene
A1 I-gene
binding I-gene
site I-gene
was 0
inserted 0
into 0
the 0
beta B-gene
- I-gene
globin I-gene
reporter I-gene
, 0
Rev B-gene
was 0
able 0
to 0
increase 0
the 0
cytoplasmic 0
levels 0
of 0
unspliced 0
mRNAs 0
to 0
14 0
% 0
. 0

To 0
date 0
, 0
two 0
such 0
proteins 0
, 0
PLZF B-gene
and 0
LAZ B-gene
- I-gene
3/BCL I-gene
3/BCL I-gene
- I-gene
6 I-gene
, 0
have 0
been 0
implicated 0
in 0
oncogenesis 0
. 0

Overexpression 0
of 0
POG1 B-gene
inhibits 0
alpha B-gene
- I-gene
factor I-gene
- 0
induced 0
G1 0
arrest 0
and 0
transcriptional 0
repression 0
of 0
the 0
CLN1 B-gene
and 0
CLN2 B-gene
genes I-gene
. 0

We 0
now 0
show 0
that 0
RNU2 B-gene
fragility 0
can 0
be 0
induced 0
by 0
transfection 0
with 0
an 0
expression 0
vector 0
encoding 0
Ad12 B-gene
E1B I-gene
55 0
kDa 0
alone 0
but 0
not 0
by 0
an 0
E1 B-gene
vector 0
encoding 0
all 0
E1 B-gene
products I-gene
( 0
3 0
E1A B-gene
proteins I-gene
, 0
as 0
well 0
as 0
the 0
E1B B-gene
19 0
kDa 0
and 0
55 0
kDa 0
proteins 0
) 0
. 0

Competitionsupershift 0
EMSA 0
assays 0
revealed 0
that 0
multiple 0
proteins 0
were 0
involved 0
in 0
bandshift 0
complex 0
formation 0
with 0
KCS B-gene
, 0
one 0
of 0
which 0
was 0
identified 0
as 0
factor 0
Sp1 0
. 0

Similarity 0
of 0
DNA 0
binding 0
and 0
transcriptional 0
regulation 0
by 0
Caenorhabditis B-gene
elegans I-gene
MAB I-gene
- I-gene
3 I-gene
and 0
Drosophila B-gene
melanogaster I-gene
DSX I-gene
suggests 0
conservation 0
of 0
sex 0
determining 0
mechanisms 0
. 0

CONTEXT 0
: 0
ThinPrep 0
, 0
AutoPap 0
, 0
and 0
Papnet 0
are 0
3 0
new 0
technologies 0
that 0
increase 0
the 0
sensitivity 0
and 0
cost 0
of 0
cervical 0
cancer 0
screening 0
. 0

Experiments 0
on 0
narcotized 0
cats 0
demonstrated 0
that 0
the 0
derivatives 0
of 0
2 0
- 0
mercaptobenzimidazole 0
possessing 0
the 0
properties 0
of 0
specific 0
bradycardic 0
agents 0
and 0
coded 0
as 0
CM 0
- 0
251 0
, 0
CM 0
- 0
266 0
, 0
and 0
CM 0
- 0
345 0
, 0
reduce 0
the 0
mean 0
rise 0
of 0
segment 0
ST 0
on 0
numerous 0
leads 0
of 0
the 0
epicardial 0
electrogram 0
during 0
5 0
- 0
min 0
occlusion 0
of 0
the 0
anterior 0
descending 0
branch 0
of 0
the 0
left 0
coronary 0
artery 0
. 0

Neither 0
the 0
p42/44 B-gene
nor 0
the 0
JNK B-gene
pathway 0
was 0
involved 0
in 0
the 0
action 0
of 0
IL B-gene
- I-gene
1beta I-gene
. 0

In 0
protocol 0
2 0
, 0
eight 0
different 0
subjects 0
performed 0
Con 0
and 0
Ecc 0
arm 0
curls 0
to 0
fatigue 0
, 0
followed 0
by 0
postexercise 0
muscle 0
ischemia 0
, 0
by 0
using 0
the 0
same 0
resistance 0
as 0
in 0
protocol 0
1 0
. 0

Airflow 0
was 0
measured 0
with 0
a 0
custom 0
- 0
designed 0
turbine 0
and 0
a 0
45 0
- 0
ft. 0
- 0
long 0
cable 0
to 0
reach 0
the 0
volume 0
- 0
measuring 0
module 0
. 0

Both 0
mutations 0
confer 0
amino 0
acid 0
substitutions 0
in 0
the 0
viral B-gene
coat I-gene
protein I-gene
but 0
differ 0
in 0
their 0
relative 0
abilities 0
to 0
utilize 0
the 0
foreign 0
scaffolding B-gene
protein I-gene
. 0

Complete 0
recovery 0
of 0
liver 0
function 0
after 0
this 0
surgery 0
tended 0
to 0
be 0
slow 0
. 0

Although 0
both 0
transcripts 0
share 0
the 0
first 0
nine 0
exons 0
, 0
exon 0
10 0
of 0
ZIS B-gene
- I-gene
2 I-gene
is 0
lacking 0
in 0
ZIS B-gene
- I-gene
1 I-gene
, 0
and 0
instead 0
, 0
exon 0
11 0
( 0
10th 0
exon 0
) 0
of 0
ZIS B-gene
- I-gene
1 I-gene
is 0
larger 0
in 0
size 0
, 0
leading 0
to 0
the 0
longer 0
3' 0
- 0
UTR 0
. 0

Expression 0
of 0
the 0
second 0
gene 0
( 0
XT3 B-gene
) 0
was 0
found 0
to 0
be 0
conserved 0
in 0
human 0
kidney 0
, 0
and 0
partial 0
sequence 0
was 0
obtained 0
from 0
a 0
human 0
cDNA 0
library 0
. 0

IFN B-gene
- I-gene
gamma I-gene
was 0
elevated 0
during 0
active 0
TB 0
when 0
compared 0
with 0
healthy 0
controls 0
, 0
declining 0
during 0
and 0
after 0
treatment 0
. 0

The 0
missing 0
5 0
' 0
sequences 0
were 0
obtained 0
by 0
5' 0
- 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
and 0
by 0
analysis 0
of 0
an 0
NHE5 B-gene
genomic I-gene
clone I-gene
, 0
and 0
the 0
missing 0
3 0
' 0
sequences 0
were 0
obtained 0
by 0
3' 0
- 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
. 0

If 0
no 0
alloantibodies 0
are 0
detected 0
, 0
further 0
analysis 0
to 0
define 0
a 0
role 0
of 0
drug 0
- 0
related 0
or 0
autoantibodies 0
is 0
required 0
. 0

This 0
dependence 0
, 0
however 0
, 0
can 0
be 0
overcome 0
to 0
a 0
large 0
extent 0
by 0
dividing 0
min 0
LVdP/dt 0
by 0
mean 0
aortic 0
pressure 0
. 0

Genoa 0
, 0
Italy 0
, 0
24 0
- 0
28 0
August 0
1997 0
. 0

Electronic 0
structure 0
of 0
delta 0
- 0
plutonium 0
and 0
of 0
single 0
Al 0
, 0
Ga 0
, 0
and 0
Sc 0
impurities 0
in 0
delta 0
- 0
plutonium 0
. 0

Bound 0
- 0
exciton 0
transfer 0
and 0
photoluminescence 0
undulation 0
spectra 0
for 0
acceptors 0
in 0
ZnTe 0
. 0

Unified 0
theory 0
of 0
segregated 0
- 0
stack 0
organic 0
charge 0
- 0
transfer 0
solids 0
: 0
Magnetic 0
properties 0
. 0

Internal 0
modes 0
of 0
a 0
soliton 0
. 0

II 0
. 0

Envelope 0
- 0
function 0
matching 0
conditions 0
for 0
GaAs/ 0
( 0
Al 0
, 0
Ga 0
) 0
As 0
heterojunctions 0
. 0

Neutron 0
scattering 0
measurements 0
of 0
critical 0
exponents 0
in 0
CsMnBr3 0
: 0
A 0
Z2 0
& 0
gt 0
; 0
= 0
1 0
antiferromagnet 0
. 0

( 0
2 0
) 0
Erythroid 0
32D 0
Epo1 B-gene
cells 0
showed 0
a 0
lower 0
level 0
of 0
bulk 0
PKC B-gene
catalytic 0
activity 0
, 0
lacked 0
the 0
expression 0
of 0
epsilon B-gene
and I-gene
eta I-gene
PKC I-gene
isoforms I-gene
, 0
and 0
showed 0
a 0
weak 0
or 0
absent 0
upregulation 0
of 0
the 0
remaining 0
isoforms 0
, 0
except 0
betaI B-gene
, 0
upon 0
readdition 0
of 0
Epo B-gene
to 0
growth 0
factor 0
- 0
starved 0
cells 0
. 0

We 0
used 0
expression 0
cloning 0
to 0
identify 0
interleukin B-gene
- I-gene
6 I-gene
( 0
IL B-gene
- I-gene
6 I-gene
) 0
as 0
one 0
factor 0
that 0
suppressed 0
growth 0
of 0
a 0
pre 0
- 0
B 0
- 0
cell 0
variant 0
line 0
, 0
1A9 0
- 0
M 0
. 0

Airflow 0
through 0
the 0
dust 0
trap 0
was 0
controlled 0
with 0
a 0
vacuum 0
pump 0
. 0

Thus 0
, 0
in 0
normal 0
intestinal 0
epithelial 0
goblet 0
cells 0
, 0
TbetaRI B-gene
and 0
TbetaRII B-gene
can 0
respond 0
to 0
autocrine 0
but 0
not 0
exogenous 0
TGF B-gene
- I-gene
beta I-gene
without 0
the 0
participation 0
of 0
TbetaRIII B-gene
. 0

The 0
history 0
of 0
exposure 0
and 0
carboxyhemoglobin B-gene
levels 0
should 0
alert 0
the 0
physician 0
to 0
this 0
diagnosis 0
. 0

The 0
odds 0
ratio 0
for 0
CHD 0
was 0
1.21 0
( 0
95 0
% 0
confidence 0
interval 0
, 0
0.84 0
- 0
1.75 0
) 0
given 0
a 0
positive 0
serostatus 0
of 0
specific 0
IgG B-gene
antibodies 0
after 0
adjustment 0
for 0
covariates 0
. 0

Another 0
group 0
of 0
HIPP 0
- 0
and 0
HCX 0
- 0
lesioned 0
animals 0
trained 0
on 0
the 0
tasks 0
after 0
the 0
lesion 0
showed 0
reduced 0
impairments 0
of 0
the 0
type 0
described 0
above 0
, 0
suggesting 0
that 0
extrahippocampal 0
structures 0
trained 0
after 0
the 0
lesion 0
can 0
assume 0
the 0
role 0
of 0
the 0
hippocampus 0
to 0
some 0
degree 0
. 0

The 0
case 0
for 0
neutrinos 0
from 0
SN 0
1987A 0
. 0

Scaling 0
of 0
fluctuations 0
in 0
one 0
- 0
dimensional 0
interface 0
and 0
hopping 0
models 0
. 0

Model 0
of 0
spatiotemporal 0
dynamics 0
of 0
stick 0
- 0
slip 0
motion 0
. 0

NMR 0
of 0
diffusing 0
atoms 0
in 0
a 0
periodic 0
porous 0
medium 0
in 0
the 0
presence 0
of 0
a 0
nonuniform 0
magnetic 0
field 0
. 0

Microstructure 0
and 0
conductivity 0
of 0
hierarchical 0
laminate 0
composites 0
. 0

Anisotropic 0
heat 0
transport 0
in 0
the 0
octylcyanobiphenyl 0
( 0
8CB 0
) 0
liquid 0
crystal 0
. 0

Direct 0
approach 0
to 0
the 0
study 0
of 0
soliton 0
perturbations 0
. 0

Mutations 0
affecting 0
only 0
CD4 B-gene
regulation 0
mapped 0
to 0
residues 0
previously 0
shown 0
to 0
mediate 0
the 0
binding 0
of 0
Nef B-gene
to 0
this 0
receptor 0
, 0
such 0
as 0
W57 0
and 0
L58 0
, 0
as 0
well 0
as 0
to 0
an 0
AP B-gene
- I-gene
recruiting I-gene
dileucine I-gene
motif I-gene
and 0
to 0
an 0
acidic 0
dipeptide 0
in 0
the 0
C 0
- 0
terminal 0
region 0
of 0
the 0
protein 0
. 0

Several 0
mutations 0
disrupted 0
the 0
endonuclease 0
and 0
helicase B-gene
activities 0
; 0
however 0
, 0
only 0
one 0
amino B-gene
- I-gene
terminal I-gene
- I-gene
charge I-gene
cluster I-gene
mutant I-gene
protein I-gene
( 0
D40A 0
- 0
D42A 0
- 0
D44A 0
) 0
completely 0
lost 0
AAV 0
hairpin 0
DNA 0
binding 0
activity 0
. 0

The 0
lytic 0
cycle 0
of 0
KSHV 0
, 0
probably 0
under 0
the 0
initial 0
control 0
of 0
the 0
KSHV/Rta B-gene
gene I-gene
, 0
may 0
directly 0
contribute 0
to 0
tumor 0
pathogenesis 0
. 0

We 0
conclude 0
that 0
( 0
i 0
) 0
we 0
have 0
identified 0
several 0
candidate 0
latency 0
genes 0
of 0
murine 0
gammaHV68 0
, 0
( 0
ii 0
) 0
expression 0
of 0
genes 0
during 0
latency 0
may 0
be 0
different 0
in 0
different 0
organs 0
, 0
consistent 0
with 0
multiple 0
latency 0
programs 0
and/or 0
multiple 0
cellular 0
sites 0
of 0
latency 0
, 0
and 0
( 0
iii 0
) 0
regions 0
of 0
the 0
viral 0
genome 0
( 0
v B-gene
- I-gene
bcl I-gene
- I-gene
2 I-gene
gene I-gene
, 0
v B-gene
- I-gene
GCR I-gene
gene I-gene
, 0
and 0
gene B-gene
73 I-gene
) 0
are 0
transcribed 0
during 0
latency 0
with 0
both 0
gammaHV68 0
and 0
primate 0
gammaherpesviruses 0
. 0

These 0
data 0
indicate 0
a 0
functional 0
role 0
for 0
U1 B-gene
in 0
NRS B-gene
- 0
mediated 0
splicing 0
inhibition 0
. 0

This 0
suggests 0
that 0
the 0
DcuS B-gene
- 0
DcuR B-gene
system 0
responds 0
to 0
external 0
substrates 0
. 0

Here 0
we 0
describe 0
the 0
identification 0
and 0
characterization 0
of 0
several 0
Sp100 B-gene
splice I-gene
variant I-gene
proteins I-gene
and 0
support 0
their 0
existence 0
by 0
elucidation 0
of 0
the 0
3' 0
- 0
end 0
of 0
the 0
Sp100 B-gene
gene I-gene
. 0

Crossover 0
in 0
the 0
specific 0
heat 0
of 0
dilute 0
magnets 0
induced 0
by 0
critical 0
spin 0
- 0
wave 0
dynamics 0
. 0

Erratum 0
: 0
Absence 0
of 0
precursor 0
effects 0
above 0
the 0
martensitic 0
transformation 0
in 0
a 0
virgin 0
crystal 0
of 0
Li 0
metal 0

Interplane 0
coupling 0
in 0
the 0
superconductor 0
Y2Ba4Cu7O15 0
as 0
revealed 0
by 0
NQR 0
spin 0
- 0
echo 0
double 0
resonance 0
. 0

Electronic 0
structure 0
of 0
a 0
buried 0
NiSi2 0
or 0
CoSi2 0
layer 0
in 0
bulk 0
Si 0
. 0

Raman 0
investigation 0
of 0
YBa2 0
- 0
xLaxCu3O7 0
ceramics 0
. 0

Effects 0
of 0
point 0
defects 0
on 0
lattice 0
parameters 0
of 0
semiconductors 0
. 0

Chaotic 0
electron 0
dynamics 0
around 0
a 0
single 0
elliptically 0
shaped 0
antidot 0
. 0

However 0
, 0
deletions 0
of 0
the 0
C 0
terminal 0
11 0
or 0
14 0
amino 0
acids 0
had 0
more 0
substantial 0
effects 0
. 0

Sixty 0
months 0
after 0
the 0
initial 0
vaccination 0
, 0
all 0
vaccinees 0
who 0
received 0
annual 0
follow 0
- 0
up 0
still 0
had 0
protective 0
levels 0
of 0
anti B-gene
- I-gene
HAV I-gene
. 0

However 0
, 0
after 0
PRK 0
at 0
5 0
weeks 0
of 0
age 0
, 0
partial 0
retreatment 0
may 0
be 0
necessary 0
due 0
to 0
regression 0
of 0
the 0
PRK 0
effect 0
. 0

Its 0
early 0
lesions 0
were 0
characterized 0
by 0
angiomatosis 0
, 0
vasculopathy 0
, 0
and 0
proliferation 0
of 0
synoviocytes 0
and 0
fibroblasts 0
. 0

Molecular 0
cloning 0
of 0
human 0
cDNA 0
encoding 0
a 0
novel 0
beta1,6 B-gene
- I-gene
N I-gene
- I-gene
acetylglucosaminyltransferase I-gene
forming 0
core 0
2 0
and 0
core 0
4 0
. 0

Interspecific 0
mouse 0
back 0
- 0
cross 0
analysis 0
identified 0
the 0
loci 0
for 0
mouse B-gene
3Ost I-gene
genes I-gene
and 0
syntenic 0
assignments 0
of 0
corresponding 0
human 0
isologs 0
were 0
confirmed 0
by 0
the 0
identification 0
of 0
mapped 0
sequence 0
- 0
tagged 0
site 0
markers 0
. 0

The 0
Scales 0
of 0
Cognitive 0
Impairment 0
Rated 0
From 0
Institutional 0
Records 0
( 0
SCIRFIR 0
) 0
, 0
a 0
battery 0
based 0
on 0
commonly 0
used 0
dementia 0
rating 0
instruments 0
, 0
was 0
tested 0
on 0
the 0
records 0
of 0
26 0
chronically 0
institutionalized 0
, 0
elderly 0
schizophrenia 0
patients 0
, 0
for 0
the 0
purpose 0
of 0
retrospectively 0
evaluating 0
the 0
long 0
- 0
term 0
course 0
of 0
cognitive 0
change 0
in 0
schizophrenia 0
and 0
relating 0
it 0
to 0
available 0
autopsy 0
materials 0
. 0

It 0
was 0
demonstrated 0
that 0
the 0
processing 0
signals 0
in 0
the 0
transcript 0
, 0
i.e 0
. 0
both 0
donor 0
splice 0
sites 0
and 0
the 0
polyadenylation 0
site 0
located 0
in 0
the 0
muscle 0
- 0
specific 0
intron 0
, 0
have 0
to 0
be 0
weak 0
. 0

Most 0
recently 0
, 0
the 0
use 0
of 0
the 0
product 0
of 0
brain 0
weight 0
and 0
clearance 0
has 0
been 0
proposed 0
. 0

Recombination 0
and 0
transcription 0
of 0
the 0
endogenous B-gene
Ig I-gene
heavy I-gene
chain I-gene
locus I-gene
is 0
effected 0
by 0
the 0
Ig B-gene
heavy I-gene
chain I-gene
intronic I-gene
enhancer I-gene
core I-gene
region I-gene
in 0
the 0
absence 0
of 0
the 0
matrix 0
attachment 0
regions 0
. 0

Two 0
of 0
these 0
motifs 0
are 0
part 0
of 0
a 0
highly 0
conserved 0
and 0
inducible 0
dyad 0
symmetry 0
element 0
shown 0
previously 0
to 0
control 0
a 0
remote 0
IL B-gene
- I-gene
2 I-gene
enhancer I-gene
and 0
the 0
CD18 B-gene
promoter I-gene
. 0

In 0
concert 0
with 0
the 0
coactivator 0
CREB B-gene
binding I-gene
protein/p300 I-gene
, 0
which 0
interacts 0
with 0
protein/p300 I-gene

TPO B-gene
by 0
itself 0
did 0
not 0
activate 0
ERK1 B-gene
, 0
ERK2 B-gene
and 0
protein B-gene
kinase I-gene
C I-gene
( 0
PKC B-gene
) 0
, 0
whereas 0
TPO B-gene
directly 0
enhanced 0
the 0
PKC B-gene
- 0
dependent 0
activation 0
of 0
ERKs B-gene
induced 0
by 0
other 0
agonists 0
including 0
thrombin B-gene
and 0
phorbol 0
esters 0
, 0
without 0
affecting 0
the 0
PKC B-gene
activation 0
by 0
those 0
agonists 0
. 0

BACKGROUND 0
: 0
In 0
the 0
ubiquitin B-gene
- 0
dependent 0
proteolysis 0
pathway 0
, 0
a 0
ubiquitin B-gene
ligase I-gene
( 0
E3 B-gene
) 0
is 0
responsible 0
for 0
substrate 0
selectivity 0
and 0
timing 0
of 0
degradation 0
. 0

CONCLUSIONS 0
: 0
Fission B-gene
yeast I-gene
SCF I-gene
is 0
composed 0
of 0
Pop1 B-gene
and 0
Pop2 B-gene
, 0
two 0
structurally 0
related 0
but 0
functionally 0
independent 0
F B-gene
- I-gene
box/WD I-gene
- I-gene
repeat I-gene
proteins I-gene
. 0

19F 0
NMR 0
studies 0
in 0
ABF4 0
- 0
type 0
layered 0
antiferromagnets 0
. 0

Optical 0
- 0
absorption 0
spectra 0
, 0
crystal 0
- 0
field 0
energy 0
levels 0
, 0
and 0
transition 0
line 0
strengths 0
of 0
holmium 0
in 0
trigonal 0
Na3 0

Observation 0
of 0
dipolar 0
interactions 0
between 0
Pb0 0
defects 0
at 0
the 0
( 0
111 0
) 0
Si/SiO2 0
interface 0
. 0

Quantum 0
- 0
statistical 0
theory 0
of 0
high 0
- 0
field 0
transport 0
phenomena 0
. 0

NH3 0
and 0
NO 0
interaction 0
with 0
Si 0
( 0
100 0
) 0
- 0
( 0
2 0
x 0
1 0
) 0
surfaces 0
. 0

Chirality 0
- 0
glass 0
and 0
spin 0
- 0
glass 0
correlations 0
in 0
the 0
two 0
- 0
dimensional 0
random 0
- 0
bond 0
XY 0
model 0
. 0

Echo 0
modulation 0
in 0
Pr3+ 0
: 0
YAlO3 0
. 0

Mechanisms 0
of 0
visible 0
- 0
light 0
emission 0
from 0
electro 0
- 0
oxidized 0
porous 0
silicon 0
. 0

Far 0
- 0
infrared 0
hopping 0
conductivity 0
in 0
the 0
CuO 0
chains 0
of 0
a 0
single 0
- 0
domain 0
YBa2Cu3O7 0
- 0
delta 0
crystal 0
. 0

Surface 0
spin 0
waves 0
in 0
a 0
Heisenberg 0
ferrimagnet 0
with 0
a 0
single 0
- 0
ion 0
anisotropy 0
( 0
uniaxial 0
and 0
nonuniaxial 0
) 0
. 0

Optically 0
detected 0
librons 0
and 0
phonons 0
in 0
crystalline 0
C60 0
. 0

Multilayer 0
- 0
relaxation 0
geometry 0
and 0
electronic 0
structure 0
of 0
a 0
W 0
( 0
111 0
) 0
surface 0
. 0

Temperature 0
dependence 0
of 0
the 0
sublattice 0
spontaneous 0
magnetization 0
of 0
YBa2Cu3O6 0
. 0

GW 0
Gamma 0
approximation 0
for 0
electron 0
self 0
- 0
energies 0
in 0
semiconductors 0
and 0
insulators 0
. 0

Precision 0
measurement 0
of 0
the 0
pion 0
mass 0
difference 0
m 0
pi 0
- 0
- 0
m 0
pi 0
0 0
. 0

Testing 0
gravity 0
to 0
second 0
post 0
- 0
Newtonian 0
order 0
: 0
A 0
field 0
- 0
theory 0
approach 0
. 0

Genetic 0
experiments 0
using 0
mutants 0
defective 0
in 0
apontic B-gene
and 0
bruno B-gene
reveal 0
a 0
functional 0
interaction 0
between 0
these 0
genes 0
. 0

In 0
the 0
current 0
model 0
, 0
Wingless/Wnt B-gene
signal 0
stabilizes 0
Wingless/Wnt I-gene

In 0
support 0
of 0
clinical 0
antianginal 0
studies 0
, 0
the 0
vasodilator 0
nicorandil 0
( 0
NIC 0
) 0
was 0
combined 0
with 0
the 0
beta B-gene
- I-gene
adrenergic I-gene
receptor I-gene
antagonists 0
propranolol 0
( 0
PRO 0
) 0
and 0
atenolol 0
( 0
ATN 0
) 0
and 0
with 0
the 0
calcium 0
channel 0
blocker 0
diltiazem 0
( 0
DTZ 0
) 0
to 0
determine 0
their 0
cardiovascular 0
and 0
pharmacokinetic 0
interactions 0
. 0

Factors 0
influencing 0
direct 0
- 0
immersion 0
( 0
DI 0
) 0
- 0
SPME 0
process 0
were 0
also 0
checked 0
and 0
chosen 0
experimentally 0
. 0

In 0
contrast 0
, 0
an 0
amino 0
- 0
terminal 0
fragment 0
containing 0
the 0
C/H1 0
domain 0
was 0
sufficient 0
for 0
coactivation 0
of 0
Zta B-gene
transcription 0
and 0
viral 0
reactivation 0
function 0
. 0

In 0
addition 0
, 0
a 0
potent 0
splicing 0
enhancer 0
sequence 0
isolated 0
in 0
the 0
selection 0
specifically 0
binds 0
a 0
20 B-gene
- I-gene
kDa I-gene
SR I-gene
protein I-gene
. 0

Elimination 0
of 0
ETH1 B-gene
in 0
apn1 B-gene
strains 0
also 0
increased 0
spontaneous 0
mutation 0
rates 0
9 0
- 0
or 0
31 0
- 0
fold 0
compared 0
to 0
the 0
wild 0
type 0
as 0
determined 0
by 0
reversion 0
to 0
adenine 0
or 0
lysine 0
prototrophy 0
, 0
respectively 0
. 0

Elimination 0
of 0
ETH1 B-gene
in 0
apn1 B-gene
strains 0
also 0
increased 0
spontaneous 0
mutation 0
rates 0
9 0
- 0
or 0
31 0
- 0
fold 0
compared 0
to 0
the 0
wild 0
type 0
as 0
determined 0
by 0
reversion 0
to 0
adenine 0
or 0
lysine 0
prototrophy 0
, 0
respectively 0
. 0

These 0
data 0
suggest 0
that 0
other 0
Ras B-gene
effectors I-gene
can 0
collaborate 0
with 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
and 0
with 0
each 0
other 0
to 0
activate 0
Pak B-gene
. 0

Mammalian 0
Ras B-gene
GTPase B-gene
- I-gene
activating I-gene
protein I-gene
( 0
GAP B-gene
) 0
, 0
p120 B-gene
Ras B-gene
- 0
GAP B-gene
, 0
has 0
been 0
implicated 0
as 0
both 0
a 0
downregulator 0
and 0
effector 0
of 0
Ras B-gene
proteins I-gene
, 0
but 0
its 0
precise 0
role 0
in 0
Ras B-gene
- 0
mediated 0
signal 0
transduction 0
pathways 0
is 0
unclear 0
. 0

Three 0
mog B-gene
- I-gene
1 I-gene
alleles I-gene
possess 0
premature 0
stop 0
codons 0
and 0
are 0
likely 0
to 0
be 0
null 0
alleles 0
, 0
and 0
one 0
is 0
a 0
missense 0
mutation 0
and 0
is 0
likely 0
to 0
retain 0
residual 0
activity 0
. 0
mog B-gene
- I-gene
1 I-gene
mRNA I-gene
is 0
expressed 0
in 0
both 0
germ 0
line 0
and 0
somatic 0
tissues 0
and 0
appears 0
to 0
be 0
ubiquitous 0
. 0

However 0
, 0
unlike 0
the 0
SIN3 B-gene
gene I-gene
of 0
Saccharomyces 0
cerevisiae 0
, 0
pst1 B-gene
( I-gene
+ I-gene
) I-gene
is 0
essential 0
for 0
cell 0
viability 0
. 0

The 0
Nmd3 B-gene
protein I-gene
sequence I-gene
does 0
not 0
contain 0
readily 0
recognizable 0
motifs 0
of 0
known 0
function 0
. 0

The 0
distribution 0
of 0
the 0
various 0
repeats 0
suggests 0
its 0
organization 0
is 0
similar 0
to 0
the 0
beta 0
- 0
heterochromatic 0
regions 0
near 0
the 0
base 0
of 0
the 0
major 0
chromosome 0
arms 0
. 0

Calcitonin B-gene
simultaneously 0
regulates 0
both 0
periosteal 0
hyperostosis 0
and 0
trabecular 0
osteopenia 0
in 0
the 0
spinal 0
hyperostotic 0
mouse 0
( 0
twy/twy B-gene
) 0
in 0
vivo 0
. 0

Electrophoretic 0
mobility 0
- 0
shift 0
assays 0
performed 0
with 0
the 0
HNF B-gene
- I-gene
3 I-gene
X 0
and 0
Y 0
sites 0
demonstrated 0
that 0
both 0
sites 0
are 0
capable 0
of 0
binding 0
HNF B-gene
- I-gene
3alpha I-gene
and 0
HNF B-gene
- I-gene
3beta I-gene
. 0

In 0
addition 0
, 0
we 0
also 0
show 0
that 0
cdk7 B-gene
may 0
phosphorylate 0
the 0
carboxy 0
- 0
terminal 0
domain 0
( 0
CTD 0
) 0
of 0
RNA B-gene
pol I-gene
II I-gene
in 0
the 0
absence 0
of 0
promoter 0
opening 0
. 0

The 0
therapy 0
with 0
a 0
H2 B-gene
- I-gene
receptor I-gene
antagonist 0
is 0
less 0
effective 0
than 0
the 0
triple 0
therapies 0
with 0
omeprazole 0
or 0
lansoprazole 0
. 0

In 0
humans 0
, 0
three 0
tissue B-gene
- I-gene
specific I-gene
plastin I-gene
isoforms I-gene
have 0
been 0
identified 0
. 0

No 0
TATA 0
or 0
Inr 0
sequence 0
was 0
found 0
. 0

The 0
inhibition 0
by 0
the 0
RIalpha B-gene
subunit I-gene
is 0
reversed 0
by 0
addition 0
of 0
nanomolar 0
concentrations 0
of 0
cAMP 0
( 0
Ka 0
= 0
40 0
nM 0
) 0
, 0
thus 0
demonstrating 0
that 0
PrKX B-gene
is 0
a 0
novel 0
, 0
type B-gene
I I-gene
cAMP I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
that 0
is 0
activated 0
at 0
lower 0
cAMP 0
concentrations 0
than 0
the 0
holoenzyme 0
with 0
the 0
Calpha B-gene
subunit I-gene
of 0
cAMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
. 0

Proteins 0
known 0
to 0
bind 0
the 0
PEPCK B-gene
CRE 0
include 0
the 0
CRE B-gene
- I-gene
binding I-gene
protein I-gene
( 0
CREB B-gene
) 0
and 0
members 0
of 0
the 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
( 0
C/EBP B-gene
) 0
family 0
. 0

This 0
construct 0
, 0
termed 0
pDeltaCREC/EBP B-gene
, 0
binds 0
pDeltaCREC/EBP I-gene

In 0
addition 0
, 0
in 0
vitro 0
mutagenesis 0
of 0
both 0
Engrailed B-gene
and 0
Pbx1 B-gene
sites I-gene
indicated 0
that 0
other 0
unidentified 0
sites 0
are 0
responsible 0
for 0
the 0
transcriptional 0
enhancement 0
observed 0
with 0
the 0
intronic 0
fragment 0
. 0

Several 0
secondary 0
structure 0
elements 0
were 0
identified 0
. 0

Here 0
, 0
we 0
evidence 0
that 0
the 0
developmental 0
functions 0
of 0
the 0
family 0
of 0
transcription 0
factors 0
characterized 0
by 0
the 0
POU B-gene
DNA I-gene
binding I-gene
motif I-gene
exerts 0
roles 0
in 0
mammalian 0
development 0
. 0

High 0
- 0
affinity 0
site 0
- 0
specific 0
DNA 0
binding 0
by 0
POU B-gene
domain I-gene
transcription I-gene
factors I-gene
requires 0
both 0
the 0
POU B-gene
- I-gene
specific I-gene
and 0
the 0
POU B-gene
- I-gene
homeodomain I-gene
. 0

In 0
the 0
Oct B-gene
- I-gene
1 I-gene
crystal 0
, 0
the 0
POU B-gene
- I-gene
specific I-gene
domain I-gene
recognizes 0
a 0
GCAT 0
half 0
- 0
site 0
, 0
while 0
the 0
corresponding 0
sequence 0
recognized 0
by 0
the 0
Pit B-gene
- I-gene
1 I-gene
POU B-gene
- 0
specific 0
domain 0
, 0
GTAT 0
, 0
is 0
on 0
the 0
opposing 0
strand 0
. 0

Systematic 0
functional 0
analysis 0
of 0
V1a/V2 B-gene
hybrid I-gene
receptors I-gene
showed 0
that 0
the 0
second 0
intracellular 0
loop 0
of 0
the 0
V1a B-gene
receptor I-gene
is 0
required 0
and 0
sufficient 0
for 0
efficient 0
coupling 0
to 0
Gq/11 B-gene
, 0
whereas 0
the 0
third 0
intracellular 0
loop 0
of 0
the 0
V2 B-gene
receptor I-gene
is 0
required 0
and 0
sufficient 0
for 0
coupling 0
to 0
Gs B-gene
. 0

Most 0
other 0
end 0
points 0
were 0
highly 0
significant 0
, 0
and 0
death 0
, 0
which 0
was 0
monitored 0
across 0
the 0
U.S. 0
program 0
, 0
was 0
different 0
with 0
p 0
< 0
0.0001 0
. 0

The 0
other 0
is 0
located 0
at 0
- 0
1335 0
, 0
outside 0
this 0
highly 0
conserved 0
region 0
. 0

The 0
fatigue 0
exercise 0
showed 0
relatively 0
high 0
blood 0
lactate 0
concentration 0
[ 0
12.5 0
( 0
SD 0
2.6 0
) 0
mmol 0
x 0
l 0
( 0
- 0
1 0
) 0
] 0
and 0
an 0
increase 0
of 0
serum B-gene
creatine I-gene
kinase I-gene
( 0
CK B-gene
) 0
activity 0
delayed 0
by 0
2 0
days 0
[ 0
540 0
( 0
SD 0
407 0
) 0
U 0
x 0
l 0
( 0
- 0
1 0
) 0
] 0
. 0

Those 0
radiological 0
aspects 0
were 0
distributed 0
in 0
two 0
categories 0
: 0
1 0
) 0
type 0
I 0
- 0
presenting 0
variable 0
sinusoidal 0
filling 0
. 0

Results 0
demonstrated 0
that 0
the 0
presence 0
of 0
myofibroblasts 0
varied 0
considerably 0
from 0
case 0
to 0
case 0
and 0
was 0
always 0
related 0
to 0
smooth 0
muscle 0
cell 0
dispersion 0
, 0
which 0
occurred 0
around 0
medium 0
- 0
sized 0
damaged 0
portal 0
vein 0
branches 0
. 0

New 0
Langevin 0
equations 0
for 0
a 0
translating 0
and 0
simultaneously 0
rotating 0
asymmetric 0
top 0
. 0

Radiative 0
corrections 0
to 0
beta 0
decay 0
and 0
the 0
possibility 0
of 0
a 0
fourth 0
generation 0
. 0

Depth 0
- 0
controlled 0
grazing 0
- 0
incidence 0
diffraction 0
of 0
synchrotron 0
x 0
radiation 0
. 0

Oscillatory 0
exchange 0
of 0
atoms 0
between 0
traps 0
containing 0
Bose 0
condensates 0
. 0

Structure 0
determination 0
of 0
an 0
adsorbate 0
- 0
induced 0
multilayer 0
reconstruction 0
: 0
( 0
1 0
x 0
2 0
) 0
- 0
H/Ni 0
( 0
110 0
) 0
. 0

Magnetic 0
trapping 0
of 0
spin 0
- 0
polarized 0
atomic 0
hydrogen 0
. 0

Northern 0
blot 0
and 0
in 0
situ 0
hybridization 0
analyses 0
revealed 0
GPR34 B-gene
mRNA I-gene
transcripts I-gene
in 0
several 0
human 0
and 0
rat 0
brain 0
regions 0
. 0

The 0
microphthalmia B-gene
- I-gene
TFE I-gene
( 0
MiT B-gene
) 0
subfamily 0
of 0
basic B-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
leucine I-gene
zipper I-gene
( I-gene
bHLH I-gene
- I-gene
ZIP I-gene
) I-gene
transcription I-gene
factors I-gene
, 0
including 0
TFE3 B-gene
, 0
TFEB B-gene
, 0
TFEC B-gene
, 0
and 0
Mitf B-gene
, 0
has 0
been 0
implicated 0
in 0
the 0
regulation 0
of 0
tissue 0
- 0
specific 0
gene 0
expression 0
in 0
several 0
cell 0
lineages 0
. 0

Fifty 0
- 0
seven 0
patients 0
aged 0
< 0
55 0
years 0
with 0
acute 0
lymphoblastic 0
leukemia 0
( 0
ALL 0
) 0
in 0
second 0
or 0
third 0
bone 0
marrow 0
( 0
BM 0
) 0
relapse 0
or 0
refractory 0
to 0
first 0
- 0
line 0
therapy 0
were 0
enrolled 0
in 0
an 0
Italian 0
cooperative 0
study 0
. 0

The 0
dorsal 0
nerves 0
of 0
the 0
penis 0
were 0
anesthetized 0
bilaterally 0
with 0
lidocaine 0
. 0

In 0
the 0
brain 0
, 0
muscarinic B-gene
receptors I-gene
mediate 0
motor 0
and 0
memory 0
function 0
by 0
interaction 0
with 0
their 0
ligand 0
acetylcholine 0
. 0

Early 0
- 0
onset 0
scleral 0
necrosis 0
after 0
iodine 0
I 0
125 0
plaque 0
radiotherapy 0
for 0
ciliochoroidal 0
melanoma 0
. 0

Successful 0
interaction 0
of 0
ARF B-gene
and 0
PKC B-gene
- I-gene
alpha I-gene
with 0
PLD1 B-gene
was 0
not 0
achieved 0
, 0
but 0
a 0
C 0
- 0
terminal 0
fragment 0
of 0
human B-gene
PLD1 I-gene
( 0
denoted 0
`` 0
D4 0
'' 0
) 0
interacted 0
with 0
the 0
active 0
mutant 0
of B-gene
RhoA I-gene
RhoA I-gene
, I-gene
RhoAVal I-gene
- I-gene
14 0
. 0

In 0
this 0
study 0
, 0
we 0
investigated 0
the 0
signal 0
transduction 0
pathways 0
that 0
are 0
involved 0
in 0
OM B-gene
- 0
induced 0
LDLR B-gene
transcription 0
. 0

Vacuum 0
Rabi 0
splitting 0
as 0
a 0
feature 0
of 0
linear 0
- 0
dispersion 0
theory 0
: 0
Analysis 0
and 0
experimental 0
observations 0
. 0

High 0
- 0
pressure 0
effects 0
on 0
ultrafast 0
- 0
relaxation 0
kinetics 0
of 0
excitons 0
in 0
polydiacetylene 0
4BCMU 0
. 0

Drag 0
reduction 0
in 0
turbulent 0
flows 0
by 0
polymers 0
. 0

Large 0
scale 0
electronic 0
structure 0
calculations 0
. 0

Current 0
world 0
literature 0
. 0

These 0
results 0
show 0
that 0
Ski B-gene
is 0
a 0
component 0
of 0
the 0
HDAC B-gene
complex I-gene
and 0
that 0
Ski B-gene
is 0
required 0
for 0
the 0
transcriptional 0
repression 0
mediated 0
by 0
this 0
complex 0
. 0

Recombinant 0
unr B-gene
acts 0
synergistically 0
with 0
recombinant 0
PTB B-gene
to 0
stimulate 0
translation 0
dependent 0
on 0
the 0
rhinovirus 0
IRES 0
. 0

Analysis 0
of 0
the 0
consensus 0
binding 0
sequence 0
and 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
ZF5 B-gene
. 0

Mapping 0
of 0
the 0
human B-gene
Voltage I-gene
- I-gene
Dependent I-gene
Anion I-gene
Channel I-gene
isoforms I-gene
1 I-gene
and I-gene
2 I-gene
reconsidered 0
. 0

Identification 0
of 0
RNase B-gene
T I-gene
as 0
a 0
high 0
- 0
copy 0
suppressor 0
of 0
the 0
UV 0
sensitivity 0
associated 0
with 0
single B-gene
- I-gene
strand I-gene
DNA I-gene
exonuclease I-gene
deficiency 0
in 0
Escherichia 0
coli 0
. 0

Inhibition 0
of 0
phosphatidylinositol B-gene
- I-gene
3 I-gene
kinase I-gene
did 0
not 0
have 0
a 0
significant 0
effect 0
on 0
p53 B-gene
conformation 0
but 0
did 0
have 0
a 0
weak 0
but 0
significant 0
effect 0
on 0
Tpo B-gene
- 0
enhanced 0
viability 0
. 0

No 0
difference 0
in 0
percentage 0
of 0
males 0
in 0
semen 0
production 0
was 0
noted 0
between 0
strains 0
, 0
CP 0
levels 0
, 0
or 0
feeding 0
regimens 0
. 0

The 0
Lp B-gene
mouse I-gene
mutant I-gene
provides 0
a 0
model 0
for 0
the 0
severe 0
human 0
neural 0
tube 0
defect 0
( 0
NTD 0
) 0
, 0
cranio 0
- 0
rachischisis 0
. 0

Further 0
analysis 0
of 0
AP B-gene
- I-gene
1 I-gene
DNA 0
binding 0
activities 0
in 0
7 0
- 0
to 0
14 0
- 0
day 0
culture 0
activated 0
HSCs 0
led 0
to 0
the 0
discovery 0
of 0
high B-gene
mobility I-gene
AP I-gene
- I-gene
1 I-gene
complexes I-gene
( 0
HMAP B-gene
- I-gene
1 I-gene
) 0
. 0

Mutations 0
of 0
the 0
AP B-gene
- I-gene
1 I-gene
site I-gene
of 0
the 0
TIMP B-gene
- I-gene
1 I-gene
promoter I-gene
that 0
prevented 0
formation 0
of 0
HMAP B-gene
- I-gene
1 I-gene
caused 0
a 0
70 0
% 0
loss 0
of 0
activity 0
in 0
transfected 0
activated 0
HSCs 0
. 0

STUDY 0
DESIGN 0
: 0
Salivary B-gene
immunoglobulin I-gene
A I-gene
levels 0
of 0
each 0
of 0
20 0
subjects 0
were 0
determined 0
on 0
3 0
occasions 0
: 0
first 0
, 0
while 0
the 0
subject 0
was 0
still 0
smoking 0
; 0
second 0
, 0
7 0
days 0
after 0
cessation 0
of 0
smoking 0
; 0
third 0
, 0
on 0
the 0
14th 0
day 0
after 0
cessation 0
. 0

Therefore 0
, 0
high 0
set 0
- 0
up 0
accuracy 0
and 0
reproducibility 0
are 0
mandatory 0
. 0

Role 0
of 0
g2 0
in 0
relating 0
the 0
Schwinger 0
and 0
Gerasimov 0
- 0
Drell 0
- 0
Hearn 0
sum 0
rules 0
. 0

Spectroscopy 0
of 0
negative 0
ions 0
utilizing 0
multiphoton 0
detachment 0
in 0
a 0
Raman 0
coupling 0
regime 0
. 0

Band 0
structure 0
effects 0
of 0
transport 0
properties 0
in 0
icosahedral 0
quasicrystals 0
. 0

Acoustic 0
transmission 0
spectra 0
in 0
the 0
Penrose 0
lattice 0
. 0

Two 0
- 0
Channel 0
Kondo 0
Lattice 0
: 0
An 0
Incoherent 0
Metal 0
. 0

Basal 0
midexpiratory 0
lower 0
esophageal 0
sphincter 0
pressure 0
was 0
similar 0
in 0
the 0
study 0
group 0
( 0
mean 0
[ 0
SD 0
] 0
20.1 0
[ 0
9.1 0
] 0
mmHg 0
) 0
and 0
controls 0
( 0
17.6 0
[ 0
6.0 0
] 0
mmHg 0
) 0
; 0
the 0
pressure 0
did 0
not 0
change 0
following 0
EVS 0
or 0
EVL 0
. 0

CPDs 0
at 0
these 0
three 0
sites 0
may 0
partially 0
displace 0
TFIIIA B-gene
, 0
thereby 0
enabling 0
rapid 0
repair 0
. 0

There 0
was 0
no 0
difference 0
in 0
the 0
hormone 0
receptor 0
status 0
between 0
the 0
cases 0
without 0
lymph 0
node 0
metastases 0
and 0
with 0
lymph 0
node 0
metastases 0
, 0
'clandestine 0
' 0
or 0
macrometastases 0
. 0

On 0
the 0
other 0
hand 0
, 0
subjects 0
with 0
air 0
trapping 0
( 0
residual 0
volume 0
( 0
RV 0
) 0
/total 0
lung 0
capacity 0
( 0
TLC 0
) 0
> 0
37 0
% 0
) 0
disclosed 0
not 0
only 0
a 0
higher 0
n 0
( 0
mit 0
) 0
( 0
0.63+/ 0
- 0
0.17 0
versus 0
0.43+/ 0
- 0
0.07 0
mt 0
x 0
microm 0
( 0
- 0
2 0
) 0
, 0
p 0
< 0
0.05 0
) 0
but 0
shorter 0
sarcomeres 0
( 0
L 0
( 0
sar 0
) 0
) 0
than 0
subjects 0
without 0
this 0
functional 0
abnormality 0
( 0
2.08+/ 0
- 0
0.16 0
to 0
2.27+/ 0
- 0
0.15 0
microm 0
, 0
p 0
< 0
0.05 0
) 0
. 0

Gel 0
filtration 0
, 0
sedimentation 0
velocity 0
, 0
and 0
immunoprecipitation 0
experiments 0
revealed 0
that 0
beta4 0
is 0
a 0
component 0
of 0
a 0
multisubunit 0
complex 0
( 0
AP B-gene
- I-gene
4 I-gene
) 0
that 0
also 0
contains 0
the 0
sigma4 0
polypeptide 0
and 0
two 0
additional 0
adaptor 0
subunit 0
homologs 0
named 0
mu4 0
( 0
mu 0
- 0
ARP2 0
) 0
and 0
epsilon 0
. 0

Cyclin B-gene
D1 I-gene
- I-gene
associated I-gene
kinase I-gene
activity 0
and 0
protein 0
levels 0
were 0
increased 0
in 0
mammary 0
tumors 0
from 0
murine 0
mammary 0
tumor 0
virus 0
- 0
pp60 B-gene
( 0
c B-gene
- I-gene
src527F I-gene
) 0
transgenic 0
mice 0
. 0

The 0
SH2 B-gene
domain I-gene
- I-gene
containing I-gene
inositol I-gene
5' I-gene
- I-gene
phosphatase I-gene
( 0
SHIP B-gene
) 0
recruits 0
the 0
p85 B-gene
subunit I-gene
of 0
phosphoinositide B-gene
3 I-gene
- I-gene
kinase I-gene
during 0
FcgammaRIIb1 B-gene
- 0
mediated 0
inhibition 0
of 0
B B-gene
cell I-gene
receptor I-gene
signaling 0
. 0

We 0
show 0
that 0
the 0
mouse 0
genome 0
contains 0
four 0
copies 0
of 0
the 0
ubc B-gene
- I-gene
9 I-gene
gene I-gene
. 0

An 0
increase 0
in 0
bone 0
mineral 0
density 0
at 0
the 0
spine 0
, 0
total 0
hip 0
, 0
and 0
total 0
body 0
has 0
been 0
reported 0
with 0
raloxifene 0
but 0
seems 0
to 0
be 0
less 0
than 0
that 0
seen 0
with 0
estrogen 0
or 0
alendronate 0
therapy 0
. 0

However 0
, 0
in 0
those 0
studies 0
due 0
to 0
the 0
presence 0
of 0
thiol 0
agents 0
in 0
the 0
PKC B-gene
preparations 0
, 0
the 0
sensitive 0
reaction 0
of 0
BPO 0
with 0
redox 0
- 0
active 0
cysteine 0
residues 0
in 0
PKC B-gene
was 0
not 0
observed 0
. 0

Interestingly 0
, 0
Csx/Nkx2 B-gene
. 0

We 0
also 0
identified 0
an 0
alternative 0
spliced 0
form 0
of 0
Lyp B-gene
RNA I-gene
, 0
Lyp2 B-gene
. 0

The 0
costs 0
were 0
DM 0
11,562 0
for 0
a 0
PE 0
, 0
DM 0
12,477 0
for 0
a 0
VR 0
and 0
DM 0
7,532 0
for 0
a 0
MR 0
. 0

We 0
now 0
provide 0
evidence 0
for 0
physical 0
and 0
functional 0
interaction 0
between 0
Doa4 B-gene
and 0
the 0
proteasome 0
. 0

Independent 0
splicing 0
events 0
involve 0
three 0
previously 0
described 0
cassette 0
exons 0
, 0
which 0
are 0
predicted 0
to 0
encode 0
most 0
of 0
the 0
second 0
transmembrane 0
domain 0
. 0

Each 0
of 0
these 0
genes 0
contains 0
a 0
putative 0
upstream 0
ORF 0
, 0
while 0
STA2 B-gene
has 0
two 0
additional 0
in 0
- 0
frame 0
AUG 0
codons 0
5 0
' 0
to 0
the 0
major 0
cistron 0
. 0

Nipponbare 0
as 0
well 0
as 0
O. 0
australiensis 0
. 0

In 0
addition 0
, 0
mapping 0
of 0
the 0
promoter 0
region 0
and 0
the 0
identification 0
of 0
putative 0
promoter 0
regulatory 0
sequences 0
should 0
give 0
insight 0
into 0
the 0
transcriptional 0
regulation 0
of 0
UCP2 B-gene
expression 0
- 0
- 0
in 0
particular 0
by 0
anyone 0
of 0
the 0
above 0
mentioned 0
factors 0
- 0
- 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

The 0
rate 0
of 0
resectability 0
is 0
low 0
and 0
5 0
- 0
year 0
survival 0
is 0
very 0
poor 0
. 0

In 0
order 0
to 0
better 0
characterize 0
the 0
distribution 0
of 0
ML 0
and 0
MAP 0
estimates 0
under 0
these 0
conditions 0
, 0
we 0
derive 0
a 0
point 0
approximation 0
to 0
density 0
values 0
of 0
the 0
conditional 0
distribution 0
of 0
such 0
estimates 0
. 0

RT 0
- 0
PCR 0
was 0
performed 0
using 0
previously 0
reported 0
degenerate 0
oligonucleotide 0
primers 0
to 0
the 0
ligand 0
binding 0
domain 0
( 0
LBD 0
) 0
of 0
known 0
beta B-gene
integrin I-gene
subunits I-gene
and 0
Bge B-gene
cDNA I-gene
. 0

The 0
lowest 0
culture 0
failure 0
rate 0
of 0
0.2 0
per 0
cent 0
was 0
found 0
after 0
EAF 0
compared 0
with 0
0.9 0
per 0
cent 0
among 0
CVS 0
. 0

Ectopic 0
expression 0
of 0
d B-gene
- I-gene
axin I-gene
inhibited 0
Wingless B-gene
signaling 0
. 0

The 0
corresponding 0
differences 0
in 0
FVIIa B-gene
and 0
PAI B-gene
- I-gene
1 I-gene
were 0
not 0
statistically 0
significant 0
. 0

Primary 0
and 0
secondary 0
structural 0
elements 0
required 0
for 0
synthesis 0
of 0
barley 0
yellow 0
dwarf 0
virus 0
subgenomic 0
RNA1 0
. 0

On 0
the 0
other 0
side 0
, 0
when 0
the 0
aortic 0
ring 0
was 0
perfused 0
with 0
L 0
- 0
NNA 0
( 0
NO 0
- 0
synthesis 0
inhibitor 0
) 0
or 0
methylene 0
blue 0
( 0
soluble 0
cGMPase B-gene
inhibitor 0
) 0
, 0
the 0
changes 0
could 0
be 0
attenuated 0
. 0

Nevertheless 0
, 0
inactivation 0
of 0
the 0
cyclin B-gene
E I-gene
- 0
Cdk2 B-gene
complex 0
in 0
response 0
to 0
mitogen 0
starvation 0
occurs 0
normally 0
in 0
MEFs 0
that 0
have 0
a 0
homozygous 0
deletion 0
of 0
the 0
p27 B-gene
gene I-gene
. 0

Identification 0
and 0
characterization 0
of 0
IS2404 B-gene
and 0
IS2606 B-gene
: 0
two 0
distinct 0
repeated 0
sequences 0
for 0
detection 0
of 0
Mycobacterium 0
ulcerans 0
by 0
PCR 0
. 0

Taken 0
together 0
, 0
these 0
results 0
are 0
consistent 0
with 0
the 0
possibility 0
that 0
p202 B-gene
protein I-gene
contributes 0
to 0
the 0
cell 0
growth 0
retardation 0
activity 0
of 0
the 0
IFNs B-gene
, 0
at 0
least 0
in 0
part 0
, 0
by 0
modulating 0
p21 B-gene
protein I-gene
levels 0
. 0

Similar 0
results 0
were 0
also 0
obtained 0
with 0
a 0
HepG2 0
hepatoblastoma 0
cell 0
line 0
carrying 0
wt B-gene
p53 I-gene
. 0

Partial 0
sequencing 0
of 0
the 0
region 0
downstream 0
of 0
ORF B-gene
- I-gene
Pto I-gene
revealed 0
homology 0
to 0
the 0
ru/AB B-gene
genes I-gene
, 0
involved 0
in 0
UV 0
resistance 0
, 0
from 0
plasmid 0
pPSR1 0
. 0

The 0
MSY2 B-gene
associated 0
kinase 0
is 0
not 0
casein B-gene
kinase I-gene
2 I-gene
, 0
the 0
kinase 0
believed 0
to 0
phosphorylate 0
mRNP3+4 B-gene
in 0
oocytes 0
, 0
but 0
a 0
yet 0
unidentified 0
kinase 0
. 0

This 0
suggests 0
that 0
helicase B-gene
- I-gene
like I-gene
genes I-gene
may 0
be 0
involved 0
in 0
the 0
biosynthesis 0
of 0
nucleic 0
acids 0
and 0
proteins 0
, 0
and 0
that 0
the 0
genes 0
can 0
be 0
transcriptionally 0
activated 0
by 0
heat 0
shock 0
to 0
compensate 0
for 0
the 0
repressed 0
synthesis 0
of 0
mRNA 0
and 0
protein 0
. 0

These 0
data 0
provide 0
the 0
molecular 0
tools 0
for 0
the 0
final 0
identification 0
of 0
the 0
MKS B-gene
and 0
the 0
MUL B-gene
genes I-gene
. 0

The 0
H 0
- 0
reflex 0
recovery 0
curve 0
was 0
obtained 0
after 0
stimulation 0
of 0
the 0
median 0
nerve 0
at 0
the 0
elbow 0
and 0
recording 0
from 0
the 0
flexor 0
carpi 0
radialis 0
. 0

The 0
origins 0
of 0
reflected 0
light 0
changes 0
associated 0
with 0
neuronal 0
activity 0
( 0
optical 0
signals 0
) 0
were 0
investigated 0
in 0
rat 0
somatosensory 0
cortex 0
with 0
optical 0
imaging 0
, 0
microspectrophotometry 0
, 0
and 0
laser 0
- 0
Doppler 0
flowmetry 0
, 0
and 0
dynamic 0
changes 0
in 0
local 0
hemoglobin B-gene
concentration 0
and 0
oxygenation 0
were 0
focused 0
on 0
. 0

Human B-gene
neuronal I-gene
Elav I-gene
- I-gene
like I-gene
proteins I-gene
contain 0
three 0
RNP 0
- 0
type 0
RNA 0
recognition 0
motifs 0
( 0
RRMs 0
) 0
. 0

Comparison 0
of 0
frequencies 0
of 0
atrial 0
fibrillation 0
after 0
coronary 0
artery 0
bypass 0
grafting 0
with 0
and 0
without 0
the 0
use 0
of 0
cardiopulmonary 0
bypass 0
. 0

The 0
results 0
of 0
supershift 0
analysis 0
using 0
specific 0
antibodies 0
against 0
transcription 0
factors 0
suggested 0
that 0
both 0
binding 0
complexes 0
contained 0
the 0
NF B-gene
- I-gene
kappaB I-gene
components 0
p50 B-gene
and 0
p65 B-gene
, 0
and 0
did 0
not 0
contain 0
other 0
NF B-gene
- I-gene
kappaB I-gene
proteins I-gene
( 0
p52 B-gene
, 0
c B-gene
- I-gene
Rel I-gene
, 0
Rel B-gene
B I-gene
) 0
, 0
AP B-gene
- I-gene
1 I-gene
proteins I-gene
( 0
c B-gene
- I-gene
Fos I-gene
, 0
C B-gene
- I-gene
Jun I-gene
) 0
, 0
CREB B-gene
or 0
C/EBPbeta B-gene
( 0
NF B-gene
- I-gene
IL6 I-gene
) 0
. 0

A 0
set 0
of 0
peptides 0
corresponding 0
to 0
the 0
individual 0
elements 0
of 0
secondary 0
structure 0
derived 0
from 0
the 0
N 0
- 0
terminal 0
domain 0
of 0
the 0
ribosomal B-gene
protein I-gene
L9 I-gene
have 0
been 0
synthesized 0
. 0

The 0
results 0
showed 0
that 0
IFN B-gene
- I-gene
gamma I-gene
stimulated 0
the 0
rapid 0
accumulation 0
of 0
interferon B-gene
regulated I-gene
factor I-gene
( I-gene
IRF I-gene
) I-gene
- I-gene
1 I-gene
mRNA I-gene
, 0
followed 0
by 0
a 0
delayed 0
and 0
dose 0
- 0
dependent 0
inhibition 0
of 0
alpha1 B-gene
( I-gene
I I-gene
) I-gene
procollagen I-gene
mRNA I-gene
expression 0
in 0
skin 0
fibroblasts 0
from 0
several 0
different 0
donors 0
. 0

Functional 0
domains 0
of 0
c B-gene
- I-gene
myc I-gene
promoter I-gene
binding I-gene
protein I-gene
1 I-gene
involved 0
in 0
transcriptional 0
repression 0
and 0
cell 0
growth 0
regulation 0
. 0

Therefore 0
, 0
we 0
have 0
named 0
this 0
gene 0
UBP43 B-gene
. 0

These 0
results 0
continue 0
to 0
support 0
the 0
hypothesis 0
that 0
HS2 0
, 0
HS3 0
, 0
and 0
HS4 0
act 0
as 0
a 0
single 0
, 0
integral 0
unit 0
to 0
regulate 0
human B-gene
globin I-gene
gene I-gene
transcription 0
as 0
a 0
holocomplex 0
, 0
but 0
they 0
can 0
also 0
be 0
interpreted 0
to 0
say 0
that 0
formation 0
of 0
a 0
DNase B-gene
I I-gene
hypersensitive 0
holocomplex 0
alone 0
is 0
not 0
sufficient 0
for 0
mediating 0
high 0
- 0
level 0
globin B-gene
gene I-gene
transcription 0
. 0

To 0
identify 0
additional 0
non 0
- 0
Sir B-gene
factors I-gene
that 0
affect 0
rDNA 0
silencing 0
, 0
we 0
performed 0
a 0
genetic 0
screen 0
designed 0
to 0
isolate 0
mutations 0
which 0
alter 0
the 0
expression 0
of 0
reporter 0
genes 0
integrated 0
within 0
the 0
rDNA 0
. 0

Because 0
there 0
is 0
great 0
need 0
for 0
iron 0
in 0
the 0
EPO B-gene
- 0
stimulated 0
erythroid 0
progenitors 0
, 0
it 0
is 0
essential 0
that 0
serum B-gene
ferritin I-gene
and 0
transferrin B-gene
saturation 0
levels 0
should 0
be 0
maintained 0
over 0
300 0
microg/liter 0
and 0
30 0
% 0
, 0
respectively 0
. 0

These 0
results 0
indicate 0
that 0
the 0
p33 B-gene
subunit I-gene
of 0
eIF3 B-gene
plays 0
an 0
important 0
role 0
in 0
the 0
initiation 0
phase 0
of 0
protein 0
synthesis 0
and 0
that 0
its 0
RNA 0
- 0
binding 0
domain 0
is 0
required 0
for 0
optimal 0
activity 0
. 0

In 0
this 0
study 0
, 0
we 0
elucidate 0
signaling 0
pathways 0
induced 0
by 0
photodynamic 0
therapy 0
( 0
PDT 0
) 0
with 0
hypericin 0
. 0

These 0
results 0
indicate 0
that 0
ATF B-gene
- I-gene
2 I-gene
plays 0
a 0
central 0
role 0
in 0
TGF B-gene
- I-gene
beta I-gene
signaling 0
by 0
acting 0
as 0
a 0
common 0
nuclear 0
target 0
of 0
both 0
Smad B-gene
and 0
TAK1 B-gene
pathways 0
. 0

KEY 0
WORDS 0
: 0
Melaleuca 0
; 0
Lake 0
Okeechobee 0
; 0
Littoral 0
zone 0
; 0
Water 0
level 0
; 0
Regulation 0
schedule 0

The 0
systolic 0
peak 0
of 0
pulmonary 0
vein 0
was 0
higher 0
than 0
the 0
diastolic 0
peak 0
in 0
45 0
out 0
of 0
56 0
cases 0
. 0

Specimens 0
were 0
assayed 0
for 0
alpha B-gene
- I-gene
fetoprotein I-gene
, 0
unconjugated 0
estriol 0
, 0
free 0
alpha B-gene
hCG I-gene
, 0
and 0
total 0
hCG B-gene
. 0

FASEB 0
Federal 0
Funding 0
Consensus 0
Conference 0
FY 0
2000 0
. 0

The 0
following 0
data 0
were 0
recorded 0
at 0
arrival 0
in 0
the 0
intensive 0
care 0
unit 0
6 0
, 0
12 0
, 0
24 0
, 0
and 0
48 0
hours 0
after 0
termination 0
of 0
CPB 0
: 0
heart 0
rate 0
, 0
blood 0
pressure 0
, 0
left 0
atrial 0
pressure 0
, 0
central 0
- 0
peripheral 0
temperature 0
difference 0
, 0
arterial 0
- 0
central 0
venous 0
oxygen 0
saturation 0
difference 0
, 0
urine 0
output 0
, 0
serum 0
creatinine 0
, 0
lactate 0
and 0
neutrophil B-gene
elastase I-gene
levels 0
, 0
the 0
Doppler 0
echocardiographic 0
factors 0
shortening 0
fraction 0
and 0
preejection 0
period/left 0
- 0
ventricular 0
ejection 0
time 0
, 0
and 0
cumulative 0
doses 0
of 0
catecholamines 0
( 0
epinephrine 0
) 0
, 0
enoximone 0
, 0
and 0
furosemide 0
. 0

MDS1/EVI1 B-gene
, 0
located 0
on 0
chromosome 0
3 0
band 0
q26 0
, 0
encodes 0
a 0
MDS1/EVI1 I-gene

Analysis 0
of 0
the 0
protein 0
sequences 0
of 0
these 0
two 0
replicases B-gene
, 0
together 0
with 0
previously 0
characterized 0
H. B-gene
pylori I-gene
plasmid I-gene
replication I-gene
proteins I-gene
, 0
supports 0
the 0
formation 0
of 0
a 0
distinct 0
class 0
of 0
H. B-gene
pylori I-gene
plasmid I-gene
proteins I-gene
. 0

The 0
JTc 0
delta 0
among 0
the 0
three 0
groups 0
did 0
not 0
differ 0
as 0
well 0
: 0
JTc 0
delta 0
of 0
the 0
VT 0
group 0
was 0
70 0
ms 0
+/ 0
- 0
30 0
ms 0
, 0
the 0
JTc 0
delta 0
of 0
the 0
PVC 0
group 0
was 0
60 0
msec 0
+/ 0
- 0
25 0
msec 0
, 0
and 0
the 0
JTc 0
delta 0
of 0
the 0
control 0
group 0
was 0
70 0
ms 0
+/ 0
- 0
30 0
ms 0
. 0

In 0
contrast 0
, 0
deletion 0
of 0
the 0
upstream 0
portion 0
of 0
the 0
delta 0
promoter 0
led 0
to 0
a 0
10 0
fold 0
decrease 0
in 0
expression 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
of 0
binding 0
sites 0
for 0
the 0
repressor B-gene
proteins I-gene
BP1 I-gene
and 0
BP2 B-gene
in 0
the 0
upstream 0
portion 0
of 0
the 0
beta B-gene
globin I-gene
gene I-gene
flanking I-gene
region I-gene
led 0
to 0
a 0
4 0
- 0
6 0
fold 0
increase 0
in 0
promoter 0
activity 0
. 0

However 0
, 0
with 0
the 0
alpha1 0
antagonist 0
prazosin 0
( 0
5 0
x 0
10 0
( 0
- 0
8 0
) 0
- 0
5 0
x 0
10 0
( 0
- 0
7 0
) 0
M 0
) 0
, 0
no 0
relaxation 0
occurred 0
. 0

Differential 0
expression 0
of 0
AP B-gene
- I-gene
2alpha I-gene
and 0
AP B-gene
- I-gene
2beta I-gene
in 0
the 0
developing 0
chick 0
retina 0
: 0
repression 0
of 0
R B-gene
- I-gene
FABP I-gene
promoter I-gene
activity 0
by 0
AP B-gene
- I-gene
2 I-gene
. 0

The 0
algorithm 0
also 0
limited 0
TG 0
to 0
20 0
and 0
64 0
% 0
, 0
apoB B-gene
to 0
6 0
and 0
20 0
% 0
, 0
and 0
Lp B-gene
( I-gene
a I-gene
) I-gene
to 0
15 0
and 0
56 0
% 0
, 0
of 0
low 0
- 0
and 0
high 0
- 0
risk 0
groups 0
, 0
respectively 0
. 0

The 0
mean 0
value 0
of 0
the 0
CD79b B-gene
to 0
the 0
CD79b B-gene
internally 0
deleted 0
ratio 0
was 0
0.64 0
+/ 0
- 0
0.20 0
SD 0
in 0
normal 0
donors 0
and 0
0.44 0
+/ 0
- 0
0.27 0
SD 0
in 0
B 0
- 0
CLL 0
( 0
P 0
=.01 0
) 0
. 0

As 0
normal 0
B 0
cells 0
also 0
present 0
this 0
variant 0
, 0
the 0
mechanism 0
of 0
CD79b B-gene
posttranscriptional 0
regulation 0
might 0
reflect 0
the 0
activation 0
stage 0
of 0
the 0
normal 0
B 0
cell 0
from 0
which 0
B 0
- 0
CLL 0
derives 0
. 0

Conformational 0
studies 0
combining 0
secondary 0
structure 0
predictions 0
, 0
CD 0
and 0
NMR 0
spectroscopy 0
together 0
with 0
ELISA 0
assays 0
, 0
showed 0
that 0
the 0
greater 0
is 0
the 0
propensity 0
of 0
the 0
epitope 0
for 0
helix 0
formation 0
the 0
higher 0
is 0
the 0
recognition 0
by 0
anti B-gene
- I-gene
K159 I-gene
. 0

Schwab 0
and 0
England 0
ADL 0
scores 0
in 0
the 0
`` 0
off 0
'' 0
state 0
were 0
improved 0
by 0
18 0
% 0
and 0
in 0
the 0
`` 0
on 0
'' 0
state 0
the 0
scores 0
declined 0
by 0
2 0
% 0
. 0

High 0
- 0
level 0
gains 0
( 0
HLGs 0
) 0
indicative 0
of 0
gene 0
amplifications 0
were 0
identified 0
at 0
11q13 0
in 0
two 0
cases 0
, 0
and 0
in 0
one 0
case 0
each 0
at 0
2q33 0
- 0
34 0
, 0
3q25 0
- 0
29 0
, 0
5p15.1 0
- 0
15.2 0
, 0
7q21 0
- 0
22 0
, 0
11p11.2 0
, 0
12p11.2 0
- 0
12 0
, 0
and 0
13q34 0
. 0

With 0
respect 0
to 0
the 0
distribution 0
of 0
active 0
MREs 0
over 0
the 0
promoter 0
region 0
, 0
the 0
hMT B-gene
- I-gene
IIA I-gene
gene I-gene
is 0
largely 0
different 0
from 0
the 0
mouse 0
metallothionein B-gene
- I-gene
I I-gene
gene I-gene
, 0
suggesting 0
that 0
MRE 0
arrangement 0
is 0
not 0
an 0
important 0
factor 0
for 0
metal 0
regulation 0
. 0

The 0
cDNA 0
was 0
expressed 0
in 0
Saccharomyces 0
cerevisiae 0
under 0
the 0
control 0
of 0
the 0
yeast B-gene
triose I-gene
phosphate I-gene
isomerase I-gene
promoter I-gene
. 0

Interestingly 0
, 0
the 0
RNA 0
sequences 0
selected 0
by 0
the 0
mutated 0
zinc B-gene
knuckle I-gene
9G8 I-gene
variant I-gene
are 0
efficiently 0
recognized 0
by 0
SRp20 B-gene
, 0
in 0
agreement 0
with 0
the 0
fact 0
that 0
the 0
RBD 0
of 0
9G8 B-gene
and 0
SRp20 B-gene
are 0
similar 0
. 0

Topoisomerase B-gene
II I-gene
is 0
a 0
major 0
target 0
of 0
the 0
protein B-gene
kinase I-gene
casein I-gene
kinase I-gene
2 I-gene
( 0
PK B-gene
CK2 I-gene
) 0
in 0
vivo 0
. 0

Recent 0
work 0
in 0
this 0
laboratory 0
has 0
shown 0
that 0
the 0
gene 0
coding 0
for 0
acetate B-gene
kinase I-gene
( 0
ackA B-gene
) 0
in 0
Sinorhizobium 0
meliloti 0
is 0
up 0
- 0
regulated 0
in 0
response 0
to 0
phosphate 0
limitation 0
. 0

All 0
numbers 0
refer 0
to 0
nucleotide 0
positions 0
on 0
the 0
wild 0
- 0
type 0
HIV 0
- 0
1 0
transcript 0
. 0

Sequence 0
analysis 0
revealed 0
that 0
the 0
MEMA B-gene
protein I-gene
is 0
identical 0
with 0
a 0
160 B-gene
kDa I-gene
nuclear I-gene
'domain I-gene
rich I-gene
in I-gene
serines I-gene
' I-gene
( I-gene
DRS I-gene
) I-gene
protein I-gene
occurring 0
free 0
in 0
the 0
nucleoplasm 0
and 0
in 0
U2 B-gene
- I-gene
ribonucleoprotein I-gene
structures I-gene
. 0

Here 0
, 0
we 0
report 0
the 0
complete 0
structure 0
of 0
the 0
human B-gene
topoisomerase I-gene
IIalpha I-gene
gene I-gene
, 0
which 0
consists 0
of 0
35 0
exons 0
spanning 0
27.5 0
kb 0
. 0

Dopaminergic 0
modulation 0
of 0
transcallosal 0
activity 0
of 0
cat 0
motor 0
cortical 0
neurons 0
. 0

Previous 0
studies 0
characterized 0
a 0
cytokine 0
- 0
inducible 0
, 0
functional 0
nuclear B-gene
factor I-gene
( I-gene
NF I-gene
) I-gene
- I-gene
kappaB I-gene
consensus I-gene
element I-gene
in 0
the 0
immediate 0
5 0
' 0
regulatory 0
region 0
of 0
the 0
MGSA/GRO B-gene
MGSA/GRO I-gene
- I-gene
alpha I-gene
gene 0
at 0
- 0
78 0
bp 0
. 0

An 0
exon 0
that 0
prevents 0
transport 0
of 0
a 0
mature 0
mRNA 0
. 0

Four 0
CsA 0
- 0
treated 0
patients 0
developed 0
persistently 0
elevated 0
UAER 0
> 0
30 0
mg/24 0
h 0
( 0
n 0
= 0
3 0
with 0
microalbuminuria 0
) 0
, 0
whereas 0
all 0
the 0
17 0
placebo 0
- 0
treated 0
patients 0
had 0
normal 0
UAER 0
( 0
< 0
30 0
mg/24 0
h 0
) 0
after 0
7 0
years 0
of 0
follow 0
- 0
up 0
. 0

Mutational 0
analysis 0
of 0
the 0
- 0
84/ 0
- 0
55 0
DNA 0
showed 0
that 0
JEG 0
- 0
3 0
nuclear 0
proteins 0
bound 0
to 0
a 0
site 0
containing 0
, 0
but 0
not 0
identical 0
to 0
, 0
the 0
SF B-gene
- I-gene
1 I-gene
sequence I-gene
. 0

In 0
contrast 0
, 0
no 0
change 0
was 0
detected 0
in 0
the 0
phenotype 0
of 0
'unstressed 0
' 0
clones 0
, 0
with 0
respect 0
to 0
any 0
of 0
the 0
following 0
parameters 0
: 0
proliferation 0
rate 0
in 0
monolayer 0
, 0
serum 0
- 0
dependence 0
for 0
proliferation 0
or 0
survival 0
, 0
tumorigenicity 0
, 0
cellular 0
morphology 0
, 0
or 0
tissue 0
- 0
specific 0
differentiation 0
markers 0
. 0

A 0
high 0
reactor 0
pH 0
( 0
+/ 0
- 0
8 0
) 0
, 0
a 0
short 0
solid 0
retention 0
time 0
( 0
< 0
150 0
days 0
) 0
, 0
and 0
the 0
presence 0
of 0
a 0
substantial 0
SRB 0
population 0
in 0
the 0
inoculum 0
may 0
considerably 0
reduce 0
the 0
time 0
required 0
for 0
acetate 0
- 0
utilising 0
SRB 0
to 0
outcompete 0
MB 0
. 0

In 0
throttling 0
valves 0
, 0
the 0
aim 0
is 0
to 0
correlate 0
the 0
effect 0
of 0
shear 0
to 0
a 0
parameter 0
related 0
to 0
the 0
inner 0
geometry 0
of 0
the 0
valve 0
and 0
to 0
operating 0
conditions 0
. 0

The 0
induced 0
respiratory 0
burst 0
was 0
investigated 0
by 0
the 0
intracellular 0
oxidative 0
transformation 0
of 0
dihydrorhodamine 0
123 0
to 0
the 0
fluorescent 0
dye 0
rhodamine 0
123 0
via 0
flow 0
cytometry 0
. 0

A 0
mutation 0
linked 0
to 0
the 0
SOC1 B-gene
gene I-gene
, 0
previously 0
defined 0
by 0
recessive 0
mutations 0
that 0
suppress 0
cbp1 B-gene
ts I-gene
alleles I-gene
and 0
stabilize 0
many 0
mitochondrial 0
mRNAs 0
, 0
was 0
also 0
isolated 0
. 0

A 0
deletion 0
mutation 0
analysis 0
of 0
the 0
recombinant 0
protein 0
has 0
shown 0
that 0
the 0
N 0
- 0
terminal 0
region 0
and 0
the 0
two 0
leucine 0
zippers 0
are 0
necessary 0
for 0
the 0
binding 0
. 0

A 0
database 0
search 0
has 0
revealed 0
as 0
the 0
most 0
significative 0
homology 0
a 0
match 0
with 0
the 0
human B-gene
mitochondrial I-gene
transcription I-gene
termination I-gene
factor I-gene
( 0
mTERF B-gene
) 0
, 0
a 0
protein 0
that 0
also 0
binds 0
DNA 0
as 0
a 0
monomer 0
and 0
contains 0
three 0
leucine 0
zippers 0
forming 0
intramolecular 0
interactions 0
. 0

In 0
all 0
trials 0
, 0
antigen 0
challenge 0
followed 0
1 0
h 0
after 0
the 0
last 0
treatment 0
. 0

31 0
, 0
1997 0
, 0
40 0
patients 0
had 0
died 0
( 0
35 0
in 0
the 0
ERA 0
- 0
II 0
group 0
and 0
5 0
in 0
the 0
ERA 0
- 0
III 0
group 0
) 0
, 0
for 0
a 0
crude 0
mortality 0
rate 0
of 0
8.0 0
% 0
. 0

We 0
found 0
that 0
total 0
PSA B-gene
can 0
be 0
detected 0
in 0
all 0
cyst 0
fluids 0
and 0
in 0
about 0
75 0
% 0
of 0
female 0
sera 0
. 0

Type 0
I 0
cysts 0
( 0
with 0
a 0
high 0
K+/ 0
Na+ 0
ratio 0
) 0
tend 0
to 0
have 0
higher 0
total 0
PSA B-gene
than 0
Type 0
II 0
cysts 0
. 0

Despite 0
this 0
DNA 0
binding 0
activity 0
, 0
AP B-gene
- I-gene
1 I-gene
reporter I-gene
activity 0
was 0
suppressed 0
in 0
these 0
cells 0
. 0

A 0
single 0
N 0
- 0
glycosylation 0
site 0
present 0
in 0
chicken B-gene
gp42 I-gene
is 0
conserved 0
among 0
all 0
five 0
of 0
these 0
proteins 0
: 0
carbohydrate 0
analysis 0
of 0
gp42 B-gene
revealed 0
the 0
presence 0
of 0
a 0
complex 0
type 0
glycan 0
chain 0
at 0
this 0
site 0
. 0

Here 0
we 0
describe 0
the 0
optimization 0
and 0
characterization 0
of 0
a 0
140 0
- 0
residue 0
fragment 0
, 0
containing 0
the 0
Runt B-gene
domain I-gene
of 0
AML1 B-gene
, 0
which 0
is 0
suitable 0
for 0
structural 0
studies 0
. 0

Judge 0
OKs 0
docs 0
' 0
bid 0
for 0
Chicago 0
hospital 0
. 0

HANYS 0
criticizes 0
laparoscopic 0
gall 0
bladder 0
guidelines 0
. 0

Groups 0
dicker 0
for 0
price 0
breaks 0
as 0
anesthetic 0
gas 0
goes 0
multi 0
- 0
source 0
. 0

Troubled 0
CareNetwork 0
gets 0
pact 0
from 0
largest 0
teacher 0
union 0
in 0
Wis 0
. 0

JCAHO 0
asks 0
for 0
hospitals 0
' 0
patience 0
. 0

Ultrasonography 0
provides 0
excellent 0
intraoperative 0
evaluation 0
of 0
spinal 0
cord 0
injury 0
. 0

UPMC 0
is 0
not 0
the 0
only 0
organization 0
pursuing 0
controlled 0
NHBC 0
organ 0
procurement 0
, 0
however 0
. 0

Because 0
of 0
concerns 0
regarding 0
blood 0
transfusion 0
- 0
related 0
communicable 0
disease 0
( 0
eg 0
, 0
acquired 0
immune 0
deficiency 0
syndrome 0
and 0
non 0
- 0
A 0
, 0
non 0
- 0
B 0
hepatitis 0
) 0
, 0
there 0
has 0
been 0
increasing 0
research 0
effort 0
into 0
postoperative 0
hemorrhage 0
related 0
to 0
cardiopulmonary 0
bypass 0
with 0
extracorporeal 0
circulation 0
. 0

They 0
contrast 0
trends 0
in 0
fertility 0
, 0
life 0
expectancy 0
ratios 0
, 0
and 0
gender 0
differences 0
in 0
these 0
countries 0
with 0
the 0
Hispanic 0
population 0
of 0
the 0
United 0
States 0
. 0

Holger 0
v 0
. 0

Hospital 0
hit 0
for 0
hiring 0
AHERF 0
physicians 0
. 0

Overexpression 0
of 0
either 0
DAP B-gene
- I-gene
1 I-gene
or 0
sentrin B-gene
causes 0
apoptosis 0
of 0
TNF B-gene
- 0
sensitive 0
L929 0
fibroblast 0
cell 0
line 0
, 0
as 0
well 0
as 0
TNF B-gene
- 0
resistant 0
osteosarcoma 0
cell 0
line 0
, 0
U2OS 0
. 0

This 0
is 0
in 0
contrast 0
to 0
PPARgamma2 B-gene
, 0
which 0
was 0
previously 0
shown 0
to 0
be 0
phosphorylated 0
at 0
a 0
single 0
site 0
in 0
a 0
motif 0
that 0
is 0
not 0
homologous 0
to 0
the 0
sites 0
now 0
described 0
in 0
PPARalpha B-gene
. 0

These 0
results 0
suggest 0
KCC3 B-gene
is 0
a 0
new 0
member 0
of 0
the 0
KCC B-gene
family I-gene
that 0
is 0
under 0
distinct 0
regulation 0
from 0
KCC1 B-gene
. 0

We 0
have 0
screened 0
the 0
elastin B-gene
gene I-gene
for 0
mutations 0
responsible 0
for 0
supravalvular 0
aortic 0
stenosis 0
( 0
SVAS 0
) 0
in 0
two 0
large 0
, 0
independently 0
collected 0
families 0
with 0
isolated 0
( 0
nonsyndromic 0
) 0
SVAS 0
. 0

Spatiotemporal 0
expression 0
of 0
the 0
PAX3 B-gene
gene I-gene
is 0
tightly 0
regulated 0
during 0
development 0
. 0

25 0
- 0
OH 0
- 0
D3 0
did 0
not 0
adversely 0
affect 0
animal 0
health 0
at 0
the 0
proposed 0
use 0
level 0
of 0
99 0
micrograms/kg 0
feed 0
when 0
replacing 0
vitamin 0
D3 0
in 0
turkey 0
rations 0
. 0

A 0
list 0
of 0
12 0
names 0
for 0
the 0
disease 0
and 0
37 0
diagnostic 0
criteria 0
were 0
proposed 0
to 0
a 0
Consensus 0
Panel 0
of 0
12 0
Italian 0
experts 0
who 0
ranked 0
them 0
in 0
order 0
so 0
as 0
to 0
identify 0
a 0
core 0
set 0
of 0
criteria 0
. 0

Methanesulfonyl 0
fluoride 0
( 0
MSF 0
) 0
: 0
a 0
double 0
- 0
blind 0
, 0
placebo 0
- 0
controlled 0
study 0
of 0
safety 0
and 0
efficacy 0
in 0
the 0
treatment 0
of 0
senile 0
dementia 0
of 0
the 0
Alzheimer 0
type 0
. 0

METHODS 0
: 0
Between 0
August 0
1991 0
and 0
June 0
1994 0
, 0
198 0
men 0
with 0
clinical 0
T2 0
or 0
T3 0
classified 0
( 0
TNM 0
) 0
prostate 0
carcinoma 0
( 0
bone 0
scan 0
negative 0
) 0
who 0
were 0
at 0
high 0
risk 0
of 0
lymph 0
node 0
involvement 0
underwent 0
a 0
111In 0
- 0
capromab 0
pendetide 0
scan 0
prior 0
to 0
staging 0
lymphadenectomy 0
. 0

Voluntary 0
wheel 0
running 0
did 0
not 0
significantly 0
increase 0
estimated 0
alanine 0
or 0
pyruvate 0
Gneo 0
or 0
absolute 0
glycerol 0
Ra 0
. 0

Immediately 0
after 0
surgery 0
, 0
dialysate 0
PGE2 0
and 0
adenosine 0
concentrations 0
were 0
3.7 0
+/ 0
- 0
0.7 0
and 0
296 0
+/ 0
- 0
127 0
nM 0
, 0
respectively 0
. 0

Because 0
of 0
the 0
probable 0
causal 0
relationship 0
between 0
constitutive 0
p210 B-gene
( 0
bcr/abl B-gene
) 0
bcr/abl I-gene

In 0
vitro 0
precipitation 0
with 0
a 0
glutathione B-gene
- I-gene
S I-gene
- I-gene
transferase I-gene
- I-gene
fusion I-gene
protein I-gene
containing 0
the 0
C 0
- 0
terminal 0
transactivation 0
domain 0
of 0
STAT5a B-gene
showed 0
GH B-gene
- 0
regulated 0
association 0
of 0
ERK1/2 B-gene
with 0
the 0
fusion 0
protein 0
, 0
while 0
this 0
was 0
not 0
seen 0
when 0
serine 0
780 0
in 0
STAT5a B-gene
was 0
changed 0
to 0
alanine 0
. 0

One 0
such 0
element 0
, 0
1P 0
, 0
was 0
employed 0
to 0
clone 0
from 0
a 0
rat 0
pituitary 0
cDNA 0
expression 0
library 0
a 0
novel 0
417 B-gene
- I-gene
amino I-gene
acid I-gene
WD I-gene
protein I-gene
, 0
designated 0
PREB B-gene
( I-gene
PRL I-gene
regulatory I-gene
element I-gene
binding I-gene
) I-gene
protein I-gene
. 0

Characterization 0
of 0
the 0
transcription B-gene
factor I-gene
MTF I-gene
- I-gene
1 I-gene
from 0
the 0
Japanese 0
pufferfish 0
( 0
Fugu 0
rubripes 0
) 0
reveals 0
evolutionary 0
conservation 0
of 0
heavy 0
metal 0
stress 0
response 0
. 0

The 0
peroxisome B-gene
proliferator I-gene
- I-gene
activated I-gene
receptors I-gene
( 0
PPARs B-gene
) 0
are 0
members 0
of 0
the 0
nuclear B-gene
hormone I-gene
receptor I-gene
superfamily I-gene
. 0

However 0
, 0
F B-gene
- I-gene
SRC I-gene
- I-gene
1 I-gene
mutant I-gene
lacking 0
CBP B-gene
- I-gene
interacting I-gene
domain I-gene
still 0
preserved 0
enhancing 0
activity 0
. 0

The 0
catalytic 0
site 0
has 0
an 0
S1 0
pocket 0
lined 0
with 0
conserved 0
hydrophobic 0
residues 0
to 0
accommodate 0
the 0
pyroglutamyl 0
residue 0
. 0

The 0
complete 0
circular 0
TTV 0
genome 0
contained 0
a 0
novel 0
sequence 0
of 0
113 0
nt 0
( 0
nt 0
3740 0
to 0
3852 0
[ 0
=0 0
] 0
) 0
in 0
between 0
the 0
known 0
3' 0
- 0
and 0
5' 0
- 0
end 0
arms 0
, 0
forming 0
a 0
117 0
- 0
nt 0
GC 0
- 0
rich 0
stretch 0
( 0
GC 0
content 0
, 0
90.6 0
% 0
at 0
nt 0
3736 0
to 0
3852 0
) 0
. 0

The 0
Asian 0
mouse 0
Mus 0
castaneus 0
is 0
resistant 0
to 0
infection 0
by 0
the 0
polytropic 0
mink 0
cell 0
focus 0
- 0
inducing 0
( 0
MCF 0
) 0
subgroup 0
of 0
murine 0
leukemia 0
viruses 0
( 0
MuLVs 0
) 0
. 0

To 0
determine 0
the 0
function 0
of 0
VZV B-gene
gK I-gene
in 0
virus 0
growth 0
, 0
a 0
series 0
of 0
gK B-gene
deletion I-gene
mutants I-gene
were 0
constructed 0
with 0
VZV 0
cosmid 0
DNA 0
derived 0
from 0
the 0
Oka 0
strain 0
. 0

CCAAT B-gene
displacement I-gene
protein I-gene
binds 0
to 0
and 0
negatively 0
regulates 0
human 0
papillomavirus 0
type 0
6 0
E6 B-gene
, 0
E7 B-gene
, 0
and 0
E1 B-gene
promoters 0
. 0

As 0
such 0
the 0
findings 0
support 0
existing 0
studies 0
that 0
have 0
identified 0
given 0
social 0
characteristics 0
of 0
drink 0
drivers 0
. 0

Three 0
different 0
site 0
- 0
directed 0
mutations 0
of 0
the 0
cyclic 0
AMP 0
response 0
element 0
each 0
reduced 0
the 0
nerve B-gene
growth I-gene
factor I-gene
effect 0
by 0
> 0
90 0
% 0
. 0

Using 0
an 0
RNase B-gene
H I-gene
protection 0
assay 0
and 0
specific 0
blocking 0
oligonucleotides 0
, 0
we 0
find 0
that 0
recognition 0
of 0
the 0
5 0
' 0
splice 0
- 0
site 0
( 0
5'ss 0
) 0
and 0
branchpoint 0
sequence 0
( 0
BPS 0
) 0
elements 0
by 0
U11 B-gene
and 0
U12 B-gene
snRNPs I-gene
, 0
respectively 0
, 0
displays 0
strong 0
cooperativity 0
, 0
requiring 0
both 0
sites 0
in 0
the 0
pre 0
- 0
mRNA 0
substrate 0
for 0
efficient 0
complex 0
formation 0
. 0

Analysis 0
of 0
lacZ B-gene
transcriptional I-gene
fusions I-gene
shows 0
that 0
the 0
KdgR B-gene
- I-gene
binding I-gene
sites I-gene
negatively 0
affect 0
the 0
expression 0
of 0
rsmB B-gene
. 0

Many 0
eukaryotic 0
cell 0
surface 0
proteins 0
are 0
anchored 0
in 0
the 0
lipid 0
bilayer 0
through 0
glycosylphosphatidylinositol 0
( 0
GPI 0
) 0
. 0

In 0
the 0
cell 0
- 0
free 0
import 0
assay 0
, 0
beta B-gene
- I-gene
catenin I-gene
rapidly 0
migrates 0
into 0
the 0
nucleus 0
without 0
the 0
exogenous 0
addition 0
of 0
cytosol 0
, 0
Ran B-gene
, 0
or 0
ATP/GTP 0
. 0

In 0
ischemic 0
and 0
hypoxic 0
hypoxia 0
, 0
a 0
strong 0
correlation 0
was 0
found 0
between 0
cyt 0
a 0
, 0
a3 0
oxidation 0
level 0
and 0
VO2 0
in 0
both 0
ischemic 0
and 0
hypoxic 0
hypoxia 0
( 0
r2 0
=.90 0
and 0
.87 0
, 0
respectively 0
) 0
. 0

An 0
endogenous 0
mammalian 0
regulator 0
of 0
this 0
process 0
, 0
named 0
Usurpin B-gene
, 0
has 0
been 0
identified 0
( 0
aliases 0
for 0
Usurpin B-gene
include 0
CASH B-gene
, 0
Casper B-gene
, 0
CLARP B-gene
, 0
FLAME B-gene
- I-gene
1 I-gene
, 0
FLIP B-gene
, 0
I B-gene
- I-gene
FLICE I-gene
and 0
MRIT B-gene
) 0
. 0

Plasma 0
glucose 0
, 0
immunoreactive B-gene
insulin I-gene
( 0
IRI B-gene
) 0
, 0
C B-gene
- I-gene
peptide I-gene
, 0
glucagon B-gene
, 0
and 0
GLP B-gene
- I-gene
1 I-gene
levels 0
at 0
each 0
time 0
point 0
during 0
OGTT 0
were 0
measured 0
. 0

Each 0
recombinant 0
product 0
was 0
a 0
fusion 0
protein 0
with 0
a 0
B 0
domain 0
of 0
Staphylococcal B-gene
protein I-gene
A I-gene
( 0
SPA B-gene
) 0
. 0

Polypyrimidine 0
and 0
ssDNA 0
binding 0
by 0
the 0
isolated 0
VH B-gene
domain I-gene
of 0
immunization 0
- 0
induced 0
anti 0
- 0
Z 0
- 0
DNA 0
Ab 0
resembles 0
the 0
activity 0
of 0
natural 0
autoantibodies 0
and 0
suggests 0
that 0
VH B-gene
- 0
dependent 0
binding 0
to 0
a 0
ligand 0
mimicked 0
by 0
polypyrimidines 0
may 0
play 0
a 0
role 0
in 0
B 0
cell 0
selection 0
before 0
immunization 0
with 0
Z 0
- 0
DNA 0
. 0

Technetium 0
- 0
99m 0
methylene 0
diphosphonate 0
scintimammography 0
for 0
evaluation 0
of 0
palpable 0
breast 0
masses 0
. 0

INTERVENTIONS 0
: 0
Study 0
patients 0
were 0
randomly 0
divided 0
into 0
four 0
parallel 0
groups 0
to 0
receive 0
either 0
terbinafine 0
250 0
mg 0
a 0
day 0
for 0
12 0
or 0
16 0
weeks 0
( 0
groups 0
T12 0
and 0
T16 0
) 0
or 0
itraconazole 0
400 0
mg 0
a 0
day 0
for 0
1 0
week 0
in 0
every 0
4 0
weeks 0
for 0
12 0
or 0
16 0
weeks 0
( 0
groups 0
I3 0
and 0
I4 0
) 0
. 0

Nuclear 0
receptors 0
( 0
NRs 0
) 0
can 0
function 0
as 0
ligandinducible 0
transregulators 0
in 0
both 0
mammalian 0
and 0
yeast 0
cells 0
, 0
indicating 0
that 0
important 0
features 0
of 0
transcriptional 0
control 0
have 0
been 0
conserved 0
throughout 0
evolution 0
. 0

When 0
tethered 0
to 0
a 0
heterologous 0
DNA 0
- 0
binding 0
domain 0
, 0
PSU1 B-gene
can 0
activate 0
transcription 0
on 0
its 0
own 0
. 0

OBJECTIVE 0
: 0
To 0
follow 0
- 0
up 0
prospectively 0
patients 0
with 0
arthritis 0
after 0
infection 0
with 0
beta 0
- 0
haemolytic 0
streptococci 0
of 0
Lancefield 0
group 0
A 0
( 0
beta 0
HSA 0
) 0
, 0
with 0
emphasis 0
on 0
clinical 0
characteristics 0
and 0
serological 0
features 0
. 0

Bacteria 0
can 0
also 0
cause 0
a 0
labyrinthitis 0
acting 0
directly 0
on 0
the 0
inner 0
ear 0
: 0
among 0
these 0
, 0
Treponemas 0
Pallidum 0
, 0
a 0
spirochaete 0
which 0
causes 0
syphilis 0
and 0
Borrelia 0
Burgdorferi 0
, 0
a 0
spirochaete 0
that 0
causes 0
Lyme 0
Disease 0
, 0
must 0
be 0
mentioned 0
. 0

We 0
found 0
that 0
the 0
expression 0
of 0
the 0
protein 0
was 0
maximum 0
in 0
mitosis 0
and 0
minimum 0
in 0
G1 0
, 0
which 0
correlated 0
with 0
the 0
expression 0
of 0
its 0
messenger 0
RNA 0
. 0

These 0
findings 0
demonstrate 0
that 0
signature 0
- 0
tagged 0
mutagenesis 0
is 0
a 0
viable 0
approach 0
to 0
identify 0
bacterial 0
genes 0
associated 0
with 0
the 0
ability 0
to 0
infect 0
the 0
urinary 0
tract 0
. 0

Pathol 0
. 0

The 0
eukaryotic 0
cell 0
cycle 0
is 0
governed 0
in 0
part 0
by 0
the 0
periodic 0
transcription 0
of 0
cyclin B-gene
genes I-gene
, 0
whose 0
protein 0
products 0
associate 0
with 0
and 0
positively 0
regulate 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinases I-gene
. 0

The 0
GAC1 B-gene
gene I-gene
encodes 0
the 0
regulatory 0
subunit 0
for 0
a 0
type B-gene
1 I-gene
serine/threonine I-gene
phosphoprotein I-gene
phosphatase I-gene
, 0
Glc7 B-gene
. 0

The 0
results 0
demonstrate 0
that 0
the 0
Glc7 B-gene
phosphatase I-gene
and 0
its 0
Gac1 B-gene
regulatory 0
subunit 0
play 0
positive 0
roles 0
in 0
HSF B-gene
activation 0
of 0
CUP1 B-gene
transcription 0
. 0

MEF B-gene
and 0
AML1B B-gene
synergistically 0
transactivated 0
an 0
interleukin B-gene
3 I-gene
promoter I-gene
reporter I-gene
gene I-gene
construct I-gene
, 0
yet 0
the 0
activating 0
activity 0
of 0
MEF B-gene
was 0
abolished 0
when 0
MEF B-gene
was 0
coexpressed 0
with 0
AML1/ETO B-gene
. 0

Mechanistically 0
, 0
the 0
presence 0
of 0
the 0
GRR 0
appears 0
to 0
stop 0
further 0
degradation 0
of 0
p50 B-gene
and 0
to 0
stabilize 0
the 0
molecule 0
. 0

This 0
phosphorylation 0
can 0
be 0
catalyzed 0
by 0
a 0
break 0
- 0
ended 0
double 0
- 0
stranded 0
DNA 0
- 0
activated 0
protein 0
kinase 0
activity 0
from 0
the 0
sea 0
urchin 0
nucleus 0
in 0
vitro 0
. 0

Concomitantly 0
, 0
the 0
total 0
cellular 0
level 0
of 0
p21 B-gene
increased 0
severalfold 0
via 0
a 0
posttranscriptional 0
mechanism 0
. 0

Moreover 0
, 0
when 0
added 0
to 0
the 0
osteoclast 0
cultures 0
, 0
mrIhh B-gene
- I-gene
N I-gene
markedly 0
stimulated 0
the 0
formation 0
of 0
resorption 0
pits 0
on 0
dentine 0
slices 0
. 0

Overall 0
, 0
our 0
results 0
suggest 0
that 0
resistant 0
genotypes 0
exist 0
among 0
the 0
WAD 0
goat 0
population 0
. 0

The 0
molecular 0
mechanism 0
by 0
which 0
Gle2p B-gene
and 0
the 0
Gle2p B-gene
- 0
Nup116p B-gene
interaction 0
function 0
in 0
mRNA 0
export 0
is 0
unknown 0
. 0

The 0
Fyn B-gene
NH2 I-gene
terminus I-gene
was 0
necessary 0
but 0
not 0
sufficient 0
for 0
interaction 0
with 0
zeta 0
and 0
both 0
Fyn B-gene
kinase I-gene
and 0
SH2 B-gene
domains I-gene
were 0
required 0
, 0
directing 0
phosphorylation 0
of 0
zeta B-gene
ITAM I-gene
tyrosines 0
and 0
binding 0
to 0
zeta B-gene
ITAM I-gene
phosphotyrosines 0
. 0

In 0
budding 0
yeast 0
, 0
the 0
protein 0
Skp1p B-gene
, 0
the 0
cullin B-gene
- I-gene
family I-gene
member I-gene
Cdc53p B-gene
, 0
and 0
the 0
F 0
- 0
box/WD 0
- 0
repeat 0
protein 0
Cdc4p B-gene
form 0
the 0
SCFCdc4p B-gene
ubiquitin B-gene
ligase I-gene
complex 0
, 0
which 0
targets 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
( 0
Cdk B-gene
) 0
inhibitor 0
Sic1p B-gene
for 0
proteolysis 0
[ 0
3 0
] 0
[ 0
4 0
] 0
[ 0
5 0
] 0
[ 0
6 0
] 0
[ 0
7 0
] 0
[ 0
8 0
] 0
. 0

We 0
show 0
here 0
that 0
, 0
despite 0
their 0
structural 0
and 0
functional 0
similarities 0
, 0
the 0
pop1 B-gene
and 0
pop2 B-gene
genes I-gene
fail 0
to 0
complement 0
each 0
other 0
's 0
deletion 0
phenotypes 0
, 0
indicating 0
that 0
they 0
perform 0
non 0
- 0
redundant 0
, 0
but 0
potentially 0
interdependent 0
, 0
functions 0
in 0
proteolysis 0
. 0

Antithrombin B-gene
III I-gene
prevents 0
60 0
min 0
warm 0
intestinal 0
ischemia 0
reperfusion 0
injury 0
in 0
rats 0
. 0

In 0
retrospect 0
, 0
the 0
diagnoses 0
were 0
reconsidered 0
applying 0
strict 0
criteria 0
. 0

These 0
observations 0
of 0
elevated 0
serum B-gene
lipase I-gene
and 0
serum 0
CA B-gene
19 I-gene
- I-gene
9 I-gene
in 0
Sjogren 0
's 0
syndrome 0
without 0
evidence 0
of 0
malignancy 0
may 0
reflect 0
pancreatic 0
involvement 0
in 0
this 0
disorder 0
. 0

Acute 0
pancreatitis 0
as 0
a 0
complication 0
of 0
polyarteritis 0
nodosa 0
. 0

Significantly 0
greater 0
improvement 0
( 0
p 0
< 0
0.05 0
) 0
in 0
the 0
sertraline 0
group 0
first 0
became 0
apparent 0
by 0
the 0
end 0
of 0
week 0
3 0
on 0
the 0
Y 0
- 0
BOCS 0
and 0
the 0
CGI 0
Improvement 0
scale 0
, 0
and 0
by 0
the 0
end 0
of 0
weeks 0
6 0
and 0
8 0
, 0
respectively 0
, 0
on 0
the 0
NIMH 0
and 0
CGI 0
Severity 0
scale 0
. 0

Stress B-gene
- I-gene
inducible I-gene
protein I-gene
kinases I-gene
capable 0
of 0
activating 0
c B-gene
- I-gene
jun I-gene
expression 0
include 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase/c I-gene
kinase/c I-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
protein I-gene
kinase I-gene
( 0
SAPK/JNK B-gene
) 0
and 0
SAPK/JNK I-gene

Transforming B-gene
growth I-gene
factor I-gene
( I-gene
TGF I-gene
) I-gene
- I-gene
beta1 I-gene
induces 0
extracellular 0
matrix 0
deposition 0
and 0
proliferation 0
of 0
mesenchymal 0
cells 0
. 0

Chronotherapeutics 0
in 0
cardiovascular 0
disease 0
. 0

Group 0
psychometric 0
functions 0
for 0
listeners 0
with 0
hearing 0
loss 0
do 0
not 0
show 0
a 0
decrease 0
in 0
performance 0
at 0
the 0
largest 0
values 0
of 0
delta 0
f 0
included 0
in 0
this 0
study 0
. 0

Uroflowmetry 0
can 0
detect 0
dysuria 0
, 0
which 0
may 0
be 0
poorly 0
perceived 0
or 0
even 0
unknown 0
to 0
the 0
subjects 0
themselves 0
. 0

Marked 0
racial 0
variation 0
in 0
birthweight 0
percentiles 0
by 0
gestational 0
age 0
was 0
evident 0
. 0

Significant 0
correlations 0
between 0
mental 0
status 0
as 0
measured 0
by 0
the 0
Mini 0
- 0
Mental 0
State 0
Examination 0
and 0
NA/mI 0
, 0
mI/Cr 0
and 0
NA 0
were 0
found 0
. 0

Glucagon B-gene
also 0
induced 0
LUC B-gene
activity 0
very 0
strongly 0
when 0
the 0
CRE1 0
and 0
CRE2 0
sites 0
were 0
combined 0
; 0
induction 0
of 0
the 0
( 0
CRE1 0
) 0
3 0
( 0
CRE2 0
) 0
2SV40 0
- 0
LUC B-gene
constructs 0
was 0
positively 0
modulated 0
by 0
the 0
pO2 0
. 0

In 0
this 0
study 0
, 0
we 0
report 0
the 0
isolation 0
and 0
characterization 0
of 0
the 0
entire 0
rat B-gene
GSTA3 I-gene
( 0
rGST B-gene
Yc1 I-gene
) 0
subunit 0
gene 0
. 0

Calcinosis 0
cutis 0
following 0
intravenous 0
infusion 0
of 0
calcium 0
gluconate 0
. 0

Initial 0
control 0
of 0
bleeding 0
is 0
similar 0
, 0
but 0
eradication 0
is 0
achieved 0
in 0
fewer 0
sessions 0
with 0
EVL 0
. 0

Finally 0
, 0
we 0
determined 0
the 0
genomic 0
organization 0
of 0
the 0
human B-gene
TrxR2 I-gene
gene I-gene
, 0
which 0
consists 0
of 0
18 0
exons 0
spanning 0
about 0
67 0
kb 0
, 0
and 0
its 0
chromosomal 0
localization 0
at 0
position 0
22q11.2 0
. 0

The 0
aims 0
of 0
this 0
study 0
were 0
to 0
determine 0
and 0
rank 0
the 0
frequency 0
of 0
self 0
reported 0
visual 0
disability 0
in 0
daily 0
tasks 0
performed 0
by 0
glaucoma 0
patients 0
; 0
to 0
examine 0
the 0
interrelation 0
between 0
disabilities 0
using 0
factor 0
analysis 0
; 0
to 0
study 0
the 0
relation 0
between 0
perceived 0
visual 0
difficulty 0
and 0
a 0
measure 0
of 0
the 0
severity 0
of 0
visual 0
field 0
loss 0
; 0
to 0
develop 0
a 0
glaucoma 0
specific 0
subgroup 0
of 0
questions 0
; 0
and 0
examine 0
the 0
validity 0
and 0
reliability 0
of 0
this 0
subgroup 0
of 0
questions 0
. 0

Furthermore 0
, 0
the 0
validity 0
of 0
this 0
new 0
subset 0
of 0
questions 0
was 0
shown 0
to 0
be 0
significant 0
( 0
r=0.037 0
, 0
p 0
< 0
0.05 0
) 0
for 0
the 0
correlation 0
between 0
a 0
measure 0
of 0
the 0
severity 0
of 0
binocular 0
visual 0
field 0
loss 0
and 0
the 0
mean 0
score 0
of 0
the 0
variables 0
used 0
in 0
the 0
glaucoma 0
specific 0
subgroup 0
of 0
questions 0
. 0

Sequence 0
comparison 0
of 0
cytochromes B-gene
bd I-gene
and 0
their 0
homologs 0
from 0
various 0
organisms 0
demonstrates 0
that 0
the 0
proteins 0
can 0
be 0
classified 0
into 0
two 0
subfamilies 0
, 0
a 0
proteobacterial 0
type 0
including 0
E. B-gene
coli I-gene
bd I-gene
and 0
a 0
more 0
widely 0
distributed 0
type 0
including 0
the 0
B. 0
stearothermophilus 0
enzyme 0
, 0
suggesting 0
that 0
the 0
latter 0
type 0
is 0
evolutionarily 0
older 0
. 0

Canalith 0
repositioning 0
is 0
the 0
mainstay 0
of 0
treatment 0
. 0

Solution 0
structure 0
and 0
mechanism 0
of 0
the 0
MutT B-gene
pyrophosphohydrolase I-gene
. 0

In 0
11 0
eyes 0
that 0
had 0
been 0
selected 0
at 0
random 0
10 0
micrograms 0
of 0
recombinant B-gene
tissue I-gene
plasminogen I-gene
activator I-gene
were 0
injected 0
midvitreally 0
24 0
hrs 0
later 0
. 0

RESULTS 0
AND 0
CONCLUSIONS 0
: 0
Brandt 0
's 0
double 0
cuff 0
- 0
tubes 0
( 0
G2 0
) 0
succeed 0
in 0
avoiding 0
uncontrolled 0
increase 0
of 0
cuff 0
- 0
pressure 0
during 0
anaesthesia 0
with 0
N2O 0
. 0

Accordingly 0
, 0
we 0
designated 0
this 0
gene B-gene
CTL1 I-gene
( 0
capping B-gene
enzyme I-gene
RNAtriphosphatase I-gene
- I-gene
like I-gene
1 I-gene
) 0
. 0

The 0
binding 0
of 0
PH B-gene
domains I-gene
to 0
Gbetagamma B-gene
was 0
inhibited 0
by 0
preincubation 0
of 0
Gbetagamma B-gene
with 0
the 0
GDP 0
- 0
bound 0
but 0
not 0
the 0
GTP 0
- 0
bound 0
form 0
of 0
Gialpha B-gene
. 0

Their 0
afterglows 0
are 0
brighter 0
than 0
supernovae 0
and 0
therefore 0
are 0
called 0
hypernovae 0
. 0

Constrictive 0
pericarditis 0
and 0
pleuropulmonary 0
disease 0
linked 0
to 0
ergot 0
dopamine 0
agonist 0
therapy 0
( 0
cabergoline 0
) 0
for 0
Parkinson 0
's 0
disease 0
. 0

An 0
undilated 0
type 0
of 0
APBD 0
is 0
frequently 0
associated 0
with 0
AMT 0
and 0
we 0
believe 0
, 0
therefore 0
, 0
that 0
clinicians 0
should 0
be 0
aware 0
of 0
a 0
possible 0
coexistence 0
of 0
APBD 0
and 0
AMT 0
. 0

In 0
addition 0
, 0
we 0
also 0
constructed 0
and 0
expressed 0
chimeric 0
fusion 0
protein 0
that 0
contains 0
HIV B-gene
- I-gene
2 I-gene
gag I-gene
with 0
V3 B-gene
domains 0
of 0
HIV 0
- 0
1IIIB 0
, 0
HIV 0
- 0
1MN 0
, 0
HIV 0
- 0
1SF2 0
and 0
HIV 0
- 0
1RF 0
. 0

Our 0
results 0
indicate 0
that 0
V3 B-gene
peptides 0
from 0
all 0
major 0
clades 0
of 0
HIV 0
- 0
1 0
carried 0
by 0
HIV B-gene
- I-gene
2 I-gene
gag I-gene
can 0
be 0
used 0
as 0
a 0
potential 0
HIV/AIDS 0
vaccine 0
. 0

Efficacy 0
was 0
determined 0
by 0
responses 0
to 0
question 0
3 0
( 0
ability 0
to 0
achieve 0
an 0
erection 0
) 0
and 0
question 0
4 0
( 0
ability 0
to 0
maintain 0
an 0
erection 0
) 0
of 0
the 0
15 0
- 0
item 0
International 0
Index 0
of 0
Erectile 0
Function 0
( 0
IIEF 0
) 0
. 0

Evidence 0
for 0
the 0
involvement 0
of 0
the 0
Glc7 B-gene
- 0
Reg1 B-gene
phosphatase 0
and 0
the 0
Snf1 B-gene
- 0
Snf4 B-gene
kinase 0
in 0
the 0
regulation 0
of 0
INO1 B-gene
transcription 0
in 0
Saccharomyces 0
cerevisiae 0
. 0

In 0
XO 0
males 0
, 0
two 0
her B-gene
- I-gene
1 I-gene
mRNAs I-gene
, 0
her B-gene
- I-gene
1a I-gene
and 0
her B-gene
- I-gene
1b I-gene
, 0
are 0
transcribed 0
from 0
two 0
separate 0
promoters 0
: 0
P1 0
, 0
located 0
in 0
the 0
5' 0
- 0
flanking 0
region 0
, 0
and 0
P2 0
, 0
located 0
in 0
the 0
large 0
second 0
intron 0
. 0

Induction 0
of 0
Fas B-gene
ligand I-gene
expression 0
by 0
HIV 0
involves 0
the 0
interaction 0
of 0
Nef B-gene
with 0
the 0
T B-gene
cell I-gene
receptor I-gene
zeta I-gene
chain I-gene
. 0

Receptor B-gene
protein I-gene
tyrosine I-gene
phosphatases I-gene
( 0
RPTPs B-gene
) 0
comprise 0
a 0
family 0
of 0
proteins 0
that 0
feature 0
intracellular 0
phosphatase 0
domains 0
and 0
an 0
ectodomain 0
with 0
putative 0
ligand 0
- 0
binding 0
motifs 0
. 0

These 0
well 0
- 0
characterized 0
brain 0
regions 0
may 0
provide 0
a 0
basis 0
for 0
future 0
studies 0
of 0
RPTP B-gene
- I-gene
kappa I-gene
function 0
. 0

Commonly 0
used 0
stressors 0
are 0
mental 0
arithmetics 0
, 0
speech 0
tasks 0
, 0
the 0
Stroop 0
test 0
, 0
videogame 0
playing 0
, 0
films 0
or 0
videotapes 0
and 0
interviews 0
. 0

The 0
control 0
group 0
included 0
8 0
afterbirth 0
samples 0
from 0
physiological 0
full 0
- 0
term 0
pregnancies 0
. 0

However 0
, 0
we 0
identified 0
a 0
gene 0
between 0
the 0
MDV2 B-gene
UL54 I-gene
and 0
UL55 B-gene
genes I-gene
with 0
homology 0
to 0
the 0
first B-gene
ORF I-gene
( I-gene
ORF I-gene
- I-gene
1 I-gene
) I-gene
of I-gene
equine I-gene
herpesvirus I-gene
type I-gene
1 I-gene
and 0
corresponding 0
gene 0
identified 0
in 0
pseudorabies 0
virus 0
. 0

In 0
contrast 0
, 0
the 0
loss 0
of 0
MAD2 B-gene
staining 0
in 0
meiosis 0
was 0
not 0
correlated 0
with 0
initial 0
microtubule 0
attachment 0
but 0
was 0
correlated 0
with 0
a 0
measure 0
of 0
tension 0
: 0
the 0
distance 0
between 0
homologous 0
or 0
sister 0
kinetochores 0
( 0
in 0
meiosis 0
I 0
and 0
II 0
, 0
respectively 0
) 0
. 0

In 0
epithelial 0
cells 0
, 0
the 0
PH B-gene
domain I-gene
of 0
Akt/PKB B-gene
localised 0
to 0
sites 0
of 0
cell 0
- 0
cell 0
and 0
cell 0
- 0
matrix 0
contact 0
, 0
distinct 0
from 0
focal 0
contacts 0
, 0
even 0
in 0
the 0
absence 0
of 0
serum 0
. 0

The 0
5 0
' 0
untranslated 0
and 0
coding 0
regions 0
are 0
contained 0
within 0
12 0
exons 0
, 0
with 0
the 0
translation 0
start 0
site 0
located 0
within 0
the 0
first 0
exon 0
. 0

The 0
motility 0
of 0
sperm 0
, 0
except 0
for 0
those 0
adjacent 0
to 0
both 0
electrodes 0
, 0
did 0
not 0
change 0
after 0
stimulation 0
for 0
60s 0
, 0
despite 0
a 0
high 0
electrical 0
energy 0
. 0

Induction 0
of 0
the 0
CINC B-gene
promoter I-gene
by 0
IL B-gene
- I-gene
17 I-gene
in 0
IEC 0
- 0
6 0
cells 0
was 0
TNF B-gene
receptor I-gene
- I-gene
associated I-gene
factor I-gene
- I-gene
6 I-gene
( 0
TRAF6 B-gene
) 0
, 0
but 0
not 0
TRAF2 B-gene
, 0
dependent 0
. 0

SCFFWD1 B-gene
may 0
be 0
critical 0
for 0
tumor 0
development 0
and 0
suppression 0
through 0
regulation 0
of 0
beta B-gene
- I-gene
catenin I-gene
protein I-gene
stability 0
. 0

A 0
Bub2p B-gene
- 0
dependent 0
spindle 0
checkpoint 0
pathway 0
regulates 0
the 0
Dbf2p B-gene
kinase I-gene
in I-gene
budding I-gene
yeast I-gene
. 0

We 0
analyzed 0
the 0
modular 0
organization 0
of 0
DNA B-gene
polymerase I-gene
beta I-gene
and 0
found 0
that 0
residues 0
making 0
contact 0
with 0
DNA 0
phosphates 0
were 0
localized 0
to 0
five 0
modules 0
. 0

RESULTS 0
: 0
Cholinergic 0
nerves 0
are 0
mainly 0
involved 0
in 0
the 0
regulation 0
of 0
enteric 0
nerve 0
responses 0
to 0
EFS 0
in 0
the 0
normal 0
IAS 0
. 0

Two 0
- 0
dimensional 0
gel 0
electrophoresis 0
of 0
anti B-gene
- I-gene
p59fyn I-gene
immunoprecipitates 0
obtained 0
from 0
non 0
- 0
transformed 0
resting 0
human 0
T 0
lymphocytes 0
resulted 0
in 0
the 0
identification 0
of 0
an 0
oligomeric 0
protein 0
complex 0
which 0
is 0
constitutively 0
formed 0
between 0
Fyn B-gene
and 0
several 0
additional 0
phosphoproteins 0
( 0
pp43 B-gene
, 0
pp72 B-gene
, 0
pp85 B-gene
, 0
the 0
protein B-gene
tyrosine I-gene
kinase I-gene
Pyk2 B-gene
, 0
as 0
well 0
as 0
the 0
two 0
recently 0
cloned 0
adaptor 0
proteins 0
, 0
SKAP55 B-gene
and 0
SLAP B-gene
- I-gene
130 I-gene
) 0
. 0

We 0
show 0
that 0
other 0
cdc33 B-gene
mutants I-gene
also 0
arrest 0
in 0
G1 0
. 0

A 0
cdc33 B-gene
- I-gene
1 I-gene
strain 0
expressing 0
either 0
stable 0
Cln3p B-gene
( 0
Cln3 B-gene
- I-gene
1p I-gene
) 0
or 0
a 0
hybrid 0
UBI4 B-gene
5' I-gene
- I-gene
CLN3 I-gene
mRNA 0
, 0
whose 0
translation 0
displays 0
decreased 0
dependence 0
on 0
eIF4E B-gene
, 0
arrested 0
randomly 0
in 0
the 0
cell 0
cycle 0
. 0

Regulatory 0
motifs 0
for 0
gene 0
expression 0
such 0
as 0
nuclear B-gene
- I-gene
factor I-gene
- I-gene
kappaB I-gene
- I-gene
binding I-gene
- I-gene
site I-gene
- I-gene
like I-gene
sequence I-gene
( 0
kappaB B-gene
site I-gene
) 0
and 0
nuclear B-gene
- I-gene
factor I-gene
- I-gene
interleukin I-gene
- I-gene
6 I-gene
- I-gene
binding I-gene
- I-gene
site I-gene
- I-gene
like I-gene
sequence I-gene
( 0
NF B-gene
- I-gene
IL I-gene
- I-gene
6 I-gene
site I-gene
) 0
were 0
found 0
in 0
the 0
5' 0
- 0
upstream 0
regulatory 0
region 0
. 0

The 0
gene 0
structure 0
of 0
Elk1 B-gene
spans 0
15.2 0
kb 0
and 0
consists 0
of 0
seven 0
exons 0
and 0
six 0
introns 0
. 0

Total 0
serum 0
calcium 0
was 0
7.8 0
+/ 0
- 0
0.8 0
mg/dl 0
, 0
whereas 0
ionized 0
calcium 0
was 0
5.7 0
+/ 0
- 0
0.7 0
mg/dl 0
, 0
phosphorus 0
3.2 0
+/ 0
- 0
1.2 0
mg/dl 0
, 0
and 0
alkaline B-gene
phosphatase I-gene
149 0
+/ 0
- 0
48.6 0
U/liter 0
. 0

Sequence 0
analysis 0
suggests 0
that 0
TtrA B-gene
contains 0
a 0
molybdopterin 0
guanine 0
dinucleotide 0
cofactor 0
and 0
a 0
[ 0
4Fe 0
- 0
4S 0
] 0
cluster 0
, 0
that 0
TtrB B-gene
binds 0
four 0
[ 0
4Fe 0
- 0
4S 0
] 0
clusters 0
, 0
and 0
that 0
TtrC B-gene
is 0
an 0
integral 0
membrane 0
protein 0
containing 0
a 0
quinol 0
oxidation 0
site 0
. 0

Cranio 0
- 0
caudal 0
differences 0
in 0
granulation 0
tissue 0
formation 0
: 0
an 0
experimental 0
study 0
in 0
the 0
rat 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
showed 0
that 0
two 0
adjacent 0
SP1 B-gene
sites I-gene
proximal 0
to 0
exon 0
1 0
were 0
equally 0
important 0
in 0
sustaining 0
basal 0
promoter 0
activity 0
. 0

Breast 0
- 0
fed 0
newborn 0
infants 0
synthesize 0
n 0
- 0
6 0
long 0
- 0
chain 0
polyunsaturated 0
fatty 0
acids 0
already 0
during 0
the 0
first 0
week 0
of 0
life 0
, 0
but 0
the 0
contribution 0
of 0
endogenous 0
synthesis 0
to 0
the 0
total 0
plasma 0
long 0
- 0
chain 0
polyunsaturated 0
pool 0
is 0
small 0
. 0

Ischemia 0
and 0
reperfusion 0
markedly 0
increased 0
the 0
release 0
of 0
6 0
- 0
keto 0
- 0
PGF1 0
alpha 0
and 0
TXB2 0
. 0

Prostate B-gene
- I-gene
specific I-gene
antigen I-gene
( 0
PSA B-gene
) 0
promoter 0
- 0
driven 0
androgen 0
- 0
inducible 0
expression 0
of 0
sodium B-gene
iodide I-gene
symporter I-gene
in 0
prostate 0
cancer 0
cell 0
lines 0
. 0

It 0
is 0
clear 0
that 0
subclinical 0
and 0
silent 0
CD 0
exist 0
in 0
a 0
large 0
subgroup 0
of 0
the 0
celiac 0
population 0
. 0

Ras2p B-gene
activates 0
invasive 0
growth 0
using 0
either 0
of 0
two 0
downstream 0
signaling 0
pathways 0
, 0
the 0
filamentation 0
MAPK B-gene
( 0
Cdc42p/Ste20p/MAPK B-gene
) 0
cascade 0
or 0
the 0
Cdc42p/Ste20p/MAPK I-gene

Consistent 0
with 0
this 0
prediction 0
, 0
transfections 0
into 0
the 0
hematopoietic 0
cell 0
line 0
Jurkat 0
showed 0
a 0
9.0 0
- 0
and 0
2.5 0
- 0
fold 0
activation 0
of 0
the 0
mim B-gene
- I-gene
1 I-gene
promoter I-gene
by 0
the 0
p32 B-gene
and 0
p30 B-gene
isoforms I-gene
, 0
respectively 0
. 0

Previous 0
work 0
has 0
shown 0
that 0
spleen B-gene
necrosis I-gene
virus I-gene
( I-gene
SNV I-gene
) I-gene
long I-gene
terminal I-gene
repeats I-gene
( 0
LTRs 0
) 0
are 0
associated 0
with 0
Rex/Rex B-gene
- 0
responsive 0
element 0
- 0
independent 0
expression 0
of 0
bovine 0
leukemia 0
virus 0
RNA 0
and 0
supports 0
the 0
hypothesis 0
that 0
SNV 0
RNA 0
contains 0
a 0
cis 0
- 0
acting 0
element 0
that 0
interacts 0
with 0
Rex/Rex I-gene

Despite 0
the 0
reported 0
detrimental 0
effects 0
on 0
CNS 0
development 0
, 0
a 0
number 0
of 0
animal 0
studies 0
have 0
shown 0
that 0
pretreatment 0
with 0
corticosteroids 0
nevertheless 0
protect 0
the 0
brain 0
from 0
hypoxia 0
- 0
ischemic 0
injury 0
; 0
however 0
, 0
clinically 0
such 0
treatment 0
is 0
no 0
longer 0
favored 0
. 0

In 0
one 0
mechanism 0
, 0
a 0
specialized 0
ubiquitin B-gene
- 0
dependent 0
proteolytic 0
system 0
( 0
called 0
the 0
APC 0
- 0
dependent 0
proteolysis 0
machinery 0
) 0
degrades 0
the 0
mitotic 0
( 0
Clb B-gene
) 0
cyclin B-gene
subunit I-gene
. 0

Predictors 0
of 0
success 0
in 0
pharmacy 0
school 0
: 0
PCAT 0
vs. 0
other 0
admission 0
criteria 0
. 0

Canadian 0
survey 0
reveals 0
widespread 0
dissatisfaction 0
among 0
physicians 0
. 0

In 0
a 0
series 0
of 0
16 0
full 0
- 0
scale 0
fire 0
tests 0
, 0
investigators 0
at 0
the 0
IIT 0
Research 0
Institute 0
have 0
concluded 0
that 0
automatic 0
door 0
control 0
in 0
the 0
room 0
of 0
fire 0
origin 0
can 0
significantly 0
reduce 0
the 0
spread 0
of 0
toxic 0
smoke 0
and 0
gases 0
. 0

Online 0
LATCH 0
demonstrates 0
a 0
shift 0
in 0
identification 0
of 0
the 0
library 0
as 0
an 0
isolated 0
unit 0
to 0
an 0
interactive 0
resource 0
center 0
. 0

Reporting 0
of 0
adverse 0
events 0
occurring 0
during 0
clinical 0
trials 0
of 0
investigational 0
drugs 0
is 0
a 0
complex 0
and 0
controversial 0
issue 0
. 0

Medicare 0
SNF 0
benefits 0
revised 0
- 0
- 0
again 0
. 0

In 0
this 0
paper 0
, 0
the 0
current 0
status 0
of 0
the 0
understanding 0
of 0
the 0
interaction 0
mechanisms 0
of 0
ultrasound 0
with 0
biological 0
media 0
and 0
the 0
factors 0
that 0
govern 0
different 0
biological 0
effects 0
are 0
surveyed 0
. 0

Members 0
of 0
the 0
mitogen B-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinase I-gene
family I-gene
, 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
, 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
- I-gene
1/c I-gene
1/c I-gene
- I-gene
Jun I-gene
NH2 I-gene
- I-gene
terminal I-gene
kinase I-gene
, 0
and 0
p38 B-gene
, 0
are 0
central 0
elements 0
that 0
transduce 0
the 0
signal 0
generated 0
by 0
growth 0
factors 0
, 0
cytokines 0
, 0
and 0
stressing 0
agents 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
have 0
investigated 0
the 0
functional 0
role 0
of 0
the 0
other 0
MAP B-gene
kinases I-gene
in 0
PDGF B-gene
- 0
mediated 0
cellular 0
responses 0
. 0

Analyses 0
of 0
tyrosine 0
residue 0
- 0
mutated 0
PDGF B-gene
receptors I-gene
show 0
that 0
Src B-gene
homology I-gene
2 I-gene
domain I-gene
- I-gene
containing I-gene
proteins I-gene
including 0
Src B-gene
family I-gene
kinases I-gene
, 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
, 0
the 0
GTPase B-gene
- I-gene
activating I-gene
protein I-gene
of 0
Ras B-gene
, 0
the 0
Src B-gene
homology I-gene
2 I-gene
domain I-gene
- I-gene
containing I-gene
phosphatase I-gene
SHP B-gene
- I-gene
2 I-gene
, 0
phospholipase B-gene
C I-gene
- I-gene
gamma I-gene
, 0
and 0
Crk B-gene
do 0
not 0
play 0
a 0
major 0
role 0
in 0
mediating 0
the 0
PDGF B-gene
- 0
induced 0
activation 0
of 0
p38 B-gene
. 0

Here 0
we 0
show 0
that 0
calpeptin B-gene
inhibits 0
tyrosine B-gene
phosphatases I-gene
, 0
enhancing 0
tyrosine 0
phosphorylation 0
particularly 0
of 0
paxillin B-gene
. 0

Three 0
- 0
dimensional 0
structural 0
studies 0
using 0
electron 0
cryomicroscopy 0
showed 0
that 0
the 0
binding 0
of 0
one 0
Fab B-gene
( 0
8H2/G5 0
) 0
does 0
not 0
affect 0
the 0
conformation 0
of 0
the 0
capsid 0
, 0
and 0
the 0
efficiency 0
of 0
mRNA 0
production 0
is 0
similar 0
to 0
that 0
of 0
the 0
native 0
subviral 0
particle 0
. 0

Further 0
, 0
mutational 0
analysis 0
of 0
NS5A B-gene
assigned 0
the 0
SH3 B-gene
- I-gene
binding I-gene
region I-gene
to 0
a 0
proline 0
- 0
rich 0
motif 0
that 0
is 0
highly 0
conserved 0
among 0
HCV 0
genotypes 0
. 0

Taken 0
together 0
, 0
these 0
findings 0
show 0
that 0
16K B-gene
hPRL I-gene
inhibits 0
the 0
VEGF B-gene
- 0
induced 0
Ras B-gene
activation 0
; 0
this 0
antagonism 0
represents 0
a 0
novel 0
and 0
potentially 0
important 0
mechanism 0
for 0
the 0
control 0
of 0
angiogenesis 0
. 0

Analysis 0
of 0
SRE 0
oligonucleotide 0
gel 0
mobility 0
shift 0
assays 0
with 0
nuclear 0
extracts 0
from 0
Sertoli 0
cells 0
demonstrated 0
the 0
presence 0
of 0
both 0
the 0
SRF B-gene
and 0
the 0
ubiquitously 0
expressed 0
bHLH 0
protein 0
E12/E47 B-gene
. 0

We 0
calculated 0
differences 0
in 0
late 0
occlusion 0
rates 0
by 0
the 0
chi2 0
( 0
chi 0
- 0
square 0
) 0
test 0
, 0
and 0
found 0
these 0
differences 0
were 0
significant 0
( 0
P=.04 0
) 0
. 0

Baseline 0
electrocorticography 0
over 0
the 0
surface 0
of 0
the 0
temporal 0
lobe 0
and 0
depth 0
electrode 0
recordings 0
in 0
the 0
amygdala 0
and 0
hippocampus 0
were 0
obtained 0
, 0
followed 0
by 0
10 0
min 0
of 0
recording 0
before 0
and 0
after 0
the 0
i.v 0
. 0
administration 0
of 0
both 0
alfentanil 0
50 0
microg/kg 0
and 0
fentanyl 0
10 0
microg/kg 0
. 0

We 0
describe 0
a 0
genetic 0
system 0
for 0
further 0
characterizing 0
the 0
role 0
of 0
the 0
extreme 0
C 0
- 0
terminus 0
of 0
the 0
beta 0
subunit 0
of 0
E. B-gene
coli I-gene
RNA I-gene
polymerase I-gene
. 0

We 0
suggest 0
that 0
FlgN B-gene
and 0
FliT B-gene
are 0
substrate 0
- 0
specific 0
flagellar 0
chaperones 0
that 0
prevent 0
oligomerization 0
of 0
the 0
HAPs B-gene
by 0
binding 0
to 0
their 0
helical 0
domains 0
before 0
export 0
. 0

Post 0
and 0
core 0
fabrication 0
for 0
divergent 0
canals 0
with 0
a 0
cast 0
post 0
and 0
core 0
and 0
a 0
prefabricated 0
dowel 0
. 0

Rep63A B-gene
( I-gene
513 I-gene
amino I-gene
acids I-gene
[ I-gene
aa I-gene
] I-gene
) I-gene
, 0
encoded 0
by 0
the 0
largest 0
ORF 0
, 0
displayed 0
strong 0
similarity 0
( 0
40 0
% 0
identity 0
) 0
to 0
the 0
replication 0
proteins 0
from 0
plasmids 0
pAMbeta1 0
, 0
pIP501 0
, 0
and 0
pSM19035 0
, 0
indicating 0
that 0
the 0
pAW63 0
replicon 0
belongs 0
to 0
the 0
pAMbeta1 0
family 0
of 0
gram 0
- 0
positive 0
theta 0
- 0
replicating 0
plasmids 0
. 0

Here 0
we 0
report 0
the 0
cloning 0
and 0
characterization 0
of 0
Xenopus B-gene
Pax I-gene
- I-gene
5 I-gene
and 0
Pax B-gene
- I-gene
8 I-gene
, 0
two 0
orthologues 0
of 0
the 0
Pax B-gene
- I-gene
2/5/8 I-gene
gene I-gene
family I-gene
. 0

Km 0
values 0
for 0
ammonium 0
, 0
2 0
- 0
oxoglutarate 0
, 0
NADH 0
, 0
glutamate 0
and 0
NAD+ 0
were 0
6.5 0
, 0
3.5 0
, 0
0.06 0
, 0
37.1 0
and 0
0.046 0
mM 0
, 0
respectively 0
. 0

Interferon B-gene
- I-gene
alpha I-gene
may 0
exacerbate 0
cryoblobulinemia 0
- 0
related 0
ischemic 0
manifestations 0
: 0
an 0
adverse 0
effect 0
potentially 0
related 0
to 0
its 0
anti 0
- 0
angiogenic 0
activity 0
. 0

Interferon B-gene
- I-gene
alpha I-gene
may 0
exacerbate 0
cryoblobulinemia 0
- 0
related 0
ischemic 0
manifestations 0
: 0
an 0
adverse 0
effect 0
potentially 0
related 0
to 0
its 0
anti 0
- 0
angiogenic 0
activity 0
. 0

In 0
addition 0
, 0
we 0
demonstrate 0
that 0
the 0
production 0
of 0
active B-gene
recombinant I-gene
telomerase I-gene
requires 0
a 0
factor 0
in 0
rabbit 0
reticulocyte 0
lysate 0
that 0
promotes 0
ribonucleoprotein 0
assembly 0
. 0

The 0
enhanced 0
binding 0
of 0
c B-gene
- I-gene
Abl I-gene
to 0
DNA 0
containing 0
5 0
- 0
methylcytosine 0
residues 0
may 0
result 0
from 0
an 0
increased 0
propensity 0
of 0
the 0
double 0
helix 0
to 0
denature 0
locally 0
coupled 0
with 0
a 0
protein 0
- 0
induced 0
reduction 0
in 0
the 0
base 0
stacking 0
interaction 0
. 0

Homozygous 0
mutation 0
in 0
two 0
children 0
led 0
to 0
amputation 0
of 0
legs 0
due 0
to 0
purpura 0
fulminans 0
. 0

According 0
to 0
pilot 0
experiments 0
which 0
considered 0
various 0
durations 0
of 0
global 0
no 0
- 0
flow 0
ischemia 0
ranging 0
from 0
10 0
to 0
20 0
minutes 0
, 0
two 0
durations 0
were 0
chosen 0
for 0
the 0
present 0
study 0
: 0
20 0
minutes 0
( 0
group 0
20 0
) 0
in 0
which 0
ventricular 0
fibrillation 0
( 0
VF 0
) 0
was 0
the 0
predominant 0
form 0
of 0
arrhythmias 0
, 0
and 0
18 0
minutes 0
( 0
group 0
18 0
) 0
in 0
which 0
the 0
prevalence 0
of 0
VF 0
was 0
markedly 0
lower 0
despite 0
the 0
small 0
difference 0
in 0
the 0
duration 0
of 0
ischemia 0
. 0

An 0
end 0
- 0
to 0
- 0
end 0
pancreaticojejunostomy 0
using 0
a 0
mechanical 0
purse 0
- 0
string 0
device 0
. 0

We 0
further 0
demonstrate 0
that 0
the 0
Stress B-gene
- I-gene
Activated I-gene
- I-gene
Protein I-gene
- I-gene
Kinase I-gene
( 0
SAPK B-gene
) 0
target 0
sites 0
of 0
ATF2 B-gene
, 0
Thr69 0
and 0
Thr71 0
are 0
not 0
required 0
for 0
the 0
formation 0
of 0
the 0
p300/CBP B-gene
- 0
p300/CBP I-gene

Blood 0
samples 0
were 0
obtained 0
daily 0
during 0
this 0
supplementation 0
period 0
and 0
5 0
d 0
thereafter 0
( 0
d 0
11 0
to 0
15 0
) 0
. 0

These 0
results 0
suggest 0
that 0
mitochondrial 0
presequences 0
interact 0
with 0
the 0
mt B-gene
- I-gene
hsp70 I-gene
during 0
or 0
after 0
mitochondrial 0
protein 0
import 0
. 0

The 0
3 0
' 0
terminus 0
of 0
the 0
genome 0
can 0
be 0
folded 0
into 0
a 0
tRNA 0
- 0
like 0
secondary 0
structure 0
that 0
has 0
a 0
valine 0
anticodon 0
; 0
the 0
tRNA 0
- 0
like 0
structure 0
lacks 0
a 0
pseudoknot 0
in 0
the 0
aminoacyl 0
stem 0
, 0
a 0
feature 0
common 0
to 0
both 0
genera 0
of 0
tetraviruses 0
. 0

O. B-gene
novo I-gene
- I-gene
ulmi I-gene
RNA I-gene
- I-gene
7 I-gene
, 0
previously 0
believed 0
to 0
be 0
a 0
satellite 0
- 0
like 0
RNA 0
, 0
is 0
shown 0
to 0
be 0
a 0
defective 0
RNA 0
, 0
derived 0
from 0
OnuMV4 B-gene
- I-gene
Ld I-gene
RNA I-gene
by 0
multiple 0
internal 0
deletions 0
. 0

Only 0
one 0
gene 0
, 0
fibronectin B-gene
( 0
FN B-gene
) 0
, 0
was 0
highly 0
overexpressed 0
( 0
> 0
60 0
- 0
fold 0
) 0
in 0
LNCaP 0
- 0
r 0
cells 0
, 0
consistent 0
with 0
previously 0
reported 0
overexpression 0
of 0
FN B-gene
in 0
prostate 0
cancer 0
. 0

We 0
also 0
observed 0
that 0
cell 0
surface 0
CD4 B-gene
( 0
- 0
) 0
CD8 B-gene
( 0
- 0
) 0
CD3 B-gene
( 0
- 0
) 0
cells 0
with 0
rearranged B-gene
TCR I-gene
genes I-gene
developed 0
from 0
Id3 B-gene
- 0
transduced 0
but 0
not 0
from 0
control 0
- 0
transduced 0
pre 0
- 0
T 0
cells 0
in 0
an 0
FTOC 0
. 0

As 0
determined 0
in 0
a 0
modified 0
yeast 0
two 0
- 0
hybrid 0
system 0
, 0
mIRS3 B-gene
bound 0
strongly 0
to 0
the 0
p85 B-gene
subunit I-gene
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
. 0

Insulin B-gene
stimulation 0
promoted 0
the 0
association 0
of 0
mIRS3 B-gene
with 0
p85 B-gene
, 0
SHP2 B-gene
, 0
Nck B-gene
, 0
and 0
Shc B-gene
. 0

The 0
mRNA 0
expression 0
of 0
RFX1 B-gene
, 0
RFX2 B-gene
, 0
and 0
RFX3 B-gene
was 0
detected 0
ubiquitously 0
, 0
but 0
in 0
transient 0
- 0
transfection 0
assays 0
, 0
multimerized B-gene
RFX I-gene
binding I-gene
sites I-gene
in 0
front 0
of 0
a 0
basal 0
promoter 0
efficiently 0
functioned 0
in 0
a 0
tissue 0
- 0
and 0
lineage 0
- 0
specific 0
manner 0
. 0

In 0
the 0
case 0
of 0
the 0
unspliceable 0
intron 0
, 0
repression 0
of 0
luciferase B-gene
expression 0
likely 0
involved 0
two 0
AUF1 B-gene
- I-gene
binding I-gene
sequences I-gene
, 0
since 0
luciferase B-gene
expression 0
was 0
increased 0
by 0
deletion 0
of 0
these 0
sites 0
. 0

Thus 0
, 0
VDR B-gene
acts 0
selectively 0
on 0
the 0
two 0
components 0
required 0
for 0
activation 0
of 0
this 0
promoter/enhancer 0
: 0
it 0
competes 0
with 0
NFAT1 B-gene
for 0
binding 0
to 0
the 0
composite 0
site 0
, 0
positioning 0
itself 0
adjacent 0
to 0
Jun B-gene
- 0
Fos B-gene
on 0
the 0
DNA 0
. 0

Two 0
evolutionarily 0
conserved 0
kinases 0
, 0
the 0
cyclin B-gene
B I-gene
( 0
Clb B-gene
) 0
/cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
( 0
Cdk/Cdc28p B-gene
) 0
and 0
Cdk/Cdc28p I-gene

The 0
RanQ69L B-gene
preincubation 0
leads 0
to 0
accumulation 0
of 0
CRM1 B-gene
at 0
the 0
cytoplasmic 0
periphery 0
of 0
the 0
nuclear 0
pore 0
complex 0
( 0
NPC 0
) 0
in 0
association 0
with 0
the 0
p62 B-gene
complex I-gene
and 0
Can/Nup214 B-gene
. 0

All 0
of 0
the 0
elements 0
exhibited 0
a 0
uniform 0
structure 0
. 0

In 0
contrast 0
, 0
the 0
deduced 0
amino 0
acid 0
sequence 0
of 0
a 0
second 0
family 0
( 0
ART5 B-gene
) 0
of 0
transferases 0
, 0
cloned 0
from 0
murine 0
lymphoma 0
cells 0
and 0
expressed 0
in 0
high 0
abundance 0
in 0
testis 0
, 0
displays 0
a 0
hydrophobic 0
amino 0
terminus 0
, 0
consistent 0
with 0
a 0
signal 0
sequence 0
, 0
but 0
lacks 0
a 0
hydrophobic 0
signal 0
sequence 0
at 0
its 0
carboxyl 0
terminus 0
, 0
suggesting 0
that 0
the 0
protein 0
is 0
destined 0
for 0
export 0
. 0

RESULTS 0
: 0
Each 0
year 0
, 0
on 0
average 0
39 0
% 0
of 0
cases 0
seen 0
in 0
Sardinia 0
are 0
notified 0
; 0
646 0
( 0
40 0
% 0
) 0
of 0
the 0
1591 0
patients 0
notified 0
during 0
the 0
study 0
period 0
were 0
never 0
seen 0
by 0
regional 0
medical 0
centres 0
. 0

This 0
dimer 0
interface 0
is 0
likely 0
important 0
for 0
increasing 0
the 0
DNA 0
- 0
binding 0
specificity 0
and 0
affinity 0
of 0
the 0
trimeric 0
form 0
of 0
HSF B-gene
, 0
as 0
well 0
as 0
for 0
increasing 0
cooperativity 0
between 0
adjacent 0
trimers 0
. 0

The 0
paramyxovirus B-gene
fusion I-gene
( I-gene
F I-gene
) I-gene
protein I-gene
mediates 0
membrane 0
fusion 0
. 0

Additionally 0
, 0
deletion 0
analysis 0
of 0
the 0
UCP2 B-gene
promoter 0
- 0
PLAP B-gene
constructs 0
indicated 0
that 0
the 0
minimal 0
region 0
exhibiting 0
the 0
promoter 0
activity 0
was 0
located 0
between 0
nt 0
- 0
33 0
and 0
+100 0
, 0
and 0
that 0
a 0
strong 0
enhancer 0
was 0
present 0
within 0
601 0
bp 0
of 0
the 0
5' 0
- 0
promoter 0
region 0
. 0

The 0
hTERT B-gene
gene I-gene
encompasses 0
more 0
than 0
37kb 0
and 0
consists 0
of 0
16 0
exons 0
. 0

Both 0
betaAPP B-gene
mRNA I-gene
and 0
Abeta B-gene
levels 0
are 0
increased 0
in 0
trisomy 0
21 0
. 0

In 0
reperfusion 0
B 0
, 0
only 0
the 0
diabetic 0
group 0
demonstrated 0
a 0
significant 0
increase 0
in 0
IL B-gene
- I-gene
8 I-gene
concentrations 0
at 0
1 0
and 0
15 0
min 0
compared 0
to 0
nondiabetics 0
. 0

This 0
repression 0
was 0
reversed 0
agonists 0
of 0
either 0
receptor 0
demonstrating 0
a 0
functional 0
interaction 0
between 0
NCoR B-gene
and 0
PPARalpha.RXRalpha B-gene
heterodimeric 0
complexes 0
in 0
mammalian 0
cells 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
show 0
that 0
SRm160/300 B-gene
is 0
required 0
for 0
a 0
purine 0
- 0
rich 0
ESE B-gene
to 0
promote 0
the 0
splicing 0
of 0
a 0
pre 0
- 0
mRNA 0
derived 0
from 0
the 0
Drosophila B-gene
doublesex I-gene
gene I-gene
. 0

Spc42p B-gene
also 0
was 0
identified 0
as 0
a 0
component 0
of 0
a 0
cytoplasmic 0
SPB 0
subcomplex 0
containing 0
Spc94p/Nud1p B-gene
, 0
Spc94p/Nud1p I-gene

The 0
average 0
coefficients 0
of 0
correlation 0
were 0
0.9998 0
and 0
0.9993 0
for 0
the 0
QMF 0
and 0
the 0
QIT 0
system 0
, 0
respectively 0
. 0

The 0
5 0
- 0
year 0
OS 0
for 0
stage 0
IIIB 0
was 0
30.9 0
% 0
, 0
compared 0
to 0
7.8 0
% 0
for 0
stage 0
IV 0
. 0

Furthermore 0
, 0
heparin B-gene
lyase I-gene
treatment 0
of 0
extracts 0
of 0
cells 0
expressing 0
recombinant B-gene
YD I-gene
- I-gene
repeat I-gene
protein I-gene
releases 0
this 0
protein 0
from 0
high 0
molecular 0
mass 0
aggregates 0
. 0

The 0
coefficient 0
of 0
determination 0
, 0
r2 0
, 0
of 0
the 0
other 0
scores 0
ranged 0
from 0
0.56 0
to 0
0.61 0
. 0

While 0
determination 0
of 0
the 0
protein 0
content 0
of 0
the 0
formulae 0
gave 0
no 0
valid 0
information 0
, 0
RAST/EAST 0
inhibition 0
was 0
highest 0
for 0
cow 0
's 0
milk 0
, 0
followed 0
by 0
the 0
partially 0
hydrolysed 0
whey 0
formula 0
, 0
partially 0
hydrolysed 0
whey/casein B-gene
formula 0
, 0
soy/pork B-gene
collagen I-gene
formula 0
, 0
and 0
the 0
amino 0
acid 0
formula 0
. 0

In 0
light 0
of 0
the 0
importance 0
of 0
GnRHR B-gene
, 0
the 0
molecular 0
mechanisms 0
underlying 0
the 0
transcriptional 0
regulation 0
of 0
the 0
human B-gene
GnRHR I-gene
( 0
hGnRHR B-gene
) 0
gene 0
become 0
a 0
key 0
issue 0
in 0
understanding 0
human 0
reproduction 0
. 0

Competitive 0
mobility 0
shift 0
assays 0
using 0
either 0
alphaT3 0
- 0
1 0
nuclear 0
extract 0
or 0
recombinant B-gene
SF I-gene
- I-gene
1 I-gene
protein I-gene
clearly 0
indicated 0
that 0
SF B-gene
- I-gene
1 I-gene
is 0
able 0
to 0
interact 0
specifically 0
with 0
this 0
GSE B-gene
element I-gene
positioned 0
at 0
- 0
134 0
. 0

Grade 0
3 0
mucositis 0
was 0
reported 0
in 0
1 0
patient 0
. 0

CDK4 B-gene
kinase I-gene
activities 0
were 0
unaffected 0
, 0
as 0
were 0
the 0
levels 0
of 0
the 0
CDK B-gene
inhibitor 0
p21Cip1 B-gene
present 0
in 0
cyclin B-gene
E I-gene
immunocomplexes I-gene
. 0

The 0
recombinant 0
purified 0
protein 0
expressed 0
in 0
the 0
baculovirus 0
system 0
had 0
an 0
approximate 0
molecular 0
size 0
20 0
kDa 0
with 0
amino 0
- 0
terminal 0
sequence 0
of 0
AVQGP 0
. 0

Induction 0
of 0
the 0
urokinase B-gene
promoter I-gene
by 0
HGF/SF B-gene
via 0
the 0
HGF/SF I-gene

Serine 0
phosphorylation 0
of 0
STAT3 B-gene
was 0
only 0
apparent 0
after 0
somatostatin B-gene
treatment 0
and 0
was 0
abolished 0
by 0
pertussis B-gene
toxin I-gene
or 0
PD 0
98059 0
, 0
together 0
with 0
the 0
associated 0
increases 0
in 0
proliferation 0
. 0

Nevertheless 0
, 0
we 0
demonstrate 0
that 0
the 0
entire 0
three 0
- 0
component 0
yeast 0
capping 0
apparatus 0
, 0
consisting 0
of 0
RNA B-gene
5' I-gene
- I-gene
triphosphatase I-gene
( 0
Cet1p B-gene
) 0
, 0
RNA B-gene
guanylyltransferase I-gene
( 0
Ceg1p B-gene
) 0
, 0
and 0
Abd1p B-gene
could 0
be 0
replaced 0
in 0
vivo 0
by 0
the 0
two 0
- 0
component 0
mammalian 0
apparatus 0
consisting 0
of 0
a 0
bifunctional 0
triphosphatase B-gene
- I-gene
guanylyltransferase I-gene
Mce1p I-gene
and 0
the 0
methyltransferase B-gene
Hcm1 I-gene
( I-gene
121 I-gene
- I-gene
476 I-gene
) I-gene
p I-gene
. 0

The 0
IC50 0
values 0
for 0
rat 0
and 0
dog 0
urinary 0
bladder 0
were 0
3.9 0
x 0
10 0
( 0
- 0
6 0
) 0
M 0
and 0
3.8 0
x 0
10 0
( 0
- 0
6 0
) 0
M 0
, 0
respectively 0
. 0

Although 0
it 0
has 0
two 0
potential 0
binding 0
sites 0
, 0
the 0
purified 0
MerR B-gene
homodimer I-gene
binds 0
only 0
one 0
Hg 0
( 0
II 0
) 0
ion 0
, 0
employing 0
Cys82 0
from 0
one 0
monomer 0
and 0
Cys117 0
and 0
Cys126 0
from 0
the 0
other 0
. 0

The 0
influence 0
of 0
Epstein 0
- 0
Barr 0
virus 0
seropositivity 0
on 0
the 0
efficacy 0
of 0
intravenous 0
immune B-gene
globulin I-gene
in 0
children 0
with 0
immune 0
thrombocytopenic 0
purpura 0
. 0

The 0
results 0
of 0
the 0
lab 0
and 0
field 0
tests 0
yielded 0
high 0
levels 0
of 0
infestation 0
in 0
larvae 0
with 0
values 0
ranging 0
from 0
90 0
to 0
100 0
% 0
and 0
from 0
85 0
to 0
95 0
% 0
, 0
respectively 0
. 0

Amisulpride 0
400 0
mg 0
had 0
several 0
adverse 0
effects 0
on 0
psychomotor 0
and 0
, 0
although 0
less 0
severe 0
, 0
on 0
cognitive 0
performance 0
on 0
the 0
fifth 0
day 0
only 0
. 0

MutY B-gene
is 0
an 0
adenine B-gene
- I-gene
DNA I-gene
glycosylase I-gene
with 0
specificity 0
for 0
mismatches 0
involving 0
8 0
- 0
oxoguanine 0
( 0
oG.A 0
) 0
or 0
guanine 0
( 0
G.A 0
) 0
. 0

The 0
kinetics 0
of 0
kinase 0
activity 0
within 0
these 0
complexes 0
compared 0
to 0
CheA B-gene
alone 0
indicate 0
approximately 0
a 0
50 0
% 0
decrease 0
in 0
the 0
KM 0
for 0
ATP 0
and 0
a 0
100 0
- 0
fold 0
increase 0
in 0
the 0
Vmax 0
. 0

Latexin B-gene
, 0
a 0
carboxypeptidase B-gene
A I-gene
inhibitor 0
, 0
is 0
expressed 0
in 0
a 0
cell 0
type 0
- 0
specific 0
manner 0
in 0
both 0
central 0
and 0
peripheral 0
nervous 0
systems 0
in 0
the 0
rat 0
. 0

Regression 0
analyses 0
identified 0
7 0
risk 0
and 0
7 0
protective 0
factors 0
with 0
minimal 0
overlap 0
. 0

During 0
1985 0
, 0
1990 0
, 0
and 0
1995 0
, 0
respectively 0
, 0
11.7 0
, 0
11.3 0
, 0
and 0
11.4 0
infants 0
per 0
100,000 0
live 0
births 0
had 0
a 0
diagnosis 0
of 0
HSV 0
( 0
P=.98 0
) 0
. 0

Subsets 0
of 0
patients 0
were 0
performed 0
according 0
to 0
the 0
severity 0
of 0
trauma 0
( 0
ISS 0
< 0
9 0
; 0
9 0
- 0
17 0
; 0
18 0
- 0
31 0
; 0
> 0
32 0
) 0
, 0
based 0
on 0
the 0
different 0
injury 0
pattern 0
, 0
and 0
survivors 0
versus 0
nonsurvivors 0
as 0
well 0
. 0

The 0
median 0
age 0
was 0
33 0
years 0
( 0
range 0
17 0
- 0
56 0
years 0
) 0
. 0

Developmental 0
follow 0
- 0
up 0
at 0
age 0
2 0
years 0
was 0
performed 0
. 0

In 0
the 0
whole 0
group 0
of 0
infected 0
children 0
, 0
an 0
age 0
- 0
specific 0
z 0
score 0
< 0
- 0
2 0
for 0
weight 0
and 0
for 0
FFM 0
was 0
significantly 0
associated 0
with 0
an 0
increased 0
risk 0
of 0
death 0
[ 0
relative 0
risk 0
( 0
95 0
% 0
CI 0
) 0
= 0
11.4 0
( 0
3.1 0
, 0
41.0 0
) 0
and 0
5.1 0
( 0
1.5 0
, 0
18.2 0
) 0
, 0
respectively 0
] 0
; 0
when 0
only 0
children 0
with 0
more 0
severe 0
disease 0
were 0
considered 0
, 0
only 0
z 0
score 0
for 0
weight 0
was 0
significantly 0
associated 0
with 0
an 0
increased 0
risk 0
[ 0
4.6 0
( 0
1.4 0
, 0
14.9 0
) 0
] 0
. 0

In 0
addition 0
, 0
these 0
cells 0
contained 0
one 0
, 0
two 0
, 0
or 0
multiple 0
nuclei 0
indicative 0
of 0
a 0
G2/M 0
delay 0
in 0
nuclear 0
division 0
and 0
also 0
a 0
defect 0
in 0
cytokinesis 0
and/or 0
cell 0
separation 0
. 0

DAF16 B-gene
is 0
known 0
to 0
be 0
a 0
component 0
of 0
a 0
signaling 0
pathway 0
that 0
has 0
been 0
partially 0
dissected 0
genetically 0
and 0
includes 0
homologues 0
of 0
the 0
insulin/IGF B-gene
insulin/IGF I-gene
- I-gene
1 I-gene
receptor I-gene
, 0
PtdIns B-gene
3 I-gene
- I-gene
kinase I-gene
and 0
PKB B-gene
. 0

However 0
, 0
neu B-gene
differentiation 0
factor 0
- 0
induced 0
heterodimers 0
of 0
ErbB2 B-gene
and 0
ErbB4 B-gene
activated 0
Stat5 B-gene
. 0

Although 0
linker 0
regions 0
in 0
transcription 0
factors 0
are 0
known 0
to 0
modulate 0
DNA 0
binding 0
specificity 0
, 0
our 0
studies 0
suggest 0
that 0
the 0
human B-gene
HSF1 I-gene
linker 0
plays 0
no 0
role 0
in 0
determining 0
HSF1 B-gene
binding 0
preferences 0
in 0
vivo 0
but 0
is 0
a 0
critical 0
determinant 0
in 0
regulating 0
the 0
HSF1 B-gene
monomer I-gene
- I-gene
trimer I-gene
equilibrium 0
. 0

Modulation 0
of 0
human B-gene
heat I-gene
shock I-gene
factor I-gene
trimerization 0
by 0
the 0
linker 0
domain 0
. 0

Both 0
functional 0
analyses 0
in 0
undifferentiated 0
and 0
differentiated 0
F9 0
cells 0
and 0
characterization 0
of 0
DNA 0
- 0
protein 0
complexes 0
in 0
vitro 0
have 0
identified 0
the 0
sequence 0
motifs 0
GTGACT 0
( 0
C 0
) 0
, 0
ATTGT 0
, 0
and 0
GATA 0
as 0
the 0
key 0
transcription 0
factor 0
binding 0
sites 0
. 0

These 0
results 0
suggest 0
that 0
the 0
phenotype 0
of 0
XLP 0
may 0
result 0
from 0
perturbed 0
signaling 0
not 0
only 0
through 0
SLAM B-gene
, 0
but 0
also 0
other 0
cell 0
surface 0
molecules 0
that 0
utilize 0
SAP B-gene
as 0
a 0
signaling 0
adaptor 0
protein 0
. 0

We 0
also 0
localized 0
the 0
Fra B-gene
- I-gene
2 I-gene
phosphorylation I-gene
sites I-gene
by 0
MAPK B-gene
to 0
three 0
threonine 0
and 0
three 0
serine 0
residues 0
in 0
the 0
COOH 0
- 0
terminal 0
region 0
by 0
means 0
of 0
site 0
- 0
directed 0
mutagenesis 0
and 0
showed 0
that 0
the 0
threonine 0
residues 0
were 0
more 0
susceptible 0
to 0
MAPK B-gene
. 0

Nevertheless 0
, 0
they 0
are 0
functionally 0
distinct 0
in 0
that 0
FcalphaRI B-gene
binds 0
human B-gene
IgA I-gene
( 0
hIgA B-gene
) 0
but 0
not 0
bovine B-gene
IgG2 I-gene
( 0
bIgG2 B-gene
) 0
, 0
whereas 0
bFcgamma2R B-gene
binds 0
bIgG2 B-gene
but 0
not 0
hIgA B-gene
. 0

Vac1p B-gene
was 0
found 0
to 0
bind 0
the 0
Sec1p B-gene
homologue I-gene
Vps45p B-gene
. 0

In 0
a 0
heterologous 0
transcriptional 0
system 0
in 0
which 0
the 0
upstream 0
regions 0
of 0
oIFNtau B-gene
were 0
inserted 0
in 0
front 0
of 0
simian B-gene
virus I-gene
40 I-gene
( I-gene
SV40 I-gene
) I-gene
promoter I-gene
, 0
the 0
regions 0
between 0
bases 0
- 0
654 0
and 0
- 0
555 0
were 0
determined 0
as 0
being 0
the 0
enhancer 0
region 0
required 0
for 0
oIFNtau B-gene
- 0
SV40 0
- 0
CAT B-gene
transactivation 0
. 0

In 0
co 0
- 0
transfection 0
studies 0
, 0
the 0
expression 0
of 0
c B-gene
- I-gene
Jun I-gene
plus 0
c B-gene
- I-gene
Fos I-gene
enhanced 0
the 0
transactivation 0
of 0
oIFNtau B-gene
- 0
CAT B-gene
but 0
the 0
expression 0
of 0
GATA B-gene
- I-gene
1 I-gene
, 0
GATA B-gene
- I-gene
2 I-gene
or 0
GATA B-gene
- I-gene
3 I-gene
did 0
not 0
. 0

To 0
identify 0
these 0
sites 0
, 0
Cdk2 B-gene
- 0
phosphorylated 0
MARCKS B-gene
was 0
digested 0
with 0
lysyl B-gene
endoprotease I-gene
and 0
analysed 0
by 0
electrospray 0
MS 0
. 0

The 0
yeast B-gene
LPD1 I-gene
gene I-gene
encoding 0
lipoamide B-gene
dehydrogenase I-gene
is 0
subject 0
to 0
the 0
general 0
control 0
of 0
amino 0
acid 0
biosynthesis 0
mediated 0
by 0
the 0
GCN4 B-gene
transcription I-gene
factor I-gene
. 0

The 0
relatively 0
mild 0
defects 0
observed 0
in 0
Rpd3 B-gene
mutants I-gene
suggest 0
that 0
the 0
recently 0
identified 0
Groucho B-gene
and 0
dCtBP B-gene
corepressor I-gene
proteins I-gene
do 0
not 0
function 0
solely 0
through 0
the 0
recruitment 0
of 0
histone B-gene
deacetylases I-gene
. 0

However 0
, 0
the 0
serum B-gene
TNF I-gene
- I-gene
a I-gene
concentration 0
decreased 0
significantly 0
in 0
patients 0
receiving 0
pentoxifylline 0
( 0
basal 0
623+/ 0
- 0
366 0
pg/ml 0
; 0
6th 0
month 0
562+/ 0
- 0
358 0
pg/ml 0
, 0
p 0
< 0
0.01 0
) 0
, 0
but 0
not 0
in 0
the 0
control 0
group 0
. 0

In 0
addition 0
, 0
we 0
show 0
that 0
the 0
expression 0
of 0
individual 0
members 0
of 0
one 0
subfamily 0
of 0
KRAB B-gene
zinc I-gene
finger I-gene
genes I-gene
is 0
restricted 0
to 0
specific 0
hematopoietic 0
cell 0
lineages 0
. 0

Employing 0
fluorescence 0
spectroscopy 0
and 0
circular 0
dichroism 0
, 0
we 0
showed 0
that 0
the 0
binding 0
of 0
Ca2+ 0
to 0
ALG B-gene
- I-gene
2 I-gene
induced 0
significant 0
conformational 0
changes 0
in 0
both 0
the 0
N 0
- 0
terminal 0
and 0
C 0
- 0
terminal 0
domains 0
of 0
the 0
protein 0
. 0

They 0
also 0
occur 0
in 0
similar 0
locations 0
in 0
the 0
promoters 0
of 0
several 0
other 0
ribosomal B-gene
protein I-gene
genes I-gene
. 0

Both 0
carbachol 0
( 0
100 0
microM 0
) 0
and 0
EGF B-gene
( 0
10 0
nM 0
) 0
induced 0
Ras B-gene
activation 0
. 0

Dominant 0
negative 0
Sos B-gene
did 0
not 0
affect 0
carbachol 0
stimulation 0
of 0
HA B-gene
- 0
ERK2 B-gene
but 0
inhibited 0
the 0
stimulatory 0
effect 0
of 0
EGF B-gene
by 0
60 0
% 0
. 0

RESULTS 0
: 0
Transpulmonary 0
passage 0
of 0
contrast 0
occurred 0
in 0
sufficient 0
amounts 0
to 0
enhance 0
the 0
intensity 0
of 0
the 0
Doppler 0
signal 0
significantly 0
, 0
but 0
the 0
duration 0
of 0
this 0
effect 0
was 0
short 0
. 0

In 0
this 0
paper 0
, 0
such 0
lesions 0
in 0
two 0
cases 0
were 0
evaluated 0
by 0
ultrasonography 0
. 0

These 0
regions 0
contain 0
inverted 0
E 0
- 0
box 0
palindromic 0
or 0
direct 0
repeat 0
motifs 0
and 0
bind 0
SREBP B-gene
- I-gene
1 I-gene
with 0
different 0
affinities 0
. 0

To 0
address 0
these 0
questions 0
, 0
a 0
recombinant 0
FRAP/mTOR B-gene
protein 0
and 0
a 0
FRAP/mTOR I-gene

Hrs B-gene
has 0
a 0
FYVE 0
double 0
zinc 0
finger 0
domain 0
, 0
which 0
specifically 0
binds 0
phosphatidylinositol 0
( 0
3 0
) 0
- 0
phosphate 0
and 0
is 0
conserved 0
in 0
several 0
proteins 0
involved 0
in 0
vesicular 0
traffic 0
. 0

The 0
coexpression 0
of 0
full 0
- 0
length 0
expression 0
constructs 0
for 0
both 0
DBP B-gene
and 0
hepatic B-gene
leukemia I-gene
factor I-gene
resulted 0
in 0
a 0
dramatic 0
increase 0
in 0
activation 0
mediated 0
by 0
the 0
GAL4 B-gene
- 0
DBP B-gene
fusion 0
proteins 0
, 0
suggesting 0
the 0
involvement 0
of 0
a 0
regulated 0
coactivator 0
in 0
this 0
process 0
. 0

Three 0
subgenomes 0
also 0
comprised 0
15 0
to 0
75 0
nucleotides 0
derived 0
from 0
the 0
5 0
' 0
part 0
of 0
the 0
NS2 B-gene
gene I-gene
. 0

Cp B-gene
is 0
normally 0
the 0
main 0
promoter 0
for 0
EBNA B-gene
mRNA I-gene
initiation 0
, 0
so 0
it 0
appears 0
that 0
EBNA3C B-gene
contributes 0
to 0
a 0
negative 0
autoregulatory 0
control 0
loop 0
. 0

These 0
indications 0
of 0
deregulated 0
signalling 0
in 0
the 0
absence 0
of 0
tyrosine 0
118 0
were 0
substantiated 0
by 0
sustained 0
activation 0
of 0
STAT3 B-gene
. 0

With 0
exon 0
trapping 0
, 0
we 0
could 0
isolate 0
five 0
potential 0
exons 0
from 0
the 0
YAC 0
946E12 0
that 0
spans 0
the 0
region 0
, 0
four 0
of 0
which 0
could 0
be 0
placed 0
in 0
the 0
contig 0
in 0
the 0
vicinity 0
of 0
the 0
breakpoints 0
. 0

Campomelic 0
dysplasia 0
translocation 0
breakpoints 0
are 0
scattered 0
over 0
1 0
Mb 0
proximal 0
to 0
SOX9 B-gene
: 0
evidence 0
for 0
an 0
extended 0
control 0
region 0
. 0

The 0
most 0
common 0
characteristics 0
of 0
VRE 0
patients 0
were 0
recent 0
prior 0
vancomycin 0
use 0
, 0
recent 0
prior 0
susceptible 0
enterococcal 0
infection 0
, 0
coinfection 0
with 0
other 0
microbial 0
pathogens 0
, 0
and 0
concurrent 0
fungal 0
infection 0
. 0

A 0
coiled 0
- 0
coil 0
domain 0
, 0
conserved 0
within 0
each 0
encoded 0
protein 0
, 0
serves 0
as 0
a 0
potential 0
interaction 0
motif 0
for 0
FLI B-gene
LRR I-gene
. 0

Binding 0
affinities 0
of 0
these 0
recombinant 0
phages 0
as 0
determined 0
by 0
the 0
retention 0
of 0
these 0
phages 0
by 0
a 0
His 0
- 0
tag 0
immobilized 0
gp17 B-gene
column 0
, 0
and 0
by 0
co 0
- 0
immunoprecipitation 0
with 0
purified 0
terminase B-gene
supported 0
the 0
specific 0
nature 0
of 0
the 0
portal B-gene
protein I-gene
and 0
terminase B-gene
interaction I-gene
sites I-gene
. 0

Although 0
the 0
terminase B-gene
apparently 0
interacts 0
with 0
this 0
gp20 B-gene
portal I-gene
peptide I-gene
, 0
polyclonal 0
antibody 0
against 0
the 0
portal 0
peptide 0
appears 0
unable 0
to 0
access 0
it 0
in 0
the 0
native 0
structure 0
, 0
suggesting 0
intimate 0
association 0
of 0
gp20 B-gene
and 0
gp17 B-gene
possibly 0
internalizes 0
terminase B-gene
regions I-gene
within 0
the 0
portal 0
in 0
the 0
packasome 0
complex 0
. 0

The 0
hybrid 0
viruses 0
were 0
found 0
to 0
accumulate 0
to 0
high 0
levels 0
in 0
infected 0
plants 0
, 0
to 0
form 0
stable 0
virions 0
, 0
and 0
to 0
be 0
mechanically 0
transmissible 0
. 0

cDNA 0
and 0
structural 0
organization 0
of 0
the 0
gene B-gene
Pole1 I-gene
for 0
the 0
mouse B-gene
DNA I-gene
polymerase I-gene
epsilon I-gene
catalytic I-gene
subunit I-gene
. 0

Nevertheless 0
cryopreservation 0
of 0
spermatozoa 0
in 0
a 0
medium 0
containing 0
neither 0
SP 0
nor 0
biological 0
substances 0
could 0
offer 0
an 0
acceptable 0
cryoprotection 0
of 0
spermatozoa 0
to 0
be 0
used 0
in 0
assisted 0
fertilization 0
procedures 0
, 0
especially 0
for 0
intracytoplasmic 0
sperm 0
injection 0
. 0

A 0
liquid 0
chromatographic 0
method 0
is 0
described 0
for 0
analysis 0
of 0
beta 0
- 0
carotene 0
in 0
medical 0
food 0
. 0

The 0
FCMS 0
conditions 0
were 0
as 0
follows 0
: 0
2 0
kW 0
maximum 0
electrical 0
power 0
consumption 0
, 0
800 0
V 0
maximum 0
capacitor 0
voltage 0
, 0
720 0
microseconds 0
pulsewidth 0
( 0
180 0
microseconds 0
rise 0
time 0
) 0
, 0
and 0
5 0
- 0
30 0
Hz 0
frequency 0
. 0

Severe 0
hemolysis 0
resulted 0
in 0
statistically 0
significant 0
changes 0
in 0
the 0
mean 0
values 0
of 0
the 0
above 0
analytes 0
in 0
addition 0
to 0
the 0
following 0
increases 0
: 0
alanine B-gene
aminotransferase I-gene
, 0
calcium 0
, 0
and 0
serum B-gene
globulins I-gene
( 0
P 0
< 0
0.001 0
) 0
and 0
albumin B-gene
and 0
total 0
protein 0
( 0
P 0
< 0
0.01 0
) 0
. 0

EMSA 0
with 0
crude 0
nuclear 0
extracts 0
demonstrated 0
that 0
stimulation 0
with 0
CD40L B-gene
results 0
in 0
the 0
induction 0
of 0
NF B-gene
- I-gene
kappaB I-gene
complexes I-gene
that 0
bind 0
to 0
each 0
of 0
the 0
three 0
NF B-gene
- I-gene
kappaB I-gene
sites I-gene
and 0
are 0
composed 0
mainly 0
of 0
p50 B-gene
and 0
RelB B-gene
, 0
but 0
also 0
include 0
c B-gene
- I-gene
Rel I-gene
and 0
p65 B-gene
. 0

Optimal 0
monitoring 0
of 0
ODA 0
remains 0
undefined 0
. 0

The 0
major 0
transcription 0
factors 0
controlling 0
arginine 0
metabolism 0
in 0
Escherichia 0
coli 0
and 0
Bacillus 0
subtilis 0
, 0
ArgR B-gene
and 0
AhrC B-gene
, 0
respectively 0
, 0
are 0
homologous 0
multimeric 0
proteins 0
that 0
form 0
l 0
- 0
arginine 0
- 0
dependent 0
DNA 0
- 0
binding 0
complexes 0
capable 0
of 0
repressing 0
transcription 0
of 0
the 0
biosynthetic 0
genes 0
( 0
both 0
) 0
, 0
activating 0
transcription 0
of 0
catabolic 0
genes 0
( 0
AhrC B-gene
only 0
) 0
or 0
facilitating 0
plasmid 0
dimer 0
resolution 0
( 0
both 0
) 0
. 0

The 0
studied 0
protein 0
fragments 0
consist 0
of 0
residues 0
Arg183 0
- 0
His267 0
of 0
the 0
human B-gene
ER I-gene
and 0
residues 0
Lys438 0
- 0
Gln520 0
of 0
the 0
rat 0
GR B-gene
. 0

The 0
exon 0
: 0
intron 0
structure 0
of 0
chicken B-gene
IL8 I-gene
corresponds 0
almost 0
exactly 0
to 0
that 0
of 0
human B-gene
IL8 I-gene
and 0
differs 0
from 0
those 0
of 0
other 0
known 0
mammalian B-gene
CXC I-gene
chemokine I-gene
genes I-gene
. 0

The 0
Aa B-gene
- I-gene
Pri2 I-gene
gene I-gene
, 0
specifically 0
expressed 0
during 0
basidiocarp 0
differentiation 0
of 0
the 0
mushroom 0
Agrocybe 0
aegerita 0
, 0
was 0
cloned 0
. 0

The 0
main 0
causes 0
of 0
liver 0
disease 0
in 0
the 0
patients 0
with 0
HCC 0
were 0
hepatitis 0
C 0
virus 0
( 0
HCV 0
) 0
( 0
77 0
% 0
) 0
, 0
alcohol 0
abuse 0
( 0
73 0
% 0
) 0
, 0
and 0
the 0
combination 0
of 0
HCV 0
and 0
alcohol 0
abuse 0
( 0
50 0
% 0
) 0
. 0

Three 0
new 0
aromatase B-gene
inhibitors 0
have 0
recently 0
completed 0
phase 0
III 0
evaluation 0
as 0
treatment 0
of 0
metastatic 0
breast 0
cancer 0
in 0
post 0
- 0
menopausal 0
women 0
whose 0
disease 0
has 0
progressed 0
despite 0
tamoxifen 0
therapy 0
: 0
anastrozole 0
( 0
ARIMIDEX 0
, 0
Zeneca 0
) 0
, 0
letrozole 0
( 0
FEMARA 0
, 0
Novartis 0
) 0
and 0
vorozole 0
( 0
RIVIZOR 0
, 0
Janssen 0
) 0
. 0

CONCLUSIONS 0
: 0
Turbutest 0
is 0
a 0
valuable 0
tool 0
in 0
asthmatic 0
patients 0
' 0
training 0
, 0
allowing 0
identification 0
and 0
improvement 0
of 0
an 0
inadequate 0
inhalation 0
technique 0
with 0
Turbuhaler 0
. 0

Of 0
those 0
injuries 0
, 0
143 0
cases 0
were 0
snowboard 0
related 0
and 0
158 0
cases 0
were 0
ski 0
related 0
. 0

The 0
femoral 0
artery/vein 0
and 0
the 0
soleus 0
and 0
gastrocnemius 0
muscles 0
were 0
examined 0
in 0
healthy 0
human 0
male 0
volunteers 0
. 0

SRFDelta5 B-gene
acts 0
as 0
a 0
naturally 0
occurring 0
dominant 0
negative 0
regulatory 0
mutant 0
that 0
blocks 0
SRF B-gene
- 0
dependent 0
skeletal B-gene
alpha I-gene
- I-gene
actin I-gene
, 0
cardiac B-gene
alpha I-gene
- I-gene
actin I-gene
, 0
smooth B-gene
alpha I-gene
- I-gene
actin I-gene
, 0
SM22alpha B-gene
, 0
and 0
SRF B-gene
promoter 0
- 0
luciferase B-gene
reporter 0
activities 0
. 0

In 0
serum 0
- 0
free 0
media 0
, 0
p50E4F B-gene
accelerated 0
E1A B-gene
- 0
induced 0
apoptosis 0
. 0

The 0
potency 0
of 0
the 0
effect 0
of 0
Nim 0
( 0
0.5 0
mg.kg 0
- 0
1 0
i.p 0
. 0
) 0
was 0
similar 0
to 0
that 0
of 0
NBP 0
( 0
10 0
mg.kg 0
- 0
1 0
i.p 0
. 0
) 0
. 0

CONCLUSION 0
: 0
NBP 0
pre 0
- 0
treatment 0
or 0
post 0
- 0
treatment 0
markedly 0
enhanced 0
the 0
rCBF 0
to 0
striatum 0
in 0
RMCAO 0
rats 0
. 0

Progression 0
after 0
first 0
- 0
line 0
chemotherapy 0
was 0
associated 0
with 0
significantly 0
worse 0
survival 0
for 0
patients 0
with 0
metastasis 0
. 0

Mutations 0
within 0
human 0
UTR1 0
modulate 0
NRF B-gene
- I-gene
1 I-gene
expression 0
by 0
interfering 0
with 0
mRNA 0
translational 0
efficiency 0
in 0
transfected 0
cells 0
and 0
in 0
an 0
in 0
vitro 0
translation 0
system 0
. 0

As 0
is 0
deduced 0
from 0
the 0
nucleotide 0
sequence 0
of 0
the 0
cDNA 0
, 0
CBS B-gene
- I-gene
1 I-gene
contains 0
an 0
open 0
reading 0
frame 0
consisting 0
of 0
182 0
amino 0
acids 0
, 0
with 0
a 0
molecular 0
weight 0
of 0
19.5kDa 0
. 0

Corticostriatal 0
and 0
corticosubthalamic 0
input 0
zones 0
from 0
the 0
presupplementary 0
motor 0
area 0
in 0
the 0
macaque 0
monkey 0
: 0
comparison 0
with 0
the 0
input 0
zones 0
from 0
the 0
supplementary 0
motor 0
area 0
. 0

Basic B-gene
fibroblast I-gene
growth I-gene
factor I-gene
( 0
bFGF B-gene
) 0
has 0
been 0
shown 0
to 0
induce 0
angiogenesis 0
in 0
various 0
animal 0
models 0
, 0
but 0
the 0
methods 0
of 0
administration 0
used 0
experimentally 0
are 0
not 0
clinically 0
feasible 0
. 0

Both 0
filters 0
equally 0
contributed 0
to 0
elevation 0
of 0
iliac 0
venous 0
pressure 0
( 0
median 0
, 0
9.3 0
and 0
7.2 0
mm 0
Hg 0
[ 0
n 0
= 0
9 0
] 0
with 0
the 0
spring 0
filter 0
and 0
RF02 0
filter 0
, 0
respectively 0
) 0
. 0

12 0
healthy 0
women 0
( 0
age 0
18 0
- 0
38 0
years 0
) 0
were 0
examined 0
using 0
the 0
2 0
- 0
hour 0
's 0
method 0
of 0
passive 0
leg 0
rising 0
( 0
PLR 0
) 0
in 0
follicular 0
( 0
FP 0
) 0
and 0
luteal 0
( 0
LP 0
) 0
phases 0
of 0
normal 0
ovulatory 0
cycle 0
. 0

Thus 0
, 0
sgRNA2 B-gene
has 0
the 0
3'TE 0
in 0
its 0
5 0
' 0
UTR 0
. 0

These 0
single 0
mutational 0
defects 0
in 0
the 0
eRF1 B-gene
- 0
eRF3 B-gene
interaction 0
became 0
evident 0
when 0
either 0
truncated 0
protein 0
eRF3C B-gene
or 0
C 0
- 0
terminally 0
altered 0
eRF1 B-gene
proteins 0
were 0
used 0
for 0
the 0
authentic 0
protein 0
, 0
providing 0
further 0
support 0
for 0
the 0
presence 0
of 0
a 0
C 0
- 0
terminal 0
interaction 0
. 0

Removal 0
of 0
each 0
of 0
three 0
contiguous 0
segments 0
from 0
the 0
N 0
- 0
terminal 0
half 0
specifically 0
inhibits 0
the 0
formation 0
of 0
5.8Ss B-gene
rRNA I-gene
, 0
whereas 0
deleting 0
part 0
of 0
the 0
C 0
- 0
terminal 0
region 0
of 0
the 0
protein 0
only 0
blocks 0
the 0
production 0
of 0
18S B-gene
rRNA I-gene
. 0

Ras B-gene
is 0
not 0
associated 0
with 0
the 0
tegument 0
. 0

Green 0
fluorescent 0
protein 0
- 0
tagged 0
UNC B-gene
- I-gene
49B I-gene
and 0
UNC B-gene
- I-gene
49C I-gene
subunits I-gene
are 0
coexpressed 0
in 0
muscle 0
cells 0
and 0
are 0
colocalized 0
to 0
synaptic 0
regions 0
. 0

We 0
show 0
that 0
a 0
protein 0
, 0
UBC9 B-gene
, 0
interacts 0
specifically 0
with 0
TEL B-gene
in 0
vitro 0
and 0
in 0
vivo 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
investigate 0
the 0
spontaneous 0
reports 0
of 0
suspected 0
adverse 0
drug 0
reactions 0
, 0
observed 0
in 0
elderly 0
patients 0
( 0
over 0
65 0
years 0
of 0
age 0
) 0
in 0
Sicily 0
( 0
Italy 0
) 0
during 0
the 0
period 0
from 0
1 0
January 0
1995 0
to 0
31 0
December 0
1997 0
. 0

Molecules 0
of 0
NH3 0
are 0
capable 0
of 0
emitting 0
stimulated 0
radiation 0
( 0
MASER 0
) 0
. 0

The 0
major 0
findings 0
of 0
our 0
studies 0
are 0
as 0
follows 0
: 0
1 0
) 0
There 0
are 0
no 0
detectable 0
signals 0
around 0
GDF B-gene
- I-gene
9 I-gene
- 0
deficient 0
follicles 0
for 0
several 0
theca 0
cell 0
layer 0
markers 0
[ 0
i.e 0
. 0

Interestingly 0
, 0
highly 0
charged 0
residues 0
were 0
abundantly 0
possessed 0
in 0
the 0
carboxy 0
- 0
terminal 0
part 0
of 0
the 0
MDV2 B-gene
UL10 I-gene
protein I-gene
. 0

Identification 0
and 0
structure 0
of 0
the 0
Marek B-gene
's I-gene
disease I-gene
virus I-gene
serotype I-gene
2 I-gene
glycoprotein I-gene
M I-gene
gene I-gene
: 0
comparison 0
with 0
glycoprotein B-gene
M I-gene
genes I-gene
of 0
Herpesviridae 0
family 0
. 0

OBJECTIVE 0
: 0
To 0
perform 0
a 0
cost 0
- 0
effectiveness 0
analysis 0
( 0
CEA 0
) 0
between 0
a 0
standard 0
antiemetic 0
regimen 0
- 0
chlorpromazine 0
+ 0
dexamethasone 0
( 0
CPM 0
- 0
DEX 0
) 0
- 0
and 0
a 0
5 B-gene
- I-gene
HT3 I-gene
receptor I-gene
antagonist 0
- 0
tropisetron 0
( 0
TROP 0
) 0
- 0
- 0
in 0
the 0
control 0
of 0
acute 0
emesis 0
induced 0
by 0
highly 0
emetogenic 0
chemotherapy 0
in 0
children 0
, 0
considering 0
two 0
analytic 0
perspectives 0
: 0
hospital 0
and 0
patients 0
. 0

Baseline 0
data 0
were 0
obtained 0
from 0
10 0
adults 0
. 0

A 0
comparison 0
of 0
the 0
nucleotide 0
and 0
deduced 0
amino 0
acid 0
sequences 0
of 0
the 0
core 0
regions 0
of 0
the 0
RNA B-gene
- I-gene
dependent I-gene
RNA I-gene
polymerase I-gene
domains I-gene
found 0
in 0
these 0
three 0
dsRNAs 0
suggested 0
that 0
these 0
dsRNAs 0
probably 0
evolved 0
independently 0
within 0
each 0
host 0
plant 0
from 0
a 0
common 0
ancestor 0
. 0

Consistent 0
with 0
this 0
possibility 0
, 0
a 0
non 0
- 0
MBD B-gene
region 0
of 0
Bin1 B-gene
was 0
sufficient 0
to 0
recruit 0
a 0
repression 0
function 0
to 0
DNA 0
that 0
was 0
unrelated 0
to 0
histone B-gene
deacetylase I-gene
. 0

Forty 0
- 0
eight 0
sequences 0
, 0
30 0
not 0
previously 0
identified 0
as 0
IR 0
- 0
responsive 0
, 0
were 0
significantly 0
regulated 0
by 0
IR 0
. 0

A 0
recently 0
described 0
protein 0
, 0
metaxin B-gene
1 I-gene
, 0
serves 0
as 0
a 0
component 0
of 0
a 0
preprotein 0
import 0
complex 0
in 0
the 0
outer 0
membrane 0
of 0
the 0
mammalian 0
mitochondrion 0
. 0

Molecular 0
cloning 0
of 0
rat B-gene
SH2 I-gene
- I-gene
containing I-gene
inositol I-gene
phosphatase I-gene
2 I-gene
( 0
SHIP2 B-gene
) 0
and 0
its 0
role 0
in 0
the 0
regulation 0
of 0
insulin B-gene
signaling 0
. 0

Slp1 B-gene
represses 0
transcription 0
via 0
this 0
binding 0
site 0
in 0
yeast 0
cells 0
, 0
consistent 0
with 0
its 0
role 0
as 0
a 0
direct 0
repressor 0
of 0
ftz B-gene
stripes 0
in 0
interstripe 0
regions 0
during 0
late 0
stages 0
of 0
embryogenesis 0
. 0

The 0
results 0
of 0
these 0
studies 0
support 0
a 0
model 0
in 0
which 0
VirB4 B-gene
dimers I-gene
or 0
homomultimers 0
contribute 0
structural 0
information 0
for 0
the 0
assembly 0
of 0
a 0
transenvelope 0
channel 0
competent 0
for 0
bidirectional 0
DNA 0
transfer 0
, 0
whereas 0
an 0
ATP 0
- 0
dependent 0
activity 0
is 0
required 0
for 0
configuring 0
this 0
channel 0
as 0
a 0
dedicated 0
export 0
machine 0
. 0

The 0
penicillin B-gene
binding I-gene
proteins I-gene
( 0
PBPs B-gene
) 0
synthesize 0
and 0
remodel 0
peptidoglycan 0
, 0
the 0
structural 0
component 0
of 0
the 0
bacterial 0
cell 0
wall 0
. 0

TCR B-gene
alpha I-gene
( 0
TCRA B-gene
) 0
expression 0
was 0
examined 0
in 0
RNA 0
samples 0
from 0
PBMC 0
and 0
isolated 0
populations 0
of 0
CD4+ B-gene
, 0
CD8+ B-gene
, 0
and 0
DN 0
T 0
cells 0
from 0
15 0
healthy 0
individuals 0
. 0

Similar 0
results 0
were 0
obtained 0
with 0
xylitol 0
, 0
an 0
activator 0
of 0
the 0
pentose 0
phosphate 0
pathway 0
. 0

The 0
high B-gene
density I-gene
lipoprotein I-gene
( I-gene
HDL I-gene
) I-gene
receptor I-gene
mediates 0
the 0
uptake 0
of 0
cholesterol 0
and 0
cholesteryl 0
esters 0
, 0
substrates 0
for 0
steroidogenesis 0
, 0
from 0
an 0
HDL B-gene
particle 0
in 0
the 0
adrenal 0
gland 0
and 0
gonads 0
. 0

D3S1261 B-gene
is 0
physically 0
located 0
at 0
or 0
near 0
the 0
MITF B-gene
locus I-gene
, 0
while 0
D3S2465 B-gene
and 0
D3S1766 B-gene
are 0
flanking 0
the 0
locus 0
at 0
about 0
17.5 0
cM 0
genetic 0
distance 0
each 0
side 0
. 0

The 0
percentages 0
of 0
recovery 0
decreased 0
with 0
storage 0
time 0
, 0
although 0
the 0
addition 0
of 0
dispersant 0
( 0
Tris 0
- 0
Tween 0
80 0
) 0
before 0
storage 0
appeared 0
to 0
partially 0
prevent 0
adhesion 0
. 0

Point 0
mutations 0
of 0
the 0
site 0
that 0
suppressed 0
Pit B-gene
- I-gene
1 I-gene
binding 0
in 0
vitro 0
restored 0
full 0
tiGH B-gene
promoter I-gene
activity 0
. 0

A 0
human B-gene
Raf I-gene
- I-gene
responsive I-gene
zinc I-gene
- I-gene
finger I-gene
protein I-gene
that 0
binds 0
to 0
divergent 0
sequences 0
. 0

We 0
are 0
reporting 0
an 0
autopsy 0
case 0
of 0
so 0
- 0
called 0
`` 0
acute 0
multiple 0
sclerosis 0
'' 0
that 0
was 0
difficult 0
to 0
differentiate 0
from 0
a 0
brain 0
tumor 0
on 0
MRI 0
findings 0
. 0

Furthermore 0
, 0
MOM B-gene
- I-gene
4 I-gene
and 0
TAK1 B-gene
bind 0
related 0
proteins 0
that 0
promote 0
their 0
kinase 0
activities 0
. 0

BACKGROUND 0
: 0
The 0
MAZE 0
- 0
III 0
is 0
the 0
surgical 0
treatment 0
of 0
choice 0
for 0
medically 0
refractory 0
atrial 0
fibrillation 0
. 0

Gab2 B-gene
, 0
a 0
new 0
pleckstrin B-gene
homology 0
domain 0
- 0
containing 0
adapter 0
protein 0
, 0
acts 0
to 0
uncouple 0
signaling 0
from 0
ERK B-gene
kinase I-gene
to 0
Elk B-gene
- I-gene
1 I-gene
. 0

The 0
presence 0
of 0
cutaneous 0
xanthomas 0
with 0
normal 0
serum 0
lipid 0
levels 0
is 0
due 0
to 0
the 0
antibetalipoproteic 0
activity 0
of 0
the 0
monoclonal B-gene
immunoglobulin I-gene
. 0

In 0
an 0
attempt 0
to 0
reduce 0
the 0
incidence 0
of 0
NSAID 0
- 0
induced 0
gastrointestinal 0
lesions 0
, 0
the 0
following 0
approaches 0
have 0
been 0
proposed 0
: 0
( 0
i 0
) 0
use 0
of 0
the 0
prostaglandin 0
analogue 0
misoprostol 0
, 0
which 0
is 0
an 0
antiulcer 0
drug 0
which 0
has 0
been 0
proven 0
to 0
be 0
as 0
effective 0
in 0
the 0
prevention 0
of 0
NSAID 0
- 0
induced 0
gastric 0
and 0
duodenal 0
ulcers 0
as 0
in 0
the 0
reduction 0
of 0
serious 0
upper 0
gastrointestinal 0
complications 0
; 0
( 0
ii 0
) 0
histamine B-gene
H2 I-gene
receptor I-gene
antagonists 0
( 0
H2 0
antagonists 0
) 0
, 0
e.g 0
. 0
ranitidine 0
, 0
cimetidine 0
and 0
famotidine 0
, 0
which 0
are 0
useful 0
in 0
the 0
prevention 0
of 0
NSAID 0
- 0
induced 0
duodenal 0
ulcers 0
during 0
long 0
term 0
treatment 0
, 0
but 0
not 0
in 0
the 0
prevention 0
of 0
NSAID 0
- 0
induced 0
gastric 0
ulcers 0
; 0
( 0
iii 0
) 0
proton 0
pump 0
inhibitors 0
, 0
e.g 0
omeprazole 0
, 0
and 0
pantoprazole 0
, 0
whose 0
efficacy 0
in 0
preventing 0
NSAID 0
- 0
associated 0
ulcers 0
has 0
been 0
recently 0
demonstrated 0
; 0
and 0
( 0
iv 0
) 0
barrier 0
agents 0
, 0
e.g 0
. 0
sucralfate 0
, 0
which 0
can 0
not 0
be 0
recommended 0
as 0
prophylactic 0
agents 0
to 0
prevent 0
NSAID 0
- 0
induced 0
gastropathy 0
. 0

Lung 0
mesenchyme 0
serves 0
as 0
a 0
'compleat 0
' 0
inducer 0
of 0
lung 0
morphogenesis 0
by 0
secreting 0
soluble 0
peptide 0
growth 0
factors 0
. 0

The 0
activation 0
of 0
the 0
HIV 0
promoter 0
required 0
the 0
nuclear 0
localization 0
of 0
c B-gene
- I-gene
Abl I-gene
and 0
could 0
be 0
correlated 0
with 0
increased 0
tyrosine 0
phosphorylation 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
. 0

The 0
bovine B-gene
papillomavirus I-gene
E2 I-gene
protein I-gene
can 0
inhibit 0
the 0
proliferation 0
of 0
HT 0
- 0
3 0
cells 0
, 0
a 0
p53 B-gene
- 0
negative 0
cervical 0
carcinoma 0
cell 0
line 0
containing 0
integrated 0
human 0
papillomavirus 0
type 0
30 0
DNA 0
. 0

E2 B-gene
point 0
mutants 0
unable 0
to 0
inhibit 0
cell 0
growth 0
did 0
not 0
repress 0
cdc25A B-gene
and 0
cdc25B B-gene
expression 0
, 0
nor 0
did 0
the 0
cell 0
cycle 0
inhibitors 0
hydroxyurea 0
and 0
mimosine 0
. 0

BACKGROUND/PURPOSE 0
: 0
Anomalous 0
arrangement 0
of 0
the 0
pancreaticobiliary 0
duct 0
( 0
AAPBD 0
) 0
is 0
closely 0
related 0
to 0
congenital 0
biliary 0
dilatation 0
and 0
frequently 0
associated 0
with 0
biliary 0
tract 0
malignancy 0
. 0

Neurospora 0
crassa 0
CYT B-gene
- I-gene
18 I-gene
, 0
can 0
rescue 0
the 0
exonic 0
trap 0
and 0
intron 0
mutants 0
which 0
cause 0
a 0
structural 0
defect 0
. 0

DDP1 B-gene
also 0
localizes 0
to 0
heterochromatin 0
in 0
interphase 0
nuclei 0
of 0
larval 0
neuroblasts 0
. 0

In 0
a 0
reconstituted 0
human 0
DNA 0
repair 0
system 0
containing 0
DNA B-gene
polymerase I-gene
beta I-gene
and 0
DNA B-gene
ligase I-gene
III I-gene
- 0
XRCC1 B-gene
, 0
accurate 0
rejoining 0
of 0
a 0
3 0
' 0
mismatched 0
base 0
residue 0
at 0
a 0
single 0
- 0
strand 0
break 0
is 0
dependent 0
on 0
addition 0
of 0
the 0
exonuclease 0
. 0

The 0
PAC 0
clone 0
with 0
an 0
insert 0
size 0
of 0
120kb 0
was 0
isolated 0
and 0
mapped 0
by 0
restriction 0
analysis 0
. 0

Sequence 0
of 0
10q24 B-gene
locus I-gene
surrounding 0
the 0
HOX11 B-gene
oncogene I-gene
reveals 0
a 0
new 0
gene 0
HUG1 B-gene
expressed 0
in 0
a 0
T 0
- 0
ALL 0
cell 0
line 0
. 0

About 0
20 0
kb 0
upstream 0
of 0
LAMB2 B-gene
we 0
found 0
a 0
gene 0
encoding 0
a 0
transcribed 0
, 0
non 0
- 0
processed 0
LAMB2 B-gene
- I-gene
like I-gene
pseudogene I-gene
( 0
LAMB2L B-gene
) 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
of 0
the 0
R2 B-gene
protein I-gene
was 0
used 0
to 0
provide 0
evidence 0
that 0
this 0
motif 0
is 0
also 0
part 0
of 0
the 0
active 0
site 0
of 0
the 0
endonuclease 0
encoded 0
by 0
this 0
element 0
. 0

The 0
infected B-gene
cell I-gene
protein I-gene
no I-gene
. I-gene
0 I-gene
( 0
ICP0 B-gene
) 0
of 0
herpes 0
simplex 0
virus 0
1 0
is 0
a 0
promiscuous 0
transactivator 0
shown 0
to 0
enhance 0
the 0
expression 0
of 0
genes 0
introducted 0
into 0
cells 0
by 0
infection 0
or 0
transfection 0
. 0

Wrist 0
measurement 0
of 0
blood 0
pressure 0
: 0
some 0
critical 0
remarks 0
to 0
oscillometry 0
. 0

G 0
- 0
box 0
- 0
directed 0
expression 0
in 0
leaves 0
required 0
the 0
presence 0
of 0
an 0
enhancer 0
region 0
from 0
the 0
cauliflower 0
mosaic 0
virus 0
( 0
CaMV 0
) 0
35S B-gene
promoter I-gene
. 0

Another 0
element 0
necessary 0
for 0
augmenting 0
the 0
amplitude 0
of 0
the 0
oscillation 0
lies 0
between 0
- 0
178 0
and 0
- 0
264 0
. 0

This 0
scFv 0
was 0
therefore 0
used 0
as 0
control 0
in 0
experiments 0
where 0
another 0
anti B-gene
- I-gene
Ras I-gene
scFv I-gene
( 0
Y259 B-gene
scFv I-gene
, 0
derived 0
from 0
the 0
neutralizing 0
anti B-gene
- I-gene
Ras I-gene
mAb I-gene
Y13 I-gene
- I-gene
259 I-gene
) 0
blocked 0
the 0
Ras B-gene
pathway 0
in 0
vitro 0
and 0
led 0
to 0
tumor 0
regression 0
in 0
a 0
nude 0
mouse 0
model 0
[ 0
Cochet 0
, 0
O. 0
, 0
Kenigsberg 0
, 0
M. 0
, 0
Delumeau 0
, 0
I. 0
, 0
Virone 0
- 0
Oddos 0
, 0
A. 0
, 0
Multon 0
, 0
M.C. 0
, 0
Fridman 0
, 0
W.H. 0
, 0
Schweighoffer 0
, 0
F. 0
, 0
Teillaud 0
, 0
J.L. 0
, 0
Tocque 0
, 0
B. 0
, 0
1998 0
. 0

There 0
was 0
no 0
competition 0
between 0
activin B-gene
A I-gene
and 0
OP B-gene
- I-gene
1 I-gene
for 0
availability 0
of 0
Smad4 B-gene
, 0
indicating 0
that 0
the 0
concentration 0
of 0
this 0
common 0
signal 0
transducer 0
is 0
not 0
limiting 0
for 0
generating 0
the 0
observed 0
biological 0
responses 0
. 0

Our 0
data 0
therefore 0
indicate 0
that 0
it 0
is 0
possible 0
to 0
engineer 0
the 0
HA B-gene
envelope I-gene
glycoprotein I-gene
by 0
fusing 0
ligands 0
to 0
its 0
amino 0
- 0
terminal 0
end 0
without 0
affecting 0
its 0
fusion 0
activity 0
. 0

However 0
, 0
the 0
favored 0
, 0
parallel 0
beta 0
helix 0
model 0
is 0
a 0
compact 0
coil 0
of 0
ten 0
helically 0
arranged 0
beta 0
strands 0
forming 0
two 0
parallel 0
beta 0
sheet 0
faces 0
. 0

This 0
is 0
predicted 0
to 0
encode 0
a 0
315 0
- 0
residue 0
protein 0
containing 0
seven 0
hydrophobic 0
helical 0
regions 0
and 0
a 0
17 0
amino 0
acid 0
motif 0
characteristic 0
of 0
the 0
R7G B-gene
family I-gene
of 0
G B-gene
- I-gene
protein I-gene
coupled I-gene
membrane I-gene
- I-gene
bound I-gene
receptors I-gene
. 0

Characterisation 0
of 0
the 0
chicken B-gene
apolipoprotein I-gene
A I-gene
- I-gene
I I-gene
gene I-gene
5' 0
- 0
flanking 0
region 0
. 0

These 0
results 0
suggest 0
that 0
members 0
of 0
the 0
ATF B-gene
family I-gene
are 0
involved 0
in 0
mediating 0
the 0
transcriptional 0
regulation 0
of 0
the 0
KGF B-gene
gene I-gene
in 0
response 0
to 0
extracellular 0
stimuli 0
via 0
a 0
novel 0
CRE 0
regulatory 0
element 0
. 0

Moreover 0
, 0
a 0
high 0
proportion 0
of 0
blood 0
samples 0
from 0
a 0
random 0
sample 0
of 0
the 0
rest 0
of 0
the 0
suspects 0
tested 0
positive 0
for 0
trypanosome 0
- 0
specific 0
DNA 0
by 0
PCR 0
( 0
79.9 0
% 0
for 0
T. 0
b. 0
gambiense 0
and 0
13.9 0
% 0
for 0
T. 0
b. 0
rhodesiense 0
) 0
. 0

A 0
multi 0
- 0
centre 0
evaluation 0
of 0
the 0
card 0
indirect 0
agglutination 0
test 0
for 0
trypanosomiasis 0
( 0
TrypTect 0
CIATT 0
) 0
. 0

Results 0
for 0
men 0
who 0
drank 0
up 0
to 0
two 0
drinks 0
per 0
day 0
suggest 0
that 0
if 0
the 0
dependence 0
criteria 0
were 0
invalid 0
, 0
reductions 0
in 0
the 0
prevalence 0
of 0
specific 0
indicators 0
of 0
alcohol 0
dependence 0
would 0
range 0
from 0
0.3 0
% 0
to 0
5.2 0
% 0
. 0

Mutagenesis 0
of 0
the 0
CDE/CHR 0
elements 0
and 0
Sp1 B-gene
sites I-gene
in 0
this 0
region 0
, 0
alone 0
or 0
in 0
combination 0
, 0
reduced 0
transcriptional 0
activity 0
by 0
40 0
- 0
60 0
% 0
in 0
asynchronously 0
growing 0
cells 0
and 0
abolished 0
cell 0
cycle 0
periodicity 0
in 0
G2 0
- 0
M 0
- 0
synchronized 0
cells 0
. 0

Using 0
Scheffe 0
's 0
procedure 0
as 0
an 0
illustration 0
, 0
comparisons 0
are 0
made 0
to 0
usual 0
sample 0
size 0
methods 0
that 0
incorrectly 0
ignore 0
the 0
stochastic 0
nature 0
of 0
S2p 0
. 0

The 0
crystal 0
structure 0
of 0
the 0
VP16 B-gene
core I-gene
has 0
been 0
determined 0
at 0
2.1 0
A 0
resolution 0
. 0

Ozagrel 0
, 0
ifenprodil 0
, 0
cinnarizine 0
and 0
dilazep 0
were 0
more 0
effective 0
than 0
pentoxifylline 0
in 0
increasing 0
rCBF 0
at 0
the 0
HPC 0
. 0

The 0
latter 0
method 0
adds 0
clamping 0
of 0
the 0
inferior 0
vena 0
cava 0
, 0
which 0
results 0
in 0
hypotension 0
, 0
requiring 0
invasive 0
anesthetic 0
management 0
. 0

By 0
contrast 0
, 0
PvirE B-gene
or 0
Plac B-gene
promoter I-gene
constructs I-gene
yielded 0
functional 0
VirE2 B-gene
only 0
if 0
virE1 B-gene
was 0
coexpressed 0
with 0
virE2 B-gene
. 0

Simian 0
parainfluenza 0
virus 0
5 0
( 0
SV5 0
) 0
is 0
a 0
prototype 0
of 0
the 0
Paramyxoviridae 0
family 0
of 0
nonsegmented 0
negative 0
- 0
sense 0
RNA 0
viruses 0
. 0

To 0
investigate 0
the 0
functions 0
of 0
GE 0
, 0
IG 0
, 0
and 0
GS 0
sequences 0
in 0
transcription 0
, 0
we 0
constructed 0
plasmids 0
containing 0
cDNAs 0
of 0
the 0
full 0
- 0
length 0
SV5 0
genome 0
in 0
which 0
the 0
gene 0
junction 0
sequences 0
( 0
GE 0
, 0
IG 0
, 0
and 0
GS 0
sequences 0
) 0
located 0
between 0
the 0
hemagglutinin B-gene
- I-gene
neuraminidase I-gene
( 0
HN B-gene
) 0
and 0
the 0
polymerase B-gene
( I-gene
L I-gene
) I-gene
genes I-gene
were 0
replaced 0
with 0
the 0
counterpart 0
sequences 0
from 0
other 0
gene 0
junctions 0
. 0

CXCR4 B-gene
is 0
a 0
chemokine 0
receptor 0
and 0
a 0
coreceptor 0
for 0
T 0
- 0
cell 0
- 0
line 0
- 0
tropic 0
( 0
X4 0
) 0
and 0
dual 0
- 0
tropic 0
( 0
R5X4 0
) 0
human 0
immunodeficiency 0
virus 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
isolates 0
. 0

These 0
data 0
will 0
help 0
us 0
to 0
better 0
detail 0
the 0
CXCR4 B-gene
structural 0
requirements 0
exhibited 0
by 0
different 0
HIV 0
- 0
1 0
strains 0
and 0
will 0
direct 0
further 0
mutagenesis 0
efforts 0
aimed 0
at 0
better 0
defining 0
the 0
domains 0
in 0
CXCR4 B-gene
involved 0
in 0
the 0
HIV 0
- 0
1 0
Env B-gene
- 0
mediated 0
fusion 0
process 0
. 0

The 0
results 0
of 0
these 0
analyses 0
indicate 0
that 0
the 0
proteinase 0
cleaves 0
at 0
amino 0
acid 0
residues 0
E960 0
- 0
A961 0
, 0
E1071 0
- 0
S1072 0
, 0
E1345 0
- 0
T1346 0
, 0
and 0
E1419 0
- 0
G1420 0
; 0
however 0
, 0
the 0
cleavage 0
efficiency 0
is 0
varied 0
. 0

y 0
. 0

SM B-gene
is 0
also 0
shown 0
to 0
be 0
associated 0
in 0
vivo 0
with 0
other 0
components 0
of 0
the 0
CRM B-gene
1 I-gene
export 0
pathway 0
, 0
including 0
the 0
small B-gene
GTPase I-gene
Ran I-gene
and 0
the 0
nucleoporin 0
CAN/Nup214 B-gene
. 0

Identification 0
of 0
a 0
spliced 0
gene 0
from 0
Kaposi 0
's 0
sarcoma 0
- 0
associated 0
herpesvirus 0
encoding 0
a 0
protein 0
with 0
similarities 0
to 0
latent B-gene
membrane I-gene
proteins I-gene
1 I-gene
and I-gene
2A I-gene
of I-gene
Epstein I-gene
- I-gene
Barr I-gene
virus I-gene
. 0

Auditory 0
clicks 0
were 0
given 0
at 0
a 0
rate 0
of 0
20 0
s 0
( 0
- 0
1 0
) 0
. 0

Myosin B-gene
light I-gene
chain I-gene
kinase I-gene
functions 0
downstream 0
of 0
Ras/ERK B-gene
to 0
promote 0
migration 0
of 0
Ras/ERK I-gene

The 0
inhibition 0
of 0
StAR B-gene
gene I-gene
transcription 0
by 0
DAX B-gene
- I-gene
1 I-gene
was 0
dose 0
- 0
dependent 0
reducing 0
transcription 0
to 0
6 0
% 0
of 0
control 0
levels 0
. 0

In 0
a 0
prospective 0
randomized 0
study 0
, 0
287 0
patients 0
with 0
advanced 0
non 0
- 0
small 0
cell 0
lung 0
cancer 0
( 0
NSCLC 0
) 0
stage 0
IIIb 0
or 0
IV 0
with 0
ECOG 0
performance 0
status 0
( 0
PS 0
) 0
0 0
- 0
1 0
or 0
2 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
best 0
supportive 0
care 0
( 0
BSC 0
) 0
or 0
supportive 0
care 0
plus 0
combination 0
chemotherapy 0
( 0
IEP 0
regimen 0
: 0
ifosfamide 0
3 0
gm/m2 0
IV 0
with 0
mesna 0
uroprotection 0
, 0
epirubicin 0
60 0
mg/m2 0
IV 0
on 0
day 0
1 0
and 0
cisplatin 0
60 0
mg/m2 0
IV 0
on 0
day 0
2 0
; 0
or 0
MVP 0
regimen 0
: 0
mitomycin 0
- 0
C 0
8 0
mg/m2 0
, 0
cisplatin 0
100 0
mg/m2 0
IV 0
on 0
day 0
1 0
, 0
vinblastine 0
4 0
mg/m2 0
IV 0
on 0
days 0
1 0
and 0
15 0
) 0
. 0

Using 0
sequence 0
information 0
from 0
human B-gene
BMAL1 I-gene
( 0
hBMAL1 B-gene
) 0
cDNAs 0
previously 0
reported 0
by 0
our 0
laboratory 0
, 0
we 0
have 0
isolated 0
and 0
characterized 0
cDNAs 0
encoding 0
three 0
splice 0
variants 0
of 0
the 0
mouse B-gene
BMAL1 I-gene
( 0
mBMAL1 B-gene
) 0
gene 0
. 0

Comparison 0
with 0
the 0
bHLH/PAS B-gene
family 0
genes 0
revealed 0
that 0
the 0
intron/exon 0
splice 0
pattern 0
of 0
bHLH/PAS I-gene

The 0
transcriptional 0
activities 0
of 0
the 0
full 0
- 0
length 0
promoter 0
( 0
- 0
295 0
to 0
+85 0
) 0
and 0
of 0
three 0
deletion 0
constructs 0
( 0
- 0
197 0
, 0
- 0
154 0
and 0
- 0
74 0
to 0
+85 0
) 0
were 0
significantly 0
down 0
- 0
regulated 0
in 0
resistant 0
cells 0
. 0

We 0
were 0
able 0
to 0
detect 0
significant 0
differences 0
in 0
functional 0
residual 0
capacity 0
adjusted 0
for 0
weight 0
or 0
height 0
, 0
and 0
compliance 0
of 0
the 0
respiratory 0
system 0
adjusted 0
for 0
weight 0
or 0
lung 0
volume 0
in 0
the 0
ILD 0
infants 0
compared 0
to 0
the 0
healthy 0
controls 0
or 0
infants 0
who 0
had 0
PPHN 0
, 0
indicating 0
that 0
these 0
PFTs 0
were 0
sensitive 0
enough 0
to 0
determine 0
abnormal 0
lung 0
function 0
in 0
this 0
age 0
group 0
. 0

A 0
13 0
- 0
bp 0
cis 0
- 0
regulatory 0
element 0
in 0
the 0
LTR 0
promoter 0
of 0
the 0
tobacco B-gene
retrotransposon I-gene
Tto1 I-gene
is 0
involved 0
in 0
responsiveness 0
to 0
tissue 0
culture 0
, 0
wounding 0
, 0
methyl 0
jasmonate 0
and 0
fungal 0
elicitors 0
. 0

In 0
this 0
study 0
we 0
describe 0
that 0
platelet B-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
( 0
PDGF B-gene
) 0
, 0
12 0
- 0
O 0
- 0
tetradecanoyl 0
- 0
phorbol 0
- 0
acetate 0
( 0
TPA 0
) 0
, 0
and 0
forskolin 0
induced 0
CREB B-gene
( 0
cAMP B-gene
- I-gene
responsive I-gene
element I-gene
- I-gene
binding I-gene
protein I-gene
) 0
Ser 0
- 0
133 0
phosphorylation 0
with 0
comparable 0
magnitude 0
and 0
kinetics 0
in 0
NIH 0
3T3 0
cells 0
. 0

This 0
constitutes 0
evidence 0
for 0
an 0
in 0
vivo 0
role 0
of 0
SRC B-gene
- I-gene
1 I-gene
in 0
dimerization 0
- 0
induced 0
activation 0
by 0
OR1/RXRalpha B-gene
. 0

By 0
contrast 0
, 0
mTRAP100 B-gene
coprecipitates 0
in 0
vivo 0
with 0
another 0
component 0
of 0
the 0
TRAP B-gene
complex I-gene
( 0
TRAP220 B-gene
) 0
, 0
which 0
directly 0
contacts 0
TR B-gene
and 0
the 0
vitamin B-gene
D I-gene
receptor I-gene
in 0
a 0
ligand 0
- 0
dependent 0
manner 0
. 0

This 0
sequence 0
also 0
confers 0
VDR B-gene
and 0
vitamin 0
D 0
responsiveness 0
to 0
a 0
heterologous 0
promoter 0
. 0

Classical 0
ligand 0
- 0
activated 0
nuclear 0
receptors 0
( 0
e.g 0
. 0
thyroid B-gene
hormone I-gene
receptor I-gene
, 0
retinoic B-gene
acid I-gene
receptor I-gene
) 0
, 0
orphan B-gene
nuclear I-gene
receptors I-gene
( 0
e.g 0
. 0

Expression 0
of 0
GlcNAc B-gene
- I-gene
TI I-gene
mRNA I-gene
in 0
tobacco 0
leaves 0
was 0
detected 0
using 0
RT 0
- 0
PCR 0
. 0

Chemical 0
stability 0
tests 0
and 0
site 0
- 0
specific 0
mutagenesis 0
identified 0
amino 0
acids 0
H219 0
and 0
D63 0
of 0
RegS B-gene
and 0
RegR B-gene
, 0
respectively 0
, 0
as 0
the 0
phosphorylated 0
residues 0
. 0

An 0
overexpression 0
of 0
the 0
betaAPP B-gene
gene I-gene
in 0
certain 0
areas 0
of 0
the 0
AD 0
brain 0
has 0
been 0
suggested 0
to 0
be 0
an 0
important 0
factor 0
in 0
the 0
neuropathology 0
of 0
AD 0
. 0

For 0
functional 0
studies 0
, 0
two 0
promoter 0
regions 0
were 0
cloned 0
upstream 0
of 0
the 0
reporter 0
gene 0
, 0
chloramphenicol B-gene
acetyl I-gene
transferase I-gene
( 0
CAT B-gene
) 0
: 0
( 0
i 0
) 0
phbetaE 0
- 0
B 0
- 0
the 0
plasmid 0
that 0
contains 0
the 0
human 0
( 0
h 0
) 0
promoter 0
region 0
( 0
- 0
2832 0
to 0
+101 0
) 0
including 0
URE 0
, 0
and 0
( 0
ii 0
) 0
prhbetaE 0
- 0
B 0
- 0
the 0
plasmid 0
that 0
contains 0
the 0
rhesus 0
( 0
rh 0
) 0
promoter 0
region 0
excluding 0
URE 0
as 0
it 0
lacks 0
a 0
270 0
bp 0
region 0
of 0
the 0
hbetaAPP B-gene
promoter I-gene
( 0
- 0
2435 0
to 0
- 0
2165 0
) 0
. 0

67 0
393 0
bp 0
of 0
contiguous 0
DNA 0
located 0
between 0
markers 0
cdc18 B-gene
and 0
cdc14 B-gene
on 0
the 0
right 0
arm 0
of 0
fission 0
yeast 0
chromosome 0
II 0
has 0
been 0
sequenced 0
as 0
part 0
of 0
the 0
European 0
Union 0
Schizosaccharomyces 0
pombe 0
genome 0
sequencing 0
project 0
. 0

67 0
393 0
bp 0
of 0
contiguous 0
DNA 0
located 0
between 0
markers 0
cdc18 B-gene
and 0
cdc14 B-gene
on 0
the 0
right 0
arm 0
of 0
fission 0
yeast 0
chromosome 0
II 0
has 0
been 0
sequenced 0
as 0
part 0
of 0
the 0
European 0
Union 0
Schizosaccharomyces 0
pombe 0
genome 0
sequencing 0
project 0
. 0

G B-gene
- I-gene
CSF I-gene
( 0
480 0
micrograms 0
subcutaneously 0
( 0
s.c. 0
) 0
) 0
were 0
used 0
in 0
55 0
and 0
GM B-gene
- I-gene
CSF I-gene
( 0
400 0
micrograms 0
s.c. 0
) 0
in 0
28 0
chemotherapeutic 0
cycles 0
. 0

Overexpression 0
of 0
H411 B-gene
cDNA I-gene
in 0
the 0
RAW 0
264.7 0
macrophage 0
cell 0
line 0
promoted 0
an 0
increased 0
growth 0
rate 0
, 0
suggesting 0
that 0
expression 0
of 0
H411 B-gene
is 0
part 0
of 0
the 0
proliferative 0
cell 0
response 0
to 0
LPS 0
. 0

Human 0
expressed 0
sequence 0
tag 0
clones 0
were 0
identified 0
by 0
sequence 0
similarity 0
to 0
mammalian B-gene
and I-gene
yeast I-gene
oligosaccharide I-gene
- I-gene
processing I-gene
mannosidases I-gene
, 0
and 0
the 0
full 0
- 0
length 0
coding 0
region 0
of 0
the 0
putative 0
mannosidase B-gene
homolog I-gene
was 0
isolated 0
by 0
a 0
combination 0
of 0
5' 0
- 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
and 0
direct 0
polymerase 0
chain 0
reaction 0
from 0
human 0
placental 0
cDNA 0
. 0

Activation 0
of 0
ERK1/2 B-gene
is 0
correlated 0
with 0
induction 0
of 0
the 0
immediate B-gene
- I-gene
early I-gene
response I-gene
genes I-gene
. 0

The 0
transcription 0
of 0
most 0
RP B-gene
genes I-gene
is 0
activated 0
by 0
two 0
Rap1p B-gene
binding I-gene
sites I-gene
, 0
250 0
to 0
400 0
bp 0
upstream 0
from 0
the 0
initiation 0
of 0
transcription 0
. 0

We 0
have 0
isolated 0
three 0
mutant 0
alleles 0
of 0
CDC4 B-gene
( 0
cdc4 B-gene
- I-gene
10 I-gene
, 0
cdc4 B-gene
- I-gene
11 I-gene
, 0
and 0
cdc4 B-gene
- I-gene
16 I-gene
) 0
which 0
suppress 0
the 0
nuclear 0
division 0
defect 0
of 0
cdc20 B-gene
- I-gene
1 I-gene
cells 0
. 0

Role 0
of 0
secondary 0
structure 0
in 0
discrimination 0
between 0
constitutive 0
and 0
inducible 0
activators 0
. 0

In 0
summary 0
, 0
Ca 0
( 0
2+ 0
) 0
- 0
dependent 0
activation 0
of 0
NO 0
production 0
mediates 0
apoptosis 0
after 0
TG B-gene
exposure 0
in 0
JT/Neo 0
cells 0
. 0

Accumulation 0
of 0
the 0
U4/U6 B-gene
duplex 0
was 0
relieved 0
by 0
overexpression 0
of 0
U4/U6 I-gene

Our 0
results 0
, 0
when 0
combined 0
with 0
previously 0
published 0
in 0
vitro 0
results 0
, 0
support 0
a 0
direct 0
role 0
for 0
Prp44p B-gene
in 0
unwinding 0
of 0
the 0
U4/U6 B-gene
helix 0
. 0

This 0
approximately 0
125 0
- 0
nt 0
RNA 0
proved 0
to 0
arise 0
via 0
RNase B-gene
E I-gene
cleavage 0
from 0
the 0
3' 0
- 0
terminal 0
region 0
of 0
the 0
mRNAs 0
bearing 0
the 0
terminator 0
. 0

The 0
mysteries 0
of 0
geographic 0
variability 0
in 0
nonmelanoma 0
skin 0
cancer 0
incidence 0
. 0

In 0
Saccharomyces 0
cerevisiae 0
the 0
cAMP B-gene
- I-gene
dependent I-gene
kinases I-gene
( 0
PKAs B-gene
) 0
promote 0
cytoplasmic 0
growth 0
and 0
modulate 0
the 0
growth 0
- 0
regulated 0
mechanism 0
triggering 0
the 0
begin 0
of 0
DNA 0
synthesis 0
. 0

We 0
have 0
shown 0
previously 0
that 0
in 0
contrast 0
to 0
other 0
extracellular 0
matrix 0
molecules 0
pepsin B-gene
- 0
solubilized 0
collagen B-gene
VI I-gene
( 0
CVI B-gene
) 0
can 0
stimulate 0
DNA 0
synthesis 0
of 0
various 0
mesenchymal 0
cell 0
types 0
, 0
apparently 0
independent 0
of 0
integrin B-gene
- 0
mediated 0
signal 0
transduction 0
. 0

A 0
recombinant 0
derivative 0
harboring 0
the 0
pMJ101 0
replication 0
region 0
proved 0
to 0
be 0
compatible 0
with 0
pJM1 0
, 0
a 0
plasmid 0
containing 0
the 0
iron 0
acquisition 0
system 0
required 0
for 0
the 0
virulence 0
of 0
V. 0
anguillarum 0
775 0
, 0
another 0
important 0
pathogen 0
that 0
causes 0
vibriosis 0
. 0

FAK B-gene
localizes 0
to 0
sites 0
of 0
transmembrane B-gene
integrin I-gene
receptor I-gene
clustering 0
and 0
facilitates 0
intracellular 0
signaling 0
events 0
. 0

Expression 0
of 0
various 0
FAK B-gene
mutants I-gene
in 0
the 0
FAK B-gene
- 0
cells 0
showed 0
that 0
FAK B-gene
kinase I-gene
activity 0
, 0
the 0
Tyr B-gene
- I-gene
397/SH2 I-gene
domain I-gene
binding I-gene
site I-gene
, 0
and 0
the 0
first 0
proline 0
- 0
rich 0
SH3 B-gene
binding I-gene
region I-gene
in 0
the 0
FAK B-gene
C I-gene
- I-gene
terminal I-gene
domain I-gene
were 0
individually 0
needed 0
to 0
promote 0
full 0
FAK B-gene
- 0
mediated 0
FAK B-gene
- 0
cell 0
migration 0
to 0
FN B-gene
whereas 0
direct 0
paxillin B-gene
binding 0
to 0
FAK B-gene
was 0
not 0
required 0
. 0

This 0
dominant 0
- 0
negative 0
effect 0
of 0
FRNK B-gene
was 0
reversed 0
by 0
a 0
point 0
mutation 0
( 0
Leu 0
- 0
1034 0
to 0
Ser 0
) 0
which 0
prevented 0
FRNK B-gene
localization 0
to 0
focal 0
contact 0
sites 0
. 0

Fifty 0
six 0
young 0
patients 0
( 0
age 0
< 0
45 0
yr 0
) 0
with 0
doppler 0
- 0
proven 0
DVT 0
were 0
investigated 0
for 0
the 0
presence 0
of 0
resistance 0
to 0
activated B-gene
protein I-gene
C I-gene
( 0
APC B-gene
- I-gene
R I-gene
) 0
, 0
lupus 0
anticoagulant 0
( 0
LA 0
) 0
, 0
anticardiolipin B-gene
antibodies I-gene
and 0
deficiencies 0
of 0
protein B-gene
C I-gene
, 0
protein B-gene
S I-gene
, 0
ATIII B-gene
activities 0
. 0

DESIGN 0
: 0
Comparison 0
of 0
number 0
of 0
women 0
with 0
PKU 0
aged 0
15 0
- 0
44 0
years 0
on 0
the 0
NSW 0
PKU 0
database 0
( 0
observed 0
number 0
) 0
with 0
expected 0
number 0
derived 0
from 0
population 0
data 0
. 0

PURPOSE 0
: 0
The 0
purposes 0
of 0
the 0
present 0
study 0
were 0
to 0
assess 0
the 0
effects 0
of 0
a 0
12 0
- 0
wk 0
laboratory 0
based 0
aerobic 0
exercise 0
program 0
on 0
cardiopulmonary 0
function 0
, 0
CD4 B-gene
cell 0
count 0
, 0
and 0
physician 0
- 0
assessed 0
health 0
status 0
among 0
symptomatic 0
pre 0
- 0
AIDS 0
HIV 0
- 0
infected 0
individuals 0
( 0
N 0
= 0
28 0
) 0
and 0
to 0
assess 0
the 0
degree 0
to 0
which 0
ill 0
health 0
was 0
associated 0
with 0
exercise 0
relapse 0
. 0

The 0
enzyme 0
displays 0
optimal 0
activity 0
at 0
about 0
0.5 0
mM 0
pantoate 0
( 0
k 0
( 0
cat 0
) 0
0.63 0
s 0
( 0
- 0
1 0
) 0
) 0
and 0
at 0
pH 0
7.8 0
. 0

Taken 0
together 0
, 0
these 0
results 0
demonstrate 0
that 0
the 0
RP B-gene
, 0
like 0
the 0
20S B-gene
proteasome I-gene
, 0
is 0
functionally 0
and 0
structurally 0
conserved 0
among 0
eukaryotes 0
and 0
indicate 0
that 0
the 0
plant B-gene
RPT I-gene
subunits I-gene
, 0
like 0
their 0
yeast 0
counterparts 0
, 0
have 0
non 0
- 0
redundant 0
functions 0
. 0

Epidemiologic 0
evidence 0
indicates 0
that 0
estrogen 0
replacement 0
therapy 0
after 0
menopause 0
increases 0
breast 0
cancer 0
risk 0
. 0

In 0
addition 0
to 0
its 0
elongation 0
activity 0
, 0
ELL B-gene
contains 0
a 0
novel 0
type 0
of 0
RNA B-gene
polymerase I-gene
II I-gene
interaction I-gene
domain I-gene
that 0
is 0
capable 0
of 0
repressing 0
polymerase 0
activity 0
in 0
promoter 0
- 0
specific 0
transcription 0
. 0

A 0
diagnosis 0
of 0
IgA B-gene
lambda I-gene
multiple 0
myeloma 0
with 0
peritoneal 0
involvement 0
was 0
made 0
. 0

The 0
radiation 0
burden 0
associated 0
with 0
the 0
majority 0
of 0
examinations 0
in 0
nuclear 0
medicine 0
expressed 0
as 0
the 0
effective 0
dose 0
is 0
comparable 0
with 0
the 0
radiation 0
burden 0
of 0
radiodiagnostic 0
examinations 0
, 0
only 0
after 0
administration 0
of 0
preparations 0
with 0
131I 0
, 0
201Tl 0
, 0
67Ga 0
and 0
111In 0
it 0
is 0
markedly 0
higher 0
. 0

Although 0
the 0
risk 0
of 0
malformation 0
in 0
children 0
born 0
after 0
ICSI 0
is 0
not 0
increased 0
there 0
is 0
an 0
increased 0
risk 0
to 0
transmit 0
genetic 0
abnormalities 0
in 0
case 0
of 0
NOA 0
( 0
such 0
as 0
the 0
rate 0
of 0
sex 0
chromosome 0
, 0
or 0
microdeletions 0
of 0
the 0
Y 0
chromosome 0
) 0
and 0
in 0
case 0
of 0
congenital 0
OA 0
( 0
mutations 0
of 0
the 0
cystic B-gene
fibrosis I-gene
gene I-gene
) 0
. 0

TaV 0
particles 0
have 0
a 0
buoyant 0
density 0
of 0
1.296 0
g/cm3 0
in 0
CsCl 0
and 0
consist 0
of 0
two 0
capsid B-gene
proteins I-gene
of 0
56 0
and 0
6 0
kDa 0
. 0

CONCLUSION 0
: 0
These 0
results 0
suggest 0
that 0
vibration 0
- 0
induced 0
neural 0
involvement 0
can 0
be 0
considered 0
neither 0
pure 0
digital 0
neuropathy 0
, 0
nor 0
definite 0
CTS 0
, 0
as 0
previously 0
described 0
. 0

In 0
about 0
770 0
bp 0
upstream 0
region 0
of 0
Spam1 B-gene
that 0
has 0
been 0
cloned 0
and 0
sequenced 0
, 0
multiple 0
transcription 0
factor 0
binding 0
sites 0
including 0
a 0
CRE 0
( 0
cAMP 0
- 0
responsive 0
element 0
) 0
were 0
found 0
. 0

The 0
in 0
vitro 0
relaxivity 0
of 0
the 0
complex 0
is 0
16.24 0
s 0
( 0
- 0
1 0
) 0
mM 0
( 0
- 0
1 0
) 0
. 0

Structure 0
and 0
expression 0
of 0
the 0
mouse B-gene
growth I-gene
hormone I-gene
receptor/growth I-gene
receptor/growth I-gene
hormone I-gene
binding I-gene
protein I-gene
gene I-gene
. 0

Bacterial 0
recovery 0
of 0
SA 0
from 0
the 0
liver/spleen 0
and 0
the 0
cecal 0
tonsil 0
in 0
contact 0
poults 0
and 0
SG 0
from 0
contact 0
chicks 0
treated 0
with 0
ILK B-gene
was 0
dramatically 0
reduced 0
when 0
compared 0
to 0
non 0
- 0
treated 0
contact 0
poults 0
and 0
chicks 0
. 0

The 0
results 0
of 0
the 0
ISIS 0
- 0
2 0
trial 0
and 0
the 0
data 0
from 0
the 0
Antiplatelet 0
Trialists 0
' 0
Collaboration 0
indicated 0
that 0
aspirin 0
is 0
mandatory 0
in 0
patients 0
with 0
acute 0
myocardial 0
infarction 0
and 0
for 0
secondary 0
prevention 0
. 0

This 0
study 0
was 0
performed 0
to 0
assess 0
the 0
role 0
of 0
additional 0
diagnostic 0
laparoscopy 0
in 0
the 0
preoperative 0
staging 0
of 0
patients 0
with 0
adenocarcinoma 0
of 0
the 0
esophagus 0
, 0
gastric 0
cancer 0
and 0
pancreatic 0
cancer 0
prior 0
to 0
intended 0
curative 0
surgery 0
. 0

This 0
report 0
presents 0
state 0
- 0
specific 0
MMRs 0
for 0
1987 0
- 0
1996 0
, 0
focusing 0
on 0
persistent 0
disparities 0
in 0
maternal 0
mortality 0
between 0
black 0
and 0
white 0
women 0
. 0

Preheparin 0
LPL B-gene
mass 0
level 0
did 0
not 0
significantly 0
differ 0
in 0
individuals 0
from 0
19 0
to 0
70 0
years 0
old 0
, 0
for 0
both 0
men 0
and 0
women 0
. 0

A 0
decrease 0
in 0
insulin B-gene
- 0
induced 0
receptor 0
kinase 0
activity 0
was 0
observed 0
for 0
solubilized 0
chimeric 0
receptors 0
. 0

Cat B-gene
- I-gene
1 I-gene
is 0
identical 0
to 0
the 0
recently 0
identified 0
binding 0
partner 0
for 0
the 0
beta B-gene
- I-gene
adrenergic I-gene
receptor I-gene
kinase I-gene
( 0
betaARK B-gene
or 0
GRK B-gene
- I-gene
2 I-gene
) 0
, 0
which 0
was 0
shown 0
to 0
have 0
Arf B-gene
- 0
GAP B-gene
activity 0
. 0

Cat B-gene
proteins I-gene
are 0
tyrosine 0
- 0
phosphorylated 0
when 0
co 0
- 0
expressed 0
in 0
cells 0
with 0
the 0
focal B-gene
adhesion I-gene
kinase I-gene
Fak B-gene
and 0
Src B-gene
. 0

Immunoprecipitation 0
experiments 0
using 0
DokR B-gene
- I-gene
specific I-gene
antibodies I-gene
revealed 0
an 0
interaction 0
between 0
endogenous B-gene
DokR I-gene
and 0
a 0
150 0
- 0
kDa 0
protein 0
that 0
is 0
tyrosine 0
- 0
phosphorylated 0
in 0
EGF B-gene
- 0
stimulated 0
BaF/3 0
cells 0
. 0

Expansins B-gene
are 0
a 0
family 0
of 0
proteins 0
that 0
catalyse 0
long 0
- 0
term 0
extension 0
of 0
isolated 0
plant 0
cell 0
walls 0
due 0
to 0
an 0
as 0
yet 0
unknown 0
biochemical 0
mechanism 0
. 0

This 0
review 0
summarizes 0
the 0
clinical 0
evidence 0
to 0
support 0
current 0
therapies 0
in 0
irritable 0
bowel 0
syndrome 0
( 0
IBS 0
) 0
. 0

The 0
responsive 0
region 0
of 0
the 0
alpha B-gene
2 I-gene
( I-gene
V I-gene
) I-gene
collagen I-gene
gene I-gene
was 0
localized 0
to 0
a 0
fragment 0
including 0
100 0
bp 0
of 0
basal 0
promoter 0
and 0
150 0
bp 0
of 0
exon 0
1 0
sequences 0
, 0
which 0
contained 0
two 0
CRE 0
- 0
like 0
elements 0
. 0

Furthermore 0
, 0
addition 0
of 0
B B-gene
- I-gene
Myb I-gene
- 0
glutathionine B-gene
S I-gene
- I-gene
transferase I-gene
fusion 0
protein 0
inhibited 0
complex 0
formation 0
. 0

APOE B-gene
- 0
epsilon4 0
count 0
predicts 0
age 0
when 0
prevalence 0
of 0
AD 0
increases 0
, 0
then 0
declines 0
: 0
the 0
Cache 0
County 0
Study 0
. 0

Repair 0
of 0
double 0
- 0
strand 0
breaks 0
( 0
DSBs 0
) 0
in 0
chromosomal 0
DNA 0
by 0
nonhomologous 0
end 0
- 0
joining 0
( 0
NHEJ 0
) 0
is 0
not 0
well 0
characterized 0
in 0
the 0
yeast 0
Saccharomyces 0
cerevisiae 0
. 0

A 0
new 0
DNA B-gene
repair I-gene
gene I-gene
from 0
Schizosaccharomyces 0
pombe 0
with 0
homology 0
to 0
RecA B-gene
was 0
identified 0
and 0
characterized 0
. 0

Among 0
mucus 0
- 0
secreting 0
cells 0
, 0
the 0
gastric 0
gland 0
mucous 0
cells 0
, 0
Brunner 0
's 0
glands 0
, 0
accessory 0
glands 0
of 0
pancreaticobiliary 0
tract 0
, 0
and 0
pancreatic 0
ducts 0
exhibiting 0
gastric 0
metaplasia 0
are 0
unique 0
in 0
that 0
they 0
express 0
class B-gene
III I-gene
mucin I-gene
identified 0
by 0
paradoxical 0
Con B-gene
A I-gene
staining 0
composed 0
of 0
periodate 0
oxidation 0
, 0
sodium 0
borohydride 0
reduction 0
, 0
Con B-gene
A I-gene
, 0
and 0
horseradish B-gene
peroxidase I-gene
reaction 0
. 0

The 0
C 0
- 0
terminal 0
mutants 0
were 0
strongly 0
dominant 0
over 0
TraR B-gene
, 0
suggesting 0
that 0
they 0
can 0
form 0
heteromultimers 0
with 0
the 0
wild 0
- 0
type 0
activator 0
. 0

Thus 0
, 0
elongin B-gene
C I-gene
is 0
found 0
to 0
oligomerize 0
in 0
solution 0
and 0
to 0
undergo 0
significant 0
structural 0
rearrangements 0
upon 0
binding 0
of 0
two 0
different 0
partner 0
proteins 0
. 0

The 0
data 0
imply 0
that 0
JAK/STAT B-gene
signaling 0
has 0
a 0
role 0
in 0
EBV 0
- 0
associated 0
malignancies 0
. 0

There 0
were 0
27 0
men 0
and 0
156 0
women 0
. 0

A. 0
, 0
Bowers 0
, 0
K.E 0
, 0
and 0
Matthews 0
, 0
C 0
. 0

Spfkh1 B-gene
is 0
transcribed 0
in 0
one 0
open 0
reading 0
frame 0
that 0
contains 0
the 0
DNA 0
binding 0
domain 0
, 0
nuclear 0
localization 0
signal 0
and 0
transactivation 0
domain 0
. 0

The 0
molecular 0
mechanism 0
of 0
Tax B-gene
- 0
mediated 0
trans 0
- 0
activation 0
has 0
been 0
well 0
investigated 0
. 0

Gel 0
filtration 0
and 0
co 0
- 0
immunoprecipitation 0
analyses 0
reveal 0
that 0
Mad2p B-gene
tightly 0
associates 0
with 0
another 0
spindle 0
checkpoint 0
component 0
, 0
Mad1p B-gene
. 0

METHODS 0
: 0
109 0
suspected 0
cases 0
with 0
SS 0
underwent 0
the 0
biopsies 0
. 0

We 0
also 0
identify 0
several 0
regulatory 0
domain 0
mutants 0
in 0
which 0
Cd 0
( 0
2+ 0
) 0
tolerance 0
of 0
the 0
mutant 0
strain 0
and 0
transport 0
activity 0
of 0
the 0
protein 0
are 0
dissociated 0
. 0

The 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
- I-gene
1 I-gene
( I-gene
HIV I-gene
- I-gene
1 I-gene
) I-gene
Tat I-gene
protein I-gene
regulates 0
transcription 0
by 0
stimulating 0
RNA B-gene
polymerase I-gene
processivity 0
. 0

One 0
of 0
these 0
SEBPs B-gene
, 0
SEBP2 B-gene
, 0
was 0
shown 0
to 0
be 0
the 0
product 0
of 0
the 0
homeotic B-gene
gene I-gene
fork B-gene
head I-gene
. 0

Identity 0
elements 0
in 0
tRNA 0
for 0
mono 0
- 0
and 0
dimethylation 0
reactions 0
by 0
the 0
recombinant B-gene
pfTrm1p I-gene
were 0
identified 0
using 0
in 0
vitro 0
T7 0
transcripts 0
of 0
33 0
variants 0
of 0
tRNA B-gene
( I-gene
Asp I-gene
) I-gene
and 0
tRNA B-gene
( I-gene
Phe I-gene
) I-gene
from 0
yeast 0
. 0

In 0
insulin B-gene
- 0
responsive 0
cells 0
, 0
Akt B-gene
phosphorylates 0
and 0
inactivates 0
the 0
serine/threonine B-gene
kinase I-gene
glycogen B-gene
synthase I-gene
kinase I-gene
- I-gene
3 I-gene
( 0
GSK B-gene
- I-gene
3 I-gene
) 0
. 0

The 0
B B-gene
cell I-gene
antigen I-gene
receptor I-gene
activates 0
the 0
Akt B-gene
( 0
protein B-gene
kinase I-gene
B I-gene
) 0
/glycogen B-gene
synthase I-gene
kinase I-gene
- I-gene
3 I-gene
signaling 0
pathway 0
via 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
. 0

Fewer 0
recombination 0
events 0
are 0
detected 0
in 0
four 0
different 0
B 0
and 0
T 0
cell 0
lines 0
that 0
do 0
not 0
undergo 0
switch 0
recombination 0
of 0
their 0
endogenous 0
genes 0
. 0

IL B-gene
- I-gene
1 I-gene
and 0
TNF B-gene
increase 0
AND B-gene
- I-gene
34 I-gene
transcript I-gene
levels 0
in 0
thymic 0
cortical 0
reticular 0
, 0
thymic 0
nurse 0
, 0
and 0
fibroblast 0
cell 0
lines 0
. 0

To 0
determine 0
what 0
role 0
eIF4E B-gene
might 0
play 0
in 0
c B-gene
- I-gene
myc I-gene
expression 0
, 0
the 0
c B-gene
- I-gene
myc I-gene
5 I-gene
' I-gene
untranslated I-gene
region I-gene
( I-gene
UTR I-gene
) I-gene
was 0
fused 0
in 0
- 0
frame 0
to 0
CAT B-gene
reporters I-gene
, 0
and 0
several 0
more 0
derivative 0
constructs 0
were 0
made 0
. 0

Analysis 0
of 0
cell 0
cycle 0
proteins 0
showed 0
that 0
24 0
h 0
of 0
lovastatin 0
treatment 0
in 0
the 0
control 0
cells 0
caused 0
an 0
elevation 0
in 0
the 0
levels 0
of 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
inhibitor 0
p27 B-gene
( 0
kip1 B-gene
) 0
, 0
inhibition 0
of 0
both 0
cyclin B-gene
E I-gene
- I-gene
and I-gene
cyclin I-gene
A I-gene
- I-gene
dependent I-gene
kinase I-gene
activity 0
, 0
and 0
decreased 0
levels 0
of 0
hyperphosphorylated 0
retinoblastoma B-gene
protein I-gene
( 0
pRb B-gene
) 0
. 0

RESULTS 0
: 0
Circulating 0
leptin B-gene
concentrations 0
in 0
AN 0
were 0
3.5+/ 0
- 0
0.5 0
versus 0
7.6+/ 0
- 0
1.2 0
ng/ml 0
in 0
control 0
subjects 0
. 0

Copyright 0
1999 0
Academic 0
Press 0
. 0

Oligonucleotide 0
probes 0
corresponding 0
to 0
wild 0
- 0
type 0
and 0
mutant 0
EpRE 0
sequences 0
were 0
used 0
in 0
gel 0
- 0
shift 0
and 0
super 0
- 0
shift 0
analyses 0
to 0
identify 0
proteins 0
binding 0
. 0

PKNbeta B-gene
had 0
high 0
sequence 0
homology 0
with 0
PKNalpha B-gene
, 0
originally 0
isolated 0
PKN B-gene
, 0
especially 0
in 0
the 0
repeats 0
of 0
charged 0
amino 0
acid 0
- 0
rich 0
region 0
with 0
leucine 0
- 0
zipper 0
like 0
sequences 0
( 0
CZ 0
region/HR1 0
) 0
, 0
in 0
the 0
carboxyl 0
- 0
terminal 0
catalytic 0
domain 0
, 0
and 0
in 0
approximately 0
130 0
amino 0
acid 0
stretch 0
( 0
D 0
region/HR2 0
) 0
, 0
located 0
between 0
CZ 0
region/HR1 0
and 0
the 0
catalytic 0
domain 0
. 0

At 0
baseline 0
, 0
serum 0
levels 0
of 0
lycopene 0
and 0
FLOP 0
were 0
abnormally 0
high 0
and 0
serum 0
FLOP 0
was 0
correlated 0
significantly 0
with 0
plasma 0
cyclosporine 0
levels 0
( 0
r 0
= 0
0.646 0
, 0
p 0
= 0
0.016 0
) 0
. 0

BACKGROUND 0
: 0
Chronic 0
alcohol 0
consumption 0
has 0
been 0
demonstrated 0
to 0
be 0
deleterious 0
to 0
bone 0
health 0
. 0

Interestingly 0
, 0
following 0
induction 0
of 0
stress 0
by 0
heat 0
shock 0
, 0
high 0
salt 0
, 0
or 0
ethanol 0
, 0
conditions 0
under 0
which 0
most 0
mRNA 0
export 0
is 0
blocked 0
, 0
Npl3p B-gene
is 0
still 0
exported 0
from 0
the 0
nucleus 0
. 0

For 0
symptomatic 0
relief 0
and 0
inhibition 0
of 0
the 0
growth 0
of 0
the 0
metastases 0
interferon B-gene
- I-gene
a I-gene
and 0
somatostatin B-gene
analogues 0
can 0
be 0
employed 0
. 0

In 0
summary 0
, 0
the 0
no 0
- 0
adverse 0
- 0
effect 0
- 0
level 0
for 0
this 0
study 0
was 0
determined 0
to 0
be 0
1000 0
ppm 0
, 0
based 0
on 0
decreased 0
weight 0
gain 0
in 0
female 0
rats 0
, 0
and 0
on 0
slight 0
organ 0
weight 0
changes 0
in 0
both 0
sexes 0
at 0
3000 0
ppm 0
. 0

Some 0
of 0
them 0
produce 0
gigantic 0
sperm 0
several 0
times 0
the 0
total 0
male 0
body 0
length 0
. 0

John 0
leonard 0
dawson 0

PDGF B-gene
A I-gene
- I-gene
chain I-gene
levels 0
increase 0
in 0
cultured 0
vascular 0
smooth 0
muscle 0
cells 0
( 0
SMCs 0
) 0
exposed 0
to 0
ATII B-gene
. 0

M B-gene
- I-gene
Ras I-gene
interacted 0
poorly 0
in 0
a 0
yeast 0
two 0
- 0
hybrid 0
assay 0
with 0
multiple 0
Ras B-gene
effectors 0
, 0
including 0
c B-gene
- I-gene
Raf I-gene
- I-gene
1 I-gene
, 0
A B-gene
- I-gene
Raf I-gene
, 0
B B-gene
- I-gene
Raf I-gene
, 0
phosphoinositol B-gene
- I-gene
3 I-gene
kinase I-gene
delta I-gene
, 0
RalGDS B-gene
, 0
and 0
Rin1 B-gene
. 0

Deletion 0
mapping 0
of 0
the 0
human B-gene
presenilin I-gene
- I-gene
1 I-gene
( 0
PS1 B-gene
) 0
promoter 0
delineated 0
the 0
most 0
active 0
fragment 0
from 0
- 0
118 0
to 0
+178 0
in 0
relation 0
to 0
the 0
transcription 0
start 0
site 0
mapped 0
in 0
this 0
study 0
, 0
in 0
both 0
human 0
neuroblastoma 0
SK 0
- 0
N 0
- 0
SH 0
and 0
hepatoma 0
HepG2 0
cells 0
. 0

Microcirculatory 0
oxygenation 0
and 0
shunting 0
in 0
sepsis 0
and 0
shock 0
. 0

Analysis 0
of 0
the 0
E2F1 B-gene
gene I-gene
promoter I-gene
showed 0
that 0
the 0
- 0
146 0
to 0
- 0
54 0
region 0
was 0
required 0
for 0
E2 B-gene
- 0
responsiveness 0
in 0
transient 0
transfection 0
assays 0
, 0
and 0
subsequent 0
deletion/mutation 0
analysis 0
showed 0
that 0
a 0
single 0
upstream 0
GC 0
- 0
rich 0
and 0
two 0
downstream 0
CCAAT 0
- 0
binding 0
sites 0
were 0
required 0
for 0
transactivation 0
by 0
E2 B-gene
. 0

In 0
the 0
course 0
of 0
investigating 0
the 0
mechanisms 0
by 0
which 0
OF5 B-gene
and 0
OF3 B-gene
regulated 0
CYP11A1 B-gene
transcription 0
, 0
we 0
found 0
that 0
OF5 B-gene
and 0
OF3 B-gene
bound 0
Sp1 B-gene
and 0
Sp3 B-gene
in 0
JEG 0
- 0
3 0
cells 0
. 0

In 0
contrast 0
, 0
the 0
differentiation 0
of 0
neoplastically 0
transformed 0
cells 0
does 0
not 0
repress 0
mitogenic 0
responsiveness 0
or 0
junB B-gene
or 0
c B-gene
- I-gene
fos I-gene
inducibility 0
. 0

Adipocyte 0
differentiation 0
of 0
nontransformed 0
cells 0
also 0
markedly 0
represses 0
the 0
ability 0
of 0
SRF B-gene
to 0
bind 0
to 0
the 0
junB B-gene
SRE 0
, 0
the 0
c B-gene
- I-gene
fos I-gene
SRE 0
, 0
and 0
other 0
SREs 0
, 0
as 0
determined 0
by 0
mobility 0
shift 0
and 0
gel 0
supershift 0
assays 0
, 0
without 0
affecting 0
the 0
DNA 0
binding 0
characteristics 0
of 0
the 0
nuclear 0
protein 0
SP 0
- 0
1 0
. 0

Transformation 0
blocks 0
differentiation 0
- 0
induced 0
inhibition 0
of 0
serum B-gene
response I-gene
factor I-gene
interactions 0
with 0
serum 0
response 0
elements 0
. 0

The 0
core B-gene
enzyme I-gene
is 0
homologous 0
to 0
those 0
of 0
bacteriophages 0
T3 0
, 0
T7 0
and 0
SP6 0
whereas 0
the 0
specificity 0
factor 0
shows 0
similarities 0
with 0
bacterial B-gene
sigma I-gene
factors I-gene
. 0

The 0
Cr.psbA B-gene
- I-gene
4 I-gene
ORF I-gene
contains 0
an 0
H 0
- 0
N 0
- 0
H 0
motif 0
, 0
and 0
possibly 0
a 0
GIY 0
- 0
YIG 0
motif 0
. 0

The 0
interaction 0
of 0
zf4 B-gene
- I-gene
6 I-gene
with 0
full B-gene
- I-gene
length I-gene
5 I-gene
S I-gene
RNA I-gene
was 0
far 0
more 0
sensitive 0
to 0
non 0
- 0
specific 0
competitor 0
concentration 0
than 0
was 0
the 0
zf4 B-gene
- I-gene
7:5 I-gene
7:5 I-gene
S I-gene
RNA I-gene
interaction 0
, 0
suggesting 0
that 0
finger 0
seven 0
contributes 0
to 0
both 0
affinity 0
and 0
specificity 0
in 0
this 0
protein 0
: 0
RNA 0
interaction 0
. 0

The 0
STAT B-gene
protein I-gene
accumulation 0
resulting 0
from 0
C/EBP B-gene
expression 0
was 0
tightly 0
coupled 0
to 0
the 0
morphological 0
conversion 0
of 0
fibroblasts 0
to 0
adipocytes 0
and 0
represents 0
an 0
expression 0
profile 0
identical 0
to 0
that 0
reported 0
for 0
mature 0
adipocytes 0
in 0
vivo 0
. 0

The 0
median 0
durations 0
for 0
response 0
and 0
survival 0
time 0
in 0
the 0
late 0
phase 0
II 0
trial 0
were 0
2.3 0
months 0
and 0
5.8 0
months 0
, 0
respectively 0
. 0

The 0
role 0
of 0
'scientific 0
psychiatry 0
' 0
in 0
understanding 0
patients 0
with 0
chronic 0
schizophrenia 0
or 0
severe 0
personality 0
disorder 0
. 0

Myocardial 0
antioxidant 0
enzymes 0
, 0
catalase B-gene
, 0
glutathione B-gene
peroxidase I-gene
and 0
superoxide B-gene
dismutase I-gene
, 0
in 0
the 0
MCT 0
- 0
treated 0
rats 0
were 0
not 0
different 0
compared 0
to 0
control 0
rats 0
. 0

The 0
second 0
goal 0
was 0
to 0
ascertain 0
the 0
somatotopic 0
arrangement 0
of 0
the 0
GPi 0
in 0
PD 0
. 0

These 0
overall 0
results 0
indicate 0
that 0
there 0
is 0
generally 0
one 0
PERV 0
copy 0
per 0
integration 0
site 0
. 0

The 0
present 0
investigation 0
conducted 0
in 0
a 0
population 0
of 0
258 0
dentally 0
aware 0
individuals 0
in 0
the 0
age 0
range 0
20 0
- 0
69 0
years 0
, 0
was 0
initiated 0
to 0
elucidate 0
the 0
relationship 0
between 0
tobacco 0
smoking 0
and 0
supragingival 0
calculus 0
, 0
taking 0
into 0
account 0
possible 0
confounding 0
factors 0
such 0
as 0
age 0
, 0
gender 0
, 0
oral 0
hygiene 0
and 0
gingival 0
inflammation 0
. 0

OBJECTIVE 0
: 0
To 0
determine 0
whether 0
administration 0
of 0
misoprostol 0
prevents 0
gastric 0
hemorrhage 0
in 0
healthy 0
dogs 0
treated 0
with 0
high 0
doses 0
of 0
methylprednisolone 0
sodium 0
succinate 0
( 0
MPSS 0
) 0
. 0

Patients 0
were 0
assessed 0
for 0
cardiac 0
MIBG 0
uptake 0
, 0
circulating 0
norepinephrine 0
concentration 0
, 0
LVEF 0
, 0
peak 0
Vo2 0
, 0
x 0
- 0
ray 0
cardiothoracic 0
ratio 0
, 0
M 0
- 0
mode 0
echographic 0
end 0
- 0
diastolic 0
diameter 0
and 0
right 0
- 0
sided 0
heart 0
catheterization 0
parameters 0
. 0

Nuclear 0
hormone 0
receptors 0
( 0
NRs 0
) 0
are 0
ligand 0
- 0
inducible 0
transcription 0
factors 0
that 0
mediate 0
critical 0
functions 0
in 0
many 0
species 0
. 0

These 0
cells 0
were 0
able 0
to 0
present 0
influenza 0
virus 0
particles 0
to 0
HLA B-gene
- I-gene
DR1 I-gene
- 0
restricted 0
T 0
cell 0
clones 0
. 0

Sequencing 0
of 0
zebrafish 0
( 0
Danio 0
rerio 0
) 0
bacterial 0
artificial 0
chromosome 0
and 0
P1 0
artificial 0
chromosome 0
genomic 0
clone 0
fragments 0
and 0
of 0
cDNA 0
clones 0
has 0
led 0
to 0
the 0
identification 0
of 0
five 0
new 0
loci 0
coding 0
for 0
beta 0
subunits 0
of 0
proteasomes 0
( 0
PSMB B-gene
) 0
. 0

In 0
addition 0
to 0
homologues 0
of 0
the 0
human B-gene
genes I-gene
PSMB5 I-gene
through 0
PSMB9 B-gene
, 0
two 0
new 0
genes 0
, 0
PSMB11 B-gene
and 0
PSMB12 B-gene
, 0
have 0
been 0
found 0
for 0
which 0
there 0
are 0
no 0
known 0
corresponding 0
genes 0
in 0
humans 0
. 0

It 0
applies 0
Udry 0
's 0
biosocial 0
perspective 0
, 0
which 0
attempts 0
to 0
reconcile 0
the 0
biological 0
and 0
sociological 0
models 0
of 0
premarital 0
sexual 0
and 0
reproductive 0
behaviour 0
. 0

Weight 0
and 0
height 0
z 0
- 0
scores 0
were 0
significantly 0
associated 0
with 0
BMD 0
z 0
- 0
scores 0
. 0

A 0
limited 0
sampling 0
strategy 0
was 0
used 0
based 0
on 0
a 0
bayesian 0
parameter 0
estimation 0
algorithm 0
that 0
is 0
part 0
of 0
the 0
ADAPT 0
II 0
software 0
package 0
. 0

Interaction 0
of 0
HRI B-gene
with 0
Hsc70 B-gene
was 0
required 0
for 0
the 0
transformation 0
of 0
HRI B-gene
, 0
as 0
the 0
Hsc70 B-gene
antagonist 0
clofibric 0
acid 0
inhibited 0
the 0
folding 0
of 0
HRI B-gene
into 0
a 0
mature 0
- 0
competent 0
conformation 0
. 0

The 0
amino 0
acid 0
changes 0
D206A 0
and 0
D208A 0
abolish 0
singly 0
or 0
in 0
combination 0
the 0
exonuclease 0
activity 0
in 0
vivo 0
. 0

Previous 0
experimental 0
evidence 0
had 0
indicated 0
that 0
Reg1 B-gene
might 0
target 0
Glc7 B-gene
to 0
nuclear 0
substrates 0
such 0
as 0
the 0
Snf1 B-gene
kinase I-gene
complex I-gene
. 0

In 0
the 0
budding 0
yeast 0
, 0
Saccharomyces 0
cerevisiae 0
, 0
replicators 0
can 0
function 0
outside 0
the 0
chromosome 0
as 0
autonomously 0
replicating 0
sequence 0
( 0
ARS 0
) 0
elements 0
; 0
however 0
, 0
within 0
chromosome 0
III 0
, 0
certain 0
ARSs 0
near 0
the 0
transcriptionally 0
silent 0
HML B-gene
locus I-gene
show 0
no 0
replication 0
origin 0
activity 0
. 0

These 0
results 0
suggest 0
that 0
, 0
for 0
the 0
HML B-gene
ARS 0
cluster 0
( 0
ARS303 B-gene
, 0
ARS320 B-gene
, 0
and 0
ARS302 B-gene
) 0
, 0
inactivity 0
of 0
origins 0
is 0
independent 0
of 0
local 0
transcriptional 0
silencing 0
, 0
even 0
though 0
origins 0
and 0
silencers 0
share 0
key 0
cis 0
- 0
and 0
trans 0
- 0
acting 0
components 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
demonstrate 0
that 0
expression 0
of 0
TD B-gene
- I-gene
IkappaBalpha I-gene
blocked 0
phorbol 0
myristate 0
acetate B-gene
- I-gene
phytohemagglutinin I-gene
or 0
tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
- 0
induced 0
IkappaBalpha B-gene
gene I-gene
transcription 0
and 0
abolished 0
NF B-gene
- I-gene
kappaB I-gene
DNA 0
binding 0
activity 0
, 0
due 0
to 0
the 0
continued 0
cytoplasmic 0
sequestration 0
of 0
RelA B-gene
( 0
p65 B-gene
) 0
by 0
TD B-gene
- I-gene
IkappaBalpha I-gene
. 0

( 0
i 0
) 0
Complete 0
Grb10 B-gene
expression 0
from 0
cDNA 0
with 0
an 0
ecdysone 0
- 0
regulated 0
transient 0
expression 0
system 0
stimulated 0
PDGF B-gene
- I-gene
BB I-gene
- 0
, 0
IGF B-gene
- I-gene
I I-gene
, 0
and 0
insulin B-gene
- 0
but 0
not 0
epidermal B-gene
growth I-gene
factor I-gene
( 0
EGF B-gene
) 0
- 0
induced 0
DNA 0
synthesis 0
in 0
an 0
ecdysone 0
dose 0
- 0
responsive 0
fashion 0
. 0

The 0
analysis 0
of 0
two 0
distinct 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
pathways 0
shows 0
that 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
- 0
Jun B-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
activation 0
, 0
resulting 0
in 0
the 0
phosphorylation 0
of 0
ATF B-gene
- I-gene
2 I-gene
, 0
c B-gene
- I-gene
Jun I-gene
, 0
and 0
JunD B-gene
, 0
is 0
required 0
not 0
only 0
for 0
the 0
IL B-gene
- I-gene
1 I-gene
- 0
but 0
also 0
for 0
the 0
TPA 0
- 0
dependent 0
induction 0
, 0
while 0
the 0
extracellular B-gene
signal I-gene
- I-gene
related I-gene
kinase I-gene
1 I-gene
( 0
ERK B-gene
- I-gene
1 I-gene
) 0
and 0
ERK B-gene
- I-gene
2 I-gene
activation 0
is 0
involved 0
in 0
the 0
TPA 0
- 0
but 0
not 0
in 0
the 0
IL B-gene
- I-gene
1 I-gene
- 0
dependent 0
stimulation 0
of 0
the 0
uPA B-gene
enhancer I-gene
. 0

CONCLUSIONS 0
: 0
In 0
healthy 0
individuals 0
, 0
whole 0
body 0
insulin B-gene
sensitivity 0
is 0
related 0
, 0
or 0
`` 0
coupled 0
, 0
`` 0
to 0
the 0
anaerobic 0
threshold 0
. 0

Interdomain 0
signaling 0
in 0
a 0
two 0
- 0
domain 0
fragment 0
of 0
the 0
human B-gene
glucocorticoid I-gene
receptor I-gene
. 0

In 0
contrast 0
, 0
the 0
xtRNA B-gene
( 0
Sec B-gene
) 0
gene 0
needs 0
the 0
binding 0
of 0
the 0
seven 0
Staf B-gene
zinc I-gene
fingers I-gene
, 0
but 0
not 0
Oct B-gene
- I-gene
1 I-gene
, 0
for 0
optimal 0
transcriptional 0
capacity 0
. 0

Collectively 0
, 0
these 0
results 0
show 0
that 0
the 0
differential 0
utilization 0
of 0
Staf B-gene
zinc I-gene
finger I-gene
1 I-gene
represents 0
a 0
new 0
, 0
critical 0
determinant 0
of 0
the 0
transcriptional 0
activation 0
mechanism 0
for 0
the 0
Xenopus B-gene
tRNA I-gene
( 0
Sec B-gene
) 0
and 0
human B-gene
U6 I-gene
snRNA I-gene
genes I-gene
. 0

In 0
B 0
cells 0
, 0
HEF1 B-gene
is 0
phosphorylated 0
by 0
a 0
cytoskeleton 0
- 0
dependent 0
mechanism 0
that 0
is 0
triggered 0
by 0
integrin B-gene
ligation 0
. 0

The 0
calcitonin B-gene
- 0
induced 0
tyrosine 0
phosphorylation 0
of 0
HEF1 B-gene
increased 0
in 0
a 0
time 0
- 0
and 0
dose 0
- 0
dependent 0
manner 0
. 0

Independent 0
protrudor 0
muscle 0
stimulation 0
increased 0
VI 0
, 0
max 0
( 0
peak 0
increase 0
61 0
% 0
, 0
P 0
< 0
0.05 0
) 0
, 0
did 0
not 0
change 0
Pcrit 0
, 0
and 0
decreased 0
Rn 0
( 0
peak 0
decrease 0
of 0
41 0
% 0
, 0
P 0
< 0
0.05 0
) 0
. 0

We 0
report 0
the 0
construction 0
of 0
an 0
approximately 0
1.7 0
- 0
Mb 0
sequence 0
- 0
ready 0
YAC/BAC 0
clone 0
contig 0
of 0
8p22 0
- 0
p23 0
. 0

The 0
human B-gene
RAD30B I-gene
and 0
mouse B-gene
Rad30b I-gene
mRNA I-gene
transcripts I-gene
, 0
like 0
many 0
repair 0
proteins 0
, 0
are 0
highly 0
expressed 0
in 0
the 0
testis 0
. 0

Analysis 0
of 0
the 0
mouse B-gene
STAP I-gene
gene I-gene
isolated 0
from 0
the 0
genomic 0
library 0
revealed 0
that 0
the 0
STAP B-gene
gene I-gene
spans 0
a 0
region 0
of 0
over 0
11 0
kb 0
and 0
comprises 0
eight 0
exons 0
. 0

A 0
reduced 0
matrix 0
distribution 0
and 0
enhanced 0
cell 0
density 0
were 0
observed 0
as 0
the 0
biofilm 0
aged 0
. 0

After 0
10 0
months 0
of 0
treatment 0
with 0
the 0
conjugated 0
estrogen 0
, 0
both 0
his 0
height 0
and 0
weight 0
showed 0
improvement 0
, 0
while 0
his 0
bone 0
mineral 0
density 0
and 0
bone 0
age 0
were 0
increased 0
. 0

Viscosity 0
experiments 0
on 0
the 0
catalytic 0
fragment 0
kinase 0
reaction 0
demonstrated 0
that 0
the 0
chemical 0
( 0
phosphoryl 0
transfer 0
) 0
step 0
had 0
a 0
reduced 0
rate 0
. 0

Velocity 0
sedimentation 0
, 0
cross 0
- 0
linking 0
, 0
and 0
immunoprecipitation 0
analyses 0
of 0
detergent 0
- 0
solubilized 0
rat 0
brain 0
revealed 0
that 0
the 0
32 0
and 0
34 0
kDa 0
polypeptides 0
reside 0
within 0
heterotetramers 0
. 0

In 0
vitro 0
expression 0
levels 0
of 0
the 0
different 0
plasmids 0
differed 0
by 0
as 0
much 0
as 0
tenfold 0
. 0

In 0
EEG 0
only 0
single 0
slow 0
waves 0
above 0
left 0
temporal 0
region 0
were 0
revealed 0
. 0

Molecular 0
characterization 0
of 0
type 0
- 0
specific 0
capsular 0
polysaccharide 0
biosynthesis 0
genes 0
of 0
Streptococcus 0
agalactiae 0
type 0
Ia 0
. 0

( 0
1998 0
) 0
FASEB 0
J 0
. 0

IL B-gene
- I-gene
1beta I-gene
( 0
10 0
ng/ml 0
) 0
drastically 0
increased 0
both 0
PDGFalphaR B-gene
and 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
delta I-gene
( 0
C/EBPdelta B-gene
) 0
mRNA 0
levels 0
in 0
a 0
time 0
dependent 0
manner 0
. 0

The 0
recruitment 0
of 0
constitutively 0
phosphorylated 0
p185 B-gene
( 0
neu B-gene
) 0
and 0
the 0
activated 0
mitogenic 0
pathway 0
proteins 0
to 0
this 0
membrane 0
- 0
microfilament 0
interaction 0
site 0
provides 0
a 0
physical 0
model 0
for 0
integrating 0
the 0
assembly 0
of 0
the 0
mitogenic 0
pathway 0
with 0
the 0
transmission 0
of 0
growth 0
factor 0
signal 0
to 0
the 0
cytoskeleton 0
. 0

Transient 0
tyrosine 0
phosphorylation 0
of 0
Crk B-gene
in 0
fibroblast B-gene
growth I-gene
factor I-gene
- I-gene
2 I-gene
- 0
stimulated 0
endothelial 0
cells 0
was 0
dependent 0
on 0
the 0
juxtamembrane 0
tyrosine 0
residue 0
463 0
in 0
FGFR B-gene
- I-gene
1 I-gene
, 0
and 0
a 0
Crk B-gene
SH2 B-gene
domain I-gene
precipitated 0
FGFR B-gene
- I-gene
1 I-gene
via 0
phosphorylated 0
Tyr 0
- 0
463 0
, 0
indicating 0
direct 0
complex 0
formation 0
between 0
Crk B-gene
and 0
FGFR B-gene
- I-gene
1 I-gene
. 0

ECG 0
- 0
gated 0
myocardial 0
Technetium 0
- 0
99m 0
sestamibi 0
SPECT 0
is 0
a 0
useful 0
technique 0
to 0
measure 0
myocardial 0
perfusion 0
and 0
function 0
simultaneously 0
. 0

Role 0
of 0
the 0
3 0
' 0
untranslated 0
region 0
of 0
baculovirus B-gene
p10 I-gene
mRNA I-gene
in 0
high 0
- 0
level 0
expression 0
of 0
foreign 0
genes 0
. 0

The 0
intron 0
RNA 0
consists 0
of 0
2492 0
nucleotides 0
which 0
can 0
be 0
folded 0
into 0
a 0
secondary 0
structure 0
with 0
all 0
the 0
expected 0
sequence 0
motifs 0
of 0
subgroup 0
- 0
IIA1 0
introns 0
( 0
Michel 0
et 0
al 0
. 0

The 0
intron 0
is 0
capable 0
of 0
splicing 0
despite 0
the 0
fact 0
that 0
both 0
the 0
EBS1/IBS1 B-gene
and 0
the 0
EBS1/IBS1 I-gene

The 0
Trk/Nerve B-gene
Growth I-gene
Factor I-gene
receptor I-gene
mediates 0
the 0
rapid 0
activation 0
of 0
a 0
number 0
of 0
intracellular 0
signaling 0
proteins 0
, 0
including 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
( 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
) 0
. 0

The 0
controversy 0
of 0
significance 0
testing 0
: 0
misconceptions 0
and 0
alternatives 0
. 0

Chemical 0
uptake 0
into 0
human 0
stratum 0
corneum 0
in 0
vivo 0
from 0
volatile 0
and 0
non 0
- 0
volatile 0
solvents 0
. 0

Like 0
DNA 0
binding 0
, 0
transcriptional 0
enhancement 0
required 0
amino 0
- 0
terminally 0
located 0
basic 0
amino 0
acid 0
residues 0
but 0
not 0
the 0
carboxyl 0
- 0
terminal 0
portion 0
of 0
Hap46 B-gene
known 0
to 0
participate 0
in 0
hsp70 B-gene
interaction 0
. 0

We 0
have 0
tested 0
the 0
function 0
of 0
two 0
potential 0
NF B-gene
- I-gene
kappaB I-gene
- I-gene
like I-gene
sites I-gene
present 0
in 0
the 0
PAI B-gene
- I-gene
2 I-gene
proximal I-gene
promoter I-gene
for 0
responsiveness 0
to 0
TNFalpha B-gene
using 0
chloramphenicol B-gene
acetyl I-gene
transferase I-gene
reporter I-gene
gene I-gene
deletion 0
and 0
mutation 0
analyses 0
. 0

N 0
- 0
terminal 0
sequence 0
analysis 0
and 0
NMR 0
measurements 0
revealed 0
that 0
this 0
fragment 0
originates 0
from 0
the 0
C 0
- 0
terminal 0
80 0
residues 0
of 0
MBF1 B-gene
and 0
form 0
a 0
well 0
structured 0
C 0
- 0
terminal 0
domain 0
of 0
MBF1 B-gene
, 0
MBF1CTD B-gene
. 0

The 0
nucleosomal 0
response 0
associated 0
with 0
immediate B-gene
- I-gene
early I-gene
gene I-gene
induction 0
is 0
mediated 0
via 0
alternative 0
MAP B-gene
kinase I-gene
cascades I-gene
: 0
MSK1 B-gene
as 0
a 0
potential 0
histone B-gene
H3/HMG I-gene
H3/HMG I-gene
- I-gene
14 I-gene
kinase 0
. 0

The 0
arrangement 0
of 0
these 0
cutoff 0
- 0
levels 0
leads 0
to 0
a 0
sensitivity 0
of 0
85 0
% 0
at 0
a 0
specificity 0
of 0
55 0
% 0
for 0
Protein B-gene
S100 I-gene
when 0
measured 0
by 0
RIA 0
, 0
and 0
to 0
a 0
sensitivity 0
of 0
77 0
% 0
at 0
a 0
specificity 0
of 0
61 0
% 0
when 0
measured 0
by 0
LIA 0
. 0

272 0
, 0
1904 0
] 0
. 0

Using 0
16 0
strains 0
of 0
C. 0
trachomatis 0
in 0
triplicate 0
assays 0
, 0
we 0
found 0
the 0
RT 0
- 0
PCR 0
method 0
consistently 0
more 0
sensitive 0
than 0
the 0
conventional 0
technique 0
for 0
all 0
eight 0
antimicrobials 0
tested 0
, 0
with 0
resultant 0
MICs 0
determined 0
by 0
RT 0
- 0
PCR 0
ranging 0
from 0
1.6 0
- 0
fold 0
higher 0
( 0
erythromycin 0
) 0
to 0
> 0
/=195 0
- 0
fold 0
higher 0
( 0
amoxicillin 0
) 0
. 0

Null 0
alleles 0
of 0
SAS4 B-gene
and 0
SAS5 B-gene
bypassed 0
the 0
role 0
of 0
the 0
Abf1p B-gene
binding I-gene
site I-gene
of 0
the 0
HMR B-gene
- I-gene
E I-gene
silencer I-gene
but 0
not 0
the 0
role 0
of 0
the 0
ACS B-gene
or 0
Rap1p B-gene
binding I-gene
site I-gene
. 0

Recent 0
molecular 0
analysis 0
has 0
revealed 0
that 0
the 0
S B-gene
locus I-gene
is 0
highly 0
polymorphic 0
and 0
contains 0
several 0
genes 0
, 0
i.e. 0
, 0
SLG B-gene
, 0
SRK B-gene
, 0
the 0
as 0
- 0
yet 0
- 0
unidentified 0
pollen B-gene
S I-gene
gene I-gene
( I-gene
s I-gene
) I-gene
, 0
and 0
other 0
linked 0
genes 0
. 0

A 0
cDNA 0
encoding 0
a 0
putative 0
RNA B-gene
and/or I-gene
DNA I-gene
helicase I-gene
has 0
been 0
isolated 0
from 0
Arabidopsis 0
thaliana 0
cDNA 0
libraries 0
. 0

In 0
vivo 0
, 0
MyoD B-gene
requires 0
this 0
tryptophan 0
motif 0
to 0
evoke 0
chromatin 0
remodeling 0
in 0
the 0
Myogenin B-gene
promoter I-gene
and 0
to 0
activate 0
Myogenin B-gene
transcription 0
. 0

RESULTS 0
: 0
256 0
Periods 0
of 0
TTP 0
or 0
PUNP 0
were 0
reported 0
by 0
men 0
and 0
174 0
by 0
women 0
. 0

Feed 0
intake 0
and 0
BW 0
gains 0
were 0
decreased 0
( 0
P 0
< 0
0.05 0
) 0
by 0
dietary 0
treatments 0
containing 0
M 0
. 0

The 0
N 0
terminus 0
of 0
beta 0
( 0
95 0
kDa 0
) 0
corresponds 0
to 0
alpha 0
with 0
the 0
integrase B-gene
domain I-gene
attached 0
to 0
the 0
C 0
terminus 0
( 0
32 0
kDa 0
) 0
. 0

Skn B-gene
- I-gene
1a I-gene
lacking 0
the 0
C 0
- 0
terminal 0
region 0
completely 0
lost 0
transactivation 0
ability 0
, 0
irrespective 0
of 0
the 0
promoter 0
tested 0
, 0
and 0
was 0
able 0
to 0
block 0
transactivation 0
by 0
normal 0
Skn B-gene
- I-gene
1a I-gene
in 0
competition 0
assays 0
. 0

In 0
early 0
Xenopus 0
embryos 0
, 0
the 0
transforming B-gene
growth I-gene
factor I-gene
- I-gene
beta I-gene
member 0
activin B-gene
induces 0
the 0
gene B-gene
Mix.2 I-gene
by 0
stimulating 0
the 0
formation 0
of 0
a 0
multiprotein 0
complex 0
, 0
activin B-gene
- I-gene
responsive I-gene
factor I-gene
( 0
ARF B-gene
) 0
. 0

To 0
further 0
characterize 0
the 0
structure 0
and 0
evolutionary 0
synthesis 0
of 0
the 0
CMT1A 0
- 0
REP 0
repeat 0
, 0
fluorescent 0
in 0
situ 0
hybridization 0
( 0
FISH 0
) 0
analysis 0
and 0
heterologous 0
PCR 0
- 0
based 0
assays 0
were 0
carried 0
out 0
for 0
a 0
series 0
of 0
primates 0
. 0

Natl 0
. 0

In 0
the 0
face 0
of 0
the 0
outbreak 0
, 0
there 0
was 0
a 0
delay 0
before 0
vaccination 0
was 0
able 0
to 0
stop 0
deaths 0
. 0

Here 0
we 0
show 0
that 0
a 0
novel 0
isoform 0
of 0
Rapl B-gene
GTPase I-gene
- I-gene
activating I-gene
protein I-gene
, 0
called 0
rap1GAPII B-gene
, 0
binds 0
specifically 0
to 0
the 0
alpha 0
- 0
subunits 0
of 0
the 0
G B-gene
( I-gene
i I-gene
) I-gene
family I-gene
of 0
heterotrimeric B-gene
G I-gene
- I-gene
proteins I-gene
. 0

The 0
B 0
- 0
oligomer 0
of 0
pertussis B-gene
toxin I-gene
deactivates 0
CC B-gene
chemokine I-gene
receptor I-gene
5 I-gene
and 0
blocks 0
entry 0
of 0
M 0
- 0
tropic 0
HIV 0
- 0
1 0
strains 0
. 0

Cross 0
- 0
linking 0
the 0
B B-gene
cell I-gene
Ag I-gene
receptor I-gene
( 0
BCR B-gene
) 0
to 0
surface B-gene
Fc I-gene
receptors I-gene
for 0
IgG B-gene
( 0
Fc B-gene
gamma I-gene
R I-gene
) 0
inhibits 0
G1 0
- 0
to 0
- 0
S 0
progression 0
; 0
the 0
mechanism 0
by 0
which 0
this 0
occurs 0
is 0
not 0
completely 0
known 0
. 0

Cross 0
- 0
linking 0
the 0
B B-gene
cell I-gene
Ag I-gene
receptor I-gene
( 0
BCR B-gene
) 0
to 0
surface B-gene
Fc I-gene
receptors I-gene
for 0
IgG B-gene
( 0
Fc B-gene
gamma I-gene
R I-gene
) 0
inhibits 0
G1 0
- 0
to 0
- 0
S 0
progression 0
; 0
the 0
mechanism 0
by 0
which 0
this 0
occurs 0
is 0
not 0
completely 0
known 0
. 0

TRAF2 B-gene
is 0
a 0
potent 0
activator 0
of 0
a 0
95 B-gene
- I-gene
kDa I-gene
serine/threonine I-gene
kinase I-gene
termed 0
germinal B-gene
center I-gene
kinase I-gene
related I-gene
( 0
GCKR B-gene
, 0
also 0
referred 0
to 0
as 0
KHS1 B-gene
) 0
, 0
which 0
signals 0
activation 0
of 0
the 0
SAPK B-gene
pathway 0
. 0

An 0
activation 0
- 0
responsive 0
element 0
in 0
single B-gene
C I-gene
motif I-gene
- I-gene
1/lymphotactin I-gene
promoter 0
is 0
a 0
site 0
of 0
constitutive 0
and 0
inducible 0
DNA 0
- 0
protein 0
interactions 0
involving 0
nuclear 0
factor 0
of 0
activated 0
T 0
cell 0
. 0

Cytokine 0
- 0
induced 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
DNA 0
binding 0
activity 0
, 0
RelA B-gene
nuclear 0
translocation 0
, 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
degradation 0
, 0
I B-gene
kappa I-gene
B I-gene
serine 0
32 0
phosphorylation 0
, 0
and 0
I B-gene
kappa I-gene
B I-gene
kinase I-gene
( 0
IKK B-gene
) 0
activity 0
were 0
blocked 0
by 0
curcumin 0
treatment 0
. 0

A 0
portion 0
of 0
p193 B-gene
is 0
nuclear 0
and 0
localizes 0
to 0
the 0
mitotic 0
spindle 0
. 0

The 0
main 0
issues 0
are 0
the 0
need 0
to 0
explain 0
a 0
number 0
of 0
still 0
unknown 0
mechanisms 0
, 0
to 0
determine 0
which 0
`` 0
natural 0
diet 0
'' 0
carries 0
the 0
minimum 0
coronary 0
risk 0
and 0
whether 0
`` 0
new 0
'' 0
foods 0
produced 0
by 0
modern 0
technology 0
are 0
really 0
needed 0
to 0
contrast 0
this 0
epidemic 0
. 0

Cotransfection 0
of 0
the 0
coactivator 0
CREB B-gene
- I-gene
binding I-gene
protein I-gene
relieved 0
the 0
transcriptional 0
repression 0
of 0
PPARalphawt B-gene
by 0
PPARalphatr B-gene
, 0
suggesting 0
that 0
the 0
dominant 0
negative 0
effect 0
of 0
PPARalphatr B-gene
might 0
occur 0
through 0
competition 0
for 0
essential 0
coactivators 0
. 0

SF B-gene
- I-gene
1 I-gene
does 0
not 0
have 0
an 0
N 0
- 0
terminal 0
AF1 0
domain 0
. 0

To 0
estimate 0
the 0
locations 0
of 0
sources 0
with 0
the 0
TF 0
- 0
MUSIC 0
algorithm 0
, 0
we 0
first 0
set 0
the 0
target 0
region 0
on 0
the 0
spectrogram 0
of 0
the 0
somatosensory 0
responses 0
. 0

We 0
discuss 0
these 0
results 0
in 0
terms 0
of 0
the 0
influence 0
that 0
time 0
and 0
nutritional 0
constraints 0
have 0
on 0
odonate 0
development 0
patterns 0
and 0
fitness 0
. 0

OBJECTIVE 0
: 0
1998 0
Surveillance 0
, 0
Epidemiology 0
, 0
and 0
End 0
Results 0
( 0
SEER 0
) 0
data 0
estimate 0
an 0
83.1 0
% 0
5 0
- 0
year 0
survival 0
rate 0
for 0
corpus 0
uteri 0
adenocarcinoma 0
FIGO 0
stage 0
II 0
. 0

A 0
novel 0
Drosophila B-gene
A I-gene
kinase I-gene
anchor I-gene
protein I-gene
, 0
Drosophila B-gene
A I-gene
kinase I-gene
anchor I-gene
protein I-gene
200 I-gene
( 0
DAKAP200 B-gene
) 0
, 0
is 0
predicted 0
to 0
be 0
involved 0
in 0
routing 0
, 0
mediating 0
, 0
and 0
integrating 0
signals 0
carried 0
by 0
cAMP 0
, 0
Ca 0
( 0
2+ 0
) 0
, 0
and 0
diacylglycerol 0
( 0
Li 0
, 0
Z. 0
, 0
Rossi 0
, 0
E 0
. 0

In 0
vitro 0
transcription 0
results 0
indicate 0
that 0
this 0
5 0
' 0
structure 0
functions 0
in 0
the 0
attenuation 0
mechanism 0
, 0
since 0
deletion 0
of 0
the 0
stem 0
- 0
loop 0
caused 0
an 0
increase 0
in 0
transcription 0
readthrough 0
. 0

A 0
5 0
' 0
RNA 0
stem 0
- 0
loop 0
participates 0
in 0
the 0
transcription 0
attenuation 0
mechanism 0
that 0
controls 0
expression 0
of 0
the 0
Bacillus B-gene
subtilis I-gene
trpEDCFBA I-gene
operon I-gene
. 0

Single 0
- 0
alanine 0
- 0
substitution 0
mutations 0
had 0
minimal 0
, 0
if 0
any 0
, 0
effects 0
on 0
S 0
- 0
induced 0
cell 0
- 0
to 0
- 0
cell 0
fusion 0
. 0

Furthermore 0
, 0
we 0
demonstrate 0
that 0
transcription 0
from 0
the 0
MMTV B-gene
5 I-gene
' I-gene
LTR I-gene
is 0
highly 0
active 0
in 0
the 0
absence 0
of 0
Stat5a B-gene
, 0
a 0
transcription 0
factor 0
that 0
had 0
been 0
shown 0
previously 0
to 0
be 0
required 0
for 0
transcription 0
from 0
the 0
MMTV B-gene
LTR I-gene
. 0

Regional 0
insertional 0
mutagenesis 0
of 0
specific 0
genes 0
on 0
the 0
CIC5F11/CIC2B9 B-gene
locus 0
of 0
Arabidopsis 0
thaliana 0
chromosome 0
5 0
using 0
the 0
CIC5F11/CIC2B9 I-gene

RESULTS 0
: 0
CK B-gene
- 0
MB B-gene
elevation 0
was 0
detected 0
in 0
313 0
patients 0
( 0
18.7 0
% 0
) 0
, 0
with 0
1 0
- 0
3x 0
in 0
12.8 0
% 0
, 0
3 0
- 0
5x 0
in 0
3.5 0
% 0
and 0
> 0
5x 0
normal 0
in 0
2.4 0
% 0
of 0
patients 0
. 0

Thus 0
, 0
NART 0
- 0
R 0
performance 0
may 0
not 0
be 0
a 0
valid 0
estimate 0
of 0
baseline 0
IQ 0
for 0
patients 0
with 0
neurologic 0
disorders 0
with 0
suspected 0
language 0
impairment 0
. 0

Activated 0
areas 0
have 0
been 0
identified 0
by 0
means 0
of 0
cross 0
- 0
correlation 0
analysis 0
. 0

Natural 0
Haemophilus 0
influenzae 0
type 0
b 0
capsular 0
polysaccharide 0
antibodies 0
in 0
412 0
infants 0
and 0
children 0
from 0
West 0
Africa 0
( 0
Burkina 0
- 0
Faso 0
) 0
and 0
France 0
: 0
a 0
cross 0
- 0
sectional 0
serosurvey 0
. 0

In 0
this 0
study 0
, 0
we 0
identified 0
Sp1 B-gene
and 0
Sp3 B-gene
as 0
major 0
factors 0
binding 0
to 0
the 0
Sp1 B-gene
sites I-gene
of 0
the 0
p21/WAF1/Cip1 B-gene
promoter 0
in 0
MG63 0
cells 0
through 0
electrophoretic 0
mobility 0
shift 0
assays 0
and 0
showed 0
that 0
TSA 0
treatment 0
did 0
not 0
change 0
their 0
binding 0
activities 0
. 0

Galoyan 0
has 0
summarized 0
the 0
results 0
of 0
his 0
discovery 0
of 0
cardioactive 0
neurohormones 0
. 0

To 0
study 0
the 0
regulation 0
of 0
its 0
expression 0
, 0
the 0
human B-gene
aldehyde I-gene
reductase I-gene
gene I-gene
and 0
promoter 0
were 0
cloned 0
and 0
characterized 0
. 0

Immunohistochemical 0
staining 0
with 0
MIB B-gene
- I-gene
1 I-gene
and 0
p53 B-gene
antibodies I-gene
showed 0
low 0
( 0
< 0
1 0
% 0
) 0
and 0
negative 0
reaction 0
. 0

The 0
C2C B-gene
- 0
Prx B-gene
is 0
encoded 0
as 0
a 0
preprotein 0
of 0
273 0
amino 0
acids 0
containing 0
a 0
putative 0
chloroplast 0
- 0
targeting 0
signal 0
of 0
65 0
amino 0
acids 0
at 0
its 0
N 0
- 0
terminus 0
. 0

Immediately 0
before 0
surgery 0
patients 0
received 0
either 0
intravenous 0
hydrocortisone 0
100 0
mg 0
or 0
placebo 0
in 0
random 0
, 0
double 0
- 0
blind 0
order 0
. 0

A 0
tyrosine 0
- 0
based 0
sorting 0
signal 0
in 0
the 0
beta2 B-gene
integrin I-gene
cytoplasmic I-gene
domain I-gene
mediates 0
its 0
recycling 0
to 0
the 0
plasma 0
membrane 0
and 0
is 0
required 0
for 0
ligand 0
- 0
supported 0
migration 0
. 0

The 0
injection 0
of 0
XDRP1 B-gene
protein I-gene
into 0
fertilized 0
Xenopus 0
eggs 0
blocked 0
embryonic 0
cell 0
division 0
. 0

Using 0
transgenic 0
Xenopus 0
embryos 0
, 0
we 0
demonstrate 0
that 0
the 0
integrity 0
of 0
these 0
two 0
sequences 0
is 0
necessary 0
for 0
correct 0
spatial 0
expression 0
of 0
a 0
Xbra2 B-gene
promoter I-gene
- I-gene
driven I-gene
reporter I-gene
gene I-gene
. 0

In 0
order 0
to 0
screen 0
for 0
such 0
cofactors 0
, 0
we 0
have 0
used 0
a 0
transcriptionally 0
inactive 0
mutant 0
of 0
Xenopus B-gene
MEF2D I-gene
in 0
a 0
yeast 0
two 0
- 0
hybrid 0
screen 0
. 0

NuA4 B-gene
has 0
an 0
apparent 0
molecular 0
mass 0
of 0
1.3 0
MDa 0
. 0

ATF1 B-gene
transcription 0
is 0
negatively 0
regulated 0
by 0
unsaturated 0
fatty 0
acids 0
and 0
oxygen 0
. 0

Two 0
patients 0
with 0
recurrent 0
tumors 0
had 0
high 0
S 0
- 0
phase 0
fractions 0
both 0
on 0
the 0
first 0
resected 0
specimens 0
and 0
at 0
the 0
time 0
of 0
the 0
second 0
operation 0
. 0

Mutation 0
of 0
TTF B-gene
- I-gene
1 I-gene
- I-gene
binding I-gene
sites I-gene
( I-gene
TBE I-gene
) I-gene
1 I-gene
, I-gene
3 I-gene
, I-gene
and I-gene
4 I-gene
in 0
combination 0
markedly 0
decreased 0
transcriptional 0
activity 0
of 0
SP B-gene
- I-gene
A I-gene
promoter 0
- 0
chloramphenicol B-gene
acetyltransferase I-gene
constructs 0
containing 0
SP B-gene
- I-gene
A I-gene
gene I-gene
sequences 0
from 0
- 0
256 0
to 0
+45 0
. 0

Insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
- I-gene
I I-gene
induces 0
bcl B-gene
- I-gene
2 I-gene
promoter I-gene
through 0
the 0
transcription 0
factor 0
cAMP B-gene
- I-gene
response I-gene
element I-gene
- I-gene
binding I-gene
protein I-gene
. 0

Synthesis 0
of 0
antisense 0
RNA 0
and 0
S 0
phase 0
- 0
dependent 0
binding 0
of 0
E2F B-gene
complexes I-gene
in 0
intron 0
1 0
. 0

Identification 0
of 0
eotaxin B-gene
- I-gene
3 I-gene
will 0
further 0
promote 0
our 0
understanding 0
of 0
the 0
control 0
of 0
eosinophil 0
trafficking 0
and 0
other 0
CCR3 B-gene
- 0
mediated 0
biological 0
phenomena 0
. 0

NF B-gene
- I-gene
kappaB I-gene
plays 0
a 0
critical 0
role 0
in 0
activation 0
of 0
HIV 0
- 0
1 0
gene 0
expression 0
by 0
cytokines 0
and 0
other 0
stimuli 0
, 0
but 0
the 0
signal 0
transduction 0
pathways 0
that 0
regulate 0
the 0
switch 0
from 0
latent 0
to 0
productive 0
infection 0
have 0
not 0
been 0
defined 0
. 0

These 0
studies 0
suggest 0
that 0
MAPK B-gene
acts 0
by 0
stimulating 0
AP B-gene
- I-gene
1 I-gene
and 0
a 0
subsequent 0
physical 0
and 0
functional 0
interaction 0
of 0
AP B-gene
- I-gene
1 I-gene
with 0
NF B-gene
- I-gene
kappaB I-gene
, 0
resulting 0
in 0
a 0
complex 0
that 0
synergistically 0
transactivates 0
the 0
HIV B-gene
- I-gene
1 I-gene
LTR I-gene
. 0

ERK B-gene
MAP B-gene
kinase I-gene
links 0
cytokine 0
signals 0
to 0
activation 0
of 0
latent 0
HIV 0
- 0
1 0
infection 0
by 0
stimulating 0
a 0
cooperative 0
interaction 0
of 0
AP B-gene
- I-gene
1 I-gene
and 0
NF B-gene
- I-gene
kappaB I-gene
. 0

A 0
human 0
nuclear 0
- 0
localized 0
chaperone 0
that 0
regulates 0
dimerization 0
, 0
DNA 0
binding 0
, 0
and 0
transcriptional 0
activity 0
of 0
bZIP B-gene
proteins I-gene
. 0

Clinical 0
differentiation 0
of 0
patients 0
with 0
mild 0
diplegic 0
cerebral 0
palsy 0
( 0
CP 0
) 0
and 0
idiopathic 0
toe 0
walking 0
( 0
ITW 0
) 0
can 0
be 0
difficult 0
. 0

Sputum B-gene
IL I-gene
- I-gene
8 I-gene
and 0
MPO B-gene
were 0
significantly 0
increased 0
after 0
BPT 0
in 0
both 0
TDI 0
- 0
and 0
grain 0
dust 0
- 0
asthma 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Montelukast 0
reduces 0
airway 0
eosinophilic 0
inflammation 0
in 0
asthma 0
: 0
a 0
randomized 0
, 0
controlled 0
trial 0
. 0

Treatment 0
of 0
unstable 0
angina 0
: 0
role 0
of 0
antithrombotic 0
therapy 0
. 0

Here 0
, 0
we 0
demonstrate 0
that 0
kinase 0
- 0
dead 0
but 0
not 0
wild 0
- 0
type 0
forms 0
of 0
Fyn B-gene
, 0
Lck B-gene
, 0
and 0
ZAP B-gene
- I-gene
70 I-gene
block 0
70Z 0
Cbl B-gene
- 0
mediated 0
NFAT B-gene
activation 0
. 0

Substitutions 0
of 0
region 0
I 0
with 0
synthetic 0
sequences 0
showed 0
that 0
no 0
specific 0
sequence 0
but 0
rather 0
repeats 0
of 0
three 0
or 0
more 0
consecutive 0
adenines 0
or 0
thymines 0
, 0
without 0
interruption 0
by 0
guanine 0
or 0
cytosine 0
, 0
are 0
required 0
for 0
the 0
ARS 0
activity 0
. 0

In 0
Saccharomyces 0
cerevisiae 0
, 0
PHO85 B-gene
encodes 0
a 0
cyclin B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
Cdk B-gene
) 0
catalytic 0
subunit 0
with 0
multiple 0
regulatory 0
roles 0
thought 0
to 0
be 0
specified 0
by 0
association 0
with 0
different 0
cyclin B-gene
partners 0
( 0
Pcls B-gene
) 0
. 0

Mutants 0
with 0
mild 0
lace B-gene
alleles I-gene
grow 0
to 0
become 0
adults 0
with 0
multiple 0
aberrant 0
morphologies 0
in 0
the 0
appendages 0
, 0
compound 0
eye 0
, 0
and 0
bristles 0
. 0

In 0
fact 0
, 0
SPT B-gene
activity 0
in 0
the 0
fly 0
expressing 0
epitope 0
- 0
tagged 0
Lace B-gene
was 0
absorbed 0
by 0
epitope 0
- 0
specific 0
antibody 0
. 0

Mutations 0
of 0
the 0
RET B-gene
gene I-gene
, 0
encoding 0
a 0
receptor B-gene
tyrosine I-gene
kinase I-gene
, 0
have 0
been 0
associated 0
with 0
the 0
inherited 0
cancer 0
syndromes 0
MEN 0
2A 0
and 0
MEN 0
2B 0
. 0

These 0
results 0
show 0
that 0
targeting 0
of 0
Ras B-gene
- 0
GAP B-gene
could 0
represent 0
a 0
novel 0
anticancer 0
approach 0
. 0

EB B-gene
- I-gene
1 I-gene
, 0
a 0
tyrosine B-gene
kinase I-gene
signal I-gene
transduction I-gene
gene I-gene
, 0
is 0
transcriptionally 0
activated 0
in 0
the 0
t 0
( 0
1 0
; 0
19 0
) 0
subset 0
of 0
pre 0
- 0
B 0
ALL 0
, 0
which 0
express 0
oncoprotein 0
E2a B-gene
- 0
Pbx1 B-gene
. 0

Protein B-gene
kinase I-gene
A I-gene
- I-gene
Ialpha I-gene
subunit 0
- 0
directed 0
antisense 0
inhibition 0
of 0
ovarian 0
cancer 0
cell 0
growth 0
: 0
crosstalk 0
with 0
tyrosine B-gene
kinase I-gene
signaling 0
pathway 0
. 0

BCL6 B-gene
encodes 0
a 0
POZ/Zn B-gene
finger I-gene
protein I-gene
, 0
a 0
structure 0
similar 0
to 0
that 0
of 0
many 0
Drosophila 0
developmental 0
regulators 0
and 0
to 0
another 0
protein 0
involved 0
in 0
a 0
human 0
hematopoietic 0
malignancy 0
, 0
PLZF B-gene
. 0

Beta B-gene
1 I-gene
integrin I-gene
- 0
and 0
proteoglycan 0
- 0
mediated 0
stimulation 0
of 0
T 0
lymphoma 0
cell 0
adhesion 0
and 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
signaling 0
by 0
thrombospondin B-gene
- I-gene
1 I-gene
and 0
thrombospondin B-gene
- I-gene
1 I-gene
peptides I-gene
. 0

Optical 0
CD 0
, 0
and 0
spectral 0
and 0
activity 0
analyses 0
were 0
used 0
to 0
examine 0
reactivity 0
of 0
HO B-gene
isozymes I-gene
with 0
NO 0
species 0
produced 0
by 0
NO 0
donors 0
. 0

The 0
phosphotransferase 0
system 0
( 0
PTS 0
) 0
of 0
Streptomyces 0
coelicolor 0
identification 0
and 0
biochemical 0
analysis 0
of 0
a 0
histidine B-gene
phosphocarrier I-gene
protein I-gene
HPr B-gene
encoded 0
by 0
the 0
gene 0
ptsH B-gene
. 0

Serum 0
concentrations 0
of 0
bone B-gene
specific I-gene
alkaline I-gene
phosphatase I-gene
( 0
BALP B-gene
) 0
and 0
osteocalcin B-gene
( 0
bone B-gene
Gla I-gene
protein I-gene
, 0
BGP B-gene
) 0
, 0
urinary 0
levels 0
of 0
pyridinoline 0
( 0
Pyr 0
) 0
and 0
deoxypyridinoline 0
( 0
Dpyr 0
) 0
and 0
computed 0
tomography 0
( 0
CT 0
) 0
measurements 0
of 0
the 0
cross 0
- 0
sectional 0
areas 0
of 0
the 0
vertebrae 0
and 0
the 0
femurs 0
, 0
the 0
apparent 0
density 0
of 0
cancellous 0
bone 0
in 0
the 0
vertebrae 0
, 0
and 0
the 0
volume 0
and 0
the 0
material 0
density 0
of 0
cortical 0
bone 0
in 0
the 0
femurs 0
were 0
determined 0
in 0
126 0
boys 0
and 0
143 0
girls 0
, 0
ages 0
7 0
- 0
18 0
years 0
. 0

In 0
another 0
study 0
, 0
intravenous 0
administration 0
of 0
devazepide 0
, 0
a 0
specific 0
cholecystokinin B-gene
- I-gene
A I-gene
receptor I-gene
antagonist 0
, 0
at 0
a 0
dose 0
of 0
0.1 0
mg/kg/hr 0
was 0
begun 0
15 0
min 0
before 0
postprandial 0
saline 0
intake 0
and 0
continued 0
for 0
1 0
hr 0
. 0

This 0
cluster 0
consisted 0
of 0
four 0
apparently 0
unrelated 0
ESTs 0
and 0
two 0
genes 0
, 0
pregnancy B-gene
- I-gene
associated I-gene
plasma I-gene
protein I-gene
- I-gene
A I-gene
( 0
PAPP B-gene
- I-gene
A I-gene
) 0
and 0
a 0
novel 0
gene 0
( 0
tentatively 0
named 0
EST B-gene
- I-gene
YD1 I-gene
) 0
. 0

Prognostic 0
value 0
of 0
a 0
treadmill 0
exercise 0
score 0
in 0
symptomatic 0
patients 0
with 0
nonspecific 0
ST 0
- 0
T 0
abnormalities 0
on 0
resting 0
ECG 0
. 0

Structural 0
changes 0
in 0
the 0
C 0
- 0
terminus 0
of 0
Ca2+ 0
- 0
bound 0
rat B-gene
S100B I-gene
( 0
beta B-gene
beta I-gene
) 0
upon 0
binding 0
to 0
a 0
peptide 0
derived 0
from 0
the 0
C 0
- 0
terminal 0
regulatory 0
domain 0
of 0
p53 B-gene
. 0

We 0
propose 0
that 0
Gly84 0
is 0
part 0
of 0
a 0
putative 0
`` 0
oxyanion 0
hole 0
'' 0
involved 0
in 0
the 0
stabilization 0
of 0
the 0
transition 0
state 0
similar 0
to 0
the B-gene
C I-gene
group I-gene
of 0
the B-gene
esterase/lipase I-gene
family 0
. 0

The 0
solution 0
structure 0
of 0
the 0
adduct 0
derived 0
from 0
the 0
covalent 0
bonding 0
of 0
the 0
fjord 0
region 0
( 0
+ 0
) 0
- 0
( 0
11S 0
, 0
12R 0
, 0
13R 0
, 0
14S 0
) 0
stereoisomer 0
of 0
anti 0
- 0
11,12 0
- 0
dihydroxy 0
- 0
13,14 0
- 0
epoxy 0
- 0
11,12,13 0
, 0
14 0
- 0
tetrahydrobenzo 0
[ 0
g 0
] 0
chrysene 0
, 0
( 0
+ 0
) 0
- 0
anti 0
- 0
B 0
[ 0
g 0
] 0
CDE 0
, 0
to 0
the 0
exocyclic 0
N 0
( 0
6 0
) 0
amino 0
group 0
of 0
the 0
adenine 0
residue 0
dA6 0
, 0
( 0
designated 0
( 0
+ 0
) 0
- 0
trans 0
- 0
anti 0
- 0
( 0
B 0
[ 0
g 0
] 0
C 0
) 0
dA6 0
) 0
, 0
positioned 0
opposite 0
a 0
thymine 0
residue 0
dT17 0
in 0
the 0
DNA 0
sequence 0
context 0
d 0
( 0
C1 0
- 0
T2 0
- 0
C3 0
- 0
T4 0
- 0
C5 0
- 0
( 0
B 0
[ 0
g 0
] 0
C 0
) 0
A6 0
- 0
C7 0
- 0
T8 0
- 0
T9 0
- 0
C10 0
- 0
C11 0
) 0
. 0
d 0
( 0
G12 0
- 0
G13 0
- 0
A14 0
- 0
A15 0
- 0
G16 0
- 0
T17 0
- 0
G18 0
- 0
A19 0
- 0
G20++ 0
+ 0
- 0
A21 0
- 0
G22 0
) 0
( 0
designated 0
( 0
B 0
[ 0
g 0
] 0
C 0
) 0
dA 0
. 0
dT 0
11 0
- 0
mer 0
duplex 0
) 0
, 0
has 0
been 0
studied 0
using 0
structural 0
information 0
derived 0
from 0
NMR 0
data 0
in 0
combination 0
with 0
molecular 0
dynamics 0
( 0
MD 0
) 0
calculations 0
. 0

Since 0
sildenafil 0
came 0
on 0
the 0
market 0
, 0
it 0
seems 0
that 0
the 0
place 0
of 0
MUSE 0
is 0
reduced 0
because 0
comparative 0
studies 0
give 0
better 0
results 0
for 0
sildenafil 0
than 0
MUSE 0
( 0
70 0
% 0
vs 0
40 0
% 0
) 0
and 0
of 0
course 0
with 0
a 0
better 0
acceptance 0
. 0

Serum 0
antibodies 0
were 0
detected 0
in 0
at 0
least 0
95 0
% 0
of 0
the 0
infected 0
guinea 0
pigs 0
between 0
4 0
- 0
30 0
WPI 0
and 0
rats 0
between 0
3 0
- 0
16 0
WPI 0
. 0

During 0
both 0
encephalopathy 0
episodes 0
, 0
CSF 0
protein 0
and 0
immunoglobulin B-gene
G I-gene
( 0
IgG B-gene
) 0
levels 0
were 0
elevated 0
without 0
an 0
increased 0
IgG B-gene
index 0
or 0
IgG B-gene
synthesis 0
rate 0
. 0

CONCLUSIONS 0
: 0
These 0
results 0
show 0
that 0
once 0
daily 0
oral 0
valganciclovir 0
can 0
produce 0
exposures 0
of 0
ganciclovir 0
( 0
AUC24 0
) 0
exceeding 0
those 0
attained 0
using 0
intravenous 0
ganciclovir 0
10 0
mg/kg 0
. 0

Except 0
for 0
nonperfusion 0
of 0
neurosensory 0
retinal 0
vessels 0
at 0
a 0
light 0
dose 0
of 0
150 0
J/cm2 0
, 0
no 0
other 0
adverse 0
events 0
were 0
of 0
concern 0
. 0

Except 0
for 0
nonperfusion 0
of 0
neurosensory 0
retinal 0
vessels 0
at 0
a 0
light 0
dose 0
of 0
150 0
J/cm2 0
, 0
no 0
other 0
adverse 0
events 0
were 0
of 0
concern 0
. 0

The 0
healing 0
rate 0
in 0
HIV 0
- 0
positive 0
patients 0
was 0
66 0
percent 0
after 0
14 0
weeks 0
and 0
100 0
percent 0
after 0
32 0
weeks 0
; 0
the 0
corresponding 0
figures 0
for 0
patients 0
with 0
acquired 0
immunodeficiency 0
syndrome 0
were 0
0 0
and 0
50 0
percent 0
. 0

The 0
P B-gene
mRNA I-gene
also 0
contains 0
a 0
third 0
ORF 0
for 0
the 0
V B-gene
protein I-gene
, 0
although 0
it 0
is 0
unclear 0
how 0
or 0
whether 0
this 0
ORF 0
is 0
accessed 0
. 0

A 0
genetic 0
screen 0
in 0
yeast 0
has 0
allowed 0
us 0
to 0
identify 0
a 0
novel 0
transcriptional 0
factor 0
binding 0
to 0
the 0
GlRE 0
, 0
i.e 0
. 0
the 0
chicken B-gene
ovalbumin I-gene
upstream I-gene
promoter I-gene
- I-gene
transcription I-gene
factor I-gene
II I-gene
( 0
COUP B-gene
- I-gene
TFII I-gene
) 0
. 0

We 0
have 0
cloned 0
the 0
single 0
- 0
copy 0
gene 0
for 0
the 0
trans B-gene
- I-gene
spliceosomal I-gene
U5 I-gene
snRNA I-gene
from 0
the 0
trypanosomatid 0
species 0
Leptomonas 0
seymouri 0
, 0
using 0
U5 B-gene
RNA I-gene
affinity 0
selection 0
and 0
cDNA 0
cloning 0
. 0

The 0
MMPI 0
- 0
A 0
( 0
Butcher 0
et 0
al. 0
, 0
1992 0
) 0
, 0
like 0
the 0
older 0
MMPI 0
( 0
Hathaway 0
& 0
McKinley 0
, 0
1983 0
) 0
, 0
distinguishes 0
between 0
anorexia 0
and 0
bulimia 0
. 0

On 0
the 0
other 0
hand 0
, 0
phosphatidyl 0
inositol 0
4,5 0
bisphosphate 0
( 0
PIP2 0
) 0
hydrolysis 0
requires 0
direct 0
phosphorylation 0
at 0
tyrosine 0
residue 0
of 0
the 0
PLC B-gene
- I-gene
gamma1 I-gene
isozyme I-gene
. 0

A 0
G22V B-gene
mutant I-gene
of 0
M B-gene
- I-gene
Ras I-gene
was 0
constitutively 0
active 0
and 0
its 0
expression 0
in 0
an 0
interleukin B-gene
- I-gene
3 I-gene
( 0
IL B-gene
- I-gene
3 I-gene
) 0
- 0
dependent 0
mast 0
cell/megakaryocyte 0
cell 0
line 0
resulted 0
in 0
increased 0
survival 0
in 0
the 0
absence 0
of 0
IL B-gene
- I-gene
3 I-gene
, 0
increased 0
growth 0
in 0
IL B-gene
- I-gene
4 I-gene
, 0
and 0
, 0
at 0
high 0
expression 0
levels 0
, 0
in 0
factor 0
- 0
independent 0
growth 0
. 0

Mammalian B-gene
M I-gene
- I-gene
Ras I-gene
and 0
a 0
Caenorhabditis 0
elegans 0
orthologue 0
exhibit 0
conserved 0
structural 0
features 0
, 0
and 0
these 0
are 0
likely 0
to 0
mediate 0
activation 0
of 0
distinctive 0
signaling 0
paths 0
that 0
function 0
in 0
parallel 0
to 0
those 0
downstream 0
of 0
p21 B-gene
Ras I-gene
. 0

Taken 0
together 0
, 0
our 0
data 0
suggest 0
that 0
PecS B-gene
attenuates 0
pelD B-gene
and 0
pelE B-gene
expression 0
rather 0
than 0
acting 0
as 0
a 0
true 0
repressor 0
like 0
KdgR B-gene
. 0

These 0
observations 0
establish 0
that 0
RsmC B-gene
negatively 0
regulates 0
rsmB B-gene
transcription 0
but 0
positively 0
affects 0
RsmA B-gene
production 0
. 0

All 0
were 0
experienced 0
hearing 0
aid 0
users 0
who 0
wore 0
linear 0
Class 0
D 0
instruments 0
with 0
input 0
compression 0
limiting 0
at 0
the 0
time 0
of 0
their 0
enrollment 0
in 0
this 0
study 0
. 0

SCOB 0
testing 0
of 0
food 0
- 0
restricted 0
animals 0
, 0
using 0
a 0
multiple 0
fixed 0
ratio 0
( 0
FR 0
) 0
/fixed 0
interval 0
( 0
FI 0
) 0
schedule 0
( 0
FR20 0
: 0
FI120 0
) 0
, 0
was 0
conducted 0
prior 0
to 0
each 0
exposure 0
to 0
maintain 0
the 0
operant 0
behavior 0
; 0
the 0
data 0
from 0
Weeks 0
- 0
1 0
, 0
4 0
, 0
8 0
, 0
and 0
13 0
were 0
evaluated 0
for 0
evidence 0
of 0
neurotoxicity 0
. 0

Ribonuclease 0
protection 0
assays 0
revealed 0
that 0
hmg1 B-gene
and 0
hmg2 B-gene
are 0
differentially 0
expressed 0
in 0
a 0
developmentally 0
- 0
and 0
spatially 0
- 0
modulated 0
manner 0
during 0
morphogenesis 0
of 0
specialized 0
terpenoid 0
- 0
containing 0
pigment 0
glands 0
in 0
embryos 0
. 0

Differential 0
expression 0
was 0
confirmed 0
by 0
Northern 0
blot 0
analysis 0
employing 0
multiple 0
normal 0
and 0
tumor 0
cell 0
lines 0
. 0

Inactivation 0
of 0
the 0
Neurospora B-gene
crassa I-gene
mitochondrial I-gene
outer I-gene
membrane I-gene
protein I-gene
TOM70 I-gene
by 0
repeat 0
- 0
induced 0
point 0
mutation 0
( 0
RIP 0
) 0
causes 0
defects 0
in 0
mitochondrial 0
protein 0
import 0
and 0
morphology 0
. 0

Several 0
genes 0
or 0
transcriptional 0
units 0
were 0
identified 0
, 0
including 0
the 0
3 0
' 0
end 0
of 0
ribosomal B-gene
s6 I-gene
kinase I-gene
( 0
Rsk3 B-gene
) 0
; 0
two 0
apparently 0
intronless 0
and 0
ORF 0
- 0
less 0
genes 0
; 0
and 0
Gpr31 B-gene
, 0
an 0
intronless 0
, 0
putative 0
G B-gene
- I-gene
protein I-gene
coupled I-gene
receptor I-gene
. 0

The 0
results 0
suggest 0
that 0
GATA B-gene
- I-gene
5 I-gene
may 0
have 0
specific 0
downstream 0
targets 0
and 0
that 0
GATA B-gene
- I-gene
4 I-gene
, I-gene
- I-gene
5 I-gene
, I-gene
and I-gene
- I-gene
6 I-gene
can 0
only 0
partially 0
substitute 0
for 0
each 0
other 0
in 0
cardiogenesis 0
. 0

This 0
study 0
was 0
designed 0
to 0
compare 0
the 0
efficacy 0
of 0
efegatran 0
plus 0
streptokinase B-gene
versus 0
heparin 0
plus 0
accelerated 0
tissue B-gene
plasminogen I-gene
activator I-gene
( 0
TPA B-gene
) 0
in 0
coronary 0
reperfusion 0
in 0
acute 0
MI 0
. 0

Recently 0
, 0
cell 0
- 0
surface 0
TRAIL B-gene
has 0
been 0
shown 0
to 0
be 0
expressed 0
by 0
activated 0
human 0
and 0
mouse 0
T 0
lymphocytes 0
, 0
raising 0
the 0
possibility 0
that 0
TRAIL B-gene
might 0
be 0
involved 0
in 0
T 0
cell 0
- 0
mediated 0
cytotoxicity 0
and/or 0
immune 0
regulation 0
. 0

A 0
panel 0
of 0
pharmacologic 0
inhibitors 0
was 0
used 0
to 0
investigate 0
the 0
signal 0
transduction 0
pathways 0
involved 0
in 0
TRAIL B-gene
gene I-gene
induction 0
following 0
T 0
lymphocyte 0
activation 0
. 0

From 0
February 0
1991 0
to 0
August 0
1997 0
, 0
124 0
patients 0
with 0
endometrial 0
carcinoma 0
were 0
treated 0
postoperatively 0
with 0
high 0
- 0
dose 0
- 0
rate 0
vaginal 0
vault 0
brachytherapy 0
as 0
the 0
only 0
adjuvant 0
treatment 0
. 0

Twelve 0
patients 0
had 0
stage 0
IBG3 0
, 0
14 0
had 0
ICG1 0
, 0
9 0
had 0
ICG2 0
, 0
and 0
3 0
had 0
ICG3 0
disease 0
. 0

Defective 0
provirus 0
genomes 0
of 0
human 0
T 0
- 0
cell 0
leukemia 0
virus 0
type 0
I 0
are 0
frequently 0
detected 0
in 0
lymphocytes 0
from 0
infected 0
individuals 0
and 0
in 0
infected 0
cell 0
lines 0
. 0

A 0
total 0
of 0
174 0
primer 0
pairs 0
gave 0
interpretable 0
banding 0
patterns 0
, 0
137 0
( 0
79 0
% 0
) 0
of 0
which 0
revealed 0
at 0
least 0
two 0
alleles 0
on 0
native 0
polyacrylamide 0
gels 0
. 0

A 0
population 0
pharmacokinetic 0
study 0
of 0
cyclosporin 0
in 0
organ 0
transplant 0
patients 0
, 0
including 0
elderly 0
allograft 0
recipients 0
up 0
to 0
75 0
years 0
of 0
age 0
, 0
did 0
not 0
identify 0
age 0
as 0
a 0
covariable 0
influencing 0
cyclosporin 0
pharmacokinetics 0
. 0

Immunofluoresence 0
data 0
indicated 0
that 0
once 0
bound 0
to 0
the 0
mutant 0
receptor 0
, 0
fluorescent 0
- 0
labeled 0
RAP B-gene
co 0
- 0
localized 0
with 0
markers 0
of 0
the 0
endosomal 0
pathway 0
, 0
whereas 0
, 0
in 0
cells 0
expressing 0
the 0
wild 0
- 0
type 0
receptor 0
, 0
RAP B-gene
fluorescence 0
co 0
- 0
localized 0
with 0
lysosomal 0
markers 0
. 0

Interleukin B-gene
- I-gene
12 I-gene
( 0
IL B-gene
- I-gene
12 I-gene
) 0
is 0
a 0
cytokine 0
produced 0
by 0
peripheral 0
blood 0
mononuclear 0
cells 0
( 0
PBMC 0
) 0
that 0
causes 0
interferon B-gene
- I-gene
gamma I-gene
( 0
IFN B-gene
- I-gene
gamma I-gene
) 0
production 0
and 0
enhancement 0
of 0
cell 0
- 0
mediated 0
cytotoxicity 0
. 0

IL B-gene
- I-gene
12 I-gene
production 0
was 0
correlated 0
with 0
C3a 0
concentration 0
measured 0
at 0
the 0
outlet 0
of 0
hemodialyzer 0
after 0
15 0
min 0
of 0
dialysis 0
( 0
r 0
= 0
0.69 0
, 0
P 0
< 0
0.01 0
) 0
. 0

In 0
HeLa 0
cells 0
, 0
the 0
JNKK2 B-gene
- 0
JNK1 B-gene
fusion 0
protein 0
showed 0
significant 0
JNK B-gene
activity 0
, 0
which 0
was 0
comparable 0
with 0
that 0
of 0
JNK1 B-gene
activated 0
by 0
many 0
stimuli 0
and 0
activators 0
, 0
including 0
EGF B-gene
, 0
TNF B-gene
- I-gene
alpha I-gene
, 0
anisomycin 0
, 0
UV 0
irradiation 0
, 0
MEKK1 B-gene
, 0
and 0
small B-gene
GTP I-gene
binding I-gene
proteins I-gene
Rac1 I-gene
and 0
Cdc42Hs B-gene
. 0

J 0
. 0

Our 0
results 0
implicate 0
TGF B-gene
- I-gene
beta I-gene
RII I-gene
as 0
a 0
direct 0
target 0
of 0
EWS B-gene
- 0
FLI1 B-gene
. 0

The 0
reduction 0
in 0
saturated 0
fatty 0
acids 0
intake 0
led 0
to 0
modest 0
( 0
but 0
in 0
group 0
1 0
significant 0
) 0
0.15 0
mmol/l 0
( 0
2.5 0
% 0
) 0
reduction 0
in 0
total 0
serum 0
cholesterol 0
level 0
. 0

Secondly 0
, 0
an 0
ethanol 0
repression 0
autoregulation 0
( 0
ERA 0
) 0
/twelve 0
- 0
fold 0
TA 0
repeat 0
( 0
TAB 0
) 0
repressor 0
element 0
was 0
identified 0
within 0
the 0
promoter 0
region 0
of 0
the 0
GLK1 B-gene
gene I-gene
. 0

A 0
crucial 0
transcription 0
factor 0
in 0
this 0
process 0
is 0
STAT6 B-gene
, 0
which 0
binds 0
to 0
a 0
specific 0
DNA 0
element 0
upon 0
cytokine 0
activation 0
. 0

CONCLUSIONS 0
: 0
Congenital 0
horizontal 0
tarsal 0
kink 0
is 0
rare 0
and 0
its 0
cause 0
is 0
unknown 0
. 0

A 0
local 0
, 0
high 0
- 0
density 0
, 0
single 0
- 0
nucleotide 0
polymorphism 0
map 0
used 0
to 0
clone 0
Caenorhabditis B-gene
elegans I-gene
cdf I-gene
- I-gene
1 I-gene
. 0

This 0
machinery 0
involves 0
a 0
secondary 0
structure 0
, 0
SECIS 0
element 0
, 0
in 0
the 0
selenoprotein B-gene
- 0
encoding 0
mRNA 0
, 0
directing 0
selenocysteine 0
insertion 0
at 0
the 0
position 0
of 0
an 0
opal 0
( 0
UGA 0
) 0
codon 0
, 0
normally 0
conferring 0
termination 0
of 0
translation 0
. 0

High 0
- 0
level 0
expression 0
in 0
Escherichia 0
coli 0
of 0
selenocysteine 0
- 0
containing 0
rat B-gene
thioredoxin I-gene
reductase I-gene
utilizing 0
gene 0
fusions 0
with 0
engineered 0
bacterial 0
- 0
type 0
SECIS 0
elements 0
and 0
co 0
- 0
expression 0
with 0
the 0
selA B-gene
, 0
selB B-gene
and 0
selC B-gene
genes I-gene
. 0

In 0
Wnt B-gene
signaling 0
, 0
beta B-gene
- I-gene
catenin I-gene
and 0
plakoglobin B-gene
transduce 0
signals 0
to 0
the 0
nucleus 0
through 0
interactions 0
with 0
TCF B-gene
- I-gene
type I-gene
transcription I-gene
factors I-gene
. 0

Assembly 0
of 0
a 0
complex 0
between 0
FAK B-gene
and 0
Src B-gene
kinases I-gene
may 0
serve 0
to 0
regulate 0
the 0
subcellular 0
localization 0
and 0
the 0
enzymatic 0
activity 0
of 0
members 0
of 0
the 0
Src B-gene
family I-gene
of 0
kinases 0
. 0

For 0
EPV 0
3 0
, 0
10 0
, 0
or 0
40 0
, 0
the 0
bias 0
exceeded 0
25 0
% 0
for 0
7 0
, 0
3 0
, 0
and 0
1 0
in 0
the 0
8 0
- 0
predictor 0
model 0
respectively 0
, 0
when 0
a 0
conventional 0
selection 0
criterion 0
was 0
used 0
( 0
alpha 0
= 0
0.05 0
) 0
. 0

Our 0
study 0
also 0
demonstrated 0
significant 0
increases 0
in 0
the 0
number 0
of 0
larger 0
myelinated 0
fibers 0
crossing 0
the 0
repair 0
site 0
in 0
comparison 0
with 0
the 0
neonatal 0
and 0
adult 0
groups 0
( 0
p 0
< 0
0.04 0
) 0
. 0

Me 0
( 0
2 0
) 0
SO 0
- 0
induced 0
neuronal 0
differentiation 0
of 0
N1E 0
- 0
115 0
neuroblastoma 0
cells 0
increased 0
both 0
the 0
expression 0
of 0
the 0
endogenous B-gene
Ntr I-gene
- I-gene
1 I-gene
gene I-gene
and 0
reporter 0
genes 0
driven 0
by 0
NTR B-gene
- I-gene
1 I-gene
promoter I-gene
sequences I-gene
by 0
3 0
- 0
4 0
- 0
fold 0
. 0

Cortical 0
dysplasias 0
, 0
genetics 0
, 0
and 0
epileptogenesis 0
. 0

In 0
the 0
work 0
reported 0
here 0
, 0
we 0
used 0
peptide 0
mapping 0
, 0
mass 0
spectrometry 0
, 0
and 0
site 0
- 0
directed 0
mutagenesis 0
to 0
identify 0
two 0
sets 0
of 0
pAP B-gene
phosphorylation 0
sites 0
. 0

Both 0
HERV 0
- 0
K 0
type 0
1 0
and 0
2 0
clones 0
were 0
isolated 0
. 0

Duch 0
, 0
and 0
F 0
. 0

At 0
all 0
time 0
- 0
points 0
, 0
most 0
patients 0
( 0
> 0
/=87 0
% 0
) 0
were 0
receiving 0
irbesartan/HCTZ 0
alone 0
. 0

Modification 0
of 0
dopamine B-gene
D2 I-gene
receptor I-gene
activity 0
by 0
pergolide 0
in 0
Parkinson 0
's 0
disease 0
: 0
an 0
in 0
vivo 0
study 0
by 0
PET 0
. 0

High 0
- 0
affinity 0
binding 0
sites 0
for 0
both 0
GR B-gene
and 0
AP B-gene
- I-gene
1 I-gene
nucleoproteins I-gene
were 0
identified 0
at 0
adjacent 0
elements 0
within 0
the 0
nGRE 0
. 0

When 0
the 0
73 0
- 0
bp 0
fragment 0
was 0
fused 0
to 0
an 0
alpha1 B-gene
- I-gene
globin I-gene
promoter 0
- 0
CAT B-gene
construct 0
and 0
cotransfected 0
with 0
CCAAT B-gene
transcription I-gene
factor I-gene
1 I-gene
( 0
CTF1 B-gene
) 0
/NF1 B-gene
into 0
Drosophila 0
Schneider 0
SL2 0
insect 0
cells 0
( 0
which 0
lack 0
NF1 B-gene
- I-gene
like I-gene
proteins I-gene
) 0
trans 0
- 0
activation 0
of 0
CAT B-gene
activity 0
was 0
observed 0
. 0

Western 0
blot 0
analysis 0
showed 0
a 0
rapid 0
corresponding 0
increase 0
in 0
p21WAF1/CIP1 B-gene
protein 0
, 0
whereas 0
protein 0
levels 0
of 0
another 0
member 0
of 0
the 0
p21WAF1/CIP1 I-gene

Aggregation 0
of 0
vHnf1 B-gene
- 0
deficient 0
embryonic 0
stem 0
cells 0
with 0
wild 0
- 0
type 0
tetraploid 0
embryos 0
, 0
which 0
contribute 0
exclusively 0
to 0
extraembryonic 0
tissues 0
, 0
rescues 0
periimplantation 0
lethality 0
and 0
allows 0
development 0
to 0
progress 0
to 0
early 0
organogenesis 0
. 0

nos B-gene
- I-gene
1 I-gene
and 0
nos B-gene
- I-gene
2 I-gene
, 0
two 0
genes 0
related 0
to 0
Drosophila B-gene
nanos I-gene
, 0
regulate 0
primordial 0
germ 0
cell 0
development 0
and 0
survival 0
in 0
Caenorhabditis 0
elegans 0
. 0

Although 0
upstream 0
regulators 0
of 0
Tec B-gene
family I-gene
kinases I-gene
are 0
relatively 0
well 0
characterized 0
, 0
little 0
is 0
known 0
of 0
the 0
downstream 0
effectors 0
of 0
these 0
enzymes 0
. 0

Efficient 0
phosphorylation 0
of 0
BRDG1 B-gene
by 0
Tec B-gene
required 0
the 0
PH B-gene
and 0
SH2 B-gene
domains I-gene
as 0
well 0
as 0
the 0
kinase 0
domain 0
of 0
the 0
latter 0
. 0

CONCLUSION 0
: 0
These 0
findings 0
imply 0
that 0
eotaxin 0
either 0
is 0
mechanistically 0
involved 0
in 0
acute 0
asthma 0
or 0
serves 0
as 0
a 0
biomarker 0
for 0
activity 0
of 0
the 0
CCR3 B-gene
receptor I-gene
ligand I-gene
system 0
, 0
which 0
is 0
functionally 0
linked 0
to 0
asthma 0
. 0

The 0
expression 0
analysis 0
of 0
the 0
KlHIS4 B-gene
gene I-gene
under 0
phosphate 0
starvation 0
or 0
high 0
adenine 0
supply 0
shows 0
that 0
factors 0
, 0
such 0
as 0
Bas1 B-gene
or 0
Bas2 B-gene
, 0
involved 0
in 0
the 0
basal 0
control 0
may 0
also 0
operate 0
in 0
a 0
different 0
way 0
in 0
K. 0
lactis 0
. 0

These 0
thyroid 0
hormone 0
changes 0
may 0
be 0
mediated 0
in 0
part 0
by 0
cytokines 0
or 0
other 0
inflammatory 0
mediators 0
, 0
acting 0
at 0
the 0
level 0
of 0
the 0
hypothalamus 0
and 0
pituitary 0
gland 0
, 0
the 0
thyroid 0
gland 0
, 0
and 0
the 0
hepatic B-gene
deiodinase I-gene
system 0
. 0

ESS 0
type 0
1 0
, 0
with 0
FT3 0
low 0
and 0
FT4 0
and 0
TSH B-gene
normal 0
, 0
is 0
the 0
most 0
frequent 0
form 0
. 0

METHODS 0
: 0
We 0
studied 0
20 0
symptomatic 0
patients 0
with 0
HOCM 0
( 0
12 0
men 0
) 0
, 0
mean 0
age 0
52 0
+/ 0
- 0
17 0
years 0
, 0
before 0
and 0
after 0
septal 0
reduction 0
using 0
echocardiography 0
and 0
electrocardiogram 0
( 0
ECG 0
) 0
. 0

Paleoceanographic 0
data 0
from 0
the 0
Laurentian 0
Fan 0
, 0
used 0
as 0
a 0
proxy 0
for 0
sea 0
surface 0
temperature 0
, 0
reveal 0
that 0
surface 0
slope 0
waters 0
north 0
of 0
the 0
Gulf 0
Stream 0
experienced 0
warming 0
during 0
the 0
Little 0
Ice 0
Age 0
of 0
the 0
16th 0
to 0
19th 0
centuries 0
and 0
support 0
the 0
notion 0
of 0
an 0
NAO 0
- 0
driven 0
coupled 0
system 0
. 0

This 0
effect 0
required 0
( 0
i 0
) 0
IR B-gene
activation 0
since 0
it 0
was 0
abrogated 0
by 0
IR B-gene
mutation 0
at 0
tyrosines 0
1162 0
and 0
1163 0
and 0
( 0
ii 0
) 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
since 0
it 0
was 0
abolished 0
by 0
overexpression 0
of 0
dominant B-gene
- I-gene
negative I-gene
IkappaB I-gene
- I-gene
alpha I-gene
( I-gene
A32/36 I-gene
) I-gene
and 0
mimicked 0
by 0
overexpression 0
of 0
the 0
NF B-gene
- I-gene
kappaB I-gene
c B-gene
- I-gene
Rel I-gene
subunit I-gene
. 0

The 0
factor 0
designated 0
B 0
formed 0
a 0
complex 0
centered 0
on 0
the 0
sequence 0
TGTGGT 0
, 0
a 0
core 0
motif 0
recognized 0
by 0
members 0
of 0
the 0
AML/CBFalpha B-gene
transcription I-gene
factor I-gene
family I-gene
. 0

Furthermore 0
, 0
overexpression 0
of 0
AML3/CBFalpha1 B-gene
could 0
rescue 0
the 0
AML3/CBFalpha1 I-gene

We 0
examined 0
Akt B-gene
activation 0
in 0
Lyn B-gene
- 0
, 0
Syk B-gene
- 0
and 0
Btk B-gene
- 0
deficient 0
DT40 0
cells 0
and 0
B 0
cells 0
from 0
Lyn B-gene
( I-gene
- I-gene
/ I-gene
- I-gene
) I-gene
mice 0
. 0

Regulators 0
of 0
G B-gene
protein I-gene
signaling I-gene
( I-gene
RGS I-gene
) I-gene
proteins I-gene
that 0
contain 0
DEP B-gene
( 0
disheveled B-gene
, 0
EGL B-gene
- I-gene
10 I-gene
, 0
pleckstrin B-gene
) 0
and 0
GGL B-gene
( 0
G B-gene
protein I-gene
gamma I-gene
subunit I-gene
- I-gene
like I-gene
) 0
domains 0
form 0
a 0
subfamily 0
that 0
includes 0
the 0
mammalian B-gene
RGS I-gene
proteins I-gene
RGS6 B-gene
, 0
RGS7 B-gene
, 0
RGS9 B-gene
, 0
and 0
RGS11 B-gene
. 0

Cloning 0
and 0
expression 0
of 0
a 0
specific 0
human B-gene
alpha I-gene
1,2 I-gene
- I-gene
mannosidase I-gene
that 0
trims 0
Man9GlcNAc2 0
to 0
Man8GlcNAc2 0
isomer 0
B 0
during 0
N 0
- 0
glycan 0
biosynthesis 0
. 0

The 0
ORs 0
of 0
GC 0
, 0
adjusted 0
for 0
age 0
and 0
sex 0
, 0
varied 0
from 0
17.1 0
, 0
for 0
those 0
with 0
baseline 0
diagnoses 0
of 0
superficial 0
intestinal 0
metaplasia 0
( 0
IM 0
) 0
, 0
to 0
29.3 0
, 0
for 0
those 0
with 0
deep 0
IM 0
or 0
mild 0
dysplasia 0
( 0
DYS 0
) 0
or 0
IM 0
with 0
glandular 0
atrophy 0
and 0
neck 0
hyperplasia 0
, 0
to 0
104.2 0
, 0
for 0
those 0
with 0
moderate 0
or 0
severe 0
DYS 0
, 0
as 0
compared 0
with 0
subjects 0
with 0
superficial 0
gastritis 0
( 0
SG 0
) 0
or 0
chronic 0
atrophic 0
gastritis 0
( 0
CAG 0
) 0
at 0
baseline 0
. 0

Here 0
we 0
report 0
that 0
Dbp5p B-gene
and 0
Rat7p B-gene
interact 0
through 0
their 0
Nterminal 0
domains 0
. 0

Thus 0
, 0
the 0
nematode 0
genes 0
could 0
be 0
the 0
homologs B-gene
of I-gene
Hh I-gene
molecules I-gene
in 0
other 0
phyla 0
. 0

A 0
subset 0
of 0
mutations 0
in 0
the 0
Psi B-gene
synthase I-gene
domain I-gene
impairs 0
association 0
of 0
the 0
altered 0
Cbf5p B-gene
proteins I-gene
with 0
selected 0
box 0
H/ACA B-gene
snoRNAs I-gene
, 0
suggesting 0
that 0
the 0
functional 0
catalytic 0
domain 0
is 0
essential 0
for 0
that 0
interaction 0
. 0

Although 0
the 0
Src B-gene
tyrosine I-gene
kinase I-gene
induces 0
constitutive 0
Stat3 B-gene
phosphorylation 0
on 0
tyrosine 0
, 0
activation 0
of 0
Stat3 B-gene
- 0
mediated 0
gene 0
regulation 0
requires 0
both 0
tyrosine 0
and 0
serine 0
phosphorylation 0
of 0
Stat3 B-gene
. 0

The 0
transcription B-gene
factor I-gene
CHOP I-gene
( 0
C/EBP B-gene
homologous I-gene
protein I-gene
10 I-gene
) 0
is 0
a 0
bZIP B-gene
protein I-gene
induced 0
by 0
a 0
variety 0
of 0
stimuli 0
that 0
evoke 0
cellular 0
stress 0
responses 0
and 0
has 0
been 0
shown 0
to 0
arrest 0
cell 0
growth 0
and 0
to 0
promote 0
programmed 0
cell 0
death 0
. 0

Thus 0
, 0
CHOP B-gene
not 0
only 0
is 0
a 0
negative 0
or 0
a 0
positive 0
regulator 0
of 0
C/EBP B-gene
target 0
genes 0
but 0
also 0
, 0
when 0
tethered 0
to 0
AP B-gene
- I-gene
1 I-gene
factors I-gene
, 0
can 0
activate 0
AP B-gene
- I-gene
1 I-gene
target 0
genes 0
. 0

This 0
motif 0
, 0
first 0
described 0
for 0
the 0
Drosophila B-gene
homeobox I-gene
activator I-gene
DEAF I-gene
- I-gene
1 I-gene
, 0
identifies 0
an 0
emerging 0
group 0
of 0
metazoan 0
transcriptional 0
modulators 0
. 0

RNase B-gene
MRP I-gene
is 0
a 0
ribonucleoprotein 0
endoribonuclease 0
that 0
has 0
been 0
shown 0
to 0
have 0
roles 0
in 0
both 0
mitochondrial 0
DNA 0
replication 0
and 0
nuclear B-gene
5.8S I-gene
rRNA I-gene
processing 0
. 0

We 0
have 0
examined 0
the 0
regulation 0
of 0
the 0
FGFR B-gene
- I-gene
1 I-gene
gene I-gene
( 0
cek B-gene
- I-gene
1 I-gene
) 0
in 0
avian 0
myogenic 0
cultures 0
by 0
immunocytochemistry 0
and 0
Northern 0
blot 0
analysis 0
. 0

Regulation 0
of 0
avian B-gene
fibroblast I-gene
growth I-gene
factor I-gene
receptor I-gene
1 I-gene
( 0
FGFR B-gene
- I-gene
1 I-gene
) 0
gene 0
expression 0
during 0
skeletal 0
muscle 0
differentiation 0
. 0

The 0
backbone 0
dynamics 0
of 0
residues 0
located 0
in 0
the 0
folded 0
part 0
of 0
CRP2 B-gene
( 0
LIM2 B-gene
) 0
R122A B-gene
have 0
been 0
characterized 0
by 0
proton 0
- 0
detected 0
( 0
15 0
) 0
N 0
NMR 0
spectroscopy 0
. 0

Rac B-gene
causes 0
uncapping 0
of 0
actin B-gene
filaments I-gene
( 0
F B-gene
- I-gene
actin I-gene
) 0
at 0
the 0
plus 0
- 0
ends 0
, 0
through 0
phosphatidylinositol 0
4,5 0
bisphosphate 0
( 0
PIP2 0
) 0
, 0
and 0
eventually 0
induces 0
membrane 0
ruffling 0
. 0

However 0
, 0
a 0
specific 0
ICE/caspase B-gene
ICE/caspase I-gene
- I-gene
1 I-gene
inhibitor 0
called 0
N1445 0
completely 0
abolished 0
the 0
CK B-gene
- 0
induced 0
apoptosis 0
by 0
reactivating 0
PKB B-gene
, 0
but 0
without 0
affecting 0
the 0
CK B-gene
- 0
induced 0
suppression 0
of 0
Ras B-gene
transformation 0
. 0

OBJECTIVE 0
: 0
Although 0
the 0
preponderance 0
of 0
findings 0
offer 0
support 0
for 0
transient 0
( 0
where 0
is 0
it 0
? 0
) 0
as 0
opposed 0
to 0
sustained 0
( 0
what 0
is 0
it 0
? 0
) 0
deficit 0
, 0
a 0
need 0
remains 0
for 0
specific 0
depiction 0
of 0
the 0
deficit 0
. 0

The 0
AL 0
- 0
R8 0
SI 0
: 0
the 0
next 0
generation 0
staging 0
container 0
for 0
plutonium 0
pits 0
at 0
the 0
USDOE 0
Pantex 0
Plant 0
. 0

RESULTS 0
: 0
Factors 0
associated 0
with 0
significantly 0
( 0
P 0
< 0
.05 0
) 0
increased 0
risk 0
of 0
treatment 0
failure 0
in 0
a 0
Cox 0
multivariate 0
analysis 0
included 0
age 0
older 0
than 0
45 0
years 0
( 0
relative 0
hazard 0
, 0
1.17 0
; 0
95 0
% 0
confidence 0
interval 0
[ 0
CI 0
] 0
, 0
1.02 0
- 0
1.33 0
) 0
, 0
Karnofsky 0
performance 0
score 0
less 0
than 0
90 0
% 0
( 0
1.27 0
; 0
95 0
% 0
CI 0
, 0
1.07 0
- 0
1.51 0
) 0
, 0
absence 0
of 0
hormone 0
receptors 0
( 0
1.31 0
; 0
95 0
% 0
CI 0
, 0
1.15 0
- 0
1.51 0
) 0
, 0
prior 0
use 0
of 0
adjuvant 0
chemotherapy 0
( 0
1.31 0
; 0
95 0
% 0
CI 0
, 0
1.10 0
- 0
1.56 0
) 0
, 0
initial 0
disease 0
- 0
free 0
survival 0
interval 0
after 0
adjuvant 0
treatment 0
of 0
no 0
more 0
than 0
18 0
months 0
( 0
1.99 0
; 0
95 0
% 0
CI 0
, 0
1.62 0
- 0
2.43 0
) 0
, 0
metastases 0
in 0
the 0
liver 0
( 0
1.47 0
; 0
95 0
% 0
CI 0
, 0
1.20 0
- 0
1.80 0
) 0
or 0
central 0
nervous 0
system 0
( 0
1.56 0
; 0
95 0
% 0
CI 0
, 0
0.99 0
- 0
2.46 0
[ 0
approaches 0
significance 0
] 0
) 0
vs 0
soft 0
tissue 0
, 0
bone 0
, 0
or 0
lung 0
, 0
3 0
or 0
more 0
sites 0
of 0
metastatic 0
disease 0
( 0
1.32 0
; 0
95 0
% 0
CI 0
, 0
1.13 0
- 0
1.54 0
) 0
, 0
and 0
incomplete 0
response 0
vs 0
complete 0
response 0
to 0
standard 0
- 0
dose 0
chemotherapy 0
( 0
1.65 0
; 0
95 0
% 0
CI 0
, 0
1.36 0
- 0
1.99 0
) 0
. 0

One 0
form 0
of 0
the 0
SBEI B-gene
gene I-gene
transcript I-gene
in 0
12 0
- 0
day 0
old 0
kernels 0
contained 0
the 0
exon 0
I+II+III 0
combination 0
at 0
the 0
5 0
' 0
end 0
, 0
whereas 0
other 0
forms 0
differed 0
by 0
inclusion 0
of 0
intron 0
1 0
or 0
exclusion 0
of 0
exon 0
II 0
sequences 0
. 0

In 0
PC 0
, 0
rare 0
MNGCs 0
had 0
intranuclear 0
inclusions 0
and 0
grooves 0
. 0

16 0
percent 0
, 0
P 0
< 0
0.001 0
) 0
, 0
and 0
sustained 0
normalization 0
of 0
serum B-gene
alanine I-gene
aminotransferase I-gene
levels 0
( 0
41 0
percent 0
vs 0
. 0

Its 0
C 0
- 0
terminal 0
catalytic 0
domain 0
was 0
found 0
to 0
be 0
highly 0
conserved 0
in 0
the 0
homologues 0
p140 B-gene
( 0
ras B-gene
- 0
GRF B-gene
) 0
and 0
Sos B-gene
. 0

356 0
, 0
93 0
- 0
98 0
] 0
. 0

The 0
proteasome 0
is 0
a 0
large 0
complex 0
consisting 0
of 0
two 0
multisubunit 0
structures 0
, 0
the 0
20S B-gene
and 0
19S B-gene
( 0
PA700 B-gene
) 0
or 0
P28 B-gene
complexes I-gene
, 0
that 0
combine 0
to 0
form 0
the 0
26S B-gene
particles I-gene
. 0

In 0
assays 0
with 0
purified 0
enzymes 0
, 0
wild 0
- 0
type 0
but 0
not 0
PTPS B-gene
- 0
S19A B-gene
was 0
a 0
specific 0
substrate 0
for 0
the 0
cGMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( I-gene
cGK I-gene
) I-gene
type I-gene
I I-gene
and I-gene
II I-gene
. 0

R. 0
, 0
Fleischmann 0
, 0
R. 0
, 0
Venter 0
, 0
J 0
. 0

The 0
N 0
- 0
terminal 0
domain 0
of 0
approximately 0
70 0
kDa 0
exhibits 0
11 0
imperfect 0
amino 0
acid 0
repeats 0
that 0
show 0
some 0
homology 0
to 0
promastigote 0
surface 0
glycoproteins 0
of 0
the 0
psa2/gp46 B-gene
complex 0
. 0

In 0
contrast 0
to 0
previously 0
characterized 0
proteophosphoglycans 0
, 0
the 0
ppg1 B-gene
gene 0
product 0
is 0
predominantly 0
membrane 0
- 0
associated 0
and 0
it 0
is 0
expressed 0
on 0
the 0
promastigote 0
cell 0
surface 0
. 0

Most 0
important 0
, 0
infection 0
of 0
the 0
cells 0
with 0
an 0
adenoviral 0
construct 0
expressing 0
this 0
mutant 0
inhibited 0
the 0
induction 0
of 0
VEGF B-gene
mRNA I-gene
under 0
conditions 0
that 0
mimic 0
hypoxia 0
. 0

Neuregulin B-gene
stimulates 0
ErbB2 B-gene
, 0
ErbB3 B-gene
, 0
and 0
ErbB4 B-gene
, 0
members 0
of 0
the 0
ErbB B-gene
family I-gene
of 0
receptor B-gene
tyrosine I-gene
kinases I-gene
. 0

Our 0
results 0
suggest 0
that 0
Anu2p B-gene
is 0
the 0
yeast B-gene
homologue I-gene
of I-gene
mammalian I-gene
epsilon I-gene
- I-gene
COP I-gene
and 0
the 0
abrupt 0
accumulation 0
of 0
the 0
ER 0
membrane 0
caused 0
by 0
a 0
blockage 0
of 0
the 0
early 0
protein 0
transport 0
pathway 0
leads 0
to 0
alteration 0
of 0
nuclear 0
morphology 0
of 0
the 0
budding 0
yeast 0
cells 0
. 0

In 0
PC12 0
cells 0
, 0
nerve B-gene
growth I-gene
factor I-gene
induces 0
neuronal 0
differentiation 0
and 0
repressed 0
expression 0
of 0
nrg B-gene
- I-gene
1 I-gene
. 0

In 0
a 0
PC12 0
cell 0
mutant 0
that 0
is 0
deficient 0
in 0
protein B-gene
kinase I-gene
A I-gene
activity 0
( 0
AB.11 0
) 0
, 0
all 0
three 0
differentiating 0
agents 0
were 0
unable 0
to 0
down 0
- 0
regulate 0
nrg B-gene
- I-gene
1 I-gene
mRNA I-gene
. 0

TSC1 B-gene
mutations I-gene
include 0
two 0
nonsense 0
mutations 0
, 0
four 0
insertions 0
, 0
and 0
three 0
splice 0
mutations 0
. 0

Twelve 0
patients 0
without 0
abnormalities 0
in 0
the 0
PTT 0
are 0
assumed 0
to 0
harbor 0
missense 0
mutations 0
, 0
probably 0
in 0
TSC2 B-gene
. 0

The 0
first 0
algorithm 0
, 0
FOREPROJ 0
, 0
is 0
a 0
fast 0
- 0
forward 0
projection 0
algorithm 0
that 0
allows 0
calculation 0
of 0
the 0
3 0
- 0
D 0
attenuation 0
correction 0
factors 0
( 0
ACF 0
's 0
) 0
directly 0
from 0
a 0
two 0
- 0
dimensional 0
( 0
2 0
- 0
D 0
) 0
transmission 0
scan 0
, 0
without 0
first 0
reconstructing 0
the 0
attenuation 0
map 0
and 0
then 0
performing 0
a 0
3 0
- 0
D 0
forward 0
projection 0
. 0

We 0
have 0
cloned 0
cDNA 0
and 0
genomic 0
DNA 0
for 0
a 0
mouse 0
gene 0
encoding 0
a 0
protein 0
with 0
significant 0
sequence 0
similarity 0
to 0
conserved 0
domains 0
found 0
in 0
proteins 0
of 0
the 0
Spo11p B-gene
family I-gene
. 0

RT 0
- 0
PCR 0
and 0
in 0
situ 0
hybridization 0
analyses 0
of 0
a 0
time 0
course 0
of 0
juvenile 0
testis 0
development 0
indicate 0
that 0
Spo11 B-gene
expression 0
begins 0
in 0
early 0
meiotic 0
Prophase 0
I 0
, 0
prior 0
to 0
the 0
pachytene 0
stage 0
, 0
with 0
increasing 0
accumulation 0
of 0
mRNA 0
through 0
the 0
pachytene 0
stage 0
. 0

Animals 0
were 0
put 0
to 0
death 0
8 0
weeks 0
later 0
and 0
the 0
grafts 0
were 0
sterilely 0
explanted 0
and 0
analyzed 0
via 0
microbiologic 0
culture 0
and 0
standard 0
histologic 0
procedures 0
for 0
evidence 0
of 0
infection 0
. 0

The 0
RMR 0
was 0
measured 0
twice 0
in 0
each 0
phase 0
and 0
found 0
to 0
be 0
similar 0
( 0
F 0
( 0
1,18 0
) 0
= 0
0.863 0
) 0
across 0
the 0
follicular 0
( 0
5018 0
kJ/24 0
h 0
) 0
and 0
the 0
luteal 0
( 0
5098 0
kJ/24 0
h 0
) 0
phases 0
. 0

Oseltamivir 0
( 0
GS4104 0
) 0
, 0
which 0
can 0
be 0
administered 0
orally 0
, 0
is 0
the 0
prodrug 0
of 0
GS4071 0
, 0
a 0
potent 0
and 0
selective 0
inhibitor 0
of 0
influenzavirus B-gene
neuraminidases I-gene
. 0

In 0
gel 0
mobility 0
shift 0
assays 0
, 0
we 0
found 0
no 0
evidence 0
for 0
VDR B-gene
- 0
TR B-gene
heterodimer 0
interaction 0
with 0
any 0
tested 0
element 0
. 0

The 0
relative 0
importance 0
of 0
these 0
two 0
mechanisms 0
differed 0
in 0
a 0
response 0
element 0
- 0
specific 0
manner 0
. 0

After 0
14 0
d 0
of 0
overfeeding 0
, 0
hepatic 0
PL 0
profiles 0
were 0
identical 0
in 0
the 0
two 0
breeds 0
and 0
similar 0
to 0
that 0
in 0
control 0
livers 0
; 0
choline 0
- 0
containing 0
PL 0
accounted 0
for 0
95 0
% 0
of 0
total 0
PL 0
. 0

C 0
- 0
SP 0
duration 0
was 0
significantly 0
reduced 0
in 0
ALS 0
patients 0
compared 0
to 0
controls 0
at 0
low 0
stimulation 0
intensity 0
corresponding 0
to 0
an 0
MEP 0
threshold 0
increased 0
by 0
15 0
% 0
. 0

These 0
data 0
show 0
that 0
the 0
spv B-gene
virulence I-gene
genes I-gene
belong 0
simultaneously 0
to 0
several 0
regulons 0
in 0
the 0
cell 0
, 0
raising 0
the 0
possibility 0
that 0
spv B-gene
expression 0
can 0
be 0
fine 0
- 0
tuned 0
in 0
response 0
to 0
multiple 0
environmental 0
inputs 0
. 0

Intensive 0
synthesis 0
of 0
PNA B-gene
in 0
the 0
cells 0
of 0
microvascular 0
wall 0
evidenced 0
of 0
their 0
high 0
functional 0
activity 0
, 0
and 0
the 0
synthesis 0
of 0
DNA 0
in 0
them 0
showed 0
their 0
ability 0
for 0
proliferation 0
, 0
i.g. 0
- 0
- 0
for 0
growth 0
. 0

Tracheal 0
transsection 0
combined 0
with 0
hilar 0
ligation 0
( 0
TL 0
& 0
PL 0
) 0
effected 0
a 0
reduction 0
of 0
19.9 0
% 0
( 0
n.s 0
. 0
) 0
. 0

Kinase 0
- 0
deficient 0
erbB B-gene
proteins I-gene
reduced 0
epidermal B-gene
growth I-gene
factor I-gene
( 0
EGF B-gene
) 0
- 0
induced 0
tyrosine 0
phosphorylation 0
of 0
endogenous 0
Shc B-gene
proteins I-gene
and 0
also 0
reduced 0
immediate 0
and 0
sustained 0
EGF B-gene
- I-gene
induced I-gene
ERK I-gene
MAPK I-gene
activities 0
in 0
human 0
glioblastoma 0
cells 0
, 0
although 0
basal 0
ERK B-gene
MAPK I-gene
activities 0
were 0
unaffected 0
. 0

Using 0
immunolocalization 0
, 0
we 0
observe 0
that 0
ACE3 B-gene
, 0
a 0
440 0
- 0
bp 0
chorion 0
element 0
that 0
contains 0
information 0
sufficient 0
to 0
drive 0
amplification 0
, 0
directs 0
DmORC B-gene
localization 0
in 0
follicle 0
cells 0
. 0

Therefore 0
, 0
homozygous 0
co 0
- 0
deletions 0
of 0
CDKN2A B-gene
and 0
CDKN2B B-gene
rather 0
than 0
mutations 0
targeting 0
individual 0
transcripts 0
are 0
frequently 0
selected 0
for 0
in 0
these 0
tumors 0
. 0

Here 0
, 0
we 0
show 0
that 0
aortic 0
explants 0
isolated 0
from 0
PPARalpha B-gene
- 0
null 0
mice 0
display 0
an 0
exacerbated 0
response 0
to 0
inflammatory 0
stimuli 0
, 0
such 0
as 0
lipopolysaccharide 0
( 0
LPS 0
) 0
, 0
as 0
demonstrated 0
by 0
increased 0
IL B-gene
- I-gene
6 I-gene
secretion 0
. 0

Albumin 0
expression 0
is 0
maintained 0
in 0
the 0
liver 0
by 0
a 0
combination 0
of 0
liver 0
- 0
enriched 0
transcription 0
factors 0
such 0
as 0
CAAT B-gene
enhancer I-gene
- I-gene
binding I-gene
protein I-gene
( I-gene
C/EBP I-gene
) I-gene
alpha I-gene
and 0
C/EBPbeta B-gene
. 0

The 0
requirement 0
for 0
proteolytic 0
activity 0
of 0
both 0
FVIIa B-gene
and 0
FXa B-gene
suggests 0
that 0
protease 0
- 0
activated 0
receptors 0
may 0
be 0
involved 0
. 0

Amyloid B-gene
beta I-gene
- I-gene
protein I-gene
( 0
Abeta B-gene
) 0
is 0
the 0
main 0
constituent 0
of 0
amyloid 0
fibrils 0
found 0
in 0
senile 0
plaques 0
and 0
cerebral 0
vessels 0
in 0
Alzheimer 0
's 0
disease 0
( 0
AD 0
) 0
and 0
is 0
derived 0
by 0
proteolysis 0
from 0
the 0
beta B-gene
- I-gene
amyloid I-gene
precursor I-gene
protein I-gene
( 0
APP B-gene
) 0
. 0

We 0
also 0
show 0
that 0
activation 0
of 0
protein B-gene
kinase I-gene
A I-gene
( 0
PKA B-gene
) 0
signaling 0
is 0
sufficient 0
to 0
down 0
- 0
regulate 0
caveolin B-gene
- I-gene
1 I-gene
protein I-gene
expression 0
and 0
promoter 0
activity 0
. 0

The 0
importin B-gene
alpha.beta I-gene
heterodimer I-gene
mediates 0
nuclear 0
import 0
of 0
proteins 0
containing 0
classical 0
nuclear 0
localization 0
signals 0
. 0

The 0
expressed 0
G1 B-gene
- 0
G2 B-gene
bound 0
to 0
both 0
hyaluronan 0
and 0
link B-gene
protein I-gene
indicating 0
that 0
the 0
immunoglobulin B-gene
- I-gene
fold I-gene
motif I-gene
and 0
proteoglycan 0
tandem 0
repeat 0
loops 0
of 0
the 0
G1 B-gene
domain I-gene
were 0
correctly 0
folded 0
. 0

The 0
results 0
suggest 0
that 0
the 0
presence 0
or 0
absence 0
per 0
se 0
of 0
keratan 0
sulfate 0
on 0
native 0
G1 0
- 0
G2 0
does 0
not 0
affect 0
the 0
activity 0
of 0
atrolysin 0
C 0
toward 0
the 0
two 0
sites 0
. 0

Despite 0
i.v 0
. 0
steroid 0
therapy 0
, 0
[ 0
NOexh 0
] 0
remained 0
elevated 0
throughout 0
recovery 0
( 0
37.9+/ 0
- 0
4.8 0
ppb 0
, 0
p 0
< 0
0.001 0
) 0
until 0
discharge 0
( 0
40.9+/ 0
- 0
4.3 0
ppb 0
, 0
p 0
< 0
0.001 0
) 0
. 0

It 0
contains 0
binding 0
sites 0
for 0
several 0
transcription 0
factors 0
, 0
for 0
example 0
: 0
( 0
i 0
) 0
a 0
well 0
- 0
characterized 0
binding 0
site 0
for 0
rel/NF B-gene
rel/NF I-gene
- I-gene
kappaB I-gene
transcription 0
factors 0
in 0
its 0
3' 0
- 0
end 0
( 0
the 0
H2TF1 B-gene
or 0
kappaB1 B-gene
element I-gene
) 0
, 0
( 0
ii 0
) 0
a 0
second 0
kappaB B-gene
site I-gene
( 0
the 0
kappaB2 B-gene
element I-gene
) 0
, 0
which 0
is 0
located 0
immediately 0
adjacent 0
5 0
' 0
to 0
the 0
H2TF1 B-gene
element I-gene
and 0
which 0
is 0
recognized 0
by 0
p65/relA B-gene
in 0
the 0
p65/relA I-gene

The 0
tumorigenic 0
E1A B-gene
+ 0
cHa B-gene
- I-gene
ras I-gene
cells 0
are 0
characterized 0
by 0
high 0
and 0
constitutive 0
DNA 0
binding 0
activities 0
of 0
AP B-gene
- I-gene
1 I-gene
, 0
in 0
contrast 0
to 0
nontransformed 0
cells 0
and 0
the 0
E1A B-gene
cells 0
. 0

The 0
yeast 0
C B-gene
- I-gene
type I-gene
cyclin I-gene
Ume3p/Srb11p B-gene
and 0
its 0
Ume3p/Srb11p I-gene

In 0
particular 0
, 0
the 0
S1 B-gene
' I-gene
specificity I-gene
site I-gene
is 0
a 0
deep 0
and 0
highly 0
hydrophobic 0
cavity 0
. 0

FZD4 B-gene
is 0
homologous 0
to 0
FZD9 B-gene
and 0
FZD10 B-gene
, 0
and 0
overall 0
amino 0
acid 0
identity 0
is 0
as 0
follows 0
: 0
FZD4 B-gene
vs 0
FZD9 B-gene
, 0
51.6 0
% 0
; 0
FZD4 B-gene
vs 0
FZD10 B-gene
, 0
51.2 0
% 0
; 0
FZD9 B-gene
vs 0
FZD10 B-gene
, 0
65.7 0
% 0
. 0

The 0
NF B-gene
- I-gene
kappaB I-gene
responsive 0
reporter 0
construct 0
, 0
( B-gene
PRDII I-gene
) I-gene
( I-gene
4 I-gene
) I-gene
- 0
CAT B-gene
, 0
was 0
used 0
to 0
explore 0
transcription 0
resulting 0
from 0
NF B-gene
- I-gene
kappaB I-gene
activated 0
by 0
Tat B-gene
. 0

The 0
RNA 0
transcripts 0
structurally 0
equivalent 0
to 0
I B-gene
( I-gene
2 I-gene
) I-gene
sgRNAs I-gene
of 0
TMV B-gene
U1 I-gene
and 0
crTMV 0
, 0
but 0
containing 0
a 0
hairpin 0
structure 0
( 0
H 0
) 0
immediately 0
upstream 0
of 0
IRES B-gene
( I-gene
MP,75 I-gene
) I-gene
( I-gene
HIRES I-gene
( I-gene
MP I-gene
) I-gene
, I-gene
( I-gene
75 I-gene
) I-gene
( I-gene
CR I-gene
) I-gene
- I-gene
MP I-gene
- I-gene
CP I-gene
- I-gene
3'UTR I-gene
; 0
HIRES B-gene
( I-gene
MP,75 I-gene
) I-gene
( I-gene
U1 I-gene
) I-gene
- I-gene
MP I-gene
- I-gene
CP I-gene
- I-gene
3'UTR I-gene
) 0
, 0
were 0
able 0
to 0
express 0
the 0
MP B-gene
gene I-gene
in 0
vitro 0
. 0

EIAV B-gene
LTR I-gene
sequence I-gene
variability 0
is 0
confined 0
mostly 0
to 0
a 0
small 0
portion 0
of 0
the 0
enhancer 0
within 0
the 0
U3 0
segment 0
of 0
the 0
LTR 0
. 0

Phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
requirement 0
in 0
activation 0
of 0
the 0
ras/C B-gene
ras/C I-gene
- I-gene
raf I-gene
- I-gene
1/MEK/ERK I-gene
and 0
1/MEK/ERK I-gene

The 0
core 0
of 0
this 0
enhancer 0
contains 0
two 0
evolutionarily 0
conserved 0
binding 0
sites 0
for 0
the 0
homeodomain B-gene
protein I-gene
Tinman B-gene
( 0
Tin B-gene
) 0
, 0
expressed 0
in 0
developing 0
cardiac 0
, 0
somatic 0
, 0
and 0
visceral 0
muscle 0
lineages 0
. 0

For 0
example 0
, 0
introduction 0
of 0
immunogenic 0
and 0
purification 0
tag 0
sequences 0
into 0
the 0
C 0
- 0
terminal 0
coding 0
region 0
significantly 0
decreased 0
bop B-gene
gene I-gene
mRNA I-gene
and 0
protein 0
accumulation 0
. 0

Furthermore 0
, 0
the 0
striking 0
ability 0
of 0
polyoma B-gene
middle I-gene
T I-gene
antigens I-gene
to 0
promote 0
retinoic 0
acid 0
- 0
induced 0
differentiation 0
appears 0
to 0
utilize 0
ERK B-gene
, 0
but 0
not 0
JNK/SPK B-gene
or 0
JNK/SPK I-gene

We 0
recommend 0
that 0
paracervical 0
block 0
with 0
lignocaine 0
should 0
be 0
used 0
in 0
conjunction 0
with 0
i.v 0
. 0
sedation/analgesia 0
during 0
egg 0
collection 0
performed 0
through 0
the 0
transvaginal 0
route 0
under 0
ultrasound 0
guidance 0
( 0
TUGOR 0
) 0
to 0
reduce 0
the 0
pain 0
of 0
the 0
procedure 0
. 0

All 0
loci 0
have 0
a 0
similar 0
organization 0
, 0
except 0
for 0
H1.8 B-gene
that 0
harbors 0
two 0
TcP2beta B-gene
genes I-gene
arranged 0
in 0
tandem 0
and 0
separated 0
by 0
a 0
short 0
repetitive 0
sequence 0
, 0
named 0
SIRE 0
( 0
short 0
interspersed 0
repetitive 0
element 0
) 0
, 0
which 0
is 0
also 0
found 0
upstream 0
of 0
the 0
first 0
gene 0
of 0
the 0
tandem 0
and 0
downstream 0
of 0
the 0
second 0
. 0

A 0
proportion 0
of 0
APC B-gene
wild 0
- 0
type 0
colon 0
carcinomas 0
and 0
melanomas 0
also 0
contains 0
constitutive 0
nuclear 0
Tcf B-gene
- I-gene
4/beta I-gene
4/beta I-gene
- I-gene
catenin I-gene
complexes 0
as 0
a 0
result 0
of 0
dominant 0
mutations 0
in 0
the 0
N 0
terminus 0
of 0
beta B-gene
- I-gene
catenin I-gene
that 0
render 0
it 0
insensitive 0
to 0
downregulation 0
by 0
APC B-gene
, 0
GSK3 B-gene
beta I-gene
, 0
and 0
Axin/Conductin B-gene
. 0

Similar 0
mechanisms 0
leading 0
to 0
deregulation 0
of 0
Tcf B-gene
target I-gene
gene I-gene
activity 0
are 0
likely 0
to 0
be 0
involved 0
in 0
melanoma 0
and 0
other 0
forms 0
of 0
cancer 0
. 0

This 0
report 0
describes 0
a 0
patient 0
with 0
a 0
previous 0
inferior 0
acute 0
myocardial 0
infarction 0
who 0
developed 0
right 0
ventricular 0
infarction 0
with 0
significant 0
anterior 0
lead 0
ST 0
segment 0
elevation 0
( 0
V1 0
- 0
V4 0
) 0
caused 0
by 0
the 0
loss 0
of 0
two 0
large 0
right 0
ventricular 0
branches 0
during 0
a 0
coronary 0
angioplasty 0
of 0
the 0
right 0
coronary 0
artery 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
Immediately 0
before 0
radical 0
prostatectomy 0
, 0
bone 0
marrow 0
aspirates 0
from 0
both 0
sides 0
of 0
the 0
iliac 0
crest 0
were 0
taken 0
from 0
287 0
patients 0
. 0

PURPOSE 0
: 0
Previous 0
WR 0
- 0
2721 0
human 0
pharmacokinetic 0
studies 0
were 0
limited 0
to 0
plasma 0
levels 0
in 0
patients 0
receiving 0
platinum 0
- 0
based 0
compounds 0
, 0
and 0
none 0
includes 0
the 0
effects 0
of 0
WR 0
- 0
2721 0
on 0
endogenous 0
thiols 0
. 0

With 0
regard 0
to 0
nonhematologic 0
toxicities 0
, 0
diarrhea 0
, 0
infection 0
and 0
elevated 0
serum B-gene
alkaline I-gene
phosphatase I-gene
of 0
grade 0
3 0
or 0
over 0
were 0
observed 0
in 0
2 0
% 0
of 0
cycles 0
, 0
but 0
were 0
tolerable 0
and 0
reversible 0
. 0

LHbeta B-gene
is 0
expressed 0
in 0
pituitary 0
gonadotrope 0
cells 0
and 0
CGbeta B-gene
is 0
expressed 0
in 0
placental 0
trophoblast 0
cells 0
. 0

Regulation 0
of 0
HIV 0
- 0
1 0
transcription 0
. 0

Human B-gene
LTBP I-gene
- I-gene
1 I-gene
is 0
known 0
to 0
exist 0
in 0
different 0
forms 0
. 0

In 0
an 0
earlier 0
study 0
( 0
Kimura 0
, 0
Y. 0
, 0
Kurzydlowski 0
, 0
K. 0
, 0
Tada 0
, 0
M. 0
, 0
and 0
MacLennan 0
, 0
D 0
. 0

It 0
consists 0
of 0
2185 0
amino 0
acid 0
residues 0
encoded 0
by 0
a 0
9 0
- 0
kilobase 0
pair 0
mRNA 0
; 0
several 0
splice 0
variants 0
have 0
been 0
detected 0
in 0
human 0
and 0
rat 0
cDNA 0
libraries 0
. 0

Cyclic B-gene
AMP I-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
binding 0
to 0
A B-gene
- I-gene
kinase I-gene
anchoring 0
proteins 0
in 0
living 0
cells 0
by 0
fluorescence 0
resonance 0
energy 0
transfer 0
of 0
green B-gene
fluorescent I-gene
protein I-gene
fusion 0
proteins 0
. 0

CONCLUSIONS 0
: 0
In 0
addition 0
to 0
the 0
superiority 0
of 0
octafluoropropane 0
- 0
filled 0
microspheres 0
to 0
air 0
- 0
filled 0
microspheres 0
for 0
LV 0
opacification 0
, 0
the 0
efficacy 0
of 0
OCTA 0
is 0
relatively 0
unaffected 0
by 0
impaired 0
LV 0
function 0
and 0
is 0
less 0
susceptible 0
to 0
the 0
effects 0
of 0
poor 0
echogenicity 0
than 0
AIR 0
. 0

Factor B-gene
XI I-gene
deficiency 0
is 0
a 0
rare 0
hereditary 0
bleeding 0
disorder 0
affecting 0
the 0
intrinsic 0
pathway 0
. 0

The 0
Ishasha 0
samples 0
show 0
a 0
range 0
encompassing 0
three 0
trophic 0
levels 0
. 0

The 0
more 0
traditional 0
SERMS 0
, 0
clomiphene 0
citrate 0
and 0
tamoxifen 0
, 0
will 0
be 0
reviewed 0
along 0
with 0
such 0
modern 0
drugs 0
as 0
raloxifene 0
and 0
faslodex 0
, 0
with 0
emphasis 0
upon 0
their 0
actions 0
on 0
breast 0
, 0
uterus 0
, 0
bone 0
and 0
lipids 0
. 0

Ti 0
exhibited 0
a 0
feather 0
- 0
like 0
morphology 0
. 0

This 0
organization 0
suggests 0
that 0
duplication 0
events 0
that 0
have 0
generated 0
the 0
primate 0
FUT3 B-gene
- 0
FUT5 B-gene
- 0
FUT6 B-gene
cluster 0
might 0
have 0
occurred 0
through 0
a 0
long 0
- 0
interspersed 0
- 0
nuclear 0
- 0
element 0
- 0
based 0
mechanism 0
of 0
unequal 0
crossing 0
over 0
, 0
as 0
described 0
for 0
the 0
globin B-gene
cluster I-gene
. 0

S. 0
, 0
Kim 0
, 0
S 0
. 0

The 0
cop B-gene
region I-gene
also 0
harbors 0
a 0
region 0
of 0
plasmid 0
incompatibility 0
, 0
inc B-gene
, 0
encompassing 0
a 0
stem 0
- 0
loop 0
structure 0
, 0
the 0
repA B-gene
promoter I-gene
, 0
Prep B-gene
, 0
as 0
well 0
as 0
two 0
distinct 0
RepA B-gene
binding I-gene
sites I-gene
, 0
BD 0
- 0
1 0
and 0
BD 0
- 0
2 0
. 0

WA 0
constructs 0
afforded 0
relaxed 0
and 0
positive 0
topoisomers 0
, 0
and 0
cyclization 0
kinetics 0
indicated 0
slow 0
interconversion 0
of 0
precursors 0
to 0
the 0
two 0
topoisomers 0
. 0

The 0
RFX B-gene
protein I-gene
family I-gene
includes 0
members 0
from 0
yeast 0
to 0
humans 0
, 0
which 0
function 0
in 0
various 0
biological 0
systems 0
, 0
and 0
share 0
a 0
DNA 0
- 0
binding 0
domain 0
and 0
a 0
conserved 0
C 0
- 0
terminal 0
region 0
. 0

Binding 0
to 0
sulphatides 0
and 0
the 0
alpha B-gene
- I-gene
dystroglycan I-gene
receptor I-gene
was 0
much 0
stronger 0
and 0
required 0
at 0
least 0
two 0
LG B-gene
modules I-gene
. 0

Here 0
, 0
we 0
propose 0
that 0
an 0
antagonistic 0
, 0
BMP/ALK2/Smad B-gene
- 0
mediated 0
signaling 0
pathway 0
is 0
active 0
on 0
the 0
right 0
side 0
of 0
the 0
Xenopus 0
embryo 0
. 0

These 0
kinases 0
belong 0
to 0
a 0
new 0
subfamily 0
related 0
to 0
the 0
Trk B-gene
subfamily I-gene
. 0

The 0
data 0
indicate 0
that 0
etr B-gene
- I-gene
1 I-gene
is 0
essential 0
for 0
muscle 0
development 0
in 0
C. 0
elegans 0
, 0
perhaps 0
by 0
playing 0
a 0
role 0
in 0
post 0
- 0
transcriptional 0
processing 0
of 0
some 0
muscle 0
component 0
, 0
and 0
thus 0
suggesting 0
a 0
possible 0
conservation 0
of 0
gene 0
function 0
with 0
human B-gene
CUG I-gene
- I-gene
bp I-gene
. 0

Gentamicin 0
given 0
by 0
DPI 0
and 0
SVN 0
significantly 0
decreased 0
the 0
sputum 0
Psa 0
density 0
( 0
p 0
< 0
0.05 0
) 0
, 0
by 0
almost 0
one 0
order 0
of 0
magnitude 0
. 0

CONCLUSIONS 0
: 0
The 0
largest 0
value 0
of 0
the 0
joint 0
space 0
may 0
be 0
used 0
when 0
evaluating 0
rheumatoid 0
AC 0
joint 0
space 0
. 0

An 0
analysis 0
of 0
sequence 0
of 0
the 0
mutant B-gene
recN I-gene
gene I-gene
revealed 0
a 0
G 0
: 0
C 0
to 0
T 0
: 0
A 0
transversion 0
near 0
the 0
3 0
' 0
end 0
of 0
the 0
coding 0
region 0
. 0

Nevertheless 0
, 0
in 0
view 0
of 0
the 0
potential 0
transmission 0
rates 0
of 0
HGV 0
and 0
the 0
lack 0
of 0
effective 0
immunization 0
, 0
HGV 0
should 0
be 0
regarded 0
as 0
a 0
potential 0
occupational 0
hazard 0
for 0
medical 0
and 0
dental 0
staff 0
. 0

Detection 0
of 0
poisoning 0
by 0
Impila 0
( 0
Callilepis 0
laureola 0
) 0
in 0
a 0
mother 0
and 0
child 0
. 0

We 0
have 0
previously 0
identified 0
mouse B-gene
and I-gene
human I-gene
cDNAs I-gene
encoding I-gene
UNC I-gene
- I-gene
51 I-gene
- I-gene
like I-gene
kinase I-gene
( 0
ULK1 B-gene
) 0
. 0

ULKs B-gene
and 0
UNC B-gene
- I-gene
51 I-gene
share 0
a 0
typical 0
domain 0
structure 0
of 0
an 0
amino 0
- 0
terminal 0
kinase 0
domain 0
, 0
a 0
central 0
proline/serine 0
rich 0
( 0
PS 0
) 0
domain 0
, 0
and 0
a 0
carboxy 0
- 0
terminal 0
( 0
C 0
) 0
domain 0
. 0

These 0
results 0
suggest 0
that 0
ULK2 B-gene
is 0
involved 0
in 0
a 0
previously 0
uncharacterized 0
signaling 0
pathway 0
in 0
mammalian 0
cells 0
. 0

Connector B-gene
enhancer I-gene
of I-gene
KSR I-gene
( 0
CNK B-gene
) 0
is 0
a 0
multidomain 0
protein 0
required 0
for 0
RAS B-gene
signaling 0
. 0

In 0
simpler 0
organisms 0
, 0
the 0
ATP B-gene
sulfurylase I-gene
and 0
APS B-gene
kinase I-gene
reactions 0
are 0
catalyzed 0
by 0
separate 0
enzymes 0
encoded 0
by 0
two 0
or 0
three 0
genes 0
, 0
suggesting 0
that 0
a 0
fusion 0
of 0
separate 0
genes 0
during 0
the 0
course 0
of 0
evolution 0
generated 0
the 0
bifunctional 0
enzyme 0
. 0

Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
( I-gene
EBV I-gene
) I-gene
latent I-gene
membrane I-gene
protein I-gene
1 I-gene
( 0
LMP1 B-gene
) 0
is 0
essential 0
for 0
EBV 0
- 0
mediated 0
transformation 0
of 0
primary 0
B 0
lymphocytes 0
. 0

The 0
amino 0
- 0
terminal 0
half 0
of 0
1a B-gene
is 0
a 0
distant 0
homolog B-gene
of I-gene
alphavirus I-gene
nonstructural I-gene
protein I-gene
nsP1 I-gene
, 0
which 0
has 0
been 0
implicated 0
in 0
capping 0
viral 0
RNAs 0
. 0

Moreover 0
, 0
a 0
recombinant 0
Ad 0
expressing 0
Ad5 B-gene
E4orf6/7 I-gene
induced 0
apoptosis 0
in 0
rat 0
cells 0
when 0
coinfected 0
with 0
wild 0
- 0
type 0
p53 B-gene
- 0
expressing 0
Ad 0
. 0

In 0
HCMV 0
( 0
Towne 0
) 0
- 0
infected 0
HF 0
cells 0
at 0
24 0
to 0
48 0
h 0
, 0
IE2 B-gene
also 0
accumulated 0
in 0
newly 0
formed 0
viral 0
DNA 0
replication 0
compartments 0
containing 0
the 0
polymerase B-gene
processivity I-gene
factor I-gene
( 0
UL44 B-gene
) 0
, 0
the 0
single B-gene
- I-gene
stranded I-gene
DNA I-gene
binding I-gene
protein I-gene
( 0
SSB B-gene
; 0
UL57 B-gene
) 0
, 0
the 0
UL112 B-gene
- I-gene
113 I-gene
accessory I-gene
protein I-gene
, 0
and 0
newly 0
incorporated 0
bromodeoxyuridine 0
( 0
BrdU 0
) 0
. 0

Macroscopic 0
researches 0
on 0
heart 0
vascularization 0
have 0
indicated 0
that 0
the 0
angioarchitecture 0
of 0
the 0
conducting 0
system 0
differs 0
from 0
that 0
of 0
the 0
normal 0
myocardium 0
. 0

CONCLUSION 0
( 0
S 0
) 0
: 0
Measuring 0
urinary 0
LH B-gene
levels 0
is 0
an 0
excellent 0
method 0
for 0
determining 0
ovulation 0
. 0

However 0
, 0
reoperation 0
for 0
bulky 0
cervical 0
disease 0
( 0
group 0
3 0
) 0
rarely 0
results 0
in 0
normal 0
calcitonin B-gene
levels 0
and 0
is 0
associated 0
with 0
a 0
high 0
incidence 0
of 0
permanent 0
hypoparathyroidism 0
. 0

We 0
present 0
a 0
case 0
of 0
carcinoma 0
of 0
the 0
breast 0
presenting 0
concurrently 0
with 0
SSc 0
that 0
subsequently 0
progressed 0
to 0
dialysis 0
- 0
dependent 0
renal 0
failure 0
in 0
just 0
1 0
month 0
. 0

PURPOSE 0
: 0
To 0
evaluate 0
the 0
disease 0
- 0
free 0
survival 0
( 0
DFS 0
) 0
and 0
overall 0
survival 0
( 0
OS 0
) 0
, 0
prognostic 0
factors 0
, 0
and 0
treatment 0
- 0
related 0
mortality 0
of 0
women 0
with 0
stage 0
IIIB 0
inflammatory 0
breast 0
cancer 0
( 0
IBC 0
) 0
treated 0
with 0
combined 0
modality 0
therapy 0
( 0
CMT 0
) 0
and 0
high 0
- 0
dose 0
chemotherapy 0
( 0
HDCT 0
) 0
with 0
autologous 0
stem 0
- 0
cell 0
transplantation 0
. 0

The 0
GPI 0
anchor 0
moiety 0
is 0
either 0
absent 0
or 0
present 0
at 0
a 0
very 0
low 0
level 0
in 0
the 0
polypeptide 0
expressed 0
from 0
the 0
cDNA 0
that 0
contained 0
both 0
the 0
signal 0
peptide 0
and 0
GPI 0
signal 0
sequences 0
. 0

We 0
have 0
cloned 0
a 0
novel 0
100 0
- 0
kDa 0
mammalian 0
protein 0
, 0
which 0
was 0
recognized 0
by 0
an 0
anti 0
- 0
peptide 0
antibody 0
against 0
an 0
epitope 0
- 0
containing 0
nuclear 0
localization 0
signal 0
of 0
NF B-gene
- I-gene
kappaB I-gene
p65 B-gene
subunit I-gene
. 0

Insulin B-gene
- 0
regulated 0
events 0
, 0
however 0
, 0
occur 0
in 0
all 0
cells 0
. 0

Regulatory 0
regions 0
in 0
the 0
promoter 0
and 0
third 0
intron 0
of 0
the 0
growth B-gene
hormone I-gene
gene I-gene
in I-gene
rainbow I-gene
trout I-gene
, 0
Oncorhynchus 0
mykiss 0
walbaum 0
. 0

Although 0
most 0
SFV 0
genes 0
have 0
homologs 0
encoded 0
by 0
other 0
Chordopoxvirinae 0
, 0
the 0
SFV 0
genome 0
lacks 0
a 0
key 0
gene 0
required 0
for 0
the 0
production 0
of 0
extracellular 0
enveloped 0
virus 0
. 0

They 0
self 0
- 0
completed 0
the 0
SF 0
- 0
36 0
questionnaire 0
and 0
their 0
QoL 0
was 0
described 0
and 0
retrospectively 0
compared 0
to 0
that 0
of 0
historical 0
controls 0
. 0

There 0
was 0
a 0
trend 0
toward 0
an 0
association 0
between 0
IENF 0
and 0
sural 0
nerve 0
unmyelinated 0
fiber 0
densities 0
( 0
r 0
= 0
0.32 0
, 0
p 0
= 0
0.054 0
) 0
. 0

In 0
addition 0
, 0
media 0
containing 0
F B-gene
beta I-gene
alpha/CG I-gene
alpha/CG I-gene
beta I-gene
displayed 0
high 0
- 0
affinity 0
binding 0
to 0
both 0
CG B-gene
and I-gene
FSH I-gene
receptors I-gene
. 0

In 0
contrast 0
, 0
AP B-gene
- I-gene
2 I-gene
binding 0
activity 0
was 0
significantly 0
greater 0
in 0
T47D 0
cells 0
, 0
and 0
Western 0
blots 0
confirmed 0
increased 0
AP B-gene
- I-gene
2 I-gene
protein I-gene
levels 0
in 0
these 0
cells 0
. 0

N. 0
van 0
Hoek 0
, 0
and 0
M 0
. 0

Here 0
, 0
we 0
describe 0
a 0
tyrosine 0
- 0
phosphorylated 0
nuclear 0
protein 0
, 0
YT521 B-gene
- I-gene
B I-gene
, 0
and 0
show 0
that 0
it 0
interacts 0
with 0
the 0
nuclear B-gene
transcriptosomal I-gene
component I-gene
scaffold I-gene
attachment I-gene
factor I-gene
B I-gene
, 0
and 0
the 0
68 B-gene
- I-gene
kDa I-gene
Src I-gene
substrate 0
associated 0
during 0
mitosis 0
, 0
Sam68 B-gene
. 0

These 0
mutants 0
all 0
failed 0
to 0
interact 0
with 0
the 0
TraR B-gene
fusion I-gene
in 0
the 0
two 0
- 0
hybrid 0
system 0
. 0

PhoP B-gene
- 0
PhoQ B-gene
homologues 0
in 0
Pseudomonas 0
aeruginosa 0
regulate 0
expression 0
of 0
the 0
outer B-gene
- I-gene
membrane I-gene
protein I-gene
OprH I-gene
and 0
polymyxin 0
B 0
resistance 0
. 0

Deletion 0
of 0
fdsR B-gene
revealed 0
a 0
dual 0
regulatory 0
effect 0
of 0
FdsR B-gene
on 0
the 0
fds B-gene
operon I-gene
by 0
acting 0
as 0
transcriptional 0
activator 0
in 0
the 0
presence 0
of 0
formate 0
or 0
as 0
repressor 0
in 0
the 0
absence 0
of 0
formate 0
. 0

With 0
constructs 0
containing 0
the 0
binding 0
site 0
of 0
one 0
gene 0
fused 0
to 0
the 0
promoter 0
of 0
the 0
other 0
, 0
we 0
demonstrated 0
that 0
the 0
positional 0
requirements 0
are 0
a 0
function 0
of 0
the 0
specific 0
binding 0
site 0
, 0
not 0
the 0
promoter 0
. 0

In 0
addition 0
, 0
all 0
three 0
Opa B-gene
proteins I-gene
of 0
C751 0
bind 0
equally 0
well 0
to 0
HeLa 0
cells 0
transfected 0
with 0
cDNA 0
encoding 0
the 0
carcinoembryonic B-gene
antigen I-gene
[ 0
CEA B-gene
( 0
CD66e B-gene
) 0
] 0
subgroup 0
of 0
the 0
CD66 B-gene
family I-gene
, 0
but 0
show 0
distinct 0
tropism 0
for 0
CGM1 B-gene
- 0
( 0
CD66d B-gene
) 0
and 0
NCA B-gene
( 0
CD66c B-gene
) 0
- 0
expressing 0
cells 0
. 0

FISH 0
using 0
a 0
whole 0
chromosome 0
4 0
paint 0
demonstrated 0
multiple 0
rearrangements 0
involving 0
chromosome 0
4 0
in 0
MCF 0
- 0
7 0
AdVp3000 0
and 0
MCF 0
- 0
7 0
MX 0
, 0
while 0
S1 0
- 0
M1 0
- 0
80 0
contained 0
only 0
a 0
simple 0
reciprocal 0
translocation 0
. 0

The 0
MXR B-gene
gene I-gene
encodes 0
a 0
half 0
- 0
transporter 0
and 0
the 0
absence 0
of 0
cytogenetic 0
evidence 0
of 0
coamplification 0
of 0
other 0
regions 0
suggests 0
that 0
a 0
partner 0
may 0
not 0
be 0
overexpressed 0
, 0
and 0
instead 0
the 0
MXR B-gene
half I-gene
- I-gene
transporter I-gene
homodimerizes 0
to 0
mediate 0
drug 0
transport 0
. 0

The 0
effect 0
of 0
smoking 0
was 0
not 0
examined 0
in 0
this 0
study 0
, 0
as 0
such 0
data 0
were 0
not 0
available 0
. 0

Serum B-gene
insulin I-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
I I-gene
( 0
IGF B-gene
- I-gene
I I-gene
) 0
SD 0
score 0
increased 0
from 0
- 0
2.2 0
and 0
- 0
4.2 0
in 0
men 0
and 0
women 0
, 0
respectively 0
, 0
to 0
1.8 0
and 0
- 0
0.9 0
at 0
6 0
months 0
and 0
0.8 0
and 0
- 0
0.7 0
at 0
12 0
months 0
. 0

BACKGROUND 0
: 0
Measurement 0
of 0
stereoacuity 0
at 0
varying 0
distances 0
, 0
by 0
real 0
or 0
simulated 0
depth 0
stereoacuity 0
tests 0
, 0
is 0
helpful 0
in 0
the 0
evaluation 0
of 0
patients 0
with 0
binocular 0
imbalance 0
or 0
strabismus 0
. 0

Additional 0
studies 0
revealed 0
that 0
bovine B-gene
brain I-gene
Galpha I-gene
( I-gene
q/11 I-gene
) I-gene
could 0
also 0
bind 0
to 0
an 0
N 0
- 0
terminal 0
construct 0
of 0
GRK2 B-gene
, 0
while 0
no 0
binding 0
of 0
Galpha B-gene
( I-gene
q/11 I-gene
) I-gene
, 0
Galpha B-gene
( I-gene
s I-gene
) I-gene
, 0
Galpha B-gene
( I-gene
i I-gene
) I-gene
, 0
or 0
Galpha B-gene
( I-gene
12/13 I-gene
) I-gene
to 0
comparable 0
constructs 0
of 0
GRK5 B-gene
or 0
GRK6 B-gene
was 0
observed 0
. 0

The 0
elm1 B-gene
kinase I-gene
functions 0
in 0
a 0
mitotic 0
signaling 0
network 0
in 0
budding 0
yeast 0
. 0

Reverse 0
transcription 0
( 0
RT 0
) 0
- 0
PCR 0
products 0
were 0
synthesized 0
with 0
two 0
degenerate 0
primers 0
derived 0
from 0
the 0
conserved 0
motifs 0
of 0
various 0
tyrosine B-gene
kinases I-gene
. 0

In 0
addition 0
, 0
the 0
acetyltransferase 0
activity 0
of 0
p300 B-gene
was 0
observed 0
to 0
be 0
distinct 0
from 0
the 0
broadly 0
essential 0
activation 0
function 0
of 0
the 0
CH3 B-gene
domain/E1A I-gene
- 0
binding 0
region 0
. 0

The 0
proliferation 0
- 0
specific 0
HNF B-gene
- I-gene
3/fork I-gene
3/fork I-gene
head I-gene
homolog I-gene
- I-gene
11B I-gene
protein 0
( 0
HFH B-gene
- I-gene
11B I-gene
; 0
also 0
known 0
as 0
Trident B-gene
and 0
Win B-gene
) 0
is 0
a 0
family 0
member 0
of 0
the 0
winged B-gene
helix/fork I-gene
helix/fork I-gene
head I-gene
transcription 0
factors 0
and 0
in 0
regenerating 0
liver 0
its 0
expression 0
is 0
reactivated 0
prior 0
to 0
hepatocyte 0
entry 0
into 0
DNA 0
replication 0
( 0
S 0
phase 0
) 0
. 0

In 0
the 0
mouse 0
, 0
CtBP1 B-gene
is 0
expressed 0
from 0
embryo 0
to 0
adult 0
, 0
but 0
CtBP2 B-gene
is 0
mainly 0
expressed 0
during 0
embryogenesis 0
. 0

The 0
multiple 0
functions 0
of 0
Pmt3p B-gene
described 0
here 0
suggest 0
that 0
several 0
nuclear 0
proteins 0
are 0
regulated 0
by 0
Pmt3p B-gene
conjugation 0
. 0

The 0
role 0
of 0
transport 0
by 0
sea 0
ice 0
from 0
the 0
Kara 0
Sea 0
into 0
the 0
Arctic 0
Ocean 0
was 0
assessed 0
by 0
a 0
small 0
subgroup 0
at 0
GEOMAR 0
. 0

We 0
determined 0
whether 0
a 0
single 0
injection 0
of 0
slow 0
- 0
release 0
estradiol 0
- 0
17beta 0
( 0
SRE2 0
) 0
would 0
induce 0
pseudopregnancy 0
in 0
gilts 0
and 0
whether 0
PGF2alpha 0
would 0
regress 0
the 0
corpora 0
lutea 0
( 0
CL 0
) 0
of 0
pseudopregnancy 0
. 0

The 0
level 0
of 0
serum B-gene
creatine I-gene
kinase I-gene
was 0
significantly 0
high 0
2 0
days 0
after 0
ESWIB 0
, 0
but 0
it 0
recovered 0
in 0
a 0
week 0
. 0

Among 0
the 0
remaining 0
22 0
sites 0
, 0
six 0
are 0
in 0
the 0
promoters 0
of 0
known 0
alpha 0
- 0
specific 0
genes 0
and 0
two 0
other 0
sites 0
have 0
an 0
alpha2 B-gene
- 0
Mcm1 B-gene
- 0
dependent 0
role 0
in 0
determining 0
the 0
direction 0
of 0
mating 0
type 0
switching 0
. 0

Activation 0
of 0
T 0
cells 0
via 0
the 0
TCR B-gene
and 0
other 0
costimulatory 0
receptors 0
triggers 0
a 0
number 0
of 0
signaling 0
cascades 0
. 0

A 0
phylogenetic 0
analysis 0
with 0
the 0
TK B-gene
domains I-gene
from 0
these 0
sequences 0
and 0
a 0
fourth 0
, 0
from 0
a 0
novel 0
scavenger B-gene
RTK I-gene
( 0
all 0
domains 0
comprise 0
the 0
signature 0
for 0
the 0
TK B-gene
class I-gene
II I-gene
receptors I-gene
) 0
, 0
showed 0
that 0
they 0
are 0
distantly 0
related 0
to 0
the 0
insulin B-gene
and 0
insulin B-gene
- I-gene
like I-gene
receptors I-gene
. 0

Several 0
7SL B-gene
RNA I-gene
- I-gene
encoding I-gene
sequences I-gene
and 0
various 0
intergenic 0
spacers 0
were 0
amplified 0
from 0
the 0
individual 0
HindIII B-gene
fragments I-gene
of 0
about 0
1.3 0
and 0
2.8 0
kb 0
. 0

Results 0
confirmed 0
that 0
stress 0
produced 0
CA3 0
dendritic 0
atrophy 0
and 0
tianeptine 0
prevented 0
it 0
. 0

We 0
have 0
isolated 0
a 0
binding 0
partner 0
for 0
the 0
Fanconi B-gene
anemia I-gene
group I-gene
C I-gene
protein I-gene
( 0
FANCC B-gene
) 0
by 0
yeast 0
two 0
- 0
hybrid 0
screening 0
. 0

These 0
results 0
suggest 0
that 0
both 0
transcription 0
activators 0
depend 0
on 0
or 0
interact 0
with 0
different 0
subunits 0
of 0
RNA B-gene
polymerase I-gene
, 0
although 0
their 0
role 0
in 0
formation 0
of 0
proper 0
DNA 0
geometry 0
may 0
also 0
be 0
crucial 0
. 0

Klebsiella 0
oxytoca 0
can 0
assimilate 0
nitrate 0
and 0
nitrite 0
by 0
using 0
enzymes 0
encoded 0
by 0
the 0
nasFEDCBA B-gene
operon I-gene
. 0

Marked 0
hemolysis 0
significantly 0
increased 0
plasma 0
values 0
of 0
potassium 0
, 0
phosphorus 0
, 0
total 0
protein 0
, 0
and 0
aspartate B-gene
aminotransferase I-gene
. 0

Studies 0
have 0
substantiated 0
the 0
involvement 0
of 0
numerous 0
loci 0
on 0
certain 0
chromosomes 0
; 0
in 0
excess 0
of 0
10 0
chromosomes 0
are 0
thought 0
to 0
be 0
involved 0
. 0

By 0
negatively 0
regulating 0
GRK B-gene
- 0
mediated 0
receptor 0
phosphorylation 0
, 0
beta B-gene
- I-gene
arrestin I-gene
- 0
mediated 0
processes 0
such 0
as 0
Src B-gene
recruitment 0
and 0
clathrin B-gene
- 0
mediated 0
internalization 0
, 0
which 0
are 0
required 0
for 0
GPCR B-gene
- 0
mediated 0
ERK B-gene
activation 0
, 0
are 0
inhibited 0
, 0
thus 0
dampening 0
further 0
ERK B-gene
activation 0
. 0

Based 0
on 0
subcellular 0
fractionation 0
, 0
the 0
47 B-gene
- I-gene
kDa I-gene
P I-gene
- I-gene
CIP2 I-gene
protein I-gene
is 0
mostly 0
cytosolic 0
. 0

Supershift 0
EMSAs 0
identified 0
that 0
upstream B-gene
stimulatory I-gene
factor I-gene
- I-gene
1 I-gene
and I-gene
- I-gene
2 I-gene
( 0
USF B-gene
- I-gene
1 I-gene
and I-gene
- I-gene
2 I-gene
) 0
were 0
part 0
of 0
these 0
complexes 0
. 0

Conversely 0
, 0
E1A B-gene
binding 0
to 0
only 0
p300/CBP B-gene
results 0
in 0
an 0
increase 0
in 0
p300/CBP I-gene

Analysis 0
of 0
its 0
genomic 0
region 0
revealed 0
that 0
the 0
13 0
- 0
kb 0
Cdc6 B-gene
gene I-gene
is 0
divided 0
into 0
12 0
exons 0
by 0
11 0
introns 0
. 0

These 0
include 0
the 0
CACCC 0
and 0
CAAT 0
motifs 0
. 0

Skin 0
pH 0
changes 0
associated 0
with 0
iontophoresis 0
. 0

This 0
distinction 0
was 0
based 0
upon 0
whether 0
the 0
diagnosis 0
provided 0
a 0
straightforward 0
range 0
of 0
prognoses 0
or 0
an 0
ambiguous 0
clinical 0
implication 0
. 0

The 0
availability 0
of 0
potent 0
regulatory 0
DNA 0
cassettes 0
harboring 0
the 0
murine B-gene
D1A I-gene
gene I-gene
promoter I-gene
could 0
aid 0
testing 0
the 0
neuronal 0
- 0
specific 0
expression 0
of 0
transgenes 0
in 0
vivo 0
. 0

It 0
may 0
be 0
dependent 0
on 0
location 0
of 0
a 0
focus 0
( 0
according 0
to 0
EEG 0
) 0
as 0
well 0
as 0
on 0
the 0
character 0
and 0
manifestation 0
of 0
the 0
accompanying 0
neuropsychologic 0
symptomatology 0
. 0

The 0
results 0
of 0
these 0
studies 0
demonstrate 0
that 0
the 0
rat 0
HDL 0
receptor 0
SR B-gene
- I-gene
BI I-gene
promoter 0
contains 0
two 0
sterol 0
response 0
elements 0
( 0
pSRE 0
and 0
dSRE 0
) 0
through 0
which 0
SREBP B-gene
- I-gene
1a I-gene
can 0
bind 0
and 0
activate 0
transcription 0
of 0
this 0
gene 0
. 0

Phosphorylation 0
of 0
myosin B-gene
- I-gene
binding I-gene
subunit I-gene
( 0
MBS B-gene
) 0
of 0
myosin B-gene
phosphatase I-gene
by 0
Rho B-gene
- I-gene
kinase I-gene
in 0
vivo 0
. 0

Of 0
these 0
patients 0
, 0
46,164 0
were 0
placed 0
on 0
a 0
waiting 0
list 0
for 0
transplantation 0
, 0
23,275 0
of 0
whom 0
received 0
a 0
first 0
cadaveric 0
transplant 0
between 0
1991 0
and 0
1997 0
. 0

In 0
electrophoretic 0
mobility 0
shift 0
assay 0
( 0
EMSA 0
) 0
, 0
this 0
GLUT4 B-gene
repressor I-gene
element I-gene
( 0
G4RE B-gene
) 0
generated 0
specific 0
bands 0
with 0
nuclear 0
extracts 0
from 0
preadipocytes 0
, 0
but 0
not 0
from 0
adipocytes 0
. 0

Syndromes 0
of 0
abnormal 0
fat 0
redistribution 0
and 0
metabolic 0
complications 0
in 0
HIV 0
- 0
infected 0
patients 0
. 0

Cytoprotection 0
with 0
amifostine 0
in 0
radiotherapy 0
or 0
radio 0
- 0
chemotherapy 0
of 0
head 0
and 0
neck 0
tumors 0

Immunohistochemical 0
staining 0
was 0
positive 0
for 0
S B-gene
- I-gene
100 I-gene
in 0
all 0
9 0
cases 0
stained 0
, 0
positive 0
for 0
HMB B-gene
- I-gene
45 I-gene
in 0
9 0
( 0
90 0
% 0
) 0
of 0
10 0
, 0
and 0
negative 0
for 0
cytokeratin B-gene
in 0
all 0
9 0
cases 0
in 0
which 0
myxoid 0
melanoma 0
remained 0
in 0
the 0
block 0
after 0
previous 0
sections 0
. 0

Patients 0
with 0
types 0
I 0
and 0
III 0
MPGN 0
did 0
not 0
differ 0
in 0
age 0
at 0
apparent 0
onset 0
, 0
age 0
at 0
diagnosis 0
, 0
or 0
interval 0
from 0
apparent 0
onset 0
of 0
symptoms 0
to 0
diagnosis 0
( 0
biopsy 0
) 0
. 0

Residual 0
urinary 0
abnormalities 0
were 0
significantly 0
more 0
frequent 0
in 0
patients 0
with 0
type 0
III 0
than 0
type 0
I 0
MPGN 0
. 0

Taken 0
together 0
, 0
differences 0
in 0
signaling 0
and 0
tissue 0
expression 0
suggest 0
that 0
the 0
human B-gene
intermediate I-gene
PRLr I-gene
differs 0
from 0
the 0
long B-gene
PRLr I-gene
in 0
physiological 0
function 0
. 0

We 0
describe 0
here 0
a 0
Drosophila B-gene
melanogaster I-gene
FAK I-gene
homologue I-gene
, 0
DFak56 B-gene
, 0
which 0
maps 0
to 0
band 0
56D 0
on 0
the 0
right 0
arm 0
of 0
the 0
second 0
chromosome 0
. 0

Because 0
the 0
Pit B-gene
- I-gene
1 I-gene
sites I-gene
in 0
the 0
hGH B-gene
- I-gene
N I-gene
gene I-gene
promoter I-gene
are 0
insufficient 0
for 0
such 0
gene 0
activation 0
in 0
vivo 0
, 0
these 0
data 0
suggested 0
a 0
unique 0
chromatin 0
- 0
mediated 0
developmental 0
role 0
for 0
Pit B-gene
- I-gene
1 I-gene
in 0
the 0
hGH B-gene
LCR I-gene
. 0

Recombinant B-gene
prenylcysteine I-gene
lyase I-gene
was 0
produced 0
in 0
a 0
baculovirus 0
- 0
Sf9 0
expression 0
system 0
. 0

We 0
show 0
here 0
that 0
the 0
third 0
SH3 B-gene
domain I-gene
binds 0
to 0
Sos B-gene
, 0
a 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
for 0
Ras B-gene
and 0
Rac B-gene
, 0
both 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

Point 0
mutations 0
in 0
the 0
third 0
SH3 B-gene
domain I-gene
abolished 0
the 0
vinexin B-gene
- 0
Sos B-gene
interaction 0
. 0

In 0
gel 0
mobility 0
shift 0
assays 0
, 0
low 0
binding 0
activity 0
of 0
CBF B-gene
to 0
the 0
wild B-gene
- I-gene
type I-gene
AtpC I-gene
promoter I-gene
sequence I-gene
was 0
observed 0
with 0
nuclear 0
extracts 0
from 0
tissue 0
with 0
low 0
AtpC B-gene
expression 0
levels 0
, 0
i.e 0
. 0
extracts 0
from 0
etiolated 0
and 0
photobleached 0
seedlings 0
, 0
whereas 0
high 0
binding 0
activity 0
was 0
detectable 0
with 0
extracts 0
from 0
tissues 0
with 0
high 0
AtpC B-gene
expression 0
levels 0
, 0
i.e 0
. 0
extracts 0
from 0
light 0
- 0
grown 0
seedlings 0
and 0
etiolated 0
seedlings 0
treated 0
with 0
cytokinin B-gene
. 0

Mycoplasma 0
hominis 0
infections 0
are 0
easily 0
missed 0
because 0
conventional 0
methods 0
for 0
bacterial 0
detection 0
may 0
fail 0
. 0

For 0
this 0
purpose 0
, 0
we 0
used 0
a 0
series 0
of 0
plasmid 0
constructs 0
encoding 0
different 0
forms 0
of 0
the 0
envelope B-gene
glycoprotein I-gene
E I-gene
of I-gene
the I-gene
flavivirus I-gene
tick I-gene
- I-gene
borne I-gene
encephalitis I-gene
virus I-gene
. 0

They 0
are 0
subdivided 0
into 0
two 0
types 0
that 0
activate 0
transduction 0
pathways 0
via 0
different 0
cell 0
surface 0
receptors 0
. 0

We 0
report 0
here 0
that 0
out 0
of 0
the 0
major 0
pro 0
- 0
inflammatory 0
cytokines 0
examined 0
, 0
IL B-gene
- I-gene
1alpha I-gene
, 0
IL B-gene
- I-gene
1beta I-gene
, 0
TNF B-gene
- I-gene
alpha I-gene
and 0
IL B-gene
- I-gene
6 I-gene
, 0
only 0
IL B-gene
- I-gene
6 I-gene
was 0
generated 0
and 0
secreted 0
in 0
PKCeta B-gene
- 0
expressing 0
cells 0
without 0
any 0
additional 0
inducer 0
in 0
serum 0
- 0
supplemented 0
cultures 0
( 0
10 0
% 0
FCS 0
) 0
. 0

Demyelinating 0
diseases 0
involving 0
the 0
grey 0
matter 0
were 0
very 0
rare 0
, 0
but 0
we 0
must 0
consider 0
the 0
presence 0
of 0
symmetrical 0
thalamic 0
involvement 0
in 0
patients 0
with 0
ADEM 0
. 0

To 0
define 0
the 0
minimal 0
VDRE 0
binding 0
domain 0
for 0
human B-gene
VDR I-gene
( 0
hVDR B-gene
) 0
, 0
a 0
series 0
of 0
C 0
- 0
terminally 0
truncated 0
hVDR B-gene
mutants I-gene
( 0
Delta134 0
, 0
Delta113 0
, 0
Delta102 0
, 0
Delta90 0
, 0
Delta84 0
, 0
Delta80 0
, 0
and 0
Delta60 0
) 0
was 0
generated 0
and 0
expressed 0
in 0
bacteria 0
. 0

By 0
an 0
induced 0
- 0
fit 0
mechanism 0
, 0
contacts 0
with 0
the 0
anticodon 0
can 0
activate 0
formation 0
of 0
a 0
robust 0
transition 0
state 0
at 0
a 0
site 0
over 0
70 0
A 0
away 0
. 0

These 0
REPs 0
, 0
or 0
clusters 0
of 0
paralogous 0
loci 0
, 0
are 0
15 0
- 0
100 0
kb 0
and 0
harbor 0
at 0
least 0
four 0
ESTs 0
and 0
an 0
expressed 0
SH3GL B-gene
pseudogene I-gene
. 0

This 0
revealed 0
a 0
minimum 0
of 0
six 0
novel 0
OSBP B-gene
- I-gene
related I-gene
proteins I-gene
, 0
designated 0
ORP B-gene
- I-gene
1 I-gene
to 0
ORP B-gene
- I-gene
6 I-gene
. 0

In 0
part 0
as 0
a 0
result 0
of 0
its 0
inability 0
to 0
sustain 0
radiative 0
loses 0
, 0
the 0
BB 0
resonator 0
has 0
extremely 0
low 0
RF 0
power 0
requirements 0
. 0

In 0
addition 0
, 0
narZ B-gene
expression 0
was 0
induced 0
approximately 0
20 0
- 0
fold 0
intracellularly 0
in 0
Madin 0
- 0
Darby 0
canine 0
kidney 0
epithelial 0
cells 0
and 0
16 0
- 0
fold 0
in 0
intracellular 0
salts 0
medium 0
, 0
which 0
is 0
believed 0
to 0
mimic 0
the 0
intracellular 0
milieu 0
. 0

However 0
, 0
mechanisms 0
underlying 0
HIV 0
- 0
1 0
gene 0
expression 0
in 0
the 0
CNS 0
are 0
poorly 0
understood 0
. 0

Is 0
radical 0
trachelectomy 0
a 0
safe 0
alternative 0
to 0
radical 0
hysterectomy 0
for 0
patients 0
with 0
stage 0
IA 0
- 0
B 0
carcinoma 0
of 0
the 0
cervix 0
? 0
BACKGROUND 0
: 0
The 0
prognosis 0
associated 0
with 0
lymph 0
node 0
negative 0
, 0
early 0
stage 0
carcinoma 0
of 0
the 0
cervix 0
is 0
excellent 0
, 0
with 0
5 0
- 0
year 0
survival 0
rates 0
greater 0
than 0
90 0
% 0
. 0

A 0
key 0
event 0
in 0
this 0
process 0
is 0
the 0
selective 0
recognition 0
of 0
the 0
target 0
membrane 0
by 0
the 0
vesicle 0
and 0
the 0
current 0
view 0
is 0
that 0
SNARE B-gene
protein I-gene
interactions 0
likely 0
play 0
a 0
central 0
role 0
in 0
vesicle 0
- 0
target 0
recognition 0
and 0
or 0
membrane 0
fusion 0
. 0

Scapulae 0
with 0
a 0
Type 0
I 0
configuration 0
were 0
found 0
to 0
have 0
low 0
values 0
for 0
the 0
coraco 0
- 0
glenoid 0
angle 0
and 0
coracoid 0
overlap 0
, 0
which 0
are 0
known 0
to 0
be 0
associated 0
with 0
a 0
short 0
coraco 0
- 0
humeral 0
distance 0
. 0

Measurements 0
in 0
the 0
LWS 0
p.a 0
. 0
, 0
LWS 0
lat 0
. 0
and 0
at 0
Ward 0
's 0
triangle 0
were 0
made 0
in 0
a 0
total 0
of 0
100 0
patients 0
. 0

A 0
group 0
of 0
66 0
DSM 0
- 0
IV 0
paranoid 0
schizophrenic 0
in 0
- 0
patients 0
were 0
assessed 0
three 0
times 0
using 0
the 0
SAPS 0
, 0
SANS 0
, 0
BPRS 0
and 0
PAS 0
. 0

In 0
conclusion 0
: 0
( 0
i 0
) 0
TECRA 0
kit 0
is 0
suggested 0
to 0
be 0
used 0
for 0
screening 0
SE 0
producing 0
strains 0
; 0
( 0
ii 0
) 0
SET 0
- 0
RPLA 0
and 0
RIDASCREEN 0
kits 0
are 0
suitable 0
for 0
epidemiological 0
investigation 0
of 0
SE 0
types 0
, 0
but 0
the 0
lack 0
of 0
ability 0
for 0
detecting 0
SEE 0
, 0
long 0
time 0
required 0
for 0
testing 0
with 0
SET 0
- 0
RPLA 0
kit 0
and 0
high 0
background 0
when 0
using 0
RIDASCREEN 0
kit 0
must 0
be 0
overcome 0
; 0
and 0
( 0
iii 0
) 0
because 0
of 0
the 0
complicated 0
test 0
procedures 0
and 0
the 0
lack 0
of 0
ability 0
for 0
detecting 0
SEE 0
, 0
the 0
practicality 0
of 0
SET 0
- 0
EIA 0
kit 0
in 0
screening 0
and 0
epidemiological 0
research 0
purposes 0
is 0
low 0
. 0

Comparison 0
of 0
immunoassay 0
kits 0
for 0
detection 0
of 0
staphylococcal B-gene
enterotoxins I-gene
produced 0
by 0
Staphylococcus 0
aureus 0

Despite 0
the 0
high 0
frequency 0
of 0
natural 0
infection 0
, 0
the 0
seropositive 0
rates 0
of 0
JEV 0
antibody 0
still 0
correlated 0
well 0
with 0
the 0
dose 0
of 0
vaccine 0
received 0
, 0
i.e. 0
, 0
67 0
% 0
( 0
1122/1664 0
) 0
, 0
66 0
% 0
( 0
65/97 0
) 0
, 0
33 0
% 0
( 0
4/12 0
) 0
and 0
40 0
% 0
( 0
19/47 0
) 0
for 0
children 0
receiving 0
3 0
, 0
2 0
, 0
1 0
, 0
and 0
0 0
dose 0
of 0
JE 0
vaccines 0
, 0
respectively 0
( 0
P 0
< 0
0.0001 0
Chi 0
- 0
square 0
for 0
trend 0
test 0
) 0
. 0

Furthermore 0
, 0
in 0
vivo 0
and 0
in 0
vitro 0
protein 0
- 0
protein 0
interaction 0
experiments 0
have 0
shown 0
that 0
SR33 B-gene
protein I-gene
interacts 0
with 0
itself 0
and 0
with 0
SR45 B-gene
protein I-gene
but 0
not 0
with 0
two 0
other 0
members 0
( 0
SRZ21 B-gene
and 0
SRZ22 B-gene
) 0
of 0
the 0
SR B-gene
family I-gene
that 0
are 0
known 0
to 0
interact 0
with 0
the 0
Arabidopsis 0
full 0
- 0
length 0
U B-gene
- I-gene
70K I-gene
only 0
. 0

In 0
summary 0
, 0
WT1 B-gene
is 0
enriched 0
by 0
oligo 0
( 0
dT 0
) 0
chromatography 0
, 0
as 0
are 0
U2AF65 B-gene
, 0
the 0
U5 B-gene
small I-gene
nuclear I-gene
RNP I-gene
- I-gene
associated I-gene
protein I-gene
p116 B-gene
and 0
hnRNP 0
A1 B-gene
. 0

Six 0
out 0
of 0
ten 0
hearts 0
from 0
macerated 0
stillborn 0
infants 0
showed 0
varying 0
degrees 0
of 0
positive 0
staining 0
. 0

Tih1 B-gene
maps 0
to 0
distal 0
mouse 0
Chr 0
1 0
and 0
human 0
Chr 0
1q31 0
, 0
chromosomal 0
regions 0
that 0
have 0
not 0
shown 0
evidence 0
for 0
imprinting 0
and 0
, 0
in 0
contrast 0
to 0
Ipl B-gene
, 0
Tih1 B-gene
is 0
expressed 0
equally 0
from 0
both 0
parental 0
alleles 0
. 0

A 0
novel 0
pleckstrin B-gene
homology I-gene
- I-gene
related I-gene
gene I-gene
family I-gene
defined 0
by 0
Ipl/Tssc3 B-gene
, 0
Ipl/Tssc3 I-gene

The 0
potential 0
for 0
highly 0
reactive 0
nanoparticles 0
( 0
RNP 0
) 0
to 0
absorb 0
destructively 0
, 0
i.e 0
. 0
to 0
neutralize 0
highly 0
toxic 0
substances 0
such 0
as 0
the 0
warfare 0
agents 0
GA 0
, 0
GB 0
, 0
HD 0
and 0
VX 0
, 0
has 0
been 0
demonstrated 0
in 0
the 0
laboratory 0
. 0

There 0
were 0
minimal 0
negative 0
effects 0
on 0
hematological 0
parameters 0
, 0
acid 0
- 0
base 0
status 0
, 0
and 0
blood 0
gases 0
. 0

Twelve 0
out 0
of 0
43 0
renal 0
failure 0
patients 0
had 0
troponin B-gene
I I-gene
0.13 0
- 0
0.9 0
microg/l 0
using 0
Axsym 0
method 0
and 0
4 0
had 0
levels 0
of 0
0.07 0
- 0
0.13 0
microg/l 0
using 0
Immuno 0
1 0
. 0

Therefore 0
, 0
we 0
propose 0
that 0
p27 B-gene
represents 0
a 0
crucial 0
molecule 0
in 0
HMBA 0
signaling 0
that 0
can 0
not 0
be 0
replaced 0
by 0
p21 B-gene
. 0

Transient 0
, 0
high 0
- 0
level 0
Ras B-gene
- 0
expression 0
induces 0
transcriptional 0
activation 0
of 0
p21 B-gene
mediated 0
by 0
a 0
GC 0
- 0
rich 0
region 0
in 0
p21 B-gene
promoter I-gene
- 0
83 0
- 0
54 0
bp 0
relative 0
to 0
the 0
transcription 0
initiation 0
site 0
containing 0
binding 0
sites 0
for 0
Sp1 B-gene
- I-gene
family I-gene
transcription I-gene
factors I-gene
. 0

The 0
RET/PTC3 B-gene
rearrangement 0
is 0
formed 0
by 0
fusion 0
of 0
the 0
RET/PTC3 I-gene

Apoptosis 0
of 0
small 0
cells 0
is 0
still 0
observed 0
after 0
co 0
- 0
transfection 0
of 0
JBD B-gene
and 0
LMP1 B-gene
but 0
in 0
addition 0
a 0
few 0
apoptotic 0
HD 0
- 0
MyZ 0
cells 0
with 0
large 0
fused 0
nuclear 0
masses 0
are 0
identified 0
suggesting 0
that 0
specific 0
inhibition 0
of 0
JNK B-gene
leads 0
also 0
to 0
apoptosis 0
of 0
LMP1 B-gene
induced 0
RS 0
cells 0
. 0

In 0
addition 0
to 0
the 0
bZIP B-gene
protein I-gene
Opaque2 I-gene
( 0
O2 B-gene
) 0
, 0
there 0
are 0
other 0
maize 0
endosperm 0
nuclear 0
proteins 0
that 0
recognize 0
the 0
O2 B-gene
box I-gene
in 0
22 0
kDa 0
zein B-gene
gene 0
promoters 0
. 0

The 0
mEmBP B-gene
- I-gene
1 I-gene
protein I-gene
can 0
activate 0
transcription 0
from 0
a 0
truncated 0
promoter 0
containing 0
a 0
pentamer 0
of 0
the 0
O2 B-gene
site I-gene
in 0
yeast 0
cells 0
; 0
however 0
, 0
it 0
inhibited 0
regulated 0
transcription 0
of 0
a 0
22 B-gene
kDa I-gene
zein I-gene
promoter I-gene
in 0
a 0
transient 0
expression 0
assay 0
using 0
cultured 0
maize 0
endosperm 0
cells 0
. 0

GHB 0
, 0
2 0
CB 0
, 0
HMB 0
, 0
are 0
some 0
of 0
these 0
recent 0
substances 0
. 0

There 0
were 0
15 0
deaths 0
, 0
seven 0
of 0
which 0
were 0
felt 0
to 0
be 0
avoidable 0
. 0

With 0
this 0
GH B-gene
and 0
estrogen 0
treatment 0
regimen 0
, 0
most 0
girls 0
with 0
TS 0
can 0
grow 0
and 0
develop 0
much 0
more 0
in 0
conformity 0
with 0
their 0
healthy 0
peers 0
. 0

We 0
propose 0
that 0
the 0
reduced 0
responsiveness 0
of 0
CYP3A2 B-gene
is 0
the 0
result 0
of 0
preferential 0
binding 0
of 0
COUP B-gene
- I-gene
TF I-gene
at 0
the 0
CYP3A2 B-gene
DexRE I-gene
- I-gene
1 I-gene
site I-gene
. 0

Higher 0
CYP3A23 B-gene
basal 0
activity 0
appears 0
to 0
be 0
due 0
to 0
an 0
E 0
- 0
box 0
in 0
3A23SiteA B-gene
that 0
interacts 0
with 0
USF1 B-gene
, 0
a 0
ubiquitous 0
bHLH/leucine B-gene
zipper I-gene
transcription I-gene
factor I-gene
. 0

The 0
first 0
one 0
is 0
a 0
TPA 0
- 0
responsive 0
element 0
that 0
controls 0
the 0
base 0
- 0
line 0
ST3 B-gene
promoter I-gene
activity 0
but 0
is 0
not 0
required 0
for 0
its 0
activation 0
. 0

To 0
understand 0
the 0
basis 0
for 0
the 0
increased 0
cell 0
surface 0
stability 0
compared 0
with 0
wild 0
- 0
type 0
peptide 0
and 0
to 0
understand 0
the 0
differences 0
in 0
T 0
cell 0
recognition 0
between 0
I1Y B-gene
and 0
I1F B-gene
, 0
we 0
determined 0
the 0
x 0
- 0
ray 0
crystal 0
structures 0
of 0
the 0
two 0
class B-gene
I I-gene
MHC I-gene
- I-gene
peptide I-gene
complexes I-gene
. 0

Redistribution 0
of 0
mannosidase B-gene
I I-gene
was 0
also 0
observed 0
in 0
cells 0
incubated 0
at 0
15 0
degrees 0
C 0
. 0

In 0
addition 0
, 0
using 0
biochemical 0
activity 0
assays 0
for 0
Rho B-gene
- 0
like 0
GTPases B-gene
, 0
we 0
show 0
that 0
the 0
expression 0
of 0
beta1A B-gene
, 0
beta1D B-gene
, 0
or 0
IL2R B-gene
- 0
beta1A B-gene
in 0
GE11 0
or 0
GD25 0
cells 0
triggers 0
activation 0
of 0
both 0
RhoA B-gene
and 0
Rac1 B-gene
, 0
but 0
not 0
of 0
Cdc42 B-gene
. 0

In 0
conclusion 0
, 0
our 0
data 0
do 0
not 0
support 0
a 0
role 0
for 0
IVIg B-gene
in 0
the 0
remyelination 0
of 0
stable 0
multiple 0
sclerosis 0
lesions 0
as 0
measured 0
by 0
central 0
conduction 0
time 0
. 0

The 0
rhabdomyosarcoma 0
R1H 0
growing 0
on 0
the 0
right 0
flank 0
of 0
male 0
WAG/Rij 0
rats 0
was 0
clamped 0
for 0
2 0
or 0
4 0
h 0
at 0
20 0
degrees 0
C 0
or 0
37 0
degrees 0
C 0
. 0

Relative 0
to 0
coherent 0
control 0
words 0
( 0
e.g. 0
, 0
quick 0
) 0
, 0
these 0
discourse 0
- 0
dependent 0
semantic 0
anomalies 0
elicited 0
a 0
large 0
N400 0
effect 0
that 0
began 0
at 0
about 0
200 0
to 0
250 0
msec 0
after 0
word 0
onset 0
. 0

These 0
synergistic 0
effects 0
were 0
strongly 0
Jem B-gene
- I-gene
1 I-gene
dose 0
- 0
dependent 0
. 0

Like 0
the 0
Tob B-gene
protein I-gene
, 0
Tob2 B-gene
inhibited 0
cell 0
cycle 0
progression 0
from 0
the 0
G0/G1 0
to 0
S 0
phases 0
. 0

The 0
coordinate 0
increase 0
in 0
cyclin B-gene
D1 I-gene
and 0
p21 B-gene
had 0
the 0
effect 0
of 0
decreasing 0
the 0
specific 0
but 0
not 0
absolute 0
activity 0
of 0
cyclin B-gene
D1/cdk4 I-gene
. 0
D1/cdk4 I-gene

In 0
addition 0
, 0
SLK B-gene
displays 0
high 0
homology 0
to 0
microtubule B-gene
and I-gene
nuclear I-gene
associated I-gene
protein I-gene
( 0
M B-gene
- I-gene
NAP I-gene
) 0
and 0
AT1 B-gene
- I-gene
46 I-gene
, 0
both 0
of 0
unknown 0
function 0
. 0

In 0
this 0
study 0
26 0
patients 0
( 0
20 0
females 0
and 0
6 0
males 0
) 0
were 0
evaluated 0
. 0

The 0
signalling 0
molecules 0
Wnt1 B-gene
and 0
Sonic B-gene
hedgehog I-gene
, 0
implicated 0
in 0
the 0
activation 0
of 0
Myf5 B-gene
in 0
myogenic 0
progenitor 0
cells 0
in 0
the 0
somite 0
, 0
are 0
also 0
produced 0
in 0
the 0
viscinity 0
of 0
the 0
Myf5 B-gene
expression I-gene
domain I-gene
in 0
the 0
mesencephalon 0
. 0

STUDY 0
DESIGN 0
AND 0
METHODS 0
: 0
A 0
study 0
was 0
initiated 0
to 0
compare 0
the 0
collection 0
of 0
PBPCs 0
with 0
the 0
new 0
device 0
, 0
the 0
AutoPBSC 0
( 0
version 0
[ 0
V 0
] 0
6.0 0
with 0
AutoPBSC 0
tubing 0
set 0
) 0
, 0
and 0
that 0
with 0
the 0
MNC 0
( 0
mononuclear 0
cell 0
) 0
procedure 0
( 0
V4.7 0
with 0
white 0
cell 0
tubing 0
set 0
) 0
, 0
for 0
patients 0
and 0
healthy 0
donors 0
. 0

Albumin B-gene
dialysis 0
: 0
effective 0
removal 0
of 0
copper 0
in 0
a 0
patient 0
with 0
fulminant 0
Wilson 0
disease 0
and 0
successful 0
bridging 0
to 0
liver 0
transplantation 0
: 0
a 0
new 0
possibility 0
for 0
the 0
elimination 0
of 0
protein 0
- 0
bound 0
toxins 0
. 0

Some 0
artificial 0
promoter 0
constructs 0
containing 0
multiple 0
Sp1 B-gene
sites I-gene
were 0
highly 0
responsive 0
to 0
ethanol 0
, 0
but 0
others 0
were 0
not 0
, 0
suggesting 0
that 0
the 0
organization 0
of 0
the 0
proximal 0
promoter 0
region 0
was 0
an 0
additional 0
factor 0
that 0
affected 0
the 0
ethanol 0
response 0
. 0

Overexpression 0
of 0
CDP/cut B-gene
in 0
ROS 0
17/2.8 0
osteosarcoma 0
cells 0
results 0
in 0
repression 0
of 0
CDP/cut I-gene

Injection 0
of 0
double 0
- 0
stranded 0
RNA 0
into 0
C. 0
elegans 0
results 0
in 0
embryonic 0
lethality 0
; 0
thus 0
, 0
the 0
SF1 B-gene
gene I-gene
is 0
essential 0
not 0
only 0
in 0
yeast 0
but 0
also 0
in 0
at 0
least 0
one 0
metazoan 0
. 0

Both 0
domains 0
were 0
required 0
for 0
specific 0
DNA 0
binding 0
to 0
the 0
beta B-gene
- I-gene
retinoic I-gene
acid I-gene
receptor I-gene
element I-gene
, 0
producing 0
a 0
DNase B-gene
I I-gene
footprint 0
covering 0
predominantly 0
one 0
strand 0
. 0

Snail B-gene
family I-gene
proteins I-gene
are 0
zinc 0
finger 0
transcriptional 0
regulators 0
first 0
identified 0
in 0
Drosophila 0
which 0
play 0
critical 0
roles 0
in 0
cell 0
fate 0
determination 0
. 0

Consistent 0
with 0
this 0
finding 0
, 0
beta B-gene
- I-gene
catenin I-gene
interacted 0
directly 0
with 0
the 0
RA B-gene
receptor I-gene
( 0
RAR B-gene
) 0
in 0
a 0
retinoid 0
- 0
dependent 0
manner 0
, 0
but 0
not 0
with 0
the 0
retinoid B-gene
X I-gene
receptor I-gene
( 0
RXR B-gene
) 0
, 0
and 0
RAR B-gene
competed 0
with 0
TCF B-gene
for 0
beta B-gene
- I-gene
catenin I-gene
binding 0
. 0

Sequence 0
analysis 0
of 0
the 0
promoter 0
region 0
showed 0
no 0
TATA 0
box 0
but 0
identified 0
consensus 0
binding 0
motifs 0
for 0
Sp1 B-gene
, 0
CREB B-gene
, 0
and 0
half 0
sites 0
of 0
the 0
estrogen B-gene
receptor I-gene
binding I-gene
site I-gene
. 0

Sak B-gene
kinase I-gene
gene 0
structure 0
and 0
transcriptional 0
regulation 0
. 0

Thrombolysis 0
was 0
followed 0
by 0
a 0
similar 0
increase 0
of 0
platelet 0
activity 0
with 0
maximal 0
values 0
reached 0
at 0
the 0
3rd 0
hour 0
in 0
both 0
groups 0
( 0
196 0
+/ 0
- 0
43 0
IU/ml 0
in 0
Group 0
1 0
and 0
192 0
+/ 0
- 0
39 0
in 0
Group 0
2 0
: 0
p 0
& 0
lt 0
; 0
001versus 0
baseline 0
and 0
p 0
NS 0
between 0
the 0
groups 0
) 0
. 0

Similar 0
to 0
Hp140 B-gene
, 0
isolated 0
Hp55 B-gene
binds 0
DNA 0
with 0
moderate 0
strength 0
and 0
was 0
a 0
specificity 0
for 0
double 0
- 0
stranded 0
primer 0
- 0
template 0
DNA 0
. 0

Finally 0
, 0
three 0
new 0
missense 0
mutations 0
, 0
E138V 0
, 0
R254G 0
, 0
and 0
P362R 0
, 0
were 0
identified 0
in 0
the 0
human B-gene
AC I-gene
gene I-gene
from 0
FD 0
patients 0
. 0

These 0
data 0
indicate 0
that 0
the 0
interaction 0
of 0
eIF4A B-gene
with 0
the 0
middle 0
region 0
of 0
eIF4GI B-gene
is 0
necessary 0
for 0
translation 0
, 0
whereas 0
the 0
interaction 0
of 0
eIF4A B-gene
with 0
the 0
C 0
- 0
terminal 0
region 0
plays 0
a 0
modulatory 0
role 0
. 0

The 0
DAP5/p86 B-gene
apoptotic 0
form 0
was 0
more 0
potent 0
than 0
DAP5/p86 I-gene

12:2684 0
- 0
2697 0
, 0
1998 0
) 0
: 0
a 0
key 0
step 0
of 0
this 0
model 0
is 0
the 0
activation 0
of 0
the 0
MAPK B-gene
Fus3p I-gene
through 0
the 0
G B-gene
( I-gene
betagamma I-gene
) I-gene
- 0
dependent 0
relocalization 0
of 0
the 0
Ste5p B-gene
- 0
MAPK B-gene
cascade 0
to 0
the 0
plasma 0
membrane 0
. 0

Consistent 0
with 0
this 0
finding 0
, 0
wild B-gene
- I-gene
type I-gene
SAGA I-gene
inhibits 0
TBP B-gene
binding 0
to 0
the 0
HIS3 B-gene
promoter I-gene
in 0
vitro 0
, 0
while 0
SAGA B-gene
lacking 0
Spt3 B-gene
or 0
Spt8 B-gene
is 0
not 0
inhibitory 0
. 0

Saccharomyces 0
cerevisiae 0
contains 0
a 0
genetically 0
and 0
biochemically 0
proven 0
CAK B-gene
gene I-gene
, 0
CAK1 B-gene
, 0
that 0
encodes 0
a 0
monomeric 0
44 B-gene
- I-gene
kDa I-gene
Cak1p I-gene
protein I-gene
unrelated 0
to 0
Cdk7 B-gene
. 0

Northern 0
blot 0
and 0
reverse 0
transcription 0
- 0
PCR 0
analyses 0
of 0
human 0
mRNA 0
samples 0
demonstrate 0
that 0
RNR B-gene
is 0
expressed 0
exclusively 0
in 0
the 0
retina 0
, 0
with 0
transcripts 0
of 0
approximately 0
7.5 0
kb 0
, 0
approximately 0
3.0 0
kb 0
, 0
and 0
approximately 0
2.3 0
kb 0
by 0
Northern 0
blot 0
analysis 0
. 0

Particularly 0
striking 0
was 0
the 0
conservation 0
of 0
an 0
AP B-gene
- I-gene
4 I-gene
binding I-gene
site I-gene
within 0
100 0
nucleotides 0
upstream 0
of 0
the 0
transcription 0
initiation 0
site 0
in 0
both 0
Aal B-gene
- 0
rpL34 B-gene
and 0
Aal B-gene
- 0
rpL8 B-gene
genes 0
. 0

Based 0
on 0
a 0
type 0
I 0
error 0
of 0
0.05 0
, 0
our 0
study 0
had 0
a 0
power 0
greater 0
than 0
or 0
equal 0
to 0
75 0
% 0
to 0
detect 0
group 0
differences 0
in 0
treatment 0
effect 0
of 0
greater 0
than 0
or 0
equal 0
to 0
15 0
% 0
to 0
20 0
% 0
. 0

CONCLUSIONS 0
: 0
Serum 0
levels 0
of 0
S B-gene
- I-gene
100beta I-gene
are 0
reliable 0
markers 0
for 0
adverse 0
neurologic 0
outcomes 0
after 0
cardiac 0
surgery 0
. 0

However 0
, 0
no 0
genetic 0
alteration 0
was 0
detected 0
in 0
any 0
of 0
the 0
cancers 0
examined 0
. 0

All 0
problems 0
were 0
associated 0
with 0
fractured 0
or 0
lost 0
screws 0
. 0

Statins B-gene
: 0
lower 0
lipids 0
and 0
better 0
bones 0
? 0
Although 0
statins 0
are 0
widely 0
used 0
as 0
cholesterol 0
- 0
lowering 0
drugs 0
, 0
a 0
recent 0
study 0
suggests 0
that 0
these 0
compounds 0
have 0
anabolic 0
effects 0
on 0
bone 0
and 0
could 0
be 0
developed 0
into 0
new 0
treatments 0
for 0
common 0
metabolic 0
bone 0
diseases 0
such 0
as 0
osteoporosis 0

The 0
accumulated 0
products 0
of 0
ancient 0
duplication 0
events 0
can 0
be 0
readily 0
observed 0
among 0
the 0
genes 0
encoding 0
voltage 0
- 0
dependent 0
Ca 0
( 0
2+ 0
) 0
ion 0
channels 0
. 0

The 0
VirR B-gene
response I-gene
regulator I-gene
from 0
Clostridium 0
perfringens 0
binds 0
independently 0
to 0
two 0
imperfect 0
direct 0
repeats 0
located 0
upstream 0
of 0
the 0
pfoA B-gene
promoter I-gene
. 0

Cloning 0
and 0
sequencing 0
of 0
the 0
upstream 0
region 0
of 0
pepX B-gene
revealed 0
the 0
presence 0
of 0
two 0
ORFs 0
of 0
360 0
and 0
1,338 0
bp 0
that 0
were 0
shown 0
to 0
be 0
able 0
to 0
encode 0
proteins 0
with 0
high 0
homology 0
to 0
GlnR B-gene
and 0
GlnA B-gene
proteins I-gene
, 0
respectively 0
. 0

Objective 0
: 0
To 0
evaluate 0
endometrial 0
thickness 0
and 0
the 0
incidence 0
of 0
uterine 0
bleeding 0
in 0
postmenopausal 0
women 0
using 0
either 0
tibolone 0
2.5 0
mg 0
or 0
continuous 0
combined 0
2 0
mg 0
estradiol 0
and 0
1 0
mg 0
norethisterone 0
acetate 0
( 0
E+NETA 0
) 0
daily 0
as 0
hormone 0
replacement 0
therapy 0
. 0

Leukocyte 0
cultures 0
, 0
prepared 0
from 0
blood 0
drawn 0
from 0
these 0
18 0
children 0
at 0
6 0
months 0
of 0
age 0
, 0
produced 0
lower 0
yields 0
of 0
IFN B-gene
than 0
those 0
of 0
the 0
remaining 0
53 0
children 0
, 0
when 0
stimulated 0
with 0
adenovirus 0
( 0
P 0
< 0
0.001 0
) 0
, 0
coronavirus 0
( 0
P 0
< 0
0.001 0
) 0
or 0
rhinovirus 0
( 0
P=0.002 0
) 0
. 0

In 0
the 0
BF 0
ECT 0
group 0
the 0
- 0
age 0
based 0
dose 0
would 0
have 0
been 0
similarly 0
dependent 0
on 0
the 0
initial 0
seizure 0
threshold 0
level 0
. 0

Histological 0
analysis 0
showed 0
that 0
the 0
neuronal 0
loss 0
in 0
the 0
DHED 0
- 0
treated 0
group 0
was 0
notably 0
reduced 0
in 0
the 0
hippocampal 0
area 0
( 0
CA1 0
) 0
of 0
ischemic 0
rats 0
and 0
in 0
the 0
dentate 0
gyrus 0
and 0
hippocampal 0
area 0
( 0
CA1 0
and 0
CA3 0
) 0
of 0
EC 0
- 0
lesioned 0
rats 0
compared 0
with 0
the 0
nontreated 0
group 0
. 0

The 0
extents 0
of 0
phosphorylation 0
of 0
Ser44 0
and 0
Ser64 0
were 0
1:1 0
, 0
whereas 0
those 0
of 0
the 0
four 0
minor 0
sites 0
all 0
together 0
were 0
< 0
30 0
% 0
of 0
the 0
major 0
one 0
. 0

Serum 0
HBV 0
- 0
DNA 0
, 0
viral 0
serology 0
, 0
and 0
liver 0
enzymes 0
were 0
measured 0
sequentially 0
; 0
liver 0
histology 0
was 0
taken 0
before 0
and 0
during 0
treatment 0
in 0
12 0
patients 0
. 0

Chem 0
. 0

Maximum 0
induction 0
of 0
AP B-gene
- I-gene
1 I-gene
was 0
reached 0
at 0
a 0
concentration 0
of 0
250 0
nmol/L 0
of 0
CalC 0
. 0

Haycocknema 0
perplexum 0
n. 0
g. 0
, 0
n. 0
sp 0
. 0

Rams 0
were 0
weighed 0
and 0
testis 0
size 0
was 0
estimated 0
by 0
orchimetry 0
at 0
each 0
time 0
period 0
. 0

Animal 0
studies 0
showed 0
that 0
beam 0
equalization 0
significantly 0
improved 0
fluoroscopic 0
and 0
angiographic 0
image 0
quality 0
. 0

Role 0
of 0
estrogen B-gene
receptor I-gene
ligand 0
and 0
estrogen 0
response 0
element 0
sequence 0
on 0
interaction 0
with 0
chicken B-gene
ovalbumin I-gene
upstream I-gene
promoter I-gene
transcription I-gene
factor I-gene
( 0
COUP B-gene
- I-gene
TF I-gene
) 0
. 0

CONCLUSION 0
: 0
In 0
Cdks B-gene
functioning 0
throughout 0
the 0
cell 0
cycle 0
, 0
tyrosine 0
phosphorylation 0
is 0
inhibitory 0
to 0
the 0
activation 0
of 0
kinase 0
, 0
whereas 0
the 0
phosphorylation 0
of 0
threonine 0
in 0
the 0
T 0
- 0
loop 0
is 0
essential 0
for 0
activation 0
. 0

We 0
also 0
report 0
that 0
AHR B-gene
interacts 0
with 0
COUP B-gene
- I-gene
TF I-gene
in 0
transfected 0
CV 0
- 0
1 0
cells 0
. 0

AB004534 B-gene
. 0

The 0
prevalence 0
of 0
hepatitis 0
C 0
virus 0
( 0
HCV 0
) 0
infection 0
is 0
relatively 0
low 0
in 0
childhood 0
, 0
with 0
anti B-gene
- I-gene
HCV I-gene
prevalence 0
rates 0
of 0
0.1 0
- 0
0.4 0
% 0
in 0
the 0
Western 0
world 0
. 0

Clear 0
and 0
evidenced 0
- 0
based 0
information 0
should 0
be 0
provided 0
to 0
patients 0
as 0
to 0
the 0
means 0
of 0
prevention 0
with 0
special 0
attention 0
to 0
individual 0
risk 0
groups 0
such 0
as 0
IV 0
drug 0
abusers 0
. 0

During 0
latency 0
, 0
more 0
than 0
1 0
% 0
of 0
neurons 0
in 0
ganglia 0
that 0
innervate 0
the 0
footpad 0
expressed 0
beta B-gene
- I-gene
galactosidase I-gene
, 0
with 0
the 0
number 0
of 0
positive 0
cells 0
remaining 0
constant 0
for 0
at 0
least 0
5 0
months 0
. 0

As 0
an 0
alternative 0
approach 0
to 0
this 0
question 0
, 0
we 0
have 0
studied 0
the 0
effects 0
of 0
ectopically 0
expressed 0
SHIP B-gene
, 0
SHP B-gene
- I-gene
1 I-gene
, 0
or 0
SHP B-gene
- I-gene
2 I-gene
SH2 0
- 0
containing 0
decoy 0
proteins 0
on 0
Fc B-gene
gamma I-gene
RIIB1 I-gene
signaling 0
. 0

Compared 0
to 0
those 0
with 0
normal 0
renal 0
functions 0
, 0
these 0
patients 0
were 0
older 0
( 0
P 0
< 0
or 0
= 0
0.01 0
) 0
, 0
had 0
significantly 0
elevated 0
blood 0
pressures 0
( 0
P 0
< 0
0.01 0
or 0
P 0
= 0
0.0001 0
) 0
, 0
and 0
in 0
the 0
case 0
of 0
Type 0
1 0
DM 0
, 0
with 0
a 0
higher 0
body 0
mass 0
index 0
( 0
P 0
= 0
0.0001 0
) 0
and 0
waist 0
- 0
hip 0
ratio 0
( 0
P 0
< 0
0.01 0
) 0
. 0

In 0
all 0
tissues 0
examined 0
only 0
transcripts 0
positive 0
for 0
insert 0
3 0
, 0
an 0
18 0
bp 0
insertion 0
in 0
repeat 0
21 0
, 0
were 0
amplified 0
, 0
even 0
under 0
conditions 0
in 0
which 0
a 0
30 0
% 0
level 0
of 0
insert 0
3 0
negative 0
transcript 0
could 0
be 0
easily 0
detected 0
in 0
artificially 0
prepared 0
control 0
samples 0
. 0

These 0
results 0
show 0
that 0
the 0
CAAT 0
- 0
region 0
is 0
involved 0
in 0
upregulating 0
the 0
MDR1 B-gene
promoter I-gene
in 0
HL60/VCR 0
cells 0
. 0

Both 0
receptors 0
utilize 0
protein B-gene
tyrosine I-gene
kinases I-gene
( 0
PTKs B-gene
) 0
for 0
the 0
phosphorylation 0
of 0
various 0
signaling 0
molecules 0
, 0
a 0
process 0
that 0
is 0
critical 0
for 0
the 0
function 0
of 0
both 0
receptors 0
. 0

Hypothermia 0
After 0
Cardiac 0
Arrest 0
( 0
HACA 0
) 0
Study 0
Group 0
. 0

The 0
synergistic 0
effect 0
due 0
to 0
the 0
5' 0
- 0
3 0
' 0
cooperation 0
was 0
at 0
least 0
fourfold 0
greater 0
than 0
the 0
sum 0
of 0
the 0
contributions 0
of 0
the 0
individual 0
UTRs 0
. 0

We 0
demonstrate 0
that 0
both 0
R B-gene
and 0
Z B-gene
activate 0
the 0
cellular 0
stress 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinases I-gene
, 0
p38 B-gene
and 0
JNK B-gene
, 0
resulting 0
in 0
phosphorylation 0
( 0
and 0
activation 0
) 0
of 0
the 0
cellular B-gene
transcription I-gene
factor I-gene
ATF2 I-gene
. 0

Two 0
US 0
commercial 0
cultivars 0
( 0
Tehama 0
and 0
Vina 0
) 0
, 0
three 0
European 0
commercial 0
cultivars 0
( 0
Esterhazy 0
, 0
139 0
, 0
G120 0
) 0
and 0
five 0
New 0
Zealand 0
selections 0
( 0
Rex 0
, 0
Dublin 0
's 0
Glory 0
, 0
Meyric 0
, 0
McKinster 0
, 0
Stanley 0
) 0
were 0
evaluated 0
. 0

Anatomy 0
of 0
the 0
uterine 0
artery 0
. 0

However 0
, 0
activation 0
of 0
the 0
cAMP 0
pathway 0
, 0
which 0
is 0
known 0
to 0
regulate 0
inhibin B-gene
alpha I-gene
expression 0
, 0
greatly 0
enhanced 0
the 0
actions 0
of 0
SF B-gene
- I-gene
1 I-gene
. 0

Deletion 0
and 0
site 0
- 0
directed 0
mutagenesis 0
localized 0
a 0
novel 0
SF B-gene
- I-gene
1 I-gene
regulatory I-gene
element I-gene
( 0
TCA 0
GGGCCA 0
; 0
- 0
137 0
to 0
- 0
129 0
) 0
adjacent 0
to 0
a 0
variant 0
cAMP 0
- 0
response 0
element 0
( 0
CRE 0
; 0
- 0
120 0
to 0
- 0
114 0
) 0
. 0

Previously 0
, 0
we 0
showed 0
that 0
the 0
APRE 0
is 0
a 0
cytokine 0
[ 0
tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNFalpha B-gene
) 0
] 0
- 0
inducible 0
enhancer 0
by 0
binding 0
the 0
heterodimeric B-gene
nuclear I-gene
factor I-gene
- I-gene
kappaB I-gene
( 0
NF B-gene
- I-gene
kappaB I-gene
) 0
complex 0
Rel B-gene
A I-gene
x 0
NF B-gene
- I-gene
kappaB1 I-gene
. 0

Angiotensin B-gene
II I-gene
induces 0
nuclear B-gene
factor I-gene
( I-gene
NF I-gene
) I-gene
- I-gene
kappaB1 I-gene
isoforms I-gene
to 0
bind 0
the 0
angiotensinogen B-gene
gene I-gene
acute 0
- 0
phase 0
response 0
element 0
: 0
a 0
stimulus 0
- 0
specific 0
pathway 0
for 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
. 0

Synthetic 0
ligands 0
have 0
been 0
identified 0
that 0
reset 0
and 0
amplify 0
the 0
cycle 0
of 0
pulsatile 0
GH B-gene
secretion 0
by 0
interacting 0
with 0
the 0
orphan B-gene
GH I-gene
- I-gene
secretagogue I-gene
receptor I-gene
( 0
GHS B-gene
- I-gene
R I-gene
) 0
. 0

The 0
collection 0
of 0
mutants 0
displaying 0
TGN 0
sorting 0
defects 0
includes 0
members 0
with 0
mutations 0
in 0
previously 0
identified 0
vacuolar B-gene
protein I-gene
sorting I-gene
genes I-gene
( 0
VPS B-gene
) 0
, 0
including 0
the 0
dynamin B-gene
family 0
member 0
VPS1 B-gene
. 0

Also 0
in 0
the 0
spectrum 0
of 0
mutants 0
with 0
TGN 0
sorting 0
defects 0
are 0
isolates 0
with 0
mutations 0
in 0
the 0
following 0
: 0
RIC1 B-gene
, 0
encoding 0
a 0
product 0
originally 0
proposed 0
to 0
participate 0
in 0
ribosome 0
biogenesis 0
; 0
LUV1 B-gene
, 0
encoding 0
a 0
product 0
potentially 0
involved 0
in 0
vacuole 0
and 0
microtubule 0
organization 0
; 0
and 0
INP53 B-gene
, 0
encoding 0
a 0
synaptojanin B-gene
- I-gene
like I-gene
inositol I-gene
polyphosphate I-gene
5 I-gene
- I-gene
phosphatase I-gene
. 0

The 0
single 0
strandedness 0
is 0
manifested 0
as 0
a 0
terminal 0
extension 0
of 0
the 0
G 0
- 0
rich 0
strand 0
( 0
G 0
tails 0
) 0
that 0
can 0
occur 0
independently 0
of 0
telomerase B-gene
, 0
suggesting 0
that 0
cdc17/pol1 B-gene
mutants 0
exhibit 0
defects 0
in 0
telomeric 0
lagging 0
- 0
strand 0
synthesis 0
. 0

In 0
addition 0
, 0
CaMig1 B-gene
formed 0
specific 0
complexes 0
with 0
the 0
URS1 0
region 0
of 0
the 0
S. B-gene
cerevisiae I-gene
FBP1 I-gene
gene I-gene
. 0

Furthermore 0
, 0
the 0
wide 0
distribution 0
of 0
the 0
GFP B-gene
- 0
POLO B-gene
protein 0
to 0
all 0
compartments 0
of 0
the 0
mitotic 0
apparatus 0
provides 0
a 0
valuable 0
tool 0
for 0
future 0
studies 0
on 0
cell 0
cycle 0
during 0
development 0
. 0

An 0
ASIC 0
- 0
chip 0
for 0
stereoscopic 0
depth 0
analysis 0
in 0
video 0
- 0
real 0
- 0
time 0
based 0
on 0
visual 0
cortical 0
cell 0
behavior 0
. 0

However 0
, 0
calphostin 0
C 0
, 0
a 0
specific 0
inhibitor 0
of 0
PKC B-gene
, 0
abolished 0
the 0
TPA 0
- 0
induced 0
increase 0
in 0
CFI B-gene
mRNA I-gene
levels 0
. 0

Preimmune B-gene
IgG I-gene
, 0
anti B-gene
- I-gene
GalT I-gene
Fab I-gene
fragments I-gene
, 0
irrelevant 0
polymers 0
and 0
monomeric 0
N 0
- 0
acetylglucosamine 0
had 0
no 0
effect 0
. 0

Arhythmacanthus 0
Yamaguti 0
, 0
1935 0
is 0
maintained 0
as 0
a 0
synonym 0
of 0
Heterosentis 0
because 0
the 0
distinction 0
between 0
two 0
and 0
three 0
hook 0
types 0
is 0
made 0
equivocal 0
when 0
the 0
transition 0
between 0
the 0
apical 0
and 0
subapical 0
hooks 0
is 0
gradual 0
. 0

We 0
describe 0
a 0
case 0
of 0
acetaminophen 0
overdose 0
that 0
was 0
treated 0
with 0
both 0
hemodialysis 0
( 0
HD 0
) 0
and 0
NAC 0
due 0
to 0
severe 0
intoxication 0
and 0
slow 0
drug 0
clearance 0
. 0

Following 0
conditioning 0
, 0
a 0
single 0
coat 0
of 0
adhesive 0
was 0
applied 0
and 0
light 0
- 0
cured 0
. 0

Downstream 0
of 0
the 0
G 0
- 0
A 0
anastomosis 0
, 0
the 0
RD 0
, 0
CC 0
, 0
E 0
( 0
p 0
) 0
and 0
loop 0
areas 0
were 0
significantly 0
different 0
from 0
REF 0
, 0
but 0
significantly 0
different 0
from 0
A 0
- 0
A 0
. 0

Induced 0
expression 0
of 0
c B-gene
- I-gene
myc I-gene
is 0
likely 0
to 0
contribute 0
to 0
the 0
proliferation 0
of 0
Stat1 B-gene
- 0
null 0
cells 0
in 0
response 0
to 0
IFNs B-gene
. 0

Eastern 0
Cooperative 0
Oncology 0
Group 0
trial 0
E3186 0
was 0
initiated 0
to 0
explore 0
this 0
question 0
. 0

We 0
determined 0
how 0
DNA 0
repair 0
is 0
affected 0
by 0
TFA1 B-gene
conditional 0
mutations 0
. 0

These 0
articles 0
both 0
report 0
the 0
results 0
of 0
multi 0
- 0
institutional 0
, 0
randomized 0
, 0
phase 0
3 0
trials 0
for 0
the 0
treatment 0
of 0
patients 0
with 0
localized 0
( 0
T1 0
- 0
3 0
N0 0
- 0
1 0
M0 0
) 0
esophageal 0
squamous 0
cell 0
carcinoma 0
( 0
SCC 0
) 0
or 0
esophageal 0
adenocarcinoma 0
. 0

Studies 0
of 0
MPO B-gene
gene I-gene
regulation 0
can 0
help 0
to 0
elucidate 0
the 0
mechanism 0
of 0
normal 0
and 0
abnormal 0
myeloid 0
differentiation 0
. 0

NDRF/NeuroD2 B-gene
was 0
co 0
- 0
precipitated 0
with 0
NDRF/NeuroD2 I-gene

Transient 0
transfection 0
assays 0
using 0
P19 0
cells 0
revealed 0
that 0
expression 0
of 0
NDRF/NeuroD2 B-gene
increased 0
the 0
transactivation 0
of 0
the 0
NDRF/NeuroD2 I-gene

Two 0
Pax2/5/8 B-gene
- I-gene
binding I-gene
sites I-gene
in 0
Engrailed2 B-gene
are 0
required 0
for 0
proper 0
initiation 0
of 0
endogenous 0
mid 0
- 0
hindbrain 0
expression 0
. 0

Upon 0
tyrosine 0
phosphorylation 0
at 0
the 0
ITIMs 0
, 0
these 0
molecules 0
recruit 0
SH2 B-gene
domain 0
- 0
containing 0
phosphatases 0
such 0
as 0
SH2 B-gene
- 0
containing 0
tyrosine B-gene
phosphatase I-gene
- I-gene
1 I-gene
and 0
negatively 0
regulate 0
cell 0
activity 0
. 0

AF154055 B-gene
. 0

Alignment 0
of 0
the 0
cervical 0
spine 0
, 0
vertebral 0
abnormalities 0
, 0
and 0
disc 0
changes 0
also 0
were 0
evaluated 0
. 0

The 0
concomitant 0
interaction 0
of 0
mSTI1 B-gene
with 0
hsp70 B-gene
and 0
hsp90 B-gene
at 0
its 0
N 0
- 0
and 0
C 0
- 0
termini 0
respectively 0
is 0
mediated 0
by 0
the 0
tetratricopeptide 0
repeat 0
( 0
TPR 0
) 0
motifs 0
in 0
these 0
regions 0
. 0

Competition 0
experiments 0
demonstrate 0
a 0
negative 0
allosteric 0
relationship 0
between 0
these 0
RGD 0
recognition 0
sites 0
. 0

Sequence 0
analysis 0
showed 0
that 0
the 0
5' 0
- 0
flanking 0
region 0
upstream 0
to 0
the 0
ATG 0
codon 0
did 0
not 0
contain 0
a 0
conventional 0
TATA 0
box 0
. 0

After 0
i.v 0
. 0
administration 0
of 0
500 0
mg 0
acetazolamide 0
and 0
disinfection 0
of 0
the 0
conjunctiva 0
, 0
50 0
micrograms 0
rt B-gene
- I-gene
PA I-gene
in 0
0.1 0
ml 0
( 0
BSS 0
) 0
and 0
0.5 0
ml 0
SF6 0
were 0
injected 0
intravitreally 0
. 0

These 0
results 0
suggest 0
that 0
VP1 B-gene
was 0
efficiently 0
transported 0
to 0
the 0
nucleus 0
and 0
localized 0
in 0
the 0
discrete 0
subnuclear 0
regions 0
, 0
possibly 0
with 0
VP2 B-gene
and 0
VP3 B-gene
. 0

Differential 0
expression 0
and 0
regulation 0
by 0
20 0
- 0
hydroxyecdysone 0
of 0
mosquito 0
ultraspiracle 0
isoforms 0
. 0

The 0
three 0
isoforms 0
purified 0
with 0
anti B-gene
- I-gene
FLAG I-gene
antibody I-gene
affinity 0
column 0
transferred 0
sulfate 0
to 0
heparan 0
sulfate 0
and 0
heparin 0
but 0
not 0
to 0
other 0
glycosaminoglycans 0
. 0

The 0
differentiation 0
and 0
maintenance 0
of 0
a 0
neurotransmitter 0
phenotype 0
is 0
guided 0
by 0
the 0
interaction 0
of 0
exogenous 0
cues 0
with 0
intrinsic 0
genetic 0
machinery 0
. 0

Analysis 0
of 0
functional 0
domains 0
of 0
Arix B-gene
reveals 0
an 0
N 0
- 0
terminal 0
activation 0
domain 0
and 0
a 0
C 0
- 0
terminal 0
repression 0
domain 0
. 0

BACKGROUND 0
: 0
Left 0
ventricular 0
hypertrophy 0
is 0
a 0
heterogeneous 0
disorder 0
with 0
distinct 0
morphologies 0
. 0

Multivariate 0
predictors 0
were 0
concentric 0
remodeling 0
( 0
P 0
< 0
0.0001 0
; 0
odds 0
ratio 0
, 0
13.5 0
) 0
, 0
left 0
ventricular 0
ejection 0
fraction 0
> 0
2 0
SD 0
above 0
normal 0
( 0
P 0
< 0
0.0001 0
) 0
, 0
and 0
single 0
- 0
vessel 0
left 0
circumflex 0
disease 0
( 0
P 0
< 0
0.0007 0
; 0
odds 0
ratio 0
, 0
7.6 0
) 0
. 0

The 0
case 0
for 0
completing 0
the 0
lymphadenectomy 0
when 0
positive 0
lymph 0
nodes 0
are 0
found 0
during 0
radical 0
hysterectomy 0
for 0
cervical 0
carcinoma 0
. 0

Overexpression 0
of 0
ICBP90 B-gene
in 0
COS 0
- 0
1 0
- 0
transfected 0
cells 0
induced 0
an 0
enhanced 0
expression 0
of 0
endogenous B-gene
topoisomerase I-gene
IIalpha I-gene
. 0

The 0
RNA 0
aptamer 0
contains 0
three 0
stems 0
separated 0
by 0
a 0
pair 0
of 0
two 0
- 0
base 0
bulges 0
, 0
and 0
adopts 0
an 0
unanticipated 0
fold 0
in 0
which 0
both 0
junctional 0
sites 0
are 0
anchored 0
through 0
base 0
triple 0
formation 0
. 0

The 0
study 0
suggests 0
the 0
presence 0
of 0
an 0
anatomical 0
sphincter 0
at 0
the 0
RSJ 0
which 0
seems 0
to 0
regulate 0
the 0
passage 0
of 0
stools 0
from 0
the 0
sigmoid 0
colon 0
to 0
the 0
rectum 0
. 0

Isolation 0
of 0
cDNAs B-gene
encoding I-gene
gibbon I-gene
and I-gene
monkey I-gene
platelet I-gene
and I-gene
T I-gene
cell I-gene
activation I-gene
antigen I-gene
1 I-gene
( 0
PTA1 B-gene
) 0
. 0

To 0
quantify 0
any 0
mechanical 0
inhibitory 0
effect 0
of 0
nasal 0
intermittent 0
positive 0
pressure 0
ventilation 0
( 0
IPPV 0
) 0
on 0
inspiratory 0
activity 0
of 0
the 0
diaphragm 0
we 0
ventilated 0
five 0
conscious 0
relaxed 0
subjects 0
on 0
two 0
occasions 0
at 0
respiratory 0
rates 0
similar 0
to 0
quiet 0
breathing 0
( 0
QB 0
) 0
and 0
at 0
three 0
levels 0
of 0
applied 0
pressure 0
( 0
Pappl 0
) 0
- 0
- 0
6 0
, 0
9 0
and 0
12 0
cmH2O 0
, 0
each 0
during 0
hypocapnia 0
( 0
P 0
( 0
CO2 0
) 0
allowed 0
to 0
decrease 0
) 0
and 0
eucapnia 0
( 0
CO2 0
added 0
to 0
inspired 0
gas 0
) 0
. 0

METHODS 0
: 0
Von B-gene
Willebrand I-gene
factor I-gene
( 0
vWF B-gene
) 0
and 0
the 0
fibrinolytic 0
factors 0
tissue B-gene
plasminogen I-gene
activator I-gene
( 0
tPA B-gene
) 0
, 0
measured 0
as 0
tPA B-gene
capacity 0
, 0
and 0
plasminogen B-gene
activator I-gene
inhibitor I-gene
1 I-gene
( 0
PAI B-gene
- I-gene
1 I-gene
) 0
, 0
platelets 0
, 0
fibrinogen B-gene
, 0
and 0
inflammatory 0
markers 0
were 0
measured 0
in 0
74 0
patients 0
with 0
active 0
seropositive 0
RA 0
. 0

Neuronal 0
signaling 0
properties 0
are 0
largely 0
determined 0
by 0
the 0
quantity 0
and 0
combination 0
of 0
ion 0
channels 0
expressed 0
. 0

Treatment 0
also 0
led 0
to 0
a 0
significant 0
dose 0
dependent 0
reduction 0
in 0
the 0
sum 0
of 0
ST 0
segment 0
depression 0
at 0
both 0
trough 0
and 0
peak 0
concentrations 0
. 0

We 0
have 0
investigated 0
the 0
contribution 0
of 0
specific 0
TATA B-gene
- I-gene
binding I-gene
protein I-gene
( 0
TBP B-gene
) 0
- 0
TATA 0
interactions 0
to 0
the 0
promoter 0
activity 0
of 0
a 0
constitutively 0
expressed 0
silkworm B-gene
tRNA I-gene
( I-gene
C I-gene
) I-gene
( I-gene
Ala I-gene
) I-gene
gene I-gene
and 0
have 0
also 0
asked 0
whether 0
the 0
lack 0
of 0
similar 0
interactions 0
accounts 0
for 0
the 0
low 0
promoter 0
activity 0
of 0
a 0
silk B-gene
gland I-gene
- I-gene
specific I-gene
tRNA I-gene
( I-gene
SG I-gene
) I-gene
( I-gene
Ala I-gene
) I-gene
gene I-gene
. 0

The 0
sequences 0
showed 0
extensive 0
homologies 0
with 0
squalene B-gene
synthase I-gene
genes I-gene
and 0
enzymes 0
from 0
a 0
number 0
of 0
other 0
organisms 0
and 0
extreme 0
amino 0
acid 0
conservation 0
within 0
the 0
binding 0
and 0
catalytic 0
domains 0
. 0

All 0
clones 0
and 0
strains 0
produced 0
have 0
been 0
deposited 0
in 0
the 0
EUROFAN 0
genetic 0
stock 0
centre 0
( 0
EUROSCARF 0
, 0
Frankfurt 0
) 0
. 0

Two 0
episodes 0
of 0
peritonitis 0
occurred 0
while 0
the 0
patient 0
received 0
CAPD 0
( 0
1 0
episode/3.5 0
patient 0
- 0
months 0
) 0
. 0

Copyright 0
2000 0
The 0
Royal 0
College 0
of 0
Radiologists 0
. 0

Two 0
estrogen B-gene
receptor I-gene
( 0
ER B-gene
) 0
isoforms 0
with 0
different 0
estrogen 0
dependencies 0
are 0
generated 0
from 0
the 0
trout B-gene
ER I-gene
gene I-gene
. 0

Induction 0
was 0
reversed 0
by 0
coexpression 0
of 0
A B-gene
- I-gene
Fos I-gene
, 0
a 0
dominant 0
negative 0
to 0
AP B-gene
- I-gene
1 I-gene
. 0

In 0
myometrial 0
SMC 0
, 0
both 0
isoforms 0
of 0
the 0
progesterone B-gene
receptor I-gene
, 0
PR B-gene
- I-gene
B I-gene
and 0
PR B-gene
- I-gene
A I-gene
, 0
caused 0
a 0
ligand 0
- 0
dependent 0
activation 0
of 0
PGDH B-gene
- I-gene
2368/luc3 I-gene
. 0

Element 0
B 0
( 0
- 0
249/ 0
- 0
229 0
) 0
shows 0
more 0
than 0
80 0
% 0
homology 0
to 0
a 0
consensus B-gene
c I-gene
- I-gene
myb I-gene
element I-gene
, 0
but 0
formed 0
two 0
specific 0
complexes 0
that 0
differed 0
from 0
that 0
of 0
c B-gene
- I-gene
myb I-gene
in 0
the 0
electrophoretic 0
mobility 0
shift 0
assay 0
. 0

High 0
resolution 0
computed 0
tomography 0
of 0
the 0
lungs 0
in 0
patients 0
with 0
rheumatoid 0
arthritis 0
. 0

Stable 0
transfection 0
of 0
the 0
truncated 0
reduced B-gene
folate I-gene
carrier I-gene
cDNA I-gene
into 0
mouse 0
L1210 0
leukemia 0
cells 0
: 0
increased 0
folate 0
accumulation 0
, 0
decreased 0
their 0
leucovorin 0
and 0
folic 0
acid 0
growth 0
requirements 0
, 0
and 0
increased 0
their 0
sensitivity 0
to 0
methotrexate 0
. 0

Characterization 0
of 0
a 0
human B-gene
alternatively I-gene
spliced I-gene
truncated I-gene
reduced I-gene
folate I-gene
carrier I-gene
increasing 0
folate 0
accumulation 0
in 0
parental 0
leukemia 0
cells 0
. 0

Electron 0
microscopic 0
and 0
enzymatic 0
analyses 0
revealed 0
that 0
the 0
A118 0
genome 0
is 0
a 0
linear 0
, 0
circularly 0
permuted 0
, 0
terminally 0
redundant 0
collection 0
of 0
double 0
- 0
stranded 0
DNA 0
molecules 0
. 0

Moreover 0
, 0
increasing 0
the 0
dosage 0
of 0
wild B-gene
- I-gene
type I-gene
Fus3 I-gene
intensifies 0
the 0
inhibition 0
of 0
both 0
Ty1 B-gene
transposition 0
and 0
invasive 0
growth 0
. 0

Consistently 0
, 0
activation 0
of 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
downstream 0
of 0
Rho B-gene
family I-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
was 0
also 0
enhanced 0
when 0
Dbl B-gene
was 0
tyrosine 0
- 0
phosphorylated 0
. 0

However 0
, 0
its 0
participation 0
in 0
collagen B-gene
binding 0
has 0
not 0
been 0
shown 0
. 0

Together 0
, 0
these 0
data 0
suggest 0
that 0
the 0
carboxyl 0
terminus 0
of 0
CFTR B-gene
contains 0
a 0
tyrosine 0
- 0
based 0
internalization 0
signal 0
that 0
interacts 0
with 0
the 0
endocytic 0
adaptor 0
complex 0
AP B-gene
- I-gene
2 I-gene
to 0
facilitate 0
efficient 0
entry 0
of 0
CFTR B-gene
into 0
clathrin B-gene
- 0
coated 0
vesicles 0
. 0

The 0
insulin B-gene
therapy 0
regimen 0
did 0
not 0
affect 0
the 0
evolution 0
of 0
the 0
patients 0
and 0
no 0
significant 0
relationship 0
existed 0
between 0
the 0
age 0
at 0
diagnosis 0
, 0
duration 0
of 0
diabetes 0
, 0
daily 0
insulin B-gene
dosage 0
or 0
metabolic 0
control 0
and 0
height 0
or 0
BMI 0
. 0

Scmh1 B-gene
maps 0
to 0
4D1 0
- 0
D2.1 0
in 0
mice 0
. 0

The 0
applicability 0
of 0
laparoscopic 0
donor 0
nephrectomy 0
( 0
LDN 0
) 0
has 0
not 0
been 0
assessed 0
in 0
the 0
obese 0
donor 0
. 0

Hyaluronan 0
treatment 0
stimulated 0
collagen B-gene
remodeling 0
in 0
the 0
peripheral 0
region 0
and 0
inhibited 0
swelling 0
of 0
the 0
meniscus 0
repaired 0
in 0
the 0
inner 0
region 0
. 0

We 0
have 0
addressed 0
these 0
issues 0
by 0
reconstituting 0
and 0
characterizing 0
the 0
KRAB B-gene
: 0
KAP B-gene
- I-gene
1 I-gene
- 0
RBCC B-gene
interaction 0
using 0
purified 0
components 0
. 0

The 0
RING 0
finger 0
, 0
B2 0
box 0
, 0
and 0
coiled 0
- 0
coil 0
region 0
are 0
required 0
for 0
oligomerization 0
of 0
KAP B-gene
- I-gene
1 I-gene
- 0
RBCC B-gene
and 0
KRAB B-gene
binding 0
, 0
as 0
mutations 0
in 0
these 0
domains 0
concomitantly 0
abolished 0
these 0
functions 0
. 0

Actins B-gene
show 0
two 0
different 0
forms 0
of 0
N 0
- 0
terminal 0
processing 0
dependent 0
on 0
their 0
N 0
- 0
terminal 0
sequence 0
. 0

All 0
four 0
domains 0
were 0
linked 0
via 0
proline 0
- 0
threonine 0
- 0
rich 0
peptides 0
. 0

JPEG 0
53 0
, 0
resulting 0
in 0
a 0
compression 0
ratio 0
of 0
1:21 0
, 0
does 0
not 0
compromise 0
the 0
diagnostic 0
performance 0
in 0
general 0
. 0

We 0
critically 0
assess 0
current 0
systematic 0
uncertainties 0
and 0
determine 0
the 0
primordial 0
Li 0
abundance 0
within 0
new 0
, 0
much 0
tighter 0
limits 0
: 0
& 0
amp 0
; 0
parl0 0
; 0
Li 0
& 0
amp 0
; 0
solm0 0
; 0
H 0
& 0
amp 0
; 0
parr0 0
; 0
p=1.23+0.68 0
- 0
0.32x10 0
- 0
10 0
. 0

Like 0
their 0
yeast 0
counterpart 0
, 0
the 0
mouse 0
GCN2 B-gene
isoforms 0
contain 0
HisRS B-gene
- I-gene
related I-gene
sequences I-gene
juxtaposed 0
to 0
the 0
kinase 0
catalytic 0
domain 0
. 0

Five 0
women 0
( 0
15.6 0
% 0
) 0
met 0
criteria 0
for 0
PMS 0
. 0

MBI 0
and 0
MMBI 0
showed 0
similar 0
Cmax 0
values 0
, 0
but 0
the 0
former 0
disappeared 0
slower 0
in 0
the 0
serum 0
than 0
the 0
latter 0
and 0
resulted 0
in 0
its 0
larger 0
AUC 0
values 0
. 0

Another 0
long 0
insertion 0
in 0
the 0
cathepsin B-gene
X I-gene
amino I-gene
acid I-gene
sequence I-gene
forms 0
a 0
beta 0
- 0
hairpin 0
pointing 0
away 0
from 0
the 0
active 0
site 0
. 0

Transfection 0
experiments 0
demonstrated 0
that 0
the 0
5' 0
- 0
flanking 0
region 0
( 0
- 0
1894 0
to 0
+37 0
) 0
of 0
the 0
mStaf B-gene
gene I-gene
drives 0
transcription 0
in 0
mouse 0
NMuMG 0
cells 0
and 0
that 0
a 0
construct 0
containing 0
a 0
fragment 0
from 0
- 0
387 0
to 0
+37 0
showed 0
the 0
highest 0
transcriptional 0
activity 0
. 0

Further 0
studies 0
in 0
T 0
- 0
24 0
cells 0
demonstrated 0
that 0
HA 0
fragments 0
also 0
induced 0
I B-gene
kappa I-gene
B I-gene
alpha I-gene
phosphorylation 0
and 0
degradation 0
, 0
kappa B-gene
B I-gene
- I-gene
linked I-gene
reporter I-gene
gene I-gene
expression 0
, 0
and 0
ICAM B-gene
- I-gene
1 I-gene
promoter I-gene
activity 0
in 0
an 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
- 0
dependent 0
manner 0
. 0

Pretreatment 0
of 0
cells 0
or 0
mouse 0
skin 0
with 0
antisense 0
oligonucleotides 0
of 0
PKCzeta B-gene
impaired 0
UV 0
- 0
induced 0
activation 0
of 0
AP B-gene
- I-gene
1 I-gene
in 0
JB6 0
cells 0
as 0
well 0
as 0
in 0
AP B-gene
- I-gene
1 I-gene
- 0
luciferase B-gene
transgenic 0
mice 0
. 0

The 0
level 0
of 0
subclinical 0
infection 0
was 0
75 0
% 0
among 0
seropositive 0
dogs 0
. 0

METHODS 0
: 0
The 0
former 0
group 0
included 0
patients 0
who 0
had 0
been 0
treated 0
with 0
at 0
least 0
four 0
PGE1 0
alpha 0
- 0
ciclodestrina 0
, 0
short 0
- 0
term 0
treatment 0
cycles 0
per 0
year 0
while 0
the 0
latter 0
was 0
a 0
historical 0
reference 0
group 0
managed 0
without 0
prostaglandins 0
. 0

Desmethylferrochloroquine 0
1a 0
and 0
didesmethylferrochloroquine 0
2 0
would 0
be 0
more 0
potent 0
against 0
schizontocides 0
than 0
CQ 0
in 0
vitro 0
against 0
two 0
strains 0
( 0
HB3 0
and 0
Dd2 0
) 0
of 0
Plasmodium 0
falciparum 0
. 0

The 0
rrd1,2delta B-gene
mutant I-gene
was 0
partially 0
rescued 0
by 0
inactivation 0
of 0
HOG1 B-gene
or 0
PBS2 B-gene
, 0
suggesting 0
an 0
interaction 0
between 0
the 0
RRD B-gene
genes I-gene
and 0
the 0
Hog1p B-gene
signal I-gene
transduction I-gene
pathway I-gene
. 0

Members 0
of 0
the 0
JAK/Tyk B-gene
family 0
of 0
JAK/Tyk I-gene

In 0
vivo 0
, 0
CARbeta/RXRalpha B-gene
activated 0
transcription 0
from 0
an 0
CARbeta/RXRalpha I-gene

Zebrafish 0
cyclops B-gene
( 0
cyc B-gene
) 0
encodes 0
a 0
Transforming B-gene
Growth I-gene
Factor I-gene
beta I-gene
( 0
TGFbeta B-gene
) 0
signaling 0
factor 0
closely 0
related 0
to 0
mouse 0
Nodal B-gene
. 0

Thus 0
, 0
SOX8 B-gene
is 0
a 0
good 0
candidate 0
gene 0
contributing 0
to 0
the 0
mental 0
retardation 0
phenotype 0
seen 0
in 0
ATR 0
- 0
16 0
patients 0
. 0

The 0
genome 0
organization 0
of 0
the 0
mite 0
- 0
transmitted 0
wheat 0
streak 0
mosaic 0
virus 0
( 0
WSMV 0
) 0
appears 0
to 0
parallel 0
that 0
of 0
members 0
of 0
the 0
Potyviridae 0
with 0
monopartite 0
genomes 0
, 0
but 0
there 0
are 0
substantial 0
amino 0
acid 0
dissimilarities 0
with 0
other 0
potyviral 0
polyproteins 0
. 0

The 0
two 0
- 0
hybrid 0
assay 0
was 0
then 0
performed 0
using 0
full 0
- 0
length 0
genes 0
of 0
CI B-gene
, 0
HC B-gene
- I-gene
Pro I-gene
, 0
P1 B-gene
, 0
P3 B-gene
, 0
and 0
CP B-gene
, 0
but 0
no 0
heterologous 0
interactions 0
were 0
detected 0
. 0

Diverse 0
endogenous 0
light 0
chains 0
contribute 0
to 0
basement 0
membrane 0
reactivity 0
in 0
nonautoimmune 0
mice 0
transgenic 0
for 0
an 0
anti B-gene
- I-gene
laminin I-gene
Ig B-gene
heavy I-gene
chain I-gene
. 0

Patch 0
test 0
results 0
obtained 0
with 0
corticosteroid 0
allergic 0
patients 0
tested 0
with 0
a 0
large 0
corticosteroid 0
series 0
validated 0
the 0
earlier 0
classification 0
of 0
corticosteroid 0
molecules 0
in 0
four 0
groups 0
of 0
cross 0
- 0
reacting 0
molecules 0
: 0
i.e. 0
, 0
group 0
A 0
( 0
hydrocortisone 0
type 0
) 0
, 0
group 0
B 0
( 0
acetonides 0
) 0
, 0
group 0
C 0
( 0
betamethasone 0
type 0
- 0
non 0
esterified 0
) 0
and 0
group 0
D 0
( 0
esters 0
) 0
. 0

Mechanisms 0
of 0
tachyphylaxis 0
in 0
regional 0
anesthesia 0
of 0
long 0
duration 0

An 0
increase 0
in 0
the 0
level 0
of 0
serum 0
enzymes 0
, 0
such 0
as 0
aspartate B-gene
transaminase I-gene
, 0
alkaline B-gene
phosphatase I-gene
, 0
creatine B-gene
phosphokinase I-gene
, 0
lactate B-gene
dehydrogenase I-gene
after 0
D. 0
russelli 0
venom 0
injection 0
in 0
albino 0
rats 0
is 0
indicative 0
of 0
cell 0
or 0
tissue 0
damage 0
. 0

The 0
partial 0
farm 0
budget 0
highlighted 0
the 0
importance 0
of 0
reducing 0
sub 0
- 0
clinical 0
lesions 0
in 0
a 0
feedlot 0
. 0

Surprisingly 0
, 0
3 0
full B-gene
- I-gene
length I-gene
murine I-gene
survivin I-gene
cDNA I-gene
clones 0
were 0
isolated 0
, 0
predicting 0
the 0
existence 0
of 0
3 0
distinct 0
survivin B-gene
proteins I-gene
. 0

Thus 0
, 0
the 0
induction 0
of 0
E2F B-gene
binding 0
to 0
the 0
E2F B-gene
- I-gene
1 I-gene
promoter I-gene
by 0
the 0
E4 B-gene
- I-gene
6/7 I-gene
protein I-gene
observed 0
in 0
vitro 0
correlates 0
with 0
transactivation 0
of 0
E2F B-gene
- I-gene
1 I-gene
promoter I-gene
activity 0
in 0
vivo 0
. 0

We 0
show 0
that 0
stabilization 0
of 0
the 0
hairpin 0
reduced 0
the 0
amount 0
of 0
tRNA 0
primer 0
that 0
is 0
annealed 0
to 0
the 0
PBS 0
. 0

Ischemia 0
- 0
induced 0
biphasic 0
arrhythmias 0
were 0
suppressed 0
in 0
both 0
zatebradine 0
and 0
propranolol 0
groups 0
. 0

ZK7 B-gene
and 0
HZF16 B-gene
genes I-gene
appear 0
to 0
be 0
the 0
splice 0
variants 0
transcribed 0
from 0
the 0
same 0
gene 0
. 0

CONCLUSION 0
: 0
Presence 0
of 0
APOE B-gene
epsilon4/* I-gene
seems 0
to 0
increase 0
the 0
risk 0
for 0
dementia 0
and 0
AD 0
independently 0
of 0
its 0
effect 0
on 0
dyslipidemia 0
and 0
atherogenesis 0
. 0

No 0
definite 0
conclusions 0
are 0
possible 0
because 0
of 0
the 0
small 0
number 0
of 0
patients 0
involved 0
in 0
this 0
phase 0
II 0
trial 0
. 0

Two 0
distinct 0
Salmonella B-gene
fimbrins I-gene
, 0
AgfA B-gene
and 0
SefA B-gene
, 0
comprising 0
thin 0
aggregative 0
fimbriae 0
SEF17 B-gene
and 0
SEF14 B-gene
, 0
respectively 0
, 0
were 0
each 0
genetically 0
engineered 0
to 0
carry 0
PT3 B-gene
, 0
an 0
alpha 0
- 0
helical 0
16 0
- 0
amino 0
acid 0
Leishmania 0
T 0
- 0
cell 0
epitope 0
derived 0
from 0
the 0
metalloprotease B-gene
gp63 B-gene
. 0

In 0
marked 0
contrast 0
to 0
AgfA B-gene
, 0
none 0
of 0
the 0
chimeric B-gene
SefA I-gene
proteins I-gene
were 0
expressed 0
or 0
assembled 0
into 0
fimbriae 0
. 0

Productive 0
growth 0
of 0
phage 0
P22 0
in 0
wild 0
- 0
type 0
Salmonella 0
typhimurium 0
correlates 0
with 0
the 0
presence 0
of 0
Abc2 B-gene
, 0
but 0
is 0
independent 0
of 0
the 0
absolute 0
level 0
of 0
ATP B-gene
- I-gene
dependent I-gene
nuclease I-gene
activity 0
, 0
suggesting 0
a 0
qualitative 0
change 0
in 0
the 0
nature 0
of 0
Abc2 B-gene
- 0
modified 0
RecBCD B-gene
nuclease I-gene
activity 0
relative 0
to 0
the 0
native 0
enzyme 0
. 0

In 0
this 0
study 0
, 0
we 0
investigated 0
the 0
molecular 0
mechanisms 0
underlying 0
the 0
inducible 0
expression 0
of 0
the 0
flt B-gene
- I-gene
1 I-gene
gene I-gene
during 0
the 0
activation 0
of 0
THP 0
- 0
1 0
cells 0
. 0

There 0
was 0
a 0
2.4 0
- 0
fold 0
difference 0
in 0
CAT B-gene
produced 0
from 0
these 0
transcripts 0
in 0
HeLa 0
cells 0
, 0
which 0
contain 0
a 0
greater 0
natural 0
abundance 0
of 0
PTB B-gene
. 0

Multiple 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
signaling 0
pathways 0
connect 0
the 0
cot B-gene
oncoprotein I-gene
to 0
the 0
c B-gene
- I-gene
jun I-gene
promoter I-gene
and 0
to 0
cellular 0
transformation 0
. 0

Dermatology 0
is 0
no 0
exception 0
. 0

4 0
. 0

In 0
the 0
present 0
study 0
we 0
have 0
investigated 0
the 0
regulatory 0
mechanism 0
for 0
CD95L B-gene
expression 0
. 0

Protein 0
sequence 0
analysis 0
reveals 0
that 0
MAN1 B-gene
shares 0
a 0
conserved 0
globular 0
domain 0
of 0
approximately 0
40 0
amino 0
acids 0
, 0
which 0
we 0
term 0
the 0
LEM B-gene
module I-gene
, 0
with 0
inner 0
nuclear 0
membrane 0
proteins 0
lamina B-gene
- I-gene
associated I-gene
polypeptide I-gene
2 I-gene
and 0
emerin B-gene
. 0

Molecular 0
cloning 0
of 0
a 0
novel 0
human B-gene
I I-gene
- I-gene
mfa I-gene
domain I-gene
- I-gene
containing I-gene
protein I-gene
that 0
differently 0
regulates 0
human 0
T 0
- 0
cell 0
leukemia 0
virus 0
type 0
I 0
and 0
HIV 0
- 0
1 0
expression 0
. 0

The 0
encoded 0
amino 0
acid 0
sequences 0
in 0
the 0
full 0
- 0
length 0
bovine 0
and 0
porcine 0
cDNAs 0
were 0
identical 0
, 0
consisting 0
of 0
209 0
amino 0
acid 0
residues 0
, 0
and 0
were 0
nearly 0
the 0
same 0
as 0
the 0
published 0
sequence 0
determined 0
by 0
Edman 0
degradation 0
. 0

With 0
chemical 0
shift 0
imaging 0
, 0
the 0
signal 0
intensity 0
decreased 0
on 0
the 0
out 0
- 0
of 0
- 0
phase 0
images 0
in 0
six 0
of 0
seven 0
( 0
86 0
% 0
) 0
patients 0
with 0
APA 0
and 0
in 0
eight 0
of 0
nine 0
( 0
89 0
% 0
) 0
patients 0
with 0
BAH 0
. 0

For 0
each 0
night 0
, 0
the 0
diary 0
allowed 0
the 0
subjective 0
measurement 0
of 0
bedtime 0
, 0
wake 0
time 0
, 0
time 0
in 0
bed 0
( 0
TIB 0
) 0
, 0
sleep 0
efficiency 0
, 0
number 0
of 0
minutes 0
of 0
wake 0
after 0
sleep 0
onset 0
( 0
WASO 0
) 0
, 0
alertness 0
on 0
awakening 0
, 0
and 0
percentage 0
of 0
morning 0
needing 0
an 0
alarm 0
( 0
or 0
a 0
person 0
functioning 0
as 0
one 0
) 0
. 0

Acad 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

The 0
central 0
( 0
R 0
) 0
domain 0
is 0
responsible 0
for 0
receptor 0
- 0
binding 0
activity 0
whereas 0
the 0
N 0
- 0
terminal 0
( 0
T 0
) 0
domain 0
mediates 0
translocation 0
, 0
the 0
process 0
by 0
which 0
the 0
C 0
- 0
terminal 0
cytotoxic 0
domain 0
is 0
transported 0
from 0
the 0
receptor 0
to 0
the 0
site 0
of 0
its 0
cytotoxicity 0
. 0

We 0
have 0
previously 0
demonstrated 0
that 0
expression 0
of 0
the 0
gene 0
for 0
the 0
reproductive 0
neuropeptide 0
, 0
GnRH B-gene
, 0
is 0
repressed 0
by 0
the 0
glutamate/NO/cyclic 0
GMP 0
( 0
cGMP 0
) 0
signal 0
transduction 0
pathway 0
through 0
cGMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
in 0
the 0
hypothalamic 0
GnRH B-gene
- 0
secreting 0
neuronal 0
cell 0
line 0
GT1 0
- 0
7 0
. 0

These 0
data 0
suggest 0
that 0
combined 0
lesions 0
of 0
cholinergic 0
and 0
serotonergic 0
neurons 0
in 0
the 0
rat 0
brain 0
do 0
not 0
alter 0
olfactory 0
perception 0
or 0
olfactory 0
short 0
- 0
term 0
memory 0
. 0

Extreme 0
potency 0
of 0
botulinum B-gene
toxin I-gene
. 0

In 0
contrast 0
, 0
c B-gene
- I-gene
Src I-gene
activated 0
by 0
isoproterenol 0
led 0
to 0
tyrosine 0
phosphorylation 0
of 0
Shc B-gene
and 0
subsequent 0
Erk B-gene
activation 0
, 0
but 0
not 0
tyrosine 0
phosphorylation 0
of 0
cortactin B-gene
or 0
Stat3 B-gene
. 0

MSSPs B-gene
are 0
believed 0
to 0
regulate 0
DNA 0
replication 0
, 0
transcription 0
, 0
apopotosis 0
and 0
cell 0
cycle 0
progression 0
by 0
interacting 0
with 0
the 0
C B-gene
- I-gene
MYC I-gene
protein I-gene
. 0

For 0
wild 0
type 0
MutT B-gene
and 0
its 0
E53D B-gene
and 0
E44D B-gene
mutants I-gene
, 0
plots 0
of 0
log 0
( 0
k 0
( 0
cat 0
) 0
) 0
versus 0
pH 0
exhibited 0
a 0
limiting 0
slope 0
of 0
1 0
on 0
the 0
ascending 0
limb 0
and 0
then 0
a 0
hump 0
, 0
i.e. 0
, 0
a 0
sharply 0
defined 0
maximum 0
near 0
pH 0
8 0
followed 0
by 0
a 0
plateau 0
, 0
yielding 0
apparent 0
pK 0
( 0
a 0
) 0
values 0
of 0
7.6 0
+/ 0
- 0
0.3 0
and 0
8.4 0
+/ 0
- 0
0.4 0
for 0
an 0
essential 0
base 0
and 0
a 0
nonessential 0
acid 0
catalyst 0
, 0
respectively 0
, 0
in 0
the 0
active 0
quaternary 0
MutT B-gene
- 0
Mg 0
( 0
2+ 0
) 0
- 0
dGTP 0
- 0
Mg 0
( 0
2+ 0
) 0
complex 0
. 0

Structural 0
changes 0
in 0
the 0
kinetically 0
more 0
damaged 0
E44D 0
mutant 0
detected 0
in 0
( 0
1 0
) 0
H 0
- 0
( 0
15 0
) 0
N 0
HSQC 0
spectra 0
were 0
largely 0
limited 0
to 0
the 0
loop 0
I 0
- 0
helix 0
I 0
motif 0
, 0
suggesting 0
that 0
Glu 0
- 0
44 0
stabilizes 0
the 0
active 0
site 0
region 0
. 0

In 0
vitro 0
expression 0
of 0
four 0
different 0
naturally 0
occurring 0
nonsense 0
and 0
missense 0
mutations 0
revealed 0
a 0
dramatically 0
altered 0
subcellular 0
location 0
of 0
the 0
protein 0
in 0
cultured 0
cells 0
. 0

After 0
i.v 0
. 0

Immunity 0
acquired 0
by 0
mice 0
during 0
I. 0
scapularis 0
nymphal 0
activity 0
in 0
early 0
summer 0
may 0
exclude 0
a 0
large 0
proportion 0
of 0
the 0
mouse 0
population 0
from 0
maintaining 0
E. 0
phagocytophila 0
during 0
the 0
period 0
of 0
larval 0
activity 0
later 0
in 0
the 0
season 0
. 0

The 0
emerging 0
view 0
based 0
on 0
studies 0
in 0
yeast 0
is 0
that 0
each 0
class 0
of 0
snoRNPs 0
is 0
composed 0
of 0
a 0
unique 0
set 0
of 0
proteins 0
. 0

BCR B-gene
cross 0
- 0
linking 0
also 0
led 0
to 0
increased 0
MAPK B-gene
- 0
activated 0
protein B-gene
kinase I-gene
- I-gene
2 I-gene
activity 0
, 0
an 0
enzyme 0
that 0
lies 0
immediately 0
downstream 0
from 0
p38 B-gene
MAPK I-gene
; 0
MAPK B-gene
- 0
activated 0
protein B-gene
kinase I-gene
- I-gene
2 I-gene
immune 0
complexes 0
phosphorylated 0
a 0
peptide 0
substrate 0
containing 0
the 0
CREB B-gene
serine I-gene
133 I-gene
phosphoacceptor I-gene
motif I-gene
. 0

Activation 0
of 0
a 0
CRE 0
- 0
dependent 0
junB B-gene
promoter/chloramphenicol I-gene
promoter/chloramphenicol I-gene
acetyltransferase I-gene
( 0
CAT B-gene
) 0
reporter 0
gene 0
by 0
the 0
BCR B-gene
was 0
also 0
blocked 0
by 0
SB203580 0
. 0

We 0
present 0
evidence 0
that 0
the 0
upstream 0
open 0
reading 0
frame 0
( 0
uORF 0
) 0
represses 0
the 0
translation 0
of 0
the 0
downstream 0
major 0
open 0
reading 0
frame 0
( 0
mORF 0
) 0
. 0

METHODS 0
: 0
TBN 0
measurements 0
were 0
performed 0
in 0
31 0
female 0
outpatients 0
with 0
breast 0
carcinoma 0
who 0
were 0
undergoing 0
standard 0
cyclophosphamide 0
, 0
methotrexate 0
, 0
and 0
5 0
- 0
fluorouracil 0
( 0
CMF 0
) 0
- 0
based 0
chemotherapy 0
( 0
median 0
age 0
, 0
48 0
years 0
; 0
range 0
, 0
26 0
- 0
77 0
years 0
) 0
. 0

A 0
385 0
bp 0
Glucocorticoid 0
Response 0
Unit 0
( 0
GRU 0
) 0
was 0
identified 0
whose 0
glucocorticoid 0
induction 0
was 0
enhanced 0
by 0
dibutyryl 0
- 0
cAMP 0
and 0
reduced 0
by 0
phorbol 0
esters 0
. 0

No 0
somatic 0
mutations 0
were 0
found 0
in 0
any 0
of 0
the 0
samples 0
, 0
suggesting 0
that 0
ING1 B-gene
is 0
not 0
a 0
tumor 0
suppressor 0
gene 0
target 0
in 0
head 0
and 0
neck 0
cancer 0
. 0

Ras B-gene
- 0
GRF1 B-gene
transiently 0
expressed 0
with 0
v B-gene
- I-gene
Src I-gene
was 0
tyrosine 0
- 0
phosphorylated 0
and 0
showed 0
significant 0
GEF B-gene
activity 0
toward 0
Rac B-gene
, 0
but 0
not 0
Rho B-gene
and 0
Cdc42 B-gene
, 0
which 0
was 0
comparable 0
with 0
that 0
induced 0
by 0
Gbetagamma B-gene
. 0

As 0
no 0
complete 0
PPARgamma B-gene
antagonists 0
have 0
been 0
described 0
hitherto 0
, 0
we 0
have 0
constructed 0
a 0
dominant 0
- 0
negative 0
mutant 0
receptor 0
to 0
inhibit 0
wild 0
- 0
type 0
PPARgamma B-gene
action 0
. 0

EMSA 0
showed 0
that 0
nuclear 0
proteins 0
from 0
PC12 0
but 0
not 0
C6 0
or 0
Rat2 0
cells 0
bind 0
the 0
CRE 0
as 0
a 0
complex 0
containing 0
activating B-gene
transcription I-gene
factor I-gene
( I-gene
ATF I-gene
) I-gene
- I-gene
4 I-gene
and 0
CCAAT B-gene
enhancer I-gene
- I-gene
binding I-gene
protein I-gene
beta I-gene
, 0
while 0
both 0
PC12 0
and 0
C6 0
cell 0
nuclear 0
extracts 0
were 0
recruited 0
by 0
the 0
CCAAT 0
- 0
box 0
as 0
a 0
complex 0
containing 0
nuclear B-gene
factor I-gene
Y I-gene
. 0

EMSA 0
showed 0
that 0
nuclear 0
proteins 0
from 0
PC12 0
but 0
not 0
C6 0
or 0
Rat2 0
cells 0
bind 0
the 0
CRE 0
as 0
a 0
complex 0
containing 0
activating B-gene
transcription I-gene
factor I-gene
( I-gene
ATF I-gene
) I-gene
- I-gene
4 I-gene
and 0
CCAAT B-gene
enhancer I-gene
- I-gene
binding I-gene
protein I-gene
beta I-gene
, 0
while 0
both 0
PC12 0
and 0
C6 0
cell 0
nuclear 0
extracts 0
were 0
recruited 0
by 0
the 0
CCAAT 0
- 0
box 0
as 0
a 0
complex 0
containing 0
nuclear B-gene
factor I-gene
Y I-gene
. 0

Despite 0
resolution 0
of 0
the 0
solid 0
portion 0
of 0
the 0
tumor 0
, 0
serial 0
MRI 0
showed 0
enlargement 0
of 0
a 0
bilobar 0
tumor 0
cyst 0
3 0
years 0
after 0
the 0
original 0
diagnosis 0
. 0

LPO 0
and 0
SOD B-gene
levels 0
were 0
measured 0
at 0
five 0
points 0
before 0
and 0
during 0
the 0
operation 0
. 0

Sustained 0
ventricular 0
tachycardia 0
and 0
its 0
successful 0
prophylaxis 0
during 0
high 0
- 0
dose 0
bolus 0
interleukin B-gene
- I-gene
2 I-gene
therapy 0
for 0
metastatic 0
renal 0
cell 0
carcinoma 0
. 0

Second 0
, 0
when 0
the 0
NBF1+R B-gene
protein I-gene
, 0
the 0
NBF2 B-gene
protein I-gene
, 0
and 0
a 0
mixture 0
of 0
the 0
two 0
proteins 0
were 0
folded 0
separately 0
and 0
analyzed 0
by 0
molecular 0
sieve 0
chomatography 0
, 0
the 0
mixture 0
was 0
found 0
to 0
elute 0
prior 0
to 0
either 0
NBF1+R B-gene
or 0
NBF2 B-gene
. 0

Collectively 0
, 0
these 0
experiments 0
demonstrate 0
that 0
CFTR B-gene
's I-gene
NBF1+R I-gene
region I-gene
and 0
its 0
NBF2 B-gene
domain I-gene
, 0
after 0
folding 0
separately 0
as 0
distinct 0
units 0
, 0
have 0
a 0
strong 0
propensity 0
to 0
interact 0
and 0
that 0
this 0
interaction 0
is 0
stable 0
in 0
the 0
absence 0
of 0
added 0
nucleotides 0
or 0
exogenously 0
induced 0
phosphorylation 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

Sulfhydryl 0
titration 0
with 0
iodoacetamide 0
, 0
monitored 0
by 0
quantitating 0
the 0
residual 0
thiols 0
after 0
reaction 0
with 0
a 0
maleimide 0
derivative 0
of 0
biotin 0
, 0
revealed 0
a 0
striking 0
difference 0
in 0
the 0
apparent 0
pK 0
( 0
a 0
) 0
values 0
of 0
the 0
cysteines 0
at 0
the 0
two 0
splice 0
junctions 0
. 0

After 0
nitric 0
oxide 0
inhalation 0
, 0
the 0
results 0
showed 0
moderate 0
increases 0
in 0
PaO2 0
and 0
SaO2 0
( 0
P 0
> 0
0.05 0
) 0
and 0
a 0
significant 0
decrease 0
in 0
Qs/Q 0
tau 0
ratio 0
( 0
P 0
< 0
0.01 0
) 0
. 0

The 0
results 0
showed 0
that 0
MIP 0
, 0
MMIF 0
, 0
FIC 0
, 0
Wimax 0
, 0
P0.1 0
and 0
minute 0
ventilation 0
( 0
Vr 0
) 0
were 0
significantly 0
increased 0
after 0
administration 0
of 0
methylphenidatum 0
and 0
aminophylline 0
. 0

Forty 0
4 0
- 0
month 0
old 0
SD 0
female 0
rats 0
were 0
randomly 0
divided 0
into 0
four 0
groups 0
, 0
namely 0
sham 0
operation 0
, 0
bilateral 0
ovariectomy 0
, 0
ovariectomy 0
plus 0
supplementary 0
ethinyl 0
estradiol 0
( 0
0.2 0
microgram/100 0
g 0
B 0
. 0

It 0
has 0
also 0
been 0
shown 0
that 0
a 0
variety 0
of 0
extracellular 0
factors 0
stimulate 0
a 0
pair 0
of 0
MAPK 0
p44 B-gene
and 0
MAPK 0
p42 B-gene
of 0
MAPK B-gene
family I-gene
members I-gene
. 0

Covalent 0
modification 0
of 0
the 0
transactivator 0
protein 0
IE2 B-gene
- 0
p86 B-gene
of 0
human 0
cytomegalovirus 0
by 0
conjugation 0
to 0
the 0
ubiquitin B-gene
- I-gene
homologous I-gene
proteins I-gene
SUMO B-gene
- I-gene
1 I-gene
and 0
hSMT3b B-gene
. 0

73:658 0
- 0
666 0
, 0
1999 0
) 0
. 0

The 0
interaction 0
between 0
U 0
( 0
L 0
) 0
3 0
. 0

Protamine B-gene
and 0
heparin 0
doses 0
, 0
their 0
sum 0
( 0
Sigma 0
- 0
dose 0
) 0
and 0
differential 0
( 0
Delta 0
- 0
dose 0
) 0
doses 0
, 0
and 0
activated 0
clotting 0
times 0
were 0
tabulated 0
. 0

In 0
this 0
study 0
, 0
a 0
common 0
mechanism 0
has 0
been 0
identified 0
to 0
coordinate 0
the 0
growth 0
- 0
and 0
FC 0
- 0
dependent 0
expression 0
of 0
caveolin B-gene
. 0

Comparison 0
of 0
the 0
plant 0
nuclear 0
tRNA 0
3 0
' 0
processing 0
enzyme 0
with 0
the 0
plant 0
mitochondrial 0
one 0
suggests 0
that 0
both 0
activities 0
are 0
different 0
enzymes 0
. 0

The 0
requirement 0
of 0
3 0
' 0
complementarity 0
for 0
a 0
ligation 0
reaction 0
is 0
reaffirmed 0
by 0
results 0
from 0
1 0
nt 0
insertions 0
on 0
either 0
the 0
3' 0
- 0
or 0
5' 0
- 0
side 0
of 0
the 0
nick 0
. 0

NKX2.1 B-gene
is 0
a 0
member 0
of 0
the 0
NK2 B-gene
family I-gene
of 0
homeodomain B-gene
- I-gene
containing I-gene
transcription I-gene
factors I-gene
whose 0
targeted 0
disruption 0
in 0
mouse 0
results 0
in 0
the 0
absence 0
of 0
thyroid 0
tissue 0
and 0
a 0
severely 0
abnormal 0
lung 0
phenotype 0
. 0

National 0
abortion 0
laws 0
usually 0
do 0
not 0
allow 0
abortion 0
when 0
a 0
foetus 0
is 0
independently 0
viable 0
, 0
i.e 0
. 0
from 0
a 0
gestational 0
age 0
of 0
about 0
24 0
weeks 0
. 0

Expression 0
in 0
early 0
postnatal 0
pituitary 0
and 0
in 0
pre 0
- 0
somatotrophic 0
cells 0
suggests 0
that 0
Zn B-gene
- I-gene
16 I-gene
could 0
play 0
a 0
role 0
in 0
pituitary 0
development 0
prior 0
to 0
somatotroph 0
differentiation 0
. 0

Mouse B-gene
growth I-gene
hormone I-gene
transcription I-gene
factor I-gene
Zn I-gene
- I-gene
16 I-gene
: 0
unique 0
bipartite 0
structure 0
containing 0
tandemly 0
repeated 0
zinc 0
finger 0
domains 0
not 0
reported 0
in 0
rat B-gene
Zn I-gene
- I-gene
15 I-gene
. 0

The 0
CCAAT 0
core 0
sequence 0
mutants 0
in 0
which 0
both 0
CIII 0
and 0
CI/CII 0
were 0
abolished 0
, 0
also 0
increased 0
the 0
promoter 0
activity 0
. 0

Deglutition 0
is 0
considered 0
to 0
be 0
immature 0
in 0
infants 0
and 0
to 0
mature 0
postnatally 0
. 0

This 0
repression 0
does 0
not 0
require 0
the 0
PU.1 B-gene
transactivation 0
or 0
PEST 0
domains 0
and 0
can 0
not 0
be 0
reversed 0
by 0
p300 B-gene
expression 0
. 0

First 0
, 0
human 0
erythroid 0
K562 0
cells 0
stably 0
integrated 0
with 0
various 0
HS B-gene
- I-gene
40 I-gene
mutants I-gene
cis 0
linked 0
to 0
a 0
human B-gene
alpha I-gene
- I-gene
globin I-gene
promoter I-gene
- 0
growth B-gene
hormone I-gene
hybrid 0
gene 0
were 0
analyzed 0
by 0
genomic 0
footprinting 0
and 0
expression 0
analysis 0
. 0

Interestingly 0
, 0
addition 0
of 0
purified 0
CBP B-gene
to 0
the 0
nuclear 0
extracts 0
of 0
T47D 0
cells 0
markedly 0
stimulated 0
progesterone 0
- 0
and 0
PR B-gene
- 0
dependent 0
transcription 0
from 0
a 0
nucleosome 0
- 0
free 0
, 0
progesterone 0
response 0
element 0
( 0
PRE 0
) 0
- 0
linked 0
reporter 0
DNA 0
template 0
. 0

Its 0
cognate 0
binding 0
protein 0
, 0
REST/NRSF B-gene
, 0
is 0
an 0
essential 0
transcription 0
factor 0
; 0
its 0
null 0
mutations 0
result 0
in 0
embryonic 0
lethality 0
, 0
and 0
its 0
dominant 0
negative 0
mutants 0
produce 0
aberrant 0
expression 0
of 0
neuron 0
- 0
specific 0
genes 0
. 0

Removal 0
of 0
all 0
core B-gene
histone I-gene
tail 0
domains 0
by 0
limited 0
trypsin B-gene
proteolysis 0
or 0
acetylation 0
of 0
the 0
core B-gene
histone I-gene
tails 0
significantly 0
relieves 0
this 0
inhibition 0
and 0
allows 0
TFIIIA B-gene
to 0
exhibit 0
high 0
- 0
affinity 0
binding 0
to 0
nucleosomal 0
DNA 0
. 0

Finally 0
, 0
the 0
mechanism 0
of 0
ASK1 B-gene
activation 0
involves 0
, 0
in 0
part 0
, 0
homo 0
- 0
oligomerization 0
. 0

OUTCOME 0
: 0
Acetylcholine B-gene
receptor I-gene
antibodies I-gene
and 0
single 0
- 0
fibre 0
electromyogram 0
were 0
useful 0
in 0
the 0
diagnosis 0
of 0
myasthenia 0
gravis 0
. 0

Two 0
other 0
patients 0
underwent 0
PRFR 0
. 0

The 0
variations 0
were 0
caused 0
by 0
opposite 0
shifts 0
in 0
TSH B-gene
frequency 0
distribution 0
in 0
mothers 0
and 0
neonates 0
. 0

Characterization 0
of 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
multidrug I-gene
resistance I-gene
protein I-gene
2 I-gene
( 0
MRP2 B-gene
) 0
gene 0
and 0
its 0
regulation 0
in 0
comparison 0
withthe 0
multidrug B-gene
resistance I-gene
protein I-gene
3 I-gene
( 0
MRP3 B-gene
) 0
gene 0
. 0

However 0
, 0
such 0
a 0
mechanism 0
was 0
not 0
detected 0
in 0
preliminary 0
observations 0
on 0
M. 0
synoviae 0
. 0

These 0
results 0
suggest 0
that 0
the 0
M. 0
jannaschii 0
as 0
well 0
as 0
related 0
archaeal B-gene
20S I-gene
proteasomes I-gene
require 0
a 0
nucleotidase 0
complex 0
such 0
as 0
PAN B-gene
to 0
mediate 0
the 0
energy 0
- 0
dependent 0
hydrolysis 0
of 0
folded 0
- 0
substrate 0
proteins 0
and 0
that 0
the 0
N 0
- 0
terminal 0
73 0
amino 0
acid 0
residues 0
of 0
PAN B-gene
are 0
not 0
absolutely 0
required 0
for 0
this 0
reaction 0
. 0

The 0
transcription 0
factor 0
E2F B-gene
plays 0
an 0
important 0
role 0
in 0
G 0
( 0
1 0
) 0
to 0
S 0
phase 0
transition 0
in 0
the 0
higher 0
eukaryotic 0
cell 0
cycle 0
. 0

In 0
two 0
- 0
field 0
nodal 0
dissection 0
, 0
two 0
components 0
are 0
included 0
with 0
( 0
modern 0
two 0
- 0
field 0
) 0
or 0
without 0
( 0
traditional 0
two 0
- 0
field 0
) 0
nodal 0
dissection 0
around 0
both 0
recurrent 0
laryngeal 0
nerve 0
chains 0
in 0
the 0
upper 0
mediastinum 0
. 0

Of 0
the 0
153 0
patients 0
studied 0
, 0
CK B-gene
- I-gene
MB I-gene
results 0
were 0
positive 0
in 0
91 0
( 0
59 0
% 0
) 0
patients 0
; 0
ECG 0
revealed 0
AMI 0
in 0
72 0
( 0
47 0
% 0
) 0
patients 0
. 0

The 0
effect 0
of 0
MIB 0
on 0
the 0
dose 0
- 0
response 0
curve 0
of 0
externally 0
applied 0
noradrenaline 0
was 0
also 0
studied 0
. 0

The 0
regional 0
blockade 0
of 0
H1R B-gene
was 0
observed 0
mainly 0
in 0
the 0
frontal 0
, 0
temporal 0
and 0
anterior 0
cingulate 0
cortices 0
, 0
and 0
the 0
intravenous 0
administration 0
of 0
d 0
- 0
chlorpheniramine 0
as 0
a 0
therapeutic 0
dose 0
( 0
2 0
mg 0
) 0
blocked 0
over 0
60 0
% 0
of 0
H1R B-gene
in 0
the 0
frontal 0
cortices 0
. 0

The 0
expression 0
of 0
the 0
yam8 B-gene
( I-gene
+ I-gene
) I-gene
cDNA I-gene
in 0
the 0
mid1 B-gene
mutant I-gene
cells 0
partially 0
remediated 0
the 0
mid 0
phenotype 0
and 0
resulted 0
in 0
a 0
slight 0
increase 0
in 0
Ca 0
( 0
2+ 0
) 0
uptake 0
activity 0
. 0

Linearized 0
overall 0
infection 0
rates 0
( 0
events/100 0
patient 0
- 0
days 0
) 0
were 0
2.05 0
+/ 0
- 0
0.33 0
( 0
heart 0
- 0
lung 0
) 0
and 0
2.34 0
+/ 0
- 0
0.34 0
( 0
double 0
- 0
lung 0
; 0
P 0
= 0
NS 0
) 0
at 0
3 0
months 0
. 0

Static 0
and 0
dynamic 0
compliance 0
was 0
measured 0
after 0
induction 0
of 0
anesthesia 0
, 0
before 0
and 0
immediately 0
after 0
filtration 0
in 0
the 0
operating 0
theater 0
, 0
1 0
hour 0
after 0
return 0
to 0
the 0
pediatric 0
intensive 0
care 0
unit 0
, 0
and 0
24 0
hours 0
after 0
the 0
operation 0
. 0

Antipyretic 0
therapy 0
: 0
physiologic 0
rationale 0
, 0
diagnostic 0
implications 0
, 0
and 0
clinical 0
consequences 0
. 0

There 0
is 0
no 0
correlation 0
between 0
C2 0
- 0
C3 0
disk 0
morphology 0
and 0
the 0
diskographically 0
provoked 0
response 0
. 0

KFC B-gene
, 0
a 0
Ste20 B-gene
- I-gene
like I-gene
kinase I-gene
with 0
mitogenic 0
potential 0
and 0
capability 0
to 0
activate 0
the 0
SAPK/JNK B-gene
pathway 0
. 0

TIP30 B-gene
has 0
an 0
intrinsic 0
kinase 0
activity 0
required 0
for 0
up 0
- 0
regulation 0
of 0
a 0
subset 0
of 0
apoptotic 0
genes 0
. 0

We 0
have 0
mapped 0
the 0
human B-gene
STAG3 I-gene
gene I-gene
to 0
the 0
7q22 0
region 0
of 0
chromosome 0
7 0
; 0
six 0
human B-gene
STAG3 I-gene
- I-gene
related I-gene
genes I-gene
have 0
also 0
been 0
mapped 0
: 0
two 0
at 0
7q22 0
near 0
the 0
functional 0
gene 0
, 0
one 0
at 0
7q11.22 0
, 0
and 0
three 0
at 0
7q11.23 0
, 0
two 0
of 0
them 0
flanking 0
the 0
breakpoints 0
commonly 0
associated 0
with 0
the 0
Williams B-gene
- I-gene
Beuren I-gene
syndrome I-gene
( I-gene
WBS I-gene
) I-gene
deletion I-gene
. 0

Reaction 0
time 0
( 0
RT 0
) 0
and 0
P300 0
were 0
collected 0
simultaneously 0
. 0

In 0
experiment 0
2 0
the 0
rats 0
had 0
free 0
access 0
to 0
two 0
bottles 0
, 0
one 0
of 0
which 0
contained 0
tap 0
water 0
, 0
and 0
the 0
other 0
contained 0
either 0
an 0
ethanol 0
( 0
6 0
% 0
) 0
or 0
a 0
sucrose 0
( 0
5 0
% 0
) 0
solution 0
. 0

Furthermore 0
, 0
Zelen 0
's 0
method 0
is 0
used 0
to 0
balance 0
the 0
number 0
of 0
patients 0
allocated 0
to 0
the 0
two 0
groups 0
within 0
each 0
institution 0
( 0
M 0
. 0

RESULTS 0
: 0
In 0
this 0
group 0
of 0
patients 0
, 0
male 0
gender 0
( 0
P 0
= 0
0 0
. 0

Selective 0
visual 0
attention 0
involves 0
dynamic 0
interplay 0
between 0
attentional 0
control 0
systems 0
and 0
sensory 0
brain 0
structures 0
. 0

The 0
patient 0
had 0
developed 0
left 0
- 0
sided 0
low 0
- 0
frequency 0
tremor 0
and 0
hemidystonia 0
after 0
a 0
severe 0
head 0
trauma 0
sustained 0
at 0
15 0
years 0
of 0
age 0
. 0

However 0
, 0
the 0
a1 0
isoform 0
is 0
expressed 0
most 0
heavily 0
in 0
brain 0
and 0
heart 0
, 0
a2 0
in 0
liver 0
and 0
kidney 0
, 0
and 0
a3 0
in 0
liver 0
, 0
lung 0
, 0
heart 0
, 0
brain 0
, 0
spleen 0
, 0
and 0
kidney 0
. 0

During 0
the 0
cloning 0
by 0
reverse B-gene
transcriptase I-gene
- 0
polymerase 0
chain 0
reaction 0
of 0
the 0
human B-gene
HIF I-gene
- I-gene
1alpha I-gene
subunit I-gene
, 0
we 0
isolated 0
two 0
cDNA 0
clones 0
which 0
corresponded 0
to 0
alternative 0
splicing 0
of 0
the 0
HIF B-gene
- I-gene
1alpha I-gene
gene I-gene
. 0

To 0
assess 0
the 0
relationship 0
between 0
G B-gene
( I-gene
q I-gene
) I-gene
/G B-gene
( I-gene
11 I-gene
) I-gene
function 0
with 0
the 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
dependent 0
pathway 0
, 0
expression 0
of 0
a 0
dominant 0
- 0
interfering 0
p85 B-gene
regulatory I-gene
subunit I-gene
, 0
as 0
well 0
as 0
wortmannin 0
treatment 0
inhibited 0
insulin B-gene
- 0
stimulated 0
but 0
not 0
G B-gene
( I-gene
q I-gene
) I-gene
/Q209L I-gene
- 0
stimulated 0
GLUT4 B-gene
- 0
EGFP B-gene
translocation 0
. 0

In 0
endemic 0
BL 0
, 0
the 0
RB2/p130 B-gene
gene 0
is 0
mutated 0
in 0
most 0
of 0
the 0
cases 0
, 0
and 0
the 0
protein 0
is 0
restricted 0
to 0
the 0
cytoplasm 0
. 0

Together 0
, 0
these 0
data 0
identify 0
ERK2 B-gene
as 0
a 0
specific 0
and 0
direct 0
target 0
of 0
HePTP B-gene
and 0
are 0
consistent 0
with 0
a 0
model 0
in 0
which 0
HePTP B-gene
negatively 0
regulates 0
ERK2 B-gene
activity 0
as 0
part 0
of 0
a 0
feedback 0
mechanism 0
. 0

Cross 0
- 0
reaction 0
between 0
a 0
monoclonal 0
antibody 0
and 0
two 0
alpha B-gene
beta I-gene
T I-gene
cell I-gene
receptors I-gene
. 0

Strontium 0
nitrate 0
mixed 0
with 0
glycolic 0
acid 0
, 0
in 0
comparison 0
with 0
glycolic 0
acid 0
alone 0
, 0
markedly 0
( 0
p 0
< 0
0.01 0
) 0
shortened 0
the 0
duration 0
of 0
the 0
irritation 0
sensation 0
from 0
24.4+/ 0
- 0
4.1 0
( 0
mean+/ 0
- 0
SEM 0
) 0
min 0
to 0
8.9+/ 0
- 0
3.7 0
( 0
mean+/ 0
- 0
SEM 0
) 0
min 0
, 0
and 0
significantly 0
( 0
p 0
< 0
0.05 0
) 0
reduced 0
the 0
mean 0
magnitude 0
of 0
the 0
irritation 0
sensation 0
at 0
all 0
time 0
points 0
( 0
overall 0
) 0
. 0

The 0
pCMBS 0
- 0
reactive 0
sulfhydryl 0
groups 0
were 0
located 0
exclusively 0
in 0
the 0
exofacial 0
half 0
of 0
the 0
plasma 0
membrane 0
and 0
, 0
when 0
presented 0
in 0
a 0
helical 0
model 0
, 0
lie 0
along 0
one 0
side 0
of 0
the 0
helices 0
. 0

Analysis 0
of 0
1 0
Mb 0
of 0
published 0
sequence 0
from 0
the 0
region 0
of 0
conserved 0
synteny 0
on 0
human 0
chromosome 0
5q31 0
- 0
q33 0
identified 0
45 0
gene 0
candidates 0
, 0
including 0
35 0
expressed 0
genes 0
in 0
the 0
human B-gene
IL I-gene
- I-gene
4 I-gene
cytokine I-gene
gene I-gene
cluster I-gene
. 0

Human B-gene
AP I-gene
- I-gene
2rep I-gene
repressed 0
both 0
reporter 0
expression 0
from 0
a 0
transiently 0
transfected 0
AP B-gene
- I-gene
2alpha I-gene
promoter I-gene
and 0
the 0
endogenous 0
AP B-gene
- I-gene
2alpha I-gene
gene I-gene
and 0
inversely 0
was 0
negatively 0
regulated 0
by 0
AP B-gene
- I-gene
2alpha I-gene
. 0

In 0
order 0
to 0
gain 0
deeper 0
insight 0
into 0
the 0
role 0
of 0
the 0
amino 0
- 0
terminal 0
domain 0
of 0
the 0
p24 B-gene
( 0
CA B-gene
) 0
protein 0
during 0
viral 0
replication 0
, 0
eight 0
highly 0
conserved 0
proline 0
residues 0
known 0
to 0
promote 0
turns 0
and 0
to 0
terminate 0
alpha 0
- 0
helices 0
within 0
the 0
p24 B-gene
tertiary 0
structure 0
were 0
replaced 0
by 0
a 0
leucine 0
residue 0
( 0
P 0
- 0
position 0
- 0
L 0
) 0
. 0

Clb/Cdc28 B-gene
kinases 0
promote 0
nuclear 0
export 0
of 0
the 0
Clb/Cdc28 I-gene

Alternatively 0
, 0
PC12 0
- 0
E2 0
cells 0
were 0
submitted 0
to 0
treatment 0
with 0
antibodies 0
to 0
the 0
fibroblast B-gene
growth I-gene
factor I-gene
( I-gene
FGF I-gene
) I-gene
receptor I-gene
, 0
inhibitors 0
of 0
the 0
nonreceptor B-gene
tyrosine I-gene
kinase I-gene
p59 B-gene
( 0
fyn B-gene
) 0
, 0
PLC B-gene
, 0
PKC B-gene
and 0
MEK B-gene
and 0
an 0
activator 0
of 0
PKC B-gene
, 0
phorbol 0
- 0
12 0
- 0
myristate 0
- 0
13 0
- 0
acetate 0
( 0
PMA 0
) 0
. 0

Cooperative 0
roles 0
of 0
Bozozok/Dharma B-gene
and 0
Bozozok/Dharma I-gene

Thiopentone 0
sodium 0
administered 0
at 0
30 0
and 0
10 0
min 0
before 0
or 0
5 0
, 0
10 0
and 0
15 0
min 0
after 0
exposure 0
to 0
NOC 0
- 0
5 0
, 0
but 0
not 0
thereafter 0
, 0
significantly 0
attenuated 0
NO 0
- 0
induced 0
neurotoxicity 0
compared 0
with 0
controls 0
. 0

We 0
also 0
show 0
that 0
zygotically 0
activated 0
Xretpos 0
transcripts 0
are 0
restricted 0
to 0
ventro 0
- 0
posterior 0
specific 0
regions 0
and 0
induced 0
by 0
UV 0
- 0
irradiation 0
and 0
BMP B-gene
- I-gene
4 I-gene
overexpression 0
in 0
cycloheximide 0
- 0
dependent 0
way 0
. 0
genesis 0
26:198 0
- 0
207 0
, 0
2000 0
. 0

In 0
all 0
other 0
cases 0
, 0
vestibular 0
neurectomy 0
or 0
chemical 0
vestibular 0
labyrinthectomy 0
, 0
by 0
means 0
of 0
intratympanic 0
low 0
concentration 0
gentamicin 0
( 0
20 0
mg/mL 0
) 0
, 0
are 0
indicated 0
. 0

However 0
, 0
when 0
, 0
where 0
and 0
how 0
the 0
DSPP B-gene
is 0
cleaved 0
into 0
DSP B-gene
and 0
DPP B-gene
is 0
not 0
clear 0
. 0

It 0
has 0
a 0
grave 0
prognosis 0
with 0
> 0
70 0
% 0
mortality 0
in 0
3 0
months 0
, 0
despite 0
mechanical 0
ventilation 0
. 0

We 0
found 0
that 0
TCR B-gene
signaling 0
induces 0
AP B-gene
- I-gene
1 I-gene
binding 0
to 0
this 0
site 0
and 0
regulates 0
the 0
fasl B-gene
promoter I-gene
function 0
in 0
a 0
fashion 0
dependent 0
on 0
NF B-gene
- I-gene
kappaB I-gene
binding 0
. 0

Thus 0
, 0
patients 0
with 0
metastatic 0
melanoma 0
are 0
not 0
tolerant 0
to 0
gp100 B-gene
Ag I-gene
based 0
on 0
the 0
detection 0
of 0
CD8+ B-gene
T 0
cells 0
specific 0
for 0
multiple 0
HLA B-gene
- I-gene
A*0201 I-gene
- 0
restricted 0
, 0
gp100 B-gene
- 0
derived 0
epitopes 0
. 0

Approximately 0
20 0
% 0
of 0
ALCLs 0
that 0
express 0
ALK B-gene
do 0
not 0
contain 0
the 0
t 0
( 0
2 0
; 0
5 0
) 0
, 0
suggesting 0
that 0
other 0
genetic 0
abnormalities 0
can 0
result 0
in 0
aberrant 0
ALK B-gene
expression 0
. 0

In 0
addition 0
, 0
expected 0
decreases 0
in 0
ATIC B-gene
enzymatic 0
function 0
in 0
ATIC B-gene
- 0
ALK B-gene
- 0
containing 0
lymphomas 0
may 0
render 0
these 0
tumors 0
more 0
sensitive 0
to 0
antifolate 0
drugs 0
such 0
as 0
methotrexate 0
. 0

Following 0
the 0
observation 0
that 0
non 0
- 0
organ 0
- 0
specific 0
antibodies 0
are 0
related 0
with 0
pregnancy 0
loss 0
and 0
preeclampsia 0
, 0
the 0
role 0
of 0
organ 0
- 0
specific 0
antibodies 0
is 0
currently 0
being 0
extensively 0
investigated 0
. 0

Manganese 0
ions 0
were 0
found 0
to 0
be 0
essential 0
for 0
autophosphorylation 0
of 0
BGLF4 B-gene
, 0
and 0
magnesium 0
can 0
stimulate 0
the 0
activity 0
. 0

The 0
Mif1 B-gene
5 I-gene
' I-gene
flanking I-gene
region I-gene
contains 0
a 0
functional 0
ER 0
stress 0
- 0
responsive 0
element 0
which 0
is 0
sufficient 0
for 0
induction 0
by 0
tunicamycin 0
. 0

Rigid 0
point 0
feature 0
registration 0
using 0
mutual 0
information 0
. 0

Methysergide 0
is 0
a 0
serotonin 0
antagonist 0
and 0
has 0
been 0
demonstrated 0
to 0
reduce 0
wound 0
blood 0
flow 0
and 0
edema 0
formation 0
. 0

Serum 0
leptin B-gene
concentrations 0
in 0
women 0
during 0
gonadotropin B-gene
stimulation 0
cycles 0
. 0

Valuing 0
families 0
: 0
social 0
work 0
practice 0
with 0
families 0
from 0
a 0
strengths 0
perspective 0
. 0

PURPOSE 0
: 0
A 0
two 0
- 0
generation 0
consanguineous 0
Pakistani 0
family 0
with 0
autosomal 0
recessive 0
Leber 0
congenital 0
amaurosis 0
( 0
LCA 0
, 0
MIM 0
204,000 0
) 0
and 0
keratoconus 0
was 0
identified 0
. 0

Ste18p B-gene
was 0
targeted 0
to 0
the 0
plasma 0
membrane 0
even 0
in 0
the 0
absence 0
of 0
prenylation 0
or 0
thioacylation 0
. 0

Here 0
, 0
we 0
show 0
that 0
IRF B-gene
- I-gene
1 I-gene
is 0
degraded 0
via 0
the 0
ubiquitin B-gene
- 0
proteasome 0
pathway 0
. 0

An 0
amino 0
- 0
acid 0
sequence 0
comparison 0
revealed 0
that 0
Bacillus B-gene
YM55 I-gene
- I-gene
1 I-gene
aspartase I-gene
shared 0
71 0
% 0
homology 0
with 0
Bacillus B-gene
subtilis I-gene
aspartase I-gene
and 0
49 0
% 0
with 0
Escherichia 0
coli 0
and 0
Pseudomonas B-gene
fluorescens I-gene
aspartases I-gene
. 0

Unique 0
to 0
this 0
system 0
, 0
the 0
activity 0
of 0
TraR B-gene
is 0
negatively 0
modulated 0
by 0
an 0
antiactivator 0
called 0
TraM B-gene
. 0

As 0
assessed 0
by 0
a 0
genetic 0
assay 0
that 0
measures 0
AAI 0
- 0
dependent 0
DNA 0
binding 0
, 0
TraM B-gene
inhibited 0
TraR B-gene
function 0
before 0
and 0
after 0
the 0
transcription 0
factor 0
had 0
bound 0
to 0
its 0
DNA 0
recognition 0
site 0
. 0

Here 0
we 0
show 0
that 0
IIIa 0
pre 0
- 0
mRNA 0
splicing 0
is 0
activated 0
more 0
than 0
200 0
- 0
fold 0
in 0
nuclear 0
extracts 0
prepared 0
from 0
late 0
adenovirus 0
- 0
infected 0
cells 0
( 0
Ad 0
- 0
NE 0
) 0
compared 0
to 0
uninfected 0
HeLa 0
cell 0
nuclear 0
extracts 0
( 0
HeLa 0
- 0
NE 0
) 0
. 0

Inactivation 0
of 0
Ulp2 B-gene
also 0
suppresses 0
several 0
ulp1 B-gene
( I-gene
ts I-gene
) I-gene
defects 0
, 0
and 0
the 0
double 0
mutant 0
accumulates 0
far 0
fewer 0
Smt3 B-gene
- I-gene
protein I-gene
conjugates 0
than 0
either 0
single 0
mutant 0
. 0

Collectively 0
, 0
the 0
results 0
suggest 0
that 0
ARF B-gene
binding 0
to 0
Mdm2 B-gene
induces 0
a 0
conformational 0
change 0
that 0
facilitates 0
nucleolar 0
import 0
of 0
the 0
ARF B-gene
- 0
Mdm2 B-gene
complex 0
and 0
p53 B-gene
- 0
dependent 0
cell 0
cycle 0
arrest 0
. 0

Cyclin B-gene
A I-gene
expression 0
is 0
repressed 0
in 0
quiescent 0
cells 0
by 0
E2F B-gene
acting 0
in 0
conjunction 0
with 0
its 0
pocket 0
protein 0
partners 0
Rb B-gene
, 0
p107 B-gene
, 0
and 0
p130 B-gene
; 0
however 0
, 0
v B-gene
- I-gene
Jun I-gene
overrides 0
this 0
control 0
, 0
causing 0
phosphorylated 0
Rb B-gene
and 0
proliferation 0
- 0
specific 0
E2F B-gene
- 0
p107 B-gene
complexes 0
to 0
persist 0
after 0
mitogen 0
withdrawal 0
. 0

D B-gene
- I-gene
cyclin I-gene
- 0
cdk B-gene
activity 0
is 0
required 0
for 0
Rb B-gene
phosphorylation 0
in 0
v B-gene
- I-gene
Jun I-gene
- 0
transformed 0
cells 0
, 0
since 0
ectopic 0
expression 0
of 0
the 0
cdk4 B-gene
- 0
and 0
cdk6 B-gene
- 0
specific 0
inhibitor 0
p16 B-gene
( 0
INK4A B-gene
) 0
inhibits 0
both 0
DNA 0
synthesis 0
and 0
cell 0
proliferation 0
. 0

CONCLUSION 0
: 0
A 0
valve 0
- 0
like 0
mechanism 0
formed 0
by 0
the 0
capsulorhexis 0
rim 0
partially 0
adhered 0
to 0
the 0
IOL 0
optic 0
can 0
occur 0
postoperatively 0
. 0

The 0
protein 0
first 0
identified 0
by 0
the 0
monoclonal B-gene
antibody I-gene
Q18 I-gene
is 0
encoded 0
by 0
a 0
gene 0
located 0
in 0
57A 0
on 0
polytene 0
chromosomes 0
and 0
has 0
been 0
consequently 0
named 0
Hrb57A B-gene
. 0

3 0
' 0
RNA 0
boundary 0
experiments 0
indicate 0
that 0
the 0
5 0
' 0
structure 0
reduces 0
the 0
number 0
of 0
( 0
G/U 0
) 0
AG 0
repeats 0
required 0
for 0
stable 0
TRAP B-gene
- 0
trp B-gene
leader 0
RNA 0
association 0
. 0

Gene 0
silencing 0
associated 0
with 0
repeated 0
DNA 0
sequences 0
has 0
been 0
reported 0
for 0
many 0
eukaryotes 0
, 0
including 0
plants 0
. 0

The 0
AtERF B-gene
genes I-gene
were 0
differentially 0
regulated 0
by 0
ethylene 0
and 0
by 0
abiotic 0
stress 0
conditions 0
, 0
such 0
as 0
wounding 0
, 0
cold 0
, 0
high 0
salinity 0
, 0
or 0
drought 0
, 0
via 0
ETHYLENE B-gene
- I-gene
INSENSITIVE2 I-gene
( 0
EIN2 B-gene
) 0
- 0
dependent 0
or 0
- 0
independent 0
pathways 0
. 0

Animals 0
received 0
a 0
dose 0
of 0
dexamethasone 0
( 0
10 0
mg/kg 0
i.p 0
. 0
) 0
prior 0
to 0
the 0
protein 0
- 0
free 0
surfactant 0
preparation 0
Exosurf 0
( 0
pure 0
phospholipids 0
containing 0
surfactant 0
, 0
Wellcome 0
GmbH 0
, 0
Burgwedel 0
, 0
Germany 0
) 0
and 0
a 0
rSP 0
- 0
C 0
based 0
surfactant 0
, 0
respectively 0
. 0

BACKGROUND 0
: 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
response 0
rates 0
and 0
toxicity 0
of 0
two 0
regimens 0
containing 0
granulocyte B-gene
- I-gene
macrophage I-gene
- I-gene
colony I-gene
stimulating I-gene
factor I-gene
( 0
GM B-gene
- I-gene
CSF I-gene
) 0
in 0
combination 0
with 0
interleukin B-gene
- I-gene
2 I-gene
( 0
IL B-gene
- I-gene
2 I-gene
) 0
in 0
the 0
treatment 0
of 0
patients 0
with 0
metastatic 0
renal 0
cell 0
carcinoma 0
. 0

We 0
show 0
, 0
by 0
injection 0
of 0
synthetic 0
mRNAs 0
, 0
that 0
the 0
cis 0
- 0
acting 0
sequences 0
responsible 0
for 0
repression 0
of 0
cyclin B-gene
B1 I-gene
mRNA I-gene
reside 0
within 0
its 0
3'UTR 0
. 0

These 0
data 0
indicate 0
that 0
expansion 0
of 0
the 0
dodecamer 0
repeat 0
located 0
in 0
the 0
proximal 0
promoter 0
of 0
CSTB B-gene
severely 0
disrupts 0
the 0
function 0
of 0
the 0
promoter 0
and 0
thereby 0
reduces 0
transcription 0
of 0
CSTB B-gene
. 0

Thus 0
, 0
while 0
the 0
genomic 0
organization 0
of 0
mHuA B-gene
is 0
similar 0
to 0
the 0
neural 0
- 0
restricted 0
members 0
of 0
the 0
Elav B-gene
family I-gene
, 0
the 0
promoter 0
element 0
differs 0
substantially 0
both 0
by 0
sequence 0
analysis 0
and 0
transcriptional 0
activity 0
in 0
non 0
- 0
neural 0
cell 0
types 0
. 0

Analysis 0
of 0
the 0
5 0
' 0
end 0
of 0
the 0
mouse B-gene
Elavl1 I-gene
( 0
mHuA B-gene
) 0
gene 0
reveals 0
a 0
transcriptional 0
regulatory 0
element 0
and 0
evidence 0
for 0
conserved 0
genomic 0
organization 0
. 0
mHuA B-gene
( 0
Elavl1 B-gene
) 0
belongs 0
to 0
a 0
highly 0
conserved 0
family 0
of 0
genes 0
encoding 0
RNA 0
- 0
binding 0
proteins 0
and 0
has 0
been 0
linked 0
to 0
cell 0
growth 0
and 0
proliferation 0
through 0
its 0
regulation 0
of 0
mRNA 0
stability 0
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
revealed 0
that 0
Sp1 B-gene
binds 0
to 0
two 0
different 0
regions 0
in 0
the 0
proximal 0
promoter 0
, 0
a 0
typical 0
Sp1 B-gene
site I-gene
located 0
at 0
( 0
- 0
38 0
; 0
- 0
33 0
) 0
and 0
a 0
G/C 0
- 0
rich 0
region 0
between 0
( 0
- 0
67 0
; 0
- 0
62 0
) 0
. 0

Fgd3 B-gene
and 0
FGD1 B-gene
share 0
a 0
high 0
degree 0
of 0
sequence 0
identity 0
that 0
spans 0
> 0
560 0
contiguous 0
amino 0
acid 0
residues 0
. 0

Molecular 0
cloning 0
of 0
mouse B-gene
thioredoxin I-gene
reductases I-gene
. 0

The 0
HPLC 0
method 0
involves 0
an 0
octadecylsilane 0
column 0
at 0
55 0
degrees 0
C 0
, 0
a 0
mixture 0
of 0
water 0
- 0
acetonitrile 0
- 0
orthophosphoric 0
acid 0
( 0
779:220:1 0
, 0
v/v 0
) 0
as 0
mobile 0
phase 0
and 0
detection 0
at 0
226 0
nm 0
. 0

Eight 0
patients 0
received 0
1.5 0
mg 0
of 0
adefovir 0
dipivoxil 0
per 0
kg 0
of 0
body 0
weight 0
, 0
and 0
six 0
patients 0
received 0
3.0 0
mg 0
of 0
adefovir 0
dipivoxil 0
per 0
kg 0
. 0

CYC2 B-gene
encodes 0
a 0
24 0
- 0
kDa 0
protein 0
that 0
has 0
sequence 0
identity 0
to 0
the 0
Neurospora B-gene
crassa I-gene
PREG1 I-gene
and 0
the 0
S. B-gene
cerevisiae I-gene
PHO80 I-gene
cyclin I-gene
. 0

To 0
determine 0
if 0
CYC2 B-gene
is 0
found 0
in 0
a 0
complex 0
with 0
previously 0
identified 0
trypanosome B-gene
cdc2 I-gene
- I-gene
related I-gene
kinases I-gene
( 0
CRKs B-gene
) 0
, 0
the 0
CYC2 B-gene
gene I-gene
was 0
fused 0
to 0
the 0
TY B-gene
epitope I-gene
tag 0
, 0
integrated 0
into 0
the 0
trypanosome 0
genome 0
, 0
and 0
expressed 0
under 0
inducible 0
control 0
. 0

These 0
findings 0
indicate 0
the 0
involvement 0
of 0
Sp1 B-gene
and 0
an 0
Inr 0
in 0
non 0
- 0
cell 0
- 0
specific 0
regulation 0
and 0
a 0
Kruppel B-gene
- I-gene
like I-gene
transcription I-gene
factor I-gene
and 0
Sp1 B-gene
in 0
the 0
cell 0
- 0
specific 0
regulation 0
of 0
the 0
LTC B-gene
( I-gene
4 I-gene
) I-gene
S I-gene
gene I-gene
. 0

Here 0
we 0
review 0
progress 0
to 0
date 0
in 0
this 0
area 0
. 0

Additionally 0
, 0
the 0
mouse 0
promoter 0
contains 0
22 0
copies 0
of 0
a 0
CT 0
dinucleotide 0
repeat 0
sequence 0
located 0
approximately 0
155 0
bp 0
5 0
' 0
to 0
exon 0
1 0
. 0

The 0
newly 0
defined 0
region 0
contains 0
an 0
intron 0
that 0
may 0
be 0
alternatively 0
spliced 0
and 0
seven 0
polyadenylation 0
signal 0
sequences 0
. 0

Depleted 0
and 0
enriched 0
U3O8 0
standard 0
reference 0
materials 0
were 0
used 0
to 0
calibrate 0
the 0
system 0
. 0

Therefore 0
, 0
the 0
positive 0
cAMP 0
control 0
of 0
the 0
hypoxic 0
SRP1 B-gene
and 0
HEM13 B-gene
genes I-gene
was 0
uncoupled 0
from 0
the 0
HOG B-gene
pathway 0
. 0

Most 0
likely 0
they 0
might 0
represent 0
regulatory 0
RNAs 0
or 0
transcribed 0
transposable 0
elements 0
. 0

This 0
paper 0
reviews 0
the 0
middleware 0
- 0
based 0
approach 0
adopted 0
by 0
CEN 0
ENV 0
12967 0
- 0
1 0
and 0
the 0
specialisation 0
necessary 0
for 0
the 0
healthcare 0
record 0
based 0
on 0
CEN 0
ENV 0
12265 0
'Electronic 0
Healthcare 0
Record 0
Architecture 0
' 0
. 0

Sequence 0
analyses 0
of 0
sos2 B-gene
mutant I-gene
alleles I-gene
reveal 0
that 0
both 0
the 0
N 0
- 0
terminal 0
catalytic 0
domain 0
and 0
the 0
C 0
- 0
terminal 0
regulatory 0
domain 0
of 0
SOS2 B-gene
are 0
functionally 0
essential 0
. 0

A 0
mutation 0
which 0
abrogates 0
the 0
binding 0
of 0
these 0
factors 0
reduces 0
Wp B-gene
reporter I-gene
activity 0
specifically 0
in 0
B 0
cell 0
lines 0
, 0
whereas 0
a 0
mutation 0
which 0
converts 0
the 0
site 0
to 0
a 0
consensus 0
CREB B-gene
- I-gene
binding I-gene
sequence I-gene
maintains 0
wild 0
- 0
type 0
promoter 0
function 0
. 0

Here 0
we 0
describe 0
the 0
cloning 0
, 0
tissue 0
- 0
specific 0
expression 0
pattern 0
, 0
and 0
functional 0
characterization 0
of 0
two 0
novel 0
TEF B-gene
- I-gene
1 I-gene
isoforms I-gene
, 0
TEF B-gene
- I-gene
1beta I-gene
and 0
TEF B-gene
- I-gene
1gamma I-gene
. 0

Therefore 0
the 0
binding 0
sites 0
for 0
liver 0
- 0
enriched 0
factors 0
, 0
present 0
in 0
the 0
hamster B-gene
CYP7A1 I-gene
proximal I-gene
promoter I-gene
in 0
close 0
vicinity 0
and 0
conserved 0
between 0
species 0
, 0
constitute 0
a 0
regulatory 0
unit 0
important 0
for 0
basal 0
hepatic 0
expression 0
and 0
tissue 0
restriction 0
of 0
the 0
action 0
of 0
hormones 0
such 0
as 0
insulin B-gene
. 0

The 0
kinase 0
activity 0
of 0
PfPK6 B-gene
is 0
sensitive 0
to 0
CDK B-gene
inhibitors 0
such 0
as 0
olomoucine 0
and 0
roscovitine 0
. 0

Although 0
MAP B-gene
( I-gene
mitogen I-gene
- I-gene
activated I-gene
protein I-gene
) I-gene
kinases I-gene
are 0
implicated 0
in 0
cell 0
proliferation 0
and 0
differentiation 0
in 0
many 0
cell 0
types 0
, 0
the 0
role 0
of 0
MAP B-gene
kinases I-gene
in 0
cardiac 0
hypertrophy 0
remains 0
unclear 0
. 0

Transfection 0
with 0
a 0
CSF B-gene
- I-gene
1R I-gene
expression 0
plasmid 0
permitted 0
CSF B-gene
- I-gene
1 I-gene
- 0
dependent 0
activation 0
of 0
the 0
signalling 0
pathway 0
targeting 0
an 0
Ets/AP1 B-gene
( 0
Ets/AP1 I-gene

Regulation 0
of 0
urokinase B-gene
plasminogen I-gene
activator I-gene
gene I-gene
transcription 0
in 0
the 0
RAW264 0
murine 0
macrophage 0
cell 0
line 0
by 0
macrophage B-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
( 0
CSF B-gene
- I-gene
1 I-gene
) 0
is 0
dependent 0
upon 0
the 0
level 0
of 0
cell 0
- 0
surface 0
receptor 0
. 0

Molecule 0
( 0
s 0
) 0
secreted 0
by 0
neuronal 0
cultures 0
contribute 0
to 0
this 0
induction 0
of 0
GLT B-gene
- I-gene
1 I-gene
, 0
but 0
little 0
is 0
known 0
about 0
the 0
signaling 0
pathways 0
mediating 0
this 0
regulation 0
. 0

Coactivation 0
of 0
endogenous 0
or 0
exogenous 0
G B-gene
( I-gene
q I-gene
) I-gene
- I-gene
coupled I-gene
receptors I-gene
with 0
the 0
delta B-gene
- I-gene
opioid I-gene
receptor I-gene
produced 0
strong 0
stimulations 0
of 0
PLCbeta B-gene
and 0
such 0
responses 0
could 0
be 0
partially 0
blocked 0
by 0
pertussis B-gene
toxin I-gene
. 0

Patients 0
enrolled 0
in 0
the 0
Integrilin 0
to 0
Minimize 0
Platelet 0
Aggregation 0
and 0
Coronary 0
Thrombosis 0
- 0
II 0
( 0
IMPACT 0
- 0
II 0
) 0
trial 0
were 0
analyzed 0
. 0

The 0
Wnt B-gene
signaling 0
pathway 0
functions 0
reiteratively 0
during 0
animal 0
development 0
to 0
control 0
cell 0
fate 0
decisions 0
. 0

This 0
mutation 0
no 0
longer 0
repressed 0
the 0
HPV 0
- 0
11 0
upstream 0
regulatory 0
region 0
- 0
controlled 0
reporter 0
expression 0
. 0

In 0
the 0
icosahaedral 0
MVMi 0
capsid 0
, 0
this 0
sequence 0
forms 0
the 0
carboxy 0
end 0
of 0
the 0
amphipathic 0
beta 0
- 0
strand 0
I 0
( 0
betaI 0
) 0
, 0
and 0
all 0
its 0
basic 0
residues 0
are 0
contiguously 0
positioned 0
at 0
the 0
face 0
that 0
in 0
the 0
unassembled 0
subunit 0
would 0
be 0
exposed 0
to 0
solvent 0
. 0

The 0
two 0
contiguous 0
IGF2 B-gene
( 0
human B-gene
insulin I-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
II I-gene
) 0
and 0
H19 B-gene
genes I-gene
are 0
reciprocally 0
imprinted 0
in 0
both 0
human 0
and 0
mouse 0
. 0

The 0
asymmetric 0
methylation 0
was 0
associated 0
with 0
tissue 0
- 0
specific 0
disruption 0
of 0
H19 B-gene
genomic 0
imprinting 0
in 0
fetal 0
brain 0
. 0

The 0
comparison 0
of 0
the 0
expression 0
patterns 0
of 0
the 0
known 0
Kv4 B-gene
family I-gene
members I-gene
shows 0
subtype 0
specificity 0
with 0
significant 0
overlaps 0
. 0

Early 0
treatment 0
mechanics 0
of 0
the 0
Class 0
II 0
division 0
2 0
malocclusion 0
. 0

Preliminary 0
use 0
of 0
the 0
Nottingham 0
Eczema 0
Severity 0
Score 0
would 0
support 0
further 0
development 0
as 0
a 0
research 0
tool 0
for 0
a 0
simple 0
assessment 0
of 0
disease 0
severity 0
that 0
could 0
be 0
used 0
in 0
epidemiological 0
studies 0
. 0

The 0
consensus 0
highlights 0
the 0
importance 0
of 0
residues 0
other 0
than 0
the 0
eight 0
motifs 0
that 0
are 0
often 0
associated 0
with 0
DEAD B-gene
- I-gene
box I-gene
RNA I-gene
helicases I-gene
, 0
as 0
well 0
as 0
de 0
- 0
emphasising 0
the 0
importance 0
of 0
the 0
`` 0
A 0
'' 0
residue 0
within 0
the 0
`` 0
DEAD 0
'' 0
motif 0
. 0

Advanced 0
adenoma 0
was 0
defined 0
as 0
an 0
adenoma 0
larger 0
than 0
10 0
mm 0
or 0
an 0
adenoma 0
of 0
any 0
size 0
with 0
villous 0
component 0
, 0
high 0
- 0
grade 0
dysplasia 0
or 0
invasive 0
carcinoma 0
. 0

In 0
transient 0
assays 0
, 0
using 0
rice 0
suspension 0
- 0
cultured 0
cells 0
transformed 0
by 0
particle 0
bombardment 0
, 0
we 0
showed 0
previously 0
that 0
Oshox1 B-gene
can 0
transcriptionally 0
repress 0
the 0
activity 0
of 0
reporter 0
gene 0
constructs 0
with 0
upstream 0
HD B-gene
- I-gene
Zip I-gene
binding 0
sites 0
. 0

Results 0
of 0
two 0
- 0
hybrid 0
assays 0
and 0
electrophoretic 0
mobility 0
shift 0
assays 0
strongly 0
suggest 0
that 0
all 0
HD B-gene
- I-gene
Zip I-gene
proteins I-gene
of 0
families 0
I 0
and 0
II 0
can 0
form 0
homodimers 0
and 0
also 0
heterodimers 0
with 0
all 0
HD B-gene
- I-gene
Zip I-gene
proteins I-gene
of 0
the 0
same 0
family 0
. 0

Among 0
mammalian B-gene
HSFs I-gene
, 0
HSF1 B-gene
has 0
been 0
shown 0
to 0
be 0
important 0
for 0
regulation 0
of 0
the 0
heat 0
- 0
induced 0
stress 0
gene 0
expression 0
, 0
whereas 0
the 0
function 0
of 0
HSF2 B-gene
in 0
stress 0
response 0
is 0
unclear 0
. 0

Importantly 0
, 0
concomitant 0
expression 0
of 0
constitutive 0
activated 0
Raf B-gene
and 0
V12N38 B-gene
Ras I-gene
results 0
in 0
almost 0
complete 0
loss 0
of 0
TTF B-gene
- I-gene
1 I-gene
activity 0
. 0

They 0
share 0
many 0
downstream 0
targets 0
, 0
including 0
remodeling 0
of 0
the 0
actin B-gene
cytoskeleton 0
, 0
activation 0
of 0
p70 B-gene
( I-gene
S6 I-gene
) I-gene
kinase I-gene
and 0
c B-gene
- I-gene
jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
( 0
JNK B-gene
) 0
, 0
and 0
regulation 0
of 0
transcription 0
and 0
cell 0
proliferation 0
. 0

Expression 0
of 0
activated 0
Cdc42 B-gene
results 0
in 0
the 0
translocation 0
of 0
PKClambda B-gene
from 0
the 0
nucleus 0
into 0
the 0
cytosol 0
, 0
and 0
Cdc42 B-gene
and 0
PKClambda B-gene
colocalize 0
at 0
the 0
plasma 0
membrane 0
and 0
in 0
the 0
cytoplasm 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

To 0
understand 0
whether 0
Shc B-gene
localization 0
in 0
membrane 0
rafts 0
is 0
sufficient 0
to 0
regulate 0
Shc B-gene
function 0
, 0
we 0
constructed 0
a 0
Shc B-gene
chimera I-gene
containing 0
the 0
Ras B-gene
membrane I-gene
localization I-gene
motif I-gene
at 0
the 0
C 0
- 0
terminus 0
. 0

Southern 0
blotting 0
and 0
single 0
strand 0
conformation 0
polymorphism 0
analyses 0
did 0
not 0
show 0
tumor 0
- 0
specific 0
alterations 0
of 0
this 0
gene 0
in 0
gliomas 0
and 0
RT 0
- 0
PCR 0
studies 0
showed 0
expression 0
in 0
glioma 0
cell 0
lines 0
, 0
suggesting 0
that 0
ANOVA B-gene
is 0
not 0
the 0
chromosome 0
19q 0
glioma 0
tumor 0
suppressor 0
gene 0
. 0

RegA B-gene
is 0
a 0
positive 0
yet 0
nonessential 0
regulator 0
of 0
tol B-gene
- 0
oprL B-gene
expression 0
. 0

Enzyme B-gene
I I-gene
of 0
the 0
phosphoenolpyruvate B-gene
: I-gene
sugar I-gene
phosphotransferase I-gene
system 0
. 0

Based 0
on 0
these 0
data 0
, 0
we 0
conclude 0
that 0
transcription 0
of 0
prgX B-gene
is 0
initiated 0
from 0
the 0
Qa B-gene
promoter I-gene
in 0
prgQ B-gene
, 0
and 0
PrgX B-gene
autoregulates 0
its 0
transcription 0
either 0
by 0
mediating 0
transcriptional 0
readthrough 0
or 0
increasing 0
mRNA 0
stability 0
. 0

It 0
was 0
established 0
that 0
intrathecal 0
or 0
intraperitoneal 0
PTFL 0
, 0
elevated 0
the 0
nociceptive 0
threshold 0
for 0
mechanical 0
stimuli 0
in 0
the 0
formalin 0
test 0
in 0
rats 0
. 0

Molecular 0
mimicry 0
of 0
human 0
cytokine 0
and 0
cytokine 0
response 0
pathway 0
genes 0
by 0
KSHV 0
. 0

Family 0
environment 0
was 0
an 0
important 0
influence 0
on 0
interpersonal 0
relationships 0
, 0
substance 0
use 0
, 0
and 0
social 0
support 0
. 0

By 0
electrophoresis 0
mobility 0
shift 0
assays 0
using 0
probes 0
corresponding 0
to 0
different 0
segments 0
of 0
the 0
putative 0
human B-gene
c I-gene
- I-gene
myb I-gene
intron I-gene
1 I-gene
transcription I-gene
pause I-gene
region I-gene
and 0
nuclear 0
extracts 0
from 0
myeloid 0
leukemia 0
HL 0
60 0
and 0
fibroblast 0
WI 0
38 0
cells 0
, 0
we 0
detected 0
a 0
HL 0
- 0
60 0
- 0
specific 0
DNA 0
- 0
protein 0
complex 0
with 0
a 0
123 0
- 0
bp 0
fragment 0
containing 0
binding 0
sites 0
for 0
the 0
interferon B-gene
regulatory I-gene
factors I-gene
( 0
IRFs B-gene
) 0
nuclear 0
proteins 0
. 0

STUDY 0
DESIGN 0
: 0
Fine 0
needle 0
aspiration 0
cytologic 0
smears 0
from 0
21 0
cases 0
of 0
invasive 0
lobular 0
carcinoma 0
( 0
ILC 0
) 0
of 0
breast 0
were 0
subjected 0
to 0
detailed 0
cytomorphologic 0
analysis 0
. 0

Electrophile 0
Response 0
Elements 0
( 0
EpREs 0
) 0
, 0
located 0
in 0
5' 0
- 0
flanking 0
sequences 0
of 0
both 0
the 0
GCSh B-gene
and 0
GCSl B-gene
subunit I-gene
genes I-gene
, 0
are 0
hypothesized 0
to 0
at 0
least 0
partially 0
mediate 0
gene 0
induction 0
following 0
xenobiotic 0
exposure 0
. 0

A 0
new 0
technique 0
to 0
create 0
an 0
artificial 0
stenosis 0
in 0
the 0
native 0
LAD 0
using 0
a 0
hemoclip 0
. 0

Dll3 B-gene
is 0
mutated 0
in 0
the 0
X 0
- 0
ray 0
- 0
induced 0
mouse B-gene
mutant I-gene
pudgy I-gene
( 0
pu B-gene
) 0
, 0
causing 0
a 0
variety 0
of 0
vertebrocostal 0
defects 0
similar 0
to 0
SD 0
phenotypes 0
. 0

Schlegel 0
, 0
J 0
. 0

TbRAB31 B-gene
behaviour 0
was 0
also 0
studied 0
during 0
the 0
cell 0
cycle 0
; 0
TbRAB31 B-gene
always 0
localised 0
to 0
a 0
discrete 0
structure 0
that 0
duplicated 0
very 0
early 0
in 0
mitosis 0
and 0
relocated 0
to 0
daughter 0
cells 0
in 0
a 0
coordinate 0
manner 0
with 0
the 0
basal 0
body 0
and 0
kinetoplast 0
, 0
suggesting 0
the 0
involvement 0
of 0
microtubules 0
. 0

The 0
early 0
dg 0
. 0
of 0
rejection 0
and 0
especially 0
acute 0
rejection 0
, 0
it 0
's 0
adequate 0
management 0
, 0
decreased 0
risk 0
for 0
the 0
future 0
chronic 0
rejection 0
nephropathy 0
. 0

Invertases B-gene
are 0
responsible 0
for 0
the 0
breakdown 0
of 0
sucrose 0
to 0
fructose 0
and 0
glucose 0
. 0

To 0
investigate 0
the 0
molecular 0
mechanisms 0
of 0
this 0
Tax B-gene
- 0
mediated 0
inhibition 0
, 0
we 0
analyzed 0
its 0
effect 0
on 0
the 0
transcriptional 0
activity 0
of 0
the 0
myogenic 0
MyoD B-gene
protein I-gene
, 0
which 0
was 0
used 0
as 0
a 0
paradigm 0
of 0
bHLH B-gene
factors I-gene
. 0

The 0
human B-gene
T I-gene
cell I-gene
leukemia/lymphotropic I-gene
virus I-gene
type I-gene
1 I-gene
Tax I-gene
protein I-gene
represses 0
MyoD B-gene
- 0
dependent 0
transcription 0
by 0
inhibiting 0
MyoD B-gene
- 0
binding 0
to 0
the 0
KIX B-gene
domain I-gene
of 0
p300 B-gene
. 0

Phosphorylation 0
and 0
spindle 0
pole 0
body 0
localization 0
of 0
the 0
Cdc15p B-gene
mitotic I-gene
regulatory I-gene
protein I-gene
kinase I-gene
in I-gene
budding I-gene
yeast I-gene
. 0

Thus 0
, 0
both 0
the 0
hyperplasia 0
and 0
thrombotic 0
complications 0
which 0
often 0
follow 0
stenting 0
might 0
be 0
minimized 0
by 0
employing 0
gold 0
stents 0
, 0
which 0
have 0
a 0
greater 0
capacity 0
than 0
steel 0
in 0
supporting 0
a 0
functional 0
neo 0
- 0
endothelium 0
. 0

The 0
cell 0
cycle 0
and 0
transcriptional 0
defects 0
caused 0
by 0
taf17 B-gene
( 0
slm7 B-gene
- I-gene
1 I-gene
) 0
are 0
consistent 0
with 0
the 0
role 0
of 0
TAF B-gene
( I-gene
II I-gene
) I-gene
s I-gene
as 0
modulators 0
of 0
transcriptional 0
activation 0
and 0
may 0
reflect 0
a 0
role 0
for 0
TAF17 B-gene
in 0
regulating 0
activation 0
by 0
SBF B-gene
and 0
MBF B-gene
. 0

Extracellular B-gene
- I-gene
regulated I-gene
kinase I-gene
( 0
ERK B-gene
) 0
activation 0
and 0
molecular 0
coupling 0
of 0
the 0
adaptor 0
proteins 0
p130 B-gene
Crk B-gene
- I-gene
associated I-gene
substrate I-gene
( 0
CAS B-gene
) 0
and 0
c B-gene
- I-gene
CrkII I-gene
( 0
Crk B-gene
) 0
represent 0
two 0
distinct 0
pathways 0
that 0
induce 0
cell 0
invasion 0
and 0
protect 0
cells 0
from 0
apoptosis 0
in 0
a 0
three 0
- 0
dimensional 0
collagen B-gene
matrix 0
. 0

Proteolysis 0
of 0
Mbp1 B-gene
and 0
Swi4 B-gene
DNA I-gene
- I-gene
protein I-gene
complexes I-gene
has 0
revealed 0
the 0
extent 0
of 0
these 0
sequences 0
, 0
and 0
C 0
- 0
terminally 0
extended 0
molecules 0
with 0
substantially 0
enhanced 0
DNA 0
binding 0
activity 0
compared 0
to 0
the 0
core 0
domains 0
alone 0
have 0
been 0
produced 0
. 0

The 0
evolution 0
of 0
the 0
CCR5 B-gene
cis I-gene
- I-gene
regulatory I-gene
region I-gene
versus 0
the 0
open 0
reading 0
frame 0
as 0
well 0
as 0
among 0
different 0
domains 0
of 0
the 0
open 0
reading 0
frame 0
differed 0
from 0
one 0
another 0
. 0

These 0
results 0
indicate 0
that 0
residue 0
266 0
serves 0
as 0
a 0
`` 0
protein 0
sensor 0
'' 0
of 0
altered 0
minor 0
groove 0
interactions 0
and 0
identifies 0
which 0
base 0
pair 0
interactions 0
are 0
altered 0
by 0
these 0
lesions 0
. 0

The 0
recombinant 0
enzymes 0
exist 0
as 0
monomers 0
. 0

A 0
pathway 0
for 0
regulation 0
of 0
B B-gene
lymphocyte I-gene
antigen I-gene
receptor I-gene
- 0
induced 0
calcium 0
flux 0
. 0

We 0
now 0
describe 0
a 0
second 0
RIM B-gene
protein I-gene
, 0
called 0
RIM2 B-gene
, 0
that 0
is 0
highly 0
homologous 0
to 0
RIM1 B-gene
and 0
also 0
expressed 0
primarily 0
in 0
brain 0
. 0

Inhibitor B-gene
- I-gene
1 I-gene
( 0
I B-gene
- I-gene
1 I-gene
) 0
and 0
inhibitor B-gene
- I-gene
2 I-gene
( 0
I B-gene
- I-gene
2 I-gene
) 0
selectively 0
inhibit 0
type B-gene
1 I-gene
protein I-gene
serine/threonine I-gene
phosphatases I-gene
( 0
PP1 B-gene
) 0
. 0

Scanning 0
mutations 0
throughout 0
the 0
AC 0
element 0
interfered 0
with 0
induction 0
but 0
allowed 0
us 0
to 0
define 0
five 0
overlapping 0
sites 0
for 0
regulatory 0
factors 0
in 0
AC 0
and 0
to 0
design 0
probes 0
binding 0
just 0
one 0
or 0
two 0
factors 0
. 0

The 0
substrates 0
for 0
glycan 0
synthesis 0
in 0
the 0
lumen 0
of 0
the 0
Golgi 0
are 0
nucleotide 0
sugars 0
that 0
must 0
be 0
transported 0
from 0
the 0
cytosol 0
by 0
specific 0
membrane 0
- 0
bound 0
transporters 0
. 0

Synaptic 0
targeting 0
of 0
the 0
postsynaptic B-gene
density I-gene
protein I-gene
PSD I-gene
- I-gene
95 I-gene
mediated 0
by 0
a 0
tyrosine 0
- 0
based 0
trafficking 0
signal 0
. 0

( 0
1998 0
) 0
J 0
. 0

Bites 0
by 0
two 0
species 0
of 0
adders 0
( 0
Vipera 0
aspis 0
and 0
Vipera 0
berus 0
) 0
can 0
lead 0
to 0
extensive 0
swelling 0
with 0
multiorgan 0
failure 0
. 0

Both 0
normal 0
and 0
transforming 0
PCPH B-gene
proteins I-gene
have 0
guanosine B-gene
diphosphatase I-gene
activity 0
but 0
only 0
the 0
oncoprotein 0
cooperates 0
with 0
Ras B-gene
in 0
activating 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
ERK1 B-gene
. 0

These 0
results 0
indicate 0
that 0
virulence 0
- 0
associated 0
genes 0
and 0
their 0
overall 0
chromosomal 0
arrangement 0
are 0
relatively 0
well 0
conserved 0
between 0
B. 0
henselae 0
and 0
other 0
gram 0
- 0
negative 0
bacteria 0
such 0
as 0
A. 0
tumefaciens 0
. 0

An 0
important 0
mechanism 0
by 0
which 0
the 0
tumor 0
suppressor 0
p53 B-gene
maintains 0
genomic 0
stability 0
is 0
to 0
induce 0
cell 0
cycle 0
arrest 0
through 0
activation 0
of 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
inhibitor 0
p21 B-gene
( 0
WAF1/Cip1 B-gene
) 0
gene 0
. 0

Paxillin B-gene
acts 0
as 0
an 0
adaptor 0
molecule 0
in 0
integrin B-gene
signaling 0
. 0

Thus 0
, 0
growth 0
factor 0
activation 0
of 0
ER B-gene
can 0
mediate 0
transactivation 0
vs 0
ER/Sp1 B-gene
binding 0
to 0
GC 0
- 0
rich 0
sites 0
and 0
represents 0
a 0
novel 0
pathway 0
for 0
ligand 0
- 0
independent 0
ER/Sp1 I-gene

Furthermore 0
, 0
analysis 0
of 0
deletion 0
promoter 0
- 0
reporter 0
constructs 0
found 0
that 0
the 0
basal 0
activity 0
of 0
P2 0
resided 0
in 0
the 0
proximal 0
region 0
of 0
P2 0
. 0

RESULTS 0
: 0
Auditory 0
thresholds 0
collected 0
during 0
audiometric 0
tests 0
increased 0
gradually 0
in 0
proportion 0
with 0
age 0
, 0
especially 0
in 0
the 0
hypertensive 0
group 0
( 0
p 0
< 0
0.05 0
) 0
. 0

In 0
addition 0
, 0
the 0
transcription 0
of 0
c B-gene
- I-gene
IAP2 I-gene
promoter I-gene
was 0
strongly 0
up 0
- 0
regulated 0
when 0
CD40 B-gene
or 0
Epstein B-gene
- I-gene
Barr I-gene
virus I-gene
latent I-gene
membrane I-gene
protein I-gene
1 I-gene
was 0
overexpressed 0
. 0

A 0
variety 0
of 0
professional 0
and 0
self 0
- 0
applied 0
fluoride 0
products 0
are 0
available 0
and 0
new 0
fluoride 0
delivery 0
systems 0
have 0
recently 0
entered 0
the 0
market 0
. 0

These 0
studies 0
identify 0
several 0
of 0
the 0
signal 0
- 0
transduction 0
events 0
involved 0
in 0
the 0
apoptosis 0
of 0
malignant 0
B 0
cells 0
that 0
transpire 0
following 0
ligation 0
of 0
CD20 B-gene
by 0
anti B-gene
- I-gene
CD20 I-gene
antibodies I-gene
in 0
the 0
presence 0
of 0
Fc B-gene
- I-gene
receptor I-gene
- 0
expressing 0
cells 0
or 0
secondary 0
goat 0
anti B-gene
- I-gene
( I-gene
mouse I-gene
Ig I-gene
) I-gene
antibodies I-gene
and 0
which 0
may 0
contribute 0
to 0
the 0
tumor 0
regressions 0
observed 0
in 0
mouse 0
models 0
and 0
clinical 0
trials 0
. 0

CONCLUSION 0
: 0
Treatment 0
of 0
sepsis 0
with 0
the 0
platelet B-gene
- I-gene
activating I-gene
factor I-gene
antagonist 0
BB 0
- 0
882 0
offers 0
no 0
advantage 0
over 0
placebo 0
on 0
survival 0
, 0
hemodynamic 0
status 0
, 0
respiratory 0
function 0
, 0
or 0
organ 0
failure 0
scores 0
. 0

Phenazone 0
potentiates 0
the 0
local 0
anaesthetic 0
effect 0
of 0
lidocaine 0
in 0
mice 0
. 0

The 0
solubility 0
of 0
all 0
the 0
mutated 0
proteins 0
was 0
remarkably 0
reduced 0
. 0

Recently 0
, 0
identical 0
RBE B-gene
sequences I-gene
have 0
been 0
identified 0
at 0
other 0
locations 0
in 0
the 0
human 0
genome 0
. 0

EM 0
analysis 0
demonstrated 0
that 0
only 0
one 0
Rep B-gene
- I-gene
DNA I-gene
complex I-gene
was 0
formed 0
on 0
ch 0
- 0
19 0
target 0
DNA 0
. 0

The 0
protein 0
was 0
associated 0
with 0
purified 0
vaccinia 0
virus 0
particles 0
and 0
with 0
membranes 0
of 0
immature 0
and 0
mature 0
virions 0
that 0
were 0
visualized 0
by 0
electron 0
microscopy 0
of 0
infected 0
cells 0
. 0

In 0
vivo 0
dimethyl 0
sulfate 0
footprinting 0
of 0
the 0
cyclin B-gene
E I-gene
promoter I-gene
revealed 0
several 0
regions 0
of 0
protection 0
and 0
hypersensitivity 0
that 0
were 0
unique 0
to 0
infected 0
cells 0
. 0

A 0
total 0
of 0
194 0
STSs 0
map 0
to 0
this 0
interval 0
of 0
3 0
Mb 0
, 0
giving 0
an 0
average 0
marker 0
resolution 0
of 0
approximately 0
one 0
per 0
15 0
kb 0
. 0

Recently 0
, 0
a 0
mutation 0
in 0
the 0
amino 0
- 0
terminus 0
of 0
IB1 B-gene
was 0
associated 0
with 0
diabetes 0
. 0

CONCLUSION 0
: 0
More 0
than 0
50 0
% 0
of 0
patients 0
with 0
perennial 0
rhinitis 0
and 0
CRS 0
do 0
not 0
improve 0
after 0
surgery 0
, 0
a 0
response 0
that 0
may 0
be 0
predicted 0
by 0
more 0
cells 0
expressing 0
IL B-gene
- I-gene
5 I-gene
mRNA I-gene
in 0
the 0
ethmoid 0
sinuses 0
. 0

Biol 0
. 0

On 0
the 0
basis 0
of 0
size 0
, 0
the 0
CRS 0
sequence 0
to 0
which 0
it 0
binds 0
, 0
and 0
its 0
tentative 0
identification 0
as 0
a 0
zinc B-gene
finger I-gene
protein I-gene
, 0
Adx B-gene
factor I-gene
has 0
been 0
identified 0
as 0
a 0
Kruppel B-gene
- I-gene
like I-gene
zinc I-gene
finger I-gene
protein I-gene
( 0
a 0
mouse B-gene
ZBP I-gene
- I-gene
89 I-gene
homologue I-gene
) 0
. 0

METHODS 0
: 0
The 0
most 0
distal 0
muscle 0
fibres 0
from 0
the 0
deep 0
and 0
superficial 0
finger 0
flexors 0
were 0
measured 0
relative 0
to 0
the 0
pisiform 0
bone 0
in 0
18 0
cadaveric 0
specimens 0
. 0

Here 0
we 0
report 0
on 0
the 0
isolation 0
of 0
ICK2 B-gene
, 0
and 0
show 0
that 0
it 0
interacts 0
with 0
Cdc2aAt B-gene
, 0
but 0
not 0
with 0
a 0
second 0
CDK B-gene
from I-gene
Arabidopsis I-gene
, 0
Cdc2bAt B-gene
. 0

Systemic 0
impact 0
of 0
risk 0
- 0
sharing 0
arrangements 0
. 0

METHODS 0
: 0
We 0
determined 0
an 0
odds 0
ratio 0
( 0
OR 0
) 0
, 0
as 0
a 0
measure 0
of 0
the 0
relative 0
risk 0
of 0
being 0
exposed 0
to 0
a 0
potential 0
interaction 0
, 0
comparing 0
the 0
use 0
of 0
the 0
H2 B-gene
- I-gene
receptor I-gene
antagonist 0
, 0
cimetidine 0
, 0
with 0
that 0
of 0
the 0
noninteracting 0
agents 0
ranitidine 0
, 0
famotidine 0
and 0
nizatidine 0
in 0
users 0
and 0
nonusers 0
of 0
warfarin 0
, 0
phenytoin 0
and 0
theophylline 0
. 0

The 0
prevalence 0
of 0
malnutrition 0
was 0
30 0
% 0
in 0
the 0
47 0
patients 0
without 0
CVD 0
and 0
was 0
significantly 0
higher 0
( 0
70 0
% 0
, 0
P 0
< 0
0.001 0
) 0
in 0
the 0
70 0
patients 0
with 0
CVD 0
, 0
who 0
also 0
had 0
lower 0
tHcy 0
, 0
SAlb 0
, 0
plasma B-gene
IGF I-gene
- I-gene
1 I-gene
, 0
serum 0
creatinine 0
( 0
SCr 0
) 0
, 0
and 0
blood B-gene
hemoglobin I-gene
. 0

Our 0
data 0
suggest 0
that 0
, 0
at 0
least 0
at 0
high 0
temperature 0
, 0
a 0
critical 0
minimal 0
level 0
of 0
Ypt B-gene
protein I-gene
prenylation 0
is 0
required 0
for 0
maintaining 0
vesicle 0
polarization 0
. 0

The 0
second 0
functional 0
pair 0
of 0
CreA B-gene
sites I-gene
is 0
located 0
between 0
the 0
two 0
transcription 0
initiation 0
sites 0
. 0

A 0
distinct 0
staining 0
pattern 0
for 0
the 0
N B-gene
- I-gene
utrophin I-gene
was 0
not 0
detectable 0
, 0
although 0
it 0
was 0
expected 0
to 0
localise 0
at 0
the 0
actin B-gene
stress 0
fibers 0
. 0

The 0
'Newcastle 0
' 0
model 0
, 0
which 0
is 0
based 0
on 0
Hotelling 0
's 0
T2 0
statistic 0
, 0
proved 0
to 0
be 0
more 0
sensitive 0
and 0
diagnosed 0
a 0
systematic 0
displacement 0
for 0
three 0
prostate 0
patients 0
. 0

The 0
MMA B-gene
, I-gene
DMA I-gene
, I-gene
and I-gene
TMA I-gene
methyltransferases I-gene
are 0
not 0
homologs 0
; 0
however 0
, 0
like 0
the 0
MMA B-gene
methyltransferase I-gene
gene I-gene
, 0
the 0
genes 0
encoding 0
the 0
DMA B-gene
and I-gene
TMA I-gene
methyltransferases I-gene
each 0
contain 0
a 0
single 0
in 0
- 0
frame 0
amber 0
codon 0
. 0

After 0
phosphorylation 0
, 0
STAT B-gene
proteins I-gene
are 0
transported 0
into 0
the 0
nucleus 0
and 0
exhibit 0
transcriptional 0
activity 0
. 0

Overexpression 0
of 0
mcl B-gene
- I-gene
1 I-gene
is 0
sufficient 0
to 0
protect 0
against 0
apoptosis 0
, 0
while 0
transfection 0
of 0
a 0
mcl B-gene
- I-gene
1 I-gene
antisense 0
plasmid 0
causes 0
cell 0
death 0
. 0

Thus 0
, 0
although 0
multiple 0
senescence 0
pathways 0
are 0
activated 0
in 0
response 0
to 0
a 0
ras B-gene
oncogene I-gene
, 0
inactivation 0
of 0
TGFbeta1 B-gene
secretion 0
or 0
response 0
is 0
sufficient 0
to 0
block 0
the 0
senescence 0
program 0
. 0

In 0
this 0
study 0
, 0
the 0
abilities 0
of 0
constitutive 0
and 0
conditional 0
forms 0
of 0
the 0
three 0
Raf B-gene
kinases I-gene
to 0
abrogate 0
the 0
cytokine 0
dependency 0
of 0
FDC 0
- 0
P1 0
cells 0
were 0
examined 0
. 0

Application 0
of 0
the 0
method 0
to 0
a 0
representative 0
set 0
of 0
50 0
known 0
genes 0
from 0
Arabidopsis 0
thaliana 0
showed 0
significant 0
improvement 0
in 0
prediction 0
accuracy 0
compared 0
to 0
previous 0
spliced 0
alignment 0
methods 0
. 0

The 0
complete 0
cDNA 0
sequence 0
of 0
human B-gene
betaV I-gene
spectrin I-gene
is 0
available 0
from 0
GenBank 0
( 0
TM 0
) 0
as 0
accession 0
number 0
. 0

Transactivation 0
of 0
naturally 0
occurring 0
HIV B-gene
- I-gene
1 I-gene
long I-gene
terminal I-gene
repeats I-gene
by 0
the 0
JNK B-gene
signaling 0
pathway 0
. 0

These 0
data 0
show 0
that 0
the 0
alpha 0
- 0
helix 0
domain 0
of 0
p57 B-gene
( 0
Kip2 B-gene
) 0
, 0
which 0
is 0
conserved 0
in 0
the 0
Cip/Kip B-gene
proteins 0
, 0
is 0
implicated 0
in 0
protein 0
- 0
protein 0
interaction 0
and 0
confers 0
a 0
specific 0
regulatory 0
mechanism 0
, 0
outside 0
of 0
their 0
Cip/Kip I-gene

The 0
mode 0
of 0
resistance 0
to 0
quinupristin/dalfopristin 0
was 0
not 0
evident 0
( 0
sat 0
A 0
- 0
negative 0
by 0
PCR 0
) 0
; 0
and 0
these 0
cases 0
illustrate 0
the 0
existence 0
of 0
streptogramin 0
- 0
resistant 0
isolates 0
before 0
the 0
introduction 0
of 0
this 0
antimicrobial 0
class 0
into 0
human 0
clinical 0
practice 0
. 0

This 0
study 0
was 0
carried 0
out 0
to 0
analyze 0
PRL B-gene
secretion 0
in 0
metastatic 0
prostate 0
cancer 0
patients 0
both 0
at 0
basal 0
conditions 0
and 0
in 0
response 0
to 0
L 0
- 0
Dopa 0
and 0
metoclopramide 0
, 0
which 0
represents 0
the 0
most 0
classical 0
inhibitory 0
and 0
stimulatory 0
tests 0
for 0
PRL B-gene
secretion 0
, 0
respectively 0
. 0

Integrin B-gene
adhesion I-gene
receptors I-gene
transduce 0
signals 0
that 0
control 0
complex 0
cell 0
functions 0
which 0
require 0
the 0
regulation 0
of 0
gene 0
expression 0
, 0
such 0
as 0
proliferation 0
, 0
differentiation 0
and 0
survival 0
. 0

Recombination 0
, 0
replication 0
, 0
repair 0
: 0
from 0
complexity 0
to 0
harmony 0
. 0

The 0
somatoform 0
conundrum 0
: 0
a 0
question 0
of 0
nosological 0
valves 0
. 0

Intra 0
- 0
operative 0
ultrasound 0
( 0
IOUS 0
) 0
has 0
been 0
widely 0
used 0
in 0
an 0
attempt 0
to 0
overcome 0
these 0
difficulties 0
, 0
but 0
is 0
limited 0
by 0
its 0
two 0
- 0
dimensional 0
nature 0
, 0
inter 0
- 0
user 0
variability 0
, 0
and 0
image 0
obliteration 0
with 0
ablative 0
or 0
resectional 0
techniques 0
. 0

CONCLUSIONS 0
: 0
This 0
randomized 0
study 0
shows 0
that 0
Vivostat 0
fibrin B-gene
sealant 0
is 0
effective 0
in 0
preventing 0
air 0
leakage 0
after 0
small 0
lung 0
resections 0
in 0
pigs 0
, 0
even 0
at 0
high 0
inspiratory 0
pressures 0
. 0

Hailey 0
- 0
Hailey 0
disease 0
is 0
caused 0
by 0
mutations 0
in 0
ATP2C1 B-gene
encoding 0
a 0
novel 0
Ca 0
( 0
2+ 0
) 0
pump 0
. 0

Hex B-gene
is 0
expressed 0
in 0
the 0
developing 0
liver 0
coincident 0
with 0
the 0
forkhead/winged B-gene
forkhead/winged I-gene
helix I-gene
transcription 0
factor 0
, 0
Hepatocyte B-gene
Nuclear I-gene
Factor I-gene
3beta I-gene
( 0
HNF3beta B-gene
) 0
. 0

As 0
an 0
extension 0
of 0
our 0
structural 0
characterization 0
of 0
the 0
exon 0
- 0
intron 0
organization 0
of 0
the 0
mouse B-gene
Pkr I-gene
gene I-gene
, 0
we 0
now 0
have 0
isolated 0
and 0
characterized 0
the 0
mouse B-gene
Pkr I-gene
promoter I-gene
region I-gene
required 0
for 0
IFN B-gene
- 0
inducible 0
transcription 0
. 0

The 0
CRE 0
, 0
5' 0
- 0
TGACGTCA 0
- 0
3 0
' 0
, 0
has 0
been 0
described 0
as 0
the 0
consensus 0
sequence 0
for 0
the 0
cis 0
- 0
element 0
that 0
directs 0
cAMP 0
- 0
regulated 0
gene 0
expression 0
. 0

Kidney 0
length 0
did 0
not 0
significantly 0
differ 0
between 0
right 0
and 0
left 0
, 0
however 0
, 0
kidney 0
width 0
, 0
cortical 0
thickness 0
and 0
size 0
did 0
( 0
p 0
< 0
0.05 0
) 0
. 0

The 0
clinical 0
stage 0
was 0
I 0
( 0
T1N0M0 0
) 0
, 0
and 0
S2 0
sleeve 0
segmentectomy 0
with 0
lymph 0
node 0
dissection 0
( 0
R 0
2 0
b 0
) 0
was 0
performed 0
. 0

Benztropine 0
for 0
venlafaxine 0
- 0
induced 0
night 0
sweats 0
. 0

A 0
cause 0
of 0
increase 0
of 0
alkaline B-gene
phosphatase I-gene
in 0
children 0

The 0
physicians 0
in 0
charge 0
of 0
all 0
patients 0
with 0
evidence 0
of 0
acute 0
Q 0
fever 0
( 0
seroconversion 0
and/or 0
presence 0
of 0
IgM B-gene
) 0
or 0
chronic 0
Q 0
fever 0
( 0
prolonged 0
disease 0
and/or 0
IgG B-gene
antibody I-gene
titer 0
to 0
phase 0
I 0
of 0
Coxiella 0
burnetii 0
> 0
or 0
= 0
800 0
) 0
were 0
asked 0
to 0
complete 0
a 0
questionnaire 0
, 0
which 0
was 0
computerized 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

Viral 0
cell 0
- 0
to 0
- 0
cell 0
movement 0
of 0
PVX B-gene
CP I-gene
mutant I-gene
was 0
complemented 0
in 0
Nicotiana 0
tabacum 0
cv 0
. 0

Induction 0
of 0
CD86 B-gene
expression 0
by 0
stimulation 0
of 0
U937 0
cells 0
with 0
IFN B-gene
- I-gene
gamma I-gene
revealed 0
the 0
presence 0
of 0
two 0
functional 0
GAS B-gene
( 0
gamma B-gene
- I-gene
interferon I-gene
activation I-gene
site I-gene
) 0
elements 0
. 0

Significantly 0
, 0
two 0
proximal 0
GATA B-gene
- I-gene
1 I-gene
- I-gene
binding I-gene
sites I-gene
( 0
- 0
118/ 0
- 0
113 0
and 0
- 0
98/ 0
- 0
93 0
) 0
and 0
a 0
region 0
located 0
within 0
- 0
518 0
to 0
- 0
315bp 0
of 0
the 0
mouse B-gene
ALAS2 I-gene
promoter I-gene
were 0
essential 0
for 0
transcriptional 0
activation 0
during 0
chemically 0
induced 0
differentiation 0
of 0
MEL 0
cells 0
, 0
implying 0
their 0
importance 0
in 0
conferring 0
erythroid 0
specificity 0
to 0
the 0
ALAS2 B-gene
transcriptional 0
activation 0
. 0

SNAP B-gene
- I-gene
23 I-gene
plays 0
an 0
important 0
role 0
in 0
the 0
regulation 0
of 0
vesicle 0
trafficking 0
in 0
mammalian 0
cells 0
. 0

The 0
HMG B-gene
domain I-gene
of 0
both 0
HMG20 B-gene
proteins I-gene
is 0
most 0
similar 0
to 0
that 0
of 0
yeast B-gene
NHP6A I-gene
( 0
38 0
% 0
to 0
42 0
% 0
) 0
. 0

IgM B-gene
and 0
IgG B-gene
anti I-gene
A I-gene
and 0
anti B-gene
B I-gene
antibody I-gene
status 0
of 0
100 0
antenatal 0
O 0
group 0
mothers 0
( 0
who 0
had 0
non 0
O 0
group 0
husbands 0
) 0
were 0
studied 0
. 0

In 0
an 0
attempt 0
to 0
understand 0
Wee1 B-gene
regulation 0
during 0
cell 0
cycle 0
, 0
yeast 0
two 0
- 0
hybrid 0
screening 0
was 0
used 0
to 0
identify 0
Wee1 B-gene
- I-gene
binding I-gene
protein I-gene
( I-gene
s I-gene
) I-gene
. 0

Retroviral 0
transduction 0
of 0
T/T B-gene
( I-gene
L I-gene
) I-gene
causes 0
a 0
rapidly 0
fatal 0
myeloproliferative 0
disease 0
in 0
a 0
murine 0
bone 0
marrow 0
transplant 0
( 0
BMT 0
) 0
model 0
, 0
whereas 0
T/T B-gene
( I-gene
F I-gene
) I-gene
causes 0
a 0
long 0
- 0
latency 0
, 0
pre 0
- 0
B 0
- 0
cell 0
lymphoblastic 0
lymphoma 0
. 0

Ab 0
- 0
MLV 0
strains 0
expressing 0
P70/S2 B-gene
failed 0
to 0
transform 0
NIH 0
3T3 0
cells 0
and 0
demonstrated 0
a 0
greatly 0
reduced 0
capacity 0
to 0
mediate 0
signaling 0
events 0
associated 0
with 0
the 0
P70/S2 I-gene

The 0
codon 0
usage 0
is 0
particularly 0
marked 0
for 0
the 0
gag B-gene
, 0
pol B-gene
, 0
and 0
env B-gene
genes I-gene
. 0

The 0
p53 B-gene
- I-gene
homolog I-gene
p73beta B-gene
also 0
activated 0
the 0
PIG3 B-gene
promoter I-gene
, 0
but 0
in 0
contrast 0
to 0
p53 B-gene
, 0
the 0
proline 0
- 0
rich 0
domain 0
of 0
p73beta B-gene
( I-gene
residues I-gene
81 I-gene
- I-gene
113 I-gene
) I-gene
was 0
dispensable 0
to 0
induce 0
the 0
PIG3 B-gene
promoter I-gene
. 0

Results 0
from 0
transient 0
assays 0
using 0
these 0
mutants 0
showed 0
that 0
the 0
DE1 0
received 0
signals 0
from 0
phytochromes B-gene
A I-gene
and I-gene
B I-gene
, 0
demonstrating 0
that 0
this 0
element 0
is 0
indeed 0
a 0
light 0
- 0
responsive 0
element 0
. 0

Co 0
- 0
immunoprecipitation 0
and 0
DNA 0
affinity 0
chromatography 0
prove 0
that 0
Sp1 B-gene
heterodimerizes 0
with 0
ZBP B-gene
- I-gene
89 I-gene
when 0
bound 0
to 0
the 0
silencer 0
element 0
to 0
yield 0
a 0
DNA 0
- 0
protein 0
complex 0
whose 0
mobility 0
is 0
indistinguishable 0
from 0
that 0
displayed 0
by 0
HeLa 0
nuclear 0
extract 0
in 0
band 0
shift 0
assays 0
. 0

The 0
ZNF274 B-gene
gene I-gene
is 0
mapped 0
distal 0
to 0
marker 0
RP 0
S28 0
1 0
in 0
the 0
human 0
chromosome 0
19qter 0
region 0
, 0
by 0
RH 0
mapping 0
. 0

The 0
C B-gene
- I-gene
terminal I-gene
Cdk2 I-gene
truncations 0
, 0
however 0
, 0
were 0
non 0
- 0
functional 0
in 0
these 0
strains 0
and 0
thus 0
dependent 0
for 0
activity 0
on 0
the 0
pho85 B-gene
coding I-gene
region I-gene
which 0
remained 0
in 0
the 0
mutant B-gene
pho85 I-gene
: 0
:HIS3 B-gene
chromosomal I-gene
locus I-gene
. 0

We 0
report 0
here 0
on 0
the 0
molecular 0
nature 0
of 0
an 0
EMS 0
- 0
induced 0
mutant 0
, 0
mn1 B-gene
- I-gene
89 I-gene
, 0
a 0
leaky 0
semidominant 0
allele 0
of 0
the 0
Miniature1 B-gene
( 0
Mn1 B-gene
) 0
seed 0
locus 0
that 0
encodes 0
a 0
seed B-gene
- I-gene
specific I-gene
cell I-gene
wall I-gene
invertase I-gene
, 0
INCW2 B-gene
. 0

We 0
conclude 0
that 0
, 0
both 0
in 0
atrial 0
myocytes 0
and 0
in 0
Xenopus 0
oocytes 0
, 0
beta 0
- 0
adrenergic 0
stimulation 0
potentiates 0
the 0
ACh 0
- 0
evoked 0
GIRK B-gene
channels I-gene
via 0
a 0
pathway 0
that 0
involves 0
PKA B-gene
- 0
catalyzed 0
phosphorylation 0
downstream 0
from 0
beta B-gene
( I-gene
2 I-gene
) I-gene
AR I-gene
. 0

Slap B-gene
negatively 0
regulates 0
Src B-gene
mitogenic 0
function 0
but 0
does 0
not 0
revert 0
Src B-gene
- 0
induced 0
cell 0
morphology 0
changes 0
. 0

Identification 0
of 0
a 0
novel 0
E2F3 B-gene
product I-gene
suggests 0
a 0
mechanism 0
for 0
determining 0
specificity 0
of 0
repression 0
by 0
Rb B-gene
proteins I-gene
. 0

In 0
DNase B-gene
I I-gene
footprinting 0
protection 0
analysis 0
, 0
both 0
SFRE B-gene
and 0
ERE 0
regions 0
were 0
protected 0
by 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
- 0
ERRalpha1 B-gene
fusion 0
protein 0
. 0

Overexpressing 0
the 0
coactivator 0
, 0
SRC1a B-gene
or 0
GRIP1 B-gene
, 0
further 0
enhances 0
ERRalpha1 B-gene
- 0
induced 0
transcriptional 0
activity 0
. 0

Estrogen B-gene
receptor I-gene
- I-gene
related I-gene
receptor I-gene
alpha I-gene
1 I-gene
interacts 0
with 0
coactivator 0
and 0
constitutively 0
activates 0
the 0
estrogen 0
response 0
elements 0
of 0
the 0
human B-gene
lactoferrin I-gene
gene I-gene
. 0

We 0
examine 0
current 0
models 0
of 0
the 0
effects 0
of 0
aging 0
on 0
mean 0
response 0
time 0
and 0
show 0
how 0
they 0
might 0
be 0
reinterpreted 0
. 0

The 0
effects 0
of 0
these 0
mutations 0
on 0
protein 0
function 0
require 0
further 0
examination 0
. 0

The 0
median 0
levels 0
of 0
particles 0
with 0
50 0
% 0
cut 0
- 0
off 0
aerodynamic 0
diameters 0
of 0
10 0
( 0
PM10 0
) 0
and 0
2.5 0
microm 0
( 0
PM2.5 0
) 0
were 0
170 0
( 0
range 0
103 0
- 0
613 0
) 0
and 0
95 0
( 0
range 0
61 0
- 0
218 0
) 0
micro 0
x 0
m 0
- 0
3 0
, 0
respectively 0
. 0

Kaposi 0
's 0
sarcoma 0
- 0
associated 0
herpesvirus 0
viral B-gene
interferon I-gene
regulatory I-gene
factor I-gene
confers 0
resistance 0
to 0
the 0
antiproliferative 0
effect 0
of 0
interferon B-gene
- I-gene
alpha I-gene
. 0

Specific 0
and 0
heritable 0
genetic 0
interference 0
by 0
double 0
- 0
stranded 0
RNA 0
in 0
Arabidopsis 0
thaliana 0
. 0

Comparison 0
of 0
sequences 0
from 0
- 0
215 0
to 0
+1 0
bp 0
identified 0
consensus 0
binding 0
sites 0
for 0
the 0
homeodomain B-gene
transcription I-gene
factor I-gene
thyroid B-gene
transcription I-gene
factor I-gene
- I-gene
1 I-gene
( 0
TTF B-gene
- I-gene
1 I-gene
) 0
. 0

Two 0
additional 0
cis 0
- 0
acting 0
sequences 0
, 0
conserved 0
in 0
both 0
the 0
region 0
1 0
and 0
3 0
promoters 0
, 0
were 0
identified 0
, 0
suggesting 0
a 0
role 0
for 0
these 0
sequences 0
in 0
the 0
coordinate 0
regulation 0
of 0
transcription 0
from 0
these 0
promoters 0
. 0

Purple 0
photosynthetic 0
bacteria 0
are 0
capable 0
of 0
generating 0
cellular 0
energy 0
from 0
several 0
sources 0
, 0
including 0
photosynthesis 0
, 0
respiration 0
, 0
and 0
H 0
( 0
2 0
) 0
oxidation 0
. 0

An 0
analysis 0
of 0
synthetic 0
peptides 0
revealed 0
a 0
minimal 0
CTD 0
sequence 0
that 0
is 0
sufficient 0
to 0
bind 0
to 0
the 0
second 0
Rsp5 B-gene
WW I-gene
domain I-gene
( 0
Rsp5 B-gene
WW2 I-gene
) 0
in 0
vitro 0
and 0
in 0
yeast 0
two 0
- 0
hybrid 0
assays 0
. 0

Furthermore 0
, 0
bone 0
marrow 0
- 0
derived 0
macrophages 0
from 0
LAT B-gene
- 0
deficient 0
mice 0
displayed 0
reduced 0
phagocytic 0
efficiency 0
in 0
comparison 0
to 0
the 0
macrophages 0
from 0
wild 0
- 0
type 0
mice 0
. 0

T1 0
- 0
weighted 0
MRI 0
on 0
the 0
49th 0
postoperative 0
day 0
demonstrated 0
bilateral 0
and 0
symmetrical 0
hyperintense 0
lesions 0
in 0
the 0
globus 0
pallidus 0
. 0

The 0
method 0
is 0
applied 0
to 0
determine 0
aberration 0
constants 0
of 0
a 0
CM300 0
FEG/UT 0
microscope 0
with 0
correction 0
of 0
the 0
three 0
- 0
fold 0
astigmatism 0
. 0

The 0
interaction 0
does 0
not 0
depend 0
on 0
the 0
presence 0
of 0
the 0
correct 0
amino 0
- 0
terminal 0
DNA 0
binding 0
domain 0
or 0
the 0
amino 0
acid 0
sequences 0
between 0
the 0
DNA 0
binding 0
domain 0
and 0
the 0
last 0
ten 0
amino 0
acids 0
. 0

METHOD 0
: 0
The 0
sample 0
of 0
subjects 0
was 0
drawn 0
from 0
the 0
Suffolk 0
County 0
Mental 0
Health 0
Project 0
, 0
a 0
longitudinal 0
epidemiologic 0
study 0
of 0
first 0
- 0
hospitalized 0
subjects 0
with 0
psychotic 0
disorders 0
; 0
the 0
present 0
study 0
focused 0
on 0
patients 0
with 0
schizophrenic 0
disorders 0
. 0

Marrow 0
dysplasia 0
is 0
a 0
major 0
characteristic 0
of 0
patients 0
with 0
myelodysplastic 0
syndrome 0
( 0
MDS 0
) 0
, 0
along 0
with 0
marrow 0
blastosis 0
, 0
cytopenia 0
and 0
cytogenetic 0
anomalies 0
. 0

Eight 0
of 0
the 0
non 0
- 0
acceptable 0
inlays/onlays 0
and 0
five 0
of 0
the 0
direct 0
restorations 0
were 0
replaced 0
, 0
while 0
the 0
other 0
ones 0
were 0
repaired 0
with 0
resin 0
composite 0
. 0

How 0
plants 0
respond 0
to 0
attack 0
by 0
the 0
range 0
of 0
herbivores 0
and 0
pathogens 0
that 0
confront 0
them 0
in 0
the 0
field 0
is 0
the 0
subject 0
of 0
considerable 0
research 0
by 0
both 0
molecular 0
biologists 0
and 0
ecologists 0
. 0

CONCLUSION 0
: 0
The 0
probability 0
of 0
cardiopulmonary 0
complications 0
increases 0
significantly 0
when 0
patients 0
develop 0
class 0
1 0
HELLP 0
syndrome 0
. 0

The 0
rate 0
- 0
limiting 0
step 0
for 0
telomerase B-gene
activity 0
seems 0
to 0
be 0
the 0
expression 0
of 0
the 0
catalytic 0
subunit 0
of 0
the 0
enzyme 0
, 0
encoded 0
by 0
the 0
human B-gene
telomerase I-gene
reverse I-gene
transcriptase I-gene
( 0
hTERT B-gene
) 0
gene 0
. 0

In 0
the 0
control 0
group 0
, 0
platelet 0
markers 0
increased 0
1 0
h 0
after 0
surgery 0
. 0

However 0
, 0
the 0
element 0
proximal 0
to 0
the 0
transcription 0
start 0
site 0
is 0
dependent 0
on 0
the 0
SRE 0
- 0
1 0
. 0

AMDA 0
white 0
paper 0
identifies 0
ways 0
to 0
improve 0
pharmaceutical 0
care 0
in 0
SNFs 0
. 0

Since 0
proteins 0
containing 0
TPR 0
elements 0
are 0
typically 0
involved 0
in 0
multiple 0
protein 0
- 0
protein 0
interactions 0
, 0
we 0
suggest 0
that 0
the 0
102kD 0
protein 0
interacts 0
within 0
the 0
tri 0
- 0
snRNP 0
with 0
both 0
the 0
U5 B-gene
and 0
U4/U6 B-gene
snRNPs 0
, 0
thus 0
bridging 0
the 0
two 0
particles 0
. 0

Antibodies 0
raised 0
against 0
a 0
C 0
- 0
terminal 0
portion 0
of 0
Sec31A B-gene
co 0
- 0
precipitate 0
Sec13 B-gene
and 0
inhibit 0
ER 0
- 0
Golgi 0
transport 0
of 0
temperature 0
- 0
arrested 0
vesicular 0
stomatitis B-gene
G I-gene
protein I-gene
in 0
a 0
semi 0
- 0
intact 0
cell 0
assay 0
. 0

Regulation 0
of 0
mitochondrial 0
single 0
- 0
stranded 0
DNA 0
- 0
binding 0
protein 0
gene 0
expression 0
links 0
nuclear 0
and 0
mitochondrial 0
DNA 0
replication 0
in 0
drosophila 0
. 0

Genetic 0
and 0
molecular 0
complexity 0
of 0
the 0
position 0
effect 0
variegation 0
modifier 0
mod B-gene
( 0
mdg4 B-gene
) 0
in 0
Drosophila 0
. 0
mod B-gene
( 0
mdg4 B-gene
) 0
, 0
also 0
known 0
as 0
E B-gene
( I-gene
var I-gene
) I-gene
3 I-gene
- I-gene
93D I-gene
, 0
is 0
involved 0
in 0
a 0
variety 0
of 0
processes 0
, 0
such 0
as 0
gene 0
silencing 0
in 0
position 0
effect 0
variegation 0
( 0
PEV 0
) 0
, 0
the 0
control 0
of 0
gypsy B-gene
insulator I-gene
sequences I-gene
, 0
regulation 0
of 0
homeotic B-gene
gene I-gene
expression 0
, 0
and 0
programmed 0
cell 0
death 0
. 0

They 0
are 0
present 0
in 0
many 0
kinds 0
of 0
living 0
things 0
, 0
but 0
their 0
functions 0
, 0
especially 0
those 0
in 0
humans 0
, 0
are 0
unclear 0
. 0

This 0
tendency 0
is 0
likely 0
due 0
to 0
the 0
biased 0
nucleotide 0
composition 0
of 0
the 0
asparagus 0
genome 0
, 0
rather 0
than 0
to 0
the 0
translational 0
selection 0
for 0
specific 0
codons 0
. 0

Transduction 0
of 0
the 0
human 0
leukemic 0
cell 0
line 0
K562 0
showed 0
that 0
viral 0
MRP1 B-gene
- 0
PG13 0
supernatants 0
routinely 0
transfer 0
the 0
MRP1 B-gene
gene I-gene
to 0
approximately 0
35 0
% 0
of 0
target 0
K562 0
cells 0
, 0
of 0
which 0
at 0
least 0
one 0
third 0
are 0
capable 0
of 0
proliferating 0
in 0
the 0
presence 0
of 0
otherwise 0
toxic 0
concentrations 0
of 0
etoposide 0
. 0

Regulation 0
of 0
pituitary 0
vasopressin B-gene
V1b I-gene
receptors I-gene
plays 0
a 0
critical 0
role 0
in 0
regulating 0
pituitary B-gene
adrenocorticotropic I-gene
hormone I-gene
( 0
ACTH B-gene
) 0
secretion 0
during 0
adaptation 0
to 0
stress 0
. 0

Identification 0
of 0
an 0
AfsA B-gene
homologue I-gene
( 0
BarX B-gene
) 0
from 0
Streptomyces 0
virginiae 0
as 0
a 0
pleiotropic 0
regulator 0
controlling 0
autoregulator 0
biosynthesis 0
, 0
virginiamycin 0
biosynthesis 0
and 0
virginiamycin 0
M1 0
resistance 0
. 0

Because 0
the 0
mutant 0
defective 0
in 0
DNA 0
binding 0
also 0
fails 0
to 0
stimulate 0
Abf1 B-gene
ARS1 0
DNA 0
- 0
binding 0
activity 0
, 0
our 0
results 0
suggest 0
that 0
Cdc6 B-gene
DNA 0
- 0
binding 0
activity 0
may 0
play 0
a 0
pivotal 0
role 0
in 0
the 0
initiation 0
of 0
DNA 0
replication 0
. 0

Given 0
its 0
relative 0
longevity 0
on 0
the 0
Web 0
, 0
TIE 0
researchers 0
have 0
been 0
in 0
a 0
unique 0
position 0
to 0
observe 0
trends 0
in 0
telemedicine 0
. 0

The 0
structural 0
study 0
of 0
peptides 0
belonging 0
to 0
the 0
terminal 0
domains 0
of 0
histone B-gene
H1 I-gene
can 0
be 0
considered 0
as 0
a 0
step 0
toward 0
the 0
understanding 0
of 0
the 0
function 0
of 0
H1 B-gene
in 0
chromatin 0
. 0

The 0
recovery 0
rates 0
for 0
the 0
MB/BacT 0
, 0
MGIT 0
960 0
, 0
and 0
solid 0
media 0
were 0
91.6 0
, 0
87.4 0
, 0
and 0
54.7 0
% 0
, 0
respectively 0
, 0
for 0
all 0
mycobacteria 0
; 0
the 0
recovery 0
rates 0
were 0
93.6 0
, 0
88.9 0
, 0
and 0
63.4 0
% 0
, 0
respectively 0
, 0
for 0
M. 0
tuberculosis 0
complex 0
alone 0
, 0
and 0
87.5 0
, 0
84.4 0
, 0
and 0
37.5 0
% 0
, 0
respectively 0
, 0
for 0
all 0
nontuberculous 0
mycobacteria 0
. 0

Cerebral 0
vasculitis 0
secondary 0
to 0
Crohn 0
's 0
disease 0
seems 0
to 0
be 0
a 0
very 0
rare 0
phenomenon 0
. 0

SELECTION 0
CRITERIA 0
: 0
Randomised 0
and 0
possibly 0
randomised 0
trials 0
using 0
acupuncture 0
to 0
treat 0
asthma 0
and 0
asthma 0
- 0
like 0
symptoms 0
. 0

SELECTION 0
CRITERIA 0
: 0
Randomised 0
trials 0
comparing 0
children 0
undergoing 0
systematic 0
therapy 0
focusing 0
on 0
the 0
family 0
in 0
conjunction 0
with 0
asthma 0
medication 0
, 0
with 0
children 0
taking 0
asthma 0
medication 0
only 0
. 0

To 0
test 0
the 0
hypothesis 0
that 0
progestin 0
- 0
mediated 0
increases 0
in 0
resting 0
core 0
temperature 0
and 0
the 0
core 0
temperature 0
threshold 0
for 0
sweating 0
onset 0
are 0
counteracted 0
by 0
estrogen 0
, 0
we 0
studied 0
eight 0
women 0
( 0
24 0
+/ 0
- 0
2 0
yr 0
) 0
at 0
27 0
degrees 0
C 0
rest 0
, 0
during 0
20 0
min 0
of 0
passive 0
heating 0
( 0
35 0
degrees 0
C 0
) 0
, 0
and 0
during 0
40 0
min 0
of 0
exercise 0
at 0
35 0
degrees 0
C 0
. 0

The 0
models 0
were 0
tested 0
by 0
studying 0
their 0
response 0
to 0
disturbances 0
of 0
the 0
afferent 0
signal 0
from 0
the 0
bladder 0
. 0

Our 0
data 0
show 0
also 0
that 0
phagocytic 0
killing 0
of 0
meningococci 0
is 0
probably 0
a 0
more 0
consistent 0
assay 0
than 0
antibody 0
titer 0
levels 0
for 0
antimeningococcal 0
immunity 0
, 0
especially 0
in 0
LCC 0
- 0
deficient 0
patients 0
. 0

These 0
studies 0
suggest 0
an 0
additional 0
component 0
or 0
cellular 0
environment 0
is 0
required 0
for 0
SPRK B-gene
activation 0
by 0
Cdc42 B-gene
. 0

M 0
. 0

Jkappa B-gene
DNA I-gene
- I-gene
binding I-gene
sites I-gene
were 0
not 0
required 0
for 0
this 0
activation 0
, 0
and 0
a 0
mutant B-gene
EBNA I-gene
- I-gene
3C I-gene
protein I-gene
unable 0
to 0
bind 0
Jkappa B-gene
activated 0
transcription 0
as 0
efficiently 0
as 0
wild B-gene
- I-gene
type I-gene
EBNA I-gene
- I-gene
3C I-gene
, 0
indicating 0
that 0
EBNA B-gene
- I-gene
3C I-gene
can 0
regulate 0
transcription 0
through 0
a 0
mechanism 0
that 0
is 0
independent 0
of 0
Jkappa B-gene
. 0

Thus 0
, 0
both 0
YY1 B-gene
and 0
CDP B-gene
appear 0
to 0
be 0
negative 0
regulators 0
of 0
the 0
differentiation 0
- 0
induced 0
HPV B-gene
- I-gene
6 I-gene
E1 I-gene
promoter I-gene
and 0
thereby 0
the 0
HPV 0
life 0
cycle 0
. 0

Sequential 0
cleavage 0
by 0
metallopeptidases B-gene
and 0
proteasomes 0
is 0
involved 0
in 0
processing 0
HIV B-gene
- I-gene
1 I-gene
ENV I-gene
epitope I-gene
for 0
endogenous 0
MHC B-gene
class I-gene
I I-gene
antigen I-gene
presentation 0
. 0

Cloning 0
and 0
characterization 0
of 0
human B-gene
Lnk I-gene
, 0
an 0
adaptor 0
protein 0
with 0
pleckstrin B-gene
homology 0
and 0
Src B-gene
homology I-gene
2 I-gene
domains I-gene
that 0
can 0
inhibit 0
T 0
cell 0
activation 0
. 0

Vancomycin 0
data 0
were 0
analyzed 0
according 0
to 0
a 0
one 0
- 0
compartment 0
open 0
model 0
with 0
use 0
of 0
NONMEM 0
population 0
pharmacokinetic 0
software 0
. 0

Finally 0
, 0
Cas B-gene
existed 0
mainly 0
in 0
cytosol 0
and 0
membrane 0
cytoskeleton 0
fractions 0
in 0
the 0
resting 0
state 0
, 0
and 0
remained 0
unchanged 0
during 0
platelet 0
aggregation 0
, 0
when 0
FAK B-gene
translocated 0
to 0
the 0
cytoskeletal 0
fraction 0
. 0

We 0
also 0
show 0
that 0
p65 B-gene
binds 0
to 0
these 0
targets 0
with 0
almost 0
equal 0
affinity 0
and 0
that 0
different 0
residues 0
have 0
variable 0
roles 0
in 0
binding 0
different 0
kappaB B-gene
targets I-gene
. 0

Transcriptional 0
regulation 0
of 0
the 0
yeast B-gene
PHO8 I-gene
promoter I-gene
in 0
comparison 0
to 0
the 0
coregulated 0
PHO5 B-gene
promoter I-gene
. 0

The 0
Siglecs B-gene
are 0
a 0
subfamily 0
of 0
I B-gene
- I-gene
type I-gene
lectins I-gene
( 0
immunoglobulin B-gene
superfamily I-gene
proteins I-gene
that 0
bind 0
sugars 0
) 0
that 0
specifically 0
recognize 0
sialic 0
acids 0
. 0

Our 0
data 0
provide 0
a 0
biochemical 0
explanation 0
for 0
the 0
similarity 0
in 0
phenotype 0
between 0
A 0
- 0
T 0
and 0
NBS 0
. 0

PATIENTS 0
OR 0
OTHER 0
PARTICIPANTS 0
: 0
Twenty 0
children 0
met 0
the 0
criteria 0
for 0
being 0
learning 0
disabled 0
. 0

Update 0
on 0
maternal 0
- 0
fetal 0
infections 0
by 0
hepatitis 0
C 0
, 0
HIV 0
and 0
cytomegalovirus 0

In 0
the 0
present 0
study 0
, 0
we 0
characterized 0
cis 0
- 0
elements 0
of 0
the 0
human B-gene
PCI I-gene
gene I-gene
required 0
for 0
expression 0
in 0
the 0
hepatoma 0
- 0
derived 0
cell 0
line 0
, 0
HepG2 0
cells 0
, 0
and 0
also 0
evaluated 0
rat B-gene
PCI I-gene
mRNA I-gene
expression 0
, 0
particularly 0
on 0
the 0
effect 0
of 0
androgen 0
in 0
rat 0
reproductive 0
tissues 0
. 0

In 0
the 0
study 0
on 0
PCI B-gene
mRNA I-gene
expression 0
in 0
the 0
reproductive 0
organs 0
, 0
we 0
first 0
cloned 0
rat B-gene
PCI I-gene
cDNA I-gene
and 0
then 0
evaluated 0
the 0
effect 0
of 0
androgen 0
on 0
the 0
PCI B-gene
mRNA I-gene
expression 0
. 0

To 0
illustrate 0
its 0
performance 0
, 0
measurements 0
of 0
photoluminescence 0
in 0
GaAs/AlGaAs 0
heterostructures 0
are 0
presented 0
. 0

The 0
stoichiometry 0
of 0
the 0
complexes 0
formed 0
with 0
the 0
dodeca 0
- 0
satellite 0
C 0
strand 0
suggests 0
that 0
, 0
in 0
DDP1 B-gene
, 0
the 0
15 0
consecutive 0
KH 0
domains 0
are 0
organized 0
such 0
that 0
they 0
define 0
two 0
nucleic 0
acid 0
binding 0
surfaces 0
. 0

Mutational 0
analysis 0
of 0
mammalian B-gene
translation I-gene
initiation I-gene
factor I-gene
5 I-gene
( 0
eIF5 B-gene
) 0
: 0
role 0
of 0
interaction 0
between 0
the 0
beta 0
subunit 0
of 0
eIF2 B-gene
and 0
eIF5 B-gene
in 0
eIF5 B-gene
function 0
in 0
vitro 0
and 0
in 0
vivo 0
. 0

Much 0
evidence 0
indicates 0
that 0
p38 B-gene
is 0
an 0
activator 0
of 0
MyoD B-gene
: 0
( 0
i 0
) 0
p38 B-gene
kinase I-gene
activity 0
is 0
required 0
for 0
the 0
expression 0
of 0
MyoD B-gene
- 0
responsive 0
genes 0
, 0
( 0
ii 0
) 0
enforced 0
induction 0
of 0
p38 B-gene
stimulates 0
the 0
transcriptional 0
activity 0
of 0
a 0
Gal4 B-gene
- 0
MyoD B-gene
fusion 0
protein 0
and 0
allows 0
efficient 0
activation 0
of 0
chromatin 0
- 0
integrated 0
reporters 0
by 0
MyoD B-gene
, 0
and 0
( 0
iii 0
) 0
MyoD B-gene
- 0
dependent 0
myogenic 0
conversion 0
is 0
reduced 0
in 0
mouse 0
embryonic 0
fibroblasts 0
derived 0
from 0
p38alpha B-gene
( I-gene
- I-gene
/ I-gene
- I-gene
) I-gene
embryos 0
. 0

This 0
activity 0
is 0
stimulated 0
by 0
complex 0
formation 0
with 0
the 0
other 0
eIF2B B-gene
subunits I-gene
. 0

Our 0
analysis 0
of 0
nonsense 0
mutations 0
indicates 0
that 0
the 0
C 0
terminus 0
of 0
eIF2Bepsilon B-gene
( I-gene
residues I-gene
518 I-gene
to I-gene
712 I-gene
) I-gene
is 0
required 0
for 0
both 0
catalytic 0
activity 0
and 0
interaction 0
with 0
eIF2 B-gene
. 0

In 0
contrast 0
, 0
mutations 0
affecting 0
the 0
other 0
two 0
Nim1p B-gene
- I-gene
related I-gene
kinases I-gene
in 0
S. 0
cerevisiae 0
, 0
Hsl1p B-gene
and 0
Kcc4p B-gene
, 0
produce 0
no 0
detectable 0
effect 0
on 0
septin B-gene
organization 0
. 0

CONCLUSIONS 0
: 0
Physiologic 0
pacing 0
provides 0
little 0
benefit 0
over 0
ventricular 0
pacing 0
for 0
the 0
prevention 0
of 0
stroke 0
or 0
death 0
due 0
to 0
cardiovascular 0
causes 0
. 0

Among 0
non 0
- 0
cirrhotics 0
, 0
lack 0
of 0
portal 0
vein 0
visualisation 0
had 0
a 0
90 0
% 0
sensitivity 0
, 0
88 0
% 0
specificity 0
, 0
94 0
% 0
negative 0
predictive 0
value 0
, 0
and 0
83 0
% 0
positive 0
predictive 0
value 0
in 0
the 0
diagnosis 0
of 0
pre 0
- 0
sinusoidal 0
portal 0
hypertension 0
. 0

D5/D1 B-gene
( I-gene
CT I-gene
) I-gene
or 0
D5/D1D B-gene
( I-gene
CT I-gene
) I-gene
tail 0
substitution 0
mutants 0
displayed 0
a 0
rank 0
order 0
of 0
potency 0
and 0
agonist 0
affinities 0
virtually 0
mimicking 0
wild B-gene
- I-gene
type I-gene
( I-gene
wt I-gene
) I-gene
D1 I-gene
receptors I-gene
, 0
as 0
indexed 0
by 0
both 0
ligand 0
binding 0
and 0
dopamine 0
- 0
stimulated 0
cAMP 0
accumulation 0
assays 0
, 0
and 0
, 0
similar 0
to 0
wt 0
D1 B-gene
receptors I-gene
, 0
did 0
not 0
exhibit 0
receptor 0
constitutive 0
activity 0
or 0
responsiveness 0
to 0
inverse 0
agonists 0
. 0

Modeling 0
also 0
revealed 0
a 0
very 0
hydrophobic 0
surface 0
due 0
to 0
the 0
absence 0
of 0
H12 0
, 0
exposing 0
residues 0
from 0
H3 0
, 0
loop 0
3 0
- 0
4 0
, 0
H4 0
, 0
and 0
H11 0
. 0

The 0
serine B-gene
- I-gene
threonine I-gene
kinase I-gene
gene I-gene
is 0
likely 0
functional 0
, 0
whereas 0
the 0
zinc 0
finger 0
motif 0
is 0
likely 0
nonfunctional 0
. 0

Stat B-gene
activation 0
in 0
response 0
to 0
GH B-gene
and 0
IL B-gene
- I-gene
6 I-gene
was 0
determined 0
by 0
reporter 0
gene 0
induction 0
. 0

HFA 0
134a 0
had 0
a 0
greater 0
tendency 0
to 0
take 0
up 0
moisture 0
from 0
the 0
environment 0
than 0
did 0
HFA 0
227 0
. 0

RESULTS 0
: 0
Abnormal 0
color 0
perception 0
was 0
found 0
in 0
32 0
% 0
of 0
the 0
epilepsy 0
patients 0
treated 0
with 0
vigabatrin 0
monotherapy 0
and 0
28 0
% 0
of 0
the 0
epilepsy 0
patients 0
treated 0
with 0
carbamazepine 0
monotherapy 0
. 0

In 0
the 0
SPP2 0
screening 0
test 0
, 0
a 0
few 0
plates 0
were 0
not 0
seen 0
in 0
both 0
groups 0
. 0

Mitogen B-gene
- I-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinase I-gene
phosphatase I-gene
- I-gene
3 I-gene
( 0
MKP B-gene
- I-gene
3 I-gene
) 0
is 0
a 0
dual 0
specificity 0
phosphatase 0
that 0
inactivates 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
( 0
ERK B-gene
) 0
MAP B-gene
kinases I-gene
. 0

Consistent 0
with 0
this 0
, 0
we 0
show 0
that 0
peptides 0
representing 0
docking 0
sites 0
within 0
the 0
target 0
substrates 0
Elk B-gene
- I-gene
1 I-gene
and 0
p90 B-gene
( 0
rsk B-gene
) 0
inhibit 0
ERK B-gene
- 0
dependent 0
activation 0
of 0
MKP B-gene
- I-gene
3 I-gene
. 0

HPLC 0
phosphopeptide 0
mapping 0
, 0
amino 0
acid 0
sequencing 0
, 0
and 0
site 0
- 0
directed 0
mutagenesis 0
determined 0
that 0
NCLK B-gene
phosphorylates 0
Ser 0
( 0
67 0
) 0
of 0
I B-gene
- I-gene
1 I-gene
. 0

When 0
the 0
entire 0
diet 0
consisted 0
of 0
SBF 0
, 0
voluntary 0
feed 0
intake 0
was 0
reduced 0
, 0
indicating 0
that 0
SBF 0
should 0
not 0
be 0
fed 0
to 0
ponies 0
as 0
the 0
sole 0
dietary 0
ingredient 0
. 0

Hepatitis 0
C 0
virus 0
infection 0
and 0
lymphoproliferative 0
diseases 0
in 0
France 0
: 0
a 0
national 0
study 0
. 0

The 0
immune 0
system 0
is 0
closely 0
integrated 0
with 0
the 0
neuroendocrine 0
system 0
, 0
and 0
infection 0
- 0
induced 0
increases 0
in 0
cytokines 0
such 0
as 0
IL B-gene
- I-gene
1 I-gene
, 0
IL B-gene
- I-gene
6 I-gene
and 0
TNF B-gene
have 0
numerous 0
effects 0
on 0
the 0
central 0
nervous 0
system 0
. 0

Interestingly 0
, 0
a 0
decreased 0
transcription 0
from 0
the 0
endogenous 0
c B-gene
- I-gene
Myb I-gene
promoter I-gene
was 0
observed 0
in 0
several 0
HTLV 0
- 0
I 0
transformed 0
T 0
- 0
cell 0
lines 0
. 0

H19 B-gene
and 0
Igf2 B-gene
monoallelic 0
expression 0
is 0
regulated 0
in 0
two 0
distinct 0
ways 0
by 0
a 0
shared 0
cis 0
acting 0
regulatory 0
region 0
upstream 0
of 0
H19 B-gene
. 0

C. 0
elegans 0
KLP B-gene
- I-gene
11/OSM I-gene
11/OSM I-gene
- I-gene
3/KAP I-gene
3/KAP I-gene
- I-gene
1 I-gene
: 0
orthologs 0
of 0
the 0
sea B-gene
urchin I-gene
kinesin I-gene
- I-gene
II I-gene
, 0
and 0
mouse 0
KIF3A/KIFB/KAP3 B-gene
KIF3A/KIFB/KAP3 I-gene

Flavonoids 0
from 0
Brosimum 0
acutifolium 0
. 0

BACKGROUND 0
: 0
Hepatic 0
encephalopathy 0
is 0
a 0
neuropsychiatric 0
syndrome 0
associated 0
with 0
acute 0
liver 0
failure 0
, 0
chronic 0
parenchymal 0
liver 0
disease 0
or 0
portal 0
systemic 0
anastomosis 0
. 0

These 0
natural 0
antisense 0
S B-gene
transcripts I-gene
co 0
- 0
exist 0
with 0
several 0
less 0
abundant 0
sense 0
S B-gene
transcripts I-gene
. 0

Nor 0
is 0
such 0
adjustment 0
possible 0
unless 0
one 0
posits 0
a 0
model 0
that 0
relates 0
the 0
missing 0
observations 0
to 0
other 0
observed 0
information 0
for 0
each 0
subject 0
- 0
models 0
that 0
are 0
inherently 0
untestable 0
. 0

However 0
, 0
the 0
presence 0
of 0
effacement 0
seems 0
to 0
be 0
a 0
more 0
reliable 0
and 0
practical 0
parameter 0
that 0
will 0
be 0
preferred 0
in 0
that 0
prediction 0
. 0

The 0
data 0
are 0
compatible 0
with 0
the 0
idea 0
that 0
YLL031c B-gene
transfers 0
the 0
ethanolaminephosphate 0
to 0
the 0
inner 0
alpha1 0
- 0
2 0
- 0
linked 0
mannose 0
, 0
i.e 0
. 0
the 0
group 0
that 0
links 0
the 0
GPI 0
lipid 0
anchor 0
to 0
proteins 0
, 0
whereas 0
Mcd4p B-gene
and 0
Gpi7p B-gene
transfer 0
ethanolaminephosphate 0
onto 0
the 0
alpha1 0
- 0
4 0
- 0
and 0
alpha1 0
- 0
6 0
- 0
linked 0
mannoses 0
of 0
the 0
GPI 0
anchor 0
, 0
respectively 0
. 0

The 0
C 0
terminus 0
of 0
TRBP B-gene
binds 0
to 0
CBP/p300 B-gene
and 0
CBP/p300 I-gene

The 0
patients 0
who 0
presented 0
with 0
mucocutaneous 0
disease 0
also 0
had 0
low 0
CD4+ B-gene
T 0
lymphocyte 0
counts 0
, 0
and 0
most 0
of 0
them 0
had 0
AIDS 0
defining 0
illnesses 0
. 0

Increased 0
dietary 0
energy 0
decreased 0
PAB 0
and 0
the 0
use 0
of 0
added 0
dietary 0
CO 0
rather 0
than 0
PF 0
decreased 0
PSHL 0
in 0
broiler 0
breeders 0
between 0
26 0
and 0
47 0
wk 0
of 0
age 0
. 0

The 0
gene 0
amplification 0
model 0
of 0
Coquelle 0
et 0
al 0
. 0

Hierarchy 0
of 0
protein B-gene
tyrosine I-gene
kinases I-gene
in 0
interleukin B-gene
- I-gene
2 I-gene
( 0
IL B-gene
- I-gene
2 I-gene
) 0
signaling 0
: 0
activation 0
of 0
syk B-gene
depends 0
on 0
Jak3 B-gene
; 0
however 0
, 0
neither 0
Syk B-gene
nor 0
Lck B-gene
is 0
required 0
for 0
IL B-gene
- I-gene
2 I-gene
- 0
mediated 0
STAT B-gene
activation 0
. 0

Immobilized 0
dimers 0
of 0
N B-gene
- I-gene
cadherin I-gene
- 0
Fc B-gene
chimera 0
mimic 0
cadherin 0
- 0
mediated 0
cell 0
contact 0
formation 0
: 0
contribution 0
of 0
both 0
outside 0
- 0
in 0
and 0
inside 0
- 0
out 0
signals 0
. 0

Although 0
the 0
OC B-gene
promoter I-gene
is 0
activated 0
in 0
a 0
C 0
terminus 0
dependent 0
manner 0
, 0
the 0
MDR B-gene
, 0
LTR 0
and 0
BSP B-gene
promoters I-gene
are 0
repressed 0
by 0
three 0
distinct 0
mechanisms 0
, 0
either 0
independent 0
of 0
or 0
involving 0
the 0
AML B-gene
C I-gene
terminus I-gene
, 0
or 0
requiring 0
only 0
the 0
conserved 0
C 0
- 0
terminal 0
pentapeptide 0
VWRPY 0
. 0

The 0
monoclonal 0
immunoglobulin B-gene
products 0
of 0
plasma 0
cell 0
neoplasm 0
can 0
give 0
rise 0
to 0
a 0
variety 0
of 0
manifestations 0
including 0
hyperviscosity 0
, 0
amyloidosis 0
, 0
cryoglobulinemia 0
, 0
neuropathy 0
, 0
and 0
renal 0
failure 0
. 0

Investigation 0
of 0
the 0
structural 0
basis 0
of 0
the 0
interaction 0
between 0
human B-gene
Igs I-gene
and 0
gp120 B-gene
shows 0
that 0
the 0
viral B-gene
gp120 I-gene
SAg I-gene
can 0
interact 0
only 0
with 0
a 0
subset 0
of 0
human B-gene
V I-gene
( I-gene
H I-gene
) I-gene
3+ I-gene
Igs I-gene
. 0

Double 0
- 0
blind 0
, 0
placebo 0
- 0
controlled 0
trial 0
. 0

Here 0
, 0
it 0
is 0
shown 0
that 0
TAFII250 B-gene
, 0
the 0
largest 0
subunit 0
of 0
TFIID B-gene
, 0
contains 0
two 0
tandem 0
bromodomain 0
modules 0
that 0
bind 0
selectively 0
to 0
multiply 0
acetylated 0
histone B-gene
H4 I-gene
peptides I-gene
. 0

Endostatin 0
treatment 0
for 0
10 0
minutes 0
or 0
24 0
hours 0
induced 0
tyrosine 0
phosphorylation 0
of 0
Shb B-gene
and 0
formation 0
of 0
multiprotein 0
complexes 0
. 0

Therefore 0
, 0
analogs 0
of 0
vitamin 0
D3 0
have 0
been 0
investigated 0
in 0
a 0
number 0
of 0
trials 0
showing 0
improvement 0
of 0
psoriasis 0
. 0

The 0
transcript 0
was 0
initially 0
identified 0
as 0
a 0
partial 0
cDNA 0
sequence 0
in 0
the 0
course 0
of 0
constructing 0
a 0
transcript 0
map 0
of 0
the 0
region 0
between 0
markers 0
D11S1765 B-gene
and 0
uteroglobin B-gene
known 0
to 0
encompass 0
the 0
gene 0
causing 0
Best 0
disease 0
. 0

The 0
real 0
challenge 0
for 0
the 0
future 0
will 0
be 0
the 0
management 0
of 0
patients 0
who 0
do 0
not 0
respond 0
to 0
first 0
- 0
line 0
treatment 0
. 0

Iodine 0
deficiency 0
disorders 0
in 0
Bangladesh 0
. 0

The 0
network 0
evolution 0
was 0
interpreted 0
by 0
an 0
approach 0
based 0
on 0
the 0
Flory 0
model 0
. 0

RESULTS 0
: 0
Soluble 0
CD23 B-gene
levels 0
were 0
significantly 0
higher 0
in 0
women 0
with 0
endometriosis 0
before 0
treatment 0
than 0
in 0
ten 0
normal 0
controls 0
. 0

CONCLUSION 0
: 0
Our 0
findings 0
suggest 0
that 0
endometriosis 0
increases 0
soluble 0
CD23 B-gene
levels 0
, 0
which 0
can 0
be 0
suppressed 0
with 0
either 0
danazol 0
or 0
leuprolide 0
acetate 0
injection 0
. 0

To 0
isolate 0
this 0
gene 0
, 0
a 0
P 0
- 0
1 0
artificial 0
chromosome 0
( 0
PAC 0
) 0
library 0
was 0
screened 0
with 0
a 0
full B-gene
length I-gene
UGT2B7 I-gene
probe 0
and 0
a 0
clone 0
of 0
approximately 0
100 0
kb 0
in 0
length 0
was 0
isolated 0
. 0

Age 0
> 0
/= 0
50 0
years 0
( 0
odds 0
ratio 0
[ 0
OR 0
] 0
, 0
14.1 0
) 0
, 0
BMI 0
> 0
/= 0
28 0
kg/m 0
( 0
2 0
) 0
( 0
OR 0
, 0
5.7 0
) 0
, 0
triglycerides 0
> 0
/= 0
1.7 0
mmol/L 0
( 0
OR 0
, 0
5 0
) 0
, 0
and 0
alanine B-gene
aminotransferase I-gene
( 0
ALT B-gene
) 0
> 0
/= 0
2N 0
( 0
OR 0
, 0
4.6 0
) 0
were 0
independently 0
associated 0
with 0
septal 0
fibrosis 0
. 0

Biologically 0
significant 0
amounts 0
of 0
platelet B-gene
activating I-gene
factor I-gene
were 0
eluted 0
from 0
the 0
sorbent 0
during 0
the 0
entire 0
treatment 0
time 0
. 0

However 0
, 0
the 0
elderly 0
group 0
showed 0
significantly 0
longer 0
mean 0
residence 0
times 0
( 0
MRTs 0
) 0
and 0
lower 0
plasma 0
clearance 0
of 0
lidocaine 0
during 0
the 0
period 0
compared 0
with 0
the 0
adult 0
group 0
( 0
P 0
< 0
.05 0
) 0
. 0

Here 0
, 0
we 0
show 0
that 0
the 0
zinc B-gene
finger I-gene
protein I-gene
Gis1 I-gene
acts 0
as 0
a 0
dosage 0
- 0
dependent 0
suppressor 0
of 0
the 0
rim15Delta B-gene
defect 0
in 0
nutrient 0
limitation 0
- 0
induced 0
transcriptional 0
derepression 0
of 0
SSA3 B-gene
. 0

The 0
so 0
- 0
called 0
`` B-gene
SH3 I-gene
'' I-gene
segment I-gene
of 0
the 0
linker 0
domain 0
, 0
in 0
contrast 0
, 0
shows 0
species 0
- 0
specific 0
sequence 0
identity 0
in 0
all 0
but 0
one 0
amino 0
acid 0
residues 0
in 0
both 0
factors 0
, 0
in 0
cattle 0
, 0
human 0
, 0
and 0
mouse 0
. 0

No 0
differences 0
in 0
total 0
cholesterol 0
levels 0
were 0
observed 0
between 0
mapuches 0
and 0
aymaras 0
. 0

Up 0
to 0
95 0
% 0
of 0
the 0
total 0
UV 0
exposure 0
received 0
is 0
in 0
the 0
UV 0
- 0
A 0
waveband 0
( 0
320 0
- 0
400 0
nm 0
) 0
. 0

To 0
begin 0
to 0
characterize 0
the 0
role 0
of 0
the 0
RNA 0
subunits 0
in 0
enzyme 0
function 0
and 0
substrate 0
specificity 0
, 0
we 0
swapped 0
two 0
hairpin 0
structures 0
( 0
MRP3 0
and 0
P3 0
) 0
between 0
RNase B-gene
MRP I-gene
RNA I-gene
and 0
RNase B-gene
P I-gene
RNA I-gene
of I-gene
S. I-gene
cerevisiae I-gene
. 0

Among 0
genes 0
induced 0
by 0
added 0
pMesogenin1 B-gene
is 0
Xwnt B-gene
- I-gene
8 I-gene
, 0
a 0
signaling 0
factor 0
that 0
induces 0
a 0
similar 0
repertoire 0
of 0
marker 0
genes 0
and 0
a 0
similar 0
cellular 0
phenotype 0
. 0

Accordingly 0
, 0
no 0
Ha B-gene
- I-gene
ras I-gene
codon I-gene
12 I-gene
mutations 0
are 0
found 0
in 0
the 0
EtNU 0
- 0
induced 0
mammary 0
tumors 0
. 0

False 0
positive 0
PET 0
FDG 0
corresponded 0
to 0
lung 0
infection 0
, 0
degenerative 0
bone 0
disease 0
, 0
and 0
reconstruction 0
artifact 0
. 0

Tumor 0
stages 0
were 0
IIB 0
( 0
T3 0
N0 0
) 0
in 0
52 0
% 0
, 0
IIIA 0
in 0
15 0
% 0
, 0
and 0
IIIB 0
in 0
27 0
% 0
of 0
patients 0
. 0

Similarly 0
, 0
comparison 0
of 0
percentage 0
reductions 0
of 0
heart 0
rate 0
at 0
supine 0
, 0
sitting 0
and 0
exercise 0
by 0
repeated 0
measure 0
analysis 0
showed 0
the 0
Malays 0
to 0
have 0
significantly 0
higher 0
change 0
compared 0
to 0
the 0
Chinese 0
( 0
p 0
= 0
0.040 0
) 0
. 0

Consistent 0
with 0
our 0
model 0
, 0
CTCF B-gene
binding 0
is 0
abolished 0
by 0
DNA 0
methylation 0
. 0

OBJECTIVE 0
: 0
To 0
determine 0
the 0
efficacy 0
and 0
safety 0
of 0
amphotericin 0
B 0
oral 0
suspension 0
( 0
ABOS 0
) 0
for 0
the 0
treatment 0
of 0
fluconazole 0
refractory 0
oral 0
candidiasis 0
in 0
persons 0
with 0
HIV 0
infection 0
. 0

Mucin B-gene
gene I-gene
expression 0
has 0
been 0
shown 0
to 0
be 0
altered 0
in 0
many 0
intestinal 0
diseases 0
and 0
especially 0
cancers 0
of 0
the 0
gastrointestinal 0
tract 0
. 0

The 0
experimentally 0
mapped 0
regions 0
of 0
RPB5 B-gene
involved 0
in 0
these 0
interactions 0
correspond 0
to 0
distinct 0
and 0
surface 0
- 0
exposed 0
alpha 0
- 0
helical 0
structures 0
. 0

The 0
model 0
indicates 0
that 0
a 0
0.076 0
% 0
reduction 0
in 0
cigarette 0
consumption 0
is 0
associated 0
with 0
the 0
availability 0
of 0
nicotine 0
patches 0
after 0
1992 0
. 0

Paper 0
alert 0
. 0

The 0
tryptase B-gene
locus I-gene
also 0
contains 0
at 0
least 0
four 0
tryptase B-gene
- I-gene
like I-gene
pseudogenes I-gene
, 0
including 0
mastin B-gene
, 0
a 0
gene 0
expressed 0
in 0
dogs 0
but 0
not 0
in 0
humans 0
. 0

The 0
cellular 0
part 0
of 0
the 0
third 0
chimeric 0
clone 0
shows 0
significant 0
homology 0
to 0
an 0
exon 0
of 0
the 0
human B-gene
tyrosine I-gene
phosphatase I-gene
1 I-gene
gene I-gene
, 0
although 0
oriented 0
in 0
the 0
antisense 0
direction 0
compared 0
to 0
the 0
adjacent 0
LTR 0
. 0

OBJECTIVE 0
: 0
This 0
study 0
was 0
conducted 0
to 0
assess 0
the 0
relative 0
roles 0
of 0
99mTc 0
- 0
sestamibi 0
scintimammography 0
and 0
sonography 0
in 0
the 0
evaluation 0
of 0
breast 0
lesions 0
that 0
are 0
indeterminate 0
or 0
suspicious 0
on 0
mammography 0
or 0
clinical 0
examination 0
. 0

Mutational 0
analyses 0
showed 0
that 0
in 0
- 0
frame 0
stop 0
codons 0
introduced 0
into 0
five 0
of 0
seven 0
RNA B-gene
2 I-gene
ORFs I-gene
did 0
not 0
affect 0
accumulation 0
of 0
progeny 0
LIYV B-gene
RNA I-gene
1 I-gene
or 0
RNA B-gene
2 I-gene
, 0
confirming 0
that 0
RNA B-gene
2 I-gene
does 0
not 0
encode 0
proteins 0
necessary 0
for 0
LIYV 0
RNA 0
replication 0
. 0

Role 0
of 0
NH 0
( 0
2 0
) 0
- 0
and 0
COOH 0
- 0
terminal 0
domains 0
of 0
the 0
P B-gene
protein I-gene
of 0
human 0
parainfluenza 0
virus 0
type 0
3 0
in 0
transcription 0
and 0
replication 0
. 0

Phosphorylation 0
of 0
tyrosine 0
residues 0
in 0
the 0
kinase 0
domain 0
and 0
juxtamembrane 0
region 0
regulates 0
the 0
biological 0
and 0
catalytic 0
activities 0
of 0
Eph B-gene
receptors I-gene
. 0

RESULTS 0
: 0
Fournier 0
's 0
gangrene 0
occurs 0
worldwide 0
. 0

Genomic 0
DNA 0
sequencing 0
in 0
the 0
vicinity 0
of 0
methylmalonyl B-gene
- I-gene
CoA I-gene
mutase I-gene
gene I-gene
( 0
mutAB B-gene
) 0
from 0
a 0
rifamycin 0
SV 0
- 0
producing 0
Amycolatopsis 0
mediterranei 0
U32 0
allowed 0
us 0
to 0
clone 0
, 0
sequence 0
, 0
and 0
identify 0
a 0
gene 0
encoding 0
a 0
novel 0
serine/threonine B-gene
protein I-gene
kinase I-gene
( 0
amk B-gene
) 0
. 0

IL B-gene
- I-gene
2 I-gene
is 0
accepted 0
as 0
a 0
standard 0
treatment 0
used 0
alone 0
, 0
or 0
in 0
combination 0
with 0
chemotherapy 0
or 0
biotherapy 0
in 0
the 0
management 0
of 0
metastatic 0
melanoma 0
and 0
metastatic 0
renal 0
cell 0
carcinoma 0
. 0

Moreover 0
, 0
expression 0
of 0
antisense B-gene
Ha I-gene
- I-gene
Ras I-gene
or 0
dominant B-gene
negative I-gene
Raf I-gene
- I-gene
1 I-gene
abrogated 0
the 0
mitogenic 0
effect 0
of 0
TGF B-gene
- I-gene
beta1 I-gene
in 0
TSU 0
- 0
Pr1 0
, 0
and 0
the 0
TGF B-gene
- I-gene
beta1 I-gene
inhibition 0
of 0
DU145 0
was 0
switched 0
to 0
stimulation 0
by 0
V12Ha B-gene
- I-gene
Ras I-gene
transfection 0
. 0

Taken 0
together 0
, 0
our 0
data 0
suggest 0
that 0
prostate 0
carcinomas 0
with 0
the 0
Ras/MAPK B-gene
pathway 0
activation 0
might 0
have 0
a 0
selective 0
growth 0
advantage 0
by 0
autocrine 0
Ras/MAPK I-gene

Vbeta B-gene
segments 0
are 0
appended 0
to 0
DJbeta B-gene
rearrangements 0
, 0
with 0
little 0
or 0
no 0
direct 0
Vbeta B-gene
to 0
Jbeta B-gene
joining 0
, 0
despite 0
12/23 0
compatibility 0
of 0
Vbeta B-gene
23 I-gene
- I-gene
RSSs I-gene
and 0
Jbeta12 B-gene
- I-gene
RSSs I-gene
. 0

For 0
oral 0
administration 0
, 0
AUC0 0
- 0
infinity 0
was 0
58.47 0
+/ 0
- 0
16.37 0
microg 0
x 0
h/ml 0
, 0
t1/2beta 0
was 0
18.39 0
+/ 0
- 0
0.06 0
hours 0
, 0
maximum 0
concentration 0
( 0
Cmax 0
) 0
was 0
2.12 0
+/ 0
- 0
00.51 0
microg/ml 0
, 0
time 0
to 0
Cmax 0
was 0
2.20 0
+/ 0
- 0
2.17 0
hours 0
, 0
mean 0
absorption 0
time 0
was 0
2.09 0
+/ 0
- 0
0.51 0
hours 0
, 0
and 0
bioavailability 0
was 0
42 0
+/ 0
- 0
0.42 0
% 0
. 0

In 0
experiment 0
2 0
, 0
no 0
difference 0
in 0
gastric 0
emptying 0
of 0
40 0
% 0
peptone 0
or 0
25 0
% 0
glucose 0
was 0
found 0
between 0
rats 0
receiving 0
TPN 0
and 0
those 0
receiving 0
intragastric 0
nutrition 0
for 0
10 0
to 0
12 0
days 0
. 0

In 0
contrast 0
, 0
H B-gene
- I-gene
NS I-gene
negative 0
regulation 0
operated 0
only 0
in 0
the 0
absence 0
of 0
Fur B-gene
. 0

Thus 0
, 0
SAG B-gene
appears 0
to 0
control 0
cell 0
cycle 0
progression 0
in 0
yeast 0
by 0
promoting 0
ubiquitination 0
and 0
degradation 0
of 0
cell 0
cycle 0
regulatory 0
proteins 0
. 0

E2F B-gene
- I-gene
1 I-gene
is 0
a 0
transcription 0
factor 0
that 0
regulates 0
cell 0
cycle 0
progression 0
into 0
S 0
- 0
phase 0
. 0

It 0
brings 0
about 0
fatigue 0
, 0
negative 0
moods 0
, 0
and 0
impaired 0
health 0
, 0
sleep 0
, 0
safety 0
, 0
and 0
working 0
capacity 0
. 0

This 0
demonstrates 0
that 0
treatment 0
of 0
the 0
graft 0
recipient 0
for 0
a 0
relatively 0
short 0
period 0
during 0
and 0
after 0
surgery 0
has 0
a 0
favorable 0
effect 0
on 0
the 0
survival 0
of 0
grafted 0
dopaminergic 0
neurons 0
. 0

The 0
relationships 0
among 0
blood 0
concentrations 0
of 0
thyroid 0
hormones 0
and 0
selenium 0
, 0
zinc 0
, 0
retinol 0
, 0
and 0
alpha 0
- 0
tocopherol 0
were 0
studied 0
in 0
44 0
healthy 0
Northern 0
Italian 0
oldest 0
- 0
old 0
subjects 0
( 0
age 0
range 0
, 0
90 0
- 0
107 0
yr 0
) 0
, 0
selected 0
by 0
the 0
criteria 0
of 0
the 0
SENIEUR 0
protocol 0
. 0

Chinese 0
Spring 0
( 0
CS 0
) 0
carrying 0
the 0
Q B-gene
gene I-gene
to 0
those 0
of 0
a 0
chromosome 0
deletion 0
line 0
of 0
CS 0
, 0
namely 0
, 0
q5 0
, 0
which 0
lacks 0
15 0
% 0
of 0
5AL 0
including 0
the 0
Q B-gene
gene I-gene
. 0

Investigations 0
using 0
hippocampal 0
slices 0
maintained 0
in 0
vitro 0
have 0
demonstrated 0
that 0
bursts 0
of 0
oscillatory 0
field 0
potentials 0
in 0
the 0
gamma 0
frequency 0
range 0
( 0
30 0
- 0
80 0
Hz 0
) 0
are 0
followed 0
by 0
a 0
slower 0
oscillation 0
in 0
the 0
beta 0
1 0
range 0
( 0
12 0
- 0
20 0
Hz 0
) 0
. 0

Karger 0
AG 0
, 0
Basel 0

During 0
surgery 0
bone 0
cysts 0
were 0
excised 0
and 0
filled 0
by 0
bone 0
grafts 0
. 0

Urinary 0
LTE4 0
increased 0
after 0
both 0
challenges 0
the 0
rise 0
being 0
higher 0
following 0
oral 0
as 0
compared 0
to 0
inhalation 0
provocation 0
( 0
p=0.0001 0
) 0
. 0

Basal 0
FVR 0
was 0
reduced 0
by 0
approximately 0
18 0
% 0
by 0
ERT 0
and 0
HRT 0
, 0
but 0
FVR 0
responses 0
to 0
noradrenaline 0
, 0
angiotensin B-gene
II I-gene
, 0
acetylcholine 0
and 0
nitroprusside 0
were 0
unaffected 0
. 0

Three 0
FGF B-gene
- I-gene
AS I-gene
cDNAs I-gene
were 0
isolated 0
; 0
the 0
full B-gene
- I-gene
length I-gene
FGF I-gene
- I-gene
AS I-gene
mRNA I-gene
and 0
two 0
alternative 0
splice 0
variants 0
lacking 0
exon 0
2 0
or 0
exons 0
2 0
and 0
3 0
of 0
the 0
FGF B-gene
- I-gene
AS I-gene
sequence I-gene
. 0

Taken 0
together 0
, 0
these 0
results 0
indicate 0
that 0
MAP B-gene
kinase I-gene
stimulates 0
the 0
hPL B-gene
- I-gene
B I-gene
enhancer I-gene
by 0
an 0
NF B-gene
- I-gene
IL I-gene
- I-gene
6 I-gene
- 0
dependent 0
pathway 0
. 0

Characterization 0
of 0
polymorphic 0
TNRs 0
in 0
novel 0
and 0
even 0
known 0
genes 0
expressed 0
in 0
human 0
spinal 0
cord 0
is 0
likely 0
to 0
help 0
in 0
the 0
identification 0
of 0
new 0
candidates 0
for 0
genes 0
involved 0
in 0
neurodegenerative 0
disorders 0
. 0

Finally 0
, 0
in 0
situ 0
RNA 0
hybridization 0
studies 0
revealed 0
a 0
very 0
specific 0
pattern 0
of 0
EphA8 B-gene
gene I-gene
expression 0
restricted 0
to 0
the 0
rostral 0
region 0
of 0
midbrain 0
tectum 0
during 0
embryonic 0
development 0
. 0

Transfection 0
of 0
cDNAs 0
for 0
three 0
mutant 0
enzymes 0
into 0
FPGS B-gene
- 0
null 0
Chinese 0
hamster 0
ovary 0
cells 0
restored 0
a 0
reduced 0
level 0
of 0
clonal 0
growth 0
, 0
whereas 0
a 0
T339I 0
mutant 0
supported 0
growth 0
at 0
a 0
level 0
comparable 0
to 0
that 0
of 0
the 0
wild 0
- 0
type 0
enzyme 0
. 0

SETTING 0
: 0
University 0
of 0
Paris 0
VII 0
hospital.Patient 0
( 0
s 0
) 0
: 0
Nine 0
women 0
had 0
embolization 0
for 0
symptomatic 0
myoma 0
, 0
with 0
12 0
pregnancies 0
observed 0
. 0

Improving 0
fissure 0
sealant 0
quality 0
: 0
mechanical 0
preparation 0
and 0
filling 0
level 0
. 0

The 0
Menopause 0
- 0
Rating 0
- 0
Scale 0
( 0
MRS 0
I 0
) 0
was 0
used 0
in 0
clinical 0
practice 0
since 0
1992 0
. 0

The 0
MRS 0
II 0
meets 0
a 0
high 0
methodological 0
standard 0
as 0
an 0
instrument 0
standardized 0
in 0
the 0
population 0
. 0

The 0
protein 0
encoded 0
by 0
the 0
fruA B-gene
transcript I-gene
is 0
well 0
conserved 0
with 0
the 0
D. B-gene
melanogaster I-gene
type I-gene
A I-gene
protein I-gene
, 0
particularly 0
the 0
BTB B-gene
protein I-gene
- 0
protein 0
- 0
binding 0
domain 0
, 0
which 0
is 0
encoded 0
by 0
exons 0
I 0
and 0
II 0
and 0
is 0
100 0
% 0
conserved 0
. 0

In 0
addition 0
, 0
the 0
mouse 0
ortholog 0
( 0
Mharp/Smarcal1 B-gene
) 0
was 0
cloned 0
, 0
and 0
the 0
Caenorhabditis 0
elegans 0
ortholog 0
( 0
Mharp/Smarcal1 I-gene

Sparfloxacin 0
and 0
clinafloxacin 0
were 0
evaluated 0
against 0
Enterococcus 0
faecium 0
SF2149 0
and 0
Enterococcus 0
faecalis 0
WH245 0
, 0
respectively 0
. 0

ECP B-gene
and 0
tryptase B-gene
levels 0
in 0
serum 0
were 0
measured 0
before 0
and 0
after 0
the 0
last 0
oral 0
challenge 0
. 0

Tolterodine 0
users 0
were 0
7.5 0
times 0
more 0
likely 0
to 0
have 0
received 0
another 0
spasmolytic 0
drug 0
( 0
RR 0
7.5 0
, 0
95 0
% 0
CI 0
4.8 0
to 0
11.9 0
) 0
. 0

For 0
an 0
unsupervised 0
program 0
, 0
the 0
costs 0
were 0
estimated 0
at 0
$ 0
311 0
for 0
the 0
first 0
year 0
and 0
$ 0
73 0
for 0
all 0
additional 0
years 0
. 0

The 0
presence 0
of 0
such 0
a 0
putative 0
RNA 0
- 0
binding 0
domain 0
suggests 0
a 0
mechanism 0
for 0
the 0
observed 0
autoregulation 0
of 0
bacteriophage 0
T4 B-gene
DNA I-gene
polymerase I-gene
synthesis 0
by 0
binding 0
to 0
its 0
own 0
mRNA 0
. 0

Deletion 0
and 0
mutational 0
analyses 0
revealed 0
two 0
positive 0
cis 0
- 0
regulatory 0
elements 0
in 0
this 0
region 0
that 0
are 0
essential 0
for 0
CSX1 B-gene
expression 0
in 0
cardiomyocytes 0
. 0

Functional 0
studies 0
which 0
introduced 0
a 0
mutation 0
in 0
the 0
AP2 B-gene
core I-gene
binding I-gene
region I-gene
as 0
well 0
as 0
cotransfection 0
experiments 0
using 0
an 0
AP2 B-gene
expression 0
vector 0
revealed 0
that 0
AP2 B-gene
exerts 0
a 0
repressive 0
role 0
on 0
the 0
HGF B-gene
gene I-gene
promoter I-gene
activity 0
. 0

Using 0
adenoviral 0
transfer 0
of 0
IkappaBalpha B-gene
( 0
IkappaBalpha B-gene
overexpression 0
) 0
, 0
the 0
production 0
of 0
TNF B-gene
- I-gene
alpha I-gene
induced 0
by 0
whole 0
GBS 0
was 0
inhibited 0
by 0
only 0
20 0
% 0
. 0

In 0
reconstitution 0
experiments 0
, 0
we 0
first 0
showed 0
that 0
expression 0
in 0
the 0
RAW 0
264.7 0
cell 0
line 0
of 0
C B-gene
- I-gene
terminal I-gene
Src I-gene
kinase I-gene
( 0
Csk B-gene
) 0
inhibited 0
and 0
that 0
of 0
a 0
membrane 0
- 0
anchored 0
, 0
gain 0
- 0
of 0
- 0
function 0
Csk B-gene
abolished 0
the 0
Fc B-gene
gamma I-gene
R I-gene
- 0
mediated 0
signaling 0
that 0
leads 0
to 0
phagocytosis 0
in 0
a 0
kinase 0
- 0
dependent 0
manner 0
. 0

In 0
contrast 0
, 0
c B-gene
- I-gene
Src I-gene
- I-gene
derived I-gene
construct I-gene
( 0
a B-gene
- I-gene
Src I-gene
) 0
, 0
that 0
was 0
excluded 0
from 0
detergent 0
- 0
resistant 0
membranes 0
, 0
could 0
not 0
restore 0
the 0
series 0
of 0
phagocytosis 0
signaling 0
. 0

The 0
delta B-gene
srb10 I-gene
mutation I-gene
also 0
influenced 0
on 0
the 0
transcript 0
levels 0
of 0
meiosis 0
- 0
inducing 0
genes 0
called 0
IME1 B-gene
and 0
IME2 B-gene
: 0
the 0
mutation 0
elevated 0
the 0
transcript 0
level 0
of 0
IME1 B-gene
but 0
reduced 0
that 0
of 0
IME2 B-gene
, 0
resulting 0
in 0
partial 0
defects 0
in 0
premeiotic 0
DNA 0
synthesis 0
and 0
meiosis 0
. 0

We 0
also 0
found 0
that 0
environmental 0
conditions 0
for 0
meiosis 0
finely 0
regulate 0
the 0
transcript 0
levels 0
of 0
KIN28 B-gene
and 0
CCL1 B-gene
, 0
such 0
that 0
nitrogen 0
starvation 0
first 0
elevates 0
them 0
but 0
subsequent 0
alkalization 0
of 0
medium 0
decreases 0
them 0
. 0

The 0
pJR 0
vectors 0
differ 0
among 0
them 0
in 0
: 0
( 0
a 0
) 0
the 0
selectable 0
marker 0
( 0
Saccharomyces 0
cerevisiae 0
LEU B-gene
2 I-gene
gene I-gene
, 0
which 0
complements 0
S. B-gene
pombe I-gene
leu1 I-gene
- I-gene
gene I-gene
and 0
S. 0
pombe 0
ura4+ B-gene
and 0
his3+ B-gene
genes I-gene
) 0
; 0
( 0
b 0
) 0
the 0
thiamine 0
- 0
repressible 0
nmt1 B-gene
promoter I-gene
( 0
3X 0
, 0
41X 0
and 0
81X 0
with 0
extremely 0
high 0
, 0
moderate 0
or 0
low 0
transcription 0
efficiency 0
, 0
respectively 0
) 0
; 0
and 0
( 0
c 0
) 0
the 0
multiple 0
cloning 0
site 0
( 0
two 0
multiple 0
cloning 0
sites 0
, 0
with 0
12 0
restriction 0
sites 0
each 0
) 0
. 0

( 0
GUT 0
) 0
Sera 0
of 0
30 0
montoux 0
negative 0
healthy 0
adults 0
( 0
age/sex 0
matched 0
) 0
were 0
taken 0
as 0
control 0
by 0
detecting 0
IgG B-gene
anti I-gene
bodies I-gene
to 0
A60 B-gene
antigen I-gene
. 0

The 0
effect 0
of 0
acute 0
, 0
mid 0
- 0
cervical 0
spinal 0
cord 0
lesions 0
on 0
neuronal 0
and 0
reflex 0
activity 0
evoked 0
by 0
the 0
noxious 0
visceral 0
stimulus 0
, 0
colorectal 0
distension 0
( 0
CRD 0
; 0
80 0
mmHg 0
, 0
20 0
s 0
) 0
, 0
was 0
determined 0
in 0
halothane 0
- 0
anesthetized 0
rats 0
. 0

Franz 0
Schubert 0
- 0
- 0
his 0
life 0
, 0
music 0
and 0
diseases 0

The 0
results 0
suggest 0
that 0
the 0
role 0
of 0
S. 0
argyrostoma 0
in 0
the 0
dissemination 0
of 0
Trichinella 0
larvae 0
in 0
nature 0
is 0
limited 0
in 0
comparison 0
to 0
the 0
role 0
played 0
by 0
mammals 0
with 0
scavenger 0
and 0
cannibalistic 0
behavior 0
. 0

The 0
equilibrium 0
dissociation 0
binding 0
constant 0
for 0
the 0
interaction 0
of 0
TnrA B-gene
with 0
the 0
nrgAB B-gene
promoter I-gene
fragment I-gene
was 0
7.7 0
nM 0
under 0
the 0
conditions 0
used 0
here 0
. 0

These 0
results 0
demonstrate 0
that 0
N 0
- 0
glycans 0
flanking 0
the 0
receptor 0
- 0
binding 0
site 0
of 0
the 0
HA B-gene
molecule I-gene
are 0
potent 0
regulators 0
of 0
influenza 0
virus 0
growth 0
, 0
with 0
the 0
glycan 0
at 0
Asn149 0
being 0
dominant 0
and 0
that 0
at 0
Asn123 0
being 0
less 0
effective 0
. 0

RESULTS 0
: 0
The 0
introduction 0
of 0
the 0
PAIP 0
resulted 0
in 0
a 0
significant 0
( 0
p 0
< 0
0.001 0
) 0
reduction 0
in 0
contaminating 0
WBCs 0
( 0
median 0
, 0
30,000 0
) 0
from 0
the 0
numbers 0
seen 0
with 0
FIP 0
( 0
median 0
, 0
2,300,000 0
) 0
while 0
maintaining 0
the 0
separation 0
efficacy 0
( 0
47 0
% 0
) 0
and 0
separation 0
time 0
. 0

All 0
were 0
tested 0
for 0
serum 0
ferritin B-gene
( 0
SF B-gene
) 0
, 0
hemoglobin B-gene
( 0
Hb B-gene
) 0
level 0
and 0
asked 0
for 0
detailed 0
histories 0
of 0
donations 0
and 0
iron 0
supplementation 0
. 0

Vascular B-gene
endothelial I-gene
growth I-gene
factor I-gene
( 0
VEGF B-gene
) 0
, 0
a 0
potent 0
agonist 0
secreted 0
by 0
virtually 0
all 0
cells 0
, 0
controls 0
migration 0
and 0
division 0
of 0
vascular 0
endothelial 0
cells 0
. 0

The 0
antioxidant 0
agent 0
pyrrolidine 0
dithiocarbamate 0
( 0
PDTC 0
) 0
has 0
been 0
shown 0
to 0
protect 0
endothelial 0
cells 0
( 0
EC 0
) 0
from 0
pro 0
- 0
inflammatory 0
- 0
induced 0
and 0
pro 0
- 0
oxidant 0
- 0
induced 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
. 0

We 0
further 0
studied 0
the 0
effects 0
of 0
SIE B-gene
- I-gene
1 I-gene
hypermethylation 0
on 0
p21WAF1 B-gene
induction 0
by 0
STAT B-gene
activation 0
. 0

Phd B-gene
antibody 0
- 0
immunoreactive 0
peptides 0
are 0
seen 0
in 0
light 0
- 0
adapted 0
mouse 0
retinal 0
cytosolic 0
and 0
nuclear 0
extracts 0
. 0

In 0
the 0
pRb B-gene
( I-gene
- I-gene
) I-gene
SAOS 0
- 0
2 0
cell 0
line 0
transiently 0
transfected 0
with 0
a 0
reporter 0
plasmid 0
containing 0
six 0
tal B-gene
- I-gene
1 I-gene
binding I-gene
site I-gene
, 0
pRb B-gene
enhances 0
the 0
transcriptional 0
activity 0
of 0
tal B-gene
- I-gene
1 I-gene
- 0
E12 B-gene
- 0
Lmo2 B-gene
and 0
tal B-gene
- I-gene
1 I-gene
- 0
E12 B-gene
- 0
Lmo2 B-gene
- 0
Ldb1 B-gene
complexes 0
but 0
not 0
that 0
of 0
a 0
tal B-gene
- I-gene
1 I-gene
- 0
E12 B-gene
heterodimer 0
. 0

This 0
effect 0
was 0
not 0
seen 0
in 0
conjunction 0
with 0
oxycodone 0
, 0
a 0
morphine B-gene
- I-gene
like I-gene
mu I-gene
- I-gene
receptor I-gene
agonist 0
. 0

In 0
contrast 0
to 0
the 0
morphological 0
criteria 0
, 0
the 0
few 0
data 0
available 0
from 0
recent 0
studies 0
at 0
the 0
genetic 0
level 0
have 0
suggested 0
that 0
EPVs 0
infecting 0
different 0
insect 0
orders 0
are 0
phylogenetically 0
distant 0
. 0

Neurofibromatosis 0
of 0
the 0
breast 0
in 0
a 0
patient 0
with 0
Morbus 0
von 0
Recklinghausen 0

In 0
the 0
premating 0
period 0
male 0
rate 0
of 0
aggression 0
was 0
not 0
significantly 0
correlated 0
with 0
testosterone 0
level 0
. 0

These 0
results 0
support 0
the 0
hypothesis 0
that 0
in 0
the 0
presence 0
of 0
tryptophan 0
the 0
ribosome 0
translating 0
tnaC B-gene
blocks 0
Rho B-gene
's 0
access 0
to 0
the 0
boxA B-gene
and 0
rut B-gene
sites I-gene
, 0
thereby 0
preventing 0
transcription 0
termination 0
. 0

In 0
situ 0
hybridization 0
with 0
the 0
antisense 0
RNA 0
probes 0
further 0
supported 0
the 0
expression 0
changes 0
of 0
these 0
six 0
clones 0
and 0
localized 0
the 0
changes 0
in 0
multiple 0
germ 0
cell 0
stages 0
as 0
well 0
as 0
other 0
cell 0
types 0
( 0
Sertoli 0
, 0
interstitial 0
and 0
peritubular 0
cells 0
) 0
. 0

The 0
administration 0
of 0
the 0
GnRH B-gene
agonist 0
reduced 0
the 0
bone 0
mineral 0
density 0
in 0
the 0
whole 0
femur 0
to 0
91.0 0
% 0
of 0
that 0
in 0
the 0
control 0
group 0
. 0

Prevention 0
, 0
differential 0
diagnosis 0
and 0
therapy 0
of 0
travel 0
diarrhea 0

This 0
study 0
shows 0
that 0
C/EBPbeta B-gene
is 0
the 0
predominant 0
C/EBP B-gene
isoform I-gene
found 0
in 0
activated 0
stellate 0
cells 0
and 0
that 0
increased 0
C/EBPbeta B-gene
protein I-gene
and 0
C/EBPbeta B-gene
binding 0
to 0
a 0
proximal 0
C/EBP B-gene
binding I-gene
site I-gene
in 0
the 0
promoter 0
mediates 0
the 0
activating 0
effect 0
of 0
acetaldehyde 0
. 0

Mutation 0
analysis 0
demonstrates 0
that 0
the 0
motif 0
TCCCCT 0
is 0
critical 0
for 0
PyRo1 B-gene
interaction 0
. 0

As 0
with 0
VP16 B-gene
, 0
the 0
transactivation 0
function 0
of 0
Luman B-gene
is 0
also 0
regulated 0
by 0
HCF B-gene
. 0

After 0
two 0
successive 0
rounds 0
of 0
selection 0
by 0
focus 0
formation 0
assay 0
, 0
a 0
transforming 0
ribozyme 0
( 0
Rz007 B-gene
) 0
was 0
identified 0
. 0

G. 0
, 0
and 0
Hyde 0
, 0
C 0
. 0

Our 0
results 0
suggest 0
that 0
proteasome 0
inhibition 0
leads 0
to 0
upregulation 0
of 0
specific 0
members 0
of 0
transcription 0
factor 0
families 0
controlling 0
cellular 0
stress 0
response 0
and 0
proliferation 0
. 0

The 0
ATR 0
- 0
X 0
syndrome 0
results 0
from 0
mutations 0
of 0
the 0
XH2 B-gene
gene I-gene
, 0
located 0
on 0
the 0
X 0
chromosome 0
( 0
Xq13.3 0
) 0
and 0
coding 0
for 0
a 0
transacting 0
factor 0
which 0
regulates 0
gene 0
expression 0
. 0

AIMS 0
: 0
To 0
evaluate 0
the 0
role 0
of 0
environmental 0
intra 0
- 0
uterine 0
factors 0
in 0
determining 0
the 0
birthweights 0
of 0
twins 0
with 0
increased 0
susceptibility 0
to 0
diabetes 0
and 0
discordant 0
for 0
abnormal 0
responses 0
to 0
the 0
oral 0
glucose 0
tolerance 0
test 0
( 0
OGTT 0
) 0
and 0
verify 0
the 0
possible 0
association 0
of 0
within 0
- 0
pair 0
birthweight 0
differences 0
and 0
metabolic 0
abnormalities 0
in 0
adult 0
life 0
. 0

In 0
NASCIS 0
III 0
, 0
a 0
randomization 0
imbalance 0
occurred 0
that 0
allocated 0
a 0
disproportionate 0
number 0
of 0
patients 0
with 0
no 0
motor 0
deficit 0
( 0
and 0
therefore 0
no 0
chance 0
for 0
recovery 0
) 0
to 0
the 0
lower 0
dose 0
control 0
group 0
. 0

Penicillin B-gene
acylase I-gene
( 0
PA B-gene
) 0
from 0
Escherichia 0
coli 0
ATCC11105 0
is 0
a 0
periplasmic 0
heterodimer 0
consisting 0
of 0
a 0
24 0
kDa 0
small 0
subunit 0
and 0
a 0
65 0
kDa 0
large 0
subunit 0
. 0

A 0
murine 0
expressed 0
sequence 0
tag 0
( 0
EST 0
) 0
showing 0
homology 0
with 0
erythropoietin B-gene
receptor I-gene
( 0
EPOR B-gene
) 0
was 0
identified 0
in 0
the 0
EST 0
database 0
. 0

When 0
the 0
LCx 0
was 0
partially 0
occluded 0
, 0
mild 0
PM 0
- 0
induced 0
tachycardia 0
resulted 0
in 0
decreased 0
AoP 0
( 0
P=0.045 0
) 0
as 0
well 0
as 0
in 0
decreased 0
SV 0
( 0
P=0.048 0
) 0
; 0
the 0
LVEDP 0
remained 0
high 0
( 0
P=0.002 0
) 0
. 0

Activation 0
of 0
nuclear B-gene
factor I-gene
( I-gene
NF I-gene
) I-gene
- I-gene
kappaB I-gene
and 0
subsequent 0
proinflammatory 0
gene 0
expression 0
in 0
human 0
airway 0
epithelial 0
cells 0
can 0
be 0
evoked 0
by 0
oxidative 0
stress 0
. 0

GAP 0
JUNCTIONS 0
IN 0
THE 0
BRAIN 0
: 0
PREFACE 0
. 0

We 0
have 0
isolated 0
and 0
functionally 0
characterized 0
the 0
mouse 0
gene 0
for 0
the 0
C2 0
subunit 0
of 0
the 0
20S B-gene
proteasome I-gene
. 0

Furthermore 0
, 0
as 0
in 0
the 0
human 0
gene 0
, 0
the 0
3 0
' 0
end 0
of 0
the 0
Cacna1f B-gene
gene I-gene
maps 0
within 0
5 0
kb 0
of 0
the 0
5 0
' 0
end 0
of 0
the 0
mouse B-gene
synaptophysin I-gene
gene I-gene
in 0
a 0
region 0
orthologous 0
to 0
Xp11.23 0
. 0

With 0
the 0
human B-gene
Rhotekin I-gene
cDNA I-gene
as 0
a 0
probe 0
, 0
Northern 0
hybridization 0
revealed 0
that 0
a 0
4.0 0
- 0
kb 0
transcript 0
was 0
expressed 0
at 0
a 0
high 0
level 0
in 0
prostate 0
and 0
at 0
a 0
middle 0
level 0
in 0
13 0
of 0
16 0
tissues 0
examined 0
, 0
but 0
it 0
can 0
not 0
be 0
detected 0
in 0
liver 0
and 0
lung 0
tissues 0
. 0

Similarly 0
, 0
co 0
- 0
expression 0
of 0
a 0
dominant 0
- 0
negative 0
mutant 0
of 0
p38alpha B-gene
, 0
but 0
not 0
of 0
ERK1 B-gene
, 0
ERK2 B-gene
, 0
JNK1 B-gene
, 0
or 0
JNK2 B-gene
, 0
reduces 0
basal 0
and 0
cadmium 0
- 0
induced 0
pE1 B-gene
- I-gene
luc I-gene
activity 0
. 0

BACKGROUND 0
: 0
Gamma 0
knife 0
radiosurgery 0
( 0
GKR 0
) 0
is 0
a 0
safe 0
and 0
effective 0
alternative 0
to 0
surgery 0
for 0
intracranial 0
lesions 0
. 0

In 0
hemodialyzed 0
patients 0
( 0
Epo B-gene
and 0
Non 0
- 0
Epo B-gene
group 0
) 0
leptin B-gene
levels 0
were 0
significantly 0
higher 0
when 0
compared 0
to 0
CAPD 0
patients 0
( 0
Epo B-gene
and 0
Non 0
- 0
Epo B-gene
group 0
, 0
respectively 0
) 0
. 0

It 0
is 0
mainly 0
transcribed 0
in 0
neural 0
structures 0
and 0
in 0
developing 0
organs 0
characterized 0
by 0
epithelial 0
- 0
mesenchymal 0
interactions 0
. 0

CONCLUSION 0
: 0
The 0
alpha2 0
- 0
adrenergic 0
antagonist 0
idazoxan 0
increases 0
glucose 0
- 0
induced 0
sympathetic 0
activity 0
but 0
not 0
energy 0
expenditure 0
in 0
obese 0
subjects 0
. 0

ID 0
- 0
PaGIA 0
diphtheria B-gene
toxin I-gene
polymer 0
particle 0
diagnostic 0
agent 0
manufactured 0
by 0
DiaMed 0
AG 0
, 0
Switzerland 0
, 0
was 0
tried 0
at 0
bacteriological 0
laboratory 0
of 0
Institute 0
of 0
Childhood 0
Infections 0
in 0
St 0
. 0

Next 0
, 0
we 0
show 0
that 0
two 0
EMS 0
- 0
induced 0
mutations 0
, 0
previously 0
shown 0
to 0
interact 0
genetically 0
with 0
zipper 0
( 0
Ebr B-gene
) 0
, 0
disrupt 0
the 0
RhoA B-gene
locus I-gene
. 0

Therefore 0
, 0
the 0
results 0
indicate 0
that 0
repeated 0
exposure 0
to 0
amphetamine 0
or 0
apomorphine 0
overcomes 0
the 0
context 0
- 0
dependent 0
component 0
of 0
sensitization 0
of 0
amphetamine 0
- 0
or 0
apomorphine 0
- 0
induced 0
stereotyped 0
behavior 0
. 0

Testing 0
for 0
serum B-gene
IgM I-gene
binding 0
to 0
GM1 0
ganglioside 0
in 0
clinical 0
practice 0
. 0

Objective 0
responses 0
also 0
occurred 0
in 0
studies 0
that 0
explored 0
sequential 0
use 0
of 0
exemestane 0
after 0
failure 0
of 0
aminoglutethimide 0
( 0
26 0
% 0
with 0
exemestane 0
200 0
mg/day 0
) 0
or 0
other 0
nonsteroidal 0
aromatase B-gene
inhibitors 0
( 0
6.6 0
% 0
with 0
exemestane 0
25 0
mg/day 0
) 0
. 0

Topics 0
reviewed 0
here 0
include 0
: 0
data 0
supporting 0
the 0
association 0
of 0
myositis 0
with 0
cancer 0
and 0
the 0
appropriate 0
evaluations 0
for 0
malignancy 0
in 0
a 0
myositis 0
patient 0
; 0
an 0
approach 0
to 0
the 0
assessment 0
of 0
patients 0
with 0
dermatomyositis 0
sine 0
myositis 0
; 0
the 0
usefulness 0
of 0
the 0
clinicopathological 0
and 0
serological 0
classifications 0
; 0
a 0
discussion 0
of 0
whether 0
childhood 0
and 0
adult 0
myositis 0
are 0
the 0
same 0
or 0
different 0
entities 0
; 0
a 0
review 0
of 0
those 0
prognostic 0
factors 0
to 0
consider 0
in 0
the 0
clinical 0
management 0
of 0
myositis 0
patients 0
; 0
current 0
approaches 0
and 0
their 0
limitations 0
for 0
assessing 0
disease 0
activity 0
and 0
damage 0
. 0

The 0
science 0
of 0
tissue 0
engineering 0
. 0

Endonuclease B-gene
III I-gene
( 0
Nth B-gene
) 0
of 0
Escherichia 0
coli 0
is 0
a 0
DNA B-gene
glycosylase I-gene
essential 0
for 0
the 0
removal 0
of 0
oxidised 0
pyrimidine 0
base 0
residues 0
from 0
DNA 0
. 0

The 0
duration 0
of 0
reactive 0
hyperemia 0
decreased 0
with 0
aging 0
, 0
but 0
the 0
difference 0
between 0
males 0
and 0
females 0
was 0
not 0
significant 0
at 0
any 0
age 0
. 0

Acquired 0
bile 0
duct 0
blockage 0
: 0
entry 0
of 0
hepatobiliary 0
agent 0
into 0
an 0
intrahepatic 0
abscess 0
. 0

Furthermore 0
, 0
this 0
study 0
looks 0
at 0
the 0
impact 0
of 0
synthesis 0
conditions 0
on 0
block 0
length 0
and 0
crystallinity 0
, 0
and 0
the 0
impact 0
of 0
the 0
blocking 0
on 0
both 0
, 0
crystallinity 0
and 0
solubility 0
of 0
the 0
polymers 0
. 0

However 0
, 0
little 0
was 0
understood 0
about 0
the 0
normal 0
function 0
of 0
CREB B-gene
- I-gene
2 I-gene
in 0
mammalian 0
development 0
or 0
organ 0
physiology 0
. 0

The 0
outer 0
diameter 0
and 0
the 0
thickness 0
of 0
the 0
rotor 0
are 0
60 0
mm 0
and 0
8 0
mm 0
, 0
respectively 0
. 0

Both 0
the 0
MVBF 0
and 0
the 0
maximum 0
EMG 0
activity 0
in 0
the 0
right 0
masseter 0
and 0
the 0
left 0
anterior 0
temporalis 0
muscles 0
were 0
significantly 0
decreased 0
during 0
muscle 0
pain 0
when 0
the 0
subjects 0
bit 0
on 0
the 0
painful 0
side 0
. 0

CONCLUSIONS 0
: 0
There 0
is 0
a 0
relation 0
in 0
the 0
topography 0
of 0
some 0
visual 0
field 0
areas 0
assessed 0
by 0
SWAP 0
and 0
the 0
inferotemporal 0
neuroretinal 0
rim 0
area 0
, 0
which 0
may 0
play 0
a 0
role 0
in 0
the 0
diagnosis 0
and 0
follow 0
- 0
up 0
of 0
suspected 0
glaucoma 0
. 0

The 0
total 0
alkaloids 0
contained 0
in 0
the 0
peel 0
of 0
Atzimba 0
, 0
Lopez 0
, 0
Marciana 0
, 0
Montsama 0
, 0
Murca 0
, 0
and 0
Puebla 0
was 0
lower 0
than 0
the 0
limits 0
recommended 0
for 0
food 0
safety 0
. 0

The 0
detection 0
success 0
rate 0
was 0
determined 0
for 0
different 0
markers 0
using 0
this 0
MEK B-gene
. 0

Herein 0
, 0
we 0
show 0
that 0
Smad3 B-gene
physically 0
interacts 0
with 0
the 0
HMG B-gene
box 0
domain 0
of 0
LEF1 B-gene
and 0
that 0
TGFbeta B-gene
and 0
Wnt B-gene
pathways 0
synergize 0
to 0
activate 0
transcription 0
of 0
the 0
Xenopus 0
homeobox 0
gene 0
twin B-gene
( 0
Xtwn B-gene
) 0
. 0

The 0
transmembrane 0
topology 0
of 0
Na 0
( 0
+ 0
) 0
/H 0
( 0
+ 0
) 0
exchanger 0
NHE3 B-gene
has 0
been 0
studied 0
using 0
in 0
vitro 0
transcription/translation 0
of 0
two 0
types 0
of 0
fusion 0
vectors 0
designed 0
to 0
test 0
membrane 0
insertion 0
properties 0
of 0
cDNA 0
sequences 0
encoding 0
putative 0
NHE3 B-gene
membrane 0
spanning 0
domains 0
( 0
msds 0
) 0
. 0

ACE B-gene
- I-gene
2 I-gene
has 0
a 0
hydrophobic 0
C 0
terminus 0
of 0
H 0
type 0
. 0

Members 0
of 0
the 0
titin/myosin B-gene
titin/myosin I-gene
light I-gene
chain I-gene
kinase I-gene
family 0
play 0
an 0
essential 0
role 0
in 0
the 0
organization 0
of 0
the 0
actin/myosin B-gene
cytoskeleton 0
, 0
especially 0
in 0
sarcomere 0
assembly 0
and 0
function 0
. 0

We 0
concluded 0
that 0
activation 0
of 0
c B-gene
- I-gene
fosER I-gene
mediated 0
transcriptional 0
inhibition 0
of 0
p21 B-gene
( 0
Cip1/WAF1 B-gene
) 0
through 0
a 0
previously 0
uncharacterized 0
Cip1/WAF1 I-gene

Furthermore 0
, 0
a 0
pTyr317 B-gene
Shc I-gene
phosphopeptide I-gene
selectively 0
recognized 0
Grb2 B-gene
, 0
Sos1 B-gene
, 0
SHIP B-gene
, 0
and 0
the 0
p85 B-gene
subunit I-gene
of 0
phosphatidylinositol B-gene
3 I-gene
' I-gene
kinase I-gene
from 0
mast 0
cells 0
, 0
as 0
characterized 0
by 0
mass 0
spectrometry 0
. 0

Although 0
increased 0
expression 0
of 0
the 0
HMG B-gene
- I-gene
I/Y I-gene
proteins I-gene
is 0
associated 0
with 0
cellular 0
proliferation 0
, 0
neoplastic 0
transformation 0
, 0
and 0
several 0
human 0
cancers 0
, 0
the 0
role 0
of 0
these 0
proteins 0
in 0
the 0
pathogenesis 0
of 0
malignancy 0
remains 0
unclear 0
. 0

The 0
naltrexone/lofexidine 0
combination 0
was 0
associated 0
with 0
a 0
more 0
rapid 0
resolution 0
of 0
the 0
opiate 0
withdrawal 0
syndrome 0
than 0
a 0
7 0
- 0
day 0
lofexidine 0
- 0
only 0
treatment 0
schedule 0
, 0
without 0
substantial 0
increases 0
in 0
withdrawal 0
symptoms 0
or 0
hypotensive 0
side 0
- 0
effects 0
. 0

The 0
first 0
symptoms 0
of 0
enzootic 0
calcinosis 0
were 0
noted 0
in 0
March 0
1998 0
, 0
when 0
some 0
of 0
the 0
cows 0
developed 0
locomotor 0
abnormalities 0
. 0

Screening 0
, 0
counseling 0
, 0
and 0
treatment 0
for 0
alcohol 0
and 0
illicit 0
drug 0
use 0
should 0
be 0
essential 0
components 0
in 0
comprehensive 0
HBP 0
care 0
. 0

Transcriptional 0
regulation 0
of 0
the 0
mouse B-gene
cytosolic I-gene
chaperonin I-gene
subunit I-gene
gene I-gene
Ccta/t B-gene
- I-gene
complex I-gene
polypeptide I-gene
1 I-gene
by 0
selenocysteine B-gene
tRNA I-gene
gene I-gene
transcription I-gene
activating I-gene
factor I-gene
family I-gene
zinc I-gene
finger I-gene
proteins I-gene
. 0

The 0
unfolded 0
protein 0
response 0
regulates 0
multiple 0
aspects 0
of 0
secretory 0
and 0
membrane 0
protein 0
biogenesis 0
and 0
endoplasmic 0
reticulum 0
quality 0
control 0
. 0

PNRC B-gene
: 0
a 0
proline 0
- 0
rich 0
nuclear 0
receptor 0
coregulatory 0
protein 0
that 0
modulates 0
transcriptional 0
activation 0
of 0
multiple 0
nuclear 0
receptors 0
including 0
orphan 0
receptors 0
SF1 B-gene
( 0
steroidogenic B-gene
factor I-gene
1 I-gene
) 0
and 0
ERRalpha1 B-gene
( 0
estrogen B-gene
related I-gene
receptor I-gene
alpha I-gene
- I-gene
1 I-gene
) 0
. 0

Studies 0
using 0
a 0
reporter 0
plasmid 0
with 0
a 0
functionally 0
disrupted 0
sterol 0
- 0
responsive 0
element 0
( 0
SRE 0
) 0
- 0
1 0
revealed 0
a 0
reduced 0
stimulatory 0
response 0
to 0
IL B-gene
- I-gene
6 I-gene
. 0

However 0
, 0
there 0
is 0
still 0
a 0
subset 0
of 0
tumors 0
that 0
displayed 0
no 0
changes 0
in 0
these 0
genes 0
. 0

We 0
have 0
shown 0
that 0
the 0
epidural 0
( 0
EPI 0
) 0
delivery 0
of 0
morphine 0
encapsulated 0
in 0
multivesicular 0
liposomes 0
( 0
DepoFoam 0
drug 0
delivery 0
system 0
) 0
produces 0
a 0
sustained 0
clearance 0
of 0
morphine 0
and 0
a 0
prolonged 0
analgesia 0
. 0

Following 0
EPI 0
- 0
C0401 0
, 0
but 0
not 0
saline 0
or 0
DepoFoam 0
vehicle 0
, 0
there 0
were 0
transient 0
( 0
< 0
72 0
hr 0
) 0
decreases 0
in 0
food 0
consumption 0
, 0
arousal 0
, 0
hindlimb 0
muscle 0
tone 0
, 0
and 0
body 0
temperature 0
. 0

Bailey 0
Instruments 0
and 0
Owen 0
Mumford 0
filaments 0
were 0
the 0
most 0
accurate 0
with 0
100 0
% 0
buckling 0
within 0
+/ 0
- 0
1.0 0
g 0
of 0
10 0
g 0
. 0

PARTICIPANTS 0
: 0
Convenience 0
sample 0
of 0
ambulatory 0
outpatients 0
with 0
hereditary 0
motor 0
and 0
sensory 0
neuropathy 0
, 0
type 0
I 0
( 0
n 0
= 0
9 0
) 0
, 0
myotonic 0
muscular 0
dystrophy 0
( 0
n 0
= 0
10 0
) 0
, 0
and 0
able 0
- 0
bodied 0
controls 0
( 0
n 0
= 0
11 0
) 0
. 0

The 0
effect 0
of 0
water 0
deprivation 0
for 0
19 0
h 0
on 0
renal 0
Na 0
excretion 0
of 0
conscious 0
adrenalectomized 0
( 0
ADX 0
) 0
sheep 0
maintained 0
on 0
a 0
constant 0
intravenous 0
infusion 0
of 0
aldosterone 0
and 0
cortisol 0
( 0
ADX 0
- 0
constant 0
steroid 0
sheep 0
) 0
was 0
investigated 0
. 0

Neither 0
is 0
it 0
a 0
major 0
cause 0
of 0
rehydration 0
- 0
induced 0
renal 0
Na 0
retention 0
. 0

CONCLUSION 0
: 0
Rheumatic 0
fever 0
in 0
the 0
Nazareth 0
area 0
is 0
still 0
manifest 0
. 0

Antithrombin B-gene
III I-gene
deficiency 0
: 0
when 0
substitute 0
, 0
when 0
heparin 0
? 0
Thrombosis 0
ABC 0
, 0
3 0
: 0
The 0
role 0
of 0
antithrombin B-gene
III I-gene

Specific 0
class B-gene
I I-gene
and I-gene
II I-gene
histone I-gene
deacetylases I-gene
( 0
HDACs B-gene
) 0
interact 0
in 0
vivo 0
with 0
BCoR B-gene
, 0
suggesting 0
that 0
BCoR B-gene
may 0
functionally 0
link 0
these 0
two 0
classes 0
of 0
HDACs B-gene
. 0

This 0
is 0
the 0
first 0
example 0
of 0
a 0
eukaryotic 0
transcription 0
factor 0
complex 0
containing 0
both 0
a 0
MADS B-gene
- I-gene
box I-gene
and 0
a 0
forkhead B-gene
protein I-gene
, 0
and 0
it 0
has 0
important 0
implications 0
for 0
the 0
regulation 0
of 0
mammalian 0
gene 0
expression 0
. 0

After 0
screening 0
the 0
Berkeley 0
Drosophila 0
Genome 0
Project 0
database 0
with 0
sequences 0
from 0
a 0
recently 0
characterized 0
Leu B-gene
- I-gene
rich I-gene
repeats I-gene
- I-gene
containing I-gene
G I-gene
protein I-gene
- I-gene
coupled I-gene
receptor I-gene
( 0
LGR B-gene
) 0
from 0
Drosophila 0
( 0
DLGR B-gene
- I-gene
1 I-gene
) 0
, 0
we 0
identified 0
a 0
second 0
gene 0
for 0
a 0
different 0
LGR B-gene
( 0
DLGR B-gene
- I-gene
2 I-gene
) 0
and 0
cloned 0
its 0
cDNA 0
. 0

Degenerate 0
primers 0
homologous 0
to 0
highly 0
conserved 0
regions 0
of 0
known 0
CYP3A B-gene
sequences I-gene
were 0
used 0
for 0
initial 0
RT 0
- 0
PCRs 0
. 0

When 0
cells 0
were 0
microinjected 0
with 0
TFOs 0
designed 0
to 0
bind 0
to 0
a 0
30 0
- 0
bp 0
polypurine 0
site 0
situated 0
between 0
the 0
two 0
TK B-gene
genes I-gene
, 0
recombination 0
was 0
observed 0
at 0
frequencies 0
in 0
the 0
range 0
of 0
1 0
% 0
, 0
2,500 0
- 0
fold 0
above 0
the 0
background 0
. 0

Methyllevamisole 0
was 0
used 0
as 0
the 0
internal 0
standard 0
. 0

Resistance 0
ratios 0
for 0
the 0
other 0
field 0
strains 0
obtained 0
by 0
comparison 0
with 0
the 0
R5 0
strain 0
ranged 0
from 0
24.5 0
to 0
239 0
for 0
topical 0
application 0
and 0
from 0
1.2 0
to 0
9.8 0
for 0
the 0
glass 0
jar 0
method 0
. 0

Only 0
transcripts 0
specific 0
for 0
TSGF B-gene
- I-gene
2 I-gene
are 0
detected 0
in 0
ovary 0
and 0
testes 0
tissues 0
of 0
adults 0
as 0
well 0
as 0
in 0
puparia 0
, 0
while 0
neither 0
gene 0
is 0
expressed 0
during 0
the 0
larval 0
developmental 0
stages 0
. 0

In 0
a 0
gel 0
retardation 0
assay 0
using 0
HepG2 0
nuclear 0
extracts 0
, 0
the 0
5 0
' 0
flanking 0
sequence 0
from 0
- 0
74 0
to 0
- 0
46 0
showed 0
a 0
shifted 0
band 0
. 0

Reliability 0
of 0
cervical 0
range 0
of 0
motion 0
using 0
the 0
OSI 0
CA 0
6000 0
spine 0
motion 0
analyser 0
on 0
asymptomatic 0
and 0
symptomatic 0
subjects 0
. 0

Coimmunoprecipitation 0
experiments 0
performed 0
in 0
transfected 0
cells 0
showed 0
that 0
BCMA B-gene
associates 0
with 0
TNFR B-gene
- I-gene
associated I-gene
factor I-gene
( I-gene
TRAF I-gene
) I-gene
1 I-gene
, 0
TRAF2 B-gene
, 0
and 0
TRAF3 B-gene
adaptor I-gene
proteins I-gene
. 0

Since 0
the 0
RINX B-gene
gene I-gene
is 0
likely 0
an 0
ortholog 0
of 0
the 0
goldfish B-gene
Vsx1 I-gene
gene I-gene
, 0
it 0
has 0
been 0
named 0
VSX1 B-gene
by 0
the 0
Human 0
Gene 0
Nomenclature 0
Committee 0
. 0

The 0
chromosomal 0
localization 0
on 0
distal 0
chromosome 0
7 0
places 0
it 0
in 0
a 0
cluster 0
of 0
imprinted 0
genes 0
, 0
flanked 0
by 0
the 0
previously 0
described 0
Tapa1 B-gene
and 0
Kcnq1 B-gene
genes I-gene
. 0

Activation 0
of 0
PKA B-gene
by 0
8 0
- 0
bromo 0
- 0
cyclic 0
AMP 0
or 0
forskolin 0
, 0
and 0
inhibition 0
of 0
PKC B-gene
by 0
calphostin 0
C 0
, 0
resulted 0
in 0
a 0
significant 0
decrease 0
in 0
3TP B-gene
activity 0
as 0
well 0
as 0
in 0
vitro 0
ERK B-gene
kinase I-gene
activity 0
in 0
CRAC 0
. 0

The 0
present 0
study 0
was 0
designed 0
to 0
evaluate 0
the 0
sensitivity 0
and 0
specificity 0
of 0
AMP 0
CT 0
( 0
Gen 0
- 0
Probe 0
Incorporated 0
, 0
San 0
Diego 0
, 0
CA 0
, 0
USA 0
) 0
on 0
urogenital 0
specimens 0
taken 0
from 0
symptomatic 0
patients 0
and 0
on 0
first 0
void 0
urine 0
( 0
FVU 0
) 0
specimens 0
from 0
asymptomatic 0
patients 0
. 0

Mus81p B-gene
also 0
shares 0
homology 0
with 0
motifs 0
found 0
in 0
the 0
XPF B-gene
endonuclease I-gene
superfamily I-gene
. 0

Double 0
mutant 0
analysis 0
suggests 0
that 0
Rad54p B-gene
and 0
Mus81p B-gene
act 0
in 0
one 0
pathway 0
for 0
the 0
repair 0
of 0
, 0
or 0
tolerance 0
to 0
, 0
UV 0
- 0
induced 0
DNA 0
damage 0
. 0

The 0
linear 0
plasmid 0
pCLU1 0
from 0
the 0
yeast 0
Kluyveromyces 0
lactis 0
normally 0
replicates 0
in 0
the 0
cytoplasm 0
, 0
with 0
the 0
aid 0
of 0
the 0
helper 0
linear 0
plasmid 0
pGKL2 0
, 0
using 0
terminal B-gene
protein I-gene
( 0
TP B-gene
) 0
as 0
a 0
primer 0
. 0

The 0
repetitive 0
ETn B-gene
( 0
early B-gene
transposon I-gene
) 0
family 0
of 0
sequences 0
represents 0
an 0
active 0
`` 0
mobile 0
mutagen 0
'' 0
in 0
the 0
mouse 0
genome 0
. 0

The 0
two 0
main 0
experimental 0
variables 0
were 0
the 0
attended 0
hemifield 0
( 0
left 0
or 0
right 0
) 0
and 0
the 0
proportion 0
of 0
trials 0
requiring 0
a 0
shift 0
within 0
that 0
hemifield 0
( 0
20 0
% 0
or 0
80 0
% 0
) 0
. 0

The 0
measurement 0
of 0
NO 0
in 0
biological 0
systems 0
using 0
chemiluminescence 0
. 0

Biochemical 0
examinations 0
of 0
calcium 0
- 0
phosphorus 0
metabolism 0
included 0
ions 0
and 0
PTH B-gene
concentrations 0
in 0
blood 0
serum 0
, 0
and 0
the 0
activity 0
of 0
bone 0
isoenzyme 0
of 0
AP B-gene
. 0

Atorvastatin 0
was 0
the 0
most 0
cost 0
- 0
effective 0
HMG B-gene
- I-gene
CoA I-gene
reductase I-gene
inhibitor 0
. 0

Pharmacoeconomic 0
assessment 0
of 0
HMG B-gene
- I-gene
CoA I-gene
reductase I-gene
inhibitor 0
therapy 0
: 0
an 0
analysis 0
based 0
on 0
the 0
CURVES 0
study 0
. 0

Interestingly 0
, 0
although 0
E 0
domains 0
of 0
these 0
two 0
receptors 0
are 0
much 0
less 0
conserved 0
, 0
replacement 0
of 0
this 0
domain 0
in 0
rtER B-gene
by 0
its 0
human 0
counterpart 0
resulted 0
in 0
higher 0
estradiol 0
sensitivity 0
but 0
no 0
increase 0
in 0
the 0
magnitude 0
of 0
transactivation 0
. 0

G 0
- 0
DNA 0
is 0
a 0
four 0
- 0
stranded 0
DNA 0
structure 0
with 0
diverse 0
putative 0
biological 0
roles 0
. 0

The 0
effectiveness 0
of 0
NRT 0
appears 0
to 0
be 0
largely 0
independent 0
of 0
the 0
intensity 0
of 0
additional 0
support 0
provided 0
to 0
the 0
smoker 0
. 0

SELECTION 0
CRITERIA 0
: 0
All 0
controlled 0
trials 0
where 0
adults 0
with 0
schizophrenia 0
or 0
similar 0
illnesses 0
were 0
randomised 0
to 0
quetiapine 0
, 0
placebo 0
or 0
other 0
neuroleptic 0
drugs 0
and 0
where 0
clinically 0
relevant 0
outcomes 0
were 0
reported 0
. 0

8 0
% 0
( 0
95 0
% 0
CI 0
, 0
21.3 0
- 0
44.3 0
% 0
) 0
. 0

In 0
contrast 0
, 0
the 0
action 0
of 0
GLP B-gene
- I-gene
1 I-gene
at 0
the 0
CRE 0
was 0
not 0
blocked 0
by 0
cotransfection 0
with 0
M1 B-gene
- I-gene
CREB I-gene
, 0
an 0
isoform 0
that 0
lacks 0
a 0
consensus 0
serine 0
residue 0
serving 0
as 0
substrate 0
for 0
PKA B-gene
- 0
mediated 0
phosphorylation 0
. 0

Because 0
all 0
PDGFbetaR B-gene
fusions I-gene
described 0
thus 0
far 0
result 0
in 0
splicing 0
to 0
a 0
common 0
exon 0
of 0
this 0
gene 0
, 0
we 0
performed 0
5' 0
- 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
PCR 0
on 0
patient 0
RNA 0
. 0

CONCLUSIONS 0
: 0
In 0
essential 0
hypertension 0
an 0
acute 0
protein 0
load 0
induces 0
a 0
decrease 0
in 0
GFR 0
that 0
may 0
normalize 0
under 0
antihypertensive 0
treatment 0
. 0

This 0
finding 0
suggested 0
that 0
the 0
PI3K B-gene
- 0
Akt B-gene
activation 0
pathway 0
plays 0
some 0
role 0
in 0
the 0
antiapoptotic 0
effect 0
of 0
EPO B-gene
. 0

Nine 0
DNA 0
fragments 0
that 0
were 0
specifically 0
recognized 0
and 0
bound 0
by 0
histidine 0
- 0
tagged 0
AdpA B-gene
were 0
isolated 0
by 0
cycles 0
of 0
a 0
gel 0
mobility 0
shift 0
- 0
PCR 0
method 0
. 0

To 0
determine 0
whether 0
the 0
NTP 0
- 0
binding 0
motif 0
is 0
important 0
for 0
Rad24 B-gene
function 0
, 0
we 0
mutated 0
the 0
conserved 0
lysine 0
( 0
115 0
) 0
residue 0
in 0
this 0
motif 0
. 0

The 0
carboxyl 0
- 0
terminal 0
proline 0
- 0
rich 0
domain 0
of 0
SOS1 B-gene
is 0
involved 0
in 0
the 0
interaction 0
with 0
the 0
PLC B-gene
- I-gene
gamma1 I-gene
SH3 B-gene
domain I-gene
. 0

From 0
transient 0
expression 0
studies 0
, 0
we 0
could 0
demonstrate 0
that 0
the 0
SH3 B-gene
domain I-gene
of 0
PLC B-gene
- I-gene
gamma1 I-gene
is 0
necessary 0
for 0
the 0
association 0
with 0
SOS1 B-gene
in 0
vivo 0
. 0

Six 0
distinct 0
Ets B-gene
mRNAs I-gene
were 0
identified 0
: 0
Ets2 B-gene
, 0
Fli1 B-gene
, 0
GABPalpha B-gene
, 0
SAP1 B-gene
, 0
Elk1 B-gene
, 0
and 0
PE1 B-gene
. 0

A 0
2 0
kb 0
transcript 0
was 0
isolated 0
from 0
brain 0
that 0
encodes 0
a 0
approximately 0
57 0
kDa 0
protein 0
; 0
the 0
predicted 0
protein 0
contains 0
the 0
known 0
N B-gene
- I-gene
terminal I-gene
Ets I-gene
domain I-gene
of 0
PE1 B-gene
and 0
a 0
novel 0
C 0
- 0
terminal 0
domain 0
with 0
signficant 0
homology 0
to 0
murine B-gene
ERF I-gene
. 0

Twenty 0
eligible 0
patients 0
with 0
cirrhosis 0
were 0
randomized 0
into 0
two 0
groups 0
: 0
10 0
patients 0
treated 0
with 0
6 0
million 0
units 0
of 0
natural 0
IFN B-gene
- I-gene
beta I-gene
twice 0
a 0
week 0
for 0
36 0
months 0
and 0
10 0
patients 0
without 0
IFN B-gene
therapy 0
. 0

Wnt B-gene
- I-gene
1 I-gene
overexpression 0
in 0
mammary 0
epithelial 0
cells 0
induced 0
cyclin B-gene
D1 I-gene
mRNA I-gene
and 0
targeted 0
overexpression 0
of 0
Wnt B-gene
- I-gene
1 I-gene
in 0
the 0
mammary 0
gland 0
of 0
transgenic 0
mice 0
increased 0
both 0
ILK B-gene
activity 0
and 0
cyclin B-gene
D1 I-gene
levels 0
. 0

Intravenous 0
versus 0
oral 0
administration 0
of 0
amitriptyline 0
in 0
patients 0
with 0
major 0
depression 0
. 0

Deletion 0
of 0
the 0
RVH B-gene
domain I-gene
resulted 0
in 0
loss 0
of 0
Ca 0
( 0
2+ 0
) 0
- 0
dependent 0
activation 0
. 0

Logistic 0
regression 0
analysis 0
revealed 0
that 0
physicians 0
were 0
3.6 0
times 0
more 0
likely 0
to 0
detect 0
thin 0
lesions 0
( 0
< 0
/=0.75 0
mm 0
) 0
compared 0
with 0
nonphysician 0
detectors 0
( 0
95 0
% 0
confidence 0
interval 0
[ 0
95 0
% 0
CI 0
] 0
, 0
2.1 0
, 0
6.5 0
; 0
P 0
= 0
0.0001 0
) 0
. 0

Erythema 0
exsudativum 0
multiforme 0
induced 0
by 0
granulocyte B-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
in 0
an 0
allogeneic 0
peripheral 0
blood 0
stem 0
cell 0
donor 0
. 0

VaI 0
and 0
VaII 0
co 0
- 0
immunoprecipitated 0
with 0
ErbB2 B-gene
, 0
but 0
not 0
with 0
ErbB1 B-gene
, 0
ErbB3 B-gene
, 0
or 0
ErbB4 B-gene
. 0

While 0
interactions 0
of 0
WT 0
and 0
variant 0
TGF B-gene
- I-gene
alpha I-gene
with 0
the 0
ErbBs B-gene
all 0
result 0
in 0
ErbB2 B-gene
activation 0
, 0
they 0
produce 0
different 0
biological 0
consequences 0
, 0
suggesting 0
that 0
the 0
various 0
TGF B-gene
- I-gene
alpha I-gene
precursors I-gene
differentially 0
modulate 0
ErbB B-gene
signaling 0
. 0

It 0
is 0
now 0
well 0
accepted 0
that 0
the 0
p53 B-gene
C I-gene
- I-gene
terminus I-gene
plays 0
a 0
central 0
role 0
in 0
controlling 0
the 0
activity 0
of 0
the 0
wild 0
- 0
type 0
molecule 0
. 0

In 0
contrast 0
to 0
full B-gene
- I-gene
length I-gene
E2F I-gene
- I-gene
3 I-gene
, 0
which 0
is 0
expressed 0
only 0
at 0
the 0
G1/S 0
boundary 0
, 0
E2F B-gene
- I-gene
3B I-gene
is 0
detected 0
throughout 0
the 0
cell 0
cycle 0
with 0
peak 0
levels 0
in 0
GO 0
where 0
it 0
is 0
associated 0
with 0
Rb B-gene
. 0

The 0
transcription 0
factor 0
Jun B-gene
( 0
c B-gene
- I-gene
Jun I-gene
) 0
functions 0
as 0
a 0
recipient 0
of 0
extracellular 0
growth 0
signals 0
and 0
converts 0
them 0
into 0
patterns 0
of 0
gene 0
expression 0
. 0

Developmental 0
toxicity 0
of 0
the 0
class 0
III 0
antiarrhythmic 0
agent 0
almokalant 0
in 0
mice 0
. 0

This 0
compound 0
is 0
the 0
main 0
bioactive 0
metabolite 0
of 0
trimebutine 0
II 0
( 0
Debridat 0
, 0
CAS 0
39133 0
- 0
31 0
- 0
8 0
) 0
, 0
an 0
antispasmodic 0
widely 0
used 0
for 0
intestinal 0
diseases 0
since 0
1969 0
. 0

In 0
addition 0
to 0
its 0
effect 0
in 0
augmenting 0
the 0
neutrophil 0
response 0
to 0
eccentric 0
exercise 0
, 0
vitamin 0
E 0
causes 0
a 0
greater 0
increase 0
in 0
circulating 0
creatine B-gene
kinase I-gene
activity 0
, 0
perhaps 0
indicating 0
increased 0
skeletal 0
muscle 0
repair 0
. 0

This 0
enabled 0
the 0
formation 0
of 0
stem 0
- 0
loop 0
templates 0
with 0
the 0
fusion 0
point 0
of 0
the 0
chimeric 0
transcript 0
in 0
the 0
loop 0
and 0
the 0
use 0
of 0
MLL B-gene
primers 0
in 0
two 0
- 0
sided 0
PCR 0
. 0

CONCLUSION 0
: 0
The 0
authors 0
emphasize 0
that 0
the 0
initial 0
management 0
of 0
primary 0
STS 0
should 0
be 0
adequate 0
and 0
suggest 0
that 0
safty 0
margin 0
of 0
> 0
or 0
= 0
2 0
cm 0
should 0
be 0
adhered 0
to 0
. 0

Measurements 0
were 0
compared 0
with 0
two 0
computerised 0
treatment 0
planning 0
systems 0
- 0
- 0
Theraplan 0
VO5B 0
and 0
ADAC 0
Pinnacle3 0
V4.0b 0
. 0

Activation 0
was 0
biphasic 0
; 0
peaking 0
at 0
5 0
- 0
10 0
min 0
and 0
24 0
h 0
after 0
treatment 0
. 0

Whereas 0
MARTA1 B-gene
is 0
clearly 0
detectable 0
in 0
crude 0
lysates 0
, 0
cytosolic 0
and 0
ribosomal 0
salt 0
- 0
wash 0
fractions 0
, 0
and 0
in 0
nuclear 0
extracts 0
, 0
MARTA2 B-gene
is 0
preferentially 0
found 0
in 0
the 0
ribosomal 0
salt 0
- 0
wash 0
preparation 0
. 0

It 0
contains 0
25 0
exons 0
coding 0
for 0
a 0
4.7kb 0
transcript 0
including 0
large 0
5' 0
- 0
and 0
3' 0
- 0
( 0
1218bp 0
and 0
701bp 0
, 0
respectively 0
) 0
untranslated 0
regions 0
( 0
UTRs 0
) 0
. 0

Five 0
of 0
the 0
PDP1 B-gene
isoforms I-gene
differ 0
by 0
the 0
substitution 0
or 0
insertion 0
of 0
amino 0
acids 0
at 0
or 0
near 0
the 0
N 0
- 0
terminal 0
of 0
the 0
protein 0
. 0

The 0
optimum 0
technique 0
for 0
the 0
pathological 0
examination 0
of 0
sentinel 0
lymph 0
nodes 0
( 0
SLNs 0
) 0
is 0
still 0
under 0
debate 0
. 0

Partial 0
correction 0
of 0
anemia 0
with 0
recombinant B-gene
human I-gene
erythropoietin I-gene
likely 0
reduces 0
left 0
ventricular 0
mass 0
and 0
volume 0
. 0

This 0
study 0
demonstrated 0
that 0
the 0
PFA 0
- 0
100 0
analyzer 0
can 0
accurately 0
assess 0
vWF B-gene
- 0
dependent 0
platelet 0
function 0
and 0
detect 0
other 0
platelet 0
defects 0
under 0
high 0
shear 0
stress 0
in 0
complex 0
patient 0
populations 0
. 0

We 0
recently 0
reported 0
the 0
molecular 0
cloning 0
of 0
a 0
PL B-gene
scramblase I-gene
of 0
human 0
( 0
HuPLSCR1 B-gene
) 0
and 0
mouse 0
origin 0
, 0
respectively 0
. 0

To 0
analyze 0
the 0
regulatory 0
activity 0
of 0
Gtx B-gene
, 0
we 0
first 0
identified 0
the 0
optimal 0
Gtx B-gene
- I-gene
binding I-gene
sequence I-gene
using 0
an 0
in 0
vitro 0
DNA 0
- 0
binding 0
assay 0
. 0

Using 0
an 0
oligomer 0
duplex 0
5' 0
- 0
A 0
( 0
GGGTTA 0
) 0
( 0
5 0
) 0
- 0
3'/5' 0
- 0
( 0
TAACCC 0
) 0
( 0
5 0
) 0
T 0
- 0
3 0
' 0
as 0
a 0
template 0
- 0
primer 0
, 0
we 0
show 0
that 0
both 0
the 0
Klenow B-gene
fragment I-gene
of I-gene
Escherichia I-gene
coli I-gene
DNA I-gene
polymerase I-gene
I I-gene
and 0
HIV B-gene
reverse I-gene
transcriptase I-gene
could 0
expand 0
telomere 0
DNA 0
sequences 0
as 0
well 0
, 0
giving 0
products 0
greater 0
than 0
the 0
size 0
of 0
the 0
template 0
DNA 0
. 0

Cdk2 B-gene
and 0
MAPK B-gene
precipitates 0
from 0
untreated 0
tumor 0
lysates 0
phosphorylated 0
recombinant B-gene
wild I-gene
- I-gene
type I-gene
p27 I-gene
but 0
not 0
the 0
T187A 0
mutant 0
in 0
vitro 0
. 0

The 0
loss 0
of 0
avirulence 0
activity 0
because 0
of 0
mutations 0
in 0
the 0
acidic 0
transcriptional 0
activation 0
domain 0
was 0
restored 0
by 0
addition 0
of 0
the 0
activation 0
domain 0
from 0
the 0
herpes B-gene
simplex I-gene
viral I-gene
protein I-gene
VP16 I-gene
. 0

Mutations 0
in 0
the 0
RP2 B-gene
locus I-gene
at I-gene
Xp11.3 I-gene
were 0
found 0
in 0
a 0
further 0
10 0
- 0
20 0
% 0
of 0
XLRP 0
patients 0
, 0
as 0
predicted 0
from 0
linkage 0
studies 0
. 0

The 0
limit 0
between 0
the 0
cecum 0
and 0
the 0
ascending 0
colon 0
was 0
externally 0
marked 0
by 0
the 0
sulcus 0
cecocolicus 0
dorsalis 0
and 0
ventralis 0
. 0

Subsequently 0
, 0
HD 0
inhibited 0
healing 0
because 0
it 0
significantly 0
delayed 0
epithelialization 0
and 0
caused 0
protracted 0
inflammation 0
. 0

The 0
effectiveness 0
of 0
the 0
haemodialysate 0
Solcoseryl 0
for 0
second 0
- 0
intention 0
wound 0
healing 0
in 0
horses 0
and 0
ponies 0
. 0

Although 0
there 0
is 0
little 0
evidence 0
that 0
diet 0
composition 0
plays 0
a 0
clinically 0
important 0
role 0
in 0
the 0
absorption 0
or 0
expenditure 0
of 0
energy 0
, 0
it 0
does 0
appear 0
to 0
play 0
a 0
role 0
in 0
food 0
intake 0
. 0

These 0
findings 0
were 0
reinforced 0
by 0
an 0
analysis 0
that 0
was 0
restricted 0
to 0
living 0
donor 0
transplants 0
without 0
acute 0
rejection 0
. 0

These 0
results 0
further 0
support 0
an 0
important 0
role 0
for 0
CBF2 B-gene
in 0
mediating 0
EBNA2 B-gene
transactivation 0
; 0
they 0
identify 0
the 0
hnRNP B-gene
protein I-gene
AUF1 I-gene
as 0
a 0
major 0
component 0
of 0
CBF2 B-gene
and 0
are 0
also 0
the 0
first 0
evidence 0
of 0
a 0
cis 0
- 0
acting 0
sequence 0
other 0
than 0
a 0
CBF1 B-gene
binding I-gene
element I-gene
that 0
is 0
able 0
to 0
confer 0
responsiveness 0
to 0
EBNA2 B-gene
. 0

The 0
genome 0
of 0
the 0
human 0
herpesvirus 0
8 0
( 0
HHV 0
- 0
8 0
) 0
contains 0
a 0
cluster 0
of 0
open 0
reading 0
frames 0
( 0
ORFs 0
) 0
encoding 0
proteins 0
with 0
homology 0
to 0
the 0
cellular 0
transcription 0
factors 0
of 0
the 0
interferon B-gene
regulatory I-gene
factor I-gene
( 0
IRF B-gene
) 0
family 0
. 0

Despite 0
these 0
limitations 0
the 0
CHIME 0
monitor 0
provides 0
an 0
opportunity 0
to 0
record 0
physiological 0
data 0
previously 0
unavailable 0
in 0
the 0
home 0
. 0

DATA 0
SYNTHESIS 0
: 0
Intracoronary 0
ultrasound 0
has 0
been 0
shown 0
to 0
improve 0
upon 0
demonstrated 0
weaknesses 0
of 0
coronary 0
angiography 0
. 0

TB 0
bone 0
area 0
( 0
p 0
< 0
0.001 0
) 0
, 0
height 0
( 0
p 0
< 0
0.01 0
) 0
, 0
years 0
in 0
present 0
colony 0
( 0
p 0
= 0
0.03 0
) 0
, 0
and 0
menses 0
( 0
p 0
< 0
0.01 0
) 0
predicted 0
TB 0
BMC 0
. 0

CREST 0
syndrome 0
; 0
a 0
changing 0
clinical 0
significance 0

Troglitazone 0
also 0
induced 0
an 0
endogenous B-gene
PPARgamma I-gene
target I-gene
gene I-gene
in 0
T24 0
cells 0
, 0
adipocyte B-gene
- I-gene
type I-gene
fatty I-gene
acid I-gene
binding I-gene
protein I-gene
( 0
A B-gene
- I-gene
FABP I-gene
) 0
, 0
the 0
expression 0
of 0
which 0
correlates 0
with 0
bladder 0
cancer 0
differentiation 0
. 0

Viruses 0
were 0
isolated 0
from 0
9 0
lungs 0
: 0
7 0
with 0
PI 0
- 0
3V 0
, 0
1 0
with 0
NCP 0
BVDV 0
type 0
1 0
, 0
and 0
1 0
with 0
both 0
BVHV 0
- 0
1 0
and 0
BVDV 0
. 0

The 0
RS447 B-gene
human B-gene
megasatellite I-gene
tandem I-gene
repetitive I-gene
sequence I-gene
encodes 0
a 0
novel 0
deubiquitinating 0
enzyme 0
with 0
a 0
functional 0
promoter 0
. 0

Previous 0
experience 0
and 0
contextual 0
cues 0
are 0
essential 0
elements 0
in 0
the 0
generation 0
of 0
a 0
subjective 0
prediction 0
. 0

To 0
characterize 0
this 0
effect 0
, 0
we 0
looked 0
for 0
targets 0
of 0
NS1 B-gene
influenza I-gene
virus I-gene
protein I-gene
among 0
cellular 0
translation 0
factors 0
. 0

Collectively 0
, 0
these 0
and 0
previously 0
published 0
data 0
suggest 0
a 0
model 0
where 0
NS1 B-gene
recruits 0
eIF4GI B-gene
specifically 0
to 0
the 0
5 0
' 0
untranslated 0
region 0
( 0
5 0
' 0
UTR 0
) 0
of 0
the 0
viral 0
mRNA 0
, 0
allowing 0
for 0
the 0
preferential 0
translation 0
of 0
the 0
influenza 0
virus 0
messengers 0
. 0

Eukaryotic B-gene
translation I-gene
initiation I-gene
factor I-gene
4GI I-gene
is 0
a 0
cellular 0
target 0
for 0
NS1 B-gene
protein I-gene
, 0
a 0
translational 0
activator 0
of 0
influenza 0
virus 0
. 0

Splicing 0
of 0
the 0
K B-gene
- I-gene
SAM I-gene
alternative 0
exon 0
of 0
the 0
fibroblast B-gene
growth I-gene
factor I-gene
receptor I-gene
2 I-gene
gene I-gene
is 0
heavily 0
dependent 0
on 0
the 0
U 0
- 0
rich 0
sequence 0
IAS1 B-gene
lying 0
immediately 0
downstream 0
from 0
its 0
5 0
' 0
splice 0
site 0
. 0

( 0
iii 0
) 0
In 0
these 0
cells 0
, 0
PKCbeta B-gene
plays 0
a 0
unique 0
Ras B-gene
- 0
independent 0
role 0
in 0
mediating 0
insulin B-gene
but 0
not 0
EGF B-gene
or 0
other 0
growth 0
factor 0
mitogenic 0
signals 0
. 0

However 0
, 0
it 0
is 0
not 0
known 0
whether 0
the 0
recently 0
identified 0
isoforms 0
Vav2 B-gene
and 0
Vav3 B-gene
, 0
which 0
are 0
broadly 0
expressed 0
, 0
can 0
couple 0
with 0
similar 0
classes 0
of 0
receptors 0
, 0
nor 0
is 0
it 0
known 0
whether 0
all 0
Vav B-gene
isoforms I-gene
possess 0
identical 0
functional 0
activities 0
. 0

Transcriptional 0
regulation 0
of 0
fbp1 B-gene
promoter I-gene
constructs I-gene
containing 0
only 0
UAS1 0
or 0
UAS2 0
confirms 0
that 0
the 0
PKA B-gene
and 0
MAPK B-gene
regulation 0
is 0
targeted 0
to 0
both 0
sites 0
. 0

X 0
- 0
ray 0
crystallographic 0
data 0
show 0
that 0
the 0
PLZF B-gene
BTB/POZ B-gene
domain 0
forms 0
an 0
obligate 0
homodimer 0
via 0
an 0
extensive 0
interface 0
. 0

The 0
ability 0
of 0
SMRT B-gene
to 0
associate 0
with 0
these 0
transcription 0
factors 0
and 0
thereby 0
to 0
mediate 0
repression 0
is 0
strongly 0
inhibited 0
by 0
activation 0
of 0
tyrosine B-gene
kinase I-gene
signaling 0
pathways 0
, 0
such 0
as 0
that 0
represented 0
by 0
the 0
epidermal B-gene
growth I-gene
factor I-gene
receptor I-gene
. 0

In 0
addition 0
, 0
the 0
ketamine 0
- 0
treated 0
rats 0
had 0
more 0
neurons 0
and 0
glial 0
cells 0
surrounding 0
the 0
ventricles 0
. 0

The 0
differences 0
were 0
as 0
follows 0
: 0
for 0
overall 0
response 0
rate 0
p 0
= 0
0.004 0
; 0
power 0
( 0
for 0
p 0
= 0
0.05 0
) 0
85 0
% 0
; 0
for 0
survival 0
p 0
= 0
0.09 0
; 0
for 0
grade 0
IV 0
granulocytopenia 0
p 0
= 0
0.3 0
; 0
and 0
for 0
febrile 0
neutropenia 0
p 0
= 0
0.61 0
. 0

Patients 0
were 0
randomly 0
assigned 0
to 0
treatment 0
with 0
the 0
ACE B-gene
inhibitor 0
perindopril 0
( 0
and 0
the 0
diuretic 0
indapamide 0
for 0
those 0
with 0
no 0
definite 0
indication 0
for 0
or 0
contraindication 0
to 0
treatment 0
with 0
a 0
diuretic 0
) 0
or 0
matching 0
placebo 0
( 0
s 0
) 0
. 0

The 0
results 0
indicate 0
that 0
the 0
open 0
- 0
section 0
effect 0
decreases 0
the 0
torsional 0
stiffness 0
and 0
stress 0
concentration 0
effects 0
decrease 0
the 0
torsional 0
strength 0
of 0
a 0
long 0
bone 0
with 0
a 0
longitudinal 0
defect 0
. 0

These 0
regions 0
may 0
be 0
differentially 0
involved 0
in 0
tissue 0
- 0
specificity 0
, 0
and/or 0
circadian 0
regulation 0
, 0
of 0
the 0
human B-gene
hPer1 I-gene
gene I-gene
transcription 0
. 0

Additionally 0
, 0
putative 0
CF1/USP B-gene
and 0
CF1/USP I-gene

Sequence 0
analysis 0
reveals 0
that 0
the 0
newly 0
discovered 0
oasA2 B-gene
gene I-gene
represents 0
a 0
pseudogene 0
that 0
is 0
still 0
transcribed 0
, 0
but 0
is 0
not 0
functionally 0
translated 0
. 0

Genomic 0
and 0
functional 0
characterization 0
of 0
the 0
oas B-gene
gene I-gene
family I-gene
encoding 0
O B-gene
- I-gene
acetylserine I-gene
( I-gene
thiol I-gene
) I-gene
lyases I-gene
, 0
enzymes 0
catalyzing 0
the 0
final 0
step 0
in 0
cysteine 0
biosynthesis 0
in 0
Arabidopsis 0
thaliana 0
. 0

Two 0
distinct 0
recessive 0
susceptibility 0
loci 0
for 0
vasculitis 0
were 0
mapped 0
on 0
chromosome 0
( 0
Chr 0
) 0
4 0
at 0
D4Mit89 B-gene
and 0
D4Mit147 B-gene
in 0
both 0
progenies 0
. 0

During 0
treatment 0
, 0
the 0
phosphorylation 0
state 0
of 0
Rb B-gene
shifted 0
to 0
a 0
hypophosphorylated 0
form 0
. 0
mRNA 0
for 0
the 0
HPV 0
E6/E7 B-gene
genes 0
decreased 0
; 0
however 0
, 0
significant 0
changes 0
in 0
the 0
E6/E7 I-gene

Further 0
characterization 0
of 0
these 0
putative 0
Hoxa B-gene
- I-gene
1 I-gene
target I-gene
genes I-gene
will 0
aid 0
in 0
delineating 0
the 0
functions 0
of 0
the 0
Hoxa B-gene
- I-gene
1 I-gene
protein I-gene
in 0
the 0
differentiation 0
processes 0
which 0
occur 0
during 0
embryogenesis 0
. 0

The 0
ability 0
of 0
U6 B-gene
- 0
U57 B-gene
mutants 0
to 0
influence 0
the 0
fidelity 0
of 0
both 0
branch 0
site 0
and 0
3 0
' 0
splice 0
site 0
recognition 0
suggests 0
that 0
this 0
nucleotide 0
may 0
participate 0
in 0
the 0
formation 0
of 0
the 0
active 0
site 0
( 0
s 0
) 0
of 0
the 0
spliceosome 0
. 0

We 0
have 0
determined 0
the 0
structure 0
of 0
the 0
WNT B-gene
- I-gene
2B I-gene
gene I-gene
. 0

The 0
role 0
of 0
daunorubicin 0
in 0
induction 0
therapy 0
for 0
adult 0
acute 0
myeloid 0
leukemia 0

Five 0
of 0
the 0
Aeromonas 0
strains 0
and 0
one 0
of 0
V 0
cholerae 0
non 0
- 0
O1 0
were 0
positive 0
for 0
enterotoxin 0
activity 0
. 0

TNF B-gene
- I-gene
alpha I-gene
induced 0
a 0
dose 0
- 0
and 0
time 0
- 0
dependent 0
increase 0
in 0
cyclooxygenase B-gene
- I-gene
2 I-gene
( 0
COX B-gene
- I-gene
2 I-gene
) 0
expression 0
and 0
PGE2 0
formation 0
in 0
human 0
NCI 0
- 0
H292 0
epithelial 0
cells 0
. 0

The 0
therapy 0
time 0
to 0
deliver 0
the 0
NCS 0
therapeutic 0
dose 0
of 0
10000 0
RBE 0
- 0
cGy 0
, 0
is 0
27 0
times 0
longer 0
when 0
157Gd 0
is 0
used 0
instead 0
of 0
10B 0
. 0

Mis3 B-gene
is 0
needed 0
for 0
the 0
formation 0
of 0
18S B-gene
ribosome I-gene
RNA I-gene
, 0
and 0
may 0
hence 0
direct 0
the 0
level 0
of 0
proteins 0
required 0
for 0
the 0
coupling 0
. 0

Losartan 0
Intervention 0
For 0
Endpoint 0
. 0

CONCLUSION 0
: 0
Vitrectomy 0
for 0
vitreous 0
hemorrhage 0
in 0
Terson 0
syndrome 0
is 0
a 0
safe 0
and 0
effective 0
procedure 0
, 0
offering 0
a 0
rapid 0
and 0
prolonged 0
improvement 0
in 0
vision 0
. 0

RNA 0
in 0
situ 0
hybridization 0
on 0
brain 0
sections 0
of 0
normal 0
human 0
embryos 0
revealed 0
a 0
strong 0
labeling 0
in 0
restricted 0
areas 0
of 0
the 0
cerebral 0
cortex 0
. 0

To 0
facilitate 0
manipulation 0
of 0
large 0
genomic 0
sequences 0
, 0
we 0
developed 0
a 0
method 0
of 0
converting 0
Escherichia 0
coli 0
P1 0
artificial 0
chromosomes 0
( 0
PACs 0
) 0
into 0
yeast 0
artificial 0
chromosomes 0
( 0
YACs 0
) 0
. 0

After 0
gamma 0
- 0
irradiation 0
, 0
the 0
majority 0
of 0
F9 0
cells 0
undergo 0
apoptosis 0
implying 0
that 0
wt B-gene
- I-gene
p53 I-gene
likely 0
triggers 0
pro 0
- 0
apoptotic 0
gene 0
expression 0
in 0
DNA 0
damaged 0
cells 0
. 0

Mobilization 0
with 0
cyclophosphamide 0
and 0
granulocyte B-gene
- I-gene
colony I-gene
stimulating I-gene
factor I-gene
was 0
effective 0
in 0
terms 0
of 0
CD34+ B-gene
cell 0
shift 0
to 0
peripheral 0
blood 0
and 0
the 0
good 0
quality 0
autograft 0
reliably 0
led 0
to 0
haematopoetic 0
recovery 0
after 0
megachemotherapy 0
. 0

This 0
suggests 0
that 0
cardiovascular 0
magnetic 0
resonance 0
is 0
the 0
preferred 0
technique 0
for 0
volume 0
and 0
ejection 0
fraction 0
estimation 0
in 0
heart 0
failure 0
patients 0
, 0
because 0
of 0
its 0
3D 0
approach 0
for 0
non 0
- 0
symmetric 0
ventricles 0
and 0
superior 0
image 0
quality 0
. 0

A 0
degenerate 0
DNA 0
transposon 0
, 0
Pat B-gene
, 0
was 0
identified 0
in 0
the 0
genomes 0
of 0
various 0
wild 0
- 0
type 0
strains 0
of 0
the 0
filamentous 0
fungus 0
Podospora 0
anserina 0
. 0

However 0
, 0
the 0
presence 0
of 0
Tax B-gene
I I-gene
increased 0
the 0
extent 0
and 0
altered 0
the 0
profile 0
of 0
proteins 0
binding 0
TRE B-gene
- I-gene
2 I-gene
in 0
vivo 0
. 0

We 0
have 0
also 0
identified 0
a 0
functional 0
domain 0
in 0
the 0
ORF 0
50 0
protein 0
, 0
an 0
immediate B-gene
- I-gene
early I-gene
gene I-gene
product I-gene
that 0
is 0
mainly 0
encoded 0
by 0
ORF 0
50 0
. 0

A 0
2.3 0
- 0
kb 0
full 0
- 0
length 0
cDNA 0
clone 0
of 0
an 0
Atlantic B-gene
halibut I-gene
Mx I-gene
gene I-gene
was 0
isolated 0
from 0
a 0
liver 0
cDNA 0
library 0
. 0

PLUS 0
- 0
3 0
is 0
a 0
new 0
Swedish 0
protocol 0
of 0
natural 0
speech 0
in 0
3 0
- 0
year 0
- 0
old 0
children 0
. 0

Once 0
HIT 0
II 0
is 0
suspected 0
, 0
heparin 0
( 0
and 0
low 0
- 0
molecular 0
- 0
weight 0
heparins 0
) 0
should 0
be 0
stopped 0
immediately 0
. 0

The 0
reduced 0
efficiency 0
in 0
the 0
glycosylase B-gene
activity 0
is 0
also 0
reflected 0
in 0
a 0
reduced 0
ability 0
of 0
S120K B-gene
MutY I-gene
to 0
prevent 0
DNA 0
mutations 0
in 0
vivo 0
. 0

METHODS 0
AND 0
RESULTS 0
: 0
We 0
prospectively 0
compared 0
the 0
automated 0
measurements 0
of 0
left 0
ventricular 0
ejection 0
fraction 0
( 0
LVEF 0
) 0
and 0
volumes 0
from 0
rest 0
- 0
injected 0
gated 0
Technetium 0
99m 0
( 0
Tc99m 0
) 0
perfusion 0
SPECT 0
with 0
equilibrium 0
radionuclide 0
angiocardiography 0
( 0
ERNA 0
) 0
in 0
62 0
patients 0
and 0
the 0
assessment 0
of 0
regional 0
function 0
with 0
echocardiography 0
in 0
22 0
patients 0
. 0

The 0
2 0
cDNAs 0
differed 0
in 0
the 0
length 0
of 0
their 0
respective 0
3 0
' 0
untranslated 0
regions 0
, 0
of 0
577 0
bp 0
in 0
Cp.F6 B-gene
and 0
72 0
bp 0
in 0
Cp.F10 B-gene
, 0
in 0
both 0
of 0
which 0
a 0
putative 0
polyadenylation 0
signal 0
was 0
identified 0
. 0

This 0
intracellular 0
signaling 0
, 0
known 0
as 0
the 0
unfolded 0
protein 0
response 0
( 0
UPR 0
) 0
, 0
is 0
mediated 0
by 0
the 0
cis 0
- 0
acting 0
ER 0
stress 0
response 0
element 0
( 0
ERSE 0
) 0
in 0
mammals 0
. 0

A 0
Y. B-gene
lipolytica I-gene
Kar2p I-gene
mutant I-gene
was 0
isolated 0
that 0
restored 0
interaction 0
with 0
an 0
Sls1p B-gene
mutant I-gene
, 0
suggesting 0
that 0
the 0
interaction 0
with 0
Sls1p B-gene
could 0
be 0
nucleotide 0
and/or 0
conformation 0
dependent 0
. 0

We 0
have 0
carried 0
out 0
a 0
comprehensive 0
and 0
systematic 0
mutagenesis 0
of 0
the 0
Cse4p B-gene
N I-gene
terminus I-gene
to 0
analyze 0
its 0
function 0
. 0

The 0
spacing 0
of 0
the 0
essential 0
N 0
- 0
terminal 0
domain 0
( 0
END 0
) 0
relative 0
to 0
the 0
HFD B-gene
can 0
be 0
changed 0
significantly 0
without 0
an 0
apparent 0
effect 0
on 0
Cse4p B-gene
function 0
. 0

The 0
bases 0
of 0
this 0
comparison 0
are 0
reviewed 0
and 0
discussed 0
. 0

In 0
invertebrates 0
, 0
Fhit B-gene
is 0
encoded 0
as 0
a 0
fusion 0
protein 0
with 0
Nit B-gene
, 0
a 0
member 0
of 0
the 0
nitrilase B-gene
superfamily I-gene
. 0

Platelet 0
counts 0
and 0
function 0
as 0
well 0
as 0
fibrinogen B-gene
and 0
von B-gene
Willebrand I-gene
factor I-gene
( 0
vWF B-gene
) 0
levels 0
were 0
determined 0
in 0
each 0
sample 0
. 0

The 0
manifestations 0
often 0
include 0
a 0
moderate 0
thrombocytopenia 0
and 0
, 0
less 0
commonly 0
, 0
hemolysis 0
. 0

A 0
beta2 B-gene
RARE I-gene
reporter I-gene
construct I-gene
in 0
which 0
the 0
methylation 0
- 0
susceptible 0
cytosines 0
in 0
the 0
sense 0
strand 0
were 0
replaced 0
by 0
thymine 0
displayed 0
marked 0
loss 0
of 0
activity 0
in 0
a 0
replicated 0
chromatin 0
- 0
dependent 0
manner 0
. 0

Non 0
- 0
poliomyelitis 0
AFP 0
rate 0
had 0
increased 0
from 0
0.9 0
in 0
1997 0
to 0
2.8 0
in 0
1998 0
. 0

Consciousness 0
is 0
connected 0
with 0
attention 0
, 0
working 0
memory 0
and 0
perception 0
. 0

Multiparity 0
had 0
a 0
protective 0
effect 0
with 0
0.66 0
less 0
risk 0
( 0
95 0
% 0
CI 0
0.44 0
- 0
0.99 0
) 0
. 0

Picture 0
the 0
smell 0
. 0

The 0
aim 0
of 0
our 0
study 0
was 0
to 0
evaluate 0
the 0
level 0
of 0
oxidative 0
stress 0
in 0
healthy 0
controls 0
( 0
CTL 0
) 0
compared 0
with 0
CRF 0
and 0
HD 0
patients 0
before 0
( 0
pre 0
- 0
HD 0
) 0
and 0
after 0
( 0
post 0
- 0
HD 0
) 0
the 0
dialysis 0
session 0
, 0
carried 0
out 0
on 0
a 0
high 0
biocompatible 0
polyacrylonitrile 0
membrane 0
AN69 0
. 0

Indirect 0
plasma 0
parameters 0
such 0
as 0
vitamin 0
E 0
, 0
thiol 0
and 0
uric 0
acid 0
levels 0
were 0
also 0
quantified 0
. 0

Only 0
two 0
of 0
27 0
participants 0
( 0
7.4 0
% 0
) 0
with 0
definite 0
POAG 0
had 0
been 0
previously 0
diagnosed 0
and 0
treated 0
, 0
and 0
66.7 0
% 0
of 0
the 0
previously 0
undiagnosed 0
had 0
IOP 0
less 0
than 0
22 0
mmHg 0
. 0

Taken 0
together 0
, 0
they 0
uphold 0
the 0
emerging 0
concern 0
that 0
women 0
with 0
ER B-gene
( I-gene
+ I-gene
) I-gene
cancers 0
may 0
not 0
benefit 0
significantly 0
from 0
endocrine 0
treatment 0
if 0
the 0
tumors 0
also 0
overexpress 0
HER B-gene
- I-gene
2 I-gene
. 0

Promoter 0
activity 0
was 0
dose 0
- 0
dependently 0
inhibited 0
by 0
cotransfection 0
with 0
either 0
ras B-gene
or 0
mos B-gene
oncogenes I-gene
, 0
but 0
oncogene 0
inhibition 0
was 0
reversed 0
and 0
the 0
overall 0
activity 0
increased 0
when 0
cells 0
were 0
treated 0
with 0
the 0
MAP B-gene
kinase I-gene
kinase I-gene
( 0
MKK B-gene
) 0
inhibitor 0
PD98059 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
expression 0
of 0
Cktsf1b1 B-gene
, 0
a 0
gene 0
associated 0
with 0
early 0
development 0
and 0
cell 0
transformation 0
, 0
is 0
sensitive 0
to 0
MKK B-gene
levels 0
and 0
may 0
be 0
regulated 0
via 0
multiple 0
transcription 0
factor 0
complexes 0
. 0

INTERVENTIONS 0
: 0
Subcutaneous 0
tissue 0
PO2 0
and 0
PCO2 0
tensions 0
were 0
measured 0
directly 0
in 0
patients 0
with 0
necrotising 0
fasciitis 0
and 0
in 0
healthy 0
volunteers 0
during 0
normobaric 0
and 0
hyperbaric 0
conditions 0
. 0

Because 0
GH B-gene
- 0
induced 0
Akt B-gene
activation 0
was 0
completely 0
inhibited 0
in 0
both 0
cells 0
by 0
the 0
same 0
concentration 0
of 0
LY294002 0
, 0
these 0
findings 0
indicate 0
that 0
the 0
wortmannin 0
sensitivity 0
of 0
both 0
the 0
IRS B-gene
- I-gene
1 I-gene
- 0
independent 0
and 0
- 0
dependent 0
GH B-gene
- 0
induced 0
MAP B-gene
kinase I-gene
activation 0
may 0
reflect 0
the 0
activity 0
of 0
another 0
wortmannin 0
- 0
sensitive 0
target 0
( 0
s 0
) 0
in 0
addition 0
to 0
PI3K B-gene
in 0
mediation 0
of 0
GH B-gene
- 0
induced 0
MAP B-gene
kinase I-gene
activation 0
in 0
these 0
cells 0
. 0

Insulin B-gene
receptor I-gene
substrate I-gene
- I-gene
1 I-gene
- 0
mediated 0
enhancement 0
of 0
growth B-gene
hormone I-gene
- 0
induced 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
activation 0
. 0

Functional 0
magnetic 0
resonance 0
imaging 0
( 0
fMRI 0
) 0
has 0
been 0
increasingly 0
used 0
in 0
studying 0
human 0
brain 0
function 0
given 0
its 0
non 0
- 0
invasive 0
feature 0
and 0
good 0
spatial 0
resolution 0
. 0

After 0
declamping 0
of 0
the 0
aorta 0
, 0
there 0
were 0
also 0
severe 0
edema 0
, 0
local 0
fibre 0
necrosis 0
, 0
and 0
adhesion 0
of 0
leucocytes 0
, 0
whereas 0
muscle 0
fibre 0
areas 0
became 0
3,935.18 0
micro 0
531 0
microm 0
( 0
2 0
) 0
for 0
type 0
I 0
and 0
5,804 0
+/ 0
- 0
1,075 0
microm 0
( 0
2 0
) 0
for 0
type 0
II 0
. 0

The 0
results 0
indicate 0
that 0
the 0
relationship 0
between 0
comprehension 0
and 0
production 0
is 0
different 0
at 0
different 0
stages 0
in 0
development 0
. 0

It 0
was 0
found 0
that 0
increase 0
in 0
the 0
RH 0
level 0
boosts 0
the 0
current 0
values 0
by 0
2 0
- 0
3 0
orders 0
of 0
magnitude 0
; 0
contrariwise 0
, 0
the 0
voltage 0
values 0
rise 0
by 0
about 0
three 0
times 0
with 0
drop 0
in 0
the 0
RH 0
. 0

On 0
long 0
- 0
term 0
follow 0
- 0
up 0
, 0
there 0
was 0
no 0
significant 0
difference 0
in 0
the 0
incidence 0
of 0
hospitalizations 0
( 0
1 0
per 0
2.1 0
vs 0
. 0

Genomic 0
libraries 0
were 0
stored 0
as 0
frozen 0
cultures 0
in 0
a 0
96 0
- 0
well 0
format 0
, 0
each 0
well 0
containing 0
approximately 0
300 0
- 0
600 0
colonies 0
( 0
12 0
plates 0
for 0
small 0
library 0
, 0
four 0
for 0
medium 0
- 0
size 0
library 0
and 0
four 0
for 0
large 0
library 0
) 0
. 0

In 0
several 0
cell 0
lines 0
, 0
mTOR B-gene
or 0
its 0
downstream 0
targets 0
can 0
be 0
regulated 0
by 0
phosphatidylinositol B-gene
( I-gene
PI I-gene
) I-gene
3 I-gene
- I-gene
kinase I-gene
; 0
protein B-gene
kinases I-gene
A I-gene
, I-gene
B I-gene
, I-gene
and I-gene
C I-gene
; 0
heterotrimeric B-gene
G I-gene
- I-gene
proteins I-gene
; 0
a 0
PD98059 0
- 0
sensitive 0
kinase 0
or 0
calcium 0
; 0
as 0
well 0
as 0
by 0
amino 0
acids 0
. 0

The 0
tumor B-gene
- I-gene
suppressor I-gene
protein I-gene
p53 I-gene
is 0
involved 0
in 0
maintaining 0
genomic 0
stability 0
. 0

Abrogation 0
of 0
p53 B-gene
function 0
by 0
E6 B-gene
resulted 0
in 0
an 0
increase 0
in 0
the 0
spontaneous 0
mutation 0
frequencies 0
at 0
the 0
heterozygous 0
thymidine B-gene
kinase I-gene
( 0
TK B-gene
) 0
locus 0
but 0
not 0
at 0
the 0
hemizygous 0
hypoxanthine B-gene
phosphoribosyl I-gene
transferase I-gene
( 0
HPRT B-gene
) 0
locus 0
. 0

Cytogenetic 0
analysis 0
of 0
LOH 0
mutants 0
by 0
chromosome 0
painting 0
indicated 0
a 0
mosaic 0
of 0
chromosomal 0
aberrations 0
involving 0
chromosome 0
17 0
, 0
in 0
which 0
partial 0
chromosome 0
deletions 0
, 0
amplifications 0
, 0
and 0
multiple 0
translocations 0
appeared 0
heterogeneously 0
in 0
a 0
single 0
mutant 0
. 0

These 0
results 0
support 0
a 0
model 0
in 0
which 0
p53 B-gene
protein I-gene
contributes 0
to 0
the 0
maintenance 0
of 0
genomic 0
integrity 0
through 0
recombinational 0
repair 0
. 0

The 0
importance 0
of 0
this 0
new 0
epidemiological 0
profile 0
of 0
schistosomiasis 0
in 0
the 0
State 0
of 0
Pernambuco 0
relies 0
on 0
the 0
fact 0
that 0
it 0
can 0
be 0
related 0
with 0
the 0
drastic 0
human 0
interference 0
on 0
the 0
environment 0
. 0

In 0
patients 0
with 0
type 0
II 0
tumors 0
, 0
the 0
pattern 0
of 0
lymphatic 0
spread 0
was 0
primarily 0
directed 0
toward 0
the 0
paracardial 0
, 0
lesser 0
curvature 0
, 0
and 0
left 0
gastric 0
artery 0
nodes 0
; 0
esophagectomy 0
offered 0
no 0
survival 0
benefit 0
over 0
extended 0
gastrectomy 0
in 0
these 0
patients 0
. 0

RESULTS 0
: 0
No 0
significant 0
deformation 0
in 0
vertebral 0
artery 0
flow 0
was 0
noted 0
in 0
the 0
flexion 0
- 0
distraction 0
Stage 0
I 0
injuries 0
within 0
the 0
physiologic 0
range 0
of 0
cervical 0
flexion 0
. 0

We 0
screened 0
a 0
K562 0
cDNA 0
library 0
and 0
identified 0
novel 0
transcripts 0
, 0
MZF1B B-gene
and 0
MZF1C B-gene
. 0

The 0
human 0
cDNA 0
clone 0
NFBD1 0
( 0
previously 0
designated 0
KIAA0170 0
) 0
encodes 0
a 0
novel 0
protein 0
( 0
2089 0
amino 0
acids 0
in 0
length 0
; 0
calculated 0
molecular 0
mass 0
226,440 0
D 0
) 0
with 0
possible 0
BRCT B-gene
domains I-gene
at 0
its 0
carboxy 0
terminus 0
( 0
amino 0
acid 0
residues 0
1894 0
- 0
2089 0
) 0
. 0

RESULTS 0
: 0
Neither 0
basal 0
FSH B-gene
level 0
nor 0
stimulated 0
FSH B-gene
level 0
alone 0
were 0
statistically 0
significant 0
predictors 0
of 0
IVF 0
success 0
; 0
however 0
, 0
no 0
patient 0
with 0
a 0
day 0
3 0
FSH B-gene
level 0
> 0
11.1 0
mIU/ml 0
or 0
a 0
stimulated 0
day 0
10 0
FSH B-gene
level 0
> 0
13.5 0
mIU/ml 0
conceived 0
and 0
carried 0
a 0
pregnancy 0
. 0

Parathyroid B-gene
hormone I-gene
regulation 0
of 0
bone B-gene
sialoprotein I-gene
( 0
BSP B-gene
) 0
gene 0
transcription 0
is 0
mediated 0
through 0
a 0
pituitary B-gene
- I-gene
specific I-gene
transcription I-gene
factor I-gene
- I-gene
1 I-gene
( 0
Pit B-gene
- I-gene
1 I-gene
) 0
motif 0
in 0
the 0
rat B-gene
BSP I-gene
gene I-gene
promoter I-gene
. 0

Recent 0
target 0
BP 0
goals 0
promulgated 0
by 0
the 0
Sixth 0
Report 0
from 0
the 0
Joint 0
National 0
Committee 0
( 0
JNC 0
VI 0
) 0
are 0
based 0
on 0
the 0
premise 0
that 0
the 0
intensity 0
of 0
treatment 0
directly 0
corresponds 0
to 0
the 0
magnitude 0
of 0
pretreatment 0
risk 0
. 0

Linking 0
continuous 0
community 0
- 0
based 0
morbidity 0
recording 0
of 0
influenza 0
- 0
like 0
illness 0
( 0
ILI 0
) 0
with 0
virological 0
sampling 0
has 0
consistently 0
proved 0
its 0
value 0
as 0
one 0
of 0
the 0
earliest 0
indicators 0
of 0
circulating 0
influenza 0
activity 0
. 0

The 0
muskox 0
is 0
a 0
new 0
host 0
record 0
for 0
T. 0
gondii 0
. 0

These 0
include 0
NPF 0
repeats 0
, 0
a 0
leucine 0
heptad 0
repeat 0
enriched 0
in 0
charged 0
residues 0
, 0
and 0
a 0
proline 0
- 0
rich 0
SH3 B-gene
- I-gene
like I-gene
and/or 0
WW 0
domain 0
- 0
binding 0
site 0
in 0
the 0
N 0
- 0
terminal 0
domain 0
, 0
which 0
is 0
followed 0
by 0
a 0
membrane 0
core 0
containing 0
four 0
putative 0
transmembrane 0
spans 0
and 0
three 0
amphiphilic 0
segments 0
that 0
are 0
the 0
most 0
highly 0
conserved 0
structural 0
elements 0
. 0

We 0
show 0
here 0
that 0
this 0
difference 0
is 0
due 0
to 0
the 0
presence 0
of 0
a 0
Mot3 B-gene
binding I-gene
site I-gene
in 0
OpA B-gene
. 0

The 0
article 0
deals 0
with 0
the 0
diagnosing 0
and 0
correction 0
of 0
reversible 0
ischemia 0
of 0
the 0
intestine 0
. 0

Mucosal 0
application 0
of 0
NCX 0
- 0
4016 0
, 0
however 0
, 0
did 0
not 0
cause 0
PD 0
reduction 0
and 0
luminal 0
H+ 0
loss 0
, 0
but 0
produced 0
a 0
marked 0
hyperemia 0
, 0
resulting 0
in 0
no 0
damage 0
in 0
the 0
stomach 0
of 0
both 0
normal 0
and 0
STZ 0
- 0
diabetic 0
rats 0
. 0

Functional 0
recognition 0
of 0
5 0
' 0
splice 0
site 0
by 0
U4/U6.U5 B-gene
tri 0
- 0
snRNP 0
defines 0
a 0
novel 0
ATP 0
- 0
dependent 0
step 0
in 0
early 0
spliceosome 0
assembly 0
. 0

As 0
control 0
, 0
the 0
cells 0
were 0
transfected 0
with 0
DNA 0
mixtures 0
containing 0
vector 0
mU6 0
- 0
C1 0
or 0
mU6 0
- 0
C2 0
. 0

The 0
amino 0
acid 0
sequence 0
of 0
matrilysin B-gene
- I-gene
2 I-gene
also 0
contains 0
a 0
threonine 0
residue 0
adjacent 0
to 0
the 0
Zn 0
- 0
binding 0
site 0
that 0
has 0
been 0
defined 0
as 0
a 0
specific 0
feature 0
of 0
matrilysin B-gene
. 0

In 0
this 0
regard 0
, 0
we 0
have 0
recently 0
observed 0
that 0
a 0
constitutively 0
active 0
G B-gene
protein I-gene
- I-gene
coupled I-gene
receptor I-gene
( 0
GPCR B-gene
) 0
encoded 0
by 0
the 0
Kaposi 0
's 0
sarcoma 0
- 0
associated 0
herpes 0
virus 0
( 0
KSHV 0
) 0
/human 0
herpes 0
virus 0
8 0
is 0
oncogenic 0
and 0
stimulates 0
angiogenesis 0
by 0
increasing 0
the 0
secretion 0
of 0
vascular B-gene
endothelial I-gene
growth I-gene
factor I-gene
( 0
VEGF B-gene
) 0
, 0
which 0
is 0
a 0
key 0
angiogenic 0
stimulator 0
and 0
a 0
critical 0
mitogen 0
for 0
the 0
development 0
of 0
Kaposi 0
's 0
sarcoma 0
. 0

No 0
specific 0
subgroup 0
of 0
clients 0
benefited 0
more 0
from 0
URD 0
, 0
although 0
a 0
prospective 0
study 0
employing 0
random 0
assignment 0
might 0
be 0
more 0
successful 0
in 0
identifying 0
such 0
a 0
group 0
. 0

In 0
the 0
lattice 0
, 0
23 0
% 0
of 0
the 0
sites 0
are 0
occupied 0
, 0
95 0
% 0
of 0
the 0
atoms 0
are 0
in 0
the 0
lowest 0
energy 0
magnetic 0
sublevel 0
, 0
and 0
37 0
% 0
are 0
in 0
the 0
lowest 0
3D 0
vibrational 0
state 0
. 0

Coexisting 0
vertical 0
and 0
horizontal 0
one 0
and 0
a 0
half 0
syndromes 0
. 0

As 0
in 0
the 0
other 0
three 0
members 0
whose 0
gene 0
expression 0
is 0
altered 0
during 0
tumorigenesis 0
, 0
PI12 B-gene
expression 0
was 0
found 0
to 0
be 0
down 0
- 0
regulated 0
in 0
tumor 0
brain 0
tissues 0
and 0
in 0
two 0
brain 0
cancer 0
cell 0
lines 0
: 0
U 0
- 0
87 0
MG 0
and 0
H4 0
. 0

Regarding 0
`` 0
the 0
relation 0
between 0
sexual 0
orientation 0
and 0
penile 0
size 0
, 0
'' 0
by 0
A 0
. 0

This 0
slope 0
was 0
further 0
significantly 0
decreased 0
at 0
5 0
min 0
ischemia 0
( 0
- 0
26.5 0
+/ 0
- 0
8.8 0
microm/mmHg 0
) 0
but 0
returned 0
toward 0
control 0
values 0
in 0
short 0
- 0
term 0
hibernating 0
myocardium 0
at 0
90 0
min 0
ischemia 0
( 0
- 0
17.2 0
+/ 0
- 0
6.6 0
microm/mmHg 0
) 0
. 0

Whereas 0
both 0
MAP 0
and 0
MSNA 0
increase 0
during 0
SHG 0
, 0
the 0
transition 0
from 0
SHG 0
to 0
PHI 0
is 0
characterized 0
by 0
a 0
transient 0
reduction 0
in 0
MAP 0
but 0
sustained 0
elevation 0
in 0
MSNA 0
, 0
facilitating 0
separation 0
of 0
these 0
factors 0
in 0
vivo 0
. 0

Analysis 0
of 0
Standard 0
Reference 0
Material 0
1846 0
, 0
Infant 0
Formula 0
, 0
gave 0
a 0
mean 0
value 0
of 0
0.95 0
+/ 0
- 0
0.088 0
mg 0
vitamin 0
K/kg 0
( 0
K 0
or 0
K1 0
? 0
) 0
( 0
n 0
= 0
31 0
) 0
with 0
a 0
coefficient 0
of 0
variation 0
of 0
9.26 0
. 0

We 0
have 0
recently 0
discovered 0
that 0
CCAAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
- I-gene
beta I-gene
( 0
C/EBP B-gene
- I-gene
beta I-gene
) 0
induces 0
gene 0
transcription 0
through 0
a 0
novel 0
IFN B-gene
response I-gene
element I-gene
called 0
the 0
gamma B-gene
- I-gene
IFN I-gene
- I-gene
activated I-gene
transcriptional I-gene
element I-gene

Northern 0
blot 0
analysis 0
demonstrated 0
that 0
the 0
STORP B-gene
gene I-gene
has 0
a 0
ubiquitous 0
pattern 0
of 0
expression 0
similar 0
to 0
that 0
of 0
the 0
PML B-gene
gene I-gene
. 0

In 0
the 0
TLE 0
patients 0
the 0
NAA 0
: 0
Cr 0
ratios 0
were 0
reduced 0
in 0
the 0
seizure 0
focus 0
, 0
while 0
in 0
the 0
FLE 0
patients 0
they 0
were 0
not 0
always 0
reduced 0
in 0
the 0
seizure 0
focus 0
. 0

The 0
Spo0F B-gene
residues I-gene
making 0
up 0
the 0
hydrophobic 0
patch 0
are 0
very 0
similar 0
in 0
all 0
response 0
regulators 0
suggesting 0
that 0
the 0
binding 0
is 0
initiated 0
through 0
the 0
same 0
residues 0
in 0
all 0
interacting 0
response 0
regulator 0
- 0
kinase 0
pairs 0
. 0

The 0
psychologic 0
factors 0
associated 0
wth 0
serious 0
illness 0
, 0
terminal 0
prognoses 0
, 0
and 0
dying 0
complicate 0
the 0
scenario 0
even 0
more 0
as 0
compared 0
with 0
that 0
of 0
nonmalignant 0
pain 0
. 0

However 0
, 0
if 0
the 0
spatial 0
resolution 0
is 0
not 0
critical 0
and 0
interest 0
is 0
to 0
compare 0
a 0
pathologic 0
area 0
with 0
a 0
contralateral 0
VOI 0
, 0
then 0
the 0
acquisition 0
of 0
two 0
single 0
- 0
voxel 0
spectra 0
may 0
be 0
preferred 0
. 0

Quantitative 0
evaluation 0
of 0
magneto 0
- 0
optical 0
parameters 0
is 0
necessary 0
in 0
order 0
to 0
apply 0
scanning 0
near 0
- 0
field 0
optical 0
microscope 0
( 0
SNOM 0
) 0
technology 0
to 0
the 0
study 0
of 0
magnetism 0
on 0
the 0
mesoscopic 0
scale 0
. 0

We 0
found 0
that 0
the 0
amplitude 0
of 0
the 0
cortical 0
evoked 0
potentials 0
( 0
amplitude 0
of 0
the 0
N2/P2 0
peak 0
) 0
increased 0
from 0
5.1 0
+/ 0
- 0
0.7 0
microV 0
at 0
5 0
mA 0
to 0
16.3 0
+/ 0
- 0
1.1 0
microV 0
at 0
20 0
mA 0
. 0

While 0
mutations 0
in 0
K B-gene
- I-gene
Rev I-gene
that 0
inactivate 0
any 0
one 0
of 0
these 0
properties 0
also 0
blocked 0
K B-gene
- I-gene
Rev I-gene
- 0
dependent 0
nuclear 0
RNA 0
export 0
, 0
several 0
K B-gene
- I-gene
Rev I-gene
mutants I-gene
were 0
comparable 0
to 0
wild 0
type 0
when 0
assayed 0
for 0
any 0
of 0
these 0
individual 0
activities 0
yet 0
nevertheless 0
defective 0
for 0
RNA 0
export 0
. 0

LMP B-gene
- I-gene
1 I-gene
is 0
targeted 0
to 0
the 0
plasma 0
membrane 0
, 0
where 0
it 0
binds 0
TRAF B-gene
, 0
TRADD B-gene
, 0
and 0
JAK B-gene
molecules I-gene
to 0
activate 0
NF B-gene
- I-gene
kappaB I-gene
- 0
, 0
AP B-gene
- I-gene
1 I-gene
- 0
, 0
and 0
STAT B-gene
- 0
dependent 0
pathways 0
as 0
does 0
CD40 B-gene
. 0

Identification 0
of 0
an 0
enhancer 0
and 0
an 0
alternative 0
promoter 0
in 0
the 0
first 0
intron 0
of 0
the 0
alpha B-gene
- I-gene
fetoprotein I-gene
gene I-gene
. 0

Studying 0
intracellular 0
signaling 0
pathways 0
, 0
which 0
may 0
be 0
involved 0
in 0
malignant 0
transformation 0
of 0
Ret B-gene
- I-gene
9bp I-gene
expressing 0
NIH3T3 0
cells 0
, 0
we 0
could 0
demonstrate 0
Ret B-gene
- I-gene
9bp I-gene
dependent 0
phosphorylation 0
of 0
insulin B-gene
receptor I-gene
substrate I-gene
- I-gene
2 I-gene
( 0
IRS B-gene
- I-gene
2 I-gene
) 0
with 0
consecutive 0
activation 0
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
( 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
) 0
and 0
protein B-gene
kinase I-gene
B I-gene
( 0
PKB/AKT B-gene
) 0
. 0

METHODS 0
: 0
In 0
the 0
current 0
study 0
the 0
authors 0
reported 0
on 0
PPB 0
cases 0
from 0
a 0
national 0
retrospective 0
search 0
performed 0
in 0
18 0
Italian 0
Associations 0
for 0
Pediatric 0
Hematology 0
and 0
Oncology 0
centers 0
. 0

Phylogenetic 0
analysis 0
showed 0
that 0
the 0
ToLCV 0
isolates 0
from 0
Bangalore 0
constitute 0
a 0
group 0
of 0
viruses 0
separated 0
from 0
those 0
of 0
Northern 0
India 0
. 0

Mutating 0
the 0
Fcp1p B-gene
- 0
binding 0
motif 0
KEFGK 0
in 0
the 0
RAP74 B-gene
( 0
Tfg1p B-gene
) 0
subunit 0
of 0
TFIIF B-gene
to 0
EEFGE 0
led 0
to 0
both 0
synthetic 0
phenotypes 0
in 0
certain 0
fcp1 B-gene
tfg1 B-gene
double 0
mutants 0
and 0
a 0
reduced 0
ability 0
of 0
Fcp1p B-gene
to 0
activate 0
transcription 0
when 0
it 0
is 0
artificially 0
tethered 0
to 0
a 0
promoter 0
. 0

These 0
results 0
suggest 0
that 0
Cdc42p B-gene
is 0
in 0
fact 0
required 0
for 0
pheromone 0
response 0
and 0
that 0
interaction 0
with 0
the 0
PAK B-gene
Ste20p B-gene
is 0
critical 0
for 0
that 0
role 0
. 0

Deletion 0
of 0
an 0
intergenic 0
DNA 0
- 0
binding 0
site 0
for 0
this 0
complex 0
from 0
a 0
human B-gene
beta I-gene
- I-gene
globin I-gene
locus I-gene
construct I-gene
results 0
in 0
delayed 0
human B-gene
gamma I-gene
- I-gene
to I-gene
beta I-gene
- I-gene
globin I-gene
switching 0
in 0
transgenic 0
mice 0
, 0
suggesting 0
that 0
the 0
PYR B-gene
complex I-gene
acts 0
to 0
facilitate 0
the 0
switch 0
. 0

The 0
product 0
of 0
rat B-gene
gene I-gene
33 I-gene
was 0
identified 0
as 0
an 0
ErbB B-gene
- I-gene
2 I-gene
- I-gene
interacting I-gene
protein I-gene
in 0
a 0
two 0
- 0
hybrid 0
screen 0
employing 0
the 0
ErbB B-gene
- I-gene
2 I-gene
juxtamembrane I-gene
and I-gene
kinase I-gene
domains I-gene
as 0
bait 0
. 0

Studies 0
suggest 0
that 0
the 0
DGOR 0
without 0
acid 0
reflux 0
may 0
result 0
in 0
symptoms 0
but 0
unless 0
acid 0
reflux 0
is 0
present 0
simultaneously 0
, 0
it 0
does 0
not 0
cause 0
oesophagitis 0
. 0

Symptoms 0
, 0
however 0
, 0
appear 0
to 0
correlate 0
poorly 0
with 0
oesophagitis 0
; 0
hence 0
, 0
severe 0
symptoms 0
do 0
not 0
indicate 0
there 0
is 0
greater 0
oesophageal 0
damage 0
. 0

OBJECTIVE 0
: 0
To 0
evaluate 0
the 0
relationship 0
between 0
blood 0
flow 0
in 0
the 0
tumor 0
assessed 0
by 0
color 0
Doppler 0
ultrasound 0
, 0
microvessel 0
density 0
, 0
and 0
vascular B-gene
endothelial I-gene
growth I-gene
factor I-gene
levels 0
in 0
endometrial 0
carcinoma 0
. 0

These 0
results 0
demonstrate 0
Ras B-gene
- 0
and 0
Raf B-gene
- 0
independent 0
ERK B-gene
MAPK 0
activation 0
maintains 0
cell 0
viability 0
following 0
heat 0
shock 0
. 0

Three 0
cDNAs 0
encoding 0
basic B-gene
leucine I-gene
zipper I-gene
( I-gene
bZIP I-gene
) I-gene
- I-gene
type I-gene
ABRE I-gene
- I-gene
binding I-gene
proteins I-gene
were 0
isolated 0
by 0
using 0
the 0
yeast 0
one 0
- 0
hybrid 0
system 0
and 0
were 0
designated 0
AREB1 B-gene
, 0
AREB2 B-gene
, 0
and 0
AREB3 B-gene
( 0
ABA B-gene
- I-gene
responsive I-gene
element I-gene
binding I-gene
protein I-gene
) 0
. 0

Recombinant 0
AROM B-gene
- 0
p64 B-gene
displayed 0
high 0
binding 0
to 0
single 0
- 0
stranded 0
DNA 0
and 0
poly 0
( 0
A 0
) 0
homopolymers 0
suggesting 0
that 0
this 0
protein 0
could 0
play 0
a 0
role 0
in 0
mRNA 0
maturation/metabolism 0
. 0

The 0
protein B-gene
- I-gene
tyrosine I-gene
kinase I-gene
fer B-gene
associates 0
with 0
signaling 0
complexes 0
containing 0
insulin B-gene
receptor I-gene
substrate I-gene
- I-gene
1 I-gene
and 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
. 0

The 0
variable 0
phenotype 0
of 0
the 0
allotetraploids 0
could 0
not 0
be 0
explained 0
by 0
cytological 0
abnormalities 0
. 0

In 0
the 0
PMR 0
target 0
area 0
but 0
not 0
in 0
the 0
nontreated 0
area 0
an 0
improvement 0
in 0
regional 0
myocardial 0
flow 0
reserve 0
occurs 0
in 0
wall 0
segments 0
with 0
initially 0
severely 0
or 0
moderately 0
reduced 0
stress 0
perfusion 0
. 0

Analysis 0
of 0
intron/exon 0
boundaries 0
of 0
the 0
genomic 0
BAC 0
clones 0
demonstrate 0
that 0
junctin B-gene
, 0
junctate B-gene
, 0
and 0
aspartyl B-gene
beta I-gene
- I-gene
hydroxylase I-gene
result 0
from 0
alternative 0
splicing 0
of 0
the 0
same 0
gene 0
. 0

It 0
is 0
now 0
estimated 0
that 0
inactivation 0
mutants 0
of 0
PTEN B-gene
exist 0
in 0
60 0
% 0
of 0
all 0
forms 0
of 0
solid 0
tumors 0
. 0

We 0
have 0
demonstrated 0
that 0
the 0
activity 0
of 0
ILK B-gene
is 0
constitutively 0
elevated 0
in 0
PTEN B-gene
mutant I-gene
cells 0
. 0

The 0
growth B-gene
factor I-gene
receptor I-gene
- I-gene
bound I-gene
protein I-gene
2 I-gene
( 0
Grb2 B-gene
) 0
adaptor 0
when 0
complexed 0
with 0
Sos B-gene
( 0
Son B-gene
of I-gene
sevenless I-gene
) 0
, 0
the 0
exchange 0
factor 0
of 0
Ras B-gene
, 0
conveys 0
the 0
signal 0
induced 0
by 0
tyrosine B-gene
kinase I-gene
- I-gene
activated I-gene
receptor I-gene
to 0
Ras B-gene
by 0
recruiting 0
Sos B-gene
to 0
the 0
membrane 0
, 0
allowing 0
activation 0
of 0
Ras B-gene
. 0

Mutations 0
in 0
genes 0
encoding 0
PR65/A B-gene
subunits I-gene
have 0
been 0
identified 0
in 0
several 0
different 0
human 0
cancers 0
and 0
the 0
PP2A B-gene
inhibitor 0
, 0
termed 0
fostriecin 0
, 0
is 0
being 0
tested 0
as 0
an 0
anticancer 0
drug 0
. 0

For 0
this 0
purpose 0
, 0
a 0
segment 0
of 0
dxr B-gene
was 0
amplified 0
from 0
Synechococcus 0
leopoliensis 0
SAUG 0
1402 0
- 0
1 0
DNA 0
via 0
PCR 0
using 0
oligonucleotides 0
for 0
conserved 0
regions 0
. 0

Perceptual 0
learning 0
for 0
a 0
pattern 0
discrimination 0
task 0
. 0

The 0
detector 0
has 0
the 0
advantage 0
of 0
finding 0
both 0
ST 0
segment 0
deviations 0
and 0
entire 0
ST 0
- 0
T 0
complex 0
changes 0
thereby 0
providing 0
a 0
wider 0
characterization 0
of 0
the 0
potential 0
ischemic 0
events 0
. 0

While 0
this 0
Saccharomyces 0
cerevisiae 0
SIN4 B-gene
gene I-gene
product I-gene
is 0
a 0
component 0
of 0
a 0
mediator 0
complex 0
associated 0
with 0
RNA B-gene
polymerase I-gene
II I-gene
, 0
various 0
studies 0
suggest 0
the 0
involvement 0
of 0
Sin4 B-gene
in 0
the 0
alteration 0
of 0
higher 0
- 0
order 0
chromatin 0
structure 0
. 0

Primary 0
adrenal 0
hypersensitivity 0
to 0
ACTH B-gene
drive 0
in 0
obesity 0
has 0
also 0
been 0
suggested 0
. 0

In 0
addition 0
, 0
a 0
noncanonical 0
C/EBP B-gene
- I-gene
binding I-gene
site I-gene
within 0
the 0
Gadd45gamma B-gene
promoter I-gene
where 0
C/EBPbeta B-gene
and 0
C/EBPdelta B-gene
could 0
bind 0
, 0
was 0
identified 0
by 0
electrophoretic 0
mobility 0
shift 0
assay 0
( 0
EMSA 0
) 0
and 0
reporter 0
gene 0
analysis 0
. 0

Src B-gene
activation 0
induced 0
by 0
FGF1 B-gene
was 0
blocked 0
by 0
the 0
SH2 B-gene
domain I-gene
of 0
Src B-gene
and 0
PP2 B-gene
, 0
a 0
specific 0
inhibitor 0
of 0
Src B-gene
. 0

The 0
use 0
of 0
the 0
PLCgamma B-gene
inhibitory I-gene
peptide I-gene
, 0
neomycin 0
and 0
the 0
calcium 0
chelator 0
BAPTA 0
- 0
AM 0
on 0
oocytes 0
expressing 0
FGFR1 B-gene
or 0
the 0
stimulation 0
by 0
PDGF B-gene
- I-gene
BB I-gene
of 0
oocytes 0
expressing 0
PDGFR B-gene
- 0
FGFR1 B-gene
mutated 0
on 0
the 0
PLCgamma B-gene
binding I-gene
site I-gene
, 0
prevented 0
GVBD 0
and 0
ERK2 B-gene
phosphorylation 0
. 0

Multiple 0
transcription 0
start 0
sites 0
were 0
revealed 0
by 0
primer 0
extension 0
analysis 0
of 0
the 0
mouse 0
gene 0
, 0
and 0
transfection 0
constructs 0
containing 0
the 0
prospective 0
promoter 0
generated 0
transcriptional 0
activity 0
comparable 0
to 0
that 0
of 0
the 0
SV40 B-gene
promoter I-gene
. 0

From 0
two 0
inhibitor 0
scaffolds 0
, 0
we 0
have 0
identified 0
potent 0
and 0
selective 0
inhibitors 0
for 0
sensitized 0
kinases 0
from 0
five 0
distinct 0
subfamilies 0
. 0

To 0
determine 0
whether 0
interaction 0
of 0
arsenite 0
with 0
the 0
hormone 0
- 0
binding 0
domain 0
results 0
in 0
receptor 0
activation 0
, 0
COS 0
- 0
1 0
cells 0
were 0
transiently 0
cotransfected 0
with 0
the 0
chimeric B-gene
receptors I-gene
GAL I-gene
- I-gene
ER I-gene
, 0
which 0
contains 0
the 0
hormone 0
- 0
binding 0
domain 0
of 0
ERalpha B-gene
and 0
the 0
DNA 0
- 0
binding 0
domain 0
of 0
the 0
transcription 0
factor 0
GAL4 B-gene
, 0
and 0
a 0
GAL4 B-gene
- 0
responsive 0
CAT B-gene
reporter I-gene
gene I-gene
. 0

By 0
progressive 0
5' 0
- 0
deletion 0
studies 0
, 0
we 0
have 0
identified 0
a 0
248 0
- 0
bp 0
DNA 0
fragment 0
( 0
- 0
1018 0
to 0
- 0
771 0
, 0
relative 0
to 0
the 0
translation 0
start 0
site 0
) 0
at 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
human B-gene
GnRHR I-gene
gene I-gene
that 0
is 0
responsible 0
for 0
the 0
GnRHa 0
- 0
mediated 0
down 0
- 0
regulation 0
of 0
human B-gene
GnRHR I-gene
promoter I-gene
activity 0
. 0

The 0
mean 0
day 0
of 0
diagnosis 0
of 0
periventricular 0
echodensities 0
was 0
3 0
+/ 0
- 0
2 0
days 0
( 0
range 0
1 0
- 0
11 0
days 0
) 0
, 0
and 0
of 0
cystic 0
PVL 0
21 0
+/ 0
- 0
8 0
days 0
( 0
range 0
2 0
- 0
47 0
days 0
) 0
. 0

The 0
LAMMER B-gene
protein 0
kinase 0
encoded 0
by 0
the 0
Doa B-gene
locus I-gene
of 0
Drosophila 0
is 0
required 0
in 0
both 0
somatic 0
and 0
germline 0
cells 0
and 0
is 0
expressed 0
as 0
both 0
nuclear 0
and 0
cytoplasmic 0
isoforms 0
throughout 0
development 0
. 0

We 0
have 0
mutated 0
to 0
cysteine 0
, 0
one 0
at 0
a 0
time 0
, 0
21 0
consecutive 0
residues 0
in 0
the 0
fourth 0
TMS 0
( 0
TM4 0
) 0
. 0

( 0
1995 0
) 0
J 0
. 0

HYPOTHESIS 0
: 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
investigate 0
the 0
oxidative 0
susceptibility 0
of 0
apolipoprotein B-gene
B I-gene
- I-gene
containing I-gene
lipoproteins I-gene
and 0
antioxidant 0
status 0
in 0
patients 0
with 0
acute 0
coronary 0
syndromes 0
and 0
chronic 0
stable 0
angina 0
pectoris 0
. 0

In 0
group 0
B 0
37 0
MBq 0
in 0
150 0
microL 0
of 0
99mTc 0
- 0
HSA 0
nanocolloid 0
was 0
additionally 0
injected 0
intradermally 0
18 0
h 0
before 0
surgery 0
( 0
3 0
- 0
6 0
aliquots 0
injected 0
perilesionally 0
) 0
. 0

Post 0
- 0
operative 0
functional 0
outcome 0
is 0
related 0
to 0
pre 0
- 0
operative 0
functional 0
status 0
. 0

We 0
cloned 0
a 0
DNA 0
fragment 0
encoding 0
the 0
N 0
- 0
terminal 0
part 0
of 0
a 0
protein 0
with 0
significant 0
similarity 0
to 0
members 0
of 0
the 0
LysR B-gene
family I-gene
of I-gene
transcriptional I-gene
regulators I-gene
( 0
LTTRs B-gene
) 0
. 0

AGO1 B-gene
is 0
similar 0
to 0
QDE B-gene
- I-gene
2 I-gene
required 0
for 0
quelling 0
and 0
RDE B-gene
- I-gene
1 I-gene
required 0
for 0
RNAi 0
. 0

Intracellular 0
localization 0
studies 0
using 0
the 0
mDAP B-gene
- I-gene
3/EGFP I-gene
fusion 0
protein 0
, 0
cell 0
fractionation 0
and 0
protease 0
protection 0
experiments 0
localized 0
3/EGFP I-gene

We 0
could 0
demonstrate 0
the 0
involvement 0
of 0
cAMP B-gene
- I-gene
dependent I-gene
protein I-gene
kinase I-gene
( 0
PKA B-gene
) 0
in 0
the 0
phosphorylation 0
of 0
CDC25Mm B-gene
in 0
fibroblasts 0
overexpressing 0
this 0
RasGEF B-gene
as 0
well 0
as 0
in 0
mouse 0
brain 0
synaptosomal 0
membranes 0
. 0

Reporter 0
gene 0
expression 0
analyses 0
indicate 0
that 0
both 0
WASP B-gene
promoters I-gene
show 0
high 0
levels 0
of 0
expression 0
in 0
different 0
hematopoietic 0
cell 0
lines 0
. 0

We 0
find 0
that 0
3T1 0
- 0
3T2 0
mixing 0
has 0
a 0
pronounced 0
effect 0
on 0
the 0
line 0
shape 0
and 0
radiative 0
decay 0
rate 0
of 0
emission 0
from 0
the 0
3T2 0
state 0
and 0
that 0
the 0
extent 0
of 0
mixing 0
depends 0
critically 0
on 0
the 0
magnitude 0
of 0
nontetrahedral 0
distortions 0
. 0

A 0
total 0
of 0
576 0
1 0
- 0
day 0
- 0
old 0
Ross 0
broiler 0
chicks 0
were 0
housed 0
in 0
six 0
treatment 0
groups 0
[ 0
six 0
replicates 0
of 0
16 0
each 0
; 0
control 0
, 0
CLI 0
( 0
15 0
g 0
kg 0
( 0
- 0
1 0
) 0
diet 0
) 0
, 0
50 0
parts 0
per 0
billion 0
( 0
ppb 0
) 0
AF B-gene
, 0
50 0
ppb 0
AF B-gene
plus 0
CLI 0
, 0
100 0
ppb 0
AF B-gene
, 0
100 0
ppb 0
AF B-gene
plus 0
CLI 0
] 0
for 0
42 0
days 0
. 0

The 0
cost 0
per 0
test 0
is 0
less 0
than 0
those 0
for 0
CC 0
, 0
kEIA 0
and 0
PACE2 0
. 0

Altogether 0
these 0
results 0
suggest 0
that 0
, 0
in 0
KG1a 0
cells 0
, 0
TNFalpha B-gene
can 0
stimulate 0
in 0
parallel 0
PC B-gene
- I-gene
PLC I-gene
and 0
PLD B-gene
, 0
whose 0
lipid 0
products 0
activate 0
in 0
turn 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
MAP B-gene
kinase I-gene
) 0
and 0
NF B-gene
- I-gene
kappaB I-gene
signalling 0
respectively 0
. 0

Concurrently 0
, 0
we 0
monitored 0
weather 0
conditions 0
and 0
used 0
time 0
- 0
activity 0
budget 0
data 0
of 0
free 0
- 0
living 0
birds 0
and 0
laboratory 0
data 0
on 0
resting 0
metabolic 0
rate 0
to 0
construct 0
time 0
- 0
activity 0
laboratory 0
( 0
TAL 0
) 0
estimates 0
of 0
daily 0
energy 0
expenditure 0
( 0
DEE 0
) 0
and 0
to 0
partition 0
the 0
verdins 0
' 0
energy 0
budget 0
into 0
thermoregulatory 0
, 0
activity 0
and 0
basal 0
components 0
. 0

L/H 0
> 0
0.61 0
( 0
chi 0
( 0
2 0
) 0
=10.8 0
; 0
P 0
: 0
< 0
0.001 0
) 0
and 0
a 0
restrictive 0
filling 0
pattern 0
( 0
chi 0
( 0
2 0
) 0
=3.6 0
; 0
P 0
: 0
< 0
0.05 0
) 0
were 0
independent 0
predictors 0
of 0
events 0
. 0

The 0
high 0
selectivity 0
of 0
arrestins B-gene
for 0
this 0
particular 0
functional 0
form 0
of 0
receptor 0
ensures 0
their 0
timely 0
binding 0
and 0
dissociation 0
. 0

When 0
cotransfected 0
in 0
fibroblasts 0
with 0
a 0
C/EBP B-gene
alpha I-gene
expression 0
vector 0
, 0
reporter 0
gene 0
expression 0
increased 0
3 0
- 0
fold 0
only 0
in 0
the 0
wild 0
- 0
type 0
constructs 0
. 0

Expression 0
of 0
a 0
dominant B-gene
negative I-gene
Smad2 I-gene
significantly 0
reduces 0
the 0
level 0
of 0
luciferase B-gene
reporter I-gene
activity 0
induced 0
by 0
nodal 0
treatment 0
. 0

Normal 0
alpha1 B-gene
( I-gene
I I-gene
) I-gene
collagen I-gene
mRNA I-gene
showed 0
no 0
significant 0
reduction 0
when 0
AR 0
or 0
IR 0
was 0
expressed 0
from 0
the 0
pHbetaAPr 0
- 0
1 0
- 0
neo 0
vector 0
and 0
a 0
small 0
( 0
10 0
- 0
20 0
% 0
) 0
but 0
significant 0
reduction 0
when 0
either 0
ribozyme 0
was 0
expressed 0
from 0
the 0
pCI.neo 0
vector 0
. 0

Nature 0
398 0
, 0
828 0
- 0
830 0
) 0
that 0
the 0
amino 0
acid 0
sequences 0
of 0
peptide 0
fragments 0
obtained 0
from 0
a 0
polypeptide 0
found 0
in 0
a 0
complex 0
of 0
proteins 0
that 0
alters 0
chromatin 0
structure 0
( 0
ARC B-gene
) 0
are 0
identical 0
to 0
portions 0
of 0
the 0
deduced 0
open 0
reading 0
frame 0
of 0
TIG B-gene
- I-gene
1 I-gene
mRNA I-gene
. 0

Abnormalities 0
of 0
plasma B-gene
cholecystokinin I-gene
were 0
observed 0
only 0
in 0
patients 0
with 0
delayed 0
gastric 0
emptying 0
. 0

5 0
( 0
Sunset 0
Yellow 0
FCF 0
) 0
were 0
determined 0
using 0
liquid 0
chromatography/mass 0
spectrometry 0
( 0
LC/MS 0
) 0
with 0
electrospray 0
ionization 0
. 0

Polysome 0
and 0
40S B-gene
ribosome I-gene
fractions 0
were 0
severely 0
decreased 0
in 0
the 0
krr1 B-gene
mutant I-gene
and 0
Kri1p B-gene
- 0
depleted 0
cells 0
. 0

They 0
also 0
negatively 0
modulate 0
the 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
catalytic 0
activity 0
but 0
to 0
different 0
extents 0
, 0
dependent 0
on 0
the 0
unique 0
N 0
- 0
terminal 0
structure 0
of 0
each 0
isoform 0
. 0

Cam B-gene
kinase I-gene
II I-gene
induces 0
in 0
vivo 0
phosphorylation 0
of 0
Smad2 B-gene
and 0
Smad4 B-gene
and 0
, 0
to 0
a 0
lesser 0
extent 0
, 0
Smad3 B-gene
. 0

The 0
Drosophila B-gene
melanogaster I-gene
suppressor I-gene
of I-gene
sable I-gene
gene I-gene
, 0
su B-gene
( I-gene
s I-gene
) I-gene
, 0
encodes 0
a 0
novel 0
, 0
150 0
- 0
kDa 0
nuclear 0
RNA 0
binding 0
protein 0
, 0
SU B-gene
( I-gene
S I-gene
) I-gene
, 0
that 0
negatively 0
regulates 0
RNA 0
accumulation 0
from 0
mutant 0
alleles 0
of 0
other 0
genes 0
that 0
have 0
transposon 0
insertions 0
in 0
the 0
5 0
' 0
transcribed 0
region 0
. 0

As 0
a 0
result 0
, 0
we 0
have 0
defined 0
two 0
arginine 0
- 0
rich 0
motifs 0
( 0
ARM1 0
and 0
ARM2 0
) 0
that 0
mediate 0
the 0
RNA 0
binding 0
activity 0
of 0
SU B-gene
( I-gene
S I-gene
) I-gene
. 0

This 0
interaction 0
inhibits 0
the 0
histone B-gene
acetyltransferase I-gene
activity 0
of 0
p300 B-gene
, 0
resulting 0
in 0
drastic 0
reduction 0
of 0
nucleosomal 0
histone B-gene
acetylation 0
and 0
alteration 0
of 0
chromatin 0
structure 0
. 0

Recombinant B-gene
BRI1 I-gene
- I-gene
KD I-gene
autophosphorylated 0
on 0
serine 0
( 0
Ser 0
) 0
and 0
threonine 0
( 0
Thr 0
) 0
residues 0
with 0
p 0
- 0
Ser 0
predominating 0
. 0

Flow 0
cytomery 0
was 0
used 0
for 0
cell 0
cycle 0
analysis 0
. 0

Further 0
research 0
is 0
required 0
to 0
better 0
measure 0
treatment 0
effects 0
, 0
modification 0
of 0
MS 0
natural 0
history 0
, 0
and 0
net 0
societal 0
costs 0
of 0
IFN B-gene
beta I-gene
- I-gene
1b I-gene
in 0
RRMS 0
. 0

Cost 0
- 0
effectiveness 0
of 0
interferon B-gene
beta I-gene
- I-gene
1b I-gene
in 0
slowing 0
multiple 0
sclerosis 0
disability 0
progression 0
. 0

Both 0
the 0
Cmax 0
and 0
AUC 0
values 0
were 0
almost 0
doubled 0
with 0
doubling 0
the 0
dose 0
. 0

Hyperactivation 0
of 0
Cdc2 B-gene
in 0
fission 0
yeast 0
causes 0
cells 0
to 0
undergo 0
a 0
lethal 0
premature 0
mitosis 0
called 0
mitotic 0
catastrophe 0
. 0

Diary 0
. 0

Cells 0
differentiate 0
in 0
response 0
to 0
various 0
extracellular 0
stimuli 0
. 0

Transforming B-gene
growth I-gene
factor I-gene
- I-gene
beta1 I-gene
( 0
TGF B-gene
- I-gene
beta1 I-gene
) 0
can 0
act 0
as 0
a 0
tumor 0
suppressor 0
or 0
a 0
tumor 0
promoter 0
depending 0
on 0
the 0
characteristics 0
of 0
the 0
malignant 0
cell 0
. 0

Vasoactive B-gene
intestinal I-gene
peptide I-gene
and 0
pituitary B-gene
adenylate I-gene
cyclase I-gene
- I-gene
activating I-gene
polypeptide I-gene
inhibit 0
nuclear B-gene
factor I-gene
- I-gene
kappa I-gene
B I-gene
- I-gene
dependent I-gene
gene I-gene
activation 0
at 0
multiple 0
levels 0
in 0
the 0
human 0
monocytic 0
cell 0
line 0
THP 0
- 0
1 0
. 0

Mn2+ 0
increased 0
both 0
the 0
junction 0
binding 0
and 0
cleaving 0
activities 0
of 0
the 0
mutant 0
proteins 0
. 0

While 0
Pt B-gene
; I-gene
cycH I-gene
; I-gene
1 I-gene
and 0
Os B-gene
; I-gene
cycH I-gene
; I-gene
1 I-gene
were 0
expressed 0
in 0
all 0
tissues 0
examined 0
, 0
the 0
transcripts 0
accumulated 0
abundantly 0
in 0
dividing 0
cells 0
. 0

Moreover 0
, 0
an 0
in 0
vitro 0
pull 0
- 0
down 0
assay 0
showed 0
that 0
Os B-gene
; I-gene
CycH I-gene
; I-gene
1 I-gene
specifically 0
bound 0
to 0
R2 B-gene
but 0
not 0
to 0
other 0
rice B-gene
CDKs I-gene
. 0

In 0
transient 0
analysis 0
using 0
particle 0
bombardment 0
of 0
tobacco 0
leaf 0
sections 0
, 0
a 0
tetramer 0
of 0
the 0
distB 0
ABRE 0
( 0
abscisic 0
acid 0
- 0
responsive 0
element 0
) 0
mediated 0
transactivation 0
by 0
ABI3 B-gene
and 0
ABI3 B-gene
- 0
dependent 0
response 0
to 0
ABA 0
, 0
whereas 0
a 0
tetramer 0
of 0
the 0
composite 0
RY/G 0
complex 0
, 0
containing 0
RY 0
repeats 0
and 0
a 0
G 0
- 0
box 0
, 0
mediated 0
only 0
ABA 0
- 0
independent 0
transactivation 0
by 0
ABI3 B-gene
. 0

The 0
major 0
neurological 0
manifestations 0
of 0
brain 0
injury 0
in 0
these 0
babies 0
are 0
spastic 0
motor 0
deficits 0
. 0

Spores 0
from 0
Rhizopus 0
stolonifer 0
were 0
suspended 0
in 0
distilled 0
water 0
( 0
1 0
x 0
10 0
( 0
6 0
) 0
spores/mL 0
) 0
and 0
used 0
as 0
starter 0
. 0

Overexpression 0
of 0
Trdpm1 B-gene
in 0
a 0
dpm1 B-gene
( I-gene
+ I-gene
) I-gene
: 0
:his7/dpm1 B-gene
( I-gene
+ I-gene
) I-gene
S.pombe 0
diploid 0
resulted 0
in 0
a 0
4 0
- 0
fold 0
increase 0
in 0
specific 0
DPM B-gene
synthase I-gene
activity 0
. 0

The 0
LMW B-gene
FGF I-gene
- I-gene
2 I-gene
up 0
- 0
regulated 0
the 0
PKC B-gene
epsilon I-gene
levels 0
by 0
1.6 0
- 0
fold 0
; 0
by 0
contrast 0
the 0
HMW B-gene
isoform I-gene
down 0
- 0
regulated 0
the 0
level 0
of 0
this 0
PKC B-gene
isotype I-gene
by 0
about 0
3 0
- 0
fold 0
and 0
increased 0
the 0
amount 0
of 0
PKC B-gene
delta I-gene
by 0
1.7 0
- 0
fold 0
. 0

Helicobacter 0
pylori 0
and 0
stomach 0
diseases 0
: 0
from 0
clinical 0
point 0
of 0
view 0

For 0
this 0
purpose 0
, 0
the 0
writhing 0
test 0
, 0
capsaicin 0
and 0
formalin 0
induced 0
- 0
pain 0
in 0
mice 0
were 0
used 0
. 0

2000 0
update 0
of 0
recommendations 0
for 0
the 0
use 0
of 0
hematopoietic B-gene
colony I-gene
- I-gene
stimulating I-gene
factors I-gene
: 0
evidence 0
- 0
based 0
, 0
clinical 0
practice 0
guidelines 0
. 0

Prominent 0
findings 0
were 0
chronic 0
pancreatitis 0
with 0
acinar 0
and 0
ductal 0
plugs 0
, 0
granulomatous 0
and 0
necrotizing 0
peripancreatic 0
steatitis 0
, 0
degenerative 0
myopathy 0
, 0
testicular 0
atrophy 0
, 0
candidiasis 0
and 0
bacterial 0
necrotizing 0
glossitis 0
. 0

Taken 0
together 0
, 0
our 0
data 0
indicate 0
that 0
multiple 0
survival 0
pathways 0
are 0
triggered 0
via 0
this 0
receptor 0
, 0
whereas 0
NF B-gene
- I-gene
kappaB/Rel I-gene
and 0
kappaB/Rel I-gene

In 0
vitro 0
, 0
Arix B-gene
and 0
NBPhox B-gene
form 0
DNA 0
- 0
independent 0
multimers 0
and 0
exhibit 0
cooperative 0
binding 0
to 0
the 0
DB1 B-gene
regulatory I-gene
element I-gene
, 0
which 0
contains 0
two 0
homeodomain B-gene
recognition I-gene
sites I-gene
. 0

We 0
conclude 0
from 0
this 0
study 0
that 0
Arix B-gene
and 0
NBPhox B-gene
exhibit 0
indistinguishable 0
and 0
independent 0
transcriptional 0
regulatory 0
properties 0
on 0
the 0
DBH B-gene
promoter I-gene
. 0

METHODS 0
AND 0
RESULTS 0
: 0
Studies 0
were 0
undertaken 0
in 0
9 0
isolated 0
guinea 0
pig 0
hearts 0
, 0
which 0
demonstrated 0
reverse 0
use 0
- 0
dependent 0
prolongation 0
of 0
cardiac 0
repolarization 0
by 0
100 0
nmol/L 0
domperidone 0
. 0

The 0
N 0
- 0
terminal 0
small 0
segment 0
of 0
yeast B-gene
TAF145 I-gene
( 0
yTAF145 B-gene
) 0
binds 0
to 0
TBP B-gene
and 0
thereby 0
inhibits 0
TBP B-gene
function 0
. 0

OBJECTIVE 0
: 0
To 0
evaluate 0
the 0
overall 0
performance 0
of 0
a 0
new 0
oscillometric 0
wrist 0
blood 0
pressure 0
monitor 0
( 0
Braun 0
PrecisionSensor 0
, 0
Braun 0
GmbH 0
, 0
Kronberg 0
, 0
Germany 0
) 0
as 0
defined 0
by 0
the 0
ANSI/AAMI 0
SP10 0
- 0
1992 0
guidelines 0
, 0
and 0
to 0
analyze 0
the 0
data 0
for 0
the 0
optimized 0
selection 0
of 0
the 0
algorithm 0
that 0
derives 0
the 0
blood 0
pressure 0
values 0
from 0
the 0
oscillometric 0
blood 0
pressure 0
curves 0
. 0

Following 0
the 0
results 0
of 0
toxicological 0
experiments 0
in 0
the 0
target 0
animals 0
`` 0
Toxicological 0
Drinking 0
Water 0
Standards 0
for 0
Animals 0
'' 0
can 0
be 0
established 0
. 0

An 0
increase 0
in 0
hypothalamic 0
expression 0
of 0
at 0
least 0
two 0
of 0
the 0
erbB B-gene
receptors I-gene
is 0
initiated 0
before 0
the 0
pubertal 0
augmentation 0
of 0
gonadal 0
steroid 0
secretion 0
and 0
is 0
completed 0
on 0
the 0
day 0
of 0
the 0
first 0
preovulatory 0
surge 0
of 0
gonadotropins B-gene
. 0

Dsh B-gene
is 0
required 0
for 0
two 0
different 0
pathways 0
, 0
the 0
Wnt B-gene
pathway 0
and 0
planar 0
polarity 0
pathway 0
in 0
Drosophila 0
. 0

Catch 0
- 0
up 0
growth 0
and 0
craniofacial 0
dimensions 0
following 0
administration 0
of 0
the 0
antineoplastic 0
agent 0
vincristine 0
to 0
young 0
rats 0
. 0

CONCLUSIONS 0
: 0
LSCC 0
malformation 0
, 0
like 0
other 0
inner 0
ear 0
malformations 0
such 0
as 0
large 0
vestibular 0
aqueduct 0
and 0
X 0
- 0
linked 0
mixed 0
deafness 0
with 0
perilymph 0
gusher 0
, 0
can 0
be 0
associated 0
with 0
CHL 0
, 0
SNHL 0
, 0
or 0
normal 0
hearing 0
. 0

Escalation 0
to 0
180 0
mg/m2 0
was 0
to 0
be 0
carried 0
out 0
if 0
white 0
blood 0
cell 0
nadir 0
count 0
was 0
> 0
2.0 0
x 0
10 0
( 0
9 0
) 0
/l 0
and 0
platelet 0
nadir 0
count 0
was 0
> 0
75 0
x 0
10 0
( 0
9 0
) 0
/l 0
. 0

Methyl 0
formate 0
was 0
used 0
as 0
the 0
solvent 0
of 0
biodegradable 0
oligoesters 0
for 0
the 0
fabrication 0
of 0
microspheres 0
with 0
encapsulated 0
bovine B-gene
serum I-gene
albumin I-gene
( 0
BSA B-gene
) 0
. 0

The 0
small B-gene
monomeric I-gene
GTP I-gene
- I-gene
binding I-gene
proteins I-gene
of 0
the 0
RAB B-gene
subfamily I-gene
are 0
key 0
regulatory 0
elements 0
of 0
the 0
machinery 0
that 0
controls 0
membrane 0
traffic 0
in 0
eukaryotic 0
cells 0
. 0

Furthermore 0
, 0
loss 0
of 0
methylation 0
also 0
greatly 0
reduced 0
the 0
association 0
of 0
another 0
yeast 0
B 0
- 0
type 0
subunit 0
, 0
Rts1p B-gene
. 0

Thus 0
, 0
methylation 0
of 0
Pph21p B-gene
is 0
important 0
for 0
formation 0
of 0
PP2A B-gene
trimeric I-gene
and I-gene
dimeric I-gene
complexes I-gene
, 0
and 0
consequently 0
, 0
for 0
PP2A B-gene
function 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
analyze 0
the 0
temporal 0
characteristics 0
and 0
the 0
spatial 0
mapping 0
of 0
the 0
independent 0
components 0
identified 0
by 0
ICA 0
when 0
the 0
subject 0
performs 0
a 0
finger 0
- 0
tapping 0
task 0
. 0

The 0
authors 0
present 0
the 0
only 0
two 0
studies 0
that 0
have 0
proved 0
successful 0
in 0
treating 0
animal 0
models 0
of 0
osteoarthritis 0
using 0
gene 0
therapy 0
, 0
and 0
propose 0
an 0
overview 0
of 0
several 0
strategies 0
for 0
the 0
development 0
of 0
gene 0
therapy 0
in 0
osteoarthritis 0
treatment 0
in 0
the 0
future 0
. 0

Together 0
, 0
these 0
results 0
indicate 0
that 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
induces 0
VEGF B-gene
gene I-gene
expression 0
at 0
both 0
transcriptional 0
and 0
post 0
- 0
transcriptional 0
levels 0
, 0
and 0
IL B-gene
- I-gene
1 I-gene
beta I-gene
evokes 0
p38 B-gene
MAPK 0
and 0
JNK B-gene
signalings 0
, 0
which 0
in 0
turn 0
stimulate 0
the 0
transcription 0
of 0
the 0
VEGF B-gene
gene I-gene
through 0
Sp1 B-gene
- I-gene
binding I-gene
sites I-gene
. 0

Binding 0
of 0
NusA B-gene
to 0
RNA 0
in 0
the 0
presence 0
of 0
alpha 0
or 0
N 0
involves 0
an 0
amino B-gene
- I-gene
terminal I-gene
S1 I-gene
homology I-gene
region I-gene
that 0
is 0
otherwise 0
inactive 0
in 0
full B-gene
- I-gene
length I-gene
NusA I-gene
. 0

The 0
subjects 0
were 0
diagnosed 0
on 0
the 0
basis 0
of 0
DSM 0
- 0
IV 0
pathological 0
gambling 0
criteria 0
and 0
completed 0
the 0
Turkish 0
Version 0
of 0
South 0
Oaks 0
Gambling 0
Screen 0
( 0
SOGS 0
) 0
. 0

Lys 0
( 0
193 0
) 0
and 0
Arg 0
( 0
194 0
) 0
, 0
located 0
at 0
the 0
COOH 0
- 0
terminal 0
end 0
of 0
HD B-gene
, 0
are 0
essential 0
for 0
dimerization 0
. 0

Elevation 0
of 0
intracellular 0
Ca 0
( 0
2+ 0
) 0
levels 0
are 0
also 0
involved 0
because 0
treatment 0
with 0
receptor 0
- 0
associated 0
protein 0
, 0
nifedipine 0
, 0
MK801 0
, 0
removal 0
of 0
Ca 0
( 0
2+ 0
) 0
from 0
the 0
medium 0
and 0
dantrolene 0
all 0
served 0
to 0
inhibit 0
calcium 0
elevation 0
and 0
attenuate 0
the 0
activation 0
of 0
CREB B-gene
. 0

The 0
present 0
study 0
shows 0
that 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
- 0
dependent 0
p38 B-gene
kinase I-gene
activation 0
regulates 0
Akt B-gene
phosphorylation 0
and 0
activity 0
in 0
human 0
neutrophils 0
. 0

When 0
BFDS 0
was 0
taken 0
as 0
the 0
reference 0
, 0
W/A 0
Z 0
scores 0
showed 0
consistent 0
positive 0
increments 0
, 0
from 0
birth 0
in 0
girls 0
and 0
1 0
mo 0
in 0
boys 0
. 0

These 0
probable 0
border 0
sequences 0
are 0
closely 0
related 0
to 0
those 0
of 0
other 0
known 0
T 0
- 0
regions 0
and 0
define 0
a 0
second 0
T 0
- 0
region 0
of 0
pTiChry5 0
, 0
called 0
T 0
- 0
right 0
( 0
TR 0
) 0
, 0
that 0
confers 0
production 0
of 0
the 0
Amadoriopines 0
. 0

Using 0
purified 0
recombinant B-gene
HMG I-gene
I I-gene
, 0
we 0
have 0
identified 0
several 0
high 0
- 0
affinity 0
binding 0
sites 0
which 0
overlap 0
important 0
transcription 0
factor 0
binding 0
sites 0
. 0

High B-gene
- I-gene
mobility I-gene
- I-gene
group I-gene
protein I-gene
I I-gene
can 0
modulate 0
binding 0
of 0
transcription 0
factors 0
to 0
the 0
U5 B-gene
region I-gene
of 0
the 0
human B-gene
immunodeficiency I-gene
virus I-gene
type I-gene
1 I-gene
proviral I-gene
promoter I-gene
. 0

Another 0
cis 0
- 0
acting 0
element 0
, 0
exonic 0
splicing 0
suppressor 0
1 0
( 0
ESS1 0
) 0
, 0
represses 0
use 0
of 0
the 0
nt 0
3225 0
3 0
' 0
splice 0
site 0
. 0

Leptinaemia 0
does 0
not 0
correlate 0
with 0
the 0
actual 0
or 0
mean 0
blood 0
pressure 0
reading 0
nor 0
with 0
stage 0
of 0
hypertension 0
according 0
to 0
the 0
WHO 0
classification 0
. 0

5' 0
- 0
RACE 0
analysis 0
suggested 0
a 0
single 0
transcription 0
initiation 0
site 0
187 0
bp 0
upstream 0
from 0
the 0
translational 0
start 0
site 0
. 0

Thus 0
, 0
diamide 0
treatment 0
of 0
nuclear 0
extracts 0
strongly 0
reduces 0
the 0
binding 0
of 0
NFI B-gene
proteins I-gene
, 0
and 0
the 0
addition 0
of 0
higher 0
concentrations 0
of 0
dithiothreitol 0
to 0
nuclear 0
extracts 0
from 0
TG B-gene
- 0
treated 0
cells 0
restores 0
NFI B-gene
- I-gene
DNA I-gene
binding 0
to 0
levels 0
in 0
extracts 0
from 0
untreated 0
cells 0
. 0

LMP2A B-gene
enhances 0
Lyn B-gene
and 0
Syk B-gene
ubiquitination 0
in 0
vivo 0
in 0
a 0
fashion 0
that 0
depends 0
on 0
the 0
activity 0
of 0
Nedd4 B-gene
family 0
members 0
and 0
correlates 0
with 0
destabilization 0
of 0
the 0
Lyn B-gene
tyrosine I-gene
kinase I-gene
. 0

Further 0
, 0
Tax B-gene
- 0
mediated 0
apoptosis 0
was 0
effectively 0
prevented 0
by 0
ectopic 0
expression 0
of 0
the 0
p300 B-gene
coactivator I-gene
. 0

Our 0
results 0
, 0
however 0
, 0
were 0
obtained 0
for 0
Z 0
itself 0
and 0
not 0
for 0
[ 0
Z 0
] 0
. 0

Fisher 0
's 0
exact 0
test 0
or 0
Pearson 0
's 0
chi2 0
test 0
were 0
used 0
for 0
statistical 0
analysis 0
. 0

RESULTS 0
: 0
In 0
the 0
pregnant 0
group 0
, 0
serum 0
PP14 B-gene
concentrations 0
were 0
markedly 0
increased 0
after 0
ET 0
, 0
and 0
a 0
significant 0
difference 0
between 0
the 0
pregnant 0
group 0
and 0
the 0
nonpregnant 0
group 0
was 0
observed 0
8 0
days 0
following 0
ET 0
( 0
p 0
< 0
0.01 0
) 0
. 0

Thromboelastography 0
is 0
a 0
test 0
that 0
could 0
potentially 0
correlate 0
with 0
the 0
degree 0
of 0
anticoagulation 0
produced 0
by 0
low 0
molecular 0
weight 0
heparin 0
. 0

High 0
expression 0
of 0
the 0
peroxisome B-gene
proliferator I-gene
- I-gene
activated I-gene
receptor I-gene
alpha I-gene
( 0
PPARalpha B-gene
) 0
differentiates 0
brown 0
fat 0
from 0
white 0
, 0
and 0
is 0
related 0
to 0
its 0
high 0
capacity 0
of 0
lipid 0
oxidation 0
. 0

This 0
- 0
2485/ 0
- 0
2458 0
element 0
bound 0
PPARalpha B-gene
and 0
PPARgamma B-gene
from 0
brown 0
fat 0
nuclei 0
. 0

These 0
results 0
provide 0
direct 0
evidence 0
for 0
differential 0
susceptibility 0
to 0
endonuclease 0
- 0
mediated 0
mRNA 0
decay 0
resulting 0
from 0
the 0
differential 0
affinity 0
of 0
a 0
RNA 0
- 0
binding 0
protein 0
for 0
cis 0
- 0
acting 0
stability 0
determinants 0
. 0

RESULTS 0
: 0
Twenty 0
- 0
two 0
( 0
26 0
% 0
) 0
patients 0
had 0
PHG 0
before 0
( 0
group 0
A 0
) 0
and 0
64 0
( 0
74 0
% 0
) 0
developed 0
PHG 0
after 0
variceal 0
eradication 0
( 0
group 0
B 0
) 0
. 0

Response 0
was 0
extremely 0
poor 0
in 0
African 0
Americans 0
and 0
those 0
with 0
HCV 0
genotype 0
1 0
. 0

Aspirin 0
causes 0
peptic 0
ulcers 0
predominately 0
by 0
reducing 0
gastric B-gene
mucosal I-gene
cyclooxygenase I-gene
( 0
COX B-gene
) 0
activity 0
and 0
prostaglandin 0
synthesis 0
. 0

A 0
total 0
of 0
1060 0
clones 0
were 0
randomly 0
selected 0
for 0
sequencing 0
of 0
one 0
end 0
. 0

Expression 0
of 0
a 0
hybrid 0
protein 0
containing 0
the 0
cytoplasmic 0
C 0
- 0
terminal 0
half 0
of 0
UhpB B-gene
fused 0
to 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
also 0
interfered 0
with 0
Uhp B-gene
signaling 0
. 0

CONCLUSIONS 0
: 0
The 0
surgical 0
or 0
multimodality 0
treatment 0
of 0
MSGT 0
has 0
provided 0
a 0
good 0
locoregional 0
control 0
( 0
78 0
% 0
) 0
and 0
68 0
% 0
10 0
- 0
year 0
survival 0
in 0
a 0
series 0
of 0
patients 0
treated 0
at 0
the 0
oncology 0
department 0
of 0
a 0
general 0
hospital 0
in 0
Quito 0
, 0
Ecuador 0
. 0

RESULTS 0
: 0
Glaucoma 0
suspects 0
were 0
divided 0
into 0
two 0
groups 0
according 0
to 0
their 0
SWAP 0
results 0
: 0
high 0
risk 0
( 0
with 0
SWAP 0
abnormalities 0
) 0
and 0
low 0
risk 0
( 0
with 0
normal 0
SWAP 0
result 0
) 0
. 0

The 0
gene 0
is 0
separated 0
into 0
four 0
exons 0
by 0
three 0
short 0
introns 0
, 0
and 0
the 0
open 0
reading 0
frame 0
consists 0
of 0
6660 0
base 0
pairs 0
( 0
bp 0
) 0
capable 0
of 0
encoding 0
a 0
polypeptide 0
of 0
2220 0
amino 0
acid 0
residues 0
. 0

Like 0
the 0
p190 B-gene
- I-gene
B I-gene
exon 0
, 0
the 0
first 0
exon 0
of 0
p190 B-gene
- I-gene
A I-gene
is 0
extremely 0
large 0
( 0
3.7 0
kb 0
in 0
length 0
) 0
, 0
encoding 0
both 0
the 0
GTPase B-gene
and 0
middle 0
domains 0
( 0
residues 0
1 0
- 0
1228 0
) 0
, 0
but 0
not 0
the 0
remaining 0
GAP B-gene
domain I-gene
, 0
suggesting 0
a 0
high 0
conservation 0
of 0
genomic 0
structure 0
between 0
two 0
p190 B-gene
genes I-gene
. 0

The 0
entire 0
human B-gene
teneurin I-gene
- I-gene
1 I-gene
( 0
TEN1 B-gene
) 0
gene 0
is 0
contained 0
in 0
eight 0
PAC 0
clones 0
representing 0
part 0
of 0
the 0
chromosomal 0
locus 0
Xq25 0
. 0

The 0
plexiform 0
neurofibroma 0
and 0
multiple 0
localized 0
neurofibromas 0
are 0
characteristic 0
of 0
NF1 B-gene
. 0

In 0
general 0
lookback 0
, 0
all 0
patients 0
who 0
received 0
blood 0
before 0
being 0
tested 0
for 0
hepatitis 0
C 0
are 0
advised 0
to 0
undergo 0
testing 0
. 0

The 0
proposed 0
algorithm 0
consists 0
of 0
several 0
steps 0
. 0

It 0
contained 0
seven 0
extra 0
amino 0
acids 0
of 0
FVVLNLQ 0
; 0
this 0
short 0
stretch 0
of 0
extra 0
sequence 0
was 0
found 0
between 0
Gln 0
( 0
421 0
) 0
and 0
Phe 0
( 0
422 0
) 0
within 0
the 0
SET B-gene
( 0
Suvar3 B-gene
- I-gene
9 I-gene
, 0
Enhancer B-gene
- I-gene
of I-gene
- I-gene
zeste I-gene
, 0
Trithorax B-gene
) 0
interacting 0
domain 0
( 0
SID 0
) 0
of 0
rMTM B-gene
. 0

MED1 B-gene
has 0
a 0
weak 0
glycosylase B-gene
activity 0
on 0
the 0
mutagenic 0
adduct 0
3 0
, 0
N 0
( 0
4 0
) 0
- 0
ethenocytosine 0
, 0
a 0
metabolite 0
of 0
vinyl 0
chloride 0
and 0
ethyl 0
carbamate 0
. 0

There 0
were 0
no 0
instances 0
of 0
major 0
flap 0
necrosis 0
although 0
two 0
flaps 0
showed 0
tip 0
ischaemia 0
. 0

These 0
results 0
suggest 0
that 0
XAB1 B-gene
is 0
a 0
novel 0
cytoplasmic B-gene
GTPase I-gene
involved 0
in 0
nuclear 0
localization 0
of 0
XPA B-gene
. 0

One 0
of 0
these 0
factors 0
, 0
IRF B-gene
- I-gene
2 I-gene
, 0
was 0
initially 0
cloned 0
as 0
an 0
antagonistic 0
counterpart 0
to 0
IRF B-gene
- I-gene
1 I-gene
with 0
oncogenic 0
potential 0
. 0

Among 0
the 0
total 0
CDSs 0
, 0
8.8 0
% 0
match 0
sequences 0
of 0
proteins 0
found 0
only 0
in 0
Bacillus 0
subtilis 0
and 0
66.7 0
% 0
are 0
widely 0
conserved 0
in 0
comparison 0
with 0
the 0
proteins 0
of 0
various 0
organisms 0
, 0
including 0
B.subtilis 0
. 0

Tobramycin 0
- 0
loaded 0
SLN 0
administered 0
i.v 0
. 0
showed 0
a 0
prolonged 0
circulation 0
time 0
compared 0
to 0
the 0
i.v 0
. 0
administered 0
tobramycin 0
solution 0
. 0

Bacteriol 0
. 0

Terminal B-gene
deoxynucleotidyl I-gene
transferase I-gene
- 0
mediated 0
nick 0
end 0
labeling 0
assays 0
revealed 0
that 0
hormonal 0
activation 0
of 0
the 0
PAX3 B-gene
repressors I-gene
induced 0
extensive 0
apoptosis 0
that 0
correlated 0
with 0
down 0
- 0
regulation 0
of 0
BCL B-gene
- I-gene
X I-gene
( I-gene
L I-gene
) I-gene
expression 0
. 0

VEGF B-gene
promoter I-gene
activity 0
in 0
transient 0
transfections 0
was 0
decreased 0
by 0
either 0
pharmacological 0
or 0
genetic 0
inhibition 0
of 0
EGFR B-gene
, 0
Ras B-gene
, 0
or 0
phosphatidylinositol B-gene
3' I-gene
- I-gene
kinase I-gene
[ B-gene
PI I-gene
( I-gene
3 I-gene
) I-gene
kinase I-gene
] I-gene
. 0

Epidermal B-gene
growth I-gene
factor I-gene
receptor I-gene
transcriptionally 0
up 0
- 0
regulates 0
vascular B-gene
endothelial I-gene
growth I-gene
factor I-gene
expression 0
in 0
human 0
glioblastoma 0
cells 0
via 0
a 0
pathway 0
involving 0
phosphatidylinositol B-gene
3' I-gene
- I-gene
kinase I-gene
and 0
distinct 0
from 0
that 0
induced 0
by 0
hypoxia 0
. 0

Thus 0
, 0
IHHNV 0
is 0
closely 0
related 0
to 0
densoviruses 0
of 0
the 0
genus 0
Brevidensovirus 0
in 0
the 0
family 0
Parvoviridae 0
, 0
and 0
we 0
therefore 0
propose 0
to 0
rename 0
this 0
virus 0
Penaeus 0
stylirostris 0
densovirus 0
( 0
PstDNV 0
) 0
. 0

Stress B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
1 I-gene
( 0
SAPK1 B-gene
) 0
, 0
also 0
called 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
( 0
JNK B-gene
) 0
, 0
becomes 0
activated 0
in 0
vivo 0
in 0
response 0
to 0
pro 0
- 0
inflammatory 0
cytokines 0
or 0
cellular 0
stresses 0
. 0

Catalytic 0
activation 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
( I-gene
MAP I-gene
) I-gene
kinase I-gene
phosphatase I-gene
- I-gene
1 I-gene
by 0
binding 0
to 0
p38 B-gene
MAP I-gene
kinase I-gene
: 0
critical 0
role 0
of 0
the 0
p38 B-gene
C I-gene
- I-gene
terminal I-gene
domain I-gene
in 0
its 0
negative 0
regulation 0
. 0

Thus 0
, 0
the 0
class B-gene
C I-gene
- 0
Vps B-gene
complex 0
directs 0
multiple 0
reactions 0
during 0
the 0
docking 0
and 0
fusion 0
of 0
vesicles 0
with 0
the 0
vacuole 0
, 0
each 0
of 0
which 0
contributes 0
to 0
the 0
overall 0
specificity 0
and 0
efficiency 0
of 0
this 0
transport 0
process 0
. 0

Combined 0
intravenous 0
and 0
intra 0
- 0
arterial 0
recombinant 0
tissue B-gene
plasminogen I-gene
activator I-gene
in 0
acute 0
ischemic 0
stroke 0
. 0

To 0
begin 0
to 0
understand 0
this 0
role 0
, 0
we 0
overexpressed 0
ATF B-gene
- I-gene
2 I-gene
in 0
a 0
human 0
cancer 0
cell 0
line 0
. 0

Signal 0
transduction 0
via 0
modulation 0
of 0
phosphorylation 0
after 0
selective 0
inhibition 0
of 0
protein B-gene
phosphatase I-gene
( I-gene
PP I-gene
) I-gene
1 I-gene
and/or 0
PP2A B-gene
appears 0
to 0
play 0
a 0
role 0
in 0
okadaic 0
acid 0
( 0
OA 0
) 0
- 0
mediated 0
effects 0
. 0

Botulinum B-gene
toxin I-gene
A I-gene
in 0
the 0
treatment 0
of 0
hemiplegic 0
spastic 0
foot 0
drop 0
- 0
- 0
clinical 0
and 0
functional 0
outcomes 0
. 0

Exon 0
A 0
is 0
located 0
approximately 0
7 0
kb 0
5 0
' 0
to 0
the 0
HSL B-gene
translation I-gene
start I-gene
site I-gene
. 0

NF B-gene
- I-gene
kappaB I-gene
is 0
a 0
redox 0
- 0
sensitive 0
transcription 0
factor 0
known 0
to 0
be 0
activated 0
by 0
oxidative 0
stress 0
as 0
well 0
as 0
chemical 0
and 0
biological 0
reductants 0
. 0

Cardiovascular 0
risk 0
factors 0
and 0
antihypertensive 0
treatment 0
. 0

What 0
to 0
look 0
for 0
during 0
a 0
compliance 0
review 0
: 0
10 0
common 0
mistakes 0
made 0
by 0
SNFs 0
. 0

CONCLUSIONS 0
: 0
EBCT 0
technology 0
allows 0
minimally 0
invasive 0
evaluation 0
of 0
intramyocardial 0
microcirculatory 0
function 0
and 0
permits 0
assessment 0
of 0
microvascular 0
BV 0
distribution 0
in 0
different 0
functional 0
components 0
. 0

These 0
two 0
mAbs 0
used 0
the 0
same 0
V 0
( 0
H 0
) 0
and 0
J 0
( 0
H 0
) 0
gene 0
segments 0
, 0
but 0
different 0
D 0
, 0
Vkappa 0
, 0
and 0
Jkappa 0
genes 0
. 0

SSF 0
experiments 0
were 0
carried 0
out 0
in 0
bench 0
- 0
scale 0
bioreactors 0
( 0
equipped 0
with 0
CO2 0
and 0
volatile 0
organic 0
traps 0
) 0
containing 0
a 0
mixture 0
of 0
lignocellulosic 0
materials 0
and 0
a 0
radiolabeled 0
pesticide 0
. 0

Characterization 0
of 0
a 0
Xenopus B-gene
laevis I-gene
CXC I-gene
chemokine I-gene
receptor I-gene
4 I-gene
: 0
implications 0
for 0
hematopoietic 0
cell 0
development 0
in 0
the 0
vertebrate 0
embryo 0
. 0

Patients 0
had 0
to 0
have 0
adequate 0
liver 0
, 0
renal 0
, 0
and 0
marrow 0
functions 0
. 0

Inhibition 0
of 0
RNA2 B-gene
translation 0
was 0
selective 0
, 0
with 0
no 0
effect 0
on 0
general 0
cellular 0
translation 0
or 0
translation 0
of 0
BMV 0
RNA1 B-gene
- 0
encoded 0
replication B-gene
factor I-gene
1a I-gene
, 0
and 0
was 0
independent 0
of 0
p20 B-gene
, 0
a 0
cellular 0
antagonist 0
of 0
DED1 B-gene
function 0
in 0
translation 0
. 0

Abbreviations 0
: 0
CAS B-gene
, 0
CRK B-gene
- I-gene
associated I-gene
substrate I-gene
; 0
CH B-gene
, 0
calponin B-gene
- I-gene
homology I-gene
domain I-gene
; 0
CSK B-gene
, 0
C B-gene
- I-gene
terminal I-gene
SRC I-gene
kinase I-gene
; 0
E6 B-gene
, 0
Papillomavirus B-gene
E6 I-gene
protein I-gene
; 0
FAK B-gene
, 0
focal B-gene
adhesion I-gene
kinase I-gene
; 0
GIT B-gene
, 0
GRK B-gene
interacter I-gene
; 0
GPCR B-gene
, 0
heterotrimeric B-gene
- I-gene
G I-gene
- I-gene
protein I-gene
- I-gene
coupled I-gene
receptor I-gene
; 0
GRK B-gene
, 0
G B-gene
- I-gene
protein I-gene
- I-gene
coupled I-gene
- I-gene
receptor I-gene
kinase I-gene
; 0
MAPK B-gene
, 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
ERK B-gene
, 0
p38 B-gene
, 0
JNK B-gene
) 0
; 0
PAK B-gene
, 0
p21 B-gene
- I-gene
activated I-gene
kinase I-gene
; 0
PBS B-gene
, 0
paxillin B-gene
- I-gene
binding I-gene
subdomain I-gene
; 0
PIX B-gene
, 0
PAK B-gene
- I-gene
interacting I-gene
exchange I-gene
factor I-gene
; 0
PKL B-gene
, 0
paxillin B-gene
kinase I-gene
linker I-gene
; 0
POR1 B-gene
, 0
partner B-gene
of I-gene
Rac I-gene
; 0
PS 0
, 0
phosphoserine 0
; 0
PT 0
, 0
phosphothreonine 0
; 0
PY 0
, 0
phosphotyrosine 0
; 0
RTK B-gene
, 0
growth B-gene
factor I-gene
receptor I-gene
tyrosine I-gene
kinase I-gene
; 0
SH B-gene
, 0
SRC B-gene
- I-gene
homology I-gene
domain I-gene
. 0

In 0
15 0
ventilator 0
- 0
dependent 0
, 0
SB 0
, 0
and 0
actively 0
expiring 0
patients 0
, 0
we 0
found 0
that 0
the 0
difference 0
PEEP 0
( 0
i 0
) 0
, 0
dyn 0
- 0
Pga 0
, 0
total 0
decay 0
( 0
mean 0
+/ 0
- 0
SD 0
, 0
5.7 0
+/ 0
- 0
1.9 0
cm 0
H 0
( 0
2 0
) 0
O 0
) 0
was 0
quite 0
similar 0
to 0
PEEP 0
( 0
i 0
) 0
, 0
dyn 0
ref 0
( 0
5.3 0
+/ 0
- 0
1.9 0
cm 0
H 0
( 0
2 0
) 0
O 0
) 0
. 0

Of 0
208 0
eligible 0
subjects 0
, 0
82 0
received 0
supervised 0
IPT 0
at 0
a 0
dose 0
of 0
900 0
mg 0
twice 0
weekly 0
for 0
6 0
mo 0
( 0
Regimen 0
A 0
) 0
, 0
73 0
received 0
unsupervised 0
IPT 0
900 0
mg 0
twice 0
weekly 0
for 0
6 0
mo 0
( 0
Regimen 0
B 0
) 0
, 0
and 0
53 0
received 0
unsupervised 0
IPT 0
300 0
mg 0
daily 0
for 0
6 0
mo 0
( 0
Regimen 0
C 0
) 0
. 0

There 0
were 0
122 0
cases 0
of 0
tuberculosis 0
over 0
an 0
average 0
10.3 0
yr 0
of 0
follow 0
- 0
up 0
( 0
crude 0
annual 0
incidence 0
, 0
76.2/100,000 0
) 0
. 0

These 0
results 0
suggested 0
that 0
BACH1t B-gene
recruits 0
BACH1 B-gene
to 0
the 0
nucleus 0
through 0
BTB B-gene
domain 0
- 0
mediated 0
interaction 0
. 0

The 0
U17/U16 B-gene
and 0
the 0
U17/U16 I-gene

Transcription 0
of 0
the 0
six 0
EBNA B-gene
genes I-gene
, 0
which 0
are 0
expressed 0
in 0
EBV 0
- 0
immortalized 0
primary 0
B 0
cells 0
, 0
arises 0
from 0
one 0
of 0
two 0
promoters 0
, 0
Cp B-gene
and 0
Wp B-gene
, 0
located 0
near 0
the 0
left 0
end 0
of 0
the 0
viral 0
genome 0
. 0

The 0
Cili B-gene
- I-gene
2 I-gene
sequences I-gene
possess 0
similarity 0
to 0
the 0
RNaseH B-gene
domain I-gene
of 0
Lian B-gene
- 0
Aa1 B-gene
, 0
a 0
mosquito B-gene
non I-gene
- I-gene
LTR I-gene
retrotransposon I-gene
. 0

This 0
dynamic 0
response 0
strongly 0
suggests 0
that 0
the 0
p53 B-gene
and 0
Rb B-gene
tumor 0
suppressor 0
pathways 0
are 0
intact 0
in 0
HeLa 0
cells 0
and 0
that 0
repression 0
of 0
HPV B-gene
E6 I-gene
and 0
E7 B-gene
mobilizes 0
these 0
pathways 0
in 0
an 0
orderly 0
fashion 0
to 0
deliver 0
growth 0
inhibitory 0
signals 0
to 0
the 0
cells 0
. 0

Thus 0
, 0
blocks 0
in 0
the 0
RARalpha B-gene
- 0
specific 0
pathway 0
of 0
retinoid 0
- 0
induced 0
differentiation 0
may 0
be 0
bypassed 0
during 0
retinoid 0
induction 0
of 0
FR B-gene
- I-gene
beta I-gene
expression 0
. 0

Is 0
more 0
better 0
? 0
About 0
dose 0
levels 0
of 0
ACE B-gene
inhibitors 0
in 0
chronic 0
heart 0
failure 0
. 0

To 0
test 0
whether 0
or 0
not 0
SOCS B-gene
- I-gene
3 I-gene
also 0
binds 0
to 0
the 0
IGFIR B-gene
, 0
we 0
cloned 0
human B-gene
SOCS I-gene
- I-gene
3 I-gene
by 0
reverse 0
transcription 0
- 0
polymerase 0
chain 0
reaction 0
from 0
human 0
skeletal 0
muscle 0
mRNA 0
. 0

A 0
protein 0
lacking 0
the 0
SH2 B-gene
and 0
RING 0
finger 0
domains 0
has 0
no 0
activity 0
, 0
but 0
a 0
chimeric 0
protein 0
with 0
the 0
SH2 B-gene
and 0
RING 0
finger 0
domains 0
of 0
SLI B-gene
- I-gene
1 I-gene
replaced 0
by 0
the 0
equivalent 0
domains 0
of 0
c B-gene
- I-gene
Cbl I-gene
has 0
activity 0
. 0

To 0
evaluate 0
the 0
effects 0
of 0
HRT 0
on 0
those 0
factors 0
in 0
end 0
- 0
stage 0
renal 0
disease 0
( 0
ESRD 0
) 0
patients 0
, 0
we 0
evaluated 0
the 0
changes 0
of 0
lipid 0
profile 0
, 0
coagulation 0
and 0
fibrinolysis 0
markers 0
, 0
and 0
plasma 0
homocysteine 0
levels 0
after 0
treatment 0
. 0

There 0
was 0
a 0
weak 0
significant 0
correlation 0
between 0
TGF B-gene
beta I-gene
1 I-gene
levels 0
and 0
normal 0
cell 0
radiosensitivity 0
( 0
lymphocyte 0
SF2 0
) 0
. 0

Acute 0
feasibility 0
and 0
safety 0
of 0
a 0
smoking 0
reduction 0
strategy 0
for 0
smokers 0
with 0
schizophrenia 0
. 0

Tightly 0
ordered 0
proteasomal 0
degradation 0
of 0
proteins 0
critical 0
for 0
cell 0
cycle 0
control 0
implies 0
a 0
role 0
of 0
the 0
proteasome 0
in 0
maintaining 0
cell 0
proliferation 0
and 0
cell 0
survival 0
. 0

The 0
sixth 0
nucleotide 0
was 0
bulged 0
out 0
to 0
allow 0
stacking 0
of 0
this 0
U.G 0
pair 0
on 0
the 0
adjacent 0
helical 0
region 0
. 0

Functional 0
analysis 0
of 0
the 0
mutant B-gene
desmin I-gene
in 0
SW13 0
( 0
vim B-gene
- 0
) 0
cells 0
showed 0
aggregation 0
of 0
abnormal 0
coarse 0
clumps 0
of 0
desmin B-gene
positive 0
material 0
dispersed 0
throughout 0
the 0
cytoplasm 0
. 0

Patients 0
with 0
lesions 0
affecting 0
the 0
PRC 0
but 0
sparing 0
the 0
PHC 0
, 0
and 0
patients 0
with 0
lesions 0
affecting 0
both 0
PRC 0
and 0
PHC 0
, 0
performed 0
an 0
oculomotor 0
delayed 0
response 0
task 0
with 0
unpredictably 0
varied 0
memory 0
delays 0
of 0
up 0
to 0
30 0
s 0
. 0

In 0
addition 0
, 0
26 0
amino 0
acid 0
residues 0
, 0
K69 0
, 0
D88 0
, 0
E94 0
, 0
D134 0
, 0
R154 0
, 0
K169 0
, 0
H197 0
, 0
D233 0
, 0
G235 0
, 0
G236 0
, 0
G237 0
, 0
F238 0
, 0
E274 0
, 0
G276 0
, 0
R277 0
, 0
Y278 0
, 0
K294 0
, 0
Y323 0
, 0
Y331 0
, 0
D332 0
, 0
C360 0
, 0
D361 0
, 0
D364 0
, 0
G387 0
, 0
Y389 0
, 0
and 0
F397 0
( 0
mouse 0
ODC B-gene
numbering 0
) 0
, 0
all 0
of 0
which 0
are 0
implicated 0
in 0
the 0
formation 0
of 0
the 0
pyridoxal 0
phosphate 0
- 0
binding 0
domain 0
and 0
the 0
substrate 0
- 0
binding 0
domain 0
and 0
in 0
dimer 0
stabilization 0
with 0
the 0
eukaryotic 0
ODCs B-gene
, 0
were 0
also 0
conserved 0
in 0
S. 0
ruminantium 0
LDC B-gene
. 0

The 0
Psc2 B-gene
cDNA I-gene
contained 0
an 0
open 0
reading 0
frame 0
homologous 0
to 0
CP2 B-gene
family I-gene
proteins I-gene
. 0

Our 0
results 0
indicate 0
that 0
Shh B-gene
can 0
drive 0
continued 0
cycling 0
in 0
immature 0
, 0
proliferating 0
CGNPs 0
. 0

The 0
QT 0
interval 0
was 0
related 0
to 0
various 0
components 0
of 0
the 0
insulin B-gene
resistance 0
syndrome 0
, 0
including 0
BP 0
and 0
insulin B-gene
sensitivity 0
. 0

The 0
wavenumbers 0
corresponding 0
to 0
the 0
normal 0
modes 0
of 0
vibration 0
were 0
calculated 0
using 0
the 0
DFT 0
( 0
B3LYP/6 0
- 0
31G** 0
) 0
approximation 0
and 0
their 0
agreement 0
with 0
the 0
measured 0
values 0
improved 0
after 0
scaling 0
of 0
the 0
associated 0
force 0
field 0
. 0

The 0
data 0
provide 0
strong 0
evidence 0
that 0
ThlA B-gene
is 0
involved 0
in 0
the 0
metabolism 0
of 0
both 0
acid 0
and 0
solvent 0
formation 0
, 0
whereas 0
the 0
physiological 0
function 0
of 0
ThlB B-gene
has 0
yet 0
to 0
be 0
elucidated 0
. 0

In 0
addition 0
, 0
npm3 B-gene
, 0
which 0
is 0
usually 0
coactivated 0
with 0
fgf8 B-gene
by 0
MMTV 0
insertion 0
, 0
was 0
not 0
up 0
- 0
regulated 0
by 0
androgens 0
in 0
SC 0
- 0
3 0
cells 0
. 0

Experiments 0
with 0
epitope 0
- 0
tagged 0
proteins 0
show 0
that 0
UEV1A B-gene
is 0
a 0
nuclear 0
protein 0
, 0
whereas 0
both 0
Kua B-gene
and 0
Kua B-gene
- 0
UEV B-gene
localize 0
to 0
cytoplasmic 0
structures 0
, 0
indicating 0
that 0
the 0
Kua B-gene
domain I-gene
determines 0
the 0
cytoplasmic 0
localization 0
of 0
Kua B-gene
- 0
UEV B-gene
. 0

Stoichiometric 0
phosphorylation 0
of 0
human B-gene
p53 I-gene
at 0
Ser315 0
stimulates 0
p53 B-gene
- 0
dependent 0
transcription 0
. 0
p53 B-gene
protein I-gene
activity 0
as 0
a 0
transcription 0
factor 0
can 0
be 0
activated 0
in 0
vivo 0
by 0
antibodies 0
that 0
target 0
its 0
C 0
- 0
terminal 0
negative 0
regulatory 0
domain 0
suggesting 0
that 0
cellular 0
enzymes 0
that 0
target 0
this 0
domain 0
may 0
play 0
a 0
role 0
in 0
stimulating 0
p53 B-gene
- 0
dependent 0
gene 0
expression 0
. 0

Interestingly 0
, 0
this 0
mutant 0
cell 0
line 0
lacks 0
expression 0
of 0
the 0
IKK B-gene
regulatory I-gene
protein I-gene
, 0
IKKgamma B-gene
. 0

The 0
Tax/IKKgamma B-gene
interaction 0
serves 0
to 0
recruit 0
Tax/IKKgamma I-gene

An 0
anchored 0
AFLP 0
- 0
and 0
retrotransposon 0
- 0
based 0
map 0
of 0
diploid 0
Avena 0
. 0

In 0
addition 0
, 0
we 0
identified 0
a 0
novel 0
type 0
of 0
inhibitory 0
domain 0
in 0
the 0
N 0
- 0
terminal 0
60 0
amino 0
acids 0
of 0
IRF B-gene
- I-gene
1 I-gene
which 0
strongly 0
inhibits 0
its 0
transcriptional 0
activity 0
. 0

Effects 0
of 0
spatial 0
and 0
temporal 0
smoothing 0
on 0
stimulated 0
brillouin 0
scattering 0
in 0
the 0
independent 0
- 0
hot 0
- 0
spot 0
model 0
limit 0
The 0
influence 0
of 0
laser 0
beam 0
smoothing 0
on 0
stimulated 0
Brillouin 0
backscattering 0
( 0
SBBS 0
) 0
is 0
studied 0
analytically 0
in 0
the 0
limit 0
of 0
the 0
independent 0
hot 0
spot 0
model 0
. 0

Simultaneous 0
determination 0
of 0
theophylline 0
and 0
its 0
metabolites 0
by 0
HPLC 0
] 0
A 0
high 0
performance 0
liquid 0
chromatography 0
( 0
HPLC 0
) 0
method 0
has 0
been 0
developed 0
for 0
the 0
simultaneous 0
determination 0
of 0
theophylline 0
and 0
its 0
metabolites 0
, 0
with 0
caffeine 0
and 0
its 0
metabolites 0
. 0

Ten 0
males 0
performed 0
both 0
test 0
conditions 0
and 0
oxygen 0
uptake 0
VO2 0
, 0
heart 0
rate 0
, 0
minute 0
ventilation 0
VE 0
, 0
perceived 0
exertion 0
and 0
spinal 0
shrinkage 0
were 0
recorded 0
. 0

CONCLUSION 0
: 0
SPT 0
is 0
more 0
useful 0
than 0
WST 0
in 0
differentiating 0
patients 0
predisposed 0
to 0
aspiration 0
. 0

Studied 0
groups 0
were 0
( 0
1 0
) 0
untreated 0
control 0
, 0
n 0
= 0
12 0
; 0
( 0
2 0
) 0
FK 0
- 0
1 0
, 0
n 0
= 0
8 0
; 0
( 0
3 0
) 0
FK 0
- 0
3 0
, 0
n 0
= 0
8 0
. 0

DNA 0
binding 0
and 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
pull 0
- 0
down 0
assays 0
demonstrate 0
that 0
binding 0
requires 0
Elk B-gene
- I-gene
1 I-gene
( I-gene
1 I-gene
- I-gene
212 I-gene
) I-gene
but 0
not 0
the 0
C 0
- 0
terminal 0
transactivation 0
domain 0
. 0

Unexpectedly 0
, 0
ALK7 B-gene
signaling 0
produced 0
a 0
remarkable 0
change 0
in 0
cell 0
morphology 0
characterized 0
by 0
cell 0
flattening 0
and 0
elaboration 0
of 0
blunt 0
, 0
short 0
cell 0
processes 0
. 0

The 0
swa2 B-gene
- I-gene
1 I-gene
allele I-gene
recovered 0
from 0
the 0
original 0
screen 0
carries 0
a 0
point 0
mutation 0
in 0
its 0
tetratricopeptide 0
repeat 0
( 0
TPR 0
) 0
domain 0
, 0
a 0
motif 0
not 0
found 0
in 0
auxilin B-gene
but 0
known 0
in 0
other 0
proteins 0
to 0
mediate 0
interaction 0
with 0
heat B-gene
- I-gene
shock I-gene
proteins I-gene
. 0

Association 0
of 0
stress 0
during 0
delivery 0
with 0
increased 0
numbers 0
of 0
nucleated 0
cells 0
and 0
hematopoietic 0
progenitor 0
cells 0
in 0
umbilical 0
cord 0
blood 0
. 0

In 0
slightly 0
older 0
embryos 0
, 0
the 0
expression 0
was 0
skewed 0
to 0
one 0
side 0
of 0
the 0
embryo 0
and 0
by 0
E6.5 0
, 0
at 0
the 0
onset 0
of 0
gastrulation 0
, 0
expression 0
was 0
seen 0
in 0
the 0
epiblast 0
, 0
visceral 0
endoderm 0
, 0
nascent 0
mesoderm 0
, 0
and 0
the 0
primitive 0
streak 0
. 0

Transformation 0
of 0
the 0
sconC3 B-gene
mutant I-gene
with 0
sconB+ B-gene
restores 0
the 0
wild 0
- 0
type 0
phenotype 0
. 0

The 0
authors 0
proposed 0
that 0
the 0
highly 0
convergent 0
inputs 0
to 0
the 0
entorhinal 0
cortex 0
indicate 0
this 0
region 0
may 0
be 0
particularly 0
important 0
for 0
selecting 0
or 0
compressing 0
information 0
. 0

Influence 0
of 0
oil 0
emulsions 0
and 0
diphenyl 0
on 0
post 0
- 0
harvest 0
physiconutritional 0
changes 0
in 0
Kagzi 0
limes 0
( 0
Citrus 0
aurantifolia 0
) 0
was 0
studied 0
. 0

Detailed 0
analysis 0
of 0
alpha1,3GT B-gene
transcripts I-gene
revealed 0
two 0
major 0
alternative 0
splicing 0
patterns 0
in 0
the 0
5' 0
- 0
untranslated 0
region 0
( 0
5' 0
- 0
UTR 0
) 0
and 0
evidence 0
for 0
minor 0
splicing 0
activity 0
that 0
occurs 0
in 0
a 0
tissue 0
- 0
specific 0
manner 0
. 0

A 0
thermal 0
Kubo 0
- 0
Martin 0
- 0
Schwinger 0
condition 0
arises 0
due 0
to 0
the 0
coupling 0
of 0
a 0
computer 0
to 0
a 0
strong 0
periodic 0
source 0
, 0
namely 0
, 0
the 0
daily 0
and 0
weekly 0
usage 0
patterns 0
of 0
the 0
system 0
. 0

The 0
non 0
- 0
homologous 0
sequences 0
in 0
the 0
5 0
' 0
untranslated 0
regions 0
might 0
be 0
acquired 0
at 0
or 0
after 0
transcription 0
during 0
retrotransposition 0
of 0
the 0
ATLN 0
elements 0
. 0

The 0
time 0
course 0
of 0
RNA1 B-gene
replication 0
and 0
RNA3 B-gene
synthesis 0
in 0
induced 0
yeast 0
paralleled 0
that 0
in 0
yeast 0
transfected 0
with 0
natural 0
FHV 0
virion 0
RNA 0
. 0

The 0
transcription 0
and 0
alternative 0
splicing 0
of 0
human B-gene
ORL1 I-gene
and 0
GAIP B-gene
are 0
cell 0
- 0
type 0
specific 0
. 0

RESULTS 0
: 0
The 0
main 0
effect 0
of 0
muscle 0
pain 0
, 0
compared 0
to 0
non 0
- 0
painful 0
stimulation 0
, 0
was 0
a 0
significant 0
and 0
long 0
- 0
lasting 0
increase 0
of 0
delta 0
( 0
1 0
- 0
3 0
Hz 0
) 0
power 0
and 0
an 0
alpha 0
- 0
1 0
( 0
9 0
- 0
11 0
Hz 0
) 0
power 0
increase 0
over 0
the 0
contralateral 0
parietal 0
locus 0
. 0

The 0
extraction 0
was 0
subsequently 0
rated 0
as 0
'easy 0
' 0
or 0
'difficult'.Taking 0
Pell 0
- 0
Gregory 0
class 0
C 0
as 0
a 0
predictor 0
of 0
a 0
'difficult 0
' 0
extraction 0
, 0
specificity 0
was 0
88 0
% 0
but 0
sensitivity 0
was 0
low 0
at 0
15 0
% 0
. 0

In 0
addition 0
, 0
our 0
results 0
show 0
that 0
ERKs B-gene
and 0
PI3Ks B-gene
can 0
synergise 0
to 0
convert 0
ectoderm 0
into 0
mesoderm 0
. 0

Based 0
on 0
16S B-gene
rRNA I-gene
gene I-gene
sequence I-gene
analysis 0
, 0
the 0
11 0
species 0
having 0
two 0
tuf B-gene
genes I-gene
all 0
have 0
a 0
common 0
ancestor 0
, 0
while 0
the 0
six 0
species 0
having 0
only 0
one 0
copy 0
diverged 0
from 0
the 0
enterococcal 0
lineage 0
before 0
that 0
common 0
ancestor 0
. 0

Nevertheless 0
, 0
protein B-gene
kinase I-gene
A I-gene
stimulation 0
induces 0
CREMalpha B-gene
to 0
activate 0
the 0
complex 0
native 0
promoter 0
in 0
the 0
phosphoenolpyruvate B-gene
carboxykinase I-gene
( 0
PEPCK B-gene
) 0
gene 0
. 0

Another 0
putative 0
HNF3 B-gene
site I-gene
in 0
close 0
apposition 0
to 0
a 0
NF1/CTF B-gene
site 0
was 0
localized 0
upstream 0
of 0
the 0
silencer 0
- 0
like 0
element 0
. 0

This 0
transcriptional 0
regulation 0
occurs 0
through 0
modulation 0
of 0
the 0
forkhead B-gene
transcription I-gene
factor I-gene
FKHR B-gene
- I-gene
L1 I-gene
, 0
and 0
IL B-gene
- I-gene
3 I-gene
inhibited 0
FKHR B-gene
- I-gene
L1 I-gene
activity 0
in 0
a 0
PI3K B-gene
- 0
dependent 0
manner 0
. 0

Taken 0
together 0
, 0
these 0
observations 0
indicate 0
that 0
inhibition 0
of 0
p27 B-gene
( 0
KIP1 B-gene
) 0
transcription 0
through 0
PI3K B-gene
- 0
induced 0
FKHR B-gene
- I-gene
L1 I-gene
phosphorylation 0
provides 0
a 0
novel 0
mechanism 0
of 0
regulating 0
cytokine 0
- 0
mediated 0
survival 0
and 0
proliferation 0
. 0

DNase B-gene
I I-gene
genomic 0
footprinting 0
revealed 0
that 0
the 0
c B-gene
- I-gene
Myb I-gene
site I-gene
is 0
occupied 0
in 0
a 0
tissue 0
- 0
specific 0
fashion 0
in 0
vivo 0
. 0

We 0
conclude 0
that 0
c B-gene
- I-gene
Myb I-gene
regulates 0
the 0
RAG B-gene
- I-gene
2 I-gene
promoter I-gene
in 0
T 0
cells 0
by 0
binding 0
to 0
this 0
consensus B-gene
c I-gene
- I-gene
Myb I-gene
binding I-gene
site I-gene
. 0

A 0
recently 0
reported 0
new 0
member 0
of 0
the 0
Vav B-gene
family I-gene
proteins I-gene
, 0
Vav3 B-gene
has 0
been 0
identified 0
as 0
a 0
Ros B-gene
receptor B-gene
protein I-gene
tyrosine I-gene
kinase I-gene
( 0
RPTK B-gene
) 0
interacting 0
protein 0
by 0
yeast 0
two 0
- 0
hybrid 0
screening 0
. 0

Subsequently 0
, 0
we 0
show 0
that 0
the 0
reexpression 0
of 0
the 0
r B-gene
- I-gene
PTPeta I-gene
gene I-gene
in 0
highly 0
malignant 0
rat 0
thyroid 0
cells 0
transformed 0
by 0
retroviruses 0
carrying 0
the 0
v B-gene
- I-gene
mos I-gene
and 0
v B-gene
- I-gene
ras I-gene
- I-gene
Ki I-gene
oncogenes I-gene
suppresses 0
their 0
malignant 0
phenotype 0
. 0

Induced 0
expression 0
of 0
Rnd3 B-gene
is 0
associated 0
with 0
transformation 0
of 0
polarized 0
epithelial 0
cells 0
by 0
the 0
Raf B-gene
- 0
MEK B-gene
- 0
extracellular 0
signal 0
- 0
regulated 0
kinase 0
pathway 0
. 0

The 0
activity 0
of 0
the 0
transcription B-gene
factor I-gene
CREB I-gene
is 0
regulated 0
by 0
extracellular 0
stimuli 0
that 0
result 0
in 0
its 0
phosphorylation 0
at 0
a 0
critical 0
serine 0
residue 0
, 0
Ser133 0
. 0

RESULTS 0
: 0
Average 0
age 0
at 0
symptom 0
onset 0
was 0
41.2 0
years 0
. 0

When 0
10 0
fields 0
were 0
analysed 0
, 0
a 0
strong 0
relationship 0
was 0
found 0
between 0
the 0
presence 0
of 0
bacteria 0
on 0
Gram 0
staining 0
and 0
the 0
final 0
diagnosis 0
of 0
VAP 0
( 0
for 0
PSB 0
and 0
PTC 0
respectively 0
: 0
sensitivity 0
74 0
and 0
81 0
% 0
, 0
specificity 0
94 0
and 0
100 0
% 0
, 0
positive 0
predictive 0
value 0
91 0
and 0
100 0
% 0
, 0
negative 0
predictive 0
value 0
82 0
and 0
88 0
% 0
) 0
. 0

Unlike 0
the 0
mammalian 0
proteins 0
, 0
XFGF3 B-gene
is 0
efficiently 0
secreted 0
as 0
a 0
Mr 0
31,000 0
glycoprotein 0
, 0
gp31 B-gene
, 0
which 0
undergoes 0
proteolytic 0
cleavage 0
to 0
produce 0
an 0
NH2 0
- 0
terminally 0
truncated 0
product 0
, 0
gp27 B-gene
. 0

NH2 0
- 0
terminal 0
trimming 0
of 0
Xenopus 0
and 0
mammalian B-gene
FGF3s I-gene
may 0
therefore 0
be 0
a 0
prerequisite 0
of 0
optimal 0
biological 0
activity 0
. 0

Here 0
, 0
we 0
identified 0
three 0
cis 0
- 0
elements 0
required 0
for 0
replication 0
within 0
the 0
200 0
bp 0
promoter 0
, 0
using 0
autonomously 0
replicating 0
plasmids 0
carrying 0
various 0
mutations 0
and 0
deletions 0
. 0

Tranilast 0
in 0
the 0
Therapy 0
of 0
Coronary 0
Artery 0
Disease 0
. 0

The 0
objectives 0
of 0
the 0
present 0
study 0
were 0
to 0
evaluate 0
the 0
effects 0
of 0
adding 0
Equex 0
to 0
a 0
TRIS 0
- 0
extender 0
, 0
diluting 0
the 0
semen 0
in 0
1 0
or 0
2 0
steps 0
, 0
freezing 0
according 0
to 0
2 0
methods 0
, 0
thawing 0
at 0
2 0
rates 0
, 0
and 0
the 0
interactions 0
between 0
these 0
treatments 0
, 0
on 0
the 0
post 0
- 0
thaw 0
survival 0
of 0
dog 0
spermatozoa 0
at 0
38 0
degrees 0
C 0
. 0

This 0
study 0
is 0
a 0
further 0
and 0
more 0
extensive 0
validation 0
of 0
the 0
clinician 0
rated 0
NIMH 0
- 0
LCM 0
- 0
p 0
. 0

The 0
Aie1 B-gene
locus I-gene
was 0
mapped 0
to 0
mouse 0
chromosome 0
7A2 0
- 0
A3 0
by 0
fluorescent 0
in 0
situ 0
hybridization 0
. 0

Psychiatric 0
disorders 0
in 0
children 0
and 0
adolescents 0
carry 0
considerable 0
morbidity 0
, 0
impede 0
development 0
, 0
and 0
carry 0
a 0
significant 0
mortality 0
by 0
suicide 0
. 0

Molecular 0
cloning 0
and 0
expression 0
of 0
human B-gene
UDP I-gene
- I-gene
d I-gene
- I-gene
Xylose I-gene
: I-gene
proteoglycan I-gene
core I-gene
protein I-gene
beta B-gene
- I-gene
d I-gene
- I-gene
xylosyltransferase I-gene
and 0
its 0
first 0
isoform B-gene
XT I-gene
- I-gene
II I-gene
. 0

Thyrotoxicosis 0
due 0
to 0
amiodarone 0
is 0
difficult 0
to 0
treat 0
and 0
is 0
further 0
complicated 0
by 0
the 0
pro 0
- 0
arrhythmic 0
potential 0
of 0
thyrotoxicosis 0
and 0
the 0
fading 0
antiarrhythmic 0
effect 0
after 0
amiodarone 0
withdrawal 0
. 0

Chaperones/HSPs B-gene
thus 0
play 0
important 0
roles 0
within 0
cell 0
cycle 0
processes 0
. 0

Oncogenic 0
signalling 0
by 0
E2F1 B-gene
has 0
recently 0
been 0
linked 0
to 0
stabilization 0
and 0
activation 0
of 0
the 0
tumour 0
suppressor 0
p53 B-gene
( 0
refs 0
1,3,4 0
) 0
. 0

This 0
study 0
allows 0
us 0
to 0
draw 0
conclusions 0
about 0
the 0
identity 0
of 0
proteins 0
required 0
for 0
the 0
development 0
of 0
the 0
nervous 0
system 0
in 0
Drosophila 0
and 0
provides 0
an 0
example 0
of 0
a 0
molecular 0
approach 0
to 0
characterize 0
en 0
masse 0
transposon 0
- 0
tagged 0
mutations 0
identified 0
in 0
genetic 0
screens 0
. 0

We 0
describe 0
the 0
identification 0
and 0
initial 0
characterization 0
of 0
neurobeachin B-gene
, 0
a 0
neuron 0
- 0
specific 0
multidomain 0
protein 0
of 0
327 0
kDa 0
with 0
a 0
high 0
- 0
affinity 0
binding 0
site 0
( 0
K 0
( 0
d 0
) 0
, 0
10 0
nm 0
) 0
for 0
the 0
type B-gene
II I-gene
regulatory I-gene
subunit I-gene
of I-gene
protein I-gene
kinase I-gene
A I-gene
( 0
PKA B-gene
RII I-gene
) 0
. 0

Children 0
with 0
ADD 0
showed 0
an 0
attenuated 0
frontal 0
CNV 0
- 0
1 0
amplitude 0
and 0
a 0
trend 0
towards 0
increased 0
CNV 0
- 0
1 0
and 0
CNV 0
- 0
2 0
occipital 0
amplitudes 0
. 0

Where 0
UMDNJ 0
is 0
headed 0
. 0

Overexpression 0
of 0
c B-gene
- I-gene
Myc I-gene
in 0
serum 0
- 0
starved 0
human 0
or 0
mouse 0
embryonic 0
cells 0
leads 0
to 0
apoptosis 0
which 0
is 0
significantly 0
reduced 0
in 0
the 0
presence 0
of 0
growth 0
factor 0
- 0
containing 0
serum 0
. 0
c B-gene
- I-gene
Myc I-gene
- 0
induced 0
apoptosis 0
appears 0
to 0
be 0
deficient 0
in 0
bax B-gene
- 0
null 0
as 0
compared 0
with 0
bax B-gene
- 0
wild 0
- 0
type 0
mouse 0
embryonic 0
fibroblasts 0
. 0

Antimicrobial 0
Susceptibility 0
of 0
Klebsiella 0
pneumoniae 0
Producing 0
Extended B-gene
- I-gene
Spectrum I-gene
beta I-gene
- I-gene
lactamase I-gene
( 0
ESBL B-gene
) 0
Isolated 0
in 0
Hospitals 0
in 0
Brazil 0
. 0

CONCLUSION 0
: 0
Our 0
results 0
suggest 0
that 0
AIF 0
peak 0
saturation 0
leads 0
to 0
a 0
significant 0
systematic 0
error 0
in 0
the 0
determination 0
of 0
CBV 0
and 0
CBF 0
values 0
and 0
has 0
necessarily 0
to 0
be 0
taken 0
into 0
account 0
for 0
dynamic 0
contrast 0
- 0
enhanced 0
MR 0
perfusion 0
studies 0
. 0

METHODS 0
: 0
T2* 0
- 0
weighted 0
, 0
three 0
- 0
dimensional 0
gradient 0
- 0
echo 0
images 0
were 0
acquired 0
by 0
exploiting 0
the 0
magnetic 0
susceptibility 0
difference 0
between 0
oxygenated 0
and 0
deoxygenated 0
hemoglobin B-gene
in 0
the 0
vasculature 0
and 0
microvasculature 0
. 0

In 0
the 0
COPD 0
patients 0
, 0
the 0
variability 0
of 0
Delta 0
- 0
inst 0
Rrs 0
( 0
30 0
% 0
) 0
was 0
greater 0
than 0
that 0
of 0
FOT 0
Rrs 0
( 0
21 0
% 0
) 0
. 0

Toward 0
this 0
end 0
, 0
we 0
prepared 0
synthetic 0
proteins 0
with 0
either 0
the 0
catalytic 0
domain 0
of 0
FAP B-gene
- I-gene
1 I-gene
( I-gene
C I-gene
- I-gene
terminal I-gene
399 I-gene
amino I-gene
acids I-gene
) I-gene
or 0
its 0
inactive 0
form 0
( 0
Cys2408 0
- 0
- 0
> 0
Ser 0
) 0
fused 0
to 0
glutathione B-gene
- I-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
. 0

Thus 0
, 0
Pet111p B-gene
could 0
play 0
dual 0
roles 0
in 0
both 0
membrane 0
localization 0
and 0
regulation 0
of 0
Cox2p B-gene
synthesis 0
within 0
mitochondria 0
. 0

Furthermore 0
, 0
transfection 0
of 0
cells 0
with 0
the 0
spacer 0
- 0
RING 0
domain 0
alone 0
suppressed 0
the 0
antiapoptotic 0
function 0
of 0
the 0
N 0
- 0
terminal 0
BIR B-gene
domain 0
of 0
c B-gene
- I-gene
IAP1 I-gene
and 0
induced 0
apoptosis 0
. 0

The 0
determination 0
of 0
the 0
double 0
bounds 0
in 0
blood 0
serum 0
lipids 0
by 0
titration 0
with 0
ozone 0
: 0
the 0
pathophysiology 0
and 0
diagnostic 0
significance 0
] 0
In 0
this 0
article 0
the 0
method 0
of 0
definition 0
of 0
double 0
binders 0
in 0
lipids 0
of 0
blood 0
serum 0
in 0
patients 0
with 0
different 0
diseases 0
basically 0
atherosclerosis 0
and 0
ischemic 0
heart 0
disease 0
, 0
with 0
use 0
titration 0
by 0
ozone 0
is 0
given 0
. 0

Ang B-gene
II I-gene
- 0
induced 0
fibronectin B-gene
mRNA 0
was 0
not 0
affected 0
by 0
PKC B-gene
inhibitors 0
or 0
PKC B-gene
depletion 0
, 0
whereas 0
specific 0
inhibition 0
of 0
EGF B-gene
- I-gene
R I-gene
function 0
by 0
a 0
dominant B-gene
negative I-gene
EGF I-gene
- I-gene
R I-gene
mutant I-gene
and 0
tyrphostin 0
AG1478 0
abolished 0
induction 0
of 0
fibronectin B-gene
mRNA I-gene
. 0

Acoust 0
. 0

Video 0
images 0
of 0
the 0
nostrils 0
were 0
captured 0
and 0
then 0
analyzed 0
for 0
area 0
, 0
perimeter 0
, 0
centroid 0
, 0
principal 0
axis 0
, 0
moments 0
about 0
the 0
major 0
and 0
minor 0
axes 0
( 0
I11 0
, 0
I22 0
) 0
, 0
anisometry 0
, 0
bulkiness 0
, 0
lateral 0
offset 0
, 0
internostril 0
angle 0
, 0
and 0
rotational 0
angle 0
. 0

MS 0
characteristics 0
of 0
coumarins 0
, 0
psoralens 0
and 0
polymethoxylated 0
flavones 0
with 0
different 0
substitution 0
patterns 0
were 0
determined 0
on 0
the 0
basis 0
of 0
the 0
response 0
obtained 0
with 0
the 0
APcI 0
interface 0
. 0

Young 0
fish 0
( 0
Oreochromis 0
mossambicus 0
) 0
were 0
exposed 0
to 0
microgravity 0
( 0
micro 0
g 0
) 0
for 0
9 0
to 0
10 0
days 0
during 0
space 0
missions 0
STS 0
- 0
55 0
and 0
STS 0
- 0
84 0
, 0
or 0
to 0
hypergravity 0
( 0
hg 0
) 0
for 0
9 0
days 0
. 0

S6K2 B-gene
is 0
highly 0
homologous 0
to 0
S6K1 B-gene
in 0
the 0
core 0
kinase 0
and 0
linker 0
regulatory 0
domains 0
but 0
differs 0
from 0
S6K1 B-gene
in 0
the 0
N 0
- 0
and 0
C 0
- 0
terminal 0
regions 0
and 0
is 0
differently 0
localized 0
primarily 0
to 0
the 0
nucleus 0
because 0
of 0
a 0
C 0
- 0
terminal 0
nuclear 0
localization 0
signal 0
unique 0
to 0
S6K2 B-gene
. 0

Pretreatment 0
of 0
cells 0
with 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
- I-gene
extracellular I-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
kinase I-gene
( 0
MEK B-gene
) 0
inhibitor 0
U0126 0
inhibited 0
S6K2 B-gene
activation 0
to 0
a 0
greater 0
extent 0
than 0
S6K1 B-gene
. 0

T 0
cells 0
express 0
two 0
isoforms 0
of 0
S6k1 B-gene
: 0
a 0
70 0
kDa 0
cytoplasmic 0
kinase 0
and 0
an 0
85 0
kDa 0
isoform 0
that 0
has 0
a 0
classic 0
nuclear 0
localisation 0
. 0

Ketanserin 0
, 0
a 0
hypotensive 0
drug 0
with 0
5 B-gene
- I-gene
HT2 I-gene
receptor I-gene
antagonism 0
, 0
when 0
administered 0
by 0
topical 0
infusion 0
of 0
a 0
0.25 0
% 0
w/v 0
solution 0
by 0
corneal 0
and 0
scleral 0
applications 0
, 0
was 0
found 0
to 0
lower 0
intraocular 0
pressure 0
with 0
four 0
times 0
more 0
activity 0
than 0
its 0
metabolite 0
, 0
ketanserinol 0
. 0

A 0
prospectively 0
gated 0
2D 0
axial 0
sequence 0
with 0
velocity 0
encoding 0
in 0
the 0
craniocaudal 0
direction 0
in 0
the 0
cervical 0
region 0
was 0
set 0
at 0
a 0
velocity 0
of 0
+/ 0
- 0
10 0
cm/s 0
. 0

It 0
was 0
subsequently 0
shown 0
that 0
Tip60 B-gene
had 0
histone B-gene
acetyltransferase I-gene
( 0
HAT B-gene
) 0
activity 0
. 0

Our 0
data 0
show 0
that 0
multiple 0
MLSN1 B-gene
transcripts I-gene
, 0
both 0
constitutively 0
expressed 0
and 0
inducible 0
, 0
are 0
present 0
in 0
cultured 0
pigmented 0
melanoma 0
cells 0
, 0
and 0
suggest 0
that 0
MLSN1 B-gene
expression 0
can 0
be 0
regulated 0
at 0
the 0
level 0
of 0
both 0
transcription 0
and 0
mRNA 0
processing 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

Plectin B-gene
and 0
desmoplakin B-gene
have 0
GSR 0
- 0
containing 0
domains 0
at 0
their 0
C 0
- 0
termini 0
and 0
we 0
further 0
demonstrate 0
that 0
the 0
GSR 0
- 0
containing 0
domain 0
of 0
plectin B-gene
, 0
but 0
not 0
desmoplakin B-gene
, 0
can 0
bind 0
to 0
MTs 0
in 0
vivo 0
. 0

Characterization 0
of 0
the 0
microtubule 0
binding 0
domain 0
of 0
microtubule B-gene
actin I-gene
crosslinking I-gene
factor I-gene
( 0
MACF B-gene
) 0
: 0
identification 0
of 0
a 0
novel 0
group 0
of 0
microtubule B-gene
associated I-gene
proteins I-gene
. 0

These 0
results 0
also 0
suggest 0
the 0
involvement 0
of 0
additional 0
elements 0
in 0
the 0
UPR 0
. 0

We 0
show 0
that 0
in 0
contrast 0
to 0
SRC1 B-gene
, 0
direct 0
binding 0
of 0
CBP B-gene
to 0
the 0
estrogen B-gene
receptor I-gene
is 0
weak 0
, 0
suggesting 0
that 0
SRC1 B-gene
functions 0
primarily 0
as 0
an 0
adaptor 0
to 0
recruit 0
CBP B-gene
and 0
p300 B-gene
. 0

Remarkably 0
, 0
a 0
construct 0
corresponding 0
to 0
residues 0
631 0
to 0
970 0
, 0
which 0
contains 0
only 0
the 0
LXXLL 0
motifs 0
and 0
the 0
AD1 0
region 0
of 0
SRC1 B-gene
, 0
retained 0
strong 0
coactivator 0
activity 0
in 0
our 0
assays 0
. 0

Since 0
MEK B-gene
acts 0
as 0
a 0
cytoplasmic 0
anchor 0
for 0
the 0
ERKs B-gene
, 0
the 0
lack 0
of 0
a 0
MEK B-gene
interaction 0
resulted 0
in 0
the 0
aberrant 0
nuclear 0
localization 0
of 0
ERK2 B-gene
- 0
Delta19 B-gene
- I-gene
25 I-gene
mutants 0
in 0
serum 0
- 0
starved 0
cells 0
. 0

Pmt2 B-gene
is 0
a 0
member 0
of 0
a 0
six 0
- 0
protein 0
family 0
in 0
yeast 0
that 0
catalyzes 0
the 0
first 0
step 0
in 0
O 0
mannosylation 0
of 0
target 0
proteins 0
. 0

Fecal 0
samples 0
were 0
collected 0
at 0
the 0
beginning 0
and 0
end 0
of 0
each 0
trial 0
period 0
and 0
were 0
analyzed 0
for 0
gastrointestinal 0
nematode 0
eggs 0
and 0
Giardia 0
cyst 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
risk 0
factors 0
for 0
background 0
diabetic 0
retinopathy 0
( 0
BDR 0
) 0
and 0
PDR 0
by 0
following 0
394 0
Japanese 0
patients 0
with 0
early 0
- 0
onset 0
type 0
2 0
diabetes 0
diagnosed 0
before 0
30 0
years 0
of 0
age 0
( 0
mean 0
age 0
27 0
, 0
mean 0
blood 0
pressure 0
at 0
entry 0
116/73 0
mm 0
Hg 0
) 0
. 0

Of 0
the 0
21 0
quadrants 0
positive 0
in 0
the 0
controls 0
, 0
17 0
were 0
correlated 0
with 0
previously 0
detected 0
jaw 0
pathoses 0
. 0

Four 0
cases 0
of 0
synovial 0
chondromatosis 0
are 0
presented 0
. 0

Previous 0
studies 0
have 0
shown 0
that 0
the 0
pro 0
- 0
inflammatory 0
cytokines 0
tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
and 0
interferon B-gene
gamma I-gene
reduce 0
the 0
expression 0
of 0
the 0
cystic B-gene
fibrosis I-gene
transmembrane I-gene
conductance I-gene
regulator I-gene
( 0
CFTR B-gene
) 0
gene 0
( 0
CFTR B-gene
) 0
in 0
HT 0
- 0
29 0
and 0
T84 0
cells 0
by 0
acting 0
post 0
- 0
transcriptionally 0
. 0

Regulation 0
of 0
RhoA B-gene
is 0
required 0
to 0
maintain 0
adhesion 0
in 0
stationary 0
cells 0
, 0
but 0
is 0
also 0
critical 0
for 0
cell 0
spreading 0
and 0
migration 0
[ 0
3 0
] 0
. 0

Here 0
we 0
show 0
in 0
mouse 0
fibroblasts 0
stably 0
transformed 0
by 0
v B-gene
- I-gene
Src I-gene
that 0
mRNA 0
and 0
protein 0
levels 0
of 0
p21 B-gene
( 0
WAF1/CIP1 B-gene
) 0
, 0
WAF1/CIP1 I-gene

ORFA 0
and 0
ccdA B-gene
were 0
constitutively 0
cotranscribed 0
as 0
determined 0
by 0
primer 0
extension 0
analysis 0
. 0

Mouse B-gene
Impact I-gene
is 0
a 0
paternally 0
expressed 0
gene 0
encoding 0
an 0
evolutionarily 0
conserved 0
protein 0
of 0
unknown 0
function 0
. 0

These 0
cells 0
produced 0
P2Y B-gene
( I-gene
11 I-gene
) I-gene
mRNA I-gene
during 0
culture 0
. 0

Coexpression 0
studies 0
indicate 0
that 0
insulin B-gene
and 0
PKB B-gene
suppress 0
transactivation 0
by 0
C/EBPbeta B-gene
, 0
but 0
not 0
C/EBPalpha B-gene
, 0
and 0
that 0
N 0
- 0
terminal 0
transactivation 0
domains 0
in 0
C/EBPbeta B-gene
are 0
required 0
. 0

Among 0
eight 0
graminaceous 0
species 0
tested 0
, 0
Ids3 B-gene
expression 0
was 0
observed 0
only 0
in 0
Fe 0
- 0
deficient 0
roots 0
of 0
H. 0
vulgare 0
and 0
Secale 0
cereale 0
. 0
which 0
not 0
only 0
secrete 0
2' 0
- 0
deoxymugineic 0
acid 0
( 0
DMA 0
) 0
, 0
but 0
also 0
mugineic 0
acid 0
( 0
MA 0
) 0
and 0
3 0
- 0
epihydroxymugineic 0
acid 0
( 0
epiHMA 0
, 0
H. 0
vulgare 0
) 0
, 0
and 0
3 0
- 0
hydroxymugineic 0
acid 0
( 0
HMA 0
, 0
S. 0
cereale 0
) 0
. 0

In 0
contrast 0
, 0
high 0
COUP B-gene
- I-gene
TFI I-gene
expression 0
impeded 0
the 0
neuronal 0
differentiation 0
of 0
P19 0
cells 0
induced 0
with 0
RA 0
, 0
resulting 0
in 0
cell 0
cultures 0
lacking 0
neurons 0
. 0

Because 0
PET 0
is 0
also 0
useful 0
for 0
the 0
pretreatment 0
and 0
follow 0
- 0
up 0
evaluation 0
, 0
the 0
use 0
of 0
stereotactic 0
PET 0
in 0
these 0
patients 0
can 0
enable 0
an 0
accurate 0
comparison 0
of 0
PET 0
- 0
based 0
metabolic 0
data 0
with 0
MR 0
- 0
based 0
anatomical 0
data 0
. 0

Therefore 0
, 0
in 0
our 0
in 0
vitro 0
model 0
, 0
the 0
localization 0
of 0
the 0
mutation 0
in 0
the 0
K B-gene
- I-gene
ras I-gene
gene I-gene
predisposes 0
to 0
a 0
different 0
level 0
of 0
aggressiveness 0
in 0
the 0
transforming 0
phenotype 0
. 0

Here 0
, 0
we 0
describe 0
the 0
isolation 0
of 0
MdPin1 B-gene
, 0
a 0
Pin1 B-gene
homologue 0
from 0
the 0
plant 0
species 0
apple 0
( 0
Malus 0
domestica 0
) 0
and 0
show 0
that 0
it 0
has 0
the 0
same 0
phosphorylation 0
- 0
specific 0
substrate 0
specificity 0
and 0
can 0
be 0
inhibited 0
by 0
juglone 0
in 0
vitro 0
, 0
as 0
is 0
the 0
case 0
for 0
Pin1 B-gene
. 0

Differential 0
association 0
of 0
products 0
of 0
alternative 0
transcripts 0
of 0
the 0
candidate 0
tumor B-gene
suppressor I-gene
ING1 I-gene
with 0
the 0
mSin3/HDAC1 B-gene
transcriptional 0
corepressor 0
complex 0
. 0

These 0
and 0
other 0
data 0
presented 0
suggest 0
that 0
TAg B-gene
're 0
- 0
models 0
' 0
host 0
cell 0
transcription 0
factors 0
that 0
are 0
used 0
early 0
in 0
viral 0
infection 0
, 0
and 0
thereby 0
mimics 0
an 0
event 0
that 0
naturally 0
occurs 0
during 0
transformation 0
. 0

This 0
sensitivity 0
analysis 0
showed 0
that 0
the 0
practical 0
limits 0
of 0
the 0
accuracy 0
of 0
the 0
used 0
screening 0
test 0
jeopardize 0
the 0
estimation 0
of 0
the 0
true 0
herd 0
prevalence 0
within 0
reasonable 0
confidence 0
limits 0
, 0
because 0
the 0
within 0
- 0
herd 0
PTB 0
true 0
prevalence 0
was 0
low.For 0
this 0
reason 0
we 0
augmented 0
the 0
herd 0
specificity 0
for 0
herds 0
with 0
larger 0
adult 0
herd 0
size 0
( 0
> 0
5 0
) 0
. 0

ORFK10.5 B-gene
encodes 0
a 0
protein 0
, 0
latency B-gene
- I-gene
associated I-gene
nuclear I-gene
antigen I-gene
2 I-gene
( 0
LANA2 B-gene
) 0
, 0
which 0
is 0
expressed 0
in 0
KSHV 0
- 0
infected 0
hematopoietic 0
tissues 0
, 0
including 0
PEL 0
and 0
CD 0
but 0
not 0
KS 0
lesions 0
. 0

As 0
hypothesized 0
, 0
believers 0
showed 0
relatively 0
higher 0
right 0
hemispheric 0
activation 0
and 0
reduced 0
hemispheric 0
asymmetry 0
of 0
functional 0
complexity 0
. 0

In 0
Xenopus 0
, 0
BMPs B-gene
act 0
as 0
epidermal 0
inducers 0
and 0
also 0
as 0
negative 0
regulators 0
of 0
neurogenesis 0
. 0

Presently 0
four 0
unique 0
variants 0
carrying 0
distinct 0
GAF B-gene
sequences I-gene
in 0
the 0
N 0
- 0
terminal 0
region 0
have 0
been 0
identified 0
. 0

Genomic 0
organization 0
of 0
the 0
human 0
phosphodiesterase B-gene
PDE11A I-gene
gene I-gene
. 0

The 0
present 0
findings 0
revealed 0
that 0
the 0
rib B-gene
- I-gene
2 I-gene
protein I-gene
was 0
a 0
unique 0
alpha1,4 B-gene
- I-gene
N I-gene
- I-gene
acetylglucosaminyltransferase I-gene
involved 0
in 0
the 0
biosynthetic 0
initiation 0
and 0
elongation 0
of 0
heparan 0
sulfate 0
. 0

Inhibition 0
of 0
the 0
Mek/Erk B-gene
pathway 0
in 0
Mek/Erk I-gene

The 0
transcription 0
factor 0
CHOP/GADD153 B-gene
gene 0
is 0
induced 0
by 0
cellular 0
stress 0
and 0
is 0
involved 0
in 0
mediating 0
apoptosis 0
. 0

Addition 0
of 0
synthetic 0
tyrosine 0
- 0
phosphorylated 0
peptides 0
derived 0
from 0
betac 0
cytoplasmic 0
tyrosines 0
prior 0
to 0
GM B-gene
- I-gene
CSF I-gene
stimulation 0
inhibited 0
the 0
in 0
vitro 0
activation 0
of 0
STAT5 B-gene
. 0

MAIN 0
OUTCOME 0
MEASURES 0
: 0
Percentage 0
change 0
in 0
the 0
apnea 0
- 0
hypopnea 0
index 0
( 0
AHI 0
; 0
apnea 0
events 0
+ 0
hypopnea 0
events 0
per 0
hour 0
of 0
sleep 0
) 0
and 0
odds 0
of 0
developing 0
moderate 0
- 0
to 0
- 0
severe 0
SDB 0
( 0
defined 0
by 0
an 0
AHI 0
> 0
or 0
=15 0
events 0
per 0
hour 0
of 0
sleep 0
) 0
, 0
with 0
respect 0
to 0
change 0
in 0
weight 0
. 0

Paraneoplastic 0
rheumatic 0
syndromes 0
. 0

This 0
article 0
reviews 0
recent 0
information 0
on 0
the 0
frequency 0
, 0
characteristics 0
, 0
and 0
possible 0
pathogenic 0
mechanisms 0
of 0
the 0
vasculitides 0
occurring 0
in 0
patients 0
with 0
the 0
main 0
connective 0
tissue 0
diseases 0
. 0

Tec B-gene
kinase I-gene
signaling 0
in 0
T 0
cells 0
is 0
regulated 0
by 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
and 0
the 0
Tec B-gene
pleckstrin B-gene
homology I-gene
domain I-gene
. 0

Current 0
evidence 0
for 0
this 0
type 0
of 0
DNA 0
supercoiling 0
- 0
dependent 0
transcriptional 0
coupling 0
, 0
based 0
largely 0
on 0
the 0
in 0
vivo 0
activities 0
of 0
promoters 0
contained 0
in 0
engineered 0
DNA 0
constructs 0
, 0
suggests 0
that 0
the 0
transcription 0
complex 0
must 0
be 0
physically 0
hindered 0
to 0
generate 0
DNA 0
supercoils 0
and 0
to 0
prevent 0
their 0
diffusion 0
throughout 0
the 0
DNA 0
duplex 0
. 0

The 0
structure 0
of 0
the 0
free 0
SH2 B-gene
domain I-gene
has 0
been 0
compared 0
to 0
that 0
of 0
the 0
SH2 B-gene
complexed 0
with 0
a 0
doubly 0
phosphorylated 0
peptide 0
derived 0
from 0
polyomavirus B-gene
middle I-gene
T I-gene
antigen I-gene
( 0
MT B-gene
) 0
. 0

We 0
have 0
identified 0
three 0
binding 0
sites 0
for 0
protein 0
complexes 0
: 0
a 0
palindrome 0
, 0
a 0
direct 0
repeat 0
, 0
and 0
a 0
C+T 0
sequence 0
that 0
corresponds 0
to 0
seven 0
GAGA 0
motifs 0
on 0
the 0
transcribed 0
strand 0
. 0

Copyright 0
2000 0
Academic 0
Press 0
. 0

Nucleotide 0
sequence 0
, 0
genome 0
organization 0
and 0
phylogenetic 0
analysis 0
of 0
pineapple 0
mealybug 0
wilt 0
- 0
associated 0
virus 0
- 0
2 0
. 0

Patients 0
underwent 0
pretreatment 0
cystoscopy 0
and 0
detailed 0
tumor 0
mapping 0
, 0
and 0
were 0
treated 0
with 0
75 0
mg. 0
/m.2 0
cisplatin 0
on 0
day 0
1 0
and 0
1 0
gm./m.2 0
daily 0
, 0
5 0
- 0
fluorouracil 0
on 0
days 0
1 0
to 0
4 0
and 0
definitive 0
radiotherapy 0
. 0

All 0
9 0
untreated 0
patients 0
underwent 0
laparoscopy 0
, 0
which 0
identified 0
3 0
intra 0
- 0
abdominal 0
, 0
3 0
vanished 0
and 0
2 0
peeping 0
testes 0
, 0
and 0
1 0
atrophic 0
testis 0
in 0
the 0
inguinal 0
canal 0
. 0

This 0
philosophy 0
was 0
instituted 0
for 0
the 0
compound 0
RP 0
73401 0
, 0
a 0
specific 0
phosphodiesterase B-gene
IV I-gene
inhibitor 0
, 0
that 0
was 0
being 0
developed 0
simultaneously 0
for 0
delivery 0
by 0
both 0
oral 0
and 0
pulmonary 0
routes 0
of 0
administration 0
. 0

Increased 0
levels 0
of 0
anticardiolipin B-gene
immunoglobulin I-gene
G I-gene
may 0
also 0
cause 0
bleeding 0
. 0

RESULTS 0
: 0
Prevalence 0
of 0
obesity 0
( 0
BMI 0
SDS 0
> 0
2.0 0
) 0
was 0
< 0
2 0
% 0
at 0
diagnosis 0
, 0
but 0
increased 0
to 0
16 0
% 0
at 0
3y 0
. 0

One 0
of 0
the 0
sequelae 0
of 0
the 0
antiphospholipid 0
- 0
antibodies 0
is 0
an 0
impaired 0
uteroplacental 0
circulation 0
. 0

Bupropion 0
to 0
aid 0
smoking 0
cessation 0
. 0

Using 0
a 0
natural 0
dominant 0
negative 0
for 0
AP B-gene
- I-gene
1 I-gene
transcriptional 0
activity 0
in 0
ROS 0
17/2.8 0
cells 0
, 0
we 0
then 0
showed 0
that 0
AP B-gene
- I-gene
1 I-gene
transcription I-gene
factors I-gene
mediated 0
TGF B-gene
- I-gene
beta1 I-gene
- 0
and 0
BMP B-gene
- I-gene
2 I-gene
- 0
regulated 0
expression 0
of 0
the 0
( B-gene
alpha1 I-gene
) I-gene
collagen I-gene
I I-gene
gene I-gene
as 0
well 0
as 0
TGF B-gene
- I-gene
beta1 I-gene
- 0
regulated 0
expression 0
of 0
the 0
parathyroid B-gene
hormone I-gene
( 0
PTH B-gene
) 0
/PTH B-gene
- I-gene
related I-gene
peptide I-gene
( I-gene
PTHrP I-gene
) I-gene
receptor I-gene
. 0

PM 0
12 0
or 0
18 0
mg/kg 0
daily 0
plus 0
a 0
standard 0
dose 0
of 0
SB 0
for 0
21 0
days 0
was 0
statistically 0
more 0
effective 0
than 0
SB 0
in 0
producing 0
a 0
final 0
cure 0
for 0
patients 0
with 0
VL 0
in 0
Bihar 0
, 0
India 0
. 0

Adjuvant 0
therapy 0
for 0
colon 0
cancer 0
] 0
Surgery 0
alone 0
may 0
fail 0
to 0
cure 0
a 0
considerable 0
number 0
of 0
locally 0
advanced 0
colon 0
cancers 0
. 0

There 0
were 0
significant 0
differences 0
( 0
p 0
< 0
0.05 0
) 0
between 0
the 0
fracture 0
and 0
nonfracture 0
groups 0
in 0
the 0
total 0
femur 0
BMD 0
( 0
13 0
% 0
) 0
, 0
trabecular 0
BMD 0
in 0
the 0
distal 0
radius 0
( 0
4 0
% 0
) 0
, 0
and 0
the 0
fractal 0
dimension 0
in 0
the 0
radiographs 0
( 0
FD2 0
) 0
( 0
3 0
% 0
) 0
. 0

BACKGROUND 0
: 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
and 0
compare 0
interleukin B-gene
- I-gene
6 I-gene
( 0
IL B-gene
- I-gene
6 I-gene
) 0
levels 0
in 0
gingival 0
crevicular 0
fluid 0
( 0
GCF 0
) 0
and 0
clinical 0
periodontal 0
findings 0
in 0
patients 0
with 0
rheumatoid 0
arthritis 0
( 0
RA 0
) 0
and 0
adult 0
periodontitis 0
( 0
AP 0
) 0
. 0

In 0
a 0
prospective 0
, 0
multicentre 0
trial 0
the 0
efficacy 0
of 0
an 0
Vitex 0
agnus 0
castus 0
L 0
extract 0
Ze 0
440 0
was 0
investigated 0
in 0
50 0
patients 0
with 0
pre 0
- 0
menstrual 0
syndrome 0
( 0
PMS 0
) 0
. 0

Studies 0
are 0
necessary 0
to 0
assess 0
the 0
source 0
of 0
contamination 0
and 0
potential 0
role 0
of 0
MRSA 0
- 0
contaminated 0
milk 0
in 0
the 0
transmission 0
of 0
MRSA 0
to 0
neonates 0
. 0

Effects 0
of 0
Trypanosoma 0
vivax 0
on 0
pregnancy 0
of 0
Yankasa 0
sheep 0
and 0
the 0
results 0
of 0
homidum 0
chloride 0
chemotherapy 0
. 0

NF B-gene
kappa I-gene
B I-gene
was 0
activated 0
to 0
a 0
much 0
greater 0
extent 0
by 0
roscovitine 0
in 0
the 0
WT 0
cells 0
than 0
in 0
Y8 0
cells 0
. 0

Depending 0
on 0
treatment 0
exposures 0
, 0
this 0
at 0
- 0
risk 0
population 0
may 0
experience 0
life 0
- 0
threatening 0
late 0
effects 0
, 0
such 0
as 0
cirrhosis 0
secondary 0
to 0
hepatitis 0
C 0
or 0
late 0
- 0
onset 0
anthracycline 0
- 0
induced 0
cardiomyopathy 0
, 0
or 0
life 0
- 0
changing 0
late 0
effects 0
, 0
such 0
as 0
cognitive 0
dysfunction 0
. 0

The 0
presence 0
of 0
locus 0
- 0
specific 0
residues 0
throughout 0
the 0
entire 0
promoter 0
region 0
strongly 0
suggests 0
that 0
the 0
various 0
HLA B-gene
class I-gene
I I-gene
loci I-gene
are 0
differentially 0
regulated 0
. 0

Because 0
the 0
number 0
of 0
parameters 0
required 0
by 0
a 0
Volterra 0
series 0
grows 0
rapidly 0
with 0
both 0
the 0
length 0
of 0
its 0
memory 0
and 0
the 0
order 0
of 0
its 0
nonlinearity 0
, 0
methods 0
for 0
identifying 0
these 0
models 0
from 0
measurements 0
of 0
input/output 0
data 0
are 0
limited 0
to 0
low 0
- 0
order 0
systems 0
with 0
relatively 0
short 0
memories 0
. 0

The 0
standard 0
method 0
for 0
calculating 0
the 0
composite 0
score 0
on 0
the 0
S 0
- 0
B 0
IV 0
excludes 0
subtests 0
with 0
a 0
raw 0
score 0
of 0
0 0
, 0
which 0
overestimates 0
cognitive 0
functioning 0
in 0
young 0
biologically 0
high 0
risk 0
children 0
. 0

NiCl 0
( 0
2 0
) 0
- 0
induced 0
MCP B-gene
- I-gene
1 I-gene
synthesis 0
required 0
activation 0
of 0
NF B-gene
- I-gene
kappaB I-gene
since 0
mutation 0
of 0
NF B-gene
- I-gene
kappaB I-gene
- I-gene
binding I-gene
sites I-gene
in 0
the 0
promoter 0
resulted 0
in 0
complete 0
loss 0
of 0
inducible 0
promoter 0
activity 0
. 0

Engagement 0
of 0
human B-gene
CD2 I-gene
by 0
mitogenic 0
pairs 0
of 0
anti B-gene
- I-gene
CD2 I-gene
mAb I-gene
induces 0
tyrosine 0
phosphorylation 0
of 0
a 0
number 0
of 0
intracellular 0
proteins 0
including 0
a 0
120 0
kDa 0
phosphoprotein 0
that 0
we 0
identify 0
as 0
the 0
proto B-gene
- I-gene
oncogene I-gene
c I-gene
- I-gene
Cbl I-gene
. 0

Validity 0
of 0
NIR 0
spectroscopy 0
for 0
quantitatively 0
measuring 0
muscle 0
oxidative 0
metabolic 0
rate 0
in 0
exercise 0
. 0

Previous 0
studies 0
have 0
demonstrated 0
that 0
tissue 0
- 0
restricted 0
transcription 0
factors 0
including 0
PU.1 B-gene
and 0
PU.1 B-gene
interaction I-gene
partner I-gene
( 0
PIP B-gene
) 0
function 0
synergistically 0
with 0
c B-gene
- I-gene
Fos I-gene
plus 0
c B-gene
- I-gene
Jun I-gene
to 0
stimulate 0
the 0
kappaE3' B-gene
- I-gene
enhancer I-gene
in 0
3T3 0
cells 0
. 0

The 0
murine B-gene
int I-gene
- I-gene
6 I-gene
locus I-gene
, 0
identified 0
as 0
a 0
frequent 0
integration 0
site 0
of 0
mouse 0
mammary 0
tumor 0
viruses 0
, 0
encodes 0
the 0
48 B-gene
- I-gene
kDa I-gene
eIF3e I-gene
subunit I-gene
of I-gene
translation I-gene
initiation I-gene
factor I-gene
eIF3 I-gene
. 0

An 0
int6 B-gene
deletion I-gene
( 0
int6Delta B-gene
) 0
mutant 0
was 0
viable 0
but 0
grew 0
slowly 0
in 0
minimal 0
medium 0
. 0

Additionally 0
, 0
MIP B-gene
- I-gene
2A I-gene
antagonizes 0
cell 0
growth 0
regulatory 0
role 0
of 0
MBP B-gene
- I-gene
1 I-gene
. 0

We 0
produced 0
transgenic 0
plants 0
expressing 0
the 0
antisense B-gene
Arabidopsis I-gene
HD I-gene
( 0
AtHD1 B-gene
) 0
gene 0
. 0

3.04+/ 0
- 0
1.2 0
, 0
P 0
< 0
0.0001 0
) 0
, 0
large 0
accelerations/30 0
min 0
( 0
1.46+/ 0
- 0
1.96 0
vs 0
. 0

Four 0
transcription 0
initiation 0
sites 0
have 0
been 0
identified 0
by 0
full 0
- 0
length 0
RNA B-gene
ligase I-gene
- 0
mediated 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
( 0
RLM 0
- 0
RACE 0
) 0
between 0
- 0
61 0
and 0
- 0
32 0
bp 0
from 0
the 0
translation 0
initiation 0
codon.Reverse 0
transcription 0
- 0
PCR 0
analysis 0
revealed 0
that 0
PFK B-gene
- I-gene
A I-gene
, 0
PFK B-gene
- I-gene
B I-gene
and 0
PFK B-gene
- I-gene
C I-gene
genes I-gene
were 0
expressed 0
, 0
in 0
all 0
mouse 0
tissues 0
tested 0
, 0
at 0
varying 0
levels 0
. 0

PFK B-gene
- I-gene
A I-gene
mRNA 0
was 0
more 0
abundantly 0
expressed 0
in 0
all 0
tissues 0
than 0
were 0
the 0
PFK B-gene
- I-gene
B I-gene
and 0
PFK B-gene
- I-gene
C I-gene
genes I-gene
. 0

We 0
used 0
the 0
Toshiba 0
IIDR 0
system 0
, 0
which 0
is 0
composed 0
of 0
an 0
X 0
- 0
ray 0
TV 0
system 0
and 0
a 0
digital 0
image 0
managing 0
circuit 0
. 0

In 0
whole 0
sardine 0
, 0
domoic 0
acid 0
was 0
detected 0
in 0
levels 0
exceeding 0
sometimes 0
the 0
regulatory 0
limit 0
. 0

In 0
addition 0
, 0
we 0
identified 0
two 0
mutations 0
, 0
Delta 0
M1281 0
and 0
IVS51+5G 0
- 0
- 0
> 0
A 0
, 0
in 0
a 0
German 0
USH1 B-gene
patient 0
. 0

Closeup 0
: 0
a 0
resource 0
for 0
nurses 0
who 0
smoke 0
. 0

[ 0
18F 0
] 0
( 0
+ 0
) 0
- 0
4 0
- 0
fluorobenzyltrozamicol 0
( 0
FBT 0
) 0
, 0
which 0
selectively 0
binds 0
to 0
the 0
vesicular 0
acetylcholine B-gene
transporter I-gene
in 0
the 0
presynaptic 0
cholinergic 0
neuron 0
, 0
has 0
previously 0
been 0
shown 0
to 0
be 0
a 0
useful 0
ligand 0
for 0
the 0
study 0
of 0
cholinergic 0
terminal 0
density 0
in 0
the 0
basal 0
ganglia 0
with 0
PET 0
. 0

We 0
demonstrate 0
that 0
the 0
protein 0
is 0
a 0
murine B-gene
homologue I-gene
of I-gene
SAF I-gene
- I-gene
A I-gene
which 0
has 0
been 0
shown 0
to 0
bind 0
selectively 0
to 0
MARs 0
and 0
is 0
responsible 0
for 0
the 0
satMa B-gene
- 0
binding 0
activity 0
in 0
the 0
chromatographic 0
fractions 0
. 0

The 0
molecular 0
associations 0
dictating 0
INCENP B-gene
behavior 0
during 0
mitosis 0
are 0
currently 0
unknown 0
. 0

Ang B-gene
II I-gene
significantly 0
induced 0
Ang2 B-gene
mRNA I-gene
accumulations 0
without 0
affecting 0
Ang1 B-gene
or 0
Tie2 B-gene
expression 0
, 0
which 0
was 0
inhibited 0
by 0
protein B-gene
kinase I-gene
C I-gene
inhibitors 0
and 0
by 0
intracellular 0
Ca 0
( 0
2+ 0
) 0
chelating 0
agents 0
. 0

Promoter 0
analysis 0
demonstrated 0
that 0
the 0
sequence 0
identical 0
to 0
consensus 0
cAMP 0
- 0
responsive 0
element 0
( 0
CRE 0
) 0
located 0
at 0
- 0
481 0
of 0
the 0
SMemb B-gene
promoter I-gene
was 0
critical 0
for 0
Hex B-gene
responsiveness 0
. 0

LH/CG B-gene
receptor I-gene
activation 0
of 0
ARNO B-gene
is 0
not 0
mediated 0
by 0
activation 0
of 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
( 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
) 0
or 0
by 0
G B-gene
protein I-gene
beta I-gene
gamma I-gene
subunits I-gene
. 0

Deletion 0
analysis 0
showed 0
that 0
the 0
- 0
321/+41 0
sequence 0
was 0
sufficient 0
for 0
both 0
the 0
constitutive 0
promoter 0
activity 0
and 0
auto 0
- 0
activation 0
and 0
electrophoretic 0
mobility 0
shift 0
assays 0
identified 0
the 0
interaction 0
of 0
C/EBPs B-gene
and 0
Sp1 B-gene
to 0
this 0
region 0
. 0

Termination 0
of 0
induced 0
VT 0
on 0
the 0
first 0
attempt 0
was 0
comparable 0
with 0
BV 0
pacing 0
( 0
87.4 0
% 0
) 0
versus 0
RV 0
pacing 0
( 0
89.6 0
% 0
) 0
. 0

We 0
compare 0
the 0
results 0
of 0
this 0
algorithm 0
with 0
the 0
results 0
obtained 0
with 0
two 0
other 0
algorithms 0
, 0
the 0
optimal 0
algorithm 0
for 0
monochannel 0
nonoverlapping 0
noise 0
and 0
the 0
optimal 0
algorithm 0
for 0
multichannel 0
additive 0
noise 0
, 0
and 0
we 0
show 0
that 0
in 0
both 0
cases 0
improvement 0
can 0
be 0
obtained 0
. 0

Changes 0
in 0
stimulation 0
levels 0
over 0
time 0
in 0
nucleus 0
22 0
cochlear 0
implant 0
users 0
. 0

Nuclease 0
probing 0
and 0
structure 0
- 0
directed 0
mutagenesis 0
revealed 0
that 0
the 0
105 0
- 0
nt 0
TE 0
( 0
TE105 0
) 0
forms 0
a 0
cruciform 0
secondary 0
structure 0
containing 0
four 0
helices 0
connected 0
by 0
single 0
- 0
stranded 0
regions 0
. 0

Tele 0
- 0
Talk 0
has 0
the 0
extra 0
capability 0
of 0
operating 0
in 0
live 0
conference 0
situations 0
using 0
microphone 0
input 0
. 0

A 0
marked 0
decrease 0
in 0
the 0
type B-gene
1 I-gene
insulin I-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
( I-gene
IGF I-gene
) I-gene
receptor I-gene
( 0
IGF B-gene
- I-gene
IR I-gene
) 0
occurs 0
in 0
prostate 0
epithelial 0
cells 0
during 0
transformation 0
from 0
the 0
benign 0
to 0
the 0
metastatic 0
state 0
. 0

The 0
P69 0
cell 0
line 0
was 0
derived 0
by 0
immortalization 0
of 0
human 0
primary 0
prostate 0
epithelial 0
cells 0
with 0
simian B-gene
virus I-gene
- I-gene
40 I-gene
T I-gene
antigen I-gene
and 0
is 0
rarely 0
tumorigenic 0
. 0

We 0
determined 0
whether 0
the 0
human B-gene
StAR I-gene
promoter I-gene
is 0
responsive 0
to 0
sterol B-gene
regulatory I-gene
element I-gene
- I-gene
binding I-gene
proteins I-gene
( 0
SREBPs B-gene
) 0
. 0

Expression 0
of 0
SREBP B-gene
- I-gene
1a I-gene
stimulated 0
StAR B-gene
promoter I-gene
activity 0
in 0
the 0
context 0
of 0
COS 0
- 0
1 0
cells 0
and 0
human 0
granulosa 0
- 0
lutein 0
cells 0
. 0

Because 0
the 0
high B-gene
- I-gene
density I-gene
lipoprotein I-gene
receptor I-gene
( 0
HDL B-gene
- I-gene
R I-gene
) 0
is 0
a 0
key 0
element 0
in 0
cholesterol 0
homeostasis 0
and 0
a 0
potential 0
therapeutic 0
target 0
for 0
hypercholesterolemic 0
drugs 0
, 0
an 0
understanding 0
of 0
HDL B-gene
- I-gene
R I-gene
regulation 0
is 0
essential 0
. 0

IFN B-gene
- I-gene
stimulated I-gene
gene I-gene
factor I-gene
- I-gene
3 I-gene
and 0
STAT1 B-gene
homodimers I-gene
formed 0
and 0
bound 0
an 0
IFN B-gene
- I-gene
stimulated I-gene
response I-gene
element I-gene
( 0
ISRE B-gene
) 0
and 0
gamma B-gene
- I-gene
activated I-gene
sequence I-gene
( 0
GAS B-gene
) 0
element 0
, 0
respectively 0
. 0

We 0
have 0
therefore 0
studied 0
the 0
molecular 0
mechanisms 0
of 0
TGF B-gene
- I-gene
beta1 I-gene
action 0
on 0
thyroglobulin B-gene
( 0
TG B-gene
) 0
gene 0
expression 0
by 0
focusing 0
our 0
attention 0
on 0
TGF B-gene
- I-gene
beta1 I-gene
regulation 0
of 0
thyroid 0
- 0
specific 0
transcription 0
factors 0
. 0

The 0
epitope 0
- 0
protected 0
lysine 0
( 0
K 0
) 0
was 0
present 0
in 0
a 0
30 B-gene
- I-gene
aa I-gene
TPO I-gene
fragment I-gene
that 0
, 0
by 0
N 0
- 0
terminal 0
sequencing 0
, 0
was 0
found 0
to 0
be 0
K713 0
. 0

To 0
understand 0
the 0
molecular 0
regulation 0
of 0
these 0
genes 0
in 0
thyroid 0
cells 0
, 0
the 0
effect 0
of 0
thyroid B-gene
transcription I-gene
factor I-gene
1 I-gene
( 0
TTF B-gene
- I-gene
1 I-gene
) 0
and 0
the 0
paired B-gene
domain I-gene
- I-gene
containing I-gene
protein I-gene
8 I-gene
( 0
Pax B-gene
- I-gene
8 I-gene
) 0
on 0
the 0
transcriptional 0
activity 0
of 0
the 0
deiodinase B-gene
promoters I-gene
were 0
studied 0
. 0

Regional 0
blood 0
blow 0
was 0
measured 0
by 0
means 0
of 0
microspheres 0
in 0
predefined 0
regions 0
of 0
the 0
C6 0
, 0
T11 0
, 0
and 0
L6 0
vertebrae 0
. 0

Activation 0
of 0
transcription 0
through 0
the 0
AP B-gene
- I-gene
1 I-gene
site I-gene
in 0
Jurkat 0
cells 0
by 0
JunD B-gene
and/or 0
Fra B-gene
- I-gene
2 I-gene
was 0
weak 0
. 0
c B-gene
- I-gene
Jun I-gene
, 0
JunB B-gene
, 0
and 0
c B-gene
- I-gene
Fos I-gene
activation 0
was 0
greater 0
, 0
although 0
the 0
level 0
was 0
still 0
less 0
than 0
that 0
with 0
Tax B-gene
. 0

The 0
mechanism 0
of 0
ligand 0
- 0
activated 0
estrogen B-gene
receptor I-gene
alpha I-gene
( 0
ERalpha B-gene
) 0
- 0
dependent 0
activation 0
of 0
gene 0
expression 0
through 0
the 0
SRE 0
was 0
determined 0
by 0
mutational 0
analysis 0
of 0
the 0
promoter 0
, 0
analysis 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( 0
MAPK B-gene
) 0
pathway 0
activation 0
by 0
E2 0
, 0
and 0
transforming B-gene
growth I-gene
factor I-gene
alpha I-gene
( 0
TGF B-gene
- I-gene
alpha I-gene
) 0
as 0
a 0
positive 0
control 0
. 0

Perfusion 0
technique 0
for 0
perfusion 0
- 0
assisted 0
direct 0
coronary 0
artery 0
bypass 0
( 0
PADCAB 0
) 0
. 0

As 0
well 0
, 0
mixtures 0
of 0
( 0
LA 0
) 0
( 0
12 0
) 0
with 0
the 0
longer 0
chain 0
PEs 0
exhibit 0
unusual 0
biomodal 0
enthalpy 0
variations 0
, 0
suggesting 0
peptide 0
immiscibility 0
in 0
thicker 0
gel 0
state 0
bilayers 0
. 0

CONCLUSIONS 0
: 0
Under 0
current 0
immunization 0
practices 0
, 0
the 0
authors 0
estimate 0
that 0
nearly 0
13,000 0
Asian 0
and 0
Pacific 0
Islander 0
children 0
living 0
in 0
the 0
United 0
States 0
today 0
will 0
become 0
infected 0
with 0
HBV 0
in 0
the 0
future 0
, 0
resulting 0
in 0
more 0
than 0
600 0
liver 0
carcinoma 0
deaths 0
. 0

We 0
observed 0
NP/NMP4/CIZ B-gene
expression 0
in 0
osteocytes 0
, 0
osteoblasts 0
, 0
and 0
chondrocytes 0
in 0
rat 0
bone 0
. 0

Chlamydia 0
and 0
cervical 0
cancer 0
: 0
a 0
real 0
association 0
? 0

A 0
novel 0
approach 0
was 0
developed 0
for 0
identifying 0
transcription 0
factor 0
activities 0
associated 0
with 0
NGF B-gene
- 0
activated 0
, 0
but 0
not 0
EGF B-gene
- 0
activated 0
, 0
signaling 0
, 0
using 0
random 0
oligonucleotide 0
clones 0
from 0
a 0
DNA 0
recognition 0
library 0
to 0
isolate 0
specific 0
DNA 0
binding 0
proteins 0
from 0
PC12 0
nuclear 0
extracts 0
. 0

NGF B-gene
elicits 0
a 0
more 0
delayed 0
and 0
sustained 0
ERK B-gene
phosphorylation 0
than 0
EGF B-gene
, 0
consistent 0
with 0
previous 0
reports 0
. 0

NGF B-gene
, 0
but 0
not 0
EGF B-gene
, 0
enhances 0
the 0
upper 0
bands 0
, 0
corresponding 0
to 0
phosphorylated B-gene
Fra I-gene
- I-gene
2 I-gene
. 0

Energy 0
expenditure 0
was 0
obtained 0
using 0
a 0
primed 0
, 0
3 0
- 0
hour 0
infusion 0
of 0
NaH 0
( 0
13 0
) 0
CO 0
( 0
3 0
' 0
) 0
, 0
breath 0
( 0
13 0
) 0
CO 0
( 0
2 0
) 0
enrichment 0
determination 0
by 0
isotope 0
ratio 0
mass 0
spectroscopy 0
, 0
and 0
the 0
application 0
of 0
a 0
standard 0
regression 0
equation 0
. 0

Workload 0
, 0
UAPs 0
, 0
and 0
you 0
. 0

The 0
actA B-gene
gene I-gene
is 0
present 0
as 0
a 0
single 0
copy 0
in 0
the 0
genome 0
of 0
A. 0
chrysogenum 0
; 0
and 0
its 0
expression 0
level 0
, 0
opposite 0
to 0
pcbC B-gene
and 0
cefEF B-gene
cephalosporin I-gene
biosynthetic I-gene
genes I-gene
, 0
was 0
steady 0
during 0
cephalosporin 0
fermentation 0
, 0
showing 0
a 0
single 0
1.4 0
- 0
kb 0
transcript 0
. 0

Adding 0
10 0
mmol 0
SDS/l 0
led 0
to 0
transient 0
inhibition 0
of 0
acidification 0
, 0
metal 0
solubilization 0
and 0
sulfur 0
oxidation 0
. 0

We 0
have 0
investigated 0
the 0
role 0
of 0
NGF B-gene
in 0
regulating 0
gene 0
transcription 0
in 0
PC12 0
and 0
INS 0
- 0
1 0
cells 0
, 0
in 0
order 0
to 0
define 0
if 0
there 0
are 0
NGF B-gene
- 0
regulated 0
genes 0
per 0
se 0
. 0

Nine 0
animals 0
served 0
as 0
control 0
animals 0
, 0
whereas 0
20 0
animals 0
received 0
a 0
focal 0
arachnoid 0
scar 0
at 0
C1 0
- 0
C2 0
, 0
which 0
was 0
produced 0
by 0
placement 0
of 0
a 0
kaolin 0
- 0
soaked 0
fibrin B-gene
sponge 0
on 0
the 0
posterior 0
surface 0
of 0
the 0
spinal 0
cord 0
. 0

The 0
Schistosoma B-gene
mansoni I-gene
homologue I-gene
( 0
SmSmad2 B-gene
) 0
was 0
overexpressed 0
in 0
bacteria 0
as 0
a 0
Sj26 B-gene
- 0
GST B-gene
fusion 0
protein 0
and 0
used 0
to 0
raise 0
specific 0
antibodies 0
. 0

These 0
data 0
indicate 0
that 0
the 0
SmSmad2 B-gene
responds 0
to 0
the 0
TGF B-gene
- I-gene
beta I-gene
signals 0
by 0
interaction 0
with 0
receptor B-gene
I I-gene
, 0
which 0
phosphorylates 0
it 0
, 0
whereupon 0
it 0
translocates 0
into 0
the 0
nucleus 0
presumably 0
to 0
regulate 0
target 0
gene 0
transcription 0
and 0
consequently 0
elicit 0
a 0
specific 0
TGF B-gene
- I-gene
beta I-gene
effect 0
. 0

Intact 0
Flag 0
- 0
tagged 0
protein 0
products 0
from 0
all 0
six 0
were 0
produced 0
from 0
genomic 0
expression 0
vectors 0
, 0
although 0
the 0
ORF40/41 0
transcript 0
encoding 0
a 0
primase B-gene
- 0
helicase B-gene
component 0
proved 0
to 0
be 0
spliced 0
with 0
a 0
127 0
- 0
bp 0
intron 0
. 0

Expression 0
of 0
the 0
src B-gene
homology I-gene
3 I-gene
( 0
SH3 B-gene
) 0
- 0
encoding 0
, 0
expressed 0
in 0
tumorigenic 0
astrocytes 0
( 0
SETA B-gene
) 0
gene 0
is 0
associated 0
with 0
astrocyte 0
transformation 0
in 0
culture 0
and 0
tumors 0
in 0
the 0
adult 0
brain 0
. 0

Naltrexone 0
hydrochloride 0
is 0
a 0
synthetic 0
opioid B-gene
receptor I-gene
antagonist 0
recently 0
used 0
in 0
efforts 0
to 0
provide 0
rapid 0
opioid 0
detoxification 0
. 0

METHODS 0
: 0
One 0
hundred 0
fourteen 0
consecutive 0
patients 0
( 0
mean 0
age 0
61 0
years 0
) 0
with 0
focal 0
pancreatic 0
masses 0
, 0
detected 0
on 0
CT 0
, 0
underwent 0
EUS 0
- 0
FNA 0
by 0
using 0
a 0
linear 0
- 0
array 0
echoendoscope 0
and 0
22 0
- 0
gauge 0
needles 0
. 0

METHODS 0
: 0
Thyroid 0
status 0
was 0
measured 0
at 0
baseline 0
( 0
1990 0
- 0
93 0
) 0
, 0
through 0
assessment 0
of 0
serum 0
antibodies 0
to 0
thyroid B-gene
peroxidase I-gene
( 0
TPO B-gene
- I-gene
Abs I-gene
, 0
positive 0
: 0
> 0
10 0
IU/ml 0
) 0
, 0
serum B-gene
TSH I-gene
levels 0
, 0
and 0
when 0
TSH B-gene
was 0
abnormal 0
( 0
< 0
0.4 0
or 0
> 0
4.0 0
mU/l 0
) 0
, 0
serum B-gene
thyroxin I-gene
levels 0
( 0
T4 0
) 0
. 0

We 0
suggest 0
that 0
ventriculopleural 0
shunting 0
should 0
be 0
considered 0
as 0
the 0
preferred 0
alternative 0
to 0
peritoneal 0
drainage 0
in 0
children 0
with 0
intra 0
- 0
abdominal 0
adhesions 0
or 0
with 0
a 0
history 0
of 0
recent 0
peritoneal 0
infection 0
. 0

Derivation 0
and 0
initial 0
characterization 0
of 0
a 0
mouse 0
mammary 0
tumor 0
cell 0
line 0
carrying 0
the 0
polyomavirus B-gene
middle I-gene
T I-gene
antigen I-gene
: 0
utility 0
in 0
the 0
development 0
of 0
novel 0
cancer 0
therapeutics 0
. 0

TBARS 0
levels 0
, 0
oxygen 0
- 0
radical 0
absorbing 0
capacity 0
assay 0
and 0
AFR 0
release 0
assessed 0
by 0
electron 0
paramagnetic 0
resonance 0
( 0
EPR 0
) 0
were 0
used 0
to 0
explore 0
the 0
existence 0
of 0
oxidative 0
stress 0
in 0
diabetes 0
. 0

Long 0
- 0
range 0
comparison 0
of 0
human B-gene
and I-gene
mouse I-gene
SCL I-gene
loci I-gene
: 0
localized 0
regions 0
of 0
sensitivity 0
to 0
restriction 0
endonucleases 0
correspond 0
precisely 0
with 0
peaks 0
of 0
conserved 0
noncoding 0
sequences 0
. 0

To 0
account 0
for 0
this 0
observation 0
, 0
other 0
possible 0
causes 0
include 0
increased 0
CSF 0
pulsation 0
in 0
children 0
creating 0
motion 0
artifact 0
, 0
changes 0
in 0
arterial 0
oxygen 0
concentration 0
intrinsic 0
to 0
propofol 0
or 0
related 0
to 0
the 0
supplemental 0
oxygen 0
normally 0
administered 0
, 0
or 0
changes 0
in 0
CSF 0
protein 0
levels 0
related 0
to 0
propofol 0
binding 0
to 0
proteins 0
for 0
uptake 0
into 0
CSF 0
. 0

The 0
utilities 0
measured 0
in 0
our 0
study 0
can 0
be 0
applied 0
directly 0
to 0
quality 0
- 0
of 0
- 0
life 0
determinations 0
in 0
clinical 0
trials 0
of 0
adjuvant 0
IFN B-gene
alpha I-gene
- I-gene
2b I-gene
to 0
measure 0
the 0
net 0
benefit 0
of 0
therapy 0
. 0

Serum B-gene
PTH I-gene
tended 0
to 0
increase 0
in 0
the 0
WL 0
group 0
but 0
not 0
in 0
the 0
WM 0
group 0
( 0
P 0
< 0
0.06 0
) 0
. 0

Structure 0
of 0
the 0
EMAPII B-gene
domain I-gene
of 0
human B-gene
aminoacyl I-gene
- I-gene
tRNA I-gene
synthetase I-gene
complex I-gene
reveals 0
evolutionary 0
dimer 0
mimicry 0
. 0

Hypomorphic 0
dSLBP B-gene
alleles I-gene
support 0
zygotic 0
development 0
but 0
cause 0
female 0
sterility 0
. 0

We 0
mapped 0
the 0
DGCR6 B-gene
gene I-gene
to 0
chromosome 0
22q11 0
within 0
a 0
low 0
copy 0
repeat 0
, 0
termed 0
sc11.1a 0
, 0
and 0
identified 0
a 0
second 0
copy 0
of 0
the 0
gene 0
, 0
DGCR6L B-gene
, 0
within 0
the 0
duplicate 0
locus 0
, 0
termed 0
sc11.1b 0
. 0

METHODS 0
: 0
The 0
passive 0
and 0
active 0
transport 0
of 0
fluorescein 0
through 0
the 0
BRB 0
was 0
quantitated 0
by 0
vitreous 0
fluorometry 0
. 0

Nerve B-gene
growth I-gene
factor I-gene
( 0
NGF B-gene
) 0
and 0
retinoic 0
acid 0
( 0
RA 0
) 0
exert 0
important 0
actions 0
on 0
PC12 0
cells 0
. 0

Recruitment 0
of 0
an 0
RNA B-gene
polymerase I-gene
II I-gene
complex I-gene
is 0
mediated 0
by 0
the 0
constitutive 0
activation 0
domain 0
in 0
CREB B-gene
, 0
independently 0
of 0
CREB B-gene
phosphorylation 0
. 0

The 0
region 0
containing 0
both 0
serines 0
is 0
homologous 0
to 0
the 0
N 0
- 0
terminal 0
destruction 0
box 0
of 0
IkappaBalpha B-gene
, I-gene
- I-gene
beta I-gene
, I-gene
and I-gene
- I-gene
epsilon I-gene
. 0

This 0
function 0
requires 0
not 0
only 0
the 0
kinase 0
domain 0
of 0
Csk B-gene
, 0
but 0
also 0
its 0
Src B-gene
homology I-gene
3 I-gene
( 0
SH3 B-gene
) 0
and 0
SH2 B-gene
regions 0
. 0

Furthermore 0
, 0
we 0
showed 0
that 0
ERSF B-gene
including 0
NF B-gene
- I-gene
Y I-gene
and 0
ATF6alpha B-gene
and/or I-gene
beta I-gene
and 0
capable 0
of 0
binding 0
to 0
ERSE 0
is 0
indeed 0
formed 0
when 0
the 0
cellular 0
UPR 0
is 0
activated 0
. 0

The 0
observed 0
phenotypes 0
may 0
be 0
explained 0
by 0
( 0
i 0
) 0
a 0
selective 0
disruption 0
of 0
very B-gene
- I-gene
low I-gene
- I-gene
density I-gene
lipoprotein I-gene
secretion 0
due 0
to 0
decreased 0
expression 0
of 0
genes 0
encoding 0
apolipoprotein B-gene
B I-gene
and 0
microsomal B-gene
triglyceride I-gene
transfer I-gene
protein I-gene
, 0
( 0
ii 0
) 0
an 0
increase 0
in 0
hepatic 0
cholesterol 0
uptake 0
due 0
to 0
increased 0
expression 0
of 0
the 0
major 0
high B-gene
- I-gene
density I-gene
lipoprotein I-gene
receptor I-gene
, 0
scavenger B-gene
receptor I-gene
BI I-gene
, 0
and 0
( 0
iii 0
) 0
a 0
decrease 0
in 0
bile 0
acid 0
uptake 0
to 0
the 0
liver 0
due 0
to 0
down 0
- 0
regulation 0
of 0
the 0
major 0
basolateral B-gene
bile I-gene
acid I-gene
transporters I-gene
sodium I-gene
taurocholate I-gene
cotransporter I-gene
protein I-gene
and 0
organic B-gene
anion I-gene
transporter I-gene
protein I-gene
1 I-gene
. 0

These 0
effects 0
were 0
not 0
seen 0
with 0
SHIP2 B-gene
possessing 0
a 0
mutation 0
in 0
the 0
SH2 B-gene
domain I-gene
( 0
R47G B-gene
) 0
. 0

The 0
gonadotrope 0
- 0
specific 0
and 0
regulated 0
expression 0
of 0
the 0
GnRH B-gene
receptor I-gene
( 0
GnRH B-gene
- I-gene
R I-gene
) 0
gene 0
is 0
dependent 0
on 0
multiple 0
transcription 0
factors 0
that 0
interact 0
with 0
the 0
noncanonical B-gene
GnRH I-gene
- I-gene
R I-gene
activating I-gene
sequence I-gene
( 0
GRAS B-gene
) 0
, 0
the 0
activator B-gene
protein I-gene
- I-gene
1 I-gene
( 0
AP B-gene
- I-gene
1 I-gene
) 0
element 0
, 0
and 0
the 0
steroidogenic B-gene
factor I-gene
- I-gene
1 I-gene
( 0
SF B-gene
- I-gene
1 I-gene
) 0
binding 0
site 0
. 0

METHODS 0
: 0
A 0
structured 0
interview 0
was 0
undertaken 0
at 0
the 0
time 0
of 0
initial 0
consultation 0
and 0
at 0
subsequent 0
1 0
- 0
year 0
intervals 0
regarding 0
type 0
of 0
BHS 0
, 0
frequency 0
of 0
spells 0
, 0
associated 0
phenomenon 0
, 0
sequelae 0
, 0
family 0
history 0
, 0
and 0
age 0
at 0
termination 0
of 0
spells 0
. 0

In 0
three 0
cases 0
( 0
21.4 0
% 0
) 0
, 0
the 0
MR 0
imaging 0
was 0
interpreted 0
as 0
negative 0
, 0
but 0
microscopic 0
tumor 0
was 0
shown 0
around 0
seroma 0
on 0
reexcision 0
. 0

Methylation 0
at 0
both 0
cytosine 0
residues 0
in 0
the 0
E2F B-gene
element 0
( 0
( 0
m 0
) 0
CG 0
( 0
m 0
) 0
CG 0
) 0
generated 0
a 0
new 0
methylcytosine 0
- 0
specific 0
DNA 0
- 0
protein 0
complex 0
. 0

These 0
mutations 0
, 0
when 0
placed 0
in 0
a 0
wild B-gene
- I-gene
type I-gene
fliF I-gene
background 0
, 0
had 0
no 0
mutant 0
phenotype 0
. 0

As 0
well 0
, 0
IFN B-gene
- I-gene
gamma I-gene
- 0
induced 0
expression 0
of 0
IRF B-gene
- I-gene
1 I-gene
and 0
its 0
binding 0
to 0
the 0
IRF B-gene
element I-gene
is 0
inhibited 0
. 0

This 0
molecule 0
, 0
wH22xeGFP B-gene
, 0
consists 0
of 0
the 0
entire B-gene
humanized I-gene
anti I-gene
- I-gene
FcgammaRI I-gene
mAb I-gene
H22 B-gene
with 0
eGFP B-gene
genetically 0
fused 0
to 0
the 0
C 0
- 0
terminal 0
end 0
of 0
each 0
CH3 B-gene
domain I-gene
. 0
wH22xeGFP B-gene
binds 0
within 0
the 0
ligand 0
- 0
binding 0
region 0
by 0
its 0
Fc B-gene
end 0
, 0
as 0
well 0
as 0
outside 0
the 0
ligand 0
- 0
binding 0
region 0
by 0
its 0
Fab B-gene
ends 0
, 0
thereby 0
cross 0
- 0
linking 0
FcgammaRI B-gene
. 0

Inactivity 0
of 0
the 0
human B-gene
cytomegalovirus I-gene
( I-gene
HCMV I-gene
) I-gene
major I-gene
immediate I-gene
- I-gene
early I-gene
regulatory I-gene
region I-gene
( 0
MIERR B-gene
) 0
, 0
which 0
is 0
composed 0
of 0
promoter 0
, 0
enhancer 0
, 0
unique 0
region 0
, 0
and 0
modulator 0
, 0
is 0
linked 0
to 0
lack 0
of 0
HCMV 0
replication 0
in 0
latently 0
infected 0
cells 0
and 0
in 0
other 0
nonpermissive 0
cell 0
types 0
, 0
including 0
human 0
embryonal 0
NTera2 0
carcinoma 0
( 0
NT2 0
) 0
cells 0
. 0

This 0
interaction 0
is 0
reciprocal 0
, 0
since 0
C/EBP B-gene
dimer I-gene
binding 0
to 0
a 0
strong 0
C/EBP B-gene
site I-gene
leads 0
to 0
enhanced 0
CREB B-gene
- I-gene
1 I-gene
recruitment 0
to 0
ATF/CREB B-gene
sites 0
that 0
are 0
weakly 0
bound 0
by 0
ATF/CREB I-gene

The 0
metabolic 0
events 0
occurring 0
at 0
or 0
near 0
that 0
structure 0
and 0
involving 0
cyclin B-gene
D3 I-gene
cause 0
the 0
translocation 0
of 0
ICP0 B-gene
to 0
the 0
cytoplasm 0
. 0

Transient 0
transfections 0
showed 0
that 0
a 0
single 0
mutation 0
( 0
556M 0
) 0
decreased 0
TBLV B-gene
enhancer I-gene
activity 0
at 0
least 0
20 0
- 0
fold 0
in 0
two 0
different 0
T 0
- 0
cell 0
lines 0
. 0

Vector 0
stocks 0
containing 0
envelope B-gene
proteins I-gene
from 0
three 0
different 0
SIVmac 0
clones 0
, 0
namely 0
, 0
SIVmac239 0
( 0
T 0
- 0
lymphocyte 0
tropic 0
[ 0
T 0
- 0
tropic 0
] 0
) 0
, 0
SIVmac316 0
( 0
macrophage 0
tropic 0
[ 0
M 0
- 0
tropic 0
] 0
) 0
, 0
and 0
SIVmac1A11 0
( 0
dualtropic 0
) 0
, 0
were 0
tested 0
. 0

Quantitative 0
PCR 0
studies 0
indicated 0
that 0
synthesis 0
and 0
transport 0
of 0
vector 0
DNA 0
into 0
the 0
nucleus 0
were 0
similar 0
for 0
macrophages 0
infected 0
with 0
the 0
clone 0
239 0
and 0
316 0
pseudotypes 0
, 0
suggesting 0
that 0
the 0
restriction 0
for 0
SIVmac239 0
infection 0
is 0
after 0
reverse 0
transcription 0
and 0
nuclear 0
import 0
of 0
viral 0
DNA 0
. 0

Thus 0
, 0
the 0
anti B-gene
- I-gene
interferon I-gene
functions 0
of 0
vIRF B-gene
- I-gene
2 I-gene
may 0
contribute 0
to 0
the 0
establishment 0
of 0
a 0
chronic 0
or 0
latent 0
infection 0
. 0

Both 0
Z B-gene
and 0
R B-gene
expression 0
resulted 0
in 0
PML 0
dispersion 0
in 0
EBV 0
- 0
positive 0
cells 0
. 0

Interestingly 0
, 0
the 0
activity 0
of 0
IkappaB B-gene
kinase I-gene
( 0
IKK B-gene
- I-gene
beta I-gene
) 0
, 0
which 0
plays 0
an 0
essential 0
role 0
in 0
NF B-gene
- I-gene
kappaB I-gene
activation 0
through 0
IkappaB B-gene
phosphorylation 0
, 0
was 0
largely 0
enhanced 0
in 0
paclitaxel 0
- 0
treated 0
cells 0
, 0
detected 0
as 0
IkappaBalpha B-gene
phosphorylation 0
. 0

Immunofluorescence 0
studies 0
in 0
C2C12 0
myotubes 0
show 0
that 0
Smad2 B-gene
and 0
MEF2A B-gene
co 0
- 0
localise 0
in 0
the 0
nucleus 0
of 0
multinuclear 0
myotubes 0
during 0
differentiation 0
. 0

We 0
propose 0
that 0
TFOs 0
represent 0
a 0
therapeutic 0
potential 0
to 0
specifically 0
diminish 0
the 0
expression 0
of 0
c B-gene
- I-gene
sis/PDGF I-gene
sis/PDGF I-gene
- I-gene
B I-gene
proto 0
- 0
oncogene 0
in 0
various 0
pathologic 0
settings 0
where 0
constitutive 0
expression 0
of 0
this 0
gene 0
has 0
been 0
observed 0
. 0

Rapid 0
evolution 0
of 0
the 0
DNA 0
- 0
binding 0
site 0
in 0
LAGLIDADG B-gene
homing I-gene
endonucleases I-gene
. 0

Southern 0
blot 0
analysis 0
of 0
genomic 0
DNA 0
from 0
somatic 0
cell 0
hybrids 0
showed 0
that 0
endothelial B-gene
- I-gene
TACC I-gene
- I-gene
related I-gene
cDNA I-gene
maps 0
to 0
chromosome 0
10 0
. 0

Copyright 0
2001 0
Academic 0
Press 0
. 0

The 0
presence 0
of 0
truncated 0
receptor 0
isoforms 0
in 0
diverse 0
species 0
suggests 0
that 0
these 0
proteins 0
may 0
have 0
important 0
functional 0
roles 0
in 0
regulating 0
EGFR B-gene
activity 0
. 0

Interestingly 0
, 0
the 0
similarities 0
with 0
the 0
endophilin B-gene
proteins I-gene
cover 0
the 0
entire 0
sequence 0
of 0
the 0
SH3GLB B-gene
family I-gene
, 0
suggesting 0
a 0
common 0
fold 0
and 0
presumably 0
a 0
common 0
mode 0
of 0
action 0
. 0

Mental 0
rotation 0
of 0
paired 0
figures 0
engendered 0
activation 0
in 0
the 0
left 0
superior 0
parietal 0
lobule 0
and 0
the 0
right 0
frontal 0
medial 0
gyrus 0
. 0

We 0
also 0
reported 0
the 0
identification 0
of 0
three 0
corresponding 0
alternative 0
first 0
exons 0
and 0
an 0
intronic 0
promoter 0
in 0
the 0
human B-gene
PDE5A I-gene
gene I-gene
. 0

The 0
glucose/insulin B-gene
stimulation 0
was 0
inhibited 0
by 0
the 0
addition 0
of 0
polyunsaturated 0
fatty 0
acids 0
. 0

The 0
continuing 0
development 0
of 0
ligands 0
that 0
function 0
as 0
selective 0
estrogens 0
or 0
antiestrogens 0
for 0
ERalpha B-gene
or 0
ERbeta B-gene
should 0
allow 0
optimized 0
tissue 0
selectivity 0
of 0
these 0
agents 0
for 0
menopausal 0
hormone 0
replacement 0
therapy 0
and 0
the 0
treatment 0
and 0
prevention 0
of 0
breast 0
cancer 0
. 0

Behavioural 0
tests 0
with 0
192 0
specimen 0
of 0
the 0
roman 0
garden 0
snail 0
Helix 0
pomatia 0
L. 0
were 0
performed 0
in 0
order 0
to 0
clarify 0
whether 0
the 0
thermopreferendum 0
of 0
this 0
pulmonate 0
is 0
influenced 0
not 0
only 0
by 0
the 0
temperature 0
of 0
the 0
substratum 0
but 0
also 0
by 0
air 0
temperature 0
. 0

In 0
the 0
present 0
work 0
, 0
the 0
complete 0
genome 0
sequences 0
of 0
Pyrococcus 0
horikoshii 0
and 0
Pyrococcus 0
abyssi 0
, 0
two 0
species 0
in 0
a 0
genus 0
of 0
hyperthermophilic 0
archaeon 0
( 0
archaebacterium 0
) 0
, 0
were 0
compared 0
to 0
detect 0
large 0
genome 0
polymorphisms 0
linked 0
with 0
restriction 0
- 0
modification 0
gene 0
homologs 0
. 0

This 0
animal 0
model 0
of 0
dystonia 0
appears 0
to 0
be 0
a 0
model 0
of 0
NAD 0
in 0
man 0
from 0
the 0
viewpoint 0
of 0
treatment 0
- 0
response 0
. 0

Peripheral 0
and 0
preemptive 0
opioid 0
antinociception 0
in 0
a 0
mouse 0
visceral 0
pain 0
model 0
. 0

Twenty 0
- 0
six 0
( 0
55 0
% 0
) 0
( 0
95 0
% 0
CI 0
, 0
41 0
- 0
69 0
% 0
) 0
patients 0
experienced 0
> 0
or 0
=grade 0
3 0
acute 0
toxicity 0
( 0
RTOG 0
) 0
. 0

No 0
'TATA 0
' 0
motif 0
was 0
identified 0
near 0
either 0
the 0
GABPalpha B-gene
or 0
ATPsynCF6 B-gene
transcription 0
start 0
sites 0
. 0

Significantly 0
higher 0
lung 0
function 0
parameters 0
were 0
obtained 0
in 0
extubated 0
recipients 0
of 0
LPD 0
preserved 0
grafts 0
2 0
weeks 0
after 0
TX 0
. 0

Acquired 0
antithrombin B-gene
deficiency 0
in 0
sepsis 0
. 0

In 0
addition 0
, 0
we 0
have 0
isolated 0
a 0
genomic 0
fragment 0
containing 0
the 0
most 0
distal 0
5 0
' 0
sequences 0
of 0
the 0
major 0
GGT B-gene
mRNA I-gene
in 0
HepG2 0
cells 0
. 0

( 0
1997 0
) 0
Nature 0
387 0
, 0
370 0
- 0
376 0
) 0
] 0
, 0
we 0
suggest 0
that 0
the 0
metal 0
fluoride 0
ions 0
replaced 0
phosphate 0
at 0
the 0
two 0
ATP 0
- 0
binding 0
sites 0
of 0
the 0
iron 0
protein 0
, 0
Kp2 B-gene
. 0

Increased 0
erythropoietin B-gene
synthesis 0
in 0
patients 0
with 0
COLD 0
or 0
left 0
heart 0
failure 0
is 0
related 0
to 0
alterations 0
in 0
renal 0
haemodynamics 0
. 0

Expression 0
of 0
herpes B-gene
simplex I-gene
virus I-gene
type I-gene
2 I-gene
US3 I-gene
affects 0
the 0
Cdc42/Rac B-gene
pathway 0
and 0
attenuates 0
Cdc42/Rac I-gene

If 0
you 0
think 0
education 0
is 0
expensive 0
- 0
- 0
try 0
ignorance 0
- 0
- 0
Bok 0
's 0
Law 0
. 0

To 0
study 0
the 0
in 0
vivo 0
role 0
of 0
p16.7 B-gene
, 0
a 0
phi29 0
mutant 0
containing 0
a 0
suppressible 0
mutation 0
in 0
gene B-gene
16.7 I-gene
was 0
constructed 0
. 0

To 0
the 0
best 0
of 0
our 0
knowledge 0
, 0
SNTCS 0
is 0
highly 0
malignant 0
. 0

The 0
extraordinary 0
stability 0
of 0
peptide B-gene
- I-gene
- I-gene
gp96 I-gene
complexes I-gene
and 0
the 0
plasticity 0
of 0
the 0
peptide 0
- 0
binding 0
pocket 0
support 0
the 0
proposed 0
relay 0
of 0
diverse 0
peptides 0
to 0
MHC B-gene
and/or 0
other 0
molecules 0
via 0
molecular 0
recognition 0
. 0

High 0
- 0
affinity 0
binding 0
of 0
NF B-gene
- I-gene
1 I-gene
to 0
PSE B-gene
- I-gene
B I-gene
, 0
but 0
not 0
to 0
PSE B-gene
- I-gene
A I-gene
, 0
was 0
confirmed 0
by 0
competition 0
of 0
DNA 0
- 0
protein 0
interactions 0
by 0
using 0
NF B-gene
- I-gene
1 I-gene
DNA 0
elements 0
and 0
antibodies 0
. 0

Coexpression 0
of 0
the 0
p120 B-gene
( 0
ctn B-gene
) 0
protein 0
with 0
an 0
N 0
- 0
terminal 0
deletion 0
, 0
which 0
eliminates 0
some 0
potential 0
tyrosine 0
phosphorylation 0
sites 0
, 0
or 0
the 0
protein 0
with 0
a 0
single 0
amino 0
acid 0
substitution 0
( 0
tyrosine 0
at 0
217 0
to 0
phenylalanine 0
) 0
resulted 0
in 0
an 0
increase 0
in 0
the 0
aggregation 0
of 0
v B-gene
- I-gene
Src I-gene
- 0
transformed 0
EL 0
and 0
EalphaCL 0
cells 0
. 0

We 0
show 0
that 0
p73 B-gene
can 0
transcriptionally 0
inhibit 0
a 0
number 0
of 0
cellular 0
and 0
viral 0
promoters 0
. 0

RESULTS 0
: 0
Of 0
the 0
24 0
patients 0
, 0
6 0
had 0
Grade 0
1 0
pneumonitis 0
, 0
and 0
13 0
had 0
Grade 0
2 0
pneumonitis 0
. 0

In 0
contrast 0
, 0
we 0
did 0
not 0
detect 0
a 0
significant 0
correlation 0
between 0
plasma B-gene
TNFalpha I-gene
and 0
radiation 0
pneumonitis 0
. 0

Using 0
immunochemical 0
co 0
- 0
precipitation 0
methods 0
, 0
we 0
also 0
found 0
that 0
the 0
two 0
proteins 0
are 0
bound 0
in 0
vivo 0
. 0

METHODS 0
: 0
Sixteen 0
pigs 0
were 0
assigned 0
randomly 0
to 0
control 0
and 0
shock 0
groups 0
. 0

Identification 0
of 0
pulmonary 0
vein 0
stenosis 0
after 0
radiofrequency 0
ablation 0
for 0
atrial 0
fibrillation 0
using 0
MRI 0
. 0

Tumor 0
cell 0
lines 0
transduced 0
at 0
an 0
MOI 0
of 0
8 0
for 0
3 0
days 0
led 0
to 0
> 0
90 0
% 0
gene 0
transfer 0
efficiency 0
. 0

Treatment 0
includes 0
both 0
medical 0
and 0
surgical 0
options 0
, 0
with 0
medical 0
therapy 0
further 0
subclassified 0
into 0
pharmacologic 0
and 0
pneumatic 0
dilation 0
. 0

Finally 0
, 0
we 0
compared 0
the 0
differential 0
screening 0
techniques 0
in 0
terms 0
of 0
sensitivity 0
, 0
efficiency 0
and 0
occurrence 0
of 0
false 0
positives 0
. 0

Serial 0
US 0
images 0
were 0
obtained 0
before 0
and 0
20 0
, 0
30 0
, 0
40 0
, 0
50 0
, 0
60 0
, 0
90 0
, 0
120 0
, 0
150 0
, 0
180 0
, 0
240 0
, 0
and 0
300 0
s 0
after 0
intravenous 0
injection 0
of 0
2 0
g 0
of 0
contrast 0
agent 0
using 0
conventional 0
and 0
harmonic 0
PD 0
US 0
. 0

To 0
investigate 0
the 0
effects 0
of 0
exogenous 0
hyaluronic 0
acid 0
, 0
the 0
development 0
of 0
port 0
- 0
site 0
metastasis 0
was 0
examined 0
using 0
mouse 0
adenocarcinoma 0
cell 0
- 0
line 0
colon 0
26 0
cells 0
. 0

Cytomegalovirus 0
, 0
Chlamydia 0
pneumoniae 0
, 0
and 0
Helicobacter 0
pylori 0
IgG B-gene
antibodies I-gene
and 0
restenosis 0
after 0
stent 0
implantation 0
: 0
an 0
angiographic 0
and 0
intravascular 0
ultrasound 0
study 0
. 0

Responses 0
of 0
single 0
- 0
unit 0
carotid 0
body 0
chemoreceptors 0
in 0
adult 0
rats 0
. 0

Architecture 0
and 0
anatomy 0
of 0
the 0
genomic 0
locus 0
encoding 0
the 0
human 0
leukemia 0
- 0
associated 0
transcription 0
factor 0
RUNX1/AML1 B-gene
. 0

Therefore 0
, 0
we 0
suggested 0
that 0
both 0
proteins 0
might 0
belong 0
to 0
the 0
PLTP B-gene
family I-gene
. 0

In 0
this 0
paper 0
the 0
tyrosine 0
dephosphorylating 0
enzymes 0
, 0
the 0
protein B-gene
- I-gene
tyrosine I-gene
phosphatases I-gene
( 0
PTPs B-gene
) 0
, 0
are 0
studied 0
which 0
can 0
be 0
grouped 0
into 0
two 0
subfamilies 0
, 0
the 0
soluble B-gene
PTPs I-gene
and 0
the 0
receptor B-gene
PTPs I-gene
( 0
RPTPs B-gene
) 0
. 0

The 0
Ig B-gene
- 0
related 0
, 0
typical 0
metazoan 0
, 0
module 0
is 0
classified 0
to 0
the 0
disulphide 0
lacking 0
Ig B-gene
members I-gene
and 0
represents 0
the 0
phylogenetic 0
earliest 0
member 0
of 0
this 0
group 0
. 0

The 0
Sox B-gene
gene I-gene
family I-gene
( 0
Sry B-gene
like I-gene
HMG I-gene
box I-gene
gene I-gene
) 0
is 0
characterised 0
by 0
a 0
conserved 0
DNA 0
sequence 0
encoding 0
a 0
domain 0
of 0
approximately 0
80 0
amino 0
acids 0
which 0
is 0
responsible 0
for 0
sequence 0
specific 0
DNA 0
binding 0
. 0

While 0
these 0
results 0
are 0
consistent 0
with 0
previously 0
reported 0
effects 0
of 0
the 0
C 0
- 0
terminal 0
domain 0
on 0
nucleotide 0
binding 0
, 0
they 0
also 0
demonstrate 0
that 0
interactions 0
with 0
the 0
N 0
- 0
terminal 0
domains 0
are 0
necessary 0
to 0
inhibit 0
proton 0
transport 0
. 0

Respiratory 0
parameters 0
suggested 0
that 0
M6G 0
produced 0
less 0
respiratory 0
depression 0
than 0
morphine 0
. 0

This 0
supports 0
previous 0
arguments 0
for 0
the 0
improbability 0
of 0
biological 0
effects 0
at 0
UHF 0
frequencies 0
unless 0
a 0
mechanism 0
can 0
be 0
found 0
for 0
accumulating 0
energy 0
over 0
time 0
and 0
space 0
and 0
focussing 0
it 0
. 0

To 0
assess 0
the 0
maximum 0
oxygen 0
uptake 0
( 0
V'O2 0
max 0
) 0
of 0
Hong 0
Kong 0
Chinese 0
children 0
and 0
to 0
explore 0
its 0
association 0
with 0
respiratory 0
illnesses 0
, 0
we 0
conducted 0
the 0
Multistage 0
Fitness 0
Test 0
( 0
MFT 0
) 0
, 0
a 0
20 0
- 0
m 0
shuttle 0
run 0
test 0
, 0
in 0
1,427 0
schoolchildren 0
aged 0
between 0
8 0
- 0
12 0
years 0
. 0

By 0
analyzing 0
5' 0
- 0
deletion 0
insulin B-gene
promoter I-gene
- I-gene
reporter I-gene
constructs I-gene
in 0
transient 0
transfections 0
of 0
clonal 0
INS B-gene
- I-gene
1 I-gene
beta I-gene
- 0
cells 0
, 0
we 0
located 0
activating 0
Hh B-gene
- 0
responsive 0
regions 0
within 0
the 0
rat B-gene
insulin I-gene
I I-gene
promoter I-gene
that 0
include 0
the 0
glucose 0
- 0
response 0
elements 0
Far 0
( 0
E2 0
) 0
and 0
Flat 0
( 0
A2/A3 0
) 0
. 0

The 0
androgen B-gene
receptor I-gene
( 0
AR B-gene
) 0
amino 0
- 0
terminus 0
imposes 0
androgen 0
- 0
specific 0
regulation 0
of 0
AR B-gene
gene I-gene
expression 0
via 0
an 0
exonic 0
enhancer 0
. 0

A 0
major 0
mechanism 0
by 0
which 0
estrogens 0
prevent 0
osteoporosis 0
seems 0
to 0
be 0
repression 0
of 0
transcription 0
of 0
NF B-gene
- I-gene
kappa I-gene
B I-gene
target I-gene
genes I-gene
, 0
such 0
as 0
the 0
osteoclast 0
- 0
activating 0
cytokines 0
interleukin B-gene
- I-gene
6 I-gene
and 0
interleukin B-gene
- I-gene
1 I-gene
. 0

To 0
identify 0
the 0
important 0
cis 0
- 0
DNA 0
regulatory 0
element 0
( 0
s 0
) 0
involved 0
in 0
the 0
tissue 0
- 0
, 0
region 0
- 0
, 0
and 0
cell 0
- 0
specific 0
expression 0
of 0
the 0
mE B-gene
- I-gene
RABP I-gene
gene I-gene
, 0
the 0
5 0
- 0
kb 0
DNA 0
fragment 0
was 0
sequenced 0
. 0

In 0
the 0
mouse 0
, 0
both 0
genes 0
reside 0
in 0
the 0
syntenic 0
region 0
8E1 0
on 0
chromosome 0
8 0
. 0

Analysis 0
of 0
the 0
genome 0
sequence 0
revealed 0
26,588 0
protein 0
- 0
encoding 0
transcripts 0
for 0
which 0
there 0
was 0
strong 0
corroborating 0
evidence 0
and 0
an 0
additional 0
approximately 0
12,000 0
computationally 0
derived 0
genes 0
with 0
mouse 0
matches 0
or 0
other 0
weak 0
supporting 0
evidence 0
. 0

The 0
corresponding 0
genotype 0
was 0
determined 0
with 0
a 0
restriction 0
enzyme 0
- 0
based 0
assay 0
. 0

An 0
additional 0
9 0
patients 0
achieved 0
normal 0
levels 0
with 0
adjunctive 0
drug 0
therapy 0
. 0

By 0
Caveman 0
. 0

Multistage 0
models 0
and 0
the 0
A 0
- 0
bomb 0
survivor 0
data 0
: 0
implications 0
for 0
carcinogenic 0
mechanisms 0
? 0

The 0
revitalization 0
of 0
surgery 0
for 0
Parkinson 0
's 0
disease 0
( 0
PD 0
) 0
has 0
fueled 0
discussion 0
about 0
the 0
best 0
methodology 0
to 0
define 0
the 0
target 0
. 0

Corneal 0
scrapping 0
and 0
deep 0
stromal 0
biopsy 0
were 0
obtained 0
and 0
stained 0
for 0
microscopic 0
evaluation 0
with 0
periodic 0
acid 0
- 0
Schiff 0
, 0
Giemsa 0
, 0
and 0
Gomori 0
's 0
methenamine 0
silver 0
stains 0
. 0

These 0
results 0
indicate 0
that 0
BACM 0
has 0
antiplaque 0
and 0
stronger 0
antidegradation 0
effects 0
than 0
GLCM 0
. 0

Multidrug 0
resistance 0
in 0
Saccharomyces 0
cerevisiae 0
mainly 0
results 0
from 0
the 0
overexpression 0
of 0
genes 0
coding 0
for 0
the 0
membrane 0
efflux 0
pumps 0
, 0
the 0
major 0
facilitators 0
and 0
the 0
ABC B-gene
binding I-gene
cassette I-gene
transporters I-gene
, 0
under 0
the 0
control 0
of 0
key 0
transcription 0
regulators 0
encoded 0
by 0
the 0
PDR1 B-gene
and 0
PDR3 B-gene
genes I-gene
. 0

Susceptibility 0
to 0
ischemia 0
- 0
induced 0
arrhythmias 0
was 0
lower 0
in 0
1 0
- 0
week 0
diabetics 0
: 0
only 0
42 0
% 0
of 0
diabetic 0
hearts 0
exhibited 0
ventricular 0
tachycardia 0
( 0
VT 0
) 0
and 0
16 0
% 0
had 0
short 0
episodes 0
of 0
ventricular 0
fibrillation 0
( 0
VF 0
) 0
as 0
compared 0
to 0
VT 0
100 0
% 0
and 0
VF 0
70 0
% 0
( 0
including 0
sustained 0
VF 0
36 0
% 0
) 0
in 0
the 0
non 0
- 0
diabetics 0
( 0
P 0
< 0
0.05 0
) 0
. 0

A 0
picture 0
is 0
emerging 0
showing 0
a 0
gradient 0
of 0
function 0
among 0
p53 B-gene
, 0
p73 B-gene
, 0
p63 B-gene
ranging 0
from 0
tumor 0
suppression 0
to 0
development 0
. 0

This 0
could 0
lead 0
to 0
subsequent 0
outbreaks 0
if 0
Babesia 0
carrier 0
animals 0
were 0
to 0
be 0
introduced 0
into 0
the 0
herd 0
. 0

Contagious 0
bovine 0
pleuropneumonia 0
is 0
a 0
major 0
threat 0
for 0
cattle 0
in 0
Africa 0
. 0

Baseline 0
BMD 0
values 0
were 0
significantly 0
lower 0
in 0
the 0
oligo 0
- 0
amenorrheic 0
group 0
than 0
in 0
the 0
two 0
others 0
at 0
the 0
level 0
of 0
lumbar 0
spine 0
( 0
anteroposterior 0
view 0
: 0
0.941+/ 0
- 0
0.039 0
in 0
oligo 0
- 0
amenorrheic 0
vs 0
1.077+/ 0
- 0
0.029 0
or 0
1.051 0
+/ 0
- 0
0.017 0
g 0
x 0
cm 0
( 0
- 0
2 0
) 0
, 0
P 0
< 0
0.005 0
, 0
in 0
the 0
eumenorrheic 0
and 0
contraceptive 0
user 0
groups 0
, 0
respectively 0
) 0
but 0
not 0
in 0
weight 0
- 0
bearing 0
bone 0
such 0
as 0
proximal 0
and 0
midshaft 0
femur 0
. 0

The 0
distribution 0
of 0
red 0
rice 0
cultivation 0
in 0
Sri 0
Lanka 0
is 0
coincident 0
with 0
the 0
HIDD 0
villages 0
. 0

The 0
increase 0
in 0
number 0
of 0
terminal 0
hairs 0
, 0
which 0
are 0
defined 0
as 0
hairs 0
more 0
than 0
60 0
microm 0
in 0
diameter 0
, 0
in 0
the 0
designated 0
area 0
( 0
0.5 0
cm 0
square 0
= 0
0.25 0
cm2 0
area 0
) 0
of 0
the 0
procyanidin 0
B 0
- 0
2 0
group 0
subjects 0
after 0
the 0
6 0
- 0
month 0
trial 0
was 0
significantly 0
greater 0
than 0
that 0
of 0
the 0
placebo 0
control 0
group 0
subjects 0
( 0
procyanidin 0
B 0
- 0
2 0
, 0
1.99 0
+/ 0
- 0
2.58 0
( 0
mean 0
+/ 0
- 0
SD 0
) 0
/0.25 0
cm2 0
; 0
placebo 0
, 0
- 0
0.82 0
+/ 0
- 0
3.40 0
( 0
mean 0
+/ 0
- 0
SD 0
) 0
/0.25 0
cm2 0
; 0
P 0
< 0
0.02 0
, 0
two 0
- 0
sample 0
t 0
test 0
) 0
. 0

Ectopic 0
expression 0
of 0
the 0
dominant B-gene
mutant I-gene
Lg3 I-gene
allele I-gene
is 0
believed 0
to 0
cause 0
the 0
phenotype 0
. 0

High 0
plasma B-gene
AVP I-gene
levels 0
observed 0
in 0
the 0
two 0
cases 0
suggest 0
that 0
SSRIs 0
stimulate 0
AVP B-gene
secretion 0
, 0
thereby 0
causing 0
SIADH 0
. 0

Thus 0
, 0
in 0
T47D 0
breast 0
carcinoma 0
cells 0
, 0
IL B-gene
- I-gene
6 I-gene
acts 0
in 0
synergy 0
with 0
EGF B-gene
receptor I-gene
autocrine 0
activity 0
to 0
signal 0
through 0
the 0
MAPK/PI3K B-gene
pathways 0
. 0

Human B-gene
homologue I-gene
of I-gene
yeast I-gene
Rad23 I-gene
protein I-gene
A I-gene
interacts 0
with 0
p300/cyclic B-gene
p300/cyclic I-gene
AMP I-gene
- I-gene
responsive I-gene
element I-gene
binding I-gene
( I-gene
CREB I-gene
) I-gene
- I-gene
binding I-gene
protein I-gene
to 0
down 0
- 0
regulate 0
transcriptional 0
activity 0
of 0
p53 B-gene
. 0

For 0
immunological 0
methods 0
, 0
identification 0
of 0
such 0
antigens 0
with 0
intermolecular 0
variability 0
, 0
e.g. 0
, 0
the 0
structural 0
aescin 0
analogs 0
, 0
is 0
of 0
unknown 0
validity 0
. 0

Most 0
patients 0
harboring 0
metronidazole 0
- 0
and 0
clarithromycin 0
- 0
resistant 0
strains 0
were 0
eradicated 0
at 0
an 0
equal 0
rate 0
by 0
each 0
of 0
the 0
three 0
regimens 0
. 0

Binding 0
of 0
cell 0
type 0
- 0
specific 0
nuclear 0
proteins 0
to 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
maize B-gene
C4 I-gene
phosphoenolpyruvate I-gene
carboxylase I-gene
gene I-gene
confers 0
its 0
differential 0
transcription 0
in 0
mesophyll 0
cells 0
. 0

RESULTS 0
: 0
During 0
the 0
stabilization 0
period 0
, 0
PaCO2 0
( 0
mean 0
+/ 0
- 0
SD 0
) 0
was 0
33 0
+/ 0
- 0
5 0
mm 0
Hg 0
, 0
and 0
arrhythmias 0
were 0
not 0
detected 0
. 0

BACKGROUND 0
: 0
Previous 0
studies 0
have 0
indicated 0
that 0
the 0
60 0
- 0
, 0
30 0
- 0
, 0
28 0
- 0
and 0
12 0
- 0
item 0
versions 0
of 0
the 0
General 0
Health 0
Questionnaire 0
( 0
GHQ 0
) 0
are 0
liable 0
to 0
retest 0
effects 0
, 0
especially 0
when 0
administered 0
multiple 0
times 0
with 0
short 0
intervals 0
. 0

Acute 0
effects 0
of 0
LI 0
160 0
( 0
extract 0
of 0
Hypericum 0
perforatum 0
, 0
St 0
John 0
's 0
wort 0
) 0
and 0
two 0
of 0
its 0
constituents 0
on 0
neuroendocrine 0
responses 0
in 0
the 0
rat 0
. 0

Decreased 0
serum B-gene
ceruloplasmin I-gene
and 0
copper 0
levels 0
in 0
cervical 0
dystonia 0
. 0

A 0
microsporidian 0
, 0
Nosema 0
algerae 0
Vavra 0
and 0
undeen 0
, 0
was 0
found 0
parasitizing 0
larvae 0
and 0
adults 0
of 0
a 0
laboratory 0
colony 0
of 0
Culex 0
pipiens 0
L. 0
originated 0
from 0
Gharbia 0
Governorate 0
. 0

Molecular 0
cloning 0
and 0
characterization 0
of 0
OsPSK B-gene
, 0
a 0
gene 0
encoding 0
a 0
precursor 0
for 0
phytosulfokine B-gene
- I-gene
alpha I-gene
, 0
required 0
for 0
rice 0
cell 0
proliferation 0
. 0

Blood 0
from 0
dams 0
was 0
collected 0
prior 0
to 0
inoculation 0
and 0
at 0
time 0
of 0
necropsy 0
for 0
measurement 0
of 0
IgM B-gene
and 0
IgG B-gene
antibodies I-gene
to 0
M. 0
pulmonis 0
. 0

Plasma 0
DHE 0
concentration 0
rose 0
promptly 0
above 0
5 0
ng/ml 0
after 0
the 0
application 0
of 0
the 0
PSA 0
tape 0
onto 0
the 0
damaged 0
skin 0
in 0
hairless 0
rat 0
. 0

Single 0
amino 0
acid 0
substitutions 0
at 0
the 0
acyl 0
- 0
CoA 0
- 0
binding 0
domain 0
interrupt 0
14 0
[ 0
C 0
] 0
palmitoyl 0
- 0
CoA 0
binding 0
of 0
ACBP2 B-gene
, 0
an 0
Arabidopsis 0
acyl B-gene
- I-gene
CoA I-gene
- I-gene
binding I-gene
protein I-gene
with 0
ankyrin B-gene
repeats 0
. 0

Implications 0
in 0
biomonitoring 0
of 0
the 0
observed 0
accumulation 0
patterns 0
, 0
especially 0
in 0
the 0
different 0
tissues 0
of 0
Posidonia 0
oceanica 0
, 0
are 0
discussed 0
. 0

Thus 0
, 0
Xlim B-gene
- I-gene
1 I-gene
not 0
only 0
contains 0
a 0
unique 0
tyrosine 0
- 0
rich 0
activation 0
domain 0
but 0
also 0
contains 0
a 0
negative 0
regulatory 0
domain 0
in 0
CT239 0
- 0
403 0
, 0
suggesting 0
a 0
complex 0
regulatory 0
mechanism 0
underlying 0
the 0
transcriptional 0
activity 0
of 0
Xlim B-gene
- I-gene
1 I-gene
in 0
the 0
organizer 0
. 0

After 0
allowing 0
time 0
for 0
absorption 0
, 0
participants 0
completed 0
a 0
bridge 0
simulator 0
task 0
. 0

The 0
bovine B-gene
PGHS I-gene
- I-gene
2 I-gene
cDNA I-gene
was 0
cloned 0
by 0
a 0
combination 0
of 0
reverse 0
transcription 0
- 0
polymerase 0
chain 0
reaction 0
and 0
cDNA 0
library 0
screening 0
. 0

The 0
regulation 0
of 0
PGHS B-gene
- I-gene
2 I-gene
mRNA I-gene
and 0
protein 0
was 0
studied 0
in 0
primary 0
cultures 0
of 0
bovine 0
uterine 0
stromal 0
cells 0
stimulated 0
with 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
( 0
PMA 0
; 0
100 0
nM 0
) 0
. 0

Functional 0
analysis 0
of 0
various 0
PTP B-gene
- 0
deficient 0
DT40 0
B 0
cell 0
lines 0
stably 0
expressing 0
wild 0
- 0
type 0
chimeric 0
Fc B-gene
gamma I-gene
RIIB1 I-gene
- I-gene
PECAM I-gene
- I-gene
1 I-gene
receptor I-gene
indicated 0
that 0
cytoplasmic B-gene
Src I-gene
homology I-gene
2 I-gene
- I-gene
domain I-gene
- I-gene
containing I-gene
phosphatases I-gene
, 0
SHP B-gene
- I-gene
1 I-gene
and 0
SHP B-gene
- I-gene
2 I-gene
, 0
were 0
both 0
necessary 0
and 0
sufficient 0
to 0
deliver 0
inhibitory 0
negative 0
regulation 0
upon 0
coligation 0
of 0
BCR B-gene
complex I-gene
with 0
inhibitory 0
receptor 0
. 0

Anti B-gene
- I-gene
nucleolin I-gene
mAb I-gene
was 0
used 0
to 0
confirm 0
the 0
antigenic 0
properties 0
of 0
this 0
p95 B-gene
component I-gene
. 0

Furthermore 0
, 0
stable 0
expression 0
of 0
a 0
constitutively 0
active 0
form 0
of 0
chicken 0
Notch1 B-gene
or 0
Notch2 B-gene
in 0
a 0
B 0
cell 0
line 0
results 0
in 0
a 0
down 0
- 0
regulation 0
of 0
surface 0
IgM B-gene
expression 0
, 0
which 0
is 0
accompanied 0
by 0
the 0
reduction 0
of 0
IgH B-gene
gene I-gene
transcripts I-gene
. 0

Substitutions 0
in 0
the 0
YFV B-gene
Ag B-gene
- I-gene
binding I-gene
region I-gene
( 0
ABR B-gene
) 0
occur 0
at 0
four 0
of 0
the 0
eight 0
highly 0
conserved 0
residues 0
that 0
are 0
essential 0
for 0
binding 0
of 0
peptide 0
- 0
Ag 0
in 0
the 0
class 0
Ia 0
molecules 0
. 0

Similarly 0
, 0
curcumin 0
( 0
diferuloylmethane 0
) 0
, 0
an 0
anti 0
- 0
inflammatory 0
agent 0
, 0
suppressed 0
OSM B-gene
- 0
stimulated 0
STAT1 B-gene
phosphorylation 0
, 0
DNA 0
- 0
binding 0
activity 0
of 0
STAT1 B-gene
, 0
and 0
c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
activation 0
without 0
affecting 0
JAK1 B-gene
, 0
JAK2 B-gene
, 0
JAK3 B-gene
, 0
ERK1/2 B-gene
, 0
and 0
p38 B-gene
phosphorylation 0
. 0

In 0
contrast 0
, 0
the 0
failure 0
of 0
the 0
QKTT 0
motif 0
and 0
TGN46 0
cytoplasmic 0
tail 0
to 0
induce 0
steady 0
- 0
state 0
ER 0
localization 0
of 0
vesicular B-gene
stomatitis I-gene
virus I-gene
glycoprotein I-gene
( 0
VSVG B-gene
) 0
chimeras 0
in 0
HeLa 0
and 0
NRK 0
cells 0
indicates 0
that 0
significant 0
differences 0
in 0
early 0
secretory 0
trafficking 0
also 0
exist 0
. 0

A 0
cDNA 0
clone 0
encoding 0
C2H2 B-gene
- I-gene
type I-gene
zinc I-gene
finger I-gene
protein I-gene
, 0
SCOF B-gene
- I-gene
1 I-gene
, 0
was 0
isolated 0
from 0
soybean 0
. 0

Consistent 0
with 0
the 0
specificity 0
observed 0
for 0
the 0
interaction 0
of 0
DmCKIIalpha B-gene
with 0
these 0
bHLH B-gene
proteins I-gene
, 0
sequence 0
alignment 0
suggests 0
that 0
only 0
m5 B-gene
, 0
m7 B-gene
, 0
and 0
m8 B-gene
contain 0
a 0
consensus 0
site 0
for 0
phosphorylation 0
by 0
CKII B-gene
within 0
a 0
subdomain 0
unique 0
to 0
these 0
three 0
proteins 0
. 0

Apart 0
from 0
antimicrobial 0
properties 0
, 0
recent 0
data 0
indicate 0
that 0
PMN 0
also 0
exert 0
anti 0
- 0
inflammatory 0
effects 0
by 0
stimulation 0
and 0
release 0
of 0
cytokine 0
antagonists 0
such 0
as 0
interleukin B-gene
- I-gene
1 I-gene
receptor I-gene
antagonist I-gene
( 0
IL B-gene
- I-gene
1ra I-gene
) 0
. 0

The 0
purpose 0
of 0
this 0
investigation 0
was 0
to 0
study 0
the 0
morphological 0
characteristics 0
of 0
the 0
fibrous 0
tissue 0
capsule 0
resulting 0
from 0
the 0
implantation 0
of 0
aluminum 0
calcium 0
phosphate 0
( 0
ALCAP 0
) 0
and 0
hydroxyapetite 0
( 0
HA 0
) 0
bioceramics 0
. 0

Sevelamer 0
hydrochloride 0
( 0
Renagel 0
) 0
is 0
a 0
nonabsorbed 0
phosphate 0
- 0
binding 0
polymer 0
marketed 0
for 0
the 0
treatment 0
of 0
hyperphosphatemia 0
in 0
adult 0
patients 0
receiving 0
hemodialysis 0
. 0

The 0
pharmacokinetic 0
profiles 0
of 0
digoxin 0
and 0
warfarin 0
were 0
not 0
altered 0
by 0
the 0
simultaneous 0
and 0
continued 0
administration 0
of 0
sevelamer 0
. 0

Before 0
PO3 0
administration 0
, 0
more 0
than 0
half 0
( 0
57.4 0
% 0
) 0
of 0
the 0
patients 0
received 0
only 0
1 0
or 0
2 0
antituberculous 0
drugs 0
( 0
ethambutole 0
and 0
ethionamide 0
or 0
ethambutole 0
and 0
oprofloxacin 0
) 0
. 0

Can 0
survival 0
be 0
prolonged 0
for 0
patients 0
with 0
hormone 0
- 0
resistant 0
prostate 0
cancer 0
? 0

Patients 0
were 0
divided 0
into 0
two 0
group 0
; 0
Control 0
group 0
A 0
in 0
which 0
a 0
hot 0
- 0
water 0
circulating 0
system 0
was 0
used 0
and 0
group 0
B 0
in 0
which 0
a 0
transtracheal 0
heating 0
and 0
humidification 0
system 0
by 0
ANAMED 0
HUMITUBE 0
was 0
used 0
, 0
during 0
gastric 0
cancer 0
operation 0
. 0

The 0
present 0
data 0
also 0
demonstrate 0
that 0
ectopic 0
expression 0
of 0
blr1 B-gene
increased 0
JNK/SAPK B-gene
activity 0
, 0
but 0
JNK/SAPK I-gene

The 0
effects 0
of 0
the 0
transfected 0
receptors 0
were 0
associated 0
with 0
antagonism 0
of 0
activator B-gene
protein I-gene
1 I-gene
( 0
AP B-gene
- I-gene
1 I-gene
) 0
activity 0
. 0

Recent 0
studies 0
using 0
isolated 0
rat 0
adipocytes 0
and 0
chemically 0
synthesized 0
PIG 0
compounds 0
point 0
to 0
IRS1/3 B-gene
tyrosine 0
phosphorylation 0
by 0
p59Lyn B-gene
kinase I-gene
as 0
the 0
site 0
of 0
cross 0
- 0
talk 0
, 0
the 0
negative 0
regulation 0
of 0
which 0
by 0
interaction 0
with 0
caveolin B-gene
is 0
apparently 0
abrogated 0
by 0
PIG 0
. 0

RESULTS 0
: 0
The 0
parameters 0
SF2 0
and 0
plating 0
efficiency 0
were 0
stable 0
throughout 0
the 0
4 0
- 0
year 0
test 0
period 0
. 0

Also 0
, 0
small 0
, 0
sense 0
and 0
antisense 0
approximately 0
22 0
nt 0
RNAs 0
, 0
derived 0
from 0
the 0
satRNA 0
, 0
were 0
associated 0
with 0
the 0
replicating 0
satellite 0
. 0

VE 0
- 0
DEF 0
animals 0
had 0
significantly 0
higher 0
( 0
p 0
< 0
0.05 0
) 0
levels 0
of 0
myocardial 0
lipid 0
peroxidation 0
and 0
lower 0
( 0
p 0
< 0
0.05 0
) 0
protein 0
thiols 0
following 0
I 0
- 0
R 0
compared 0
to 0
the 0
CON 0
animals 0
. 0

Grippers 0
with 0
integrated 0
piezoresistive 0
force 0
sensors 0
and 0
with 0
attached 0
strain 0
gauges 0
have 0
been 0
reported 0
. 0

The 0
child 0
left 0
behind 0
. 0

Transition 0
between 0
P 0
- 0
and 0
H 0
- 0
BPPV 0
was 0
found 0
in 0
6 0
cases 0
. 0

The 0
contrasting 0
effects 0
of 0
dopaminergic 0
stimulation 0
on 0
the 0
motor 0
performance 0
and 0
on 0
some 0
aspects 0
of 0
cognitive 0
processing 0
suggest 0
the 0
existence 0
of 0
complex 0
interactions 0
within 0
pre 0
- 0
and 0
postsynaptic 0
brain B-gene
dopamine I-gene
receptors I-gene
, 0
and 0
an 0
intervention 0
of 0
segregated 0
basal 0
ganglia 0
- 0
prefrontal 0
cortex 0
loops 0
in 0
motor 0
and 0
cognitive 0
behaviour 0
. 0

HexA71 B-gene
negatively 0
affects 0
RpoS B-gene
, 0
as 0
the 0
levels 0
of 0
this 0
alternative 0
sigma B-gene
factor I-gene
are 0
higher 0
in 0
the 0
HexA B-gene
- I-gene
mutant I-gene
than 0
in 0
the 0
HexA+ B-gene
strain 0
. 0

Multiple 0
copies 0
of 0
rsmB+ B-gene
DNA I-gene
, 0
on 0
the 0
other 0
hand 0
, 0
stimulate 0
exoenzyme 0
production 0
by 0
relieving 0
the 0
negative 0
effects 0
of 0
a 0
chromosomal 0
copy 0
of 0
hexA+ B-gene
. 0

0 0
% 0
) 0
and 0
IL B-gene
- I-gene
12 I-gene
( 0
42.6 0
% 0
vs 0
. 0

Systematic 0
review 0
of 0
diagnostic 0
tests 0
for 0
vaginal 0
trichomoniasis 0
. 0

CHAP 0
and 0
the 0
Department 0
of 0
Veterans 0
Affairs 0
. 0

More 0
importantly 0
, 0
this 0
fusion 0
converted 0
a 0
less 0
effective 0
vaccine 0
into 0
one 0
with 0
significant 0
potency 0
against 0
established 0
E7 B-gene
- 0
expressing 0
metastatic 0
tumors 0
. 0

We 0
compared 0
previously 0
the 0
methylation 0
status 0
between 0
normal 0
liver 0
and 0
liver 0
tumors 0
in 0
SV40 B-gene
T/t I-gene
antigen I-gene
transgenic 0
mice 0
( 0
MT 0
- 0
D2 0
mice 0
) 0
using 0
Restriction 0
Landmark 0
Genomic 0
Scanning 0
for 0
Methylation 0
( 0
RLGS 0
- 0
M 0
) 0
and 0
identified 0
several 0
loci/spots 0
that 0
appeared 0
to 0
be 0
methylated 0
frequently 0
in 0
liver 0
tumors 0
. 0

The 0
Genescan 0
program 0
predicted 0
an 0
open 0
reading 0
frame 0
of 0
a 0
novel 0
, 0
intron 0
- 0
less 0
gene 0
adjacent 0
to 0
the 0
B236 0
spot 0
that 0
encodes 0
a 0
putative 0
493 0
- 0
amino 0
acid 0
protein 0
containing 0
the 0
SNAG 0
repressor 0
motif 0
in 0
the 0
NH2 0
- 0
terminal 0
region 0
and 0
five 0
C2H2 0
- 0
type 0
zinc 0
finger 0
motifs 0
in 0
the 0
COOH 0
- 0
terminal 0
half 0
. 0

Northern 0
blot 0
analysis 0
revealed 0
that 0
mlt B-gene
1 I-gene
is 0
normally 0
expressed 0
in 0
brain 0
, 0
spleen 0
, 0
stom 0
ach 0
, 0
and 0
liver 0
. 0

Treatment 0
of 0
N18TG 0
- 0
2 0
cells 0
with 0
a 0
demethylating 0
agent 0
, 0
5 0
- 0
aza 0
- 0
deoxycytidine 0
, 0
resulted 0
in 0
an 0
expression 0
of 0
mlt B-gene
1 I-gene
, 0
indicating 0
that 0
the 0
repression 0
of 0
mlt B-gene
1 I-gene
is 0
attributable 0
to 0
methylation 0
Thus 0
, 0
mlt B-gene
1 I-gene
is 0
a 0
novel 0
target 0
gene 0
that 0
is 0
silenced 0
by 0
methylation 0
during 0
liver 0
tumorigenesis 0
initiated 0
by 0
SV40 B-gene
T I-gene
antigen I-gene
. 0

As 0
an 0
oral 0
, 0
nontoxic 0
compound 0
with 0
a 0
mechanism 0
of 0
action 0
distinct 0
from 0
that 0
of 0
ABL B-gene
tyrosine I-gene
kinase I-gene
inhibition 0
, 0
FTI 0
SCH66336 0
shows 0
promise 0
for 0
the 0
treatment 0
of 0
BCR/ABL B-gene
- 0
induced 0
leukemia 0
. 0

These 0
results 0
suggested 0
a 0
critical 0
role 0
for 0
tyrosine 0
residue 0
1229 0
in 0
the 0
regulation 0
of 0
L1 B-gene
endocytosis 0
. 0

We 0
conclude 0
that 0
RPMS B-gene
acts 0
as 0
a 0
negative 0
regulator 0
of 0
EBNA2 B-gene
and 0
Notch B-gene
activity 0
through 0
its 0
interactions 0
with 0
the 0
CBF1 B-gene
- I-gene
associated I-gene
corepressor I-gene
complex I-gene
. 0

Folate 0
metabolism 0
in 0
the 0
human 0
malaria 0
parasite 0
Plasmodium 0
falciparum 0
is 0
an 0
essential 0
activity 0
for 0
cell 0
growth 0
and 0
replication 0
, 0
and 0
the 0
target 0
of 0
an 0
important 0
class 0
of 0
therapeutic 0
agents 0
in 0
widespread 0
use 0
. 0

The 0
BFA 0
System 0
reads 0
a 0
text 0
file 0
with 0
flows 0
, 0
measured 0
with 0
fluorescent 0
microsphere 0
technique 0
, 0
and 0
constructs 0
the 0
lung 0
anatomy 0
with 0
volumetric 0
pixels 0
showing 0
the 0
flows 0
with 0
a 0
color 0
schema 0
. 0

Retinoids 0
participate 0
in 0
the 0
onset 0
of 0
differentiation 0
, 0
apoptosis 0
and 0
the 0
inhibition 0
of 0
growth 0
in 0
a 0
wide 0
variety 0
of 0
normal 0
and 0
cancerous 0
cells 0
. 0

Transactivation 0
of 0
oIFNtau B-gene
enhancer 0
- 0
reporter 0
constructs 0
was 0
primarily 0
regulated 0
by 0
three 0
regions 0
containing 0
AP B-gene
- I-gene
1 I-gene
site I-gene
, 0
GATA B-gene
like I-gene
sequence I-gene
and 0
site 0
( 0
s 0
) 0
unidentified 0
. 0

These 0
results 0
indicate 0
that 0
evaluation 0
of 0
exposure 0
to 0
S. 0
neurona 0
by 0
WB 0
analysis 0
of 0
serum 0
may 0
be 0
misleading 0
in 0
young 0
horses 0
. 0

Drosophila B-gene
Menin1 I-gene
gene I-gene
transcripts I-gene
use 0
alternative 0
polyadenylation 0
sites 0
resulting 0
in 0
4.3 0
and 0
5 0
- 0
kb 0
messages 0
. 0

Sequence 0
analysis 0
indicates 0
that 0
RBP21 B-gene
shares 0
homology 0
with 0
other 0
retinoblastoma B-gene
- I-gene
binding I-gene
proteins I-gene
in 0
the 0
pRb B-gene
- I-gene
binding I-gene
motif I-gene
LxCxE 0
at 0
the 0
C 0
- 0
terminal 0
region 0
. 0

In 0
addition 0
, 0
the 0
consensus 0
amino 0
acid 0
motif 0
for 0
serine B-gene
threonine I-gene
receptor I-gene
kinases I-gene
was 0
also 0
present 0
. 0

We 0
have 0
also 0
isolated 0
and 0
analyzed 0
the 0
5 0
' 0
flanking 0
region 0
of 0
the 0
pea 0
33RNP B-gene
gene I-gene
. 0

OsBBPI B-gene
was 0
found 0
to 0
be 0
rapidly 0
induced 0
in 0
rice 0
seedling 0
leaf 0
in 0
response 0
to 0
cut B-gene
, 0
exogenous 0
jasmonic 0
acid 0
( 0
JA 0
) 0
, 0
and 0
two 0
potent 0
protein B-gene
phosphatase I-gene
2A I-gene
( 0
PP2A B-gene
) 0
inhibitors 0
, 0
cantharidin 0
( 0
CN 0
) 0
and 0
endothall 0
( 0
EN 0
) 0
, 0
in 0
a 0
light/dark 0
- 0
, 0
time 0
- 0
and 0
dose 0
- 0
dependent 0
manner 0
; 0
this 0
induction 0
was 0
completely 0
inhibited 0
by 0
cycloheximide 0
( 0
CHX 0
) 0
, 0
indicating 0
a 0
requirement 0
for 0
de 0
novo 0
protein 0
synthesis 0
in 0
its 0
induction 0
. 0

Copyright 0
2000 0
John 0
Wiley 0
& 0
Sons 0
, 0
Ltd 0
. 0

The 0
effects 0
of 0
chlordiazepoxide 0
( 0
2.5 0
- 0
15.0mg/kg 0
) 0
, 0
a 0
full 0
benzodiazepine B-gene
receptor I-gene
agonist 0
, 0
and 0
bretazenil 0
( 0
5.0 0
- 0
30.0mg/kg 0
) 0
, 0
a 0
partial 0
benzodiazepine B-gene
receptor I-gene
agonist 0
, 0
were 0
examined 0
in 0
the 0
murine 0
elevated 0
plus 0
- 0
maze 0
paradigm 0
. 0

However 0
, 0
plasmids 0
carrying 0
the 0
yeast B-gene
TyrRS I-gene
gene I-gene
could 0
not 0
be 0
stably 0
maintained 0
in 0
E. 0
coli 0
. 0

In 0
mammalian 0
tissue 0
culture 0
cells 0
, 0
overexpression 0
of 0
any 0
of 0
the 0
four 0
mouse 0
deltex 0
homologs 0
suppressed 0
the 0
transcriptional 0
activity 0
of 0
E47 B-gene
, 0
a 0
basic B-gene
helix I-gene
- I-gene
loop I-gene
- I-gene
helix I-gene
( I-gene
bHLH I-gene
) I-gene
protein I-gene
, 0
in 0
a 0
manner 0
similar 0
to 0
suppression 0
by 0
an 0
activated 0
form 0
of 0
human B-gene
Notch1 I-gene
or 0
human B-gene
DTX1 I-gene
. 0

Multiparous 0
women 0
presented 0
higher 0
BMI 0
( 0
P 0
= 0
0.01 0
) 0
and 0
PBF 0
( 0
P 0
= 0
0.03 0
) 0
compared 0
with 0
primi 0
- 0
and 0
nulliparous 0
groups 0
. 0

The 0
authors 0
did 0
not 0
detect 0
any 0
significant 0
correlations 0
between 0
parameters 0
of 0
the 0
lipids 0
of 0
bone 0
marrow 0
and 0
leptin B-gene
levels 0
in 0
serum 0
and 0
bone 0
marrow 0
. 0

Fluorimetric 0
determination 0
of 0
methylmercury 0
as 0
an 0
ion 0
- 0
association 0
complex 0
with 0
rhodamine 0
B 0
in 0
the 0
presence 0
of 0
iodide 0
. 0

The 0
position 0
of 0
the 0
analyst 0
as 0
expert 0
: 0
yesterday 0
and 0
today 0
. 0

Our 0
results 0
suggest 0
that 0
the 0
central 0
role 0
of 0
the 0
Notch B-gene
- 0
CBF1/RBP B-gene
CBF1/RBP I-gene
- I-gene
Jkappa I-gene
signaling 0
pathway 0
in 0
cell 0
fate 0
decisions 0
renders 0
it 0
susceptible 0
to 0
pathways 0
of 0
viral 0
replication 0
and 0
oncogenic 0
conversion 0
. 0

Using 0
a 0
novel 0
method 0
combining 0
chromatin 0
immunoprecipitation 0
and 0
genomic 0
array 0
hybridization 0
, 0
we 0
have 0
identified 0
a 0
460 B-gene
- I-gene
kb I-gene
CENP I-gene
- I-gene
A I-gene
- I-gene
binding I-gene
DNA I-gene
domain I-gene
of 0
a 0
neocentromere 0
derived 0
from 0
the 0
20p12 0
region 0
of 0
an 0
invdup 0
( 0
20p 0
) 0
human 0
marker 0
chromosome 0
. 0

We 0
describe 0
a 0
total 0
of 0
39 0
DEAH B-gene
helicases I-gene
in 0
these 0
four 0
species 0
. 0

Two 0
cases 0
with 0
marked 0
chronic 0
arm 0
lymphoedema 0
reported 0
major 0
and 0
persistent 0
improvements 0
in 0
arm 0
volume 0
for 0
at 0
least 0
12 0
months 0
after 0
treatment 0
with 0
HBO2 0
. 0

The 0
sensitivity 0
of 0
human 0
neuroblastoma 0
cells 0
SK 0
- 0
N 0
- 0
SH 0
to 0
undergo 0
apoptosis 0
induced 0
by 0
thapsigargin 0
was 0
examined 0
. 0

Prophylactic 0
lymph 0
node 0
dissection 0
or 0
radiation 0
therapy 0
to 0
the 0
nodal 0
chain 0
may 0
decrease 0
local 0
recurrence 0
but 0
does 0
not 0
consistently 0
affect 0
overall 0
survival 0
. 0

Currently 0
, 0
the 0
clinical 0
use 0
of 0
5 0
- 0
aminolaevulinic 0
acid 0
( 0
ALA 0
) 0
induced 0
protoporphyrin B-gene
IX I-gene
( 0
PPIX B-gene
) 0
for 0
photodynamic 0
therapy 0
( 0
PDT 0
) 0
is 0
limited 0
by 0
the 0
maximum 0
tolerated 0
oral 0
ALA 0
dose 0
( 0
60 0
mg/kg 0
) 0
. 0

We 0
can 0
classify 0
antibiotics 0
into 0
two 0
groups 0
based 0
on 0
initial 0
bactericidal 0
activity 0
against 0
P. 0
aeruginosa 0
; 0
one 0
class 0
is 0
antibiotics 0
having 0
rapid 0
initial 0
killing 0
such 0
as 0
AMK 0
, 0
IPM 0
and 0
PAPM 0
, 0
the 0
other 0
is 0
CAZ 0
, 0
MEPM 0
showing 0
slow 0
initial 0
killing 0
. 0

Managing 0
HIV 0
. 0

In 0
Klinefelter 0
's 0
syndrome 0
( 0
47XXY 0
) 0
, 0
serum 0
testosterone 0
levels 0
are 0
at 0
the 0
lower 0
end 0
of 0
the 0
normal 0
range 0
and 0
dihydrotestosterone 0
levels 0
are 0
low 0
. 0

The 0
histamine B-gene
H1 I-gene
receptor I-gene
antagonists 0
( 0
antihistamines 0
) 0
are 0
an 0
important 0
class 0
of 0
medications 0
used 0
for 0
the 0
relief 0
of 0
common 0
symptoms 0
associated 0
with 0
hyperhistaminic 0
conditions 0
occurring 0
in 0
children 0
and 0
adults 0
. 0

Conclusion 0
: 0
The 0
Lp B-gene
( I-gene
a I-gene
) I-gene
levels 0
in 0
these 0
children 0
were 0
the 0
lower 0
ever 0
reported 0
. 0

A 0
subset 0
of 0
patients 0
( 0
n=30 0
) 0
underwent 0
multichannel 0
pressure 0
flow 0
studies 0
, 0
which 0
demonstrated 0
that 0
transrectal 0
HIFU 0
reduces 0
bladder 0
outflow 0
obstruction 0
. 0

AIMS 0
: 0
To 0
establish 0
a 0
baseline 0
and 0
intraindividual 0
fluctuations 0
of 0
the 0
tumour 0
markers 0
CEA B-gene
, 0
CA B-gene
50 I-gene
and 0
CA B-gene
242 I-gene
in 0
patients 0
cured 0
from 0
colorectal 0
cancer 0
, 0
and 0
to 0
test 0
the 0
hypothesis 0
that 0
serum 0
concentrations 0
and 0
intraindividual 0
fluctuations 0
do 0
not 0
differ 0
from 0
the 0
concentrations 0
in 0
cancer 0
- 0
free 0
individuals 0
. 0

The 0
homologous 0
active 0
- 0
site 0
framework 0
of 0
these 0
enzymes 0
with 0
distinct 0
structures 0
suggests 0
convergent 0
evolution 0
of 0
a 0
common 0
catalytic 0
mechanism 0
. 0

Cells 0
containing 0
alpha 0
subunits 0
that 0
lacked 0
a 0
distal 0
domain 0
( 0
term 0
- 0
3 0
) 0
or 0
had 0
the 0
alternatively 0
spliced 0
alpha 0
- 0
2 0
distal 0
domain 0
showed 0
markedly 0
decreased 0
ability 0
to 0
support 0
tyrosine 0
phosphorylation 0
of 0
Jak B-gene
- I-gene
2 I-gene
and 0
its 0
substrates 0
or 0
to 0
up 0
- 0
regulate 0
CD86 B-gene
. 0

We 0
found 0
that 0
RhoA B-gene
can 0
initiate 0
a 0
linear 0
kinase 0
cascade 0
leading 0
to 0
the 0
activation 0
of 0
ERK6 B-gene
( 0
p38 B-gene
gamma I-gene
) 0
, 0
a 0
recently 0
identified 0
member 0
of 0
the 0
p38 B-gene
family I-gene
of 0
MAPKs 0
. 0

We 0
show 0
that 0
several 0
heme 0
- 0
responsive 0
mechanisms 0
combine 0
to 0
regulate 0
DAN/TIR B-gene
gene 0
expression 0
. 0

In 0
strains 0
lacking 0
tup11 B-gene
and 0
tup12 B-gene
, 0
the 0
atf1 B-gene
- 0
pcr1 B-gene
transcriptional 0
activator 0
continues 0
to 0
play 0
a 0
central 0
role 0
in 0
fbp1 B-gene
- 0
lacZ B-gene
expression 0
; 0
however 0
, 0
spc1 B-gene
MAPK I-gene
phosphorylation 0
of 0
atf1 B-gene
is 0
no 0
longer 0
essential 0
for 0
its 0
activation 0
. 0

In 0
vitro 0
binding 0
studies 0
demonstrate 0
that 0
eIF B-gene
- I-gene
5A I-gene
is 0
required 0
for 0
efficient 0
interaction 0
of 0
Rev B-gene
- 0
NES B-gene
with 0
CRM1/exportin1 B-gene
and 0
that 0
CRM1/exportin1 I-gene

Structural 0
studies 0
have 0
shown 0
that 0
class B-gene
I I-gene
major I-gene
histocompatibility I-gene
complex I-gene
( 0
MHC B-gene
) 0
- 0
restricted 0
peptide 0
- 0
specific 0
T B-gene
cell I-gene
receptor I-gene
( I-gene
TCR I-gene
) I-gene
- I-gene
alpha/betas I-gene
make 0
multiple 0
contacts 0
with 0
the 0
alpha1 0
and 0
alpha2 0
helices 0
of 0
the 0
MHC B-gene
, 0
but 0
it 0
is 0
unclear 0
which 0
or 0
how 0
many 0
of 0
these 0
interactions 0
contribute 0
to 0
functional 0
binding 0
. 0

In 0
Saccharomyces 0
cerevisiae 0
, 0
eIF6 B-gene
is 0
encoded 0
by 0
a 0
single 0
- 0
copy 0
essential 0
gene 0
. 0

Mice 0
homozygous 0
for 0
the 0
dlg B-gene
mutation 0
exhibit 0
growth 0
retardation 0
in 0
utero 0
, 0
have 0
hypoplasia 0
of 0
the 0
premaxilla 0
and 0
mandible 0
, 0
have 0
a 0
cleft 0
secondary 0
palate 0
, 0
and 0
die 0
perinatally 0
. 0

Moreover 0
, 0
a 0
complex 0
containing 0
PTP B-gene
phi I-gene
, 0
paxillin B-gene
, 0
and 0
a 0
paxillin B-gene
- I-gene
associated I-gene
tyrosine I-gene
kinase I-gene
, 0
Pyk2 B-gene
, 0
can 0
be 0
immunoprecipitated 0
from 0
macrophage 0
lysates 0
, 0
and 0
the 0
catalytic 0
domain 0
of 0
PTP B-gene
phi I-gene
selectively 0
binds 0
paxillin B-gene
and 0
Pyk2 B-gene
in 0
vitro 0
. 0

A 0
single 0
base 0
change 0
( 0
A8G 0
) 0
in 0
either 0
sequence 0
reduces 0
hnRNP B-gene
A2 I-gene
binding 0
and 0
, 0
in 0
the 0
case 0
of 0
A2RE B-gene
- I-gene
2 I-gene
, 0
inhibits 0
RNA 0
transport 0
. 0

Baseline 0
variables 0
associated 0
with 0
CD 0
included 0
a 0
less 0
frequent 0
use 0
of 0
prestroke 0
aspirin 0
and 0
a 0
higher 0
incidence 0
of 0
early 0
CT 0
changes 0
of 0
edema 0
or 0
mass 0
effect 0
or 0
dense 0
middle 0
cerebral 0
artery 0
sign 0
. 0

IL B-gene
- I-gene
1beta I-gene
was 0
significantly 0
higher 0
in 0
endometrioma 0
than 0
in 0
lesions 0
of 0
other 0
localizations 0
. 0

A 0
complete 0
drug 0
history 0
was 0
compiled 0
, 0
specifying 0
the 0
amount 0
and 0
duration 0
of 0
VGB 0
medication 0
. 0

TaqMan 0
analysis 0
of 0
gene 0
expression 0
following 0
chronic 0
FA 0
treatment 0
showed 0
neither 0
a 0
decrease 0
in 0
the 0
amount 0
of 0
leptin B-gene
receptor I-gene
( 0
Ob B-gene
- I-gene
R I-gene
) 0
mRNA 0
, 0
nor 0
an 0
increase 0
in 0
the 0
negative 0
regulators 0
of 0
STAT B-gene
signalling 0
, 0
SOCS3 B-gene
( 0
suppressors B-gene
of I-gene
cytokine I-gene
signalling I-gene
) 0
or 0
cytokine B-gene
inducible I-gene
sequence I-gene
( 0
CIS B-gene
) 0
. 0

The 0
mutant 0
receptors 0
, 0
as 0
well 0
as 0
sBMPR B-gene
- I-gene
IA I-gene
, 0
were 0
expressed 0
as 0
fusion 0
proteins 0
with 0
thioredoxin B-gene
in 0
Escherichia 0
coli 0
, 0
and 0
purified 0
using 0
reverse 0
phase 0
high 0
performance 0
liquid 0
chromatography 0
( 0
RP 0
- 0
HPLC 0
) 0
after 0
digestion 0
with 0
enterokinase B-gene
. 0

The 0
authors 0
undertook 0
a 0
retrospective 0
analysis 0
of 0
pathology 0
with 0
quantification 0
of 0
the 0
percentage 0
of 0
papillary 0
serous 0
component 0
( 0
% 0
PSC 0
) 0
and 0
p53 B-gene
expression 0
. 0

For 0
this 0
purpose 0
, 0
the 0
immediate 0
and 0
the 0
final 0
( 0
after 0
swelling 0
) 0
fixation 0
strengths 0
of 0
two 0
variations 0
of 0
the 0
swellable 0
bone 0
anchor 0
designs 0
( 0
a 0
smooth 0
anchor 0
and 0
a 0
screw 0
anchor 0
) 0
were 0
measured 0
in 0
two 0
different 0
foams 0
( 0
used 0
to 0
simulate 0
bone 0
) 0
with 0
different 0
densities 0
. 0

Constitutive 0
phosphorylation 0
and 0
nuclear 0
localization 0
of 0
Smad3 B-gene
are 0
correlated 0
with 0
increased 0
collagen B-gene
gene I-gene
transcription 0
in 0
activated 0
hepatic 0
stellate 0
cells 0
. 0

Cloning 0
and 0
characterization 0
of 0
the 0
murine B-gene
beta I-gene
( I-gene
3 I-gene
) I-gene
integrin I-gene
gene I-gene
promoter 0
: 0
identification 0
of 0
an 0
interleukin B-gene
- I-gene
4 I-gene
responsive I-gene
element I-gene
and 0
regulation 0
by 0
STAT B-gene
- I-gene
6 I-gene
. 0

CONCLUSIONS 0
: 0
Although 0
the 0
levels 0
of 0
oxLDL B-gene
antibodies I-gene
might 0
be 0
modified 0
in 0
early 0
hypertension 0
, 0
once 0
advanced 0
coronary 0
artery 0
disease 0
has 0
developed 0
the 0
presence 0
of 0
hypertension 0
does 0
not 0
affect 0
anti B-gene
- I-gene
oxLDL I-gene
levels 0
. 0

GafChromic 0
( 0
MD 0
- 0
55 0
- 0
2 0
) 0
radiochromic 0
film 0
has 0
become 0
increasingly 0
popular 0
for 0
medical 0
applications 0
and 0
has 0
proven 0
to 0
be 0
useful 0
for 0
brachytherapy 0
dosimetry 0
. 0

RESULTS 0
: 0
Within 0
7 0
days 0
, 0
all 0
groups 0
re 0
- 0
acquired 0
responding 0
for 0
heroin 0
under 0
CRF 0
at 0
rates 0
similar 0
to 0
their 0
pre 0
- 0
lesion 0
performance 0
. 0

Cis 0
- 0
acting 0
CCAAT 0
elements 0
are 0
frequently 0
found 0
in 0
eukaryotic 0
promoter 0
regions 0
. 0

Twenty 0
- 0
five 0
patients 0
also 0
received 0
PET 0
examinations 0
during 0
the 0
staging 0
procedures 0
. 0

The 0
Gap69C B-gene
is 0
a 0
single 0
- 0
copy 0
gene 0
producing 0
a 0
major 0
2.1 0
- 0
kb 0
mRNA 0
throughout 0
development 0
, 0
but 0
its 0
amount 0
is 0
decreased 0
in 0
larvae 0
. 0

Cases 0
of 0
lung 0
cancer 0
with 0
intramedullary 0
metastasis 0
are 0
rare 0
, 0
especially 0
those 0
diagnosed 0
before 0
death 0
. 0

A 0
novel 0
growth 0
- 0
related 0
nuclear 0
protein 0
binds 0
and 0
inhibits 0
rat 0
aldolase B-gene
B I-gene
gene I-gene
promoter 0
. 0

OBJECTIVE 0
: 0
To 0
investigate 0
the 0
association 0
between 0
complete 0
congenital 0
heart 0
block 0
( 0
CCHB 0
) 0
in 0
the 0
fetus 0
and 0
adult 0
disease 0
. 0

This 0
study 0
examined 0
the 0
role 0
of 0
cholesteryl 0
ester 0
transfer 0
( 0
CET 0
) 0
, 0
cholesteryl B-gene
ester I-gene
transfer I-gene
protein I-gene
( 0
CETP B-gene
) 0
activity 0
, 0
and 0
phospholipid B-gene
transfer I-gene
protein I-gene
( 0
PLTP B-gene
) 0
activity 0
in 0
the 0
increased 0
prevalence 0
of 0
coronary 0
artery 0
calcification 0
( 0
CAC 0
) 0
in 0
diabetic 0
subjects 0
compared 0
with 0
nondiabetic 0
subjects 0
and 0
in 0
the 0
loss 0
of 0
the 0
sex 0
difference 0
in 0
CAC 0
in 0
diabetes 0
. 0

Two 0
families 0
with 0
concordant 0
inheritance 0
of 0
DNAH9 B-gene
alleles I-gene
in 0
affected 0
individuals 0
were 0
observed 0
. 0

The 0
blood 0
levels 0
of 0
lactate 0
, 0
pyruvate 0
and 0
amino 0
acids 0
were 0
not 0
elevated 0
. 0

Efficacy 0
of 0
first 0
- 0
generation 0
Cavermap 0
to 0
verify 0
location 0
and 0
function 0
of 0
cavernous 0
nerves 0
during 0
radical 0
prostatectomy 0
: 0
a 0
multi 0
- 0
institutional 0
evaluation 0
by 0
experienced 0
surgeons 0
. 0

The 0
( 0
two 0
- 0
motif 0
) 0
domain 0
fold 0
contains 0
a 0
pair 0
of 0
calcium 0
binding 0
sites 0
very 0
similar 0
to 0
those 0
found 0
in 0
a 0
two B-gene
- I-gene
domain I-gene
prokaryotic I-gene
betagamma I-gene
- I-gene
crystallin I-gene
fold I-gene
family I-gene
member I-gene
, 0
Protein B-gene
S I-gene
. 0

Deletional 0
analyses 0
of 0
VDR B-gene
indicated 0
that 0
GRIP1 B-gene
and 0
RAC3 B-gene
required 0
an 0
intact 0
VDR B-gene
activation 0
function 0
( 0
AF 0
- 0
2 0
) 0
domain 0
for 0
efficient 0
interaction 0
as 0
well 0
as 0
additional 0
but 0
distinct 0
regions 0
of 0
the 0
VDR B-gene
. 0

Mechanism 0
in 0
the 0
sequential 0
control 0
of 0
cell 0
morphology 0
and 0
S 0
phase 0
entry 0
by 0
epidermal B-gene
growth I-gene
factor I-gene
involves 0
distinct 0
MEK/ERK B-gene
activations 0
. 0

The 0
expression 0
of 0
alpha B-gene
- I-gene
amylase I-gene
can 0
be 0
transactivated 0
by 0
the 0
transcription 0
factor 0
GAMyb B-gene
, 0
which 0
is 0
itself 0
induced 0
by 0
GA 0
. 0

3D 0
image 0
- 0
processing 0
permits 0
to 0
analyse 0
ultrasound 0
data 0
interactively 0
in 0
three 0
orthogonal 0
planes 0
( 0
section 0
mode 0
) 0
or 0
in 0
realistic 0
3D 0
views 0
( 0
rendering 0
mode 0
) 0
. 0

Only 0
nine 0
patients 0
were 0
offered 0
surgery 0
( 0
six 0
were 0
resected 0
and 0
three 0
were 0
found 0
inoperable 0
) 0
. 0

Direct 0
superoxide 0
scavenging 0
activity 0
of 0
nonsteroidal 0
anti 0
- 0
inflammatory 0
drugs 0
: 0
determination 0
by 0
electron 0
spin 0
resonance 0
using 0
the 0
spin 0
trap 0
method 0
. 0

BACKGROUND 0
: 0
Dermoscopy 0
is 0
a 0
noninvasive 0
technique 0
that 0
increases 0
the 0
diagnostic 0
accuracy 0
of 0
pigmented 0
skin 0
lesions 0
, 0
particularly 0
improving 0
the 0
diagnosis 0
of 0
patients 0
with 0
cutaneous 0
melanoma 0
in 0
situ 0
( 0
CMIS 0
) 0
and 0
early 0
invasive 0
melanoma 0
. 0

Moreover 0
, 0
PTax B-gene
expressed 0
higher 0
background 0
activities 0
than 0
PTF B-gene
, 0
indicating 0
that 0
the 0
sequence 0
of 0
the 0
synthetic 0
regulatory 0
region 0
can 0
influence 0
background 0
levels 0
. 0

However 0
, 0
the 0
promoter 0
region 0
contains 0
several 0
potential 0
cis 0
- 0
regulatory 0
elements 0
such 0
as 0
Sp1 B-gene
, 0
early B-gene
growth I-gene
response I-gene
- I-gene
1 I-gene
, 0
activator B-gene
protein I-gene
- I-gene
2 I-gene
, 0
MyoD B-gene
, 0
p300 B-gene
, 0
nuclear B-gene
factor I-gene
- I-gene
kappaB I-gene
, 0
myeloid B-gene
zinc I-gene
finger I-gene
protein I-gene
- I-gene
1 I-gene
, 0
caudal B-gene
- I-gene
related I-gene
homeobox I-gene
( I-gene
Cdx I-gene
) I-gene
gene I-gene
A I-gene
, 0
and 0
Cdx B-gene
protein I-gene
- I-gene
2 I-gene
binding I-gene
sites I-gene
. 0

Thus 0
, 0
the 0
interaction 0
of 0
Tat B-gene
with 0
the 0
components 0
of 0
this 0
rel/AP1 B-gene
cooperative 0
complex 0
seems 0
to 0
induce 0
quantitative 0
and 0
qualitative 0
alterations 0
of 0
this 0
complex 0
as 0
activation 0
progresses 0
, 0
resulting 0
in 0
a 0
decrease 0
of 0
rel/AP1 I-gene

2001 0
. 0

Adjuvant 0
and 0
neoadjuvant 0
treatment 0
of 0
breast 0
cancer 0
. 0

Unlike 0
other 0
progenitor 0
cells 0
of 0
the 0
brain 0
, 0
SVZa 0
progenitor 0
cells 0
have 0
the 0
capacity 0
to 0
divide 0
even 0
though 0
they 0
express 0
a 0
neuronal 0
phenotype 0
. 0

A 0
minimal 0
ER3 0
sequence 0
of 0
DNA 0
was 0
further 0
demonstrated 0
to 0
function 0
as 0
a 0
FXR B-gene
HRE I-gene
and 0
was 0
bound 0
in 0
vitro 0
by 0
FXR B-gene
- 0
expressing 0
yeast 0
extracts 0
. 0

OBJECTIVE 0
: 0
To 0
determine 0
the 0
association 0
of 0
depressive 0
symptoms 0
with 0
HIV 0
- 0
related 0
mortality 0
and 0
decline 0
in 0
CD4 B-gene
lymphocyte 0
counts 0
among 0
women 0
with 0
HIV 0
. 0

An 0
economic 0
analysis 0
using 0
West 0
of 0
Scotland 0
Coronary 0
Prevention 0
Study 0
( 0
WOSCOPS 0
) 0
findings 0
indicates 0
that 0
statin B-gene
treatment 0
would 0
have 0
prevented 0
318 0
events 0
per 0
10,000 0
patients 0
in 0
a 0
population 0
similar 0
to 0
that 0
in 0
WOSCOPS 0
( 0
average 0
1.5 0
% 0
annual 0
risk 0
of 0
a 0
cardiovascular 0
event 0
) 0
at 0
a 0
discounted 0
cost 0
per 0
life 0
- 0
year 0
gained 0
of 0
20,375 0
pounds 0
( 0
$ 0
31,818 0
) 0
. 0

Furthermore 0
, 0
the 0
soluble 0
forms 0
of 0
ATF6 B-gene
and 0
the 0
G13 B-gene
gene I-gene
product I-gene
are 0
unable 0
to 0
bind 0
to 0
several 0
point 0
mutants 0
of 0
the 0
cis 0
- 0
acting 0
ER 0
stress 0
response 0
element 0
in 0
vitro 0
that 0
hardly 0
respond 0
to 0
ER 0
stress 0
in 0
vivo 0
. 0

Sequence 0
analysis 0
revealed 0
significant 0
differences 0
between 0
the 0
5 0
' 0
region 0
of 0
the 0
beta 0
subunit 0
gene 0
and 0
the 0
corresponding 0
regions 0
of 0
the 0
homologous B-gene
GlyR I-gene
alpha I-gene
subunit I-gene
genes I-gene
; 0
it 0
also 0
identified 0
a 0
novel 0
exon 0
( 0
exon 0
0 0
) 0
that 0
encodes 0
most 0
of 0
the 0
5' 0
- 0
untranslated 0
portion 0
of 0
the 0
GlyR B-gene
beta I-gene
mRNA I-gene
. 0

The 0
present 0
study 0
was 0
initiated 0
to 0
explore 0
the 0
potential 0
of 0
a 0
hybrid 0
biological 0
reactor 0
, 0
combining 0
trickling 0
filter 0
( 0
TF 0
) 0
and 0
activated 0
sludge 0
process 0
( 0
ASP 0
) 0
, 0
to 0
treat 0
wastewater 0
containing 0
trichloroethylene 0
( 0
TCE 0
) 0
at 0
ambient 0
temperature 0
at 0
different 0
hydraulic 0
retention 0
time 0
( 0
HRT 0
) 0
. 0

In 0
DNA 0
strand 0
exchange 0
reactions 0
using 0
oligonucleotides 0
, 0
we 0
found 0
that 0
Rec2 B-gene
exhibited 0
a 0
pairing 0
bias 0
that 0
is 0
opposite 0
that 0
of 0
RecA B-gene
. 0

Anecdotal 0
observations 0
scattered 0
throughout 0
the 0
literature 0
have 0
often 0
provided 0
clues 0
to 0
underlying 0
variations 0
in 0
humans 0
' 0
ability 0
to 0
handle 0
dietary 0
chemicals 0
. 0

Forskolin 0
treatment 0
( 0
10 0
microM 0
) 0
of 0
the 0
transfected 0
cells 0
for 0
3 0
- 0
- 0
6 0
h 0
maximally 0
induced 0
luciferase B-gene
threefold 0
. 0

Analysis 0
of 0
ace2Delta 0
cells 0
reveals 0
that 0
Ace2p B-gene
is 0
required 0
for 0
cell 0
separation 0
but 0
not 0
for 0
polarized 0
growth 0
. 0

The 0
results 0
presented 0
here 0
show 0
that 0
AR1 B-gene
of 0
the 0
promoter 0
- 0
proximal 0
CAP B-gene
subunit I-gene
was 0
required 0
for 0
papBA B-gene
transcription 0
even 0
in 0
the 0
absence 0
of 0
the 0
histone B-gene
- I-gene
like I-gene
protein I-gene
H B-gene
- I-gene
NS I-gene
. 0

A. 0
, 0
Slatkin 0
, 0
D 0
. 0

RESULTS 0
: 0
A 0
significant 0
correlation 0
( 0
p 0
< 0
0.001 0
) 0
was 0
observed 0
for 0
mean 0
wall 0
thickness 0
and 0
vessel 0
wall 0
area 0
between 0
MRI 0
and 0
histopathology 0
( 0
r 0
= 0
0.87 0
and 0
r 0
= 0
0.85 0
, 0
respectively 0
) 0
. 0

Our 0
data 0
indicate 0
that 0
SIP1 B-gene
is 0
required 0
to 0
confine 0
XBra B-gene
gene I-gene
expression 0
to 0
the 0
mesoderm 0
. 0

SIP1 B-gene
( 0
Smad B-gene
interacting I-gene
protein I-gene
1 I-gene
) 0
and 0
deltaEF1 B-gene
( 0
delta B-gene
- I-gene
crystallin I-gene
enhancer I-gene
binding I-gene
factor I-gene
) 0
are 0
structurally 0
similar 0
transcriptional 0
repressors 0
. 0

B B-gene
- I-gene
myb I-gene
is 0
essential 0
for 0
G1/S 0
transition 0
and 0
has 0
been 0
shown 0
to 0
be 0
phosphorylated 0
by 0
the 0
cyclin B-gene
A2/cdk2 I-gene
complex 0
. 0

Nucleotide 0
sequence 0
, 0
transcription 0
map 0
, 0
and 0
mutation 0
analysis 0
of 0
the 0
13q14 0
chromosomal 0
region 0
deleted 0
in 0
B 0
- 0
cell 0
chronic 0
lymphocytic 0
leukemia 0
. 0

Human B-gene
T I-gene
- I-gene
cell I-gene
leukemia I-gene
virus I-gene
type I-gene
I I-gene
( I-gene
HTLV I-gene
- I-gene
I I-gene
) I-gene
Tax I-gene
is 0
a 0
potent 0
transcriptional 0
regulator 0
that 0
can 0
activate 0
or 0
repress 0
specific 0
cellular 0
genes 0
and 0
that 0
has 0
been 0
proposed 0
to 0
contribute 0
to 0
leukemogenesis 0
in 0
adult 0
T 0
- 0
cell 0
leukemia 0
. 0

Requirements 0
for 0
the 0
nuclear 0
- 0
cytoplasmic 0
translocation 0
of 0
infected B-gene
- I-gene
cell I-gene
protein I-gene
0 I-gene
of 0
herpes 0
simplex 0
virus 0
1 0
. 0

The 0
human B-gene
cytomegalovirus I-gene
( I-gene
HCMV I-gene
) I-gene
major I-gene
immediate I-gene
- I-gene
early I-gene
protein I-gene
IE2 I-gene
is 0
a 0
nuclear 0
phosphoprotein 0
that 0
is 0
believed 0
to 0
be 0
a 0
key 0
regulator 0
in 0
both 0
lytic 0
and 0
latent 0
infections 0
. 0

OBJECTIVE 0
: 0
To 0
determine 0
whether 0
RSTD 0
predicts 0
coronary 0
anatomy 0
during 0
acute 0
coronary 0
occlusion 0
. 0

The 0
Novacor 0
Left 0
Ventricular 0
Assist 0
System 0
( 0
LVAS 0
) 0
( 0
Novacor 0
Corp 0
, 0
Oakland 0
, 0
CA 0
) 0
was 0
initially 0
console 0
- 0
based 0
and 0
has 0
been 0
available 0
since 0
1993 0
in 0
a 0
wearable 0
configuration 0
. 0

Atheroma 0
appears 0
as 0
a 0
very 0
low 0
signal 0
intensity 0
area 0
on 0
2 0
- 0
dimensional 0
time 0
- 0
of 0
- 0
flight 0
( 0
TOF 0
) 0
magnetic 0
resonance 0
( 0
MR 0
) 0
images 0
, 0
and 0
its 0
components 0
have 0
various 0
signal 0
intensities 0
on 0
spin 0
- 0
echo 0
( 0
SE 0
) 0
images 0
. 0

Body 0
fat 0
distribution 0
was 0
determined 0
by 0
abdominal 0
computed 0
tomography 0
. 0

The 0
flux 0
rates 0
of 0
p 0
- 0
toluidine 0
decreased 0
as 0
the 0
pH 0
value 0
in 0
the 0
donor 0
solution 0
increased 0
. 0

We 0
have 0
now 0
tested 0
all 0
known 0
mammalian B-gene
Groucho I-gene
family I-gene
members I-gene
for 0
their 0
ability 0
to 0
interact 0
specifically 0
with 0
individual 0
Tcf/Lef B-gene
family 0
members 0
. 0

We 0
show 0
here 0
that 0
the 0
in 0
vitro 0
transcription 0
extract 0
contains 0
a 0
binding 0
activity 0
that 0
is 0
specific 0
for 0
the 0
initiator 0
element 0
and 0
thus 0
may 0
participate 0
in 0
recruiting 0
RNA B-gene
polymerase I-gene
II I-gene
to 0
the 0
SL 0
RNA 0
gene 0
promoter 0
. 0

The 0
protein 0
is 0
composed 0
of 0
two 0
major 0
domains 0
separated 0
by 0
a 0
hydrophobic 0
linker 0
region 0
of 0
20 0
amino 0
acid 0
residues 0
. 0

The 0
438 B-gene
bp I-gene
EcoRI I-gene
fragment I-gene
, 0
which 0
was 0
detected 0
by 0
Southern 0
hybridization 0
, 0
reveals 0
an 0
open 0
reading 0
frame 0
which 0
encodes 0
a 0
protein 0
of 0
103 0
amino 0
acids 0
. 0

We 0
performed 0
the 0
present 0
study 0
to 0
clarify 0
the 0
relationship 0
between 0
the 0
DOX 0
binding 0
ability 0
( 0
% 0
DB 0
) 0
and 0
the 0
histologic 0
response 0
, 0
rate 0
of 0
decrease 0
in 0
tumor 0
volume 0
of 0
malignant 0
soft 0
tissue 0
tumors 0
after 0
preoperative 0
chemotherapy 0
and 0
prognosis 0
. 0

To 0
avoid 0
misinterpretations 0
, 0
special 0
reference 0
values 0
should 0
be 0
applied 0
for 0
preadolescents 0
, 0
at 0
least 0
with 0
regard 0
to 0
FVC 0
and 0
FEV1 0
. 0

Nephrotoxicity 0
after 0
orthotopic 0
liver 0
transplantation 0
in 0
cyclosporin 0
A 0
and 0
FK 0
506 0
- 0
treated 0
patients 0
. 0

Compared 0
with 0
normal 0
control 0
subjects 0
, 0
all 0
74 0
TOF 0
patients 0
had 0
decreased 0
systolic 0
and 0
diastolic 0
myocardial 0
velocities 0
and 0
a 0
longer 0
isovolumic 0
relaxation 0
time 0
. 0

Acetoin 0
can 0
be 0
reused 0
by 0
the 0
bacteria 0
during 0
stationary 0
phase 0
when 0
other 0
carbon 0
sources 0
have 0
been 0
depleted 0
. 0

Mutational 0
analysis 0
showed 0
that 0
the 0
U 0
- 0
box 0
, 0
like 0
the 0
RING 0
finger 0
in 0
other 0
proteins 0
, 0
forms 0
the 0
physical 0
basis 0
for 0
the 0
interaction 0
with 0
E2 B-gene
enzymes I-gene
. 0

Thus 0
, 0
our 0
studies 0
define 0
Rac/Cdc42/Pak B-gene
as 0
a 0
module 0
upstream 0
of 0
Rac/Cdc42/Pak I-gene

Nrf2 B-gene
regulates 0
expression 0
of 0
genes 0
encoding 0
enzymes 0
with 0
antioxidant 0
( 0
e.g 0
. 0
heme B-gene
oxygenase I-gene
- I-gene
1 I-gene
( 0
HO B-gene
- I-gene
1 I-gene
) 0
) 0
or 0
xenobiotic 0
detoxification 0
( 0
e.g 0
. 0

These 0
results 0
indicate 0
that 0
ATF4 B-gene
regulates 0
basal 0
and 0
CdCl 0
( 0
2 0
) 0
- 0
induced 0
expression 0
of 0
the 0
ho B-gene
- I-gene
1 I-gene
gene I-gene
in 0
a 0
cell 0
- 0
specific 0
manner 0
and 0
possibly 0
in 0
a 0
complex 0
with 0
Nrf2 B-gene
. 0

On 0
the 0
other 0
hand 0
, 0
forced 0
overexpression 0
of 0
the 0
wild 0
type 0
, 0
but 0
not 0
the 0
kinase 0
- 0
inactivated 0
mutant 0
of 0
nm23H1 B-gene
, 0
converted 0
the 0
GDP 0
- 0
bound 0
forms 0
of 0
Rac1 B-gene
, 0
Cdc42 B-gene
, 0
and 0
RhoA B-gene
to 0
their 0
GTP 0
- 0
bound 0
forms 0
in 0
vitro 0
by 0
its 0
nucleoside B-gene
diphosphate I-gene
kinase I-gene
activity 0
, 0
but 0
nm23H1 B-gene
alone 0
apparently 0
did 0
not 0
produce 0
the 0
GTP 0
- 0
bound 0
form 0
of 0
these 0
GTPases B-gene
in 0
vivo 0
. 0

This 0
effect 0
was 0
observed 0
in 0
the 0
absence 0
of 0
de 0
novo 0
protein 0
synthesis 0
and 0
was 0
independent 0
of 0
histone B-gene
deacetylase I-gene
activity 0
. 0

Deletion 0
of 0
the 0
potential 0
initiator 0
element 0
does 0
not 0
affect 0
repression 0
of 0
the 0
p21 B-gene
promoter I-gene
by 0
c B-gene
- I-gene
Myc I-gene
. 0

Fetal 0
lung 0
volume 0
: 0
estimation 0
at 0
MR 0
imaging 0
- 0
initial 0
results 0
. 0

Of 0
its 0
gene 0
products 0
, 0
E6 B-gene
binds 0
to 0
and 0
inactivates 0
p53 B-gene
tumor I-gene
suppressor I-gene
protein I-gene
by 0
ubiquitin/proteasome B-gene
- 0
dependent 0
degradation 0
. 0

In 0
mouse 0
, 0
Mmip1 B-gene
( 0
Mad B-gene
member I-gene
interacting I-gene
protein I-gene
1 I-gene
) 0
and 0
Smc3 B-gene
share 0
99 0
% 0
sequence 0
identity 0
and 0
are 0
products 0
of 0
the 0
same 0
gene 0
. 0

An 0
element 0
within 0
the 0
5 0
' 0
untranslated 0
region 0
of 0
human B-gene
Hsp70 I-gene
mRNA I-gene
which 0
acts 0
as 0
a 0
general 0
enhancer 0
of 0
mRNA 0
translation 0
. 0

In 0
SN 0
- 0
48 0
neuronal 0
cells 0
that 0
express 0
MR B-gene
, 0
GR B-gene
, 0
and 0
5 B-gene
- I-gene
HT1A I-gene
receptors I-gene
, 0
deletion 0
or 0
inactivation 0
of 0
the 0
nGRE 0
( 0
negative 0
GRE 0
) 0
eliminated 0
negative 0
regulation 0
of 0
the 0
rat B-gene
5 I-gene
- I-gene
HT1A I-gene
or 0
heterologous 0
promoters 0
by 0
corticosteroids 0
, 0
whereas 0
its 0
inclusion 0
conferred 0
corticosteroid 0
- 0
induced 0
inhibition 0
to 0
a 0
heterologous 0
promoter 0
. 0

Corticosteroid 0
- 0
mediated 0
transcriptional 0
inhibition 0
was 0
greater 0
for 0
MR/GR B-gene
in 0
combination 0
than 0
for 0
MR/GR I-gene

Whereas 0
Smad2 B-gene
was 0
rapidly 0
phosphorylated 0
by 0
TGF B-gene
- I-gene
beta I-gene
and 0
involved 0
in 0
the 0
initial 0
activation 0
of 0
Agc B-gene
expression 0
in 0
confluent 0
cells 0
, 0
Smad2 B-gene
activation 0
was 0
not 0
required 0
for 0
maintaining 0
the 0
high 0
level 0
of 0
Agc B-gene
expression 0
. 0

Furthermore 0
, 0
this 0
kinase 0
- 0
deficient 0
mutant 0
inhibited 0
2 0
- 0
MeSADP 0
- 0
induced 0
caspase B-gene
- I-gene
3 I-gene
stimulation 0
and 0
the 0
associated 0
decrease 0
in 0
cell 0
number 0
. 0

Reverse B-gene
transcriptase I-gene
- 0
polymerase 0
chain 0
reaction 0
assays 0
showed 0
that 0
PKRDeltaE7 B-gene
is 0
expressed 0
in 0
a 0
broad 0
range 0
of 0
human 0
tissues 0
at 0
variable 0
levels 0
. 0

Both 0
pancreatic 0
and 0
intestinal 0
cell 0
lines 0
were 0
found 0
to 0
express 0
a 0
number 0
of 0
POU B-gene
( 0
OCT B-gene
binding 0
) 0
homeodomain 0
proteins 0
examined 0
by 0
electrophoretic 0
mobility 0
shift 0
assay 0
. 0

SV1 B-gene
has 0
a 0
33 0
- 0
amino 0
acid 0
insert 0
in 0
the 0
S1 0
transmembrane 0
domain 0
that 0
does 0
not 0
alter 0
S1 0
overall 0
hydrophobicity 0
, 0
but 0
makes 0
the 0
S0 0
- 0
S1 0
linker 0
longer 0
. 0

Polyclonal 0
antibodies 0
against 0
the 0
N 0
- 0
terminal 0
part 0
( 0
amino 0
acids 0
12 0
- 0
363 0
) 0
and 0
the 0
C 0
- 0
terminal 0
part 0
( 0
amino 0
acids 0
330 0
- 0
730 0
) 0
of 0
rainbow B-gene
trout I-gene
HIF I-gene
- I-gene
1alpha I-gene
protein I-gene
recognized 0
rainbow B-gene
trout I-gene
and I-gene
chinook I-gene
salmon I-gene
HIF I-gene
- I-gene
1alpha I-gene
protein I-gene
in 0
Western 0
blot 0
analysis 0
. 0

The 0
v B-gene
- I-gene
Src I-gene
SH3 B-gene
domain I-gene
facilitates 0
a 0
cell 0
adhesion 0
- 0
independent 0
association 0
with 0
focal B-gene
adhesion I-gene
kinase I-gene
. 0

A 0
20 0
- 0
base 0
pair 0
oligonucleotide 0
containing 0
this 0
nonamer 0
confers 0
up 0
- 0
regulation 0
by 0
hypoxia 0
and 0
inhibition 0
by 0
unsaturated 0
fatty 0
acids 0
when 0
placed 0
upstream 0
of 0
a 0
heterologous 0
promoter 0
in 0
a 0
lacZ B-gene
reporter I-gene
construct I-gene
. 0

Deletion 0
analyses 0
implicate 0
the 0
N 0
- 0
terminal 0
110 0
amino 0
acids 0
of 0
Grb14 B-gene
and 0
ankyrin B-gene
repeats 0
10 0
- 0
19 0
of 0
tankyrase B-gene
2 I-gene
in 0
mediating 0
this 0
interaction 0
. 0

Mutagenesis 0
of 0
SNT1 B-gene
( 0
IRS B-gene
) 0
CX B-gene
identified 0
three 0
classes 0
of 0
effector 0
motifs 0
within 0
SNT B-gene
critical 0
for 0
both 0
sustained 0
ERK B-gene
activation 0
and 0
neuronal 0
differentiation 0
: 0
1 0
) 0
four 0
phosphotyrosine 0
motifs 0
that 0
mediate 0
recruitment 0
of 0
Grb2 B-gene
, 0
2 0
) 0
two 0
phosphotyrosine 0
motifs 0
that 0
mediate 0
recruitment 0
of 0
Shp2 B-gene
, 0
and 0
3 0
) 0
a 0
C 0
- 0
terminal 0
motif 0
that 0
functions 0
by 0
helping 0
to 0
recruit 0
Sos B-gene
. 0

Exchanging 0
the 0
human 0
propeptide 0
in 0
this 0
chimera 0
with 0
either 0
the 0
murine B-gene
MIC I-gene
- I-gene
1 I-gene
or 0
TGF B-gene
- I-gene
beta1 I-gene
propeptide I-gene
resulted 0
in 0
secretion 0
of 0
the 0
unprocessed 0
, 0
monomeric 0
chimera 0
, 0
suggesting 0
a 0
specific 0
interaction 0
between 0
the 0
human B-gene
MIC I-gene
- I-gene
1 I-gene
propeptide I-gene
and 0
mature 0
peptide 0
. 0

Radiolabeled 0
biantennary 0
N 0
- 0
glycans 0
synthesized 0
by 0
Pro 0
( 0
- 0
) 0
5Lec20 0
were 0
proportionately 0
less 0
ricin 0
- 0
bound 0
than 0
similar 0
species 0
from 0
parental 0
CHO 0
cells 0
, 0
and 0
Lec20 0
cell 0
extracts 0
had 0
a 0
markedly 0
reduced 0
ability 0
to 0
transfer 0
Gal 0
to 0
GlcNAc 0
- 0
terminating 0
acceptors 0
. 0

We 0
found 0
that 0
the 0
SOCS B-gene
box I-gene
interacted 0
with 0
Cullin B-gene
- I-gene
2 I-gene
and 0
promoted 0
ubiquitination 0
of 0
TEL B-gene
- 0
JAK2 B-gene
. 0

Neuron B-gene
- I-gene
specific I-gene
Bcl I-gene
- I-gene
2 I-gene
homology I-gene
3 I-gene
domain I-gene
- I-gene
only I-gene
splice I-gene
variant I-gene
of 0
Bak B-gene
is 0
anti 0
- 0
apoptotic 0
in 0
neurons 0
, 0
but 0
pro 0
- 0
apoptotic 0
in 0
non 0
- 0
neuronal 0
cells 0
. 0

Finally 0
a 0
10 0
- 0
nucleotide 0
region 0
flanking 0
the 0
exon 0
4 0
protein 0
- 0
binding 0
site 0
is 0
homologous 0
to 0
instability 0
elements 0
within 0
five 0
other 0
transcripts 0
, 0
suggesting 0
that 0
a 0
common 0
coding 0
region 0
determinant 0
may 0
exist 0
. 0

Sequence 0
comparison 0
and 0
binding 0
studies 0
of 0
the 0
18 B-gene
- I-gene
bp I-gene
MOK2 I-gene
- I-gene
binding I-gene
sites I-gene
present 0
in 0
intron 0
2 0
of 0
human 0
, 0
bovine 0
, 0
and 0
mouse B-gene
IRBP I-gene
genes I-gene
show 0
that 0
the 0
3' 0
- 0
half 0
sequence 0
is 0
the 0
essential 0
core 0
element 0
for 0
MOK2 B-gene
binding 0
. 0

Furthermore 0
, 0
SB203580 0
inhibited 0
LPS 0
- 0
induced 0
activation 0
of 0
Sp1 B-gene
, 0
as 0
well 0
as 0
the 0
promoter 0
activity 0
in 0
cells 0
transfected 0
with 0
a 0
plasmid 0
containing 0
the 0
Sp1 B-gene
consensus 0
sequence 0
. 0

We 0
confirmed 0
the 0
interaction 0
between 0
TLS B-gene
and 0
p65 B-gene
by 0
the 0
pull 0
- 0
down 0
assay 0
in 0
vitro 0
and 0
by 0
a 0
coimmunoprecipitation 0
experiment 0
followed 0
by 0
Western 0
blot 0
of 0
the 0
cultured 0
cell 0
in 0
vivo 0
. 0

Analysis 0
of 0
regulatory 0
regions 0
in 0
the 0
promoter 0
of 0
the 0
ctr4 B-gene
( I-gene
+ I-gene
) I-gene
copper I-gene
transporter I-gene
gene I-gene
in 0
fission 0
yeast 0
Schizosaccharomyces 0
pombe 0
reveals 0
the 0
identity 0
of 0
a 0
conserved 0
copper 0
- 0
signaling 0
element 0
( 0
CuSE 0
) 0
, 0
which 0
is 0
recognized 0
by 0
the 0
transcription B-gene
factor I-gene
Cuf1 I-gene
. 0

Based 0
on 0
mutational 0
data 0
and 0
possible 0
mRNA 0
structure 0
, 0
we 0
hypothesized 0
about 0
the 0
effect 0
of 0
mRNA 0
structure 0
on 0
translation 0
of 0
the 0
two 0
major 0
C/EBPepsilon B-gene
isoforms I-gene
: 0
p32 B-gene
and 0
p30 B-gene
. 0

WRN B-gene
helicase I-gene
resolves 0
alternate 0
DNA 0
structures 0
including 0
tetraplex 0
and 0
triplex 0
DNA 0
, 0
and 0
Holliday 0
junctions 0
. 0

These 0
data 0
suggest 0
that 0
ADAM B-gene
- I-gene
TS12 I-gene
may 0
play 0
roles 0
in 0
pulmonary 0
cells 0
during 0
fetal 0
development 0
or 0
in 0
tumor 0
processes 0
through 0
its 0
proteolytic 0
activity 0
or 0
as 0
a 0
molecule 0
potentially 0
involved 0
in 0
regulation 0
of 0
cell 0
adhesion 0
. 0

Binding 0
of 0
serum B-gene
response I-gene
factor I-gene
to 0
CArG 0
box 0
sequences 0
is 0
necessary 0
but 0
not 0
sufficient 0
to 0
restrict 0
gene 0
expression 0
to 0
arterial 0
smooth 0
muscle 0
cells 0
. 0

Together 0
, 0
these 0
results 0
identify 0
HPK1 B-gene
as 0
a 0
new 0
component 0
of 0
TCR B-gene
signaling 0
. 0

Biol 0
. 0

The 0
size 0
of 0
the 0
infarct 0
was 0
determined 0
using 0
the 0
creatine B-gene
kinase I-gene
integral 0
method 0
. 0

A 0
new 0
echocardiographic 0
technique 0
is 0
described 0
with 0
a 0
conventional 0
M 0
mode 0
, 0
digitalised 0
2D 0
and 0
tissular 0
Doppler 0
which 0
has 0
a 0
comparable 0
ability 0
to 0
identify 0
the 0
anomalous 0
pathways 0
of 0
electric 0
conduction 0
using 0
a 0
non 0
- 0
invasive 0
method 0
. 0

SELECTION 0
CRITERIA 0
: 0
Randomised 0
controlled 0
trials 0
of 0
cabergoline 0
versus 0
placebo 0
in 0
patients 0
with 0
a 0
clinical 0
diagnosis 0
of 0
idiopathic 0
Parkinson 0
's 0
disease 0
and 0
long 0
- 0
term 0
complications 0
of 0
levodopa 0
therapy 0
. 0

CONCLUSIONS 0
: 0
Using 0
icodextrin 0
- 0
based 0
instead 0
of 0
glucose 0
- 0
based 0
PD 0
fluids 0
can 0
largely 0
reduce 0
the 0
formation 0
of 0
Amadori 0
albumin B-gene
and 0
AGEs 0
. 0

In 0
contrast 0
, 0
exogenous B-gene
PTHrP1 I-gene
- I-gene
34 I-gene
and I-gene
1 I-gene
- I-gene
86 I-gene
peptides I-gene
did 0
not 0
significantly 0
affect 0
IL B-gene
- I-gene
8 I-gene
production 0
; 0
moreover 0
, 0
PTHrP B-gene
- I-gene
neutralizing I-gene
antibodies I-gene
did 0
not 0
inhibit 0
the 0
production 0
of 0
IL B-gene
- I-gene
8 I-gene
by 0
transfected 0
PTHrP B-gene
. 0

Deterministic 0
effects 0
. 0

Unusual 0
two B-gene
- I-gene
domain I-gene
arginine I-gene
kinases I-gene
( 0
AKs B-gene
) 0
arose 0
independently 0
at 0
least 0
two 0
times 0
during 0
molecular 0
evolution 0
of 0
phosphagen B-gene
kinases I-gene
: 0
AKs B-gene
from 0
the 0
primitive 0
sea 0
anemone 0
Anthopleurura 0
japonicus 0
and 0
from 0
the 0
clam 0
Pseudocardium 0
sachalinensis 0
. 0

The 0
mouse B-gene
platelet I-gene
- I-gene
derived I-gene
growth I-gene
factor I-gene
( I-gene
PDGF I-gene
) I-gene
beta I-gene
- I-gene
receptor I-gene
promoter I-gene
contains 0
a 0
CCAAT 0
motif 0
, 0
and 0
NF B-gene
- I-gene
Y I-gene
plays 0
an 0
essential 0
role 0
in 0
its 0
transcription 0
. 0

Baseline 0
MBF 0
in 0
females 0
was 0
significantly 0
( 0
P 0
< 0
0.001 0
) 0
higher 0
than 0
in 0
males 0
. 0

No 0
preferential 0
VH/VL B-gene
- 0
chains 0
correlated 0
with 0
any 0
of 0
the 0
12 0
different 0
antigen 0
reactivities 0
, 0
even 0
for 0
mAbs 0
with 0
nearly 0
identical 0
cross 0
- 0
reactivities 0
. 0

Recently 0
, 0
it 0
was 0
shown 0
that 0
purified 0
RAG1/2 B-gene
proteins I-gene
can 0
cleave 0
DNA 0
hairpins 0
in 0
vitro 0
, 0
but 0
the 0
same 0
activity 0
was 0
also 0
described 0
for 0
a 0
protein 0
complex 0
of 0
the 0
DNA 0
repair 0
proteins 0
Nbs1/Mre11/Rad50 B-gene
. 0

In 0
addition 0
, 0
we 0
did 0
not 0
detect 0
significant 0
differences 0
in 0
CDR3 B-gene
sequences I-gene
of 0
endogenous B-gene
Ig I-gene
lambdaL I-gene
and 0
kappaL B-gene
chain I-gene
gene I-gene
loci I-gene
cloned 0
from 0
peripheral 0
blood 0
lymphocytes 0
of 0
an 0
NBS 0
patient 0
and 0
of 0
healthy 0
individuals 0
. 0

Phase 0
II 0
study 0
of 0
paclitaxel 0
and 0
oral 0
etoposide 0
in 0
patients 0
with 0
locally 0
advanced 0
or 0
metastatic 0
non 0
- 0
small 0
cell 0
lung 0
cancer 0
. 0

Oral 0
supplementation 0
of 0
L 0
- 0
arginine 0
significantly 0
increased 0
plasma 0
L 0
- 0
citrulline 0
, 0
which 0
indicated 0
enhancement 0
of 0
NO 0
production 0
. 0

This 0
activation 0
was 0
then 0
blocked 0
by 0
CGS 0
12066A 0
. 0

Our 0
results 0
suggest 0
that 0
WASP B-gene
activates 0
transcription 0
following 0
TCR B-gene
stimulation 0
in 0
a 0
manner 0
that 0
is 0
independent 0
of 0
its 0
role 0
in 0
Arp2/3 B-gene
- 0
directed 0
actin B-gene
polymerization 0
. 0

Two 0
independent 0
transgenic 0
lines 0
were 0
produced 0
, 0
and 0
both 0
showed 0
expression 0
of 0
the 0
Gus B-gene
gene I-gene
specifically 0
in 0
the 0
endosperm 0
during 0
mid 0
- 0
development 0
( 0
first 0
detected 0
10 0
- 0
12 0
d 0
after 0
anthesis 0
) 0
. 0

Here 0
we 0
demonstrate 0
that 0
native B-gene
MRCK I-gene
exists 0
in 0
high 0
- 0
molecular 0
- 0
weight 0
complexes 0
. 0

These 0
data 0
define 0
a 0
conserved 0
pathway 0
wherein 0
sequential 0
histone B-gene
modifications 0
establish 0
a 0
`` B-gene
histone I-gene
code 0
'' 0
essential 0
for 0
the 0
epigenetic 0
inheritance 0
of 0
heterochromatin 0
assembly 0
. 0

Regression 0
analyses 0
showed 0
that 0
SOREMP 0
dream 0
occurrences 0
were 0
significantly 0
related 0
to 0
the 0
amount 0
of 0
REM 0
sleep 0
, 0
while 0
NREMP 0
dream 0
occurrences 0
were 0
related 0
to 0
arousals 0
from 0
NREM 0
sleep 0
. 0

Instead 0
, 0
TRPS1 B-gene
potently 0
and 0
specifically 0
represses 0
transcriptional 0
activation 0
mediated 0
by 0
other 0
GATA B-gene
factors I-gene
. 0

9.7 0
( 0
95 0
% 0
CI 0
: 0
9.6 0
- 0
9.7 0
) 0
micromol/L 0
among 0
women 0
( 0
P 0
= 0
0.003 0
) 0
. 0

Three 0
patients 0
received 0
additional 0
cycles 0
of 0
5 0
- 0
fluorouracil 0
+/ 0
- 0
leucovorin 0
as 0
maintenance 0
chemotherapy.RESULTS 0
: 0
Thirty 0
males 0
and 0
21 0
females 0
with 0
a 0
median 0
age 0
of 0
55 0
years 0
( 0
range 0
31 0
- 0
- 0
73 0
years 0
) 0
were 0
treated 0
. 0

The 0
Delta6CCI 0
virus 0
was 0
extremely 0
attenuated 0
in 0
replication 0
capacity 0
yet 0
retained 0
infectiousness 0
for 0
CEMx174 0
and 0
MT4 0
cells 0
. 0

Secretion 0
of 0
interleukin B-gene
- I-gene
8 I-gene
, 0
RANTES B-gene
, 0
macrophage B-gene
inflammatory I-gene
protein I-gene
1alpha I-gene
, 0
and 0
10 B-gene
- I-gene
kappaDa I-gene
IFN I-gene
- I-gene
gamma I-gene
- I-gene
inducible I-gene
protein I-gene
were 0
increased 0
in 0
differentiating 0
keratinocytes 0
by 0
E6 B-gene
. 0

Another 0
mutant 0
, 0
T255A 0
, 0
lost 0
the 0
ability 0
to 0
bind 0
E4orf6 B-gene
, 0
but 0
unexpectedly 0
, 0
viral 0
late 0
- 0
gene 0
expression 0
was 0
not 0
affected 0
. 0

Herein 0
PPARgamma B-gene
, 0
liganded 0
by 0
either 0
natural 0
( 0
15d 0
- 0
PGJ 0
( 0
2 0
) 0
and 0
PGD 0
( 0
2 0
) 0
) 0
or 0
synthetic 0
ligands 0
( 0
BRL49653 0
and 0
troglitazone 0
) 0
, 0
selectively 0
inhibited 0
expression 0
of 0
the 0
cyclin B-gene
D1 I-gene
gene I-gene
. 0

Here 0
we 0
demonstrate 0
that 0
the 0
Ras B-gene
- 0
activated 0
Raf B-gene
- 0
MEK B-gene
- 0
extracellular B-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
( 0
ERK B-gene
) 0
signaling 0
pathway 0
can 0
specifically 0
control 0
the 0
expression 0
of 0
individual 0
integrin B-gene
subunits I-gene
in 0
a 0
variety 0
of 0
human 0
and 0
mouse 0
cell 0
lines 0
. 0

PABP B-gene
is 0
a 0
modular 0
protein 0
, 0
with 0
four 0
N 0
- 0
terminal 0
RNA 0
- 0
binding 0
domains 0
and 0
an 0
extensive 0
C 0
terminus 0
. 0

Children 0
who 0
developed 0
lower 0
respiratory 0
tract 0
infections 0
or 0
PCP 0
had 0
increased 0
rates 0
of 0
decline 0
of 0
CD4 B-gene
cell 0
counts 0
during 0
the 0
first 0
6 0
months 0
of 0
life 0
. 0

The 0
reproductive 0
effects 0
of 0
the 0
administration 0
of 0
4 0
- 0
chloro 0
- 0
2 0
- 0
methylphenoxyacetic 0
acid 0
( 0
MCPA 0
) 0
to 0
rats 0
were 0
evaluated 0
through 0
two 0
generations 0
, 0
from 0
prior 0
to 0
mating 0
, 0
throughout 0
mating 0
, 0
to 0
gestation 0
and 0
lactation 0
. 0

Coexposure 0
to 0
FP 0
also 0
resulted 0
in 0
a 0
more 0
pronounced 0
and 0
sustained 0
activation 0
of 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
kinase/extracellular I-gene
kinase/extracellular I-gene
signal I-gene
- I-gene
regulated I-gene
protein I-gene
kinase I-gene
cascade 0
after 0
PMA 0
treatment 0
, 0
although 0
disruption 0
of 0
this 0
pathway 0
by 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
kinase I-gene
1 I-gene
inhibitor 0
U0126 0
did 0
not 0
prevent 0
potentiation 0
of 0
apoptosis 0
. 0

Also 0
, 0
the 0
EWS B-gene
protein I-gene
stimulates 0
transcription 0
mediated 0
by 0
the 0
COOH 0
- 0
terminal 0
transactivation 0
domain 0
of 0
the 0
cofactor 0
CREB B-gene
- I-gene
binding I-gene
protein I-gene
( 0
CBP B-gene
) 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
have 0
determined 0
the 0
ICBP90 B-gene
gene I-gene
structure 0
by 0
screening 0
of 0
a 0
human 0
placenta 0
genomic 0
library 0
and 0
PCR 0
analysis 0
. 0

Tumor 0
- 0
like 0
accumulation 0
on 0
Tl 0
- 0
201 0
SPECT 0
in 0
subacute 0
hemorrhagic 0
cerebral 0
infarction 0
. 0

METHODS 0
: 0
126 0
patients 0
with 0
histologically 0
confirmed 0
MFH 0
were 0
analyzed 0
. 0

It 0
is 0
surprising 0
that 0
dnaE173 0
, 0
a 0
potent 0
mutator 0
mutation 0
specific 0
for 0
sequence 0
substitution 0
as 0
well 0
as 0
single 0
- 0
base 0
frameshift 0
, 0
did 0
not 0
enhance 0
the 0
frequency 0
of 0
the 0
hot 0
- 0
spot 0
frameshift 0
mutation 0
. 0

Its 0
transcription 0
in 0
vitro 0
by 0
pol B-gene
III I-gene
requires 0
the 0
same 0
factors 0
as 0
the 0
U6 B-gene
gene I-gene
with 0
the 0
major 0
exception 0
that 0
the 0
modified 0
TATA 0
- 0
box 0
of 0
this 0
construct 0
only 0
interacts 0
with 0
a 0
TATA B-gene
- I-gene
binding I-gene
protein I-gene
( 0
TBP B-gene
) 0
mutant 0
( 0
TBP B-gene
- I-gene
DR2 I-gene
) 0
but 0
not 0
with 0
TBP B-gene
wild I-gene
- I-gene
type I-gene
( 0
TBPwt B-gene
) 0
. 0

HSF B-gene
binds 0
DNA 0
as 0
a 0
trimer 0
, 0
and 0
additional 0
trimers 0
can 0
bind 0
DNA 0
co 0
- 0
operatively 0
. 0

We 0
also 0
demonstrate 0
that 0
the 0
spo20 B-gene
( I-gene
+ I-gene
) I-gene
gene I-gene
product I-gene
is 0
structurally 0
homologous 0
to 0
Saccharomyces B-gene
cerevisiae I-gene
Sec14 I-gene
, 0
the 0
major 0
phosphatidylinositol 0
transfer 0
protein 0
of 0
budding 0
yeast 0
. 0

There 0
was 0
no 0
evidence 0
of 0
linkage 0
disequilibrium 0
between 0
the 0
polymorphic 0
site 0
in 0
the 0
B 0
cell 0
specific 0
promoter 0
and 0
those 0
in 0
the 0
3 0
' 0
UTR 0
. 0

Their 0
numbers 0
have 0
regularly 0
increased 0
since 0
the 0
mid 0
- 0
1970s 0
. 0

Specimen 0
mass 0
reduction 0
increased 0
with 0
irradiance 0
from 0
19 0
to 0
72 0
% 0
of 0
the 0
initial 0
mass 0
for 0
9 0
- 0
- 0
31 0
W/cm 0
( 0
2 0
) 0
, 0
respectively 0
. 0

In 0
addition 0
, 0
another 0
derivative 0
of 0
pCMVJS21 0
( 0
pCMVJS21DeltaGP 0
) 0
in 0
which 0
the 0
gag B-gene
, 0
pol B-gene
( 0
and 0
orf B-gene
- I-gene
x I-gene
) 0
coding 0
sequences 0
were 0
deleted 0
also 0
gave 0
transformed 0
foci 0
. 0

In 0
conclusion 0
, 0
tube 0
size 0
estimated 0
by 0
Cole 0
's 0
formula 0
tends 0
to 0
be 0
smaller 0
than 0
practically 0
appropriate 0
tube 0
size 0
for 0
pediatric 0
cardiac 0
anesthesia 0
, 0
and 0
therefore 0
we 0
suggest 0
new 0
formula 0
to 0
estimate 0
the 0
tube 0
size 0
. 0

An 0
F222W B-gene
: I-gene
W21F I-gene
rGST I-gene
A1 I-gene
- I-gene
1 I-gene
double I-gene
mutant I-gene
provides 0
a 0
direct 0
fluorescence 0
probe 0
of 0
changes 0
in 0
the 0
environment 0
of 0
the 0
C 0
- 0
terminal 0
residue 0
. 0

The 0
recessive 0
hos1 B-gene
mutation 0
causes 0
enhanced 0
induction 0
of 0
the 0
CBF B-gene
transcription I-gene
factors I-gene
by 0
low 0
temperature 0
as 0
well 0
as 0
of 0
their 0
downstream 0
cold 0
- 0
responsive 0
genes 0
. 0

Stable 0
transfection 0
of 0
human B-gene
CHOP I-gene
cDNA I-gene
into 0
mammary 0
carcinoma 0
cells 0
demonstrated 0
that 0
CHOP B-gene
functioned 0
not 0
as 0
a 0
mediator 0
of 0
hGH B-gene
- 0
stimulated 0
mitogenesis 0
but 0
rather 0
enhanced 0
the 0
protection 0
from 0
apoptosis 0
afforded 0
by 0
hGH B-gene
in 0
a 0
p38 B-gene
MAPK 0
- 0
dependent 0
manner 0
. 0

In 0
contrast 0
, 0
neither 0
I. 0
argentina 0
nor 0
I. 0
theezans 0
exerted 0
any 0
effect 0
on 0
BF 0
or 0
intestinal 0
propulsion 0
. 0

A 0
comparison 0
of 0
the 0
duplicated 0
Vkappa B-gene
genes I-gene
suggests 0
positive 0
selection 0
on 0
the 0
complementarity 0
- 0
determining 0
regions 0
of 0
the 0
duplicated 0
genes 0
by 0
point 0
mutations 0
. 0

In 0
contrast 0
, 0
the 0
ubiquitous 0
expression 0
of 0
p19 B-gene
( 0
INK4d B-gene
) 0
has 0
not 0
been 0
previously 0
described 0
in 0
human 0
or 0
murine 0
B 0
- 0
lineage 0
cells 0
. 0

The 0
results 0
show 0
that 0
cognitive 0
stimulation 0
enhanced 0
performance 0
on 0
the 0
Boston 0
Naming 0
Test 0
and 0
a 0
Word 0
List 0
Recognition 0
Task 0
; 0
physical 0
intervention 0
, 0
however 0
, 0
did 0
not 0
reach 0
statistical 0
significance 0
. 0

Instead 0
, 0
affective 0
flattening 0
was 0
associated 0
with 0
both 0
dopamine B-gene
receptor I-gene
sensitivity 0
and 0
psychomotor 0
slowing 0
. 0

Homo 0
- 0
oligomerisation 0
and 0
nuclear 0
localisation 0
of 0
mouse B-gene
histone I-gene
deacetylase I-gene
1 I-gene
. 0

These 0
data 0
reveal 0
a 0
complex 0
network 0
of 0
interactions 0
between 0
GTPases B-gene
in 0
the 0
ARF B-gene
family I-gene
and 0
their 0
effectors 0
and 0
reveal 0
a 0
potential 0
for 0
cross 0
- 0
talk 0
not 0
demonstrated 0
previously 0
. 0

With 0
NEU B-gene
overexpression 0
, 0
nodal 0
control 0
decreased 0
from 0
72 0
% 0
to 0
34 0
% 0
( 0
p 0
= 0
.008 0
) 0
. 0

At 0
the 0
time 0
of 0
the 0
blind 0
therapeutic 0
doses 0
, 0
Tg B-gene
- 0
off 0
values 0
ranged 0
from 0
8 0
to 0
608 0
microg/l 0
. 0

Effects 0
of 0
a 0
booster 0
dose 0
of 0
tetanus 0
toxoid 0
after 0
different 0
primary 0
courses 0
of 0
vaccination 0
: 0
implications 0
on 0
the 0
use 0
of 0
immune B-gene
globulin I-gene
. 0

Using 0
RACE 0
techniques 0
we 0
have 0
cloned 0
and 0
sequenced 0
one 0
of 0
the 0
hamster 0
liver 0
3 B-gene
- I-gene
hydroxy I-gene
- I-gene
hexobarbital I-gene
dehydrogenases I-gene
which 0
catalyze 0
not 0
only 0
cyclic 0
alcohols 0
but 0
also 0
17beta 0
- 0
hydroxy 0
- 0
steroids 0
and 0
3alpha 0
- 0
hydroxysteroids 0
. 0

A 0
mutation 0
in 0
the 0
C 0
domain 0
of 0
Rb B-gene
, 0
L901Q 0
, 0
has 0
been 0
identified 0
that 0
completely 0
abolishes 0
cdk4/D1 B-gene
phosphorylation 0
of 0
the 0
isolated 0
C 0
domain 0
. 0

An 0
association 0
was 0
demonstrated 0
between 0
the 0
expression 0
of 0
aberrantly 0
and/or 0
alternatively 0
spliced 0
mdm2 B-gene
mRNAs I-gene
and 0
a 0
lack 0
of 0
progesterone B-gene
receptor I-gene
. 0

Histological 0
examination 0
showed 0
lichenoid 0
changes 0
, 0
acantholytic 0
blister 0
formation 0
and 0
apoptotic 0
keratinocytes 0
. 0

We 0
find 0
that 0
our 0
response 0
function 0
is 0
well 0
approximated 0
by 0
the 0
GSER 0
only 0
within 0
a 0
particular 0
frequency 0
range 0
determined 0
by 0
the 0
material 0
parameters 0
of 0
both 0
the 0
bead 0
and 0
the 0
network 0
. 0

It 0
is 0
shown 0
that 0
, 0
for 0
any 0
periodic 0
input 0
, 0
the 0
map 0
representing 0
the 0
relation 0
between 0
input 0
phases 0
at 0
consecutive 0
discharge 0
times 0
can 0
be 0
restricted 0
to 0
a 0
piecewise 0
continuous 0
, 0
orientation 0
preserving 0
circle 0
map 0
. 0

Nine 0
strains 0
were 0
subtyped 0
as 0
Camp 0
. 0
jejuni 0
subsp 0
. 0
jejuni 0
biotype 0
II 0
and 0
the 0
remaining 0
ones 0
as 0
biotype 0
I 0
. 0

Analysis 0
of 0
mCTR B-gene
mRNAs I-gene
has 0
revealed 0
that 0
the 0
three 0
alternative 0
promoters 0
give 0
rise 0
to 0
at 0
least 0
seven 0
mCTR B-gene
isoforms I-gene
in 0
the 0
5 0
' 0
region 0
of 0
the 0
gene 0
and 0
generate 0
5' 0
- 0
untranslated 0
regions 0
of 0
very 0
different 0
lengths 0
. 0

We 0
previously 0
showed 0
that 0
this 0
proteolysis 0
1 0
) 0
can 0
be 0
acutely 0
promoted 0
by 0
the 0
phorbol 0
ester 0
phorbol 0
12 0
- 0
myristate 0
13 0
- 0
acetate 0
( 0
PMA 0
) 0
, 0
2 0
) 0
requires 0
a 0
metalloprotease B-gene
activity 0
, 0
3 0
) 0
generates 0
both 0
shed 0
GHBP B-gene
and 0
a 0
membrane B-gene
- I-gene
associated I-gene
GHR I-gene
transmembrane/cytoplasmic I-gene
domain I-gene
remnant 0
, 0
and 0
4 0
) 0
results 0
in 0
down 0
- 0
regulation 0
of 0
GHR B-gene
abundance 0
and 0
GH B-gene
signaling 0
. 0

Effects 0
of 0
3 0
' 0
terminus 0
modifications 0
on 0
mRNA 0
functional 0
decay 0
during 0
in 0
vitro 0
protein 0
synthesis 0
. 0

A 0
comprehensive 0
neuropsychological 0
battery 0
was 0
administered 0
to 0
48 0
veterans 0
with 0
Gulf 0
War 0
Illness 0
( 0
GWI 0
) 0
characterized 0
by 0
severe 0
fatigue 0
( 0
GV 0
- 0
F 0
) 0
and 0
39 0
healthy 0
veterans 0
( 0
GV 0
- 0
H 0
) 0
. 0

Reverse 0
transcription 0
- 0
PCR 0
analysis 0
of 0
mRNA 0
from 0
patients 0
shows 0
that 0
each 0
of 0
these 0
five 0
mutations 0
results 0
in 0
aberrant 0
splicing 0
. 0

RESULTS 0
: 0
Coronary 0
mortality 0
during 0
the 0
median 0
follow 0
- 0
up 0
time 0
of 0
17 0
months 0
was 0
6 0
- 0
fold 0
higher 0
in 0
the 0
highest 0
tertile 0
for 0
CRP B-gene
and 0
IL B-gene
- I-gene
6 I-gene
and 0
3.5 0
- 0
fold 0
higher 0
in 0
the 0
highest 0
tertile 0
for 0
fibrinogen B-gene
and 0
TNF B-gene
- I-gene
alpha I-gene
than 0
in 0
the 0
respective 0
combined 0
lower 0
tertiles 0
. 0

The 0
relationship 0
of 0
the 0
factor B-gene
V I-gene
Leiden I-gene
mutation I-gene
or 0
the 0
deletion 0
- 0
deletion 0
polymorphism 0
of 0
the 0
angiotensin B-gene
converting I-gene
enzyme I-gene
to 0
postoperative 0
thromboembolic 0
events 0
following 0
total 0
joint 0
arthroplasty 0
. 0

These 0
disorders 0
include 0
low 0
- 0
back 0
pain 0
, 0
saddle 0
anesthesia 0
, 0
bilateral 0
sciatica 0
, 0
then 0
motor 0
weakness 0
of 0
the 0
lower 0
extremities 0
or 0
chronic 0
paraplegia 0
and 0
, 0
bladder 0
dysfunction 0
. 0

Sural 0
nerve 0
biopsy 0
showed 0
mild 0
thickening 0
of 0
the 0
perineurium 0
, 0
vascular 0
alterations 0
with 0
inflammatory 0
cell 0
infiltration 0
in 0
the 0
perineurium 0
, 0
and 0
remarkable 0
loss 0
of 0
large 0
and 0
small 0
myelinated 0
fibers 0
. 0

To 0
examine 0
transcriptional 0
regulation 0
of 0
the 0
rat B-gene
eIF4E I-gene
gene I-gene
, 0
2.1 0
kB 0
of 0
the 0
rat B-gene
eIF4E I-gene
promoter I-gene
region I-gene
was 0
cloned 0
and 0
the 0
contribution 0
of 0
specific 0
elements 0
in 0
regulating 0
transcription 0
was 0
determined 0
in 0
primary 0
cultures 0
of 0
rat 0
cardiocytes 0
and 0
in 0
a 0
murine 0
C 0
( 0
2 0
) 0
C 0
( 0
12 0
) 0
myoblast 0
cell 0
line 0
. 0

When 0
this 0
CCAAT 0
box 0
was 0
inserted 0
into 0
a 0
heterologous 0
promoter 0
construct 0
, 0
OA 0
induction 0
was 0
dependent 0
on 0
an 0
intact 0
CCAAT 0
box 0
. 0

The 0
JHRLSS 0
has 0
been 0
used 0
in 0
prior 0
studies 0
to 0
assess 0
RLS 0
severity 0
, 0
but 0
has 0
not 0
previously 0
been 0
validated 0
in 0
relation 0
to 0
direct 0
measures 0
of 0
the 0
morbidity 0
associated 0
with 0
RLS 0
. 0

In 0
the 0
remaining 0
case 0
, 0
the 0
aneurysm 0
originated 0
from 0
the 0
proximal 0
end 0
of 0
the 0
associated 0
A1 0
fenestration 0
. 0

GABA B-gene
( I-gene
B I-gene
) I-gene
R1g I-gene
was 0
expressed 0
in 0
both 0
brain 0
and 0
peripheral 0
tissues 0
. 0

Raes 0
, 0
P 0
. 0

NF B-gene
- I-gene
kappaB I-gene
pathway 0
activation 0
occurs 0
during 0
transformation 0
induced 0
by 0
a 0
number 0
of 0
classical 0
oncogenes 0
, 0
including 0
Bcr/Abl B-gene
, 0
Bcr/Abl I-gene

We 0
used 0
a 0
rev B-gene
- 0
and 0
RRE B-gene
- 0
defective 0
HIV 0
type 0
1 0
( 0
HIV 0
- 0
1 0
) 0
molecular 0
clone 0
in 0
complementation 0
experiments 0
to 0
establish 0
a 0
method 0
for 0
the 0
rapid 0
isolation 0
of 0
posttranscriptional 0
regulatory 0
elements 0
from 0
the 0
mammalian 0
genome 0
by 0
selecting 0
for 0
rescue 0
of 0
virus 0
replication 0
. 0

Copyright 0
2001 0
Academic 0
Press 0
. 0

A 0
novel 0
myeloid 0
- 0
restricted 0
zebrafish 0
CCAAT/enhancer B-gene
- I-gene
binding I-gene
protein I-gene
with 0
a 0
potent 0
transcriptional 0
activation 0
domain 0
. 0

Recently 0
, 0
we 0
discovered 0
that 0
alanine 0
substitutions 0
of 0
the 0
active 0
center 0
cleft 0
residues 0
significantly 0
impair 0
the 0
depurinating 0
and 0
ribosome 0
inhibitory 0
activity 0
of 0
PAP B-gene
. 0

SH2D1A B-gene
protein I-gene
levels 0
are 0
up 0
- 0
regulated 0
by 0
CD40 B-gene
cross 0
- 0
linking 0
and 0
down 0
- 0
regulated 0
by 0
B B-gene
cell I-gene
receptor I-gene
ligation 0
. 0

Cross 0
- 0
linking 0
FcalphaR B-gene
on 0
wt B-gene
- I-gene
ITAM I-gene
or 0
IIA B-gene
- I-gene
ITAM I-gene
cells 0
triggered 0
equivalent 0
PI B-gene
3 I-gene
- I-gene
kinase I-gene
- 0
dependent 0
activation 0
of 0
PKBalpha B-gene
. 0

RPM/RGL3 B-gene
resembled 0
RPM/RGL3 I-gene

A 0
novel 0
potential 0
effector 0
of 0
M B-gene
- I-gene
Ras I-gene
and 0
p21 B-gene
Ras I-gene
negatively 0
regulates 0
p21 B-gene
Ras I-gene
- 0
mediated 0
gene 0
induction 0
and 0
cell 0
growth 0
. 0

The 0
mice 0
are 0
phenotypically 0
normal 0
and 0
do 0
not 0
develop 0
spontaneous 0
tumors 0
at 0
an 0
early 0
age 0
, 0
in 0
contrast 0
to 0
knock 0
- 0
out 0
( 0
p53 B-gene
( I-gene
- I-gene
/ I-gene
- I-gene
) I-gene
) 0
strains 0
with 0
a 0
defective 0
p53 B-gene
gene I-gene
. 0

Our 0
results 0
suggest 0
that 0
the 0
C 0
- 0
terminal 0
region 0
of 0
Crk B-gene
contains 0
negative 0
regulatory 0
elements 0
important 0
for 0
both 0
Abl B-gene
and 0
FAK B-gene
dependent 0
signal 0
pathways 0
, 0
and 0
offers 0
a 0
paradigm 0
for 0
an 0
autoinhibitory 0
region 0
in 0
the 0
SH3 B-gene
linker/C 0
- 0
terminal 0
SH3 B-gene
domain 0
. 0

Cyclins B-gene
are 0
one 0
of 0
the 0
pivotal 0
determinants 0
regulating 0
cell 0
cycle 0
progression 0
. 0

Evidence 0
- 0
based 0
care 0
: 0
a 0
new 0
formula 0
for 0
an 0
old 0
problem 0
? 0

Further 0
, 0
the 0
osteo 0
- 0
retentive 0
ability 0
of 0
the 0
hydroxyapatite 0
in 0
the 0
sockets 0
was 0
seen 0
to 0
be 0
close 0
to 0
significance 0
( 0
after 0
six 0
months 0
width 0
differences 0
, 0
in 0
the 0
canine 0
region 0
: 0
P 0
= 0
0.059 0
, 0
LHS 0
, 0
and 0
P 0
= 0
0.065 0
, 0
RHS 0
) 0
. 0

The 0
cleavage 0
site 0
between 0
VPg B-gene
and 0
RNA B-gene
dependent I-gene
RNA I-gene
polymerase I-gene
was 0
predicted 0
to 0
be 0
E445 0
- 0
T446 0
based 0
on 0
the 0
amino 0
acid 0
sequence 0
analysis 0
of 0
the 0
polyprotein 0
from 0
different 0
sobemoviruses 0
. 0

The 0
% 0
SVend 0
of 0
HCM 0
- 0
I 0
was 0
significantly 0
lower 0
than 0
the 0
respective 0
values 0
of 0
the 0
HCM 0
- 0
II 0
and 0
Control 0
groups 0
. 0

Nearly 0
all 0
isolates 0
of 0
S. 0
intermedius 0
and 0
most 0
isolates 0
of 0
S. 0
constellatus 0
, 0
but 0
only 0
19 0
% 0
of 0
those 0
of 0
S. 0
anginosus 0
, 0
were 0
associated 0
with 0
abscess 0
. 0

DESIGN 0
: 0
Retrospective 0
study 0
. 0

Human 0
brain 0
cDNA 0
library 0
screening 0
and 0
5 0
' 0
rapid 0
amplification 0
of 0
cDNA 0
ends 0
yielded 0
full B-gene
- I-gene
length I-gene
DENTT I-gene
cDNA I-gene
containing 0
an 0
1899 0
- 0
bp 0
open 0
reading 0
frame 0
encoding 0
a 0
predicted 0
633 0
- 0
amino 0
- 0
acid 0
protein 0
with 0
four 0
potential 0
nuclear 0
localization 0
signals 0
( 0
NLSs 0
) 0
and 0
two 0
coiled 0
- 0
coil 0
regions 0
. 0

Transfection 0
of 0
EGFP B-gene
- 0
tagged 0
DENTT B-gene
NLS 0
deletion 0
constructs 0
lacking 0
the 0
bipartite 0
NLS B-gene
- I-gene
1 I-gene
were 0
excluded 0
from 0
the 0
nucleolus 0
. 0

These 0
genes 0
encode 0
a 0
tryptophanyl B-gene
tRNA I-gene
, 0
the 0
protein B-gene
translocase I-gene
component 0
SecE B-gene
, 0
the 0
antiterminator B-gene
protein I-gene
NusG I-gene
, 0
and 0
the 0
ribosomal 0
proteins 0
L11 B-gene
and 0
L1 B-gene
in 0
addition 0
to 0
PkwR B-gene
, 0
a 0
putative 0
regulatory 0
protein 0
of 0
the 0
LacI B-gene
- 0
GalR B-gene
family 0
. 0

Rapamycin 0
( 0
FRAP/mTOR B-gene
inhibitor 0
) 0
blocked 0
FRAP/mTOR I-gene

Sixteen 0
out 0
of 0
52 0
seropositive 0
MS 0
patients 0
( 0
30.8 0
% 0
) 0
showed 0
intrathecal 0
synthesis 0
of 0
C. B-gene
pneumoniae I-gene
- I-gene
specific I-gene
IgG I-gene
but 0
only 0
one 0
of 0
43 0
seropositive 0
controls 0
( 0
2.3 0
% 0
) 0
. 0

Far 0
Western 0
blot 0
analysis 0
suggested 0
that 0
the 0
tandem 0
SH2 B-gene
domains I-gene
of 0
SHP2 B-gene
bind 0
to 0
Gab1 B-gene
in 0
a 0
specific 0
orientation 0
, 0
in 0
which 0
the 0
N B-gene
- I-gene
SH2 I-gene
domain I-gene
binds 0
to 0
phosphotyrosine 0
( 0
Tyr 0
( 0
P 0
) 0
) 0
- 0
627 0
and 0
the 0
C B-gene
- I-gene
SH2 I-gene
domain I-gene
binds 0
to 0
Tyr 0
( 0
P 0
) 0
- 0
659 0
. 0

Molecular 0
cloning 0
, 0
genomic 0
mapping 0
, 0
and 0
expression 0
of 0
two 0
secretor B-gene
blood I-gene
group I-gene
alpha I-gene
( I-gene
1,2 I-gene
) I-gene
fucosyltransferase I-gene
genes I-gene
differentially 0
regulated 0
in 0
mouse 0
uterine 0
epithelium 0
and 0
gastrointestinal 0
tract 0
. 0

The 0
UBA B-gene
domains I-gene
of 0
RAD23 B-gene
and 0
DDI1 B-gene
are 0
required 0
for 0
these 0
interactions 0
. 0

It 0
was 0
found 0
that 0
intrathecal 0
administration 0
( 0
i.t 0
. 0
) 0
of 0
D2 B-gene
receptor I-gene
agonist 0
LY171555 0
or 0
D1/D2 B-gene
receptor I-gene
agonist 0
apomorphine 0
increased 0
pain 0
threshold 0
and 0
had 0
a 0
potentiating 0
effect 0
on 0
AA 0
. 0

The 0
R2 0
between 0
MFI 0
of 0
fresh 0
and 0
frozen 0
muscle 0
was 0
0.94 0
and 0
0.92 0
for 0
lamb 0
and 0
pork 0
longissimus 0
, 0
respectively 0
. 0

After 0
all 0
doses 0
of 0
d 0
- 0
amphetamine 0
, 0
responding 0
occurred 0
largely 0
on 0
the 0
saline 0
key 0
under 0
both 0
schedules 0
. 0

Intravenous 0
L 0
- 0
carnitine 0
treatment 0
increased 0
plasma 0
carnitine 0
concentrations 0
, 0
improved 0
patient 0
- 0
assessed 0
fatigue 0
, 0
and 0
may 0
prevent 0
the 0
decline 0
in 0
peak 0
exercise 0
capacity 0
in 0
hemodialysis 0
patients 0
. 0

Elevated 0
expression 0
of 0
full B-gene
- I-gene
length I-gene
UhpB I-gene
or 0
of 0
a 0
soluble 0
hybrid 0
protein 0
, 0
GST B-gene
- 0
Bc B-gene
, 0
which 0
is 0
glutathione B-gene
S I-gene
- I-gene
transferase I-gene
( 0
GST B-gene
) 0
fused 0
to 0
the 0
cytoplasmic 0
C 0
- 0
terminal 0
portion 0
of 0
UhpB B-gene
, 0
results 0
in 0
complete 0
blockage 0
of 0
uhpT B-gene
expression 0
in 0
a 0
uhp B-gene
( I-gene
+ I-gene
) I-gene
strain 0
. 0

This 0
unique 0
location 0
of 0
cavernous 0
malformation 0
is 0
associated 0
with 0
a 0
risk 0
of 0
permanent 0
loss 0
of 0
the 0
vision 0
. 0

Here 0
we 0
show 0
that 0
PKC B-gene
and 0
p44/p42MAPK B-gene
signalings 0
are 0
required 0
for 0
the 0
p44/p42MAPK I-gene

Through 0
two 0
novel 0
mechanisms 0
, 0
Arf B-gene
inhibits 0
the 0
oncoprotein B-gene
Hdm2 I-gene
, 0
a 0
negative 0
regulator 0
of 0
p53 B-gene
. 0

In 0
the 0
free 0
- 0
swimming 0
rotatory 0
test 0
mice 0
spend 0
most 0
of 0
the 0
time 0
swimming 0
close 0
to 0
the 0
wall 0
of 0
the 0
container 0
attempting 0
to 0
escape 0
from 0
an 0
aversive 0
test 0
situation 0
. 0

Examination 0
of 0
various 0
promoter 0
deletion 0
mutants 0
indicated 0
that 0
SF B-gene
- I-gene
1 I-gene
acts 0
through 0
the 0
proximal 0
promoter 0
region 0
and 0
upstream 0
promoter 0
sequences 0
. 0

The 0
MSL B-gene
complex I-gene
is 0
specifically 0
localized 0
on 0
the 0
male 0
X 0
chromosome 0
to 0
increase 0
its 0
expression 0
approximately 0
2 0
- 0
fold 0
. 0

Prrp B-gene
can 0
also 0
associate 0
with 0
the 0
EVH1 B-gene
domain I-gene
of 0
Mena B-gene
, 0
another 0
microfilament 0
- 0
associated 0
protein 0
. 0

Srb10 B-gene
is 0
a 0
physiological 0
regulator 0
of 0
Gcn4 B-gene
stability 0
because 0
both 0
phosphorylation 0
and 0
turnover 0
of 0
Gcn4 B-gene
are 0
diminished 0
in 0
srb10 B-gene
mutants I-gene
. 0

Consistent 0
effects 0
on 0
pVHL B-gene
function 0
were 0
observed 0
for 0
all 0
mutations 0
within 0
each 0
subclass 0
. 0

A 0
new 0
intron 0
of 0
476 0
base 0
pairs 0
was 0
found 0
in 0
the 0
middle 0
of 0
the 0
5' 0
- 0
untranslated 0
leader 0
sequence 0
and 0
was 0
shown 0
to 0
robustly 0
enhance 0
the 0
promoter 0
activity 0
. 0

Based 0
on 0
this 0
analysis 0
, 0
we 0
propose 0
that 0
the 0
interactions 0
of 0
Sos B-gene
with 0
the 0
switch 0
1 0
and 0
switch 0
2 0
regions 0
of 0
Ras B-gene
have 0
distinct 0
functional 0
consequences 0
: 0
the 0
interaction 0
with 0
switch 0
2 0
mediates 0
the 0
anchoring 0
of 0
Ras B-gene
to 0
Sos B-gene
, 0
whereas 0
the 0
interaction 0
with 0
switch 0
1 0
leads 0
to 0
disruption 0
of 0
the 0
nucleotide 0
- 0
binding 0
site 0
and 0
GDP 0
dissociation 0
. 0

A 0
log 0
- 0
linear 0
dose 0
- 0
response 0
was 0
obtained 0
for 0
the 0
average 0
increase 0
in 0
FEV1 0
up 0
to 0
6 0
h 0
( 0
AUC0 0
- 0
6 0
h 0
) 0
and 0
peak 0
FEV1 0
across 0
the 0
dose 0
range 0
administered 0
by 0
Respimat 0
. 0

Bandshift 0
experiments 0
demonstrate 0
that 0
BmHR3A B-gene
binds 0
specifically 0
to 0
RORE B-gene
( 0
Retinoic B-gene
acid I-gene
- I-gene
related I-gene
Orphan I-gene
receptor I-gene
Response I-gene
Element I-gene
) 0
- 0
like 0
sequences 0
in 0
the 0
promoters 0
of 0
both 0
genes 0
, 0
thus 0
suggesting 0
a 0
direct 0
role 0
for 0
BmHR3A B-gene
in 0
regulating 0
the 0
expression 0
of 0
BmGATAbeta B-gene
and 0
ESP B-gene
genes I-gene
during 0
vitellogenesis 0
. 0

This 0
was 0
most 0
pronounced 0
during 0
the 0
initial 0
phase 0
of 0
Erk B-gene
activation 0
. 0

The 0
iterative 0
method 0
proposed 0
by 0
Bengtsson 0
[ 0
Appl 0
. 0

Here 0
, 0
we 0
identify 0
Rsc3 B-gene
and 0
Rsc30 B-gene
as 0
novel 0
components 0
of 0
the 0
essential 0
yeast B-gene
remodeler I-gene
RSC I-gene
complex I-gene
. 0

The 0
COD 0
and 0
color 0
removals 0
were 0
both 0
more 0
than 0
90 0
% 0
when 0
FeCl3 0
was 0
used 0
as 0
the 0
coagulation 0
( 0
dosages 0
of 0
two 0
- 0
step 0
coagulation 0
were 0
0.031 0
and 0
0.012 0
mol/L 0
respectively 0
) 0
after 0
a 0
ferrous 0
hydrogen 0
peroxide 0
oxidation 0
pretreatment 0
at 0
a 0
H2O2 0
dosage 0
of 0
0.06 0
mol/L 0
. 0

Although 0
there 0
was 0
a 0
high 0
correlation 0
between 0
sap 0
flux 0
densities 0
registered 0
by 0
the 0
old 0
and 0
new 0
sensors 0
, 0
significant 0
differences 0
in 0
sap 0
flux 0
densities 0
between 0
the 0
duplicated 0
sensors 0
were 0
detected 0
. 0

Three 0
of 0
the 0
proteins 0
involved 0
in 0
checkpoint 0
signaling 0
, 0
Rad1 B-gene
, 0
Hus1 B-gene
, 0
and 0
Rad9 B-gene
, 0
have 0
been 0
shown 0
to 0
interact 0
by 0
immunoprecipitation 0
and 0
yeast 0
two 0
- 0
hybrid 0
studies 0
. 0

Based 0
on 0
the 0
hypothesis 0
that 0
evolutionarily 0
conserved 0
regions 0
are 0
functionally 0
important 0
and 0
likely 0
to 0
interact 0
with 0
coactivators 0
, 0
we 0
compared 0
the 0
amino 0
acid 0
sequence 0
of 0
C/EBPalpha B-gene
from 0
different 0
species 0
( 0
frog 0
to 0
human 0
) 0
and 0
identified 0
four 0
highly 0
conserved 0
regions 0
( 0
CR1 0
- 0
CR4 0
) 0
within 0
the 0
transactivation 0
domain 0
. 0

Tolerance 0
to 0
ADAL 0
- 0
2 0
was 0
similar 0
to 0
that 0
of 0
Vicryl 0
suture 0
and 0
tolerance 0
to 0
ADAL 0
- 0
2 0
was 0
superior 0
to 0
that 0
to 0
Tisuacryl 0
. 0

Of 0
the 0
patients 0
in 0
each 0
regimen 0
who 0
reached 0
study 0
end 0
points 0
, 0
17 0
of 0
29 0
( 0
59 0
% 0
) 0
were 0
in 0
regimen 0
A 0
, 0
11 0
of 0
20 0
( 0
55 0
% 0
) 0
were 0
in 0
regimen 0
B 0
, 0
and 0
28 0
of 0
43 0
( 0
65 0
% 0
) 0
were 0
in 0
regimen 0
C 0
met 0
the 0
treatment 0
success 0
criterion 0
. 0

Early 0
indicators 0
of 0
the 0
effect 0
of 0
a 0
breast 0
cancer 0
screening 0
program 0
for 0
low 0
- 0
income 0
women 0
. 0

SAMPLE 0
POPULATION 0
: 0
MCB 0
from 0
7 0
racing 0
Greyhounds 0
euthanatized 0
for 0
reasons 0
unrelated 0
to 0
MCB 0
abnormalities 0
. 0

CONCLUSIONS 0
AND 0
CLINICAL 0
RELEVANCE 0
: 0
Increased 0
cortical 0
thickness 0
and 0
geometric 0
properties 0
of 0
left 0
MCB 0
- 0
IV 0
and 0
- 0
V 0
of 0
Greyhounds 0
, 0
together 0
with 0
altered 0
turnover 0
and 0
orientation 0
of 0
osteons 0
in 0
the 0
dorsal 0
quadrants 0
of 0
left 0
MCB 0
, 0
are 0
site 0
- 0
specific 0
adaptive 0
responses 0
associated 0
with 0
asymmetric 0
cyclic 0
loading 0
as 0
a 0
result 0
of 0
racing 0
on 0
circular 0
tracks 0
. 0

Linear 0
eight 0
- 0
or 0
nine 0
- 0
residue 0
D 0
- 0
peptides 0
derived 0
from 0
the 0
pocket 0
- 0
binding 0
domain 0
of 0
the 0
cyclic 0
molecules 0
also 0
bind 0
specifically 0
. 0

METHODS 0
AND 0
RESULTS 0
: 0
Palmaz 0
- 0
Schatz 0
stents 0
were 0
dip 0
- 0
coated 0
with 0
paclitaxel 0
( 0
0 0
, 0
0.2 0
, 0
15 0
, 0
or 0
187 0
microgram/stent 0
) 0
by 0
immersion 0
in 0
ethanolic 0
paclitaxel 0
and 0
evaporation 0
of 0
the 0
solvent 0
. 0

Percentages 0
of 0
recovery 0
for 0
overload 0
and 0
dilution 0
tests 0
were 0
between 0
87 0
and 0
120 0
% 0
. 0

One 0
of 0
the 0
conserved 0
RNA 0
subdomains 0
, 0
designated 0
P3 B-gene
, 0
has 0
previously 0
been 0
shown 0
to 0
be 0
required 0
for 0
nucleolar 0
localization 0
. 0

In 0
Cd 0
- 0
spiked 0
OECD 0
soil 0
, 0
internal 0
Cd 0
levels 0
were 0
linearly 0
related 0
to 0
external 0
Cd 0
concentrations 0
, 0
whereas 0
the 0
springtails 0
maintained 0
fixed 0
internal 0
levels 0
of 0
Cu 0
and 0
Zn 0
regardless 0
of 0
spiked 0
concentrations 0
. 0

Nutritional 0
status 0
in 0
adults 0
on 0
an 0
alternative 0
or 0
traditional 0
diet 0
] 0
BACKGROUND 0
: 0
Plant 0
food 0
lacks 0
vitamin 0
B12 0
, 0
vitamin 0
D 0
and 0
higher 0
n 0
- 0
3 0
polyunsaturated 0
fatty 0
acids 0
. 0

It 0
is 0
useful 0
as 0
an 0
adjunct 0
to 0
mammography 0
in 0
those 0
patients 0
with 0
radiographically 0
dense 0
breasts 0
for 0
the 0
characterization 0
of 0
palpable 0
masses 0
. 0

Measurements 0
were 0
obtained 0
: 0
( 0
i 0
) 0
just 0
after 0
the 0
traumatic 0
exposure 0
( 0
D0 0
) 0
; 0
( 0
ii 0
) 0
3 0
days 0
after 0
this 0
first 0
measurement 0
( 0
D3 0
) 0
; 0
and 0
( 0
iii 0
) 0
30 0
days 0
after 0
( 0
D30 0
) 0
. 0

Here 0
we 0
present 0
evidence 0
that 0
the 0
distal 0
half 0
( 0
Stem 0
2 0
) 0
of 0
the 0
conserved 0
base 0
- 0
paired 0
stem 0
structure 0
found 0
in 0
all 0
hY B-gene
RNAs I-gene
also 0
plays 0
a 0
critical 0
role 0
in 0
the 0
export 0
process 0
. 0

Changes 0
of 0
the 0
DB 0
sequence 0
without 0
affecting 0
the 0
postulated 0
stem 0
structure 0
led 0
to 0
drastic 0
losses 0
of 0
translation 0
efficiency 0
. 0

It 0
has 0
been 0
suggested 0
that 0
members 0
of 0
this 0
protein 0
family 0
exhibit 0
both 0
prolyl B-gene
isomerase I-gene
and 0
chaperone 0
activity 0
. 0

Inhibition 0
of 0
the 0
Raf B-gene
- I-gene
1 I-gene
target I-gene
ERK B-gene
kinase I-gene
( 0
MEK B-gene
) 0
either 0
attenuated 0
or 0
abolished 0
Rp 0
- 0
cAMPS 0
- 0
and 0
PKI B-gene
- 0
induced 0
ERK B-gene
activation 0
, 0
caldesmon B-gene
phosphorylation 0
, 0
and 0
stress 0
fiber 0
formation 0
. 0

PACAP B-gene
mRNA I-gene
was 0
widely 0
expressed 0
in 0
most 0
human 0
tissues 0
; 0
in 0
transfected 0
cells 0
, 0
PACAP B-gene
was 0
diffusely 0
expressed 0
in 0
the 0
cytoplasm 0
. 0

Here 0
we 0
provide 0
the 0
first 0
evidence 0
for 0
the 0
involvement 0
of 0
GCN1 B-gene
- 0
GCN2 B-gene
interaction 0
in 0
activation 0
of 0
GCN2 B-gene
per 0
se 0
. 0

The 0
radial 0
forearm 0
flap 0
is 0
used 0
most 0
commonly 0
, 0
however 0
the 0
lateral 0
arm 0
flap 0
may 0
be 0
the 0
flap 0
of 0
choice 0
in 0
certain 0
situations 0
. 0

By 0
comparison 0
, 0
in 0
nontumorigenic 0
Ad5 0
cells 0
, 0
class 0
I 0
expression 0
is 0
high 0
due 0
to 0
negligible 0
binding 0
of 0
COUP B-gene
- I-gene
TF I-gene
and 0
strong 0
binding 0
of 0
NF B-gene
- I-gene
kappaB I-gene
. 0

As 0
an 0
application 0
of 0
reverse 0
genetics 0
, 0
we 0
introduced 0
one 0
nucleotide 0
change 0
( 0
UCU 0
to 0
ACU 0
) 0
to 0
immediate 0
downstream 0
of 0
the 0
RNA 0
- 0
editing 0
site 0
of 0
the 0
V B-gene
gene I-gene
in 0
the 0
full 0
- 0
length 0
hPIV2 0
cDNA 0
and 0
were 0
able 0
to 0
obtain 0
infectious 0
viruses 0
[ 0
rPIV2V 0
( 0
- 0
) 0
] 0
from 0
the 0
cDNA 0
. 0

The 0
frameshift 0
initiated 0
by 0
ADEx2 0
is 0
believed 0
to 0
alter 0
the 0
regular 0
coding 0
sequence 0
, 0
acting 0
as 0
a 0
loss 0
- 0
of 0
- 0
function 0
ASIP B-gene
mutation I-gene
. 0

In 0
regards 0
to 0
the 0
latter 0
activity 0
, 0
it 0
has 0
been 0
shown 0
that 0
S3 B-gene
contains 0
vigorous 0
N B-gene
- I-gene
glycosylase I-gene
activity 0
for 0
the 0
removal 0
of 0
8 0
- 0
oxoguanine 0
residues 0
in 0
DNA 0
that 0
leaves 0
baseless 0
sites 0
in 0
their 0
places 0
. 0

Here 0
we 0
report 0
the 0
isolation 0
and 0
characterization 0
of 0
the 0
forkhead B-gene
homologue I-gene
in I-gene
rhabdomyosarcoma I-gene
( 0
FKHR B-gene
) 0
, 0
a 0
recently 0
described 0
member 0
of 0
the 0
hepatocyte B-gene
nuclear I-gene
factor I-gene
3/forkhead I-gene
3/forkhead I-gene

The 0
improved 0
CSF 0
outflow 0
conductance 0
may 0
increase 0
the 0
intracranial 0
compliance 0
and 0
thereby 0
dampen 0
a 0
pathological 0
ICP 0
waveform 0
. 0

A 0
new 0
species 0
of 0
Euspondylus 0
is 0
described 0
based 0
on 0
a 0
female 0
( 0
taken 0
within 0
a 0
bromeliad 0
) 0
from 0
Cerro 0
El 0
Humo 0
, 0
Sucre 0
, 0
northeastern 0
Venezuela 0
. 0

The 0
cyclins B-gene
bind 0
to 0
and 0
activate 0
the 0
CDK B-gene
, 0
which 0
leads 0
to 0
phosphorylation 0
( 0
and 0
then 0
inhibition 0
) 0
of 0
the 0
tumor 0
suppressor 0
protein 0
, 0
pRb B-gene
. 0
pRb B-gene
controls 0
commitment 0
to 0
progress 0
from 0
the 0
G1 0
to 0
S 0
phase 0
, 0
at 0
least 0
in 0
part 0
by 0
repressing 0
the 0
activity 0
of 0
the 0
E2F B-gene
transcription I-gene
factors I-gene
known 0
to 0
promote 0
cell 0
proliferation 0
. 0

Additional 0
education 0
and 0
research 0
is 0
needed 0
to 0
provide 0
further 0
direction 0
for 0
intervention 0
and 0
incorporation 0
into 0
practice 0
. 0

Proliferative 0
vasculopathy 0
and 0
cutaneous 0
hemorrhages 0
in 0
porcine 0
neonates 0
infected 0
with 0
the 0
porcine 0
reproductive 0
and 0
respiratory 0
syndrome 0
virus 0
. 0

The 0
difference 0
of 0
hardness 0
over 0
time 0
of 0
composite 0
specimens 0
was 0
measured 0
using 0
Knoop 0
hardness 0
measurements 0
taken 0
at 0
the 0
top 0
and 0
bottom 0
surfaces 0
of 0
resin 0
specimens 0
made 0
in 0
a 0
Teflon 0
mold 0
the 0
same 0
dimensions 0
as 0
the 0
cavity 0
prepared 0
in 0
dentin 0
. 0

An 0
18 0
- 0
kb 0
genomic 0
clone 0
including 0
sequences 0
encoding 0
for 0
the 0
two 0
GHS B-gene
- I-gene
R I-gene
variants I-gene
was 0
isolated 0
. 0

Saccharomyces 0
cerevisiae 0
activates 0
a 0
regulatory 0
network 0
called 0
`` 0
general 0
control 0
'' 0
that 0
provides 0
the 0
cell 0
with 0
sufficient 0
amounts 0
of 0
protein 0
precursors 0
during 0
amino 0
acid 0
starvation 0
. 0

In 0
Ka13 0
cells 0
, 0
CoCl 0
( 0
2 0
) 0
stimulated 0
expression 0
of 0
a 0
luciferase B-gene
reporter I-gene
gene I-gene
under 0
the 0
control 0
of 0
a 0
15 B-gene
- I-gene
kilobase I-gene
pair I-gene
mouse I-gene
ho I-gene
- I-gene
1 I-gene
promoter I-gene
( 0
pHO15luc B-gene
) 0
. 0

Mutation 0
analyses 0
identified 0
the 0
cobalt 0
- 0
responsive 0
sequences 0
as 0
the 0
stress 0
- 0
response 0
elements 0
( 0
StREs 0
) 0
. 0

Members 0
of 0
the 0
AP B-gene
- I-gene
1 I-gene
superfamily I-gene
of I-gene
basic I-gene
- I-gene
leucine I-gene
zipper I-gene
factors I-gene
bind 0
to 0
the 0
StRE 0
. 0

Descriptions 0
of 0
this 0
locus 0
would 0
allow 0
comparison 0
with 0
functionally 0
relevant 0
molecular 0
genetic 0
features 0
of 0
other 0
species 0
' 0
homologous 0
loci 0
including 0
the 0
single 0
- 0
copy 0
equid 0
LH/CGbeta B-gene
gene 0
and 0
the 0
primate 0
LH/CGbeta I-gene

Like 0
the 0
consensus B-gene
mammalian I-gene
LHbeta I-gene
gene I-gene
, 0
the 0
5' 0
- 0
flanking 0
region 0
of 0
the 0
gpLH/CGbeta B-gene
gene 0
contains 0
a 0
single 0
TATA 0
sequence 0
37 0
bp 0
upstream 0
of 0
the 0
translation 0
start 0
codon 0
. 0

This 0
shows 0
that 0
in 0
situations 0
of 0
separated 0
breaks 0
, 0
NHEJ 0
deficiency 0
leads 0
to 0
genomic 0
rearrangements 0
, 0
in 0
agreement 0
with 0
chromosomal 0
studies 0
. 0

Expression 0
of 0
human B-gene
RACK1 I-gene
efficiently 0
relieves 0
E1A B-gene
- 0
mediated 0
growth 0
inhibition 0
in 0
HF7c 0
and 0
protects 0
human 0
tumor 0
cells 0
from 0
E1A B-gene
- 0
induced 0
apoptosis 0
. 0

Foxp1 B-gene
and 0
Foxp2 B-gene
are 0
expressed 0
at 0
high 0
levels 0
in 0
the 0
lung 0
as 0
early 0
as 0
E12.5 0
of 0
mouse 0
development 0
with 0
Foxp2 B-gene
expression 0
restricted 0
to 0
the 0
airway 0
epithelium 0
. 0

Molecular 0
analysis 0
of 0
the 0
pRA2 0
partitioning 0
region 0
: 0
ParB B-gene
autoregulates 0
parAB B-gene
transcription 0
and 0
forms 0
a 0
nucleoprotein 0
complex 0
with 0
the 0
plasmid 0
partition 0
site 0
, 0
parS B-gene
. 0

Immunological 0
and 0
biochemical 0
characterization 0
of 0
streptococcal B-gene
pyrogenic I-gene
exotoxins I-gene
I I-gene
and I-gene
J I-gene
( 0
SPE B-gene
- I-gene
I I-gene
and 0
SPE B-gene
- I-gene
J I-gene
) 0
from 0
Streptococcus 0
pyogenes 0
. 0

Several 0
dozen 0
HIF B-gene
- I-gene
1 I-gene
targets I-gene
are 0
known 0
, 0
including 0
the 0
gene 0
encoding 0
vascular B-gene
endothelial I-gene
growth I-gene
factor I-gene
( 0
VEGF B-gene
) 0
. 0

We 0
previously 0
reported 0
that 0
Tax B-gene
induced 0
cell 0
cycle 0
progression 0
from 0
G0/G1 0
phase 0
to 0
S 0
and 0
G2/M 0
phases 0
in 0
human 0
T 0
- 0
cell 0
line 0
Kit 0
225 0
cells 0
. 0

Most 0
yeast B-gene
peroxisomal I-gene
matrix I-gene
proteins I-gene
contain 0
a 0
type 0
1C 0
- 0
terminal 0
peroxisomal 0
targeting 0
signal 0
( 0
PTS1 0
) 0
consisting 0
of 0
the 0
tripeptide 0
SKL 0
or 0
a 0
conservative 0
variant 0
thereof 0
. 0

Here 0
, 0
the 0
PEX5 B-gene
- 0
TPR 0
domains 0
from 0
human 0
, 0
tobacco 0
, 0
and 0
nematode 0
were 0
inserted 0
into 0
a 0
TPR 0
- 0
less 0
yeast 0
Pex5p B-gene
construct 0
to 0
generate 0
Pex5p B-gene
chimaeras 0
. 0

HIV 0
- 0
1 0
and 0
hepatitis 0
B 0
virus 0
infections 0
in 0
adolescents 0
lodged 0
in 0
security 0
institutes 0
of 0
Buenos 0
Aires 0
. 0

Immunofixation 0
experiments 0
of 0
C4A B-gene
and 0
C4B B-gene
demonstrate 0
> 0
41 0
allotypes 0
in 0
the 0
two 0
classes 0
of 0
proteins 0
. 0

However 0
, 0
C4B B-gene
proteins I-gene
encoded 0
by 0
monomodular 0
short 0
genes 0
may 0
have 0
relatively 0
higher 0
concentrations 0
than 0
those 0
from 0
long B-gene
C4A I-gene
genes I-gene
. 0

In 0
the 0
course 0
of 0
screening 0
for 0
transcription 0
factors 0
which 0
interact 0
with 0
the 0
human B-gene
myeloperoxidase I-gene
( 0
MPO B-gene
) 0
promoter 0
we 0
, 0
for 0
the 0
first 0
time 0
, 0
identified 0
and 0
cloned 0
the 0
cDNA 0
and 0
genomic 0
DNA 0
for 0
human B-gene
HBP1 I-gene
( 0
HMG B-gene
- I-gene
Box I-gene
containing I-gene
protein I-gene
1 I-gene
) 0
, 0
a 0
member 0
of 0
the 0
high B-gene
mobility I-gene
group I-gene
of I-gene
non I-gene
- I-gene
histone I-gene
chromosomal I-gene
proteins I-gene
. 0

The 0
human 0
protein 0
sequence 0
exhibits 0
a 0
putative 0
DNA 0
- 0
binding 0
domain 0
similar 0
to 0
that 0
seen 0
in 0
rat B-gene
HBP1 I-gene
and 0
shows 0
homology 0
with 0
the 0
activation 0
and 0
repressor 0
domains 0
previously 0
demonstrated 0
in 0
the 0
rat 0
protein 0
. 0

Promoter 0
transcriptional 0
activity 0
was 0
determined 0
for 0
a 0
wide 0
5 0
' 0
portion 0
of 0
the 0
human 0
annexin B-gene
A5 I-gene
gene I-gene
, 0
from 0
bp 0
- 0
1275 0
to 0
+79 0
relative 0
to 0
the 0
most 0
5 0
' 0
of 0
several 0
discrete 0
transcription 0
start 0
points 0
. 0

In 0
contrast 0
the 0
human 0
and 0
mouse B-gene
BCNT I-gene
proteins I-gene
contain 0
one 0
repeat 0
unit 0
and 0
lack 0
the 0
RTE B-gene
- I-gene
1 I-gene
- 0
derived 0
portion 0
. 0

Molecular 0
identification 0
of 0
smg B-gene
- I-gene
4 I-gene
, 0
required 0
for 0
mRNA 0
surveillance 0
in 0
C. 0
elegans 0
. 0

Two 0
remotely 0
situated 0
exons 0
within 0
the 0
complement B-gene
C3 I-gene
gene 0
locus 0
encode 0
an 0
alternate 0
5 0
' 0
end 0
and 0
proximal 0
ORF 0
under 0
the 0
control 0
of 0
a 0
bidirectional 0
promoter 0
. 0

CONCLUSIONS 0
: 0
Adding 0
MMF 0
, 0
a 0
potent 0
topical 0
corticosteroid 0
, 0
to 0
an 0
emollient 0
cream 0
is 0
statistically 0
significantly 0
more 0
effective 0
than 0
emollient 0
cream 0
alone 0
in 0
reducing 0
acute 0
radiation 0
dermatitis 0
. 0

Recent 0
advances 0
have 0
shown 0
that 0
volatile 0
sulfur 0
is 0
a 0
result 0
of 0
ecological 0
interactions 0
and 0
transformation 0
processes 0
through 0
planktonic 0
food 0
webs 0
. 0

The 0
first 0
hypothesis 0
was 0
supported 0
in 0
the 0
sense 0
that 0
stimulus 0
differences 0
might 0
affect 0
behaviour 0
even 0
without 0
their 0
successful 0
attentive 0
processing 0
in 0
normal 0
participants 0
. 0

There 0
was 0
an 0
increase 0
in 0
protein 0
binding 0
onto 0
this 0
element 0
only 0
after 0
peptide 0
treatment 0
. 0

CSR 0
is 0
directed 0
to 0
specific 0
heavy 0
chain 0
isotypes 0
by 0
cytokines 0
and 0
B 0
cell 0
activators 0
that 0
induce 0
transcription 0
from 0
the 0
unrearranged 0
, 0
or 0
germline 0
( 0
GL 0
) 0
, 0
C B-gene
( I-gene
H I-gene
) I-gene
region I-gene
genes I-gene
. 0

In 0
this 0
manuscript 0
we 0
demonstrate 0
that 0
two 0
tandem B-gene
Ets I-gene
sites I-gene
in 0
the 0
mouse B-gene
GL I-gene
alpha I-gene
promoter I-gene
bind 0
the 0
transcription B-gene
factors I-gene
Elf I-gene
- I-gene
1 I-gene
and 0
PU.1 B-gene
, 0
and 0
that 0
the 0
3 0
' 0
site 0
is 0
essential 0
for 0
expression 0
of 0
a 0
luciferase B-gene
reporter I-gene
gene I-gene
driven 0
by 0
the 0
GL B-gene
alpha I-gene
promoter I-gene
. 0

Cell 0
. 0

The 0
mean 0
serum 0
creatinine 0
level 0
did 0
not 0
change 0
during 0
the 0
first 0
6 0
months 0
after 0
withdrawal 0
of 0
MMF 0
. 0

The 0
proportion 0
of 0
the 0
biopsies 0
found 0
to 0
be 0
seropositive 0
for 0
HBs B-gene
antigen I-gene
was 0
27.9 0
% 0
, 0
and 0
these 0
showed 0
either 0
MGN 0
or 0
MPGN 0
pattern 0
. 0

They 0
correspond 0
to 0
nucleotides 0
equivalent 0
to 0
base 0
- 0
pair 0
C1 0
- 0
G72 0
and 0
discriminator 0
base 0
A73 0
in 0
the 0
amino 0
acid 0
- 0
acceptor 0
branch 0
of 0
the 0
molecule 0
. 0

This 0
domain 0
without 0
the 0
canonical 0
anticodon 0
loop 0
or 0
the 0
tyrosine 0
anticodon 0
acts 0
as 0
an 0
anchor 0
for 0
TyrRS B-gene
interaction 0
leading 0
to 0
a 0
better 0
efficiency 0
of 0
tyrosylation 0
. 0

During 0
most 0
of 0
the 0
cell 0
cycle 0
, 0
separase B-gene
is 0
kept 0
inactive 0
by 0
binding 0
to 0
an 0
inhibitory 0
protein 0
called 0
securin B-gene
. 0

Mechanical 0
ventilation 0
in 0
control 0
lungs 0
produced 0
a 0
47 0
% 0
decrease 0
in 0
chord 0
compliance 0
, 0
an 0
increase 0
in 0
lung 0
lavage 0
levels 0
of 0
tumor B-gene
necrosis I-gene
factor I-gene
( I-gene
TNF I-gene
) I-gene
- I-gene
alpha I-gene
( 0
722 0
+/ 0
- 0
306 0
pg/ml 0
) 0
, 0
interleukin B-gene
( I-gene
IL I-gene
) I-gene
- I-gene
1beta I-gene
( 0
902 0
+/ 0
- 0
322 0
pg/ml 0
) 0
, 0
and 0
macrophage B-gene
inflammatory I-gene
protein I-gene
- I-gene
2 I-gene
( 0
MIP B-gene
- I-gene
2 I-gene
) 0
( 0
363 0
+/ 0
- 0
104 0
pg/ml 0
) 0
as 0
compared 0
with 0
low 0
levels 0
of 0
cytokines 0
detected 0
in 0
preventilation 0
data 0
, 0
and 0
no 0
change 0
in 0
percentage 0
of 0
surfactant 0
large 0
aggregates 0
( 0
LA 0
) 0
. 0

Maternal 0
p 0
, 0
p'DDE 0
and 0
beta 0
- 0
HCH 0
levels 0
were 0
also 0
associated 0
with 0
newborn 0
levels 0
, 0
but 0
levels 0
of 0
PCBs 0
were 0
not 0
. 0

Multiple 0
regression 0
analysis 0
performed 0
between 0
these 0
long 0
- 0
term 0
abiotic 0
factors 0
and 0
nymphal 0
abundance 0
in 0
positive 0
sites 0
showed 0
high 0
relationship 0
( 0
R2 0
coefficients 0
) 0
for 0
every 0
habitat 0
category 0
and 0
explained 0
> 0
50 0
% 0
of 0
the 0
variation 0
in 0
tick 0
abundance 0
. 0

In 0
summary 0
, 0
we 0
conclude 0
that 0
the 0
adenoviral 0
oncoprotein 0
E1A B-gene
activates 0
transcription 0
from 0
the 0
endogenous 0
AP B-gene
- I-gene
2alpha I-gene
gene I-gene
, 0
an 0
effect 0
that 0
involves 0
transcriptional 0
derepression 0
of 0
the 0
AP B-gene
- I-gene
2alpha I-gene
promoter I-gene
by 0
interaction 0
of 0
E1A B-gene
with 0
the 0
AP B-gene
- I-gene
2rep I-gene
corepressor 0
CtBP1 B-gene
. 0

Additional 0
factors 0
such 0
as 0
advanced 0
age 0
, 0
concomitant 0
use 0
of 0
corticosteroids 0
or 0
anticoagulants 0
, 0
prior 0
ulcer 0
complications 0
and 0
co 0
- 0
morbid 0
diseases 0
may 0
further 0
increase 0
the 0
risk 0
of 0
bleeding 0
. 0

SERS 0
spectra 0
were 0
obtained 0
by 0
vacuum 0
evaporation 0
and 0
casting 0
of 0
p 0
- 0
NTP 0
onto 0
silver 0
island 0
films 0
, 0
and 0
also 0
from 0
colloidal 0
silver 0
solutions 0
. 0

Copyright 0
2001 0
Academic 0
Press 0
. 0

The 0
core 0
promoter 0
of 0
human B-gene
thioredoxin I-gene
reductase I-gene
1 I-gene
: 0
cloning 0
, 0
transcriptional 0
activity 0
, 0
and 0
Oct B-gene
- I-gene
1 I-gene
, 0
Sp1 B-gene
, 0
and 0
Sp3 B-gene
binding 0
reveal 0
a 0
housekeeping 0
- 0
type 0
promoter 0
for 0
the 0
AU 0
- 0
rich 0
element 0
- 0
regulated 0
gene 0
. 0

Here 0
we 0
show 0
that 0
phosphorylation 0
- 0
induced 0
loss 0
of 0
the 0
protein 0
kinase 0
activity 0
of 0
DNA B-gene
- I-gene
PK I-gene
is 0
restored 0
by 0
the 0
addition 0
of 0
the 0
purified 0
catalytic 0
subunit 0
of 0
either 0
protein B-gene
phosphatase I-gene
1 I-gene
or 0
protein B-gene
phosphatase I-gene
2A I-gene
( 0
PP2A B-gene
) 0
and 0
that 0
this 0
reactivation 0
is 0
blocked 0
by 0
the 0
potent 0
protein 0
phosphatase 0
inhibitor 0
, 0
microcystin 0
. 0

The 0
first 0
exon 0
( 0
exon 0
1A 0
) 0
that 0
corresponded 0
to 0
the 0
5' 0
- 0
untranslated 0
region 0
of 0
the 0
GHR B-gene
1A I-gene
mRNA I-gene
was 0
15,250 0
bp 0
upstream 0
from 0
exon 0
2 0
in 0
the 0
GHR B-gene
gene I-gene
. 0

These 0
corrections 0
do 0
not 0
involve 0
sequences 0
predicted 0
to 0
function 0
as 0
transcription 0
factor 0
binding 0
sites 0
. 0

FLP B-gene
and 0
Cre B-gene
recombinase I-gene
function 0
in 0
Xenopus 0
embryos 0
. 0

A 0
method 0
of 0
three 0
- 0
station 0
three 0
- 0
dimensional 0
magnetic 0
resonance 0
( 0
MR 0
) 0
angiography 0
of 0
the 0
lower 0
extremities 0
with 0
segmented 0
volume 0
acquisition 0
is 0
presented 0
. 0

A 0
single 0
nucleotide 0
polymorphism 0
( 0
SNP 0
) 0
in 0
exon 0
2 0
, 0
which 0
is 0
tightly 0
liked 0
to 0
another 0
SNP 0
( 0
GTG83/ATG83 0
) 0
, 0
creates 0
an 0
additional 0
alternative 0
in 0
- 0
frame 0
AUG 0
in 0
B B-gene
- I-gene
type I-gene
MTH1 I-gene
mRNAs I-gene
yielding 0
the 0
fourth 0
MTH1 B-gene
polypeptide I-gene
, 0
p26 B-gene
that 0
possesses 0
an 0
additional 0
mitochondrial 0
targeting 0
signal 0
. 0

Our 0
previous 0
studies 0
have 0
shown 0
that 0
SHP B-gene
- I-gene
1 I-gene
, 0
a 0
SH2 B-gene
domain I-gene
- I-gene
containing I-gene
protein I-gene
- I-gene
tyrosine I-gene
phosphatase I-gene
, 0
is 0
expressed 0
not 0
only 0
in 0
cells 0
of 0
hematopoietic 0
lineages 0
, 0
but 0
also 0
in 0
many 0
non 0
- 0
hematopoietic 0
cells 0
under 0
the 0
control 0
of 0
an 0
alternative 0
tissue 0
- 0
specific 0
promoter 0
, 0
P1 0
. 0

Unexpectedly 0
, 0
Arg1 B-gene
- 0
expressing 0
COS1 0
cells 0
showed 0
no 0
significant 0
proteinase 0
activity 0
to 0
various 0
synthesized 0
substrates 0
under 0
neutral 0
or 0
acidic 0
conditions 0
in 0
this 0
study 0
. 0

ORF1 0
( 0
1029 0
bp 0
; 0
EMBL 0
databank 0
, 0
Accession 0
No 0
. 0

In 0
the 0
meantime 0
, 0
one 0
has 0
succeeded 0
to 0
establish 0
the 0
deammonification 0
processes 0
in 0
a 0
continuous 0
flow 0
moving 0
- 0
bed 0
pilot 0
plant 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
simplified 0
methods 0
for 0
estimation 0
of 0
Technetium 0
Tc 0
99m 0
( 0
99mTc 0
) 0
- 0
pentetate 0
and 0
orthoiodohippurate 0
I 0
131 0
( 0
131I 0
- 0
OIH 0
) 0
plasma 0
clearance 0
in 0
dogs 0
and 0
cats 0
with 0
1 0
and 0
2 0
blood 0
samples 0
. 0

A 0
patient 0
is 0
described 0
with 0
skin 0
lesions 0
resembling 0
Kaposi 0
's 0
sarcoma 0
( 0
KS 0
) 0
. 0

Interventions 0
aimed 0
at 0
these 0
specific 0
mediators 0
and 0
processes 0
may 0
be 0
successful 0
in 0
reducing 0
the 0
very 0
significant 0
human 0
and 0
economic 0
costs 0
of 0
vascular 0
access 0
dysfunction 0
. 0

In 0
addition 0
, 0
stonin B-gene
2 I-gene
binds 0
to 0
the 0
C2B 0
domains 0
of 0
synaptotagmins B-gene
I I-gene
and I-gene
II I-gene
. 0

This 0
partial 0
transection 0
could 0
permit 0
vasopressin B-gene
to 0
be 0
secreted 0
in 0
response 0
to 0
a 0
larger 0
rise 0
in 0
plasma 0
sodium 0
concentration 0
. 0

In 0
conclusion 0
, 0
USPIO 0
- 0
enhanced 0
MRI 0
data 0
were 0
capable 0
to 0
characterize 0
tumor 0
microvessel 0
properties 0
in 0
this 0
breast 0
cancer 0
model 0
: 0
microvascular 0
permeability 0
( 0
determined 0
using 0
USPIO 0
) 0
correlated 0
significantly 0
with 0
tumor 0
grade 0
. 0

The 0
images 0
showed 0
rapid 0
, 0
predominantly 0
urinary 0
excretion 0
of 0
99mTc 0
ciprofloxacin 0
, 0
with 0
low 0
to 0
absent 0
brain 0
, 0
lung 0
and 0
bone 0
marrow 0
uptake 0
and 0
low 0
liver 0
uptake 0
and 0
excretion 0
. 0

To 0
this 0
end 0
, 0
an 0
expression 0
cassette 0
consisting 0
of 0
the 0
gene 0
for 0
a 0
green B-gene
fluorescent I-gene
protein I-gene
( 0
GFP B-gene
) 0
flanked 0
at 0
its 0
3 0
' 0
end 0
by 0
EAV 0
- 0
specific 0
transcription 0
- 0
regulating 0
sequences 0
was 0
constructed 0
. 0

However 0
, 0
the 0
N63S 0
mutation 0
in 0
the 0
wild B-gene
- I-gene
type I-gene
VP5 I-gene
background 0
increased 0
the 0
interaction 0
, 0
as 0
judged 0
by 0
the 0
beta B-gene
- I-gene
galactosidase I-gene
activity 0
, 0
by 0
a 0
factor 0
of 0
9 0
relative 0
to 0
when 0
the 0
PR7 0
mutation 0
was 0
present 0
. 0

In 0
addition 0
, 0
severe 0
vision 0
loss 0
can 0
be 0
seen 0
with 0
interferon B-gene
alfa I-gene
- I-gene
2b I-gene
- 0
associated 0
retinopathy 0
. 0

The 0
mechanism 0
of 0
the 0
induction 0
of 0
3beta B-gene
- I-gene
HSD I-gene
type I-gene
1 I-gene
gene I-gene
expression 0
was 0
further 0
characterized 0
in 0
ZR 0
- 0
75 0
- 0
1 0
human 0
breast 0
cancer 0
cells 0
. 0

An 0
integrated 0
RTC 0
algorithm 0
for 0
the 0
urban 0
wastewater 0
system 0
is 0
formulated 0
, 0
the 0
parameters 0
of 0
which 0
are 0
optimized 0
using 0
various 0
global 0
optimization 0
routines 0
. 0

SKP1 B-gene
- 0
SnRK B-gene
protein 0
kinase 0
interactions 0
mediate 0
proteasomal 0
binding 0
of 0
a 0
plant 0
SCF B-gene
ubiquitin I-gene
ligase I-gene
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
Between 0
June 0
1991 0
and 0
December 0
1996 0
, 0
we 0
administered 0
the 0
nucleoside 0
analog 0
2 0
- 0
chlorodeoxyadenosine 0
( 0
2 0
- 0
CDA 0
) 0
to 0
73 0
children 0
with 0
primary 0
AML 0
and 0
20 0
children 0
with 0
secondary 0
AML 0
or 0
myelodysplastic 0
syndrome 0
( 0
MDS 0
) 0
. 0

The 0
severity 0
of 0
pathologic 0
changes 0
increased 0
with 0
the 0
magnitude 0
of 0
percussion 0
. 0

Experimental 0
study 0
of 0
ta 0
chengchi 0
tang 0
decoction 0
for 0
relieving 0
lung 0
injury 0
during 0
acute 0
necrotizing 0
pancreatitis 0
] 0
The 0
objectives 0
of 0
the 0
study 0
were 0
to 0
investigate 0
the 0
changes 0
of 0
leukocyte 0
adhesiveness 0
and 0
tumor B-gene
necrosis I-gene
factor I-gene
( 0
TNF B-gene
) 0
in 0
the 0
early 0
stage 0
of 0
acute 0
necrotizing 0
pancreatitis 0
( 0
ANP 0
) 0
, 0
to 0
go 0
further 0
into 0
the 0
relation 0
of 0
those 0
changes 0
to 0
lung 0
injury 0
of 0
ANP 0
, 0
and 0
to 0
evaluate 0
the 0
prohibitive 0
effect 0
of 0
ta 0
chengchi 0
tang 0
Decoction 0
on 0
leukocyte 0
adhesion 0
and 0
TNF B-gene
secretion 0
. 0

A 0
variety 0
of 0
receptor 0
- 0
mediated 0
signaling 0
pathways 0
are 0
controlled 0
by 0
both 0
positive 0
and 0
negative 0
extracellular 0
regulators 0
. 0

TT 0
cells 0
, 0
a 0
human 0
MTC 0
cell 0
line 0
expressing 0
MEN B-gene
2A I-gene
type I-gene
RET I-gene
, 0
display 0
transcriptionally 0
active 0
RelA B-gene
( I-gene
p65 I-gene
) I-gene
in 0
the 0
nucleus 0
. 0

Inhibition 0
of 0
constitutive 0
NF B-gene
- I-gene
kappaB I-gene
activity 0
results 0
in 0
cell 0
death 0
of 0
TT 0
cells 0
and 0
blocks 0
focus 0
formation 0
induced 0
by 0
oncogenic 0
forms 0
of 0
RET B-gene
in 0
NIH 0
3T3 0
cells 0
. 0

Reciprocally 0
, 0
HMGI B-gene
- I-gene
C I-gene
expression 0
also 0
coordinately 0
enhances 0
PIAS3 B-gene
- 0
mediated 0
repression 0
of 0
STAT3 B-gene
- 0
dependent 0
transactivation 0
. 0

A 0
central 0
finding 0
is 0
the 0
identification 0
of 0
a 0
GC 0
- 0
rich 0
sequence 0
in 0
the 0
- 0
99/ 0
- 0
91 0
Cp B-gene
region 0
that 0
is 0
essential 0
for 0
oriPI 0
- 0
EBNA1 B-gene
- 0
independent 0
as 0
well 0
as 0
oriPI 0
- 0
EBNA1 B-gene
- 0
dependent 0
activity 0
of 0
the 0
promoter 0
. 0

Additional 0
deletion 0
mutations 0
revealed 0
a 0
new 0
, 0
67 0
- 0
amino 0
- 0
acid 0
functional 0
domain 0
within 0
the 0
proline 0
- 0
rich 0
region 0
of 0
SLP B-gene
- I-gene
76 I-gene
, 0
which 0
we 0
have 0
termed 0
the 0
P 0
- 0
1 0
domain 0
. 0

Finally 0
, 0
profiling 0
of 0
a 0
gcn4Delta B-gene
mutant I-gene
uncovered 0
an 0
alternative 0
induction 0
pathway 0
operating 0
at 0
many 0
Gcn4p B-gene
target I-gene
genes I-gene
in 0
histidine 0
- 0
starved 0
cells 0
. 0

Evidence 0
from 0
a 0
Northern 0
hybridization 0
indicated 0
that 0
jadM B-gene
expression 0
is 0
correlated 0
with 0
jadomycin B-gene
B I-gene
synthesis 0
. 0

Right 0
LHR 0
( 0
R 0
- 0
LHR 0
) 0
provided 0
the 0
best 0
interobserver 0
and 0
intraobserver 0
reproducibility 0
. 0

CONCLUSIONS 0
: 0
The 0
methodology 0
of 0
LHR 0
measurement 0
significantly 0
influences 0
the 0
clinical 0
contribution 0
of 0
Tl 0
- 0
201 0
lung 0
uptake 0
evaluation 0
. 0

Mutation 0
of 0
the 0
NF B-gene
- I-gene
kappaB I-gene
site I-gene
in 0
the 0
Mdr1b B-gene
promoter I-gene
prevents 0
its 0
induction 0
by 0
TNF B-gene
- I-gene
alpha I-gene
. 0

To 0
determine 0
the 0
genomic 0
complexity 0
of 0
the 0
deleted 0
region 0
shared 0
among 0
tumors 0
, 0
we 0
assembled 0
a 0
physical 0
map 0
of 0
the 0
I 0
Mbp 0
SRO 0
consisting 0
predominantly 0
of 0
bacteriophage 0
P1 0
- 0
derived 0
artificial 0
chromosome 0
( 0
PAC 0
) 0
clones 0
. 0

Online 0
teaching 0
: 0
design 0
and 0
techniques 0
. 0

The 0
application 0
of 0
the 0
biotechnology 0
at 0
the 0
plants 0
for 0
treatment 0
of 0
the 0
surface 0
storm 0
waters 0
from 0
the 0
industrial 0
zone 0
Telychka 0
of 0
the 0
city 0
of 0
Kyiv 0
has 0
allowed 0
the 0
content 0
of 0
petroleum 0
in 0
water 0
dropped 0
to 0
the 0
Dnieper 0
to 0
be 0
constantly 0
reduced 0
50 0
- 0
100 0
times 0
. 0

Data 0
were 0
obtained 0
from 0
2 0
undergraduate 0
student 0
samples 0
, 0
a 0
self 0
- 0
report 0
group 0
( 0
n 0
= 0
132 0
) 0
who 0
provided 0
NEO 0
- 0
PI 0
- 0
R 0
self 0
- 0
ratings 0
on 0
2 0
occasions 0
separated 0
by 0
a 0
7 0
- 0
to 0
14 0
- 0
day 0
interval 0
and 0
an 0
informant 0
group 0
( 0
n 0
= 0
109 0
) 0
who 0
provided 0
ratings 0
of 0
well 0
- 0
known 0
friends 0
or 0
relatives 0
on 0
2 0
occasions 0
separated 0
by 0
a 0
6 0
month 0
interval 0
. 0

Northern 0
blot 0
analysis 0
of 0
RNAs 0
from 0
a 0
number 0
of 0
mouse 0
tissues 0
reveals 0
that 0
Atp6i B-gene
is 0
expressed 0
predominantly 0
in 0
osteoclasts 0
, 0
and 0
this 0
predominant 0
expression 0
was 0
confirmed 0
by 0
reverse 0
- 0
transcription 0
polymerase 0
chain 0
reaction 0
( 0
RT 0
- 0
PCR 0
) 0
assay 0
and 0
immunohistochemical 0
analysis 0
. 0

Indeed 0
, 0
mutation 0
of 0
two 0
of 0
these 0
motifs 0
, 0
known 0
to 0
be 0
important 0
to 0
regulation 0
of 0
sid1 B-gene
, 0
altered 0
the 0
differential 0
regulation 0
of 0
sid2 B-gene
by 0
iron 0
. 0

The 0
described 0
results 0
show 0
that 0
DTD 0
is 0
fast 0
, 0
simple 0
, 0
and 0
easy 0
to 0
automate 0
; 0
requires 0
only 0
a 0
small 0
amount 0
of 0
sample 0
( 0
approximately 0
50 0
mg 0
) 0
; 0
and 0
affords 0
quantitative 0
information 0
about 0
the 0
main 0
groups 0
of 0
compounds 0
present 0
in 0
cheeses 0
. 0

Guidelines 0
for 0
performing 0
a 0
routine 0
spiral 0
assay 0
are 0
presented 0
, 0
and 0
alternative 0
test 0
methods 0
intended 0
to 0
overcome 0
a 0
variety 0
of 0
technical 0
difficulties 0
( 0
such 0
as 0
restricted 0
sample 0
availability 0
, 0
sample 0
viscosity 0
or 0
volatility 0
, 0
etc 0
. 0
) 0
are 0
recommended 0
. 0

In 0
conclusion 0
, 0
obesity 0
, 0
alcohol 0
intake 0
, 0
and 0
multimetabolic 0
disorders 0
were 0
determined 0
to 0
be 0
independent 0
predictors 0
for 0
the 0
development 0
of 0
hyperuricemia 0
. 0

Fans 0
in 0
tunnels 0
and 0
open 0
windows 0
at 0
aboveground 0
locations 0
appeared 0
to 0
greatly 0
reduce 0
the 0
likelihood 0
of 0
high 0
PH3 0
concentrations 0
in 0
enclosed 0
areas 0
. 0

Autoregulation 0
enables 0
different 0
pathways 0
to 0
control 0
CCAAT/enhancer B-gene
binding I-gene
protein I-gene
beta I-gene
( 0
C/EBP B-gene
beta I-gene
) 0
transcription 0
. 0

The 0
first 0
case 0
of 0
HCV 0
seroconversion 0
in 0
Portugal 0
after 0
the 0
introduction 0
of 0
HCV 0
NAT 0
screening 0
. 0

As 0
a 0
reflection 0
of 0
uncertainties 0
in 0
the 0
estimates 0
for 0
individual 0
sources 0
, 0
the 0
90th 0
percentiles 0
of 0
PCDD/F 0
releases 0
for 0
1999 0
ranged 0
up 0
to 0
4.1 0
g 0
I 0
- 0
TEQ/y 0
. 0

Gabapentin 0
for 0
opiod 0
- 0
related 0
myoclonus 0
in 0
cancer 0
patients 0
. 0

CONCLUSIONS 0
: 0
Our 0
meta 0
- 0
analysis 0
of 0
randomized 0
controlled 0
trials 0
of 0
HRT 0
noted 0
a 0
statistically 0
significant 0
reduction 0
in 0
nonvertebral 0
fractures 0
. 0

Newcastle B-gene
disease I-gene
antibody I-gene
titre 0
is 0
dependent 0
on 0
serum 0
calcium 0
concentration 0
. 0

A 0
total 0
of 0
25 0
patients 0
with 0
malignant 0
brain 0
tumours 0
were 0
investigated 0
. 0

Net 0
lift 0
and 0
combined 0
drag 0
from 0
all 0
8 0
bearings 0
of 0
the 0
4 0
- 0
bladed 0
impeller 0
are 0
compared 0
with 0
predictions 0
based 0
on 0
2 0
- 0
D 0
theory 0
. 0

Our 0
results 0
indicate 0
that 0
Gab1 B-gene
is 0
involved 0
in 0
the 0
control 0
of 0
egr B-gene
- I-gene
1 I-gene
expression 0
regulated 0
by 0
insulin B-gene
. 0

The 0
observed 0
triplexes 0
depend 0
on 0
the 0
length 0
of 0
the 0
repeat 0
. 0

The 0
co 0
- 0
existence 0
of 0
TE B-gene
domains I-gene
within 0
modular 0
PKSs B-gene
along 0
with 0
physically 0
separated 0
, 0
monofunctional 0
TEs B-gene
( 0
TE B-gene
IIs I-gene
) 0
has 0
been 0
reported 0
for 0
a 0
number 0
of 0
modular 0
polyketide 0
and 0
non B-gene
- I-gene
ribosomal I-gene
peptide I-gene
synthases I-gene
( 0
NRPS B-gene
) 0
. 0

To 0
gain 0
an 0
understanding 0
of 0
the 0
mGSTM2 B-gene
regulation 0
, 0
we 0
have 0
also 0
cloned 0
and 0
analyzed 0
its 0
promoter 0
region 0
. 0

10.0 0
+/ 0
- 0
2.0 0
pmol/24 0
h 0
, 0
P 0
< 0
0.01 0
) 0
and 0
remained 0
elevated 0
. 0

SELECTION 0
CRITERIA 0
: 0
All 0
randomised 0
controlled 0
trials 0
comparing 0
IUSs 0
with 0
other 0
forms 0
of 0
reversible 0
contraceptives 0
and 0
reporting 0
on 0
pre 0
- 0
determined 0
outcomes 0
in 0
women 0
of 0
reproductive 0
years 0
. 0

OBJECTIVES 0
: 0
The 0
objective 0
of 0
this 0
review 0
was 0
to 0
compare 0
the 0
effectiveness 0
, 0
safety 0
and 0
acceptability 0
of 0
the 0
diaphragm 0
with 0
and 0
without 0
spermicide 0
. 0

To 0
test 0
the 0
hypothesis 0
that 0
these 0
elements 0
are 0
required 0
for 0
promoter 0
activity 0
, 0
we 0
compared 0
the 0
reporter 0
expression 0
activity 0
of 0
segments 0
containing 0
mutations 0
of 0
these 0
elements 0
with 0
activity 0
of 0
the 0
parent B-gene
Hlx I-gene
promoter I-gene
sequence I-gene
. 0

In 0
all 0
of 0
these 0
cases 0
, 0
expression 0
of 0
the 0
implicated 0
genes 0
was 0
absent 0
. 0

CONCLUSIONS 0
: 0
Ketamine 0
- 0
induced 0
dissociative 0
anesthesia 0
produces 0
persistently 0
elevated 0
BIS 0
index 0
which 0
is 0
different 0
from 0
thiamylal 0
and 0
those 0
reported 0
with 0
other 0
conventional 0
anesthetic 0
agents 0
. 0

Our 0
results 0
are 0
reassuring 0
and 0
we 0
therefore 0
advise 0
that 0
in 0
patients 0
undergoing 0
free 0
jejunum 0
flap 0
reconstruction 0
of 0
the 0
hypopharyngo 0
- 0
esophageal 0
tract 0
voice 0
restoration 0
should 0
be 0
attempted 0
by 0
placing 0
a 0
voice 0
prosthesis 0
through 0
a 0
secondary 0
tracheo 0
- 0
esophageal 0
puncture 0
and 0
providing 0
intensive 0
speech 0
training 0
. 0

Hypercalcemia 0
associated 0
with 0
elevated 0
serum B-gene
PTH I-gene
concentration 0
indicating 0
primary 0
hyperparathyroidism 0
was 0
found 0
in 0
7 0
BC 0
patients 0
( 0
7 0
% 0
) 0
and 0
in 0
none 0
of 0
healthy 0
women 0
or 0
patients 0
with 0
thyroid 0
cancer 0
. 0

Positive 0
and 0
significant 0
correlations 0
were 0
found 0
between 0
the 0
weeks 0
of 0
pregnancy 0
and 0
Se 0
levels 0
in 0
kidney 0
( 0
r=0.433 0
, 0
P=0.023 0
) 0
and 0
heart 0
( 0
r=0.313 0
, 0
P=0.030 0
) 0
. 0

This 0
study 0
suggests 0
that 0
PSP 0
is 0
more 0
common 0
than 0
previously 0
considered 0
, 0
is 0
commonly 0
misdiagnosed 0
and 0
that 0
the 0
majority 0
of 0
cases 0
are 0
not 0
initially 0
referred 0
to 0
neurologists 0
. 0

In 0
Saccharomyces 0
cerevisiae 0
, 0
entry 0
into 0
mitosis 0
requires 0
activation 0
of 0
the 0
cyclin B-gene
- I-gene
dependent I-gene
kinase I-gene
Cdc28 B-gene
in 0
its 0
cyclin B-gene
B I-gene
( 0
Clb B-gene
) 0
- 0
associated 0
form 0
. 0

We 0
investigated 0
the 0
production 0
of 0
hyaluronan 0
( 0
HA 0
) 0
and 0
its 0
effect 0
on 0
cell 0
motility 0
in 0
cells 0
expressing 0
the 0
v B-gene
- I-gene
src I-gene
mutants I-gene
. 0

Our 0
results 0
indicate 0
that 0
D 0
( 0
4 0
) 0
and 0
D 0
( 0
2L 0
) 0
receptors 0
activate 0
the 0
ERK B-gene
kinase I-gene
cascade 0
by 0
first 0
mobilizing 0
signaling 0
by 0
the 0
PDGF B-gene
receptor I-gene
, 0
followed 0
by 0
the 0
subsequent 0
activation 0
of 0
ERK1/2 B-gene
by 0
pathways 0
associated 0
with 0
this 0
receptor B-gene
tyrosine I-gene
kinase I-gene
. 0

Karger 0
AG 0
, 0
Basel 0

We 0
used 0
stored 0
plasma 0
samples 0
from 0
409 0
patients 0
in 0
the 0
National 0
Institute 0
of 0
Neurological 0
Diseases 0
and 0
Stroke 0
( 0
NINDS 0
) 0
tissue B-gene
plasminogen I-gene
activator I-gene
( 0
t B-gene
- I-gene
PA I-gene
) 0
Stroke 0
Trial 0
to 0
examine 0
the 0
relationship 0
between 0
an 0
apolipoprotein B-gene
( I-gene
Apo I-gene
) I-gene
E2 I-gene
or 0
an 0
Apo B-gene
E4 I-gene
phenotype 0
and 0
a 0
favorable 0
outcome 0
3 0
months 0
after 0
stroke 0
, 0
the 0
risk 0
of 0
intracerebral 0
hemorrhage 0
, 0
and 0
the 0
response 0
to 0
intravenous 0
t B-gene
- I-gene
PA I-gene
therapy 0
. 0

NIRS 0
was 0
used 0
for 0
the 0
quantitative 0
measurement 0
of 0
muscle 0
O 0
( 0
2 0
) 0
consumption 0
( 0
mV.O 0
( 0
2 0
) 0
) 0
and 0
forearm 0
blood 0
flow 0
( 0
FBF 0
) 0
in 0
78 0
healthy 0
subjects 0
. 0

No 0
dominant 0
clinical 0
factor 0
of 0
risk 0
was 0
found 0
, 0
but 0
multiple 0
regression 0
analysis 0
identified 0
age 0
, 0
body 0
surface 0
area 0
, 0
valve 0
size 0
, 0
shop 0
order 0
fracture 0
rate 0
, 0
and 0
manufacturing 0
period 0
as 0
risk 0
factors 0
for 0
OSF 0
. 0

In 0
this 0
report 0
this 0
technique 0
was 0
applied 0
to 0
human 0
breast 0
carcinoma 0
MDA 0
- 0
MB231 0
cells 0
overexpressing 0
human B-gene
MPG I-gene
in 0
order 0
to 0
assess 0
whether 0
up 0
- 0
regulation 0
of 0
the 0
initial 0
step 0
in 0
BER 0
alters 0
the 0
activity 0
of 0
selected 0
other 0
BER 0
( 0
hOGG1 B-gene
and 0
APE/ref B-gene
APE/ref I-gene
- I-gene
1 I-gene
) 0
or 0
direct 0
reversal 0
( 0
MGMT B-gene
) 0
repair 0
activities 0
. 0

The 0
selective 0
alteration 0
of 0
the 0
genome 0
using 0
Cre B-gene
recombinase I-gene
to 0
target 0
the 0
rearrangement 0
of 0
genes 0
flanked 0
by 0
LOX B-gene
recognition I-gene
sequences I-gene
has 0
required 0
the 0
use 0
of 0
two 0
separate 0
genetic 0
constructs 0
in 0
trans 0
, 0
one 0
containing 0
cre 0
and 0
the 0
other 0
containing 0
the 0
gene 0
of 0
interest 0
flanked 0
by 0
LOX B-gene
sites I-gene
. 0

Colorectal 0
cancer 0
was 0
shown 0
to 0
disproportionately 0
overburden 0
Ashkenazi 0
Jews 0
, 0
who 0
may 0
also 0
be 0
at 0
increased 0
risk 0
for 0
ovarian 0
, 0
pancreatic 0
and 0
stomach 0
cancer 0
, 0
and 0
non 0
- 0
Hodgkin 0
's 0
lymphoma 0
. 0

Influence 0
of 0
compression 0
therapy 0
on 0
symptoms 0
following 0
soft 0
tissue 0
injury 0
from 0
maximal 0
eccentric 0
exercise 0
. 0

Keratoconjunctivitis 0
sicca 0
appears 0
to 0
be 0
a 0
common 0
ocular 0
complication 0
and 0
all 0
children 0
with 0
JRA 0
should 0
be 0
screened 0
for 0
it 0
with 0
a 0
comprehensive 0
battery 0
of 0
tests 0
. 0

STAT5A B-gene
mutations 0
in 0
the 0
Src B-gene
homology I-gene
2 I-gene
( 0
SH2 B-gene
) 0
and 0
SH3 B-gene
domains I-gene
did 0
not 0
alter 0
the 0
BTK B-gene
- 0
mediated 0
tyrosine 0
phosphorylation 0
. 0

In 0
conclusion 0
, 0
primary 0
chemotherapy 0
based 0
on 0
high 0
dose 0
MTX 0
and 0
ara 0
- 0
C 0
is 0
highly 0
efficient 0
in 0
PCNSL 0
. 0

RANTES B-gene
( 0
regulated B-gene
upon I-gene
activation I-gene
, I-gene
normally I-gene
T I-gene
- I-gene
cell I-gene
expressed I-gene
and I-gene
presumably I-gene
secreted I-gene
) 0
is 0
a 0
CC 0
chemokine 0
which 0
recruits 0
and 0
activates 0
monocytes 0
, 0
lymphocytes 0
, 0
and 0
eosinophils 0
, 0
all 0
cell 0
types 0
present 0
in 0
the 0
lung 0
inflammatory 0
infiltrate 0
induced 0
by 0
RSV 0
infection 0
. 0

Reovirus 0
mRNAs 0
are 0
efficiently 0
translated 0
within 0
host 0
cells 0
despite 0
the 0
absence 0
of 0
3 0
' 0
polyadenylated 0
tails 0
. 0

Analyses 0
revealed 0
that 0
scale 0
matters 0
above 0
and 0
beyond 0
the 0
effect 0
of 0
quadrat 0
area 0
. 0

Myasthenia 0
gravis 0
is 0
an 0
autoimmune 0
disease 0
resulting 0
from 0
the 0
production 0
of 0
antibodies 0
against 0
the 0
ACh B-gene
receptors I-gene
of 0
the 0
neuromuscular 0
synapse 0
. 0

Copyright 0
2001 0
Academic 0
Press 0
. 0

Using 0
the 0
postural 0
and 0
force 0
data 0
as 0
input 0
to 0
a 0
3 0
- 0
D 0
biomechanical 0
model 0
, 0
the 0
lumbosacral 0
spinal 0
compression 0
was 0
calculated 0
. 0

Angina 0
( 0
Q 0
) 0
persistence 0
showed 0
marked 0
associations 0
with 0
previous 0
myocardial 0
infarction 0
, 0
diagnosed 0
angina 0
, 0
electrocardiogram 0
ischemia 0
, 0
and 0
subsequent 0
major 0
ischemic 0
heart 0
disease 0
events 0
from 0
Q5 0
onward 0
. 0

In 0
the 0
past 0
decade 0
, 0
there 0
have 0
been 0
enormous 0
advances 0
in 0
the 0
use 0
of 0
Bayesian 0
methodology 0
for 0
analysis 0
of 0
epidemiologic 0
data 0
, 0
and 0
there 0
are 0
now 0
many 0
practical 0
advantages 0
to 0
the 0
Bayesian 0
approach 0
. 0

To 0
assess 0
more 0
specific 0
PKA B-gene
- 0
dependent 0
mediation 0
of 0
LH B-gene
's I-gene
contribution 0
to 0
combined 0
hormonal 0
drive 0
, 0
the 0
LDL B-gene
receptor I-gene
( I-gene
- I-gene
1076 I-gene
to I-gene
+11 I-gene
bp I-gene
) I-gene
reporter I-gene
plasmid 0
was 0
cotransfected 0
with 0
a 0
full B-gene
- I-gene
sequence I-gene
rabbit I-gene
muscle I-gene
protein I-gene
kinase I-gene
inhibitor I-gene
( 0
PKI B-gene
) 0
minigene 0
driven 0
constitutively 0
by 0
a 0
Rous B-gene
sarcoma I-gene
virus I-gene
promoter I-gene
. 0

To 0
investigate 0
the 0
convergent 0
role 0
of 0
the 0
insulin/IGF B-gene
insulin/IGF I-gene
- I-gene
I I-gene
effector 0
pathway 0
mediating 0
bihormonal 0
stimulation 0
of 0
LDL B-gene
receptor I-gene
promoter I-gene
expression 0
, 0
transfected 0
granulosa 0
- 0
luteal 0
cells 0
were 0
pretreated 0
for 0
30 0
min 0
with 0
two 0
specific 0
inhibitors 0
of 0
phophatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
, 0
wortmannin 0
( 0
100 0
nM 0
) 0
and 0
LY 0
294002 0
( 0
10 0
microM 0
) 0
, 0
or 0
of 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
kinase I-gene
, 0
PD 0
98059 0
( 0
50 0
microM 0
) 0
, 0
U0126 0
( 0
10 0
microM 0
) 0
, 0
or 0
the 0
latter 0
's 0
inactive 0
derivative 0
, 0
U0124 0
( 0
10 0
microM 0
) 0
. 0

Concerted 0
transcriptional 0
activation 0
of 0
the 0
low B-gene
density I-gene
lipoprotein I-gene
receptor I-gene
gene I-gene
by 0
insulin B-gene
and 0
luteinizing B-gene
hormone I-gene
in 0
cultured 0
porcine 0
granulosa 0
- 0
luteal 0
cells 0
: 0
possible 0
convergence 0
of 0
protein B-gene
kinase I-gene
a I-gene
, 0
phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
, 0
and 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
signaling 0
pathways 0
. 0

These 0
studies 0
demonstrate 0
that 0
site 0
- 0
specific 0
recognition 0
of 0
the 0
bxd B-gene
PRE I-gene
by 0
d 0
( 0
GA 0
) 0
( 0
n 0
) 0
repeat 0
binding 0
activities 0
mediates 0
PcG B-gene
- 0
dependent 0
silencing 0
. 0

Our 0
findings 0
further 0
our 0
understanding 0
of 0
how 0
ZBP B-gene
- I-gene
89 I-gene
modulates 0
cell 0
proliferation 0
and 0
reveals 0
a 0
novel 0
mechanism 0
by 0
which 0
the 0
p53 B-gene
protein I-gene
is 0
stabilized 0
. 0

A 0
computerized 0
method 0
of 0
determining 0
the 0
focal 0
point 0
of 0
electrical 0
activity 0
in 0
the 0
pallidum 0
of 0
parkinsonian 0
patients 0
was 0
developed 0
using 0
on 0
- 0
line 0
quantitative 0
physiological 0
data 0
analysis 0
. 0

Five 0
modalities 0
of 0
nonpharmacologic 0
approaches 0
are 0
recommended 0
at 0
present 0
for 0
lifestyle 0
modification 0
and 0
control 0
of 0
arterial 0
blood 0
pressure 0
elevation 0
: 0
1 0
) 0
weight 0
reduction 0
to 0
ideal 0
body 0
weight 0
, 0
since 0
it 0
reduces 0
risk 0
of 0
hypertension 0
as 0
well 0
as 0
overall 0
cardiovascular 0
morbidity 0
and 0
mortality 0
; 0
2 0
) 0
dietary 0
sodium 0
restriction 0
to 0
less 0
than 0
2 0
g 0
a 0
day 0
, 0
without 0
assurance 0
that 0
it 0
will 0
normalize 0
arterial 0
pressure 0
although 0
it 0
may 0
help 0
reduce 0
dosage 0
and 0
numbers 0
of 0
prescribed 0
antihypertensive 0
drugs 0
; 0
3 0
) 0
moderation 0
of 0
alcohol 0
consumption 0
to 0
less 0
than 0
1 0
ounce 0
a 0
day 0
; 0
4 0
) 0
a 0
regular 0
isotonic 0
exercise 0
program 0
; 0
and 0
5 0
) 0
cessation 0
of 0
tobacco 0
consumption 0
. 0

Isolated 0
Systolic 0
Hypertension 0
: 0
An 0
Update 0
. 0

Ga 0
- 0
67 0
and 0
Tl 0
- 0
201 0
scintigraphy 0
in 0
extramedullary 0
plasmacytoma 0
: 0
a 0
case 0
report 0
. 0

Arterial 0
blood 0
gas 0
tensions 0
were 0
similar 0
across 0
all 0
ventilation 0
modes 0
. 0

As 0
expected 0
, 0
homologous B-gene
loxP I-gene
sequences I-gene
efficiently 0
underwent 0
Cre B-gene
- 0
mediated 0
recombination 0
. 0

The 0
N 0
- 0
terminal 0
portion 0
of 0
Notch B-gene
( I-gene
IC I-gene
) I-gene
inhibited 0
p50 B-gene
DNA 0
binding 0
and 0
interacted 0
specifically 0
with 0
p50 B-gene
subunit I-gene
, 0
not 0
p65 B-gene
of 0
NF B-gene
- I-gene
kappaB I-gene
. 0

Conformational 0
changes 0
of 0
the 0
ferric B-gene
uptake I-gene
regulation I-gene
protein I-gene
upon 0
metal 0
activation 0
and 0
DNA 0
binding 0
; 0
first 0
evidence 0
of 0
structural 0
homologies 0
with 0
the 0
diphtheria B-gene
toxin I-gene
repressor I-gene
. 0

As 0
a 0
complement 0
to 0
genome 0
- 0
wide 0
mapping 0
and 0
sequencing 0
efforts 0
, 0
it 0
is 0
often 0
important 0
to 0
generate 0
detailed 0
maps 0
and 0
sequence 0
data 0
for 0
specific 0
regions 0
of 0
interest 0
. 0

Granulocyte B-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
( 0
G B-gene
- I-gene
CSF I-gene
) 0
administration 0
in 0
vivo 0
has 0
been 0
shown 0
to 0
improve 0
the 0
defence 0
mechanisms 0
against 0
infection 0
by 0
different 0
microbes 0
. 0

Among 0
individuals 0
, 0
however 0
, 0
changes 0
were 0
strongly 0
correlated 0
with 0
ACR 0
levels 0
at 0
baseline 0
. 0

Thus 0
, 0
the 0
screen 0
for 0
toxic 0
p53 B-gene
mutants I-gene
in 0
yeast 0
can 0
identify 0
novel 0
p53 B-gene
variants 0
that 0
may 0
be 0
useful 0
in 0
dissecting 0
p53 B-gene
regulated 0
cellular 0
responses 0
and 0
in 0
developing 0
p53 B-gene
- 0
based 0
cancer 0
therapies 0
. 0

This 0
is 0
necessary 0
if 0
psychiatric 0
diagnoses 0
are 0
ultimately 0
going 0
to 0
be 0
refined 0
and 0
validated 0
against 0
biological 0
criteria 0
. 0

Since 0
the 0
latter 0
is 0
very 0
small 0
for 0
physiological 0
flows 0
, 0
the 0
result 0
is 0
that 0
alpha 0
< 0
1 0
even 0
at 0
relatively 0
high 0
values 0
of 0
the 0
Reynolds 0
number 0
( 0
i.e. 0
, 0
for 0
non 0
- 0
negligible 0
inertia 0
) 0
and 0
we 0
validate 0
our 0
perturbation 0
theory 0
results 0
by 0
comparison 0
with 0
a 0
numerical 0
integration 0
of 0
the 0
full 0
model 0
. 0

Cells 0
lacking 0
p116 B-gene
exhibit 0
a 0
striking 0
defect 0
in 0
the 0
formation 0
of 0
these 0
macropinocytic 0
structures 0
, 0
a 0
concomitant 0
reduction 0
in 0
the 0
rate 0
of 0
fluid 0
phase 0
pinocytosis 0
, 0
a 0
significant 0
decrease 0
in 0
the 0
efficiency 0
of 0
chemotactic 0
aggregation 0
, 0
and 0
a 0
decrease 0
in 0
cellular 0
F B-gene
- I-gene
actin I-gene
content 0
. 0

The 0
validity 0
of 0
the 0
FPS 0
- 0
R 0
was 0
further 0
supported 0
by 0
strong 0
positive 0
correlations 0
with 0
the 0
VAS 0
( 0
r=0.92 0
, 0
N=45 0
) 0
and 0
the 0
CAS 0
( 0
r=0.84 0
, 0
N=45 0
) 0
in 0
this 0
clinical 0
sample 0
. 0

The 0
susceptibility 0
of 0
Aspergillus 0
fumigatus 0
to 0
mulundocandin 0
, 0
an 0
echinocandin 0
- 0
like 0
compound 0
, 0
and 0
other 0
antifungal 0
agents 0
was 0
assessed 0
by 0
the 0
National 0
Committee 0
for 0
Clinical 0
Laboratory 0
Standards 0
( 0
NCCLS 0
) 0
M38 0
- 0
P 0
method 0
, 0
a 0
2,3 0
- 0
bis 0
( 0
2 0
- 0
methoxy 0
- 0
4 0
- 0
nitro 0
- 0
5 0
- 0
sulfophenyl 0
) 0
- 0
5 0
- 0
[ 0
( 0
phenyl 0
- 0
amino 0
) 0
carbonyl 0
] 0
- 0
2H 0
- 0
tetrazolium 0
hydroxide 0
( 0
XTT 0
) 0
- 0
based 0
colorimetric 0
assay 0
, 0
and 0
determination 0
of 0
morphologic 0
alterations 0
by 0
microscopy 0
. 0

The 0
Van 0
der 0
Hoeve 0
's 0
syndrome 0
lesions 0
as 0
poorly 0
mineralized 0
, 0
with 0
low 0
calcium 0
salt 0
and 0
apparent 0
increase 0
of 0
phosphates 0
. 0

A 0
5 0
- 0
month 0
- 0
old 0
infant 0
with 0
persistent 0
congenital 0
stridor 0
and 0
acute 0
respiratory 0
distress 0
is 0
presented 0
. 0

DESIGN 0
: 0
A 0
retrospective 0
chart 0
review 0
of 0
9,322 0
patients 0
undergoing 0
surgical 0
procedures 0
in 0
the 0
period 0
January 0
1993 0
to 0
December 0
1998 0
. 0

Pulmonary 0
vein 0
varix 0
in 0
association 0
with 0
bilateral 0
pulmonary 0
vein 0
stenosis 0
. 0

Biochemical 0
experiments 0
have 0
shown 0
that 0
CopG B-gene
co 0
- 0
operatively 0
associates 0
to 0
its 0
target 0
DNA 0
at 0
low 0
protein 0
: 0
DNA 0
ratios 0
, 0
completely 0
protecting 0
four 0
helical 0
turns 0
on 0
the 0
same 0
face 0
of 0
the 0
double 0
helix 0
in 0
both 0
directions 0
from 0
the 0
inverted 0
repeat 0
that 0
constitutes 0
the 0
CopG B-gene
primary 0
target 0
. 0

We 0
demonstrated 0
that 0
, 0
under 0
serum 0
- 0
starved 0
conditions 0
, 0
KMS 0
- 0
11 0
and 0
OPM 0
- 0
2 0
cells 0
express 0
appreciable 0
levels 0
of 0
phosphorylated 0
FGFR3 B-gene
mutants I-gene
indicating 0
a 0
constitutive 0
activation 0
of 0
the 0
Y373C B-gene
and I-gene
K650E I-gene
receptors I-gene
; 0
the 0
addition 0
of 0
the 0
aFGF B-gene
ligand I-gene
further 0
increased 0
the 0
level 0
of 0
receptor 0
phosphorylation 0
. 0

[ 0
figure 0
: 0
see 0
text 0
] 0
The 0
Stille 0
coupling 0
reaction 0
has 0
been 0
performed 0
in 0
1 0
- 0
butyl 0
- 0
3 0
- 0
methylimidazolium 0
tetrafluoroborate 0
( 0
BMIM 0
BF4 0
) 0
, 0
a 0
room 0
- 0
temperature 0
ionic 0
liquid 0
( 0
RTIL 0
) 0
. 0

Special 0
issues 0
devoted 0
to 0
the 0
biosynthesis 0
of 0
woody 0
plant 0
biopolymers 0
and 0
related 0
substances 0
. 0

Interactions 0
between 0
the 0
checkpoint 0
abrogator 0
UCN 0
- 0
01 0
and 0
several 0
pharmacological 0
inhibitors 0
of 0
the 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( I-gene
MAPK I-gene
) I-gene
kinase I-gene
( 0
MEK B-gene
) 0
/MAPK B-gene
pathway 0
have 0
been 0
examined 0
in 0
a 0
variety 0
of 0
human 0
leukemia 0
cell 0
lines 0
. 0

Low 0
affinity 0
binding 0
of 0
Rab6A B-gene
- I-gene
GTP I-gene
was 0
also 0
observed 0
( 0
K 0
( 0
d 0
) 0
= 0
16 0
microm 0
) 0
, 0
whereas 0
Rab1B B-gene
, I-gene
- I-gene
5 I-gene
, I-gene
- I-gene
7 I-gene
, I-gene
- I-gene
8 I-gene
, I-gene
or I-gene
- I-gene
11A I-gene
did 0
not 0
bind 0
. 0

The 0
students 0
who 0
had 0
abnormal 0
urine 0
screening 0
results 0
at 0
the 0
first 0
time 0
received 0
a 0
second 0
urine 0
analysis 0
10 0
to 0
15 0
days 0
later 0
to 0
confirm 0
the 0
abnormal 0
urine 0
analysis 0
. 0

PURPOSE 0
: 0
The 0
objective 0
of 0
this 0
study 0
was 0
to 0
assess 0
first 0
embryo 0
cleavage 0
( 0
FEC 0
) 0
25 0
- 0
27 0
h 0
after 0
intracytoplasmic 0
sperm 0
injection 0
( 0
ICSI 0
) 0
as 0
a 0
parameter 0
for 0
the 0
embryo 0
selection 0
process 0
. 0

Regulation 0
of 0
laminin B-gene
beta2 I-gene
chain I-gene
gene I-gene
expression 0
in 0
human 0
cancer 0
cell 0
lines 0
. 0

Northern 0
and 0
Western 0
blot 0
analyses 0
demonstrated 0
that 0
Graf2 B-gene
is 0
expressed 0
in 0
several 0
tissues 0
, 0
with 0
the 0
highest 0
expression 0
in 0
skeletal 0
muscle 0
. 0

However 0
, 0
when 0
directed 0
to 0
the 0
nucleosome 0
by 0
fusion 0
to 0
core B-gene
histone I-gene
H2A I-gene
or 0
H2B B-gene
, 0
the 0
non 0
- 0
histone B-gene
tail 0
forms 0
an 0
MCB 0
that 0
appears 0
identical 0
to 0
that 0
of 0
the 0
endogenous 0
protein 0
. 0

These 0
data 0
suggest 0
that 0
proper 0
direct 0
binding 0
of 0
Nhp2p B-gene
to 0
H/ACA B-gene
snoRNAs I-gene
is 0
required 0
for 0
the 0
assembly 0
of 0
H/ACA B-gene
snoRNPs I-gene
and 0
hence 0
for 0
the 0
stability 0
of 0
some 0
of 0
their 0
components 0
. 0

Telomerase B-gene
is 0
a 0
ribonucleoprotein 0
complex 0
that 0
synthesizes 0
telomeric 0
DNA 0
onto 0
chromosomes 0
using 0
its 0
RNA 0
component 0
as 0
template 0
. 0

SIT B-gene
( 0
SHP2 B-gene
- I-gene
interacting I-gene
transmembrane I-gene
adaptor I-gene
protein I-gene
) 0
is 0
a 0
recently 0
identified 0
transmembrane 0
adaptor 0
protein 0
, 0
which 0
is 0
expressed 0
in 0
lymphocytes 0
. 0

In 0
35 0
of 0
those 0
patients 0
DD 0
was 0
measured 0
also 0
with 0
microlatex 0
tests 0
- 0
- 0
Tinaquant 0
and 0
BC 0
d 0
- 0
dimer 0
. 0

Cytosolic B-gene
acetyl I-gene
- I-gene
CoA I-gene
synthetase I-gene
( 0
AceCS1 B-gene
) 0
activates 0
acetate 0
to 0
supply 0
the 0
cells 0
with 0
acetyl 0
- 0
CoA 0
for 0
lipid 0
synthesis 0
. 0

Ileal 0
digestibilities 0
of 0
DM 0
, 0
OM 0
, 0
CP 0
, 0
total 0
dietary 0
fiber 0
( 0
TDF 0
) 0
, 0
fat 0
and 0
gross 0
energy 0
( 0
GE 0
) 0
were 0
lower 0
( 0
P 0
< 0
0.05 0
) 0
for 0
dogs 0
fed 0
diets 0
containing 0
supplemental 0
fiber 0
compared 0
with 0
dogs 0
fed 0
the 0
control 0
diet 0
. 0

Together 0
these 0
data 0
imply 0
that 0
the 0
HFV B-gene
R I-gene
region I-gene
acts 0
in 0
the 0
nucleus 0
to 0
modify 0
the 0
cytoplasmic 0
fate 0
of 0
target 0
HFV 0
mRNA 0
. 0

These 0
TxRE B-gene
contain 0
cyclic 0
AMP 0
- 0
responsive 0
elements 0
( 0
CRE 0
) 0
, 0
but 0
, 0
remarkably 0
, 0
the 0
`` 0
TGACGTCA 0
'' 0
consensus 0
is 0
never 0
strictly 0
conserved 0
in 0
any 0
viral 0
strain 0
( 0
e.g. 0
, 0
AGACGTCA 0
, 0
TGACGGCA 0
, 0
TGACCTCA 0
) 0
. 0

And 0
, 0
most 0
importantly 0
, 0
reconstitution 0
of 0
a 0
consensus 0
CRE 0
, 0
within 0
the 0
21 0
- 0
bp 0
enhancers 0
increases 0
binding 0
of 0
CREB/ATF B-gene
proteins 0
but 0
abrogates 0
basal 0
repression 0
of 0
LTR 0
- 0
directed 0
transcription 0
in 0
vitro 0
. 0

Site 0
- 0
directed 0
mutagenesis 0
of 0
CAR B-gene
revealed 0
that 0
CAR B-gene
residues 0
Leu73 0
and 0
Lys121 0
and/or 0
Lys123 0
are 0
critical 0
contact 0
residues 0
, 0
with 0
Tyr80 0
and 0
Tyr83 0
being 0
peripherally 0
involved 0
in 0
the 0
binding 0
interaction 0
with 0
the 0
Ad5 B-gene
, I-gene
Ad9 I-gene
, I-gene
Ad12 I-gene
, I-gene
and I-gene
Ad41L I-gene
fiber I-gene
knobs I-gene
. 0

This 0
subfamily 0
of 0
genes 0
all 0
have 0
a 0
single 0
ATP 0
- 0
binding 0
domain 0
at 0
the 0
N 0
- 0
terminus 0
and 0
a 0
single 0
C 0
- 0
terminal 0
set 0
of 0
transmembrane 0
segments 0
. 0

Tolerance 0
in 0
renal 0
transplantation 0
after 0
allogeneic 0
bone 0
marrow 0
transplantation 0
- 0
6 0
- 0
year 0
follow 0
- 0
up 0
. 0

The 0
promoter 0
activity 0
of 0
the 0
proximal 0
region 0
was 0
found 0
to 0
be 0
restricted 0
to 0
a 0
subset 0
of 0
prestalk 0
cells 0
. 0

Substitution 0
of 0
serine 0
residues 0
at 0
the 0
C 0
- 0
terminus 0
indicated 0
that 0
loss 0
of 0
phosphorylation 0
sites 0
did 0
not 0
appear 0
to 0
have 0
any 0
effect 0
on 0
transcription 0
and 0
replication 0
. 0

Thus 0
, 0
replication 0
fork 0
movement 0
near 0
HML B-gene
pauses 0
at 0
a 0
silent 0
origin 0
which 0
is 0
competent 0
for 0
replication 0
initiation 0
but 0
kept 0
silent 0
through 0
Orc2p B-gene
, 0
a 0
component 0
of 0
the 0
replication 0
initiator 0
. 0

These 0
findings 0
suggest 0
that 0
the 0
adapter 0
Gab1 B-gene
may 0
redirect 0
c B-gene
- I-gene
Met I-gene
signaling 0
through 0
PI3K B-gene
away 0
from 0
a 0
c B-gene
- I-gene
Akt/Pak1 I-gene
cell 0
survival 0
pathway 0
. 0

We 0
have 0
cloned 0
a 0
novel 0
mouse 0
protein 0
, 0
TAF B-gene
( I-gene
II I-gene
) I-gene
140 I-gene
, 0
containing 0
an 0
HFD B-gene
and 0
a 0
plant B-gene
homeodomain I-gene
( 0
PHD B-gene
) 0
finger 0
, 0
which 0
we 0
demonstrated 0
by 0
immunoprecipitation 0
to 0
be 0
a 0
mammalian B-gene
TFIID I-gene
component I-gene
. 0

The 0
other 0
inhibitor 0
was 0
a 0
single 0
TAR B-gene
decoy 0
, 0
driven 0
by 0
the 0
U6 B-gene
small I-gene
nuclear I-gene
RNA I-gene
promoter I-gene
( 0
U6 B-gene
- I-gene
P I-gene
) 0
. 0

In 0
contrast 0
to 0
MPc3 B-gene
, 0
data 0
indicate 0
that 0
the 0
Pc B-gene
protein I-gene
M33 B-gene
does 0
not 0
interact 0
with 0
AF9 B-gene
. 0

Foreigners 0
return 0
. 0

Long 0
- 0
term 0
results 0
with 0
MACOP 0
- 0
B 0
and 0
radiation 0
therapy 0
for 0
aggressive 0
lymphomas 0
] 0
BACKGROUND 0
: 0
Long 0
- 0
term 0
results 0
are 0
needed 0
to 0
evaluate 0
chemotherapy 0
regimens 0
and 0
prognostic 0
factors 0
in 0
non 0
- 0
Hodgkin 0
's 0
lymphomas 0
( 0
NHL 0
) 0
. 0

At 0
20 0
days 0
( 0
D 0
) 0
and 0
at 0
3 0
months 0
post 0
- 0
TBI 0
, 0
irradiated 0
rats 0
had 0
a 0
significantly 0
lower 0
percentage 0
of 0
avoidance 0
than 0
controls 0
but 0
no 0
statistical 0
difference 0
was 0
found 0
at 0
5 0
months 0
post 0
- 0
TBI 0
. 0
b/ 0
Two 0
- 0
way 0
avoidance 0
test 0
: 0
this 0
test 0
was 0
performed 0
only 0
after 0
TBI 0
. 0

At 0
the 0
end 0
of 0
each 0
day 0
of 0
migration 0
the 0
pulmonary 0
hemolymph 0
PO2 0
decreased 0
by 0
1 0
- 0
2.5 0
kPa 0
, 0
but 0
the 0
hemocyanin 0
remained 0
saturated 0
with 0
O2 0
and 0
the 0
venous 0
reserve 0
was 0
largely 0
unchanged 0
( 0
O2 0
> 0
0.4 0
mmol 0
x 0
l 0
( 0
- 0
1 0
) 0
) 0
. 0

DESIGN 0
: 0
Prospective 0
cohort 0
study 0
with 0
a 0
20 0
y 0
follow 0
- 0
up 0
period 0
, 0
the 0
First 0
National 0
Health 0
and 0
Examination 0
Survey 0
( 0
NHANES 0
1 0
) 0
Epidemiologic 0
Follow 0
- 0
up 0
Study 0
( 0
NHEFS 0
) 0
. 0

Mean 0
Hg 0
concentrations 0
in 0
the 0
livers 0
of 0
mice 0
at 0
some 0
sites 0
in 0
Isle 0
Royale 0
are 0
not 0
significantly 0
lower 0
( 0
P 0
= 0
0.62 0
) 0
than 0
Hg 0
concentrations 0
considered 0
by 0
some 0
government 0
agencies 0
to 0
be 0
unhealthy 0
for 0
human 0
consumption 0
. 0

There 0
are 0
many 0
different 0
proposals 0
for 0
the 0
statistical 0
analysis 0
of 0
data 0
to 0
determine 0
early 0
onset 0
of 0
action 0
. 0

The 0
assay 0
herein 0
described 0
allows 0
the 0
comparison 0
of 0
relative 0
FGFR B-gene
expression 0
levels 0
, 0
both 0
within 0
a 0
single 0
RNA 0
pool 0
and 0
among 0
multiple 0
RNA 0
pool 0
samples 0
. 0

The 0
amount 0
of 0
drained 0
effusion 0
was 0
measured 0
, 0
and 0
fluid 0
was 0
sent 0
for 0
diagnostic 0
assessment 0
. 0

The 0
system 0
, 0
designed 0
to 0
exploit 0
the 0
relatively 0
constant 0
small 0
intestine 0
transit 0
time 0
, 0
consists 0
of 0
a 0
drug 0
- 0
containing 0
core 0
coated 0
with 0
a 0
polymeric 0
matrix 0
formed 0
by 0
a 0
channeling 0
agent 0
( 0
NaCl 0
, 0
mannitol 0
, 0
and 0
Emdex 0
) 0
and 0
an 0
inert 0
polymer 0
( 0
Eudragit 0
RS100 0
) 0
. 0

STUDY 0
OBJECTIVE 0
: 0
This 0
study 0
assessed 0
several 0
methodological 0
aspects 0
related 0
to 0
the 0
quality 0
of 0
published 0
controlled 0
clinical 0
trials 0
( 0
CCTs 0
) 0
in 0
relation 0
to 0
the 0
participation 0
of 0
an 0
epidemiologist/biostatistician 0
( 0
E/B 0
) 0
. 0

The 0
median 0
preoperative 0
best 0
- 0
corrected 0
visual 0
acuity 0
of 0
0.08 0
( 0
range 0
hand 0
motions/0.003 0
to 0
0.4 0
) 0
, 0
improved 0
by 0
5 0
lines 0
to 0
a 0
median 0
final 0
postoperative 0
best 0
- 0
corrected 0
visual 0
acuity 0
of 0
0.25 0
( 0
range 0
0.025 0
- 0
0.5 0
) 0
( 0
P 0
= 0
0.001 0
) 0
. 0

A 0
rare 0
case 0
of 0
primary 0
group 0
A 0
streptococcal 0
peritonitis 0
. 0

Gimpl 0
, 0
F 0
. 0

The 0
present 0
chemotherapy 0
of 0
AE 0
is 0
based 0
on 0
the 0
administration 0
of 0
benzimidazole 0
carbamate 0
derivatives 0
, 0
such 0
as 0
mebendazole 0
and 0
albendazole 0
. 0

Topological 0
and 0
mutational 0
analysis 0
of 0
Saccharomyces B-gene
cerevisiae I-gene
Ste14p I-gene
, 0
founding 0
member 0
of 0
the 0
isoprenylcysteine B-gene
carboxyl I-gene
methyltransferase I-gene
family I-gene
. 0

Hormonal 0
regulation 0
of 0
multiple 0
promoters 0
of 0
the 0
rat B-gene
mitochondrial I-gene
glycerol I-gene
- I-gene
3 I-gene
- I-gene
phosphate I-gene
dehydrogenase I-gene
gene I-gene
: 0
identification 0
of 0
a 0
complex 0
hormone 0
- 0
response 0
element 0
in 0
the 0
ubiquitous 0
promoter 0
B 0
. 0

BACKGROUND/AIMS 0
: 0
Hepatitis 0
C 0
and 0
nonalcoholic 0
fatty 0
liver 0
disease 0
( 0
NAFL 0
) 0
are 0
the 0
two 0
most 0
common 0
forms 0
of 0
liver 0
disease 0
in 0
the 0
United 0
States 0
. 0

Statistical 0
Analysis 0
included 0
ANOVA 0
, 0
the 0
Pearson 0
Product 0
Moment 0
Correlation 0
Coefficient 0
, 0
Principal 0
Components 0
Analysis 0
and 0
Discriminant 0
Function 0
Analysis 0
and 0
the 0
calculation 0
of 0
Cronbach 0
's 0
alpha 0
( 0
alpha 0
) 0
RESULTS 0
: 0
Both 0
Sensitivity 0
and 0
specificity 0
exceed 0
90.00 0
at 0
23/24 0
, 0
Chronbach 0
's 0
alpha 0
for 0
the 0
total 0
scale 0
was 0
equal 0
to 0
0.95 0
. 0

The 0
telomerase B-gene
RNA I-gene
- I-gene
protein I-gene
complex I-gene
responsible 0
for 0
maintenance 0
of 0
telomeric 0
DNA 0
at 0
chromosome 0
ends 0
, 0
is 0
usually 0
inactive 0
in 0
most 0
primary 0
somatic 0
human 0
cells 0
, 0
but 0
is 0
specifically 0
activated 0
with 0
in 0
vitro 0
immortalization 0
and 0
during 0
tumorigenesis 0
. 0

The 0
titer 0
of 0
TSH B-gene
binding I-gene
inhibitor I-gene
immunoglobulin I-gene
( 0
TBII B-gene
) 0
, 0
which 0
had 0
been 0
8.6 0
% 0
at 0
initial 0
presentation 0
, 0
rose 0
to 0
14.9 0
% 0
in 0
2 0
weeks 0
. 0

Our 0
results 0
show 0
that 0
CVN B-gene
specifically 0
recognizes 0
with 0
nanomolar 0
affinity 0
Man 0
( 0
9 0
) 0
GlcNAc 0
( 0
2 0
) 0
and 0
the 0
D1D3 0
isomer 0
of 0
Man 0
( 0
8 0
) 0
GlcNAc 0
( 0
2 0
) 0
. 0

Here 0
we 0
show 0
that 0
independent 0
of 0
uncertainties 0
in 0
the 0
models 0
, 0
terrestrial 0
planets 0
with 0
dense 0
atmosphere 0
like 0
Venus 0
can 0
evolve 0
into 0
one 0
of 0
only 0
four 0
possible 0
rotation 0
states 0
. 0

Enantiomer 0
separation 0
of 0
venlafaxine 0
and 0
O 0
- 0
desmethylvenlafaxine 0
in 0
human 0
plasma 0
. 0

TE 0
- 0
671 0
cells 0
that 0
were 0
transfected 0
with 0
cAMP 0
response 0
element 0
mutant 0
constructs 0
demonstrated 0
a 0
diminished 0
basal 0
activity 0
of 0
the 0
GnRH B-gene
- I-gene
II I-gene
promoter I-gene
. 0

They 0
consist 0
of 0
at 0
least 0
two 0
separable 0
components 0
, 0
one 0
heat 0
stable 0
and 0
the 0
other 0
heat 0
labile 0
. 0

Altogether 0
, 0
we 0
confirm 0
that 0
all 0
genes 0
of 0
the 0
Rad52 B-gene
recombinational 0
repair 0
pathway 0
are 0
required 0
for 0
the 0
survival 0
of 0
rad27 B-gene
Delta I-gene
strains 0
at 0
both 0
permissive 0
( 0
23 0
degrees 0
C 0
) 0
and 0
semipermissive 0
( 0
30 0
degrees 0
C 0
) 0
temperatures 0
for 0
growth 0
. 0

In 0
the 0
last 0
case 0
, 0
both 0
hydroxychloroquine 0
, 0
carbamazepine 0
and 0
fluvoxamine 0
had 0
a 0
common 0
imputability 0
which 0
was 0
plausible 0
. 0

We 0
investigate 0
the 0
reaction 0
kinetics 0
of 0
small 0
spherical 0
particles 0
with 0
inertia 0
, 0
obeying 0
coalescence 0
type 0
of 0
reaction 0
, 0
B+B 0
- 0
- 0
> 0
B 0
, 0
and 0
being 0
advected 0
by 0
hydrodynamical 0
flows 0
with 0
time 0
- 0
periodic 0
forcing 0
. 0

The 0
role 0
of 0
the 0
Vp1 B-gene
DBD I-gene
during 0
infection 0
was 0
investigated 0
by 0
taking 0
advantage 0
of 0
NLS 0
phenotypic 0
complementation 0
( 0
N 0
. 0

2 0
were 0
nonviable 0
, 0
and 0
the 0
mutant B-gene
Vp1s I-gene
unexpectedly 0
failed 0
to 0
localize 0
to 0
the 0
nucleus 0
though 0
Vp2 B-gene
and 0
Vp3 B-gene
did 0
, 0
suggesting 0
that 0
the 0
mutated B-gene
NLS1 I-gene
acted 0
as 0
a 0
dominant 0
signal 0
for 0
the 0
cytoplasmic 0
localization 0
of 0
Vp1 B-gene
. 0

Zhu 0
, 0
V 0
. 0

Fasting 0
gastrin B-gene
levels 0
( 0
normal 0
range 0
: 0
25 0
- 0
110 0
mU/L 0
) 0
varied 0
from 0
48.78 0
mU/L 0
- 0
168.20 0
( 0
mean 0
: 0
85.23 0
mU/L 0
) 0
. 0

Here 0
, 0
we 0
show 0
that 0
the 0
phorbol 0
ester 0
PMA 0
decreases 0
both 0
basal 0
and 0
dexamethasone/cAMP 0
- 0
induced 0
expression 0
of 0
a 0
luciferase B-gene
gene I-gene
under 0
the 0
control 0
of 0
the 0
G6Pase B-gene
promoter I-gene
in 0
transiently 0
transfected 0
H4IIE 0
hepatoma 0
cells 0
. 0

Through 0
deletion 0
mutagenesis 0
, 0
we 0
identify 0
amino 0
acids 0
2003 0
to 0
2212 0
of 0
CBP B-gene
, 0
which 0
we 0
call 0
carboxy 0
- 0
terminal 0
region 0
2 0
( 0
CR2 0
) 0
, 0
as 0
the 0
minimal 0
region 0
for 0
Tax B-gene
interaction 0
. 0

Such 0
knowledge 0
could 0
advance 0
diagnosis 0
and 0
treatment 0
of 0
the 0
patient 0
and 0
counseling 0
of 0
the 0
affected 0
family 0
. 0

BACKGROUND 0
: 0
There 0
is 0
increasing 0
interest 0
on 0
the 0
part 0
of 0
investigators 0
and 0
the 0
public 0
at 0
large 0
in 0
finding 0
ways 0
to 0
study 0
and 0
improve 0
treatments 0
for 0
the 0
seriously 0
mentally 0
ill 0
without 0
exposing 0
such 0
individuals 0
to 0
unnecessary 0
risks 0
. 0

In 0
the 0
next 0
week 0
, 0
the 0
beta 0
- 0
adrenergic 0
antagonist 0
atenolol 0
was 0
added 0
at 0
an 0
initial 0
dose 0
of 0
25 0
mg/day 0
and 0
titrated 0
to 0
50 0
mg/day 0
within 0
1 0
week 0
. 0

Lack 0
of 0
association 0
between 0
Kawasaki 0
syndrome 0
and 0
infection 0
with 0
Rickettsia 0
conorii 0
, 0
Rickettsia 0
typhi 0
, 0
Coxiella 0
burnetii 0
or 0
Ehrlichia 0
phagocytophila 0
group 0
. 0

The 0
presence 0
of 0
AS 0
- 0
oligo 0
had 0
no 0
further 0
effect 0
on 0
the 0
FSH B-gene
- 0
mediated 0
activation 0
of 0
the 0
EB* 0
- 0
mTf B-gene
- 0
CAT B-gene
construct 0
but 0
reduced 0
cAMP 0
- 0
mediated 0
activation 0
. 0

This 0
is 0
a 0
challenging 0
task 0
insofar 0
as 0
direct 0
measures 0
of 0
ISF 0
glucose 0
are 0
not 0
readily 0
available 0
. 0

We 0
report 0
the 0
results 0
of 0
a 0
detailed 0
policy 0
analysis 0
comparing 0
2 0
CJD 0
- 0
related 0
decisions 0
: 0
a 0
1995 0
recall 0
of 0
blood 0
from 0
a 0
donor 0
with 0
classic 0
CJD 0
and 0
the 0
1999 0
decision 0
to 0
defer 0
donations 0
from 0
individuals 0
with 0
a 0
6 0
- 0
month 0
travel 0
history 0
to 0
the 0
UK 0
between 0
1980 0
and 0
1996 0
due 0
to 0
concerns 0
related 0
to 0
variant 0
CJD 0
. 0

The 0
novel 0
approach 0
to 0
insulin B-gene
administration 0
known 0
as 0
chronic 0
intermittent 0
intravenous 0
insulin B-gene
therapy 0
( 0
CIIIT 0
) 0
delivers 0
insulin B-gene
in 0
a 0
pulsatile 0
fashion 0
and 0
achieves 0
physiological 0
insulin B-gene
concentration 0
in 0
the 0
portal 0
vein 0
. 0

At 0
visit 0
5 0
, 0
the 0
isokinetic 0
test 0
showed 0
impaired 0
muscle 0
function 0
recovery 0
from 0
23 0
% 0
to 0
32 0
% 0
, 0
while 0
the 0
manual 0
test 0
showed 0
almost 0
full 0
recovery 0
. 0

We 0
developed 0
a 0
system 0
for 0
domain 0
shuffling 0
to 0
establish 0
the 0
function 0
of 0
C1 B-gene
domains 0
from 0
human B-gene
Raf I-gene
kinase I-gene
and 0
rat B-gene
PKC I-gene
eta I-gene
in 0
yeast 0
. 0

We 0
interpret 0
these 0
data 0
as 0
further 0
evidence 0
that 0
interaction 0
with 0
a 0
small B-gene
GTPase I-gene
is 0
the 0
main 0
regulatory 0
function 0
of 0
the 0
C1 B-gene
domain 0
in 0
yeast 0
. 0

Breast 0
cancer 0
risk 0
assessment 0
: 0
Who 0
holds 0
the 0
magic 0
crystal 0
ball 0
? 0

Patients 0
with 0
type 0
III 0
SOD 0
may 0
have 0
visceral 0
hyperalgesia 0
; 0
a 0
trial 0
of 0
antidepressants 0
or 0
a 0
therapeutic 0
trial 0
with 0
botulinum B-gene
toxin I-gene
injection 0
into 0
the 0
ampulla 0
should 0
be 0
considered 0
prior 0
to 0
more 0
invasive 0
endoscopic 0
therapy 0
. 0

The 0
activity 0
of 0
Rac1 B-gene
leads 0
to 0
STAT3 B-gene
translocation 0
to 0
the 0
nucleus 0
coincident 0
with 0
STAT3 B-gene
- 0
dependent 0
gene 0
expression 0
. 0

RESULTS 0
: 0
There 0
is 0
a 0
considerable 0
amount 0
of 0
variation 0
between 0
the 0
results 0
of 0
TRA1 0
and 0
TRA2 0
and 0
between 0
the 0
results 0
of 0
both 0
TRA 0
's 0
and 0
the 0
door 0
- 0
to 0
- 0
door 0
survey 0
. 0

In 0
addition 0
, 0
these 0
patients 0
show 0
both 0
quantitative 0
and 0
qualitative 0
differences 0
in 0
their 0
infectious 0
microbiological 0
spectrum 0
, 0
mainly 0
in 0
clean 0
- 0
contaminated 0
, 0
contaminated 0
and 0
dirty 0
surgical 0
procedures 0
. 0

CONCLUSION 0
: 0
Extrusion 0
cooking 0
is 0
effective 0
for 0
the 0
inactivation 0
of 0
DON 0
but 0
is 0
of 0
limited 0
value 0
for 0
AFB1 B-gene
, 0
even 0
if 0
metabisulphite 0
is 0
added 0
. 0

The 0
differences 0
in 0
the 0
CPIgG B-gene
, 0
CRP B-gene
, 0
and 0
fibrinogen B-gene
levels 0
in 0
patients 0
who 0
were 0
diagnosed 0
with 0
ACS 0
versus 0
those 0
who 0
were 0
not 0
( 0
non 0
- 0
ACS 0
) 0
were 0
evaluated 0
. 0

NaeI B-gene
, 0
a 0
novel 0
DNA B-gene
endonuclease I-gene
, 0
shows 0
topoisomerase B-gene
and 0
recombinase B-gene
activities 0
when 0
a 0
Lys 0
residue 0
is 0
substituted 0
for 0
Leu 0
43 0
. 0

Mss4 B-gene
also 0
acts 0
as 0
a 0
relatively 0
inefficient 0
guanine B-gene
nucleotide I-gene
exchange I-gene
factor I-gene
( 0
GEF B-gene
) 0
. 0

The 0
decrements 0
in 0
cerebrovascular 0
resistance 0
induced 0
by 0
hexamethonium 0
, 0
in 0
mm 0
Hg 0
ml 0
( 0
- 0
1 0
) 0
.min 0
( 0
- 0
1 0
) 0
, 0
were 0
: 0
under 0
control 0
. 0

The 0
desirability 0
function 0
is 0
based 0
on 0
the 0
search 0
for 0
a 0
global 0
optimum 0
[ 0
D 0
= 0
f 0
( 0
Y1 0
, 0
Y2 0
, 0
... 0
, 0
Yn 0
) 0
] 0
by 0
the 0
transformation 0
of 0
the 0
measured 0
property 0
to 0
a 0
dimensionless 0
scale 0
for 0
each 0
criterion 0
. 0

She 0
has 0
since 0
developed 0
a 0
positive 0
anti B-gene
- I-gene
cardiolipin I-gene
antibody I-gene
but 0
does 0
not 0
meet 0
diagnostic 0
criteria 0
for 0
systemic 0
lupus 0
erythematosis 0
. 0
CONCLUSION 0
: 0
The 0
presence 0
of 0
known 0
autoimmune 0
disease 0
in 0
a 0
woman 0
with 0
POF 0
should 0
not 0
dissuade 0
the 0
clinician 0
from 0
evaluating 0
for 0
a 0
potential 0
genetic 0
cause 0
. 0

RESULTS 0
: 0
In 0
vivo 0
, 0
there 0
was 0
a 0
wide 0
distribution 0
with 0
the 0
coefficient 0
of 0
variation 0
( 0
SD/mean 0
x 0
100 0
% 0
) 0
for 0
different 0
valve 0
sizes 0
ranging 0
from 0
21 0
% 0
to 0
39 0
% 0
in 0
the 0
St 0
Jude 0
Medical 0
valve 0
and 0
from 0
25 0
% 0
to 0
33 0
% 0
in 0
the 0
Omnicarbon 0
valve 0
. 0

Even 0
if 0
the 0
electrocardiographic 0
signs 0
are 0
subdued 0
, 0
the 0
underlying 0
blockade 0
of 0
I 0
( 0
Kr 0
) 0
current 0
may 0
precipitate 0
the 0
occurrence 0
of 0
arrhythmia 0
. 0

Effects 0
of 0
aerosol 0
- 0
vapor 0
JP 0
- 0
8 0
jet 0
fuel 0
on 0
the 0
functional 0
observational 0
battery 0
, 0
and 0
learning 0
and 0
memory 0
in 0
the 0
rat 0
. 0

The 0
production 0
of 0
ceramide 0
is 0
emerging 0
as 0
a 0
fixture 0
of 0
programmed 0
cell 0
death 0
. 0

We 0
randomly 0
assigned 0
1,219 0
subjects 0
to 0
receive 0
either 0
the 0
standard 0
three 0
- 0
times 0
- 0
weekly 0
( 0
TIW 0
) 0
interferon B-gene
alfa I-gene
- I-gene
2b I-gene
dose 0
( 0
3 0
MIU 0
) 0
or 0
the 0
once 0
- 0
weekly 0
( 0
QW 0
) 0
peginterferon B-gene
alfa I-gene
- I-gene
2b I-gene
( 0
0.5 0
, 0
1.0 0
, 0
or 0
1.5 0
microg/kg 0
) 0
. 0

At 0
cross 0
purposes 0
. 0

CONCLUSION 0
: 0
There 0
are 0
no 0
differences 0
in 0
the 0
measurement 0
data 0
derived 0
from 0
this 0
method 0
and 0
actual 0
measurement 0
data 0
from 0
an 0
object 0
created 0
by 0
the 0
computer 0
- 0
aided 0
dental 0
design 0
program 0
. 0

Among 0
the 0
transcription 0
factors 0
known 0
to 0
interact 0
with 0
Groucho B-gene
- I-gene
related I-gene
protein I-gene
, 0
only 0
RUNX1 B-gene
was 0
appreciably 0
downregulated 0
by 0
E2A B-gene
- 0
HLF B-gene
. 0

Many 0
factors 0
do 0
influence 0
the 0
educational 0
outcome 0
in 0
students 0
and 0
large 0
statistical 0
power 0
( 0
such 0
as 0
meta 0
analysis 0
) 0
should 0
be 0
helpful 0
to 0
eliminate 0
many 0
sources 0
of 0
error 0
. 0

The 0
combination 0
of 0
ifosfamide 0
, 0
epirubicin 0
and 0
etoposide 0
( 0
IEV 0
) 0
is 0
an 0
effective 0
salvage 0
regimen 0
for 0
lymphoproliferative 0
disease 0
. 0

A 0
prospective 0
trial 0
was 0
undertaken 0
to 0
determine 0
( 0
1 0
) 0
clinical 0
characteristics 0
of 0
patients 0
with 0
chest 0
pain 0
; 0
( 0
2 0
) 0
value 0
of 0
cardiac 0
markers 0
troponin B-gene
T I-gene
, 0
myoglobin B-gene
and 0
CK B-gene
- 0
MB B-gene
mass 0
in 0
differentiating 0
cardiac 0
and 0
noncardiac 0
chest 0
pain 0
; 0
( 0
3 0
) 0
the 0
proportion 0
of 0
patients 0
with 0
ACS 0
in 0
whom 0
these 0
markers 0
provided 0
helpful 0
additional 0
information 0
on 0
admission 0
and 0
afterwards 0
. 0

Cardiac 0
markers 0
troponin B-gene
T I-gene
, 0
CK B-gene
- 0
MB B-gene
mass 0
and 0
myoglobin B-gene
were 0
helpful 0
in 0
the 0
differential 0
diagnosis 0
of 0
chest 0
pain 0
, 0
even 0
when 0
the 0
ECG 0
was 0
unremarkable 0
or 0
nonspecific 0
. 0

At 0
termination 0
( 0
gd 0
20 0
) 0
, 0
confirmed 0
- 0
pregnant 0
females 0
( 0
21 0
to 0
25 0
per 0
group 0
) 0
were 0
evaluated 0
for 0
clinical 0
status 0
and 0
gestational 0
outcome 0
; 0
live 0
fetuses 0
were 0
examined 0
for 0
external 0
, 0
visceral 0
, 0
and 0
skeletal 0
malformations 0
. 0

One 0
maternal 0
death 0
, 0
reduced 0
body 0
weight 0
, 0
and 0
reduced 0
weight 0
gain 0
were 0
noted 0
at 0
the 0
high 0
dose 0
; 0
confirmed 0
pregnancy 0
rates 0
were 0
84 0
to 0
100 0
% 0
for 0
each 0
group 0
. 0

In 0
the 0
further 0
development 0
of 0
bladder 0
neck 0
suspension 0
according 0
to 0
Stamey 0
- 0
Pereyra 0
, 0
the 0
use 0
of 0
miniature 0
bone 0
anchors 0
received 0
considerable 0
support 0
. 0

Our 0
results 0
demonstrated 0
that 0
50 0
% 0
of 0
the 0
hepatic 0
artery 0
- 0
alone 0
ALT 0
graft 0
showed 0
almost 0
normal 0
structure 0
histologically 0
at 0
1 0
month 0
after 0
grafting 0
, 0
with 0
bile 0
secretion 0
preserved 0
. 0

Simulating 0
the 0
impact 0
during 0
human 0
jumping 0
by 0
means 0
of 0
a 0
4 0
- 0
degrees 0
- 0
of 0
- 0
freedom 0
model 0
with 0
time 0
- 0
dependent 0
properties 0
. 0

A 0
1 0
- 0
base 0
pair 0
mismatch 0
within 0
the 0
corresponding 0
region 0
of 0
the 0
CYP3A4 B-gene
gene I-gene
was 0
sufficient 0
for 0
a 0
differential 0
enhancer 0
activity 0
. 0

The 0
authors 0
made 0
an 0
analysis 0
of 0
social 0
- 0
economical 0
conditions 0
limiting 0
the 0
possibilities 0
of 0
rendering 0
cardiosurgical 0
care 0
to 0
children 0
. 0

METHODS 0
: 0
93 0
female 0
and 0
43 0
male 0
patients 0
undergoing 0
thyroid 0
surgery 0
were 0
stratified 0
according 0
to 0
gender 0
and 0
then 0
randomised 0
to 0
receive 0
double 0
- 0
blind 0
one 0
of 0
four 0
antiemetic 0
regimes 0
: 0
50 0
mg 0
dolasetron 0
given 0
orally 0
45 0
minutes 0
prior 0
to 0
induction 0
of 0
anaesthesia 0
( 0
group 0
I 0
) 0
, 0
12.5 0
mg 0
dolasetron 0
given 0
intravenously 0
during 0
induction 0
of 0
anaesthesia 0
( 0
group 0
II 0
) 0
, 0
1.25 0
mg 0
DHB B-gene
given 0
intravenously 0
during 0
induction 0
of 0
anaesthesia 0
( 0
group 0
III 0
) 0
or 0
placebo 0
( 0
group 0
IV 0
) 0
. 0

This 0
slow 0
progression 0
through 0
the 0
early 0
G1 0
- 0
phase 0
resulted 0
in 0
decreased 0
phosphorylation 0
of 0
the 0
RB B-gene
protein I-gene
and 0
subsequent 0
delay 0
into 0
the 0
S 0
phase 0
transition 0
. 0

In 0
mammals 0
, 0
the 0
transcriptional 0
repressors 0
in 0
the 0
Wnt B-gene
pathway 0
are 0
not 0
well 0
defined 0
. 0

The 0
human B-gene
ABCG1 I-gene
gene I-gene
encodes 0
a 0
member 0
of 0
the 0
ATP B-gene
- I-gene
binding I-gene
cassette I-gene
( 0
ABC B-gene
) 0
superfamily 0
of 0
transporter B-gene
proteins I-gene
and 0
is 0
highly 0
induced 0
when 0
macrophages 0
are 0
incubated 0
with 0
oxysterols 0
. 0

Despite 0
abundant 0
expression 0
of 0
NtmybAS B-gene
transcripts I-gene
in 0
mature 0
pollen 0
, 0
gPAL1 B-gene
transcripts I-gene
were 0
not 0
detectable 0
in 0
pollen 0
. 0

C/EBPbeta B-gene
LIP I-gene
overexpressing 0
HC11 0
cells 0
did 0
not 0
express 0
beta B-gene
- I-gene
casein I-gene
mRNA I-gene
( 0
mammary 0
epithelial 0
cell 0
differentiation 0
marker 0
) 0
in 0
response 0
to 0
lactogenic 0
hormones 0
. 0

Identical 0
effects 0
were 0
obtained 0
when 0
inhibitors 0
and 0
dominant 0
negative 0
mutants 0
were 0
tested 0
on 0
the 0
- 0
29 0
to 0
+139 0
bp 0
region 0
of 0
the 0
cyclin B-gene
D1 I-gene
promoter I-gene
. 0

These 0
findings 0
suggest 0
a 0
novel 0
ankyrin B-gene
- 0
independent 0
role 0
for 0
LAD B-gene
- I-gene
1 I-gene
related 0
to 0
FGFR B-gene
signaling 0
. 0

Moreover 0
, 0
elderly 0
men 0
with 0
bioavailable 0
estradiol 0
levels 0
below 0
the 0
median 0
[ 0
40 0
pmol/liter 0
( 0
11 0
pg/ml 0
) 0
] 0
had 0
significantly 0
higher 0
rates 0
of 0
bone 0
loss 0
and 0
levels 0
of 0
bone 0
resorption 0
markers 0
than 0
men 0
with 0
bioavailable 0
estradiol 0
levels 0
above 0
40 0
pmol/liter 0
. 0

Competition 0
electrophoretic 0
mobility 0
shift 0
and 0
immunoshift 0
assays 0
confirmed 0
that 0
NF1 B-gene
factors I-gene
present 0
in 0
nuclear 0
extracts 0
of 0
HeLa 0
and 0
CV 0
- 0
1 0
cells 0
bind 0
to 0
the 0
BKV B-gene
- I-gene
MLP I-gene
. 0

This 0
study 0
demonstrates 0
that 0
inducible 0
expression 0
in 0
response 0
to 0
either 0
PMA 0
or 0
TPO B-gene
is 0
mediated 0
through 0
the 0
Ets B-gene
site I-gene
in 0
the 0
proximal 0
promoter 0
of 0
GPIX B-gene
and 0
is 0
dependent 0
upon 0
the 0
upstream 0
activation 0
of 0
MAPK/extracellular B-gene
MAPK/extracellular I-gene
signal I-gene
- I-gene
regulated I-gene
kinase I-gene
. 0

RESULTS 0
: 0
The 0
analyzed 0
fragment 0
has 0
significant 0
activity 0
in 0
EpCAM B-gene
positive 0
cells 0
, 0
and 0
it 0
is 0
regulated 0
negatively 0
by 0
tumor B-gene
necrosis I-gene
factor I-gene
alpha I-gene
( 0
TNFalpha B-gene
) 0
. 0

On 0
Cox 0
proportional 0
hazards 0
regression 0
adenocarcinoma 0
( 0
P=0.006 0
) 0
, 0
the 0
development 0
of 0
BPF 0
( 0
P=0.003 0
) 0
, 0
older 0
age 0
( 0
P=0.03 0
) 0
and 0
higher 0
pathological 0
stage 0
( 0
P=0.02 0
) 0
were 0
independent 0
adverse 0
predictors 0
of 0
survival 0
. 0

Phosphatidylinositol B-gene
3 I-gene
- I-gene
kinase I-gene
potentiates 0
, 0
but 0
does 0
not 0
trigger 0
, 0
T 0
cell 0
proliferation 0
mediated 0
by 0
the 0
IL B-gene
- I-gene
2 I-gene
receptor I-gene
. 0

In 0
the 0
stable 0
transfectants 0
( 0
BM3 0
cells 0
) 0
expressing 0
a 0
mutant B-gene
bacterial I-gene
P450 I-gene
AA I-gene
epoxygenase I-gene
, 0
F87V 0
BM3 0
, 0
which 0
was 0
genetically 0
engineered 0
to 0
metabolize 0
arachidonic 0
acid 0
only 0
to 0
14,15 0
- 0
EET 0
, 0
AA 0
did 0
not 0
induce 0
apoptosis 0
and 0
protected 0
against 0
agonist 0
- 0
induced 0
apoptosis 0
. 0

The 0
loop 0
domain 0
of 0
heat B-gene
shock I-gene
transcription I-gene
factor I-gene
1 I-gene
dictates 0
DNA 0
- 0
binding 0
specificity 0
and 0
responses 0
to 0
heat 0
stress 0
. 0

EXAFS 0
measurements 0
around 0
the 0
Ge 0
- 0
K 0
edge 0
have 0
been 0
carried 0
out 0
for 0
liquid 0
Ge 0
- 0
Si 0
alloys 0
for 0
the 0
first 0
time 0
to 0
investigate 0
the 0
local 0
structure 0
around 0
a 0
Ge 0
atom 0
. 0

Progressive 0
study 0
and 0
robustness 0
test 0
of 0
QSAR 0
model 0
based 0
on 0
quantum 0
chemical 0
parameters 0
for 0
predicting 0
BCF 0
of 0
selected 0
polychlorinated 0
organic 0
compounds 0
( 0
PCOCs 0
) 0
. 0

Of 0
the 0
six 0
cases 0
of 0
malignant 0
polyposis 0
, 0
none 0
were 0
identified 0
using 0
CT 0
, 0
and 0
only 0
two 0
were 0
diagnosed 0
by 0
small 0
bowel 0
follow 0
- 0
through 0
. 0

Using 0
the 0
two 0
- 0
hybrid 0
system 0
, 0
we 0
show 0
that 0
nonprenylated 0
Rac1 B-gene
interacts 0
very 0
weakly 0
with 0
Rho B-gene
- I-gene
GDI I-gene
, 0
pointing 0
to 0
the 0
predominant 0
role 0
of 0
protein 0
- 0
isoprene 0
interaction 0
in 0
complex 0
formation 0
. 0

Although 0
metabolized 0
by 0
the 0
cytochrome B-gene
P I-gene
- I-gene
450 I-gene
( 0
CYP B-gene
) 0
system 0
, 0
venlafaxine 0
inhibits 0
CYP B-gene
2D6 I-gene
and I-gene
3A4 I-gene
to 0
a 0
far 0
lesser 0
extent 0
than 0
do 0
the 0
SSRIs 0
. 0

Analysis 0
of 0
the 0
promoter 0
sequence 0
revealed 0
the 0
presence 0
of 0
a 0
major 0
transcriptional 0
start 0
site 0
, 0
a 0
canonical 0
TATA 0
box 0
and 0
putative 0
cis 0
regulatory 0
elements 0
for 0
pituitary 0
specific 0
expression 0
as 0
well 0
as 0
an 0
E 0
- 0
responsive 0
element 0
. 0

Novel 0
intronic 0
promoter 0
in 0
the 0
rat B-gene
ER I-gene
alpha I-gene
gene I-gene
responsible 0
for 0
the 0
transient 0
transcription 0
of 0
a 0
variant 0
receptor 0
. 0

Pitx2 B-gene
rescues 0
the 0
GABAergic 0
differentiation 0
defect 0
and 0
partially 0
rescues 0
the 0
axon 0
guidance 0
and 0
behavioral 0
phenotypes 0
of 0
unc B-gene
- I-gene
30 I-gene
mutants I-gene
, 0
indicating 0
a 0
high 0
degree 0
of 0
functional 0
conservation 0
between 0
these 0
evolutionarily 0
related 0
genes 0
. 0

The 0
patterns 0
of 0
early 0
mRNA 0
and 0
protein 0
expression 0
in 0
these 0
seven 0
mutants 0
were 0
examined 0
, 0
and 0
it 0
was 0
found 0
that 0
mutation 0
of 0
the 0
T B-gene
' I-gene
( I-gene
135 I-gene
) I-gene
acceptor 0
site 0
resulted 0
in 0
the 0
utilization 0
of 0
cryptic 0
splice 0
sites 0
and 0
the 0
generation 0
of 0
new 0
T B-gene
' I-gene
species 0
. 0

Sixty 0
- 0
one 0
cases 0
of 0
cholera 0
, 0
all 0
caused 0
by 0
V. 0
cholerae 0
O1 0
, 0
were 0
reported 0
. 0

Subsequently 0
, 0
these 0
coordinates 0
must 0
be 0
interpreted 0
to 0
define 0
particular 0
tissues 0
and 0
organs 0
. 0

Testing 0
was 0
associated 0
with 0
a 0
history 0
of 0
nonsexual 0
risk 0
behavior 0
, 0
increased 0
knowledge 0
of 0
the 0
hepatitis 0
C 0
virus 0
, 0
and 0
healthcare 0
provider 0
communication 0
. 0

Low 0
- 0
selenium 0
diet 0
has 0
a 0
human 0
unfavourable 0
impact 0
. 0

Thus 0
, 0
BALB/c 0
mice 0
appear 0
to 0
be 0
the 0
most 0
appropriate 0
strain 0
of 0
mice 0
to 0
perform 0
studies 0
on 0
the 0
possible 0
connection 0
between 0
infection 0
with 0
T. 0
canis 0
and 0
allergic 0
asthma 0
. 0

We 0
have 0
previously 0
shown 0
that 0
the 0
adenoviral B-gene
12S I-gene
E1A I-gene
protein I-gene
modulates 0
the 0
phosphorylation 0
status 0
of 0
p130 B-gene
and 0
p107 B-gene
without 0
apparent 0
changes 0
in 0
the 0
cell 0
cycle 0
dependent 0
phosphorylation 0
of 0
the 0
retinoblastoma B-gene
protein I-gene
. 0

The 0
prevalence 0
of 0
tobacco 0
dependence 0
diagnosed 0
according 0
to 0
the 0
ICD 0
- 0
10 0
criteria 0
was 0
higher 0
in 0
alcohol 0
- 0
dependent 0
individuals 0
( 0
58.1 0
% 0
) 0
than 0
in 0
nondrinkers 0
or 0
social 0
drinkers 0
( 0
12.8 0
% 0
) 0
. 0

Diffuse 0
myalgias 0
were 0
more 0
frequent 0
in 0
patients 0
with 0
than 0
without 0
an 0
MMF 0
lesion 0
at 0
deltoid 0
muscle 0
biopsy 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

Furthermore 0
, 0
hormonal 0
regulation 0
of 0
G 0
( 0
1 0
) 0
gene 0
transcription 0
can 0
occur 0
even 0
without 0
additional 0
activation 0
of 0
the 0
Mek B-gene
- 0
Erk1/2 B-gene
pathway 0
by 0
estrogen B-gene
receptors I-gene
. 0

Therefore 0
, 0
to 0
understand 0
how 0
ErbB1/ErbB2 B-gene
signaling 0
contributes 0
to 0
this 0
process 0
, 0
we 0
used 0
the 0
ErbB1/ErbB2 I-gene

This 0
plus 0
the 0
reduced 0
phosphorylation 0
of 0
p27 B-gene
by 0
MAPK B-gene
enhanced 0
the 0
stability 0
of 0
p27 B-gene
that 0
associated 0
with 0
nuclear B-gene
Cdk2 I-gene
at 0
high 0
stoichiometry 0
and 0
inhibited 0
its 0
kinase 0
activity 0
. 0

ICA 0
in 0
the 0
reference 0
solution 0
was 0
characterised 0
by 0
LC 0
and 0
time 0
- 0
of 0
- 0
flight 0
( 0
TOF 0
) 0
MS 0
and 0
quantified 0
by 0
LC 0
chemiluminescent 0
nitrogen 0
detection 0
( 0
LC 0
- 0
CLND 0
) 0
. 0

Forced 0
expression 0
of 0
BZAP45 B-gene
strongly 0
stimulates 0
H4 B-gene
promoter I-gene
( 0
nt 0
- 0
215 0
to 0
- 0
1 0
) 0
/CAT B-gene
reporter 0
gene 0
activity 0
. 0

Local 0
control 0
rates 0
were 0
91 0
% 0
for 0
metastatic 0
lung 0
cancer 0
, 0
89 0
% 0
for 0
primary 0
lung 0
cancer 0
and 0
85 0
% 0
for 0
T1 0
, 0
2N0M0 0
cases 0
. 0

Utility 0
of 0
OAE 0
screener 0
( 0
GSI 0
70 0
) 0
for 0
the 0
evaluation 0
of 0
distortion 0
product 0
otoacoustic 0
emissions 0
] 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
investigate 0
the 0
ability 0
of 0
the 0
OAE 0
screener 0
GSI 0
70 0
to 0
evaluate 0
of 0
cochlea 0
function 0
in 0
neonates 0
, 0
infants 0
and 0
adults 0
. 0

For 0
the 0
sample 0
of 0
systematic 0
reviews 0
drawn 0
from 0
ACP 0
Journal 0
Club 0
( 0
n 0
= 0
103 0
) 0
, 0
the 0
PubMed 0
strategy 0
achieved 0
a 0
sensitivity 0
of 0
97 0
% 0
( 0
CI 0
, 0
91 0
% 0
to 0
99 0
% 0
) 0
. 0

Additionally 0
, 0
a 0
CaCO3 0
- 0
CO2/N2 0
buffered 0
solution 0
was 0
necessary 0
to 0
maintain 0
a 0
pH 0
of 0
8 0
. 0

Inhibition 0
of 0
JNK1 B-gene
and 0
ERK B-gene
kinase 0
activities 0
either 0
by 0
expression 0
of 0
the 0
dominant 0
negative 0
mutant 0
JNK1 B-gene
or 0
by 0
treatment 0
with 0
a 0
selective 0
chemical 0
inhibitor 0
of 0
ERK B-gene
( 0
PD098059 0
) 0
substantially 0
abrogates 0
the 0
UV 0
induction 0
of 0
the 0
GADD45 B-gene
promoter I-gene
. 0

With 0
a 0
GC 0
content 0
of 0
45 0
% 0
the 0
one 0
segment 0
would 0
correspond 0
to 0
`` B-gene
isochore I-gene
H1 I-gene
'' 0
and 0
the 0
other 0
segment 0
( 0
39 0
% 0
GC 0
in 0
human 0
, 0
40 0
% 0
GC 0
in 0
mouse 0
) 0
to 0
`` 0
isochore B-gene
L1/L2 B-gene
'' 0
. 0

Copyright 0
2001 0
S 0
. 0

No 0
mutation 0
of 0
the 0
NRL B-gene
gene I-gene
was 0
found 0
in 0
any 0
of 0
the 0
two 0
families 0
. 0

NF B-gene
- I-gene
kappaB I-gene
is 0
involved 0
in 0
the 0
regulation 0
of 0
CD154 B-gene
( 0
CD40 B-gene
ligand I-gene
) 0
expression 0
in 0
primary 0
human 0
T 0
cells 0
. 0

After 0
nerve 0
injury 0
, 0
the 0
nociceptive 0
responses 0
through 0
type 0
I 0
neurons 0
, 0
which 0
are 0
polymodal 0
C 0
- 0
fibers 0
and 0
drive 0
NK1 B-gene
- I-gene
receptor I-gene
mechanisms 0
in 0
spinal 0
pain 0
transmission 0
, 0
were 0
completely 0
lost 0
, 0
but 0
without 0
changes 0
in 0
type 0
II 0
ones 0
, 0
which 0
are 0
polymodal 0
C 0
- 0
fibers 0
and 0
drive 0
NMDA B-gene
receptor I-gene
- 0
mechanisms 0
, 0
while 0
type 0
III 0
ones 0
, 0
which 0
are 0
capsaicin 0
- 0
insensitive 0
( 0
possibly 0
A 0
- 0
fibers 0
) 0
and 0
drive 0
NMDA B-gene
- I-gene
receptor I-gene
mechanisms 0
, 0
were 0
markedly 0
enhanced 0
. 0

This 0
article 0
reports 0
the 0
design 0
and 0
development 0
of 0
an 0
ECG 0
simulator 0
intended 0
for 0
use 0
in 0
the 0
testing 0
, 0
calibration 0
and 0
maintenance 0
of 0
electrocardiographic 0
equipment 0
. 0

Subacute 0
diencephalic 0
angioencephalopathy 0
( 0
SDAE 0
) 0
is 0
a 0
rare 0
and 0
fatal 0
disease 0
of 0
unknown 0
etiology 0
that 0
involves 0
the 0
thalami 0
bilaterally 0
. 0

Third 0
, 0
consistent 0
with 0
these 0
data 0
, 0
N 0
- 0
acetylcysteine 0
reduced 0
the 0
stimulatory 0
effect 0
of 0
HGF B-gene
on 0
stress B-gene
kinase I-gene
activities 0
, 0
while 0
p42/44 B-gene
mitogen 0
activated 0
kinase 0
( 0
MAPK 0
) 0
was 0
unmodified 0
, 0
suggesting 0
an 0
involvement 0
of 0
c B-gene
- I-gene
Jun I-gene
- I-gene
N I-gene
- I-gene
terminal I-gene
kinase I-gene
( 0
JNK B-gene
) 0
and 0
p38 B-gene
MAPK 0
in 0
HIF B-gene
- I-gene
1 I-gene
activation 0
. 0

Mutation 0
of 0
the 0
octamer 0
element 0
also 0
significantly 0
reduced 0
the 0
ability 0
of 0
HDAC1 B-gene
to 0
confer 0
repression 0
of 0
inducible 0
HLA B-gene
- I-gene
DRA I-gene
promoter I-gene
activation 0
. 0

There 0
was 0
no 0
significant 0
difference 0
in 0
developmental 0
scores 0
at 0
9 0
or 0
18 0
months 0
, 0
although 0
PDF 0
infants 0
had 0
a 0
2.8 0
( 0
- 0
1.3 0
- 0
6.8 0
) 0
point 0
advantage 0
in 0
Bayley 0
motor 0
score 0
scales 0
. 0

In 0
the 0
single 0
case 0
the 0
restoration 0
of 0
a 0
structured 0
daily 0
routine 0
represents 0
the 0
presupposition 0
for 0
a 0
cognitive 0
therapy 0
. 0

However 0
these 0
search 0
engines 0
respond 0
with 0
such 0
cumbersome 0
results 0
that 0
domain 0
specific 0
experts 0
can 0
not 0
tolerate 0
. 0

The 0
binary 0
and 0
tertiary 0
combinations 0
of 0
plant 0
- 0
derived 0
molluscicides 0
Azadirachta 0
indica 0
and 0
Cedrus 0
deodara 0
oil 0
with 0
synergists 0
MGK 0
- 0
264 0
, 0
piperonyl 0
butoxide 0
( 0
PB 0
) 0
and 0
fruit 0
powder 0
of 0
Embelia 0
ribes 0
were 0
used 0
against 0
the 0
Lymnaea 0
acuminata 0
. 0

From 0
the 0
above 0
results 0
, 0
we 0
might 0
infer 0
that 0
the 0
seizure 0
type 0
of 0
TLE 0
and 0
a 0
high 0
frequency 0
of 0
seizure 0
are 0
two 0
major 0
independent 0
precipitate 0
factors 0
for 0
abnormal 0
latencies 0
of 0
P300 0
in 0
the 0
epileptic 0
patients 0
. 0

Audiological 0
findings 0
in 0
pregnancy 0
. 0

The 0
deubiquitinating 0
enzyme 0
DUB B-gene
- I-gene
2 I-gene
is 0
induced 0
in 0
response 0
to 0
IL B-gene
- I-gene
2 I-gene
but 0
as 0
yet 0
its 0
function 0
has 0
not 0
been 0
determined 0
. 0

The 0
isoform 0
, 0
designated 0
HDAC9a B-gene
, 0
is 0
132 0
aa 0
shorter 0
at 0
the 0
C 0
terminus 0
than 0
HDAC9 B-gene
. 0

Pulmonary 0
embolectomy 0
and 0
lung 0
transplantation 0
are 0
the 0
main 0
indications 0
for 0
the 0
use 0
of 0
heart 0
- 0
lung 0
- 0
machine 0
. 0

In 0
such 0
conditions 0
, 0
the 0
following 0
kinetic 0
reactions 0
have 0
been 0
studied 0
: 0
N2 0
( 0
A 0
) 0
+ 0
N2 0
( 0
A 0
) 0
- 0
- 0
> 0
N2 0
( 0
C 0
, 0
B 0
, 0
V 0
' 0
) 0
+ 0
N2 0
( 0
X 0
) 0
, 0
N2 0
( 0
A 0
) 0
+ 0
N2 0
( 0
X 0
, 0
V 0
> 0
5 0
) 0
- 0
- 0
> 0
N2 0
( 0
X 0
) 0
+ 0
N2 0
( 0
B 0
, 0
V 0
' 0
) 0
in 0
pure 0
N2 0
post 0
- 0
discharges 0
and 0
N2 0
( 0
A 0
) 0
+ 0
CH4 0
- 0
- 0
> 0
products 0
, 0
C 0
+ 0
N 0
+ 0
M2 0
- 0
- 0
> 0
CN 0
( 0
B 0
, 0
V 0
' 0
) 0
+ 0
M2 0
, 0
N2 0
( 0
X 0
, 0
V 0
> 0
4 0
) 0
+ 0
CN 0
- 0
- 0
> 0
N2 0
( 0
X 0
) 0
+ 0
CN 0
( 0
B 0
, 0
A 0
, 0
V 0
' 0
) 0
, 0
in 0
N2 0
- 0
1 0
% 0
CH4 0
post 0
- 0
discharges 0
. 0

The 0
NAUSICAA 0
system 0
gives 0
a 0
good 0
knowledge 0
of 0
LET 0
spectra 0
for 0
the 0
first 0
time 0
in 0
space 0
dosimetry 0
. 0

In 0
order 0
to 0
quantify 0
these 0
effects 0
, 0
tests 0
were 0
conducted 0
in 0
the 0
NASA 0
MSFC 0
Neutral 0
Buoyancy 0
Simulator 0
, 0
in 0
the 0
NASA 0
KC 0
- 0
135 0
in 0
parabolic 0
flight 0
, 0
and 0
in 0
space 0
with 0
the 0
EASE 0
program 0
during 0
the 0
Shuttle 0
Atlantis 0
mission 0
61 0
- 0
B 0
. 0

This 0
article 0
comparatively 0
evaluates 0
five 0
Generic 0
Systems 0
that 0
describe 0
the 0
basic 0
alternatives 0
to 0
composting 0
facility 0
design 0
and 0
control 0
. 0

Different 0
thermoluminescent 0
detectors 0
( 0
TLD 0
) 0
have 0
been 0
used 0
to 0
measure 0
the 0
contribution 0
of 0
the 0
low 0
linear 0
energy 0
transfer 0
component 0
( 0
LET 0
< 0
10 0
keV/micrometer 0
) 0
and 0
plastic 0
nuclear 0
track 0
detectors 0
( 0
PNTD 0
) 0
for 0
the 0
high 0
linear 0
energy 0
tranfer 0
( 0
LET 0
) 0
component 0
. 0

Responses 0
of 0
TLD 0
Mg2SiO4 0
: 0
Tb 0
and 0
radiophotoluminescent 0
glass 0
to 0
heavy 0
charged 0
particles 0
and 0
space 0
radiation 0
. 0

The 0
absorbed 0
dose 0
was 0
measured 0
by 0
combination 0
of 0
two 0
integrating 0
detectors 0
: 0
thermo 0
- 0
luminescent 0
dosemeter 0
of 0
Mg2SiO4 0
: 0
Tb 0
( 0
TDMS 0
) 0
and 0
plastic 0
nuclear 0
track 0
detector 0
( 0
PNTD 0
) 0
. 0

Six 0
of 0
the 0
gstC B-gene
' I-gene
mutants I-gene
, 0
primarily 0
in 0
the 0
C 0
- 0
terminal 0
half 0
of 0
C B-gene
' I-gene
, 0
exhibited 0
a 0
defect 0
in 0
the 0
ability 0
to 0
bind 0
L B-gene
protein I-gene
. 0

Thus 0
, 0
while 0
the 0
folds 0
of 0
all 0
Myb B-gene
domains I-gene
resemble 0
each 0
other 0
closely 0
, 0
the 0
function 0
of 0
each 0
Myb B-gene
domain I-gene
depends 0
on 0
the 0
amino 0
acid 0
residues 0
that 0
are 0
located 0
on 0
the 0
surface 0
of 0
each 0
protein 0
. 0

METHODS 0
: 0
Experiments 0
testing 0
the 0
new 0
catheter 0
and 0
comparing 0
it 0
to 0
the 0
existing 0
catheter 0
included 0
: 0
( 0
1 0
) 0
measurement 0
of 0
the 0
laser 0
output 0
beam 0
sizes 0
and 0
divergences 0
; 0
( 0
2 0
) 0
evaluation 0
of 0
particulate 0
matter 0
generation 0
during 0
ablation 0
of 0
atherosclerotic 0
tissue 0
; 0
( 0
3 0
) 0
measurement 0
of 0
ablation 0
hole 0
sizes 0
and 0
tissue 0
penetration 0
rates 0
; 0
( 0
4 0
) 0
histopathologic 0
examination 0
of 0
laser 0
- 0
induced 0
in 0
vivo 0
vessel 0
wall 0
injury 0
. 0

A 0
proposal 0
of 0
50 0
performance 0
indicators 0
divided 0
into 0
five 0
different 0
groups 0
is 0
presented 0
here 0
, 0
namely 0
structural 0
indicators 0
, 0
operational 0
indicators 0
, 0
water 0
and 0
service 0
quality 0
indicators 0
, 0
personnel 0
indicators 0
and 0
economic 0
indicators 0
. 0

Overexpression 0
of 0
RORgamma B-gene
has 0
been 0
shown 0
to 0
inhibit 0
T B-gene
cell I-gene
receptor I-gene
- 0
mediated 0
apoptosis 0
in 0
T 0
cell 0
hybridomas 0
and 0
to 0
repress 0
the 0
induction 0
of 0
Fas B-gene
- I-gene
ligand I-gene
and 0
interleukin B-gene
2 I-gene
. 0

Once 0
ICP 0
reaches 0
critical 0
values 0
( 0
> 0
30 0
mm 0
Hg 0
) 0
herniation 0
occurs 0
, 0
usually 0
within 0
2 0
to 0
5 0
days 0
. 0

Other 0
therapies 0
are 0
also 0
available 0
, 0
including 0
hypertonic 0
saline 0
solution 0
, 0
THAM 0
( 0
Tris 0
- 0
hydroxy 0
- 0
methyl 0
- 0
aminomethane 0
) 0
buffer 0
, 0
and 0
high 0
- 0
dose 0
barbiturates 0
. 0

CONCLUSIONS 0
: 0
ChromaFlo 0
- 0
enhanced 0
IVUS 0
demonstrates 0
colorized 0
blood 0
flow 0
inside 0
the 0
vessel 0
lumen 0
, 0
which 0
is 0
helpful 0
in 0
distinguishing 0
echolucent 0
disease 0
from 0
luminal 0
blood 0
flow 0
and 0
can 0
also 0
be 0
used 0
to 0
perform 0
peripheral 0
interventions 0
in 0
patients 0
with 0
renal 0
failure 0
or 0
allergy 0
, 0
avoiding 0
the 0
use 0
of 0
contrast 0
media 0
. 0

CYP2C19 B-gene
genotype I-gene
was 0
determined 0
by 0
the 0
polymerase 0
chain 0
reaction 0
- 0
restriction 0
fragment 0
length 0
polymorphism 0
method 0
. 0

The 0
results 0
indicate 0
that 0
a 0
more 0
differentiated 0
diagnosis 0
of 0
the 0
molar 0
relationship 0
will 0
allow 0
for 0
a 0
more 0
causally 0
directed 0
correction 0
of 0
Class 0
II 0
molar 0
relationship 0
. 0

Similar 0
data 0
were 0
also 0
obtained 0
when 0
either 0
dominant 0
negative 0
EGFR B-gene
- 0
CD533 B-gene
or 0
dominant B-gene
negative I-gene
Ras I-gene
N17 I-gene
were 0
used 0
to 0
block 0
MAPK B-gene
activation 0
. 0

These 0
analyses 0
re 0
- 0
open 0
the 0
question 0
whether 0
all 0
the 0
CesA B-gene
genes I-gene
encode 0
cellulose B-gene
synthases I-gene
or 0
whether 0
some 0
of 0
the 0
sub 0
- 0
class 0
members 0
may 0
encode 0
other 0
non B-gene
- I-gene
cellulosic I-gene
( I-gene
1 I-gene
- I-gene
- I-gene
> I-gene
4 I-gene
) I-gene
beta I-gene
- I-gene
glycan I-gene
synthases I-gene
in 0
plants 0
. 0

The 0
hatcher 0
incubators 0
of 0
both 0
companies 0
were 0
also 0
persistently 0
contaminated 0
with 0
Salmonella 0
livingstone 0
and 0
Salmonella 0
thomasville 0
in 0
company 0
A 0
and 0
with 0
Salmonella 0
senftenberg 0
in 0
company 0
B 0
. 0

At 0
both 0
companies 0
sites 0
Salmonella 0
enteritidis 0
and 0
Salmonella 0
typhimurium 0
Tr104 0
were 0
also 0
isolated 0
occasionally 0
from 0
various 0
locations 0
. 0

The 0
mutation 0
experiments 0
showed 0
that 0
the 0
most 0
critical 0
sequence 0
for 0
the 0
repression 0
of 0
PTH B-gene
was 0
5' 0
- 0
GGGGGAGGGGAG 0
- 0
3 0
' 0
( 0
+1 0
to 0
+12 0
) 0
of 0
PTHSR B-gene
. 0

Cardiac 0
output 0
at 0
anaerobic 0
threshold 0
( 0
COAT 0
) 0
< 0
or 0
= 0
7.3 0
L/min 0
was 0
the 0
best 0
cutoff 0
value 0
for 0
identifying 0
multivessel 0
coronary 0
artery 0
disease 0
( 0
relative 0
risk 0
, 0
3.1 0
) 0
. 0

Experience 0
with 0
xylene 0
- 0
free 0
sections 0
since 0
1995 0
at 0
the 0
Vrinnevi 0
Hospital 0
is 0
favorable 0
. 0

A 0
randomized 0
mix 0
of 0
180 0
sections 0
( 0
10 0
samples 0
x 0
3 0
tissues 0
x 0
3 0
stains 0
x 0
2 0
) 0
gave 0
90 0
matched 0
pairs 0
. 0

Interestingly 0
, 0
the 0
CYP71D20 B-gene
- I-gene
encoded I-gene
enzyme I-gene
activity 0
was 0
capable 0
of 0
converting 0
both 0
5 0
- 0
epi 0
- 0
aristolochene 0
and 0
1 0
- 0
deoxycapsidiol 0
to 0
capsidiol 0
in 0
vitro 0
, 0
consistent 0
with 0
the 0
notion 0
that 0
this 0
P450 B-gene
enzyme I-gene
catalyzes 0
both 0
hydroxylations 0
of 0
its 0
hydrocarbon 0
substrate 0
. 0

In 0
conclusion 0
, 0
NF B-gene
- I-gene
Y I-gene
and 0
Sp1 B-gene
binding 0
sites 0
play 0
a 0
decisive 0
role 0
in 0
the 0
basal 0
expression 0
of 0
the 0
rat B-gene
mrp2 I-gene
gene I-gene
, 0
while 0
the 0
human B-gene
MRP2 I-gene
gene I-gene
is 0
regulated 0
differently 0
. 0

E2F1 B-gene
- 0
mediated 0
transcriptional 0
inhibition 0
of 0
the 0
plasminogen B-gene
activator I-gene
inhibitor I-gene
type I-gene
1 I-gene
gene I-gene
. 0

Transcriptional 0
regulation 0
of 0
the 0
estrogen 0
- 0
inducible 0
pS2 B-gene
breast B-gene
cancer I-gene
marker I-gene
gene I-gene
by 0
the 0
ERR B-gene
family I-gene
of 0
orphan B-gene
nuclear I-gene
receptors I-gene
. 0

NB 0
- 0
506 0
completely 0
inhibits 0
the 0
capacity 0
of 0
topoisomerase B-gene
I I-gene
to 0
phosphorylate 0
, 0
in 0
vitro 0
, 0
the 0
human B-gene
splicing I-gene
factor I-gene
2/alternative I-gene
2/alternative I-gene
splicing I-gene
factor I-gene
( 0
SF2/ASF B-gene
) 0
. 0

However 0
, 0
during 0
our 0
work 0
with 0
a 0
replication 0
- 0
deficient 0
virus 0
expressing 0
the 0
ASF/SF2 B-gene
splicing 0
factor 0
from 0
a 0
progesterone 0
antagonist 0
- 0
inducible 0
gene 0
cassette 0
, 0
we 0
discovered 0
that 0
ASF/SF2 I-gene

DNA 0
binding 0
assays 0
confirmed 0
the 0
interference 0
of 0
p30 B-gene
( I-gene
II I-gene
) I-gene
with 0
the 0
assembly 0
of 0
CREB B-gene
- 0
Tax B-gene
- 0
p300/CBP B-gene
multiprotein 0
complexes 0
on 0
21 0
- 0
bp 0
repeat 0
oligonucleotides 0
in 0
vitro 0
. 0

Using 0
the 0
presented 0
categorical 0
structure 0
as 0
domain 0
model 0
a 0
prototype 0
DSS 0
for 0
dipslide 0
urine 0
cultures 0
has 0
been 0
developed 0
. 0

DNA 0
recognition 0
by 0
F B-gene
factor I-gene
TraI36 B-gene
: 0
highly 0
sequence 0
- 0
specific 0
binding 0
of 0
single 0
- 0
stranded 0
DNA 0
. 0

E47 B-gene
protein I-gene
levels 0
remain 0
high 0
until 0
the 0
double 0
positive 0
developmental 0
stage 0
, 0
at 0
which 0
point 0
they 0
drop 0
to 0
relatively 0
moderate 0
levels 0
, 0
and 0
are 0
further 0
downregulated 0
upon 0
transition 0
to 0
the 0
single 0
positive 0
stage 0
. 0

The 0
dual 0
specificity 0
kinases 0
mitogen B-gene
- I-gene
activated I-gene
protein I-gene
kinase I-gene
( I-gene
MAPK I-gene
) I-gene
kinase I-gene
( I-gene
MKK I-gene
) I-gene
7 I-gene
and 0
MKK4 B-gene
are 0
the 0
only 0
molecules 0
known 0
to 0
directly 0
activate 0
the 0
stress 0
kinases 0
stress B-gene
- I-gene
activated I-gene
protein I-gene
kinases I-gene
( 0
SAPKs B-gene
) 0
/c B-gene
- I-gene
Jun I-gene
N I-gene
- I-gene
terminal I-gene
kinases I-gene
( 0
JNKs B-gene
) 0
in 0
response 0
to 0
environmental 0
or 0
mitogenic 0
stimuli 0
. 0

SAPK/JNK B-gene
activation 0
was 0
completely 0
abolished 0
in 0
the 0
absence 0
of 0
SAPK/JNK I-gene

Thus 0
, 0
MKK7 B-gene
is 0
an 0
essential 0
and 0
specific 0
regulator 0
of 0
stress 0
- 0
induced 0
SAPK/JNK B-gene
activation 0
in 0
mast 0
cells 0
and 0
SAPK/JNK I-gene

The 0
small 0
copepod 0
Pseudonychocamptus 0
proximus 0
progressively 0
replaced 0
the 0
large 0
Tisbe 0
furcata 0
in 0
sand 0
filters 0
during 0
the 0
fall 0
of 0
1995 0
and 0
was 0
responsible 0
for 0
the 0
large 0
increase 0
in 0
meiofaunal 0
biomass 0
observed 0
after 0
spring 0
1996 0
. 0

When 0
mixed 0
with 0
aqueous 0
solutions 0
of 0
TMT 0
- 0
55 0
, 0
aqueous 0
solutions 0
of 0
either 0
reagent 0
- 0
grade 0
zinc 0
, 0
cadmium 0
, 0
or 0
lead 0
salts 0
precipitate 0
crystalline 0
`` 0
Zn 0
- 0
TMT 0
'' 0
, 0
amorphous 0
or 0
crystalline 0
`` 0
Cd 0
- 0
TMT 0
'' 0
or 0
amorphous 0
`` 0
Pb 0
- 0
TMT 0
'' 0
( 0
M3 0
[ 0
S3C3N3 0
] 0
2.nH2O 0
, 0
where 0
M=Cd2+ 0
, 0
Pb2+ 0
, 0
and 0
Zn2+ 0
and 0
n 0
> 0
or 0
= 0
0 0
) 0
that 0
may 0
eventually 0
crystallize 0
if 0
stored 0
in 0
air 0
. 0

Many 0
of 0
the 0
important 0
genes 0
associated 0
with 0
G1 0
regulation 0
have 0
been 0
shown 0
to 0
play 0
a 0
key 0
role 0
in 0
proliferation 0
, 0
differentiation 0
and 0
oncogenic 0
transformation 0
and 0
programmed 0
cell 0
death 0
( 0
apoptosis 0
) 0
. 0

The 0
probability 0
of 0
treatment 0
with 0
lamotrigine 0
being 0
maintained 0
for 0
six 0
months 0
was 0
86 0
% 0
, 0
for 0
twelve 0
months 0
61 0
% 0
and 0
for 0
three 0
years 0
31 0
% 0
. 0

These 0
results 0
indicate 0
the 0
presence 0
of 0
TATA 0
- 0
unified 0
transcription 0
systems 0
in 0
contemporary 0
eukaryotes 0
and 0
provide 0
insight 0
into 0
the 0
residual 0
need 0
for 0
TBP B-gene
by 0
all 0
three 0
Pols B-gene
in 0
other 0
eukaryotes 0
despite 0
a 0
lack 0
of 0
TATA 0
elements 0
in 0
their 0
promoters 0
. 0

Thus 0
, 0
through 0
a 0
change 0
in 0
conformation 0
upon 0
repair 0
of 0
the 0
6RG 0
lesion 0
, 0
MGMT B-gene
switches 0
from 0
a 0
DNA 0
repair 0
factor 0
to 0
a 0
transcription 0
regulator 0
( 0
R B-gene
- I-gene
MGMT I-gene
) 0
, 0
enabling 0
the 0
cell 0
to 0
sense 0
as 0
well 0
as 0
respond 0
to 0
mutagens 0
. 0

Data 0
from 0
in 0
vitro 0
splicing 0
assays 0
, 0
UV 0
crosslinking 0
and 0
RNA 0
- 0
binding 0
competition 0
experiments 0
indicates 0
a 0
strong 0
correlation 0
between 0
the 0
binding 0
affinities 0
of 0
PSI B-gene
for 0
the 0
SELEX 0
sequences 0
and 0
their 0
ability 0
to 0
modulate 0
splicing 0
of 0
P B-gene
element I-gene
IVS3 B-gene
in 0
vitro 0
. 0

A 0
split 0
motor 0
domain 0
in 0
a 0
cytoplasmic B-gene
dynein I-gene
. 0

In 0
hypertensive 0
nephrosclerosis 0
, 0
therapy 0
containing 0
an 0
ACEI 0
alone 0
or 0
in 0
combination 0
significantly 0
reduces 0
the 0
incidence 0
of 0
renal 0
events 0
. 0

Body 0
weight 0
reduction 0
increases 0
insulin B-gene
sensitivity 0
and 0
improves 0
both 0
blood 0
glucose 0
and 0
blood 0
pressure 0
control 0
. 0

Here 0
we 0
suggest 0
that 0
uvrA B-gene
and 0
the 0
nucleotide 0
excision 0
repair 0
pathway 0
are 0
involved 0
in 0
the 0
repair 0
of 0
acid 0
- 0
induced 0
DNA 0
damage 0
and 0
are 0
associated 0
with 0
successful 0
adaptation 0
of 0
S. 0
mutans 0
to 0
low 0
pH 0
. 0

The 0
best 0
regression 0
model 0
for 0
predicting 0
changes 0
in 0
the 0
WCXR 0
included 0
time 0
to 0
first 0
positive 0
culture 0
and 0
antibody 0
titer 0
for 0
Pa B-gene
elastase I-gene
. 0

Temperature 0
measurement 0
in 0
microfluidic 0
systems 0
using 0
a 0
temperature 0
- 0
dependent 0
fluorescent 0
dye 0
. 0

APC B-gene
- 0
resistance 0
was 0
determined 0
with 0
a 0
functional 0
method 0
with 0
high 0
sensitivity 0
and 0
specificity 0
for 0
the 0
factor B-gene
V I-gene
Leiden I-gene
mutation I-gene
. 0

Zarix 0
expected 0
patient 0
enrollment 0
in 0
Canadian 0
clinical 0
sites 0
to 0
begin 0
in 0
Spring 0
2001 0
[ 0
397955 0
] 0
, 0
[ 0
405928 0
] 0
. 0

RESULTS 0
: 0
The 0
subjects 0
in 0
the 0
augmented 0
feedback 0
group 0
significantly 0
reduced 0
their 0
peak 0
vertical 0
ground 0
reaction 0
force 0
in 0
both 0
post 0
- 0
test 0
conditions 0
( 0
2 0
- 0
minute 0
post 0
- 0
test 0
reduction 0
, 0
0.85+/ 0
- 0
0.62 0
; 0
1 0
- 0
week 0
post 0
- 0
test 0
reduction 0
, 0
0.74+/ 0
- 0
0.58 0
) 0
as 0
compared 0
to 0
the 0
sensory 0
, 0
control 0
I 0
, 0
and 0
control 0
II 0
feedback 0
groups 0
. 0

Four 0
casein B-gene
kinase I-gene
I I-gene
isoforms I-gene
are 0
differentially 0
partitioned 0
between 0
nucleus 0
and 0
cytoplasm 0
. 0

Use 0
of 0
a 0
dual 0
- 0
pulse 0
lithotripter 0
to 0
generate 0
a 0
localized 0
and 0
intensified 0
cavitation 0
field 0
. 0

This 0
paper 0
describes 0
the 0
results 0
of 0
an 0
initial 0
study 0
on 0
the 0
application 0
of 0
linear 0
solvation 0
energy 0
relationships 0
( 0
LSERs 0
) 0
to 0
the 0
prediction 0
of 0
internal 0
standard 0
compounds 0
in 0
reversed 0
- 0
phase 0
liquid 0
chromatographic 0
( 0
RPLC 0
) 0
method 0
development 0
. 0

When 0
the 0
blood 0
clot 0
is 0
formed 0
in 0
the 0
vitreous 0
cavity 0
, 0
intravitreal 0
injection 0
of 0
t B-gene
- I-gene
PA I-gene
can 0
convert 0
plasminogen B-gene
to 0
plasmin B-gene
and 0
remove 0
the 0
clot 0
. 0

Management 0
of 0
postvitrectomy 0
diabetic 0
vitreous 0
hemorrhage 0
with 0
tissue B-gene
plasminogen I-gene
activator I-gene
( 0
t B-gene
- I-gene
PA I-gene
) 0
and 0
volume 0
homeostatic 0
fluid 0
- 0
fluid 0
exchanger 0
. 0

Effect 0
of 0
heat 0
treatments 0
on 0
the 0
meltability 0
of 0
cheeses 0
. 0

RESULTS 0
: 0
Sixty 0
per 0
cent 0
of 0
African 0
Americans 0
exposed 0
in 0
26 0
community 0
outbreaks 0
were 0
TST 0
positive 0
compared 0
to 0
only 0
40 0
% 0
of 0
whites 0
following 0
comparable 0
exposures 0
. 0

The 0
mean 0
waiting 0
time 0
to 0
receive 0
the 0
pancreas 0
transplant 0
was 0
244 0
days 0
for 0
SPK 0
and 0
167 0
days 0
for 0
PAK 0
recipients 0
( 0
P 0
= 0
0.001 0
) 0
. 0

Patients 0
with 0
antibody 0
peaks 0
, 0
defined 0
as 0
fivefold 0
or 0
higher 0
increase 0
in 0
antibody 0
titer 0
compared 0
to 0
the 0
lowest 0
antibody 0
titer 0
over 0
the 0
course 0
of 0
GBS 0
, 0
had 0
higher 0
disability 0
scores 0
during 0
the 0
first 0
two 0
weeks 0
of 0
GBS 0
and 0
a 0
worse 0
clinical 0
outcome 0
( 0
anti B-gene
- I-gene
GM1 I-gene
IgG I-gene
and 0
anti B-gene
- I-gene
GD1a I-gene
IgM I-gene
antibody I-gene
peaks 0
) 0
and 0
axonal 0
damage 0
( 0
anti B-gene
- I-gene
GD1a I-gene
IgM I-gene
antibody I-gene
peaks 0
) 0
, 0
compared 0
to 0
patients 0
without 0
peak 0
antibody 0
titers 0
. 0

Following 0
baseline 0
clinical 0
examination 0
and 0
initial 0
periodontal 0
therapy 0
, 0
32 0
patients 0
received 0
mucogingival 0
surgery 0
with 0
free 0
gingival 0
grafts 0
for 0
treatment 0
of 0
insufficient 0
attached 0
gingiva 0
. 0

However 0
, 0
patients 0
with 0
isolated 0
office 0
hypertension 0
had 0
fewer 0
previous 0
cardiovascular 0
complications 0
. 0

In 0
the 0
TVD 0
- 0
patients 0
decreases 0
in 0
skin 0
blood 0
flow 0
were 0
similar 0
compared 0
with 0
the 0
healthy 0
controls 0
. 0

2 0
: 0
The 0
dynamic 0
moduli 0
of 0
microcrystalline 0
cellulose 0
. 0

These 0
findings 0
suggest 0
that 0
an 0
intracellular 0
WT B-gene
- I-gene
1/HSAL2 I-gene
pathway 0
may 0
play 0
a 0
role 0
in 0
development 0
and 0
hematopoiesis 0
. 0

ICAM B-gene
- I-gene
1 I-gene
has 0
been 0
suggested 0
a 0
predictor 0
of 0
the 0
onset 0
of 0
GO 0
. 0

Phosphotyrosyl 0
peptides 0
block 0
Stat3 B-gene
- 0
mediated 0
DNA 0
binding 0
activity 0
, 0
gene 0
regulation 0
, 0
and 0
cell 0
transformation 0
. 0

Plane 0
wave 0
geometry 0
is 0
impractical 0
for 0
clinical 0
use 0
but 0
the 0
results 0
of 0
this 0
work 0
encouraged 0
us 0
to 0
further 0
develop 0
the 0
P3 0
approximation 0
for 0
a 0
spherical 0
geometry 0
, 0
described 0
in 0
this 0
paper 0
. 0

The 0
diagnosis 0
of 0
HCV 0
arthritis 0
in 0
patients 0
with 0
positive 0
rheumatoid B-gene
factor I-gene
and 0
chronic 0
inflammatory 0
polyarthritis 0
may 0
be 0
difficult 0
. 0

METHODS 0
: 0
We 0
retrospectively 0
selected 0
13 0
TFCD 0
patients 0
who 0
underwent 0
surgery 0
for 0
intractable 0
epilepsy 0
with 0
the 0
aim 0
of 0
removing 0
the 0
magnetic 0
resonance 0
( 0
MR 0
) 0
- 0
detectable 0
lesion 0
and/or 0
the 0
epileptogenic 0
zone 0
defined 0
by 0
stereoelectroencephalographic 0
recordings 0
. 0

RESULTS 0
: 0
At 0
latest 0
examination 0
, 0
mean 0
UPDRS 0
II 0
and 0
III 0
scores 0
had 0
improved 0
by 0
30 0
% 0
( 0
on 0
stimulation 0
, 0
off 0
therapy 0
) 0
with 0
mean 0
50 0
% 0
reduction 0
in 0
daily 0
off 0
time 0
. 0

In 0
Exp 0
. 0

Several 0
distinct 0
apoptotic 0
stimuli 0
induce 0
the 0
expression 0
and 0
caspase B-gene
- 0
dependent 0
cleavage 0
of 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
80 I-gene
delta I-gene
. 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
80 I-gene
delta I-gene
, 0
unlike 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
80 I-gene
, 0
forms 0
a 0
TFIID B-gene
- I-gene
like I-gene
complex I-gene
lacking 0
hTAF B-gene
( I-gene
II I-gene
) I-gene
31 I-gene
. 0

Endovascular 0
aneurysm 0
repair 0
with 0
the 0
AneuRx 0
stent 0
- 0
graft 0
is 0
safe 0
, 0
but 0
is 0
it 0
effective 0
? 0

Chronic 0
nutritional 0
diseases 0
of 0
infectious 0
origin 0
: 0
an 0
assessment 0
of 0
a 0
nascent 0
field 0
. 0

Drug 0
interactions 0
have 0
been 0
found 0
with 0
drugs 0
that 0
compete 0
for 0
the 0
same 0
CYP450 B-gene
isoenzymes I-gene
as 0
statins 0
. 0

METHODS 0
: 0
We 0
studied 0
the 0
clinical 0
benefit 0
of 0
depth 0
- 0
dependent 0
RR 0
, 0
nonuniform 0
AC 0
using 0
a 0
scanning 0
line 0
source 0
, 0
and 0
scatter 0
correction 0
( 0
photon 0
energy 0
recovery 0
[ 0
PER 0
] 0
) 0
compared 0
with 0
filtered 0
backprojection 0
alone 0
. 0

Because 0
of 0
differences 0
in 0
patient 0
characteristics 0
, 0
control 0
measurements 0
were 0
obtained 0
from 0
normal 0
muscle 0
in 0
all 0
patients 0
. 0

However 0
, 0
the 0
abi1 B-gene
- I-gene
1 I-gene
gene I-gene
product I-gene
has 0
no 0
effect 0
on 0
the 0
ABA 0
suppression 0
of 0
a 0
GA 0
- 0
responsive 0
alpha B-gene
- I-gene
amylase I-gene
gene I-gene
. 0

In 0
children 0
unable 0
to 0
perform 0
forced 0
expiratory 0
maneuvers 0
( 0
n 0
= 0
25 0
) 0
, 0
FOT 0
, 0
contrary 0
to 0
the 0
interrupter 0
technique 0
, 0
clearly 0
identified 0
a 0
subgroup 0
of 0
young 0
children 0
with 0
high 0
resistance 0
values 0
at 0
baseline 0
, 0
which 0
returned 0
to 0
normal 0
after 0
bronchodilation 0
. 0

In 0
budding 0
yeast 0
, 0
this 0
latter 0
checkpoint 0
response 0
involves 0
the 0
proteins 0
Mad1 B-gene
, I-gene
2 I-gene
, I-gene
3 I-gene
, 0
Bub1 B-gene
and 0
Bub3 B-gene
, 0
whose 0
vertebrate 0
counterparts 0
localize 0
to 0
unattached 0
kinetochores 0
. 0

HTLV 0
- 0
1 0
decreases 0
Th2 0
type 0
of 0
immune 0
response 0
in 0
patients 0
with 0
strongyloidiasis 0
. 0

However 0
, 0
the 0
beta5L 0
splice 0
variant 0
was 0
found 0
only 0
in 0
the 0
retina 0
. 0

PROCEDURE 0
: 0
Cannulas 0
were 0
surgically 0
positioned 0
in 0
the 0
abomasal 0
body 0
and 0
pyloric 0
antrum 0
of 0
each 0
calf 0
. 0

METHODS 0
: 0
Humphrey 0
Field 0
Analyzer 0
model 0
630 0
( 0
HFA 0
I 0
, 0
program 0
30 0
- 0
2 0
with 0
a 0
rectangular 0
6 0
degrees 0
x 0
6 0
degrees 0
grid 0
) 0
was 0
used 0
as 0
the 0
conventional 0
perimetric 0
method 0
. 0

Transforming B-gene
growth I-gene
factor I-gene
- I-gene
beta I-gene
( 0
TGF B-gene
- I-gene
beta I-gene
) 0
induced 0
growth 0
arrest 0
of 0
cells 0
involves 0
regulation 0
of 0
the 0
activities 0
of 0
both 0
D B-gene
- I-gene
and I-gene
E I-gene
- I-gene
type I-gene
cyclin I-gene
kinase I-gene
complexes I-gene
thought 0
to 0
be 0
mediated 0
primarily 0
by 0
the 0
regulation 0
of 0
p15 B-gene
( 0
Ink4b B-gene
) 0
and 0
p27 B-gene
( 0
Kip1 B-gene
) 0
cyclin 0
kinase 0
inhibitors 0
. 0

Alignment 0
of 0
different 0
cDNAs 0
of 0
the 0
NR5A2 B-gene
( 0
hB1F B-gene
) 0
gene 0
with 0
the 0
genomic 0
sequence 0
facilitated 0
the 0
delineation 0
of 0
its 0
structural 0
organization 0
, 0
which 0
spans 0
over 0
150 0
kb 0
and 0
consists 0
of 0
eight 0
exons 0
interrupted 0
by 0
seven 0
introns 0
. 0

The 0
genomic 0
structure 0
of 0
the 0
human B-gene
SPEC1 I-gene
gene I-gene
reveals 0
complex 0
splicing 0
and 0
close 0
promoter 0
proximity 0
to 0
the 0
AF1q B-gene
translocation I-gene
gene I-gene
. 0

Hp 0
positive 0
relatives 0
of 0
gastric 0
cancer 0
had 0
a 0
markedly 0
higher 0
prevalence 0
of 0
atrophy 0
than 0
those 0
with 0
Hp 0
negativity 0
without 0
cancer 0
relatives 0
( 0
29 0
vs 0
. 0

Peripheral 0
metabolism 0
of 0
androgens 0
takes 0
place 0
in 0
various 0
areas 0
within 0
the 0
pilosebaceous 0
unit 0
, 0
as 0
indicated 0
by 0
local 0
differences 0
in 0
the 0
activities 0
of 0
aromatase B-gene
, 0
5alpha B-gene
- I-gene
reductase I-gene
as 0
well 0
as 0
of 0
the 0
presence 0
of 0
the 0
androgen B-gene
receptors I-gene
. 0

The 0
uptake 0
of 0
fluorine 0
- 0
18 0
fluorodeoxyglucose 0
( 0
F 0
- 0
18 0
FDG 0
) 0
by 0
a 0
malignant 0
tumor 0
depends 0
on 0
the 0
blood 0
glucose 0
level 0
. 0

Northern 0
blot 0
analysis 0
with 0
one 0
of 0
the 0
PARNAs B-gene
revealed 0
a 0
highly 0
abundant 0
signal 0
of 0
approximately 0
2.0 0
kilobases 0
( 0
kb 0
) 0
present 0
in 0
all 0
cell 0
lines 0
tested 0
. 0

This 0
analysis 0
supports 0
the 0
use 0
of 0
fluticasone 0
propionate 0
88 0
microg 0
twice 0
daily 0
as 0
first 0
- 0
line 0
treatment 0
in 0
patients 0
with 0
persistent 0
asthma 0
previously 0
treated 0
with 0
short 0
- 0
acting 0
beta2 B-gene
- 0
agonist 0
alone 0
. 0

By 0
using 0
space 0
- 0
discrete/continuous 0
metapopulation 0
dynamic 0
models 0
and 0
computer 0
simulations 0
, 0
we 0
show 0
that 0
there 0
can 0
be 0
two 0
principally 0
different 0
regimes 0
of 0
metapopulation 0
dynamics 0
. 0

Eight 0
CAD 0
patients 0
who 0
were 0
matched 0
to 0
the 0
treated 0
patients 0
for 0
age 0
( 0
+/ 0
- 0
3 0
years 0
) 0
, 0
baseline 0
low B-gene
density I-gene
lipoprotein I-gene
( 0
+/ 0
- 0
5 0
mg/dL 0
) 0
, 0
and 0
triglycerides 0
( 0
+/ 0
- 0
50 0
mg/dL 0
) 0
but 0
who 0
had 0
never 0
been 0
treated 0
with 0
lipid 0
- 0
lowering 0
drugs 0
were 0
selected 0
as 0
controls 0
. 0

The 0
corresponding 0
orifice 0
voltages 0
for 0
the 0
three 0
instruments 0
were 0
20/50/80 0
V 0
( 0
API 0
365 0
) 0
, 0
30/90/130 0
V 0
( 0
API 0
2000 0
) 0
and 0
40/80/120 0
V 0
( 0
API 0
3000 0
) 0
. 0

RESULTS 0
: 0
A 0
novel 0
gene 0
was 0
cloned 0
. 0

The 0
moduli 0
of 0
elasticity 0
of 0
the 0
gray 0
and 0
white 0
matter 0
were 0
3.4+/ 0
- 0
1.4 0
kPa 0
( 0
mean 0
+/ 0
- 0
standard 0
deviation 0
) 0
and 0
3.4+/ 0
- 0
0.9 0
kPa 0
in 0
the 0
axial 0
section 0
, 0
3+/ 0
- 0
0.3 0
kPa 0
and 0
3.5+/ 0
- 0
0.5 0
kPa 0
in 0
the 0
frontal 0
section 0
, 0
and 0
3.5+/ 0
- 0
0.9 0
kPa 0
and 0
2.8+/ 0
- 0
0.4 0
kPa 0
in 0
the 0
sagittal 0
section 0
, 0
respectively 0
. 0

The 0
LA 0
50s 0
derived 0
from 0
this 0
combined 0
data 0
when 0
compared 0
with 0
our 0
earlier 0
series 0
from 0
1965 0
to 0
1970 0
also 0
did 0
not 0
show 0
a 0
significant 0
change 0
in 0
mortality 0
. 0

Direct 0
current 0
polarography 0
and 0
differential 0
pulse 0
polarographic 0
methods 0
have 0
been 0
developed 0
for 0
the 0
qualitative 0
as 0
well 0
as 0
quantitative 0
analysis 0
of 0
vitamin 0
B1 0
, 0
B2 0
and 0
B6 0
. 0

Against 0
gram 0
- 0
positive 0
organisms 0
, 0
E 0
- 0
4767 0
and 0
E 0
- 0
5065 0
were 0
, 0
in 0
general 0
, 0
eight 0
- 0
and 0
fourfold 0
more 0
active 0
than 0
tosufloxacin 0
, 0
which 0
is 0
the 0
most 0
potent 0
of 0
the 0
reference 0
compounds 0
. 0

However 0
, 0
most 0
produced 0
significant 0
alteration 0
of 0
small 0
intestinal 0
permeability 0
. 0

These 0
included 0
HNF B-gene
- I-gene
3 I-gene
beta I-gene
, 0
HFH B-gene
- I-gene
1 I-gene
, 0
HFH B-gene
- I-gene
2 I-gene
, 0
HFH B-gene
- I-gene
3 I-gene
, 0
C/EBP B-gene
, 0
and 0
C/EBP B-gene
beta I-gene
, 0
all 0
of 0
which 0
are 0
consistent 0
with 0
the 0
tissue 0
- 0
specific 0
expression 0
profiles 0
of 0
the 0
gene 0
. 0

Managing 0
vertigo 0
and 0
vertigo 0
syndromes 0
in 0
the 0
elderly 0

The 0
MABP 0
and 0
MCBFV 0
signals 0
were 0
bandpass 0
filtered 0
in 0
the 0
very 0
low 0
- 0
frequency 0
range 0
( 0
VLF 0
, 0
0.015 0
- 0
0.07 0
Hz 0
) 0
, 0
low 0
- 0
frequency 0
range 0
( 0
LF 0
, 0
0.07 0
- 0
0.15 0
Hz 0
) 0
and 0
high 0
- 0
frequency 0
range 0
( 0
HF 0
, 0
0.15 0
- 0
0.40 0
Hz 0
) 0
before 0
applying 0
CCF 0
for 0
the 0
purpose 0
of 0
studying 0
the 0
effect 0
of 0
different 0
bandwidths 0
on 0
the 0
resulting 0
mean 0
CCFs 0
. 0

Treatment 0
of 0
ischemic 0
heart 0
disease 0
in 0
the 0
elderly 0

Hepatitis 0
B 0
and 0
C 0
seroprevalence 0
rates 0
among 0
high 0
- 0
risk 0
adolescents 0
are 0
lower 0
in 0
El 0
Paso 0
than 0
in 0
other 0
similar 0
US 0
populations 0
, 0
presenting 0
an 0
ideal 0
climate 0
for 0
prevention 0
programs 0
. 0

A 0
twelfth 0
insertion 0
disrupts 0
two 0
genes 0
, 0
Nrk B-gene
, 0
a 0
`` B-gene
neurospecific I-gene
'' I-gene
receptor I-gene
tyrosine I-gene
kinase I-gene
, 0
and B-gene
Tpp I-gene
, 0
which 0
encodes B-gene
a I-gene
neuropeptidase I-gene
. 0

A 0
peculiar 0
people 0
: 0
`` 0
the 0
physiological 0
aspects 0
of 0
Mormonism 0
1850 0
- 0
1975 0
. 0
'' 0

Not 0
Available 0

This 0
unique 0
work 0
needs 0
to 0
be 0
edited 0
critically 0
and 0
afterwards 0
translated 0
into 0
Urdu 0
and 0
other 0
languages 0
for 0
the 0
benefit 0
of 0
the 0
present 0
day 0
students 0
and 0
scholars 0
. 0

Comparison 0
of 0
German 0
language 0
versions 0
of 0
the 0
QWB 0
- 0
SA 0
and 0
SF 0
- 0
36 0
evaluating 0
outcomes 0
for 0
patients 0
with 0
prostate 0
disease 0
. 0

Disciplinary 0
action 0
for 0
DNA 0
violation 0
. 0

Epithelial 0
cytotoxicity 0
of 0
combined 0
antibiotics 0
was 0
additive 0
, 0
with 0
no 0
evidence 0
of 0
competition 0
or 0
synergism 0
. 0

Pro 0
- 0
inflammatory 0
cytokine 0
, 0
tumor B-gene
necrosis I-gene
factor I-gene
- I-gene
alpha I-gene
( 0
TNF B-gene
- I-gene
alpha I-gene
) 0
, 0
produced 0
from 0
adipose 0
tissues 0
in 0
obese 0
subjects 0
, 0
is 0
known 0
to 0
play 0
a 0
predominant 0
role 0
in 0
inducing 0
insulin B-gene
resistance 0
. 0

She 0
drank 0
alcohol 0
once 0
or 0
twice 0
a 0
week 0
and 0
regularly 0
took 0
an 0
analgesic 0
preparation 0
, 0
containing 0
aspirin 0
and 0
acetaminophen 0
, 0
for 0
alleviation 0
of 0
headaches 0
. 0

The 0
most 0
important 0
risk 0
factors 0
are 0
: 0
1 0
) 0
genetic 0
; 0
2 0
) 0
Epstein 0
- 0
Barr 0
virus 0
( 0
infectious 0
mononucleosis 0
) 0
; 0
3 0
) 0
congenital 0
and 0
acquired 0
immunodeficiency 0
; 0
4 0
) 0
occupational 0
exposure 0
( 0
the 0
wood 0
industry 0
) 0
. 0

The 0
most 0
important 0
finding 0
, 0
however 0
, 0
was 0
that 0
IMT 0
values 0
were 0
related 0
with 0
24 0
h 0
SBP 0
or 0
PP 0
standard 0
deviation 0
( 0
P 0
< 0
0.001 0
) 0
, 0
a 0
measure 0
of 0
overall 0
SBP 0
or 0
PP 0
variability 0
. 0

The 0
difference 0
between 0
the 0
patients 0
and 0
the 0
controls 0
was 0
statistically 0
significant 0
( 0
p 0
= 0
0.03 0
) 0
. 0

The 0
effect 0
of 0
crude 0
oil 0
spillage 0
on 0
growth 0
, 0
productivity 0
and 0
nutrient 0
uptake 0
of 0
maize 0
( 0
Zea 0
mays 0
L. 0
) 0
was 0
assessed 0
in 0
a 0
pot 0
experiment 0
using 0
an 0
Evwreni 0
manifold 0
sample 0
of 0
a 0
petroleum 0
development 0
company 0
, 0
which 0
had 0
a 0
specific 0
gravity 0
of 0
0.8778 0
. 0

NO 0
metabolites 0
were 0
determined 0
by 0
the 0
measurement 0
of 0
nitrate/nitrite 0
( 0
NOx 0
, 0
micromol/mmol 0
creatinine 0
) 0
and 0
cyclic 0
guanosine 0
monophosphate 0
( 0
cGMP 0
, 0
nmol/mmol 0
creatinine 0
) 0
in 0
plasma 0
and 0
urine 0
. 0

In 0
the 0
base 0
- 0
case 0
analysis 0
, 0
total 0
direct 0
costs 0
per 0
patient 0
were 0
$ 0
728 0
for 0
zoledronic 0
acid 0
and 0
$ 0
776 0
for 0
pamidronate 0
. 0

The 0
diet 0
of 0
migrants 0
showed 0
both 0
positive 0
( 0
macronutrients 0
) 0
and 0
negative 0
( 0
micronutrients 0
) 0
differences 0
with 0
the 0
general 0
Dutch 0
diet 0
. 0

C. 0
elegans 0
embryogenesis 0
begins 0
with 0
a 0
stereotyped 0
sequence 0
of 0
asymmetric 0
cell 0
divisions 0
that 0
are 0
largely 0
responsible 0
for 0
establishing 0
the 0
nematode 0
body 0
plan 0
. 0

Finally 0
, 0
a 0
chromogenic 0
method 0
was 0
used 0
, 0
based 0
on 0
thrombin B-gene
inhibition 0
and 0
the 0
substrate 0
S 0
- 0
2238 0
. 0

[ 0
Diabetologia 0
( 0
2001 0
) 0
44 0
[ 0
Suppl 0
3 0
] 0
: 0
B37 0
- 0
B44 0
] 0

The 0
5 0
' 0
flanking 0
sequence 0
of 0
the 0
3B B-gene
gene I-gene
is 0
extremely 0
A 0
+ 0
T 0
rich 0
but 0
contains 0
five 0
G/C 0
rich 0
stretches 0
, 0
each 0
approximately 0
7bp 0
long 0
, 0
which 0
have 0
strong 0
sequence 0
similarity 0
to 0
the 0
G 0
boxes 0
found 0
upstream 0
of 0
other 0
developmentally 0
regulated 0
Dictyostelium 0
genes 0
. 0

Considering 0
that 0
the 0
reactor 0
is 0
thoroughly 0
mixed 0
during 0
each 0
discharge 0
and 0
that 0
LD50 0
= 0
0.9 0
values 0
are 0
nearly 0
independent 0
of 0
E. 0
coli 0
concentrations 0
in 0
the 0
range 0
of 0
2 0
x 0
10 0
( 0
3 0
) 0
< 0
or 0
= 0
E 0
coli/cfu 0
mL 0
( 0
- 0
1 0
) 0
< 0
or 0
= 0
3 0
x 0
10 0
( 0
6 0
) 0
, 0
we 0
ascribe 0
the 0
nonexponential 0
Pn 0
decay 0
of 0
single 0
- 0
strain 0
E. 0
coli 0
colonies 0
to 0
a 0
shielding 0
phenomenon 0
where 0
inactive 0
cells 0
protect 0
the 0
successively 0
smaller 0
numbers 0
of 0
viable 0
cells 0
in 0
the 0
EHD 0
. 0

OBJECTIVES 0
: 0
The 0
objective 0
of 0
this 0
review 0
was 0
to 0
assess 0
the 0
effects 0
of 0
prophylactic 0
prostaglandin 0
use 0
in 0
the 0
third 0
stage 0
of 0
labour 0
. 0

In 0
the 0
long 0
term 0
, 0
questions 0
still 0
remain 0
about 0
whether 0
pre 0
- 0
dialysis 0
rHu B-gene
EPO I-gene
either 0
speeds 0
up 0
or 0
delays 0
the 0
onset 0
of 0
dialysis 0
. 0

METHODS 0
: 0
This 0
retrospective 0
review 0
comprised 0
2711 0
eyes 0
that 0
had 0
LASIK 0
between 0
September 0
1996 0
and 0
September 0
1999 0
. 0

No 0
ISREs B-gene
could 0
be 0
identified 0
in 0
the 0
mouse 0
promoter 0
. 0

BACKGROUND 0
: 0
Ischemic 0
heart 0
disease 0
is 0
the 0
primary 0
cause 0
of 0
morbidity 0
and 0
mortality 0
among 0
diabetics 0
, 0
especially 0
those 0
who 0
became 0
ill 0
at 0
a 0
young 0
age 0
. 0

A 0
38 0
- 0
year 0
- 0
old 0
woman 0
with 0
ulcerative 0
colitis 0
subsequently 0
developed 0
sarcoidosis 0
. 0

Cholesteryl B-gene
ester I-gene
transfer I-gene
protein I-gene
and 0
atherosclerosis 0
in 0
Japanese 0
subjects 0
: 0
a 0
study 0
based 0
on 0
coronary 0
angiography 0
. 0

Electrophoretic 0
mobility 0
shift 0
assays 0
and 0
coimmunoprecipitation 0
studies 0
suggest 0
that 0
homo 0
- 0
and 0
heterodimerization 0
occurs 0
between 0
cKrox B-gene
family I-gene
members I-gene
. 0

The 0
hcKrox B-gene
gene 0
family 0
regulates 0
multiple 0
extracellular 0
matrix 0
genes 0
. 0

A 0
review 0
of 0
the 0
literature 0
identified 0
8 0
comprehensive 0
clinical 0
studies 0
, 0
all 0
of 0
which 0
failed 0
to 0
document 0
any 0
relationship 0
between 0
NF1 B-gene
and 0
intracranial 0
aneurysms 0
. 0

These 0
utilisation 0
data 0
imply 0
annual 0
drug 0
costs 0
in 0
the 0
range 0
of 0
$ 0
US 0
480,000 0
to 0
$ 0
US 0
3,600,000 0
for 0
TNF B-gene
antagonists 0
for 0
RA 0
per 0
1 0
million 0
population 0
. 0

Under 0
our 0
conditions 0
, 0
the 0
combination 0
O3/UV 0
did 0
not 0
improve 0
the 0
degradation 0
rate 0
obtained 0
by 0
ozonation 0
. 0

This 0
study 0
investigated 0
whether 0
boron 0
would 0
enhance 0
the 0
ability 0
of 0
17beta 0
- 0
estradiol 0
( 0
E2 0
) 0
or 0
parathyroid B-gene
hormone I-gene
( 0
PTH B-gene
) 0
to 0
improve 0
bone 0
quality 0
in 0
ovariectomized 0
OVX 0
rats 0
. 0

We 0
found 0
in 0
the 0
control 0
subjects 0
rCBF 0
increases 0
in 0
regions 0
associated 0
with 0
the 0
meso 0
- 0
striatal 0
and 0
meso 0
- 0
corticolimbic 0
circuits 0
in 0
response 0
to 0
both 0
monetary 0
reward 0
and 0
nonmonetary 0
reinforcement 0
. 0

Doxorubicin 0
( 0
DOX 0
) 0
is 0
commonly 0
used 0
for 0
the 0
treatment 0
of 0
hematological 0
and 0
solid 0
tumors 0
. 0

The 0
event 0
rate 0
in 0
patients 0
with 0
chronic 0
Irr 0
- 0
rMFP 0
or 0
Un 0
- 0
nrMFP 0
was 0
markedly 0
higher 0
than 0
it 0
was 0
in 0
those 0
with 0
Rev 0
- 0
rMFP 0
or 0
Sta 0
- 0
nrMFP 0
. 0

Subtraction 0
hybridization 0
identified 0
melanoma B-gene
differentiation I-gene
associated I-gene
gene I-gene
- I-gene
7 I-gene
( 0
mda B-gene
- I-gene
7 I-gene
) 0
, 0
as 0
a 0
gene 0
induced 0
during 0
these 0
physiological 0
changes 0
in 0
human 0
melanoma 0
cells 0
. 0

Therefore 0
, 0
vitamin 0
D3 0
analogues 0
have 0
a 0
substantial 0
antipsoriatic 0
effect 0
. 0

Hydrocoele 0
is 0
common 0
in 0
men 0
in 0
Wuchereria 0
bancrofti 0
- 0
endemic 0
areas 0
, 0
the 0
treatment 0
for 0
which 0
is 0
currently 0
surgical 0
intervention 0
. 0

Growth B-gene
hormone I-gene
and 0
insulin B-gene
- I-gene
like I-gene
growth I-gene
factor I-gene
I I-gene
receptors I-gene
in 0
the 0
temporomandibular 0
joint 0
of 0
the 0
rat 0
. 0

On 0
the 0
other 0
hand 0
, 0
hepatic 0
arterial 0
infusion 0
therapy 0
prolongs 0
the 0
survival 0
of 0
H3 0
patients 0
only 0
. 0

In 0
addition 0
to 0
that 0
, 0
she 0
received 0
hepatic 0
intra 0
- 0
arterial 0
infusion 0
of 0
levoforinate 0
( 0
l 0
- 0
LV 0
) 0
250 0
mg 0
and 0
5 0
- 0
fluorouracil 0
( 0
5 0
- 0
FU 0
) 0
500 0
mg 0
for 0
combined 0
multiple 0
hepatic 0
metastases 0
starting 0
on 0
postoperative 0
day 0
14 0
, 0
and 0
these 0
medications 0
were 0
administered 0
over 0
48 0
hours 0
once 0
weekly 0
by 0
infuser 0
pump 0
. 0

The 0
astronaut 0
crew 0
operates 0
the 0
payload 0
and 0
documents 0
its 0
operation 0
. 0

For 0
these 0
patients 0
the 0
introduction 0
of 0
a 0
separate 0
category 0
`` 0
extended 0
oligoarthritis 0
at 0
onset 0
'' 0
should 0
be 0
considered 0
to 0
establish 0
comparable 0
patient 0
groups 0
. 0

Finally 0
, 0
there 0
are 0
a 0
growing 0
number 0
of 0
arguments 0
favouring 0
the 0
use 0
of 0
ACE B-gene
inhibitors 0
very 0
early 0
in 0
patients 0
with 0
diabetes 0
mellitus 0
. 0

Phase 0
II 0
trial 0
of 0
the 0
anti B-gene
- I-gene
G I-gene
( I-gene
D2 I-gene
) I-gene
monoclonal I-gene
antibody I-gene
3F8 I-gene
and 0
granulocyte B-gene
- I-gene
macrophage I-gene
colony I-gene
- I-gene
stimulating I-gene
factor I-gene
for 0
neuroblastoma 0
. 0

Hepatitis 0
A 0
infected 0
food 0
handler 0
at 0
an 0
Edmonton 0
, 0
Alberta 0
retail 0
food 0
facility 0
: 0
public 0
health 0
protection 0
strategies 0
. 0

Hydrogels 0
for 0
tissue 0
engineering 0
. 0

Eliminating 0
any 0
subset 0
of 0
ASCUS 0
reduces 0
the 0
ASCUS/SIL 0
ratio 0
but 0
also 0
significantly 0
diminishes 0
the 0
sensitivity 0
of 0
the 0
Papanicolaou 0
test 0
. 0

Eliminating 0
any 0
subset 0
of 0
ASCUS 0
reduces 0
the 0
ASCUS/SIL 0
ratio 0
but 0
also 0
significantly 0
diminishes 0
the 0
sensitivity 0
of 0
the 0
Papanicolaou 0
test 0
. 0

Two 0
nuclear 0
medicine 0
physicians 0
blinded 0
to 0
the 0
surgical 0
findings 0
interpreted 0
all 0
available 0
images 0
and 0
various 0
Tc 0
- 0
99m 0
MIBI 0
image 0
combinations 0
at 0
15 0
minutes 0
alone 0
; 0
15 0
minutes 0
and 0
2 0
hours 0
, 0
15 0
minutes 0
and 0
4 0
hours 0
; 0
and 0
15 0
minutes 0
and 0
2 0
and 0
4 0
hours 0
each 0
with 0
and 0
without 0
correlative 0
pertechnetate 0
thyroid 0
imaging 0
. 0

Is 0
clopidogrel 0
superior 0
to 0
aspirin 0
in 0
secondary 0
prevention 0
of 0
vascular 0
disease 0
? 0
The 0
cornerstone 0
in 0
clinical 0
evidence 0
of 0
the 0
relative 0
efficacy 0
of 0
thienopyridines 0
( 0
clopidogrel 0
, 0
ticlopidine 0
) 0
versus 0
aspirin 0
in 0
the 0
secondary 0
prevention 0
of 0
vascular 0
disease 0
is 0
the 0
Clopidogrel 0
versus 0
Aspirin 0
in 0
Patients 0
at 0
Risk 0
of 0
Ischaemic 0
Events 0
trial 0
. 0

We 0
hypothesize 0
that 0
proprioception 0
may 0
be 0
used 0
to 0
calibrate 0
the 0
efference 0
copy 0
during 0
development 0
and 0
in 0
response 0
to 0
perturbations 0
by 0
signaling 0
potential 0
mismatches 0
between 0
eye 0
movement 0
information 0
derived 0
from 0
the 0
efferent 0
command 0
and 0
the 0
actual 0
motion 0
of 0
the 0
eye 0
transduced 0
by 0
the 0
proprioceptive 0
organs 0
. 0

Between 0
1967 0
and 0
1994 0
, 0
495 0
patients 0
underwent 0
surgery 0
for 0
primary 0
PTC 0
at 0
the 0
Department 0
of 0
Surgery 0
, 0
Helsinki 0
University 0
Central 0
Hospital 0
. 0

ISS 0
and 0
the 0
acute 0
physiology 0
and 0
chronic 0
health 0
evaluation 0
( 0
APACHE 0
II 0
) 0
calculated 0
on 0
admission 0
. 0

The 0
procedure 0
is 0
less 0
aggressive 0
and 0
painful 0
than 0
sternotomy 0
. 0

Paul 0
Monagle 0
addresses 0
the 0
epidemiology 0
of 0
neonatal 0
thrombosis 0
outside 0
of 0
the 0
central 0
nervous 0
system 0
in 0
both 0
arterial 0
and 0
venous 0
locations 0
, 0
and 0
those 0
that 0
occur 0
in 0
utero 0
. 0

[ 0
Clinical 0
and 0
epidemiological 0
characteristics 0
of 0
squamous 0
cell 0
carcinoma 0
of 0
the 0
oral 0
cavity 0
in 0
women 0
] 0
BACKGROUND 0
: 0
Squamous 0
cell 0
carcinoma 0
( 0
SCC 0
) 0
of 0
the 0
oral 0
cavity 0
occurs 0
mainly 0
in 0
the 0
male 0
population 0
. 0

Regarding 0
gestational 0
risk 0
, 0
3,243 0
drugs 0
used 0
( 0
34 0
% 0
) 0
belonged 0
to 0
category 0
A 0
risk 0
, 0
1,923 0
( 0
22.6 0
% 0
) 0
to 0
category 0
B 0
, 0
3,798 0
( 0
39.7 0
% 0
) 0
to 0
category 0
C 0
, 0
289 0
( 0
3.0 0
% 0
) 0
to 0
category 0
D 0
, 0
and 0
55 0
( 0
0.6 0
% 0
) 0
to 0
category 0
X 0
. 0

The 0
severity 0
of 0
clinical 0
course 0
was 0
expressed 0
by 0
means 0
of 0
SOFA 0
score 0
( 0
group 0
A 0
0.3 0
- 0
1 0
- 0
1.3 0
point 0
, 0
group 0
B 0
2.2 0
- 0
2.9 0
- 0
2.6 0
point 0
, 0
group 0
C 0
7.4 0
- 0
8.3 0
- 0
7.7 0
point 0
) 0
and 0
APACHE 0
II 0
score 0
( 0
group 0
A 0
3.7 0
- 0
7.6 0
- 0
8.1 0
point 0
, 0
group 0
B 0
8.6 0
- 0
11.1 0
- 0
10.5 0
point 0
, 0
group 0
C 0
16.3 0
- 0
15.2 0
- 0
14.3 0
point 0
) 0
. 0

The 0
process 0
has 0
been 0
applied 0
to 0
the 0
river 0
reclamation 0
in 0
Yangpu 0
District 0
of 0
Shanghai 0
City 0
, 0
China 0
. 0

Physical 0
principles 0
in 0
therapeutic 0
apheresis 0
. 0

These 0
results 0
were 0
compared 0
with 0
the 0
estimates 0
of 0
penetration 0
from 0
steady 0
- 0
state 0
calculations 0
, 0
square 0
root 0
of 0
time 0
calculations 0
, 0
and 0
a 0
biologically 0
based 0
mathematical 0
model 0
. 0

Rind 0
et 0
al 0
. 0
's 0
study 0
's 0
main 0
conclusions 0
were 0
not 0
supported 0
by 0
the 0
original 0
data 0
. 0

Of 0
major 0
concern 0
to 0
food 0
processors 0
is 0
the 0
inadvertent 0
cross 0
- 0
contact 0
of 0
food 0
products 0
with 0
allergenic 0
residues 0
, 0
which 0
could 0
result 0
in 0
potentially 0
life 0
- 0
threatening 0
reactions 0
in 0
those 0
with 0
a 0
food 0
allergy 0
. 0

Lactate 0
accumulation 0
peak 0
was 0
unaffected 0
by 0
supplementation 0
( 0
HMB 0
, 0
8.1 0
+/ 0
- 0
1.1 0
mM 0
; 0
LEU 0
, 0
6.2 0
+/ 0
- 0
0.8 0
mM 0
; 0
CON 0
, 0
7.5 0
+/ 0
- 0
1.3 0
mM 0
) 0
. 0

The 0
increased 0
clearance 0
observed 0
in 0
young 0
infants 0
is 0
in 0
contrast 0
to 0
other 0
opioids 0
. 0

These 0
results 0
were 0
robust 0
to 0
changes 0
in 0
the 0
baseline 0
assumptions 0
of 0
the 0
model 0
. 0

CONCLUSION 0
: 0
The 0
training 0
of 0
novices 0
using 0
MIST 0
- 0
VR 0
yields 0
quantifiable 0
changes 0
in 0
skill 0
that 0
are 0
transferable 0
to 0
a 0
simple 0
real 0
task 0
and 0
are 0
similar 0
to 0
the 0
results 0
achieved 0
with 0
conventional 0
training 0
. 0

The 0
patients 0
and 0
their 0
families 0
were 0
closely 0
questioned 0
, 0
and 0
full 0
clinical 0
examination 0
included 0
a 0
test 0
for 0
orthostasia 0
. 0

They 0
have 0
not 0
been 0
previously 0
reported 0
as 0
a 0
reaction 0
to 0
i.v 0
. 0
contrast 0
material 0
. 0

There 0
was 0
a 0
statistically 0
significant 0
correlation 0
between 0
simultaneous 0
weekly 0
average 0
pollen 0
levels 0
in 0
Philadelphia 0
and 0
in 0
Cherry 0
Hill 0
( 0
Acer 0
, 0
r 0
( 0
p 0
) 0
= 0
0.987 0
, 0
Quercus 0
, 0
r 0
( 0
p 0
) 0
= 0
0.645 0
, 0
Betula 0
, 0
r 0
( 0
p 0
) 0
= 0
0.896 0
, 0
Pinus 0
, 0
r 0
( 0
p 0
) 0
= 0
0.732 0
, 0
Cupressaceae 0
, 0
r 0
( 0
p 0
) 0
= 0
0.695 0
, 0
Poaceae 0
, 0
r 0
( 0
p 0
) 0
= 0
0.950 0
, 0
Ambrosia 0
, 0
r 0
( 0
p 0
) 0
= 0
0.903 0
, 0
and 0
Rumex 0
, 0
r 0
( 0
p 0
) 0
= 0
0.572 0
, 0
P 0
< 0
0.001 0
) 0
. 0

Encouraged 0
by 0
a 0
Dutch 0
study 0
using 0
etidronate/fluoride 0
in 0
corticoid 0
- 0
induced 0
osteoporosis 0
, 0
we 0
performed 0
a 0
pilot 0
study 0
in 0
33 0
men 0
with 0
severe 0
established 0
primary 0
osteoporosis 0
giving 0
cyclically 0
etidronate 0
for 0
14 0
days 0
followed 0
by 0
fluoride 0
plus 0
calcium/vitamin 0
D 0
for 0
76 0
days 0
. 0

Treadmill 0
training 0
at 0
least 0
for 0
2 0
weeks 0
can 0
reduce 0
the 0
infarction 0
size 0
and 0
edema 0
caused 0
by 0
MCA 0
occlusion 0
( 0
P 0
< 0
0.01 0
) 0
. 0

In 0
order 0
to 0
overcome 0
the 0
false 0
positive 0
readings 0
that 0
are 0
possible 0
in 0
sphincter 0
manometry 0
, 0
we 0
proposed 0
to 0
use 0
secretin B-gene
stimulated 0
endoscopic 0
ultrasound 0
( 0
SSEUS 0
) 0
to 0
measure 0
pancreatic 0
ductal 0
response 0
as 0
an 0
adjunctive 0
method 0
to 0
aid 0
and 0
supplement 0
the 0
diagnosis 0
. 0

The 0
cut 0
- 0
off 0
percentage 0
positivity 0
value 0
was 0
established 0
using 0
500 0
brucellosis 0
- 0
positive 0
and 0
500 0
brucellosis 0
- 0
negative 0
serum 0
samples 0
, 0
confirmed 0
with 0
reference 0
to 0
the 0
sample 0
data 0
using 0
the 0
indirect 0
ELISA 0
kit 0
. 0

An 0
analysis 0
of 0
the 0
dynamics 0
is 0
performed 0
of 0
exactly 0
solvable 0
models 0
for 0
fragile 0
and 0
strong 0
glasses 0
, 0
exploiting 0
the 0
partitioning 0
of 0
the 0
free 0
- 0
energy 0
landscape 0
in 0
inherent 0
structures 0
. 0

Fifty 0
- 0
six 0
semen 0
samples 0
were 0
included 0
in 0
this 0
study 0
; 0
18 0
were 0
subnormal 0
( 0
G1 0
) 0
and 0
38 0
were 0
normal 0
( 0
G2 0
) 0
based 0
on 0
World 0
Health 0
Organization 0
criteria 0
, 0
except 0
for 0
morphology 0
, 0
which 0
was 0
evaluated 0
according 0
to 0
strict 0
criteria 0
. 0

At 0
this 0
timepoint 0
, 0
many 0
leucocytes 0
in 0
the 0
ME 0
and 0
ET 0
mucosa 0
had 0
incorporated 0
BrdU 0
( 0
between 0
15 0
and 0
25 0
% 0
within 0
the 0
subsets 0
) 0
. 0

Modality 0
- 0
specific 0
areas 0
( 0
e.g. 0
, 0
right 0
Wernicke 0
, 0
left 0
fusiform 0
gyrus 0
, 0
Broca 0
BA44 0
, 0
supramarginal 0
gyrus 0
) 0
, 0
appear 0
to 0
cope 0
with 0
the 0
computations 0
relevant 0
to 0
making 0
contact 0
with 0
these 0
more 0
abstract 0
dimensions 0
. 0

We 0
found 0
no 0
correlation 0
between 0
plasma 0
COP 0
and 0
body 0
weight 0
at 0
the 0
same 0
age 0
( 0
r2 0
= 0
0.05 0
, 0
P 0
= 0
0.155 0
) 0
. 0

Their 0
chemical 0
structures 0
were 0
elucidated 0
as 0
1 0
alpha,2 0
alpha 0
- 0
diacetoxy 0
- 0
8 0
beta 0
- 0
isobutanoyloxy 0
- 0
9 0
alpha 0
- 0
benzoyloxy 0
- 0
13 0
- 0
( 0
alpha 0
- 0
methyl 0
) 0
butanoyloxy 0
- 0
4 0
beta 0
, 0
6 0
beta 0
- 0
dihydroxy 0
- 0
beta 0
- 0
dihydroagarofuran 0
( 0
1 0
) 0
, 0
1 0
alpha,2 0
alpha 0
- 0
diacetoxy 0
- 0
8 0
beta 0
- 0
( 0
beta 0
- 0
furancarbonyloxy 0
) 0
- 0
9 0
alpha 0
- 0
benzoyloxy 0
- 0
13 0
- 0
isobutanoyloxy 0
- 0
4 0
beta 0
, 0
6 0
beta 0
- 0
dihydroxy 0
- 0
beta 0
- 0
dihydroagarofuran 0
( 0
2 0
) 0
and 0
1 0
alpha 0
, 0
6 0
beta 0
, 0
8 0
alpha,13 0
- 0
tetraacetoxy 0
- 0
9 0
alpha 0
- 0
benzoyloxy 0
- 0
2 0
alpha 0
- 0
hydroxy 0
- 0
beta 0
- 0
dihydroagarofuran 0
( 0
3 0
) 0
mainly 0
by 0
analyses 0
NMR 0
and 0
MS 0
spectral 0
data 0
. 0

Both 0
toxins 0
in 0
a 0
dose 0
10 0
- 0
fold 0
surpassing 0
the 0
maximum 0
permissible 0
concentration 0
increased 0
activity 0
of 0
glutathione B-gene
peroxidase I-gene
in 0
brain 0
tissue 0
; 0
moreover 0
, 0
toluene 0
increased 0
chemiluminescence 0
intensity 0
, 0
which 0
attested 0
to 0
activation 0
of 0
free 0
radical 0
processes 0
. 0

Saunders 0
Company 0
. 0

The 0
performance 0
of 0
pH 0
- 0
sensitive 0
particles 0
is 0
attributed 0
to 0
their 0
ability 0
to 0
release 0
the 0
drug 0
selectively 0
in 0
the 0
upper 0
part 0
of 0
the 0
intestine 0
in 0
a 0
molecular 0
or 0
amorphous 0
form 0
. 0

Comparison 0
of 0
remnant 0
- 0
like 0
lipoprotein 0
particles 0
in 0
postmenopausal 0
women 0
with 0
and 0
without 0
coronary 0
artery 0
disease 0
and 0
in 0
men 0
with 0
coronary 0
artery 0
disease 0
. 0

Because 0
results 0
of 0
recent 0
randomized 0
trials 0
indicate 0
minimal 0
efficacy 0
of 0
continuing 0
MAC 0
prophylaxis 0
in 0
patients 0
who 0
respond 0
to 0
potent 0
combination 0
antiretroviral 0
therapy 0
, 0
the 0
observed 0
high 0
incidence 0
of 0
macrolide 0
- 0
resistant 0
bacterial 0
colonization 0
of 0
the 0
respiratory 0
tract 0
in 0
this 0
trial 0
supports 0
the 0
discontinuation 0
of 0
macrolide 0
prophylaxis 0
in 0
all 0
AIDS 0
patients 0
whose 0
CD4 B-gene
counts 0
have 0
risen 0
above 0
100 0
cells/microL 0
. 0

Acute 0
stress 0
in 0
7 0
rats 0
also 0
increased 0
the 0
mean 0
amount 0
of 0
IL B-gene
- I-gene
6 I-gene
released 0
in 0
the 0
urine 0
by 0
31.5 0
% 0
from 0
775.9 0
+/ 0
- 0
69.2 0
to 0
1,021.1 0
+/ 0
- 0
93.3 0
pg./ml 0
. 0

Patients 0
with 0
CF 0
and 0
meconium 0
ileus 0
presented 0
a 0
poor 0
nutritional 0
status 0
at 0
diagnosis 0
and 0
a 0
lower 0
survival 0
rate 0
compared 0
to 0
the 0
general 0
CF 0
population 0
. 0

( 0
Cactaceae 0
) 0
waste 0
matter 0
. 0

Skin 0
cancers 0
, 0
followed 0
by 0
gastrointestinal 0
tract 0
and 0
male 0
genital 0
system 0
affected 0
mostly 0
older 0
age 0
patients 0
. 0

CONCLUSION 0
: 0
MMF 0
( 0
2 0
- 0
3 0
g/day 0
) 0
is 0
unable 0
to 0
control 0
the 0
signs 0
of 0
mucocutaneous 0
Adamantiades 0
- 0
Behcet 0
's 0
disease 0
. 0

In 0
the 0
treatment 0
of 0
opioid 0
naive 0
patients 0
who 0
underwent 0
surgery 0
and 0
received 0
opioids 0
for 0
acute 0
pain 0
, 0
oral 0
ADL 0
8 0
- 0
2698 0
( 0
6.0 0
mg 0
) 0
improved 0
the 0
management 0
of 0
postoperative 0
ileus 0
( 0
POI 0
) 0
by 0
shortening 0
the 0
time 0
to 0
achieve 0
normal 0
bowel 0
function 0
and 0
, 0
ultimately 0
, 0
hospital 0
stay 0
. 0

METHODS 0
: 0
302 0
consecutive 0
patients 0
with 0
BS 0
and 0
438 0
patients 0
with 0
other 0
rheumatological 0
conditions 0
were 0
surveyed 0
for 0
the 0
presence 0
or 0
absence 0
of 0
the 0
features 0
of 0
BS 0
by 0
means 0
of 0
a 0
standard 0
form 0
which 0
had 0
been 0
prepared 0
according 0
to 0
ISG 0
criteria 0
. 0

Evidence 0
suggests 0
that 0
PHACES 0
syndrome 0
is 0
not 0
a 0
random 0
association 0
but 0
a 0
true 0
phakomatosis 0
; 0
further 0
studies 0
are 0
awaited 0
to 0
shed 0
light 0
on 0
a 0
possible 0
genetic 0
background 0
. 0

A 0
computer 0
program 0
, 0
ACCESS 0
- 0
IAQ 0
, 0
is 0
developed 0
to 0
simulate 0
the 0
airflow 0
pattern 0
, 0
the 0
time 0
history 0
of 0
the 0
contaminant 0
concentrations 0
in 0
the 0
occupied 0
zone 0
, 0
and 0
the 0
inhalation 0
exposures 0
. 0

Moreover 0
, 0
a 0
severe 0
decrease 0
of 0
antithrombin B-gene
activity 0
became 0
evident 0
during 0
both 0
experiments 0
( 0
eg 0
, 0
in 0
experiment 0
2 0
from 0
95.6 0
+/ 0
- 0
4.8 0
to 0
59.2 0
+/ 0
- 0
6.6 0
% 0
) 0
. 0

The 0
Penn 0
State 0
Worry 0
Questionnaire 0
for 0
Children 0
( 0
PSWQ 0
- 0
C 0
) 0
is 0
a 0
14 0
- 0
item 0
self 0
- 0
report 0
questionnaire 0
that 0
intends 0
to 0
measure 0
the 0
tendency 0
of 0
children 0
to 0
engage 0
in 0
excessive 0
, 0
generalized 0
, 0
and 0
uncontrollable 0
worry 0
( 0
Chorpita 0
et 0
al. 0
, 0
Behav 0
. 0

Classification 0
according 0
to 0
the 0
ILAR 0
criteria 0
was 0
possible 0
in 0
321 0
patients 0
; 0
290 0
patients 0
had 0
a 0
disease 0
duration 0
> 0
or 0
= 0
3 0
months 0
and 0
were 0
classified 0
according 0
to 0
the 0
EULAR 0
criteria 0
. 0

Described 0
X 0
- 0
ray 0
projection 0
were 0
performed 0
in 0
70 0
patients 0
. 0

We 0
conducted 0
a 0
clinical 0
and 0
pathologic 0
review 0
of 0
nine 0
patients 0
with 0
immature 0
ovarian 0
teratoma 0
. 0

Pyrethroid 0
insecticides 0
are 0
widely 0
used 0
in 0
agriculture 0
and 0
private 0
households 0
. 0

The 0
sorption 0
mechanisms 0
changed 0
from 0
adsorption 0
to 0
partition 0
in 0
the 0
process 0
of 0
repetitious 0
sorption 0
. 0

Although 0
the 0
spatial 0
and 0
temporal 0
variability 0
of 0
LDF 0
signals 0
evoked 0
by 0
cerebrocortical 0
microflow 0
is 0
in 0
the 0
same 0
range 0
as 0
with 0
other 0
methods 0
and 0
in 0
other 0
organs 0
, 0
LDF 0
cerebrocortical 0
mapping 0
is 0
restricted 0
by 0
the 0
large 0
temporal 0
and 0
spatial 0
heterogeneity 0
of 0
the 0
cerebrocortical 0
vasculature 0
. 0

The 0
5 0
- 0
year 0
overall 0
survival 0
( 0
OS 0
) 0
and 0
progression 0
- 0
free 0
survival 0
( 0
PFS 0
) 0
rates 0
were 0
58.9 0
% 0
and 0
55.4 0
% 0
for 0
arm 0
A 0
and 0
44.5 0
% 0
and 0
41.3 0
% 0
for 0
arm 0
B 0
( 0
P 0
=.007 0
and 0
P 0
=.02 0
) 0
, 0
respectively 0
. 0

METHODS 0
: 0
P B-gene
- I-gene
selectin I-gene
expression 0
of 0
nonstimulated 0
and 0
ADP 0
- 0
stimulated 0
platelets 0
was 0
flow 0
cytometrically 0
measured 0
before 0
the 0
clopidogrel 0
loading 0
dose 0
and 0
on 0
3 0
consecutive 0
days 0
in 0
52 0
patients 0
with 0
coronary 0
artery 0
disease 0
: 0
21 0
patients 0
in 0
group 0
1 0
received 0
300 0
mg 0
of 0
clopidogrel 0
after 0
stent 0
implantation 0
and 0
11 0
patients 0
in 0
group 0
2 0
received 0
the 0
higher 0
450 0
- 0
mg 0
clopidogrel 0
loading 0
dose 0
followed 0
by 0
a 0
daily 0
dose 0
of 0
75 0
mg 0
of 0
clopidogrel 0
for 0
both 0
groups 0
. 0

Traditional 0
surgical 0
exploration 0
was 0
followed 0
by 0
survey 0
with 0
a 0
gamma 0
- 0
detecting 0
probe 0
. 0

No 0
effect 0
of 0
the 0
intervention 0
on 0
depression 0
scores 0
was 0
found 0
. 0

IV 0
. 0
combined 0
sclerosis 0
and 0
resorption 0
of 0
the 0
skull 0
base 0
( 0
6 0
cases 0
, 0
2 0
group 0
I 0
lesions 0
and 0
4 0
group 0
II 0
lesions 0
) 0
. 0

The 0
quantity 0
of 0
each 0
population 0
( 0
L. 0
bulgaricus 0
, 0
S. 0
thermophilus 0
) 0
was 0
then 0
estimated 0
in 0
the 0
pellet 0
by 0
PyMS 0
, 0
and 0
the 0
data 0
were 0
analysed 0
by 0
artificial 0
neural 0
networks 0
( 0
ANNs 0
) 0
. 0

AF B-gene
showed 0
a 0
mixed 0
nuclear/cytoplasmic 0
pattern 0
of 0
expression 0
in 0
the 0
epithelial 0
, 0
endothelial 0
, 0
and 0
stromal 0
component 0
of 0
the 0
normal 0
breast 0
and 0
benign 0
lesions 0
, 0
whereas 0
an 0
impressive 0
loss 0
of 0
AF B-gene
expression 0
was 0
noted 0
in 0
in 0
situ 0
and 0
invasive 0
breast 0
cancer 0
and 0
tumoral 0
stroma 0
. 0

We 0
derive 0
joint 0
probability 0
density 0
distributions 0
for 0
three 0
key 0
uncertain 0
properties 0
of 0
the 0
climate 0
system 0
, 0
using 0
an 0
optimal 0
fingerprinting 0
approach 0
to 0
compare 0
simulations 0
of 0
an 0
intermediate 0
complexity 0
climate 0
model 0
with 0
three 0
distinct 0
diagnostics 0
of 0
recent 0
climate 0
observations 0
. 0

Frequency 0
of 0
seeing 0
curves 0
were 0
examined 0
for 0
the 0
method 0
most 0
similar 0
to 0
FDT 0
. 0

Chronic 0
graft 0
- 0
versus 0
- 0
host 0
disease 0
( 0
cGVHD 0
) 0
is 0
a 0
major 0
complication 0
of 0
allogeneic 0
hematopoietic 0
cell 0
transplantation 0
. 0

Compared 0
to 0
white 0
- 0
on 0
- 0
white 0
( 0
W 0
- 0
W 0
) 0
perimetry 0
, 0
SWAP 0
is 0
limited 0
clinically 0
by 0
: 0
greater 0
variability 0
associated 0
with 0
the 0
estimation 0
of 0
threshold 0
, 0
ocular 0
media 0
absorption 0
, 0
increased 0
examination 0
duration 0
and 0
an 0
additional 0
learning 0
effect 0
. 0

Preservatives 0
are 0
an 0
important 0
component 0
of 0
ophthalmic 0
preparations 0
, 0
providing 0
antimicrobial 0
activity 0
in 0
the 0
bottle 0
and 0
preventing 0
decomposition 0
of 0
active 0
drug 0
. 0

Comparative 0
analysis 0
of 0
various 0
techniques 0
of 0
prostatic 0
drainage 0
in 0
patients 0
with 0
chronic 0
obstructive 0
prostatitis 0
] 0
The 0
efficacy 0
of 0
prostatic 0
drainage 0
using 0
transurethral 0
vacuum 0
aspiration 0
( 0
Introl 0
- 0
4 0
unit 0
) 0
and 0
transrectal 0
pneumovibromassage 0
( 0
PVM 0
- 0
R 0
- 0
01 0
) 0
was 0
compared 0
in 0
1511 0
patients 0
with 0
chronic 0
obstructive 0
prostatitis 0
. 0

The 0
results 0
are 0
discussed 0
in 0
relation 0
to 0
acoustical 0
models 0
of 0
sound 0
propagation 0
and 0
physiology 0
, 0
and 0
it 0
is 0
suggested 0
that 0
height 0
- 0
dependent 0
degradation 0
within 0
a 0
forest 0
is 0
an 0
important 0
selection 0
pressure 0
for 0
transmissibility 0
in 0
avian 0
communication 0
. 0

Consumption 0
of 0
4 0
% 0
sucrose 0
was 0
not 0
affected 0
by 0
excitotoxic 0
lesions 0
of 0
the 0
PPTg 0
, 0
but 0
PPTg 0
lesioned 0
rats 0
consumed 0
significantly 0
more 0
12 0
% 0
and 0
20 0
% 0
sucrose 0
than 0
sham 0
controls 0
. 0

Actuarial 0
freedom 0
from 0
ventricular 0
arrhythmias 0
at 0
4 0
- 0
year 0
follow 0
- 0
up 0
was 0
74.1 0
+/ 0
- 0
6.0 0
% 0
in 0
group 0
A 0
vs 0
. 0

Mental 0
development 0
is 0
generally 0
normal 0
. 0

Influence 0
of 0
different 0
methods 0
of 0
chemical 0
disinfection 0
on 0
the 0
physical 0
properties 0
of 0
type 0
IV 0
and 0
V 0
gypsum 0
dies 0
] 0
Several 0
instruments 0
and 0
materials 0
frequently 0
used 0
in 0
prosthodontics 0
- 0
- 0
such 0
as 0
stone 0
casts 0
, 0
dental 0
impressions 0
, 0
interocclusal 0
records 0
- 0
- 0
are 0
classified 0
, 0
by 0
the 0
dental 0
literature 0
, 0
as 0
vehicles 0
of 0
transmission 0
of 0
infectious 0
diseases 0
to 0
those 0
who 0
handle 0
them 0
. 0

In 0
sterilized 0
milk 0
there 0
was 0
a 0
slight 0
decrease 0
of 0
linoleic 0
acid 0
( 0
C18:2n6 0
; 0
- 0
0.7 0
% 0
vs. 0
fresh 0
; 0
P 0
= 0
0.006 0
) 0
and 0
arachidonic 0
acid 0
( 0
C20:4n6 0
; 0
- 0
2.5 0
% 0
; 0
P 0
= 0
0.045 0
) 0
. 0

Vitrectomy 0
and 0
removal 0
of 0
retained 0
lens 0
fragments 0
restores 0
good 0
visual 0
acuity 0
and 0
reduces 0
secondary 0
glaucoma 0
in 0
the 0
majority 0
of 0
patients 0
. 0

CONCLUSIONS 0
: 0
The 0
mechanism 0
of 0
MIRI 0
is 0
Qi 0
deficiency 0
and 0
blood 0
stasis 0
in 0
TCM 0
, 0
its 0
treating 0
principles 0
should 0
be 0
promoting 0
Qi 0
and 0
removing 0
the 0
blood 0
stasis 0
. 0

Effects 0
of 0
activating 0
blood 0
circulation 0
to 0
remove 0
blood 0
stasis 0
on 0
barrier 0
action 0
of 0
gastric 0
wall 0
in 0
chronic 0
atrophic 0
gastritis 0

Proteomic 0
patterns 0
of 0
nipple 0
aspirate 0
fluids 0
obtained 0
by 0
SELDI 0
- 0
TOF 0
: 0
potential 0
for 0
new 0
biomarkers 0
to 0
aid 0
in 0
the 0
diagnosis 0
of 0
breast 0
cancer 0
. 0

According 0
to 0
the 0
laboratory 0
results 0
, 0
the 0
application 0
of 0
neural 0
network 0
can 0
solve 0
the 0
problem 0
successfully 0
. 0

A 0
high 0
- 0
efficiency 0
cross 0
- 0
flow 0
micronebulizer 0
interface 0
for 0
capillary 0
electrophoresis 0
and 0
inductively 0
coupled 0
plasma 0
mass 0
spectrometry 0
. 0

The 0
electrodes 0
themselves 0
do 0
not 0
need 0
to 0
be 0
polished 0
prior 0
to 0
their 0
use 0
but 0
are 0
observed 0
to 0
be 0
slightly 0
recessed 0
from 0
the 0
surrounding 0
insulating 0
surface 0
. 0

The 0
experimental 0
results 0
showed 0
that 0
the 0
coagulation 0
- 0
electrooxidation 0
process 0
could 0
efficiently 0
remove 0
the 0
color 0
and 0
the 0
COD 0
from 0
the 0
simulated 0
dye 0
wastewater 0
. 0

Cyclic 0
loading 0
of 0
bone 0
during 0
normal 0
daily 0
activity 0
leads 0
to 0
the 0
formation 0
of 0
microcracks 0
within 0
the 0
tissue 0
matrix 0
of 0
compact 0
bone 0
. 0

The 0
weight 0
- 0
bearing 0
surface 0
of 0
the 0
PE 0
head 0
became 0
smoother 0
with 0
time 0
after 0
THA 0
, 0
and 0
the 0
friction 0
coefficient 0
did 0
not 0
differ 0
significantly 0
from 0
that 0
of 0
an 0
unused 0
PE 0
head 0
. 0

OBJECTIVE 0
: 0
To 0
demonstrate 0
a 0
lack 0
of 0
effect 0
of 0
steady 0
- 0
state 0
concentrations 0
of 0
cilomilast 0
, 0
a 0
new 0
oral 0
phosphodiesterase B-gene
4 I-gene
inhibitor 0
for 0
the 0
treatment 0
of 0
chronic 0
obstructive 0
pulmonary 0
disease 0
, 0
on 0
warfarin 0
- 0
induced 0
anticoagulation 0
. 0

Postdocs 0
face 0
hardship 0
across 0
mainland 0
Europe 0
. 0

The 0
design 0
principle 0
based 0
on 0
a 0
uniform 0
vibration 0
mode 0
is 0
presented 0
. 0

Because 0
the 0
DPPD B-gene
gene I-gene
is 0
not 0
present 0
in 0
non 0
- 0
tuberculous 0
bacilli 0
, 0
these 0
results 0
suggest 0
that 0
this 0
molecule 0
can 0
be 0
an 0
additional 0
tool 0
for 0
a 0
more 0
specific 0
diagnosis 0
of 0
tuberculosis 0
. 0

Dynamic 0
imaging 0
of 0
nuclear 0
wave 0
functions 0
with 0
ultrashort 0
UV 0
laser 0
pulses 0
. 0

Efficacy 0
and 0
safety 0
of 0
aspirin 0
in 0
the 0
long 0
- 0
term 0
management 0
of 0
atherothrombosis 0
. 0

The 0
General 0
Practice 0
Research 0
Database 0
( 0
GPRD 0
) 0
is 0
the 0
world 0
's 0
largest 0
computerized 0
database 0
of 0
anonymized 0
longitudinal 0
patient 0
records 0
from 0
general 0
practice 0
and 0
is 0
a 0
unique 0
public 0
health 0
research 0
tool 0
. 0

This 0
paper 0
reports 0
the 0
results 0
of 0
a 0
laboratory 0
study 0
on 0
aldicarb 0
and 0
its 0
main 0
metabolites 0
, 0
aldicarb 0
sulfone 0
and 0
aldicarb 0
sulfoxide 0
. 0

Only 0
one 0
DC 0
cardioversion 0
was 0
required 0
in 0
the 0
HBS 0
group 0
, 0
whereas 0
2 0
DC 0
in 0
the 0
CBC 0
group 0
and 0
total 0
7 0
DC 0
in 0
the 0
GIK 0
group 0
. 0

Since 0
August 0
1994 0
, 0
the 0
ENRP 0
has 0
retained 0
70.3 0
metric 0
tons 0
of 0
TP 0
that 0
otherwise 0
would 0
have 0
entered 0
the 0
Everglades 0
. 0

It 0
was 0
found 0
that 0
the 0
disappearance 0
of 0
BOD5 0
and 0
NH3 0
- 0
N 0
could 0
be 0
approximated 0
using 0
first 0
- 0
order 0
kinetics 0
, 0
but 0
the 0
kinetics 0
of 0
TP 0
removal 0
were 0
unclear 0
. 0

It 0
was 0
found 0
that 0
the 0
disappearance 0
of 0
BOD5 0
and 0
NH3 0
- 0
N 0
could 0
be 0
approximated 0
using 0
first 0
- 0
order 0
kinetics 0
, 0
but 0
the 0
kinetics 0
of 0
TP 0
removal 0
were 0
unclear 0
. 0

Losses 0
of 0
dichlofluanid 0
( 0
54 0
% 0
) 0
, 0
chlozolinate 0
( 0
22 0
% 0
) 0
, 0
and 0
etridiazole 0
( 0
40 0
% 0
) 0
, 0
previously 0
reported 0
to 0
occur 0
during 0
ambient 0
processing 0
of 0
apples 0
, 0
were 0
reduced 0
to 0
barely 0
significant 0
levels 0
( 0
10 0
, 0
17 0
, 0
and 0
14 0
% 0
, 0
respectively 0
) 0
by 0
cryogenic 0
processing 0
. 0

The 0
TB 0
incidence 0
in 0
the 0
`` 0
AIRIN 0
'' 0
area 0
, 0
where 0
about 0
20 0
% 0
TB 0
patients 0
are 0
homeless 0
, 0
shows 0
highest 0
rate 0
of 0
above 0
1,000/100,000 0
. 0

It 0
is 0
shown 0
that 0
the 0
displacement 0
distribution 0
measured 0
by 0
q 0
- 0
space 0
MRI 0
in 0
both 0
the 0
large 0
displacement 0
( 0
i.e. 0
, 0
large 0
r 0
) 0
and 0
the 0
long 0
- 0
wavelength 0
( 0
i.e. 0
, 0
small 0
q 0
) 0
limits 0
is 0
the 0
same 0
3D 0
Gaussian 0
displacement 0
distribution 0
assumed 0
in 0
DT 0
- 0
MRI 0
. 0

The 0
procedure 0
facilitated 0
the 0
retention 0
of 0
a 0
mandibular 0
molar 0
with 0
a 0
Class 0
III 0
FI 0
in 0
a 0
manner 0
acceptable 0
to 0
both 0
the 0
patient 0
and 0
the 0
clinician 0
. 0

The 0
results 0
of 0
our 0
ten 0
- 0
fold 0
cross 0
- 0
validation 0
experiments 0
show 0
that 0
, 0
on 0
the 0
average 0
, 0
the 0
system 0
increases 0
the 0
specificity 0
from 0
0.19 0
( 0
0.35 0
) 0
to 0
0.69 0
( 0
0.74 0
) 0
at 0
a 0
sensitivity 0
level 0
of 0
1.0 0
( 0
0.95 0
) 0
. 0

The 0
physical 0
characteristics 0
of 0
these 0
calls 0
vary 0
among 0
species 0
of 0
bat 0
, 0
and 0
variations 0
also 0
exist 0
in 0
the 0
timing 0
and 0
patterns 0
of 0
respiratory 0
muscle 0
recruitment 0
during 0
echolocation 0
. 0

Clicking 0
on 0
`` 0
Examples 0
and 0
Explanations 0
of 0
APA 0
Form 0
'' 0
provides 0
a 0
help 0
system 0
with 0
examples 0
of 0
the 0
various 0
sections 0
of 0
a 0
review 0
article 0
, 0
journal 0
article 0
that 0
has 0
one 0
experiment 0
, 0
or 0
journal 0
article 0
that 0
has 0
two 0
or 0
more 0
experiments 0
. 0

The 0
drug 0
packets 0
contained 0
acetyl 0
aspirin 0
, 0
acetaminophen 0
and 0
chloramphenicol 0
. 0

Karger 0
AG 0
, 0
Basel 0

AIM 0
: 0
To 0
understand 0
the 0
role 0
of 0
nutritional 0
status 0
in 0
cirrhotic 0
patients 0
without 0
clinical 0
porto 0
- 0
systemic 0
encephalopathy 0
( 0
PSE 0
) 0
.METHODS 0
: 0
Fifty 0
- 0
one 0
non 0
- 0
alcoholic 0
patients 0
with 0
cirrhosis 0
without 0
PSE 0
were 0
studied 0
prospectively 0
and 0
compared 0
with 0
20 0
healthy 0
volunteers 0
. 0

MAIN 0
OUTCOME 0
MEASURE 0
( 0
S 0
) 0
: 0
Serum 0
levels 0
of 0
FSH B-gene
, 0
LH B-gene
, 0
and 0
inhibin B-gene
A I-gene
and I-gene
B I-gene
. 0

For 0
instance 0
, 0
a 0
total 0
SIP 0
score 0
of 0
an 0
individual 0
patient 0
of 0
28.3 0
% 0
( 0
which 0
is 0
taken 0
as 0
an 0
example 0
, 0
being 0
the 0
mean 0
score 0
in 0
the 0
study 0
population 0
) 0
should 0
decrease 0
by 0
at 0
least 0
9.26 0
% 0
or 0
approximately 0
13 0
items 0
, 0
before 0
any 0
improvement 0
beyond 0
reproducibility 0
noise 0
can 0
be 0
detected 0
. 0

Group 0
I 0
comprised 0
5 0
adult 0
Collies 0
that 0
received 0
at 0
least 0
400 0
microg/kg 0
ivermectin 0
p.o 0
. 0
and 0
were 0
presented 0
to 0
the 0
VMTH 0
3 0
hours 0
after 0
intoxication 0
. 0

Patients 0
with 0
a 0
secondary 0
cardiac 0
event 0
had 0
more 0
common 0
Type 0
A 0
behavior 0
patterns 0
and 0
higher 0
Bortner 0
scores 0
than 0
patients 0
without 0
a 0
secondary 0
cardiac 0
event 0
. 0

Interestingly 0
, 0
continuation 0
of 0
the 0
interferon B-gene
therapy 0
in 0
the 0
presence 0
of 0
a 0
mild 0
- 0
to 0
- 0
moderate 0
exacerbation 0
of 0
sarcoidosis 0
may 0
be 0
safe 0
in 0
a 0
minority 0
of 0
patients 0
with 0
noncritical 0
organ 0
involvement 0
. 0

No 0
increased 0
tumor 0
- 0
related 0
mortality 0
was 0
observed 0
after 0
a 0
mean 0
follow 0
- 0
up 0
of 0
44 0
months 0
. 0

Dissociable 0
effects 0
of 0
lidocaine 0
inactivation 0
of 0
the 0
rostral 0
and 0
caudal 0
basolateral 0
amygdala 0
on 0
the 0
maintenance 0
and 0
reinstatement 0
of 0
cocaine 0
- 0
seeking 0
behavior 0
in 0
rats 0
. 0

The 0
population 0
studied 0
comprised 0
4472 0
men 0
and 0
5212 0
women 0
aged 0
30 0
- 0
74 0
years 0
, 0
without 0
coronary 0
heart 0
disease 0
, 0
who 0
had 0
CRP B-gene
measurements 0
in 0
the 0
Third 0
National 0
Health 0
and 0
Nutrition 0
Examination 0
Survey 0
( 0
NHANES 0
III 0
) 0
. 0

Herceptin 0
, 0
which 0
recognizes 0
the 0
HER B-gene
- I-gene
2/neu I-gene
antigen 0
and 0
has 0
similar 0
size 0
( 0
10 0
nm 0
) 0
to 0
G6 0
- 0
( 0
1B4M 0
- 0
Gd 0
) 0
( 0
256 0
) 0
, 0
accumulated 0
and 0
internalized 0
in 0
the 0
WIBC 0
- 0
9 0
tumors 0
more 0
quickly 0
than 0
in 0
the 0
control 0
MC 0
- 0
5 0
tumors 0
that 0
progress 0
with 0
normal 0
angiogenesis 0
. 0

Forty 0
- 0
eight 0
pigs 0
were 0
removed 0
from 0
sows 0
at 0
1 0
d 0
of 0
age 0
and 0
randomly 0
assigned 0
to 0
one 0
of 0
three 0
treatments 0
: 0
1 0
) 0
control 0
with 0
lactose 0
as 0
the 0
carbohydrate 0
source 0
, 0
2 0
) 0
lactose 0
replaced 0
( 0
gram 0
for 0
gram 0
) 0
with 0
CSS 0
( 0
dextrose 0
equivalent 0
[ 0
DE 0
] 0
- 0
20 0
) 0
, 0
and 0
3 0
) 0
lactose 0
replaced 0
with 0
DE 0
- 0
42 0
. 0

CONCLUSIONS 0
: 0
AMVT 0
is 0
rare 0
but 0
a 0
potentially 0
lethal 0
emergency 0
disease 0
. 0

There 0
was 0
no 0
difference 0
in 0
apnea 0
duration 0
between 0
the 0
supine 0
and 0
prone 0
positions 0
. 0

Therefore 0
, 0
in 0
a 0
large 0
animal 0
model 0
of 0
permanent 0
focal 0
ischemia 0
in 0
which 0
transfusion 0
starts 0
30 0
min 0
after 0
ischemia 0
, 0
tetrameric 0
cross 0
- 0
linked 0
hemoglobin B-gene
transfusion 0
can 0
augment 0
oxygen 0
transport 0
to 0
the 0
ischemic 0
cortex 0
, 0
but 0
the 0
increase 0
can 0
be 0
delayed 0
and 0
not 0
necessarily 0
provide 0
protection 0
. 0

Since 0
the 0
early 0
1980s 0
there 0
has 0
been 0
increasing 0
awareness 0
of 0
the 0
importance 0
of 0
quantifying 0
health 0
- 0
related 0
quality 0
of 0
life 0
( 0
HRQL 0
) 0
in 0
patients 0
with 0
chronic 0
respiratory 0
disorders 0
included 0
in 0
clinical 0
trials 0
. 0

They 0
were 0
randomly 0
allocated 0
to 0
receive 0
either 0
625 0
mg 0
of 0
calcium 0
carbonate 0
( 0
250 0
mg 0
of 0
elemental 0
calcium 0
) 0
at 0
the 0
end 0
of 0
a 0
meal 0
three 0
times 0
a 0
day 0
( 0
group 0
A 0
, 0
n=26 0
) 0
or 0
calcium 0
carbonate 0
in 0
the 0
same 0
manner 0
plus 0
0.625 0
mg/day 0
of 0
conjugated 0
equine 0
estrogen 0
and 0
5 0
mg 0
medrogestone 0
acetate 0
from 0
day 0
1 0
- 0
12 0
each 0
month 0
( 0
group 0
B 0
, 0
n=30 0
) 0
. 0

TNFalpha B-gene
and 0
IL B-gene
- I-gene
6 I-gene
levels 0
were 0
determined 0
in 0
the 0
culture 0
supernatants 0
. 0

Therefore 0
, 0
this 0
study 0
has 0
demonstrated 0
that 0
prenatal 0
disturbance 0
can 0
induce 0
a 0
lasting 0
change 0
in 0
cytokine 0
biology 0
, 0
which 0
persists 0
well 0
beyond 0
the 0
fetal 0
and 0
infant 0
stage 0
. 0

The 0
two 0
- 0
wave 0
, 0
1995 0
- 0
1996 0
National 0
Longitudinal 0
Study 0
of 0
Adolescent 0
Health 0
uses 0
a 0
measure 0
of 0
depressive 0
symptomatology 0
across 0
a 0
12 0
- 0
month 0
interval 0
. 0

METHODS 0
: 0
9 0
cases 0
of 0
conventional 0
intermittent 0
tissue 0
expansion 0
( 0
CITE 0
) 0
and 0
9 0
cases 0
of 0
continuous 0
pressure 0
- 0
controlled 0
tissue 0
expansion 0
( 0
CPTE 0
) 0
were 0
chosen 0
for 0
the 0
study 0
. 0

Wegener 0
's 0
granulomatosis 0

There 0
was 0
a 0
significant 0
effect 0
of 0
hematocrit 0
on 0
the 0
General 0
Health 0
scale 0
on 0
the 0
SF 0
- 0
36 0
( 0
P 0
= 0
0.03 0
) 0
. 0

Based 0
on 0
analytic 0
precisions 0
, 0
a 0
+/ 0
- 0
2 0
% 0
urine 0
- 0
plasma 0
difference 0
was 0
set 0
as 0
the 0
cut 0
- 0
off 0
value 0
. 0

Schistosoma 0
mansoni 0
schistosomiasis 0
] 0
Schistosomosis 0
are 0
parasitic 0
diseases 0
caused 0
by 0
blood 0
flukes 0
of 0
the 0
Schistosoma 0
genus 0
. 0

A 0
global 0
response 0
rate 0
was 0
17 0
% 0
( 0
95 0
% 0
confidence 0
interval 0
( 0
95 0
% 0
CI 0
) 0
: 0
2 0
% 0
- 0
32 0
% 0
) 0
and 0
the 0
median 0
overall 0
survival 0
was 0
12 0
months 0
. 0

We 0
also 0
studied 0
a 0
new 0
parameter 0
: 0
the 0
angle 0
to 0
maximal 0
peak 0
torque 0
( 0
APT 0
) 0
. 0

For 0
the 0
2.5 0
to 0
4 0
ng/mL 0
model 0
, 0
the 0
AUC 0
of 0
the 0
ANN 0
ROC 0
curve 0
was 0
significantly 0
higher 0
than 0
the 0
AUCs 0
for 0
percentage 0
of 0
free 0
PSA B-gene
( 0
P 0
=.0239 0
) 0
, 0
PSA 0
- 0
TZ 0
( 0
P 0
=.0204 0
) 0
, 0
and 0
PSA B-gene
density 0
and 0
total 0
prostate 0
volume 0
( 0
P 0
< 0
.01 0
for 0
both 0
) 0
. 0

Potential 0
treatments 0
include 0
dobutamine 0
, 0
KATP 0
channel 0
activators 0
, 0
and 0
21 0
- 0
aminosteroids 0
. 0

Selenium 0
is 0
an 0
essential 0
element 0
for 0
humans 0
, 0
animals 0
and 0
some 0
species 0
of 0
microorganisms 0
. 0

The 0
GT 0
- 0
foreign 0
- 0
pictures 0
showed 0
that 0
the 0
judgment 0
of 0
other 0
subjects 0
changed 0
toward 0
hedonic 0
and 0
permeability 0
directions 0
. 0

Emphysematous 0
cholecystitis 0
: 0
sonographic 0
findings 0
. 0

Age 0
was 0
categorized 0
into 0
four 0
groups 0
: 0
20 0
- 0
44 0
, 0
45 0
- 0
64 0
, 0
65 0
- 0
74 0
, 0
and 0
75+.RESULTS 0
: 0
At 0
the 0
initiation 0
of 0
dialysis 0
PD 0
patients 0
were 0
approximately 0
6 0
years 0
younger 0
( 0
P 0
< 0
0.0001 0
) 0
than 0
HD 0
patients 0
. 0

RESULTS 0
: 0
The 0
target 0
dose 0
was 0
comparable 0
in 0
the 0
3D 0
- 0
CRT 0
and 0
IMRT 0
plans 0
, 0
although 0
improvements 0
were 0
seen 0
when 0
seven 0
and 0
nine 0
IMRT 0
fields 0
were 0
used 0
. 0

We 0
therefore 0
applied 0
a 0
radiolabelled 0
serumalbumin B-gene
method 0
to 0
determine 0
blood 0
volume 0
after 0
haemodilution 0
with 0
crosslinked 0
or 0
conjugated 0
haemoglobin B-gene
, 0
in 0
comparison 0
with 0
a 0
reference 0
solution 0
of 0
hydroxyethyl 0
starch 0
( 0
HES 0
) 0
. 0

The 0
equilibrium 0
phosphorus 0
content 0
( 0
EPC0 0
) 0
of 0
surface 0
soil 0
was 0
generally 0
higher 0
than 0
the 0
SRP 0
content 0
of 0
drainage 0
water 0
, 0
at 0
one 0
farm 0
by 0
1 0
order 0
of 0
magnitude 0
. 0

The 0
long 0
- 0
term 0
prediction 0
is 0
based 0
on 0
an 0
algorithm 0
for 0
R 0
- 0
R 0
interval 0
estimation 0
. 0

Despite 0
considerable 0
research 0
, 0
an 0
explanation 0
of 0
this 0
effect 0
has 0
been 0
elusive 0
. 0

The 0
structure 0
has 0
been 0
established 0
by 0
a 0
study 0
of 0
its 0
mono 0
- 0
and 0
bidimensional 0
NMR 0
spectra 0
and 0
mass 0
spectrometry 0
. 0

We 0
argue 0
that 0
this 0
is 0
the 0
general 0
property 0
of 0
QSAR 0
models 0
developed 0
using 0
LOO 0
cross 0
- 0
validation 0
. 0

We 0
compared 0
the 0
efficacy 0
and 0
costs 0
of 0
valacyclovir 0
in 0
preventing 0
HSV 0
reactivation 0
among 0
HSV 0
seropositive 0
autologous 0
progenitor 0
cell 0
transplantation 0
( 0
APCT 0
) 0
patients 0
with 0
historical 0
controls 0
in 0
whom 0
intravenous 0
acyclovir 0
or 0
no 0
HSV 0
prophylaxis 0
were 0
used 0
. 0

All 0
adults 0
attending 0
the 0
outpatient 0
clinics 0
of 0
a 0
dermatological 0
hospital 0
on 0
predetermined 0
days 0
were 0
given 0
the 0
12 0
- 0
item 0
General 0
Health 0
Questionnaire 0
. 0

Data 0
on 0
prosthesis 0
use 0
are 0
encouraging 0
, 0
although 0
a 0
follow 0
- 0
up 0
study 0
is 0
required 0
to 0
determine 0
the 0
functional 0
outcome 0
for 0
prosthesis 0
users 0
and 0
non 0
- 0
users 0
. 0

A 0
mail 0
survey 0
of 0
Georgia 0
members 0
of 0
the 0
American 0
College 0
of 0
Obstetricians 0
and 0
Gynecologists 0
was 0
conducted 0
. 0

HIV 0
- 0
1 0
C 0
subtype 0
in 0
IDUs 0
accounted 0
for 0
61.3 0
% 0
. 0

When 0
a 0
plateau 0
of 0
enhancement 0
was 0
reached 0
, 0
a 0
single 0
lesion 0
in 0
each 0
patient 0
was 0
imaged 0
using 0
five 0
different 0
continuous 0
scanning 0
modes 0
, 0
fundamental 0
grey 0
scale 0
( 0
FGS 0
) 0
; 0
fundamental 0
colour 0
Doppler 0
( 0
FCD 0
) 0
; 0
fundamental 0
power 0
Doppler 0
( 0
FPD 0
) 0
; 0
second 0
harmonic 0
grey 0
scale 0
( 0
HGS 0
) 0
; 0
and 0
pulse 0
inversion 0
mode 0
( 0
Pim 0
) 0
using 0
an 0
HDI5000 0
scanner 0
and 0
C5 0
- 0
2 0
probe 0
( 0
ATL 0
, 0
Bothell 0
, 0
WA 0
) 0
. 0

A 0
comparative 0
study 0
of 0
the 0
effects 0
of 0
carbamazepine 0
and 0
the 0
NMDA B-gene
receptor I-gene
antagonist 0
remacemide 0
on 0
road 0
tracking 0
and 0
car 0
- 0
following 0
performance 0
in 0
actual 0
traffic 0
. 0

We 0
find 0
that 0
the 0
measured 0
Nusselt 0
number 0
decreased 0
about 0
20 0
% 0
over 0
the 0
range 0
of 0
Pr 0
spanned 0
in 0
the 0
experiment 0
. 0

Viral 0
and 0
atypical 0
pathogens 0
as 0
causes 0
of 0
type 0
1 0
acute 0
exacerbations 0
of 0
chronic 0
bronchitis 0
. 0

Treatment 0
for 0
this 0
condition 0
often 0
involves 0
use 0
of 0
a 0
wax 0
softening 0
or 0
dispersing 0
agent 0
( 0
cerumenolytic 0
) 0
before 0
syringing 0
. 0

In 0
addition 0
, 0
benzocaine 0
and 0
2 0
- 0
phenoxyethanol 0
depressed 0
complement 0
activity 0
and 0
phagocytosis 0
, 0
while 0
MS222 0
and 0
quinaldine 0
sulphate 0
did 0
not 0
. 0

The 0
EC 0
( 0
50 0
) 0
for 0
suppression 0
of 0
long 0
- 0
term 0
memory 0
( 0
the 0
concentration 0
decreasing 0
memory 0
by 0
50 0
% 0
) 0
of 0
fear 0
conditioning 0
to 0
context 0
was 0
2.00 0
% 0
plus/minus 0
0.01 0
% 0
( 0
mean 0
plus/minus 0
SEM 0
) 0
, 0
and 0
for 0
fear 0
conditioning 0
to 0
tone 0
was 0
3.45 0
% 0
plus/minus 0
0.26 0
% 0
, 0
( 0
P 0
< 0
0.05 0
) 0
. 0

The 0
utility 0
of 0
such 0
analyses 0
in 0
the 0
design 0
of 0
ceramic/substrate 0
bilayer 0
systems 0
for 0
optimal 0
resistance 0
to 0
lifetime 0
- 0
threatening 0
damage 0
is 0
discussed 0
. 0

It 0
has 0
been 0
proposed 0
that 0
insulin B-gene
resistance 0
( 0
IR 0
) 0
underlies 0
a 0
cluster 0
of 0
cardiovascular 0
disease 0
( 0
CVD 0
) 0
risk 0
factors 0
constituting 0
a 0
`` 0
metabolic 0
syndrome 0
. 0
'' 0
CVD 0
is 0
a 0
leading 0
cause 0
of 0
premature 0
mortality 0
among 0
indigenous 0
Australians 0
. 0

Dementia 0
is 0
being 0
avoided 0
in 0
NHS 0
and 0
social 0
care 0
. 0

HIV 0
- 0
1 0
infection 0
in 0
rural 0
Africa 0
: 0
is 0
there 0
a 0
difference 0
in 0
median 0
time 0
to 0
AIDS 0
and 0
survival 0
compared 0
with 0
that 0
in 0
industrialized 0
countries 0
? 0
OBJECTIVES 0
: 0
To 0
describe 0
the 0
progression 0
times 0
of 0
HIV 0
- 0
1 0
infection 0
from 0
seroconversion 0
to 0
AIDS 0
and 0
to 0
death 0
, 0
and 0
time 0
from 0
first 0
developing 0
AIDS 0
to 0
death 0
in 0
rural 0
Uganda 0
. 0

The 0
use 0
of 0
highly 0
active 0
antiretroviral 0
therapy 0
( 0
HAART 0
) 0
has 0
resulted 0
in 0
significant 0
improvements 0
in 0
the 0
treatment 0
of 0
HIV 0
infection 0
, 0
including 0
a 0
decrease 0
in 0
the 0
incidence 0
and 0
severity 0
of 0
several 0
acquired 0
immune 0
deficiency 0
syndrome 0
( 0
AIDS 0
) 0
- 0
related 0
malignancies 0
. 0

Time 0
to 0
progression 0
was 0
6 0
months 0
( 0
5 0
- 0
7 0
months 0
) 0
with 0
a 0
median 0
survival 0
from 0
registration 0
of 0
9.6 0
months 0
( 0
95 0
% 0
CI 0
8 0
- 0
12 0
months 0
) 0
. 0

Heparin 0
( 0
100 0
U 0
. 0
kg 0
( 0
- 0
1 0
) 0
. 0
day 0
( 0
- 0
1 0
) 0
) 0
was 0
injected 0
subcutaneously 0
to 0
the 0
rats 0
in 0
H 0
group 0
while 0
normal 0
saline 0
to 0
those 0
in 0
N 0
group 0
once 0
a 0
day 0
. 0

MAIN 0
OUTCOME 0
MEASURE 0
: 0
A 0
positive 0
test 0
result 0
for 0
gonococcal 0
or 0
chlamydial 0
infection 0
by 0
the 0
ligase B-gene
chain 0
reaction 0
assay 0
; 0
secondary 0
outcome 0
measure 0
was 0
a 0
positive 0
test 0
result 0
for 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
develop 0
a 0
reliable 0
and 0
culturally 0
meaningful 0
exercise 0
self 0
- 0
efficacy 0
questionnaire 0
for 0
older 0
Mexican 0
American 0
women 0
. 0

Neutrophil 0
: 0
lymphocyte 0
ratio 0
, 0
plasma 0
haptoglobin B-gene
, 0
and 0
CBG B-gene
levels 0
were 0
greater 0
( 0
P 0
< 0
0.01 0
) 0
during 0
the 0
INITIAL 0
period 0
than 0
during 0
the 0
PRE 0
or 0
POST 0
periods 0
but 0
did 0
not 0
differ 0
between 0
treatments 0
. 0

Adjacent 0
to 0
those 0
lesions 0
, 0
and 0
in 0
homologous 0
contralateral 0
structures 0
, 0
FMZ 0
binding 0
was 0
analysed 0
in 0
four 0
pairs 0
of 0
cortical 0
9 0
x 0
9 0
- 0
mm 0
regions 0
of 0
interest 0
( 0
ROIs 0
) 0
placed 0
on 0
transaxial 0
and 0
coronal 0
slices 0
, 0
respectively 0
, 0
as 0
well 0
as 0
in 0
the 0
lesion 0
volume 0
and 0
its 0
mirror 0
region 0
. 0

Because 0
a 0
close 0
correlation 0
between 0
regional 0
decreases 0
in 0
FMZ 0
binding 0
and 0
spiking 0
activity 0
was 0
recently 0
demonstrated 0
in 0
neocortical 0
epilepsies 0
, 0
abnormal 0
peri 0
- 0
lesional 0
FMZ 0
binding 0
may 0
bear 0
some 0
relation 0
to 0
the 0
mechanisms 0
of 0
epileptogenesis 0
in 0
symptomatic 0
epilepsies 0
. 0

CD 0
was 0
determined 0
using 0
the 0
Farnsworth 0
D 0
- 0
15 0
method 0
. 0

Here 0
is 0
presented 0
the 0
monitoring 0
of 0
the 0
accidental 0
spill 0
on 0
vertical 0
distribution 0
of 0
heavy 0
metals 0
in 0
the 0
estuarine 0
sediments 0
. 0

The 0
large 0
fluxes 0
of 0
239+240Pu 0
might 0
be 0
attributed 0
to 0
episodic 0
lateral 0
transport 0
of 0
particles 0
that 0
flow 0
down 0
the 0
continental 0
slope 0
with 0
the 0
nepheloid 0
layer 0
which 0
was 0
considered 0
to 0
be 0
significant 0
for 0
239+240Pu 0
transport 0
on 0
the 0
continental 0
slope 0
in 0
the 0
East 0
China 0
Sea 0
. 0

Rigorous 0
treatment 0
protocols 0
for 0
diet 0
delivery 0
and 0
EEN 0
- 0
related 0
GI 0
adverse 0
effects 0
were 0
applied 0
. 0

We 0
found 0
three 0
out 0
of 0
four 0
original 0
( 0
Volkan 0
's 0
) 0
groups 0
of 0
linking 0
objects 0
, 0
but 0
also 0
an 0
additional 0
one 0
, 0
hitherto 0
undescribed 0
, 0
comprising 0
objects 0
used 0
for 0
designing 0
a 0
memorial 0
shrine 0
to 0
the 0
deceased 0
. 0

The 0
range 0
of 0
200 0
000 0
- 0
300 0
000 0
spermatozoa/microl 0
appeared 0
to 0
be 0
a 0
reasonable 0
compromise 0
for 0
both 0
criteria 0
. 0

Gastritis 0
score 0
was 0
significantly 0
lower 0
in 0
nod 0
- 0
/CagA B-gene
- 0
children 0
than 0
in 0
nod+/CagA B-gene
- 0
( 0
p 0
=.004 0
) 0
, 0
nod 0
- 0
/CagA+ B-gene
( 0
p 0
=.002 0
) 0
and 0
nod+/CagA+ B-gene
( 0
p 0
< 0
.001 0
) 0
, 0
both 0
in 0
the 0
antrum 0
and 0
corpus 0
. 0

The 0
mean 0
thickness 0
of 0
the 0
visceral 0
peritoneum 0
was 0
comparable 0
in 0
both 0
groups 0
of 0
animals 0
, 0
but 0
, 0
macroscopically 0
, 0
more 0
severe 0
fibrosis 0
was 0
found 0
in 0
the 0
peritoneum 0
of 0
rats 0
exposed 0
to 0
CAPD 0
3 0
as 0
compared 0
with 0
animals 0
treated 0
with 0
CAPD 0
3 0
Balance 0
( 0
p 0
< 0
0.05 0
) 0
. 0

A 0
further 0
analysis 0
has 0
been 0
performed 0
using 0
the 0
series 0
of 0
maximum 0
intensity 0
for 0
fixed 0
duration 0
( 0
1 0
, 0
3 0
, 0
6 0
, 0
12 0
, 0
24 0
hrs 0
) 0
and 0
annual 0
daily 0
maxima 0
. 0

BACKGROUND 0
: 0
We 0
hypothesized 0
that 0
the 0
postoperative 0
serum 0
level 0
of 0
TA90 B-gene
- I-gene
IC I-gene
, 0
an 0
immune 0
complex 0
of 0
a 0
90 0
- 0
kDa 0
tumor 0
- 0
associated 0
antigen 0
and 0
its 0
antibody 0
, 0
might 0
have 0
a 0
significant 0
correlation 0
with 0
recurrence 0
and 0
survival 0
in 0
patients 0
with 0
thick 0
primary 0
melanomas 0
. 0

Genetics 0
Institute 0
has 0
developed 0
and 0
launched 0
oprelvekin B-gene
( 0
rhIL B-gene
- I-gene
11 I-gene
; 0
Neumega 0
) 0
, 0
a 0
recombinant 0
form 0
of 0
human B-gene
IL I-gene
- I-gene
11 I-gene
. 0

Patients 0
subsequently 0
returned 0
to 0
the 0
clinic 0
every 0
3 0
days 0
to 0
have 0
the 0
wounds 0
checked 0
and 0
dressings 0
changed 0
. 0

Elements 0
that 0
are 0
fundamental 0
to 0
the 0
safety 0
evaluation 0
of 0
flavor 0
ingredients 0
include 0
exposure 0
, 0
structural 0
analogy 0
, 0
metabolism 0
, 0
pharmacokinetics 0
and 0
toxicology 0
. 0

The 0
mass 0
- 0
specific 0
resting 0
minute 0
ventilation 0
( 0
E 0
) 0
and 0
the 0
ventilatory 0
equivalent 0
( 0
VE/ 0
( 0
O 0
( 0
2 0
) 0
) 0
) 0
were 0
approximately 0
the 0
same 0
at 0
the 0
two 0
ages 0
, 0
with 0
a 0
breathing 0
pattern 0
significantly 0
deeper 0
and 0
slower 0
at 0
day 0
1 0
. 0

INTERPRETATION 0
: 0
It 0
is 0
probable 0
that 0
the 0
cognitive 0
dissonance 0
created 0
by 0
more 0
health 0
information 0
on 0
smoking 0
after 0
1964 0
, 0
i.e 0
. 0
the 0
necessary 0
motivation 0
to 0
quit 0
, 0
was 0
reduced 0
as 0
a 0
result 0
of 0
strategic 0
changes 0
in 0
the 0
amount 0
and 0
content 0
of 0
advertising 0
. 0

Nine 0
cases 0
of 0
GBS 0
and 0
five 0
of 0
TM 0
reported 0
to 0
the 0
active 0
AFP 0
surveillance 0
were 0
not 0
found 0
in 0
the 0
hospital 0
searches 0
. 0

The 0
ability 0
of 0
rats 0
with 0
control 0
or 0
hippocampal 0
lesions 0
to 0
learn 0
an 0
object 0
- 0
place 0
, 0
odor 0
- 0
place 0
, 0
or 0
object 0
- 0
odor 0
paired 0
- 0
associate 0
task 0
was 0
assessed 0
in 0
a 0
cheeseboard 0
maze 0
apparatus 0
. 0

The 0
shift 0
in 0
the 0
earliest 0
activation 0
site 0
after 0
administration 0
of 0
esmolol 0
was 0
compared 0
with 0
the 0
shift 0
after 0
RFA 0
. 0
RESULTS 0
: 0
The 0
heart 0
rate 0
at 0
rest 0
and 0
in 0
drug 0
- 0
free 0
state 0
ranged 0
between 0
95 0
and 0
125 0
beats/min 0
( 0
mean 0
99 0
+/ 0
- 0
14 0
beats/min 0
) 0
. 0

Urine 0
samples 0
collected 0
after 0
the 0
administration 0
of 0
these 0
supplements 0
can 0
test 0
positive 0
. 0

CONCLUSIONS 0
: 0
Lymphoscintigraphy 0
of 0
the 0
cynomolgus 0
monkey 0
eyelids 0
reveals 0
discrete 0
lymphatic 0
drainage 0
pathways 0
for 0
the 0
upper 0
and 0
lower 0
eyelids 0
and 0
a 0
dual 0
pathway 0
for 0
the 0
central 0
upper 0
eyelid 0
. 0

Data 0
management 0
in 0
practice 0
- 0
based 0
research 0
. 0

We 0
have 0
previously 0
reported 0
reduced 0
levels 0
of 0
choline B-gene
acetyltransferase I-gene
activity 0
in 0
the 0
cerebral 0
cortex 0
of 0
patients 0
who 0
died 0
after 0
a 0
head 0
injury 0
, 0
demonstrating 0
that 0
there 0
is 0
a 0
loss 0
of 0
cortical 0
cholinergic 0
innervation 0
. 0

After 0
taking 0
smears 0
from 0
lesions 0
of 0
the 0
oral 0
mucosa 0
( 0
tongue 0
, 0
cheeks 0
, 0
palate 0
) 0
and 0
the 0
contiguous 0
denture 0
surface 0
by 0
cotton 0
wool 0
swabs 0
and 0
inoculating 0
them 0
onto 0
Sabouraud 0
glucose 0
agar 0
and 0
CHROMagar 0
Candida 0
, 0
individual 0
yeast 0
species 0
were 0
identified 0
by 0
a 0
germ 0
tube 0
, 0
filamentous 0
, 0
and 0
assimilation 0
tests 0
employing 0
the 0
commercial 0
kit 0
AuxaColor 0
. 0

The 0
effects 0
of 0
pharmacological 0
treatment 0
and 0
professional 0
care 0
and 0
support 0
may 0
improve 0
when 0
dementia 0
is 0
detected 0
in 0
an 0
early 0
stage 0
. 0

Sexually 0
conditioned 0
incentives 0
: 0
attenuation 0
of 0
motivational 0
impact 0
during 0
dopamine B-gene
receptor I-gene
antagonism 0
. 0

One 0
CKD 0
patient 0
's 0
journey 0
. 0

PATIENTS 0
AND 0
METHODS 0
: 0
This 0
study 0
is 0
a 0
retrospective 0
cohort 0
study 0
of 0
all 0
children 0
with 0
cancer 0
admitted 0
to 0
a 0
single 0
institution 0
with 0
fever 0
and 0
neutropenia 0
( 0
defined 0
as 0
an 0
absolute 0
neutrophil 0
count 0
< 0
500 0
cells/mm3 0
) 0
in 0
a 0
1 0
- 0
year 0
period 0
. 0

Concentrations 0
of 0
N 0
( 0
O3 0
- 0
) 0
- 0
N 0
and 0
N 0
( 0
H3 0
- 0
) 0
- 0
N 0
at 0
Deoprayag 0
varied 0
from 0
0.30 0
to 0
0.50 0
and 0
0.02 0
to 0
0.12 0
mg/L 0
, 0
respectively 0
, 0
depending 0
on 0
season 0
. 0

Steal 0
is 0
a 0
pathophysiological 0
process 0
in 0
which 0
increased 0
blood 0
flow 0
through 0
a 0
low 0
- 0
resistance 0
vascular 0
bed 0
is 0
sufficient 0
to 0
divert 0
flow 0
away 0
from 0
a 0
region 0
of 0
the 0
central 0
nervous 0
system 0
. 0

The 0
orientations 0
of 0
the 0
contact 0
surfaces 0
and 0
their 0
locations 0
relative 0
to 0
the 0
object 0
's 0
center 0
of 0
mass 0
were 0
varied 0
. 0

The 0
results 0
are 0
given 0
as 0
: 0
flux 0
, 0
number 0
of 0
stars 0
per 0
cm3 0
, 0
charge 0
of 0
the 0
ions 0
, 0
comparison 0
with 0
other 0
detectors 0
( 0
plastics 0
, 0
AgCl 0
crystals 0
, 0
LiF 0
) 0
, 0
energy 0
loss 0
, 0
hit 0
region 0
in 0
the 0
biological 0
objects 0
. 0

Nodal 0
domains 0
are 0
regions 0
where 0
a 0
function 0
has 0
definite 0
sign 0
. 0

DESIGN 0
: 0
Prospective 0
, 0
randomized 0
, 0
double 0
- 0
blind 0
, 0
controlled 0
trial 0
. 0

CONCLUSIONS 0
: 0
This 0
retrospective 0
uncontrolled 0
study 0
shows 0
that 0
in 0
patients 0
with 0
type 0
1 0
HRS 0
, 0
terlipressin 0
- 0
induced 0
improved 0
renal 0
function 0
is 0
associated 0
with 0
an 0
increase 0
in 0
survival 0
. 0

In 0
patients 0
who 0
respond 0
to 0
quetiapine 0
, 0
therapy 0
should 0
be 0
continued 0
at 0
the 0
optimal 0
dose 0
that 0
maintains 0
remission 0
, 0
within 0
the 0
range 0
of 0
150 0
to 0
750 0
mg/d 0
. 0

Calcimimetic 0
agents 0
directly 0
inhibit 0
PTH B-gene
secretion 0
by 0
activating 0
the 0
calcium 0
- 0
sensing 0
receptor 0
in 0
the 0
parathyroid 0
glands 0
, 0
but 0
clinical 0
experience 0
with 0
them 0
is 0
limited 0
. 0

With 0
such 0
analysis 0
, 0
one 0
can 0
test 0
hypotheses 0
about 0
the 0
structure 0
of 0
latent 0
variability 0
within 0
a 0
given 0
data 0
set 0
. 0

The 0
subjects 0
were 0
shown 0
to 0
be 0
capable 0
of 0
assessing 0
integrally 0
the 0
value 0
of 0
accelerations 0
and 0
estimating 0
it 0
with 0
an 0
error 0
of 0
0.1 0
- 0
0.12 0
g 0
. 0

The 0
observed 0
incidence 0
rates 0
were 0
compared 0
to 0
expected 0
rates 0
in 0
the 0
general 0
population 0
. 0

The 0
only 0
predictor 0
of 0
response 0
to 0
tacrolimus 0
was 0
a 0
previous 0
response 0
to 0
cyclosporin 0
and 0
prednisone 0
, 0
either 0
as 0
a 0
complete 0
or 0
partial 0
remission 0
( 0
remission 0
rate 0
75 0
% 0
vs 0
15.3 0
; 0
P=0.036 0
) 0
. 0

Based 0
on 0
a 0
morphological 0
study 0
of 0
the 0
resin 0
- 0
dentine 0
interface 0
, 0
a 0
broad 0
selection 0
of 0
dentine 0
adhesive 0
systems 0
was 0
classified 0
following 0
their 0
adhesion 0
- 0
strategy 0
. 0

Copyright 0
2002 0
American 0
Cancer 0
Society.DOI 0
10.1002/cncr.10318 0

In 0
this 0
study 0
we 0
wanted 0
to 0
assess 0
the 0
DR 0
using 0
the 0
'combined 0
test 0
' 0
in 0
an 0
unselected 0
population 0
of 0
self 0
- 0
referred 0
pregnant 0
women 0
at 0
a 0
false 0
- 0
positive 0
rate 0
( 0
FPR 0
) 0
of 0
about 0
5 0
% 0
. 0

As 0
measured 0
by 0
the 0
PDQ 0
- 0
39 0
, 0
STN 0
- 0
DBS 0
significantly 0
improves 0
important 0
aspects 0
of 0
QoL 0
in 0
patients 0
with 0
advanced 0
PD 0
. 0

